dIdentification O
of O
APC2 O
, O
a O
homologue O
of O
the O
adenomatous B
polyposis I
coli I
tumour I
suppressor O
. O

The O
adenomatous B
polyposis I
coli I
( I
APC I
) I
tumour I
- O
suppressor O
protein O
controls O
the O
Wnt O
signalling O
pathway O
by O
forming O
a O
complex O
with O
glycogen O
synthase O
kinase O
3beta O
( O
GSK O
- O
3beta O
) O
, O
axin O
/ O
conductin O
and O
betacatenin O
. O

Complex O
formation O
induces O
the O
rapid O
degradation O
of O
betacatenin O
. O

In O
colon B
carcinoma I
cells O
, O
loss O
of O
APC O
leads O
to O
the O
accumulation O
of O
betacatenin O
in O
the O
nucleus O
, O
where O
it O
binds O
to O
and O
activates O
the O
Tcf O
- O
4 O
transcription O
factor O
( O
reviewed O
in O
[ O
1 O
] O
[ O
2 O
] O
) O
. O

Here O
, O
we O
report O
the O
identification O
and O
genomic O
structure O
of O
APC O
homologues O
. O

Mammalian O
APC2 O
, O
which O
closely O
resembles O
APC O
in O
overall O
domain O
structure O
, O
was O
functionally O
analyzed O
and O
shown O
to O
contain O
two O
SAMP O
domains O
, O
both O
of O
which O
are O
required O
for O
binding O
to O
conductin O
. O

Like O
APC O
, O
APC2 O
regulates O
the O
formation O
of O
active O
betacatenin O
- O
Tcf O
complexes O
, O
as O
demonstrated O
using O
transient O
transcriptional O
activation O
assays O
in O
APC O
- O
/ O
- O
colon B
carcinoma I
cells O
. O

Human O
APC2 O
maps O
to O
chromosome O
19p13 O
. O

3 O
. O

APC O
and O
APC2 O
may O
therefore O
have O
comparable O
functions O
in O
development O
and O
cancer B
. O

A O
common O
MSH2 O
mutation O
in O
English O
and O
North O
American O
HNPCC B
families O
: O
origin O
, O
phenotypic O
expression O
, O
and O
sex O
specific O
differences O
in O
colorectal B
cancer I
. O

The O
frequency O
, O
origin O
, O
and O
phenotypic O
expression O
of O
a O
germline O
MSH2 O
gene O
mutation O
previously O
identified O
in O
seven O
kindreds O
with O
hereditary B
non I
- I
polyposis I
cancer I
syndrome I
( O
HNPCC B
) O
was O
investigated O
. O

The O
mutation O
( O
A O
- O
- O
> O
T O
at O
nt943 O
+ O
3 O
) O
disrupts O
the O
3 O
splice O
site O
of O
exon O
5 O
leading O
to O
the O
deletion O
of O
this O
exon O
from O
MSH2 O
mRNA O
and O
represents O
the O
only O
frequent O
MSH2 O
mutation O
so O
far O
reported O
. O

Although O
this O
mutation O
was O
initially O
detected O
in O
four O
of O
33 O
colorectal B
cancer I
families O
analysed O
from O
eastern O
England O
, O
more O
extensive O
analysis O
has O
reduced O
the O
frequency O
to O
four O
of O
52 O
( O
8 O
% O
) O
English O
HNPCC B
kindreds O
analysed O
. O

In O
contrast O
, O
the O
MSH2 O
mutation O
was O
identified O
in O
10 O
of O
20 O
( O
50 O
% O
) O
separately O
identified O
colorectal B
families O
from O
Newfoundland O
. O

To O
investigate O
the O
origin O
of O
this O
mutation O
in O
colorectal B
cancer I
families O
from O
England O
( O
n O
= O
4 O
) O
, O
Newfoundland O
( O
n O
= O
10 O
) O
, O
and O
the O
United O
States O
( O
n O
= O
3 O
) O
, O
haplotype O
analysis O
using O
microsatellite O
markers O
linked O
to O
MSH2 O
was O
performed O
. O

Within O
the O
English O
and O
US O
families O
there O
was O
little O
evidence O
for O
a O
recent O
common O
origin O
of O
the O
MSH2 O
splice O
site O
mutation O
in O
most O
families O
. O

In O
contrast O
, O
a O
common O
haplotype O
was O
identified O
at O
the O
two O
flanking O
markers O
( O
CA5 O
and O
D2S288 O
) O
in O
eight O
of O
the O
Newfoundland O
families O
. O

These O
findings O
suggested O
a O
founder O
effect O
within O
Newfoundland O
similar O
to O
that O
reported O
by O
others O
for O
two O
MLH1 O
mutations O
in O
Finnish O
HNPCC B
families O
. O

We O
calculated O
age O
related O
risks O
of O
all O
, O
colorectal B
, I
endometrial I
, I
and I
ovarian I
cancers I
in O
nt943 O
+ O
3 O
A O
- O
- O
> O
T O
MSH2 O
mutation O
carriers O
( O
n O
= O
76 O
) O
for O
all O
patients O
and O
for O
men O
and O
women O
separately O
. O

For O
both O
sexes O
combined O
, O
the O
penetrances O
at O
age O
60 O
years O
for O
all O
cancers B
and O
for O
colorectal B
cancer I
were O
0 O
. O

86 O
and O
0 O
. O

57 O
, O
respectively O
. O

The O
risk O
of O
colorectal B
cancer I
was O
significantly O
higher O
( O
p O
< O
0 O
. O
01 O
) O
in O
males O
than O
females O
( O
0 O
. O
63 O
v O
0 O
. O
30 O
and O
0 O
. O
84 O
v O
0 O
. O
44 O
at O
ages O
50 O
and O
60 O
years O
, O
respectively O
) O
. O

For O
females O
there O
was O
a O
high O
risk O
of O
endometrial B
cancer I
( O
0 O
. O
5 O
at O
age O
60 O
years O
) O
and O
premenopausal B
ovarian I
cancer I
( O
0 O
. O
2 O
at O
50 O
years O
) O
. O

These O
intersex O
differences O
in O
colorectal B
cancer I
risks O
have O
implications O
for O
screening O
programmes O
and O
for O
attempts O
to O
identify O
colorectal B
cancer I
susceptibility O
modifiers O
. O

Age O
of O
onset O
in O
Huntington B
disease I
: O
sex O
specific O
influence O
of O
apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
. O

Age O
of O
onset O
( O
AO O
) O
of O
Huntington B
disease I
( O
HD B
) O
is O
known O
to O
be O
correlated O
with O
the O
length O
of O
an O
expanded O
CAG O
repeat O
in O
the O
HD B
gene O
. O

Apolipoprotein O
E O
( O
APOE O
) O
genotype O
, O
in O
turn O
, O
is O
known O
to O
influence O
AO O
in O
Alzheimer B
disease I
, O
rendering O
the O
APOE O
gene O
a O
likely O
candidate O
to O
affect O
AO O
in O
other O
neurological B
diseases I
too O
. O

We O
therefore O
determined O
APOE O
genotype O
and O
normal O
CAG O
repeat O
length O
in O
the O
HD B
gene O
for O
138 O
HD B
patients O
who O
were O
previously O
analysed O
with O
respect O
to O
CAG O
repeat O
length O
. O

Genotyping O
for O
APOE O
was O
performed O
blind O
to O
clinical O
information O
. O

In O
addition O
to O
highlighting O
the O
effect O
of O
the O
normal O
repeat O
length O
upon O
AO O
in O
maternally O
inherited O
HD B
and O
in O
male O
patients O
, O
we O
show O
that O
the O
APOE O
epsilon2epsilon3 O
genotype O
is O
associated O
with O
significantly O
earlier O
AO O
in O
males O
than O
in O
females O
. O

Such O
a O
sex O
difference O
in O
AO O
was O
not O
apparent O
for O
any O
of O
the O
other O
APOE O
genotypes O
. O

Our O
findings O
suggest O
that O
subtle O
differences O
in O
the O
course O
of O
the O
neurodegeneration B
in O
HD B
may O
allow O
interacting O
genes O
to O
exert O
gender O
specific O
effects O
upon O
AO O
. O

Familial B
deficiency I
of I
the I
seventh I
component I
of I
complement I
associated O
with O
recurrent O
bacteremic B
infections I
due I
to I
Neisseria I
. O

The O
serum O
of O
a O
29 O
- O
year O
old O
woman O
with O
a O
recent O
episode O
of O
disseminated B
gonococcal I
infection I
and O
a O
history O
of O
meningococcal B
meningitis I
and O
arthritis B
as O
a O
child O
was O
found O
to O
lack O
serum O
hemolytic O
complement O
activity O
. O

The O
seventh O
component O
of O
complement O
( O
C7 O
) O
was O
not O
detected O
by O
functional O
or O
immunochemical O
assays O
, O
whereas O
other O
components O
were O
normal O
by O
hemolytic O
and O
immunochemical O
assessment O
. O

Her O
fresh O
serum O
lacked O
complement O
- O
mediated O
bactericidal O
activity O
against O
Neisseria O
gonorrhoeae O
, O
but O
the O
addition O
of O
fresh O
normal O
serum O
or O
purified O
C7 O
restored O
bactericidal O
activity O
as O
well O
as O
hemolytic O
activity O
. O

The O
absence B
of I
functional I
C7 I
activity O
could O
not O
be O
accounted O
for O
on O
the O
basis O
of O
an O
inhibitor O
. O

Opsonization O
and O
generation O
of O
chemotactic O
activity O
functioned O
normally O
. O

Complete B
absence I
of I
C7 I
was O
also O
found O
in O
one O
sibling O
who O
had O
the O
clinical O
syndrome O
of O
meningococcal B
meningitis I
and O
arthritis B
as O
a O
child O
and O
in O
this O
siblings O
clinically O
well O
eight O
- O
year O
- O
old O
son O
. O

HLA O
histocompatibility O
typing O
of O
the O
family O
members O
did O
not O
demonstrate O
evidence O
for O
genetic O
linkage O
of O
C7 B
deficiency I
with O
the O
major O
histocompatibility O
loci O
. O

This O
report O
represents O
the O
first O
cases O
of O
C7 B
deficiency I
associated O
with O
infectious O
complications O
and O
suggests O
that O
bactericidal O
activity O
may O
be O
important O
in O
host O
defense O
against O
bacteremic B
neisseria I
infections I
. O

Increased O
incidence O
of O
cancer B
in O
patients O
with O
cartilage B
- I
hair I
hypoplasia I
. O

OBJECTIVE O
Previous O
reports O
have O
suggested O
an O
increased O
risk O
of O
cancer B
among O
patients O
with O
cartilage B
- I
hair I
hypoplasia I
( O
CHH B
) O
. O

This O
study O
was O
carried O
out O
to O
further O
evaluate O
this O
risk O
among O
patients O
with O
CHH B
and O
their O
first O
- O
degree O
relatives O
. O

STUDY O
DESIGN O
One O
hundred O
twenty O
- O
two O
patients O
with O
CHH B
were O
identified O
through O
2 O
countrywide O
epidemiologic O
surveys O
in O
1974 O
and O
in O
1986 O
. O

Their O
parents O
and O
nonaffected O
siblings O
were O
identified O
through O
the O
Population O
Register O
Center O
. O

This O
cohort O
underwent O
follow O
- O
up O
for O
cancer B
incidence O
through O
the O
Finnish O
Cancer O
Registry O
to O
the O
end O
of O
1995 O
. O

RESULTS O
A O
statistically O
significant O
excess O
risk O
of O
cancer B
was O
seen O
among O
the O
patients O
with O
CHH B
( O
standardized O
incidence O
ratio O
6 O
. O
9 O
, O
95 O
% O
confidence O
interval O
2 O
. O
3 O
to O
16 O
) O
, O
which O
was O
mainly O
attributable O
to O
non B
- I
Hodgkins I
lymphoma I
( O
standardized O
incidence O
ratio O
90 O
, O
95 O
% O
confidence O
interval O
18 O
to O
264 O
) O
. O

In O
addition O
, O
a O
significant O
excess O
risk O
of O
basal B
cell I
carcinoma I
was O
seen O
( O
standardized O
incidence O
ratio O
35 O
, O
95 O
% O
confidence O
interval O
7 O
. O
2 O
to O
102 O
) O
. O

The O
cancer B
incidence O
among O
the O
siblings O
or O
the O
parents O
did O
not O
differ O
from O
the O
average O
cancer B
incidence O
in O
the O
Finnish O
population O
. O

CONCLUSIONS O
This O
study O
confirms O
an O
increased O
risk O
of O
cancer B
, O
especially O
non B
- I
Hodgkins I
lymphoma I
, O
probably O
attributable O
to O
defective O
immunity O
, O
among O
patients O
with O
CHH B
. O

Genotype O
and O
phenotype O
in O
patients O
with O
dihydropyrimidine B
dehydrogenase I
deficiency I
. O

Dihydropyrimidine B
dehydrogenase I
( I
DPD I
) I
deficiency I
is O
an O
autosomal B
recessive I
disease I
characterised O
by O
thymine O
- O
uraciluria O
in O
homozygous O
deficient O
patients O
and O
has O
been O
associated O
with O
a O
variable O
clinical O
phenotype O
. O

In O
order O
to O
understand O
the O
genetic O
and O
phenotypic O
basis O
for O
DPD B
deficiency I
, O
we O
have O
reviewed O
17 O
families O
presenting O
22 O
patients O
with O
complete O
deficiency B
of I
DPD I
. O

In O
this O
group O
of O
patients O
, O
7 O
different O
mutations O
have O
been O
identified O
, O
including O
2 O
deletions O
[ O
295 O
- O
298delTCAT O
, O
1897delC O
] O
, O
1 O
splice O
- O
site O
mutation O
[ O
IVS14 O
+ O
1G O
> O
A O
) O
] O
and O
4 O
missense O
mutations O
( O
85T O
> O
C O
, O
703C O
> O
T O
, O
2658G O
> O
A O
, O
2983G O
> O
T O
) O
. O

Analysis O
of O
the O
prevalence O
of O
the O
various O
mutations O
among O
DPD B
patients O
has O
shown O
that O
the O
G O
- O
- O
> O
A O
point O
mutation O
in O
the O
invariant O
splice O
donor O
site O
is O
by O
far O
the O
most O
common O
( O
52 O
% O
) O
, O
whereas O
the O
other O
six O
mutations O
are O
less O
frequently O
observed O
. O

A O
large O
phenotypic O
variability O
has O
been O
observed O
, O
with O
convulsive B
disorders I
, O
motor B
retardation I
and O
mental B
retardation I
being O
the O
most O
abundant O
manifestations O
. O

A O
clear O
correlation O
between O
the O
genotype O
and O
phenotype O
has O
not O
been O
established O
. O

An O
altered O
beta O
- O
alanine O
, O
uracil O
and O
thymine O
homeostasis O
might O
underlie O
the O
various O
clinical B
abnormalities I
encountered O
in O
patients O
with O
DPD B
deficiency I
. O

Fibroblast O
growth O
factor O
homologous O
factor O
2 O
( O
FHF2 O
) O
: O
gene O
structure O
, O
expression O
and O
mapping O
to O
the O
Borjeson B
- I
Forssman I
- I
Lehmann I
syndrome I
region O
in O
Xq26 O
delineated O
by O
a O
duplication O
breakpoint O
in O
a O
BFLS B
- O
like O
patient O
. O

Borjeson B
- I
Forssman I
- I
Lehmann I
syndrome I
( O
BFLS B
) O
is O
a O
syndromal O
X B
- I
linked I
mental I
retardation I
, O
which O
maps O
by O
linkage O
to O
the O
q26 O
region O
of O
the O
human O
X O
chromosome O
. O

We O
have O
identified O
a O
male O
patient O
with O
BFLS B
- O
like O
features O
and O
a O
duplication O
, O
46 O
, O
Y O
, O
dup O
( O
X O
) O
( O
q26q28 O
) O
, O
inherited O
from O
his O
phenotypically O
normal O
mother O
. O

Fluorescence O
in O
situ O
hybridisation O
using O
yeast O
artificial O
chromosome O
clones O
from O
Xq26 O
localised O
the O
duplication O
breakpoint O
to O
an O
approximately O
400 O
- O
kb O
interval O
in O
the O
Xq26 O
. O

3 O
region O
between O
DXS155 O
and O
DXS294 O
/ O
DXS730 O
. O

Database O
searches O
and O
analysis O
of O
available O
genomic O
DNA O
sequence O
from O
the O
region O
revealed O
the O
presence O
of O
the O
fibroblast O
growth O
factor O
homologous O
factor O
gene O
, O
FHF2 O
, O
within O
the O
duplication O
breakpoint O
interval O
. O

The O
gene O
structure O
of O
FHF2 O
was O
determined O
and O
two O
new O
exons O
were O
identified O
, O
including O
a O
new O
5 O
end O
exon O
, O
1B O
. O

FHF2 O
is O
a O
large O
gene O
extending O
over O
approximately O
200 O
kb O
in O
Xq26 O
. O

3 O
and O
is O
composed O
of O
at O
least O
seven O
exons O
. O

It O
shows O
tissue O
- O
specific O
alternative O
splicing O
and O
alternative O
transcription O
starts O
. O

Northern O
blot O
hybridisation O
showed O
highest O
expression O
in O
brain O
and O
skeletal O
muscle O
. O

The O
FHF2 O
gene O
localisation O
and O
tissue O
- O
specific O
expression O
pattern O
suggest O
it O
to O
be O
a O
candidate O
gene O
for O
familial O
cases O
of O
the O
BFLS B
syndrome I
and O
other O
syndromal O
and O
non O
- O
specific O
forms O
of O
X B
- I
linked I
mental I
retardation I
mapping O
to O
the O
region O
. O

Germline O
E O
- O
cadherin O
gene O
( O
CDH1 O
) O
mutations O
predispose O
to O
familial B
gastric I
cancer I
and O
colorectal B
cancer I
. O

Inherited O
mutations O
in O
the O
E O
- O
cadherin O
gene O
( O
CDH1 O
) O
were O
described O
recently O
in O
three O
Maori O
kindreds O
with O
familial B
gastric I
cancer I
. O

Familial B
gastric I
cancer I
is O
genetically O
heterogeneous O
and O
it O
is O
not O
clear O
what O
proportion O
of O
gastric B
cancer I
susceptibility O
in O
non O
- O
Maori O
populations O
is O
due O
to O
germline O
CDH1 O
mutations O
. O

Therefore O
, O
we O
screened O
eight O
familial B
gastric I
cancer I
kindreds O
of O
British O
and O
Irish O
origin O
for O
germline O
CDH1 O
mutations O
, O
by O
SSCP O
analysis O
of O
all O
16 O
exons O
and O
flanking O
sequences O
. O

Each O
family O
contained O
( O
i O
) O
two O
cases O
of O
gastric B
cancer I
in O
first O
degree O
relatives O
with O
one O
affected O
before O
age O
50 O
years O
; O
or O
( O
ii O
) O
three O
or O
more O
cases O
of O
gastric B
cancer I
. O

Novel O
germline O
CDH1 O
mutations O
( O
a O
nonsense O
and O
a O
splice O
site O
) O
were O
detected O
in O
two O
families O
( O
25 O
% O
) O
. O

Both O
mutations O
were O
predicted O
to O
truncate O
the O
E O
- O
cadherin O
protein O
in O
the O
signal O
peptide O
domain O
. O

In O
one O
family O
there O
was O
evidence O
of O
non O
- O
penetrance O
and O
susceptibility O
to O
both O
gastric B
and I
colorectal I
cancer I
; O
thus O
, O
in O
addition O
to O
six O
cases O
of O
gastric B
cancer I
, O
a O
CDH1 O
mutation O
carrier O
developed O
colorectal B
cancer I
at O
age O
30 O
years O
. O

We O
have O
confirmed O
that O
germline O
mutations O
in O
the O
CDH1 O
gene O
cause O
familial B
gastric I
cancer I
in O
non O
- O
Maori O
populations O
. O

However O
, O
only O
a O
minority O
of O
familial O
gastric B
cancers I
can O
be O
accounted O
for O
by O
CDH1 O
mutations O
. O

Loss O
of O
E O
- O
cadherin O
function O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
sporadic O
colorectal B
and I
other I
cancers I
, O
and O
our O
findings O
provide O
evidence O
that O
germline O
CDH1 O
mutations O
predispose O
to O
early O
onset O
colorectal B
cancer I
. O

Thus O
, O
CDH1 O
should O
be O
investigated O
as O
a O
cause O
of O
inherited O
susceptibility O
to O
both O
gastric B
and I
colorectal I
cancers I
. O

A O
zinc O
finger O
truncation O
of O
murine O
WT1 O
results O
in O
the O
characteristic O
urogenital B
abnormalities I
of O
Denys B
- I
Drash I
syndrome I
. O

The O
Wilms B
tumor I
- O
suppressor O
gene O
, O
WT1 O
, O
plays O
a O
key O
role O
in O
urogenital O
development O
, O
and O
WT1 B
dysfunction I
is O
implicated O
in O
both O
neoplastic B
( O
Wilms B
tumor I
, O
mesothelioma B
, O
leukemias B
, O
and O
breast B
cancer I
) O
and O
nonneoplastic B
( O
glomerulosclerosis B
) O
disease O
. O

The O
analysis O
of O
diseases O
linked O
specifically O
with O
WT1 O
mutations O
, O
such O
as O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
can O
provide O
valuable O
insight O
concerning O
the O
role O
of O
WT1 O
in O
development O
and O
disease O
. O

DDS B
is O
a O
rare O
childhood O
disease O
characterized O
by O
a O
nephropathy B
involving O
mesangial B
sclerosis I
, O
XY O
pseudohermaphroditism B
, O
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

DDS B
patients O
are O
constitutionally O
heterozygous O
for O
exonic O
point O
mutations O
in O
WT1 O
, O
which O
include O
mutations O
predicted O
to O
truncate O
the O
protein O
within O
the O
C O
- O
terminal O
zinc O
finger O
( O
ZF O
) O
region O
. O

We O
report O
that O
heterozygosity O
for O
a O
targeted O
murine O
Wt1 O
allele O
, O
Wt1 O
( O
tmT396 O
) O
, O
which O
truncates O
ZF3 O
at O
codon O
396 O
, O
induces O
mesangial B
sclerosis I
characteristic O
of O
DDS B
in O
adult O
heterozygous O
and O
chimeric O
mice O
. O

Male B
genital I
defects I
also O
were O
evident O
and O
there O
was O
a O
single O
case O
of O
Wilms B
tumor I
in O
which O
the O
transcript O
of O
the O
nontargeted O
allele O
showed O
an O
exon O
9 O
skipping O
event O
, O
implying O
a O
causal O
link O
between O
Wt1 B
dysfunction I
and O
Wilms B
tumorigenesis I
in O
mice O
. O

However O
, O
the O
mutant O
WT1 O
( O
tmT396 O
) O
protein O
accounted O
for O
only O
5 O
% O
of O
WT1 O
in O
both O
heterozygous O
embryonic O
stem O
cells O
and O
the O
WT B
. O

This O
has O
implications O
regarding O
the O
mechanism O
by O
which O
the O
mutant O
allele O
exerts O
its O
effect O
. O

Mechanism O
of O
increased O
iron O
absorption O
in O
murine O
model O
of O
hereditary B
hemochromatosis I
: O
increased O
duodenal O
expression O
of O
the O
iron O
transporter O
DMT1 O
. O

Hereditary B
hemochromatosis I
( O
HH B
) O
is O
a O
common O
autosomal B
recessive I
disorder I
characterized O
by O
tissue O
iron O
deposition O
secondary O
to O
excessive O
dietary O
iron O
absorption O
. O

We O
recently O
reported O
that O
HFE O
, O
the O
protein O
defective O
in O
HH B
, O
was O
physically O
associated O
with O
the O
transferrin O
receptor O
( O
TfR O
) O
in O
duodenal O
crypt O
cells O
and O
proposed O
that O
mutations O
in O
HFE O
attenuate O
the O
uptake O
of O
transferrin O
- O
bound O
iron O
from O
plasma O
by O
duodenal O
crypt O
cells O
, O
leading O
to O
up O
- O
regulation O
of O
transporters O
for O
dietary O
iron O
. O

Here O
, O
we O
tested O
the O
hypothesis O
that O
HFE O
- O
/ O
- O
mice O
have O
increased O
duodenal O
expression O
of O
the O
divalent O
metal O
transporter O
( O
DMT1 O
) O
. O

By O
4 O
weeks O
of O
age O
, O
the O
HFE O
- O
/ O
- O
mice O
demonstrated O
iron O
loading O
when O
compared O
with O
HFE O
+ O
/ O
+ O
littermates O
, O
with O
elevated O
transferrin O
saturations O
( O
68 O
. O
4 O
% O
vs O
. O
49 O
. O
8 O
% O
) O
and O
elevated O
liver O
iron O
concentrations O
( O
985 O
micrograms O
vs O
. O
381 O
micrograms O
) O
. O

By O
using O
Northern O
blot O
analyses O
, O
we O
quantitated O
duodenal O
expression O
of O
both O
classes O
of O
DMT1 O
transcripts O
one O
containing O
an O
iron O
responsive O
element O
( O
IRE O
) O
, O
called O
DMT1 O
( O
IRE O
) O
, O
and O
one O
containing O
no O
IRE O
, O
called O
DMT1 O
( O
non O
- O
IRE O
) O
. O

The O
positive O
control O
for O
DMT1 O
up O
- O
regulation O
was O
a O
murine O
model O
of O
dietary B
iron I
deficiency I
that O
demonstrated O
greatly O
increased O
levels O
of O
duodenal O
DMT1 O
( O
IRE O
) O
mRNA O
. O

HFE O
- O
/ O
- O
mice O
also O
demonstrated O
an O
increase O
in O
duodenal O
DMT1 O
( O
IRE O
) O
mRNA O
( O
average O
7 O
. O
7 O
- O
fold O
) O
, O
despite O
their O
elevated O
transferrin O
saturation O
and O
hepatic O
iron O
content O
. O

Duodenal O
expression O
of O
DMT1 O
( O
non O
- O
IRE O
) O
was O
not O
increased O
, O
nor O
was O
hepatic O
expression O
of O
DMT1 O
increased O
. O

These O
data O
support O
the O
model O
for O
HH O
in O
which O
HFE O
mutations O
lead O
to O
inappropriately O
low O
crypt O
cell O
iron O
, O
with O
resultant O
stabilization O
of O
DMT1 O
( O
IRE O
) O
mRNA O
, O
up O
- O
regulation O
of O
DMT1 O
, O
and O
increased O
absorption O
of O
dietary O
iron O
. O

Neurophysiologic O
follow O
- O
up O
of O
long O
- O
term O
dietary O
treatment O
in O
adult O
- O
onset O
adrenoleukodystrophy B
. O

OBJECTIVE O
To O
monitor O
the O
effects O
of O
dietary O
treatment O
in O
adult O
- O
onset O
adrenoleukodystrophy B
( O
ALD B
) O
by O
means O
of O
somatosensory O
evoked O
potentials O
( O
SEPs O
) O
and O
motor O
evoked O
potentials O
( O
MEPs O
) O
. O

BACKGROUND O
SEPs O
and O
MEPs O
have O
proved O
useful O
in O
revealing O
signs O
of O
progressively O
severe O
, O
central O
dying B
- I
back I
axonopathy I
in O
early O
stages O
of O
adult O
- O
onset O
ALD B
. O

METHODS O
Eight O
patients O
with O
adult O
- O
onset O
ALD B
underwent O
clinical O
examination O
, O
brain O
and O
spine O
MRI O
, O
and O
SEP O
and O
MEP O
studies O
before O
and O
after O
3 O
years O
of O
Lorenzos O
oil O
dietary O
therapy O
. O

RESULTS O
Before O
treatment O
, O
brain O
MRI O
was O
normal O
in O
five O
patients O
. O

Three O
of O
these O
patients O
had O
pure O
spinal B
SEP I
abnormalities I
and O
in O
the O
remaining O
two O
patients O
SEPs O
showed O
signs O
of O
involvement O
of O
both O
the O
spinal O
and O
cerebral O
somatosensory O
tracts O
. O

After O
treatment O
, O
the O
three O
patients O
with O
pure O
spinal B
abnormalities I
showed O
clinical O
and O
neurophysiologic O
worsening O
, O
whereas O
the O
two O
patients O
with O
a O
more O
advanced O
stage O
of O
disease O
( O
exhibited O
by O
SEPs O
) O
showed O
substantially O
unchanged O
clinical O
and O
neurophysiologic O
features O
. O

The O
patients O
with O
abnormal O
brain O
MRI O
at O
the O
onset O
of O
treatment O
showed O
clinical O
and O
neurophysiologic O
worsening O
. O

CONCLUSIONS O
Lorenzos O
oil O
therapy O
had O
no O
effect O
on O
patients O
with O
evidence O
of O
inflammatory B
brain I
lesions I
. O

Moreover O
, O
in O
patients O
without O
clear O
signs O
of O
inflammatory O
damage O
, O
this O
treatment O
does O
not O
modify O
significantly O
the O
natural O
course O
of O
the O
disease O
. O

However O
, O
because O
effective O
treatments O
should O
begin O
before O
the O
onset O
of O
severe O
neurologic O
symptoms O
, O
SEPs O
and O
MEPs O
should O
be O
considered O
to O
evaluate O
the O
effectiveness O
of O
other O
experimental O
treatments O
in O
the O
patient O
with O
a O
negative O
brain O
MRI O
. O

GCH1 O
mutation O
in O
a O
patient O
with O
adult O
- O
onset O
oromandibular B
dystonia I
. O

The O
authors O
report O
a O
mutation O
in O
exon O
5 O
of O
GCH1 O
in O
a O
patient O
with O
adult O
- O
onset O
oromandibular B
dystonia I
and O
no O
obvious O
family O
history O
of O
dystonia B
. O

The O
patient O
responded O
positively O
to O
treatment O
with O
L O
- O
dopa O
. O

These O
findings O
demonstrate O
that O
GCH1 O
mutations O
must O
be O
considered O
even O
in O
patients O
with O
dystonic B
symptoms O
not O
typical O
of O
dopa B
- I
responsive I
dystonia I
. O

Germline O
mutations O
of O
the O
APC B
gene O
in O
Korean O
familial B
adenomatous I
polyposis I
patients O
. O

We O
extensively O
analyzed O
genomic O
DNA O
and O
messenger O
RNA O
( O
mRNA O
) O
from O
62 O
unrelated O
Korean O
patients O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
for O
identification O
of O
germline O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O

We O
adopted O
both O
single O
- O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
analysis O
and O
a O
method O
of O
analysis O
involving O
the O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
followed O
by O
a O
protein O
truncation O
test O
( O
PTT O
) O
. O

DNA O
sequencing O
confirmed O
all O
alterations O
represented O
by O
aberrant O
bands O
. O

Germline O
mutations O
were O
identified O
in O
38 O
patients O
( O
61 O
% O
) O
. O

Nineteen O
of O
the O
detected O
mutations O
were O
presumed O
to O
be O
novel O
, O
thus O
emphasizing O
the O
heterogeneity O
of O
the O
mutational O
spectrum O
in O
Korean O
FAP B
patients O
. O

In O
the O
initial O
48 O
patients O
, O
SSCP O
analysis O
was O
followed O
by O
PTT O
for O
those O
patients O
for O
whom O
no O
detectable O
mutations O
were O
found O
by O
SSCP O
. O

Using O
this O
combined O
approach O
, O
we O
identified O
germline O
APC B
gene O
mutations O
in O
29 O
of O
the O
48 O
FAP B
patients O
( O
60 O
% O
) O
, O
including O
6 O
patients O
in O
whom O
SSCP O
analysis O
failed O
to O
distinguish O
the O
mutant O
allele O
. O

In O
the O
14 O
later O
patients O
, O
we O
identified O
truncating O
mutations O
in O
9 O
patients O
( O
64 O
% O
) O
using O
PTT O
only O
. O

Our O
results O
confirm O
that O
the O
mutation O
detection O
rate O
with O
PTT O
was O
superior O
to O
that O
with O
SSCP O
, O
and O
suggest O
that O
PTT O
would O
be O
a O
more O
practical O
screening O
method O
to O
detect O
germline O
mutations O
of O
the O
APC B
gene O
in O
FAP B
patients O
. O

Molecular O
epidemiology O
of O
C9 B
deficiency I
heterozygotes O
with O
an O
Arg95Stop O
mutation O
of O
the O
C9 O
gene O
in O
Japan O
. O

Deficiency B
of I
the I
ninth I
component I
of I
human I
complement I
( O
C9 O
) O
is O
the O
most O
common O
complement B
deficiency I
in O
Japan O
, O
with O
an O
incidence O
of O
approximately O
one O
homozygote O
in O
1000 O
, O
but O
is O
very O
rare O
in O
other O
countries O
. O

Genetic O
analyses O
of O
Japanese O
C9 B
deficiency I
have O
shown O
that O
a O
C O
- O
to O
- O
T O
transition O
leading O
to O
TGA O
stop O
codon O
for O
Arg95 O
in O
exon O
4 O
of O
the O
C9 O
gene O
( O
Arg95Stop O
) O
is O
common O
in O
Japanese O
C9 B
deficiency I
. O

To O
determine O
the O
prevalence O
of O
heterozygous O
carriers O
of O
the O
Arg95Stop O
mutation O
in O
a O
Japanese O
population O
, O
we O
collected O
DNA O
samples O
from O
300 O
individuals O
in O
two O
of O
the O
four O
main O
islands O
of O
Japan O
. O

Heterozygote O
detection O
was O
performed O
with O
an O
allele O
- O
specific O
polymerase O
chain O
reaction O
( O
PCR O
) O
system O
designed O
to O
detect O
exclusively O
only O
one O
of O
the O
normal O
and O
mutant O
alleles O
, O
followed O
by O
confirmation O
with O
PCR O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
analysis O
and O
direct O
sequencing O
. O

Twenty O
individuals O
were O
heterozygous O
for O
the O
Arg95Stop O
mutation O
. O

None O
was O
homozygous O
. O

The O
prevalence O
of O
carriers O
of O
the O
Arg95Stop O
mutation O
was O
6 O
. O

7 O
% O
( O
20 O
/ O
300 O
) O
. O

An O
estimated O
frequency O
( O
0 O
. O
12 O
% O
) O
of O
complete O
C9 B
deficiency I
due O
to O
homozygous O
Arg95Stop O
mutation O
was O
consistent O
with O
frequencies O
determined O
by O
serological O
studies O

The O
hereditary B
hemochromatosis I
protein O
, O
HFE O
, O
specifically O
regulates O
transferrin O
- O
mediated O
iron O
uptake O
in O
HeLa O
cells O
. O

HFE O
is O
the O
protein O
product O
of O
the O
gene O
mutated O
in O
the O
autosomal B
recessive I
disease I
hereditary B
hemochromatosis I
( O
Feder O
, O
J O
. O

N O
. O
, O
Gnirke O
, O
A O
. O
, O
Thomas O
, O
W O
. O
, O
Tsuchihashi O
, O
Z O
. O
, O
Ruddy O
, O
D O
. O

A O
. O
, O
Basava O
, O
A O
. O
, O
Dormishian O
, O
F O
. O
, O
Domingo O
, O
R O
. O

J O
. O
, O
Ellis O
, O
M O
. O

C O
. O
, O
Fullan O
, O
A O
. O
, O
Hinton O
, O
L O
. O

M O
. O
, O
Jones O
, O
N O
. O

L O
. O
, O
Kimmel O
, O
B O
. O

E O
. O
, O
Kronmal O
, O
G O
. O

S O
. O
, O
Lauer O
, O
P O
. O
, O
Lee O
, O
V O
. O

K O
. O
, O
Loeb O
, O
D O
. O

B O
. O
, O
Mapa O
, O
F O
. O

A O
. O
, O
McClelland O
, O
E O
. O
, O
Meyer O
, O
N O
. O

C O
. O
, O
Mintier O
, O
G O
. O

A O
. O
, O
Moeller O
, O
N O
. O
, O
Moore O
, O
T O
. O
, O
Morikang O
, O
E O
. O
, O
Prasss O
, O
C O
. O

E O
. O
, O
Quintana O
, O
L O
. O
, O
Starnes O
, O
S O
. O

M O
. O
, O
Schatzman O
, O
R O
. O

C O
. O
, O
Brunke O
, O
K O
. O

J O
. O
, O
Drayna O
, O
D O
. O

T O
. O
, O
Risch O
, O
N O
. O

J O
. O
, O
Bacon O
, O
B O
. O

R O
. O
, O
and O
Wolff O
, O
R O
. O

R O
. O

( O
1996 O
) O
Nat O
. O

Genet O
. O

13 O
, O
399 O
- O
408 O
) O
. O

At O
the O
cell O
surface O
, O
HFE O
complexes O
with O
transferrin O
receptor O
( O
TfR O
) O
, O
increasing O
the O
dissociation O
constant O
of O
transferrin O
( O
Tf O
) O
for O
its O
receptor O
10 O
- O
fold O
( O
Gross O
, O
C O
. O

N O
. O
, O
Irrinki O
, O
A O
. O
, O
Feder O
, O
J O
. O
N O
. O
, O
and O
Enns O
, O
C O
. O
A O
. O
( O
1998 O
) O
J O
. O
Biol O
. O
Chem O
. O
273 O
, O
22068 O
- O
22074 O
; O
Feder O
, O
J O
. O
N O
. O
, O
Penny O
, O
D O
. O
M O
. O
, O
Irrinki O
, O
A O
. O
, O
Lee O
, O
V O
. O
K O
. O
, O
Lebron O
, O
J O
. O
A O
. O
, O
Watson O
, O
N O
. O
, O
Tsuchihashi O
, O
Z O
. O
, O
Sigal O
, O
E O
. O
, O
Bjorkman O
, O
P O
. O
J O
. O
, O
and O
Schatzman O
, O
R O
. O
C O
. O

( O
1998 O
) O
Proc O
. O
Natl O
. O

Acad O
. O

Sci O
. O

U O
S O
A O
95 O
, O
1472 O
- O
1477 O
) O
. O

HFE O
does O
not O
remain O
at O
the O
cell O
surface O
, O
but O
traffics O
with O
TfR O
to O
Tf O
- O
positive O
internal O
compartments O
( O
Gross O
et O
al O
. O
, O
1998 O
) O
. O

Using O
a O
HeLa O
cell O
line O
in O
which O
the O
expression O
of O
HFE O
is O
controlled O
by O
tetracycline O
, O
we O
show O
that O
the O
expression O
of O
HFE O
reduces O
55Fe O
uptake O
from O
Tf O
by O
33 O
% O
but O
does O
not O
affect O
the O
endocytic O
or O
exocytic O
rates O
of O
TfR O
cycling O
. O

Therefore O
, O
HFE O
appears O
to O
reduce O
cellular O
acquisition O
of O
iron O
from O
Tf O
within O
endocytic O
compartments O
. O

HFE O
specifically O
reduces O
iron O
uptake O
from O
Tf O
, O
as O
non O
- O
Tf O
- O
mediated O
iron O
uptake O
from O
Fe O
- O
nitrilotriacetic O
acid O
is O
not O
altered O
. O

These O
results O
explain O
the O
decreased O
ferritin O
levels O
seen O
in O
our O
HeLa O
cell O
system O
and O
demonstrate O
the O
specific O
control O
of O
HFE O
over O
the O
Tf O
- O
mediated O
pathway O
of O
iron O
uptake O
. O

These O
results O
also O
have O
implications O
for O
the O
understanding O
of O
cellular O
iron O
homeostasis O
in O
organs O
such O
as O
the O
liver O
, O
pancreas O
, O
heart O
, O
and O
spleen O
that O
are O
iron O
loaded O
in O
hereditary B
hemochromatotic I
individuals O
lacking O
functional O
HFE O
. O

Mutation O
and O
haplotype O
studies O
of O
familial B
Mediterranean I
fever I
reveal O
new O
ancestral O
relationships O
and O
evidence O
for O
a O
high O
carrier O
frequency O
with O
reduced O
penetrance O
in O
the O
Ashkenazi O
Jewish O
population O
. O

Familial B
Mediterranean I
fever I
( O
FMF B
) O
is O
a O
recessive B
disorder I
characterized O
by O
episodes O
of O
fever O
with O
serositis B
or O
synovitis B
. O

The O
FMF B
gene O
( O
MEFV O
) O
was O
cloned O
recently O
, O
and O
four O
missense O
mutations O
were O
identified O
. O

Here O
we O
present O
data O
from O
non O
- O
Ashkenazi O
Jewish O
and O
Arab O
patients O
in O
whom O
we O
had O
not O
originally O
found O
mutations O
and O
from O
a O
new O
, O
more O
ethnically O
diverse O
panel O
. O

Among O
90 O
symptomatic O
mutation O
- O
positive O
individuals O
, O
11 O
mutations O
accounted O
for O
79 O
% O
of O
carrier O
chromosomes O
. O

Of O
the O
two O
mutations O
that O
are O
novel O
, O
one O
alters O
the O
same O
residue O
( O
680 O
) O
as O
a O
previously O
known O
mutation O
, O
and O
the O
other O
( O
P369S O
) O
is O
located O
in O
exon O
3 O
. O

Consistent O
with O
another O
recent O
report O
, O
the O
E148Q O
mutation O
was O
observed O
in O
patients O
of O
several O
ethnicities O
and O
on O
multiple O
microsatellite O
haplotypes O
, O
but O
haplotype O
data O
indicate O
an O
ancestral O
relationships O
between O
non O
- O
Jewish O
Italian O
and O
Ashkenazi O
Jewish O
patients O
with O
FMF B
and O
other O
affected O
populations O
. O

Among O
approximately O
200 O
anonymous O
Ashkenazi O
Jewish O
DNA O
samples O
, O
the O
MEFV O
carrier O
frequency O
was O
21 O
% O
, O
with O
E148Q O
the O
most O
common O
mutation O
. O

Several O
lines O
of O
evidence O
indicate O
reduced O
penetrance O
among O
Ashkenazi O
Jews O
, O
especially O
for O
E148Q O
, O
P369S O
, O
and O
K695R O
. O

Nevertheless O
, O
E148Q O
helps O
account O
for O
recessive O
inheritance O
in O
an O
Ashkenazi O
family O
previously O
reported O
as O
an O
unusual O
case O
of O
dominantly O
inherited O
FMF B
. O

The O
presence O
of O
three O
frequent O
MEFV O
mutations O
in O
multiple O
Mediterranean O
populations O
strongly O
suggests O
a O
heterozygote O
advantage O
in O
this O
geographic O
region O
. O

Autoimmune B
lymphoproliferative I
syndrome I
with O
defective O
Fas O
: O
genotype O
influences O
penetrance O
. O

Autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
is O
a O
disorder B
of I
lymphocyte I
homeostasis I
and I
immunological I
tolerance I
. O

Most O
patients O
have O
a O
heterozygous O
mutation O
in O
the O
APT1 O
gene O
, O
which O
encodes O
Fas O
( O
CD95 O
, O
APO O
- O
1 O
) O
, O
mediator O
of O
an O
apoptotic O
pathway O
crucial O
to O
lymphocyte O
homeostasis O
. O

Of O
17 O
unique O
APT1 O
mutations O
in O
unrelated O
ALPS B
probands O
, O
12 O
( O
71 O
% O
) O
occurred O
in O
exons O
7 O
- O
9 O
, O
which O
encode O
the O
intracellular O
portion O
of O
Fas O
. O

In O
vitro O
, O
activated O
lymphocytes O
from O
all O
17 O
patients O
showed O
apoptotic O
defects O
when O
exposed O
to O
an O
anti O
- O
Fas O
agonist O
monoclonal O
antibody O
. O

Similar O
defects O
were O
found O
in O
a O
Fas O
- O
negative O
cell O
line O
transfected O
with O
cDNAs O
bearing O
each O
of O
the O
mutations O
. O

In O
cotransfection O
experiments O
, O
Fas O
constructs O
with O
either O
intra O
- O
or O
extracellular O
mutations O
caused O
dominant O
inhibition O
of O
apoptosis O
mediated O
by O
wild O
- O
type O
Fas O
. O

Two O
missense O
Fas O
variants O
, O
not O
restricted O
to O
patients O
with O
ALPS B
, O
were O
identified O
. O

Variant O
A O
( O
- O
1 O
) O
T O
at O
the O
Fas O
signal O
- O
sequence O
cleavage O
site O
, O
which O
mediates O
apoptosis O
less O
well O
than O
wild O
- O
type O
Fas O
and O
is O
partially O
inhibitory O
, O
was O
present O
in O
13 O
% O
of O
African O
American O
alleles O
. O

Among O
the O
ALPS B
- O
associated O
Fas O
mutants O
, O
dominant O
inhibition O
of O
apoptosis O
was O
much O
more O
pronounced O
in O
mutants O
affecting O
the O
intracellular O
, O
versus O
extracellular O
, O
portion O
of O
the O
Fas O
receptor O
. O

Mutations O
causing O
disruption O
of O
the O
intracellular O
Fas O
death O
domain O
also O
showed O
a O
higher O
penetrance O
of O
ALPS B
phenotype O
features O
in O
mutation O
- O
bearing O
relatives O
. O

Significant O
ALPS B
- O
related O
morbidity O
occurred O
in O
44 O
% O
of O
relatives O
with O
intracellular O
mutations O
, O
versus O
0 O
% O
of O
relatives O
with O
extracellular O
mutations O
. O

Thus O
, O
the O
location O
of O
mutations O
within O
APT1 O
strongly O
influences O
the O
development O
and O
the O
severity O
of O
ALPS B
. O

Multicentric O
origin O
of O
hemochromatosis B
gene O
( O
HFE O
) O
mutations O
. O

Genetic B
hemochromatosis I
( O
GH B
) O
is O
believed O
to O
be O
a O
disease O
restricted O
to O
those O
of O
European O
ancestry O
. O

In O
northwestern O
Europe O
, O
> O
80 O
% O
of O
GH B
patients O
are O
homozygous O
for O
one O
mutation O
, O
the O
substitution O
of O
tyrosine O
for O
cysteine O
at O
position O
282 O
( O
C282Y O
) O
in O
the O
unprocessed O
protein O
. O

In O
a O
proportion O
of O
GH B
patients O
, O
two O
mutations O
are O
present O
, O
C282Y O
and O
H63D O
. O

The O
clinical O
significance O
of O
this O
second O
mutation O
is O
such O
that O
it O
appears O
to O
predispose O
1 O
% O
- O
2 O
% O
of O
compound O
heterozygotes O
to O
expression O
of O
the O
disease O
. O

The O
distribution O
of O
the O
two O
mutations O
differ O
, O
C282Y O
being O
limited O
to O
those O
of O
northwestern O
European O
ancestry O
and O
H63D O
being O
found O
at O
allele O
frequencies O
> O
5 O
% O
, O
in O
Europe O
, O
in O
countries O
bordering O
the O
Mediterranean O
, O
in O
the O
Middle O
East O
, O
and O
in O
the O
Indian O
subcontinent O
. O

The O
C282Y O
mutation O
occurs O
on O
a O
haplotype O
that O
extends O
< O
/ O
= O
6 O
Mb O
, O
suggesting O
that O
this O
mutation O
has O
arisen O
during O
the O
past O
2 O
, O
000 O
years O
. O

The O
H63D O
mutation O
is O
older O
and O
does O
not O
occur O
on O
such O
a O
large O
extended O
haplotype O
, O
the O
haplotype O
in O
this O
case O
extending O
< O
/ O
= O
700 O
kb O
. O

Here O
we O
report O
the O
finding O
of O
the O
H63D O
and O
C282Y O
mutations O
on O
new O
haplotypes O
. O

In O
Sri O
Lanka O
we O
have O
found O
H63D O
on O
three O
new O
haplotypes O
and O
have O
found O
C282Y O
on O
one O
new O
haplotype O
, O
demonstrating O
that O
these O
mutations O
have O
arisen O
independently O
on O
this O
island O
. O

These O
results O
suggest O
that O
the O
HFE O
gene O
has O
been O
the O
subject O
of O
selection O
pressure O
. O

These O
selection O
pressures O
could O
be O
due O
to O
infectious B
diseases I
, O
environmental O
conditions O
, O
or O
other O
genetic B
disorders I
such O
as O
anemia B
. O

A O
retrospective O
anonymous O
pilot O
study O
in O
screening O
newborns O
for O
HFE O
mutations O
in O
Scandinavian O
populations O
. O

We O
have O
retrospectively O
analyzed O
837 O
random O
anonymized O
dried O
blood O
spot O
( O
DBS O
) O
samples O
from O
neonatal O
screening O
programs O
in O
Scandinavia O
for O
mutations O
in O
HFE O
, O
the O
candidate O
gene O
for O
hemochromatosis B
. O

We O
have O
found O
C282Y O
allele O
frequencies O
of O
2 O
. O

3 O
% O
( O
+ O
2 O
. O
0 O
% O
) O
( O
- O
1 O
. O
3 O
% O
) O
in O
Greenland O
, O
4 O
. O

5 O
% O
+ O
/ O
- O
1 O
. O

9 O
% O
in O
Iceland O
, O
5 O
. O

1 O
% O
+ O
/ O
- O
2 O
. O

3 O
% O
in O
the O
Faeroe O
Islands O
, O
and O
8 O
. O

2 O
% O
+ O
/ O
- O
2 O
. O

7 O
% O
in O
Denmark O
. O

The O
high O
prevalence O
of O
HFE O
mutations O
in O
Denmark O
suggests O
that O
population O
screening O
for O
the O
C282Y O
mutation O
could O
be O
highly O
advantageous O
in O
terms O
of O
preventive O
health O
care O
. O

Long O
- O
term O
follow O
- O
up O
evaluation O
of O
C282Y O
homozygotes O
and O
H63D O
/ O
C282Y O
compound O
heterozygotes O
will O
give O
an O
indication O
of O
the O
penetrance O
of O
the O
mutations O
. O

Identification O
of O
the O
mutation O
in O
the O
alkaptonuria B
mouse O
model O
. O

Alkaptonuria B
( O
aku B
) O
, O
an O
inborn B
error I
of I
metabolism I
caused O
by O
the O
loss O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGD O
) O
, O
has O
been O
described O
in O
a O
mouse O
model O
created O
by O
ethylnitrosourea O
mutagenesis O
but O
the O
mutation O
in O
these O
mice O
has O
not O
previously O
been O
identified O
. O

We O
used O
RT O
- O
PCR O
to O
amplify O
the O
Hgd O
cDNA O
from O
Hgd O
( O
aku O
) O
/ O
Hgd O
( O
aku O
) O
mice O
. O

Two O
products O
shorter O
than O
the O
wild O
- O
type O
product O
were O
amplified O
. O

Restriction O
mapping O
and O
DNA O
sequencing O
were O
then O
used O
to O
identify O
the O
Hgd O
( O
aku O
) O
mouse O
mutation O
, O
found O
to O
be O
a O
single O
base O
change O
in O
a O
splice O
donor O
consensus O
sequence O
, O
causing O
exon O
skipping O
and O
frame O
- O
shifted O
products O
. O

This O
base O
change O
allowed O
us O
to O
create O
a O
non O
- O
radioactive O
genotyping O
assay O
for O
this O
allele O
. O

Non B
- I
syndromic I
hearing I
loss I
associated O
with O
enlarged B
vestibular I
aqueduct I
is O
caused O
by O
PDS B
mutations O
. O

Enlarged B
vestibular I
aqueduct I
( O
EVA B
) O
, O
known O
as O
the O
most O
common O
form O
of O
inner B
ear I
abnormality I
, O
has O
recently O
been O
of O
particular O
genetic O
interest O
because O
this O
anomaly O
is O
inherited O
in O
a O
recessive O
manner O
. O

The O
locus O
for O
non B
- I
syndromic I
sensorineural I
hearing I
loss I
with O
EVA B
has O
been O
mapped O
to O
the O
same O
chromosomal O
region O
, O
7q31 O
, O
as O
the O
Pendred B
syndrome I
locus O
. O

In O
the O
present O
study O
, O
seven O
mutations O
in O
the O
PDS B
gene O
( O
PDS O
) O
, O
the O
gene O
responsible O
for O
Pendred B
syndrome I
, O
have O
been O
found O
in O
families O
of O
non B
- I
syndromic I
sensorineural I
hearing I
loss I
with O
EVA B
. O

One O
family O
is O
homozygous O
, O
three O
families O
are O
compound O
heterozygotes O
, O
and O
two O
families O
are O
heterozygous O
but O
with O
no O
other O
mutation O
detected O
. O

The O
present O
results O
provide O
evidence O
that O
mutations O
in O
PDS O
cause O
both O
syndromic B
and I
non I
- I
syndromic I
hearing I
loss I
. O
. O

Mutational O
analysis O
and O
genotype O
- O
phenotype O
correlation O
of O
29 O
unrelated O
Japanese O
patients O
with O
X B
- I
linked I
adrenoleukodystrophy I
. O

BACKGROUND O
X B
- I
linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
an O
inherited B
disease I
characterized O
by O
progressive O
neurologic B
dysfunction I
, O
occasionally O
associated O
with O
adrenal B
insufficiency I
. O

The O
classic O
form O
of O
ALD B
usually O
has O
onset O
in O
childhood O
( O
childhood B
cerebral I
ALD I
) O
, O
with O
rapid O
neurologic B
deterioration I
leading O
to O
a O
vegetative O
state O
. O

Adult O
- O
onset O
cerebral B
ALD I
also O
presents O
with O
rapidly O
progressive O
neurologic B
dysfunction I
. O

Milder O
phenotypes O
such O
as O
adrenomyeloneuropathy B
and O
Addison B
disease I
only O
also O
have O
been O
recognized O
. O

Despite O
discovery O
of O
the O
causative O
gene O
, O
a O
molecular O
basis O
for O
the O
diverse O
clinical O
presentations O
remains O
to O
be O
elucidated O
. O

OBJECTIVES O
To O
conduct O
mutational O
analyses O
in O
29 O
Japanese O
patients O
with O
ALD B
from O
29 O
unrelated O
families O
, O
to O
obtain O
knowledge O
of O
the O
spectrum O
of O
mutations O
in O
this O
gene O
, O
and O
to O
study O
genotype O
- O
phenotype O
correlations O
in O
Japanese O
patients O
. O

METHODS O
The O
29 O
patients O
comprised O
13 O
patients O
with O
childhood B
cerebral I
ALD I
, O
11 O
patients O
with O
adult O
- O
onset O
cerebral B
ALD I
, O
and O
5 O
patients O
with O
adrenomyeloneuropathy B
. O

We O
conducted O
detailed O
mutational O
analyses O
of O
29 O
unrelated O
Japanese O
patients O
with O
ALD B
by O
genomic O
Southern O
blot O
analysis O
and O
direct O
nucleotide O
sequence O
analysis O
of O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
products O
derived O
from O
total O
RNA O
that O
was O
extracted O
from O
cultured O
skin O
fibroblasts O
, O
lymphoblastoid O
cells O
, O
or O
peripheral O
blood O
leukocytes O
. O

RESULTS O
Three O
patients O
with O
adult O
- O
onset O
cerebral B
ALD I
were O
identified O
as O
having O
large O
genomic O
rearrangements O
. O

The O
remaining O
26 O
patients O
were O
identified O
as O
having O
21 O
independent O
mutations O
, O
including O
12 O
novel O
mutations O
resulting O
in O
small O
nucleotide O
alterations O
in O
the O
ALD B
gene O
. O

Eighteen O
( O
69 O
% O
) O
of O
26 O
mutations O
were O
missense O
mutations O
. O

Most O
missense O
mutations O
involved O
amino O
acids O
conserved O
in O
homologous O
gene O
products O
, O
including O
PMP70 O
, O
mALDRP O
, O
and O
Pxa1p O
. O

The O
AG O
dinucleotide O
deletion O
at O
position O
1081 O
- O
1082 O
, O
which O
has O
been O
reported O
previously O
to O
be O
the O
most O
common O
mutation O
in O
white O
patients O
( O
12 O
% O
- O
17 O
% O
) O
, O
was O
also O
identified O
as O
the O
most O
common O
mutation O
in O
Japanese O
patients O
( O
12 O
% O
) O
. O

All O
phenotypes O
were O
associated O
with O
mutations O
resulting O
in O
protein O
truncation O
or O
subtle O
amino O
acid O
changes O
. O

There O
were O
no O
differences O
in O
phenotypic O
expressions O
between O
missense O
mutations O
involving O
conserved O
amino O
acids O
and O
those O
involving O
nonconserved O
amino O
acids O
. O

CONCLUSIONS O
There O
are O
no O
obvious O
correlations O
between O
the O
phenotypes O
of O
patients O
with O
ALD B
and O
their O
genotypes O
, O
suggesting O
that O
other O
genetic O
or O
environmental O
factors O
modify O
the O
phenotypic O
expressions O
of O
ALD B
. O
. O

A O
common O
human O
skin B
tumour I
is O
caused O
by O
activating O
mutations O
in O
beta O
- O
catenin O
. O

WNT O
signalling O
orchestrates O
a O
number O
of O
developmental O
programs O
. O

In O
response O
to O
this O
stimulus O
, O
cytoplasmic O
beta O
- O
catenin O
( O
encoded O
by O
CTNNB1 O
) O
is O
stabilized O
, O
enabling O
downstream O
transcriptional O
activation O
by O
members O
of O
the O
LEF O
/ O
TCF O
family O
. O

One O
of O
the O
target O
genes O
for O
beta O
- O
catenin O
/ O
TCF O
encodes O
c O
- O
MYC O
, O
explaining O
why O
constitutive O
activation O
of O
the O
WNT O
pathway O
can O
lead O
to O
cancer B
, O
particularly O
in O
the O
colon O
. O

Most O
colon B
cancers I
arise O
from O
mutations O
in O
the O
gene O
encoding O
adenomatous B
polyposis I
coli I
( O
APC B
) O
, O
a O
protein O
required O
for O
ubiquitin O
- O
mediated O
degradation O
of O
beta O
- O
catenin O
, O
but O
a O
small O
percentage O
of O
colon B
and I
some I
other I
cancers I
harbour O
beta O
- O
catenin O
- O
stabilizing O
mutations O
. O

Recently O
, O
we O
discovered O
that O
transgenic O
mice O
expressing O
an O
activated O
beta O
- O
catenin O
are O
predisposed O
to O
developing O
skin B
tumours I
resembling O
pilomatricomas B
. O

Given O
that O
the O
skin O
of O
these O
adult O
mice O
also O
exhibits O
signs O
of O
de O
novo O
hair O
- O
follicle O
morphogenesis O
, O
we O
wondered O
whether O
human O
pilomatricomas B
might O
originate O
from O
hair O
matrix O
cells O
and O
whether O
they O
might O
possess O
beta O
- O
catenin O
- O
stabilizing O
mutations O
. O

Here O
, O
we O
explore O
the O
cell O
origin O
and O
aetiology O
of O
this O
common O
human O
skin B
tumour I
. O

We O
found O
nuclear O
LEF O
- O
1 O
in O
the O
dividing O
tumour B
cells O
, O
providing O
biochemical O
evidence O
that O
pilomatricomas B
are O
derived O
from O
hair O
matrix O
cells O
. O

At O
least O
75 O
% O
of O
these O
tumours B
possess O
mutations O
affecting O
the O
amino O
- O
terminal O
segment O
, O
normally O
involved O
in O
phosphorylation O
- O
dependent O
, O
ubiquitin O
- O
mediated O
degradation O
of O
the O
protein O
. O

This O
percentage O
of O
CTNNB1 O
mutations O
is O
greater O
than O
in O
all O
other O
human O
tumours B
examined O
thus O
far O
, O
and O
directly O
implicates O
beta O
- O
catenin O
/ O
LEF O
misregulation O
as O
the O
major O
cause O
of O
hair O
matrix O
cell O
tumorigenesis O
in O
humans O
. O
. O

The O
Pendred B
syndrome I
gene O
encodes O
a O
chloride O
- O
iodide O
transport O
protein O
. O

Pendred B
syndrome I
is O
the O
most O
common O
form O
of O
syndromic B
deafness I
and O
characterized O
by O
congenital O
sensorineural B
hearing I
loss I
and O
goitre B
. O

This O
disorder O
was O
mapped O
to O
chromosome O
7 O
and O
the O
gene O
causing O
Pendred B
syndrome I
( O
PDS B
) O
was O
subsequently O
identified O
by O
positional O
cloning O
. O

PDS O
encodes O
a O
putative O
transmembrane O
protein O
designated O
pendrin O
. O

Pendrin O
is O
closely O
related O
to O
a O
family O
of O
sulfate O
transport O
proteins O
that O
includes O
the O
rat O
sulfate O
- O
anion O
transporter O
( O
encoded O
by O
Sat O
- O
1 O
; O
29 O
% O
amino O
acid O
sequence O
identity O
) O
, O
the O
human O
diastrophic B
dysplasia I
sulfate O
transporter O
( O
encoded O
by O
DTD O
; O
32 O
% O
) O
and O
the O
human O
sulfate O
transporter O
downregulated O
in O
adenoma B
( O
encoded O
by O
DRA O
; O
45 O
% O
) O
. O

On O
the O
basis O
of O
this O
homology O
and O
the O
presence O
of O
a O
slightly O
modified O
sulfate O
- O
transporter O
signature O
sequence O
comprising O
its O
putative O
second O
transmembrane O
domain O
, O
pendrin O
has O
been O
proposed O
to O
function O
as O
a O
sulfate O
transporter O
. O

We O
were O
unable O
to O
detect O
evidence O
of O
sulfate O
transport O
following O
the O
expression O
of O
pendrin O
in O
Xenopus O
laevis O
oocytes O
by O
microinjection O
of O
PDS O
cRNA O
or O
in O
Sf9 O
cells O
following O
infection O
with O
PDS O
- O
recombinant O
baculovirus O
. O

The O
rates O
of O
transport O
for O
iodide O
and O
chloride O
were O
significantly O
increased O
following O
the O
expression O
of O
pendrin O
in O
both O
cell O
systems O
. O

Our O
results O
demonstrate O
that O
pendrin O
functions O
as O
a O
transporter O
of O
chloride O
and O
iodide O
, O
but O
not O
sulfate O
, O
and O
may O
provide O
insight O
into O
thyroid O
physiology O
and O
the O
pathophysiology O
of O
Pendred B
syndrome I
. O
. O

HFE O
mutations O
analysis O
in O
711 O
hemochromatosis B
probands O
: O
evidence O
for O
S65C O
implication O
in O
mild O
form O
of O
hemochromatosis B
. O

Hereditary B
hemochromatosis I
( O
HH B
) O
is O
a O
common O
autosomal B
recessive I
genetic I
disorder I
of O
iron O
metabolism O
. O

The O
HFE O
candidate O
gene O
encoding O
an O
HLA O
class O
I O
- O
like O
protein O
involved O
in O
HH B
was O
identified O
in O
1996 O
. O

Two O
missense O
mutations O
have O
been O
described O
C282Y O
, O
accounting O
for O
80 O
% O
to O
90 O
% O
of O
HH B
chromosomes O
, O
and O
H63D O
, O
which O
is O
associated O
with O
a O
milder O
form O
of O
the O
disease O
representing O
40 O
% O
to O
70 O
% O
of O
non O
- O
C282Y O
HH B
chromosomes O
. O

We O
report O
here O
on O
the O
analysis O
of O
C282Y O
, O
H63D O
, O
and O
the O
193A O
- O
- O
> O
T O
substitution O
leading O
to O
the O
S65C O
missense O
substitution O
in O
a O
large O
series O
of O
probands O
and O
controls O
. O

The O
results O
confirm O
that O
the O
C282Y O
substitution O
was O
the O
main O
mutation O
involved O
in O
hemochromatosis B
, O
accounting O
for O
85 O
% O
of O
carrier O
chromosomes O
, O
whereas O
the O
H63D O
substitution O
represented O
39 O
% O
of O
the O
HH B
chromosomes O
that O
did O
not O
carry O
the O
C282Y O
mutation O
. O

In O
addition O
, O
our O
screening O
showed O
that O
the O
S65C O
substitution O
was O
significantly O
enriched O
in O
probands O
with O
at O
least O
one O
chromosome O
without O
an O
assigned O
mutation O
. O

This O
substitution O
accounted O
for O
7 O
. O

8 O
% O
of O
HH B
chromosomes O
that O
were O
neither O
C282Y O
nor O
H63D O
. O

This O
enrichment O
of O
S65C O
among O
HH B
chromosomes O
suggests O
that O
the O
S65C O
substitution O
is O
associated O
with O
the O
mild O
form O
of O
hemochromatosis B
. O

Germline O
BRCA1 O
alterations O
in O
a O
population O
- O
based O
series O
of O
ovarian B
cancer I
cases O
. O

The O
objective O
of O
this O
study O
was O
to O
provide O
more O
accurate O
frequency O
estimates O
of O
breast B
cancer I
susceptibility O
gene O
1 O
( O
BRCA1 O
) O
germline O
alterations O
in O
the O
ovarian B
cancer I
population O
. O

To O
achieve O
this O
, O
we O
determined O
the O
prevalence O
of O
BRCA1 O
alterations O
in O
a O
population O
- O
based O
series O
of O
consecutive O
ovarian B
cancer I
cases O
. O

This O
is O
the O
first O
population O
- O
based O
ovarian B
cancer I
study O
reporting O
BRCA1 O
alterations O
derived O
from O
a O
comprehensive O
screen O
of O
the O
entire O
coding O
region O
. O

One O
hundred O
and O
seven O
ovarian B
cancer I
cases O
were O
analyzed O
for O
BRCA1 O
alterations O
using O
the O
RNase O
mismatch O
cleavage O
assay O
followed O
by O
direct O
sequencing O
. O

Two O
truncating O
mutations O
, O
962del4 O
and O
3600del11 O
, O
were O
identified O
. O

Both O
patients O
had O
a O
family O
history O
of O
breast B
or I
ovarian I
cancer I
. O

Several O
novel O
as O
well O
as O
previously O
reported O
uncharacterized O
variants O
were O
also O
identified O
, O
some O
of O
which O
were O
associated O
with O
a O
family O
history O
of O
cancer B
. O

The O
frequency O
distribution O
of O
common O
polymorphisms O
was O
determined O
in O
the O
91 O
Caucasian O
cancer B
cases O
in O
this O
series O
and O
24 O
sister O
controls O
using O
allele O
- O
specific O
amplification O
. O

The O
rare O
form O
of O
the O
Q356R O
polymorphism O
was O
significantly O
( O
P O
= O
0 O
. O
03 O
) O
associated O
with O
a O
family O
history O
of O
ovarian B
cancer I
, O
suggesting O
that O
this O
polymorphism O
may O
influence O
ovarian B
cancer I
risk O
. O

In O
summary O
, O
our O
data O
suggest O
a O
role O
for O
some O
uncharacterized O
variants O
and O
rare O
forms O
of O
polymorphisms O
in O
determining O
ovarian B
cancer I
risk O
, O
and O
highlight O
the O
necessity O
to O
screen O
for O
missense O
alterations O
as O
well O
as O
truncating O
mutations O
in O
this O
population O
. O

Adrenoleukodystrophy O
- O
related O
protein O
can O
compensate O
functionally O
for O
adrenoleukodystrophy B
protein I
deficiency I
( O
X B
- I
ALD I
) O
: O
implications O
for O
therapy O
. O

Inherited B
defects I
in O
the O
peroxisomal O
ATP O
- O
binding O
cassette O
( O
ABC O
) O
transporter O
adrenoleukodystrophy B
protein O
( O
ALDP O
) O
lead O
to O
the O
lethal O
peroxisomal B
disorder I
X B
- I
linked I
adrenoleukodystrophy I
( O
X B
- I
ALD I
) O
, O
for O
which O
no O
efficient O
treatment O
has O
been O
established O
so O
far O
. O

Three O
other O
peroxisomal O
ABC O
transporters O
currently O
are O
known O
adrenoleukodystrophy O
- O
related O
protein O
( O
ALDRP O
) O
, O
70 O
kDa O
peroxisomal O
membrane O
protein O
( O
PMP70 O
) O
and O
PMP70 O
- O
related O
protein O
. O

By O
using O
transient O
and O
stable O
overexpression O
of O
human O
cDNAs O
encoding O
ALDP O
and O
its O
closest O
relative O
ALDRP O
, O
we O
could O
restore O
the O
impaired O
peroxisomal O
beta O
- O
oxidation O
in O
fibroblasts O
of O
X B
- I
ALD I
patients O
. O

The O
pathognomonic O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
could O
also O
be O
prevented O
by O
overexpression O
of O
ALDRP O
in O
immortalized O
X O
- O
ALD O
cells O
. O

Immunofluorescence O
analysis O
demonstrated O
that O
the O
functional O
replacement O
of O
ALDP O
by O
ALDRP O
was O
not O
due O
to O
stabilization O
of O
the O
mutated O
ALDP O
itself O
. O

Moreover O
, O
we O
were O
able O
to O
restore O
the O
peroxisomal O
beta O
- O
oxidation O
defect O
in O
the O
liver O
of O
ALDP O
- O
deficient O
mice O
by O
stimulation O
of O
ALDRP O
and O
PMP70 O
gene O
expression O
through O
a O
dietary O
treatment O
with O
the O
peroxisome O
proliferator O
fenofibrate O
. O

These O
results O
suggest O
that O
a O
correction O
of O
the O
biochemical O
defect O
in O
X B
- I
ALD I
could O
be O
possible O
by O
drug O
- O
induced O
overexpression O
or O
ectopic O
expression O
of O
ALDRP O
. O
. O

Centrosome O
amplification O
and O
a O
defective O
G2 O
- O
M O
cell O
cycle O
checkpoint O
induce O
genetic O
instability O
in O
BRCA1 O
exon O
11 O
isoform O
- O
deficient O
cells O
. O

Germline O
mutations O
of O
the O
Brca1 O
tumor B
suppressor O
gene O
predispose O
women O
to O
breast B
and I
ovarian I
cancers I
. O

To O
study O
mechanisms O
underlying O
BRCA1 O
- O
related O
tumorigenesis O
, O
we O
derived O
mouse O
embryonic O
fibroblast O
cells O
carrying O
a O
targeted O
deletion O
of O
exon O
11 O
of O
the O
Brca1 O
gene O
. O

We O
show O
that O
the O
mutant O
cells O
maintain O
an O
intact O
G1 O
- O
S O
cell O
cycle O
checkpoint O
and O
proliferate O
poorly O
. O

However O
, O
a O
defective O
G2 O
- O
M O
checkpoint O
in O
these O
cells O
is O
accompanied O
by O
extensive O
chromosomal B
abnormalities I
. O

Mutant O
fibroblasts O
contain O
multiple O
, O
functional O
centrosomes O
, O
which O
lead O
to O
unequal O
chromosome O
segregation O
, O
abnormal O
nuclear O
division O
, O
and O
aneuploidy B
. O

These O
data O
uncover O
an O
essential O
role O
of O
BRCA1 O
in O
maintaining O
genetic O
stability O
through O
the O
regulation O
of O
centrosome O
duplication O
and O
the O
G2 O
- O
M O
checkpoint O
and O
provide O
a O
molecular O
basis O
for O
the O
role O
of O
BRCA1 O
in O
tumorigenesis O
. O
. O

Defective O
CD95 O
/ O
APO O
- O
1 O
/ O
Fas O
signal O
complex O
formation O
in O
the O
human O
autoimmune B
lymphoproliferative I
syndrome I
, I
type I
Ia I
. O

Heterozygous O
mutations O
in O
the O
CD95 O
( O
APO O
- O
1 O
/ O
Fas O
) O
receptor O
occur O
in O
most O
individuals O
with O
autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
and O
dominantly O
interfere O
with O
apoptosis O
by O
an O
unknown O
mechanism O
. O

We O
show O
that O
local O
or O
global O
alterations O
in O
the O
structure O
of O
the O
cytoplasmic O
death O
domain O
from O
nine O
independent O
ALPS B
CD95 O
death O
- O
domain O
mutations O
result O
in O
a O
failure O
to O
bind O
the O
FADD O
/ O
MORT1 O
signaling O
protein O
. O

Despite O
heterozygosity O
for O
the O
abnormal O
allele O
, O
lymphocytes O
from O
ALPS B
patients O
showed O
markedly O
decreased O
FADD O
association O
and O
a O
loss O
of O
caspase O
recruitment O
and O
activation O
after O
CD95 O
crosslinking O
. O

These O
data O
suggest O
that O
intracytoplasmic O
CD95 O
mutations O
in O
ALPS B
impair O
apoptosis O
chiefly O
by O
disrupting O
death O
- O
domain O
interactions O
with O
the O
signaling O
protein O
FADD O
/ O
MORT1 O
. O
. O

Analysis O
of O
alkaptonuria B
( O
AKU B
) O
mutations O
and O
polymorphisms O
reveals O
that O
the O
CCC O
sequence O
motif O
is O
a O
mutational O
hot O
spot O
in O
the O
homogentisate O
1 O
, O
2 O
dioxygenase O
gene O
( O
HGO O
) O
. O

We O
recently O
showed O
that O
alkaptonuria B
( O
AKU B
) O
is O
caused O
by O
loss O
- O
of O
- O
function O
mutations O
in O
the O
homogentisate O
1 O
, O
2 O
dioxygenase O
gene O
( O
HGO O
) O
. O

Herein O
we O
describe O
haplotype O
and O
mutational O
analyses O
of O
HGO O
in O
seven O
new O
AKU B
pedigrees O
. O

These O
analyses O
identified O
two O
novel O
single O
- O
nucleotide O
polymorphisms O
( O
INV4 O
+ O
31A O
- O
- O
> O
G O
and O
INV11 O
+ O
18A O
- O
- O
> O
G O
) O
and O
six O
novel O
AKU B
mutations O
( O
INV1 O
- O
1G O
- O
- O
> O
A O
, O
W60G O
, O
Y62C O
, O
A122D O
, O
P230T O
, O
and O
D291E O
) O
, O
which O
further O
illustrates O
the O
remarkable O
allelic O
heterogeneity O
found O
in O
AKU B
. O

Reexamination O
of O
all O
29 O
mutations O
and O
polymorphisms O
thus O
far O
described O
in O
HGO O
shows O
that O
these O
nucleotide O
changes O
are O
not O
randomly O
distributed O
; O
the O
CCC O
sequence O
motif O
and O
its O
inverted O
complement O
, O
GGG O
, O
are O
preferentially O
mutated O
. O

These O
analyses O
also O
demonstrated O
that O
the O
nucleotide O
substitutions O
in O
HGO O
do O
not O
involve O
CpG O
dinucleotides O
, O
which O
illustrates O
important O
differences O
between O
HGO O
and O
other O
genes O
for O
the O
occurrence O
of O
mutation O
at O
specific O
short O
- O
sequence O
motifs O
. O

Because O
the O
CCC O
sequence O
motifs O
comprise O
a O
significant O
proportion O
( O
34 O
. O
5 O
% O
) O
of O
all O
mutated O
bases O
that O
have O
been O
observed O
in O
HGO O
, O
we O
conclude O
that O
the O
CCC O
triplet O
is O
a O
mutational O
hot O
spot O
in O
HGO O
. O

Fabry B
disease I
: O
identification O
of O
novel O
alpha O
- O
galactosidase O
A O
mutations O
and O
molecular O
carrier O
detection O
by O
use O
of O
fluorescent O
chemical O
cleavage O
of O
mismatches O
. O

Fabry B
disease I
( O
FD B
) O
( O
angiokeratoma B
corporis I
diffusum I
) O
is O
an O
X B
- I
linked I
inborn I
error I
of I
glycosphingolipid I
metabolism I
caused O
by O
defects O
in O
the O
lysosomal O
alpha O
- O
galactosidase O
A O
gene O
( O
GLA O
) O
. O

The O
enzymatic O
defect O
leads O
to O
the O
systemic O
accumulation O
of O
neutral O
glycosphingolipids O
with O
terminal O
alpha O
- O
galactosyl O
moieties O
. O

Clinically O
, O
affected O
hemizygous O
males O
have O
angiokeratoma B
, O
severe B
acroparesthesia I
, O
renal B
failure I
, O
and O
vasculopathy B
of I
the I
heart I
and I
brain I
. O

While O
demonstration O
of O
alpha B
- I
galactosidase I
deficiency I
in O
leukocytes O
is O
diagnostic O
in O
affected O
males O
, O
enzymatic O
detection O
of O
female O
carriers O
is O
often O
inconclusive O
, O
due O
to O
random O
X O
- O
chromosomal O
inactivation O
, O
underlining O
the O
need O
of O
molecular O
investigations O
for O
accurate O
genetic O
counseling O
. O

By O
use O
of O
chemical O
cleavage O
of O
mismatches O
adapted O
to O
fluorescence O
- O
based O
detection O
systems O
, O
we O
have O
characterized O
the O
mutations O
underlying O
alpha B
- I
Gal I
A I
deficiency I
in O
16 O
individuals O
from O
six O
unrelated O
families O
with O
FD B
. O

The O
mutational O
spectrum O
included O
five O
missense O
mutations O
( O
C202W O
, O
C223G O
, O
N224D O
, O
R301Q O
, O
and O
Q327K O
) O
and O
one O
splice O
- O
site O
mutation O
[ O
IVS3 O
G O
( O
- O
1 O
) O
- O
- O
> O
C O
] O
. O

Studies O
at O
the O
mRNA O
level O
showed O
that O
the O
latter O
led O
to O
altered O
pre O
- O
mRNA O
splicing O
with O
consequent O
alteration O
of O
the O
mRNA O
translational O
reading O
frame O
and O
generation O
of O
a O
premature O
termination O
codon O
of O
translation O
. O

By O
use O
of O
this O
strategy O
, O
carrier O
status O
was O
accurately O
assessed O
in O
all O
seven O
at O
- O
risk O
females O
tested O
, O
whereas O
enzymatic O
dosages O
failed O
to O
diagnose O
or O
exclude O
heterozygosity O
. O
. O

Prenatal O
diagnosis O
by O
FISH O
in O
a O
family O
with O
Pelizaeus B
- I
Merzbacher I
disease I
caused O
by O
duplication O
of O
PLP O
gene O
. O

A O
diagnosis O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
MIM O
312080 O
) O
was O
made O
in O
a O
young O
boy O
. O

No O
mutation O
in O
the O
coding O
region O
of O
the O
proteolipid O
protein O
( O
PLP O
) O
gene O
had O
been O
found O
. O

The O
boys O
maternal O
aunt O
came O
for O
prenatal O
diagnosis O
when O
16 O
+ O
weeks O
pregnant O
and O
carrying O
a O
male O
fetus O
. O

Samples O
were O
tested O
for O
duplication O
of O
the O
PLP O
gene O
, O
by O
interphase O
FISH O
, O
in O
lymphocyte O
preparations O
from O
the O
proband O
, O
his O
aunt O
and O
an O
amniotic O
fluid O
cell O
preparation O
from O
the O
fetus O
. O

The O
proband O
was O
found O
to O
carry O
the O
duplication O
, O
thus O
confirming O
the O
diagnosis O
of O
Pelizaeus B
Merzbacher I
disease I
, O
but O
neither O
the O
aunt O
nor O
the O
fetus O
carried O
a O
duplication O
. O
. O

Dominant O
negative O
effect O
of O
the O
APC1309 O
mutation O
: O
a O
possible O
explanation O
for O
genotype O
- O
phenotype O
correlations O
in O
familial B
adenomatous I
polyposis I
. O

Inactivation O
of O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
product O
initiates O
colorectal O
tumorigenesis O
. O

Patients O
with O
familial B
APC I
( O
FAP B
) O
carry O
germ O
- O
line O
mutations O
in O
the O
APC B
gene O
and O
develop O
multiple O
colorectal B
adenomas I
and O
subsequent O
carcinomas B
early O
in O
life O
. O

The O
severity O
of O
the O
disease O
correlates O
with O
the O
position O
of O
the O
inherited O
APC B
mutation O
( O
genotype O
- O
phenotype O
correlation O
) O
. O

Together O
with O
the O
fact O
that O
both O
germ O
- O
line O
and O
sporadic O
APC B
mutations O
cluster O
in O
the O
central O
region O
of O
the O
APC B
gene O
, O
this O
points O
to O
a O
dominant O
negative O
effect O
of O
certain O
APC B
mutants O
. O

Loss O
of O
APC B
function O
was O
recently O
shown O
to O
result O
in O
enhanced O
beta O
- O
catenin O
- O
/ O
Tcf O
- O
mediated O
transcription O
in O
colon O
epithelial O
cells O
. O

Here O
, O
we O
provide O
experimental O
evidence O
for O
a O
dominant O
negative O
effect O
of O
APC B
gene O
products O
associated O
with O
severe O
polyposis B
. O

Wild O
- O
type O
APC B
activity O
in O
beta O
- O
catenin O
- O
/ O
Tcf O
- O
mediated O
transcription O
was O
strongly O
inhibited O
by O
a O
mutant O
APC B
that O
is O
truncated O
at O
codon O
1309 O
. O

In O
contrast O
, O
mutant O
APC B
gene O
products O
that O
are O
associated O
with O
attenuated B
polyposis I
( O
codon O
386 O
or O
1465 O
) O
interfered O
only O
weakly O
with O
wild O
- O
type O
APC B
activity O
. O

These O
results O
suggest O
a O
molecular O
explanation O
for O
the O
genotype O
- O
phenotype O
correlation O
in O
FAP B
patients O
and O
support O
the O
idea O
that O
colorectal B
tumor I
growth O
might O
be O
, O
in O
part O
, O
driven O
by O
selection O
for O
a O
mutation O
in O
the O
mutation O
cluster O
region O
. O
. O

BRCA1 O
interacts O
with O
components O
of O
the O
histone O
deacetylase O
complex O
. O

Germ O
- O
line O
mutations O
in O
the O
BRCA1 O
tumor O
- O
suppressor O
gene O
are O
associated O
with O
an O
increased O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
. O

BRCA1 O
contains O
a O
carboxyl O
- O
terminal O
domain O
( O
BRCT O
) O
that O
is O
shared O
with O
several O
other O
proteins O
involved O
in O
maintaining O
genome O
integrity O
. O

In O
an O
effort O
to O
understand O
the O
function O
of O
BRCA1 O
, O
we O
sought O
to O
isolate O
proteins O
that O
interact O
with O
the O
BRCT O
domain O
. O

Purified O
BRCT O
polypeptide O
was O
used O
as O
a O
probe O
to O
screen O
a O
human O
placenta O
cDNA O
expression O
library O
by O
Far O
Western O
analysis O
. O

Here O
we O
report O
that O
BRCA1 O
interacts O
in O
vivo O
and O
in O
vitro O
with O
the O
Rb O
- O
binding O
proteins O
, O
RbAp46 O
and O
RbAp48 O
, O
as O
well O
as O
with O
Rb O
. O

Moreover O
, O
the O
BRCT O
domain O
associates O
with O
the O
histone O
deacetylases O
HDAC1 O
and O
HDAC2 O
. O

These O
results O
demonstrate O
that O
BRCA1 O
interacts O
with O
components O
of O
the O
histone O
deacetylase O
complex O
, O
and O
therefore O
may O
explain O
the O
involvement O
of O
BRCA1 O
in O
multiple O
processes O
such O
as O
transcription O
, O
DNA O
repair O
, O
and O
recombination O
. O
. O

Combined B
genetic I
deficiency I
of I
C6 I
and I
C7 I
in O
man O
. O

By O
routine O
screening O
of O
sera O
, O
a O
subject O
was O
discovered O
who O
showed O
a O
sub B
- I
total I
deficiency I
of I
C6 I
and I
C7 I
. O

No O
clinical O
disease O
was O
associated O
with O
this O
deficiency O
which O
was O
transmitted O
through O
the O
subjects O
family O
as O
a O
single O
genetic O
characteristic O
, O
the O
C6 B
deficiency I
being O
associated O
with O
a O
silent O
allele O
at O
the O
structural O
locus O
. O

The O
propositus O
was O
found O
to O
have O
low O
quantities O
of O
an O
abnormal O
C6 O
which O
was O
both O
antigenically O
deficient O
and O
smaller O
in O
size O
than O
normal O
C6 O
( O
110 O
, O
000 O
daltons O
compared O
with O
140 O
, O
000 O
daltons O
) O
and O
small O
quantities O
of O
apparently O
normal O
C7 O
. O

It O
is O
concluded O
that O
the O
most O
likely O
explanation O
for O
this O
defect O
is O
that O
the O
subject O
has O
a O
structural O
mutation O
in O
his O
C6 O
gene O
which O
produces O
hyopsynthesis O
not O
only O
of O
C6 O
but O
also O
of O
the O
closely O
linked O
gene O
for O
C7 O
. O

These O
findings O
suggest O
the O
possibility O
that O
C6 O
and O
C7 O
may O
function O
as O
a O
single O
genetic O
unit O
and O
that O
the O
primary O
transcript O
copied O
from O
the O
genome O
includes O
information O
for O
both O
proteins O
. O
. O

Changes O
at O
P183 O
of O
emerin O
weaken O
its O
protein O
- O
protein O
interactions O
resulting O
in O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
. O

Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
is O
an O
X B
- I
linked I
recessive I
muscular I
dystrophy I
characterized O
by O
early O
contractures B
of I
the I
elbows I
, I
Achilles I
tendons I
and I
spine I
, O
slowly O
progressive O
muscle B
wasting I
and O
weakness B
, O
and O
cardiomyopathy B
associated O
with O
cardiac B
conduction I
defects I
. O

The O
emerin O
gene O
has O
been O
mapped O
to O
Xq28 O
and O
encodes O
a O
34 O
- O
kDa O
serine O
- O
rich O
protein O
, O
emerin O
, O
which O
has O
been O
localized O
to O
the O
nuclear O
envelope O
in O
a O
wide O
variety O
of O
tissues O
, O
including O
skeletal O
and O
cardiac O
muscle O
. O

Mutations O
spanning O
the O
emerin O
gene O
have O
been O
identified O
in O
patients O
with O
EDMD B
. O

We O
present O
here O
the O
effect O
, O
on O
emerin O
protein O
expression O
, O
of O
two O
missense O
mutations O
identified O
in O
unrelated O
EDMD B
patients O
. O

These O
alterations O
predict O
the O
replacement O
of O
a O
proline O
residue O
at O
position O
183 O
with O
either O
a O
histidine O
or O
a O
threonine O
. O

Biochemical O
analysis O
has O
demonstrated O
that O
the O
mobility O
and O
expression O
levels O
of O
the O
mutant O
forms O
of O
emerin O
are O
indistinguishable O
from O
that O
of O
wild O
- O
type O
emerin O
, O
but O
that O
they O
have O
weakened O
interactions O
with O
nuclear O
lamina O
components O
. O

In O
comparison O
with O
the O
usual O
EDMD B
phenotype O
, O
patients O
with O
P183 O
missense O
mutations O
have O
a O
later O
age O
at O
onset O
of O
first O
symptoms O
, O
elbow B
contractures I
, O
ankle B
contractures I
, O
upper B
limb I
weakness I
and O
lower B
limb I
weakness I
, O
but O
there O
is O
no O
difference O
for O
the O
age O
at O
onset O
of O
cardiac B
involvement I
. O

This O
is O
the O
first O
report O
of O
protein O
studies O
on O
patients O
with O
missense O
mutations O
resulting O
in O
the O
clinical O
features O
of O
EDMD B
. O

These O
studies O
demonstrate O
the O
importance O
of O
proline O
183 O
for O
the O
proper O
structure O
/ O
function O
of O
emerin O
. O
. O

Microdeletions O
at O
chromosome O
bands O
1q32 O
- O
q41 O
as O
a O
cause O
of O
Van B
der I
Woude I
syndrome I
. O

Van B
der I
Woude I
syndrome I
( O
VWS B
) O
is O
an O
autosomal B
dominant I
disorder I
comprising O
cleft B
lip I
and O
/ O
or O
cleft B
palate I
and O
lip B
pits I
. O

We O
reported O
previously O
a O
family O
whose O
underlying O
mutation O
is O
a O
500 O
- O
800 O
kb O
deletion O
localized O
to O
chromosome O
bands O
1q32 O
- O
q41 O
[ O
Sander O
et O
al O
. O
, O
1994 O
Hum O
Mol O
Genet O
3 O
576 O
- O
578 O
] O
. O

Along O
with O
cleft B
lip I
/ I
palate I
and O
lip B
pits I
, O
affected O
relatives O
exhibit O
developmental B
delays I
, O
suggesting O
that O
the O
function O
of O
a O
gene O
nearby O
may O
also O
be O
disrupted O
. O

To O
further O
localize O
the O
VWS B
gene O
we O
searched O
for O
other O
deletions O
that O
cause O
VWS B
. O

An O
allele O
loss O
assay O
was O
performed O
using O
a O
novel O
highly O
polymorphic O
marker O
, O
D1S3753 O
. O

From O
a O
panel O
of O
37 O
unrelated O
individuals O
, O
we O
detected O
an O
allele O
loss O
in O
one O
family O
, O
indicating O
the O
presence O
of O
a O
deletion O
. O

In O
this O
family O
, O
the O
phenotype O
in O
three O
generations O
of O
affected O
individuals O
was O
confined O
to O
the O
cardinal O
signs O
of O
VWS B
. O

Surprisingly O
, O
mapping O
of O
the O
new O
deletion O
showed O
that O
it O
extended O
0 O
. O

2 O
- O
1 O
Mb O
beyond O
the O
proximal O
breakpoint O
for O
the O
deletion O
described O
previously O
. O

No O
deletions O
were O
detected O
in O
seven O
cases O
of O
popliteal B
pterygia I
syndrome I
, O
76 O
cases O
of O
mixed O
syndromic B
forms I
of I
cleft I
lip I
and I
palate I
, O
and O
178 O
cases O
of O
nonsyndromic B
cleft I
lip I
and I
palate I
. O

Splicing O
defects O
in O
the O
ataxia B
- I
telangiectasia I
gene O
, O
ATM O
: O
underlying O
mutations O
and O
consequences O
. O

Mutations O
resulting O
in O
defective O
splicing O
constitute O
a O
significant O
proportion O
( O
30 O
/ O
62 O
[ O
48 O
% O
] O
) O
of O
a O
new O
series O
of O
mutations O
in O
the O
ATM O
gene O
in O
patients O
with O
ataxia B
- I
telangiectasia I
( O
AT B
) O
that O
were O
detected O
by O
the O
protein O
- O
truncation O
assay O
followed O
by O
sequence O
analysis O
of O
genomic O
DNA O
. O

Fewer O
than O
half O
of O
the O
splicing O
mutations O
involved O
the O
canonical O
AG O
splice O
- O
acceptor O
site O
or O
GT O
splice O
- O
donor O
site O
. O

A O
higher O
percentage O
of O
mutations O
occurred O
at O
less O
stringently O
conserved O
sites O
, O
including O
silent O
mutations O
of O
the O
last O
nucleotide O
of O
exons O
, O
mutations O
in O
nucleotides O
other O
than O
the O
conserved O
AG O
and O
GT O
in O
the O
consensus O
splice O
sites O
, O
and O
creation O
of O
splice O
- O
acceptor O
or O
splice O
- O
donor O
sites O
in O
either O
introns O
or O
exons O
. O

These O
splicing O
mutations O
led O
to O
a O
variety O
of O
consequences O
, O
including O
exon O
skipping O
and O
, O
to O
a O
lesser O
degree O
, O
intron O
retention O
, O
activation O
of O
cryptic O
splice O
sites O
, O
or O
creation O
of O
new O
splice O
sites O
. O

In O
addition O
, O
5 O
of O
12 O
nonsense O
mutations O
and O
1 O
missense O
mutation O
were O
associated O
with O
deletion O
in O
the O
cDNA O
of O
the O
exons O
in O
which O
the O
mutations O
occurred O
. O

No O
ATM O
protein O
was O
detected O
by O
western O
blotting O
in O
any O
AT B
cell O
line O
in O
which O
splicing O
mutations O
were O
identified O
. O

Several O
cases O
of O
exon O
skipping O
in O
both O
normal O
controls O
and O
patients O
for O
whom O
no O
underlying O
defect O
could O
be O
found O
in O
genomic O
DNA O
were O
also O
observed O
, O
suggesting O
caution O
in O
the O
interpretation O
of O
exon O
deletions O
observed O
in O
ATM O
cDNA O
when O
there O
is O
no O
accompanying O
identification O
of O
genomic O
mutations O
. O
. O

Alpha O
- O
cardiac O
actin O
is O
a O
novel O
disease O
gene O
in O
familial B
hypertrophic I
cardiomyopathy I
. O

We O
identified O
the O
alpha O
- O
cardiac O
actin O
gene O
( O
ACTC O
) O
as O
a O
novel O
disease O
gene O
in O
a O
pedigree O
suffering O
from O
familial B
hypertrophic I
cardiomyopathy I
( O
FHC B
) O
. O

Linkage O
analyses O
excluded O
all O
the O
previously O
reported O
FHC B
loci O
as O
possible O
disease O
loci O
in O
the O
family O
studied O
, O
with O
lod O
scores O
varying O
between O
- O
2 O
. O

5 O
and O
- O
6 O
. O

0 O
0 O
. O

Further O
linkage O
analyses O
of O
plausible O
candidate O
genes O
highly O
expressed O
in O
the O
adult O
human O
heart O
identified O
ACTC O
as O
the O
most O
likely O
disease O
gene O
, O
showing O
a O
maximal O
lod O
score O
of O
3 O
. O

6 O
6 O
. O

Mutation O
analysis O
of O
ACTC O
revealed O
an O
Ala295Ser O
mutation O
in O
exon O
5 O
close O
to O
2 O
missense O
mutations O
recently O
described O
to O
cause O
the O
inherited O
form O
of O
idiopathic B
dilated I
cardiomyopathy I
( O
IDC B
) O
. O

Overgrowth B
of I
oral I
mucosa I
and I
facial I
skin I
, O
a O
novel O
feature O
of O
aspartylglucosaminuria B
. O

Aspartylglucosaminuria B
( O
AGU B
) O
is O
a O
lysosomal B
storage I
disorder I
caused O
by O
deficiency B
of I
aspartylglucosaminidase I
( O
AGA O
) O
. O

The O
main O
symptom O
is O
progressive O
mental B
retardation I
. O

A O
spectrum O
of O
different O
mutations O
has O
been O
reported O
in O
this O
disease O
, O
one O
missense O
mutation O
( O
Cys163Ser O
) O
being O
responsible O
for O
the O
majority O
of O
Finnish O
cases O
. O

We O
were O
able O
to O
examine O
66 O
Finnish O
AGU B
patients O
for O
changes O
in O
the O
oral O
mucosa O
and O
44 O
of O
these O
for O
changes O
in O
facial O
skin O
. O

Biopsy O
specimens O
of O
16 O
oral O
lesions O
, O
12 O
of O
them O
associated O
with O
the O
teeth O
, O
plus O
two O
facial B
lesions I
were O
studied O
histologically O
. O

Immunohistochemical O
staining O
for O
AGA O
was O
performed O
on O
15 O
oral O
specimens O
. O

Skin O
was O
seborrhoeic O
in O
adolescent O
and O
adult O
patients O
, O
with O
erythema B
of I
the I
facial I
skin I
already O
common O
in O
childhood O
. O

Of O
44 O
patients O
, O
nine O
( O
20 O
% O
) O
had O
facial B
angiofibromas I
, O
tumours B
primarily O
occurring O
in O
association O
with O
tuberous B
sclerosis I
. O

Oedemic B
buccal I
mucosa I
( O
leucoedema B
) O
and O
gingival B
overgrowths I
were O
more O
frequent O
in O
AGU B
patients O
than O
in O
controls O
( O
p O
< O
0 O
. O
001 O
) O
. O

Of O
16 O
oral B
mucosal I
lesions I
studied O
histologically O
, O
15 O
represented O
fibroepithelial B
or I
epithelial I
hyperplasias I
and O
were O
reactive O
in O
nature O
. O

Cytoplasmic O
vacuolisation O
was O
evident O
in O
four O
. O

Immunohistochemically O
, O
expression O
of O
AGA O
in O
AGU B
patients O
mucosal B
lesions I
did O
not O
differ O
from O
that O
seen O
in O
corresponding O
lesions O
of O
normal O
subjects O
. O

Thus O
, O
the O
high O
frequency O
of O
mucosal B
overgrowth I
in O
AGU B
patients O
does O
not O
appear O
to O
be O
directly O
associated O
with O
lysosomal O
storage O
or O
with O
alterations O
in O
the O
level O
of O
AGA O
expression O
. O

Characterization O
of O
a O
germline O
mosaicism O
in O
families O
with O
Lowe B
syndrome I
, O
and O
identification O
of O
seven O
novel O
mutations O
in O
the O
OCRL1 O
gene O
. O

The O
oculocerebrorenal B
syndrome I
of I
Lowe I
( O
OCRL B
) O
is O
an O
X B
- I
linked I
disorder I
characterized O
by O
major O
abnormalities B
of I
eyes I
, I
nervous I
system I
, I
and I
kidneys I
. O

Mutations O
in O
the O
OCRL1 O
gene O
have O
been O
associated O
with O
the O
disease O
. O

OCRL1 O
encodes O
a O
phosphatidylinositol O
4 O
, O
5 O
- O
biphosphate O
( O
PtdIns O
[ O
4 O
, O
5 O
] O
P2 O
) O
5 O
- O
phosphatase O
. O

We O
have O
examined O
the O
OCRL1 O
gene O
in O
eight O
unrelated O
patients O
with O
OCRL B
and O
have O
found O
seven O
new O
mutations O
and O
one O
recurrent O
in O
- O
frame O
deletion O
. O

Among O
the O
new O
mutations O
, O
two O
nonsense O
mutations O
( O
R317X O
and O
E558X O
) O
and O
three O
other O
frameshift O
mutations O
caused O
premature O
termination O
of O
the O
protein O
. O

A O
missense O
mutation O
, O
R483G O
, O
was O
located O
in O
the O
highly O
conserved O
PtdIns O
( O
4 O
, O
5 O
) O
P2 O
5 O
- O
phosphatase O
domain O
. O

Finally O
, O
one O
frameshift O
mutation O
, O
2799delC O
, O
modifies O
the O
C O
- O
terminal O
part O
of O
OCRL1 O
, O
with O
an O
extension O
of O
six O
amino O
acids O
. O

Altogether O
, O
70 O
% O
of O
missense O
mutations O
are O
located O
in O
exon O
15 O
, O
and O
52 O
% O
of O
all O
mutations O
cluster O
in O
exons O
11 O
- O
15 O
. O

We O
also O
identified O
two O
new O
microsatellite O
markers O
for O
the O
OCRL1 O
locus O
, O
and O
we O
detected O
a O
germline O
mosaicism O
in O
one O
family O
. O

This O
observation O
has O
direct O
implications O
for O
genetic O
counseling O
of O
Lowe B
syndrome I
families O
. O
. O

MEFV O
- O
Gene O
analysis O
in O
armenian O
patients O
with O
Familial B
Mediterranean I
fever I
: O
diagnostic O
value O
and O
unfavorable O
renal O
prognosis O
of O
the O
M694V O
homozygous O
genotype O
- O
genetic O
and O
therapeutic O
implications O
. O

Familial B
Mediterranean I
fever I
( O
FMF B
) O
is O
a O
recessively B
inherited I
disorder I
that O
is O
common O
in O
patients O
of O
Armenian O
ancestry O
. O

To O
date O
, O
its O
diagnosis O
, O
which O
can O
be O
made O
only O
retrospectively O
, O
is O
one O
of O
exclusion O
, O
based O
entirely O
on O
nonspecific O
clinical O
signs O
that O
result O
from O
serosal B
inflammation I
and O
that O
may O
lead O
to O
unnecessary O
surgery O
. O

Renal B
amyloidosis I
, O
prevented O
by O
colchicine O
, O
is O
the O
most O
severe O
complication O
of O
FMF B
, O
a O
disorder O
associated O
with O
mutations O
in O
the O
MEFV O
gene O
. O

To O
evaluate O
the O
diagnostic O
and O
prognostic O
value O
of O
MEFV O
- O
gene O
analysis O
, O
we O
investigated O
90 O
Armenian O
FMF B
patients O
from O
77 O
unrelated O
families O
that O
were O
not O
selected O
through O
genetic O
- O
linkage O
analysis O
. O

Eight O
mutations O
, O
one O
of O
which O
( O
R408Q O
) O
is O
new O
, O
were O
found O
to O
account O
for O
93 O
% O
of O
the O
163 O
independent O
FMF B
alleles O
, O
with O
both O
FMF B
alleles O
identified O
in O
89 O
% O
of O
the O
patients O
. O

In O
several O
instances O
, O
family O
studies O
provided O
molecular O
evidence O
for O
pseudodominant O
transmission O
and O
incomplete O
penetrance O
of O
the O
disease O
phenotype O
. O

The O
M694V O
homozygous O
genotype O
was O
found O
to O
be O
associated O
with O
a O
higher O
prevalence O
of O
renal B
amyloidosis I
and O
arthritis B
, O
compared O
with O
other O
genotypes O
( O
P O
= O
. O
0002 O
and O
P O
= O
. O
006 O
, O
respectively O
) O
. O

The O
demonstration O
of O
both O
the O
diagnostic O
and O
prognostic O
value O
of O
MEFV O
analysis O
and O
particular O
modes O
of O
inheritance O
should O
lead O
to O
new O
ways O
for O
management O
of O
FMF O
- O
including O
genetic O
counseling O
and O
therapeutic O
decisions O
in O
affected O
families O
. O

Noninvasive O
test O
for O
fragile B
X I
syndrome I
, O
using O
hair O
root O
analysis O
. O

Identification O
of O
the O
FMR1 O
gene O
and O
the O
repeat O
- O
amplification O
mechanism O
causing O
fragile B
X I
syndrome I
led O
to O
development O
of O
reliable O
DNA O
- O
based O
diagnostic O
methods O
, O
including O
Southern O
blot O
hybridization O
and O
PCR O
. O

Both O
methods O
are O
performed O
on O
DNA O
isolated O
from O
peripheral O
blood O
cells O
and O
measure O
the O
repeat O
size O
in O
FMR1 O
. O

Using O
an O
immunocytochemical O
technique O
on O
blood O
smears O
, O
we O
recently O
developed O
a O
novel O
test O
for O
identification O
of O
patients O
with O
fragile B
X I
syndrome I
. O

This O
method O
, O
also O
called O
" O
antibody O
test O
, O
" O
uses O
monoclonal O
antibodies O
against O
the O
FMR1 O
gene O
product O
( O
FMRP O
) O
and O
is O
based O
on O
absence O
of O
FMRP O
in O
patients O
cells O
. O

Here O
we O
describe O
a O
new O
diagnostic O
test O
to O
identify O
male O
patients O
with O
fragile B
X I
syndrome I
, O
on O
the O
basis O
of O
lack O
of O
FMRP O
in O
their O
hair O
roots O
. O

Expression O
of O
FMRP O
in O
hair O
roots O
was O
studied O
by O
use O
of O
an O
FMRP O
- O
specific O
antibody O
test O
, O
and O
the O
percentage O
of O
FMRP O
- O
expressing O
hair O
roots O
in O
controls O
and O
in O
male O
fragile B
X I
patients O
was O
determined O
. O

Control O
individuals O
showed O
clear O
expression O
of O
FMRP O
in O
nearly O
every O
hair O
root O
, O
whereas O
male O
fragile B
X I
patients O
lacked O
expression O
of O
FMRP O
in O
almost O
all O
their O
hair O
roots O
. O

Mentally B
retarded I
female O
patients O
with O
a O
full O
mutation O
showed O
FMRP O
expression O
in O
only O
some O
of O
their O
hair O
roots O
( O
< O
55 O
% O
) O
, O
and O
no O
overlap O
with O
normal O
female O
controls O
was O
observed O
. O

The O
advantages O
of O
this O
test O
are O
( O
1 O
) O
plucking O
of O
hair O
follicles O
does O
no O
appreciable O
harm O
to O
the O
mentally B
retarded I
patient O
, O
( O
2 O
) O
hairs O
can O
be O
sent O
in O
a O
simple O
envelope O
to O
a O
diagnostic O
center O
, O
and O
( O
3 O
) O
the O
result O
of O
the O
test O
is O
available O
within O
5 O
h O
of O
plucking O
. O

In O
addition O
, O
this O
test O
enabled O
us O
to O
identify O
two O
fragile B
X I
patients O
who O
did O
not O
show O
the O
full O
mutation O
by O
analysis O
of O
DNA O
isolated O
from O
blood O
cells O
. O
. O

In O
Swedish O
families O
with O
hereditary B
prostate I
cancer I
, O
linkage O
to O
the O
HPC1 O
locus O
on O
chromosome O
1q24 O
- O
25 O
is O
restricted O
to O
families O
with O
early O
- O
onset O
prostate B
cancer I
. O

Prostate B
cancer I
clusters O
in O
some O
families O
, O
and O
an O
estimated O
5 O
% O
- O
10 O
% O
of O
all O
cases O
are O
estimated O
to O
result O
from O
inheritance O
of O
prostate O
cancer O
- O
susceptibility O
genes O
. O

We O
previously O
reported O
evidence O
of O
linkage O
to O
the O
1q24 O
- O
25 O
region O
( O
HPC1 O
) O
in O
91 O
North O
American O
and O
Swedish O
families O
each O
with O
multiple O
cases O
of O
prostate B
cancer I
( O
Smith O
et O
al O
. O
1996 O
) O
. O

In O
the O
present O
report O
we O
analyze O
40 O
( O
12 O
original O
and O
28 O
newly O
identified O
) O
Swedish O
families O
with O
hereditary B
prostate I
cancer I
( O
HPC B
) O
that O
, O
on O
the O
basis O
of O
40 O
markers O
spanning O
a O
25 O
- O
cM O
interval O
within O
1q24 O
- O
25 O
, O
have O
evidence O
of O
linkage O
. O

In O
the O
complete O
set O
of O
families O
, O
a O
maximum O
two O
- O
point O
LOD O
score O
of O
1 O
. O

10 O
was O
observed O
at O
D1S413 O
( O
at O
a O
recombination O
fraction O
[ O
theta O
] O
of O
. O
1 O
) O
, O
with O
a O
maximum O
NPL O
( O
nonparametric O
linkage O
) O
Z O
score O
of O
1 O
. O

64 O
at O
D1S202 O
( O
P O
= O
. O
05 O
) O
. O

The O
evidence O
of O
linkage O
to O
this O
region O
originated O
almost O
exclusively O
from O
the O
subset O
of O
12 O
early O
- O
onset O
( O
age O
< O
65 O
years O
) O
families O
, O
which O
yielded O
a O
maximum O
LOD O
score O
of O
2 O
. O

38 O
at O
D1S413 O
( O
straight O
theta O
= O
0 O
) O
and O
an O
NPL O
Z O
score O
of O
1 O
. O

95 O
at O
D1S422 O
( O
P O
= O
. O
03 O
) O
. O

Estimates O
from O
heterogeneity O
tests O
suggest O
that O
, O
within O
Sweden O
, O
as O
many O
as O
50 O
% O
of O
early O
- O
onset O
families O
had O
evidence O
of O
linkage O
to O
the O
HPC1 O
region O
. O

These O
results O
are O
consistent O
with O
the O
hypothesis O
of O
linkage O
to O
HPC1 O
in O
a O
subset O
of O
families O
with O
prostate B
cancer I
, O
particularly O
those O
with O
an O
early O
age O
at O
diagnosis O
. O

Molecular O
basis O
of O
feline O
beta B
- I
glucuronidase I
deficiency I
: O
an O
animal O
model O
of O
mucopolysaccharidosis B
VII I
. O

A O
family O
of O
domestic O
cats O
was O
found O
that O
exhibited O
clinical O
and O
biochemical O
abnormalities O
consistent O
with O
mucopolysaccharidosis B
VII I
, O
an O
autosomal B
recessive I
lysosomal I
storage I
disorder I
caused O
by O
beta B
- I
glucuronidase I
deficiency I
. O

beta O
- O
Glucuronidase O
activity O
was O
undetectable O
in O
affected O
cat O
fibroblasts O
and O
restored O
by O
retroviral O
gene O
transfer O
of O
rat O
beta O
- O
glucuronidase O
cDNA O
. O

beta O
- O
Glucuronidase O
mRNA O
was O
normal O
in O
affected O
cat O
testis O
by O
Northern O
blot O
analysis O
. O

Normal O
feline O
beta O
- O
glucuronidase O
cDNA O
was O
cloned O
and O
characterized O
, O
and O
amplified O
from O
affected O
cat O
fibroblasts O
by O
reverse O
transcription O
coupled O
polymerase O
chain O
reaction O
. O

There O
was O
a O
G O
- O
to O
- O
A O
transition O
in O
the O
affected O
cat O
cDNA O
that O
predicted O
an O
E351K O
substitution O
, O
destroyed O
a O
BssSI O
site O
, O
and O
eliminated O
GUSB O
enzymatic O
activity O
in O
expression O
studies O
. O

Multiple O
species O
comparison O
and O
the O
crystal O
structure O
of O
human O
beta O
- O
glucuronidase O
indicated O
that O
E351 O
is O
a O
highly O
conserved O
residue O
most O
likely O
essential O
in O
maintenance O
of O
the O
enzymes O
conformation O
. O

BssSI O
digestion O
of O
polymerase O
chain O
reaction O
products O
amplified O
from O
genomic O
DNA O
indicated O
that O
affected O
cats O
were O
homozygous O
and O
cats O
with O
half O
- O
normal O
beta O
- O
glucuronidase O
activity O
were O
heterozygous O
for O
the O
missense O
mutation O
. O

Carriers O
identified O
in O
this O
manner O
produced O
affected O
kittens O
in O
prospective O
breedings O
, O
and O
a O
feline O
MPS B
VII I
breeding O
colony O
has O
been O
established O
. O
. O

A O
common O
molecular O
basis O
for O
rearrangement B
disorders I
on O
chromosome O
22q11 O
. O

The O
chromosome O
22q11 O
region O
is O
susceptible O
to O
rearrangements O
that O
are O
associated O
with O
congenital B
anomaly I
disorders I
and O
malignant B
tumors I
. O

Three O
congenital B
anomaly I
disorders I
, O
cat B
- I
eye I
syndrome I
, O
der B
( I
) I
syndrome I
and O
velo B
- I
cardio I
- I
facial I
syndrome I
/ O
DiGeorge B
syndrome I
( O
VCFS B
/ O
DGS B
) O
are O
associated O
with O
tetrasomy O
, O
trisomy O
or O
monosomy O
, O
respectively O
, O
for O
part O
of O
chromosome O
22q11 O
. O

VCFS B
/ O
DGS B
is O
the O
most O
common O
syndrome O
associated O
with O
22q11 O
rearrangements O
. O

In O
order O
to O
determine O
whether O
there O
are O
particular O
regions O
on O
22q11 O
that O
are O
prone O
to O
rearrangements O
, O
the O
deletion O
end O
- O
points O
in O
a O
large O
number O
of O
VCFS B
/ O
DGS B
patients O
were O
defined O
by O
haplotype O
analysis O
. O

Most O
VCFS B
/ O
DGS B
patients O
have O
a O
similar O
3 O
Mb O
deletion O
, O
some O
have O
a O
nested O
distal O
deletion O
breakpoint O
resulting O
in O
a O
1 O
. O

5 O
Mb O
deletion O
and O
a O
few O
rare O
patients O
have O
unique O
deletions O
or O
translocations O
. O

The O
high O
prevalence O
of O
the O
disorder O
in O
the O
population O
and O
the O
fact O
that O
most O
cases O
occur O
sporadically O
suggest O
that O
sequences O
at O
or O
near O
the O
breakpoints O
confer O
susceptibility O
to O
chromosome O
rearrangements O
. O

To O
investigate O
this O
hypothesis O
, O
we O
developed O
hamster O
- O
human O
somatic O
hybrid O
cell O
lines O
from O
VCFS B
/ O
DGS B
patients O
with O
all O
three O
classes O
of O
deletions O
and O
we O
now O
show O
that O
the O
breakpoints O
occur O
within O
similar O
low O
copy O
repeats O
, O
termed O
LCR22s O
. O

To O
support O
this O
idea O
further O
, O
we O
identified O
a O
family O
that O
carries O
an O
interstitial O
duplication O
of O
the O
same O
3 O
Mb O
region O
that O
is O
deleted O
in O
VCFS B
/ O
DGS B
patients O
. O

We O
present O
models O
to O
explain O
how O
the O
LCR22s O
can O
mediate O
different O
homologous O
recombination O
events O
, O
thereby O
generating O
a O
number O
of O
rearrangements O
that O
are O
associated O
with O
congenital B
anomaly I
disorders I
. O

We O
identified O
five O
additional O
copies O
of O
the O
LCR22 O
on O
22q11 O
that O
may O
mediate O
other O
rearrangements O
leading O
to O
disease O
. O

Functional O
consequences O
of O
mutations O
in O
the O
early O
growth O
response O
2 O
gene O
( O
EGR2 O
) O
correlate O
with O
severity O
of O
human O
myelinopathies B
. O

The O
early O
growth O
response O
2 O
gene O
( O
EGR2 O
) O
is O
a O
Cys2His2zinc O
finger O
transcription O
factor O
which O
is O
thought O
to O
play O
a O
role O
in O
the O
regulation O
of O
peripheral O
nervous O
system O
myelination O
. O

This O
idea O
is O
based O
partly O
on O
the O
phenotype O
of O
homozygous O
Krox20 O
( O
Egr2 O
) O
knockout O
mice O
, O
which O
display O
hypomyelination B
of I
the I
PNS I
and O
a O
block O
of O
Schwann O
cells O
at O
an O
early O
stage O
of O
differentiation O
. O

Mutations O
in O
the O
human O
EGR2 O
gene O
have O
recently O
been O
associated O
with O
the O
inherited B
peripheral I
neuropathies I
Charcot B
- I
Marie I
- I
Tooth I
type I
1 I
, O
Dejerine B
- I
Sottas I
syndrome I
and O
congenital B
hypomyelinating I
neuropathy I
. O

Three O
of O
the O
four O
EGR2 O
mutations O
are O
dominant O
and O
occur O
within O
the O
zinc O
finger O
DNA O
- O
binding O
domain O
. O

The O
fourth O
mutation O
is O
recessive O
and O
affects O
the O
inhibitory O
domain O
( O
R1 O
) O
that O
binds O
the O
NAB O
transcriptional O
co O
- O
repressors O
. O

A O
combination O
of O
DNA O
- O
binding O
assays O
and O
transcriptional O
analysis O
was O
used O
to O
determine O
the O
functional O
consequences O
of O
these O
mutations O
. O

The O
zinc O
finger O
mutations O
affect O
DNA O
binding O
and O
the O
amount O
of O
residual O
binding O
directly O
correlates O
with O
disease O
severity O
. O

The O
R1 O
domain O
mutation O
prevents O
interaction O
of O
EGR2 O
with O
the O
NAB O
co O
- O
repressors O
and O
thereby O
increases O
transcriptional O
activity O
. O

These O
data O
provide O
insight O
into O
the O
possible O
disease O
mechanisms O
underlying O
EGR2 O
mutations O
and O
the O
reason O
for O
varying O
severity O
and O
differences O
in O
inheritance O
patterns O
. O
. O

Autosomal B
recessive I
familial I
neurohypophyseal I
diabetes I
insipidus I
with O
continued O
secretion O
of O
mutant O
weakly O
active O
vasopressin O
. O

Familial B
neurohypophyseal I
diabetes I
insipidus I
is O
an O
autosomal B
dominant I
disorder I
characterized O
by O
post O
- O
natal O
development O
of O
arginine B
vasopressin I
( I
AVP I
) I
deficiency I
due O
to O
mutations O
in O
the O
AVP O
gene O
. O

All O
published O
mutations O
affect O
the O
signal O
peptide O
or O
the O
neurophysin O
- O
II O
carrier O
protein O
and O
are O
presumed O
to O
interfere O
with O
processing O
of O
the O
preprohormone O
, O
leading O
to O
neuronal B
damage I
. O

We O
studied O
an O
unusual O
Palestinian O
family O
consisting O
of O
asymptomatic O
first O
cousin O
parents O
and O
three O
children O
affected O
with O
neurohypophyseal B
diabetes I
insipidus I
, O
suggesting O
autosomal O
recessive O
inheritance O
. O

All O
three O
affected O
children O
were O
homozygous O
and O
the O
parents O
heterozygous O
for O
a O
single O
novel O
mutation O
( O
C301 O
- O
> O
T O
) O
in O
exon O
1 O
, O
replacing O
Pro7 O
of O
mature O
AVP O
with O
Leu O
( O
Leu O
- O
AVP O
) O
. O

Leu O
- O
AVP O
was O
a O
weak O
agonist O
with O
approximately O
30 O
- O
fold O
reduced O
binding O
to O
the O
human O
V2 O
receptor O
. O

Measured O
by O
radioimmunoassay O
with O
a O
synthetic O
Leu O
- O
AVP O
standard O
, O
serum O
Leu O
- O
AVP O
levels O
were O
elevated O
in O
all O
three O
children O
and O
further O
increased O
during O
water O
deprivation O
to O
as O
high O
as O
30 O
times O
normal O
. O

The O
youngest O
child O
( O
2 O
years O
old O
) O
was O
only O
mildly O
affected O
but O
had O
Leu O
- O
AVP O
levels O
similar O
to O
her O
severely O
affected O
8 O
- O
year O
- O
old O
brother O
, O
suggesting O
that O
unknown O
mechanisms O
may O
partially O
compensate O
for O
a O
deficiency B
of I
active I
AVP I
in O
very O
young O
children O
. O
. O

X O
inactivation O
and O
somatic O
cell O
selection O
rescue O
female O
mice O
carrying O
a O
Piga O
- O
null O
mutation O
. O

A O
somatic O
mutation O
in O
the O
X O
linked O
PIGA O
gene O
is O
responsible O
for O
the O
deficiency B
of I
glycosyl I
phosphatidylinositol I
( I
GPI I
) I
- I
anchored I
proteins I
on O
blood O
cells O
from O
patients O
with O
paroxysmal B
nocturnal I
hemoglobinuria I
. O

No O
inherited O
form O
of O
GPI B
- I
anchor I
deficiency I
has O
been O
described O
. O

Because O
conventional O
Piga O
gene O
knockout O
is O
associated O
with O
high O
embryonic B
lethality I
in O
chimeric O
mice O
, O
we O
used O
the O
Cre O
/ O
loxP O
system O
. O

We O
generated O
mice O
in O
which O
two O
loxP O
sites O
flank O
part O
of O
Piga O
exon O
2 O
. O

After O
crossbreeding O
with O
female O
mice O
of O
the O
EIIa O
- O
cre O
strain O
, O
the O
floxed O
allele O
undergoes O
Cre O
- O
mediated O
recombination O
with O
high O
efficiency O
during O
early O
embryonic O
development O
. O

Because O
of O
X O
chromosome O
inactivation O
, O
female O
offspring O
are O
mosaic O
for O
cells O
that O
express O
or O
lack O
GPI O
- O
linked O
proteins O
. O

Analysis O
of O
mosaic O
mice O
showed O
that O
in O
heart O
, O
lung O
, O
kidney O
, O
brain O
, O
and O
liver O
, O
mainly O
wild O
- O
type O
Piga O
is O
active O
, O
suggesting O
that O
these O
tissues O
require O
GPI O
- O
linked O
proteins O
. O

The O
salient O
exceptions O
were O
spleen O
, O
thymus O
, O
and O
red O
blood O
cells O
, O
which O
had O
almost O
equal O
numbers O
of O
cells O
expressing O
the O
wild O
- O
type O
or O
the O
recombined O
allele O
, O
implying O
that O
GPI O
- O
linked O
proteins O
are O
not O
essential O
for O
the O
derivation O
of O
these O
tissues O
. O

PIGA O
( O
- O
) O
cells O
had O
no O
growth O
advantage O
, O
suggesting O
that O
other O
factors O
are O
needed O
for O
their O
clonal O
dominance O
in O
patients O
with O
paroxysmal B
nocturnal I
hemoglobinuria I
. O
. O

The O
C282Y O
mutation O
causing O
hereditary B
hemochromatosis I
does O
not O
produce O
a O
null O
allele O
. O

Targeted O
mutagenesis O
was O
used O
to O
produce O
two O
mutations O
in O
the O
murine O
hemochromatosis B
gene O
( O
Hfe O
) O
locus O
. O

The O
first O
mutation O
deletes O
a O
large O
portion O
of O
the O
coding O
sequence O
, O
generating O
a O
null O
allele O
. O

The O
second O
mutation O
introduces O
a O
missense O
mutation O
( O
C282Y O
) O
into O
the O
Hfe O
locus O
, O
but O
otherwise O
leaves O
the O
gene O
intact O
. O

This O
mutation O
is O
identical O
to O
the O
disease O
- O
causing O
mutation O
in O
patients O
with O
hereditary B
hemochromatosis I
. O

Mice O
carrying O
each O
of O
the O
two O
mutations O
were O
bred O
and O
analyzed O
. O

Homozygosity O
for O
either O
mutation O
results O
in O
postnatal O
iron O
loading O
. O

The O
effects O
of O
the O
null O
mutation O
are O
more O
severe O
than O
the O
effects O
of O
the O
C282Y O
mutation O
. O

Mice O
heterozygous O
for O
either O
mutation O
accumulate O
more O
iron O
than O
normal O
controls O
. O

Interestingly O
, O
although O
liver O
iron O
stores O
are O
greatly O
increased O
, O
splenic O
iron O
is O
decreased O
. O

We O
conclude O
that O
the O
C282Y O
mutation O
does O
not O
result O
in O
a O
null O
allele O
. O
. O

Genotype O
- O
phenotype O
analysis O
in O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
and O
identification O
of O
a O
missense O
mutation O
associated O
with O
a O
milder O
phenotype O
. O

Direct O
sequencing O
of O
the O
emerin O
gene O
in O
22 O
families O
with O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EMD B
) O
revealed O
mutations O
in O
21 O
( O
95 O
% O
) O
, O
confirming O
that O
emerin O
mutations O
can O
be O
identified O
in O
the O
majority O
of O
families O
with O
X B
- I
linked I
EMD I
. O

Most O
emerin O
mutations O
result O
in O
absence O
of O
the O
protein O
. O

In O
this O
study O
three O
mutations O
( O
a O
missense O
mutation O
Pro183Thr O
and O
two O
in O
- O
frame O
deletions O
removing O
residues O
95 O
- O
99 O
and O
236 O
- O
241 O
, O
respectively O
) O
were O
unusual O
in O
being O
associated O
with O
expression O
of O
mutant O
protein O
. O

The O
phenotype O
in O
these O
families O
was O
compared O
in O
detail O
with O
the O
clinical O
features O
in O
cases O
with O
typical O
null O
mutations O
. O

For O
the O
in O
- O
frame O
deletions O
there O
were O
no O
significant O
differences O
. O

In O
the O
family O
with O
the O
missense O
mutation O
the O
phenotype O
was O
milder O
. O

Age O
at O
onset O
was O
later O
for O
first O
symptoms O
and O
for O
development O
of O
ankle B
contractures I
and O
muscle B
weakness I
. O

These O
findings O
have O
diagnostic O
implications O
as O
well O
as O
pointing O
to O
functionally O
important O
regions O
of O
the O
emerin O
protein O
. O
. O

Severe O
clinical O
expression O
in O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
. O

X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
is O
a O
relatively O
rare O
benign B
neuromuscular I
disorder I
which O
can O
vary O
remarkably O
in O
onset O
, O
course O
and O
severity O
. O

In O
the O
present O
study O
, O
a O
TCTAC O
deletion O
spanning O
the O
nucleotides O
631 O
- O
635 O
of O
the O
emerin O
gene O
caused O
an O
unusually O
severe O
disease O
phenotype O
including O
loss B
of I
ambulation I
and O
severe O
muscle B
wasting I
in O
two O
affected O
brothers O
. O

The O
same O
mutation O
has O
been O
reported O
previously O
in O
an O
unrelated O
family O
showing O
a O
significantly O
milder O
phenotype O
. O

The O
interfamilial O
heterogeneity O
in O
distribution O
and O
in O
severity O
of O
the O
features O
in O
the O
two O
families O
point O
to O
environmental O
or O
genetic O
modification O
as O
the O
cause O
of O
clinical O
variability O
in O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
. O
. O

Common O
mutations O
in O
BRCA1 O
and O
BRCA2 O
do O
not O
contribute O
to O
early O
prostate B
cancer I
in O
Jewish O
men O
. O

BACKGROUND O
Families O
with O
a O
high O
incidence O
of O
hereditary B
breast I
cancer I
, O
and O
subsequently O
shown O
to O
have O
terminating O
mutations O
in O
BRCA1 O
or O
BRCA2 O
, O
appear O
to O
have O
a O
higher O
incidence O
of O
prostate B
cancer I
among O
male O
relatives O
. O

We O
aimed O
to O
determine O
whether O
the O
common O
germline O
mutations O
of O
BRCA1 O
or O
BRCA2 O
in O
Ashkenazi O
Jewish O
men O
predisposed O
them O
to O
prostate B
cancer I
. O

METHODS O
We O
examined O
genomic O
DNA O
from O
83 O
( O
for O
BRCA1 O
185delAG O
) O
or O
82 O
( O
for O
BRCA2 O
6174delT O
) O
Ashkenazi O
Jewish O
prostate B
cancer I
patients O
, O
most O
of O
whom O
were O
treated O
at O
a O
relatively O
young O
age O
, O
for O
the O
most O
common O
germline O
mutation O
in O
each O
gene O
seen O
in O
the O
Ashkenazi O
population O
. O

RESULTS O
Our O
study O
should O
have O
been O
able O
to O
detect O
a O
4 O
- O
5 O
- O
fold O
increase O
in O
the O
risk O
of O
prostate B
cancer I
due O
to O
mutation O
of O
BRCA1 O
or O
BRCA2 O
. O

However O
, O
only O
one O
( O
1 O
. O
15 O
% O
; O
95 O
% O
confidence O
interval O
, O
0 O
- O
3 O
. O
6 O
% O
) O
of O
the O
patients O
was O
heterozygous O
for O
the O
BRCA1 O
mutant O
allele O
, O
and O
only O
two O
were O
heterozygous O
for O
the O
BRCA2 O
mutation O
( O
2 O
. O
4 O
% O
; O
95 O
% O
confidence O
interval O
, O
0 O
- O
6 O
. O
2 O
% O
) O
. O

CONCLUSIONS O
The O
incidence O
of O
each O
of O
the O
germline O
mutations O
in O
these O
prostate B
cancer I
patients O
closely O
matched O
their O
incidence O
( O
about O
1 O
% O
) O
in O
the O
general O
Ashkenazi O
Jewish O
population O
. O

This O
suggests O
that O
unlike O
cases O
of O
breast B
and I
ovarian I
cancers I
, O
mutations O
in O
BRCA1 O
or O
BRCA2 O
do O
not O
significantly O
predispose O
men O
to O
prostate B
cancer I

Beta O
- O
catenin O
accumulation O
and O
mutation O
of O
the O
CTNNB1 O
gene O
in O
hepatoblastoma B
. O

Hepatoblastoma B
is O
a O
rare O
malignant B
tumor I
of I
the I
liver I
that O
occurs O
in O
children O
at O
an O
average O
age O
of O
2 O
to O
3 O
years O
. O

Epidemiologic O
studies O
have O
shown O
an O
increased O
frequency O
of O
this O
tumor B
type O
in O
families O
affected O
by O
adenomatous B
polyposis I
coli I
. O

In O
addition O
to O
the O
epidemiologic O
data O
, O
molecular O
genetic O
studies O
suggest O
that O
inactivation O
of O
the O
APC B
tumor I
suppressor O
may O
be O
involved O
in O
hepatoblastoma B
tumorigenesis O
. O

A O
major O
function O
of O
APC O
is O
the O
downregulation O
of O
beta O
- O
catenin O
, O
a O
transcription O
- O
activating O
protein O
with O
oncogenic O
potential O
. O

In O
an O
ongoing O
immunohistochemical O
study O
of O
beta O
- O
catenin O
expression O
in O
sporadic O
cases O
of O
tumor B
types O
that O
are O
associated O
with O
adenomatous B
polyposis I
coli I
, O
we O
observed O
increased O
beta O
- O
catenin O
levels O
in O
the O
cytoplasm O
and O
in O
the O
nuclei O
of O
three O
investigated O
hepatoblastomas B
. O

Sequencing O
of O
exon O
3 O
of O
the O
beta O
- O
catenin O
gene O
( O
CTNNB1 O
) O
revealed O
an O
activating O
mutation O
in O
one O
of O
the O
tumor B
samples O
. O

Our O
data O
indicate O
for O
the O
first O
time O
that O
beta O
- O
catenin O
accumulation O
may O
play O
a O
role O
in O
the O
development O
of O
hepatoblastoma B
and O
that O
activating O
mutations O
of O
the O
beta O
- O
catenin O
gene O
may O
substitute O
biallelic O
APC O
inactivation O
in O
this O
tumor B
type O
. O

Genes O
Chromosomes O
Cancer O
25 O
399 O
- O
402 O
, O
1999 O
. O
. O

Decrease O
in O
GTP O
cyclohydrolase O
I O
gene O
expression O
caused O
by O
inactivation O
of O
one O
allele O
in O
hereditary B
progressive I
dystonia I
with O
marked O
diurnal O
fluctuation O
. O

Hereditary B
progressive I
dystonia I
with O
marked O
diurnal O
fluctuation O
( O
HPD B
; O
dopa B
- I
responsive I
dystonia I
, O
DRD B
) O
have O
been O
recently O
found O
to O
be O
caused O
by O
a O
genetic B
defect I
in O
the O
GTP O
cyclohydrolase O
I O
( O
GCH1 O
) O
gene O
. O

In O
this O
study O
, O
we O
quantified O
the O
mRNA O
level O
of O
GCH1 O
in O
phytohemagglutinin O
( O
PHA O
) O
- O
stimulated O
mononuclear O
blood O
cells O
from O
one O
Japanese O
family O
that O
do O
not O
have O
a O
mutation O
in O
the O
coding O
region O
or O
splice O
junctions O
of O
the O
gene O
. O

The O
results O
showed O
that O
the O
amounts O
of O
the O
GCH1 O
mRNA O
were O
decreased O
to O
about O
40 O
% O
of O
the O
normal O
level O
in O
both O
patients O
and O
carriers O
. O

In O
addition O
, O
we O
found O
that O
the O
GCH1 O
mRNA O
was O
transcribed O
from O
only O
one O
allele O
, O
indicating O
that O
the O
other O
allele O
was O
in O
an O
inactive O
state O
. O

These O
results O
suggest O
that O
some O
novel O
mutations O
should O
exist O
on O
one O
of O
the O
alleles O
in O
some O
unknown O
region O
of O
the O
GCH1 O
gene O
, O
and O
may O
decrease O
the O
GCH1 O
mRNA O
causing O
the O
HPD B
/ O
DRD B
symptoms O
. O
. O

Sulfate O
transport O
is O
not O
impaired O
in O
pendred B
syndrome I
thyrocytes O
. O

Pendred B
syndrome I
is O
the O
most O
common O
form O
of O
syndromic B
deafness I
, O
characterized O
by O
dyshormonogenic B
goiter I
associated O
with O
sensory B
- I
neural I
deafness I
. O

The O
gene O
responsible O
for O
the O
disease O
( O
PDS B
) O
has O
been O
cloned O
, O
but O
its O
function O
is O
as O
yet O
unknown O
and O
the O
connection O
between O
thyroid B
goiter I
and O
sensory B
- I
neural I
deafness I
remains O
an O
enigma O
. O

PDS O
codes O
for O
a O
novel O
protein O
, O
pendrin O
, O
which O
is O
closely O
related O
to O
a O
number O
of O
sufate O
transporters O
. O

Mechanisms O
by O
which O
abnormal O
sulfate O
transport O
could O
deleteriously O
affect O
iodide O
organification O
have O
been O
proposed O
. O

We O
tested O
sulfate O
transport O
in O
thyrocytes O
obtained O
from O
Pendred B
syndrome I
patients O
and O
found O
that O
it O
was O
not O
defective O
. O

This O
suggests O
that O
pendrin O
in O
fact O
may O
not O
be O
a O
sulfate O
transporter O
, O
and O
emphasizes O
the O
importance O
of O
functional O
studies O
on O
this O
novel O
protein O
. O
. O

Small O
deletions O
in O
the O
type O
II O
collagen O
triple O
helix O
produce O
kniest B
dysplasia I
. O

Kniest B
dysplasia I
is O
a O
moderately O
severe O
type B
II I
collagenopathy I
, O
characterized O
by O
short O
trunk O
and O
limbs O
, O
kyphoscoliosis B
, O
midface B
hypoplasia I
, O
severe O
myopia B
, O
and O
hearing B
loss I
. O

Mutations O
in O
the O
gene O
that O
encodes O
type O
II O
collagen O
( O
COL2A1 O
) O
, O
the O
predominant O
protein O
of O
cartilage O
, O
have O
been O
identified O
in O
a O
number O
of O
individuals O
with O
Kniest B
dysplasia I
. O

All O
but O
two O
of O
these O
previously O
described O
mutations O
cause O
in O
- O
frame O
deletions O
in O
type O
II O
collagen O
, O
either O
by O
small O
deletions O
in O
the O
gene O
or O
splice O
site O
alterations O
. O

Furthermore O
, O
all O
but O
one O
of O
these O
mutations O
is O
located O
between O
exons O
12 O
and O
24 O
in O
the O
COL2A1 O
gene O
. O

We O
used O
heteroduplex O
analysis O
to O
identify O
sequence O
anomalies O
in O
five O
individuals O
with O
Kniest B
dysplasia I
. O

Sequencing O
of O
the O
index O
patients O
genomic O
DNA O
identified O
four O
new O
dominant O
mutations O
in O
COL2A1 O
that O
result O
in O
Kniest B
dysplasia I
a O
21 O
- O
bp O
deletion O
in O
exon O
16 O
, O
an O
18 O
- O
bp O
deletion O
in O
exon O
19 O
, O
and O
4 O
- O
bp O
deletions O
in O
the O
splice O
donor O
sites O
of O
introns O
14 O
and O
20 O
. O

A O
previously O
described O
28 O
- O
bp O
deletion O
at O
the O
COL2A1 O
exon O
12 O
- O
intron O
12 O
junction O
, O
deleting O
the O
splice O
donor O
site O
, O
was O
identified O
in O
the O
fifth O
case O
. O

The O
latter O
three O
mutations O
are O
predicted O
to O
result O
in O
exon O
skipping O
in O
the O
mRNA O
encoded O
from O
the O
mutant O
allele O
. O

These O
data O
suggest O
that O
Kniest B
dysplasia I
results O
from O
shorter O
type O
II O
collagen O
monomers O
, O
and O
support O
the O
hypothesis O
that O
alteration O
of O
a O
specific O
COL2A1 O
domain O
, O
which O
may O
span O
from O
exons O
12 O
to O
24 O
, O
leads O
to O
the O
Kniest B
dysplasia I
phenotype O
. O
. O

Classical B
galactosemia I
and O
mutations O
at O
the O
galactose O
- O
1 O
- O
phosphate O
uridyl O
transferase O
( O
GALT O
) O
gene O
. O

Classical B
galactosemia I
is O
caused O
by O
a O
deficiency O
in O
activity O
of O
the O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridyl O
transferase O
( O
GALT O
) O
, O
which O
, O
in O
turn O
, O
is O
caused O
by O
mutations O
at O
the O
GALT O
gene O
. O

The O
disorder O
exhibits O
considerable O
allelic O
heterogeneity O
and O
, O
at O
the O
end O
of O
1998 O
, O
more O
than O
150 O
different O
base O
changes O
were O
recorded O
in O
24 O
different O
populations O
and O
ethnic O
groups O
in O
15 O
countries O
worldwide O
. O

The O
mutations O
most O
frequently O
cited O
are O
Q188R O
, O
K285N O
, O
S135L O
, O
and O
N314D O
. O

Q188R O
is O
the O
most O
common O
mutation O
in O
European O
populations O
or O
in O
those O
predominantly O
of O
European O
descent O
. O

Overall O
, O
it O
accounts O
for O
60 O
- O
70 O
% O
of O
mutant O
chromosomes O
, O
but O
there O
are O
significant O
differences O
in O
its O
relative O
frequency O
in O
individual O
populations O
. O

Individuals O
homoallelic O
for O
Q188R O
tend O
to O
have O
a O
severe O
phenotype O
and O
this O
is O
in O
keeping O
with O
the O
virtually O
complete O
loss O
of O
enzyme O
activity O
observed O
in O
in O
vitro O
expression O
systems O
. O

Globally O
, O
K285N O
is O
rarer O
, O
but O
in O
many O
European O
populations O
it O
can O
be O
found O
on O
25 O
- O
40 O
% O
of O
mutant O
chromosomes O
. O

It O
is O
invariably O
associated O
with O
a O
severe O
phenotype O
. O

S135L O
is O
found O
almost O
exclusively O
in O
African O
Americans O
. O

In O
vitro O
expression O
results O
are O
discrepant O
, O
but O
some O
individuals O
carrying O
S135L O
appear O
to O
exhibit O
GALT O
activity O
in O
some O
tissues O
. O

Duarte O
1 O
( O
or O
Los O
Angeles O
) O
and O
Duarte O
2 O
( O
or O
Duarte O
) O
variants O
carry O
the O
same O
amino O
acid O
substitution O
, O
N314D O
, O
even O
though O
D1 O
is O
associated O
with O
increased O
erythrocyte O
GALT O
activity O
and O
D2 O
with O
reduced O
activity O
. O

N314D O
is O
in O
linkage O
disequilibrium O
with O
other O
base O
changes O
that O
differ O
on O
the O
D1 O
and O
D2 O
alleles O
. O

N314D O
does O
not O
impair O
GALT O
activity O
in O
in O
vitro O
expression O
systems O
. O

However O
, O
there O
are O
differences O
in O
the O
abundance O
of O
GALT O
protein O
in O
lymphoblastoid O
cells O
lines O
from O
D2 O
and O
D1 O
individuals O
. O

It O
is O
unclear O
whether O
the O
specific O
molecular O
changes O
that O
distinguish O
the O
D1 O
and O
D2 O
alleles O
account O
for O
the O
different O
activities O
. O

The O
considerable O
genetic O
heterogeneity O
documented O
to O
date O
undoubtedly O
contributes O
to O
the O
phenotypic O
heterogeneity O
that O
is O
observed O
in O
galactosemia B
. O

The O
additional O
effects O
of O
nonallelic O
variation O
and O
other O
constitutional O
factors O
on O
phenotypic O
variability O
remain O
to O
be O
elucidated O
. O
. O

Mutations O
of O
the O
VHL B
gene O
in O
sporadic B
renal I
cell I
carcinoma I
: O
definition O
of O
a O
risk O
factor O
for O
VHL B
patients O
to O
develop O
an O
RCC B
. O

To O
investigate O
the O
nature O
of O
somatic O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
mutations O
, O
we O
analyzed O
173 O
primary O
sporadic O
human O
renal B
cell I
carcinomas I
for O
mutations O
of O
the O
VHL B
tumor I
suppressor O
gene O
, O
using O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
single O
- O
strand O
conformational O
polymorphism O
analysis O
( O
SSCP O
) O
of O
DNA O
. O

We O
detected O
abnormal O
SSCP O
pattern O
in O
73 O
samples O
. O

After O
sequencing O
, O
we O
identified O
microdeletions O
in O
58 O
% O
of O
cases O
, O
microinsertions O
in O
17 O
% O
, O
nonsense O
mutations O
in O
8 O
% O
, O
and O
missense O
mutations O
in O
17 O
% O
. O

Among O
these O
mutations O
, O
50 O
% O
correspond O
to O
new O
mutations O
. O

VHL B
mutations O
were O
found O
only O
in O
the O
nonpapillary B
renal I
cell I
carcinoma I
( O
RCC B
) O
subtype O
, O
as O
previously O
reported O
. O

To O
compare O
somatic O
and O
germline O
mutations O
, O
we O
used O
the O
VHL B
database O
, O
which O
includes O
507 O
mutations O
. O

The O
study O
of O
mutational O
events O
revealed O
a O
significant O
difference O
between O
somatic O
and O
germline O
mutations O
with O
mutations O
leading O
to O
truncated O
proteins O
observed O
in O
78 O
% O
of O
somatic O
mutations O
vs O
only O
37 O
% O
in O
germline O
mutations O
( O
P O
< O
0 O
. O
001 O
) O
. O

We O
postulated O
that O
a O
specific O
pattern O
of O
VHL B
mutations O
is O
associated O
with O
sporadic B
RCC I
. O

This O
pattern O
corresponds O
to O
mutations O
leading O
mainly O
to O
truncated O
proteins O
with O
few O
specific O
missense O
mutations O
. O

We O
then O
analyzed O
the O
occurrence O
of O
RCC B
in O
VHL B
families O
, O
based O
on O
the O
nature O
of O
mutations O
. O

We O
observed O
RCC B
in O
at O
least O
one O
member O
of O
the O
VHL B
families O
in O
77 O
% O
of O
cases O
with O
mutations O
leading O
to O
truncated O
proteins O
versus O
55 O
% O
in O
cases O
with O
missense O
mutations O
( O
P O
< O
0 O
. O
05 O
) O
. O

Thus O
, O
mutations O
resulting O
in O
truncated O
proteins O
may O
lead O
to O
a O
higher O
risk O
of O
RCC B
in O
VHL B
patients O

Defective O
CTLA O
- O
4 O
cycling O
pathway O
in O
Chediak B
- I
Higashi I
syndrome I
: O
a O
possible O
mechanism O
for O
deregulation O
of O
T O
lymphocyte O
activation O
. O

Cytotoxic O
T O
lymphocyte O
- O
associated O
antigen O
4 O
( O
CTLA O
- O
4 O
, O
also O
known O
as O
CD152 O
) O
has O
been O
shown O
to O
play O
a O
major O
role O
in O
the O
regulation O
of O
T O
cell O
activation O
. O

Its O
membrane O
expression O
is O
highly O
regulated O
by O
endocytosis O
and O
trafficking O
through O
the O
secretory O
lysosome O
pathway O
. O

Chediak B
- I
Higashi I
syndrome I
( O
CHS B
) O
is O
an O
inherited B
disorder I
caused O
by O
mutations O
in O
the O
lysosomal O
trafficking O
regulator O
gene O
, O
LYST O
. O

It O
results O
in O
defective O
membrane O
targeting O
of O
the O
proteins O
present O
in O
secretory O
lysosomes O
, O
and O
it O
is O
associated O
with O
a O
variety O
of O
features O
, O
including O
a O
lymphoproliferative B
syndrome I
with O
hemophagocytosis B
. O

The O
murine O
equivalent O
of O
CHS B
, O
beige O
mice O
, O
present O
similar O
characteristics O
but O
do O
not O
develop O
the O
lymphoproliferative B
syndrome I
. O

We O
show O
herein O
that O
CTLA O
- O
4 O
is O
present O
in O
enlarged O
, O
abnormal O
vesicles O
in O
CHS B
T O
cells O
and O
is O
not O
properly O
expressed O
at O
the O
cell O
surface O
after O
T O
cell O
activation O
, O
whereas O
its O
surface O
expression O
is O
not O
impaired O
. O

It O
is O
therefore O
proposed O
that O
the O
defective O
surface O
expression O
of O
CTLA O
- O
4 O
by O
CHS B
T O
cells O
is O
involved O
in O
the O
generation O
of O
lymphoproliferative B
disease I
. O

This O
observation O
may O
provide O
insight O
into O
the O
role O
of O
CTLA O
- O
4 O
in O
humans O
. O
. O

Proteolipoprotein O
gene O
analysis O
in O
82 O
patients O
with O
sporadic O
Pelizaeus B
- I
Merzbacher I
Disease I
: O
duplications O
, O
the O
major O
cause O
of O
the O
disease O
, O
originate O
more O
frequently O
in O
male O
germ O
cells O
, O
but O
point O
mutations O
do O
not O
. O

The O
Clinical O
European O
Network O
on O
Brain B
Dysmyelinating I
Disease I
. O

Pelizaeus B
- I
Merzbacher I
Disease I
( O
PMD B
) O
is O
an O
X B
- I
linked I
developmental I
defect I
of I
myelination I
affecting O
the O
central O
nervous O
system O
and O
segregating O
with O
the O
proteolipoprotein O
( O
PLP O
) O
locus O
. O

Investigating O
82 O
strictly O
selected O
sporadic O
cases O
of O
PMD B
, O
we O
found O
PLP O
mutations O
in O
77 O
% O
; O
complete O
PLP O
- O
gene O
duplications O
were O
the O
most O
frequent O
abnormality O
( O
62 O
% O
) O
, O
whereas O
point O
mutations O
in O
coding O
or O
splice O
- O
site O
regions O
of O
the O
gene O
were O
involved O
less O
frequently O
( O
38 O
% O
) O
. O

We O
analyzed O
the O
maternal O
status O
of O
56 O
cases O
to O
determine O
the O
origin O
of O
both O
types O
of O
PLP O
mutation O
, O
since O
this O
is O
relevant O
to O
genetic O
counseling O
. O

In O
the O
22 O
point O
mutations O
, O
68 O
% O
of O
mothers O
were O
heterozygous O
for O
the O
mutation O
, O
a O
value O
identical O
to O
the O
two O
- O
thirds O
of O
carrier O
mothers O
that O
would O
be O
expected O
if O
there O
were O
an O
equal O
mutation O
rate O
in O
male O
and O
female O
germ O
cells O
. O

In O
sharp O
contrast O
, O
among O
the O
34 O
duplicated O
cases O
, O
91 O
% O
of O
mothers O
were O
carriers O
, O
a O
value O
significantly O
( O
chi2 O
= O
9 O
. O
20 O
, O
P O
< O
. O
01 O
) O
in O
favor O
of O
a O
male O
bias O
, O
with O
an O
estimation O
of O
the O
male O
/ O
female O
mutation O
frequency O
( O
k O
) O
of O
9 O
. O

3 O
3 O
. O

Moreover O
, O
we O
observed O
the O
occurrence O
of O
de O
novo O
mutations O
between O
parental O
and O
grandparental O
generations O
in O
17 O
three O
- O
generation O
families O
, O
which O
allowed O
a O
direct O
estimation O
of O
the O
k O
value O
( O
k O
= O
11 O
) O
. O

Again O
, O
a O
significant O
male O
mutation O
imbalance O
was O
observed O
only O
for O
the O
duplications O
. O

Chromosome O
breakage O
in O
the O
Prader B
- I
Willi I
and I
Angelman I
syndromes I
involves O
recombination O
between O
large O
, O
transcribed O
repeats O
at O
proximal O
and O
distal O
breakpoints O
. O

Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
and O
Angelman B
syndrome I
( O
AS B
) O
are O
distinct O
neurobehavioral B
disorders I
that O
most O
often O
arise O
from O
a O
4 O
- O
Mb O
deletion O
of O
chromosome O
15q11 O
- O
q13 O
during O
paternal O
or O
maternal O
gametogenesis O
, O
respectively O
. O

At O
a O
de O
novo O
frequency O
of O
approximately O
. O

67 O
- O
1 O
/ O
10 O
, O
000 O
births O
, O
these O
deletions O
represent O
a O
common O
structural O
chromosome O
change O
in O
the O
human O
genome O
. O

To O
elucidate O
the O
mechanism O
underlying O
these O
events O
, O
we O
characterized O
the O
regions O
that O
contain O
two O
proximal O
breakpoint O
clusters O
and O
a O
distal O
cluster O
. O

Novel O
DNA O
sequences O
potentially O
associated O
with O
the O
breakpoints O
were O
positionally O
cloned O
from O
YACs O
within O
or O
near O
these O
regions O
. O

Analyses O
of O
rodent O
- O
human O
somatic O
- O
cell O
hybrids O
, O
YAC O
contigs O
, O
and O
FISH O
of O
normal O
or O
rearranged O
chromosomes O
15 O
identified O
duplicated O
sequences O
( O
the O
END O
repeats O
) O
at O
or O
near O
the O
breakpoints O
. O

The O
END O
- O
repeat O
units O
are O
derived O
from O
large O
genomic O
duplications O
of O
a O
novel O
gene O
( O
HERC2 O
) O
, O
many O
copies O
of O
which O
are O
transcriptionally O
active O
in O
germline O
tissues O
. O

One O
of O
five O
PWS B
/ O
AS B
patients O
analyzed O
to O
date O
has O
an O
identifiable O
, O
rearranged O
HERC2 O
transcript O
derived O
from O
the O
deletion O
event O
. O

We O
postulate O
that O
the O
END O
repeats O
flanking O
15q11 O
- O
q13 O
mediate O
homologous O
recombination O
resulting O
in O
deletion O
. O

Furthermore O
, O
we O
propose O
that O
active O
transcription O
of O
these O
repeats O
in O
male O
and O
female O
germ O
cells O
may O
facilitate O
the O
homologous O
recombination O
process O
. O

Linkage O
analysis O
in O
a O
large O
Brazilian O
family O
with O
van B
der I
Woude I
syndrome I
suggests O
the O
existence O
of O
a O
susceptibility O
locus O
for O
cleft B
palate I
at O
17p11 O
. O
2 O
- O
11 O
. O
1 O
. O

van B
der I
Woude I
syndrome I
( O
VWS B
) O
, O
which O
has O
been O
mapped O
to O
1q32 O
- O
41 O
, O
is O
characterized O
by O
pits B
and I
/ I
or I
sinuses I
of I
the I
lower I
lip I
, O
cleft B
lip I
/ I
palate I
( O
CL B
/ I
P I
) O
, O
cleft B
palate I
( O
CP B
) O
, O
bifid B
uvula I
, O
and O
hypodontia B
( O
H B
) O
. O

The O
expression O
of O
VWS B
, O
which O
has O
incomplete O
penetrance O
, O
is O
highly O
variable O
. O

Both O
the O
occurrence O
of O
CL B
/ I
P I
and O
CP B
within O
the O
same O
genealogy O
and O
a O
recurrence O
risk O
< O
40 O
% O
for O
CP B
among O
descendants O
with O
VWS B
have O
suggested O
that O
the O
development O
of O
clefts B
in O
this O
syndrome O
is O
influenced O
by O
modifying O
genes O
at O
other O
loci O
. O

To O
test O
this O
hypothesis O
, O
we O
have O
conducted O
linkage O
analysis O
in O
a O
large O
Brazilian O
kindred O
with O
VWS B
, O
considering O
as O
affected O
the O
individuals O
with O
CP B
, O
regardless O
of O
whether O
it O
is O
associated O
with O
other O
clinical O
signs O
of O
VWS B
. O

Our O
results O
suggest O
that O
a O
gene O
at O
17p11 O
. O

2 O
- O
11 O
2 O
- O
11 O
. O

1 O
, O
together O
with O
the O
VWS B
gene O
at O
1p32 O
- O
41 O
, O
enhances O
the O
probability O
of O
CP B
in O
an O
individual O
carrying O
the O
two O
at O
- O
risk O
genes O
. O

If O
this O
hypothesis O
is O
confirmed O
in O
other O
VWS B
pedigrees O
, O
it O
will O
represent O
one O
of O
the O
first O
examples O
of O
a O
gene O
, O
mapped O
through O
linkage O
analysis O
, O
which O
modifies O
the O
expression O
of O
a O
major O
gene O
. O

New O
mutations O
, O
polymorphisms O
, O
and O
rare O
variants O
in O
the O
ATM O
gene O
detected O
by O
a O
novel O
SSCP O
strategy O
. O

The O
gene O
for O
ataxia B
- I
telangiectasia I
, O
ATM O
, O
spans O
about O
150 O
kb O
of O
genomic O
DNA O
. O

ATM O
mutations O
are O
found O
along O
the O
entire O
gene O
, O
with O
no O
evidence O
of O
a O
mutational O
hot O
spot O
. O

Using O
DNA O
as O
the O
starting O
material O
, O
we O
screened O
the O
ATM O
gene O
in O
92 O
A B
- I
T I
patients O
, O
using O
an O
optimized O
single O
- O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
technique O
that O
detected O
all O
previously O
known O
mutations O
in O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
segments O
being O
analyzed O
. O

To O
expedite O
screening O
, O
we O
sequentially O
loaded O
the O
SSCP O
gels O
with O
three O
different O
sets O
of O
PCR O
products O
that O
were O
pretested O
to O
avoid O
overlapping O
patterns O
. O

Many O
of O
the O
DNA O
changes O
we O
detected O
were O
intragenic O
polymorphisms O
. O

Of O
an O
expected O
177 O
unknown O
mutations O
, O
we O
detected O
approximately O
70 O
% O
, O
mostly O
protein O
truncating O
mutations O
( O
that O
would O
have O
been O
detectable O
by O
protein O
truncation O
testing O
if O
RNA O
starting O
material O
had O
been O
available O
) O
. O

Mutations O
have O
now O
been O
defined O
for O
every O
exon O
of O
the O
ATM O
gene O
. O

Herein O
, O
we O
present O
35 O
new O
mutations O
and O
34 O
new O
intragenic O
polymorphisms O
or O
rare O
variants O
within O
the O
ATM O
gene O
. O

This O
is O
the O
most O
comprehensive O
compilation O
of O
ATM O
polymorphisms O
assembled O
to O
date O
. O

Defining O
polymorphic O
sites O
as O
well O
as O
mutations O
in O
the O
ATM O
gene O
will O
be O
of O
great O
importance O
in O
designing O
automated O
methods O
for O
detecting O
mutations O
. O
. O

A O
novel O
frameshift O
mutation O
in O
the O
McLeod B
syndrome I
gene O
in O
a O
Japanese O
family O
. O

We O
report O
a O
novel O
mutation O
in O
the O
XK O
gene O
( O
XK O
) O
in O
a O
Japanese O
patient O
with O
McLeod B
syndrome I
. O

A O
50 O
- O
year O
- O
old O
man O
showed O
progressive O
muscular B
atrophy I
, O
choreic B
movement I
, O
elevated O
level O
of O
serum O
creatinine O
kinase O
, O
and O
acanthocytosis B
. O

The O
expression O
level O
of O
all O
the O
Kell O
antigens O
in O
erythrocyte O
was O
decreased O
and O
molecular O
analysis O
revealed O
a O
single O
- O
base O
( O
T O
) O
deletion O
at O
the O
nucleotide O
position O
1095 O
in O
XK O
. O

This O
deletion O
caused O
a O
frameshift O
in O
translation O
, O
leading O
to O
a O
premature O
stop O
codon O
at O
the O
amino O
acid O
position O
408 O
. O

We O
conclude O
this O
single O
- O
base O
deletion O
causes O
defective O
Kx O
protein O
, O
which O
is O
responsible O
for O
the O
McLeod B
phenotype O
in O
this O
patient O
. O
. O

Association O
of O
BRCA1 O
with O
the O
hRad50 O
- O
hMre11 O
- O
p95 O
complex O
and O
the O
DNA O
damage O
response O
. O

BRCA1 O
encodes O
a O
tumor B
suppressor O
that O
is O
mutated O
in O
familial B
breast I
and I
ovarian I
cancers I
. O

Here O
, O
it O
is O
shown O
that O
BRCA1 O
interacts O
in O
vitro O
and O
in O
vivo O
with O
hRad50 O
, O
which O
forms O
a O
complex O
with O
hMre11 O
and O
p95 O
/ O
nibrin O
. O

Upon O
irradiation O
, O
BRCA1 O
was O
detected O
in O
discrete O
foci O
in O
the O
nucleus O
, O
which O
colocalize O
with O
hRad50 O
. O

Formation O
of O
irradiation O
- O
induced O
foci O
positive O
for O
BRCA1 O
, O
hRad50 O
, O
hMre11 O
, O
or O
p95 O
was O
dramatically O
reduced O
in O
HCC O
/ O
1937 O
breast B
cancer I
cells O
carrying O
a O
homozygous O
mutation O
in O
BRCA1 O
but O
was O
restored O
by O
transfection O
of O
wild O
- O
type O
BRCA1 O
. O

Ectopic O
expression O
of O
wild O
- O
type O
, O
but O
not O
mutated O
, O
BRCA1 O
in O
these O
cells O
rendered O
them O
less O
sensitive O
to O
the O
DNA O
damage O
agent O
, O
methyl O
methanesulfonate O
. O

These O
data O
suggest O
that O
BRCA1 O
is O
important O
for O
the O
cellular O
responses O
to O
DNA O
damage O
that O
are O
mediated O
by O
the O
hRad50 O
- O
hMre11 O
- O
p95 O
complex O
. O
. O

Relationship O
among O
genotype O
, O
biochemical O
phenotype O
, O
and O
cognitive O
performance O
in O
females O
with O
phenylalanine B
hydroxylase I
deficiency I
: O
report O
from O
the O
Maternal B
Phenylketonuria I
Collaborative O
Study O
. O

OBJECTIVE O
To O
examine O
the O
relationship O
of O
phenylalanine O
hydroxylase O
( O
PAH O
) O
genotypes O
to O
biochemical O
phenotype O
and O
cognitive O
development O
in O
maternal B
phenylketonuria I
( O
PKU B
) O
. O

METHODOLOGY O
PAH O
gene O
mutations O
were O
examined O
in O
222 O
hyperphenylalaninemic B
females O
enrolled O
in O
the O
Maternal B
PKU I
Collaborative O
Study O
( O
MPKUCS O
) O
. O

A O
total O
of O
84 O
different O
mutations O
were O
detected O
, O
and O
complete O
genotype O
was O
obtained O
in O
199 O
individuals O
. O

Based O
on O
previous O
knowledge O
about O
mutation O
- O
phenotype O
associations O
, O
78 O
of O
the O
mutations O
could O
be O
assigned O
to O
one O
of O
four O
classes O
of O
severity O
( O
severe O
PKU B
, O
moderate O
PKU B
, O
mild O
PKU B
, O
and O
mild B
hyperphenylalaninemia I
[ O
MHP B
] O
) O
. O

Then O
, O
189 O
MPKUCS O
subjects O
were O
grouped O
according O
to O
the O
various O
combinations O
of O
mutation O
classifications O
. O

The O
sample O
sizes O
were O
large O
enough O
for O
statistical O
testing O
in O
four O
groups O
with O
at O
least O
one O
mutation O
that O
completely O
abolishes O
enzyme O
activity O
. O

These O
patients O
are O
considered O
functionally O
hemizygous O
. O

RESULTS O
The O
biochemical O
phenotype O
predicted O
from O
the O
genotype O
in O
functionally O
hemizygous O
patients O
was O
related O
significantly O
to O
the O
assigned O
phenylalanine O
level O
. O

Cognitive O
performance O
( O
IQ O
) O
was O
also O
significantly O
related O
to O
genotype O
. O

The O
IQ O
of O
PAH B
- I
deficient I
mothers O
with O
a O
severe O
PKU B
mutation O
in O
combination O
with O
a O
MHP B
mutation O
or O
a O
mild O
PKU B
mutation O
was O
99 O
and O
96 O
, O
respectively O
, O
whereas O
the O
IQ O
of O
PKU B
mothers O
with O
two O
severe O
PKU B
mutations O
or O
with O
one O
severe O
and O
one O
moderate O
PKU B
mutation O
was O
83 O
and O
84 O
, O
respectively O
. O

Of O
the O
patients O
with O
PKU B
, O
92 O
% O
had O
been O
treated O
during O
childhood O
. O

Those O
who O
were O
untreated O
or O
treated O
late O
had O
lower O
than O
average O
IQ O
scores O
for O
their O
group O
of O
mutation O
combinations O
. O

Females O
with O
moderate O
or O
mild O
PKU B
who O
were O
treated O
early O
and O
treated O
for O
> O
6 O
years O
showed O
IQ O
scores O
10 O
points O
above O
average O
for O
their O
group O
. O

CONCLUSIONS O
The O
reproductive O
outcome O
in O
maternal B
phenylketonuria I
is O
dependent O
on O
prenatal O
metabolic O
control O
and O
postnatal O
environmental O
circumstances O
. O

Both O
factors O
depend O
on O
the O
intellectual O
resources O
of O
the O
mother O
with O
PKU B
. O

The O
significant O
relationship O
among O
genotype O
, O
biochemical O
phenotype O
, O
and O
cognitive O
performance O
observed O
in O
the O
present O
study O
is O
of O
importance O
for O
the O
development O
of O
an O
optimal O
strategy O
for O
future O
treatment O
of O
females O
with O
PKU B
who O
plan O
pregnancy O
. O
. O

Spinal B
xanthomatosis I
: O
a O
variant O
of O
cerebrotendinous B
xanthomatosis I
. O

We O
describe O
seven O
Dutch O
patients O
from O
six O
families O
with O
a O
slowly O
progressive O
, O
mainly O
spinal B
cord I
syndrome I
that O
remained O
for O
many O
years O
the O
sole O
expression O
of O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O

MRI O
demonstrated O
white B
matter I
abnormalities I
in O
the O
lateral O
and O
dorsal O
columns O
of O
the O
spinal O
cord O
. O

Post O
- O
mortem O
examination O
of O
one O
of O
the O
patients O
showed O
extensive O
myelin O
loss O
in O
these O
columns O
. O

An O
array O
of O
genotypes O
was O
found O
in O
these O
patients O
. O

We O
conclude O
that O
spinal B
xanthomatosis I
is O
a O
clinical O
and O
radiological O
separate O
entity O
of O
CTX B
that O
should O
be O
included O
in O
the O
differential O
diagnosis O
of O
chronic B
myelopathy I
. O
. O

A O
transgene O
insertion O
creating O
a O
heritable O
chromosome O
deletion O
mouse O
model O
of O
Prader B
- I
Willi I
and I
angelman I
syndromes I
. O

Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
and O
Angelman B
syndrome I
( O
AS B
) O
result O
from O
the O
loss O
of O
function O
of O
imprinted O
genes O
in O
human O
chromosome O
15q11 O
- O
q13 O
. O

The O
central O
part O
of O
mouse O
chromosome O
7 O
is O
homologous O
to O
human O
15q11 O
- O
q13 O
, O
with O
conservation O
of O
both O
gene O
order O
and O
imprinted O
features O
. O

We O
report O
here O
the O
characterization O
of O
a O
transgene O
insertion O
( O
Epstein O
- O
Barr O
virus O
Latent O
Membrane O
Protein O
2A O
, O
LMP2A O
) O
into O
mouse O
chromosome O
7C O
, O
which O
has O
resulted O
in O
mouse O
models O
for O
PWS B
and O
AS B
dependent O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O

Epigenotype O
( O
allelic O
expression O
and O
DNA O
methylation O
) O
and O
fluorescence O
in O
situ O
hybridization O
analyses O
indicate O
that O
the O
transgene O
- O
induced O
mutation O
has O
generated O
a O
complete O
deletion O
of O
the O
PWS B
/ O
AS B
- O
homologous O
region O
but O
has O
not O
deleted O
flanking O
loci O
. O

Because O
the O
intact O
chromosome O
7 O
, O
opposite O
the O
deleted O
homolog O
, O
maintains O
the O
correct O
imprint O
in O
somatic O
cells O
of O
PWS B
and O
AS B
mice O
and O
establishes O
the O
correct O
imprint O
in O
male O
and O
female O
germ O
cells O
of O
AS B
mice O
, O
homologous O
association O
and O
replication O
asynchrony O
are O
not O
part O
of O
the O
imprinting O
mechanism O
. O

This O
heritable O
- O
deletion O
mouse O
model O
will O
be O
particularly O
useful O
for O
the O
identification O
of O
the O
etiological O
genes O
and O
mechanisms O
, O
phenotypic O
basis O
, O
and O
investigation O
of O
therapeutic O
approaches O
for O
PWS B
. O
. O

Linkage O
analysis O
of O
5 O
novel O
van B
der I
Woude I
syndrome I
kindreds O
to O
1q32 O
- O
q41 O
markers O
further O
supports O
locus O
homogeneity O
of O
the O
disease O
trait O
. O

van B
der I
Woude I
syndrome I
( O
vWS B
, O
MIM O
119300 O
) O
is O
a O
rare O
autosomal B
dominant I
clefting I
condition I
with O
cardinal O
features O
of O
mucous B
cysts I
( O
lower B
- I
lip I
pits I
) O
and O
clefts B
to I
the I
lip I
and I
/ I
or I
palate I
. O

The O
vWS B
gene O
has O
been O
assigned O
to O
a O
locus O
in O
1q32 O
- O
q41 O
by O
linkage O
analysis O
and O
physical O
mapping O
. O

We O
have O
investigated O
5 O
novel O
vWS B
families O
through O
probands O
attended O
for O
cleft B
lip I
and I
/ I
or I
palate I
repair O
at O
the O
Department O
of O
Maxillofacial O
Surgery O
of O
Hopital O
Trousseau O
, O
Paris O
, O
in O
order O
to O
tentatively O
refine O
the O
genetic O
map O
of O
the O
vWS B
region O
in O
1q32 O
- O
q41 O
and O
possibly O
identify O
unlinked O
pedigrees O
. O

Linkage O
analysis O
was O
carried O
out O
to O
6 O
microsatellite O
markers O
( O
D1S249 O
, O
D1S425 O
, O
D1S491 O
, O
D1S205 O
, O
D1S414 O
, O
D1S425 O
) O
, O
yielding O
a O
maximum O
cumulative O
LOD O
score O
of O
Z O
= O
3 O
. O

27 O
at O
theta O
= O
0 O
. O

00 O
for O
D1S245 O
. O

The O
innermost O
four O
markers O
were O
found O
to O
be O
tightly O
linked O
to O
one O
another O
, O
with O
no O
evidence O
for O
recombination O
. O

Our O
results O
support O
linkage O
of O
vWS B
within O
a O
region O
of O
tightly O
linked O
markers O
and O
do O
not O
favour O
locus O
heterogeneity O
of O
the O
disease O
trait O
. O

Null O
mutation O
of O
the O
murine O
ATP7B O
( O
Wilson B
disease I
) O
gene O
results O
in O
intracellular B
copper I
accumulation I
and O
late B
- I
onset I
hepatic I
nodular I
transformation I
. O

The O
Atp7b O
protein O
is O
a O
copper O
- O
transporting O
ATPase O
expressed O
predominantly O
in O
the O
liver O
and O
to O
a O
lesser O
extent O
in O
most O
other O
tissues O
. O

Mutations O
in O
the O
ATP7B O
gene O
lead O
to O
Wilson B
disease I
, O
a O
copper B
toxicity I
disorder I
characterized O
by O
dramatic O
build O
- O
up O
of O
intracellular O
hepatic O
copper O
with O
subsequent O
hepatic B
and I
neuro I
- I
logical I
abnormalities I
. O

Using O
homologous O
recombination O
to O
disrupt O
the O
normal O
translation O
of O
ATP7B O
, O
we O
have O
generated O
a O
strain O
of O
mice O
that O
are O
homozygous O
mutants O
( O
null O
) O
for O
the O
Wilson B
disease I
gene O
. O

The O
ATP7B O
null O
mice O
display O
a O
gradual O
accumulation O
of O
hepatic O
copper O
that O
increases O
to O
a O
level O
60 O
- O
fold O
greater O
than O
normal O
by O
5 O
months O
of O
age O
. O

An O
increase O
in O
copper O
concentration O
was O
also O
observed O
in O
the O
kidney O
, O
brain O
, O
placenta O
and O
lactating O
mammary O
glands O
of O
homo O
- O
zygous O
mutants O
, O
although O
milk O
from O
the O
mutant O
glands O
was O
copper B
deficient I
. O

Morphological B
abnormalities I
resembling O
cirrhosis B
developed O
in O
the O
majority O
of O
the O
livers O
from O
homozygous O
mutants O
older O
than O
7 O
months O
of O
age O
. O

Progeny O
of O
the O
homozygous O
mutant O
females O
demonstrated O
neurological B
abnormalities I
and O
growth B
retardation I
characteristic O
of O
copper B
deficiency I
. O

Copper O
concentration O
in O
the O
livers O
of O
the O
newborn O
homozygous O
null O
mutants O
was O
decreased O
dramatically O
. O

In O
summary O
, O
inactivation O
of O
the O
murine O
ATP7B O
gene O
produces O
a O
form O
of O
cirrhotic B
liver I
disease I
that O
resembles O
Wilson B
disease I
in O
humans O
and O
the O
toxic O
milk O
phenotype O
in O
the O
mouse O
. O
. O

French O
Machado B
- I
Joseph I
disease I
patients O
do O
not O
exhibit O
gametic O
segregation O
distortion O
: O
a O
sperm O
typing O
analysis O
. O

Segregation O
distortion O
has O
been O
reported O
to O
occur O
in O
a O
number O
of O
the O
trinucleotide B
repeat I
disorders I
. O

On O
the O
basis O
of O
a O
sperm O
typing O
study O
performed O
in O
patients O
of O
Japanese O
descent O
with O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
, O
it O
was O
reported O
that O
disease O
alleles O
are O
preferentially O
transmitted O
during O
meiosis O
. O

We O
performed O
a O
sperm O
typing O
study O
of O
five O
MJD B
patients O
of O
French O
descent O
and O
analysis O
of O
the O
pooled O
data O
shows O
a O
ratio O
of O
mutant O
to O
normal O
alleles O
of O
379 O
436 O
( O
46 O
. O
5 O
53 O
. O
5 O
% O
) O
, O
which O
does O
not O
support O
meiotic O
segregation O
distortion O
. O

To O
confirm O
these O
results O
, O
sperm O
typing O
analysis O
was O
also O
performed O
using O
a O
polymorphic O
marker O
, O
D14S1050 O
, O
closely O
linked O
to O
the O
MJD1 O
gene O
. O

Among O
910 O
sperm O
analyzed O
, O
the O
allele O
linked O
to O
the O
disease O
chromosome O
was O
detected O
in O
50 O
. O

3 O
% O
of O
the O
samples O
and O
the O
allele O
linked O
to O
the O
normal O
chromosome O
was O
found O
in O
49 O
. O

6 O
% O
of O
the O
sperm O
. O

The O
difference O
in O
frequency O
of O
these O
two O
alleles O
is O
not O
significant O
( O
P O
= O
0 O
. O
8423 O
) O
. O

Likelihood O
- O
based O
analysis O
of O
segregation O
distortion O
in O
the O
single O
sperm O
data O
using O
the O
SPERMSEG O
program O
also O
showed O
no O
support O
for O
segregation O
distortion O
at O
the O
gamete O
level O
in O
this O
patient O
population O
. O

The O
previous O
report O
on O
the O
Japanese O
patients O
also O
suggested O
that O
disease O
allele O
stability O
may O
be O
influenced O
by O
a O
trans O
effect O
of O
an O
intragenic O
polymorphism O
( O
987 O
G O
/ O
C O
) O
in O
the O
wild O
- O
type O
allele O
. O

All O
of O
the O
French O
patients O
were O
heterozygous O
for O
this O
polymorphism O
. O

However O
, O
analysis O
of O
the O
variance O
in O
repeat O
number O
in O
sperm O
from O
the O
French O
MJD B
patients O
overlapped O
significantly O
with O
the O
variance O
in O
repeat O
number O
observed O
in O
the O
C O
/ O
C O
homozygous O
Japanese O
patients O
. O

Missense O
mutation O
in O
the O
alternative O
splice O
region O
of O
the O
PAX6 O
gene O
in O
eye B
anomalies I
. O

The O
PAX6 O
gene O
is O
involved O
in O
ocular O
morphogenesis O
, O
and O
PAX6 O
mutations O
have O
been O
detected O
in O
various O
types O
of O
ocular B
anomalies I
, O
including O
aniridia B
, O
Peters B
anomaly I
, O
corneal B
dystrophy I
, O
congenital B
cataract I
, O
and O
foveal B
hypoplasia I
. O

The O
gene O
encodes O
a O
transcriptional O
regulator O
that O
recognizes O
target O
genes O
through O
its O
paired O
- O
type O
DNA O
- O
binding O
domain O
. O

The O
paired O
domain O
is O
composed O
of O
two O
distinct O
DNA O
- O
binding O
subdomains O
, O
the O
N O
- O
terminal O
subdomain O
( O
NTS O
) O
and O
the O
C O
- O
terminal O
subdomain O
( O
CTS O
) O
, O
which O
bind O
respective O
consensus O
DNA O
sequences O
. O

The O
human O
PAX6 O
gene O
produces O
two O
alternative O
splice O
isoforms O
that O
have O
the O
distinct O
structure O
of O
the O
paired O
domain O
. O

The O
insertion O
, O
into O
the O
NTS O
, O
of O
14 O
additional O
amino O
acids O
encoded O
by O
exon O
5a O
abolishes O
the O
DNA O
- O
binding O
activity O
of O
the O
NTS O
and O
unmasks O
the O
DNA O
- O
binding O
ability O
of O
the O
CTS O
. O

Thus O
, O
exon O
5a O
appears O
to O
function O
as O
a O
molecular O
switch O
that O
specifies O
target O
genes O
. O

We O
ascertained O
a O
novel O
missense O
mutation O
in O
four O
pedigrees O
with O
Peters B
anomaly I
, O
congenital B
cataract I
, O
Axenfeldt B
anomaly I
, O
and O
/ O
or O
foveal B
hypoplasia I
, O
which O
, O
to O
our O
knowledge O
, O
is O
the O
first O
mutation O
identified O
in O
the O
splice O
- O
variant O
region O
. O

A O
T O
- O
- O
> O
A O
transition O
at O
the O
20th O
nucleotide O
position O
of O
exon O
5a O
results O
in O
a O
Val O
- O
- O
> O
Asp O
( O
GTC O
- O
- O
> O
GAC O
) O
substitution O
at O
the O
7th O
codon O
of O
the O
alternative O
splice O
region O
. O

Functional O
analyses O
demonstrated O
that O
the O
V54D O
mutation O
slightly O
increased O
NTS O
binding O
and O
decreased O
CTS O
transactivation O
activity O
to O
almost O
half O
. O
. O

Penetrances O
of O
BRCA1 O
1675delA O
and O
1135insA O
with O
respect O
to O
breast B
cancer I
and O
ovarian B
cancer I
. O

For O
genetic O
counseling O
and O
predictive O
testing O
in O
families O
with O
inherited B
breast I
- I
ovarian I
cancer I
, O
penetrances O
and O
expressions O
of O
the O
underlying O
mutations O
should O
be O
known O
. O

We O
have O
previously O
reported O
two O
BRCA1 O
founder O
mutations O
in O
the O
Norwegian O
population O
. O

Index O
cases O
for O
the O
present O
study O
were O
found O
two O
different O
ways O
through O
a O
series O
of O
consecutive O
ovarian B
cancers I
( O
n O
= O
16 O
) O
and O
through O
our O
family O
cancer B
clinic O
( O
n O
= O
14 O
) O
. O

Altogether O
, O
20 O
of O
the O
patients O
had O
BRCA1 O
1675delA O
, O
and O
10 O
had O
1135insA O
. O

Their O
relatives O
were O
described O
with O
respect O
to O
absence O
/ O
presence O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

Of O
133 O
living O
female O
relatives O
, O
83 O
( O
62 O
% O
) O
were O
tested O
for O
the O
presence O
of O
a O
mutation O
. O

No O
difference O
, O
in O
penetrance O
and O
expression O
, O
between O
the O
two O
mutations O
were O
found O
, O
whereas O
differences O
according O
to O
method O
of O
ascertainment O
were O
seen O
. O

The O
overall O
findings O
were O
that O
disease O
started O
to O
occur O
at O
age O
30 O
years O
and O
that O
by O
age O
50 O
years O
48 O
% O
of O
the O
mutation O
- O
carrying O
women O
had O
experienced O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

More O
ovarian B
cancers I
than O
breast B
cancers I
were O
recorded O
. O

Both O
penetrance O
and O
expression O
( O
breast B
cancer I
vs O
. O
ovarian B
cancer I
) O
were O
different O
from O
those O
in O
reports O
of O
the O
Ashkenazi O
founder O
mutations O
. O

Whether O
the O
reported O
differences O
reflect O
true O
differences O
and O
/ O
or O
methodological O
problems O
is O
discussed O
. O

An O
observed O
excess O
of O
mutation O
carriers O
could O
not O
be O
accounted O
for O
by O
methodological O
problems O
; O
possible O
explanations O
were O
a O
" O
true O
" O
low O
penetrance O
or O
preferential O
segregation O
. O
. O

The O
dermatofibrosarcoma B
protuberans I
- O
associated O
collagen O
type O
Ialpha1 O
/ O
platelet O
- O
derived O
growth O
factor O
( O
PDGF O
) O
B O
- O
chain O
fusion O
gene O
generates O
a O
transforming O
protein O
that O
is O
processed O
to O
functional O
PDGF O
- O
BB O
. O

Dermatofibrosarcoma B
protuberans I
( O
DFSP B
) O
displays O
chromosomal O
rearrangements O
involving O
chromosome O
17 O
and O
22 O
, O
which O
fuse O
the O
collagen O
type O
Ialpha1 O
( O
COLIA1 O
) O
gene O
to O
the O
platelet O
- O
derived O
growth O
factor O
( O
PDGF O
) O
B O
- O
chain O
( O
PDGFB O
) O
gene O
. O

To O
characterize O
the O
functional O
and O
structural O
properties O
of O
the O
COLIA1 O
/ O
PDGFB O
fusion O
protein O
, O
we O
generated O
a O
stable O
NIH3T3 O
cell O
line O
that O
contained O
a O
tumor O
- O
derived O
chimeric O
gene O
resulting O
from O
a O
COIA1 O
intron O
7 O
- O
PDGFB O
intron O
1 O
fusion O
. O

Expression O
of O
the O
fusion O
protein O
led O
to O
morphological O
transformation O
and O
increased O
growth O
rate O
of O
these O
cells O
. O

The O
PDGF O
receptor O
kinase O
inhibitor O
CGP57148B O
reversed O
the O
transformed O
phenotype O
and O
reduced O
the O
growth O
rate O
of O
COLIA1 O
/ O
PDGFB O
- O
expressing O
cells O
but O
had O
no O
effects O
on O
control O
cells O
. O

The O
presence O
of O
dimeric O
COLIA1 O
/ O
PDGFB O
precursors O
was O
demonstrated O
through O
PDGFB O
immunoprecipitations O
of O
metabolically O
labeled O
cells O
and O
also O
by O
PDGFB O
immunoprecipitations O
followed O
by O
immunoblotting O
with O
COLIA1 O
antibodies O
. O

Pulse O
- O
chase O
studies O
demonstrated O
that O
the O
COLIA1 O
/ O
PDGFB O
precursor O
was O
processed O
to O
an O
end O
product O
that O
was O
indistinguishable O
from O
wild O
- O
type O
PDGF O
- O
BB O
. O

Finally O
, O
COLIA1 O
/ O
PDGFB O
- O
expressing O
cells O
generated O
tumors B
after O
s O
. O

c O
c O
. O
injection O
into O
nude O
mice O
, O
and O
tumor B
growth O
was O
reduced O
by O
treatment O
with O
CGP57148B O
. O

We O
conclude O
that O
the O
COLIA1 O
/ O
PDGFB O
fusion O
associated O
with O
DFSP B
contributes O
to O
tumor B
development O
through O
ectopic O
production O
of O
PDGF O
- O
BB O
and O
the O
formation O
of O
an O
autocrine O
loop O
. O

Our O
findings O
, O
thus O
, O
suggest O
that O
PDGF O
receptors O
could O
be O
a O
target O
for O
pharmacological O
treatment O
of O
DFSP B
and O
giant B
cell I
fibroblastoma I
, O
e O
. O
g O
. O
, O
through O
the O
use O
of O
PDGF O
receptor O
kinase O
inhibitors O
such O
as O
CGP57148B O
. O

Identification O
of O
a O
common O
PEX1 O
mutation O
in O
Zellweger B
syndrome I
. O

The O
Zellweger B
spectrum I
of I
disease I
, O
encompassing O
Zellweger B
syndrome I
and O
the O
progressively O
milder O
phenotypes O
of O
neonatal B
adrenoleukodystrophy I
and O
infantile B
Refsum I
disease I
, O
is O
due O
to O
a O
failure O
to O
form O
functional O
peroxisomes O
. O

Cell O
fusion O
complementation O
studies O
demonstrated O
that O
these O
diseases O
are O
genetically O
heterogeneous O
, O
with O
two O
- O
thirds O
of O
all O
patients O
lying O
within O
a O
single O
complementation O
group O
, O
CG1 O
. O

Molecular O
genetic O
and O
cell O
biology O
studies O
have O
shown O
that O
PEX1 O
is O
deficient O
in O
many O
CG1 O
patients O
. O

However O
, O
previous O
studies O
have O
focused O
on O
mildly O
affected O
patients O
and O
there O
is O
still O
no O
report O
of O
two O
mutant O
PEX1 O
alleles O
in O
any O
Zellweger B
syndrome I
patient O
. O

Furthermore O
, O
mutations O
in O
the O
PMP70 O
gene O
have O
also O
been O
identified O
in O
two O
Zellweger B
syndrome I
patients O
from O
CG1 O
, O
raising O
the O
possibility O
that O
CG1 O
patients O
may O
represent O
a O
mixture O
of O
PEX1 O
- O
deficient O
and O
PMP70 O
- O
deficient O
individuals O
. O

To O
address O
the O
molecular O
basis O
of O
disease O
in O
Zellweger B
syndrome I
patients O
from O
CG1 O
, O
we O
examined O
all O
24 O
PEX1 O
exons O
in O
four O
patients O
, O
including O
both O
patients O
that O
have O
mutations O
in O
PMP70 O
. O

PEX1 O
mutations O
were O
detected O
in O
all O
four O
patients O
, O
including O
a O
1 O
- O
bp O
insertion O
( O
c O
. O
2097insT O
) O
in O
exon O
13 O
that O
was O
present O
in O
three O
of O
the O
four O
patients O
. O

Subsequent O
studies O
demonstrated O
that O
this O
mutation O
is O
present O
in O
one O
- O
half O
of O
all O
CG1 O
patients O
and O
correlates O
with O
the O
Zellweger B
syndrome I
phenotype O
. O

As O
this O
mutation O
leads O
to O
a O
loss O
of O
protein O
function O
its O
frequency O
makes O
it O
the O
most O
common O
cause O
of O
Zellweger B
syndrome I
, O
helping O
to O
explain O
the O
high O
percentage O
of O
patients O
that O
belong O
to O
CG1 O
. O

Novel O
mutations O
in O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
gene O
and O
their O
effects O
on O
transcriptional O
, O
translational O
, O
and O
clinical O
phenotypes O
. O

Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
is O
an O
X B
- I
linked I
recessive I
immunodeficiency I
characterized O
by O
thrombocytopenia B
, O
eczema B
, O
and O
recurrent O
infections O
, O
and O
caused O
by O
mutations O
in O
the O
WAS B
protein O
( O
WASP O
) O
gene O
. O

WASP O
contains O
several O
functional O
domains O
through O
which O
it O
interacts O
with O
proteins O
involved O
in O
intracellular O
signaling O
and O
regulation O
of O
the O
actin O
cytoskeleton O
. O

In O
this O
report O
, O
17 O
WASP O
gene O
mutations O
were O
identified O
, O
12 O
of O
which O
are O
novel O
. O

DNA O
of O
affected O
males O
and O
obligate O
carriers O
was O
PCR O
amplified O
and O
analyzed O
by O
SSCA O
, O
heteroduplex O
analysis O
, O
and O
direct O
sequencing O
. O

The O
effects O
of O
the O
mutations O
at O
the O
mRNA O
and O
protein O
level O
were O
ascertained O
by O
RT O
- O
PCR O
and O
Western O
blot O
analyses O
. O

All O
missense O
mutations O
were O
located O
in O
exons O
1 O
- O
4 O
. O

Most O
of O
the O
nonsense O
, O
frameshift O
and O
splice O
site O
mutations O
were O
found O
in O
exons O
6 O
- O
11 O
. O

Mutations O
that O
alter O
splice O
sites O
led O
to O
the O
synthesis O
of O
several O
types O
of O
mRNAs O
, O
a O
fraction O
of O
which O
represented O
the O
normally O
spliced O
product O
. O

The O
presence O
of O
normally O
spliced O
transcripts O
was O
correlated O
with O
a O
milder O
phenotype O
. O

When O
one O
such O
case O
was O
studied O
by O
Western O
blotting O
, O
reduced O
amounts O
of O
normal O
- O
size O
WASP O
were O
present O
. O

In O
other O
cases O
as O
well O
, O
a O
correlation O
was O
found O
between O
the O
amount O
of O
normal O
or O
mutant O
WASP O
present O
and O
the O
phenotypes O
of O
the O
affected O
individuals O
. O

No O
protein O
was O
detected O
in O
two O
individuals O
with O
severe O
WAS B
. O

Reduced O
levels O
of O
a O
normal O
- O
size O
WASP O
with O
a O
missense O
mutation O
were O
seen O
in O
two O
individuals O
with O
XLT B
. O

It O
is O
concluded O
that O
mutation O
analysis O
at O
the O
DNA O
level O
is O
not O
sufficient O
for O
predicting O
clinical O
course O
. O

Studies O
at O
the O
transcript O
and O
protein O
level O
are O
needed O
for O
a O
better O
assessment O
. O
. O

Aminoglycoside O
antibiotics O
restore O
dystrophin O
function O
to O
skeletal O
muscles O
of O
mdx O
mice O
. O

Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
is O
caused O
by O
mutations O
in O
the O
dystrophin O
gene O
, O
leading O
to O
the O
absence O
of O
the O
dystrophin O
protein O
in O
striated O
muscle O
. O

A O
significant O
number O
of O
these O
mutations O
are O
premature O
stop O
codons O
. O

On O
the O
basis O
of O
the O
observation O
that O
aminoglycoside O
treatment O
can O
suppress O
stop O
codons O
in O
cultured O
cells O
, O
we O
tested O
the O
effect O
of O
gentamicin O
on O
cultured O
muscle O
cells O
from O
the O
mdx O
mouse O
- O
an O
animal O
model O
for O
DMD B
that O
possesses O
a O
premature O
stop O
codon O
in O
the O
dystrophin O
gene O
. O

Exposure O
of O
mdx O
myotubes O
to O
gentamicin O
led O
to O
the O
expression O
and O
localization O
of O
dystrophin O
to O
the O
cell O
membrane O
. O

We O
then O
evaluated O
the O
effects O
of O
differing O
dosages O
of O
gentamicin O
on O
expression O
and O
functional O
protection O
of O
the O
muscles O
of O
mdx O
mice O
. O

We O
identified O
a O
treatment O
regimen O
that O
resulted O
in O
the O
presence O
of O
dystrophin O
in O
the O
cell O
membrane O
in O
all O
striated O
muscles O
examined O
and O
that O
provided O
functional O
protection O
against O
muscular B
injury I
. O

To O
our O
knowledge O
, O
our O
results O
are O
the O
first O
to O
demonstrate O
that O
aminoglycosides O
can O
suppress O
stop O
codons O
not O
only O
in O
vitro O
but O
also O
in O
vivo O
. O

Furthermore O
, O
these O
results O
raise O
the O
possibility O
of O
a O
novel O
treatment O
regimen O
for O
muscular B
dystrophy I
and O
other O
diseases O
caused O
by O
premature O
stop O
codon O
mutations O
. O

This O
treatment O
could O
prove O
effective O
in O
up O
to O
15 O
% O
of O
patients O
with O
DMD B
. O
. O

Loss O
of O
the O
ataxia B
- I
telangiectasia I
gene O
product O
causes O
oxidative O
damage O
in O
target O
organs O
. O

Ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
is O
characterized O
by O
a O
markedly O
increased O
sensitivity O
to O
ionizing O
radiation O
, O
increased O
incidence O
of O
cancer B
, O
and O
neurodegeneration B
, O
especially O
of O
the O
cerebellar O
Purkinje O
cells O
. O

Ionizing O
radiation O
oxidizes O
macromolecules O
and O
causes O
tissue O
damage O
through O
the O
generation O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
. O

We O
therefore O
hypothesized O
that O
A B
- I
T I
is O
due O
to O
oxidative O
damage O
resulting O
from O
loss O
of O
function O
of O
the O
A B
- I
T I
gene O
product O
. O

To O
assess O
this O
hypothesis O
, O
we O
employed O
an O
animal O
model O
of O
A B
- I
T I
, O
the O
mouse O
with O
a O
disrupted O
Atm O
gene O
. O

We O
show O
that O
organs O
which O
develop O
pathologic O
changes O
in O
the O
Atm O
- O
deficient O
mice O
are O
targets O
of O
oxidative O
damage O
, O
and O
that O
cerebellar O
Purkinje O
cells O
are O
particularly O
affected O
. O

These O
observations O
provide O
a O
mechanistic O
basis O
for O
the O
A B
- I
T I
phenotype O
and O
lay O
a O
rational O
foundation O
for O
therapeutic O
intervention O
. O
. O

Recessively O
inherited O
multiple B
epiphyseal I
dysplasia I
with O
normal O
stature O
, O
club B
foot I
, O
and O
double B
layered I
patella I
caused O
by O
a O
DTDST O
mutation O
. O

We O
have O
observed O
over O
25 O
different O
mutations O
in O
the O
diastrophic B
dysplasia I
sulphate O
transporter O
gene O
( O
DTDST O
) O
in O
association O
with O
the O
recessive B
disorders I
achondrogenesis B
1B I
, O
atelosteogenesis B
2 I
, O
and O
diastrophic B
dysplasia I
. O

The O
c862t O
( O
R279W O
) O
transition O
is O
the O
most O
common O
mutation O
in O
non O
- O
Finnish O
patients O
, O
but O
in O
these O
disorders O
it O
is O
usually O
combined O
with O
other O
DTDST O
mutations O
. O

We O
had O
not O
seen O
a O
case O
of O
homozygosity O
for O
c862t O
( O
R279W O
) O
until O
we O
analysed O
DNA O
from O
a O
36 O
year O
old O
male O
with O
tall O
- O
normal O
stature O
( O
180 O
cm O
) O
who O
asked O
for O
genetic O
counselling O
for O
suspected O
multiple B
epiphyseal I
dysplasia I
. O

He O
was O
treated O
for O
club B
foot I
and O
hip B
dysplasia I
at O
birth O
. O

Skeletal O
changes O
consistent O
with O
multiple B
epiphyseal I
dysplasia I
, O
with O
the O
peculiar O
finding O
of O
a O
double B
layered I
patella I
, O
were O
recognised O
during O
childhood O
. O

Cleft B
palate I
, O
swelling B
of I
the I
ear I
pinna I
, O
and O
hitch B
hiker I
thumb I
were O
absent O
. O

He O
was O
found O
to O
be O
homozygous O
, O
and O
both O
healthy O
parents O
heterozygous O
, O
for O
the O
R279W O
mutation O
in O
DTDST O
, O
and O
his O
fibroblasts O
showed O
a O
sulphate O
incorporation O
defect O
typical O
of O
DTDST B
disorders I
. O

Counselling O
was O
given O
for O
a O
recessive B
disorder I
, O
thereby O
considerably O
reducing O
the O
probability O
of O
affected O
offspring O
. O

Multiple B
epiphyseal I
dysplasia I
is O
more O
frequently O
caused O
by O
dominant O
mutations O
in O
the O
COMP O
( O
EDM1 B
, O
McKusick O
132400 O
) O
and O
COL9A2 O
genes O
( O
EDM2 B
, O
McKusick O
600204 O
) O
. O

A O
few O
other O
patients O
and O
families O
with O
features O
similar O
to O
our O
proband O
have O
been O
described O
previously O
and O
considered O
to O
have O
autosomal O
recessive O
MED B
( O
EDM4 B
, O
McKusick O
226900 O
) O
. O

This O
observation O
confirms O
the O
existence O
of O
this O
entity O
and O
assigns O
it O
to O
the O
phenotypic O
spectrum O
associated O
with O
mutations O
at O
the O
DTDST O
locus O
. O
. O

Homozygosity O
for O
a O
novel O
DTDST O
mutation O
in O
a O
child O
with O
a O
' O
broad O
bone O
- O
platyspondylic O
' O
variant O
of O
diastrophic B
dysplasia I
. O

Atypical O
or O
variant O
forms O
of O
well O
- O
known O
chondrodysplasias B
may O
pose O
diagnostic O
problems O
. O

We O
report O
on O
a O
girl O
with O
clinical O
features O
suggesting O
diastrophic B
dysplasia I
but O
with O
unusual O
radiographic O
features O
including O
severe O
platyspondyly B
, O
wide O
metaphyses O
, O
and O
fibular O
overgrowth O
, O
which O
are O
partially O
reminiscent O
of O
metatropic B
dysplasia I
. O

The O
diagnosis O
was O
clarified O
by O
molecular O
analysis O
of O
the O
DTDST O
gene O
, O
which O
revealed O
homozygosity O
for O
a O
previously O
undescribed O
mutation O
leading O
to O
a O
Q454P O
substitution O
in O
the O
10th O
transmembrane O
domain O
of O
the O
DTDST O
sulfate O
transporter O
. O

Molecular O
analysis O
may O
be O
of O
particular O
value O
in O
such O
atypical O
cases O
. O
. O

The O
type O
of O
somatic O
mutation O
at O
APC O
in O
familial B
adenomatous I
polyposis I
is O
determined O
by O
the O
site O
of O
the O
germline O
mutation O
: O
a O
new O
facet O
to O
Knudson O
' O
s O
' O
two O
- O
hit O
' O
hypothesis O
. O

APC O
is O
often O
cited O
as O
a O
prime O
example O
of O
a O
tumor B
suppressor O
gene O
. O

Truncating O
germline O
and O
somatic O
mutations O
( O
or O
, O
infrequently O
, O
allelic O
loss O
) O
occur O
in O
tumors B
in O
FAP B
( O
familial B
adenomatous I
polyposis I
) O
. O

Most O
sporadic B
colorectal I
cancers I
also O
have O
two O
APC B
mutations O
. O

Clues O
from O
attenuated B
polyposis I
, O
missense O
germline O
variants O
with O
mild O
disease O
and O
the O
somatic O
mutation O
cluster O
region O
( O
codons O
1 O
, O
250 O
- O
1 O
, O
450 O
) O
indicate O
, O
however O
, O
that O
APC B
mutations O
might O
not O
result O
in O
simple O
loss O
of O
protein O
function O
. O

We O
have O
found O
that O
FAP B
patients O
with O
germline O
APC B
mutations O
within O
a O
small O
region O
( O
codons O
1 O
, O
194 O
- O
1 O
, O
392 O
at O
most O
) O
mainly O
show O
allelic O
loss O
in O
their O
colorectal B
adenomas I
, O
in O
contrast O
to O
other O
FAP B
patients O
, O
whose O
second O
hits O
tend O
to O
occur O
by O
truncating O
mutations O
in O
the O
mutation O
cluster O
region O
. O

Our O
results O
indicate O
that O
different O
APC B
mutations O
provide O
cells O
with O
different O
selective O
advantages O
, O
with O
mutations O
close O
to O
codon O
1 O
, O
300 O
providing O
the O
greatest O
advantage O
. O

Allelic O
loss O
is O
selected O
strongly O
in O
cells O
with O
one O
mutation O
near O
codon O
1 O
, O
300 O
. O

A O
different O
germline O
- O
somatic O
APC B
mutation O
association O
exists O
in O
FAP B
desmoids I
. O

APC O
is O
not O
, O
therefore O
, O
a O
classical O
tumor B
suppressor O
. O

Our O
findings O
also O
indicate O
a O
new O
mechanism O
for O
disease O
severity O
if O
a O
broader O
spectrum O
of O
mutations O
is O
selected O
in O
tumors B
, O
the O
somatic O
mutation O
rate O
is O
effectively O
higher O
and O
more O
tumors B
grow O
. O
. O

Mxi1 O
mutations O
in O
human O
neurofibrosarcomas B
. O

Mxi1 O
is O
thought O
to O
negatively O
regulate O
Myc O
function O
and O
may O
therefore O
be O
a O
potential O
tumor B
suppressor O
gene O
. O

Little O
effort O
has O
yet O
been O
made O
to O
find O
alterations O
involving O
this O
gene O
in O
human O
solid B
tumors I
. O

We O
screened O
31 O
human O
gastric B
cancers I
, O
7 O
esophageal B
cancers I
, O
85 O
bone B
and I
soft I
tissue I
tumors I
of O
various O
types O
, O
including O
4 O
neurofibrosarcomas B
. O

We O
also O
examined O
29 O
human O
tumor B
cell O
lines O
consisting O
of O
12 O
esophageal B
cancers I
, O
7 O
glioma B
/ O
glioblastomas B
and O
10 O
others O
for O
Mxi1 O
mutations O
in O
exons O
1 O
, O
2 O
, O
4 O
( O
HLH O
domain O
) O
, O
5 O
and O
6 O
. O

Polymerase O
chain O
reaction O
- O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
and O
subsequent O
sequencing O
revealed O
three O
distinct O
polymorphisms O
in O
the O
intron O
- O
exon O
boundary O
upstream O
from O
exon O
6 O
. O

We O
discovered O
a O
missense O
mutation O
, O
GCA O
to O
GTA O
( O
Ala O
54 O
Val O
) O
, O
in O
exon O
2 O
in O
a O
neurofibrosarcoma B
patient O
( O
case O
1 O
) O
, O
two O
missense O
mutations O
, O
AAA O
to O
CAA O
( O
Lys O
118 O
Gln O
) O
and O
GAA O
to O
GGA O
( O
Glu O
154 O
Gly O
) O
in O
exon O
5 O
of O
another O
neurofibrosarcoma B
patient O
( O
case O
2 O
) O
, O
and O
3 O
amino O
acid O
substitutions O
, O
GTG O
to O
GCG O
( O
Val O
179 O
Ala O
) O
, O
GTT O
to O
GCT O
( O
Val O
181 O
Ala O
) O
and O
TTC O
to O
CTC O
( O
Phe O
186 O

Leu O
) O
, O
in O
a O
third O
neurofibrosarcoma B
patient O
( O
case O
3 O
) O
. O

In O
case O
3 O
, O
loss O
of O
heterozygosity O
was O
also O
demonstrated O
by O
informative O
( O
TTC O
) O
3 O
/ O
( O
TTC O
) O
2 O
polymorphism O
. O

Our O
data O
demonstrate O
that O
mutations O
occur O
in O
the O
Mxi1 O
gene O
in O
neurofibrosarcoma B
. O

Missense O
mutations O
in O
the O
functional O
domain O
of O
Mxi1 O
in O
these O
cases O
may O
be O
involved O
in O
the O
pathogenesis O
of O
neurofibrosarcoma B
. O
. O

A O
population O
- O
based O
study O
of O
the O
clinical O
expression O
of O
the O
hemochromatosis B
gene O
. O

BACKGROUND O
AND O
METHODS O
Hereditary B
hemochromatosis I
is O
associated O
with O
homozygosity O
for O
the O
C282Y O
mutation O
in O
the O
hemochromatosis B
( O
HFE O
) O
gene O
on O
chromosome O
6 O
, O
elevated O
serum O
transferrin O
saturation O
, O
and O
excess B
iron I
deposits I
throughout O
the O
body O
. O

To O
assess O
the O
prevalence O
and O
clinical O
expression O
of O
the O
HFE O
gene O
, O
we O
conducted O
a O
population O
- O
based O
study O
in O
Busselton O
, O
Australia O
. O

In O
1994 O
, O
we O
obtained O
blood O
samples O
for O
the O
determination O
of O
serum O
transferrin O
saturation O
and O
ferritin O
levels O
and O
the O
presence O
or O
absence O
of O
the O
C282Y O
mutation O
and O
the O
H63D O
mutation O
( O
which O
may O
contribute O
to O
increased O
hepatic O
iron O
levels O
) O
in O
3011 O
unrelated O
white O
adults O
. O

We O
evaluated O
all O
subjects O
who O
had O
persistently O
elevated O
transferrin O
- O
saturation O
values O
( O
45 O
percent O
or O
higher O
) O
or O
were O
homozygous O
for O
the O
C282Y O
mutation O
. O

We O
recommended O
liver O
biopsy O
for O
subjects O
with O
serum O
ferritin O
levels O
of O
300 O
ng O
per O
milliliter O
or O
higher O
. O

The O
subjects O
were O
followed O
for O
up O
to O
four O
years O
. O

RESULTS O
Sixteen O
of O
the O
subjects O
( O
0 O
. O
5 O
percent O
) O
were O
homozygous O
for O
the O
C282Y O
mutation O
, O
and O
424 O
( O
14 O
. O
1 O
percent O
) O
were O
heterozygous O
. O

The O
serum O
transferrin O
saturation O
was O
45 O
percent O
or O
higher O
in O
15 O
of O
the O
16 O
who O
were O
homozygous O
; O
in O
1 O
subject O
it O
was O
43 O
percent O
. O

Four O
of O
the O
homozygous O
subjects O
had O
previously O
been O
given O
a O
diagnosis O
of O
hemochromatosis B
, O
and O
12 O
had O
not O
. O

Seven O
of O
these O
12 O
patients O
had O
elevated O
serum O
ferritin O
levels O
in O
1994 O
; O
6 O
of O
the O
7 O
had O
further O
increases O
in O
1998 O
, O
and O
1 O
had O
a O
decrease O
, O
although O
the O
value O
remained O
elevated O
. O

The O
serum O
ferritin O
levels O
in O
the O
four O
other O
homozygous O
patients O
remained O
in O
the O
normal O
range O
. O

Eleven O
of O
the O
16 O
homozygous O
subjects O
underwent O
liver O
biopsy O
; O
3 O
had O
hepatic B
fibrosis I
, O
and O
1 O
, O
who O
had O
a O
history O
of O
excessive B
alcohol I
consumption I
, O
had O
cirrhosis B
and O
mild O
microvesicular B
steatosis I
. O

Eight O
of O
the O
16 O
homozygous O
subjects O
had O
clinical O
findings O
that O
were O
consistent O
with O
the O
presence O
of O
hereditary B
hemochromatosis I
, O
such O
as O
hepatomegaly B
, O
skin B
pigmentation I
, O
and O
arthritis B
. O

CONCLUSIONS O
In O
a O
population O
of O
white O
adults O
of O
northern O
European O
ancestry O
, O
0 O
. O

5 O
percent O
were O
homozygous O
for O
the O
C282Y O
mutation O
in O
the O
HFE O
gene O
. O

However O
, O
only O
half O
of O
those O
who O
were O
homozygous O
had O
clinical O
features O
of O
hemochromatosis B
, O
and O
one O
quarter O
had O
serum O
ferritin O
levels O
that O
remained O
normal O
over O
a O
four O
- O
year O
period O
. O

Large O
heterozygous O
deletion O
masquerading O
as O
homozygous O
missense O
mutation O
: O
a O
pitfall O
in O
diagnostic O
mutation O
analysis O
. O

The O
clinical O
use O
of O
molecular O
analyses O
in O
recessive B
disorders I
relies O
on O
the O
exact O
characterization O
of O
both O
mutant O
alleles O
in O
the O
affected O
patient O
. O

This O
can O
be O
problematic O
when O
only O
part O
of O
the O
gene O
is O
examined O
or O
when O
relevant O
DNA O
alterations O
are O
not O
recognized O
by O
standard O
methods O
. O

We O
present O
a O
child O
in O
whom O
phenylketonuria B
was O
apparently O
caused O
by O
homozygosity O
for O
the O
mutation O
E390G O
in O
exon O
11 O
of O
the O
phenylalanine O
hydroxylase O
( O
PAH O
) O
gene O
. O

However O
, O
the O
clinical O
severity O
of O
the O
disease O
was O
not O
quite O
as O
mild O
as O
expected O
, O
the O
mutation O
was O
not O
identified O
in O
the O
father O
despite O
confirmed O
paternity O
, O
and O
the O
paternal O
allele O
showed O
a O
highly O
unusual O
pattern O
of O
polymorphic O
markers O
in O
the O
PAH O
gene O
. O

Presence O
of O
a O
large O
deletion O
involving O
exons O
9 O
, O
10 O
and O
11 O
of O
the O
phenylalanine O
hydroxylase O
gene O
was O
confirmed O
by O
long O
- O
range O
PCR O
. O

Diagnostic O
DNA O
analyses O
should O
include O
a O
comprehensive O
examination O
of O
the O
whole O
relevant O
gene O
in O
the O
patient O
and O
confirmation O
of O
carrier O
status O
in O
both O
parents O
. O
. O

Early O
onset O
of O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
in O
a O
boy O
with O
emerin O
gene O
deletion O
. O

A O
boy O
developed O
contractures B
of I
the I
Achilles I
tendons I
at O
3 O
years O
and O
of O
the O
postcervical O
muscles O
at O
7 O
years O
, O
although O
neither O
contractures B
of I
the I
elbows I
nor O
cardiac B
abnormality I
were O
recognized O
by O
the O
age O
of O
9 O
years O
. O

Muscle O
computed O
tomography O
scanning O
revealed O
changes O
characteristic O
of O
muscle O
involvement O
. O

Emerin O
was O
not O
detected O
in O
the O
biopsied O
muscle O
, O
and O
RT O
- O
PCR O
and O
PCR O
- O
based O
genomic O
DNA O
analyses O
of O
the O
emerin O
gene O
demonstrated O
no O
amplification O
product O
in O
the O
patient O
. O

These O
results O
confirmed O
the O
diagnosis O
of O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
, O
and O
reinforce O
the O
necessity O
of O
molecular O
genetic O
diagnosis O
of O
the O
membrane O
protein O
emerin O
in O
younger O
patients O
with O
possible O
EDMD B
before O
appearance O
of O
the O
typical O
symptoms O
, O
to O
avoid O
sudden B
cardiac I
death I
. O
. O

Duchenne B
/ I
Becker I
muscular I
dystrophy I
: O
correlation O
of O
phenotype O
by O
electroretinography O
with O
sites O
of O
dystrophin O
mutations O
. O

The O
dark O
- O
adapted O
electroretinogram O
( O
ERG O
) O
of O
patients O
with O
Duchenne B
and I
Becker I
muscular I
dystrophy I
( O
DMD B
/ O
BMD B
) O
shows O
a O
marked O
reduction O
in O
b O
- O
wave O
amplitude O
. O

Genotype O
- O
phenotype O
studies O
of O
mouse O
models O
for O
DMD B
show O
position O
- O
specific O
effects O
of O
the O
mutations O
upon O
the O
phenotype O
mice O
with O
5 O
defects O
of O
dystrophin O
have O
normal O
ERGs O
, O
those O
with O
defects O
in O
the O
central O
region O
have O
a O
normal O
b O
- O
wave O
amplitude O
associated O
with O
prolonged O
implicit O
times O
for O
both O
the O
b O
- O
wave O
and O
oscillatory O
potentials O
, O
and O
mice O
with O
3 O
defects O
have O
a O
phenotype O
similar O
to O
that O
seen O
in O
DMD B
/ O
BMD B
patients O
. O

The O
mouse O
studies O
suggest O
a O
key O
role O
for O
the O
carboxyl O
terminal O
dystrophin O
isoform O
, O
Dp260 O
, O
in O
retinal O
electrophysiology O
. O

We O
have O
undertaken O
a O
systematic O
evaluation O
of O
DMD B
/ O
BMD B
patients O
through O
clinical O
examination O
and O
review O
of O
the O
literature O
in O
order O
to O
determine O
whether O
the O
position O
- O
specific O
effects O
of O
mutations O
noted O
in O
the O
mouse O
are O
present O
in O
man O
. O

We O
have O
found O
that O
, O
in O
man O
, O
a O
wider O
variation O
of O
DMD B
defects I
correlate O
with O
reductions O
in O
the O
b O
- O
wave O
amplitude O
. O

Individuals O
with O
normal O
ERGs O
have O
mutations O
predominantly O
located O
5 O
of O
the O
transcript O
initiation O
site O
of O
Dp260 O
. O

Our O
results O
suggest O
that O
the O
most O
important O
determinant O
in O
the O
ERG O
b O
- O
wave O
phenotype O
is O
the O
mutation O
position O
, O
rather O
than O
muscle B
disease I
severity O
. O

Forty O
- O
six O
per O
cent O
of O
patients O
with O
mutations O
5 O
of O
the O
Dp260 O
transcript O
start O
site O
have O
abnormal O
ERGs O
, O
as O
opposed O
to O
94 O
% O
with O
more O
distal O
mutations O
. O

The O
human O
genotype O
- O
phenotype O
correlations O
are O
consistent O
with O
a O
role O
for O
Dp260 O
in O
normal O
retinal O
electrophysiology O
and O
may O
also O
reflect O
the O
expression O
of O
other O
C O
- O
terminal O
dystrophin O
isoforms O
and O
their O
contributions O
to O
retinal O
signal O
transmission O
. O
. O

Cis O
and O
trans O
effects O
of O
the O
myotonic B
dystrophy I
( O
DM B
) O
mutation O
in O
a O
cell O
culture O
model O
. O

The O
mutation O
causing O
myotonic B
dystrophy I
( O
DM B
) O
has O
been O
identified O
as O
a O
CTG O
expansion O
in O
the O
3 O
- O
untranslated O
region O
( O
3 O
- O
UTR O
) O
of O
the O
DM B
protein O
kinase O
gene O
( O
DMPK O
) O
, O
but O
the O
mechanism O
( O
s O
) O
of O
pathogenesis O
remain O
unknown O
. O

Studies O
using O
DM B
patient O
materials O
have O
often O
produced O
confusing O
results O
. O

Therefore O
, O
to O
study O
the O
effects O
of O
the O
DM B
mutation O
in O
a O
controlled O
environment O
, O
we O
have O
established O
a O
cell O
culture O
model O
system O
using O
C2C12 O
mouse O
myoblasts O
. O

By O
expressing O
chimeric O
reporter O
constructs O
containing O
a O
reporter O
gene O
fused O
to O
a O
human O
DMPK O
3 O
- O
UTR O
, O
we O
identified O
both O
cis O
and O
trans O
effects O
that O
are O
mediated O
by O
the O
DM B
mutation O
. O

Our O
data O
show O
that O
a O
mutant O
DMPK O
3 O
- O
UTR O
, O
with O
as O
few O
as O
57 O
CTGs O
, O
had O
a O
negative O
cis O
effect O
on O
protein O
expression O
and O
resulted O
in O
the O
aggregation O
of O
reporter O
transcripts O
into O
discrete O
nuclear O
foci O
. O

We O
determined O
by O
deletion O
analysis O
that O
an O
expanded O
( O
CTG O
) O
( O
n O
) O
tract O
alone O
was O
sufficient O
to O
mediate O
these O
cis O
effects O
. O

Furthermore O
, O
in O
contrast O
to O
the O
normal O
DMPK O
3 O
- O
UTR O
mRNA O
, O
a O
mutant O
DMPK O
3 O
- O
UTR O
mRNA O
with O
( O
CUG O
) O
( O
200 O
) O
selectively O
inhibited O
myogenic O
differentiation O
of O
C2C12 O
myoblasts O
. O

Genetic O
analysis O
and O
the O
Cre O
- O
loxP O
system O
were O
used O
to O
clearly O
demonstrate O
that O
the O
myoblast O
fusion O
defect O
could O
be O
rescued O
by O
eliminating O
the O
expression O
of O
the O
mutant O
DMPK O
3 O
- O
UTR O
transcript O
. O

Characterization O
of O
spontaneous O
deletion O
events O
mapped O
the O
inhibitory O
effect O
to O
the O
( O
CTG O
) O
( O
n O
) O
expansion O
and O
/ O
or O
the O
3 O
end O
of O
the O
DMPK O
3 O
- O
UTR O
. O

These O
results O
provide O
evidence O
that O
the O
DM B
mutation O
acts O
in O
cis O
to O
reduce O
protein O
production O
( O
consistent O
with O
DMPK B
haploinsufficiency I
) O
and O
in O
trans O
as O
a O
riboregulator O
to O
inhibit O
myogenesis O
. O
. O

Coats B
' I
disease I
of O
the O
retina O
( O
unilateral B
retinal I
telangiectasis I
) O
caused O
by O
somatic O
mutation O
in O
the O
NDP O
gene O
: O
a O
role O
for O
norrin O
in O
retinal O
angiogenesis O
. O

Coats B
disease I
is O
characterized O
by O
abnormal B
retinal I
vascular I
development I
( O
so O
- O
called O
retinal B
telangiectasis I
) O
which O
results O
in O
massive O
intraretinal B
and I
subretinal I
lipid I
accumulation I
( O
exudative B
retinal I
detachment I
) O
. O

The O
classical O
form O
of O
Coats B
disease I
is O
almost O
invariably O
isolated O
, O
unilateral O
and O
seen O
in O
males O
. O

A O
female O
with O
a O
unilateral O
variant O
of O
Coats B
disease I
gave O
birth O
to O
a O
son O
affected O
by O
Norrie B
disease I
. O

Both O
carried O
a O
missense O
mutation O
within O
the O
NDP O
gene O
on O
chromosome O
Xp11 O
. O

2 O
2 O
. O

Subsequently O
analysis O
of O
the O
retinas O
of O
nine O
enucleated O
eyes O
from O
males O
with O
Coats B
disease I
demonstrated O
in O
one O
a O
somatic O
mutation O
in O
the O
NDP O
gene O
which O
was O
not O
present O
within O
non O
- O
retinal O
tissue O
. O

We O
suggest O
that O
Coats B
telangiectasis I
is O
secondary O
to O
somatic O
mutation O
in O
the O
NDP O
gene O
which O
results O
in O
a O
deficiency B
of I
norrin I
( O
the O
protein O
product O
of O
the O
NDP O
gene O
) O
within O
the O
developing O
retina O
. O

This O
supports O
recent O
observations O
that O
the O
protein O
is O
critical O
for O
normal O
retinal O
vasculogenesis O
. O

Hereditary O
TP53 O
codon O
292 O
and O
somatic O
P16INK4A O
codon O
94 O
mutations O
in O
a O
Li B
- I
Fraumeni I
syndrome I
family O
. O

Li B
- I
Fraumeni I
syndrome I
is O
an O
autosomal B
dominant I
disorder I
that O
is O
characterized O
by O
various O
types O
of O
cancer B
in O
childhood O
and O
adult O
cases O
. O

Although O
hereditary O
TP53 O
mutation O
is O
very O
rare O
in O
different O
human O
cancers B
, O
it O
has O
been O
frequently O
reported O
in O
Li B
- I
Fraumeni I
syndrome I
. O

On O
the O
other O
hand O
, O
hereditary O
mutations O
of O
TP57KIP2 O
, O
P15INK4B O
, O
and O
P16INK4A O
, O
which O
affect O
the O
cell O
cycle O
similar O
to O
TP53 O
, O
were O
observed O
in O
some O
types O
of O
cancer B
. O

In O
a O
Turkish O
family O
with O
the O
diagnosis O
of O
Li B
- I
Fraumeni I
syndrome I
, O
we O
analyzed O
the O
mutation O
pattern O
of O
TP53 O
, O
P57KIP2 O
, O
P15INK4B O
, O
and O
P16INK4A O
in O
the O
peripheral O
blood O
, O
and O
loss O
of O
heterozygosity O
( O
homo O
/ O
hemizygous O
deletion O
) O
pattern O
of O
TP53 O
and O
P15INK4B O
/ O
P16INK4A O
in O
two O
tumor B
tissues O
. O

The O
propositus O
had O
a O
seminoma B
, O
his O
daughter O
a O
medulloblastoma B
, O
and O
one O
of O
his O
healthy O
cousins O
, O
a O
TP53 O
codon O
292 O
missense O
point O
mutation O
( O
AAA O
- O
- O
> O
ATA O
; O
Lys O
- O
- O
> O
Ile O
) O
in O
the O
peripheral O
blood O
cells O
. O

Tumor O
tissue O
obtained O
from O
the O
propositus O
with O
the O
seminoma B
revealed O
loss O
of O
heterozygosity O
in O
the O
TP53 O
gene O
. O

In O
the O
analyses O
of O
tumor B
tissues O
from O
the O
propositus O
and O
his O
daughter O
, O
a O
P16INK4A O
codon O
94 O
missense O
point O
mutation O
( O
GCG O
- O
- O
> O
GAG O
; O
Ala O
- O
- O
> O
Glu O
) O
was O
observed O
with O
the O
hereditary O
TP53 O
mutation O
. O

P16INK4A O
codon O
94 O
mutation O
observed O
in O
our O
family O
is O
a O
novel O
mutation O
in O
Li B
- I
Fraumeni I
syndrome I
. O

No O
other O
gene O
alteration O
in O
TP53 O
, O
P57KIP2 O
, O
P15INK4B O
, O
and O
P16INK4A O
was O
observed O
. O

Existence O
of O
the O
P16INK4A O
mutation O
and O
the O
hereditary O
TP53 O
mutation O
with O
or O
without O
loss O
of O
heterozygosity O
in O
the O
TP53 O
gene O
( O
seminoma B
/ O
medulloblastoma B
) O
may O
be O
evidence O
for O
a O
common O
mechanism O
involved O
in O
tumorogenesis B
. O

The O
gene O
alterations O
in O
TP53 O
and O
P16INK4A O
genes O
may O
be O
used O
as O
tumor B
markers O
in O
our O
family O
. O
. O

A O
novel O
mutation O
in O
the O
sodium O
/ O
iodide O
symporter O
gene O
in O
the O
largest O
family O
with O
iodide B
transport I
defect I
. O

We O
previously O
reported O
nine O
children O
with O
an O
autosomally O
recessive O
form O
of O
congenital B
hypothyroidism I
due O
to O
an O
iodide B
transport I
defect I
in O
a O
large O
Hutterite O
family O
with O
extensive O
consanguinity O
living O
in O
central O
Canada O
. O

Since O
the O
original O
report O
, O
we O
have O
diagnosed O
congenital B
hypothyroidism I
by O
newborn O
TSH O
screening O
in O
9 O
additional O
children O
from O
the O
family O
. O

We O
performed O
direct O
sequencing O
of O
the O
PCR O
products O
of O
each O
NIS O
( O
sodium O
/ O
iodide O
symporter O
) O
gene O
exon O
with O
flanking O
introns O
amplified O
from O
genomic O
DNA O
extracted O
from O
peripheral O
blood O
cells O
of O
the O
patients O
. O

We O
identified O
a O
novel O
NIS O
gene O
mutation O
, O
G395R O
( O
Gly395 O
- O
- O
> O
Arg O
; O
GGA O
- O
- O
> O
AGA O
) O
, O
in O
10 O
patients O
examined O
in O
the O
present O
study O
. O

All O
of O
the O
parents O
tested O
were O
heterozygous O
for O
the O
mutation O
, O
suggesting O
that O
the O
patients O
were O
homozygous O
. O

The O
mutation O
was O
located O
in O
the O
10th O
transmembrane O
helix O
. O

Expression O
experiments O
by O
transfection O
of O
the O
mutant O
NIS O
complimentary O
DNA O
into O
COS O
- O
7 O
cells O
showed O
no O
perchlorate O
- O
sensitive O
iodide O
uptake O
, O
confirming O
that O
the O
mutation O
is O
the O
direct O
cause O
of O
the O
iodide B
transport I
defect I
in O
these O
patients O
. O

A O
patient O
who O
showed O
an O
intermediate O
saliva O
/ O
serum O
technetium O
ratio O
( O
14 O
. O
0 O
; O
normal O
, O
> O
or O
= O
20 O
) O
and O
was O
considered O
to O
have O
a O
partial O
or O
less O
severe O
defect O
in O
the O
previous O
report O
( O
IX O
- O
24 O
) O
did O
not O
have O
a O
NIS O
gene O
mutation O
. O

It O
is O
now O
possible O
to O
use O
gene O
diagnostics O
of O
this O
unique O
NIS O
mutation O
to O
identify O
patients O
with O
congenital B
hypothyroidism I
due O
to O
an O
iodide B
transport I
defect I
in O
this O
family O
and O
to O
determine O
the O
carrier O
state O
of O
potential O
parents O
for O
genetic O
counseling O
and O
arranging O
rapid O
and O
early O
diagnosis O
of O
their O
infants O
. O

Molecular O
analysis O
in O
familial B
neurohypophyseal I
diabetes I
insipidus I
: O
early O
diagnosis O
of O
an O
asymptomatic O
carrier O
. O

Familial B
neurohypophyseal I
diabetes I
insipidus I
( O
FNDI B
) O
is O
an O
inherited O
deficiency B
of I
the I
hormone I
arginine I
vasopressin I
( O
AVP O
) O
and O
is O
transmitted O
as O
an O
autosomal O
dominant O
trait O
. O

In O
the O
present O
study O
we O
have O
analyzed O
the O
AVP O
- O
neurophysin O
II O
( O
AVP O
- O
NPII O
) O
gene O
in O
a O
Spanish O
kindred O
. O

Studies O
were O
performed O
on O
seven O
members O
( O
four O
clinically O
affected O
) O
of O
the O
family O
. O

Patients O
were O
diagnosed O
at O
the O
Hospital O
Universitario O
Gregorio O
Maranon O
( O
Madrid O
, O
Spain O
) O
. O

The O
entire O
coding O
region O
of O
the O
AVP O
- O
NPII O
gene O
of O
all O
family O
members O
was O
amplified O
by O
PCR O
and O
sequenced O
. O

All O
affected O
individuals O
presented O
a O
missense O
mutation O
( O
G1757 O
- O
- O
> O
A O
) O
that O
replaces O
glycine O
at O
position O
23 O
with O
arginine O
within O
the O
NPII O
domain O
. O

The O
substitution O
was O
confirmed O
by O
restriction O
endonuclease O
analysis O
and O
was O
present O
in O
heterozygosis O
. O

Additionally O
, O
one O
of O
the O
asymptomatic O
relatives O
( O
a O
girl O
8 O
months O
old O
at O
the O
time O
of O
study O
) O
was O
identified O
as O
carrier O
of O
the O
same O
mutation O
and O
developed O
the O
disease O
3 O
months O
later O
. O

The O
alteration O
found O
in O
the O
second O
exon O
of O
the O
gene O
in O
this O
family O
seems O
to O
be O
responsible O
for O
the O
disease O
, O
as O
all O
individuals O
harboring O
the O
mutation O
had O
been O
previously O
diagnosed O
or O
have O
eventually O
developed O
FNDI B
. O

Identification O
of O
the O
molecular O
defect O
underlying O
FNDI B
in O
affected O
families O
is O
a O
powerful O
tool O
for O
early O
asymptomatic O
diagnosis O
in O
infants O
. O
. O

Deficit O
of O
in O
vivo O
mitochondrial O
ATP O
production O
in O
patients O
with O
Friedreich B
ataxia I
. O

Friedreich B
ataxia I
( O
FRDA B
) O
, O
the O
most O
common O
of O
the O
inherited B
ataxias I
, O
is O
an O
autosomal B
recessive I
degenerative I
disorder I
, O
characterized O
clinically O
by O
onset O
before O
the O
age O
of O
25 O
of O
progressive B
gait I
and I
limb I
ataxia I
, O
absence B
of I
deep I
tendon I
reflexes I
, O
extensor B
plantar I
responses I
, O
and O
loss B
of I
position I
and I
vibration I
sense I
in O
the O
lower O
limbs O
. O

FRDA B
is O
caused O
by O
a O
GAA O
triplet O
expansion O
in O
the O
first O
intron O
of O
the O
FRDA B
gene O
on O
chromosome O
9q13 O
in O
97 O
% O
of O
patients O
. O

The O
FRDA B
gene O
encodes O
a O
widely O
expressed O
210 O
- O
aa O
protein O
, O
frataxin O
, O
which O
is O
located O
in O
mitochondria O
and O
is O
severely O
reduced O
in O
FRDA B
patients O
. O

Frataxin O
function O
is O
still O
unknown O
but O
the O
knockout O
of O
the O
yeast O
frataxin O
homologue O
gene O
( O
YFH1 O
) O
showed O
a O
severe O
defect O
of O
mitochondrial O
respiration O
and O
loss O
of O
mtDNA O
associated O
with O
elevated O
intramitochondrial O
iron O
. O

Here O
we O
report O
in O
vivo O
evidence O
of O
impaired O
mitochondrial O
respiration O
in O
skeletal O
muscle O
of O
FRDA B
patients O
. O

Using O
phosphorus O
magnetic O
resonance O
spectroscopy O
we O
demonstrated O
a O
maximum O
rate O
of O
muscle O
mitochondrial O
ATP O
production O
( O
V O
( O
max O
) O
) O
below O
the O
normal O
range O
in O
all O
12 O
FRDA B
patients O
and O
a O
strong O
negative O
correlation O
between O
mitochondrial O
V O
( O
max O
) O
and O
the O
number O
of O
GAA O
repeats O
in O
the O
smaller O
allele O
. O

Our O
results O
show O
that O
FRDA B
is O
a O
nuclear O
- O
encoded O
mitochondrial B
disorder I
affecting O
oxidative O
phosphorylation O
and O
give O
a O
rationale O
for O
treatments O
aimed O
to O
improve O
mitochondrial O
function O
in O
this O
condition O
. O
. O

Identification O
of O
a O
novel O
R21X O
mutation O
in O
the O
liver O
- O
type O
arginase O
gene O
( O
ARG1 O
) O
in O
four O
Portuguese O
patients O
with O
argininemia B
. O

Argininemia B
is O
a O
rare O
autossomal B
recessive I
disorder I
caused O
by O
deficiency B
in I
the I
cytosolic I
liver I
- I
type I
arginase I
enzyme I
( O
L O
- O
arginine O
urea O
- O
hydrolase O
; O
E O
. O
C O
. O
3 O
. O
5 O
. O
3 O
. O
1 O
) O
. O

In O
order O
to O
investigate O
the O
molecular O
basis O
for O
argininemia B
in O
four O
unrelated O
Portuguese O
patients O
( O
two O
from O
northern O
Portugal O
and O
two O
from O
Madeira O
Island O
) O
we O
performed O
a O
DNA O
sequence O
analysis O
of O
all O
the O
exons O
and O
exon O
/ O
intron O
boundaries O
of O
the O
liver O
- O
type O
arginase O
gene O
( O
ARG1 O
) O
. O

All O
patients O
were O
found O
to O
be O
homozygous O
for O
a O
newly O
identified O
C O
- O
> O
T O
transition O
in O
codon O
21 O
( O
exon O
2 O
) O
substituting O
arginine O
for O
a O
premature O
stop O
codon O
( O
R21X O
CGA O
to O
TGA O
) O
and O
generating O
a O
NlaIII O
restriction O
site O
. O

Restriction O
digestion O
following O
PCR O
amplification O
of O
ARG1 O
exon O
2 O
confirmed O
the O
presence O
of O
the O
mutation O
. O

Mutation O
of O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
results O
in O
truncation O
of O
mRNA O
expressed O
in O
leucocytes O
in O
a O
Japanese O
family O
with O
cerebrotendinous B
xanthomatosis I
. O

OBJECTIVES O
A O
Japanese O
family O
with O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
was O
investigated O
for O
a O
sequence O
alteration O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
. O

The O
expression O
of O
CYP27 O
has O
been O
mostly O
explored O
using O
cultured O
fibroblasts O
, O
prompting O
the O
examination O
of O
the O
transcripts O
from O
blood O
leucocytes O
as O
a O
simple O
and O
rapid O
technique O
. O

METHODS O
An O
alteration O
in O
CYP27 O
of O
the O
proband O
was O
searched O
for O
by O
polymerase O
chain O
reaction O
- O
single O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
and O
subsequent O
sequencing O
. O

Samples O
of O
RNA O
were O
subjected O
to O
reverse O
transcription O
PCR O
( O
RT O
- O
PCR O
) O
and O
the O
product O
of O
the O
proband O
was O
amplified O
with O
nested O
primers O
and O
sequenced O
. O

RESULTS O
A O
homozygous O
G O
to O
A O
transition O
at O
the O
5 O
end O
of O
intron O
7 O
was O
detected O
in O
the O
patient O
. O

In O
RT O
- O
PCR O
analysis O
, O
only O
a O
truncated O
transcript O
was O
detected O
in O
the O
patient O
, O
whereas O
both O
normal O
and O
truncated O
transcripts O
were O
detected O
in O
the O
siblings O
. O

The O
sequencing O
of O
the O
patients O
cDNA O
fragment O
disclosed O
a O
direct O
conjuction O
of O
exon O
6 O
and O
exon O
8 O
. O

CONCLUSION O
The O
mutation O
at O
splice O
donor O
site O
and O
the O
truncation O
of O
mRNA O
were O
identical O
with O
those O
of O
a O
recently O
reported O
Italian O
patient O
, O
although O
different O
in O
symptomatology O
. O

The O
application O
of O
blood O
leucocytes O
can O
be O
a O
simple O
technique O
on O
analysing O
a O
constructive O
abnormality B
of I
CYP27 I
mRNA O
. O
. O

Clinical O
and O
molecular O
genetic O
analysis O
of O
19 O
Wolfram B
syndrome I
kindreds O
demonstrating O
a O
wide O
spectrum O
of O
mutations O
in O
WFS1 O
. O

Wolfram B
syndrome I
is O
an O
autosomal B
recessive I
neurodegenerative I
disorder I
characterized O
by O
juvenile B
- I
onset I
diabetes I
mellitus I
and O
progressive O
optic B
atrophy I
. O

mtDNA O
deletions O
have O
been O
described O
, O
and O
a O
gene O
( O
WFS1 O
) O
recently O
has O
been O
identified O
, O
on O
chromosome O
4p16 O
, O
encoding O
a O
predicted O
890 O
amino O
acid O
transmembrane O
protein O
. O

Direct O
DNA O
sequencing O
was O
done O
to O
screen O
the O
entire O
coding O
region O
of O
the O
WFS1 O
gene O
in O
30 O
patients O
from O
19 O
British O
kindreds O
with O
Wolfram B
syndrome I
. O

DNA O
was O
also O
screened O
for O
structural O
rearrangements O
( O
deletions O
and O
duplications O
) O
and O
point O
mutations O
in O
mtDNA O
. O

No O
pathogenic O
mtDNA O
mutations O
were O
found O
in O
our O
cohort O
. O

We O
identified O
24 O
mutations O
in O
the O
WFS1 O
gene O
8 O
nonsense O
mutations O
, O
8 O
missense O
mutations O
, O
3 O
in O
- O
frame O
deletions O
, O
1 O
in O
- O
frame O
insertion O
, O
and O
4 O
frameshift O
mutations O
. O

Of O
these O
, O
23 O
were O
novel O
mutations O
, O
and O
most O
occurred O
in O
exon O
8 O
. O

The O
majority O
of O
patients O
were O
compound O
heterozygotes O
for O
two O
mutations O
, O
and O
there O
was O
no O
common O
founder O
mutation O
. O

The O
data O
were O
also O
analyzed O
for O
genotype O
- O
phenotype O
relationships O
. O

Although O
some O
interesting O
cases O
were O
noted O
, O
consideration O
of O
the O
small O
sample O
size O
and O
frequency O
of O
each O
mutation O
indicated O
no O
clear O
- O
cut O
correlations O
between O
any O
of O
the O
observed O
mutations O
and O
disease O
severity O
. O

There O
were O
no O
obvious O
mutation O
hot O
spots O
or O
clusters O
. O

Hence O
, O
molecular O
screening O
for O
Wolfram B
syndrome I
in O
affected O
families O
and O
for O
Wolfram B
syndrome I
- O
carrier O
status O
in O
subjects O
with O
psychiatric B
disorders I
or O
diabetes B
mellitus I
will O
require O
complete O
analysis O
of O
exon O
8 O
and O
upstream O
exons O
. O
. O

Late O
- O
onset O
familial B
Mediterranean I
fever I
( O
FMF B
) O
: O
a O
subset O
with O
distinct O
clinical O
, O
demographic O
, O
and O
molecular O
genetic O
characteristics O
. O

To O
determine O
the O
prevalence O
and O
characterize O
demographic O
, O
clinical O
, O
and O
genetic O
features O
of O
familial B
Mediterranean I
fever I
( O
FMF B
) O
of O
late O
onset O
, O
all O
patients O
experiencing O
their O
first O
FMF B
attack O
at O
age O
40 O
years O
or O
more O
were O
identified O
using O
the O
computerized O
registry O
of O
our O
FMF B
clinic O
, O
and O
then O
thoroughly O
interviewed O
and O
examined O
. O

The O
control O
group O
consisted O
of O
40 O
consecutive O
FMF B
patients O
, O
who O
arrived O
at O
the O
FMF B
clinic O
for O
their O
regular O
follow O
- O
up O
visit O
and O
were O
40 O
years O
of O
age O
or O
older O
at O
the O
time O
of O
the O
examination O
. O

The O
severity O
of O
the O
disease O
in O
patients O
and O
controls O
was O
determined O
using O
a O
modified O
score O
, O
developed O
previously O
. O

Mutational O
analysis O
in O
the O
FMF B
gene O
was O
performed O
using O
a O
commercial O
kit O
. O

Only O
20 O
of O
4000 O
( O
0 O
. O
5 O
% O
) O
patients O
had O
late O
- O
onset O
FMF B
. O

These O
patients O
were O
mostly O
men O
, O
of O
non O
- O
North O
African O
origin O
, O
P O
< O
0 O
. O

05 O
compared O
to O
controls O
. O

All O
had O
abdominal O
attacks O
and O
in O
most O
these O
were O
the O
only O
manifestation O
of O
their O
disease O
, O
P O
< O
0 O
. O

001 O
001 O
. O

None O
had O
chronic O
or O
prolonged O
manifestations O
of O
FMF B
, O
for O
example O
, O
amyloidosis B
, O
chronic B
arthritis I
, O
or O
protracted O
myalgia B
, O
P O
< O
0 O
. O

001 O
. O

The O
response O
to O
treatment O
was O
good O
despite O
using O
low O
colchicine O
dose O
, O
P O
< O
0 O
. O

05 O
. O

The O
overall O
severity O
score O
indicated O
a O
mild O
disease O
, O
P O
< O
0 O
. O

001 O
. O

Mutational O
analysis O
revealed O
absence O
of O
M694V O
homozygosity O
, O
P O
< O
0 O
. O

01 O
, O
compared O
to O
our O
regular O
FMF B
population O
. O

We O
conclude O
that O
the O
onset O
of O
FMF B
in O
a O
late O
age O
defines O
a O
milder O
form O
of O
disease O
with O
typical O
clinical O
, O
demographic O
, O
and O
molecular O
genetic O
characteristics O

A O
highly O
accurate O
, O
low O
cost O
test O
for O
BRCA1 O
mutations O
. O

The O
hereditary B
breast I
and I
ovarian I
cancer I
syndrome I
is O
associated O
with O
a O
high O
frequency O
of O
BRCA1 O
mutations O
. O

However O
, O
the O
widespread O
use O
of O
BRCA1 O
testing O
has O
been O
limited O
to O
date O
by O
three O
principal O
concerns O
the O
fear O
of O
loss O
of O
health O
and O
life O
insurance O
, O
the O
uncertain O
clinical O
value O
of O
a O
positive O
test O
result O
, O
and O
the O
current O
lack O
of O
an O
inexpensive O
and O
sensitive O
screening O
test O
for O
BRCA1 O
mutations O
. O

We O
have O
developed O
an O
inexpensive O
system O
for O
gene O
mutational O
scanning O
, O
based O
on O
a O
combination O
of O
extensive O
multiplex O
PCR O
amplification O
and O
two O
dimensional O
electrophoresis O
. O

The O
efficiency O
of O
this O
system O
, O
as O
a O
screening O
test O
for O
BRCA1 O
mutations O
, O
was O
evaluated O
in O
a O
panel O
of O
60 O
samples O
from O
high O
risk O
women O
, O
14 O
of O
which O
contained O
a O
previously O
identified O
mutation O
in O
BRCA1 O
. O

All O
14 O
mutations O
were O
identified O
, O
as O
well O
as O
an O
additional O
five O
that O
had O
previously O
escaped O
detection O
. O

In O
addition O
to O
the O
19 O
mutations O
, O
a O
total O
of O
15 O
different O
polymorphic O
variants O
were O
scored O
, O
most O
of O
which O
were O
recurring O
. O

All O
were O
confirmed O
by O
nucleotide O
sequencing O
. O

The O
cost O
of O
screening O
per O
sample O
was O
calculated O
to O
be O
approximately O
US O
$ O
70 O
for O
the O
manual O
technique O
used O
in O
this O
study O
, O
and O
may O
be O
reduced O
to O
approximately O
US O
$ O
10 O
with O
the O
introduction O
of O
commercially O
available O
PCR O
robotics O
and O
fluorescent O
imaging O
. O

Implementation O
of O
this O
method O
of O
mutation O
screening O
in O
the O
research O
and O
clinical O
setting O
should O
permit O
rapid O
accrual O
of O
quantitative O
data O
on O
genotype O
- O
phenotype O
associations O
for O
the O
evaluation O
of O
diagnostic O
testing O
. O
. O

Maternal B
uniparental I
disomy I
for I
chromosome I
14 I
in O
a O
boy O
with O
a O
normal O
karyotype O
. O

We O
report O
on O
a O
boy O
with O
a O
maternal B
uniparental I
disomy I
for I
chromosome I
14 I
( O
UPD B
( O
14 O
) O
) O
. O

At O
7 O
years O
of O
age O
he O
was O
referred O
to O
us O
by O
the O
paediatrician O
because O
of O
symptoms O
of O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

He O
showed O
short B
stature I
, O
obesity B
, O
mild O
developmental B
delay I
, O
cryptorchidism B
, O
and O
some O
mild O
dysmorphic B
features I
. O

The O
history O
further O
indicated O
intrauterine B
growth I
retardation I
at O
the O
end O
of O
the O
pregnancy O
. O

His O
mother O
was O
44 O
years O
of O
age O
at O
the O
time O
of O
his O
birth O
. O

After O
birth O
he O
showed O
hypotonia B
with O
poor O
sucking O
, O
for O
which O
gavage O
feeding O
was O
needed O
. O

Motor O
development O
was O
delayed O
. O

After O
1 O
year O
he O
became O
obese B
despite O
a O
normal O
appetite O
. O

Recurrent O
middle B
ear I
infections I
, O
a O
high O
pain O
threshold O
, O
and O
a O
great O
skill O
with O
jigsaw O
puzzles O
were O
reported O
. O

There O
were O
no O
behavioural O
problems O
or O
sleep O
disturbance O
. O

Chromosomal O
analysis O
was O
normal O
( O
46 O
, O
XY O
) O
. O

DNA O
analysis O
for O
Prader B
- I
Willi I
syndrome I
showed O
no O
abnormalities O
. O

Two O
years O
later O
he O
was O
re O
- O
examined O
because O
we O
thought O
his O
features O
fitted O
the O
PWS B
- O
like O
phenotype O
associated O
with O
maternal O
UPD B
( O
14 O
) O
. O

At O
that O
time O
precocious O
puberty O
was O
evident O
. O

DNA O
analysis O
showed O
maternal B
heterodisomy I
for O
chromosome O
14 O
. O

In O
all O
the O
previously O
described O
11 O
cases O
with O
maternal O
UPD B
( O
14 O
) O
, O
a O
Robertsonian O
translocation O
involving O
chromosome O
14 O
was O
detected O
cytogenetically O
before O
DNA O
analysis O
. O

This O
is O
the O
first O
report O
of O
diagnosis O
of O
maternal O
UPD B
( O
14 O
) O
based O
on O
clinical O
features O
. O

This O
finding O
underlines O
the O
importance O
of O
DNA O
analysis O
for O
maternal O
UPD O
( O
14 O
) O
in O
patients O
with O
a O
similar O
PWS B
- O
like O
phenotype O
even O
without O
previous O
identification O
of O
a O
Robertsonian O
translocation O
involving O
chromosome O
14 O
. O
. O

Clinical O
and O
genetic O
study O
of O
Friedreich B
ataxia I
in O
an O
Australian O
population O
. O

Friedreich B
ataxia I
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
mutations O
in O
the O
FRDA B
gene O
that O
encodes O
a O
210 O
- O
amino O
acid O
protein O
called O
frataxin O
. O

An O
expansion O
of O
a O
GAA O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
gene O
is O
present O
in O
more O
than O
95 O
% O
of O
mutant O
alleles O
. O

Of O
the O
83 O
people O
we O
studied O
who O
have O
mutations O
in O
FRDA O
, O
78 O
are O
homozygous O
for O
an O
expanded O
GAA O
repeat O
; O
the O
other O
five O
patients O
have O
an O
expansion O
in O
one O
allele O
and O
a O
point O
mutation O
in O
the O
other O
. O

Here O
we O
present O
a O
detailed O
clinical O
and O
genetic O
study O
of O
a O
subset O
of O
51 O
patients O
homozygous O
for O
an O
expansion O
of O
the O
GAA O
repeat O
. O

We O
found O
a O
correlation O
between O
the O
size O
of O
the O
smaller O
of O
the O
two O
expanded O
alleles O
and O
age O
at O
onset O
, O
age O
into O
wheelchair O
, O
scoliosis B
, O
impaired O
vibration O
sense O
, O
and O
the O
presence O
of O
foot B
deformity I
. O

There O
was O
no O
significant O
correlation O
between O
the O
size O
of O
the O
smaller O
allele O
and O
cardiomyopathy B
, O
diabetes B
mellitus I
, O
loss B
of I
proprioception I
, O
or O
bladder B
symptoms I
. O

The O
larger O
allele O
size O
correlated O
with O
bladder B
symptoms I
and O
the O
presence O
of O
foot B
deformity I
. O

The O
duration O
of O
disease O
is O
correlated O
with O
wheelchair O
use O
and O
the O
presence O
of O
diabetes B
, O
scoliosis B
, O
bladder B
symptoms I
and O
impaired B
proprioception I
, O
and O
vibration O
sense O
but O
no O
other O
complications O
studied O
. O
. O

Novel O
mutations O
in O
XLRS1 O
causing O
retinoschisis B
, O
including O
first O
evidence O
of O
putative O
leader O
sequence O
change O
. O

Juvenile B
retinoschisis I
is O
an O
X B
- I
linked I
recessive I
disease I
caused O
by O
mutations O
in O
the O
XLRS1 O
gene O
. O

We O
screened O
31 O
new O
unrelated O
patients O
and O
families O
for O
XLRS1 O
mutations O
in O
addition O
to O
previously O
reported O
mutations O
for O
60 O
of O
our O
families O
( O
Retinoschisis B
Consortium O
, O
Hum O
Mol O
Genet O
1998 O
; O
7 O
1185 O
- O
1192 O
) O
. O

Twenty O
- O
three O
different O
mutations O
including O
12 O
novel O
ones O
were O
identified O
in O
28 O
patients O
. O

Mutations O
identified O
in O
this O
study O
include O
19 O
missense O
mutations O
, O
two O
nonsense O
mutations O
, O
one O
intragenic O
deletion O
, O
four O
microdeletions O
, O
one O
insertion O
, O
and O
one O
intronic O
sequence O
substitution O
that O
is O
likely O
to O
result O
in O
a O
splice O
site O
defect O
. O

Two O
novel O
mutations O
, O
c O
. O

38T O
- O
- O
> O
C O
( O
L13P O
) O
and O
c O
. O

667T O
- O
- O
> O
C O
( O
C223R O
) O
, O
respectively O
, O
present O
the O
first O
genetic O
evidence O
for O
the O
functional O
significance O
of O
the O
putative O
leader O
peptide O
sequence O
and O
for O
the O
functional O
significance O
at O
the O
carboxyl O
terminal O
of O
the O
XLRS1 O
protein O
beyond O
the O
discoidin O
domain O
. O

Mutations O
in O
25 O
of O
the O
families O
were O
localized O
to O
exons O
4 O
- O
6 O
, O
emphasizing O
the O
critical O
functional O
significance O
of O
the O
discoidin O
domain O
of O
the O
XLRS1 O
protein O

Growth O
hormone O
treatment O
increases O
CO O
( O
2 O
) O
response O
, O
ventilation O
and O
central O
inspiratory O
drive O
in O
children O
with O
Prader B
- I
Willi I
syndrome I
. O

We O
studied O
whether O
the O
beneficial O
effects O
of O
growth O
hormone O
( O
GH O
) O
treatment O
on O
growth O
and O
body O
composition O
in O
PWS B
are O
accompanied O
by O
an O
improvement O
in O
respiratory O
function O
. O

We O
measured O
resting O
ventilation O
, O
airway O
occlusion O
pressure O
( O
P O
( O
0 O
. O
1 O
) O
) O
and O
ventilatory O
response O
to O
CO O
( O
2 O
) O
in O
nine O
children O
, O
aged O
7 O
- O
14 O
years O
, O
before O
and O
6 O
- O
9 O
months O
after O
the O
start O
of O
GH O
treatment O
. O

During O
GH O
treatment O
, O
resting O
ventilation O
increased O
by O
26 O
% O
, O
P O
( O
0 O
. O
1 O
) O
by O
72 O
% O
and O
the O
response O
to O
CO O
( O
2 O
) O
by O
65 O
% O
( O
P O
< O
0 O
. O
002 O
, O
< O
0 O
. O
04 O
and O
< O
0 O
. O
02 O
, O
respectively O
) O
. O

This O
observed O
increase O
in O
ventilatory O
output O
was O
not O
correlated O
to O
changes O
in O
body O
mass O
index O
. O

CONCLUSION O
Treatment O
of O
children O
with O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
seems O
to O
have O
a O
stimulatory O
effect O
on O
central O
respiratory O
structures O
. O

The O
observed O
increase O
in O
ventilation O
and O
inspiratory O
drive O
may O
contribute O
to O
the O
improved O
activity O
level O
reported O
by O
parents O
of O
PWS B
children O
during O
growth O
hormone O
therapy O

G130V O
, O
a O
common O
FRDA B
point O
mutation O
, O
appears O
to O
have O
arisen O
from O
a O
common O
founder O
. O

Friedreich B
ataxia I
( O
FRDA B
) O
is O
the O
most O
common O
inherited B
ataxia I
. O

About O
98 O
% O
of O
mutant O
alleles O
have O
an O
expansion O
of O
a O
GAA O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
affected O
gene O
, O
FRDA O
. O

The O
other O
2 O
% O
are O
point O
mutations O
. O

Of O
the O
17 O
point O
mutations O
so O
far O
described O
, O
three O
appear O
to O
be O
more O
common O
. O

One O
of O
these O
is O
the O
G130V O
mutation O
in O
exon O
4 O
of O
FRDA O
. O

G130V O
, O
when O
present O
with O
an O
expanded O
GAA O
repeat O
on O
the O
other O
allele O
, O
is O
associated O
with O
an O
atypical O
FRDA B
phenotype O
. O

Haplotype O
analysis O
was O
undertaken O
on O
the O
four O
families O
who O
have O
been O
described O
with O
this O
mutation O
. O

The O
results O
suggest O
a O
common O
founder O
for O
this O
mutation O
. O

Although O
marked O
differences O
in O
extragenic O
marker O
haplotypes O
were O
seen O
in O
one O
family O
, O
similar O
intragenic O
haplotyping O
suggests O
the O
same O
mutation O
founder O
for O
this O
family O
with O
the O
differences O
explicable O
by O
two O
recombination O
events O
. O
. O

Synergistic O
effect O
of O
histone O
hyperacetylation O
and O
DNA O
demethylation O
in O
the O
reactivation O
of O
the O
FMR1 O
gene O
. O

Most O
fragile B
X I
syndrome I
patients O
have O
expansion O
of O
a O
( O
CGG O
) O
( O
n O
) O
sequence O
with O
> O
200 O
repeats O
( O
full O
mutation O
) O
in O
the O
FMR1 O
gene O
responsible O
for O
this O
condition O
. O

Hypermethylation O
of O
the O
expanded O
repeat O
and O
of O
the O
FMR1 O
promoter O
is O
almost O
always O
present O
and O
apparently O
suppresses O
transcription O
, O
resulting O
in O
absence O
of O
the O
FMR1 O
protein O
. O

We O
recently O
showed O
that O
transcriptional O
reactivation O
of O
FMR1 O
full O
mutations O
can O
be O
achieved O
by O
inducing O
DNA O
demethylation O
with O
5 O
- O
azadeoxycytidine O
( O
5 O
- O
azadC O
) O
. O

The O
level O
of O
histone O
acetylation O
is O
another O
important O
factor O
in O
regulating O
gene O
expression O
; O
therefore O
, O
we O
treated O
lymphoblastoid O
cell O
lines O
of O
non O
- O
mosaic O
full O
mutation O
patients O
with O
three O
drugs O
capable O
of O
inducing O
histone O
hyperacetylation O
. O

We O
observed O
a O
consistent O
, O
although O
modest O
, O
reactivation O
of O
the O
FMR1 O
gene O
with O
4 O
- O
phenylbutyrate O
, O
sodium O
butyrate O
and O
trichostatin O
A O
, O
as O
shown O
by O
RT O
- O
PCR O
. O

However O
, O
we O
report O
that O
combining O
these O
drugs O
with O
5 O
- O
azadC O
results O
in O
a O
2 O
- O
to O
5 O
- O
fold O
increase O
in O
FMR1 O
mRNA O
levels O
obtained O
with O
5 O
- O
azadC O
alone O
, O
thus O
showing O
a O
marked O
synergistic O
effect O
of O
histone O
hyperacetylation O
and O
DNA O
demethylation O
in O
the O
reactivation O
of O
FMR1 O
full O
mutations O
. O
. O

Constitutional O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
gene O
deletions O
detected O
in O
VHL B
families O
by O
fluorescence O
in O
situ O
hybridization O
. O

von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
is O
an O
autosomal B
dominantly I
inherited I
cancer I
syndrome I
predisposing O
to O
a O
variety O
of O
tumor B
types O
that O
include O
retinal O
hemangioblastomas B
, O
hemangioblastomas B
of O
the O
central O
nervous O
system O
, O
renal B
cell I
carcinomas I
, O
pancreatic B
cysts I
and I
tumors I
, O
pheochromocytomas B
, O
endolymphatic B
sac I
tumors I
, O
and O
epididymal B
cystadenomas I
[ O
W O
. O

M O
. O

Linehan O
et O
al O
. O
, O
J O
. O

Am O
. O
Med O
. O
Assoc O
. O
, O
273 O
564 O
- O
570 O
, O
1995 O
; O
E O
. O
A O
. O
Maher O
and O
W O
. O
G O
. O
Kaelin O
, O
Jr O
. O
, O
Medicine O
( O
Baltimore O
) O
, O
76 O
381 O
- O
391 O
, O
1997 O
; O
W O
. O
M O
. O
Linehan O
and O
R O
. O
D O
. O
Klausner O
, O
In O
B O
. O
Vogelstein O
and O
K O
. O
Kinzler O
( O
eds O
. O
) O
, O
The O
Genetic O
Basis O
of O
Human O
Cancer O
, O
pp O
. O

455 O
- O
473 O
, O
McGraw O
- O
Hill O
, O
1998 O
] O
. O

The O
VHL B
gene O
was O
localized O
to O
chromosome O
3p25 O
- O
26 O
and O
cloned O
[ O
F O
. O
Latif O
et O
al O
. O
, O
Science O
( O
Washington O
DC O
) O
, O
260 O
1317 O
- O
1320 O
, O
1993 O
] O
. O

Germline O
mutations O
in O
the O
VHL B
gene O
have O
been O
detected O
in O
the O
majority O
of O
VHL B
kindreds O
. O

The O
reported O
frequency O
of O
detection O
of O
VHL B
germline O
mutations O
has O
varied O
from O
39 O
to O
80 O
% O
( O
J O
. O
M O
. O
Whaley O
et O
al O
. O
, O
Am O
. O
J O
. O
Hum O
. O
Genet O
. O
, O
55 O
1092 O
- O
1102 O
, O
1994 O
; O
Clinical O
Research O
Group O
for O
Japan O
, O
Hum O
. O
Mol O
. O
Genet O
. O
, O
4 O
2233 O
- O
2237 O
, O
1995 O
; O
F O
. O
Chen O
et O
al O
. O
, O
Hum O
. O
Mutat O
. O
, O
5 O
66 O
- O
75 O
, O
1995 O
; O
E O
. O
R O
. O
Maher O
et O
al O
. O
, O
J O
. O
Med O
. O
Genet O
. O
, O
33 O
328 O
- O
332 O
, O
1996 O
; O

B O
. O
Zbar O
, O
Cancer O
Surv O
. O
, O
25 O
219 O
- O
232 O
, O
1995 O
) O
. O

Recently O
a O
quantitative O
Southern O
blotting O
procedure O
was O
found O
to O
improve O
this O
frequency O
( O
C O
. O
Stolle O
et O
al O
. O
, O
Hum O
. O
Mutat O
. O
, O
12 O
417 O
- O
423 O
, O
1998 O
) O
. O

In O
the O
present O
study O
, O
we O
report O
the O
use O
of O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
as O
a O
method O
to O
detect O
and O
characterize O
VHL B
germline O
deletions O
. O

We O
reexamined O
a O
group O
of O
VHL B
patients O
shown O
previously O
by O
single O
- O
strand O
conformation O
and O
sequencing O
analysis O
not O
to O
harbor O
point O
mutations O
in O
the O
VHL B
locus O
. O

We O
found O
constitutional O
deletions O
in O
29 O
of O
30 O
VHL B
patients O
in O
this O
group O
using O
cosmid O
and O
P1 O
probes O
that O
cover O
the O
VHL B
locus O
. O

We O
then O
tested O
six O
phenotypically O
normal O
offspring O
from O
four O
of O
these O
VHL B
families O
two O
were O
found O
to O
carry O
the O
deletion O
and O
the O
other O
four O
were O
deletion O
- O
free O
. O

In O
addition O
, O
germline O
mosaicism O
of O
the O
VHL B
gene O
was O
identified O
in O
one O
family O
. O

In O
sum O
, O
FISH O
was O
found O
to O
be O
a O
simple O
and O
reliable O
method O
to O
detect O
VHL B
germline O
deletions O
and O
practically O
useful O
in O
cases O
where O
other O
methods O
of O
screening O
have O
failed O
to O
detect O
a O
VHL B
gene I
abnormality I

Spectrum O
of O
hSNF5 O
/ O
INI1 O
somatic O
mutations O
in O
human O
cancer B
and O
genotype O
- O
phenotype O
correlations O
. O

The O
hSNF5 O
/ O
INI1 O
gene O
which O
encodes O
a O
member O
of O
the O
SWI O
/ O
SNF O
chromatin O
ATP O
- O
dependent O
remodeling O
complex O
, O
is O
a O
new O
tumor B
suppressor O
gene O
localized O
on O
chromosome O
22q11 O
. O

2 O
and O
recently O
shown O
to O
be O
mutated O
in O
malignant B
rhabdoid I
tumors I
. O

We O
have O
searched O
for O
hSNF5 O
/ O
INI1 O
mutations O
in O
229 O
tumors B
of O
various O
origins O
using O
a O
screening O
method O
based O
on O
denaturing O
high O
- O
performance O
liquid O
chromatography O
. O

A O
total O
of O
31 O
homozygous O
deletions O
and O
36 O
point O
alterations O
were O
identified O
. O

Point O
mutations O
were O
scattered O
along O
the O
coding O
sequence O
and O
included O
15 O
nonsense O
, O
15 O
frameshift O
, O
three O
splice O
site O
, O
two O
missense O
and O
one O
editing O
mutations O
. O

Mutations O
were O
retrieved O
in O
most O
rhabdoid B
tumors I
, O
whatever O
their O
sites O
of O
occurrence O
, O
indicating O
the O
common O
pathogenetic O
origin O
of O
these O
tumors B
. O

Recurrent O
hSNF5 O
/ O
INI1 O
alterations O
were O
also O
observed O
in O
choroid B
plexus I
carcinomas I
and O
in O
a O
subset O
of O
central O
primitive O
neuroectodermal B
tumors I
( O
cPNETs O
) O
and O
medulloblastomas B
. O

In O
contrast O
, O
hSNF5 O
/ O
INI1 O
point O
mutations O
were O
not O
detected O
in O
breast B
cancers I
, O
Wilms B
tumors I
, O
gliomas B
, O
ependymomas B
, O
sarcomas B
and O
other O
tumor B
types O
, O
even O
though O
most O
analyzed O
cases O
harbored O
loss O
of O
heterozygosity O
at O
22q11 O
. O

2 O
loci O
. O

These O
results O
suggest O
that O
rhabdoid B
tumors I
, O
choroid B
plexus I
carcinomas I
and O
a O
subset O
of O
medulloblastomas B
and O
cPNETs O
share O
common O
pathways O
of O
oncogenesis O
related O
to O
hSNF5 O
/ O
INI1 O
alteration O
and O
that O
hSNF5 O
/ O
INI1 O
mutations O
define O
a O
genetically O
homogeneous O
family O
of O
highly O
aggressive O
cancers B
mainly O
occurring O
in O
young O
children O
and O
frequently O
, O
but O
not O
always O
, O
exhibiting O
a O
rhabdoid B
phenotype O

Ataxin O
- O
3 O
with O
an O
altered O
conformation O
that O
exposes O
the O
polyglutamine O
domain O
is O
associated O
with O
the O
nuclear O
matrix O
. O

Spinocerebellar B
ataxia I
type I
- I
3 I
or O
Machado B
- I
Joseph I
disease I
( O
SCA3 B
/ O
MJD B
) O
is O
a O
member O
of O
the O
CAG B
/ I
polyglutamine I
repeat I
disease I
family O
. O

In O
this O
family O
of O
disorders O
, O
a O
normally O
polymorphic O
CAG O
repeat O
becomes O
expanded O
, O
resulting O
in O
expression O
of O
an O
expanded O
polyglutamine O
domain O
in O
the O
disease O
gene O
product O
. O

Experimental O
models O
of O
polyglutamine B
disease I
implicate O
the O
nucleus O
in O
pathogenesis O
; O
however O
, O
the O
link O
between O
intranuclear O
expression O
of O
expanded O
polyglutamine O
and O
neuronal B
dysfunction I
remains O
unclear O
. O

Here O
we O
demonstrate O
that O
ataxin O
- O
3 O
, O
the O
disease O
protein O
in O
SCA3 B
/ O
MJD B
, O
adopts O
a O
unique O
conformation O
when O
expressed O
within O
the O
nucleus O
of O
transfected O
cells O
. O

The O
monoclonal O
antibody O
1C2 O
is O
known O
preferentially O
to O
bind O
expanded O
polyglutamine O
, O
but O
we O
find O
that O
it O
also O
binds O
a O
fragment O
of O
ataxin O
- O
3 O
containing O
a O
normal O
glutamine O
repeat O
. O

In O
addition O
, O
expression O
of O
ataxin O
- O
3 O
within O
the O
nucleus O
exposes O
the O
glutamine O
domain O
of O
the O
full O
- O
length O
non O
- O
pathological O
protein O
, O
allowing O
it O
to O
bind O
the O
monoclonal O
antibody O
1C2 O
. O

Fractionation O
and O
immunochemical O
experiments O
indicate O
that O
this O
novel O
conformation O
of O
intranuclear O
ataxin O
- O
3 O
is O
not O
due O
to O
proteolysis O
, O
suggesting O
instead O
that O
association O
with O
nuclear O
protein O
( O
s O
) O
alters O
the O
structure O
of O
full O
- O
length O
ataxin O
- O
3 O
which O
exposes O
the O
polyglutamine O
domain O
. O

This O
conformationally O
altered O
ataxin O
- O
3 O
is O
bound O
to O
the O
nuclear O
matrix O
. O

The O
pathological O
form O
of O
ataxin O
- O
3 O
with O
an O
expanded O
polyglutamine O
domain O
also O
associates O
with O
the O
nuclear O
matrix O
. O

These O
data O
suggest O
that O
an O
early O
event O
in O
the O
pathogenesis O
of O
SCA3 B
/ O
MJD B
may O
be O
an O
altered O
conformation O
of O
ataxin O
- O
3 O
within O
the O
nucleus O
that O
exposes O
the O
polyglutamine O
domain O
. O
. O

The O
human O
MAGEL2 O
gene O
and O
its O
mouse O
homologue O
are O
paternally O
expressed O
and O
mapped O
to O
the O
Prader B
- I
Willi I
region O
. O

Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
is O
a O
complex O
neurogenetic B
disorder I
. O

The O
phenotype O
is O
likely O
to O
be O
a O
contiguous B
gene I
syndrome I
involving O
genes O
which O
are O
paternally O
expressed O
only O
, O
located O
in O
the O
human O
15q11 O
- O
q13 O
region O
. O

Four O
mouse O
models O
of O
PWS B
have O
been O
reported O
but O
these O
do O
not O
definitively O
allow O
the O
delineation O
of O
the O
critical O
region O
and O
the O
associated O
genes O
involved O
in O
the O
aetiology O
of O
PWS B
. O

Moreover O
, O
targeted O
mutagenesis O
of O
mouse O
homologues O
of O
the O
human O
candidate O
PWS B
genes O
does O
not O
appear O
to O
result O
in O
any O
of O
the O
features O
of O
PWS B
. O

Therefore O
, O
the O
isolation O
of O
new O
genes O
in O
this O
region O
remains O
crucial O
for O
a O
better O
understanding O
of O
the O
molecular O
basis O
of O
PWS B
. O

In O
this O
manuscript O
, O
we O
report O
the O
characterization O
of O
MAGEL2 O
and O
its O
mouse O
homologue O
Magel2 O
. O

These O
are O
located O
in O
the O
human O
15q11 O
- O
q13 O
and O
mouse O
7C O
regions O
, O
in O
close O
proximity O
to O
NDN O
/ O
Ndn O
. O

By O
northern O
blot O
analysis O
we O
did O
not O
detect O
any O
expression O
of O
MAGEL2 O
/ O
Magel2 O
but O
by O
RT O
- O
PCR O
analysis O
, O
specific O
expression O
was O
detected O
in O
fetal O
and O
adult O
brain O
and O
in O
placenta O
. O

Both O
genes O
are O
intronless O
with O
tandem O
direct O
repeat O
sequences O
contained O
within O
a O
CpG O
island O
in O
the O
5 O
- O
untranscribed O
region O
. O

The O
transcripts O
encode O
putative O
proteins O
that O
are O
homologous O
to O
the O
MAGE O
proteins O
and O
NDN O
. O

Moreover O
, O
MAGEL2 O
/ O
Magel2 O
are O
expressed O
only O
from O
the O
paternal O
allele O
in O
brain O
, O
suggesting O
a O
potential O
role O
in O
the O
aetiology O
of O
PWS B
and O
its O
mouse O
model O
, O
respectively O
. O
. O

cDNA O
microarrays O
detect O
activation O
of O
a O
myogenic O
transcription O
program O
by O
the O
PAX3 O
- O
FKHR O
fusion O
oncogene O
. O

Alveolar B
rhabdomyosarcoma I
is O
an O
aggressive O
pediatric B
cancer I
of I
striated I
muscle I
characterized O
in O
60 O
% O
of O
cases O
by O
a O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
. O

This O
results O
in O
the O
fusion O
of O
PAX3 O
, O
a O
developmental O
transcription O
factor O
required O
for O
limb O
myogenesis O
, O
with O
FKHR O
, O
a O
member O
of O
the O
forkhead O
family O
of O
transcription O
factors O
. O

The O
resultant O
PAX3 O
- O
FKHR O
gene O
possesses O
transforming O
properties O
; O
however O
, O
the O
effects O
of O
this O
chimeric O
oncogene O
on O
gene O
expression O
are O
largely O
unknown O
. O

To O
investigate O
the O
actions O
of O
these O
transcription O
factors O
, O
both O
Pax3 O
and O
PAX3 O
- O
FKHR O
were O
introduced O
into O
NIH O
3T3 O
cells O
, O
and O
the O
resultant O
gene O
expression O
changes O
were O
analyzed O
with O
a O
murine O
cDNA O
microarray O
containing O
2 O
, O
225 O
elements O
. O

We O
found O
that O
PAX3 O
- O
FKHR O
but O
not O
PAX3 O
activated O
a O
myogenic O
transcription O
program O
including O
the O
induction O
of O
transcription O
factors O
MyoD O
, O
Myogenin O
, O
Six1 O
, O
and O
Slug O
as O
well O
as O
a O
battery O
of O
genes O
involved O
in O
several O
aspects O
of O
muscle O
function O
. O

Notable O
among O
this O
group O
were O
the O
growth O
factor O
gene O
Igf2 O
and O
its O
binding O
protein O
Igfbp5 O
. O

Relevance O
of O
this O
model O
was O
suggested O
by O
verification O
that O
three O
of O
these O
genes O
( O
IGFBP5 O
, O
HSIX1 O
, O
and O
Slug O
) O
were O
also O
expressed O
in O
alveolar B
rhabdomyosarcoma I
cell O
lines O
. O

This O
study O
utilizes O
cDNA O
microarrays O
to O
elucidate O
the O
pattern O
of O
gene O
expression O
induced O
by O
an O
oncogenic O
transcription O
factor O
and O
demonstrates O
the O
profound O
myogenic O
properties O
of O
PAX3 O
- O
FKHR O
in O
NIH O
3T3 O
cells O
. O
. O

Experimental O
hemochromatosis B
due O
to O
MHC O
class O
I O
HFE B
deficiency I
: O
immune O
status O
and O
iron O
metabolism O
. O

The O
puzzling O
linkage O
between O
genetic O
hemochromatosis B
and O
histocompatibility O
loci O
became O
even O
more O
so O
when O
the O
gene O
involved O
, O
HFE O
, O
was O
identified O
. O

Indeed O
, O
within O
the O
well O
defined O
, O
mainly O
peptide O
- O
binding O
, O
MHC O
class O
I O
family O
of O
molecules O
, O
HFE O
seems O
to O
perform O
an O
unusual O
yet O
essential O
function O
. O

As O
yet O
, O
our O
understanding O
of O
HFE O
function O
in O
iron O
homeostasis O
is O
only O
partial O
; O
an O
even O
more O
open O
question O
is O
its O
possible O
role O
in O
the O
immune O
system O
. O

To O
advance O
on O
both O
of O
these O
avenues O
, O
we O
report O
the O
deletion O
of O
HFE O
alpha1 O
and O
alpha2 O
putative O
ligand O
binding O
domains O
in O
vivo O
. O

HFE B
- I
deficient I
animals O
were O
analyzed O
for O
a O
comprehensive O
set O
of O
metabolic O
and O
immune O
parameters O
. O

Faithfully O
mimicking O
human O
hemochromatosis B
, O
mice O
homozygous O
for O
this O
deletion O
develop O
iron O
overload O
, O
characterized O
by O
a O
higher O
plasma O
iron O
content O
and O
a O
raised O
transferrin O
saturation O
as O
well O
as O
an O
elevated O
hepatic O
iron O
load O
. O

The O
primary O
defect O
could O
, O
indeed O
, O
be O
traced O
to O
an O
augmented O
duodenal O
iron O
absorption O
. O

In O
parallel O
, O
measurement O
of O
the O
gut O
mucosal O
iron O
content O
as O
well O
as O
iron O
regulatory O
proteins O
allows O
a O
more O
informed O
evaluation O
of O
various O
hypotheses O
regarding O
the O
precise O
role O
of O
HFE O
in O
iron O
homeostasis O
. O

Finally O
, O
an O
extensive O
phenotyping O
of O
primary O
and O
secondary O
lymphoid O
organs O
including O
the O
gut O
provides O
no O
compelling O
evidence O
for O
an O
obvious O
immune O
- O
linked O
function O
for O
HFE O
. O
. O

Somatic O
rearrangement O
of O
chromosome O
14 O
in O
human O
lymphocytes O
. O

Ataxia B
- I
telangiectasia I
is O
a O
rare O
genetic B
disorder I
associated O
with O
immune B
deficiency I
, O
chromosome B
instability I
, O
and O
a O
predisposition O
to O
lymphoid B
malignancy I
. O

We O
have O
detected O
chromosomally O
anomalous O
clones O
of O
lymphocytes O
in O
eight O
patients O
with O
this O
disorder O
. O

Chromosome O
banding O
disclosed O
that O
the O
clones O
are O
consistently O
marked O
by O
structural O
rearrangement O
of O
the O
long O
arm O
( O
q O
) O
of O
chromosome O
14 O
. O

A O
translocation O
involving O
14q O
was O
found O
in O
clones O
obtained O
from O
seven O
of O
the O
eight O
patients O
whereas O
a O
ring O
14 O
chromosome O
was O
found O
in O
a O
clone O
obtained O
from O
the O
other O
. O

These O
findings O
as O
well O
as O
data O
obtained O
by O
others O
for O
patients O
with O
ataxia B
- I
telangiectasia I
suggest O
that O
structural O
rearrangement O
of O
14q O
is O
the O
initial O
chromosomal O
change O
in O
lymphocyte O
clones O
of O
patients O
with O
this O
disorder O
. O

Chromosomes O
of O
lymphocytes O
from O
one O
of O
the O
patients O
were O
studied O
before O
and O
after O
the O
onset O
of O
chronic B
lymphocytic I
leukemia I
. O

Before O
leukemia B
was O
diagnosed O
, O
the O
patient O
had O
a O
lymphocyte O
clone O
with O
a O
14q O
translocation O
. O

This O
clone O
appears O
to O
have O
given O
rise O
to O
the O
leukemic B
cells O
. O

We O
hypothesize O
that O
structural O
rearrangement O
of O
14q O
is O
directly O
related O
to O
abnormal O
growth O
of O
lymphocytes O
and O
that O
it O
may O
be O
a O
step O
toward O
the O
development O
of O
lymphoid B
malignancies I
. O

Increasing O
evidence O
, O
provided O
by O
others O
, O
for O
the O
nonrandom O
involvement O
of O
14q O
in O
African O
- O
type O
Burkitts B
lymphoma I
and O
other O
lymphoid B
neoplasms I
further O
strengthens O
this O
hypothesis O
. O
. O

Exon O
9 O
mutations O
in O
the O
WT1 O
gene O
, O
without O
influencing O
KTS O
splice O
isoforms O
, O
are O
also O
responsible O
for O
Frasier B
syndrome I
. O

We O
report O
new O
mutations O
in O
exon O
9 O
of O
the O
WT1 O
gene O
that O
did O
not O
alter O
the O
ratio O
of O
+ O
/ O
- O
KTS O
splice O
isoforms O
in O
two O
unrelated O
patients O
with O
Frasier B
syndrome I
( O
FS B
) O
. O

The O
mutation O
of O
intron O
9 O
inducing O
defective O
alternative O
splicing O
was O
reported O
to O
be O
responsible O
for O
this O
syndrome O
. O

The O
mutations O
found O
in O
our O
cases O
occurred O
in O
the O
same O
exon O
of O
the O
WT1 O
gene O
as O
detected O
in O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
and O
could O
not O
be O
explained O
by O
the O
previously O
proposed O
mechanism O
. O

The O
results O
suggest O
that O
the O
two O
syndromes O
originate O
from O
the O
same O
WT1 B
gene I
abnormality I
. O

From O
a O
molecular O
biological O
point O
of O
view O
, O
we O
concluded O
that O
the O
two O
diseases O
were O
not O
separable O
, O
and O
that O
FS B
should O
be O
included O
as O
an O
atypical O
form O
of O
DDS B
. O
. O

Splice O
- O
site O
mutation O
in O
the O
PDS B
gene O
may O
result O
in O
intrafamilial O
variability O
for O
deafness B
in O
Pendred B
syndrome I
. O

Pendred B
syndrome I
is O
a O
recessive B
inherited I
disorder I
that O
consists O
of O
developmental B
abnormalities I
of I
the I
cochlea I
, O
sensorineural B
hearing I
loss I
, O
and O
diffuse B
thyroid I
enlargement I
( O
goiter B
) O
. O

This O
disorder O
may O
account O
for O
up O
to O
10 O
% O
of O
cases O
of O
hereditary B
deafness I
. O

The O
disease O
gene O
( O
PDS B
) O
has O
been O
mapped O
to O
chromosome O
7q22 O
- O
q31 O
, O
and O
encodes O
a O
chloride O
- O
iodide O
transport O
protein O
. O

We O
performed O
mutation O
analysis O
of O
individual O
exons O
of O
the O
PDS B
gene O
in O
one O
Spanish O
family O
that O
shows O
intrafamilial O
variability O
of O
the O
deafness B
phenotype O
( O
two O
patients O
with O
profound O
and O
one O
with O
moderate O
- O
severe O
deafness B
) O
. O

We O
identified O
a O
new O
splice O
- O
site O
mutation O
affecting O
intron O
4 O
of O
the O
PDS B
gene O
, O
at O
nucleotide O
position O
639 O
+ O
7 O
. O

RNA O
analysis O
from O
lymphocytes O
of O
the O
affected O
patients O
showed O
that O
mutation O
639 O
+ O
7A O
- O
- O
> O
G O
generates O
a O
new O
donor O
splice O
site O
, O
leading O
to O
an O
mRNA O
with O
an O
insertion O
of O
six O
nucleotides O
from O
intron O
4 O
of O
PDS O
. O

Since O
the O
newly O
created O
donor O
splice O
site O
is O
likely O
to O
compete O
with O
the O
normal O
one O
, O
variations O
of O
the O
levels O
of O
normal O
and O
aberrant O
transcripts O
of O
the O
PDS B
gene O
in O
the O
cochlea O
may O
explain O
the O
variability O
in O
the O
deafness B
presentation O
. O
. O

The O
molecular O
basis O
of O
Sjogren B
- I
Larsson I
syndrome I
: O
mutation O
analysis O
of O
the O
fatty O
aldehyde O
dehydrogenase O
gene O
. O

Sjogren B
- I
Larsson I
syndrome I
( O
SLS B
) O
is O
an O
autosomal B
recessive I
disorder I
characterized O
by O
ichthyosis B
, O
mental B
retardation I
, O
spasticity B
, O
and O
deficient B
activity I
of I
fatty I
aldehyde I
dehydrogenase I
( O
FALDH O
) O
. O

To O
define O
the O
molecular O
defects O
causing O
SLS B
, O
we O
performed O
mutation O
analysis O
of O
the O
FALDH O
gene O
in O
probands O
from O
63 O
kindreds O
with O
SLS B
. O

Among O
these O
patients O
, O
49 O
different O
mutations O
- O
including O
10 O
deletions O
, O
2 O
insertions O
, O
22 O
amino O
acid O
substitutions O
, O
3 O
nonsense O
mutations O
, O
9 O
splice O
- O
site O
defects O
, O
and O
3 O
complex O
mutations O
- O
were O
found O
. O

All O
of O
the O
patients O
with O
SLS B
were O
found O
to O
carry O
mutations O
. O

Nineteen O
of O
the O
missense O
mutations O
resulted O
in O
a O
severe O
reduction O
of O
FALDH O
enzyme O
catalytic O
activity O
when O
expressed O
in O
mammalian O
cells O
, O
but O
one O
mutation O
( O
798G O
- O
- O
> O
C O
[ O
K266N O
] O
) O
seemed O
to O
have O
a O
greater O
effect O
on O
mRNA O
stability O
. O

The O
splice O
- O
site O
mutations O
led O
to O
exon O
skipping O
or O
utilization O
of O
cryptic O
acceptor O
- O
splice O
sites O
. O

Thirty O
- O
seven O
mutations O
were O
private O
, O
and O
12 O
mutations O
were O
seen O
in O
two O
or O
more O
probands O
of O
European O
or O
Middle O
Eastern O
descent O
. O

Four O
single O
- O
nucleotide O
polymorphisms O
( O
SNPs O
) O
were O
found O
in O
the O
FALDH O
gene O
. O

At O
least O
four O
of O
the O
common O
mutations O
( O
551C O
- O
- O
> O
T O
, O
682C O
- O
- O
> O
T O
, O
733G O
- O
- O
> O
A O
, O
and O
798 O
+ O
1delG O
) O
were O
associated O
with O
multiple O
SNP O
haplotypes O
, O
suggesting O
that O
these O
mutations O
originated O
independently O
on O
more O
than O
one O
occasion O
or O
were O
ancient O
SLS B
genes O
that O
had O
undergone O
intragenic O
recombination O
. O

Our O
results O
demonstrate O
that O
SLS B
is O
caused O
by O
a O
strikingly O
heterogeneous O
group O
of O
mutations O
in O
the O
FALDH O
gene O
and O
provide O
a O
framework O
for O
understanding O
the O
genetic O
basis O
of O
SLS B
and O
the O
development O
of O
DNA O
- O
based O
diagnostic O
tests O
. O
. O

Loss O
- O
of O
- O
function O
mutations O
in O
the O
cathepsin O
C O
gene O
result O
in O
periodontal B
disease I
and O
palmoplantar B
keratosis I
. O

Papillon B
- I
Lefevre I
syndrome I
, O
or O
keratosis B
palmoplantaris I
with O
periodontopathia B
( O
PLS B
, O
MIM O
245000 O
) O
, O
is O
an O
autosomal B
recessive I
disorder I
that O
is O
mainly O
ascertained O
by O
dentists O
because O
of O
the O
severe O
periodontitis B
that O
afflicts O
patients O
. O

Both O
the O
deciduous O
and O
permanent O
dentitions O
are O
affected O
, O
resulting O
in O
premature O
tooth B
loss I
. O

Palmoplantar B
keratosis I
, O
varying O
from O
mild O
psoriasiform O
scaly O
skin O
to O
overt O
hyperkeratosis B
, O
typically O
develops O
within O
the O
first O
three O
years O
of O
life O
. O

Keratosis B
also O
affects O
other O
sites O
such O
as O
elbows O
and O
knees O
. O

Most O
PLS B
patients O
display O
both O
periodontitis B
and O
hyperkeratosis B
. O

Some O
patients O
have O
only O
palmoplantar B
keratosis I
or O
periodontitis B
, O
and O
in O
rare O
individuals O
the O
periodontitis B
is O
mild O
and O
of O
late O
onset O
. O

The O
PLS O
locus O
has O
been O
mapped O
to O
chromosome O
11q14 O
- O
q21 O
( O
refs O
7 O
, O
8 O
, O
9 O
) O
. O

Using O
homozygosity O
mapping O
in O
eight O
small O
consanguineous O
families O
, O
we O
have O
narrowed O
the O
candidate O
region O
to O
a O
1 O
. O

2 O
- O
cM O
interval O
between O
D11S4082 O
and O
D11S931 O
. O

The O
gene O
( O
CTSC O
) O
encoding O
the O
lysosomal O
protease O
cathepsin O
C O
( O
or O
dipeptidyl O
aminopeptidase O
I O
) O
lies O
within O
this O
interval O
. O

We O
defined O
the O
genomic O
structure O
of O
CTSC O
and O
found O
mutations O
in O
all O
eight O
families O
. O

In O
two O
of O
these O
families O
we O
used O
a O
functional O
assay O
to O
demonstrate O
an O
almost O
total O
loss O
of O
cathepsin O
C O
activity O
in O
PLS B
patients O
and O
reduced O
activity O
in O
obligate O
carriers O
. O

Confirmation O
of O
linkage O
of O
Van B
der I
Woude I
syndrome I
to O
chromosome O
1q32 O
: O
evidence O
of O
association O
with O
STR O
alleles O
suggests O
possible O
unique O
origin O
of O
the O
disease O
mutation O
. O

Van B
der I
Woude I
syndrome I
( O
VWS B
) O
is O
an O
autosomal B
dominant I
craniofacial I
disorder I
with O
high O
penetrance O
and O
variable O
expression O
. O

Its O
clinical O
features O
are O
variably O
expressed O
, O
but O
include O
cleft B
lip I
and O
/ O
or O
cleft B
palate I
, O
lip B
pits I
and O
hypodontia B
. O

All O
VWS B
families O
studied O
to O
date O
map O
the O
disease O
gene O
to O
a O
< O
2 O
cM O
region O
of O
chromosome O
1q32 O
, O
with O
no O
evidence O
of O
locus O
heterogeneity O
. O

The O
aim O
of O
this O
study O
is O
to O
refine O
the O
localization O
of O
the O
VWS B
gene O
and O
to O
further O
assess O
possible O
heterogeneity O
. O

We O
analyzed O
four O
multiplex O
VWS B
families O
. O

All O
available O
members O
were O
clinically O
assessed O
and O
genotyped O
for O
19 O
short O
tandem O
repeat O
markers O
on O
chromosome O
1 O
in O
the O
VWS B
candidate O
gene O
region O
. O

We O
performed O
two O
- O
point O
and O
multipoint O
limit O
of O
detection O
( O
LOD O
) O
score O
analyses O
using O
a O
high O
penetrance O
autosomal O
dominant O
model O
. O

All O
families O
showed O
positive O
LOD O
scores O
without O
any O
recombination O
in O
the O
candidate O
region O
. O

The O
largest O
two O
- O
point O
LOD O
score O
was O
5 O
. O

87 O
87 O
. O

Our O
assay O
method O
for O
short O
tandem O
repeat O
( O
STR O
) O
markers O
provided O
highly O
accurate O
size O
estimation O
of O
marker O
allele O
fragment O
sizes O
, O
and O
therefore O
enabled O
us O
to O
determine O
the O
specific O
alleles O
segregating O
with O
the O
VWS B
gene O
in O
each O
of O
our O
four O
families O
. O

We O
observed O
a O
striking O
pattern O
of O
STR O
allele O
sharing O
at O
several O
closely O
linked O
loci O
among O
our O
four O
Caucasian O
VWS B
families O
recruited O
at O
three O
different O
locations O
in O
the O
US O
. O

These O
results O
suggest O
the O
possibility O
of O
a O
unique O
origin O
for O
a O
mutation O
responsible O
for O
many O
or O
most O
cases O
of O
VWS B
. O

A O
point O
mutation O
Thr O
( O
799 O
) O
Met O
on O
the O
alpha O
( O
2 O
) O
integrin O
leads O
to O
the O
formation O
of O
new O
human O
platelet O
alloantigen O
Sit O
( O
a O
) O
and O
affects O
collagen O
- O
induced O
aggregation O
. O

A O
new O
platelet O
- O
specific O
alloantigen O
, O
termed O
Sit O
( O
a O
) O
, O
was O
identified O
in O
a O
severe O
case O
of O
neonatal B
alloimmune I
thrombocytopenia I
. O

The O
Sit O
( O
a O
) O
alloantigen O
is O
of O
low O
frequency O
( O
1 O
/ O
400 O
) O
in O
the O
German O
population O
. O

Immunochemical O
studies O
demonstrated O
that O
the O
Sit O
( O
a O
) O
epitopes O
reside O
on O
platelet O
glycoprotein O
( O
GP O
) O
Ia O
. O

Nucleotide O
sequence O
analysis O
of O
GPIa O
cDNA O
derived O
from O
Sit O
( O
a O
) O
- O
positive O
platelets O
showed O
C O
( O
2531 O
) O
- O
- O
> O
T O
( O
2531 O
) O
point O
mutation O
, O
resulting O
in O
Thr O
( O
799 O
) O
Met O
dimorphism O
. O

Analysis O
of O
genomic O
DNA O
from O
22 O
Sit O
( O
a O
) O
- O
negative O
normal O
individuals O
showed O
that O
the O
Thr O
( O
799 O
) O
is O
encoded O
by O
ACG O
( O
2532 O
) O
( O
90 O
. O
9 O
% O
) O
or O
ACA O
( O
2532 O
) O
( O
9 O
. O
1 O
% O
) O
. O

To O
establish O
a O
DNA O
typing O
technique O
, O
we O
elucidated O
the O
organization O
of O
the O
GPIa O
gene O
adjacent O
to O
the O
polymorphic O
bases O
. O

The O
introns O
( O
421 O
bp O
and O
1 O
. O
2 O
kb O
) O
encompass O
a O
142 O
- O
bp O
exon O
with O
the O
2 O
polymorphic O
bases O
2531 O
and O
2532 O
. O

Polymerase O
chain O
reaction O
- O
restriction O
fragment O
length O
polymorphism O
analysis O
on O
DNA O
derived O
from O
100 O
donors O
using O
the O
restriction O
enzyme O
Mae O
III O
showed O
that O
the O
Met O
( O
799 O
) O
form O
of O
GPIa O
is O
restricted O
to O
Sit O
( O
a O
) O
( O
+ O
) O
phenotype O
. O

Analysis O
of O
stable O
Chinese O
hamster O
ovary O
transfectants O
expressing O
allele O
- O
specific O
recombinant O
forms O
of O
GPIa O
showed O
that O
anti O
- O
Sit O
( O
a O
) O
exclusively O
reacted O
with O
the O
Glu O
( O
505 O
) O
Met O
( O
799 O
) O
, O
but O
not O
with O
the O
Glu O
( O
505 O
) O
Thr O
( O
799 O
) O
and O
the O
Lys O
( O
505 O
) O
Thr O
( O
799 O
) O
isoforms O
. O

In O
contrast O
, O
anti O
- O
Br O
( O
a O
) O
( O
HPA O
- O
5b O
) O
only O
recognized O
the O
Lys O
( O
505 O
) O
Thr O
( O
799 O
) O
form O
, O
whereas O
anti O
- O
Br O
( O
b O
) O
( O
HPA O
- O
5a O
) O
reacted O
with O
both O
Glu O
( O
505 O
) O
Thr O
( O
799 O
) O
and O
Glu O
( O
505 O
) O
Met O
( O
799 O
) O
isoforms O
. O

These O
results O
demonstrated O
that O
the O
Met O
( O
799 O
) O
is O
responsible O
for O
formation O
of O
the O
Sit O
( O
a O
) O
alloantigenic O
determinants O
, O
whereas O
amino O
acid O
505 O
( O
Lys O
or O
Glu O
) O
specifically O
controls O
the O
expression O
of O
Br O
( O
a O
) O
and O
Br O
( O
b O
) O
epitopes O
, O
respectively O
. O

Platelet O
aggregation O
responses O
of O
Sit O
( O
a O
) O
( O
+ O
) O
individuals O
were O
diminished O
in O
response O
to O
collagen O
, O
indicating O
that O
the O
Thr O
( O
799 O
) O
Met O
mutation O
affects O
the O
function O
of O
the O
GPIa O
/ O
IIa O
complex O

Mutations O
of O
the O
cathepsin O
C O
gene O
are O
responsible O
for O
Papillon B
- I
Lefevre I
syndrome I
. O

Papillon B
- I
Lefevre I
syndrome I
( O
PLS B
) O
is O
an O
autosomal B
recessive I
disorder I
characterised O
by O
palmoplantar B
hyperkeratosis I
and O
severe O
early O
onset O
periodontitis B
that O
results O
in O
the O
premature O
loss O
of O
the O
primary O
and O
secondary O
dentitions O
. O

A O
major O
gene O
locus O
for O
PLS B
has O
been O
mapped O
to O
a O
2 O
. O

8 O
cM O
interval O
on O
chromosome O
11q14 O
. O

Correlation O
of O
physical O
and O
genetic O
maps O
of O
this O
interval O
indicate O
it O
includes O
at O
least O
40 O
ESTs O
and O
six O
known O
genes O
including O
the O
lysosomal O
protease O
cathepsin O
C O
gene O
( O
CTSC O
) O
. O

The O
CTSC O
message O
is O
expressed O
at O
high O
levels O
in O
a O
variety O
of O
immune O
cells O
including O
polymorphonuclear O
leucocytes O
, O
macrophages O
, O
and O
their O
precursors O
. O

By O
RT O
- O
PCR O
, O
we O
found O
CTSC O
is O
also O
expressed O
in O
epithelial O
regions O
commonly O
affected O
by O
PLS B
, O
including O
the O
palms O
, O
soles O
, O
knees O
, O
and O
oral O
keratinised O
gingiva O
. O

The O
4 O
. O

7 O
kb O
CTSC O
gene O
consists O
of O
two O
exons O
. O

Sequence O
analysis O
of O
CTSC O
from O
subjects O
affected O
with O
PLS B
from O
five O
consanguineous O
Turkish O
families O
identified O
four O
different O
mutations O
. O

An O
exon O
1 O
nonsense O
mutation O
( O
856C O
- O
- O
> O
T O
) O
introduces O
a O
premature O
stop O
codon O
at O
amino O
acid O
286 O
. O

Three O
exon O
2 O
mutations O
were O
identified O
, O
including O
a O
single O
nucleotide O
deletion O
( O
2692delA O
) O
of O
codon O
349 O
introducing O
a O
frameshift O
and O
premature O
termination O
codon O
, O
a O
2 O
bp O
deletion O
( O
2673 O
- O
2674delCT O
) O
that O
results O
in O
introduction O
of O
a O
stop O
codon O
at O
amino O
acid O
343 O
, O
and O
a O
G O
- O
- O
> O
A O
substitution O
in O
codon O
429 O
( O
2931G O
- O
- O
> O
A O
) O
introducing O
a O
premature O
termination O
codon O
. O

All O
PLS B
patients O
were O
homozygous O
for O
cathepsin O
C O
mutations O
inherited O
from O
a O
common O
ancestor O
. O

Parents O
and O
sibs O
heterozygous O
for O
cathepsin O
C O
mutations O
do O
not O
show O
either O
the O
palmoplantar B
hyperkeratosis I
or O
severe O
early O
onset O
periodontitis B
characteristic O
of O
PLS B
. O

A O
more O
complete O
understanding O
of O
the O
functional O
physiology O
of O
cathepsin O
C O
carries O
significant O
implications O
for O
understanding O
normal O
and O
abnormal O
skin O
development O
and O
periodontal B
disease I
susceptibility O

Mutational O
analysis O
of O
the O
HGO O
gene O
in O
Finnish O
alkaptonuria B
patients O
. O

Alkaptonuria B
( O
AKU B
) O
, O
the O
prototypic O
inborn B
error I
of I
metabolism I
, O
has O
recently O
been O
shown O
to O
be O
caused O
by O
loss O
of O
function O
mutations O
in O
the O
homogentisate O
- O
1 O
, O
2 O
- O
dioxygenase O
gene O
( O
HGO O
) O
. O

So O
far O
17 O
mutations O
have O
been O
characterised O
in O
AKU B
patients O
of O
different O
ethnic O
origin O
. O

We O
describe O
three O
novel O
mutations O
( O
R58fs O
, O
R330S O
, O
and O
H371R O
) O
and O
one O
common O
AKU B
mutation O
( O
M368V O
) O
, O
detected O
by O
mutational O
and O
polymorphism O
analysis O
of O
the O
HGO O
gene O
in O
five O
Finnish O
AKU B
pedigrees O
. O

The O
three O
novel O
AKU B
mutations O
are O
most O
likely O
specific O
for O
the O
Finnish O
population O
and O
have O
originated O
recently O
. O
. O

The O
identical O
5 O
' O
splice O
- O
site O
acceptor O
mutation O
in O
five O
attenuated B
APC I
families O
from O
Newfoundland O
demonstrates O
a O
founder O
effect O
. O

Inherited O
mutations O
of O
the O
APC B
gene O
predispose O
carriers O
to O
multiple O
adenomatous B
polyps I
of I
the I
colon I
and I
rectum I
and O
to O
colorectal B
cancer I
. O

Mutations O
located O
at O
the O
extreme O
5 O
end O
of O
the O
APC B
gene O
, O
however O
, O
are O
associated O
with O
a O
less O
severe O
disease O
known O
as O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

Many O
individuals O
with O
AAPC B
develop O
relatively O
few O
colorectal B
polyps I
but O
are O
still O
at O
high O
risk O
for O
colorectal B
cancer I
. O

We O
report O
here O
the O
identification O
of O
a O
5 O
APC B
germline O
mutation O
in O
five O
separately O
ascertained O
AAPC B
families O
from O
Newfoundland O
, O
Canada O
. O

This O
disease O
- O
causing O
mutation O
is O
a O
single O
basepair O
change O
( O
G O
to O
A O
) O
in O
the O
splice O
- O
acceptor O
region O
of O
APC B
intron O
3 O
that O
creates O
a O
mutant O
RNA O
without O
exon O
4 O
of O
APC O
. O

The O
observation O
of O
the O
same O
APC B
mutation O
in O
five O
families O
from O
the O
same O
geographic O
area O
demonstrates O
a O
founder O
effect O
. O

Furthermore O
, O
the O
identification O
of O
this O
germline O
mutation O
strengthens O
the O
correlation O
between O
the O
5 O
location O
of O
an O
APC B
disease O
- O
causing O
mutation O
and O
the O
attenuated B
polyposis I
phenotype O
. O
. O

Alstrom B
syndrome I
: O
further O
evidence O
for O
linkage O
to O
human O
chromosome O
2p13 O
. O

Alstrom B
syndrome I
is O
a O
rare O
autosomal B
recessive I
disorder I
characterized O
by O
retinal B
degeneration I
, O
sensorineural B
hearing I
loss I
, O
early O
- O
onset O
obesity B
, O
and O
non B
- I
insulin I
- I
dependent I
diabetes I
mellitus I
. O

The O
gene O
for O
Alstrom B
syndrome I
( O
ALMS1 O
) O
has O
been O
previously O
localized O
to O
human O
chromosome O
2p13 O
by O
homozygosity O
mapping O
in O
two O
distinct O
isolated O
populations O
- O
French O
Acadian O
and O
North O
African O
. O

Pair O
- O
wise O
analyses O
resulted O
in O
maximum O
lod O
( O
logarithm O
of O
the O
odds O
ratio O
) O
scores O
of O
3 O
. O

84 O
and O
2 O
. O

9 O
, O
respectively O
. O

To O
confirm O
these O
findings O
, O
a O
large O
linkage O
study O
was O
performed O
in O
twelve O
additional O
families O
segregating O
for O
Alstrom B
syndrome I
. O

A O
maximum O
two O
- O
point O
lod O
score O
of O
7 O
. O

13 O
( O
theta O
= O
0 O
. O
00 O
) O
for O
marker O
D2S2110 O
and O
a O
maximum O
cumulative O
multipoint O
lod O
score O
of O
9 O
. O

16 O
for O
marker O
D2S2110 O
were O
observed O
, O
further O
supporting O
linkage O
to O
chromosome O
2p13 O
. O

No O
evidence O
of O
genetic O
heterogeneity O
was O
observed O
in O
these O
families O
. O

Meiotic O
recombination O
events O
have O
localized O
the O
critical O
region O
containing O
ALMS1 O
to O
a O
6 O
. O

1 O
- O
cM O
interval O
flanked O
by O
markers O
D2S327 O
and O
D2S286 O
. O

A O
fine O
resolution O
radiation O
hybrid O
map O
of O
31 O
genes O
and O
markers O
has O
been O
constructed O
. O

Pendred B
syndrome I
: O
phenotypic O
variability O
in O
two O
families O
carrying O
the O
same O
PDS B
missense O
mutation O
. O

Pendred B
syndrome I
comprises O
congenital B
sensorineural I
hearing I
loss I
, O
thyroid B
goiter I
, O
and O
positive O
perchlorate O
discharge O
test O
. O

Recently O
, O
this O
autosomal B
recessive I
disorder I
was O
shown O
to O
be O
caused O
by O
mutations O
in O
the O
PDS B
gene O
, O
which O
encodes O
an O
anion O
transporter O
called O
pendrin O
. O

Molecular O
analysis O
of O
the O
PDS B
gene O
was O
performed O
in O
two O
consanguineous O
large O
families O
from O
Southern O
Tunisia O
comprising O
a O
total O
of O
23 O
individuals O
affected O
with O
profound O
congenital B
deafness I
; O
the O
same O
missense O
mutation O
, O
L445W O
, O
was O
identified O
in O
all O
affected O
individuals O
. O

A O
widened B
vestibular I
aqueduct I
was O
found O
in O
all O
patients O
who O
underwent O
computed O
tomography O
( O
CT O
) O
scan O
exploration O
of O
the O
inner O
ear O
. O

In O
contrast O
, O
goiter B
was O
present O
in O
only O
11 O
affected O
individuals O
, O
who O
interestingly O
had O
a O
normal O
result O
of O
the O
perchlorate O
discharge O
test O
whenever O
performed O
. O

The O
present O
results O
question O
the O
sensitivity O
of O
the O
perchlorate O
test O
for O
the O
diagnosis O
of O
Pendred B
syndrome I
and O
support O
the O
use O
of O
a O
molecular O
analysis O
of O
the O
PDS B
gene O
in O
the O
assessment O
of O
individuals O
with O
severe O
to O
profound O
congenital B
hearing I
loss I
associated O
with O
inner B
ear I
morphological I
anomaly I
even O
in O
the O
absence O
of O
a O
thyroid B
goiter I
. O
. O

Knobloch B
syndrome I
involving O
midline B
scalp I
defect I
of I
the I
frontal I
region I
. O

We O
report O
on O
a O
4 O
- O
year O
- O
old O
boy O
with O
Knobloch B
syndrome I
. O

He O
has O
vitreoretinal B
degeneration I
, O
high B
myopia I
, O
cataract B
, O
telecanthus B
, O
hypertelorism B
, O
and O
a O
high B
- I
arched I
palate I
. O

He O
also O
has O
a O
defect B
of I
the I
anterior I
midline I
scalp I
with O
involvement O
of O
the O
frontal O
bone O
as O
documented O
by O
a O
computed O
tomography O
( O
CT O
) O
scan O
. O

The O
brain O
was O
normal O
on O
CT O
scan O
and O
magnetic O
resonance O
imaging O
. O

We O
present O
a O
review O
of O
the O
23 O
published O
cases O
with O
this O
syndrome O
. O

Our O
patient O
illustrates O
the O
importance O
of O
investigating O
for O
underlying O
ocular O
and O
central O
nervous O
system O
pathology O
whenever O
midline B
scalp I
defects I
are O
present O
. O
. O

The O
DNA O
double O
- O
strand O
break O
repair O
gene O
hMRE11 O
is O
mutated O
in O
individuals O
with O
an O
ataxia B
- I
telangiectasia I
- I
like I
disorder I
. O

We O
show O
that O
hypomorphic O
mutations O
in O
hMRE11 O
, O
but O
not O
in O
ATM O
, O
are O
present O
in O
certain O
individuals O
with O
an O
ataxia B
- I
telangiectasia I
- I
like I
disorder I
( O
ATLD B
) O
. O

The O
cellular O
features O
resulting O
from O
these O
hMRE11 O
mutations O
are O
similar O
to O
those O
seen O
in O
A B
- I
T I
as O
well O
as O
NBS B
and O
include O
hypersensitivity B
to I
ionizing I
radiation I
, O
radioresistant O
DNA O
synthesis O
, O
and O
abrogation O
of O
ATM O
- O
dependent O
events O
, O
such O
as O
the O
activation O
of O
Jun O
kinase O
following O
exposure O
to O
gamma O
irradiation O
. O

Although O
the O
mutant O
hMre11 O
proteins O
retain O
some O
ability O
to O
interact O
with O
hRad50 O
and O
Nbs1 O
, O
formation O
of O
ionizing O
radiation O
- O
induced O
hMre11 O
and O
Nbs1 O
foci O
was O
absent O
in O
hMRE11 O
mutant O
cells O
. O

These O
data O
demonstrate O
that O
ATM O
and O
the O
hMre11 O
/ O
hRad50 O
/ O
Nbs1 O
protein O
complex O
act O
in O
the O
same O
DNA O
damage O
response O
pathway O
and O
link O
hMre11 O
to O
the O
complex O
pathology O
of O
A B
- I
T I
. O
. O

Mutations O
in O
TNFRSF11A O
, O
affecting O
the O
signal O
peptide O
of O
RANK O
, O
cause O
familial B
expansile I
osteolysis I
. O

Familial B
expansile I
osteolysis I
( O
FEO B
, O
MIM O
174810 O
) O
is O
a O
rare O
, O
autosomal B
dominant I
bone I
disorder I
characterized O
by O
focal O
areas O
of O
increased B
bone I
remodelling I
. O

The O
osteolytic B
lesions I
, O
which O
develop O
usually O
in O
the O
long O
bones O
during O
early O
adulthood O
, O
show O
increased O
osteoblast O
and O
osteoclast O
activity O
. O

Our O
previous O
linkage O
studies O
mapped O
the O
gene O
responsible O
for O
FEO B
to O
an O
interval O
of O
less O
than O
5 O
cM O
between O
D18S64 O
and O
D18S51 O
on O
chromosome O
18q21 O
. O

2 O
- O
21 O
2 O
- O
21 O
. O

3 O
in O
a O
large O
Northern O
Irish O
family O
. O

The O
gene O
encoding O
receptor O
activator O
of O
nuclear O
factor O
- O
kappa O
B O
( O
RANK O
; O
ref O
. O
5 O
) O
, O
TNFRSF11A O
, O
maps O
to O
this O
region O
. O

RANK O
is O
essential O
in O
osteoclast O
formation O
. O

We O
identified O
two O
heterozygous O
insertion O
mutations O
in O
exon O
1 O
of O
TNFRSF11A O
in O
affected O
members O
of O
four O
families O
with O
FEO B
or O
familial B
Paget I
disease I
of I
bone I
( O
PDB B
) O
. O

One O
was O
a O
duplication O
of O
18 O
bases O
and O
the O
other O
a O
duplication O
of O
27 O
bases O
, O
both O
of O
which O
affected O
the O
signal O
peptide O
region O
of O
the O
RANK O
molecule O
. O

Expression O
of O
recombinant O
forms O
of O
the O
mutant O
RANK O
proteins O
revealed O
perturbations O
in O
expression O
levels O
and O
lack O
of O
normal O
cleavage O
of O
the O
signal O
peptide O
. O

Both O
mutations O
caused O
an O
increase O
in O
RANK O
- O
mediated O
nuclear O
factor O
- O
kappaB O
( O
NF O
- O
kappaB O
) O
signalling O
in O
vitro O
, O
consistent O
with O
the O
presence O
of O
an O
activating O
mutation O
. O

Cardiac O
Na O
( O
+ O
) O
channel O
dysfunction O
in O
Brugada B
syndrome I
is O
aggravated O
by O
beta O
( O
1 O
) O
- O
subunit O
. O

BACKGROUND O
Mutations O
in O
the O
gene O
encoding O
the O
human O
cardiac O
Na O
( O
+ O
) O
channel O
alpha O
- O
subunit O
( O
hH1 O
) O
are O
responsible O
for O
chromosome O
3 O
- O
linked O
congenital B
long I
- I
QT I
syndrome I
( O
LQT3 B
) O
and O
idiopathic B
ventricular I
fibrillation I
( O
IVF B
) O
. O

An O
auxiliary O
beta O
( O
1 O
) O
- O
subunit O
, O
widely O
expressed O
in O
excitable O
tissues O
, O
shifts O
the O
voltage O
dependence O
of O
steady O
- O
state O
inactivation O
toward O
more O
negative O
potentials O
and O
restores O
normal O
gating O
kinetics O
of O
brain O
and O
skeletal O
muscle O
Na O
( O
+ O
) O
channels O
expressed O
in O
Xenopus O
oocytes O
but O
has O
little O
if O
any O
functional O
effect O
on O
the O
cardiac O
isoform O
. O

Here O
, O
we O
characterize O
the O
altered O
effects O
of O
a O
human O
beta O
( O
1 O
) O
- O
subunit O
( O
hbeta O
( O
1 O
) O
) O
on O
the O
heterologously O
expressed O
hH1 O
mutation O
( O
T1620M O
) O
previously O
associated O
with O
IVF B
. O

METHODS O
AND O
RESULTS O
When O
expressed O
alone O
in O
Xenopus O
oocytes O
, O
T1620M O
exhibited O
no O
persistent O
currents O
, O
in O
contrast O
to O
the O
LQT3 B
mutant O
channels O
, O
but O
the O
midpoint O
of O
steady O
- O
state O
inactivation O
( O
V O
( O
1 O
/ O
2 O
) O
) O
was O
significantly O
shifted O
toward O
more O
positive O
potentials O
than O
for O
wild O
- O
type O
hH1 O
. O

Coexpression O
of O
hbeta O
( O
1 O
) O
did O
not O
significantly O
alter O
current O
decay O
or O
recovery O
from O
inactivation O
of O
wild O
- O
type O
hH1 O
; O
however O
, O
it O
further O
shifted O
the O
V O
( O
1 O
/ O
2 O
) O
and O
accelerated O
the O
recovery O
from O
inactivation O
of O
T1620M O
. O

Oocyte O
macropatch O
analysis O
revealed O
that O
the O
activation O
kinetics O
of O
T1620M O
were O
normal O
. O

CONCLUSIONS O
It O
is O
suggested O
that O
coexpression O
of O
hbeta O
( O
1 O
) O
exposes O
a O
more O
severe O
functional O
defect O
that O
results O
in O
a O
greater O
overlap O
in O
the O
relationship O
between O
channel O
inactivation O
and O
activation O
( O
window O
current O
) O
in O
T1620M O
, O
which O
is O
proposed O
to O
be O
a O
potential O
pathophysiological O
mechanism O
of O
IVF B
in O
vivo O
. O

One O
possible O
explanation O
for O
our O
finding O
is O
an O
altered O
alpha O
- O
/ O
beta O
( O
1 O
) O
- O
subunit O
association O
in O
the O
mutant O
. O
. O

Meiotic O
segregation O
analysis O
of O
RB1 O
alleles O
in O
retinoblastoma B
pedigrees O
by O
use O
of O
single O
- O
sperm O
typing O
. O

In O
hereditary B
retinoblastoma I
, O
different O
epidemiological O
studies O
have O
indicated O
a O
preferential O
paternal O
transmission O
of O
mutant O
retinoblastoma B
alleles O
to O
offspring O
, O
suggesting O
the O
occurrence O
of O
a O
meiotic O
drive O
. O

To O
investigate O
this O
mechanism O
, O
we O
analyzed O
sperm O
samples O
from O
six O
individuals O
from O
five O
unrelated O
families O
affected O
with O
hereditary B
retinoblastoma I
. O

Single O
- O
sperm O
typing O
techniques O
were O
performed O
for O
each O
sample O
by O
study O
of O
two O
informative O
short O
tandem O
repeats O
located O
either O
in O
or O
close O
to O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

The O
segregation O
probability O
of O
mutant O
RB1 O
alleles O
in O
sperm O
samples O
was O
assessed O
by O
use O
of O
the O
SPERMSEG O
program O
, O
which O
includes O
experimental O
parameters O
, O
recombination O
fractions O
between O
the O
markers O
, O
and O
segregation O
parameters O
. O

A O
total O
of O
2 O
, O
952 O
single O
sperm O
from O
the O
six O
donors O
were O
analyzed O
. O

We O
detected O
a O
significant O
segregation O
distortion O
in O
the O
data O
as O
a O
whole O
( O
P O
= O
. O
0099 O
) O
and O
a O
significant O
heterogeneity O
in O
the O
segregation O
rate O
across O
donors O
( O
. O
0092 O
) O
. O

Further O
analysis O
shows O
that O
this O
result O
can O
be O
explained O
by O
segregation O
distortion O
in O
favor O
of O
the O
normal O
allele O
in O
one O
donor O
only O
and O
that O
it O
does O
not O
provide O
evidence O
of O
a O
significant O
segregation O
distortion O
in O
the O
other O
donors O
. O

The O
segregation O
distortion O
favoring O
the O
mutant O
RB1 O
allele O
does O
not O
seem O
to O
occur O
during O
spermatogenesis O
, O
and O
, O
thus O
, O
meiotic O
drive O
may O
result O
either O
from O
various O
mechanisms O
, O
including O
a O
fertilization O
advantage O
or O
a O
better O
mobility O
in O
sperm O
bearing O
a O
mutant O
RB1 O
gene O
, O
or O
from O
the O
existence O
of O
a O
defectively O
imprinted O
gene O
located O
on O
the O
human O
X O
chromosome O
. O

Friedreich B
ataxia I
: O
an O
overview O
. O

Friedreich B
ataxia I
, O
an O
autosomal B
recessive I
neurodegenerative I
disease I
, O
is O
the O
most O
common O
of O
the O
inherited B
ataxias I
. O

The O
recent O
discovery O
of O
the O
gene O
that O
is O
mutated O
in O
this O
condition O
, O
FRDA O
, O
has O
led O
to O
rapid O
advances O
in O
the O
understanding O
of O
the O
pathogenesis O
of O
Friedreich B
ataxia I
. O

About O
98 O
% O
of O
mutant O
alleles O
have O
an O
expansion O
of O
a O
GAA O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
gene O
. O

This O
leads O
to O
reduced O
levels O
of O
the O
protein O
, O
frataxin O
. O

There O
is O
mounting O
evidence O
to O
suggest O
that O
Friedreich B
ataxia I
is O
the O
result O
of O
accumulation O
of O
iron O
in O
mitochondria O
leading O
to O
excess O
production O
of O
free O
radicals O
, O
which O
then O
results O
in O
cellular O
damage O
and O
death O
. O

Currently O
there O
is O
no O
known O
treatment O
that O
alters O
the O
natural O
course O
of O
the O
disease O
. O

The O
discovery O
of O
the O
FRDA B
gene O
and O
its O
possible O
function O
has O
raised O
hope O
that O
rational O
therapeutic O
strategies O
will O
be O
developed O
. O
. O

X B
- I
linked I
retinoschisis I
with O
point O
mutations O
in O
the O
XLRS1 O
gene O
. O

BACKGROUND O
X B
- I
linked I
retinoschisis I
( O
XLRS B
) O
is O
a O
relatively O
rare O
vitreoretinal B
dystrophy I
that O
causes O
visual B
loss I
in O
young O
men O
. O

Recently O
, O
a O
gene O
responsible O
for O
this O
disease O
, O
designated O
XLRS1 O
, O
was O
identified O
, O
and O
several O
deleterious O
gene O
mutations O
were O
reported O
. O

OBJECTIVE O
To O
analyze O
Japanese O
patients O
clinically O
diagnosed O
as O
having O
XLRS B
formutational O
changes O
in O
the O
XLRS1 O
gene O
. O

METHODS O
Ten O
patients O
with O
XLRS B
underwent O
full O
ophthalmologic O
examination O
, O
including O
slitlamp O
biomicroscopy O
and O
dilated O
funduscopy O
. O

Genomic O
DNA O
was O
isolated O
from O
leukocytes O
, O
and O
all O
exons O
of O
the O
XLRS1 O
gene O
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
analyzed O
using O
a O
direct O
sequencing O
method O
. O

RESULTS O
Point O
mutations O
in O
the O
XLRS1 O
gene O
were O
identified O
in O
all O
10 O
patients O
. O

The O
mutations O
were O
identical O
in O
each O
of O
2 O
pairs O
of O
brothers O
. O

Six O
of O
the O
point O
mutations O
represented O
missense O
mutations O
, O
1 O
was O
a O
nonsense O
mutation O
, O
and O
1 O
was O
a O
frameshift O
mutation O
. O

Five O
of O
the O
mutations O
are O
newly O
reported O
herein O
. O

CONCLUSIONS O
The O
discovery O
of O
new O
point O
mutations O
in O
this O
study O
increases O
the O
available O
information O
regarding O
the O
spectrum O
of O
genetic B
abnormalities I
and O
clinical O
manifestations O
of O
XLRS B
. O

However O
, O
the O
limited O
data O
failed O
to O
reveal O
a O
correlation O
between O
mutation O
and O
disease O
phenotype O
. O

CLINICAL O
RELEVANCE O
Identification O
of O
mutations O
in O
the O
XLRS1 O
gene O
and O
expanded O
information O
on O
clinical O
manifestations O
will O
facilitate O
early O
diagnosis O
, O
appropriate O
early O
therapy O
, O
and O
genetic O
counseling O
regarding O
the O
prognosis O
of O
XLRS B
. O
. O

Atm O
and O
Bax O
cooperate O
in O
ionizing O
radiation O
- O
induced O
apoptosis O
in O
the O
central O
nervous O
system O
. O

Ataxia B
- I
telangiectasia I
is O
a O
hereditary B
multisystemic I
disease I
resulting O
from O
mutations O
of O
ataxia B
telangiectasia I
, O
mutated O
( O
ATM O
) O
and O
is O
characterized O
by O
neurodegeneration B
, O
cancer B
, O
immune B
defects I
, O
and O
hypersensitivity B
to I
ionizing I
radiation I
. O

The O
molecular O
details O
of O
ATM O
function O
in O
the O
nervous O
system O
are O
unclear O
, O
although O
the O
neurological B
lesion I
in O
ataxia B
- I
telangiectasia I
becomes O
apparent O
early O
in O
life O
, O
suggesting O
a O
developmental O
origin O
. O

The O
central O
nervous O
system O
( O
CNS O
) O
of O
Atm O
- O
null O
mice O
shows O
a O
pronounced O
defect O
in O
apoptosis O
induced O
by O
genotoxic O
stress O
, O
suggesting O
ATM O
functions O
to O
eliminate O
neurons O
with O
excessive O
genomic O
damage O
. O

Here O
, O
we O
report O
that O
the O
death O
effector O
Bax O
is O
required O
for O
a O
large O
proportion O
of O
Atm O
- O
dependent O
apoptosis O
in O
the O
developing O
CNS O
after O
ionizing O
radiation O
( O
IR O
) O
. O

Although O
many O
of O
the O
same O
regions O
of O
the O
CNS O
in O
both O
Bax O
- O
/ O
- O
and O
Atm O
- O
/ O
- O
mice O
were O
radioresistant O
, O
mice O
nullizygous O
for O
both O
Bax O
and O
Atm O
showed O
additional O
reduction O
in O
IR O
- O
induced O
apoptosis O
in O
the O
CNS O
. O

Therefore O
, O
although O
the O
major O
IR O
- O
induced O
apoptotic O
pathway O
in O
the O
CNS O
requires O
Atm O
and O
Bax O
, O
a O
p53 O
- O
dependent O
collateral O
pathway O
exists O
that O
has O
both O
Atm O
- O
and O
Bax O
- O
independent O
branches O
. O

Further O
, O
Atm O
- O
and O
Bax O
- O
dependent O
apoptosis O
in O
the O
CNS O
also O
required O
caspase O
- O
3 O
activation O
. O

These O
data O
implicate O
Bax O
and O
caspase O
- O
3 O
as O
death O
effectors O
in O
neurodegenerative O
pathways O
. O
. O

Haim B
- I
Munk I
syndrome I
and O
Papillon B
- I
Lefevre I
syndrome I
are O
allelic O
mutations O
in O
cathepsin O
C O
. O

Of O
the O
many O
palmoplantar B
keratoderma I
( I
PPK I
) I
conditions I
, O
only O
Papillon B
- I
Lefevre I
syndrome I
( O
PLS B
) O
and O
Haim B
- I
Munk I
syndrome I
( O
HMS B
) O
are O
associated O
with O
premature O
periodontal O
destruction O
. O

Although O
both O
PLS B
and O
HMS B
share O
the O
cardinal O
features O
of O
PPK B
and O
severe O
periodontitis B
, O
a O
number O
of O
additional O
findings O
are O
reported O
in O
HMS B
including O
arachnodactyly B
, O
acro B
- I
osteolysis I
, O
atrophic B
changes I
of I
the I
nails I
, O
and O
a O
radiographic B
deformity I
of I
the I
fingers I
. O

While O
PLS B
cases O
have O
been O
identified O
throughout O
the O
world O
, O
HMS B
has O
only O
been O
described O
among O
descendants O
of O
a O
religious O
isolate O
originally O
from O
Cochin O
, O
India O
. O

Parental O
consanguinity O
is O
a O
characteristic O
of O
many O
cases O
of O
both O
conditions O
. O

Although O
autosomal O
recessive O
transmission O
of O
PLS B
is O
evident O
, O
a O
more O
" O
complex O
" O
autosomal O
recessive O
pattern O
of O
inheritance O
with O
phenotypic O
influences O
from O
a O
closely O
linked O
modifying O
locus O
has O
been O
hypothesised O
for O
HMS B
. O

Recently O
, O
mutations O
of O
the O
cathepsin O
C O
gene O
have O
been O
identified O
as O
the O
underlying O
genetic B
defect I
in O
PLS B
. O

To O
determine O
if O
a O
cathepsin O
C O
mutation O
is O
also O
responsible O
for O
HMS B
, O
we O
sequenced O
the O
gene O
in O
affected O
and O
unaffected O
subjects O
from O
the O
Cochin O
isolate O
in O
which O
both O
the O
PLS B
and O
HMS B
phenotypes O
appear O
. O

Here O
we O
report O
identification O
of O
a O
mutation O
of O
cathepsin O
C O
( O
exon O
6 O
, O
2127A O
- O
- O
> O
G O
) O
that O
changes O
a O
highly O
conserved O
amino O
acid O
in O
the O
cathepsin O
C O
peptide O
. O

This O
mutation O
segregates O
with O
HMS B
in O
four O
nuclear O
families O
. O

Additionally O
, O
the O
existence O
of O
a O
shared O
common O
haplotype O
for O
genetic O
loci O
flanking O
the O
cathepsin O
C O
gene O
suggests O
that O
affected O
subjects O
descended O
from O
the O
Cochin O
isolate O
are O
homozygous O
for O
a O
mutation O
inherited O
" O
identical O
by O
descent O
" O
from O
a O
common O
ancestor O
. O

This O
finding O
supports O
simple O
autosomal O
recessive O
inheritance O
for O
HMS B
in O
these O
families O
. O

We O
also O
report O
a O
mutation O
of O
the O
same O
exon O
6 O
CTSC O
codon O
( O
2126C O
- O
- O
> O
T O
) O
in O
a O
Turkish O
family O
with O
classical O
PLS B
. O

These O
findings O
provide O
evidence O
that O
PLS B
and O
HMS B
are O
allelic O
variants O
of O
cathepsin O
C O
gene O
mutations O
. O
. O

ATM O
- O
heterozygous O
germline O
mutations O
contribute O
to O
breast B
cancer I
- O
susceptibility O
. O

Approximately O
0 O
. O

5 O
% O
- O
1 O
% O
of O
the O
general O
population O
has O
been O
estimated O
to O
be O
heterozygous O
for O
a O
germline O
mutation O
in O
the O
ATM O
gene O
. O

Mutations O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
( O
MIM O
208900 O
) O
. O

The O
finding O
that O
ATM O
- O
heterozygotes O
have O
an O
increased O
relative O
risk O
for O
breast B
cancer I
was O
supported O
by O
some O
studies O
but O
not O
confirmed O
by O
others O
. O

In O
view O
of O
this O
discrepancy O
, O
we O
examined O
the O
frequency O
of O
ATM O
germline O
mutations O
in O
a O
selected O
group O
of O
Dutch O
patients O
with O
breast B
cancer I
. O

We O
have O
analyzed O
ATM O
germline O
mutations O
in O
normal O
blood O
lymphocytes O
, O
using O
the O
protein O
- O
truncation O
test O
followed O
by O
genomic O
- O
sequence O
analysis O
. O

A O
high O
percentage O
of O
ATM O
germline O
mutations O
was O
demonstrated O
among O
patients O
with O
sporadic B
breast I
cancer I
. O

The O
82 O
patients O
included O
in O
this O
study O
had O
developed O
breast B
cancer I
at O
age O
< O
45 O
and O
had O
survived O
> O
/ O
= O
5 O
years O
( O
mean O
15 O
years O
) O
, O
and O
in O
33 O
( O
40 O
% O
) O
of O
the O
patients O
a O
contralateral O
breast O
tumor O
had O
been O
diagnosed O
. O

Among O
these O
patients O
we O
identified O
seven O
( O
8 O
. O
5 O
% O
) O
ATM O
germline O
mutations O
, O
of O
which O
five O
are O
distinct O
. O

One O
splice O
- O
site O
mutation O
( O
IVS10 O
- O
6T O
- O
- O
> O
G O
) O
was O
detected O
three O
times O
in O
our O
series O
. O

Four O
heterozygous O
carriers O
were O
patients O
with O
bilateral O
breast O
cancer O
. O

Our O
results O
indicate O
that O
the O
mutations O
identified O
in O
this O
study O
are O
" O
A O
- O
T O
disease O
- O
causing O
" O
mutations O
that O
might O
be O
associated O
with O
an O
increased O
risk O
of O
breast O
cancer O
in O
heterozygotes O
. O

We O
conclude O
that O
ATM O
heterozygotes O
have O
an O
approximately O
ninefold O
- O
increased O
risk O
of O
developing O
a O
type O
of O
breast O
cancer O
characterized O
by O
frequent O
bilateral O
occurrence O
, O
early O
age O
at O
onset O
, O
and O
long O
- O
term O
survival O
. O

The O
specific O
characteristics O
of O
our O
population O
of O
patients O
may O
explain O
why O
such O
a O
high O
frequency O
was O
not O
found O
in O
other O
series O
. O

Human O
mutations O
in O
glucose O
6 O
- O
phosphate O
dehydrogenase O
reflect O
evolutionary O
history O
. O

Glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
is O
a O
cytosolic O
enzyme O
encoded O
by O
a O
housekeeping O
X O
- O
linked O
gene O
whose O
main O
function O
is O
to O
produce O
NADPH O
, O
a O
key O
electron O
donor O
in O
the O
defense O
against O
oxidizing O
agents O
and O
in O
reductive O
biosynthetic O
reactions O
. O

Inherited O
G6PD B
deficiency I
is O
associated O
with O
either O
episodic B
hemolytic I
anemia I
( O
triggered O
by O
fava O
beans O
or O
other O
agents O
) O
or O
life B
- I
long I
hemolytic I
anemia I
. O

We O
show O
here O
that O
an O
evolutionary O
analysis O
is O
a O
key O
to O
understanding O
the O
biology O
of O
a O
housekeeping O
gene O
. O

From O
the O
alignment O
of O
the O
amino O
acid O
( O
aa O
) O
sequence O
of O
52 O
glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
species O
from O
42 O
different O
organisms O
, O
we O
found O
a O
striking O
correlation O
between O
the O
aa O
replacements O
that O
cause O
G6PD B
deficiency I
in O
humans O
and O
the O
sequence O
conservation O
of O
G6PD O
two O
- O
thirds O
of O
such O
replacements O
are O
in O
highly O
and O
moderately O
conserved O
( O
50 O
- O
99 O
% O
) O
aa O
; O
relatively O
few O
are O
in O
fully O
conserved O
aa O
( O
where O
they O
might O
be O
lethal O
) O
or O
in O
poorly O
conserved O
aa O
, O
where O
presumably O
they O
simply O
would O
not O
cause O
G6PD B
deficiency I
. O

This O
is O
consistent O
with O
the O
notion O
that O
all O
human O
mutants O
have O
residual O
enzyme O
activity O
and O
that O
null O
mutations O
are O
lethal O
at O
some O
stage O
of O
development O
. O

Comparing O
the O
distribution O
of O
mutations O
in O
a O
human O
housekeeping O
gene O
with O
evolutionary O
conservation O
is O
a O
useful O
tool O
for O
pinpointing O
amino O
acid O
residues O
important O
for O
the O
stability O
or O
the O
function O
of O
the O
corresponding O
protein O
. O

In O
view O
of O
the O
current O
explosive O
increase O
in O
full O
genome O
sequencing O
projects O
, O
this O
tool O
will O
become O
rapidly O
available O
for O
numerous O
other O
genes O
. O
. O

Constitutive O
and O
regulated O
modes O
of O
splicing O
produce O
six O
major O
myotonic B
dystrophy I
protein O
kinase O
( O
DMPK O
) O
isoforms O
with O
distinct O
properties O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
the O
most O
prevalent O
inherited B
neuromuscular I
disease I
in O
adults O
. O

The O
genetic B
defect I
is O
a O
CTG O
triplet O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
the O
myotonic B
dystrophy I
protein O
kinase O
( O
DMPK O
) O
gene O
, O
consisting O
of O
15 O
exons O
. O

Using O
a O
transgenic O
DMPK O
- O
overexpressor O
mouse O
model O
, O
we O
demonstrate O
here O
that O
the O
endogenous O
mouse O
DMPK O
gene O
and O
the O
human O
DMPK O
transgene O
produce O
six O
major O
alternatively O
spliced O
mRNAs O
which O
have O
almost O
identical O
cell O
type O
- O
dependent O
distribution O
frequencies O
and O
expression O
patterns O
. O

Use O
of O
a O
cryptic O
5 O
splice O
site O
in O
exon O
8 O
, O
which O
results O
in O
absence O
or O
presence O
of O
15 O
nucleotides O
specifying O
a O
VSGGG O
peptide O
motif O
, O
and O
/ O
or O
use O
of O
a O
cryptic O
3 O
splice O
site O
in O
exon O
14 O
, O
which O
leads O
to O
a O
frameshift O
in O
the O
mRNA O
reading O
frame O
, O
occur O
as O
independent O
stochastic O
events O
in O
all O
tissues O
examined O
. O

In O
contrast O
, O
the O
excision O
of O
exons O
13 O
/ O
14 O
that O
causes O
a O
frameshift O
and O
creates O
a O
C O
- O
terminally O
truncated O
protein O
is O
clearly O
cell O
type O
dependent O
and O
occurs O
predominantly O
in O
smooth O
muscle O
. O

We O
generated O
all O
six O
full O
- O
length O
mouse O
cDNAs O
that O
result O
from O
combinations O
of O
these O
three O
major O
splicing O
events O
and O
show O
that O
their O
transfection O
into O
cells O
in O
culture O
leads O
to O
production O
of O
four O
different O
approximately O
74 O
kDa O
full O
- O
length O
( O
heart O
- O
, O
skeletal O
muscle O
- O
or O
brain O
- O
specific O
) O
and O
two O
C O
- O
terminally O
truncated O
approximately O
68 O
kDa O
( O
smooth O
muscle O
- O
specific O
) O
isoforms O
. O

Information O
on O
DMPK O
mRNA O
and O
protein O
isoform O
expression O
patterns O
will O
be O
useful O
for O
recognizing O
differential O
effects O
of O
( O
CTG O
) O
( O
n O
) O
expansion O
in O
DM B
manifestation O
. O
. O

Genetic O
analysis O
, O
phenotypic O
diagnosis O
, O
and O
risk O
of O
venous B
thrombosis I
in O
families O
with O
inherited O
deficiencies B
of I
protein I
S I
. O

Protein B
S I
deficiency I
is O
a O
recognized O
risk O
factor O
for O
venous B
thrombosis I
. O

Of O
all O
the O
inherited O
thrombophilic B
conditions I
, O
it O
remains O
the O
most O
difficult O
to O
diagnose O
because O
of O
phenotypic O
variability O
, O
which O
can O
lead O
to O
inconclusive O
results O
. O

We O
have O
overcome O
this O
problem O
by O
studying O
a O
cohort O
of O
patients O
from O
a O
single O
center O
where O
the O
diagnosis O
was O
confirmed O
at O
the O
genetic O
level O
. O

Twenty O
- O
eight O
index O
patients O
with O
protein B
S I
deficiency I
and O
a O
PROS1 B
gene I
defect I
were O
studied O
, O
together O
with O
109 O
first O
- O
degree O
relatives O
. O

To O
avoid O
selection O
bias O
, O
we O
confined O
analysis O
of O
total O
and O
free O
protein O
S O
levels O
and O
thrombotic O
risk O
to O
the O
patients O
relatives O
. O

In O
this O
group O
of O
relatives O
, O
a O
low O
free O
protein O
S O
level O
was O
the O
most O
reliable O
predictor O
of O
a O
PROS1 B
gene I
defect I
( O
sensitivity O
97 O
. O
7 O
% O
, O
specificity O
100 O
% O
) O
. O

First O
- O
degree O
relatives O
with O
a O
PROS1 B
gene I
defect I
had O
a O
5 O
. O

0 O
- O
fold O
higher O
risk O
of O
thrombosis B
( O
95 O
% O
confidence O
interval O
, O
1 O
. O
5 O
- O
16 O
. O
8 O
) O
than O
those O
with O
a O
normal O
PROS1 O
gene O
and O
no O
other O
recognized O
thrombophilic B
defect I
. O

Although O
pregnancy O
/ O
puerperium O
and O
immobility O
/ O
trauma B
were O
important O
precipitating O
factors O
for O
thrombosis B
, O
almost O
half O
of O
the O
events O
were O
spontaneous O
. O

Relatives O
with O
splice O
- O
site O
or O
major O
structural O
defects B
in I
the I
PROS1 I
gene I
were O
more O
likely O
to O
have O
had O
a O
thrombotic O
event O
and O
had O
significantly O
lower O
total O
and O
free O
protein O
S O
levels O
than O
those O
relatives O
having O
missense O
mutations O
. O

We O
conclude O
that O
persons O
with O
PROS1 B
gene I
defects I
and O
protein B
S I
deficiency I
are O
at O
increased O
risk O
of O
thrombosis B
and O
that O
free O
protein O
S O
estimation O
offers O
the O
most O
reliable O
way O
of O
diagnosing O
the O
deficiency O
. O

( O
Blood O
. O
2000 O
; O
95 O
1935 O
- O
1941 O
) O
. O

Autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
in O
a O
child O
from O
consanguineous O
parents O
: O
a O
dominant O
or O
recessive O
disease O
? O

Autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
is O
characterized O
by O
autoimmune O
features O
and O
lymphoproliferations O
and O
is O
generally O
caused O
by O
defective O
Fas O
- O
mediated O
apoptosis O
. O

This O
report O
describes O
a O
child O
with O
clinical O
features O
of O
ALPS B
without O
detectable O
Fas O
expression O
on O
freshly O
isolated O
blood O
leukocytes O
. O

Detection O
of O
FAS O
transcripts O
via O
real O
- O
time O
quantitative O
PCR O
made O
a O
severe O
transcriptional O
defect O
unlikely O
. O

Sequencing O
of O
the O
FAS O
gene O
revealed O
a O
20 O
- O
nucleotide O
duplication O
in O
the O
last O
exon O
affecting O
the O
cytoplasmic O
signaling O
domain O
. O

The O
patient O
was O
homozygous O
for O
this O
mutation O
, O
whereas O
the O
consanguineous O
parents O
and O
the O
siblings O
were O
heterozygous O
. O

The O
patient O
reported O
here O
is O
a O
human O
homologue O
of O
the O
Fas O
- O
null O
mouse O
, O
inasmuch O
as O
she O
carries O
an O
autosomal O
homozygous O
mutation O
in O
the O
FAS O
gene O
and O
she O
shows O
the O
severe O
and O
accelerated O
ALPS B
phenotype O
. O

The O
heterozygous O
family O
members O
did O
not O
have O
the O
ALPS B
phenotype O
, O
indicating O
that O
the O
disease O
- O
causing O
FAS O
mutation O
in O
this O
family O
is O
autosomal O
recessive O
. O
. O

Identification O
of O
novel O
imprinted O
transcripts O
in O
the O
Prader B
- I
Willi I
syndrome I
and O
Angelman B
syndrome I
deletion O
region O
: O
further O
evidence O
for O
regional O
imprinting O
control O
. O

Deletions O
and O
other O
abnormalities O
of O
human O
chromosome O
15q11 O
- O
q13 O
are O
associated O
with O
two O
developmental O
disorders O
, O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
and O
Angelman B
syndrome I
( O
AS B
) O
. O

Loss O
of O
expression O
of O
imprinted O
, O
paternally O
expressed O
genes O
has O
been O
implicated O
in O
PWS B
. O

However O
, O
the O
number O
of O
imprinted O
genes O
that O
contribute O
to O
PWS B
, O
and O
the O
range O
over O
which O
the O
imprinting O
signal O
acts O
to O
silence O
one O
copy O
of O
the O
gene O
in O
a O
parent O
- O
of O
- O
origin O
- O
specific O
manner O
, O
are O
unknown O
. O

To O
identify O
additional O
imprinted O
genes O
that O
could O
contribute O
to O
the O
PWS B
phenotype O
and O
to O
understand O
the O
regional O
control O
of O
imprinting O
in O
15q11 O
- O
q13 O
, O
we O
have O
constructed O
an O
imprinted O
transcript O
map O
of O
the O
PWS O
- O
AS O
deletion O
interval O
. O

The O
imprinting O
status O
of O
22 O
expressed O
sequence O
tags O
derived O
from O
the O
radiation O
- O
hybrid O
human O
transcript O
maps O
or O
physical O
maps O
was O
determined O
in O
a O
reverse O
transcriptase O
- O
PCR O
assay O
and O
correlated O
with O
the O
position O
of O
the O
transcripts O
on O
the O
physical O
map O
. O

Seven O
new O
paternally O
expressed O
transcripts O
localize O
to O
an O
approximately O
1 O
. O

5 O
- O
Mb O
domain O
surrounding O
the O
SNRPN O
- O
associated O
imprinting O
center O
, O
which O
already O
includes O
four O
imprinted O
, O
paternally O
expressed O
genes O
. O

All O
other O
tested O
new O
transcripts O
in O
the O
deletion O
region O
were O
expressed O
from O
both O
alleles O
. O

A O
domain O
of O
exclusive O
paternal O
expression O
surrounding O
the O
imprinting O
center O
suggests O
strong O
regional O
control O
of O
the O
imprinting O
process O
. O

This O
study O
provides O
the O
means O
for O
further O
investigation O
of O
additional O
genes O
that O
cause O
or O
modify O
the O
phenotypes O
associated O
with O
rearrangements O
of O
15q11 O
- O
q13 O
. O

Combined O
analysis O
of O
hereditary B
prostate I
cancer I
linkage O
to O
1q24 O
- O
25 O
: O
results O
from O
772 O
hereditary B
prostate I
cancer I
families O
from O
the O
International O
Consortium O
for O
Prostate B
Cancer I
Genetics O
. O

A O
previous O
linkage O
study O
provided O
evidence O
for O
a O
prostate B
cancer I
- O
susceptibility O
locus O
at O
1q24 O
- O
25 O
. O

Subsequent O
reports O
in O
additional O
collections O
of O
families O
have O
yielded O
conflicting O
results O
. O

In O
addition O
, O
evidence O
for O
locus O
heterogeneity O
has O
been O
provided O
by O
the O
identification O
of O
other O
putative O
hereditary B
prostate I
cancer I
loci O
on O
Xq27 O
- O
28 O
, O
1q42 O
- O
43 O
, O
and O
1p36 O
. O

The O
present O
study O
describes O
a O
combined O
analysis O
for O
six O
markers O
in O
the O
1q24 O
- O
25 O
region O
in O
772 O
families O
affected O
by O
hereditary B
prostate I
cancer I
and O
ascertained O
by O
the O
members O
of O
the O
International O
Consortium O
for O
Prostate B
Cancer I
Genetics O
( O
ICPCG O
) O
from O
North O
America O
, O
Australia O
, O
Finland O
, O
Norway O
, O
Sweden O
, O
and O
the O
United O
Kingdom O
. O

Overall O
, O
there O
was O
some O
evidence O
for O
linkage O
, O
with O
a O
peak O
parametric O
multipoint O
LOD O
score O
assuming O
heterogeneity O
( O
HLOD O
) O
of O
1 O
. O

40 O
( O
P O
= O
. O
01 O
) O
at O
D1S212 O
. O

The O
estimated O
proportion O
of O
families O
( O
alpha O
) O
linked O
to O
the O
locus O
was O
. O

06 O
( O
1 O
- O
LOD O
support O
interval O
. O
01 O
- O
. O
12 O
) O
. O

This O
evidence O
was O
not O
observed O
by O
a O
nonparametric O
approach O
, O
presumably O
because O
of O
the O
extensive O
heterogeneity O
. O

Further O
parametric O
analysis O
revealed O
a O
significant O
effect O
of O
the O
presence O
of O
male O
- O
to O
- O
male O
disease O
transmission O
within O
the O
families O
. O

In O
the O
subset O
of O
491 O
such O
families O
, O
the O
peak O
HLOD O
was O
2 O
. O

In O
the O
subset O
of O
491 O
such O
families O
, O
the O
peak O
HLOD O
was O
2 O
. O

56 O
( O
P O
= O
. O
0006 O
) O
and O
alpha O
= O
. O

11 O
( O
1 O
- O
LOD O
support O
interval O
. O
04 O
- O
. O
19 O
) O
, O
compared O
with O
HLODs O
of O
0 O
in O
the O
remaining O
281 O
families O
. O

Within O
the O
families O
with O
male O
- O
to O
- O
male O
disease O
transmission O
, O
alpha O
increased O
with O
the O
early O
mean O
age O
at O
diagnosis O
( O
< O
65 O
years O
, O
alpha O
= O
. O
19 O
, O
with O
1 O
- O
LOD O
support O
interval O
. O
06 O
- O
. O
34 O
) O
and O
the O
number O
of O
affected O
family O
members O
( O
five O
or O
more O
family O
members O
, O
alpha O
= O
. O
15 O
, O
with O
1 O
- O
LOD O
support O
interval O
. O
04 O
- O
. O
28 O
) O
. O

The O
highest O
value O
of O
alpha O
was O
observed O
for O
the O
48 O
families O
that O
met O
all O
three O
criteria O
( O
peak O
HLOD O
= O
2 O
. O
25 O
, O
P O
= O
. O
001 O
, O
alpha O
= O
. O
29 O
, O
with O
1 O
- O
LOD O
support O
interval O
. O
08 O
- O
. O
53 O
) O
. O

These O
results O
support O
the O
finding O
of O
a O
prostate B
cancer I
- O
susceptibility O
gene O
linked O
to O
1q24 O
- O
25 O
, O
albeit O
in O
a O
defined O
subset O
of O
prostate B
cancer I
families O
. O

Although O
HPC1 O
accounts O
for O
only O
a O
small O
proportion O
of O
all O
families O
affected O
by O
hereditary B
prostate I
cancer I
, O
it O
appears O
to O
play O
a O
more O
prominent O
role O
in O
the O
subset O
of O
families O
with O
several O
members O
affected O
at O
an O
early O
age O
and O
with O
male O
- O
to O
- O
male O
disease O
transmission O
. O

A O
recurrent O
expansion O
of O
a O
maternal O
allele O
with O
36 O
CAG O
repeats O
causes O
Huntington B
disease I
in O
two O
sisters O
. O

Large O
intergenerational O
repeat O
expansions O
of O
the O
CAG O
trinucleotide O
repeat O
in O
the O
HD B
gene O
have O
been O
well O
documented O
for O
the O
male O
germline O
. O

We O
describe O
a O
recurrent O
large O
expansion O
of O
a O
maternal O
allele O
with O
36 O
CAG O
repeats O
( O
to O
66 O
and O
57 O
repeats O
, O
respectively O
, O
in O
two O
daughters O
) O
associated O
with O
onset O
of O
Huntington B
disease I
( O
HD B
) O
in O
the O
second O
and O
third O
decade O
in O
a O
family O
without O
history O
of O
HD B
. O

Our O
findings O
give O
evidence O
of O
a O
gonadal O
mosaicism O
in O
the O
unaffected O
mother O
. O

We O
hypothesize O
that O
large O
expansions O
also O
occur O
in O
the O
female O
germline O
and O
that O
a O
negative O
selection O
of O
oocytes O
with O
long O
repeats O
might O
explain O
the O
different O
instability O
behavior O
of O
the O
male O
and O
the O
female O
germlines O
. O
. O

Abnormal O
development O
of O
Purkinje O
cells O
and O
lymphocytes O
in O
Atm O
mutant O
mice O
. O

Motor B
incoordination I
, O
immune B
deficiencies I
, O
and O
an O
increased O
risk O
of O
cancer B
are O
the O
characteristic O
features O
of O
the O
hereditary B
disease I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
which O
is O
caused O
by O
mutations O
in O
the O
ATM O
gene O
. O

Through O
gene O
targeting O
, O
we O
have O
generated O
a O
line O
of O
Atm O
mutant O
mice O
, O
Atm O
( O
y O
/ O
y O
) O
mice O
. O

In O
contrast O
to O
other O
Atm O
mutant O
mice O
, O
Atm O
( O
y O
/ O
y O
) O
mice O
show O
a O
lower O
incidence O
of O
thymic B
lymphoma I
and O
survive O
beyond O
a O
few O
months O
of O
age O
. O

Atm O
( O
y O
/ O
y O
) O
mice O
exhibit O
deficits O
in O
motor O
learning O
indicative O
of O
cerebellar B
dysfunction I
. O

Even O
though O
we O
found O
no O
gross O
cerebellar B
degeneration I
in O
older O
Atm O
( O
y O
/ O
y O
) O
animals O
, O
ectopic O
and O
abnormally O
differentiated O
Purkinje O
cells O
were O
apparent O
in O
mutant O
mice O
of O
all O
ages O
. O

These O
findings O
establish O
that O
some O
neuropathological B
abnormalities I
seen O
in O
A B
- I
T I
patients O
also O
are O
present O
in O
Atm O
mutant O
mice O
. O

In O
addition O
, O
we O
report O
a O
previously O
unrecognized O
effect O
of O
Atm B
deficiency I
on O
development O
or O
maintenance O
of O
CD4 O
( O
+ O
) O
8 O
( O
+ O
) O
thymocytes O
. O

We O
discuss O
these O
findings O
in O
the O
context O
of O
the O
hypothesis O
that O
abnormal O
development O
of O
Purkinje O
cells O
and O
lymphocytes O
contributes O
to O
the O
pathogenesis O
of O
A B
- I
T I
. O
. O

Novel O
mutations O
of O
the O
ATP7B O
gene O
in O
Japanese O
patients O
with O
Wilson B
disease I
. O

Wilson B
disease I
( O
WD B
) O
is O
an O
autosomal B
recessive I
disorder I
characterized O
by O
copper O
accumulation O
in O
the O
liver O
, O
brain O
, O
kidneys O
, O
and O
corneas O
, O
and O
culminating O
in O
copper O
toxication O
in O
these O
organs O
. O

In O
this O
study O
, O
we O
analyzed O
mutations O
of O
the O
responsible O
gene O
, O
ATP7B O
, O
in O
four O
Japanese O
patients O
with O
WD B
. O

By O
direct O
sequencing O
, O
we O
identified O
five O
mutations O
, O
of O
which O
two O
were O
novel O
, O
and O
16 O
polymorphisms O
, O
of O
which O
6 O
were O
novel O
. O

The O
mutations O
2871delC O
and O
2513delA O
shift O
the O
reading O
frame O
so O
that O
truncated O
abnormal O
protein O
is O
expected O
. O

In O
contrast O
to O
these O
mutations O
found O
in O
patients O
with O
hepatic O
- O
type O
of O
early O
onset O
, O
the O
mutations O
A874V O
, O
R778L O
, O
and O
3892delGTC O
were O
either O
missense O
mutations O
or O
in O
frame O
1 O
- O
amino O
acid O
deletion O
, O
and O
occurred O
in O
the O
patients O
with O
hepato O
- O
neurologic O
type O
of O
late O
onset O
. O

The O
mutations O
2871delC O
and O
R778L O
have O
been O
previously O
reported O
in O
a O
relatively O
large O
number O
of O
Japanese O
patients O
. O

In O
particular O
, O
R778L O
is O
known O
to O
be O
more O
prevalent O
in O
Asian O
countries O
than O
in O
other O
countries O
of O
the O
world O
. O

Our O
data O
are O
compatible O
with O
the O
hypothesis O
that O
the O
mutations O
tend O
to O
occur O
in O
a O
population O
- O
specific O
manner O
. O

Therefore O
, O
the O
accumulation O
of O
the O
types O
of O
mutations O
in O
Japanese O
patients O
with O
WD B
will O
facilitate O
the O
fast O
and O
effective O
genetic O
diagnosis O
of O
WD B
in O
Japanese O
patients O
. O
. O

Autoinhibition O
and O
activation O
mechanisms O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
. O

The O
Rho O
- O
family O
GTPase O
, O
Cdc42 O
, O
can O
regulate O
the O
actin O
cytoskeleton O
through O
activation O
of O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
family O
members O
. O

Activation O
relieves O
an O
autoinhibitory O
contact O
between O
the O
GTPase O
- O
binding O
domain O
and O
the O
carboxy O
- O
terminal O
region O
of O
WASP O
proteins O
. O

Here O
we O
report O
the O
autoinhibited O
structure O
of O
the O
GTPase O
- O
binding O
domain O
of O
WASP O
, O
which O
can O
be O
induced O
by O
the O
C O
- O
terminal O
region O
or O
by O
organic O
co O
- O
solvents O
. O

In O
the O
autoinhibited O
complex O
, O
intramolecular O
interactions O
with O
the O
GTPase O
- O
binding O
domain O
occlude O
residues O
of O
the O
C O
terminus O
that O
regulate O
the O
Arp2 O
/ O
3 O
actin O
- O
nucleating O
complex O
. O

Binding O
of O
Cdc42 O
to O
the O
GTPase O
- O
binding O
domain O
causes O
a O
dramatic O
conformational O
change O
, O
resulting O
in O
disruption O
of O
the O
hydrophobic O
core O
and O
release O
of O
the O
C O
terminus O
, O
enabling O
its O
interaction O
with O
the O
actin O
regulatory O
machinery O
. O

These O
data O
show O
that O
intrinsically O
unstructured O
peptides O
such O
as O
the O
GTPase O
- O
binding O
domain O
of O
WASP O
can O
be O
induced O
into O
distinct O
structural O
and O
functional O
states O
depending O
on O
context O
. O
. O

hCds1 O
- O
mediated O
phosphorylation O
of O
BRCA1 O
regulates O
the O
DNA O
damage O
response O
. O

Mutations O
in O
the O
BRCA1 O
( O
ref O
. O
1 O
) O
tumour B
suppressor O
gene O
are O
found O
in O
almost O
all O
of O
the O
families O
with O
inherited B
breast I
and I
ovarian I
cancers I
and O
about O
half O
of O
the O
families O
with O
only O
breast B
cancer I
. O

Although O
the O
biochemical O
function O
of O
BRCA1 O
is O
not O
well O
understood O
, O
it O
is O
important O
for O
DNA O
damage O
repair O
and O
cell O
- O
cycle O
checkpoint O
. O

BRCA1 O
exists O
in O
nuclear O
foci O
but O
is O
hyperphosphorylated O
and O
disperses O
after O
DNA O
damage O
. O

It O
is O
not O
known O
whether O
BRCA1 O
phosphorylation O
and O
dispersion O
and O
its O
function O
in O
DNA O
damage O
response O
are O
related O
. O

In O
yeast O
the O
DNA O
damage O
response O
and O
the O
replication O
- O
block O
checkpoint O
are O
mediated O
partly O
through O
the O
Cds1 O
kinase O
family O
. O

Here O
we O
report O
that O
the O
human O
Cds1 O
kinase O
( O
hCds1 O
/ O
Chk2 O
) O
regulates O
BRCA1 O
function O
after O
DNA O
damage O
by O
phosphorylating O
serine O
988 O
of O
BRCA1 O
. O

We O
show O
that O
hCds1 O
and O
BRCA1 O
interact O
and O
co O
- O
localize O
within O
discrete O
nuclear O
foci O
but O
separate O
after O
gamma O
irradiation O
. O

Phosphorylation O
of O
BRCA1 O
at O
serine O
988 O
is O
required O
for O
the O
release O
of O
BRCA1 O
from O
hCds1 O
. O

This O
phosphorylation O
is O
also O
important O
for O
the O
ability O
of O
BRCA1 O
to O
restore O
survival O
after O
DNA O
damage O
in O
the O
BRCA1 O
- O
mutated O
cell O
line O
HCC1937 O
. O
. O

Characterization O
of O
the O
rat O
spinocerebellar O
ataxia O
type O
3 O
gene O
. O

Machado B
- I
Joseph I
disease I
( O
MJD B
) O
belongs O
to O
a O
group O
of O
clinically O
and O
genetically O
heterogeneous O
neurodegenerative B
disorders I
characterized O
by O
progressive B
cerebellar I
ataxia I
. O

The O
disease O
- O
causing O
mutation O
has O
recently O
been O
identified O
as O
an O
unstable O
and O
expanded O
( O
CAG O
) O
n O
trinucleotide O
repeat O
in O
a O
novel O
gene O
of O
unknown O
function O
. O

In O
Caucasians O
, O
repeat O
expansions O
in O
the O
MJD1 O
gene O
have O
also O
been O
found O
in O
patients O
with O
the O
clinically O
distinct O
autosomal O
dominant O
spinocerebellar B
ataxia I
type I
3 I
( O
SCA3 B
) O
. O

In O
order O
to O
gain O
insight O
into O
the O
biology O
of O
the O
MJD1 O
/ O
SCA3 O
gene O
we O
cloned O
the O
rat O
homologue O
and O
studied O
its O
expression O
. O

The O
rat O
and O
human O
ataxin O
- O
3 O
genes O
are O
highly O
homologous O
with O
an O
overall O
sequence O
identity O
of O
approximately O
88 O
% O
. O

However O
, O
the O
C O
- O
terminal O
end O
of O
the O
putative O
protein O
differs O
strongly O
from O
the O
published O
human O
sequence O
. O

The O
( O
CAG O
) O
n O
block O
in O
the O
rat O
cDNA O
consists O
of O
just O
three O
interrupted O
units O
suggesting O
that O
a O
long O
polyglutamine O
stretch O
is O
not O
essential O
for O
the O
normal O
function O
of O
the O
ataxin O
- O
3 O
protein O
in O
rodents O
. O

The O
expression O
pattern O
of O
the O
SCA3 O
gene O
in O
various O
rat O
and O
human O
tissues O
was O
investigated O
by O
Northern O
blot O
analyses O
. O

The O
mature O
transcript O
is O
approximately O
6 O
kb O
in O
length O
. O

In O
rat O
testis O
, O
a O
smaller O
transcript O
of O
1 O
. O

3 O
kb O
was O
identified O
. O

Transcription O
of O
rsca3 O
was O
detected O
in O
most O
rat O
tissues O
including O
brain O
. O

Analyzing O
the O
expression O
level O
of O
the O
SCA3 O
gene O
in O
several O
human O
brain O
sections O
revealed O
no O
significant O
higher O
mRNA O
level O
in O
regions O
predominantly O
affected O
in O
MJD B
. O

Thus O
additional O
molecules O
and O
/ O
or O
regulatory O
events O
are O
necessary O
to O
explain O
the O
exclusive O
degeneration B
of I
certain I
brain I
areas I
. O

Emerin B
, I
deficiency I
of O
which O
causes O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
, O
is O
localized O
at O
the O
inner O
nuclear O
membrane O
. O

X B
- I
linked I
recessive I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
is O
an O
inherited B
muscle I
disorder I
characterized O
by O
the O
clinical O
triad O
of O
progressive O
wasting B
of I
humero I
- I
peroneal I
muscles I
, O
early O
contractures B
of I
the I
elbows I
, I
Achilles I
tendons I
and I
postcervical I
muscles I
, O
and O
cardiac B
conduction I
block I
with O
a O
high O
risk O
of O
sudden B
death I
. O

The O
gene O
for O
EDMD B
on O
Xq28 O
encodes O
a O
novel O
protein O
named O
emerin O
that O
localizes O
at O
the O
nuclear O
membrane O
of O
skeletal O
, O
cardiac O
and O
smooth O
muscles O
and O
some O
other O
non O
- O
muscle O
tissues O
. O

To O
investigate O
a O
possible O
physiological O
role O
for O
emerin O
, O
we O
examined O
the O
ultrastructural O
localization O
of O
the O
protein O
in O
human O
skeletal O
muscle O
and O
HeLa O
cells O
, O
using O
ultrathin O
cryosections O
. O

We O
found O
that O
the O
immune O
- O
labeled O
colloidal O
gold O
particles O
were O
localized O
on O
the O
nucleoplasmic O
surface O
of O
the O
inner O
nuclear O
membrane O
, O
but O
not O
on O
the O
nuclear O
pore O
. O

Emerin O
stayed O
on O
the O
cytoplasmic O
surface O
of O
the O
nuclear O
lamina O
, O
even O
after O
detergent O
treatment O
that O
solubilizes O
membrane O
lipids O
and O
washes O
out O
membrane O
proteins O
. O

These O
results O
suggest O
that O
emerin O
anchors O
at O
the O
inner O
nuclear O
membrane O
through O
the O
hydrophobic O
stretch O
, O
and O
protrudes O
from O
the O
hydrophilic O
region O
to O
the O
nucleoplasm O
where O
it O
interacts O
with O
the O
nuclear O
lamina O
. O

We O
speculate O
that O
emerin O
contributes O
to O
maintain O
the O
nuclear O
structure O
and O
stability O
, O
as O
well O
as O
nuclear O
functions O
, O
particularly O
in O
muscle O
tissues O
that O
have O
severe O
stress O
with O
rigorous O
contraction O
- O
relaxation O
movements O
and O
calcium O
flux O
. O
. O

Locus O
heterogeneity O
in O
Friedreich B
ataxia I
. O

Friedreich B
ataxia I
( O
FRDA B
) O
is O
the O
most O
common O
form O
of O
autosomal B
recessive I
ataxia I
. O

The O
disease O
locus O
was O
assigned O
to O
chromosome O
9 O
and O
the O
disease O
gene O
, O
STM7 O
/ O
X25 O
, O
has O
been O
isolated O
. O

To O
date O
most O
data O
suggest O
locus O
homogeneity O
in O
FRDA B
. O

We O
now O
provide O
strong O
evidence O
of O
a O
second O
FRDA B
locus O
. O

Studying O
two O
siblings O
with O
FRDA B
from O
two O
families O
we O
did O
not O
detect O
a O
mutation O
in O
STM7 O
/ O
X25 O
. O

Haplotype O
analysis O
of O
the O
STM7 O
/ O
X25 O
region O
of O
chromosome O
9 O
demonstrated O
that O
the O
relevant O
portion O
of O
chromosome O
9 O
differs O
in O
the O
patients O
. O

Although O
the O
patients O
studied O
had O
typical O
FRDA B
, O
one O
sibpair O
had O
the O
uncommon O
symptom O
of O
retained O
tendon O
reflexes O
. O

In O
order O
to O
investigate O
whether O
retained O
tendon O
reflexes O
are O
characteristic O
of O
FRDA B
caused O
by O
the O
second O
locus O
, O
FRDA2 O
, O
we O
studied O
an O
unrelated O
FRDA B
patient O
with O
retained O
tendon O
reflexes O
. O

The O
observation O
of O
typical O
mutations O
in O
STM7 O
/ O
X25 O
( O
GAA O
expansions O
) O
in O
this O
patient O
demonstrates O
that O
the O
two O
genetically O
different O
forms O
of O
FRDA B
cannot O
be O
distinguished O
clinically O
. O
. O

Glycerol O
as O
a O
correlate O
of O
impaired B
glucose I
tolerance I
: O
dissection O
of O
a O
complex O
system O
by O
use O
of O
a O
simple O
genetic O
trait O
. O

Glycerol O
kinase O
( O
GK O
) O
represents O
the O
primary O
entry O
of O
glycerol O
into O
glucose O
and O
triglyceride O
metabolism O
. O

Impaired B
glucose I
tolerance I
( O
IGT B
) O
and O
hypertriglyceridemia B
are O
associated O
with O
an O
increased O
risk O
of O
diabetes B
mellitus I
and O
cardiovascular B
disease I
. O

The O
relationship O
between O
glycerol O
and O
the O
risk O
of O
IGT B
, O
however O
, O
is O
poorly O
understood O
. O

We O
therefore O
undertook O
the O
study O
of O
fasting O
plasma O
glycerol O
levels O
in O
a O
cohort O
of O
1 O
, O
056 O
unrelated O
men O
and O
women O
of O
French O
- O
Canadian O
descent O
. O

Family O
screening O
in O
the O
initial O
cohort O
identified O
18 O
men O
from O
five O
families O
with O
severe O
hyperglycerolemia B
( O
values O
above O
2 O
. O
0 O
mmol O
/ O
liter O
) O
and O
demonstrated O
an O
X O
- O
linked O
pattern O
of O
inheritance O
. O

Linkage O
analysis O
of O
the O
data O
from O
12 O
microsatellite O
markers O
surrounding O
the O
Xp21 O
. O

3 O
GK O
gene O
resulted O
in O
a O
peak O
LOD O
score O
of O
3 O
. O

46 O
, O
centered O
around O
marker O
DXS8039 O
. O

In O
addition O
, O
since O
all O
of O
the O
families O
originated O
in O
a O
population O
with O
a O
proven O
founder O
effect O
- O
the O
Saguenay O
Lac O
- O
St O
. O

- O
Jean O
region O
of O
Quebec O
- O
a O
common O
disease O
haplotype O
was O
sought O
. O

Indeed O
, O
a O
six O
- O
marker O
haplotype O
extending O
over O
a O
region O
of O
5 O
. O

5 O
cM O
was O
observed O
in O
all O
families O
. O

Resequencing O
of O
the O
GK O
gene O
in O
family O
members O
led O
to O
the O
discovery O
of O
a O
N288D O
missense O
mutation O
in O
exon O
10 O
, O
which O
resulted O
in O
the O
substitution O
of O
a O
highly O
conserved O
asparagine O
residue O
by O
a O
negatively O
charged O
aspartic O
acid O
. O

Clinical O
and O
molecular O
genetics O
of O
primary B
dystonias I
. O

Primary B
dystonias I
are O
movement B
disorders I
with O
dystonia B
as O
a O
major O
symptom O
. O

They O
are O
frequently O
inherited O
as O
Mendelian O
traits O
. O

There O
are O
at O
least O
eight O
clinically O
distinct O
autosomal O
dominant O
and O
two O
X O
- O
linked O
recessive O
forms O
. O

In O
addition O
, O
pedigree O
analyses O
suggest O
the O
occurrence O
of O
an O
autosomal O
recessive O
variant O
. O

The O
clinical O
classification O
is O
increasingly O
being O
replaced O
by O
a O
genetic O
one O
. O

To O
date O
gene O
loci O
have O
been O
identified O
in O
at O
least O
six O
autosomal O
dominant O
forms O
, O
i O
. O
e O
. O
, O
in O
idiopathic B
torsion I
dystonia I
( O
9q34 O
) O
, O
focal B
dystonia I
( O
18p O
) O
, O
adult O
- O
onset O
idiopathic B
torsion I
dystonia I
of O
mixed O
type O
( O
8p21 O
- O
q22 O
) O
, O
dopa B
- I
responsive I
dystonia I
( O
14q22 O
. O
1 O
- O
q22 O
. O
2 O
) O
, O
and O
paroxysmal B
dystonic I
choreoathetosis I
( O
2q25 O
- O
q33 O
; O
1p21 O
- O

p13 O
. O
3 O
) O
. O

Gene O
loci O
in O
the O
X O
- O
linked O
recessive O
forms O
have O
been O
assigned O
to O
Xq13 O
. O

1 O
in O
the O
X B
- I
linked I
dystonia I
parkinsonism I
syndrome I
and O
to O
Xq22 O
in O
X B
- I
linked I
sensorineural I
deafness I
, O
dystonia B
, O
and O
mental B
retardation I
. O

The O
disease O
genes O
have O
been O
identified O
in O
two O
autosomal O
dominant O
forms O
and O
in O
one O
X O
- O
linked O
recessive O
form O
. O

Mutations O
in O
a O
gene O
coding O
for O
an O
ATP O
- O
binding O
protein O
were O
detected O
in O
idiopathic B
torsion I
dystonia I
( O
DYT1 O
) O
, O
and O
the O
GTP O
cyclohydrolase O
1 O
gene O
is O
mutated O
in O
dopa B
- I
responsive I
dystonia I
( O
DYT5 O
) O
. O

In O
sensorineural B
deafness I
, O
dystonia B
, O
and O
mental B
retardation I
, O
mutations O
were O
found O
in O
the O
gene O
DDP O
coding O
for O
a O
polypeptide O
of O
unknown O
function O
. O

This O
article O
reviews O
the O
clinical O
and O
molecular O
genetics O
of O
primary B
dystonias I
, O
critically O
discusses O
present O
findings O
, O
and O
proposes O
referring O
to O
the O
known O
forms O
, O
most O
of O
which O
can O
be O
distinguished O
by O
genetic O
criteria O
, O
as O
dystonias B
1 I
- I
12 I
. O

Determination O
of O
30 O
X B
- I
linked I
adrenoleukodystrophy I
mutations O
, O
including O
15 O
not O
previously O
described O
. O

X B
- I
linked I
Adrenoleukodystrophy I
( O
X B
- I
ALD I
) O
is O
the O
most O
frequent O
peroxisomal B
disease I
. O

It O
mainly O
involves O
the O
nervous O
system O
white O
matter O
, O
adrenal O
cortex O
and O
testes O
. O

Several O
distinct O
clinical O
phenotypes O
are O
known O
. O

The O
principal O
biochemical O
abnormality O
is O
the O
accumulation O
of O
saturated O
very O
- O
long O
- O
chain O
fatty O
acids O
( O
VLCFAs O
> O
C22 O
0 O
, O
mainly O
C26 O
0 O
) O
, O
which O
is O
due O
to O
impaired O
capacity O
for O
beta O
- O
oxidation O
in O
peroxisomes O
. O

Diagnosis O
is O
usually O
based O
on O
the O
VLCFA O
levels O
in O
plasma O
or O
cultured O
skin O
fibroblasts O
in O
both O
patients O
and O
carriers O
. O

In O
0 O
. O

1 O
% O
of O
affected O
males O
, O
however O
, O
the O
plasma O
C26 O
0 O
level O
is O
borderline O
normal O
, O
and O
15 O
% O
of O
obligate O
female O
carriers O
have O
normal O
results O
. O

Effective O
mutation O
detection O
in O
these O
families O
is O
therefore O
fundamental O
to O
unambiguously O
determine O
the O
genetic O
status O
of O
each O
individual O
at O
risk O
. O

Of O
particular O
concern O
are O
female O
members O
of O
kindreds O
segregating O
X B
- I
ALD I
mutations O
, O
because O
normal O
VLCFA O
levels O
do O
not O
guarantee O
lack O
of O
carrier O
status O
. O

We O
describe O
a O
fast O
method O
for O
detection O
of O
X B
- I
ALD I
mutations O
. O

The O
method O
is O
based O
on O
SSCP O
analysis O
of O
nested O
PCR O
fragments O
followed O
by O
sequence O
- O
determination O
reactions O
. O

Using O
this O
methodology O
we O
have O
found O
X B
- I
ALD I
mutations O
in O
30 O
kindreds O
, O
including O
15 O
not O
previously O
reported O
. O

beta O
- O
galactosidase O
gene O
mutations O
affecting O
the O
lysosomal O
enzyme O
and O
the O
elastin O
- O
binding O
protein O
in O
GM1 B
- I
gangliosidosis I
patients O
with O
cardiac B
involvement I
. O

GM1 B
- I
gangliosidosis I
is O
a O
lysosomal B
storage I
disorder I
caused O
by O
deficiency B
of I
acid I
beta I
- I
galactosidase I
( O
GLB1 O
) O
. O

We O
report O
five O
new O
beta O
- O
galactosidase O
gene O
mutations O
in O
nine O
Italian O
patients O
and O
one O
fetus O
, O
segregating O
in O
seven O
unrelated O
families O
. O

Six O
of O
the O
eight O
patients O
with O
the O
infantile O
, O
severe O
form O
of O
the O
disease O
presented O
cardiac B
involvement I
, O
a O
feature O
rarely O
associated O
with O
GM1 B
- I
gangliosidosis I
. O

Molecular O
analysis O
of O
the O
patients O
RNA O
and O
DNA O
identified O
two O
new O
RNA O
splicing O
defects O
, O
three O
new O
and O
three O
previously O
described O
amino O
acid O
substitutions O
. O

Interestingly O
, O
all O
patients O
with O
cardiac B
involvement I
were O
homozygous O
for O
one O
of O
these O
mutations O
R59H O
, O
Y591C O
, O
Y591N O
, O
or O
IVS14 O
- O
2A O
> O
G O
. O

In O
contrast O
, O
all O
other O
patients O
were O
compound O
heterozygous O
for O
one O
of O
the O
following O
mutations O
R201H O
, O
R482H O
, O
G579D O
, O
IVS8 O
+ O
2T O
> O
C O
. O

Although O
we O
could O
not O
directly O
correlate O
the O
presence O
of O
cardiac B
abnormalities I
with O
specific O
genetic B
lesions I
, O
the O
mutations O
identified O
in O
patients O
with O
cardiomyopathy B
fell O
in O
the O
GLB1 O
cDNA O
region O
common O
to O
the O
lysosomal O
enzyme O
and O
the O
Hbeta O
- O
Gal O
- O
related O
protein O
, O
also O
known O
as O
the O
elastin O
binding O
protein O
( O
EBP O
) O
. O

Consequently O
, O
both O
molecules O
are O
affected O
by O
the O
mutations O
, O
and O
they O
may O
contribute O
differently O
to O
the O
occurrence O
of O
specific O
clinical O
manifestations O
. O
. O

In O
vivo O
modulation O
of O
Hmgic O
reduces O
obesity B
. O

The O
HMGI O
family O
of O
proteins O
consists O
of O
three O
members O
, O
HMGIC O
, O
HMGI O
and O
HMGI O
( O
Y O
) O
, O
that O
function O
as O
architectural O
factors O
and O
are O
essential O
components O
of O
the O
enhancesome O
. O

HMGIC O
is O
predominantly O
expressed O
in O
proliferating O
, O
undifferentiated O
mesenchymal O
cells O
and O
is O
not O
detected O
in O
adult O
tissues O
. O

It O
is O
disrupted O
and O
misexpressed O
in O
a O
number O
of O
mesenchymal B
tumour I
cell O
types O
, O
including O
fat B
- I
cell I
tumours I
( O
lipomas B
) O
. O

In O
addition O
Hmgic O
- O
/ O
- O
mice O
have O
a O
deficiency O
in O
fat O
tissue O
. O

To O
study O
its O
role O
in O
adipogenesis O
and O
obesity B
, O
we O
examined O
Hmgic O
expression O
in O
the O
adipose O
tissue O
of O
adult O
, O
obese B
mice O
. O

Mice O
with O
a O
partial B
or I
complete I
deficiency I
of I
Hmgic I
resisted O
diet O
- O
induced O
obesity B
. O

Disruption O
of O
Hmgic O
caused O
a O
reduction O
in O
the O
obesity B
induced O
by O
leptin B
deficiency I
( O
Lepob O
/ O
Lepob O
) O
in O
a O
gene O
- O
dose O
- O
dependent O
manner O
. O

Our O
studies O
implicate O
a O
role O
for O
HMGIC O
in O
fat O
- O
cell O
proliferation O
, O
indicating O
that O
it O
may O
be O
an O
adipose O
- O
specific O
target O
for O
the O
treatment O
of O
obesity B
. O
. O

Molecular O
analysis O
of O
the O
genotype O
- O
phenotype O
relationship O
in O
factor B
X I
deficiency I
. O

Factor B
X I
deficiency I
is O
a O
rare O
haemorrhagic B
condition I
, O
normally O
inherited O
as O
an O
autosomal O
recessive O
trait O
, O
in O
which O
a O
variable O
clinical O
presentation O
correlates O
poorly O
with O
laboratory O
phenotype O
. O

The O
factor O
X O
( O
F10 O
) O
genes O
of O
14 O
unrelated O
individuals O
with O
factor B
X I
deficiency I
( O
12 O
familial O
and O
two O
sporadic O
cases O
) O
were O
sequenced O
yielding O
a O
total O
of O
13 O
novel O
mutations O
. O

Family O
studies O
were O
performed O
in O
order O
to O
distinguish O
the O
contributions O
of O
individual O
mutant O
F10 O
alleles O
to O
the O
clinical O
and O
laboratory O
phenotypes O
. O

Missense O
mutations O
were O
studied O
by O
means O
of O
molecular O
modelling O
, O
whereas O
single O
basepair O
substitutions O
in O
splice O
sites O
and O
the O
5 O
flanking O
region O
were O
examined O
by O
in O
vitro O
splicing O
assay O
and O
luciferase O
reporter O
gene O
assay O
respectively O
. O

The O
deletion O
allele O
of O
a O
novel O
hexanucleotide O
insertion O
/ O
deletion O
polymorphism O
in O
the O
F10 O
gene O
promoter O
region O
was O
shown O
by O
reporter O
gene O
assay O
, O
to O
reduce O
promoter O
activity O
by O
approximately O
20 O
% O
. O

One O
family O
manifesting O
an O
autosomal O
dominant O
pattern O
of O
inheritance O
possessed O
three O
clinically O
affected O
members O
who O
were O
heterozygous O
for O
a O
splice O
- O
site O
mutation O
that O
was O
predicted O
to O
lead O
to O
the O
production O
of O
a O
truncated O
protein O
product O
. O

A O
model O
which O
accounts O
for O
the O
dominant O
negative O
effect O
of O
this O
lesion O
is O
presented O
. O

Variation O
in O
the O
antigen O
level O
of O
heterozygous O
relatives O
of O
probands O
was O
found O
to O
be O
significantly O
higher O
between O
families O
than O
within O
families O
, O
consistent O
with O
the O
view O
that O
the O
nature O
of O
the O
F10 O
lesion O
( O
s O
) O
segregating O
in O
a O
given O
family O
is O
a O
prime O
determinant O
of O
the O
laboratory O
phenotype O
. O

By O
contrast O
, O
no O
such O
relationship O
could O
be O
discerned O
between O
laboratory O
phenotype O
and O
polymorphism O
genotype O
. O
. O

Transgenic O
mice O
expressing O
a O
truncated O
form O
of O
the O
high O
mobility O
group O
I O
- O
C O
protein O
develop O
adiposity O
and O
an O
abnormally O
high O
prevalence O
of O
lipomas B
. O

Chromosomal O
translocations O
in O
human O
lipomas B
frequently O
create O
fusion O
transcripts O
encoding O
high O
mobility O
group O
( O
HMG O
) O
I O
- O
C O
DNA O
- O
binding O
domains O
and O
C O
- O
terminal O
sequences O
from O
different O
presumed O
transcription O
factors O
, O
suggesting O
a O
potential O
role O
for O
HMG O
I O
- O
C O
in O
the O
development O
of O
lipomas B
. O

To O
evaluate O
the O
role O
of O
the O
HMG O
I O
- O
C O
component O
, O
the O
three O
DNA O
- O
binding O
domains O
of O
HMG O
I O
- O
C O
have O
now O
been O
expressed O
in O
transgenic O
mice O
. O

Despite O
the O
ubiquitous O
expression O
of O
the O
truncated O
HMG O
I O
- O
C O
protein O
, O
the O
transgenic O
mice O
develop O
a O
selective O
abundance O
of O
fat O
tissue O
early O
in O
life O
, O
show O
marked O
adipose B
tissue I
inflammation I
, O
and O
have O
an O
abnormally O
high O
incidence O
of O
lipomas B
. O

These O
findings O
demonstrate O
that O
the O
DNA O
- O
binding O
domains O
of O
HMG O
I O
- O
C O
, O
in O
the O
absence O
of O
a O
C O
- O
terminal O
fusion O
partner O
, O
are O
sufficient O
to O
perturb O
adipogenesis O
and O
predispose O
to O
lipomas B
. O

We O
provide O
data O
supporting O
the O
central O
utility O
of O
this O
animal O
model O
as O
a O
tool O
to O
understand O
the O
molecular O
mechanisms O
underlying O
the O
development O
of O
one O
of O
the O
most O
common O
kind O
of O
human O
benign B
tumors I
. O
. O

ATM O
phosphorylates O
p95 O
/ O
nbs1 O
in O
an O
S O
- O
phase O
checkpoint O
pathway O
. O

The O
rare B
diseases I
ataxia B
- I
telangiectasia I
( O
AT B
) O
, O
caused O
by O
mutations O
in O
the O
ATM O
gene O
, O
and O
Nijmegen B
breakage I
syndrome I
( O
NBS B
) O
, O
with O
mutations O
in O
the O
p95 O
/ O
nbs1 O
gene O
, O
share O
a O
variety O
of O
phenotypic B
abnormalities I
such O
as O
chromosomal B
instability I
, O
radiation O
sensitivity O
and O
defects O
in O
cell O
- O
cycle O
checkpoints O
in O
response O
to O
ionizing O
radiation O
. O

The O
ATM O
gene O
encodes O
a O
protein O
kinase O
that O
is O
activated O
by O
ionizing O
radiation O
or O
radiomimetic O
drugs O
, O
whereas O
p95 O
/ O
nbs1 O
is O
part O
of O
a O
protein O
complex O
that O
is O
involved O
in O
responses O
to O
DNA O
double O
- O
strand O
breaks O
. O

Here O
, O
because O
of O
the O
similarities O
between O
AT B
and O
NBS B
, O
we O
evaluated O
the O
functional O
interactions O
between O
ATM O
and O
p95 O
/ O
nbs1 O
. O

Activation O
of O
the O
ATM O
kinase O
by O
ionizing O
radiation O
and O
induction O
of O
ATM O
- O
dependent O
responses O
in O
NBS B
cells O
indicated O
that O
p95 O
/ O
nbs1 O
may O
not O
be O
required O
for O
signalling O
to O
ATM O
after O
ionizing O
radiation O
. O

However O
, O
p95 O
/ O
nbs1 O
was O
phosphorylated O
on O
serine O
343 O
in O
an O
ATM O
- O
dependent O
manner O
in O
vitro O
and O
in O
vivo O
after O
ionizing O
radiation O
. O

A O
p95 O
/ O
nbs1 O
construct O
mutated O
at O
the O
ATM O
phosphorylation O
site O
abrogated O
an O
S O
- O
phase O
checkpoint O
induced O
by O
ionizing O
radiation O
in O
normal O
cells O
and O
failed O
to O
compensate O
for O
this O
functional O
deficiency O
in O
NBS B
cells O
. O

These O
observations O
link O
ATM O
and O
p95 O
/ O
nbs1 O
in O
a O
common O
signalling O
pathway O
and O
provide O
an O
explanation O
for O
phenotypic O
similarities O
in O
these O
two O
diseases O
. O
. O

Understanding O
the O
molecular O
basis O
of O
fragile B
X I
syndrome I
. O

Fragile B
X I
syndrome I
, O
a O
common O
form O
of O
inherited B
mental I
retardation I
, O
is O
mainly O
caused O
by O
massive O
expansion O
of O
CGG O
triplet O
repeats O
located O
in O
the O
5 O
- O
untranslated O
region O
of O
the O
fragile B
X I
mental I
retardation I
- O
1 O
( O
FMR1 O
) O
gene O
. O

In O
patients O
with O
fragile B
X I
syndrome I
, O
the O
expanded O
CGG O
triplet O
repeats O
are O
hypermethylated O
and O
the O
expression O
of O
the O
FMR1 O
gene O
is O
repressed O
, O
which O
leads O
to O
the O
absence O
of O
FMR1 O
protein O
( O
FMRP O
) O
and O
subsequent O
mental B
retardation I
. O

FMRP O
is O
an O
RNA O
- O
binding O
protein O
that O
shuttles O
between O
the O
nucleus O
and O
cytoplasm O
. O

This O
protein O
has O
been O
implicated O
in O
protein O
translation O
as O
it O
is O
found O
associated O
with O
polyribosomes O
and O
the O
rough O
endoplasmic O
reticulum O
. O

We O
discuss O
here O
the O
recent O
progress O
made O
towards O
understanding O
the O
molecular O
mechanism O
of O
CGG O
repeat O
expansion O
and O
physiological O
function O
( O
s O
) O
of O
FMRP O
. O

These O
studies O
will O
not O
only O
help O
to O
illuminate O
the O
molecular O
basis O
of O
the O
general O
class O
of O
human O
diseases O
with O
trinucleotide O
repeat O
expansion O
but O
also O
provide O
an O
avenue O
to O
understand O
aspects O
of O
human O
cognition O
and O
intelligence O
. O
. O

Haploinsufficiency B
of I
the I
transcription I
factors I
FOXC1 I
and I
FOXC2 I
results O
in O
aberrant O
ocular O
development O
. O

Anterior B
segment I
developmental I
disorders I
, O
including O
Axenfeld B
- I
Rieger I
anomaly I
( O
ARA B
) O
, O
variably O
associate O
with O
harmfully O
elevated O
intraocular O
pressure O
( O
IOP O
) O
, O
which O
causes O
glaucoma B
. O

Clinically O
observed O
dysgenesis O
does O
not O
correlate O
with O
IOP O
, O
however O
, O
and O
the O
etiology O
of O
glaucoma B
development O
is O
not O
understood O
. O

The O
forkhead O
transcription O
factor O
genes O
Foxc1 O
( O
formerly O
Mf1 O
) O
and O
Foxc2 O
( O
formerly O
Mfh1 O
) O
are O
expressed O
in O
the O
mesenchyme O
from O
which O
the O
ocular O
drainage O
structures O
derive O
. O

Mutations O
in O
the O
human O
homolog O
of O
Foxc1 O
, O
FKHL7 O
, O
cause O
dominant O
anterior B
segment I
defects I
and O
glaucoma B
in O
various O
families O
. O

We O
show O
that O
Foxc1 O
( O
+ O
/ O
- O
) O
mice O
have O
anterior B
segment I
abnormalities I
similar O
to O
those O
reported O
in O
human O
patients O
. O

These O
abnormalities O
include O
small O
or O
absent O
Schlemms O
canal O
, O
aberrantly O
developed O
trabecular O
meshwork O
, O
iris B
hypoplasia I
, O
severely O
eccentric O
pupils O
and O
displaced O
Schwalbes O
line O
. O

The O
penetrance O
of O
clinically O
obvious O
abnormalities O
varies O
with O
genetic O
background O
. O

In O
some O
affected O
eyes O
, O
collagen O
bundles O
were O
half O
normal O
diameter O
, O
or O
collagen O
and O
elastic O
tissue O
were O
very O
sparse O
. O

Thus O
, O
abnormalities O
in O
extracellular O
matrix O
synthesis O
or O
organization O
may O
contribute O
to O
development O
of O
the O
ocular O
phenotypes O
. O

Despite O
the O
abnormalities O
in O
ocular O
drainage O
structures O
in O
Foxc1 O
( O
+ O
/ O
- O
) O
mice O
, O
IOP O
was O
normal O
in O
almost O
all O
mice O
analyzed O
, O
on O
all O
genetic O
backgrounds O
and O
at O
all O
ages O
. O

Similar O
abnormalities O
were O
found O
in O
Foxc2 O
( O
+ O
/ O
- O
) O
mice O
, O
but O
no O
disease O
- O
associated O
mutations O
were O
identified O
in O
the O
human O
homolog O
FKHL14 O
in O
32 O
ARA B
patients O
. O

Foxc1 O
( O
+ O
/ O
- O
) O
and O
Foxc2 O
( O
+ O
/ O
- O
) O
mice O
are O
useful O
models O
for O
studying O
anterior O
segment O
development O
and O
its O
anomalies O
, O
and O
may O
allow O
identification O
of O
genes O
that O
interact O
with O
Foxc1 O
and O
Foxc2 O
( O
or O
FKHL7 O
and O
FKHL14 O
) O
to O
produce O
a O
phenotype O
with O
elevated O
IOP O
and O
glaucoma B
. O
. O

( O
Over O
) O
correction O
of O
FMR1 B
deficiency I
with O
YAC O
transgenics O
: O
behavioral O
and O
physical O
features O
. O

Fragile B
X I
syndrome I
is O
a O
common O
cause O
of O
mental B
retardation I
involving O
loss O
of O
expression O
of O
the O
FMR1 O
gene O
. O

The O
role O
of O
FMR1 O
remains O
undetermined O
but O
the O
protein O
appears O
to O
be O
involved O
in O
RNA O
metabolism O
. O

Fmr1 O
knockout O
mice O
exhibit O
a O
phenotype O
with O
some O
similarities O
to O
humans O
, O
such O
as O
macroorchidism B
and O
behavioral O
abnormalities O
. O

As O
a O
step O
toward O
understanding O
the O
function O
of O
FMR1 O
and O
the O
determination O
of O
the O
potential O
for O
therapeutic O
approaches O
to O
fragile B
X I
syndrome I
, O
yeast O
artificial O
chromosome O
( O
YAC O
) O
transgenic O
mice O
were O
generated O
in O
order O
to O
determine O
whether O
the O
Fmr1 O
knockout O
mouse O
phenotype O
could O
be O
rescued O
. O

Several O
transgenic O
lines O
were O
generated O
that O
carried O
the O
entire O
FMR1 O
locus O
with O
extensive O
amounts O
of O
flanking O
sequence O
. O

We O
observed O
that O
the O
YAC O
transgene O
supported O
production O
of O
the O
human O
protein O
( O
FMRP O
) O
which O
was O
present O
at O
levels O
10 O
to O
15 O
times O
that O
of O
endogenous O
protein O
and O
was O
expressed O
in O
a O
cell O
- O
and O
tissue O
- O
specific O
manner O
. O

Macro O
- O
orchidism O
was O
absent O
in O
knockout O
mice O
carrying O
the O
YAC O
transgene O
indicating O
functional O
rescue O
by O
the O
human O
protein O
. O

Given O
the O
complex O
behavioral O
phenotype O
in O
fragile B
X I
patients O
and O
the O
mild O
phenotype O
previously O
reported O
for O
the O
Fmr1 O
knockout O
mouse O
, O
we O
performed O
a O
more O
thorough O
evaluation O
of O
the O
Fmr1 O
knockout O
phenotype O
using O
additional O
behavioral O
assays O
that O
had O
not O
previously O
been O
reported O
for O
this O
animal O
model O
. O

The O
mouse O
displayed O
reduced O
anxiety B
- O
related O
responses O
with O
increased O
exploratory O
behavior O
. O

FMR1 O
YAC O
transgenic O
mice O
overexpressing O
the O
human O
protein O
did O
produce O
opposing O
behavioral O
responses O
and O
additional O
abnormal O
behaviors O
were O
also O
observed O
. O

These O
findings O
have O
significant O
implications O
for O
gene O
therapy O
for O
fragile B
X I
syndrome I
since O
overexpression O
of O
the O
gene O
may O
harbor O
its O
own O
phenotype O
. O
. O

Transgenic O
mice O
carrying O
large O
human O
genomic O
sequences O
with O
expanded O
CTG O
repeat O
mimic O
closely O
the O
DM B
CTG O
repeat O
intergenerational O
and O
somatic O
instability O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
caused O
by O
a O
CTG O
repeat O
expansion O
in O
the O
3UTR O
of O
the O
DM B
protein O
kinase O
( O
DMPK O
) O
gene O
. O

A O
very O
high O
level O
of O
instability O
is O
observed O
through O
successive O
generations O
and O
the O
size O
of O
the O
repeat O
is O
generally O
correlated O
with O
the O
severity O
of O
the O
disease O
and O
with O
age O
at O
onset O
. O

Furthermore O
, O
tissues O
from O
DM B
patients O
exhibit O
somatic O
mosaicism O
that O
increases O
with O
age O
. O

We O
generated O
transgenic O
mice O
carrying O
large O
human O
genomic O
sequences O
with O
20 O
, O
55 O
or O
> O
300 O
CTG O
, O
cloned O
from O
patients O
from O
the O
same O
affected O
DM B
family O
. O

Using O
large O
human O
flanking O
sequences O
and O
a O
large O
amplification O
, O
we O
demonstrate O
that O
the O
intergenerational O
CTG O
repeat O
instability O
is O
reproduced O
in O
mice O
, O
with O
a O
strong O
bias O
towards O
expansions O
and O
with O
the O
same O
sex O
- O
and O
size O
- O
dependent O
characteristics O
as O
in O
humans O
. O

Moreover O
, O
a O
high O
level O
of O
instability O
, O
increasing O
with O
age O
, O
can O
be O
observed O
in O
tissues O
and O
in O
sperm O
. O

Although O
we O
did O
not O
observe O
dramatic O
expansions O
( O
or O
big O
jumps O
over O
several O
hundred O
CTG O
repeats O
) O
as O
in O
congenital O
forms O
of O
DM B
, O
our O
model O
carrying O
> O
300 O
CTG O
is O
the O
first O
to O
show O
instability O
so O
close O
to O
the O
human O
DM B
situation O
. O

Our O
three O
models O
carrying O
different O
sizes O
of O
CTG O
repeat O
provide O
insight O
on O
the O
different O
factors O
modulating O
the O
CTG O
repeat O
instability O
. O
. O

Inactivation O
of O
the O
Friedreich B
ataxia I
mouse O
gene O
leads O
to O
early O
embryonic B
lethality I
without O
iron O
accumulation O
. O

Friedreich B
ataxia I
( O
FRDA B
) O
, O
the O
most O
common O
autosomal B
recessive I
ataxia I
, O
is O
caused O
in O
almost O
all O
cases O
by O
homozygous O
intronic O
expansions O
resulting O
in O
the O
loss O
of O
frataxin O
, O
a O
mitochondrial O
protein O
conserved O
through O
evolution O
, O
and O
involved O
in O
mitochondrial O
iron O
homeostasis O
. O

Yeast O
knockout O
models O
, O
and O
histological O
and O
biochemical O
data O
from O
patient O
heart O
biopsies O
or O
autopsies O
indicate O
that O
the O
frataxin O
defect O
causes O
a O
specific O
iron B
- I
sulfur I
protein I
deficiency I
and O
mitochondrial O
iron O
accumulation O
leading O
to O
the O
pathological O
changes O
. O

Affected O
human O
tissues O
are O
rarely O
available O
to O
further O
examine O
this O
hypothesis O
. O

To O
study O
the O
mechanism O
of O
the O
disease O
, O
we O
generated O
a O
mouse O
model O
by O
deletion O
of O
exon O
4 O
leading O
to O
inactivation O
of O
the O
Frda B
gene O
product O
. O

We O
show O
that O
homozygous O
deletions O
cause O
embryonic B
lethality I
a O
few O
days O
after O
implantation O
, O
demonstrating O
an O
important O
role O
for O
frataxin O
during O
early O
development O
. O

These O
results O
suggest O
that O
the O
milder O
phenotype O
in O
humans O
is O
due O
to O
residual O
frataxin O
expression O
associated O
with O
the O
expansion O
mutations O
. O

Surprisingly O
, O
in O
the O
frataxin O
knockout O
mouse O
, O
no O
iron O
accumulation O
was O
observed O
during O
embryonic O
resorption O
, O
suggesting O
that O
cell O
death O
could O
be O
due O
to O
a O
mechanism O
independent O
of O
iron O
accumulation O
. O
. O

Gaucher B
disease I
: O
the O
origins O
of O
the O
Ashkenazi O
Jewish O
N370S O
and O
84GG O
acid O
beta O
- O
glucosidase O
mutations O
. O

Type O
1 O
Gaucher B
disease I
( O
GD B
) O
, O
a O
non O
- O
neuronopathic O
lysosomal B
storage I
disorder I
, O
results O
from O
the O
deficient O
activity O
of O
acid O
beta O
- O
glucosidase O
( O
GBA O
) O
. O

Type O
1 O
disease O
is O
panethnic O
but O
is O
more O
prevalent O
in O
individuals O
of O
Ashkenazi O
Jewish O
( O
AJ O
) O
descent O
. O

Of O
the O
causative O
GBA O
mutations O
, O
N370S O
is O
particularly O
frequent O
in O
the O
AJ O
population O
, O
( O
q O
approximately O
. O
03 O
) O
, O
whereas O
the O
84GG O
insertion O
( O
q O
approximately O
. O
003 O
) O
occurs O
exclusively O
in O
the O
Ashkenazim O
. O

To O
investigate O
the O
genetic O
history O
of O
these O
mutations O
in O
the O
AJ O
population O
, O
short O
tandem O
repeat O
( O
STR O
) O
markers O
were O
used O
to O
map O
a O
9 O
. O

3 O
- O
cM O
region O
containing O
the O
GBA O
locus O
and O
to O
genotype O
261 O
AJ O
N370S O
chromosomes O
, O
60 O
European O
non O
- O
Jewish O
N370S O
chromosomes O
, O
and O
62 O
AJ O
84GG O
chromosomes O
. O

A O
highly O
conserved O
haplotype O
at O
four O
markers O
flanking O
GBA O
( O
PKLR O
, O
D1S1595 O
, O
D1S2721 O
, O
and O
D1S2777 O
) O
was O
observed O
on O
both O
the O
AJ O
chromosomes O
and O
the O
non O
- O
Jewish O
N370S O
chromosomes O
, O
suggesting O
the O
occurrence O
of O
a O
founder O
common O
to O
both O
populations O
. O

Of O
note O
, O
the O
presence O
of O
different O
divergent O
haplotypes O
suggested O
the O
occurrence O
of O
de O
novo O
, O
recurrent O
N370S O
mutations O
. O

In O
contrast O
, O
a O
different O
conserved O
haplotype O
at O
these O
markers O
was O
identified O
on O
the O
84GG O
chromosomes O
, O
which O
was O
unique O
to O
the O
AJ O
population O
. O

On O
the O
basis O
of O
the O
linkage O
disequilibrium O
( O
LD O
) O
delta O
values O
, O
the O
non O
- O
Jewish O
European O
N370S O
chromosomes O
had O
greater O
haplotype O
diversity O
and O
less O
LD O
at O
the O
markers O
flanking O
the O
conserved O
haplotype O
than O
did O
the O
AJ O
N370S O
chromosomes O
. O

This O
finding O
is O
consistent O
with O
the O
presence O
of O
the O
N370S O
mutation O
in O
the O
non O
- O
Jewish O
European O
population O
prior O
to O
the O
founding O
of O
the O
AJ O
population O
. O

Coalescence O
analyses O
for O
the O
N370S O
and O
84GG O
mutations O
estimated O
similar O
coalescence O
times O
, O
of O
48 O
and O
55 O
. O
5 O
generations O
ago O
, O
respectively O
. O

The O
results O
of O
these O
studies O
are O
consistent O
with O
a O
significant O
bottleneck O
occurring O
in O
the O
AJ O
population O
during O
the O
first O
millennium O
, O
when O
the O
population O
became O
established O
in O
Europe O
. O

HLA O
B27 O
and O
the O
genetics O
of O
ankylosing B
spondylitis I
. O

One O
hundred O
and O
twenty O
- O
eight O
of O
145 O
patients O
with O
ankylosing B
spondylitis I
( O
AS B
) O
were O
found O
to O
be O
HLA O
B27 O
positive O
. O

Five O
patients O
had O
evidence O
of O
a O
sero O
- O
negative O
peripheral B
arthritis I
resembling O
peripheral B
psoriatic I
arthritis I
and O
3 O
of O
these O
were O
B27 O
negative O
. O

One O
further O
B27 O
negative O
patients O
had O
a O
sister O
with O
ankylosing B
spondylitis I
and O
ulcerative B
colitis I
and O
a O
mother O
with O
ulcerative B
colitis I
. O

There O
was O
evidence O
of O
a O
somewhat O
later O
age O
of O
onset O
of O
symptoms O
in O
B27 O
negative O
patients O
. O

These O
findings O
are O
interpreted O
as O
suggesting O
some O
degree O
of O
clinical O
and O
genetic O
heterogeneity O
in O
ankylosing B
spondylitis I
with O
genes O
for O
psoriasis B
and O
inflammatory B
bowel I
disease I
being O
important O
in O
some O
individuals O
, O
particularly O
those O
who O
are O
B27 O
negative O
. O

Twenty O
- O
five O
first O
- O
degree O
relatives O
with O
ankylosing B
spondylitis I
were O
all O
B27 O
positive O
. O

The O
only O
instance O
of O
disassociation O
of O
B27 O
and O
spondylitis B
in O
a O
family O
was O
where O
the O
proband O
had O
ulcerative B
colitis I
as O
well O
as O
spondylitis B
. O

Of O
13 O
B27 O
positive O
fathers O
3 O
could O
be O
diagnosed O
as O
having O
definite O
ankylosing B
spondylitis I
( O
23 O
% O
) O
. O

These O
findings O
are O
thought O
to O
provide O
evidence O
against O
the O
concept O
that O
the O
gene O
for O
ankylosing B
spondylitis I
is O
not O
B27 O
but O
a O
closely O
linked O
gene O
and O
favour O
the O
occurrence O
of O
an O
environmental O
event O
affecting O
approximately O
one O
- O
fifth O
of O
B27 O
positive O
males O
to O
result O
in O
disease O
. O
. O

Founder O
mutations O
in O
the O
BRCA1 O
gene O
in O
Polish O
families O
with O
breast B
- I
ovarian I
cancer I
. O

We O
have O
undertaken O
a O
hospital O
- O
based O
study O
, O
to O
identify O
possible O
BRCA1 O
and O
BRCA2 O
founder O
mutations O
in O
the O
Polish O
population O
. O

The O
study O
group O
consisted O
of O
66 O
Polish O
families O
with O
cancer B
who O
have O
at O
least O
three O
related O
females O
affected O
with O
breast B
or I
ovarian I
cancer I
and O
who O
had O
cancer B
diagnosed O
, O
in O
at O
least O
one O
of O
the O
three O
affected O
females O
, O
at O
age O
< O
50 O
years O
. O

A O
total O
of O
26 O
families O
had O
both O
breast B
and I
ovarian I
cancers I
, O
4 O
families O
had O
ovarian B
cancers I
only O
, O
and O
36 O
families O
had O
breast B
cancers I
only O
. O

Genomic O
DNA O
was O
prepared O
from O
the O
peripheral O
blood O
leukocytes O
of O
at O
least O
one O
affected O
woman O
from O
each O
family O
. O

The O
entire O
coding O
region O
of O
BRCA1 O
and O
BRCA2 O
was O
screened O
for O
the O
presence O
of O
germline O
mutations O
, O
by O
use O
of O
SSCP O
followed O
by O
direct O
sequencing O
of O
observed O
variants O
. O

Mutations O
were O
found O
in O
35 O
( O
53 O
% O
) O
of O
the O
66 O
families O
studied O
. O

All O
but O
one O
of O
the O
mutations O
were O
detected O
within O
the O
BRCA1 O
gene O
. O

BRCA1 B
abnormalities I
were O
identified O
in O
all O
four O
families O
with O
ovarian B
cancer I
only O
, O
in O
67 O
% O
of O
27 O
families O
with O
both O
breast B
and I
ovarian I
cancer I
, O
and O
in O
34 O
% O
of O
35 O
families O
with O
breast B
cancer I
only O
. O

The O
single O
family O
with O
a O
BRCA2 O
mutation O
had O
the O
breast B
- I
ovarian I
cancer I
syndrome I
. O

Seven O
distinct O
mutations O
were O
identified O
; O
five O
of O
these O
occurred O
in O
two O
or O
more O
families O
. O

In O
total O
, O
recurrent O
mutations O
were O
found O
in O
33 O
( O
94 O
% O
) O
of O
the O
35 O
families O
with O
detected O
mutations O
. O

Three O
BRCA1 B
abnormalities I
- O
5382insC O
, O
C61G O
, O
and O
4153delA O
- O
accounted O
for O
51 O
% O
, O
20 O
% O
, O
and O
11 O
% O
of O
the O
identified O
mutations O
, O
respectively O
. O
. O

Molecular O
basis O
of O
very B
long I
chain I
acyl I
- I
CoA I
dehydrogenase I
deficiency I
in O
three O
Israeli O
patients O
: O
identification O
of O
a O
complex O
mutant O
allele O
with O
P65L O
and O
K247Q O
mutations O
, O
the O
former O
being O
an O
exonic O
mutation O
causing O
exon O
3 O
skipping O
. O

Very B
long I
chain I
acyl I
- I
CoA I
dehydrogenase I
( I
VLCAD I
) I
deficiency I
is O
a O
life O
- O
threatening O
disorder O
of O
mitochondrial O
fatty O
acid O
beta O
- O
oxidation O
. O

We O
identified O
four O
novel O
mutations O
in O
three O
unrelated O
patients O
. O

All O
patients O
had O
the O
severe O
childhood O
form O
of O
VLCAD B
deficiency I
with O
early O
onset O
and O
high O
mortality O
. O

Immunoblot O
analysis O
revealed O
that O
VLCAD O
protein O
was O
undetectable O
in O
patients O
2 O
and O
3 O
, O
whereas O
normal O
- O
size O
VLCAD O
protein O
and O
an O
aberrant O
form O
of O
VLCAD O
( O
4kDa O
smaller O
) O
were O
detected O
in O
patient O
1 O
. O

As O
expected O
, O
null O
mutations O
were O
found O
in O
patients O
2 O
and O
3 O
patient O
2 O
is O
homozygous O
for O
a O
frameshift O
mutation O
, O
del O
4 O
bp O
at O
798 O
- O
801 O
, O
and O
patient O
3 O
is O
homozygous O
for O
a O
nonsense O
mutation O
65C O
> O
A O
( O
S22X O
) O
. O

Patient O
1 O
was O
homozygous O
for O
a O
complex O
mutant O
allele O
containing O
two O
alterations O
, O
including O
a O
194C O
> O
T O
transition O
( O
P65L O
) O
and O
739A O
> O
C O
transversion O
( O
K247Q O
) O
; O
in O
the O
case O
of O
P65L O
, O
the O
amino O
acid O
change O
does O
not O
reduce O
enzyme O
activity O
. O

However O
, O
the O
nucleotide O
change O
resulted O
in O
exon O
3 O
skipping O
, O
whereas O
the O
latter O
K247Q O
mutation O
had O
a O
drastic O
effect O
on O
enzyme O
activity O
. O

We O
verified O
these O
events O
by O
in O
vivo O
splicing O
experiments O
and O
transient O
expression O
analysis O
of O
mutant O
cDNAs O
. O

The O
P65L O
mutation O
locates O
11 O
bases O
upstream O
of O
a O
splice O
donor O
site O
of O
intron O
3 O
. O

This O
is O
an O
example O
of O
an O
exonic O
mutation O
which O
affects O
exon O
- O
splicing O
. O
. O

Submicroscopic O
deletion O
in O
cousins O
with O
Prader B
- I
Willi I
syndrome I
causes O
a O
grandmatrilineal O
inheritance O
pattern O
: O
effects O
of O
imprinting O
. O

The O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
critical O
region O
on O
15q11 O
- O
q13 O
is O
subject O
to O
imprinting O
. O

PWS B
becomes O
apparent O
when O
genes O
on O
the O
paternally O
inherited O
chromosome O
are O
not O
expressed O
. O

Familial B
PWS I
is O
rare O
. O

We O
report O
on O
a O
family O
in O
which O
a O
male O
and O
a O
female O
paternal O
first O
cousin O
both O
have O
PWS B
with O
cytogenetically O
normal O
karyotypes O
. O

Fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
analysis O
shows O
a O
submicroscopic O
deletion O
of O
SNRPN O
, O
but O
not O
the O
closely O
associated O
loci O
D15S10 O
, O
D15S11 O
, O
D15S63 O
, O
and O
GABRB3 O
. O

The O
cousins O
fathers O
and O
two O
paternal O
aunts O
have O
the O
same O
deletion O
and O
are O
clinically O
normal O
. O

The O
grandmother O
of O
the O
cousins O
is O
deceased O
and O
not O
available O
for O
study O
, O
and O
their O
grandfather O
is O
not O
deleted O
for O
SNRPN O
. O

DNA O
methylation O
analysis O
of O
D15S63 O
is O
consistent O
with O
an O
abnormality O
of O
the O
imprinting O
center O
associated O
with O
PWS B
. O

" O
Grandmatrilineal O
" O
inheritance O
occurs O
when O
a O
woman O
with O
deletion O
of O
an O
imprinted O
, O
paternally O
expressed O
gene O
is O
at O
risk O
of O
having O
affected O
grandchildren O
through O
her O
sons O
. O

In O
this O
case O
, O
PWS B
does O
not O
become O
evident O
as O
long O
as O
the O
deletion O
is O
passed O
through O
the O
matrilineal O
line O
. O

This O
represents O
a O
unique O
inheritance O
pattern O
due O
to O
imprinting O
. O
. O

Human O
glycine O
decarboxylase O
gene O
( O
GLDC O
) O
and O
its O
highly O
conserved O
processed O
pseudogene O
( O
psiGLDC O
) O
: O
their O
structure O
and O
expression O
, O
and O
the O
identification O
of O
a O
large O
deletion O
in O
a O
family O
with O
nonketotic B
hyperglycinemia I
. O

Mutations O
in O
the O
glycine O
decarboxylase O
gene O
( O
GLDC O
) O
cause O
nonketotic B
hyperglycinemia I
( O
NKH B
) O
, O
an O
in B
- I
born I
error I
of I
metabolism I
characterized O
by O
severe O
neurological B
disturbance I
. O

We O
have O
determined O
the O
structure O
of O
GLDC O
and O
of O
its O
pseudogene O
( O
psiGLDC O
) O
and O
studied O
their O
expression O
for O
a O
molecular O
analysis O
of O
NKH B
. O

The O
GLDC O
gene O
spans O
at O
least O
135 O
kb O
and O
consists O
of O
25 O
exons O
. O

All O
donor O
and O
acceptor O
sites O
adhere O
to O
the O
canonical O
GT O
- O
AG O
rule O
, O
except O
for O
the O
donor O
site O
of O
intron O
21 O
, O
where O
a O
variant O
form O
GC O
is O
used O
instead O
of O
GT O
. O

The O
transcription O
initiation O
site O
has O
been O
assigned O
to O
a O
residue O
163 O
bp O
upstream O
from O
the O
translation O
initiation O
triplet O
by O
primer O
extension O
analysis O
. O

The O
psiGLDC O
gene O
has O
no O
intron O
and O
shares O
97 O
. O

5 O
% O
homology O
with O
the O
coding O
region O
of O
functional O
GLDC O
, O
suggesting O
that O
psiGLDC O
is O
a O
processed O
pseudogene O
that O
arose O
from O
the O
GLDC O
transcript O
about O
4 O
- O
8 O
million O
years O
ago O
. O

RNA O
blotting O
analysis O
has O
revealed O
that O
GLDC O
is O
expressed O
in O
human O
liver O
, O
kidney O
, O
brain O
, O
and O
placenta O
. O

We O
have O
also O
examined O
a O
patient O
with O
NKH B
with O
no O
detectable O
GLDC O
mRNA O
in O
his O
lymphoblasts O
. O

Exons O
1 O
- O
3 O
of O
the O
functional O
GLDC O
gene O
from O
this O
patient O
are O
not O
amplified O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
, O
whereas O
those O
from O
control O
subjects O
are O
. O

These O
results O
suggest O
a O
large O
homozygous O
deletion O
( O
at O
least O
30 O
kb O
) O
in O
the O
patient O
. O

Furthermore O
, O
we O
have O
devised O
a O
semi O
- O
quantitative O
PCR O
to O
estimate O
the O
number O
of O
GLDC O
alleles O
by O
using O
psiGLDC O
as O
an O
internal O
control O
and O
have O
confirmed O
the O
homozygosity O
and O
heterozygosity O
of O
the O
deletion O
in O
the O
patient O
and O
his O
parents O
, O
respectively O
. O

Structural O
information O
of O
GLDC O
and O
psiGLDC O
should O
facilitate O
the O
molecular O
analysis O
of O
NKH B
. O

De O
novo O
deletions O
of O
SNRPN O
exon O
1 O
in O
early O
human O
and O
mouse O
embryos O
result O
in O
a O
paternal O
to O
maternal O
imprint O
switch O
. O

Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
is O
a O
neurogenetic B
disease I
characterized O
by O
infantile B
hypotonia I
, O
gonadal B
hypoplasia I
, O
obsessive O
behaviour O
and O
neonatal O
feeding O
difficulties O
followed O
by O
hyperphagia B
, O
leading O
to O
profound O
obesity B
. O

PWS B
is O
due O
to O
a O
lack O
of O
paternal O
genetic O
information O
at O
15q11 O
- O
q13 O
( O
ref O
. O
2 O
) O
. O

Five O
imprinted O
, O
paternally O
expressed O
genes O
map O
to O
the O
PWS B
region O
, O
MKRN3 O
( O
ref O
. O
3 O
) O
, O
NDN O
( O
ref O
. O
4 O
) O
, O
NDNL1 O
( O
ref O
. O
5 O
) O
, O
SNRPN O
( O
refs O
6 O
- O
8 O
) O
and O
IPW O
( O
ref O
. O
9 O
) O
, O
as O
well O
as O
two O
poorly O
characterized O
framents O
designated O
PAR O
- O
1 O
and O
PAR O
- O
5 O
( O
ref O
. O
10 O
) O
. O

Imprinting O
of O
this O
region O
involves O
a O
bipartite O
imprinting O
centre O
( O
IC O
) O
, O
which O
overlaps O
SNRPN O
( O
refs O
10 O
, O
11 O
) O
. O

Deletion O
of O
the O
SNRPN O
promoter O
/ O
exon O
1 O
region O
( O
the O
PWS B
IC O
element O
) O
appears O
to O
impair O
the O
establishment O
of O
the O
paternal O
imprint O
in O
the O
male O
germ O
line O
and O
leads O
to O
PWS B
. O

Here O
we O
report O
a O
PWS B
family O
in O
which O
the O
father O
is O
mosaic O
for O
an O
IC O
deletion O
on O
his O
paternal O
chromosome O
. O

The O
deletion O
chromosome O
has O
acquired O
a O
maternal O
methylation O
imprint O
in O
his O
somatic O
cells O
. O

We O
have O
made O
identical O
findings O
in O
chimaeric O
mice O
generated O
from O
two O
independent O
embryonic O
stem O
( O
ES O
) O
cell O
lines O
harbouring O
a O
similar O
deletion O
. O

Our O
studies O
demonstrate O
that O
the O
PWS B
IC O
element O
is O
not O
only O
required O
for O
the O
establishment O
of O
the O
paternal O
imprint O
, O
but O
also O
for O
its O
postzygotic O
maintenance O
. O
. O

Mice O
deficient B
in I
Six5 I
develop O
cataracts B
: O
implications O
for O
myotonic B
dystrophy I
. O

Expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
UTR O
of O
the O
gene O
DMPK O
at O
the O
DM1 O
locus O
on O
chromosome O
19 O
causes O
myotonic B
dystrophy I
, O
a O
dominantly B
inherited I
disease I
characterized O
by O
skeletal O
muscle B
dystrophy I
and O
myotonia B
, O
cataracts B
and O
cardiac B
conduction I
defects I
. O

Targeted O
deletion O
of O
Dm15 O
, O
the O
mouse O
orthologue O
of O
human O
DMPK O
, O
produced O
mice O
with O
a O
mild O
myopathy B
and O
cardiac B
conduction I
abnormalities I
, O
but O
without O
other O
features O
of O
myotonic B
dystrophy I
, O
such O
as O
myotonia B
and O
cataracts B
. O

We O
, O
and O
others O
, O
have O
demonstrated O
that O
repeat O
expansion O
decreases O
expression O
of O
the O
adjacent O
gene O
SIX5 O
( O
refs O
7 O
, O
8 O
) O
, O
which O
encodes O
a O
homeodomain O
transcription O
factor O
. O

To O
determine O
whether O
SIX5 B
deficiency I
contributes O
to O
the O
myotonic B
dystrophy I
phenotype O
, O
we O
disrupted O
mouse O
Six5 O
by O
replacing O
the O
first O
exon O
with O
a O
beta O
- O
galactosidase O
reporter O
. O

Six5 O
- O
mutant O
mice O
showed O
reporter O
expression O
in O
multiple O
tissues O
, O
including O
the O
developing O
lens O
. O

Homozygous O
mutant O
mice O
had O
no O
apparent O
abnormalities B
of I
skeletal I
muscle I
function I
, O
but O
developed O
lenticular B
opacities I
at O
a O
higher O
rate O
than O
controls O
. O

Our O
results O
suggest O
that O
SIX5 B
deficiency I
contributes O
to O
the O
cataract B
phenotype O
in O
myotonic B
dystrophy I
, O
and O
that O
myotonic B
dystrophy I
represents O
a O
multigenic B
disorder I
. O
. O

Heterozygous O
loss O
of O
Six5 O
in O
mice O
is O
sufficient O
to O
cause O
ocular O
cataracts B
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disorder I
characterized O
by O
skeletal O
muscle B
wasting I
, O
myotonia B
, O
cardiac B
arrhythmia I
, O
hyperinsulinaemia B
, O
mental B
retardation I
and O
ocular O
cataracts B
. O

The O
genetic B
defect I
in O
DM B
is O
a O
CTG O
repeat O
expansion O
located O
in O
the O
3 O
untranslated O
region O
of O
DMPK O
and O
5 O
of O
a O
homeodomain O
- O
encoding O
gene O
, O
SIX5 O
( O
formerly O
DMAHP O
; O
refs O
2 O
- O
5 O
) O
. O

There O
are O
three O
mechanisms O
by O
which O
CTG O
expansion O
can O
result O
in O
DM B
. O

First O
, O
repeat O
expansion O
may O
alter O
the O
processing O
or O
transport O
of O
the O
mutant O
DMPK O
mRNA O
and O
consequently O
reduce O
DMPK O
levels O
. O

Second O
, O
CTG O
expansion O
may O
establish O
a O
region O
of O
heterochromatin O
3 O
of O
the O
repeat O
sequence O
and O
decrease O
SIX5 O
transcription O
. O

Third O
, O
toxic O
effects O
of O
the O
repeat O
expansion O
may O
be O
intrinsic O
to O
the O
repeated O
elements O
at O
the O
level O
of O
DNA O
or O
RNA O
( O
refs O
10 O
, O
11 O
) O
. O

Previous O
studies O
have O
demonstrated O
that O
a O
dose O
- O
dependent O
loss O
of O
Dm15 O
( O
the O
mouse O
DMPK O
homologue O
) O
in O
mice O
produces O
a O
partial O
DM B
phenotype O
characterized O
by O
decreased O
development O
of O
skeletal O
muscle O
force O
and O
cardiac B
conduction I
disorders I
. O

To O
test O
the O
role O
of O
Six5 O
loss O
in O
DM B
, O
we O
have O
analysed O
a O
strain O
of O
mice O
in O
which O
Six5 O
was O
deleted O
. O

Our O
results O
demonstrate O
that O
the O
rate O
and O
severity O
of O
cataract B
formation O
is O
inversely O
related O
to O
Six5 O
dosage O
and O
is O
temporally O
progressive O
. O

Six5 O
+ O
/ O
- O
and O
Six5 O
- O
/ O
- O
mice O
show O
increased O
steady O
- O
state O
levels O
of O
the O
Na O
+ O
/ O
K O
+ O
- O
ATPase O
alpha O
- O
1 O
subunit O
and O
decreased O
Dm15 O
mRNA O
levels O
. O

Thus O
, O
altered O
ion O
homeostasis O
within O
the O
lens O
may O
contribute O
to O
cataract B
formation O
. O

As O
ocular O
cataracts B
are O
a O
characteristic O
feature O
of O
DM B
, O
these O
results O
demonstrate O
that O
decreased O
SIX5 O
transcription O
is O
important O
in O
the O
aetiology O
of O
DM B
. O

Our O
data O
support O
the O
hypothesis O
that O
DM B
is O
a O
contiguous O
gene O
syndrome O
associated O
with O
the O
partial O
loss O
of O
both O
DMPK O
and O
SIX5 O
. O
. O

ATM O
- O
dependent O
phosphorylation O
of O
nibrin O
in O
response O
to O
radiation O
exposure O
. O

Mutations O
in O
the O
gene O
ATM O
are O
responsible O
for O
the O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
which O
is O
characterized O
by O
cerebellar B
dysfunction I
, O
radiosensitivity O
, O
chromosomal O
instability O
and O
cancer B
predisposition O
. O

Both O
the O
A B
- I
T I
phenotype O
and O
the O
similarity O
of O
the O
ATM O
protein O
to O
other O
DNA O
- O
damage O
sensors O
suggests O
a O
role O
for O
ATM O
in O
biochemical O
pathways O
involved O
in O
the O
recognition O
, O
signalling O
and O
repair O
of O
DNA O
double O
- O
strand O
breaks O
( O
DSBs O
) O
. O

There O
are O
strong O
parallels O
between O
the O
pattern O
of O
radiosensitivity O
, O
chromosomal O
instability O
and O
cancer B
predisposition O
in O
A B
- I
T I
patients O
and O
that O
in O
patients O
with O
Nijmegen B
breakage I
syndrome I
( O
NBS B
) O
. O

The O
protein O
defective O
in O
NBS B
, O
nibrin O
( O
encoded O
by O
NBS1 O
) O
, O
forms O
a O
complex O
with O
MRE11 O
and O
RAD50 O
( O
refs O
1 O
, O
2 O
) O
. O

This O
complex O
localizes O
to O
DSBs O
within O
30 O
minutes O
after O
cellular O
exposure O
to O
ionizing O
radiation O
( O
IR O
) O
and O
is O
observed O
in O
brightly O
staining O
nuclear O
foci O
after O
a O
longer O
period O
of O
time O
. O

The O
overlap O
between O
clinical O
and O
cellular O
phenotypes O
in O
A B
- I
T I
and O
NBS B
suggests O
that O
ATM O
and O
nibrin O
may O
function O
in O
the O
same O
biochemical O
pathway O
. O

Here O
we O
demonstrate O
that O
nibrin O
is O
phosphorylated O
within O
one O
hour O
of O
treatment O
of O
cells O
with O
IR O
. O

This O
response O
is O
abrogated O
in O
A B
- I
T I
cells O
that O
either O
do O
not O
express O
ATM O
protein O
or O
express O
near O
full O
- O
length O
mutant O
protein O
. O

We O
also O
show O
that O
ATM O
physically O
interacts O
with O
and O
phosphorylates O
nibrin O
on O
serine O
343 O
both O
in O
vivo O
and O
in O
vitro O
. O

Phosphorylation O
of O
this O
site O
appears O
to O
be O
functionally O
important O
because O
mutated O
nibrin O
( O
S343A O
) O
does O
not O
completely O
complement O
radiosensitivity O
in O
NBS B
cells O
. O

ATM O
phosphorylation O
of O
nibrin O
does O
not O
affect O
nibrin O
- O
MRE11 O
- O
RAD50 O
association O
as O
revealed O
by O
radiation O
- O
induced O
foci O
formation O
. O

Our O
data O
provide O
a O
biochemical O
explanation O
for O
the O
similarity O
in O
phenotype O
between O
A B
- I
T I
and O
NBS B
. O
. O

Clinicopathologic O
features O
of O
BRCA B
- I
linked I
and I
sporadic I
ovarian I
cancer I
. O

CONTEXT O
Most O
hereditary B
ovarian I
cancers I
are O
associated O
with O
germline O
mutations O
in O
BRCA1 O
or O
BRCA2 O
. O

Attempts O
to O
define O
the O
clinical O
significance O
of O
BRCA O
mutation O
status O
in O
ovarian B
cancer I
have O
produced O
conflicting O
results O
, O
especially O
regarding O
survival O
. O

OBJECTIVE O
To O
determine O
whether O
hereditary B
ovarian I
cancers I
have O
distinct O
clinical O
and O
pathological O
features O
compared O
with O
sporadic B
( I
nonhereditary I
) I
ovarian I
cancers I
. O

DESIGN O
AND O
SETTING O
Retrospective O
cohort O
study O
of O
a O
consecutive O
series O
of O
933 O
ovarian B
cancers I
diagnosed O
and O
treated O
at O
our O
institution O
, O
which O
is O
a O
comprehensive O
cancer B
center O
as O
designated O
by O
the O
National O
Cancer B
Institute O
, O
over O
a O
12 O
- O
year O
period O
( O
December O
1986 O
to O
August O
1998 O
) O
. O

PATIENTS O
The O
study O
was O
restricted O
to O
patients O
of O
Jewish O
origin O
because O
of O
the O
ease O
of O
BRCA1 O
and O
BRCA2 O
genotyping O
in O
this O
ethnic O
group O
. O

From O
the O
189 O
patients O
who O
identified O
themselves O
as O
Jewish O
, O
88 O
hereditary O
cases O
were O
identified O
with O
the O
presence O
of O
a O
germline O
founder O
mutation O
in O
BRCA1 O
or O
BRCA2 O
. O

The O
remaining O
101 O
cases O
from O
the O
same O
series O
not O
associated O
with O
a O
BRCA O
mutation O
and O
2 O
additional O
groups O
( O
Gynecologic O
Oncology O
Group O
protocols O
52 O
and O
111 O
) O
with O
ovarian B
cancer I
from O
clinical O
trials O
( O
for O
the O
survival O
analysis O
) O
were O
included O
for O
comparison O
. O

MAIN O
OUTCOME O
MEASURES O
Age O
at O
diagnosis O
, O
surgical O
stage O
, O
histologic O
cell O
type O
and O
grade O
, O
and O
surgical O
outcome O
; O
and O
response O
to O
chemotherapy O
and O
survival O
for O
advanced O
- O
stage O
( O
II O
and O
IV O
) O
cases O
. O

RESULTS O
Hereditary B
cancers I
were O
rarely O
diagnosed O
before O
age O
40 O
years O
and O
were O
common O
after O
age O
60 O
years O
, O
with O
mean O
age O
at O
diagnosis O
being O
significantly O
younger O
for O
BRCA1 O
- O
vs O
BRCA2 O
- O
linked O
patients O
( O
54 O
vs O
62 O
years O
; O
P O
= O
. O
04 O
) O
. O

Histology O
, O
grade O
, O
stage O
, O
and O
success O
of O
cytoreductive O
surgery O
were O
similar O
for O
hereditary O
and O
sporadic O
cases O
. O

The O
hereditary O
group O
had O
a O
longer O
disease O
- O
free O
interval O
following O
primary O
chemotherapy O
in O
comparison O
with O
the O
nonhereditary O
group O
, O
with O
a O
median O
time O
to O
recurrence O
of O
14 O
months O
and O
7 O
months O
, O
respectively O
( O
P O
< O
. O
001 O
) O
. O

Those O
with O
hereditary B
cancers I
had O
improved O
survival O
compared O
with O
the O
nonhereditary O
group O
( O
P O
= O
. O
004 O
) O
. O

For O
stage B
III I
cancers I
, O
BRCA O
mutation O
status O
was O
an O
independent O
prognostic O
variable O
( O
P O
= O
. O
03 O
) O
. O

CONCLUSIONS O
Although O
BRCA B
- I
associated I
hereditary I
ovarian I
cancers I
in O
this O
population O
have O
surgical O
and O
pathological O
characteristics O
similar O
to O
those O
of O
sporadic B
cancers I
, O
advanced B
- I
stage I
hereditary I
cancer I
patients O
survive O
longer O
than O
nonhereditary B
cancer I
patients O
. O

Age O
penetrance O
is O
greater O
for O
BRCA1 B
- I
linked I
than I
for I
BRCA2 I
- I
linked I
cancers I
in O
this O
population O
. O

The O
gene O
for O
familial B
Mediterranean I
fever I
, O
MEFV O
, O
is O
expressed O
in O
early O
leukocyte O
development O
and O
is O
regulated O
in O
response O
to O
inflammatory O
mediators O
. O

Familial B
Mediterranean I
fever I
( O
FMF B
) O
is O
a O
recessive B
disorder I
characterized O
by O
episodes O
of O
fever B
and O
neutrophil B
- I
mediated I
serosal I
inflammation I
. O

We O
recently O
identified O
the O
gene O
causing O
FMF B
, O
designated O
MEFV O
, O
and O
found O
it O
to O
be O
expressed O
in O
mature O
neutrophils O
, O
suggesting O
that O
it O
functions O
as O
an O
inflammatory O
regulator O
. O

To O
facilitate O
our O
understanding O
of O
the O
normal O
function O
of O
MEFV O
, O
we O
extended O
our O
previous O
studies O
. O

MEFV O
messenger O
RNA O
was O
detected O
by O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
in O
bone O
marrow O
leukocytes O
, O
with O
differential O
expression O
observed O
among O
cells O
by O
in O
situ O
hybridization O
. O

CD34 O
hematopoietic O
stem O
- O
cell O
cultures O
induced O
toward O
the O
granulocytic O
lineage O
expressed O
MEFV O
at O
the O
myelocyte O
stage O
, O
concurrently O
with O
lineage O
commitment O
. O

The O
prepromyelocytic O
cell O
line O
HL60 O
expressed O
MEFV O
only O
at O
granulocytic O
and O
monocytic O
differentiation O
. O

MEFV O
was O
also O
expressed O
in O
the O
monocytic O
cell O
lines O
U937 O
and O
THP O
- O
1 O
. O

Among O
peripheral O
blood O
leukocytes O
, O
MEFV O
expression O
was O
detected O
in O
neutrophils O
, O
eosinophils O
, O
and O
to O
varying O
degrees O
, O
monocytes O
. O

Consistent O
with O
the O
tissue O
specificity O
of O
expression O
, O
complete O
sequencing O
and O
analysis O
of O
upstream O
regulatory O
regions O
of O
MEFV O
revealed O
homology O
to O
myeloid O
- O
specific O
promoters O
and O
to O
more O
broadly O
expressed O
inflammatory O
promoter O
elements O
. O

In O
vitro O
stimulation O
of O
monocytes O
with O
the O
proinflammatory O
agents O
interferon O
( O
IFN O
) O
gamma O
, O
tumor B
necrosis O
factor O
, O
and O
lipopolysaccharide O
induced O
MEFV O
expression O
, O
whereas O
the O
antiinflammatory O
cytokines O
interleukin O
( O
IL O
) O
4 O
, O
IL O
- O
10 O
, O
and O
transforming O
growth O
factor O
beta O
inhibited O
such O
expression O
. O

Induction O
by O
IFN O
- O
gamma O
occurred O
rapidly O
and O
was O
resistant O
to O
cycloheximide O
. O

IFN O
- O
alpha O
also O
induced O
MEFV O
expression O
. O

In O
granulocytes O
, O
MEFV O
was O
up O
- O
regulated O
by O
IFN O
- O
gamma O
and O
the O
combination O
of O
IFN O
- O
alpha O
and O
colchicine O
. O

These O
results O
refine O
understanding O
of O
MEFV O
by O
placing O
the O
gene O
in O
the O
myelomonocytic O
- O
specific O
proinflammatory O
pathway O
and O
identifying O
it O
as O
an O
IFN O
- O
gamma O
immediate O
early O
gene O
. O
. O

Biochemical O
and O
structural O
analysis O
of O
missense O
mutations O
in O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
causing O
mucopolysaccharidosis B
IVA I
phenotypes O
. O

Mucopolysaccharidosis B
IVA I
( O
MPS B
IVA I
; O
OMIM O
# O
253000 O
) O
, O
a O
lysosomal B
storage I
disorder I
caused O
by O
a O
deficiency B
of I
N I
- I
acetylgalactosamine I
- I
6 I
- I
sulfate I
sulfatase I
( O
GALNS O
) O
, O
has O
variable O
clinical O
phenotypes O
. O

To O
date O
we O
have O
identified O
65 O
missense O
mutations O
in O
the O
GALNS O
gene O
from O
MPS B
IVA I
patients O
, O
but O
the O
correlation O
between O
genotype O
and O
phenotype O
has O
remained O
unclear O
. O

We O
studied O
17 O
missense O
mutations O
using O
biochemical O
approaches O
and O
32 O
missense O
mutations O
, O
using O
structural O
analyses O
. O

Fifteen O
missense O
mutations O
and O
two O
newly O
engineered O
active O
site O
mutations O
( O
C79S O
, O
C79T O
) O
were O
characterized O
by O
transient O
expression O
analysis O
. O

Mutant O
proteins O
, O
except O
for O
C79S O
and O
C79T O
, O
were O
destabilized O
and O
detected O
as O
insoluble O
precursor O
forms O
while O
the O
C79S O
and O
C79T O
mutants O
were O
of O
a O
soluble O
mature O
size O
. O

Mutants O
found O
in O
the O
severe O
phenotype O
had O
no O
activity O
. O

Mutants O
found O
in O
the O
mild O
phenotype O
had O
a O
considerable O
residual O
activity O
( O
1 O
. O
3 O
- O
13 O
. O
3 O
% O
of O
wild O
- O
type O
GALNS O
activity O
) O
. O

Sulfatases O
, O
including O
GALNS O
, O
are O
members O
of O
a O
highly O
conserved O
gene O
family O
sharing O
an O
extensive O
sequence O
homology O
. O

Thus O
, O
a O
tertiary O
structural O
model O
of O
human O
GALNS O
was O
constructed O
from O
the O
X O
- O
ray O
crystal O
structure O
of O
N O
- O
acetylgalacto O
- O
samine O
- O
4 O
- O
sulfatase O
and O
arylsulfatase O
A O
, O
using O
homology O
modeling O
, O
and O
32 O
missense O
mutations O
were O
investigated O
. O

Consequently O
, O
we O
propose O
that O
there O
are O
at O
least O
three O
different O
reasons O
for O
the O
severe O
phenotype O
( O
i O
) O
destruction O
of O
the O
hydrophobic O
core O
or O
modification O
of O
the O
packing O
; O
( O
ii O
) O
removal O
of O
a O
salt O
bridge O
to O
destabilize O
the O
entire O
conformation O
; O
( O
iii O
) O
modification O
of O
the O
active O
site O
. O

In O
contrast O
, O
mild O
mutations O
were O
mostly O
located O
on O
the O
surface O
of O
the O
GALNS O
protein O
. O

These O
studies O
shed O
further O
light O
on O
the O
genotype O
- O
phenotype O
correlation O
of O
MPS B
IVA I
and O
structure O
- O
function O
relationship O
in O
the O
sulfatase O
family O
. O

Mutations O
at O
the O
ataxia B
- I
telangiectasia I
locus O
and O
clinical O
phenotypes O
of O
A B
- I
T I
patients O
. O

Mutations O
at O
the O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
locus O
on O
chromosome O
band O
11q22 O
cause O
a O
distinctive O
autosomal B
recessive I
syndrome I
in O
homozygotes O
and O
predispose O
heterozygotes O
to O
cancer B
, O
ischemic B
heart I
disease I
, O
and O
early O
mortality O
. O

PCR O
amplification O
from O
genomic O
DNA O
and O
automated O
sequencing O
of O
the O
entire O
coding O
region O
( O
66 O
exons O
) O
and O
splice O
junctions O
detected O
77 O
mutations O
( O
85 O
% O
) O
in O
90 O
A B
- I
T I
chromosomes O
. O

Heteroduplex O
analysis O
detected O
another O
42 O
mutations O
at O
the O
A B
- I
T I
locus O
. O

Out O
of O
a O
total O
of O
71 O
unique O
mutations O
, O
50 O
were O
found O
only O
in O
a O
single O
family O
, O
and O
51 O
had O
not O
been O
reported O
previously O
. O

Most O
( O
58 O
/ O
71 O
, O
82 O
% O
) O
mutations O
were O
frameshift O
and O
nonsense O
mutations O
that O
are O
predicted O
to O
cause O
truncation O
of O
the O
A B
- I
T I
protein O
; O
the O
less O
common O
mutation O
types O
were O
missense O
( O
9 O
/ O
71 O
, O
13 O
% O
) O
, O
splicing O
( O
3 O
/ O
71 O
, O
4 O
% O
) O
and O
one O
in O
- O
frame O
deletion O
, O
2546 O
3 O
( O
1 O
/ O
71 O
, O
1 O
% O
) O
. O

The O
mean O
survival O
and O
height O
distribution O
of O
134 O
A B
- I
T I
patients O
correlated O
significantly O
with O
the O
specific O
mutations O
present O
in O
the O
patients O
. O

Patients O
homozygous O
for O
a O
single O
truncating O
mutation O
, O
typically O
near O
the O
N O
- O
terminal O
end O
of O
the O
gene O
, O
or O
heterozygous O
for O
the O
in O
- O
frame O
deletion O
2546 O
3 O
, O
were O
shorter O
and O
had O
significantly O
shorter O
survival O
than O
those O
heterozygous O
for O
a O
splice O
site O
or O
missense O
mutation O
, O
or O
heterozygous O
for O
two O
truncating O
mutations O
. O

Alterations O
of O
the O
length O
or O
amino O
acid O
composition O
of O
the O
A B
- I
T I
gene O
product O
affect O
the O
A B
- I
T I
clinical O
phenotype O
in O
different O
ways O
. O

Mutation O
analysis O
at O
the O
A B
- I
T I
locus O
may O
help O
estimate O
the O
prognosis O
of O
A B
- I
T I
patients O
. O
. O

Isolation O
, O
genomic O
organization O
, O
and O
expression O
analysis O
of O
the O
mouse O
and O
rat O
homologs O
of O
MEFV O
, O
the O
gene O
for O
familial B
mediterranean I
fever I
. O

Familial B
Mediterranean I
fever I
( O
FMF B
) O
is O
a O
recessive B
disorder I
characterized O
by O
episodes O
of O
fever B
with O
serositis B
or O
synovitis B
. O

Recently O
the O
FMF B
gene O
( O
MEFV O
) O
was O
cloned O
; O
the O
protein O
product O
, O
pyrin O
/ O
marenostrin O
, O
is O
thought O
to O
regulate O
inflammation O
in O
myeloid O
cells O
. O

In O
this O
manuscript O
we O
report O
the O
mouse O
and O
rat O
homologs O
of O
MEFV O
. O

The O
murine O
gene O
contains O
ten O
exons O
with O
a O
coding O
sequence O
of O
2304 O
bp O
, O
while O
the O
rat O
homolog O
has O
nine O
exons O
with O
a O
coding O
sequence O
of O
2253 O
bp O
. O

A O
considerable O
amino O
acid O
sequence O
homology O
was O
observed O
between O
the O
mouse O
and O
human O
( O
47 O
. O
6 O
% O
identity O
and O
65 O
. O
5 O
% O
similarity O
) O
and O
between O
the O
mouse O
and O
rat O
genes O
( O
73 O
. O
5 O
% O
identity O
and O
82 O
. O
1 O
% O
similarity O
) O
. O

The O
predicted O
rodent O
proteins O
have O
several O
important O
domains O
and O
signals O
found O
in O
human O
pyrin O
, O
including O
a O
B O
- O
box O
zinc O
finger O
domain O
, O
Robbins O
- O
Dingwall O
nuclear O
localization O
signal O
, O
and O
coiled O
- O
coil O
domain O
. O

However O
, O
perhaps O
because O
of O
an O
ancient O
frame O
- O
shift O
mutation O
, O
neither O
the O
mouse O
nor O
the O
rat O
protein O
has O
an O
intact O
C O
- O
terminal O
B30 O
. O

2 O
domain O
, O
in O
which O
most O
FMF B
- O
associated O
mutations O
have O
been O
found O
in O
human O
MEFV O
. O

Nevertheless O
, O
like O
the O
human O
gene O
, O
mouse O
Mefv O
is O
expressed O
in O
peripheral O
blood O
granulocytes O
but O
not O
lymphocytes O
. O

Consistent O
with O
its O
expression O
in O
granulocytes O
, O
Mefv O
was O
detected O
at O
high O
levels O
in O
the O
primary O
follicles O
and O
marginal O
zones O
of O
the O
splenic O
white O
pulp O
. O

Mefv O
is O
localized O
on O
mouse O
Chromosome O
( O
Chr O
) O
16 O
, O
region O
A3 O
- O
B1 O
, O
extending O
a O
region O
of O
synteny O
with O
human O
Chr O
16p13 O
. O

3 O
. O

Development O
of O
knockout O
and O
knockin O
mouse O
models O
may O
provide O
further O
insights O
into O
the O
functional O
evolution O
of O
this O
gene O
. O

Additional O
copies O
of O
the O
proteolipid O
protein O
gene O
causing O
Pelizaeus B
- I
Merzbacher I
disease I
arise O
by O
separate O
integration O
into O
the O
X O
chromosome O
. O

The O
proteolipid O
protein O
gene O
( O
PLP O
) O
is O
normally O
present O
at O
chromosome O
Xq22 O
. O

Mutations O
and O
duplications O
of O
this O
gene O
are O
associated O
with O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

Here O
we O
describe O
two O
new O
families O
in O
which O
males O
affected O
with O
PMD B
were O
found O
to O
have O
a O
copy O
of O
PLP O
on O
the O
short O
arm O
of O
the O
X O
chromosome O
, O
in O
addition O
to O
a O
normal O
copy O
on O
Xq22 O
. O

In O
the O
first O
family O
, O
the O
extra O
copy O
was O
first O
detected O
by O
the O
presence O
of O
heterozygosity O
of O
the O
AhaII O
dimorphism O
within O
the O
PLP O
gene O
. O

The O
results O
of O
FISH O
analysis O
showed O
an O
additional O
copy O
of O
PLP O
in O
Xp22 O
. O

1 O
, O
although O
no O
chromosomal O
rearrangements O
could O
be O
detected O
by O
standard O
karyotype O
analysis O
. O

Another O
three O
affected O
males O
from O
the O
family O
had O
similar O
findings O
. O

In O
a O
second O
unrelated O
family O
with O
signs O
of O
PMD B
, O
cytogenetic O
analysis O
showed O
a O
pericentric O
inversion O
of O
the O
X O
chromosome O
. O

In O
the O
inv O
( O
X O
) O
carried O
by O
several O
affected O
family O
members O
, O
FISH O
showed O
PLP O
signals O
at O
Xp11 O
. O

4 O
and O
Xq22 O
. O

A O
third O
family O
has O
previously O
been O
reported O
, O
in O
which O
affected O
members O
had O
an O
extra O
copy O
of O
the O
PLP O
gene O
detected O
at O
Xq26 O
in O
a O
chromosome O
with O
an O
otherwise O
normal O
banding O
pattern O
. O

The O
identification O
of O
three O
separate O
families O
in O
which O
PLP O
is O
duplicated O
at O
a O
noncontiguous O
site O
suggests O
that O
such O
duplications O
could O
be O
a O
relatively O
common O
but O
previously O
undetected O
cause O
of O
genetic B
disorders I
. O

The O
exon O
13 O
duplication O
in O
the O
BRCA1 O
gene O
is O
a O
founder O
mutation O
present O
in O
geographically O
diverse O
populations O
. O

The O
BRCA1 O
Exon O
13 O
Duplication O
Screening O
Group O
. O

Recently O
, O
a O
6 O
- O
kb O
duplication O
of O
exon O
13 O
, O
which O
creates O
a O
frameshift O
in O
the O
coding O
sequence O
of O
the O
BRCA1 O
gene O
, O
has O
been O
described O
in O
three O
unrelated O
U O
. O

S O
S O
. O
families O
of O
European O
ancestry O
and O
in O
one O
Portuguese O
family O
. O

Here O
, O
our O
goal O
was O
to O
estimate O
the O
frequency O
and O
geographic O
diversity O
of O
carriers O
of O
this O
duplication O
. O

To O
do O
this O
, O
a O
collaborative O
screening O
study O
was O
set O
up O
that O
involved O
39 O
institutions O
from O
19 O
countries O
and O
included O
3 O
, O
580 O
unrelated O
individuals O
with O
a O
family O
history O
of O
the O
disease O
and O
934 O
early O
- O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
cases O
. O

A O
total O
of O
11 O
additional O
families O
carrying O
this O
mutation O
were O
identified O
in O
Australia O
( O
1 O
) O
, O
Belgium O
( O
1 O
) O
, O
Canada O
( O
1 O
) O
, O
Great O
Britain O
( O
6 O
) O
, O
and O
the O
United O
States O
( O
2 O
) O
. O

Haplotyping O
showed O
that O
they O
are O
likely O
to O
derive O
from O
a O
common O
ancestor O
, O
possibly O
of O
northern O
British O
origin O
. O

Our O
results O
demonstrate O
that O
it O
is O
strongly O
advisable O
, O
for O
laboratories O
carrying O
out O
screening O
either O
in O
English O
- O
speaking O
countries O
or O
in O
countries O
with O
historical O
links O
with O
Britain O
, O
to O
include O
within O
their O
BRCA1 O
screening O
protocols O
the O
polymerase O
chain O
reaction O
- O
based O
assay O
described O
in O
this O
report O
. O

Genotype O
- O
phenotype O
correlations O
in O
families O
with O
deletions O
in O
the O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
gene O
. O

Von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
is O
a O
hereditary B
tumor I
syndrome I
characterized O
by O
predisposition O
for O
bilateral B
and I
multi I
- I
centric I
hemangioblastoma I
in O
the O
retina O
and O
central O
nervous O
system O
, O
pheochromocytoma B
, O
renal B
cell I
carcinoma I
, O
and O
cysts B
in I
the I
kidney I
, I
pancreas I
, I
and I
epididymis I
. O

We O
describe O
five O
families O
for O
which O
direct O
sequencing O
of O
the O
coding O
region O
of O
the O
VHL B
gene O
had O
failed O
to O
identify O
the O
family O
- O
specific O
mutation O
. O

Further O
molecular O
analysis O
revealed O
deletions O
involving O
the O
VHL B
gene O
in O
each O
of O
these O
families O
. O

In O
four O
families O
, O
partial O
deletions O
of O
one O
or O
more O
exons O
were O
detected O
by O
Southern O
blot O
analysis O
. O

In O
the O
fifth O
family O
, O
FISH O
analysis O
demonstrated O
the O
deletion O
of O
the O
entire O
VHL B
gene O
. O

Our O
results O
show O
that O
( O
quantitative O
) O
Southern O
blot O
analysis O
is O
a O
sensitive O
method O
for O
detecting O
germline O
deletions O
of O
the O
VHL B
gene O
and O
should O
be O
implemented O
in O
routine O
DNA O
diagnosis O
for O
VHL B
disease I
. O

Our O
data O
support O
the O
previously O
established O
observation O
that O
families O
with O
a O
germline O
deletion O
have O
a O
low O
risk O
for O
pheochromocytoma B
. O

Further O
unraveling O
of O
genotype O
- O
phenotype O
correlations O
in O
VHL B
disease I
has O
revealed O
that O
families O
with O
a O
full O
or O
partial O
deletion O
of O
the O
VHL B
gene O
exhibit O
a O
phenotype O
with O
a O
preponderance O
of O
central B
nervous I
system I
hemangioblastoma I
. O
. O

Age O
of O
the O
intronic O
GAA O
triplet O
repeat O
expansion O
mutation O
in O
Friedreich B
ataxia I
. O

Friedreich B
ataxia I
( O
FRDA B
) O
, O
the O
most O
frequently O
inherited B
ataxia I
, O
is O
due O
in O
the O
vast O
majority O
of O
cases O
to O
a O
large O
expansion O
of O
an O
intronic O
GAA O
repeat O
. O

Using O
linkage O
disequilibrium O
analysis O
based O
on O
haplotype O
data O
of O
seven O
polymorphic O
markers O
close O
to O
the O
frataxin O
gene O
, O
the O
age O
of O
FRDA B
founding O
mutational O
event O
( O
s O
) O
is O
estimated O
to O
be O
at O
least O
682 O
+ O
/ O
- O
203 O
generations O
( O
95 O
% O
confidence O
interval O
564 O
- O
801 O
g O
) O
, O
a O
dating O
which O
is O
consistent O
with O
little O
or O
no O
negative O
selection O
and O
provides O
further O
evidence O
for O
an O
ancient O
spread O
of O
a O
pre O
- O
mutation O
( O
at O
- O
risk O
alleles O
) O
in O
western O
Europe O
. O
. O

Functional O
link O
between O
ataxia B
- I
telangiectasia I
and O
Nijmegen B
breakage I
syndrome I
gene O
products O
. O

Ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
and O
Nijmegen B
breakage I
syndrome I
( O
NBS B
) O
are O
recessive B
genetic I
disorders I
with O
susceptibility O
to O
cancer B
and O
similar O
cellular O
phenotypes O
. O

The O
protein O
product O
of O
the O
gene O
responsible O
for O
A B
- I
T I
, O
designated O
ATM O
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
characterized O
by O
a O
carboxy O
- O
terminal O
phosphatidylinositol O
3 O
- O
kinase O
- O
like O
domain O
. O

The O
NBS1 O
protein O
is O
specifically O
mutated O
in O
patients O
with O
Nijmegen B
breakage I
syndrome I
and O
forms O
a O
complex O
with O
the O
DNA O
repair O
proteins O
Rad50 O
and O
Mrel1 O
. O

Here O
we O
show O
that O
phosphorylation O
of O
NBS1 O
, O
induced O
by O
ionizing O
radiation O
, O
requires O
catalytically O
active O
ATM O
. O

Complexes O
containing O
ATM O
and O
NBS1 O
exist O
in O
vivo O
in O
both O
untreated O
cells O
and O
cells O
treated O
with O
ionizing O
radiation O
. O

We O
have O
identified O
two O
residues O
of O
NBS1 O
, O
Ser O
278 O
and O
Ser O
343 O
that O
are O
phosphorylated O
in O
vitro O
by O
ATM O
and O
whose O
modification O
in O
vivo O
is O
essential O
for O
the O
cellular O
response O
to O
DNA O
damage O
. O

This O
response O
includes O
S O
- O
phase O
checkpoint O
activation O
, O
formation O
of O
the O
NBS1 O
/ O
Mrel1 O
/ O
Rad50 O
nuclear O
foci O
and O
rescue O
of O
hypersensitivity B
to I
ionizing I
radiation I
. O

Together O
, O
these O
results O
demonstrate O
a O
biochemical O
link O
between O
cell O
- O
cycle O
checkpoints O
activated O
by O
DNA O
damage O
and O
DNA O
repair O
in O
two O
genetic B
diseases I
with O
overlapping O
phenotypes O
. O
. O

Homozygosity O
mapping O
in O
a O
family O
with O
microcephaly B
, O
mental B
retardation I
, O
and O
short B
stature I
to O
a O
Cohen B
syndrome I
region O
on O
8q21 O
. O
3 O
- O
8q22 O
. O
1 O
: O
redefining O
a O
clinical O
entity O
. O

A O
syndrome O
of O
microcephaly B
, O
progressive O
postnatal B
growth I
deficiency I
, O
and O
mental B
retardation I
was O
observed O
in O
two O
brothers O
and O
their O
cousin O
from O
a O
multiply O
consanguineous O
kindred O
of O
Lebanese O
descent O
. O

Hypotonia B
, O
chorioretinal B
dystrophy I
, O
and O
myopia B
were O
also O
identified O
. O

The O
severity O
of O
the O
condition O
varied O
among O
the O
closely O
related O
patients O
. O

Because O
of O
absence O
of O
a O
distinctive O
facial O
appearance O
, O
the O
degree O
of O
mental B
retardation I
, O
and O
short B
stature I
, O
the O
initially O
considered O
clinical O
diagnosis O
of O
Cohen B
syndrome I
was O
withdrawn O
and O
a O
novel O
genetic O
entity O
was O
assumed O
. O

Homozygosity O
mapping O
in O
this O
family O
assigned O
the O
gene O
to O
a O
26 O
. O

8 O
- O
cM O
region O
on O
the O
chromosome O
band O
8q21 O
. O

3 O
- O
22 O
. O

1 O
, O
between O
the O
microsatellites O
at O
D8S270 O
and O
D8S514 O
. O

The O
maximum O
two O
- O
point O
LOD O
score O
was O
found O
for O
marker O
at O
D8S267 O
( O
Zmax O
= O
3 O
. O
. O
237 O
at O
Omax O
= O
0 O
. O
00 O
) O
. O

Intriguingly O
enough O
, O
the O
identified O
gene O
region O
overlaps O
the O
refined O
gene O
region O
for O
Cohen B
syndrome I
( O
COH1 O
) O
[ O
Kolehmainen O
et O
al O
. O
, O
1997 O
Euro O
J O
Hum O
Genet O
5 O
206 O
- O
213 O
] O
. O

This O
fact O
encourages O
the O
hypothesis O
that O
the O
described O
kindred O
segregates O
for O
a O
variant O
of O
Cohen B
syndrome I
and O
suggests O
a O
redefinition O
of O
its O
phenotype O

Polymorphisms O
of O
the O
CYP2D6 O
gene O
increase O
susceptibility O
to O
ankylosing B
spondylitis I
. O

Ankylosing B
spondylitis I
( O
AS B
) O
is O
a O
common O
and O
highly O
familial O
rheumatic B
disorder I
. O

The O
sibling O
recurrence O
risk O
ratio O
for O
the O
disease O
is O
63 O
and O
heritability O
assessed O
in O
twins O
> O
90 O
% O
. O

Although O
MHC O
genes O
, O
including O
HLA O
- O
B27 O
, O
contribute O
only O
20 O
- O
50 O
% O
of O
the O
genetic O
risk O
for O
the O
disease O
, O
no O
non O
- O
MHC O
gene O
has O
yet O
been O
convincingly O
demonstrated O
to O
influence O
either O
susceptibility O
to O
the O
disease O
or O
its O
phenotypic O
expression O
. O

Previous O
linkage O
and O
association O
studies O
have O
suggested O
the O
presence O
of O
a O
susceptibility O
gene O
for O
AS B
close O
to O
, O
or O
within O
, O
the O
cytochrome O
P450 O
2D6 O
gene O
( O
CYP2D6 O
, O
debrisoquine O
hydroxylase O
) O
located O
at O
chromosome O
22q13 O
. O
1 O
. O

We O
performed O
a O
linkage O
study O
of O
chromosome O
22 O
in O
200 O
families O
with O
AS B
affected O
sibling O
- O
pairs O
. O

Association O
of O
alleles O
of O
the O
CYP2D6 O
gene O
was O
examined O
by O
both O
case O
- O
control O
and O
within O
- O
family O
means O
. O

For O
case O
- O
control O
studies O
, O
617 O
unrelated O
individuals O
with O
AS B
( O
361 O
probands O
from O
sibling O
- O
pair O
and O
parent O
- O
case O
trio O
families O
and O
256 O
unrelated O
non O
- O
familial O
sporadic O
cases O
) O
and O
402 O
healthy O
ethnically O
matched O
controls O
were O
employed O
. O

For O
within O
- O
family O
association O
studies O
, O
361 O
families O
including O
161 O
parent O
- O
case O
trios O
and O
200 O
affected O
sibling O
- O
pair O
families O
were O
employed O
. O

Homozygosity O
for O
poor O
metabolizer O
alleles O
was O
found O
to O
be O
associated O
with O
AS B
. O

Heterozygosity O
for O
the O
most O
frequent O
poor O
metabolizer O
allele O
( O
CYP2D6 O
* O
4 O
) O
was O
not O
associated O
with O
increased O
susceptibility O
to O
AS B
. O

Significant O
within O
- O
family O
association O
of O
CYP2D6 O
* O
4 O
alleles O
and O
AS B
was O
demonstrated O
. O

Weak O
linkage O
was O
also O
demonstrated O
between O
CYP2D6 O
and O
AS B
. O

We O
postulate O
that O
altered O
metabolism O
of O
a O
natural O
toxin O
or O
antigen O
by O
the O
CYP2D6 O
gene O
may O
increase O
susceptibility O
to O
AS B
. O

Functional O
differences O
of O
the O
PDS B
gene O
product O
are O
associated O
with O
phenotypic O
variation O
in O
patients O
with O
Pendred B
syndrome I
and O
non B
- I
syndromic I
hearing I
loss I
( O
DFNB4 B
) O
. O

The O
PDS B
gene O
encodes O
a O
transmembrane O
protein O
, O
known O
as O
pendrin O
, O
which O
functions O
as O
a O
transporter O
of O
iodide O
and O
chloride O
. O

Mutations O
in O
this O
gene O
are O
responsible O
for O
Pendred B
syndrome I
and O
autosomal B
recessive I
non I
- I
syndromic I
hearing I
loss I
at O
the O
DFNB4 B
locus O
on O
chromosome O
7q31 O
. O

A O
screen O
of O
20 O
individuals O
from O
the O
midwestern O
USA O
with O
non B
- I
syndromic I
hearing I
loss I
and O
dilated O
vestibular O
aqueducts O
identified O
three O
people O
( O
15 O
% O
) O
with O
PDS B
mutations O
. O

To O
determine O
whether O
PDS B
mutations O
in O
individuals O
with O
Pendred B
syndrome I
differ O
functionally O
from O
PDS B
mutations O
in O
individuals O
with O
non B
- I
syndromic I
hearing I
loss I
, O
we O
compared O
three O
common O
Pendred B
syndrome I
allele O
variants O
( O
L236P O
, O
T416P O
and O
E384G O
) O
, O
with O
three O
PDS B
mutations O
reported O
only O
in O
individuals O
with O
non B
- I
syndromic I
hearing I
loss I
( O
V480D O
, O
V653A O
and O
I490L O
/ O
G497S O
) O
. O

The O
mutations O
associated O
with O
Pendred B
syndrome I
have O
complete O
loss O
of O
pendrin O
- O
induced O
chloride O
and O
iodide O
transport O
, O
while O
alleles O
unique O
to O
people O
with O
DFNB4 B
are O
able O
to O
transport O
both O
iodide O
and O
chloride O
, O
albeit O
at O
a O
much O
lower O
level O
than O
wild O
- O
type O
pendrin O
. O

We O
hypothesize O
that O
this O
residual O
level O
of O
anion O
transport O
is O
sufficient O
to O
eliminate O
or O
postpone O
the O
onset O
of O
goiter B
in O
individuals O
with O
DFNB4 B
. O

We O
propose O
a O
model O
for O
pendrin O
function O
in O
the O
thyroid O
in O
which O
pendrin O
transports O
iodide O
across O
the O
apical O
membrane O
of O
the O
thyrocyte O
into O
the O
colloid O
space O
. O
. O

The O
human O
factor O
IX O
gene O
as O
germline O
mutagen O
test O
: O
samples O
from O
Mainland O
China O
have O
the O
putatively O
endogenous O
pattern O
of O
mutation O
. O

Germline O
mutations O
are O
the O
major O
source O
of O
genetic O
variation O
that O
allows O
a O
species O
to O
evolve O
over O
time O
but O
at O
the O
cost O
of O
Mendelian B
disease I
and O
genetic O
predisposition O
to O
multifactorial B
diseases I
. O

Previous O
analyses O
have O
revealed O
that O
the O
pattern O
of O
germline O
mutations O
in O
the O
factor O
IX O
gene O
( O
F9 O
) O
is O
similar O
among O
a O
variety O
of O
ethnically O
and O
geographically O
diverse O
populations O
and O
compatible O
with O
the O
ancient O
pattern O
that O
has O
shaped O
the O
mammalian O
genome O
. O

Here O
, O
we O
compare O
the O
pattern O
of O
germline O
mutation O
in O
a O
population O
of O
hemophilia B
B I
patients O
from O
Mainland O
China O
( O
n O
= O
66 O
) O
to O
that O
in O
U O
. O

S O
. O

Caucasians O
, O
Blacks O
, O
and O
Mexican O
Hispanics O
and O
stratify O
by O
disease O
severity O
and O
ethnicity O
. O

The O
similar O
pattern O
of O
germline O
mutation O
in O
all O
ethnic O
groups O
studied O
to O
date O
provides O
additional O
data O
compatible O
with O
the O
inference O
that O
endogenous O
processes O
predominate O
in O
germline O
mutations O
. O

Fas O
preassociation O
required O
for O
apoptosis O
signaling O
and O
dominant O
inhibition O
by O
pathogenic O
mutations O
. O

Heterozygous O
mutations O
encoding O
abnormal O
forms O
of O
the O
death O
receptor O
Fas O
dominantly O
interfere O
with O
Fas O
- O
induced O
lymphocyte O
apoptosis O
in O
human O
autoimmune B
lymphoproliferative I
syndrome I
. O

This O
effect O
, O
rather O
than O
depending O
on O
ligand O
- O
induced O
receptor O
oligomerization O
, O
was O
found O
to O
stem O
from O
ligand O
- O
independent O
interaction O
of O
wild O
- O
type O
and O
mutant O
Fas O
receptors O
through O
a O
specific O
region O
in O
the O
extracellular O
domain O
. O

Preassociated O
Fas O
complexes O
were O
found O
in O
living O
cells O
by O
means O
of O
fluorescence O
resonance O
energy O
transfer O
between O
variants O
of O
green O
fluorescent O
protein O
. O

These O
results O
show O
that O
formation O
of O
preassociated O
receptor O
complexes O
is O
necessary O
for O
Fas O
signaling O
and O
dominant O
interference O
in O
human O
disease O
. O
. O

Determination O
of O
carrier O
status O
for O
the O
Wiskott B
- I
Aldrich I
syndrome I
by O
flow O
cytometric O
analysis O
of O
Wiskott B
- I
Aldrich I
syndrome I
protein O
expression O
in O
peripheral O
blood O
mononuclear O
cells O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
is O
caused O
by O
defects O
in O
the O
WAS B
protein O
( O
WASP O
) O
gene O
on O
the O
X O
chromosome O
. O

Previous O
study O
disclosed O
that O
flow O
cytometric O
analysis O
of O
intracellular O
WASP O
expression O
( O
FCM O
- O
WASP O
analysis O
) O
in O
lymphocytes O
was O
useful O
for O
the O
diagnosis O
of O
WAS B
patients O
. O

Lymphocytes O
from O
all O
WAS B
patients O
showed O
WASPdim O
instead O
of O
WASPbright O
. O

Here O
we O
report O
that O
FCM O
- O
WASP O
analysis O
in O
monocytes O
could O
be O
a O
useful O
tool O
for O
the O
WAS B
carrier O
diagnosis O
. O

Monocytes O
from O
all O
nine O
WAS B
carriers O
showed O
varied O
population O
of O
WASPdim O
together O
with O
WASPbright O
. O

None O
of O
control O
individuals O
possessed O
the O
WASPdim O
population O
. O

In O
contrast O
, O
lymphocytes O
from O
all O
the O
carriers O
except O
two O
lacked O
the O
WASPdim O
population O
. O

The O
difference O
of O
the O
WASPdim O
population O
in O
monocytes O
and O
lymphocytes O
observed O
in O
WAS B
carriers O
suggests O
that O
WASP O
plays O
a O
more O
critical O
role O
in O
the O
development O
of O
lymphocytes O
than O
in O
that O
of O
monocytes O
. O

The O
present O
studies O
suggest O
that O
a O
skewed O
X O
- O
chromosomal O
inactivation O
pattern O
observed O
in O
WAS B
carrier O
peripheral O
blood O
cells O
is O
not O
fixed O
at O
the O
hemopoietic O
stem O
cell O
level O
but O
progresses O
after O
the O
lineage O
commitment O
. O
. O

Restoration O
of O
photoreceptor O
ultrastructure O
and O
function O
in O
retinal B
degeneration I
slow O
mice O
by O
gene O
therapy O
. O

The O
gene O
Prph2 O
encodes O
a O
photoreceptor O
- O
specific O
membrane O
glycoprotein O
, O
peripherin O
- O
2 O
( O
also O
known O
as O
peripherin O
/ O
rds O
) O
, O
which O
is O
inserted O
into O
the O
rims O
of O
photoreceptor O
outer O
segment O
discs O
in O
a O
complex O
with O
rom O
- O
1 O
( O
ref O
. O
2 O
) O
. O

The O
complex O
is O
necessary O
for O
the O
stabilization O
of O
the O
discs O
, O
which O
are O
renewed O
constantly O
throughout O
life O
, O
and O
which O
contain O
the O
visual O
pigments O
necessary O
for O
photon O
capture O
. O

Mutations O
in O
Prph2 O
have O
been O
shown O
to O
result O
in O
a O
variety O
of O
photoreceptor B
dystrophies I
, O
including O
autosomal B
dominant I
retinitis I
pigmentosa I
and O
macular B
dystrophy I
. O

A O
common O
feature O
of O
these O
diseases O
is O
the O
loss O
of O
photoreceptor O
function O
, O
also O
seen O
in O
the O
retinal B
degeneration I
slow O
( O
rds O
or O
Prph2 O
Rd2 O
/ O
Rd2 O
) O
mouse O
, O
which O
is O
homozygous O
for O
a O
null O
mutation O
in O
Prph2 O
. O

It O
is O
characterized O
by O
a O
complete O
failure O
to O
develop O
photoreceptor O
discs O
and O
outer O
segments O
, O
downregulation O
of O
rhodopsin O
and O
apoptotic O
loss O
of O
photoreceptor O
cells O
. O

The O
electroretinograms O
( O
ERGs O
) O
of O
Prph2Rd2 O
/ O
Rd2 O
mice O
have O
greatly O
diminished O
a O
- O
wave O
and O
b O
- O
wave O
amplitudes O
, O
which O
decline O
to O
virtually O
undetectable O
concentrations O
by O
two O
months O
. O

Subretinal O
injection O
of O
recombinant O
adeno O
- O
associated O
virus O
( O
AAV O
) O
encoding O
a O
Prph2 O
transgene O
results O
in O
stable O
generation O
of O
outer O
segment O
structures O
and O
formation O
of O
new O
stacks O
of O
discs O
containing O
both O
perpherin O
- O
2 O
and O
rhodopsin O
, O
which O
in O
many O
cases O
are O
morphologically O
similar O
to O
normal O
outer O
segments O
. O

Moreover O
, O
the O
re O
- O
establishment O
of O
the O
structural O
integrity O
of O
the O
photoreceptor O
layer O
also O
results O
in O
electrophysiological O
correction O
. O

These O
studies O
demonstrate O
for O
the O
first O
time O
that O
a O
complex O
ultrastructural O
cell O
defect O
can O
be O
corrected O
both O
morphologically O
and O
functionally O
by O
in O
vivo O
gene O
transfer O
. O
. O

Mutations O
in O
the O
fibrinogen O
aalpha O
gene O
account O
for O
the O
majority O
of O
cases O
of O
congenital B
afibrinogenemia I
. O

Congenital B
afibrinogenemia I
is O
a O
rare O
, O
autosomal B
, I
recessive I
disorder I
characterized O
by O
the O
complete O
absence O
of O
detectable O
fibrinogen O
. O

We O
previously O
identified O
the O
first O
causative O
mutations O
in O
a O
nonconsanguineous O
Swiss O
family O
; O
the O
4 O
affected O
persons O
have O
homozygous O
deletions O
of O
approximately O
11 O
kb O
of O
the O
fibrinogen O
alpha O
( O
FGA O
) O
gene O
. O

Haplotype O
data O
implied O
that O
these O
deletions O
occurred O
on O
distinct O
ancestral O
chromosomes O
, O
suggesting O
that O
this O
region O
may O
be O
susceptible O
to O
deletion O
by O
a O
common O
mechanism O
. O

We O
subsequently O
showed O
that O
all O
the O
deletions O
were O
identical O
to O
the O
base O
pair O
and O
probably O
resulted O
from O
a O
nonhomologous O
recombination O
mediated O
by O
7 O
- O
bp O
direct O
repeats O
. O

In O
this O
study O
, O
we O
have O
collected O
data O
on O
13 O
additional O
unrelated O
patients O
to O
identify O
the O
causative O
mutations O
and O
to O
determine O
the O
prevalence O
of O
the O
11 O
- O
kb O
deletion O
. O

A O
common O
recurrent O
mutation O
, O
at O
the O
donor O
splice O
site O
of O
FGA O
intron O
4 O
( O
IVS4 O
+ O
1 O
G O
> O
T O
) O
, O
accounted O
for O
14 O
of O
the O
26 O
( O
54 O
% O
) O
alleles O
. O

One O
patient O
was O
heterozygous O
for O
the O
previously O
identified O
deletion O
. O

Three O
more O
frameshift O
mutations O
, O
2 O
nonsense O
mutations O
, O
and O
a O
second O
splice O
site O
mutation O
were O
also O
identified O
. O

Consequently O
, O
86 O
% O
of O
afibrinogenemia B
alleles O
analyzed O
to O
date O
have O
truncating O
mutations O
of O
FGA O
, O
though O
mutations O
in O
all O
3 O
fibrinogen O
genes O
, O
FGG O
, O
FGA O
, O
and O
FGB O
, O
might O
be O
predicted O
to O
cause O
congenital B
afibrinogenemia I
. O
. O

Myotonic B
dystrophy I
: O
the O
role O
of O
the O
CUG O
triplet O
repeats O
in O
splicing O
of O
a O
novel O
DMPK O
exon O
and O
altered O
cytoplasmic O
DMPK O
mRNA O
isoform O
ratios O
. O

The O
mechanism O
by O
which O
( O
CTG O
) O
n O
expansion O
in O
the O
3 O
UTR O
of O
the O
DMPK O
gene O
causes O
myotonic B
dystrophy I
( O
DM B
) O
is O
unknown O
. O

We O
identified O
four O
RNA O
splicing O
factors O
- O
- O
hnRNP O
C O
, O
U2AF O
( O
U2 O
auxiliary O
factor O
) O
, O
PTB O
( O
polypyrimidine O
tract O
binding O
protein O
) O
, O
and O
PSF O
( O
PTB O
associated O
splicing O
factor O
) O
- O
- O
that O
bind O
to O
two O
short O
regions O
3 O
of O
the O
( O
CUG O
) O
n O
, O
and O
found O
a O
novel O
3 O
DMPK O
exon O
resulting O
in O
an O
mRNA O
lacking O
the O
repeats O
. O

We O
propose O
that O
the O
( O
CUG O
) O
n O
is O
an O
essential O
cis O
acting O
element O
for O
this O
splicing O
event O
. O

In O
contrast O
to O
( O
CUG O
) O
n O
containing O
mRNAs O
, O
the O
novel O
isoform O
is O
not O
retained O
in O
the O
nucleus O
in O
DM B
cells O
, O
resulting O
in O
imbalances O
in O
relative O
levels O
of O
cytoplasmic O
DMPK O
mRNA O
isoforms O
and O
a O
new O
dominant O
effect O
of O
the O
mutation O
on O
DMPK O
. O
. O

Expression O
and O
imprinting O
of O
MAGEL2 O
suggest O
a O
role O
in O
Prader B
- I
willi I
syndrome I
and O
the O
homologous O
murine O
imprinting O
phenotype O
. O

Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
is O
caused O
by O
the O
loss O
of O
expression O
of O
imprinted O
genes O
in O
chromosome O
15q11 O
- O
q13 O
. O

Affected O
individuals O
exhibit O
neonatal B
hypotonia I
, O
developmental B
delay I
and O
childhood B
- I
onset I
obesity I
. O

Necdin O
, O
a O
protein O
implicated O
in O
the O
terminal O
differentiation O
of O
neurons O
, O
is O
the O
only O
PWS B
candidate O
gene O
to O
reduce O
viability O
when O
disrupted O
in O
a O
mouse O
model O
. O

In O
this O
study O
, O
we O
have O
characterized O
MAGEL2 O
( O
also O
known O
as O
NDNL1 O
) O
, O
a O
gene O
with O
51 O
% O
amino O
acid O
sequence O
similarity O
to O
necdin O
and O
located O
41 O
kb O
distal O
to O
NDN O
in O
the O
PWS B
deletion O
region O
. O

MAGEL2 O
is O
expressed O
predominantly O
in O
brain O
, O
the O
primary O
tissue O
affected O
in O
PWS B
and O
in O
several O
fetal O
tissues O
as O
shown O
by O
northern O
blot O
analysis O
. O

MAGEL2 O
is O
imprinted O
with O
monoallelic O
expression O
in O
control O
brain O
, O
and O
paternal O
- O
only O
expression O
in O
the O
central O
nervous O
system O
as O
demonstrated O
by O
its O
lack O
of O
expression O
in O
brain O
from O
a O
PWS B
- O
affected O
individual O
. O

The O
orthologous O
mouse O
gene O
( O
Magel2 O
) O
is O
located O
within O
150 O
kb O
of O
NDN O
, O
is O
imprinted O
with O
paternal O
- O
only O
expression O
and O
is O
expressed O
predominantly O
in O
late O
developmental O
stages O
and O
adult O
brain O
as O
shown O
by O
northern O
blotting O
, O
RT O
- O
PCR O
and O
whole O
- O
mount O
RNA O
in O
situ O
hybridization O
. O

Magel2 O
distribution O
partially O
overlaps O
that O
of O
NDN O
, O
with O
strong O
expression O
being O
detected O
in O
the O
central O
nervous O
system O
in O
mid O
- O
gestation O
mouse O
embryos O
by O
in O
situ O
hybridization O
. O

We O
hypothesize O
that O
, O
although O
loss O
of O
necdin O
expression O
may O
be O
important O
in O
the O
neonatal O
presentation O
of O
PWS B
, O
loss O
of O
MAGEL2 O
may O
be O
critical O
to O
abnormalities B
in I
brain I
development I
and O
dysmorphic B
features I
in O
individuals O
with O
PWS B
. O
. O

Retinoschisin O
, O
the O
X B
- I
linked I
retinoschisis I
protein O
, O
is O
a O
secreted O
photoreceptor O
protein O
, O
and O
is O
expressed O
and O
released O
by O
Weri O
- O
Rb1 O
cells O
. O

X B
- I
linked I
retinoschisis I
is O
characterized O
by O
microcystic O
- O
like O
changes O
of O
the O
macular O
region O
and O
schisis O
within O
the O
inner O
retinal O
layers O
, O
leading O
to O
visual B
deterioration I
in O
males O
. O

Many O
missense O
and O
protein O
- O
truncating O
mutations O
of O
the O
causative O
gene O
RS1 O
have O
now O
been O
identified O
and O
are O
thought O
to O
be O
inactivating O
. O

RS1 O
encodes O
a O
224 O
amino O
acid O
protein O
, O
retinoschisin O
, O
which O
contains O
a O
discoidin O
domain O
but O
is O
of O
unknown O
function O
. O

We O
have O
generated O
a O
polyclonal O
antibody O
against O
a O
peptide O
from O
a O
unique O
region O
within O
retinoschisin O
, O
which O
detects O
a O
protein O
of O
approximately O
28 O
kDa O
in O
retinal O
samples O
reduced O
with O
dithiothreitol O
, O
but O
multimers O
sized O
> O
40 O
kDa O
under O
non O
- O
reducing O
conditions O
. O

A O
screen O
of O
human O
tissues O
with O
this O
antibody O
reveals O
retinoschisin O
to O
be O
retina O
specific O
and O
the O
antibody O
detects O
a O
protein O
of O
similar O
size O
in O
bovine O
and O
murine O
retinae O
. O

We O
investigated O
the O
expression O
pattern O
in O
the O
retina O
of O
both O
RS1 O
mRNA O
( O
using O
in O
situ O
hybridization O
with O
riboprobes O
) O
and O
retinoschisin O
( O
using O
immunohistochemistry O
) O
. O

The O
antisense O
riboprobe O
detected O
RS1 O
mRNA O
only O
in O
the O
photoreceptor O
layer O
but O
the O
protein O
product O
of O
the O
gene O
was O
present O
both O
in O
the O
photoreceptors O
and O
within O
the O
inner O
portions O
of O
the O
retina O
. O

Furthermore O
, O
differentiated O
retinoblastoma B
cells O
( O
Weri O
- O
Rb1 O
cells O
) O
were O
found O
to O
express O
RS1 O
mRNA O
and O
to O
release O
retinoschisin O
. O

These O
results O
suggest O
that O
retinoschisin O
is O
released O
by O
photo O
- O
receptors O
and O
has O
functions O
within O
the O
inner O
retinal O
layers O
. O

Thus O
, O
X B
- I
linked I
retinoschisis I
is O
caused O
by O
abnormalities O
in O
a O
putative O
secreted O
photoreceptor O
protein O
and O
is O
the O
first O
example O
of O
a O
secreted O
photo O
- O
receptor O
protein O
associated O
with O
a O
retinal B
dystrophy I
. O
. O

Study O
of O
the O
voltage O
- O
gated O
sodium O
channel O
beta O
1 O
subunit O
gene O
( O
SCN1B O
) O
in O
the O
benign B
familial I
infantile I
convulsions I
syndrome I
( O
BFIC B
) O
. O

Benign B
familial I
infantile I
convulsions I
( O
BFIC B
) O
is O
a O
rare O
autosomal B
dominant I
epilepsy I
syndrome I
. O

This O
syndrome O
has O
been O
recently O
described O
in O
Italian O
and O
French O
pedigrees O
. O

Patients O
present O
with O
partial O
, O
then O
generalized O
seizures O
, O
with O
onset O
at O
age O
three O
months O
. O

The O
seizures O
usually O
spontaneously O
cease O
after O
one O
year O
without O
treatment O
, O
leaving O
no O
neurological B
abnormalities I
. O

We O
have O
mapped O
BFIC B
to O
chromosome O
19q O
in O
five O
Italian O
pedigrees O
. O

The O
sodium O
channel O
beta1 O
subunit O
gene O
( O
SCN1B O
) O
maps O
to O
this O
candidate O
region O
and O
has O
been O
shown O
to O
be O
involved O
in O
one O
Australian O
pedigree O
with O
generalized B
epilepsy I
and I
febrile I
seizures I
" I
plus I
" I
( O
GEFS O
+ O
) O
. O

In O
this O
family O
, O
a O
missense O
mutation O
in O
SCN1B O
cosegregates O
with O
the O
GEFS O
+ O
phenotype O
. O

BFIC B
and O
GEFS O
+ O
have O
clinical O
features O
in O
common O
, O
therefore O
SCN1B O
is O
a O
candidate O
gene O
for O
BFIC B
. O

We O
studied O
SCN1B O
exons O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
and O
5 O
, O
using O
four O
SSCP O
methods O
in O
10 O
Caucasian O
BFIC B
probands O
of O
Western O
Europe O
. O

We O
found O
no O
exon O
variants O
. O

One O
variant O
was O
identified O
in O
intron O
5 O
( O
IVS5 O
- O
10C O
> O
G O
) O
, O
which O
did O
not O
segregate O
with O
BFIC B
and O
was O
observed O
in O
9 O
. O

2 O
% O
controls O
. O

A O
second O
variant O
in O
intron O
5 O
was O
identified O
( O
IVS5 O
+ O
30G O
> O
A O
) O
. O

It O
was O
rare O
, O
as O
not O
observed O
in O
controls O
, O
but O
not O
segregating O
with O
the O
BFIC B
phenotype O
. O

Inactivation O
of O
germline O
mutant O
APC B
alleles O
by O
attenuated O
somatic O
mutations O
: O
a O
molecular O
genetic O
mechanism O
for O
attenuated B
familial I
adenomatous I
polyposis I
. O

Germline O
mutations O
of O
the O
adenomatous B
polyposis I
coli I
( I
APC I
) I
tumor I
- O
suppressor O
gene O
result O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

Patients O
with O
FAP B
typically O
develop O
hundreds O
to O
thousands O
of O
benign B
colorectal I
tumors I
and O
early O
- O
onset O
colorectal B
cancer I
. O

A O
subset O
of O
germline O
APC B
mutations O
results O
in O
an O
attenuated B
FAP I
( O
AFAP B
) O
phenotype O
, O
in O
which O
patients O
develop O
fewer O
tumors B
and O
develop O
them O
at O
an O
older O
age O
. O

Although O
a O
genotype O
- O
phenotype O
correlation O
between O
the O
locations O
of O
APC B
germline O
mutations O
and O
the O
development O
of O
AFAP B
has O
been O
well O
documented O
, O
the O
mechanism O
for O
AFAP B
has O
not O
been O
well O
defined O
. O

We O
investigated O
the O
mechanism O
for O
AFAP B
in O
patients O
carrying O
a O
mutant O
APC B
allele O
( O
APC O
( O
AS9 O
) O
) O
that O
has O
a O
mutation O
in O
the O
alternatively O
spliced O
region O
of O
exon O
9 O
. O

APC O
( O
AS9 O
) O
was O
found O
to O
down O
- O
regulate O
beta O
- O
catenin O
- O
regulated O
transcription O
, O
the O
major O
tumor B
- O
suppressor O
function O
of O
APC O
, O
as O
did O
the O
wild O
- O
type O
APC O
. O

Mutation O
analysis O
showed O
that O
both O
APC O
( O
AS9 O
) O
and O
the O
wild O
- O
type O
APC B
alleles O
were O
somatically O
mutated O
in O
most O
colorectal B
tumors I
from O
these O
patients O
. O

Functional O
analysis O
showed O
that O
4666insA O
, O
a O
common O
somatic O
mutation O
in O
APC O
( O
AS9 O
) O
in O
these O
tumors B
, O
did O
not O
inactivate O
the O
wild O
- O
type O
APC O
. O

Our O
results O
indicate O
that O
carriers O
of O
APC O
( O
AS9 O
) O
develop O
fewer O
colorectal B
tumors I
than O
do O
typical O
patients O
with O
FAP B
because O
somatic O
inactivation O
of O
both O
APC B
alleles O
is O
necessary O
for O
colorectal O
tumorigenesis O
. O

However O
, O
these O
patients O
develop O
colorectal B
tumors I
more O
frequently O
than O
does O
the O
general O
population O
because O
APC O
( O
AS9 O
) O
is O
inactivated O
by O
mutations O
that O
do O
not O
inactivate O
the O
wild O
- O
type O
APC O
. O
. O

Iron O
- O
dependent O
self O
- O
assembly O
of O
recombinant O
yeast O
frataxin O
: O
implications O
for O
Friedreich B
ataxia I
. O

Frataxin B
deficiency I
is O
the O
primary O
cause O
of O
Friedreich B
ataxia I
( O
FRDA B
) O
, O
an O
autosomal B
recessive I
cardiodegenerative I
and I
neurodegenerative I
disease I
. O

Frataxin O
is O
a O
nuclear O
- O
encoded O
mitochondrial O
protein O
that O
is O
widely O
conserved O
among O
eukaryotes O
. O

Genetic O
inactivation O
of O
the O
yeast O
frataxin O
homologue O
( O
Yfh1p O
) O
results O
in O
mitochondrial B
iron I
accumulation I
and O
hypersensitivity B
to I
oxidative I
stress I
. O

Increased O
iron O
deposition O
and O
evidence O
of O
oxidative O
damage O
have O
also O
been O
observed O
in O
cardiac O
tissue O
and O
cultured O
fibroblasts O
from O
patients O
with O
FRDA B
. O

These O
findings O
indicate O
that O
frataxin O
is O
essential O
for O
mitochondrial O
iron O
homeostasis O
and O
protection O
from O
iron O
- O
induced O
formation O
of O
free O
radicals O
. O

The O
functional O
mechanism O
of O
frataxin O
, O
however O
, O
is O
still O
unknown O
. O

We O
have O
expressed O
the O
mature O
form O
of O
Yfh1p O
( O
mYfh1p O
) O
in O
Escherichia O
coli O
and O
have O
analyzed O
its O
function O
in O
vitro O
. O

Isolated O
mYfh1p O
is O
a O
soluble O
monomer O
( O
13 O
, O
783 O
Da O
) O
that O
contains O
no O
iron O
and O
shows O
no O
significant O
tendency O
to O
self O
- O
associate O
. O

Aerobic O
addition O
of O
ferrous O
iron O
to O
mYfh1p O
results O
in O
assembly O
of O
regular O
spherical O
multimers O
with O
a O
molecular O
mass O
of O
approximately O
1 O
. O

1 O
MDa O
( O
megadaltons O
) O
and O
a O
diameter O
of O
13 O
+ O
/ O
- O
2 O
nm O
. O

Each O
multimer O
consists O
of O
approximately O
60 O
subunits O
and O
can O
sequester O
> O
3 O
, O
000 O
atoms O
of O
iron O
. O

Titration O
of O
mYfh1p O
with O
increasing O
iron O
concentrations O
supports O
a O
stepwise O
mechanism O
of O
multimer O
assembly O
. O

Sequential O
addition O
of O
an O
iron O
chelator O
and O
a O
reducing O
agent O
results O
in O
quantitative O
iron O
release O
with O
concomitant O
disassembly O
of O
the O
multimer O
, O
indicating O
that O
mYfh1p O
sequesters O
iron O
in O
an O
available O
form O
. O

In O
yeast O
mitochondria O
, O
native O
mYfh1p O
exists O
as O
monomer O
and O
a O
higher O
- O
order O
species O
with O
a O
molecular O
weight O
> O
600 O
, O
000 O
. O

After O
addition O
of O
( O
55 O
) O
Fe O
to O
the O
medium O
, O
immunoprecipitates O
of O
this O
species O
contain O
> O
16 O
atoms O
of O
( O
55 O
) O
Fe O
per O
molecule O
of O
mYfh1p O
. O

We O
propose O
that O
iron O
- O
dependent O
self O
- O
assembly O
of O
recombinant O
mYfh1p O
reflects O
a O
physiological O
role O
for O
frataxin O
in O
mitochondrial O
iron O
sequestration O
and O
bioavailability O
. O
. O

A O
mutation O
in O
the O
pleckstrin O
homology O
( O
PH O
) O
domain O
of O
the O
FGD1 O
gene O
in O
an O
Italian O
family O
with O
faciogenital B
dysplasia I
( O
Aarskog B
- I
Scott I
syndrome I
) O
. O

Aarskog B
- I
Scott I
Syndrome I
( O
AAS B
) O
is O
an O
X B
- I
linked I
disorder I
characterised O
by O
short B
stature I
and O
multiple O
facial B
, I
limb I
and I
genital I
abnormalities I
. O

A O
gene O
, O
FGD1 O
, O
altered O
in O
a O
patient O
with O
AAS B
phenotype O
, O
has O
been O
identified O
and O
found O
to O
encode O
a O
protein O
with O
homology O
to O
Rho O
/ O
Rac O
guanine O
nucleotide O
exchange O
factors O
( O
Rho O
/ O
Rac O
GEF O
) O
. O

However O
, O
since O
this O
original O
report O
on O
identification O
of O
a O
mutated O
FGD1 O
gene O
in O
an O
AAS B
patient O
, O
no O
additional O
mutations O
in O
the O
FGD1 O
gene O
have O
been O
described O
. O

We O
analysed O
13 O
independent O
patients O
with O
clinical O
diagnosis O
of O
AAS B
. O

One O
patient O
presented O
a O
mutation O
that O
results O
in O
a O
nucleotide O
change O
in O
exon O
10 O
of O
the O
FGD1 O
gene O
( O
G2559 O
> O
A O
) O
substituting O
a O
Gln O
for O
Arg O
in O
position O
610 O
. O

The O
mutation O
was O
found O
to O
segregate O
with O
the O
AAS B
phenotype O
in O
affected O
males O
and O
carrier O
females O
in O
the O
family O
of O
this O
patient O
. O

Interestingly O
, O
Arg O
- O
610 O
is O
located O
within O
one O
of O
the O
two O
pleckstrin O
homology O
( O
PH O
) O
domains O
of O
the O
FGD1 O
gene O
and O
it O
corresponds O
to O
a O
highly O
conserved O
residue O
which O
has O
been O
involved O
in O
InsP O
binding O
in O
PH O
domains O
of O
other O
proteins O
. O

The O
same O
residue O
is O
often O
mutated O
in O
the O
Brutons O
tyrosine O
kinase O
( O
Btk O
) O
gene O
in O
patients O
with O
an O
X B
- I
linked I
agammaglobulinemia I
. O

The O
Arg610Gln O
mutation O
represents O
the O
first O
case O
of O
a O
mutation O
in O
the O
PH O
domain O
of O
the O
FGD1 O
gene O
and O
additional O
evidence O
that O
mutations O
in O
PH O
domains O
can O
be O
associated O
to O
human O
diseases O
. O
. O

Amino O
- O
terminal O
fragments O
of O
mutant O
huntingtin O
show O
selective O
accumulation O
in O
striatal O
neurons O
and O
synaptic O
toxicity O
. O

Huntington B
disease I
( O
HD B
) O
is O
caused O
by O
expansion O
of O
a O
glutamine O
repeat O
in O
the O
amino O
- O
terminal O
region O
of O
huntingtin O
. O

Despite O
its O
widespread O
expression O
, O
mutant O
huntingtin O
induces O
selective O
neuronal O
loss O
in O
striatal O
neurons O
. O

Here O
we O
report O
that O
, O
in O
mutant O
mice O
expressing O
HD B
repeats O
, O
the O
production O
and O
aggregation O
of O
N O
- O
terminal O
huntingtin O
fragments O
preferentially O
occur O
in O
HD B
- O
affected O
neurons O
and O
their O
processes O
and O
axonal O
terminals O
. O

N O
- O
terminal O
fragments O
of O
mutant O
huntingtin O
form O
aggregates O
and O
induce O
neuritic B
degeneration I
in O
cultured O
striatal O
neurons O
. O

N O
- O
terminal O
mutant O
huntingtin O
also O
binds O
to O
synaptic O
vesicles O
and O
inhibits O
their O
glutamate O
uptake O
in O
vitro O
. O

The O
specific O
processing O
and O
accumulation O
of O
toxic O
fragments O
of O
N O
- O
terminal O
huntingtin O
in O
HD B
- O
affected O
striatal O
neurons O
, O
especially O
in O
their O
neuronal O
processes O
and O
axonal O
terminals O
, O
may O
contribute O
to O
the O
selective O
neuropathology O
of O
HD B
. O
. O

BRCA1 O
is O
associated O
with O
a O
human O
SWI O
/ O
SNF O
- O
related O
complex O
: O
linking O
chromatin O
remodeling O
to O
breast B
cancer I
. O

Germline O
mutations O
in O
the O
tumor B
suppressor O
gene O
, O
BRCA1 O
, O
predispose O
individuals O
to O
breast B
and I
ovarian I
cancers I
. O

Using O
a O
combination O
of O
affinity O
- O
and O
conventional O
chromatographic O
techniques O
, O
we O
have O
isolated O
a O
predominant O
form O
of O
a O
multiprotein O
BRCA1 O
- O
containing O
complex O
from O
human O
cells O
displaying O
chromatin O
- O
remodeling O
activity O
. O

Mass O
spectrometric O
sequencing O
of O
components O
of O
this O
complex O
indicated O
that O
BRCA1 O
is O
associated O
with O
a O
SWI O
/ O
SNF O
- O
related O
complex O
. O

We O
show O
that O
BRCA1 O
can O
directly O
interact O
with O
the O
BRG1 O
subunit O
of O
the O
SWI O
/ O
SNF O
complex O
. O

Moreover O
, O
p53 O
- O
mediated O
stimulation O
of O
transcription O
by O
BRCA1 O
was O
completely O
abrogated O
by O
either O
a O
dominant O
- O
negative O
mutant O
of O
BRG1 O
or O
the O
cancer B
- O
causing O
deletion O
in O
exon O
11 O
of O
BRCA1 O
. O

These O
findings O
reveal O
a O
direct O
function O
for O
BRCA1 O
in O
transcriptional O
control O
through O
modulation O
of O
chromatin O
structure O
. O
. O

Asef O
, O
a O
link O
between O
the O
tumor B
suppressor O
APC O
and O
G O
- O
protein O
signaling O
. O

The O
adenomatous B
polyposis I
coli I
gene O
( O
APC O
) O
is O
mutated O
in O
familial B
adenomatous I
polyposis I
and O
in O
sporadic O
colorectal B
tumors I
. O

Here O
the O
APC B
gene O
product O
is O
shown O
to O
bind O
through O
its O
armadillo O
repeat O
domain O
to O
a O
Rac O
- O
specific O
guanine O
nucleotide O
exchange O
factor O
( O
GEF O
) O
, O
termed O
Asef O
. O

Endogenous O
APC O
colocalized O
with O
Asef O
in O
mouse O
colon O
epithelial O
cells O
and O
neuronal O
cells O
. O

Furthermore O
, O
APC O
enhanced O
the O
GEF O
activity O
of O
Asef O
and O
stimulated O
Asef O
- O
mediated O
cell O
flattening O
, O
membrane O
ruffling O
, O
and O
lamellipodia O
formation O
in O
MDCK O
cells O
. O

These O
results O
suggest O
that O
the O
APC O
- O
Asef O
complex O
may O
regulate O
the O
actin O
cytoskeletal O
network O
, O
cell O
morphology O
and O
migration O
, O
and O
neuronal O
function O
. O
. O

Function O
of O
an O
axonal O
chemoattractant O
modulated O
by O
metalloprotease O
activity O
. O

The O
axonal O
chemoattractant O
netrin O
- O
1 O
guides O
spinal O
commissural O
axons O
by O
activating O
its O
receptor O
DCC O
( O
Deleted O
in O
Colorectal B
Cancer I
) O
. O

We O
have O
found O
that O
chemical O
inhibitors O
of O
metalloproteases O
potentiate O
netrin O
- O
mediated O
axon O
outgrowth O
in O
vitro O
. O

We O
have O
also O
found O
that O
DCC O
is O
a O
substrate O
for O
metalloprotease O
- O
dependent O
ectodomain O
shedding O
, O
and O
that O
the O
inhibitors O
block O
proteolytic O
processing O
of O
DCC O
and O
cause O
an O
increase O
in O
DCC O
protein O
levels O
on O
axons O
within O
spinal O
cord O
explants O
. O

Thus O
, O
potentiation O
of O
netrin O
activity O
by O
inhibitors O
may O
result O
from O
stabilization O
of O
DCC O
on O
the O
axons O
, O
and O
proteolytic O
activity O
may O
regulate O
axon O
migration O
by O
controlling O
the O
number O
of O
functional O
extracellular O
axon O
guidance O
receptors O
. O
. O

Myotonic B
dystrophy I
in O
transgenic O
mice O
expressing O
an O
expanded O
CUG O
repeat O
. O

Myotonic B
dystrophy I
( O
DM B
) O
, O
the O
most O
common O
form O
of O
muscular B
dystrophy I
in O
adult O
humans O
, O
results O
from O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
gene O
. O

The O
mutant O
DMPK O
messenger O
RNA O
( O
mRNA O
) O
contains O
an O
expanded O
CUG O
repeat O
and O
is O
retained O
in O
the O
nucleus O
. O

We O
have O
expressed O
an O
untranslated O
CUG O
repeat O
in O
an O
unrelated O
mRNA O
in O
transgenic O
mice O
. O

Mice O
that O
expressed O
expanded O
CUG O
repeats O
developed O
myotonia B
and O
myopathy B
, O
whereas O
mice O
expressing O
a O
nonexpanded O
repeat O
did O
not O
. O

Thus O
, O
transcripts O
with O
expanded O
CUG O
repeats O
are O
sufficient O
to O
generate O
a O
DM B
phenotype O
. O

This O
result O
supports O
a O
role O
for O
RNA O
gain O
of O
function O
in O
disease O
pathogenesis O
. O
. O

Genomic O
rearrangements O
of O
the O
APC B
tumor I
- O
suppressor O
gene O
in O
familial B
adenomatous I
polyposis I
. O

Germline O
mutations O
of O
the O
adenomatous B
polyposis I
coli I
( I
APC I
) I
tumor I
- O
suppressor O
gene O
result O
in O
the O
hereditary B
colorectal I
cancer I
syndrome I
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

Almost O
all O
APC B
mutations O
that O
have O
been O
identified O
are O
single O
- O
nucleotide O
alterations O
, O
small O
insertions O
, O
or O
small O
deletions O
that O
would O
truncate O
the O
protein O
product O
of O
the O
gene O
. O

No O
well O
- O
characterized O
intragenic O
rearrangement O
of O
APC O
has O
been O
described O
, O
and O
the O
prevalence O
of O
this O
type O
of O
mutation O
in O
FAP B
patients O
is O
not O
clear O
. O

We O
screened O
49 O
potential O
FAP B
families O
and O
identified O
26 O
different O
germline O
APC B
mutations O
in O
30 O
families O
. O

Four O
of O
these O
mutations O
were O
genomic O
rearrangements O
resulting O
from O
homologous O
and O
nonhomologous O
recombinations O
mediated O
by O
Alu O
elements O
. O

Two O
of O
these O
four O
rearrangements O
were O
complex O
, O
involving O
deletion O
and O
insertion O
of O
nucleotides O
. O

Of O
these O
four O
rearrangements O
, O
one O
resulted O
in O
the O
deletion O
of O
exons O
11 O
and O
12 O
and O
two O
others O
resulted O
in O
either O
complete O
or O
partial O
deletion O
of O
exon O
14 O
. O

The O
fourth O
rearrangement O
grossly O
altered O
the O
sequence O
within O
intron O
14 O
. O

Although O
this O
rearrangement O
did O
not O
affect O
any O
coding O
sequence O
of O
APC O
at O
the O
genomic O
DNA O
level O
, O
it O
caused O
inappropriate O
splicing O
of O
exon O
14 O
. O

These O
rearrangements O
were O
initially O
revealed O
by O
analyzing O
cDNAs O
and O
could O
not O
have O
been O
identified O
by O
using O
mutation O
detection O
methods O
that O
screened O
each O
exon O
individually O
. O

The O
identification O
of O
a O
rearrangement O
that O
did O
not O
alter O
any O
coding O
exons O
yet O
affected O
the O
splicing O
further O
underscores O
the O
importance O
of O
using O
cDNA O
for O
mutation O
analysis O
. O

The O
identification O
of O
four O
genomic O
rearrangements O
among O
30 O
mutations O
suggests O
that O
genomic O
rearrangements O
are O
frequent O
germline O
APC B
mutations O
. O
. O

Detection O
of O
a O
novel O
missense O
mutation O
and O
second O
recurrent O
mutation O
in O
the O
CACNA1A O
gene O
in O
individuals O
with O
EA B
- I
2 I
and O
FHM B
. O

Mutations O
in O
the O
brain O
specific O
P O
/ O
Q O
type O
Ca2 O
+ O
channel O
alpha1 O
subunit O
gene O
, O
CACNA1A O
, O
have O
been O
identified O
in O
three O
clinically O
distinct O
disorders O
, O
viz O
. O
episodic B
ataxia I
type I
2 I
( O
EA B
- I
2 I
) O
, O
familial B
hemiplegic I
migraine I
( O
FHM B
) O
and O
spinocerebellar B
ataxia I
6 I
( O
SCA6 B
) O
. O

For O
individuals O
with O
EA B
- I
2 I
, O
the O
mutations O
described O
thus O
far O
are O
presumed O
to O
result O
in O
a O
truncated O
protein O
product O
. O

Several O
different O
missense O
mutations O
have O
been O
identified O
in O
patients O
with O
FHM B
. O

At O
least O
two O
of O
these O
mutations O
have O
been O
identified O
on O
two O
different O
chromosome O
19p13 O
haplotypes O
and O
thus O
represent O
recurrent O
mutations O
. O

In O
the O
present O
study O
, O
we O
have O
screened O
several O
individuals O
for O
mutations O
in O
all O
47 O
exons O
in O
the O
CACNA1A O
gene O
by O
single O
- O
strand O
conformation O
analysis O
. O

We O
have O
characterised O
a O
novel O
missense O
mutation O
, O
G5260A O
, O
in O
exon O
32 O
in O
a O
family O
segregating O
for O
EA B
- I
2 I
. O

The O
consequence O
of O
this O
mutation O
is O
an O
amino O
acid O
substitution O
at O
a O
highly O
conserved O
position O
within O
the O
CACNA1A O
gene O
. O

This O
represents O
the O
first O
point O
mutation O
not O
resulting O
in O
a O
proposed O
truncated O
protein O
. O

Furthermore O
, O
this O
mutation O
has O
been O
detected O
in O
a O
family O
member O
with O
mild O
clinical O
signs O
including O
only O
migraine B
. O

Additionally O
, O
a O
second O
previously O
identified O
recurrent O
muta O
tion O
, O
C2272T O
, O
in O
exon O
16 O
has O
been O
discovered O
in O
a O
patient O
with O
FHM B
. O
. O

Analbuminemia B
in O
a O
neonate O
. O

A O
small O
- O
for O
- O
gestational O
- O
age O
infant O
, O
found O
to O
have O
analbuminemia B
in O
the O
neonatal O
period O
, O
is O
reported O
and O
the O
twelve O
cases O
recorded O
in O
the O
world O
literature O
are O
reviewed O
. O

Patients O
lacking O
this O
serum O
protein O
are O
essentially O
asymptomatic O
, O
apart O
from O
minimal O
ankle B
edema I
and O
ease B
of I
fatigue I
. O

Apparent O
compensatory O
mechanisms O
which O
come O
into O
play O
when O
serum O
albumin O
is O
low O
include O
prolonged O
half O
- O
life O
of O
albumin O
and O
transferrin O
, O
an O
increase O
in O
serum O
globulins O
, O
beta O
lipoprotein O
, O
and O
glycoproteins O
, O
arterial B
hypotension I
with O
reduced O
capillary O
hydrostatic O
pressure O
, O
and O
the O
ability O
to O
respond O
with O
rapid O
sodium O
and O
chloride O
diuresis O
in O
response O
to O
small O
volume O
changes O
. O

Examination O
of O
plasma O
amino O
acids O
, O
an O
investigation O
not O
previously O
reported O
, O
revealed O
an O
extremely O
low O
plasma O
tryptophan O
level O
, O
a O
finding O
which O
may O
be O
important O
in O
view O
of O
the O
role O
of O
tryptophan O
in O
albumin O
synthesis O
. O
. O

Histidinemia B
. O

Classical O
and O
atypical O
form O
in O
siblings O
. O

Two O
brothers O
, O
6 O
and O
13 O
years O
old O
, O
had O
histidinemia B
. O

On O
the O
basis O
of O
clinical O
and O
biochemical O
observations O
, O
the O
younger O
boy O
was O
considered O
to O
have O
a O
classical O
type O
of O
the O
disease O
, O
while O
the O
older O
boy O
had O
an O
atypical O
form O
characterized O
by O
partial O
impairment O
of O
the O
skin O
histidase O
activity O
and O
a O
moderately O
prolonged O
half O
- O
life O
of O
blood O
histidine O
. O

The O
mother O
is O
a O
heterozygous O
carrier O
, O
while O
the O
father O
and O
sister O
seem O
to O
be O
normal O
. O
. O

Carrier O
detection O
of O
pyruvate B
carboxylase I
deficiency I
in O
fibroblasts O
and O
lymphocytes O
. O

Pyruvate O
carboxylase O
( O
E O
. O
C O
. O
6 O
. O
4 O
. O
1 O
. O
1 O
) O
activity O
was O
determined O
in O
the O
circulating O
peripheral O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
from O
the O
family O
of O
a O
patient O
with O
hepatic O
, O
cerebral O
, O
renal O
cortical O
, O
leukocyte O
, O
and O
fibroblast O
pyruvate B
carboxylase I
deficiency I
( O
PC B
Portland I
deficiency I
) O
. O

Lymphocyte O
activities O
were O
mother O
, O
33 O
- O
- O
39 O
% O
; O
father O
, O
11 O
- O
- O
29 O
% O
; O
brother O
, O
82 O
- O
- O
103 O
% O
; O
and O
sister O
, O
38 O
- O
- O
48 O
% O
of O
the O
lowest O
normal O
. O

Fibroblasts O
from O
the O
patients O
mother O
and O
father O
had O
42 O
and O
34 O
% O
, O
respectively O
, O
of O
the O
activity O
of O
the O
lowest O
normal O
. O

These O
data O
demonstrate O
that O
the O
disease O
is O
inherited O
in O
an O
autosomal O
recessive O
manner O
and O
that O
lymphocytes O
and O
fibroblasts O
can O
be O
used O
to O
detect O
carriers O
. O

Neither O
pyruvate O
carboxylase O
nor O
mitochondrial O
PEPCK O
activity O
in O
lymphocytes O
was O
increased O
by O
a O
21 O
- O
hr O
fast O
. O

Glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variants O
from O
Italian O
subjects O
associated O
with O
severe B
neonatal I
jaundice I
. O

Screening O
for O
the O
G6PD B
deficiency I
was O
carried O
out O
at O
the O
Maternity O
Division O
of O
the O
Galliera O
Hospital O
in O
Genoa O
, O
Italy O
. O

Two O
groups O
of O
subjects O
with O
hyperbilirubinaemia B
of O
non O
- O
immunological O
origin O
were O
examined O
( O
a O
) O
302 O
newborn O
babies O
of O
Sardinian O
extraction O
( O
on O
cord O
blood O
) O
and O
( O
b O
) O
201 O
newborn O
babies O
of O
south O
Italian O
ancestry O
( O
on O
peripheral O
blood O
) O
. O

Among O
503 O
subjects O
, O
43 O
showed O
an O
enzyme O
deficiency O
; O
in O
39 O
the O
defect O
was O
of O
the O
Mediterranean O
type O
. O

In O
one O
case O
, O
previously O
described O
, O
the O
enzyme O
was O
of O
the O
A O
- O
type O
. O

In O
the O
remaining O
cases O
three O
different O
variants O
were O
identified O
. O

In O
the O
present O
work O
these O
three O
cases O
, O
each O
with O
severe B
neonatal I
jaundice I
, O
are O
reported O
. O

Their O
parents O
originated O
from O
Calabria O
, O
from O
Sardinia O
and O
from O
Sicily O
. O

The O
abnormal O
enzymes O
are O
respectively O
designated O
as O
GdDcbrousse O
- O
like O
, O
GdGallura O
and O
GdAgrigento O
. O
. O

Cytogenetic O
investigations O
in O
families O
with O
ataxia B
- I
telangiectasia I
. O

Chromosomal O
studies O
were O
performed O
on O
peripheral O
blood O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
from O
five O
Israeli O
- O
Moroccan O
families O
with O
ataxia B
- I
telangiectasia I
. O

A O
total O
of O
24 O
individuals O
, O
including O
seven O
propositi O
, O
was O
investigated O
. O

Among O
the O
probands O
, O
significantly O
elevated O
rates O
of O
chromosome O
damage O
were O
observed O
in O
both O
blood O
and O
skin O
. O

Skin O
fibroblasts O
of O
affected O
individuals O
showed O
several O
orders O
of O
magnitude O
more O
chromosome O
breakage O
than O
lymphocytes O
. O

Increased O
rates O
of O
chromosome O
damage O
were O
also O
observed O
in O
the O
fibroblasts O
of O
some O
phenotypically O
normal O
family O
members O
( O
obligate O
heterozygotes O
and O
sibs O
) O
when O
compared O
to O
normal O
controls O
. O

An O
apparent O
abnormal O
clone O
of O
cells O
, O
possessing O
a O
large O
acrocentric O
marker O
chromosome O
( O
14q O
+ O
) O
, O
was O
observed O
in O
varying O
proportions O
among O
cells O
of O
all O
the O
propositi O
( O
2 O
- O
5 O
% O
of O
lymphocytes O
; O
1 O
- O
9 O
% O
of O
fibroblasts O
) O
. O
. O

Prenatal O
diagnosis O
of O
Wolman B
disease I
. O

Two O
pregnancies O
at O
risk O
for O
Wolman B
disease I
were O
monitored O
by O
assay O
and O
electrophoresis O
of O
acid O
lipase O
in O
cultured O
amniotic O
- O
fluid O
cells O
. O

Cells O
from O
patient O
1 O
had O
5 O
% O
of O
control O
levels O
of O
acid O
lipase O
, O
using O
14C O
- O
triolein O
as O
substrate O
; O
however O
, O
when O
artificial O
substrates O
( O
esters O
of O
4 O
- O
methylumbelliferone O
and O
p O
- O
nitrophenol O
) O
were O
used O
to O
measure O
acid O
lipase O
, O
these O
cells O
had O
30 O
% O
of O
control O
levels O
. O

Electrophoresis O
of O
cell O
extracts O
revealed O
the O
absence O
of O
the O
A O
form O
of O
acid O
lipase O
, O
consistent O
with O
the O
diagnosis O
of O
Wolman B
disease I
. O

Analysis O
of O
fetal O
tissues O
following O
prostaglandin O
termination O
of O
this O
pregnancy O
confirmed O
the O
diagnosis O
. O

Assay O
of O
fetal O
- O
skin O
fibroblasts O
with O
14C O
- O
triolein O
, O
as O
well O
as O
with O
artificial O
substrates O
, O
showed O
marked O
deficiency O
of O
acid O
lipase O
activity O
. O

Electrophoresis O
of O
fetal O
- O
tissue O
extracts O
also O
demonstrated O
the O
absence O
of O
the O
A O
form O
of O
acid O
lipase O
. O

Amniotic O
- O
fluid O
cells O
from O
patient O
2 O
showed O
normal O
levels O
of O
acid O
lipase O
with O
all O
substrates O
tested O
; O
the O
electrophoretic O
pattern O
of O
acid O
lipase O
was O
normal O
. O

The O
results O
suggest O
that O
the O
prenatal O
diagnosis O
of O
Wolman B
disease I
be O
made O
using O
the O
radioassay O
of O
acid O
lipase O
and O
/ O
or O
electrophoresis O
. O
. O

Malignant B
neoplasms I
in O
the O
families O
of O
patients O
with O
ataxia B
- I
telangiectasia I
. O

Ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
is O
an O
autosomal B
recessive I
syndrome I
associated O
with O
a O
greatly O
increased O
incidence O
of O
malignant B
neoplasms I
in O
homozygous O
affected O
individuals O
. O

Heterozygotes O
for O
the O
gene O
for O
A B
- I
T I
are O
thought O
to O
comprise O
about O
1 O
% O
of O
the O
general O
population O
and O
, O
therefore O
, O
it O
is O
important O
to O
know O
whether O
this O
gene O
also O
predisposes O
the O
heterozygous O
carrier O
to O
cancers B
. O

Heterozygous O
carriers O
of O
this O
gene O
are O
common O
among O
the O
close O
relatives O
of O
patients O
with O
A B
- I
T I
, O
although O
individual O
carriers O
cannot O
be O
identified O
by O
any O
clinical O
criterion O
or O
laboratory O
test O
. O

For O
this O
reason O
, O
we O
compared O
the O
incidence O
of O
death O
from O
malignant B
neoplasms I
in O
2 O
families O
of O
patients O
with O
A B
- I
T I
to O
that O
expected O
in O
a O
random O
sample O
of O
the O
general O
population O
. O

There O
were O
59 O
deaths O
from O
malignant B
neoplasms I
in O
relatives O
dying O
before O
age O
75 O
, O
compared O
to O
42 O
. O

6 O
expected O
( O
p O
less O
than O
0 O
. O
02 O
) O
. O

For O
A B
- I
T I
heterozygotes O
younger O
than O
age O
45 O
, O
the O
risk O
of O
dying O
from O
a O
malignant B
neoplasm I
was O
estimated O
to O
be O
greater O
than O
5 O
times O
the O
risk O
for O
the O
general O
population O
. O

A B
- I
T I
heterozygotes O
may O
comprise O
more O
than O
5 O
% O
of O
all O
persons O
dying O
from O
a O
cancer B
before O
age O
45 O
. O

The O
incidence O
of O
ovarian B
, I
gastric I
, I
and I
biliary I
system I
carcinomas I
and O
of O
leukemia B
and O
lymphoma B
was O
increased O
in O
these O
A B
- I
T I
families O
. O

Other O
neoplasms B
that O
may O
be O
associated O
with O
this O
gene O
in O
heterozygotes O
include O
pancreatic B
, I
basal I
cell I
, I
colonic I
, I
breast I
, I
and I
cervical I
carcinomas I
. O

Striking O
prevalence O
of O
ankylosing B
spondylitis I
in O
" O
healthy O
" O
w27 O
positive O
males O
and O
females O
. O

Ankylosing B
spondylitis I
is O
diagnosed O
once O
or O
twice O
in O
each O
1000 O
males O
and O
one O
tenth O
as O
frequently O
in O
females O
, O
but O
the O
true O
prevalence O
is O
unknown O
. O

Indentification O
of O
genetic O
marker O
, O
HL O
- O
A O
W27 O
, O
for O
susceptible O
persons O
has O
provided O
a O
tool O
facilitating O
epidemiologic O
studies O
and O
allowing O
identification O
of O
" O
control O
" O
populations O
without O
the O
marker O
. O

Evaluation O
by O
postal O
questionnaires O
, O
and O
pelvic O
radiography O
of O
78 O
HL O
- O
A O
27W O
- O
positive O
blood O
donors O
selected O
from O
a O
group O
of O
apparently O
healthy O
subjects O
revealed O
14 O
who O
satisfied O
the O
criteria O
for O
definite O
ankylosing B
spondylitis I
. O

The O
prevalence O
was O
similar O
in O
both O
sexes O
. O

One O
hundred O
and O
twenty O
- O
six O
W27 O
- O
negative O
controls O
matched O
for O
race O
, O
sex O
, O
and O
age O
failed O
to O
yield O
a O
single O
case O
. O

For O
a O
person O
of O
either O
sex O
with O
HL O
- O
A O
W27 O
, O
there O
appears O
to O
be O
about O
a O
20 O
per O
cent O
chance O
that O
ankylosing B
spondylitis I
will O
develop O
, O
suggesting O
a O
prevalence O
of O
10 O
to O
15 O
per O
thousand O
. O

Hitherto O
accepted O
figures O
may O
underestimate O
the O
frequency O
by O
a O
factor O
of O
10 O
to O
20 O
. O
. O

Analbuminemia B
in O
an O
American O
Indian O
girl O
. O

Analbuminemia B
was O
fortuitously O
detected O
in O
a O
nonedematous O
12 O
- O
year O
- O
old O
American O
Indian O
girl O
with O
atopic B
dermatitis I
, O
mild O
bronchial B
asthma I
, O
a O
mild O
seizure B
disorder I
, O
and O
hyperlipoproteinemia B
with O
a O
corneal B
arcus I
. O

Immunologic O
methods O
revealed O
trace O
amounts O
( O
17 O
mg O
/ O
100 O
ml O
) O
of O
apparently O
normal O
serum O
albumin O
. O

The O
patients O
parents O
were O
remotely O
related O
. O

The O
pedigree O
and O
clinical O
findings O
were O
compatible O
with O
autosomal O
recessive O
transmission O
of O
analbuminemia B
. O

Heterozygotes O
had O
subnormal O
levels O
of O
serum O
albumin O
. O

The O
Gc O
- O
locus O
is O
closely O
linked O
to O
the O
structural O
albumin O
locus O
. O

Gc O
- O
protein O
levels O
were O
normal O
in O
the O
patient O
and O
together O
with O
normal O
chromosomal O
banding O
studies O
make O
it O
unlikely O
that O
a O
chromosomal O
deletion O
caused O
analbuminemia B
. O

Gc O
- O
types O
in O
the O
family O
were O
compatible O
with O
, O
but O
did O
not O
prove O
, O
linkage O
of O
analbuminemia B
to O
the O
Gc O
- O
locus O
. O

These O
findings O
suggest O
a O
" O
thalassemia B
" O
- O
like O
mutation O
for O
this O
disorder O
. O
. O

Deletion O
of O
the O
KIT O
and O
PDGFRA O
genes O
in O
a O
patient O
with O
piebaldism B
. O

We O
have O
previously O
shown O
that O
human O
piebaldism B
results O
from O
mutations O
of O
the O
KIT O
gene O
, O
which O
encodes O
the O
receptor O
for O
the O
mast O
/ O
stem O
cell O
growth O
factor O
and O
is O
located O
in O
chromosome O
segment O
4q12 O
. O

Using O
DNA O
of O
a O
patient O
with O
piebaldism B
, O
mental B
retardation I
, O
and O
multiple B
congenital I
anomalies I
associated O
with O
a O
46 O
, O
XY O
, O
del O
( O
4 O
) O
( O
q12q21 O
. O
1 O
) O
karyotype O
, O
we O
carried O
out O
quantitative O
Southern O
blot O
hybridization O
analyses O
of O
the O
KIT O
gene O
and O
the O
adjacent O
PDGFRA O
( O
platelet O
- O
derived O
growth O
factor O
receptor O
alpha O
subunit O
) O
genes O
. O

The O
patient O
was O
hemizygous O
for O
both O
the O
KIT O
and O
PDGFRA O
genes O
, O
indicating O
that O
both O
of O
these O
genes O
are O
included O
within O
the O
deleted O
region O
. O

Therefore O
, O
deletion O
of O
the O
KIT O
and O
PDGFRA O
genes O
may O
account O
for O
the O
piebald B
phenotype O
in O
this O
patient O
. O

A O
germ O
line O
mutation O
within O
the O
coding O
sequence O
for O
the O
putative O
5 O
- O
phosphoribosyl O
- O
1 O
- O
pyrophosphate O
binding O
site O
of O
hypoxanthine O
- O
guanine O
phosphoribosyltransferase O
( O
HPRT O
) O
in O
a O
Lesch B
- I
Nyhan I
patient O
: O
missense O
mutations O
within O
a O
functionally O
important O
region O
probably O
cause O
disease O
. O

Lesch B
- I
Nyhan I
syndrome I
caused O
by O
a O
complete B
deficiency I
of I
hypoxanthine I
guanine I
phosphoribosyltransferase I
( O
HPRT O
) O
is O
the O
result O
of O
a O
heterogeneous O
group O
of O
germ O
line O
mutations O
. O

Identification O
of O
each O
mutant O
gene O
provides O
valuable O
information O
as O
to O
the O
type O
of O
mutation O
that O
occurs O
spontaneously O
. O

We O
report O
here O
a O
newly O
identified O
HPRT O
mutation O
in O
a O
Japanese O
patient O
with O
Lesch B
- I
Nyhan I
syndrome I
. O

This O
gene O
, O
designated O
HPRT O
Tokyo O
, O
had O
a O
single O
nucleotide O
change O
from O
G O
to O
A O
, O
as O
identified O
by O
sequencing O
cDNA O
amplified O
by O
the O
polymerase O
chain O
reaction O
. O

Allele O
specific O
oligonucleotide O
hybridization O
analysis O
using O
amplified O
genomic O
DNA O
showed O
that O
the O
mutant O
gene O
was O
transmitted O
from O
the O
maternal O
germ O
line O
. O

This O
mutation O
would O
lead O
to O
an O
amino O
acid O
substitution O
of O
Asp O
for O
Gly O
at O
the O
amino O
acid O
position O
140 O
located O
within O
the O
putative O
5 O
- O
phosphoribosyl O
- O
1 O
- O
pyrophosphate O
( O
PRPP O
) O
binding O
region O
. O

Missense O
mutations O
in O
human O
HPRT B
deficient I
patients O
thus O
far O
reported O
tend O
to O
accumulate O
in O
this O
functionally O
active O
region O
. O

However O
, O
a O
comparison O
of O
the O
data O
suggested O
that O
both O
missense O
and O
synonymous O
mutations O
can O
occur O
at O
any O
coding O
sequence O
of O
the O
human O
germ O
line O
HPRT O
gene O
, O
but O
that O
a O
limited O
percentage O
of O
all O
the O
missense O
mutations O
cause O
disease O
. O

The O
probability O
that O
a O
mutation O
will O
cause O
disease O
tends O
to O
be O
higher O
when O
the O
missense O
mutation O
is O
within O
a O
functionally O
important O
sequence O
. O
. O

Characterisation O
of O
a O
new O
rare O
fragile O
site O
easily O
confused O
with O
the O
fragile B
X I
. O

A O
new O
fragile O
site O
( O
FRAXE O
) O
in O
Xq28 O
is O
described O
. O

It O
appears O
to O
be O
a O
typical O
folate O
sensitive O
fragile O
site O
. O

The O
fragile O
site O
is O
not O
associated O
with O
mental B
retardation I
, O
it O
does O
not O
give O
abnormal O
results O
when O
subjected O
to O
Southern O
analysis O
with O
probe O
pfxa3 O
which O
detects O
the O
unstable O
DNA O
sequence O
characteristic O
of O
fragile B
X I
syndrome I
. O

In O
situ O
hybridization O
mapping O
locates O
the O
fragile O
site O
between O
150 O
kb O
and O
600 O
kb O
distal O
to O
FRAXA O
. O

The O
distinction O
between O
the O
two O
fragile O
sites O
is O
important O
clinically O
since O
cytogenetic O
detection O
of O
FRAXE O
, O
without O
molecular O
analysis O
, O
could O
result O
in O
misdiagnosis O
of O
fragile B
X I
syndrome I
. O
. O

The O
Norrie B
disease I
gene O
maps O
to O
a O
150 O
kb O
region O
on O
chromosome O
Xp11 O
. O
3 O
. O

Norrie B
disease I
is O
a O
human O
X B
- I
linked I
recessive I
disorder I
of O
unknown O
etiology O
characterized O
by O
congenital B
blindness I
, O
sensory B
neural I
deafness I
and O
mental B
retardation I
. O

This O
disease O
gene O
was O
previously O
linked O
to O
the O
DXS7 O
( O
L1 O
. O
28 O
) O
locus O
and O
the O
MAO O
genes O
in O
band O
Xp11 O
. O

3 O
3 O
. O

We O
report O
here O
fine O
physical O
mapping O
of O
the O
obligate O
region O
containing O
the O
Norrie B
disease I
gene O
( O
NDP O
) O
defined O
by O
a O
recombination O
and O
by O
the O
smallest O
submicroscopic O
chromosomal O
deletion O
associated O
with O
Norrie B
disease I
identified O
to O
date O
. O

Analysis O
, O
using O
in O
addition O
two O
overlapping O
YAC O
clones O
from O
this O
region O
, O
allowed O
orientation O
of O
the O
MAOA O
and O
MAOB O
genes O
in O
a O
5 O
- O
3 O
- O
3 O
- O
5 O
configuration O
. O

A O
recombination O
event O
between O
a O
( O
GT O
) O
n O
polymorphism O
in O
intron O
2 O
of O
the O
MAOB O
gene O
and O
the O
NDP O
locus O
, O
in O
a O
family O
previously O
reported O
to O
have O
a O
recombination O
between O
DXS7 O
and O
NDP O
, O
delineates O
a O
flanking O
marker O
telomeric O
to O
this O
disease O
gene O
. O

An O
anonymous O
DNA O
probe O
, O
dc12 O
, O
present O
in O
one O
of O
the O
YACs O
and O
in O
a O
patient O
with O
a O
submicroscopic O
deletion O
which O
includes O
MAOA O
and O
MAOB O
but O
not O
L1 O
. O

28 O
, O
serves O
as O
a O
flanking O
marker O
centromeric O
to O
the O
disease O
gene O
. O

An O
Alu O
- O
PCR O
fragment O
from O
the O
right O
arm O
of O
the O
MAO O
YAC O
( O
YMAO O
. O
AluR O
) O
is O
not O
deleted O
in O
this O
patient O
and O
also O
delineates O
the O
centromeric O
extent O
of O
the O
obligate O
disease O
region O
. O

The O
apparent O
order O
of O
these O
loci O
is O
telomere O
. O

DXS7 O
- O
MAOA O
- O
MAOB O
- O
NDP O
- O
dc12 O
- O
YMAO O
DXS7 O
- O
MAOA O
- O
MAOB O
- O
NDP O
- O
dc12 O
- O
YMAO O
. O

AluR O
. O
centromere O
. O

Together O
these O
data O
define O
the O
obligate O
region O
containing O
the O
NDP O
gene O
to O
a O
chromosomal O
segment O
less O
than O
150 O
kb O
. O

Molecular O
basis O
of O
phenylketonuria B
and O
related O
hyperphenylalaninemias B
: O
mutations O
and O
polymorphisms O
in O
the O
human O
phenylalanine O
hydroxylase O
gene O
. O

Mutations O
in O
the O
human O
phenylalanine O
hydroxylase O
gene O
producing O
phenylketonuria B
or O
hyperphenylalaninemia B
have O
now O
been O
identified O
in O
many O
patients O
from O
various O
ethnic O
groups O
. O

These O
mutations O
all O
exhibit O
a O
high O
degree O
of O
association O
with O
specific O
restriction O
fragment O
- O
length O
polymorphism O
haplotypes O
at O
the O
PAH O
locus O
. O

About O
50 O
of O
these O
mutations O
are O
single O
- O
base O
substitutions O
, O
including O
six O
nonsense O
mutations O
and O
eight O
splicing O
mutations O
, O
with O
the O
remainder O
being O
missense O
mutations O
. O

One O
splicing O
mutation O
results O
in O
a O
3 O
amino O
acid O
in O
- O
frame O
insertion O
. O

Two O
or O
3 O
large O
deletions O
, O
2 O
single O
codon O
deletions O
, O
and O
2 O
single O
base O
deletions O
have O
been O
found O
. O

Twelve O
of O
the O
missense O
mutations O
apparently O
result O
from O
the O
methylation O
and O
subsequent O
deamination O
of O
highly O
mutagenic O
CpG O
dinucleotides O
. O

Recurrent O
mutation O
has O
been O
observed O
at O
several O
of O
these O
sites O
, O
producing O
associations O
with O
different O
haplotypes O
in O
different O
populations O
. O

About O
half O
of O
all O
missense O
mutations O
have O
been O
examined O
by O
in O
vitro O
expression O
analysis O
, O
and O
a O
significant O
correlation O
has O
been O
observed O
between O
residual O
PAH O
activity O
and O
disease O
phenotype O
. O

Since O
continuing O
advances O
in O
molecular O
methodologies O
have O
dramatically O
accelerated O
the O
rate O
in O
which O
new O
mutations O
are O
being O
identified O
and O
characterized O
, O
this O
register O
of O
mutations O
will O
be O
updated O
periodically O
. O
. O

A O
glycine250 O
- O
- O
> O
aspartate O
substitution O
in O
the O
alpha O
- O
subunit O
of O
hexosaminidase O
A O
causes O
juvenile O
- O
onset O
Tay B
- I
Sachs I
disease I
in O
a O
Lebanese O
- O
Canadian O
family O
. O

The O
mutation O
causing O
juvenile O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
in O
two O
sibs O
of O
Lebanese O
- O
Maronite O
origin O
is O
described O
. O

An O
mRNA O
- O
containing O
extract O
of O
cultured O
fibroblasts O
obtained O
from O
one O
of O
the O
probands O
was O
used O
as O
a O
template O
to O
amplify O
the O
coding O
sequence O
of O
the O
hexosaminidase O
A O
( O
Hex O
A O
) O
alpha O
- O
subunit O
. O

Sequencing O
of O
amplified O
cDNA O
fragments O
revealed O
a O
single O
alteration O
, O
guanine O
to O
adenine O
at O
nt O
749 O
creating O
a O
G250D O
mutation O
. O

The O
mutation O
introduces O
a O
new O
recognition O
site O
for O
the O
restriction O
enzyme O
Eco O
RV O
, O
permitting O
identification O
of O
heterozygotes O
for O
this O
allele O
following O
PCR O
amplification O
and O
Eco O
RV O
digestion O
of O
exon O
7 O
sequences O
from O
genomic O
DNA O
templates O
. O

In O
order O
to O
test O
the O
effect O
of O
this O
substitution O
, O
an O
in O
vitro O
mutagenized O
cDNA O
construct O
was O
introduced O
into O
a O
mammalian O
expression O
vector O
and O
transfected O
into O
monkey O
Cos O
- O
1 O
cells O
separately O
or O
along O
with O
a O
beta O
- O
cDNA O
expression O
vector O
. O

When O
the O
mutant O
alpha O
- O
cDNA O
was O
the O
only O
gene O
introduced O
into O
COS O
cells O
no O
enzymatic O
activity O
above O
endogenous O
COS O
cell O
activity O
was O
detected O
. O

Cotransfection O
of O
normal O
alpha O
- O
cDNA O
and O
beta O
- O
cDNA O
followed O
by O
immunoprecipitation O
of O
human O
Hex O
A O
resulted O
in O
20 O
- O
fold O
increase O
in O
the O
ratio O
between O
positive O
and O
negative O
( O
mock O
transfection O
) O
control O
values O
. O

This O
allowed O
the O
detection O
of O
some O
residual O
activity O
( O
12 O
% O
of O
the O
positive O
control O
) O
when O
the O
mutant O
alpha O
- O
cDNA O
replaced O
its O
wild O
- O
type O
counterpart O
. O

The O
predicted O
protein O
environment O
in O
which O
the O
mutation O
occurs O
is O
compared O
to O
that O
of O
the O
adult O
- O
onset O
Tay B
- I
Sachs I
disease I
mutation O
caused O
by O
a O
Gly269 O
- O
- O
> O
Ser O
substitution O
in O
exon O
7 O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Novel O
Tay B
- I
Sachs I
disease I
mutations O
from O
China O
. O

We O
describe O
three O
HEXA O
mutations O
associated O
with O
infantile O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
in O
three O
unrelated O
nonconsanguineous O
Chinese O
families O
. O

Novel O
mutations O
were O
found O
in O
two O
of O
these O
families O
. O

The O
third O
is O
a O
previously O
reported O
mutation O
( O
G O
- O
- O
> O
A O
transition O
at O
nt O
1444 O
) O
( O
Nakano O
et O
al O
. O
, O
1988 O
) O
. O

Direct O
sequencing O
of O
PCR O
products O
identified O
a O
novel O
insertion O
of O
an O
A O
after O
nt O
547 O
in O
family O
1 O
. O

This O
change O
generates O
an O
early O
termination O
codon O
6 O
bp O
downstream O
from O
the O
insertion O
site O
. O

Allele O
- O
specific O
oligonucleotide O
hybridization O
confirmed O
homozygosity O
in O
the O
proband O
. O

Single O
strand O
conformational O
polymorphism O
analysis O
and O
direct O
sequencing O
of O
amplified O
exon O
13 O
revealed O
a O
T O
- O
- O
> O
C O
transition O
at O
nt O
1453 O
with O
the O
corresponding O
amino O
acid O
substitution O
W485R O
in O
the O
second O
family O
. O

This O
mutation O
creates O
an O
Fnu4HI O
restriction O
site O
. O

The O
proband O
is O
homozygous O
for O
this O
allele O
. O

When O
the O
site O
- O
specific O
mutagenized O
alpha O
cDNA O
carrying O
the O
T O
- O
- O
> O
C O
transition O
at O
nt O
1453 O
was O
expressed O
in O
COS O
1 O
cells O
hexosaminidase O
S O
activity O
was O
not O
detectable O
above O
background O
. O

A O
G O
- O
- O
> O
A O
transition O
at O
nt O
1444 O
( O
exon O
13 O
) O
corresponding O
to O
the O
E482K O
substitution O
was O
found O
in O
the O
third O
family O
. O

This O
mutation O
occurs O
at O
a O
CpG O
dinucleotide O
. O

It O
has O
been O
reported O
in O
an O
Italian O
TSD B
proband O
and O
causes O
defective O
intracellular O
transport O
of O
the O
alpha O
- O
subunit O
from O
the O
rough O
endoplasmic O
reticulum O
to O
the O
Golgi O
apparatus O
. O

Two O
missense O
mutations O
causing O
mild O
hyperphenylalaninemia B
associated O
with O
DNA O
haplotype O
12 O
. O

The O
genetic B
defects I
responsible O
for O
most O
phenylketonuria B
( O
PKU B
) O
and O
hyperphenylalaninemia B
( O
HPA B
) O
cases O
are O
located O
in O
the O
phenylalanine O
hydroxylase O
( O
PAH O
) O
gene O
. O

Approximately O
50 O
- O
60 O
mutations O
have O
been O
reported O
in O
Caucasians O
and O
are O
reflected O
in O
a O
wide O
range O
of O
clinical O
severities O
. O

Most O
mutations O
are O
linked O
to O
specific O
haplotypes O
, O
as O
defined O
by O
eight O
polymorphic O
restriction O
sites O
in O
the O
PAH O
gene O
. O

We O
hypothesized O
that O
there O
is O
at O
least O
one O
mild O
mutation O
linked O
to O
haplotype O
12 O
in O
the O
Swedish O
PKU B
/ O
HPA B
population O
, O
since O
7 O
of O
8 O
patients O
carrying O
haplotype O
12 O
had O
mild O
HPA B
. O

Sequence O
analysis O
revealed O
a O
C O
- O
to O
- O
G O
transversion O
at O
the O
second O
base O
of O
codon O
322 O
, O
resulting O
in O
a O
substitution O
of O
glycine O
for O
alanine O
, O
in O
four O
mutant O
haplotype O
12 O
genes O
, O
and O
a O
G O
- O
to O
- O
A O
transition O
at O
the O
second O
base O
of O
codon O
408 O
, O
resulting O
in O
a O
substitution O
of O
glutamine O
for O
arginine O
, O
in O
another O
three O
mutant O
haplotype O
12 O
genes O
. O

These O
mutations O
segregated O
with O
mutant O
haplotype O
12 O
alleles O
in O
nuclear O
families O
but O
were O
not O
present O
on O
normal O
or O
other O
mutant O
alleles O
. O

Both O
mutations O
were O
tested O
in O
a O
eukaryotic O
expression O
system O
in O
which O
enzyme O
activities O
of O
different O
mutant O
PAH O
enzymes O
reflect O
the O
relative O
severities O
of O
the O
mutations O
, O
although O
these O
in O
vitro O
activities O
cannot O
be O
translated O
directly O
into O
in O
vivo O
hepatic O
activities O
. O

The O
A322G O
mutant O
PAH O
had O
about O
75 O
% O
and O
the O
R408Q O
mutant O
PAH O
about O
55 O
% O
of O
the O
wild O
- O
type O
PAH O
enzyme O
activity O
. O

These O
in O
vitro O
activities O
are O
the O
highest O
reported O
for O
mutant O
PAH O
enzymes O
produced O
in O
the O
same O
expression O
system O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

In O
vitro O
and O
in O
vivo O
correlations O
for O
I65T O
and O
M1V O
mutations O
at O
the O
phenylalanine O
hydroxylase O
locus O
. O

Mutations O
at O
the O
phenylalanine O
hydroxylase O
( O
PAH O
) O
locus O
are O
the O
major O
cause O
of O
hyperphenylalaninemia B
. O

We O
have O
previously O
described O
four O
mutations O
( O
M1V O
, O
IVS12nt1 O
, O
R408W O
, O
and O
S349P O
) O
at O
the O
PAH O
locus O
in O
French O
Canadians O
with O
ancestry O
in O
eastern O
Quebec O
. O

Here O
we O
report O
( O
1 O
) O
identification O
of O
another O
mutation O
, O
on O
a O
haplotype O
9 O
chromosome O
, O
which O
converts O
codon O
65 O
from O
isoleucine O
( O
ATT O
) O
to O
threonine O
( O
ACT O
) O
, O
( O
2 O
) O
expression O
analysis O
of O
the O
I65T O
mutation O
in O
COS O
cells O
demonstrating O
75 O
% O
loss O
of O
both O
immunoreactive O
protein O
and O
enzyme O
activity O
, O
and O
( O
3 O
) O
expression O
analysis O
of O
the O
most O
prevalent O
PKU B
allele O
( O
M1V O
) O
in O
eastern O
Quebec O
, O
showing O
nondetectable O
levels O
of O
PAH O
protein O
and O
activity O
, O
a O
finding O
compatible O
with O
a O
mutation O
in O
the O
translation O
initiation O
codon O
. O

Homozygosity O
for O
M1V O
and O
codominant O
inheritance O
of O
I65T O
/ O
R408W O
were O
both O
associated O
with O
classical B
phenylketonuria I
. O
. O

Molecular O
basis O
of O
hexosaminidase B
A I
deficiency I
and O
pseudodeficiency O
in O
the O
Berks O
County O
Pennsylvania O
Dutch O
. O

Following O
the O
birth O
of O
two O
infants O
with O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
, O
a O
non O
- O
Jewish O
, O
Pennsylvania O
Dutch O
kindred O
was O
screened O
for O
TSD B
carriers O
using O
the O
biochemical O
assay O
. O

A O
high O
frequency O
of O
individuals O
who O
appeared O
to O
be O
TSD B
heterozygotes O
was O
detected O
( O
Kelly O
et O
al O
. O
, O
1975 O
) O
. O

Clinical O
and O
biochemical O
evidence O
suggested O
that O
the O
increased O
carrier O
frequency O
was O
due O
to O
at O
least O
two O
altered O
alleles O
for O
the O
hexosaminidase O
A O
alpha O
- O
subunit O
. O

We O
now O
report O
two O
mutant O
alleles O
in O
this O
Pennsylvania O
Dutch O
kindred O
, O
and O
one O
polymorphism O
. O

One O
allele O
, O
reported O
originally O
in O
a O
French O
TSD B
patient O
( O
Akli O
et O
al O
. O
, O
1991 O
) O
, O
is O
a O
GT O
- O
- O
> O
AT O
transition O
at O
the O
donor O
splice O
- O
site O
of O
intron O
9 O
. O

The O
second O
, O
a O
C O
- O
- O
> O
T O
transition O
at O
nucleotide O
739 O
( O
Arg247Trp O
) O
, O
has O
been O
shown O
by O
Triggs O
- O
Raine O
et O
al O
. O

( O
1992 O
) O
to O
be O
a O
clinically O
benign O
" O
pseudodeficient O
" O
allele O
associated O
with O
reduced O
enzyme O
activity O
against O
artificial O
substrate O
. O

Finally O
, O
a O
polymorphism O
[ O
G O
- O
- O
> O
A O
( O
759 O
) O
] O
, O
which O
leaves O
valine O
at O
codon O
253 O
unchanged O
, O
is O
described O
. O

A O
mutation O
common O
in O
non O
- O
Jewish O
Tay B
- I
Sachs I
disease I
: O
frequency O
and O
RNA O
studies O
. O

Tay B
- I
Sachs I
disease I
( O
TSD B
) O
is O
an O
autosomal B
recessive I
genetic I
disorder I
resulting O
from O
mutation O
of O
the O
HEXA O
gene O
encoding O
the O
alpha O
- O
subunit O
of O
the O
lysosomal O
enzyme O
, O
beta O
- O
N O
- O
acetylhexosaminidase O
A O
( O
Hex O
A O
) O
. O

We O
have O
discovered O
that O
a O
Tay B
- I
Sachs I
mutation O
, O
IVS O
- O
9 O
+ O
1 O
G O
- O
- O
> O
A O
, O
first O
detected O
by O
Akli O
et O
al O
. O

( O
Genomics O
11 O
124 O
- O
134 O
, O
1991 O
) O
, O
is O
a O
common O
disease O
allele O
in O
non O
- O
Jewish O
Caucasians O
( O
10 O
/ O
58 O
alleles O
examined O
) O
. O

A O
PCR O
- O
based O
diagnostic O
test O
, O
which O
detects O
an O
NlaIII O
site O
generated O
by O
the O
mutation O
, O
revealed O
a O
frequency O
among O
enzyme O
- O
defined O
carriers O
of O
9 O
/ O
64 O
( O
14 O
% O
) O
. O

Most O
of O
those O
carrying O
the O
allele O
trace O
their O
origins O
to O
the O
United O
Kingdom O
, O
Ireland O
, O
or O
Western O
Europe O
. O

It O
was O
not O
identified O
among O
12 O
Black O
American O
TSD B
alleles O
or O
in O
any O
of O
18 O
Ashkenazi O
Jewish O
, O
enzyme O
- O
defined O
carriers O
who O
did O
not O
carry O
any O
of O
the O
mutations O
common O
to O
this O
population O
. O

No O
normally O
spliced O
RNA O
was O
detected O
in O
PCR O
products O
generated O
from O
reverse O
transcription O
of O
RNA O
carrying O
the O
IVS O
- O
9 O
mutation O
. O

Instead O
, O
the O
low O
levels O
of O
mRNA O
from O
this O
allele O
were O
comprised O
of O
aberrant O
species O
resulting O
from O
the O
use O
of O
either O
of O
two O
cryptic O
donor O
sites O
, O
one O
truncating O
exon O
9 O
and O
the O
other O
within O
IVS O
- O
9 O
, O
spliced O
to O
exon O
10 O
. O

Numerous O
additional O
splice O
products O
were O
detected O
, O
most O
involving O
skipping O
of O
one O
or O
more O
surrounding O
exons O
. O

Together O
with O
a O
recently O
identified O
allele O
responsible O
for O
Hex O
A O
pseudodeficiency O
( O
Triggs O
- O
Raine O
et O
al O
. O
Am O
J O
Hum O
Genet O
, O
1992 O
) O
, O
these O
two O
alleles O
accounted O
for O
almost O
50 O
% O
( O
29 O
/ O
64 O
) O
of O
TSD B
or O
carrier O
alleles O
ascertained O
by O
enzyme O
screening O
tests O
in O
non O
- O
Jewish O
Caucasians O
. O
. O

Aberrant O
splicing O
of O
the O
CHM B
gene O
is O
a O
significant O
cause O
of O
choroideremia B
. O

Choroideremia B
( O
CHM B
) O
is O
an O
X B
- I
linked I
progressive I
degeneration I
of I
the I
choroid I
and I
retina I
. O

12 O
% O
of O
unrelated O
male O
patients O
carry O
deletions O
of O
the O
partially O
cloned O
CHM B
gene O
. O

In O
Finland O
, O
there O
are O
more O
than O
120 O
living O
CHM B
patients O
belonging O
to O
eight O
apparently O
unrelated O
pedigrees O
. O

Molecular O
deletions O
involving O
the O
CHM B
gene O
have O
been O
detected O
in O
three O
families O
. O

We O
have O
screened O
the O
remaining O
five O
families O
for O
point O
mutations O
. O

In O
one O
large O
family O
a O
single O
nucleotide O
( O
T O
) O
insertion O
into O
the O
donor O
splice O
site O
of O
exon O
C O
leads O
to O
two O
aberrantly O
spliced O
mRNAs O
both O
producing O
a O
premature O
stop O
codon O
. O

The O
mutation O
can O
be O
assayed O
easily O
by O
amplification O
and O
digestion O
with O
Msel O
. O

Our O
findings O
provide O
additional O
evidence O
for O
the O
pathogenetic O
role O
of O
CHM B
mutations O
and O
provide O
a O
diagnostic O
tool O
for O
one O
fifth O
of O
the O
worlds O
known O
CHM B
patients O
. O
. O

Germline O
intronic O
and O
exonic O
mutations O
in O
the O
Wilms B
' I
tumour I
gene O
( O
WT1 O
) O
affecting O
urogenital O
development O
. O

Denys B
- I
Drash I
syndrome I
is O
a O
rare O
human O
developmental B
disorder I
affecting O
the O
urogenital O
system O
and O
leading O
to O
renal B
failure I
, O
intersex B
disorders I
and O
Wilms B
tumour I
. O

In O
this O
report O
, O
four O
individuals O
with O
this O
syndrome O
are O
described O
carrying O
germline O
point O
mutations O
in O
the O
Wilms B
tumour I
suppressor O
gene O
, O
WT1 O
. O

Three O
of O
these O
mutations O
were O
in O
the O
zinc O
finger O
domains O
of O
WT1 O
. O

The O
fourth O
occurred O
within O
intron O
9 O
, O
preventing O
splicing O
at O
one O
of O
the O
alternatively O
chosen O
splice O
donor O
sites O
of O
exon O
9 O
when O
assayed O
in O
vitro O
. O

These O
results O
provide O
genetic O
evidence O
for O
distinct O
functional O
roles O
of O
the O
WT1 O
isoforms O
in O
urogenital O
development O
. O
. O

Characterization O
of O
the O
myotonic B
dystrophy I
region O
predicts O
multiple O
protein O
isoform O
- O
encoding O
mRNAs O
. O

The O
mutation O
underlying O
myotonic B
dystrophy I
( O
DM B
) O
has O
been O
identified O
as O
an O
expansion O
of O
a O
polymorphic O
CTG O
- O
repeat O
in O
a O
gene O
encoding O
protein O
kinase O
activity O
. O

Brain O
and O
heart O
transcripts O
of O
the O
DM O
- O
kinase O
( O
DMR O
- O
B15 O
) O
gene O
are O
subject O
to O
alternative O
RNA O
splicing O
in O
both O
human O
and O
mouse O
. O

The O
unstable O
[ O
CTG O
] O
5 O
- O
30 O
motif O
is O
found O
uniquely O
in O
humans O
, O
although O
the O
flanking O
nucleotides O
are O
also O
present O
in O
mouse O
. O

Characterization O
of O
the O
DM B
region O
of O
both O
species O
reveals O
another O
active O
gene O
( O
DMR O
- O
N9 O
) O
in O
close O
proximity O
to O
the O
kinase O
gene O
. O

DMR O
- O
N9 O
transcripts O
, O
mainly O
expressed O
in O
brain O
and O
testis O
, O
possess O
a O
single O
, O
large O
open O
reading O
frame O
, O
but O
the O
function O
of O
its O
protein O
product O
is O
unknown O
. O

Clinical O
manifestation O
of O
DM B
may O
be O
caused O
by O
the O
expanded O
CTG O
- O
repeat O
compromising O
the O
( O
alternative O
) O
expression O
of O
DM O
- O
kinase O
or O
DMR O
- O
N9 O
proteins O
. O
. O

Fragile B
X I
syndrome I
without O
CCG O
amplification O
has O
an O
FMR1 O
deletion O
. O

We O
describe O
a O
patient O
with O
typical O
clinical O
features O
of O
the O
fragile B
X I
syndrome I
, O
but O
without O
cytogenetic O
expression O
of O
the O
fragile B
X I
or O
an O
amplified O
CCG O
trinucleotide O
repeat O
fragment O
. O

The O
patient O
has O
a O
previously O
uncharacterized O
submicroscopic O
deletion O
encompassing O
the O
CCG O
repeat O
, O
the O
entire O
FMR1 O
gene O
and O
about O
2 O
. O

5 O
megabases O
of O
flanking O
sequences O
. O

This O
finding O
confirms O
that O
the O
fragile B
X I
phenotype O
can O
exist O
, O
without O
amplification O
of O
the O
CCG O
repeat O
or O
cytogenetic O
expression O
of O
the O
fragile B
X I
, O
and O
that O
fragile B
X I
syndrome I
is O
a O
genetically O
homogeneous O
disorder O
involving O
FMR1 O
. O

We O
also O
found O
random O
X O
- O
inactivation O
in O
the O
mother O
of O
the O
patient O
who O
was O
shown O
to O
be O
a O
carrier O
of O
this O
deletion O
. O

Cloning O
of O
the O
Huntington B
disease I
region O
in O
yeast O
artificial O
chromosomes O
. O

The O
gene O
responsible O
for O
Huntington B
disease I
has O
been O
localized O
to O
a O
2 O
. O

5 O
million O
base O
pair O
( O
Mb O
) O
region O
between O
the O
loci O
D4S10 O
and O
D4S168 O
on O
the O
short O
arm O
of O
chromosome O
4 O
. O

As O
part O
of O
a O
strategy O
to O
clone O
the O
HD B
gene O
on O
the O
basis O
of O
its O
chromosomal O
location O
, O
we O
isolated O
genomic O
DNA O
from O
the O
HD B
region O
as O
a O
set O
of O
overlapping O
yeast O
artificial O
chromosome O
( O
YAC O
) O
clones O
. O

Twenty O
- O
eight O
YAC O
clones O
were O
identified O
by O
screening O
human O
YAC O
libraries O
with O
twelve O
PCR O
- O
based O
sequence O
- O
tagged O
sites O
( O
STSs O
) O
from O
the O
region O
. O

We O
assembled O
the O
YAC O
clones O
into O
overlapping O
sets O
by O
hybridizing O
them O
to O
a O
large O
number O
of O
DNA O
probes O
from O
the O
HD B
region O
, O
including O
the O
STSs O
. O

In O
addition O
, O
we O
isolated O
the O
ends O
of O
the O
human O
DNA O
inserts O
of O
most O
of O
the O
YAC O
clones O
to O
assist O
in O
the O
construction O
of O
the O
contig O
. O

Although O
almost O
half O
of O
the O
YACs O
appear O
to O
contain O
chimeric O
inserts O
and O
several O
contain O
internal O
deletions O
or O
other O
rearrangements O
, O
we O
were O
able O
to O
obtain O
over O
2 O
. O

2 O
Mb O
of O
the O
HD B
region O
in O
YACs O
, O
including O
one O
continuous O
segment O
of O
2 O
. O

0 O
Mb O
covering O
the O
region O
that O
most O
likely O
contains O
the O
HD B
gene O
. O

Ten O
of O
the O
twenty O
eight O
YAC O
clones O
comprise O
a O
minimal O
set O
spanning O
the O
2 O
. O

2 O
Mb O
. O

These O
clones O
provide O
reagents O
for O
the O
complete O
characterization O
of O
this O
region O
of O
the O
genome O
and O
for O
the O
eventual O
isolation O
of O
the O
HD B
gene O
. O

Characterization O
of O
a O
YAC O
containing O
part O
or O
all O
of O
the O
Norrie B
disease I
locus O
. O

It O
has O
been O
shown O
from O
pulsed O
- O
field O
gel O
electrophoresis O
( O
PFGE O
) O
that O
the O
monoamine O
oxidase O
genes O
A O
and O
B O
( O
MAOA O
& O
MAOB O
) O
and O
DXS7 O
loci O
are O
physically O
very O
close O
. O

We O
have O
therefore O
extended O
studies O
on O
their O
relationship O
through O
the O
characterisation O
of O
a O
650 O
kb O
YAC O
isolated O
using O
L1 O
. O

28 O
( O
recognising O
the O
DXS7 O
locus O
) O
as O
a O
probe O
. O

Restriction O
mapping O
of O
the O
YAC O
indicates O
that O
it O
contains O
both O
MAOA O
and O
MAOB O
genes O
in O
addition O
to O
the O
DXS7 O
locus O
. O

The O
map O
derived O
from O
the O
YL1 O
. O

28 O
- O
YAC O
is O
compatible O
both O
with O
the O
map O
from O
an O
independently O
derived O
YAC O
carrying O
MAOA O
and O
B O
genes O
and O
with O
the O
long O
range O
genomic O
map O
for O
the O
region O
. O

A O
series O
of O
subclones O
prepared O
from O
a O
phage O
library O
( O
lambda O
DASH O
II O
) O
of O
the O
YAC O
have O
been O
characterised O
and O
have O
been O
employed O
to O
determine O
the O
end O
point O
of O
the O
deletion O
of O
a O
Norrie B
disease I
( O
NDP B
) O
patient O
who O
has O
been O
shown O
to O
lack O
both O
DXS7 O
and O
MAO O
coding O
sequences O
. O

The O
pattern O
of O
retention O
of O
subclones O
in O
the O
deletion O
patient O
place O
the O
end O
point O
of O
the O
deletion O
within O
30 O
- O
130 O
kb O
of O
the O
proximal O
end O
of O
the O
YAC O
. O

By O
combining O
the O
data O
with O
established O
recombination O
analysis O
, O
we O
provide O
evidence O
that O
all O
or O
part O
of O
the O
NDP O
lies O
in O
the O
interval O
of O
approximately O
250kb O
within O
the O
YAC O
. O

Both O
mutations O
in O
G6PD O
A O
- O
are O
necessary O
to O
produce O
the O
G6PD B
deficient I
phenotype O
. O

The O
high O
prevalence O
of O
glucose B
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
in O
African O
populations O
is O
due O
almost O
entirely O
to O
the O
enzyme O
variant O
A O
- O
, O
which O
differs O
from O
the O
wild O
- O
type O
G6PD O
B O
by O
two O
amino O
acid O
replacements O
, O
68 O
Val O
- O
- O
> O
Met O
and O
126 O
Asn O
- O
- O
> O
Asp O
. O

The O
non O
- O
deficient O
polymorphic O
variant O
G6PD O
A O
contains O
only O
the O
mutation O
126 O
Asn O
- O
- O
> O
Asp O
. O

The O
frequencies O
of O
the O
G6PD O
A O
and O
of O
the O
G6PD O
A O
- O
genes O
in O
parts O
of O
Africa O
are O
both O
about O
0 O
. O

2 O
. O

The O
68 O
Val O
- O
- O
> O
Met O
mutation O
has O
not O
been O
found O
in O
a O
B O
background O
. O

This O
could O
be O
because O
the O
68 O
Val O
- O
- O
> O
Met O
mutation O
happened O
to O
arise O
in O
an O
A O
gene O
in O
the O
first O
instance O
, O
or O
because O
the O
68 O
Val O
- O
- O
> O
Met O
mutation O
alone O
is O
not O
sufficient O
to O
cause O
G6PD B
deficiency I
. O

We O
have O
approached O
this O
question O
by O
producing O
G6PD O
B O
, O
A O
, O
A O
- O
, O
and O
G6PD O
68 O
Val O
- O
- O
> O
Met O
in O
a O
bacterial O
expression O
system O
and O
analysing O
their O
biochemical O
properties O
. O

With O
each O
single O
mutation O
we O
found O
a O
slight O
decrease O
in O
both O
the O
specific O
activity O
and O
the O
yield O
of O
enzyme O
when O
compared O
to O
G6PD O
B O
. O

When O
both O
mutations O
were O
introduced O
together O
, O
there O
was O
a O
roughly O
additive O
effect O
on O
specific O
activity O
, O
but O
a O
much O
more O
drastic O
effect O
on O
enzyme O
yield O
( O
4 O
% O
of O
normal O
) O
. O

This O
synergistic O
effect O
was O
also O
demonstrated O
on O
thermal O
stability O
, O
especially O
at O
low O
NADP O
concentrations O
. O

Comparable O
results O
were O
produced O
when O
the O
replacement O
119 O
Gln O
- O
- O
> O
Glu O
was O
studied O
instead O
of O
126 O
Asn O
- O
- O
> O
Asp O
. O

We O
infer O
that O
the O
coexistence O
of O
the O
two O
mutations O
is O
responsible O
for O
enzyme B
deficiency I
in I
G6PD I
A O
- O
because O
they O
act O
synergistically O
in O
causing O
instability O
of O
the O
enzyme O
. O

Small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
, O
an O
expressed O
gene O
in O
the O
Prader B
- I
Willi I
syndrome I
critical O
region O
. O

Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
is O
associated O
with O
paternally O
derived O
chromosomal O
deletions O
in O
region O
15q11 O
- O
13 O
or O
with O
maternal B
disomy I
for I
chromosome I
15 I
. O

Therefore O
, O
loss O
of O
the O
expressed O
paternal O
alleles O
of O
maternally O
imprinted O
genes O
must O
be O
responsible O
for O
the O
PWS B
phenotype O
. O

We O
have O
mapped O
the O
gene O
encoding O
the O
small O
nuclear O
RNA O
associated O
polypeptide O
SmN O
( O
SNRPN O
) O
to O
human O
chromosome O
15q12 O
and O
a O
processed O
pseudogene O
SNRPNP1 O
to O
chromosome O
region O
6pter O
- O
p21 O
. O

Furthermore O
, O
SNRPN O
was O
mapped O
to O
the O
minimal O
deletion O
interval O
that O
is O
critical O
for O
PWS B
. O

The O
fact O
that O
the O
mouse O
Snrpn O
gene O
is O
maternally O
imprinted O
in O
brain O
suggests O
that O
loss O
of O
the O
paternally O
derived O
SNRPN O
allele O
may O
be O
involved O
in O
the O
PWS B
phenotype O
. O
. O

The O
presence O
of O
two O
different O
infantile O
Tay B
- I
Sachs I
disease I
mutations O
in O
a O
Cajun O
population O
. O

A O
study O
was O
undertaken O
to O
characterize O
the O
mutation O
( O
s O
) O
responsible O
for O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
in O
a O
Cajun O
population O
in O
southwest O
Louisiana O
and O
to O
identify O
the O
origins O
of O
these O
mutations O
. O

Eleven O
of O
12 O
infantile O
TSD B
alleles O
examined O
in O
six O
families O
had O
the O
beta O
- O
hexosaminidase O
A O
( O
Hex O
A O
) O
alpha O
- O
subunit O
exon O
11 O
insertion O
mutation O
that O
is O
present O
in O
approximately O
70 O
% O
of O
Ashkenazi O
Jewish O
TSD B
heterozygotes O
. O

The O
mutation O
in O
the O
remaining O
allele O
was O
a O
single O
- O
base O
transition O
in O
the O
donor O
splice O
site O
of O
the O
alpha O
- O
subunit O
intron O
9 O
. O

To O
determine O
the O
origins O
of O
these O
two O
mutations O
in O
the O
Cajun O
population O
, O
the O
TSD B
carrier O
status O
was O
enzymatically O
determined O
for O
90 O
members O
of O
four O
of O
the O
six O
families O
, O
and O
extensive O
pedigrees O
were O
constructed O
for O
all O
carriers O
. O

A O
single O
ancestral O
couple O
from O
France O
was O
found O
to O
be O
common O
to O
most O
of O
the O
carriers O
of O
the O
exon O
11 O
insertion O
. O

Pedigree O
data O
suggest O
that O
this O
mutation O
has O
been O
in O
the O
Cajun O
population O
since O
its O
founding O
over O
2 O
centuries O
ago O
and O
that O
it O
may O
be O
widely O
distributed O
within O
the O
population O
. O

In O
contrast O
, O
the O
intron O
9 O
mutation O
apparently O
was O
introduced O
within O
the O
last O
century O
and O
probably O
is O
limited O
to O
a O
few O
Louisiana O
families O
. O
. O

Mutations O
in O
the O
candidate O
gene O
for O
Norrie B
disease I
. O

Recently O
, O
we O
and O
others O
have O
isolated O
a O
candidate O
gene O
for O
X B
linked I
Norrie I
disease I
( O
ND B
) O
which O
was O
found O
to O
be O
deleted O
or O
disrupted O
in O
several O
patients O
. O

As O
a O
prerequisite O
for O
the O
identification O
of O
point O
mutations O
in O
the O
ND B
gene O
we O
have O
established O
the O
exon O
- O
intron O
structure O
of O
this O
gene O
. O

In O
17 O
unrelated O
patients O
and O
15 O
controls O
, O
PCR O
products O
derived O
from O
the O
promoter O
region O
, O
exons O
1 O
and O
2 O
as O
well O
as O
the O
coding O
part O
of O
exon O
3 O
were O
analysed O
with O
the O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
technique O
. O

In O
12 O
patients O
altered O
PCR O
fragments O
were O
detected O
which O
were O
studied O
in O
detail O
by O
direct O
sequencing O
. O

Eleven O
different O
mutations O
were O
found O
, O
and O
all O
but O
one O
are O
likely O
to O
give O
rise O
to O
significant O
structural O
changes O
in O
the O
predicted O
protein O
. O

These O
findings O
, O
and O
the O
absence O
of O
functionally O
relevant O
base O
changes O
in O
healthy O
controls O
, O
emphasize O
the O
causal O
role O
of O
this O
candidate O
gene O
in O
Norrie B
disease I
and O
pave O
the O
way O
for O
reliable O
diagnosis O
and O
carrier O
detection O
. O
. O

Detection O
of O
a O
nonsense O
mutation O
in O
the O
dystrophin O
gene O
by O
multiple O
SSCP O
. O

A O
combination O
of O
multiplex O
PCR O
with O
the O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
technique O
was O
employed O
to O
screen O
for O
point O
mutations O
in O
the O
human O
dystrophin O
gene O
. O

Co O
- O
amplification O
of O
11 O
exons O
from O
genomic O
DNA O
of O
Duchenne B
and I
Becker I
muscular I
dystrophy I
( O
DMD B
/ O
BMD B
) O
patients O
with O
no O
deletion O
or O
duplication O
was O
performed O
and O
the O
samples O
subjected O
to O
multiple O
SSCP O
analysis O
. O

We O
report O
the O
case O
of O
a O
nonsense O
mutation O
in O
a O
Duchenne B
patient O
identified O
by O
this O
approach O
. O

The O
mutation O
introduces O
a O
termination O
codon O
within O
exon O
8 O
of O
the O
dystrophin O
gene O
. O

It O
is O
predicted O
to O
cause O
a O
very O
premature O
translational O
termination O
accounting O
for O
the O
severe O
phenotype O
observed O
. O

The O
patient O
inherited O
this O
mutation O
from O
his O
mother O
. O

In O
addition O
the O
analysis O
revealed O
5 O
polymorphisms O
useful O
for O
internal O
control O
. O
. O

Proliferation O
- O
related O
expression O
of O
p19 O
/ O
nm23 O
nucleoside O
diphosphate O
kinase O
. O

High O
level O
expression O
of O
the O
nm23 O
- O
H1 O
gene O
, O
which O
encodes O
for O
a O
nucleoside O
diphosphate O
kinase O
, O
has O
been O
found O
to O
correlate O
with O
diminished O
metastasis O
in O
some O
tumors B
but O
not O
in O
others O
. O

We O
have O
previously O
identified O
the O
protein O
product O
of O
the O
nm23 O
- O
H1 O
gene O
in O
two O
- O
dimensional O
electrophoretic O
gels O
and O
have O
designated O
it O
p19 O
/ O
nm23 O
. O

In O
neuroblastoma B
, O
higher O
levels O
of O
p19 O
/ O
nm23 O
, O
which O
are O
associated O
with O
amplification O
of O
the O
N O
- O
myc O
oncogene O
, O
large O
tumor B
mass O
, O
and O
metastasis O
, O
were O
observed O
in O
advanced O
stage O
tumors B
compared O
with O
limited O
stage O
disease O
. O

Because O
of O
the O
variable O
expression O
of O
nm23 O
- O
H1 O
in O
different O
tumors B
, O
we O
have O
investigated O
the O
relationship O
between O
amounts O
of O
the O
protein O
and O
cell O
proliferation O
. O

The O
levels O
of O
p19 O
/ O
nm23 O
were O
compared O
between O
resting O
and O
mitotically O
stimulated O
normal O
human O
PBLs O
and O
in O
leukemia B
cells O
. O

The O
amount O
of O
p19 O
/ O
nm23 O
increased O
in O
normal O
lymphocytes O
in O
response O
to O
mitotic O
stimulation O
and O
paralleled O
the O
increase O
in O
DNA O
synthesis O
. O

In O
leukemia B
cells O
obtained O
from O
patients O
with O
different O
subtypes O
of O
acute B
leukemia I
, O
p19 O
/ O
nm23 O
levels O
were O
also O
increased O
relative O
to O
resting O
normal O
lymphocytes O
. O

Treatment O
of O
mitotically O
stimulated O
lymphocytes O
with O
cyclosporin O
, O
which O
inhibits O
proliferation O
, O
blocked O
the O
increase O
in O
p19 O
/ O
nm23 O
; O
treatment O
of O
the O
leukemia B
cell O
line O
HL O
- O
60 O
with O
dimethylsulfoxide O
, O
which O
induces O
terminal O
differentiation O
, O
resulted O
in O
diminished O
levels O
of O
p19 O
/ O
nm23 O
. O

Our O
data O
therefore O
provide O
evidence O
that O
nm23 O
- O
H1 O
expression O
is O
related O
to O
cell O
proliferative O
activity O
. O
. O

An O
intrachromosomal O
insertion O
causing O
5q22 O
deletion O
and O
familial B
adenomatous I
polyposis I
coli I
in O
two O
generations O
. O

We O
report O
familial B
adenomatous I
polyposis I
coli I
( O
FAPC B
) O
with O
epidermoid B
cysts I
, O
osteomata B
, O
and O
areas O
of O
congenital B
hypertrophy I
of I
the I
retinal I
pigment I
epithelium I
( O
CHRPEs B
) O
in O
a O
male O
patient O
and O
his O
maternal O
aunt O
, O
both O
of O
whom O
suffered O
a O
mild O
to O
moderate O
degree O
of O
mental B
handicap I
. O

Both O
had O
an O
interstitial O
deletion O
of O
the O
long O
arm O
of O
chromosome O
5 O
( O
del O
( O
5 O
) O
( O
q22q23 O
. O
2 O
) O
) O
. O

Two O
other O
normal O
family O
members O
had O
the O
underlying O
direct O
insertion O
of O
chromosome O
5 O
( O
dir O
ins O
( O
5 O
) O
( O
q31 O
. O
3q22q23 O
3q22q23 O
. O
2 O
) O
) O
. O

Molecular O
genetic O
and O
fluorescent O
hybridisation O
studies O
have O
shown O
that O
loci O
D5S37 O
and O
D5S98 O
are O
outside O
the O
deletion O
whereas O
loci O
detected O
by O
probes O
EF5 O
. O

44 O
and O
YN5 O
. O

48 O
are O
lost O
. O

As O
expected O
, O
the O
molecular O
analyses O
indicate O
loss O
of O
one O
allele O
at O
the O
MCC O
and O
APC B
loci O
. O

The O
APC B
gene O
is O
located O
within O
band O
5q22 O
. O

Familial O
direct O
insertions O
should O
be O
considered O
as O
a O
cause O
of O
recurrent O
microdeletion O
syndromes O
. O

Chromosome O
mapping O
of O
the O
rod O
photoreceptor O
cGMP O
phosphodiesterase O
beta O
- O
subunit O
gene O
in O
mouse O
and O
human O
: O
tight O
linkage O
to O
the O
Huntington B
disease I
region O
( O
4p16 O
. O
3 O
) O
. O

The O
retinal B
degeneration I
mouse O
( O
gene O
symbol O
, O
rd O
) O
is O
an O
animal O
model O
for O
certain O
forms O
of O
human O
hereditary B
retinopathies I
. O

Recent O
findings O
of O
a O
nonsense O
mutation O
in O
the O
rd O
mouse O
PDE O
beta O
- O
subunit O
gene O
( O
Pdeb O
) O
prompted O
us O
to O
investigate O
the O
chromosome O
locations O
of O
the O
mouse O
and O
human O
genes O
. O

We O
have O
utilized O
backcross O
analysis O
in O
mice O
to O
verify O
and O
define O
more O
precisely O
the O
location O
of O
the O
Pdeb O
locus O
6 O
. O

1 O
+ O
/ O
- O
2 O
. O

3 O
cM O
distal O
of O
Mgsa O
on O
mouse O
chromosome O
5 O
. O

We O
have O
determined O
that O
the O
human O
gene O
( O
PDEB O
) O
maps O
to O
4p16 O
. O

3 O
, O
very O
close O
to O
the O
Huntington B
disease I
( O
HD B
) O
region O
. O

Analysis O
of O
the O
comparative O
map O
for O
mice O
and O
humans O
shows O
that O
the O
mouse O
homologue O
of O
the O
HD B
gene O
will O
reside O
on O
chromosome O
5 O
. O

Linkage O
of O
the O
mouse O
Pdeb O
locus O
with O
other O
homologues O
in O
the O
human O
4p16 O
. O

3 O
region O
is O
maintained O
but O
gene O
order O
is O
not O
, O
suggesting O
at O
least O
three O
possible O
sites O
for O
the O
corresponding O
mouse O
HD B
gene O
. O

Coincident O
Kaposi B
sarcoma I
and O
T B
- I
cell I
lymphoma I
in O
a O
patient O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

A O
24 O
year O
old O
male O
with O
a O
history O
of O
eczema B
, O
recurrent O
mild O
infections O
, O
and O
thrombocytopenia B
consistent O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
presented O
with O
a O
mediastinal O
mass O
, O
generalized O
lymphadenopathy B
, O
splenomegaly B
, O
and O
severe O
thrombocytopenia B
. O

Studies O
of O
immune O
function O
including O
immunoglobulin O
levels O
and O
T O
- O
cell O
subsets O
were O
normal O
. O

Furthermore O
, O
his O
T O
lymphocytes O
proliferated O
normally O
in O
response O
to O
phytohemagglutinin O
, O
concanavalin O
A O
, O
and O
the O
combination O
of O
neuraminidase O
/ O
galactose O
oxidase O
. O

However O
, O
their O
proliferative O
responses O
to O
anti O
- O
CD43 O
antibody O
and O
periodate O
were O
diminished O
, O
consistent O
with O
the O
clinical O
diagnosis O
of O
WAS B
. O

An O
initial O
inguinal O
lymph O
node O
biopsy O
surprisingly O
revealed O
Kaposi B
sarcoma I
. O

However O
, O
following O
splenectomy O
to O
increase O
the O
platelet O
count O
, O
biopsy O
of O
the O
mediastinal O
mass O
revealed O
T B
- I
cell I
large I
cell I
lymphoma I
. O

Studies O
of O
biopsied O
tissue O
for O
the O
presence O
of O
Epstein B
- I
Barr I
virus I
and O
cytomegalovirus B
were O
negative O
, O
as O
were O
studies O
of O
blood O
, O
including O
the O
polymerase O
chain O
reaction O
, O
for O
the O
presence O
of O
the O
human B
immunodeficiency I
virus I
( O
HIV B
) O
. O

This O
is O
the O
first O
report O
of O
Kaposi B
sarcoma I
arising O
in O
a O
patient O
with O
a O
congenital B
immunodeficiency I
syndrome I
. O

Although O
Kaposi B
sarcoma I
can O
arise O
in O
the O
face O
of O
the O
severe O
immunosuppression O
that O
follows O
allograft O
transplantation O
and O
in O
patients O
infected O
with O
HIV B
, O
we O
postulate O
that O
longevity O
in O
the O
face O
of O
mild O
immunosuppression O
was O
the O
major O
factor O
in O
the O
development O
of O
Kaposi B
sarcoma I
in O
this O
patient O
. O
. O

The O
APC B
gene O
, O
responsible O
for O
familial B
adenomatous I
polyposis I
, O
is O
mutated O
in O
human O
gastric B
cancer I
. O

Although O
gastric B
cancer I
is O
the O
most O
common O
cancer B
in O
the O
world O
, O
genetic O
changes O
during O
its O
carcinogenesis O
are O
not O
well O
understood O
. O

Since O
some O
gastric B
cancers I
are O
considered O
to O
originate O
from O
the O
intestinal O
metaplasia O
, O
it O
is O
likely O
that O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
, O
the O
mutation O
of O
which O
causes O
adenomatous B
polyps I
in I
the I
colon I
, O
is O
associated O
with O
carcinogenesis O
of O
gastric B
cancer I
. O

Based O
on O
this O
idea O
, O
DNAs O
isolated O
from O
gastric B
cancers I
were O
examined O
by O
means O
of O
a O
RNase O
protection O
analysis O
coupled O
with O
polymerase O
chain O
reaction O
followed O
by O
sequencing O
of O
the O
polymerase O
chain O
reaction O
products O
. O

By O
screening O
nearly O
one O
- O
half O
of O
the O
coding O
region O
of O
the O
APC B
gene O
in O
44 O
tumors B
, O
somatic O
mutations O
were O
detected O
in O
three O
tumors B
a O
missense O
mutation O
, O
a O
nonsense O
mutation O
, O
and O
a O
5 O
- O
base O
pair O
deletion O
resulting O
in O
a O
frame O
shift O
which O
causes O
truncation O
of O
the O
gene O
product O
. O

These O
results O
suggest O
that O
the O
mutation O
of O
the O
APC B
gene O
also O
plays O
an O
important O
role O
during O
the O
carcinogenesis O
of O
at O
least O
some O
gastric B
cancers I
. O
. O

A O
71 O
- O
kilodalton O
protein O
is O
a O
major O
product O
of O
the O
Duchenne B
muscular I
dystrophy I
gene O
in O
brain O
and O
other O
nonmuscle O
tissues O
. O

The O
known O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
products O
, O
the O
muscle O
- O
and O
brain O
- O
type O
dystrophin O
isoforms O
, O
are O
427 O
- O
kDa O
proteins O
translated O
from O
14 O
- O
kilobase O
( O
kb O
) O
mRNAs O
. O

Recently O
we O
described O
a O
6 O
. O

5 O
- O
kb O
mRNA O
that O
also O
is O
transcribed O
from O
the O
DMD B
gene O
. O

Cloning O
and O
in O
vitro O
transcription O
and O
translation O
of O
the O
entire O
coding O
region O
show O
that O
the O
6 O
. O

5 O
- O
kb O
mRNA O
encodes O
a O
70 O
. O

8 O
- O
kDa O
protein O
that O
is O
a O
major O
product O
of O
the O
DMD B
gene O
. O

It O
contains O
the O
C O
- O
terminal O
and O
the O
cysteine O
- O
rich O
domains O
of O
dystrophin O
, O
seven O
additional O
amino O
acids O
at O
the O
N O
terminus O
, O
and O
some O
modifications O
formed O
by O
alternative O
splicing O
in O
the O
C O
- O
terminal O
domain O
. O

It O
lacks O
the O
entire O
large O
domain O
of O
spectrin O
- O
like O
repeats O
and O
the O
actin O
- O
binding O
N O
- O
terminal O
domain O
of O
dystrophin O
. O

This O
protein O
is O
the O
major O
DMD B
gene O
product O
in O
brain O
and O
other O
nonmuscle O
tissues O
but O
is O
undetectable O
in O
skeletal O
muscle O
extracts O
. O

Correlation O
between O
the O
location O
of O
germ O
- O
line O
mutations O
in O
the O
APC B
gene O
and O
the O
number O
of O
colorectal B
polyps I
in O
familial B
adenomatous I
polyposis I
patients O
. O

Recently O
we O
have O
isolated O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
which O
causes O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
and O
its O
germ O
- O
line O
mutations O
in O
a O
substantial O
number O
of O
FAP B
patients O
have O
been O
identified O
. O

On O
the O
basis O
of O
this O
information O
, O
we O
compared O
the O
location O
of O
germ O
- O
line O
mutations O
in O
the O
APC B
gene O
in O
22 O
unrelated O
patients O
( O
12 O
of O
whom O
have O
been O
reported O
previously O
) O
with O
the O
number O
of O
colorectal B
polyps I
developed O
in O
FAP B
patients O
; O
17 O
were O
sparse O
types O
and O
five O
were O
profuse O
types O
. O

All O
but O
one O
of O
the O
mutations O
were O
considered O
to O
cause O
truncation O
of O
the O
gene O
product O
by O
frame O
- O
shift O
due O
to O
deletion O
( O
14 O
cases O
) O
or O
nonsense O
mutation O
( O
seven O
cases O
) O
. O

The O
location O
of O
the O
germ O
- O
line O
mutations O
seems O
to O
correlate O
with O
the O
two O
clinical O
types O
; O
germ O
- O
line O
mutations O
in O
five O
FAP B
patients O
with O
profuse O
polyps B
were O
observed O
between O
codon O
1250 O
and O
codon O
1464 O
, O
whereas O
mutations O
in O
17 O
FAP B
patients O
with O
fewer O
polyps B
were O
observed O
in O
the O
other O
regions O
of O
the O
APC B
gene O
. O

The O
result O
suggests O
that O
the O
number O
of O
colorectal B
polyps I
in O
FAP B
patients O
may O
be O
associated O
with O
a O
difference O
in O
the O
stability O
or O
biological O
function O
of O
the O
truncated O
APC B
protein O
. O
. O

Identification O
and O
rapid O
detection O
of O
three O
Tay B
- I
Sachs I
mutations O
in O
the O
Moroccan O
Jewish O
population O
. O

Infantile O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
is O
caused O
by O
mutations O
in O
the O
HEXA O
gene O
that O
result O
in O
the O
complete O
absence O
of O
beta O
- O
hexosaminidase O
A O
activity O
. O

It O
is O
well O
known O
that O
an O
elevated O
frequency O
of O
TSD B
mutations O
exists O
among O
Ashkenazi O
Jews O
. O

More O
recently O
it O
has O
become O
apparent O
that O
elevated O
carrier O
frequencies O
for O
TSD B
also O
occur O
in O
several O
other O
ethnic O
groups O
, O
including O
Moroccan O
Jews O
, O
a O
subgroup O
of O
Sephardic O
Jews O
. O

Elsewhere O
we O
reported O
an O
in O
- O
frame O
deletion O
of O
one O
of O
the O
two O
adjacent O
phenylalanine O
codons O
at O
position O
304 O
or O
305 O
( O
delta O
F304 O
/ O
305 O
) O
in O
one O
HEXA O
allele O
of O
a O
Moroccan O
Jewish O
TSD B
patient O
and O
in O
three O
obligate O
carriers O
from O
six O
unrelated O
Moroccan O
Jewish O
families O
. O

We O
have O
now O
identified O
two O
additional O
mutations O
within O
exon O
5 O
of O
the O
HEXA O
gene O
that O
account O
for O
the O
remaining O
TSD B
alleles O
in O
the O
patient O
and O
carriers O
. O

One O
of O
the O
mutations O
is O
a O
novel O
C O
- O
to O
- O
G O
transversion O
, O
resulting O
in O
a O
replacement O
of O
Tyr180 O
by O
a O
stop O
codon O
. O

The O
other O
mutation O
is O
a O
G O
- O
to O
- O
A O
transition O
resulting O
in O
an O
Arg170 O
- O
to O
- O
Gln O
substitution O
. O

This O
mutation O
is O
at O
a O
CpG O
site O
in O
a O
Japanese O
infant O
with O
Tay B
- I
Sachs I
disease I
and O
was O
described O
elsewhere O
. O

Analysis O
of O
nine O
obligate O
carriers O
from O
seven O
unrelated O
families O
showed O
that O
four O
harbor O
the O
delta O
F304 O
/ O
305 O
mutation O
, O
two O
the O
Arg170 O
- O
- O
- O
- O
Gln O
mutation O
, O
and O
one O
the O
Tyr180 O
- O
- O
- O
- O
Stop O
mutation O
. O

We O
also O
have O
developed O
rapid O
, O
nonradioactive O
assays O
for O
the O
detection O
of O
each O
mutation O
, O
which O
should O
be O
helpful O
for O
carrier O
screening O
. O
. O

Molecular O
characterization O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
by O
natural O
and O
amplification O
created O
restriction O
sites O
: O
five O
mutations O
account O
for O
most O
G6PD B
deficiency I
cases O
in O
Taiwan O
. O

We O
have O
developed O
a O
rapid O
and O
simple O
method O
to O
diagnose O
the O
molecular O
defects O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
in O
Chinese O
in O
Taiwan O
. O

This O
method O
involves O
the O
selective O
amplification O
of O
a O
DNA O
fragment O
from O
human O
G6PD O
gene O
with O
specific O
oligonucleotide O
primers O
followed O
by O
digestion O
with O
restriction O
enzymes O
that O
recognize O
artificially O
created O
or O
naturally O
occurring O
restriction O
sites O
. O

Ninety O
- O
four O
Chinese O
males O
with O
G6PD B
deficiency I
were O
studied O
. O

The O
results O
show O
that O
50 O
% O
( O
47 O
of O
94 O
) O
were O
G O
to O
T O
mutation O
at O
nucleotide O
( O
nt O
) O
1376 O
, O
21 O
. O

3 O
% O
( O
20 O
of O
94 O
) O
were O
G O
to O
A O
mutation O
at O
nt O
1388 O
, O
7 O
. O

4 O
% O
( O
7 O
of O
94 O
) O
were O
A O
to O
G O
mutation O
at O
nt O
493 O
, O
7 O
. O

4 O
% O
( O
7 O
of O
94 O
) O
were O
A O
to O
G O
mutation O
at O
nt O
95 O
, O
4 O
. O

2 O
% O
( O
4 O
of O
94 O
) O
were O
C O
to O
T O
mutation O
at O
nt O
1024 O
, O
1 O
. O

1 O
% O
( O
1 O
of O
94 O
) O
was O
G O
to O
T O
mutation O
at O
nt O
392 O
, O
and O
1 O
. O

1 O
% O
( O
1 O
of O
94 O
) O
was O
G O
to O
A O
mutation O
at O
nt O
487 O
. O

These O
results O
show O
that O
the O
former O
five O
mutations O
account O
for O
more O
than O
90 O
% O
of O
G6PD B
deficiency I
cases O
in O
Taiwan O
. O

Aside O
from O
showing O
that O
G O
to O
T O
change O
at O
nt O
1376 O
is O
the O
most O
common O
mutation O
, O
our O
research O
indicates O
that O
nt O
493 O
mutation O
is O
a O
frequent O
mutation O
among O
Chinese O
in O
Taiwan O
. O

We O
compared O
G6PD O
activity O
among O
different O
mutations O
, O
without O
discovering O
significant O
differences O
between O
them O
. O

Eight O
novel O
inactivating O
germ O
line O
mutations O
at O
the O
APC B
gene O
identified O
by O
denaturing O
gradient O
gel O
electrophoresis O
. O

Familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
dominantly O
inherited O
condition O
predisposing O
to O
colorectal B
cancer I
. O

The O
recent O
isolation O
of O
the O
responsible O
gene O
( O
adenomatous B
polyposis I
coli I
or O
APC B
) O
has O
facilitated O
the O
search O
for O
germ O
line O
mutations O
in O
affected O
individuals O
. O

Previous O
authors O
have O
used O
the O
RNase O
protection O
assay O
and O
the O
single O
- O
strand O
conformation O
polymorphisms O
procedure O
to O
screen O
for O
mutations O
. O

In O
this O
study O
we O
used O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
. O

DGGE O
analysis O
of O
10 O
APC B
exons O
( O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
, O
12 O
, O
13 O
, O
14 O
, O
and O
part O
of O
15 O
) O
in O
33 O
unrelated O
Dutch O
FAP B
patients O
has O
led O
to O
the O
identification O
of O
eight O
novel O
germ O
line O
mutations O
resulting O
in O
stop O
codons O
or O
frameshifts O
. O

The O
results O
reported O
here O
indicate O
that O
( O
1 O
) O
familial B
adenomatous I
polyposis I
is O
caused O
by O
an O
extremely O
heterogeneous O
spectrum O
of O
point O
mutations O
; O
( O
2 O
) O
all O
the O
mutations O
found O
in O
this O
study O
are O
chain O
terminating O
; O
and O
( O
3 O
) O
DGGE O
represents O
a O
rapid O
and O
sensitive O
technique O
for O
the O
detection O
of O
mutations O
in O
the O
unusually O
large O
APC B
gene O
. O

An O
extension O
of O
the O
DGGE O
analysis O
to O
the O
entire O
coding O
region O
in O
a O
sufficient O
number O
of O
clinically O
well O
- O
characterized O
, O
unrelated O
patients O
will O
facilitate O
the O
establishment O
of O
genotype O
- O
phenotype O
correlations O
. O

On O
the O
other O
hand O
, O
the O
occurrence O
of O
an O
extremely O
heterogeneous O
spectrum O
of O
mutations O
spread O
throughout O
the O
entire O
length O
of O
the O
large O
APC B
gene O
among O
the O
FAP B
patients O
indicates O
that O
this O
approach O
may O
not O
be O
useful O
as O
a O
rapid O
presymptomatic O
diagnostic O
procedure O
in O
a O
routine O
laboratory O
. O

Nevertheless O
, O
the O
above O
DGGE O
approach O
has O
incidentally O
led O
to O
the O
identification O
of O
a O
common O
polymorphism O
in O
exon O
13 O
. O

Such O
intragenic O
polymorphisms O
offer O
a O
practical O
approach O
to O
a O
more O
rapid O
procedure O
for O
presymptomatic O
diagnosis O
of O
FAP B
by O
linkage O
analysis O
in O
informative O
families O
. O
. O

Yeast O
artificial O
chromosomes O
for O
the O
molecular O
analysis O
of O
the O
familial B
polyposis I
APC I
gene O
region O
. O

Two O
yeast O
artificial O
chromosomes O
( O
YACs O
) O
spanning O
a O
total O
distance O
of O
1 O
. O

1 O
megabase O
pairs O
of O
DNA O
around O
the O
MCC O
( O
for O
mutated O
in O
colorectal B
carcinoma I
) O
and O
APC B
( O
for O
adenomatous B
polyposis I
coli I
) O
genes O
at O
5q21 O
have O
been O
isolated O
and O
characterized O
. O

Starting O
from O
the O
MCC O
gene O
, O
a O
strategy O
was O
undertaken O
to O
identify O
constitutional O
submicroscopic O
deletions O
in O
familial B
adenomatous I
polyposis I
patients O
that O
might O
considerably O
narrow O
down O
the O
position O
of O
the O
APC B
gene O
. O

To O
this O
end O
, O
YACs O
identified O
by O
the O
MCC O
gene O
were O
screened O
across O
a O
chromosome O
5 O
- O
specific O
cosmid O
library O
to O
provide O
a O
source O
of O
DNA O
probes O
for O
genomic O
scanning O
. O

The O
cosmids O
isolated O
from O
these O
experiments O
were O
used O
to O
screen O
a O
panel O
of O
somatic O
cell O
hybrids O
containing O
chromosome O
5 O
segregated O
from O
patients O
suspected O
to O
carry O
putative O
interstitial O
deletions O
. O

This O
screening O
approach O
led O
to O
the O
confirmation O
of O
a O
small O
heterozygous O
deletion O
in O
a O
polyposis B
patient O
that O
overlaps O
one O
of O
the O
two O
isolated O
YACs O
. O

This O
YAC O
has O
been O
shown O
to O
contain O
the O
entire O
APC B
gene O
, O
in O
addition O
to O
a O
significant O
portion O
of O
DNA O
flanking O
the O
5 O
end O
of O
the O
gene O
, O
and O
should O
therefore O
prove O
a O
valuable O
resource O
for O
functional O
studies O
by O
transfer O
to O
colorectal B
tumor I
- O
derived O
cell O
lines O
. O

Inherited O
WT1 O
mutation O
in O
Denys B
- I
Drash I
syndrome I
. O

Patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
Wilms B
tumor I
, O
genital B
anomalies I
, O
and O
nephropathy B
) O
have O
been O
demonstrated O
to O
carry O
de O
novo O
constitutional O
mutations O
in O
WT1 O
, O
the O
Wilms B
tumor I
gene O
at O
chromosome O
11p13 O
. O

We O
report O
three O
new O
cases O
, O
two O
carrying O
a O
previously O
described O
WT1 O
exon O
9 O
mutation O
and O
one O
with O
a O
novel O
WT1 O
exon O
8 O
mutation O
. O

However O
, O
unlike O
patients O
in O
previous O
reports O
, O
one O
of O
our O
three O
patients O
inherited O
the O
affected O
allele O
from O
his O
phenotypically O
unaffected O
father O
. O

This O
observation O
indicates O
that O
the O
WT1 O
exon O
9 O
mutation O
affecting O
394Arg O
demonstrated O
in O
over O
one O
- O
half O
of O
the O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
may O
exhibit O
incomplete O
penetrance O
. O

Consequently O
, O
familial O
studies O
in O
patients O
affected O
by O
this O
syndrome O
are O
recommended O
. O
. O

Submicroscopic O
deletions O
at O
the O
WAGR B
locus O
, O
revealed O
by O
nonradioactive O
in O
situ O
hybridization O
. O

Fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
with O
biotin O
- O
labeled O
probes O
mapping O
to O
11p13 O
has O
been O
used O
for O
the O
molecular O
analysis O
of O
deletions O
of O
the O
WAGR B
( O
Wilms B
tumor I
, O
aniridia B
, O
genitourinary B
abnormalities I
, O
and O
mental B
retardation I
) O
locus O
. O

We O
have O
detected O
a O
submicroscopic O
11p13 O
deletion O
in O
a O
child O
with O
inherited O
aniridia B
who O
subsequently O
presented O
with O
Wilms B
tumor I
in O
a O
horseshoe O
kidney O
, O
only O
revealed O
at O
surgery O
. O

The O
mother O
, O
who O
has O
aniridia B
, O
was O
also O
found O
to O
carry O
a O
deletion O
including O
both O
the O
aniridia B
candidate O
gene O
( O
AN2 O
) O
and O
the O
Wilms B
tumor I
predisposition O
gene O
( O
WT1 O
) O
. O

This O
is O
therefore O
a O
rare O
case O
of O
an O
inherited O
WAGR B
deletion O
. O

Wilms B
tumor I
has O
so O
far O
only O
been O
associated O
with O
sporadic O
de O
novo O
aniridia B
cases O
. O

We O
have O
shown O
that O
a O
cosmid O
probe O
for O
a O
candidate O
aniridia B
gene O
, O
homologous O
to O
the O
mouse O
Pax O
- O
6 O
gene O
, O
is O
deleted O
in O
cell O
lines O
from O
aniridia B
patients O
with O
previously O
characterized O
deletions O
at O
11p13 O
, O
while O
another O
cosmid O
marker O
mapping O
between O
two O
aniridia B
- O
associated O
translocation O
breakpoints O
( O
and O
hence O
a O
second O
candidate O
marker O
) O
is O
present O
on O
both O
chromosomes O
. O

These O
results O
support O
the O
Pax O
- O
6 O
homologue O
as O
a O
strong O
candidate O
for O
the O
AN2 O
gene O
. O

FISH O
with O
cosmid O
probes O
has O
proved O
to O
be O
a O
fast O
and O
reliable O
technique O
for O
the O
molecular O
analysis O
of O
deletions O
. O

It O
can O
be O
used O
with O
limited O
amounts O
of O
material O
and O
has O
strong O
potential O
for O
clinical O
applications O
. O
. O

Linkage O
of O
gene O
for O
C2 B
deficiency I
and O
the O
major O
histocompatibility O
complex O
MHC O
in O
man O
. O

Family O
study O
of O
a O
further O
case O
. O

Close O
linkage O
between O
HL O
- O
A O
and O
C2 B
deficiency I
was O
first O
reported O
by O
FU O
and O
co O
- O
workers O
in O
1974 O
. O

We O
present O
here O
a O
pedigree O
of O
a O
31 O
- O
year O
- O
old O
C2 B
- I
deficient I
individual O
with O
clinical O
manifestations O
of O
Hodgkins B
disease I
. O

The O
following O
markers O
were O
tested O
C2 O
levels O
, O
factor O
B O
polymorphism O
, O
blood O
groups O
, O
and O
enzyme O
typing O
. O

In O
addition O
to O
close O
linkage O
between O
HL O
- O
A O
and O
C2 B
deficiency I
, O
both O
parents O
were O
heterozygous O
for O
Bf O
( O
HL O
- O
A O
linked O
, O
electrophoretic O
variation O
of O
B O
) O
. O

The O
two O
HL O
- O
A O
haplotypes O
closely O
linked O
to O
C2 B
deficiency I
are O
different O
2 O
, O
W18 O
and O
W24 O
, O
W18 O
. O

They O
share O
, O
however O
, O
the O
SD2 O
antigen O
W18 O
and O
the O
LD O
type O
7a O
. O
. O

Screening O
for O
germ O
- O
line O
mutations O
in O
familial B
adenomatous I
polyposis I
patients O
: O
61 O
new O
patients O
and O
a O
summary O
of O
150 O
unrelated O
patients O
. O

We O
report O
here O
the O
result O
of O
a O
screening O
for O
germ O
- O
line O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
in O
61 O
new O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
patients O
as O
well O
as O
a O
summary O
of O
the O
results O
of O
150 O
patients O
. O

Examination O
of O
the O
entire O
coding O
region O
of O
the O
APC B
gene O
, O
based O
on O
a O
ribonuclease O
protection O
assay O
coupled O
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
, O
disclosed O
mutations O
that O
were O
considered O
to O
cause O
significant O
defects O
in O
the O
APC B
product O
in O
97 O
of O
150 O
unrelated O
FAP B
patients O
. O

Our O
findings O
revealed O
the O
following O
characteristics O
of O
the O
germ O
- O
line O
mutations O
of O
APC O
1 O
) O
the O
great O
majority O
of O
the O
mutations O
were O
found O
to O
truncate O
the O
APC B
product O
; O
2 O
) O
almost O
all O
of O
the O
mutations O
were O
located O
within O
the O
first O
half O
of O
the O
coding O
region O
; O
3 O
) O
no O
correlation O
was O
observed O
between O
the O
locations O
of O
germ O
- O
line O
mutations O
and O
extracolonic O
manifestations O
in O
FAP B
patients O
; O
4 O
) O
more O
than O
80 O
% O
of O
base O
substitutions O
in O
the O
APC B
gene O
were O
from O
cytosine O
to O
other O
nucleotides O
, O
nearly O
one O
- O
third O
of O
which O
occurred O
at O
the O
GpG O
site O
. O

Our O
results O
provide O
information O
helpful O
to O
an O
understanding O
of O
the O
APC B
gene O
and O
will O
also O
contribute O
to O
presymptomatic O
diagnosis O
of O
members O
in O
FAP B
families O
. O
. O

Somatic O
mutations O
of O
the O
APC B
gene O
in O
colorectal B
tumors I
: O
mutation O
cluster O
region O
in O
the O
APC B
gene O
. O

We O
examined O
somatic O
mutations O
of O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
in O
63 O
colorectal B
tumors I
( O
16 O
adenomas B
and O
47 O
carcinomas B
) O
developed O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
and O
non O
- O
FAP O
patients O
. O

In O
addition O
to O
loss O
of O
heterozygosity O
( O
LOH O
) O
at O
the O
APC B
locus O
in O
30 O
tumors B
, O
43 O
other O
somatic O
mutations O
were O
detected O
. O

Twenty O
- O
one O
of O
them O
were O
point O
mutations O
; O
16 O
nonsense O
and O
two O
missense O
mutations O
, O
and O
three O
occurred O
in O
introns O
at O
the O
splicing O
site O
. O

Twenty O
- O
two O
tumors B
had O
frameshift O
mutations O
due O
to O
deletion O
or O
insertion O
; O
nineteen O
of O
them O
were O
deletions O
of O
one O
to O
31 O
bp O
and O
three O
were O
a O
1 O
- O
bp O
insertion O
. O

One O
tumor B
had O
a O
1 O
- O
bp O
deletion O
in O
an O
intron O
near O
the O
splicing O
site O
. O

Hence O
, O
41 O
( O
95 O
% O
) O
of O
43 O
mutations O
resulted O
in O
truncation O
of O
the O
APC B
protein O
. O

Over O
60 O
% O
of O
the O
somatic O
mutations O
in O
the O
APC B
gene O
were O
clustered O
within O
a O
small O
region O
of O
exon O
15 O
, O
designated O
as O
MCR O
( O
mutation O
cluster O
region O
) O
, O
which O
accounted O
for O
less O
than O
10 O
% O
of O
the O
coding O
region O
. O

Combining O
these O
data O
and O
the O
results O
of O
LOH O
, O
more O
than O
80 O
% O
of O
tumors B
( O
14 O
adenomas B
and O
39 O
carcinomas B
) O
had O
at O
least O
one O
mutation O
in O
the O
APC B
gene O
, O
of O
which O
more O
than O
60 O
% O
( O
9 O
adenomas B
and O
23 O
carcinomas B
) O
had O
two O
mutations O
. O

These O
results O
strongly O
suggest O
that O
somatic O
mutations O
of O
the O
APC B
gene O
are O
associated O
with O
development O
of O
a O
great O
majority O
of O
colorectal B
tumors I
. O
. O

Constitutional O
mutations O
in O
the O
WT1 O
gene O
in O
patients O
with O
Denys B
- I
Drash I
syndrome I
. O

The O
Denys B
- I
Drash I
syndrome I
is O
characterised O
by O
a O
typical O
nephropathy B
, O
genital B
abnormalities I
and O
also O
predisposes O
to O
the O
development O
of O
Wilms B
tumor I
. O

These O
patients O
eventually O
go O
into O
end O
stage O
renal B
failure I
. O

A O
candidate O
Wilms B
tumor I
gene O
, O
WT1 O
, O
from O
the O
11p13 O
chromosome O
region O
has O
recently O
been O
cloned O
. O

We O
have O
analysed O
the O
DNA O
sequence O
in O
constitutional O
cells O
from O
eight O
patients O
and O
have O
shown O
heterozygous O
mutations O
in O
six O
of O
them O
. O

Four O
of O
the O
mutations O
were O
in O
exon O
9 O
, O
all O
resulting O
in O
missense O
mutations O
. O

Three O
were O
at O
nucleotide O
position O
1180 O
resulting O
in O
an O
arg O
> O
trp O
amino O
acid O
change O
. O

The O
other O
was O
at O
position O
1186 O
converting O
an O
asp O
> O
asn O
in O
the O
predicted O
resultant O
protein O
. O

One O
patient O
had O
a O
missense O
mutation O
in O
exon O
8 O
, O
converting O
an O
arg O
> O
his O
. O

A O
single O
base O
pair O
insertion O
at O
nucleotide O
position O
821 O
in O
exon O
6 O
resulted O
in O
the O
generation O
of O
a O
premature O
stop O
codon O
in O
the O
last O
patient O
. O

We O
were O
unable O
to O
find O
a O
mutation O
in O
one O
patient O
despite O
complete O
sequencing O
of O
the O
genomic O
sequence O
of O
the O
gene O
. O

The O
last O
patient O
carried O
a O
constitutional O
deletion O
of O
the O
11p13 O
region O
and O
no O
additional O
mutation O
was O
found O
. O

There O
was O
no O
obvious O
correlation O
between O
the O
type O
of O
mutation O
and O
phenotypic O
expression O
. O

These O
results O
further O
demonstrate O
that O
the O
WT1 O
gene O
is O
important O
in O
both O
the O
development O
of O
the O
kidney O
and O
the O
genito O
- O
urinary O
system O
. O
. O

Linkage O
disequilibrium O
mapping O
in O
isolated O
founder O
populations O
: O
diastrophic B
dysplasia I
in O
Finland O
. O

Linkage O
disequilibrium O
mapping O
in O
isolated O
populations O
provides O
a O
powerful O
tool O
for O
fine O
structure O
localization O
of O
disease O
genes O
. O

Here O
, O
Luria O
and O
Delbrucks O
classical O
methods O
for O
analysing O
bacterial O
cultures O
are O
adapted O
to O
the O
study O
of O
human O
isolated O
founder O
populations O
in O
order O
to O
estimate O
( O
i O
) O
the O
recombination O
fraction O
between O
a O
disease O
locus O
and O
a O
marker O
; O
( O
ii O
) O
the O
expected O
degree O
of O
allelic O
homogeneity O
in O
a O
population O
; O
and O
( O
iii O
) O
the O
mutation O
rate O
of O
marker O
loci O
. O

Using O
these O
methods O
, O
we O
report O
striking O
linkage O
disequilibrium O
for O
diastrophic B
dysplasia I
( O
DTD B
) O
in O
Finland O
indicating O
that O
the O
DTD B
gene O
should O
lie O
within O
0 O
. O

06 O
centimorgans O
( O
or O
about O
60 O
kilobases O
) O
of O
the O
CSF1R O
gene O
. O

Predictions O
about O
allelic O
homogeneity O
in O
Finland O
and O
mutation O
rates O
in O
simple O
sequence O
repeats O
are O
confirmed O
by O
independent O
observations O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
: O
refinement O
of O
the O
localization O
on O
Xp O
and O
identification O
of O
another O
closely O
linked O
marker O
locus O
, O
OATL1 O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
has O
previously O
been O
mapped O
to O
the O
proximal O
short O
arm O
of O
the O
X O
chromosome O
between O
the O
DXS14 O
and O
DXS7 O
loci O
. O

In O
this O
study O
, O
further O
segregation O
analysis O
has O
been O
performed O
using O
a O
newly O
identified O
WAS B
family O
as O
well O
as O
an O
additional O
marker O
probe O
, O
HOATL1 O
. O

The O
results O
indicate O
close O
linkage O
between O
the O
WAS B
and O
OATL1 O
loci O
( O
Z O
= O
6 O
. O
08 O
at O
theta O
= O
0 O
. O
00 O
) O
and O
localize O
the O
TIMP O
, O
OATL1 O
, O
DXS255 O
, O
and O
WAS B
loci O
distal O
to O
DXS146 O
and O
the O
OATL1 O
and O
WAS B
loci O
proximal O
to O
TIMP O
. O

These O
linkage O
data O
narrow O
the O
boundaries O
within O
which O
the O
WAS B
locus O
maps O
to O
the O
chromosomal O
region O
bracketed O
by O
TIMP O
and O
DXS146 O
and O
support O
the O
loci O
order O
Xpter O
- O
DXS7 O
- O
TIMP O
- O
( O
OATL1 O
, O
WAS O
, O
DXS255 O
) O
- O
DXS146 O
. O

Detection O
of O
an O
unstable O
fragment O
of O
DNA O
specific O
to O
individuals O
with O
myotonic B
dystrophy I
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
the O
most O
common O
form O
of O
adult O
muscular B
dystrophy I
, O
with O
a O
prevalence O
of O
2 O
- O
14 O
per O
100 O
, O
000 O
individuals O
. O

The O
disease O
is O
characterized O
by O
progressive O
muscle B
weakness I
and O
sustained B
muscle I
contraction I
, O
often O
with O
a O
wide O
range O
of O
accompanying O
symptoms O
. O

The O
age O
at O
onset O
and O
severity O
of O
the O
disease O
show O
extreme O
variation O
, O
both O
within O
and O
between O
families O
. O

Despite O
its O
clinical O
variability O
, O
this O
dominant O
condition O
segregates O
as O
a O
single O
locus O
at O
chromosome O
19q13 O
. O

3 O
in O
every O
population O
studied O
. O

It O
is O
flanked O
by O
the O
tightly O
linked O
genetic O
markers O
ERCC1 O
proximally O
and O
D19S51 O
distally O
; O
these O
define O
the O
DM B
critical O
region O
. O

We O
report O
the O
isolation O
of O
an O
expressed O
sequence O
from O
this O
region O
which O
detects O
a O
DNA O
fragment O
that O
is O
larger O
in O
affected O
individuals O
than O
in O
normal O
siblings O
or O
unaffected O
controls O
. O

The O
size O
of O
this O
fragment O
varies O
between O
affected O
siblings O
, O
and O
increases O
in O
size O
through O
generations O
in O
parallel O
with O
increasing O
severity O
of O
the O
disease O
. O

We O
postulate O
that O
this O
unstable O
DNA O
sequence O
is O
the O
molecular O
feature O
that O
underlies O
DM B
. O

Common O
sequence O
motifs O
at O
the O
rearrangement O
sites O
of O
a O
constitutional O
X O
/ O
autosome O
translocation O
and O
associated O
deletion O
. O

Reciprocal O
chromosome O
translocations O
are O
common O
de O
novo O
rearrangements O
that O
occur O
randomly O
throughout O
the O
human O
genome O
. O

To O
learn O
about O
causative O
mechanisms O
, O
we O
have O
cloned O
and O
sequenced O
the O
breakpoints O
of O
a O
cytologically O
balanced O
constitutional O
reciprocal O
translocation O
, O
t O
( O
X O
; O
4 O
) O
( O
p21 O
. O
2 O
; O
q31 O
. O
22 O
) O
, O
present O
in O
a O
girl O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

Physical O
mapping O
of O
the O
derivative O
chromosomes O
, O
after O
their O
separation O
in O
somatic O
cell O
hybrids O
, O
reveals O
that O
the O
translocation O
disrupts O
the O
DMD B
gene O
in O
Xp21 O
within O
the O
18 O
- O
kb O
intron O
16 O
. O

Restriction O
mapping O
and O
sequencing O
of O
clones O
that O
span O
both O
translocation O
breakpoints O
as O
well O
as O
the O
corresponding O
normal O
regions O
indicate O
the O
loss O
of O
approximately O
5 O
kb O
in O
the O
formation O
of O
the O
derivative O
X O
chromosome O
, O
with O
4 O
- O
6 O
bp O
deleted O
from O
chromosome O
4 O
. O

RFLP O
and O
Southern O
analyses O
indicate O
that O
the O
de O
novo O
translocation O
is O
a O
paternal O
origin O
and O
that O
the O
fathers O
X O
chromosome O
contains O
the O
DNA O
that O
is O
deleted O
in O
the O
derivative O
X O
. O

Most O
likely O
, O
deletion O
and O
translation O
arose O
simultaneously O
from O
a O
complex O
rearrangement O
event O
that O
involves O
three O
chromosomal O
breakpoints O
. O

Short O
regions O
of O
sequence O
homology O
were O
present O
at O
the O
three O
sites O
. O

A O
5 O
- O
bp O
sequence O
, O
GGAAT O
, O
found O
exactly O
at O
the O
translocation O
breakpoints O
on O
both O
normal O
chromosomes O
X O
and O
4 O
, O
has O
been O
preserved O
only O
on O
the O
der O
( O
4 O
) O
chromosome O
. O

It O
is O
likely O
that O
the O
X O
- O
derived O
sequence O
GGAATCA O
has O
been O
lost O
in O
the O
formation O
of O
the O
der O
( O
X O
) O
chromosome O
, O
as O
it O
matches O
an O
inverted O
GAATCA O
sequence O
present O
on O
the O
opposite O
strand O
exactly O
at O
the O
other O
end O
of O
the O
deleted O
5 O
- O
kb O
fragment O
. O

A O
genetic O
etiology O
for O
DiGeorge B
syndrome I
: O
consistent O
deletions O
and O
microdeletions O
of O
22q11 O
. O

DiGeorge B
syndrome I
( O
DGS B
) O
, O
a O
developmental O
field O
defect O
of O
the O
third O
and O
fourth O
pharyngeal O
pouches O
, O
is O
characterized O
by O
aplasia B
or I
hypoplasia I
of I
the I
thymus I
and I
parathyroid I
glands I
and O
by O
conotruncal B
cardiac I
malformations I
. O

Cytogenetic O
studies O
support O
the O
presence O
of O
a O
DGS B
critical O
region O
in O
band O
22q11 O
. O

In O
the O
present O
study O
, O
we O
report O
the O
results O
of O
clinical O
, O
cytogenetic O
, O
and O
molecular O
studies O
of O
14 O
patients O
with O
DGS B
. O

Chromosome O
analysis O
, O
utilizing O
high O
- O
resolution O
banding O
techniques O
, O
detected O
interstitial O
deletions O
in O
five O
probands O
and O
was O
inconclusive O
for O
a O
deletion O
in O
three O
probands O
. O

The O
remaining O
six O
patients O
had O
normal O
karyotypes O
. O

In O
contrast O
, O
molecular O
analysis O
detected O
DNA O
deletions O
in O
all O
14 O
probands O
. O

Two O
of O
10 O
loci O
tested O
, O
D22S75 O
and O
D22S259 O
, O
are O
deleted O
in O
all O
14 O
patients O
. O

A O
third O
locus O
, O
D22S66 O
, O
is O
deleted O
in O
the O
eight O
DGS B
probands O
tested O
. O

Physical O
mapping O
using O
somatic O
cell O
hybrids O
places O
D22S66 O
between O
D22S75 O
and O
D22S259 O
, O
suggesting O
that O
it O
should O
be O
deleted O
in O
the O
remaining O
six O
cases O
. O

Parent O
- O
of O
- O
origin O
studies O
were O
performed O
in O
five O
families O
. O

Four O
probands O
failed O
to O
inherit O
a O
maternal O
allele O
, O
and O
one O
failed O
to O
inherit O
a O
paternal O
allele O
. O

On O
the O
basis O
of O
these O
families O
, O
and O
of O
six O
maternally O
and O
five O
paternally O
derived O
unbalanced O
- O
translocation O
DGS B
probands O
in O
the O
literature O
, O
parent O
of O
origin O
or O
imprinting O
does O
not O
appear O
to O
play O
an O
important O
role O
in O
the O
pathogenesis O
of O
DGS B
. O

Deletion O
of O
the O
same O
three O
loci O
in O
all O
14 O
DGS B
probands O
begins O
to O
delineate O
the O
region O
of O
chromosome O
22 O
critical O
for O
DGS B
and O
confirms O
the O
hypothesis O
that O
submicroscopic O
deletions O
of O
22q11 O
are O
etiologic O
in O
the O
vast O
majority O
of O
cases O
. O
. O

Loss O
of O
normal O
allele O
of O
the O
APC B
gene O
in O
an O
adrenocortical B
carcinoma I
from O
a O
patient O
with O
familial B
adenomatous I
polyposis I
. O

Endocrine B
neoplasms I
have O
been O
reported O
occasionally O
in O
patients O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

An O
adrenocorotical B
carcinoma I
was O
studied O
in O
a O
patient O
with O
a O
family O
history O
of O
FAP B
. O

Loss O
of O
heterozygosity O
( O
LOH O
) O
in O
the O
region O
close O
to O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
was O
detected O
in O
this O
carcinoma B
, O
and O
evidence O
was O
obtained O
that O
there O
was O
a O
loss O
of O
the O
normal O
allele O
of O
the O
APC B
gene O
. O

This O
is O
the O
first O
demonstration O
of O
LOH O
at O
the O
APC B
locus O
in O
adrenocortical B
tumors I
. O

The O
present O
results O
and O
our O
previous O
data O
on O
LOH O
in O
a O
recurring O
desmoid B
tumor I
suggest O
that O
the O
heterozygous O
mutant O
/ O
wild O
- O
type O
condition O
of O
the O
APC B
gene O
may O
give O
rise O
to O
benign B
tumors I
, O
and O
that O
functional O
loss O
of O
this O
gene O
leads O
to O
development O
of O
tumors B
not O
only O
in O
the O
colon O
but O
also O
in O
other O
various O
parts O
of O
the O
body O
in O
FAP B
patients O
. O
. O

Oncogenic O
point O
mutations O
in O
exon O
20 O
of O
the O
RB1 O
gene O
in O
families O
showing O
incomplete O
penetrance O
and O
mild O
expression O
of O
the O
retinoblastoma B
phenotype O
. O

The O
retinoblastoma B
- O
predisposition O
gene O
, O
RB1 O
, O
segregates O
as O
an O
autosomal O
dominant O
trait O
with O
high O
( O
90 O
% O
) O
penetrance O
. O

Certain O
families O
, O
however O
, O
show O
an O
unusual O
low O
- O
penetrance O
phenotype O
with O
many O
individuals O
being O
unaffected O
, O
unilaterally O
affected O
, O
or O
with O
evidence O
of O
spontaneously O
regressed O
tumors B
. O

We O
have O
used O
single O
- O
strand O
conformation O
polymorphism O
analysis O
and O
PCR O
sequencing O
to O
study O
two O
such O
families O
. O

Mutations O
were O
found O
in O
exon O
20 O
of O
RB1 O
in O
both O
cases O
. O

In O
one O
family O
a O
C O
- O
- O
- O
- O
T O
transition O
in O
codon O
661 O
converts O
an O
arginine O
( O
CGG O
) O
to O
a O
tryptophan O
( O
TGG O
) O
codon O
. O

In O
this O
family O
, O
incomplete O
penetrance O
and O
mild O
phenotypic O
expression O
were O
observed O
in O
virtually O
all O
patients O
, O
possibly O
indicating O
that O
single O
amino O
acid O
changes O
may O
modify O
protein O
structure O
/ O
function O
such O
that O
tumorigenesis O
is O
not O
inevitable O
. O

In O
the O
second O
family O
the O
mutation O
in O
codon O
675 O
is O
a O
G O
- O
- O
- O
- O
T O
transversion O
that O
converts O
a O
glutamine O
( O
GAA O
) O
to O
a O
stop O
( O
TAA O
) O
codon O
. O

However O
, O
this O
mutation O
also O
occurs O
near O
a O
potential O
cryptic O
splice O
acceptor O
site O
, O
raising O
the O
possibility O
of O
alternative O
splicing O
resulting O
in O
a O
less O
severely O
disrupted O
protein O
. O
. O

Late O
- O
onset O
metachromatic B
leukodystrophy I
: O
molecular O
pathology O
in O
two O
siblings O
. O

We O
report O
on O
a O
new O
allele O
at O
the O
arylsulfatase O
A O
( O
ARSA O
) O
locus O
causing O
late O
- O
onset O
metachromatic B
leukodystrophy I
( O
MLD B
) O
. O

In O
that O
allele O
arginine84 O
, O
a O
residue O
that O
is O
highly O
conserved O
in O
the O
arylsulfatase O
gene O
family O
, O
is O
replaced O
by O
glutamine O
. O

In O
contrast O
to O
alleles O
that O
cause O
early O
- O
onset O
MLD B
, O
the O
arginine84 O
to O
glutamine O
substitution O
is O
associated O
with O
some O
residual O
ARSA O
activity O
. O

A O
comparison O
of O
genotypes O
, O
ARSA O
activities O
, O
and O
clinical O
data O
on O
4 O
individuals O
carrying O
the O
allele O
of O
81 O
patients O
with O
MLD B
examined O
, O
further O
validates O
the O
concept O
that O
different O
degrees O
of O
residual O
ARSA O
activity O
are O
the O
basis O
of O
phenotypical O
variation O
in O
MLD B
. O
. O

Trisomy B
15 I
with O
loss O
of O
the O
paternal O
15 O
as O
a O
cause O
of O
Prader B
- I
Willi I
syndrome I
due O
to O
maternal B
disomy I
. O

Uniparental B
disomy I
has O
recently O
been O
recognized O
to O
cause O
human O
disorders O
, O
including O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
describe O
a O
particularly O
instructive O
case O
which O
raises O
important O
issues O
concerning O
the O
mechanisms O
producing O
uniparental B
disomy I
and O
whose O
evaluation O
provides O
evidence O
that O
trisomy O
may O
precede O
uniparental B
disomy I
in O
a O
fetus O
. O

Chorionic O
villus O
sampling O
performed O
for O
advanced O
maternal O
age O
revealed O
trisomy B
15 I
in O
all O
direct O
and O
cultured O
cells O
, O
though O
the O
fetus O
appeared O
normal O
. O

Chromosome O
analysis O
of O
amniocytes O
obtained O
at O
15 O
wk O
was O
normal O
in O
over O
100 O
cells O
studied O
. O

The O
child O
was O
hypotonic B
at O
birth O
, O
and O
high O
- O
resolution O
banding O
failed O
to O
reveal O
the O
deletion O
of O
15q11 O
- O
13 O
, O
a O
deletion O
which O
is O
found O
in O
50 O
% O
- O
70 O
% O
of O
patients O
with O
PWS B
. O

Over O
time O
, O
typical O
features O
of O
PWS B
developed O
. O

Molecular O
genetic O
analysis O
using O
probes O
for O
chromosome O
15 O
revealed O
maternal O
disomy O
. O

Maternal O
nondisjunction O
with O
fertilization O
of O
a O
disomic O
egg O
by O
a O
normal O
sperm O
, O
followed O
by O
loss O
of O
the O
paternal O
15 O
, O
is O
a O
likely O
cause O
of O
confined O
placental O
mosaicism O
and O
uniparental B
disomy I
in O
this O
case O
of O
PWS B
, O
and O
advanced O
maternal O
age O
may O
be O
a O
predisposing O
factor O
. O
. O

Genetic O
heterogeneity O
in O
X B
- I
linked I
amelogenesis I
imperfecta I
. O

The O
AMELX O
gene O
located O
at O
Xp22 O
. O

1 O
- O
p22 O
. O

3 O
encodes O
for O
the O
enamel O
protein O
amelogenin O
and O
has O
been O
implicated O
as O
the O
gene O
responsible O
for O
the O
inherited B
dental I
abnormality I
X B
- I
linked I
amelogenesis I
imperfecta I
( O
XAI B
) O
. O

Three O
families O
with O
XAI B
have O
been O
investigated O
using O
polymorphic O
DNA O
markers O
flanking O
the O
position O
of O
AMELX O
. O

Using O
two O
- O
point O
linkage O
analysis O
, O
linkage O
was O
established O
between O
XAI B
and O
several O
of O
these O
markers O
in O
two O
families O
, O
with O
a O
combined O
lod O
score O
of O
6 O
. O

05 O
for O
DXS16 O
at O
theta O
= O
0 O
. O

04 O
04 O
. O

This O
supports O
the O
involvement O
of O
AMELX O
, O
located O
close O
to O
DXS16 O
, O
in O
the O
XAI B
disease I
process O
( O
AIH1 O
) O
in O
those O
families O
. O

Using O
multipoint O
linkage O
analysis O
, O
the O
combined O
maximum O
lod O
score O
for O
these O
two O
families O
was O
7 O
. O

30 O
for O
a O
location O
of O
AIH1 O
at O
2 O
cM O
distal O
to O
DXS16 O
. O

The O
support O
interval O
around O
this O
location O
extended O
about O
8 O
cM O
proximal O
to O
DXS92 O
, O
and O
the O
AIH1 O
location O
could O
not O
be O
precisely O
defined O
by O
multipoint O
mapping O
. O

Study O
of O
recombination O
events O
indicated O
that O
AIH1 O
lies O
in O
the O
interval O
between O
DXS143 O
and O
DXS85 O
. O

There O
was O
significant O
evidence O
against O
linkage O
to O
this O
region O
in O
the O
third O
family O
, O
indicating O
locus O
heterogeneity O
in O
XAI B
. O

Further O
analysis O
with O
markers O
on O
the O
long O
arm O
of O
the O
X O
chromosome O
showed O
evidence O
of O
linkage O
to O
DXS144E O
and O
F9 O
with O
no O
recombination O
with O
either O
of O
these O
markers O
. O

Two O
- O
point O
analysis O
gave O
a O
peak O
lod O
score O
at O
DXS144E O
with O
a O
maximum O
lod O
score O
of O
2 O
. O

83 O
at O
theta O
= O
0 O
, O
with O
a O
peak O
lod O
score O
in O
multipoint O
linkage O
analysis O
of O
2 O
. O

84 O
at O
theta O
= O
0 O
. O

The O
support O
interval O
extended O
9 O
cM O
proximal O
to O
DXS144E O
and O
14 O
cM O
distal O
to O
F9 O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Multiple O
origins O
for O
phenylketonuria B
in O
Europe O
. O

Phenylketonuria B
( O
PKU B
) O
, O
a O
disorder B
of I
amino I
acid I
metabolism I
prevalent O
among O
Caucasians O
and O
other O
ethnic O
groups O
, O
is O
caused O
primarily O
by O
a O
deficiency B
of I
the I
hepatic I
enzyme I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

PKU B
is O
a O
highly O
heterogeneous O
disorder O
, O
with O
more O
than O
60 O
molecular O
lesions O
identified O
in O
the O
PAH O
gene O
. O

The O
haplotype O
associations O
, O
relative O
frequencies O
, O
and O
distributions O
of O
five O
prevalent O
PAH O
mutations O
( O
R158Q O
, O
R261Q O
, O
IVS10nt546 O
, O
R408W O
, O
and O
IVS12n1 O
) O
were O
established O
in O
a O
comprehensive O
European O
sample O
population O
and O
subsequently O
were O
examined O
to O
determine O
the O
potential O
roles O
of O
several O
genetic O
mechanisms O
in O
explaining O
the O
present O
distribution O
of O
the O
major O
PKU B
alleles O
. O

Each O
of O
these O
five O
mutations O
was O
strongly O
associated O
with O
only O
one O
of O
the O
more O
than O
70 O
chromosomal O
haplotypes O
defined O
by O
eight O
RFLPs O
in O
or O
near O
the O
PAH O
gene O
. O

These O
findings O
suggest O
that O
each O
of O
these O
mutations O
arose O
through O
a O
single O
founding O
event O
that O
occurred O
within O
time O
periods O
ranging O
from O
several O
hundred O
to O
several O
thousand O
years O
ago O
. O

From O
the O
significant O
differences O
observed O
in O
the O
relative O
frequencies O
and O
distributions O
of O
these O
five O
alleles O
throughout O
Europe O
, O
four O
of O
these O
putative O
founding O
events O
could O
be O
localized O
to O
specific O
ethnic O
subgroups O
. O

Together O
, O
these O
data O
suggest O
that O
there O
were O
multiple O
, O
geographically O
and O
ethnically O
distinct O
origins O
for O
PKU B
within O
the O
European O
population O
. O
. O

Complement B
factor I
2 I
deficiency I
: O
a O
clinical O
and O
serological O
family O
study O
. O

Inherited B
complement I
deficiencies I
are O
associated O
with O
a O
variety O
of O
connective O
tissue O
diseases O
. O

A O
family O
with O
inherited B
deficiency I
of I
complement I
factor I
2 I
( O
C2 O
) O
is O
described O
in O
which O
two O
family O
members O
with O
homozygous O
C2 B
deficiency I
developed O
cutaneous B
vasculitis I
and O
sicca B
syndrome I
. O

The O
other O
family O
members O
had O
heterozygous O
C2 B
deficiency I
and O
each O
member O
had O
the O
HLA O
- O
A25 O
, O
B18 O
, O
DR2 O
( O
w15 O
) O
haplotype O
. O

The O
mother O
had O
seropositive B
rheumatoid I
arthritis I
. O

Further O
studies O
showed O
the O
presence O
of O
cryoglobulins O
, O
antibodies O
against O
endothelial O
cells O
, O
and O
anticardiolipin O
antibodies O
. O
. O

New O
variant O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
( O
PLP O
) O
gene O
in O
a O
family O
with O
Pelizaeus B
- I
Merzbacher I
disease I
. O

A O
C O
- O
- O
greater O
than O
G O
transversion O
has O
been O
found O
in O
exon O
3 O
of O
the O
PLP O
gene O
of O
affected O
males O
and O
their O
mother O
in O
a O
single O
sibship O
with O
Pelizaeus B
- I
merzbacher I
disease I
( O
PMD B
) O
. O

The O
transversion O
should O
not O
result O
in O
an O
amino O
acid O
change O
in O
the O
protein O
but O
it O
does O
result O
in O
the O
loss O
of O
a O
HaeIII O
restriction O
endonuclease O
cleavage O
site O
. O

It O
is O
concordant O
with O
the O
disease O
in O
this O
family O
. O

One O
- O
hundred O
- O
ten O
unrelated O
X O
chromosomes O
are O
negative O
for O
this O
mutation O
. O

No O
other O
sequence O
defect O
was O
found O
in O
the O
PLP O
exons O
of O
the O
affected O
males O
. O

The O
cause O
of O
disease O
in O
this O
family O
remains O
unknown O
, O
but O
the O
association O
between O
this O
rare O
mutation O
and O
PMD B
is O
intriguing O
. O

The O
mutation O
can O
serve O
as O
a O
marker O
for O
following O
segregation O
of O
the O
PLP O
gene O
. O
. O

Uncoupling O
of O
hypomyelination B
and O
glial B
cell I
death I
by O
a O
mutation O
in O
the O
proteolipid O
protein O
gene O
. O

Proteolipid O
protein O
( O
PLP O
; O
M O
( O
r O
) O
30 O
, O
000 O
) O
is O
a O
highly O
conserved O
major O
polytopic O
membrane O
protein O
in O
myelin O
but O
its O
cellular O
function O
remains O
obscure O
. O

Neurological O
mutant O
mice O
can O
often O
provide O
model O
systems O
for O
human O
genetic B
disorders I
. O

Mutations O
of O
the O
X O
- O
chromosome O
- O
linked O
PLP O
gene O
are O
lethal O
, O
identified O
first O
in O
the O
jimpy O
mouse O
and O
subsequently O
in O
patients O
with O
Pelizaeus B
- I
Merzbacher I
disease I
. O

The O
unexplained O
phenotype O
of O
these O
mutations O
includes O
degeneration B
and I
premature I
cell I
death I
of I
oligodendrocytes I
with O
associated O
hypomyelination B
. O

Here O
we O
show O
that O
a O
new O
mouse O
mutant O
rumpshaker O
is O
defined O
by O
the O
amino O
- O
acid O
substitution O
Ile O
- O
to O
- O
Thr O
at O
residue O
186 O
in O
a O
membrane O
- O
embedded O
domain O
of O
PLP O
. O

Surprisingly O
, O
rumpshaker O
mice O
, O
although O
myelin B
- I
deficient I
, O
have O
normal O
longevity O
and O
a O
full O
complement O
of O
morphologically O
normal O
oligodendrocytes O
. O

Hypomyelination B
can O
thus O
be O
genetically O
separated O
from O
the O
PLP O
- O
dependent O
oligodendrocyte B
degeneration I
. O

We O
suggest O
that O
PLP O
has O
a O
vital O
function O
in O
glial O
cell O
development O
, O
distinct O
from O
its O
later O
role O
in O
myelin O
assembly O
, O
and O
that O
this O
dichotomy O
of O
action O
may O
explain O
the O
clinical O
spectrum O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O
. O

A O
pseudodeficiency O
allele O
common O
in O
non O
- O
Jewish O
Tay B
- I
Sachs I
carriers O
: O
implications O
for O
carrier O
screening O
. O

Deficiency B
of I
beta I
- I
hexosaminidase I
A I
( O
Hex O
A O
) O
activity O
typically O
results O
in O
Tay B
- I
Sachs I
disease I
. O

However O
, O
healthy O
subjects O
found O
to O
be O
deficient B
in I
Hex I
A I
activity O
( O
i O
. O
e O
. O
, O
pseudodeficient O
) O
by O
means O
of O
in O
vitro O
biochemical O
tests O
have O
been O
described O
. O

We O
analyzed O
the O
HEXA O
gene O
of O
one O
pseudodeficient O
subject O
and O
identified O
both O
a O
C739 O
- O
to O
- O
T O
substitution O
that O
changes O
Arg247 O
- O
- O
- O
- O
Trp O
on O
one O
allele O
and O
a O
previously O
identified O
Tay B
- I
Sachs I
disease I
mutation O
on O
the O
second O
allele O
. O

Six O
additional O
pseudodeficient O
subjects O
were O
found O
to O
have O
the O
C739 O
- O
to O
- O
T O
mutation O
. O

This O
allele O
accounted O
for O
32 O
% O
( O
20 O
/ O
62 O
) O
of O
non O
- O
Jewish O
enzyme O
- O
defined O
Tay B
- I
Sachs I
disease I
carriers O
but O
for O
none O
of O
36 O
Jewish O
enzyme O
- O
defined O
carriers O
who O
did O
not O
have O
one O
of O
three O
known O
mutations O
common O
to O
this O
group O
. O

The O
C739 O
- O
to O
- O
T O
allele O
, O
together O
with O
a O
" O
true O
" O
Tay B
- I
Sachs I
disease I
allele O
, O
causes O
Hex O
A O
pseudodeficiency O
. O

Given O
both O
the O
large O
proportion O
of O
non O
- O
Jewish O
carriers O
with O
this O
allele O
and O
that O
standard O
biochemical O
screening O
cannot O
differentiate O
between O
heterozygotes O
for O
the O
C739 O
- O
to O
- O
T O
mutations O
and O
Tay B
- I
Sachs I
disease I
carriers O
, O
DNA O
testing O
for O
this O
mutation O
in O
at O
- O
risk O
couples O
is O
essential O
. O

Pelizaeus B
- I
Merzbacher I
disease I
: O
detection O
of O
mutations O
Thr181 O
- O
- O
- O
- O
Pro O
and O
Leu223 O
- O
- O
- O
- O
Pro O
in O
the O
proteolipid O
protein O
gene O
, O
and O
prenatal O
diagnosis O
. O

A O
family O
with O
an O
apparent O
history O
of O
X O
- O
linked O
Pelizaeus B
- I
Merzbacher I
disease I
presented O
for O
genetic O
counseling O
, O
requesting O
carrier O
detection O
and O
prenatal O
diagnosis O
. O

RFLP O
analysis O
using O
the O
proteolipid O
protein O
( O
PLP O
) O
gene O
probe O
was O
uninformative O
in O
this O
family O
. O

A O
prenatal O
diagnosis O
on O
a O
chorionic O
villus O
sample O
( O
CVS O
) O
was O
carried O
out O
using O
single O
- O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
analysis O
of O
a O
variant O
in O
exon O
4 O
of O
the O
PLP O
gene O
. O

The O
fetus O
was O
predicted O
to O
be O
unaffected O
. O

Sequencing O
of O
the O
exon O
from O
the O
CVS O
, O
the O
predicted O
- O
carrier O
mother O
, O
and O
the O
obligate O
- O
carrier O
grandmother O
revealed O
an O
A O
- O
to O
- O
C O
change O
at O
nucleotide O
541 O
in O
the O
two O
women O
but O
not O
in O
the O
fetus O
. O

As O
this O
change O
results O
in O
a O
Thr O
- O
to O
- O
Pro O
change O
at O
amino O
acid O
181 O
in O
a O
region O
of O
the O
gene O
predicted O
to O
be O
part O
of O
a O
transmembrane O
segment O
, O
it O
was O
concluded O
that O
this O
was O
the O
mutation O
causing O
the O
disease O
in O
this O
family O
. O

In O
addition O
, O
in O
a O
second O
family O
, O
an O
exon O
5 O
variant O
band O
pattern O
on O
SSCP O
analysis O
was O
shown O
by O
sequencing O
to O
be O
due O
to O
a O
T O
- O
to O
- O
C O
change O
at O
nucleotide O
668 O
. O

This O
results O
in O
a O
Leu O
- O
to O
- O
Pro O
change O
in O
a O
carrier O
mother O
and O
in O
her O
two O
affected O
sons O
. O

These O
results O
provide O
further O
examples O
of O
mutations O
in O
PLP O
that O
cause O
Pelizaeus B
- I
Merzbacher I
disease I
and O
illustrate O
the O
value O
of O
SSCP O
in O
genetic O
analysis O
. O
. O

von B
Willebrand I
disease I
type I
B I
: O
a O
missense O
mutation O
selectively O
abolishes O
ristocetin O
- O
induced O
von B
Willebrand I
factor O
binding O
to O
platelet O
glycoprotein O
Ib O
. O

von B
Willebrand I
factor O
( O
vWF O
) O
is O
a O
multimeric O
glycoprotein O
that O
mediates O
the O
adhesion O
of O
platelets O
to O
the O
subendothelium O
by O
binding O
to O
platelet O
glycoprotein O
Ib O
. O

For O
human O
vWF O
, O
this O
interaction O
can O
be O
induced O
in O
vitro O
by O
the O
antibiotic O
ristocetin O
or O
the O
snake O
venom O
protein O
botrocetin O
. O

A O
missense O
mutation O
, O
Gly O
- O
561 O
- O
- O
> O
Ser O
, O
was O
identified O
within O
the O
proposed O
glycoprotein O
Ib O
binding O
domain O
of O
vWF O
in O
the O
proband O
with O
von B
Willebrand I
disease I
type I
B I
, O
a O
unique O
variant O
characterized O
by O
no O
ristocetin O
- O
induced O
, O
but O
normal O
botrocetin O
- O
induced O
, O
binding O
to O
glycoprotein O
Ib O
. O

The O
corresponding O
mutant O
recombinant O
protein O
, O
rvWF O
( O
G561S O
) O
, O
formed O
normal O
multimers O
and O
exhibited O
the O
same O
functional O
defect O
as O
the O
patients O
plasma O
vWF O
, O
confirming O
that O
this O
mutation O
causes O
von B
Willebrand I
disease I
type I
B I
. O

These O
data O
show O
that O
botrocetin O
and O
ristocetin O
cofactor O
activities O
of O
vWF O
can O
be O
dissociated O
by O
a O
point O
mutation O
and O
confirm O
that O
these O
mediators O
promote O
vWF O
binding O
to O
platelets O
by O
different O
mechanisms O
. O

The O
normal O
botrocetin O
- O
induced O
binding O
and O
the O
defective O
ristocetin O
- O
induced O
binding O
of O
rvWF O
( O
G561S O
) O
suggest O
that O
the O
primary O
defect O
in O
von B
Willebrand I
disease I
type I
B I
may O
be O
a O
failure O
of O
normal O
allosteric O
regulation O
of O
the O
glycoprotein O
Ib O
binding O
function O
of O
vWF O
. O
. O

Typical O
and O
partial O
cat B
eye I
syndrome I
: O
identification O
of O
the O
marker O
chromosome O
by O
FISH O
. O

Three O
children O
are O
reported O
with O
typical O
cat B
eye I
syndrome I
( O
CES B
) O
and O
three O
more O
children O
with O
partial O
CES B
because O
of O
absence O
of O
coloboma O
, O
in O
which O
the O
supernumerary O
marker O
chromosome O
was O
studied O
by O
FISH O
. O

Using O
a O
genomic O
library O
, O
and O
also O
a O
centromeric O
and O
particularly O
a O
cosmid O
probe O
of O
22q11 O
, O
partial O
tetrasomy B
was O
shown O
in O
all O
cases O
. O
. O

[ O
Genetic O
heterogeneity O
of O
G6PD B
deficiency I
: O
mutant O
alleles O
of O
G6PD O
in O
the O
Shekii O
district O
of O
Azerbaijan O
] O

Examination O
on O
G6PD B
deficiency I
in O
349 O
patients O
of O
Shekii O
district O
hospital O
( O
Azerbaijan O
) O
revealed O
16 O
hemi O
- O
, O
4 O
homo O
- O
and O
9 O
heterozygotic O
carriers O
of O
the O
defect O
. O

Gd O
- O
frequency O
, O
calculated O
from O
the O
data O
obtained O
( O
7 O
. O
7 O
% O
) O
, O
may O
be O
compared O
to O
neighbouring O
regions O
frequencies O
( O
6 O
- O
30 O
% O
) O
. O

Carriers O
of O
G6PD B
deficiency I
are O
residents O
of O
11 O
villages O
located O
in O
Alasani O
- O
Aphtalan O
valley O
, O
highly O
endemic O
with O
malaria B
in O
the O
past O
; O
nearly O
all O
marriages O
are O
endogamic O
. O

Physico O
- O
chemical O
and O
kinetic O
study O
of O
10 O
mutant O
forms O
of O
G6PD O
, O
according O
to O
WHO O
program O
, O
led O
to O
identification O
of O
5 O
variants O
of O
the O
II O
class O
( O
Shekii O
, O
Bideiz O
, O
Shirin O
- O
Bulakh O
, O
Okhut O
I O
and O
Zakataly O
) O
and O
2 O
variants O
of O
the O
III O
class O
( O
Okhut O
II O
and O
Martinique O
- O
like O
) O
. O

Resemblance O
of O
the O
majority O
of O
variants O
in O
electrophoretic O
mobility O
and O
the O
level O
of O
erythrocyte O
enzyme O
activity O
permit O
to O
suggest O
the O
existence O
of O
a O
common O
parental O
mutant O
G6PD O
allele O
distributed O
in O
this O
area O
. O

Craniofrontonasal B
dysplasia I
. O

We O
report O
on O
nine O
patients O
with O
craniofrontonasal B
dysplasia I
( O
CFND B
) O
. O

Seven O
classical O
cases O
had O
facial O
features O
suggestive O
of O
frontonasal B
dysplasia I
and O
coronal B
craniosynostosis I
. O

Extracranial B
abnormalities I
such O
as O
brittle B
nails I
with I
prominent I
longitudinal I
grooves I
or O
syndactyly B
of I
fingers I
and I
toes I
were O
observed O
in O
individual O
patients O
. O

In O
two O
families O
the O
father O
of O
classical O
cases O
showed O
a O
milder O
pattern O
of O
abnormalities O
, O
consistent O
with O
the O
diagnosis O
. O

We O
present O
a O
2 O
- O
to O
13 O
- O
year O
follow O
- O
up O
on O
our O
patients O
. O

Hypotonia B
and O
laxity B
of I
joints I
are O
common O
and O
may O
necessitate O
supportive O
measures O
. O

Mild O
developmental B
delay I
was O
noted O
in O
three O
out O
of O
six O
classical O
cases O
studied O
in O
detail O
. O

Unlike O
almost O
all O
other O
X B
- I
linked I
disorders I
, O
clinical O
expression O
in O
CFND B
is O
generally O
much O
more O
severe O
in O
females O
than O
in O
males O
. O

In O
contrast O
to O
previous O
reports O
of O
this O
condition O
, O
one O
of O
our O
severely O
affected O
cases O
is O
a O
male O
. O
. O

The O
intron O
7 O
donor O
splice O
site O
transition O
: O
a O
second O
Tay B
- I
Sachs I
disease I
mutation O
in O
French O
Canada O
. O

Mutations O
at O
the O
hexosaminidase O
A O
( O
HEXA O
) O
gene O
which O
cause O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
have O
elevated O
frequency O
in O
the O
Ashkenazi O
Jewish O
and O
French O
- O
Canadian O
populations O
. O

We O
report O
a O
novel O
TSD B
allele O
in O
the O
French O
- O
Canadian O
population O
associated O
with O
the O
infantile O
form O
of O
the O
disease O
. O

The O
mutation O
, O
a O
G O
- O
- O
> O
A O
transition O
at O
the O
+ O
1 O
position O
of O
intron O
7 O
, O
abolishes O
the O
donor O
splice O
site O
. O

Cultured O
human O
fibroblasts O
from O
a O
compound O
heterozygote O
for O
this O
transition O
( O
and O
for O
a O
deletion O
mutation O
) O
produce O
no O
detectable O
HEXA O
mRNA O
. O

The O
intron O
7 O
+ O
1 O
mutation O
occurs O
in O
the O
base O
adjacent O
to O
the O
site O
of O
the O
adult O
- O
onset O
TSD B
mutation O
( O
G805A O
) O
. O

In O
both O
mutations O
a O
restriction O
site O
for O
the O
endonuclease O
EcoRII O
is O
abolished O
. O

Unambiguous O
diagnosis O
, O
therefore O
, O
requires O
allele O
- O
specific O
oligonucleotide O
hybridization O
to O
distinguish O
between O
these O
two O
mutant O
alleles O
. O

The O
intron O
7 O
+ O
1 O
mutation O
has O
been O
detected O
in O
three O
unrelated O
families O
. O

Obligate O
heterozygotes O
for O
the O
intron O
7 O
+ O
1 O
mutation O
were O
born O
in O
the O
Saguenay O
- O
Lac O
- O
St O
- O
Jean O
region O
of O
Quebec O
. O

The O
most O
recent O
ancestors O
common O
to O
obligate O
carriers O
of O
this O
mutation O
were O
from O
the O
Charlevoix O
region O
of O
the O
province O
of O
Quebec O
. O

This O
mutation O
thus O
has O
a O
different O
geographic O
centre O
of O
diffusion O
and O
is O
probably O
less O
common O
than O
the O
exon O
1 O
deletion O
TSD B
mutation O
in O
French O
Canadians O
. O

Neither O
mutation O
has O
been O
detected O
in O
France O
, O
the O
ancestral O
homeland O
of O
French O
Canada O
. O
. O

Assignment O
of O
the O
aspartylglucosaminidase O
gene O
( O
AGA O
) O
to O
4q33 O
- O
- O
- O
- O
q35 O
based O
on O
decreased O
activity O
in O
a O
girl O
with O
a O
46 O
, O
XX O
, O
del O
( O
4 O
) O
( O
q33 O
) O
karyotype O
. O

Aspartylglucosaminuria B
( O
AGU B
) O
is O
a O
recessive O
autosomally O
inherited O
lysosomal B
storage I
disorder I
due O
to O
deficiency B
of I
the I
enzyme I
aspartylglucosaminidase I
( O
AGA O
) O
. O

The O
structural O
gene O
for O
this O
human O
enzyme O
( O
AGA O
) O
has O
been O
assigned O
to O
the O
region O
4q21 O
- O
- O
- O
- O
qter O
. O

We O
determined O
the O
AGA O
activity O
in O
cultured O
fibroblasts O
of O
a O
girl O
with O
a O
46 O
, O
XX O
, O
del O
( O
4 O
) O
( O
q33 O
) O
karyotype O
. O

The O
results O
indicate O
that O
the O
girl O
is O
a O
hemizygote O
for O
AGA O
, O
permitting O
the O
assignment O
of O
human O
AGA O
to O
the O
region O
4q33 O
- O
- O
- O
- O
qter O
. O
. O

Resolution O
of O
the O
two O
loci O
for O
autosomal O
dominant O
aniridia B
, O
AN1 O
and O
AN2 O
, O
to O
a O
single O
locus O
on O
chromosome O
11p13 O
. O

Two O
distinct O
loci O
have O
been O
proposed O
for O
aniridia B
; O
AN1 O
for O
autosomal O
dominant O
aniridia B
on O
chromosome O
2p O
and O
AN2 O
for O
the O
aniridia B
in O
the O
WAGR B
contiguous I
gene I
syndrome I
on O
chromosome O
11p13 O
. O

In O
this O
report O
, O
the O
kindred O
segregating O
for O
autosomal O
dominant O
aniridia B
, O
which O
suggested O
linkage O
to O
acid O
phosphatase O
- O
1 O
( O
ACP1 O
) O
and O
led O
to O
the O
assignment O
of O
the O
AN1 O
locus O
on O
chromosome O
2p O
, O
has O
been O
updated O
and O
expanded O
. O

Linkage O
analysis O
between O
the O
aniridia B
phenotype O
and O
ACP1 O
does O
not O
support O
the O
original O
linkage O
results O
, O
excluding O
linkage O
up O
to O
theta O
= O
0 O
. O

17 O
with O
Z O
= O
- O
2 O
. O

Tests O
for O
linkage O
to O
other O
chromosome O
2p O
markers O
. O

APOB O
, O
D2S71 O
, O
D2S5 O
, O
and O
D2S1 O
, O
also O
excluded O
linkage O
to O
aniridia B
. O

Markers O
that O
have O
been O
isolated O
from O
the O
chromosome O
11p13 O
region O
were O
then O
analyzed O
in O
this O
aniridia B
family O
. O

Two O
RFLPs O
at O
the O
D11S323 O
locus O
give O
significant O
evidence O
for O
linkage O
. O

The O
PvuII O
polymorphism O
detected O
by O
probe O
p5S1 O
. O

6 O
detects O
no O
recombinants O
, O
with O
a O
maximum O
lod O
score O
of O
Z O
= O
6 O
. O

97 O
at O
theta O
= O
0 O
. O

00 O
00 O
. O

The O
HaeIII O
polymorphism O
detected O
by O
the O
probe O
p5BE1 O
. O

2 O
gives O
a O
maximum O
lod O
score O
of O
Z O
= O
2 O
. O

57 O
at O
theta O
= O
0 O
. O

00 O
00 O
. O

Locus O
D11S325 O
gives O
a O
lod O
score O
of O
Z O
= O
1 O
. O

53 O
at O
theta O
= O
0 O
. O

00 O
00 O
. O

These O
data O
suggest O
that O
a O
locus O
for O
aniridia B
( O
AN1 O
) O
on O
chromosome O
2p O
has O
been O
misassigned O
and O
that O
this O
autosomal O
dominant O
aniridia B
family O
is O
segregating O
for O
an O
aniridia B
mutation O
linked O
to O
markers O
in O
the O
11p13 O
region O
. O

Fatal O
pyoderma B
gangrenosum I
in O
association O
with O
C7 B
deficiency I
. O

Although O
pyoderma B
gangrenosum I
( O
PG B
) O
is O
often O
associated O
with O
systemic B
diseases I
, O
it O
has O
not O
been O
reported O
in O
association O
with O
congenital B
complement I
deficiencies I
. O

We O
describe O
an O
aggressive O
and O
ultimately O
fatal O
case O
of O
PG B
in O
a O
patient O
with O
a O
congenital O
C7 B
deficiency I
. O

Deficiencies B
of I
C7 I
can O
be O
associated O
with O
decreased O
neutrophil O
chemotaxis O
, O
phagocytosis O
, O
and O
opsonization O
, O
similar O
to O
the O
immunologic B
abnormalities I
described O
in O
patients O
with O
PG B
. O

Our O
patients O
decreased O
complement O
level O
, O
if O
not O
directly O
related O
to O
the O
development O
of O
PG B
, O
may O
have O
contributed O
to O
the O
aggressive O
nature O
of O
her O
disease O
. O
. O

Diverse O
point O
mutations O
result O
in O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
polymorphism O
in O
Taiwan O
. O

Glucose B
- I
6 I
- I
PHOSPHATE I
dehydrogenase I
( I
G6PD I
; I
EC I
1 I
. I
1 I
. I
1 I
. I
49 I
) I
deficiency I
is O
the O
most O
common O
human O
enzymopathy B
, O
affecting O
more O
than O
200 O
million O
people O
worldwide O
. O

Although O
greater O
than O
400 O
variants O
have O
been O
described O
based O
on O
clinical O
and O
biochemical O
criteria O
, O
little O
is O
known O
about O
the O
molecular O
basis O
of O
these O
G6PD B
deficiencies I
. O

Recently O
, O
the O
gene O
that O
encodes O
human O
G6PD O
has O
been O
cloned O
and O
sequenced O
, O
which O
enables O
us O
to O
examine O
directly O
the O
heterogeneity O
of O
G6PD O
at O
the O
DNA O
level O
. O

During O
the O
past O
10 O
years O
, O
we O
examined O
the O
G6PD O
activity O
in O
21 O
, O
271 O
newborn O
Chinese O
infants O
( O
11 O
, O
400 O
males O
and O
9 O
, O
871 O
females O
) O
and O
identified O
314 O
( O
2 O
. O
8 O
% O
) O
males O
and O
246 O
( O
2 O
. O
5 O
% O
) O
females O
having O
low O
G6PD O
activity O
. O

The O
G6PD O
gene O
from O
10 O
randomly O
selected O
affected O
individuals O
and O
their O
relatives O
was O
polymerase O
chain O
reaction O
( O
PCR O
) O
amplified O
, O
subcloned O
, O
and O
sequenced O
. O

Our O
results O
indicate O
that O
at O
least O
four O
types O
of O
mutation O
are O
responsible O
for O
the O
G6PD O
polymorphism O
in O
Taiwan O
. O

The O
first O
type O
of O
mutation O
( O
487 O
G O
- O
- O
- O
- O
A O
) O
was O
found O
in O
an O
affected O
Chinese O
with O
a O
G O
to O
A O
change O
at O
nucleotide O
487 O
, O
which O
results O
in O
a O
( O
163 O
) O
Gly O
to O
Ser O
substitution O
. O

The O
second O
type O
of O
mutation O
( O
493 O
A O
- O
- O
- O
- O
G O
) O
is O
a O
novel O
mutation O
that O
has O
not O
been O
reported O
in O
any O
other O
ethnic O
group O
and O
was O
identified O
in O
two O
affected O
Chinese O
. O

This O
mutation O
causes O
an O
A O
to O
G O
change O
at O
nucleotide O
position O
493 O
, O
producing O
an O
( O
165 O
) O
Asn O
to O
Asp O
substitution O
. O

Interestingly O
, O
the O
487 O
G O
- O
- O
- O
- O
A O
and O
493 O
A O
- O
- O
- O
- O
G O
mutations O
create O
Alu O
I O
and O
Ava O
II O
recognition O
sites O
, O
respectively O
, O
which O
enabled O
us O
to O
rapidly O
detect O
these O
two O
mutations O
by O
PCR O
/ O
restriction O
enzyme O
( O
RE O
) O
digestion O
method O
. O

The O
third O
mutation O
( O
1376 O
G O
- O
- O
- O
- O
T O
) O
was O
found O
in O
four O
affected O
Chinese O
. O

This O
mutation O
causes O
a O
G O
to O
T O
change O
at O
nucleotide O
position O
1376 O
that O
results O
in O
an O
( O
459 O
) O
Arg O
to O
Leu O
substitution O
. O

The O
1376 O
G O
- O
- O
- O
- O
T O
mutation O
seems O
to O
be O
the O
dominant O
allele O
that O
causes O
G6PD B
deficiency I
in O
Taiwan O
. O

Finally O
, O
two O
affected O
Chinese O
were O
identified O
as O
having O
the O
fourth O
mutation O
( O
1388 O
G O
- O
- O
- O
- O
A O
) O
. O

This O
mutation O
causes O
a O
G O
to O
A O
change O
at O
nucleotide O
1388 O
that O
produces O
an O
( O
463 O
) O
Arg O
to O
His O
substitution O
. O

Our O
studies O
provide O
the O
direct O
proof O
of O
the O
genetic O
heterogeneity O
of O
G6PD B
deficiency I
in O
the O
Chinese O
populations O
of O
Taiwan O
and O
the O
PCR O
/ O
RE O
digestion O
method O
is O
suitable O
for O
simultaneous O
detection O
of O
the O
487 O
G O
- O
- O
- O
- O
A O
and O
493 O
A O
- O
- O
- O
- O
G O
mutations O
. O

An O
error O
in O
dystrophin O
mRNA O
processing O
in O
golden B
retriever I
muscular I
dystrophy I
, O
an O
animal O
homologue O
of O
Duchenne B
muscular I
dystrophy I
. O

Golden B
retriever I
muscular I
dystrophy I
( O
GRMD B
) O
is O
a O
spontaneous O
, O
X O
- O
linked O
, O
progressively O
fatal O
disease O
of O
dogs O
and O
is O
also O
a O
homologue O
of O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

Two O
- O
thirds O
of O
DMD B
patients O
carry O
detectable O
deletions O
in O
their O
dystrophin O
gene O
. O

The O
defect O
underlying O
the O
remaining O
one O
- O
third O
of O
DMD B
patients O
is O
undetermined O
. O

Analysis O
of O
the O
canine O
dystrophin O
gene O
in O
normal O
and O
GRMD B
dogs O
has O
failed O
to O
demonstrate O
any O
detectable O
loss O
of O
exons O
. O

Here O
, O
we O
have O
demonstrated O
a O
RNA O
processing O
error O
in O
GRMD B
that O
results O
from O
a O
single O
base O
change O
in O
the O
3 O
consensus O
splice O
site O
of O
intron O
6 O
. O

The O
seventh O
exon O
is O
then O
skipped O
, O
which O
predicts O
a O
termination O
of O
the O
dystrophin O
reading O
frame O
within O
its O
N O
- O
terminal O
domain O
in O
exon O
8 O
. O

This O
is O
the O
first O
example O
of O
dystrophin B
deficiency I
caused O
by O
a O
splice O
- O
site O
mutation O
. O
. O

Type B
I I
human I
complement I
C2 I
deficiency I
. O

A O
28 O
- O
base O
pair O
gene O
deletion O
causes O
skipping O
of O
exon O
6 O
during O
RNA O
splicing O
. O

Two O
variants O
of O
a O
genetic O
deficiency B
of I
complement I
protein I
C2 I
( O
C2D O
) O
have O
been O
previously O
identified O
. O

No O
C2 O
protein O
translation O
is O
detected O
in O
type O
I O
deficiency O
, O
while O
type O
II O
deficiency O
is O
characterized O
by O
a O
selective O
block O
in O
C2 O
secretion O
. O

Type B
I I
C2 I
deficiency I
was O
described O
in O
a O
family O
in O
which O
the O
C2 O
null O
allele O
( O
C2Q0 O
) O
is O
associated O
with O
the O
major O
histocompatibility O
haplotype O
/ O
complotype O
HLA O
- O
A25 O
, O
B18 O
, O
C2Q0 O
, O
BfS O
, O
C4A4 O
, O
C4B2 O
, O
Drw2 O
; O
this O
extended O
haplotype O
occurs O
in O
over O
90 O
% O
of O
C2 B
- I
deficient I
individuals O
( O
common O
complotype O
/ O
haplotype O
) O
. O

To O
determine O
the O
molecular O
basis O
of O
type B
I I
C2 I
deficiency I
, O
the O
C2 O
gene O
and O
cDNA O
were O
characterized O
from O
a O
homozygous O
type B
I I
C2 I
- I
deficient I
individual O
with O
the O
common O
associated O
haplotype O
/ O
complotype O
. O

We O
found O
a O
28 O
- O
base O
pair O
deletion O
in O
the O
type O
I O
C2Q0 O
gene O
, O
beginning O
9 O
base O
pairs O
upstream O
of O
the O
3 O
- O
end O
of O
exon O
6 O
, O
that O
generates O
a O
C2 O
transcript O
with O
a O
complete O
deletion O
of O
exon O
6 O
( O
134 O
base O
pair O
) O
and O
a O
premature O
termination O
codon O
. O

In O
studies O
of O
eight O
kindred O
, O
the O
28 O
- O
base O
pair O
deletion O
was O
observed O
in O
all O
C2Q0 O
alleles O
associated O
with O
the O
common O
type O
I O
deficient O
complotype O
/ O
haplotype O
; O
this O
deletion O
was O
not O
present O
in O
normal O
C2 O
nor O
in O
type B
II I
C2 I
- I
deficient I
genes O
. O

These O
data O
demonstrate O
that O
1 O
) O
type B
I I
human I
complement I
C2 I
deficiency I
is O
caused O
by O
a O
28 O
- O
base O
pair O
genomic O
deletion O
that O
causes O
skipping O
of O
exon O
6 O
during O
RNA O
splicing O
, O
resulting O
in O
generation O
of O
a O
premature O
termination O
codon O
, O
2 O
) O
the O
28 O
- O
base O
pair O
deletion O
in O
the O
type O
I O
C2Q0 O
gene O
is O
strongly O
associated O
with O
the O
HLA O
haplotype O
/ O
complotype O
A25 O
, O
B18 O
, O
C2Q0 O
, O
BfS O
, O
C4A4 O
, O
C4B2 O
, O
Drw2 O
, O
suggesting O
that O
all O
C2 B
- I
deficient I
individuals O
with O
this O

haplotype O
/ O
complotype O
will O
harbor O
the O
28 O
- O
base O
pair O
C2 O
gene O
deletion O
, O
and O
3 O
) O
type B
II I
C2 I
deficiency I
is O
caused O
by O
a O
different O
, O
as O
yet O
uncharacterized O
, O
molecular O
genetic B
defect I
. O
. O

Molecular O
characterization O
of O
two O
galactosemia B
mutations O
and O
one O
polymorphism O
: O
implications O
for O
structure O
- O
function O
analysis O
of O
human O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
. O

We O
report O
here O
the O
molecular O
characterization O
of O
two O
galactosemia B
mutations O
, O
L74P O
and O
F171S O
, O
and O
one O
polymorphism O
, O
S135L O
, O
in O
human O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
. O

Both O
galactosemia B
mutations O
result O
in O
reduced O
enzymatic O
activity O
when O
reconstructed O
in O
the O
cDNA O
and O
overexpressed O
. O

The O
polymorphism O
, O
in O
contrast O
, O
has O
near O
normal O
activity O
. O

Both O
mutations O
affect O
evolutionarily O
conserved O
residues O
, O
suggesting O
that O
they O
are O
functionally O
important O
, O
while O
the O
polymorphism O
occurs O
in O
a O
nonconserved O
domain O
which O
is O
presumably O
not O
critical O
for O
enzymatic O
function O
. O

The O
F171S O
mutation O
is O
close O
to O
the O
putative O
active O
- O
site O
nucleophile O
. O

Our O
data O
further O
support O
the O
notion O
of O
molecular O
heterogeneity O
of O
galactosemia B
and O
suggest O
that O
galactosemia B
mutations O
and O
GALT O
polymorphisms O
may O
be O
useful O
tools O
in O
highlighting O
different O
functional O
domains O
in O
human O
GALT O
. O
. O

Linkage O
relationship O
of O
C2 B
deficiency I
, O
HLA O
and O
glyoxalase O
I O
loci O
. O

Immunogenetic O
analysis O
of O
a O
homozygous O
C2 B
- I
deficient I
individual O
and O
family O
members O
demonstrated O
linkage O
of O
HLA O
- O
A25 O
, O
B18 O
and O
C2o O
. O

HLA O
- O
D O
typing O
showed O
that O
5 O
members O
typed O
with O
homozygous O
Dw2 O
typing O
cells O
from O
an O
individual O
with O
C2 B
deficiency I
but O
not O
with O
Dw2 O
typing O
cells O
from O
2 O
individuals O
with O
normal O
C2 O
. O

The O
homozygous O
C2 B
- I
deficient I
propositus O
and O
brother O
were O
HLA O
- O
A O
and O
B O
homozygous O
but O
heterozygous O
at O
the O
HLA O
- O
D O
and O
glyoxalase O
I O
loci O
. O

Therefore O
, O
in O
this O
family O
, O
the O
C2o O
gene O
is O
linked O
with O
two O
distinct O
haplotypes O
HLA O
- O
A25 O
, O
B18 O
, O
Dw2 O
, O
GLO1 O
and O
HLA O
- O
A25 O
, O
B18 O
, O
D O
unknown O
, O
GL02 O
. O

These O
results O
could O
be O
explained O
by O
an O
ancestral O
recombinant O
event O
, O
which O
occurred O
between O
the O
C2o O
locus O
and O
HLA O
- O
D O
locus O
in O
which O
C2o O
segregated O
with O
HLA O
- O
B O
. O

This O
would O
suggest O
that O
the O
locus O
for O
the O
C2o O
gene O
maps O
between O
HLA O
- O
B O
and O
HLA O
- O
D O
on O
the O
sixth O
chromosome O
. O
. O

Germline O
mutations O
in O
the O
Wilms B
' I
tumor I
suppressor O
gene O
are O
associated O
with O
abnormal O
urogenital O
development O
in O
Denys B
- I
Drash I
syndrome I
. O

Denys B
- I
Drash I
syndrome I
is O
a O
rare O
human O
condition O
in O
which O
severe O
urogenital B
aberrations I
result O
in O
renal B
failure I
, O
pseudohermaphroditism B
, O
and O
Wilms B
tumor I
( O
nephroblastoma B
) O
. O

To O
investigate O
its O
possible O
role O
, O
we O
have O
analyzed O
the O
coding O
exons O
of O
the O
Wilms B
tumor I
suppressor O
gene O
( O
WT1 O
) O
for O
germline O
mutations O
. O

In O
ten O
independent O
cases O
of O
Denys B
- I
Drash I
syndrome I
, O
point O
mutations O
in O
the O
zinc O
finger O
domains O
of O
one O
WT1 O
gene O
copy O
were O
found O
. O

Nine O
of O
these O
mutations O
are O
found O
within O
exon O
9 O
( O
zinc O
finger O
III O
) O
; O
the O
remaining O
mutation O
is O
in O
exon O
8 O
( O
zinc O
finger O
II O
) O
. O

These O
mutations O
directly O
affect O
DNA O
sequence O
recognition O
. O

In O
two O
families O
analyzed O
, O
the O
mutations O
were O
shown O
to O
arise O
de O
novo O
. O

Wilms B
tumors I
from O
three O
individuals O
and O
one O
juvenile O
granulosa O
cell O
tumor B
demonstrate O
reduction O
to O
homozygosity O
for O
the O
mutated O
WT1 O
allele O
. O

Our O
results O
provide O
evidence O
of O
a O
direct O
role O
for O
WT1 O
in O
Denys B
- I
Drash I
syndrome I
and O
thus O
urogenital O
system O
development O
. O
. O

Linkage O
analysis O
in O
X B
- I
linked I
adrenoleukodystrophy I
and O
application O
in O
post O
- O
and O
prenatal O
diagnosis O
. O

We O
have O
performed O
linkage O
analysis O
with O
the O
DNA O
markers O
DXS52 O
and O
the O
clotting O
factor O
VIII O
gene O
( O
F8C O
) O
, O
in O
several O
large O
families O
with O
X B
- I
linked I
adrenoleukodystrophy I
( O
ALD B
) O
. O

The O
tight O
linkage O
to O
DXS52 O
could O
be O
extended O
giving O
a O
maximal O
LOD O
score O
of O
22 O
. O

5 O
at O
1 O
cM O
. O

F8C O
was O
also O
tightly O
linked O
to O
ALD B
with O
a O
maximal O
LOD O
score O
of O
7 O
. O

8 O
without O
recombination O
. O

Multipoint O
linkage O
analysis O
with O
the O
markers O
DXS304 O
, O
DXS52 O
, O
and O
F8C O
indicated O
that O
both O
the O
gene O
for O
ALD B
and O
for O
F8C O
are O
distal O
to O
DXS52 O
. O

In O
four O
patients O
with O
ALD B
, O
no O
major O
structural O
rearrangement O
in O
the O
Xqter O
region O
was O
observed O
; O
in O
particular O
, O
there O
were O
no O
abnormalities B
in I
the I
vision I
blindness I
genes I
. O

DNA O
analysis O
appeared O
to O
be O
of O
use O
in O
determination O
of O
the O
carrier O
status O
of O
females O
at O
risk O
, O
for O
the O
determination O
of O
the O
origin O
of O
the O
mutation O
in O
a O
particular O
family O
, O
and O
for O
prenatal O
diagnosis O
. O

Two O
distinct O
mutations O
at O
a O
single O
BamHI O
site O
in O
phenylketonuria B
. O

Classical B
phenylketonuria I
is O
an O
autosomal B
recessive I
disease I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

The O
abolition O
of O
an O
invariant O
BamHI O
site O
located O
in O
the O
coding O
sequence O
of O
the O
PAH O
gene O
( O
exon O
7 O
) O
led O
to O
the O
recognition O
of O
two O
new O
point O
mutations O
at O
codon O
272 O
and O
273 O
( O
272gly O
- O
- O
- O
- O
stop O
and O
273ser O
- O
- O
- O
- O
phe O
, O
respectively O
) O
. O

Both O
mutations O
were O
detected O
in O
north O
eastern O
France O
or O
Belgium O
and O
occurred O
on O
the O
background O
of O
RFLP O
haplotype O
7 O
alleles O
. O

The O
present O
study O
supports O
the O
view O
that O
the O
clinical O
heterogeneity O
in O
PKU B
is O
accounted O
for O
by O
the O
large O
variety O
of O
mutant O
genotypes O
associated O
with O
PAH B
deficiencies I
. O
. O

A O
detailed O
multipoint O
map O
of O
human O
chromosome O
4 O
provides O
evidence O
for O
linkage O
heterogeneity O
and O
position O
- O
specific O
recombination O
rates O
. O

Utilizing O
the O
CEPH O
reference O
panel O
and O
genotypic O
data O
for O
53 O
markers O
, O
we O
have O
constructed O
a O
20 O
- O
locus O
multipoint O
genetic O
map O
of O
human O
chromosome O
4 O
. O

New O
RFLPs O
are O
reported O
for O
four O
loci O
. O

The O
map O
integrates O
a O
high O
- O
resolution O
genetic O
map O
of O
4p16 O
into O
a O
continuous O
map O
extending O
to O
4q31 O
and O
an O
unlinked O
cluster O
of O
three O
loci O
at O
4q35 O
. O

The O
20 O
linked O
markers O
form O
a O
continuous O
linkage O
group O
of O
152 O
cM O
in O
males O
and O
202 O
cM O
in O
females O
. O

Likely O
genetic O
locations O
are O
provided O
for O
25 O
polymorphic O
anonymous O
sequences O
and O
28 O
gene O
- O
specific O
RFLPs O
. O

The O
map O
was O
constructed O
employing O
the O
LINKAGE O
and O
CRIMAP O
computational O
methodologies O
to O
build O
the O
multipoint O
map O
via O
a O
stepwise O
algorithm O
. O

A O
detailed O
10 O
- O
point O
map O
of O
the O
4p16 O
region O
constructed O
from O
the O
CEPH O
panel O
provides O
evidence O
for O
heterogeneity O
in O
the O
linkage O
maps O
constructed O
from O
families O
segregating O
for O
Huntington B
disease I
( O
HD B
) O
. O

It O
additionally O
provides O
evidence O
for O
position O
- O
specific O
recombination O
frequencies O
in O
the O
telomeric O
region O
of O
4p O
. O
. O

Carrier O
detection O
and O
prenatal O
diagnosis O
of O
Pelizaeus B
- I
Merzbacher I
disease I
using O
a O
combination O
of O
anonymous O
DNA O
polymorphisms O
and O
the O
proteolipid O
protein O
( O
PLP O
) O
gene O
cDNA O
. O

We O
report O
carrier O
identification O
and O
a O
prenatal O
diagnosis O
using O
DNA O
polymorphisms O
in O
2 O
families O
with O
X B
- I
linked I
Pelizaeus I
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

In O
both O
families O
, O
the O
proteolipid O
protein O
( O
PLP O
) O
gene O
in O
the O
single O
affected O
male O
could O
be O
traced O
back O
to O
his O
unaffected O
maternal O
grandfather O
. O

Therefore O
, O
each O
family O
contains O
a O
new O
mutation O
. O

In O
the O
case O
of O
the O
prenatal O
diagnosis O
, O
the O
fetus O
was O
shown O
by O
cytogenetic O
analysis O
to O
be O
a O
female O
, O
who O
we O
predict O
will O
be O
a O
noncarrier O
of O
PMD B
based O
on O
her O
genotype O
with O
the O
PLP O
intragenic O
polymorphism O
. O
. O

Identification O
of O
deletion O
mutations O
and O
three O
new O
genes O
at O
the O
familial B
polyposis I
locus O
. O

Small O
( O
100 O
- O
260 O
kb O
) O
, O
nested O
deletions O
were O
characterized O
in O
DNA O
from O
two O
unrelated O
patients O
with O
familial B
adenomatous I
polyposis I
coli I
( O
APC B
) O
. O

Three O
candidate O
genes O
located O
within O
the O
deleted O
region O
were O
ascertained O
and O
a O
previous O
candidate O
gene O
, O
MCC O
, O
was O
shown O
to O
be O
located O
outside O
the O
deleted O
region O
. O

One O
of O
the O
new O
genes O
contained O
sequence O
identical O
to O
SRP19 O
, O
the O
gene O
coding O
for O
the O
19 O
kd O
component O
of O
the O
ribosomal O
signal O
recognition O
particle O
. O

The O
second O
, O
provisionally O
designated O
DP1 O
( O
deleted O
in O
polyposis O
1 O
) O
, O
was O
found O
to O
be O
transcribed O
in O
the O
same O
orientation O
as O
MCC O
. O

Two O
other O
cDNAs O
, O
DP2 O
and O
DP3 O
, O
were O
found O
to O
overlap O
, O
forming O
a O
single O
gene O
, O
DP2 O
. O

5 O
, O
that O
is O
transcribed O
in O
the O
same O
orientation O
as O
SRP19 O
. O

Exclusion O
of O
linkage O
between O
familial B
Mediterranean I
fever I
and O
the O
human O
serum O
amyloid O
A O
( O
SAA O
) O
gene O
cluster O
. O

We O
studied O
the O
relationship O
between O
the O
autosomal O
recessive O
trait O
familial B
Mediterranean I
fever I
( O
FMF B
) O
and O
the O
serum O
amyloid O
A O
( O
SAA O
) O
genes O
by O
comparing O
alleles O
of O
a O
highly O
polymorphic O
dinucleotide O
repeat O
and O
a O
conventional O
restriction O
fragment O
length O
polymorphism O
( O
RFLP O
) O
in O
the O
SAA O
gene O
cluster O
in O
Israeli O
FMF B
kindreds O
. O

By O
haplotype O
analysis O
, O
our O
data O
indicate O
a O
minimum O
crossover O
frequency O
of O
22 O
% O
between O
the O
SAA O
gene O
marker O
and O
FMF B
. O

By O
conventional O
linkage O
analysis O
this O
eliminates O
a O
minimum O
of O
10 O
. O

4 O
cM O
including O
and O
surrounding O
the O
SAA O
gene O
cluster O
as O
the O
site O
of O
the O
FMF B
mutation O
although O
SAA O
proteins O
are O
prominent O
physiologic O
markers O
of O
the O
acute O
attacks O
. O

PRAD1 O
, O
a O
candidate O
BCL1 O
oncogene O
: O
mapping O
and O
expression O
in O
centrocytic B
lymphoma I
. O

Rearrangement O
of O
the O
BCL1 O
( O
B O
- O
cell O
lymphoma O
1 O
) O
region O
on O
chromosome O
11q13 O
appears O
to O
be O
highly O
characteristic O
of O
centrocytic B
lymphoma I
and O
also O
is O
found O
infrequently O
in O
other O
B B
- I
cell I
neoplasms I
. O

Rearrangement O
is O
thought O
to O
deregulate O
a O
nearby O
protooncogene O
, O
but O
transcribed O
sequences O
in O
the O
immediate O
vicinity O
of O
BCL1 O
breakpoints O
had O
not O
been O
identified O
. O

PRAD1 O
, O
previously O
designated O
D11S287E O
, O
was O
identified O
on O
11q13 O
as O
a O
chromosomal O
breakpoint O
region O
rearranged O
with O
the O
parathyroid O
hormone O
gene O
in O
a O
subset O
of O
parathyroid B
adenomas I
; O
this O
highly O
conserved O
putative O
oncogene O
, O
which O
encodes O
a O
novel O
cyclin O
, O
has O
been O
linked O
to O
BCL1 O
and O
implicated O
also O
in O
subsets O
of O
breast B
and I
squamous I
cell I
neoplasms I
with O
11q13 O
amplification O
. O

We O
report O
pulsed O
- O
field O
gel O
electrophoresis O
data O
showing O
BCL1 O
and O
PRAD1 O
to O
be O
no O
more O
than O
130 O
kilobases O
apart O
. O

PRAD1 O
mRNA O
is O
abundantly O
expressed O
in O
seven O
of O
seven O
centrocytic B
lymphomas I
( O
Kiel O
classification O
) O
, O
in O
contrast O
to O
13 O
closely O
related O
but O
noncentrocytic B
lymphomas I
. O

Three O
of O
the O
seven O
centrocytic B
lymphomas I
had O
detectable O
BCL1 O
DNA O
rearrangement O
. O

Also O
, O
two O
unusual O
cases O
of O
CLL O
with O
BCL1 O
rearrangement O
overexpressed O
PRAD1 O
, O
in O
contrast O
to O
five O
CLL O
controls O
. O

Thus O
, O
PRAD1 O
is O
an O
excellent O
candidate O
" O
BCL1 O
oncogene O
. O

" O
Its O
overexpression O
may O
be O
a O
key O
consequence O
of O
rearrangement O
of O
the O
BCL1 O
vicinity O
in O
B B
- I
cell I
neoplasms I
and O
a O
unifying O
pathogenetic O
feature O
in O
centrocytic B
lymphoma I
. O

Two O
new O
arylsulfatase O
A O
( O
ARSA O
) O
mutations O
in O
a O
juvenile O
metachromatic B
leukodystrophy I
( O
MLD B
) O
patient O
. O

Fragments O
of O
the O
arylsulfatase O
A O
( O
ARSA O
) O
gene O
from O
a O
patient O
with O
juvenile O
- O
onset O
metachromatic B
leukodystrophy I
( O
MLD B
) O
were O
amplified O
by O
PCR O
and O
ligated O
into O
MP13 O
cloning O
vectors O
. O

Clones O
hybridizing O
with O
cDNA O
for O
human O
ARSA O
were O
selected O
, O
examined O
for O
appropriate O
size O
inserts O
, O
and O
used O
to O
prepare O
single O
- O
stranded O
phage O
DNA O
. O

Examination O
of O
the O
entire O
coding O
and O
most O
of O
the O
intronic O
sequence O
revealed O
two O
putative O
disease O
- O
related O
mutations O
. O

One O
, O
a O
point O
mutation O
in O
exon O
3 O
, O
resulted O
in O
the O
substitution O
of O
isoleucine O
by O
serine O
. O

Introduction O
of O
this O
alteration O
into O
the O
normal O
ARSA O
cDNA O
sequence O
resulted O
in O
a O
substantial O
decrease O
in O
ARSA O
activity O
on O
transient O
expression O
in O
cultured O
baby O
hamster O
kidney O
cells O
. O

About O
5 O
% O
of O
the O
control O
expression O
was O
observed O
, O
suggesting O
a O
small O
residual O
activity O
in O
the O
mutated O
ARSA O
. O

The O
second O
mutation O
, O
a O
G O
- O
to O
- O
A O
transition O
, O
occurred O
in O
the O
other O
allele O
and O
resulted O
in O
an O
altered O
splice O
- O
recognition O
sequence O
between O
exon O
7 O
and O
the O
following O
intron O
. O

The O
mutation O
also O
resulted O
in O
the O
loss O
of O
a O
restriction O
site O
. O

Apparently O
normal O
levels O
of O
mRNA O
were O
generated O
from O
this O
allele O
, O
but O
no O
ARSA O
activity O
or O
immuno O
- O
cross O
- O
reactive O
material O
could O
be O
detected O
. O

A O
collection O
of O
DNA O
samples O
from O
known O
or O
suspected O
MLD B
patients O
, O
members O
of O
their O
families O
, O
and O
normal O
controls O
was O
screened O
for O
these O
mutations O
. O

Four O
additional O
individuals O
carrying O
each O
of O
the O
mutations O
were O
found O
among O
the O
nearly O
100 O
MLD B
patients O
in O
the O
sample O
. O

Gene O
segregation O
in O
the O
original O
patients O
family O
was O
consistent O
with O
available O
clinical O
and O
biochemical O
data O
. O

No O
individuals O
homozygous O
for O
either O
of O
these O
two O
mutations O
were O
identified O
. O

However O
, O
combinations O
with O
other O
MLD B
mutations O
suggest O
that O
the O
point O
mutation O
in O
exon O
3 O
does O
result O
in O
some O
residual O
enzyme O
activity O
and O
is O
associated O
with O
late O
- O
onset O
forms O
of O
the O
disease O
. O

The O
splice O
- O
site O
mutation O
following O
exon O
7 O
produces O
late O
- O
infantile O
MLD B
when O
combined O
with O
other O
enzyme O
- O
null O
mutations O
, O
implying O
that O
it O
is O
completely O
silent O
enzymatically O
. O
. O

Analysis O
of O
X O
- O
chromosome O
inactivation O
and O
presumptive O
expression O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
gene O
in O
hematopoietic O
cell O
lineages O
of O
a O
thrombocytopenic O
carrier O
female O
of O
WAS B
. O

We O
report O
on O
a O
thrombocytopenic B
female O
belonging O
to O
a O
pedigree O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
. O

Restriction O
fragment O
length O
polymorphism O
( O
RFLP O
) O
analysis O
with O
probe O
M27 O
beta O
, O
closely O
linked O
to O
the O
WAS B
gene O
, O
demonstrated O
that O
she O
is O
a O
carrier O
of O
WAS B
. O

Both O
small O
- O
sized O
and O
normal O
- O
sized O
platelets O
were O
present O
, O
suggesting O
that O
, O
unlike O
the O
vast O
majority O
of O
WAS B
carriers O
, O
she O
does O
not O
manifest O
nonrandom O
X O
- O
chromosome O
inactivation O
in O
the O
thrombopoietic O
cell O
lineage O
. O

Study O
of O
X O
- O
chromosome O
inactivation O
by O
means O
of O
RFLP O
and O
methylation O
analysis O
demonstrated O
that O
the O
pattern O
of O
X O
- O
chromosome O
inactivation O
was O
nonrandom O
in O
T O
lymphocytes O
, O
but O
random O
in O
granulocytes O
. O

While O
this O
is O
the O
first O
complete O
report O
on O
the O
occurrence O
of O
thrombocytopenia B
in O
a O
carrier O
female O
of O
WAS B
as O
the O
result O
of O
atypical O
lyonization O
, O
it O
also O
suggests O
that O
expression O
of O
the O
WAS B
gene O
occurs O
at O
( O
or O
extends O
up O
to O
) O
a O
later O
stage O
than O
the O
multipotent O
stem O
cell O
along O
the O
hematopoietic O
differentiation O
pathway O
. O
. O

A O
new O
mutation O
in O
the O
proteolipid O
protein O
( O
PLP O
) O
gene O
in O
a O
German O
family O
with O
Pelizaeus B
- I
Merzbacher I
disease I
. O

A O
C O
- O
to O
- O
T O
transition O
in O
exon O
4 O
of O
the O
PLP O
gene O
was O
found O
in O
2 O
affected O
males O
and O
two O
obligate O
carriers O
in O
a O
German O
family O
with O
Pelizaeus B
- I
Merzbacher I
disease I
. O

The O
mutation O
, O
which O
causes O
loss O
of O
an O
HphI O
site O
and O
changes O
amino O
acid O
155 O
from O
threonine O
to O
isoleucine O
, O
was O
absent O
from O
108 O
normal O
chromosomes O
. O

There O
are O
5 O
concordances O
and O
1 O
discrepancy O
between O
these O
results O
and O
those O
obtained O
by O
magnetic O
resonance O
imaging O
in O
this O
family O
. O
. O

A O
3 O
- O
base O
pair O
in O
- O
frame O
deletion O
of O
the O
phenylalanine O
hydroxylase O
gene O
results O
in O
a O
kinetic O
variant O
of O
phenylketonuria B
. O

Phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disease I
due O
to O
deficiency B
of I
a I
hepatic I
enzyme I
, I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

The O
absence O
of O
PAH O
activity O
results O
in O
typical O
PKU B
while O
persistence O
of O
a O
residual O
enzyme O
activity O
gives O
rise O
to O
variant O
forms O
of O
the O
disease O
. O

We O
report O
here O
a O
3 O
- O
base O
pair O
in O
- O
frame O
deletion O
of O
the O
PAH O
gene O
( O
delta O
194 O
) O
in O
a O
mild O
variant O
, O
with O
markedly O
reduced O
affinity O
of O
the O
enzyme O
for O
phenylalanine O
( O
Km O
= O
160 O
nM O
) O
, O
and O
we O
provide O
functional O
evidence O
for O
responsibility O
of O
the O
deletion O
in O
the O
mutant O
phenotype O
. O

Since O
the O
deletion O
was O
located O
in O
the O
third O
exon O
of O
the O
gene O
, O
which O
presents O
no O
homology O
with O
other O
hydroxylases O
, O
we O
suggest O
that O
exon O
3 O
is O
involved O
in O
the O
specificity O
of O
the O
enzyme O
for O
phenylalanine O
. O

Finally O
, O
since O
none O
of O
the O
98 O
PKU B
patients O
tested O
were O
found O
to O
carry O
this O
particular O
deletion O
, O
our O
study O
suggests O
that O
this O
molecular O
event O
probably O
occurred O
recently O
on O
the O
background O
of O
a O
haplotype O
2 O
gene O
in O
Portugal O
. O
. O

Mutation O
of O
the O
KIT O
( O
mast O
/ O
stem O
cell O
growth O
factor O
receptor O
) O
protooncogene O
in O
human O
piebaldism B
. O

Piebaldism B
is O
an O
autosomal B
dominant I
genetic I
disorder I
characterized O
by O
cogenital O
patches O
of O
skin O
and O
hair O
from O
which O
melanocytes O
are O
completely O
absent O
. O

A O
similar O
disorder O
of O
mouse O
, O
dominant O
white O
spotting O
( O
W O
) O
, O
results O
from O
mutations O
of O
the O
c O
- O
Kit O
protooncogene O
, O
which O
encodes O
and O
receptor O
for O
mast O
/ O
stem O
cell O
growth O
factor O
. O

We O
identified O
a O
KIT O
gene O
mutation O
in O
a O
proband O
with O
classic O
autosomal O
dominant O
piebaldism B
. O

This O
mutation O
results O
in O
a O
Gly O
- O
- O
- O
- O
Arg O
substitution O
at O
codon O
664 O
, O
within O
the O
tyrosine O
kinase O
domain O
. O

This O
substitution O
was O
not O
seen O
in O
any O
normal O
individuals O
and O
was O
completely O
linked O
to O
the O
piebald B
phenotype O
in O
the O
probands O
family O
. O

Piebaldism B
in O
this O
family O
thus O
appears O
to O
be O
the O
human O
homologue O
to O
dominant O
white O
spotting O
( O
W O
) O
of O
the O
mouse O
. O
. O

Genetic O
analysis O
of O
a O
Japanese O
family O
with O
normotriglyceridemic B
abetalipoproteinemia I
indicates O
a O
lack O
of O
linkage O
to O
the O
apolipoprotein O
B O
gene O
. O

Normotriglyceridemic B
abetalipoproteinemia I
is O
a O
rare O
familial B
disorder I
characterized O
by O
an O
isolated O
deficiency B
of I
apoB I
- I
100 I
. O

We O
have O
previously O
reported O
a O
patient O
with O
this O
disease O
, O
who O
had O
normal O
apoB O
- O
48 O
but O
no O
apoB O
- O
100 O
. O

To O
elucidate O
the O
genetic B
abnormalities I
in O
this O
family O
, O
we O
studied O
the O
linkage O
of O
apoB O
gene O
using O
three O
genetic O
markers O
. O

The O
proband O
and O
her O
affected O
brother O
showed O
completely O
different O
apoB O
gene O
alleles O
, O
suggesting O
that O
the O
apoB O
gene O
itself O
is O
not O
related O
to O
this O
disorder O
in O
this O
family O
. O

By O
contrast O
, O
an O
American O
case O
had O
a O
point O
substitution O
in O
the O
apoB O
gene O
generating O
an O
in O
- O
frame O
stop O
codon O
. O

These O
results O
indicate O
that O
this O
disorder O
can O
be O
caused O
by O
defect O
( O
s O
) O
of O
either O
an O
apoB O
gene O
or O
other O
genes O
. O
. O

Localisation O
of O
the O
gene O
for O
Norrie B
disease I
to O
between O
DXS7 O
and O
DXS426 O
on O
Xp O
. O

A O
highly O
informative O
microsatellite O
marker O
, O
DXS426 O
, O
which O
maps O
proximal O
to O
DXS7 O
in O
the O
interval O
Xp11 O
. O

4 O
- O
Xp11 O
4 O
- O
Xp11 O
. O

23 O
, O
has O
been O
used O
to O
refine O
further O
the O
localisation O
of O
the O
gene O
for O
Norrie B
disease I
( O
NDP B
) O
. O

The O
results O
from O
a O
multiply O
informative O
crossover O
localize O
the O
NDP B
gene O
proximal O
to O
DXS7 O
. O

In O
conjunction O
with O
information O
from O
2 O
NDP B
patients O
who O
have O
a O
deletion O
for O
DXS7 O
but O
not O
for O
DSX426 O
, O
our O
data O
indicate O
that O
the O
NDP B
gene O
lies O
between O
DXS7 O
and O
DXS426 O
on O
proximal O
Xp O
. O

Aberrant O
splicing O
of O
phenylalanine O
hydroxylase O
mRNA O
: O
the O
major O
cause O
for O
phenylketonuria B
in O
parts O
of O
southern O
Europe O
. O

We O
report O
a O
mutation O
within O
the O
phenylalanine O
hydroxylase O
( O
PAH O
) O
gene O
that O
causes O
aberrant O
splicing O
of O
the O
mRNA O
and O
that O
is O
in O
tight O
association O
with O
chromosomal O
haplotypes O
6 O
, O
10 O
, O
and O
36 O
. O

Because O
of O
the O
high O
frequency O
of O
these O
particular O
haplotypes O
in O
Bulgaria O
, O
Italy O
, O
and O
Turkey O
, O
it O
appears O
to O
be O
one O
of O
the O
more O
frequent O
defects O
in O
the O
PAH O
gene O
causing O
classical O
phenylketonuria B
in O
this O
part O
of O
Europe O
. O

The O
mutation O
is O
a O
G O
to O
A O
transition O
at O
position O
546 O
in O
intron O
10 O
of O
the O
PAH O
gene O
, O
11 O
bp O
upstream O
from O
the O
intron O
10 O
/ O
exon O
11 O
boundary O
. O

It O
activates O
a O
cryptic O
splice O
site O
and O
results O
in O
an O
in O
- O
frame O
insertion O
of O
9 O
nucleotides O
between O
exon O
10 O
and O
exon O
11 O
of O
the O
processed O
mRNA O
. O

Normal O
amounts O
of O
liver O
PAH O
protein O
are O
present O
in O
homozygous O
patients O
, O
but O
no O
catalytic O
activity O
can O
be O
detected O
. O

This O
loss O
of O
enzyme O
activity O
is O
probably O
caused O
by O
conformational O
changes O
resulting O
from O
the O
insertion O
of O
three O
additional O
amino O
acids O
( O
Gly O
- O
Leu O
- O
Gln O
) O
between O
the O
normal O
sequences O
encoded O
by O
exon O
10 O
and O
exon O
11 O
. O
. O

Gardner B
syndrome I
in O
a O
boy O
with O
interstitial O
deletion O
of O
the O
long O
arm O
of O
chromosome O
5 O
. O

We O
described O
a O
15 O
- O
year O
- O
old O
boy O
with O
Gardner B
syndrome I
( O
GS B
) O
, O
mental B
retardation I
, O
and O
craniofacial B
abnormalities I
. O

High O
- O
resolution O
banding O
analysis O
showed O
an O
interstitial O
deletion O
of O
the O
long O
arm O
of O
chromosome O
5 O
( O
q22 O
. O
1 O
- O
- O
- O
- O
q31 O
1 O
- O
- O
- O
- O
q31 O
. O
1 O
) O
. O

The O
breakpoints O
in O
the O
present O
case O
and O
in O
3 O
previously O
reported O
5q O
- O
patients O
with O
adenomatous B
polyposis I
coli I
suggest O
that O
the O
gene O
responsible O
for O
GS B
/ O
or O
familial B
polyposis I
coli I
( O
FPC B
) O
is O
in O
the O
5q22 O
region O
, O
a O
result O
consistent O
with O
the O
findings O
of O
linkage O
studies O

Huntington B
disease I
and O
childhood O
- O
onset O
Tourette B
syndrome I
. O

A O
40 O
- O
year O
- O
old O
man O
with O
childhood O
- O
onset O
Tourette B
syndrome I
( O
TS B
) O
developed O
Huntington B
disease I
( O
HD B
) O
. O

We O
believe O
this O
to O
be O
the O
first O
reported O
case O
of O
childhood O
- O
onset O
TS B
with O
adult O
onset O
HD B
. O

Discovery O
of O
other O
cases O
with O
both O
disorders O
may O
provide O
clues O
to O
the O
pathophysiology O
of O
both O
conditions O
. O
. O

Sequence O
of O
DNA O
flanking O
the O
exons O
of O
the O
HEXA O
gene O
, O
and O
identification O
of O
mutations O
in O
Tay B
- I
Sachs I
disease I
. O

The O
rapid O
identification O
of O
mutations O
causing O
Tay B
- I
Sachs I
disease I
requires O
the O
capacity O
to O
readily O
screen O
the O
regions O
of O
the O
HEXA O
gene O
most O
likely O
to O
be O
affected O
by O
mutation O
. O

We O
have O
sequenced O
the O
portions O
of O
the O
introns O
flanking O
each O
of O
the O
14 O
HEXA O
exons O
in O
order O
to O
specify O
oligonucleotide O
primers O
for O
the O
PCR O
- O
dependent O
amplification O
of O
each O
exon O
and O
splice O
- O
junction O
sequence O
. O

The O
amplified O
products O
were O
analyzed O
, O
by O
electrophoresis O
in O
nondenaturing O
polyacrylamide O
gels O
, O
for O
the O
presence O
of O
either O
heteroduplexes O
, O
derived O
from O
the O
annealing O
of O
normal O
and O
mutant O
DNA O
strands O
, O
or O
single O
- O
strand O
conformational O
polymorphisms O
( O
SSCP O
) O
, O
derived O
from O
the O
renaturation O
of O
single O
- O
stranded O
DNA O
. O

Five O
novel O
mutations O
from O
Tay B
- I
Sachs I
disease I
patients O
were O
detected O
a O
5 O
- O
bp O
deletion O
of O
TCTCC O
in O
IVS O
- O
9 O
; O
a O
2 O
- O
bp O
deletion O
of O
TG O
in O
exon O
5 O
; O
G78 O
to O
A O
, O
giving O
a O
stop O
codon O
in O
exon O
1 O
; O
G533 O
to O
T O
in O
exon O
5 O
, O
producing O
the O
third O
amino O
acid O
substitution O
detected O
at O
this O
site O
; O
and O
G O
to O
C O
at O
position O
1 O
of O
IVS O
- O
2 O
, O
expected O
to O
produce O
abnormal O
splicing O
. O

In O
addition O
, O
two O
mutations O
, O
( O
G1496 O
to O
A O
in O
exon O
13 O
and O
a O
4 O
- O
bp O
insertion O
in O
exon O
11 O
) O
that O
have O
previously O
been O
reported O
were O
identified O
. O
. O

Molecular O
characterization O
of O
two O
galactosemia B
mutations O
: O
correlation O
of O
mutations O
with O
highly O
conserved O
domains O
in O
galactose O
- O
1 O
- O
phosphate O
uridyl O
transferase O
. O

Galactosemia B
is O
an O
autosomal B
recessive I
disorder I
of I
human I
galactose I
metabolism I
caused O
by O
deficiency B
of I
the I
enzyme I
galactose I
- I
1 I
- I
phosphate I
uridyl I
transferase I
( O
GALT O
) O
. O

The O
molecular O
basis O
of O
this O
disorder O
is O
at O
present O
not O
well O
understood O
. O

We O
report O
here O
two O
missense O
mutations O
which O
result O
in O
low O
or O
undetectable O
enzymatic O
activity O
. O

First O
, O
we O
identified O
at O
nucleotide O
591 O
a O
transition O
which O
substitutes O
glutamine O
188 O
by O
arginine O
. O

The O
mutated O
glutamine O
is O
not O
only O
highly O
conserved O
in O
evolution O
( O
conserved O
also O
in O
Escherichia O
coli O
and O
Saccharomyces O
cerevisiae O
) O
, O
but O
is O
also O
two O
amino O
acid O
residues O
downstream O
from O
the O
active O
site O
histidine O
- O
proline O
- O
histidine O
triad O
and O
results O
in O
about O
10 O
% O
of O
normal O
enzymatic O
activity O
. O

The O
arginine O
188 O
mutation O
is O
the O
most O
common O
galactosemia B
mutation O
characterized O
to O
date O
. O

It O
accounts O
for O
one O
- O
fourth O
of O
the O
galactosemia B
alleles O
studied O
. O

Second O
, O
we O
report O
the O
substitution O
of O
arginine O
333 O
by O
tryptophan O
, O
caused O
by O
a O
transition O
at O
nucleotide O
1025 O
. O

The O
area O
surrounding O
this O
missense O
mutation O
is O
the O
most O
highly O
conserved O
domain O
in O
the O
homologous O
enzymes O
from O
E O
. O
coli O
, O
yeast O
, O
and O
humans O
, O
and O
this O
mutation O
results O
in O
undetectable O
enzymatic O
activity O
, O
suggesting O
that O
this O
is O
a O
severe O
mutation O
. O

This O
second O
mutation O
appears O
to O
be O
rare O
, O
since O
it O
was O
found O
only O
in O
the O
patient O
we O
sequenced O
. O

Our O
data O
provide O
further O
evidence O
for O
the O
heterogeneity O
of O
galactosemia B
at O
the O
molecular O
level O
, O
heterogeneity O
which O
might O
be O
related O
to O
the O
variable O
clinical O
outcome O
observed O
in O
this O
disorder O
. O
. O

Hypoxanthine B
- I
guanine I
phosphoribosyltransferase I
deficiency I
: O
analysis O
of O
HPRT O
mutations O
by O
direct O
sequencing O
and O
allele O
- O
specific O
amplification O
. O

The O
Lesch B
- I
Nyhan I
syndrome I
is O
a O
severe O
X B
chromosome I
- I
linked I
human I
disease I
caused O
by O
a O
virtual O
absence B
of I
hypoxanthine I
- I
guanine I
phosphoribosyltransferase I
( I
HPRT I
) I
activity I
. O

A O
partial O
deficiency O
in O
the O
activity O
of O
this O
enzyme O
can O
result O
in O
gouty B
arthritis I
. O

To O
determine O
the O
genetic O
basis O
for O
reduction O
or O
loss O
of O
enzyme O
activity O
, O
we O
have O
amplified O
and O
sequenced O
the O
coding O
region O
of O
HPRT O
cDNA O
from O
four O
patients O
one O
with O
Lesch B
- I
Nyhan I
syndrome I
( O
HPRTPerth O
) O
and O
three O
with O
partial B
deficiencies I
of I
HPRT I
activity I
, O
which O
have O
been O
designated O
HPRTUrangan O
, O
HPRTSwan O
and O
HPRTToowong O
. O

In O
all O
four O
patients O
, O
the O
only O
mutation O
identified O
was O
a O
single O
base O
substitution O
in O
exons O
2 O
or O
3 O
of O
the O
coding O
region O
, O
which O
in O
each O
case O
predicts O
a O
single O
amino O
acid O
substitution O
in O
the O
translated O
protein O
. O

Each O
base O
change O
was O
confirmed O
by O
allele O
- O
specific O
amplification O
of O
the O
patients O
genomic O
DNA O
. O

It O
is O
interesting O
to O
note O
that O
the O
mutation O
found O
for O
HPRTPerth O
is O
identical O
to O
that O
reported O
for O
HPRTFlint O
. O

It O
appears O
that O
the O
two O
mutations O
are O
de O
novo O
events O
. O
. O

Molecular O
and O
metabolic O
basis O
for O
the O
metabolic B
disorder I
normotriglyceridemic B
abetalipoproteinemia I
. O

We O
have O
previously O
described O
a O
disorder O
, O
normotriglyceridemic B
abetalipoproteinemia I
, O
that O
is O
characterized O
by O
the O
virtual O
absence O
of O
plasma O
low O
density O
lipoproteins O
and O
complete O
absence O
of O
apoB O
- O
100 O
, O
but O
with O
apparently O
normal O
secretion O
of O
triglyceride O
- O
rich O
lipoproteins O
containing O
apoB O
- O
48 O
. O

The O
patients O
plasma O
lipoproteins O
were O
shown O
on O
polyacrylamide O
gels O
and O
by O
antibody O
mapping O
to O
have O
a O
new O
truncated O
apoB O
variant O
, O
apoB O
- O
50 O
, O
circulating O
along O
with O
her O
apoB O
- O
48 O
. O

We O
have O
found O
this O
individual O
to O
be O
homozygous O
for O
a O
single O
C O
- O
to O
- O
T O
nucleotide O
substitution O
at O
apoB O
codon O
2252 O
, O
which O
produces O
a O
premature O
in O
- O
frame O
stop O
codon O
. O

Thus O
, O
this O
is O
a O
rare O
example O
of O
homozygous B
hypobetalipoproteinemia I
. O

Electron O
photomicrographs O
revealed O
that O
the O
diameters O
of O
particles O
in O
the O
d O
less O
than O
1 O
. O

006 O
g O
/ O
ml O
lipoprotein O
fraction O
, O
in O
both O
the O
postprandial O
and O
postabsorptive O
state O
, O
are O
bimodally O
distributed O
. O

The O
molar O
ratio O
of O
apoE O
to O
apoB O
in O
these O
particles O
is O
3 O
. O

5 O
1 O
, O
similar O
to O
normal O
VLDL O
. O

The O
plasma O
LDL O
interval O
contains O
both O
spherical O
and O
cuboidal O
particles O
. O

Autologous O
reinfusion O
of O
labeled O
d O
less O
than O
1 O
. O

006 O
g O
/ O
ml O
lipoproteins O
showed O
exponential O
disappearance O
from O
plasma O
, O
with O
an O
apparent O
half O
- O
removal O
time O
of O
50 O
min O
, O
somewhat O
slower O
than O
for O
normal O
chylomicrons O
but O
within O
the O
normal O
range O
for O
VLDL O
. O

The O
calculated O
production O
rate O
for O
apoB O
was O
within O
the O
normal O
range O
in O
this O
subject O
. O

A O
single O
origin O
of O
phenylketonuria B
in O
Yemenite O
Jews O
. O

Phenylketonuria B
( O
PKU B
) O
is O
a O
metabolic B
disease I
caused O
by O
recessive O
mutations O
of O
the O
gene O
encoding O
the O
hepatic O
enzyme O
phenylalanine O
hydroxylase O
( O
PAH O
) O
. O

The O
incidence O
of O
PKU B
varies O
widely O
across O
different O
geographic O
areas O
, O
and O
is O
highest O
( O
about O
1 O
in O
5 O
, O
000 O
live O
births O
) O
in O
Ireland O
and O
western O
Scotland O
, O
and O
among O
Yemenite O
Jews O
. O

A O
limited O
number O
of O
point O
mutations O
account O
for O
most O
of O
the O
PKU B
cases O
in O
the O
European O
population O
. O

Here O
we O
report O
that O
a O
single O
molecular O
defect O
- O
- O
a O
deletion O
spanning O
the O
third O
exon O
of O
the O
PAH O
gene O
- O
- O
is O
responsible O
for O
all O
the O
PKU B
cases O
among O
the O
Yemenite O
Jews O
. O

Examination O
of O
a O
random O
sample O
of O
Yemenite O
Jews O
using O
a O
molecular O
probe O
that O
detects O
the O
carriers O
of O
this O
deletion O
indicated O
a O
high O
frequency O
of O
the O
defective O
gene O
in O
this O
community O
. O

Although O
the O
deleted O
PAH O
gene O
was O
traced O
to O
25 O
different O
locations O
throughout O
Yemen O
, O
family O
histories O
and O
official O
documents O
of O
the O
Yemenite O
Jewish O
community O
showed O
that O
the O
common O
ancestor O
of O
all O
the O
carriers O
of O
this O
genetic B
defect I
lived O
in O
Sana O
, O
the O
capital O
of O
Yemen O
, O
before O
the O
eighteenth O
century O
. O
. O

Linkage O
of O
aspartylglucosaminuria B
( O
AGU B
) O
to O
marker O
loci O
on O
the O
long O
arm O
of O
chromosome O
4 O
. O

Aspartylglucosaminuria B
( O
AGU B
) O
is O
caused O
by O
deficient O
activity O
of O
the O
enzyme O
aspartylglucosaminidase O
( O
AGA O
) O
. O

The O
structural O
gene O
for O
AGA O
has O
been O
assigned O
to O
the O
region O
4q21 O
- O
qter O
of O
chromosome O
4 O
. O

We O
have O
studied O
the O
map O
position O
of O
the O
AGU O
locus O
in O
relation O
to O
other O
marker O
loci O
on O
the O
long O
arm O
of O
chromosome O
4 O
using O
linkage O
analyses O
. O

Restriction O
fragment O
length O
polymorphism O
alleles O
for O
the O
ADH2 O
, O
ADH3 O
, O
EGF O
, O
FG O
alpha O
and O
FG O
beta O
loci O
and O
blood O
group O
antigens O
for O
the O
MNS O
locus O
were O
determined O
in O
a O
panel O
of O
12 O
Finnish O
AGU B
families O
. O

The O
heterozygous O
family O
members O
were O
identified O
by O
reduced O
activity O
of O
AGA O
in O
lymphocytes O
. O

Linkage O
studies O
were O
performed O
using O
both O
pairwise O
and O
multipoint O
analyses O
. O

Loose O
linkage O
of O
the O
AGU B
locus O
to O
the O
FG O
and O
MNS O
loci O
was O
observed O
( O
z O
= O
1 O
. O
16 O
, O
z O
= O
1 O
. O
39 O
, O
respectively O
) O
. O

Multipoint O
analysis O
to O
the O
fixed O
map O
[ O
ADH O
- O
( O
0 O
. O
03 O
) O
- O
EGF O
- O
( O
0 O
. O
35 O
) O
- O
FG O
- O
( O
0 O
. O
11 O
) O
- O
MNS O
] O
suggests O
that O
the O
location O
of O
the O
AGU O
locus O
is O
0 O
. O

05 O
- O
0 O
. O

30 O
recombination O
units O
distal O
to O
MNS O
( O
z O
= O
3 O
. O
03 O
) O
. O

The O
order O
cen O
- O
ADH O
- O
EGF O
- O
FG O
- O
MNS O
- O
AGU O
is O
35 O
times O
more O
likely O
than O
the O
next O
best O
order O
cen O
- O
ADH O
- O
EGF O
- O
AGU O
- O
FG O
- O
MNS O
. O

Linkage O
relationships O
of O
the O
apolipoprotein O
C1 O
gene O
and O
a O
cytochrome O
P450 O
gene O
( O
CYP2A O
) O
to O
myotonic B
dystrophy I
. O

We O
have O
studied O
the O
genetic O
linkage O
of O
two O
markers O
, O
the O
apolipoprotein O
C1 O
( O
APOC1 O
) O
gene O
and O
a O
cytochrome O
P450 O
( O
CYP2A O
) O
gene O
, O
in O
relation O
to O
the O
gene O
for O
myotonic B
dystrophy I
( O
DM B
) O
. O

A O
peak O
lod O
score O
of O
9 O
. O

29 O
at O
2 O
cM O
was O
observed O
for O
APOC1 O
- O
DM O
, O
with O
a O
lod O
score O
of O
8 O
. O

55 O
at O
4 O
cM O
for O
CYP2A O
- O
DM O
. O

These O
two O
markers O
also O
show O
close O
linkage O
to O
each O
other O
( O
theta O
max O
= O
0 O
. O
05 O
, O
Zmax O
= O
9 O
. O
09 O
) O
. O

From O
examination O
of O
the O
genotypes O
of O
the O
recombinant O
individuals O
, O
CYP2A O
appears O
to O
map O
proximal O
to O
DM O
because O
in O
one O
recombinant O
individual O
CYP2A O
, O
APOC2 O
and O
CKMM O
had O
all O
recombined O
with O
DM O
. O

Evidence O
from O
another O
CYP2A O
- O
DM O
recombinant O
individual O
places O
CYP2A O
proximal O
to O
APOC2 O
and O
CKMM O
. O

Localisation O
of O
CYP2A O
on O
a O
panel O
of O
somatic O
cell O
hybrids O
also O
suggests O
that O
it O
is O
proximal O
to O
DM O
and O
APOC2 O
/ O
C1 O
/ O
E O
gene O
cluster O
. O

Genetic O
linkage O
map O
of O
six O
polymorphic O
DNA O
markers O
around O
the O
gene O
for O
familial B
adenomatous I
polyposis I
on O
chromosome O
5 O
. O

A O
genetic O
linkage O
map O
of O
six O
polymorphic O
DNA O
markers O
close O
to O
the O
gene O
( O
APC O
) O
for O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
on O
chromosome O
5q O
is O
reported O
. O

One O
hundred O
fifty O
- O
five O
typed O
members O
of O
nine O
FAP B
kindred O
provided O
more O
than O
90 O
meioses O
for O
linkage O
analysis O
. O

A O
number O
of O
crucial O
recombination O
events O
have O
been O
identified O
which O
are O
informative O
at O
three O
or O
more O
loci O
, O
allowing O
confident O
ordering O
of O
parts O
of O
the O
map O
. O

There O
was O
no O
evidence O
of O
genetic O
heterogeneity O
, O
with O
all O
families O
showing O
linkage O
of O
at O
least O
one O
chromosome O
5 O
marker O
to O
the O
gene O
. O

Recombination O
data O
and O
two O
- O
point O
linkage O
analysis O
support O
a O
locus O
order O
of O
centromere O
- O
pi O
227 O
- O
C11P11 O
- O
ECB27 O
- O
L5 O
. O

62 O
- O
APC O
- O
EF5 O
62 O
- O
APC O
- O
EF5 O
. O

44 O
- O
YN5 O
44 O
- O
YN5 O
. O

48 O
- O
telomer O
e O
, O
although O
EF5 O
. O

44 O
could O
lie O
in O
the O
interval O
L5 O
. O

62 O
- O
APC O
or O
ECB27 O
- O
L5 O
. O

62 O
. O

No O
recombinants O
were O
identified O
between O
APC O
and O
either O
EF5 O
. O

44 O
or O
YN5 O
. O

48 O
, O
but O
published O
deletion O
mapping O
in O
colorectal B
carcinomas I
and O
linkage O
analysis O
in O
FAP B
suggest O
that O
YN5 O
. O

48 O
is O
1 O
- O
3 O
cM O
from O
APC O
. O

The O
present O
study O
suggests O
that O
YN5 O
. O

48 O
and O
L5 O
. O

62 O
delineate O
a O
small O
region O
of O
chromosome O
5 O
within O
which O
the O
EF5 O
. O

44 O
locus O
lies O
very O
close O
to O
the O
APC B
gene O
. O

These O
data O
not O
only O
allow O
use O
of O
flanking O
markers O
for O
presymptomatic O
diagnosis O
of O
FAP B
but O
also O
provide O
a O
high O
- O
density O
map O
of O
the O
region O
for O
isolation O
of O
the O
APC B
gene O
itself O
and O
for O
further O
assessment O
of O
the O
role O
of O
chromosome O
5 O
deletions O
in O
the O
biology O
of O
sporadic O
colorectal B
cancer I
. O

Serum O
amyloid O
A O
and O
P O
protein O
genes O
in O
familial B
Mediterranean I
fever I
. O

Two O
recent O
studies O
have O
suggested O
the O
involvement O
of O
serum O
amyloid O
A O
( O
SAA O
) O
and O
P O
( O
APCS O
) O
genes O
in O
familial B
Mediterranean I
fever I
( O
MEF B
) O
. O

To O
test O
the O
role O
of O
SAA O
and O
APCS O
in O
MEF B
and O
MEF B
- I
amyloidosis I
, O
we O
studied O
17 O
informative O
families O
( O
15 O
Armenians O
, O
2 O
non O
- O
Ashkenazi O
Jews O
) O
and O
8 O
MEF B
patients O
with O
amyloidosis B
using O
a O
candidate O
gene O
approach O
. O

No O
evidence O
for O
any O
MEF B
- O
associated O
polymorphism O
was O
found O
in O
any O
of O
the O
41 O
Armenian O
and O
Jewish O
MEF B
patients O
tested O
. O

Our O
family O
studies O
allowed O
us O
to O
rule O
out O
tight O
linkage O
between O
SAA O
and O
MEF B
( O
lod O
score O
= O
- O
2 O
. O
16 O
, O
theta O
less O
than O
or O
equal O
to O
0 O
. O
06 O
) O
. O

For O
APCS O
we O
found O
that O
the O
allele O
frequency O
in O
the O
MEF B
- I
amyloidosis I
patients O
was O
similar O
to O
that O
in O
18 O
unrelated O
MEF B
patients O
without O
amyloidosis B
and O
their O
33 O
healthy O
parents O
. O

Some O
Mexican O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variants O
revisited O
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
appears O
to O
be O
fairly O
common O
in O
Mexico O
. O

We O
have O
now O
examined O
the O
DNA O
of O
three O
previously O
reported O
electrophoretically O
fast O
Mexican O
G6PD O
variants O
, O
- O
G6PD O
Distrito O
Federal O
, O
G6PD O
Tepic O
, O
and O
G6PD O
Castilla O
. O

All O
three O
of O
these O
variants O
, O
believed O
on O
the O
basis O
of O
biochemical O
characterization O
and O
population O
origin O
to O
be O
unique O
, O
have O
the O
G O
- O
- O
- O
- O
A O
transition O
at O
nucleotide O
202 O
and O
the O
A O
- O
- O
- O
- O
G O
transition O
at O
nucleotide O
376 O
, O
mutations O
that O
we O
now O
recognize O
to O
be O
characteristic O
of O
G6PD O
A O
- O
. O

Two O
other O
Mexican O
males O
with O
G6PD B
deficiency I
were O
found O
to O
have O
the O
same O
mutation O
. O

All O
five O
have O
the O
( O
NlaIII O
/ O
FokI O
/ O
PvuII O
/ O
PstI O
) O
haplotype O
characteristic O
of O
G6PD O
A O
- O
in O
Africa O
. O

Since O
the O
PvuII O
+ O
genotype O
seems O
to O
be O
rare O
in O
Europe O
, O
we O
conclude O
that O
all O
of O
these O
G6PD O
A O
- O
genes O
had O
their O
ancient O
origin O
in O
Africa O
, O
although O
in O
many O
of O
the O
Mexican O
patients O
with O
G6PD O
A O
- O
202A O
/ O
376G O
the O
gene O
may O
have O
been O
imported O
more O
recently O
from O
Spain O
, O
where O
this O
variant O
, O
formerly O
known O
as O
G6PD O
Betica O
, O
is O
also O
prevalent O
. O
. O

Hereditary O
deficiency B
of I
C5 I
in O
association O
with O
discoid B
lupus I
erythematosus I
. O

A O
29 O
- O
year O
- O
old O
woman O
with O
discoid B
lupus I
erythematosus I
had O
undetectable O
classic O
pathway O
complement O
activity O
. O

Hypocomplementemia B
was O
due O
to O
selective O
deficiency B
of I
C5 I
. O

One O
of O
her O
children O
was O
also O
deficient O
. O

To O
our O
knowledge O
this O
is O
the O
first O
documented O
case O
of O
an O
association O
between O
discoid B
lupus I
erythematosus I
and O
C5 B
deficiency I
. O
. O

Founder O
effect O
of O
a O
prevalent O
phenylketonuria B
mutation O
in O
the O
Oriental O
population O
. O

A O
missense O
mutation O
has O
been O
identified O
in O
the O
human O
phenylalanine O
hydroxylase O
[ O
PAH O
; O
phenylalanine O
4 O
- O
monooxygenase O
; O
L O
- O
phenylalanine O
, O
tetrahydrobiopterin O
oxygen O
oxidoreductase O
( O
4 O
- O
hydroxylating O
) O
, O
EC O
1 O
. O
14 O
. O
16 O
. O
1 O
] O
gene O
in O
a O
Chinese O
patient O
with O
classic O
phenylketonuria B
( O
PKU B
) O
. O

A O
G O
- O
to O
- O
C O
transition O
at O
the O
second O
base O
of O
codon O
413 O
in O
exon O
12 O
of O
the O
gene O
results O
in O
the O
substitution O
of O
Pro413 O
for O
Arg413 O
in O
the O
mutant O
protein O
. O

This O
mutation O
( O
R413P O
) O
results O
in O
negligible O
enzymatic O
activity O
when O
expressed O
in O
heterologous O
mammalian O
cells O
and O
is O
compatible O
with O
a O
classic O
PKU B
phenotype O
in O
the O
patient O
. O

Population O
genetic O
studies O
reveal O
that O
this O
mutation O
is O
tightly O
linked O
to O
restriction O
fragment O
length O
polymorphism O
haplotype O
4 O
, O
which O
is O
the O
predominant O
haplotype O
of O
the O
PAH O
locus O
in O
the O
Oriental O
population O
. O

It O
accounts O
for O
13 O
. O

8 O
% O
of O
northern O
Chinese O
and O
27 O
% O
of O
Japanese O
PKU B
alleles O
, O
but O
it O
is O
rare O
in O
southern O
Chinese O
( O
2 O
. O
2 O
% O
) O
and O
is O
absent O
in O
the O
Caucasian O
population O
. O

The O
data O
demonstrate O
unambiguously O
that O
the O
mutation O
occurred O
after O
racial O
divergence O
of O
Orientals O
and O
Caucasians O
and O
suggest O
that O
the O
allele O
has O
spread O
throughout O
the O
Orient O
by O
a O
founder O
effect O
. O

Previous O
protein O
polymorphism O
studies O
in O
eastern O
Asia O
have O
led O
to O
the O
hypothesis O
that O
" O
northern O
Mongoloids O
" O
represented O
a O
founding O
population O
in O
Asia O
. O

Our O
results O
are O
compatible O
with O
this O
hypothesis O
in O
that O
the O
PKU B
mutation O
might O
have O
occurred O
in O
northern O
Mongoloids O
and O
subsequently O
spread O
to O
the O
Chinese O
and O
Japanese O
populations O
. O

Glucose B
/ I
galactose I
malabsorption I
caused O
by O
a O
defect O
in O
the O
Na O
+ O
/ O
glucose O
cotransporter O
. O

Glucose B
/ I
galactose I
malabsorption I
( O
GGM B
) O
is O
an O
autosomal B
recessive I
disease I
manifesting O
within O
the O
first O
weeks O
of O
life O
and O
characterized O
by O
a O
selective O
failure O
to O
absorb O
dietary O
glucose O
and O
galactose O
from O
the O
intestine O
. O

The O
consequent O
severe O
diarrhoea B
and O
dehydration B
are O
usually O
fatal O
unless O
these O
sugars O
are O
eliminated O
from O
the O
diet O
. O

Intestinal O
biopsies O
of O
GGM B
patients O
have O
revealed O
a O
specific O
defect O
in O
Na O
( O
+ O
) O
- O
dependent O
absorption O
of O
glucose O
in O
the O
brush O
border O
. O

Normal O
glucose O
absorption O
is O
mediated O
by O
the O
Na O
+ O
/ O
glucose O
cotransporter O
in O
the O
brush O
border O
membrane O
of O
the O
intestinal O
epithelium O
. O

Cellular O
influx O
is O
driven O
by O
the O
transmembrane O
Na O
+ O
electrochemical O
potential O
gradient O
; O
thereafter O
the O
sugar O
moves O
to O
the O
blood O
across O
the O
basolateral O
membrane O
via O
the O
facilitated O
glucose O
carrier O
. O

We O
have O
previously O
cloned O
and O
sequenced O
a O
Na O
+ O
/ O
glucose O
cotransporter O
from O
normal O
human O
ileum O
and O
shown O
that O
this O
gene O
, O
SGLT1 O
, O
resides O
on O
the O
distal O
q O
arm O
of O
chromosome O
22 O
. O

We O
have O
now O
amplified O
SGLT1 O
complementary O
DNA O
and O
genomic O
DNA O
from O
members O
of O
a O
family O
affected O
with O
GGM B
by O
the O
polymerase O
chain O
reaction O
. O

Sequence O
analysis O
of O
the O
amplified O
products O
has O
revealed O
a O
single O
missense O
mutation O
in O
SGLT1 O
which O
cosegregates O
with O
the O
GGM B
phenotype O
and O
results O
in O
a O
complete O
loss O
of O
Na O
( O
+ O
) O
- O
dependent O
glucose O
transport O
in O
Xenopus O
oocytes O
injected O
with O
this O
complementary O
RNA O
. O
. O

A O
de O
novo O
unbalanced O
reciprocal O
translocation O
identified O
as O
paternal O
in O
origin O
in O
the O
Prader B
- I
Willi I
syndrome I
. O

Interstitial O
cytogenetic O
deletions O
involving O
the O
paternally O
derived O
chromosome O
15q11 O
- O
13 O
have O
been O
described O
in O
patients O
with O
the O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
report O
a O
child O
with O
PWS B
and O
a O
de O
novo O
unbalanced O
karyotype O
- O
45 O
, O
XY O
, O
- O
9 O
, O
- O
15 O
, O
+ O
der O
( O
9 O
) O
t O
( O
9 O
; O
15 O
) O
( O
q34 O
; O
q13 O
) O
. O

Molecular O
studies O
with O
the O
DNA O
probe O
pML34 O
confirmed O
that O
only O
a O
single O
Prader B
Willi I
critical O
region O
( O
PWCR O
15q11 O
. O
2 O
- O
q12 O
) O
copy O
was O
present O
. O

Hybridisation O
of O
patient O
and O
parental O
DNA O
with O
the O
multi O
- O
allelic O
probe O
CMW1 O
, O
which O
maps O
to O
pter O
- O
15q13 O
, O
showed O
that O
the O
chromosome O
involved O
in O
the O
translocation O
was O
paternal O
in O
origin O
. O

This O
is O
the O
first O
example O
of O
a O
paternally O
- O
derived O
PWCR O
allele O
loss O
caused O
by O
an O
unbalanced O
translocation O
that O
has O
arisen O
de O
novo O
. O

Localisation O
of O
the O
myotonic B
dystrophy I
locus O
to O
19q13 O
. O
2 O
- O
19q13 O
. O
3 O
and O
its O
relationship O
to O
twelve O
polymorphic O
loci O
on O
19q O
. O

The O
order O
of O
fourteen O
polymorphic O
markers O
localised O
to O
the O
long O
arm O
of O
human O
chromosome O
19 O
has O
been O
established O
by O
multipoint O
mapping O
in O
a O
set O
of O
40 O
CEPH O
( O
Centre O
dEtude O
de O
Polymorphisme O
Humain O
, O
Paris O
) O
reference O
families O
. O

We O
report O
here O
the O
linkage O
relationship O
of O
the O
myotonic B
dystrophy I
( O
DM B
) O
locus O
to O
twelve O
of O
these O
markers O
as O
studied O
in O
45 O
families O
with O
DM B
. O

The O
resulting O
genetic O
map O
is O
supported O
by O
the O
localisation O
of O
the O
DNA O
markers O
in O
a O
panel O
of O
somatic O
cell O
hybrids O
. O

Ten O
of O
the O
twelve O
markers O
have O
been O
shown O
to O
be O
proximal O
to O
the O
DM B
gene O
and O
two O
, O
PRKCG O
and O
D19S22 O
, O
distal O
but O
at O
distances O
of O
approximately O
25 O
cM O
and O
15 O
cM O
, O
respectively O
. O

The O
closest O
proximal O
markers O
are O
APOC2 O
( O
apolipoprotein O
C O
- O
II O
) O
and O
CKM O
( O
creatine O
kinase O
, O
muscle O
) O
approximately O
3 O
cM O
and O
2 O
cM O
from O
the O
DM B
gene O
respectively O
, O
in O
the O
order O
APOC2 O
- O
CKM O
- O
DM O
. O

The O
distance O
between O
APOC2 O
, O
CKM O
and O
DM B
( O
of O
the O
order O
of O
2 O
million O
base O
pairs O
) O
and O
their O
known O
orientation O
should O
permit O
directional O
chromosome O
walking O
and O
jumping O
. O

The O
data O
presented O
here O
should O
enable O
us O
to O
determine O
whether O
or O
not O
new O
markers O
are O
distal O
to O
APOC2 O
/ O
CKM O
and O
thus O
potentially O
flank O
the O
DM B
gene O
. O
. O

Localization O
of O
histidase O
to O
human O
chromosome O
region O
12q22 O
- O
- O
- O
- O
q24 O
. O
1 O
and O
mouse O
chromosome O
region O
10C2 O
- O
- O
- O
- O
D1 O
. O

The O
human O
gene O
for O
histidase O
( O
histidine O
ammonia O
- O
lyase O
; O
HAL O
) O
, O
the O
enzyme O
deficient O
in O
histidinemia B
, O
was O
assigned O
to O
human O
chromosome O
12 O
by O
Southern O
blot O
analysis O
of O
human O
X O
mouse O
somatic O
cell O
hybrid O
DNA O
. O

The O
gene O
was O
sublocalized O
to O
region O
12q22 O
- O
- O
- O
- O
q24 O
. O

1 O
by O
in O
situ O
hybridization O
, O
using O
a O
human O
histidase O
cDNA O
. O

The O
homologous O
locus O
in O
the O
mouse O
( O
Hal O
) O
was O
mapped O
to O
region O
10C2 O
- O
- O
- O
- O
D1 O
by O
in O
situ O
hybridization O
, O
using O
a O
cell O
line O
from O
a O
mouse O
homozygous O
for O
a O
1 O
. O

10 O
Robertsonian O
translocation O
. O

These O
assignments O
extend O
the O
conserved O
syntenic O
region O
between O
human O
chromosome O
12 O
and O
mouse O
chromosome O
10 O
that O
includes O
the O
genes O
for O
phenylalanine O
hydroxylase O
, O
gamma O
interferon O
, O
peptidase O
, O
and O
citrate O
synthase O
. O

The O
localization O
of O
histidase O
to O
mouse O
chromosome O
10 O
suggests O
that O
the O
histidase O
regulatory O
locus O
( O
Hsd O
) O
and O
the O
histidinemia O
mutation O
( O
his O
) O
, O
which O
are O
both O
known O
to O
be O
on O
chromosome O
10 O
, O
may O
be O
alleles O
of O
the O
histidase O
structural O
gene O
locus O
. O

Determination O
of O
the O
mutations O
responsible O
for O
the O
Lesch B
- I
Nyhan I
syndrome I
in O
17 O
subjects O
. O

Hypoxanthine O
- O
- O
guanine O
phosphoribosyltransferase O
( O
HPRT O
) O
is O
a O
purine O
salvage O
enzyme O
that O
catalyzes O
the O
conversion O
of O
hypoxanthine O
to O
inosine O
monophosphate O
and O
guanine O
to O
guanosine O
monophosphate O
. O

Previous O
studies O
of O
mutant O
HPRT O
proteins O
analyzed O
at O
the O
molecular O
level O
have O
shown O
a O
significant O
heterogeneity O
. O

This O
investigation O
further O
verifies O
this O
heterogeneity O
and O
identifies O
insertions O
, O
deletions O
, O
and O
point O
mutations O
. O

The O
direct O
sequencing O
of O
the O
polymerase O
chain O
reaction O
- O
amplified O
product O
of O
reverse O
- O
transcribed O
HPRT O
mRNA O
enabled O
the O
rapid O
identification O
of O
the O
mutations O
found O
in O
17 O
previously O
uncharacterized O
cell O
lines O
derived O
from O
patients O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O
. O

Linkage O
of O
DNA O
markers O
at O
Xq28 O
to O
adrenoleukodystrophy B
and O
adrenomyeloneuropathy B
present O
within O
the O
same O
family O
. O

We O
present O
a O
large O
kindred O
that O
contained O
patients O
with O
either O
adrenoleukodystrophy B
( O
ALD B
) O
or O
adrenomyeloneuropathy B
( O
AMN B
) O
. O

The O
pedigree O
clearly O
supported O
the O
X O
- O
linked O
mode O
of O
inheritance O
of O
the O
nonneonatal O
form O
of O
ALD B
/ O
AMN B
. O

Analysis O
with O
DNA O
markers O
at O
Xq28 O
suggested O
segregation O
of O
both O
ALD B
and O
AMN B
with O
an O
identical O
haplotype O
. O

This O
indicated O
that O
nonneonatal O
ALD B
and O
AMN B
are O
caused O
by O
a O
mutation O
in O
the O
same O
gene O
at O
Xq28 O
. O

It O
showed O
, O
furthermore O
, O
that O
phenotypic O
differences O
between O
ALD B
and O
AMN B
are O
not O
necessarily O
the O
consequence O
of O
allelic O
heterogeneity O
due O
to O
different O
mutations O
within O
the O
same O
gene O
. O

The O
maximal O
lod O
score O
for O
linkage O
of O
the O
ALD B
/ O
AMN B
gene O
and O
the O
multiallelic O
anonymous O
DNA O
marker O
at O
DXS52 O
was O
3 O
. O

0 O
at O
a O
recombination O
fraction O
of O
0 O
. O

00 O
. O

This O
made O
a O
prenatal O
or O
presymptomatic O
diagnosis O
and O
heterozygote O
detection O
by O
DNA O
analysis O
with O
this O
marker O
reliable O
. O

Skewed O
X O
inactivation O
in O
a O
female O
MZ O
twin O
results O
in O
Duchenne B
muscular I
dystrophy I
. O

One O
of O
female O
MZ O
twins O
presented O
with O
muscular B
dystrophy I
. O

Physical O
examination O
, O
creatine O
phosphokinase O
levels O
, O
and O
muscle O
biopsy O
were O
consistent O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

However O
, O
because O
of O
her O
sex O
she O
was O
diagnosed O
as O
having O
limb B
- I
girdle I
muscular I
dystrophy I
. O

With O
cDNA O
probes O
to O
the O
DMD B
gene O
, O
a O
gene O
deletion O
was O
detected O
in O
the O
twins O
and O
their O
mother O
. O

The O
de O
novo O
mutation O
which O
arose O
in O
the O
mother O
was O
shown O
by O
novel O
junction O
fragments O
generated O
by O
HindIII O
, O
PstI O
, O
or O
TaqI O
when O
probed O
with O
cDNA8 O
. O

Additional O
evidence O
of O
a O
large O
gene O
deletion O
was O
given O
by O
novel O
SfiI O
junction O
fragments O
detected O
by O
probes O
p20 O
, O
J O
- O
Bir O
, O
and O
J O
- O
66 O
on O
pulsed O
- O
field O
gel O
electrophoresis O
( O
PFGE O
) O
. O

Immunoblot O
analysis O
of O
muscle O
from O
the O
affected O
twin O
showed O
dystrophin O
of O
normal O
size O
but O
of O
reduced O
amount O
. O

Immunofluorescent O
visualization O
of O
dystrophin O
revealed O
foci O
of O
dystrophin O
- O
positive O
fibers O
adjacent O
to O
foci O
of O
dystrophin O
- O
negative O
fibers O
. O

These O
data O
indicate O
that O
the O
affected O
twin O
is O
a O
manifesting O
carrier O
of O
an O
abnormal O
DMD B
gene O
, O
her O
myopathy B
being O
a O
direct O
result O
of O
underexpression O
of O
dystrophin O
. O

Cytogenetic O
analysis O
revealed O
normal O
karyotypes O
, O
eliminating O
the O
possibility O
of O
a O
translocation O
affecting O
DMD B
gene O
function O
. O

Both O
linkage O
analysis O
and O
DNA O
fingerprint O
analysis O
revealed O
that O
each O
twin O
has O
two O
different O
X O
chromosomes O
, O
eliminating O
the O
possibility O
of O
uniparental B
disomy I
as O
a O
mechanism O
for O
DMD B
expression O
. O

On O
the O
basis O
of O
methylation O
differences O
of O
the O
paternal O
and O
maternal O
X O
chromosomes O
in O
these O
MZ O
twins O
, O
we O
propose O
uneven O
lyonization O
( O
X O
chromosome O
inactivation O
) O
as O
the O
underlying O
mechanism O
for O
disease O
expression O
in O
the O
affected O
female O
. O
. O

Adrenoleukodystrophy B
and O
adrenomyeloneuropathy B
associated O
with O
partial O
adrenal B
insufficiency I
in O
three O
generations O
of O
a O
kindred O
. O

Four O
cases O
of O
adrenoleukodystrophy B
( O
ALD B
) O
and O
one O
case O
of O
adrenomyeloneuropathy B
( O
AMN B
) O
have O
developed O
in O
a O
kindred O
over O
three O
generations O
demonstrating O
that O
AMN B
is O
a O
clinical O
variant O
of O
ALD B
. O

Pituitary O
- O
adrenal O
function O
studies O
were O
performed O
in O
10 O
family O
members O
, O
including O
two O
affected O
males O
and O
four O
females O
identified O
as O
carriers O
of O
ALD B
/ O
AMN B
. O

No O
pituitary B
- I
adrenal I
abnormality I
was O
found O
in O
the O
carriers O
. O

However O
, O
basal O
morning O
plasma O
adrenocorticotropic O
hormone O
( O
ACTH O
) O
levels O
were O
markedly O
elevated O
in O
the O
two O
males O
with O
ALD B
and O
AMN B
, O
despite O
the O
fact O
that O
they O
had O
no O
clinical O
signs O
of O
adrenal B
insufficiency I
and O
that O
morning O
plasma O
cortisol O
levels O
and O
their O
response O
to O
maximal O
exogenous O
ACTH O
stimulation O
appeared O
to O
be O
normal O
. O

In O
addition O
, O
the O
integrated O
24 O
- O
hour O
response O
to O
the O
administration O
were O
also O
subnormal O
in O
these O
two O
cases O
. O

Thus O
, O
people O
with O
ALD B
and O
AMN B
may O
have O
subclinical O
partial O
adrenocrotical B
insufficiency I
. O

No O
other O
endocrinologic B
dysfunction I
was O
identified O
. O
. O

Regional O
localisation O
of O
the O
Friedreich B
ataxia I
locus O
to O
human O
chromosome O
9q13 O
- O
- O
- O
- O
q21 O
. O
1 O
. O

We O
have O
previously O
assigned O
the O
Friedreich B
ataxia I
locus O
( O
FRDA O
) O
to O
chromosome O
9 O
; O
the O
current O
maximal O
lod O
score O
between O
FRDA O
and O
MCT112 O
( O
D9S15 O
) O
is O
greater O
than O
50 O
at O
a O
recombination O
fraction O
of O
theta O
= O
0 O
. O

The O
physical O
assignment O
of O
the O
locus O
defined O
by O
MCT112 O
, O
and O
hence O
FRDA O
, O
has O
not O
been O
determined O
, O
although O
linkage O
analysis O
of O
MCT112 O
with O
other O
chromosome O
9 O
markers O
inferred O
a O
location O
close O
to O
the O
centromere O
. O

We O
have O
used O
in O
situ O
hybridisation O
with O
MCT112 O
, O
a O
corresponding O
cosmid O
MJ1 O
, O
and O
DR47 O
( O
D9S5 O
) O
, O
coupled O
with O
mapping O
studies O
on O
hybrid O
cell O
panels O
, O
to O
define O
more O
precisely O
the O
location O
of O
the O
disease O
locus O
. O

The O
in O
situ O
location O
of O
all O
three O
probes O
is O
9q13 O
- O
- O
- O
- O
q21 O
. O

1 O
, O
distal O
to O
the O
variable O
heterochromatin O
region O
. O

Physical O
assignment O
of O
FRDA O
will O
allow O
us O
to O
identify O
hybrid O
cell O
lines O
containing O
the O
mutated O
gene O
. O

Increased O
high O
- O
density O
lipoprotein O
levels O
caused O
by O
a O
common O
cholesteryl O
- O
ester O
transfer O
protein O
gene O
mutation O
. O

BACKGROUND O
AND O
METHODS O
. O

The O
plasma O
cholesteryl O
- O
ester O
transfer O
protein O
( O
CETP O
) O
catalyzes O
the O
transfer O
of O
cholesteryl O
esters O
from O
high O
- O
density O
lipoprotein O
( O
HDL O
) O
to O
other O
lipoproteins O
. O

We O
recently O
described O
a O
Japanese O
family O
with O
increased O
HDL O
levels O
and O
CETP B
deficiency I
due O
to O
a O
splicing O
defect O
of O
the O
CETP O
gene O
. O

To O
assess O
the O
frequency O
and O
phenotype O
of O
this O
condition O
, O
we O
screened O
11 O
additional O
families O
with O
high O
HDL O
levels O
by O
means O
of O
a O
radioimmunoassay O
for O
CETP O
and O
DNA O
analysis O
. O

RESULTS O
. O

We O
found O
the O
same O
CETP O
gene O
mutation O
in O
four O
families O
from O
three O
different O
regions O
of O
Japan O
. O

Analysis O
of O
restriction O
- O
fragment O
- O
length O
polymorphisms O
of O
the O
mutant O
CETP O
allele O
showed O
that O
all O
probands O
were O
homozygous O
for O
the O
identical O
haplotype O
. O

Family O
members O
homozygous O
for O
CETP B
deficiency I
( O
n O
= O
10 O
) O
had O
moderate O
hypercholesterolemia B
( O
mean O
total O
cholesterol O
level O
[ O
+ O
/ O
- O
SD O
] O
, O
7 O
. O
01 O
+ O
/ O
- O
0 O
. O
83 O
mmol O
per O
liter O
) O
, O
markedly O
increased O
levels O
of O
HDL O
cholesterol O
( O
4 O
. O
24 O
+ O
/ O
- O
1 O
. O
01 O
mmol O
per O
liter O
) O
and O
apolipoprotein O
A O
- O
I O
, O
and O
decreased O
levels O
of O
low O
- O
density O
lipoprotein O
cholesterol O
( O
1 O
. O
99 O
+ O
/ O
- O
0 O
. O
80 O
mmol O
per O
liter O
) O
and O

apolipoprotein O
B O
. O

Members O
heterozygous O
for O
the O
deficiency O
( O
n O
= O
20 O
) O
, O
whose O
CETP O
levels O
were O
in O
the O
lower O
part O
of O
the O
normal O
range O
, O
had O
moderately O
increased O
levels O
of O
HDL O
cholesterol O
and O
apolipoprotein O
A O
- O
I O
and O
an O
increased O
ratio O
of O
HDL O
subclass O
2 O
to O
HDL O
subclass O
3 O
, O
as O
compared O
with O
unaffected O
family O
members O
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
8 O
vs O
. O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
4 O
) O
. O

CETP B
deficiency I
was O
not O
found O
in O
six O
unrelated O
subjects O
with O
elevated O
HDL O
cholesterol O
levels O
who O
were O
from O
different O
parts O
of O
the O
United O
States O
. O

CONCLUSIONS O
. O

CETP B
deficiency I
appears O
to O
be O
a O
frequent O
cause O
of O
increased O
HDL O
levels O
in O
the O
population O
of O
Japan O
, O
possibly O
because O
of O
a O
founder O
effect O
. O

The O
results O
that O
we O
observed O
in O
heterozygotes O
suggest O
that O
CETP O
normally O
plays O
a O
part O
in O
the O
regulation O
of O
levels O
of O
HDL O
subclass O
2 O
. O

There O
was O
no O
evidence O
of O
premature B
atherosclerosis I
in O
the O
families O
with O
CETP B
deficiency I
. O

In O
fact O
, O
the O
lipoprotein O
profile O
of O
persons O
with O
CETP B
deficiency I
is O
potentially O
antiatherogenic O
and O
may O
be O
associated O
with O
an O
increased O
life O
span O
. O

Further O
mapping O
of O
an O
ataxia B
- I
telangiectasia I
locus O
to O
the O
chromosome O
11q23 O
region O
. O

We O
recently O
mapped O
the O
gene O
for O
ataxia B
- I
telangiectasia I
group O
A O
( O
ATA O
) O
to O
chromosome O
11q22 O
- O
23 O
by O
linkage O
analysis O
, O
using O
the O
genetic O
markers O
THY1 O
and O
pYNB3 O
. O

12 O
( O
D11S144 O
) O
. O

The O
most O
likely O
order O
was O
cent O
- O
AT O
- O
S144 O
- O
THY1 O
. O

The O
present O
paper O
describes O
further O
mapping O
of O
the O
AT B
locus O
by O
means O
of O
a O
panel O
of O
10 O
markers O
that O
span O
approximately O
60 O
cM O
in O
the O
11q22 O
- O
23 O
region O
centered O
around O
S144 O
and O
THY1 O
. O

Location O
scores O
indicate O
that O
three O
contiguous O
subsegments O
within O
the O
[ O
S144 O
- O
THY1 O
] O
segment O
, O
as O
well O
as O
three O
contiguous O
segments O
telomeric O
to O
THY1 O
, O
are O
each O
unlikely O
to O
contain O
the O
AT B
locus O
, O
while O
the O
more O
centromeric O
[ O
STMY O
- O
S144 O
] O
segment O
is O
most O
likely O
to O
contain O
the O
AT B
locus O
. O

These O
data O
, O
together O
with O
recent O
refinements O
in O
the O
linkage O
and O
physical O
maps O
of O
11q22 O
- O
23 O
, O
place O
the O
AT B
locus O
at O
11q23 O
. O

Recurrent O
meningitis B
in O
a O
patient O
with O
congenital B
deficiency I
of I
the I
C9 I
component I
of I
complement I
. O

First O
case O
of O
C9 B
deficiency I
in O
Europe O
. O

We O
describe O
the O
first O
cases O
, O
to O
our O
knowledge O
, O
of O
C9 B
deficiency I
in O
Europe O
that O
were O
detected O
in O
a O
Swiss O
family O
, O
of O
which O
two O
members O
- O
- O
one O
with O
a O
complete O
deficiency O
and O
the O
other O
with O
approximately O
half O
- O
normal O
C9 O
levels O
- O
- O
experienced O
bacterial B
meningitis I
. O

The O
index O
patient O
, O
a O
56 O
- O
year O
- O
old O
white O
man O
with O
a O
history O
of O
purulent B
meningitis I
at O
the O
age O
of O
23 O
years O
, O
presented O
with O
an O
acute B
meningococcal I
meningitis I
. O

No O
impairment B
of I
cellular I
immunity I
or O
immunoglobulin B
deficiency I
could O
be O
found O
. O

Complement O
assays O
showed O
a O
complete B
deficiency I
of I
the I
C9 I
component I
, O
while O
the O
other O
individual O
component O
levels O
were O
normal O
and O
the O
hemolytic O
activity O
( O
measured O
using O
the O
CH50 O
assay O
) O
was O
only O
slightly O
reduced O
. O

A O
family O
study O
revealed O
complete B
C9 I
deficiency I
in O
the O
patients O
healthy O
brother O
and O
half O
- O
normal O
C9 O
concentrations O
in O
his O
sister O
, O
his O
son O
( O
who O
also O
had O
experienced O
an O
episode O
of O
bacterial B
meningitis I
) O
, O
and O
his O
niece O
, O
consistent O
with O
an O
inherited O
C9 B
deficiency I
. O

This O
first O
case O
of O
recurrent B
meningitis I
in O
a O
white O
patient O
with O
complete B
C9 I
deficiency I
suggests O
that O
this O
complement B
defect I
may O
also O
be O
a O
risk O
factor O
for O
bacterial B
, I
especially I
neisserial I
, I
infections I
. O
. O

Detection O
of O
98 O
% O
of O
DMD B
/ O
BMD B
gene O
deletions O
by O
polymerase O
chain O
reaction O
. O

We O
describe O
oligonucleotide O
primer O
sequences O
that O
can O
be O
used O
to O
amplify O
eight O
exons O
plus O
the O
muscle O
promoter O
of O
the O
dystrophin O
gene O
in O
a O
single O
multiplex O
polymerase O
chain O
reaction O
( O
PCR O
) O
. O

When O
used O
in O
conjunction O
with O
an O
existing O
primer O
set O
, O
these O
two O
multiplex O
reactions O
detect O
about O
98 O
% O
of O
deletions O
in O
patients O
with O
Duchenne B
or I
Becker I
muscular I
dystrophy I
( O
DMD B
, O
BMD B
) O
. O

Furthermore O
, O
these O
primers O
amplify O
most O
of O
the O
exons O
in O
the O
deletion O
prone O
" O
hot O
spot O
" O
region O
around O
exons O
44 O
to O
53 O
, O
allowing O
determination O
of O
deletion O
endpoints O
and O
prediction O
of O
mutational O
effects O
on O
the O
translational O
reading O
frame O
. O

Thus O
, O
use O
of O
these O
PCR O
- O
based O
assays O
will O
allow O
deletion O
detection O
and O
prenatal O
diagnosis O
for O
most O
DMD B
/ O
BMD B
patients O
in O
a O
fraction O
of O
the O
time O
required O
for O
Southern O
blot O
analysis O
. O
. O

Genetic O
heterogeneity O
at O
the O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
locus O
in O
southern O
Italy O
: O
a O
study O
on O
a O
population O
from O
the O
Matera O
district O
. O

Glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
has O
been O
analyzed O
by O
gel O
electrophoresis O
and O
by O
quantitative O
assay O
in O
an O
unselected O
sample O
of O
1524 O
schoolboys O
from O
the O
province O
of O
Matera O
( O
Lucania O
) O
in O
southern O
Italy O
. O

We O
have O
identified O
43 O
subjects O
with O
a O
G6PD O
variant O
. O

Of O
these O
, O
31 O
had O
severe O
G6PD B
deficiency I
, O
nine O
had O
mild O
to O
moderate O
deficiency O
, O
and O
three O
had O
a O
non O
- O
deficient O
electrophoretic O
variant O
. O

The O
overall O
rate O
of O
G6PD B
deficiency I
was O
2 O
. O

6 O
% O
. O

The O
frequency O
of O
G6PD B
deficiency I
, O
ranging O
from O
7 O
. O

2 O
% O
on O
the O
Ionian O
Coast O
to O
zero O
on O
the O
eastern O
side O
of O
the O
Lucanian O
Apennines O
, O
appears O
to O
be O
inversely O
related O
to O
the O
distance O
of O
each O
town O
examined O
from O
the O
Ionian O
Coast O
, O
suggesting O
that O
this O
geographic O
distribution O
may O
reflect O
, O
at O
least O
in O
part O
, O
gene O
flow O
from O
Greek O
settlers O
. O

Biochemical O
characterization O
has O
shown O
that O
most O
of O
the O
G6PD B
deficiency I
in O
this O
population O
is O
accounted O
for O
by O
G6PD O
Mediterranean O
. O

In O
addition O
, O
we O
have O
found O
several O
examples O
of O
two O
other O
known O
polymorphic O
variants O
( O
G6PD O
Cagliari O
and O
G6PD O
A O
- O
) O
; O
three O
new O
polymorphic O
variants O
, O
G6PD O
Metaponto O
( O
class O
III O
) O
, O
G6PD O
Montalbano O
( O
class O
III O
) O
, O
and O
G6PD O
Pisticci O
( O
class O
IV O
) O
; O
and O
two O
sporadic O
variants O
, O
G6PD O
Tursi O
( O
class O
III O
) O
and O
G6PD O
Ferrandina O
( O
class O
II O
) O
. O

These O
data O
provide O
further O
evidence O
for O
the O
marked O
genetic O
heterogeneity O
of O
G6PD B
deficiency I
within O
a O
relatively O
narrow O
geographic O
area O
and O
they O
prove O
the O
presence O
in O
the O
Italian O
peninsula O
of O
a O
gene O
( O
GdA O
- O
) O
regarded O
as O
characteristically O
African O
. O

Deficiency B
of I
the I
murine I
fifth I
complement I
component I
( I
C5 I
) I
. O

A O
2 O
- O
base O
pair O
gene O
deletion O
in O
a O
5 O
' O
- O
exon O
. O

To O
ascertain O
the O
molecular O
mechanism O
that O
causes O
murine O
C5 B
deficiency I
, O
genomic O
and O
cDNA O
libraries O
were O
constructed O
from O
mouse O
liver O
DNA O
and O
mRNA O
employing O
the O
congenic O
strains O
B10 O
. O

D2 O
/ O
nSnJ O
and O
B10 O
. O

D2 O
/ O
oSnJ O
that O
are O
sufficient O
and O
deficient B
for I
C5 I
, O
respectively O
. O

Genomic O
fragments O
were O
isolated O
which O
correspond O
to O
PvuII O
and O
HindIII O
restriction O
fragment O
length O
polymorphisms O
associated O
with O
C5 B
deficiency I
. O

Sequence O
analyses O
demonstrated O
that O
each O
of O
these O
polymorphisms O
resulted O
from O
single O
base O
pair O
substitutions O
and O
that O
neither O
substitution O
would O
probably O
cause O
or O
contribute O
to O
the O
C5 B
deficiency I
. O

Sequence O
analyses O
of O
C5 O
sufficient O
and O
deficient O
cDNAs O
revealed O
a O
2 O
base O
- O
pair O
deletion O
in O
the O
deficient O
cDNAs O
. O

The O
" O
TA O
" O
deletion O
was O
located O
near O
the O
5 O
end O
of O
the O
cDNA O
. O

This O
deletion O
shifts O
the O
reading O
frame O
of O
the O
C5 O
mRNA O
so O
that O
the O
termination O
codon O
UGA O
is O
present O
4 O
base O
pairs O
downstream O
from O
the O
deletion O
. O

Genomic O
DNA O
was O
amplified O
and O
sequenced O
corresponding O
to O
the O
area O
surrounding O
the O
2 O
- O
base O
pair O
deletion O
. O

Six O
C5 B
- I
deficient I
strains O
, O
A O
/ O
HeJ O
, O
AKR O
/ O
J O
, O
DBA O
/ O
2J O
, O
NZB O
/ O
B1NJ O
, O
SWR O
/ O
J O
, O
and O
B10 O
. O

D2 O
/ O
oSnJ O
, O
and O
four O
C5 O
- O
sufficient O
strains O
, O
Balb O
/ O
CJ O
, O
C57Bl O
/ O
6J O
, O
DBA O
/ O
1J O
, O
and O
B10 O
. O

D2 O
/ O
nSnJ O
, O
were O
analyzed O
. O

The O
sequencing O
data O
revealed O
that O
the O
2 O
base O
pairs O
were O
deleted O
from O
the O
C5 O
gene O
of O
each O
deficient O
mouse O
tested O
but O
not O
from O
the O
C5 O
gene O
of O
any O
sufficient O
mouse O
. O

These O
data O
demonstrate O
that O
1 O
) O
there O
is O
an O
identical O
2 O
- O
base O
pair O
deletion O
in O
an O
exon O
of O
the O
C5 O
gene O
in O
several O
different O
C5 B
- I
deficient I
mouse O
strains O
; O
2 O
) O
the O
mRNA O
transcribed O
from O
the O
C5D O
gene O
retains O
this O
deletion O
; O
and O
3 O
) O
this O
mutation O
should O
result O
in O
C5 B
protein I
deficiency I
. O

Molecular O
genetics O
of O
PKU B
in O
eastern O
Europe O
: O
a O
nonsense O
mutation O
associated O
with O
haplotype O
4 O
of O
the O
phenylalanine O
hydroxylase O
gene O
. O

Phenylketonuria B
( O
PKU B
) O
is O
a O
genetic B
disorder I
secondary O
to O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

Several O
mutations O
in O
the O
PAH O
gene O
have O
recently O
been O
reported O
, O
and O
linkage O
disequilibrium O
was O
observed O
between O
RFLP O
haplotypes O
and O
specific O
mutations O
. O

A O
new O
molecular B
lesion I
has O
been O
identified O
in O
exon O
7 O
of O
the O
PAH O
gene O
in O
a O
Hungarian O
PKU B
patient O
by O
direct O
sequencing O
of O
PCR O
- O
amplified O
DNA O
. O

The O
C O
- O
to O
- O
T O
transition O
causes O
the O
substitution O
of O
Arg243 O
to O
a O
termination O
codon O
, O
and O
the O
mutant O
allele O
is O
associated O
with O
haplotype O
4 O
of O
the O
PAH O
gene O
. O

The O
mutation O
is O
present O
in O
two O
of O
nine O
mutant O
haplotype O
4 O
alleles O
among O
Eastern O
Europeans O
and O
is O
not O
present O
among O
Western O
Europeans O
and O
Asians O
. O

The O
rarity O
of O
this O
mutant O
allele O
and O
its O
restricted O
geographic O
distribution O
suggest O
that O
the O
mutational O
event O
occurred O
recently O
on O
a O
normal O
haplotype O
4 O
background O
in O
Eastern O
Europe O
. O
. O

The O
red O
- O
green O
visual O
pigment O
gene O
region O
in O
adrenoleukodystrophy B
. O

Although O
recent O
data O
established O
that O
a O
specific O
very O
- O
long O
- O
chain O
fatty O
acyl O
- O
CoA O
synthetase O
is O
defective O
in O
X B
- I
linked I
adrenoleukodystrophy I
( O
ALD B
) O
, O
the O
ALD B
gene O
is O
still O
unidentified O
. O

The O
ALD B
locus O
has O
been O
mapped O
to O
Xq28 O
, O
like O
the O
red O
and O
green O
color O
pigment O
genes O
. O

Abnormal B
color I
vision I
has O
been O
observed O
in O
12 O
of O
27 O
patients O
with O
adrenomyeloneuropathy B
( O
AMN B
) O
, O
a O
milder O
form O
of O
ALD B
. O

Furthermore O
, O
rearrangements O
of O
the O
color O
vision O
gene O
cluster O
were O
found O
in O
four O
of O
eight O
ALD B
kindreds O
. O

This O
led O
us O
to O
propose O
that O
a O
single O
DNA O
rearrangement O
could O
underlie O
both O
ALD B
and O
abnormal B
color I
vision I
in O
these O
patients O
. O

Study O
of O
34 O
French O
ALD B
patients O
failed O
to O
reveal O
a O
higher O
than O
expected O
frequency O
of O
green O
/ O
red O
visual O
pigment O
rearrangements O
3 O
to O
the O
red O
/ O
green O
color O
vision O
gene O
complex O
. O

The O
previous O
report O
of O
such O
rearrangements O
was O
based O
on O
small O
numbers O
and O
lack O
of O
knowledge O
that O
the O
frequency O
of O
" O
abnormal O
" O
color O
vision O
arrays O
on O
molecular O
analysis O
was O
twice O
as O
high O
as O
expected O
on O
the O
basis O
of O
the O
frequency O
of O
phenotypic B
color I
vision I
defects I
. O

The O
red O
/ O
green O
color O
pigment O
( O
R O
/ O
GCP O
) O
region O
was O
studied O
by O
pulsed O
- O
field O
gel O
electrophoresis O
in O
14 O
of O
these O
patients O
, O
and O
we O
did O
not O
find O
any O
fragment O
size O
difference O
between O
the O
patients O
and O
normal O
individuals O
who O
have O
the O
same O
number O
of O
pigment O
genes O
. O

The O
R O
/ O
GCP O
region O
was O
also O
analyzed O
in O
29 O
French O
and O
seven O
North O
American O
ALD B
patients O
by O
using O
six O
genomic O
DNA O
probes O
, O
isolated O
from O
a O
cosmid O
walk O
, O
that O
flank O
the O
color O
vision O
genes O
. O

No O
deletions O
were O
found O
with O
probes O
that O
lie O
3 O
of O
the O
green O
pigment O
genes O
. O

One O
of O
the O
eight O
previously O
reported O
ALD B
individuals O
has O
a O
long O
deletion O
5 O
of O
the O
red O
pigment O
gene O
, O
a O
deletion O
causing O
blue O
cone O
monochromacy O
. O

This O
finding O
and O
the O
previous O
findings O
of O
a O
45 O
% O
frequency O
of O
phenotypic O
color O
vision O
defects O
in O
patients O
with O
AMN B
may O
suggest O
that O
the O
ALD B
/ O
AMN B
gene O
lies O
5 O
to O
the O
red O
pigment O
gene O
and O
that O
the O
frequent O
phenotypic O
color B
vision I
anomalies I
owe O
their O
origin O
to O
deleted O
DNA O
that O
includes O
regulatory O
genes O
for O
color O
vision O
. O

It O
is O
possible O
, O
however O
, O
that O
phenotypic O
color B
vision I
anomalies I
in O
AMN B
may O
be O
phenocopies O
secondary O
to O
retinal O
or O
neural O
involvement O
by O
the O
disease O
. O

The O
single O
case O
of O
blue O
cone O
monochromacy O
may O
therefore O
be O
a O
fortuitous O
coincidence O
of O
two O
diseases O
. O
. O

Paroxysmal B
nocturnal I
haemoglobinuria I
with O
coexisting O
deficiency B
of I
the I
ninth I
component I
of I
complement I
: O
lack O
of O
massive O
haemolytic B
attack I
. O

A O
47 O
- O
year O
- O
old O
woman O
with O
paroxysmal B
nocturnal I
haemoglobinuria I
( O
PNH B
) O
was O
found O
to O
have O
an O
inherited B
deficiency I
in I
the I
ninth I
complement I
component I
( O
C9 O
) O
. O

In O
complement O
- O
sensitivity O
lysis O
tests O
, O
80 O
% O
of O
her O
erythrocytes O
were O
markedly O
complement O
- O
sensitive O
( O
PNH O
- O
III O
) O
. O

Laser O
cytofluorimetry O
with O
a O
monoclonal O
antibody O
against O
decay O
- O
accelerating O
factor O
( O
DAF O
) O
revealed O
that O
95 O
% O
of O
her O
erythrocytes O
were O
DAF O
- O
negative O
. O

Surprisingly O
, O
she O
has O
suffered O
only O
mild O
haemolysis B
and O
has O
never O
experienced O
massive O
spontaneous O
haemolysis B
. O

Gross O
haemoglobinuria B
and O
jaundice B
occurred O
only O
after O
receiving O
postoperative O
transfusion O
of O
whole O
blood O
. O

In O
her O
serum O
, O
C9 O
was O
not O
detectable O
either O
by O
immunological O
or O
by O
functional O
assays O
. O

Both O
the O
Ham O
test O
and O
the O
sugar O
water O
test O
using O
normal O
human O
serum O
or O
plasma O
yielded O
marked O
haemolysis O
of O
the O
patients O
erythrocytes O
. O

When O
the O
patients O
serum O
or O
plasma O
was O
used O
, O
only O
a O
trace O
of O
lysis O
was O
detected O
. O

Addition O
of O
purified O
human O
C9 O
to O
her O
plasma O
fully O
restored O
haemolysis O
. O

These O
observations O
indicated O
that O
C9 O
may O
play O
a O
critical O
role O
in O
haemolytic B
attacks I
in O
patients O
with O
PNH B
and O
that O
characteristic O
haemolysis B
in O
PNH B
may O
be O
tempered O
by O
coexisting O
C9 B
deficiency I
. O
. O

Duplicational O
mutation O
at O
the O
Duchenne B
muscular I
dystrophy I
locus O
: O
its O
frequency O
, O
distribution O
, O
origin O
, O
and O
phenotypegenotype O
correlation O
. O

Partial O
gene O
deletion O
is O
the O
major O
cause O
of O
mutation O
leading O
to O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
and O
Becker B
muscular I
dystrophy I
( O
BMD B
) O
. O

Partial O
gene O
duplication O
has O
also O
been O
recognized O
in O
a O
few O
cases O
. O

We O
have O
conducted O
a O
survey O
for O
duplication O
in O
72 O
unrelated O
nondeletion O
patients O
, O
analyzed O
by O
Southern O
blot O
hybridization O
with O
clones O
representing O
the O
entire O
DMD B
cDNA O
. O

With O
careful O
quantitative O
analysis O
of O
hybridization O
band O
intensity O
, O
10 O
cases O
were O
found O
to O
carry O
a O
duplication O
of O
part O
of O
the O
gene O
, O
a O
frequency O
of O
14 O
% O
for O
nondeletion O
cases O
( O
10 O
/ O
72 O
) O
, O
or O
6 O
% O
for O
all O
cases O
( O
10 O
/ O
181 O
) O
. O

The O
extent O
of O
these O
duplications O
has O
been O
characterized O
according O
to O
the O
published O
exon O
- O
containing O
HindIII O
fragment O
map O
, O
and O
in O
six O
of O
the O
10 O
duplications O
a O
novel O
restriction O
fragment O
that O
spanned O
the O
duplication O
junction O
was O
detected O
. O

The O
resulting O
translational O
reading O
frame O
of O
mRNA O
has O
been O
predicted O
for O
nine O
duplications O
. O

A O
shift O
of O
the O
reading O
frame O
was O
predicted O
in O
four O
of O
the O
six O
DMD B
cases O
and O
in O
one O
of O
the O
two O
intermediate O
cases O
, O
while O
the O
reading O
frame O
remained O
uninterrupted O
in O
both O
BMD B
cases O
. O

RFLP O
and O
quantitative O
Southern O
blot O
analyses O
revealed O
a O
grandpaternal O
origin O
of O
duplication O
in O
four O
families O
and O
grandmaternal O
origin O
in O
one O
family O
. O

In O
all O
five O
families O
, O
the O
duplication O
was O
found O
to O
originate O
from O
a O
single O
X O
chromosome O
. O

Unequal O
sister O
- O
chromatid O
exchange O
is O
proposed O
to O
be O
the O
mechanism O
for O
the O
formation O
of O
these O
duplications O
. O
. O

Glucose O
6 O
- O
phosphate O
dehydrogenase O
variants O
: O
Gd O
( O
+ O
) O
Alexandra O
associated O
with O
neonatal B
jaundice I
and O
Gd O
( O
- O
) O
Camperdown O
in O
a O
young O
man O
with O
lamellar B
cataracts I
. O

Two O
male O
subjects O
are O
described O
, O
with O
unusual O
clinical O
presentations O
and O
with O
hitherto O
undescribed O
G6PD O
variants O
. O

The O
first O
, O
of O
Italian O
extraction O
, O
suffered O
from O
severe O
neonatal B
jaundice I
following O
maternal O
ingestion O
of O
fresh O
broad O
beans O
( O
Vicia O
fava O
) O
both O
prenatally O
and O
postnatally O
the O
expression O
of O
the O
enzymatic O
defect O
was O
much O
more O
severe O
in O
the O
neonatal O
period O
than O
on O
retesting O
in O
adolescence O
, O
when O
biochemical O
characterization O
showed O
unique O
features O
which O
justify O
designation O
as O
a O
new O
variant O
Gd O
( O
+ O
) O
Alexandra O
. O

The O
second O
patient O
, O
a O
boy O
of O
Maltese O
extraction O
who O
was O
found O
to O
have O
bilateral B
lamellar I
cataracts I
at O
the O
age O
of O
4 O
years O
, O
was O
identified O
as O
G6PD B
deficient I
only O
as O
a O
result O
of O
a O
survey O
of O
children O
of O
Mediterranean O
origin O
with O
unexplained O
cataract B
formation O
; O
he O
has O
approximately O
15 O
% O
of O
normal O
enzyme O
activity O
, O
with O
another O
unique O
combination O
of O
biochemical O
characteristics O
which O
has O
led O
to O
its O
designation O
as O
Gd O
( O
- O
) O
Camperdown O
. O

Although O
this O
association O
may O
be O
coincidental O
, O
it O
prompts O
further O
attention O
to O
the O
possibility O
that O
under O
certain O
circumstances O
G6PD B
deficiency I
may O
favor O
cataract B
formation O
. O

The O
two O
cases O
illustrate O
the O
value O
of O
characterization O
of O
the O
mutant O
enzyme O
whenever O
unexpected O
clinical O
or O
laboratory O
results O
are O
obtained O
. O
. O

Statistical O
analysis O
of O
the O
two O
stage O
mutation O
model O
in O
von B
Hippel I
- I
Lindau I
disease I
, O
and O
in O
sporadic B
cerebellar I
haemangioblastoma I
and O
renal B
cell I
carcinoma I
. O

Analysis O
of O
the O
age O
incidence O
curves O
for O
unilateral B
and I
bilateral I
retinoblastoma I
led O
Knudson O
to O
propose O
that O
hereditary B
tumours I
may O
arise O
by O
a O
single O
event O
and O
sporadic B
tumours I
by O
a O
two O
stage O
mutation O
process O
. O

It O
has O
been O
suggested O
recently O
that O
sporadic B
renal I
cell I
carcinoma I
may O
arise O
from O
a O
two O
stage O
mutation O
process O
. O

We O
analysed O
the O
age O
incidence O
curves O
for O
symptomatic O
renal B
cell I
carcinoma I
( O
n O
= O
26 O
) O
and O
cerebellar B
haemangioblastoma I
( O
n O
= O
68 O
) O
in O
109 O
patients O
with O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
, O
and O
compared O
them O
to O
104 O
patients O
with O
sporadic B
renal I
cell I
carcinoma I
and O
43 O
patients O
with O
sporadic B
cerebellar I
haemangioblastoma I
. O

The O
age O
incidence O
curves O
for O
renal B
cell I
carcinoma I
and O
cerebellar B
haemangioblastoma I
in O
VHL B
disease I
were O
compatible O
with O
a O
single O
mutation O
model O
, O
whereas O
the O
age O
incidence O
curves O
for O
sporadic B
renal I
cell I
carcinoma I
and O
cerebellar B
haemangioblastoma I
suggested O
a O
two O
stage O
mutation O
process O
. O

These O
data O
are O
compatible O
with O
the O
VHL B
gene O
functioning O
as O
a O
recessive O
tumour B
suppressor O
gene O
. O

Sporadic B
cerebellar I
haemangioblastoma I
and O
some O
renal B
cell I
carcinoma I
may O
arise O
from O
somatic O
mutations O
inactivating O
both O
alleles O
at O
the O
VHL B
locus O
. O
. O

Screening O
for O
carriers O
of O
Tay B
- I
Sachs I
disease I
among O
Ashkenazi O
Jews O
. O

A O
comparison O
of O
DNA O
- O
based O
and O
enzyme O
- O
based O
tests O
. O

BACKGROUND O
AND O
METHODS O
. O

The O
prevention O
of O
Tay B
- I
Sachs I
disease I
( O
GM2 B
gangliosidosis I
, I
type I
1 I
) O
depends O
on O
the O
identification O
of O
carriers O
of O
the O
gene O
for O
this O
autosomal B
recessive I
disorder I
. O

We O
compared O
the O
enzyme O
- O
based O
test O
widely O
used O
in O
screening O
for O
Tay B
- I
Sachs I
disease I
with O
a O
test O
based O
on O
analysis O
of O
DNA O
. O

We O
developed O
methods O
to O
detect O
the O
three O
mutations O
in O
the O
HEXA O
gene O
that O
occur O
with O
high O
frequency O
among O
Ashkenazi O
Jews O
two O
mutations O
cause O
infantile O
Tay B
- I
Sachs I
disease I
, O
and O
the O
third O
causes O
the O
adult O
- O
onset O
form O
of O
the O
disease O
. O

DNA O
segments O
containing O
these O
mutation O
sites O
were O
amplified O
with O
the O
polymerase O
chain O
reaction O
and O
analyzed O
for O
the O
presence O
of O
the O
mutations O
. O

RESULTS O
. O

Among O
62 O
Ashkenazi O
obligate O
carriers O
of O
Tay B
- I
Sachs I
disease I
, O
the O
three O
specific O
mutations O
accounted O
for O
all O
but O
one O
of O
the O
mutant O
alleles O
( O
98 O
percent O
) O
. O

In O
216 O
Ashkenazi O
carriers O
identified O
by O
the O
enzyme O
test O
, O
DNA O
analysis O
showed O
that O
177 O
( O
82 O
percent O
) O
had O
one O
of O
the O
identified O
mutations O
. O

Of O
the O
177 O
, O
79 O
percent O
had O
the O
exon O
11 O
insertion O
mutation O
, O
18 O
percent O
had O
the O
intron O
12 O
splice O
- O
junction O
mutation O
, O
and O
3 O
percent O
had O
the O
less O
severe O
exon O
7 O
mutation O
associated O
with O
adult O
- O
onset O
disease O
. O

The O
results O
of O
the O
enzyme O
tests O
in O
the O
39 O
subjects O
( O
18 O
percent O
) O
who O
were O
defined O
as O
carriers O
but O
in O
whom O
DNA O
analysis O
did O
not O
identify O
a O
mutant O
allele O
were O
probably O
false O
positive O
( O
although O
there O
remains O
some O
possibility O
of O
unidentified O
mutations O
) O
. O

In O
addition O
, O
of O
152 O
persons O
defined O
as O
noncarriers O
by O
the O
enzyme O
- O
based O
test O
, O
1 O
was O
identified O
as O
a O
carrier O
by O
DNA O
analysis O
( O
i O
. O
e O
e O
. O
, O
a O
false O
negative O
enzyme O
- O
test O
result O
) O
. O

CONCLUSIONS O
. O

The O
increased O
specificity O
and O
predictive O
value O
of O
the O
DNA O
- O
based O
test O
make O
it O
a O
useful O
adjunct O
to O
the O
diagnostic O
tests O
currently O
used O
to O
screen O
for O
carriers O
of O
Tay B
- I
Sachs I
disease I
. O

Total B
deficiency I
of I
plasma I
cholesteryl I
ester I
transfer I
protein I
in O
subjects O
homozygous O
and O
heterozygous O
for O
the O
intron O
14 O
splicing O
defect O
. O

The O
molecular O
basis O
of O
cholesteryl B
ester I
transfer I
protein I
( I
CETP I
) I
deficiency I
was O
investigated O
in O
4 O
unrelated O
CETP B
- I
deficient I
families O
. O

The O
high O
density O
lipoprotein O
- O
cholesterol O
levels O
of O
the O
probands O
exceeded O
150 O
mg O
/ O
dl O
. O

The O
plasma O
of O
the O
probands O
was O
totally O
deficient O
in O
CETP O
activity O
and O
mass O
. O

The O
genomic O
DNA O
of O
the O
patients O
was O
amplified O
by O
polymerase O
chain O
reaction O
, O
using O
two O
oligonucleotide O
primers O
located O
in O
the O
intron O
12 O
and O
14 O
of O
the O
CETP O
gene O
, O
and O
the O
amplified O
products O
were O
directly O
sequenced O
. O

Two O
patients O
were O
homozygous O
for O
a O
G O
- O
to O
- O
A O
change O
at O
the O
5 O
- O
splice O
donor O
site O
of O
the O
intron O
14 O
. O

The O
G O
- O
to O
- O
A O
change O
would O
cause O
impaired O
splicing O
of O
pre O
- O
messenger O
RNA O
. O

The O
other O
two O
probands O
were O
heterozygous O
for O
the O
mutation O
, O
but O
totally O
lacked O
CETP O
. O

Their O
lipoprotein O
patterns O
were O
also O
similar O
to O
those O
of O
the O
two O
homozygotes O
. O

Thus O
, O
other O
genetic B
defects I
or O
metabolic O
factors O
influencing O
CETP O
expression O
are O
implicated O
. O

The O
data O
suggest O
that O
the O
G O
- O
to O
- O
A O
mutation O
may O
be O
common O
in O
human O
plasma O
CETP B
deficiency I
. O

Furthermore O
, O
there O
could O
be O
compound O
heterozygotes O
who O
totally O
lack O
plasma O
CETP O
and O
have O
lipoprotein O
profiles O
similar O
to O
those O
of O
homozygotes O
. O
. O

Molecular O
genetics O
of O
the O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
Mediterranean O
variant O
and O
description O
of O
a O
new O
G6PD O
mutant O
, O
G6PD O
Andalus1361A O
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
; I
E I
. I
C I
. I
1 I
. I
1 I
. I
1 I
. I
49 I
) I
deficiency I
is O
the O
most O
common O
human O
enzymopathy B
; O
more O
than O
300 O
different O
biochemical O
variants O
of O
the O
enzyme O
have O
been O
described O
. O

In O
many O
parts O
of O
the O
world O
the O
Mediterranean O
type O
of O
G6PD B
deficiency I
is O
prevalent O
. O

However O
, O
G6PD O
Mediterranean O
has O
come O
to O
be O
regarded O
as O
a O
generic O
term O
applied O
to O
similar O
G6PD O
mutations O
thought O
, O
however O
, O
to O
represent O
a O
somewhat O
heterogeneous O
group O
. O

A O
C O
- O
- O
- O
- O
T O
mutation O
at O
nucleotide O
563 O
of O
G6PD O
Mediterranean O
has O
been O
identified O
by O
Vulliamy O
et O
al O
. O
, O
and O
the O
same O
mutation O
has O
been O
found O
by O
De O
Vita O
et O
al O
. O
in O
G6PD O
Mediterranean O
, O
G6PD O
Sassari O
, O
and O
G6PD O
Cagliari O
. O

The O
latter O
subjects O
had O
an O
additional O
mutation O
, O
at O
nucleotide O
1311 O
, O
that O
did O
not O
produce O
a O
coding O
change O
. O

We O
have O
examined O
genomic O
DNA O
of O
five O
patients O
- O
- O
four O
of O
Spanish O
origin O
and O
one O
of O
Jewish O
origin O
- O
- O
having O
enzymatically O
documented O
G6PD O
Mediterranean O
. O

All O
had O
both O
the O
mutation O
at O
nucleotide O
563 O
and O
that O
at O
nucleotide O
1311 O
. O

A O
sixth O
sample O
, O
resembling O
G6PD O
Mediterranean O
kinetically O
but O
with O
a O
slightly O
rapid O
electrophoretic O
mobility O
, O
was O
designated O
G6PD O
Andalus O
and O
was O
found O
to O
have O
a O
different O
mutation O
, O
a O
G O
- O
- O
- O
- O
A O
transition O
at O
nucleotide O
1361 O
, O
producing O
an O
arginine O
- O
to O
- O
histidine O
substitution O
. O

These O
studies O
suggest O
that O
G6PD O
Mediterranean O
is O
, O
after O
all O
, O
relatively O
homogeneous O
. O

A O
normal O
male O
with O
an O
inherited O
deletion O
of O
one O
exon O
within O
the O
DMD B
gene O
. O

We O
describe O
two O
brothers O
with O
identical O
inherited O
deletions O
of O
one O
single O
exon O
within O
the O
middle O
of O
the O
DMD B
gene O
; O
one O
brother O
has O
Becker B
muscular I
dystrophy I
diagnosed O
at O
11 O
years O
of O
age O
, O
whereas O
the O
older O
brother O
is O
normal O
at O
18 O
. O

These O
results O
have O
implications O
for O
genetic O
counselling O
and O
prenatal O
diagnosis O
in O
families O
with O
Becker B
muscular I
dystrophy I
. O
. O

Duchenne B
muscular I
dystrophy I
gene O
expression O
in O
normal O
and O
diseased O
human O
muscle O
. O

A O
probe O
for O
the O
5 O
end O
of O
the O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
was O
used O
to O
study O
expression O
of O
the O
gene O
in O
normal O
human O
muscle O
, O
myogenic O
cell O
cultures O
, O
and O
muscle O
from O
patients O
with O
DMD B
. O

Expression O
was O
found O
in O
RNA O
from O
normal O
fetal O
muscle O
, O
adult O
cardiac O
and O
skeletal O
muscle O
, O
and O
cultured O
muscle O
after O
myoblast O
fusion O
. O

In O
DMD B
muscle O
, O
expression O
of O
this O
portion O
of O
the O
gene O
was O
also O
revealed O
by O
in O
situ O
RNA O
hybridization O
, O
particularly O
in O
regenerating O
muscle O
fibers O
. O
. O

Molecular O
and O
phenotypic O
analysis O
of O
patients O
with O
deletions O
within O
the O
deletion O
- O
rich O
region O
of O
the O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
. O

Eighty O
unrelated O
individuals O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
or O
Becker B
muscular I
dystrophy I
( O
BMD B
) O
were O
found O
to O
have O
deletions O
in O
the O
major O
deletion O
- O
rich O
region O
of O
the O
DMD B
locus O
. O

This O
region O
includes O
the O
last O
five O
exons O
detected O
by O
cDNA5b O
- O
7 O
, O
all O
exons O
detected O
by O
cDNA8 O
, O
and O
the O
first O
two O
exons O
detected O
by O
cDNA9 O
. O

These O
80 O
individuals O
account O
for O
approximately O
75 O
% O
of O
109 O
deletions O
of O
the O
gene O
, O
detected O
among O
181 O
patients O
analyzed O
with O
the O
entire O
dystrophin O
cDNA O
. O

Endpoints O
for O
many O
of O
these O
deletions O
were O
further O
characterized O
using O
two O
genomic O
probes O
, O
p20 O
( O
DXS269 O
; O
Wapenaar O
et O
al O
. O
) O
and O
GMGX11 O
( O
DXS239 O
; O
present O
paper O
) O
. O

Clinical O
findings O
are O
presented O
for O
all O
80 O
patients O
allowing O
a O
correlation O
of O
phenotypic O
severity O
with O
the O
genotype O
. O

Thirty O
- O
eight O
independent O
patients O
were O
old O
enough O
to O
be O
classified O
as O
DMD B
, O
BMD B
, O
or O
intermediate O
phenotype O
and O
had O
deletions O
of O
exons O
with O
sequenced O
intron O
/ O
exon O
boundaries O
. O

Of O
these O
, O
eight O
BMD B
patients O
and O
one O
intermediate O
patient O
had O
gene O
deletions O
predicted O
to O
leave O
the O
reading O
frame O
intact O
, O
while O
21 O
DMD B
patients O
, O
7 O
intermediate O
patients O
, O
and O
1 O
BMD B
patient O
had O
gene O
deletions O
predicted O
to O
disrupt O
the O
reading O
frame O
. O

Thus O
, O
with O
two O
exceptions O
, O
frameshift O
deletions O
of O
the O
gene O
resulted O
in O
more O
severe O
phenotype O
than O
did O
in O
- O
frame O
deletions O
. O

This O
is O
in O
agreement O
with O
recent O
findings O
by O
Baumbach O
et O
al O
. O
and O
Koenig O
et O
al O
. O
but O
is O
in O
contrast O
to O
findings O
, O
by O
Malhotra O
et O
al O
. O
at O
the O
5 O
' O
end O
of O
the O
gene O
. O

Cloning O
of O
breakpoints O
of O
a O
chromosome O
translocation O
identifies O
the O
AN2 O
locus O
. O

Chromosome O
translocations O
involving O
11p13 O
have O
been O
associated O
with O
familial B
aniridia I
in O
two O
kindreds O
highlighting O
the O
chromosomal O
localization O
of O
the O
AN2 O
locus O
. O

This O
locus O
is O
also O
part O
of O
the O
WAGR B
complex O
( O
Wilms B
tumor I
, O
aniridia B
, O
genitourinary B
abnormalities I
, O
and O
mental B
retardation I
) O
. O

In O
one O
kindred O
, O
the O
translocation O
is O
associated O
with O
a O
deletion O
, O
and O
probes O
for O
this O
region O
were O
used O
to O
identify O
and O
clone O
the O
breakpoints O
of O
the O
translocation O
in O
the O
second O
kindred O
. O

Comparison O
of O
phage O
restriction O
maps O
exclude O
the O
presence O
of O
any O
sizable O
deletion O
in O
this O
case O
. O

Sequences O
at O
the O
chromosome O
11 O
breakpoint O
are O
conserved O
in O
multiple O
species O
, O
suggesting O
that O
the O
translocation O
falls O
within O
the O
AN2 O
gene O
. O
. O

Linkage O
analysis O
of O
the O
apolipoprotein O
C2 O
gene O
and O
myotonic B
dystrophy I
on O
human O
chromosome O
19 O
reveals O
linkage O
disequilibrium O
in O
a O
French O
- O
Canadian O
population O
. O

The O
gene O
for O
human O
apolipoprotein O
C2 O
( O
APOC2 O
) O
, O
situated O
on O
the O
proximal O
long O
arm O
of O
chromosome O
19 O
, O
is O
closely O
linked O
to O
the O
gene O
for O
the O
most O
common O
form O
of O
adult O
muscular B
dystrophy I
, O
myotonic B
dystrophy I
( O
DM B
) O
. O

Six O
APOC2 O
RFLPs O
( O
TaqI O
, O
BglI O
, O
BanI O
, O
BamHI O
, O
NcoI O
, O
and O
AvaII O
) O
have O
been O
identified O
to O
date O
. O

We O
have O
conducted O
a O
comprehensive O
DM B
linkage O
study O
utilizing O
all O
six O
RFLPs O
and O
involving O
50 O
families O
and O
372 O
individuals O
. O

The O
most O
informative O
RFLPs O
are O
, O
in O
descending O
order O
, O
NcoI O
( O
lod O
= O
6 O
. O
64 O
, O
theta O
= O
0 O
. O
05 O
) O
, O
BglI O
( O
lod O
= O
6 O
. O
12 O
, O
theta O
= O
0 O
. O
05 O
) O
, O
AvaII O
( O
lod O
= O
6 O
. O
02 O
, O
theta O
= O
0 O
. O
03 O
) O
, O
BanI O
( O
lod O
= O
5 O
. O
76 O
, O
theta O
= O
0 O
. O
04 O
) O
, O
TaqI O
( O
lod O
= O
4 O
. O
29 O
, O
theta O
= O
0 O
. O
06 O
) O
, O
and O
BamHI O
( O
lod O
= O
1 O
. O
75 O
, O
theta O
= O
0 O
. O
01 O

) O
. O

A O
substantial O
increase O
in O
the O
lod O
scores O
over O
those O
seen O
with O
the O
individual O
RFLPs O
was O
obtained O
when O
the O
linkage O
of O
the O
entire O
APOC2 O
haplotype O
( O
composed O
of O
the O
six O
RFLPs O
) O
was O
studied O
( O
lod O
= O
17 O
. O
87 O
, O
theta O
= O
0 O
. O
04 O
) O
. O

We O
have O
observed O
significant O
inter O
- O
APOC2 O
RFLP O
linkage O
disequilibrium O
. O

Consequently O
, O
the O
three O
most O
informative O
RFLPs O
have O
been O
found O
to O
be O
BanI O
, O
TaqI O
, O
and O
either O
BglI O
, O
AvaII O
, O
or O
NcoI O
polymorphisms O
. O

We O
also O
demonstrate O
linkage O
disequilibrium O
between O
DM O
and O
APOC2 O
in O
our O
French O
- O
Canadian O
population O
( O
standardized O
disequilibrium O
constant O
phi O
= O
. O
22 O
, O
chi O
2 O
= O
5 O
. O
12 O
, O
df O
= O
1 O
, O
P O
less O
than O
0 O
. O
04 O
) O
. O

This O
represents O
the O
first O
evidence O
of O
linkage O
disequilibrium O
between O
APOC2 O
and O
the O
DM B
locus O
. O

Phenylalanine O
hydroxylase O
gene O
haplotypes O
in O
Polynesians O
: O
evolutionary O
origins O
and O
absence O
of O
alleles O
associated O
with O
severe O
phenylketonuria B
. O

A O
total O
of O
630 O
haplotypes O
for O
the O
phenylalanine O
hydroxylase O
( O
PAH O
) O
gene O
locus O
were O
established O
in O
five O
groups O
of O
Polynesians O
comprising O
Samoans O
, O
Tongans O
, O
Cook O
Islanders O
, O
Maori O
, O
and O
Niueans O
. O

Considerable O
genetic O
continuity O
was O
demonstrated O
between O
these O
widely O
dispersed O
populations O
, O
since O
three O
common O
haplotypes O
( O
4 O
, O
1 O
, O
and O
7 O
) O
constituted O
over O
95 O
% O
of O
alleles O
. O

A O
control O
group O
of O
individuals O
from O
Southeast O
Asia O
shared O
the O
same O
major O
haplotypes O
, O
4 O
, O
1 O
, O
and O
7 O
, O
with O
Polynesians O
. O

These O
data O
provide O
further O
support O
for O
the O
theories O
of O
genetic O
homogeneity O
and O
of O
Asian O
affinities O
of O
the O
Polynesian O
precursor O
populations O
. O

The O
absence O
of O
severe O
phenylketonuria B
( O
PKU B
) O
in O
both O
Polynesians O
and O
Southeast O
Asians O
is O
consistent O
with O
the O
lack O
of O
PAH O
haplotypes O
2 O
and O
3 O
, O
on O
which O
the O
severe O
PKU B
mutants O
have O
arisen O
among O
Caucasians O
. O
. O

Preferential O
germline O
mutation O
of O
the O
paternal O
allele O
in O
retinoblastoma B
. O

The O
event O
triggering O
malignant O
proliferation O
in O
70 O
% O
of O
retinoblastoma B
tumours I
is O
loss O
of O
heterozygosity O
for O
chromosome O
13q14 O
, O
whereby O
the O
normal O
retinoblastoma B
gene O
( O
RB1 O
) O
allele O
is O
lost O
and O
an O
already O
mutated O
RB1 O
allele O
remains O
in O
the O
tumour B
. O

The O
first O
allele O
suffers O
a O
mutational O
event O
- O
- O
deletion O
, O
duplication O
or O
point O
mutation O
( O
manuscript O
in O
preparation O
) O
- O
- O
either O
in O
the O
germ O
line O
( O
all O
bilateral O
patients O
) O
or O
in O
a O
somatic O
retinal O
cell O
( O
most O
unilateral O
patients O
) O
. O

Most O
bilateral O
patients O
have O
no O
family O
history O
of O
retinoblastoma B
and O
are O
presumed O
to O
have O
new O
germline O
mutations O
which O
arose O
in O
the O
egg O
, O
sperm O
or O
early O
embryo O
. O

We O
have O
determined O
the O
parental O
origin O
of O
the O
retained O
allele O
in O
nine O
retinoblastoma B
tumours I
from O
eight O
unrelated O
non O
- O
familial O
cases O
by O
using O
RB1 O
- O
linked O
genetic O
markers O
. O

Six O
tumours B
retained O
the O
paternal O
allele O
and O
three O
retained O
the O
maternal O
allele O
. O

Of O
the O
three O
unilateral B
tumours I
, O
only O
one O
retained O
the O
paternal O
RB1 O
allele O
. O

Thus O
, O
there O
is O
no O
evidence O
that O
the O
paternal O
RB1 O
allele O
is O
preferentially O
retained O
in O
retinoblastoma B
, O
as O
has O
been O
suggested O
to O
be O
the O
case O
in O
osteosarcoma B
. O

By O
contrast O
, O
tumours B
from O
four O
of O
the O
five O
bilateral O
patients O
retained O
the O
paternal O
RB1 O
allele O
. O

This O
suggests O
either O
that O
new O
germline O
RB1 O
mutations O
arise O
more O
frequently O
during O
spermatogenesis O
than O
during O
oogenesis O
, O
or O
that O
imprinting O
in O
the O
early O
embryo O
affects O
chromosomal O
susceptibility O
to O
mutation O
. O
. O

Haplotype O
analysis O
of O
the O
phenylalanine O
hydroxylase O
gene O
in O
Turkish O
phenylketonuria B
families O
. O

We O
have O
estimated O
the O
haplotype O
distribution O
of O
mutant O
and O
normal O
phenylalanine O
hydroxylase O
( O
PAH O
) O
alleles O
for O
17 O
Turkish O
phenylketonuria B
( O
PKU B
) O
families O
20 O
normal O
and O
27 O
mutated O
PAH O
alleles O
could O
be O
identified O
. O

Of O
the O
latter O
, O
the O
most O
prevalent O
were O
associated O
with O
haplotype O
6 O
( O
29 O
. O
6 O
% O
) O
, O
1 O
( O
18 O
. O
5 O
% O
) O
and O
36 O
( O
11 O
. O
1 O
% O
) O
, O
while O
the O
normal O
alleles O
were O
preferentially O
associated O
with O
haplotype O
1 O
( O
20 O
% O
) O
. O

Of O
the O
19 O
different O
haplotypes O
observed O
, O
5 O
have O
not O
been O
described O
previously O
. O

The O
haplotype O
distribution O
differed O
significantly O
from O
that O
of O
the O
Northern O
European O
population O
. O

Two O
of O
the O
eight O
polymorphic O
sites O
were O
in O
association O
with O
PKU B
. O

No O
deletions O
of O
exon O
sequences O
were O
found O
in O
the O
families O
analysed O
. O

Huntington B
disease I
: O
no O
evidence O
for O
locus O
heterogeneity O
. O

A O
total O
of O
63 O
families O
with O
Huntington B
disease I
( O
HD B
) O
were O
examined O
for O
linkage O
between O
HD B
and O
G8 O
( O
D4S10 O
) O
. O

The O
families O
included O
57 O
Caucasian O
, O
four O
Black O
American O
, O
and O
two O
Japanese O
. O

The O
combined O
maximum O
lod O
score O
was O
87 O
. O

69 O
at O
theta O
= O
0 O
. O

04 O
( O
99 O
% O
confidence O
interval O
0 O
. O
018 O
- O
0 O
. O
071 O
) O
. O

The O
maximum O
frequency O
of O
recombination O
was O
0 O
. O

03 O
in O
males O
and O
0 O
. O

05 O
in O
females O
. O

Fifty O
- O
seven O
families O
gave O
positive O
lod O
scores O
; O
five O
small O
families O
gave O
mildly O
negative O
lod O
scores O
. O

The O
maximum O
likelihood O
estimate O
of O
alpha O
, O
the O
proportion O
of O
linked O
loci O
, O
was O
1 O
. O

0 O
with O
a O
lower O
99 O
% O
confidence O
interval O
of O
0 O
. O

88 O
. O

These O
data O
suggest O
that O
there O
is O
only O
one O
HD B
locus O
, O
although O
a O
second O
rare O
locus O
cannot O
be O
ruled O
out O
. O

Haplotype O
and O
multipoint O
linkage O
analysis O
in O
Finnish O
choroideremia B
families O
. O

Multipoint O
linkage O
analysis O
of O
choroideremia B
( O
TCD B
) O
and O
seven O
X O
chromosomal O
restriction O
fragment O
length O
polymorphisms O
( O
RFLPs O
) O
was O
carried O
out O
in O
18 O
Finnish O
TCD B
families O
. O

The O
data O
place O
TCD B
distal O
to O
PGK O
and O
DXS72 O
, O
very O
close O
to O
DXYS1 O
and O
DXYS5 O
( O
Zmax O
= O
24 O
at O
theta O
= O
0 O
) O
and O
proximal O
to O
DXYS4 O
and O
DXYS12 O
. O

This O
agrees O
with O
the O
data O
obtained O
from O
other O
linkage O
studies O
and O
from O
physical O
mapping O
. O

All O
the O
TCD B
males O
and O
carrier O
females O
studied O
have O
the O
same O
DXYS1 O
allele O
in O
coupling O
with O
TCD B
. O

In O
Northeastern O
Finland O
, O
66 O
/ O
69 O
chromosomes O
carrying O
TCD B
had O
the O
same O
haplotype O
at O
loci O
DXS72 O
, O
DXYS1 O
, O
DXYS4 O
, O
and O
DXYS12 O
. O

The O
same O
haplotype O
is O
seen O
in O
only O
15 O
/ O
99 O
chromosomes O
not O
carrying O
TCD B
. O

Moreover O
, O
in O
71 O
/ O
104 O
non O
- O
TCD O
chromosomes O
, O
the O
haplotype O
at O
six O
marker O
loci O
is O
different O
from O
those O
seen O
in O
any O
of O
the O
76 O
TCD B
chromosomes O
. O

This O
supports O
the O
previously O
described O
hypothesis O
that O
the O
large O
Northern O
Finnish O
choroideremia B
pedigrees O
, O
comprising O
a O
total O
of O
over O
80 O
living O
patients O
representing O
more O
than O
a O
fifth O
of O
all O
TCD B
patients O
described O
worldwide O
, O
carry O
the O
same O
mutation O
. O

These O
linkage O
and O
haplotype O
data O
provide O
improved O
opportunities O
for O
prenatal O
diagnosis O
based O
on O
RFLP O
studies O
. O
. O

Autosomal O
dominant O
aniridia B
linked O
to O
the O
chromosome O
11p13 O
markers O
catalase O
and O
D11S151 O
in O
a O
large O
Dutch O
family O
. O

In O
a O
large O
pedigree O
with O
autosomal O
dominant O
aniridia B
, O
we O
found O
close O
linkage O
between O
the O
aniridia B
locus O
AN2 O
and O
the O
markers O
catalase O
( O
CAT O
) O
( O
zeta O
= O
7 O
. O
27 O
at O
theta O
= O
0 O
. O
00 O
) O
and O
D11S151 O
( O
zeta O
= O
3 O
. O
86 O
at O
theta O
= O
0 O
. O
10 O
) O
flanking O
the O
AN2 O
locus O
on O
11p13 O
. O

Positive O
lod O
scores O
were O
also O
obtained O
for O
the O
11p13 O
- O
- O
- O
- O
11p14 O
markers O
D11S16 O
and O
FSHB O
with O
the O
linkage O
group O
CAT O
/ O
AN2 O
/ O
D11S151 O
. O

We O
conclude O
that O
the O
autosomal O
dominant O
aniridia B
in O
this O
family O
is O
due O
to O
a O
mutation O
at O
the O
AN2 O
locus O
on O
11p13 O
. O

We O
have O
excluded O
linkage O
( O
zeta O
less O
than O
- O
2 O
at O
theta O
less O
than O
0 O
. O
18 O
) O
between O
the O
aniridia B
and O
the O
chromosome O
2p25 O
marker O
D2S1 O
( O
linked O
to O
ACP1 O
) O
. O

Recombination O
events O
that O
locate O
myotonic B
dystrophy I
distal O
to O
APOC2 O
on O
19q O
. O

We O
previously O
reported O
a O
recombination O
in O
an O
individual O
with O
myotonic B
dystrophy I
( O
DM B
) O
which O
placed O
the O
markers O
D19S19 O
and O
APOC2 O
on O
the O
same O
side O
of O
the O
DM B
locus O
. O

Haplotyping O
of O
this O
family O
with O
more O
recently O
characterized O
probes O
which O
are O
either O
tightly O
linked O
to O
DM B
or O
distal O
to O
the O
linkage O
group O
at O
q13 O
. O

2 O
shows O
that O
the O
DM B
locus O
is O
distal O
to O
APOC2 O
. O

This O
is O
confirmed O
by O
other O
recombinants O
where O
DM B
segregates O
with O
distal O
probes O
. O

Additional O
marker O
to O
marker O
recombinations O
in O
unaffected O
individuals O
are O
reported O
and O
support O
the O
order O
and O
orientation O
of O
the O
DM B
linkage O
group O
as O
pter O
- O
( O
INSR O
, O
LDLR O
, O
S9 O
) O
- O
( O
S19 O
, O
BCL3 O
, O
APOC2 O
) O
- O
( O
CKMM O
, O
DM O
) O
- O
( O
S22 O
, O
+ O
+ O
+ O
PRKCG O
) O
- O
qter O
. O

The O
data O
presented O
here O
cannot O
determine O
whether O
DM B
is O
proximal O
or O
distal O
to O
CKMM O
. O

The O
consequences O
of O
this O
probe O
order O
for O
antenatal O
diagnosis O
and O
future O
research O
aiming O
to O
isolate O
the O
gene O
which O
is O
affected O
in O
DM B
are O
discussed O
. O

Mutations O
in O
the O
RB1 O
gene O
and O
their O
effects O
on O
transcription O
. O

Inactivation O
of O
both O
alleles O
of O
the O
RB1 O
gene O
during O
normal O
retinal O
development O
initiates O
the O
formation O
of O
a O
retinoblastoma B
( I
RB I
) I
tumor I
. O

To O
identify O
the O
mutations O
which O
inactivate O
RB1 O
, O
21 O
RB B
tumors I
isolated O
from O
19 O
patients O
were O
analyzed O
with O
the O
polymerase O
chain O
reaction O
or O
an O
RNase O
protection O
assay O
or O
both O
. O

Mutations O
were O
identified O
in O
13 O
of O
21 O
RB B
tumors I
; O
in O
8 O
tumors B
, O
the O
precise O
errors O
in O
nucleotide O
sequence O
were O
characterized O
. O

Each O
of O
four O
germ O
line O
mutations O
involved O
a O
small O
deletion O
or O
duplication O
, O
while O
three O
somatic O
mutations O
were O
point O
mutations O
leading O
to O
splice O
alterations O
and O
loss O
of O
an O
exon O
from O
the O
mature O
RB1 O
mRNA O
. O

We O
were O
unable O
to O
detect O
expression O
of O
the O
mutant O
allele O
in O
lymphoblasts O
of O
three O
bilaterally O
affected O
patients O
, O
although O
the O
mutation O
was O
present O
in O
the O
genomic O
DNA O
and O
transcripts O
containing O
the O
mutations O
were O
obvious O
in O
the O
RB B
tumors I
in O
the O
absence O
of O
a O
normal O
RB1 O
allele O
. O

The O
variations O
in O
the O
level O
of O
expression O
of O
mutant O
transcripts O
suggest O
deregulation O
of O
RB1 O
transcription O
in O
the O
absence O
of O
a O
functional O
RB1 O
gene O
product O
. O
. O

Partial O
deletion O
8q O
without O
Langer B
- I
Giedion I
syndrome I
: O
a O
recognisable O
syndrome O
. O

We O
report O
two O
de O
novo O
cases O
of O
del O
( O
8 O
) O
( O
pter O
- O
- O
- O
- O
q24 O
. O
1 O
) O
with O
breakpoints O
involving O
the O
distal O
part O
of O
band O
8q24 O
. O

1 O
1 O
. O

The O
clinical O
features O
were O
similar O
and O
there O
were O
no O
obvious O
stigmata O
of O
Langer B
- I
Giedion I
syndrome I
( O
LGS B
) O
. O

There O
are O
three O
other O
cases O
reported O
with O
a O
deletion O
of O
chromosome O
8 O
at O
approximately O
the O
same O
breakpoint O
, O
one O
without O
LGS B
and O
some O
similarities O
to O
our O
cases O
, O
the O
other O
two O
with O
LGS B
. O

Our O
findings O
would O
support O
the O
observation O
that O
the O
critical O
segment O
for O
the O
assignment O
of O
LGS B
is O
proximal O
to O
or O
involves O
the O
proximal O
part O
of O
8q24 O
. O

1 O
, O
but O
a O
review O
of O
published O
reports O
suggests O
that O
the O
aetiology O
of O
LGS B
may O
be O
a O
more O
complex O
issue O

Myotonic B
dystrophy I
is O
closely O
linked O
to O
the O
gene O
for O
muscle O
- O
type O
creatine O
kinase O
( O
CKMM O
) O
. O

We O
have O
studied O
genetic O
linkage O
between O
the O
gene O
for O
creatine O
kinase O
muscle O
type O
( O
CKMM O
) O
and O
the O
gene O
for O
myotonic B
dystrophy I
( O
DM B
) O
. O

In O
a O
panel O
of O
65 O
myotonic B
dystrophy I
families O
from O
Canada O
and O
the O
Netherlands O
, O
a O
maximum O
lod O
score O
( O
Zmax O
) O
of O
22 O
. O

8 O
at O
a O
recombination O
frequency O
( O
theta O
) O
of O
0 O
. O

03 O
was O
obtained O
. O

Tight O
linkage O
was O
also O
demonstrated O
for O
CKMM O
and O
the O
gene O
for O
apolipoprotein O
C2 O
( O
ApoC2 O
) O
. O

This O
establishes O
CKMM O
as O
a O
useful O
marker O
for O
myotonic B
dystrophy I

Color B
vision I
defects I
in O
adrenomyeloneuropathy B
. O

The O
relationship O
between O
abnormal B
color I
vision I
and O
adrenomyeloneuropathy B
( O
AMN B
) O
was O
investigated O
in O
27 O
AMN B
patients O
and O
31 O
age O
- O
matched O
controls O
by O
using O
the O
Farnsworth O
- O
Munsell O
100 O
Hue O
test O
. O

Twelve O
( O
44 O
% O
) O
of O
27 O
patients O
showed O
test O
scores O
significantly O
above O
normal O
. O

The O
axes O
of O
bipolarity O
determined O
by O
the O
testing O
differed O
widely O
between O
the O
patients O
with O
abnormal O
scores O
, O
compatible O
with O
the O
notion O
that O
different O
alterations O
in O
visual O
pigment O
genes O
occur O
in O
different O
AMN B
kindreds O
. O

These O
observations O
confirm O
our O
earlier O
impression O
that O
the O
frequency O
of O
abnormal B
color I
vision I
is O
increased O
in O
these O
kindreds O
, O
and O
it O
supports O
our O
contentions O
that O
( O
1 O
) O
AMN B
( O
and O
its O
companion O
, O
adrenoleukodystrophy B
) O
are O
very O
closely O
linked O
to O
the O
visual O
pigment O
loci O
at O
Xq28 O
and O
( O
2 O
) O
this O
proximity O
might O
provide O
the O
opportunity O
to O
observe O
contiguous B
gene I
defects I
. O
. O

Molecular O
analysis O
of O
a O
female O
Lesch B
- I
Nyhan I
patient O
. O

We O
report O
the O
identification O
of O
a O
female O
patient O
with O
the O
X O
- O
linked O
recessive O
Lesch B
- I
Nyhan I
syndrome I
( O
hypoxanthine B
phosphoribosyltransferase I
[ I
HPRT I
] I
deficiency I
) O
. O

Cytogenetic O
and O
carrier O
studies O
revealed O
structurally O
normal O
chromosomes O
for O
this O
patient O
and O
her O
parents O
and O
demonstrated O
that O
this O
mutation O
arose O
through O
a O
de O
novo O
gametic O
event O
. O

Comparison O
of O
this O
patients O
DNA O
with O
the O
DNA O
of O
her O
parents O
revealed O
that O
a O
microdeletion O
, O
which O
occurred O
within O
a O
maternal O
gamete O
and O
involved O
the O
entire O
HPRT O
gene O
, O
was O
partially O
responsible O
for O
the O
disease O
in O
this O
patient O
. O

Somatic O
cell O
hybrids O
, O
generated O
to O
separate O
maternal O
and O
paternal O
X O
chromosomes O
, O
showed O
that O
expression O
of O
two O
additional O
X O
- O
linked O
enzymes O
, O
phosphoglycerate O
kinase O
and O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
, O
were O
expressed O
only O
in O
cells O
that O
contained O
the O
maternal O
X O
chromosome O
, O
suggesting O
the O
presence O
of O
a O
functionally O
inactive O
paternal O
X O
chromosome O
. O

Furthermore O
, O
comparison O
of O
methylation O
patterns O
within O
a O
region O
of O
the O
HPRT O
gene O
known O
to O
be O
important O
in O
gene O
regulation O
revealed O
differences O
between O
DNA O
from O
the O
father O
and O
the O
patient O
, O
in O
keeping O
with O
an O
active O
HPRT O
locus O
in O
the O
father O
and O
an O
inactive O
HPRT O
locus O
in O
the O
patient O
. O

Together O
these O
data O
indicate O
that O
nonrandom O
inactivation O
of O
the O
cytogenetically O
normal O
paternal O
X O
chromosome O
and O
a O
microdeletion O
of O
the O
HPRT O
gene O
on O
an O
active O
maternal O
X O
chromosome O
were O
responsible O
for O
the O
absence O
of O
HPRT O
in O
this O
patient O
. O
. O

Pelizaeus B
- I
Merzbacher I
disease I
: O
an O
X B
- I
linked I
neurologic I
disorder I
of I
myelin I
metabolism I
with O
a O
novel O
mutation O
in O
the O
gene O
encoding O
proteolipid O
protein O
. O

The O
nosology O
of O
the O
inborn B
errors I
of I
myelin I
metabolism I
has O
been O
stymied O
by O
the O
lack O
of O
molecular O
genetic O
analysis O
. O

Historically O
, O
Pelizaeus B
- I
Merzbacher I
disease I
has O
encompassed O
a O
host O
of O
neurologic B
disorders I
that O
present O
with O
a O
deficit B
of I
myelin I
, O
the O
membrane O
elaborated O
by O
glial O
cells O
that O
encircles O
and O
successively O
enwraps O
axons O
. O

We O
describe O
here O
a O
Pelizaeus B
- I
Merzbacher I
pedigree O
of O
the O
classical O
type O
, O
with O
X O
- O
linked O
inheritance O
, O
a O
typical O
clinical O
progression O
, O
and O
a O
pathologic O
loss O
of O
myelinating O
cells O
and O
myelin O
in O
the O
central O
nervous O
system O
. O

To O
discriminate O
variants O
of O
Pelizaeus B
- I
Merzbacher I
disease I
, O
a O
set O
of O
oligonucleotide O
primers O
was O
constructed O
to O
polymerase O
- O
chain O
- O
reaction O
( O
PCR O
) O
amplify O
and O
sequence O
the O
gene O
encoding O
proteolipid O
protein O
( O
PLP O
) O
, O
a O
structural O
protein O
that O
comprises O
half O
of O
the O
protein O
of O
the O
myelin O
sheath O
. O

The O
PLP O
gene O
in O
one O
of O
two O
affected O
males O
and O
the O
carrier O
mother O
of O
this O
family O
exhibited O
a O
single O
base O
difference O
in O
the O
more O
than O
2 O
kb O
of O
the O
PLP O
gene O
sequenced O
, O
a O
C O
- O
- O
- O
- O
T O
transition O
that O
would O
create O
a O
serine O
substitution O
for O
proline O
at O
the O
carboxy O
end O
of O
the O
protein O
. O

Our O
results O
delineate O
the O
clinical O
features O
of O
Pelizaeus B
- I
Merzbacher I
disease I
, O
define O
the O
possible O
molecular O
pathology O
of O
this O
dysmyelinating B
disorder I
, O
and O
address O
the O
molecular O
classification O
of O
inborn B
errors I
of I
myelin I
metabolism I
. O

Patients O
with O
the O
classical O
form O
( O
type O
I O
) O
and O
the O
more O
severely O
affected O
, O
connatal O
variant O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( I
type I
II I
) I
would O
be O
predicted O
to O
display O
mutation O
at O
the O
PLP O
locus O
. O

The O
other O
variants O
( O
types O
III O
- O
VI O
) O
, O
which O
have O
sometimes O
been O
categorized O
as O
Pelizaeus B
- I
Merzbacher I
disease I
, O
may O
represent O
mutations O
in O
genes O
encoding O
other O
structural O
myelin O
proteins O
or O
proteins O
critical O
to O
myelination O
. O
. O

Molecular O
basis O
of O
human O
von B
Willebrand I
disease I
: O
analysis O
of O
platelet O
von B
Willebrand I
factor O
mRNA O
. O

von B
Willebrand I
disease I
( O
vWD B
) O
, O
the O
most O
common O
inherited B
bleeding I
disorder I
in O
humans O
, O
can O
result O
from O
either O
a O
quantitative O
or O
a O
qualitative O
defect O
in O
the O
adhesive O
glycoprotein O
, O
von B
Willebrand I
factor O
( O
vWF O
) O
. O

Molecular O
studies O
of O
vWD B
have O
been O
limited O
by O
the O
large O
size O
of O
the O
vWF O
gene O
and O
difficulty O
in O
obtaining O
the O
vWF O
mRNA O
from O
patients O
. O

By O
use O
of O
an O
adaptation O
of O
the O
polymerase O
chain O
reaction O
, O
vWF O
mRNA O
was O
amplified O
and O
sequenced O
from O
peripheral O
blood O
platelets O
. O

A O
silent O
vWF O
allele O
was O
identified O
, O
resulting O
from O
a O
cis O
defect O
in O
vWF O
mRNA O
transcription O
or O
processing O
. O

In O
two O
type B
IIA I
vWD I
patients O
, O
two O
different O
but O
adjacent O
missense O
mutations O
were O
identified O
, O
the O
locations O
of O
which O
may O
identify O
an O
important O
vWF O
functional O
domain O
. O

Expression O
in O
heterologous O
cells O
of O
recombinant O
vWF O
containing O
one O
of O
these O
latter O
mutations O
reproduced O
the O
characteristic O
structural O
abnormality O
seen O
in O
type B
IIA I
vWD I
plasma O
. O
. O

Familial B
deficiency I
of I
the I
seventh I
component I
of I
complement I
associated O
with O
recurrent O
meningococcal B
infections I
. O

We O
describe O
an O
11 O
- O
year O
- O
old O
girl O
suffering O
from O
recurrent B
meningitis I
with O
a O
complete O
absence B
of I
the I
seventh I
component I
of I
complement I
( O
C7 O
) O
. O

Diagnosis O
was O
established O
by O
haemolytic O
titration O
and O
western O
blotting O
. O

The O
patients O
serum O
lacked O
the O
85 O
kDa O
C7 O
chain O
. O

Haemolytic O
activity O
of O
serum O
was O
reconstituted O
with O
either O
pooled O
normal O
human O
serum O
or O
with O
purified O
C7 O
. O

The O
relatives O
( O
parents O
and O
one O
sister O
) O
had O
half O
- O
normal O
levels O
of O
both O
immunochemically O
and O
functionally O
determined O
C7 O
, O
indicating O
a O
heterozygous O
state O
for O
C7 B
deficiency I
. O
. O

Translocation O
t O
( O
5 O
; O
11 O
) O
( O
q13 O
. O
1 O
; O
p13 O
) O
associated O
with O
familial O
isolated B
aniridia I
. O

A O
father O
and O
daughter O
with O
isolated B
aniridia I
were O
observed O
to O
have O
an O
apparently O
balanced O
, O
reciprocal O
translocation O
involving O
chromosomes O
5 O
and O
11 O
[ O
t O
( O
5 O
; O
11 O
) O
( O
q13 O
. O
1 O
; O
p13 O
) O
] O
. O

No O
other O
clinical O
characteristics O
often O
associated O
with O
the O
deletion O
of O
11p13 O
were O
observed O
in O
this O
family O
. O

This O
finding O
, O
in O
association O
with O
3 O
other O
instances O
of O
single O
breaks O
at O
11p13 O
and O
aniridia B
, O
supports O
the O
assignment O
of O
AN2 O
to O
11p13 O
. O

Homozygous B
hypobetalipoproteinemia I
: O
a O
disease O
distinct O
from O
abetalipoproproteinemia B
at O
the O
molecular O
level O
. O

apoB O
DNA O
, O
RNA O
, O
and O
protein O
from O
two O
patients O
with O
homozygous B
hypobetalipoproteinemia I
( O
HBL B
) O
were O
evaluated O
and O
compared O
with O
normal O
individuals O
. O

Southern O
blot O
analysis O
with O
10 O
different O
cDNA O
probes O
revealed O
a O
normal O
gene O
without O
major O
insertions O
, O
deletions O
, O
or O
rearrangements O
. O

Northern O
and O
slot O
blot O
analyses O
of O
total O
liver O
mRNA O
from O
HBL B
patients O
documented O
a O
normal O
size O
apoB O
mRNA O
that O
was O
present O
in O
greatly O
reduced O
quantities O
. O

ApoB O
protein O
was O
detected O
within O
HBL B
hepatocytes O
utilizing O
immunohistochemical O
techniques O
; O
however O
, O
it O
was O
markedly O
reduced O
in O
quantity O
when O
compared O
with O
control O
samples O
. O

No O
apoB O
was O
detectable O
in O
the O
plasma O
of O
HBL B
individuals O
with O
an O
ELISA O
assay O
. O

These O
data O
are O
most O
consistent O
with O
a O
mutation O
in O
the O
coding O
portion O
of O
the O
apoB O
gene O
in O
HBL B
patients O
, O
leading O
to O
an O
abnormal O
apoB O
protein O
and O
apoB O
mRNA O
instability O
. O

These O
results O
are O
distinct O
from O
those O
previously O
noted O
in O
abetalipoproteinemia B
, O
which O
was O
characterized O
by O
an O
elevated O
level O
of O
hepatic O
apoB O
mRNA O
and O
accumulation O
of O
intracellular O
hepatic O
apoB O
protein O
. O
. O

Spontaneous O
reversion O
of O
novel O
Lesch B
- I
Nyhan I
mutation O
by O
HPRT O
gene O
rearrangement O
. O

Molecular O
analysis O
of O
an O
unusual O
patient O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
has O
suggested O
that O
the O
mutation O
is O
due O
to O
a O
partial O
HPRT O
gene O
duplication O
. O

We O
now O
report O
the O
cloning O
and O
sequencing O
of O
the O
mutant O
HPRT O
cDNA O
which O
shows O
the O
precise O
duplication O
of O
exons O
2 O
and O
3 O
. O

This O
mutation O
is O
the O
result O
of O
an O
internal O
duplication O
of O
16 O
- O
20 O
kilobases O
of O
the O
gene O
. O

The O
structure O
of O
the O
mutant O
gene O
suggests O
that O
the O
duplication O
was O
not O
generated O
by O
a O
single O
unequal O
crossing O
- O
over O
event O
between O
two O
normal O
HPRT O
alleles O
. O

Growth O
of O
Epstein B
- I
Barr I
virus O
- O
transformed O
lymphoblasts O
from O
this O
patient O
in O
selective O
medium O
has O
permitted O
isolation O
of O
spontaneous O
HPRT O
+ O
revertants O
of O
this O
mutation O
. O

The O
reversion O
event O
involves O
a O
second O
major O
HPRT O
gene O
rearrangement O
where O
most O
or O
all O
of O
the O
duplicated O
portion O
of O
the O
mutant O
gene O
is O
deleted O
. O

The O
original O
mutation O
therefore O
has O
the O
potential O
for O
spontaneous O
somatic O
reversion O
. O

This O
may O
explain O
the O
relatively O
mild O
symptoms O
of O
the O
Lesch B
- I
Nyhan I
syndrome I
exhibited O
by O
this O
patient O
. O
. O

Complex B
glycerol I
kinase I
deficiency I
: O
molecular O
- O
genetic O
, O
cytogenetic O
, O
and O
clinical O
studies O
of O
five O
Japanese O
patients O
. O

Five O
male O
Japanese O
patients O
with O
complex B
glycerol I
kinase I
deficiency I
( O
CGKD B
) O
and O
their O
relatives O
were O
studied O
clinically O
, O
cytogenetically O
, O
and O
molecular O
- O
genetically O
. O

All O
patients O
had O
muscular B
dystrophy I
or O
muscle B
weakness I
, O
mental B
retardation I
, O
congenital B
adrenal I
hypoplasia I
, O
and O
glycerol B
kinase I
deficiency I
. O

High O
- O
resolution O
GTG O
- O
banded O
chromosomes O
showed O
a O
microdeletion O
in O
the O
Xp21 O
region O
in O
all O
four O
patients O
examined O
and O
in O
all O
five O
mothers O
. O

Southern O
hybridizations O
, O
after O
digestions O
by O
restriction O
endonucleases O
, O
with O
various O
cloned O
DNAs O
( O
D2 O
, O
99 O
- O
6 O
, O
B24 O
, O
C7 O
, O
L1 O
- O
4 O
, O
cDMD13 O
- O
14 O
, O
J66 O
- O
HI O
, O
P20 O
, O
J O
- O
Bir O
, O
ERT87 O
- O
30 O
, O
ERT87 O
- O
15 O
, O
ERT87 O
- O
8 O
, O
ERT87 O
- O
1 O
, O
XJ O
- O
1 O
. O
1 O
, O
754 O
, O
cx5 O
. O
7 O
, O
and O
OTC O
- O
1 O
) O
that O
are O
located O
around O
Xp21 O
also O
showed O
a O
deletion O

in O
the O
genome O
of O
all O
patients O
and O
mothers O
. O

Although O
the O
deletion O
differed O
in O
size O
among O
patients O
, O
a O
segment O
commonly O
absent O
was O
located O
between O
the O
genomic O
sequences O
corresponding O
to O
L1 O
- O
4 O
and O
cDMD13 O
- O
14 O
. O

This O
finding O
indicated O
that O
the O
gene O
coding O
for O
glycerol O
kinase O
( O
GK O
) O
is O
located O
within O
this O
segment O
. O

A O
comparison O
of O
the O
clinical O
manifestations O
of O
the O
present O
five O
patients O
and O
reported O
CGKD B
or O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
patients O
with O
DNA O
deletion O
suggests O
the O
existence O
of O
a O
certain O
gene O
responsible O
for O
gonadotropin B
deficiency I
( O
GTD B
) O
. O

The O
result O
of O
the O
present O
study O
and O
results O
of O
previous O
studies O
suggest O
that O
genes O
for O
ornithine O
transcarbamylase O
( O
OTC O
) O
, O
DMD B
, O
and O
GK O
and O
putative O
genes O
responsible O
for O
congenital B
adrenal I
hypoplasia I
( O
AHC B
) O
and O
GTD B
are O
arranged O
from O
telomere O
to O
centromere O
as O
pter O
- O
- O
GTD O
- O
- O
AHC O
- O
- O
GK O
- O
- O
DMD O
- O
- O
OTC O
- O
- O
cen O

Genetically O
determined O
low O
C4 O
: O
a O
predisposing O
factor O
to O
autoimmune B
chronic I
active I
hepatitis I
. O

Of O
26 O
patients O
with O
autoimmune B
chronic I
active I
hepatitis I
( O
CAH B
) O
starting O
in O
childhood O
18 O
( O
69 O
% O
) O
had O
low O
C4 O
and O
5 O
( O
19 O
% O
) O
had O
low O
C3 O
serum O
levels O
. O

Impaired O
hepatic O
synthesis O
and O
immune O
- O
consumption O
were O
unlikely O
since O
transferrin O
levels O
were O
normal O
in O
all O
patients O
, O
albumin O
levels O
were O
persistently O
low O
in O
only O
3 O
, O
and O
only O
3 O
had O
raised O
levels O
of O
activation O
fragment O
C3d O
. O

C4d O
was O
normal O
in O
all O
patients O
studied O
. O

In O
the O
families O
of O
12 O
probands O
with O
low O
C4 O
, O
7 O
parents O
had O
low O
C4 O
and O
2 O
had O
levels O
which O
were O
at O
the O
lower O
limit O
of O
normal O
. O

5 O
of O
10 O
siblings O
from O
5 O
families O
had O
low O
C4 O
. O

These O
results O
suggest O
that O
low O
C4 O
levels O
in O
CAH B
are O
genetically O
determined O
. O

C4 O
phenotyping O
in O
20 O
patients O
and O
in O
26 O
parents O
showed O
that O
90 O
% O
and O
81 O
% O
, O
respectively O
, O
had O
null O
allotypes O
at O
either O
the O
C4A O
or O
C4B O
locus O
compared O
with O
59 O
% O
in O
controls O
, O
indicating O
that O
defective O
expression O
of O
structural O
genes O
may O
contribute O
to O
the O
observed O
C4 B
deficiency I
. O
. O

An O
amino O
- O
acid O
substitution O
involved O
in O
phenylketonuria B
is O
in O
linkage O
disequilibrium O
with O
DNA O
haplotype O
2 O
. O

Phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
human I
genetic I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
, O
phenylalanine O
4 O
- O
monooxygenase O
, O
EC O
1 O
. O
14 O
. O
16 O
. O
1 O
) O
. O

PKU B
is O
a O
common O
inborn B
error I
of I
amino I
- I
acid I
metabolism I
in O
caucasian O
populations O
and O
approximately O
1 O
in O
50 O
individuals O
are O
carriers O
of O
a O
PKU B
allele O
. O

To O
define O
the O
molecular O
basis O
of O
PKU B
, O
we O
characterized O
twelve O
restriction O
fragment O
- O
length O
polymorphism O
( O
RFLP O
) O
haplotypes O
of O
the O
PAH O
locus O
in O
the O
northern O
European O
population O
and O
observed O
that O
90 O
% O
of O
the O
PKU B
alleles O
in O
this O
population O
are O
confined O
to O
four O
common O
RFLP O
haplotypes O
. O

We O
have O
recently O
reported O
a O
splicing O
mutation O
in O
the O
PAH O
gene O
that O
is O
associated O
with O
RFLP O
haplotype O
3 O
which O
is O
present O
at O
about O
40 O
% O
of O
mutant O
alleles O
. O

We O
now O
report O
the O
molecular B
lesion I
associated O
with O
the O
RFLP O
haplotype O
2 O
mutant O
allele O
. O

This O
defect O
is O
caused O
by O
a O
C O
- O
to O
- O
T O
transition O
in O
exon O
12 O
resulting O
in O
an O
amino O
- O
acid O
substitution O
( O
Arg O
to O
Trp O
) O
at O
residue O
408 O
of O
PAH O
. O

Direct O
hybridization O
analysis O
of O
the O
point O
mutation O
using O
a O
specific O
oligonucleotide O
probe O
demonstrated O
that O
this O
mutation O
is O
also O
in O
linkage O
disequilibrium O
with O
RFLP O
haplotype O
2 O
alleles O
that O
make O
up O
about O
20 O
% O
of O
mutant O
PAH O
genes O

Choroideremia B
: O
close O
linkage O
to O
DXYS1 O
and O
DXYS12 O
demonstrated O
by O
segregation O
analysis O
and O
historical O
- O
genealogical O
evidence O
. O

Linkage O
studies O
using O
restriction O
fragment O
length O
polymorphisms O
were O
conducted O
in O
the O
X B
- I
linked I
disorder I
, O
choroideremia B
, O
designated O
TCD B
for O
Progressive B
Tapeto I
- I
Choroidal I
Dystrophy I
. O

Previously O
demonstrated O
close O
linkage O
with O
locus O
DXYS1 O
was O
confirmed O
( O
lod O
11 O
. O
44 O
at O
0 O
recombination O
distance O
) O
. O

In O
addition O
, O
locus O
DXYS12 O
was O
found O
to O
be O
closely O
linked O
with O
TCD B
( O
lod O
3 O
. O
31 O
at O
0 O
recombination O
distance O
) O
. O

The O
disease O
mainly O
occurs O
in O
three O
large O
kindreds O
in O
remote O
Northern O
Finland O
. O

While O
formal O
genealogical O
proof O
is O
lacking O
, O
all O
presently O
living O
( O
more O
than O
80 O
affected O
males O
and O
120 O
carrier O
females O
) O
probably O
originate O
from O
a O
common O
founder O
couple O
born O
in O
1644 O
and O
1646 O
, O
twelve O
generations O
ago O
. O

All O
36 O
patients O
and O
48 O
carriers O
tested O
from O
the O
three O
kindreds O
had O
the O
same O
haplotype O
( O
TCD B
/ O
DXYS1 O
, O
11kb O
/ O
DXYS12 O
, O
1 O
. O
6kb O
) O
. O

Given O
that O
at O
least O
105 O
female O
meioses O
transmitting O
TCD B
have O
occurred O
since O
1650 O
in O
these O
kindreds O
, O
extremely O
close O
linkage O
between O
TCD B
, O
DXYS1 O
and O
DXYS12 O
is O
suggested O
. O

The O
above O
haplotype O
is O
a O
very O
useful O
diagnostic O
tool O
in O
these O
TCD B
families O
. O

We O
suggest O
that O
our O
historical O
- O
genealogical O
approach O
to O
linkage O
analysis O
may O
be O
possible O
elsewhere O
in O
similar O
isolated O
populations O

Von B
Hippel I
- I
Lindau I
disease I
maps O
to O
the O
region O
of O
chromosome O
3 O
associated O
with O
renal B
cell I
carcinoma I
. O

Von B
Hippel I
- I
Lindau I
disease I
( O
VHL B
) O
is O
an O
autosomal B
dominant I
disorder I
with O
inherited O
susceptibility O
to O
various O
forms O
of O
cancer B
, O
including O
hemangioblastomas B
of O
the O
central O
nervous O
system O
, O
phaeochromocytomas B
, O
pancreatic B
malignancies I
, O
and O
renal B
cell I
carcinomas I
. O

Renal B
cell I
carcinomas I
constitute O
a O
particularly O
frequent O
cause O
of O
death O
in O
this O
disorder O
, O
occurring O
as O
bilateral B
and I
multifocal I
tumours I
, O
and O
presenting O
at O
an O
earlier O
age O
than O
in O
sporadic O
, O
non O
- O
familial O
cases O
of O
this O
tumour B
type O
. O

We O
report O
here O
that O
the O
VHL B
gene O
is O
linked O
to O
the O
locus O
encoding O
the O
human O
homologoue O
of O
the O
RAF1 O
oncogene O
, O
which O
maps O
to O
chromosome O
3p25 O
( O
ref O
. O
4 O
) O
. O

Crossovers O
with O
the O
VHL B
locus O
suggest O
that O
the O
defect O
responsible O
for O
the O
VHL B
phenotype O
is O
not O
a O
mutation O
in O
the O
RAF1 O
gene O
itself O
. O

An O
alternative O
or O
prior O
event O
to O
oncogene O
activation O
in O
tumour B
formation O
may O
be O
the O
inactivation O
of O
a O
putative O
tumour B
suppressor O
which O
can O
be O
associated O
with O
both O
the O
inherited B
and I
sporadic I
forms I
of I
the I
cancer I
. O

Sporadic B
renal I
cell I
carcinomas I
have O
previously O
been O
associated O
with O
the O
loss O
of O
regions O
on O
chromosome O
3p O
( O
refs O
5 O
, O
6 O
) O
. O

Consequently O
, O
sporadic O
and O
VHL O
- O
associated O
forms O
of O
renal B
cell I
carcinoma I
might O
both O
result O
from O
alterations O
causing O
loss O
of O
function O
of O
the O
same O
tumour B
suppressor O
gene O
on O
this O
chromosome O
. O
. O

Tightly O
linked O
flanking O
markers O
for O
the O
Lowe B
oculocerebrorenal I
syndrome I
, O
with O
application O
to O
carrier O
assessment O
. O

The O
Lowe B
oculocerebrorenal I
syndrome I
( O
OCRL B
) O
is O
characterized O
by O
congenital O
cataract B
, O
mental B
retardation I
, O
and O
defective B
renal I
tubular I
function I
. O

A O
map O
assignment O
of O
OCRL B
to O
Xq24 O
- O
q26 O
has O
been O
made O
previously O
by O
linkage O
analysis O
with O
DXS42 O
at O
Xq24 O
- O
q26 O
( O
theta O
= O
0 O
, O
z O
= O
5 O
. O
09 O
) O
and O
with O
DXS10 O
at O
Xq26 O
( O
theta O
= O
0 O
, O
z O
= O
6 O
. O
45 O
) O
. O

Two O
additional O
families O
were O
studied O
and O
three O
additional O
polymorphisms O
were O
identified O
at O
DXS42 O
by O
using O
a O
35 O
- O
kb O
sequence O
isolated O
with O
the O
probe O
detecting O
the O
original O
polymorphism O
at O
DXS42 O
. O

With O
additional O
OCRL B
families O
made O
informative O
for O
DXS42 O
, O
theta O
remained O
0 O
with O
z O
= O
6 O
. O

63 O
; O
and O
for O
DXS10 O
theta O
= O
0 O
. O

03 O
and O
z O
= O
7 O
. O

07 O
. O

Evidence O
for O
placing O
OCRL O
at O
Xq25 O
also O
comes O
from O
a O
female O
with O
Lowe B
syndrome I
and O
an O
X O
; O
3 O
translocation O
. O

We O
have O
used O
the O
Xq25 O
breakpoint O
in O
this O
patient O
to O
determine O
the O
position O
of O
OCRL O
relative O
to O
the O
two O
linked O
markers O
. O

Each O
derivative O
chromosome O
was O
isolated O
away O
from O
its O
normal O
counterpart O
in O
somatic O
cell O
hybrids O
. O

DXS42 O
was O
mapped O
to O
the O
derivative O
chromosome O
X O
containing O
Xpterq25 O
, O
and O
DXS10 O
was O
mapped O
to O
the O
derivative O
chromosome O
3 O
containing O
Xq25 O
- O
qter O
. O

The O
markers O
DXS10 O
and O
DXS42 O
therefore O
show O
tight O
linkage O
with O
OCRL B
in O
six O
families O
and O
flank O
the O
Xq25 O
breakpoint O
in O
a O
female O
patient O
with O
an O
X O
; O
3 O
translocation O
. O

Linkage O
analysis O
with O
flanking O
markers O
was O
used O
to O
assess O
OCRL B
carrier O
status O
in O
women O
at O
risk O
. O

Results O
, O
when O
compared O
with O
carrier O
determination O
by O
ophthalmologic O
examination O
, O
indicated O
that O
the O
slit O
- O
lamp O
exam O
can O
be O
a O
sensitive O
and O
specific O
method O
of O
carrier O
determination O
in O
many O
cases O

Identification O
of O
a O
single O
nucleotide O
change O
in O
the O
hypoxanthine O
- O
guanine O
phosphoribosyltransferase O
gene O
( O
HPRTYale O
) O
responsible O
for O
Lesch B
- I
Nyhan I
syndrome I
. O

Complete O
deficiency B
of I
hypoxanthine I
- I
guanine I
phosphoribosyltransferase I
( O
HPRT O
) O
causes O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

Previous O
characterization O
of O
a O
mutant O
form O
of O
HPRT O
, O
HPRTYale O
, O
from O
a O
subject O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
revealed O
normal O
mRNA O
and O
protein O
concentrations O
, O
no O
residual O
catalytic O
activity O
, O
and O
cathodal O
migration O
upon O
PAGE O
. O

We O
have O
cloned O
and O
sequenced O
HPRTYale O
cDNA O
. O

The O
nucleotide O
sequence O
of O
full O
- O
length O
HPRTYale O
cDNA O
revealed O
a O
single O
nucleotide O
substitution O
compared O
with O
normal O
HPRT O
cDNA O
G O
- O
- O
- O
- O
C O
at O
nucleotide O
position O
211 O
. O

This O
transversion O
predicts O
substitution O
of O
arginine O
for O
glycine O
at O
amino O
acid O
position O
71 O
, O
explaining O
the O
cathodal O
migration O
of O
HPRTYale O
. O

Chou O
- O
Fasman O
secondary O
structure O
analysis O
predicts O
a O
change O
in O
the O
probability O
of O
beta O
- O
turn O
formation O
in O
the O
region O
containing O
the O
mutation O
. O

Inclusion O
of O
the O
bulky O
arginine O
side O
chain O
in O
place O
of O
glycine O
probably O
disrupts O
protein O
folding O
as O
well O
. O

Cloning O
mutant O
forms O
of O
cDNA O
allows O
identification O
of O
specific O
mutations O
, O
provides O
insight O
into O
mutational O
mechanisms O
, O
and O
facilitates O
structure O
- O
function O
analysis O
of O
mutant O
proteins O
. O
. O

Two O
point O
mutations O
are O
responsible O
for O
G6PD O
polymorphism O
in O
Sardinia O
. O

The O
human O
X O
- O
linked O
gene O
encoding O
glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
is O
highly O
polymorphic O
; O
more O
than O
300 O
G6PD O
variants O
have O
been O
identified O
. O

G6PD B
deficiency I
in O
different O
geographical O
areas O
appears O
to O
have O
arisen O
through O
independent O
mutational O
events O
, O
but O
within O
the O
same O
population O
it O
may O
also O
be O
heterogeneous O
. O

One O
example O
is O
the O
island O
of O
Sardinia O
, O
where O
careful O
clinical O
and O
biochemical O
studies O
have O
identified O
four O
different O
G6PD O
variants O
. O

We O
cloned O
and O
sequenced O
the O
four O
G6PD O
variants O
from O
Sardinia O
and O
found O
that O
only O
two O
mutations O
are O
responsible O
for O
G6PD B
deficiency I
in O
this O
area O
one O
mutation O
is O
the O
cause O
of O
the O
G6PD B
Seattle I
- I
like I
phenotype I
, O
a O
milder O
form O
of O
G6PD B
deficiency I
; O
the O
other O
mutation O
is O
responsible O
for O
all O
forms O
of O
very O
severe O
G6PD B
deficiency I
in O
Sardinia O
and O
, O
possibly O
, O
in O
the O
Mediterranean O
. O
. O

Chronic B
nonspherocytic I
hemolytic I
anemia I
( O
CNSHA B
) O
and O
glucose B
6 I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
in O
a O
patient O
with O
familial B
amyloidotic I
polyneuropathy I
( O
FAP B
) O
. O

Molecular O
study O
of O
a O
new O
variant O
( O
G6PD O
Clinic O
) O
with O
markedly O
acidic O
pH O
optimum O
. O

A O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
variant O
with O
severe O
erythrocytic B
G6PD I
deficiency I
and O
a O
unique O
pH O
optimum O
is O
described O
in O
a O
young O
patient O
with O
chronic B
nonspherocytic I
hemolytic I
anemia I
( O
CNSHA B
) O
and O
familial B
amyloidotic I
polyneuropathy I
( O
FAP B
) O
. O

Chronic B
hemolysis I
was O
present O
in O
the O
absence O
of O
infections O
, O
oxidant O
drugs O
or O
ingestion O
of O
faba O
beans O
. O

Residual O
enzyme O
activity O
was O
about O
2 O
. O

6 O
% O
and O
63 O
% O
of O
normal O
activity O
in O
erythrocytes O
and O
leucocytes O
, O
respectively O
. O

A O
molecular O
study O
using O
standard O
methods O
showed O
G6PD O
in O
the O
patient O
to O
have O
normal O
electrophoretic O
mobility O
( O
at O
pH O
7 O
. O
0 O
, O
8 O
. O
0 O
and O
8 O
. O
8 O
) O
, O
normal O
apparent O
affinity O
for O
substrates O
( O
Km O
, O
G6P O
and O
NADP O
) O
and O
a O
slightly O
abnormal O
utilization O
of O
substrate O
analogues O
( O
decreased O
deamino O
- O
NADP O
and O
increased O
2 O
- O
deoxyglucose O
- O
6 O
- O
phosphate O
utilization O
) O
. O

Heat O
stability O
was O
found O
to O
be O
markedly O
decreased O
( O
8 O
% O
of O
residual O
activity O
after O
20 O
min O
of O
incubation O
at O
46 O
degrees O
C O
) O
and O
a O
particular O
characteristic O
of O
this O
enzyme O
was O
a O
biphasic O
pH O
curve O
with O
a O
greatly O
increased O
activity O
at O
low O
pH O
. O

Although O
molecular O
characteristics O
of O
this O
variant O
closely O
resemble O
those O
of O
G6PD O
Bangkok O
and O
G6PD O
Duarte O
, O
it O
can O
be O
distinguished O
from O
these O
and O
all O
other O
previously O
reported O
variants O
by O
virtue O
of O
its O
unusual O
pH O
curve O
. O

Therefore O
the O
present O
variant O
has O
been O
designated O
G6PD O
Clinic O
to O
distinguish O
it O
from O
other O
G6PD O
variants O
previously O
described O

Molecular O
detection O
of O
chromosomal O
translocations O
that O
disrupt O
the O
putative O
retinoblastoma B
susceptibility O
locus O
. O

A O
candidate O
DNA O
sequence O
with O
many O
of O
the O
properties O
predicted O
for O
the O
retinoblastoma B
susceptibility O
( O
RB1 O
) O
locus O
has O
been O
cloned O
( O
S O
. O
H O
. O
Friend O
, O
R O
. O
Bernards O
, O
S O
. O
Rogelj O
, O
R O
. O
A O
. O
Weinberg O
, O
J O
. O
M O
. O
Rapaport O
, O
D O
. O
M O
. O
Albert O
, O
and O
T O
. O
P O
. O
Dryja O
, O
Nature O
[ O
London O
] O
323 O
643 O
- O
645 O
, O
1986 O
) O
. O

The O
large O
size O
of O
this O
gene O
( O
ca O
. O
200 O
kilobases O
[ O
kb O
] O
) O
and O
its O
multiple O
dispersed O
exons O
( O
Wiggs O
et O
al O
. O
, O
N O
. O
Engl O
. O
J O
. O
Med O
. O
318 O
151 O
- O
157 O
, O
1988 O
) O
complicate O
molecular O
screening O
strategies O
important O
in O
prenatal O
and O
presymptomatic O
diagnosis O
and O
in O
carrier O
detection O
. O

Here O
we O
used O
field O
inversion O
gel O
electrophoresis O
( O
FIGE O
) O
to O
construct O
a O
restriction O
map O
of O
approximately O
1 O
, O
000 O
kb O
of O
DNA O
surrounding O
the O
RB1 O
locus O
and O
to O
detect O
the O
translocation O
breakpoints O
in O
three O
retinoblastoma B
patients O
. O

DNA O
probes O
from O
either O
the O
5 O
or O
3 O
end O
of O
the O
gene O
were O
used O
to O
detect O
a O
250 O
- O
kb O
EagI O
restriction O
fragment O
in O
DNA O
from O
unaffected O
individuals O
. O

Both O
probes O
identified O
an O
additional O
hybridizing O
fragment O
in O
the O
DNA O
from O
each O
patient O
, O
permitting O
the O
breakpoints O
in O
all O
three O
to O
be O
mapped O
within O
the O
cloned O
RB1 O
gene O
. O

Analysis O
of O
the O
breakpoint O
in O
one O
translocation O
cell O
line O
allowed O
the O
RB1 O
gene O
to O
be O
oriented O
with O
its O
5 O
end O
toward O
the O
centromere O
. O

The O
5 O
end O
of O
the O
gene O
also O
appeared O
to O
be O
associated O
with O
a O
clustering O
of O
sites O
for O
several O
infrequently O
cleaving O
restriction O
enzymes O
, O
indicating O
the O
presence O
of O
an O
HpaII O
tiny O
fragment O
island O
. O

The O
detection O
and O
mapping O
of O
the O
translocation O
breakpoints O
of O
all O
three O
retinoblastoma B
patients O
to O
within O
the O
putative O
RB1 O
gene O
substantiated O
the O
authenticity O
of O
this O
candidate O
sequence O
and O
demonstrated O
the O
utility O
of O
FIGE O
in O
detecting O
chromosomal O
rearrangements O
affecting O
this O
locus O
. O

Inherited O
C3 B
deficiency I
with O
recurrent O
infections O
and O
glomerulonephritis B
. O

A O
10 O
- O
year O
- O
old O
Laotian O
boy O
had O
homozygous O
deficiency B
of I
the I
third I
component I
of I
complement I
and O
recurrent O
bacterial B
infections I
beginning O
at O
age O
5 O
months O
. O

Cellular O
and O
humoral O
immunity O
were O
normal O
, O
as O
were O
polymorphonuclear O
leukocyte O
chemotaxis O
and O
bactericidal O
activities O
. O

Serum O
complement O
- O
mediated O
hemolytic O
, O
chemotactic O
, O
and O
opsonic O
activities O
were O
deficient O
. O

In O
vitro O
addition O
of O
purified O
C3 O
to O
patient O
serum O
restored O
hemolytic O
complement O
to O
normal O
levels O
, O
and O
plasma O
infusion O
during O
each O
of O
four O
episodes O
of O
pneumonia B
significantly O
enhanced O
serum O
opsonic O
activity O
for O
as O
long O
as O
36 O
hours O
. O

A O
renal O
biopsy O
specimen O
revealed O
mesangiopathic B
glomerulonephritis I
, O
although O
significant O
levels O
of O
circulating O
IgG O
immune O
complexes O
were O
not O
detected O
. O

These O
findings O
further O
support O
the O
association O
of O
C3 B
deficiency I
with O
immune B
- I
complex I
disease I
and O
suggest O
that O
plasma O
infusion O
may O
be O
an O
adjunct O
to O
antibiotic O
therapy O
in O
the O
management O
of O
severe O
pyogenic B
infections I
in O
patients O
with O
C3 B
deficiency I
. O
. O

DNA O
restriction O
fragments O
associated O
with O
alpha O
1 O
- O
antitrypsin O
indicate O
a O
single O
origin O
for O
deficiency O
allele O
PI O
Z O
. O

The O
alpha O
1 O
- O
protease O
inhibitor O
, O
or O
alpha O
- O
antitrypsin O
( O
AAT O
) O
, O
a O
major O
plasma O
inhibitor O
of O
leukocyte O
elastase O
and O
bacterial O
proteases O
, O
is O
encoded O
at O
the O
PI O
locus O
on O
chromosome O
14 O
( O
14q24 O
. O
3 O
- O
q32 O
. O
1 O
) O
. O

A O
deficiency B
of I
AAT I
in O
individuals O
homozygous O
for O
the O
PI O
Z O
allele O
occurs O
in O
about O
1 O
in O
2 O
, O
000 O
- O
8 O
, O
000 O
caucasians O
and O
is O
associated O
with O
an O
increased O
risk O
of O
early O
adult O
onset O
emphysema B
and O
liver B
disease I
in O
childhood O
. O

We O
have O
now O
used O
DNA O
polymorphisms O
associated O
with O
the O
AAT O
gene O
to O
investigate O
the O
origin O
of O
the O
PI O
Z O
allele O
. O

Using O
two O
genomic O
probes O
extending O
into O
the O
5 O
and O
3 O
flanking O
regions O
, O
respectively O
, O
we O
have O
identified O
eight O
polymorphic O
restriction O
sites O
. O

Extensive O
linkage O
disequilibrium O
occurs O
throughout O
the O
probed O
region O
with O
the O
PI O
Z O
allele O
, O
but O
not O
with O
normal O
PI O
M O
alleles O
. O

The O
Z O
allele O
occurs O
mainly O
with O
one O
haplotype O
, O
indicating O
a O
single O
, O
relatively O
recent O
, O
origin O
in O
caucasians O

Segregation O
analysis O
of O
a O
marker O
localised O
Xp21 O
. O
2 O
- O
Xp21 O
. O
3 O
in O
Duchenne B
and I
Becker I
muscular I
dystrophy I
families O
. O

A O
DNA O
marker O
C7 O
, O
localised O
Xp21 O
. O

1 O
- O
Xp21 O
. O

3 O
, O
has O
been O
studied O
in O
kindreds O
segregating O
for O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
and O
Becker B
muscular I
dystrophy I
( O
BMD B
) O
. O

In O
DMD B
families O
four O
crossovers O
were O
observed O
in O
38 O
informative O
meioses O
between O
C7 O
and O
the O
DMD B
locus O
( O
theta O
= O
0 O
. O
12 O
, O
z O
max O
= O
+ O
2 O
. O
72 O
) O
. O

In O
BMD B
families O
no O
recombinants O
were O
observed O
in O
the O
16 O
informative O
meioses O
studied O
. O

These O
data O
are O
consistent O
with O
the O
localisation O
of O
the O
mutations O
in O
these O
disorders O
being O
in O
the O
same O
region O
of O
Xp21 O
. O

Studies O
in O
families O
also O
segregating O
for O
the O
DNA O
marker O
754 O
support O
the O
previously O
reported O
physical O
order O
of O
these O
loci O
as O
X O
centromere O
- O
754 O
- O
DMD O
- O
BMD O
- O
C7 O
- O
X O
telomere O
. O

A O
recombination O
fraction O
of O
0 O
. O

11 O
( O
z O
max O
= O
+ O
5 O
. O
58 O
) O
was O
found O
between O
DMD O
- O
754 O
by O
combining O
our O
previously O
published O
data O
with O
the O
data O
presented O
here O
. O

C7 O
and O
754 O
thus O
provide O
good O
bridging O
markers O
for O
the O
diagnosis O
of O
DMD B
and O
BMD B

Isolation O
of O
molecular O
probes O
associated O
with O
the O
chromosome O
15 O
instability O
in O
the O
Prader B
- I
Willi I
syndrome I
. O

Flow O
cytometry O
and O
recombinant O
DNA O
techniques O
have O
been O
used O
to O
obtain O
reagents O
for O
a O
molecular O
analysis O
of O
the O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

HindIII O
total O
- O
digest O
libraries O
were O
prepared O
in O
lambda O
phage O
Charon O
21A O
from O
flow O
- O
sorted O
inverted O
duplicated O
no O
. O
15 O
human O
chromosomes O
and O
propagated O
on O
recombination O
- O
proficient O
( O
LE392 O
) O
and O
recBC O
- O
, O
sbcB O
- O
( O
DB1257 O
) O
bacteria O
. O

Twelve O
distinct O
chromosome O
15 O
- O
specific O
probes O
have O
been O
isolated O
. O

Eight O
localized O
to O
the O
region O
15q11 O
- O
- O
- O
- O
13 O
. O

Four O
of O
these O
eight O
sublocalized O
to O
band O
15q11 O
. O

2 O
and O
are O
shown O
to O
be O
deleted O
in O
DNA O
of O
one O
of O
two O
patients O
examined O
with O
the O
PWS B
. O

Heteroduplex O
analysis O
of O
two O
of O
these O
clones O
, O
which O
grew O
on O
DB1257 O
but O
not O
on O
LE392 O
, O
revealed O
stem O
- O
loop O
structures O
in O
the O
inserts O
, O
indicative O
of O
inverted O
, O
repeated O
DNA O
elements O
. O

Such O
DNA O
repeats O
might O
account O
for O
some O
of O
the O
cloning O
instability O
of O
DNA O
segments O
from O
proximal O
15q O
. O

Analysis O
of O
the O
genetic O
and O
physical O
instability O
associated O
with O
the O
repeated O
sequences O
we O
have O
isolated O
from O
band O
15q11 O
. O

2 O
may O
elucidate O
the O
molecular O
basis O
for O
the O
instability O
of O
this O
chromosomal O
region O
in O
patients O
with O
the O
PWS B
or O
other O
diseases O
associated O
with O
chromosomal B
abnormalities I
in O
the O
proximal O
long O
arm O
of O
human O
chromosome O
15 O

Analysis O
of O
deletions O
in O
DNA O
from O
patients O
with O
Becker B
and I
Duchenne I
muscular I
dystrophy I
. O

Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
is O
an O
X B
- I
linked I
recessive I
genetic I
disorder I
for O
which O
the O
biochemical O
defect O
is O
as O
yet O
unknown O
. O

Recently O
, O
two O
cloned O
segments O
of O
human O
X O
- O
chromosome O
DNA O
have O
been O
described O
which O
detect O
structural O
alterations O
within O
or O
near O
the O
genetic O
locus O
responsible O
for O
the O
disorder O
. O

Both O
of O
these O
cloned O
segments O
were O
described O
as O
tightly O
linked O
to O
the O
locus O
and O
were O
capable O
of O
detecting O
deletions O
in O
the O
DNA O
of O
boys O
affected O
with O
DMD B
. O

In O
an O
attempt O
to O
determine O
more O
precisely O
the O
occurrence O
of O
these O
deletions O
within O
a O
large O
population O
of O
DMD B
patients O
and O
the O
accuracy O
of O
one O
of O
the O
segments O
, O
DXS164 O
( O
pERT87 O
) O
, O
in O
determining O
the O
inheritance O
of O
the O
DMD B
X O
chromosome O
, O
the O
subclones O
1 O
, O
8 O
and O
15 O
were O
made O
available O
to O
many O
investigators O
throughout O
the O
world O
. O

Here O
we O
describe O
the O
combined O
results O
of O
more O
than O
20 O
research O
laboratories O
with O
respect O
to O
the O
occurrence O
of O
deletions O
at O
the O
DXS164 O
locus O
in O
DNA O
samples O
isolated O
from O
patients O
with O
DMD B
and O
Becker B
muscular I
dystrophy I
( O
BMD B
) O
. O

The O
results O
indicate O
that O
the O
DXS164 O
locus O
apparently O
recombines O
with O
DMD B
5 O
% O
of O
the O
time O
, O
but O
is O
probably O
located O
between O
independent O
sites O
of O
mutation O
which O
yield O
DMD B
. O

The O
breakpoints O
of O
some O
deletions O
are O
delineated O
within O
the O
DXS164 O
locus O
, O
and O
it O
is O
evident O
that O
the O
deletions O
at O
the O
DMD B
locus O
are O
frequent O
and O
extremely O
large O
. O
. O

A O
potential O
animal O
model O
for O
Lesch B
- I
Nyhan I
syndrome I
through O
introduction O
of O
HPRT O
mutations O
into O
mice O
. O

The O
human O
Lesch B
- I
Nyhan I
syndrome I
is O
a O
rare O
neurological B
and I
behavioural I
disorder I
, O
affecting O
only O
males O
, O
which O
is O
caused O
by O
an O
inherited B
deficiency I
in O
the O
level O
of O
activity O
of O
the O
purine O
salvage O
enzyme O
hypoxanthine O
- O
guanosine O
phosphoribosyl O
transferase O
( O
HPRT O
) O
. O

How O
the O
resulting O
alterations O
in O
purine O
metabolism O
lead O
to O
the O
severe O
symptoms O
characteristic O
of O
Lesch B
- I
Nyhan I
patients O
is O
still O
not O
understood O
. O

No O
mutations O
at O
the O
Hprt O
locus O
leading O
to O
loss O
of O
activity O
have O
been O
described O
in O
laboratory O
animals O
. O

To O
derive O
an O
animal O
model O
for O
the O
Lesch B
- I
Nyhan I
syndrome I
, O
we O
have O
used O
cultured O
mouse O
embryonic O
stem O
cells O
, O
mutagenized O
by O
retroviral O
insertion O
and O
selected O
for O
loss O
of O
HPRT O
activity O
, O
to O
construct O
chimaeric O
mice O
. O

Two O
clonal O
lines O
carrying O
different O
mutant O
Hprt O
alleles O
have O
given O
rise O
to O
germ O
cells O
in O
chimaeras O
, O
allowing O
the O
derivation O
of O
strains O
of O
mutant O
mice O
having O
the O
same O
biochemical O
defect O
as O
Lesch B
- I
Nyhan I
patients O
. O

Male O
mice O
carrying O
the O
mutant O
alleles O
are O
viable O
and O
analysis O
of O
their O
cells O
shows O
a O
total O
lack O
of O
HPRT O
activity O
. O
. O

Re O
- O
evaluation O
of O
the O
sublocalization O
of O
esterase O
D O
and O
its O
relation O
to O
the O
retinoblastoma B
locus O
by O
in O
situ O
hybridization O
. O

In O
situ O
hybridization O
of O
a O
cDNA O
probe O
for O
the O
esterase O
D O
gene O
( O
ESD O
) O
was O
carried O
out O
on O
human O
chromosomes O
. O

The O
probe O
hybridized O
most O
strongly O
to O
13q14 O
. O

2 O
and O
13q14 O
. O

3 O
. O

This O
observation O
raises O
doubts O
concerning O
the O
most O
recently O
published O
assignment O
of O
ESD O
to O
13q14 O
. O

1 O
. O

A O
deletion O
in O
an O
individual O
with O
retinoblastoma B
was O
reported O
to O
separate O
the O
closely O
linked O
ESD O
and O
retinoblastoma B
( O
RB1 O
) O
loci O
, O
placing O
ESD O
proximal O
to O
RB1 O
. O

Quantitative O
in O
situ O
hybridization O
studies O
of O
this O
deletion O
do O
not O
confirm O
this O
interpretation O
. O

Rather O
, O
they O
suggest O
that O
ESD O
is O
missing O
from O
the O
deleted O
chromosome O
13 O
and O
duplicated O
on O
the O
normal O
homolog O
. O

From O
these O
findings O
, O
we O
conclude O
that O
the O
deletion O
in O
this O
individual O
cannot O
be O
used O
to O
determine O
the O
orientation O
nor O
the O
sublocalization O
of O
ESD O
and O
RB1 O
within O
the O
13q14 O
region O
. O

Hereditary B
C2 I
deficiency I
associated O
with O
common O
variable O
immunodeficiency B
. O

Homozygous O
C2 B
deficiency I
in O
a O
19 O
- O
year O
- O
old O
boy O
was O
associated O
with O
variable O
immunodeficiency B
manifested O
by O
marked O
hypoimmunoglobulinemia B
and O
impaired O
antibody O
responses O
, O
normal O
circulating O
B O
lymphocytes O
, O
and O
subnormal O
T O
- O
cell O
functions O
. O

Neither O
antilymphocytic O
autoantibodies O
nor O
chromosomal B
abnormalities I
were O
found O
. O

Serum O
immunoglobulin O
levels O
were O
within O
normal O
limits O
in O
his O
parents O
and O
brother O
who O
were O
heterozygous O
for O
C2 B
deficiency I
. O

The O
patients O
lymphocytes O
were O
homozygous O
at O
the O
HLA O
- O
D O
locus O
but O
expressed O
an O
antigen O
different O
from O
DW2 O
. O
. O

Mild O
and O
severe O
muscular B
dystrophy I
associated O
with O
deletions O
in O
Xp21 O
of O
the O
human O
X O
chromosome O
. O

We O
have O
analysed O
over O
300 O
patients O
suffering O
from O
Duchenne B
or I
Becker I
muscular I
dystrophy I
( O
DMD B
or O
BMD B
) O
. O

Deletions O
have O
been O
characterised O
which O
encompass O
either O
the O
pERT87 O
( O
DXS164 O
) O
locus O
only O
, O
the O
XJ1 O
. O

1 O
( O
DXS206 O
) O
and O
HIP25 O
loci O
only O
, O
or O
all O
three O
loci O
. O

These O
loci O
have O
been O
shown O
to O
lie O
within O
the O
DMD B
region O
covering O
several O
hundred O
kilobases O
( O
kb O
) O
of O
DNA O
. O

One O
mildly O
affected O
BMD B
patient O
possesses O
a O
deletion O
of O
at O
least O
110 O
kb O
including O
exons O
of O
the O
DMD B
gene O
. O

Other O
patients O
with O
similar O
exon O
deletions O
, O
or O
smaller O
deletions O
, O
show O
the O
more O
severe O
phenotype O
typical O
of O
DMD B
. O

We O
conclude O
from O
these O
studies O
that O
the O
severity O
of O
the O
clinical O
phenotype O
cannot O
be O
explained O
on O
the O
basis O
of O
the O
size O
of O
the O
deletion O
. O

We O
discuss O
this O
in O
the O
context O
of O
candidate O
gene O
sequences O
. O

Patterns O
of O
exon O
deletions O
in O
Duchenne B
and I
Becker I
muscular I
dystrophy I
. O

A O
panel O
of O
patients O
with O
Duchenne B
and I
Becker I
muscular I
dystrophy I
( O
DMD B
and O
BMD B
) O
has O
been O
screened O
with O
the O
cDNA O
probes O
Cf56a O
and O
Cf23a O
, O
which O
detect O
exons O
in O
the O
central O
part O
of O
the O
DMD B
gene O
. O

One O
or O
more O
exons O
were O
deleted O
in O
60 O
% O
of O
patients O
. O

The O
deletions O
were O
mapped O
and O
prove O
to O
be O
heterogeneous O
in O
size O
and O
extent O
, O
particularly O
in O
DMD B
. O

Deletions O
specific O
to O
DMD B
and O
to O
BMD B
are O
described O
. O

Half O
of O
all O
BMD B
patients O
have O
a O
deletion O
of O
one O
particular O
small O
group O
of O
exons O
; O
smaller O
deletions O
within O
this O
same O
group O
produce O
the O
more O
severe O
DMD B
. O
. O

Hereditary B
deficiency I
of I
the I
third I
component I
of I
complement I
in O
a O
child O
with O
fever B
, O
skin B
rash I
, O
and O
arthralgias B
: O
response O
to O
transfusion O
of O
whole O
blood O
. O

A O
previously O
well O
34 O
- O
month O
- O
old O
male O
presenting O
with O
fever B
, O
skin B
rash I
, O
and O
arthralgias B
was O
found O
to O
lack O
C3 O
by O
immunochemical O
( O
undetectable O
) O
and O
hemolytic O
( O
1 O
% O
normal O
) O
assays O
. O

No O
infectious O
agent O
could O
be O
demonstrated O
. O

Protein O
levels O
of O
Clq O
. O

C4 O
, O
C5 O
, O
properdin O
, O
and O
C3b O
- O
INA O
and O
hemolytic O
activities O
of O
complement O
components O
C1 O
to O
C9 O
except O
C3 O
were O
normal O
or O
elevated O
; O
total O
hemolytic O
complement O
activity O
was O
13 O
% O
of O
normal O
and O
was O
reconstituted O
by O
purified O
C3 O
. O

Properdin O
factor O
B O
was O
702 O
( O
normal O
175 O
to O
275 O
) O
mug O
/ O
ml O
, O
and O
was O
not O
cleaver O
upon O
addition O
of O
zymosan O
or O
cobra O
venom O
factor O
. O

The O
serum O
had O
normal O
immune O
adherence O
activity O
, O
but O
was O
deficient O
in O
ability O
to O
opsonize O
Candida O
albicans O
for O
uptake O
and O
Escherichia O
coli O
for O
killing O
by O
neurophils O
, O
generate O
neutrophil O
chemotactic O
factors O
and O
inhibit O
the O
growth O
of O
E O
. O
coli O
; O
these O
activities O
were O
restored O
by O
purified O
C3 O
. O

A O
transfusion O
of O
320 O
ml O
1 O
- O
hour O
- O
old O
normal O
whole O
blood O
on O
the O
fifty O
- O
second O
day O
resulted O
in O
transitory O
elevation O
of O
the O
C3 O
level O
to O
25 O
mg O
/ O
dl O
with O
a O
fall O
- O
off O
( O
approximately O
2 O
1 O
/ O
2 O
% O
per O
hour O
) O
to O
undetectable O
levels O
by O
69 O
hours O
; O
it O
was O
followed O
by O
disappearance O
of O
the O
skin B
rash I
and O
arthralgias B
and O
return O
to O
normal O
of O
the O
previously O
elevated O
temperature O
and O
CRP O
levels O
. O

C3 O
levels O
in O
family O
members O
( O
seven O
of O
24 O
half O
- O
normal O
) O
, O
lack O
of O
anti O
- O
C3 O
activity O
, O
normal O
C3b O
- O
INA O
levels O
and O
a O
normal O
rate O
of O
catabolism O
of O
transfused O
C3 O
indicated O
that O
the O
deficiency O
was O
inherited O
with O
autosomal O
codominance O
and O
involved O
decreased B
synthesis I
of I
C3 I
. O

Thus O
, O
this O
child O
is O
a O
unique O
individual O
with O
inherited B
C3 I
deficiency I
presenting O
with O
absence O
of O
repeated O
infections O
, O
whose O
symptoms O
of O
fever B
, O
skin B
rash I
, O
and O
arthralgia B
were O
abated O
by O
whole O
blood O
transfusion O
. O
. O

Glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variants O
and O
their O
frequency O
in O
Guangdong O
, O
China O
. O

Erythrocyte O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
was O
characterized O
in O
blood O
samples O
obtained O
from O
97 O
randomly O
selected O
males O
with O
enzyme B
deficiency I
from O
various O
regions O
of O
Guangdong O
Province O
, O
China O
. O

Nine O
new O
variants O
( O
Gd O
Kaiping O
, O
Gd O
Boluo O
, O
Gd O
Huiyang O
, O
Gd O
Gaomin O
, O
Gd O
Qing O
- O
Baijiang O
, O
Gd O
Gaozhou O
, O
Gd O
Huazhou O
, O
Gd O
Nanhai O
, O
and O
Gd O
Guangzhou O
) O
were O
identified O
. O

Of O
the O
31 O
variants O
found O
in O
this O
province O
, O
Gd O
Kaiping O
, O
Gd O
Taiwan O
- O
Hakka O
, O
Gd O
Haad O
Yai O
, O
Gd O
Haad O
Yai O
- O
like O
and O
Gd O
Huiyang O
occurred O
most O
frequently O
. O

The O
frequency O
of O
each O
variant O
was O
calculated O
. O

The O
results O
demonstrated O
that O
the O
genetic O
heterogeneity O
of O
G6PD B
deficiency I
was O
high O
in O
this O
area O
. O
. O

Homozygous O
and O
heterozygous O
deletions O
of O
the O
von B
Willebrand I
factor O
gene O
in O
patients O
and O
carriers O
of O
severe B
von I
Willebrand I
disease I
. O

Severe B
von I
Willebrand I
disease I
is O
characterized O
by O
undetectable O
or O
trace O
quantities O
of O
von B
Willebrand I
factor O
in O
plasma O
and O
tissue O
stores O
. O

We O
have O
studied O
the O
genomic O
DNA O
of O
10 O
affected O
individuals O
from O
six O
families O
with O
this O
disorder O
using O
probes O
from O
the O
5 O
and O
3 O
ends O
of O
the O
vWF O
cDNA O
and O
with O
a O
probe O
extending O
from O
the O
5 O
end O
into O
the O
central O
region O
. O

Southern O
blots O
of O
restriction O
endonuclease O
digests O
and O
gene O
dosage O
analysis O
measurements O
carried O
out O
with O
quantitative O
slot O
blots O
of O
undigested O
genomic O
DNA O
separated O
these O
patients O
into O
three O
groups O
. O

The O
first O
group O
consisted O
of O
a O
family O
with O
complete O
homozygous O
deletions O
of O
the O
vWF O
gene O
in O
the O
four O
probands O
. O

Gene O
dosage O
analysis O
was O
consistent O
with O
heterozygous O
deletions O
in O
both O
of O
the O
asymptomatic O
parents O
and O
four O
asymptomatic O
siblings O
of O
this O
kindred O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

The O
second O
group O
was O
comprised O
of O
a O
family O
in O
which O
there O
was O
a O
complete O
heterozygous O
deletion O
of O
the O
vWF O
gene O
in O
the O
proband O
and O
one O
asymptomatic O
parent O
, O
suggesting O
that O
a O
different O
type O
of O
genetic B
abnormality I
was O
inherited O
from O
the O
other O
parent O
. O

Thus O
, O
the O
patient O
appeared O
to O
be O
doubly O
heterozygous O
for O
interacting O
genetic B
abnormalities I
affecting O
vWF O
expression O
. O

In O
the O
third O
group O
, O
no O
gene O
deletions O
could O
be O
detected O
. O

Alloantibodies O
developed O
only O
in O
the O
kindred O
with O
homozygous O
deletions O
. O

These O
techniques O
should O
prove O
useful O
in O
identifying O
carriers O
of O
severe B
von I
Willebrand I
disease I
and O
also O
in O
defining O
patients O
predictably O
at O
risk O
of O
developing O
alloantibodies O
to O
vWF O
. O

Sjogren B
- I
Larsson I
syndrome I
. O

Impaired O
fatty O
alcohol O
oxidation O
in O
cultured O
fibroblasts O
due O
to O
deficient O
fatty O
alcohol O
: O
nicotinamide O
adenine O
dinucleotide O
oxidoreductase O
activity O
. O

Lipid O
metabolism O
was O
studied O
in O
cultured O
skin O
fibroblasts O
from O
patients O
with O
the O
inherited B
disorder I
, O
Sjogren B
- I
Larsson I
syndrome I
( O
SLS B
) O
. O

Intact O
SLS B
fibroblasts O
incubated O
in O
the O
presence O
of O
[ O
1 O
- O
14C O
] O
palmitate O
accumulated O
more O
radioactive O
hexadecanol O
than O
did O
normal O
cells O
, O
whereas O
incorporation O
of O
radioactivity O
into O
other O
cellular O
lipids O
was O
unaltered O
. O

The O
hexadecanol O
content O
of O
SLS B
fibroblasts O
was O
abnormally O
elevated O
. O

Hexadecanol O
accumulation O
was O
not O
due O
to O
increased O
fatty O
alcohol O
synthesis O
nor O
its O
deficient O
utilization O
for O
glycerol O
ether O
synthesis O
. O

The O
half O
- O
life O
of O
intracellular O
hexadecanol O
loaded O
into O
SLS B
fibroblasts O
was O
increased O
( O
70 O
min O
) O
compared O
with O
normal O
( O
15 O
min O
) O
, O
and O
intact O
SLS B
fibroblasts O
showed O
impaired O
oxidation O
of O
[ O
14C O
] O
- O
hexadecanol O
to O
fatty O
acid O
. O

Fatty O
alcohol O
NAD O
+ O
oxidoreductase O
, O
the O
enzyme O
catalyzing O
this O
reaction O
, O
was O
deficient O
in O
SLS B
fibroblasts O
. O

Mean O
total O
activity O
in O
SLS B
fibroblasts O
( O
n O
= O
5 O
) O
was O
13 O
% O
of O
that O
in O
normal O
fibroblasts O
, O
and O
palmitoyl O
CoA O
- O
inhibitable O
activity O
was O
1 O
% O
of O
normal O
. O

Fibroblasts O
from O
two O
obligate O
SLS B
heterozygotes O
had O
enzyme O
activities O
intermediate O
between O
that O
in O
normal O
fibroblasts O
and O
individuals O
with O
SLS B
. O

These O
results O
suggest O
that O
the O
primary O
defect O
in O
SLS B
is O
deficiency B
of I
fatty I
alcohol I
NAD I
+ I
oxidoreductase I
. O

SLS B
represents O
the O
first O
inherited B
disorder I
in O
man O
associated O
with O
an O
isolated O
abnormality B
in I
fatty I
alcohol I
metabolism I
. O
. O

Germinal O
mosaicism O
in O
Duchenne B
muscular I
dystrophy I
. O

We O
have O
identified O
a O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
pedigree O
where O
the O
disease O
is O
associated O
with O
a O
molecular O
deletion O
within O
the O
DMD B
locus O
. O

We O
have O
examined O
the O
meiotic O
segregation O
products O
of O
the O
common O
female O
ancestor O
using O
marker O
restriction O
fragment O
length O
polymorphisms O
( O
RFLPs O
) O
detected O
by O
probes O
that O
lie O
within O
this O
deletion O
. O

These O
studies O
show O
that O
this O
female O
has O
transmitted O
three O
distinct O
types O
of O
X O
chromosome O
to O
her O
offspring O
. O

This O
observation O
may O
be O
explained O
by O
postulating O
that O
the O
mutation O
arose O
as O
a O
postzygotic O
deletion O
within O
this O
common O
ancestor O
, O
who O
was O
consequently O
germinally O
mosaic O
. O
. O

Nebulin O
seen O
in O
DMD B
males O
including O
one O
patient O
with O
a O
large O
DNA O
deletion O
encompassing O
the O
DMD B
gene O
. O

The O
presence O
of O
nebulin O
in O
a O
muscle O
specimen O
from O
a O
patient O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
due O
to O
a O
large O
deletion O
precludes O
the O
possibility O
that O
this O
protein O
is O
the O
DMD B
gene O
product O
. O
. O

Expression O
of O
the O
murine O
Duchenne B
muscular I
dystrophy I
gene O
in O
muscle O
and O
brain O
. O

Complementary O
DNA O
clones O
were O
isolated O
that O
represent O
the O
5 O
terminal O
2 O
. O

5 O
kilobases O
of O
the O
murine O
Duchenne B
muscular I
dystrophy I
( O
Dmd O
) O
messenger O
RNA O
( O
mRNA O
) O
. O

Mouse O
Dmd O
mRNA O
was O
detectable O
in O
skeletal O
and O
cardiac O
muscle O
and O
at O
a O
level O
approximately O
90 O
percent O
lower O
in O
brain O
. O

Dmd O
mRNA O
is O
also O
present O
, O
but O
at O
much O
lower O
than O
normal O
levels O
, O
in O
both O
the O
muscle O
and O
brain O
of O
three O
different O
strains O
of O
dystrophic B
mdx O
mice O
. O

The O
identification O
of O
Dmd O
mRNA O
in O
brain O
raises O
the O
possibility O
of O
a O
relation O
between O
human O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
expression O
and O
the O
mental B
retardation I
found O
in O
some O
DMD B
males O
. O

These O
results O
also O
provide O
evidence O
that O
the O
mdx O
mutations O
are O
allelic O
variants O
of O
mouse O
Dmd O
gene O
mutations O
. O

Glucose B
6 I
- I
phosphate I
dehydrogenase I
deficiency I
and O
incidence O
of O
hematologic B
malignancy I
. O

We O
have O
evaluated O
the O
hypothesis O
of O
a O
negative O
association O
between O
glucose B
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
and O
cancer B
in O
a O
cohort O
of O
481 O
Sardinian O
males O
with O
hematological B
malignancies I
. O

The O
frequency O
of O
G6PD B
deficiency I
in O
the O
patients O
was O
not O
different O
from O
the O
incidence O
in O
a O
group O
of O
16 O
, O
219 O
controls O
. O

The O
same O
conclusion O
resulted O
from O
the O
comparison O
of O
the O
frequency O
of O
expression O
of O
the O
GdB O
gene O
in O
23 O
heterozygous O
women O
having O
a O
clonal O
hematologic B
disease I
and O
a O
control O
group O
of O
37 O
healthy O
heterozygotes O
. O

Therefore O
at O
present O
there O
is O
no O
evidence O
that O
G6PD B
deficiency I
has O
a O
protective O
effect O
against O
development O
of O
hematologic B
neoplasms I
. O
. O

Hepatoblastoma B
, O
pigmented B
ocular I
fundus I
lesions I
and O
jaw B
lesions I
in O
Gardner B
syndrome I
. O

Hepatoblastoma B
is O
a O
rare O
neoplasm B
of O
infants O
and O
children O
only O
recently O
documented O
in O
association O
with O
hereditary B
adenomatous I
polyposis I
of I
the I
colon I
[ O
Kingston O
et O
al O
. O
, O
1983 O
] O
. O

We O
report O
four O
children O
with O
hepatoblastoma B
from O
four O
unrelated O
families O
with O
Gardner B
syndrome I
( O
GS B
) O
. O

One O
child O
, O
now O
19 O
years O
old O
, O
survived O
after O
a O
resection O
of O
a O
hepatoblastoma B
in O
infancy O
and O
recently O
was O
found O
to O
have O
GS B
. O

He O
has O
an O
associated O
odontoma B
and O
pigmented B
ocular I
fundus I
lesions I
, O
both O
of O
which O
have O
been O
shown O
to O
be O
clinical O
markers O
of O
GS B
. O

Many O
individuals O
in O
these O
four O
GS B
families O
, O
both O
affected O
and O
at O
risk O
, O
have O
osteomatous B
jaw I
lesions I
and O
pigmented B
ocular I
fundus I
lesions I
. O

A O
search O
for O
colonic B
polyps I
should O
be O
made O
in O
families O
of O
infants O
and O
children O
with O
hepatoblastoma B
. O

If O
the O
child O
survives O
, O
he O
or O
she O
should O
be O
monitored O
for O
the O
later O
appearance O
of O
colonic B
polyps I
. O

The O
finding O
of O
jaw B
lesions I
and O
/ O
or O
pigmented B
ocular I
fundus I
lesions I
in O
relatives O
at O
risk O
are O
indications O
of O
the O
possible O
presence O
of O
the O
GS B
gene O
. O

Identification O
of O
an O
altered O
splice O
site O
in O
Ashkenazi O
Tay B
- I
Sachs I
disease I
. O

Tay B
- I
Sachs I
disease I
is O
an O
autosomal B
recessive I
genetic I
disorder I
resulting O
from O
mutation O
of O
the O
HEXA O
gene O
encoding O
the O
alpha O
- O
subunit O
of O
the O
lysosomal O
enzyme O
, O
beta O
- O
N O
- O
acetylhexosaminidase O
A O
( O
ref O
. O
1 O
) O
. O

A O
relatively O
high O
frequency O
of O
carriers O
( O
1 O
/ O
27 O
) O
of O
a O
lethal O
, O
infantile O
form O
of O
the O
disease O
is O
found O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
it O
is O
not O
yet O
evident O
whether O
this O
has O
resulted O
from O
a O
founder O
effect O
and O
random O
genetic O
drift O
or O
from O
a O
selective O
advantage O
of O
heterozygotes O
. O

We O
have O
identified O
a O
single O
- O
base O
mutation O
in O
a O
cloned O
fragment O
of O
the O
HEXA O
gene O
from O
an O
Ashkenazi O
Jewish O
patient O
. O

This O
change O
, O
the O
substitution O
of O
a O
C O
for O
G O
in O
the O
first O
nucleotide O
of O
intron O
12 O
is O
expected O
to O
result O
in O
defective O
splicing O
of O
the O
messenger O
RNA O
. O

A O
test O
for O
the O
mutant O
allele O
based O
on O
amplification O
of O
DNA O
by O
the O
polymerase O
chain O
rection O
and O
cleavage O
of O
a O
DdeI O
restriction O
site O
generated O
by O
the O
mutation O
revealed O
that O
this O
case O
and O
two O
other O
cases O
of O
the O
Ashkenazi O
, O
infantile O
form O
of O
Tay B
- I
Sachs I
disease I
are O
heterozygous O
for O
two O
different O
mutations O
. O

The O
occurrence O
of O
multiple O
mutant O
alleles O
warrants O
further O
examination O
of O
the O
selective O
advantage O
hypothesis O
. O
. O

X B
- I
linked I
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
in O
Mus O
musculus O
. O

A O
mouse O
with O
X B
- I
linked I
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
has O
been O
recovered O
in O
offspring O
of O
1 O
- O
ethyl O
- O
1 O
- O
nitrosourea O
- O
treated O
male O
mice O
. O

The O
activity O
alteration O
was O
detected O
in O
blood O
but O
can O
also O
be O
observed O
in O
other O
tissue O
extracts O
. O

Hemizygous O
, O
heterozygous O
, O
and O
homozygous O
mutants O
have O
, O
respectively O
, O
about O
15 O
, O
60 O
, O
and O
15 O
% O
G6PD O
remaining O
activity O
in O
the O
blood O
as O
compared O
to O
the O
wild O
type O
. O

Erythrocyte O
indices O
did O
not O
show O
differences O
between O
mutants O
and O
wild O
types O
. O

The O
mutation O
does O
not O
affect O
the O
electrophoretic O
migration O
, O
the O
isoelectric O
point O
, O
or O
the O
thermal O
stability O
. O

Kinetic O
properties O
, O
such O
as O
the O
Km O
for O
glucose O
- O
6 O
- O
phosphate O
or O
for O
NADP O
and O
the O
relative O
utilization O
of O
substrate O
analogues O
, O
showed O
no O
differences O
between O
wild O
types O
and O
mutants O
with O
the O
exception O
of O
the O
relative O
utilization O
of O
deamino O
- O
NADP O
which O
was O
significantly O
lower O
in O
mutants O
. O

This O
is O
presently O
the O
only O
animal O
model O
for O
X B
- I
linked I
G6PD I
deficiency I
in O
humans O
. O
. O

Diverse O
point O
mutations O
in O
the O
human O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
gene O
cause O
enzyme B
deficiency I
and O
mild O
or O
severe O
hemolytic B
anemia I
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
; I
EC I
1 I
. I
1 I
. I
1 I
. I
49 I
) I
deficiency I
is O
a O
common O
genetic B
abnormality I
affecting O
an O
estimated O
400 O
million O
people O
worldwide O
. O

Clinical O
and O
biochemical O
analyses O
have O
identified O
many O
variants O
exhibiting O
a O
range O
of O
phenotypes O
, O
which O
have O
been O
well O
characterized O
from O
the O
hematological O
point O
of O
view O
. O

However O
, O
until O
now O
, O
their O
precise O
molecular O
basis O
has O
remained O
unknown O
. O

We O
have O
cloned O
and O
sequenced O
seven O
mutant O
G6PD O
alleles O
. O

In O
the O
nondeficient O
polymorphic O
African O
variant O
G6PD O
A O
we O
have O
found O
a O
single O
point O
mutation O
. O

The O
other O
six O
mutants O
investigated O
were O
all O
associated O
with O
enzyme B
deficiency I
. O

In O
one O
of O
the O
commonest O
, O
G6PD O
Mediterranean O
, O
which O
is O
associated O
with O
favism B
among O
other O
clinical O
manifestations O
, O
a O
single O
amino O
acid O
replacement O
was O
found O
( O
serine O
- O
- O
- O
- O
phenylalanine O
) O
it O
must O
be O
responsible O
for O
the O
decreased O
stability O
and O
the O
reduced O
catalytic O
efficiency O
of O
this O
enzyme O
. O

Single O
point O
mutations O
were O
also O
found O
in O
G6PD O
Metaponto O
( O
Southern O
Italy O
) O
and O
in O
G6PD O
Ilesha O
( O
Nigeria O
) O
, O
which O
are O
asymptomatic O
, O
and O
in O
G6PD O
Chatham O
, O
which O
was O
observed O
in O
an O
Indian O
boy O
with O
neonatal B
jaundice I
. O

In O
G6PD O
" O
Matera O
, O
" O
which O
is O
now O
known O
to O
be O
the O
same O
as O
G6PD O
A O
- O
, O
two O
separate O
point O
mutations O
were O
found O
, O
one O
of O
which O
is O
the O
same O
as O
in O
G6PD O
A O
. O

In O
G6PD O
Santiago O
, O
a O
de O
novo O
mutation O
( O
glycine O
- O
- O
- O
- O
arginine O
) O
is O
associated O
with O
severe O
chronic O
hemolytic B
anemia I
. O

The O
mutations O
observed O
show O
a O
striking O
predominance O
of O
C O
- O
- O
- O
- O
T O
transitions O
, O
with O
CG O
doublets O
involved O
in O
four O
of O
seven O
cases O
. O

Thus O
, O
diverse O
point O
mutations O
may O
account O
largely O
for O
the O
phenotypic O
heterogeneity O
of O
G6PD B
deficiency I
. O

Tight O
linkage O
between O
myotonic B
dystrophy I
and O
apolipoprotein O
E O
genes O
revealed O
with O
allele O
- O
specific O
oligonucleotides O
. O

In O
16 O
families O
with O
myotonic B
dystrophy I
( O
DM B
) O
a O
novel O
approach O
based O
on O
use O
of O
allele O
- O
specific O
oligonucleotides O
has O
been O
employed O
to O
study O
the O
linkage O
relationship O
between O
the O
apolipoprotein O
E O
( O
APOE O
) O
gene O
and O
DM B
. O

Synthetic O
oligonucleotides O
, O
designed O
to O
discriminate O
between O
APOE O
alleles O
epsilon O
3 O
and O
epsilon O
4 O
, O
enabled O
us O
to O
distinguish O
heterozygous O
carriers O
in O
a O
hybridization O
assay O
. O

In O
a O
subset O
of O
families O
, O
the O
relevant O
segment O
of O
the O
APOE O
gene O
was O
enzymatically O
amplified O
to O
increase O
the O
sensitivity O
of O
the O
method O
. O

For O
DM O
and O
APOE O
, O
a O
maximum O
lod O
score O
( O
zmax O
of O
7 O
. O

47 O
was O
obtained O
at O
a O
recombination O
frequency O
( O
theta O
) O
of O
0 O
. O

047 O
( O
male O
theta O
= O
female O
theta O
) O
. O

No O
recombination O
( O
maximum O
lod O
score O
of O
5 O
. O
61 O
at O
theta O
= O
0 O
. O
0 O
) O
was O
found O
between O
APOE O
and O
the O
apolipoprotein O
CII O
( O
APOC2 O
) O
gene O
. O

These O
results O
suggest O
that O
, O
in O
addition O
to O
APOC2 O
, O
APOE O
is O
a O
useful O
marker O
for O
presymptomatic O
DM B
diagnosis O
. O

Regional O
localization O
of O
polymorphic O
DNA O
loci O
on O
the O
proximal O
long O
arm O
of O
the O
X O
chromosome O
using O
deletions O
associated O
with O
choroideremia B
. O

In O
two O
unrelated O
families O
, O
males O
have O
been O
identified O
who O
suffer O
from O
choroideremia B
and O
at O
the O
same O
time O
have O
an O
interstitial O
deletion O
on O
the O
proximal O
long O
arm O
of O
the O
X O
chromosome O
. O

By O
high O
- O
resolution O
banding O
we O
have O
characterized O
the O
deletion O
chromosomes O
as O
del O
( O
X O
) O
( O
q21 O
. O
1 O
- O
q21 O
1 O
- O
q21 O
. O
33 O
) O
and O
del O
( O
X O
) O
( O
q21 O
. O
2 O
- O
q21 O
2 O
- O
q21 O
. O
31 O
) O
respectively O
. O

By O
Southern O
blot O
analysis O
we O
have O
mapped O
ten O
different O
polymorphic O
DNA O
loci O
relative O
to O
the O
position O
of O
the O
deletion O
and O
the O
choroideremia B
locus O
TCD O
. O

One O
probe O
, O
p31 O
, O
was O
shown O
to O
cover O
one O
of O
the O
breakpoints O
of O
the O
smallest O
deletion O
. O

The O
following O
order O
of O
the O
loci O
was O
suggested O
by O
deletion O
mapping O
cen O
- O
DXS106 O
- O
DXS72 O
- O
TCD O
- O
( O
DXYS1 O
/ O
DXYS23 O
/ O
DXYS5 O
) O
- O
DXYS2 O
- O
( O
DXYS12 O
/ O
DXS3 O
) O
- O
( O
DXS17 O
/ O
DXS101 O
) O
- O
Xqter O
. O

Retroviral O
- O
mediated O
gene O
transfer O
of O
human O
phenylalanine O
hydroxylase O
into O
NIH O
3T3 O
and O
hepatoma B
cells O
. O

Phenylketonuria B
( O
PKU B
) O
is O
caused O
by O
deficiency B
of I
the I
hepatic I
enzyme I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

A O
full O
- O
length O
human O
PAH O
cDNA O
sequence O
has O
been O
inserted O
into O
pzip O
- O
neoSV O
( O
X O
) O
, O
which O
is O
a O
retroviral O
vector O
containing O
the O
bacterial O
neo O
gene O
. O

The O
recombinant O
has O
been O
transfected O
into O
psi O
2 O
cells O
, O
which O
provide O
synthesis O
of O
the O
retroviral O
capsid O
. O

Recombinant O
virus O
was O
detected O
in O
the O
culture O
medium O
of O
the O
transfected O
psi O
2 O
cells O
, O
which O
is O
capable O
of O
transmitting O
the O
human O
PAH O
gene O
into O
mouse O
NIH O
3T3 O
cells O
by O
infection O
leading O
to O
stable O
incorporation O
of O
the O
recombinant O
provirus O
. O

Infected O
cells O
express O
PAH O
mRNA O
, O
immunoreactive O
PAH O
protein O
, O
and O
exhibit O
pterin O
- O
dependent O
phenylalanine O
hydroxylase O
activity O
. O

The O
recombinant O
virus O
is O
also O
capable O
of O
infecting O
a O
mouse O
hepatoma B
cell O
line O
that O
does O
not O
normally O
synthesize O
PAH O
. O

PAH O
activity O
is O
present O
in O
the O
cellular O
extracts O
and O
the O
entire O
hydroxylation O
system O
is O
reconstituted O
in O
the O
hepatoma B
cells O
infected O
with O
the O
recombinant O
viruses O
. O

Thus O
, O
recombinant O
viruses O
containing O
human O
PAH O
cDNA O
provide O
a O
means O
for O
introducing O
functional O
PAH O
into O
mammalian O
cells O
of O
hepatic O
origin O
and O
can O
potentially O
be O
introduced O
into O
whole O
animals O
as O
a O
model O
for O
somatic O
gene O
therapy O
for O
PKU B
. O
. O

Estimation O
of O
the O
male O
to O
female O
ratio O
of O
mutation O
rates O
from O
the O
segregation O
of O
X O
- O
chromosomal O
DNA O
haplotypes O
in O
Duchenne B
muscular I
dystrophy I
families O
. O

A O
novel O
procedure O
is O
presented O
to O
estimate O
the O
ratio O
of O
male O
to O
female O
mutation O
rates O
for O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

X O
- O
specific O
restriction O
fragment O
length O
polymorphisms O
are O
used O
to O
establish O
DNA O
haplotypes O
in O
three O
- O
generation O
DMD B
families O
. O

From O
the O
proportion O
of O
DMD B
patients O
who O
have O
inherited O
their O
maternal O
grandfathers O
X O
chromosome O
, O
the O
ratio O
of O
mutation O
rates O
can O
be O
calculated O
. O

In O
contrast O
to O
classical O
methods O
, O
the O
proposed O
procedure O
is O
not O
restricted O
to O
sporadic O
or O
familiar O
cases O
nor O
is O
any O
information O
on O
the O
carrier O
status O
of O
female O
relatives O
required O
. O
. O

Deletions O
of O
a O
DNA O
sequence O
in O
retinoblastomas B
and O
mesenchymal B
tumors I
: O
organization O
of O
the O
sequence O
and O
its O
encoded O
protein O
. O

Retinoblastoma B
is O
a O
childhood B
tumor I
that O
can O
arise O
because O
of O
mutant O
alleles O
acquired O
as O
somatic O
or O
germinal O
mutations O
. O

The O
mutant O
allele O
can O
be O
carried O
in O
the O
germ O
line O
. O

The O
mutations O
creating O
these O
alleles O
act O
by O
inactivating O
copies O
of O
a O
recessive O
oncogene O
located O
within O
band O
q14 O
of O
chromosome O
13 O
and O
termed O
the O
RB1 O
locus O
. O

We O
have O
reported O
isolation O
of O
a O
cDNA O
fragment O
that O
recognizes O
chromosomal O
sequences O
possessing O
many O
of O
the O
attributes O
of O
the O
retinoblastoma B
gene O
associated O
with O
the O
RB1 O
locus O
. O

We O
now O
report O
that O
this O
segment O
is O
additionally O
the O
target O
of O
somatic O
mutations O
in O
mesenchymal B
tumors I
among O
patients O
having O
no O
apparent O
predisposition O
to O
retinoblastoma B
and O
no O
previous O
evidence O
of O
retinoblastoma B
. O

These O
tumors B
provide O
additional O
evidence O
that O
the O
cloned O
sequences O
are O
representative O
of O
a O
gene O
that O
is O
a O
frequent O
target O
of O
inactivation O
during O
tumorigenesis O
. O

Sequence O
analysis O
of O
this O
cDNA O
provides O
little O
insight O
into O
its O
normal O
functional O
role O
. O
. O

Treatment O
of O
Duchenne B
muscular I
dystrophy I
with O
growth O
hormone O
inhibitors O
. O

A O
controlled O
, O
double O
- O
blind O
therapeutic O
trial O
with O
the O
drug O
mazindol O
, O
a O
growth O
hormone O
inhibitor O
, O
was O
performed O
in O
a O
pair O
of O
7 O
1 O
/ O
2 O
year O
- O
old O
monozygotic O
twins O
, O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

The O
rationale O
for O
this O
trial O
was O
based O
on O
a O
patient O
( O
reported O
previously O
) O
affected O
simultaneously O
with O
DMD B
and O
growth B
hormone I
( I
GH I
) I
deficiency I
, O
who O
is O
showing O
a O
benign O
course O
of O
the O
dystrophic B
process I
and O
is O
still O
walking O
at O
18 O
years O
. O

One O
of O
the O
twins O
received O
2 O
mg O
of O
mazindol O
daily O
, O
while O
the O
other O
received O
a O
placebo O
. O

The O
assessment O
, O
repeated O
every O
2 O
months O
, O
included O
weight O
and O
height O
measurements O
, O
functional O
and O
motor O
ability O
tests O
, O
ergometry O
and O
determinations O
of O
serum O
enzymes O
and O
GH O
levels O
. O

After O
one O
year O
of O
trial O
the O
code O
was O
broken O
and O
it O
was O
seen O
that O
the O
twin O
under O
placebo O
treatment O
was O
strikingly O
worse O
than O
his O
brother O
, O
the O
progression O
of O
whose O
condition O
was O
practically O
arrested O
. O

These O
results O
strongly O
suggest O
that O
treatment O
with O
a O
GH O
inhibitor O
is O
beneficial O
for O
DMD B
patients O
. O
. O

Identification O
and O
localization O
of O
mutations O
at O
the O
Lesch B
- I
Nyhan I
locus O
by O
ribonuclease O
A O
cleavage O
. O

Many O
mutations O
leading O
to O
human O
disease O
are O
the O
result O
of O
single O
DNA O
base O
pair O
changes O
that O
cannot O
be O
identified O
by O
Southern O
analysis O
. O

This O
has O
prompted O
the O
development O
of O
alternative O
assays O
for O
point O
mutation O
detection O
. O

The O
recently O
described O
ribonuclease O
A O
cleavage O
procedure O
, O
with O
a O
polyuridylic O
acid O
- O
paper O
affinity O
chromatography O
step O
, O
has O
been O
used O
to O
identify O
the O
mutational O
lesions O
in O
the O
hypoxanthine O
phosphoribosyltransferase O
( O
HPRT O
) O
messenger O
RNAs O
of O
patients O
with O
Lesch B
- I
Nyhan I
syndrome I
. O

Distinctive O
ribonuclease O
A O
cleavage O
patterns O
were O
identified O
in O
messenger O
RNA O
from O
5 O
of O
14 O
Lesch B
- I
Nyhan I
patients O
who O
were O
chosen O
because O
no O
HPRT O
Southern O
or O
Northern O
blotting O
pattern O
changes O
had O
been O
found O
. O

This O
approach O
now O
allows O
HPRT O
mutation O
detection O
in O
50 O
percent O
of O
the O
cases O
of O
Lesch B
- I
Nyhan I
syndrome I
. O

The O
polyuridylic O
acid O
- O
paper O
affinity O
procedure O
provides O
a O
general O
method O
for O
analysis O
of O
low O
abundance O
messenger O
RNAs O
. O
. O

Two O
new O
variants O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
associated O
with O
hereditary B
non I
- I
spherocytic I
hemolytic I
anemia I
: O
G6PD O
Wayne O
and O
G6PD O
Huron O
. O

Two O
new O
deficient O
variants O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
causing O
hereditary B
nonspherocytic I
hemolytic I
anemia I
( O
HNSHA B
) O
are O
described O
. O

Both O
of O
these O
are O
unique O
and O
they O
have O
been O
named O
G6PD O
Wayne O
and O
G6PD O
Huron O
. O

Patients O
with O
G6PD O
Wayne O
underwent O
splenectomy O
and O
no O
objective O
improvement O
was O
noted O
. O

The O
patients O
with O
G6PD O
Huron O
were O
under O
medical O
observation O
for O
a O
considerable O
period O
of O
time O
without O
the O
diagnosis O
of O
G6PD B
deficiency I
being O
entertained O
because O
the O
family O
was O
of O
Northern O
European O
origin O
. O

Since O
sporadic O
variants O
of O
G6PD O
causing O
HNSHA B
show O
no O
special O
racial O
predilection O
, O
the O
diagnosis O
of O
G6PD B
deficiency I
should O
always O
be O
considered O
in O
patients O
with O
this O
syndrome O
. O
. O

Sialophorin O
, O
a O
surface O
sialoglycoprotein O
defective O
in O
the O
Wiskott B
- I
Aldrich I
syndrome I
, O
is O
involved O
in O
human O
T O
lymphocyte O
proliferation O
. O

The O
mAb O
L10 O
was O
used O
to O
determine O
the O
distribution O
and O
the O
function O
of O
sialophorin O
, O
the O
heavily O
glycosylated O
surface O
molecule O
that O
is O
deficient O
/ O
defective O
in O
lymphocytes O
of O
patients O
with O
the O
X B
- I
linked I
immunodeficiency I
Wiskott I
- I
Aldrich I
syndrome I
. O

Dual O
- O
parameter O
FACS O
analysis O
indicated O
that O
sialophorin O
is O
expressed O
on O
CD4 O
+ O
and O
CD8 O
+ O
lymphocytes O
, O
on O
a O
subpopulation O
of O
peripheral O
blood O
B O
lymphocytes O
, O
on O
all O
thymocytes O
, O
and O
on O
a O
subpopulation O
of O
bone O
marrow O
cells O
. O

Functional O
studies O
demonstrated O
that O
L10 O
mAb O
stimulates O
the O
proliferation O
of O
peripheral O
blood O
T O
lymphocytes O
as O
measured O
by O
stimulation O
of O
[ O
3H O
] O
thymidine O
incorporation O
. O

The O
time O
course O
and O
magnitude O
of O
increased O
[ O
3H O
] O
thymidine O
incorporation O
by O
T O
lymphocytes O
in O
response O
to O
L10 O
mAb O
paralleled O
that O
induced O
by O
anti O
- O
CD3 O
mAb O
. O

Effective O
stimulation O
was O
dependent O
on O
the O
presence O
of O
monocytes O
and O
the O
Fc O
portion O
of O
L10 O
mAb O
. O

Stimulation O
of O
lymphocytes O
by O
L10 O
, O
like O
stimulation O
by O
anti O
- O
CD3 O
mAb O
, O
involves O
increased O
expression O
of O
4F2 O
, O
HLA O
- O
DR O
, O
and O
IL O
- O
2 O
- O
R O
. O

These O
observations O
suggest O
that O
sialophorin O
functions O
in O
T O
cell O
activation O
. O
. O

Hypopigmentation B
in O
the O
Prader B
- I
Willi I
syndrome I
. O

Cutaneous B
and I
ocular I
pigmentation I
were O
evaluated O
in O
29 O
individuals O
with O
the O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Criteria O
for O
hypopigmentation B
included O
the O
presence O
of O
type O
I O
or O
II O
skin O
, O
the O
lightest O
skin O
type O
in O
the O
family O
by O
history O
, O
and O
iris O
translucency O
on O
globe O
transillumination O
. O

On O
the O
basis O
of O
these O
criteria O
, O
48 O
% O
of O
the O
PWS B
individuals O
were O
hypopigmented B
. O

The O
presence O
of O
hypopigmentation B
correlated O
with O
a O
small O
interstitial O
deletion O
on O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
; O
however O
, O
this O
deletion O
was O
also O
found O
in O
individuals O
who O
did O
not O
meet O
the O
full O
criteria O
for O
hypopigmentation B
. O

Hairbulb O
tyrosinase O
activity O
and O
glutathione O
content O
, O
as O
well O
as O
urine O
cysteinyldopa O
excretion O
, O
were O
low O
in O
PWS B
individuals O
with O
and O
without O
hypopigmentation B
and O
did O
not O
separate O
these O
two O
groups O
. O

We O
conclude O
that O
hypopigmentation B
is O
found O
in O
a O
significant O
proportion O
of O
individuals O
with O
PWS B
and O
that O
the O
hypopigmentation B
may O
be O
associated O
with O
a O
deletion O
of O
the O
long O
arm O
of O
chromosome O
15 O
. O

The O
mechanism O
for O
the O
hypopigmentation B
is O
unknown O
. O
. O

Phenotype O
heterogeneity O
among O
hemizygotes O
in O
a O
family O
biochemically O
screened O
for O
adrenoleukodystrophy B
. O

We O
report O
on O
two O
clinically O
, O
neurologically O
normal O
relatives O
of O
a O
boy O
affected O
by O
adrenoleukodystrophy B
( O
ALD B
) O
; O
they O
were O
found O
repeatedly O
to O
have O
the O
biochemical O
defect O
of O
an O
ALD B
hemizygote O
. O

The O
assay O
consisted O
in O
the O
determination O
of O
very O
- O
long O
- O
chain O
fatty O
acids O
in O
lyophilized O
and O
reconstituted O
plasma O
. O

While O
no O
evidence O
of O
neurologic B
disease I
( O
leukodystrophy B
or O
myeloneuropathy B
) O
was O
present O
in O
these O
hemizygotes O
, O
adrenocortical B
insufficiency I
provoking O
compensatory O
high O
ACTH O
release O
was O
found O
in O
both O
. O

These O
findings O
should O
be O
taken O
into O
consideration O
when O
counseling O
families O
in O
which O
cases O
with O
clinically O
expressed O
ALD B
are O
represented O
in O
several O
generations O
. O
. O

The O
mapping O
of O
a O
cDNA O
from O
the O
human O
X B
- I
linked I
Duchenne I
muscular I
dystrophy I
gene O
to O
the O
mouse O
X O
chromosome O
. O

The O
recent O
discovery O
of O
sequences O
at O
the O
site O
of O
the O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
in O
humans O
has O
opened O
up O
the O
possibility O
of O
a O
detailed O
molecular O
analysis O
of O
the O
genes O
in O
humans O
and O
in O
related O
mammalian O
species O
. O

Until O
relatively O
recently O
, O
there O
was O
no O
obvious O
mouse O
model O
of O
this O
genetic B
disease I
for O
the O
development O
of O
therapeutic O
strategies O
. O

The O
identification O
of O
a O
mouse O
X O
- O
linked O
mutant O
showing O
muscular B
dystrophy I
, O
mdx O
, O
has O
provided O
a O
candidate O
mouse O
genetic O
homologue O
to O
the O
DMD B
locus O
; O
the O
relatively O
mild O
pathological O
features O
of O
mdx O
suggest O
it O
may O
have O
more O
in O
common O
with O
mutations O
of O
the O
Becker B
muscular I
dystrophy I
type O
at O
the O
same O
human O
locus O
, O
however O
. O

But O
the O
close O
genetic O
linkage O
of O
mdx O
to O
G6PD O
and O
Hprt O
on O
the O
mouse O
X O
chromosome O
, O
coupled O
with O
its O
comparatively O
mild O
pathology O
, O
have O
suggested O
that O
the O
mdx O
mutation O
may O
instead O
correspond O
to O
Emery B
Dreifuss I
muscular I
dystrophy I
which O
itself O
is O
closely O
linked O
to O
DNA O
markers O
at O
Xq28 O
- O
qter O
in O
the O
region O
of O
G6PD O
on O
the O
human O
X O
chromosome O
. O

Using O
an O
interspecific O
mouse O
domesticus O
/ O
spretus O
cross O
, O
segregating O
for O
a O
variety O
of O
markers O
on O
the O
mouse O
X O
chromosome O
, O
we O
have O
positioned O
on O
the O
mouse O
X O
chromosome O
sequences O
homologous O
to O
a O
DMD B
cDNA O
clone O
. O

These O
sequences O
map O
provocatively O
close O
to O
the O
mdx O
mutation O
and O
unexpectedly O
distant O
from O
sparse O
fur O
, O
spf O
, O
the O
mouse O
homologue O
of O
OTC O
( O
ornithine O
transcarbamylase O
) O
which O
is O
closely O
linked O
to O
DMD B
on O
the O
human O
X O
chromosome O
. O
. O

Localization O
of O
the O
region O
homologous O
to O
the O
Duchenne B
muscular I
dystrophy I
locus O
on O
the O
mouse O
X O
chromosome O
. O

Recent O
progress O
has O
resulted O
in O
part O
of O
the O
gene O
mutated O
in O
Duchenne B
and I
the I
milder I
Becker I
muscular I
dystrophies I
being O
cloned O
and O
has O
suggested O
that O
the O
gene O
itself O
extends O
over O
1 O
, O
000 O
to O
2 O
, O
000 O
kilobases O
( O
kb O
) O
. O

To O
study O
how O
mutations O
in O
this O
gene O
affect O
muscle O
development O
and O
integrity O
, O
it O
would O
be O
of O
interest O
to O
have O
available O
a O
mouse O
model O
of O
the O
human O
disease O
. O

The O
mouse O
mdx O
mutation O
affects O
muscle O
and O
confers O
a O
mild O
dystrophic B
syndrome I
, O
but O
it O
is O
not O
clear O
whether O
this O
mutation O
is O
equivalent O
to O
Duchenne B
/ I
Becker I
muscular I
dystrophy I
in O
man O
. O

Here O
we O
describe O
the O
use O
of O
two O
sequences O
from O
the O
human O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
that O
cross O
- O
hybridize O
to O
mouse O
X O
- O
linked O
sequences O
to O
localize O
the O
gene O
homologous O
to O
DMD B
in O
the O
mouse O
. O

Both O
sequences O
map O
to O
the O
region O
of O
10 O
centimorgan O
lying O
between O
the O
Tabby O
( O
Ta O
) O
and O
St14 O
- O
1 O
( O
DxPas8 O
) O
loci O
, O
close O
to O
the O
phosphorylase O
b O
kinase O
locus O
( O
Phk O
) O
. O

By O
analogy O
with O
the O
human O
X O
- O
chromosome O
, O
we O
conclude O
that O
the O
region O
in O
the O
mouse O
around O
the O
G6pd O
and O
St14 O
- O
1 O
loci O
may O
contain O
two O
genes O
corresponding O
to O
distinct O
human O
myopathies B
Emery B
Dreifuss I
muscular I
dystrophy I
which O
is O
known O
to O
be O
closely O
linked O
to O
St14 O
- O
1 O
in O
man O
and O
the O
DMD B
homologue O
described O
here O
. O
. O

GT O
to O
AT O
transition O
at O
a O
splice O
donor O
site O
causes O
skipping O
of O
the O
preceding O
exon O
in O
phenylketonuria B
. O

Classical B
Phenylketonuria I
( O
PKU B
) O
is O
an O
autosomal B
recessive I
human I
genetic I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

We O
isolated O
several O
mutant O
PAH O
cDNA O
clones O
from O
a O
PKU B
carrier O
individual O
and O
showed O
that O
they O
contained O
an O
internal O
116 O
base O
pair O
deletion O
, O
corresponding O
precisely O
to O
exon O
12 O
of O
the O
human O
chromosomal O
PAH O
gene O
. O

The O
deletion O
causes O
the O
synthesis O
of O
a O
truncated O
protein O
lacking O
the O
C O
- O
terminal O
52 O
amino O
acids O
. O

Gene O
transfer O
and O
expression O
studies O
using O
the O
mutant O
PAH O
cDNA O
indicated O
that O
the O
deletion O
abolishes O
PAH O
activity O
in O
the O
cell O
as O
a O
result O
of O
protein O
instability O
. O

To O
determine O
the O
molecular O
basis O
of O
the O
deletion O
, O
the O
mutant O
chromosomal O
PAH O
gene O
was O
isolated O
from O
this O
individual O
and O
shown O
to O
contain O
a O
GT O
- O
- O
greater O
than O
AT O
substitution O
at O
the O
5 O
splice O
donor O
site O
of O
intron O
12 O
. O

Thus O
, O
the O
consequence O
of O
the O
splice O
donor O
site O
mutation O
in O
the O
human O
liver O
is O
the O
skipping O
of O
the O
preceding O
exon O
during O
RNA O
splicing O
. O
. O

Conservation O
of O
the O
Duchenne B
muscular I
dystrophy I
gene O
in O
mice O
and O
humans O
. O

A O
portion O
of O
the O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
gene O
transcript O
from O
human O
fetal O
skeletal O
muscle O
and O
mouse O
adult O
heart O
was O
sequenced O
, O
representing O
approximately O
25 O
percent O
of O
the O
total O
, O
14 O
- O
kb O
DMD B
transcript O
. O

The O
nucleic O
acid O
and O
predicted O
amino O
acid O
sequences O
from O
the O
two O
species O
are O
nearly O
90 O
percent O
homologous O
. O

The O
amino O
acid O
sequence O
that O
is O
predicted O
from O
this O
portion O
of O
the O
DMD B
gene O
indicates O
that O
the O
protein O
product O
might O
serve O
a O
structural O
role O
in O
muscle O
, O
but O
the O
abundance O
and O
tissue O
distribution O
of O
the O
messenger O
RNA O
suggests O
that O
the O
DMD B
protein O
is O
not O
nebulin O
. O
. O

Familial O
Prader B
- I
Willi I
syndrome I
with O
apparently O
normal O
chromosomes O
. O

We O
report O
on O
4 O
sibs O
( O
2F O
, O
2M O
) O
with O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Diagnosis O
was O
made O
clinically O
on O
the O
basis O
of O
history O
, O
behavior O
, O
and O
physical O
findings O
in O
3 O
of O
the O
sibs O
. O

The O
other O
child O
had O
died O
at O
age O
10 O
months O
with O
a O
history O
and O
clinical O
findings O
typical O
of O
first O
phase O
of O
PWS B
. O

Results O
of O
chromosome O
studies O
on O
the O
parents O
and O
surviving O
sibs O
were O
normal O
. O

The O
implications O
of O
this O
unusual O
familial O
occurrence O
for O
our O
understanding O
of O
PWS B
are O
discussed O
. O
. O

Nebulin O
and O
titin O
expression O
in O
Duchenne B
muscular I
dystrophy I
appears O
normal O
. O

Monoclonal O
antibodies O
which O
recognize O
different O
epitopes O
on O
either O
titin O
or O
nebulin O
show O
normal O
staining O
patterns O
on O
frozen O
sections O
of O
three O
muscle O
biopsies O
of O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

Gel O
electrophoresis O
and O
immunoblotting O
performed O
on O
two O
of O
these O
muscle O
biopsies O
show O
the O
normal O
pattern O
of O
titin O
and O
nebulin O
polypeptides O
. O

Since O
the O
donor O
of O
one O
of O
these O
biopsies O
has O
a O
large O
deletion O
of O
the O
5 O
- O
region O
of O
the O
DMD B
gene O
, O
our O
results O
argue O
against O
the O
recent O
proposal O
that O
nebulin O
is O
the O
gene O
mutated O
in O
DMD B
. O
. O

Heterozygous B
C2 I
deficiency I
associated O
with O
angioedema B
, O
myasthenia B
gravis I
, O
and O
systemic B
lupus I
erythematosus I
. O

We O
describe O
a O
patient O
with O
myasthenia B
gravis I
, O
systemic B
lupus I
erythematosus I
, O
and O
angioedema B
associated O
with O
heterozygous O
complement B
factor I
2 I
( I
C2 I
) I
deficiency I
. O

The O
significance O
of O
this O
association O
is O
controversial O
, O
though O
the O
association O
of O
C2 B
deficiency I
with O
certain O
histocompatibility O
antigens O
suggests O
possible O
linkage O
to O
immune O
response O
genes O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
of O
heterozygous O
C2 B
deficiency I
in O
association O
with O
this O
combination O
of O
autoimmune B
disorders I
, O
and O
we O
discuss O
the O
aetiological O
implications O
. O
. O

Genetic O
analysis O
of O
an O
inherited O
deficiency B
of I
the I
third I
component I
of I
complement I
in O
Brittany O
spaniel O
dogs O
. O

Genetically O
determined O
C3 B
deficiency I
in O
Brittany O
spaniel O
dogs O
shares O
a O
number O
of O
biochemical O
and O
clinical O
characteristics O
with O
the O
human O
disorder O
. O

In O
humans O
, O
the O
gene O
for O
C3 B
deficiency I
is O
a O
null O
gene O
that O
is O
allelic O
to O
the O
structural O
gene O
for O
C3 O
and O
is O
not O
linked O
to O
the O
major O
histocompatibility O
locus O
. O

The O
current O
study O
used O
allotype O
analysis O
of O
canine O
C3 O
in O
order O
to O
demonstrate O
that O
the O
gene O
for O
C3 B
deficiency I
in O
these O
dogs O
is O
also O
a O
null O
gene O
allelic O
to O
the O
structural O
gene O
for O
C3 O
. O

In O
addition O
, O
preliminary O
pedigree O
analysis O
suggests O
that O
the O
gene O
for O
canine O
C3 B
deficiency I
is O
apparently O
not O
closely O
linked O
to O
the O
major O
histocompatibility O
complex O
of O
the O
dog O
. O

Thus O
, O
it O
appears O
that O
C3 B
deficiency I
in O
Brittany O
spaniel O
dogs O
not O
only O
shares O
biochemical O
and O
clinical O
features O
with O
C3 B
deficiency I
in O
humans O
, O
but O
also O
shares O
some O
genetic O
characteristics O
with O
the O
human O
disorder O
. O
. O

Gene O
transfer O
and O
expression O
of O
human O
phenylalanine O
hydroxylase O
. O

Phenylketonuria B
( O
PKU B
) O
is O
caused O
by O
a O
genetic O
deficiency B
of I
the I
enzyme I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

A O
full O
- O
length O
complementary O
DNA O
clone O
of O
human O
PAH O
was O
inserted O
into O
a O
eukaryotic O
expression O
vector O
and O
transferred O
into O
mouse O
NIH3T3 O
cells O
which O
do O
not O
normally O
express O
PAH O
. O

The O
transformed O
mouse O
cells O
expressed O
PAH O
messenger O
RNA O
, O
immunoreactive O
protein O
, O
and O
enzymatic O
activity O
that O
are O
characteristic O
of O
the O
normal O
human O
liver O
products O
, O
demonstrating O
that O
a O
single O
gene O
contains O
all O
of O
the O
necessary O
genetic O
information O
to O
code O
for O
functional O
PAH O
. O

These O
results O
support O
the O
use O
of O
the O
human O
PAH O
probe O
in O
prenatal O
diagnosis O
and O
detection O
of O
carriers O
, O
to O
provide O
new O
opportunities O
for O
the O
biochemical O
characterization O
of O
normal O
and O
mutant O
enzymes O
, O
and O
in O
the O
investigation O
of O
alternative O
genetic O
therapies O
for O
PKU B
. O
. O

Regional O
mapping O
of O
the O
phenylalanine O
hydroxylase O
gene O
and O
the O
phenylketonuria B
locus O
in O
the O
human O
genome O
. O

Phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
of O
amino O
acid O
metabolism O
caused O
by O
a O
deficiency B
of I
the I
hepatic I
enzyme I
phenylalanine I
hydroxylase I
( O
PAH O
; O
phenylalanine O
4 O
- O
monooxygenase O
, O
EC O
1 O
. O
14 O
. O
16 O
. O
1 O
) O
. O

A O
cDNA O
clone O
for O
human O
PAH O
has O
previously O
been O
used O
to O
assign O
the O
corresponding O
gene O
to O
human O
chromosome O
12 O
. O

To O
define O
the O
regional O
map O
position O
of O
the O
disease O
locus O
and O
the O
PAH O
gene O
on O
human O
chromosome O
12 O
, O
DNA O
was O
isolated O
from O
human O
- O
hamster O
somatic O
cell O
hybrids O
with O
various O
deletions O
of O
human O
chromosome O
12 O
and O
was O
analyzed O
by O
Southern O
blot O
analysis O
using O
the O
human O
cDNA O
PAH O
clone O
as O
a O
hybridization O
probe O
. O

From O
these O
results O
, O
together O
with O
detailed O
biochemical O
and O
cytogenetic O
characterization O
of O
the O
hybrid O
cells O
, O
the O
region O
on O
chromosome O
12 O
containing O
the O
human O
PAH O
gene O
has O
been O
defined O
as O
12q14 O
. O

3 O
- O
- O
- O
- O
qter O
3 O
- O
- O
- O
- O
qter O
. O

The O
PAH O
map O
position O
on O
chromosome O
12 O
was O
further O
localized O
by O
in O
situ O
hybridization O
of O
125I O
- O
labeled O
human O
PAH O
cDNA O
to O
chromosomes O
prepared O
from O
a O
human O
lymphoblastoid O
cell O
line O
. O

Results O
of O
these O
experiments O
demonstrated O
that O
the O
region O
on O
chromosome O
12 O
containing O
the O
PAH O
gene O
and O
the O
PKU B
locus O
in O
man O
is O
12q22 O
- O
- O
- O
- O
12q24 O
. O

1 O
. O

These O
results O
not O
only O
provide O
a O
regionalized O
map O
position O
for O
a O
major O
human O
disease O
locus O
but O
also O
can O
serve O
as O
a O
reference O
point O
for O
linkage O
analysis O
with O
other O
DNA O
markers O
on O
human O
chromosome O
12 O

Heterogeneity O
of O
type B
I I
von I
Willebrand I
disease I
: O
evidence O
for O
a O
subgroup O
with O
an O
abnormal O
von B
Willebrand I
factor O
. O

Type B
I I
von I
Willebrand I
disease I
( O
vWD B
) O
is O
characterized O
by O
equally O
low O
plasma O
concentrations O
of O
von B
Willebrand I
factor O
antigen O
( O
vWF O
Ag O
) O
and O
ristocetin O
cofactor O
( O
RiCof O
) O
and O
by O
the O
presence O
of O
all O
vWF O
multimers O
in O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
- O
agarose O
gel O
electrophoresis O
. O

For O
17 O
patients O
( O
13 O
kindreds O
) O
diagnosed O
with O
these O
criteria O
, O
we O
have O
studied O
the O
platelet O
contents O
of O
vWF O
Ag O
and O
RiCof O
and O
the O
changes O
of O
these O
in O
plasma O
after O
DDAVP O
infusion O
. O

Platelet O
vWF O
Ag O
and O
RiCof O
were O
normal O
in O
four O
kindreds O
( O
called O
" O
platelet O
normal O
" O
subgroup O
) O
; O
following O
1 O
- O
deamino O
- O
8 O
- O
D O
- O
arginine O
vasopressin O
; O
plasma O
vWF O
Ag O
, O
RiCof O
and O
the O
bleeding O
time O
( O
BT O
) O
became O
normal O
. O

In O
six O
kindreds O
, O
platelet O
vWF O
Ag O
and O
RiCof O
were O
equally O
low O
( O
platelet O
low O
) O
; O
after O
DDAVP O
, O
plasma O
vWF O
Ag O
and O
RiCof O
remained O
low O
, O
and O
the O
BT O
was O
prolonged O
. O

In O
three O
additional O
kindreds O
, O
platelets O
contained O
normal O
concentrations O
of O
vWF O
Ag O
, O
but O
RiCof O
was O
very O
low O
( O
platelet O
discordant O
) O
; O
even O
though O
a O
complete O
set O
of O
multimers O
was O
found O
in O
plasma O
and O
platelets O
, O
there O
was O
a O
relatively O
small O
amount O
of O
large O
multimers O
. O

After O
DDAVP O
, O
plasma O
vWF O
Ag O
became O
normal O
, O
but O
RiCof O
remained O
low O
and O
the O
BT O
was O
very O
prolonged O
. O

These O
findings O
demonstrated O
that O
there O
can O
be O
an O
abnormal O
vWF O
( O
RiCof O
less O
than O
vWF O
Ag O
) O
even O
in O
type B
I I
vWD I
, O
coexisting O
with O
a O
complete O
set O
of O
vWF O
multimers O
( O
platelet O
discordant O
) O
; O
that O
the O
abnormal O
vWF O
can O
be O
shown O
more O
clearly O
in O
platelets O
than O
in O
plasma O
or O
else O
in O
plasma O
after O
DDAVP O
infusion O
; O
and O
that O
DDAVP O
normalizes O
the O
BT O
only O
in O
those O
patients O
with O
normal O
platelet O
levels O
of O
both O
vWF O
Ag O
and O
RiCof O
( O
platelet O
normal O
) O
. O
. O

Genetic O
analysis O
in O
families O
with O
van B
der I
Woude I
syndrome I
. O

We O
have O
brought O
together O
information O
on O
864 O
affected O
individuals O
in O
164 O
families O
( O
including O
three O
new O
pedigrees O
) O
reported O
in O
the O
137 O
year O
period O
since O
1845 O
when O
Demarquay O
first O
described O
a O
family O
with O
what O
was O
later O
called O
van B
der I
Woude I
syndrome I
( O
VWS B
) O
. O

Both O
types O
of O
oral B
cleft I
, O
cleft B
palate I
( O
CP B
) O
and O
cleft B
lip I
with O
or O
without O
CP B
( O
CLP B
) O
, O
segregate O
in O
these O
families O
together O
with O
lower O
lip B
pits I
or O
fistulae B
in O
an O
autosomal O
dominant O
mode O
with O
high O
penetrance O
estimated O
to O
be O
K O
= O
. O

89 O
and O
. O

99 O
by O
different O
methods O
. O

Cleft O
types O
( O
CLP B
and O
CP B
) O
occur O
in O
VWS B
in O
the O
same O
proportions O
as O
in O
the O
general O
non O
- O
VWS O
population O
, O
ie O
, O
about O
twice O
as O
many O
cleft O
- O
bearing O
individuals O
have O
CLP B
as O
have O
CP B
. O

On O
the O
other O
hand O
, O
we O
do O
not O
find O
the O
usually O
observed O
excess O
of O
females O
with O
CP B
and O
excess O
of O
males O
with O
CLP B
; O
in O
VWS B
the O
sex O
ratios O
are O
more O
nearly O
equal O
. O

Lip B
pits I
also O
are O
equally O
distributed O
between O
the O
sexes O
. O

Affected O
males O
and O
females O
are O
equally O
likely O
to O
transmit O
VWS B
. O

However O
, O
there O
is O
an O
excess O
of O
less O
severely O
affected O
individuals O
among O
transmitters O
and O
a O
deficiency O
of O
more O
severely O
affected O
, O
brought O
about O
by O
a O
proband O
bias O
and O
differential O
fecundity O
. O

The O
expression O
of O
VWS B
is O
significantly O
modified O
by O
the O
genetic O
background O
More O
extreme O
phenotypes O
in O
parents O
tend O
to O
produce O
more O
extreme O
expression O
in O
their O
children O
. O

For O
a O
VWS B
gene O
carrier O
the O
relative O
risk O
of O
transmitting O
a O
cleft O
is O
26 O
. O

45 O
% O
; O
that O
of O
transmitting O
lower O
lip B
pits I
is O
23 O
. O

55 O
% O
. O

Three O
pedigrees O
of O
lip B
pits I
in O
the O
literature O
show O
no O
clefts O
among O
a O
significant O
number O
of O
affected O
individuals O
. O

Control O
of O
gene O
expression O
in O
VWS B
in O
the O
three O
target O
tissues O
appears O
to O
be O
independent O
and O
separately O
designated O
. O

Mutation O
rate O
of O
the O
VWS B
gene O
is O
calculated O
to O
be O
1 O
. O

8 O
X O
10 O
( O
- O
5 O
) O

Hereditary B
C7 I
deficiency I
. O

Diagnosis O
and O
HLA O
studies O
in O
a O
French O
- O
Canadian O
family O
. O

The O
serum O
of O
a O
44 O
- O
yr O
- O
old O
woman O
of O
French O
- O
Canadian O
descent O
having O
a O
B O
- O
27 O
positive O
ankylosing B
spondylitis I
was O
deficient B
in I
the I
seventh I
component I
of I
complement I
( O
C7 O
) O
as O
determined O
by O
hemolytic O
and O
immunochemical O
methods O
. O

No O
inhibitor O
against O
C7 O
was O
detected O
, O
and O
the O
levels O
of O
all O
other O
complement O
components O
were O
normal O
. O

No O
deficiency O
in O
the O
opsonic O
activity O
of O
the O
serum O
was O
found O
, O
and O
the O
results O
of O
basic O
coagulation O
studies O
of O
the O
plasma O
were O
normal O
. O

On O
investigation O
of O
the O
patients O
family O
, O
two O
sisters O
were O
found O
to O
have O
the O
same O
deficiency O
but O
were O
otherwise O
in O
good O
health O
. O

The O
seven O
other O
siblings O
were O
heterozygous O
for O
C7 B
deficiency I
, O
while O
the O
paternal O
aunt O
had O
a O
normal O
C7 O
level O
. O

In O
the O
third O
generation O
, O
six O
children O
of O
the O
three O
homozygous O
sisters O
and O
five O
children O
of O
heterozygotes O
were O
available O
for O
testing O
. O

Studies O
of O
the O
HLA O
antigens O
in O
all O
the O
22 O
subjects O
and O
in O
three O
spouses O
indicated O
no O
close O
linkage O
between O
the O
CM B
deficienty I
and O
the O
HLA O
system O
. O

In O
addition O
, O
the O
simultaneous O
occurrence O
of O
two O
hereditary O
complement B
deficiencies I
( I
C2 I
and I
C7 I
) I
was O
discovered O
in O
one O
family O
of O
this O
remarkable O
kindred O
. O
. O

Genetic O
defect B
in I
secretion I
of I
complement I
C5 I
in O
mice O
. O

A O
genetic O
deficiency B
of I
the I
fifth I
( I
C5 I
) I
component I
of I
complement1 I
- I
3 I
, O
a O
serum O
glycoprotein O
of O
molecular O
weight O
( O
MW O
) O
220 O
, O
000 O
( O
ref O
. O
4 O
) O
, O
has O
been O
found O
in O
39 O
% O
of O
inbred O
strains O
of O
mice3 O
. O

Sera O
of O
deficient O
mice O
lack O
detectable O
C5 O
activity O
and O
protein2 O
, O
3 O
. O

In O
addition O
deficient O
mice O
produce O
antibody O
to O
mouse O
C5 O
when O
injected O
with O
sera O
from O
C5 O
sufficient O
( O
normal O
) O
strains O
. O

Levy O
et O
al O
. O

5 O
showed O
that O
somatic O
cell O
hybrids O
between O
C5 O
deficient O
( O
B10 O
. O
D2 O
/ O
old O
line O
) O
macrophages O
and O
either O
C5 O
sufficient O
( O
B10 O
. O
D2 O
/ O
new O
line O
) O
mouse O
kidney O
or O
chicken O
erythroblasts O
secreted O
haemolytically O
active O
mouse O
C5 O
in O
vitro O
. O

Several O
possible O
molecular O
mechanisms O
to O
account O
for O
the O
findings O
were O
considered O
, O
but O
insufficient O
direct O
data O
were O
available O
to O
choose O
among O
them O
. O

We O
recently O
reported O
that O
mouse O
( O
CD O
. O
1 O
strain O
) O
peritoneal O
cells O
in O
culture O
synthesise O
and O
secrete O
a O
single O
chain O
precursor O
, O
pro O
- O
C5 O
( O
MW O
approximately O
210 O
, O
000 O
) O
, O
of O
the O
two O
- O
chain O
( O
alpha O
chain O
, O
125 O
, O
000 O
and O
beta O
chain O
83 O
, O
000 O
MW O
) O
C5 O
protein6 O
. O

Radiolabelled O
precursor O
C5 O
was O
contained O
within O
the O
cells O
and O
was O
secreted O
into O
the O
tissue O
culture O
media O
. O

Using O
similar O
methods O
, O
we O
now O
find O
that O
C5 B
deficiency I
in O
each O
of O
five O
different O
mouse O
strains O
( O
AKR O
, O
SWR O
, O
DBA O
/ O
2J8 O
A O
/ O
HeJ O
and O
B10 O
. O
D2 O
/ O
old O
line O
) O
is O
due O
to O
a O
failure O
in O
secretion O
of O
C5 O
protein O
and O
not O
to O
a O
failure O
in O
biosynthesis O
of O
pro O
- O
C5 O

Recurrent O
meningococcal B
meningitis I
with O
absence B
of I
the I
sixth I
component I
of I
complement I
: O
an O
evaluation O
of O
underlying O
immunologic O
mechanisms O
. O

A O
51 O
/ O
2 O
- O
year O
- O
old O
black O
girl O
with O
recurrent O
meningococcal B
meningitis I
and O
absence B
of I
the I
sixth I
component I
of I
complement I
( O
C6 O
) O
is O
reported O
. O

To O
explore O
the O
pathogenesis O
of O
recurrent O
neisserial B
infections I
in O
C6 B
deficiency I
, O
a O
detailed O
analysis O
of O
her O
immune O
competence O
was O
conducted O
. O

Her O
serum O
had O
normal O
chemotactic O
, O
opsonic O
, O
alternative O
complement O
pathway O
, O
and O
specific O
antibody O
activity O
, O
but O
lacked O
complement O
- O
mediated O
bacteriolytic O
activity O
. O

In O
addition O
, O
her O
C6 B
- I
deficient I
serum O
was O
indistinguishable O
from O
normal O
serum O
in O
a O
complement O
- O
dependent O
assay O
of O
phagocyte O
bactericidal O
activity O
. O

Absent O
bacteriolysis O
remains O
the O
only O
consistent O
defect O
associated O
with O
recurrent O
neisserial B
infections I
and O
absence O
of O
one O
of O
the O
late O
- O
acting O
complement O
components O
. O
. O

Deficiency B
of I
the I
fifth I
component I
of I
complement I
in O
human O
subjects O
. O

Clinical O
, O
genetic O
and O
immunologic O
studies O
in O
a O
large O
kindred O
. O

The O
discovery O
of O
a O
large O
kindred O
with O
a O
heritable O
deficiency B
of I
the I
fifth I
component I
of I
complement I
( O
C5 O
) O
has O
permitted O
the O
accumulation O
of O
new O
clinical O
, O
genetic O
and O
immunologic O
data O
concerning O
the O
role O
of O
C5 O
in O
human O
subjects O
. O

The O
proband O
, O
who O
has O
had O
nine O
episodes O
of O
disseminated O
gonococcal B
infection I
, O
has O
a O
hemolytic O
C5 O
level O
of O
approximately O
0 O
. O

5 O
per O
cent O
of O
normal O
. O

No O
C5 O
protein O
was O
detectable O
, O
but O
low O
levels O
of O
functional O
C5 O
activity O
could O
be O
found O
using O
a O
sensitive O
bactericidal O
assay O
. O

The O
probands O
twin O
as O
well O
as O
another O
sister O
also O
had O
extremely O
low O
levels O
of O
hemolytic O
C5 O
( O
approximately O
0 O
. O
5 O
per O
cent O
normal O
) O
, O
but O
both O
these O
subjects O
have O
been O
healthy O
. O

Hemolytic O
complement O
and O
bacteriolytic O
activity O
could O
be O
restored O
by O
the O
addition O
of O
purified O
C5 O
. O

No O
chemotactic O
activity O
for O
polymorphonuclear O
leukocytes O
could O
be O
generated O
in O
the O
C5 B
- I
deficient I
serums O
upon O
activation O
of O
either O
the O
classic O
or O
alternative O
pathways O
, O
again O
demonstrating O
the O
importance O
of O
C5 O
in O
human O
subjects O
for O
the O
production O
of O
chemotactic O
factors O
. O

The O
chemotactic O
responsiveness O
of O
the O
patients O
polymorphonuclear O
leukocytes O
and O
monocytes O
to O
preformed O
chemotactic O
factors O
was O
not O
depressed O
. O

Twenty O
- O
two O
of O
32 O
other O
family O
members O
from O
three O
generations O
had O
depressed O
whole O
hemolytic O
complement O
levels O
. O

In O
19 O
of O
30 O
family O
members O
, O
levels O
of O
hemolytic O
C5 O
ranged O
from O
13 O
to O
64 O
per O
cent O
of O
normal O
. O

No O
linkage O
for O
C5 B
deficiency I
and O
the O
A O
or O
B O
loci O
of O
the O
major O
histocompatibility O
complex O
could O
be O
found O
. O

These O
data O
suggest O
an O
autosomal O
codominant O
mode O
of O
inheritance O
of O
C5 B
deficiency I
. O

Deficiency B
of I
C5 I
is O
compatible O
with O
good O
health O
, O
but O
it O
can O
be O
associated O
with O
repeated O
disseminated O
gonococcal B
infection I

Incidence O
and O
characteristics O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variants O
in O
Japan O
. O

A O
total O
of O
3000 O
men O
living O
in O
Yamaguchi O
were O
screened O
for O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
using O
Beutlers O
spot O
test O
and O
three O
types O
of O
starch O
gel O
electrophoresis O
. O

These O
electrophoresis O
used O
a O
phosphate O
buffer O
system O
at O
pH O
7 O
. O

0 O
, O
a O
TRIS O
- O
EDTA O
- O
borate O
buffer O
system O
at O
pH O
8 O
. O

6 O
, O
and O
a O
TRIS O
- O
hydrochloride O
buffer O
system O
at O
pH O
8 O
. O
. O

Fifteen O
G6PD B
- I
deficient I
variants O
were O
found O
at O
the O
rate O
of O
0 O
. O

5 O
% O
and O
classified O
into O
four O
groups O
. O

As O
new O
variants O
, O
G6PD O
Konan O
, O
Kamiube O
, O
and O
Kiwa O
were O
identified O
. O

These O
three O
variants O
had O
a O
mild O
to O
moderate O
G6PD B
deficiency I
and O
were O
not O
associated O
with O
any O
clinical O
signs O
. O

G6PD O
Konan O
had O
fast O
electrophoretic O
mobility O
as O
compared O
with O
normal O
levels O
, O
G6PD O
Kiwa O
had O
slightly O
elevated O
electrophoretic O
mobility O
, O
and O
G6PD O
Kamiube O
had O
normal O
electrophoretic O
mobility O
. O

These O
three O
variants O
had O
normal O
levels O
of O
Km O
G6P O
, O
Km O
NADP O
, O
and O
Ki O
NADPH O
, O
normal O
utilizations O
of O
both O
2 O
- O
deoxy O
- O
G6P O
and O
deamino O
- O
NAPD O
, O
normal O
heat O
stability O
, O
and O
a O
normal O
pH O
curve O
. O

The O
other O
variant O
was O
G6PD O
Ube O
, O
which O
we O
had O
previously O
found O
in O
Yamaguchi O
( O
Nakashima O
et O
al O
. O
, O
1977 O
) O
. O

One O
boy O
with O
G6PD O
Ube O
was O
Korean O

Utilization O
of O
purines O
by O
an O
HPRT O
variant O
in O
an O
intelligent O
, O
nonmutilative O
patient O
with O
features O
of O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

The O
patient O
, O
H O
. O

Chr O
. O

B O
. O
, O
was O
among O
the O
first O
reported O
with O
hyperuricemia B
and O
central B
nervous I
system I
symptoms I
. O

He O
has O
been O
found O
to O
have O
a O
variant O
of O
hypoxanthine O
guanine O
phosphoribosyl O
transferase O
( O
HPRT O
; O
E O
. O
C O
. O
2 O
. O
4 O
. O
2 O
. O
8 O
) O
distinct O
from O
the O
enzyme O
present O
in O
patients O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

The O
patient O
had O
chroeoathetosis B
, O
spasticity B
, O
dysarthric B
speech I
, O
and O
hyperuricemia B
. O

However O
, O
his O
intelligence O
was O
normal O
and O
he O
had O
no O
evidence O
of O
self O
- O
mutilation O
. O

There O
was O
no O
activity O
of O
HPRT O
in O
the O
lysates O
of O
erythrocytes O
and O
cultured O
fibroblasts O
when O
analyzed O
in O
the O
usual O
manner O
. O

Using O
a O
newly O
developed O
method O
for O
the O
study O
of O
purine O
metabolism O
in O
intact O
cultured O
cells O
, O
this O
patient O
was O
found O
to O
metabolize O
some O
9 O
% O
of O
8 O
- O
14C O
- O
hypoxanthine O
, O
and O
90 O
% O
of O
the O
isotope O
utilized O
was O
converted O
to O
adenine O
and O
guanine O
nucleotides O
. O

In O
contrast O
, O
cells O
from O
patients O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
were O
virtually O
completely O
unable O
to O
convert O
hypoxanthine O
to O
nucleotides O
. O

The O
patients O
fibroblasts O
were O
even O
more O
efficient O
in O
the O
metabolism O
of O
8 O
- O
14C O
- O
guanine O
, O
which O
was O
utilized O
to O
the O
extent O
of O
27 O
% O
, O
over O
80 O
% O
of O
which O
was O
converted O
to O
guanine O
and O
adenine O
nucleotides O
. O

The O
growth O
of O
the O
cultured O
fibroblasts O
of O
this O
patient O
was O
intermediate O
in O
media O
containing O
hypoxanthine O
aminopterin O
thymidine O
( O
HAT O
) O
, O
whereas O
the O
growth O
of O
Lesch B
- I
Nyhan I
cells O
was O
inhibited O
and O
normal O
cells O
grew O
normally O
. O

Similarly O
in O
8 O
- O
azaguanine O
, O
6 O
- O
thioguanine O
, O
and O
8 O
- O
azahypoxanthine O
, O
the O
growth O
of O
the O
patients O
cells O
was O
intermediate O
between O
normal O
and O
Lesch B
- I
Nyhan I
cells O
. O

These O
observations O
provide O
further O
evidence O
for O
genetic O
heterogeneity O
among O
patients O
with O
disorders O
in O
purine O
metabolism O
involving O
the O
HPRT O
gene O
. O

They O
document O
that O
this O
famous O
patient O
did O
not O
have O
the O
Lesch B
- I
Nyhan I
syndrome I

Localisation O
of O
the O
Becker B
muscular I
dystrophy I
gene O
on O
the O
short O
arm O
of O
the O
X O
chromosome O
by O
linkage O
to O
cloned O
DNA O
sequences O
. O

A O
linkage O
study O
in O
30 O
Becker B
muscular I
dystrophy I
( O
BMD B
) O
kindreds O
using O
three O
cloned O
DNA O
sequences O
from O
the O
X O
chromosome O
which O
demonstrate O
restriction O
fragment O
length O
polymorphisms O
( O
RFLPs O
) O
, O
suggests O
that O
the O
BMD B
gene O
is O
located O
on O
the O
short O
arm O
of O
the O
X O
chromosome O
, O
in O
the O
p21 O
region O
. O

The O
genes O
for O
Becker B
and I
Duchenne I
dystrophies I
must O
therefore O
be O
closely O
linked O
, O
if O
not O
allelic O
, O
and O
any O
future O
DNA O
probes O
found O
to O
be O
of O
practical O
use O
in O
one O
disorder O
should O
be O
equally O
applicable O
to O
the O
other O
. O

The O
linkage O
analysis O
also O
provides O
data O
on O
the O
frequency O
of O
recombination O
along O
the O
short O
arm O
of O
the O
X O
chromosome O
, O
and O
across O
the O
centromeric O
region O
. O
. O

Molecular O
evidence O
for O
new O
mutation O
at O
the O
hprt O
locus O
in O
Lesch B
- I
Nyhan I
patients O
. O

Hypoxanthine O
- O
guanine O
phosphoribosyltransferase O
( O
HPRT O
; O
EC2 O
. O
4 O
. O
2 O
. O
8 O
) O
, O
which O
functions O
in O
the O
metabolic O
salvage O
of O
purines O
, O
is O
encoded O
by O
an O
X O
- O
linked O
gene O
in O
man O
. O

Partial O
HPRT B
deficiencies I
are O
associated O
with O
gouty B
arthritis I
, O
while O
absence O
of O
activity O
results O
in O
Lesch B
- I
Nyhan I
syndrome I
( O
L B
- I
N I
) O
. O

L B
- I
N I
patients O
fail O
to O
reproduce O
and O
the O
heterozygous O
state O
appears O
to O
confer O
no O
selective O
advantage O
. O

Thus O
, O
Haldanes O
principle O
predicts O
that O
new O
mutations O
at O
the O
hprt O
locus O
must O
occur O
frequently O
in O
order O
for O
L B
- I
N I
syndrome I
to O
be O
maintained O
in O
the O
population O
. O

This O
constant O
introduction O
of O
new O
mutations O
would O
be O
expected O
to O
result O
in O
a O
heterogeneous O
collection O
of O
genetic B
lesions I
, O
some O
of O
which O
may O
be O
novel O
. O

As O
we O
report O
here O
, O
the O
mutations O
in O
the O
hprt O
gene O
of O
seven O
L B
- I
N I
patients O
, O
selected O
from O
an O
initial O
survey O
of O
28 O
patients O
, O
have O
been O
characterized O
and O
all O
were O
found O
to O
be O
distinctly O
different O
, O
as O
predicted O
. O

The O
origin O
of O
one O
unusual O
mutation O
has O
been O
identified O
by O
analysis O
of O
DNA O
from O
four O
generations O
of O
family O
members O
. O

Further O
molecular O
analysis O
of O
the O
origin O
of O
new O
mutations O
at O
the O
hprt O
locus O
should O
aid O
in O
resolving O
the O
issue O
of O
an O
apparent O
difference O
in O
the O
frequency O
of O
hprt O
mutations O
in O
males O
and O
females O

Allelic O
exclusion O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
in O
platelets O
and O
T O
lymphocytes O
from O
a O
Wiskott B
- I
Aldrich I
syndrome I
carrier O
. O

An O
obligate O
carrier O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
who O
was O
also O
heterozygous O
for O
the O
A O
and O
B O
types O
of O
X O
- O
linked O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
was O
found O
. O

With O
her O
it O
became O
possible O
to O
determine O
whether O
allelic O
exclusion O
occurs O
in O
particular O
cell O
- O
types O
of O
the O
WAS B
carrier O
. O

If O
so O
, O
the O
remaining O
cells O
of O
a O
particular O
cell O
- O
type O
would O
express O
only O
the O
normal O
X O
chromosome O
and O
only O
one O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
isoenzyme O
would O
be O
demonstrable O
. O

This O
carrier O
had O
only O
the O
B O
isoenzyme O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
in O
platelets O
and O
thymus O
- O
derived O
T O
lymphocytes O
, O
although O
both O
isoenzymes O
A O
and O
B O
were O
present O
in O
erythrocytes O
and O
neutrophils O
. O

These O
findings O
suggest O
that O
selection O
against O
the O
WAS B
gene O
occurs O
in O
platelets O
and O
thymus O
- O
derived O
T O
lymphocytes O
and O
that O
the O
defects O
associated O
with O
WAS B
expressed O
in O
these O
cell O
- O
types O
may O
be O
implicated O
in O
the O
genesis O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O
. O

Complement B
deficiency I
and O
nephritis B
. O

A O
report O
of O
a O
family O
. O

A O
family O
is O
described O
in O
which O
three O
children O
had O
homozygous O
deficiency B
of I
C3 I
and O
in O
which O
both O
parents O
and O
two O
other O
children O
were O
heterozygous O
for O
the O
C3 O
null O
gene O
. O

One O
child O
with O
heterozygous O
C3 B
deficiency I
was O
found O
to O
have O
membranoproliferative O
glomerulonephritis B
; O
proteinuria B
and O
/ O
or O
microscopical O
haematuria B
was O
present O
in O
all O
three O
homozygous O
C3 B
- I
deficient I
children O
. O

All O
children O
with O
homozygous O
or O
heterozygous O
C3 B
deficiency I
were O
, O
to O
a O
varying O
degree O
, O
susceptible O
to O
infection O
. O

The O
only O
child O
of O
the O
family O
with O
normal O
complement O
had O
no O
increased O
risk O
of O
infection O
and O
no O
renal B
disease I
. O

This O
family O
study O
provides O
further O
support O
for O
the O
proposal O
that O
C3 B
deficiency I
predisposes O
to O
nephritis B
. O
. O

Heterogeneity O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
in O
Algeria O
. O

Study O
in O
Northern O
Algeria O
with O
description O
of O
five O
new O
variants O
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
was O
found O
in O
3 O
. O

2 O
% O
of O
the O
male O
population O
living O
in O
the O
urban O
area O
of O
Algiers O
. O

The O
deficient O
subjects O
originated O
from O
multiple O
geographic O
regions O
of O
Northern O
Algeria O
, O
with O
prevalence O
of O
individuals O
of O
Berber O
- O
Kabyle O
origin O
. O

Red O
blood O
cell O
G6PD O
was O
partially O
purified O
and O
characterized O
in O
deficient O
males O
from O
17 O
families O
, O
and O
six O
different O
variants O
were O
found O
. O

Among O
them O
, O
only O
one O
, O
the O
Gd O
( O
- O
) O
Kabyle O
variant O
, O
had O
been O
previously O
described O
. O

It O
was O
detected O
in O
nine O
families O
. O

The O
other O
five O
variants O
were O
new O
Gd O
( O
- O
) O
Laghouat O
( O
four O
cases O
) O
, O
Gd O
( O
- O
) O
Blida O
( O
one O
case O
) O
, O
Gd O
( O
- O
) O
Thenia O
( O
one O
case O
) O
, O
Gd O
( O
- O
) O
Titteri O
( O
one O
case O
) O
, O
and O
Gd O
( O
- O
) O
Alger O
( O
two O
brothers O
) O
. O

Strikingly O
, O
the O
common O
Mediterranean O
variant O
was O
not O
found O
. O

G6PD B
deficiency I
is O
heterogeneous O
in O
northern O
Algeria O
where O
autochtonous O
variants O
seem O
to O
prevail O
. O

The O
Kabyle O
variant O
may O
be O
common O
in O
this O
country O
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
inhibits O
in O
vitro O
growth O
of O
Plasmodium O
falciparum O
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
; I
EC I
1 I
. I
1 I
. I
1 I
. I
49 I
) I
- I
deficient I
red O
blood O
cells O
from O
male O
hemizygotes O
and O
female O
heterozygotes O
from O
the O
island O
of O
Sardinia O
were O
studied O
for O
their O
ability O
to O
support O
growth O
in O
vitro O
of O
the O
malaria B
- O
causing O
organism O
Plasmodium O
falciparum O
. O

Parasite O
growth O
was O
approximately O
one O
- O
third O
of O
normal O
in O
both O
hemi O
- O
and O
heterozygotes O
for O
G6PD B
deficiency I
. O

In O
Sardinians O
with O
the O
beta O
0 O
- O
thalassemia O
trait O
, O
parasite O
growth O
was O
normal O
except O
when O
G6PD B
deficiency I
occurred O
together O
with O
the O
thalassemia B
trait O
. O

The O
data O
support O
the O
hypothesis O
that O
G6PD B
deficiency I
may O
confer O
a O
selective O
advantage O
in O
a O
malarious B
area O
; O
the O
female O
heterozygote O
may O
be O
at O
a O
particular O
advantage O
because O
resistance O
to O
malaria B
equals O
that O
of O
male O
hemizygotes O
, O
but O
the O
risk O
of O
fatal B
hemolysis I
may O
be O
less O
. O

However O
, O
more O
female O
heterozygotes O
must O
be O
studied O
to O
confirm O
this O
hypothesis O
. O

No O
protective O
effect O
of O
beta O
0 O
- O
thalassemia O
trait O
could O
be O
demonstrated O
in O
vitro O
. O

Bone O
marrow O
transplant O
in O
adrenoleukodystrophy B
. O

An O
allogeneic O
bone O
marrow O
transplant O
( O
BMT O
) O
from O
a O
normal O
HLA O
identical O
sibling O
donor O
was O
performed O
in O
a O
13 O
- O
year O
- O
old O
boy O
with O
rapidly O
progressive O
adrenoleukodystrophy B
( O
ALD B
) O
. O

Engraftment O
and O
complete O
hematologic O
recovery O
occurred O
within O
4 O
weeks O
, O
but O
neurologic B
deterioration I
continued O
. O

The O
patient O
died O
of O
an O
adenovirus B
infection I
141 O
days O
after O
BMT O
. O

ALD B
is O
characterized O
by O
abnormally O
high O
plasma O
levels O
of O
very O
long O
chain O
fatty O
acids O
( O
VLCFA O
) O
as O
a O
result O
of O
impaired O
capacity O
to O
degrade O
them O
. O

Ten O
days O
after O
BMT O
, O
the O
white O
blood O
cell O
VLCFA O
levels O
and O
enzyme O
activity O
became O
normal O
; O
after O
3 O
months O
, O
there O
was O
progressive O
reduction O
of O
plasma O
VLCFA O
to O
levels O
only O
slightly O
above O
normal O
. O
. O

[ O
Gd O
- O
allele O
distribution O
patterns O
in O
Azerbaijan O
. O
III O
. O
The O
identification O
of O
mutant O
forms O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
] O

In O
28 O
families O
with O
G6PD B
deficiency I
living O
in O
3 O
settlements O
of O
Shekii O
district O
of O
Azerbaijan O
11 O
G6PD O
variants O
of O
II O
and O
III O
classes O
differing O
by O
kinetic O
properties O
were O
identified O
according O
WHO O
program O
. O

9 O
of O
them O
are O
characterized O
with O
the O
same O
electrophoretic O
mobility O
. O

Comparison O
of O
G6PD O
spectra O
in O
two O
subpopulations O
and O
in O
a O
mixed O
group O
permits O
to O
make O
a O
conclusion O
about O
existence O
of O
common O
and O
rare O
G6PD O
alleles O
in O
examined O
population O
. O

They O
distribute O
by O
gene O
drift O
supported O
by O
natural O
selection O
. O

Among O
7 O
samples O
of O
G6PD O
with O
normal O
and O
increased O
activity O
two O
new O
variants O
of O
IV O
class O
- O
- O
Nukha O
and O
Bash O
- O
Kungut O
- O
- O
were O
found O
. O
. O

Adrenoleukodystrophy B
: O
survey O
of O
303 O
cases O
: O
biochemistry O
, O
diagnosis O
, O
and O
therapy O
. O

Adrenoleukodystrophy B
( O
ALD B
) O
is O
a O
genetically O
determined O
disorder O
associated O
with O
progressive B
central I
demyelination I
and O
adrenal B
cortical I
insufficiency I
. O

All O
affected O
persons O
show O
increased O
levels O
of O
saturated O
unbranched O
very O
- O
long O
- O
chain O
fatty O
acids O
, O
particularly O
hexacosanoate O
( O
C26 O
0 O
) O
, O
because O
of O
impaired O
capacity O
to O
degrade O
these O
acids O
. O

This O
degradation O
normally O
takes O
place O
in O
a O
subcellular O
organelle O
called O
the O
peroxisome O
, O
and O
ALD B
, O
together O
with O
Zellwegers B
cerebrohepatorenal I
syndrome I
, O
is O
now O
considered O
to O
belong O
to O
the O
newly O
formed O
category O
of O
peroxisomal B
disorders I
. O

Biochemical O
assays O
permit O
prenatal O
diagnosis O
, O
as O
well O
as O
identification O
of O
most O
heterozygotes O
. O

We O
have O
identified O
303 O
patients O
with O
ALD B
in O
217 O
kindreds O
. O

These O
patients O
show O
a O
wide O
phenotypic O
variation O
. O

Sixty O
percent O
of O
patients O
had O
childhood O
ALD B
and O
17 O
% O
adrenomyeloneuropathy B
, O
both O
of O
which O
are O
X O
- O
linked O
, O
with O
the O
gene O
mapped O
to O
Xq28 O
. O

Neonatal B
ALD I
, O
a O
distinct O
entity O
with O
autosomal O
recessive O
inheritance O
and O
points O
of O
resemblance O
to O
Zellwegers B
syndrome I
, O
accounted O
for O
7 O
% O
of O
the O
cases O
. O

Although O
excess O
C26 O
0 O
in O
the O
brain O
of O
patients O
with O
ALD B
is O
partially O
of O
dietary O
origin O
, O
dietary O
C26 O
0 O
restriction O
did O
not O
produce O
clear O
benefit O
. O

Bone O
marrow O
transplant O
lowered O
the O
plasma O
C26 O
0 O
level O
but O
failed O
to O
arrest O
neurological O
progression O
. O
. O

Genetic O
polymorphism O
of O
G6PD O
in O
a O
Bulgarian O
population O
. O

Considerable O
genetic O
heterogeneity O
in O
G6PD O
was O
found O
in O
the O
Bulgarian O
population O
- O
14 O
G6PD O
variants O
isolated O
from O
117 O
hemizygous O
carriers O
of O
G6PD B
deficiency I
. O

Of O
these O
, O
G6PD O
Mediterranean O
type O
was O
a O
polymorphic O
variant O
and O
G6PD O
Corinth O
occurred O
with O
high O
frequency O
. O

Two O
new O
variants O
were O
identified O
- O
G6PD O
Rudosem O
and O
G6PD O
Nedelino O
. O

In O
a O
selected O
group O
of O
78 O
subjects O
with O
clinical O
manifestations O
, O
four O
variants O
were O
established O
G6PD O
Mediterranian O
, O
G6PD O
Corinth O
, O
G6PD O
Seattle O
and O
G6PD O
Ohut O
II O
. O
. O

Clinical O
use O
of O
DNA O
markers O
linked O
to O
the O
gene O
for O
Duchenne B
muscular I
dystrophy I
. O

Seventy O
families O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
known O
to O
the O
Institute O
of O
Child O
Health O
fall O
into O
three O
categories O
with O
respect O
to O
potential O
linkage O
analysis O
with O
the O
X O
chromosome O
DNA O
markers O
RC8 O
and O
L1 O
. O

28 O
that O
bridge O
the O
DMD B
gene O
. O

Families O
in O
which O
there O
is O
at O
least O
one O
obligatory O
female O
heterozygote O
( O
n O
= O
13 O
) O
. O

Here O
prediction O
and O
exclusion O
of O
DMD B
gene O
transmission O
may O
be O
possible O
, O
the O
accuracy O
being O
dependent O
on O
the O
closeness O
of O
the O
linkage O
of O
the O
DNA O
marker O
( O
s O
) O
to O
the O
DMD B
gene O
; O
an O
illustrative O
case O
is O
reported O
. O

Families O
in O
which O
there O
is O
a O
single O
affected O
boy O
, O
who O
also O
has O
one O
or O
more O
healthy O
brothers O
( O
n O
= O
26 O
) O
. O

Given O
an O
informative O
restriction O
fragment O
length O
polymorphism O
( O
RFLP O
) O
, O
the O
probability O
that O
the O
boy O
represents O
a O
new O
mutation O
can O
be O
reassessed O
; O
it O
is O
also O
possible O
to O
exclude O
the O
DMD B
gene O
in O
a O
sister O
. O

Families O
with O
a O
single O
affected O
boy O
with O
no O
brother O
( O
n O
= O
30 O
) O
. O

Here O
exclusion O
of O
the O
DMD B
gene O
in O
a O
sister O
may O
be O
possible O
. O

Only O
in O
one O
family O
was O
there O
no O
possibility O
of O
useful O
linkage O
analysis O
. O

The O
linkage O
analysis O
required O
is O
described O
, O
and O
the O
need O
to O
check O
DMD B
families O
for O
informative O
RFLPs O
is O
stressed O
. O

Family O
studies O
in O
Bechterew B
' I
s I
syndrome I
( O
ankylosing B
spondylitis I
) O
III O
. O

Genetics O
. O

The O
results O
of O
segregation O
analyses O
in O
75 O
families O
where O
the O
proband O
had O
ankylosing B
spondylitis I
, O
are O
presented O
. O

Of O
the O
278 O
adult O
, O
living O
first O
degree O
relatives O
, O
approximately O
85 O
% O
cooperated O
in O
the O
study O
. O

Clinical O
and O
radiographical O
examinations O
were O
performed O
and O
HLA O
typing O
was O
conducted O
. O

The O
results O
were O
in O
agreement O
with O
our O
hypothesis O
that O
ankylosing B
spondylitis I
is O
part O
of O
a O
syndrome O
where O
different O
genetic O
factors O
interact O
. O

Such O
known O
factors O
are O
HLA O
B27 O
associated O
disease O
susceptibility O
, O
susceptibility O
to O
psoriatic B
arthropathy I
and O
susceptibility O
to O
entero B
- I
arthropathy I
. O

Radiographical O
sacro B
- I
iliitis I
was O
restricted O
to O
HLA O
B27 O
positive O
relatives O
, O
and O
was O
more O
frequently O
found O
in O
relatives O
to O
probands O
with O
psoriasis B
than O
in O
relatives O
to O
probands O
without O
psoriasis B
. O

Environmental O
factors O
( O
intestinal O
bacteria O
) O
are O
known O
to O
trigger O
the O
disease O
at O
least O
in O
some O
persons O
, O
and O
we O
have O
postulated O
that O
all O
or O
most O
of O
them O
have O
the O
predisposition O
to O
develop O
disease O
. O

Thus O
, O
the O
syndrome O
has O
a O
multifactorial O
etiology O
. O

The O
phenotypic O
expressions O
of O
the O
different O
genetic O
predispositions O
involved O
, O
include O
sacro B
- I
iliitis I
, O
psoriasis B
, O
acute B
anterior I
uveitis I
, O
peripheral O
arthropathy B
and O
inflammatory B
bowel I
disease I
. O

We O
suggest O
the O
descriptive O
name O
HEREDITARY B
MULTIFOCAL I
RELAPSING I
INFLAMMATION I
( O
HEMRI B
) O
for O
this O
syndrome O
. O

Ankylosing B
spondylitis I
, O
psoriatic B
arthropathy I
and O
entero B
- I
arthropathy I
may O
be O
regarded O
as O
clinical O
sub O
- O
types O
of O
the O
syndrome O
. O
. O

Prader B
- I
Willi I
syndrome I
and O
chromosome O
15 O
. O

A O
clinical O
discussion O
of O
20 O
cases O
. O

A O
chromosome B
15 I
anomaly I
was O
observed O
in O
12 O
of O
20 O
patients O
, O
17 O
of O
whom O
were O
clinically O
suspected O
of O
having O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

The O
clinical O
features O
of O
eight O
cases O
with O
15q11 O
- O
12 O
deletion O
were O
very O
similar O
to O
those O
originally O
described O
in O
PWS B
. O

On O
the O
other O
hand O
, O
the O
group O
of O
normal O
karyotype O
patients O
is O
heterogeneous O
, O
and O
their O
features O
do O
not O
strictly O
correspond O
to O
the O
clinical O
definition O
of O
PWS B
. O

However O
, O
the O
hypothesis O
that O
PWS B
is O
associated O
with O
deletion O
of O
15q11 O
- O
12 O
can O
neither O
explain O
the O
apparently O
balanced O
translocations O
of O
chromosome O
15 O
nor O
account O
for O
the O
small O
supernumerary O
metacentric O
chromosomes O
corresponding O
to O
an O
isochromosome O
15 O
for O
band O
15q11 O
observed O
in O
some O
cases O
. O
. O

The O
Tay B
- I
Sachs I
disease I
gene O
in O
North O
American O
Jewish O
populations O
: O
geographic O
variations O
and O
origin O
. O

From O
data O
collected O
in O
a O
North O
American O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
heterozygote O
screening O
program O
, O
the O
TSD B
carrier O
frequency O
among O
46 O
, O
304 O
Jewish O
individuals O
was O
found O
to O
be O
. O

0324 O
( O
1 O
in O
31 O
individuals O
) O
. O

This O
frequency O
is O
consistent O
with O
earlier O
estimates O
based O
on O
TSD B
incidence O
data O
. O

TSD B
carrier O
frequencies O
were O
then O
examined O
by O
single O
country O
and O
single O
region O
of O
origin O
in O
28 O
, O
029 O
Jews O
within O
this O
sample O
for O
whom O
such O
data O
were O
available O
for O
analysis O
. O

Jews O
with O
Polish O
and O
/ O
or O
Russian O
ancestry O
constituted O
88 O
% O
of O
this O
sample O
and O
had O
a O
TSD B
carrier O
frequency O
of O
. O

0327 O
. O

No O
TSD B
carriers O
were O
observed O
among O
the O
166 O
Jews O
of O
Near O
Eastern O
origins O
. O

Relative O
to O
Jews O
of O
Polish O
and O
Russian O
origins O
, O
there O
was O
at O
least O
a O
twofold O
increase O
in O
the O
TSD B
carrier O
frequency O
in O
Jews O
of O
Austrian O
, O
Hungarian O
, O
and O
Czechoslovakian O
origins O
( O
P O
less O
than O
. O
005 O
) O
. O

These O
findings O
suggest O
that O
the O
TSD B
gene O
proliferated O
among O
the O
antecedents O
of O
modern O
Ashkenazi O
Jewry O
after O
the O
Second O
Diaspora O
( O
70 O
A O
. O
D O
. O
) O
and O
before O
their O
major O
migrations O
to O
regions O
of O
Poland O
and O
Russia O
( O
before O
1100 O
A O
. O
D O
. O
) O
. O

Human O
deficiency B
of I
the I
sixth I
component I
of I
complement I
in O
a O
patient O
with O
meningococcal B
meningitis I
and O
no O
haemostasis B
abnormality I
. O

A O
case O
of O
human O
complete O
C6 B
deficiency I
is O
reported O
. O

The O
patient O
, O
a O
31 O
year O
old O
white O
male O
, O
was O
seen O
on O
the O
occasion O
of O
an O
isolated O
episode O
of O
meningococcal B
meningitis I
. O

Serum O
complement O
hemolytic O
and O
bactericidal O
activities O
were O
lacking O
and O
could O
be O
restored O
to O
normal O
by O
addition O
of O
appropriate O
amounts O
of O
purified O
C6 O
. O

No O
hemostatic B
abnormalities I
were O
observed O
. O
. O

Absence B
of I
the I
seventh I
component I
of I
complement I
in O
a O
patient O
with O
chronic B
meningococcemia I
presenting O
as O
vasculitis B
. O

A O
previously O
healthy O
40 O
- O
year O
- O
old O
man O
presenting O
with O
fever B
, O
arthritis B
, O
and O
cutaneous B
vasculitis I
was O
found O
to O
have O
chronic B
meningococcemia I
. O

Evaluation O
of O
his O
complement O
system O
showed O
an O
absence O
of O
functional O
and O
antigenic O
C7 O
, O
compatible O
with O
a O
complete O
deficiency B
of I
the I
seventh I
component I
of I
complement I
. O

Study O
of O
the O
patients O
family O
spanning O
four O
generations O
showed O
heterozygous O
deficiency B
of I
C7 I
in O
five O
members O
. O

Chronic B
neisserial I
infection I
can O
be O
associated O
with O
C7 B
deficiency I
and O
must O
be O
distinguished O
from O
other O
causes O
of O
cutaneous B
vasculitis I
. O
. O

Familial B
discoid I
lupus I
erythematosus I
associated O
with O
heterozygote O
C2 B
deficiency I
. O

Two O
siblings O
with O
chronic B
discoid I
lupus I
erythematosus I
and O
several O
family O
members O
were O
found O
with O
heterozygous O
C2 B
deficiency I
. O

An O
association O
with O
histocompatibility O
markers O
HLA O
- O
B18 O
and O
HLA O
- O
Dw2 O
was O
demonstrated O
, O
and O
the O
slow O
allotype O
of O
factor O
B O
was O
present O
. O

Linkage O
studies O
in O
this O
family O
suggested O
a O
close O
linkage O
between O
the O
C2 B
deficiency I
gene O
and O
genes O
coding O
for O
B18 O
, O
Dw2 O
, O
and O
BfS O
antigens O
. O

One O
HLA O
- O
ACB O
/ O
DBf O
recombinant O
was O
observed O
showing O
closer O
linkage O
between O
HLA O
- O
D O
and O
Bf O
than O
between O
HLA O
- O
B O
and O
Bf O
. O
. O

Severe B
- I
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
associated O
with O
chronic O
hemolytic B
anemia I
, O
granulocyte B
dysfunction I
, O
and O
increased O
susceptibility O
to O
infections O
: O
description O
of O
a O
new O
molecular O
variant O
( O
G6PD O
Barcelona O
) O
. O

Molecular O
, O
kinetic O
, O
and O
functional O
studies O
were O
carried O
out O
on O
erythrocytes O
and O
leukocytes O
in O
a O
Spanish O
male O
with O
G6PD B
deficiency I
, O
congenital B
nonspherocytic I
hemolytic I
anemia I
( O
CNSHA B
) O
, O
and O
increased O
susceptibility O
to O
infections O
. O

G6PD O
activity O
was O
absent O
in O
patients O
red O
cells O
and O
was O
about O
2 O
% O
of O
normal O
in O
leukocytes O
. O

Molecular O
studies O
using O
standard O
methods O
( O
WHO O
, O
1967 O
) O
showed O
G6PD O
in O
the O
patient O
to O
have O
a O
slightly O
fast O
electrophoretic O
mobility O
at O
pH O
8 O
. O

0 O
with O
otherwise O
normal O
properties O
( O
heat O
stability O
at O
46 O
degrees O
C O
, O
apparent O
affinity O
for O
substrates O
, O
optimum O
pH O
, O
and O
utilization O
of O
substrate O
analogues O
) O
. O

Other O
tests O
showed O
the O
patients O
granulocytes O
to O
engulf O
latex O
particles O
normally O
, O
but O
to O
have O
impaired O
reduction O
of O
nitroblue O
tetrazolium O
and O
ferricytochrome O
- O
c O
as O
well O
as O
reduced O
iodination O
. O

Chemotaxis O
and O
random O
migration O
of O
the O
patients O
granulocytes O
were O
normal O
as O
were O
myeloperoxidase O
, O
leukocyte O
alkaline O
phosphatase O
( O
LAP O
) O
, O
and O
ultrastructural O
features O
. O

The O
molecular O
characteristics O
of O
G6PD O
in O
the O
patient O
differed O
from O
those O
of O
all O
previously O
reported O
variants O
associated O
with O
CNSHA B
, O
so O
the O
present O
variant O
was O
provisionally O
called O
G6PD O
Barcelona O
to O
distinguish O
it O
from O
other O
G6PD O
variants O
previously O
described O
. O

Possible O
mechanisms O
for O
the O
severe O
deficiency B
of I
G6PD I
in O
erythrocytes O
and O
granulocytes O
was O
investigated O
by O
studies O
on O
the O
immunologic O
specific O
activity O
of O
the O
mutant O
enzyme O
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
in O
Papua O
New O
Guinea O
. O

The O
description O
of O
13 O
new O
variants O
. O

A O
total O
of O
362 O
males O
from O
various O
regions O
of O
Papua O
New O
Guinea O
were O
screened O
for O
red O
cell O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
activity O
. O

Twenty O
- O
six O
G6PD B
deficient I
individuals O
were O
identified O
. O

Biochemical O
characterization O
of O
G6PD O
purified O
from O
these O
subjects O
has O
revealed O
13 O
new O
variants O
and O
several O
copies O
of O
previously O
described O
forms O
of O
G6PD O
. O

This O
study O
illustrates O
the O
extreme O
heterogeneity O
of O
G6PD B
deficiency I
among O
the O
people O
of O
Papua O
New O
Guinea O
. O
. O

Heterogeneity O
of O
" O
Mediterranean O
type O
" O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
in O
Spain O
and O
description O
of O
two O
new O
variants O
associated O
with O
favism B
. O

Glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
; O
EC O
1 O
. O

1 O
. O

1 O
. O

49 O
from O
thirty O
- O
six O
unrelated O
Spanish O
males O
was O
partially O
purified O
from O
blood O
, O
and O
the O
variants O
were O
characterized O
biochemically O
and O
electrophoretically O
according O
to O
the O
methods O
recommended O
by O
the O
world O
Health O
Organization O
. O

Subjects O
were O
from O
multiple O
geographic O
regions O
within O
Spain O
, O
and O
all O
suffered O
from O
hemolytic B
anemia I
, O
either O
acute O
( O
34 O
cases O
) O
or O
chronic O
nonspherocytic O
( O
2 O
cases O
) O
. O

Almost O
all O
the O
variants O
studied O
presented O
residual O
erythrocyte O
G6PD O
activity O
ranging O
from O
0 O
to O
10 O
% O
of O
normal O
, O
and O
five O
different O
mutants O
were O
responsible O
for O
the O
deficient O
phenotype O
. O

Three O
variants O
were O
similar O
to O
others O
previously O
described O
G6PD O
Mediterranean O
( O
11 O
cases O
) O
, O
G6PD O
Athens O
- O
like O
( O
3 O
cases O
) O
, O
and O
G6PD O
Union O
( O
2 O
cases O
) O
. O

The O
remaining O
variants O
were O
different O
from O
the O
numerous O
variants O
already O
reported O
and O
have O
been O
considered O
as O
new O
mutants O
. O

Provisionally O
they O
are O
called O
G6PD O
Betica O
( O
19 O
cases O
) O
and O
G6PD O
Menorca O
( O
1 O
case O
) O
. O

The O
present O
study O
constitutes O
the O
first O
attempt O
to O
characterize O
the O
deficient B
G6PD I
variants O
found O
in O
Spain O
and O
supplies O
new O
data O
on O
the O
relationship O
between O
molecular O
characteristics O
of O
deficient O
variants O
and O
their O
clinical O
manifestations O
. O

The O
most O
important O
findings O
can O
be O
summarized O
as O
follows O
( O
1 O
) O
The O
Spanish O
population O
is O
characterized O
by O
an O
important O
heterogeneity O
in O
G6PD B
deficiency I
. O

( O
2 O
) O
Although O
G6PD O
Mediterranean O
is O
very O
frequent O
, O
it O
presents O
a O
relatively O
high O
degree O
of O
polymorphism O
. O

( O
3 O
) O
Favism B
has O
been O
observed O
associated O
with O
all O
kinds O
of O
variants O
described O
here O
. O

( O
4 O
) O
G6PD O
Betica O
, O
which O
is O
the O
most O
frequent O
variant O
found O
in O
subjects O
of O
Southern O
Spanish O
origin O
, O
has O
been O
observed O
associated O
with O
favism B
in O
all O
cases O
except O
one O
. O

A O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variant O
( O
G6PD O
Nagano O
) O
associated O
with O
congenital B
hemolytic I
anemia I
. O

A O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
variant O
associated O
with O
chronic B
nonspherocytic I
hemolytic I
anemia I
was O
reported O
. O

The O
patient O
, O
a O
6 O
- O
year O
- O
old O
Japanese O
male O
, O
was O
noticed O
to O
have O
hemolytic B
anemia I
soon O
after O
birth O
, O
and O
a O
diagnosis O
of O
G6PD B
deficiency I
was O
made O
at O
the O
age O
of O
2 O
. O

He O
had O
episodes O
of O
hemolytic B
crisis I
several O
times O
after O
upper B
respiratory I
infection I
. O

G6PD O
activity O
of O
the O
patient O
was O
5 O
. O

5 O
% O
of O
normal O
. O

The O
enzymatic O
characteristics O
were O
examined O
when O
he O
was O
5 O
years O
old O
, O
and O
his O
G6PD O
showed O
faster O
- O
than O
- O
normal O
electrophoretic O
mobility O
, O
low O
Km O
G6P O
, O
high O
Km O
NADP O
, O
low O
Ki O
NADPH O
, O
normal O
utilization O
of O
substrate O
analogues O
, O
heat O
instability O
, O
and O
a O
normal O
pH O
optimum O
curve O
. O

From O
these O
results O
, O
this O
was O
considered O
to O
be O
a O
new O
variant O
and O
was O
designated O
G6PD O
Nagano O
. O

Infection O
- O
induced O
hemolysis B
and O
chronic B
hemolytic I
anemia I
seem O
to O
be O
due O
to O
markedly O
impaired O
enzyme O
activity O
and O
thermal O
instability O
. O

Heterozygous O
C2 B
- I
deficiency I
and O
myasthenia B
gravis I
. O

Complement B
deficiency I
states O
in O
myasthenia B
gravis I
( O
MG B
) O
have O
not O
been O
reported O
previously O
. O

We O
describe O
a O
19 O
- O
year O
- O
old O
woman O
with O
typical O
MG B
and O
heterozygous O
C2 B
deficiency I
, O
along O
with O
HLA O
typing O
of O
the O
patient O
and O
her O
immediate O
family O
. O
. O

Adrenoleukodystrophy B
: O
increased O
plasma O
content O
of O
saturated O
very O
long O
chain O
fatty O
acids O
. O

With O
a O
new O
method O
we O
measured O
the O
saturated O
very O
long O
chain O
fatty O
acids O
in O
the O
plasma O
of O
adrenoleukodystrophy B
( O
ALD B
) O
hemizygotes O
, O
ALD B
heterozygotes O
, O
and O
controls O
. O

ALD B
hemizygotes O
showed O
increased O
levels O
of O
hexacosanoate O
( O
C26 O
fatty O
acid O
) O
which O
represented O
0 O
. O

081 O
+ O
/ O
- O
0 O
. O

0066 O
% O
( O
SEM O
) O
of O
total O
fatty O
acids O
, O
compared O
to O
0 O
. O

015 O
+ O
/ O
- O
0 O
. O

0032 O
% O
in O
the O
controls O
. O

C25 O
, O
C24 O
, O
and O
C23 O
fatty O
acids O
were O
also O
increased O
, O
but O
the O
C22 O
and O
C20 O
fatty O
acids O
were O
normal O
. O

C26 O
levels O
were O
also O
increased O
in O
most O
ALD B
heterozygotes O
, O
with O
a O
mean O
level O
0 O
. O

057 O
+ O
/ O
- O
0 O
. O

0063 O
% O
of O
total O
fatty O
acids O
. O

The O
technique O
can O
be O
used O
for O
diagnosis O
and O
carrier O
identification O
, O
and O
in O
the O
evaluation O
of O
therapy O
. O

Abnormal O
high O
density O
lipoproteins O
in O
cerebrotendinous B
xanthomatosis I
. O

The O
plasma O
lipoprotein O
profiles O
and O
high O
density O
lipoproteins O
( O
HDL O
) O
were O
characterized O
in O
patients O
with O
the O
genetic B
disease I
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O

Abnormalities B
in I
the I
HDL I
may O
contribute O
to O
their O
increased O
atherogenesis O
and O
excessive O
deposits O
of O
tissue O
sterols O
in O
the O
presence O
of O
low O
or O
low O
- O
normal O
concentrations O
of O
plasma O
cholesterol O
( O
165 O
+ O
/ O
- O
25 O
mg O
/ O
dl O
) O
and O
low O
density O
lipoproteins O
( O
LDL O
) O
. O

The O
mean O
HDL O
- O
cholesterol O
concentration O
in O
the O
CTX B
plasmas O
was O
14 O
. O

5 O
+ O
/ O
- O
3 O
. O

2 O
mg O
/ O
dl O
, O
about O
one O
- O
third O
the O
normal O
value O
. O

The O
low O
HDL O
- O
cholesterol O
reflects O
a O
low O
concentration O
and O
an O
abnormal O
lipid O
composition O
of O
the O
plasma O
HDL O
. O

Relative O
to O
normal O
HDL O
, O
the O
cholesteryl O
esters O
are O
low O
, O
free O
cholesterol O
and O
phospholipids O
essentially O
normal O
, O
and O
triglycerides O
increased O
. O

The O
ratio O
of O
apoprotein O
( O
apo O
) O
to O
total O
cholesterol O
in O
the O
HDL O
of O
CTX B
was O
two O
to O
three O
times O
greater O
than O
normal O
. O

In O
the O
CTX B
HDL O
, O
the O
ratio O
of O
apoAI O
to O
apoAII O
was O
high O
, O
the O
proportion O
of O
apoC O
low O
, O
and O
a O
normally O
minor O
form O
of O
apoAI O
increased O
relative O
to O
other O
forms O
. O

The O
HDL O
in O
electron O
micrographs O
appeared O
normal O
morphologically O
and O
in O
particle O
size O
. O

The O
abnormalities O
in O
lipoprotein O
distribution O
profile O
and O
composition O
of O
the O
plasma O
HDL O
result O
from O
metabolic O
defects O
that O
are O
not O
understood O
but O
may O
be O
linked O
to O
the O
genetic B
defect I
in O
bile O
acid O
synthesis O
in O
CTX B
. O

As O
a O
consequence O
, O
it O
is O
probable O
that O
the O
normal O
functions O
of O
the O
HDL O
, O
possibly O
including O
modulation O
of O
LDL O
- O
cholesterol O
uptake O
and O
the O
removal O
of O
excess O
cholesterol O
from O
peripheral O
tissues O
, O
are O
perturbed O
significantly O
in O
this O
disease O
. O

Genetics O
of O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
: O
an O
autosomal O
recessive O
trait O
with O
high O
gene O
frequency O
in O
Sephardim O
of O
Moroccan O
origin O
. O

We O
described O
6 O
patients O
( O
from O
3 O
families O
) O
affected O
with O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O

All O
are O
Sephardic O
Jews O
of O
Moroccan O
extraction O
. O

In O
view O
of O
the O
small O
number O
of O
CTX B
patients O
diagnosed O
in O
the O
world O
( O
a O
total O
of O
50 O
including O
our O
6 O
patients O
) O
, O
we O
are O
probably O
dealing O
with O
an O
ethnic O
subgroup O
with O
a O
high O
CTX O
gene O
frequency O
, O
which O
we O
have O
estimated O
to O
be O
1 O
/ O
108 O
. O

Since O
there O
are O
differences O
in O
expression O
in O
this O
disease O
, O
we O
recommend O
cholestanol O
study O
in O
cases O
of O
undiagnosed O
cataract B
or O
tendinous B
xanthomas I
in O
childhood O
or O
early O
adolescence O
. O

The O
diagnosis O
in O
CTX B
is O
important O
not O
only O
for O
genetic O
counseling O
, O
but O
also O
in O
veiw O
of O
possible O
treatment O
. O
. O

New O
genetic O
variants O
of O
glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
in O
Italy O
. O

Six O
new O
variants O
of O
human O
erythrocyte O
G6PD O
have O
been O
characterized O
. O

All O
of O
them O
were O
found O
in O
Italian O
males O
and O
all O
were O
associated O
with O
enzyme B
deficiency I
, O
but O
only O
two O
with O
signs O
of O
haemolysis B
. O

These O
and O
other O
variants O
reported O
in O
the O
literature O
, O
which O
must O
thus O
far O
be O
regarded O
as O
sporadic O
, O
are O
found O
to O
map O
in O
parts O
of O
Italy O
where O
common O
types O
of O
G6PD B
deficiency I
are O
also O
prevalent O
. O
. O

Variants O
of O
erythrocyte O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
in O
Bulgarian O
populations O
. O

Ten O
variants O
of O
erythrocyte O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
were O
identified O
in O
22 O
patients O
with O
G6PD B
deficiency I
from O
three O
districts O
of O
Bulgaria O
. O

Corinth O
- O
like O
and O
Fayoum O
- O
like O
variants O
were O
the O
most O
frequent O
; O
Mediterranean O
, O
Ohut O
II O
, O
Kilgore O
, O
Boston O
, O
Poznan O
, O
and O
Panay O
variants O
and O
two O
new O
variants O
, O
Petrich O
and O
Gotze O
Delchev O
, O
were O
each O
found O
in O
one O
or O
two O
carriers O
. O

No O
correlation O
was O
revealed O
between O
clinical O
and O
biochemical O
polymorphism O
. O
. O

Nephropathy B
in O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

Nephropathy B
was O
detected O
in O
five O
of O
32 O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
who O
were O
participating O
in O
a O
study O
of O
transfer O
factor O
( O
TF O
) O
therapy O
. O

In O
two O
patients O
, O
nephropathy B
was O
present O
before O
TF O
and O
did O
not O
appear O
changed O
by O
TF O
therapy O
. O

One O
of O
these O
patients O
subsequently O
developed O
progressive O
renal B
failure I
requiring O
dialysis O
beginning O
5 O
1 O
/ O
2 O
years O
after O
TF O
therapy O
. O

In O
two O
patients O
, O
decreased O
renal O
function O
appeared O
very O
soon O
after O
the O
administration O
of O
TF O
. O

One O
patient O
showed O
gradually O
decreasing O
renal O
function O
beginning O
after O
two O
years O
of O
TF O
therapy O
. O

An O
additional O
patient O
was O
identified O
who O
died O
with O
renal B
failure I
without O
having O
received O
TF O
. O

The O
results O
suggest O
that O
renal B
failure I
occurs O
in O
the O
Wiskott B
- I
Aldrich I
syndrome I
more O
frequently O
than O
generally O
recognized O
and O
that O
administration O
of O
TF O
may O
precipitate O
or O
accelerate O
the O
renal B
disease I
in O
patients O
with O
this O
syndrome O
. O
. O

Wiskott B
- I
Aldrich I
syndrome I
: O
cellular O
impairments O
and O
their O
implication O
for O
carrier O
detection O
. O

A O
family O
in O
which O
two O
male O
siblings O
were O
affected O
with O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
was O
studied O
using O
G O
- O
6 O
- O
PD O
isoenzymes O
as O
an O
X O
- O
linked O
marker O
in O
order O
to O
investigate O
the O
nature O
of O
cellular O
abnormalities O
. O

Isolated O
peripheral O
blood O
cell O
types O
from O
the O
doubly O
heterozygous O
mother O
of O
the O
affected O
males O
seemingly O
failed O
to O
express O
the O
G O
- O
6 O
- O
PD O
allele O
in O
cis O
position O
with O
the O
WAS B
allele O
while O
her O
cultured O
skin O
fibroblasts O
expressed O
both O
G O
- O
6 O
- O
PD O
alleles O
. O

Additionally O
, O
a O
histogram O
analysis O
of O
platelet O
size O
revealed O
a O
single O
population O
of O
abnormally O
small O
platelets O
in O
the O
affected O
propositus O
, O
whereas O
the O
heterozygous O
mother O
had O
no O
appreciable O
small O
platelet O
subpopulation O
. O

In O
vitro O
culture O
of O
hemopoietic O
progenitor O
cells O
of O
the O
heterozygous O
mother O
showed O
that O
the O
majority O
of O
progenitor O
cells O
did O
not O
express O
the O
WAS B
allele O
. O

However O
, O
a O
small O
number O
of O
cells O
expressing O
the O
G O
- O
6 O
- O
PD O
type O
linked O
with O
the O
WAS B
allele O
were O
detected O
. O

The O
proportion O
of O
the O
latter O
progenitors O
was O
significantly O
higher O
among O
more O
primitive O
progenitors O
( O
those O
giving O
rise O
to O
later O
appearing O
colonies O
) O
. O

This O
observation O
suggests O
that O
selection O
against O
cells O
expressing O
the O
Wiskott B
- I
Aldrich I
defect I
takes O
place O
in O
the O
hemopoietic O
system O
of O
the O
heterozygous O
female O
and O
offers O
a O
possible O
means O
of O
carrier O
detection O
in O
some O
women O
. O

Linkage O
studies O
in O
this O
family O
revealed O
one O
example O
of O
probable O
recombination O
between O
the O
loci O
for O
WAS B
and O
G O
- O
6 O
- O
PD O
among O
three O
informative O
subjects O
, O
suggesting O
that O
these O
two O
loci O
may O
not O
be O
closely O
linked O
on O
the O
X O
- O
chromosome O
. O
. O

A O
new O
CT O
pattern O
in O
adrenoleukodystrophy B
. O

A O
new O
CT O
pattern O
was O
observed O
in O
2 O
patients O
with O
adrenoleukodystrophy B
( O
ALD B
) O
. O

This O
pattern O
, O
which O
the O
authors O
call O
Type O
II O
, O
is O
characterized O
by O
the O
absence O
of O
posterior O
periventricular O
areas O
of O
decreased O
attenuation O
around O
the O
trigone O
on O
non O
- O
contrast O
scans O
after O
contrast O
infusion O
, O
however O
, O
there O
is O
striking O
enhancement O
of O
various O
white O
- O
matter O
structures O
( O
tracts O
or O
fiber O
systems O
) O
such O
as O
the O
internal O
capsules O
, O
corpus O
callosum O
, O
corona O
radiata O
, O
forceps O
major O
, O
and O
cerebral O
peduncles O
. O

This O
is O
different O
from O
numerous O
previous O
descriptions O
of O
the O
CT O
pattern O
in O
ALD B
. O

Type B
II I
ALD I
does O
not O
appear O
to O
have O
been O
seen O
in O
any O
other O
leukoencephalopathy B
and O
is O
probably O
specific O
for O
a O
phenotypic O
variant O
or O
an O
evolving O
stage O
of O
ALD B
. O
. O

Further O
evidence O
for O
heterogeneity O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
in O
Papua O
New O
Guinea O
. O

Four O
new O
G6PD O
variants O
have O
been O
characterized O
in O
individuals O
from O
Papua O
New O
Guinea O
. O

This O
study O
demonstrates O
that O
the O
previously O
reported O
Markham O
variant O
and O
the O
newly O
characterized O
Salata O
variant O
may O
be O
widely O
distributed O
in O
Papua O
New O
Guinea O
. O

Th O
data O
presented O
here O
together O
with O
those O
of O
previously O
published O
studies O
demonstrate O
a O
degree O
of O
heterogeneity O
of O
G6PD B
deficiency I
that O
is O
much O
higher O
than O
that O
in O
other O
regions O
of O
the O
world O
where O
G6PD B
deficiency I
is O
common O
. O
. O

Increased O
incidence O
of O
cataracts B
in O
male O
subjects O
deficient B
in I
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
in O
RBCs O
was O
found O
significantly O
more O
frequently O
in O
210 O
male O
cataractous B
patients O
than O
in O
672 O
control O
subjects O
of O
Sardinian O
origin O
. O

The O
frequency O
of O
the O
deficiency O
was O
increasingly O
higher O
in O
presenile O
cataracts B
. O

In O
the O
G6PD B
- I
deficient I
group O
, O
the O
incidence O
of O
cortical B
and I
total I
cataracts I
was O
also O
increased O
. O

It O
is O
suggested O
that O
decrease O
of O
the O
G6PD O
activity O
in O
the O
lens O
, O
which O
accompanies O
its O
deficiency O
in O
the O
erythrocyte O
, O
might O
play O
a O
role O
in O
the O
cataracto O
- O
genesis O
of O
these O
patients O
. O

Moreover O
, O
G6PD B
deficiency I
should O
be O
added O
to O
other O
conditions O
, O
such O
as O
the O
galactosemic B
states O
and O
riboflavin B
deficiency I
, O
where O
cataracts B
represent O
a O
sensitive O
indicator O
of O
metabolic B
abnormalities I
of O
the O
RBC O
. O
. O

Molecular O
basis O
of O
human O
mitochondrial O
very B
- I
long I
- I
chain I
acyl I
- I
CoA I
dehydrogenase I
deficiency I
causing O
cardiomyopathy B
and O
sudden B
death I
in O
childhood O
. O

beta O
- O
Oxidation O
of O
long O
- O
chain O
fatty O
acids O
provides O
the O
major O
source O
of O
energy O
in O
the O
heart O
. O

Defects O
in O
enzymes O
of O
the O
beta O
- O
oxidation O
pathway O
cause O
sudden B
, I
unexplained I
death I
in O
childhood O
, O
acute O
hepatic B
encephalopathy I
or O
liver B
failure I
, O
skeletal B
myopathy I
, O
and O
cardiomyopathy B
. O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
[ O
VLCAD O
; O
very O
- O
long O
- O
chain O
- O
acyl O
- O
CoA O
( O
acceptor O
) O
2 O
, O
3 O
- O
oxidoreductase O
, O
EC O
1 O
. O
3 O
3 O
. O
99 O
99 O
. O
13 O
] O
catalyzes O
the O
first O
step O
in O
beta O
- O
oxidation O
. O

We O
have O
isolated O
the O
human O
VLCAD O
cDNA O
and O
gene O
and O
determined O
the O
complete O
nucleotide O
sequences O
. O

Polymerase O
chain O
reaction O
amplification O
of O
VLCAD O
mRNA O
and O
genomic O
exons O
defined O
the O
molecular O
defects O
in O
two O
patients O
with O
VLCAD B
deficiency I
who O
presented O
with O
unexplained O
cardiac B
arrest I
and O
cardiomyopathy B
. O

In O
one O
, O
a O
homozygous O
mutation O
in O
the O
consensus O
dinucleotide O
of O
the O
donor O
splice O
site O
( O
g O
+ O
1 O
- O
- O
> O
a O
) O
was O
associated O
with O
universal O
skipping O
of O
the O
prior O
exon O
( O
exon O
11 O
) O
. O

The O
second O
patient O
was O
a O
compound O
heterozygote O
, O
with O
a O
missense O
mutation O
, O
C1837 O
- O
- O
> O
T O
, O
changing O
the O
arginine O
at O
residue O
613 O
to O
tryptophan O
on O
one O
allele O
and O
a O
single O
base O
deletion O
at O
the O
intron O
- O
exon O
6 O
boundary O
as O
the O
second O
mutation O
. O

This O
initial O
delineation O
of O
human O
mutations O
in O
VLCAD O
suggests O
that O
VLCAD B
deficiency I
reduces O
myocardial O
fatty O
acid O
beta O
- O
oxidation O
and O
energy O
production O
and O
is O
associated O
with O
cardiomyopathy B
and O
sudden B
death I
in O
childhood O
. O

Aberrant O
subcellular O
localization O
of O
BRCA1 O
in O
breast B
cancer I
. O

The O
BRCA1 O
gene O
product O
was O
identified O
as O
a O
220 O
- O
kilodalton O
nuclear O
phosphoprotein O
in O
normal O
cells O
, O
including O
breast O
ductal O
epithelial O
cells O
, O
and O
in O
18 O
of O
20 O
tumor B
cell O
lines O
derived O
from O
tissues O
other O
than O
breast O
and O
ovary O
. O

In O
16 O
of O
17 O
breast B
and I
ovarian I
cancer I
lines O
and O
17 O
of O
17 O
samples O
of O
cells O
obtained O
from O
malignant O
effusions O
, O
however O
, O
BRCA1 O
localized O
mainly O
in O
cytoplasm O
. O

Absence O
of O
BRCA1 O
or O
aberrant O
subcellular O
location O
was O
also O
observed O
to O
a O
variable O
extent O
in O
histological O
sections O
of O
many O
breast B
cancer I
biopsies O
. O

These O
findings O
suggest O
that O
BRCA1 B
abnormalities I
may O
be O
involved O
in O
the O
pathogenesis O
of O
many O
breast B
cancers I
, O
sporadic O
as O
well O
as O
familial O
. O
. O

Mapping O
of O
the O
mouse O
homologue O
of O
the O
Wilson B
disease I
gene O
to O
mouse O
chromosome O
8 O
. O

ATP7B O
, O
the O
gene O
altered O
in O
Wilson B
disease I
( O
WD B
) O
patients O
, O
lies O
in O
a O
block O
of O
homology O
shared O
between O
human O
chromosome O
13q14 O
and O
the O
central O
region O
of O
mouse O
chromosome O
14 O
. O

However O
, O
we O
have O
mapped O
the O
murine O
homologue O
of O
ATP7B O
( O
Atp7b O
) O
to O
mouse O
chromosome O
8 O
by O
somatic O
cell O
hybrid O
analysis O
. O

Analysis O
of O
80 O
interspecific O
backcross O
offspring O
was O
used O
to O
position O
Atp7b O
close O
to O
D8Mit3 O
and O
another O
ATPase O
locus O
, O
Atp4b O
, O
on O
mouse O
chromosome O
8 O
. O

ATP4B O
lies O
in O
13q34 O
and O
is O
separated O
from O
ATP7B O
by O
several O
loci O
whose O
mouse O
homologues O
map O
to O
mouse O
chromosome O
14 O
. O

The O
assignment O
of O
Atp7b O
to O
mouse O
chromosome O
8 O
identifies O
a O
previously O
unrecognized O
region O
of O
homology O
between O
this O
chromosome O
and O
human O
chromosome O
13 O
. O

This O
assignment O
suggests O
a O
possible O
location O
for O
the O
toxic O
milk O
mutation O
in O
the O
mouse O
, O
which O
has O
been O
proposed O
as O
a O
homologue O
of O
WD B
. O
. O

Germline O
mutations O
of O
the O
BRCA1 O
gene O
in O
breast B
and I
ovarian I
cancer I
families O
provide O
evidence O
for O
a O
genotype O
- O
phenotype O
correlation O
. O

Mutations O
in O
the O
BRCA1 O
gene O
, O
discovered O
in O
1994 O
, O
are O
associated O
with O
an O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
. O

We O
have O
analysed O
60 O
families O
with O
a O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
for O
germline O
mutations O
in O
BRCA1 O
. O

Twenty O
- O
two O
different O
mutations O
were O
detected O
in O
32 O
families O
( O
53 O
% O
) O
, O
of O
which O
14 O
are O
previously O
unreported O
. O

We O
observed O
a O
significant O
correlation O
between O
the O
location O
of O
the O
mutation O
in O
the O
gene O
and O
the O
ratio O
of O
breast B
to I
ovarian I
cancer I
incidence O
within O
each O
family O
. O

Our O
data O
suggest O
a O
transition O
in O
risk O
such O
that O
mutations O
in O
the O
3 O
third O
of O
the O
gene O
are O
associated O
with O
a O
lower O
proportion O
of O
ovarian B
cancer I
. O

Haplotype O
analysis O
supports O
previous O
data O
which O
suggest O
some O
BRCA1 O
mutation O
carriers O
have O
common O
ancestors O
; O
however O
, O
we O
have O
found O
at O
least O
two O
examples O
where O
recurrent O
mutations O
appear O
to O
have O
arisen O
independently O
. O
. O

Hereditary O
deficiency B
of I
the I
seventh I
component I
of I
complement I
and O
recurrent O
meningococcal B
infection I
: O
investigations O
of O
an O
Irish O
family O
using O
a O
novel O
haemolytic O
screening O
assay O
for O
complement O
activity O
and O
C7 O
M O
/ O
N O
allotyping O
. O

Terminal B
complement I
component I
deficiency I
predisposes O
to O
meningococcal B
infection I
and O
is O
inherited O
in O
an O
autosomal O
co O
- O
dominant O
manner O
. O

An O
Irish O
family O
is O
described O
, O
in O
which O
2 O
of O
3 O
brothers O
had O
recurrent O
meningococcal B
infection I
. O

A O
novel O
screening O
assay O
was O
used O
to O
investigate O
for O
terminal B
complement I
deficiency I
and O
the O
2 O
affected O
brothers O
were O
found O
to O
be O
completely B
deficient I
in I
the I
seventh I
component I
of I
complement I
( O
C7 O
) O
. O

Enzyme O
- O
linked O
immunosorbent O
assay O
for O
C7 O
revealed O
lower O
than O
normal O
levels O
in O
the O
remaining O
brother O
and O
parents O
. O

C7 O
M O
/ O
N O
protein O
polymorphism O
allotyping O
, O
used O
to O
investigate O
the O
segregation O
of O
the O
C7 B
deficiency I
genes O
, O
showed O
that O
the O
apparently O
complement O
sufficient O
brother O
was O
heterozygous O
C7 B
deficient I
and O
a O
carrier O
of O
one O
of O
the O
deficiency O
genes O
. O

Complement O
screening O
should O
be O
carried O
out O
in O
any O
individual O
suffering O
recurrent O
meningococcal B
infection I
or O
infection O
with O
an O
uncommon O
meningococcal B
serogroup O
. O

Identification O
of O
complement B
deficient I
patients O
allows O
the O
implementation O
of O
strategies O
to O
prevent O
recurrent O
infection O
. O
. O

Molecular O
basis O
of O
subtotal B
complement I
C6 I
deficiency I
. O

A O
carboxy O
- O
terminally O
truncated O
but O
functionally O
active O
C6 O
. O

Individuals O
with O
subtotal B
complement I
C6 I
deficiency I
possess O
a O
C6 O
molecule O
that O
is O
14 O
% O
shorter O
than O
normal O
C6 O
and O
present O
in O
low O
but O
detectable O
concentrations O
( O
1 O
- O
2 O
% O
of O
the O
normal O
mean O
) O
. O

We O
now O
show O
that O
this O
dysmorphic O
C6 O
is O
bactericidally O
active O
and O
lacks O
an O
epitope O
that O
was O
mapped O
to O
the O
most O
carboxy O
- O
terminal O
part O
of O
C6 O
using O
C6 O
cDNA O
fragments O
expressed O
as O
fusion O
proteins O
in O
the O
pUEX O
expression O
system O
. O

We O
thus O
predicted O
that O
the O
abnormal O
C6 O
molecule O
might O
be O
carboxy O
- O
terminally O
truncated O
and O
sought O
a O
mutation O
in O
an O
area O
approximately O
14 O
% O
from O
the O
carboxy O
- O
terminal O
end O
of O
the O
coding O
sequence O
. O

By O
sequencing O
PCR O
- O
amplified O
products O
from O
this O
region O
, O
we O
found O
, O
in O
three O
individuals O
from O
two O
families O
, O
a O
mutation O
that O
might O
plausibly O
be O
responsible O
for O
the O
defect O
. O

All O
three O
have O
an O
abnormal O
5 O
splice O
donor O
site O
of O
intron O
15 O
, O
which O
would O
probably O
prevent O
splicing O
. O

An O
in O
- O
frame O
stop O
codon O
is O
found O
17 O
codons O
downstream O
from O
the O
intron O
boundary O
, O
which O
would O
lead O
to O
a O
truncated O
polypeptide O
13 O
. O

5 O
% O
smaller O
than O
normal O
C6 O
. O

This O
result O
was O
unexpected O
, O
as O
earlier O
studies O
mapped O
the O
C5b O
binding O
site O
, O
or O
a O
putative O
enzymatic O
region O
, O
to O
this O
part O
of O
C6 O
. O

Interestingly O
, O
all O
three O
subjects O
were O
probably O
heterozygous O
for O
both O
subtotal B
C6 I
and I
complete I
C6 I
deficiency I
. O

Myotonic B
dystrophy I
: O
evidence O
for O
a O
possible O
dominant O
- O
negative O
RNA O
mutation O
. O

The O
trinucleotide O
expansion O
mutation O
causing O
myotonic B
dystrophy I
is O
in O
the O
3 O
untranslated O
region O
of O
a O
protein O
kinase O
gene O
. O

The O
molecular O
mechanisms O
by O
which O
the O
expanded O
repeat O
causes O
the O
clinically O
variable O
and O
multisystemic B
disease I
, O
myotonic B
dystrophy I
, O
are O
not O
understood O
. O

It O
has O
been O
particularly O
difficult O
to O
rationalize O
the O
dominant O
inheritance O
with O
the O
fact O
that O
the O
expansion O
mutation O
lies O
outside O
of O
the O
protein O
- O
encoding O
gene O
elements O
, O
and O
should O
not O
be O
translated O
into O
protein O
. O

Here O
we O
use O
muscle O
biopsies O
from O
classical O
adult O
- O
onset O
myotonic B
dystrophy I
patients O
to O
study O
the O
accumulation O
of O
transcripts O
from O
both O
the O
normal O
and O
expanded O
DM B
kinase O
genes O
in O
patient O
muscle O
, O
and O
compare O
the O
results O
to O
normal O
and O
myopathic B
controls O
. O

We O
found O
relatively O
small O
decreases O
of O
DM B
kinase O
RNA O
in O
the O
total O
RNA O
pool O
from O
muscle O
; O
however O
, O
these O
reductions O
were O
not O
disease O
specific O
. O

Analysis O
of O
poly O
( O
A O
) O
+ O
RNA O
showed O
dramatic O
decreases O
of O
both O
the O
mutant O
and O
normal O
DM B
kinase O
RNAs O
, O
and O
these O
changes O
were O
disease O
- O
specific O
. O

Our O
findings O
are O
consistent O
with O
a O
novel O
molecular O
pathogenetic O
mechanism O
for O
myotonic B
dystrophy I
both O
the O
normal O
and O
expanded O
DM B
kinase O
genes O
are O
transcribed O
in O
patient O
muscle O
, O
but O
the O
abnormal O
expansion O
- O
containing O
RNA O
has O
a O
dominant O
effect O
on O
RNA O
metabolism O
by O
preventing O
the O
accumulation O
of O
poly O
( O
A O
) O
+ O
RNA O
. O

The O
ability O
of O
the O
expansion O
mutation O
to O
alter O
accumulation O
of O
poly O
( O
A O
) O
+ O
RNA O
in O
trans O
suggests O
that O
myotonic B
dystrophy I
may O
be O
the O
first O
example O
of O
a O
dominant O
- O
negative O
mutation O
manifested O
at O
the O
RNA O
level O
. O
. O

A O
strong O
candidate O
for O
the O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

A O
strong O
candidate O
for O
the O
17q O
- O
linked O
BRCA1 O
gene O
, O
which O
influences O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
, O
has O
been O
identified O
by O
positional O
cloning O
methods O
. O

Probable O
predisposing O
mutations O
have O
been O
detected O
in O
five O
of O
eight O
kindreds O
presumed O
to O
segregate O
BRCA1 O
susceptibility O
alleles O
. O

The O
mutations O
include O
an O
11 O
- O
base O
pair O
deletion O
, O
a O
1 O
- O
base O
pair O
insertion O
, O
a O
stop O
codon O
, O
a O
missense O
substitution O
, O
and O
an O
inferred O
regulatory O
mutation O
. O

The O
BRCA1 O
gene O
is O
expressed O
in O
numerous O
tissues O
, O
including O
breast O
and O
ovary O
, O
and O
encodes O
a O
predicted O
protein O
of O
1863 O
amino O
acids O
. O

This O
protein O
contains O
a O
zinc O
finger O
domain O
in O
its O
amino O
- O
terminal O
region O
, O
but O
is O
otherwise O
unrelated O
to O
previously O
described O
proteins O
. O

Identification O
of O
BRCA1 O
should O
facilitate O
early O
diagnosis O
of O
breast B
and I
ovarian I
cancer I
susceptibility O
in O
some O
individuals O
as O
well O
as O
a O
better O
understanding O
of O
breast B
cancer I
biology O
. O
. O

Molecular O
characterization O
of O
galactosemia B
( O
type O
1 O
) O
mutations O
in O
Japanese O
. O

We O
characterized O
two O
novel O
mutations O
of O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
in O
two O
Japanese O
patients O
with O
GALT B
deficiency I
and O
identified O
N314D O
and O
R333W O
mutations O
, O
previously O
found O
in O
Caucasians O
. O

One O
novel O
missense O
mutation O
was O
an O
G O
- O
to O
- O
A O
transition O
in O
exon O
8 O
, O
resulting O
in O
the O
substitution O
of O
arginine O
by O
histidine O
at O
the O
codon O
231 O
( O
R231H O
) O
. O

GALT O
activity O
of O
the O
R231H O
mutant O
construct O
was O
reduced O
to O
15 O
% O
of O
normal O
controls O
in O
a O
COS O
cell O
expression O
system O
. O

The O
other O
was O
a O
splicing O
mutation O
, O
an O
A O
- O
to O
- O
G O
transition O
at O
the O
38th O
nucleotide O
in O
exon O
3 O
( O
318A O
- O
- O
> O
G O
) O
, O
resulting O
in O
a O
38 O
- O
bp O
deletion O
in O
the O
GALT O
cDNA O
by O
activating O
a O
cryptic O
splice O
acceptor O
site O
. O

In O
seven O
Japanese O
families O
( O
14 O
alleles O
for O
classic O
form O
and O
one O
allele O
for O
Duarte O
variant O
) O
with O
GALT B
deficiency I
, O
the O
R231H O
and O
318A O
- O
- O
> O
G O
mutations O
were O
found O
only O
on O
both O
alleles O
of O
the O
proband O
. O

The O
N314D O
and O
R333W O
mutations O
were O
found O
on O
one O
allele O
each O
. O

The O
Q188R O
was O
prevalent O
in O
the O
United O
States O
but O
not O
in O
Japanese O
patients O
. O

The O
N314D O
mutation O
was O
associated O
with O
the O
Duarte O
variant O
in O
Japanese O
persons O
, O
as O
well O
as O
in O
the O
United O
States O
. O

We O
speculate O
that O
classic B
galactosemia I
mutations O
appear O
to O
differ O
between O
Japanese O
and O
Caucasian O
patients O
. O

Our O
limited O
data O
set O
on O
galactosemia B
mutations O
in O
Japanese O
suggests O
that O
the O
N314D O
GALT O
mutation O
encoding O
the O
Duarte O
variant O
arose O
before O
Asian O
and O
Caucasian O
people O
diverged O
and O
that O
classic B
galactosemia I
mutations O
arose O
and O
/ O
or O
accumulated O
after O
the O
divergence O
of O
Asian O
and O
Caucasian O
populations O
. O
. O

Three O
novel O
aniridia B
mutations O
in O
the O
human O
PAX6 O
gene O
. O

Aniridia B
( O
iris B
hypoplasia I
) O
is O
an O
autosomal B
dominant I
congenital I
disorder I
of I
the I
eye I
. O

Mutations O
in O
the O
human O
aniridia B
( O
PAX6 O
) O
gene O
have O
now O
been O
identified O
in O
many O
patients O
from O
various O
ethnic O
groups O
. O

In O
the O
study O
reported O
here O
we O
describe O
PAX6 O
mutations O
in O
one O
sporadic O
and O
five O
familial O
cases O
with O
aniridia B
. O

Of O
the O
four O
different O
mutations O
identified O
, O
one O
was O
identical O
to O
a O
previously O
reported O
mutation O
( O
C O
- O
- O
> O
T O
transition O
at O
codon O
240 O
) O
, O
and O
three O
were O
novel O
two O
in O
the O
glycine O
- O
rich O
region O
and O
one O
in O
the O
proline O
/ O
serine O
/ O
threonine O
- O
rich O
( O
PST O
) O
region O
. O

One O
PAX6 O
mutation O
found O
in O
the O
PST O
region O
was O
associated O
with O
cataracts B
in O
an O
aniridia B
family O
. O

Another O
splice O
mutation O
in O
the O
PST O
domain O
occurred O
in O
an O
aniridia B
patient O
with O
anosmia B
( O
inability O
to O
smell O
) O
. O

The O
six O
new O
aniridia B
cases O
reported O
here O
have O
mutations O
predicted O
to O
generate O
incomplete O
PAX6 O
proteins O
. O

These O
results O
support O
the O
theory O
that O
human O
aniridia B
is O
caused O
by O
haploinsufficiency B
of I
PAX6 I
. O
. O

The O
carrier O
frequency O
of O
the O
BRCA1 O
185delAG O
mutation O
is O
approximately O
1 O
percent O
in O
Ashkenazi O
Jewish O
individuals O
. O

Since O
BRCA1 O
, O
the O
first O
major O
gene O
responsible O
for O
inherited B
breast I
cancer I
, O
was O
cloned O
, O
more O
than O
50 O
unique O
mutations O
have O
been O
detected O
in O
the O
germline O
of O
individuals O
with O
breast B
and I
ovarian I
cancer I
. O

In O
high O
- O
risk O
pedigrees O
, O
female O
carriers O
of O
BRCA1 O
mutations O
have O
an O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
, O
and O
a O
40 O
- O
50 O
% O
risk O
of O
ovarian B
cancer I
. O

However O
, O
the O
mutation O
stats O
of O
individuals O
unselected O
for O
breast B
or I
ovarian I
cancer I
has O
not O
been O
determined O
, O
and O
it O
is O
not O
known O
whether O
mutations O
in O
such O
individuals O
confer O
the O
same O
risk O
of O
cancer B
as O
in O
individuals O
from O
the O
high O
- O
risk O
families O
studied O
so O
far O
. O

Following O
the O
finding O
of O
a O
185delAG O
frameshift O
mutation O
in O
several O
Ashkenazi O
Jewish O
breast O
/ O
ovarian O
families O
, O
we O
have O
determined O
the O
frequency O
of O
this O
mutation O
in O
858 O
Ashkenazim O
seeking O
genetic O
testing O
for O
conditions O
unrelated O
to O
cancer B
, O
and O
in O
815 O
reference O
individuals O
not O
selected O
for O
ethnic O
origin O
. O

We O
observed O
the O
185delAG O
mutation O
in O
0 O
. O

9 O
% O
of O
Ashkenazim O
( O
95 O
% O
confidence O
limit O
, O
0 O
. O
4 O
- O
1 O
. O
8 O
% O
) O
and O
in O
none O
of O
the O
reference O
samples O
. O

Our O
results O
suggest O
that O
one O
in O
a O
hundred O
women O
of O
Ashkenazi O
descent O
may O
be O
at O
especially O
high O
risk O
of O
developing O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

Identification O
and O
localization O
of O
huntingtin O
in O
brain O
and O
human O
lymphoblastoid O
cell O
lines O
with O
anti O
- O
fusion O
protein O
antibodies O
. O

The O
Huntington B
disease I
( O
HD B
) O
phenotype O
is O
associated O
with O
expansion O
of O
a O
trinucleotide O
repeat O
in O
the O
IT15 O
gene O
, O
which O
is O
predicted O
to O
encode O
a O
348 O
- O
kDa O
protein O
named O
huntington O
. O

We O
used O
polyclonal O
and O
monoclonal O
anti O
- O
fusion O
protein O
antibodies O
to O
identify O
native O
huntingtin O
in O
rat O
, O
monkey O
, O
and O
human O
. O

Western O
blots O
revealed O
a O
protein O
with O
the O
expected O
molecular O
weight O
which O
is O
present O
in O
the O
soluble O
fraction O
of O
rat O
and O
monkey O
brain O
tissues O
and O
lymphoblastoid O
cells O
from O
control O
cases O
. O

In O
lymphoblastoid O
cell O
lines O
from O
juvenile O
- O
onset O
heterozygote O
HD B
cases O
, O
both O
normal O
and O
mutant O
huntingtin O
are O
expressed O
, O
and O
increasing O
repeat O
expansion O
leads O
to O
lower O
levels O
of O
the O
mutant O
protein O
. O

Immunocytochemistry O
indicates O
that O
huntingtin O
is O
located O
in O
neurons O
throughout O
the O
brain O
, O
with O
the O
highest O
levels O
evident O
in O
larger O
neurons O
. O

In O
the O
human O
striatum O
, O
huntingtin O
is O
enriched O
in O
a O
patch O
- O
like O
distribution O
, O
potentially O
corresponding O
to O
the O
first O
areas O
affected O
in O
HD B
. O

Subcellular O
localization O
of O
huntingtin O
is O
consistent O
with O
a O
cytosolic O
protein O
primarily O
found O
in O
somatodendritic O
regions O
. O

Huntingtin O
appears O
to O
particularly O
associate O
with O
microtubules O
, O
although O
some O
is O
also O
associated O
with O
synaptic O
vesicles O
. O

On O
the O
basis O
of O
the O
localization O
of O
huntingtin O
in O
association O
with O
microtubules O
, O
we O
speculate O
that O
the O
mutation O
impairs O
the O
cytoskeletal O
anchoring O
or O
transport O
of O
mitochondria O
, O
vesicles O
, O
or O
other O
organelles O
or O
molecules O
. O
. O

Marked O
phenotypic O
heterogeneity O
associated O
with O
expansion O
of O
a O
CAG O
repeat O
sequence O
at O
the O
spinocerebellar B
ataxia I
3 I
/ I
Machado I
- I
Joseph I
disease I
locus O
. O

The O
spinocerebellar B
ataxia I
3 I
locus O
( O
SCA3 B
) O
for O
type B
I I
autosomal I
dominant I
cerebellar I
ataxia I
( O
ADCA B
type I
I I
) O
, O
a O
clinically O
and O
genetically O
heterogeneous O
group O
of O
neurodegenerative B
disorders I
, O
has O
been O
mapped O
to O
chromosome O
14q32 O
. O

1 O
1 O
. O

ADCA B
type I
I I
patients O
from O
families O
segregating O
SCA3 B
share O
clinical O
features O
in O
common O
with O
those O
with O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
, O
the O
gene O
of O
which O
maps O
to O
the O
same O
region O
. O

We O
show O
here O
that O
the O
disease O
gene O
segregating O
in O
each O
of O
three O
French O
ADCA B
type I
I I
kindreds O
and O
in O
a O
French O
family O
with O
neuropathological O
findings O
suggesting O
the O
ataxochoreic O
form O
of O
dentatorubropallidoluysian B
atrophy I
carries O
an O
expanded O
CAG O
repeat O
sequence O
located O
at O
the O
same O
locus O
as O
that O
for O
MJD B
. O

Analysis O
of O
the O
mutation O
in O
these O
families O
shows O
a O
strong O
negative O
correlation O
between O
size O
of O
the O
expanded O
CAG O
repeat O
and O
age O
at O
onset O
of O
clinical O
disease O
. O

Instability O
of O
the O
expanded O
triplet O
repeat O
was O
not O
found O
to O
be O
affected O
by O
sex O
of O
the O
parent O
transmitting O
the O
mutation O
. O

Evidence O
was O
found O
for O
somatic O
and O
gonadal O
mosaicism O
for O
alleles O
carrying O
expanded O
trinucleotide O
repeats O
. O

Overexpression O
of O
DM20 O
messenger O
RNA O
in O
two O
brothers O
with O
Pelizaeus B
- I
Merzbacher I
disease I
. O

Pelizaeus B
- I
Merzbacher I
disease I
is O
a O
rare B
, I
sex I
- I
linked I
recessive I
, I
dysmyelinating I
disease I
of I
the I
central I
nervous I
system I
that O
has O
been O
associated O
with O
mutations O
in O
the O
myelin O
proteolipid O
protein O
( O
PLP O
) O
gene O
. O

Only O
25 O
% O
of O
patients O
studied O
with O
Pelizaeus B
- I
Merzbacher I
disease I
have O
exonic O
mutations O
in O
this O
gene O
, O
the O
underlying O
cause O
of O
the O
disease O
in O
the O
remaining O
patients O
is O
unknown O
. O

The O
PLP O
gene O
encodes O
two O
major O
alternatively O
spliced O
transcripts O
called O
PLP O
and O
DM20 O
. O

PLP O
messenger O
RNA O
is O
specifically O
expressed O
in O
central O
nervous O
system O
tissue O
, O
whereas O
DM20 O
messenger O
RNA O
is O
found O
in O
central O
nervous O
system O
, O
cardiac O
, O
and O
other O
tissues O
. O

We O
studied O
cultured O
skin O
fibroblasts O
from O
2 O
brothers O
with O
Pelizaeus B
- I
Merzbacher I
disease I
who O
exhibited O
no O
detectable O
exonic O
mutation O
of O
the O
PLP O
gene O
. O

Examination O
of O
RNA O
from O
these O
cells O
showed O
that O
the O
level O
of O
DM20 O
messenger O
RNA O
is O
elevated O
sixfold O
relative O
to O
male O
control O
skin O
fibroblasts O
. O

An O
unrelated O
female O
carrier O
, O
also O
with O
no O
detectable O
exonic O
mutation O
, O
showed O
a O
threefold O
increase O
in O
DM20 O
messenger O
RNA O
in O
cultured O
skin O
fibroblasts O
. O

Our O
findings O
suggest O
that O
in O
some O
patients O
, O
Pelizaeus B
- I
Merzbacher I
disease I
is O
caused O
by O
overexpression O
of O
PLP O
gene O
transcripts O
, O
and O
that O
in O
these O
families O
a O
50 O
% O
increase O
of O
DM20 O
messenger O
RNA O
in O
females O
, O
relative O
to O
the O
increase O
in O
affected O
males O
, O
can O
identify O
a O
female O
carrier O
. O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
and O
X B
- I
linked I
congenital I
thrombocytopenia I
are O
caused O
by O
mutations O
of O
the O
same O
gene O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
is O
an O
X B
- I
linked I
recessive I
disorder I
characterized O
by O
thrombocytopenia B
, O
small O
platelets O
, O
eczema B
, O
recurrent O
infections O
, O
and O
immunodeficiency B
. O

Besides O
the O
classic O
WAS B
phenotype O
, O
there O
is O
a O
group O
of O
patients O
with O
congenital B
X I
- I
linked I
thrombocytopenia I
( O
XLT B
) O
who O
have O
small O
platelets O
but O
only O
transient O
eczema B
, O
if O
any O
, O
and O
minimal O
immune B
deficiency I
. O

Because O
the O
gene O
responsible O
for O
WAS B
has O
been O
sequenced O
, O
it O
was O
possible O
to O
correlate O
the O
WAS B
phenotypes O
with O
WAS B
gene O
mutations O
. O

Using O
a O
fingerprinting O
screening O
technique O
, O
we O
determined O
the O
approximate O
location O
of O
the O
mutation O
in O
13 O
unrelated O
WAS B
patients O
with O
mild O
to O
severe O
clinical O
symptoms O
. O

Direct O
sequence O
analysis O
of O
cDNA O
and O
genomic O
DNA O
obtained O
from O
patient O
- O
derived O
cell O
lines O
showed O
12 O
unique O
mutations O
distributed O
throughout O
the O
WAS B
gene O
, O
including O
insertions O
, O
deletions O
, O
and O
point O
mutations O
resulting O
in O
amino O
acid O
substitutions O
, O
termination O
, O
exon O
skipping O
, O
or O
splicing O
defects O
. O

Of O
4 O
unrelated O
patients O
with O
the O
XLT B
phenotype O
, O
3 O
had O
missense O
mutations O
affecting O
exon O
2 O
and O
1 O
had O
a O
splice O
- O
site O
mutation O
affecting O
exon O
9 O
. O

Patients O
with O
classic O
WAS B
had O
more O
complex O
mutations O
, O
resulting O
in O
termination O
codons O
, O
frameshift O
, O
and O
early O
termination O
. O

These O
findings O
provide O
direct O
evidence O
that O
XLT B
and O
WAS B
are O
caused O
by O
mutations O
of O
the O
same O
gene O
and O
suggest O
that O
severe O
clinical O
phenotypes O
are O
associated O
with O
complex O
mutations O
. O
. O

Myotonia B
levior I
is O
a O
chloride B
channel I
disorder I
. O

The O
group O
of O
dominant B
non I
- I
dystrophic I
myotonias I
, O
comprising O
disorders O
characterized O
by O
clinically O
similar O
forms O
of O
myogenic O
muscle O
stiffness O
, O
is O
genetically O
inhomogeneous O
. O

Dominant B
myotonia I
congenita I
( O
Thomsens B
disease I
) O
is O
linked O
to O
CLCN1 O
, O
the O
gene O
encoding O
the O
major O
muscle O
chloride O
channel O
, O
localized O
on O
chromosome O
7q35 O
. O

In O
contrast O
, O
dominant B
myotonias I
sensitive O
to O
potassium O
are O
caused O
by O
point O
mutations O
in O
SCN4A O
on O
chromosome O
17q O
, O
the O
gene O
for O
the O
alpha O
subunit O
of O
the O
adult O
skeletal O
muscle O
sodium O
channel O
. O

No O
linkage O
or O
molecular O
genetic O
data O
are O
as O
yet O
available O
on O
myotonia B
levior I
characterized O
by O
milder O
symptoms O
and O
later O
onset O
of O
myotonia B
than O
in O
Thomsens B
disease I
, O
and O
absence O
of O
muscle B
hypertrophy I
. O

We O
report O
a O
CLCN1 O
Gln O
- O
552 O
- O
Arg O
substitution O
for O
a O
family O
with O
dominant O
inheritance O
previously O
diagnosed O
to O
have O
myotonia B
levior I
. O

Thus O
, O
this O
disorder O
appears O
as O
a O
variant O
of O
Thomsens B
disease I
due O
to O
mutations O
leading O
to O
low O
clinical O
expressivity O
. O

In O
addition O
, O
we O
report O
a O
novel O
Ile O
- O
290 O
- O
Met O
CLCN1 O
mutation O
for O
a O
typical O
Thomsen O
pedigree O
. O

In O
another O
family O
previously O
diagnosed O
as O
having O
Thomsens B
disease I
, O
we O
unexpectedly O
found O
a O
CLCN1 O
14 O
bp O
deletion O
known O
to O
cause O
recessive B
myotonia I
, O
and O
a O
rare O
Trp O
- O
118 O
- O
Gly O
polymorphism O
. O
. O

Southern O
analysis O
reveals O
a O
large O
deletion O
at O
the O
hypoxanthine O
phosphoribosyltransferase O
locus O
in O
a O
patient O
with O
Lesch B
- I
Nyhan I
syndrome I
. O

Whole O
genomic O
hprt O
clones O
were O
used O
in O
Southern O
analysis O
to O
screen O
the O
integrity O
of O
the O
hprt O
gene O
in O
a O
family O
that O
includes O
a O
patient O
with O
HPRT B
enzyme I
deficiency I
causal O
to O
Lesch B
- I
Nyhan I
syndrome I
. O

A O
5 O
kb O
DNA O
sequence O
deletion O
was O
found O
to O
have O
its O
endpoints O
in O
the O
first O
and O
third O
introns O
. O

The O
probes O
identified O
the O
carrier O
status O
of O
female O
family O
members O
, O
aided O
by O
an O
RFLP O
carried O
by O
the O
mothers O
normal O
X O
- O
chromosome O
. O
. O

Characterisation O
of O
molecular O
defects O
in O
X B
- I
linked I
amelogenesis I
imperfecta I
( O
AIH1 O
) O
. O

Amelogenins O
are O
an O
heterogenous O
family O
of O
proteins O
produced O
by O
ameloblasts O
of O
the O
enamel O
organ O
during O
tooth O
development O
. O

Disturbances O
of O
enamel O
formation O
occur O
in O
amelogenesis B
imperfecta I
, O
a O
clinically O
heterogenous O
group O
of O
inherited B
disorders I
characterised O
by O
defective O
enamel O
biomineralisation O
. O

An O
amelogenin O
gene O
, O
AMGX O
, O
has O
been O
mapped O
to O
the O
short O
of O
the O
X O
chromosome O
( O
Xp22 O
. O
1 O
- O
p22 O
. O
3 O
) O
and O
has O
been O
implicated O
in O
the O
molecular O
pathology O
of O
X B
- I
linked I
amelogenesis I
imperfecta I
( O
AIH1 B
) O
. O

We O
have O
identified O
three O
families O
exhibiting O
AIH1 B
and O
screened O
the O
AMGX O
gene O
for O
mutations O
using O
single O
- O
strand O
conformational O
polymorphism O
analysis O
and O
DNA O
sequencing O
. O

Three O
novel O
mutations O
were O
identified O
a O
C O
- O
T O
substitution O
in O
exon O
5 O
, O
and O
a O
G O
- O
T O
substitution O
and O
single O
cytosine O
deletion O
in O
exon O
6 O
, O
confirming O
the O
existence O
of O
extensive O
allelic O
heterogeneity O
in O
this O
condition O
. O

The O
identification O
of O
family O
- O
specific O
mutations O
will O
enable O
early O
identification O
of O
affected O
individuals O
and O
correlation O
of O
clinical O
phenotype O
with O
genotype O
will O
facilitate O
an O
objective O
system O
of O
disease O
classification O
. O

Frequency O
of O
exon O
15 O
missense O
mutation O
( O
442D O
: O
G O
) O
in O
cholesteryl O
ester O
transfer O
protein O
gene O
in O
hyperalphalipoproteinemic B
Japanese O
subjects O
. O

Cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
transfers O
cholesteryl O
ester O
from O
high O
density O
lipoprotein O
( O
HDL O
) O
to O
apo O
B O
- O
containing O
lipoproteins O
. O

The O
hyperalphalipoproteinemia B
caused O
by O
CETP B
deficiency I
is O
fairly O
common O
in O
Japan O
and O
one O
of O
the O
most O
common O
mutations O
in O
the O
CETP O
gene O
is O
the O
splicing O
defect O
of O
the O
intron O
14 O
, O
the O
allelic O
frequency O
of O
which O
has O
been O
shown O
to O
be O
0 O
. O

0049 O
in O
the O
Japanese O
general O
population O
. O

Recently O
, O
we O
have O
reported O
a O
missense O
mutation O
in O
exon O
15 O
of O
the O
CETP O
gene O
( O
442D O
G O
) O
, O
showing O
a O
dominant O
effect O
on O
the O
CETP O
activity O
and O
HDL O
- O
cholesterol O
level O
. O

In O
the O
current O
study O
, O
we O
determined O
the O
frequency O
of O
this O
new O
mutation O
in O
Japanese O
hyperalphalipoproteinemic B
( O
HDL O
- O
cholesterol O
> O
or O
= O
100 O
mg O
/ O
dl O
) O
subjects O
. O

A O
rapid O
and O
easy O
screening O
method O
for O
this O
new O
mutation O
was O
developed O
using O
a O
polymerase O
chain O
reaction O
( O
PCR O
) O
- O
mediated O
site O
- O
directed O
mutagenesis O
. O

Among O
117 O
Japanese O
hyperalphalipoproteinemic B
subjects O
( O
HDL O
- O
cholesterol O
; O
116 O
. O
7 O
+ O
/ O
- O
16 O
. O
5 O
mg O
/ O
dl O
, O
mean O
+ O
/ O
- O
S O
. O
D O
. O
) O
without O
the O
intron O
14 O
splice O
defect O
, O
three O
homozygotes O
( O
2 O
. O
5 O
% O
) O
and O
34 O
heterozygotes O
( O
29 O
. O
1 O
% O
) O
were O
found O
to O
have O
the O
442D O
G O
mutation O
. O

The O
relative O
allelic O
frequency O
of O
this O
mutation O
was O
calculated O
to O
be O
0 O
. O

17 O
. O

One O
of O
the O
homozygotes O
for O
the O
442D O
G O
mutation O
was O
the O
patient O
previously O
described O
by O
us O
as O
having O
hyperalphalipoproteinemia B
with O
corneal B
opacity I
and O
coronary B
heart I
disease I
. O

This O
was O
the O
first O
reported O
subject O
homozygous O
for O
the O
CETP B
deficiency I
who O
also O
demonstrated O
atherosclerotic B
symptoms I
. O

In O
homozygous O
subjects O
, O
CETP O
activity O
ranged O
from O
37 O
% O
to O
62 O
% O
of O
the O
normal O
value O
, O
which O
was O
consistent O
with O
the O
results O
obtained O
from O
the O
transient O
expression O
experiment O
previously O
reported O
; O
however O
, O
the O
specific O
activity O
of O
CETP O
was O
not O
as O
low O
as O
expected O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Mucopolysaccharidosis B
type I
IVA I
: O
common O
double O
deletion O
in O
the O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfatase O
gene O
( O
GALNS O
) O
. O

Mucopolysaccharidosis B
IVA I
( O
MPS B
IVA I
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
in I
N I
- I
acetylgalactosamine I
- I
6 I
- I
sulfatase I
( O
GALNS O
) O
. O

We O
found O
two O
separate O
deletions O
of O
nearly O
8 O
. O

0 O
and O
6 O
. O

0 O
kb O
in O
the O
GALNS O
gene O
, O
including O
some O
exons O
. O

There O
are O
Alu O
repetitive O
elements O
near O
the O
breakpoints O
of O
the O
8 O
. O

0 O
- O
kb O
deletion O
, O
and O
this O
deletion O
resulted O
from O
an O
Alu O
- O
Alu O
recombination O
. O

The O
other O
6 O
. O

0 O
- O
kb O
deletion O
involved O
illegitimate O
recombinational O
events O
between O
incomplete O
short O
direct O
repeats O
of O
8 O
bp O
at O
deletion O
breakpoints O
. O

The O
same O
rearrangement O
has O
been O
observed O
in O
a O
heteroallelic O
state O
in O
four O
unrelated O
patients O
. O

This O
is O
the O
first O
documentation O
of O
a O
common O
double O
deletion O
a O
gene O
that O
is O
not O
a O
member O
of O
a O
gene O
cluster O
. O

Detection O
of O
eight O
BRCA1 O
mutations O
in O
10 O
breast B
/ I
ovarian I
cancer I
families O
, O
including O
1 O
family O
with O
male B
breast I
cancer I
. O

Genetic O
epidemiological O
evidence O
suggests O
that O
mutations O
in O
BRCA1 O
may O
be O
responsible O
for O
approximately O
one O
half O
of O
early O
onset O
familial B
breast I
cancer I
and O
the O
majority O
of O
familial B
breast I
/ I
ovarian I
cancer I
. O

The O
recent O
cloning O
of O
BRCA1 O
allows O
for O
the O
direct O
detection O
of O
mutations O
, O
but O
the O
feasibility O
of O
presymptomatic O
screening O
for O
cancer B
susceptibility O
is O
unknown O
. O

We O
analyzed O
genomic O
DNA O
from O
one O
affected O
individual O
from O
each O
of O
24 O
families O
with O
at O
least O
three O
cases O
of O
ovarian B
or I
breast I
cancer I
, O
using O
SSCP O
assays O
. O

Variant O
SSCP O
bands O
were O
subcloned O
and O
sequenced O
. O

Allele O
- O
specific O
oligonucleotide O
hybridization O
was O
used O
to O
verify O
sequence O
changes O
and O
to O
screen O
DNA O
from O
control O
individuals O
. O

Six O
frameshift O
and O
two O
missense O
mutations O
were O
detected O
in O
10 O
different O
families O
. O

A O
frameshift O
mutation O
was O
detected O
in O
a O
male O
proband O
affected O
with O
both O
breast B
and I
prostate I
cancer I
. O

A O
40 O
- O
bp O
deletion O
was O
detected O
in O
a O
patient O
who O
developed O
intra B
- I
abdominal I
carcinomatosis I
1 O
year O
after O
prophylactic O
oophorectomy O
. O

Mutations O
were O
detected O
throughout O
the O
gene O
, O
and O
only O
one O
was O
detected O
in O
more O
than O
a O
single O
family O
. O

These O
results O
provide O
further O
evidence O
that O
inherited B
breast I
and I
ovarian I
cancer I
can O
occur O
as O
a O
consequence O
of O
a O
wide O
array O
of O
BRCA1 O
mutations O
. O

These O
results O
suggests O
that O
development O
of O
a O
screening O
test O
for O
BRCA1 O
mutations O
will O
be O
technically O
challenging O
. O

The O
finding O
of O
a O
mutation O
in O
a O
family O
with O
male B
breast I
cancer I
, O
not O
previously O
thought O
to O
be O
related O
to O
BRCA1 O
, O
also O
illustrates O
the O
potential O
difficulties O
of O
genetic O
counseling O
for O
individuals O
known O
to O
carry O
mutations O
. O
. O

Natural O
selection O
of O
hemi O
- O
and O
heterozygotes O
for O
G6PD B
deficiency I
in O
Africa O
by O
resistance O
to O
severe O
malaria B
. O

Glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
, O
the O
most O
common O
enzymopathy B
of O
humans O
, O
affects O
over O
400 O
million O
people O
. O

The O
geographical O
correlation O
of O
its O
distribution O
with O
the O
historical O
endemicity O
of O
malaria B
suggests O
that O
this O
disorder O
has O
risen O
in O
frequency O
through O
natural O
selection O
by O
malaria B
. O

However O
, O
attempts O
to O
confirm O
that O
G6PD B
deficiency I
is O
protective O
in O
case O
- O
control O
studies O
of O
malaria B
have O
yielded O
conflicting O
results O
. O

Hence O
, O
for O
this O
X B
- I
linked I
disorder I
, O
it O
is O
unclear O
whether O
both O
male O
hemizygotes O
and O
female O
heterozygotes O
are O
protected O
or O
, O
as O
frequently O
suggested O
, O
only O
females O
. O

Furthermore O
, O
how O
much O
protection O
may O
be O
afforded O
is O
unknown O
. O

Here O
we O
report O
that O
, O
in O
two O
large O
case O
- O
control O
studies O
of O
over O
2 O
, O
000 O
African O
children O
, O
the O
common O
African O
form O
of O
G6PD B
deficiency I
( O
G6PD B
A I
- I
) O
is O
associated O
with O
a O
46 O
- O
58 O
% O
reduction O
in O
risk O
of O
severe O
malaria B
for O
both O
female O
heterozygotes O
and O
male O
hemizygotes O
. O

A O
mathematical O
model O
incorporating O
the O
measured O
selective O
advantage O
against O
malaria B
suggests O
that O
a O
counterbalancing O
selective O
disadvantage O
, O
associated O
with O
this O
enzyme B
deficiency I
, O
has O
retarded O
its O
rise O
in O
frequency O
in O
malaria B
- O
endemic O
regions O
. O

Although O
G6PD B
deficiency I
is O
now O
regarded O
as O
a O
generally O
benign O
disorder O
, O
in O
earlier O
environmental O
conditions O
it O
could O
have O
been O
significantly O
disadvantageous O
. O
. O

The O
alveolar B
rhabdomyosarcoma I
PAX3 O
/ O
FKHR O
fusion O
protein O
is O
a O
transcriptional O
activator O
. O

Chimeric O
transcription O
factors O
, O
created O
by O
gene O
fusions O
as O
the O
result O
of O
chromosomal O
translocations O
, O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
several O
pathologically O
disparate O
solid B
tumors I
. O

The O
PAX3 O
/ O
FKHR O
fusion O
gene O
, O
formed O
by O
a O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
in O
alveolar B
rhabdomyosarcoma I
, O
encodes O
a O
hybrid O
protein O
that O
contains O
both O
PAX3 O
DNA O
binding O
domains O
, O
the O
paired O
box O
and O
homeodomain O
, O
linked O
to O
the O
bisected O
DNA O
binding O
domain O
of O
FKHR O
, O
a O
member O
of O
the O
forkhead O
family O
of O
transcription O
factors O
. O

Here O
we O
report O
that O
PAX3 O
and O
PAX3 O
/ O
FKHR O
display O
similar O
, O
but O
not O
identical O
transactivation O
activities O
when O
tested O
with O
model O
Pax O
recognition O
sequences O
. O

No O
functional O
role O
could O
be O
ascribed O
solely O
to O
the O
residual O
FKHR O
binding O
domain O
present O
in O
the O
fusion O
protein O
, O
but O
FKHR O
was O
found O
to O
contribute O
a O
strong O
carboxyl O
terminal O
activation O
domain O
replacing O
the O
one O
located O
in O
the O
unrearranged O
PAX3 O
gene O
. O

We O
show O
that O
the O
native O
PAX3 O
/ O
FKHR O
protein O
present O
in O
tumor B
cells O
with O
this O
translocation O
has O
transcriptional O
characteristics O
similar O
to O
the O
in O
vitro O
expressed O
protein O
. O

The O
ability O
of O
the O
PAX3 O
/ O
FKHR O
hybrid O
protein O
to O
bind O
DNA O
in O
a O
sequence O
specific O
manner O
and O
to O
transactivate O
the O
expression O
of O
artificial O
reporter O
genes O
suggests O
that O
its O
aberrant O
expression O
could O
subvert O
the O
transcriptional O
programs O
that O
normally O
control O
the O
growth O
, O
differentiation O
, O
and O
survival O
of O
primitive O
myogenic O
precursors O
in O
vivo O
. O
. O

A O
p16INK4a O
- O
insensitive O
CDK4 O
mutant O
targeted O
by O
cytolytic O
T O
lymphocytes O
in O
a O
human O
melanoma B
. O

A O
mutated O
cyclin O
- O
dependent O
kinase O
4 O
( O
CDK4 O
) O
was O
identified O
as O
a O
tumor B
- O
specific O
antigen O
recognized O
by O
HLA O
- O
A2 O
. O

1 O
- O
restricted O
autologous O
cytolytic O
T O
lymphocytes O
( O
CTLs O
) O
in O
a O
human O
melanoma B
. O

The O
mutated O
CDK4 O
allele O
was O
present O
in O
autologous O
cultured O
melanoma B
cells O
and O
metastasis O
tissue O
, O
but O
not O
in O
the O
patients O
lymphocytes O
. O

The O
mutation O
, O
an O
arginine O
- O
to O
- O
cysteine O
exchange O
at O
residue O
24 O
, O
was O
part O
of O
the O
CDK4 O
peptide O
recognized O
by O
CTLs O
and O
prevented O
binding O
of O
the O
CDK4 O
inhibitor O
p16INK4a O
, O
but O
not O
of O
p21 O
or O
of O
p27KIP1 O
. O

The O
same O
mutation O
was O
found O
in O
one O
additional O
melanoma B
among O
28 O
melanomas B
analyzed O
. O

These O
results O
suggest O
that O
mutation O
of O
CDK4 O
can O
create O
a O
tumor B
- O
specific O
antigen O
and O
can O
disrupt O
the O
cell O
- O
cycle O
regulation O
exerted O
by O
the O
tumor B
suppressor O
p16INK4a O
. O
. O

Rapid O
detection O
of O
BRCA1 O
mutations O
by O
the O
protein O
truncation O
test O
. O

More O
than O
75 O
% O
of O
the O
reported O
mutations O
in O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
result O
in O
truncated O
proteins O
. O

We O
have O
used O
the O
protein O
truncation O
test O
( O
PTT O
) O
to O
screen O
for O
mutations O
in O
exon O
11 O
, O
which O
encodes O
61 O
% O
of O
BRCA1 O
. O

In O
45 O
patients O
from O
breast B
and I
/ I
or I
ovarian I
cancer I
families O
we O
found O
six O
novel O
mutations O
two O
single O
nucleotide O
insertions O
, O
three O
small O
deletions O
( O
1 O
- O
5 O
bp O
) O
and O
a O
nonsense O
mutation O
identified O
two O
unrelated O
families O
. O

Furthermore O
, O
we O
were O
able O
to O
amplify O
the O
remaining O
coding O
region O
by O
RT O
- O
PCR O
using O
lymphocyte O
RNA O
. O

Combined O
with O
PTT O
, O
we O
detected O
aberrantly O
spliced O
products O
affecting O
exons O
5 O
and O
6 O
in O
one O
of O
two O
BRCA1 O
- O
linked O
families O
examined O
. O

The O
protein O
truncation O
test O
promises O
to O
become O
a O
valuable O
technique O
in O
detecting O
BRCA1 O
mutations O
. O
. O

Cloning O
of O
human O
very O
- O
long O
- O
chain O
acyl O
- O
coenzyme O
A O
dehydrogenase O
and O
molecular O
characterization O
of O
its O
deficiency O
in O
two O
patients O
. O

Two O
overlapping O
cDNA O
clones O
( O
1 O
, O
991 O
bp O
and O
736 O
bp O
, O
respectively O
) O
encoding O
the O
precursor O
of O
human O
mitochondrial O
very O
- O
long O
- O
chain O
acyl O
- O
coenzyme O
A O
dehydrogenase O
( O
VLCAD O
) O
were O
cloned O
and O
sequenced O
. O

The O
cDNA O
inserts O
of O
these O
clones O
together O
encompass O
a O
region O
of O
2 O
, O
177 O
bases O
, O
encoding O
the O
entire O
protein O
of O
655 O
amino O
acids O
, O
including O
a O
40 O
- O
amino O
acid O
leader O
peptide O
and O
a O
615 O
- O
amino O
acid O
mature O
polypeptide O
. O

PCR O
- O
amplified O
VLCAD O
cDNAs O
were O
sequenced O
in O
cultured O
fibroblasts O
from O
two O
VLCAD B
- I
deficient I
patients O
. O

In O
both O
patients O
, O
a O
105 O
- O
bp O
deletion O
encompassing O
bases O
1078 O
- O
1182 O
in O
VLCAD O
cDNA O
was O
identified O
. O

The O
deletion O
seems O
to O
occur O
due O
to O
exon O
skipping O
during O
processing O
of O
VLCAD O
pre O
- O
mRNA O
. O

This O
is O
the O
first O
demonstration O
of O
a O
mutation O
causing O
VLCAD B
deficiency I
. O

Quantitative O
cDNA O
expression O
of O
normal O
human O
VLCAD O
was O
performed O
in O
the O
patients O
fibroblasts O
, O
using O
vaccinia O
viral O
system O
, O
which O
demonstrated O
that O
the O
deficiency B
of I
the I
normal I
VLCAD I
protein I
causes O
impaired O
long O
- O
chain O
fatty O
acid O
beta O
- O
oxidation O
activity O
in O
the O
patients O
fibroblasts O
. O

In O
patient O
fibroblasts O
, O
raising O
VLCAD O
activity O
to O
approximately O
20 O
% O
of O
normal O
control O
fibroblast O
activity O
raised O
palmitic O
acid O
beta O
- O
oxidation O
flux O
to O
the O
level O
found O
in O
control O
fibroblasts O
, O
which O
may O
offer O
important O
information O
for O
the O
rational O
design O
of O
future O
somatic O
gene O
therapy O
for O
VLCAD B
deficiency I
. O
. O

Brain B
disease I
and O
molecular O
analysis O
in O
myotonic B
dystrophy I
. O

Abnormal O
amplification O
of O
a O
CTG O
repeat O
on O
chromosome O
19 O
is O
the O
molecular O
basis O
of O
myotonic B
dystrophy I
( O
DM B
) O
. O

Expansion O
of O
the O
repeat O
has O
been O
correlated O
with O
severity O
of O
several O
clinical O
features O
of O
the O
disease O
. O

We O
performed O
extensive O
cognitive O
testing O
, O
cerebral O
magnetic O
resonance O
imaging O
( O
MRI O
) O
and O
a O
molecular O
analysis O
in O
28 O
cases O
of O
DM B
to O
determine O
the O
relationship O
between O
the O
molecular O
defect O
and O
brain B
disease I
. O

Performance O
in O
two O
or O
more O
cognitive O
tests O
was O
pathological O
in O
10 O
cases O
. O

Fourteen O
patients O
had O
subcortical O
white B
matter I
lesions I
on O
MRI O
, O
14 O
had O
cerebral B
atrophy I
. O

Amplification O
of O
the O
CTG O
repeat O
showed O
a O
strong O
correlation O
with O
cognitive O
test O
deficits O
when O
exceeding O
a O
length O
of O
over O
1000 O
trinucleotides O
. O

MRI O
lesions O
were O
associated O
with O
impaired O
psychometric O
performance O
, O
but O
MRI O
and O
molecular O
findings O
were O
only O
weakly O
related O
. O

Disease O
duration O
influenced O
the O
appearance O
and O
amount O
of O
white B
matter I
lesions I
on O
MRI O
. O

Quantification O
of O
CTG O
repeat O
size O
may O
allow O
an O
early O
estimate O
on O
the O
probability O
of O
brain O
involvement O
in O
DM B
; O
cognitive B
dysfunction I
is O
associated O
with O
white B
matter I
lesions I
and O
cerebral B
atrophy I
later O
on O
in O
the O
course O
. O
. O

Mutations O
in O
the O
gene O
for O
X B
- I
linked I
adrenoleukodystrophy I
in O
patients O
with O
different O
clinical O
phenotypes O
. O

Recently O
, O
the O
gene O
for O
the O
most O
common O
peroxisomal B
disorder I
, O
X B
- I
linked I
adrenoleukodystrophy I
( O
X B
- I
ALD I
) O
, O
has O
been O
described O
encoding O
a O
peroxisomal O
membrane O
transporter O
protein O
. O

We O
analyzed O
the O
entire O
protein O
- O
coding O
sequence O
of O
this O
gene O
by O
reverse O
- O
transcription O
PCR O
, O
SSCP O
, O
and O
DNA O
sequencing O
in O
five O
patients O
with O
different O
clinical O
expression O
of O
X B
- I
ALD I
and O
in O
their O
female O
relatives O
; O
these O
clinical O
expressions O
were O
cerebral O
childhood O
ALD B
, O
adrenomyeloneuropathy B
( O
AMN B
) O
, O
and O
" O
Addison B
disease I
only I
" O
( O
ADO B
) O
phenotype O
. O

In O
the O
three O
patients O
exhibiting O
the O
classical O
picture O
of O
severe O
childhood O
ALD B
we O
identified O
in O
the O
5 O
portion O
of O
the O
X B
- I
ALD I
gene O
a O
38 O
- O
bp O
deletion O
that O
causes O
a O
frameshift O
mutation O
, O
a O
3 O
- O
bp O
deletion O
leading O
to O
a O
deletion O
of O
an O
amino O
acid O
in O
the O
ATP O
- O
binding O
domain O
of O
the O
ALD B
protein O
, O
and O
a O
missense O
mutation O
. O

In O
the O
patient O
with O
the O
clinical O
phenotype O
of O
AMN B
, O
a O
nonsense O
mutation O
in O
codon O
212 O
, O
along O
with O
a O
second O
site O
mutation O
at O
codon O
178 O
, O
was O
observed O
. O

Analysis O
of O
the O
patient O
with O
the O
ADO B
phenotype O
revealed O
a O
further O
missense O
mutation O
at O
a O
highly O
conserved O
position O
in O
the O
ALDP O
/ O
PMP70 O
comparison O
. O

The O
disruptive O
nature O
of O
two O
mutations O
( O
i O
. O
e O
. O
, O
the O
frameshift O
and O
the O
nonsense O
mutation O
) O
in O
patients O
with O
biochemically O
proved O
childhood O
ALD B
and O
AMN B
further O
strongly O
supports O
the O
hypothesis O
that O
alterations O
in O
this O
gene O
play O
a O
crucial O
role O
in O
the O
pathogenesis O
of O
X B
- I
ALD I
. O

Since O
the O
current O
biochemical O
techniques O
for O
X B
- I
ALD I
carrier O
detection O
in O
affected O
families O
lack O
sufficient O
reliability O
, O
our O
procedure O
described O
for O
systematic O
mutation O
scanning O
is O
also O
capable O
of O
improving O
genetic O
counseling O
and O
prenatal O
diagnosis O

Duchenne B
muscular I
dystrophy I
and O
myotonic B
dystrophy I
in O
the O
same O
patient O
. O

We O
report O
on O
the O
first O
patient O
identified O
with O
myotonic B
dystrophy I
and O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

The O
family O
of O
the O
propositus O
had O
a O
strong O
history O
of O
myotonic B
dystrophy I
, O
and O
there O
was O
an O
intrafamilial O
pathological O
expansion O
of O
the O
responsible O
CTG O
repeat O
between O
the O
mildly O
affected O
mother O
( O
160 O
repeats O
; O
normal O
27 O
repeats O
) O
and O
her O
more O
severely O
affected O
son O
( O
650 O
repeats O
) O
, O
and O
his O
sister O
( O
650 O
repeats O
) O
. O

The O
propositus O
was O
an O
isolated O
case O
of O
Duchenne B
muscular I
dystrophy I
with O
marked O
dystrophin B
deficiency I
in O
muscle O
biopsy O
. O

The O
patient O
was O
still O
ambulatory O
post O
age O
16 O
. O

Myotonic B
dystrophy I
could O
interfere O
to O
some O
extent O
with O
the O
progression O
of O
Duchenne B
dystrophy I
. O

However O
, O
other O
interpretations O
are O
possible O
. O

Twelve O
percent O
of O
dystrophin O
revertant O
fibers O
as O
observed O
by O
immunohistochemistry O
could O
be O
sufficient O
to O
ameliorate O
typical O
DMD B
clinical O
severity O
, O
or O
the O
patient O
may O
present O
a O
somatic O
mosaic O
. O

The O
pathophysiological O
interactions O
of O
these O
two O
unlinked O
disorders O
are O
discussed O
at O
the O
clinical O
and O
histopathological O
levels O
. O
. O

Age O
at O
diagnosis O
as O
an O
indicator O
of O
eligibility O
for O
BRCA1 O
DNA O
testing O
in O
familial B
breast I
cancer I
. O

We O
searched O
for O
criteria O
that O
could O
indicate O
breast B
cancer I
families O
with O
a O
high O
prior O
probability O
of O
being O
caused O
by O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
locus O
BRCA1 O
on O
chromosome O
17 O
. O

To O
this O
end O
, O
we O
performed O
a O
linkage O
study O
with O
59 O
consecutively O
collected O
Dutch O
breast B
cancer I
families O
, O
including O
16 O
with O
at O
least O
one O
case O
of O
ovarian B
cancer I
. O

We O
used O
an O
intake O
cut O
- O
off O
of O
at O
least O
three O
first O
- O
degree O
relatives O
with O
breast B
and I
/ I
or I
ovarian I
cancer I
at O
any O
age O
. O

Significant O
evidence O
for O
linkage O
was O
found O
only O
among O
the O
13 O
breast B
cancer I
families O
with O
a O
mean O
age O
at O
diagnosis O
of O
less O
than O
45 O
years O
. O

An O
unexpectedly O
low O
proportion O
of O
the O
breast B
- I
ovarian I
cancer I
families O
were O
estimated O
to O
be O
linked O
to O
BRCA1 O
, O
which O
could O
be O
due O
to O
a O
founder O
effect O
in O
the O
Dutch O
population O
. O

Given O
the O
expected O
logistical O
problems O
in O
clinical O
management O
now O
that O
BRCA1 O
has O
been O
identified O
, O
we O
propose O
an O
interim O
period O
in O
which O
only O
families O
with O
a O
strong O
positive O
family O
history O
for O
early O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
will O
be O
offered O
BRCA1 O
mutation O
testing O
. O
. O

Linkage O
analysis O
of O
26 O
Canadian O
breast B
and I
breast I
- I
ovarian I
cancer I
families O
. O

We O
have O
examined O
26 O
Canadian O
families O
with O
hereditary B
breast I
or I
ovarian I
cancer I
for O
linkage O
to O
markers O
flanking O
the O
BRCA1 O
gene O
on O
chromosome O
17q12 O
- O
q21 O
. O

Of O
the O
15 O
families O
that O
contain O
cases O
of O
ovarian B
cancer I
, O
94 O
% O
were O
estimated O
to O
be O
linked O
to O
BRCA1 O
. O

In O
contrast O
, O
there O
was O
no O
overall O
evidence O
of O
linkage O
in O
the O
group O
of O
10 O
families O
with O
breast B
cancer I
without O
ovarian B
cancer I
. O

A O
genetic O
recombinant O
in O
a O
breast B
- I
ovarian I
cancer I
family O
indicates O
a O
placement O
of O
BRCA1 O
telomeric O
to O
D17S776 O
, O
and O
helps O
to O
define O
the O
region O
of O
assignment O
of O
the O
cancer B
susceptibility O
gene O
. O

Other O
cancers B
of O
interest O
that O
appeared O
in O
the O
BRCA1 O
- O
linked O
families O
included O
primary B
peritoneal I
cancer I
, O
cancer B
of I
the I
fallopian I
tube I
, O
and O
malignant B
melanoma I
. O
. O

Structural O
analysis O
of O
the O
5 O
' O
region O
of O
mouse O
and O
human O
Huntington B
disease I
genes O
reveals O
conservation O
of O
putative O
promoter O
region O
and O
di O
- O
and O
trinucleotide O
polymorphisms O
. O

We O
have O
previously O
cloned O
and O
characterized O
the O
murine O
homologue O
of O
the O
Huntington B
disease I
( O
HD B
) O
gene O
and O
shown O
that O
it O
maps O
to O
mouse O
chromosome O
5 O
within O
a O
region O
of O
conserved O
synteny O
with O
human O
chromosome O
4p16 O
. O

3 O
3 O
. O

Here O
we O
present O
a O
detailed O
comparison O
of O
the O
sequence O
of O
the O
putative O
promoter O
and O
the O
organization O
of O
the O
5 O
genomic O
region O
of O
the O
murine O
( O
Hdh O
) O
and O
human O
HD B
genes O
encompassing O
the O
first O
five O
exons O
. O

We O
show O
that O
in O
this O
region O
these O
two O
genes O
share O
identical O
exon O
boundaries O
, O
but O
have O
different O
- O
size O
introns O
. O

Two O
dinucleotide O
( O
CT O
) O
and O
one O
trinucleotide O
intronic O
polymorphism O
in O
Hdh O
and O
an O
intronic O
CA O
polymorphism O
in O
the O
HD B
gene O
were O
identified O
. O

Comparison O
of O
940 O
- O
bp O
sequence O
5 O
to O
the O
putative O
translation O
start O
site O
reveals O
a O
highly O
conserved O
region O
( O
78 O
. O
8 O
% O
nucleotide O
identity O
) O
between O
Hdh O
and O
the O
HD B
gene O
from O
nucleotide O
- O
56 O
to O
- O
206 O
( O
of O
Hdh O
) O
. O

Neither O
Hdh O
nor O
the O
HD B
gene O
have O
typical O
TATA O
or O
CCAAT O
elements O
, O
but O
both O
show O
one O
putative O
AP2 O
binding O
site O
and O
numerous O
potential O
Sp1 O
binding O
sites O
. O

The O
high O
sequence O
identity O
between O
Hdh O
and O
the O
HD B
gene O
for O
approximately O
200 O
bp O
5 O
to O
the O
putative O
translation O
start O
site O
indicates O
that O
these O
sequences O
may O
play O
a O
role O
in O
regulating O
expression O
of O
the O
Huntington B
disease I
gene O

The O
protein O
deficient O
in O
Lowe B
syndrome I
is O
a O
phosphatidylinositol O
- O
4 O
, O
5 O
- O
bisphosphate O
5 O
- O
phosphatase O
. O

Lowe B
syndrome I
, O
also O
known O
as O
oculocerebrorenal B
syndrome I
, O
is O
caused O
by O
mutations O
in O
the O
X O
chromosome O
- O
encoded O
OCRL O
gene O
. O

The O
OCRL O
protein O
is O
51 O
% O
identical O
to O
inositol O
polyphosphate O
5 O
- O
phosphatase O
II O
( O
5 O
- O
phosphatase O
II O
) O
from O
human O
platelets O
over O
a O
span O
of O
744 O
aa O
, O
suggesting O
that O
OCRL O
may O
be O
a O
similar O
enzyme O
. O

We O
engineered O
a O
construct O
of O
the O
OCRL O
cDNA O
that O
encodes O
amino O
acids O
homologous O
to O
the O
platelet O
5 O
- O
phosphatase O
for O
expression O
in O
baculovirus O
- O
infected O
Sf9 O
insect O
cells O
. O

This O
cDNA O
encodes O
aa O
264 O
- O
968 O
of O
the O
OCRL O
protein O
. O

The O
recombinant O
protein O
was O
found O
to O
catalyze O
the O
reactions O
also O
carried O
out O
by O
platelet O
5 O
- O
phosphatase O
II O
. O

Thus O
OCRL O
converts O
inositol O
1 O
, O
4 O
, O
5 O
- O
trisphosphate O
to O
inositol O
1 O
, O
4 O
- O
bisphosphate O
, O
and O
it O
converts O
inositol O
1 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrakisphosphate O
to O
inositol O
1 O
, O
3 O
, O
4 O
- O
trisphosphate O
. O

Most O
important O
, O
the O
enzyme O
converts O
phosphatidylinositol O
4 O
, O
5 O
- O
bisphosphate O
to O
phosphatidylinositol O
4 O
- O
phosphate O
. O

The O
relative O
ability O
of O
OCRL O
to O
catalyze O
the O
three O
reactions O
is O
different O
from O
that O
of O
5 O
- O
phosphatase O
II O
and O
from O
that O
of O
another O
5 O
- O
phosphatase O
isoenzyme O
from O
platelets O
, O
5 O
- O
phosphatase O
I O
. O

The O
recombinant O
OCRL O
protein O
hydrolyzes O
the O
phospholipid O
substrate O
10 O
- O
to O
30 O
- O
fold O
better O
than O
5 O
- O
phosphatase O
II O
, O
and O
5 O
- O
phosphatase O
I O
does O
not O
cleave O
the O
lipid O
at O
all O
. O

We O
also O
show O
that O
OCRL O
functions O
as O
a O
phosphatidylinositol O
4 O
, O
5 O
- O
bisphosphate O
5 O
- O
phosphatase O
in O
OCRL O
- O
expressing O
Sf9 O
cells O
. O

These O
results O
suggest O
that O
OCRL O
is O
mainly O
a O
lipid O
phosphatase O
that O
may O
control O
cellular O
levels O
of O
a O
critical O
metabolite O
, O
phosphatidylinositol O
4 O
, O
5 O
- O
bisphosphate O
. O

Deficiency O
of O
this O
enzyme O
apparently O
causes O
the O
protean O
manifestations O
of O
Lowe B
syndrome I
. O
. O

New O
founder O
haplotypes O
at O
the O
myotonic B
dystrophy I
locus O
in O
southern O
Africa O
. O

The O
association O
between O
normal O
alleles O
at O
the O
CTG O
repeat O
and O
two O
nearby O
polymorphisms O
in O
the O
myotonin O
protein O
kinase O
gene O
, O
the O
Alu O
insertion O
/ O
deletion O
polymorphism O
and O
the O
myotonic B
dystrophy I
kinase O
( O
DMK O
) O
( O
G O
/ O
T O
) O
intron O
9 O
/ O
HinfI O
polymorphism O
, O
has O
been O
analyzed O
in O
South O
African O
Negroids O
, O
a O
population O
in O
which O
myotonic B
dystrophy I
( O
DM B
) O
has O
not O
been O
described O
. O

South O
African O
Negroids O
have O
a O
CTG O
allelic O
distribution O
that O
is O
significantly O
different O
from O
that O
in O
Caucasoids O
and O
Japanese O
the O
CTG O
repeat O
lengths O
of O
> O
or O
= O
19 O
are O
very O
rare O
. O

The O
striking O
linkage O
disequilibrium O
between O
specific O
alleles O
at O
the O
Alu O
polymorphism O
( O
Alu O
( O
ins O
) O
and O
Alu O
( O
del O
) O
) O
, O
the O
HinfI O
polymorphism O
( O
HinfI O
- O
1 O
and O
HinfI O
- O
2 O
) O
, O
and O
the O
CTG O
repeat O
polymorphism O
seen O
in O
Caucasoid O
( O
Europeans O
and O
Canadians O
) O
populations O
was O
also O
found O
in O
the O
South O
African O
Negroid O
population O
. O

Numerous O
haplotypes O
, O
not O
previously O
described O
in O
Europeans O
, O
were O
, O
however O
, O
found O
. O

It O
thus O
seems O
likely O
that O
only O
a O
small O
number O
of O
these O
" O
African O
" O
chromosomes O
were O
present O
in O
the O
progenitors O
of O
all O
non O
- O
African O
peoples O
. O

These O
data O
provide O
support O
for O
the O
" O
out O
of O
Africa O
" O
model O
for O
the O
origin O
of O
modern O
humans O
and O
suggest O
that O
the O
rare O
ancestral O
DM B
mutation O
event O
may O
have O
occurred O
after O
the O
migration O
from O
Africa O
, O
hence O
the O
absence O
of O
DM B
in O
sub O
- O
Saharan O
Negroid O
peoples O
. O
. O

Discordant O
clinical O
outcome O
in O
myotonic B
dystrophy I
relatives O
showing O
( O
CTG O
) O
n O
> O
700 O
repeats O
. O

A O
myotonic B
dystrophy I
( O
DM B
) O
family O
is O
described O
in O
which O
discordant O
DM B
phenotypes O
were O
found O
in O
the O
children O
of O
two O
affected O
sisters O
with O
similar O
CTG O
expansion O
and O
clinical O
manifestations O
. O

In O
this O
family O
, O
congenital O
as O
well O
as O
early O
severe O
childhood O
and O
later O
childhood O
onset O
DM B
coexist O
. O

This O
observation O
strengthens O
the O
limited O
ability O
of O
lymphocytes O
CTG O
repeat O
number O
analysis O
in O
predicting O
genotype O
- O
phenotype O
correlations O
in O
DM B
patients O
. O
. O

Purification O
of O
human O
very O
- O
long O
- O
chain O
acyl O
- O
coenzyme O
A O
dehydrogenase O
and O
characterization O
of O
its O
deficiency O
in O
seven O
patients O
. O

Mitochondrial O
very O
- O
long O
- O
chain O
acyl O
- O
coenzyme O
A O
dehydrogenase O
( O
VLCAD O
) O
was O
purified O
from O
human O
liver O
. O

The O
molecular O
masses O
of O
the O
native O
enzyme O
and O
the O
subunit O
were O
estimated O
to O
be O
154 O
and O
70 O
kD O
, O
respectively O
. O

The O
enzyme O
was O
found O
to O
catalyze O
the O
major O
part O
of O
mitochondrial O
palmitoylcoenzyme O
A O
dehydrogenation O
in O
liver O
, O
heart O
, O
skeletal O
muscle O
, O
and O
skin O
fibroblasts O
( O
89 O
- O
97 O
, O
86 O
- O
99 O
, O
96 O
- O
99 O
, O
and O
78 O
- O
87 O
% O
, O
respectively O
) O
. O

Skin O
fibroblasts O
from O
26 O
patients O
suspected O
of O
having O
a O
disorder O
of O
mitochondrial O
beta O
- O
oxidation O
were O
analyzed O
for O
VLCAD O
protein O
using O
immunoblotting O
, O
and O
7 O
of O
them O
contained O
undetectable O
or O
trace O
levels O
of O
the O
enzyme O
. O

The O
seven O
deficient O
fibroblast O
lines O
were O
characterized O
by O
measuring O
acyl O
- O
coenzyme O
A O
dehydrogenation O
activities O
, O
overall O
palmitic O
acid O
oxidation O
, O
and O
VLCAD O
protein O
synthesis O
using O
pulse O
- O
chase O
, O
further O
confirming O
the O
diagnosis O
of O
VLCAD B
deficiency I
. O

These O
results O
suggested O
the O
heterogenous O
nature O
of O
the O
mutations O
causing O
the O
deficiency O
in O
the O
seven O
patients O
. O

Clinically O
, O
all O
patients O
with O
VLCAD B
deficiency I
exhibited O
cardiac B
disease I
. O

At O
least O
four O
of O
them O
presented O
with O
hypertrophic B
cardiomyopathy I
. O

This O
frequency O
( O
> O
57 O
% O
) O
was O
much O
higher O
than O
that O
observed O
in O
patients O
with O
other O
disorders O
of O
mitochondrial O
long O
- O
chain O
fatty O
acid O
oxidation O
that O
may O
be O
accompanied O
by O
cardiac B
disease I
in O
infants O
. O
. O

Hereditary B
deficiency I
of I
the I
fifth I
component I
of I
complement I
in O
man O
. O

II O
. O

Biological O
properties O
of O
C5 B
- I
deficient I
human O
serum O
. O

The O
first O
known O
human O
kindred O
with O
hereditary B
deficiency I
of I
the I
fifth I
component I
of I
complement I
( O
C5 O
) O
was O
documented O
in O
the O
accompanying O
report O
. O

This O
study O
examines O
several O
biological O
properties O
of O
C5 B
- I
deficient I
( O
C5D B
) O
human O
serum O
, O
particularly O
sera O
obtained O
from O
two O
C5D B
homozygotes O
. O

The O
proband O
, O
who O
has O
inactive O
systemic B
lupus I
erythematosus I
is O
completely O
lacking O
C5 O
, O
while O
her O
healthy O
half O
- O
sister O
has O
1 O
- O
2 O
% O
of O
normal O
levels O
. O

Both O
sera O
were O
severely O
impaired O
in O
their O
ability O
to O
generate O
chemotactic O
activity O
for O
normal O
human O
neutrophils O
upon O
incubation O
with O
aggregated O
human O
gamma O
- O
globulin O
or O
Escherichia O
coli O
endotoxin O
. O

This O
function O
was O
fully O
restored O
in O
the O
siblings O
serum O
, O
and O
substantially O
improved O
in O
the O
probands O
serum O
, O
by O
addition O
of O
highly O
purified O
human O
C5 O
to O
normal O
serum O
concentrations O
. O

Sera O
from O
eight O
family O
members O
who O
were O
apparently O
heterozygous O
for O
C5 B
deficiency I
gave O
normal O
chemotactic O
scores O
. O

The O
ability O
of O
C5D B
serum O
to O
opsonize O
Saccharomyces O
cerevisiae O
( O
bakers O
yeast O
) O
or O
Candida O
albicans O
for O
ingestion O
by O
normal O
neutrophils O
was O
completely O
normal O
. O

In O
addition O
, O
C5D B
serum O
was O
capable O
of O
promoting O
normal O
phagocytosis O
and O
intracellular O
killing O
of O
Staphylococcus O
aureus O
. O

The O
probands O
serum O
was O
incapable O
of O
mediating O
lysis O
of O
erythrocytes O
from O
a O
patient O
with O
paroxysmal B
nocturnal I
hemoglobinuria I
in O
both O
the O
sucrose O
hemolysia O
and O
acid O
hemolysis O
tests O
, O
and O
also O
lacked O
bactericidal O
activity O
against O
sensitized O
or O
unsensitized O
Salmonella O
typhi O
. O

The O
siblings O
serum O
, O
containing O
only O
1 O
- O
2 O
% O
of O
normal O
C5 O
, O
effectively O
lysed O
S O
. O
typhi O
, O
but O
only O
at O
eightfold O
lower O
serum O
dilutions O
as O
compared O
to O
normals O
. O

These O
findings O
underscore O
the O
critical O
role O
of O
C5 O
in O
the O
generation O
of O
chemotactic O
activity O
and O
in O
cytolytic O
reactions O
, O
as O
opposed O
to O
a O
nonobligatory O
or O
minimal O
role O
in O
opsonization O
, O
at O
least O
for O
the O
organisms O
under O
study O
. O
. O

Human O
peroxisomal O
targeting O
signal O
- O
1 O
receptor O
restores O
peroxisomal O
protein O
import O
in O
cells O
from O
patients O
with O
fatal O
peroxisomal B
disorders I
. O

Two O
peroxisomal O
targeting O
signals O
, O
PTS1 O
and O
PTS2 O
, O
are O
involved O
in O
the O
import O
of O
proteins O
into O
the O
peroxisome O
matrix O
. O

Human O
patients O
with O
fatal O
generalized O
peroxisomal B
deficiency I
disorders I
fall O
into O
at O
least O
nine O
genetic O
complementation O
groups O
. O

Cells O
from O
many O
of O
these O
patients O
are O
deficient O
in O
the O
import O
of O
PTS1 O
- O
containing O
proteins O
, O
but O
the O
causes O
of O
the O
protein O
- O
import O
defect O
in O
these O
patients O
are O
unknown O
. O

We O
have O
cloned O
and O
sequenced O
the O
human O
cDNA O
homologue O
( O
PTS1R O
) O
of O
the O
Pichia O
pastoris O
PAS8 O
gene O
, O
the O
PTS1 O
receptor O
( O
McCollum O
, O
D O
. O
, O
E O
. O
Monosov O
, O
and O
S O
. O
Subramani O
. O
1993 O
. O
J O
. O
Cell O
Biol O
. O
121 O
761 O
- O
774 O
) O
. O

The O
PTS1R O
mRNA O
is O
expressed O
in O
all O
human O
tissues O
examined O
. O

Antibodies O
to O
the O
human O
PTS1R O
recognize O
this O
protein O
in O
human O
, O
monkey O
, O
rat O
, O
and O
hamster O
cells O
. O

The O
protein O
is O
localized O
mainly O
in O
the O
cytosol O
but O
is O
also O
found O
to O
be O
associated O
with O
peroxisomes O
. O

Part O
of O
the O
peroxisomal O
PTS1R O
protein O
is O
tightly O
bound O
to O
the O
peroxisomal O
membrane O
. O

Antibodies O
to O
PTS1R O
inhibit O
peroxisomal O
protein O
- O
import O
of O
PTS1 O
- O
containing O
proteins O
in O
a O
permeabilized O
CHO O
cell O
system O
. O

In O
vitro O
- O
translated O
PTS1R O
protein O
specifically O
binds O
a O
serine O
- O
lysine O
- O
leucine O
- O
peptide O
. O

A O
PAS8 O
- O
PTS1R O
fusion O
protein O
complements O
the O
P O
. O
pastoris O
pas8 O
mutant O
. O

The O
PTS1R O
cDNA O
also O
complements O
the O
PTS1 B
protein I
- I
import I
defect I
in O
skin O
fibroblasts O
from O
patients O
- O
- O
belonging O
to O
complementation O
group O
two O
- O
- O
diagnosed O
as O
having O
neonatal B
adrenoleukodystrophy I
or O
Zellweger B
syndrome I
. O

The O
PTS1R O
gene O
has O
been O
localized O
to O
a O
chromosomal O
location O
where O
no O
other O
peroxisomal B
disorder I
genes O
are O
known O
to O
map O
. O

Our O
findings O
represent O
the O
only O
case O
in O
which O
the O
molecular O
basis O
of O
the O
protein B
- I
import I
deficiency I
in O
human O
peroxisomal B
disorders I
is O
understood O
. O

Spectrum O
of O
germline O
mutations O
in O
the O
RB1 O
gene O
: O
a O
study O
of O
232 O
patients O
with O
hereditary B
and I
non I
hereditary I
retinoblastoma I
. O

Germline O
mutations O
in O
the O
RB1 O
gene O
confer O
hereditary O
predisposition O
to O
retinoblastoma B
. O

We O
have O
performed O
a O
mutation O
survey O
of O
the O
RB1 O
gene O
in O
232 O
patients O
with O
hereditary B
or I
non I
hereditary I
retinoblastoma I
. O

We O
systematically O
explored O
all O
27 O
exons O
and O
flanking O
sequences O
as O
well O
as O
the O
promotor O
. O

All O
types O
of O
point O
mutations O
are O
represented O
and O
are O
found O
unequally O
distributed O
along O
the O
RB1 O
gene O
sequence O
. O

In O
the O
population O
we O
studied O
, O
exons O
3 O
, O
8 O
, O
18 O
and O
19 O
are O
preferentially O
altered O
. O

The O
range O
of O
frequency O
of O
detection O
of O
germline O
mutations O
is O
about O
20 O
% O
, O
indicating O
that O
other O
mechanisms O
of O
inactivation O
of O
RB1 O
should O
be O
involved O
. O

The O
spectrum O
of O
mutations O
presented O
here O
should O
help O
to O
improve O
the O
clinical O
management O
of O
retinoblastoma B
and O
to O
understand O
the O
molecular O
mechanisms O
leading O
to O
tumorigenesis O
. O
. O

Aniridia B
- O
associated O
cytogenetic O
rearrangements O
suggest O
that O
a O
position O
effect O
may O
cause O
the O
mutant O
phenotype O
. O

Current O
evidence O
suggests O
that O
aniridia B
( O
absence B
of I
iris I
) O
is O
caused O
by O
loss O
of O
function O
of O
one O
copy O
of O
the O
PAX6 O
gene O
, O
which O
maps O
to O
11p13 O
. O

We O
present O
the O
further O
characterisation O
of O
two O
aniridia B
pedigrees O
in O
which O
the O
disease O
segregates O
with O
chromosomal O
rearrangements O
which O
involve O
11p13 O
but O
do O
not O
disrupt O
the O
PAX6 O
gene O
. O

We O
have O
isolated O
three O
human O
YAC O
clones O
which O
encompass O
the O
PAX6 O
locus O
and O
we O
have O
used O
these O
to O
show O
that O
in O
both O
cases O
the O
chromosomal O
breakpoint O
is O
at O
least O
85 O
kb O
distal O
of O
the O
3 O
end O
of O
PAX6 O
. O

In O
addition O
, O
the O
open O
reading O
frame O
of O
PAX6 O
is O
apparently O
free O
of O
mutations O
. O

We O
propose O
that O
the O
PAX6 O
gene O
on O
the O
rearranged O
chromosome O
11 O
is O
in O
an O
inappropriate O
chromatin O
environment O
for O
normal O
expression O
and O
therefore O
that O
a O
position O
effect O
is O
the O
underlying O
mechanism O
of O
disease O
in O
these O
families O
. O
. O

Somatic O
mutations O
in O
the O
BRCA1 O
gene O
in O
sporadic B
ovarian I
tumours I
. O

The O
BRCA1 O
gene O
on O
chromosome O
17q21 O
is O
responsible O
for O
an O
autosomal B
dominant I
syndrome I
of O
increased O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
but O
no O
somatic O
mutations O
in O
tumours B
have O
yet O
been O
described O
. O

To O
study O
the O
potential O
role O
of O
BRCA1 O
in O
sporadic O
carcinogenesis O
, O
we O
analysed O
the O
genomic O
DNA O
of O
tumour B
and O
normal O
fractions O
of O
47 O
ovarian B
cancers I
for O
mutations O
in O
BRCA1 O
using O
the O
single O
- O
strand O
conformation O
polymorphism O
technique O
. O

We O
now O
describe O
somatic O
mutations O
in O
the O
DNA O
of O
four O
tumours B
which O
also O
had O
loss O
of O
heterozygosity O
( O
LOH O
) O
at O
a O
BRCA1 O
intragenic O
marker O
. O

Our O
data O
support O
a O
tumour B
suppressor O
mechanism O
for O
BRCA1 O
; O
somatic O
mutations O
and O
LOH O
may O
result O
in O
inactivation O
of O
BRCA1 O
in O
at O
least O
a O
small O
number O
of O
ovarian B
cancers I
. O
. O

Decreased O
expression O
of O
BRCA1 O
accelerates O
growth O
and O
is O
often O
present O
during O
sporadic B
breast I
cancer I
progression O
. O

We O
have O
characterized O
expression O
of O
the O
familial B
breast I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
in O
cases O
of O
non B
- I
hereditary I
( I
sporadic I
) I
breast I
cancer I
and O
analyzed O
the O
effect O
of O
antisense O
inhibition O
of O
BRCA1 O
on O
the O
proliferative O
rate O
of O
mammary O
epithelial O
cells O
. O

BRCA1 O
mRNA O
levels O
are O
markedly O
decreased O
during O
the O
transition O
from O
carcinoma B
in I
situ I
to O
invasive B
cancer I
. O

Experimental O
inhibition O
of O
BRCA1 O
expression O
with O
antisense O
oligonucleotides O
produced O
accelerated O
growth O
of O
normal O
and O
malignant O
mammary O
cells O
, O
but O
had O
no O
effect O
on O
non O
- O
mammary O
epithelial O
cells O
. O

These O
studies O
suggest O
that O
BRCA1 O
may O
normally O
serve O
as O
a O
negative O
regulator O
of O
mammary O
epithelial O
cell O
growth O
whose O
function O
is O
compromised O
in O
breast B
cancer I
either O
by O
direct O
mutation O
or O
alterations O
in O
gene O
expression O
. O
. O

Additional O
case O
of O
female O
monozygotic O
twins O
discordant O
for O
the O
clinical O
manifestations O
of O
Duchenne B
muscular I
dystrophy I
due O
to O
opposite O
X O
- O
chromosome O
inactivation O
. O

A O
pair O
of O
female O
monozygotic O
( O
MZ O
) O
twins O
, O
heterozygous O
carriers O
for O
a O
deletion O
in O
the O
DMD B
gene O
and O
discordant O
for O
the O
clinical O
manifestations O
of O
Duchenne B
muscular I
dystrophy I
, O
were O
analyzed O
by O
molecular O
studies O
, O
in O
situ O
hybridization O
, O
and O
methylation O
pattern O
of O
X O
chromosomes O
to O
search O
for O
opposite O
X O
inactivation O
as O
an O
explanation O
of O
their O
clinical O
discordance O
. O

Results O
in O
lymphocytes O
and O
skin O
fibroblast O
cell O
lines O
suggest O
a O
partial O
mirror O
inactivation O
with O
the O
normal O
X O
chromosome O
preferentially O
active O
in O
the O
unaffected O
twin O
, O
and O
the O
maternal O
deleted O
X O
chromosome O
preferentially O
active O
in O
the O
affected O
twin O
. O

A O
review O
shows O
that O
MZ O
female O
twins O
discordant O
for O
X B
- I
linked I
diseases I
are O
not O
uncommon O
. O

Twinning O
and O
X O
inactivation O
may O
be O
interrelated O
and O
could O
explain O
the O
female O
twins O
discordant O
for O
X O
- O
linked O
traits O
. O
. O

X B
- I
linked I
adrenoleukodystrophy I
( O
ALD B
) O
: O
a O
novel O
mutation O
of O
the O
ALD B
gene O
in O
6 O
members O
of O
a O
family O
presenting O
with O
5 O
different O
phenotypes O
. O

Fragments O
of O
the O
adrenoleukodystrophy B
( O
ALD B
) O
cDNA O
from O
a O
patient O
with O
adolescent B
ALD I
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
subcloned O
. O

Bidirectional O
sequencing O
of O
the O
entire O
coding O
ALD B
gene O
disclosed O
a O
cytosine O
to O
guanine O
transversion O
at O
nucleotide O
1451 O
in O
exon O
five O
, O
resulting O
in O
substitution O
of O
proline O
484 O
by O
arginine O
. O

Five O
of O
nine O
siblings O
of O
the O
patient O
, O
comprising O
two O
cerebral B
ALD I
, O
one O
adrenomyeloneuropathy B
, O
one O
Addison B
only I
as O
well O
as O
the O
symptomatic O
mother O
( O
all O
accumulating O
very O
long O
chain O
fatty O
acids O
) O
carried O
this O
mutation O
, O
which O
was O
not O
found O
in O
the O
unaffected O
persons O
, O
in O
five O
unrelated O
ALD B
patients O
, O
and O
in O
twenty O
controls O
. O

We O
propose O
that O
this O
missense O
mutation O
generated O
the O
disease O
per O
se O
as O
well O
as O
the O
metabolic O
defect O
; O
the O
different O
phenotypes O
, O
however O
, O
must O
have O
originated O
by O
means O
of O
additional O
pathogenetic O
factors O
. O
. O

Novel O
mutation O
at O
the O
initiation O
codon O
in O
the O
Norrie B
disease I
gene O
in O
two O
Japanese O
families O
. O

We O
have O
identified O
a O
new O
mutation O
of O
Norrie B
disease I
( O
ND B
) O
gene O
in O
two O
Japanese O
males O
from O
unrelated O
families O
; O
they O
showed O
typical O
ocular O
features O
of O
ND B
but O
no O
mental B
retardation I
or O
hearing B
impairment I
. O

A O
mutation O
was O
found O
in O
both O
patients O
at O
the O
initiation O
codon O
of O
exon O
2 O
of O
the O
ND B
gene O
( O
ATG O
to O
GTG O
) O
, O
with O
otherwise O
normal O
nucleotide O
sequences O
. O

Their O
mothers O
had O
the O
normal O
and O
mutant O
types O
of O
the O
gene O
, O
which O
was O
expected O
for O
heterozygotes O
of O
the O
disease O
. O

The O
mutation O
of O
the O
initiation O
codon O
would O
cause O
the O
failure O
of O
ND B
gene O
expression O
or O
a O
defect O
in O
translation O
thereby O
truncating O
the O
amino O
terminus O
of O
ND B
protein O
. O

In O
view O
of O
the O
rarity O
and O
marked O
heterogeneity O
of O
mutations O
in O
the O
ND B
gene O
, O
the O
present O
apparently O
unrelated O
Japanese O
families O
who O
have O
lived O
in O
the O
same O
area O
for O
over O
two O
centuries O
presumably O
share O
the O
origin O
of O
the O
mutation O
. O
. O

Anticipation O
resulting O
in O
elimination O
of O
the O
myotonic B
dystrophy I
gene O
: O
a O
follow O
up O
study O
of O
one O
extended O
family O
. O

We O
have O
re O
- O
examined O
an O
extended O
myotonic B
dystrophy I
( O
DM B
) O
family O
, O
previously O
described O
in O
1955 O
, O
in O
order O
to O
study O
the O
long O
term O
effects O
of O
anticipation O
in O
DM B
and O
in O
particular O
the O
implications O
for O
families O
affected O
by O
this O
disease O
. O

This O
follow O
up O
study O
provides O
data O
on O
35 O
gene O
carriers O
and O
46 O
asymptomatic O
at O
risk O
family O
members O
in O
five O
generations O
. O

Clinical O
anticipation O
, O
defined O
as O
the O
cascade O
of O
mild O
, O
adult O
, O
childhood O
, O
or O
congenital B
disease I
in O
subsequent O
generations O
, O
appeared O
to O
be O
a O
relentless O
process O
, O
occurring O
in O
all O
affected O
branches O
of O
the O
family O
. O

The O
cascade O
was O
found O
to O
proceed O
asynchronously O
in O
the O
different O
branches O
, O
mainly O
because O
of O
an O
unequal O
number O
of O
generations O
with O
mild O
disease O
. O

The O
transition O
from O
the O
mild O
to O
the O
adult O
type O
was O
associated O
with O
transmission O
through O
a O
male O
parent O
. O

Stable O
transmission O
of O
the O
asymptomatic O
/ O
mild O
phenotype O
showed O
a O
female O
transmission O
bias O
. O

We O
further O
examined O
the O
extent O
and O
causes O
of O
gene O
loss O
in O
this O
pedigree O
. O

Gene O
loss O
in O
the O
patient O
group O
was O
complete O
, O
owing O
to O
infertility B
of O
the O
male O
patients O
with O
adult O
onset O
disease O
and O
the O
fact O
that O
mentally B
retarded I
patients O
did O
not O
procreate O
. O

Out O
of O
the O
46 O
at O
risk O
subjects O
in O
the O
two O
youngest O
generations O
, O
only O
one O
was O
found O
to O
have O
a O
full O
mutation O
. O

This O
is O
the O
only O
subject O
who O
may O
transmit O
the O
gene O
to O
the O
sixth O
generation O
. O

No O
protomutation O
carriers O
were O
found O
in O
the O
fourth O
and O
fifth O
generations O
. O

Therefore O
it O
is O
highly O
probable O
that O
the O
DM B
gene O
will O
be O
eliminated O
from O
this O
pedigree O
within O
one O
generation O
. O

The O
high O
population O
frequency O
of O
DM B
can O
at O
present O
not O
be O
explained O
by O
the O
contribution O
of O
asymptomatic O
cases O
in O
the O
younger O
generations O
of O
known O
families O
, O
but O
is O
probably O
caused O
by O
the O
events O
in O
the O
ancestral O
generations O
. O
. O

The O
gene O
for O
spinal B
cerebellar I
ataxia I
3 O
( O
SCA3 O
) O
is O
located O
in O
a O
region O
of O
approximately O
3 O
cM O
on O
chromosome O
14q24 O
. O
3 O
- O
q32 O
. O
2 O
. O

SCA3 O
, O
the O
gene O
for O
spinal B
cerebellar I
ataxia I
3 O
, O
was O
recently O
mapped O
to O
a O
15 O
- O
cM O
interval O
between O
D14S67 O
and O
D14S81 O
on O
chromosome O
14q O
, O
by O
linkage O
analysis O
in O
two O
families O
of O
French O
ancestry O
. O

The O
SCA3 O
candidate O
region O
has O
now O
been O
refined O
by O
linkage O
analysis O
with O
four O
new O
microsatellite O
markers O
( O
D14S256 O
, O
D14S291 O
, O
D14S280 O
, O
and O
AFM343vf1 O
) O
in O
the O
same O
two O
families O
, O
in O
which O
19 O
additional O
individuals O
were O
genotyped O
, O
and O
in O
a O
third O
French O
family O
. O

Combined O
two O
- O
point O
linkage O
analyses O
show O
that O
the O
new O
markers O
, O
D14S280 O
and O
AFM343vf1 O
, O
are O
tightly O
linked O
to O
the O
SCA3 O
locus O
, O
with O
maximal O
lod O
scores O
, O
at O
recombination O
fraction O
, O
( O
theta O
) O
= O
. O

00 O
, O
of O
7 O
. O

05 O
and O
13 O
. O

70 O
, O
respectively O
. O

Combined O
multipoint O
and O
recombinant O
haplotype O
analyses O
localize O
the O
SCA3 O
locus O
to O
a O
3 O
- O
cM O
interval O
flanked O
by O
D14S291 O
and O
D14S81 O
. O

The O
same O
allele O
for O
D14S280 O
segregates O
with O
the O
disease O
locus O
in O
the O
three O
kindreds O
. O

This O
allele O
is O
frequent O
in O
the O
French O
population O
, O
however O
, O
and O
linkage O
disequilibrium O
is O
not O
clearly O
established O
. O

The O
SCA3 O
locus O
remains O
within O
the O
29 O
- O
cM O
region O
on O
14q24 O
. O

3 O
- O
q32 O
. O

2 O
containing O
the O
gene O
for O
the O
Machado B
- I
Joseph I
disease I
, O
which O
is O
clinically O
related O
to O
the O
phenotype O
determined O
by O
SCA3 O
, O
but O
it O
cannot O
yet O
be O
concluded O
that O
both O
diseases O
result O
from O
alterations O
of O
the O
same O
gene O

An O
evaluation O
of O
genetic O
heterogeneity O
in O
145 O
breast B
- I
ovarian I
cancer I
families O
. O

Breast B
Cancer I
Linkage O
Consortium O
. O

The O
breast B
- I
ovary I
cancer I
- I
family I
syndrome I
is O
a O
dominant O
predisposition O
to O
cancer B
of I
the I
breast I
and I
ovaries I
which O
has O
been O
mapped O
to O
chromosome O
region O
17q12 O
- O
q21 O
. O

The O
majority O
, O
but O
not O
all O
, O
of O
breast B
- I
ovary I
cancer I
families O
show O
linkage O
to O
this O
susceptibility O
locus O
, O
designated O
BRCA1 O
. O

We O
report O
here O
the O
results O
of O
a O
linkage O
analysis O
of O
145 O
families O
with O
both O
breast B
and I
ovarian I
cancer I
. O

These O
families O
contain O
either O
a O
total O
of O
three O
or O
more O
cases O
of O
early O
- O
onset O
( O
before O
age O
60 O
years O
) O
breast B
cancer I
or O
ovarian B
cancer I
. O

All O
families O
contained O
at O
least O
one O
case O
of O
ovarian B
cancer I
. O

Overall O
, O
an O
estimated O
76 O
% O
of O
the O
145 O
families O
are O
linked O
to O
the O
BRCA1 O
locus O
. O

None O
of O
the O
13 O
families O
with O
cases O
of O
male B
breast I
cancer I
appear O
to O
be O
linked O
, O
but O
it O
is O
estimated O
that O
92 O
% O
( O
95 O
% O
confidence O
interval O
76 O
% O
- O
100 O
% O
) O
of O
families O
with O
no O
male B
breast I
cancer I
and O
with O
two O
or O
more O
ovarian B
cancers I
are O
linked O
to O
BRCA1 O
. O

These O
data O
suggest O
that O
the O
breast B
- I
ovarian I
cancer I
- I
family I
syndrome I
is O
genetically O
heterogeneous O
. O

However O
, O
the O
large O
majority O
of O
families O
with O
early O
- O
onset O
breast B
cancer I
and O
with O
two O
or O
more O
cases O
of O
ovarian B
cancer I
are O
likely O
to O
be O
due O
to O
BRCA1 O
mutations O
. O
. O

Molecular O
basis O
of O
essential B
fructosuria I
: O
molecular O
cloning O
and O
mutational O
analysis O
of O
human O
ketohexokinase O
( O
fructokinase O
) O
. O

Essential B
fructosuria I
is O
one O
of O
the O
oldest O
known O
inborn B
errors I
of I
metabolism I
. O

It O
is O
a O
benign O
condition O
which O
is O
believed O
to O
result O
from O
deficiency B
of I
hepatic I
fructokinase I
( O
ketohexokinase O
, O
KHK O
, O
E O
. O
C O
. O
2 O
. O
7 O
. O
1 O
. O
3 O
) O
. O

This O
enzyme O
catalyses O
the O
first O
step O
of O
metabolism O
of O
dietary O
fructose O
, O
conversion O
of O
fructose O
to O
fructose O
- O
1 O
- O
phosphate O
. O

Despite O
the O
early O
recognition O
of O
this O
disorder O
, O
the O
primary O
structure O
of O
human O
KHK O
and O
the O
molecular O
basis O
of O
essential B
fructosuria I
have O
not O
been O
previously O
defined O
. O

In O
this O
report O
, O
the O
isolation O
and O
sequencing O
of O
full O
- O
length O
cDNA O
clones O
encoding O
human O
ketohexokinase O
are O
described O
. O

Alternative O
mRNA O
species O
and O
alternative O
KHK O
isozymes O
are O
produced O
by O
alternative O
polyadenylation O
and O
splicing O
of O
the O
KHK O
gene O
. O

The O
KHK O
proteins O
show O
a O
high O
level O
of O
sequence O
conservation O
relative O
to O
rat O
KHK O
. O

Direct O
evidence O
that O
mutation O
of O
the O
KHK O
structural O
gene O
is O
the O
cause O
of O
essential B
fructosuria I
was O
also O
obtained O
. O

In O
a O
well O
- O
characterized O
family O
, O
in O
which O
three O
of O
eight O
siblings O
have O
fructosuria B
, O
all O
affected O
individuals O
are O
compound O
heterozygotes O
for O
two O
mutations O
Gly40Arg O
and O
Ala43Thr O
. O

Both O
mutations O
result O
from O
G O
- O
- O
> O
A O
transitions O
, O
and O
each O
alters O
the O
same O
conserved O
region O
of O
the O
KHK O
protein O
. O

Neither O
mutation O
was O
seen O
in O
a O
sample O
of O
52 O
unrelated O
control O
individuals O
. O

An O
additional O
conservative O
amino O
acid O
change O
( O
Val49IIe O
) O
was O
present O
on O
the O
KHK O
allele O
bearing O
Ala43Thr O

Homozygous O
presence O
of O
the O
crossover O
( O
fusion O
gene O
) O
mutation O
identified O
in O
a O
type B
II I
Gaucher I
disease I
fetus O
: O
is O
this O
analogous O
to O
the O
Gaucher O
knock O
- O
out O
mouse O
model O
? O

Gaucher B
disease I
( O
GD B
) O
is O
an O
inherited O
deficiency B
of I
beta I
- I
glucocerebrosidase I
( O
EC O
3 O
. O
1 O
. O
2 O
. O
45 O
, O
gene O
symbol O
GBA O
) O
. O

In O
type B
I I
GD I
, O
the O
CNS O
is O
not O
involved O
( O
nonneuronopathic O
) O
, O
whereas O
in O
type B
II I
GD I
( O
acute O
neuronopathic O
) O
CNS O
involvement O
is O
early O
and O
rapidly O
progressive O
, O
while O
in O
type B
III I
GD I
( O
subacute O
neuronopathic O
) O
CNS O
involvement O
occurs O
later O
and O
is O
slowly O
progressive O
. O

The O
T6433C O
( O
L444P O
) O
substitution O
is O
prevalent O
in O
type B
GD I
II I
. O

It O
may O
occur O
alone O
as O
a O
single O
base O
- O
pair O
mutation O
but O
often O
is O
found O
as O
part O
of O
a O
complex O
allele O
containing O
additional O
GBA O
nucleotide O
substitutions O
, O
G6468C O
( O
A456P O
) O
and O
G6482C O
( O
V460V O
) O
, O
without O
( O
recNciI O
) O
or O
with O
( O
recTL O
) O
G5957C O
( O
D409H O
) O
. O

This O
complex O
allele O
is O
presumed O
to O
have O
formed O
by O
recombination O
( O
crossover O
, O
fusion O
) O
of O
the O
structural O
gene O
with O
the O
pseudogene O
, O
which O
contains O
the O
mutated O
sequences O
. O

Two O
complex O
alleles O
have O
never O
been O
demonstrated O
to O
coexist O
in O
any O
individual O
. O

We O
devised O
a O
selective O
PCR O
method O
for O
the O
specific O
amplification O
of O
the O
normal O
and O
/ O
or O
fusion O
gene O
. O

Using O
this O
procedure O
we O
demonstrated O
the O
fusion O
gene O
in O
homozygous O
form O
for O
the O
first O
time O
, O
in O
a O
Macedonian O
/ O
Ashkenazi O
Jewish O
GD B
type I
II I
fetus O
. O

Both O
parents O
were O
carriers O
of O
the O
recombination O
. O

This O
was O
confirmed O
by O
direct O
sequence O
analysis O
. O

A O
previous O
conceptus O
in O
this O
family O
was O
stillborn B
at O
36 O
weeks O
, O
with O
features O
of O
severe O
type B
II I
GD I
. O

Neonates O
showing O
a O
severe O
clinical O
phenotype O
, O
analogous O
to O
the O
early O
neonatal O
lethal O
disease O
occurring O
in O
mice O
homozygous O
for O
a O
null O
allele O
produced O
by O
targeted O
disruption O
of O
GBA O
, O
have O
been O
described O
elsewhere O
, O
but O
the O
specific O
mutations O
in O
these O
cases O
have O
not O
yet O
been O
characterized O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Late O
infantile O
metachromatic B
leukodystrophy I
in O
Israel O
. O

Metachromatic B
Leukodystrophy I
( O
MLD B
) O
is O
a O
neurodegenerative B
disease I
in O
which O
the O
lysosomal O
enzyme O
, O
Aryl O
sulfatase O
A O
( O
ARSA O
) O
is O
deficient O
. O

The O
disease O
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
and O
its O
frequency O
is O
estimated O
to O
be O
1 O
/ O
40 O
, O
000 O
live O
births O
. O

The O
gene O
of O
ARSA O
has O
been O
cloned O
and O
up O
to O
now O
eight O
mutations O
causing O
MLD B
have O
been O
reported O
. O

Another O
mutation O
, O
PD O
, O
leads O
to O
the O
deficiency O
of O
the O
enzyme O
in O
vitro O
( O
pseudodeficiency O
) O
without O
any O
known O
clinical O
effect O
. O

The O
PD O
mutation O
is O
frequent O
in O
all O
populations O
. O

In O
Israel O
, O
late O
infantile O
MLD B
was O
found O
to O
be O
very O
frequent O
in O
a O
small O
Jewish O
isolate O
, O
the O
Habbanite O
Jews O
( O
1 O
/ O
75 O
live O
births O
) O
. O

The O
molecular O
analysis O
demonstrated O
that O
in O
the O
Habbanite O
population O
, O
the O
mutation O
occurred O
on O
an O
allele O
with O
the O
PD O
mutation O
. O

The O
loss O
of O
ARSA O
activity O
is O
due O
to O
a O
point O
mutation O
C O
> O
T O
leading O
to O
a O
change O
of O
proline O
to O
leucine O
. O

MLD B
is O
also O
frequent O
among O
Moslem O
Arabs O
in O
Jerusalem O
. O

The O
mutation O
is O
a O
transition O
G O
> O
A O
destroying O
the O
splice O
donor O
site O
of O
exon O
2 O
. O

This O
mutation O
has O
been O
reported O
in O
patients O
with O
the O
late O
infantile O
MLD B
from O
different O
ethnic O
groups O
. O

The O
Christian O
Arabs O
in O
Israel O
also O
have O
a O
high O
incidence O
of O
the O
disease O
( O
1 O
/ O
10 O
, O
000 O
live O
births O
) O
; O
the O
mutation O
in O
this O
population O
is O
still O
unknown O
. O

Knowledge O
of O
the O
different O
mutations O
causing O
MLD B
in O
these O
defined O
populations O
will O
allow O
a O
carrier O
screening O
program O
to O
be O
carried O
out O
and O
prevent O
the O
birth O
of O
additional O
affected O
children O
. O
. O

A O
single O
amino O
acid O
substitution O
( O
G103D O
) O
in O
the O
type O
II O
collagen O
triple O
helix O
produces O
Kniest B
dysplasia I
. O

Kniest B
dysplasia I
is O
a O
moderately O
severe O
chondrodysplasia B
phenotype O
that O
results O
from O
mutations O
in O
the O
gene O
for O
type O
II O
collagen O
, O
COL2A1 O
. O

Characteristics O
of O
the O
disorder O
include O
a O
short B
trunk I
and I
extremities I
, O
mid B
- I
face I
hypoplasia I
, O
cleft B
palate I
, O
myopia B
, O
retinal B
detachment I
, O
and O
hearing B
loss I
. O

Recently O
, O
deletions O
of O
all O
or O
part O
of O
exon O
12 O
have O
been O
identified O
in O
individuals O
with O
Kniest B
dysplasia I
, O
suggesting O
that O
mutations O
within O
this O
region O
of O
the O
protein O
may O
primarily O
result O
in O
the O
Kniest B
dysplasia I
phenotype O
. O

We O
used O
SSCP O
to O
analyze O
an O
amplified O
genomic O
DNA O
fragment O
containing O
exon O
12 O
from O
seven O
individuals O
with O
Kniest B
dysplasia I
. O

An O
abnormality O
was O
identified O
in O
one O
patient O
. O

DNA O
sequence O
analysis O
demonstrated O
that O
the O
patient O
was O
heterozygous O
for O
a O
G O
to O
A O
transition O
that O
implied O
substitution O
of O
glycine103 O
of O
the O
triple O
helical O
domain O
by O
aspartate O
. O

The O
mutation O
was O
not O
observed O
in O
DNA O
from O
either O
of O
the O
clinically O
unaffected O
parents O
of O
the O
proband O
. O

Protein O
microsequencing O
demonstrated O
expression O
of O
the O
abnormal O
allele O
in O
cartilage O
. O

These O
data O
demonstrate O
that O
point O
mutations O
which O
result O
in O
single O
amino O
acid O
substitutions O
can O
produce O
Kniest B
dysplasia I
and O
further O
support O
the O
hypothesis O
that O
alteration O
of O
a O
domain O
, O
which O
includes O
the O
region O
encoded O
by O
exon O
12 O
, O
in O
the O
type O
II O
collagen O
protein O
leads O
to O
this O
disorder O
. O
. O

CAG O
expansions O
in O
a O
novel O
gene O
for O
Machado B
- I
Joseph I
disease I
at O
chromosome O
14q32 O
. O
1 O
. O

We O
have O
identified O
a O
novel O
gene O
containing O
CAG O
repeats O
and O
mapped O
it O
to O
chromosome O
14q32 O
. O

1 O
, O
the O
genetic O
locus O
for O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
. O

In O
normal O
individuals O
the O
gene O
contains O
between O
13 O
and O
36 O
CAG O
repeats O
, O
whereas O
most O
of O
the O
clinically O
diagnosed O
patients O
and O
all O
of O
the O
affected O
members O
of O
a O
family O
with O
the O
clinical O
and O
pathological O
diagnosis O
of O
MJD B
show O
expansion O
of O
the O
repeat O
- O
number O
( O
from O
68 O
- O
79 O
) O
. O

Southern O
blot O
analyses O
and O
genomic O
cloning O
demonstrates O
the O
existence O
of O
related O
genes O
. O

These O
results O
raise O
the O
possibility O
that O
similar O
abnormalities O
in O
related O
genes O
may O
give O
rise O
to O
diseases O
similar O
to O
MJD B
. O

Mutations O
in O
the O
BRCA1 O
gene O
in O
families O
with O
early O
- O
onset O
breast B
and I
ovarian I
cancer I
. O

We O
analysed O
50 O
probands O
with O
a O
family O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
for O
germline O
mutations O
in O
the O
coding O
region O
of O
the O
BRCA1 O
candidate O
gene O
, O
using O
single O
- O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
analysis O
on O
PCR O
- O
amplified O
genomic O
DNA O
. O

A O
total O
of O
eight O
putative O
disease O
- O
causing O
alterations O
were O
identified O
four O
of O
these O
are O
frameshifts O
and O
two O
are O
nonsense O
mutations O
. O

In O
addition O
, O
we O
found O
two O
missense O
mutations O
, O
one O
of O
which O
changes O
the O
final O
cysteine O
of O
the O
BRCA1 O
zinc O
finger O
motif O
to O
glycine O
. O

These O
data O
are O
consistent O
with O
a O
tumour B
suppressor O
model O
, O
and O
support O
the O
notion O
that O
this O
candidate O
gene O
is O
in O
fact O
BRCA1 O
. O

The O
heterogeneity O
of O
mutations O
, O
coupled O
with O
the O
large O
size O
of O
the O
gene O
, O
indicates O
that O
clinical O
application O
of O
BRCA1 O
mutation O
testing O
will O
be O
technically O
challenging O
. O
. O

Confirmation O
of O
BRCA1 O
by O
analysis O
of O
germline O
mutations O
linked O
to O
breast B
and I
ovarian I
cancer I
in O
ten O
families O
. O

We O
provide O
genetic O
evidence O
supporting O
the O
identity O
of O
the O
candidate O
gene O
for O
BRCA1 O
through O
the O
characterization O
of O
germline O
mutations O
in O
63 O
breast B
cancer I
patients O
and O
10 O
ovarian B
cancer I
patients O
in O
ten O
families O
with O
cancer B
linked O
to O
chromosome O
17q21 O
. O

Nine O
different O
mutations O
were O
detected O
by O
screening O
BRCA1 O
DNA O
and O
RNA O
by O
single O
- O
strand O
conformation O
polymorphism O
analysis O
and O
direct O
sequencing O
. O

Seven O
mutations O
lead O
to O
protein O
truncations O
at O
sites O
throughout O
the O
gene O
. O

One O
missense O
mutation O
( O
which O
occurred O
independently O
in O
two O
families O
) O
leads O
to O
loss O
of O
a O
cysteine O
in O
the O
zinc O
binding O
domain O
. O

An O
intronic O
single O
basepair O
substitution O
destroys O
an O
acceptor O
site O
and O
activates O
a O
cryptic O
splice O
site O
, O
leading O
to O
a O
59 O
basepair O
insertion O
and O
chain O
termination O
. O

The O
four O
families O
with O
both O
breast B
and I
ovarian I
cancer I
had O
chain O
termination O
mutations O
in O
the O
N O
- O
terminal O
half O
of O
the O
protein O
. O
. O

High O
resolution O
genetic O
analysis O
suggests O
one O
ancestral O
predisposing O
haplotype O
for O
the O
origin O
of O
the O
myotonic B
dystrophy I
mutation O
. O

The O
mutation O
causing O
myotonic B
dystrophy I
( O
DM B
) O
has O
been O
identified O
as O
an O
amplification O
of O
an O
unstable O
trinucleotide O
( O
CTG O
) O
n O
repeat O
in O
over O
99 O
% O
of O
the O
global O
DM B
population O
. O

It O
is O
in O
complete O
linkage O
disequilibrium O
with O
an O
Alu O
element O
polymorphism O
within O
the O
DM B
kinase O
gene O
, O
suggesting O
that O
DM B
is O
a O
consequence O
of O
one O
or O
few O
ancestral O
mutations O
. O

A O
recent O
analysis O
utilizing O
this O
polymorphism O
as O
well O
as O
a O
flanking O
dinucleotide O
marker O
, O
suggested O
that O
similar O
to O
Fragile B
X I
syndrome I
, O
DM B
exhibited O
a O
founder O
effect O
( O
Imbert O
et O
al O
. O
, O
1993 O
Nature O
Genet O
. O
4 O
, O
72 O
- O
76 O
) O
. O

In O
contrast O
, O
the O
low O
reproductive O
fitness O
of O
individuals O
with O
congenital O
DM B
( O
the O
endpoint O
of O
genetic O
anticipation O
in O
myotonic B
dystrophy I
) O
suggests O
a O
higher O
rate O
of O
new O
mutations O
. O

We O
present O
a O
high O
resolution O
genetic O
analysis O
of O
the O
DM B
locus O
using O
PCR O
based O
assays O
of O
nine O
polymorphisms O
, O
spanning O
a O
physical O
distance O
of O
30 O
kb O
, O
within O
and O
immediately O
flanking O
the O
DM B
kinase O
gene O
. O

The O
persistent O
complete O
allelic O
association O
of O
the O
DM B
mutation O
with O
all O
these O
polymorphisms O
provides O
further O
support O
to O
previous O
observations O
and O
suggests O
more O
strongly O
that O
the O
DM B
mutation O
occurred O
on O
the O
background O
of O
a O
particular O
haplotype O
in O
which O
the O
( O
CTG O
) O
n O
repeat O
became O
inherently O
unstable O
and O
therefore O
predisposed O
to O
amplification O
. O

Genetic O
instability O
in O
human O
ovarian B
cancer I
cell O
lines O
. O

We O
have O
analyzed O
the O
stability O
of O
microsatellites O
in O
cell O
lines O
derived O
from O
human O
ovarian B
cancers I
and O
found O
that O
5 O
out O
of O
10 O
of O
the O
ovarian B
tumor I
cell O
lines O
are O
genetically O
unstable O
at O
the O
majority O
of O
the O
loci O
analyzed O
. O

In O
clones O
and O
subclones O
derived O
serially O
from O
one O
of O
these O
cell O
lines O
( O
2774 O
; O
serous B
cystadenocarcinoma I
) O
, O
a O
very O
high O
proportion O
of O
microsatellites O
distributed O
in O
many O
different O
regions O
of O
the O
genome O
change O
their O
size O
in O
a O
mercurial O
fashion O
. O

We O
conclude O
that O
genomic O
instability O
in O
ovarian B
tumors I
is O
a O
dynamic O
and O
ongoing O
process O
whose O
high O
frequency O
may O
have O
been O
previously O
underestimated O
by O
PCR O
- O
based O
allelotyping O
of O
bulk O
tumor B
tissue O
. O

We O
have O
identified O
the O
source O
of O
the O
genetic O
instability O
in O
one O
ovarian B
tumor I
as O
a O
point O
mutation O
( O
R524P O
) O
in O
the O
human O
mismatch O
- O
repair O
gene O
MSH2 O
( O
Salmonella O
MutS O
homologue O
) O
, O
which O
has O
recently O
been O
shown O
to O
be O
involved O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
. O

Patient O
2774 O
was O
a O
38 O
- O
year O
- O
old O
heterozygote O
, O
and O
her O
normal O
tissue O
carried O
both O
mutant O
and O
wild O
- O
type O
alleles O
of O
the O
human O
MSH2 O
gene O
. O

However O
the O
wild O
- O
type O
allele O
was O
lost O
at O
some O
point O
early O
during O
tumorigenesis O
so O
that O
DNA O
isolated O
either O
from O
the O
patients O
ovarian B
tumor I
or O
from O
the O
2774 O
cell O
line O
carries O
only O
the O
mutant O
allele O
of O
the O
human O
MSH2 O
gene O
. O

The O
genetic O
instability O
observed O
in O
the O
tumor B
and O
cell O
line O
DNA O
, O
together O
with O
the O
germ O
- O
line O
mutation O
in O
a O
mismatch O
- O
repair O
gene O
, O
suggest O
that O
the O
MSH2 O
gene O
is O
involved O
in O
the O
onset O
and O
/ O
or O
progression O
in O
a O
subset O
of O
ovarian B
cancer I
. O
. O

BRCA1 O
mutations O
in O
primary O
breast B
and I
ovarian I
carcinomas I
. O

Loss O
of O
heterozygosity O
data O
from O
familial B
tumors I
suggest O
that O
BRCA1 O
, O
a O
gene O
that O
confers O
susceptibility O
to O
ovarian B
and I
early I
- I
onset I
breast B
cancer I
, O
encodes O
a O
tumor B
suppressor O
. O

The O
BRCA1 O
region O
is O
also O
subject O
to O
allelic O
loss O
in O
sporadic B
breast I
and I
ovarian I
cancers I
, O
an O
indication O
that O
BRCA1 O
mutations O
may O
occur O
somatically O
in O
these O
tumors B
. O

The O
BRCA1 O
coding O
region O
was O
examined O
for O
mutations O
in O
primary O
breast B
and I
ovarian I
tumors I
that O
show O
allele O
loss O
at O
the O
BRCA1 O
locus O
. O

Mutations O
were O
detected O
in O
3 O
of O
32 O
breast O
and O
1 O
of O
12 O
ovarian B
carcinomas I
; O
all O
four O
mutations O
were O
germline O
alterations O
and O
occurred O
in O
early O
- O
onset O
cancers B
. O

These O
results O
suggest O
that O
mutation O
of O
BRCA1 O
may O
not O
be O
critical O
in O
the O
development O
of O
the O
majority O
of O
breast B
and I
ovarian I
cancers I
that O
arise O
in O
the O
absence O
of O
a O
mutant O
germline O
allele O
. O
. O

PAX6 O
gene O
dosage O
effect O
in O
a O
family O
with O
congenital B
cataracts I
, O
aniridia B
, O
anophthalmia B
and O
central B
nervous I
system I
defects I
. O

The O
human O
eye O
malformation O
aniridia B
results O
from O
haploinsufficiency B
of I
PAX6 I
, O
a O
paired O
box O
DNA O
- O
binding O
protein O
. O

To O
study O
this O
dosage O
effect O
, O
we O
characterized O
two O
PAX6 O
mutations O
in O
a O
family O
segregating O
aniridia B
and O
a O
milder O
syndrome O
consisting O
of O
congenital B
cataracts I
and O
late O
onset O
corneal B
dystrophy I
. O

The O
nonsense O
mutations O
, O
at O
codons O
103 O
and O
353 O
, O
truncate O
PAX6 O
within O
the O
N O
- O
terminal O
paired O
and O
C O
- O
terminal O
PST O
domains O
, O
respectively O
. O

The O
wild O
- O
type O
PST O
domain O
activates O
transcription O
autonomously O
and O
the O
mutant O
form O
has O
partial O
activity O
. O

A O
compound O
heterozygote O
had O
severe O
craniofacial B
and I
central I
nervous I
system I
defects I
and O
no B
eyes I
. O

The O
pattern O
of O
malformations O
is O
similar O
to O
that O
in O
homozygous O
Sey O
mice O
and O
suggests O
a O
critical O
role O
for O
PAX6 O
in O
controlling O
the O
migration O
and O
differentiation O
of O
specific O
neuronal O
progenitor O
cells O
in O
the O
brain O
. O
. O

A O
physical O
map O
and O
candidate O
genes O
in O
the O
BRCA1 O
region O
on O
chromosome O
17q12 O
- O
21 O
. O

We O
have O
constructed O
a O
physical O
map O
of O
a O
4 O
cM O
region O
on O
chromosome O
17q12 O
- O
21 O
that O
contains O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
BRCA1 O
. O

The O
map O
comprises O
a O
contig O
of O
137 O
overlapping O
yeast O
artificial O
chromosomes O
and O
P1 O
clones O
, O
onto O
which O
we O
have O
placed O
112 O
PCR O
markers O
. O

We O
have O
localized O
more O
than O
20 O
genes O
on O
this O
map O
, O
ten O
of O
which O
had O
not O
been O
mapped O
to O
the O
region O
previously O
, O
and O
have O
isolated O
30 O
cDNA O
clones O
representing O
partial O
sequences O
of O
as O
yet O
unidentified O
genes O
. O

Two O
genes O
that O
lie O
within O
a O
narrow O
region O
defined O
by O
meiotic O
breakpoints O
in O
BRCA1 O
patients O
have O
been O
sequenced O
in O
breast B
cancer I
patients O
without O
revealing O
any O
deleterious O
mutations O
. O

These O
new O
reagents O
should O
facilitate O
the O
identification O
of O
BRCA1 O
. O
. O

The O
LEC O
rat O
has O
a O
deletion O
in O
the O
copper O
transporting O
ATPase O
gene O
homologous O
to O
the O
Wilson B
disease I
gene O
. O

The O
Long O
- O
Evans O
Cinnamon O
( O
LEC O
) O
rat O
shows O
similarity O
to O
Wilson B
disease I
in O
many O
clinical O
and O
biochemical O
features O
. O

We O
have O
cloned O
cDNAs O
for O
the O
rat O
gene O
( O
Atp7b O
) O
homologous O
to O
the O
human O
Wilson B
disease I
gene O
( O
ATP7B O
) O
and O
have O
used O
them O
to O
identify O
a O
partial O
deletion O
in O
the O
Atp7b O
gene O
in O
the O
LEC O
rat O
. O

The O
deletion O
removes O
at O
least O
900 O
bp O
of O
the O
coding O
region O
at O
the O
3 O
end O
, O
includes O
the O
crucial O
ATP O
binding O
domain O
and O
extends O
downstream O
of O
the O
gene O
. O

Our O
results O
provide O
convincing O
evidence O
for O
defining O
the O
LEC O
rat O
as O
an O
animal O
model O
for O
Wilson B
disease I
. O

This O
model O
will O
be O
important O
for O
studying O
liver O
pathophysiology O
, O
for O
developing O
therapy O
for O
Wilson B
disease I
and O
for O
studying O
the O
pathway O
of O
copper O
transport O
and O
its O
possible O
interaction O
with O
other O
heavy O
metals O
. O
. O

Genomic O
organization O
of O
the O
adrenoleukodystrophy B
gene O
. O

Adrenoleukodystrophy B
( O
ALD B
) O
, O
the O
most O
frequent O
peroxisomal B
disorder I
, O
is O
a O
severe O
neurodegenerative B
disease I
associated O
with O
an O
impairment B
of I
very I
long I
chain I
fatty I
acids I
beta I
- I
oxidation I
. O

We O
have O
recently O
identified O
by O
positional O
cloning O
the O
gene O
responsible O
for O
ALD B
, O
located O
in O
Xq28 O
. O

It O
encodes O
a O
new O
member O
of O
the O
" O
ABC O
" O
superfamily O
of O
membrane O
- O
associated O
transporters O
that O
shows O
, O
in O
particular O
, O
significant O
homology O
to O
the O
70 O
- O
kDa O
peroxisomal O
membrane O
protein O
( O
PMP70 O
) O
. O

We O
report O
here O
a O
detailed O
characterization O
of O
the O
ALD B
gene O
structure O
. O

It O
extends O
over O
21 O
kb O
and O
consists O
of O
10 O
exons O
. O

To O
facilitate O
the O
detection O
of O
mutations O
in O
ALD B
patients O
, O
we O
have O
determined O
the O
intronic O
sequences O
flanking O
the O
exons O
as O
well O
as O
the O
sequence O
of O
the O
3 O
untranslated O
region O
and O
of O
the O
immediate O
5 O
promoter O
region O
. O

Sequences O
present O
in O
distal O
exons O
cross O
- O
hybridize O
strongly O
to O
additional O
sequences O
in O
the O
human O
genome O
. O

The O
ALD B
gene O
has O
been O
positioned O
on O
a O
pulsed O
- O
field O
map O
between O
DXS15 O
and O
the O
L1CAM O
gene O
, O
about O
650 O
kb O
upstream O
from O
the O
color O
pigment O
genes O
. O

The O
frequent O
occurrence O
of O
color O
vision O
anomalies O
observed O
in O
patients O
with O
adrenomyeloneuropathy B
( O
the O
adult O
onset O
form O
of O
ALD B
) O
thus O
does O
not O
represent O
a O
contiguous B
gene I
syndrome I
but O
a O
secondary O
manifestation O
of O
ALD B
. O
. O

The O
murine O
homologues O
of O
the O
Huntington B
disease I
gene O
( O
Hdh O
) O
and O
the O
alpha O
- O
adducin O
gene O
( O
Add1 O
) O
map O
to O
mouse O
chromosome O
5 O
within O
a O
region O
of O
conserved O
synteny O
with O
human O
chromosome O
4p16 O
. O
3 O
. O

Huntington B
disease I
( O
HD B
) O
is O
a O
severe O
autosomal B
dominant I
neurodegenerative I
disorder I
associated O
with O
a O
novel O
gene O
( O
IT15 O
) O
. O

Recently O
, O
we O
reported O
the O
cloning O
of O
Hdh O
, O
the O
murine O
homologue O
of O
IT15 O
. O

Here O
, O
using O
an O
interspecific O
backcross O
, O
we O
have O
mapped O
both O
Hdh O
and O
the O
mouse O
homologue O
of O
human O
alpha O
- O
adducin O
( O
Add1 O
) O
, O
a O
membrane O
- O
associated O
cytoskeletal O
protein O
gene O
. O

Both O
of O
these O
genes O
map O
in O
the O
same O
position O
on O
mouse O
chromosome O
5 O
in O
a O
region O
associated O
with O
ancestral O
chromosomal O
rearrangements O
and O
show O
no O
recombination O
with O
D5H4S43 O
, O
D5H4S115 O
, O
and O
D5H4S62 O
, O
the O
murine O
homologues O
of O
D4S43 O
, O
D4S115 O
, O
and O
D4S62 O
, O
respectively O
. O

Further O
mapping O
studies O
of O
humans O
, O
mice O
, O
and O
other O
mammalian O
species O
should O
reveal O
the O
nature O
of O
the O
rearrangements O
affecting O
this O
chromosomal O
segment O
during O
mammalian O
evolution O
. O
. O

Genetic O
cholesteryl B
ester I
transfer I
protein I
deficiency I
caused O
by O
two O
prevalent O
mutations O
as O
a O
major O
determinant O
of O
increased O
levels O
of O
high O
density O
lipoprotein O
cholesterol O
. O

Genetic O
determinants O
of O
HDL O
cholesterol O
( O
HDL O
- O
C O
) O
levels O
in O
the O
general O
population O
are O
poorly O
understood O
. O

We O
previously O
described O
plasma O
cholesteryl B
ester I
transfer I
protein I
( I
CETP I
) I
deficiency I
due O
to O
an O
intron O
14 O
G O
( O
+ O
1 O
) O
- O
to O
- O
A O
mutation O
( O
Int14 O
A O
) O
in O
several O
families O
with O
very O
high O
HDL O
- O
C O
levels O
in O
Japan O
. O

Subjects O
with O
HDL O
- O
C O
> O
or O
= O
100 O
mg O
/ O
dl O
( O
n O
= O
130 O
) O
were O
screened O
by O
PCR O
single O
strand O
conformational O
polymorphism O
analysis O
of O
the O
CETP O
gene O
. O

Two O
other O
mutations O
were O
identified O
by O
DNA O
sequencing O
or O
primer O
- O
mediated O
restriction O
map O
modification O
of O
PCR O
products O
a O
novel O
intron O
14 O
splice O
donor O
site O
mutation O
caused O
by O
a O
T O
insertion O
at O
position O
+ O
3 O
from O
the O
exon14 O
/ O
intron14 O
boundary O
( O
Int14 O
T O
) O
and O
a O
missense O
mutation O
( O
Asp442 O
to O
Gly O
) O
within O
exon O
15 O
( O
D442G O
) O
. O

The O
Int14 O
T O
mutation O
was O
only O
found O
in O
one O
family O
. O

However O
, O
the O
D442G O
and O
Int14 O
A O
mutations O
were O
highly O
prevalent O
in O
subjects O
with O
HDL O
- O
C O
> O
or O
= O
60 O
mg O
/ O
dl O
, O
with O
combined O
allele O
frequencies O
of O
9 O
% O
, O
12 O
% O
, O
21 O
% O
and O
43 O
% O
for O
HDL O
- O
C O
60 O
- O
79 O
, O
80 O
- O
99 O
, O
100 O
- O
119 O
, O
and O
> O
or O
= O
120 O
mg O
/ O
dl O
, O
respectively O
. O

Furthermore O
, O
prevalences O
of O
the O
D442G O
and O
Int14 O
A O
mutations O
were O
extremely O
high O
in O
a O
general O
sample O
of O
Japanese O
men O
( O
n O
= O
236 O
) O
, O
with O
heterozygote O
frequencies O
of O
7 O
% O
and O
2 O
% O
, O
respectively O
. O

These O
two O
mutations O
accounted O
for O
about O
10 O
% O
of O
the O
total O
variance O
of O
HDL O
- O
C O
in O
this O
population O
. O

The O
phenotype O
in O
a O
genetic O
compound O
heterozygote O
( O
Int14 O
T O
and O
Int14 O
A O
) O
was O
similar O
to O
that O
of O
Int14 O
A O
homozygotes O
( O
no O
detectable O
CETP O
and O
markedly O
increased O
HDL O
- O
C O
) O
, O
indicating O
that O
the O
Int14 O
T O
produces O
a O
null O
allele O
. O

In O
four O
D442G O
homozygotes O
, O
mean O
HDL O
- O
C O
levels O
( O
86 O
+ O
/ O
- O
26 O
mg O
/ O
dl O
) O
were O
lower O
than O
in O
Int14 O
A O
homozygotes O
( O
158 O
+ O
/ O
- O
35 O
mg O
/ O
dl O
) O
, O
reflecting O
residual O
CETP O
activity O
in O
plasma O
. O

In O
47 O
D442G O
heterozygotes O
, O
mean O
HDL O
- O
C O
levels O
were O
91 O
+ O
/ O
- O
23 O
mg O
/ O
dl O
, O
similar O
to O
the O
level O
in O
D442G O
homozygotes O
, O
and O
significantly O
greater O
than O
mean O
HDL O
- O
C O
levels O
in O
Int14 O
A O
heterozygotes O
( O
69 O
+ O
/ O
- O
15 O
mg O
/ O
dl O
) O
. O

Thus O
, O
the O
D442G O
mutation O
acts O
differently O
to O
the O
null O
mutations O
with O
weaker O
effects O
on O
HDL O
in O
the O
homozygous O
state O
and O
stronger O
effects O
in O
the O
heterozygotes O
, O
suggesting O
dominant O
expression O
of O
a O
partially O
defective O
allele O
. O

CETP B
deficiency I
, O
reflecting O
two O
prevalent O
mutations O
( O
D442G O
and O
Int14 O
A O
) O
, O
is O
the O
first O
example O
of O
a O
genetic B
deficiency I
state O
which O
is O
sufficiently O
common O
to O
explain O
a O
significant O
fraction O
of O
the O
variation O
in O
HDL O
- O
C O
in O
the O
general O
population O
. O
. O

Treatment O
of O
cerebrotendinous B
xanthomatosis I
: O
effects O
of O
chenodeoxycholic O
acid O
, O
pravastatin O
, O
and O
combined O
use O
. O

Treatments O
by O
oral O
administration O
of O
chenodeoxycholic O
acid O
( O
CDCA O
) O
alone O
, O
3 O
- O
hydroxy O
- O
3 O
- O
methylglutaryl O
( O
HMG O
) O
CoA O
reductase O
inhibitor O
( O
pravastatin O
) O
alone O
, O
and O
combination O
of O
the O
two O
drugs O
were O
attempted O
for O
7 O
patients O
with O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O

CDCA O
treatment O
at O
a O
dose O
of O
300 O
mg O
/ O
day O
reduced O
serum O
cholestanol O
( O
67 O
. O
3 O
% O
reduction O
) O
, O
lathosterol O
( O
50 O
. O
8 O
% O
) O
, O
campesterol O
( O
61 O
. O
7 O
% O
) O
and O
sitosterol O
( O
12 O
. O
7 O
% O
) O
. O

However O
, O
the O
sera O
of O
the O
patients O
changed O
to O
be O
" O
atherogenic O
" O
; O
total O
cholesterol O
, O
triglyceride O
and O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
- O
cholesterol O
were O
increased O
, O
while O
high O
- O
density O
lipoprotein O
( O
HDL O
) O
- O
cholesterol O
was O
decreased O
. O

Contrarily O
, O
pravastatin O
at O
a O
dose O
of O
10 O
mg O
/ O
day O
improved O
the O
sera O
of O
the O
patients O
to O
be O
markedly O
" O
anti O
- O
atherogenic O
" O
, O
but O
the O
reductions O
of O
cholestanol O
( O
30 O
. O
4 O
% O
) O
, O
lathosterol O
( O
44 O
. O
0 O
% O
) O
, O
campesterol O
( O
22 O
. O
9 O
% O
) O
and O
sitosterol O
( O
9 O
. O
6 O
% O
) O
were O
inadequate O
. O

Combined O
treatment O
with O
CDCA O
and O
pravastatin O
showed O
good O
overlapping O
of O
the O
effects O
of O
each O
drug O
alone O
. O

The O
sera O
of O
the O
patients O
were O
apparently O
more O
" O
anti O
- O
atherogenic O
" O
than O
those O
after O
CDCA O
treatment O
. O

Serum O
cholestanol O
concentration O
was O
still O
2 O
. O

7 O
times O
higher O
than O
in O
controls O
, O
but O
the O
serum O
lathosterol O
level O
was O
within O
the O
normal O
range O
, O
indicating O
that O
the O
enhancement O
of O
overall O
cholesterol O
synthesis O
in O
the O
patients O
was O
sufficiently O
suppressed O
. O

Plant O
sterol O
levels O
were O
also O
within O
the O
normal O
range O
. O

The O
combination O
of O
CDCA O
and O
pravastatin O
was O
a O
good O
treatment O
for O
CTX B
, O
based O
on O
the O
improvement O
of O
serum O
lipoprotein O
metabolism O
, O
the O
suppression O
of O
cholesterol O
synthesis O
, O
and O
reductions O
of O
cholestanol O
and O
plant O
sterol O
levels O
. O

In O
all O
of O
7 O
patients O
, O
the O
progression O
of O
disease O
was O
arrested O
, O
but O
dramatic O
effects O
on O
clinical O
manifestations O
, O
xanthoma B
, O
and O
electrophysiological O
findings O
could O
not O
be O
found O
after O
the O
treatment O
of O
these O
drugs O

Mutation O
spectrum O
in O
the O
CHM B
gene O
of O
Danish O
and O
Swedish O
choroideremia B
patients O
. O

The O
recent O
isolation O
of O
the O
complete O
open O
reading O
frame O
of O
the O
choroideremia B
( O
CHM B
) O
gene O
and O
the O
characterization O
of O
the O
exon O
- O
intron O
boundaries O
has O
paved O
the O
way O
to O
mutation O
detection O
in O
patients O
with O
classical O
choroideremia B
. O

We O
have O
performed O
mutation O
screening O
in O
patients O
from O
15 O
Danish O
and O
Swedish O
families O
by O
using O
Southern O
blot O
hybridization O
and O
the O
polymerase O
chain O
reaction O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
technique O
. O

Causative O
mutations O
in O
the O
CHM B
gene O
were O
detected O
in O
at O
least O
12 O
families O
, O
indicating O
that O
a O
substantial O
part O
of O
the O
mutations O
can O
be O
identified O
by O
this O
approach O
. O

In O
four O
of O
these O
families O
deletions O
of O
different O
sizes O
were O
found O
. O

Thus O
, O
in O
one O
patient O
, O
the O
deletion O
resulted O
in O
the O
absence O
of O
only O
one O
exon O
, O
while O
in O
another O
the O
deletion O
comprised O
the O
entire O
CHM B
gene O
. O

Mapping O
of O
the O
deletion O
endpoints O
in O
these O
four O
patients O
and O
in O
another O
11 O
male O
patients O
with O
sizeable O
deletions O
enabled O
us O
to O
construct O
a O
very O
detailed O
map O
of O
intervals O
2 O
and O
3 O
of O
Xq21 O
. O

In O
the O
remaining O
11 O
Danish O
and O
Swedish O
families O
at O
least O
8 O
causative O
mutations O
were O
found O
by O
PCR O
- O
SSCP O
analysis O
and O
direct O
sequencing O
. O

Interestingly O
, O
all O
CHM B
gene O
mutations O
detected O
thus O
far O
in O
choroideremia B
patients O
give O
rise O
to O
the O
introduction O
of O
a O
premature O
stop O
codon O
. O
. O

Predominance O
of O
the O
adrenomyeloneuropathy B
phenotype O
of O
X B
- I
linked I
adrenoleukodystrophy I
in O
The O
Netherlands O
: O
a O
survey O
of O
30 O
kindreds O
. O

X B
- I
linked I
adrenoleukodystrophy I
( O
X B
- I
ALD I
) O
is O
an O
inherited B
disorder I
of O
peroxisomal O
beta O
- O
oxidation O
associated O
with O
accumulation O
of O
saturated O
very O
long O
- O
chain O
fatty O
acids O
, O
which O
results O
in O
central O
and O
peripheral O
demyelination B
and O
in O
impaired B
function I
of I
adrenal I
cortex I
and I
testes I
. O

The O
phenotypic O
expression O
is O
highly O
variable O
, O
childhood B
cerebral I
ALD I
( O
CCALD B
) O
and O
adrenomyeloneuropathy B
( O
AMN B
) O
being O
the O
main O
variants O
. O

We O
explored O
the O
30 O
Dutch O
kindreds O
well O
known O
to O
the O
Dutch O
X B
- I
ALD I
/ O
AMN B
Study O
Group O
and O
phenotyped O
77 O
male O
patients O
35 O
( O
46 O
% O
) O
had O
AMN B
and O
24 O
( O
31 O
% O
) O
CCALD B
or O
adolescent B
cerebral I
ALD I
( O
AdolCALD B
) O
. O

These O
percentages O
differ O
significantly O
from O
previous O
reports O
, O
in O
which O
25 O
to O
28 O
% O
of O
the O
patients O
developed O
AMN B
and O
53 O
to O
57 O
% O
CCALD B
or O
AdolCALD B
. O

Our O
findings O
indicate O
that O
- O
- O
at O
least O
in O
the O
Netherlands O
- O
- O
AMN B
may O
be O
the O
most O
frequent O
phenotype O
of O
X B
- I
ALD I
. O
. O

Adrenoleukodystrophy B
gene O
encodes O
an O
80 O
kDa O
membrane O
protein O
. O

An O
antibody O
against O
the O
synthetic O
C O
- O
terminal O
peptides O
deduced O
from O
the O
cDNA O
of O
the O
gene O
responsible O
for O
X B
- I
linked I
adrenoleukodystrophy I
( O
ALD B
) O
was O
produced O
to O
characterize O
the O
product O
of O
the O
ALD B
gene O
. O

The O
antibody O
reacted O
with O
the O
80 O
kDa O
band O
protein O
in O
control O
fibroblasts O
, O
while O
no O
bands O
were O
detected O
in O
the O
fibroblasts O
from O
a O
patient O
with O
ALD B
( O
# O
163 O
) O
, O
in O
which O
mRNA O
of O
the O
ALD B
gene O
was O
undetectable O
based O
on O
Northern O
blot O
analysis O
. O

The O
293T O
cells O
transfected O
with O
the O
full O
- O
coding O
cDNA O
inserted O
in O
the O
expression O
vector O
produced O
a O
new O
80 O
kDa O
protein O
, O
as O
detected O
by O
Western O
blot O
. O

In O
an O
immunocytological O
study O
, O
the O
staining O
was O
in O
a O
punctate O
pattern O
, O
in O
the O
normal O
fibroblasts O
. O

However O
, O
there O
was O
no O
punctate O
staining O
in O
the O
# O
163 O
cells O
. O

These O
data O
thus O
indicate O
that O
the O
ALD B
gene O
encodes O
an O
80 O
kDa O
membrane O
protein O
. O
. O

Isolation O
of O
the O
gene O
for O
McLeod B
syndrome I
that O
encodes O
a O
novel O
membrane O
transport O
protein O
. O

McLeod B
syndrome I
is O
an O
X B
- I
linked I
multisystem I
disorder I
characterized O
by O
abnormalities O
in O
the O
neuromuscular O
and O
hematopoietic O
systems O
. O

We O
have O
assembled O
a O
cosmid O
contig O
of O
360 O
kb O
that O
encompasses O
the O
McLeod B
gene O
locus O
. O

A O
50 O
kb O
deletion O
was O
detected O
by O
screening O
DNA O
from O
patients O
with O
radiolabeled O
whole O
cosmids O
, O
and O
two O
transcription O
units O
were O
identified O
within O
this O
deletion O
. O

The O
mRNA O
expression O
pattern O
of O
one O
of O
them O
, O
designated O
as O
XK O
, O
correlates O
closely O
to O
the O
McLeod B
phenotype O
. O

XK O
encodes O
a O
novel O
protein O
with O
structural O
characteristics O
of O
prokaryotic O
and O
eukaryotic O
membrane O
transport O
proteins O
. O

Nucleotide O
sequence O
analysis O
of O
XK O
from O
two O
unrelated O
McLeod B
patients O
has O
identified O
point O
mutations O
at O
conserved O
splice O
donor O
and O
acceptor O
sites O
. O

These O
findings O
provide O
direct O
evidence O
that O
XK O
is O
responsible O
for O
McLeod B
syndrome I
. O
. O

X B
- I
linked I
spastic I
paraplegia I
and O
Pelizaeus B
- I
Merzbacher I
disease I
are O
allelic B
disorders I
at O
the O
proteolipid O
protein O
locus O
. O

Three O
forms O
of O
X B
- I
linked I
spastic I
paraplegia I
( O
SPG B
) O
have O
been O
defined O
. O

One O
locus O
( O
SPG O
1 O
) O
maps O
to O
Xq28 O
while O
two O
clinically O
distinct O
forms O
map O
to O
Xq22 O
( O
SPG2 O
) O
. O

A O
rare O
X B
- I
linked I
dysmyelinating I
disorder I
of O
the O
central O
nervous O
system O
, O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
, O
has O
also O
been O
mapped O
to O
Xq21 O
- O
q22 O
, O
and O
is O
caused O
by O
mutations O
in O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
which O
encodes O
two O
myelin O
proteins O
, O
PLP O
and O
DM20 O
. O

While O
narrowing O
the O
genetic O
interval O
containing O
SPG2 O
in O
a O
large O
pedigree O
, O
we O
found O
that O
PLP O
was O
the O
closest O
marker O
to O
the O
disease O
locus O
, O
implicating O
PLP O
as O
a O
possible O
candidate O
gene O
. O

We O
have O
found O
that O
a O
point O
mutation O
( O
His139Tyr O
) O
in O
exon O
3B O
of O
an O
affected O
male O
produces O
a O
mutant O
PLP O
but O
a O
normal O
DM20 O
, O
and O
segregates O
with O
the O
disease O
( O
Zmax O
= O
6 O
. O
63 O
, O
theta O
= O
0 O
. O
00 O
) O
. O

It O
appears O
, O
therefore O
, O
that O
SPG2 O
and O
PMD B
are O
allelic B
disorders I

Canavan B
disease I
: O
mutations O
among O
Jewish O
and O
non O
- O
Jewish O
patients O
. O

Canavan B
disease I
is O
an O
autosomal B
recessive I
leukodystrophy I
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
ASPA O
) O
. O

Sixty O
- O
four O
probands O
were O
analyzed O
for O
mutations O
in O
the O
ASPA O
gene O
. O

Three O
point O
mutations O
- O
- O
693C O
- O
- O
> O
A O
, O
854A O
- O
- O
> O
C O
, O
and O
914C O
- O
- O
> O
A O
- O
- O
were O
identified O
in O
the O
coding O
sequence O
. O

The O
693C O
- O
- O
> O
A O
and O
914C O
- O
- O
> O
A O
base O
changes O
, O
resulting O
in O
nonsense O
tyr231 O
- O
- O
> O
ter O
and O
missense O
ala305 O
- O
- O
> O
glu O
mutations O
, O
respectively O
, O
lead O
to O
complete O
loss O
of O
ASPA O
activity O
in O
in O
vitro O
expression O
studies O
. O

The O
854A O
- O
- O
> O
C O
transversion O
converted O
glu O
to O
ala O
in O
codon O
285 O
. O

The O
glu285 O
- O
- O
> O
ala O
mutant O
ASPA O
has O
2 O
. O

5 O
% O
of O
the O
activity O
expressed O
by O
the O
wild O
- O
type O
enzyme O
. O

A O
fourth O
mutation O
, O
433 O
- O
- O
2 O
( O
A O
- O
- O
> O
G O
) O
transition O
, O
was O
identified O
at O
the O
splice O
- O
acceptor O
site O
in O
intron O
2 O
. O

The O
splice O
- O
site O
mutation O
would O
lead O
to O
skipping O
of O
exon O
3 O
, O
accompanied O
by O
a O
frameshift O
, O
and O
thus O
would O
produce O
aberrant O
ASPA O
. O

Of O
the O
128 O
unrelated O
Canavan B
chromosomes O
analyzed O
, O
88 O
were O
from O
probands O
of O
Ashkenazi O
Jewish O
descent O
. O

The O
glu285 O
- O
- O
> O
ala O
mutation O
was O
predominant O
( O
82 O
. O
9 O
% O
) O
in O
this O
population O
, O
followed O
by O
the O
tyr231 O
- O
- O
> O
ter O
( O
14 O
. O
8 O
% O
) O
and O
433 O
- O
- O
2 O
( O
A O
- O
- O
> O
G O
) O
( O
1 O
. O
1 O
% O
) O
mutations O
. O

The O
three O
mutations O
account O
for O
98 O
. O

8 O
% O
of O
the O
Canavan B
chromosomes O
of O
Ashkenazi O
Jewish O
origin O
. O

The O
ala305 O
- O
- O
> O
glu O
mutation O
was O
found O
exclusively O
in O
non O
- O
Jewish O
probands O
of O
European O
descent O
and O
constituted O
60 O
% O
of O
the O
40 O
mutant O
chromosomes O
. O

Predominant O
occurrence O
of O
certain O
mutations O
among O
Ashkenazi O
Jewish O
and O
non O
- O
Jewish O
patients O
with O
Canavan B
disease I
would O
suggest O
a O
founding O
- O
father O
effect O
in O
propagation O
of O
these O
mutant O
chromosomes O

Intelligence O
quotient O
profile O
in O
myotonic B
dystrophy I
, O
intergenerational O
deficit O
, O
and O
correlation O
with O
CTG O
amplification O
. O

An O
abbreviated O
Wechsler O
Adult O
Intelligence O
Scale O
Revised O
( O
WAIS O
- O
R O
) O
was O
used O
to O
assess O
verbal O
and O
arithmetical O
cognitive O
performance O
in O
55 O
subjects O
with O
myotonic B
dystrophy I
( O
DM B
) O
, O
covering O
all O
grades O
of O
disease O
severity O
, O
and O
31 O
controls O
at O
50 O
% O
risk O
of O
inheriting O
DM B
. O

Scaled O
scores O
from O
the O
assessment O
were O
converted O
into O
an O
intelligence O
quotient O
( O
IQ O
) O
estimation O
on O
each O
person O
. O

Significant O
IQ O
differences O
were O
found O
between O
( O
1 O
) O
all O
55 O
DM B
subjects O
( O
mean O
90 O
. O
2 O
, O
SD O
16 O
. O
1 O
) O
and O
31 O
controls O
( O
102 O
. O
6 O
, O
SD O
9 O
. O
4 O
) O
, O
with O
no O
sex O
differences O
in O
either O
group O
; O
( O
2 O
) O
15 O
affected O
parents O
( O
99 O
. O
3 O
, O
SD O
12 O
. O
2 O
) O
and O
their O
affected O
children O
( O
88 O
. O
1 O
, O
SD O
17 O
. O
2 O
) O
, O
where O
significance O
was O
dependent O
on O
parental O
sex O
being O
female O
; O
and O
( O
3 O
) O
15 O
pairs O
of O
affected O
sibs O
( O
89 O
. O
6 O
, O
SD O
13 O
. O
2 O
) O
and O
their O
normal O
sibs O
( O
100 O
. O
2 O
, O
SD O
7 O
. O
6 O
) O
. O

IQ O
steadily O
declined O
as O
( O
1 O
) O
the O
age O
of O
onset O
of O
signs O
and O
symptoms O
decreased O
, O
and O
( O
2 O
) O
the O
CTG O
expansion O
size O
increased O
. O

The O
correlation O
appeared O
to O
be O
more O
linear O
with O
age O
of O
onset O
. O

The O
correlation O
of O
IQ O
difference O
and O
CTG O
expansion O
difference O
in O
both O
the O
DM B
parent O
- O
child O
pairs O
and O
normal O
sib O
- O
affected O
sib O
pairs O
was O
poor O
, O
indicating O
that O
CTG O
expansion O
is O
not O
a O
reliable O
predictor O
of O
IQ O
either O
in O
individual O
persons O
or O
families O
. O

Further O
analysis O
of O
cognitive O
function O
in O
DM B
is O
required O
to O
clarify O
specific O
deficits O
characteristic O
of O
this O
patient O
group O

Adenomatous B
polyposis I
coli I
and O
a O
cytogenetic O
deletion O
of O
chromosome O
5 O
resulting O
from O
a O
maternal O
intrachromosomal O
insertion O
. O

We O
present O
the O
clinical O
and O
laboratory O
findings O
in O
an O
institutionalised O
adult O
patient O
originally O
referred O
for O
autism B
. O

A O
high O
risk O
of O
colorectal B
cancer I
was O
predicted O
when O
an O
interstitial O
deletion O
of O
the O
long O
arm O
of O
chromosome O
5 O
, O
del O
( O
5 O
) O
( O
q15q22 O
. O
3 O
) O
, O
was O
detected O
in O
her O
lymphocytes O
and O
deletion O
of O
the O
MCC O
and O
APC B
genes O
confirmed O
by O
molecular O
analysis O
. O

Adenomatous B
polyposis I
coli I
and O
carcinoma B
of I
the I
rectum I
were O
subsequently O
diagnosed O
in O
the O
patient O
. O

She O
was O
profoundly O
mentally B
retarded I
, O
autistic B
, O
and O
had O
minor O
dysmorphic B
features I
consistent O
with O
those O
of O
previous O
patients O
with O
similar O
deletions O
. O

The O
deletion O
arose O
as O
a O
result O
of O
recombination O
within O
the O
small O
insertion O
loop O
formed O
at O
meiosis O
by O
the O
direct O
insertion O
( O
dir O
ins O
( O
5 O
) O
( O
q22 O
. O
3q14 O
. O
2q15 O
) O
) O
found O
in O
the O
patients O
mother O
. O

This O
family O
further O
confirms O
the O
cytogenetic O
mapping O
of O
both O
MCC O
and O
APC B
genes O
to O
5q22 O
and O
comparison O
with O
other O
recent O
cases O
suggests O
that O
both O
genes O
and O
their O
closely O
linked O
markers O
lie O
within O
the O
5q22 O
. O

1 O
subband O

Familial B
male I
breast I
cancer I
is O
not O
linked O
to O
the O
BRCA1 O
locus O
on O
chromosome O
17q O
. O

Breast B
cancer I
in O
men O
is O
about O
a O
hundredfold O
less O
common O
than O
in O
women O
and O
this O
has O
hindered O
research O
into O
its O
genetic O
basis O
. O

We O
have O
examined O
22 O
families O
with O
at O
least O
one O
case O
of O
male B
breast I
cancer I
for O
linkage O
to O
the O
hereditary B
breast I
and I
ovarian I
cancer I
locus O
, O
BRCA1 O
, O
on O
chromosome O
17q O
. O

We O
found O
strong O
evidence O
against O
linkage O
to O
BRCA1 O
( O
lod O
score O
- O
16 O
. O
63 O
) O
and O
the O
best O
estimate O
of O
the O
proportion O
of O
linked O
families O
was O
0 O
% O
( O
95 O
% O
CI O
0 O
- O
18 O
% O
) O
. O

Our O
results O
indicate O
that O
there O
is O
a O
gene O
( O
s O
) O
other O
than O
BRCA1 O
which O
predisposes O
to O
early O
- O
onset O
breast B
cancer I
in O
women O
and O
which O
confers O
a O
higher O
risk O
of O
male B
breast I
cancer I
. O

Identification O
of O
additional O
pedigrees O
that O
include O
cases O
of O
male B
breast I
cancer I
may O
therefore O
facilitate O
the O
mapping O
and O
isolation O
of O
this O
gene O
. O

The O
EWS O
gene O
, O
involved O
in O
Ewing B
family I
of I
tumors I
, O
malignant B
melanoma I
of I
soft I
parts I
and O
desmoplastic B
small I
round I
cell I
tumors I
, O
codes O
for O
an O
RNA O
binding O
protein O
with O
novel O
regulatory O
domains O
. O

The O
EWS O
gene O
, O
which O
maps O
to O
band O
q12 O
of O
human O
chromosome O
22 O
, O
is O
involved O
in O
a O
wide O
variety O
of O
human O
solid B
tumors I
including O
Ewing B
sarcoma I
, O
related O
primitive O
neuroectodermal B
tumors I
, O
malignant B
melanoma I
of I
soft I
parts I
and O
desmoplastic B
small I
round I
cell I
tumors I
. O

In O
these O
tumors B
, O
the O
EWS O
is O
fused O
to O
genes O
encoding O
transcriptional O
activators O
/ O
repressors O
, O
like O
Fli O
- O
1 O
or O
erg O
or O
ATF O
1 O
or O
wt1 O
. O

To O
better O
understand O
the O
function O
of O
the O
EWS O
protein O
, O
we O
cloned O
the O
EWS O
cDNA O
. O

Sequence O
analysis O
of O
this O
cDNA O
revealed O
differential O
splicing O
involving O
two O
exons O
encoding O
72 O
amino O
acids O
. O

Both O
alternatively O
spliced O
transcripts O
, O
EWS O
and O
EWS O
- O
b O
, O
are O
expressed O
in O
a O
variety O
of O
cells O
. O

Because O
EWS O
proteins O
contain O
putative O
conserved O
RNA O
binding O
motifs O
, O
we O
studied O
the O
RNA O
binding O
properties O
of O
the O
EWS O
protein O
. O

The O
EWS O
- O
b O
protein O
binds O
to O
RNA O
in O
vitro O
and O
, O
specifically O
, O
to O
poly O
G O
and O
poly O
U O
. O

The O
RNA O
binding O
activity O
was O
localized O
to O
the O
carboxy O
terminal O
86 O
amino O
acids O
, O
which O
constitute O
RGG O
box O
. O

Thus O
the O
amino O
terminal O
domain O
of O
EWS O
( O
NTD O
- O
EWS O
) O
, O
which O
is O
involved O
in O
chromosome O
translocation O
may O
regulate O
the O
specificity O
of O
RNA O
binding O
activity O
of O
EWS O
. O

An O
EWS O
- O
erg O
chimeric O
protein O
, O
which O
is O
found O
in O
Ewings B
sarcoma I
cells O
, O
functions O
as O
a O
transcriptional O
activator O
. O

Mutational O
analysis O
of O
EWS O
- O
erg O
chimeric O
protein O
revealed O
that O
NTD O
- O
EWS O
functions O
as O
a O
regulatory O
domain O
for O
the O
transcriptional O
activation O
properties O
of O
EWS O
- O
erg O
chimeric O
protein O
. O
. O

Canavan B
disease I
: O
genomic O
organization O
and O
localization O
of O
human O
ASPA O
to O
17p13 O
- O
ter O
and O
conservation O
of O
the O
ASPA O
gene O
during O
evolution O
. O

Canavan B
disease I
, O
or O
spongy B
degeneration I
of I
the I
brain I
, O
is O
a O
severe O
leukodystrophy B
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
ASPA O
) O
. O

Recently O
, O
a O
missense O
mutation O
was O
identified O
in O
human O
ASPA O
coding O
sequence O
from O
patients O
with O
Canavan B
disease I
. O

The O
human O
ASPA O
gene O
has O
been O
cloned O
and O
found O
to O
span O
29 O
kb O
of O
the O
genome O
. O

Human O
aspartoacylase O
is O
coded O
by O
six O
exons O
intervened O
by O
five O
introns O
. O

The O
exons O
vary O
from O
94 O
( O
exon O
III O
) O
to O
514 O
( O
exon O
VI O
) O
bases O
. O

The O
exon O
/ O
intron O
splice O
junction O
sites O
follow O
the O
gt O
/ O
ag O
consensus O
sequence O
rule O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
human O
/ O
mouse O
somatic O
cell O
hybrid O
cell O
lines O
localized O
ASPA O
to O
human O
chromosome O
17 O
. O

The O
human O
ASPA O
locus O
was O
further O
mapped O
in O
the O
17p13 O
- O
ter O
region O
by O
fluorescence O
in O
situ O
hybridization O
. O

The O
bovine O
aspa O
gene O
has O
also O
been O
cloned O
, O
and O
its O
exon O
/ O
intron O
organization O
is O
identical O
to O
that O
of O
the O
human O
gene O
. O

The O
500 O
- O
base O
sequence O
upstream O
of O
the O
initiator O
ATG O
codon O
in O
the O
human O
gene O
and O
that O
in O
the O
bovine O
gene O
are O
77 O
% O
identical O
. O

Human O
ASPA O
coding O
sequences O
cross O
- O
hybridize O
with O
genomic O
DNA O
from O
yeast O
, O
chicken O
, O
rabbit O
, O
cow O
, O
dog O
, O
mouse O
, O
rat O
, O
and O
monkey O
. O

The O
specificity O
of O
cross O
- O
species O
hybridization O
of O
coding O
sequences O
suggests O
that O
aspartoacylase O
has O
been O
conserved O
during O
evolution O
. O

It O
should O
now O
be O
possible O
to O
identify O
mutations O
in O
the O
noncoding O
genomic O
sequences O
that O
lead O
to O
Canavan B
disease I
and O
to O
study O
the O
regulation O
of O
ASPA O
. O
. O

Myotonic B
dystrophy I
: O
size O
- O
and O
sex O
- O
dependent O
dynamics O
of O
CTG O
meiotic O
instability O
, O
and O
somatic O
mosaicism O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
a O
progressive O
neuromuscular B
disorder I
which O
results O
from O
elongations O
of O
an O
unstable O
( O
CTG O
) O
n O
repeat O
, O
located O
in O
the O
3 O
untranslated O
region O
of O
the O
DM B
gene O
. O

A O
correlation O
has O
been O
demonstrated O
between O
the O
increase O
in O
the O
repeat O
number O
of O
this O
sequence O
and O
the O
severity O
of O
the O
disease O
. O

However O
, O
the O
clinical O
status O
of O
patients O
cannot O
be O
unambiguously O
ascertained O
solely O
on O
the O
basis O
of O
the O
number O
of O
CTG O
repeats O
. O

Moreover O
, O
the O
exclusive O
maternal O
inheritance O
of O
the O
congenital O
form O
remains O
unexplained O
. O

Our O
observation O
of O
differently O
sized O
repeats O
in O
various O
DM B
tissues O
from O
the O
same O
individual O
may O
explain O
why O
the O
size O
of O
the O
mutation O
observed O
in O
lymphocytes O
does O
not O
necessarily O
correlate O
with O
the O
severity O
and O
nature O
of O
symptoms O
. O

Through O
a O
molecular O
and O
genetic O
study O
of O
142 O
families O
including O
418 O
DM B
patients O
, O
we O
have O
investigated O
the O
dynamics O
of O
the O
CTG O
repeat O
meiotic O
instability O
. O

A O
positive O
correlation O
between O
the O
size O
of O
the O
repeat O
and O
the O
intergenerational O
enlargement O
was O
observed O
similarly O
through O
male O
and O
female O
meioses O
for O
< O
or O
= O
0 O
. O

5 O
- O
kb O
CTG O
sequences O
. O

Beyond O
0 O
. O

5 O
kb O
, O
the O
intergenerational O
variation O
was O
more O
important O
through O
female O
meioses O
, O
whereas O
a O
tendency O
to O
compression O
was O
observed O
almost O
exclusively O
in O
male O
meioses O
, O
for O
> O
or O
= O
1 O
. O

5 O
- O
kb O
fragments O
. O

This O
implies O
a O
size O
- O
and O
sex O
- O
dependent O
meiotic O
instability O
. O

Moreover O
, O
segregation O
analysis O
supports O
the O
hypothesis O
of O
a O
maternal O
as O
well O
as O
a O
familial O
predisposition O
for O
the O
occurrence O
of O
the O
congenital O
form O
. O

Finally O
, O
this O
analysis O
reveals O
a O
significant O
excess O
of O
transmitting O
grandfathers O
partially O
accounted O
for O
by O
increased O
fertility O
in O
affected O
males O

Illegitimate O
transcription O
of O
the O
phenylalanine O
hydroxylase O
gene O
in O
lymphocytes O
for O
identification O
of O
mutations O
in O
phenylketonuria B
. O

Taking O
advantage O
of O
the O
illegitimate O
transcription O
of O
the O
phenylalanine O
hydroxylase O
( O
PAH O
) O
gene O
, O
we O
have O
been O
able O
to O
analyse O
the O
PAH O
cDNA O
sequence O
of O
hyperphenylalaninemic B
children O
in O
circulating O
lymphocytes O
. O

Using O
this O
approach O
, O
we O
have O
also O
identified O
3 O
novel O
mutations O
in O
cDNA O
from O
liver O
and O
lymphocytes O
of O
two O
patients O
. O

One O
mutation O
, O
detected O
by O
the O
abnormal O
pattern O
of O
migration O
of O
an O
amplified O
fragment O
, O
is O
a O
C O
to O
T O
transition O
in O
the O
splice O
acceptor O
site O
of O
intron O
10 O
, O
which O
resulted O
in O
the O
skipping O
of O
exon O
11 O
with O
the O
premature O
termination O
of O
RNA O
translation O
downstream O
from O
exon O
12 O
( O
- O
3 O
IVS10 O
) O
. O

The O
other O
two O
mutations O
are O
missense O
mutations O
in O
exons O
10 O
and O
11 O
( O
respectively O
, O
L333F O
and O
E390G O
) O
. O

The O
present O
study O
supports O
the O
view O
that O
circulating O
lymphocytes O
give O
easy O
access O
to O
PAH O
gene O
transcripts O
whose O
nucleotide O
sequence O
is O
identical O
to O
that O
reported O
in O
liver O
and O
therefore O
represent O
a O
useful O
tool O
for O
molecular O
genetic O
studies O
in O
phenylketonuria B
. O
. O

High O
residual O
arylsulfatase O
A O
( O
ARSA O
) O
activity O
in O
a O
patient O
with O
late B
- I
infantile I
metachromatic I
leukodystrophy I
. O

We O
identified O
a O
patient O
suffering O
from O
late B
- I
infantile I
metachromatic I
leukodystrophy I
( O
MLD B
) O
who O
has O
a O
residual O
arylsulfatase O
A O
( O
ARSA O
) O
activity O
of O
about O
10 O
% O
. O

Fibroblasts O
of O
the O
patient O
show O
significant O
sulfatide O
degradation O
activity O
exceeding O
that O
of O
adult B
MLD I
patients O
. O

Analysis O
of O
the O
ARSA O
gene O
in O
this O
patient O
revealed O
heterozygosity O
for O
two O
new O
mutant O
alleles O
in O
one O
allele O
, O
deletion O
of O
C O
447 O
in O
exon O
2 O
leads O
to O
a O
frameshift O
and O
to O
a O
premature O
stop O
codon O
at O
amino O
acid O
position O
105 O
; O
in O
the O
second O
allele O
, O
a O
G O
- O
- O
> O
A O
transition O
in O
exon O
5 O
causes O
a O
Gly309 O
- O
- O
> O
Ser O
substitution O
. O

Transient O
expression O
of O
the O
mutant O
Ser309 O
- O
ARSA O
resulted O
in O
only O
13 O
% O
enzyme O
activity O
of O
that O
observed O
in O
cells O
expressing O
normal O
ARSA O
. O

The O
mutant O
ARSA O
is O
correctly O
targeted O
to O
the O
lysosomes O
but O
is O
unstable O
. O

These O
findings O
are O
in O
contrast O
to O
previous O
results O
showing O
that O
the O
late B
- I
infantile I
type I
of I
MLD I
is O
always O
associated O
with O
the O
complete O
absence O
of O
ARSA O
activity O
. O

The O
expression O
of O
the O
mutant O
ARSA O
protein O
may O
be O
influenced O
by O
particular O
features O
of O
oligodendrocytes O
, O
such O
that O
the O
level O
of O
mutant O
enzyme O
is O
lower O
in O
these O
cells O
than O
in O
others O
. O
. O

An O
arylsulfatase O
A O
( O
ARSA O
) O
missense O
mutation O
( O
T274M O
) O
causing O
late B
- I
infantile I
metachromatic I
leukodystrophy I
. O

Metachromatic B
leukodystrophy I
( O
MLD B
) O
is O
an O
autosomal B
recessive I
lysosomal I
storage I
disorder I
caused O
by O
a O
deficiency B
of I
arylsulfatase I
A I
( O
ARSA O
; O
EC O
3 O
. O
1 O
. O
6 O
. O
8 O
) O
. O

The O
8 O
ARSA O
exons O
and O
adjacent O
intron O
boundaries O
from O
a O
patient O
with O
late B
- I
infantile I
metachromatic I
leukodystrophy I
were O
polymerase O
chain O
reaction O
( O
PCR O
) O
amplified O
in O
seven O
discrete O
reactions O
. O

Amplified O
ARSA O
exons O
were O
analysed O
for O
the O
presence O
of O
sequence O
alterations O
by O
single O
- O
strand O
conformation O
polymorphism O
analysis O
, O
followed O
by O
direct O
sequencing O
of O
PCR O
products O
. O

The O
patient O
was O
found O
to O
be O
homozygous O
for O
a O
C O
- O
- O
> O
T O
transition O
in O
exon O
IV O
that O
results O
in O
the O
substitution O
of O
a O
highly O
conserved O
threonine O
residue O
at O
amino O
acid O
274 O
with O
a O
methionine O
( O
T274M O
) O
. O

Analysis O
of O
a O
further O
29 O
MLD B
patients O
revealed O
the O
presence O
of O
five O
additional O
homozygotes O
for O
T274M O
. O

All O
6 O
T274M O
homozygotes O
( O
representing O
four O
families O
) O
were O
of O
Lebanese O
descent O
, O
and O
all O
were O
known O
to O
be O
the O
result O
of O
consanguineous O
marriages O
. O

The O
altered O
amino O
acid O
is O
rigidly O
conserved O
among O
10 O
sulfatases O
from O
Escherichia O
coli O
to O
humans O
; O
therefore O
, O
it O
is O
most O
likely O
that O
the O
resultant O
mutant O
protein O
will O
have O
little O
or O
no O
enzyme O
activity O
. O

This O
is O
consistent O
with O
the O
very O
low O
ARSA O
activity O
measured O
in O
these O
patients O
and O
their O
uniformly O
severe O
clinical O
presentation O

Mutations O
in O
the O
PAX6 O
gene O
in O
patients O
with O
hereditary O
aniridia B
. O

The O
14 O
exons O
of O
the O
PAX6 O
gene O
have O
been O
analysed O
exon O
- O
by O
- O
exon O
using O
SSCP O
in O
6 O
aniridia B
families O
. O

In O
each O
family O
band O
shifts O
were O
observed O
on O
the O
SSCP O
gels O
for O
only O
one O
exon O
and O
direct O
PCR O
- O
sequencing O
revealed O
mutations O
in O
each O
case O
. O

Two O
mutations O
involved O
C O
- O
- O
> O
T O
transitions O
in O
CGAarg O
codons O
in O
exons O
9 O
and O
11 O
. O

Another O
C O
- O
- O
> O
T O
transition O
converted O
a O
CAG O
- O
glutamine O
to O
a O
TAG O
- O
stop O
in O
exon O
7 O
. O

Small O
insertions O
created O
frameshifts O
which O
produced O
downstream O
stop O
codons O
in O
another O
two O
patients O
and O
an O
A O
- O
- O
> O
T O
mutation O
disrupted O
the O
splice O
donor O
site O
of O
exon O
5 O
in O
the O
remaining O
family O
. O

Thus O
, O
complete O
inactivation O
of O
the O
PAX6 O
gene O
is O
predicted O
in O
all O
cases O
. O

Analysis O
of O
other O
affected O
members O
of O
the O
families O
showed O
that O
, O
in O
each O
case O
, O
all O
affected O
individuals O
carried O
the O
same O
family O
- O
specific O
mutation O
. O

One O
polymorphism O
was O
found O
in O
exon O
7 O
. O

This O
data O
strongly O
supports O
the O
candidature O
of O
PAX6 O
as O
the O
gene O
responsible O
for O
hereditary O
aniridia B
. O
. O

Three O
novel O
mutations O
in O
five O
unrelated O
subjects O
with O
hereditary O
protein B
S I
deficiency I
type I
I I
. O

A O
panel O
of O
eight O
unrelated O
subjects O
with O
inherited O
type B
I I
protein I
S I
deficiency I
was O
screened O
for O
mutations O
in O
the O
PROS1 O
gene O
. O

In O
five O
subjects O
an O
abnormality O
was O
found O
but O
mutations O
were O
not O
detected O
in O
the O
remaining O
three O
subjects O
. O

Two O
subjects O
shared O
a O
G O
- O
- O
> O
A O
transition O
at O
position O
+ O
5 O
of O
the O
donor O
splice O
site O
consensus O
sequence O
of O
intron O
10 O
. O

Also O
in O
two O
subjects O
an O
A O
- O
- O
> O
T O
transversion O
was O
detected O
in O
the O
stopcodon O
of O
the O
PROS1 O
gene O
; O
this O
transversion O
predicts O
a O
protein O
S O
molecule O
that O
is O
extended O
by O
14 O
amino O
acids O
. O

The O
fifth O
subject O
was O
found O
to O
possess O
two O
sequence O
abnormalities O
. O

One O
allele O
carried O
a O
G O
- O
- O
> O
A O
transition O
near O
the O
donor O
splice O
junction O
of O
intron O
2 O
, O
but O
this O
abnormality O
is O
probably O
neutral O
, O
since O
it O
was O
inherited O
from O
the O
parent O
with O
normal O
protein O
S O
antigen O
levels O
. O

In O
the O
other O
allele O
a O
single O
T O
insertion O
in O
codon O
- O
25 O
was O
found O
. O

Analysis O
of O
platelet O
RNA O
showed O
that O
only O
the O
mRNA O
with O
the O
A O
- O
- O
> O
T O
mutation O
in O
the O
stopcodon O
is O
present O
in O
amounts O
comparable O
to O
wildtype O
RNA O
. O

mRNA O
from O
the O
alleles O
with O
the O
other O
two O
mutations O
was O
either O
undetectable O
or O
present O
in O
greatly O
reduced O
amounts O
. O

The O
latter O
indicates O
that O
a O
mRNA O
based O
approach O
is O
not O
feasible O
for O
the O
genetic O
analysis O
of O
protein B
S I
deficiency I
type I
I I
. O
. O

Characteristics O
of O
intergenerational O
contractions O
of O
the O
CTG O
repeat O
in O
myotonic B
dystrophy I
. O

In O
myotonic B
dystrophy I
( O
DM B
) O
, O
the O
size O
of O
a O
CTG O
repeat O
in O
the O
DM B
kinase O
gene O
generally O
increases O
in O
successive O
generations O
with O
clinical O
evidence O
of O
anticipation O
. O

However O
, O
there O
have O
also O
been O
cases O
with O
an O
intergenerational O
contraction O
of O
the O
repeat O
. O

We O
examined O
1 O
, O
489 O
DM B
parent O
- O
offspring O
pairs O
, O
of O
which O
95 O
( O
6 O
. O
4 O
% O
) O
showed O
such O
contractions O
in O
peripheral O
blood O
leukocytes O
( O
PBL O
) O
. O

In O
56 O
of O
the O
95 O
pairs O
, O
clinical O
data O
allowed O
an O
analysis O
of O
their O
anticipation O
status O
. O

It O
is O
surprising O
that O
anticipation O
occurred O
in O
27 O
( O
48 O
% O
) O
of O
these O
56 O
pairs O
, O
while O
none O
clearly O
showed O
a O
later O
onset O
of O
DM B
in O
the O
symptomatic O
offspring O
. O

The O
contraction O
occurred O
in O
76 O
( O
10 O
% O
) O
of O
753 O
paternal O
transmissions O
and O
in O
19 O
( O
3 O
% O
) O
of O
736 O
maternal O
transmissions O
. O

Anticipation O
was O
observed O
more O
frequently O
in O
maternal O
( O
85 O
% O
) O
than O
in O
paternal O
( O
37 O
% O
) O
transmissions O
( O
P O
< O
. O
001 O
) O
. O

The O
parental O
repeat O
size O
correlated O
with O
the O
size O
of O
intergenerational O
contraction O
( O
r2 O
= O
. O
50 O
, O
P O
< O
< O
. O
001 O
) O
, O
and O
the O
slope O
of O
linear O
regression O
was O
steeper O
in O
paternal O
( O
- O
. O
62 O
) O
than O
in O
maternal O
( O
- O
. O
30 O
) O
transmissions O
( O
P O
< O
< O
. O
001 O
) O
. O

Sixteen O
DM B
parents O
had O
multiple O
DM B
offspring O
with O
the O
CTG O
repeat O
contractions O
. O

This O
frequency O
was O
higher O
than O
the O
frequency O
expected O
from O
the O
probability O
of O
the O
repeat O
contractions O
( O
6 O
. O
4 O
% O
) O
and O
the O
size O
of O
DM B
sib O
population O
( O
1 O
. O
54 O
DM B
offspring O
per O
DM B
parent O
, O
in O
968 O
DM B
parents O
) O
. O

We O
conclude O
that O
( O
1 O
) O
intergenerational O
contractions O
of O
the O
CTG O
repeat O
in O
leukocyte O
DNA O
frequently O
accompanies O
apparent O
anticipation O
, O
especially O
when O
DM B
is O
maternally O
transmitted O
, O
and O
( O
2 O
) O
the O
paternal O
origin O
of O
the O
repeat O
and O
the O
presence O
of O
the O
repeat O
contraction O
in O
a O
sibling O
increase O
the O
probability O
of O
the O
CTG O
repeat O
contraction O

Gonosomal O
mosaicism O
in O
myotonic B
dystrophy I
patients O
: O
involvement O
of O
mitotic O
events O
in O
( O
CTG O
) O
n O
repeat O
variation O
and O
selection O
against O
extreme O
expansion O
in O
sperm O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
caused O
by O
abnormal O
expansion O
of O
a O
polymorphic O
( O
CTG O
) O
n O
repeat O
, O
located O
in O
the O
DM B
protein O
kinase O
gene O
. O

We O
determined O
the O
( O
CTG O
) O
n O
repeat O
lengths O
in O
a O
broad O
range O
of O
tissue O
DNAs O
from O
patients O
with O
mild O
, O
classical O
, O
or O
congenital O
manifestation O
of O
DM B
. O

Differences O
in O
the O
repeat O
length O
were O
seen O
in O
somatic O
tissues O
from O
single O
DM B
individuals O
and O
twins O
. O

Repeats O
appeared O
to O
expand O
to O
a O
similar O
extent O
in O
tissues O
originating O
from O
the O
same O
embryonal O
origin O
. O

In O
most O
male O
patients O
carrying O
intermediate O
- O
or O
small O
- O
sized O
expansions O
in O
blood O
, O
the O
repeat O
lengths O
covered O
a O
markedly O
wider O
range O
in O
sperm O
. O

In O
contrast O
, O
male O
patients O
with O
large O
allele O
expansions O
in O
blood O
( O
> O
700 O
CTGs O
) O
had O
similar O
or O
smaller O
repeats O
in O
sperm O
, O
when O
detectable O
. O

Sperm O
alleles O
with O
> O
1 O
, O
000 O
CTGs O
were O
not O
seen O
. O

We O
conclude O
that O
DM B
patients O
can O
be O
considered O
gonosomal O
mosaics O
, O
i O
. O

e O
e O
. O
, O
combined O
somatic O
and O
germ O
- O
line O
tissue O
mosaics O
. O

Most O
remarkably O
, O
we O
observed O
multiple O
cases O
where O
the O
length O
distributions O
of O
intermediate O
- O
or O
small O
- O
sized O
alleles O
in O
fathers O
sperm O
were O
significantly O
different O
from O
that O
in O
their O
offsprings O
blood O
. O

Our O
combined O
findings O
indicate O
that O
intergenerational O
length O
changes O
in O
the O
unstable O
CTG O
repeat O
are O
most O
likely O
to O
occur O
during O
early O
embryonic O
mitotic O
divisions O
in O
both O
somatic O
and O
germ O
- O
line O
tissue O
formation O
. O

Both O
the O
initial O
CTG O
length O
, O
the O
overall O
number O
of O
cell O
divisions O
involved O
in O
tissue O
formation O
, O
and O
perhaps O
a O
specific O
selection O
process O
in O
spermatogenesis O
may O
influence O
the O
dynamics O
of O
this O
process O
. O

A O
model O
explaining O
mitotic O
instability O
and O
sex O
- O
dependent O
segregation O
phenomena O
in O
DM B
manifestation O
is O
discussed O

Regionally O
clustered O
APC B
mutations O
are O
associated O
with O
a O
severe O
phenotype O
and O
occur O
at O
a O
high O
frequency O
in O
new O
mutation O
cases O
of O
adenomatous B
polyposis I
coli I
. O

Germline O
mutation O
in O
APC O
at O
5q21 O
- O
22 O
results O
in O
the O
dominantly O
inherited O
syndrome O
adenomatous B
polyposis I
coli I
( O
APC B
) O
. O

Somatic O
mutation O
in O
this O
gene O
is O
an O
early O
event O
in O
colorectal O
tumourigenesis O
. O

Both O
types O
of O
mutation O
are O
concentrated O
in O
the O
5 O
half O
of O
exon O
15 O
. O

We O
have O
used O
single O
strand O
conformational O
polymorphism O
( O
SSCP O
) O
and O
heteroduplex O
analysis O
to O
screen O
for O
variants O
in O
this O
region O
of O
the O
gene O
in O
a O
total O
of O
45 O
affected O
but O
unrelated O
individuals O
. O

Eighteen O
patients O
had O
no O
family O
history O
of O
the O
disease O
; O
of O
these O
11 O
were O
classified O
as O
having O
a O
severe O
phenotype O
, O
based O
on O
an O
early O
age O
at O
presentation O
or O
cancer B
development O
. O

This O
compared O
with O
6 O
of O
27 O
familial O
cases O
. O

A O
5 O
bp O
deletion O
at O
codon O
1309 O
reported O
to O
occur O
in O
10 O
- O
15 O
% O
of O
unselected O
APC B
patients O
worldwide O
, O
was O
found O
in O
5 O
of O
the O
18 O
new O
mutation O
cases O
and O
4 O
of O
the O
27 O
familial O
cases O
all O
nine O
were O
classed O
as O
severe O
. O

A O
further O
3 O
new O
mutations O
and O
1 O
familial O
mutation O
were O
located O
downstream O
from O
codon O
1309 O
, O
these O
individuals O
similarly O
being O
classed O
as O
phenotypically O
severe O
. O

In O
contrast O
all O
of O
the O
APC B
mutations O
detected O
in O
affected O
individuals O
with O
an O
average O
phenotype O
were O
located O
prior O
to O
codon O
1309 O
. O

The O
frequent O
association O
of O
a O
severe O
phenotype O
with O
fresh O
mutation O
may O
explain O
the O
apparent O
conflict O
of O
a O
high O
mutation O
rate O
( O
20 O
- O
30 O
% O
) O
in O
a O
condition O
, O
which O
on O
average O
, O
is O
lethal O
at O
a O
post O
- O
reproductive O
age O
. O
. O

Mutations O
at O
the O
PAX6 O
locus O
are O
found O
in O
heterogeneous O
anterior B
segment I
malformations I
including O
Peters B
' I
anomaly I
. O

Mutation O
or O
deletion O
of O
the O
PAX6 O
gene O
underlies O
many O
cases O
of O
aniridia B
. O

Three O
lines O
of O
evidence O
now O
converge O
to O
implicate O
PAX6 O
more O
widely O
in O
anterior B
segment I
malformations I
including O
Peters B
anomaly I
. O

First O
, O
a O
child O
with O
Peters B
anomaly I
is O
deleted O
for O
one O
copy O
of O
PAX6 O
. O

Second O
, O
affected O
members O
of O
a O
family O
with O
dominantly O
inherited O
anterior B
segment I
malformations I
, O
including O
Peters B
anomaly I
are O
heterozygous O
for O
an O
R26G O
mutation O
in O
the O
PAX6 O
paired O
box O
. O

Third O
, O
a O
proportion O
of O
Sey O
/ O
+ O
Smalleye O
mice O
, O
heterozygous O
for O
a O
nonsense O
mutation O
in O
murine O
Pax O
- O
6 O
, O
have O
an O
ocular O
phenotype O
resembling O
Peters B
anomaly I
. O

We O
therefore O
propose O
that O
a O
variety O
of O
anterior B
segment I
anomalies I
may O
be O
associated O
with O
PAX6 O
mutations O
. O
. O

Huntington B
disease I
without O
CAG O
expansion O
: O
phenocopies O
or O
errors O
in O
assignment O
? O

Huntington B
disease I
( O
HD B
) O
has O
been O
shown O
to O
be O
associated O
with O
an O
expanded O
CAG O
repeat O
within O
a O
novel O
gene O
on O
4p16 O
. O

3 O
( O
IT15 O
) O
. O

A O
total O
of O
30 O
of O
1 O
, O
022 O
affected O
persons O
( O
2 O
. O
9 O
% O
of O
our O
cohort O
) O
did O
not O
have O
an O
expanded O
CAG O
in O
the O
disease O
range O
. O

The O
reasons O
for O
not O
observing O
expansion O
in O
affected O
individuals O
are O
important O
for O
determining O
the O
sensitivity O
of O
using O
repeat O
length O
both O
for O
diagnosis O
of O
affected O
patients O
and O
for O
predictive O
testing O
programs O
and O
may O
have O
biological O
relevance O
for O
the O
understanding O
of O
the O
molecular O
mechanism O
underlying O
HD B
. O

Here O
we O
show O
that O
the O
majority O
( O
18 O
) O
of O
the O
individuals O
with O
normal O
sized O
alleles O
represent O
misdiagnosis O
, O
sample O
mix O
- O
up O
, O
or O
clerical O
error O
. O

The O
remaining O
12 O
patients O
represent O
possible O
phenocopies O
for O
HD B
. O

In O
at O
least O
four O
cases O
, O
family O
studies O
of O
these O
phenocopies O
excluded O
4p16 O
. O

3 O
as O
the O
region O
responsible O
for O
the O
phenotype O
. O

Mutations O
in O
the O
HD B
gene O
that O
are O
other O
than O
CAG O
expansion O
have O
not O
been O
excluded O
for O
the O
remaining O
eight O
cases O
; O
however O
, O
in O
as O
many O
as O
seven O
of O
these O
persons O
, O
retrospective O
review O
of O
these O
patients O
clinical O
features O
identified O
characteristics O
not O
typical O
for O
HD B
. O

This O
study O
shows O
that O
on O
rare O
occasions O
mutations O
in O
other O
, O
as O
- O
yet O
- O
undefined O
genes O
can O
present O
with O
a O
clinical O
phenotype O
very O
similar O
to O
that O
of O
HD B

Frequent O
detection O
of O
codon O
877 O
mutation O
in O
the O
androgen O
receptor O
gene O
in O
advanced B
prostate I
cancers I
. O

Prostatic O
tissue O
specimens O
derived O
from O
transurethral O
resections O
of O
patients O
with O
metastatic B
prostate I
cancer I
were O
analyzed O
for O
genetic O
alterations O
in O
the O
hormone O
- O
binding O
domain O
of O
the O
androgen O
receptor O
( O
AR O
) O
gene O
. O

Direct O
sequencing O
of O
the O
polymerase O
chain O
reaction O
- O
derived O
DNAs O
of O
6 O
of O
24 O
specimens O
revealed O
a O
codon O
877 O
mutation O
( O
ACT O
- O
- O
> O
GCT O
, O
Thr O
- O
- O
> O
Ala O
) O
in O
the O
hormone O
- O
binding O
domain O
of O
the O
AR O
gene O
. O

This O
same O
AR O
mutation O
has O
been O
reported O
previously O
in O
a O
metastatic B
prostate I
cancer I
cell O
line O
, O
LNCaP O
, O
where O
this O
mutation O
confers O
upon O
the O
AR O
an O
altered O
ligand O
- O
binding O
specificity O
which O
is O
stimulated O
by O
estrogens O
, O
progestagens O
, O
and O
antiandrogens O
. O

It O
is O
possible O
that O
analogous O
to O
an O
activated O
/ O
altered O
growth O
factor O
receptor O
oncogene O
, O
codon O
877 O
mutant O
AR O
with O
altered O
ligand O
binding O
may O
provide O
a O
selective O
growth O
advantage O
in O
the O
genesis O
of O
a O
subset O
of O
advanced B
prostate I
cancer I
. O

Although O
estrogens O
are O
used O
infrequently O
, O
antiandrogens O
are O
used O
increasingly O
in O
hormonal O
therapy O
for O
patients O
with O
advanced B
prostate I
cancer I
. O

The O
stimulatory O
effect O
of O
these O
therapeutic O
agents O
on O
the O
codon O
877 O
mutant O
AR O
further O
suggests O
that O
this O
frequently O
observed O
AR O
mutation O
may O
contribute O
to O
the O
treatment O
refractory O
disease O
. O
. O

The O
human O
gene O
for O
alkaptonuria B
( O
AKU B
) O
maps O
to O
chromosome O
3q O
. O

Alkaptonuria B
( O
AKU B
; O
McKusick O
no O
. O
203500 O
) O
is O
a O
rare O
autosomal B
recessive I
disorder I
caused O
by O
the O
lack O
of O
homogentisic O
acid O
oxidase O
activity O
. O

Patients O
excrete O
large O
amounts O
of O
homogentisic O
acid O
in O
their O
urine O
and O
a O
black O
ochronotic O
pigment O
is O
deposited O
in O
their O
cartilage O
and O
collagenous O
tissues O
. O

Ochronosis B
is O
the O
predominant O
clinical O
complication O
of O
the O
disease O
leading O
to O
ochronotic B
arthropathy I
, O
dark O
urine O
, O
pigment O
changes O
of O
the O
skin O
, O
and O
other O
clinical O
features O
. O

A O
mutation O
causing O
alkaptonuria B
in O
the O
mouse O
has O
mapped O
to O
chromosome O
16 O
. O

Considering O
conserved O
synteny O
, O
we O
were O
able O
to O
map O
the O
human O
gene O
to O
chromosome O
3q O
in O
six O
alkaptonuria B
pedigrees O
of O
Slovak O
origin O
. O
. O

Structure O
of O
the O
human O
Na O
+ O
/ O
glucose O
cotransporter O
gene O
SGLT1 O
. O

Intestinal O
uptake O
of O
dietary O
glucose O
and O
galactose O
is O
mediated O
by O
the O
SGLT1 O
Na O
+ O
/ O
glucose O
cotransporter O
of O
the O
brush O
border O
. O

An O
SGLT1 O
missense O
mutation O
underlies O
hereditary B
glucose I
/ I
galactose I
malabsorption I
, O
characterized O
by O
potentially O
fatal O
diarrhea B
; O
conversely O
, O
oral O
rehydration O
therapy O
exploits O
normal O
transport O
to O
alleviate O
life O
- O
threatening O
diarrhea B
of O
infectious O
origin O
. O

We O
have O
mapped O
the O
entire O
human O
SGLT1 O
Na O
+ O
/ O
glucose O
cotransporter O
gene O
from O
cosmid O
and O
lambda O
phage O
clones O
representing O
a O
genomic O
region O
of O
112 O
kilobases O
. O

Transcription O
initiation O
occurred O
from O
a O
site O
27 O
base O
pairs O
3 O
of O
a O
TATAA O
sequence O
. O

All O
exon O
- O
flanking O
regions O
were O
sequenced O
, O
and O
the O
entire O
112 O
- O
kilobase O
region O
mapped O
with O
four O
restriction O
enzymes O
. O

SGLT1 O
is O
comprised O
of O
15 O
exons O
( O
spanning O
72 O
kilobases O
) O
; O
a O
possible O
evolutionary O
origin O
from O
a O
six O
- O
membrane O
- O
span O
ancestral O
precursor O
via O
a O
gene O
duplication O
event O
is O
suggested O
from O
comparison O
of O
exons O
against O
protein O
secondary O
structure O
and O
from O
sequence O
considerations O
. O

A O
new O
missense O
mutation O
in O
exon O
1 O
causing O
glucose B
/ I
galactose I
malabsorption I
is O
also O
described O
. O

This O
is O
the O
first O
Na O
( O
+ O
) O
- O
dependent O
cotransporter O
gene O
structure O
reported O
. O

These O
data O
facilitate O
the O
search O
for O
new O
glucose B
/ I
galactose I
malabsorption I
- O
related O
mutations O
in O
this O
important O
gene O
and O
provide O
a O
basis O
for O
future O
evolutionary O
comparisons O
with O
other O
Na O
( O
+ O
) O
- O
dependent O
cotransporters O
. O
. O

Four O
novel O
PEPD O
alleles O
causing O
prolidase B
deficiency I
. O

Mutations O
at O
the O
PEPD O
locus O
cause O
prolidase B
deficiency I
( O
McKusick O
170100 O
) O
, O
a O
rare O
autosomal B
recessive I
disorder I
characterized O
by O
iminodipeptiduria B
, O
skin B
ulcers I
, O
mental B
retardation I
, O
and O
recurrent O
infections O
. O

Four O
PEPD O
mutations O
from O
five O
severely O
affected O
individuals O
were O
characterized O
by O
analysis O
of O
reverse O
- O
transcribed O
, O
PCR O
- O
amplified O
( O
RT O
- O
PCR O
) O
cDNA O
. O

We O
used O
SSCP O
analysis O
on O
four O
overlapping O
cDNA O
fragments O
covering O
the O
entire O
coding O
region O
of O
the O
PEPD O
gene O
and O
detected O
abnormal O
SSCP O
bands O
for O
the O
fragment O
spanning O
all O
or O
part O
of O
exons O
13 O
- O
15 O
in O
three O
of O
the O
probands O
. O

Direct O
sequencing O
of O
the O
mutant O
cDNAs O
showed O
a O
G O
- O
- O
> O
A O
, O
1342 O
substitution O
( O
G448R O
) O
in O
two O
patients O
and O
a O
3 O
- O
bp O
deletion O
( O
delta O
E452 O
or O
delta O
E453 O
) O
in O
another O
. O

In O
the O
other O
two O
probands O
the O
amplified O
products O
were O
of O
reduced O
size O
. O

Direct O
sequencing O
of O
these O
mutant O
cDNAs O
revealed O
a O
deletion O
of O
exon O
5 O
in O
one O
patient O
and O
of O
exon O
7 O
in O
the O
other O
. O

Intronic O
sequences O
flanking O
exons O
5 O
and O
7 O
were O
identified O
using O
inverse O
PCR O
followed O
by O
direct O
sequencing O
. O

Conventional O
PCR O
and O
direct O
sequencing O
then O
established O
the O
intron O
- O
exon O
borders O
of O
the O
mutant O
genomic O
DNA O
revealing O
two O
splice O
acceptor O
mutations O
a O
G O
- O
- O
> O
C O
substitution O
at O
position O
- O
1 O
of O
intron O
4 O
and O
an O
A O
- O
- O
> O
G O
substitution O
at O
position O
- O
2 O
of O
intron O
6 O
. O

Our O
results O
indicate O
that O
the O
severe O
form O
of O
prolidase B
deficiency I
is O
caused O
by O
multiple O
PEPD O
alleles O
. O

In O
this O
report O
we O
attempt O
to O
begin O
the O
process O
of O
describing O
these O
alleles O
and O
cataloging O
their O
phenotypic O
expression O
. O
. O

Recombinations O
in O
individuals O
homozygous O
by O
descent O
localize O
the O
Friedreich B
ataxia I
locus O
in O
a O
cloned O
450 O
- O
kb O
interval O
. O

The O
locus O
for O
Friedreich B
ataxia I
( O
FRDA B
) O
, O
a O
severe O
neurodegenerative B
disease I
, O
is O
tightly O
linked O
to O
markers O
D9S5 O
and O
D9S15 O
, O
and O
analysis O
of O
rare O
recombination O
events O
has O
suggested O
the O
order O
cen O
- O
FRDA O
- O
D9S5 O
- O
D9S15 O
- O
qter O
. O

We O
report O
here O
the O
construction O
of O
a O
YAC O
contig O
extending O
800 O
kb O
centromeric O
to O
D9S5 O
and O
the O
isolation O
of O
five O
new O
microsatellite O
markers O
from O
this O
region O
. O

In O
order O
to O
map O
these O
markers O
with O
respect O
to O
the O
FRDA B
locus O
, O
all O
within O
a O
1 O
- O
cM O
confidence O
interval O
, O
we O
sought O
to O
increase O
the O
genetic O
information O
of O
available O
FRDA B
families O
by O
considering O
homozygosity O
by O
descent O
and O
association O
with O
founder O
haplotypes O
in O
isolated O
populations O
. O

This O
approach O
allowed O
us O
to O
identify O
one O
phase O
- O
known O
recombination O
and O
one O
probable O
historic O
recombination O
on O
haplotypes O
from O
Reunion O
Island O
patients O
, O
both O
of O
which O
place O
three O
of O
the O
five O
markers O
proximal O
to O
FRDA B
. O

This O
represents O
the O
first O
identification O
of O
close O
FRDA B
flanking O
markers O
on O
the O
centromeric O
side O
. O

The O
two O
other O
markers O
allowed O
us O
to O
narrow O
the O
breakpoint O
of O
a O
previously O
identified O
distal O
recombination O
that O
is O
> O
180 O
kb O
from O
D9S5 O
( O
26P O
) O
. O

Taken O
together O
, O
the O
results O
place O
the O
FRDA B
locus O
in O
a O
450 O
- O
kb O
interval O
, O
which O
is O
small O
enough O
for O
direct O
search O
of O
candidate O
genes O
. O

A O
detailed O
rare O
cutter O
restriction O
map O
and O
a O
cosmid O
contig O
covering O
this O
interval O
were O
constructed O
and O
should O
facilitate O
the O
search O
of O
genes O
in O
this O
region O
. O
. O

Investigation O
of O
thermoregulatory O
characteristics O
in O
patients O
with O
Prader B
- I
Willi I
syndrome I
. O

A O
survey O
instrument O
is O
used O
to O
assess O
temperature O
regulation O
characteristics O
in O
children O
with O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
compared O
to O
3 O
control O
groups O
sibs O
of O
PWS B
patients O
( O
SIB O
) O
, O
neurodevelopmentally B
handicapped I
children O
( O
ND O
) O
, O
and O
age O
and O
gender O
matched O
well O
children O
( O
WC O
) O
. O

Significant O
differences O
were O
found O
between O
PWS B
patients O
, O
SIB O
controls O
, O
and O
WC O
controls O
in O
the O
prevalence O
of O
febrile O
convulsions O
, O
fever O
- O
associated O
symptoms O
, O
and O
temperature O
less O
than O
94 O
degrees O
F O
. O

No O
differences O
were O
noted O
in O
any O
variable O
between O
the O
PWS B
patients O
and O
the O
ND O
controls O
, O
suggesting O
that O
these O
abnormalities O
are O
not O
unique O
to O
PWS B
, O
but O
can O
occur O
in O
any O
neurodevelopmentally B
handicapped I
individual O
, O
further O
suggesting O
these O
do O
not O
necessarily O
reflect O
syndrome O
- O
specific O
hypothalamic B
abnormalities I
. O
. O

Phenotypic O
variation O
including O
retinitis B
pigmentosa I
, O
pattern B
dystrophy I
, O
and O
fundus B
flavimaculatus I
in O
a O
single O
family O
with O
a O
deletion O
of O
codon O
153 O
or O
154 O
of O
the O
peripherin O
/ O
RDS O
gene O
. O

BACKGROUND O
AND O
OBJECTIVES O
Mutations O
of O
the O
peripherin O
/ O
RDS O
gene O
have O
been O
reported O
in O
autosomal B
dominant I
retinitis I
pigmentosa I
, O
pattern O
macular B
dystrophy I
, O
and O
retinitis B
punctata I
albescens I
. O

We O
report O
herein O
the O
occurrence O
of O
three O
separate O
phenotypes O
within O
a O
single O
family O
with O
a O
novel O
3 O
- O
base O
pair O
deletion O
of O
codon O
153 O
or O
154 O
of O
the O
peripherin O
/ O
RDS O
gene O
. O

DESIGN O
Case O
reports O
with O
clinical O
features O
, O
fluorescein O
angiography O
, O
kinetic O
perimetry O
, O
electrophysiological O
studies O
, O
and O
molecular O
genetics O
. O

SETTING O
University O
medical O
centers O
. O

PATIENTS O
A O
75 O
- O
year O
- O
old O
woman O
, O
her O
two O
daughters O
( O
aged O
44 O
and O
50 O
years O
) O
, O
and O
her O
49 O
- O
year O
- O
old O
son O
were O
screened O
for O
peripherin O
/ O
RDS O
mutations O
because O
of O
the O
presence O
of O
multiple O
phenotypes O
within O
the O
same O
family O
. O

RESULTS O
The O
mother O
presented O
at O
age O
63 O
years O
with O
a O
profoundly O
abnormal O
electroretinogram O
( O
ERG O
) O
and O
adult O
- O
onset O
retinitis B
pigmentosa I
that O
progressed O
dramatically O
over O
12 O
years O
, O
with O
marked O
loss O
of O
peripheral O
visual O
field O
. O

One O
daughter O
developed O
pattern B
macular I
dystrophy I
at O
age O
31 O
years O
. O

At O
age O
44 O
years O
, O
her O
ERG O
was O
moderately O
abnormal O
but O
her O
clinical O
disease O
was O
limited O
to O
the O
macula O
. O

Another O
daughter O
presented O
at O
age O
42 O
years O
with O
macular B
degeneration I
and O
over O
10 O
years O
developed O
the O
clinical O
picture O
of O
fundus B
flavimaculatus I
. O

Her O
peripheral O
visual O
field O
was O
preserved O
but O
her O
ERG O
was O
moderately O
abnormal O
. O

The O
son O
had O
onset O
of O
macular B
degeneration I
at O
age O
44 O
years O
. O

Pericentral B
scotomas I
were O
present O
and O
the O
ERG O
was O
markedly O
abnormal O
. O

Fluorescein O
angiography O
revealed O
punctate O
pigment O
epithelial O
transmission O
defects O
. O

CONCLUSIONS O
A O
3 O
- O
base O
pair O
deletion O
of O
codon O
153 O
or O
154 O
of O
the O
peripherin O
/ O
RDS O
gene O
can O
produce O
clinically O
disparate O
phenotypes O
even O
within O
the O
same O
family O
. O
. O

Assignment O
of O
the O
human O
Na O
+ O
/ O
glucose O
cotransporter O
gene O
SGLT1 O
to O
chromosome O
22q13 O
. O
1 O
. O

The O
Na O
+ O
/ O
glucose O
cotransporter O
gene O
SGLT1 O
encodes O
the O
primary O
carrier O
protein O
responsible O
for O
the O
uptake O
of O
the O
dietary O
sugars O
glucose O
and O
galactose O
from O
the O
intestinal O
lumen O
. O

SGLT1 O
transport O
activity O
is O
currently O
exploited O
in O
oral O
rehydration O
therapy O
. O

The O
75 O
- O
kDa O
glycoprotein O
is O
localized O
in O
the O
brush O
border O
of O
the O
intestinal O
epithelium O
and O
is O
predicted O
to O
comprise O
12 O
membrane O
spans O
. O

In O
two O
patients O
with O
the O
autosomal B
recessive I
disease I
glucose I
/ I
galactose I
malabsorption I
, O
the O
underlying O
cause O
was O
found O
to O
be O
a O
missense O
mutation O
in O
SGLT1 O
, O
and O
the O
Asp28 O
- O
- O
> O
Asn O
change O
was O
demonstrated O
in O
vitro O
to O
eliminate O
SGLT1 O
transport O
activity O
. O

The O
SGLT1 O
gene O
was O
previously O
shown O
to O
reside O
on O
the O
distal O
q O
arm O
of O
chromosome O
22 O
( O
11 O
. O
2 O
- O
- O
> O
qter O
) O
. O

We O
have O
used O
a O
cosmid O
probe O
for O
fluorescence O
in O
situ O
hybridization O
, O
which O
refines O
the O
localization O
to O
22q13 O
. O

1 O
, O
and O
provide O
an O
example O
of O
the O
utility O
of O
the O
SGLT1 O
probe O
as O
a O
diagnostic O
for O
genetic B
diseases I
associated O
with O
translocations O
of O
chromosome O
22 O
. O

Restriction O
of O
ocular O
fundus O
lesions O
to O
a O
specific O
subgroup O
of O
APC B
mutations O
in O
adenomatous B
polyposis I
coli I
patients O
. O

In O
humans O
, O
alteration O
of O
the O
tumor B
suppressor O
gene O
, O
APC B
, O
causes O
adenomatous B
polyposis I
coli I
, O
a O
condition O
causing O
predisposition O
to O
colorectal B
cancer I
. O

The O
syndrome O
inconsistently O
associates O
characteristic O
patches O
of O
congenital B
hypertrophy I
of I
the I
retinal I
pigment I
epithelium I
( O
CHRPE B
) O
. O

Ocular O
examination O
revealed O
that O
patients O
expressing O
CHRPE B
tend O
to O
cluster O
within O
specific O
families O
. O

The O
exact O
APC B
mutation O
was O
identified O
in O
42 O
unrelated O
patients O
. O

In O
all O
cases O
these O
mutations O
were O
predicted O
to O
lead O
to O
the O
synthesis O
of O
a O
truncated O
protein O
. O

The O
extent O
of O
CHRPE B
was O
found O
to O
be O
dependent O
on O
the O
position O
of O
the O
mutation O
along O
the O
coding O
sequence O
. O

CHRPE B
lesions O
are O
almost O
always O
absent O
if O
the O
mutation O
occurs O
before O
exon O
9 O
, O
but O
are O
systematically O
present O
if O
it O
occurs O
after O
this O
exon O
. O

Thus O
, O
the O
range O
of O
phenotypic O
expression O
observed O
among O
affected O
patients O
may O
result O
in O
part O
from O
different O
allelic O
manifestations O
of O
APC B
mutations O
. O
. O

The O
effects O
of O
dystrophin O
gene O
mutations O
on O
the O
ERG O
in O
mice O
and O
humans O
. O

PURPOSE O
. O

The O
authors O
earlier O
findings O
of O
a O
negative O
electroretinogram O
( O
ERG O
) O
in O
a O
boy O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
led O
them O
to O
investigate O
dystrophin O
gene O
deletions O
and O
ERGs O
in O
five O
boys O
with O
DMD B
. O

The O
authors O
wanted O
to O
determined O
whether O
there O
were O
similar O
ERG O
findings O
in O
an O
animal O
model O
for O
DMD B
, O
the O
mdx O
mouse O
. O

METHODS O
. O

Ganzfeld O
ERGs O
were O
recorded O
in O
five O
boys O
with O
DMD B
after O
a O
complete O
ophthalmic O
examination O
. O

The O
dystrophin O
gene O
was O
analyzed O
by O
Southern O
blot O
hybridization O
. O

ERGs O
were O
recorded O
in O
anesthetized O
mdx O
and O
control O
mice O
with O
a O
modified O
Grass O
photostimulator O
( O
Grass O
Instrument O
Company O
, O
Quincy O
, O
MA O
) O
. O

RESULTS O
. O

Ophthalmic O
examinations O
in O
all O
five O
boys O
had O
normal O
findings O
, O
yet O
an O
abnormal O
negative O
ERG O
was O
recorded O
for O
each O
subject O
. O

The O
subjects O
gene O
deletions O
were O
variable O
, O
ranging O
from O
large O
deletions O
to O
no O
detectable O
deletions O
. O

The O
ERGs O
of O
the O
mdx O
mice O
were O
normal O
and O
did O
not O
differ O
significantly O
from O
those O
of O
the O
control O
mice O
. O

CONCLUSIONS O
. O

The O
authors O
believe O
the O
unique O
ERG O
recorded O
for O
the O
human O
subjects O
is O
a O
manifestation O
of O
DMD B
associated O
with O
defects O
at O
the O
dystrophin O
gene O
locus O
and O
represents O
a O
new O
clinical O
entity O
. O

The O
ERG O
of O
the O
mdx O
mouse O
may O
be O
spared O
for O
several O
reasons O
, O
including O
milder O
effects O
of O
the O
mouse O
gene O
defect O
, O
differences O
in O
muscle O
and O
retinal O
gene O
product O
, O
or O
species O
differences O
in O
the O
biochemical O
role O
of O
dystrophin O
. O

The O
ERG O
shows O
promise O
of O
becoming O
a O
noninvasive O
diagnostic O
tool O
for O
DMD B
and O
its O
milder O
allelic O
forms O
. O
. O

Association O
of O
the O
APC B
tumor I
suppressor O
protein O
with O
catenins O
. O

Mutations O
of O
APC O
appear O
to O
initiate O
sporadic O
and O
inherited O
forms O
of O
human O
colorectal B
cancer I
. O

Although O
these O
mutations O
have O
been O
well O
characterized O
, O
little O
is O
known O
about O
the O
function O
of O
the O
APC B
gene O
product O
. O

Two O
cellular O
proteins O
that O
associate O
with O
APC B
were O
identified O
by O
nucleotide O
sequence O
analysis O
and O
peptide O
mapping O
as O
the O
E O
- O
cadherin O
- O
associated O
proteins O
alpha O
- O
and O
beta O
- O
catenin O
. O

A O
27 O
- O
residue O
fragment O
of O
APC O
containing O
a O
15 O
- O
amino O
acid O
repeat O
was O
sufficient O
for O
the O
interaction O
with O
the O
catenins O
. O

These O
results O
suggest O
an O
important O
link O
between O
tumor B
initiation O
and O
cell O
adhesion O
. O
. O

Difference O
in O
methylation O
patterns O
within O
the O
D15S9 O
region O
of O
chromosome O
15q11 O
- O
13 O
in O
first O
cousins O
with O
Angelman B
syndrome I
and O
Prader B
- I
Willi I
syndrome I
. O

Abnormalities O
of O
chromosome O
region O
15q11 O
- O
13 O
are O
associated O
with O
Angelman B
syndrome I
( O
AS B
) O
and O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Differences O
between O
the O
methylation O
patterns O
of O
the O
region O
of O
chromosome O
15q11 O
- O
13 O
which O
hybridizes O
to O
the O
highly O
conserved O
DNA O
, O
DN34 O
, O
in O
normal O
individuals O
and O
in O
patients O
with O
AS B
and O
PWS B
have O
been O
described O
. O

We O
report O
on O
a O
family O
in O
which O
first O
cousins O
are O
affected O
by O
AS B
and O
PWS B
as O
a O
result O
of O
a O
familial O
paracentric O
inversion O
of O
15q11 O
- O
q13 O
. O

The O
results O
of O
the O
studies O
on O
this O
family O
demonstrate O
the O
differences O
in O
the O
methylation O
patterns O
in O
the O
2 O
conditions O
and O
the O
phenomenon O
of O
genomic O
imprinting O
, O
whereby O
genetic O
information O
is O
expressed O
differently O
dependent O
on O
the O
parent O
of O
origin O
. O
. O

Haplotype O
studies O
in O
Wilson B
disease I
. O

In O
51 O
families O
with O
Wilson B
disease I
, O
we O
have O
studied O
DNA O
haplotypes O
of O
dinucleotide O
repeat O
polymorphisms O
( O
CA O
repeats O
) O
in O
the O
13q14 O
. O

3 O
region O
, O
to O
examine O
these O
markers O
for O
association O
with O
the O
Wilson B
disease I
gene O
( O
WND B
) O
. O

In O
addition O
to O
a O
marker O
( O
D13S133 O
) O
described O
elsewhere O
, O
we O
have O
developed O
three O
new O
highly O
polymorphic O
markers O
( O
D13S314 O
, O
D13S315 O
, O
and O
D13S316 O
) O
close O
to O
the O
WND B
locus O
. O

We O
have O
examined O
the O
distribution O
of O
marker O
alleles O
at O
the O
loci O
studied O
and O
have O
found O
that O
D13S314 O
, O
D13S133 O
, O
and O
D13S316 O
each O
show O
nonrandom O
distribution O
on O
chromosomes O
carrying O
the O
WND B
mutation O
. O

We O
have O
studied O
haplotypes O
of O
these O
three O
markers O
and O
have O
found O
that O
there O
are O
highly O
significant O
differences O
between O
WND B
and O
normal O
haplotypes O
in O
northern O
European O
families O
. O

These O
findings O
have O
important O
implications O
for O
mutation O
detection O
and O
molecular O
diagnosis O
in O
families O
with O
Wilson B
disease I
. O

Genetic O
analysis O
of O
the O
BRCA1 O
region O
in O
a O
large O
breast O
/ O
ovarian O
family O
: O
refinement O
of O
the O
minimal O
region O
containing O
BRCA1 O
. O

We O
have O
analyzed O
a O
single O
multi O
- O
affected O
breast B
/ I
ovarian I
cancer I
pedigree O
( O
BOV3 O
) O
and O
have O
shown O
consistent O
inheritance O
of O
markers O
on O
chromosome O
17q O
with O
the O
disease O
confirming O
that O
this O
family O
is O
due O
to O
the O
BRCA1 O
gene O
. O

Analysis O
of O
17q O
haplotypes O
shows O
a O
recombination O
event O
in O
a O
bilateral O
breast B
cancer I
case O
which O
suggests O
that O
the O
BRCA1 O
gene O
lies O
distal O
to O
D17S857 O
; O
D17S857 O
is O
thus O
the O
new O
proximal O
boundary O
for O
the O
region O
containing O
BRCA1 O
. O

Combining O
this O
information O
with O
previously O
published O
mapping O
information O
suggests O
that O
BRCA1 O
is O
contained O
in O
a O
region O
estimated O
at O
1 O
- O
1 O
. O

5 O
Mb O
in O
length O
. O

All O
seven O
breast B
tumour I
/ O
blood O
pairs O
examined O
from O
this O
family O
show O
loss O
of O
heterozygosity O
in O
the O
tumours B
. O

The O
allel O
retained O
in O
each O
tumour B
was O
from O
the O
disease O
- O
bearing O
chromosome O
implicating O
BRCA1 O
as O
a O
tumour B
suppressor O
gene O
. O

We O
have O
sequenced O
the O
17 O
beta O
- O
oestradiol O
dehydrogenase O
genes O
( O
EDH17B1 O
and O
EDH17B2 O
) O
which O
have O
been O
suggested O
as O
candidate O
genes O
for O
BRCA1 O
in O
four O
members O
of O
this O
family O
. O

No O
germline O
mutations O
were O
detected O
. O

Myotonic B
dystrophy I
kinase O
is O
a O
component O
of O
neuromuscular O
junctions O
. O

The O
clinical O
manifestation O
of O
myotonic B
dystrophy I
( O
DM B
) O
is O
correlated O
to O
the O
extent O
of O
expansion O
of O
an O
unstable O
[ O
CTG O
] O
n O
DNA O
motif O
. O

Recent O
studies O
have O
demonstrated O
that O
this O
trinucleotide O
motif O
forms O
part O
of O
the O
last O
, O
3 O
untranslated O
exon O
of O
a O
gene O
which O
potentially O
encodes O
multiple O
protein O
isoforms O
of O
a O
serine O
/ O
threonine O
protein O
kinase O
( O
myotonic B
dystrophy I
protein O
kinase O
, O
DM O
- O
PK O
) O
. O

We O
report O
here O
on O
the O
development O
of O
antisera O
against O
synthetic O
DM O
- O
PK O
peptide O
antigens O
and O
their O
use O
in O
biochemical O
and O
histochemical O
studies O
. O

Immunoreactive O
DM O
- O
kinase O
protein O
of O
53 O
kD O
is O
present O
at O
low O
levels O
in O
skeletal O
and O
cardiac O
muscle O
extracts O
of O
DM B
patients O
and O
normal O
controls O
. O

Immunohistochemical O
staining O
revealed O
that O
DM O
- O
PK O
is O
localised O
prominently O
at O
sites O
of O
neuromuscular O
and O
myotendinous O
junctions O
( O
NMJs O
and O
MTJs O
) O
of O
human O
and O
rodent O
skeletal O
muscles O
. O

Furthermore O
, O
very O
low O
levels O
of O
immunoreactive O
DM O
- O
PK O
protein O
are O
present O
in O
the O
sarcoplasm O
of O
predominantly O
type O
I O
fibres O
in O
various O
muscles O
. O

Strikingly O
, O
presence O
of O
the O
protein O
can O
also O
be O
demonstrated O
for O
NMJs O
of O
muscular O
tissues O
of O
adult O
and O
congenital O
cases O
of O
DM B
, O
with O
no O
gross O
changes O
in O
structural O
organisation O
. O

Our O
findings O
provide O
a O
basis O
for O
further O
characterisation O
of O
the O
role O
of O
the O
kinase O
in O
protein O
assembly O
processes O
or O
signal O
mediation O
at O
synaptic O
sites O
and O
ultimately O
for O
the O
understanding O
of O
the O
complex O
pathophysiology O
of O
DM B
. O
. O

Markedly O
accelerated O
catabolism O
of O
apolipoprotein O
A O
- O
II O
( O
ApoA O
- O
II O
) O
and O
high O
density O
lipoproteins O
containing O
ApoA O
- O
II O
in O
classic O
lecithin O
: O
cholesterol B
acyltransferase I
deficiency I
and O
fish B
- I
eye I
disease I
. O

Classic B
( I
complete I
) I
lecithin I
cholesterol I
acyltransferase I
( I
LCAT I
) I
deficiency I
and O
Fish B
- I
eye I
disease I
( O
partial B
LCAT I
deficiency I
) O
are O
genetic O
syndromes O
associated O
with O
markedly O
decreased O
plasma O
levels O
of O
high O
density O
lipoprotein O
( O
HDL O
) O
cholesterol O
but O
not O
with O
an O
increased O
risk O
of O
atherosclerotic B
cardiovascular I
disease I
. O

We O
investigated O
the O
metabolism O
of O
the O
HDL O
apolipoproteins O
( O
apo O
) O
apoA O
- O
I O
and O
apoA O
- O
II O
in O
a O
total O
of O
five O
patients O
with O
LCAT B
deficiency I
, O
one O
with O
classic B
LCAT I
deficiency I
and O
four O
with O
Fish B
- I
eye I
disease I
. O

Plasma O
levels O
of O
apoA O
- O
II O
were O
decreased O
to O
a O
proportionately O
greater O
extent O
( O
23 O
% O
of O
normal O
) O
than O
apoA O
- O
I O
( O
30 O
% O
of O
normal O
) O
. O

In O
addition O
, O
plasma O
concentrations O
of O
HDL O
particles O
containing O
both O
apoA O
- O
I O
and O
apoA O
- O
II O
( O
LpA O
- O
I O
A O
- O
II O
) O
were O
much O
lower O
( O
18 O
% O
of O
normal O
) O
than O
those O
of O
particles O
containing O
only O
apoA O
- O
I O
( O
LpA O
- O
I O
) O
( O
51 O
% O
of O
normal O
) O
. O

The O
metabolic O
basis O
for O
the O
low O
levels O
of O
apoA O
- O
II O
and O
LpA O
- O
I O
A O
- O
II O
was O
investigated O
in O
all O
five O
patients O
using O
both O
exogenous O
radiotracer O
and O
endogenous O
stable O
isotope O
labeling O
techniques O
. O

The O
mean O
plasma O
residence O
time O
of O
apoA O
- O
I O
was O
decreased O
at O
2 O
. O

08 O
+ O
/ O
- O
0 O
. O

27 O
d O
( O
controls O
4 O
. O
74 O
+ O
/ O
- O
0 O
. O
65 O
days O
) O
; O
however O
, O
the O
residence O
time O
of O
apoA O
- O
II O
was O
even O
shorter O
at O
1 O
. O

66 O
+ O
/ O
- O
0 O
. O

24 O
d O
( O
controls O
5 O
. O
25 O
+ O
/ O
- O
0 O
. O
61 O
d O
) O
. O

In O
addition O
, O
the O
catabolism O
of O
apoA O
- O
I O
in O
LpA O
- O
I O
A O
- O
II O
was O
substantially O
faster O
than O
that O
of O
apoA O
- O
I O
in O
LpA O
- O
I O
. O

In O
summary O
, O
genetic O
syndromes O
of O
either O
complete B
or I
partial I
LCAT I
deficiency I
result O
in O
low O
levels O
of O
HDL O
through O
preferential O
hypercatabolism O
of O
apoA O
- O
II O
and O
HDL O
particles O
containing O
apoA O
- O
II O
. O

Because O
LpA O
- O
I O
has O
been O
proposed O
to O
be O
more O
protective O
than O
LpA O
- O
I O
A O
- O
II O
against O
atherosclerosis B
, O
this O
selective O
effect O
on O
the O
metabolism O
of O
LpA O
- O
I O
A O
- O
II O
may O
provide O
a O
potential O
explanation O
why O
patients O
with O
classic B
LCAT I
deficiency I
and O
Fish B
- I
eye I
disease I
are O
not O
at O
increased O
risk O
for O
premature O
atherosclerosis B
despite O
markedly O
decreased O
levels O
of O
HDL O
cholesterol O
and O
apoA O
- O
I O

X B
linked I
recessive I
thrombocytopenia I
. O

A O
Saudi O
Arab O
boy O
presented O
in O
early O
childhood O
with O
thrombocytopenia B
, O
morphologically O
large O
and O
normal O
sized O
platelets O
, O
increased O
mean O
platelet O
volume O
, O
and O
a O
hypermegakaryocytic O
bone O
marrow O
. O

There O
was O
no O
clinical O
and O
laboratory O
evidence O
of O
any O
significant O
immunological B
abnormalities I
. O

Similar O
findings O
in O
two O
other O
brothers O
suggested O
strongly O
that O
they O
were O
all O
suffering O
from O
an O
X B
linked I
recessive I
thrombocytopenic I
disorder I
. O

Results O
of O
DNA O
analysis O
with O
the O
probe O
M27 O
beta O
are O
consistent O
with O
X O
linkage O
and O
indicate O
also O
that O
the O
locus O
of O
the O
relevant O
gene O
lies O
close O
to O
or O
is O
identical O
to O
the O
locus O
of O
the O
gene O
for O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
. O

Because O
of O
various O
features O
which O
include O
the O
presence O
of O
large O
and O
normal O
sized O
platelets O
( O
rather O
than O
small O
platelets O
) O
and O
freedom O
from O
significant O
immune B
deficiencies I
, O
it O
is O
likely O
that O
the O
X B
linked I
recessive I
thrombocytopenia I
in O
this O
family O
is O
an O
isolated O
entity O
quite O
distinct O
from O
the O
classical O
WAS B
phenotype O
. O

However O
, O
a O
modified O
expression O
of O
the O
WAS B
gene O
producing O
a O
mild O
phenotypic O
variant O
cannot O
be O
excluded O
entirely O
. O
. O

Macular B
dystrophy I
associated O
with O
mutations O
at O
codon O
172 O
in O
the O
human O
retinal B
degeneration I
slow O
gene O
. O

BACKGROUND O
Recently O
, O
mutations O
in O
the O
retinal B
degeneration I
slow O
( O
rds O
) O
gene O
which O
codes O
for O
peripherin O
- O
rds O
have O
been O
implicated O
as O
a O
cause O
of O
autosomal B
dominant I
retinitis I
pigmentosa I
. O

Because O
this O
gene O
is O
expressed O
in O
both O
rods O
and O
cones O
, O
mutations O
in O
the O
rds O
gene O
might O
be O
expected O
to O
cause O
degeneration O
affecting O
either O
the O
scotopic O
or O
photopic O
systems O
. O

Mutations O
at O
codon O
172 O
of O
the O
rds O
gene O
have O
been O
identified O
in O
three O
families O
with O
autosomal O
dominantly O
inherited O
, O
progressive O
macular B
dystrophy I
. O

METHODS O
Affected O
individuals O
underwent O
ophthalmic O
examination O
, O
scotopic O
perimetry O
, O
dark O
adaptometry O
, O
measurement O
of O
color O
- O
contrast O
sensitivity O
, O
and O
electroretinography O
to O
characterize O
the O
photoreceptor O
dysfunction O
. O

RESULTS O
In O
all O
but O
one O
affected O
member O
, O
symptoms O
of O
progressive O
central O
visual B
loss I
developed O
in O
the O
third O
or O
fourth O
decade O
of O
life O
accompanied O
by O
central B
scotoma I
and O
well O
- O
demarcated O
atrophy B
of I
the I
retinal I
pigment I
epithelium I
and O
choriocapillaris B
of I
the I
macula I
. O

In O
general O
, O
cone O
and O
rod O
thresholds O
were O
elevated O
, O
and O
color O
- O
contrast O
sensitivity O
was O
absent O
in O
the O
central O
visual O
field O
. O

Peripherally O
, O
the O
scotopic O
sensitivities O
were O
normal O
, O
as O
was O
the O
recovery O
from O
bleach O
. O

Cone O
electroretinograms O
were O
diminished O
in O
amplitude O
, O
and O
delayed O
in O
all O
affected O
adults O
except O
one O
. O

Rod O
electroretinograms O
were O
normal O
or O
near O
normal O
in O
amplitude O
, O
and O
had O
normal O
implicit O
times O
. O

Affected O
asymptomatic O
children O
had O
macular O
changes O
, O
abnormal O
color O
- O
contrast O
sensitivity O
, O
and O
reduced O
pattern O
and O
cone O
electroretinograms O
. O

CONCLUSION O
These O
results O
indicate O
that O
mutations O
in O
the O
rds O
gene O
can O
be O
expressed O
as O
a O
macular B
dystrophy I
, O
with O
evidence O
of O
primary O
cone B
dysfunction I
and O
preservation O
of O
peripheral O
rod O
function O
. O
. O

Anonymous O
marker O
loci O
within O
400 O
kb O
of O
HLA O
- O
A O
generate O
haplotypes O
in O
linkage O
disequilibrium O
with O
the O
hemochromatosis B
gene O
( O
HFE O
) O

The O
hemochromatosis B
gene O
( O
HFE O
) O
maps O
to O
6p21 O
. O

3 O
and O
is O
less O
than O
1 O
cM O
from O
the O
HLA O
class O
I O
genes O
; O
however O
, O
the O
precise O
physical O
location O
of O
the O
gene O
has O
remained O
elusive O
and O
controversial O
. O

The O
unambiguous O
identification O
of O
a O
crossover O
event O
within O
hemochromatosis B
families O
is O
very O
difficult O
; O
it O
is O
particularly O
hampered O
by O
the O
variability O
of O
the O
phenotypic O
expression O
as O
well O
as O
by O
the O
sex O
- O
and O
age O
- O
related O
penetrance O
of O
the O
disease O
. O

For O
these O
practical O
considerations O
, O
traditional O
linkage O
analysis O
could O
prove O
of O
limited O
value O
in O
further O
refining O
the O
extrapolated O
physical O
position O
of O
HFE O
. O

We O
therefore O
embarked O
upon O
a O
linkage O
- O
disequilibrium O
analysis O
of O
HFE O
and O
normal O
chromosomes O
from O
the O
Brittany O
population O
. O

In O
the O
present O
report O
, O
66 O
hemochromatosis B
families O
yielding O
151 O
hemochromatosis B
chromosomes O
and O
182 O
normal O
chromosomes O
were O
RFLP O
- O
typed O
with O
a O
battery O
of O
probes O
, O
including O
two O
newly O
derived O
polymorphic O
markers O
from O
the O
6 O
. O

7 O
and O
HLA O
- O
F O
loci O
located O
150 O
and O
250 O
kb O
telomeric O
to O
HLA O
- O
A O
, O
respectively O
. O

The O
results O
suggest O
a O
strong O
peak O
of O
existing O
linkage O
disequilibrium O
focused O
within O
the O
i82 O
- O
to O
- O
6 O
. O

7 O
interval O
( O
approximately O
250 O
kb O
) O
. O

The O
zone O
of O
linkage O
disequilibrium O
is O
flanked O
by O
the O
i97 O
locus O
, O
positioned O
30 O
kb O
proximal O
to O
i82 O
, O
and O
the O
HLA O
- O
F O
gene O
, O
found O
250 O
kb O
distal O
to O
HLA O
- O
A O
, O
markers O
of O
which O
display O
no O
significant O
association O
with O
HFE O
. O

These O
data O
support O
the O
possibility O
that O
HFE O
resides O
within O
the O
400 O
- O
kb O
expanse O
of O
DNA O
between O
i97 O
and O
HLA O
- O
F O
. O

Alternatively O
, O
the O
very O
tight O
association O
of O
HLA O
- O
A3 O
and O
allele O
1 O
of O
the O
6 O
. O

7 O
locus O
, O
both O
of O
which O
are O
comprised O
by O
the O
major O
ancestral O
or O
founder O
HFE O
haplotype O
in O
Brittany O
, O
supports O
the O
possibility O
that O
the O
disease O
gene O
may O
reside O
immediately O
telomeric O
to O
the O
6 O
. O

7 O
locus O
within O
the O
linkage O
- O
disequilibrium O
zone O
. O

Additionally O
, O
hemochromatosis B
haplotypes O
possessing O
HLA O
- O
A11 O
and O
the O
low O
- O
frequency O
HLA O
- O
F O
polymorphism O
( O
allele O
2 O
) O
are O
supportive O
of O
a O
separate O
founder O
chromosome O
containing O
a O
second O
, O
independently O
arising O
mutant O
allele O
. O

Overall O
, O
the O
establishment O
of O
a O
likely O
" O
hemochromatosis B
critical O
region O
" O
centromeric O
boundary O
and O
the O
identification O
of O
a O
linkage O
- O
disequilibrium O
zone O
both O
significantly O
contribute O
to O
a O
reduction O
in O
the O
amount O
of O
DNA O
required O
to O
be O
searched O
for O
novel O
coding O
sequences O
constituting O
the O
HFE B
defect I

Genomic O
structure O
of O
the O
EWS O
gene O
and O
its O
relationship O
to O
EWSR1 O
, O
a O
site O
of O
tumor B
- O
associated O
chromosome O
translocation O
. O

The O
EWS O
gene O
has O
been O
identified O
based O
on O
its O
location O
at O
the O
chromosome O
22 O
breakpoint O
of O
the O
t O
( O
11 O
; O
22 O
) O
( O
q24 O
; O
q12 O
) O
translocation O
that O
characterizes O
Ewing B
sarcoma I
and O
related O
neuroectodermal B
tumors I
. O

The O
EWS O
gene O
spans O
about O
40 O
kb O
of O
DNA O
and O
is O
encoded O
by O
17 O
exons O
. O

The O
nucleotide O
sequence O
of O
the O
exons O
is O
identical O
to O
that O
of O
the O
previously O
described O
cDNA O
. O

The O
first O
7 O
exons O
encode O
the O
N O
- O
terminal O
domain O
of O
EWS O
, O
which O
consists O
of O
a O
repeated O
degenerated O
polypeptide O
of O
7 O
to O
12 O
residues O
rich O
in O
tyrosine O
, O
serine O
, O
threonine O
, O
glycine O
, O
and O
glutamine O
. O

Exons O
11 O
, O
12 O
, O
and O
13 O
encode O
the O
putative O
RNA O
binding O
domain O
. O

The O
three O
glycine O
- O
and O
arginine O
- O
rich O
motifs O
of O
the O
gene O
are O
mainly O
encoded O
by O
exons O
8 O
- O
9 O
, O
14 O
, O
and O
16 O
. O

The O
DNA O
sequence O
in O
the O
5 O
region O
of O
the O
gene O
has O
features O
of O
a O
CpG O
- O
rich O
island O
and O
lacks O
canonical O
promoter O
elements O
, O
such O
as O
TATA O
and O
CCAAT O
consensus O
sequences O
. O

Positions O
of O
the O
chromosome O
22 O
breakpoints O
were O
determined O
for O
19 O
Ewing B
tumors I
. O

They O
were O
localized O
in O
introns O
7 O
or O
8 O
in O
18 O
cases O
and O
in O
intron O
10 O
in O
1 O
case O
. O
. O

Norrie B
disease I
gene O
: O
characterization O
of O
deletions O
and O
possible O
function O
. O

Positional O
cloning O
experiments O
have O
resulted O
recently O
in O
the O
isolation O
of O
a O
candidate O
gene O
for O
Norrie B
disease I
( O
pseudoglioma B
; O
NDP B
) O
, O
a O
severe O
X B
- I
linked I
neurodevelopmental I
disorder I
. O

Here O
we O
report O
the O
isolation O
and O
analysis O
of O
human O
genomic O
DNA O
clones O
encompassing O
the O
NDP B
gene O
. O

The O
gene O
spans O
28 O
kb O
and O
consists O
of O
3 O
exons O
, O
the O
first O
of O
which O
is O
entirely O
contained O
within O
the O
5 O
untranslated O
region O
. O

Detailed O
analysis O
of O
genomic O
deletions O
in O
Norrie B
patients O
shows O
that O
they O
are O
heterogeneous O
, O
both O
in O
size O
and O
in O
position O
. O

By O
PCR O
analysis O
, O
we O
found O
that O
expression O
of O
the O
NDP B
gene O
was O
not O
confined O
to O
the O
eye O
or O
to O
the O
brain O
. O

An O
extensive O
DNA O
and O
protein O
sequence O
comparison O
between O
the O
human O
NDP B
gene O
and O
related O
genes O
from O
the O
database O
revealed O
homology O
with O
cysteine O
- O
rich O
protein O
- O
binding O
domains O
of O
immediate O
- O
- O
early O
genes O
implicated O
in O
the O
regulation O
of O
cell O
proliferation O
. O

We O
propose O
that O
NDP O
is O
a O
molecule O
related O
in O
function O
to O
these O
genes O
and O
may O
be O
involved O
in O
a O
pathway O
that O
regulates O
neural O
cell O
differentiation O
and O
proliferation O
. O
. O

The O
normal O
Huntington B
disease I
( O
HD B
) O
allele O
, O
or O
a O
closely O
linked O
gene O
, O
influences O
age O
at O
onset O
of O
HD B
. O

We O
evaluated O
the O
hypothesis O
that O
Huntington B
disease I
( O
HD B
) O
is O
influenced O
by O
the O
normal O
HD B
allele O
by O
comparing O
transmission O
patterns O
of O
genetically O
linked O
markers O
at O
the O
D4S10 O
locus O
in O
the O
normal O
parent O
against O
age O
at O
onset O
in O
the O
affected O
offspring O
. O

Analysis O
of O
information O
from O
21 O
sibships O
in O
14 O
kindreds O
showed O
a O
significant O
tendency O
for O
sibs O
who O
have O
similar O
onset O
ages O
to O
share O
the O
same O
D4S10 O
allele O
from O
the O
normal O
parent O
. O

Affected O
sibs O
who O
inherited O
different O
D4S10 O
alleles O
from O
the O
normal O
parent O
tended O
to O
have O
more O
variable O
ages O
at O
onset O
. O

These O
findings O
suggest O
that O
the O
expression O
of O
HD B
is O
modulated O
by O
the O
normal O
HD B
allele O
or O
by O
a O
closely O
linked O
locus O
. O
. O

Further O
investigation O
of O
the O
HEXA O
gene O
intron O
9 O
donor O
splice O
site O
mutation O
frequently O
found O
in O
non O
- O
Jewish O
Tay B
- I
Sachs I
disease I
patients O
from O
the O
British O
Isles O
. O

In O
a O
previous O
study O
we O
found O
that O
a O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
causing O
mutation O
in O
the O
intron O
9 O
donor O
splice O
site O
of O
the O
HEXA O
gene O
occurs O
at O
high O
frequency O
in O
non O
- O
Jewish O
patients O
and O
carriers O
from O
the O
British O
Isles O
. O

It O
was O
found O
more O
frequently O
in O
subjects O
of O
Irish O
, O
Scottish O
, O
and O
Welsh O
origin O
compared O
with O
English O
origin O
( O
63 O
% O
and O
31 O
% O
respectively O
) O
. O

We O
have O
now O
tested O
, O
in O
a O
blind O
study O
, O
26 O
American O
TSD B
carriers O
and O
28 O
non O
- O
carriers O
who O
have O
British O
ancestry O
for O
the O
intron O
9 O
splice O
site O
mutation O
. O

Six O
of O
the O
carriers O
and O
none O
of O
the O
controls O
were O
positive O
for O
the O
mutation O
. O

All O
six O
had O
Irish O
ancestry O
, O
compared O
with O
nine O
of O
the O
20 O
other O
( O
intron O
9 O
mutation O
negative O
) O
TSD B
carriers O
( O
p O
< O
0 O
. O
05 O
) O
. O

These O
results O
confirm O
the O
previously O
found O
high O
frequency O
of O
the O
intron O
9 O
mutation O
in O
non O
- O
Jewish O
TSD B
families O
of O
British O
Isles O
, O
particularly O
Irish O
, O
origin O
, O
and O
reinforce O
the O
need O
to O
screen O
such O
families O
for O
this O
mutation O
. O

Molecular O
mechanisms O
of O
oncogenic O
mutations O
in O
tumors B
from O
patients O
with O
bilateral B
and I
unilateral I
retinoblastoma I
. O

The O
RB1 O
gene O
from O
12 O
human O
retinoblastoma B
tumors I
has O
been O
analyzed O
exon O
- O
by O
- O
exon O
with O
the O
single O
- O
strand O
conformation O
polymorphism O
technique O
. O

Mutations O
were O
found O
in O
all O
tumors B
, O
and O
one O
- O
third O
of O
the O
tumors B
had O
independent O
mutations O
in O
both O
alleles O
neither O
of O
which O
were O
found O
in O
the O
germ O
line O
, O
confirming O
their O
true O
sporadic O
nature O
. O

In O
the O
remaining O
two O
- O
thirds O
of O
the O
tumors B
only O
one O
mutation O
was O
found O
, O
consistent O
with O
the O
loss O
- O
of O
- O
heterozygosity O
theory O
of O
tumorigenesis O
. O

Point O
mutations O
, O
the O
majority O
of O
which O
were O
C O
- O
- O
> O
T O
transitions O
, O
were O
the O
most O
common O
abnormality O
and O
usually O
resulted O
in O
the O
conversion O
of O
an O
arginine O
codon O
to O
a O
stop O
codon O
. O

Small O
deletions O
were O
the O
second O
most O
common O
abnormality O
and O
most O
often O
created O
a O
downstream O
stop O
codon O
as O
the O
result O
of O
a O
reading O
frameshift O
. O

Deletions O
and O
point O
mutations O
also O
affected O
splice O
junctions O
. O

Direct O
repeats O
were O
present O
at O
the O
breakpoint O
junctions O
in O
the O
majority O
of O
deletions O
, O
supporting O
a O
slipped O
- O
mispairing O
mechanism O
. O

Point O
mutations O
generally O
produced O
DNA O
sequences O
which O
resulted O
in O
perfect O
homology O
with O
endogenous O
sequences O
which O
lay O
within O
14 O
bp O
. O
. O

PAX6 O
mutations O
in O
aniridia B
. O

Aniridia B
is O
a O
congenital B
malformation I
of I
the I
eye I
, O
chiefly O
characterised O
by O
iris B
hypoplasia I
, O
which O
can O
cause O
blindness B
. O

The O
PAX6 O
gene O
was O
isolated O
as O
a O
candidate O
aniridia B
gene O
by O
positional O
cloning O
from O
the O
smallest O
region O
of O
overlap O
of O
aniridia B
- O
associated O
deletions O
. O

Subsequently O
PAX6 O
intragenic O
mutations O
were O
demonstrated O
in O
Smalleye O
, O
a O
mouse O
mutant O
which O
is O
an O
animal O
model O
for O
aniridia B
, O
and O
six O
human O
aniridia B
patients O
. O

In O
this O
paper O
we O
describe O
four O
additional O
PAX6 O
point O
mutations O
in O
aniridia B
patients O
, O
both O
sporadic O
and O
familial O
. O

These O
mutations O
highlight O
regions O
of O
the O
gene O
which O
are O
essential O
for O
normal O
PAX6 O
function O
. O

In O
addition O
, O
the O
frequency O
at O
which O
we O
have O
found O
PAX6 O
mutations O
suggests O
that O
lesions O
in O
PAX6 O
will O
account O
for O
most O
cases O
of O
aniridia B
. O
. O

Detection O
of O
a O
novel O
arginine O
vasopressin O
defect O
by O
dideoxy O
fingerprinting O
. O

Autosomal B
dominant I
neurohypophyseal I
diabetes I
insipidus I
is O
a O
familial O
form O
of O
diabetes B
insipidus I
. O

This O
disorder O
is O
associated O
with O
variable O
levels O
of O
arginine O
vasopressin O
( O
AVP O
) O
and O
diabetes B
insipidus I
of O
varying O
severity O
, O
which O
responds O
to O
exogenous O
AVP O
. O

To O
determine O
the O
molecular O
basis O
of O
autosomal B
dominant I
neurohypophyseal I
diabetes I
insipidus I
, O
the O
AVP O
genes O
of O
members O
of O
a O
large O
kindred O
were O
analyzed O
. O

A O
new O
method O
, O
called O
dideoxy O
fingerprinting O
, O
was O
used O
to O
detect O
an O
AVP O
mutation O
that O
was O
characterized O
by O
DNA O
sequencing O
. O

The O
novel O
defect O
found O
changes O
the O
last O
codon O
of O
the O
AVP O
signal O
peptide O
from O
alanine O
to O
threonine O
, O
which O
should O
perturb O
cleavage O
of O
mature O
AVP O
from O
its O
precursor O
protein O
and O
inhibit O
its O
secretion O
or O
action O
. O
. O

Germinal O
mosaicism O
in O
a O
Duchenne B
muscular I
dystrophy I
family O
: O
implications O
for O
genetic O
counselling O
. O

In O
this O
study O
we O
describe O
a O
three O
- O
generation O
family O
in O
which O
two O
siblings O
were O
affected O
by O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
. O

Immunohistochemical O
analysis O
of O
muscle O
dystrophin O
and O
haplotype O
analysis O
of O
the O
DMD B
locus O
revealed O
that O
the O
X O
chromosome O
carrying O
the O
DMD B
gene O
was O
transmitted O
from O
the O
healthy O
maternal O
grandfather O
to O
his O
three O
daughters O
, O
including O
the O
probands O
mother O
. O

These O
findings O
indicate O
that O
the O
grandfather O
was O
a O
germinal O
mosaic O
for O
the O
DMD B
gene O
. O

The O
definition O
of O
the O
carrier O
status O
in O
two O
possible O
carriers O
led O
us O
to O
give O
accurate O
genetic O
counselling O
and O
to O
prevent O
the O
birth O
of O
an O
affected O
boy O
. O

The O
results O
of O
this O
study O
demonstrate O
the O
usefulness O
of O
haplotype O
analysis O
and O
immunohistochemical O
muscle O
dystrophin O
studies O
to O
detect O
hidden O
germinal O
mosaicism O
and O
to O
improve O
genetic O
counselling O
. O
. O

Genetic O
mapping O
of O
the O
breast B
- I
ovarian I
cancer I
syndrome I
to O
a O
small O
interval O
on O
chromosome O
17q12 O
- O
21 O
: O
exclusion O
of O
candidate O
genes O
EDH17B2 O
and O
RARA O
. O

A O
susceptibility O
gene O
for O
hereditary B
breast I
- I
ovarian I
cancer I
, O
BRCA1 O
, O
has O
been O
assigned O
by O
linkage O
analysis O
to O
chromosome O
17q21 O
. O

Candidate O
genes O
in O
this O
region O
include O
EDH17B2 O
, O
which O
encodes O
estradiol O
17 O
beta O
- O
hydroxysteroid O
dehydrogenase O
II O
( O
17 O
beta O
- O
HSD O
II O
) O
, O
and O
RARA O
, O
the O
gene O
for O
retinoic O
acid O
receptor O
alpha O
. O

We O
have O
typed O
22 O
breast B
and I
breast I
- I
ovarian I
cancer I
families O
with O
eight O
polymorphisms O
from O
the O
chromosome O
17q12 O
- O
21 O
region O
, O
including O
two O
in O
the O
EDH17B2 O
gene O
. O

Genetic O
recombination O
with O
the O
breast B
cancer I
trait O
excludes O
RARA O
from O
further O
consideration O
as O
a O
candidate O
gene O
for O
BRCA1 O
. O

Both O
BRCA1 O
and O
EDH17B2 O
map O
to O
a O
6 O
cM O
interval O
( O
between O
THRA1 O
and O
D17S579 O
) O
and O
no O
recombination O
was O
observed O
between O
the O
two O
genes O
. O

However O
, O
direct O
sequencing O
of O
overlapping O
PCR O
products O
containing O
the O
entire O
EDH17B2 O
gene O
in O
four O
unrelated O
affected O
women O
did O
not O
uncover O
any O
sequence O
variation O
, O
other O
than O
previously O
described O
polymorphisms O
. O

Mutations O
in O
the O
EDH17B2 O
gene O
, O
therefore O
do O
not O
appear O
to O
be O
responsible O
for O
the O
hereditary B
breast I
- I
ovarian I
cancer I
syndrome I
. O

Single O
meiotic O
crossovers O
in O
affected O
women O
suggest O
that O
BRCA1 O
is O
flanked O
by O
the O
loci O
RARA O
and O
D17S78 O
. O
. O

A O
missense O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
with O
possible O
dominant O
effects O
on O
plasma O
high O
density O
lipoproteins O
. O

Plasma O
HDL O
are O
a O
negative O
risk O
factor O
for O
atherosclerosis B
. O

Cholesteryl O
ester O
transfer O
protein O
( O
CETP O
; O
476 O
amino O
acids O
) O
transfers O
cholesteryl O
ester O
from O
HDL O
to O
other O
lipoproteins O
. O

Subjects O
with O
homozygous O
CETP B
deficiency I
caused O
by O
a O
gene O
splicing O
defect O
have O
markedly O
elevated O
HDL O
; O
however O
, O
heterozygotes O
have O
only O
mild O
increases O
in O
HDL O
. O

We O
describe O
two O
probands O
with O
a O
CETP O
missense O
mutation O
( O
442 O
D O
G O
) O
. O

Although O
heterozygous O
, O
they O
have O
threefold O
increases O
in O
HDL O
concentration O
and O
markedly O
decreased O
plasma O
CETP O
mass O
and O
activity O
, O
suggesting O
that O
the O
mutation O
has O
dominant O
effects O
on O
CETP O
and O
HDL O
in O
vivo O
. O

Cellular O
expression O
of O
mutant O
cDNA O
results O
in O
secretion O
of O
only O
30 O
% O
of O
wild O
type O
CETP O
activity O
. O

Moreover O
, O
coexpression O
of O
wild O
type O
and O
mutant O
cDNAs O
leads O
to O
inhibition O
of O
wild O
type O
secretion O
and O
activity O
. O

The O
dominant O
effects O
of O
the O
CETP O
missense O
mutation O
during O
cellular O
expression O
probably O
explains O
why O
the O
probands O
have O
markedly O
increased O
HDL O
in O
the O
heterozygous O
state O
, O
and O
suggests O
that O
the O
active O
molecular O
species O
of O
CETP O
may O
be O
multimeric O
. O
. O

Familial B
Mediterranean I
fever I
in O
the O
colchicine O
era O
: O
the O
fate O
of O
one O
family O
. O

In O
order O
to O
demonstrate O
the O
effect O
of O
prophylactic O
colchicine O
treatment O
on O
the O
natural O
history O
of O
familial B
Mediterranean I
fever I
( O
FMF B
) O
, O
a O
family O
is O
presented O
with O
6 O
out O
of O
9 O
siblings O
affected O
by O
FMF B
. O

Each O
patient O
represents O
a O
different O
stage O
of O
the O
amyloidotic B
kidney I
disease I
of O
FMF B
and O
the O
effect O
of O
continuous O
colchicine O
treatment O
on O
its O
course O
. O

Considered O
together O
, O
the O
members O
of O
this O
family O
present O
an O
almost O
complete O
clinical O
, O
genetic O
, O
and O
behavioral O
picture O
of O
the O
disease O
. O
. O

Detection O
of O
a O
new O
submicroscopic O
Norrie B
disease I
deletion O
interval O
with O
a O
novel O
DNA O
probe O
isolated O
by O
differential O
Alu O
PCR O
fingerprint O
cloning O
. O

Differential O
Alu O
PCR O
fingerprint O
cloning O
was O
used O
to O
isolate O
a O
DNA O
probe O
from O
the O
Xp11 O
. O

4 O
- O
- O
> O
p11 O
. O

21 O
region O
of O
the O
human O
X O
chromosome O
. O

This O
novel O
sequence O
, O
cpXr318 O
( O
DXS742 O
) O
, O
detects O
a O
new O
submicroscopic O
deletion O
interval O
at O
the O
Norrie B
disease I
locus O
( O
NDP O
) O
. O

Combining O
our O
data O
with O
the O
consensus O
genetic O
map O
of O
the O
proximal O
short O
arm O
of O
the O
X O
chromosome O
, O
we O
propose O
the O
physical O
order O
Xcen O
- O
DXS14 O
- O
DXS255 O
- O
( O
DXS426 O
, O
TIMP O
) O
- O
( O
DXS742 O
- O
( O
[ O
MAOB O
- O
MAOA O
- O
DXS7 O
] O
, O
NDP O
) O
- O
DXS77 O
- O
DXS228 O
) O
- O
DXS209 O
- O
DXS148 O
- O
DXS196 O
- O
+ O
+ O
+ O
Xpter O
. O

The O
cpXr318 O
probe O
and O
a O
subclone O
from O
a O
cosmid O
corresponding O
to O
the O
DXS7 O
locus O
were O
converted O
into O
sequence O
- O
tagged O
sites O
. O

Finally O
, O
DXS742 O
, O
DSX7 O
, O
DXS77 O
, O
and O
MAOA O
were O
integrated O
into O
a O
physical O
map O
spanning O
the O
Norrie B
disease I
locus O

Putative O
X B
- I
linked I
adrenoleukodystrophy I
gene O
shares O
unexpected O
homology O
with O
ABC O
transporters O
. O

Adrenoleukodystrophy B
( O
ALD B
) O
is O
an O
X B
- I
linked I
disease I
affecting O
1 O
/ O
20 O
, O
000 O
males O
either O
as O
cerebral B
ALD I
in O
childhood O
or O
as O
adrenomyeloneuropathy B
( O
AMN B
) O
in O
adults O
. O

Childhood O
ALD B
is O
the O
more O
severe O
form O
, O
with O
onset O
of O
neurological O
symptoms O
between O
5 O
- O
12 O
years O
of O
age O
. O

Central B
nervous I
system I
demyelination I
progresses O
rapidly O
and O
death O
occurs O
within O
a O
few O
years O
. O

AMN B
is O
a O
milder O
form O
of O
the O
disease O
with O
onset O
at O
15 O
- O
30 O
years O
of O
age O
and O
a O
more O
progressive O
course O
. O

Adrenal B
insufficiency I
( O
Addisons B
disease I
) O
may O
remain O
the O
only O
clinical O
manifestation O
of O
ALD B
. O

The O
principal O
biochemical O
abnormality O
of O
ALD B
is O
the O
accumulation O
of O
very O
- O
long O
- O
chain O
fatty O
acids O
( O
VLCFA O
) O
because O
of O
impaired O
beta O
- O
oxidation O
in O
peroxisomes O
. O

The O
normal O
oxidation O
of O
VLCFA O
- O
CoA O
in O
patients O
fibroblasts O
suggested O
that O
the O
gene O
coding O
for O
the O
VLCFA O
- O
CoA O
synthetase O
could O
be O
a O
candidate O
gene O
for O
ALD B
. O

Here O
we O
use O
positional O
cloning O
to O
identify O
a O
gene O
partially O
deleted O
in O
6 O
of O
85 O
independent O
patients O
with O
ALD B
. O

In O
familial O
cases O
, O
the O
deletions O
segregated O
with O
the O
disease O
. O

An O
identical O
deletion O
was O
detected O
in O
two O
brothers O
presenting O
with O
different O
clinical O
ALD B
phenotypes O
. O

Candidate O
exons O
were O
identified O
by O
computer O
analysis O
of O
genomic O
sequences O
and O
used O
to O
isolate O
complementary O
DNAs O
by O
exon O
connection O
and O
screening O
of O
cDNA O
libraries O
. O

The O
deduced O
protein O
sequence O
shows O
significant O
sequence O
identity O
to O
a O
peroxisomal O
membrane O
protein O
of O
M O
( O
r O
) O
70K O
that O
is O
involved O
in O
peroxisome O
biogenesis O
and O
belongs O
to O
the O
ATP O
- O
binding O
cassette O
superfamily O
of O
transporters O
. O
. O

Targeted O
modification O
of O
the O
apolipoprotein O
B O
gene O
results O
in O
hypobetalipoproteinemia B
and O
developmental B
abnormalities I
in O
mice O
. O

Familial B
hypobetalipoproteinemia I
is O
an O
autosomal B
codominant I
disorder I
resulting O
in O
a O
dramatic O
reduction O
in O
plasma O
concentrations O
of O
apolipoprotein O
( O
apo O
) O
B O
, O
cholesterol O
, O
and O
beta O
- O
migrating O
lipoproteins O
. O

A O
benefit O
of O
hypobetalipoproteinemia B
is O
that O
mildly O
affected O
individuals O
may O
be O
protected O
from O
coronary B
vascular I
disease I
. O

We O
have O
used O
gene O
targeting O
to O
generate O
mice O
with O
a O
modified O
Apob O
allele O
. O

Mice O
containing O
this O
allele O
display O
all O
of O
the O
hallmarks O
of O
human O
hypobetalipoproteinemia B
they O
produce O
a O
truncated O
apoB O
protein O
, O
apoB70 O
, O
and O
have O
markedly O
decreased O
plasma O
concentrations O
of O
apoB O
, O
beta O
- O
lipoproteins O
, O
and O
total O
cholesterol O
. O

In O
addition O
, O
the O
mice O
manifest O
several O
characteristics O
that O
are O
occasionally O
observed O
in O
human O
hypobetalipoproteinemia B
, O
including O
reduced O
plasma O
triglyceride O
concentrations O
, O
fasting O
chylomicronemia B
, O
and O
reduced O
high O
density O
lipoprotein O
cholesterol O
. O

An O
unexpected O
finding O
is O
that O
the O
modified O
Apob O
allele O
is O
strongly O
associated O
with O
exencephalus B
and O
hydrocephalus B
. O

These O
mice O
should O
help O
increase O
our O
understanding O
of O
hypobetalipoproteinemia B
, O
atherogenesis B
, O
and O
the O
etiology O
of O
exencephalus B
and O
hydrocephalus B
. O
. O

A O
novel O
disease O
with O
deficiency B
of I
mitochondrial I
very I
- I
long I
- I
chain I
acyl I
- I
CoA I
dehydrogenase I
. O

Palmitoyl O
- O
CoA O
dehydrogenase O
activity O
in O
skin O
fibroblasts O
from O
seven O
patients O
with O
unidentified O
defects O
of O
fatty O
acid O
oxidation O
was O
measured O
in O
the O
presence O
and O
absence O
of O
antibodies O
against O
medium O
- O
chain O
, O
long O
- O
chain O
, O
and O
very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenases O
( O
VLCAD O
) O
. O

Two O
of O
the O
patients O
, O
4 O
- O
5 O
month O
old O
boys O
, O
were O
found O
to O
have O
a O
novel O
disease O
, O
VLCAD B
deficiency I
, O
as O
judged O
from O
the O
results O
of O
very O
low O
palmitoyl O
- O
CoA O
dehydrogenase O
activity O
and O
the O
lack O
of O
immunoreactivity O
toward O
antibody O
raised O
to O
purified O
VLCAD O
. O
. O

Molecular O
characterization O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
in O
patients O
of O
Chinese O
descent O
and O
identification O
of O
new O
base O
substitutions O
in O
the O
human O
G6PD O
gene O
. O

The O
underlying O
DNA O
changes O
associated O
with O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
- I
deficient I
Asians O
have O
not O
been O
extensively O
investigated O
. O

To O
fill O
this O
gap O
, O
we O
sequenced O
the O
G6PD O
gene O
of O
43 O
G6PD B
- I
deficient I
Chinese O
whose O
G6PD O
was O
well O
characterized O
biochemically O
. O

DNA O
samples O
were O
obtained O
from O
peripheral O
blood O
of O
these O
individuals O
for O
sequencing O
using O
a O
direct O
polymerase O
chain O
reaction O
( O
PCR O
) O
sequencing O
procedure O
. O

From O
these O
43 O
samples O
, O
we O
have O
identified O
five O
different O
types O
of O
nucleotide O
substitutions O
in O
the O
G6PD O
gene O
at O
cDNA O
1388 O
from O
G O
to O
A O
( O
Arg O
to O
His O
) O
; O
at O
cDNA O
1376 O
from O
G O
to O
T O
( O
Arg O
to O
Leu O
) O
; O
at O
cDNA O
1024 O
from O
C O
to O
T O
( O
Leu O
to O
Phe O
) O
; O
at O
cDNA O
392 O
from O
G O
to O
T O
( O
Gly O
to O
Val O
) O
; O
at O
cDNA O
95 O
from O
A O
to O
G O
( O
His O
to O
Arg O
) O
. O

These O
five O
nucleotide O
substitutions O
account O
for O
over O
83 O
% O
of O
our O
43 O
G6PD B
- I
deficient I
samples O
and O
these O
substitutions O
have O
not O
been O
reported O
in O
non O
- O
Asians O
. O

The O
substitutions O
found O
at O
cDNA O
392 O
and O
cDNA O
1024 O
are O
new O
findings O
. O

The O
substitutions O
at O
cDNA O
1376 O
and O
1388 O
account O
for O
over O
50 O
% O
of O
the O
43 O
samples O
examined O
indicating O
a O
high O
prevalence O
of O
these O
two O
alleles O
among O
G6PD B
- I
deficient I
Chinese O
. O

Our O
findings O
add O
support O
to O
the O
notion O
that O
diverse O
point O
mutations O
may O
account O
largely O
for O
much O
of O
the O
phenotypic O
heterogeneity O
of O
G6PD B
deficiency I
. O
. O

Identification O
of O
mutations O
in O
Danish O
choroideremia B
families O
. O

We O
have O
searched O
for O
mutations O
in O
the O
choroideremia B
gene O
( O
CHM B
) O
in O
patients O
from O
12 O
Danish O
families O
in O
which O
CHM B
is O
segregating O
. O

Employing O
polymerase O
chain O
reaction O
( O
PCR O
) O
, O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
analysis O
, O
and O
direct O
DNA O
sequencing O
, O
different O
mutations O
have O
been O
identified O
in O
6 O
patients O
. O

All O
the O
mutations O
will O
interfere O
with O
the O
correct O
translation O
of O
the O
mRNA O
predicting O
a O
truncated O
protein O
or O
no O
gene O
product O
at O
all O
. O
. O

Structure O
and O
genomic O
sequence O
of O
the O
myotonic B
dystrophy I
( O
DM B
kinase O
) O
gene O
. O

The O
mutation O
causing O
myotonic B
dystrophy I
( O
DM B
) O
has O
recently O
been O
identified O
as O
an O
unstable O
CTG O
trinucleotide O
repeat O
located O
in O
the O
3 O
untranslated O
region O
of O
a O
gene O
encoding O
for O
a O
protein O
with O
putative O
serine O
- O
threonine O
protein O
kinase O
activity O
. O

In O
this O
report O
we O
present O
the O
genomic O
sequences O
of O
the O
human O
and O
murine O
DM B
kinase O
gene O
. O

A O
comparison O
of O
these O
sequences O
with O
each O
other O
and O
with O
known O
cDNA O
sequences O
from O
both O
species O
, O
led O
us O
to O
predict O
a O
translation O
initiation O
codon O
, O
as O
well O
as O
determine O
the O
organization O
of O
the O
DM B
kinase O
gene O
. O

Several O
polymorphisms O
within O
the O
human O
DM B
kinase O
gene O
have O
been O
identified O
, O
and O
PCR O
assays O
to O
detect O
two O
of O
these O
are O
described O
. O

The O
complete O
sequence O
and O
characterization O
of O
the O
structure O
of O
the O
DM B
kinase O
gene O
, O
as O
well O
as O
the O
identification O
of O
novel O
polymorphisms O
within O
the O
gene O
, O
represent O
an O
important O
step O
in O
a O
further O
understanding O
of O
the O
genetics O
of O
myotonic B
dystrophy I
and O
the O
molecular O
biology O
of O
the O
gene O
. O
. O

Autosomal O
recessive O
transmission O
of O
hemophilia B
A I
due O
to O
a O
von B
Willebrand I
factor O
mutation O
. O

The O
differential O
diagnosis O
of O
the O
genetic B
bleeding I
disorders I
, O
hemophilia B
A I
and O
von B
Willebrand I
disease I
, O
is O
occasionally O
confounded O
by O
the O
close O
molecular O
relationship O
of O
coagulation O
factor O
VIII O
and O
von B
Willebrand I
factor O
( O
vWF O
) O
. O

This O
report O
describes O
the O
autosomal O
inheritance O
of O
a O
hemophilia B
A I
phenotype O
due O
to O
a O
mutation O
of O
vWF O
that O
results O
in O
defective O
factor O
VIII O
binding O
. O

The O
proband O
was O
a O
female O
patient O
with O
low O
levels O
of O
factor O
VIII O
activity O
. O

Polymerase O
chain O
reaction O
( O
PCR O
) O
amplification O
and O
DNA O
sequencing O
were O
employed O
to O
examine O
exons O
encoding O
the O
putative O
factor O
VIII O
binding O
domain O
of O
vWF O
. O

The O
patient O
was O
found O
to O
be O
homozygous O
for O
a O
single O
point O
mutation O
causing O
a O
Thr O
- O
- O
> O
Met O
substitution O
at O
amino O
acid O
position O
28 O
in O
the O
mature O
vWF O
subunit O
. O

The O
phenotypic O
expression O
of O
the O
mutation O
was O
determined O
to O
be O
recessive O
because O
heterozygous O
family O
members O
were O
clinically O
unaffected O
. O

Recombinant O
vWF O
containing O
the O
observed O
amino O
acid O
substitution O
was O
expressed O
in O
COS O
- O
1 O
cells O
. O

The O
mutant O
vWF O
was O
processed O
and O
secreted O
normally O
, O
and O
was O
functionally O
equivalent O
to O
wild O
- O
type O
vWF O
in O
its O
ability O
to O
bind O
to O
platelets O
. O

However O
, O
the O
mutant O
failed O
to O
bind O
factor O
VIII O
, O
demonstrating O
that O
the O
mutation O
was O
functionally O
related O
to O
the O
observed O
hemophilia B
phenotype O
. O

The O
family O
we O
describe O
demonstrates O
the O
recessive O
inheritance O
of O
a O
recently O
recognized O
class O
of O
genetic O
bleeding O
disorders O
, O
we O
call O
" O
autosomal O
hemophilia B
. O

" O
We O
conclude O
that O
vWF O
mutation O
may O
be O
an O
under O
recognized O
cause O
of O
hemophilia B
, O
especially O
in O
cases O
where O
the O
inheritance O
pattern O
is O
not O
consistent O
with O
X O
- O
linked O
transmission O
. O

Somatic O
von B
Hippel I
- I
Lindau I
mutation O
in O
clear O
cell O
papillary B
cystadenoma I
of I
the I
epididymis I
. O

Papillary B
cystadenoma I
of I
the I
epididymis I
is O
an O
uncommon O
benign O
lesion O
that O
may O
occur O
sporadically O
or O
as O
a O
manifestation O
of O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
. O

Neither O
immunohistochemical O
studies O
nor O
molecular O
genetic O
analyses O
of O
the O
VHL B
gene O
have O
been O
reported O
previously O
for O
this O
lesion O
. O

The O
authors O
describe O
two O
cases O
of O
clear O
cell O
papillary B
cystadenoma I
of I
the I
epididymis I
, O
both O
of O
which O
were O
initially O
confused O
with O
metastatic B
renal I
cell I
carcinoma I
. O

Both O
lesions O
showed O
positive O
immunohistochemical O
staining O
for O
low O
and O
intermediate O
molecular O
weight O
keratins O
( O
Cam O
5 O
. O
2 O
and O
AE1 O
/ O
AE3 O
) O
, O
EMA O
, O
vimentin O
, O
alpha O
1 O
- O
antitrypsin O
, O
and O
alpha O
1 O
- O
antichymotrypsin O
. O

Each O
was O
negative O
for O
CEA O
. O

Because O
clear O
cell O
papillary B
cystadenoma I
is O
similar O
to O
renal B
cell I
carcinoma I
histologically O
, O
and O
because O
both O
occur O
as O
components O
of O
the O
von B
Hippel I
- I
Lindau I
disease I
complex O
, O
the O
authors O
analyzed O
both O
cases O
for O
the O
presence O
of O
mutations O
in O
the O
VHL B
gene O
. O

A O
somatic O
VHL B
gene O
mutation O
was O
detected O
in O
one O
of O
the O
two O
tumors B
by O
polymerase O
chain O
reaction O
followed O
by O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

Direct O
sequencing O
revealed O
a O
cytosine O
to O
thymine O
transition O
at O
nucleotide O
694 O
, O
resulting O
in O
the O
replacement O
of O
an O
arginine O
with O
a O
stop O
codon O
after O
the O
sixth O
amino O
acid O
of O
exon O
3 O
. O

As O
the O
VHL B
gene O
is O
believed O
to O
function O
as O
a O
tumor B
suppressor O
gene O
, O
VHL B
gene O
mutations O
may O
play O
a O
role O
in O
the O
initiation O
of O
tumorigenesis O
in O
sporadic O
cystadenomas B
of I
the I
epididymis I
. O

Identification O
of O
WASP O
mutations O
in O
patients O
with O
Wiskott B
- I
Aldrich I
syndrome I
and O
isolated B
thrombocytopenia I
reveals O
allelic O
heterogeneity O
at O
the O
WAS B
locus O
. O

Mutation O
in O
the O
gene O
encoding O
the O
recently O
isolated O
WASP O
protein O
has O
now O
been O
identified O
as O
the O
genetic B
defect I
responsible O
for O
the O
X B
- I
linked I
Wiskott I
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
a O
primary O
immunodeficiency B
disease I
associated O
with O
extensive O
phenotypic O
variability O
. O

To O
elucidate O
the O
range O
of O
WASP O
mutations O
responsible O
for O
WAS B
, O
we O
used O
PCR O
- O
SSCP O
analysis O
to O
screen O
for O
WASP O
gene O
mutation O
in O
19 O
unrelated O
boys O
with O
the O
diagnosis O
of O
classical O
or O
attenuated O
WAS B
or O
isolated B
thrombocytopenia I
. O

All O
19 O
patients O
had O
WASP O
mutations O
, O
each O
of O
which O
localized O
to O
the O
initial O
three O
or O
terminal O
three O
exons O
of O
the O
gene O
, O
and O
the O
majority O
of O
which O
were O
unique O
in O
each O
case O
. O

However O
, O
a O
missense O
mutation O
which O
results O
in O
substitution O
of O
the O
arginine O
at O
WAS B
codon O
86 O
was O
identified O
in O
three O
boys O
with O
severe O
WAS B
as O
well O
as O
in O
one O
boy O
presenting O
with O
thrombocytopenia B
alone O
. O

While O
the O
three O
mutations O
found O
in O
the O
isolated B
thrombocytopenia I
patients O
leave O
the O
reading O
frame O
intact O
, O
about O
one O
- O
half O
of O
the O
gene O
alterations O
detected O
in O
both O
severe O
and O
attenuated O
WAS B
patients O
result O
in O
frameshifted O
transcript O
and O
premature O
translation O
termination O
. O

These O
findings O
therefore O
confirm O
the O
association O
of O
WAS B
with O
WASP O
mutation O
and O
identify O
WASP O
mutation O
as O
a O
cause O
for O
isolated O
congenital B
thrombocytopenia I
in O
males O
. O

While O
the O
WASP O
gene O
defects O
responsible O
for O
isolated B
thrombocytopenia I
and O
other O
mild O
presentations O
of O
WAS B
do O
not O
appear O
distinct O
from O
those O
resulting O
in O
severe O
WAS B
, O
these O
data O
indicate O
that O
analysis O
of O
WASP O
gene O
mutation O
provides O
a O
valuable O
tool O
for O
distinguishing O
the O
spectrum O
of O
WAS B
patients O
and O
the O
subset O
of O
males O
with O
isolated B
thrombocytopenia I
who O
represent O
mild O
cases O
of O
WAS B
. O
. O

WASP O
gene O
mutations O
in O
Wiskott B
- I
Aldrich I
syndrome I
and O
X B
- I
linked I
thrombocytopenia I
. O

The O
WASP O
gene O
has O
been O
recently O
cloned O
from O
Xp11 O
. O

23 O
and O
shown O
to O
be O
mutated O
in O
three O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
. O

We O
have O
developed O
a O
screening O
protocol O
for O
identifying O
WASP O
gene O
alterations O
in O
genomic O
DNA O
and O
have O
identified O
a O
spectrum O
of O
novel O
mutations O
in O
12 O
additional O
unrelated O
families O
. O

These O
missense O
, O
nonsense O
and O
frameshift O
mutations O
involve O
eight O
of O
the O
12 O
exons O
of O
the O
gene O
. O

Two O
mutations O
creating O
premature O
termination O
codons O
were O
associated O
with O
lack O
of O
detectable O
mRNA O
on O
Northern O
blots O
. O

Four O
amino O
acid O
substitutions O
, O
Leu27Phe O
, O
Thr48Ile O
, O
Val75Met O
and O
Arg477Lys O
, O
were O
found O
in O
patients O
with O
congenital B
thrombocytopenia I
and O
no O
clinically O
evident O
immune O
defect O
indicating O
that O
the O
WASP O
gene O
is O
the O
site O
for O
mutations O
in O
X B
- I
linked I
thrombocytopenia I
as O
well O
as O
in O
WAS B
. O

A O
T O
- O
cell O
line O
from O
a O
WAS B
patient O
contained O
two O
independent O
DNA O
alterations O
, O
a O
constitutional O
frameshift O
mutation O
, O
also O
present O
in O
peripheral O
blood O
leukocytes O
from O
the O
patient O
, O
and O
compensatory O
splice O
site O
mutation O
unique O
to O
the O
cell O
line O
. O

The O
distribution O
of O
eight O
missense O
mutations O
provides O
valuable O
information O
on O
amino O
acids O
which O
are O
essential O
for O
normal O
protein O
function O
, O
and O
suggests O
that O
sites O
in O
the O
first O
two O
exons O
are O
hot O
- O
spots O
for O
mutation O
. O

Evidence O
for O
inter O
- O
generational O
instability O
in O
the O
CAG O
repeat O
in O
the O
MJD1 O
gene O
and O
for O
conserved O
haplotypes O
at O
flanking O
markers O
amongst O
Japanese O
and O
Caucasian O
subjects O
with O
Machado B
- I
Joseph I
disease I
. O

The O
size O
of O
the O
( O
CAG O
) O
n O
repeat O
array O
in O
the O
3 O
' O
end O
of O
the O
MJD1 O
gene O
and O
the O
haplotype O
at O
a O
series O
of O
microsatellite O
markers O
surrounding O
the O
MJD1 O
gene O
were O
examined O
in O
a O
large O
cohort O
of O
Japanese O
and O
Caucasian O
subjects O
affected O
with O
Machado B
- I
Joseph I
disease I
( O
MJD B
) O
. O

Our O
data O
provide O
five O
novel O
observations O
. O

First O
, O
MJD B
is O
associated O
with O
expansion O
fo O
the O
array O
from O
the O
normal O
range O
of O
14 O
- O
37 O
repeats O
to O
68 O
- O
84 O
repeats O
in O
most O
Japanese O
and O
Caucasian O
subjects O
, O
but O
no O
subjects O
were O
observed O
with O
expansions O
intermediate O
in O
size O
between O
those O
of O
the O
normal O
and O
MJD B
affected O
groups O
. O

Second O
, O
the O
expanded O
allele O
associated O
with O
MJD B
displays O
inter O
- O
generational O
instability O
, O
particularly O
in O
male O
meioses O
, O
and O
this O
instability O
was O
associated O
with O
the O
clinical O
phenomenon O
of O
anticipation O
. O

Third O
, O
the O
size O
of O
the O
expanded O
allele O
is O
not O
only O
inversely O
correlated O
with O
the O
age O
- O
of O
- O
onset O
of O
MJD B
( O
r O
= O
- O
0 O
. O
738 O
, O
p O
< O
0 O
. O
001 O
) O
, O
but O
is O
also O
correlated O
with O
the O
frequency O
of O
other O
clinical O
features O
[ O
e O
. O
g O
. O
pseudoexophthalmos O
and O
pyramidal O
signs O
were O
more O
frequent O
in O
subjects O
with O
large O
repeats O
( O
p O
< O
0 O
. O
001 O
and O
p O
< O
0 O
. O
05 O
respectively O
) O
] O
. O

Fourth O
, O
the O
disease O
phenotype O
is O
significantly O
more O
severe O
and O
had O
an O
early O
age O
of O
onset O
( O
16 O
years O
) O
in O
a O
subject O
homozygous O
for O
the O
expanded O
allele O
, O
which O
contrasts O
with O
Huntington B
disease I
and O
suggests O
that O
the O
expanded O
allele O
in O
the O
MJD1 O
gene O
could O
exert O
its O
effect O
either O
by O
a O
dominant O
negative O
effect O
( O
putatively O
excluded O
in O
HD B
) O
or O
by O
a O
gain O
of O
function O
effect O
as O
proposed O
for O
HD B
. O

Finally O
, O
Japanese O
and O
Caucasian O
subjects O
affected O
with O
MJD B
share O
haplotypes O
at O
several O
markers O
surrounding O
the O
MJD1 O
gene O
, O
which O
are O
uncommon O
in O
the O
normal O
Japanese O
and O
Caucasian O
population O
, O
and O
which O
suggests O
the O
existence O
either O
of O
common O
founders O
in O
these O
populations O
or O
of O
chromosomes O
susceptible O
to O
pathologic O
expansion O
of O
the O
CAG O
repeat O
in O
the O
MJD1 O
gene O
. O

A O
4 O
- O
megabase O
YAC O
contig O
that O
spans O
the O
Langer B
- I
Giedion I
syndrome I
region O
on O
human O
chromosome O
8q24 O
. O
1 O
: O
use O
in O
refining O
the O
location O
of O
the O
trichorhinophalangeal B
syndrome I
and O
multiple O
exostoses O
genes O
( O
TRPS1 O
and O
EXT1 O
) O
. O

We O
have O
constructed O
a O
physical O
map O
covering O
over O
4 O
Mb O
of O
human O
chromosome O
8q24 O
. O

1 O
and O
used O
this O
map O
to O
refine O
the O
locations O
of O
the O
genes O
responsible O
for O
Langer B
- I
Giedion I
syndrome I
. O

The O
map O
is O
composed O
of O
overlapping O
YAC O
clones O
that O
were O
identified O
and O
ordered O
in O
relation O
to O
sequence O
tagged O
sites O
mapped O
to O
the O
Langer O
- O
Giedion O
chromosomal O
region O
on O
somatic O
cell O
hybrids O
. O

The O
minimal O
region O
of O
overlap O
of O
Langer B
- I
Giedion I
syndrome I
deletions O
, O
previously O
identified O
by O
analysis O
of O
15 O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 O
patients O
whose O
deletions O
define O
the O
endpoints O
. O

The O
chromosome O
8 O
breakpoint O
of O
a O
balanced O
t O
( O
8 O
; O
9 O
) O
( O
q24 O
. O
11 O
; O
q33 O
. O
3 O
) O
translocation O
from O
a O
patient O
with O
trichorhinophalangeal B
syndrome I
( O
TRPS B
I O
) O
was O
found O
to O
be O
located O
just O
within O
the O
proximal O
end O
of O
the O
minimal O
deletion O
region O
. O

A O
deletion O
of O
8q24 O
. O

11 O
- O
q24 O
. O

3 O
in O
a O
patient O
with O
multiple O
exostoses O
was O
found O
to O
overlap O
the O
distal O
end O
of O
the O
LGS B
deletion O
region O
, O
indicating O
that O
the O
EXT1 O
gene O
is O
distal O
to O
the O
TRPS1 O
gene O
and O
supporting O
the O
hypothesis O
that O
Langer B
- I
Giedion I
syndrome I
is O
due O
to O
loss O
of O
functional O
copies O
of O
both O
the O
TRPS1 O
and O
the O
EXT1 O
genes O

BRCA1 O
mutations O
in O
a O
population O
- O
based O
sample O
of O
young O
women O
with O
breast B
cancer I
. O

BACKGROUND O
. O

Inherited O
mutations O
in O
the O
BRCA1 O
gene O
are O
associated O
with O
a O
high O
risk O
of O
breast B
and I
ovarian I
cancer I
in O
some O
families O
. O

However O
, O
little O
is O
known O
about O
the O
contribution O
of O
BRCA1 O
mutations O
to O
breast B
cancer I
in O
the O
general O
population O
. O

We O
analyzed O
DNA O
samples O
from O
women O
enrolled O
in O
a O
population O
- O
based O
study O
of O
early O
- O
onset O
breast B
cancer I
to O
assess O
the O
spectrum O
and O
frequency O
of O
germ O
- O
line O
BRCA1 O
mutations O
in O
young O
women O
with O
breast B
cancer I
. O

METHODS O
. O

We O
studied O
80 O
women O
in O
whom O
breast B
cancer I
was O
diagnosed O
before O
the O
age O
of O
35 O
, O
and O
who O
were O
not O
selected O
on O
the O
basis O
of O
family O
history O
. O

Genomic O
DNA O
was O
studied O
for O
BRCA1 O
mutations O
by O
analysis O
involving O
single O
- O
strand O
conformation O
polymorphisms O
and O
with O
allele O
- O
specific O
assays O
. O

Alterations O
were O
defined O
by O
DNA O
sequencing O
. O

RESULTS O
. O

Germ O
- O
line O
BRCA1 O
mutations O
were O
identified O
in O
6 O
of O
the O
80 O
women O
. O

Four O
additional O
rare O
sequence O
variants O
of O
unknown O
functional O
importance O
were O
also O
identified O
. O

Two O
of O
the O
mutations O
and O
three O
of O
the O
rare O
sequence O
variants O
were O
found O
among O
the O
39 O
women O
who O
reported O
no O
family O
history O
of O
breast B
or I
ovarian I
cancer I
. O

None O
of O
the O
mutations O
and O
only O
one O
of O
the O
rare O
variants O
was O
identified O
in O
a O
reference O
population O
of O
73 O
unrelated O
subjects O
. O

CONCLUSIONS O
. O

Alterations O
in O
BRCA1 O
were O
identified O
in O
approximately O
10 O
percent O
of O
this O
cohort O
of O
young O
women O
with O
breast B
cancer I
. O

The O
risk O
of O
harboring O
a O
mutation O
was O
not O
limited O
to O
women O
with O
family O
histories O
of O
breast B
or I
ovarian I
cancer I
. O

These O
results O
represent O
a O
minimal O
estimate O
of O
the O
frequency O
of O
BRCA1 O
mutations O
in O
this O
population O
. O

Comprehensive O
methods O
of O
identifying O
BRCA1 O
mutations O
and O
understanding O
their O
importance O
will O
be O
needed O
before O
testing O
of O
women O
in O
the O
general O
population O
can O
be O
undertaken O
. O
. O

Novel O
inherited O
mutations O
and O
variable O
expressivity O
of O
BRCA1 O
alleles O
, O
including O
the O
founder O
mutation O
185delAG O
in O
Ashkenazi O
Jewish O
families O
. O

Thirty O
- O
seven O
families O
with O
four O
or O
more O
cases O
of O
breast B
cancer I
or O
breast B
and I
ovarian I
cancer I
were O
analyzed O
for O
mutations O
in O
BRCA1 O
. O

Twelve O
different O
germ O
- O
line O
mutations O
, O
four O
novel O
and O
eight O
previously O
observed O
, O
were O
detected O
in O
16 O
families O
. O

Five O
families O
of O
Ashkenazi O
Jewish O
descent O
carried O
the O
185delAG O
mutation O
and O
shared O
the O
same O
haplotype O
at O
eight O
polymorphic O
markers O
spanning O
approximately O
850 O
kb O
at O
BRCA1 O
. O

Expressivity O
of O
185delAG O
in O
these O
families O
varied O
, O
from O
early O
- O
onset O
breast B
cancer I
without O
ovarian B
cancer I
. O

Mutation O
4184delTCAA O
occurred O
independently O
in O
two O
families O
. O

In O
one O
family O
, O
penetrance O
was O
complete O
, O
with O
females O
developing O
early O
- O
onset O
breast B
cancer I
or O
ovarian B
cancer I
and O
the O
male O
carrier O
developing O
prostatic B
cancer I
, O
whereas O
, O
in O
the O
other O
family O
, O
penetrance O
was O
incomplete O
and O
only O
breast B
cancer I
occurred O
, O
diagnosed O
at O
ages O
38 O
- O
81 O
years O
. O

Two O
novel O
nonsense O
mutations O
led O
to O
the O
loss O
of O
mutant O
BRCA1 O
transcript O
in O
families O
with O
10 O
and O
6 O
cases O
of O
early O
- O
onset O
breast B
cancer I
and O
ovarian B
cancer I
. O

A O
665 O
- O
nt O
segment O
of O
the O
BRCA1 O
3 O
- O
UTR O
and O
1 O
. O

3 O
kb O
of O
genomic O
sequence O
including O
the O
putative O
promoter O
region O
were O
invariant O
by O
single O
- O
strand O
conformation O
analysis O
in O
13 O
families O
without O
coding O
- O
sequence O
mutations O
. O

Overall O
in O
our O
series O
, O
BRCA1 O
mutations O
have O
been O
detected O
in O
26 O
families O
16 O
with O
positive O
BRCA1 O
lod O
scores O
, O
7 O
with O
negative O
lod O
scores O
( O
reflecting O
multiple O
sporadic O
breast B
cancers I
) O
, O
and O
3 O
not O
tested O
for O
linkage O
. O

Three O
other O
families O
have O
positive O
lod O
scores O
for O
linkage O
to O
BRCA2 O
, O
but O
13 O
families O
without O
detected O
BRCA1 O
mutations O
have O
negative O
lod O
scores O
for O
both O
BRCA1 O
and O
BRCA2 O
. O

A O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variant O
, O
G6PD O
Orissa O
( O
44 O
Ala O
- O
- O
> O
Gly O
) O
, O
is O
the O
major O
polymorphic O
variant O
in O
tribal O
populations O
in O
India O
. O

Deficiency B
of I
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( O
G6PD O
) O
is O
usually O
found O
at O
high O
frequencies O
in O
areas O
of O
the O
world O
where O
malaria B
has O
been O
endemic O
. O

The O
frequency O
and O
genetic O
basis O
of O
G6PD B
deficiency I
have O
been O
studied O
in O
Africa O
, O
around O
the O
Mediterranean O
, O
and O
in O
the O
Far O
East O
, O
but O
little O
such O
information O
is O
available O
about O
the O
situation O
in O
India O
. O

To O
determine O
the O
extent O
of O
heterogeneity O
of O
G6PD O
, O
we O
have O
studied O
several O
different O
Indian O
populations O
by O
screening O
for O
G6PD B
deficiency I
, O
followed O
by O
molecular O
analysis O
of O
deficient O
alleles O
. O

The O
frequency O
of O
G6PD B
deficiency I
varies O
between O
3 O
% O
and O
15 O
% O
in O
different O
tribal O
and O
urban O
groups O
. O

Remarkably O
, O
a O
previously O
unreported O
deficient O
variant O
, O
G6PD O
Orissa O
( O
44 O
Ala O
- O
- O
> O
Gly O
) O
, O
is O
responsible O
for O
most O
of O
the O
G6PD B
deficiency I
in O
tribal O
Indian O
populations O
but O
is O
not O
found O
in O
urban O
populations O
, O
where O
most O
of O
the O
G6PD B
deficiency I
is O
due O
to O
the O
G6PD O
Mediterranean O
( O
188 O
Ser O
- O
- O
> O
Phe O
) O
variant O
. O

The O
KmNADP O
of O
G6PD O
Orissa O
is O
fivefold O
higher O
than O
that O
of O
the O
normal O
enzyme O
. O

This O
may O
be O
due O
to O
the O
fact O
that O
the O
alanine O
residue O
that O
is O
replaced O
by O
glycine O
is O
part O
of O
a O
putative O
coenzyme O
- O
binding O
site O
. O
. O

Evidence O
for O
linkage O
of O
bipolar B
disorder I
to O
chromosome O
18 O
with O
a O
parent O
- O
of O
- O
origin O
effect O
. O

A O
susceptibility O
gene O
on O
chromosome O
18 O
and O
a O
parent O
- O
of O
- O
origin O
effect O
have O
been O
suggested O
for O
bipolar B
affective I
disorder I
( O
BPAD B
) O
. O

We O
have O
studied O
28 O
nuclear O
families O
selected O
for O
apparent O
unilineal O
transmission O
of O
the O
BPAD B
phenotype O
, O
by O
using O
31 O
polymorphic O
markers O
spanning O
chromosome O
18 O
. O

Evidence O
for O
linkage O
was O
tested O
with O
affected O
- O
sib O
- O
pair O
and O
LOD O
score O
methods O
under O
two O
definitions O
of O
the O
affected O
phenotype O
. O

The O
affected O
- O
sibpair O
analyses O
indicated O
excess O
allele O
sharing O
for O
markers O
on O
18p O
within O
the O
region O
reported O
previously O
. O

The O
greatest O
sharing O
was O
at O
D18S37 O
64 O
% O
in O
bipolar O
and O
recurrent O
unipolar O
( O
RUP O
) O
sib O
pairs O
( O
P O
= O
. O
0006 O
) O
. O

In O
addition O
, O
excess O
sharing O
of O
the O
paternally O
, O
but O
not O
maternally O
, O
transmitted O
alleles O
was O
observed O
at O
three O
markers O
on O
18q O
at O
D18S41 O
, O
51 O
bipolar O
and O
RUP O
sib O
pairs O
were O
concordant O
for O
paternally O
transmitted O
alleles O
, O
and O
21 O
pairs O
were O
discordant O
( O
P O
= O
0004 O
) O
. O

The O
evidence O
for O
linkage O
to O
loci O
on O
both O
18p O
and O
18q O
was O
strongest O
in O
the O
11 O
paternal O
pedigrees O
, O
i O
. O

e O
e O
. O
, O
those O
in O
which O
the O
father O
or O
one O
of O
the O
fathers O
sibs O
is O
affected O
. O

In O
these O
pedigrees O
, O
the O
greatest O
allele O
sharing O
( O
81 O
% O
; O
P O
= O
. O
00002 O
) O
and O
the O
highest O
LOD O
score O
( O
3 O
. O
51 O
; O
phi O
= O
0 O
. O
0 O
) O
were O
observed O
at O
D18S41 O
. O

Our O
results O
provide O
further O
support O
for O
linkage O
of O
BPAD B
to O
chromosome O
18 O
and O
the O
first O
molecular O
evidence O
for O
a O
parent O
- O
of O
- O
origin O
effect O
operating O
in O
this O
disorder O
. O

The O
number O
of O
loci O
involved O
, O
and O
their O
precise O
location O
, O
require O
further O
study O

A O
prevalent O
mutation O
for O
galactosemia B
among O
black O
Americans O
. O

OBJECTIVE O
To O
define O
the O
mutation O
causing O
galactosemia B
in O
patients O
of O
black O
American O
origin O
who O
have O
no O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
activity O
in O
erythrocytes O
but O
good O
clinical O
outcome O
. O

METHODS O
We O
discovered O
a O
mutation O
caused O
by O
a O
C O
- O
- O
> O
T O
transition O
at O
base O
- O
pair O
1158 O
of O
the O
GALT O
gene O
that O
results O
in O
a O
serine O
- O
to O
- O
leucine O
substitution O
at O
codon O
135 O
( O
S135L O
) O
. O

We O
developed O
a O
method O
with O
which O
to O
screen O
populations O
for O
its O
prevalence O
. O

We O
compared O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
among O
erythrocytes O
, O
leukocytes O
, O
and O
transformed O
lymphoblasts O
, O
as O
well O
as O
total O
body O
oxidation O
of O
D O
- O
( O
13C O
) O
- O
galactose O
to O
13CO2 O
among O
three O
genotypes O
for O
GALT O
( O
S135L O
/ O
S135L O
, O
Q188R O
/ O
Q188R O
, O
and O
Normal O
/ O
Normal O
) O
. O

RESULTS O
We O
found O
a O
48 O
% O
prevalence O
of O
the O
S135L O
mutation O
among O
17 O
black O
American O
patients O
with O
classic B
galactosemia I
and O
a O
1 O
% O
prevalence O
in O
a O
population O
of O
50 O
black O
Americans O
without O
galactosemia B
. O

The O
S135L O
mutation O
was O
not O
found O
in O
84 O
white O
patients O
with O
G O
/ O
G O
galactosemia B
nor O
in O
87 O
white O
control O
subjects O
without O
galactosemia B
. O

We O
found O
normal O
whole O
body O
oxidation O
of O
D O
- O
( O
13C O
) O
- O
galactose O
by O
the O
patient O
homozygous O
for O
S135L O
and O
various O
degrees O
of O
enzyme O
impairment O
among O
different O
tissues O
. O

CONCLUSIONS O
The O
S135L O
mutation O
in O
the O
GALT O
gene O
is O
a O
prevalent O
cause O
of O
galactosemia B
among O
black O
patients O
. O

Because O
GALT O
activity O
varies O
in O
different O
tissues O
of O
patients O
homozygous O
for O
S135L O
, O
they O
may O
have O
a O
better O
clinical O
outcome O
than O
patients O
who O
are O
homozygous O
for O
Q188R O
when O
both O
are O
treated O
from O
infancy O
. O
. O

A O
high O
incidence O
of O
BRCA1 O
mutations O
in O
20 O
breast B
- I
ovarian I
cancer I
families O
. O

We O
have O
analyzed O
20 O
breast B
- I
ovarian I
cancer I
families O
, O
the O
majority O
of O
which O
show O
positive O
evidence O
of O
linkage O
to O
chromosome O
17q12 O
for O
germ O
- O
line O
mutations O
in O
the O
BRCA1 O
gene O
. O

BRCA1 O
mutations O
cosegregating O
with O
breast B
and I
ovarian I
cancer I
susceptibility O
were O
identified O
in O
16 O
families O
, O
including O
1 O
family O
with O
a O
case O
of O
male B
breast I
cancer I
. O

Nine O
of O
these O
mutations O
have O
not O
been O
reported O
previously O
. O

The O
majority O
of O
mutations O
were O
found O
to O
generate O
a O
premature O
stop O
codon O
leading O
to O
the O
formation O
of O
a O
truncated O
BRCA1 O
protein O
of O
2 O
% O
- O
88 O
% O
of O
the O
expected O
normal O
length O
. O

Two O
mutations O
altered O
the O
RING O
finger O
domain O
. O

Sequencing O
of O
genomic O
DNA O
led O
to O
the O
identification O
of O
a O
mutation O
in O
the O
coding O
region O
of O
BRCA1 O
in O
12 O
families O
, O
and O
cDNA O
analysis O
revealed O
an O
abnormal O
or O
missing O
BRCA1 O
transcript O
in O
4 O
of O
the O
8 O
remaining O
families O
. O

A O
total O
of O
eight O
mutations O
were O
associated O
with O
a O
reduced O
quantity O
of O
BRCA1 O
transcript O
. O

We O
were O
unable O
to O
detect O
BRCA1 O
mutations O
in O
4 O
of O
the O
20 O
families O
, O
but O
only O
1 O
of O
these O
was O
clearly O
linked O
to O
BRCA1 O
. O

It O
is O
expected O
that O
the O
majority O
of O
clear O
examples O
of O
the O
breast B
- I
ovarian I
syndrome I
will O
be O
associated O
with O
germ O
- O
line O
mutations O
in O
the O
coding O
region O
of O
BRCA1 O
. O
. O

Brca1 B
deficiency I
results O
in O
early O
embryonic B
lethality I
characterized O
by O
neuroepithelial B
abnormalities I
. O

The O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
, O
BRCA1 O
, O
has O
been O
cloned O
and O
shown O
to O
encode O
a O
zinc O
- O
finger O
protein O
of O
unknown O
function O
. O

Mutations O
in O
BRCA1 O
account O
for O
at O
least O
80 O
% O
of O
families O
with O
both O
breast B
and I
ovarian I
cancer I
, O
as O
well O
as O
some O
non O
- O
familial O
sporadic O
ovarian B
cancers I
. O

The O
loss O
of O
wild O
- O
type O
BRCA1 O
in O
tumours B
of O
individuals O
carrying O
one O
nonfunctional O
BRCA1 O
allele O
suggests O
that O
BRCA1 O
encodes O
a O
tumour B
suppressor O
that O
may O
inhibit O
the O
proliferation O
of O
mammary O
epithelial O
cells O
. O

To O
examine O
the O
role O
of O
BRCA1 O
in O
normal O
tissue O
growth O
and O
differentiation O
, O
and O
to O
generate O
a O
potential O
model O
for O
the O
cancer B
susceptibility O
associated O
with O
loss O
of O
BRCA1 O
function O
, O
we O
have O
created O
a O
mouse O
line O
carrying O
a O
mutation O
in O
one O
Brca1 O
allele O
. O

Analysis O
of O
mice O
homozygous O
for O
the O
mutant O
allele O
indicate O
that O
Brca1 O
is O
critical O
for O
normal O
development O
, O
as O
these O
mice O
died O
in O
utero O
between O
10 O
and O
13 O
days O
of O
gestation O
( O
E10 O
- O
E13 O
) O
. O

Abnormalities O
in O
Brca1 B
- I
deficient I
embryos O
were O
most O
evident O
in O
the O
neural O
tube O
, O
with O
40 O
% O
of O
the O
embryos O
presenting O
with O
varying O
degrees O
of O
spina B
bifida I
and O
anencephaly B
. O

In O
addition O
, O
the O
neuroepithelium O
in O
Brca1 B
- I
deficient I
embryos O
appeared O
disorganized O
, O
with O
signs O
of O
both O
rapid O
proliferation O
and O
excessive O
cell O
death O
. O
. O

Identification O
of O
mutations O
in O
the O
ALD O
- O
gene O
of O
20 O
families O
with O
adrenoleukodystrophy B
/ O
adrenomyeloneuropathy B
. O

Adrenoleukodystrophy B
( O
ALD B
) O
, O
an O
X B
- I
linked I
inherited I
metabolic I
disorder I
, O
is O
the O
most O
frequent O
inborn B
peroxisomal I
disease I
. O

It O
leads O
to O
demyelination B
in I
the I
central I
and I
peripheral I
nervous I
system I
. O

Defective O
beta O
- O
oxidation O
of O
saturated O
very O
long O
chain O
fatty O
acids O
( O
VLCFAs O
; O
C22 O
0 O
- O
C26 O
0 O
) O
in O
peroxisomes O
has O
been O
shown O
to O
lead O
to O
an O
accumulation O
of O
VLCFAs O
in O
leukoid O
areas O
of O
the O
central O
nervous O
system O
, O
peripheral O
nerves O
, O
adrenal O
gland O
, O
and O
blood O
. O

The O
ALD B
gene O
has O
been O
recently O
identified O
and O
encodes O
a O
745 O
- O
amino O
- O
acid O
protein O
. O

We O
screened O
patients O
with O
adrenoleukodystrophy B
/ O
adrenomyeloneuropathy B
( O
ALD B
/ O
AMN B
) O
from O
20 O
kindreds O
for O
mutations O
in O
the O
ALD B
gene O
. O

Eleven O
missense O
and O
two O
nonsense O
mutations O
, O
five O
deletions O
, O
and O
one O
insertion O
were O
detected O
by O
direct O
sequencing O
of O
eight O
reverse O
transcribed O
fragments O
of O
the O
ALD B
- O
gene O
mRNA O
. O

Four O
mutations O
could O
be O
shown O
to O
be O
de O
novo O
. O

All O
mutations O
could O
be O
confirmed O
in O
carriers O
by O
sequencing O
genomic O
DNA O
. O

No O
correlation O
between O
the O
type O
of O
mutation O
and O
the O
severity O
of O
the O
phenotype O
could O
be O
observed O
. O

The O
mutations O
were O
not O
detected O
in O
the O
ALD B
gene O
of O
30 O
healthy O
persons O
. O
. O

The O
murine O
homolog O
of O
the O
human O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
Brca1 O
maps O
to O
mouse O
chromosome O
11D O
. O

The O
recently O
cloned O
human O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
, O
BRCA1 O
, O
is O
located O
on O
human O
chromosome O
17q21 O
. O

We O
have O
isolated O
murine O
genomic O
clones O
containing O
Brca1 O
as O
a O
first O
step O
in O
generating O
a O
mouse O
model O
for O
the O
loss O
of O
BRCA1 O
function O
. O

A O
mouse O
genomic O
library O
was O
screened O
using O
probes O
corresponding O
to O
exon O
11 O
of O
the O
human O
BRCA1 O
gene O
. O

Two O
overlapping O
mouse O
clones O
were O
identified O
that O
hybridized O
to O
human O
BRCA1 O
exons O
9 O
- O
12 O
. O

Sequence O
analysis O
of O
1 O
. O

4 O
kb O
of O
the O
region O
of O
these O
clones O
corresponding O
to O
part O
of O
human O
exon O
11 O
revealed O
72 O
% O
nucleic O
acid O
identity O
but O
only O
50 O
% O
amino O
acid O
identity O
with O
the O
human O
gene O
. O

The O
longest O
of O
the O
mouse O
Brca1 O
genomic O
clones O
maps O
to O
chromosome O
11D O
, O
as O
determined O
by O
two O
- O
color O
fluorescence O
in O
situ O
hybridization O
. O

The O
synteny O
to O
human O
chromosome O
17 O
was O
confirmed O
by O
cohybridization O
with O
the O
mouse O
probe O
for O
the O
NF1 O
- O
gene O
. O

This O
comparative O
study O
confirms O
that O
the O
relative O
location O
of O
the O
BRCA1 O
gene O
has O
been O
conserved O
between O
mice O
and O
humans O
. O

Atelosteogenesis B
type I
II I
is O
caused O
by O
mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
- O
transporter O
gene O
( O
DTDST O
) O
: O
evidence O
for O
a O
phenotypic O
series O
involving O
three O
chondrodysplasias B
. O

Atelosteogenesis B
type I
II I
( O
AO B
II I
) O
is O
a O
neonatally O
lethal O
chondrodysplasia B
whose O
clinical O
and O
histological O
characteristics O
resemble O
those O
of O
another O
chondrodysplasia B
, O
the O
much O
less O
severe O
diastrophic B
dysplasia I
( O
DTD B
) O
. O

The O
similarity O
suggests O
a O
shared O
pathogenesis O
involving O
lesions O
in O
the O
same O
biochemical O
pathway O
and O
perhaps O
the O
same O
gene O
. O

DTD B
is O
caused O
by O
mutations O
in O
the O
recently O
identified O
diastrophic B
dysplasia I
sulfate O
- O
transporter O
gene O
( O
DTDST O
) O
. O

Here O
, O
we O
report O
that O
AOII B
patients O
also O
have O
DTDST O
mutations O
, O
which O
lead O
to O
defective O
uptake O
of O
inorganic O
sulfate O
and O
insufficient O
sulfation O
of O
macromolecules O
by O
patient O
mesenchymal O
cells O
in O
vitro O
. O

Together O
with O
our O
recent O
observation O
that O
a O
third O
even O
more O
severe O
chondrodysplasia B
, O
achondrogenesis O
type O
IB O
, O
is O
also O
caused O
by O
mutations O
in O
DTDST O
, O
these O
results O
demonstrate O
a O
phenotypic O
series O
of O
three O
chondrodysplasias B
of O
increasing O
severity O
caused O
by O
lesions O
in O
a O
single O
sulfate O
- O
transporter O
gene O
. O

The O
severity O
of O
the O
phenotype O
appears O
to O
be O
correlated O
with O
the O
predicted O
effect O
of O
the O
mutations O
on O
the O
residual O
activity O
of O
the O
DTDST O
protein O
. O
. O

Haplotype O
and O
phenotype O
analysis O
of O
six O
recurrent O
BRCA1 O
mutations O
in O
61 O
families O
: O
results O
of O
an O
international O
study O
. O

Several O
BRCA1 O
mutations O
have O
now O
been O
found O
to O
occur O
in O
geographically O
diverse O
breast B
and I
ovarian I
cancer I
families O
. O

To O
investigate O
mutation O
origin O
and O
mutation O
- O
specific O
phenotypes O
due O
to O
BRCA1 O
, O
we O
constructed O
a O
haplotype O
of O
nine O
polymorphic O
markers O
within O
or O
immediately O
flanking O
the O
BRCA1 O
locus O
in O
a O
set O
of O
61 O
breast B
/ I
ovarian I
cancer I
families O
selected O
for O
having O
one O
of O
six O
recurrent O
BRCA1 O
mutations O
. O

Tests O
of O
both O
mutations O
and O
family O
- O
specific O
differences O
in O
age O
at O
diagnosis O
were O
not O
significant O
. O

A O
comparison O
of O
the O
six O
mutations O
in O
the O
relative O
proportions O
of O
cases O
of O
breast B
and I
ovarian I
cancer I
was O
suggestive O
of O
an O
effect O
( O
P O
= O
. O
069 O
) O
, O
with O
57 O
% O
of O
women O
presumed O
affected O
because O
of O
the O
1294 O
del O
40 O
BRCA1 O
mutation O
having O
ovarian B
cancer I
, O
compared O
with O
14 O
% O
of O
affected O
women O
with O
the O
splice O
- O
site O
mutation O
in O
intron O
5 O
of O
BRCA1 O
. O

For O
the O
BRCA1 O
mutations O
studied O
here O
, O
the O
individual O
mutations O
are O
estimated O
to O
have O
arisen O
9 O
- O
170 O
generations O
ago O
. O

In O
general O
, O
a O
high O
degree O
of O
haplotype O
conservation O
across O
the O
region O
was O
observed O
, O
with O
haplotype O
differences O
most O
often O
due O
to O
mutations O
in O
the O
short O
- O
tandem O
- O
repeat O
markers O
, O
although O
some O
likely O
instances O
of O
recombination O
also O
were O
observed O
. O

For O
several O
of O
the O
instances O
, O
there O
was O
evidence O
for O
multiple O
, O
independent O
, O
BRCA1 O
mutational O
events O
. O

Isolation O
of O
the O
mouse O
homologue O
of O
BRCA1 O
and O
genetic O
mapping O
to O
mouse O
chromosome O
11 O
. O

The O
BRCA1 O
gene O
is O
in O
large O
part O
responsible O
for O
hereditary B
human I
breast I
and I
ovarian I
cancer I
. O

Here O
we O
report O
the O
isolation O
of O
the O
murine O
Brca1 O
homologue O
cDNA O
clones O
. O

In O
addition O
, O
we O
identified O
genomic O
P1 O
clones O
that O
contain O
most O
, O
if O
not O
all O
, O
of O
the O
mouse O
Brca1 O
locus O
. O

DNA O
sequence O
analysis O
revealed O
that O
the O
mouse O
and O
human O
coding O
regions O
are O
75 O
% O
identical O
at O
the O
nucleotide O
level O
while O
the O
predicted O
amino O
acid O
identity O
is O
only O
58 O
% O
. O

A O
DNA O
sequence O
variant O
in O
the O
Brca1 O
locus O
was O
identified O
and O
used O
to O
map O
this O
gene O
on O
a O
( O
Mus O
m O
. O
musculus O
Czech O
II O
x O
C57BL O
/ O
KsJ O
) O
F1 O
x O
C57BL O
/ O
KsJ O
intersubspecific O
backcross O
to O
distal O
mouse O
chromosome O
11 O
. O

The O
mapping O
of O
this O
gene O
to O
a O
region O
highly O
syntenic O
with O
human O
chromosome O
17 O
, O
coupled O
with O
Southern O
and O
Northern O
analyses O
, O
confirms O
that O
we O
isolated O
the O
murine O
Brca1 O
homologue O
rather O
than O
a O
related O
RING O
finger O
gene O
. O

The O
isolation O
of O
the O
mouse O
Brca1 O
homologue O
will O
facilitate O
the O
creation O
of O
mouse O
models O
for O
germline O
BRCA1 B
defects I
. O
. O

Emerin B
deficiency I
at O
the O
nuclear O
membrane O
in O
patients O
with O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
. O

Mutations O
in O
the O
STA O
gene O
at O
the O
Xq28 O
locus O
have O
been O
found O
in O
patients O
with O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
. O

This O
gene O
encodes O
a O
hitherto O
unknown O
protein O
named O
emerin O
. O

To O
elucidate O
the O
subcellular O
localization O
of O
emerin O
, O
we O
raised O
two O
antisera O
against O
synthetic O
peptide O
fragments O
predicted O
from O
emerin O
cDNA O
. O

Using O
both O
antisera O
, O
we O
found O
positive O
nuclear O
membrane O
staining O
in O
skeletal O
, O
cardiac O
and O
smooth O
muscles O
in O
the O
normal O
controls O
and O
in O
patients O
with O
neuromuscular B
diseases I
other O
than O
EDMD B
. O

In O
contrast O
, O
a O
deficiency O
in O
immunofluorescent O
staining O
of O
skeletal O
and O
cardiac O
muscle O
from O
EDMD B
patients O
was O
observed O
. O

A O
34 O
kD O
protein O
is O
immunoreactive O
with O
the O
antisera O
- O
- O
the O
protein O
is O
equivalent O
to O
that O
predicted O
for O
emerin O
. O

Together O
, O
our O
findings O
suggest O
the O
specific O
deficiency B
of I
emerin I
in O
the O
nuclear O
membrane O
of O
muscle O
cells O
in O
patients O
with O
EDMD B
. O
. O

Growth B
retardation I
and O
tumour B
inhibition O
by O
BRCA1 O
. O

Inherited O
mutations O
in O
BRCA1 O
predispose O
to O
breast B
and I
ovarian I
cancer I
, O
but O
the O
role O
of O
BRCA1 O
in O
sporadic O
breast B
and I
ovarian I
cancer I
has O
previously O
been O
elusive O
. O

Here O
, O
we O
show O
that O
retroviral O
transfer O
of O
the O
wild O
- O
type O
BRCA1 O
gene O
inhibits O
growth O
in O
vitro O
of O
all O
breast B
and I
ovarian I
cancer I
cell O
lines O
tested O
, O
but O
not O
colon B
or I
lung I
cancer I
cells O
or O
fibroblasts O
. O

Mutant O
BRCA1 O
has O
no O
effect O
on O
growth O
of O
breast B
cancer I
cells O
; O
ovarian B
cancer I
cell O
growth O
is O
not O
affected O
by O
BRCA1 O
mutations O
in O
the O
5 O
portion O
of O
the O
gene O
, O
but O
is O
inhibited O
by O
3 O
BRCA1 O
mutations O
. O

Development O
of O
MCF B
- I
7 I
tumours I
in O
nude O
mice O
is O
inhibited O
when O
MCF O
- O
7 O
cells O
are O
transfected O
with O
wild O
- O
type O
, O
but O
not O
mutant O
, O
BRCA1 O
. O

Most O
importantly O
, O
among O
mice O
with O
established O
MCF B
- I
7 I
tumours I
, O
peritoneal O
treatment O
with O
a O
retroviral O
vector O
expressing O
wild O
- O
type O
BRCA1 O
significantly O
inhibits O
tumour B
growth O
and O
increased O
survival O
. O
. O

A O
, O
, O
, O
was O
admitted O
for O
a O
2 O
years O
history O
of O
. O

 O
The O
patient O
described O
: O
especially O
throughout O
the O
and O
that O
preceded O
the O
seizure O
and O
he O
denied O
any O
. O

 O
Some O
of O
the O
consisted O
only O
of O
a O
brief O
period O
of O
without O
any O
, O
but O
a O
typical O
would O
consist O
of O
sudden O
accompanied O
by O
in O
both O
arms O
, O
more O
often O
being O
involved O
his O
, O
without O
, O
which O
lasted O
. O

 O
He O
had O
other O
than O
being O
a O
: O
. O

 O
The O
frequency O
of O
the O
was O
initially O
, O
but O
increased O
progressively O
over O
time O
to O
about O
, O
despite O
 O
at O
the O
time O
of O
he O
was O
taking O
 O
and O
. O

 O
With O
the O
we O
have O
been O
able O
to O
record O
a O
couple O
of O
seizures O
on O
the O
Video O
 O
EEG O
His O
was O
. O

 O
Diagnosis O
was O
made O
on O
native O
: O
minimal O
hypodense O
frontal O
right O
paramedian O
( O
Figure O
1A O
) O
, O
cerebral O
( O
Figure O
1 O
B O
 O
F O
) O
showed O
a O
small O
right O
parenchymal O
homogeneous O
, O
, O
involving O
, O
without O
perilesional O
and O
, O
hyperintense O
both O
on O
T1 O
and O
T2 O
MR O
sequences O
, O
. O

 O
The O
cerebral O
was O
also O
documented O
on O
and O
recordings O
: O
3 O
with O
and O
were O
recorded O
( O
Figure O
1I O
) O

 O
Using O
an O
interhemispheric O
, O
and O
the O
, O
at O
the O
level O
of O
, O
a O
yellow O
 O
gray O
, O
infiltrative O
, O
having O
a O
moderate O
had O
been O
identified O
and O
totally O
. O

 O
The O
revealed O
a O
grade O
 O
astrocytoma B
. O

 O
The O
patient O
very O
well O
, O
without O
, O
no O
gelastic B
seizures I
or O
; O
he O
is O
still O
free O
of O
. O

 O
A O
control O
postop O
revealed O
no O
( O
1 O
G O
, O
H O
) O

An O
was O
diagnosed O
with O
attention B
- I
deficit I
hyperactivity I
disorder I
( O
ADHD B
) O
in O
. O

 O
He O
was O
overweight O
with O
a O
( O
) O
of O
. O

 O
He O
was O
started O
on O
in O
and O
in O
. O

 O
In O
the O
he O
was O
to O
his O
with O
, O
, O
, O
and O
. O

 O
On O
the O
was O
, O
and O
the O
revealed O
a O
of O
, O
of O
3.55 O
kPa O
, O
of O
7.76 O
kPa O
, O
and O
of O
5.1 O
mmol O
/ O
l. O

 O
was O
. O

 O
The O
showed O
an O
. O

 O
He O
developed O
and O
was O
treated O
with O
unfractionated O
in O
suspicion O
of O
. O

 O
He O
subsequently O
developed O
cardiogenic B
shock I
and O
was O
treated O
with O
. O

 O
In O
spite O
of O
the O
treatment O
he O
became O
and O
his O
were O
. O

 O
He O
was O
to O
our O
for O
further O
treatment O
. O

 O
On O
the O
was O
, O
despite O
infusion O
with O
. O

 O
His O
was O
and O
his O
was O
. O

 O
A O
thoracic O
. O

 O
revealed O
and O
left O
ventricular O
end O
diastolic O
diameter O
was O
. O

 O
The O
was O
severely O
with O
an O
( O
) O
of O
. O

 O
The O
was O
markedly O
, O
and O
there O
was O
a O
moderate O
. O

 O
Intermittent O
was O
initiated O
. O

 O
His O
improved O
slightly O
, O
but O
despite O
the O
with O
increasing O
. O

 O
there O
was O
a O
further O
worsening O
of O
the O
with O
an O
of O
and O
marked O
with O
estimated O
to O
. O

 O
The O
clinical O
picture O
resembled O
dilated O
cardiomyopathy B
with O
causing O
renal O
and O
liver O
. O

 O
We O
suspected O
drug O
- O
induced O
and O
and O
were O
discontinued O
. O

 O
, O
, O
and O
or O
were O
all O
. O

 O
After O
three O
days O
he O
was O
transferred O
to O
the O
with O
ongoing O
and O
. O

 O
Shortly O
after O
admission O
an O
( O
) O
was O
inserted O
and O
was O
replaced O
by O
. O

 O
was O
. O

 O
Endomyocardial O
from O
the O
did O
not O
reveal O
any O
distinct O
myocardial B
pathology I
. O

 O
On O
treatment O
with O
, O
, O
and O
dialysis O
, O
the O
clinical O
situation O
gradually O
improved O
and O
the O
returned O
to O
. O

 O
His O
also O
with O
increasing O
and O
fell O
from O
to O
98 O
mol O
/ O
l. O

 O
His O
was O
still O
markedly O
reduced O
( O
) O
. O

 O
Because O
of O
and O
, O
he O
was O
denied O
a O
. O

 O
He O
was O
treated O
with O
for O
, O
and O
he O
was O
back O
to O
. O

 O
At O
that O
time O
his O
were O
. O

 O
He O
was O
treated O
with O
an O
, O
a O
, O
and O
. O

 O
During O
the O
following O
two O
weeks O
his O
clinical O
status O
improved O
and O
he O
was O
subsequently O
to O
his O
home O
. O

 O
The O
still O
showed O
markedly O
dilated O
left O
ventricle O
with O
of O
. O

 O
In O
, O
his O
was O
and O
he O
was O
in O
( O
New O
York O
Heart O
Association O
) O
with O
an O
estimated O
by O
to O
. O

A O
suffered O
from O
an O
abdominal O
at O
, O
lasting O
for O
. O

 O
Shortly O
ahead O
of O
her O
medical O
consultation O
, O
4 O
ascaris O
- O
like O
worms O
were O
out O
, O
individually O
with O
a O
length O
of O
about O
. O

 O
She O
had O
a O
previous O
onset O
of O
ascariasis B
, O
during O
which O
low O
- O
grade O
( O
) O
occurred O
without O
apparent O
, O
, O
or O
. O

 O
revealed O
at O
. O

 O
Her O
was O
consisting O
of O
. O

 O
Serum O
and O
urine O
were O
and O
928 O
, O
respectively O
. O

 O
In O
terms O
of O
, O
the O
level O
of O
rose O
up O
to O
, O
meanwhile O
the O
were O
similarly O
( O
163 O
 O
U O
/ O
L O
; O
) O
. O

 O
Abdominal O
described O
the O
of O
the O
, O
( O
1.5 O
 O
cm O
in O
diameter O
) O
and O
( O
) O
. O

 O
Furthermore O
, O
the O
intrahepatic O
bile O
duct O
was O
also O
discovered O
to O
be O
filled O
with O
and O
. O

 O
Based O
on O
such O
evidences O
, O
she O
was O
clinically O
diagnosed O
as O
biliary O
ascariasis B
with O
a O
concomitant O
manifestation O
of O
biliary O
duct O
infection B
. O

 O
Through O
a O
, O
the O
and O
were O
visually O
confirmed O
, O
as O
well O
as O
the O
massive O
storage O
of O
within O
the O
. O

 O
Subsequently O
, O
a O
1 O
 O
cm O
was O
made O
on O
the O
common O
bile O
duct O
in O
order O
to O
facilitate O
the O
of O
the O
pathogenic O
, O
which O
were O
then O
( O
Fig.1 O
) O
. O

 O
Once O
the O
contained O
were O
virtually O
cleared O
out O
under O
, O
was O
employed O
to O
seek O
for O
more O
hidden O
inside O
the O
( O
Fig.2 O
) O
. O

 O
After O
finishing O
the O
removal O
of O
, O
the O
biliary O
duct O
, O
with O
a O
in O
situ O
( O
Fig.3 O
) O
. O

 O
Eventually O
, O
a O
standard O
laparoscopic O
was O
performed O
, O
followed O
by O
the O
and O
drainage O
tube O
placement O
( O
Fig.4 O
) O
. O

 O
The O
total O
amount O
of O
inside O
the O
summed O
up O
to O
( O
Fig.5 O
) O
. O

 O
Postoperatively O
, O
she O
was O
treated O
with O
oral O
for O
. O

 O
The O
every O
day O
, O
and O
during O
the O
first O
3 O
days O
, O
6 O
more O
were O
additionally O
washed O
out O
. O

 O
The O
patient O
experienced O
a O
smooth O
and O
was O
finally O
without O
any O
. O

A O
developed O
diabetes B
insipidus I
with O
up O
to O
in O
. O

 O
, O
he O
complained O
of O
, O
, O
and O
, O
and O
a O
symptomatic O
occipital O
. O

 O
showed O
an O
abnormal O
( O
Table O
1 O
) O
, O
the O
patient O
was O
negative O
for O
. O

 O
As O
shown O
in O
Fig.1 O
, O
abdominal O
showed O
multiple O
low O
- O
density O
in O
the O
on O
the O
and O
obvious O
expansion O
of O
the O
intrahepatic O
bile O
duct O
on O
the O
. O

 O
revealed O
multifocal O
intrahepatic O
bile O
duct O
and O
, O
but O
the O
common O
hepatic O
duct O
was O
normal O
, O
it O
was O
highly O
suggestive O
of O
SC B
. O

 O
The O
neurohypophyseal O
area O
showed O
the O
and O
a O
low O
- O
density O
of O
in O
size O
in O
the O
. O

 O
A O
multisystem O
, O
high O
- O
risk O
organ O
LCH B
was O
confirmed O
after O
occipital O
mass O
was O
in O
the O
, O
the O
patient O
was O
given O
. O

 O
Then O
, O
he O
began O
to O
receive O
a O
course O
of O
( O
, O
1000 O
 O
mg O
; O
, O
2 O
 O
mg O
; O
, O
90 O
 O
mg O
; O
and O
, O
) O
in O
. O

 O
However O
, O
on O
the O
5th O
day O
of O
the O
1st O
COEP O
chemotherapy O
, O
the O
patient O
appeared O
to O
severe O
liver O
function O
injury O
with O
an O
obvious O
increase O
of O
serum O
bilirubin O
( O
Table O
1 O
) O
. O

 O
He O
refused O
further O
. O

 O
, O
the O
patient O
developed O
liver O
decompensation B
with O
bleeding O
esophageal O
, O
, O
and O
, O
and O
he O
was O
referred O
to O
( O
Model O
for O
End O
Stage O
Liver O
Disease O
score O
17 O
) O
. O

 O
He O
underwent O
successful O
orthotopic O
in O
in O
our O
, O
and O
the O
came O
from O
voluntary O
deceased O
citizen O
organ O
donation O
in O
. O

 O
after O
revealed O
micronodular O
cirrhosis O
with O
SC B
and O
positive O
( O
and O
) O
, O
suggestive O
of O
LCH B
involving O
in O
the O
( O
Fig.2 O
) O
. O

 O
Postoperatively O
, O
the O
man O
continued O
to O
be O
immunosuppressed B
with O
and O
. O

 O
The O
patient O
is O
currently O
with O
normal O
and O
no O
evidence O
of O
of O
LCH B
for O
. O

A O
visited O
our O
outpatient O
clinic O
with O
a O
mass O
on O
his O
left O
hip O
. O

 O
He O
had O
and O
. O

 O
On O
, O
a O
large O
measuring O
10 O
cm O
in O
diameter O
was O
observed O
on O
his O
hip O
and O
an O
approximate O
5 O
cm O
left O
inguinal O
lymph O
node O
was O
palpable O
( O
Figure O
1 O
) O
. O

 O
Serum O
tumor O
markers O
, O
including O
CEA O
and O
CA O
19 O
- O
9 O
, O
were O
within O
normal O
limits O
, O
whereas O
serum O
amylase O
( O
227 O
IU O
/ O
L O
, O
normal O
range O
43 O
- O
116 O
IU O
/ O
L O
) O
, O
lipase O
( O
378 O
IU O
/ O
L O
, O
normal O
range O
7 O
- O
60 O
) O
, O
fasting O
blood O
sugar O
( O
144 O
mg O
/ O
dL O
, O
normal O
range O
, O
70 O
- O
100 O
mg O
/ O
dL O
) O
, O
and O
liver O
function O
test O
levels O
[ O
including O
aspartate O
aminotransferase O
( O
178 O
IU O
/ O
L O
, O
normal O
range O
, O
7 O
- O
38 O
IU O
/ O
L O
) O
, O
alanine O
aminotransferase O
( O
225 O
IU O
/ O
L O
; O
normal O
range O
, O
4 O
- O
43 O
IU O
/ O
L O
) O
, O
and O
serum O
alkaline O
phosphatase O
( O
370 O
IU O
/ O
L O
, O
normal O
range O
, O
103 O
- O
335 O
IU O
/ O
L O
) O
] O
were O
all O
above O
normal O
ranges O
. O

 O
An O
abdominal O
computerized O
tomography O
( O
CT O
) O
scan O
demonstrated O
not O
only O
a O
left O
hip O
mass O
and O
an O
enlarged O
left O
inguinal O
lymph O
node O
, O
but O
also O
a O
huge O
heterogeneous O
enhancing O
mass O
on O
the O
body O
of O
the O
pancreas O
( O
Figure O
2 O
) O
. O

 O
On O
a O
PET O
scan O
, O
additional O
metastases O
were O
not O
found O
. O

 O
We O
planned O
a O
staged O
surgery O
and O
performed O
a O
hip O
and O
inguinal O
mass O
excision O
on O
December O
19 O
, O
2014 O
. O

 O
The O
histopathological O
report O
revealed O
a O
metastatic O
small O
cell O
neuroendocrine O
carcinoma O
with O
a O
maximal O
diameter O
of O
10.5 O
cm O
on O
the O
buttock O
mass O
and O
a O
7 O
cm O
growth O
on O
an O
inguinal O
lymph O
node O
. O

 O
The O
mitotic O
index O
was O
over O
50 O
mitoses O
per O
50 O
HPF O
and O
the O
Ki-67 O
index O
measured O
at O
50 O
% O
. O

 O
On O
January O
21 O
, O
2015 O
, O
we O
performed O
a O
total O
pancreatectomy O
and O
a O
total O
gastrectomy O
, O
with O
the O
findings O
revealing O
a O
tumor O
of O
the O
body O
of O
the O
pancreas O
about O
9 O
cm O
 O
6 O
cm O
in O
diameter O
involving O
the O
left O
gastric O
artery O
, O
splenic O
artery O
, O
and O
splenic O
vein O
. O

 O
The O
histopathological O
report O
was O
the O
same O
as O
that O
of O
a O
metastatic O
lesion O
. O

 O
Additionally O
, O
the O
tumor O
had O
spread O
to O
8 O
of O
the O
32 O
lymph O
nodes O
( O
Figure O
3 O
) O
. O

 O
On O
the O
7th O
post O
- O
operative O
day O
, O
the O
patient O
developed O
a O
high O
fever O
and O
leukocytosis O
. O

 O
We O
administered O
an O
abdominal O
CT O
scan O
, O
which O
revealed O
infected O
fluid O
collection O
in O
the O
lesser O
sac O
and O
a O
4.7 O
cm O
- O
sized O
recurring O
mass O
which O
was O
detected O
at O
the O
operative O
bed O
of O
the O
left O
hip O
( O
Figure O
(Figure4).4 O
) O
. O

 O
After O
infection O
of O
the O
abdominal O
cavity O
was O
treated O
by O
antibiotics O
, O
we O
removed O
the O
left O
hip O
recurring O
mass O
on O
February O
3 O
, O
2015 O
. O

 O
The O
histopathology O
was O
the O
same O
as O
in O
the O
previous O
report O
; O
with O
a O
maximum O
diameter O
of O
7.5 O
cm O
. O

 O
The O
patient O
was O
discharged O
without O
other O
complications O
on O
February O
9 O
, O
2015 O
. O

 O
He O
is O
currently O
receiving O
based O
on O
and O
treatment O
. O

The O
patient O
, O
a O
, O
was O
diagnosed O
as O
having O
Blau B
syndrome I
based O
on O
the O
manifestation O
of O
typical O
clinical O
features O
( O
ankle O
and O
wrist O
arthritis B
/ O
tenosynovitis B
, O
diffuse O
eczematous O
, O
and O
uveitis B
) O
, O
histologic O
evidence O
of O
noncaseating O
granulomas B
, O
and O
a O
heterozygous O
( O
) O
. O

 O
Ocular O
involvement O
was O
initially O
controlled O
by O
topical O
and O
oral O
, O
but O
visual B
impairment I
. O

 O
Other O
manifestations O
of O
Blau B
syndrome I
( O
arthritis B
and O
) O
subsided O
. O

 O
Bilateral O
panuveitis B
progressed O
after O
age O
5 O
years O
, O
and O
was O
initially O
treated O
with O
. O

 O
However O
, O
ocular O
inflammation B
despite O
the O
addition O
of O
local O
and O
repeated O
intravenous O
( O
IV O
) O
bolus O
; O
therefore O
, O
when O
the O
patient O
was O
age O
10 O
years O
, O
( O
initially O
at O
increased O
to O
10 O
mg O
/ O
kg O
IV O
) O
was O
initiated O
. O

 O
Although O
there O
was O
an O
initial O
improvement O
, O
uveitis B
, O
and O
at O
age O
12 O
years O
was O
. O

 O
( O
) O
was O
then O
initiated O
and O
the O
dosage O
of O
( O
) O
was O
. O

 O
However O
, O
ocular B
disease I
remained O
. O

 O
( O
) O
and O
then O
( O
) O
were O
sequentially O
administered O
, O
without O
significant O
improvement O
. O

 O
At O
age O
16 O
years O
the O
patient O
still O
had O
granulomatous O
retinal O
lesions B
and O
anterior O
chamber O
inflammation B
, O
and O
macular O
edema O
developed O
, O
which O
led O
to O
retinal O
detachment O
. O

 O
In O
addition O
to O
the O
other O
steroid O
therapy O
, O
was O
necessary O
to O
control O
disease O
flares O
, O
with O
an O
average O
of O
for O
. O

 O
Because O
of O
the O
supposed O
autoinflammatory O
nature O
of O
Blau O
syndrome O
, O
we O
initiated O
a O
trial O
of O
IL-1 O
antibody O
administration O
( O
2 O
mg O
/ O
kg O
/ O
month O
of O
) O
. O

 O
During O
the O
6 O
months O
that O
followed O
, O
no O
ocular B
flare I
occurred O
and O
no O
was O
necessary O
. O

 O
Concomitant O
treatment O
with O
oral O
and O
low O
- O
dose O
( O
) O
remained O
unchanged O
. O

 O
Figure O
1 O
shows O
before O
treatment O
and O
after O
the O
first O
6 O
injections O
. O

 O
The O
drug O
was O
, O
and O
findings O
on O
( O
performed O
) O
were O
. O

A O
of O
with O
presents O
with O
subacute O
onset O
of O
right O
- O
sided O
and O
aphasia B
, O
with O
marked O
expressive O
aphasia B
, O
word O
- O
finding O
difficulty O
, O
and O
rare O
. O

 O
demonstrated O
right O
central O
facial O
, O
23/5 O
in O
the O
right O
and O
, O
and O
in O
the O
right O
upper O
and O
lower O
. O

 O
were O
on O
the O
with O
a O
right O
- O
sided O
. O

 O
of O
the O
showed O
multiple O
bilateral O
concentric O
ring O
- O
like O
in O
the O
and O
the O
on O
( O
figure O
, O
A O
) O
, O
consistent O
with O
the O
pattern O
of O
Balo B
concentric I
sclerosis I
. O

 O
There O
was O
associated O
restricted O
diffusion O
in O
3 O
and O
incomplete O
ring O
enhancement O
in O
1 O
. O

 O
showed O
30 O
( O
79 O
% O
, O
4 O
% O
) O
, O
count O
was O
850 O
, O
and O
were O
. O

 O
He O
was O
treated O
with O
1 O
g O
of O
IV O
for O
, O
with O
little O
improvement O
. O

 O
He O
then O
underwent O
5 O
, O
with O
significant O
improvement O
of O
, O
, O
speech O
deficits O
, O
and O
. O

 O
, O
his O
showed O
4+/5 O
in O
the O
and O
a O
right O
- O
sided O
. O

 O
and O
tandem O
were O
. O

 O
He O
was O
placed O
on O
subcutaneously O
, O
for O
treatment O
of O
presumed O
clinically B
isolated I
syndrome I
, O
with O
good O
. O

 O
, O
his O
was O
. O

 O
There O
was O
. O

 O
His O
has O
a O
significant O
history O
of O
and O
, O
and O
was O
found O
to O
be O
a O
consistent O
with O
( O
) O
. O

 O
His O
had O
a O
, O
and O
a O
history O
of O
, O
but O
has O
. O

 O
in O
the O
patient O
showed O
the O
( O
) O
. O

 O
Skin O
showed O
electron O
- O
dense O
extracellular O
in O
close O
apposition O
to O
the O
smooth O
muscle O
of O
the O
vascular O
media1 O
( O
figure O
, O
B O
) O
. O

A O
, O
with O
controlled O
hypertension O
and O
stage O
2 O
obesity O
presented O
to O
our O
institution O
with O
a O
complaint O
of O
progressive O
fatigue O
with O
moderate O
to O
light O
exertion O
of O
approximately O
1 O
year O
s O
duration O
. O

 O
During O
that O
period O
, O
he O
had O
undergone O
myocardial O
perfusion O
scintigraphy O
without O
evidence O
of O
obstructive O
ischemic O
disease O
. O

 O
He O
had O
no O
clinical O
evidence O
of O
systolic O
heart O
failure O
. O

 O
He O
had O
undergone O
biological O
mitral O
valve O
replacement O
3 O
years O
previously O
for O
mitral O
valve O
stenosis O
and O
had O
undergone O
ablation O
of O
atrioventricular O
nodal O
reentry O
tachycardia O
18 O
months O
previously O
. O

 O
At O
the O
time O
of O
valve O
replacement O
, O
there O
was O
no O
reported O
evidence O
of O
pulmonary O
arterial O
hypertension O
. O

 O
The O
patient O
s O
medication O
list O
included O
aspirin O
100 O
mg O
/ O
day O
, O
carvedilol O
50 O
mg O
/ O
day O
, O
atorvastatin O
10 O
mg O
/ O
day O
, O
and O
losartan O
25 O
mg O
/ O
day O
. O

 O
His O
echocardiogram O
showed O
normal O
function O
of O
a O
mitral O
prosthesis O
, O
global O
left O
ventricular O
systolic O
function O
within O
normal O
limits O
( O
left O
ventricular O
ejection O
fraction O
62 O
% O
measured O
using O
the O
Teichholz O
method O
) O
, O
stage O
I O
diastolic O
dysfunction O
, O
and O
mean O
pulmonary O
arterial O
systolic O
blood O
pressure O
of O
50 O
mmHg O
. O

 O
In O
the O
6 O
- O
minute O
walk O
test O
, O
the O
patient O
walked O
104 O
meters O
( O
Table O
1 O
) O
. O

 O
Catheterization O
of O
his O
right O
heart O
chambers O
and O
pulmonary O
arteries O
confirmed O
the O
diagnosis O
of O
pulmonary O
hypertension O
( O
Table O
2 O
) O
. O

 O
During O
the O
follow O
- O
up O
period O
, O
therapy O
with O
nifedipine O
and O
sildenafil O
was O
not O
tolerated O
secondary O
to O
orthostatic O
hypotension O
. O

 O
The O
patient O
was O
referred O
for O
radiofrequency O
ablation O
of O
the O
pulmonary O
artery O
trunk O
for O
the O
treatment O
of O
refractory O
pulmonary O
hypertension O
. O

 O
The O
procedure O
was O
performed O
in O
the O
catheterization O
laboratory O
with O
direct O
visualization O
using O
fluoroscopy O
and O
radiopaque O
contrast O
dye O
. O

 O
The O
patient O
remained O
under O
unconscious O
sedation O
. O

 O
Catheterization O
of O
the O
right O
femoral O
artery O
via O
the O
standard O
Seldinger O
technique O
was O
performed O
using O
an O
8 O
- O
French O
valved O
short O
sheath O
after O
subcutaneous O
injection O
of O
a O
local O
anesthetic O
. O

 O
Subsequently O
, O
this O
sheath O
was O
replaced O
with O
a O
steerable O
long O
sheath O
( O
Agilis O
 O
; O
St. O
Jude O
Medical O
, O
St. O
Paul O
, O
MN O
, O
USA O
) O
using O
the O
standard O
over O
- O
the O
- O
wire O
technique O
. O

 O
Unfractionated O
heparin O
was O
administered O
intravenously O
, O
targeting O
an O
activated O
coagulation O
time O
between O
250 O
and O
350 O
seconds O
. O

 O
Electroanatomic O
reconstruction O
of O
both O
the O
right O
ventricular O
outflow O
tract O
and O
pulmonary O
artery O
was O
performed O
using O
the O
EnSite O
Velocity O
Cardiac O
Mapping O
System O
( O
St. O
Jude O
Medical O
) O
under O
direct O
fluoroscopic O
visualization O
, O
and O
a O
merger O
was O
made O
with O
the O
formatted O
image O
obtained O
by O
performing O
cardiac O
computed O
tomography O
angiography O
( O
Fig.1 O
) O
. O

 O
The O
Agilis O
 O
sheath O
was O
advanced O
into O
the O
right O
ventricular O
outflow O
tract O
just O
before O
reaching O
the O
pulmonary O
valve O
. O

 O
Through O
this O
long O
sheath O
, O
we O
introduced O
an O
ablation O
catheter O
with O
an O
open O
irrigated O
tip O
( O
St. O
Jude O
Medical O
) O
. O

 O
The O
parameters O
used O
for O
each O
application O
according O
to O
our O
protocol O
were O
as O
follows O
: O
power O
of O
5 O
W O
, O
maximum O
temperature O
of O
48 O
 O
C O
, O
60 O
- O
second O
duration O
in O
each O
spot O
, O
maximum O
impedance O
variation O
of O
10 O
% O
from O
baseline O
values O
, O
and O
an O
irrigation O
flow O
rate O
of O
17 O
ml O
/ O
minute O
, O
which O
created O
a O
circle O
in O
the O
pulmonary O
artery O
trunk O
. O

 O
The O
patient O
was O
the O
. O

 O
No O
noteworthy O
before O
or O
after O
the O
procedure O
or O
before O
in O
the O
patient O
s O
were O
seen O
. O

 O
The O
patient O
s O
in O
and O
the O
were O
determined O
before O
and O
at O
the O
procedure O
. O

 O
The O
results O
are O
shown O
in O
Table O
2 O
. O

 O
At O
the O
patient O
s O
examination O
, O
he O
showed O
an O
improvement O
in O
. O

 O
He O
also O
demonstrated O
an O
increased O
distance O
walked O
in O
the O
6 O
- O
minute O
and O
reduction O
of O
the O
in O
both O
the O
and O
the O
. O

 O
Currently O
, O
with O
of O
clinical O
, O
he O
has O
maintained O
his O
improvement O
in O
and O
is O
. O

A O
with O
a O
history O
of O
for O
and O
for O
the O
, O
, O
and O
, O
presented O
with O
several O
episodes O
of O
and O
abdominal O
for O
. O

 O
( O
) O
, O
performed O
for O
abdominal O
, O
had O
revealed O
no O
esophageal O
, O
gastric O
, O
portal O
hypertensive O
gastropathy B
, O
or O
other O
GI O
. O

 O
revealed O
a O
 O
= O
 O
, O
 O
= O
 O
60 O
 O
beats O
/ O
min O
, O
no O
, O
no O
stigmata O
of O
chronic O
liver O
disease O
, O
a O
soft O
abdomen O
with O
mild O
epigastric O
tenderness O
but O
no O
rebound O
tenderness O
, O
no O
abdominal O
bruit O
, O
and O
no O
pulsatile O
abdominal O
mass O
. O

 O
revealed O
gross O
melena O
. O

 O
Laboratory O
tests O
revealed O
hemoglobin O
 O
= O
 O
12.5 O
 O
g O
/ O
dL O
, O
platelets O
 O
= O
 O
301,000 O
/ O
mL O
, O
INR O
( O
international O
normalized O
ratio O
) O
 O
= O
 O
1.0 O
, O
blood O
urea O
nitrogen O
 O
= O
 O
20 O
 O
mg O
/ O
dL O
, O
and O
creatinine O
 O
= O
 O
1.1 O
 O
mg O
/ O
dL. O

 O
Serum O
aspartate O
aminotransferase O
 O
= O
 O
21 O
 O
IU O
/ O
L O
, O
alanine O
aminotransferase O
 O
= O
 O
16 O
 O
IU O
/ O
L O
, O
total O
bilirubin O
 O
= O
 O
0.6 O
 O
mg O
/ O
dL O
, O
alkaline O
phosphatase O
 O
= O
 O
64 O
 O
IU O
/ O
L O
, O
albumin O
 O
= O
 O
4.4 O
 O
gm O
/ O
dL O
, O
and O
lipase O
 O
= O
 O
32 O
 O
U O
/ O
dL. O

 O
The O
hemoglobin O
declined O
acutely O
to O
9.3 O
 O
g O
/ O
dL. O

 O
Abdomino O
- O
pelvic O
computerized O
tomography O
( O
CT O
) O
, O
with O
intravenous O
contrast O
, O
revealed O
a O
5 O
- O
cm O
wide O
, O
irregular O
, O
pancreatic O
/ O
peripancreatic O
mass O
, O
compressing O
both O
the O
lesser O
curvature O
of O
the O
stomach O
and O
the O
SV O
( O
Fig.1A O
, O
B O
) O
, O
a O
normal O
portal O
vein O
, O
and O
normal O
liver O
parenchyma O
. O

 O
The O
SV O
compression O
was O
pathophysiologically O
significant O
as O
indicated O
by O
proximal O
SV O
dilatation O
. O

 O
EGD O
revealed O
in O
the O
proximal O
stomach O
a O
fine O
, O
reticular O
, O
pale O
- O
white O
, O
polygonal O
, O
mucosal O
, O
network O
in O
a O
snakeskin O
pattern O
, O
and O
characteristic O
of O
portal O
hypertensive O
gastropathy O
that O
was O
actively O
oozing O
; O
extensive O
coffee O
- O
ground O
, O
blood O
clots O
in O
the O
stomach O
; O
small O
gastric O
cardial O
and O
fundal O
varices O
without O
stigmata O
of O
recent O
hemorrhage O
( O
SRH O
) O
; O
and O
no O
esophageal O
varices O
( O
Fig.2 O
) O
. O

 O
The O
extrinsic O
mass O
produced O
a O
large O
, O
round O
bulge O
extending O
into O
the O
lumen O
of O
the O
proximal O
gastric O
body O
along O
the O
lesser O
curvature O
( O
Fig.2 O
) O
. O

 O
Magnetic O
resonance O
cholangio O
- O
pancreatography O
( O
MRCP O
) O
revealed O
a O
5 O
- O
cm O
wide O
, O
enhancing O
, O
vascular O
mass O
likely O
arising O
from O
the O
LGA O
and O
located O
between O
the O
gastric O
lesser O
curvature O
and O
distal O
pancreatic O
body O
; O
compressing O
the O
stomach O
; O
compressing O
the O
middle O
SV O
; O
and O
resulting O
in O
large O
collateral O
veins O
draining O
the O
SV O
into O
the O
superior O
mesenteric O
vein O
( O
Fig.3A O
, O
B O
) O
. O

 O
Abdominal O
ultrasound O
with O
Doppler O
studies O
demonstrated O
large O
, O
turbulent O
arterial O
flow O
into O
this O
vascular O
mass O
, O
suggesting O
a O
large O
PA O
( O
Fig.4 O
) O
. O

 O
Visceral O
arteriogram O
showed O
a O
5.3 O
 O
 O
 O
2.2 O
- O
cm O
- O
wide O
PA O
supplied O
by O
an O
LGA O
branch O
( O
Fig.5A O
) O
, O
which O
was O
embolized O
and O
occluded O
with O
microcoils O
( O
Fig.5B O
) O
. O

 O
, O
the O
patient O
had O
a O
stable O
level O
with O
no O
further O
GI O
. O

 O
Abdomino O
- O
pelvic O
CT O
demonstrated O
the O
PA B
had O
markedly O
decreased O
in O
diameter O
, O
, O
and O
had O
(Fig.1C O
) O
. O

A O
with O
Crohn B
's I
disease I
( O
CD B
) O
of O
the O
diagnosed O
at O
the O
, O
with O
multiple O
nonmelanoma B
skin I
cancers I
( O
NMSCs B
) O
; O
these O
had O
developed O
coinciding O
with O
the O
initiation O
of O
a O
prolonged O
course O
of O
the O
( O
, O
6 O
- O
MP O
) O
. O

 O
He O
was O
diagnosed O
with O
a O
total O
of O
84 O
NMSC B
: O
72 O
NMSC O
at O
, O
12 O
from O
. O

 O
He O
was O
also O
awaiting O
and O
for O
additional O
lesions O
. O

 O
His O
CD B
was O
initially O
treated O
with O
and O
intermittent O
at O
diagnosis O
, O
but O
for O
the O
he O
had O
been O
taking O
. O

 O
In O
the O
after O
beginning O
he O
developed O
NMSC B
; O
14 O
were O
squamous B
cell I
carcinoma I
( O
SCC B
) O
and O
were O
basal B
cell I
carcinoma I
( O
BCC B
) O
. O

 O
The O
patient O
was O
then O
for O
the O
. O

 O
This O
, O
however O
, O
he O
to O
the O
with O
over O
new O
suggestive O
of O
malignancy B
on O
his O
and O
. O

 O
Subsequent O
to O
this O
exam O
, O
he O
had O
biopsy O
- O
proven O
of O
NMCS B
; O
were O
SCC B
and O
were O
BCC B
. O

 O
In O
addition O
, O
of O
the O
SCCs B
were O
and O
were O
and O
some O
of O
his O
larger O
skin O
cancers O
have O
necessitated O
and O
. O

 O
The O
largest O
of O
his O
was O
and O
measured O
( O
Figure O
1 O
) O
. O

 O
He O
was O
awaiting O
for O
many O
other O
suspicious O
lesions O
. O

 O
The O
patient O
had O
Fitzpatrick O
II O
and O
admitted O
to O
excessive O
for O
in O
. O

 O
Early O
on O
he O
did O
not O
use O
, O
and O
would O
a O
catamaran O
. O

 O
He O
also O
revealed O
that O
his O
had O
and O
denied O
ever O
having O
been O
a O
. O

 O
Within O
the O
he O
discontinued O
and O
began O
using O
( O
) O
and O
later O
( O
) O
hoping O
to O
attenuate O
the O
progression O
of O
NMSC O
, O
and O
continued O
to O
have O
monthly O
. O

 O
Overall O
, O
he O
was O
for O
his O
CD B
, O
but O
never O
required O
any O
intestinal O
. O

 O
Unfortunately O
, O
in O
his O
most O
recent O
he O
was O
diagnosed O
with O
metastatic O
adenocarcinoma B
of O
the O
, O
and O
. O

A O
with O
Goldenhar B
syndrome I
with O
post O
- O
natal O
genetic O
diagnosis O
was O
referred O
to O
our O
for O
of O
the O
. O

 O
The O
patient O
underwent O
a O
. O

 O
Brilliance O
CT-64 O
- O
channel O
( O
) O
was O
employed O
. O

 O
The O
protocol O
generated O
and O
a O
current O
of O
150 O
mA. O

 O
of O
the O
images O
was O
with O
a O
. O

 O
Images O
in O
were O
processed O
on O
a O
PC O
using O
commercial O
software O
, O
obtaining O
a O
of O
. O

 O
The O
3 O
- O
dimensional O
reconstruction O
of O
the O
skin O
plans O
showed O
hypoplasia O
of O
the O
that O
on O
the O
right O
side O
consisted O
of O
a O
simple O
dysmorphic O
rough O
. O

 O
The O
had O
regular O
and O
. O

 O
Atresia B
of O
the O
and O
a O
normal O
were O
observed O
. O

 O
The O
upper O
images O
showed O
partial O
ossification O
of O
the O
cranium O
typical O
in O
paediatric O
age O
. O

 O
Description O
of O
the O
profile O
: O
typical O
II O
class O
very O
convex O
profile O
with O
interposition O
of O
the O
inferior O
lip O
and O
a O
reduced O
neck O
- O
chin O
angle.(Fig.1 O
) O
. O

 O
Skeletal O
studies O
show O
that O
the O
mandibular O
condyle O
, O
ramus O
and O
corpus O
were O
shorter O
on O
the O
affected O
side O
. O

 O
Tilting O
of O
oral O
rhyme O
, O
occlusal O
plane O
and O
mandibular O
plane O
were O
evident O
. O

 O
Number O
or O
form O
abnormalities O
were O
not O
found O
during O
mixed O
dentition O
. O

 O
Mandibular O
condyles O
and O
temporo O
- O
mandibular O
joints O
seemed O
to O
be O
asymmetric O
, O
and O
in O
particular O
the O
right O
condyle O
was O
deformed O
, O
shorter O
and O
wider O
than O
the O
other O
side O
( O
mandibular O
condyle O
dimensions O
were O
11 O
 O
7 O
mm O
right O
and O
14 O
 O
7 O
mm O
left O
) O
. O

 O
The O
3 O
- O
dimensional O
reconstruction O
of O
the O
skeleton O
planes O
showed O
the O
different O
morphology O
of O
the O
right O
and O
left O
hemimandibula O
. O

 O
Mandibular O
3 O
- O
dimensional O
reconstruction O
showed O
in O
detail O
the O
shift O
of O
the O
medial O
axis O
to O
the O
hypoplastic O
right O
side O
and O
the O
asymmetry O
of O
the O
right O
mandibular O
condyles O
that O
appears O
dysmorphic O
short O
and O
wide O
in O
axial O
and O
coronal O
scansions O
( O
Figs.2 O
, O
3 O
) O
. O

 O
The O
study O
of O
the O
temporal O
bone O
showed O
on O
the O
right O
side O
an O
external O
auditory O
canal O
atresia O
, O
hypoplasia O
of O
tympanic O
cavity O
that O
was O
not O
pneumatized O
and O
occupied O
by O
dense O
materials O
from O
soft O
parts O
. O

 O
No O
pneumatization O
was O
present O
in O
. O

 O
Left O
external O
auditory O
canal O
dimensions O
and O
morphology O
were O
normal O
. O

 O
The O
was O
normally O
formed O
and O
totally O
occupied O
by O
dense O
materials O
from O
soft O
tissues O
. O

 O
Both O
right O
and O
presented O
minor O
hypoplasia B
of O
in O
the O
. O

 O
In O
agreement O
with O
the O
resolution O
of O
our O
instrument O
, O
normal O
representation O
of O
the O
that O
seemed O
articulated O
with O
a O
dysmorphic O
rough O
of O
a O
deformed O
was O
observed O
; O
it O
was O
impossible O
to O
see O
the O
staples O
. O

 O
The O
and O
were O
visible O
and O
appeared O
to O
be O
articulated O
in O
an O
abnormal O
manner O
( O
reduce O
contact O
surface O
) O
; O
the O
was O
difficult O
to O
observe O
but O
seemed O
to O
have O
regular O
morphology O
. O

 O
and O
of O
, O
and O
were O
unaltered O
( O
Figs.4-7 O
) O
. O

 O
In O
conclusion O
, O
through O
3D O
- O
CT O
valuation O
of O
this O
young O
patient O
we O
observed O
asymmetry O
of O
the O
; O
in O
particular O
, O
the O
was O
, O
short O
and O
wide O
; O
the O
of O
the O
was O
hypoplastic B
, O
only O
a O
dysmorphic O
rough O
was O
present O
; O
the O
had O
a O
hypoplastic O
; O
the O
has O
an O
atresic B
. O

A O
who O
had O
been O
to O
our O
due O
to O
sudden O
chest O
was O
diagnosed O
with O
ST B
- I
segment I
elevation I
myocardial I
infarction I
( O
STEMI B
) O
. O

 O
He O
had O
no O
coronary O
risk O
factors O
except O
for O
a O
. O

 O
Primary O
percutaneous O
was O
performed O
, O
and O
a O
long O
, O
string O
- O
shaped O
was O
observed O
in O
the O
( O
Fig.1A O
) O
. O

 O
( O
) O
imaging O
revealed O
an O
odd O
, O
smooth O
- O
surfaced O
( O
Fig.1B O
) O
. O

 O
A O
long O
, O
white O
object O
which O
looked O
like O
a O
parasitic O
worm O
was O
retrieved O
via O
and O
was O
successfully O
completed O
since O
neither O
plaque O
rupture O
or O
the O
presence O
of O
thrombus O
was O
detected O
by O
( O
Fig.1C O
) O
. O

 O
On O
the O
eleventh O
hospital O
day O
, O
transthoracic O
revealed O
a O
new O
floating O
in O
the O
. O

 O
revealed O
a O
huge O
that O
was O
recognized O
at O
admission O
in O
the O
with O
( O
Fig.1D O
) O
. O

 O
Although O
the O
were O
negative O
for O
a O
, O
a O
of O
the O
aspirated O
coronary O
revealed O
pleomorphic O
lung O
carcinoma B
( O
Fig.2 O
) O
. O

 O
The O
patient O
was O
diagnosed O
with O
STEMI B
due O
to O
coronary O
associated O
with O
lung O
carcinoma B
. O

 O
Brain O
revealed O
that O
the O
patient O
had O
an O
asymptomatic O
cerebral O
in O
the O
and O
a O
small O
parietal O
lobe O
was O
diagnosed O
to O
be O
. O

 O
Given O
all O
these O
observations O
, O
he O
was O
diagnosed O
with O
right O
lung O
carcinoma B
, O
( O
) O
. O

 O
He O
was O
treated O
according O
to O
the O
regimens O
( O
& O
) O
known O
to O
be O
effective O
for O
the O
treatment O
of O
advanced O
non O
- O
small O
cell O
lung O
cancer O
. O

 O
He O
responded O
to O
the O
treatment O
and O
showed O
a O
good O
afterwards O
( O
Fig.3 O
) O
. O

 O
with O
a O
total O
of O
of O
the O
same O
regimen O
was O
used O
and O
the O
was O
. O

 O
He O
has O
been O
for O
more O
than O
two O
years O
of O
and O
has O
been O
. O

A O
complained O
of O
in O
the O
for O
without O
scalp O
or O
. O

 O
( O
) O
was O
right O
eye O
and O
. O

 O
were O
. O

 O
revealed O
left O
optic O
nerve O
and O
a O
small O
disc O
margin O
. O

 O
was O
, O
was O
( O
normal O
020 O
mm O
/ O
hr O
) O
and O
was O
( O
normal O
01.0 O
mg O
/ O
dL O
) O
. O

 O
, O
she O
noted O
new O
left O
eye O
and O
her O
declined O
to O
. O

 O
There O
was O
no O
. O

 O
The O
was O
and O
; O
the O
was O
, O
and O
there O
was O
a O
relative O
left O
afferent O
pupillary O
. O

 O
The O
left O
optic O
nerve O
was O
with O
a O
few O
peripapillary O
nerve O
fiber O
layer O
along O
with O
a O
cherry O
red O
and O
mild O
macular O
consistent O
with O
central B
retinal I
artery I
occlusion I
; O
there O
were O
no O
posterior O
pole O
or O
peripheral O
retinal O
. O

 O
were O
seen O
in O
the O
, O
but O
in O
the O
. O

 O
Repeat O
, O
and O
were O
. O

 O
Treponemal O
and O
Bartonella O
, O
the O
, O
, O
and O
carotid O
Doppler O
were O
. O

 O
Brain O
contrast O
demonstrated O
no O
enhancement O
. O

 O
, O
left O
eye O
and O
, O
and O
the O
patient O
complained O
of O
jaw O
and O
scalp O
. O

 O
declined O
to O
in O
the O
with O
1 O
+ O
in O
and O
2 O
+ O
. O

 O
revealed O
extensive O
retinal O
and O
diffuse O
with O
multiple O
areas O
of O
focal O
( O
Fig.1 O
) O
, O
consistent O
with O
acute B
retinal I
necrosis I
. O

 O
Vitreous O
fluid O
was O
examined O
by O
for O
amplifiable O
, O
, O
and O
sequences O
and O
returned O
positive O
for O
. O

 O
She O
was O
treated O
with O
a O
one O
- O
time O
intravitreal O
injection O
of O
in O
the O
, O
oral O
for O
14 O
days O
and O
oral O
for O
followed O
by O
for O
. O

 O
starting O
treatment O
, O
because O
she O
had O
recently O
developed O
jaw O
claudication O
and O
intermittent O
scalp O
pain O
, O
a O
temporal O
artery O
was O
performed O
. O

 O
was O
( O
Fig.2 O
) O
while O
demonstrated O
in O
the O
; O
evaluation O
of O
adjacent O
sections O
for O
and O
( O
CD45 O
, O
not O
shown O
) O
was O
( O
Fig.3 O
) O
. O

 O
Antiviral O
therapy O
was O
altered O
to O
intravenous O
, O
for O
, O
and O
were O
discontinued O
. O

A O
previously O
healthy O
at O
the O
with O
generalized O
( O
and O
) O
, O
, O
and O
hepatic B
coma I
. O

 O
The O
relatives O
declared O
that O
he O
was O
known O
to O
have O
a O
urinary B
bladder I
carcinoma I
that O
was O
diagnosed O
at O
a O
routine O
control O
performed O
but O
no O
medical O
papers O
to O
prove O
this O
diagnosis O
were O
shown O
. O

 O
They O
also O
mentioned O
a O
2 O
- O
month O
history O
of O
progressive O
, O
, O
and O
temporary O
. O

 O
No O
or O
other O
clinical O
signs O
were O
mentioned O
. O

 O
No O
previously O
viral B
hepatitis I
or O
was O
reported O
. O

 O
was O
declared O
. O

 O
At O
the O
present O
admission O
, O
the O
abdominal O
showed O
marked O
with O
multiple O
small O
( O
in O
diameter O
) O
that O
was O
supposed O
to O
be O
hepatic O
from O
the O
bladder B
carcinoma I
. O

 O
The O
showed O
a O
bilateral O
without O
abnormal O
. O

 O
The O
patient O
with O
hepatic B
encephalopathy I
at O
admission O
. O

 O
Prior O
to O
the O
, O
signed O
informed O
consent O
of O
the O
relatives O
was O
obtained O
for O
the O
case O
publication O
. O

 O
Being O
about O
a O
case O
report O
, O
no O
Ethical O
Committee O
approval O
was O
necessary O
. O

 O
At O
autopsy O
, O
the O
showed O
a O
huge O
( O
) O
with O
widely O
distributed O
white O
of O
( O
Fig.1 O
) O
. O

 O
The O
was O
, O
but O
a O
30 O
 O
30 O
 O
50 O
 O
mm O
prostate O
with O
was O
observed O
( O
Fig.2 O
) O
. O

 O
The O
bilateral O
was O
confirmed O
, O
without O
any O
central O
. O

 O
A O
10 O
- O
mm O
white O
was O
identified O
encasing O
a O
from O
the O
, O
without O
( O
Fig.3 O
) O
. O

 O
Except O
for O
moderate O
, O
no O
other O
brain O
were O
identified O
. O

 O
The O
other O
organs O
did O
not O
show O
. O

 O
The O
tissues O
were O
fixed O
in O
10 O
% O
neutral O
formalin O
and O
embedded O
in O
paraffin O
together O
with O
iliac O
crest O
bone O
grafting O
. O

 O
of O
the O
showed O
a O
3 O
+ O
3 O
Gleason O
's O
grade O
2 O
occult O
adenocarcinoma B
( O
Fig.2 O
) O
. O

 O
Clusters O
and O
sheets O
of O
small O
round O
cells O
were O
seen O
in O
the O
liver O
parenchyma O
( O
Fig.1 O
) O
and O
the O
lymph O
nodes O
from O
the O
hepatic O
hilum O
. O

 O
Examination O
of O
the O
lung O
parenchyma O
showed O
a O
peribronchial O
SCLC O
with O
multiple O
tumor O
emboli O
in O
both O
veins O
and O
lymphatic O
vessels O
and O
multiple O
 O
coin O
- O
shaped O
 O
tumor O
nodules O
of O
1 O
to O
2 O
 O
mm O
in O
diameter O
below O
the O
pleura O
( O
Fig.3 O
) O
. O

 O
The O
small O
round O
tumor O
cells O
were O
also O
seen O
in O
bone O
marrow O
from O
the O
iliac O
crest O
bone O
( O
Fig.3 O
) O
. O

 O
No O
brain O
have O
been O
detected O
. O

 O
Based O
on O
the O
macro- O
and O
microscopic O
features O
and O
clinical O
picture O
, O
the O
final O
diagnosis O
was O
 O
peribronchial O
and O
coin O
- O
like O
peripheral O
SCLC B
with O
massive O
angiolymphatic O
invasion B
and O
in O
the O
, O
and O
, O
associated O
with O
encephalopathy B
and O
synchronous O
occult O
adenocarcinoma B
of O
the O
. O
 O

We O
report O
the O
case O
of O
a O
with O
, O
presented O
with O
an O
upper O
gastrointestinal O
and O
in O
. O

 O
Physical O
examination O
found O
a O
and O
signs O
of O
portosystemic B
collateral I
formation I
including O
abdominal O
wall O
and O
rectal O
. O

 O
No O
were O
noted O
besides O
those O
due O
to O
hypersplenism B
( O
and O
) O
. O

 O
The O
patient O
underwent O
upper O
gastrointestinal O
that O
showed O
stage O
III O
oesophageal O
with O
portal B
hypertensive I
gastropathy I
and O
. O

 O
revealed O
a O
of O
the O
measuring O
in O
diameter O
with O
; O
no O
were O
detected O
( O
Figure O
1 O
) O
. O

 O
The O
portal O
showed O
a O
. O

 O
were O
found O
, O
including O
, O
of O
the O
and O
a O
splenorenal O
. O

 O
A O
complementary O
angio O
- O
allowed O
a O
better O
assessment O
of O
the O
portal O
system O
that O
contained O
some O
in O
the O
and O
the O
( O
Figure O
2 O
, O
Figure O
3 O
, O
Figure O
4 O
) O
. O

 O
were O
noted O
such O
as O
oesophageal O
and O
gastric O
, O
parietal O
collateral O
circulation O
associated O
to O
findings O
. O

 O
Liver B
cirrhosis I
was O
confirmed O
by O
and O
. O

A O
man O
with O
chronic O
lymphocytic B
leukemia I
underwent O
allogeneic O
in O
. O

 O
The O
was O
mismatched O
at O
a O
single O
human O
leukocyte O
antigen O
allele O
( O
DQB1 O
) O
, O
and O
was O
T O
- O
cell O
depleted O
using O
in O
vivo O
alemtuzumab O
. O

 O
He O
engrafted O
on O
day O
12 O
after O
transplant O
. O

 O
Aside O
from O
persistent O
lymphopenia O
and O
diarrhea O
from O
norovirus O
infection O
, O
his O
posttransplant O
course O
was O
unremarkable O
until O
mid O
- O
October O
when O
he O
developed O
tinnitus O
and O
rapidly O
progressive O
sensorineural O
deafness O
, O
resulting O
in O
subtotal O
hearing O
loss O
bilaterally O
( O
> O
95 O
dB O
) O
over O
23 O
weeks O
. O

 O
Brain O
magnetic O
resonance O
imaging O
( O
MRI O
) O
was O
unremarkable O
, O
as O
was O
cerebrospinal O
fluid O
( O
CSF O
) O
analysis O
( O
4 O
leukocytes/L O
with O
50 O
% O
neutrophils O
and O
50 O
% O
lymphocytes O
, O
6 O
red O
blood O
cells/L O
, O
glucose O
2.4 O
mmol O
/ O
L O
[ O
normal O
range O
, O
2.24.7 O
mmol O
/ O
L O
] O
, O
protein O
61 O
mg O
/ O
dL O
[ O
normal O
range O
, O
1545 O
mg O
/ O
L O
] O
, O
absence O
of O
oligoclonal O
bands O
) O
. O

 O
Viral O
polymerase O
chain O
reaction O
( O
PCR O
) O
testing O
of O
CSF O
was O
negative O
for O
enterovirus O
and O
herpesvirus O
infection O
. O

 O
The O
patient O
was O
treated O
empirically O
with O
high O
- O
dose O
valacyclovir O
, O
broad O
- O
spectrum O
antibiotics O
, O
and O
2 O
g O
/ O
kg O
intravenous O
immunoglobulin O
( O
IVIG O
) O
. O

 O
Despite O
these O
interventions O
, O
he O
developed O
new O
symptoms O
of O
central O
dyspnea O
, O
postural O
hypotension O
, O
nausea O
, O
and O
gradually O
worsening O
balance O
. O

 O
Repeat O
neurological O
assessment O
confirmed O
persistent O
vestibulocochlear O
dysfunction O
6 O
weeks O
after O
symptom O
onset O
. O

 O
By O
mid O
- O
December O
, O
the O
patient O
had O
become O
increasingly O
withdrawn O
, O
irritable O
, O
and O
intermittently O
agitated O
. O

 O
He O
remained O
lymphopenic O
( O
lymphocytes O
0.54 O
 O
106 O
/ O
L O
[ O
normal O
range O
, O
1.23.6 O
 O
106 O
/ O
L O
] O
) O
. O

 O
MRI O
scans O
of O
the O
brain O
were O
unremarkable O
, O
as O
was O
serum O
testing O
for O
antineuronal O
antibodies O
; O
an O
electroencephalogram O
revealed O
only O
diffuse O
encephalopathy O
. O

 O
Given O
continued O
suspicion O
for O
a O
viral O
etiology O
, O
the O
patient O
was O
treated O
with O
high O
- O
dose O
glucocorticoids O
and O
again O
with O
IVIG O
. O

 O
He O
began O
refusing O
fluids O
, O
food O
, O
and O
medication O
, O
and O
was O
detained O
under O
the O
UK O
Mental O
Health O
Act O
. O

 O
Repeat O
MRI O
scanning O
showed O
interval O
development O
of O
new O
, O
nonenhancing O
signal O
abnormalities O
in O
both O
thalami O
and O
midbrain O
with O
cranial O
nerve O
involvement O
but O
no O
meningeal O
enhancement O
( O
Figure O
1A O
) O
. O

 O
Near O
the O
end O
of O
December O
, O
a O
frontal O
lobe O
biopsy O
was O
performed O
. O

 O
Histology O
revealed O
reactive O
gliosis O
and O
diffuse O
infiltration O
with O
CD3+/8 O
+ O
lymphocytes O
( O
Figure O
1B O
) O
. O

 O
Extensive O
microbiological O
testing O
of O
the O
biopsy O
tissue O
for O
an O
infectious O
etiology O
was O
negative O
( O
Supplementary O
Table O
1 O
) O
. O

 O
Given O
the O
absence O
of O
a O
diagnosis O
and O
the O
patient O
's O
progressive O
neurological O
deterioration O
, O
CSF O
and O
brain O
biopsy O
tissue O
were O
analyzed O
in O
January O
2014 O
by O
metagenomic O
next O
- O
generation O
sequencing O
( O
NGS O
) O
[ O
2 O
] O
. O

 O
NGS O
analysis O
of O
the O
brain O
biopsy O
, O
genome O
assembly O
, O
and O
in O
situ O
hybridization O
revealed O
findings O
of O
neuroinvasive O
astrovirus O
( O
AstV O
) O
infection O
. O

 O
Despite O
lack O
of O
approved O
therapies O
, O
the O
patient O
was O
treated O
with O
ribavirin O
and O
IVIG O
. O

 O
However O
, O
he O
did O
not O
respond O
to O
these O
interventions O
, O
and O
remained O
in O
a O
minimally O
conscious O
state O
following O
withdrawal O
of O
sedation O
in O
March O
2014 O
. O

 O
He O
eventually O
at O
the O
, O
the O
diagnosis O
and O
approximately O
onset O
of O
. O

A O
to O
our O
with O
a O
history O
of O
; O
productive O
of O
whitish O
. O

 O
At O
presentation O
, O
he O
denied O
, O
, O
, O
chest O
, O
, O
back O
, O
recent O
or O
sick O
. O

 O
He O
reported O
that O
he O
had O
approximately O
a O
1520 O
pound O
during O
the O
. O

 O
He O
, O
socially O
, O
and O
in O
the O
past O
. O

 O
On O
admission O
, O
his O
was O
; O
was O
, O
was O
, O
was O
, O
and O
was O
on O
. O

 O
showed O
oral O
, O
decreased O
and O
on O
the O
. O

 O
No O
cutaneous O
were O
reported O
and O
the O
rest O
of O
was O
. O

 O
His O
( O
) O
showed O
of O
, O
, O
and O
of O
164109 O
/ O
L. O

 O
His O
was O
, O
and O
was O
10 O
mg O
/ O
dL. O

 O
of O
the O
showed O
extensive O
right O
and O
left O
perihilar O
, O
and O
( O
) O
scan O
of O
the O
showed O
a O
right O
sided O
large O
perihilar O
( O
Figure O
1 O
) O
with O
multiple O
thoracic O
and O
lumbar O
vertebrae O
, O
ribs O
, O
and O
sternal O
tiny O
lytic O
consistent O
with O
bony O
metastasis B
( O
Figure O
2 O
) O
. O

 O
Blood O
and O
sputum O
were O
. O

 O
Tuberculosis B
was O
ruled O
out O
by O
three O
consecutive O
negative O
for O
and O
a O
negative O
. O

 O
He O
tested O
for O
( O
) O
and O
his O
came O
back O
at O
7 O
cells O
/ O
uL. O

 O
He O
was O
started O
on O
with O
and O
for O
opportunistic O
infections O
. O

 O
with O
was O
performed O
but O
was O
and O
he O
underwent O
a O
video O
assisted O
with O
of O
the O
. O

 O
showed O
positive O
for O
, O
, O
, O
and O
with O
diffuse O
positivity O
for O
diagnostic O
of O
KS B
. O

 O
He O
started O
treatment O
with O
in O
the O
form O
of O
and O
. O

 O
The O
patient O
was O
actively O
involved O
in O
decisions O
regarding O
management O
options O
. O

 O
He O
favored O
HAART O
isolated O
regimen O
without O
. O

 O
His O
condition O
showed O
continuing O
; O
a O
repeat O
scan O
of O
the O
at O
showed O
profound O
of O
the O
disease O
with O
disappearance O
of O
most O
of O
the O
( O
Figure O
3 O
) O
. O

A O
to O
our O
with O
and O
features O
of O
uremic O
encephalopathy B
. O

 O
Ten O
days O
prior O
to O
this O
presentation O
, O
he O
had O
experienced O
severe O
upper O
abdominal O
pain O
and O
vomiting O
, O
and O
he O
had O
been O
treated O
in O
a O
primary O
care O
facility O
for O
having O
a O
case O
of O
acute O
pancreatitis O
. O

 O
His O
initial O
symptoms O
improved O
; O
however O
, O
he O
gradually O
became O
anuric O
and O
disoriented O
. O

 O
Then O
he O
was O
transferred O
to O
our O
hospital O
for O
further O
management O
. O

 O
At O
presentation O
to O
our O
hospital O
, O
he O
was O
severely O
agitated O
, O
restless O
, O
and O
disoriented O
. O

 O
He O
was O
tachypneic O
with O
. O

 O
Mild O
pedal O
was O
present O
; O
however O
, O
his O
was O
. O

 O
His O
was O
, O
his O
was O
, O
and O
his O
was O
. O

 O
Signs O
of O
meningeal O
were O
absent O
, O
and O
his O
was O
. O

 O
His O
fundus O
could O
not O
be O
evaluated O
, O
and O
of O
his O
was O
. O

 O
His O
showed O
features O
of O
renal B
dysfunction I
( O
, O
) O
, O
( O
[ O
reference O
up O
to O
100 O
U O
/ O
L O
] O
, O
[ O
reference O
1360 O
U O
/ O
L O
) O
, O
normal O
tests O
( O
, O
, O
, O
, O
) O
, O
normal O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
His O
, O
including O
, O
, O
, O
, O
and O
, O
were O
. O

 O
An O
of O
his O
whole O
was O
, O
but O
non O
- O
contrast O
- O
enhanced O
( O
) O
findings O
were O
suggestive O
of O
acute O
pancreatitis B
( O
Fig.1 O
) O
. O

 O
His O
were O
, O
however O
. O

 O
The O
patient O
was O
managed O
as O
having O
a O
case O
of O
AKI B
and O
acute O
pancreatitis B
. O

 O
Urgent O
was O
initiated O
. O

 O
After O
he O
had O
received O
two O
sessions O
of O
, O
his O
, O
but O
he O
complained O
of O
profound O
visual B
loss I
. O

 O
An O
assessment O
revealed O
only O
. O

 O
A O
showed O
and O
extensive O
cotton O
wool O
exudates O
as O
well O
as O
( O
Fig.2 O
) O
compatible O
with O
Purtscher B
s I
retinopathy I
. O

 O
High O
- O
dose O
parenteral O
( O
1 O
g O
intravenously O
for O
) O
was O
administered O
. O

 O
For O
, O
a O
renal O
was O
done O
; O
the O
were O
compatible O
with O
renal B
cortical I
necrosis I
( O
Fig.3 O
) O
. O

 O
The O
patient O
. O

 O
He O
. O

 O
, O
nor O
did O
he O
have O
a O
history O
of O
throughout O
the O
course O
of O
his O
current O
illness O
. O

 O
The O
patient O
was O
finally O
diagnosed O
with O
acute O
pancreatitis B
complicated O
with O
renal B
cortical I
necrosis I
leading O
to O
AKI B
and O
Purtscher B
s I
retinopathy I
leading O
to O
complete O
bilateral O
blindness B
. O

 O
He O
his O
initial O
presentation O
as O
a O
result O
of O
a O
recurrent O
attack O
of O
acute O
pancreatitis B
. O

 O
Before O
that O
, O
he O
had O
been O
undergoing O
maintenance O
; O
however O
, O
his O
, O
though O
his O
vision O
was O
improved O
to O
at O
. O

A O
known O
for O
HHT B
is O
to O
our O
clinic O
for O
recurrent O
for O
. O

 O
She O
has O
had O
recurrent O
since O
the O
age O
of O
16 O
when O
her O
was O
diagnosed O
. O

 O
and O
her O
mother O
passed O
away O
from O
an O
intracranial O
hemorrhage O
. O

 O
to O
presentation O
she O
had O
undergone O
a O
left O
- O
sided O
via O
a O
lateral O
approach O
. O

 O
This O
had O
significantly O
reduced O
the O
frequency O
of O
her O
and O
for O
several O
years O
her O
was O
with O
the O
use O
of O
low O
dose O
. O

 O
However O
, O
she O
was O
to O
our O
due O
to O
increased O
severity O
and O
frequency O
necessitating O
more O
frequent O
. O

 O
At O
the O
time O
of O
the O
patient O
was O
concerned O
about O
daily O
severe O
left O
sided O
despite O
several O
months O
use O
of O
topical O
and O
oral O
. O

 O
She O
required O
intravenous O
and O
. O

 O
Her O
baseline O
at O
the O
time O
of O
our O
was O
( O
normal O
 O
= O
 O
120 O
 O
160 O
g O
/ O
L O
) O
. O

 O
Her O
[ O
17 O
] O
was O
( O
) O
. O

 O
On O
, O
she O
had O
multiple O
on O
her O
, O
, O
and O
. O

 O
Her O
revealed O
bilateral O
along O
the O
. O

 O
There O
was O
extensive O
along O
the O
entire O
with O
which O
any O
resulted O
in O
immediate O
profuse O
. O

 O
Given O
the O
severity O
of O
the O
patient O
s O
epistaxis O
despite O
medical O
therapy O
, O
she O
was O
offered O
endoscopic O
left O
- O
sided O
. O

 O
The O
surgical O
goals O
were O
to O
improve O
her O
quality O
of O
life O
by O
reducing O
the O
number O
and O
severity O
of O
epistaxis O
episodes O
while O
diminishing O
the O
need O
for O
blood O
transfusions O
. O

 O
The O
patient O
was O
content O
with O
the O
treatment O
plan O
and O
agreed O
to O
undergo O
surgical O
intervention O
. O

 O
The O
was O
performed O
under O
general O
anesthesia O
with O
endotracheal O
. O

 O
The O
nasal O
cavity O
was O
by O
inserting O
pledgets O
soaked O
in O
topical O
( O
) O
placed O
in O
for O
decongestion O
. O

 O
Using O
a O
zero O
degree O
endoscope O
the O
residual O
STSG O
and O
mucosa O
of O
the O
left O
septum O
was O
that O
resulted O
in O
the O
expected O
significant O
diffuse O
. O

 O
Immediate O
was O
attained O
using O
a O
, O
( O
FloSeal O
Hemostatic O
Matrix O
; O
Baxter O
Healthcare O
Corporation O
, O
Deerfield O
, O
IL O
, O
USA O
) O
( O
Fig.1 O
) O
. O

 O
The O
( O
Fig.2 O
) O
measured O
approximately O
in O
. O

 O
A O
4 O
x O
2 O
cm O
split O
thickness O
from O
the O
, O
and O
then O
placed O
endoscopically O
. O

 O
As O
seen O
in O
Fig.3 O
, O
the O
was O
placed O
with O
an O
. O

 O
Finally O
, O
2 O
mL O
of O
( O
TISSEEL O
fibrin O
sealant O
, O
Baxter O
Healthcare O
Corporation O
, O
Deerfield O
, O
IL O
, O
USA O
) O
was O
then O
( O
Fig.4 O
) O
. O

 O
was O
not O
used O
post O
- O
operatively O
and O
the O
patient O
was O
. O

 O
Clinical O
surgery O
( O
Fig.5 O
) O
showed O
that O
the O
entire O
graft O
had O
taken O
and O
the O
left O
- O
sided O
had O
dramatically O
diminished O
. O

 O
The O
patient O
was O
very O
content O
with O
the O
results O
of O
the O
procedure O
. O

 O
At O
6 O
months O
, O
her O
baseline O
had O
improved O
to O
and O
she O
was O
requiring O
with O
her O
hematologist O
s O
intent O
to O
stop O
the O
transfusions O
if O
her O
hemoglobin O
remained O
greater O
than O
100 O
g O
/ O
L. O

 O
Her O
at O
6 O
month O
follow O
up O
was O
( O
) O
. O

A O
was O
to O
our O
for O
cancer B
that O
was O
detected O
during O
screening O
by O
. O

 O
was O
identified O
, O
except O
. O

 O
Initial O
data O
showed O
a O
of O
( O
normal O
range O
: O
0 O
- O
15 O
ng O
/ O
mL O
) O
, O
but O
no O
other O
abnormality O
, O
which O
included O
other O
tumor O
markers O
, O
such O
as O
, O
and O
. O

 O
revealed O
a O
5 O
- O
cm O
ulcerofungating O
that O
was O
. O

 O
A O
of O
confirmed O
the O
presence O
of O
moderately O
differentiated O
tubular O
adenocarcinoma B
. O

 O
Subsequent O
abdominopelvic O
visualized O
a O
gastric O
. O

 O
No O
were O
observed O
in O
the O
, O
or O
, O
and O
showed O
. O

 O
Radical O
subtotal O
with O
and O
Billroth O
II O
were O
performed O
. O

 O
Grossly O
, O
the O
resected O
specimen O
contained O
double O
lesions O
: O
the O
first O
was O
a O
5.8 O
cm O
 O
3.2 O
cm O
ulcerofungating O
mass O
in O
the O
antrum O
, O
with O
extensive O
hemorrhage O
and O
light O
gray O
fibrosis O
; O
and O
the O
second O
was O
a O
nearby O
2.5 O
cm O
 O
2.0 O
cm O
ulcerative O
lesion O
( O
Figure O
1 O
) O
. O

 O
Microscopically O
, O
massive O
numbers O
of O
pleomorphic O
, O
bizarre O
tumor O
cells O
with O
hemorrhage O
( O
syncytiotrophoblasts O
and O
cytotrophoblasts O
) O
were O
observed O
in O
the O
first O
lesion O
. O

 O
Hematoxylin O
and O
eosin O
( O
HE)-stained O
tissues O
revealed O
a O
bubbly O
purple O
cytoplasm O
and O
giant O
nuclei O
at O
a O
magnification O
of O
40 O
 O
( O
Figure O
2A O
) O
and O
100 O
 O
( O
Figure O
2B O
) O
. O

 O
The O
tumor O
involved O
the O
proper O
muscle O
layer O
( O
T2a O
) O
and O
metastasis O
was O
found O
in O
four O
of O
56 O
regional O
lymph O
nodes O
( O
N1 O
) O
. O

 O
Immunohistochemical O
staining O
showed O
positive O
immunoreactivity O
for O
 O
- O
human O
chorionic O
gonadotropin O
( O
HCG O
) O
( O
Figure O
3A O
) O
and O
focal O
positivity O
for O
AFP O
( O
Figure O
3B O
) O
. O

 O
These O
findings O
confirmed O
the O
presence O
of O
gastric O
choriocarcinoma O
that O
contained O
small O
foci O
of O
an O
AFP O
- O
producing O
adenocarcinoma O
. O

 O
The O
second O
lesion O
was O
moderately O
differentiated O
tubular O
adenocarcinoma O
, O
which O
extended O
to O
the O
submucosal O
layer O
( O
T1b O
) O
. O

 O
It O
was O
close O
to O
, O
but O
distinct O
from O
the O
first O
lesion O
, O
which O
was O
negative O
by O
immunohistochemical O
staining O
for O
 O
- O
HCG O
and O
AFP O
. O

 O
The O
patient O
had O
an O
uneventful O
and O
was O
on O
. O

 O
, O
his O
was O
( O
normal O
range O
: O
0 O
- O
10 O
mIU O
/ O
mL O
) O
and O
his O
was O
10.0 O
ng O
/ O
mL. O

 O
Six O
cycles O
of O
with O
( O
Xeloda O
; O
Hoffmann O
- O
La O
Roche O
Inc. O
, O
Nutley O
, O
NJ O
, O
USA O
) O
was O
started O
at O
. O

 O
, O
his O
had O
declined O
to O
, O
and O
has O
since O
remained O
at O
this O
level O
. O

 O
No O
or O
had O
occurred O
at O
his O
. O

We O
present O
a O
case O
of O
pancreatic O
tumor O
without O
a O
history O
of O
trauma O
or O
panceratitis O
. O

 O
A O
with O
a O
history O
of O
was O
to O
the O
in O
because O
of O
fluid O
chronic O
with O
4 O
with O
out O
is O
associated O
with O
vomiting O
with O
out O
abdominal O
pain O
or O
fever O
with O
a O
weight O
loss O
not O
encrypted O
dating O
. O

 O
were O
. O

 O
Nonspecific O
elevations O
of O
serum O
. O

 O
Patient O
underwent O
an O
abdominal O
and O
( O
) O
that O
revealed O
: O
Aspect O
of O
ileitis O
of O
the O
last O
ileal O
loop O
extended O
by O
300 O
mm O
with O
distended O
ileal O
loops O
upstream O
, O
cystic O
image O
at O
the O
tail O
of O
the O
pancreas O
with O
clean O
wall O
uncalcified O
and O
hypodense O
content O
of O
fluid O
density O
without O
endoluminal O
bourgeon O
or O
pancreatic O
duct O
dilatation O
, O
measuring O
28 O
x O
22 O
mm O
( O
Figure O
1 O
) O
. O

 O
The O
of O
the O
was O
. O

 O
There O
were O
no O
( O
Figure O
2 O
) O
. O

 O
Aspect O
of O
bilateral O
sacroiliitis B
and O
bilateral O
coxarthrosis B
. O

 O
show O
an O
aspect O
of O
ileitis O
of O
the O
last O
ileal O
loop O
and O
the O
cystic O
nature O
of O
a O
pancreatic O
lesion O
, O
with O
parietal O
enhancement O
at O
the O
caudal O
portion O
of O
the O
pancreas O
with O
a O
slight O
dilation O
of O
the O
Wirsung O
. O

 O
Otherwise O
, O
gallbladder O
contains O
multiple O
gallstones O
and O
biliary O
sludge O
. O

 O
Tumor O
markers O
are O
normal.on O
the O
other O
hand O
, O
in O
colonoscopy O
terminal O
ileum O
appears O
swollen O
, O
inflamed O
, O
with O
frequent O
ulcerations O
and O
biopsies O
were O
made O
. O

 O
The O
biopsies O
were O
taken O
and O
show O
a O
subacute O
and O
ulcerative O
ileitis O
compatible O
with O
Crohn O
's O
disease O
. O

 O
Esophagogastroduodenoscopy O
was O
normal O
. O

 O
The O
patient O
was O
operated O
by O
laparoscopy O
, O
he O
had O
a O
caudal O
pancreatectomy O
and O
cholecystectomy O
.1.5 O
cm O
cystic O
tumor O
in O
the O
tail O
of O
pancreas O
was O
resected O
and O
sent O
for O
pathological O
examination O
. O

 O
The O
was O
uneventful O
. O

 O
Patient O
was O
in O
a O
good O
. O

 O
There O
were O
no O
after O
normal O
administration O
. O

 O
The O
revealed O
well O
differentiated O
cystic O
neuro B
endocrine I
tumor I
of O
the O
according O
to O
the O
classification O
of O
WHO O
2010 O
( O
mitosis O
< O
2/10CFG O
and O
Ki67<2 O
% O
) O
associated O
with O
neuroendocrine O
hyperplasia O
lesions O
of O
islets O
of O
Langerhans O
, O
surgical O
limit O
was O
healthy O
, O
pTNM O
pT2 O
, O
ectopic O
spleen O
, O
chronic O
cholecystitis O
. O

 O
the O
patient O
come O
for O
at O
the O
, O
he O
, O
with O
no O
severe O
and O
with O
correct O
periodic O
findings O
and O
normal O
. O

A O
( O
body O
surface O
area O
: O
1.3 O
m2 O
) O
known O
to O
have O
dilated B
cardiomyopathy I
( O
DCM B
) O
, O
was O
admitted O
for O
worsening O
heart B
failure I
( O
) O
. O

 O
He O
presented O
with O
a O
history O
of O
, O
progressive O
, O
and O
recurrent O
upper O
abdominal O
started O
. O

 O
On O
his O
were O
, O
, O
, O
and O
showed O
atrial B
fibrillation I
with O
. O

 O
revealed O
the O
jugular O
venous O
, O
significant O
tender O
and O
bilateral O
pitting O
at O
. O

 O
showed O
elevated O
of O
( O
normal O
0 O
to O
227 O
pg O
/ O
ml O
) O
and O
unremarkable O
. O

 O
and O
of O
the O
demonstrated O
consolidation O
of O
bilateral O
lower O
lobes O
with O
, O
while O
his O
venous O
of O
was O
. O

 O
Based O
on O
his O
clinical O
condition O
, O
was O
immediately O
inserted O
. O

 O
There O
were O
severe O
, O
especially O
of O
the O
( O
) O
( O
) O
with O
spherical O
shape O
, O
, O
impaired O
and O
severe O
mitral O
regurgitation O
on O
( O
) O
. O

 O
Parasternal O
short O
axis O
and O
subxyphoid O
view O
( O
Figure O
1 O
) O
showed O
the O
mobile O
right O
atrial O
highly O
suspicious O
of O
a O
thrombus B
traversing O
the O
during O
the O
cardiac O
cycle O
accompanying O
with O
free O
- O
floating O
small O
parts O
of O
the O
thrombi B
. O

 O
( O
) O
was O
performed O
to O
further O
confirm O
the O
nature O
of O
. O

 O
It O
showed O
a O
highly O
mobile O
thrombus B
, O
, O
measured O
which O
floating O
around O
the O
and O
( O
Figure O
2 O
) O
. O

 O
In O
addition O
, O
evaluated O
( O
) O
with O
( O
Figure O
3 O
) O
. O

 O
He O
was O
maintained O
on O
, O
, O
, O
and O
. O

 O
At O
the O
same O
time O
was O
started O
with O
low O
- O
molecular O
- O
weight O
and O
. O

 O
The O
patient O
had O
an O
uneventful O
and O
confirmed O
adequate O
removal O
of O
the O
thrombus B
( O
Figures O
4A O
and O
4B O
) O
. O

Our O
patient O
was O
a O
with O
chronic O
obstructive O
pulmonary O
disease O
. O

 O
She O
had O
but O
was O
found O
to O
have O
a O
progressive O
solitary O
pulmonary O
( O
) O
. O

 O
A O
right O
lower O
wedge O
was O
performed O
in O
and O
the O
identified O
the O
as O
a O
LCNEC B
. O

 O
Approximately O
her O
operation O
, O
our O
patient O
started O
having O
slowly O
progressing O
. O

 O
A O
( O
) O
scan O
performed O
in O
, O
, O
was O
for O
recurrence O
or O
metastasis O
. O

 O
Repeat O
( O
) O
in O
( O
) O
did O
not O
show O
any O
( O
Figure O
1 O
) O
. O

 O
Our O
patient O
had O
an O
( O
) O
and O
that O
revealed O
no O
of O
her O
but O
of O
and O
. O

 O
In O
, O
found O
of O
the O
, O
with O
a O
of O
. O

 O
Our O
patient O
was O
treated O
with O
with O
partial O
. O

 O
Thus O
far O
, O
resection O
, O
our O
patient O
had O
been O
able O
to O
maintain O
her O
and O
her O
, O
including O
, O
and O
levels O
. O

 O
However O
, O
in O
, O
she O
reported O
worsening O
and O
of O
. O

 O
She O
was O
to O
our O
for O
further O
treatment O
of O
her O
achalasia B
. O

 O
A O
repeat O
showed O
an O
elevated O
of O
as O
well O
non O
- O
propagative O
, O
non O
- O
peristaltic O
throughout O
her O
( O
Figure O
2 O
) O
. O

 O
A O
repeat O
with O
an O
intention O
to O
perform O
therapeutic O
showed O
a O
nearly O
circumferential O
ulcerated O
, O
fungating O
from O
approximately O
36 O
cm O
that O
extended O
to O
her O
. O

 O
Biopsies O
revealed O
a O
LCNEC B
with O
, O
and O
was O
concluded O
to O
be O
a O
. O

 O
Subsequently O
, O
a O
repeat O
revealed O
progressive O
diffuse O
metastatic B
disease I
. O

 O
Our O
patient O
underwent O
two O
courses O
of O
but O
from O
the O
disease O
. O

A O
had O
a O
diagnosis O
of O
MCTD B
with O
the O
presence O
of O
Raynaud B
's I
phenomenon I
, O
, O
elevated O
plasma O
, O
and O
antibodies O
against O
in O
and O
received O
10 O
mg O
of O
. O

 O
estimated O
by O
was O
( O
) O
in O
. O

 O
She O
felt O
progressive O
on O
in O
. O

 O
Pulmonary O
arterial O
hypertension O
was O
diagnosed O
with O
74 O
mmHg O
of O
( O
) O
evaluated O
by O
( O
) O
in O
. O

 O
Cyclophosphamide O
- O
based O
was O
proposed O
but O
refused O
because O
of O
possible O
early O
. O

 O
Treatment O
with O
of O
and O
of O
was O
initiated O
. O

 O
However O
, O
in O
, O
her O
deteriorated O
( O
) O
, O
and O
she O
was O
to O
our O
. O

 O
A O
showed O
low O
( O
) O
, O
( O
) O
, O
low O
( O
( O
) O
) O
, O
jugular O
venous O
, O
and O
severe O
systemic O
. O

 O
Coarse O
and O
were O
detected O
. O

 O
She O
was O
unable O
to O
undergo O
the O
due O
to O
severe O
. O

 O
showed O
elevated O
plasma O
( O
) O
level O
( O
) O
, O
( O
, O
) O
, O
and O
the O
( O
) O
as O
well O
as O
( O
, O
) O
. O

 O
A O
chest O
showed O
and O
( O
Figure O
) O
. O

 O
showed O
in O
the O
. O

 O
demonstrated O
elevated O
( O
) O
with O
normal O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
A O
showed O
no O
signs O
of O
pulmonary B
thromboembolism I
. O

 O
No O
signs O
of O
chronic B
obstructive I
pulmonary I
disease I
or O
interstitial B
lung I
diseases I
were O
found O
with O
. O

 O
Her O
was O
therefore O
considered O
to O
be O
due O
to O
MCTD O
- O
associated O
PAH B
which O
was O
refractory O
to O
and O
therapy O
. O

 O
In O
addition O
to O
with O
and O
( O
of O
) O
, O
initiation O
of O
of O
as O
well O
as O
gradual O
increment O
in O
the O
dose O
of O
was O
chosen O
as O
an O
additional O
treatment O
. O

 O
However O
, O
her O
remained O
unchanged O
, O
and O
her O
plasma O
level O
. O

 O
( O
) O
was O
initiated O
, O
and O
the O
dose O
of O
was O
increased O
to O
. O

 O
Her O
then O
ameliorated O
, O
and O
she O
became O
able O
to O
undergo O
the O
( O
, O
) O
. O

 O
Her O
plasma O
level O
also O
after O
the O
initiation O
of O
( O
Figure O
) O
. O

 O
the O
, O
a O
follow O
- O
up O
revealed O
improved O
( O
65 O
to O
) O
, O
( O
1,547 O
to O
) O
, O
and O
( O
1.69 O
to O
) O
( O
Table O
) O
. O

 O
Since O
she O
remained O
but O
did O
not O
obtain O
further O
improvements O
the O
( O
Table O
) O
, O
we O
consider O
parenteral O
or O
as O
a O
subsequent O
treatment O
. O

A O
with O
a O
history O
of O
. O

 O
He O
was O
diagnosed O
with O
a O
middle O
thoracic O
oesophageal O
squamous B
cell I
carcinoma I
by O
both O
a O
and O
a O
. O

 O
A O
chest O
( O
) O
scan O
showed O
an O
( O
a O
diameter O
of O
) O
that O
was O
a O
continuation O
of O
the O
( O
Fig.1a O
, O
b O
) O
. O

 O
A O
scan O
of O
the O
showed O
a O
in O
the O
and O
direct O
of O
the O
into O
the O
. O

 O
After O
with O
the O
and O
the O
, O
we O
decided O
to O
perform O
a O
McKeown O
. O

 O
The O
patient O
was O
with O
a O
and O
underwent O
a O
standard O
posterolateral O
by O
. O

 O
We O
first O
performed O
the O
jugular O
and O
femoral O
vein O
percutaneous O
puncture O
to O
create O
a O
and O
then O
connected O
the O
to O
the O
monitor O
. O

 O
The O
monitor O
displayed O
the O
real O
- O
time O
pressure O
value O
of O
the O
jugular O
vein O
and O
the O
femoral O
vein O
. O

 O
, O
the O
of O
the O
was O
approximately O
( O
Fig.1c O
) O
, O
and O
the O
superior O
edge O
of O
the O
adhered O
tightly O
to O
the O
. O

 O
When O
the O
arch O
of O
the O
azygos O
vein O
was O
with O
a O
to O
dissociate O
it O
from O
the O
, O
the O
monitor O
showed O
that O
the O
femoral O
vein O
to O
; O
the O
pressure O
returned O
to O
a O
when O
we O
opened O
the O
between O
the O
femoral O
vein O
and O
the O
jugular O
vein O
( O
Fig.2 O
) O
. O

 O
The O
surgery O
was O
performed O
smoothly O
, O
without O
injury B
to O
the O
, O
and O
the O
was O
. O

 O
The O
pathology O
of O
the O
resected O
specimen O
showed O
a O
poorly O
differentiated O
squamous B
cell I
carcinoma I
and O
no O
evidence O
of O
in O
15 O
of O
the O
. O

 O
After O
of O
, O
the O
patient O
was O
, O
with O
no O
evidence O
of O
recurrent B
disease I
either O
clinically O
or O
on O
. O

A O
with O
a O
of O
enlarging O
involving O
the O
history O
of O
trauma O
. O

 O
Physical O
examination O
showed O
a O
mass O
of O
an O
3x4 O
cm O
in O
diameter O
, O
localized O
in O
the O
right O
inter O
- O
scapular O
region O
. O

 O
The O
mass O
was O
ulcerative O
helophytic O
, O
grayish O
in O
colour O
, O
hard O
in O
consistency O
and O
easily O
bleeding O
on O
manipulation O
. O

 O
The O
remainder O
of O
the O
examination O
was O
unremarkable O
; O
no O
lymphadenopathy O
and O
no O
abdominal O
masses O
were O
felt O
. O

 O
After O
resection O
, O
the O
histological O
examinations O
of O
the O
specimens O
have O
concluded O
for O
basal O
cell O
carcinoma O
. O

 O
A O
local O
recurrence O
was O
observed O
18 O
months O
later O
; O
the O
patient O
was O
admitted O
to O
our O
institution O
for O
Lumpectomy O
( O
Figure O
1 O
) O
. O

 O
Histopathological O
examination O
revealed O
a O
syringomatous O
pattern O
infiltrating O
the O
dermis O
( O
Figure O
2 O
, O
Figure O
3 O
) O
, O
subcutis O
and O
skeletal O
muscle O
. O

 O
The O
neoplastic O
epithelial O
cells O
were O
arranged O
in O
interconnecting O
cords O
with O
microcystic O
areas O
. O

 O
Nests O
, O
cords O
, O
and O
tubules O
of O
the O
tumour O
extended O
into O
the O
dermis O
and O
into O
the O
adjacent O
muscle O
. O

 O
Many O
lobules O
showed O
squamous O
differentiation O
. O

 O
Sclerosis O
of O
stroma O
around O
the O
cords O
was O
present O
. O

 O
Tumour O
cells O
were O
not O
connected O
to O
the O
epidermis O
. O

 O
The O
immunohistochemical O
analysis O
showed O
positivity O
for O
anti O
- O
CK7 O
( O
Figure O
4 O
) O
, O
AE1 O
/ O
AE3 O
and O
negativity O
for O
anti O
CEA O
and O
anti O
CK20 O
. O

 O
Based O
upon O
her O
histological O
and O
immunohistochemical O
presentation O
, O
the O
diagnosis O
of O
syringomatous B
eccrine I
carcinoma I
was O
established O
. O

 O
of O
the O
involved O
area O
was O
performed O
( O
) O

, O
a O
patient O
complaining O
of O
local O
bone O
in O
the O
. O

 O
On O
, O
the O
patient O
underwent O
a O
left O
distal O
femoral O
tumor O
en O
bloc O
resection O
and O
reconstruction O
with O
a O
modular O
femoral O
prosthetic O
system O
. O

 O
Pathology O
diagnosis O
confirmed O
osteoblastic O
osteosarcoma B
( O
Fig.2 O
) O
. O

 O
One O
cycle O
of O
neoadjuvant O
and O
of O
with O
( O
high O
- O
dose O
, O
, O
and O
) O
were O
administered O
. O

 O
In O
, O
a O
was O
found O
on O
the O
. O

 O
Tumor O
was O
confirmed O
by O
on O
. O

 O
However O
, O
only O
an O
upper O
femur O
was O
carried O
out O
, O
as O
the O
patient O
refused O
hip O
. O

 O
After O
, O
the O
patient O
in O
the O
help O
of O
, O
but O
refused O
to O
receive O
further O
due O
to O
concerns O
regarding O
the O
chemotherapy O
toxicities O
such O
as O
nausea O
, O
vomiting O
, O
leucopenia O
, O
deadlimb O
, O
and O
headache O
. O

 O
About O
the O
amputation O
, O
the O
patient O
got O
occasional O
and O
chest O
. O

 O
Then O
a O
thin O
chest O
( O
) O
was O
performed O
on O
. O

 O
The O
CT O
results O
revealed O
multiple O
pulmonary O
( O
Table O
1 O
) O
, O
considering O
the O
possibility O
of O
. O

 O
The O
patient O
still O
rejected O
further O
. O

 O
was O
suggestive O
of O
CD31 O
+ O
and O
CD34 O
+ O
cells O
( O
Fig.3 O
) O
. O

 O
Furthermore O
, O
most O
showed O
strong O
positive O
( O
Fig.3 O
) O
. O

 O
was O
administered O
at O
a O
dose O
of O
. O

 O
Half O
a O
month O
later O
, O
the O
symptoms O
disappeared O
, O
but O
a O
progressive O
wound O
necrosis O
appeared O
. O

 O
A O
debridement O
surgery O
was O
finally O
conducted O
and O
an O
enlarged O
lymph O
node O
near O
iliac O
vessels O
was O
resected O
on O
February O
24 O
, O
2016 O
( O
Fig.(Fig.4).4 O
) O
. O

 O
The O
result O
of O
pathological O
examination O
revealed O
an O
inflammatory O
hyperplasia O
lymph O
node O
. O

 O
Apatinib O
administration O
was O
stopped O
during O
the O
3 O
weeks O
of O
wound O
healing O
period O
. O

 O
The O
thin O
chest O
CT O
was O
performed O
7 O
and O
11 O
months O
following O
apatinib O
administration O
. O

 O
At O
the O
7 O
- O
month O
follow O
- O
up O
time O
point O
, O
2 O
out O
of O
5 O
measurable O
and O
9 O
out O
of O
17 O
non O
- O
measurable O
lesions O
disappeared O
, O
but O
1 O
new O
measurable O
nodule O
and O
6 O
new O
non O
- O
measurable O
lesions O
were O
observed O
( O
Table O
1 O
, O
Fig.5 O
) O
, O
which O
considered O
PD O
according O
to O
the O
Response O
Evaluation O
Criteria O
in O
Solid O
Tumors O
( O
RECIST O
) O
1.1 O
standard O
. O

 O
However O
, O
at O
the O
11 O
- O
month O
follow O
- O
up O
time O
point O
, O
a O
total O
of O
9 O
lesions O
disappeared O
, O
including O
1 O
measurable O
nodule O
and O
2 O
non O
- O
measurable O
lesions O
presented O
before O
apatinib O
treatment O
as O
well O
as O
6 O
non O
- O
measureable O
lesions O
presented O
7 O
months O
after O
apatinib O
treatment O
. O

 O
No O
new O
lesion O
was O
raised O
. O

 O
After O
target O
lesion O
measurement O
according O
to O
the O
RECIST O
1.1 O
standard O
, O
it O
was O
narrowly O
considered O
PR O
. O

 O
The O
toxicities O
the O
patient O
experienced O
included O
mild O
hand O
- O
foot O
syndrome O
and O
slight O
high O
blood O
pressure O
. O

 O
Both O
were O
well O
controlled O
after O
appropriate O
treatment O
. O

 O
No O
severe O
toxicities O
and O
other O
treatment O
- O
related O
adverse O
events O
were O
observed O
. O

 O
The O
patient O
continued O
to O
use O
apatinib O
as O
maintenance O
therapy O
without O
major O
toxic O
effects O
, O
and O
went O
back O
to O
normal O
life O
, O
even O
an O
. O

A O
visited O
our O
outpatient O
clinic O
with O
a O
mass O
on O
his O
left O
hip O
. O

 O
He O
had O
and O
. O

 O
On O
, O
a O
large O
measuring O
10 O
cm O
in O
diameter O
was O
observed O
on O
his O
hip O
and O
an O
approximate O
5 O
cm O
left O
inguinal O
lymph O
node O
was O
palpable O
( O
Figure O
1 O
) O
. O

 O
Serum O
tumor O
markers O
, O
including O
CEA O
and O
CA O
19 O
- O
9 O
, O
were O
within O
normal O
limits O
, O
whereas O
serum O
amylase O
( O
227 O
IU O
/ O
L O
, O
normal O
range O
43 O
- O
116 O
IU O
/ O
L O
) O
, O
lipase O
( O
378 O
IU O
/ O
L O
, O
normal O
range O
7 O
- O
60 O
) O
, O
fasting O
blood O
sugar O
( O
144 O
mg O
/ O
dL O
, O
normal O
range O
, O
70 O
- O
100 O
mg O
/ O
dL O
) O
, O
and O
liver O
function O
test O
levels O
[ O
including O
aspartate O
aminotransferase O
( O
178 O
IU O
/ O
L O
, O
normal O
range O
, O
7 O
- O
38 O
IU O
/ O
L O
) O
, O
alanine O
aminotransferase O
( O
225 O
IU O
/ O
L O
; O
normal O
range O
, O
4 O
- O
43 O
IU O
/ O
L O
) O
, O
and O
serum O
alkaline O
phosphatase O
( O
370 O
IU O
/ O
L O
, O
normal O
range O
, O
103 O
- O
335 O
IU O
/ O
L O
) O
] O
were O
all O
above O
normal O
ranges O
. O

 O
An O
abdominal O
computerized O
tomography O
( O
CT O
) O
scan O
demonstrated O
not O
only O
a O
left O
hip O
mass O
and O
an O
enlarged O
left O
inguinal O
lymph O
node O
, O
but O
also O
a O
huge O
heterogeneous O
enhancing O
mass O
on O
the O
body O
of O
the O
pancreas O
( O
Figure O
2 O
) O
. O

 O
On O
a O
PET O
scan O
, O
additional O
metastases O
were O
not O
found O
. O

 O
We O
planned O
a O
staged O
surgery O
and O
performed O
a O
hip O
and O
inguinal O
mass O
excision O
on O
December O
19 O
, O
2014 O
. O

 O
The O
histopathological O
report O
revealed O
a O
metastatic O
small O
cell O
neuroendocrine O
carcinoma O
with O
a O
maximal O
diameter O
of O
10.5 O
cm O
on O
the O
buttock O
mass O
and O
a O
7 O
cm O
growth O
on O
an O
inguinal O
lymph O
node O
. O

 O
The O
mitotic O
index O
was O
over O
50 O
mitoses O
per O
50 O
HPF O
and O
the O
Ki-67 O
index O
measured O
at O
50 O
% O
. O

 O
On O
January O
21 O
, O
2015 O
, O
we O
performed O
a O
total O
pancreatectomy O
and O
a O
total O
gastrectomy O
, O
with O
the O
findings O
revealing O
a O
tumor O
of O
the O
body O
of O
the O
pancreas O
about O
9 O
cm O
 O
6 O
cm O
in O
diameter O
involving O
the O
left O
gastric O
artery O
, O
splenic O
artery O
, O
and O
splenic O
vein O
. O

 O
The O
histopathological O
report O
was O
the O
same O
as O
that O
of O
a O
metastatic O
lesion O
. O

 O
Additionally O
, O
the O
tumor O
had O
spread O
to O
8 O
of O
the O
32 O
lymph O
nodes O
( O
Figure O
3 O
) O
. O

 O
On O
the O
7th O
post O
- O
operative O
day O
, O
the O
patient O
developed O
a O
high O
fever O
and O
leukocytosis O
. O

 O
We O
administered O
an O
abdominal O
CT O
scan O
, O
which O
revealed O
infected O
fluid O
collection O
in O
the O
lesser O
sac O
and O
a O
4.7 O
cm O
- O
sized O
recurring O
mass O
which O
was O
detected O
at O
the O
operative O
bed O
of O
the O
left O
hip O
( O
Figure O
(Figure4).4 O
) O
. O

 O
After O
infection O
of O
the O
abdominal O
cavity O
was O
treated O
by O
antibiotics O
, O
we O
removed O
the O
left O
hip O
recurring O
mass O
on O
February O
3 O
, O
2015 O
. O

 O
The O
histopathology O
was O
the O
same O
as O
in O
the O
previous O
report O
; O
with O
a O
maximum O
diameter O
of O
7.5 O
cm O
. O

 O
The O
patient O
was O
discharged O
without O
other O
complications O
on O
February O
9 O
, O
2015 O
. O

 O
He O
is O
currently O
receiving O
based O
on O
and O
treatment O
. O

A O
was O
to O
because O
of O
and O
. O

 O
Her O
medical O
history O
included O
with O
regular O
hemodialysis O
3 O
times O
per O
week O
for O
, O
hyperuricemia B
and O
gout B
. O

 O
She O
also O
had O
comorbidity O
such O
as O
dyslipidemia B
, O
, O
secondary O
hyperparathyroidism B
, O
and O
diabetes B
. O

 O
The O
revealed O
a O
white O
blood O
cell O
count O
( O
WBC O
) O
of O
700 O
/ O
L O
, O
with O
2 O
% O
neutrophils O
, O
94 O
% O
lymphocytes O
and O
2 O
% O
monocytes O
, O
hemoglobin O
11.1 O
 O
g O
/ O
dL O
, O
and O
platelet O
count O
, O
131,000 O
/ O
L. O

 O
Under O
the O
impression O
of O
febrile O
neutropenia O
and O
acute O
pharyngitis O
, O
she O
was O
admitted O
to O
our O
hematologic O
ward O
for O
further O
survey O
and O
management O
. O

 O
Broad O
- O
spectrum O
with O
2 O
 O
g O
and O
0.25 O
 O
gm O

 O
q8h O
had O
been O
administered O
and O
her O
infection O
sign O
resolved O
gradually O
. O

 O
Upon O
admission O
, O
we O
reviewed O
her O
oral O
medication O
: O
glipizide O
5 O
 O
mg O
tid O
, O
saxagliptin O
2.5 O
 O
mg O
qd O
, O
fenofibrate O
600 O
 O
mg O
qd O
, O
aluminum O
hydroxide O
324 O
 O
mg O
tid O
, O
folic O
acid O
5 O
 O
mg O
qd O
, O
calcium O
carbonate O
1000 O
 O
mg O
tid O
, O
and O
febuxostat O
40 O
 O
mg O
qd O
. O

 O
Besides O
, O
she O
also O
received O
epoetin O
- O
beta O
2000 O
iu O
i.v.tiw O
. O

 O
Except O
for O
febuxostat O
, O
all O
the O
other O
drugs O
had O
been O
used O
for O
more O
than O
1 O
year O
. O

 O
Febuxostat O
was O
administered O
2 O
months O
before O
admission O
for O
inadequate O
serum O
uric O
acid O
control O
by O
allopurinol O
50 O
 O
mg O
qd O
. O

 O
Two O
weeks O
before O
febuxostat O
exposure O
, O
routine O
laboratory O
test O
revealed O
WBC O
6000 O
/ O
L O
and O
serum O
uric O
acid O
level O
9.8 O
 O
mg O
/ O
dL. O

 O
Febuxostat O
was O
discontinued O
thereafter O
due O
to O
the O
causal O
relationship O
of O
agranulocytosis O
can O
not O
be O
excluded O
. O

 O
Besides O
, O
we O
also O
surveyed O
viral O
infection O
and O
autoimmune O
disorder O
. O

 O
There O
were O
no O
clinical O
or O
laboratory O
evidence O
of O
Epstein O
 O
Barr O
virus O
, O
cytomegalovirus O
, O
or O
human O
immunodeficiency O
virus O
infections O
; O
antinuclear O
antibody O
( O
ANA O
) O
and O
antiextractable O
nuclear O
antigen O
( O
anti O
- O
ENA O
) O
were O
both O
negative O
. O

 O
Bone O
marrow O
examination O
during O
hospitalization O
showed O
hypocellular O
marrow O
with O
a O
marked O
decrease O
in O
myeloid O
component O
but O
no O
evidence O
of O
hematologic O
neoplasms O
. O

 O
of O
was O
. O

 O
The O
patient O
. O

 O
After O
stopping O
for O
, O
her O
neutropenia O
improved O
significantly O
( O
WBC O
2100 O
/ O
L O
, O
and O
neutrophil O
66 O
% O
) O
, O
without O
any O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
support O
. O

 O
After O
, O
her O
and O
was O
completely O
during O
( O
Fig.1 O
) O
. O

 O
This O
study O
was O
approved O
by O
our O
institutional O
review O
board O
. O

A O
with O
lifelong O
secondary O
to O
was O
referred O
for O
symptoms O
of O
and O
( O
) O
. O

 O
She O
averaged O
one O
Bristol O
Type O
12 O
stool O
every O
5 O
days O
requiring O
frequent O
. O

 O
Additionally O
, O
she O
reported O
twice O
weekly O
episodes O
of O
urgent O
, O
which O
required O
the O
use O
of O
daily O
. O

 O
Her O
symptoms O
did O
not O
improve O
with O
the O
addition O
of O
and O
. O

 O
A O
suggested O
of O
the O
and O
with O
EAS O
muscle O
. O

 O
( O
) O
showed O
a O
normal O
resting O
pressure O
with O
no O
augmentation O
of O
squeeze O
pressure O
, O
consistent O
with O
weak O
EAS O
( O
Figure O
1 O
) O
. O

 O
During O
bearing O
down O
, O
fixed O
perineal O
descent O
was O
noted O
with O
the O
inability O
to O
widen O
the O
posterior O
anorectal O
angle O
and O
poor O
evacuation O
of O
contrast O
with O
straining O
, O
consistent O
with O
DD O
. O

 O
With O
pushing O
, O
ARM O
similarly O
demonstrated O
type O
IV O
DD O
, O
which O
is O
classified O
as O
inability O
to O
generate O
adequate O
propulsive O
forces O
along O
with O
absent O
or O
incomplete O
relaxation O
of O
the O
anal O
sphincter O
[ O
8 O
] O
( O
Figure O
2 O
) O
. O

 O
Reflex O
and O
sensory O
testing O
indicated O
an O
intact O
rectoanal O
inhibitory O
reflex O
and O
rectal O
hypersensitivity O
. O

 O
The O
patient O
failed O
management O
with O
home O
and O
conventional O
biofeedback O
therapy O
. O

 O
Following O
a O
successful O
trial O
of O
temporary O
SNS O
with O
improvement O
in O
FI O
symptoms O
by O
75 O
% O
, O
the O
patient O
had O
a O
permanent O
SNS O
placed O
. O

 O
, O
the O
patient O
reports O
sustained O
improvement O
in O
and O
symptoms O
. O

A O
with O
a O
past O
medical O
history O
of O
poorly O
controlled O
hypertension B
and O
type B
2 I
diabetes I
, O
to O
the O
for O
a O
cardiogenic B
shock I
complicating O
acute O
myocardial B
infarction I
. O

 O
revealed O
reduced O
( O
) O
and O
weak O
; O
a O
of O
, O
80 O
% O
of O
, O
capillary O
at O
, O
a O
, O
and O
in O
. O

 O
showed O
neither O
nor O
. O

 O
on O
showed O
normal O
sinus O
, O
with O
of O
and O
in O
. O

 O
demonstrated O
level O
of O
, O
( O
) O
was O
, O
was O
, O
level O
, O
and O
18.6 O
mg O
/ O
L. O

 O
The O
patient O
was O
and O
, O
were O
started O
( O
0.4g O
/ O
kg O
/ O
min O
and O
) O
. O

 O
Chest O
showed O
diffuse O
alveolar B
syndrome I
. O

 O
Transthoracic O
revealed O
namely O
extensive O
of O
anteroseptal O
, O
anterior O
, O
lateral O
and O
inferior O
, O
and O
( O
of O
) O
. O

 O
was O
initiated O
; O
therapy O
for O
acute O
coronary O
syndrome O
was O
started O
( O
500 O
mg O
of O
and O
( O
0.6ml O
of O
) O
) O
and O
patient O
was O
prepared O
for O
by O
coronary O
. O

 O
Because O
of O
non O
- O
improvement O
of O
and O
occurrence O
of O
, O
a O
brain O
was O
indicated O
and O
revealed O
infratentorial O
diffuse O
( O
) O
( O
Figure O
1 O
) O
. O

 O
Cerebral O
confirmed O
a O
dissecting B
aneurysm I
of O
an O
between O
and O
the O
Figure O
2 O
that O
was O
successfully O
. O

 O
, O
the O
patient O
improved O
with O
withdrawal O
of O
in O
. O

 O
Left O
hemicorporeal O
persisted O
despite O
treatment O
. O

 O
Control O
brain O
did O
not O
report O
and O
showed O
complete O
exclusion O
of O
the O
aneurysm B
while O
the O
revealed O
a O
diffuse O
brain B
damage I
. O

 O
admission O
, O
the O
patient O
was O
in O
stable O
but O
still O
suffers O
from O
amnesia B
. O

An O
with O
and O
gout B
was O
to O
Taichung O
Veterans O
General O
Hospital O
due O
to O
abdominal O
and O
. O

 O
She O
began O
to O
suffer O
from O
intermittent O
, O
and O
a O
4 O
cm O
gastric O
was O
found O
. O

 O
The O
abdominal O
admission O
, O
and O
she O
to O
a O
where O
abdominal O
scan O
revealed O
a O
gastric O
about O
in O
length O
with O
well O
- O
circumscribed O
calcification(figure O
1 O
) O
. O

 O
was O
suggested O
, O
but O
she O
declined O
. O

 O
About O
admission O
, O
passage O
was O
noted O
, O
and O
was O
found O
. O

 O
revealed O
submucosal O
gastric O
with O
and O
she O
was O
then O
to O
our O
. O

 O
showed O
upper O
abdominal O
with O
mild O
muscle O
. O

 O
The O
plain O
showed O
an O
irregular O
shape O
over O
. O

 O
revealed O
deep O
gastric O
with O
. O

 O
scan O
showed O
an O
irregularly O
shaped O
space O
- O
occupying O
in O
front O
of O
the O
with O
plate O
calcifications O
and O
localized O
( O
figures O
2 O
and O
3 O
) O
. O

 O
Under O
the O
impression O
of O
perforated O
gastric O
tumor O
, O
emergent O
was O
performed O
. O

 O
An O
infiltrative O
between O
the O
and O
was O
noted O
during O
operation O
. O

 O
A O
sharp O
, O
bone O
- O
like O
and O
thick O
penetrating O
into O
the O
and O
was O
observed O
. O

 O
A O
submucosal O
about O
in O
size O
adherent O
to O
the O
was O
also O
noted O
( O
figures O
4 O
and O
5 O
) O
. O

 O
Distal O
subtotal O
and O
partial O
were O
performed O
. O

 O
The O
patient O
was O
operation O
uneventfully O
. O

 O
Microscopically O
, O
spindle O
- O
shaped O
with O
low O
( O
) O
were O
found O
. O

 O
of O
the O
demonstrated O
diffusely O
strong O
positive O
reactivity O
for O
, O
positive O
reactivity O
for O
, O
but O
negative O
reactivity O
for O
and O
. O

 O
The O
diagnosis O
of O
the O
tumor O
was O
established O
as O
GIST B
. O

 O
Due O
to O
the O
small O
size O
and O
the O
paucity O
of O
mitotic O
figures O
of O
the O
tumor O
located O
in O
the O
stomach O
, O
it O
was O
classified O
as O
very O
low O
risk[4 O
] O
. O

 O
Sporadic O
GIST O
was O
impressed O
due O
to O
nor O
other O
GIST O
presented O
in O
this O
patient O
. O

A O
to O
our O
with O
severe O
abdominal O
. O

 O
She O
had O
. O

 O
She O
said O
that O
she O
had O
intermittent O
bloody O
. O

 O
revealed O
rebound O
and O
over O
the O
. O

 O
was O
for O
amoeba O
trophozoites O
or O
any O
parasites O
. O

 O
was O
. O

 O
Sedimentation O
was O
27 O
mm O
/ O
s O
, O
CRP O
( O
nephelometry O
) O
was O
65.6 O
mg O
/ O
L O
( O
normal O
range O
05 O
) O
, O
anti O
- O
nuclear O
antibody O
was O
0.4 O
( O
00.8 O
negative O
) O
, O
anti O
- O
ds O
DNA O
< O
10 O
( O
< O
20 O
negative O
) O
, O
white O
blood O
cell O
count O
was O
14.98 O
( O
normal O
range O
410 O
) O
, O
hemoglobin O
level O
was O
10.9 O
, O
neutro O
- O
phil O
count O
was O
13.14 O
, O
platelet O
count O
was O
473 O
( O
100300 O
) O
, O
urea O
level O
was O
17 O
mg O
/ O
dl O
, O
BUN O
level O
was O
7.94 O
mg O
/ O
dl O
, O
creatinine O
level O
was O
0.56 O
mg O
/ O
dl O
, O
AST O
was O
20 O
U O
/ O
L O
, O
and O
ALT O
was O
24 O
U O
/ O
L. O

 O
was O
. O

 O
Abdominal O
scanning O
showed O
free O
fluid O
at O
the O
right O
paracolic O
, O
perihepatic O
, O
left O
paracolic O
gutters O
and O
pelvis O
. O

 O
Upon O
detection O
of O
air O
- O
fluid O
level O
and O
free O
air O
under O
the O
diaphragm O
on O
erect O
abdominal O
, O
emergency O
was O
performed O
. O

 O
In O
the O
operation O
, O
multiple O
areas O
were O
found O
in O
the O
, O
, O
and O
. O

 O
Wide O
of O
the O
with O
descending O
and O
sigmoid O
colon O
was O
undertaken O
( O
Figure O
1 O
) O
. O

 O
was O
. O

 O
The O
patient O
had O
recurrent O
oral O
and O
genital O
aphthous O
ulcers B
. O

 O
results O
were O
. O

 O
revealed O
extensive O
thrombus B
within O
the O
extending O
through O
the O
( O
Figure O
2 O
) O
. O

 O
The O
patient O
received O
, O
, O
and O
. O

 O
Our O
patient O
is O
still O
and O
( O
Figure O
3 O
) O
. O

 O
In O
, O
the O
was O
and O
and O
were O
in O
length O
. O

 O
were O
in O
diameter O
. O

 O
Perforation B
areas O
were O
evident O
in O
the O
. O

 O
Colonic O
wall O
and O
bowel O
mucosa O
was O
and O
. O

 O
were O
in O
their O
course O
. O

 O
There O
were O
3 O
roundish O
, O
punched O
- O
out O
perforations B
in O
the O
and O
in O
the O
, O
which O
were O
somewhat O
separate O
from O
the O
colonic O
wall O
, O
with O
the O
in O
diameter O
( O
Figure O
4 O
) O
. O

 O
There O
were O
multiple O
ulcers O
( O
the O
largest O
was O
1 O
cm O
in O
diameter O
) O
in O
different O
locations O
, O
which O
were O
not O
merging O
together O
, O
and O
were O
somewhat O
separate O
from O
the O
surrounding O
mucosa O
via O
a O
certain O
limit O
, O
covered O
with O
exudate O
and O
surrounded O
by O
a O
hyperemic O
region O
. O

 O
There O
were O
no O
in O
the O
. O

 O
Numerous O
samples O
were O
taken O
from O
ulcerated O
and O
perforated O
regions O
and O
normal O
mucosa O
. O

 O
The O
samples O
were O
submitted O
for O
routine O
. O

 O
, O
and O
were O
prepared O
for O
examination O
. O

 O
In O
, O
there O
were O
neutrophil O
leukocyte O
and O
lymphocyte O
reaction O
around O
and O
within O
the O
walls O
and O
lumens O
of O
arterioles O
, O
and O
venules O
around O
the O
perforated O
and O
ulcerated O
lesions O
( O
Figures O
5 O
and O
and6).6 O
) O
. O

 O
There O
were O
well O
- O
organized O
thrombi O
and O
intimal O
proliferation O
within O
some O
vessels O
( O
Figures O
7 O
and O
and8).8 O
) O
. O

 O
There O
was O
marked O
acute O
peritonitis O
. O

 O
Surface O
epithelium O
and O
colonic O
crypts O
were O
regular O
within O
the O
colonic O
mucosa O
apart O
from O
the O
ulcerated O
or O
perforated O
lesions O
. O

 O
Samples O
were O
free O
of O
parasites B
or O
their O
eggs O
. O

The O
patient O
, O
a O
, O
was O
first O
diagnosed O
with O
medulloblastoma B
at O
. O

 O
included O
of O
the O
followed O
by O
systemic O
( O
, O
, O
, O
, O
, O
) O
, O
and O
craniospinal O
( O
) O
with O
boost O
to O
the O
posterior O
fossa O
( O
) O
. O

 O
was O
subsequently O
administered O
for O
eleven O
, O
14 O
- O
day O
cycles O
( O
) O
, O
over O
a O
for O
a O
cumulative O
dose O
of O
( O
) O
. O

 O
She O
completed O
at O
. O

 O
At O
, O
she O
was O
diagnosed O
with O
radiation O
- O
induced O
central O
hypothyroidism B
and O
growth B
hormone I
deficiency I
( O
GHD B
) O
. O

 O
She O
was O
treated O
with O
with O
subsequent O
biochemical O
. O

 O
Given O
status O
and O
an O
abnormal O
of O
, O
( O
) O
therapy O
was O
initiated O
at O
( O
) O
with O
subsequent O
increased O
of O
; O
however O
, O
initiation O
of O
, O
increased O
was O
noted O
at O
and O
, O
concomitant O
with O
declining O
( O
) O
. O

 O
and O
were O
significant O
for O
discrepancy O
: O
the O
right O
lower O
extremity O
1.75 O
cm O
shorter O
than O
the O
left O
( O
right O
femur O
24.9 O
cm O
, O
right O
tibia O
19.6 O
cm O
, O
right O
lower O
extremity O
44.5 O
cm O
, O
left O
femur O
25.25 O
cm O
, O
left O
tibia O
21 O
cm O
, O
and O
left O
lower O
extremity O
46.25 O
cm O
) O
. O

 O
Prior O
to O
initiation O
of O
GH O
, O
height O
( O
102 O
cm O
) O
( O
Figure O
1 O
) O
and O
armspan O
( O
102 O
cm O
) O
were O
similar O
, O
with O
upper O
segment O
/ O
lower O
segment O
ratio O
of O
one O
; O
seven O
months O
after O
GH O
, O
height O
increased O
minimally O
( O
105.6 O
cm O
) O
compared O
to O
the O
more O
significant O
increase O
in O
armspan O
( O
109.2 O
cm O
) O
, O
with O
upper O
segment O
/ O
lower O
segment O
ratio O
remaining O
at O
one O
. O

 O
revealed O
poorly O
visualized O
growth O
plates O
in O
both O
distal O
and O
proximal O
femurs O
and O
tibias O
( O
Figure O
2A O
- O
B O
) O
, O
raising O
concern O
for O
premature B
closure I
of I
the I
physes I
. O

 O
This O
lower O
limb O
growth O
plate O
closure O
would O
normally O
be O
observed O
at O
the O
time O
of O
late O
- O
stage O
puberty O
. O

 O
By O
contrast O
, O
all O
using O
left O
hand O
and O
wrist O
over O
the O
displayed O
open O
( O
Figure O
2C O
- O
D O
) O
. O

A O
with O
a O
history O
of O
stage O
IV O
chronic B
kidney I
disease I
and O
three O
- O
vessel O
coronary O
artery O
disease O
was O
admitted O
for O
coronary O
artery O
bypass O
graft O
surgery O
and O
mitral O
valve O
repair O
. O

 O
On O
post O
- O
operative O
day O
two O
, O
the O
patient O
developed O
cardiac O
tamponade O
and O
subsequently O
progressed O
to O
a O
cardiac O
arrest O
while O
temporary O
pacing O
wires O
were O
being O
removed O
. O

 O
Advanced O
cardiovascular O
life O
support O
and O
emergent O
exploratory O
sternotomy O
were O
performed O
, O
and O
the O
patient O
was O
transferred O
to O
the O
intensive O
care O
unit O
( O
ICU O
) O
for O
further O
care O
. O

 O
During O
the O
patient O
s O
ICU O
admission O
, O
his O
renal O
failure O
progressed O
, O
requiring O
hemodialysis O
. O

 O
A O
nasogastric O
tube O
was O
placed O
on O
post O
- O
operative O
day O
two O
for O
establishing O
early O
enteral O
nutrition O
. O

 O
PEG O
tube O
insertion O
was O
suggested O
given O
his O
cognitive O
impairment O
and O
poor O
swallowing O
function O
on O
the O
Modified O
Barium O
Swallow O
test O
. O

 O
His O
coagulation O
profile O
prior O
to O
the O
procedure O
revealed O
an O
international O
normalized O
ratio O
of O
1.04 O
and O
partial O
thromboplastin O
time O
of O
36 O
seconds O
. O

 O
A O
complete O
blood O
count O
showed O
a O
hemoglobin O
of O
11.6 O
grams O
per O
deciliter O
, O
a O
hematocrit O
of O
34.9 O
% O
, O
and O
281103 O
platelets O
per O
microliter O
. O

 O
His O
blood O
urea O
nitrogen O
was O
55 O
milligrams O
/ O
deciliter O
, O
and O
his O
serum O
creatinine O
was O
5.22 O
milligrams O
/ O
deciliter O
. O

 O
The O
patient O
was O
taking O
aspirin O
81 O
mg O
per O
day O
due O
to O
recent O
cardiac O
surgery O
, O
but O
was O
not O
on O
any O
anticoagulant O
agents O
. O

 O
He O
also O
did O
not O
have O
a O
history O
of O
coagulopathy O
. O

 O
PEG O
tube O
insertion O
was O
performed O
on O
post O
- O
operative O
day O
eight O
under O
intravenous O
anesthesia O
. O

 O
The O
esophagogastroduodenoscopy O
( O
EGD O
) O
was O
accomplished O
without O
difficulty O
, O
revealing O
diffuse O
moderately O
erythematous O
mucosa O
without O
bleeding O
in O
the O
gastric O
antrum O
. O

 O
While O
attempting O
PEG O
tube O
placement O
, O
a O
rapidly O
expanding O
hematoma O
( O
Figure O
1 O
) O
developed O
at O
the O
needle O
insertion O
site O
. O

 O
The O
procedure O
was O
stopped O
and O
the O
patient O
was O
sent O
back O
to O
the O
ICU O
with O
a O
nasogastric O
tube O
. O

 O
A O
single O
dose O
of O
intravenous O
desmopressin O
( O
0.3 O
microgram O
/ O
kilogram O
) O
was O
administered O
under O
the O
suspicion O
of O
uremic O
bleeding O
. O

 O
No O
further O
gastrointestinal O
bleeding O
events O
were O
noted O
. O

 O
To O
assess O
platelet O
function O
, O
a O
platelet O
function O
assay O
( O
PFA O
) O
was O
ordered O
after O
desmopressin O
injection O
. O

 O
PFA O
collagen O
/ O
epinephrine O
closure O
time O
was O
195 O
seconds O
( O
normal O
< O
174 O
seconds O
) O
, O
and O
collagen O
/ O
ADP O
closure O
time O
was O
76 O
seconds O
( O
normal O
< O
120 O
seconds O
) O
, O
indicating O
platelet O
dysfunction O
due O
to O
either O
aspirin O
or O
uremia O
. O

 O
was O
discontinued O
, O
and O
he O
was O
with O
a O
daily O
and O
. O

 O
the O
patient O
underwent O
a O
second O
attempt O
at O
. O

 O
prior O
to O
this O
had O
to O
, O
possibly O
due O
to O
withholding O
and O
an O
improvement O
in O
. O

 O
showed O
an O
area O
of O
flat O
, O
bluish O
gastric O
submucosal O
at O
the O
site O
of O
the O
previous O
( O
Figure O
2 O
) O
. O

 O
The O
was O
placed O
successfully O
at O
an O
. O

 O
Over O
the O
course O
of O
the O
, O
the O
patient O
continued O
to O
undergo O
through O
the O
with O
no O
. O

A O
had O
experienced O
a O
, O
, O
and O
abdominal O
. O

 O
The O
patient O
passed O
loose O
, O
soft O
that O
were O
. O

 O
The O
results O
of O
performed O
by O
the O
( O
) O
were O
all O
, O
but O
upper O
and O
lower O
showed O
atrophic O
gastritis B
. O

 O
Therefore O
, O
we O
assessed O
the O
patient O
for O
and O
performed O
the O
and O
a O
, O
all O
of O
which O
were O
. O

 O
In O
June O
, O
the O
patient O
received O
from O
a O
, O
but O
because O
the O
symptoms O
did O
not O
improve O
and O
his O
further O
, O
he O
stopped O
the O
; O
he O
was O
to O
our O
in O
. O

 O
The O
patient O
had O
been O
suffering O
from O
. O

 O
( O
) O
administration O
was O
initiated O
in O
2005 O
, O
and O
from O
May O
2008 O
; O
the O
patient O
is O
currently O
receiving O
30 O
mg O
/ O
day O
of O
. O

 O
He O
denied O
the O
use O
of O
any O
other O
or O
. O

 O
He O
had O
. O

 O
showed O
that O
the O
patient O
had O
a O
height O
of O
, O
a O
body O
weight O
of O
, O
and O
of O
. O

 O
His O
was O
; O
, O
; O
, O
; O
, O
; O
and O
( O
) O
was O
. O

 O
The O
patient O
had O
no O
, O
or O
jugular O
venous O
. O

 O
The O
patient O
had O
bilateral O
pitting O
on O
his O
and O
presented O
with O
unilateral O
gaze O
- O
evoked O
as O
well O
as O
a O
mildly O
and O
thermal O
in O
the O
and O
. O

 O
Moreover O
, O
the O
results O
and O
were O
, O
and O
his O
patellar O
and O
Achilles O
tendon O
had O
. O

 O
was O
observed O
in O
the O
patient O
, O
and O
the O
revised O
( O
) O
score O
was O
( O
cut O
- O
off O
point O
: O
20 O
) O
. O

 O
The O
were O
as O
follows O
: O
, O
; O
, O
; O
, O
; O
, O
; O
, O
; O
, O
; O
, O
; O
, O
( O
reference O
value O
: O
64 O
- O
187 O
g O
/ O
dL O
) O
; O
, O
( O
reference O
value O
: O
50 O
- O
200 O
ng O
/ O
mL O
) O
; O
( O
) O
level O
, O
( O
reference O
value O
: O
-18.4 O
pg O
/ O
mL O
) O
; O
and O
, O
( O
reference O
value O
: O
24 O
- O
66 O
ng O
/ O
mL O
) O
. O

 O
An O
was O
and O
chest O
showed O
a O
normal O
( O
) O
without O
either O
or O
pleural B
effusion I
. O

 O
Cranial O
fluid O
- O
attenuated O
inversion O
recovery O
- O
findings O
revealed O
periaqueductal O
( O
Fig.1 O
) O
; O
therefore O
, O
Wernicke B
encephalopathy I
was O
diagnosed O
. O

 O
Moreover O
, O
as O
sinus O
and O
a O
tendency O
towards O
were O
noted O
, O
no O
clear O
symptoms O
of O
heart B
failure I
or O
were O
observed O
; O
it O
was O
thus O
inferred O
that O
the O
vitamin B
B1 I
deficiency I
had O
likely O
played O
a O
role O
in O
both O
of O
the O
conditions O
. O

 O
The O
were O
discontinued O
, O
and O
the O
intravenous O
administration O
of O
, O
the O
patient O
's O
, O
, O
and O
disappeared O
, O
and O
his O
. O

 O
was O
ameliorated O
on O
, O
but O
the O
patient O
still O
had O
, O
and O
the O
and O
absence O
of O
deep O
tendon O
reflexes O
. O

 O
Since O
the O
were O
ameliorated O
and O
his O
to O
, O
the O
PCP O
resumed O
the O
administration O
of O
on O
. O

 O
, O
the O
patient O
complained O
of O
recurrent O
and O
. O

 O
After O
experiencing O
( O
) O
, O
he O
passed O
soft O
, O
and O
his O
to O
so O
he O
to O
our O
again O
the O
resumption O
of O
for O
treatment O
. O

 O
His O
were O
as O
follows O
: O
, O
; O
, O
; O
and O
, O
. O

 O
The O
showed O
of O
his O
symptoms O
. O

 O
The O
were O
as O
follows O
: O
, O
139 O
mEq O
/ O
L O
; O
, O
2.9 O
mEq O
/ O
L O
; O
and O
, O
116 O
mEq O
/ O
L. O

 O
was O
noted O
, O
and O
the O
; O
additionally O
, O
the O
were O
as O
follows O
: O
, O
; O
, O
, O
and O
, O
11 O
mmol O
/ O
L. O

 O
The O
findings O
were O
as O
follows O
: O
, O
; O
, O
; O
, O
; O
and O
, O
, O
and O
there O
was O
no O
apparent O
increase O
in O
; O
however O
, O
this O
seemed O
to O
be O
due O
to O
the O
from O
the O
( O
6 O
) O
. O

 O
Plain O
abdominal O
and O
abdominal O
findings O
revealed O
the O
continuous O
dilation O
of O
the O
entire O
intestinal O
tract O
( O
Fig.2 O
) O
; O
therefore O
, O
the O
patient O
was O
diagnosed O
with O
intestinal B
pseudo I
- I
obstruction I
. O

 O
After O
discontinuing O
, O
the O
and O
were O
promptly O
ameliorated O
. O

 O
Duodenal O
findings O
after O
discontinuing O
showed O
that O
the O
observed O
before O
discontinuation O
as O
well O
as O
the O
had O
both O
clearly O
ameliorated O
( O
Fig.3 O
) O
. O

This O
young O
boy O
is O
the O
first O
child O
of O
healthy O
non O
- O
consanguineous O
, O
white O
British O
. O

 O
He O
was O
following O
an O
uneventful O
pregnancy O
weighing O
( O
9th25th O
centile O
) O
. O

 O
was O
thought O
to O
be O
. O

 O
At O
he O
developed O
tonic O
upward O
associated O
with O
of O
his O
arms O
and O
neck O
consistent O
with O
infantile B
spasms I
. O

 O
An O
( O
) O
at O
this O
time O
was O
( O
) O
and O
strongly O
supported O
a O
diagnosis O
of O
West B
Syndrome I
. O

 O
Cranial O
was O
reported O
as O
. O

 O
was O
prescribed O
and O
treated O
the O
seizures O
effectively O
. O

 O
were O
weaned O
and O
he O
remained O
free O
for O
a O
. O

 O
By O
the O
, O
it O
was O
apparent O
that O
his O
early O
was O
and O
that O
he O
was O
functioning O
at O
the O
68 O
month O
. O

 O
Seizures O
returned O
shortly O
and O
were O
, O
and O
, O
involving O
his O
, O
and O
. O

 O
briefly O
improved O
frequency O
, O
but O
subsequently O
his O
epilepsy B
has O
proved O
. O

 O
Prolonged O
of O
have O
been O
associated O
with O
a O
stepwise O
regression O
in O
his O
. O

 O
Seizure O
semiology O
is O
now O
predominantly O
one O
of O
epilepsia B
partialis I
continua I
involving O
the O
, O
and O
. O

 O
The O
development O
of O
focal O
seizures O
and O
the O
progressive O
nature O
of O
the O
condition O
prompted O
a O
second O
cranial O
at O
the O
. O

 O
By O
contrast O
with O
the O
previous O
scan O
, O
this O
revealed O
symmetrical O
subcortical O
white O
matter O
( O
Fig.1A O
) O
with O
of O
the O
( O
Fig.1B O
) O
. O

 O
On O
, O
the O
patient O
had O
small O
, O
round O
, O
anteriorly O
rotated O
and O
a O
broad O
. O

 O
He O
demonstrated O
no O
but O
. O

 O
was O
in O
with O
of O
. O

 O
were O
. O

 O
Brief O
were O
evident O
throughout O
the O
examination O
. O

A O
with O
a O
history O
of O
stage O
IV O
chronic B
kidney I
disease I
and O
three O
- O
vessel O
coronary O
artery O
disease O
was O
admitted O
for O
coronary O
artery O
bypass O
graft O
surgery O
and O
mitral O
valve O
repair O
. O

 O
On O
post O
- O
operative O
day O
two O
, O
the O
patient O
developed O
cardiac O
tamponade O
and O
subsequently O
progressed O
to O
a O
cardiac O
arrest O
while O
temporary O
pacing O
wires O
were O
being O
removed O
. O

 O
Advanced O
cardiovascular O
life O
support O
and O
emergent O
exploratory O
sternotomy O
were O
performed O
, O
and O
the O
patient O
was O
transferred O
to O
the O
intensive O
care O
unit O
( O
ICU O
) O
for O
further O
care O
. O

 O
During O
the O
patient O
s O
ICU O
admission O
, O
his O
renal O
failure O
progressed O
, O
requiring O
hemodialysis O
. O

 O
A O
nasogastric O
tube O
was O
placed O
on O
post O
- O
operative O
day O
two O
for O
establishing O
early O
enteral O
nutrition O
. O

 O
PEG O
tube O
insertion O
was O
suggested O
given O
his O
cognitive O
impairment O
and O
poor O
swallowing O
function O
on O
the O
Modified O
Barium O
Swallow O
test O
. O

 O
His O
coagulation O
profile O
prior O
to O
the O
procedure O
revealed O
an O
international O
normalized O
ratio O
of O
1.04 O
and O
partial O
thromboplastin O
time O
of O
36 O
seconds O
. O

 O
A O
complete O
blood O
count O
showed O
a O
hemoglobin O
of O
11.6 O
grams O
per O
deciliter O
, O
a O
hematocrit O
of O
34.9 O
% O
, O
and O
281103 O
platelets O
per O
microliter O
. O

 O
His O
blood O
urea O
nitrogen O
was O
55 O
milligrams O
/ O
deciliter O
, O
and O
his O
serum O
creatinine O
was O
5.22 O
milligrams O
/ O
deciliter O
. O

 O
The O
patient O
was O
taking O
aspirin O
81 O
mg O
per O
day O
due O
to O
recent O
cardiac O
surgery O
, O
but O
was O
not O
on O
any O
anticoagulant O
agents O
. O

 O
He O
also O
did O
not O
have O
a O
history O
of O
coagulopathy O
. O

 O
PEG O
tube O
insertion O
was O
performed O
on O
post O
- O
operative O
day O
eight O
under O
intravenous O
anesthesia O
. O

 O
The O
esophagogastroduodenoscopy O
( O
EGD O
) O
was O
accomplished O
without O
difficulty O
, O
revealing O
diffuse O
moderately O
erythematous O
mucosa O
without O
bleeding O
in O
the O
gastric O
antrum O
. O

 O
While O
attempting O
PEG O
tube O
placement O
, O
a O
rapidly O
expanding O
hematoma O
( O
Figure O
1 O
) O
developed O
at O
the O
needle O
insertion O
site O
. O

 O
The O
procedure O
was O
stopped O
and O
the O
patient O
was O
sent O
back O
to O
the O
ICU O
with O
a O
nasogastric O
tube O
. O

 O
A O
single O
dose O
of O
intravenous O
desmopressin O
( O
0.3 O
microgram O
/ O
kilogram O
) O
was O
administered O
under O
the O
suspicion O
of O
uremic O
bleeding O
. O

 O
No O
further O
gastrointestinal O
bleeding O
events O
were O
noted O
. O

 O
To O
assess O
platelet O
function O
, O
a O
platelet O
function O
assay O
( O
PFA O
) O
was O
ordered O
after O
desmopressin O
injection O
. O

 O
PFA O
collagen O
/ O
epinephrine O
closure O
time O
was O
195 O
seconds O
( O
normal O
< O
174 O
seconds O
) O
, O
and O
collagen O
/ O
ADP O
closure O
time O
was O
76 O
seconds O
( O
normal O
< O
120 O
seconds O
) O
, O
indicating O
platelet O
dysfunction O
due O
to O
either O
aspirin O
or O
uremia O
. O

 O
was O
discontinued O
, O
and O
he O
was O
with O
a O
daily O
and O
. O

 O
the O
patient O
underwent O
a O
second O
attempt O
at O
. O

 O
prior O
to O
this O
had O
to O
, O
possibly O
due O
to O
withholding O
and O
an O
improvement O
in O
. O

 O
showed O
an O
area O
of O
flat O
, O
bluish O
gastric O
submucosal O
at O
the O
site O
of O
the O
previous O
( O
Figure O
2 O
) O
. O

 O
The O
was O
placed O
successfully O
at O
an O
. O

 O
Over O
the O
course O
of O
the O
, O
the O
patient O
continued O
to O
undergo O
through O
the O
with O
no O
. O

A O
to O
our O
with O
signs O
and O
symptoms O
of O
acute O
heart B
failure I
after O
a O
of O
progressive O
. O

 O
He O
had O
a O
history O
of O
recurrent O
skin O
and O
atopic O
dermatitis B
and O
regularly O
a O
in O
our O
hospital O
. O

 O
On O
at O
our O
, O
his O
extremities O
were O
and O
. O

 O
According O
to O
the O
, O
he O
had O
class O
III O
congestive B
heart I
failure I
( O
CHF B
) O
. O

 O
An O
revealed O
diffuse O
nonspecific O
, O
low O
voltage O
( O
< O
5 O
mm O
) O
in O
the O
and O
poor O
R O
- O
wave O
progression O
in O
the O
. O

 O
Multiple O
sporadic O
ventricular O
were O
seen O
( O
Figure O
1 O
) O
. O

 O
Chest O
film O
confirmed O
right O
pleural B
effusion I
, O
and O
mild O
but O
no O
pulmonary B
congestion I
( O
Figure O
2 O
) O
. O

 O
showed O
severely O
elevated O
( O
) O
and O
markedly O
raised O
( O
) O
without O
( O
of O
) O
. O

 O
revealed O
no O
significant O
findings O
: O
of O
[ O
reference O
value O
( O
RV O
): O
7.0022.00 O
] O
, O
of O
( O
RV O
: O
0.601.00 O
) O
, O
( O
) O
of O
( O
RV O
: O
0.000.50 O
) O
, O
( O
) O
of O
( O
RV O
: O
08.0 O
) O
, O
and O
of O
( O
RV O
: O
00.1 O
) O
. O

 O
revealed O
negative O
and O
no O
elevation O
of O
. O

 O
The O
distribution O
of O
and O
in O
the O
was O
. O

 O
Serum O
did O
not O
reveal O
, O
and O
revealed O
no O
. O

 O
Transthoracic O
( O
Figure O
3 O
) O
showed O
concentric O
mild O
left O
ventricular O
( O
LV O
) O
( O
) O
without O
the O
characteristic O
and O
pericardial B
effusion I
, O
preserved O
( O
) O
, O
and O
bi O
- O
atrial O
with O
normal O
. O

 O
Doppler O
- O
derived O
LV O
demonstrated O
a O
restrictive O
pattern O
with O
a O
trans O
- O
mitral O
early O
filling O
wave O
deceleration O
time O
of O
160 O
ms O
and O
an O
elevated O
E O
/ O
A O
ratio O
of O
2.8 O
. O

 O
A O
markedly O
elevation O
of O
E O
/ O
e O
 O
ratio O
of O
27.3 O
indicated O
elevated O
LV O
filling O
pressure O
. O

 O
On O
day O
1 O
of O
hospitalization O
, O
we O
prescribed O
an O
angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
and O
low O
- O
dose O
diuretics O
. O

 O
On O
day O
3 O
of O
hospitalization O
, O
after O
initiating O
ACE O
inhibitor O
and O
diuretic O
therapy O
, O
the O
patient O
s O
symptoms O
resolved O
. O

 O
The O
dermatologists O
performed O
a O
of O
a O
blue O
of O
the O
. O

 O
On O
, O
we O
introduced O
a O
low O
- O
dose O
and O
performed O
an O
( O
) O
, O
obtaining O
3 O
fragments O
of O
the O
right O
ventricular O
septum O
because O
diagnostic O
confirmation O
of O
cardiac O
amyloidosis B
requires O
the O
demonstration O
of O
. O

 O
In O
addition O
, O
we O
performed O
right O
heart O
catheterization O
( O
RHC O
) O
, O
and O
coronary O
angiography O
to O
exclude O
obstructive O
coronary O
artery O
disease O
. O

 O
The O
data O
obtained O
from O
the O
RHC O
indicated O
subset O
type O
IV O
according O
to O
the O
Forrester O
classification O
. O

 O
The O
right O
ventricular O
pressure O
curve O
did O
not O
show O
a O
dip O
- O
and O
- O
plateau O
configuration O
. O

 O
Skin O
biopsy O
revealed O
hyperkeratosis O
in O
the O
epidermis O
and O
mild O
inflammatory O
changes O
throughout O
the O
dermis O
with O
an O
infiltration O
of O
lymphocytes O
. O

 O
The O
specimen O
exhibited O
apple O
- O
green O
birefringence O
with O
polarized O
light O
after O
Congo O
red O
staining O
( O
Figure O
4 O
) O
. O

 O
Histological O
examination O
of O
the O
myocardial O
specimen O
showed O
no O
signs O
suggesting O
myocarditis O
, O
eosinophilic O
granulomas O
, O
or O
cardiomyopathy O
with O
iron O
deposition O
, O
but O
Congo O
red O
staining O
revealed O
amyloid O
deposits O
( O
Figure O
5 O
) O
. O

 O
In O
addition O
, O
a O
strongly O
positive O
immunohistochemical O
reaction O
to O
immunoglobulin O
 O
- O
chain O
in O
the O
myocardial O
interstitium O
led O
us O
to O
diagnose O
this O
patient O
s O
systemic O
amyloidosis O
as O
AL O
amyloidosis O
. O

 O
The O
patient O
generally O
tolerated O
the O
low O
- O
dose O
 O
- O
blocker O
well O
and O
was O
discharged O
on O
day O
10 O
with O
no O
complications O
. O

 O
The O
patient O
is O
currently O
being O
at O
as O
an O
out O
- O
patient O
, O
with O
no O
exacerbation O
of O
the O
CHF B
thus O
far O
. O

A O
to O
our O
complaining O
of O
, O
, O
and O
that O
had O
. O

 O
He O
was O
a O
and O
denied O
any O
previous O
medical O
histories O
. O

 O
He O
was O
a O
and O
drank O
alcohol O
about O
once O
a O
month O
. O

 O
His O
were O
: O
, O
, O
, O
, O
, O
, O
and O
, O
. O

 O
On O
the O
, O
decreased O
was O
noted O
in O
the O
. O

 O
revealed O
a O
( O
) O
level O
of O
, O
a O
level O
of O
, O
and O
and O
levels O
of O
and O
, O
respectively O
. O

 O
His O
was O
, O
while O
his O
was O
( O
) O
. O

 O
In O
the O
checked O
, O
, O
, O
, O
, O
and O
levels O
were O
, O
, O
, O
, O
and O
, O
respectively O
. O

 O
A O
was O
. O

 O
Mycoplasma O
and O
Chlamydia O
were O
. O

 O
Streptococcal O
and O
Legionella O
were O
. O

 O
Anti O
- O
nuclear O
and O
anti O
- O
neutrophilic O
were O
also O
. O

 O
A O
chest O
showed O
in O
the O
. O

 O
Chest O
showed O
with O
in O
the O
with O
a O
small O
amount O
of O
pleural B
effusion I
in O
the O
( O
Fig.1 O
) O
. O

 O
Abdominal O
revealed O
no O
abnormal O
finding O
in O
the O
. O

 O
We O
began O
to O
administer O
4 O
L O
/ O
min O
of O
and O
empirical O
with O
third O
generation O
and O
following O
a O
diagnosis O
of O
community O
- O
acquired O
pneumonia B
. O

 O
On O
the O
second O
day O
in O
the O
hospital O
, O
the O
patient O
s O
was O
sustained O
and O
he O
complained O
of O
. O

 O
His O
was O
aggravated O
such O
that O
he O
required O
7 O
L O
/ O
min O
of O
via O
a O
and O
the O
and O
pleural B
effusion I
had O
markedly O
progressed O
( O
Fig.2a O
) O
. O

 O
We O
performed O
bronchoscopy O
and O
. O

 O
Multiplex O
( O
) O
was O
positive O
for O
human O
adenovirus O
while O
other O
were O
negative O
. O

 O
Pleural O
fluid O
was O
lymphocyte O
- O
dominant O
exudate O
and O
was O
also O
positive O
for O
human O
adenovirus O
. O

 O
Under O
the O
diagnosis O
of O
adenovirus B
pneumonia I
, O
we O
started O
with O
oral O
while O
maintaining O
. O

 O
On O
hospital O
, O
his O
had O
subsided O
and O
were O
much O
improved O
. O

 O
The O
levels O
, O
and O
platelet O
counts O
gradually O
( O
Fig.3 O
) O
. O

 O
A O
follow O
- O
up O
chest O
was O
( O
Fig.2b O
) O
and O
he O
was O
in O
hospital O
without O
any O
. O

A O
was O
to O
the O
of O
the O
due O
to O
epigastric O
. O

 O
revealed O
no O
palpable O
, O
, O
or O
. O

 O
On O
, O
several O
submucosal O
were O
identified O
in O
the O
and O
the O
( O
Fig.1 O
) O
. O

 O
( O
) O
( O
, O
) O
demonstrated O
that O
the O
were O
homogeneously O
originating O
from O
the O
( O
Fig.2 O
) O
and O
the O
initial O
diagnosis O
was O
digestive O
neuroendocrine B
tumors I
. O

 O
revealed O
in O
multiple O
regions O
( O
, O
, O
, O
and O
) O
and O
intracavitary O
in O
the O
. O

 O
To O
reach O
a O
definitive O
diagnosis O
, O
the O
patient O
underwent O
repeat O
and O
was O
performed O
. O

 O
On O
, O
a O
2 O
 O
1 O
- O
cm O
columnar O
uplift O
in O
the O
and O
multiple O
submucosal O
in O
the O
were O
identified O
( O
Fig.3 O
) O
. O

 O
EUS O
revealed O
that O
the O
in O
the O
were O
sized O
and O
the O
in O
the O
were O
sized O
almost O
, O
they O
were O
all O
and O
. O

 O
of O
the O
biopsied O
specimens O
from O
the O
of O
the O
showed O
diffuse O
and O
by O
( O
Fig.4 O
) O
. O

 O
On O
, O
the O
cells O
were O
positive O
for O
, O
, O
, O
, O
and O
, O
but O
negative O
for O
and O
, O
which O
was O
compatible O
with O
the O
diagnosis O
of O
MCL B
. O

 O
revealed O
a O
. O

 O
Based O
on O
these O
findings O
, O
the O
diagnosis O
of O
Ann O
Arbor O
stage O
IV O
MCL B
was O
confirmed O
. O

 O
The O
patient O
was O
referred O
for O
combination O
with O
, O
, O
, O
, O
and O
( O
) O
. O

 O
The O
patient O
has O
been O
in O
clinically O
. O

A O
who O
initially O
with O
, O
and O
painless O
, O
was O
subsequently O
found O
to O
have O
adenocarcinoma B
of O
the O
. O

 O
An O
initial O
workup O
revealed O
localized O
cancer B
with O
no O
evidence O
of O
distant O
metastases B
. O

 O
He O
then O
underwent O
with O
complete O
of O
a O
5 O
cm O
moderately O
differentiated O
pancreatic O
adenocarcinoma B
. O

 O
Although O
our O
patient O
underwent O
complete O
surgical O
resection O
, O
a O
pathological O
examination O
revealed O
a O
neoplastic O
invasion O
of O
the O
resected O
adjacent O
organs O
, O
and O
one O
out O
of O
the O
seven O
resected O
lymph O
nodes O
contained O
cancer O
( O
T3N1M0 O
) O
. O

 O
At O
that O
point O
, O
the O
oncology O
department O
recommended O
to O
proceed O
with O
adjuvant O
chemotherapy O
with O
gemcitabine O
( O
1000mg O
/ O
m2 O
IV O
on O
days O
1 O
, O
8 O
, O
15 O
on O
a O
28 O
- O
day O
cycle O
for O
six O
cycles O
) O
to O
try O
to O
reduce O
the O
likelihood O
of O
recurrence O
. O

 O
However O
, O
after O
completing O
two O
cycles O
( O
a O
total O
of O
six O
doses O
) O
of O
chemotherapy O
, O
he O
presented O
to O
the O
emergency O
department O
with O
worsening O
exertional O
dyspnea O
, O
three O
- O
pillow O
orthopnea O
, O
paroxysmal O
nocturnal O
dyspnea O
and O
fatigue O
. O

 O
His O
physical O
examination O
revealed O
an O
elevated O
jugular O
venous O
pressure O
( O
JVP O
) O
( O
10 O
cm O
above O
the O
sternal O
angle O
) O
, O
bibasilar O
rales O
and O
+2 O
pitting O
edema O
of O
both O
lower O
extremities O
. O

 O
Cardiac O
auscultation O
revealed O
a O
gallop O
rhythm O
with O
an O
S3 O
and O
a O
grade O
3 O
holosystolic O
murmur O
over O
precordium O
. O

 O
A O
chest O
X O
- O
ray O
showed O
cardiomegaly O
with O
mild O
to O
moderate O
- O
sized O
right O
- O
sided O
pleural O
effusion O
. O

 O
It O
was O
thought O
that O
his O
presentation O
was O
consistent O
with O
fluid O
overload O
secondary O
to O
congestive O
heart O
failure O
( O
CHF O
) O
and O
he O
was O
started O
on O
intravenous O
( O
IV O
) O
furosemide O
with O
partial O
improvement O
in O
his O
symptoms O
. O

 O
The O
next O
day O
, O
a O
two O
- O
dimensional O
echocardiography O
( O
2D O
Echo O
) O
was O
performed O
, O
which O
showed O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
of O
15 O
to O
20 O
percent O
with O
global O
hypokinesia O
along O
with O
moderate O
mitral O
regurgitation O
. O

 O
Given O
the O
findings O
of O
2D O
Echo O
and O
the O
absence O
of O
significant O
risk O
factors O
for O
coronary O
artery O
disease O
( O
CAD O
) O
and O
ischemic O
cardiomyopathy O
( O
CMP O
) O
, O
it O
was O
concluded O
that O
our O
patient O
s O
CMP O
was O
related O
to O
the O
recent O
use O
of O
gemcitabine O
. O

 O
Our O
patient O
was O
then O
started O
on O
carvedilol O
and O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
addition O
to O
diuretics O
and O
he O
was O
discharged O
from O
the O
hospital O
two O
days O
later O
in O
a O
euvolemic O
state O
. O

 O
At O
that O
point O
, O
the O
cardiology O
department O
recommended O
stopping O
further O
chemotherapy O
with O
gemcitabine O
. O

 O
The O
oncology O
department O
advised O
further O
testing O
to O
rule O
out O
ischemia O
as O
a O
cause O
of O
CMP O
as O
, O
in O
their O
opinion O
, O
chemotherapy O
with O
gemcitabine O
was O
the O
only O
option O
to O
reduce O
the O
risk O
of O
recurrence O
in O
this O
patient O
. O

 O
Two O
weeks O
later O
, O
our O
patient O
underwent O
myocardial O
perfusion O
imaging O
( O
MPI O
) O
, O
which O
showed O
a O
fixed O
small- O
to O
moderate O
- O
sized O
inferior O
wall O
defect O
without O
any O
evidence O
of O
active O
ischemia O
. O

 O
The O
ejection O
fraction O
( O
EF O
) O
on O
MPI O
was O
calculated O
to O
be O
around O
17 O
to O
20 O
percent O
with O
severe O
global O
hypokinesia O
. O

 O
Our O
patient O
was O
continued O
on O
standard O
heart O
failure O
therapy O
with O
one O
more O
admission O
to O
the O
hospital O
for O
CHF O
exacerbation O
about O
two O
months O
later O
. O

 O
He O
responded O
well O
to O
IV O
furosemide O
and O
adjustment O
of O
heart O
failure O
therapy O
. O

 O
A O
2D O
Echo O
was O
repeated O
a O
few O
months O
later O
and O
it O
showed O
improvement O
in O
systolic O
function O
with O
an O
LVEF O
of O
40 O
percent O
. O

 O
Due O
to O
his O
poor O
functional O
status O
and O
underlying O
CMP O
, O
further O
gemcitabine O
chemotherapy O
was O
stopped O
. O

 O
Later O
, O
our O
patient O
developed O
a O
recurrence O
of O
his O
pancreatic O
cancer O
; O
he O
refused O
further O
chemotherapy O
and O
decided O
to O
proceed O
with O
. O

 O
Although O
the O
exact O
etiology O
of O
our O
patient O
s O
dilated O
cardiomyopathy B
remains O
unclear O
, O
remains O
the O
most O
likely O
culprit O
. O

 O
The O
temporal O
relationship O
of O
his O
symptoms O
to O
the O
initiation O
of O
; O
the O
lack O
of O
and O
prior O
history O
of O
CAD B
, O
finding O
of O
global O
on O
, O
absence O
of O
on O
; O
and O
improvement O
in O
his O
after O
discontinuation O
of O
were O
all O
consistent O
with O
- O
induced O
cardiomyopathy B
. O

A O
with O
presented O
with O
a O
sudden O
onset O
of O
requiring O
and O
. O

 O
She O
denied O
preceding O
symptoms O
of O
chest O
, O
, O
or O
infection B
. O

 O
The O
patient O
was O
and O
, O
with O
a O
sinus O
of O
. O

 O
The O
was O
remarkable O
for O
an O
elevated O
at O
the O
, O
a O
left O
- O
sided O
and O
bibasilar O
in O
fields O
. O

 O
The O
, O
and O
were O
within O
normal O
limits O
. O

 O
An O
initial O
revealed O
in O
, O
suggestive O
of O
anterolateral B
ischemia I
( O
Figure O
1 O
) O
. O

 O
A O
chest O
demonstrated O
pulmonary O
consistent O
with O
a O
diagnosis O
of O
pulmonary B
edema I
( O
Figure O
2 O
) O
. O

 O
An O
revealed O
normal O
, O
normal O
and O
mild O
diastolic B
dysfunction I
with O
an O
of O
less O
than O
1 O
, O
prolonged O
( O
) O
and O
a O
reduced O
early O
diastolic O
annular O
velocity O
of O
the O
. O

 O
Following O
aggressive O
and O
requiring O
minimal O
, O
the O
patient O
was O
her O
initial O
presentation O
. O

 O
of O
extubation O
, O
the O
patient O
developed O
recurrent O
pulmonary B
edema I
clinically O
and O
, O
requiring O
. O

 O
was O
performed O
and O
revealed O
. O

 O
of O
the O
coronary O
care O
unit O
, O
the O
patient O
failed O
a O
repeat O
attempt O
at O
. O

 O
A O
scan O
revealed O
a O
4 O
cm O
 O
9 O
cm O
multinodular O
goiter B
extending O
into O
the O
and O
suspected O
associated O
tracheal O
( O
Figure O
3 O
) O
. O

 O
With O
a O
diagnosis O
of O
NPPE B
secondary O
to O
an O
enlarged O
goiter B
, O
the O
patient O
underwent O
for O
a O
. O

 O
Intraoperative O
revealed O
tracheal O
stenosis O
of O
. O

 O
The O
was O
uncomplicated O
, O
and O
, O
the O
patient O
to O
her O
without O
subjective O
. O

A O
to O
the O
hospital O
with O
worsening O
exertional O
associated O
with O
and O
lower O
extremity O
for O
. O

 O
She O
had O
a O
long O
- O
standing O
history O
of O
and O
documented O
G6PD B
deficiency I
with O
prior O
episodes O
of O
. O

 O
She O
was O
a O
and O
had O
family O
members O
with O
, O
and O
. O

 O
revealed O
a O
of O
, O
of O
, O
of O
, O
of O
and O
97 O
% O
on O

 O
She O
was O
at O
. O

 O
Her O
showed O
, O
inspiratory O
in O
, O
a O
laterally O
displaced O
and O
bipedal O
. O

 O
The O
showed O
left O
ventricular O
and O
inferolateral O
. O

 O
Chest O
revealed O
and O
mild O
pulmonary O
. O

 O
The O
and O
levels O
were O
but O
the O
was O
at O
826.5 O
 O
pg O
/ O
mL. O

 O
showed O
a O
with O
an O
( O
) O
of O
and O
mild O
right O
ventricular O
systolic B
dysfunction I
. O

 O
Coronary O
artery O
revealed O
normal O
. O

 O
at O
was O
chosen O
for O
diuresis O
. O

 O
She O
but O
still O
had O
, O
so O
we O
added O
. O

 O
Subsequently O
, O
and O
were O
included O
in O
the O
regimen O
. O

 O
Repeat O
chest O
showed O
resolution O
of O
pulmonary O
. O

 O
The O
patient O
's O
during O
her O
hospital O
stay O
did O
not O
show O
signs O
of O
nor O
. O

 O
She O
did O
not O
develop O
and O
was O
discharged O
home O
. O

, O
with O
, O
presented O
with O
progressive O
of O
. O

 O
Medical O
History O
. O

 O
His O
medical O
history O
included O
. O

 O
He O
had O
fallen O
approximately O
8 O
feet O
and O
had O
landed O
on O
the O
right O
side O
of O
his O
back O
and O
on O
his O
right O
shoulder O
. O

 O
The O
patient O
had O
sustained O
bilateral O
, O
right O
iliopsoas O
muscle O
, O
multiple O
right O
costal O
, O
of O
the O
and O
the O
, O
and O
displaced O
of O
the O
. O

 O
That O
had O
lasted O
, O
during O
which O
time O
the O
clinicians O
had O
not O
detected O
any O
or O
requested O
a O
. O

 O
The O
patient O
returned O
to O
from O
the O
and O
remained O
for O
one O
year O
. O

 O
Upon O
his O
at O
our O
, O
revealed O
bibasilar O
and O
a O
pansystolic O
. O

 O
Chest O
showed O
mild O
lung O
; O
and O
transthoracic O
, O
limited O
by O
suboptimal O
acoustic O
windows O
, O
revealed O
severe O
, O
eccentric O
. O

 O
The O
valvular O
and O
subvalvular O
apparatus O
appeared O
to O
be O
structurally O
normal O
, O
and O
the O
left O
atrium O
was O
only O
mildly O
. O

 O
The O
patient O
was O
treated O
with O
intravenous O
until O
the O
were O
relieved O
. O

 O
Coronary O
revealed O
an O
absence O
of O
substantial O
coronary B
disease I
. O

 O
We O
therefore O
planned O
an O
elective O
surgical O
procedure O
for O
. O

 O
Surgical O
Procedure O
. O

 O
During O
intraoperative O
( O
) O
, O
we O
observed O
both O
a O
trivial O
central O
and O
a O
severe O
, O
this O
last O
originating O
from O
a O
ventriculoatrial O
( O
Fig.1 O
) O
. O

 O
Further O
examination O
confirmed O
the O
absence O
of O
structural B
disease I
involving O
the O
or O
. O

 O
After O
of O
the O
, O
a O
small O
( O
) O
could O
be O
seen O
, O
in O
a O
, O
involving O
also O
the O
and O
the O
. O

 O
The O
absence O
of O
leaflet O
abnormalities O
or O
vegetations O
suggested O
the O
posttraumatic O
origin O
of O
the O
. O

 O
was O
successfully O
achieved O
by O
direct O
of O
the O
tear O
with O
three O
5 O
- O
0 O
Prolene O
stitches O
and O
by O
the O
subsequent O
insertion O
of O
a O
30 O
- O
mm O
mitral O
annuloplasty O
ring O
. O

 O
The O
patient O
was O
the O
next O
day O
and O
his O
was O
. O

 O
, O
he O
was O
, O
and O
his O
one O
- O
year O
transthoracic O
of O
his O
surgical O
treatment O
. O

A O
was O
with O
progressive O
for O
and O
5 O
kg O
. O

 O
Her O
past O
medical O
history O
was O
significant O
for O
treated O
with O
, O
, O
for O
. O

 O
Upper O
gastrointestinal O
described O
a O
4 O
cm O
whitish O
firm O
mass O
in O
the O
middle O
esophagus O
( O
Fig.1 O
) O
and O
a O
semi O
- O
circumferential O
deep O
ulcer O
with O
irregular O
borders O
on O
the O
opposite O
mucosa O
( O
Fig.2 O
) O
. O

 O
During O
endoscopy O
a O
pedicle O
was O
not O
identify O
by O
handling O
a O
polipectomy O
snare O
around O
the O
esophageal O
mass O
. O

 O
Upper O
gastrointestinal O
series O
with O
gastrografin O
( O
Fig.3 O
) O
revealed O
an O
ovoid O
lacunar O
image O
at O
the O
distal O
part O
of O
the O
esophagus O
esophageal O
, O
inhomogeneous O
, O
with O
calcifications O
and O
smooth O
contours O
. O

 O
During O
peristalsis O
the O
image O
was O
mobile O
and O
no O
pedicle O
was O
identified O
. O

 O
The O
esophageal O
lumen O
was O
enlarged O
with O
a O
diverticula O
development O
at O
the O
posterior O
wall O
. O

 O
Also O
computer O
tomography O
of O
the O
thorax O
excluded O
a O
pedunculated O
tumor O
, O
describing O
an O
intra O
- O
luminal O
calcified O
esophageal O
mass O
( O
Fig.4 O
) O
. O

 O
The O
biopsies O
obtained O
from O
the O
esophageal O
ulcerated O
mucosa O
revealed O
inflammatory O
cells O
, O
without O
malignancy O
. O

 O
Based O
on O
these O
endoscopic O
and O
imagistic O
results O
a O
bezoar O
was O
supposed O
to O
have O
been O
developed O
in O
an O
esophageal O
diverticula O
, O
subsequently O
with O
ulcerated O
mucosa O
. O

 O
The O
esophageal O
mass O
was O
removed O
with O
an O
endoscopic O
snare O
in O
one O
piece O
, O
as O
the O
fragmentation O
was O
not O
physically O
possible O
. O

 O
The O
macroscopic O
appearance O
revealed O
a O
4 O
cm O
, O
globular O
mass O
, O
heterogeneous O
, O
dense O
, O
whitish O
, O
in O
places O
with O
harsh O
yellow O
foci O
, O
most O
likely O
dystrophic O
calcification O
. O

 O
The O
macroscopic O
examination O
on O
cross O
section O
revealed O
a O
light O
gray O
aspect O
( O
fibrous O
appearance O
) O
that O
includes O
multiple O
harsh O
yellow O
- O
orange O
structures O
, O
difficult O
to O
section O
( O
Fig.5 O
) O
. O

 O
This O
mass O
was O
immersed O
into O
trichloracetic O
acid O
for O
decalcification O
. O

 O
Microscopic O
examination O
revealed O
hyaline O
fibrous O
tissue O
( O
Fig.6a O
) O
, O
stained O
in O
green O
in O
Tricrom O
Mason O
( O
Fig.6b O
) O
, O
with O
numerous O
crystalline O
basophils O
deposits O
of O
minerals O
, O
rare O
fibrocytes O
and O
very O
few O
vessels O
. O

 O
The O
presence O
of O
capillary O
structures O
, O
rare O
fibroblasts O
and O
collagen O
fibers O
brought O
in O
discussion O
a O
mesenchymal O
originating O
mass O
, O
most O
likely O
a O
fibrovascular O
polyp O
. O

 O
A O
definitive O
histological O
diagnosis O
was O
not O
possible O
, O
as O
the O
pedicle O
was O
not O
identified O
, O
but O
the O
presence O
of O
the O
connective O
tissue O
suggested O
the O
previous O
presence O
of O
a O
pedicle O
into O
the O
lesion O
. O

 O
The O
long O
term O
calcium O
tablets O
intake O
might O
explain O
the O
calcification O
process O
developed O
into O
the O
vascular O
- O
connective O
tissue O
, O
revealed O
on O
histology O
by O
the O
numerous O
crystalline O
basophils O
deposits O
of O
minerals O
. O

 O
One O
month O
later O
the O
patient O
was O
. O

 O
The O
did O
not O
revealed O
an O
, O
the O
of O
the O
esophageal O
mucosa O
was O
( O
without O
) O
and O
no O
was O
identified O
. O

 O
No O
were O
found O
on O
esophageal O
. O

 O
Based O
on O
the O
clinical O
course O
, O
the O
and O
a O
diagnosis O
of O
an O
mesenchymal O
originating O
( O
most O
probably O
a O
fibrovascular B
polyp I
) O
and O
was O
formulated O
. O

A O
patient O
was O
admitted O
. O

 O
His O
major O
complaints O
were O
gradually O
aggravated O
and O
, O
on O
suspicion O
of O
obstructive B
disease I
in O
upper O
digestive O
tract O
. O

 O
He O
before O
, O
and O
then O
before O
admission O
. O

 O
. O

 O
Thorough O
of O
his O
, O
, O
, O
and O
failed O
to O
identify O
any O
superficial O
. O

 O
Additionally O
, O
including O
, O
, O
and O
such O
as O
, O
, O
, O
, O
and O
were O
all O
. O

 O
Therefore O
, O
further O
endoscopic O
and O
radiological O
were O
carried O
out O
for O
accurate O
diagnosis O
. O

 O
revealed O
a O
slightly O
pigmented O
, O
irregular O
, O
which O
was O
located O
in O
, O
measuring O
in O
size O
. O

 O
Fine O
needle O
of O
the O
revealed O
esophageal O
melanoma B
, O
which O
was O
confirmed O
by O
. O

 O
Besides O
chest O
and O
abdomen O
( O
) O
, O
enhanced O
cranial O
( O
) O
and O
bone O
( O
) O
showed O
mediastinal O
, O
nd O
also O
celiac O
( O
Fig.1A O
) O
, O
without O
obvious O
of O
supraclavicular O
. O

 O
Concurrently O
, O
the O
showed O
an O
isolated O
, O
irregular O
pulmonary O
( O
Fig.1B O
) O
. O

 O
was O
not O
carried O
out O
, O
because O
it O
was O
not O
covered O
by O
health O
insurance O
of O
this O
patient O
. O

 O
Therefore O
, O
this O
patient O
was O
as O
according O
to O
the O
for O
esophageal B
cancer I
. O

 O
CT O
- O
guided O
percutaneous O
pulmonary O
was O
avoided O
, O
with O
the O
aim O
to O
diminish O
the O
risk O
of O
tumor O
dissemination O
. O

 O
Single O
- O
stage O
of O
the O
esophageal O
and O
pulmonary O
was O
assumed O
to O
be O
reasonable O
after O
multidisciplinary O
, O
which O
was O
approved O
by O
Ethical O
Committee O
of O
Xuzhou O
Central O
Hospital O
. O

 O
Because O
the O
prognosis O
of O
this O
patient O
probably O
was O
extremely O
poor O
without O
targeted O
antibodies O
, O
which O
he O
could O
not O
afford O
for O
financial O
reasons O
. O

 O
After O
his O
informed O
consent O
, O
simultaneous O
Ivor O
- O
Lewis O
and O
right O
upper O
were O
performed O
successfully O
, O
under O
, O
after O
double O
- O
lumen O
endotracheal O
, O
followed O
by O
systemic O
of O
located O
in O
and O
, O
in O
accordance O
with O
the O
principles O
of O
oncological O
surgery O
. O

 O
The O
operation O
time O
was O
, O
without O
obvious O
during O
the O
surgery O
. O

 O
Postoperative O
of O
the O
specimen O
revealed O
and O
abundant O
( O
Fig.1C O
) O
, O
whereas O
demonstrated O
positive O
expression O
of O
( O
) O
, O
( O
) O
, O
and O
, O
and O
of O
, O
, O
and O
( O
) O
, O
which O
was O
consistent O
with O
melanoma B
. O

 O
The O
resection O
margin O
and O
were O
pathologically O
- O
negative O
. O

 O
In O
addition O
, O
of O
the O
patient O
indicated O
( O
BRAF O
) O
V600E. O

 O
Based O
on O
these O
findings O
, O
a O
diagnosis O
of O
advanced O
PMME B
was O
tentatively O
established O
as O
( O
) O
, O
because O
there O
was O
insufficient O
evidence O
to O
distinguish O
synchronous O
primary O
pulmonary O
melanoma O
from O
metastasis O
for O
this O
patient O
. O

 O
The O
was O
, O
and O
the O
patient O
was O
. O

 O
Subsequently O
, O
4 O
cycles O
of O
adjuvant O
conventional O
with O
an O
interval O
of O
3 O
weeks O
were O
completed O
, O
with O
controlled O
moderate O
toxic O
effects O
including O
, O
, O
, O
, O
and O
. O

 O
The O
detailed O
chemotherapy O
regimen O
is O
as O
follows O
: O
paclitaxel O
liposome O
for O
injection O
on O
day O
1 O
and O
day O
8 O
( O
135 O
 O
mg O
per O
square O
meter O
of O
body O
surface O
area O
; O
Nanjing O
Luye O
Sike O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jiangsu O
, O
China O
. O
) O
, O
tegafur O
injection O
on O
day O
2 O
to O
4 O
( O
1000 O
 O
mg O
per O
square O
meter O
of O
body O
- O
surface O
area O
; O
Shandong O
Qilu O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jinan O
, O
China O
. O
) O
plus O
cis O
- O
platinum O
on O
day O
2 O
to O
3 O
( O
75 O
 O
mg O
per O
square O
meter O
of O
body O
- O
surface O
area O
; O
Shandong O
Qilu O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jinan O
, O
China O
) O
. O

 O
This O
patient O
suffered O
from O
moderate O
leukopenia/ O
after O
the O
second O
cycle O
of O
TPF O
, O
and O
he O
quickly O
after O
the O
administration O
of O
( O
) O
. O

 O
Concurrently O
, O
recombinant O
( O
Harbin O
pharmaceutical O
group O
biological O
engineering O
Co. O
, O
Ltd O
, O
Harbin O
, O
China O
) O
was O
administrated O
via O
thereafter O
( O
; O
Fig.2 O
) O
, O
lasting O
. O

 O
The O
patient O
was O
continuously O
after O
the O
surgery O
. O

 O
Chest O
and O
abdomen O
, O
cranial O
, O
bone O
, O
and O
thorough O
were O
carried O
out O
. O

 O
Encouragingly O
, O
the O
patient O
without O
loco O
- O
regional O
or O
remote O
during O
the O
of O
up O
to O
now O
( O
Fig.3 O
) O
. O

The O
patient O
is O
a O
diagnosed O
with O
PD O
at O
the O
. O

 O
Fluctuations O
with O
recurring O
 O
off O
 O
states O
and O
peak O
dose O
dyskinesias O
had O
severely O
diminished O
the O
patient O
s O
quality O
of O
life O
. O

 O
Thus O
, O
the O
patient O
was O
deemed O
a O
candidate O
for O
bilateral O
subthalamic O
DBS O
. O

 O
Multidisciplinary O
evaluation O
with O
75 O
% O
positive O
response O
in O
the O
standardized O
levodopa O
test O
, O
exclusion O
of O
cognitive O
decline O
or O
psychiatric O
comorbitity O
, O
and O
absence O
of O
structural O
brain O
damage O
potentially O
relevant O
to O
the O
lead O
placement O
led O
to O
the O
unanimous O
decision O
for O
DBS O
placement O
. O

 O
When O
decision O
was O
made O
to O
proceed O
to O
surgery O
the O
medication O
consisted O
of O
1112.5 O
mg O
of O
levodopa O
and O
150 O
mg O
of O
piribedil O
. O

 O
There O
was O
no O
history O
of O
orofacial O
or O
cervical O
dystonia O
. O

 O
In O
the O
 O
on O
 O
state O
the O
patient O
was O
alert O
without O
any O
signs O
of O
psychiatric O
comorbidity O
. O

 O
Neuropsychological O
testing O
was O
adequate O
. O

 O
No O
cranial O
nerve O
deficits O
were O
found O
and O
swallowing O
was O
normal O
. O

 O
Gait O
and O
postural O
stability O
was O
normal O
with O
minimal O
rigidity O
in O
the O
neck O
and O
right O
arm O
. O

 O
Coordinative O
motor O
skills O
such O
as O
rapid O
pro- O
and O
supination O
were O
restricted O
in O
the O
left O
hand O
. O

 O
Dyskinesias O
were O
evident O
with O
moderate O
impairment O
. O

 O
In O
the O
 O
off O
 O
state O
after O
the O
medication O
was O
held O
for O
12 O
h O
, O
the O
patient O
showed O
mild O
dysarthria O
and O
dysphonia O
, O
resting O
tremor O
of O
the O
right O
arm O
and O
leg O
, O
as O
well O
as O
slight O
action O
tremor O
in O
the O
right O
hand O
. O

 O
Rigidity O
was O
severe O
in O
the O
neck O
, O
marked O
in O
the O
right O
, O
and O
mild O
on O
the O
left O
side O
. O

 O
Motor O
skills O
of O
the O
hands O
were O
markedly O
impaired O
. O

 O
Gait O
was O
slow O
but O
unaided O
and O
comprised O
of O
by O
intermittent O
freezing O
; O
there O
was O
mild O
dystonic O
posturing O
of O
the O
right O
foot O
. O

 O
There O
were O
no O
signs O
of O
laryngeal O
spasms O
, O
however O
. O

 O
On O
the O
day O
before O
surgery O
, O
the O
last O
dose O
of O
dopaminergic O
medication O
was O
administered O
at O
07:00 O
p.m. O
, O
the O
bedtime O
dose O
of O
levodopa O
was O
held O
to O
facilitate O
intraoperative O
testing O
. O

 O
On O
the O
day O
of O
the O
operation O
, O
the O
patient O
underwent O
placement O
of O
the O
stereotactic O
frame O
under O
local O
anaesthesia O
around O
09:00 O
a.m. O

 O
After O
planning O
standard O
STN O
coordinates O
and O
trajectories O
, O
the O
patient O
was O
placed O
in O
a O
semi O
- O
sitting O
position O
on O
the O
O.R. O

 O
table O
, O
with O
the O
frame O
attached O
to O
the O
table O
. O

 O
At O
the O
patient O
s O
request O
, O
the O
head O
was O
slightly O
flexed O
anteriorly O
for O
comfort O
. O

 O
The O
left O
electrode O
was O
placed O
uneventfully O
. O

 O
When O
performing O
the O
bur O
hole O
on O
the O
right O
side O
, O
the O
patient O
complained O
of O
cramping O
in O
the O
neck O
and O
facial O
muscles O
as O
well O
as O
difficulties O
breathing O
although O
at O
that O
point O
, O
pulse O
oximetry O
showed O
good O
saturation O
readings O
at O
95 O
% O
. O

 O
He O
progressed O
to O
dystonic O
dysarthria O
[ O
6 O
] O
. O

 O
Microelectrode O
recordings O
had O
already O
been O
done O
and O
macroelectrode O
test O
stimulation O
was O
about O
to O
begin O
, O
when O
the O
patient O
showed O
high O
- O
pitched O
inspiratory O
stridor O
. O

 O
Pulse O
oximetry O
showed O
decreasing O
oxygen O
saturation O
at O
02:15 O
p.m. O

 O
and O
, O
shortly O
thereafter O
, O
narrow O
complex O
tachycardia O
was O
noted O
. O

 O
Within O
a O
minute O
, O
the O
patient O
became O
unresponsive O
. O

 O
Cardiac O
resuscitation O
was O
initiated O
and O
the O
patient O
was O
fiberoptically O
intubated O
after O
removal O
of O
the O
front O
bar O
of O
the O
stereotactic O
frame O
. O

 O
During O
fiberoptic O
intubation O
laryngeal O
spasm O
was O
confirmed O
visually O
. O

 O
A O
transthoracic O
echocardiogram O
obtained O
immediately O
after O
successful O
resuscitation O
showed O
no O
cardiac O
pathology O
or O
any O
air O
bubbles O
. O

 O
Stimulation O
using O
the O
implanted O
lead O
to O
resolve O
the O
symptoms O
was O
not O
possible O
as O
at O
that O
time O
the O
lead O
was O
subcutaneously O
tunnelled O
with O
no O
impulse O
generator O
attached O
. O

 O
The O
right O
permanent O
electrode O
was O
placed O
without O
further O
testing O
according O
to O
microelectrode O
recordings O
. O

 O
50 O
mg O
levodopa O
was O
administered O
over O
a O
nasogastric O
tube O
every O
two O
hours O
during O
the O
subsequent O
postoperative O
period O
. O

 O
Postoperative O
head O
CT O
scan O
done O
immediately O
after O
the O
procedure O
was O
normal O
. O

 O
The O
patient O
was O
transferred O
to O
the O
intensive O
care O
unit O
and O
was O
extubated O
at O
02:00 O
p.m. O

 O
the O
following O
day O
without O
any O
neurological O
deficit O
or O
signs O
of O
laryngeal O
spasms O
. O

 O
By O
then O
, O
the O
nasogastric O
tube O
was O
discontinued O
and O
the O
preoperative O
medication O
was O
resumed O
. O

 O
Cardiac O
workup O
was O
negative O
. O

 O
The O
impulse O
generator O
was O
implanted O
and O
the O
patient O
showed O
good O
symptom O
control O
of O
PD B
. O

A O
with O
a O
of O
on O
, O
associated O
with O
both O
lower O
extremity O
. O

 O
Before O
this O
admission O
, O
he O
also O
had O
suffered O
from O
abdominal O
bloating O
and O
tasteless O
for O
a O
year O
with O
noticeable O
body O
weight O
loss O
at O
the O
same O
time O
( O
up O
to O
20 O
kg O
) O
. O

 O
Over O
the O
past O
6 O
months O
, O
he O
developed O
a O
multiple O
system O
disorder O
, O
which O
included O
painless O
paresthesias O
in O
the O
lower O
limbs O
, O
erectile O
dysfunction O
, O
and O
chronic O
diarrhea O
. O

 O
He O
had O
an O
average O
stool O
frequency O
of O
up O
to O
ten O
times O
per O
day O
, O
with O
no O
obvious O
blood O
or O
mucus O
and O
no O
abdominal O
pain O
or O
tenesmus O
. O

 O
Unfortunately O
, O
previous O
stomach O
and O
rectum O
biopsy O
did O
not O
examine O
for O
accumulations O
of O
amyloid O
fibril O
protein O
. O

 O
His O
family O
history O
was O
unremarkable O
. O

 O
On O
physical O
examination O
, O
his O
blood O
pressure O
was O
82/56 O
mmHg O
and O
heart O
rate O
was O
52 O
bpm O
. O

 O
Significant O
jugular O
venous O
distention O
, O
moderate O
hepatomegaly O
, O
and O
lower O
extremity O
edema O
were O
noted O
. O

 O
A O
neurological O
examination O
revealed O
weakness O
and O
muscular O
atrophy O
in O
the O
bilateral O
tibialis O
anterior O
and O
gastrocnemius O
. O

 O
Hyporeflexia O
was O
noted O
on O
both O
knees O
and O
ankles O
. O

 O
Sensory O
examination O
revealed O
diminished O
tactile O
and O
pain O
sensation O
in O
a O
stocking O
and O
glove O
pattern O
and O
vibratory O
sensation O
was O
distally O
reduced O
in O
the O
lower O
limbs O
. O

 O
The O
motor O
and O
sensory O
functions O
of O
upper O
extremities O
were O
relatively O
spared O
. O

 O
Initial O
laboratory O
data O
that O
included O
full O
blood O
count O
, O
transaminase O
, O
creatinine O
, O
electrolytes O
, O
cardiac O
troponin O
, O
and O
thyroid O
function O
were O
normal O
or O
negative O
. O

 O
N O
- O
terminal O
fragment O
of O
pro O
- O
brain O
natriuretic O
peptide O
( O
NT O
- O
proBNP O
) O
was O
3,996 O
pg O
/ O
mL. O

 O
Nerve O
conduction O
studies O
confirmed O
bilateral O
sensory O
- O
motor O
neuropathy O
( O
Table O
1 O
) O
. O

 O
An O
electromyography O
study O
demonstrated O
active O
denervation O
and O
chronic O
reinnervation O
changes O
in O
the O
tibialis O
anterior O
and O
gastrocnemius O
. O

 O
Electrocardiogram O
( O
ECG O
) O
revealed O
sinus O
rhythm O
, O
low O
voltages O
in O
limb O
leads O
, O
QS O
waves O
in O
precordial O
and O
inferior O
leads O
, O
first O
- O
degree O
atrioventricular O
block O
, O
and O
prolonged O
QTc O
( O
Figure O
1 O
) O
. O

 O
Two O
- O
dimensional O
echocardiography O
revealed O
marked O
concentrically O
thickened O
and O
speckled O
appearance O
of O
ventricular O
walls O
, O
biatrial O
dilatation O
, O
and O
left O
ventricular O
ejection O
fraction O
of O
70 O
% O
( O
Figure O
2 O
) O
. O

 O
Doppler O
revealed O
a O
severe O
restrictive O
mitral O
filling O
pattern O
with O
E O
/ O
A O
ratio O
2.1 O
. O

 O
Coronary O
angiography O
findings O
were O
normal O
. O

 O
The O
combined O
occurrence O
of O
low O
QRS O
voltage O
in O
the O
ECG O
, O
ventricular O
thickening O
, O
and O
signs O
of O
diastolic O
dysfunction O
is O
strongly O
suggestive O
of O
cardiac O
amyloidosis O
. O

 O
The O
following O
serum O
 O
light O
- O
chain O
concentration O
was O
1,763 O
( O
normal O
range O
: O
5981,329 O
mg O
/ O
dL O
, O
and O
 O
light O
- O
chain O
concentration O
was O
normal O
. O

 O
Rectum O
biopsy O
confirmed O
amyloid O
infiltrate O
( O
Figure O
3 O
) O
. O

 O
So O
, O
the O
diagnosis O
of O
AL O
amyloidosis O
was O
established O
. O

 O
Despite O
chemotherapy O
administration O
of O
melphalan O
, O
dexamethasone O
, O
immunomodulator O
lenalidomide O
, O
and O
supportive O
therapy O
including O
montmorillonite O
to O
decrease O
diarrhea O
and O
low O
- O
dose O
furosemide O
to O
alleviate O
fluid O
retention O
, O
the O
patient O
continued O
to O
deteriorate O
and O
at O
after O
the O
initial O
diagnosis O
. O

An O
with O
S549R/1717 O
- O
1 O
G O
 O
> O
 O
A O
genotype O
was O
started O
on O
( O
) O
on O
compassionate O
use O
. O

 O
At O
the O
he O
was O
diagnosed O
with O
CF B
due O
to O
failure B
to I
thrive I
. O

 O
His O
previous O
history O
was O
remarkable O
for O
requiring O
endoscopic O
surgery O
and O
necessitating O
enzyme O
replacement O
therapy O
. O

 O
He O
. O

 O
He O
suffered O
from O
rather O
mild O
, O
primarily O
intermittent O
productive O
, O
and O
had O
close O
to O
normal O
parameters O
in O
previous O
years O
as O
measured O
by O
and O
( O
) O
. O

 O
grew O
and O
on O
. O

 O
After O
of O
treatment O
, O
the O
patient O
reported O
clinical O
improvements O
in O
frequency O
, O
sputum O
production O
, O
physical O
performance O
, O
and O
less O
. O

 O
He O
gained O
1.4 O
kg O
in O
without O
changing O
the O
dose O
of O
his O
therapy O
. O

 O
His O
( O
Macroduct O
 O
) O
decreased O
from O
before O
ivacaftor O
to O
and O
( O
normal O
 O
< O
 O
30 O
mmol O
/ O
l O
[ O
11 O
] O
) O
of O
treatment O
. O

 O
His O
increased O
from O
( O
) O
to O
( O
) O
of O
therapy O
. O

 O
The O
( O
normal O
 O
< O
 O
8) O
decreased O
from O
to O
and O
of O
treatment O
( O
Table O
1 O
and O
Fig.1 O
) O
. O

We O
present O
the O
case O
of O
a O
, O
admitted O
to O
our O
clinic O
with O
severe O
abdominal O
, O
, O
, O
and O
. O

 O
The O
anamnesis O
revealed O
that O
the O
girl O
comes O
from O
a O
, O
and O
that O
she O
also O
, O
her O
. O

 O
The O
patient O
's O
personal O
history O
underlined O
that O
approximately O
she O
presented O
with O
severe O
abdominal O
, O
being O
diagnosed O
with O
acute O
appendicitis B
and O
she O
underwent O
, O
but O
the O
, O
thus O
due O
to O
, O
the O
suspicion O
of O
saturnine B
colic I
rose O
, O
and O
she O
was O
diagnosed O
with O
lead B
poisoning I
( O
: O
) O
, O
but O
she O
received O
only O
. O

 O
Approximately O
admission O
to O
our O
clinic O
, O
she O
was O
to O
the O
with O
another O
episode O
of O
saturnine B
colic I
( O
: O
) O
, O
and O
with O
EDTA O
( O
the O
admission O
in O
our O
clinic O
) O
was O
initiated O
, O
with O
a O
dose O
of O
, O
associated O
with O
. O

 O
The O
performed O
at O
the O
time O
of O
admission O
revealed O
the O
following O
pathological O
elements O
: O
, O
, O
of O
the O
, O
blue O
of O
the O
, O
at O
, O
and O
: O
. O

 O
The O
performed O
upon O
admission O
revealed O
hypochromic O
( O
( O
): O
, O
( O
): O
, O
( O
): O
) O
, O
increased O
level O
of O
( O
( O
): O
, O
( O
): O
, O
( O
): O
) O
, O
( O
( O
): O
) O
, O
( O
: O
) O
, O
and O
( O
: O
) O
. O

 O
The O
systolic O
was O
, O
and O
the O
diastolic O
was O
. O

 O
The O
blood O
level O
was O
, O
the O
urinary O
one O
was O
( O
normal O
< O
50 O
 O
g O
/ O
L O
) O
and O
the O
value O
of O
was O
( O
normal O
< O
4.5 O
 O
mg O
/ O
L O
) O
. O

 O
We O
also O
performed O
abdominal O
which O
revealed O
a O
of O
the O
in O
. O

 O
We O
requested O
from O
an O
, O
who O
recommended O
the O
continuation O
of O
with O
, O
increasing O
the O
dose O
at O
. O

 O
We O
also O
required O
a O
neurological O
, O
and O
the O
specialist O
established O
the O
diagnosis O
of O
behavioral B
disorders I
with O
depressive B
elements O
, O
and O
recommended O
. O

 O
Based O
on O
all O
these O
clinical O
and O
laboratory O
findings O
, O
we O
established O
the O
diagnosis O
of O
lead B
poisoning I
. O

 O
We O
initiated O
an O
intense O
i.v O
. O
in O
order O
to O
favor O
lead O
elimination O
, O
approximately O
initially O
, O
and O
we O
decreased O
progressively O
the O
quantity O
once O
she O
ceased O
to O
, O
and O
she O
was O
. O

 O
We O
associated O
, O
initially O
, O
but O
the O
values O
of O
the O
persisted O
, O
therefore O
we O
were O
forced O
to O
introduce O
also O
an O
, O
with O
the O
remission O
of O
. O

 O
Regarding O
the O
liver O
function O
, O
we O
administered O
, O
associated O
with O
. O

 O
We O
also O
administered O
in O
order O
to O
improve O
the O
neurological O
impairment O
. O

 O
The O
was O
, O
in O
the O
first O
the O
admission O
, O
the O
patient O
continued O
to O
present O
severe O
abdominal O
, O
, O
and O
she O
also O
complained O
of O
in O
the O
. O

 O
All O
the O
presented O
of O
the O
values O
after O
of O
. O

 O
On O
the O
of O
admission O
, O
we O
ceased O
the O
with O
. O

 O
We O
also O
repeated O
the O
blood O
and O
urinary O
lead O
levels O
. O

 O
The O
blood O
level O
was O
45.57 O
 O
g O
/ O
dL O
, O
and O
the O
urinary O
one O
was O
836.4 O
 O
g O
/ O
L O
before O
the O
patient O
. O

 O
The O
abdominal O
reevaluation O
revealed O
no O
. O

 O
of O
admission O
, O
the O
patient O
was O
without O
any O
, O
and O
we O
recommended O
no O
further O
exposure O
to O
lead O
, O
avoiding O
the O
contact O
and O
the O
working O
in O
the O
pottery O
process O
. O

 O
The O
long O
- O
term O
outcome O
of O
this O
case O
depends O
on O
further O
exposure O
to O
this O
heavy O
metal O
. O

 O
. O

A O
with O
a O
retroperitoneal O
in O
( O
) O
imaging O
with O
a O
history O
of O
right O
liver O
in O
, O
pulmonary O
wedge O
in O
, O
and O
in O
, O
in O
which O
the O
postoperative O
suggested O
the O
mixed O
liver B
cancer I
, O
and O
poorly O
differentiated O
lung B
cancer I
from O
liver O
. O

 O
At O
, O
the O
was O
very O
close O
to O
the O
, O
, O
, O
and O
. O

 O
The O
patient O
with O
unresectable O
had O
and O
when O
he O
was O
treated O
with O
, O
and O
for O
. O

 O
He O
kept O
a O
constant O
of O
, O
the O
of O
, O
and O
the O
of O
. O

 O
The O
patient O
had O
no O
obvious O
sense O
of O
abdominal O
, O
, O
, O
and O
. O

 O
On O
a O
test O
of O
levels O
, O
the O
results O
were O
, O
which O
showed O
3.7 O
 O
ng O
/ O
mL O
, O
17.3 O
 O
ng O
/ O
mL O
, O
and O
levels O
6.1 O
 O
U O
/ O
mL. O

 O
In O
this O
study O
, O
the O
procedure O
was O
approved O
by O
the O
ethics O
committee O
of O
the O
First O
Affiliated O
Hospital O
of O
Zhejiang O
University O
. O

 O
The O
efficacy O
of O
local O
was O
estimated O
with O
, O
which O
appraised O
the O
variations O
both O
in O
tumor O
size O
and O
lesion O
density O
on O
( O
) O
imaging O
: O
complete O
response O
, O
disappearance O
of O
all O
lesions O
and O
no O
new O
lesions O
; O
partial O
response O
( O
PR O
) O
, O
a O
decrease O
in O
size O
of O
10 O
% O
or O
a O
decrease O
in O
tumor O
density O
over O
15 O
% O
on O
CT O
and O
no O
new O
lesions O
; O
stable O
disease O
, O
not O
fit O
for O
complete O
response O
, O
PR O
, O
or O
progressive O
disease O
; O
and O
progressive O
disease O
, O
an O
increase O
in O
tumor O
size O
over O
10 O
% O
and O
not O
fit O
for O
PR O
by O
tumor O
density O
on O
CT O
or O
new O
lesions.[19 O
] O

 O
Preoperative O
imaging O
scan O
showed O
a O
of O
in O
size O
close O
to O
the O
, O
, O
and O
( O
Fig.1A O
) O
. O

 O
During O
substance O
phase O
, O
MR O
images O
indicated O
mildly O
high O
around O
the O
and O
intermediate O
low O
in O
the O
and O
in O
the O
( O
Fig.1B O
) O
. O

 O
Before O
the O
initial O
, O
there O
was O
a O
retroperitoneal O
mild O
on O
axial O
image O
( O
Fig.1C O
) O
. O

 O
In O
this O
study O
, O
the O
inpatient O
underwent O
percutaneous O
transhepatic O
and O
to O
avoid O
the O
nearby O
blood O
vessels O
, O
the O
procedure O
of O
which O
was O
performed O
under O
and O
mild O
. O

 O
We O
used O
to O
guide O
the O
inserting O
of O
2 O
Nd O
: O
YAG O
laser O
fibers O
( O
Echolaser O
X4 O
, O
ESAOTE O
, O
Italy O
) O
in O
0.3 O
 O
mm O
diameter O
through O
a O
21 O
- O
gauge O
Chiba O
needle O
into O
the O
lesions O
( O
Fig.1D O
) O
. O

 O
Although O
part O
of O
the O
heat O
ran O
off O
by O
blood O
flow,[20 O
] O
ablation O
could O
keep O
valid O
area O
from O
12 O
to O
15 O
 O
mm O
with O
the O
power O
of O
5 O
 O
W O
in O
5 O
to O
6 O
minutes O
. O

 O
Subsequently O
, O
immediate O
ultrasonography O
showed O
that O
the O
whole O
lesion O
was O
covered O
with O
hyperechoic O
zone O
( O
Fig.(Fig.1E O
and O
F O
) O
. O

 O
However O
, O
the O
next O
day O
contrast O
- O
enhanced O
ultrasound O
( O
CEUS O
) O
revealed O
an O
abnormal O
residual O
of O
proximal O
part O
of O
the O
pancreatic O
head O
( O
Fig.2A O
) O
. O

 O
At O
5 O
- O
day O
follow O
- O
up O
contrast O
- O
enhanced O
CT O
images O
, O
the O
lower O
mass O
had O
low O
signal O
intensity O
and O
upper O
tumor O
revealed O
intermediate O
high O
signal O
intensity O
of O
residual O
in O
substance O
phase O
( O
Fig.2B O
and O
C O
) O
. O

 O
Surprizingly O
, O
1 O
- O
week O
follow O
- O
up O
CEUS O
image O
showed O
an O
enlarged O
retroperitoneal O
lymph O
node O
located O
near O
the O
pancreatic O
head O
, O
which O
could O
be O
fusion O
of O
these O
residuary O
small O
nodules O
( O
Fig.2D O
) O
. O

 O
Then O
the O
patient O
undergoing O
the O
2nd O
ablation O
with O
2 O
laser O
fibers O
showed O
the O
lesions O
well O
- O
defined O
hyperechoic O
zone O
( O
Fig.2E O
and O
F O
) O
. O

 O
On O
the O
2nd O
day O
, O
postoperative O
CEUS O
images O
showed O
they O
were O
still O
remanent O
( O
Fig.2 O
G O
and O
I O
) O
. O

 O
At O
the O
corresponding O
MR O
imaging O
, O
it O
also O
showed O
this O
in O
left O
of O
tumor O
( O
Fig.2H O
) O
. O

 O
Thus O
, O
the O
3rd O
laser O
ablation O
was O
performed O
( O
Fig.2J)2J O
) O
and O
3 O
days O
later O
CEUS O
found O
that O
there O
was O
still O
a O
minor O
lesion O
located O
in O
the O
separation O
gap O
of O
last O
2 O
needles O
( O
Fig.3A O
) O
. O

 O
Subsequently O
the O
patient O
had O
the O
4th O
ablation O
along O
this O
separation O
gap O
until O
hyperechoic O
overlay O
( O
Fig.3B O
 O
D O
) O
, O
then O
3 O
days O
later O
, O
based O
on O
these O
4 O
treatments O
, O
enhanced O
CT O
image O
of O
the O
retroperitoneal O
mass O
suggested O
complete O
necrosis O
( O
Fig.3E O
 O
G).3E O
 O
G O
) O
. O

 O
After O
the O
following O
1 O
month O
, O
substance O
phase O
MR O
revealed O
low O
- O
intensity O
signal O
of O
tumor O
necrosis O
with O
resolution O
of O
his O
problems O
( O
Fig.3H O
) O
. O

 O
Until O
5 O
months O
after O
4 O
ablations O
, O
CT O
showed O
the O
tumor O
PR O
with O
little O
enhanced O
recurrence O
( O
yellow O
arrows O
) O
, O
which O
located O
in O
the O
left O
lower O
edge O
of O
original O
lesions O
( O
Fig.4A O
and O
B O
) O
. O

 O
On O
laboratory O
test O
of O
tumor O
markers O
, O
the O
levels O
of O
carcinoembryonic O
antigen O
, O
alpha O
fetoprotein O
, O
and O
carbohydrate O
antigen O
199 O
indicated O
3.6 O
 O
ng O
/ O
mL O
, O
26.7 O
 O
ng O
/ O
mL O
, O
and O
8.1 O
 O
U O
/ O
mL O
, O
respectively O
. O

 O
No O
obvious O
were O
discovered O
in O
this O
case O
during O
these O
procedures O
. O

A O
was O
referred O
to O
our O
department O
from O
an O
external O
hospital O
because O
of O
severe O
abdominal O
pain O
of O
unclear O
aetiology O
. O

 O
The O
patient O
suffered O
from O
Friedreich O
's O
ataxia.1 O
2 O
His O
most O
recent O
transthoracic O
echocardiography O
, O
performed O
on O
the O
day O
of O
admission O
, O
showed O
a O
dilated O
cardiomyopathy O
, O
impaired O
left O
ventricular O
function O
with O
an O
ejection O
fraction O
of O
30 O
% O
and O
a O
pulmonary O
artery O
pressure O
of O
55 O
 O
mm O
 O
Hg O
; O
all O
findings O
were O
unchanged O
from O
previous O
examinations O
. O

 O
At O
that O
time O
, O
he O
lived O
alone O
in O
a O
residential O
home O
and O
was O
mobile O
using O
a O
wheelchair O
. O

 O
On O
arrival O
at O
our O
emergency O
department O
, O
the O
patient O
was O
somnolent O
and O
disoriented O
. O

 O
His O
axillary O
body O
temperature O
was O
35.7 O
 O
 O
C O
and O
his O
arterial O
blood O
pressure O
125/89 O
 O
mm O
 O
Hg O
, O
with O
a O
pulse O
rate O
of O
84 O
rhythmic O
beats O
/ O
min O
. O

 O
He O
complained O
of O
an O
increasing O
, O
diffuse O
abdominal O
pain O
during O
the O
whole O
day O
, O
combined O
with O
absence O
of O
appetite O
and O
vomiting O
on O
a O
single O
occasion O
. O

 O
His O
daily O
medication O
was O
perindopril O
2.5 O
 O
mg O
, O
torasemide O
7.5 O
 O
mg O
and O
esomeprazole O
40 O
 O
mg O
. O

 O
On O
physical O
examination O
, O
we O
found O
a O
tender O
abdomen O
with O
painful O
epigastric O
palpation O
. O

 O
Normal O
bowel O
sounds O
were O
auscultated O
in O
the O
upper O
right O
and O
lower O
left O
quadrants O
. O

 O
The O
renal O
bed O
was O
free O
of O
pain O
on O
palpation O
. O

 O
On O
cardiac O
auscultation O
, O
a O
2/6 O
systolic O
murmur O
was O
audible O
. O

 O
Lung O
auscultation O
showed O
normal O
respiration O
. O

 O
Laboratory O
findings O
were O
slightly O
elevated O
C O
reactive O
protein O
( O
CRP O
) O
of O
16 O
 O
mg O
/ O
l O
( O
normal O
: O
< O
5 O
 O
mg O
/ O
l O
) O
, O
elevated O
troponin O
- O
T O
- O
hs O
of O
0.070 O
 O
g O
/ O
l O
( O
normal O
: O
< O
0.014 O
 O
g O
/ O
l O
) O
and O
highly O
elevated O
pro O
- O
B O
- O
type O
natriuretic O
peptide O
of O
7382 O
 O
pg O
/ O
ml O
( O
normal O
: O
< O
63 O
 O
pg O
/ O
ml O
) O
. O

 O
Kidney O
function O
parameters O
were O
in O
the O
upper O
normal O
range O
, O
with O
creatinine O
of O
100 O
mol O
/ O
l O
and O
a O
calculated O
glomerular O
filtration O
rate O
of O
73 O
 O
ml O
/ O
min O
. O

 O
Blood O
count O
revealed O
leucocytosis O
of O
15.6109 O
/ O
litre O
. O

 O
Regarding O
thyroid O
function O
, O
thyroid O
- O
stimulating O
hormone O
, O
f O
- O
T3 O
and O
f O
- O
T4 O
were O
in O
the O
reference O
range O
. O

 O
Urine O
analysis O
showed O
no O
pathology O
. O

 O
In O
abdominal O
sonography O
, O
all O
organs O
were O
normal O
, O
especially O
the O
kidneys O
. O

 O
No O
free O
fluid O
was O
detected O
( O
figure O
1 O
) O
. O

 O
As O
the O
severe O
pain O
persisted O
all O
night O
, O
despite O
analgesia O
with O
paracetamol O
1 O
 O
g O
, O
metamizole O
1 O
 O
g O
and O
pethidine O
75 O
 O
g O
, O
a O
contrast O
- O
enhanced O
abdominal O
CT O
was O
performed O
revealing O
infarction O
of O
the O
right O
kidney O
, O
which O
appeared O
as O
a O
hypodense O
area O
although O
kidney O
arteries O
and O
veins O
were O
assessed O
as O
open O
( O
figures O
2 O
and O
3 O
) O
. O

 O
Cardiac O
dysfunction O
is O
the O
most O
frequent O
cause O
of O
death O
in O
patients O
affected O
by O
Friedreich O
's O
ataxia O
, O
most O
commonly O
from O
congestive O
heart O
failure O
or O
arrhythmia O
. O

 O
Renal O
artery O
embolism O
is O
not O
a O
rare O
event O
in O
these O
patients O
. O

 O
However O
, O
other O
non O
- O
abdominal O
viscous O
causes O
of O
severe O
diffuse O
abdominal O
pain O
such O
as O
porphyria O
, O
familial O
Mediterranean O
fever O
, O
diabetic O
ketoacidosis O
, O
tocopherol O
deficiency O
also O
had O
to O
be O
excluded O
. O

 O
The O
negative O
cardiolipin O
test O
excluded O
tabetic O
crises O
. O

 O
No O
evidence O
for O
pre O
- O
existing O
porphyria O
was O
encountered O
for O
example O
, O
quantitative O
determination O
of O
 O
- O
aminolevulinic O
acid O
, O
porphobilinogen O
and O
porphyrin O
in O
24 O
- O
h O
urine O
was O
negative O
. O

 O
Further O
genetic O
diagnosis O
regarding O
, O
for O
example O
, O
clotting O
disorder O
, O
was O
also O
not O
conclusive O
. O

 O
Hypovitaminosis O
was O
not O
present O
. O

 O
The O
patient O
had O
no O
endocrinopathies O
, O
for O
example O
, O
no O
diabetes O
and O
no O
evidence O
for O
hypothyreosis O
or O
hyperthyreosis O
. O

 O
The O
patient O
was O
hospitalised O
without O
delay O
at O
the O
department O
of O
nephrology O
. O

 O
Immediate O
anticoagulation O
with O
heparin O
was O
initiated O
and O
later O
replaced O
by O
lifelong O
oral O
anticoagulation O
with O
phenprocoumon O
. O

 O
During O
11 O
 O
days O
of O
hospitalisation O
, O
no O
complications O
occurred O
. O

 O
Kidney O
function O
parameters O
remained O
normal O
. O

 O
Transoesophageal O
echocardiography O
on O
the O
fifth O
day O
showed O
no O
cardiac O
thrombus O
and O
no O
patent O
foramen O
ovale O
. O

 O
Deep O
vein O
thrombosis O
was O
excluded O
with O
duplex O
sonography O
. O

 O
Anticardiolipin O
antibody O
testing O
and O
genetic O
testing O
regarding O
clotting O
disorders O
were O
both O
negative O
. O

 O
Urine O
tests O
revealed O
no O
evidence O
of O
porphyria O
. O

 O
During O
hospitalisation O
the O
patient O
remained O
stable O
regarding O
cardiological O
function O
, O
while O
diuretics O
were O
adjusted O
according O
to O
the O
fluid O
balance O
. O

 O
The O
patient O
had O
already O
been O
treated O
with O
levofloxacin O
for O
pneumonic O
infection O
prior O
to O
hospitalisation O
. O

 O
The O
antibiotic O
treatment O
was O
continued O
because O
of O
increasing O
inflammatory O
parameters O
in O
the O
further O
course O
of O
disease O
. O

 O
A O
CRP O
increase O
of O
up O
to O
200 O
 O
mg O
/ O
l O
was O
interpreted O
as O
an O
inflammatory O
response O
to O
renal O
infarction O
. O

 O
By O
, O
were O
. O

A O
the O
in O
because O
of O
a O
complaint O
of O
sudden O
. O

 O
She O
was O
previously O
diagnosed O
with O
and O
prescribed O
a O
combination O
oral O
( O
drospirenone O
/ O
, O
, O
) O
. O

 O
Following O
the O
Kumamoto O
Earthquakes O
and O
subsequent O
aftershocks O
in O
, O
she O
spent O
7 O
nights O
in O
a O
. O

 O
She O
noticed O
sudden O
when O
she O
the O
car O
on O
the O
the O
. O

 O
Although O
she O
for O
personal O
reasons O
during O
the O
daytime O
, O
she O
spent O
nights O
in O
her O
small O
car O
with O
her O
legs O
in O
a O
hanging O
position O
. O

 O
She O
noticed O
swelling O
and O
pain O
in O
her O
left O
lower O
extremity O
, O
and O
her O
serum O
D O
- O
dimer O
levels O
were O
13.2 O
g O
/ O
mL. O

 O
Deep B
vein I
thrombosis I
( O
DVT B
) O
was O
suspected O
by O
her O
home O
doctor O
. O

 O
A O
contrast O
- O
enhanced O
( O
CT)-scan O
revealed O
a O
contrast O
deficit O
in O
the O
bilateral O
pulmonary O
artery O
( O
Fig.2A O
) O
and O
in O
the O
left O
lower O
extremity O
( O
posterior O
tibial O
, O
soleus O
and O
gastrocnemius O
vein O
) O
( O
Fig.2B O
) O
. O

 O
Her O
right O
ventricular O
function O
was O
intact O
( O
estimated O
pulmonary O
artery O
pressure=29/8 O
mmHg O
in O
cardiac O
ultrasound O
) O
. O

 O
Her O
plasma O
brain O
natriuretic O
peptide O
and O
high O
- O
sense O
troponin O
T O
concentration O
levels O
were O
97.2 O
pg O
/ O
mL O
and O
0.0061 O
ng O
/ O
mL O
, O
respectively O
. O

 O
She O
was O
diagnosed O
with O
PTE O
and O
admitted O
to O
our O
department O
. O

 O
On O
admission O
, O
her O
blood O
pressure O
was O
129/80 O
mmHg O
and O
her O
heart O
rate O
was O
72 O
beats O
per O
minute O
. O

 O
Her O
degree O
of O
oxygen O
saturation O
( O
SaO2 O
) O
in O
arterial O
blood O
gas O
was O
97.7 O
% O
. O

 O
Her O
was O
. O

 O
and O
cardiac O
did O
not O
indicate O
heart B
failure I
. O

 O
An O
investigation O
of O
most O
( O
including O
, O
, O
, O
and O
) O
revealed O
that O
all O
such O
factors O
were O
. O

 O
The O
discontinuation O
of O
the O
oral O
and O
the O
administration O
of O
( O
) O
, O
a O
direct O
oral O
( O
, O
) O
was O
initiated O
( O
3 O
) O
. O

 O
, O
a O
contrast O
- O
enhanced O
scan O
revealed O
a O
reduction O
in O
the O
thrombosis B
( O
Fig.3 O
) O
. O

 O
The O
patient O
was O
with O
. O

 O
The O
patient O
gave O
her O
consent O
for O
the O
publication O
of O
this O
study O
. O

A O
Caucasian O
woman O
of O
Ashkenazi O
Jewish O
descent O
presented O
with O
the O
chief O
complaint O
of O
severe O
and O
constant O
throbbing O
in O
her O
. O

 O
She O
reported O
that O
her O
was O
aggravated O
by O
, O
and O
started O
the O
initial O
consultation O
visit O
. O

 O
was O
reported O
at O
the O
. O

 O
Past O
medical O
history O
was O
remarkable O
for O
Gaucher B
disease I
, O
left O
hip O
, O
gall O
bladder O
, O
, O
spleen O
, O
hepatitis B
C I
infection I
, O
and O
asthma B
. O

 O
Social O
history O
was O
significant O
for O
20 O
pack O
- O
years O
of O
. O

 O
Her O
family O
history O
was O
. O

 O
Her O
medications O
included O
the O
oral O
antiresorptive O
drug O
for O
early O
osteoporosis O
associated O
with O
Gaucher O
disease O
( O
70 O
mg O
weekly O
for O
2 O
years O
) O
, O
, O
, O
, O
, O
, O
, O
, O
and O
. O

 O
She O
reported O
that O
she O
had O
been O
on O
enzyme O
replacement O
therapy O
( O
ERT O
) O
for O
to O
treat O
her O
Gaucher B
disease I
which O
was O
diagnosed O
. O

 O
She O
received O
intravenous O
injections O
twice O
a O
month O
for O
and O
recounted O
after O
each O
infusion O
. O

 O
She O
also O
reported O
receiving O
and O
medications O
for O
her O
pain O
but O
they O
were O
not O
helpful O
. O
, O
and O
were O
. O

 O
was O
completed O
using O
, O
and O
for O
evaluation O
of O
her O
in O
the O
region O
of O
the O
chief O
complaint O
. O

 O
Her O
was O
and O
, O
while O
her O
remaining O
were O
normal O
on O
with O
of O
several O
opposing O
non O
- O
restored O
and O
non O
- O
carious O
as O
internal O
controls O
. O

 O
in O
both O
were O
and O
there O
was O
no O
gross O
evidence O
of O
or O
. O

 O
in O
her O
ranged O
from O
with O
no O
significant O
. O

 O
Full O
mouth O
and O
a O
panoramic O
were O
taken O
and O
showed O
relatively O
well O
- O
defined O
radiolucent O
in O
multiple O
regions O
of O
the O
, O
with O
a O
( O
) O
appearance O
; O
cone O
- O
beam O
confirmed O
these O
findings O
and O
revealed O
a O
large O
lytic O
of O
her O
in O
the O
region O
of O
her O
chief O
complaint O
( O
Figure O
1).Our O
clinical O
and O
radiographic O
differential O
diagnosis O
for O
her O
chief O
complaint O
included O
chronic O
apical B
periodontitis I
, O
radicular B
cyst I
, O
central B
giant I
cell I
granuloma I
, O
keratocystic O
odontogenic B
tumor I
, O
ameloblastoma B
, O
odontogenic B
fibroma I
, O
/ O
neuropathy B
or O
mandibular O
involvement O
of O
Gaucher B
disease I
given O
her O
medical O
history O
. O

 O
Our O
findings O
were O
with O
the O
patient O
and O
written O
consent O
was O
obtained O
for O
surgical O
of O
her O
with O
for O
more O
definitive O
diagnosis O
. O

 O
A O
four O
- O
corner O
was O
reflected O
in O
her O
extending O
from O
the O
to O
the O
, O
and O
cortical O
bone O
was O
with O
a O
to O
for O
access O
to O
the O
. O

 O
was O
evident O
through O
the O
access O
window O
. O

 O
The O
entire O
along O
with O
the O
bone O
from O
the O
access O
window O
was O
submitted O
to O
the O
pathology O
laboratory O
for O
. O

 O
revealed O
of O
with O
fibrous O
connective O
tissue O
containing O
abundant O
( O
Figure O
2 O
) O
. O

 O
There O
was O
no O
evidence O
of O
or O
, O
granuloma B
or O
. O

 O
was O
, O
and O
the O
patient O
reported O
of O
her O
chief O
complaint O
and O
symptomatology O
at O
. O

 O
She O
was O
to O
her O
for O
and O
further O
as O
related O
to O
her O
Gaucher B
disease I
status O
following O
our O
findings O
. O

 O
She O
was O
again O
treated O
with O
and O
at O
was O
still O
free O
in O
her O
. O

A O
with O
known O
diastolic O
congestive B
heart I
failure I
( B
CHF I
) I
presented O
to O
the O
with O
of O
CHF B
and O
a O
decreased O
. O

 O
Brachial O
blood O
pressure O
( O
BP O
) O
was O
measured O
at O
. O

 O
The O
patient O
had O
four O
recent O
with O
exacerbation O
of O
CHF O
. O

 O
Her O
medical O
history O
was O
also O
significant O
for O
autoimmune O
hepatitis B
, O
but O
preserved O
; O
esophageal O
varices O
with O
a O
bleeding O
episode O
; O
and O
long O
- O
term O
complicated O
by O
adrenal O
insufficiency O
, O
type B
2 I
diabetes I
mellitus I
and O
osteoporosis B
. O

 O
Recent O
had O
revealed O
concentric O
left O
ventricular O
hypertrophy B
with O
, O
and O
mild O
to O
moderate O
mitral B
regurgitation I
. O

 O
Cardiac O
catheterization O
in O
a O
recent O
demonstrated O
50 O
% O
stenosis O
in O
the O
, O
with O
mild O
diffuse O
disease O
in O
the O
. O

 O
Right O
ventricular O
endomyocardial O
had O
ruled O
out O
myocarditis O
and O
infiltrative O
cardiomyopathies B
, O
but O
healing O
ischemic B
microinfarcts I
with O
atheroemboli B
were O
observed O
. O

 O
Previous O
were O
also O
; O
was O
between O
and O
, O
and O
was O
between O
and O
. O

 O
Following O
, O
was O
started O
for O
hypotension O
management O
and O
was O
later O
replaced O
with O
. O

 O
The O
patient O
developed O
atrial B
flutter I
but O
successfully O
converted O
to O
sinus O
rhythm O
with O
two O
direct O
current O
. O

 O
Cardiology O
consultation O
resulted O
in O
to O
the O
. O

 O
On O
to O
the O
, O
was O
measured O
at O
in O
the O
but O
was O
not O
detectable O
in O
the O
. O

 O
An O
was O
inserted O
via O
the O
, O
and O
was O
measured O
at O
. O

 O
BP O
values O
were O
consistently O
much O
through O
the O
than O
the O
cuff O
on O
the O
arms O
, O
and O
was O
in O
the O
than O
in O
the O
. O

 O
For O
instance O
, O
, O
was O
measured O
at O
through O
the O
, O
while O
on O
the O
arms O
were O
on O
the O
left O
and O
on O
the O
right O
. O

 O
To O
investigate O
the O
inconsistency O
between O
brachial O
and O
femoral O
BP O
values O
, O
a O
( O
CT O
) O
of O
the O
was O
obtained O
using O
, O
both O
before O
and O
after O
intravenous O
contrast O
injection O
with O
sagittal O
and O
coronal O
planar O
reformatting O
of O
maximum O
- O
intensity O
projection O
images O
. O

 O
Analysis O
of O
the O
initial O
unenhanced O
CT O
images O
showed O
densely O
calcified O
plaque O
or O
thrombus O
at O
the O
origins O
of O
both O
subclavian O
arteries O
and O
the O
right O
common O
carotid O
artery O
. O

 O
The O
CT O
angiogram O
showed O
absence O
of O
flow O
in O
the O
right O
subclavian O
artery O
, O
a O
very O
tight O
stenosis O
at O
the O
origin O
of O
the O
left O
subclavian O
artery O
and O
a O
tight O
stenosis O
at O
the O
origin O
of O
the O
right O
common O
carotid O
artery O
. O

 O
Both O
vertebral O
arteries O
showed O
normal O
calibre O
and O
flow O
( O
Figure O
1 O
) O
. O

 O
Further O
management O
following O
the O
insertion O
of O
the O
femoral O
arterial O
line O
was O
based O
on O
femoral O
BP O
readings O
with O
diuretics O
and O
BP O
- O
lowering O
agents O
. O

 O
The O
patient O
was O
eventually O
discharged O
in O
stable O
condition O
. O

 O
She O
remained O
stable O
, O
without O
further O
exacerbation O
of O
CHF B
or O
related O
. O

A O
with O
a O
history O
of O
metastatic O
mucinous O
appendiceal O
adenocarcinoma O
presents O
for O
evaluation O
of O
a O
desquamating O
rash O
on O
his O
face O
that O
has O
spread O
to O
his O
scalp O
, O
inguinal O
region O
, O
and O
perineum O
over O
the O
past O
4 O
months O
( O
Figure O
1 O
) O
. O

 O
The O
rash O
has O
been O
accompanied O
by O
diffuse O
alopecia O
of O
the O
face O
, O
scalp O
, O
axilla O
, O
and O
groin O
. O

 O
There O
was O
no O
improvement O
in O
the O
rash O
despite O
multiple O
rounds O
of O
oral O
fluconazole O
, O
topical O
antibiotic O
ointment O
, O
and O
intravenous O
antibiotics O
. O

 O
Prior O
to O
the O
development O
of O
his O
rash O
, O
he O
completed O
neoadjuvant O
chemotherapy O
followed O
by O
surgical O
resection O
. O

 O
He O
underwent O
colostomy O
after O
he O
failed O
surgical O
correction O
for O
an O
enterocutaneous O
fistula O
, O
and O
he O
has O
required O
total O
parenteral O
nutrition O
( O
TPN O
) O
for O
the O
past O
year O
. O

 O
He O
did O
not O
notice O
any O
significant O
changes O
in O
ostomy O
output O
during O
this O
time O
. O

 O
Dermatological O
examination O
reveals O
widespread O
erythematous O
plaques O
on O
the O
face O
, O
scalp O
, O
and O
medial O
aspect O
of O
thighs O
bilaterally O
and O
scattered O
papules O
with O
scaling O
on O
face O
, O
scalp O
, O
chest O
, O
and O
back O
. O

 O
Diffuse O
, O
non O
- O
scarring O
alopecia O
is O
present O
on O
the O
face O
, O
scalp O
, O
axillae O
, O
and O
groin O
. O

 O
The O
patient O
had O
acquired O
AE O
, O
a O
rare O
dermatologic O
condition O
caused O
by O
zinc O
deficiency O
. O

 O
This O
patient O
developed O
acquired O
zinc O
deficiency O
in O
the O
setting O
of O
inadequate O
zinc O
supplementation O
in O
TPN O
. O

 O
The O
patient O
had O
not O
received O
trace O
elements O
for O
approximately O
one O
year O
due O
to O
a O
national O
shortage O
. O

 O
The O
key O
to O
the O
correct O
diagnosis O
of O
acquired O
AE O
is O
the O
combination O
of O
desquamating O
rash O
coupled O
with O
alopecia O
in O
the O
setting O
of O
chronic O
supplemental O
alimentation O
. O

 O
Although O
it O
is O
reasonable O
to O
consider O
a O
skin O
biopsy O
, O
a O
skin O
biopsy O
would O
not O
definitively O
establish O
the O
diagnosis O
. O

 O
A O
paraneoplastic O
panel O
could O
be O
considered O
, O
but O
it O
would O
delay O
diagnosis O
, O
and O
the O
presentation O
is O
most O
consistent O
with O
nutritional O
deficiency O
. O

 O
It O
is O
not O
appropriate O
to O
start O
a O
topical O
steroid O
cream O
until O
a O
diagnosis O
is O
determined O
. O

 O
The O
patient O
had O
a O
level O
of O
( O
normal O
range O
56 O
- O
134 O
ug O
/ O
dL O
) O
. O

 O
He O
received O
in O
his O
TPN O
, O
and O
within O
one O
month O
, O
the O
patient O
had O
complete O
resolution O
of O
rash O
and O
fatigue O
, O
and O
gradual O
return O
of O
hair O
growth O
( O
Figure O
2 O
) O
. O

 O
Repeat O
zinc O
level O
following O
supplementation O
was O
90 O
ug O
/ O
dL. O

 O
Although O
the O
patient O
recovered O
from O
his O
zinc O
deficiency O
, O
he O
later O
. O

A O
at O
our O
complaining O
of O
intracranial O
. O

 O
The O
cranial O
nerve O
and O
were O
. O

 O
A O
DVAF B
was O
considered O
, O
was O
performed O
, O
which O
showed O
a O
Cognard B
II I
DVAF I
in O
the O
location O
of O
( O
) O
. O

 O
The O
was O
fed O
by O
the O
of O
the O
, O
and O
the O
within O
the O
that O
was O
the O
mainly O
. O

 O
was O
insisted O
upon O
by O
the O
patient O
because O
of O
the O
associated O
intolerable O
intracranial O
. O

 O
Treatment O
was O
performed O
by O
under O
using O
a O
. O

 O
were O
used O
. O

 O
The O
into O
the O
. O

 O
Marathon O
flow O
directed O
catheter O
( O
eV3 O
) O
was O
subsequently O
navigated O
over O
a O
Mirage.008 O
microwire O
( O
eV3 O
) O
to O
reach O
as O
near O
as O
possible O
to O
the O
fistula O
. O

 O
The O
with O
of O
. O

 O
The O
dead O
space O
of O
the O
microcatheter O
was O
subsequently O
filled O
with O
dimethyl O
sulfoxide O
( O
DMSO O
) O
. O

 O
Onyx-18 O
was O
then O
injected O
over O
two O
minutes O
to O
fill O
the O
microcatheter O
and O
to O
replace O
the O
DMSO O
in O
the O
dead O
space O
. O

 O
The O
injection O
was O
stopped O
until O
unwanted O
flow O
into O
branches O
of O
the O
right O
ascending O
pharyngeal O
artery O
was O
observed O
. O

 O
The O
follow O
- O
up O
showed O
no O
( O
Figure O
1 O
) O
. O

 O
The O
disappeared O
immediately O
after O
the O
operation O
. O

 O
For O
the O
toxicity O
of O
DMSO O
, O
was O
for O
. O

 O
On O
the O
, O
the O
patient O
complainted O
of O
to O
the O
left O
. O

 O
Cranial O
nerve O
was O
only O
significant O
for O
a O
. O

 O
The O
patient O
was O
from O
our O
without O
. O

 O
At O
, O
the O
patient O
's O
main O
complaint O
were O
difficulty O
swallowing O
( O
) O
and O
slurred O
speech O
( O
) O
. O

 O
In O
addition O
, O
his O
tongue O
deviated O
toward O
the O
right O
during O
tongue O
protrusion O
, O
and O
marked O
right O
- O
sided O
was O
observed O
( O
Figure O
2 O
) O
. O

 O
The O
cranial O
nerve O
showed O
persisted O
. O

 O
We O
telephone O
the O
patient O
at O
and O
requested O
a O
by O
an O
in O
a O
. O

 O
Vocal O
cord O
was O
not O
found O
, O
and O
there O
was O
no O
evidence O
of O
vagus O
nerve O
. O

 O
was O
used O
and O
his O
prognosis O
was O
still O
at O
a O
long O
. O

A O
was O
referred O
by O
to O
with O
suspected O
LTG B
due O
to O
repeatedly O
irregular O
, O
advanced O
optic O
disc O
cupping O
, O
normal O
( O
) O
and O
a O
family O
history O
of O
glaucoma B
. O

 O
The O
patient O
subjectively O
felt O
that O
vision O
in O
his O
 O
good O
 O
( O
) O
, O
which O
normally O
had O
a O
visual O
acuity O
of O
, O
started O
to O
deteriorate O
; O
at O
the O
point O
of O
referral O
it O
was O
best O
corrected O
to O
. O

 O
His O
( O
) O
was O
known O
to O
be O
amblyopic B
with O
a O
visual O
acuity O
of O
. O

 O
His O
medical O
history O
included O
considerable O
risk O
factors O
for O
systemic O
vasculopathy O
, O
such O
as O
hypertension B
, O
hypercholesterolaemia B
, O
of O
and O
type B
2 I
diabetes I
with O
no O
diabetic B
retinopathy I
. O

 O
Despite O
detailed O
questioning O
, O
he O
denied O
any O
apart O
from O
experiencing O
increased O
. O

 O
Clinical O
examination O
at O
revealed O
advanced O
bilateral O
with O
a O
right O
( O
) O
and O
left O
( O
; O
figure O
1 O
) O
. O

 O
Furthermore O
, O
the O
findings O
from O
the O
referring O
of O
equal O
and O
reactive O
pupils O
, O
normal O
eye O
movements O
and O
in O
were O
confirmed O
. O

 O
showed O
constricted O
in O
both O
, O
albeit O
with O
considerably O
raised O
false O
- O
negative O
error O
rates O
( O
figure O
2A O
) O
. O

 O
Since O
this O
can O
be O
a O
result O
of O
poor O
concentration O
and O
attention O
span O
with O
testing O
compounded O
, O
especially O
with O
an O
amblyopic O
, O
the O
was O
repeated O
( O
figure O
2B O
) O
. O

 O
At O
this O
visit O
, O
the O
patient O
experienced O
further O
deterioration O
of O
his O
 O
good O
 O
. O

 O
measured O
( O
loss O
of O
one O
Snellen O
line O
) O
in O
his O
amblyopic O
, O
and O
( O
loss O
of O
two O
Snellen O
lines O
) O
in O
his O
, O
which O
now O
also O
showed O
depressed O
. O

 O
An O
urgent O
of O
the O
patient O
's O
and O
was O
requested O
to O
rule O
out O
a O
compressive O
lesion B
and O
was O
carried O
out O
to O
screen O
for O
other O
causes O
of O
optic B
neuropathy I
including O
, O
and O
. O

 O
revealed O
a O
large O
mass B
centred O
at O
the O
measuring O
approximately O
( O
figure O
3A O
 O
C O
) O
extending O
into O
the O
and O
. O

 O
The O
and O
both O
were O
and O
. O

 O
The O
mass B
showed O
heterogeneous O
and O
T2 O
with O
multiple O
most O
likely O
due O
to O
previous O
haemorrhage B
and O
low O
- O
signal O
components O
suggesting O
calcifications B
. O

 O
The O
appearance O
was O
probably O
due O
to O
a O
craniopharyngioma B
or O
haemorrhagic O
pituitary B
adenoma I
. O

 O
The O
patient O
was O
referred O
urgently O
to O
the O
and O
was O
found O
to O
have O
markedly O
raised O
of O
, O
confirming O
the O
diagnosis O
of O
a O
giant O
prolactinoma B
. O

 O
In O
cooperation O
with O
the O
local O
endocrinology O
service O
, O
he O
was O
started O
on O
and O
. O

 O
this O
led O
to O
a O
dramatic O
improvement O
of O
the O
patient O
's O
to O
RE O
and O
to O
. O

 O
His O
showed O
a O
similar O
dramatic O
response O
with O
levels O
coming O
down O
to O
336 O
 O
mIU O
/ O
L. O

 O
his O
in O
his O
and O
were O
and O
, O
respectively O
, O
and O
showed O
striking O
recovery O
with O
( O
figure O
2C O
) O
. O

A O
was O
in O
the O
( O
) O
for O
chest O
and O
. O

 O
She O
was O
found O
to O
have O
a O
urinary O
tract O
infection B
and O
was O
sent O
home O
with O
an O
and O
. O

 O
, O
she O
returned O
with O
epigastric O
, O
, O
and O
. O

 O
The O
patient O
had O
and O
denied O
; O
however O
, O
she O
complained O
of O
a O
for O
the O
. O

 O
There O
was O
. O

 O
She O
was O
and O
had O
. O

 O
On O
examination O
, O
she O
was O
( O
170/105 O
 O
mm O
 O
Hg O
) O
, O
( O
125 O
 O
bpm O
) O
, O
had O
and O
looking O
. O

 O
She O
was O
found O
to O
have O
an O
elevated O
of O
( O
normal O
60110 O
 O
mol O
/ O
l O
) O
. O

 O
After O
receiving O
1.5 O
 O
l O
of O
intravenous O
fluids O
for O
presumed O
volume O
depletion O
and O
prerenal O
azotaemia O
she O
became O
. O

 O
were O
noted O
on O
of O
her O
and O
a O
portable O
chest O
film O
demonstrated O
hazy O
infiltrates O
that O
likely O
represented O
pulmonary O
oedema O
. O

 O
She O
then O
developed O
with O
systolic O
pressures O
in O
the O
90s O
. O

 O
Non O
- O
invasive O
positive O
pressure O
ventilation O
was O
initiated O
. O

 O
An O
ECG O
demonstrated O
sinus O
tachycardia O
with O
a O
rate O
of O
130 O
 O
bpm O
and O
minimal O
ST O
depression O
on O
the O
precordial O
leads O
. O

 O
In O
consultation O
with O
a O
cardiologist O
, O
the O
patient O
received O
40 O
 O
mg O
of O
intravenous O
furosemide O
. O

 O
An O
echocardiogram O
demonstrated O
global O
hypokinesis O
with O
a O
left O
- O
ventricular O
ejection O
fraction O
< O
10 O
% O
( O
see O
figure O
1 O
) O
. O

 O
The O
patient O
was O
transferred O
to O
the O
intensive O
care O
unit O
where O
she O
became O
more O
anxious O
and O
tachycardic O
to O
170 O
 O
bpm O
. O

 O
She O
was O
intubated O
and O
sedated O
. O

 O
Despite O
the O
placement O
of O
a O
Foley O
catheter O
and O
administration O
of O
intravenous O
loop O
diuretics O
, O
she O
remained O
anuric O
for O
the O
first O
12 O
 O
h O
of O
hospitalisation O
. O

 O
She O
developed O
signs O
of O
acute O
kidney O
injury O
with O
a O
creatinine O
that O
increased O
to O
350 O
 O
mol O
/ O
l O
within O
the O
first O
24 O
 O
h O
of O
hospitalisation O
. O

 O
She O
received O
norepinephrine O
and O
milrinone O
to O
improve O
cardiac O
output O
. O

 O
On O
the O
second O
day O
of O
hospitalisation O
, O
she O
was O
evaluated O
by O
a O
cardiologist O
and O
cardiothoracic O
surgeon O
for O
emergent O
circulatory O
support O
as O
she O
had O
developed O
signs O
of O
poor O
tissue O
perfusion O
with O
a O
lactic O
acidosis O
( O
8.4 O
 O
mmol O
/ O
l O
; O
normal O
< O
2.2 O
 O
mmol O
/ O
l O
) O
and O
transaminitis O
with O
aspartate O
aminotransferase O
/ O
alanine O
transaminase O
  O
> O
150 O
 O
IU O
/ O
l O
( O
normal O
< O
40 O
 O
U O
/ O
l O
) O
. O

 O
She O
was O
taken O
to O
the O
cardiac O
catheterisation O
laboratory O
for O
emergent O
right O
heart O
catheterisation O
and O
biopsy O
to O
exclude O
acute O
myocarditis O
. O

 O
Over O
the O
next O
few O
days O
, O
she O
was O
gently O
fluid O
resuscitated O
( O
guided O
by O
bioreactance O
non O
- O
invasive O
cardiac O
output O
) O
, O
the O
pressors O
were O
gradually O
weaned O
off O
and O
she O
became O
non O
- O
oliguric O
. O

 O
She O
slowly O
regained O
renal O
function O
and O
organ O
perfusion O
improved O
with O
resolution O
of O
the O
lactic O
acidosis O
and O
a O
decrease O
in O
liver O
transaminases O
. O

 O
On O
hospital O
day O
5 O
she O
was O
transferred O
to O
the O
medical O
ward O
and O
was O
eventually O
discharged O
home O
on O
non O
- O
selective O
 O
blockade O
, O
an O
ACE O
inhibitor O
and O
nitrate O
with O
planned O
follow O
- O
up O
at O
the O
heart O
- O
failure O
clinic O
. O

 O
The O
patient O
returned O
to O
the O
with O
an O
elevated O
blood O
pressure O
, O
nausea O
and O
abdominal O
pain O
. O

 O
A O
contrast O
scan O
of O
her O
abdomen O
revealed O
pancreatitis B
and O
an O
adrenal O
. O

 O
During O
her O
treatment O
for O
pancreatitis B
she O
began O
to O
have O
of O
, O
, O
and O
abdominal O
with O
corresponding O
to O
the O
and O
to O
with O
a O
baseline O
of O
( O
see O
figure O
2 O
) O
. O

 O
Her O
urinary O
and O
plasma O
were O
and O
confirmed O
on O
repeat O
testing O
. O

 O
She O
was O
given O
aggressive O
and O
for O
a O
planned O
. O

 O
Prior O
to O
her O
had O
to O
on O
( O
see O
figure O
1 O
) O
. O

 O
of O
her O
was O
consistent O
with O
a O
non O
- O
malignant O
pheochromocytoma B
( O
see O
figure O
3 O
) O
. O

A O
with O
and O
to O
our O
with O
vague O
and O
. O

 O
Her O
pertinent O
history O
includes O
and O
for O
. O

 O
At O
the O
time O
of O
admission O
, O
she O
was O
undergoing O
care O
for O
an O
infected O
diabetic O
of O
her O
. O

 O
Of O
note O
, O
she O
did O
not O
have O
a O
history O
of O
CAPD B
or O
a O
history O
of O
renal B
disease I
: O
1.23 O
mg O
/ O
dL O
, O
16 O
mg O
/ O
dL. O

 O
Her O
were O
via O
subcutaneous O
; O
she O
reported O
a O
( O
due O
to O
poor O
drug O
compliance O
) O
. O

 O
Her O
were O
decreased O
to O
a O
range O
of O
after O
implementation O
of O
a O
stricter O
upon O
admission O
. O

 O
A O
non O
- O
contrast O
showed O
confluent O
, O
bilobar O
geographic O
regions O
of O
in O
a O
throughout O
her O
( O
Fig.1 O
) O
. O

 O
A O
protocol O
was O
performed O
for O
further O
evaluation O
of O
these O
indeterminate O
findings O
to O
assess O
for O
possible O
vascular O
etiology O
as O
areas O
of O
infarction O
could O
also O
be O
possible O
in O
this O
patient O
. O

 O
In O
- O
phase O
images O
demonstrated O
hyperintense O
in O
her O
in O
a O
distribution O
corresponding O
to O
the O
hypoattenuating O
regions O
seen O
on O
CT O
. O

 O
On O
the O
opposed O
- O
phase O
sequence O
, O
there O
was O
loss O
in O
signal O
within O
these O
areas O
indicating O
the O
presence O
of O
intracellular O
fat O
and O
water O
( O
Fig.2 O
) O
. O

 O
In O
addition O
, O
these O
areas O
were O
hypointense O
to O
the O
remaining O
hepatic O
parenchyma O
on O
the O
fat O
suppression O
MR O
sequences O
, O
confirming O
presence O
of O
fat O
and O
thus O
establishing O
a O
diagnosis O
of O
SHS O
. O

 O
Furthermore O
, O
a O
follow O
- O
up O
of O
her O
and O
was O
performed O
, O
which O
showed O
of O
these O
findings O
( O
Fig.3 O
) O
. O

 O
Of O
note O
, O
stricter O
glucose O
control O
had O
decreased O
her O
average O
to O
below O
200 O
mg O
/ O
dL. O

An O
with O
a O
history O
of O
headaches O
and O
vomiting O
that O
had O
been O
present O
for O
. O

 O
Physical O
examination O
showed O
papilledema B
without O
the O
presence O
of O
any O
other O
neurological B
deficits I
. O

 O
( O
) O
revealed O
a O
large O
prepontine O
with O
dorsal O
of O
the O
and O
a O
secondary O
obstructive O
hydrocephalus B
due O
to O
of O
the O
. O

 O
The O
had O
an O
inhomogeneous O
on O
the O
( O
) O
and O
an O
inhomogeneous O
on O
the O
( O
) O
. O

 O
After O
administration O
of O
IV O
, O
there O
was O
some O
inhomogeneous O
( O
Fig.1 O
) O
. O

 O
( O
) O
imaging O
showed O
no O
. O

 O
During O
the O
first O
operation O
, O
a O
ventriculoperitoneal O
was O
inserted O
into O
the O
to O
treat O
the O
. O

 O
A O
careful O
study O
of O
the O
MRI O
suggested O
that O
this O
infra- O
and O
supratentorially O
located O
tumour O
might O
be O
resected O
through O
a O
single O
approach O
. O

 O
A O
left O
frontotemporal O
was O
performed O
to O
gain O
access O
to O
the O
tumour O
. O

 O
The O
tumour O
had O
well O
- O
defined O
margins O
and O
was O
entirely O
located O
in O
the O
intradural O
plane O
. O

 O
There O
were O
no O
attachments O
to O
the O
cranial O
nerves O
or O
brainstem O
. O

 O
A O
macroscopic O
complete O
resection O
was O
performed O
. O

 O
Postoperatively O
, O
the O
patient O
had O
developed O
a O
left O
oculomotor O
nerve O
palsy O
, O
which O
completely O
recovered O
within O
the O
next O
4 O
weeks O
. O

 O
The O
postoperative O
MRI O
showed O
a O
complete O
removal O
of O
the O
tumour O
( O
Fig.2 O
) O
. O

 O
After O
careful O
consideration O
by O
a O
multidisciplinary O
team O
, O
we O
decided O
that O
there O
was O
no O
indication O
for O
postoperative O
radiation O
therapy O
. O

 O
At O
follow O
- O
up O
one O
and O
a O
half O
years O
later O
, O
the O
patient O
was O
found O
to O
have O
remained O
asymptomatic O
. O

 O
There O
were O
no O
signs O
of O
tumour O
recurrence O
on O
the O
MRI O
scan O
. O

 O
At O
a O
follow O
- O
up O
of O
more O
than O
6 O
years O
after O
treatment O
, O
there O
were O
still O
no O
signs O
of O
tumour O
recurrence O
on O
the O
MRI O
scan O
. O

 O
Histological O
examination O
showed O
a O
slightly O
lobulated O
tumour O
consisting O
of O
a O
chondromyxoid O
matrix O
. O

 O
The O
tumour O
cells O
showed O
a O
vacuolated O
and O
pale O
cytoplasm O
. O

 O
Moderate O
nuclear O
polymorphism O
was O
observed O
but O
no O
obvious O
mitotic O
activity O
( O
Fig.3 O
) O
. O

 O
Some O
calcifications O
were O
seen O
. O

 O
The O
tumour O
cells O
stained O
positive O
for O
pan O
- O
keratin O
, O
S-100 O
and O
epithelial O
membrane O
antigen O
( O
EMA O
) O
. O

 O
These O
findings O
suggest O
a O
histopathological O
diagnosis O
of O
chordoma B
. O

Our O
patient O
was O
a O
with O
bicuspid O
and O
ascending O
. O

 O
He O
had O
undergone O
a O
free O
- O
hand O
aortic O
with O
of O
the O
using O
a O
in O
( O
at O
the O
age O
of O
41 O
) O
. O

 O
evaluations O
were O
performed O
and O
showed O
mild O
. O

 O
After O
8 O
years O
of O
, O
the O
patient O
to O
with O
and O
the O
showed O
severe O
due O
to O
a O
of O
, O
worsening O
of O
with O
( O
) O
( O
4045 O
% O
) O
and O
( O
, O
respectively O
) O
. O

 O
The O
patient O
presented O
and O
, O
which O
needed O
infusion O
of O
and O
. O

 O
scan O
showed O
on O
the O
, O
and O
no O
signs O
of O
( O
Fig.1 O
) O
. O

 O
Since O
the O
were O
, O
the O
final O
diagnosis O
was O
an O
early O
structural B
deterioration I
of O
the O
, O
due O
to O
a O
severe O
process O
. O

 O
The O
operation O
was O
performed O
through O
median O
and O
with O
standard O
aorta O
- O
right O
atrium O
for O
the O
extracorporeal O
circulation O
. O

 O
The O
leaflets O
and O
the O
annulus O
of O
the O
homograft O
presented O
severe O
calcifications O
and O
no O
signs O
of O
endocarditis B
were O
found O
. O

 O
An O
Edwards O
Intuity O
bioprosthesis O
( O
21 O
mm O
) O
was O
then O
( O
Fig.2 O
) O
. O

 O
The O
time O
was O
41 O
min O
, O
and O
the O
time O
was O
. O

 O
The O
patient O
required O
and O
at O
for O
bypass O
weaning O
. O

 O
No O
occurred O
during O
the O
postoperative O
period O
. O

 O
before O
the O
showed O
the O
absence O
of O
, O
a O
of O
and O
an O
of O
. O

 O
Follow O
- O
up O
from O
the O
operation O
showed O
neither O
nor O
of O
the O
Edwards O
Intuity O
, O
a O
of O
and O
initial O
recovery O
of O
the O
( O
valued O
) O
. O

 O
Patient O
was O
again O
. O

An O
was O
from O
the O
University O
Clinic O
for O
having O
low O
( O
Hg O
) O
. O

 O
till O
when O
he O
presented O
with O
easy O
, O
postural O
, O
and O
. O

 O
He O
gave O
history O
of O
30 O
kg O
. O

 O
On O
, O
he O
looked O
, O
not O
or O
. O

 O
His O
were O
all O
, O
except O
for O
an O
elevated O
( O
) O
. O

 O
Cardiovascular O
, O
respiratory O
and O
abdominal O
were O
. O

 O
Primary O
in O
our O
revealed O
low O
level O
( O
) O
, O
low O
( O
) O
, O
and O
a O
positive O
. O

 O
A O
provisional O
diagnosis O
of O
microcytic B
hypochromic I
anemia I
for O
further O
workup O
was O
made O
. O

 O
and O
revealed O
, O
depicting O
. O

 O
Upper O
GI O
showed O
erosive O
antral O
gastritis B
with O
patchy O
ulcerative O
. O

 O
Abdominal O
showed O
a O
slightly O
with O
a O
rounded O
echogenic O
in O
the O
suggestive O
of O
hemangioma B
. O

 O
The O
spleen O
was O
slightly O
and O
with O
no O
focal O
. O

 O
( O
) O
scan O
of O
the O
and O
showed O
a O
fairly O
large O
well O
defined O
soft O
tissue O
located O
in O
the O
and O
engulfing O
jejunal O
loops O
causing O
bowel O
wall O
. O

 O
The O
patient O
underwent O
an O
exploratory O
and O
of O
the O
jejunal O
. O

 O
revealed O
an O
annular O
located O
and O
. O

 O
revealed O
a O
situated O
in O
the O
and O
and O
the O
. O

 O
The O
were O
arranged O
in O
( O
Fig.1a O
, O
b O
) O
. O

 O
were O
in O
shape O
with O
( O
Fig.1c O
) O
. O

 O
The O
. O

 O
Scattered O
osteoclast O
- O
like O
multinucleated O
were O
also O
identified O
( O
Fig.1b O
, O
c O
) O
. O

 O
Frequent O
mitotic O
figures O
and O
were O
noted O
. O

 O
All O
lymph O
nodes O
were O
not O
. O

 O
, O
the O
neoplastic O
cells O
were O
strongly O
and O
diffusely O
positive O
for O
( O
Fig.1d O
) O
. O

 O
They O
were O
also O
positive O
for O
. O

 O
( O
and O
) O
, O
( O
, O
and O
) O
, O
, O
, O
, O
, O
and O
were O
all O
in O
the O
. O

 O
( O
) O
analysis O
for O
on O
showed O
evidence O
of O
a O
in O
scored O
. O

 O
The O
native O
state O
of O
EWSR1 O
break O
apart O
probe O
will O
be O
seen O
as O
two O
adjacent O
or O
fused O
( O
overlapping O
) O
red O
/ O
green O
( O
yellow O
) O
signals O
. O

 O
However O
, O
EWSR1 O
gene O
rearrangement O
presented O
as O
one O
red O
and O
one O
green O
separated O
signal O
( O
Fig.1e O
) O
. O

 O
The O
patient O
did O
not O
receive O
or O
. O

 O
During O
the O
clinical O
, O
the O
patient O
remained O
for O
until O
he O
with O
local O
. O

 O
The O
treatment O
plan O
was O
surgical O
but O
the O
patient O
sought O
medical O
advice O
in O
a O
where O
he O
of O
the O
disease O
. O

A O
69 O
- O
year O
- O
old O
man O
became O
aware O
of O
the O
onset O
of O
exertional O
in O
. O

 O
He O
had O
a O
history O
of O
. O

 O
His O
. O

 O
His O
. O

 O
He O
had O
. O

 O
Due O
to O
the O
exertional O
, O
he O
was O
to O
the O
for O
and O
( O
) O
. O

 O
indicated O
that O
he O
had O
severe O
PAH B
, O
because O
his O
( O
) O
was O
, O
and O
his O
right O
heart O
was O
( O
the O
: O
) O
. O

 O
showed O
that O
he O
had O
not O
only O
PAH B
, O
but O
also O
a O
thrombus B
in O
the O
. O

 O
However O
, O
the O
region O
in O
the O
lung O
affected O
by O
this O
was O
considered O
too O
small O
to O
induce O
such O
a O
severe O
PAH O
. O

 O
In O
addition O
, O
he O
, O
so O
he O
was O
diagnosed O
as O
IPAH B
combined O
with O
PE B
. O

 O
He O
was O
treated O
with O
( O
with O
a O
target O
of O
the O
[ O
] O
between O
) O
and O
targeted O
PAH O
therapy O
( O
) O
. O

 O
The O
patient O
's O
was O
relieved O
slightly O
after O
the O
use O
of O
these O
for O
and O
the O
retested O
by O
echocardiography O
was O
to O
, O
but O
all O
the O
after O
taking O
these O
for O
. O

 O
In O
, O
he O
to O
the O
in O
for O
further O
treatment O
. O

 O
Right O
heart O
revealed O
, O
( O
) O
, O
, O
, O
and O
7.3 O
Wood O
units O
. O

 O
He O
was O
retested O
for O
that O
showed O
that O
the O
thrombus B
in O
the O
disappeared O
. O

 O
He O
was O
still O
diagnosed O
as O
having O
IPAH B
, O
so O
treated O
with O
( O
) O
and O
( O
) O
targeted O
and O
oral O
( O
, O
but O
the O
daily O
dose O
was O
adjusted O
by O
that O
was O
between O
) O
. O

 O
Disappointingly O
, O
his O
was O
not O
relieved O
and O
the O
tested O
by O
the O
echocardiography O
was O
. O

 O
In O
, O
he O
the O
in O
because O
of O
no O
relief O
of O
. O

 O
showed O
that O
was O
with O
; O
revealed O
a O
mild O
obstructive B
dysfunction I
of O
the O
( O
, O
Prediction O
) O
and O
a O
severe O
reduction O
in O
the O
diffusing O
capacity O
of O
the O
lungs O
for O
carbon O
monoxide O
( O
) O
; O
6 O
- O
minute O
was O
385 O
 O
m. O

 O
Chest O
high O
- O
resolution O
computed O
tomography O
( O
) O
( O
Fig.1A O
and O
B O
) O
showed O
smooth O
thickening O
of O
, O
diffuse O
centrilobular O
, O
and O
the O
of O
. O

 O
The O
right O
heart O
revealed O
that O
was O
and O
was O
. O

 O
was O
. O

 O
and O
were O
both O
; O
pulmonary O
( O
) O
scan O
showed O
a O
. O

 O
showed O
an O
percentage O
( O
) O
of O
with O
the O
( O
the O
normal O
range O
: O
020 O
) O
. O

 O
He O
was O
still O
diagnosed O
as O
having O
IPAH B
, O
but O
he O
was O
suspected O
as O
actually O
having O
PVOD B
. O

 O
He O
was O
continuously O
treated O
with O
the O
targeted O
, O
and O
he O
was O
asked O
to O
continue O
his O
, O
but O
he O
stopped O
anticoagulation O
treatment O
( O
he O
failed O
to O
recall O
the O
exact O
date O
. O
) O
because O
he O
felt O
that O
it O
was O
too O
cumbersome O
to O
frequently O
test O
the O
INR O
for O
blood O
coagulation O
monitoring O
. O

 O
Furthermore O
, O
after O
he O
discontinued O
his O
warfarin O
therapy O
, O
he O
also O
failed O
to O
to O
prevent O
PE O
recurrence O
. O

 O
His O
was O
relatively O
stable O
, O
but O
he O
developed O
many O
, O
but O
not O
fatal O
, O
episodes O
of O
pulmonary B
edema I
during O
the O
therapy O
. O

 O
In O
, O
he O
was O
to O
because O
his O
was O
suddenly O
. O

 O
showed O
a O
thrombus B
in O
the O
( O
Fig.1C O
) O
. O

 O
was O
administered O
for O
, O
but O
this O
medication O
did O
not O
relieve O
his O
, O
therefore O
, O
he O
was O
. O

 O
Instead O
, O
he O
was O
bound O
to O
his O
wheelchair O
for O
. O

 O
The O
severe O
PAH B
( O
suspected O
as O
PVOD B
) O
combined O
with O
a O
life O
- O
threatening O
PE B
mandates O
a O
for O
his O
survival O
. O

 O
, O
he O
was O
undergone O
a O
bilateral O
sequential O
allogenic O
assisted O
by O
( O
) O
after O
he O
signed O
the O
written O
consent O
on O
. O

 O
of O
the O
showed O
pulmonary O
vein O
occlusion O
( O
Fig.1D O
 O
F O
) O
and O
the O
pulmonary O
embolism O
in O
the O
right O
pulmonary O
artery O
. O

 O
Until O
then O
, O
he O
was O
confirmed O
as O
having O
PVOD B
combined O
with O
PE B
, O
instead O
of O
IPAH B
. O

 O
He O
has O
been O
living O
without O
for O
after O
the O
lung O
transplantation O
and O
the O
showed O
the O
normalizations O
of O
and O
the O
once O
. O

 O
This O
study O
was O
approved O
by O
the O
Ethics O
Committee O
of O
The O
People O
's O
Hospital O
of O
Zhongshan O
City O
. O

 O
The O
written O
informed O
consent O
was O
obtained O
from O
the O
patient O
. O

A O
presented O
to O
the O
emergency O
department O
with O
a O
rash O
on O
his O
arms O
and O
neck O
( O
figure O
1 O
) O
. O

 O
It O
had O
developed O
over O
the O
course O
of O
36 O
 O
h O
from O
discrete O
 O
pin O
prick O
 O
areas O
of O
erythema O
into O
a O
maculopapular O
rash O
with O
vesicles O
( O
figure O
2 O
) O
. O

 O
It O
covered O
his O
forearms O
from O
the O
dorsal O
aspect O
of O
the O
hands O
to O
the O
flexor O
surface O
of O
the O
elbows O
. O

 O
It O
was O
also O
beginning O
to O
develop O
around O
his O
neck O
( O
figure O
3 O
) O
. O

 O
He O
described O
the O
rash O
as O
itchy O
and O
painful O
, O
and O
was O
feeling O
 O
under O
the O
weather O
 O
. O

 O
The O
patient O
had O
no O
previous O
dermatological O
or O
other O
medical O
history O
of O
note O
. O

 O
He O
took O
no O
. O

 O
He O
but O
there O
was O
. O

 O
He O
. O

 O
were O
entirely O
and O
. O

 O
Closer O
examination O
of O
the O
rash O
revealed O
that O
it O
was O
present O
only O
on O
skin O
exposed O
to O
the O
sun O
when O
wearing O
a O
short O
- O
sleeved O
shirt O
; O
the O
most O
striking O
feature O
was O
the O
 O
V O
 O
shape O
on O
the O
patient O
's O
chest O
in O
keeping O
with O
the O
neck O
line O
of O
a O
polo O
shirt O
. O

 O
On O
further O
questioning O
the O
patient O
described O
a O
period O
of O
time O
48 O
 O
h O
prior O
to O
presentation O
( O
and O
12 O
 O
h O
prior O
to O
the O
development O
of O
the O
rash O
) O
spent O
strimming O
the O
grass O
under O
the O
hedges O
in O
his O
garden O
. O

 O
including O
, O
and O
, O
and O
were O
all O
. O

 O
The O
list O
of O
potential O
differential O
diagnoses O
for O
a O
maculopapular O
rash O
is O
long O
, O
but O
given O
the O
distribution O
of O
the O
rash O
and O
the O
history O
of O
plant O
material O
exposure O
a O
diagnosis O
of O
phytophotodermatitis B
was O
made O
. O

 O
The O
patient O
was O
discharged O
with O
, O
and O
the O
when O
gardening O
in O
the O
future O
. O

 O
The O
resolved O
over O
a O
. O

 O
remained O
throughout O
healing O
but O
the O
associated O
settled O
. O

 O
Residual O
is O
beginning O
to O
fade O
presentation O
. O

An O
was O
in O
our O
due O
to O
abdominal O
and O
. O

 O
He O
had O
a O
previous O
history O
of O
in O
treatment O
with O
a O
and O
a O
previous O
episode O
of O
abdominal O
which O
was O
diagnosed O
as O
spontaneous O
mesenchimal B
haematoma I
and O
. O

 O
He O
denied O
any O
kind O
of O
, O
and O
had O
no O
or O
. O

 O
At O
the O
patient O
was O
and O
suffered O
from O
intense O
at O
the O
with O
no O
defense O
. O

 O
Blood O
tests O
showed O
a O
of O
. O

 O
was O
as O
expected O
. O

 O
showed O
massive O
( O
Figure O
1 O
) O
and O
the O
already O
known O
mesenteric B
hematoma I
( O
Figure O
2 O
) O
. O

 O
Assuming O
the O
diagnosis O
of O
expansive O
mesenteric B
hematoma I
plus O
ongoing O
a O
was O
performed O
. O

 O
During O
first O
exploration O
, O
of O
were O
found O
. O

 O
At O
the O
a O
torsionated O
and O
perforated O
meckel B
diverticulum I
with O
intradiverticular O
was O
found O
( O
Figure O
3 O
) O
and O
a O
diverticular O
was O
performed O
. O

 O
The O
was O
and O
the O
patient O
was O
at O
the O
. O

A O
to O
the O
of O
in O
( O
) O
with O
a O
hypogastric O
region O
, O
especially O
in O
the O
for O
. O

 O
The O
was O
a O
which O
had O
, O
. O

 O
The O
radiated O
to O
the O
and O
was O
alleviated O
by O
. O

 O
were O
reported O
. O

 O
Furthermore O
, O
the O
patient O
complained O
of O
a O
23 O
kg O
over O
the O
last O
one O
month O
followed O
by O
. O

 O
However O
, O
no O
symptoms O
of O
, O
, O
, O
or O
were O
demonstrated O
. O

 O
He O
was O
first O
to O
for O
, O
then O
was O
to O
for O
further O
evaluation O
. O

 O
The O
patient O
had O
undergone O
a O
for O
his O
to O
. O

 O
Also O
, O
he O
had O
a O
history O
of O
due O
to O
dyspepsia B
, O
which O
was O
found O
to O
be O
at O
that O
time O
and O
which O
was O
after O
a O
. O

 O
was O
recorded O
. O

 O
His O
were O
at O
the O
time O
of O
admission O
. O

 O
On O
, O
the O
abdomen O
was O
soft O
, O
there O
was O
no O
, O
and O
were O
. O

 O
However O
, O
in O
the O
with O
no O
was O
noted O
. O

 O
The O
is O
shown O
in O
Table O
1 O
. O

 O
, O
, O
and O
were O
all O
. O

 O
An O
abdominal O
scan O
showed O
a O
well O
- O
demarcated O
and O
homogenous O
solitary O
in O
the O
with O
no O
in O
the O
. O

 O
The O
ileum O
wall O
was O
( O
Figure O
1 O
) O
. O

 O
A O
revealed O
a O
large O
mass O
like O
in O
the O
( O
Figure O
2 O
) O
; O
during O
the O
procedure O
a O
was O
taken O
from O
the O
. O

 O
The O
was O
by O
a O
number O
of O
PMNCs O
admixed O
by O
some O
( O
Figure O
3 O
) O
. O

 O
was O
positive O
for O
and O
. O

 O
( O
) O
was O
while O
, O
( O
) O
, O
and O
were O
. O

 O
There O
were O
no O
reports O
of O
, O
, O
or O
( O
Figure O
4).When O
the O
colonoscopy O
was O
performed O
, O
the O
evidences O
of O
invasive O
obstruction O
lead O
us O
to O
the O
suspicion O
of O
a O
malignant B
tumor I
. O

 O
After O
pathological O
confirmation O
of O
IMT B
, O
the O
patient O
was O
referred O
for O
in O
order O
to O
remove O
the O
mass O
. O

 O
On O
, O
approximately O
were O
found O
in O
the O
. O

 O
A O
was O
seen O
in O
the O
with O
ileocolic O
. O

 O
Afterwards O
, O
the O
patient O
underwent O
right O
with O
an O
end O
- O
to O
- O
end O
. O

 O
No O
were O
observed O
. O

 O
The O
patient O
was O
surgery O
and O
had O
no O
during O
. O

A O
to O
the O
in O
, O
for O
of O
right O
- O
sided O
paralysis B
and O
left O
- O
sided O
after O
being O
down O
in O
her O
home O
between O
her O
nightstand O
and O
her O
bed O
. O

 O
The O
symptoms O
began O
after O
at O
a O
local O
restaurant O
chain O
, O
, O
and O
one O
cigarette O
dipped O
in O
liquid O
phencyclidine O
( O
PCP O
) O
. O

 O
She O
was O
and O
went O
to O
bed O
without O
. O

 O
She O
was O
down O
next O
to O
the O
bed O
. O

 O
The O
patient O
denied O
any O
physical B
trauma I
other O
than O
from O
the O
bed O
. O

 O
She O
had O
. O

 O
The O
patient O
had O
a O
history O
of O
viral B
meningitis I
, O
, O
and O
, O
and O
she O
was O
treated O
for O
a O
presumed O
urinary B
tract I
infection I
to O
admission O
at O
an O
. O

 O
Her O
triage O
were O
as O
follows O
: O
, O
, O
, O
, O
and O
an O
of O
on O
. O

 O
On O
, O
the O
patient O
was O
and O
to O
, O
, O
and O
. O

 O
Her O
cranial O
nerves O
II O
 O
XII O
were O
grossly O
intact O
. O

 O
She O
had O
2/5 O
strength O
in O
her O
right O
lower O
extremity O
, O
3/5 O
in O
her O
left O
lower O
extremity O
, O
and O
4/5 O
bilaterally O
in O
her O
upper O
extremities O
. O

 O
Her O
was O
. O

 O
She O
opened O
her O
eyes O
spontaneously O
, O
her O
verbal O
response O
was O
oriented O
and O
appropriate O
, O
and O
she O
obeyed O
commands O
, O
resulting O
in O
a O
score O
of O
. O

 O
Pupils O
were O
equal O
, O
round O
, O
and O
reactive O
to O
light O
. O

 O
She O
had O
tenderness O
to O
palpation O
over O
the O
cervical O
, O
thoracic O
, O
and O
lumbar O
spine O
without O
obvious O
external O
signs O
of O
trauma O
. O

 O
Her O
anal O
sphincter O
tone O
was O
intact O
. O

 O
Multiple O
laboratory O
abnormalities O
were O
noted O
on O
admission O
, O
including O
hyperlactemia O
, O
elevated O
liver O
function O
tests O
, O
and O
electrolyte O
derangements O
. O

 O
Her O
complete O
blood O
count O
and O
remainder O
of O
her O
complete O
metabolic O
panel O
were O
within O
normal O
limits O
. O

 O
These O
values O
are O
summarized O
along O
with O
reference O
ranges O
in O
Table O
1 O
. O

 O
Her O
was O
positive O
for O
. O

 O
drawn O
on O
admission O
grew O
the O
aerobic O
bacteria O
Salmonella O
enterica O
, O
and O
then O
drawn O
grew O
group O
B O
streptococcus B
( O
and O
) O
. O

 O
Subsequent O
blood O
cultures O
were O
negative O
, O
as O
were O
. O

 O
and O
therapy O
was O
initiated O
empirically O
, O
with O
transition O
to O
upon O
learning O
of O
the O
culture O
results O
. O

 O
In O
addition O
, O
she O
had O
a O
detailed O
including O
( O
ANA O
) O
and O
, O
all O
of O
which O
returned O
. O

 O
Admission O
scan O
of O
her O
cervical O
, O
thoracic O
, O
and O
lumbar O
revealed O
no O
spinal O
fractures B
. O

 O
( O
) O
revealed O
no O
acute O
intracranial O
, O
but O
enhancement O
within O
the O
central O
aspect O
of O
C3 O
 O
T2 O
suggested O
spinal O
cord O
, O
at O
, O
, O
and O
, O
and O
bilateral O
posterior O
neck O
muscle O
. O

 O
A O
was O
not O
initially O
performed O
upon O
patient O
admission O
due O
to O
concerns O
about O
raised O
intracranial O
pressure O
from O
suspected O
trauma O
. O

 O
presentation O
, O
her O
had O
progressively O
to O
in O
. O

 O
She O
lost O
in O
her O
and O
developed O
absent O
. O

 O
The O
patient O
was O
to O
the O
with O
further O
deterioration O
ultimately O
requiring O
endotracheal O
due O
to O
respiratory B
failure I
. O

 O
Upon O
her O
positive O
blood O
culture O
results O
, O
was O
performed O
, O
which O
demonstrated O
a O
pattern O
consistent O
with O
ATM B
, O
the O
results O
of O
which O
are O
summarized O
in O
Table O
2 O
. O

 O
An O
extensive O
was O
also O
completed O
, O
with O
the O
results O
summarized O
in O
Table O
3 O
. O

 O
was O
initiated O
with O
a O
suspected O
diagnosis O
of O
ATM B
. O

 O
Despite O
maximal O
medical O
, O
the O
patient O
remains O
quadriplegic B
, O
is O
experiencing O
neurologic O
, O
received O
a O
due O
to O
prolonged O
respiratory B
failure I
, O
and O
required O
a O
feeding O
placement O
at O
the O
time O
of O
this O
report O
. O

A O
previously O
healthy O
at O
the O
with O
generalized O
( O
and O
) O
, O
, O
and O
hepatic B
coma I
. O

 O
The O
relatives O
declared O
that O
he O
was O
known O
to O
have O
a O
urinary B
bladder I
carcinoma I
that O
was O
diagnosed O
at O
a O
routine O
control O
performed O
but O
no O
medical O
papers O
to O
prove O
this O
diagnosis O
were O
shown O
. O

 O
They O
also O
mentioned O
a O
2 O
- O
month O
history O
of O
progressive O
, O
, O
and O
temporary O
. O

 O
No O
or O
other O
clinical O
signs O
were O
mentioned O
. O

 O
No O
previously O
viral B
hepatitis I
or O
was O
reported O
. O

 O
was O
declared O
. O

 O
At O
the O
present O
admission O
, O
the O
abdominal O
showed O
marked O
with O
multiple O
small O
( O
in O
diameter O
) O
that O
was O
supposed O
to O
be O
hepatic O
from O
the O
bladder B
carcinoma I
. O

 O
The O
showed O
a O
bilateral O
without O
abnormal O
. O

 O
The O
patient O
with O
hepatic B
encephalopathy I
at O
admission O
. O

 O
Prior O
to O
the O
, O
signed O
informed O
consent O
of O
the O
relatives O
was O
obtained O
for O
the O
case O
publication O
. O

 O
Being O
about O
a O
case O
report O
, O
no O
Ethical O
Committee O
approval O
was O
necessary O
. O

 O
At O
autopsy O
, O
the O
showed O
a O
huge O
( O
) O
with O
widely O
distributed O
white O
of O
( O
Fig.1 O
) O
. O

 O
The O
was O
, O
but O
a O
30 O
 O
30 O
 O
50 O
 O
mm O
prostate O
with O
was O
observed O
( O
Fig.2 O
) O
. O

 O
The O
bilateral O
was O
confirmed O
, O
without O
any O
central O
. O

 O
A O
10 O
- O
mm O
white O
was O
identified O
encasing O
a O
from O
the O
, O
without O
( O
Fig.3 O
) O
. O

 O
Except O
for O
moderate O
, O
no O
other O
brain O
were O
identified O
. O

 O
The O
other O
organs O
did O
not O
show O
. O

 O
The O
tissues O
were O
fixed O
in O
10 O
% O
neutral O
formalin O
and O
embedded O
in O
paraffin O
together O
with O
iliac O
crest O
bone O
grafting O
. O

 O
of O
the O
showed O
a O
3 O
+ O
3 O
Gleason O
's O
grade O
2 O
occult O
adenocarcinoma B
( O
Fig.2 O
) O
. O

 O
Clusters O
and O
sheets O
of O
small O
round O
cells O
were O
seen O
in O
the O
liver O
parenchyma O
( O
Fig.1 O
) O
and O
the O
lymph O
nodes O
from O
the O
hepatic O
hilum O
. O

 O
Examination O
of O
the O
lung O
parenchyma O
showed O
a O
peribronchial O
SCLC O
with O
multiple O
tumor O
emboli O
in O
both O
veins O
and O
lymphatic O
vessels O
and O
multiple O
 O
coin O
- O
shaped O
 O
tumor O
nodules O
of O
1 O
to O
2 O
 O
mm O
in O
diameter O
below O
the O
pleura O
( O
Fig.3 O
) O
. O

 O
The O
small O
round O
tumor O
cells O
were O
also O
seen O
in O
bone O
marrow O
from O
the O
iliac O
crest O
bone O
( O
Fig.3 O
) O
. O

 O
No O
brain O
have O
been O
detected O
. O

 O
Based O
on O
the O
macro- O
and O
microscopic O
features O
and O
clinical O
picture O
, O
the O
final O
diagnosis O
was O
 O
peribronchial O
and O
coin O
- O
like O
peripheral O
SCLC B
with O
massive O
angiolymphatic O
invasion B
and O
in O
the O
, O
and O
, O
associated O
with O
encephalopathy B
and O
synchronous O
occult O
adenocarcinoma B
of O
the O
. O
 O

A O
was O
into O
our O
in O
with O
, O
a O
high O
, O
and O
subnormal O
levels O
. O

 O
showed O
a O
normal O
male O
. O

 O
were O
negative O
for O
the O
BCR O
- O
ABL1 O
rearrangement O
, O
but O
revealed O
the O
JAK2V617F O
mutation O
with O
an O
allele O
burden O
of O
44.9 O
% O
. O

 O
A O
diagnosis O
of O
PV B
was O
made O
on O
the O
basis O
of O
a O
morphological O
according O
to O
the O
. O

 O
The O
patient O
was O
started O
on O
, O
, O
and O
, O
all O
of O
which O
were O
well O
tolerated O
. O

 O
, O
an O
abdominal O
scan O
revealed O
the O
presence O
of O
dense O
bilateral O
perinephric O
, O
which O
was O
confirmed O
by O
a O
whole O
- O
body O
computed O
tomography O
( O
) O
scan O
, O
and O
a O
( O
) O
scan O
demonstrated O
increased O
in O
the O
. O

 O
Morphological O
confirmed O
the O
previous O
diagnosis O
of O
PV B
and O
showed O
no O
evident O
change O
in O
the O
grading O
of O
bone O
marrow O
fibrosis B
( O
MF-0 O
according O
to O
the O
EUMNET O
consensus),13 O
whereas O
revealed O
the O
following O
complex O
male O
: O
. O

 O
The O
of O
the O
perinephric O
was O
identified O
by O
means O
of O
a O
CT O
- O
guided O
core O
of O
the O
. O

 O
demonstrated O
the O
accumulation O
of O
foamy O
histiocytes O
that O
were O
positive O
for O
and O
negative O
for O
the O
dendritic O
cell O
markers O
and O
, O
surrounded O
by O
fibrosis B
and O
a O
scanty O
lympho O
- O
monocytic O
( O
Figure O
(Figure1).1 O
) O
. O

 O
The O
detection O
of O
the O
led O
to O
a O
diagnosis O
of O
ECD B
. O

 O
Cardiac O
( O
) O
revealed O
pseudo O
- O
tumoral O
of O
the O
atrioventricular O
wall,14 O
and O
a O
showed O
symmetrically O
irregular O
radiotracer O
in O
the O
consistent O
with O
ECD B
( O
Figure O
(Figure22)2 O
; O
the O
findings O
of O
cerebral O
and O
pulmonary O
were O
. O

 O
In O
accordance O
with O
the O
most O
recent O
guidelines O
for O
the O
treatment O
of O
ECD,1 O
the O
patient O
started O
therapy O
with O
pegylated O
and O
, O
of O
treatment O
, O
a O
new O
abdominal O
scan O
revealed O
the O
complete O
resolution O
of O
the O
dense O
bilateral O
perinephric O
, O
and O
the O
normalization O
of O
the O
was O
achieved O
. O

An O
presented O
to O
a O
local O
clinic O
with O
on O
exertion O
and O
left O
back O
persisting O
for O
a O
month O
. O

 O
She O
was O
to O
our O
because O
of O
left O
on O
a O
chest O
. O

 O
She O
suffered O
and O
dyslipidemia O
but O
had O
, O
nor O
a O
smoking O
history O
or O
dust O
exposure O
. O

 O
On O
, O
her O
and O
were O
( O
: O
) O
. O

 O
A O
revealed O
a O
on O
the O
left O
side O
of O
her O
back O
with O
and O
in O
the O
. O

 O
The O
rest O
of O
the O
were O
. O

 O
revealed O
elevated O
levels O
of O
, O
( O
) O
, O
and O
( O
) O
( O
Table O
1 O
) O
. O

 O
A O
chest O
( O
Fig.1 O
) O
showed O
left O
with O
. O

 O
, O
an O
was O
inserted O
, O
and O
after O
drainage O
, O
chest O
( O
) O
( O
Fig.2 O
) O
revealed O
an O
irregular O
pleural O
invading O
her O
with O
rib O
and O
. O

 O
The O
was O
, O
but O
the O
lateral O
side O
of O
the O
mass O
was O
thick O
and O
invading O
the O
chest O
wall O
, O
so O
we O
diagnosed O
this O
mass O
as O
a O
chest O
wall O
tumor O
. O

 O
The O
pleural O
fluid O
was O
serous O
and O
not O
. O

 O
A O
showed O
it O
to O
be O
, O
and O
. O

 O
The O
was O
, O
and O
did O
not O
show O
any O
evidence O
of O
( O
Table O
1 O
) O
. O

 O
CT O
- O
guided O
needle O
was O
performed O
. O

 O
The O
results O
supported O
a O
diagnosis O
of O
diffuse B
large I
B I
- I
cell I
lymphoma I
( O
DLBCL B
) O
that O
was O
positive O
for O
and O
but O
negative O
for O
and O
( O
Fig.3 O
) O
. O

 O
( O
) O
revealed O
in O
the O
left O
chest O
wall O
mass O
without O
any O
other O
uptake O
( O
Fig.4A O
and O
B O
) O
, O
so O
we O
diagnosed O
her O
with O
primary O
malignant O
lymphoma O
originating O
from O
the O
chest O
wall O
. O

 O
We O
reconfirmed O
her O
medical O
history O
, O
and O
she O
. O

 O
Her O
( O
) O
was O
because O
of O
her O
back O
pain O
and O
. O

 O
Owing O
to O
her O
bad O
PS O
and O
age O
, O
it O
was O
difficult O
to O
perform O
an O
operation O
or O
administer O
combination O
chemotherapy O
with O
Rituximab O
, O
so O
low O
- O
dose O
oral O
( O
) O
was O
administered O
. O

 O
Her O
disappeared O
, O
her O
back O
disappeared O
, O
and O
her O
improved O
to O
. O

 O
performed O
showed O
( O
Fig.4C O
and O
D O
) O
. O

 O
She O
continued O
oral O
and O
maintained O
a O
good O
for O
. O

A O
patient O
had O
a O
history O
of O
under O
regular O
bronchodilator O
treatment O
. O

 O
In O
, O
he O
suffered O
from O
severe O
productive O
with O
and O
unintentional O
body O
. O

 O
After O
and O
chest O
in O
, O
he O
was O
diagnosed O
of O
squamous B
cell I
carcinoma I
in O
( O
, O
) O
. O

 O
Then O
he O
received O
neoadjuvant O
chemoradiotherapy O
( O
etoposide O
70 O
 O
mg O
[ O
45 O
 O
mg O
/ O
m2 O
] O
 O
+ O
 O
cisplatin O
79 O
 O
mg O
[ O
50 O
 O
mg O
/ O
m2 O
] O
; O
4500 O
 O
cGY O
in O
25 O
fractions O
) O
. O

 O
In O
, O
was O
arranged O
. O

 O
Because O
the O
was O
located O
at O
and O
invaded O
and O
, O
video O
- O
assisted O
thoracoscopic O
with O
right O
side O
intrapericardial O
was O
performed O
. O

 O
Postoperatively O
, O
revealed O
squamous B
cell I
carcinoma I
, O
, O
. O

 O
The O
was O
but O
he O
suffered O
from O
severe O
and O
right O
chest O
. O

 O
revealed O
( O
 O
= O
 O
) O
and O
elevated O
to O
23.94 O
 O
mg O
/ O
dL. O

 O
Chest O
showed O
and O
showed O
and O
with O
in O
the O
( O
Fig.1A O
) O
. O

 O
According O
to O
the O
patient O
's O
history O
, O
results O
of O
laboratory O
exams O
, O
and O
imaging O
findings O
, O
postpneumonectomy O
empyema O
was O
diagnosed O
and O
bronchopleural B
fistula I
was O
highly O
suspected O
. O

 O
After O
admission O
, O
chest O
was O
inserted O
and O
bronchoscopic O
was O
performed O
. O

 O
However O
, O
persistent O
was O
presented O
and O
we O
decided O
to O
the O
bronchial O
stump O
with O
. O

 O
Because O
the O
patient O
just O
received O
neoadjuvant O
a O
few O
months O
ago O
, O
the O
flaps O
harvested O
from O
chest O
area O
were O
not O
appropriate O
because O
the O
pedicle O
arteries O
might O
have O
been O
injured O
by O
irradiation O
. O

 O
After O
discussing O
with O
the O
plastic O
surgeon O
, O
we O
decided O
to O
the O
bronchial O
stump O
by O
a O
. O

 O
Intraoperatively O
, O
the O
patient O
was O
. O

 O
Right O
side O
exploratory O
was O
performed O
and O
the O
was O
located O
. O

 O
The O
and O
was O
identified O
and O
the O
location O
of O
the O
was O
( O
Fig.2A O
) O
. O

 O
Then O
the O
TRAM O
flap O
was O
harvested O
from O
right O
rectus O
abdominis O
( O
Fig.2B O
) O
and O
was O
deepithelialized O
( O
Fig.2C O
) O
. O

 O
Through O
a O
subcutaneous O
tunnel O
, O
the O
TRAM O
flap O
was O
moved O
toward O
the O
right O
thoracic O
space O
with O
no O
tension O
or O
kinking O
on O
the O
pedicle O
( O
Fig.2D O
) O
. O

 O
Then O
the O
TRAM O
flap O
was O
fixed O
to O
posterior O
chest O
wall O
to O
cover O
the O
bronchial O
stump O
( O
Fig.2E O
) O
and O
the O
tissue O
glue O
was O
also O
applied O
to O
the O
bronchial O
stump O
under O
bronchoscope O
. O

 O
The O
donor O
site O
of O
flap O
was O
closed O
with O
mesh O
repair O
. O

 O
The O
was O
and O
the O
was O
gradually O
. O

 O
Then O
the O
patient O
was O
under O
and O
was O
free O
from O
( O
Fig.1B O
) O
. O

 O
The O
patient O
provided O
written O
informed O
consent O
for O
publication O
of O
this O
report O
and O
all O
accompanying O
images O
. O

A O
with O
a O
history O
of O
and O
to O
the O
with O
a O
history O
of O
gradual O
but O
progressive O
of O
her O
and O
. O

 O
She O
denied O
any O
chest O
, O
, O
paroxysmal O
nocturnal O
or O
. O

 O
were O
. O

 O
was O
remarkable O
for O
an O
elevated O
( O
) O
of O
about O
with O
a O
. O

 O
There O
was O
a O
prominent O
heard O
over O
the O
. O

 O
There O
was O
no O
or O
. O

 O
The O
lungs O
were O
clear O
to O
. O

 O
The O
patient O
was O
markedly O
from O
the O
to O
the O
. O

 O
She O
was O
for O
further O
and O
. O

 O
She O
was O
diagnosed O
with O
HIV B
around O
and O
had O
been O
on O
. O

 O
She O
had O
not O
used O
for O
. O

 O
Renal B
and I
hepatic I
diseases I
were O
ruled O
out O
through O
and O
. O

 O
Peritoneal O
fluid O
was O
negative O
for O
malignancy B
. O

 O
showed O
a O
thickened O
bright O
adjacent O
to O
the O
( O
figure O
1 O
) O
with O
parallel O
separation O
between O
epicardial O
and O
pericardial O
echoes O
( O
railroad O
track O
sign O
) O
, O
and O
lack O
of O
. O

 O
Annulus O
paradoxus O
was O
demonstrated O
on O
tissue O
( O
figure O
2 O
) O
. O

 O
was O
. O

 O
The O
right O
ventricle O
was O
normal O
in O
and O
. O

 O
There O
was O
moderate O
. O

 O
There O
was O
no O
, O
but O
the O
pericardial O
space O
was O
remarkable O
for O
. O

 O
Constrictive B
physiology I
was O
demonstrated O
by O
study O
of O
tricuspid O
and O
mitral O
inflows O
( O
figure O
3 O
) O
during O
and O
; O
was O
also O
demonstrated O
in O
the O
during O
. O

 O
There O
was O
marked O
of O
the O
with O
no O
change O
during O
or O
. O

 O
of O
the O
revealed O
of O
the O
with O
no O
evidence O
of O
. O

 O
There O
were O
no O
lung O
. O

 O
Bilateral O
pleural B
effusions I
and O
interstitial O
were O
present O
in O
the O
. O

 O
Cardiac O
confirmed O
the O
presence O
of O
a O
diffusely O
thickened O
at O
. O

 O
The O
inferior O
vena O
cava O
and O
hepatic O
veins O
appeared O
. O

 O
There O
was O
a O
rapid O
and O
associated O
secondary O
to O
hindered O
( O
figure O
4 O
) O
. O

 O
The O
patient O
showed O
a O
good O
response O
to O
. O

 O
She O
underwent O
right O
and O
left O
heart O
to O
confirm O
constrictive B
physiology I
. O

A O
with O
a O
1 O
month O
history O
of O
intermittent O
episodes O
of O
small O
volume O
epistaxis O
. O

 O
There O
was O
. O

 O
revealed O
a O
left O
palatal O
fleshy O
centered O
at O
. O

 O
A O
demonstrated O
a O
large O
on O
the O
, O
involving O
the O
and O
abutting O
the O
. O

 O
( O
) O
of O
the O
showed O
a O
lobulated O
, O
expansile O
lytic O
of O
[ O
Fig O
1 O
] O
with O
a O
and O
. O

 O
The O
was O
associated O
with O
a O
that O
demonstrated O
mild O
heterogeneous O
. O

 O
The O
was O
centered O
at O
the O
, O
involving O
the O
, O
and O
. O

 O
The O
also O
involved O
the O
and O
was O
abutting O
the O
, O
with O
no O
gross O
orbital O
. O

 O
The O
patient O
subsequently O
underwent O
. O

 O
The O
mass O
centered O
in O
left O
maxilla O
was O
hypermetabolic O
, O
with O
index O
SUVmax O
9.7 O
[ O
Fig O
2 O
] O
. O

 O
There O
was O
no O
FDG O
- O
avid O
metastatic B
disease I
. O

 O
A O
trans O
- O
oral O
of O
the O
left O
palatal O
was O
performed O
and O
was O
suggestive O
of O
a O
preliminary O
diagnosis O
of O
mesenchymal B
chondrosarcoma I
, O
as O
evidenced O
by O
a O
featuring O
with O
and O
. O

 O
The O
patient O
underwent O
left O
subtotal O
via O
lateral O
and O
. O

 O
The O
final O
was O
conclusive O
of O
a O
5 O
cm O
high O
- O
grade O
( O
Grade O
3 O
) O
mesenchymal B
chondrosarcoma I
. O

 O
One O
of O
the O
resection O
margins O
was O
positive O
for O
and O
the O
patient O
was O
planned O
for O
adjuvant O
. O

A O
with O
a O
history O
of O
for O
and O
for O
the O
, O
, O
and O
, O
presented O
with O
several O
episodes O
of O
and O
abdominal O
for O
. O

 O
( O
) O
, O
performed O
for O
abdominal O
, O
had O
revealed O
no O
esophageal O
, O
gastric O
, O
portal O
hypertensive O
gastropathy B
, O
or O
other O
GI O
. O

 O
revealed O
a O
 O
= O
 O
, O
 O
= O
 O
60 O
 O
beats O
/ O
min O
, O
no O
, O
no O
stigmata O
of O
chronic O
liver O
disease O
, O
a O
soft O
abdomen O
with O
mild O
epigastric O
tenderness O
but O
no O
rebound O
tenderness O
, O
no O
abdominal O
bruit O
, O
and O
no O
pulsatile O
abdominal O
mass O
. O

 O
revealed O
gross O
melena O
. O

 O
Laboratory O
tests O
revealed O
hemoglobin O
 O
= O
 O
12.5 O
 O
g O
/ O
dL O
, O
platelets O
 O
= O
 O
301,000 O
/ O
mL O
, O
INR O
( O
international O
normalized O
ratio O
) O
 O
= O
 O
1.0 O
, O
blood O
urea O
nitrogen O
 O
= O
 O
20 O
 O
mg O
/ O
dL O
, O
and O
creatinine O
 O
= O
 O
1.1 O
 O
mg O
/ O
dL. O

 O
Serum O
aspartate O
aminotransferase O
 O
= O
 O
21 O
 O
IU O
/ O
L O
, O
alanine O
aminotransferase O
 O
= O
 O
16 O
 O
IU O
/ O
L O
, O
total O
bilirubin O
 O
= O
 O
0.6 O
 O
mg O
/ O
dL O
, O
alkaline O
phosphatase O
 O
= O
 O
64 O
 O
IU O
/ O
L O
, O
albumin O
 O
= O
 O
4.4 O
 O
gm O
/ O
dL O
, O
and O
lipase O
 O
= O
 O
32 O
 O
U O
/ O
dL. O

 O
The O
hemoglobin O
declined O
acutely O
to O
9.3 O
 O
g O
/ O
dL. O

 O
Abdomino O
- O
pelvic O
computerized O
tomography O
( O
CT O
) O
, O
with O
intravenous O
contrast O
, O
revealed O
a O
5 O
- O
cm O
wide O
, O
irregular O
, O
pancreatic O
/ O
peripancreatic O
mass O
, O
compressing O
both O
the O
lesser O
curvature O
of O
the O
stomach O
and O
the O
SV O
( O
Fig.1A O
, O
B O
) O
, O
a O
normal O
portal O
vein O
, O
and O
normal O
liver O
parenchyma O
. O

 O
The O
SV O
compression O
was O
pathophysiologically O
significant O
as O
indicated O
by O
proximal O
SV O
dilatation O
. O

 O
EGD O
revealed O
in O
the O
proximal O
stomach O
a O
fine O
, O
reticular O
, O
pale O
- O
white O
, O
polygonal O
, O
mucosal O
, O
network O
in O
a O
snakeskin O
pattern O
, O
and O
characteristic O
of O
portal O
hypertensive O
gastropathy O
that O
was O
actively O
oozing O
; O
extensive O
coffee O
- O
ground O
, O
blood O
clots O
in O
the O
stomach O
; O
small O
gastric O
cardial O
and O
fundal O
varices O
without O
stigmata O
of O
recent O
hemorrhage O
( O
SRH O
) O
; O
and O
no O
esophageal O
varices O
( O
Fig.2 O
) O
. O

 O
The O
extrinsic O
mass O
produced O
a O
large O
, O
round O
bulge O
extending O
into O
the O
lumen O
of O
the O
proximal O
gastric O
body O
along O
the O
lesser O
curvature O
( O
Fig.2 O
) O
. O

 O
Magnetic O
resonance O
cholangio O
- O
pancreatography O
( O
MRCP O
) O
revealed O
a O
5 O
- O
cm O
wide O
, O
enhancing O
, O
vascular O
mass O
likely O
arising O
from O
the O
LGA O
and O
located O
between O
the O
gastric O
lesser O
curvature O
and O
distal O
pancreatic O
body O
; O
compressing O
the O
stomach O
; O
compressing O
the O
middle O
SV O
; O
and O
resulting O
in O
large O
collateral O
veins O
draining O
the O
SV O
into O
the O
superior O
mesenteric O
vein O
( O
Fig.3A O
, O
B O
) O
. O

 O
Abdominal O
ultrasound O
with O
Doppler O
studies O
demonstrated O
large O
, O
turbulent O
arterial O
flow O
into O
this O
vascular O
mass O
, O
suggesting O
a O
large O
PA O
( O
Fig.4 O
) O
. O

 O
Visceral O
arteriogram O
showed O
a O
5.3 O
 O
 O
 O
2.2 O
- O
cm O
- O
wide O
PA O
supplied O
by O
an O
LGA O
branch O
( O
Fig.5A O
) O
, O
which O
was O
embolized O
and O
occluded O
with O
microcoils O
( O
Fig.5B O
) O
. O

 O
, O
the O
patient O
had O
a O
stable O
level O
with O
no O
further O
GI O
. O

 O
Abdomino O
- O
pelvic O
CT O
demonstrated O
the O
PA B
had O
markedly O
decreased O
in O
diameter O
, O
, O
and O
had O
(Fig.1C O
) O
. O

A O
was O
to O
our O
in O
because O
of O
detected O
during O
a O
medical O
checkup O
. O

 O
The O
patient O
had O
been O
diagnosed O
with O
nephrotic B
syndrome I
in O
. O

 O
showed O
elevated O
and O
, O
and O
the O
presence O
of O
. O

 O
Serologic O
markers O
for O
and O
viruses O
were O
. O

 O
of O
a O
liver O
obtained O
at O
revealed O
non O
- O
suppurative O
destructive O
cholangitis B
in O
the O
( O
Figure O
1 O
) O
. O

 O
The O
diagnosis O
of O
PBC B
( O
Scheuer B
stage I
3 I
) O
was O
confirmed O
and O
, O
, O
was O
started O
. O

 O
In O
, O
the O
patient O
underwent O
plus O
as O
well O
as O
for O
worsening O
. O

 O
In O
, O
the O
patient O
was O
for O
the O
treatment O
of O
recurrent O
. O

 O
The O
had O
ranged O
between O
and O
for O
, O
but O
it O
was O
noted O
to O
from O
in O
to O
. O

 O
Before O
the O
deterioration O
of O
, O
the O
patient O
had O
no O
infectious B
diseases I
and O
received O
no O
other O
. O

 O
On O
, O
the O
patient O
had O
neither O
nor O
. O

 O
Table O
1 O
shows O
the O
laboratory O
data O
on O
admission O
. O

 O
The O
was O
markedly O
. O

 O
Bone O
marrow O
revealed O
without O
. O

 O
and O
revealed O
a O
with O
, O
, O
and O
. O

 O
The O
had O
remained O
from O
. O

 O
Based O
on O
these O
findings O
, O
the O
association O
of O
PBC B
( O
decompensated B
liver I
cirrhosis I
) O
with O
ITP B
was O
diagnosed O
. O

 O
determined O
by O
or O
( O
SRL O
, O
Inc. O
, O
Tokyo O
, O
Japan O
) O
detected O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
and O
. O

 O
The O
for O
was O
. O

 O
Figure O
2 O
shows O
the O
clinical O
course O
. O

 O
Oral O
, O
, O
for O
was O
started O
on O
, O
and O
combined O
with O
for O
was O
performed O
. O

 O
As O
the O
, O
with O
, O
, O
was O
added O
on O
. O

 O
However O
, O
the O
was O
and O
. O

 O
On O
, O
mild O
was O
identified O
. O

 O
The O
patient O
was O
given O
a O
trial O
of O
intravenous O
, O
, O
on O
, O
combined O
with O
a O
second O
round O
of O
intravenous O
on O
. O

 O
Because O
a O
moderate O
was O
observed O
, O
prednisolone O
was O
continued O
, O
and O
the O
. O

 O
The O
with O
at O
. O

 O
Considering O
the O
decompensated B
liver I
cirrhosis I
and O
the O
, O
we O
determined O
the O
patient O
required O
careful O
of O
without O
. O

A O
with O
a O
past O
medical O
history O
significant O
for O
stage O
1 O
sarcoidosis B
to O
our O
with O
a O
chief O
complaint O
of O
. O

 O
, O
she O
with O
bilateral O
uveitis B
and O
( O
) O
on O
her O
and O
was O
subsequently O
diagnosed O
with O
sarcoidosis B
. O

 O
She O
was O
successfully O
for O
these O
conditions O
and O
her O
sarcoidosis B
remained O
until O
, O
when O
, O
at O
an O
, O
she O
was O
to O
have O
laryngeal O
. O

 O
She O
was O
with O
for O
and O
eventually O
tapered O
to O
. O

 O
Her O
sarcoidosis B
remained O
on O
this O
maintenance O
dose O
of O
until O
, O
at O
which O
time O
she O
self O
- O
discontinued O
her O
in O
favor O
of O
the O
homeopathic O
treatment O
, O
which O
unsubstantially O
claimed O
to O
have O
anti O
- O
inflammatory O
properties O
[ O
4 O
] O
. O

 O
Subsequently O
, O
she O
developed O
progressing O
to O
. O

 O
During O
this O
time O
her O
voice O
became O
increasingly O
hoarse O
and O
she O
experienced O
frequent O
episodes O
of O
. O

 O
In O
our O
, O
her O
was O
concerning O
for O
as O
she O
presented O
with O
and O
. O

 O
She O
also O
had O
chronic O
- O
appearing O
, O
indurated O
on O
her O
. O

 O
Given O
that O
she O
had O
signs O
of O
upper B
airway I
disease I
for O
impending O
respiratory O
failure O
, O
an O
emergent O
bedside O
was O
performed O
, O
revealing O
an O
obstructed B
with O
the O
epiglottis O
over O
the O
and O
significant O
in O
the O
and O
. O

 O
She O
was O
immediately O
treated O
with O
high O
- O
dose O
intravenous O
and O
emergently O
to O
the O
( O
) O
to O
secure O
her O
airway O
for O
concern O
for O
complete O
upper O
airway O
obstruction B
, O
which O
was O
confirmed O
with O
of O
her O
in O
the O
. O

 O
She O
was O
for O
a O
, O
and O
after O
taking O
from O
the O
lingual O
surface O
of O
her O
, O
a O
# O
4 O
cuffed O
Shiley O
 O
was O
placed O
. O

 O
Her O
immediately O
, O
was O
, O
and O
to O
our O
. O

 O
Her O
was O
exchanged O
to O
a O
# O
4 O
cuffless O
on O
postoperative O
. O

 O
During O
this O
time O
she O
was O
transitioned O
from O
intravenous O
to O
. O

 O
ultimately O
revealed O
non O
- O
necrotizing O
epithelioid O
consistent O
with O
sarcoidosis B
( O
Figure O
1 O
) O
. O

 O
She O
was O
prescribed O
this O
for O
, O
and O
after O
receiving O
education O
for O
self O
- O
tracheostomy O
care O
, O
she O
was O
. O

 O
At O
her O
subsequent O
and O
visits O
, O
she O
denied O
any O
further O
. O

 O
Repeat O
showed O
significant O
in O
the O
in O
the O
and O
, O
but O
the O
epiglottis O
continued O
to O
obscure B
the O
despite O
therapy O
with O
high O
- O
dose O
. O

 O
was O
initiated O
while O
was O
tapered O
to O
; O
however O
, O
this O
regimen O
failed O
and O
her O
dosage O
was O
increased O
to O
to O
reduce O
edema O
. O

 O
Because O
she O
declined O
, O
she O
will O
continue O
with O
medical O
management O
with O
to O
facilitate O
eventual O
de O
- O
cannulation O
. O

A O
( O
body O
surface O
area O
: O
1.3 O
m2 O
) O
known O
to O
have O
dilated B
cardiomyopathy I
( O
DCM B
) O
, O
was O
admitted O
for O
worsening O
heart B
failure I
( O
) O
. O

 O
He O
presented O
with O
a O
history O
of O
, O
progressive O
, O
and O
recurrent O
upper O
abdominal O
started O
. O

 O
On O
his O
were O
, O
, O
, O
and O
showed O
atrial B
fibrillation I
with O
. O

 O
revealed O
the O
jugular O
venous O
, O
significant O
tender O
and O
bilateral O
pitting O
at O
. O

 O
showed O
elevated O
of O
( O
normal O
0 O
to O
227 O
pg O
/ O
ml O
) O
and O
unremarkable O
. O

 O
and O
of O
the O
demonstrated O
consolidation O
of O
bilateral O
lower O
lobes O
with O
, O
while O
his O
venous O
of O
was O
. O

 O
Based O
on O
his O
clinical O
condition O
, O
was O
immediately O
inserted O
. O

 O
There O
were O
severe O
, O
especially O
of O
the O
( O
) O
( O
) O
with O
spherical O
shape O
, O
, O
impaired O
and O
severe O
mitral O
regurgitation O
on O
( O
) O
. O

 O
Parasternal O
short O
axis O
and O
subxyphoid O
view O
( O
Figure O
1 O
) O
showed O
the O
mobile O
right O
atrial O
highly O
suspicious O
of O
a O
thrombus B
traversing O
the O
during O
the O
cardiac O
cycle O
accompanying O
with O
free O
- O
floating O
small O
parts O
of O
the O
thrombi B
. O

 O
( O
) O
was O
performed O
to O
further O
confirm O
the O
nature O
of O
. O

 O
It O
showed O
a O
highly O
mobile O
thrombus B
, O
, O
measured O
which O
floating O
around O
the O
and O
( O
Figure O
2 O
) O
. O

 O
In O
addition O
, O
evaluated O
( O
) O
with O
( O
Figure O
3 O
) O
. O

 O
He O
was O
maintained O
on O
, O
, O
, O
and O
. O

 O
At O
the O
same O
time O
was O
started O
with O
low O
- O
molecular O
- O
weight O
and O
. O

 O
The O
patient O
had O
an O
uneventful O
and O
confirmed O
adequate O
removal O
of O
the O
thrombus B
( O
Figures O
4A O
and O
4B O
) O
. O

A O
presented O
to O
our O
cardiology O
service O
with O
signs O
and O
symptoms O
of O
congestive O
heart O
failure O
. O

 O
Her O
was O
, O
however O
and O
soon O
after O
her O
third O
, O
she O
had O
been O
in O
another O
hospital O
for O
acute B
pulmonary I
oedema I
after O
labor O
. O

 O
Cor O
triatriatum O
with O
obstructive O
behavior O
causing O
pulmonary O
hypertension O
had O
bee O
diagnosed O
, O
while O
the O
left O
ventricle O
was O
structurally O
and O
functionally O
intact O
. O

 O
The O
patient O
at O
that O
time O
denied O
and O
had O
been O
on O
medical O
therapy O
. O

 O
At O
present O
admission O
the O
patient O
with O
NYHA O
functional O
class O
III O
, O
symptoms O
of O
as O
a O
result O
of O
. O

 O
On O
a O
loud O
pulmonary O
component O
of O
the O
2nd O
heart O
sound O
and O
a O
diastolic O
murmur O
was O
heard O
in O
the O
. O

 O
Signs O
of O
right O
- O
sided O
heart B
failure I
were O
absent O
. O

 O
A O
revealed O
a O
moderately O
dilated O
left O
ventricle O
( O
LV O
) O
, O
globally O
hypokinetic B
, O
with O
severely O
impaired O
systolic O
function O
( O
EF O
estimated O
30 O
% O
) O
. O

 O
( O
) O
was O
dilated O
, O
with O
a O
echogenic O
structure O
into O
it O
. O

 O
( O
) O
documented O
a O
fibromuscular O
membrane O
across O
the O
LA O
, O
dividing O
it O
into O
two O
compartments O
, O
a O
proximal O
one O
receiving O
the O
pulmonary O
venous O
flow O
and O
a O
distal O
one O
containing O
the O
( O
) O
. O

 O
The O
two O
chambers O
communicated O
via O
a O
non O
- O
restrictive O
, O
but O
the O
prolapsed O
towards O
the O
inflow O
causing O
severe O
obstruction O
. O

 O
appeared O
normal O
, O
with O
mild O
regurgitation O
. O

 O
Patent B
foramen I
ovale I
( O
PFO B
) O
, O
atrial B
septal I
defect I
( O
ASD B
) O
and O
anomalous O
venous O
connections O
were O
ruled O
out O
and O
the O
diagnosis O
of O
cor B
triatriatum I
was O
reconfirmed O
. O

 O
( O
) O
of O
the O
heart O
also O
revealed O
the O
fibromuscular O
septum O
into O
the O
and O
the O
low O
left O
ventricular O
ejection O
fraction O
[ O
( O
LVEF O
) O
, O
cardiac O
index O
, O
cardiac O
output O
] O
( O
figure O
1 O
) O
. O

 O
Coronary O
angiography O
showed O
normal O
. O

 O
With O
these O
findings O
the O
patient O
was O
for O
surgery O
. O

 O
Anesthetic O
induction O
was O
achieved O
with O
standard O
technique O
including O
administration O
of O
, O
, O
fentanyl O
and O
. O

 O
Invasive O
monitoring O
included O
the O
use O
of O
right O
radial O
arterial O
lines O
, O
a O
pulmonary O
artery O
catheter O
and O
a O
foley O
catheter O
with O
temperature O
probe O
to O
measure O
bladder O
temperature O
as O
an O
indicator O
of O
core O
body O
temperature O
. O

 O
( O
) O
was O
also O
instituted O
. O

 O
Surgery O
was O
performed O
through O
a O
. O

 O
Connection O
to O
cardiopulmonary O
bypass O
( O
CPB O
) O
was O
achieved O
by O
standard O
ascending O
aorta O
and O
bicaval O
cannulation O
. O

 O
Mildly O
hypothermic O
( O
) O
CPB O
was O
established O
. O

 O
Cold O
blood O
cardioplegia O
was O
administered O
in O
an O
antegrade O
fashion O
through O
the O
aortic O
root O
after O
clamping O
the O
aorta O
. O

 O
The O
interatrial O
groove O
was O
developed O
and O
the O
common O
pulmonary O
venous O
chamber O
of O
the O
left O
atrium O
was O
opened O
through O
a O
vertical O
incision O
anterior O
to O
the O
right O
pulmonary O
veins O
, O
exactly O
as O
for O
mitral O
valve O
surgery O
. O

 O
After O
insertion O
of O
a O
self O
- O
retaining O
retractor O
to O
facilitate O
exposure O
, O
the O
diaphragm O
was O
exposed O
and O
the O
central O
hole O
in O
it O
was O
identified O
. O

 O
A O
preliminary O
incision O
out O
from O
the O
hole O
improved O
exposure O
for O
the O
definitive O
excision O
. O

 O
Orifices O
of O
the O
pulmonary O
veins O
on O
both O
sides O
were O
located O
. O

 O
Position O
of O
the O
atrial O
septum O
was O
also O
identified O
by O
a O
small O
opening O
in O
the O
right O
atrium O
and O
by O
inserting O
a O
curved O
clamp O
to O
displace O
the O
septum O
into O
the O
common O
pulmonary O
venous O
chamber O
of O
the O
left O
atrium O
. O

 O
There O
was O
no O
atrial B
septal I
defect I
or O
patent B
foramen I
ovale I
. O

 O
The O
was O
then O
easily O
completely O
excised O
exposing O
the O
( O
figure O
2 O
) O
. O

 O
The O
left O
atrial O
appendage O
was O
closed O
from O
inside O
the O
left O
atrium O
using O
a O
running O
3 O
- O
0 O
polypropylene O
suture O
to O
prevent O
future O
. O

 O
The O
were O
closed O
, O
the O
heart O
having O
been O
filled O
with O
blood O
before O
the O
last O
few O
sutures O
were O
placed O
. O

 O
The O
patient O
was O
rewarmed O
, O
the O
aortic O
cross O
- O
clamp O
was O
removed O
and O
additional O
de O
- O
airing O
was O
carried O
out O
in O
the O
usual O
manner O
. O

 O
CPB O
was O
terminated O
with O
minimal O
inotropic O
support O
, O
involving O
milrinone O
and O
levophed O
with O
good O
hemodynamics O
. O

 O
The O
postoperative O
course O
was O
uneventful O
and O
the O
patient O
was O
extubated O
after O
12 O
hours O
and O
discharged O
from O
the O
hospital O
on O
the O
fifth O
postoperative O
day O
. O

 O
At O
3 O
months O
follow O
- O
up O
, O
the O
patient O
was O
( O
NYHA O
class O
I O
) O
, O
in O
sinus O
rhythm O
. O

 O
TTE O
and O
MRI O
revealed O
a O
mildly O
dilated O
LV O
with O
great O
improvement O
in O
systolic O
function O
and O
an O
estimated O
LVEF O
of O
. O

A O
was O
to O
our O
for O
the O
evaluation O
of O
for O
9 O
months O
. O

 O
He O
had O
associated O
symptoms O
of O
and O
but O
denied O
, O
, O
, O
and O
. O

 O
He O
was O
an O
and O
consumed O
alcohol O
for O
30 O
years O
. O

 O
revealed O
no O
peripheral O
, O
, O
, O
or O
in O
the O
. O

 O
were O
: O
negative O
, O
negative O
, O
and O
. O

 O
Test O
for O
was O
. O

 O
Chest O
( O
) O
was O
notable O
for O
a O
huge O
well O
- O
circumscribed O
and O
homogeneous O
cylindrical O
mesenchymal O
measuring O
in O
with O
( O
Fig.1A O
) O
. O

 O
revealed O
no O
in O
the O
, O
, O
, O
or O
. O

 O
showed O
a O
submucosal O
in O
the O
starting O
at O
extending O
( O
Fig.1B O
) O
. O

 O
( O
) O
revealed O
hypoechoic O
with O
a O
clear O
boundary O
located O
in O
the O
. O

 O
The O
appeared O
as O
a O
and O
was O
preoperatively O
diagnosed O
as O
esophageal B
leiomyoma I
based O
on O
chest O
CT O
, O
endoscopic O
examination O
, O
and O
EUS O
findings O
. O

 O
Endoscopic O
mucosal O
or O
endoscopic O
submucosal O
was O
not O
possible O
because O
of O
large O
size O
. O

 O
Hence O
, O
surgical O
was O
planned O
and O
informed O
written O
consent O
was O
taken O
. O

 O
The O
patient O
underwent O
thoracoscopic O
- O
assisted O
of O
the O
with O
gastroesophageal O
, O
thoracic O
duct O
, O
and O
. O

 O
was O
. O

 O
Grossly O
, O
a O
spindle O
shaped O
measuring O
, O
was O
observed O
in O
the O
resected O
, O
which O
grew O
into O
the O
and O
blocked O
most O
of O
. O

 O
This O
located O
in O
the O
was O
, O
without O
, O
ulcer B
, O
and O
hemorrhage B
. O

 O
Its O
cut O
surface O
was O
to O
in O
color O
. O

 O
using O
and O
revealed O
that O
was O
, O
arising O
and O
expanding O
in O
to O
the O
. O

 O
The O
was O
. O

 O
( O
Fig.2A O
 O
C O
) O
. O

 O
The O
. O

 O
These O
possessed O
, O
, O
, O
and O
( O
Fig.2D O
) O
. O

 O
was O
. O

 O
No O
lymphoepithelial O
was O
recognized O
in O
the O
. O

 O
On O
, O
epithelium O
was O
diffusely O
positive O
for O
( O
Fig.3A O
) O
, O
and O
the O
tumor O
cells O
were O
diffusely O
positive O
for O
, O
( O
Fig.3B O
) O
, O
and O
( O
Fig.3D O
) O
. O

 O
Small O
deposits O
of O
tumor O
cells O
, O
which O
were O
distributed O
mainly O
in O
the O
collagen O
fibers O
, O
were O
positive O
for O
, O
, O
and O
. O

 O
Several O
tumor O
cells O
were O
also O
positive O
for O
. O

 O
Small O
lymphocytes O
were O
positive O
for O
and O
. O

 O
Follicular O
dendritic O
cells O
were O
for O
and O
( O
Fig.3C O
) O
. O

 O
All O
cells O
were O
negative O
for O
, O
, O
, O
and O
. O

 O
These O
follicular O
dendritic O
cells O
were O
arranged O
in O
nodules O
in O
which O
the O
tumor O
cells O
were O
relatively O
evenly O
distributed O
. O

 O
This O
pattern O
was O
suggestive O
of O
follicular O
colonizations O
seen O
in O
MALT O
lymphoma O
. O

 O
In O
this O
case O
, O
gene O
rearragements O
and O
clonality O
analysis O
of O
immunoglobulin O
heavy O
chain O
gene O
, O
kappa O
light O
chain O
gene O
, O
and O
lambda O
light O
chain O
gene O
was O
performed O
using O
the O
IdentiCloneTM O
IGH O
/ O
IGK O
/ O
IGL O
Gene O
Clonality O
Assay O
( O
InVivoScribe O
Technologies O
, O
CA O
) O
. O

 O
On O
monoclonal O
gene O
rearrangement O
, O
1 O
band O
appeared O
within O
150 O
to O
175 O
base O
pairs O
( O
bp O
) O
in O
heavy O
chain O
gene O
, O
2 O
discrete O
bands O
within O
225 O
to O
250 O
 O
bp O
in O
kappa O
light O
chain O
gene O
, O
and O
1 O
band O
within O
125 O
to O
150 O
 O
bp O
in O
lambda O
light O
chain O
gene O
( O
Fig.4 O
) O
. O

 O
In O
addition O
, O
no O
Epstein O
 O
Barr O
virus O
was O
observed O
in O
this O
lymphoma O
on O
in O
situ O
hybridization O
using O
the O
EB O
virus O
- O
encoded O
small O
RNA O
( O
Fig.3E O
, O
F O
) O
. O

 O
Based O
on O
the O
clinical O
data O
, O
pathological O
, O
immunohistochemical O
, O
and O
gene O
rearragements O
analysis O
, O
final O
diagnosis O
of O
primary O
esophageal O
MALT O
lymphoma O
was O
made O
. O

 O
After O
the O
surgical O
resection O
, O
no O
additional O
therapy O
in O
the O
form O
of O
chemotherapy O
or O
radiotherapy O
was O
administered O
. O

 O
Over O
the O
8 O
months O
of O
, O
no O
evidence O
of O
or O
was O
found O
on O
and O
the O
patient O
has O
been O
. O

 O
Ethical O
approval O
for O
this O
study O
was O
obtained O
from O
Medical O
Ethics O
Committee O
of O
the O
Third O
Affiliated O
Hospital O
, O
the O
Third O
Military O
Medical O
University O
. O

 O
Written O
informed O
consent O
was O
obtained O
from O
the O
patient O
for O
the O
publication O
of O
this O
case O
report O
and O
the O
accompanying O
images O
. O

A O
with O
a O
complaint O
of O
right O
upper O
quadrant O
. O

 O
, O
the O
patient O
was O
incidentally O
diagnosed O
with O
idiopathic O
BCS B
during O
health O
; O
Doppler O
( O
) O
examination O
showed O
of O
the O
, O
and O
investigations O
for O
underlying O
thrombophilia B
were O
unremarkable O
. O

 O
She O
was O
treated O
with O
to O
maintain O
an O
, O
but O
discontinued O
after O
at O
least O
1 O
year O
due O
to O
non O
- O
compliance O
; O
the O
patient O
did O
not O
with O
any O
doctors O
for O
. O

 O
She O
has O
remained O
for O
the O
until O
recently O
she O
started O
experiencing O
steadily O
worsening O
, O
intermittent O
in O
the O
of O
her O
abdomen O
, O
with O
no O
associated O
or O
alleviating O
factors O
. O

 O
was O
only O
notable O
for O
mild O
right O
upper O
quadrant O
. O

 O
Laboratory O
tests O
revealed O
mildly O
elevated O
bilirubin O
( O
2.2 O
mg O
/ O
dL O
) O
and O
albumin O
deficit O
( O
2.38 O
g O
/ O
dL O
) O
. O

 O
Her O
Child O
- O
Pugh O
( O
CP O
) O
score O
was O
8 O
, O
Model O
for O
End O
- O
Stage O
Liver O
Disease O
( O
MELD O
) O
score O
was O
11 O
, O
Rotterdam O
score O
was O
0.15 O
, O
and O
BCS O
- O
TIPS O
prognostic O
index O
( O
BCS O
- O
TIPS O
PI O
) O
score O
was O
6.3 O
. O

 O
A O
contrast O
- O
enhanced O
computed O
tomography O
( O
CT O
) O
scan O
showed O
non O
- O
visualized O
middle O
and O
left O
hepatic O
veins O
, O
hepatomegaly O
with O
hypertrophy O
of O
the O
caudate O
lobe O
, O
splenomegaly O
, O
hepatic O
venous O
collaterals O
, O
and O
a O
saccular O
aneurysm O
located O
at O
the O
extrahepatic O
portal O
vein O
main O
branch O
measuring O
3.2 O
cm O
in O
height O
and O
2.5 O
cm O
 O
2.4 O
cm O
in O
diameter O
( O
Figure O
1A O
) O
. O

 O
The O
aneurysm O
was O
thought O
to O
be O
associated O
with O
BCS O
as O
there O
was O
no O
preceding O
history O
of O
trauma O
and O
it O
had O
not O
been O
present O
on O
Doppler O
US O
examination O
performed O
3 O
years O
previously O
. O

 O
Although O
the O
patient O
had O
no O
ascites O
or O
variceal O
bleeding O
, O
the O
decision O
was O
made O
to O
create O
a O
TIPS O
to O
relieve O
hepatic O
venous O
outflow O
obstruction O
because O
of O
increasing O
pain O
and O
concern O
for O
complications O
due O
to O
aneurysm O
size O
; O
direct O
approach O
to O
the O
aneurysm O
was O
not O
considered O
due O
to O
risk O
of O
associated O
complications O
in O
the O
setting O
of O
portal O
hypertension O
, O
and O
stent O
- O
grafting O
was O
not O
considered O
due O
to O
concerns O
about O
patency O
in O
the O
settings O
of O
hepatic O
venous O
outflow O
obstruction O
and O
underlying O
thrombophilia O
. O

 O
After O
informed O
consent O
was O
obtained O
, O
the O
patient O
was O
brought O
to O
the O
interventional O
radiology O
suite O
. O

 O
The O
procedure O
was O
performed O
with O
the O
patient O
under O
conscious O
sedation O
. O

 O
Portal O
vein O
access O
was O
obtained O
via O
the O
right O
hepatic O
vein O
under O
fluoroscopy O
, O
and O
portography O
showed O
a O
saccular O
aneurysm O
located O
at O
the O
main O
portal O
vein O
, O
extensive O
intrahepatic O
portal O
vein O
thrombosis O
, O
and O
small O
splenorenal O
varices O
( O
Figure O
2A O
) O
. O

 O
A O
10 O
- O
mm O
diameter O
expanded O
polytetrafluoroethylene O
( O
ePTFE O
) O
covered O
stent O
- O
graft O
( O
Fluency O
Plus O
; O
Bard O
Peripheral O
Vascular O
, O
Tempe O
, O
Arizona O
, O
United O
States O
) O
was O
deployed O
across O
the O
liver O
parenchymal O
tract O
; O
deploying O
the O
stent O
- O
graft O
into O
the O
main O
portal O
vein O
trunk O
to O
cover O
the O
aneurysm O
neck O
was O
not O
considered O
because O
it O
would O
obstruct O
blood O
flow O
to O
the O
portal O
vein O
branches O
. O

 O
Completion O
portography O
showed O
a O
widely O
patent O
shunt O
and O
markedly O
decreased O
aneurysm O
filling O
( O
Figure O
2B O
) O
. O

 O
The O
portosystemic O
pressure O
gradient O
( O
PPG O
) O
was O
decreased O
from O
19 O
mmHg O
to O
8 O
mmHg O
. O

 O
The O
patient O
recovered O
uneventfully O
and O
had O
complete O
resolution O
of O
her O
abdominal O
pain O
in O
2 O
d. O

 O
She O
was O
discharged O
on O
long O
- O
term O
warfarin O
and O
remained O
after O
of O
. O

 O
Most O
recent O
revealed O
normal O
, O
and O
Doppler O
examination O
performed O
at O
confirmed O
a O
. O

 O
Her O
score O
was O
5 O
, O
score O
was O
8 O
, O
score O
was O
0.12 O
, O
and O
score O
was O
. O

 O
scans O
showed O
that O
the O
had O
decreased O
in O
size O
to O
and O
at O
( O
Figure O
1B O
) O
, O
and O
had O
further O
decreased O
to O
and O
at O
( O
Figure O
1C O
) O
. O

A O
in O
her O
was O
found O
to O
have O
screen O
detected O
invasive O
lobular O
breast O
carcinoma O
of O
the O
right O
breast O
and O
invasive O
ductal O
carcinoma O
, O
no O
special O
type O
, O
of O
the O
left O
breast O
. O

 O
Staging O
CT O
imaging O
prior O
to O
mastectomy O
showed O
a O
12 O
 O
cm O
pelvic O
mass O
which O
on O
initial O
impression O
was O
thought O
to O
be O
a O
fibroid O
uterus O
. O

 O
Associated O
postmenopausal O
bleeding O
led O
to O
pelvic O
ultrasound O
, O
hysteroscopy O
and O
biopsy O
. O

 O
The O
biopsy O
showed O
undifferentiated O
sarcoma O
, O
unclassifiable O
with O
immunohistochemistry O
. O

 O
Following O
discussion O
at O
a O
multidisciplinary O
team O
meeting O
it O
was O
felt O
that O
the O
uterine O
tumour O
was O
a O
separate O
primary O
malignancy O
rather O
than O
metastasis O
from O
the O
breast O
. O

 O
Hysterectomy O
and O
bilateral O
salpingo O
- O
oophorectomy O
was O
performed O
for O
both O
treatment O
purposes O
and O
to O
fully O
categorise O
the O
malignancy O
to O
guide O
further O
adjuvant O
therapy O
. O

 O
Histological O
examination O
of O
the O
resection O
specimen O
showed O
a O
partially O
necrotic O
tumour O
with O
a O
discrete O
outline O
located O
within O
and O
extending O
throughout O
the O
myometrium O
. O

 O
The O
tumour O
was O
composed O
of O
malignant O
spindle O
cells O
( O
figure O
1A O
) O
, O
with O
an O
intermittent O
component O
of O
pleomorphic O
cells O
with O
abundant O
eosinophilic O
cytoplasm O
. O

 O
Plentiful O
osteoclast O
- O
like O
giant O
cells O
were O
present O
( O
figure O
1B O
) O
. O

 O
Mitoses O
were O
numerous O
and O
structurally O
abnormal O
forms O
were O
common O
. O

 O
Neoplastic O
cells O
were O
surrounded O
by O
hyaline O
osteoid O
matrix O
and O
foci O
of O
coarse O
neoplastic O
woven O
bone O
( O
figure O
1C O
) O
. O

 O
Generous O
sampling O
of O
the O
tumour O
showed O
no O
admixed O
neoplastic O
epithelial O
elements O
, O
thus O
ruling O
out O
the O
more O
common O
carcinosarcoma O
( O
malignant O
mixed O
Mllerian O
tumour O
) O
. O

 O
Tumour O
cells O
showed O
immunohistochemical O
expression O
for O
vimentin O
, O
smooth O
muscle O
actin O
( O
SMA O
) O
, O
desmin O
( O
focally O
) O
and O
CD99 O
. O

 O
Epithelial O
markers O
were O
not O
expressed O
. O

 O
The O
morphological O
and O
immunohistochemical O
appearances O
were O
in O
keeping O
with O
primary O
uterine O
osteoblastic O
variant O
of O
osteosarcoma O
. O

 O
Unfortunately O
, O
despite O
treatment O
, O
further O
CT O
imaging O
showed O
the O
development O
of O
multiple O
peritoneal O
and O
pulmonary O
deposits O
, O
confirmed O
on O
biopsy O
to O
be O
metastatic O
osteosarcoma O
. O

 O
The O
patient O
received O
palliative O
chemotherapy O
and O
. O

A O
with O
a O
of O
on O
, O
associated O
with O
both O
lower O
extremity O
. O

 O
Before O
this O
admission O
, O
he O
also O
had O
suffered O
from O
abdominal O
bloating O
and O
tasteless O
for O
a O
year O
with O
noticeable O
body O
weight O
loss O
at O
the O
same O
time O
( O
up O
to O
20 O
kg O
) O
. O

 O
Over O
the O
past O
6 O
months O
, O
he O
developed O
a O
multiple O
system O
disorder O
, O
which O
included O
painless O
paresthesias O
in O
the O
lower O
limbs O
, O
erectile O
dysfunction O
, O
and O
chronic O
diarrhea O
. O

 O
He O
had O
an O
average O
stool O
frequency O
of O
up O
to O
ten O
times O
per O
day O
, O
with O
no O
obvious O
blood O
or O
mucus O
and O
no O
abdominal O
pain O
or O
tenesmus O
. O

 O
Unfortunately O
, O
previous O
stomach O
and O
rectum O
biopsy O
did O
not O
examine O
for O
accumulations O
of O
amyloid O
fibril O
protein O
. O

 O
His O
family O
history O
was O
unremarkable O
. O

 O
On O
physical O
examination O
, O
his O
blood O
pressure O
was O
82/56 O
mmHg O
and O
heart O
rate O
was O
52 O
bpm O
. O

 O
Significant O
jugular O
venous O
distention O
, O
moderate O
hepatomegaly O
, O
and O
lower O
extremity O
edema O
were O
noted O
. O

 O
A O
neurological O
examination O
revealed O
weakness O
and O
muscular O
atrophy O
in O
the O
bilateral O
tibialis O
anterior O
and O
gastrocnemius O
. O

 O
Hyporeflexia O
was O
noted O
on O
both O
knees O
and O
ankles O
. O

 O
Sensory O
examination O
revealed O
diminished O
tactile O
and O
pain O
sensation O
in O
a O
stocking O
and O
glove O
pattern O
and O
vibratory O
sensation O
was O
distally O
reduced O
in O
the O
lower O
limbs O
. O

 O
The O
motor O
and O
sensory O
functions O
of O
upper O
extremities O
were O
relatively O
spared O
. O

 O
Initial O
laboratory O
data O
that O
included O
full O
blood O
count O
, O
transaminase O
, O
creatinine O
, O
electrolytes O
, O
cardiac O
troponin O
, O
and O
thyroid O
function O
were O
normal O
or O
negative O
. O

 O
N O
- O
terminal O
fragment O
of O
pro O
- O
brain O
natriuretic O
peptide O
( O
NT O
- O
proBNP O
) O
was O
3,996 O
pg O
/ O
mL. O

 O
Nerve O
conduction O
studies O
confirmed O
bilateral O
sensory O
- O
motor O
neuropathy O
( O
Table O
1 O
) O
. O

 O
An O
electromyography O
study O
demonstrated O
active O
denervation O
and O
chronic O
reinnervation O
changes O
in O
the O
tibialis O
anterior O
and O
gastrocnemius O
. O

 O
Electrocardiogram O
( O
ECG O
) O
revealed O
sinus O
rhythm O
, O
low O
voltages O
in O
limb O
leads O
, O
QS O
waves O
in O
precordial O
and O
inferior O
leads O
, O
first O
- O
degree O
atrioventricular O
block O
, O
and O
prolonged O
QTc O
( O
Figure O
1 O
) O
. O

 O
Two O
- O
dimensional O
echocardiography O
revealed O
marked O
concentrically O
thickened O
and O
speckled O
appearance O
of O
ventricular O
walls O
, O
biatrial O
dilatation O
, O
and O
left O
ventricular O
ejection O
fraction O
of O
70 O
% O
( O
Figure O
2 O
) O
. O

 O
Doppler O
revealed O
a O
severe O
restrictive O
mitral O
filling O
pattern O
with O
E O
/ O
A O
ratio O
2.1 O
. O

 O
Coronary O
angiography O
findings O
were O
normal O
. O

 O
The O
combined O
occurrence O
of O
low O
QRS O
voltage O
in O
the O
ECG O
, O
ventricular O
thickening O
, O
and O
signs O
of O
diastolic O
dysfunction O
is O
strongly O
suggestive O
of O
cardiac O
amyloidosis O
. O

 O
The O
following O
serum O
 O
light O
- O
chain O
concentration O
was O
1,763 O
( O
normal O
range O
: O
5981,329 O
mg O
/ O
dL O
, O
and O
 O
light O
- O
chain O
concentration O
was O
normal O
. O

 O
Rectum O
biopsy O
confirmed O
amyloid O
infiltrate O
( O
Figure O
3 O
) O
. O

 O
So O
, O
the O
diagnosis O
of O
AL O
amyloidosis O
was O
established O
. O

 O
Despite O
chemotherapy O
administration O
of O
melphalan O
, O
dexamethasone O
, O
immunomodulator O
lenalidomide O
, O
and O
supportive O
therapy O
including O
montmorillonite O
to O
decrease O
diarrhea O
and O
low O
- O
dose O
furosemide O
to O
alleviate O
fluid O
retention O
, O
the O
patient O
continued O
to O
deteriorate O
and O
at O
after O
the O
initial O
diagnosis O
. O

A O
with O
a O
chief O
complaint O
of O
in O
. O

 O
He O
was O
diagnosed O
with O
in O
early O
childhood O
. O

 O
He O
was O
born O
at O
term O
with O
normal O
birth O
weight O
. O

 O
There O
was O
. O

 O
This O
patient O
had O
characteristic O
features O
of O
achondroplasia O
( O
i.e. O
, O
short O
stature O
, O
lumbar O
lordosis O
, O
short O
proximal O
long O
bones O
, O
large O
hands O
, O
frontal O
bossing O
, O
and O
flat O
nasal O
bridge O
) O
[ O
Figure O
1 O
] O
. O

 O
His O
height O
was O
. O

 O
Best O
corrected O
was O
in O
the O
with O
and O
in O
the O
with O
: O
. O

 O
Pupils O
were O
equal O
in O
size O
, O
round O
and O
reactive O
to O
light O
with O
no O
reverse O
afferent O
pupillary O
defect O
. O

 O
was O
in O
and O
was O
. O

 O
The O
was O
12 O
mm O
Hg O
by O
. O

 O
of O
the O
and O
left O
eyes O
were O
, O
and O
557 O
, O
respectively O
. O

 O
revealed O
a O
well O
- O
demarcated O
circular O
macular O
in O
. O

 O
In O
the O
right O
eye O
, O
this O
was O
approximately O
2.5 O
disc O
diameters O
( O
DD O
) O
in O
width O
and O
2.7 O
DD O
in O
length O
. O

 O
In O
the O
left O
eye O
, O
this O
was O
approximately O
and O
. O

 O
The O
border O
of O
the O
was O
. O

 O
Underlying O
choroidal O
and O
overlying O
retinal O
appeared O
. O

 O
In O
addition O
, O
a O
emanated O
and O
coursed O
[ O
Figure O
2 O
] O
. O

 O
Fluorescein O
of O
the O
and O
of O
the O
( O
Stratus O
; O
Carl O
Zeiss O
GmbH O
, O
Jena O
, O
Germany O
) O
were O
performed O
[ O
Figures O
[Figures3 O
and O
4 O
] O
. O

 O
Due O
to O
the O
background O
maculopathy O
, O
the O
patient O
could O
not O
appropriately O
fixate O
on O
the O
target O
during O
image O
acquisition O
resulting O
in O
slightly O
decentered O
fluorescein O
angiography O
images O
[ O
Figure O
3 O
] O
. O

An O
was O
for O
evaluation O
of O
. O

 O
He O
was O
born O
at O
term O
weighing O
4 O
 O
kg O
to O
and O
attained O
normal O
early O
developmental O
milestones O
. O

 O
Height O
and O
weight O
were O
on O
the O
10th O
and O
50th O
centiles O
, O
respectively O
. O

 O
Preliminary O
examination O
was O
remarkable O
only O
for O
hepatomegaly O
extending O
3.5 O
 O
cm O
below O
the O
right O
costal O
margin O
. O

 O
Initial O
laboratory O
evaluation O
revealed O
normochromic O
normocytic O
anaemia O
( O
haemoglobin O
7.8 O
 O
g O
/ O
dL O
( O
11.516 O
) O
, O
mean O
corpuscular O
volume O
( O
MCV O
) O
85.8 O
 O
fL O
( O
7587 O
) O
and O
mean O
corpuscular O
haemoglobin O
( O
MCH O
) O
25.4 O
 O
pg O
( O
2535 O
) O
) O
with O
marked O
anisocytosis O
( O
red O
- O
cell O
distribution O
width O
( O
RDW O
) O
29 O
% O
( O
1114.5 O
) O
) O
. O

 O
Hypochromia O
and O
teardrops O
were O
evident O
on O
a O
blood O
film O
. O

 O
Leucopoenia O
was O
also O
a O
feature O
( O
white O
cell O
count O
2.9109 O
/ O
L O
( O
4.513.5 O
) O
, O
neutrophils O
1.7109 O
/ O
L O
( O
27.5 O
) O
and O
lymphocytes O
0.8109 O
/ O
L O
( O
1.54 O
) O
) O
. O

 O
A O
bone O
marrow O
aspirate O
and O
biopsy O
revealed O
a O
hypercellular O
marrow O
with O
erythroid O
hyperplasia O
. O

 O
An O
iron O
stain O
revealed O
that O
approximately O
50 O
% O
of O
erythroblasts O
were O
ringed O
sideroblasts O
. O

 O
Marrow O
cytogenetics O
were O
normal O
including O
fluorescence O
in O
situ O
hybridisation O
studies O
of O
chromosomes O
5q O
, O
7 O
and O
8 O
and O
flow O
cytometry O
did O
not O
detect O
a O
blast O
population O
. O

 O
Serum O
copper O
and O
lead O
were O
normal O
, O
as O
were O
blood O
smears O
on O
the O
proband O
s O
parents O
and O
sister O
. O

 O
Analysis O
of O
several O
genes O
responsible O
for O
hereditary O
SA O
( O
ALAS2 O
, O
ABC7 O
, O
FECH O
and O
PUS1 O
) O
revealed O
no O
reported O
pathogenic O
variants O
. O

 O
Fasting O
lactate O
was O
elevated O
at O
3.8 O
 O
mmol O
/ O
L. O

 O
Neurological O
examination O
identified O
upper O
motor O
neuron O
signs O
in O
the O
lower O
limbs O
bilaterally O
; O
however O
, O
cerebellar O
signs O
were O
negative O
. O

 O
MRI O
of O
the O
brain O
demonstrated O
volume O
loss O
with O
slight O
prominence O
of O
the O
cerebellar O
folia O
. O

 O
Urine O
organic O
acids O
revealed O
elevated O
3 O
- O
methylglutaconate O
and O
3 O
- O
methylglutarate O
. O

 O
The O
lactate O
: O
pyruvate O
ratio O
was O
elevated O
( O
30:1 O
) O
. O

 O
Muscle O
biopsy O
revealed O
a O
structurally O
normal O
muscle O
and O
biochemical O
assay O
of O
respiratory O
chain O
components O
resulted O
in O
a O
diagnosis O
of O
partial O
complex O
IV O
deficiency O
. O

 O
He O
subsequently O
commenced O
a O
high O
- O
fat O
diet O
and O
coenzyme O
Q O
with O
a O
resultant O
improvement O
in O
energy O
. O

 O
Analysis O
of O
mtDNA O
in O
leucocytes O
and O
muscle O
utilising O
PCR O
did O
not O
reveal O
a O
deletion O
. O

 O
Carnitine O
, O
vitamin O
A O
, O
thiamine O
, O
pyridoxine O
, O
folate O
and O
uridine O
were O
supplemented O
without O
improvement O
in O
his O
anaemia O
. O

 O
Haemoglobin O
levels O
fell O
to O
4.4 O
 O
g O
/ O
dL O
, O
leading O
to O
occasional O
and O
then O
regular O
three O
- O
weekly O
red O
cell O
transfusions O
. O

 O
With O
repeated O
transfusions O
, O
ferritin O
rose O
to O
1700 O
 O
g O
/ O
L O
, O
necessitating O
iron O
chelation O
. O

 O
Peak O
growth O
hormone O
and O
cortisol O
to O
insulin O
- O
induced O
hypoglycaemia O
were O
30.9 O
 O
mU O
/ O
L O
( O
normal O
> O
20 O
) O
and O
447 O
 O
nmol O
/ O
L O
( O
normal O
> O
500 O
) O
, O
respectively O
, O
at O
age O
13 O
years O
. O

 O
Thyroid O
function O
was O
normal O
. O

 O
Repeat O
peak O
cortisol O
was O
384 O
 O
nmol O
/ O
L O
following O
adrenocorticotropic O
hormone O
( O
ACTH O
) O
stimulation O
. O

 O
Plasma O
renin O
activity O
was O
elevated O
to O
15 O
 O
ng O
/ O
mL O
/ O
h O
, O
and O
adrenal O
androgens O
were O
below O
the O
lower O
limit O
of O
assay O
detection O
. O

 O
A O
urinary O
steroid O
profile O
was O
qualitatively O
normal O
, O
as O
was O
an O
abdominal O
ultrasound O
. O

 O
Hydrocortisone O
5 O
 O
mg O
twice O
daily O
and O
fludrocortisone O
100 O
 O
g O
daily O
were O
initiated O
. O

 O
Adrenal O
autoantibodies O
to O
21 O
- O
hydroxylase O
were O
negative O
and O
very O
- O
long O
- O
chain O
fatty O
acids O
were O
normal O
. O

 O
The O
patient O
has O
recently O
developed O
a O
renal O
tubular O
Fanconi O
syndrome O
including O
glycosuria O
, O
hypokalaemia O
, O
hypophosphataemia O
with O
low O
maximal O
tubular O
reabsorption O
of O
phosphate O
and O
a O
generalised O
aminoaciduria O
. O

 O
In O
addition O
, O
he O
was O
incidentally O
noted O
to O
have O
hyperglycaemia O
during O
an O
admission O
for O
percutaneous O
endoscopic O
gastrostomy O
insertion O
. O

 O
Glycated O
haemoglobin O
was O
elevated O
to O
62 O
 O
mmol O
/ O
mol O
( O
7.8 O
% O
) O
despite O
rapid O
red O
cell O
turnover O
. O

 O
Pancreatic O
autoantibodies O
were O
negative O
( O
glutamic O
acid O
decarboxylase O
, O
anti O
- O
insulin O
, O
anti O
- O
islet O
antigen O
2 O
and O
pancreatic O
islet O
cell O
antibodies O
) O
. O

 O
He O
is O
maintained O
on O
twice O
daily O
with O
satisfactory O
glycaemic O
control O
with O
( O
205285 O
) O
. O

A O
who O
to O
the O
with O
, O
and O
for O
. O

 O
He O
complained O
of O
mild O
but O
had O
normal O
. O

 O
He O
did O
not O
have O
chest O
or O
. O

 O
Further O
inquiry O
revealed O
that O
he O
was O
. O

 O
On O
, O
patient O
was O
, O
. O

 O
His O
was O
and O
. O

 O
Rest O
of O
the O
was O
. O

 O
Initial O
performed O
on O
the O
day O
of O
admission O
revealed O
neutrophil O
, O
mild O
and O
microscopic O
( O
Table O
1 O
) O
. O

 O
and O
were O
. O

 O
revealed O
, O
. O

 O
( O
) O
was O
. O

 O
A O
clinical O
diagnosis O
of O
leptospirosis B
was O
made O
and O
he O
was O
started O
on O
intravenous O
in O
addition O
to O
adequate O
. O

 O
On O
the O
of O
illness O
, O
he O
developed O
with O
and O
. O

 O
revealed O
sinus O
with O
[ O
Figure O
1 O
] O
. O

 O
His O
( O
) O
showed O
gross O
cardiomegaly B
and O
bilateral O
pulmonary O
[ O
Figure O
2 O
] O
. O

 O
CVP O
( O
) O
was O
and O
2D O
revealed O
of O
, O
severe O
global O
hypokinesia B
and O
of O
20 O
% O
. O

 O
Troponin O
I O
was O
12.77 O
ng O
/ O
ml O
( O
normal O
range O
 O
< O
 O
0.40 O
) O
. O

 O
He O
was O
diagnosed O
to O
have O
early O
and O
severe O
myocarditis B
. O

 O
Patient O
was O
to O
( O
) O
as O
he O
needed O
. O

 O
Intravenous O
including O
, O
and O
were O
continued O
. O

 O
Patient O
was O
electively O
on O
the O
of O
illness O
due O
to O
severe O
respiratory B
distress I
. O

 O
On O
the O
same O
day O
, O
he O
developed O
rapid O
atrial B
fibrillation I
[ O
Figure O
3 O
] O
unresponsive O
to O
and O
intravenous O
. O

 O
to O
and O
he O
was O
given O
to O
prevent O
bleeding O
[ O
Table O
1 O
] O
. O

 O
We O
started O
intravenous O
based O
on O
previous O
studies O
showing O
a O
mortality O
benefit O
in O
severe O
leptospirosis O
complicated O
with O
myocarditis O
[ O
11 O
] O
. O

 O
His O
serum O
to O
by O
the O
of O
illness O
and O
( O
) O
and O
( O
) O
were O
markedly O
up O
to O
and O
respectively O
. O

 O
Dengue O
and O
Mycoplasma O
infections B
were O
excluded O
. O

 O
were O
. O

 O
Leptospira O
IgM O
performed O
on O
the O
of O
illness O
was O
positive O
( O
) O
. O

 O
Patient O
developed O
refractory B
shock I
and O
of O
persistent O
ventricular O
despite O
optimal O
in O
the O
. O

A O
was O
into O
our O
in O
with O
, O
a O
high O
, O
and O
subnormal O
levels O
. O

 O
showed O
a O
normal O
male O
. O

 O
were O
negative O
for O
the O
BCR O
- O
ABL1 O
rearrangement O
, O
but O
revealed O
the O
JAK2V617F O
mutation O
with O
an O
allele O
burden O
of O
44.9 O
% O
. O

 O
A O
diagnosis O
of O
PV B
was O
made O
on O
the O
basis O
of O
a O
morphological O
according O
to O
the O
. O

 O
The O
patient O
was O
started O
on O
, O
, O
and O
, O
all O
of O
which O
were O
well O
tolerated O
. O

 O
, O
an O
abdominal O
scan O
revealed O
the O
presence O
of O
dense O
bilateral O
perinephric O
, O
which O
was O
confirmed O
by O
a O
whole O
- O
body O
computed O
tomography O
( O
) O
scan O
, O
and O
a O
( O
) O
scan O
demonstrated O
increased O
in O
the O
. O

 O
Morphological O
confirmed O
the O
previous O
diagnosis O
of O
PV B
and O
showed O
no O
evident O
change O
in O
the O
grading O
of O
bone O
marrow O
fibrosis B
( O
MF-0 O
according O
to O
the O
EUMNET O
consensus),13 O
whereas O
revealed O
the O
following O
complex O
male O
: O
. O

 O
The O
of O
the O
perinephric O
was O
identified O
by O
means O
of O
a O
CT O
- O
guided O
core O
of O
the O
. O

 O
demonstrated O
the O
accumulation O
of O
foamy O
histiocytes O
that O
were O
positive O
for O
and O
negative O
for O
the O
dendritic O
cell O
markers O
and O
, O
surrounded O
by O
fibrosis B
and O
a O
scanty O
lympho O
- O
monocytic O
( O
Figure O
(Figure1).1 O
) O
. O

 O
The O
detection O
of O
the O
led O
to O
a O
diagnosis O
of O
ECD B
. O

 O
Cardiac O
( O
) O
revealed O
pseudo O
- O
tumoral O
of O
the O
atrioventricular O
wall,14 O
and O
a O
showed O
symmetrically O
irregular O
radiotracer O
in O
the O
consistent O
with O
ECD B
( O
Figure O
(Figure22)2 O
; O
the O
findings O
of O
cerebral O
and O
pulmonary O
were O
. O

 O
In O
accordance O
with O
the O
most O
recent O
guidelines O
for O
the O
treatment O
of O
ECD,1 O
the O
patient O
started O
therapy O
with O
pegylated O
and O
, O
of O
treatment O
, O
a O
new O
abdominal O
scan O
revealed O
the O
complete O
resolution O
of O
the O
dense O
bilateral O
perinephric O
, O
and O
the O
normalization O
of O
the O
was O
achieved O
. O

A O
was O
to O
the O
with O
a O
chief O
complaint O
of O
progressive O
for O
. O

 O
He O
also O
complained O
of O
a O
drastic O
of O
in O
the O
. O

 O
He O
, O
but O
had O
a O
chronic O
atrophic O
for O
. O

 O
Also O
, O
there O
was O
. O

 O
showed O
. O

 O
Admission O
showed O
a O
slight O
decrease O
in O
( O
) O
. O

 O
Upper O
gastrointestinal O
( O
GI O
) O
using O
showed O
a O
large O
the O
( O
Figure O
1 O
) O
. O

 O
( O
) O
scan O
revealed O
a O
soft O
in O
the O
with O
lymph O
node O
in O
the O
( O
Figure O
2 O
) O
. O

 O
showed O
a O
black O
in O
the O
and O
a O
bulky O
black O
the O
, O
as O
well O
as O
two O
black O
crater O
- O
like O
in O
the O
( O
Figure O
3 O
) O
. O

 O
specimens O
taken O
from O
the O
were O
identified O
as O
poorly O
differentiated O
adenocarcinoma B
. O

 O
Preoperative O
of O
this O
case O
was O
scored O
based O
on O
the O
( O
NRS O
2002)[6 O
] O
. O

 O
Because O
of O
the O
caused O
by O
the O
, O
a O
of O
distal O
and O
proximal O
was O
performed O
. O

 O
Esophagogastric O
and O
was O
then O
completed O
with O
. O

 O
Intraoperatively O
, O
the O
tumor O
was O
found O
located O
at O
the O
esophago O
- O
gastric O
junction O
and O
the O
tumor O
infiltrated O
the O
whole O
layer O
with O
lymph O
node O
metastasis O
at O
station O
four O
. O

 O
No O
or O
was O
observed O
in O
the O
. O

 O
The O
measured O
in O
size O
with O
( O
Figure O
4 O
) O
. O

 O
There O
were O
several O
pigmented O
satellite O
beside O
the O
, O
the O
being O
in O
diameter O
. O

 O
Moreover O
, O
two O
ulceration O
were O
found O
at O
the O
. O

 O
, O
the O
excised O
was O
composed O
of O
non O
- O
organized O
and O
pleomorphic O
cells O
exhibiting O
atypical O
nuclei O
, O
and O
abundant O
melanin O
granules O
( O
Figure O
5 O
) O
. O

 O
identified O
this O
case O
at O
a O
of O
( O
) O
. O

 O
showed O
that O
the O
was O
positive O
for O
, O
, O
and O
, O
but O
negative O
for O
and O
( O
Figure O
6 O
) O
. O

 O
Based O
on O
these O
results O
, O
a O
diagnosis O
of O
primary O
advanced O
esophago O
- O
gastric O
melanoma B
was O
established O
. O

 O
The O
was O
and O
without O
. O

 O
The O
patient O
gradually O
and O
was O
surgery O
. O

 O
As O
the O
patient O
denied O
a O
postoperative O
, O
abdominal O
and O
hepatic O
were O
found O
by O
a O
postoperative O
. O

 O
No O
was O
administered O
afterwards O
. O

 O
The O
patient O
of O
diffuse O
metastatic B
disease I
. O

A O
with O
a O
45 O
- O
year O
history O
of O
our O
for O
the O
diagnosis O
of O
an O
abnormal O
chest O
on O
. O

 O
He O
and O
had O
not O
been O
prescribed O
or O
. O

 O
A O
( O
) O
scan O
revealed O
a O
huge O
in O
the O
( O
maximum O
size O
: O
in O
diameter O
) O
that O
subsequently O
expanded O
to O
the O
and O
, O
as O
well O
as O
an O
intrapulmonary O
located O
in O
the O
, O
pleural B
effusion I
on O
the O
, O
and O
multiple O
liver O
ranging O
from O
in O
diameter O
( O
Fig.1 O
) O
. O

 O
Of O
note O
, O
some O
of O
the O
liver O
were O
, O
and O
the O
liver O
surface O
was O
irregularly O
. O

 O
The O
were O
as O
follows O
: O
11,900 O
/ O
mm3 O
, O
14.8 O
g O
/ O
dL O
, O
214,000 O
/ O
mm3 O
, O
31 O
IU O
/ O
L O
, O
19 O
IU O
/ O
L O
, O
and O
( O
) O
749 O
IU O
/ O
L. O

 O
No O
were O
found O
. O

 O
A O
subsequent O
of O
a O
tumor O
specimen O
obtained O
by O
confirmed O
the O
diagnosis O
of O
small B
cell I
carcinoma I
. O

 O
On O
considering O
the O
clinical O
diagnosis O
, O
performance O
status O
, O
and O
age O
of O
the O
patient O
, O
we O
decided O
on O
a O
regimen O
of O
antitumor O
consisting O
of O
( O
on O
) O
and O
( O
on O
) O
. O

 O
On O
from O
the O
initial O
scan O
, O
he O
started O
his O
first O
session O
. O

 O
On O
after O
initiating O
chemotherapy O
, O
he O
complained O
of O
abdominal O
, O
and O
his O
showed O
( O
) O
and O
( O
) O
. O

 O
A O
showed O
severe O
( O
) O
that O
had O
dramatically O
from O
14.8 O
g O
/ O
dL O
. O

 O
We O
attempted O
to O
identify O
the O
bleeding O
site O
on O
gastrointestinal O
, O
to O
no O
avail O
, O
but O
a O
scan O
revealed O
the O
rapid O
of O
a O
liver O
in O
the O
, O
which O
contained O
partial O
on O
the O
, O
and O
also O
a O
novel O
finding O
of O
showing O
, O
all O
suggesting O
a O
ruptured O
liver O
and O
associated O
hemorrhagic O
( O
Fig.2 O
) O
. O

 O
A O
subsequent O
contrast O
- O
enhanced O
image O
was O
negative O
for O
. O

 O
He O
underwent O
for O
the O
, O
but O
we O
only O
observed O
obscure O
tumor O
vessels O
in O
the O
left O
hepatic O
lobe O
without O
( O
Fig.3A O
) O
. O

 O
We O
suspected O
this O
might O
be O
due O
to O
the O
hypovascularity O
of O
the O
metastatic O
tumors O
and O
inactive O
bleeding O
at O
the O
time O
. O

 O
Although O
the O
benefit O
of O
therapeutic O
embolization O
of O
the O
hepatic O
artery O
was O
uncertain O
based O
on O
the O
findings O
on O
angiography O
, O
we O
performed O
( O
) O
of O
the O
using O
to O
prevent O
future O
re O
- O
bleeding O
. O

 O
Post O
- O
embolization O
revealed O
a O
slowed O
in O
the O
, O
and O
the O
peripheral O
vessels O
were O
weakly O
visualized O
( O
Fig.3B O
) O
. O

 O
After O
the O
embolization O
concomitant O
with O
, O
including O
of O
in O
total O
, O
the O
of O
the O
patient O
. O

 O
His O
remained O
around O
, O
disappeared O
, O
and O
the O
was O
improved O
after O
transfusion O
and O
did O
not O
progress O
again O
. O

 O
Liver O
did O
not O
appear O
. O

 O
the O
embolization O
, O
he O
was O
in O
relatively O
good O
and O
re O
- O
started O
his O
antitumor O
, O
which O
he O
continued O
( O
first O
- O
line O
regimen O
) O
for O
. O

 O
A O
good O
partial O
was O
gained O
after O
for O
both O
the O
lung O
and O
liver O
. O

This O
is O
a O
patient O
who O
went O
to O
our O
hospital O
with O
chief O
complaint O
of O
massive O
gum O
for O
. O

 O
The O
patient O
had O
a O
history O
of O
chronic O
hepatitis O
C. O

 O
( O
) O
plus O
( O
) O
were O
prescribed O
to O
the O
patient O
. O

 O
He O
before O
treatment O
. O

 O
The O
baseline O
revealed O
high O
( O
) O
with O
1b O
. O

 O
Rapid O
virological O
response O
was O
not O
achieved O
at O
the O
fourth O
week O
( O
: O
) O
. O

 O
Partial O
early O
virological O
response O
( O
HCV O
RNA O
: O
103 O
 O
IU O
/ O
mL O
at O
week O
12 O
) O
and O
delayed O
virological O
response O
( O
HCV O
RNA O
: O
< O
15 O
 O
IU O
/ O
mL O
at O
Week O
24 O
) O
were O
noted O
. O

 O
However O
, O
fatigue O
, O
anemia O
, O
and O
depression O
syndrome O
were O
progressed O
at O
30th O
week O
. O

 O
The O
patient O
requested O
to O
stop O
treatment O
at O
Week O
36 O
. O

 O
The O
viral O
load O
at O
the O
end O
- O
of O
- O
treatment O
( O
EOT O
) O
was O
undetectable O
. O

 O
The O
platelet O
count O
at O
EOT O
was O
92 O
 O
 O
 O
103 O
 O
cells O
/ O
L O
and O
elevated O
to O
159 O
 O
 O
 O
103 O
 O
cells O
/ O
L O
1 O
week O
later O
. O

 O
Two O
weeks O
following O
EOT O
, O
the O
patient O
developed O
massive O
gum O
bleeding O
. O

 O
The O
physical O
examination O
showed O
the O
multiple O
petechiae O
on O
the O
extremities O
. O

 O
There O
is O
no O
sign O
of O
intracerebral O
hemorrhage O
, O
gastrointestinal O
bleeding O
, O
or O
other O
internal O
bleeding O
. O

 O
The O
initial O
platelet O
count O
was O
4 O
 O
 O
 O
103cells O
/ O
L. O

 O
Coagulation O
profile O
showed O
normal O
prothrombin O
time O
, O
activated O
partial O
thromboplastin O
time O
, O
fibrinogen O
, O
d O
- O
dimer O
, O
and O
fibrin O
degradation O
product O
. O

 O
Peripheral O
blood O
smear O
showed O
neither O
fragmented O
red O
blood O
cells O
, O
helmet O
cells O
nor O
abnormal O
platelet O
aggregation O
. O

 O
Concomitant O
autoimmune O
connective O
tissue O
diseases O
such O
as O
systemic O
lupus O
erythematosus O
or O
cryoglobulinemia O
were O
excluded O
due O
to O
negative O
anti O
- O
nuclear O
antibody O
and O
cryoglobulin O
except O
for O
positive O
anti O
- O
cardiolipin O
IgG O
( O
116 O
GPL O
, O
normal O
range O
< O
20 O
GPL O
) O
and O
anti O
- O
phospholipid O
IgG O
( O
165 O
 O
U O
, O
normal O
range O
< O
15 O
 O
U O
) O
. O

 O
Anti O
- O
phospholipid O
syndrome O
was O
excluded O
due O
to O
no O
previous O
thromboembolic O
events O
, O
according O
to O
2006 O
Sapporo O
criteria.12 O
Bone O
marrow O
biopsy O
was O
also O
performed O
, O
which O
revealed O
hypocellular O
marrow O
with O
even O
cellular O
distribution O
and O
without O
evidence O
of O
lymphoid O
neoplasia O
. O

 O
The O
potential O
drugs O
that O
may O
cause O
platelet O
lysis O
were O
ruled O
out O
. O

 O
Blood O
transfusion O
of O
platelet O
was O
performed O
, O
but O
poor O
response O
with O
rapid O
decline O
of O
platelet O
count O
in O
the O
next O
day O
of O
transfusion O
. O

 O
A O
diagnosis O
of O
immune O
thrombocytopenic O
purpura O
was O
made O
. O

 O
We O
started O
intravenous O
methylprednisolone O
therapy O
( O
40 O
 O
mg O
, O
3 O
times O
daily O
) O
on O
November O
27 O
combined O
with O
platelet O
transfusion O
treatments O
. O

 O
It O
still O
showed O
no O
significant O
improvement O
. O

 O
Azathioprine O
( O
100 O
 O
mg O
, O
oral O
, O
once O
daily O
) O
was O
added O
since O
December O
3 O
. O

 O
Hydroxychloroquine O
( O
400 O
 O
mg O
, O
oral O
, O
once O
daily O
) O
was O
also O
prescribed O
due O
to O
positive O
anti O
- O
phospholipid O
antibodies O
. O

 O
Platelet O
count O
gradually O
increased O
to O
93 O
 O
 O
 O
103 O
 O
cells O
/ O
L O
17 O
days O
after O
admission O
, O
so O
methylprednisolone O
was O
changed O
to O
oral O
form O
and O
slowly O
tapered O
off O
. O

 O
On O
December O
15 O
, O
the O
patient O
was O
due O
to O
with O
to O
( O
Figure O
1 O
) O
. O

 O
Followed O
after O
5 O
months O
revealed O
sustained O
, O
, O
and O
decreased O
( O
) O
and O
( O
) O
levels O
. O

A O
woman O
, O
, O
, O
with O
good O
, O
with O
a O
normal O
, O
during O
the O
was O
, O
admitted O
for O
elective O
at O
38 O
weeks O
of O
. O

 O
During O
realization O
of O
the O
spinal O
the O
patient O
presented O
peak O
of O
the O
( O
) O
which O
without O
. O

 O
In O
, O
of O
the O
caesarian O
section O
the O
lady O
presented O
a O
severe O
with O
then O
she O
developed O
three O
episodes O
of O
generalized O
tonico O
- O
clonic O
. O

 O
The O
1st O
ceased O
the O
measures O
of O
and O
injection O
of O
. O

 O
The O
post O
- O
critical O
found O
an O
patient O
and O
at O
and O
with O
at O
without O
any O
, O
there O
was O
no O
neck O
, O
was O
preserved O
. O

 O
The O
by O
was O
( O
+ O
+ O
+ O
) O
. O

 O
The O
2nd O
and O
3th O
stoped O
spontaneously O
within O
few O
seconds O
. O

 O
Laboratory O
findings O
of O
HELLP B
syndrome I
include O
raised O
( O
525 O
IU O
/ O
L O
and O
) O
, O
( O
hemoglobinemia O
in O
7 O
mg O
/ O
dl O
) O
and O
low O
platelet O
count O
( O
44 O
000 O
platelet O
/ O
mL O
) O
. O

 O
Other O
investigations O
included O
the O
renal O
function O
tests O
, O
the O
inflammatory O
markers O
, O
the O
thyroid O
hormones O
were O
normal O
. O

 O
The O
viral O
serology O
was O
negative O
. O

 O
The O
patient O
was O
transferred O
to O
intensive O
care O
unit O
; O
she O
was O
treated O
immediately O
by O
magnesium O
sulfate O
associated O
to O
calcium O
channel O
blocker O
( O
nicardipine O
) O
, O
antiepileptic O
( O
phenobarbital O
) O
and O
preventive O
dose O
of O
low O
molecular O
weight O
heparin O
. O

 O
The O
anemia O
and O
thrombopenia O
corrected O
by O
transfusion O
of O
packed O
red O
blood O
cells O
and O
platelet O
respectively O
. O

 O
The O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
realized O
one O
hour O
after O
the O
first O
episode O
of O
convulsion O
showed O
zones O
in O
hyposignal O
T1 O
, O
hypersignal O
T2 O
and O
flair O
sequences O
, O
interesting O
the O
cerebral O
cortex O
, O
parietal O
and O
occipital O
sub O
- O
cortical O
and O
the O
white O
matter O
. O

 O
Intracranial O
venous O
sinuses O
were O
permeable O
. O

 O
The O
diagnosis O
of O
the O
PRES O
syndrome O
secondary O
to O
the O
severe O
preeclampsia O
immediate O
post O
- O
partum O
was O
retained O
( O
Figure O
1 O
) O
. O

 O
The O
electroencephalogram O
( O
EEG O
) O
realized O
in O
the O
second O
day O
did O
not O
showed O
anomaly O
. O

 O
The O
evolution O
was O
marked O
by O
the O
normalization O
of O
blood O
pressure O
, O
the O
normalization O
of O
the O
neurological O
state O
and O
of O
the O
biological O
analysis O
. O

 O
The O
patient O
in O
good O
on O
, O
with O
and O
maintained O
during O
. O

 O
THE O
of O
the O
controle O
made O
showed O
complete O
resolution O
of O
cerebral O
Figure O
2 O
. O

A O
to O
our O
complaining O
of O
, O
, O
and O
that O
had O
. O

 O
He O
was O
a O
and O
denied O
any O
previous O
medical O
histories O
. O

 O
He O
was O
a O
and O
drank O
alcohol O
about O
once O
a O
month O
. O

 O
His O
were O
: O
, O
, O
, O
, O
, O
, O
and O
, O
. O

 O
On O
the O
, O
decreased O
was O
noted O
in O
the O
. O

 O
revealed O
a O
( O
) O
level O
of O
, O
a O
level O
of O
, O
and O
and O
levels O
of O
and O
, O
respectively O
. O

 O
His O
was O
, O
while O
his O
was O
( O
) O
. O

 O
In O
the O
checked O
, O
, O
, O
, O
, O
and O
levels O
were O
, O
, O
, O
, O
and O
, O
respectively O
. O

 O
A O
was O
. O

 O
Mycoplasma O
and O
Chlamydia O
were O
. O

 O
Streptococcal O
and O
Legionella O
were O
. O

 O
Anti O
- O
nuclear O
and O
anti O
- O
neutrophilic O
were O
also O
. O

 O
A O
chest O
showed O
in O
the O
. O

 O
Chest O
showed O
with O
in O
the O
with O
a O
small O
amount O
of O
pleural B
effusion I
in O
the O
( O
Fig.1 O
) O
. O

 O
Abdominal O
revealed O
no O
abnormal O
finding O
in O
the O
. O

 O
We O
began O
to O
administer O
4 O
L O
/ O
min O
of O
and O
empirical O
with O
third O
generation O
and O
following O
a O
diagnosis O
of O
community O
- O
acquired O
pneumonia B
. O

 O
On O
the O
second O
day O
in O
the O
hospital O
, O
the O
patient O
s O
was O
sustained O
and O
he O
complained O
of O
. O

 O
His O
was O
aggravated O
such O
that O
he O
required O
7 O
L O
/ O
min O
of O
via O
a O
and O
the O
and O
pleural B
effusion I
had O
markedly O
progressed O
( O
Fig.2a O
) O
. O

 O
We O
performed O
bronchoscopy O
and O
. O

 O
Multiplex O
( O
) O
was O
positive O
for O
human O
adenovirus O
while O
other O
were O
negative O
. O

 O
Pleural O
fluid O
was O
lymphocyte O
- O
dominant O
exudate O
and O
was O
also O
positive O
for O
human O
adenovirus O
. O

 O
Under O
the O
diagnosis O
of O
adenovirus B
pneumonia I
, O
we O
started O
with O
oral O
while O
maintaining O
. O

 O
On O
hospital O
, O
his O
had O
subsided O
and O
were O
much O
improved O
. O

 O
The O
levels O
, O
and O
platelet O
counts O
gradually O
( O
Fig.3 O
) O
. O

 O
A O
follow O
- O
up O
chest O
was O
( O
Fig.2b O
) O
and O
he O
was O
in O
hospital O
without O
any O
. O

A O
at O
40 O
week O
of O
gestation O
was O
to O
a O
for O
elective O
repeated O
cesarean O
delivery O
due O
to O
slanting O
position O
of O
the O
fetus O
. O

 O
Both O
her O
. O

 O
Her O
and O
. O

 O
The O
was O
performed O
following O
the O
administration O
of O
standard O
spinal O
. O

 O
During O
surgery O
the O
patient O
became O
and O
was O
to O
maintain O
her O
blood O
pressure O
in O
the O
normal O
range O
. O

 O
Three O
hours O
after O
delivery O
of O
healthy O
male O
, O
the O
patient O
complained O
of O
, O
increasing O
and O
. O

 O
On O
with O
ventricular O
and O
pulmonary O
were O
detected O
. O

 O
Her O
was O
and O
demanded O
the O
administration O
of O
( O
initially O
continuous O
infusion O
of O
followed O
by O
) O
. O

 O
Owing O
to O
worsening O
of O
and O
gradual O
, O
was O
applied O
and O
the O
patient O
was O
to O
. O

 O
Chest O
indicated O
pulmonary B
congestion I
. O

 O
Emergency O
excluded O
pulmonary B
thromboembolism I
( O
PE B
) O
and O
confirmed O
severe O
pulmonary B
oedema I
( O
Fig.1 O
) O
. O

 O
The O
patient O
received O
, O
, O
at O
initial O
, O
which O
was O
. O

 O
The O
was O
discontinued O
of O
treatment O
. O

 O
The O
disclosed O
with O
of O
with O
in O
and O
of O
in O
II O
, O
III O
, O
aVF O
, O
( O
Fig.2 O
) O
. O

 O
showed O
elevated O
( O
normal O
value O
< O
14 O
pg O
/ O
ml O
) O
, O
( O
normal O
value O
< O
125 O
pg O
/ O
ml O
) O
. O

 O
The O
bedside O
( O
) O
revealed O
severe O
( O
) O
systolic B
dysfunction I
. O

 O
Therefore O
the O
patient O
was O
to O
. O

 O
Repeated O
showed O
LV O
with O
of O
the O
mid O
and O
basal O
segments O
of O
with O
preserved O
of O
the O
. O

 O
Urgent O
presented O
. O

 O
The O
diagnosis O
of O
inverted O
stress- O
induced O
cardiomyopathy B
was O
set O
upon O
the O
overall O
clinical O
data O
. O

 O
the O
patient O
was O
weaned O
from O
and O
. O

 O
Following O
hemodynamic O
improvement O
, O
were O
tapered O
gradually O
. O

 O
Both O
and O
( O
Figs.3 O
and O
4 O
) O
performed O
showed O
complete O
recovery O
of O
. O

 O
The O
patient O
was O
in O
good O
. O

 O
At O
12- O
month O
she O
remained O
with O
no O
. O

A O
with O
a O
history O
of O
carnitine B
deficiency I
presented O
with O
exertional O
and O
. O

 O
She O
was O
first O
diagnosed O
with O
nonischemic O
cardiomyopathy B
at O
, O
when O
she O
presented O
with O
symptoms O
of O
congestive O
heart B
failure I
and O
( O
) O
revealed O
severe O
left O
ventricular O
( O
LV B
) O
dysfunction B
. O

 O
At O
that O
time O
, O
her O
was O
( O
normal O
range O
, O
2569 O
mol O
/ O
L O
) O
, O
and O
her O
was O
( O
normal O
range O
, O
1660 O
mol O
/ O
L O
) O
. O

 O
The O
cardiomyopathy O
was O
attributed O
to O
carnitine B
deficiency I
. O

 O
After O
of O
therapy O
with O
, O
her O
and O
free O
carnitine O
had O
increased O
to O
and O
, O
respectively O
, O
and O
her O
left O
ventricular O
had O
normalized O
, O
with O
fractional O
shortening O
of O
. O

 O
At O
the O
current O
admission O
, O
the O
patient O
reported O
that O
, O
over O
the O
past O
10 O
years O
, O
she O
had O
only O
been O
intermittently O
compliant O
with O
her O
, O
and O
that O
, O
approximately O
, O
her O
total O
carnitine O
and O
had O
dropped O
to O
and O
, O
respectively O
. O

 O
She O
underwent O
followed O
by O
( O
) O
with O
gadolinium O
enhancement O
. O

 O
The O
TTE O
showed O
normal O
and O
mild O
, O
concentric O
LV B
hypertrophy I
( O
Fig.1 O
) O
. O

 O
Results O
of O
CMR O
confirmed O
normal O
and O
but O
showed O
focal O
increased O
at O
the O
and O
mid O
lateral O
( O
, O
) O
( O
Fig.2 O
) O
with O
patchy O
( O
Fig.3 O
) O
. O

 O
On O
the O
basis O
of O
the O
patient O
's O
family O
history O
of O
sudden B
cardiac I
death I
, O
abnormal O
, O
and O
underlying B
disease I
process I
, O
a O
dual O
- O
chamber O
was O
placed O
for O
primary O
prevention O
of O
sudden O
cardiac O
death O
from O
both O
bradyarrhythmias O
and O
tachyarrhythmias O
. O

A O
patient O
with O
a O
treated O
by O
in O
for O
a O
painful O
erythematous O
of O
the O
. O

 O
The O
were O
, O
the O
was O
considered O
as O
an O
abscesses O
and O
the O
patient O
was O
treated O
with O
and O
without O
. O

 O
The O
evolution O
was O
characterized O
by O
the O
appearance O
of O
an O
erythematous O
vesiculobullous O
taking O
the O
treated O
several O
times O
by O
unsuccessfully O
. O

 O
of O
this O
lesion O
was O
initially O
. O

 O
In O
, O
the O
patient O
was O
for O
and O
in O
the O
context O
of O
. O

 O
He O
had O
a O
quiescent O
UC B
disease I
. O

 O
The O
found O
an O
erythematous O
of O
of O
diameter O
, O
with O
a O
and O
, O
taking O
the O
and O
( O
Figure O
1 O
) O
. O

 O
There O
was O
also O
an O
infiltrated O
erythematous O
on O
the O
( O
Figure O
2 O
) O
and O
another O
topped O
with O
a O
large O
pustule O
at O
the O
( O
Figure O
3 O
) O
. O

 O
In O
biology O
, O
there O
was O
a O
biological B
inflammatory I
syndrome I
and O
high O
. O

 O
and O
were O
. O

 O
showed O
at O
the O
and O
the O
dermis O
infiltrate O
rich O
in O
neutrophils O
with O
leukocytoclastic O
vasculitis O
finding O
a O
PG B
( O
Figure O
4 O
) O
. O

 O
Other O
biopsies O
taken O
at O
infiltrated O
erythematous O
plaques O
of O
the O
ankle O
showed O
a O
normal O
appearance O
of O
skin O
, O
edema O
of O
the O
superficial O
dermis O
based O
on O
an O
infiltrate O
rich O
in O
neutrophils O
without O
vasculitis O
confirming O
the O
diagnosis O
of O
SS B
( O
Figure O
5 O
) O
. O

 O
treatment O
was O
then O
started O
with O
at O
a O
dose O
of O
1mg O
/ O
Kg O
/ O
j. O

 O
The O
evolution O
was O
marked O
by O
the O
( O
Figure O
6 O
) O
, O
the O
and O
disappearance O
of O
biological B
inflammatory I
syndrome I
. O

A O
to O
the O
with O
low O
- O
grade O
for O
, O
for O
and O
for O
. O

 O
She O
also O
reported O
and O
for O
. O

 O
There O
was O
. O

 O
was O
but O
she O
reported O
gradually O
progressive O
. O

 O
Family O
history O
included O
. O

 O
On O
, O
the O
patient O
was O
conscious O
and O
alert O
. O

 O
She O
was O
dyspnoeic O
and O
. O

 O
Severe O
was O
present O
with O
mild O
pedal O
. O

 O
was O
and O
of O
. O

 O
No O
evidence O
of O
, O
clubbing O
or O
lymphadenopathy B
was O
found O
. O

 O
revealed O
bibasilar O
end O
- O
inspiratory O
in O
and O
. O

 O
There O
was O
no O
hepatosplenomegaly O
or O
. O

 O
was O
. O

 O
She O
was O
found O
to O
have O
bilateral O
, O
which O
was O
gradually O
progressive O
for O
5 O
 O
years O
. O

 O
The O
were O
bilaterally O
. O

 O
The O
patient O
was O
to O
the O
for O
a O
comprehensive O
. O

 O
Her O
was O
documented O
as O
in O
with O
no O
obvious O
. O

 O
showed O
( O
figure O
1 O
) O
with O
( O
figure O
2 O
) O
. O

 O
Distant O
direct O
revealed O
( O
a O
suggestive O
confirmation O
of O
the O
presence O
of O
) O
; O
and O
peripheral O
retina O
revealed O
multiple O
yellowish O
white O
lesion O
- O
like O
flecks O
in O
the O
mid O
- O
periphery O
, O
and O
few O
blot O
haemorrhages O
indicative O
of O
( O
figures O
3 O
and O
4 O
) O
. O

A O
was O
in O
the O
( O
) O
for O
chest O
and O
. O

 O
She O
was O
found O
to O
have O
a O
urinary O
tract O
infection B
and O
was O
sent O
home O
with O
an O
and O
. O

 O
, O
she O
returned O
with O
epigastric O
, O
, O
and O
. O

 O
The O
patient O
had O
and O
denied O
; O
however O
, O
she O
complained O
of O
a O
for O
the O
. O

 O
There O
was O
. O

 O
She O
was O
and O
had O
. O

 O
On O
examination O
, O
she O
was O
( O
170/105 O
 O
mm O
 O
Hg O
) O
, O
( O
125 O
 O
bpm O
) O
, O
had O
and O
looking O
. O

 O
She O
was O
found O
to O
have O
an O
elevated O
of O
( O
normal O
60110 O
 O
mol O
/ O
l O
) O
. O

 O
After O
receiving O
1.5 O
 O
l O
of O
intravenous O
fluids O
for O
presumed O
volume O
depletion O
and O
prerenal O
azotaemia O
she O
became O
. O

 O
were O
noted O
on O
of O
her O
and O
a O
portable O
chest O
film O
demonstrated O
hazy O
infiltrates O
that O
likely O
represented O
pulmonary O
oedema O
. O

 O
She O
then O
developed O
with O
systolic O
pressures O
in O
the O
90s O
. O

 O
Non O
- O
invasive O
positive O
pressure O
ventilation O
was O
initiated O
. O

 O
An O
ECG O
demonstrated O
sinus O
tachycardia O
with O
a O
rate O
of O
130 O
 O
bpm O
and O
minimal O
ST O
depression O
on O
the O
precordial O
leads O
. O

 O
In O
consultation O
with O
a O
cardiologist O
, O
the O
patient O
received O
40 O
 O
mg O
of O
intravenous O
furosemide O
. O

 O
An O
echocardiogram O
demonstrated O
global O
hypokinesis O
with O
a O
left O
- O
ventricular O
ejection O
fraction O
< O
10 O
% O
( O
see O
figure O
1 O
) O
. O

 O
The O
patient O
was O
transferred O
to O
the O
intensive O
care O
unit O
where O
she O
became O
more O
anxious O
and O
tachycardic O
to O
170 O
 O
bpm O
. O

 O
She O
was O
intubated O
and O
sedated O
. O

 O
Despite O
the O
placement O
of O
a O
Foley O
catheter O
and O
administration O
of O
intravenous O
loop O
diuretics O
, O
she O
remained O
anuric O
for O
the O
first O
12 O
 O
h O
of O
hospitalisation O
. O

 O
She O
developed O
signs O
of O
acute O
kidney O
injury O
with O
a O
creatinine O
that O
increased O
to O
350 O
 O
mol O
/ O
l O
within O
the O
first O
24 O
 O
h O
of O
hospitalisation O
. O

 O
She O
received O
norepinephrine O
and O
milrinone O
to O
improve O
cardiac O
output O
. O

 O
On O
the O
second O
day O
of O
hospitalisation O
, O
she O
was O
evaluated O
by O
a O
cardiologist O
and O
cardiothoracic O
surgeon O
for O
emergent O
circulatory O
support O
as O
she O
had O
developed O
signs O
of O
poor O
tissue O
perfusion O
with O
a O
lactic O
acidosis O
( O
8.4 O
 O
mmol O
/ O
l O
; O
normal O
< O
2.2 O
 O
mmol O
/ O
l O
) O
and O
transaminitis O
with O
aspartate O
aminotransferase O
/ O
alanine O
transaminase O
  O
> O
150 O
 O
IU O
/ O
l O
( O
normal O
< O
40 O
 O
U O
/ O
l O
) O
. O

 O
She O
was O
taken O
to O
the O
cardiac O
catheterisation O
laboratory O
for O
emergent O
right O
heart O
catheterisation O
and O
biopsy O
to O
exclude O
acute O
myocarditis O
. O

 O
Over O
the O
next O
few O
days O
, O
she O
was O
gently O
fluid O
resuscitated O
( O
guided O
by O
bioreactance O
non O
- O
invasive O
cardiac O
output O
) O
, O
the O
pressors O
were O
gradually O
weaned O
off O
and O
she O
became O
non O
- O
oliguric O
. O

 O
She O
slowly O
regained O
renal O
function O
and O
organ O
perfusion O
improved O
with O
resolution O
of O
the O
lactic O
acidosis O
and O
a O
decrease O
in O
liver O
transaminases O
. O

 O
On O
hospital O
day O
5 O
she O
was O
transferred O
to O
the O
medical O
ward O
and O
was O
eventually O
discharged O
home O
on O
non O
- O
selective O
 O
blockade O
, O
an O
ACE O
inhibitor O
and O
nitrate O
with O
planned O
follow O
- O
up O
at O
the O
heart O
- O
failure O
clinic O
. O

 O
The O
patient O
returned O
to O
the O
with O
an O
elevated O
blood O
pressure O
, O
nausea O
and O
abdominal O
pain O
. O

 O
A O
contrast O
scan O
of O
her O
abdomen O
revealed O
pancreatitis B
and O
an O
adrenal O
. O

 O
During O
her O
treatment O
for O
pancreatitis B
she O
began O
to O
have O
of O
, O
, O
and O
abdominal O
with O
corresponding O
to O
the O
and O
to O
with O
a O
baseline O
of O
( O
see O
figure O
2 O
) O
. O

 O
Her O
urinary O
and O
plasma O
were O
and O
confirmed O
on O
repeat O
testing O
. O

 O
She O
was O
given O
aggressive O
and O
for O
a O
planned O
. O

 O
Prior O
to O
her O
had O
to O
on O
( O
see O
figure O
1 O
) O
. O

 O
of O
her O
was O
consistent O
with O
a O
non O
- O
malignant O
pheochromocytoma B
( O
see O
figure O
3 O
) O
. O

A O
sought O
for O
and O
over O
, O
and O
. O

 O
These O
were O
associated O
with O
, O
and O
. O

 O
Along O
with O
this O
she O
also O
complained O
of O
in O
. O

 O
There O
was O
. O

 O
She O
did O
not O
report O
any O
significant O
or O
. O

 O
On O
, O
her O
was O
, O
was O
and O
was O
. O

 O
There O
were O
and O
over O
, O
and O
distributed O
symmetrically O
showing O
areas O
of O
and O
. O

 O
Surrounding O
them O
were O
( O
figure O
1A O
, O
B O
) O
. O

 O
On O
per O
was O
present O
in O
the O
. O

 O
Patient O
's O
initial O
showed O
a O
of O
with O
. O

 O
The O
level O
was O
and O
was O
30 O
 O
mm O
/ O
h. O

 O
, O
and O
levels O
were O
within O
limits O
. O

 O
from O
showed O
only O
neutrophils O
without O
any O
organisms O
and O
did O
not O
show O
any O
growth O
after O
. O

 O
A O
taken O
from O
the O
showed O
in O
with O
and O
( O
figure O
2A O
, O
B O
) O
. O

 O
Abdominal O
revealed O
intraluminal O
gall O
bladder O
suggestive O
of O
. O

 O
On O
the O
basis O
of O
these O
findings O
a O
final O
diagnosis O
of O
SS B
associated O
with O
was O
made O
. O

 O
She O
was O
started O
on O
oral O
in O
dose O
of O
along O
with O
. O

 O
Her O
responded O
dramatically O
and O
subsided O
completely O
after O
of O
( O
figure O
3A O
, O
B O
) O
. O

 O
Dose O
of O
was O
tapered O
and O
an O
open O
was O
performed O
. O

 O
of O
confirmed O
it O
to O
be O
adenocarcinoma B
forming O
glands O
and O
papillae O
infiltrating O
the O
muscularis O
propria O
superficially O
. O

 O
were O
free O
of O
( O
figure O
2C O
, O
D O
) O
. O

 O
Patient O
's O
postoperative O
period O
was O
uneventful O
and O
she O
was O
discharged O
on O
of O
with O
advice O
to O
follow O
- O
up O
periodically O
. O

A O
was O
to O
the O
of O
the O
in O
with O
right O
upper O
quadrant O
and O
. O

 O
She O
was O
a O
. O

 O
Her O
level O
was O
1185.3 O
ng O
/ O
mL. O

 O
and O
( O
) O
revealed O
a O
10 O
- O
cm O
in O
the O
posterior O
segments O
of O
the O
. O

 O
A O
1.5 O
- O
cm O
was O
also O
found O
in O
the O
. O

 O
These O
clinical O
signs O
indicated O
that O
the O
patient O
had O
inoperable O
HCC B
and O
Child O
- O
Pugh O
class O
A O
cirrhosis B
. O

 O
was O
offered O
to O
the O
patient O
. O

 O
demonstrated O
no O
obvious O
hepatic O
, O
but O
multiple O
smaller O
in O
. O

 O
An O
emulsion O
of O
, O
, O
and O
were O
prepared O
, O
and O
of O
the O
were O
administered O
to O
the O
, O
respectively O
. O

 O
The O
patient O
experienced O
right O
upper O
quadrant O
after O
TACE O
and O
had O
an O
uneventful O
. O

 O
, O
a O
second O
procedure O
was O
performed O
via O
the O
and O
40 O
mL O
of O
the O
was O
administered O
. O

 O
On O
the O
, O
she O
experienced O
sudden O
acute O
and O
the O
to O
. O

 O
The O
chest O
showed O
some O
increased O
reticular O
in O
the O
, O
especially O
in O
the O
, O
and O
a O
chest O
scan O
revealed O
multiple O
iodized O
oil O
- O
like O
high O
- O
density O
in O
( O
Figure O
1 O
) O
. O

 O
After O
10 O
mg O
and O
other O
were O
administered O
, O
the O
was O
attenuated O
. O

 O
, O
the O
patient O
suffered O
from O
a O
serious O
and O
transient O
, O
accompanying O
and O
followed O
by O
, O
lower O
extremity O
. O

 O
Non O
- O
contrast O
enhanced O
scanning O
showed O
multiple O
disseminated O
hyper O
- O
intense O
in O
the O
, O
consistent O
with O
of O
( O
Figure O
2 O
) O
. O

 O
, O
her O
respiratory O
and O
neurologic O
disappeared O
completely O
, O
and O
she O
was O
. O

 O
The O
patient O
also O
consequently O
completed O
the O
other O
three O
procedures O
, O
during O
which O
no O
similar O
occurred O
. O

A O
presented O
to O
the O
emergency O
department O
with O
a O
rash O
on O
his O
arms O
and O
neck O
( O
figure O
1 O
) O
. O

 O
It O
had O
developed O
over O
the O
course O
of O
36 O
 O
h O
from O
discrete O
 O
pin O
prick O
 O
areas O
of O
erythema O
into O
a O
maculopapular O
rash O
with O
vesicles O
( O
figure O
2 O
) O
. O

 O
It O
covered O
his O
forearms O
from O
the O
dorsal O
aspect O
of O
the O
hands O
to O
the O
flexor O
surface O
of O
the O
elbows O
. O

 O
It O
was O
also O
beginning O
to O
develop O
around O
his O
neck O
( O
figure O
3 O
) O
. O

 O
He O
described O
the O
rash O
as O
itchy O
and O
painful O
, O
and O
was O
feeling O
 O
under O
the O
weather O
 O
. O

 O
The O
patient O
had O
no O
previous O
dermatological O
or O
other O
medical O
history O
of O
note O
. O

 O
He O
took O
no O
. O

 O
He O
but O
there O
was O
. O

 O
He O
. O

 O
were O
entirely O
and O
. O

 O
Closer O
examination O
of O
the O
rash O
revealed O
that O
it O
was O
present O
only O
on O
skin O
exposed O
to O
the O
sun O
when O
wearing O
a O
short O
- O
sleeved O
shirt O
; O
the O
most O
striking O
feature O
was O
the O
 O
V O
 O
shape O
on O
the O
patient O
's O
chest O
in O
keeping O
with O
the O
neck O
line O
of O
a O
polo O
shirt O
. O

 O
On O
further O
questioning O
the O
patient O
described O
a O
period O
of O
time O
48 O
 O
h O
prior O
to O
presentation O
( O
and O
12 O
 O
h O
prior O
to O
the O
development O
of O
the O
rash O
) O
spent O
strimming O
the O
grass O
under O
the O
hedges O
in O
his O
garden O
. O

 O
including O
, O
and O
, O
and O
were O
all O
. O

 O
The O
list O
of O
potential O
differential O
diagnoses O
for O
a O
maculopapular O
rash O
is O
long O
, O
but O
given O
the O
distribution O
of O
the O
rash O
and O
the O
history O
of O
plant O
material O
exposure O
a O
diagnosis O
of O
phytophotodermatitis B
was O
made O
. O

 O
The O
patient O
was O
discharged O
with O
, O
and O
the O
when O
gardening O
in O
the O
future O
. O

 O
The O
resolved O
over O
a O
. O

 O
remained O
throughout O
healing O
but O
the O
associated O
settled O
. O

 O
Residual O
is O
beginning O
to O
fade O
presentation O
. O

A O
was O
presented O
to O
the O
because O
of O
an O
history O
of O
recurrent O
( O
) O
, O
productive O
, O
and O
. O

 O
Prior O
to O
admission O
, O
he O
was O
diagnosed O
of O
pneumonia B
and O
treated O
with O
, O
, O
, O
and O
at O
. O

 O
However O
, O
no O
was O
observed O
. O

 O
Moreover O
, O
he O
was O
a O
with O
a O
. O

 O
However O
, O
were O
informed O
. O

 O
On O
, O
, O
; O
, O
; O
, O
; O
and O
, O
. O

 O
revealed O
, O
but O
no O
were O
heard O
, O
and O
was O
except O
moderate O
of O
. O

 O
showed O
, O
53.5 O
 O
mm O
 O
Hg O
, O
and O
. O

 O
Laboratory O
data O
( O
Table O
(Table1)1 O
) O
revealed O
of O
with O
, O
and O
elevated O
of O
5.16 O
 O
ng O
/ O
mL. O

 O
Chest O
, O
presence O
of O
, O
, O
, O
and O
, O
is O
noted O
( O
Fig.1A O
) O
. O

 O
Meanwhile O
, O
it O
was O
soon O
alerted O
in O
with O
presence O
of O
filamentous O
, O
gram O
- O
positive O
, O
weakly O
acid O
- O
fast O
, O
and O
beaded O
bacilli O
with O
possible O
diagnosis O
of O
Nocardia B
infection I
( O
Fig.1B O
, O
C O
) O
. O

 O
( O
) O
with O
noninvasive O
was O
promptly O
administered O
. O

 O
showed O
that O
were O
precisely O
determined O
to O
be O
by O
the O
method O
of O
on O
( O
Fig.1D O
) O
. O

 O
were O
thus O
modified O
to O
and O
in O
addition O
to O
in O
accordance O
with O
the O
sensitivity O
test O
. O

 O
However O
, O
the O
patient O
was O
not O
as O
expected O
and O
eventually O
from O
severe O
on O
the O
. O

A O
to O
our O
with O
progressive O
abdominal O
and O
irregular O
vaginal O
of O
 O
duration O
. O

 O
A O
contrast O
CT O
abdomen O
and O
pelvis O
revealed O
an O
ill O
- O
defined O
, O
irregular O
in O
the O
/ O
( O
Figure O
1 O
) O
. O

 O
There O
were O
multiple O
peritoneal O
and O
omental O
, O
pelvic O
and O
paraaortic O
, O
and O
large O
- O
volume O
. O

 O
The O
initial O
was O
significant O
for O
of O
, O
of O
, O
and O
of O
. O

 O
Serum O
was O
at O
13.1 O
mg O
/ O
dL. O

 O
and O
were O
. O

 O
was O
. O

 O
A O
revealed O
a O
fungating O
vaginal O
. O

 O
The O
patient O
underwent O
of O
the O
and O
the O
vaginal O
, O
which O
revealed O
a O
high O
- O
grade O
with O
. O

 O
was O
positive O
for O
, O
, O
and O
, O
consistent O
with O
a O
diagnosis O
of O
high O
- O
grade O
endometrial B
stromal I
sarcoma I
( O
Figure O
2 O
) O
. O

 O
The O
was O
negative O
for O
, O
with O
rare O
cells O
positive O
for O
. O

 O
Although O
for O
was O
, O
a O
could O
not O
be O
entirely O
ruled O
out O
given O
the O
small O
size O
of O
the O
biopsy O
specimen O
relative O
to O
the O
tumor O
. O

 O
The O
patient O
s O
was O
markedly O
at O
( O
nl O
34 O
) O
. O

 O
Contrast O
revealed O
a O
right O
- O
sided O
pleural B
effusion I
but O
no O
suspicious O
or O
lymphadenopathy B
. O

 O
The O
patient O
was O
deemed O
to O
have O
operable B
disease I
and O
was O
scheduled O
for O
. O

 O
However O
, O
preoperative O
showed O
that O
her O
serum O
had O
further O
to O
19.2 O
mg O
/ O
dL. O

 O
She O
had O
also O
developed O
evidence O
of O
acute O
kidney O
injury B
, O
with O
her O
to O
and O
to O
1.81 O
mg O
/ O
dL. O

 O
On O
, O
she O
was O
noted O
to O
be O
, O
with O
dry O
mucous O
membranes O
. O

 O
The O
was O
due O
to O
the O
patient O
s O
medical B
instability I
. O

 O
Further O
workup O
revealed O
an O
elevated O
of O
( O
nl O
1427 O
) O
, O
a O
level O
of O
( O
nl O
1565 O
) O
, O
and O
a O
level O
of O
( O
nl O
30100 O
) O
, O
consistent O
with O
humoral B
hypercalcemia I
of I
malignancy I
. O

 O
The O
patient O
was O
treated O
with O
, O
, O
and O
intravenous O
. O

 O
She O
eventually O
required O
temporary O
and O
for O
refractory O
. O

 O
The O
patient O
improved O
with O
regard O
to O
her O
. O

 O
Given O
the O
extent O
of O
her O
disease O
, O
she O
was O
planned O
for O
neoadjuvant O
followed O
by O
if O
a O
good O
response O
was O
achieved O
. O

 O
She O
was O
started O
on O
a O
regimen O
of O
and O
, O
which O
she O
received O
for O
. O

 O
She O
also O
had O
palliative O
to O
the O
to O
control O
. O

 O
However O
, O
her O
disease O
failed O
to O
respond O
significantly O
to O
chemotherapy O
, O
and O
she O
ultimately O
from O
complications B
of I
malignancy I
. O

A O
patient O
had O
previously O
undergone O
a O
radical O
resection O
of O
a O
T2bN0M0G3 O
Stage O
III O
retroperitoneal B
sarcoma I
, O
including O
right O
and O
, O
in O
. O

 O
demonstrated O
a O
25 O
 O
cm O
high O
- O
grade O
liposarcoma B
with O
, O
including O
, O
, O
, O
and O
. O

 O
were O
as O
the O
tumor O
did O
not O
the O
, O
and O
since O
the O
renal O
vein O
and O
ureter O
were O
free O
of O
as O
well O
. O

 O
The O
patient O
did O
not O
undergo O
any O
. O

 O
Surveillance O
in O
revealed O
an O
isolated O
in O
the O
. O

 O
An O
exploratory O
revealed O
of O
the O
, O
, O
, O
and O
with O
severe O
, O
leading O
to O
the O
intraoperative O
assessment O
of O
unresectable B
disease I
. O

 O
Subsequently O
, O
the O
patient O
underwent O
stereotactic O
body O
to O
the O
retroperitoneal O
in O
for O
a O
, O
without O
. O

 O
Postradiation O
revealed O
near O
complete O
resolution O
of O
the O
retroperitoneal O
. O

 O
, O
the O
patient O
with O
, O
postprandial O
abdominal O
, O
and O
. O

 O
revealed O
a O
7 O
 O
cm O
with O
involvement O
of O
the O
( O
Figure O
1 O
) O
. O

 O
However O
, O
there O
was O
no O
obvious O
of O
the O
or O
the O
that O
were O
noted O
to O
be O
involved O
during O
the O
previous O
laparotomy O
. O

 O
We O
elected O
to O
perform O
another O
attempt O
, O
including O
a O
possible O
pancreatoduodenectomy O
or O
retroperitoneal O
vascular O
resection O
if O
necessary O
. O

 O
At O
, O
the O
residual O
was O
an O
entirely O
, O
pedunculated O
at O
the O
distal O
to O
the O
ampulla O
that O
filled O
the O
entire O
duodenal O
lumen O
. O

 O
The O
patient O
underwent O
a O
and O
of O
the O
polypoid O
, O
followed O
by O
partial O
duodenal O
with O
hand O
- O
sewn O
duodenojejunal O
( O
Figure O
2 O
) O
. O

 O
revealed O
a O
9.5 O
 O
cm O
recurrent O
high O
- O
grade O
liposarcoma B
with O
containing O
, O
, O
, O
and O
. O

 O
were O
as O
the O
came O
of O
the O
and O
there O
was O
no O
evidence O
of O
additional O
within O
the O
remaining O
resected O
. O

 O
The O
was O
, O
and O
the O
patient O
has O
demonstrated O
no O
up O
to O
this O
resection O
. O

, O
with O
, O
presented O
with O
progressive O
of O
. O

 O
Medical O
History O
. O

 O
His O
medical O
history O
included O
. O

 O
He O
had O
fallen O
approximately O
8 O
feet O
and O
had O
landed O
on O
the O
right O
side O
of O
his O
back O
and O
on O
his O
right O
shoulder O
. O

 O
The O
patient O
had O
sustained O
bilateral O
, O
right O
iliopsoas O
muscle O
, O
multiple O
right O
costal O
, O
of O
the O
and O
the O
, O
and O
displaced O
of O
the O
. O

 O
That O
had O
lasted O
, O
during O
which O
time O
the O
clinicians O
had O
not O
detected O
any O
or O
requested O
a O
. O

 O
The O
patient O
returned O
to O
from O
the O
and O
remained O
for O
one O
year O
. O

 O
Upon O
his O
at O
our O
, O
revealed O
bibasilar O
and O
a O
pansystolic O
. O

 O
Chest O
showed O
mild O
lung O
; O
and O
transthoracic O
, O
limited O
by O
suboptimal O
acoustic O
windows O
, O
revealed O
severe O
, O
eccentric O
. O

 O
The O
valvular O
and O
subvalvular O
apparatus O
appeared O
to O
be O
structurally O
normal O
, O
and O
the O
left O
atrium O
was O
only O
mildly O
. O

 O
The O
patient O
was O
treated O
with O
intravenous O
until O
the O
were O
relieved O
. O

 O
Coronary O
revealed O
an O
absence O
of O
substantial O
coronary B
disease I
. O

 O
We O
therefore O
planned O
an O
elective O
surgical O
procedure O
for O
. O

 O
Surgical O
Procedure O
. O

 O
During O
intraoperative O
( O
) O
, O
we O
observed O
both O
a O
trivial O
central O
and O
a O
severe O
, O
this O
last O
originating O
from O
a O
ventriculoatrial O
( O
Fig.1 O
) O
. O

 O
Further O
examination O
confirmed O
the O
absence O
of O
structural B
disease I
involving O
the O
or O
. O

 O
After O
of O
the O
, O
a O
small O
( O
) O
could O
be O
seen O
, O
in O
a O
, O
involving O
also O
the O
and O
the O
. O

 O
The O
absence O
of O
leaflet O
abnormalities O
or O
vegetations O
suggested O
the O
posttraumatic O
origin O
of O
the O
. O

 O
was O
successfully O
achieved O
by O
direct O
of O
the O
tear O
with O
three O
5 O
- O
0 O
Prolene O
stitches O
and O
by O
the O
subsequent O
insertion O
of O
a O
30 O
- O
mm O
mitral O
annuloplasty O
ring O
. O

 O
The O
patient O
was O
the O
next O
day O
and O
his O
was O
. O

 O
, O
he O
was O
, O
and O
his O
one O
- O
year O
transthoracic O
of O
his O
surgical O
treatment O
. O

A O
was O
to O
our O
for O
cancer B
that O
was O
detected O
during O
screening O
by O
. O

 O
was O
identified O
, O
except O
. O

 O
Initial O
data O
showed O
a O
of O
( O
normal O
range O
: O
0 O
- O
15 O
ng O
/ O
mL O
) O
, O
but O
no O
other O
abnormality O
, O
which O
included O
other O
tumor O
markers O
, O
such O
as O
, O
and O
. O

 O
revealed O
a O
5 O
- O
cm O
ulcerofungating O
that O
was O
. O

 O
A O
of O
confirmed O
the O
presence O
of O
moderately O
differentiated O
tubular O
adenocarcinoma B
. O

 O
Subsequent O
abdominopelvic O
visualized O
a O
gastric O
. O

 O
No O
were O
observed O
in O
the O
, O
or O
, O
and O
showed O
. O

 O
Radical O
subtotal O
with O
and O
Billroth O
II O
were O
performed O
. O

 O
Grossly O
, O
the O
resected O
specimen O
contained O
double O
lesions O
: O
the O
first O
was O
a O
5.8 O
cm O
 O
3.2 O
cm O
ulcerofungating O
mass O
in O
the O
antrum O
, O
with O
extensive O
hemorrhage O
and O
light O
gray O
fibrosis O
; O
and O
the O
second O
was O
a O
nearby O
2.5 O
cm O
 O
2.0 O
cm O
ulcerative O
lesion O
( O
Figure O
1 O
) O
. O

 O
Microscopically O
, O
massive O
numbers O
of O
pleomorphic O
, O
bizarre O
tumor O
cells O
with O
hemorrhage O
( O
syncytiotrophoblasts O
and O
cytotrophoblasts O
) O
were O
observed O
in O
the O
first O
lesion O
. O

 O
Hematoxylin O
and O
eosin O
( O
HE)-stained O
tissues O
revealed O
a O
bubbly O
purple O
cytoplasm O
and O
giant O
nuclei O
at O
a O
magnification O
of O
40 O
 O
( O
Figure O
2A O
) O
and O
100 O
 O
( O
Figure O
2B O
) O
. O

 O
The O
tumor O
involved O
the O
proper O
muscle O
layer O
( O
T2a O
) O
and O
metastasis O
was O
found O
in O
four O
of O
56 O
regional O
lymph O
nodes O
( O
N1 O
) O
. O

 O
Immunohistochemical O
staining O
showed O
positive O
immunoreactivity O
for O
 O
- O
human O
chorionic O
gonadotropin O
( O
HCG O
) O
( O
Figure O
3A O
) O
and O
focal O
positivity O
for O
AFP O
( O
Figure O
3B O
) O
. O

 O
These O
findings O
confirmed O
the O
presence O
of O
gastric O
choriocarcinoma O
that O
contained O
small O
foci O
of O
an O
AFP O
- O
producing O
adenocarcinoma O
. O

 O
The O
second O
lesion O
was O
moderately O
differentiated O
tubular O
adenocarcinoma O
, O
which O
extended O
to O
the O
submucosal O
layer O
( O
T1b O
) O
. O

 O
It O
was O
close O
to O
, O
but O
distinct O
from O
the O
first O
lesion O
, O
which O
was O
negative O
by O
immunohistochemical O
staining O
for O
 O
- O
HCG O
and O
AFP O
. O

 O
The O
patient O
had O
an O
uneventful O
and O
was O
on O
. O

 O
, O
his O
was O
( O
normal O
range O
: O
0 O
- O
10 O
mIU O
/ O
mL O
) O
and O
his O
was O
10.0 O
ng O
/ O
mL. O

 O
Six O
cycles O
of O
with O
( O
Xeloda O
; O
Hoffmann O
- O
La O
Roche O
Inc. O
, O
Nutley O
, O
NJ O
, O
USA O
) O
was O
started O
at O
. O

 O
, O
his O
had O
declined O
to O
, O
and O
has O
since O
remained O
at O
this O
level O
. O

 O
No O
or O
had O
occurred O
at O
his O
. O

A O
with O
a O
history O
of O
and O
to O
the O
with O
a O
history O
of O
gradual O
but O
progressive O
of O
her O
and O
. O

 O
She O
denied O
any O
chest O
, O
, O
paroxysmal O
nocturnal O
or O
. O

 O
were O
. O

 O
was O
remarkable O
for O
an O
elevated O
( O
) O
of O
about O
with O
a O
. O

 O
There O
was O
a O
prominent O
heard O
over O
the O
. O

 O
There O
was O
no O
or O
. O

 O
The O
lungs O
were O
clear O
to O
. O

 O
The O
patient O
was O
markedly O
from O
the O
to O
the O
. O

 O
She O
was O
for O
further O
and O
. O

 O
She O
was O
diagnosed O
with O
HIV B
around O
and O
had O
been O
on O
. O

 O
She O
had O
not O
used O
for O
. O

 O
Renal B
and I
hepatic I
diseases I
were O
ruled O
out O
through O
and O
. O

 O
Peritoneal O
fluid O
was O
negative O
for O
malignancy B
. O

 O
showed O
a O
thickened O
bright O
adjacent O
to O
the O
( O
figure O
1 O
) O
with O
parallel O
separation O
between O
epicardial O
and O
pericardial O
echoes O
( O
railroad O
track O
sign O
) O
, O
and O
lack O
of O
. O

 O
Annulus O
paradoxus O
was O
demonstrated O
on O
tissue O
( O
figure O
2 O
) O
. O

 O
was O
. O

 O
The O
right O
ventricle O
was O
normal O
in O
and O
. O

 O
There O
was O
moderate O
. O

 O
There O
was O
no O
, O
but O
the O
pericardial O
space O
was O
remarkable O
for O
. O

 O
Constrictive B
physiology I
was O
demonstrated O
by O
study O
of O
tricuspid O
and O
mitral O
inflows O
( O
figure O
3 O
) O
during O
and O
; O
was O
also O
demonstrated O
in O
the O
during O
. O

 O
There O
was O
marked O
of O
the O
with O
no O
change O
during O
or O
. O

 O
of O
the O
revealed O
of O
the O
with O
no O
evidence O
of O
. O

 O
There O
were O
no O
lung O
. O

 O
Bilateral O
pleural B
effusions I
and O
interstitial O
were O
present O
in O
the O
. O

 O
Cardiac O
confirmed O
the O
presence O
of O
a O
diffusely O
thickened O
at O
. O

 O
The O
inferior O
vena O
cava O
and O
hepatic O
veins O
appeared O
. O

 O
There O
was O
a O
rapid O
and O
associated O
secondary O
to O
hindered O
( O
figure O
4 O
) O
. O

 O
The O
patient O
showed O
a O
good O
response O
to O
. O

 O
She O
underwent O
right O
and O
left O
heart O
to O
confirm O
constrictive B
physiology I
. O

A O
with O
a O
45 O
- O
year O
history O
of O
our O
for O
the O
diagnosis O
of O
an O
abnormal O
chest O
on O
. O

 O
He O
and O
had O
not O
been O
prescribed O
or O
. O

 O
A O
( O
) O
scan O
revealed O
a O
huge O
in O
the O
( O
maximum O
size O
: O
in O
diameter O
) O
that O
subsequently O
expanded O
to O
the O
and O
, O
as O
well O
as O
an O
intrapulmonary O
located O
in O
the O
, O
pleural B
effusion I
on O
the O
, O
and O
multiple O
liver O
ranging O
from O
in O
diameter O
( O
Fig.1 O
) O
. O

 O
Of O
note O
, O
some O
of O
the O
liver O
were O
, O
and O
the O
liver O
surface O
was O
irregularly O
. O

 O
The O
were O
as O
follows O
: O
11,900 O
/ O
mm3 O
, O
14.8 O
g O
/ O
dL O
, O
214,000 O
/ O
mm3 O
, O
31 O
IU O
/ O
L O
, O
19 O
IU O
/ O
L O
, O
and O
( O
) O
749 O
IU O
/ O
L. O

 O
No O
were O
found O
. O

 O
A O
subsequent O
of O
a O
tumor O
specimen O
obtained O
by O
confirmed O
the O
diagnosis O
of O
small B
cell I
carcinoma I
. O

 O
On O
considering O
the O
clinical O
diagnosis O
, O
performance O
status O
, O
and O
age O
of O
the O
patient O
, O
we O
decided O
on O
a O
regimen O
of O
antitumor O
consisting O
of O
( O
on O
) O
and O
( O
on O
) O
. O

 O
On O
from O
the O
initial O
scan O
, O
he O
started O
his O
first O
session O
. O

 O
On O
after O
initiating O
chemotherapy O
, O
he O
complained O
of O
abdominal O
, O
and O
his O
showed O
( O
) O
and O
( O
) O
. O

 O
A O
showed O
severe O
( O
) O
that O
had O
dramatically O
from O
14.8 O
g O
/ O
dL O
. O

 O
We O
attempted O
to O
identify O
the O
bleeding O
site O
on O
gastrointestinal O
, O
to O
no O
avail O
, O
but O
a O
scan O
revealed O
the O
rapid O
of O
a O
liver O
in O
the O
, O
which O
contained O
partial O
on O
the O
, O
and O
also O
a O
novel O
finding O
of O
showing O
, O
all O
suggesting O
a O
ruptured O
liver O
and O
associated O
hemorrhagic O
( O
Fig.2 O
) O
. O

 O
A O
subsequent O
contrast O
- O
enhanced O
image O
was O
negative O
for O
. O

 O
He O
underwent O
for O
the O
, O
but O
we O
only O
observed O
obscure O
tumor O
vessels O
in O
the O
left O
hepatic O
lobe O
without O
( O
Fig.3A O
) O
. O

 O
We O
suspected O
this O
might O
be O
due O
to O
the O
hypovascularity O
of O
the O
metastatic O
tumors O
and O
inactive O
bleeding O
at O
the O
time O
. O

 O
Although O
the O
benefit O
of O
therapeutic O
embolization O
of O
the O
hepatic O
artery O
was O
uncertain O
based O
on O
the O
findings O
on O
angiography O
, O
we O
performed O
( O
) O
of O
the O
using O
to O
prevent O
future O
re O
- O
bleeding O
. O

 O
Post O
- O
embolization O
revealed O
a O
slowed O
in O
the O
, O
and O
the O
peripheral O
vessels O
were O
weakly O
visualized O
( O
Fig.3B O
) O
. O

 O
After O
the O
embolization O
concomitant O
with O
, O
including O
of O
in O
total O
, O
the O
of O
the O
patient O
. O

 O
His O
remained O
around O
, O
disappeared O
, O
and O
the O
was O
improved O
after O
transfusion O
and O
did O
not O
progress O
again O
. O

 O
Liver O
did O
not O
appear O
. O

 O
the O
embolization O
, O
he O
was O
in O
relatively O
good O
and O
re O
- O
started O
his O
antitumor O
, O
which O
he O
continued O
( O
first O
- O
line O
regimen O
) O
for O
. O

 O
A O
good O
partial O
was O
gained O
after O
for O
both O
the O
lung O
and O
liver O
. O

An O
was O
from O
the O
University O
Clinic O
for O
having O
low O
( O
Hg O
) O
. O

 O
till O
when O
he O
presented O
with O
easy O
, O
postural O
, O
and O
. O

 O
He O
gave O
history O
of O
30 O
kg O
. O

 O
On O
, O
he O
looked O
, O
not O
or O
. O

 O
His O
were O
all O
, O
except O
for O
an O
elevated O
( O
) O
. O

 O
Cardiovascular O
, O
respiratory O
and O
abdominal O
were O
. O

 O
Primary O
in O
our O
revealed O
low O
level O
( O
) O
, O
low O
( O
) O
, O
and O
a O
positive O
. O

 O
A O
provisional O
diagnosis O
of O
microcytic B
hypochromic I
anemia I
for O
further O
workup O
was O
made O
. O

 O
and O
revealed O
, O
depicting O
. O

 O
Upper O
GI O
showed O
erosive O
antral O
gastritis B
with O
patchy O
ulcerative O
. O

 O
Abdominal O
showed O
a O
slightly O
with O
a O
rounded O
echogenic O
in O
the O
suggestive O
of O
hemangioma B
. O

 O
The O
spleen O
was O
slightly O
and O
with O
no O
focal O
. O

 O
( O
) O
scan O
of O
the O
and O
showed O
a O
fairly O
large O
well O
defined O
soft O
tissue O
located O
in O
the O
and O
engulfing O
jejunal O
loops O
causing O
bowel O
wall O
. O

 O
The O
patient O
underwent O
an O
exploratory O
and O
of O
the O
jejunal O
. O

 O
revealed O
an O
annular O
located O
and O
. O

 O
revealed O
a O
situated O
in O
the O
and O
and O
the O
. O

 O
The O
were O
arranged O
in O
( O
Fig.1a O
, O
b O
) O
. O

 O
were O
in O
shape O
with O
( O
Fig.1c O
) O
. O

 O
The O
. O

 O
Scattered O
osteoclast O
- O
like O
multinucleated O
were O
also O
identified O
( O
Fig.1b O
, O
c O
) O
. O

 O
Frequent O
mitotic O
figures O
and O
were O
noted O
. O

 O
All O
lymph O
nodes O
were O
not O
. O

 O
, O
the O
neoplastic O
cells O
were O
strongly O
and O
diffusely O
positive O
for O
( O
Fig.1d O
) O
. O

 O
They O
were O
also O
positive O
for O
. O

 O
( O
and O
) O
, O
( O
, O
and O
) O
, O
, O
, O
, O
, O
and O
were O
all O
in O
the O
. O

 O
( O
) O
analysis O
for O
on O
showed O
evidence O
of O
a O
in O
scored O
. O

 O
The O
native O
state O
of O
EWSR1 O
break O
apart O
probe O
will O
be O
seen O
as O
two O
adjacent O
or O
fused O
( O
overlapping O
) O
red O
/ O
green O
( O
yellow O
) O
signals O
. O

 O
However O
, O
EWSR1 O
gene O
rearrangement O
presented O
as O
one O
red O
and O
one O
green O
separated O
signal O
( O
Fig.1e O
) O
. O

 O
The O
patient O
did O
not O
receive O
or O
. O

 O
During O
the O
clinical O
, O
the O
patient O
remained O
for O
until O
he O
with O
local O
. O

 O
The O
treatment O
plan O
was O
surgical O
but O
the O
patient O
sought O
medical O
advice O
in O
a O
where O
he O
of O
the O
disease O
. O

In O
, O
a O
was O
to O
with O
symptoms O
of O
intermittent O
, O
, O
, O
skin O
over O
the O
, O
and O
in O
the O
fingers O
and O
palms O
. O

 O
The O
patient O
was O
previously O
, O
had O
, O
and O
took O
. O

 O
He O
also O
had O
and O
. O

 O
He O
had O
been O
in O
his O
usual O
state O
of O
health O
until O
one O
month O
before O
admission O
, O
when O
intermittent O
high O
developed O
( O
, O
) O
. O

 O
In O
addition O
, O
he O
reported O
, O
bilateral O
and O
symmetric O
on O
the O
and O
( O
with O
an O
inflammatory O
pattern O
) O
, O
petechiae O
over O
the O
palms O
and O
fingers O
, O
salmon O
- O
colored O
rash O
on O
the O
trunk O
, O
nausea O
, O
and O
vomiting O
. O

 O
An O
evanescent O
, O
salmon O
- O
colored O
rash O
was O
observed O
on O
his O
chest O
and O
abdomen O
, O
and O
2 O
- O
mm O
petechiae O
covered O
the O
palms O
and O
the O
fingers O
. O

 O
No O
signs O
suggested O
arthritis O
, O
and O
there O
was O
no O
lymphadenopathy O
or O
hepatosplenomegaly O
. O

 O
Blood O
testing O
showed O
elevated O
inflammatory O
markers O
( O
Table O
II O
) O
. O

 O
The O
electrocardiographic O
( O
ECG O
) O
and O
chest O
radiographic O
results O
were O
normal O
. O

 O
Ibuprofen O
( O
1,200 O
mg O
/ O
d O
) O
and O
acetaminophen O
( O
as O
needed O
) O
were O
begun O
and O
provided O
symptomatic O
relief O
. O

 O
An O
extensive O
evaluation O
was O
performed O
, O
including O
blood O
cultures O
, O
viral O
and O
bacterial O
serologic O
studies O
, O
immunologic O
screening O
( O
rheumatoid O
factor O
and O
antinuclear O
antibodies O
) O
, O
and O
computed O
tomographic O
( O
CT O
) O
studies O
of O
the O
chest O
, O
abdomen O
, O
pelvis O
, O
and O
cranium O
. O

 O
No O
significant O
changes O
were O
found O
. O

 O
However O
, O
a O
transthoracic O
echocardiogram O
( O
TTE O
) O
showed O
circumferential O
, O
mild O
pericardial O
effusion O
( O
maximal O
diameter O
, O
8 O
mm O
) O
, O
with O
no O
signs O
of O
tamponade O
or O
other O
relevant O
findings O
. O

 O
A O
few O
days O
later O
, O
dyspnea O
and O
diffuse O
chest O
pain O
developed O
. O

 O
The O
pain O
was O
relieved O
by O
chest O
anteflexion O
and O
aggravated O
by O
deep O
inspiration O
and O
by O
lying O
supine O
. O

 O
The O
patient O
was O
hypotensive O
, O
tachycardic O
, O
and O
hyperpneic O
, O
and O
he O
manifested O
jugular O
venous O
distention O
. O

 O
The O
ECG O
showed O
sinus O
tachycardia O
and O
diffuse O
ST O
- O
segment O
elevation O
( O
Fig.1 O
) O
, O
the O
chest O
radiograph O
revealed O
an O
enlarged O
cardiac O
silhouette O
( O
Fig.2 O
) O
, O
and O
the O
inflammatory O
markers O
were O
again O
elevated O
( O
Table O
II O
) O
. O

 O
A O
repeat O
TTE O
showed O
an O
increase O
in O
the O
pericardial O
effusion O
( O
maximal O
diameter O
, O
12 O
mm O
) O
( O
Fig.3 O
) O
and O
collapse O
of O
the O
right O
heart O
chambers O
. O

 O
Emergency O
pericardiocentesis O
drained O
60 O
mL O
of O
serosanguineous O
fluid O
. O

 O
When O
repeated O
, O
CT O
of O
the O
chest O
and O
abdomen O
revealed O
mild O
right O
and O
severe O
left O
pleural O
effusion O
, O
as O
well O
as O
mild O
ascites O
. O

 O
Thoracocentesis O
was O
then O
performed O
, O
during O
which O
350 O
mL O
of O
serosanguineous O
pleural O
fluid O
was O
drained O
. O

 O
Both O
heart O
and O
lung O
fluids O
were O
exudates O
that O
yielded O
negative O
microbiologic O
examination O
and O
were O
unremarkable O
upon O
histologic O
analysis O
. O

 O
The O
diagnosis O
of O
AOSD O
was O
established O
, O
and O
the O
patient O
was O
medicated O
with O
prednisone O
( O
0.5 O
mg O
/ O
kg O
/ O
d O
) O
, O
with O
major O
clinical O
and O
laboratory O
improvement O
( O
Table O
II O
) O
. O

 O
There O
was O
also O
ST O
- O
segment O
normalization O
, O
and O
the O
follow O
- O
up O
echocardiogram O
showed O
only O
mild O
pericardial O
effusion O
( O
23 O
mm O
) O
, O
without O
hemodynamic O
compromise O
. O

 O
Screening O
for O
autoimmune O
and O
infectious O
disorders O
was O
repeated O
, O
and O
no O
significant O
changes O
were O
found O
. O

 O
The O
patient O
was O
discharged O
from O
the O
hospital O
on O
a O
regimen O
of O
prednisone O
. O

 O
There O
was O
a O
recurrence O
of O
pericardial O
and O
pleural O
effusion O
2 O
months O
after O
discharge O
( O
after O
corticosteroid O
weaning O
and O
withdrawal O
) O
, O
which O
was O
resolved O
by O
resuming O
the O
prednisone O
therapy O
. O

 O
discharge O
, O
the O
patient O
at O
our O
for O
a O
. O

 O
He O
was O
and O
was O
maintained O
on O
therapy O
. O

 O
Follow O
- O
up O
and O
showed O
( O
Figs.4 O
and O
5 O
) O
. O

A O
was O
referred O
to O
our O
department O
from O
an O
external O
hospital O
because O
of O
severe O
abdominal O
pain O
of O
unclear O
aetiology O
. O

 O
The O
patient O
suffered O
from O
Friedreich O
's O
ataxia.1 O
2 O
His O
most O
recent O
transthoracic O
echocardiography O
, O
performed O
on O
the O
day O
of O
admission O
, O
showed O
a O
dilated O
cardiomyopathy O
, O
impaired O
left O
ventricular O
function O
with O
an O
ejection O
fraction O
of O
30 O
% O
and O
a O
pulmonary O
artery O
pressure O
of O
55 O
 O
mm O
 O
Hg O
; O
all O
findings O
were O
unchanged O
from O
previous O
examinations O
. O

 O
At O
that O
time O
, O
he O
lived O
alone O
in O
a O
residential O
home O
and O
was O
mobile O
using O
a O
wheelchair O
. O

 O
On O
arrival O
at O
our O
emergency O
department O
, O
the O
patient O
was O
somnolent O
and O
disoriented O
. O

 O
His O
axillary O
body O
temperature O
was O
35.7 O
 O
 O
C O
and O
his O
arterial O
blood O
pressure O
125/89 O
 O
mm O
 O
Hg O
, O
with O
a O
pulse O
rate O
of O
84 O
rhythmic O
beats O
/ O
min O
. O

 O
He O
complained O
of O
an O
increasing O
, O
diffuse O
abdominal O
pain O
during O
the O
whole O
day O
, O
combined O
with O
absence O
of O
appetite O
and O
vomiting O
on O
a O
single O
occasion O
. O

 O
His O
daily O
medication O
was O
perindopril O
2.5 O
 O
mg O
, O
torasemide O
7.5 O
 O
mg O
and O
esomeprazole O
40 O
 O
mg O
. O

 O
On O
physical O
examination O
, O
we O
found O
a O
tender O
abdomen O
with O
painful O
epigastric O
palpation O
. O

 O
Normal O
bowel O
sounds O
were O
auscultated O
in O
the O
upper O
right O
and O
lower O
left O
quadrants O
. O

 O
The O
renal O
bed O
was O
free O
of O
pain O
on O
palpation O
. O

 O
On O
cardiac O
auscultation O
, O
a O
2/6 O
systolic O
murmur O
was O
audible O
. O

 O
Lung O
auscultation O
showed O
normal O
respiration O
. O

 O
Laboratory O
findings O
were O
slightly O
elevated O
C O
reactive O
protein O
( O
CRP O
) O
of O
16 O
 O
mg O
/ O
l O
( O
normal O
: O
< O
5 O
 O
mg O
/ O
l O
) O
, O
elevated O
troponin O
- O
T O
- O
hs O
of O
0.070 O
 O
g O
/ O
l O
( O
normal O
: O
< O
0.014 O
 O
g O
/ O
l O
) O
and O
highly O
elevated O
pro O
- O
B O
- O
type O
natriuretic O
peptide O
of O
7382 O
 O
pg O
/ O
ml O
( O
normal O
: O
< O
63 O
 O
pg O
/ O
ml O
) O
. O

 O
Kidney O
function O
parameters O
were O
in O
the O
upper O
normal O
range O
, O
with O
creatinine O
of O
100 O
mol O
/ O
l O
and O
a O
calculated O
glomerular O
filtration O
rate O
of O
73 O
 O
ml O
/ O
min O
. O

 O
Blood O
count O
revealed O
leucocytosis O
of O
15.6109 O
/ O
litre O
. O

 O
Regarding O
thyroid O
function O
, O
thyroid O
- O
stimulating O
hormone O
, O
f O
- O
T3 O
and O
f O
- O
T4 O
were O
in O
the O
reference O
range O
. O

 O
Urine O
analysis O
showed O
no O
pathology O
. O

 O
In O
abdominal O
sonography O
, O
all O
organs O
were O
normal O
, O
especially O
the O
kidneys O
. O

 O
No O
free O
fluid O
was O
detected O
( O
figure O
1 O
) O
. O

 O
As O
the O
severe O
pain O
persisted O
all O
night O
, O
despite O
analgesia O
with O
paracetamol O
1 O
 O
g O
, O
metamizole O
1 O
 O
g O
and O
pethidine O
75 O
 O
g O
, O
a O
contrast O
- O
enhanced O
abdominal O
CT O
was O
performed O
revealing O
infarction O
of O
the O
right O
kidney O
, O
which O
appeared O
as O
a O
hypodense O
area O
although O
kidney O
arteries O
and O
veins O
were O
assessed O
as O
open O
( O
figures O
2 O
and O
3 O
) O
. O

 O
Cardiac O
dysfunction O
is O
the O
most O
frequent O
cause O
of O
death O
in O
patients O
affected O
by O
Friedreich O
's O
ataxia O
, O
most O
commonly O
from O
congestive O
heart O
failure O
or O
arrhythmia O
. O

 O
Renal O
artery O
embolism O
is O
not O
a O
rare O
event O
in O
these O
patients O
. O

 O
However O
, O
other O
non O
- O
abdominal O
viscous O
causes O
of O
severe O
diffuse O
abdominal O
pain O
such O
as O
porphyria O
, O
familial O
Mediterranean O
fever O
, O
diabetic O
ketoacidosis O
, O
tocopherol O
deficiency O
also O
had O
to O
be O
excluded O
. O

 O
The O
negative O
cardiolipin O
test O
excluded O
tabetic O
crises O
. O

 O
No O
evidence O
for O
pre O
- O
existing O
porphyria O
was O
encountered O
for O
example O
, O
quantitative O
determination O
of O
 O
- O
aminolevulinic O
acid O
, O
porphobilinogen O
and O
porphyrin O
in O
24 O
- O
h O
urine O
was O
negative O
. O

 O
Further O
genetic O
diagnosis O
regarding O
, O
for O
example O
, O
clotting O
disorder O
, O
was O
also O
not O
conclusive O
. O

 O
Hypovitaminosis O
was O
not O
present O
. O

 O
The O
patient O
had O
no O
endocrinopathies O
, O
for O
example O
, O
no O
diabetes O
and O
no O
evidence O
for O
hypothyreosis O
or O
hyperthyreosis O
. O

 O
The O
patient O
was O
hospitalised O
without O
delay O
at O
the O
department O
of O
nephrology O
. O

 O
Immediate O
anticoagulation O
with O
heparin O
was O
initiated O
and O
later O
replaced O
by O
lifelong O
oral O
anticoagulation O
with O
phenprocoumon O
. O

 O
During O
11 O
 O
days O
of O
hospitalisation O
, O
no O
complications O
occurred O
. O

 O
Kidney O
function O
parameters O
remained O
normal O
. O

 O
Transoesophageal O
echocardiography O
on O
the O
fifth O
day O
showed O
no O
cardiac O
thrombus O
and O
no O
patent O
foramen O
ovale O
. O

 O
Deep O
vein O
thrombosis O
was O
excluded O
with O
duplex O
sonography O
. O

 O
Anticardiolipin O
antibody O
testing O
and O
genetic O
testing O
regarding O
clotting O
disorders O
were O
both O
negative O
. O

 O
Urine O
tests O
revealed O
no O
evidence O
of O
porphyria O
. O

 O
During O
hospitalisation O
the O
patient O
remained O
stable O
regarding O
cardiological O
function O
, O
while O
diuretics O
were O
adjusted O
according O
to O
the O
fluid O
balance O
. O

 O
The O
patient O
had O
already O
been O
treated O
with O
levofloxacin O
for O
pneumonic O
infection O
prior O
to O
hospitalisation O
. O

 O
The O
antibiotic O
treatment O
was O
continued O
because O
of O
increasing O
inflammatory O
parameters O
in O
the O
further O
course O
of O
disease O
. O

 O
A O
CRP O
increase O
of O
up O
to O
200 O
 O
mg O
/ O
l O
was O
interpreted O
as O
an O
inflammatory O
response O
to O
renal O
infarction O
. O

 O
By O
, O
were O
. O

A O
was O
admitted O
with O
a O
history O
of O
increasing O
, O
, O
, O
generalised O
and O
deteriorating O
. O

 O
Her O
medical O
history O
included O
a O
, O
and O
. O

 O
Her O
medications O
included O
, O
, O
and O
. O

 O
On O
admission O
, O
the O
patient O
was O
, O
( O
) O
. O

 O
Her O
( O
) O
was O
, O
her O
abbreviated O
was O
and O
she O
was O
noted O
to O
be O
in O
her O
responses O
. O

 O
showed O
reduced O
power O
in O
her O
lower O
limbs O
( O
34/5 O
) O
in O
a O
pyramidal O
distribution O
, O
and O
brisk O
reflexes O
with O
intact O
sensation O
in O
all O
modalities O
. O

 O
Cardiovascular O
, O
respiratory O
and O
gastrointestinal O
were O
unremarkable O
and O
there O
were O
no O
demonstrable O
features O
of O
hepatic B
disease I
. O

 O
Routine O
was O
. O

 O
The O
patient O
's O
alanine O
transaminase O
was O
7 O
 O
u O
/ O
L O
( O
115 O
) O
, O
alkaline O
phosphatase O
61 O
 O
u O
/ O
L O
( O
30130 O
) O
, O
 O
- O
glutamyl O
transferase O
17 O
 O
u O
/ O
L O
( O
< O
45 O
) O
and O
bilirubin O
was O
6 O
 O
mol O
/ O
L O
( O
< O
21 O
) O
. O

 O
She O
had O
normal O
serum O
and O
levels O
, O
and O
normal O
thyroid O
function O
tests O
. O

 O
Serum O
levels O
were O
. O

 O
Her O
serum O
was O
( O
11.235.4 O
) O
and O
concentrations O
were O
( O
50100 O
) O
. O

 O
Brain O
imaging O
including O
CT O
and O
MRI O
did O
not O
show O
any O
haemorrhage O
or O
intracranial O
mass O
. O

 O
Lumbar O
puncture O
demonstrated O
clear O
cerebrospinal O
fluid O
( O
white O
cell O
count O
< O
1106 O
/ O
L O
, O
protein O
0.25 O
 O
g O
/ O
L O
( O
0.20.4 O
) O
) O
. O

 O
EEG O
demonstrated O
mild O
variable O
slowing O
and O
irregularity O
of O
background O
activity O
( O
likely O
due O
to O
medication O
) O
. O

 O
The O
differential O
diagnosis O
included O
encephalitis B
, O
Guillain B
- I
Barr I
syndrome I
and O
acute B
disseminated I
encephalomyelitis I
( O
ADEM B
) O
, O
which O
were O
excluded O
through O
our O
investigations O
. O

 O
In O
view O
of O
the O
raised O
valproate O
and O
ammonia O
levels O
, O
a O
diagnosis O
of O
valproate B
hyperammonaemic I
encephalopathy I
( O
VHE B
) O
was O
made O
at O
this O
point O

 O
The O
dose O
of O
was O
rather O
than O
being O
completely O
withdrawn O
. O

 O
This O
was O
due O
to O
the O
complex O
and O
challenging O
nature O
of O
managing O
the O
patient O
's O
schizo B
- I
affective I
disorder I
. O

 O
Within O
3 O
 O
days O
, O
there O
was O
evident O
clinical O
in O
her O
. O

 O
The O
patient O
was O
able O
to O
and O
with O
the O
team O
, O
and O
her O
to O
10/10.The O
serum O
ammonia O
normalised O
and O
valproate O
levels O
decreased O
to O
the O
therapeutic O
range O
. O

 O
she O
was O
. O

 O
Results O
of O
of O
her O
were O
awaited O
. O

 O
postdischarge O
, O
the O
patient O
was O
clinically O
stable O
in O
terms O
of O
, O
having O
had O
no O
further O
episodes O
of O
or O
. O

 O
However O
, O
she O
continued O
to O
have O
and O
( O
due O
to O
residual O
leg O
) O
. O

 O
Results O
of O
her O
serum O
revealed O
that O
our O
patient O
had O
carnitine B
deficiency I
evident O
by O
low O
, O
low O
free O
serum O
( O
, O
normal O
range O
: O
2352 O
) O
and O
low O
total O
serum O
( O
, O
normal O
range O
: O
2763 O
) O
. O

 O
She O
was O
started O
on O
oral O
. O

 O
, O
her O
resolved O
completely O
with O
normalisation O
of O
serum O
levels O
( O
free O
25.2 O
 O
mol O
/ O
L O
and O
total O
of O
) O
. O

 O
The O
was O
initially O
stopped O
completely O
, O
but O
due O
to O
a O
serious O
relapse O
of O
the O
patient O
's O
schizo B
- I
affective I
disorder I
, O
it O
was O
restarted O
and O
she O
is O
now O
well O
on O
and O
long O
- O
term O
. O

A O
infant O
with O
a O
and O
was O
admitted O
to O
our O
centre O
for O
the O
. O

 O
We O
received O
an O
patient O
, O
mechanically O
in O
a O
, O
with O
a O
( O
FiO2 O
) O
( O
, O
, O
) O
. O

 O
A O
chest O
of O
the O
was O
performed O
on O
( O
figure O
1A O
) O
, O
and O
the O
first O
surgery O
( O
figure O
1B O
) O
, O
showing O
improvement O
of O
the O
bilateral O
posterior O
atelectasis B
in O
the O
. O

 O
Owing O
to O
the O
difficulty O
of O
progressing O
in O
the O
weaning O
process O
from O
mechanical O
ventilation O
after O
the O
VEPTRs O
were O
implanted O
to O
expand O
the O
thorax O
, O
a O
bronchoscopy O
was O
performed O
, O
showing O
bronchomalacia O
predominantly O
in O
both O
upper O
lobar O
bronchi O
. O

 O
As O
prolonged O
mechanical O
ventilation O
was O
expected O
, O
a O
tracheostomy O
was O
previously O
performed O
. O

 O
After O
an O
initial O
CT O
scan O
( O
figure O
2A O
) O
, O
a O
follow O
- O
up O
CT O
scan O
( O
figure O
2B O
) O
a O
month O
after O
the O
surgery O
showed O
a O
resolution O
of O
the O
posterior O
- O
basal O
atelectasis O
, O
coinciding O
with O
a O
decrease O
of O
FiO2 O
to O
0.21 O
. O

 O
Postoperatively O
, O
the O
patient O
was O
on O
the O
Servo O
- O
i O
ventilator O
in O
a O
volume O
- O
controlled O
mode O
and O
needed O
variable O
PIPs O
between O
25 O
and O
45 O
 O
cm O
 O
H2O O
and O
PEEP O
values O
of O
711 O
 O
cm O
 O
H2O. O

 O
During O
the O
attempts O
to O
wean O
the O
patient O
off O
the O
ventilator O
in O
the O
following O
months O
, O
he O
was O
unable O
to O
activate O
the O
inspiratory O
flow O
trigger O
and O
required O
significant O
sedoanalgesia O
to O
adapt O
to O
the O
ventilator O
due O
to O
repeated O
episodes O
of O
desaturation O
, O
on O
some O
occasions O
with O
bradycardia O
, O
associated O
to O
bronchial O
collapse O
. O

 O
He O
continued O
to O
have O
asynchrony O
which O
required O
boluses O
of O
sedation O
in O
addition O
to O
existing O
medications O
. O

 O
He O
initially O
received O
fentanyl O
and O
midazolam O
through O
a O
continuous O
infusion O
pump O
with O
progressive O
increase O
in O
the O
doses O
as O
well O
as O
continuous O
cisatracurium O
as O
a O
muscular O
relaxant O
to O
adapt O
to O
mechanical O
ventilation O
( O
figure O
3 O
) O
. O

 O
As O
clinical O
stabilisation O
was O
achieved O
, O
the O
muscular O
relaxant O
was O
withdrawn O
and O
a O
progressive O
decrease O
of O
sedation O
was O
initiated O
along O
with O
a O
change O
in O
the O
drug O
regimen O
. O

 O
During O
this O
period O
, O
the O
patient O
developed O
an O
ocular O
flutter O
which O
was O
attributed O
to O
a O
pharmacological O
cause O
after O
neurological O
alterations O
were O
ruled O
out O
with O
normal O
EEG O
, O
ophthalmoscopy O
, O
metabolic O
workup O
and O
cranial O
MRI O
. O

 O
At O
5 O
 O
months O
of O
age O
, O
the O
NAVA O
mode O
started O
to O
improve O
the O
patient O
's O
adaptation O
to O
the O
ventilator O
through O
the O
use O
of O
a O
neural O
trigger O
. O

 O
The O
NAVA O
catheter O
additionally O
costs O
around O
 O
200 O
per O
catheter O
; O
according O
to O
the O
manufacturer O
it O
should O
be O
changed O
every O
5 O
 O
days O
. O

 O
It O
was O
required O
for O
7 O
 O
months O
; O
nevertheless O
the O
catheters O
were O
changed O
every O
15 O
 O
days O
without O
observing O
a O
deterioration O
of O
the O
Edi O
signal O
. O

 O
According O
to O
the O
literature O
, O
Jarcho O
- O
Levin O
syndrome O
does O
not O
appear O
with O
mental O
retardation O
and O
life O
expectancy O
is O
pretty O
long O
, O
so O
ethically O
, O
we O
considered O
that O
this O
patient O
should O
have O
an O
opportunity O
to O
overcome O
his O
thoracic O
insufficiency O
if O
it O
were O
technically O
possible O
. O

 O
Tachypnoea O
was O
initially O
observed O
with O
a O
RR O
of O
55 O
without O
other O
signs O
of O
increase O
in O
his O
work O
of O
breathing O
and O
his O
RR O
eventually O
returned O
to O
normal O
for O
his O
age O
( O
40 O
) O
over O
the O
next O
few O
days O
. O

 O
The O
synchrony O
achieved O
with O
the O
ventilator O
allowed O
a O
progressive O
decrease O
of O
the O
sedoanalgesia O
he O
received O
until O
it O
was O
completely O
withdrawn O
in O
10 O
 O
days O
; O
and O
the O
need O
for O
extra O
boluses O
of O
sedation O
was O
reduced O
to O
zero O
. O

 O
Concurrently O
to O
the O
reduction O
of O
sedation O
, O
his O
ocular O
flutter O
disappeared O
and O
he O
showed O
significant O
progress O
in O
his O
psychomotor O
development O
. O

 O
The O
settings O
used O
were O
: O
NAVA O
level O
of O
1 O
 O
cm O
 O
H2O/V O
, O
PEEP O
11 O
 O
cm O
 O
H2O O
, O
Edi O
trigger O
0.5 O
 O
V. O

 O
The O
patient O
had O
tidal O
volumes O
( O
Vt O
) O
of O
67 O
 O
mL O
/ O
kg O
( O
figure O
3 O
) O
. O

 O
After O
10 O
 O
days O
on O
the O
NAVA O
mode O
, O
he O
did O
not O
require O
any O
type O
of O
sedation O
and O
the O
sporadic O
episodes O
of O
bronchial O
collapse O
were O
resolved O
with O
a O
quick O
increase O
of O
PEEP O
to O
20 O
 O
cm O
 O
H2O O
or O
manual O
ventilation O
with O
the O
self O
- O
inflating O
bag O
. O

 O
Once O
he O
was O
stabilised O
on O
the O
NAVA O
mode O
, O
his O
PIPs O
oscillated O
between O
15 O
and O
45 O
 O
cm O
 O
H2O O
with O
a O
NAVA O
level O
of O
0.4 O
and O
Edi O
peaks O
between O
15 O
and O
100 O
 O
V. O

 O
A O
posterior O
pulmonary O
CT O
scan O
performed O
2 O
 O
months O
after O
the O
first O
surgery O
, O
1 O
 O
month O
after O
starting O
NAVA O
and O
prior O
to O
the O
first O
thoracic O
expansion O
, O
showed O
a O
significant O
reduction O
in O
the O
posterobasal O
atelectases O
previously O
observed O
( O
figure O
2B O
) O
. O

 O
When O
he O
turned O
1 O
 O
year O
old O
, O
after O
several O
attempts O
with O
different O
devices O
Trilogy O
100 O
( O
Philips O
) O
, O
Astral O
150 O
( O
ResMed O
) O
, O
the O
patient O
finally O
tolerated O
mechanical O
ventilation O
with O
a O
home O
ventilator O
( O
Monnal O
T-50 O
, O
Air O
Liquide O
) O
in O
a O
volume O
assisted O
/ O
controlled O
mode O
with O
the O
following O
settings O
: O
Vt O
80 O
 O
mL O
( O
9 O
 O
mL O
/ O
kg O
) O
, O
PEEP O
10 O
 O
cm O
 O
H2O O
, O
flow O
trigger O
0.5 O
 O
L O
/ O
min O
. O

 O
His O
PIPs O
were O
around O
30 O
 O
cm O
 O
H2O. O

 O
He O
did O
not O
tolerate O
a O
decrease O
of O
PEEP O
below O
9 O
 O
cm O
 O
H2O O
or O
short O
disconnections O
from O
the O
ventilator O
. O

 O
Currently O
, O
the O
patient O
is O
19 O
 O
months O
old O
, O
is O
and O
his O
seems O
to O
be O
. O

A O
with O
a O
history O
of O
was O
to O
our O
with O
a O
recent O
diagnosis O
of O
Burkitt B
lymphoma I
. O

 O
Her O
level O
was O
and O
the O
diameter O
of O
her O
mediastinal O
was O
. O

 O
Her O
was O
normal O
, O
and O
basal O
( O
) O
showed O
with O
a O
of O
. O

 O
( O
; O
, O
, O
) O
revealed O
normal O
with O
an O
( O
) O
of O
, O
mild O
mitral O
and O
tricuspid O
, O
and O
moderate O
. O

 O
A O
of O
the O
patient O
put O
her O
into O
a O
category O
and O
she O
underwent O
( O
) O
protocol O
. O

 O
Her O
are O
summarized O
in O
Table O
1 O
. O

 O
She O
received O
high O
- O
dose O
for O
, O
for O
, O
for O
, O
for O
, O
and O
2mg O
/ O
day O
for O
2 O
days O
. O

 O
The O
total O
treatment O
dose O
of O
cyclophosphamide O
and O
doxorubicin O
received O
was O
1800mg O
/ O
m2 O
and O
50mg O
/ O
m2 O
, O
respectively O
. O

 O
She O
was O
given O
allopurinol O
300mg O
/ O
day O
perorally O
, O
sodium O
bicarbonate O
( O
8.4 O
% O
, O
10 O
flacon O
/ O
day O
) O
infusion O
for O
24 O
hours O
before O
chemotherapy O
, O
and O
mesna O
600mg O
/ O
m2 O
/ O
day O
for O
2 O
days O
as O
prophylaxis O
against O
tumor O
lysis O
syndrome O
and O
hemorrhagic O
cystitis O
, O
respectively O
. O

 O
She O
also O
received O
granisetron O
2mg O
/ O
day O
and O
lansoprazole O
30mg O
/ O
day O
as O
antiemetogenic O
and O
gastric O
prophylaxis O
, O
respectively O
. O

 O
The O
patient O
developed O
dyspnea O
on O
the O
seventh O
day O
of O
therapy O
. O

 O
A O
physical O
examination O
revealed O
blood O
pressure O
of O
100/60mmHg O
and O
a O
heart O
rate O
of O
110 O
beats O
/ O
minute O
. O

 O
On O
chest O
auscultation O
, O
no O
inspiratory O
sounds O
were O
heard O
at O
lower O
zones O
and O
inspiratory O
crackles O
were O
heard O
at O
middle O
zones O
. O

 O
Neither O
cardiac O
murmurs O
nor O
S3 O
were O
heard O
. O

 O
An O
ECG O
showed O
low O
voltage O
in O
the O
limb O
and O
precordial O
leads O
. O

 O
TTE O
showed O
diffusely O
increased O
myocardial O
echogenicity O
, O
mild O
pericardial O
effusion O
, O
and O
generally O
impaired O
biventricular O
systolic O
functions O
with O
an O
LVEF O
31 O
% O
and O
right O
ventricular O
mid O
- O
apical O
akinesis O
. O

 O
Manifest O
pleural O
effusion O
was O
also O
detected O
. O

 O
Drug O
- O
induced O
cardiotoxicity O
( O
myocarditis O
) O
was O
suspected O
. O

 O
Furosemide O
and O
ramipril O
were O
started O
. O

 O
The O
beta O
- O
blocker O
therapy O
the O
patient O
was O
already O
taking O
for O
hypertension O
was O
continued O
. O

 O
After O
12 O
days O
, O
TTE O
showed O
an O
LVEF O
of O
37 O
% O
and O
normal O
right O
ventricular O
functions O
. O

 O
Her O
dyspnea O
decreased O
and O
she O
was O
discharged O
on O
day O
20 O
. O

 O
After O
1 O
month O
, O
TTE O
showed O
normal O
biventricular O
functions O
with O
an O
LVEF O
of O
60 O
% O
. O

 O
After O
the O
first O
course O
of O
the O
R O
- O
Hyper O
- O
CVAD O
chemotherapy O
protocol O
, O
she O
underwent O
a O
high O
- O
dose O
methotrexate O
and O
cytarabine O
cycle O
. O

 O
She O
had O
severe O
and O
pneumonia B
. O

 O
She O
had O
no O
during O
this O
course O
, O
but O
she O
declined O
another O
course O
of O
. O

 O
She O
is O
still O
in O
despite O
the O
abbreviated O
course O
of O
. O

A O
with O
a O
was O
to O
in O
for O
a O
left O
upper O
lobe O
lung O
with O
multiple O
bilateral O
intrapulmonary O
, O
left O
pleural B
effusion I
, O
and O
2R/4R/10L/11L O
lymphadenopathy B
. O

 O
Pleural O
fluid O
revealed O
adenocarcinoma B
and O
( O
) O
. O

 O
showed O
no O
detectable O
. O

 O
He O
commenced O
with O
and O
. O

 O
However O
, O
after O
a O
single O
cycle O
, O
his O
worsened O
and O
imaging O
confirmed O
progressive O
disease B
. O

 O
A O
from O
the O
and O
a O
computed O
tomography O
 O
guided O
of O
the O
left O
upper O
lobe O
was O
performed O
to O
permit O
additional O
molecular O
testing O
. O

 O
In O
the O
interim O
, O
the O
patient O
commenced O
and O
. O

 O
Unfortunately O
, O
after O
two O
cycles O
his O
worsened O
, O
with O
evidence O
of O
further O
progression O
on O
his O
( O
Fig.1A O
) O
. O

 O
Molecular O
testing O
on O
his O
repeat O
specimen O
revealed O
no O
mutations O
by O
SNaPshot O
multiplex O
( O
Life O
Technologies O
, O
Carlsbad O
, O
CA O
) O
. O

 O
However O
, O
although O
technically O
negative O
, O
the O
ALK O
break O
- O
apart O
showed O
an O
. O

 O
Specifically O
, O
68 O
% O
of O
cells O
demonstrated O
single O
copies O
of O
the O
5 O
ALK O
signal O
and O
numerous O
cells O
with O
doublets O
of O
the O
5 O
ALK O
signal O
combined O
with O
one O
3 O
ALK O
signal O
( O
Fig.2A O
) O
. O

 O
Subsequently O
, O
confirmatory O
demonstrated O
ALK O
protein O
expression O
by O
IHC O
using O
the O
D5F3 O
antibody O
( O
Cell O
Signaling O
Technology O
Inc. O
, O
Danvers O
, O
MA O
; O
H O
score O
= O
150 O
; O
Fig.2B O
) O
and O
the O
presence O
of O
an O
echinoderm O
microtubule O
- O
associated O
protein O
- O
like O
4 O
( O
EML4)-ALK O
transcript O
( O
E13 O
; O
A20 O
) O
by O
RT O
- O
PCR O
( O
Fig.2C O
) O
. O

 O
The O
patient O
then O
received O
( O
) O
as O
third O
- O
line O
therapy O
in O
with O
an O
impressive O
and O
CT O
response O
after O
1 O
month O
of O
therapy O
( O
Fig.1B O
) O
. O

 O
He O
remains O
on O
treatment O
with O
with O
no O
evidence O
of O
as O
of O
. O

The O
proband O
is O
a O
, O
first O
child O
of O
healthy O
unrelated O
parents O
. O

 O
Her O
. O

 O
She O
was O
. O

 O
The O
perinatal O
period O
was O
uneventful O
and O
her O
was O
referred O
to O
as O
, O
but O
after O
, O
psychomotor B
delay I
became O
evident O
. O

 O
She O
started O
walking O
autonomously O
at O
22 O
 O
months O
, O
with O
poor O
and O
frequent O
. O

 O
At O
, O
she O
developed O
a O
demyelinating B
sensorimotor I
neuropathy I
and O
a O
brain O
disclosed O
supratentorial O
leukodystrophy B
. O

 O
During O
her O
childhood O
, O
the O
remained O
. O

 O
At O
, O
her O
walking B
difficulties I
, O
and O
limb O
and O
ensued O
. O

 O
The O
showed O
, O
, O
ataxic O
and O
in O
the O
with O
muscle B
wasting I
. O

 O
She O
was O
able O
to O
walk O
alone O
only O
for O
a O
few O
steps O
with O
an O
ataxic O
. O

 O
Mild O
cognitive B
impairment I
was O
documented O
( O
75 O
, O
) O
. O

 O
of O
a O
muscle O
showed O
of O
. O

 O
The O
was O
. O

 O
At O
her O
last O
examination O
, O
at O
, O
she O
was O
able O
to O
only O
with O
ankle O
- O
foot O
and O
had O
developed O
a O
marked O
dorsal O
- O
lumbar O
scoliosis B
. O

 O
Other O
were O
. O

 O
confirmed O
worsening O
of O
her O
mixed O
axonal O
demyelinating B
peripheral I
neuropathy I
. O

 O
Brain O
and O
spinal O
cord O
showed O
mild O
extension O
of O
and O
extensive O
in O
the O
; O
the O
cerebellum O
and O
brainstem O
were O
spared O
but O
the O
spinal O
cord O
was O
thin O
with O
no O
obvious O
focal O
( O
figure O
1A O
) O
. O

 O
was O
( O
n.v O
. O
< O
2.1 O
) O
. O

A O
Caucasian O
woman O
of O
Ashkenazi O
Jewish O
descent O
presented O
with O
the O
chief O
complaint O
of O
severe O
and O
constant O
throbbing O
in O
her O
. O

 O
She O
reported O
that O
her O
was O
aggravated O
by O
, O
and O
started O
the O
initial O
consultation O
visit O
. O

 O
was O
reported O
at O
the O
. O

 O
Past O
medical O
history O
was O
remarkable O
for O
Gaucher B
disease I
, O
left O
hip O
, O
gall O
bladder O
, O
, O
spleen O
, O
hepatitis B
C I
infection I
, O
and O
asthma B
. O

 O
Social O
history O
was O
significant O
for O
20 O
pack O
- O
years O
of O
. O

 O
Her O
family O
history O
was O
. O

 O
Her O
medications O
included O
the O
oral O
antiresorptive O
drug O
for O
early O
osteoporosis O
associated O
with O
Gaucher O
disease O
( O
70 O
mg O
weekly O
for O
2 O
years O
) O
, O
, O
, O
, O
, O
, O
, O
, O
and O
. O

 O
She O
reported O
that O
she O
had O
been O
on O
enzyme O
replacement O
therapy O
( O
ERT O
) O
for O
to O
treat O
her O
Gaucher B
disease I
which O
was O
diagnosed O
. O

 O
She O
received O
intravenous O
injections O
twice O
a O
month O
for O
and O
recounted O
after O
each O
infusion O
. O

 O
She O
also O
reported O
receiving O
and O
medications O
for O
her O
pain O
but O
they O
were O
not O
helpful O
. O
, O
and O
were O
. O

 O
was O
completed O
using O
, O
and O
for O
evaluation O
of O
her O
in O
the O
region O
of O
the O
chief O
complaint O
. O

 O
Her O
was O
and O
, O
while O
her O
remaining O
were O
normal O
on O
with O
of O
several O
opposing O
non O
- O
restored O
and O
non O
- O
carious O
as O
internal O
controls O
. O

 O
in O
both O
were O
and O
there O
was O
no O
gross O
evidence O
of O
or O
. O

 O
in O
her O
ranged O
from O
with O
no O
significant O
. O

 O
Full O
mouth O
and O
a O
panoramic O
were O
taken O
and O
showed O
relatively O
well O
- O
defined O
radiolucent O
in O
multiple O
regions O
of O
the O
, O
with O
a O
( O
) O
appearance O
; O
cone O
- O
beam O
confirmed O
these O
findings O
and O
revealed O
a O
large O
lytic O
of O
her O
in O
the O
region O
of O
her O
chief O
complaint O
( O
Figure O
1).Our O
clinical O
and O
radiographic O
differential O
diagnosis O
for O
her O
chief O
complaint O
included O
chronic O
apical B
periodontitis I
, O
radicular B
cyst I
, O
central B
giant I
cell I
granuloma I
, O
keratocystic O
odontogenic B
tumor I
, O
ameloblastoma B
, O
odontogenic B
fibroma I
, O
/ O
neuropathy B
or O
mandibular O
involvement O
of O
Gaucher B
disease I
given O
her O
medical O
history O
. O

 O
Our O
findings O
were O
with O
the O
patient O
and O
written O
consent O
was O
obtained O
for O
surgical O
of O
her O
with O
for O
more O
definitive O
diagnosis O
. O

 O
A O
four O
- O
corner O
was O
reflected O
in O
her O
extending O
from O
the O
to O
the O
, O
and O
cortical O
bone O
was O
with O
a O
to O
for O
access O
to O
the O
. O

 O
was O
evident O
through O
the O
access O
window O
. O

 O
The O
entire O
along O
with O
the O
bone O
from O
the O
access O
window O
was O
submitted O
to O
the O
pathology O
laboratory O
for O
. O

 O
revealed O
of O
with O
fibrous O
connective O
tissue O
containing O
abundant O
( O
Figure O
2 O
) O
. O

 O
There O
was O
no O
evidence O
of O
or O
, O
granuloma B
or O
. O

 O
was O
, O
and O
the O
patient O
reported O
of O
her O
chief O
complaint O
and O
symptomatology O
at O
. O

 O
She O
was O
to O
her O
for O
and O
further O
as O
related O
to O
her O
Gaucher B
disease I
status O
following O
our O
findings O
. O

 O
She O
was O
again O
treated O
with O
and O
at O
was O
still O
free O
in O
her O
. O

A O
with O
stage O
IV O
NSCLC B
was O
treated O
with O
and O
without O
disease O
response O
. O

 O
of O
was O
at O
that O
time O
. O

 O
However O
, O
her O
demographic O
profile O
( O
, O
minimal O
, O
non O
- O
small O
cell O
histology O
) O
predicted O
her O
disease O
would O
harbor O
EGFR O
TKI O
sensitive O
cells O
[ O
2 O
] O
. O

 O
Therefore O
, O
she O
then O
initiated O
standard O
daily O
dosing O
of O
( O
) O
and O
responded O
. O

 O
, O
she O
acquired O
resistance O
to O
with O
progression O
of O
. O

 O
Following O
further O
progression O
through O
an O
experimental O
angiogenesis O
inhibitor O
, O
she O
initiated O
pemetrexed O
and O
resumed O
standard O
dose O
erlotinib O
. O

 O
After O
initial O
response O
, O
11 O
months O
later O
, O
her O
disease O
again O
progressed O
. O

 O
DNA O
was O
extracted O
from O
biopsy O
of O
a O
progressing O
lung O
lesion O
and O
examined O
using O
established O
techniques O
for O
analysis O
of O
EGFR O
mutations O
[ O
5 O
] O
. O

 O
Direct O
sequencing O
of O
exons O
1821 O
encoding O
the O
kinase O
domain O
of O
EGFR O
revealed O
the O
L858R O
mutation O
associated O
with O
EGFR O
TKI O
sensitivity O
( O
Fig.1 O
) O
[ O
2 O
] O
. O

 O
It O
also O
demonstrated O
the O
T790 O
M O
mutation O
associated O
with O
acquired O
EGFR O
TKI O
resistance O
( O
Fig.1 O
) O
[ O
2 O
] O
. O

 O
She O
also O
developed O
headaches O
and O
there O
was O
a O
high O
clinical O
suspicion O
of O
CNS O
metastases O
despite O
negative O
imaging O
( O
not O
shown O
) O
. O

 O
She O
refused O
a O
lumbar O
puncture O
. O

 O
She O
initiated O
empiric O
temozolomide O
plus O
standard O
dose O
erlotinib O
( O
150 O
mg O
daily O
) O
for O
presumed O
CNS O
disease O
, O
but O
after O
one O
cycle O
her O
headaches O
worsened O
, O
and O
she O
developed O
nausea O
and O
vomiting O
concerning O
for O
CNS O
metastases O
with O
associated O
raised O
intracranial O
pressure O
. O

 O
Magnetic O
resonance O
imaging O
( O
MRI O
) O
of O
the O
brain O
now O
demonstrated O
LM O
( O
Fig.2 O
) O
confirmed O
by O
CSF O
cytology O
( O
not O
shown O
) O
. O

 O
By O
direct O
sequencing O
, O
DNA O
from O
CSF O
cells O
harbored O
L858R O
predicting O
EGFR O
TKI O
sensitivity O
( O
Fig.3 O
, O
left O
panel O
) O
but O
not O
the O
T790 O
M O
resistance O
mutation O
( O
data O
not O
shown O
) O
. O

 O
Because O
the O
result O
for O
T790 O
M O
was O
negative O
in O
this O
sample O
, O
we O
performed O
a O
more O
sensitive O
fluorescence O
detection O
PCR O
- O
based O
assay O
that O
takes O
advantage O
of O
a O
PCR O
restriction O
fragment O
length O
polymorphism O
generated O
by O
the O
specific O
missense O
mutation O
( O
Fig.3 O
, O
right O
panel O
, O
arrow O
, O
positive O
control O
) O
[ O
6 O
] O
. O

 O
That O
result O
was O
also O
negative O
, O
as O
only O
the O
wild O
type O
peak O
was O
detected O
( O
Fig.3 O
, O
right O
panel O
, O
bottom O
) O
. O

 O
Therefore O
, O
we O
hypothesized O
that O
the O
LM O
remained O
sensitive O
to O
an O
EGFR O
TKI O
if O
sufficiently O
high O
concentrations O
of O
drug O
could O
be O
achieved O
in O
the O
CSF O
. O

 O
The O
erlotinib O
concentration O
required O
to O
inhibit O
growth O
of O
cell O
lines O
harboring O
L858R O
by O
50 O
% O
( O
IC50 O
) O
is O
100 O
nM O
( O
nM O
) O
[ O
2 O
] O
. O

 O
Standard O
dose O
erlotinib O
( O
150 O
mg O
daily O
) O
achieves O
3000 O
nM O
in O
plasma O
[ O
7 O
] O
, O
but O
CSF O
concentrations O
of O
EGFR O
TKIs O
are O
as O
low O
as O
1 O
% O
plasma O
levels O
below O
the O
IC50 O
[ O
3 O
, O
8 O
] O
. O

 O
Increasing O
the O
daily O
dose O
of O
gefitinib O
to O
enhance O
CSF O
penetration O
has O
been O
an O
effective O
strategy O
[ O
3 O
] O
, O
but O
gefitinib O
is O
no O
longer O
available O
in O
the O
United O
States O
following O
failure O
in O
phase O
III O
NSCLC O
trials O
. O

 O
An O
analogous O
increase O
of O
the O
daily O
erlotinib O
dose O
above O
150200 O
mg O
daily O
induces O
unacceptable O
toxicity O
. O

 O
However O
, O
weekly O
high O
- O
dose O
erlotinib O
up O
to O
2000 O
mg O
is O
tolerable O
[ O
4 O
] O
. O

 O
Pharmacokinetic O
analysis O
of O
CSF O
from O
another O
patient O
with O
NSCLC O
LM O
( O
not O
shown O
) O
treated O
with O
1500 O
mg O
erlotinib O
weekly O
demonstrated O
a O
peak O
plasma O
concentration O
of O
11,300 O
nM O
with O
a O
concurrent O
CSF O
concentration O
of O
130 O
nM. O

 O
Therefore O
, O
such O
high O
dose O
weekly O
administration O
of O
erlotinib O
achieved O
a O
CSF O
concentration O
exceeding O
the O
IC50 O
. O

 O
Therefore O
, O
to O
increase O
CSF O
penetrance O
over O
standard O
daily O
erlotinib O
dosing O
in O
this O
patient O
, O
we O
initiated O
high O
- O
dose O
weekly O
erlotinib O
at O
1000 O
mg O
then O
1200 O
mg O
; O
persistent O
nausea O
precluded O
higher O
doses O
. O

 O
Pharmacokinetic O
analysis O
was O
not O
undertaken O
in O
this O
patient O
. O

 O
After O
1 O
month O
there O
was O
a O
partial O
radiographic O
response O
of O
LM O
on O
brain O
MRI O
( O
Fig.2b O
) O
and O
after O
2 O
months O
in O
the O
cauda O
equina O
( O
not O
shown O
) O
. O

 O
However O
, O
hydrocephalus O
and O
persistent O
symptoms O
referable O
to O
increased O
intracranial O
pressure O
led O
to O
a O
VP O
shunt O
and O
whole O
- O
brain O
radiation O
therapy O
, O
after O
which O
she O
resumed O
treatment O
with O
1500 O
mg O
weekly O
erlotinib O
. O

 O
One O
month O
later O
, O
progressive O
intra O
- O
thoracic O
disease O
led O
to O
initiation O
of O
cetixumab O
and O
erlotinib O
was O
continued O
but O
changed O
to O
low O
dose O
( O
100 O
mg O
) O
daily O
. O

 O
She O
. O

A O
, O
with O
controlled O
hypertension O
and O
stage O
2 O
obesity O
presented O
to O
our O
institution O
with O
a O
complaint O
of O
progressive O
fatigue O
with O
moderate O
to O
light O
exertion O
of O
approximately O
1 O
year O
s O
duration O
. O

 O
During O
that O
period O
, O
he O
had O
undergone O
myocardial O
perfusion O
scintigraphy O
without O
evidence O
of O
obstructive O
ischemic O
disease O
. O

 O
He O
had O
no O
clinical O
evidence O
of O
systolic O
heart O
failure O
. O

 O
He O
had O
undergone O
biological O
mitral O
valve O
replacement O
3 O
years O
previously O
for O
mitral O
valve O
stenosis O
and O
had O
undergone O
ablation O
of O
atrioventricular O
nodal O
reentry O
tachycardia O
18 O
months O
previously O
. O

 O
At O
the O
time O
of O
valve O
replacement O
, O
there O
was O
no O
reported O
evidence O
of O
pulmonary O
arterial O
hypertension O
. O

 O
The O
patient O
s O
medication O
list O
included O
aspirin O
100 O
mg O
/ O
day O
, O
carvedilol O
50 O
mg O
/ O
day O
, O
atorvastatin O
10 O
mg O
/ O
day O
, O
and O
losartan O
25 O
mg O
/ O
day O
. O

 O
His O
echocardiogram O
showed O
normal O
function O
of O
a O
mitral O
prosthesis O
, O
global O
left O
ventricular O
systolic O
function O
within O
normal O
limits O
( O
left O
ventricular O
ejection O
fraction O
62 O
% O
measured O
using O
the O
Teichholz O
method O
) O
, O
stage O
I O
diastolic O
dysfunction O
, O
and O
mean O
pulmonary O
arterial O
systolic O
blood O
pressure O
of O
50 O
mmHg O
. O

 O
In O
the O
6 O
- O
minute O
walk O
test O
, O
the O
patient O
walked O
104 O
meters O
( O
Table O
1 O
) O
. O

 O
Catheterization O
of O
his O
right O
heart O
chambers O
and O
pulmonary O
arteries O
confirmed O
the O
diagnosis O
of O
pulmonary O
hypertension O
( O
Table O
2 O
) O
. O

 O
During O
the O
follow O
- O
up O
period O
, O
therapy O
with O
nifedipine O
and O
sildenafil O
was O
not O
tolerated O
secondary O
to O
orthostatic O
hypotension O
. O

 O
The O
patient O
was O
referred O
for O
radiofrequency O
ablation O
of O
the O
pulmonary O
artery O
trunk O
for O
the O
treatment O
of O
refractory O
pulmonary O
hypertension O
. O

 O
The O
procedure O
was O
performed O
in O
the O
catheterization O
laboratory O
with O
direct O
visualization O
using O
fluoroscopy O
and O
radiopaque O
contrast O
dye O
. O

 O
The O
patient O
remained O
under O
unconscious O
sedation O
. O

 O
Catheterization O
of O
the O
right O
femoral O
artery O
via O
the O
standard O
Seldinger O
technique O
was O
performed O
using O
an O
8 O
- O
French O
valved O
short O
sheath O
after O
subcutaneous O
injection O
of O
a O
local O
anesthetic O
. O

 O
Subsequently O
, O
this O
sheath O
was O
replaced O
with O
a O
steerable O
long O
sheath O
( O
Agilis O
 O
; O
St. O
Jude O
Medical O
, O
St. O
Paul O
, O
MN O
, O
USA O
) O
using O
the O
standard O
over O
- O
the O
- O
wire O
technique O
. O

 O
Unfractionated O
heparin O
was O
administered O
intravenously O
, O
targeting O
an O
activated O
coagulation O
time O
between O
250 O
and O
350 O
seconds O
. O

 O
Electroanatomic O
reconstruction O
of O
both O
the O
right O
ventricular O
outflow O
tract O
and O
pulmonary O
artery O
was O
performed O
using O
the O
EnSite O
Velocity O
Cardiac O
Mapping O
System O
( O
St. O
Jude O
Medical O
) O
under O
direct O
fluoroscopic O
visualization O
, O
and O
a O
merger O
was O
made O
with O
the O
formatted O
image O
obtained O
by O
performing O
cardiac O
computed O
tomography O
angiography O
( O
Fig.1 O
) O
. O

 O
The O
Agilis O
 O
sheath O
was O
advanced O
into O
the O
right O
ventricular O
outflow O
tract O
just O
before O
reaching O
the O
pulmonary O
valve O
. O

 O
Through O
this O
long O
sheath O
, O
we O
introduced O
an O
ablation O
catheter O
with O
an O
open O
irrigated O
tip O
( O
St. O
Jude O
Medical O
) O
. O

 O
The O
parameters O
used O
for O
each O
application O
according O
to O
our O
protocol O
were O
as O
follows O
: O
power O
of O
5 O
W O
, O
maximum O
temperature O
of O
48 O
 O
C O
, O
60 O
- O
second O
duration O
in O
each O
spot O
, O
maximum O
impedance O
variation O
of O
10 O
% O
from O
baseline O
values O
, O
and O
an O
irrigation O
flow O
rate O
of O
17 O
ml O
/ O
minute O
, O
which O
created O
a O
circle O
in O
the O
pulmonary O
artery O
trunk O
. O

 O
The O
patient O
was O
the O
. O

 O
No O
noteworthy O
before O
or O
after O
the O
procedure O
or O
before O
in O
the O
patient O
s O
were O
seen O
. O

 O
The O
patient O
s O
in O
and O
the O
were O
determined O
before O
and O
at O
the O
procedure O
. O

 O
The O
results O
are O
shown O
in O
Table O
2 O
. O

 O
At O
the O
patient O
s O
examination O
, O
he O
showed O
an O
improvement O
in O
. O

 O
He O
also O
demonstrated O
an O
increased O
distance O
walked O
in O
the O
6 O
- O
minute O
and O
reduction O
of O
the O
in O
both O
the O
and O
the O
. O

 O
Currently O
, O
with O
of O
clinical O
, O
he O
has O
maintained O
his O
improvement O
in O
and O
is O
. O

A O
was O
initially O
19 O
months O
prior O
to O
the O
current O
presentation O
, O
at O
which O
time O
fluorescein O
and O
indocyanine O
green O
angiography O
showed O
a O
medium O
- O
sized O
subfoveal O
classic O
CNV B
in O
the O
, O
which O
had O
. O

 O
She O
did O
not O
return O
for O
until O
the O
current O
presentation O
, O
when O
she O
noted O
in O
the O
. O

 O
The O
( O
) O
was O
. O

 O
showed O
a O
small O
yellowish O
in O
the O
and O
. O

 O
Structural O
revealed O
the O
, O
and O
a O
hyper O
- O
reflective O
indicating O
type O
II O
CNV B
. O

 O
with O
intravitreal O
were O
administered O
with O
a O
. O

 O
( O
Fig.1 O
) O
showed O
noticeable O
reduction O
in O
by O
injection O
, O
with O
at O
. O

 O
and O
were O
, O
probably O
due O
to O
the O
decreased O
flow O
or O
temporary O
closure O
of O
the O
smaller O
anastomoses O
. O

 O
Significant O
re O
- O
appearance O
of O
CNV B
was O
noticeable O
at O
after O
the O
first O
injection O
and O
again O
at O
after O
the O
second O
injection O
. O

 O
The O
vascular O
pattern O
of O
the O
re O
- O
enlarged O
CNV B
( O
Fig.1A O
) O
was O
very O
similar O
to O
the O
initial O
pretreatment O
CNV O
, O
suggesting O
that O
the O
recurrence O
may O
be O
reopening O
of O
original O
channels O
rather O
than O
growth O
of O
new O
vessels O
. O

 O
Comparing O
the O
CNV O
network O
prior O
to O
the O
3rd O
injection O
to O
the O
baseline O
, O
it O
is O
notable O
that O
there O
were O
fewer O
smaller O
channels O
, O
while O
the O
larger O
caliber O
channels O
remained O
. O

 O
Quantitative O
measurements O
from O
( O
Fig.2A O
) O
showed O
reduction O
in O
and O
with O
subsequent O
return O
. O

 O
Retinal O
thickness O
( O
Fig.2B O
) O
showed O
the O
fluid O
resorption O
over O
the O
first O
4 O
weeks O
in O
the O
first O
treatment O
cycle O
continuing O
at O
least O
2 O
weeks O
into O
the O
second O
treatment O
cycle O
, O
at O
which O
time O
no O
fluid O
remained O
( O
Fig.1B O
) O
. O

 O
But O
after O
the O
2nd O
injection O
. O

 O
( O
Fig.2B O
) O
over O
the O
3 O
treatment O
cycles O
. O

This O
case O
report O
was O
approved O
by O
the O
Review O
Board O
of O
Shandong O
Power O
Central O
Hospital O
and O
the O
patient O
's O
parents O
signed O
informed O
consent O
for O
publication O
of O
the O
case O
report O
and O
any O
accompanying O
images O
. O

 O
A O
child O
at O
the O
with O
slowly O
enlarging O
, O
painless O
, O
symmetrical O
of O
. O

 O
When O
the O
girl O
was O
approximately O
2 O
years O
old O
, O
the O
parents O
noticed O
a O
, O
which O
later O
became O
more O
obvious O
. O

 O
On O
palpation O
, O
the O
were O
and O
in O
consistency O
. O

 O
The O
skin O
over O
the O
swelling O
was O
smooth O
and O
freely O
movable O
, O
with O
no O
increase O
in O
( O
Fig.1 O
) O
. O

 O
There O
was O
. O

 O
. O

 O
Panoramic O
revealed O
of O
both O
the O
and O
the O
, O
and O
showed O
a O
soap O
bubble O
- O
like O
multilocular O
with O
. O

 O
Unerupted O
teeth O
included O
: O
15 O
, O
25 O
, O
35 O
, O
37 O
, O
45 O
, O
and O
47 O
was O
( O
Fig.2 O
) O
. O

 O
Multislice O
showed O
the O
presence O
of O
multilocular O
cystic O
filled O
with O
and O
dental O
affecting O
the O
. O

 O
Similar O
were O
also O
observed O
in O
the O
( O
Fig.3 O
) O
. O

 O
A O
was O
obtained O
from O
the O
. O

 O
showed O
many O
large O
multinucleated O
giant O
cells O
in O
a O
loose O
, O
delicate O
fibrillar O
connective O
tissue O
stroma O
containing O
large O
numbers O
of O
fibroblasts O
and O
many O
small O
blood O
vessels O
( O
Fig.4 O
) O
. O

 O
As O
the O
child O
grows O
older O
, O
the O
lesions O
often O
become O
static O
and O
may O
show O
regression O
at O
puberty O
. O

 O
In O
the O
current O
case O
, O
no O
was O
under O
taken O
and O
the O
patient O
was O
at O
. O

The O
patient O
was O
a O
who O
had O
previously O
been O
due O
to O
. O

 O
At O
that O
time O
, O
a O
chest O
and O
( O
) O
revealed O
diffuse O
( O
) O
in O
the O
fields O
( O
Fig.1,2 O
) O
, O
and O
a O
revealed O
the O
of O
large O
amounts O
of O
in O
the O
and O
( O
Fig.3 O
) O
. O

 O
The O
patient O
's O
( O
) O
was O
and O
contained O
numerous O
. O

 O
A O
of O
the O
revealed O
. O

 O
An O
and O
transthoracic O
revealed O
. O

 O
A O
questionnaire O
that O
was O
completed O
at O
that O
time O
did O
not O
reveal O
the O
patient O
's O
hemorrhagic O
episode O
or O
a O
family O
history O
of O
bleeding O
disease O
, O
with O
the O
exception O
of O
his O
younger O
brother O
who O
had O
been O
diagnosed O
with O
hepatitis O
C. O

 O
Furthermore O
, O
he O
had O
not O
received O
any O
that O
had O
the O
. O

 O
Following O
the O
above O
- O
mentioned O
examinations O
, O
DAH B
due O
to O
some O
sort O
of O
vasculitis B
was O
suspected O
. O

 O
Thus O
, O
treatment O
with O
high O
- O
dose O
intravenous O
( O
) O
for O
followed O
by O
( O
) O
was O
initiated O
. O

 O
This O
relieved O
his O
. O

 O
Chest O
showed O
the O
resolution O
of O
the O
. O

 O
The O
patient O
's O
dose O
was O
and O
eventually O
at O
after O
his O
from O
our O
. O

 O
The O
patient O
was O
to O
our O
with O
a O
recurrence O
of O
. O

 O
The O
above O
- O
described O
therapy O
was O
initiated O
and O
led O
to O
the O
improvement O
of O
his O
condition O
. O

 O
The O
dose O
was O
from O
to O
a O
maintenance O
dose O
of O
. O

 O
, O
he O
was O
to O
our O
with O
a O
further O
recurrence O
of O
. O

 O
At O
this O
point O
, O
he O
had O
- O
induced O
diabetes B
mellitus I
, O
which O
was O
treated O
with O
( O
) O
. O

 O
At O
, O
his O
was O
and O
; O
his O
were O
as O
follows O
: O
, O
; O
, O
, O
, O
in O
; O
and O
, O
. O

 O
Chest O
revealed O
fine O
in O
the O
field O
. O

 O
No O
skin O
, O
subcutaneous O
or O
joint O
were O
present O
. O

 O
A O
chest O
and O
showed O
the O
presence O
of O
diffuse O
in O
the O
fields O
. O

 O
Mild O
was O
observed O
( O
, O
) O
, O
although O
levels O
had O
been O
prior O
to O
the O
hemoptysis O
episode O
. O

 O
The O
( O
) O
was O
prolonged O
to O
( O
normal O
range O
, O
25.1 O
- O
40.7 O
seconds O
) O
. O

 O
showed O
that O
the O
patient O
's O
and O
levels O
were O
and O
, O
respectively O
, O
due O
to O
the O
steroid O
- O
induced O
diabetes B
mellitus I
. O

 O
were O
( O
Table O
) O
. O

 O
We O
diagnosed O
the O
condition O
as O
a O
recurrence O
of O
DAH B
and O
again O
administered O
high O
- O
dose O
intravenous O
for O
, O
followed O
by O
( O
) O
. O

 O
His O
, O
as O
had O
been O
observed O
during O
the O
previous O
episodes O
. O

 O
A O
further O
detailed O
inquiry O
regarding O
the O
patient O
's O
medical O
history O
revealed O
that O
, O
, O
he O
had O
been O
and O
; O
however O
, O
a O
specific O
congenital O
bleeding O
disorder O
had O
not O
been O
diagnosed O
. O

 O
It O
was O
also O
revealed O
that O
his O
. O

 O
Considering O
the O
possibility O
of O
hemophilia B
, O
his O
were O
examined O
, O
revealing O
that O
his O
was O
. O

 O
The O
patient O
was O
subsequently O
diagnosed O
with O
moderate O
hemophilia O
B. O

 O
By O
the O
time O
of O
this O
diagnosis O
, O
the O
patient O
's O
DAH B
had O
already O
resolved O
with O
the O
. O

 O
We O
decided O
to O
continue O
treating O
the O
patient O
using O
alone O
, O
without O
. O

 O
No O
recurrence O
of O
DAH B
or O
have O
been O
observed O
since O
the O
tapering O
and O
discontinuation O
of O
. O

A O
( O
65 O
kg O
) O
underwent O
under O
, O
which O
was O
induced O
using O
a O
combination O
of O
a O
bolus O
of O
( O
0.5 O
g O
/ O
kg O
) O
and O
. O

 O
Muscle O
paralysis O
was O
obtained O
with O
( O
) O
. O

 O
Transoral O
was O
performed O
with O
a O
( O
) O
and O
a O
size O
7 O
mm O
diameter O
reinforced O
was O
easily O
and O
gently O
placed O
in O
the O
, O
on O
the O
first O
attempt O
and O
was O
then O
fixed O
to O
the O
. O

 O
No O
problems B
were O
encountered O
during O
and O
. O

 O
The O
cuff O
of O
the O
was O
inflated O
with O
a O
pressure O
 O
20 O
cm O
H2O. O

 O
No O
was O
made O
intra O
- O
operatively O
. O

 O
was O
not O
used O
for O
inhalation O
anaesthesia O
. O

 O
The O
was O
placed O
in O
the O
to O
avoid O
the O
passage O
of O
blood O
in O
the O
aero O
- O
digestive O
tract O
. O

 O
General O
anaesthesia O
was O
maintained O
with O
and O
in O
. O

 O
Moderate O
was O
maintained O
with O
a O
cuff O
of O
approximately O
. O

 O
The O
operation O
was O
carried O
out O
in O
a O
with O
the O
and O
laterally O
and O
. O

 O
Duration O
of O
the O
operation O
was O
. O

 O
The O
patient O
was O
, O
after O
removal O
of O
the O
without O
problems O
. O

 O
The O
following O
day O
the O
patient O
complained O
of O
, O
and O
. O

 O
Examination O
revealed O
of O
the O
to O
the O
right O
side O
and O
vocal O
cord O
paralysis B
, O
expression O
of O
hypoglossal O
and O
recurrent O
laryngeal O
nerve B
injury I
without O
local O
or O
. O

 O
The O
of O
the O
pharynx O
and O
soft O
palate O
were O
. O

 O
Meticulous O
, O
including O
also O
( O
) O
revealed O
no O
other O
evidence O
of O
central O
or O
cranial O
. O

 O
Conservative O
management O
included O
, O
together O
with O
speech O
and O
swallowing O
. O

 O
Full O
recovery O
of O
lingual O
and O
laryngeal O
was O
obtained O
surgery O
. O

A O
with O
a O
presented O
with O
an O
abnormal O
measuring O
in O
the O
imaged O
through O
chest O
( O
) O
scanning O
in O
in O
a O
. O

 O
He O
had O
. O

 O
suggested O
no O
significant O
. O

 O
were O
, O
except O
for O
a O
( O
) O
level O
of O
( O
normal O
range O
, O
05 O
 O
ng O
/ O
mL O
) O
found O
in O
the O
. O

 O
Subsequently O
, O
a O
( O
PET)/CT O
scan O
showed O
a O
lung O
with O
a O
of O
, O
which O
was O
highly O
suspected O
to O
be O
a O
malignant B
tumor I
( O
Fig.1 O
) O
. O

 O
Subsequently O
, O
he O
underwent O
left O
upper O
lung O
and O
. O

 O
Postoperative O
revealed O
an O
adenocarcinoma B
( O
ADC B
) O
( O
Fig.2A O
) O
. O

 O
( O
) O
staining O
results O
were O
positive O
for O
, O
, O
, O
and O
and O
negative O
for O
, O
, O
, O
and O
( O
20%30 O
% O
) O
. O

 O
The O
was O
classified O
as O
( O
) O
. O

 O
Because O
the O
was O
still O
in O
an O
early O
stage O
, O
the O
patient O
did O
not O
receive O
but O
continued O
to O
be O
through O
regular O
hospital O
. O

 O
The O
patient O
's O
had O
been O
until O
the O
onset O
of O
left O
chest O
in O
. O

 O
The O
patient O
was O
to O
our O
( O
a O
) O
for O
further O
treatment O
. O

 O
suggested O
a O
significant O
in O
the O
. O

 O
showed O
only O
a O
single O
parameter O
outside O
the O
normal O
range O
: O
the O
( O
) O
level O
was O
in O
the O
( O
normal O
range O
 O
= O
 O
03.3 O
 O
ng O
/ O
mL O
) O
. O

 O
and O
/ O
scans O
highlighted O
the O
serious O
of O
, O
showing O
bilateral O
lung O
( O
Fig.3A O
and O
E O
) O
. O

 O
At O
that O
point O
, O
the O
was O
to O
. O

 O
After O
the O
CT O
- O
guided O
left O
pleura O
, O
pathological O
showed O
positive O
staining O
for O
, O
, O
, O
and O
, O
while O
and O
staining O
were O
absent O
, O
supporting O
a O
diagnosis O
of O
squamous B
cell I
carcinoma I
( O
SCC B
) O
( O
Fig.2B O
) O
. O

 O
Meanwhile O
, O
confirmed O
an O
in O
exon O
21 O
and O
a O
in O
( O
Fig.4B O
and O
C O
) O
. O

 O
. O

 O
( O
Fig.4A O
) O
. O

 O
To O
relieve O
the O
acute O
pain O
in O
the O
left O
pleura O
as O
quickly O
as O
possible O
, O
palliative O
( O
) O
for O
the O
chest O
lesion O
was O
delivered O
at O
a O
total O
dose O
of O
( O
f O
) O
, O
and O
( O
Fig.5 O
) O
. O

 O
The O
volume O
over O
radiation O
dose O
5 O
 O
Gy O
( O
V5 O
) O
values O
of O
the O
left O
, O
right O
, O
and O
total O
lungs O
were O
20 O
% O
, O
0 O
% O
, O
and O
7.8 O
% O
, O
respectively O
; O
the O
volume O
over O
radiation O
dose O
20 O
 O
Gy O
( O
V20 O
) O
values O
were O
10 O
% O
, O
0 O
% O
, O
and O
5 O
% O
, O
respectively O
; O
the O
mean O
lung O
dose O
( O
MLD O
) O
was O
5 O
 O
Gy O
. O

 O
Meanwhile O
, O
considering O
the O
MST O
pathology O
was O
that O
of O
SCC O
, O
the O
patient O
received O
GP O
chemotherapy O
( O
cisplatin O
75 O
 O
mg O
/ O
m2 O
d1 O
, O
gemcitabine O
1250 O
 O
mg O
/ O
m2 O
d1 O
, O
d8 O
, O
for O
21 O
days O
as O
a O
cycle O
) O
for O
4 O
cycles O
, O
and O
the O
patient O
achieved O
partial O
remission O
( O
PR O
) O
after O
2 O
cycles O
, O
followed O
by O
stable O
disease O
( O
SD O
) O
after O
4 O
cycles O
( O
Fig.3[B3[B O
and O
F O
] O
and O
[ O
C O
and O
G O
] O
) O
according O
to O
response O
evaluation O
criteria O
in O
solid O
tumors O
( O
RECIST O
) O
1.1 O
. O

 O
Then O
, O
( O
) O
was O
used O
as O
maintenance O
treatment O
onward O
. O

 O
During O
the O
treatment O
, O
was O
given O
for O
. O

 O
The O
patient O
is O
currently O
under O
surveillance O
with O
( O
Fig.3D O
and O
H O
) O
and O
with O
scores O
of O
. O

A O
presented O
at O
the O
with O
aggravating O
right O
upper O
abdominal O
for O
. O

 O
The O
patient O
was O
diagnosed O
and O
non O
- O
alcoholics O
. O

 O
. O

 O
Initial O
was O
, O
, O
, O
. O

 O
The O
were O
( O
: O
) O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
16.6/0.7 O
mg O
/ O
dL. O

 O
And O
were O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
< O
20 O
IU O
/ O
mL O
, O
( O
- O
) O
and O
( O
) O
. O

 O
The O
patient O
's O
( O
) O
was O
and O
( O
) O
< O
0.6 O
U O
/ O
mL. O

 O
She O
took O
an O
abdominal O
scan O
, O
which O
showed O
a O
9 O
cm O
sized O
necrotic O
with O
internal O
hemorrhage O
at O
the O
and O
( O
Fig.1A O
) O
, O
so O
an O
emergency O
hepatic O
central O
was O
done O
( O
Fig.2A O
) O
. O

 O
The O
initial O
histological O
diagnosis O
was O
cHCC B
- I
CC I
with O
( O
Fig.2B O
) O
. O

 O
The O
was O
to O
at O
time O
of O
. O

 O
Regarding O
as O
cHCC B
- I
CC I
, O
postoperative O
adjuvant O
with O
( O
) O
was O
administrated O
for O
. O

 O
, O
abdominal O
scanning O
showed O
previously O
unseen O
a O
sized O
left O
subphrenic O
with O
mild O
in O
( O
Fig.3A O
, O
B O
) O
and O
was O
to O
312.06 O
ng O
/ O
mL. O

 O
She O
underwent O
laparoscopic O
with O
. O

 O
On O
, O
mesenchymal O
elements O
consisted O
of O
a O
proliferation O
of O
primitive O
- O
appearing O
mesenchymal O
spindle O
- O
shaped O
cells O
, O
intimately O
admixed O
with O
the O
epithelial O
elements O
in O
a O
highly O
cellular O
pattern O
. O

 O
Cytoplasm O
was O
more O
abundant O
than O
that O
of O
mature O
fibroblasts O
, O
and O
the O
nucleus O
was O
elongated O
and O
plump O
. O

 O
These O
cells O
blended O
progressively O
with O
areas O
of O
less O
intense O
cellular O
mesenchymal O
proliferation O
, O
and O
with O
relatively O
acellular O
, O
fibrous O
septa O
. O

 O
Osteoid O
was O
present O
either O
within O
the O
primitive O
mesenchyme O
, O
near O
the O
fibrous O
septa O
or O
pseudocapsule O
, O
or O
admixed O
within O
the O
epithelial O
elements O
. O

 O
Osteoid O
foci O
contained O
cells O
morphologically O
identical O
to O
osteoblasts O
( O
Fig.4A O
) O
. O

 O
The O
immunohistochemistry O
stains O
showed O
expression O
of O
hepatocyte O
, O
 O
- O
HCG O
, O
AFP O
, O
vimentin O
, O
CK7 O
, O
CK19 O
, O
CD56 O
and O
 O
- O
catenin O
and O
negativity O
for O
CEA.(Fig.4B O
, O
C O
, O
D O
, O
E O
, O
F O
, O
G O
) O
. O

 O
Metastatic O
hepatoblastoma O
was O
confirmed O
by O
histologic O
examination O
with O
immunohistochemistry O
stains O
, O
so O
immunohistochemistrically O
re O
- O
examination O
of O
previous O
surgical O
specimens O
was O
also O
confirmed O
as O
hepatoblastoma O
. O

 O
Follow O
- O
up O
abdominal O
CT O
scan O
performed O
1 O
month O
after O
reoperation O
showed O
a O
newly O
onset O
1.7 O
cm O
sized O
subtle O
enhancing O
soft O
tissue O
mass O
in O
splenic O
bed O
, O
and O
positron O
emission O
tomography O
( O
PET O
) O
showed O
multiple O
FDG O
uptake(max O
SUV O
> O
3.80 O
) O
in O
left O
upper O
and O
lower O
quadrant O
area O
of O
abdomen O
, O
paralumbar O
area O
including O
right O
subphrenic O
area O
( O
Fig.5A O
, O
B O
, O
C O
) O
. O

 O
Follow O
- O
up O
AFP O
was O
162.69 O
ng O
/ O
mL. O

 O
Systemic O
chemotherapy O
started O
with O
cisplatin O
( O
60 O
mg O
/ O
m2 O
) O
, O
5 O
- O
fluorourasil O
( O
5 O
- O
FU O
) O
( O
600 O
mg O
/ O
m2 O
) O
, O
vincristine O
( O
1.5 O
mg O
/ O
m2 O
) O
and O
total O
3 O
cycles O
of O
chemotherapy O
were O
done O
every O
4 O
week O
. O

 O
Entecavir O
0.5 O
mg O
was O
also O
started O
for O
chemoprophylaxis O
of O
CHB O
. O

 O
After O
the O
3rd O
chemotherapy O
cycle O
, O
follow O
- O
up O
abdominal O
CT O
and O
PET O
scan O
showed O
progression O
of O
multiple O
intraperitoneal O
metastasis O
with O
large O
amount O
of O
intraperitoneal O
fluid O
( O
Fig.6A O
, O
B O
) O
and O
follow O
- O
up O
AFP O
was O
further O
increased O
to O
254 O
ng O
/ O
mL. O

 O
So O
chemotherapy O
regimen O
was O
changed O
to O
carboplatin O
( O
350 O
mg O
/ O
m2 O
) O
with O
doxorubicin O
( O
30 O
mg O
/ O
m2 O
) O
every O
3 O
weeks O
. O

 O
The O
patient O
experienced O
neutropenia O
after O
the O
new O
regimen O
, O
but O
recovered O
shortly O
after O
treatment O
with O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
. O

 O
After O
second O
carboplatin O
with O
doxorubicin O
chemotherapy O
, O
follow O
- O
up O
AFP O
was O
increased O
1510.19 O
ng O
/ O
mL O
, O
but O
abdominal O
CT O
scan O
showed O
that O
amount O
of O
ascites O
was O
decreased O
( O
Fig.7 O
) O
. O

 O
Because O
of O
radiologic O
improvements O
, O
third O
and O
fourth O
chemotherapy O
were O
performed O
. O

 O
After O
4th O
chemotherapy O
, O
follow O
- O
up O
abdominal O
CT O
revealed O
progression O
of O
multiple O
intraperitoneal O
metastatic O
masses O
, O
newly O
developed O
hepatic O
metastasis O
and O
large O
amount O
of O
intraperitoneal O
fluid O
( O
Fig.8 O
) O
. O

 O
A O
diagnostic O
paracentesis O
was O
performed O
and O
showed O
white O
blood O
cell O
310 O
/ O
mm3 O
( O
poly O
20 O
% O
, O
lymph O
80 O
% O
) O
, O
protein O
3.6 O
g O
/ O
dL O
and O
albumin O
2.3 O
g O
/ O
dL O
on O
ascitic O
fluid O
analysis O
. O

 O
The O
serum O
albumin O
was O
3.1 O
g O
/ O
dL O
and O
serum O
- O
ascites O
albumin O
gradient O
( O
SAAG O
) O
was O
0.8 O
g O
/ O
dL. O

 O
The O
AFB O
stain O
and O
culture O
were O
all O
negative O
in O
ascitic O
fluid O
. O

 O
The O
AFP O
was O
6881.93 O
ng O
/ O
mL O
on O
serum O
. O

 O
Regarded O
as O
peritoneal O
carcinomatosis O
, O
the O
patient O
underwent O
conservative O
treatments O
including O
the O
use O
of O
repeated O
therapeutic O
paracentesis O
for O
1 O
month O
before O
. O

A O
was O
to O
the O
of O
the O
in O
with O
right O
upper O
quadrant O
and O
. O

 O
She O
was O
a O
. O

 O
Her O
level O
was O
1185.3 O
ng O
/ O
mL. O

 O
and O
( O
) O
revealed O
a O
10 O
- O
cm O
in O
the O
posterior O
segments O
of O
the O
. O

 O
A O
1.5 O
- O
cm O
was O
also O
found O
in O
the O
. O

 O
These O
clinical O
signs O
indicated O
that O
the O
patient O
had O
inoperable O
HCC B
and O
Child O
- O
Pugh O
class O
A O
cirrhosis B
. O

 O
was O
offered O
to O
the O
patient O
. O

 O
demonstrated O
no O
obvious O
hepatic O
, O
but O
multiple O
smaller O
in O
. O

 O
An O
emulsion O
of O
, O
, O
and O
were O
prepared O
, O
and O
of O
the O
were O
administered O
to O
the O
, O
respectively O
. O

 O
The O
patient O
experienced O
right O
upper O
quadrant O
after O
TACE O
and O
had O
an O
uneventful O
. O

 O
, O
a O
second O
procedure O
was O
performed O
via O
the O
and O
40 O
mL O
of O
the O
was O
administered O
. O

 O
On O
the O
, O
she O
experienced O
sudden O
acute O
and O
the O
to O
. O

 O
The O
chest O
showed O
some O
increased O
reticular O
in O
the O
, O
especially O
in O
the O
, O
and O
a O
chest O
scan O
revealed O
multiple O
iodized O
oil O
- O
like O
high O
- O
density O
in O
( O
Figure O
1 O
) O
. O

 O
After O
10 O
mg O
and O
other O
were O
administered O
, O
the O
was O
attenuated O
. O

 O
, O
the O
patient O
suffered O
from O
a O
serious O
and O
transient O
, O
accompanying O
and O
followed O
by O
, O
lower O
extremity O
. O

 O
Non O
- O
contrast O
enhanced O
scanning O
showed O
multiple O
disseminated O
hyper O
- O
intense O
in O
the O
, O
consistent O
with O
of O
( O
Figure O
2 O
) O
. O

 O
, O
her O
respiratory O
and O
neurologic O
disappeared O
completely O
, O
and O
she O
was O
. O

 O
The O
patient O
also O
consequently O
completed O
the O
other O
three O
procedures O
, O
during O
which O
no O
similar O
occurred O
. O

A O
, O
, O
, O
was O
admitted O
for O
a O
2 O
years O
history O
of O
. O

 O
The O
patient O
described O
: O
especially O
throughout O
the O
and O
that O
preceded O
the O
seizure O
and O
he O
denied O
any O
. O

 O
Some O
of O
the O
consisted O
only O
of O
a O
brief O
period O
of O
without O
any O
, O
but O
a O
typical O
would O
consist O
of O
sudden O
accompanied O
by O
in O
both O
arms O
, O
more O
often O
being O
involved O
his O
, O
without O
, O
which O
lasted O
. O

 O
He O
had O
other O
than O
being O
a O
: O
. O

 O
The O
frequency O
of O
the O
was O
initially O
, O
but O
increased O
progressively O
over O
time O
to O
about O
, O
despite O
 O
at O
the O
time O
of O
he O
was O
taking O
 O
and O
. O

 O
With O
the O
we O
have O
been O
able O
to O
record O
a O
couple O
of O
seizures O
on O
the O
Video O
 O
EEG O
His O
was O
. O

 O
Diagnosis O
was O
made O
on O
native O
: O
minimal O
hypodense O
frontal O
right O
paramedian O
( O
Figure O
1A O
) O
, O
cerebral O
( O
Figure O
1 O
B O
 O
F O
) O
showed O
a O
small O
right O
parenchymal O
homogeneous O
, O
, O
involving O
, O
without O
perilesional O
and O
, O
hyperintense O
both O
on O
T1 O
and O
T2 O
MR O
sequences O
, O
. O

 O
The O
cerebral O
was O
also O
documented O
on O
and O
recordings O
: O
3 O
with O
and O
were O
recorded O
( O
Figure O
1I O
) O

 O
Using O
an O
interhemispheric O
, O
and O
the O
, O
at O
the O
level O
of O
, O
a O
yellow O
 O
gray O
, O
infiltrative O
, O
having O
a O
moderate O
had O
been O
identified O
and O
totally O
. O

 O
The O
revealed O
a O
grade O
 O
astrocytoma B
. O

 O
The O
patient O
very O
well O
, O
without O
, O
no O
gelastic B
seizures I
or O
; O
he O
is O
still O
free O
of O
. O

 O
A O
control O
postop O
revealed O
no O
( O
1 O
G O
, O
H O
) O

A O
patient O
was O
admitted O
. O

 O
His O
major O
complaints O
were O
gradually O
aggravated O
and O
, O
on O
suspicion O
of O
obstructive B
disease I
in O
upper O
digestive O
tract O
. O

 O
He O
before O
, O
and O
then O
before O
admission O
. O

 O
. O

 O
Thorough O
of O
his O
, O
, O
, O
and O
failed O
to O
identify O
any O
superficial O
. O

 O
Additionally O
, O
including O
, O
, O
and O
such O
as O
, O
, O
, O
, O
and O
were O
all O
. O

 O
Therefore O
, O
further O
endoscopic O
and O
radiological O
were O
carried O
out O
for O
accurate O
diagnosis O
. O

 O
revealed O
a O
slightly O
pigmented O
, O
irregular O
, O
which O
was O
located O
in O
, O
measuring O
in O
size O
. O

 O
Fine O
needle O
of O
the O
revealed O
esophageal O
melanoma B
, O
which O
was O
confirmed O
by O
. O

 O
Besides O
chest O
and O
abdomen O
( O
) O
, O
enhanced O
cranial O
( O
) O
and O
bone O
( O
) O
showed O
mediastinal O
, O
nd O
also O
celiac O
( O
Fig.1A O
) O
, O
without O
obvious O
of O
supraclavicular O
. O

 O
Concurrently O
, O
the O
showed O
an O
isolated O
, O
irregular O
pulmonary O
( O
Fig.1B O
) O
. O

 O
was O
not O
carried O
out O
, O
because O
it O
was O
not O
covered O
by O
health O
insurance O
of O
this O
patient O
. O

 O
Therefore O
, O
this O
patient O
was O
as O
according O
to O
the O
for O
esophageal B
cancer I
. O

 O
CT O
- O
guided O
percutaneous O
pulmonary O
was O
avoided O
, O
with O
the O
aim O
to O
diminish O
the O
risk O
of O
tumor O
dissemination O
. O

 O
Single O
- O
stage O
of O
the O
esophageal O
and O
pulmonary O
was O
assumed O
to O
be O
reasonable O
after O
multidisciplinary O
, O
which O
was O
approved O
by O
Ethical O
Committee O
of O
Xuzhou O
Central O
Hospital O
. O

 O
Because O
the O
prognosis O
of O
this O
patient O
probably O
was O
extremely O
poor O
without O
targeted O
antibodies O
, O
which O
he O
could O
not O
afford O
for O
financial O
reasons O
. O

 O
After O
his O
informed O
consent O
, O
simultaneous O
Ivor O
- O
Lewis O
and O
right O
upper O
were O
performed O
successfully O
, O
under O
, O
after O
double O
- O
lumen O
endotracheal O
, O
followed O
by O
systemic O
of O
located O
in O
and O
, O
in O
accordance O
with O
the O
principles O
of O
oncological O
surgery O
. O

 O
The O
operation O
time O
was O
, O
without O
obvious O
during O
the O
surgery O
. O

 O
Postoperative O
of O
the O
specimen O
revealed O
and O
abundant O
( O
Fig.1C O
) O
, O
whereas O
demonstrated O
positive O
expression O
of O
( O
) O
, O
( O
) O
, O
and O
, O
and O
of O
, O
, O
and O
( O
) O
, O
which O
was O
consistent O
with O
melanoma B
. O

 O
The O
resection O
margin O
and O
were O
pathologically O
- O
negative O
. O

 O
In O
addition O
, O
of O
the O
patient O
indicated O
( O
BRAF O
) O
V600E. O

 O
Based O
on O
these O
findings O
, O
a O
diagnosis O
of O
advanced O
PMME B
was O
tentatively O
established O
as O
( O
) O
, O
because O
there O
was O
insufficient O
evidence O
to O
distinguish O
synchronous O
primary O
pulmonary O
melanoma O
from O
metastasis O
for O
this O
patient O
. O

 O
The O
was O
, O
and O
the O
patient O
was O
. O

 O
Subsequently O
, O
4 O
cycles O
of O
adjuvant O
conventional O
with O
an O
interval O
of O
3 O
weeks O
were O
completed O
, O
with O
controlled O
moderate O
toxic O
effects O
including O
, O
, O
, O
, O
and O
. O

 O
The O
detailed O
chemotherapy O
regimen O
is O
as O
follows O
: O
paclitaxel O
liposome O
for O
injection O
on O
day O
1 O
and O
day O
8 O
( O
135 O
 O
mg O
per O
square O
meter O
of O
body O
surface O
area O
; O
Nanjing O
Luye O
Sike O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jiangsu O
, O
China O
. O
) O
, O
tegafur O
injection O
on O
day O
2 O
to O
4 O
( O
1000 O
 O
mg O
per O
square O
meter O
of O
body O
- O
surface O
area O
; O
Shandong O
Qilu O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jinan O
, O
China O
. O
) O
plus O
cis O
- O
platinum O
on O
day O
2 O
to O
3 O
( O
75 O
 O
mg O
per O
square O
meter O
of O
body O
- O
surface O
area O
; O
Shandong O
Qilu O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jinan O
, O
China O
) O
. O

 O
This O
patient O
suffered O
from O
moderate O
leukopenia/ O
after O
the O
second O
cycle O
of O
TPF O
, O
and O
he O
quickly O
after O
the O
administration O
of O
( O
) O
. O

 O
Concurrently O
, O
recombinant O
( O
Harbin O
pharmaceutical O
group O
biological O
engineering O
Co. O
, O
Ltd O
, O
Harbin O
, O
China O
) O
was O
administrated O
via O
thereafter O
( O
; O
Fig.2 O
) O
, O
lasting O
. O

 O
The O
patient O
was O
continuously O
after O
the O
surgery O
. O

 O
Chest O
and O
abdomen O
, O
cranial O
, O
bone O
, O
and O
thorough O
were O
carried O
out O
. O

 O
Encouragingly O
, O
the O
patient O
without O
loco O
- O
regional O
or O
remote O
during O
the O
of O
up O
to O
now O
( O
Fig.3 O
) O
. O

The O
affected O
individual O
, O
a O
, O
was O
the O
fourth O
child O
born O
to O
an O
Arab O
Muslim O
family O
of O
Palestinian O
origin O
. O

 O
are O
. O

 O
One O
, O
a O
girl O
died O
at O
the O
age O
of O
1 O
month O
due O
to O
SIDS O
according O
to O
parents O
, O
without O
any O
investigation O
. O

 O
Informed O
consent O
for O
muscle O
, O
skin O
biopsy O
and O
exome O
sequencing O
was O
obtained O
from O
the O
parents O
, O
and O
the O
study O
was O
approved O
by O
the O
local O
institutional O
review O
board O
. O

 O
During O
pregnancy O
, O
the O
patient O
was O
suspected O
to O
have O
IUGR O
and O
was O
delivered O
by O
Cesarian O
section O
at O
36 O
+ O
2 O
gestational O
weeks O
with O
Apgar O
scores O
9 O
and O
10 O
. O

 O
Birth O
weight O
was O
2.3 O
 O
kg O
( O
10th O
percentile O
) O
and O
head O
circumference O
32 O
 O
cm O
( O
10th O
percentile O
) O
. O

 O
Physical O
exam O
after O
birth O
, O
detected O
a O
systolic O
murmur O
3/6 O
. O

 O
On O
the O
first O
day O
of O
life O
, O
the O
patient O
developed O
metabolic O
acidosis O
with O
lactate O
level O
of O
27 O
 O
mm O
( O
normal O
range O
0.52.4 O
 O
mm O
) O
and O
elevated O
ammonia O
levels O
277 O
 O
m O
( O
normal O
range O
1060 O
 O
m O
) O
. O

 O
Metabolic O
work O
up O
showed O
normal O
acylcarnitines O
, O
elevated O
alanine O
level O
1400 O
 O
m O
( O
normal O
< O
700 O
 O
m O
) O
, O
and O
urine O
organic O
acids O
showed O
increased O
lactic O
acidosis O
and O
ketones O
. O

 O
Chest O
X O
- O
ray O
revealed O
cardiomegaly O
, O
and O
cardiac O
Echo O
revealed O
symmetrical O
left O
ventricular O
hypertrophy O
tricuspid O
regurge O
and O
pulmonary O
hypertension O
. O

 O
The O
patient O
was O
transported O
to O
the O
NICU O
and O
treated O
with O
bicarbonate O
, O
acetate O
and O
diuretics O
. O

 O
At O
the O
age O
of O
4 O
days O
, O
quadriceps O
muscle O
biopsy O
was O
performed O
. O

 O
Pathology O
showed O
decreased O
cytochrome O
c O
oxidase O
stain O
. O

 O
Brain O
ultrasound O
performed O
at O
age O
5 O
days O
was O
normal O
. O

 O
Subsequently O
, O
head O
circumference O
grew O
rapidly O
adding O
13 O
centimeters O
by O
age O
35 O
days O
, O
repeated O
brain O
US O
revealed O
dilated O
ventricles O
confirmed O
by O
head O
CT O
, O
which O
also O
showed O
subcortical O
and O
white O
matter O
cortical O
hemorrhage O
in O
the O
occipital O
region O
. O

 O
At O
15 O
weeks O
, O
a O
ventriculoperitoneal O
( O
VP O
) O
shunt O
was O
inserted O
. O

 O
Head O
CT O
performed O
at O
age O
2 O
years O
showed O
prominent O
dilatation O
of O
the O
ventricles O
( O
Figure O
1 O
) O
. O

 O
Due O
to O
hypotonia O
with O
feeding O
difficulties O
and O
recurrent O
aspirations O
, O
a O
percutaneous O
endoscopic O
gastrostomy O
( O
PEG O
) O
feeding O
tube O
was O
inserted O
at O
age O
10 O
weeks O
. O

 O
Eye O
examination O
at O
the O
age O
of O
15 O
weeks O
revealed O
cortical O
blindness O
. O

 O
Hearing O
test O
ABR O
was O
normal O
. O

 O
Repeated O
cardiac O
Echo O
continued O
to O
show O
mild O
tricuspid O
regurge O
, O
mild O
left O
ventricular O
hypertrophy O
( O
LVH O
) O
and O
pulmonary O
hypertension O
( O
PHTN O
) O
in O
the O
first O
months O
of O
life O
. O

 O
At O
the O
age O
of O
4 O
months O
, O
he O
started O
developing O
hypertrophic O
obstructive O
cardiomyopathy O
, O
he O
was O
started O
on O
diuretics O
and O
beta O
blockers O
and O
later O
calcium O
channel O
blockers O
were O
added O
; O
follow O
- O
up O
Echo O
at O
the O
age O
of O
2 O
years O
revealed O
improvement O
in O
the O
LVH O
and O
no O
PHTN O
. O

 O
Coenzyme O
Q10 O
supplementation O
( O
60 O
 O
mg O
twice O
daily O
) O
was O
initiated O
at O
4 O
months O
but O
discontinued O
by O
the O
parents O
. O

 O
In O
the O
following O
months O
, O
the O
patient O
was O
admitted O
several O
times O
to O
the O
hospital O
mainly O
due O
to O
chest O
infections O
, O
shunt O
malfunctioning O
and O
fevers O
. O

 O
He O
at O
the O
due O
to O
severe O
hypoxemia O
after O
a O
febrile B
illness I
with O
chest O
infection B
and O
pulmonary O
; O
parents O
refused O
and O
refused O
. O

A O
was O
to O
our O
hospital O
for O
perioperative O
cardiac O
evaluation O
of O
abdominal O
aortic O
aneurysm B
. O

 O
The O
patient O
had O
undergone O
coronary O
artery O
bypass O
grafting O
( O
CABG O
) O
for O
severe O
stenosis O
of O
the O
left O
main O
coronary O
artery O
( O
LMCA O
) O
, O
which O
consisted O
of O
the O
( O
) O
to O
the O
( O
) O
and O
( O
) O
to O
the O
( O
) O
. O

 O
Due O
to O
continual O
growth O
of O
the O
abdominal O
aortic O
aneurysm O
over O
the O
years O
, O
surgery O
was O
indicated O
. O

 O
Left O
coronary O
angiogram O
showed O
90 O
% O
stenosis O
of O
the O
LMCA O
and O
total O
occlusion O
of O
both O
grafts O
. O

 O
PCI O
was O
performed O
for O
LMCA O
stenosis O
( O
Fig.1 O
) O
. O

 O
A O
7 O
- O
Fr O
sheath O
was O
inserted O
into O
the O
right O
femoral O
artery O
, O
and O
a O
CLS4 O
guiding O
catheter O
( O
Boston O
Scientific O
, O
Natick O
, O
MA O
, O
USA O
) O
was O
engaged O
into O
the O
left O
coronary O
artery O
( O
LCA O
) O
ostium O
. O

 O
A O
guidewire O
( O
SION O
Blue O
, O
Asahi O
Intecc O
, O
Aichi O
, O
Japan O
) O
was O
inserted O
into O
the O
distal O
LAD O
, O
and O
another O
guidewire O
( O
Hi O
- O
Torque O
Pilot O
50 O
, O
Abbott O
Vascular O
, O
Santa O
Clara O
, O
California O
, O
USA O
) O
was O
inserted O
into O
the O
distal O
LCX O
. O

 O
Intravascular O
ultrasound O
( O
IVUS O
) O
( O
Intra O
- O
focus O
WR O
, O
Terumo O
Corp O
, O
Tokyo O
, O
Japan O
) O
demonstrated O
heavy O
circumferential O
calcification O
in O
the O
LMCA O
lesion O
. O

 O
After O
a O
4.0 O
 O
 O
 O
15 O
- O
mm O
Quantum O
Maverick O
balloon O
catheter O
( O
Boston O
Scientific O
) O
was O
inflated O
in O
the O
lesion O
, O
LCA O
angiogram O
revealed O
a O
large O
dissection O
( O
Fig.2 O
) O
. O

 O
A O
4.0 O
 O
 O
 O
28 O
- O
mm O
Multi O
- O
Link O
Vision O
stent O
( O
Abbott O
Vascular O
) O
was O
immediately O
deployed O
. O

 O
Angiographic O
image O
of O
the O
residual O
dissection O
disappeared O
and O
the O
stent O
was O
dilated O
by O
a O
5.0 O
 O
 O
 O
15 O
- O
mm O
Quantum O
Maverick O
balloon O
catheter O
. O

 O
The O
absence O
of O
residual O
dissection O
was O
confirmed O
by O
angiography O
after O
stent O
implantation O
. O

 O
Next O
, O
LMCA O
- O
LAD O
and O
LMCA O
- O
LCX O
kissing O
balloon O
angioplasty O
was O
initiated O
using O
a O
4.0 O
 O
 O
 O
28 O
- O
mm O
stent O
delivery O
balloon O
in O
the O
LAD O
and O
a O
3.0 O
mm O
 O
 O
 O
15 O
- O
mm O
Ikazuchi O
balloon O
( O
Kaneka O
Medics O
, O
Tokyo O
, O
Japan O
) O
in O
the O
LCX O
. O

 O
The O
final O
angiographic O
imaging O
showed O
optimal O
results O
, O
and O
IVUS O
imaging O
of O
the O
lesion O
showed O
completely O
sealing O
by O
the O
stent O
( O
Fig.3 O
) O
. O

 O
A O
large O
hematoma O
at O
the O
femoral O
puncture O
site O
and O
local O
bleeding O
was O
observed O
after O
removal O
of O
the O
femoral O
sheath O
and O
manual O
compression O
was O
applied O
for O
haemostasis O
. O

 O
The O
hematoma O
did O
not O
appear O
to O
have O
spread O
the O
next O
day O
and O
the O
patient O
was O
discharged O
from O
the O
hospital O
on O
the O
fifth O
day O
after O
PCI O
. O

 O
Unexpectedly O
, O
the O
patient O
was O
admitted O
to O
our O
emergency O
room O
with O
new O
- O
onset O
chest O
pain O
and O
dyspnoea O
the O
next O
day O
after O
the O
discharge O
. O

 O
His O
vital O
signs O
indicated O
cardiogenic O
shock O
. O

 O
Electrocardiogram O
showed O
ST O
elevation O
in O
leads O
V1 O
- O
V3 O
. O

 O
Although O
echocardiography O
could O
not O
detect O
left O
ventricular O
asynergy O
, O
a O
large O
mass O
on O
the O
outflow O
tract O
of O
right O
ventricular O
chamber O
was O
observed O
( O
Fig.4 O
) O
. O

 O
Contrast O
- O
enhanced O
computed O
tomography O
showed O
a O
40 O
- O
mm O
hematoma O
compressing O
the O
main O
pulmonary O
artery O
trunk O
and O
the O
right O
ventricle O
( O
Fig.5 O
) O
. O

 O
During O
examination O
, O
the O
patient O
suffered O
sudden O
cardiopulmonary O
arrest O
. O

 O
He O
received O
immediate O
cardiopulmonary O
resuscitation O
and O
returned O
to O
spontaneous O
circulation O
after O
the O
insertion O
of O
a O
percutaneous O
cardiopulmonary O
support O
device O
. O

 O
The O
patient O
underwent O
emergent O
surgery O
for O
the O
removal O
of O
the O
hematoma O
after O
informed O
consent O
was O
obtained O
from O
the O
patient O
's O
family O
. O

 O
During O
surgery O
, O
large O
, O
dark O
red O
clots O
between O
the O
pulmonary O
artery O
trunk O
and O
aorta O
were O
observed O
. O

 O
The O
suspected O
origin O
of O
the O
epicardial O
hematoma O
was O
blood O
oozing O
from O
the O
LMCA O
stent O
site O
. O

 O
Despite O
successful O
surgical O
repair O
, O
the O
patient O
from O
aortic O
rupture O
induced O
by O
. O

The O
patient O
in O
this O
case O
had O
a O
6 O
- O
year O
history O
of O
diffuse O
cutaneous O
SSc B
( O
Fig.1 O
) O
and O
had O
not O
received O
regular O
or O
therapy O
. O

 O
He O
had O
experienced O
, O
, O
and O
progressive O
for O
and O
for O
. O

 O
He O
was O
to O
our O
with O
renal B
failure I
and O
pulmonary O
. O

 O
In O
the O
emergency O
department O
, O
his O
blood O
pressure O
, O
pulse O
rate O
, O
and O
respiratory O
rate O
were O
, O
, O
and O
, O
respectively O
. O

 O
revealed O
the O
following O
values O
: O
, O
7730 O
/ O
L O
( O
350011,000 O
/ O
L O
) O
; O
, O
8.6 O
 O
g O
/ O
dL O
( O
1216 O
 O
g O
/ O
dL O
): O
, O
87000 O
/ O
L O
( O
150,000400,000 O
/ O
L O
) O
; O
, O
78 O
 O
mg O
/ O
dL O
( O
621 O
 O
mg O
/ O
dL O
) O
; O
, O
8.9 O
 O
mg O
/ O
dL O
( O
1.11.5 O
 O
mg O
/ O
dL O
) O
; O
, O
8.2 O
 O
mg O
/ O
dL O
( O
8.810.3 O
 O
mg O
/ O
dL O
) O
; O
, O
5.4 O
 O
mg O
/ O
dL O
( O
2.74.5 O
 O
mg O
/ O
dL O
) O
; O
, O
< O
6.56 O
 O
mg O
/ O
dL O
( O
30200 O
 O
mg O
/ O
dL O
) O
; O
and O
, O
( O
106211 O
 O
U O
/ O
L O
) O
. O

 O
A O
routine O
revealed O
a O
( O
) O
, O
of O
35 O
/ O
high O
power O
field O
, O
and O
of O
. O

 O
The O
indicated O
an O
level O
of O
( O
, O
) O
. O

 O
Tests O
for O
, O
, O
, O
, O
and O
were O
all O
. O

 O
Kidney O
showed O
a O
without O
. O

 O
Despite O
the O
chronic O
changes O
visible O
on O
the O
echogram O
, O
the O
patient O
had O
developed O
acute O
pulmonary O
and O
only O
admission O
. O

 O
Accordingly O
, O
a O
clinical O
diagnosis O
of O
acute O
- O
on O
- O
chronic O
renal B
failure I
was O
made O
. O

 O
A O
further O
diagnosis O
of O
SRC B
was O
supported O
by O
the O
presence O
of O
renal B
failure I
with O
microangiopathic O
hemolytic O
and O
, O
and O
the O
patient O
was O
started O
on O
captopril O
therapy O
. O

 O
The O
sustained O
and O
had O
led O
to O
a O
requirement O
for O
regular O
from O
admission O
. O

 O
, O
was O
changed O
to O
because O
the O
patient O
developed O
a O
severe O
, O
intolerable O
thought O
to O
be O
associated O
with O
captopril O
. O

 O
His O
was O
. O

 O
At O
approximately O
the O
initiation O
of O
maintenance O
, O
the O
patient O
newly O
developed O
a O
generalized O
tonic O
- O
clonic O
seizure B
disorder I
. O

 O
A O
brain O
( O
) O
scan O
revealed O
a O
small O
lacunar O
infarct B
over O
the O
without O
intracranial O
hemorrhage B
or O
large O
infarct B
. O

 O
The O
seizure O
resolved O
spontaneously O
without O
, O
and O
the O
patient O
was O
finally O
without O
incident O
and O
scheduled O
for O
regular O
hemodialysis O
. O

 O
However O
, O
at O
discharge O
, O
the O
patient O
developed O
a O
sudden O
- O
onset O
and O
with O
and O
recurrence O
of O
the O
generalized O
tonic O
- O
clonic O
. O

 O
He O
at O
the O
with O
a O
of O
, O
of O
, O
of O
, O
and O
a O
( O
Fig.2 O
) O
. O

 O
Brain O
revealed O
, O
and O
revealed O
. O

 O
Cerebrospinal O
were O
for O
, O
, O
and O
. O

 O
Brain O
( O
) O
showed O
bilateral O
in O
the O
on O
a O
( O
Fig.3 O
) O
. O

 O
Finally O
, O
the O
patient O
was O
diagnosed O
with O
PRES B
. O

 O
We O
resumed O
therapy O
at O
a O
dose O
of O
. O

 O
As O
it O
was O
difficult O
to O
differentiate O
SRC O
from O
TTP O
, O
we O
also O
considered O
plasma O
exchange O
treatment O
. O

 O
However O
, O
the O
patient O
's O
returned O
to O
within O
in O
the O
absence O
of O
, O
and O
a O
follow O
- O
up O
of O
the O
showed O
complete O
resolution O
of O
cerebral O
( O
Fig.4 O
) O
. O

 O
Therefore O
, O
SRC O
- O
related O
PRES B
was O
confirmed O
. O

 O
Although O
the O
patient O
experienced O
a O
, O
his O
and O
he O
remained O
. O

The O
patient O
is O
a O
who O
had O
noted O
a O
rapidly O
enlarging O
on O
the O
in O
. O

 O
She O
underwent O
a O
total O
and O
central O
neck O
, O
which O
revealed O
a O
anaplastic O
thyroid B
cancer I
arising O
in O
a O
background O
of O
an O
oncocytic O
variant O
of O
poorly O
differentiated O
thyroid B
cancer I
( O
Fig.1A O
, O
and O
Fig O
. O
S1 O
in O
Supplementary O
Appendix O
1 O
, O
available O
with O
the O
full O
text O
of O
this O
article O
at O
NEJM.org O
) O
. O

 O
Resection O
margins O
were O
positive O
, O
and O
3 O
of O
12 O
lymph O
nodes O
were O
. O

 O
At O
surgery O
, O
the O
serum O
level O
was O
, O
with O
undetectable O
. O

 O
The O
patient O
received O
concurrent O
and O
weekly O
and O
. O

 O
The O
serum O
level O
at O
the O
completion O
of O
chemotherapy O
and O
radiation O
therapy O
was O
. O

 O
Restaging O
obtained O
revealed O
a O
new O
, O
right O
- O
sided O
hilar O
( O
Fig.1C O
) O
, O
and O
the O
patient O
enrolled O
in O
a O
phase O
2 O
clinical O
trial O
of O
, O
which O
was O
administered O
at O
a O
dose O
of O
. O

 O
, O
follow O
- O
up O
showed O
that O
the O
had O
greatly O
( O
from O
to O
) O
( O
Fig.1D O
) O
. O

 O
After O
of O
a O
sustained O
to O
, O
revealed O
progressive B
disease I
( O
Fig.1E O
) O
. O

 O
The O
patient O
underwent O
a O
with O
of O
an O
, O
which O
contained O
metastatic O
anaplastic O
thyroid B
cancer I
( O
Fig.1B O
, O
and O
Fig O
. O
S1 O
in O
Supplementary O
Appendix O
1 O
) O
. O

 O
Whole O
- O
exome O
was O
performed O
on O
samples O
of O
the O
as O
well O
as O
on O
a O
. O

We O
present O
the O
case O
of O
a O
patient O
with O
with O
chest O
that O
was O
treated O
with O
by O
her O
. O

 O
The O
next O
day O
she O
to O
the O
, O
where O
an O
revealed O
posterolateral O
ST O
elevation O
myocardial B
infarction I
. O

 O
The O
patient O
was O
immediately O
to O
the O
. O

 O
A O
successful O
was O
performed O
on O
an O
acutely O
that O
was O
supplying O
a O
large O
portion O
of O
the O
( O
Figure O
1 O
) O
. O

 O
The O
patient O
, O
but O
she O
suddenly O
went O
into O
cardiogenic B
shock I
. O

 O
An O
was O
placed O
, O
and O
an O
demonstrated O
that O
she O
had O
severe O
mitral B
regurgitation I
from O
a O
ruptured B
( O
Figure O
2 O
) O
. O

 O
The O
patient O
, O
on O
maximal O
, O
with O
progressive O
, O
, O
and O
florid O
pulmonary O
. O

 O
In O
spite O
of O
the O
very O
high O
risk O
, O
we O
decided O
to O
intervene O
surgically O
. O

 O
Once O
in O
the O
operating O
room O
, O
transesophageal O
confirmed O
severe O
mitral B
regurgitation I
with O
a O
ruptured B
and O
a O
. O

 O
Shortly O
after O
the O
patient O
was O
put O
on O
, O
the O
resolved O
and O
she O
began O
to O
. O

 O
Excellent O
of O
the O
was O
obtained O
using O
a O
through O
the O
. O

 O
The O
valve O
was O
carefully O
and O
the O
ruptured B
was O
seen O
( O
Figure O
3 O
) O
. O

 O
There O
was O
a O
large O
chunk O
of O
muscle O
to O
the O
. O

 O
The O
anterior O
leaflet O
of O
the O
mitral O
valve O
was O
while O
keeping O
the O
posterior O
leaflet O
. O

 O
A O
27 O
- O
mm O
St O
Jude O
Epic O
was O
inserted O
( O
Figure O
4 O
) O
. O

 O
She O
was O
placed O
on O
that O
was O
successfully O
. O

 O
Following O
this O
, O
she O
made O
a O
remarkable O
early O
. O

 O
, O
just O
prior O
to O
, O
she O
after O
developing O
pneumonia B
that O
progressed O
to O
sepsis B
with O
multiorgan B
failure I
. O

A O
to O
our O
with O
progressive O
abdominal O
and O
irregular O
vaginal O
of O
 O
duration O
. O

 O
A O
contrast O
CT O
abdomen O
and O
pelvis O
revealed O
an O
ill O
- O
defined O
, O
irregular O
in O
the O
/ O
( O
Figure O
1 O
) O
. O

 O
There O
were O
multiple O
peritoneal O
and O
omental O
, O
pelvic O
and O
paraaortic O
, O
and O
large O
- O
volume O
. O

 O
The O
initial O
was O
significant O
for O
of O
, O
of O
, O
and O
of O
. O

 O
Serum O
was O
at O
13.1 O
mg O
/ O
dL. O

 O
and O
were O
. O

 O
was O
. O

 O
A O
revealed O
a O
fungating O
vaginal O
. O

 O
The O
patient O
underwent O
of O
the O
and O
the O
vaginal O
, O
which O
revealed O
a O
high O
- O
grade O
with O
. O

 O
was O
positive O
for O
, O
, O
and O
, O
consistent O
with O
a O
diagnosis O
of O
high O
- O
grade O
endometrial B
stromal I
sarcoma I
( O
Figure O
2 O
) O
. O

 O
The O
was O
negative O
for O
, O
with O
rare O
cells O
positive O
for O
. O

 O
Although O
for O
was O
, O
a O
could O
not O
be O
entirely O
ruled O
out O
given O
the O
small O
size O
of O
the O
biopsy O
specimen O
relative O
to O
the O
tumor O
. O

 O
The O
patient O
s O
was O
markedly O
at O
( O
nl O
34 O
) O
. O

 O
Contrast O
revealed O
a O
right O
- O
sided O
pleural B
effusion I
but O
no O
suspicious O
or O
lymphadenopathy B
. O

 O
The O
patient O
was O
deemed O
to O
have O
operable B
disease I
and O
was O
scheduled O
for O
. O

 O
However O
, O
preoperative O
showed O
that O
her O
serum O
had O
further O
to O
19.2 O
mg O
/ O
dL. O

 O
She O
had O
also O
developed O
evidence O
of O
acute O
kidney O
injury B
, O
with O
her O
to O
and O
to O
1.81 O
mg O
/ O
dL. O

 O
On O
, O
she O
was O
noted O
to O
be O
, O
with O
dry O
mucous O
membranes O
. O

 O
The O
was O
due O
to O
the O
patient O
s O
medical B
instability I
. O

 O
Further O
workup O
revealed O
an O
elevated O
of O
( O
nl O
1427 O
) O
, O
a O
level O
of O
( O
nl O
1565 O
) O
, O
and O
a O
level O
of O
( O
nl O
30100 O
) O
, O
consistent O
with O
humoral B
hypercalcemia I
of I
malignancy I
. O

 O
The O
patient O
was O
treated O
with O
, O
, O
and O
intravenous O
. O

 O
She O
eventually O
required O
temporary O
and O
for O
refractory O
. O

 O
The O
patient O
improved O
with O
regard O
to O
her O
. O

 O
Given O
the O
extent O
of O
her O
disease O
, O
she O
was O
planned O
for O
neoadjuvant O
followed O
by O
if O
a O
good O
response O
was O
achieved O
. O

 O
She O
was O
started O
on O
a O
regimen O
of O
and O
, O
which O
she O
received O
for O
. O

 O
She O
also O
had O
palliative O
to O
the O
to O
control O
. O

 O
However O
, O
her O
disease O
failed O
to O
respond O
significantly O
to O
chemotherapy O
, O
and O
she O
ultimately O
from O
complications B
of I
malignancy I
. O

The O
was O
to O
hospital O
in O
the O
with O
( O
) O
. O

 O
After O
receiving O
was O
. O

 O
All O
, O
were O
. O

 O
the O
, O
and O
the O
was O
performed O
because O
of O
. O

 O
Liveborn O
female O
and O
male O
were O
delivered O
. O

 O
The O
postoperative O
course O
was O
initially O
. O

 O
she O
experienced O
sudden O
. O

 O
The O
rose O
to O
. O

 O
Laboratory O
findings O
showed O
, O
, O
and O
an O
increase O
in O
serum O
creatinine O
and O
aminotransferases O
( O
Table O
I O
) O
. O

 O
Intravenous O
was O
administered O
. O

 O
disclosed O
an O
empty O
without O
. O

 O
, O
the O
patient O
was O
to O
the O
because O
of O
, O
, O
and O
suspicion O
of O
DIC B
. O

 O
On O
she O
was O
and O
. O

 O
The O
combination O
of O
, O
, O
and O
suggested O
a O
postpartum B
HELLP I
syndrome I
, O
complicated O
by O
. O

 O
The O
patient O
was O
, O
and O
treatment O
was O
instituted O
with O
fresh O
plasma O
, O
, O
platelets O
, O
and O
kybernin O
P O
( O
) O
. O

 O
High O
, O
, O
and O
were O
compatible O
with O
acute O
renal B
failure I
. O

 O
A O
of O
failed O
to O
. O

 O
her O
was O
and O
. O

 O
the O
patient O
had O
acute O
cardiac B
arrest I
, O
and O
started O
. O

 O
was O
successful O
, O
and O
was O
re O
- O
established O
; O
rose O
to O
, O
and O
was O
. O

 O
were O
, O
and O
development O
of O
acute O
renal B
failure I
indicated O
the O
necessity O
of O
urgent O
. O

 O
, O
the O
patient O
was O
, O
. O

 O
patient O
developed O
again O
cardiopulmonary B
arrest I
. O

 O
Despite O
the O
outcome O
was O
. O

 O
Due O
to O
the O
fact O
that O
death O
occurred O
in O
the O
hospital O
a O
short O
time O
after O
a O
surgical O
intervention O
, O
a O
was O
. O

 O
An O
revealed O
of O
the O
and O
as O
well O
as O
of O
right O
and O
left O
ventricles O
. O

 O
( O
900 O
mL O
) O
, O
( O
2500 O
mL O
) O
, O
and O
( O
) O
were O
present O
. O

 O
The O
field O
of O
operation O
of O
the O
caesarean O
section O
was O
unremarkable O
. O

 O
were O
observed O
under O
the O
, O
, O
in O
the O
of O
the O
, O
and O
of O
the O
. O

 O
revealed O
, O
with O
and O
, O
as O
well O
as O
confluent O
in O
, O
, O
and O
. O

 O
was O
attributed O
to O
organ B
failure I
due O
to O
DIC B
as O
a O
consequence O
of O
HELLP B
syndrome I
. O

A O
who O
had O
been O
to O
our O
due O
to O
sudden O
chest O
was O
diagnosed O
with O
ST B
- I
segment I
elevation I
myocardial I
infarction I
( O
STEMI B
) O
. O

 O
He O
had O
no O
coronary O
risk O
factors O
except O
for O
a O
. O

 O
Primary O
percutaneous O
was O
performed O
, O
and O
a O
long O
, O
string O
- O
shaped O
was O
observed O
in O
the O
( O
Fig.1A O
) O
. O

 O
( O
) O
imaging O
revealed O
an O
odd O
, O
smooth O
- O
surfaced O
( O
Fig.1B O
) O
. O

 O
A O
long O
, O
white O
object O
which O
looked O
like O
a O
parasitic O
worm O
was O
retrieved O
via O
and O
was O
successfully O
completed O
since O
neither O
plaque O
rupture O
or O
the O
presence O
of O
thrombus O
was O
detected O
by O
( O
Fig.1C O
) O
. O

 O
On O
the O
eleventh O
hospital O
day O
, O
transthoracic O
revealed O
a O
new O
floating O
in O
the O
. O

 O
revealed O
a O
huge O
that O
was O
recognized O
at O
admission O
in O
the O
with O
( O
Fig.1D O
) O
. O

 O
Although O
the O
were O
negative O
for O
a O
, O
a O
of O
the O
aspirated O
coronary O
revealed O
pleomorphic O
lung O
carcinoma B
( O
Fig.2 O
) O
. O

 O
The O
patient O
was O
diagnosed O
with O
STEMI B
due O
to O
coronary O
associated O
with O
lung O
carcinoma B
. O

 O
Brain O
revealed O
that O
the O
patient O
had O
an O
asymptomatic O
cerebral O
in O
the O
and O
a O
small O
parietal O
lobe O
was O
diagnosed O
to O
be O
. O

 O
Given O
all O
these O
observations O
, O
he O
was O
diagnosed O
with O
right O
lung O
carcinoma B
, O
( O
) O
. O

 O
He O
was O
treated O
according O
to O
the O
regimens O
( O
& O
) O
known O
to O
be O
effective O
for O
the O
treatment O
of O
advanced O
non O
- O
small O
cell O
lung O
cancer O
. O

 O
He O
responded O
to O
the O
treatment O
and O
showed O
a O
good O
afterwards O
( O
Fig.3 O
) O
. O

 O
with O
a O
total O
of O
of O
the O
same O
regimen O
was O
used O
and O
the O
was O
. O

 O
He O
has O
been O
for O
more O
than O
two O
years O
of O
and O
has O
been O
. O

The O
patient O
is O
a O
diagnosed O
with O
PD O
at O
the O
. O

 O
Fluctuations O
with O
recurring O
 O
off O
 O
states O
and O
peak O
dose O
dyskinesias O
had O
severely O
diminished O
the O
patient O
s O
quality O
of O
life O
. O

 O
Thus O
, O
the O
patient O
was O
deemed O
a O
candidate O
for O
bilateral O
subthalamic O
DBS O
. O

 O
Multidisciplinary O
evaluation O
with O
75 O
% O
positive O
response O
in O
the O
standardized O
levodopa O
test O
, O
exclusion O
of O
cognitive O
decline O
or O
psychiatric O
comorbitity O
, O
and O
absence O
of O
structural O
brain O
damage O
potentially O
relevant O
to O
the O
lead O
placement O
led O
to O
the O
unanimous O
decision O
for O
DBS O
placement O
. O

 O
When O
decision O
was O
made O
to O
proceed O
to O
surgery O
the O
medication O
consisted O
of O
1112.5 O
mg O
of O
levodopa O
and O
150 O
mg O
of O
piribedil O
. O

 O
There O
was O
no O
history O
of O
orofacial O
or O
cervical O
dystonia O
. O

 O
In O
the O
 O
on O
 O
state O
the O
patient O
was O
alert O
without O
any O
signs O
of O
psychiatric O
comorbidity O
. O

 O
Neuropsychological O
testing O
was O
adequate O
. O

 O
No O
cranial O
nerve O
deficits O
were O
found O
and O
swallowing O
was O
normal O
. O

 O
Gait O
and O
postural O
stability O
was O
normal O
with O
minimal O
rigidity O
in O
the O
neck O
and O
right O
arm O
. O

 O
Coordinative O
motor O
skills O
such O
as O
rapid O
pro- O
and O
supination O
were O
restricted O
in O
the O
left O
hand O
. O

 O
Dyskinesias O
were O
evident O
with O
moderate O
impairment O
. O

 O
In O
the O
 O
off O
 O
state O
after O
the O
medication O
was O
held O
for O
12 O
h O
, O
the O
patient O
showed O
mild O
dysarthria O
and O
dysphonia O
, O
resting O
tremor O
of O
the O
right O
arm O
and O
leg O
, O
as O
well O
as O
slight O
action O
tremor O
in O
the O
right O
hand O
. O

 O
Rigidity O
was O
severe O
in O
the O
neck O
, O
marked O
in O
the O
right O
, O
and O
mild O
on O
the O
left O
side O
. O

 O
Motor O
skills O
of O
the O
hands O
were O
markedly O
impaired O
. O

 O
Gait O
was O
slow O
but O
unaided O
and O
comprised O
of O
by O
intermittent O
freezing O
; O
there O
was O
mild O
dystonic O
posturing O
of O
the O
right O
foot O
. O

 O
There O
were O
no O
signs O
of O
laryngeal O
spasms O
, O
however O
. O

 O
On O
the O
day O
before O
surgery O
, O
the O
last O
dose O
of O
dopaminergic O
medication O
was O
administered O
at O
07:00 O
p.m. O
, O
the O
bedtime O
dose O
of O
levodopa O
was O
held O
to O
facilitate O
intraoperative O
testing O
. O

 O
On O
the O
day O
of O
the O
operation O
, O
the O
patient O
underwent O
placement O
of O
the O
stereotactic O
frame O
under O
local O
anaesthesia O
around O
09:00 O
a.m. O

 O
After O
planning O
standard O
STN O
coordinates O
and O
trajectories O
, O
the O
patient O
was O
placed O
in O
a O
semi O
- O
sitting O
position O
on O
the O
O.R. O

 O
table O
, O
with O
the O
frame O
attached O
to O
the O
table O
. O

 O
At O
the O
patient O
s O
request O
, O
the O
head O
was O
slightly O
flexed O
anteriorly O
for O
comfort O
. O

 O
The O
left O
electrode O
was O
placed O
uneventfully O
. O

 O
When O
performing O
the O
bur O
hole O
on O
the O
right O
side O
, O
the O
patient O
complained O
of O
cramping O
in O
the O
neck O
and O
facial O
muscles O
as O
well O
as O
difficulties O
breathing O
although O
at O
that O
point O
, O
pulse O
oximetry O
showed O
good O
saturation O
readings O
at O
95 O
% O
. O

 O
He O
progressed O
to O
dystonic O
dysarthria O
[ O
6 O
] O
. O

 O
Microelectrode O
recordings O
had O
already O
been O
done O
and O
macroelectrode O
test O
stimulation O
was O
about O
to O
begin O
, O
when O
the O
patient O
showed O
high O
- O
pitched O
inspiratory O
stridor O
. O

 O
Pulse O
oximetry O
showed O
decreasing O
oxygen O
saturation O
at O
02:15 O
p.m. O

 O
and O
, O
shortly O
thereafter O
, O
narrow O
complex O
tachycardia O
was O
noted O
. O

 O
Within O
a O
minute O
, O
the O
patient O
became O
unresponsive O
. O

 O
Cardiac O
resuscitation O
was O
initiated O
and O
the O
patient O
was O
fiberoptically O
intubated O
after O
removal O
of O
the O
front O
bar O
of O
the O
stereotactic O
frame O
. O

 O
During O
fiberoptic O
intubation O
laryngeal O
spasm O
was O
confirmed O
visually O
. O

 O
A O
transthoracic O
echocardiogram O
obtained O
immediately O
after O
successful O
resuscitation O
showed O
no O
cardiac O
pathology O
or O
any O
air O
bubbles O
. O

 O
Stimulation O
using O
the O
implanted O
lead O
to O
resolve O
the O
symptoms O
was O
not O
possible O
as O
at O
that O
time O
the O
lead O
was O
subcutaneously O
tunnelled O
with O
no O
impulse O
generator O
attached O
. O

 O
The O
right O
permanent O
electrode O
was O
placed O
without O
further O
testing O
according O
to O
microelectrode O
recordings O
. O

 O
50 O
mg O
levodopa O
was O
administered O
over O
a O
nasogastric O
tube O
every O
two O
hours O
during O
the O
subsequent O
postoperative O
period O
. O

 O
Postoperative O
head O
CT O
scan O
done O
immediately O
after O
the O
procedure O
was O
normal O
. O

 O
The O
patient O
was O
transferred O
to O
the O
intensive O
care O
unit O
and O
was O
extubated O
at O
02:00 O
p.m. O

 O
the O
following O
day O
without O
any O
neurological O
deficit O
or O
signs O
of O
laryngeal O
spasms O
. O

 O
By O
then O
, O
the O
nasogastric O
tube O
was O
discontinued O
and O
the O
preoperative O
medication O
was O
resumed O
. O

 O
Cardiac O
workup O
was O
negative O
. O

 O
The O
impulse O
generator O
was O
implanted O
and O
the O
patient O
showed O
good O
symptom O
control O
of O
PD B
. O

A O
presented O
with O
left O
flank O
dull O
. O

 O
On O
the O
abdominal O
, O
a O
solid O
renal O
in O
the O
was O
identified O
. O

 O
The O
was O
measured O
in O
size O
, O
was O
. O

 O
The O
patient O
had O
no O
, O
such O
as O
suspected O
distant O
or O
lymph O
node O
. O

 O
Radical O
was O
performed O
on O
. O

 O
On O
, O
the O
measured O
and O
the O
was O
a O
solid O
, O
measured O
in O
size O
. O

 O
demonstrated O
trabecular O
and O
ribbonlike O
patterns O
with O
minimal O
fibrotic O
stroma O
. O

 O
The O
was O
and O
with O
with O
and O
. O

 O
Mitoses O
were O
not O
found O
( O
0 O
per O
10 O
high O
- O
power O
fields O
) O
on O
. O

 O
The O
final O
revealed O
a O
well O
- O
differentiated O
neuroendocrine B
( I
carcinoid I
) I
tumor I
confined O
to O
the O
( O
Fig.1 O
) O
. O

 O
demonstrated O
labeling O
with O
, O
and O
( O
Fig.2 O
) O
, O
and O
the O
was O
as O
measured O
by O
. O

 O
Further O
and O
were O
not O
received O
. O

 O
radical O
nephrectomy O
, O
of O
the O
demonstrated O
a O
2 O
cm O
 O
 O
 O
1.8 O
cm O
cyst O
in O
the O
and O
multiple O
in O
. O

 O
No O
were O
found O
in O
the O
. O

 O
and O
for O
hepatic B
cyst I
were O
performed O
by O
. O

 O
demonstrated O
( O
Fig.3 O
) O
, O
and O
( O
) O
. O

 O
Advanced O
revealed O
that O
the O
was O
for O
( O
Fig.4 O
) O
and O
CD56 O
, O
but O
negative O
for O
and O
. O

 O
These O
features O
are O
supported O
in O
a O
neuroendocrine B
tumor I
. O

 O
Due O
to O
the O
similar O
pathologic O
characteristics O
between O
the O
primary O
renal O
carcinoid O
tumor O
and O
liver O
tumor O
. O

 O
The O
final O
pathology O
report O
indicated O
a O
carcinoid B
tumor I
of O
the O
with O
liver O
. O

A O
presented O
in O
the O
, O
with O
, O
, O
lower O
extremities O
swelling O
, O
. O

 O
She O
had O
a O
history O
of O
diagnosed O
by O
her O
and O
history O
of O
cardiac B
failure I
NYHA O
( O
New O
York O
Heart O
Association O
) O
class O
. O

 O
revealed O
an O
irregular O
pulse O
, O
of O
, O
on O
chest O
, O
. O

 O
revealed O
a O
IVth O
degree O
at O
the O
. O

 O
The O
jugular O
veins O
were O
. O

 O
The O
patient O
complained O
of O
in O
the O
, O
. O

 O
The O
liver O
margin O
was O
tender O
, O
round O
, O
of O
6 O
cm O
below O
the O
costal O
rib O
, O
with O
a O
smooth O
liver O
surface O
. O

 O
The O
spleen O
could O
not O
be O
felt O
. O

 O
: O
of O
, O
, O
infero O
- O
lateral O
. O

 O
Transabdominal O
showed O
a O
homogenous O
, O
. O

 O
The O
suprahepatic O
veins O
were O
, O
as O
well O
as O
the O
( O
, O
without O
respiratory O
variations O
) O
. O

 O
revealed O
a O
of O
( O
Figure O
1 O
) O
, O
of O
, O
of O
, O
of O
. O

 O
Atrial O
septal O
defect O
ostium O
secundum O
type O
, O
of O
6 O
cm O
( O
Figure O
2 O
) O
, O
with O
left O
 O
to O
 O
right O
shunt O
. O

 O
Severe O
tricuspid O
insufficiency O
with O
maximum O
gradient O
of O
55,4 O
mm O
Hg O
. O

 O
4th O
degree O
mitral B
insufficiency I
. O

 O
Severe O
pulmonary O
of O
. O

 O
The O
of O
. O

 O
. O

 O
Interventricular O
sept O
with O
paradoxical O
motion O
. O

 O
of O
the O
( O
Figure O
3 O
) O
. O

 O
The O
diagnosis O
was O
IVth O
degree O
chronic B
heart I
failure I
NYHA O
. O

 O

 O

 O

 O

 O

 O
. O

The O
patient O
presented O
to O
the O
closest O
emergency O
department O
at O
8 O
PM O
for O
nausea O
, O
numbness O
of O
the O
left O
limbs O
, O
incoordination O
of O
walking O
and O
dysarthria O
, O
with O
the O
symptomatology O
installed O
in O
a O
progressive O
mode O
4 O
hours O
before O
presentation O
. O

 O
The O
nausea O
was O
the O
initial O
symptom O
, O
starting O
at O
4 O
PM O
( O
without O
headache O
, O
nuchal O
pain O
, O
or O
vomit O
) O
and O
then O
, O
after O
5.30 O
PM O
, O
the O
numbness O
of O
the O
left O
limbs O
and O
the O
incoordination O
of O
walking O
and O
by O
7 O
PM O
dysarthria O
was O
added O
to O
the O
entire O
clinical O
constellation O
. O

 O
. O

 O
He O
was O
a O
. O

 O
. O

 O
. O

 O
. O

 O
He O
was O
first O
by O
a O
in O
the O
and O
had O
a O
brain O
scan O
that O
highlighted O
infracentimetric O
in O
the O
, O
on O
the O
and O
at O
the O
in O
the O
, O
and O
also O
a O
chest O
that O
revealed O
a O
of O
the O
, O
without O
any O
. O

 O
Following O
this O
evaluation O
, O
he O
was O
to O
the O
for O
and O
. O

 O
During O
the O
ambulance O
, O
he O
had O
repeated O
episodes O
of O
. O

 O
The O
initial O
( O
at O
) O
showed O
normal O
: O
, O
and O
normal O
. O

 O
The O
was O
. O

 O
No O
were O
registered O
. O

 O
The O
was O
notable O
for O
. O

 O
The O
patient O
had O
equal O
, O
reactive O
, O
divergent O
to O
the O
, O
horizontal O
, O
normal O
, O
mild O
paresis B
of O
the O
, O
ataxia B
of O
, O
with O
an O
, O
of O
the O
, O
bilateral O
response O
present O
at O
all O
deep O
tendons O
, O
on O
the O
, O
stereotypical O
. O

 O
The O
patient O
was O
and O
to O
. O

 O
The O
highlighted O
a O
normal O
, O
normal O
level O
( O
normal O
range O
3,9 O
- O
5,8mmol/ O
L O
) O
, O
( O
range O
0,5 O
- O
0,9mmol/ O
L O
) O
, O
( O
normal O
range O
< O
5,2 O
mmol/ O
L O
) O
. O

 O
The O
tests O
for O
were O
. O

 O
He O
also O
presented O
a O
normal O
on O
the O
. O

 O
The O
brain O
performed O
at O
the O
first O
emergency O
unit O
, O
as O
mentioned O
above O
, O
revealed O
a O
infracentimetric O
at O
the O
and O
at O
the O
in O
the O
. O

 O
Doppler O
for O
highlighted O
the O
marked O
frena O
in O
the O
of O
the O
, O
an O
accentuated O
aspect O
in O
the O
high O
V2 O
segments O
with O
the O
complete O
disappearance O
of O
the O
in O
the O
, O
without O
carotid O
atheromatous O
or O
. O

 O
Overall O
, O
there O
was O
a O
possibility O
of O
a O
dissection B
of O
the O
in O
the O
with O
indication O
of O
cerebral O
and O
angio O
. O

 O
Cerebral O
and O
angio O
showed O
: O
areas O
with O
T2 O
, O
, O
with O
an O
important O
and O
low O
, O
situated O
in O
the O
, O
, O
, O
, O
as O
well O
as O
, O
with O
an O
that O
was O
recently O
constituted O
. O

 O
was O
present O
on O
the O
and O
the O
. O

 O
On O
the O
sequence O
, O
the O
presence O
of O
the O
rapid O
of O
the O
could O
be O
viewed O
, O
, O
where O
there O
was O
a O
progressive O
with O
an O
aspect O
of O
. O

 O
Distal O
of O
this O
level O
, O
there O
was O
an O
absence O
of O
the O
signal O
and O
also O
a O
lack O
of O
. O

 O
The O
aspect O
suggested O
a O
subacute O
dissection B
of O
the O
. O

 O
The O
cerebral O
ventricular O
system O
had O
normal O
, O
, O
and O
. O

 O
The O
pericerebral O
fluid O
spaces O
and O
the O
basal O
cisterns O
were O
normal O
. O

 O
Conclusions O
: O
there O
were O
some O
ischemic O
lesions O
recently O
constituted O
in O
the O
vertebrobasilar O
territory O
and O
also O
a O
subacute O
dissection O
of O
the O
right O
vertebral O
artery O
. O

 O
administration O
was O
started O
immediately O
in O
the O
process O
of O
hospitalization O
because O
of O
the O
dissection O
. O

 O
The O
was O
kept O
in O
the O
. O

 O
Also O
, O
the O
for O
was O
performed O
. O

 O
from O
the O
debut O
, O
the O
patient O
was O
transitioned O
to O
for O
long O
- O
term O
anticoagulation O
. O

 O
The O
treatment O
with O
acenocumarol O
was O
instituted O
with O
the O
heparin O
overlap O
until O
getting O
the O
in O
the O
. O

 O
The O
was O
, O
the O
patient O
regaining O
the O
and O
the O
capacity O
for O
. O

 O
The O
ataxia B
was O
and O
, O
but O
registered O
a O
lot O
of O
improvement O
. O

 O
The O
patient O
was O
with O
the O
. O

 O
The O
was O
not O
possible O
because O
the O
patient O
did O
not O
return O
to O
the O
hospital O
. O

A O
with O
a O
5 O
- O
month O
history O
of O
recurring O
sinusitis O
presented O
with O
, O
, O
, O
and O
. O

 O
Thoracic O
revealed O
reduced O
, O
and O
chest O
showed O
bilateral O
diffuse O
alveolar O
. O

 O
showed O
elevation O
of O
( O
) O
and O
( O
) O
with O
nonnephrotic O
and O
microscopic O
glomerular O
. O

 O
An O
for O
community O
acquired O
and O
atypical O
pneumoniae O
with O
levofloxacin O
500 O
 O
mg O
daily O
iv O
was O
established O
, O
but O
on O
the O
3rd O
day O
from O
admission O
the O
patient O
developed O
respiratory O
failure O
unresponsive O
to O
noninvasive O
ventilation O
and O
had O
to O
be O
intubated O
. O

 O
White O
lung O
with O
consolidations O
and O
ground O
glass O
areas O
at O
computed O
tomography O
scan O
( O
Fig.1 O
) O
, O
diffuse O
airways O
bleeding O
at O
fiberoptic O
bronchoscopy O
, O
mild O
normocytic O
anemia O
( O
9 O
 O
g O
/ O
dL O
) O
, O
and O
ANCA O
- O
PR3 O
positivity O
( O
18.9 O
 O
U O
/ O
mL O
) O
were O
consistent O
with O
the O
diagnosis O
of O
GPA O
. O

 O
Despite O
maximal O
ventilatory O
support O
, O
gas O
exchange O
did O
not O
improve O
( O
pH O
7.33 O
, O
PaO2 O
71 O
 O
mm O
 O
Hg O
, O
PaCO2 O
51 O
 O
mm O
 O
Hg O
, O
HCO3 O
 O
25 O
 O
mmol O
/ O
L O
, O
SaO2 O
94 O
% O
) O
requiring O
extracorporeal O
membrane O
oxygenation O
( O
ECMO O
) O
. O

 O
Treatment O
with O
high O
- O
dose O
methylprednisolone O
( O
1 O
 O
g O
daily O
for O
3 O
days O
and O
1 O
 O
mg O
/ O
kg O
daily O
thereafter O
) O
, O
cyclophosphamide O
( O
1.2 O
 O
g O
/ O
pulse O
every O
2 O
weeks O
for O
the O
1st O
3 O
pulses O
, O
followed O
by O
infusions O
every O
3 O
weeks O
for O
the O
next O
2 O
pulses O
) O
, O
and O
plasma O
exchange O
( O
PE O
) O
, O
according O
to O
European O
vasculitis O
study O
group O
recommendations,[4 O
] O
was O
immediately O
started O
with O
respiratory O
improvement O
that O
allowed O
ECMO O
and O
orotracheal O
tube O
withdrawal O
and O
subsequent O
discharge O
from O
intensive O
care O
unit O
. O

 O
After O
9 O
days O
from O
the O
beginning O
of O
treatment O
ANCA O
- O
PR3 O
levels O
normalized O
( O
3 O
 O
U O
/ O
mL O
) O
. O

 O
Two O
months O
later O
, O
after O
the O
5th O
bolus O
of O
cyclophosphamide O
and O
with O
prednisone O
0.3 O
 O
mg O
/ O
kg O
/ O
day O
, O
the O
patient O
complained O
arthromyalgia O
and O
testicular O
pain O
with O
edema O
, O
cough O
, O
and O
shortness O
of O
breath O
: O
laboratory O
data O
showed O
worsening O
of O
renal O
function O
, O
mild O
anemia O
, O
and O
hypoxemia O
( O
PaO2 O
61 O
 O
mm O
 O
Hg O
) O
. O

 O
Epididymitis O
was O
confirmed O
by O
ultrasound O
. O

 O
Because O
of O
rapidly O
progressive O
renal O
failure O
( O
estimated O
glomerular O
filtration O
rate O
35 O
 O
mL O
/ O
min O
) O
renal O
biopsy O
was O
performed O
and O
showed O
prominent O
intracapillary O
and O
extracapillary O
proliferation O
, O
with O
the O
formation O
of O
some O
fibrocellular O
crescents O
and O
focal O
capillary O
necrosis O
( O
Fig.2 O
) O
. O

 O
Lung O
computed O
tomography O
- O
scan O
and O
fiberoptic O
bronchoscopy O
also O
confirmed O
alveolar O
hemorrhage O
relapse O
. O

 O
Treatment O
with O
high O
- O
dose O
methylprednisolone O
( O
1 O
 O
g O
daily O
for O
3 O
consecutive O
days O
) O
and O
rituximab O
( O
375 O
 O
mg O
/ O
m2 O
weekly O
for O
4 O
weeks O
) O
was O
started O
with O
rapid O
resolution O
of O
urologic O
and O
pulmonary O
involvement O
but O
delayed O
and O
partial O
improvement O
of O
renal O
function O
. O

 O
At O
a O
1 O
- O
year O
, O
the O
patient O
is O
and O
under O
treatment O
with O
( O
) O
and O
( O
) O
. O

 O
has O
( O
estimated O
) O
same O
as O
( O
7.42 O
, O
86 O
 O
mm O
 O
Hg O
, O
36 O
 O
mm O
 O
Hg O
, O
 O
23 O
 O
mmol O
/ O
L O
, O
) O
. O

 O
The O
patient O
signed O
institutional O
informed O
consent O
form O
at O
the O
time O
of O
admission O
to O
hospitalization O
. O

 O
An O
approval O
by O
ethics O
committee O
was O
not O
necessary O
because O
of O
the O
routine O
health O
care O
. O

We O
present O
a O
case O
of O
pancreatic O
tumor O
without O
a O
history O
of O
trauma O
or O
panceratitis O
. O

 O
A O
with O
a O
history O
of O
was O
to O
the O
in O
because O
of O
fluid O
chronic O
with O
4 O
with O
out O
is O
associated O
with O
vomiting O
with O
out O
abdominal O
pain O
or O
fever O
with O
a O
weight O
loss O
not O
encrypted O
dating O
. O

 O
were O
. O

 O
Nonspecific O
elevations O
of O
serum O
. O

 O
Patient O
underwent O
an O
abdominal O
and O
( O
) O
that O
revealed O
: O
Aspect O
of O
ileitis O
of O
the O
last O
ileal O
loop O
extended O
by O
300 O
mm O
with O
distended O
ileal O
loops O
upstream O
, O
cystic O
image O
at O
the O
tail O
of O
the O
pancreas O
with O
clean O
wall O
uncalcified O
and O
hypodense O
content O
of O
fluid O
density O
without O
endoluminal O
bourgeon O
or O
pancreatic O
duct O
dilatation O
, O
measuring O
28 O
x O
22 O
mm O
( O
Figure O
1 O
) O
. O

 O
The O
of O
the O
was O
. O

 O
There O
were O
no O
( O
Figure O
2 O
) O
. O

 O
Aspect O
of O
bilateral O
sacroiliitis B
and O
bilateral O
coxarthrosis B
. O

 O
show O
an O
aspect O
of O
ileitis O
of O
the O
last O
ileal O
loop O
and O
the O
cystic O
nature O
of O
a O
pancreatic O
lesion O
, O
with O
parietal O
enhancement O
at O
the O
caudal O
portion O
of O
the O
pancreas O
with O
a O
slight O
dilation O
of O
the O
Wirsung O
. O

 O
Otherwise O
, O
gallbladder O
contains O
multiple O
gallstones O
and O
biliary O
sludge O
. O

 O
Tumor O
markers O
are O
normal.on O
the O
other O
hand O
, O
in O
colonoscopy O
terminal O
ileum O
appears O
swollen O
, O
inflamed O
, O
with O
frequent O
ulcerations O
and O
biopsies O
were O
made O
. O

 O
The O
biopsies O
were O
taken O
and O
show O
a O
subacute O
and O
ulcerative O
ileitis O
compatible O
with O
Crohn O
's O
disease O
. O

 O
Esophagogastroduodenoscopy O
was O
normal O
. O

 O
The O
patient O
was O
operated O
by O
laparoscopy O
, O
he O
had O
a O
caudal O
pancreatectomy O
and O
cholecystectomy O
.1.5 O
cm O
cystic O
tumor O
in O
the O
tail O
of O
pancreas O
was O
resected O
and O
sent O
for O
pathological O
examination O
. O

 O
The O
was O
uneventful O
. O

 O
Patient O
was O
in O
a O
good O
. O

 O
There O
were O
no O
after O
normal O
administration O
. O

 O
The O
revealed O
well O
differentiated O
cystic O
neuro B
endocrine I
tumor I
of O
the O
according O
to O
the O
classification O
of O
WHO O
2010 O
( O
mitosis O
< O
2/10CFG O
and O
Ki67<2 O
% O
) O
associated O
with O
neuroendocrine O
hyperplasia O
lesions O
of O
islets O
of O
Langerhans O
, O
surgical O
limit O
was O
healthy O
, O
pTNM O
pT2 O
, O
ectopic O
spleen O
, O
chronic O
cholecystitis O
. O

 O
the O
patient O
come O
for O
at O
the O
, O
he O
, O
with O
no O
severe O
and O
with O
correct O
periodic O
findings O
and O
normal O
. O

A O
underwent O
for O
the O
treatment O
of O
a O
metachronous O
solitary O
liver O
metastasis O
from O
rectal O
adenocarcinoma B
, O
which O
had O
been O
with O
preoperative O
and O
. O

 O
The O
lesion O
was O
located O
in O
. O

 O
The O
procedure O
went O
well O
and O
the O
patient O
was O
initially O
haemodynamically O
stable O
. O

 O
her O
. O

 O
She O
was O
clinically O
and O
had O
and O
. O

 O
We O
detected O
and O
. O

 O
Emergency O
showed O
a O
of O
and O
markedly O
elevated O
. O

 O
A O
revealed O
an O
accumulation O
of O
intraperitoneal O
fluid O
in O
the O
and O
two O
liver O
haematomas B
. O

 O
The O
showed O
, O
( O
Figure O
(Figure1A1A--C)C O
) O
and O
another O
, O
( O
Figure O
(Figure2).2 O
) O
. O

 O
The O
patient O
had O
no O
serious O
or O
after O
the O
, O
or O
any O
other O
complications O
that O
might O
have O
caused O
increased O
abdominal O
pressure O
and O
tumour O
rupture O
. O

 O
Subsequently O
, O
the O
patient O
received O
a O
and O
. O

 O
She O
was O
after O
the O
second O
and O
. O

 O
The O
patient O
remained O
in O
bed O
for O
. O

 O
No O
was O
required O
. O

A O
with O
complaints O
of O
and O
for O
; O
she O
also O
complained O
of O
intermittent O
type O
of O
in O
the O
. O

 O
revealed O
presence O
of O
and O
a O
palpable O
tender O
globular O
in O
the O
measuring O
. O

 O
A O
clinical O
diagnosis O
of O
obstructive O
secondary O
to O
periampullary B
carcinoma I
was O
made O
. O

 O
of O
the O
and O
revealed O
( O
) O
, O
with O
multiple O
freely O
mobile O
and O
a O
( O
) O
measuring O
with O
. O

 O
showed O
moderate O
, O
with O
suspicious O
at O
the O
, O
and O
a O
distal O
CBD O
. O

 O
There O
was O
no O
evidence O
of O
any O
distant O
( O
Fig.1 O
) O
. O

 O
A O
preoperative O
diagnosis O
of O
periampullary B
carcinoma I
with O
chronic B
cholecystitis I
was O
made O
, O
and O
the O
patient O
planned O
for O
a O
( O
) O
after O
optimization O
. O

 O
The O
patient O
underwent O
a O
classical O
; O
of O
the O
revealed O
multiple O
in O
the O
with O
area O
of O
at O
the O
and O
an O
irregular O
circumferential O
involving O
the O
. O

 O
was O
, O
and O
the O
patient O
. O

 O
of O
the O
( O
Figs.2 O
and O
3 O
) O
revealed O
at O
the O
with O
multiple O
small O
, O
the O
largest O
measuring O
( O
Fig.3 O
) O
. O

 O
Sections O
studied O
from O
the O
area O
of O
thickening O
showed O
features O
suggestive O
of O
adenocarcinoma B
limited O
to O
the O
. O

 O
obtained O
from O
the O
distal O
CBD O
region O
showed O
adenocarcinoma B
of O
the O
with O
into O
the O
. O

 O
studied O
from O
the O
were O
free O
of O
. O

 O
A O
pathological O
staging O
of O
pT1aN0M0 O
for O
adenocarcinoma O
of O
the O
gall O
bladder O
and O
pT2N0M0 O
for O
adenocarcinoma O
of O
the O
distal O
CBD O
was O
made O
, O
and O
the O
patient O
was O
not O
subjected O
to O
any O
. O

 O
The O
patient O
was O
disease O
- O
free O
. O

A O
was O
to O
the O
general O
surgery O
department O
of O
our O
hospital O
for O
a O
one O
- O
month O
history O
of O
progressive O
dysphagia O
for O
solids O
, O
which O
was O
not O
associated O
with O
malnutrition O
or O
significant O
weight O
loss O
. O

 O
The O
patient O
had O
recently O
undergone O
esophagogastroduodenoscopy O
in O
another O
hospital O
, O
which O
revealed O
a O
bleeding O
, O
ulcerative O
lesion O
in O
the O
middle O
third O
of O
the O
esophagus O
, O
but O
no O
biopsy O
had O
been O
collected O
. O

 O
The O
medical O
past O
history O
included O
COPD O
diagnosed O
in O
1999 O
and O
a O
myocardial O
infarction O
in O
2002 O
. O

 O
The O
patient O
had O
smoked O
approximately O
25 O
cigarettes O
per O
day O
for O
several O
years O
. O

 O
Physical O
examination O
was O
unremarkable O
. O

 O
Computed O
tomography O
( O
CT O
) O
of O
the O
chest O
and O
abdomen O
revealed O
stenosis O
involving O
a O
5 O
- O
cm O
segment O
of O
the O
middle O
third O
of O
the O
esophagus O
with O
no O
other O
lesions O
in O
the O
thoracic O
or O
abdominal O
organs O
. O

 O
Barium O
studies O
disclosed O
a O
swelling O
in O
the O
esophageal O
wall O
7 O
cm O
above O
the O
cardia O
with O
an O
ulcerative O
pattern O
, O
which O
reduced O
the O
diameter O
of O
the O
lumen O
to O
5 O
mm O
. O

 O
An O
endoscopic O
biopsy O
of O
the O
oesophageal O
mass O
demonstrated O
poorly O
differentiated O
( O
G3 O
) O
squamous O
cell O
carcinoma O
. O

 O
Mid O
- O
distal O
esophagectomy O
was O
performed O
with O
oesophagogastric O
anastomosis O
and O
gastric O
tube O
reconstruction O
. O

 O
Pathological O
examination O
of O
the O
surgical O
specimen O
confirmed O
the O
biopsy O
diagnosis O
of O
poorly O
differentiated O
( O
G3 O
) O
SCC O
. O

 O
The O
tumor O
, O
which O
measured O
3 O
cm O
of O
length O
, O
had O
infiltrated O
the O
oesophageal O
wall O
and O
the O
surrounding O
paraesophageal O
fat O
. O

 O
Surgical O
margins O
were O
tumor O
- O
free O
, O
as O
the O
seven O
perigastric O
limph O
- O
nodes O
dissected O
( O
pT3 O
N0 O
) O
. O

 O
The O
postoperative O
period O
was O
quite O
unremarkable O
, O
and O
a O
contrast O
enhanced O
x O
- O
ray O
obtained O
on O
the O
9th O
POD O
showed O
normal O
esophageal O
and O
gastric O
transit O
. O

 O
On O
the O
14th O
POD O
, O
the O
patient O
was O
discharged O
with O
an O
oncology O
referral O
for O
routine O
medical O
follow O
- O
up O
. O

 O
Nine O
months O
after O
the O
operation O
, O
CT O
and O
esophagogastroduodenoscopy O
were O
repeated O
. O

 O
The O
imaging O
study O
revealed O
mild O
splenomegaly O
with O
multiple O
nonspecific O
nodules O
within O
the O
organ O
( O
Figure O
1 O
) O
. O

 O
The O
patient O
was O
virtually O
asymptomatic O
with O
the O
exception O
of O
a O
vague O
sensation O
of O
mild O
discomfort O
in O
the O
left O
upper O
quadrant O
of O
the O
abdomen O
. O

 O
FNAC O
of O
the O
spleen O
revealed O
a O
pattern O
of O
numerous O
inflammatory O
cells O
admixed O
with O
large O
cells O
displaying O
immunohistochemical O
positivity O
for O
several O
cytokeratins O
( O
Figure O
2 O
) O
. O

 O
The O
specimen O
was O
Gram O
stain O
- O
negative O
. O

 O
A O
bone O
- O
marrow O
biopsy O
was O
negative O
for O
metastatic O
involvement O
. O

 O
The O
diagnosis O
was O
isolated O
metastases O
of O
the O
spleen O
with O
inflammatory O
and O
necrotic O
alterations O
. O

 O
The O
patient O
was O
referred O
to O
our O
centre O
for O
splenectomy O
, O
which O
was O
performed O
as O
a O
routine O
procedure O
to O
role O
out O
, O
also O
, O
a O
spontaneous O
rupture O
of O
the O
spleen O
. O

 O
On O
12th O
December O
2007 O
, O
the O
patient O
had O
transabdominal O
total O
splenectomy O
with O
splenic O
and O
celiac O
artery O
lymph O
node O
dissection O
. O

 O
The O
postoperative O
course O
was O
uneventful O
. O

 O
On O
the O
7th O
postoperative O
day O
, O
Doppler O
ultrasonography O
revealed O
portal O
- O
tree O
patency O
with O
no O
signs O
of O
thrombosis O
. O

 O
Ten O
days O
later O
, O
the O
patient O
was O
discharged O
with O
a O
stable O
platelet O
count O
( O
780,000 O
/ O
mm3 O
) O
, O
Hb O
10.9 O
g O
/ O
dL O
, O
and O
a O
WBC O
count O
of O
16,500 O
/ O
mm3 O
. O

 O
Pathological O
examination O
of O
the O
spleen O
described O
multiple O
nodules O
containing O
medium O
to O
large O
- O
sized O
cells O
, O
some O
of O
which O
were O
keratinized O
. O

 O
The O
nodules O
were O
mostly O
solid O
with O
areas O
of O
central O
necrosis O
( O
Figure O
3 O
) O
. O

 O
The O
findings O
were O
consistent O
with O
metastases O
of O
SCC O
. O

 O
Thereafter O
, O
the O
patient O
was O
referred O
to O
the O
oncology O
department O
of O
our O
hospital O
, O
where O
he O
received O
two O
3 O
- O
day O
cycles O
( O
separated O
by O
a O
3 O
- O
week O
interval O
) O
of O
systemic O
chemotherapy O
based O
on O
5 O
- O
fluorouracil O
( O
800 O
mg O
/ O
day O
IV O
) O
and O
cisplatin O
( O
20 O
mg O
/ O
day O
) O
. O

 O
Three O
months O
after O
the O
splenectomy O
, O
multiple O
liver O
metastases O
were O
seen O
on O
the O
CT O
scan O
, O
and O
cutaneous O
metastases O
were O
also O
present O
. O

 O
The O
patient O
. O

A O
was O
found O
lying O
down O
after O
1012 O
hours O
of O
. O

 O
She O
was O
taken O
to O
an O
outlying O
( O
) O
, O
and O
subsequently O
to O
our O
with O
and O
and O
for O
further O
management O
. O

 O
She O
had O
a O
past O
history O
of O
, O
congestive O
heart O
failure O
, O
controlled O
hypertension O
, O
and O
alcoholism O
. O

 O
She O
. O

 O
On O
, O
she O
had O
a O
of O
, O
of O
, O
, O
( O
) O
. O

 O
on O
showed O
a O
of O
, O
60 O
, O
61 O
mm O
/ O
Hg O
, O
29 O
mEq O
/ O
L O
, O
and O
which O
improved O
to O
with O
by O
a O
. O

 O
On O
she O
was O
, O
, O
, O
but O
without O
. O

 O
Scattered O
were O
noted O
along O
with O
normal O
. O

 O
The O
remaining O
results O
of O
her O
physical O
examination O
and O
routine O
were O
with O
the O
exception O
of O
a O
of O
with O
. O

 O
Repeated O
were O
consistent O
with O
a O
normal O
but O
evidence O
of O
in O
the O
monitor O
. O

 O
Repeated O
on O
the O
showed O
: O
7.22 O
, O
78 O
, O
140 O
mm O
Hg O
, O
30 O
mEq O
/ O
L O
, O
and O
. O

 O
In O
the O
she O
was O
started O
on O
IV O
and O
for O
a O
COPD B
. O

 O
As O
part O
of O
the O
, O
she O
underwent O
a O
chest O
that O
did O
not O
show O
any O
or O
any O
major O
. O

 O
The O
was O
only O
significant O
for O
sinus O
. O

 O
Given O
the O
negative O
findings O
on O
chest O
x O
ray O
, O
sinus O
tachycardia O
on O
ECG O
, O
and O
an O
increased O
A O
- O
a O
gradient O
, O
the O
patient O
was O
sent O
for O
a O
spiral O
chest O
to O
rule O
out O
a O
pulmonary O
embolism B
. O

 O
During O
about O
100150 O
mL O
of O
air O
was O
inadvertently O
injected O
through O
the O
using O
a O
( O
estimated O
by O
the O
technician O
and O
approximation O
of O
volumes O
on O
available O
imaging O
) O
. O

 O
Concurrent O
( O
CT O
) O
showed O
a O
significant O
in O
the O
and O
( O
Figure O
1 O
) O
, O
and O
in O
the O
and O
its O
( O
Figure O
2 O
) O
. O

 O
Concurrently O
, O
a O
filling O
defect O
was O
noted O
in O
the O
right O
lower O
lobe O
artery O
consistent O
with O
pulmonary O
thromboembolism B
( O
Figures O
3 O
, O
,4).4 O
) O
. O

 O
The O
patient O
maintained O
with O
, O
and O
( O
) O
, O
and O
alone O
and O
she O
was O
to O
the O
( O
) O
for O
observation O
. O

 O
Her O
worsened O
, O
and O
she O
was O
placed O
temporarily O
on O
( O
) O
without O
and O
she O
was O
and O
placed O
on O
. O

 O
Intravenous O
full O
dose O
( O
) O
was O
initiated O
for O
treatment O
of O
concurrent O
thromboembolism B
. O

 O
did O
not O
show O
any O
evidence O
of O
. O

 O
Subsequent O
done O
did O
not O
show O
any O
evidence O
of O
intracardiac O
and O
complete O
resolution O
of O
the O
air O
embolism B
. O

 O
, O
she O
remained O
with O
no O
requirements O
of O
. O

 O
She O
was O
finally O
. O

 O
She O
was O
later O
on O
with O
subsequent O
outpatient O
. O

A O
with O
stage O
IV O
NSCLC B
was O
treated O
with O
and O
without O
disease O
response O
. O

 O
of O
was O
at O
that O
time O
. O

 O
However O
, O
her O
demographic O
profile O
( O
, O
minimal O
, O
non O
- O
small O
cell O
histology O
) O
predicted O
her O
disease O
would O
harbor O
EGFR O
TKI O
sensitive O
cells O
[ O
2 O
] O
. O

 O
Therefore O
, O
she O
then O
initiated O
standard O
daily O
dosing O
of O
( O
) O
and O
responded O
. O

 O
, O
she O
acquired O
resistance O
to O
with O
progression O
of O
. O

 O
Following O
further O
progression O
through O
an O
experimental O
angiogenesis O
inhibitor O
, O
she O
initiated O
pemetrexed O
and O
resumed O
standard O
dose O
erlotinib O
. O

 O
After O
initial O
response O
, O
11 O
months O
later O
, O
her O
disease O
again O
progressed O
. O

 O
DNA O
was O
extracted O
from O
biopsy O
of O
a O
progressing O
lung O
lesion O
and O
examined O
using O
established O
techniques O
for O
analysis O
of O
EGFR O
mutations O
[ O
5 O
] O
. O

 O
Direct O
sequencing O
of O
exons O
1821 O
encoding O
the O
kinase O
domain O
of O
EGFR O
revealed O
the O
L858R O
mutation O
associated O
with O
EGFR O
TKI O
sensitivity O
( O
Fig.1 O
) O
[ O
2 O
] O
. O

 O
It O
also O
demonstrated O
the O
T790 O
M O
mutation O
associated O
with O
acquired O
EGFR O
TKI O
resistance O
( O
Fig.1 O
) O
[ O
2 O
] O
. O

 O
She O
also O
developed O
headaches O
and O
there O
was O
a O
high O
clinical O
suspicion O
of O
CNS O
metastases O
despite O
negative O
imaging O
( O
not O
shown O
) O
. O

 O
She O
refused O
a O
lumbar O
puncture O
. O

 O
She O
initiated O
empiric O
temozolomide O
plus O
standard O
dose O
erlotinib O
( O
150 O
mg O
daily O
) O
for O
presumed O
CNS O
disease O
, O
but O
after O
one O
cycle O
her O
headaches O
worsened O
, O
and O
she O
developed O
nausea O
and O
vomiting O
concerning O
for O
CNS O
metastases O
with O
associated O
raised O
intracranial O
pressure O
. O

 O
Magnetic O
resonance O
imaging O
( O
MRI O
) O
of O
the O
brain O
now O
demonstrated O
LM O
( O
Fig.2 O
) O
confirmed O
by O
CSF O
cytology O
( O
not O
shown O
) O
. O

 O
By O
direct O
sequencing O
, O
DNA O
from O
CSF O
cells O
harbored O
L858R O
predicting O
EGFR O
TKI O
sensitivity O
( O
Fig.3 O
, O
left O
panel O
) O
but O
not O
the O
T790 O
M O
resistance O
mutation O
( O
data O
not O
shown O
) O
. O

 O
Because O
the O
result O
for O
T790 O
M O
was O
negative O
in O
this O
sample O
, O
we O
performed O
a O
more O
sensitive O
fluorescence O
detection O
PCR O
- O
based O
assay O
that O
takes O
advantage O
of O
a O
PCR O
restriction O
fragment O
length O
polymorphism O
generated O
by O
the O
specific O
missense O
mutation O
( O
Fig.3 O
, O
right O
panel O
, O
arrow O
, O
positive O
control O
) O
[ O
6 O
] O
. O

 O
That O
result O
was O
also O
negative O
, O
as O
only O
the O
wild O
type O
peak O
was O
detected O
( O
Fig.3 O
, O
right O
panel O
, O
bottom O
) O
. O

 O
Therefore O
, O
we O
hypothesized O
that O
the O
LM O
remained O
sensitive O
to O
an O
EGFR O
TKI O
if O
sufficiently O
high O
concentrations O
of O
drug O
could O
be O
achieved O
in O
the O
CSF O
. O

 O
The O
erlotinib O
concentration O
required O
to O
inhibit O
growth O
of O
cell O
lines O
harboring O
L858R O
by O
50 O
% O
( O
IC50 O
) O
is O
100 O
nM O
( O
nM O
) O
[ O
2 O
] O
. O

 O
Standard O
dose O
erlotinib O
( O
150 O
mg O
daily O
) O
achieves O
3000 O
nM O
in O
plasma O
[ O
7 O
] O
, O
but O
CSF O
concentrations O
of O
EGFR O
TKIs O
are O
as O
low O
as O
1 O
% O
plasma O
levels O
below O
the O
IC50 O
[ O
3 O
, O
8 O
] O
. O

 O
Increasing O
the O
daily O
dose O
of O
gefitinib O
to O
enhance O
CSF O
penetration O
has O
been O
an O
effective O
strategy O
[ O
3 O
] O
, O
but O
gefitinib O
is O
no O
longer O
available O
in O
the O
United O
States O
following O
failure O
in O
phase O
III O
NSCLC O
trials O
. O

 O
An O
analogous O
increase O
of O
the O
daily O
erlotinib O
dose O
above O
150200 O
mg O
daily O
induces O
unacceptable O
toxicity O
. O

 O
However O
, O
weekly O
high O
- O
dose O
erlotinib O
up O
to O
2000 O
mg O
is O
tolerable O
[ O
4 O
] O
. O

 O
Pharmacokinetic O
analysis O
of O
CSF O
from O
another O
patient O
with O
NSCLC O
LM O
( O
not O
shown O
) O
treated O
with O
1500 O
mg O
erlotinib O
weekly O
demonstrated O
a O
peak O
plasma O
concentration O
of O
11,300 O
nM O
with O
a O
concurrent O
CSF O
concentration O
of O
130 O
nM. O

 O
Therefore O
, O
such O
high O
dose O
weekly O
administration O
of O
erlotinib O
achieved O
a O
CSF O
concentration O
exceeding O
the O
IC50 O
. O

 O
Therefore O
, O
to O
increase O
CSF O
penetrance O
over O
standard O
daily O
erlotinib O
dosing O
in O
this O
patient O
, O
we O
initiated O
high O
- O
dose O
weekly O
erlotinib O
at O
1000 O
mg O
then O
1200 O
mg O
; O
persistent O
nausea O
precluded O
higher O
doses O
. O

 O
Pharmacokinetic O
analysis O
was O
not O
undertaken O
in O
this O
patient O
. O

 O
After O
1 O
month O
there O
was O
a O
partial O
radiographic O
response O
of O
LM O
on O
brain O
MRI O
( O
Fig.2b O
) O
and O
after O
2 O
months O
in O
the O
cauda O
equina O
( O
not O
shown O
) O
. O

 O
However O
, O
hydrocephalus O
and O
persistent O
symptoms O
referable O
to O
increased O
intracranial O
pressure O
led O
to O
a O
VP O
shunt O
and O
whole O
- O
brain O
radiation O
therapy O
, O
after O
which O
she O
resumed O
treatment O
with O
1500 O
mg O
weekly O
erlotinib O
. O

 O
One O
month O
later O
, O
progressive O
intra O
- O
thoracic O
disease O
led O
to O
initiation O
of O
cetixumab O
and O
erlotinib O
was O
continued O
but O
changed O
to O
low O
dose O
( O
100 O
mg O
) O
daily O
. O

 O
She O
. O

A O
with O
complaints O
of O
and O
for O
; O
she O
also O
complained O
of O
intermittent O
type O
of O
in O
the O
. O

 O
revealed O
presence O
of O
and O
a O
palpable O
tender O
globular O
in O
the O
measuring O
. O

 O
A O
clinical O
diagnosis O
of O
obstructive O
secondary O
to O
periampullary B
carcinoma I
was O
made O
. O

 O
of O
the O
and O
revealed O
( O
) O
, O
with O
multiple O
freely O
mobile O
and O
a O
( O
) O
measuring O
with O
. O

 O
showed O
moderate O
, O
with O
suspicious O
at O
the O
, O
and O
a O
distal O
CBD O
. O

 O
There O
was O
no O
evidence O
of O
any O
distant O
( O
Fig.1 O
) O
. O

 O
A O
preoperative O
diagnosis O
of O
periampullary B
carcinoma I
with O
chronic B
cholecystitis I
was O
made O
, O
and O
the O
patient O
planned O
for O
a O
( O
) O
after O
optimization O
. O

 O
The O
patient O
underwent O
a O
classical O
; O
of O
the O
revealed O
multiple O
in O
the O
with O
area O
of O
at O
the O
and O
an O
irregular O
circumferential O
involving O
the O
. O

 O
was O
, O
and O
the O
patient O
. O

 O
of O
the O
( O
Figs.2 O
and O
3 O
) O
revealed O
at O
the O
with O
multiple O
small O
, O
the O
largest O
measuring O
( O
Fig.3 O
) O
. O

 O
Sections O
studied O
from O
the O
area O
of O
thickening O
showed O
features O
suggestive O
of O
adenocarcinoma B
limited O
to O
the O
. O

 O
obtained O
from O
the O
distal O
CBD O
region O
showed O
adenocarcinoma B
of O
the O
with O
into O
the O
. O

 O
studied O
from O
the O
were O
free O
of O
. O

 O
A O
pathological O
staging O
of O
pT1aN0M0 O
for O
adenocarcinoma O
of O
the O
gall O
bladder O
and O
pT2N0M0 O
for O
adenocarcinoma O
of O
the O
distal O
CBD O
was O
made O
, O
and O
the O
patient O
was O
not O
subjected O
to O
any O
. O

 O
The O
patient O
was O
disease O
- O
free O
. O

The O
patient O
in O
this O
case O
had O
a O
6 O
- O
year O
history O
of O
diffuse O
cutaneous O
SSc B
( O
Fig.1 O
) O
and O
had O
not O
received O
regular O
or O
therapy O
. O

 O
He O
had O
experienced O
, O
, O
and O
progressive O
for O
and O
for O
. O

 O
He O
was O
to O
our O
with O
renal B
failure I
and O
pulmonary O
. O

 O
In O
the O
emergency O
department O
, O
his O
blood O
pressure O
, O
pulse O
rate O
, O
and O
respiratory O
rate O
were O
, O
, O
and O
, O
respectively O
. O

 O
revealed O
the O
following O
values O
: O
, O
7730 O
/ O
L O
( O
350011,000 O
/ O
L O
) O
; O
, O
8.6 O
 O
g O
/ O
dL O
( O
1216 O
 O
g O
/ O
dL O
): O
, O
87000 O
/ O
L O
( O
150,000400,000 O
/ O
L O
) O
; O
, O
78 O
 O
mg O
/ O
dL O
( O
621 O
 O
mg O
/ O
dL O
) O
; O
, O
8.9 O
 O
mg O
/ O
dL O
( O
1.11.5 O
 O
mg O
/ O
dL O
) O
; O
, O
8.2 O
 O
mg O
/ O
dL O
( O
8.810.3 O
 O
mg O
/ O
dL O
) O
; O
, O
5.4 O
 O
mg O
/ O
dL O
( O
2.74.5 O
 O
mg O
/ O
dL O
) O
; O
, O
< O
6.56 O
 O
mg O
/ O
dL O
( O
30200 O
 O
mg O
/ O
dL O
) O
; O
and O
, O
( O
106211 O
 O
U O
/ O
L O
) O
. O

 O
A O
routine O
revealed O
a O
( O
) O
, O
of O
35 O
/ O
high O
power O
field O
, O
and O
of O
. O

 O
The O
indicated O
an O
level O
of O
( O
, O
) O
. O

 O
Tests O
for O
, O
, O
, O
, O
and O
were O
all O
. O

 O
Kidney O
showed O
a O
without O
. O

 O
Despite O
the O
chronic O
changes O
visible O
on O
the O
echogram O
, O
the O
patient O
had O
developed O
acute O
pulmonary O
and O
only O
admission O
. O

 O
Accordingly O
, O
a O
clinical O
diagnosis O
of O
acute O
- O
on O
- O
chronic O
renal B
failure I
was O
made O
. O

 O
A O
further O
diagnosis O
of O
SRC B
was O
supported O
by O
the O
presence O
of O
renal B
failure I
with O
microangiopathic O
hemolytic O
and O
, O
and O
the O
patient O
was O
started O
on O
captopril O
therapy O
. O

 O
The O
sustained O
and O
had O
led O
to O
a O
requirement O
for O
regular O
from O
admission O
. O

 O
, O
was O
changed O
to O
because O
the O
patient O
developed O
a O
severe O
, O
intolerable O
thought O
to O
be O
associated O
with O
captopril O
. O

 O
His O
was O
. O

 O
At O
approximately O
the O
initiation O
of O
maintenance O
, O
the O
patient O
newly O
developed O
a O
generalized O
tonic O
- O
clonic O
seizure B
disorder I
. O

 O
A O
brain O
( O
) O
scan O
revealed O
a O
small O
lacunar O
infarct B
over O
the O
without O
intracranial O
hemorrhage B
or O
large O
infarct B
. O

 O
The O
seizure O
resolved O
spontaneously O
without O
, O
and O
the O
patient O
was O
finally O
without O
incident O
and O
scheduled O
for O
regular O
hemodialysis O
. O

 O
However O
, O
at O
discharge O
, O
the O
patient O
developed O
a O
sudden O
- O
onset O
and O
with O
and O
recurrence O
of O
the O
generalized O
tonic O
- O
clonic O
. O

 O
He O
at O
the O
with O
a O
of O
, O
of O
, O
of O
, O
and O
a O
( O
Fig.2 O
) O
. O

 O
Brain O
revealed O
, O
and O
revealed O
. O

 O
Cerebrospinal O
were O
for O
, O
, O
and O
. O

 O
Brain O
( O
) O
showed O
bilateral O
in O
the O
on O
a O
( O
Fig.3 O
) O
. O

 O
Finally O
, O
the O
patient O
was O
diagnosed O
with O
PRES B
. O

 O
We O
resumed O
therapy O
at O
a O
dose O
of O
. O

 O
As O
it O
was O
difficult O
to O
differentiate O
SRC O
from O
TTP O
, O
we O
also O
considered O
plasma O
exchange O
treatment O
. O

 O
However O
, O
the O
patient O
's O
returned O
to O
within O
in O
the O
absence O
of O
, O
and O
a O
follow O
- O
up O
of O
the O
showed O
complete O
resolution O
of O
cerebral O
( O
Fig.4 O
) O
. O

 O
Therefore O
, O
SRC O
- O
related O
PRES B
was O
confirmed O
. O

 O
Although O
the O
patient O
experienced O
a O
, O
his O
and O
he O
remained O
. O

A O
with O
a O
history O
of O
severe B
aplastic I
anemia I
( O
SAA B
) O
underwent O
bone O
marrow O
transplantation O
from O
his O
HLA O
- O
haploidentical O
mother O
in O
. O

 O
The O
conditioning O
regimens O
consisted O
of O
and O
( O
BUCY+ATG O
) O
( O
10 O
) O
. O

 O
( O
CsA O
) O
and O
short O
- O
term O
( O
) O
plus O
( O
) O
were O
used O
as O
prophylaxis O
against O
graft B
- I
versus I
- I
host I
disease I
( O
GVHD B
) O
( O
11 O
) O
. O

 O
Standard O
measures O
were O
adopted O
for O
the O
prevention O
of O
infectious B
complications I
, O
which O
included O
for O
antifungal O
and O
to O
prevent O
herpes O
- O
related O
infections B
. O

 O
A O
revealed O
the O
reconstruction O
of O
granulocytes O
( O
ANC>0.5109 O
/ O
L O
) O
on O
day O
+12 O
post O
- O
transplantation O
. O

 O
The O
patient O
developed O
grade O
II O
acute O
GVHD B
of O
the O
skin O
on O
day O
+42 O
post O
- O
transplantation O
. O

 O
This O
was O
treated O
by O
treatment O
with O
a O
standard O
- O
dose O
of O
methyl O
- O
prednisolone O
, O
which O
achieved O
a O
complete O
response O
( O
CR O
) O
. O

 O
The O
patient O
's O
chronic O
GVHD O
( O
cGVHD O
) O
of O
the O
skin O
gradually O
progressed O
from O
day O
+100 O
post O
- O
transplantation O
and O
he O
was O
treated O
with O
prednisolone O
and O
CsA. O

 O
On O
day O
120 O
post O
- O
transplantation O
, O
he O
complained O
of O
a O
cough O
and O
antibiotics O
were O
administered O
. O

 O
A O
blood O
analysis O
revealed O
the O
following O
: O
WBC O
, O
2.34109 O
/ O
L O
; O
ANC O
, O
1.72109 O
/ O
L O
; O
hemoglobin O
, O
85 O
g O
/ O
L O
; O
and O
platelets O
, O
72109 O
/ O
L. O

 O
Although O
both O
a O
chest O
computed O
tomography O
( O
CT O
) O
scan O
and O
tests O
for O
pathogens O
via O
routine O
culturing O
, O
including O
blood O
tests O
for O
Beta O
- O
D O
glucan O
( O
G O
- O
test O
) O
and O
Galactomannan O
( O
GM O
- O
test O
) O
were O
all O
negative O
, O
the O
patient O
's O
cough O
did O
not O
respond O
to O
antibiotics O
and O
we O
empirically O
initiated O
treatment O
with O
voriconazole O
( O
6 O
mg O
/ O
kg/12h O
for O
the O
first O
day O
, O
followed O
by O
4 O
mg O
/ O
kg/12h O
) O
. O

 O
Liver O
toxicity O
occurred O
during O
voriconazole O
treatment O
, O
thus O
the O
anti O
- O
fungal O
regimen O
was O
changed O
to O
micafungin O
( O
100 O
mg O
/ O
d O
) O
. O

 O
However O
, O
the O
persistent O
cough O
did O
not O
improve O
and O
hoarseness O
developed O
after O
two O
weeks O
of O
treatment O
- O
ulcers O
were O
then O
observed O
in O
the O
throat O
by O
laryngoscopy O
( O
Fig.1a O
) O
. O

 O
The O
patient O
developed O
severe O
dyspnea O
in O
the O
following O
week O
when O
anti O
- O
infection O
and O
topical O
treatments O
were O
applied O
. O

 O
Fiberoptic O
bronchoscopy O
revealed O
an O
irregular O
, O
nodular O
material O
with O
white O
moss O
, O
which O
nearly O
obstructed O
the O
bronchus O
; O
however O
, O
chest O
CT O
imaging O
was O
negative O
( O
Fig.1b O
and O
c O
) O
. O

 O
The O
histopathological O
examination O
of O
biopsy O
specimens O
revealed O
an O
Aspergillus O
species O
( O
Fig.1d O
) O
. O

 O
The O
patient O
was O
diagnosed O
with O
pseudomembranous O
Aspergillus O
tracheobronchitis O
type O
ITBA O
based O
on O
the O
results O
of O
bronchoscopy O
and O
a O
pathological O
examination O
( O
12 O
) O
. O

 O
The O
antibiotic O
and O
micafungin O
treatments O
were O
ceased O
and O
liposomal O
amphotericin O
B O
( O
liposomal O
AmB O
) O
was O
administered O
daily O
at O
a O
target O
dose O
of O
3 O
mg O
/ O
kg O
. O

 O
The O
patient O
's O
serum O
creatinine O
level O
rose O
from O
60.4 O
mol O
/ O
L O
to O
168 O
mol O
/ O
L O
during O
the O
first O
7 O
days O
of O
liposomal O
AmB O
treatment O
. O

 O
Due O
to O
progressive O
renal O
dysfunction O
, O
the O
anti O
- O
fungal O
regimen O
was O
switched O
to O
a O
combination O
of O
posaconazole O
( O
400 O
mg/12 O
h O
) O
and O
caspofungin O
[ O
50 O
mg O
, O
daily O
( O
70 O
mg O
for O
the O
first O
dose O
) O
] O
. O

 O
The O
combination O
therapy O
continued O
for O
2 O
weeks O
, O
until O
the O
previous O
nodules O
in O
the O
throat O
completely O
disappeared O
under O
bronchoscopy O
( O
Fig.2a O
) O
; O
however O
, O
a O
repeat O
chest O
CT O
scan O
showed O
progression O
( O
Fig.2b O
) O
. O

 O
The O
symptom O
of O
dyspnea O
gradually O
progressed O
, O
thus O
fiberoptic O
bronchoscopy O
was O
performed O
to O
remove O
the O
obstructive O
material O
from O
the O
patient O
's O
airways O
once O
a O
week O
for O
two O
weeks O
. O

 O
All O
of O
the O
symptoms O
were O
relieved O
and O
the O
final O
chest O
CT O
scan O
showed O
negative O
results O
before O
the O
discontinuation O
of O
anti O
- O
fungal O
therapy O
, O
and O
all O
of O
the O
tests O
were O
negative O
for O
Aspergillus O
. O

 O
Posaconazole O
was O
administered O
as O
a O
secondary O
prophylactic O
treatment O
and O
the O
patient O
was O
discharged O
from O
hospital O
. O

 O
The O
patient O
is O
still O
being O
and O
remains O
free O
of O
any O
recurrence O
of O
invasive O
fungal O
infection B
. O

A O
with O
was O
to O
in O
to O
be O
for O
lung O
and O
kidney O
. O

 O
Patients O
with O
cystic O
fibrosis O
are O
known O
to O
develop O
chronic O
lung O
infections O
that O
adapt O
over O
time O
to O
this O
unique O
anatomic O
niche O
( O
14 O
, O
15 O
) O
. O

 O
His O
complicated O
medical O
history O
included O
pancreatic B
insufficiency I
, O
liver O
transplantation O
in O
2004 O
, O
steroid O
- O
induced O
diabetes O
, O
end O
- O
stage O
renal O
disease O
, O
and O
testicular O
cancer O
. O

 O
He O
had O
a O
long O
history O
of O
respiratory B
infections I
with O
several O
multidrug O
- O
resistant O
bacteria O
, O
including O
MRSA O
. O

 O
He O
was O
treated O
with O
ceftaroline O
at O
an O
outside O
hospital O
immediately O
prior O
to O
transfer O
to O
Houston O
Methodist O
Hospital O
. O

 O
The O
patient O
was O
periodically O
hospitalized O
from O
January O
to O
July O
2013 O
and O
was O
treated O
for O
recurrent O
respiratory O
and O
catheter O
- O
related O
infections O
caused O
by O
MRSA O
and O
multidrug O
- O
resistant O
Pseudomonas O
aeruginosa O
. O

 O
His O
antibiotic O
exposure O
included O
long O
treatment O
courses O
with O
various O
agents O
, O
including O
, O
, O
, O
, O
, O
, O
, O
and O
inhaled O
and O
systemic O
and O
. O

 O
Shortly O
after O
being O
to O
our O
in O
, O
MRSA B
was O
grown O
from O
of O
and O
. O

 O
These O
two O
were O
resistant O
to O
, O
, O
, O
and O
and O
susceptible O
to O
minocycline O
, O
rifampin O
, O
and O
. O

 O
His O
blood O
grew O
confluently O
around O
the O
, O
yielding O
an O
. O

 O
Five O
additional O
S. O
aureus O
respiratory O
tract O
were O
available O
for O
further O
study O
. O

 O
All O
MRSA O
isolates O
from O
this O
patient O
had O
a O
small O
- O
colony O
- O
variant O
( O
SCV O
) O
phenotype O
. O

A O
with O
developed O
, O
and O
on O
over O
the O
to O
her O
to O
our O
. O

 O
At O
the O
time O
of O
presentation O
, O
she O
also O
reported O
of O
dry O
, O
, O
paroxysmal O
nocturnal O
, O
generalised O
and O
intermittent O
of O
her O
and O
. O

 O
Social O
history O
was O
negative O
for O
, O
or O
. O

 O
was O
, O
except O
for O
jugular O
venous O
, O
audible O
S1 O
and O
S2 O
sounds O
, O
bilateral O
crackles O
on O
lung O
auscultation O
and O
bilateral O
pitting O
oedema O
. O

 O
Chest O
X O
- O
ray O
showed O
cardiomegaly O
, O
pulmonary O
oedema O
and O
small O
- O
sized O
bilateral O
pleural O
effusions O
. O

 O
A O
12 O
- O
lead O
ECG O
demonstrated O
normal O
sinus O
rhythm O
, O
low O
- O
voltage O
complexes O
and O
extreme O
right O
- O
axis O
deviation O
( O
figure O
1 O
) O
. O

 O
Transthoracic O
echocardiogram O
( O
TTE O
) O
demonstrated O
asymmetric O
biventricular O
hypertrophy O
with O
preserved O
ejection O
fraction O
of O
60 O
% O
, O
elevated O
right O
- O
ventricular O
systolic O
pressure O
of O
36 O
 O
mm O
 O
Hg O
and O
abnormal O
myocardial O
texture O
, O
described O
as O
 O
granular O
sparkling O
 O
( O
figure O
2 O
) O
. O

 O
Coronary O
CT O
angiogram O
demonstrated O
normal O
coronary O
arteries O
. O

 O
Subsequently O
, O
cardiac O
MRI O
demonstrated O
early O
and O
diffuse O
subendocardial O
delayed O
enhancement O
, O
concerning O
for O
infiltrative O
myocardial O
disease O
and O
for O
diffuse O
biventricular O
hypertrophy O
, O
with O
normal O
ejection O
fraction O
( O
figure O
3 O
) O
. O

 O
The O
patient O
underwent O
right O
heart O
catheterisation O
with O
endomyocardial O
biopsy O
, O
revealing O
diffuse O
amyloidosis O
with O
amorphous O
proteinaceous O
material O
around O
cardiac O
myocytes O
and O
within O
blood O
vessels O
, O
which O
was O
positive O
for O
Congo O
red O
stain O
( O
figure O
4 O
) O
. O

 O
Subsequent O
laboratory O
evaluation O
registered O
elevated O
, O
free O
 O
light O
chains O
( O
86.3 O
 O
mg O
/ O
L O
( O
normal O
: O
5.726.3 O
 O
mg O
/ O
L O
) O
) O
and O
positive O
Bence O
- O
Jones O
protein O
( O
0.37 O
 O
g/24 O
 O
h O
) O
in O
the O
urine O
. O

 O
Bone O
marrow O
biopsy O
revealed O
greater O
than O
10 O
% O
infiltration O
of O
CD19 O
CD56 O
+ O
CD138 O
+ O
plasma O
cells O
with O
reversal O
of O
marrow O
 O
/ O
 O
ratio O
( O
< O
1:2 O
, O
normal O
: O
2:1 O
) O
, O
consistent O
with O
MM O
. O

 O
The O
patient O
was O
eventually O
diagnosed O
with O
systemic O
AL O
amyloidosis O
with O
advanced O
, O
stage O
III O
, O
cardiac O
amyloidosis O
due O
to O
underlying O
MM O
. O

 O
Given O
her O
advanced O
cardiac O
amyloidosis O
, O
the O
patient O
was O
deemed O
a O
poor O
candidate O
for O
autologous O
stem O
- O
cell O
transplantation O
. O

 O
The O
patient O
was O
started O
on O
systemic O
chemotherapy O
with O
melphalan O
and O
dexamethasone O
. O

 O
Despite O
receiving O
standard O
therapy O
for O
heart O
failure O
 O
including O
diuretics O
, O
 O
- O
blockers O
and O
ACE O
inhibitors O
 O
the O
patient O
's O
condition O
continued O
to O
worsen O
and O
she O
to O
sudden B
cardiac I
death I
. O

A O
patient O
was O
to O
the O
because O
of O
an O
abnormal O
pre O
- O
employment O
chest O
. O

 O
He O
had O
been O
about O
. O

 O
He O
. O

 O
He O
was O
an O
and O
. O

 O
His O
. O

 O
On O
, O
the O
patient O
was O
not O
. O

 O
There O
were O
no O
signs O
of O
or O
pulmonary O
hypertension B
. O

 O
His O
on O
was O
and O
to O
after O
up O
. O

 O
revealed O
a O
restrictive O
pattern O
of O
lung B
disease I
with O
a O
( O
) O
and O
a O
( O
) O
of O
( O
69 O
% O
of O
predicted O
) O
and O
( O
68 O
% O
of O
predicted O
) O
, O
respectively O
. O

 O
The O
was O
. O

 O
His O
( O
) O
, O
serum O
( O
[ O
normal O
, O
1.1 O
- O
7.3 O
] O
) O
and O
( O
) O
levels O
were O
. O

 O
24 O
- O
hour O
urine O
was O
also O
with O
a O
24 O
- O
hour O
of O
2.8 O
L. O

 O
His O
chest O
( O
Fig.1A O
) O
revealed O
dense O
micronodular O
and O
predominantly O
in O
the O
giving O
the O
. O

 O
The O
cardiac O
borders O
were O
obscured O
by O
the O
sand O
- O
like O
. O

 O
A O
high O
- O
resolution O
computed O
tomography O
( O
) O
scan O
of O
the O
( O
Fig.1B O
) O
showed O
widespread O
tiny O
throughout O
the O
with O
a O
preponderance O
of O
in O
the O
. O

 O
There O
were O
associated O
areas O
of O
interlobular O
and O
. O

 O
Subpleural O
were O
also O
seen O
in O
giving O
rise O
to O
the O
' O
' O
( O
Fig.1C O
) O
( O
2 O
) O
. O

 O
No O
pneumothorax B
or O
pleural B
effusion I
was O
present O
. O

 O
Both O
the O
bronchial O
system O
( O
including O
the O
small O
bronchioles O
) O
and O
the O
of O
the O
pulmonary O
vessels O
were O
. O

 O
As O
this O
was O
diffuse B
parenchymal I
lung I
disease I
, O
( O
) O
lung O
was O
planned O
but O
the O
procedure O
was O
converted O
into O
a O
because O
there O
was O
. O

 O
There O
was O
a O
moderate O
pneumothorax B
postmini O
- O
thoracotomy O
from O
which O
the O
patient O
fully O
after O
in O
the O
. O

 O
The O
lung O
specimen O
revealed O
features O
consistent O
with O
PAM B
, O
with O
numerous O
within O
the O
( O
Fig.1D O
) O
. O

 O
The O
intervening O
alveolar O
septae O
were O
and O
showed O
mild O
with O
of O
mainly O
. O

A O
presented O
with O
a O
left O
buttock O
, O
which O
had O
been O
first O
detected O
approximately O
, O
and O
had O
recently O
gradually O
enlarged O
. O

 O
Physical O
examination O
revealed O
a O
relatively O
well O
- O
circumscribed O
skin O
- O
colored O
tumor O
with O
hyperkeratosis O
, O
measuring O
43 O
x O
38 O
mm O
in O
diameter O
, O
in O
her O
left O
buttock O
. O

 O
The O
biopsy O
specimen O
revealed O
Bowen O
s O
disease O
( O
squamous O
cell O
carcinoma O
in O
situ O
) O
, O
and O
subsequently O
, O
total O
resection O
of O
the O
tumor O
was O
performed O
. O

 O
Histopathological O
study O
of O
the O
resected O
specimen O
revealed O
proliferation O
of O
atypical O
squamous O
cells O
in O
the O
entire O
layer O
of O
the O
acanthotic O
epidermis O
accompanied O
by O
hyperparakeratosis O
( O
Figure O
1A O
) O
. O

 O
These O
atypical O
squamous O
cells O
had O
enlarged O
and O
hyperchromatic O
nuclei O
( O
Figure O
1B O
) O
, O
and O
multinucleated O
atypical O
squamous O
cells O
were O
also O
present O
. O

 O
Mitotic O
figures O
were O
scattered O
and O
present O
in O
the O
upper O
portion O
of O
the O
epidermis O
. O

 O
Atypical O
mitotic O
figures O
were O
also O
observed O
( O
Figure O
1B O
) O
. O

 O
No O
invasive O
neoplastic O
growth O
was O
noted O
( O
Figure O
1A O
) O
. O

 O
Approximately O
95 O
% O
of O
the O
lesion O
was O
composed O
of O
the O
above O
- O
mentioned O
Bowen O
s O
disease O
( O
squamous O
cell O
carcinoma O
in O
situ O
) O
, O
and O
superficial O
sebaceous O
carcinoma O
was O
present O
in O
the O
central O
area O
of O
the O
lesion O
. O

 O
This O
latter O
component O
was O
composed O
of O
proliferation O
of O
nests O
of O
atypical O
cells O
with O
vacuolated O
clear O
cytoplasm O
and O
large O
nuclei O
containing O
conspicuous O
nucleoli O
( O
Figure O
1C O
, O
,1D).1D O
) O
. O

 O
Sebaceous O
carcinoma O
had O
invaded O
into O
the O
superficial O
reticular O
dermis O
( O
Figure O
1C O
) O
. O

 O
Moreover O
, O
atypical O
cells O
containing O
vacuolated O
cytoplasm O
were O
present O
within O
the O
lesion O
of O
Bowen O
s O
disease O
adjacent O
to O
the O
sebaceous O
carcinoma O
( O
Figure O
1E O
) O
. O

 O
Immunohistochemical O
studies O
were O
performed O
using O
an O
autostainer O
( O
Ventana O
) O
by O
the O
same O
method O
as O
previously O
reported O
[ O
9 O
- O
12 O
] O
. O

 O
Epithelial O
membrane O
antigen O
( O
EMA O
) O
, O
cytokeratin O
7 O
, O
and O
adipophilin O
were O
expressed O
in O
the O
sebaceous O
carcinoma O
component O
, O
but O
not O
in O
Bowen O
s O
disease O
( O
Figure O
2A O
) O
. O

 O
Androgen O
receptor O
was O
also O
expressed O
in O
some O
of O
the O
tumor O
cells O
of O
the O
sebaceous O
carcinoma O
, O
but O
not O
in O
Bowen O
s O
disease O
. O

 O
Moreover O
, O
atypical O
vacuolated O
cells O
within O
the O
lesion O
of O
Bowen O
s O
disease O
were O
also O
positive O
for O
adipophilin O
( O
Figure O
2B O
) O
. O

 O
Overexpression O
of O
p53 O
protein O
was O
observed O
in O
both O
the O
sebaceous O
carcinoma O
and O
Bowen O
s O
disease O
. O

 O
Accordingly O
, O
an O
ultimate O
diagnosis O
of O
sebaceous B
carcinoma I
associated O
with O
Bowen B
s I
disease I
was O
made O
. O

An O
patient O
with O
a O
history O
of O
was O
to O
our O
in O
because O
of O
progressive O
and O
recurring O
. O

 O
revealed O
a O
grade O
III O
severe O
symptomatic O
aortic B
stenosis I
. O

 O
Due O
to O
relevant O
comorbidities O
( O
of O
) O
and O
severe O
femoral O
arteriopathy O
, O
he O
was O
scheduled O
for O
trans O
- O
subclavian O
. O

 O
After O
successful O
implantation O
of O
a O
( O
) O
[ O
Medtronic O
World O
Headquarters O
Medtronic O
Parkway O
Minneapolis O
, O
Minnesota O
, O
USA O
] O
( O
) O
and O
initial O
, O
he O
was O
back O
to O
the O
because O
of O
due O
to O
bilateral O
pleural B
effusions I
. O

 O
( O
) O
showed O
a O
severe O
( O
MR O
) O
, O
which O
was O
subsequently O
treated O
by O
interventional O
using O
the O
( O
) O
and O
procedurally O
dependent O
( O
St. O

 O
Jude O
Medical O
GmbH O
, O
Helfmann O
- O
Park O
7 O
, O
Eschborn O
, O
Germany O
) O
. O

 O
secondary O
, O
the O
patient O
developed O
progressive O
heart B
failure I
in O
combination O
with O
acute O
renal B
failure I
. O

 O
Immediate O
revealed O
a O
moderate O
- O
to O
- O
severe O
aortic O
regurgitation O
and O
recurrent O
severe O
. O

 O
resulted O
from O
a O
slight O
but O
significant O
towards O
the O
, O
which O
had O
caused O
and O
partial O
posterior O
( O
Fig.1 O
) O
. O

 O
As O
a O
consequence O
of O
these O
findings O
, O
the O
patient O
was O
to O
our O
. O

 O
Preoperative O
coronary O
revealed O
a O
progression O
of O
the O
coronary B
artery I
disease I
. O

 O
Consequently O
the O
patient O
was O
scheduled O
for O
conventional O
aortic O
and O
mitral O
, O
as O
well O
as O
coronary O
artery O
bypass O
surgery O
. O

 O
The O
operation O
was O
performed O
via O
. O

 O
On O
initialization O
of O
cardiopulmonary O
bypass O
, O
the O
ascending O
aorta O
was O
opened O
for O
exploration O
of O
the O
aortic O
valve O
( O
Fig.2A O
) O
. O

 O
After O
careful O
removal O
of O
the O
CoreValve O
prosthesis O
, O
an O
Edwards O
Perimount O
aortic O
valve O
prosthesis O
( O
diameter O
25 O
mm O
) O
was O
implanted O
. O

 O
After O
vein O
- O
grafting O
of O
the O
circumflex O
coronary O
artery O
, O
the O
mitral O
valve O
was O
explored O
via O
the O
left O
atrium O
and O
excised O
with O
the O
attached O
clip O
. O

 O
Thereafter O
, O
an O
Edwards O
Perimount O
mitral O
valve O
prosthesis O
( O
diameter O
31 O
mm O
) O
was O
implanted O
. O

 O
More O
recently O
, O
the O
atrial O
septal O
occluder O
was O
removed O
prior O
to O
direct O
closure O
of O
the O
resulting O
septal O
defect O
with O
a O
single O
- O
suture O
line O
( O
Fig.2B O
) O
. O

 O
Intraoperative O
echocardiography O
revealed O
adequate O
function O
of O
both O
prostheses O
and O
the O
operation O
was O
completed O
in O
the O
usual O
manner O
. O

 O
During O
the O
postoperative O
phase O
, O
the O
patient O
recovered O
well O
from O
surgery O
although O
hospitalization O
was O
prolonged O
by O
transient O
renal O
failure O
and O
recurring O
pleural O
effusions O
. O

 O
After O
a O
month O
of O
postoperative O
care O
, O
the O
patient O
was O
discharged O
from O
hospital O
to O
rehabilitation O
in O
a O
good O
condition O
, O
without O
signs O
for O
heart O
failure O
. O

 O
At O
surgery O
, O
the O
patient O
was O
still O
in O
a O
cardiopulmonary O
stable O
, O
undergoing O
additional O
. O

The O
affected O
individual O
, O
a O
, O
was O
the O
fourth O
child O
born O
to O
an O
Arab O
Muslim O
family O
of O
Palestinian O
origin O
. O

 O
are O
. O

 O
One O
, O
a O
girl O
died O
at O
the O
age O
of O
1 O
month O
due O
to O
SIDS O
according O
to O
parents O
, O
without O
any O
investigation O
. O

 O
Informed O
consent O
for O
muscle O
, O
skin O
biopsy O
and O
exome O
sequencing O
was O
obtained O
from O
the O
parents O
, O
and O
the O
study O
was O
approved O
by O
the O
local O
institutional O
review O
board O
. O

 O
During O
pregnancy O
, O
the O
patient O
was O
suspected O
to O
have O
IUGR O
and O
was O
delivered O
by O
Cesarian O
section O
at O
36 O
+ O
2 O
gestational O
weeks O
with O
Apgar O
scores O
9 O
and O
10 O
. O

 O
Birth O
weight O
was O
2.3 O
 O
kg O
( O
10th O
percentile O
) O
and O
head O
circumference O
32 O
 O
cm O
( O
10th O
percentile O
) O
. O

 O
Physical O
exam O
after O
birth O
, O
detected O
a O
systolic O
murmur O
3/6 O
. O

 O
On O
the O
first O
day O
of O
life O
, O
the O
patient O
developed O
metabolic O
acidosis O
with O
lactate O
level O
of O
27 O
 O
mm O
( O
normal O
range O
0.52.4 O
 O
mm O
) O
and O
elevated O
ammonia O
levels O
277 O
 O
m O
( O
normal O
range O
1060 O
 O
m O
) O
. O

 O
Metabolic O
work O
up O
showed O
normal O
acylcarnitines O
, O
elevated O
alanine O
level O
1400 O
 O
m O
( O
normal O
< O
700 O
 O
m O
) O
, O
and O
urine O
organic O
acids O
showed O
increased O
lactic O
acidosis O
and O
ketones O
. O

 O
Chest O
X O
- O
ray O
revealed O
cardiomegaly O
, O
and O
cardiac O
Echo O
revealed O
symmetrical O
left O
ventricular O
hypertrophy O
tricuspid O
regurge O
and O
pulmonary O
hypertension O
. O

 O
The O
patient O
was O
transported O
to O
the O
NICU O
and O
treated O
with O
bicarbonate O
, O
acetate O
and O
diuretics O
. O

 O
At O
the O
age O
of O
4 O
days O
, O
quadriceps O
muscle O
biopsy O
was O
performed O
. O

 O
Pathology O
showed O
decreased O
cytochrome O
c O
oxidase O
stain O
. O

 O
Brain O
ultrasound O
performed O
at O
age O
5 O
days O
was O
normal O
. O

 O
Subsequently O
, O
head O
circumference O
grew O
rapidly O
adding O
13 O
centimeters O
by O
age O
35 O
days O
, O
repeated O
brain O
US O
revealed O
dilated O
ventricles O
confirmed O
by O
head O
CT O
, O
which O
also O
showed O
subcortical O
and O
white O
matter O
cortical O
hemorrhage O
in O
the O
occipital O
region O
. O

 O
At O
15 O
weeks O
, O
a O
ventriculoperitoneal O
( O
VP O
) O
shunt O
was O
inserted O
. O

 O
Head O
CT O
performed O
at O
age O
2 O
years O
showed O
prominent O
dilatation O
of O
the O
ventricles O
( O
Figure O
1 O
) O
. O

 O
Due O
to O
hypotonia O
with O
feeding O
difficulties O
and O
recurrent O
aspirations O
, O
a O
percutaneous O
endoscopic O
gastrostomy O
( O
PEG O
) O
feeding O
tube O
was O
inserted O
at O
age O
10 O
weeks O
. O

 O
Eye O
examination O
at O
the O
age O
of O
15 O
weeks O
revealed O
cortical O
blindness O
. O

 O
Hearing O
test O
ABR O
was O
normal O
. O

 O
Repeated O
cardiac O
Echo O
continued O
to O
show O
mild O
tricuspid O
regurge O
, O
mild O
left O
ventricular O
hypertrophy O
( O
LVH O
) O
and O
pulmonary O
hypertension O
( O
PHTN O
) O
in O
the O
first O
months O
of O
life O
. O

 O
At O
the O
age O
of O
4 O
months O
, O
he O
started O
developing O
hypertrophic O
obstructive O
cardiomyopathy O
, O
he O
was O
started O
on O
diuretics O
and O
beta O
blockers O
and O
later O
calcium O
channel O
blockers O
were O
added O
; O
follow O
- O
up O
Echo O
at O
the O
age O
of O
2 O
years O
revealed O
improvement O
in O
the O
LVH O
and O
no O
PHTN O
. O

 O
Coenzyme O
Q10 O
supplementation O
( O
60 O
 O
mg O
twice O
daily O
) O
was O
initiated O
at O
4 O
months O
but O
discontinued O
by O
the O
parents O
. O

 O
In O
the O
following O
months O
, O
the O
patient O
was O
admitted O
several O
times O
to O
the O
hospital O
mainly O
due O
to O
chest O
infections O
, O
shunt O
malfunctioning O
and O
fevers O
. O

 O
He O
at O
the O
due O
to O
severe O
hypoxemia O
after O
a O
febrile B
illness I
with O
chest O
infection B
and O
pulmonary O
; O
parents O
refused O
and O
refused O
. O

A O
patient O
had O
previously O
undergone O
a O
radical O
resection O
of O
a O
T2bN0M0G3 O
Stage O
III O
retroperitoneal B
sarcoma I
, O
including O
right O
and O
, O
in O
. O

 O
demonstrated O
a O
25 O
 O
cm O
high O
- O
grade O
liposarcoma B
with O
, O
including O
, O
, O
, O
and O
. O

 O
were O
as O
the O
tumor O
did O
not O
the O
, O
and O
since O
the O
renal O
vein O
and O
ureter O
were O
free O
of O
as O
well O
. O

 O
The O
patient O
did O
not O
undergo O
any O
. O

 O
Surveillance O
in O
revealed O
an O
isolated O
in O
the O
. O

 O
An O
exploratory O
revealed O
of O
the O
, O
, O
, O
and O
with O
severe O
, O
leading O
to O
the O
intraoperative O
assessment O
of O
unresectable B
disease I
. O

 O
Subsequently O
, O
the O
patient O
underwent O
stereotactic O
body O
to O
the O
retroperitoneal O
in O
for O
a O
, O
without O
. O

 O
Postradiation O
revealed O
near O
complete O
resolution O
of O
the O
retroperitoneal O
. O

 O
, O
the O
patient O
with O
, O
postprandial O
abdominal O
, O
and O
. O

 O
revealed O
a O
7 O
 O
cm O
with O
involvement O
of O
the O
( O
Figure O
1 O
) O
. O

 O
However O
, O
there O
was O
no O
obvious O
of O
the O
or O
the O
that O
were O
noted O
to O
be O
involved O
during O
the O
previous O
laparotomy O
. O

 O
We O
elected O
to O
perform O
another O
attempt O
, O
including O
a O
possible O
pancreatoduodenectomy O
or O
retroperitoneal O
vascular O
resection O
if O
necessary O
. O

 O
At O
, O
the O
residual O
was O
an O
entirely O
, O
pedunculated O
at O
the O
distal O
to O
the O
ampulla O
that O
filled O
the O
entire O
duodenal O
lumen O
. O

 O
The O
patient O
underwent O
a O
and O
of O
the O
polypoid O
, O
followed O
by O
partial O
duodenal O
with O
hand O
- O
sewn O
duodenojejunal O
( O
Figure O
2 O
) O
. O

 O
revealed O
a O
9.5 O
 O
cm O
recurrent O
high O
- O
grade O
liposarcoma B
with O
containing O
, O
, O
, O
and O
. O

 O
were O
as O
the O
came O
of O
the O
and O
there O
was O
no O
evidence O
of O
additional O
within O
the O
remaining O
resected O
. O

 O
The O
was O
, O
and O
the O
patient O
has O
demonstrated O
no O
up O
to O
this O
resection O
. O

A O
to O
the O
with O
, O
from O
the O
dental O
extraction O
site O
and O
a O
widespread O
purpuric O
, O
secondary O
to O
acute O
idiopathic O
thrombocytopenia O
. O

 O
Two O
days O
prior O
to O
this O
, O
he O
developed O
a O
generalised O
. O

 O
While O
in O
the O
department O
it O
was O
noted O
that O
his O
ranged O
, O
he O
was O
otherwise O
with O
a O
normal O
and O
in O
. O

 O
He O
had O
a O
short O
systolic O
at O
the O
. O

 O
He O
had O
no O
clinical O
evidence O
of O
myocarditis B
or O
heart B
failure I
. O

 O
He O
had O
extensive O
generalised O
and O
purpuric O
( O
figure O
1 O
) O
secondary O
to O
acute O
presumed O
to O
be O
due O
to O
varicella B
infection I
. O

 O
Apparently O
he O
was O
prior O
to O
this O
admission O
. O

 O
There O
was O
. O

 O
An O
was O
performed O
which O
showed O
complete O
heart B
block I
( O
figure O
2 O
) O
. O

 O
He O
was O
to O
the O
for O
close O
overnight O
. O

 O
The O
presumed O
diagnosis O
was O
complete O
heart B
block I
secondary O
to O
varicella O
infection.1 O
2 O
The O
initial O
investigation O
showed O
normal O
, O
, O
, O
and O
levels O
. O

 O
The O
showed O
a O
normal O
and O
. O

 O
But O
the O
was O
that O
is O
, O
13109 O
/ O
l. O

 O
The O
without O
any O
. O

 O
The O
titres O
and O
the O
were O
. O

 O
. O

 O
The O
showed O
a O
and O
tape O
showed O
persistence O
of O
complete O
heart B
block I
. O

 O
Following O
these O
investigations O
a O
diagnosis O
of O
congenital O
complete O
heart B
block I
was O
made O
. O

 O
On O
his O
remains O
, O
but O
he O
remains O
without O
any O
. O

 O
The O
need O
for O
a O
is O
being O
considered O
on O
. O

 O
The O
incidental O
finding O
of O
complete O
heart O
block O
was O
congenital O
in O
aetiology O
with O
no O
association O
with O
varicella O
infection O
or O
acute O
thrombocytopenia O
. O

 O
This O
case O
highlights O
that O
asymptomatic O
late O
- O
presenting O
congenital O
complete O
heart O
block O
must O
be O
considered O
as O
a O
differential O
diagnosis O
in O
children O
presenting O
with O
asymptomatic O
bradycardia O
to O
the O
emergency O
department O
. O

A O
presented O
with O
a O
in O
her O
. O

 O
She O
had O
macrocephaly B
and O
milimetric O
on O
the O
giving O
a O
appearance O
. O

 O
The O
( O
) O
showed O
circumscribed O
, O
oval O
masses B
in O
each O
. O

 O
An O
US O
- O
guided O
core O
was O
performed O
for O
the O
palpable O
masses B
which O
were O
confirmed O
as O
juvenile O
fibroadenomas B
. O

 O
After O
the O
biopsy O
, O
a O
breast O
was O
done O
as O
follow O
- O
up O
for O
. O

 O
During O
the O
surveillance O
period O
, O
core O
were O
performed O
, O
followed O
by O
US O
- O
guided O
vacuum O
- O
assisted O
core O
or O
of O
lesions B
with O
. O

 O
Pathologic O
results O
were O
fibroadenoma B
, O
tubular B
adenoma I
or O
atypical B
ductal I
hyperplasia I
( O
ADH B
) O
involving O
fibroadenoma O
. O

 O
At O
the O
, O
the O
patient O
underwent O
a O
for O
a O
palpable O
mass B
in O
the O
. O

 O
Several O
indeterminate O
were O
revealed O
in O
both O
. O

 O
A O
follow O
- O
up O
revealed O
that O
some O
of O
those O
nodules O
. O

 O
The O
patient O
underwent O
a O
total O
and O
the O
pathologic O
result O
revealed O
an O
invasive O
follicular B
carcinoma I
in O
the O
and O
follicular B
adenoma I
in O
the O
( O
Fig.1A O
) O
. O

 O
At O
the O
age O
of O
21 O
years O
, O
she O
visited O
the O
due O
to O
a O
swelling O
of O
her O
. O

 O
Head O
and O
neck O
revealed O
a O
vascular O
mass B
in O
the O
extended O
into O
the O
. O

 O
An O
external O
carotid O
confirmed O
the O
diagnosis O
of O
an O
AVM O
with O
feeder O
vessel O
arising O
from O
the O
( O
Fig.1B O
) O
. O

 O
A O
partial O
embolization O
decreased O
the O
blood O
flow O
through O
the O
AVM O
, O
alleviating O
the O
patient O
's O
symptom O
. O

 O
She O
was O
referred O
to O
under O
the O
suggestion O
of O
a O
Cowden B
syndrome I
and O
the O
DNA O
sequencing O
test O
of O
her O
revealed O
a O
frameshift O
mutation O
, O
( O
) O
. O

 O
At O
the O
age O
of O
22 O
years O
, O
the O
patient O
presented O
with O
a O
mass B
with O
and O
increased O
vascularity O
in O
the O
. O

 O
An O
US O
- O
guided O
vacuum O
- O
assisted O
core O
revealed O
a O
ductal B
carcinoma I
in I
situ I
( O
DCIS B
) O
of O
and O
a O
involving O
fibroadenoma B
( O
Fig.1C O
) O
. O

 O
The O
contrast O
- O
enhanced O
breast O
for O
the O
preoperative O
evaluation O
demonstrated O
, O
, O
enhancing O
masses B
in O
both O
( O
Fig.1D O
) O
. O

 O
All O
masses B
showed O
high O
or O
intermediate O
on O
( O
Fig.1E O
) O
. O

 O
Several O
masses B
showed O
an O
with O
washout O
kinetic O
pattern O
on O
time O
- O
signal O
intensity O
curve O
evaluation O
, O
which O
tends O
to O
be O
associated O
with O
malignancy B
( O
Fig.1F O
) O
. O

 O
A O
bilateral O
prophylactic O
with O
immediate O
was O
performed O
in O
view O
of O
multiple O
bilateral O
breast O
masses B
with O
suspicious O
on O
breast O
and O
a O
high O
risk O
for O
breast B
cancer I
of O
Cowden B
syndrome I
. O

 O
The O
surgical O
histopathology O
revealed O
ADH B
involving O
tubular B
adenoma I
without O
residual O
carcinoma O
in O
the O
left O
breast O
and O
multiple O
tubular O
adenomas O
, O
fibroadenomas O
and O
intraductal O
papillomas O
in O
both O
breasts O
. O

 O
The O
patient O
had O
no O
family O
history O
of O
breast B
cancer I
or O
Cowden B
syndrome I
. O

This O
, O
with O
a O
and O
, O
had O
recently O
noticed O
left O
arm O
exercise O
. O

 O
The O
and O
of O
the O
showed O
critical O
of O
the O
with O
near O
the O
( O
Fig.1 O
) O
. O

 O
Percutaneous O
was O
done O
via O
, O
and O
severe O
left O
SCA O
was O
confirmed O
( O
Fig.2A O
) O
( O
Supplementary O
Video O
1 O
, O
only O
online O
) O
. O

 O
Direct O
in O
the O
was O
carried O
out O
with O
a O
( O
Boston O
Scientific O
Corporation O
, O
Natick O
, O
MA O
, O
USA O
) O
( O
Fig.2B O
) O
up O
to O
. O

 O
However O
, O
and O
developed O
after O
. O

 O
The O
was O
down O
to O
, O
and O
the O
was O
up O
to O
. O

 O
The O
was O
down O
to O
. O

 O
Emergent O
, O
, O
with O
were O
given O
. O

 O
The O
immediate O
showed O
in O
the O
( O
Fig.2C O
) O
( O
Supplementary O
Video O
2 O
, O
only O
online O
) O
. O

 O
Emergency O
was O
done O
with O
an O
. O

 O
The O
cardiovascular O
surgeon O
was O
also O
. O

 O
However O
, O
due O
to O
the O
high O
surgical O
risk O
of O
bypass O
, O
was O
suggested O
. O

 O
We O
decided O
to O
do O
a O
retrograde O
approach O
through O
the O
left O
brachial O
artery O
by O
surgical O
cut O
- O
down O
. O

 O
Since O
there O
was O
no O
suitable O
graft O
stent O
in O
our O
cath O
lab O
, O
we O
modified O
and O
cut O
the O
iliac O
extension O
of O
self O
- O
expanding O
Endurant O
II O
graft O
stent O
1082 O
mm O
( O
Medtronic O
, O
Inc. O
, O
Minneapolis O
, O
MN O
, O
USA O
) O
, O
which O
was O
originally O
designed O
to O
treat O
abdominal O
aortic O
aneurysms O
( O
AAA O
) O
, O
to O
a O
suitable O
length O
( O
around O
30 O
mm O
) O
( O
Fig.3 O
) O
. O

 O
After O
retrograde O
wiring O
, O
an O
operator O
- O
modified O
Endurant O
II O
graft O
stent O
was O
deployed O
in O
the O
stent O
segment O
( O
Fig.2D O
) O
and O
the O
perforation O
was O
sealed O
successfully O
. O

 O
After O
stenting O
of O
the O
graft O
stent O
, O
however O
, O
slow O
flow O
of O
left O
common O
carotid O
artery O
( O
LCCA O
) O
was O
noted O
, O
and O
angiography O
confirmed O
the O
near O
total O
occlusion O
of O
the O
LCCA O
, O
occluded O
by O
the O
SCA O
graft O
stent O
( O
Fig.2E O
) O
( O
Supplementary O
Video O
3 O
, O
only O
online O
) O
. O

 O
A O
firm O
wire O
( O
Conquest O
pro O
, O
Asahi O
Inc O
, O
Seto O
, O
Japan O
) O
was O
successfully O
advanced O
outside O
the O
graft O
stent O
and O
into O
the O
LCCA O
. O

 O
Despite O
sequent O
balloon O
dilations O
at O
the O
bifurcation O
site O
, O
the O
flow O
to O
the O
LCCA O
was O
still O
poor O
. O

 O
Intravascular O
ultrasound O
also O
confirmed O
the O
severe O
compromise O
of O
the O
LCCA O
ostium O
which O
was O
caused O
by O
the O
graft O
stent O
( O
Fig.2F O
) O
. O

 O
Therefore O
, O
we O
put O
a O
balloon O
- O
expansible O
carotid O
stent O
, O
Express O
737 O
mm O
( O
Boston O
Scientific O
Corporation O
) O
, O
from O
the O
LCCA O
to O
the O
left O
brachiocephalic O
artery O
( O
Fig.4A O
) O
. O

 O
TIMI O
III O
flow O
of O
the O
LCCA O
was O
restored O
after O
stenting O
( O
Fig.4B O
- O
E O
) O
( O
Supplementary O
Video O
4 O
, O
only O
online O
) O
. O

 O
Intravascular O
ultrasound O
also O
confirmed O
proper O
expansion O
of O
the O
LCCA O
stent O
( O
Fig.4F O
) O
. O

 O
The O
follow O
- O
up O
chest O
radiography O
revealed O
left O
- O
side O
hemothorax O
. O

 O
After O
thoracocentesis O
with O
drainage O
and O
proper O
care O
, O
the O
patient O
was O
discharged O
. O

 O
Till O
now O
, O
the O
patient O
has O
been O
free O
from O
for O
. O

This O
was O
the O
first O
child O
to O
. O

 O
. O

 O
He O
was O
well O
until O
starting O
school O
at O
when O
he O
was O
found O
to O
be O
, O
, O
and O
to O
have O
. O

 O
were O
performed O
that O
initially O
revealed O
borderline O
values O
for O
and O
he O
was O
therefore O
treated O
for O
a O
period O
with O
without O
any O
. O

 O
At O
age O
16 O
years O
, O
compared O
with O
a O
standardized O
Swedish O
growth O
chart O
. O

 O
at O
showed O
and O
. O

 O
An O
was O
performed O
and O
showed O
a O
severe O
. O

 O
He O
had O
decreased O
, O
, O
, O
and O
. O

 O
has O
been O
noted O
since O
. O

 O
A O
year O
later O
, O
and O
were O
developed O
. O

 O
The O
at O
. O

 O
He O
is O
now O
blind O
. O

 O
At O
, O
he O
was O
referred O
for O
. O

 O
A O
showed O
mild O
, O
and O
together O
with O
mild O
to O
moderate O
, O
in O
the O
, O
and O
. O

 O
revealed O
a O
mild O
bilateral O
. O

 O
At O
, O
he O
had O
an O
and O
he O
has O
since O
then O
been O
with O
. O

 O
was O
identified O
at O
, O
with O
increased O
to O
( O
reference O
interval O
3090 O
 O
mol O
/ O
l O
) O
, O
with O
at O
( O
reference O
interval<20 O
 O
mg O
/ O
l O
) O
, O
and O
ratio O
at O
( O
reference O
interval O
<3 O
 O
g O
/ O
mol O
) O
. O

 O
A O
demonstrated O
. O

 O
showed O
a O
of O

 O
The O
over O
time O
to O
at O
. O

 O
Since O
14 O
years O
of O
age O
, O
have O
demonstrated O
of O
the O
( O
+3 O
SD O
compared O
with O
normal O
) O
with O
normal O
systolic O
and O
diastolic O
function O
and O
without O
obstruction O
of O
the O
outflow O
. O

 O
were O
performed O
at O
. O

 O
Blood O
levels O
of O
and O
were O
and O
, O
respectively O
, O
leading O
to O
a O
ratio O
of O
33 O
( O
reference O
interval O
< O
20 O
) O
, O
while O
( O
) O
levels O
of O
and O
were O
and O
respectively O
, O
leading O
to O
a O
of O
. O

 O
The O
was O
. O

 O
The O
was O
increased O
to O
( O
reference O
level O
< O
225 O
 O
mg O
/ O
l O
) O
and O
he O
also O
had O
an O
increased O
of O
( O
reference O
level O
< O
5 O
) O
. O

 O
The O
and O
were O
normal O
. O

 O
The O
was O
to O
( O
reference O
interval O
< O
3.5 O
 O
kat O
/ O
l O
) O
. O

The O
institutional O
review O
board O
( O
Chengdu O
Military O
General O
Hospital O
) O
approved O
this O
work O
and O
waived O
the O
need O
for O
informed O
consent O
. O

 O
In O
, O
a O
with O
a O
history O
of O
and O
hypertension O
presented O
to O
the O
Emergency O
Department O
with O
continuous O
, O
, O
profuse O
and O
with O
no O
obvious O
predisposing O
causes B
. O

 O
The O
patient O
experienced O
a O
sudden O
drop O
in O
and O
acute O
. O

 O
After O
an O
immediate O
, O
his O
was O
gradually O
restored O
, O
and O
relieved O
. O

 O
Then O
, O
this O
patient O
was O
to O
the O
for O
further O
and O
. O

 O
The O
patient O
's O
was O
upon O
admission O
, O
with O
a O
of O
, O
of O
and O
of O
. O

 O
The O
heart O
border O
, O
with O
the O
located O
in O
the O
, O
. O

 O
The O
patient O
had O
a O
history O
of O
hypertension O
over O
without O
regular O
. O

 O
The O
highest O
was O
. O

 O
There O
was O
. O

 O
He O
. O

 O
He O
also O
reported O
. O

 O
Twelve O
- O
lead O
surface O
( O
) O
of O
VT B
indicated O
that O
the O
origin O
of O
VT O
was O
at O
the O
boundary O
between O
( O
) O
and O
. O

 O
When O
VT B
increased O
to O
, O
no O
were O
found O
in O
the O
( O
Figure1A O
and O
B O
) O
. O

 O
In O
contrast O
, O
when O
VT B
to O
, O
appeared O
in O
( O
Figure1C O
) O
. O

 O
Notably O
, O
the O
epsilon O
waves O
preceded O
QRS O
waves O
in O
leads O
V1 O
 O
V2 O
, O
while O
endocardiac O
tracing O
confirmed O
that O
the O
corresponding O
local O
potential O
originating O
from O
RVOT O
appeared O
prior O
to O
the O
ventricular O
rhythm O
( O
Figure O
(Figure1D).1D O
) O
. O

 O
Sinus O
ECG O
in O
the O
year O
of O
2013 O
suggested O
a O
slight O
left O
deviation O
of O
electric O
axis O
, O
with O
a O
heart O
rate O
of O
87 O
beats O
/ O
min O
and O
flat O
T O
waves O
in O
lead O
II O
. O

 O
T O
wave O
inversions O
were O
found O
in O
leads O
III O
, O
avF O
and O
V1 O
 O
V3 O
, O
meanwhile O
epsilon O
waves O
were O
found O
following O
QRS O
complex O
in O
leads O
V1 O
 O
V3 O
( O
Figure O
(Figure2B).2B O
) O
. O

 O
When O
the O
lead O
avR O
was O
amplified O
, O
epsilon O
waves O
were O
also O
found O
behind O
QRS O
waves O
( O
Figure O
2C O
) O
. O

 O
Atrial O
premature O
beats O
appeared O
occasionally O
. O

 O
Moreover O
, O
ventricular O
premature O
beats O
were O
also O
found O
to O
originate O
from O
the O
right O
ventricular O
apex O
, O
with O
epsilon O
waves O
appearing O
behind O
QRS O
waves O
( O
Figure O
(Figure2B).2B O
) O
. O

 O
In O
contrast O
, O
sinus O
ECG O
obtained O
in O
the O
year O
of O
1999 O
revealed O
similar O
left O
deviation O
of O
electric O
axis O
, O
flat O
T O
waves O
and O
T O
wave O
inversions O
, O
but O
absence O
of O
epsilon O
waves O
( O
Figure O
(Figure2A).2A O
) O
. O

 O
Data O
from O
biochemical O
assays O
were O
as O
follows O
: O
cardiac O
troponin O
I O
level O
was O
0.714 O
 O
g O
/ O
L O
( O
normal O
range O
, O
00.06 O
 O
g O
/ O
L O
) O
, O
serum O
B O
- O
type O
natriuretic O
peptide O
level O
was O
466.530 O
 O
pg O
/ O
mL O
( O
normal O
range O
, O
0100 O
 O
pg O
/ O
mL O
) O
, O
serum O
d O
- O
dimer O
level O
was O
8.14 O
 O
mg O
/ O
L O
( O
normal O
range O
, O
00.55 O
 O
mg O
/ O
L O
) O
, O
blood O
urea O
level O
was O
11.69 O
 O
mmol O
/ O
L O
( O
normal O
range O
, O
2.907.20 O
 O
mmol O
/ O
L O
) O
, O
serum O
creatinine O
level O
was O
144.00 O
 O
mol O
/ O
L O
( O
normal O
range O
, O
44133 O
 O
mol O
/ O
L O
) O
, O
serum O
uric O
acid O
level O
was O
611.40 O
 O
mol O
/ O
L O
( O
normal O
range O
, O
100432 O
 O
mol O
/ O
L O
) O
, O
and O
endogenous O
creatinine O
clearing O
value O
was O
57.90 O
 O
mL O
/ O
min O
( O
normal O
range O
, O
> O
80 O
 O
mL O
/ O
min O
) O
. O

 O
Echo O
data O
revealed O
remarkably O
enlarged O
right O
atrium O
and O
right O
ventricle O
, O
and O
widened O
ROVT O
. O

 O
Uncoordinated O
motions O
of O
the O
left O
and O
right O
ventricular O
walls O
were O
also O
detected O
. O

 O
Moreover O
, O
we O
also O
found O
aortic O
valve O
degradation O
with O
slight O
regurgitation O
, O
slight O
mitral O
regurgitation O
, O
and O
moderate O
to O
severe O
tricuspid O
regurgitation O
. O

 O
The O
left O
ventricular O
diastolic O
function O
was O
reduced O
to O
55 O
% O
( O
Figure O
3A O
and O
B O
) O
. O

 O
The O
coronary O
angiogram O
revealed O
no O
vascular O
stenosis O
( O
Figure O
3C O
 O
E O
) O
. O

 O
Based O
on O
the O
above O
- O
mentioned O
examinations O
, O
this O
patient O
met O
at O
least O
2 O
major O
criteria O
, O
the O
bilateral O
ventricular O
dilation O
and O
the O
existence O
of O
epsilon O
waves O
, O
providing O
diagnostic O
support O
for O
ARVC O
. O

 O
A O
diet O
with O
low O
salt O
and O
low O
fat O
was O
suggested O
. O

 O
The O
patient O
was O
also O
treated O
with O
metoprolol O
succinate O
sustained O
- O
release O
tablets O
( O
23.75 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
amiodarone O
( O
200 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
furosemide O
( O
20 O
 O
mg O
daily O
, O
i.v O
. O
) O
, O
and O
compound O
 O
- O
ketoacid O
tablets O
( O
2.52 O
 O
g O
daily O
, O
p.o O
. O
) O
. O

 O
Moreover O
, O
VTs O
with O
different O
morphologies O
and O
cycle O
lengths O
were O
found O
during O
radiofrequency O
ablation O
( O
Figure O
4 O
) O
. O

 O
The O
substrate O
voltage O
mapping O
revealed O
that O
the O
anterior O
wall O
of O
RVOT O
was O
wrapped O
by O
circular O
scar O
( O
Figure O
5A O
) O
. O

 O
Considering O
the O
association O
of O
VT O
with O
scar O
areas O
, O
substrate O
ablation O
was O
chosen O
for O
this O
patient O
. O

 O
The O
residual O
potentials O
in O
the O
scar O
areas O
were O
searched O
, O
and O
then O
linear O
and O
focal O
ablations O
were O
performed O
( O
Figure O
5B O
) O
. O

 O
Neither O
programmed O
stimulation O
nor O
induced O
stimulation O
could O
induce O
VT O
after O
the O
procedure O
was O
completed O
, O
indicating O
the O
success O
of O
operation O
. O

 O
The O
ECG O
after O
radiofrequency O
ablation O
showed O
sinus O
rhythm O
, O
with O
a O
heart O
rate O
of O
61 O
beats O
/ O
min O
, O
T O
wave O
inversions O
in O
leads O
III O
and O
avF O
, O
and O
epsilon O
waves O
and O
T O
wave O
inversions O
in O
leads O
V1 O
 O
V3 O
( O
Figure O
2D O
) O
. O

 O
This O
patient O
was O
discharged O
from O
hospital O
on O
day O
9 O
with O
a O
regimen O
of O
metoprolol O
succinate O
sustained O
- O
release O
tablets O
( O
23.75 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
amiodarone O
hydrochloride O
tablets O
( O
200 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
spironolactone O
tablets O
( O
40 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
and O
fosinopril O
sodium O
tablets O
( O
10 O
 O
mg O
daily O
, O
p.o O
. O
) O
. O

 O
The O
patient O
was O
followed O
up O
3 O
months O
after O
discharge O
. O

 O
He O
had O
no O
recurrent O
, O
chest O
, O
profuse O
or O
. O

 O
. O

A O
to O
our O
with O
complaints O
of O
since O
to O
admission O
. O

 O
on O
admission O
revealed O
an O
elevation O
of O
, O
, O
, O
and O
. O

 O
Serum O
total O
bilirubin O
and O
tumor O
markers O
, O
carcinoembryonic O
antigen O
( O
CEA O
) O
, O
carbohydrate O
antigen O
19 O
- O
9 O
( O
CA19 O
- O
9 O
) O
, O
SPan-1 O
, O
and O
neuron O
- O
specific O
enolase O
( O
NSE O
) O
, O
were O
all O
within O
normal O
ranges O
. O

 O
Abdominal O
computed O
tomography O
( O
CT O
) O
and O
magnetic O
resonance O
cholangiopancreatography O
( O
MRCP O
) O
showed O
a O
mass O
in O
an O
enlarged O
gallbladder O
and O
bulky O
hepatic O
lymph O
nodes O
surrounding O
the O
hepatic O
hilum O
( O
Fig.1a O
, O
b O
) O
. O

 O
There O
were O
also O
no O
apparent O
lesions O
in O
upper O
and O
lower O
gastrointestinal O
endoscopy O
. O

 O
Endoscopic O
ultrasound O
- O
guided O
fine O
- O
needle O
aspiration O
( O
EUS O
- O
FNA O
) O
was O
performed O
to O
obtain O
tissue O
from O
the O
hilar O
lymph O
node O
. O

 O
Immunohistochemical O
staining O
of O
the O
specimen O
identified O
diffuse O
positivity O
for O
keratin O
, O
CD56 O
, O
and O
synaptophysin O
in O
the O
tumor O
cells O
, O
which O
is O
consistent O
with O
NEC O
. O

 O
An O
endoscopic O
naso O
- O
gallbladder O
drainage O
( O
ENGBD O
) O
catheter O
was O
placed O
, O
and O
the O
bile O
cytology O
revealed O
class O
V O
malignant O
cells O
. O

 O
Therefore O
, O
positron O
emission O
tomography O
/ O
computed O
tomography O
( O
PET O
/ O
CT O
) O
examination O
was O
performed O
to O
evaluate O
other O
primary O
or O
metastatic O
lesions O
. O

 O
It O
revealed O
that O
no O
other O
accumulated O
lesions O
were O
identified O
, O
and O
the O
accumulation O
of O
18F O
fluorodeoxyglucose O
( O
FDG O
) O
was O
in O
the O
gallbladder O
( O
SUVmax O
7.8 O
) O
and O
lymph O
nodes O
( O
SUVmax O
13.4 O
) O
( O
Fig.1c O
, O
d O
) O
. O

 O
On O
the O
basis O
of O
these O
findings O
, O
the O
most O
likely O
diagnosis O
was O
a O
gallbladder O
NEC O
that O
was O
confined O
to O
the O
regional O
hepatic O
hilar O
lymph O
nodes O
metastasis O
. O

 O
Finally O
, O
we O
decided O
to O
perform O
surgical O
resection O
prior O
to O
chemotherapy O
because O
of O
concerns O
about O
complications O
developing O
from O
mechanical O
obstruction O
of O
the O
hepatic O
hilum O
by O
the O
enlarged O
lymph O
node O
. O

 O
She O
underwent O
cholecystectomy O
, O
hepatic O
hilar O
lymphadenectomy O
, O
extrahepatic O
biliary O
duct O
resection O
, O
and O
hepaticojejunostomy O
. O

 O
The O
bulky O
lymph O
nodes O
were O
totally O
resected O
as O
 O
en O
bloc O
 O
. O

 O
There O
were O
no O
apparent O
residual O
lesions O
surgically O
. O

 O
The O
postoperative O
course O
was O
uneventful O
and O
she O
was O
discharged O
on O
the O
tenth O
day O
after O
surgery O
. O

 O
Macroscopically O
, O
the O
tumor O
was O
58 O
 O
 O
 O
42 O
mm O
in O
size O
and O
was O
located O
in O
the O
fundus O
, O
which O
contained O
a O
yellowish O
gallstone O
( O
Fig.2a O
) O
. O

 O
A O
portion O
of O
the O
hepatic O
hilar O
lymph O
nodes O
( O
71 O
 O
 O
 O
37 O
mm O
) O
was O
also O
excised O
separately O
( O
Fig.2b O
) O
. O

 O
Microscopic O
examination O
of O
the O
gallbladder O
revealed O
a O
moderate O
to O
well O
differentiated O
tubular O
adenocarcinoma O
infiltrating O
from O
the O
mucosa O
to O
the O
muscular O
layer O
, O
but O
not O
the O
serosal O
surface O
, O
without O
any O
NEC O
components O
( O
Fig.2c O
, O
d O
) O
. O

 O
The O
tumor O
cells O
in O
the O
gallbladder O
are O
slightly O
positive O
for O
synaptophysin O
and O
CD56 O
, O
but O
negative O
for O
chromogranin O
A O
( O
Fig.2e O
 O
g O
) O
. O

 O
The O
resection O
margin O
from O
the O
liver O
bed O
was O
negative O
for O
tumor O
cells O
. O

 O
The O
epithelium O
around O
the O
carcinoma O
showed O
intestinal O
metaplasia O
with O
the O
goblet O
cells O
( O
Fig.4a O
) O
, O
which O
area O
was O
stained O
by O
alcian O
blue O
( O
Fig.4b O
) O
. O

 O
On O
the O
other O
hand O
, O
the O
hepatic O
hilar O
lymph O
nodes O
were O
composed O
of O
small O
round O
tumor O
cells O
with O
hyperchromatic O
nuclei O
and O
scant O
cytoplasm O
( O
Fig.3a O
) O
. O

 O
Some O
of O
the O
tumor O
cells O
were O
large O
and O
had O
vesicular O
nuclei O
. O

 O
The O
tumor O
cells O
were O
arranged O
in O
sheets O
, O
cords O
, O
or O
in O
a O
trabecular O
or O
rosette O
fashion O
and O
were O
interspersed O
with O
focal O
necrosis O
. O

 O
They O
were O
immunohistochemically O
positive O
for O
CD56 O
, O
synaptophysin O
, O
and O
chromogranin O
A O
( O
Fig.3b3d O
) O
. O

 O
The O
mitotic O
count O
was O
24 O
per O
10 O
high O
- O
power O
microscopic O
fields O
, O
and O
the O
Ki-67 O
proliferation O
index O
was O
7080 O
% O
, O
consistent O
with O
NEC O
. O

 O
The O
surgical O
dissection O
margin O
of O
the O
hepatic O
lymph O
nodes O
was O
microscopically O
cauterized O
within O
the O
tumor O
cells O
. O

 O
There O
was O
no O
invasion O
to O
the O
extrahepatic O
biliary O
duct O
. O

 O
As O
the O
result O
of O
thorough O
pathological O
re O
- O
evaluation O
by O
total O
segmentation O
, O
a O
negligible O
area O
of O
adenocarcinoma O
was O
detected O
in O
the O
lymph O
nodes O
( O
Fig.3e O
, O
f O
) O
. O

 O
The O
adenocarcinoma O
component O
and O
the O
intestinal O
metaplastic O
epithelium O
in O
the O
gallbladder O
were O
both O
positive O
for O
CDX2 O
( O
Fig.4a O
) O
, O
but O
the O
neuroendocrine O
component O
in O
hilar O
lymph O
nodes O
was O
negative O
for O
CDX2 O
( O
Fig.4b O
) O
. O

 O
Postoperatively O
, O
the O
patient O
received O
three O
cycles O
of O
carboplatin O
( O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
repeated O
every O
21 O
days O
) O
and O
etoposide O
( O
80 O
mg O
/ O
m2 O
on O
days O
1 O
through O
3 O
repeated O
every O
21 O
days O
) O
. O

 O
During O
the O
first O
course O
, O
grade O
4 O
neutropenia O
occurred O
and O
it O
was O
managed O
with O
prophylactic O
fluoroquinolones O
. O

 O
After O
4 O
months O
, O
multiple O
recurrences O
in O
the O
para O
- O
aortic O
lymph O
nodes O
were O
detected O
, O
which O
was O
pathologically O
demonstrated O
via O
EUS O
- O
FNA O
to O
be O
NEC O
. O

 O
The O
patient O
underwent O
second O
- O
line O
chemotherapy O
with O
amrubicin O
( O
24 O
mg O
/ O
m2 O
on O
days O
1 O
through O
3 O
repeated O
every O
21 O
days O
) O
. O

 O
Grade O
4 O
neutropenia O
and O
anemia O
developed O
during O
the O
courses O
, O
and O
she O
needed O
to O
receive O
pegylated O
granulocyte O
colony O
- O
stimulating O
factor O
and O
red O
blood O
cell O
transfusion O
. O

 O
However O
, O
she O
of O
progressive B
disease I
surgery O
. O

The O
was O
to O
hospital O
in O
the O
with O
( O
) O
. O

 O
After O
receiving O
was O
. O

 O
All O
, O
were O
. O

 O
the O
, O
and O
the O
was O
performed O
because O
of O
. O

 O
Liveborn O
female O
and O
male O
were O
delivered O
. O

 O
The O
postoperative O
course O
was O
initially O
. O

 O
she O
experienced O
sudden O
. O

 O
The O
rose O
to O
. O

 O
Laboratory O
findings O
showed O
, O
, O
and O
an O
increase O
in O
serum O
creatinine O
and O
aminotransferases O
( O
Table O
I O
) O
. O

 O
Intravenous O
was O
administered O
. O

 O
disclosed O
an O
empty O
without O
. O

 O
, O
the O
patient O
was O
to O
the O
because O
of O
, O
, O
and O
suspicion O
of O
DIC B
. O

 O
On O
she O
was O
and O
. O

 O
The O
combination O
of O
, O
, O
and O
suggested O
a O
postpartum B
HELLP I
syndrome I
, O
complicated O
by O
. O

 O
The O
patient O
was O
, O
and O
treatment O
was O
instituted O
with O
fresh O
plasma O
, O
, O
platelets O
, O
and O
kybernin O
P O
( O
) O
. O

 O
High O
, O
, O
and O
were O
compatible O
with O
acute O
renal B
failure I
. O

 O
A O
of O
failed O
to O
. O

 O
her O
was O
and O
. O

 O
the O
patient O
had O
acute O
cardiac B
arrest I
, O
and O
started O
. O

 O
was O
successful O
, O
and O
was O
re O
- O
established O
; O
rose O
to O
, O
and O
was O
. O

 O
were O
, O
and O
development O
of O
acute O
indicated O
the O
necessity O
of O
urgent O
. O

 O
, O
the O
patient O
was O
, O
. O

 O
patient O
developed O
again O
cardiopulmonary B
arrest I
. O

 O
Despite O
the O
outcome O
was O
. O

 O
Due O
to O
the O
fact O
that O
death O
occurred O
in O
the O
hospital O
a O
short O
time O
after O
a O
surgical O
intervention O
, O
a O
was O
. O

 O
An O
revealed O
of O
the O
and O
as O
well O
as O
of O
right O
and O
left O
ventricles O
. O

 O
( O
900 O
mL O
) O
, O
( O
2500 O
mL O
) O
, O
and O
( O
) O
were O
present O
. O

 O
The O
field O
of O
operation O
of O
the O
caesarean O
section O
was O
unremarkable O
. O

 O
were O
observed O
under O
the O
, O
, O
in O
the O
of O
the O
, O
and O
of O
the O
. O

 O
revealed O
, O
with O
and O
, O
as O
well O
as O
confluent O
in O
, O
, O
and O
. O

 O
was O
attributed O
to O
organ B
failure I
due O
to O
DIC B
as O
a O
consequence O
of O
HELLP B
syndrome I
. O

A O
presented O
with O
left O
flank O
dull O
. O

 O
On O
the O
abdominal O
, O
a O
solid O
renal O
in O
the O
was O
identified O
. O

 O
The O
was O
measured O
in O
size O
, O
was O
. O

 O
The O
patient O
had O
no O
, O
such O
as O
suspected O
distant O
or O
lymph O
node O
. O

 O
Radical O
was O
performed O
on O
. O

 O
On O
, O
the O
measured O
and O
the O
was O
a O
solid O
, O
measured O
in O
size O
. O

 O
demonstrated O
trabecular O
and O
ribbonlike O
patterns O
with O
minimal O
fibrotic O
stroma O
. O

 O
The O
was O
and O
with O
with O
and O
. O

 O
Mitoses O
were O
not O
found O
( O
0 O
per O
10 O
high O
- O
power O
fields O
) O
on O
. O

 O
The O
final O
revealed O
a O
well O
- O
differentiated O
neuroendocrine B
( I
carcinoid I
) I
tumor I
confined O
to O
the O
( O
Fig.1 O
) O
. O

 O
demonstrated O
labeling O
with O
, O
and O
( O
Fig.2 O
) O
, O
and O
the O
was O
as O
measured O
by O
. O

 O
Further O
and O
were O
not O
received O
. O

 O
radical O
nephrectomy O
, O
of O
the O
demonstrated O
a O
2 O
cm O
 O
 O
 O
1.8 O
cm O
cyst O
in O
the O
and O
multiple O
in O
. O

 O
No O
were O
found O
in O
the O
. O

 O
and O
for O
hepatic B
cyst I
were O
performed O
by O
. O

 O
demonstrated O
( O
Fig.3 O
) O
, O
and O
( O
) O
. O

 O
Advanced O
revealed O
that O
the O
was O
for O
( O
Fig.4 O
) O
and O
CD56 O
, O
but O
negative O
for O
and O
. O

 O
These O
features O
are O
supported O
in O
a O
neuroendocrine B
tumor I
. O

 O
Due O
to O
the O
similar O
pathologic O
characteristics O
between O
the O
primary O
renal O
carcinoid O
tumor O
and O
liver O
tumor O
. O

 O
The O
final O
pathology O
report O
indicated O
a O
carcinoid B
tumor I
of O
the O
with O
liver O
. O

A O
with O
in O
the O
and O
. O

 O
and O
a O
revealed O
a O
in O
the O
, O
with O
a O
well O
defined O
located O
at O
the O
. O

 O
The O
patient O
underwent O
, O
and O
her O
postoperative O
clinical O
course O
was O
uneventful O
. O

 O
of O
the O
showed O
an O
, O
which O
was O
filled O
with O
thick O
. O

 O
A O
distinct O
which O
involved O
the O
, O
and O
measured O
maximally O
, O
was O
identified O
in O
the O
. O

 O
There O
was O
no O
evidence O
of O
, O
of O
into O
the O
, O
or O
pseudomyxoma B
peritonei I
during O
surgery O
. O

 O
showed O
combined O
GCC B
and O
MCA B
of O
the O
( O
Figure O
1A O
) O
. O

 O
The O
was O
and O
lined O
by O
mucin O
- O
containing O
( O
Figure O
1B O
) O
. O

 O
There O
was O
no O
significant O
, O
and O
no O
were O
identified O
. O

 O
of O
the O
, O
and O
mild O
were O
present O
. O

 O
In O
addition O
, O
the O
appendiceal O
wall O
was O
infiltrated O
by O
of O
which O
were O
arranged O
in O
and O
. O

 O
These O
comprised O
2 O
distinct O
types O
of O
cells O
: O
( O
1 O
) O
small O
to O
intermediate O
sized O
monotonous O
with O
a O
small O
amount O
of O
finely O
granular O
eosinophilic O
cytoplasm O
, O
and O
mild O
( O
Figure O
(Figure1C);1C O
) O
; O
( O
2 O
) O
mucin O
- O
filled O
intermediate O
sized O
cells O
( O
) O
, O
with O
peripherally O
located O
small O
, O
crescent O
- O
like O
, O
and O
indistinct O
( O
Figure O
(Figure1D).1D O
) O
. O

 O
Scattered O
infiltrating O
single O
goblet O
neoplastic O
cells O
were O
. O

 O
As O
previously O
described[1 O
] O
the O
tumor O
nests O
appeared O
to O
arise O
from O
the O
basiglandular O
region O
of O
the O
intestinal O
crypts O
in O
close O
proximity O
to O
the O
MCA O
( O
Figure O
(Figure1E).1E O
) O
. O

 O
There O
was O
no O
, O
although O
perineural O
and O
was O
present O
. O

 O
The O
infiltrated O
the O
full O
thickness O
of O
the O
and O
extended O
to O
the O
. O

 O
Ten O
lymph O
nodes O
were O
histologically O
identified O
, O
of O
which O
all O
were O
negative O
for O
malignancy B
. O

 O
( O
Table O
1 O
) O
, O
the O
of O
the O
GCC B
were O
positive O
for O
, O
, O
and O
, O
which O
are O
. O

 O
Diffuse O
staining O
for O
( O
CK O
) O
20 O
( O
Figure O
2 O
) O
, O
and O
was O
also O
present O
. O

 O
The O
revealed O
nuclear O
staining O
in O
approximately O
15 O
% O
of O
the O
tumor O
cells O
. O

 O
There O
was O
no O
staining O
for O

A O
child O
to O
our O
for O
abdominal O
. O

 O
The O
child O
occasionally O
felt O
that O
was O
. O

 O
The O
child O
showed O
no O
obvious O
and O
. O

 O
He O
was O
. O

 O
His O
medical O
history O
included O
, O
but O
he O
had O
only O
received O
an O
. O

 O
. O

 O
of O
this O
child O
showed O
that O
the O
abdomen O
was O
obviously O
. O

 O
The O
could O
be O
touched O
. O

 O
There O
were O
no O
other O
positive O
signs O
. O

 O
The O
results O
of O
were O
, O
including O
( O
) O
level O
. O

 O
The O
was O
. O

 O
Abdominal O
showed O
an O
uneven O
in O
the O
and O
a O
diagnosis O
of O
HB B
was O
considered O
. O

 O
Enhancement O
( O
) O
scanning O
showed O
a O
large O
in O
the O
and O
with O
an O
. O

 O
The O
size O
of O
the O
was O
( O
Fig.1 O
) O
. O

 O
There O
was O
an O
uneven O
nodular O
shadow O
and O
the O
edge O
was O
obvious O
when O
the O
was O
enhanced O
. O

 O
and O
an O
were O
not O
observed O
. O

 O
The O
was O
pressed O
and O
the O
. O

 O
Abnormal O
was O
not O
observed O
in O
the O
. O

 O
According O
to O
the O
medical O
history O
, O
the O
diagnosis O
of O
HB B
was O
considered O
. O

 O
We O
did O
not O
recommend O
a O
to O
the O
patient O
because O
it O
might O
cause O
bleeding O
and O
tumor O
diffusion O
. O

 O
An O
was O
necessary O
. O

 O
The O
patient O
underwent O
. O

 O
showed O
an O
in O
the O
( O
Fig.2 O
) O
. O

 O
After O
the O
operation O
, O
the O
sample O
was O
split O
. O

 O
The O
edge O
of O
the O
tumor O
was O
clear O
but O
no O
envelope O
. O

 O
Tremelloid O
mesenchyme O
was O
seen O
on O
the O
section O
( O
Fig.2C O
) O
. O

 O
The O
pathological O
examination O
showed O
that O
the O
sample O
was O
grey O
red O
and O
14 O
 O
 O
 O
13 O
 O
 O
 O
7 O
 O
cm O
in O
size O
. O

 O
The O
color O
of O
the O
section O
was O
grey O
red O
and O
grey O
white O
. O

 O
MHL B
was O
diagnosed O
( O
Fig.3 O
) O
. O

 O
( O
Fig.4 O
) O
were O
the O
following O
: O
( O
+ O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
) O
. O

 O
After O
9 O
days O
of O
, O
the O
patient O
without O
. O

 O
A O
follow O
- O
up O
examination O
, O
which O
included O
, O
, O
, O
and O
at O
, O
did O
not O
show O
any O
. O

 O
No O
was O
presented O
. O

A O
patient O
with O
a O
treated O
by O
in O
for O
a O
painful O
erythematous O
of O
the O
. O

 O
The O
were O
, O
the O
was O
considered O
as O
an O
abscesses O
and O
the O
patient O
was O
treated O
with O
and O
without O
. O

 O
The O
evolution O
was O
characterized O
by O
the O
appearance O
of O
an O
erythematous O
vesiculobullous O
taking O
the O
treated O
several O
times O
by O
unsuccessfully O
. O

 O
of O
this O
lesion O
was O
initially O
. O

 O
In O
, O
the O
patient O
was O
for O
and O
in O
the O
context O
of O
. O

 O
He O
had O
a O
quiescent O
UC B
disease I
. O

 O
The O
found O
an O
erythematous O
of O
of O
diameter O
, O
with O
a O
and O
, O
taking O
the O
and O
( O
Figure O
1 O
) O
. O

 O
There O
was O
also O
an O
infiltrated O
erythematous O
on O
the O
( O
Figure O
2 O
) O
and O
another O
topped O
with O
a O
large O
pustule O
at O
the O
( O
Figure O
3 O
) O
. O

 O
In O
biology O
, O
there O
was O
a O
biological B
inflammatory I
syndrome I
and O
high O
. O

 O
and O
were O
. O

 O
showed O
at O
the O
and O
the O
dermis O
infiltrate O
rich O
in O
neutrophils O
with O
leukocytoclastic O
vasculitis O
finding O
a O
PG B
( O
Figure O
4 O
) O
. O

 O
Other O
biopsies O
taken O
at O
infiltrated O
erythematous O
plaques O
of O
the O
ankle O
showed O
a O
normal O
appearance O
of O
skin O
, O
edema O
of O
the O
superficial O
dermis O
based O
on O
an O
infiltrate O
rich O
in O
neutrophils O
without O
vasculitis O
confirming O
the O
diagnosis O
of O
SS B
( O
Figure O
5 O
) O
. O

 O
treatment O
was O
then O
started O
with O
at O
a O
dose O
of O
1mg O
/ O
Kg O
/ O
j. O

 O
The O
evolution O
was O
marked O
by O
the O
( O
Figure O
6 O
) O
, O
the O
and O
disappearance O
of O
biological B
inflammatory I
syndrome I
. O

Our O
patient O
was O
a O
with O
chronic O
obstructive O
pulmonary O
disease O
. O

 O
She O
had O
but O
was O
found O
to O
have O
a O
progressive O
solitary O
pulmonary O
( O
) O
. O

 O
A O
right O
lower O
wedge O
was O
performed O
in O
and O
the O
identified O
the O
as O
a O
LCNEC B
. O

 O
Approximately O
her O
operation O
, O
our O
patient O
started O
having O
slowly O
progressing O
. O

 O
A O
( O
) O
scan O
performed O
in O
, O
, O
was O
for O
recurrence O
or O
metastasis O
. O

 O
Repeat O
( O
) O
in O
( O
) O
did O
not O
show O
any O
( O
Figure O
1 O
) O
. O

 O
Our O
patient O
had O
an O
( O
) O
and O
that O
revealed O
no O
of O
her O
but O
of O
and O
. O

 O
In O
, O
found O
of O
the O
, O
with O
a O
of O
. O

 O
Our O
patient O
was O
treated O
with O
with O
partial O
. O

 O
Thus O
far O
, O
resection O
, O
our O
patient O
had O
been O
able O
to O
maintain O
her O
and O
her O
, O
including O
, O
and O
levels O
. O

 O
However O
, O
in O
, O
she O
reported O
worsening O
and O
of O
. O

 O
She O
was O
to O
our O
for O
further O
treatment O
of O
her O
achalasia B
. O

 O
A O
repeat O
showed O
an O
elevated O
of O
as O
well O
non O
- O
propagative O
, O
non O
- O
peristaltic O
throughout O
her O
( O
Figure O
2 O
) O
. O

 O
A O
repeat O
with O
an O
intention O
to O
perform O
therapeutic O
showed O
a O
nearly O
circumferential O
ulcerated O
, O
fungating O
from O
approximately O
36 O
cm O
that O
extended O
to O
her O
. O

 O
Biopsies O
revealed O
a O
LCNEC B
with O
, O
and O
was O
concluded O
to O
be O
a O
. O

 O
Subsequently O
, O
a O
repeat O
revealed O
progressive O
diffuse O
metastatic B
disease I
. O

 O
Our O
patient O
underwent O
two O
courses O
of O
but O
from O
the O
disease O
. O

A O
underwent O
a O
primary O
double O
lung O
transplantation O
for O
cystic O
fibrosis O
in O
. O

 O
Her O
and O
the O
patient O
had O
no O
known O
history O
of O
pulmonary O
tuberculosis O
or O
tuberculosis O
contact O
. O

 O
On O
, O
she O
underwent O
for O
chronic O
lung B
allograft I
dysfunction I
. O

 O
During O
the O
retransplantation O
, O
4 O
remained O
for O
and O
and O
real O
- O
time O
( O
) O
testing O
. O

 O
On O
postoperative O
, O
deterioration O
of O
her O
prompted O
a O
chest O
- O
( O
) O
scan O
revealing O
sub O
- O
centimeter O
bilateral O
primarily O
located O
in O
the O
and O
a O
bilateral O
pleural B
effusion I
( O
Fig.1 O
) O
. O

 O
The O
same O
day O
, O
a O
( O
) O
yielded O
a O
positive O
real O
- O
time O
for O
, O
confirmed O
by O
on O
postoperative O
. O

 O
( O
) O
or O
interferon O
- O
 O
release O
assay O
( O
) O
test O
were O
not O
performed O
. O

 O
All O
the O
BALs O
performed O
on O
postoperative O
period O
yielded O
except O
for O
the O
one O
performed O
on O
that O
cultured O
; O
the O
adjunctive O
was O
, O
3 O
 O
g O
/ O
d. O

 O
of O
a O
lung O
performed O
retransplantation O
revealed O
a O
and O
. O

 O
Acid O
- O
fast O
bacilli O
were O
identified O
as O
rifampicin O
- O
susceptible O
M. O
tuberculosis O
by O
real O
- O
time O
. O

 O
On O
postoperative O
, O
the O
patient O
's O
with O
severe O
, O
shock B
unresponsive O
to O
high O
dose O
, O
and O
multiorgan B
failure I
. O

 O
The O
patient O
died O
on O
postoperative O
, O
despite O
treatment O
combining O
, O
, O
, O
and O
. O

 O
Retrospective O
real O
- O
time O
testing O
of O
the O
and O
BALs O
performed O
on O
postoperative O
days O
1 O
, O
7 O
, O
and O
21 O
remained O
. O

 O
The O
died O
of O
posttraumatic O
intracerebral O
hemorrhage O
. O

 O
was O
with O
other O
than O
. O

 O
TST O
results O
were O
not O
available O
. O

 O
During O
hospitalization O
, O
a O
lung O
CT O
- O
scan O
showed O
no O
signs O
of O
active O
or O
previous O
tuberculosis O
and O
no O
TST O
or O
IGRA O
test O
results O
were O
available O
. O

 O
Routine O
cultures O
of O
per O
- O
transplantation O
right O
lung O
biopsy O
yielded O
Candida O
albicans O
. O

 O
Retrospective O
M. O
tuberculosis O
real O
- O
time O
PCR O
yielded O
negative O
results O
on O
the O
left O
and O
right O
donor O
- O
lung O
biopsies O
. O

 O
Both O
kidneys O
from O
the O
same O
were O
. O

 O
Six O
months O
after O
transplantation O
, O
neither O
of O
the O
. O

A O
was O
with O
a O
history O
of O
continuous O
, O
moderate O
right O
upper O
quadrant O
associated O
with O
, O
as O
well O
as O
( O
over O
) O
and O
a O
liver O
identified O
by O
. O

 O
The O
pain O
sensation O
seemed O
different O
from O
previous O
the O
patient O
had O
experienced O
before O
she O
underwent O
laparoscopic O
. O

 O
On O
, O
she O
was O
( O
) O
, O
with O
noted O
over O
the O
, O
and O
. O

 O
Imaging O
modalities O
included O
( O
) O
, O
( O
) O
and O
( O
) O
( O
Fig.1 O
) O
. O

 O
The O
patient O
underwent O
exploratory O
. O

 O
Intraoperative O
revealed O
a O
cystic O
measuring O
within O
the O
, O
. O

 O
Intraoperative O
demonstrated O
an O
extensive O
obliterating O
the O
, O
with O
partial O
of O
the O
. O

 O
An O
extended O
left O
was O
done O
. O

 O
On O
, O
all O
were O
. O

 O
was O
performed O
with O
a O
Roux O
- O
en O
- O
Y O
to O
in O
the O
. O

 O
Intraoperatively O
, O
was O
applied O
to O
the O
. O

 O
After O
this O
, O
the O
patient O
underwent O
of O
image O
- O
guided O
external O
beam O
centred O
on O
the O
labelled O
at O
surgery O
. O

 O
The O
final O
pathology O
described O
this O
tumour O
as O
an O
infiltrating O
, O
moderately O
differentiated O
squamous B
cell I
carcinoma I
associated O
with O
severe O
dysplasia B
of O
the O
( O
Fig.2 O
) O
. O

 O
The O
patient O
without O
and O
was O
the O
initial O
surgical O
procedure O
, O
with O
an O
unremarkable O
. O

A O
was O
to O
our O
with O
 O
history O
of O
massive O
rectal O
( O
rectorrhagia O
) O
. O

 O
He O
had O
past O
history O
of O
passage O
of O
fresh O
blood O
mixed O
stool O
since O
. O

 O
He O
first O
complained O
of O
. O

 O
He O
went O
numerous O
times O
for O
this O
; O
multiple O
were O
done O
but O
disease O
was O
not O
cured O
completely O
. O

 O
During O
one O
of O
his O
hospital O
visit O
in O
the O
past O
( O
patient O
forgot O
the O
date O
) O
, O
he O
was O
diagnosed O
and O
treated O
as O
hemorrhoids O
. O

 O
The O
symptom O
was O
relieved O
for O
a O
while O
and O
then O
recurred O
again O
. O

 O
Thirty O
years O
ago O
, O
he O
was O
diagnosed O
as O
rectal O
hemangioma O
and O
managed O
with O
cryotherapy O
in O
our O
hospital O
. O

 O
That O
could O
also O
just O
relieve O
the O
symptom O
for O
few O
years O
and O
it O
recurred O
again O
. O

 O
Then O
, O
he O
consulted O
many O
other O
hospitals O
, O
but O
could O
only O
get O
short O
- O
term O
symptomatic O
relief O
without O
proper O
treatment O
of O
the O
cause O
. O

 O
Since O
5 O
months O
, O
the O
severity O
of O
rectal O
bleeding O
increased O
. O

 O
He O
then O
went O
to O
local O
hospital O
where O
intervention O
was O
done O
to O
control O
bleeding O
and O
symptomatic O
treatment O
was O
done O
with O
intravenous O
fluid O
and O
blood O
transfusion O
. O

 O
He O
finally O
referred O
to O
our O
hospital O
for O
further O
evaluation O
. O

 O
Intermediate O
rectal O
bleeding O
of O
fresh O
blood O
was O
presented O
on O
admission O
. O

 O
Patient O
complained O
of O
dizziness O
on O
standing O
, O
shortness O
of O
breath O
, O
and O
palpitation O
on O
walking O
a O
short O
distance O
. O

 O
There O
was O
. O

 O
On O
, O
patient O
appeared O
, O
but O
his O
and O
were O
during O
rest O
. O

 O
He O
lost O
5 O
 O
kg O
of O
his O
body O
weight O
. O

 O
On O
, O
was O
seen O
and O
soft O
was O
felt O
on O
. O

 O
On O
, O
and O
rectum O
were O
seen O
filled O
with O
, O
but O
, O
, O
or O
was O
not O
detected O
. O

 O
On O
, O
was O
( O
Normal O
: O
4.325.72 O
 O
 O
 O
1012 O
/ O
L O
) O
and O
was O
( O
Normal O
: O
135175 O
 O
g O
/ O
L O
) O
. O

 O
were O
. O

 O
None O
enhanced O
showed O
isodense O
( O
35 O
 O
HU O
) O
homogenous O
bowel O
wall O
that O
on O
contrast O
- O
enhanced O
venous O
phase O
. O

 O
Multiple O
were O
seen O
in O
the O
and O
around O
the O
. O

 O
was O
seen O
extending O
from O
to O
( O
Fig.1 O
) O
. O

 O
Multiple O
hypodense O
were O
also O
seen O
in O
( O
Fig.2 O
) O
. O

 O
After O
initial O
management O
of O
, O
the O
patient O
underwent O
abdominal O
followed O
by O
. O

 O
During O
surgery O
, O
25 O
 O
cm O
long O
was O
found O
extending O
from O
to O
. O

 O
Whole O
of O
the O
rectum O
and O
part O
of O
the O
sigmoid O
colon O
were O
excised O
and O
sigmoid O
- O
anus O
was O
done O
. O

 O
Postsurgical O
of O
showed O
submucosal O
multiple O
thin O
- O
walled O
vessel O
of O
varying O
size O
with O
interposed O
stroma O
. O

 O
Some O
vessels O
lumen O
consisted O
of O
blood O
cells O
( O
consistent O
with O
blood O
vessel O
) O
, O
whereas O
other O
consisted O
of O
clear O
fluid O
( O
consistent O
with O
lymph O
vessel O
) O
. O

 O
of O
specimen O
showed O
endothelial O
cells O
positive O
for O
and O
. O

 O
Some O
cells O
were O
positive O
for O
, O
while O
others O
were O
negative O
for O
( O
Fig.3 O
) O
. O

 O
On O
the O
basis O
of O
histopathological O
report O
and O
immunohistochemistry O
, O
hemolymphangioma B
was O
diagnosed O
. O

 O
The O
surgery O
, O
which O
followed O
by O
complication O
( O
intestinal O
infection B
) O
, O
was O
well O
managed O
and O
the O
patient O
was O
from O
on O
the O
of O
surgery O
. O

 O
Then O
after O
, O
no O
further O
or O
was O
noticed O
during O
. O

 O
This O
study O
was O
approved O
by O
the O
First O
Affiliated O
Hospital O
of O
Sun O
Yat O
- O
Sen O
University O
Institutional O
Review O
Board O
. O

 O
Written O
consent O
for O
this O
case O
report O
was O
obtained O
from O
the O
patient O
. O

This O
case O
report O
was O
approved O
by O
the O
Review O
Board O
of O
Shandong O
Power O
Central O
Hospital O
and O
the O
patient O
's O
parents O
signed O
informed O
consent O
for O
publication O
of O
the O
case O
report O
and O
any O
accompanying O
images O
. O

 O
A O
child O
at O
the O
with O
slowly O
enlarging O
, O
painless O
, O
symmetrical O
of O
. O

 O
When O
the O
girl O
was O
approximately O
2 O
years O
old O
, O
the O
parents O
noticed O
a O
, O
which O
later O
became O
more O
obvious O
. O

 O
On O
palpation O
, O
the O
were O
and O
in O
consistency O
. O

 O
The O
skin O
over O
the O
swelling O
was O
smooth O
and O
freely O
movable O
, O
with O
no O
increase O
in O
( O
Fig.1 O
) O
. O

 O
There O
was O
. O

 O
. O

 O
Panoramic O
revealed O
of O
both O
the O
and O
the O
, O
and O
showed O
a O
soap O
bubble O
- O
like O
multilocular O
with O
. O

 O
Unerupted O
teeth O
included O
: O
15 O
, O
25 O
, O
35 O
, O
37 O
, O
45 O
, O
and O
47 O
was O
( O
Fig.2 O
) O
. O

 O
Multislice O
showed O
the O
presence O
of O
multilocular O
cystic O
filled O
with O
and O
dental O
affecting O
the O
. O

 O
Similar O
were O
also O
observed O
in O
the O
( O
Fig.3 O
) O
. O

 O
A O
was O
obtained O
from O
the O
. O

 O
showed O
many O
large O
multinucleated O
giant O
cells O
in O
a O
loose O
, O
delicate O
fibrillar O
connective O
tissue O
stroma O
containing O
large O
numbers O
of O
fibroblasts O
and O
many O
small O
blood O
vessels O
( O
Fig.4 O
) O
. O

 O
As O
the O
child O
grows O
older O
, O
the O
lesions O
often O
become O
static O
and O
may O
show O
regression O
at O
puberty O
. O

 O
In O
the O
current O
case O
, O
no O
was O
under O
taken O
and O
the O
patient O
was O
at O
. O

We O
present O
the O
case O
of O
a O
who O
was O
, O
with O
known O
, O
, O
and O
. O

 O
She O
was O
to O
our O
complaining O
of O
progressive O
and O
. O

 O
On O
examination O
, O
her O
was O
and O
her O
was O
. O

 O
revealed O
a O
systolic O
at O
the O
with O
and O
. O

 O
revealed O
, O
except O
for O
sinus O
. O

 O
showed O
an O
elevated O
N O
- O
terminal O
and O
chest O
showed O
signs O
of O
. O

 O
The O
patient O
was O
to O
the O
with O
the O
diagnosis O
of O
acute O
decompensated O
heart B
failure I
. O

 O
Transthoracic O
showed O
a O
left O
ventricle O
with O
severely O
depressed O
due O
to O
generalized O
and O
a O
mild O
( O
fig.1a O
) O
. O

 O
During O
admission O
, O
the O
patient O
had O
several O
episodes O
of O
paroxysmal O
despite O
treatment O
with O
and O
. O

 O
Due O
to O
the O
clinical O
suspicion O
of O
adrenal B
gland I
disease I
, O
24 O
- O
hour O
urinary O
and O
metanephrine O
tests O
were O
requested O
. O

 O
Cardiac O
was O
performed O
in O
order O
to O
complete O
the O
, O
and O
confirmed O
the O
echocardiographic O
findings O
as O
well O
as O
revealed O
an O
incidental O
finding O
of O
a O
great O
left O
renal O
. O

 O
The O
24 O
- O
hour O
urine O
showed O
markedly O
elevated O
levels O
of O
, O
, O
and O
with O
normal O
values O
: O
24 O
- O
hour O
norepinephrine O
( O
normal O
range O
: O
23 O
- O
105 O
) O
, O
24 O
- O
hour O
13 O
g O
( O
normal O
range O
: O
4 O
- O
20 O
) O
, O
24 O
- O
hour O
658 O
g O
( O
normal O
range O
: O
217 O
- O
575 O
) O
, O
24 O
- O
hour O
2,988 O
g O
( O
normal O
range O
: O
105 O
- O
354 O
) O
, O
24 O
- O
hour O
( O
normal O
range O
: O
0 O
- O
1,000 O
) O
. O

 O
Therefore O
, O
an O
abdominal O
was O
performed O
, O
which O
showed O
the O
presence O
of O
two O
cystic O
( O
fig.2 O
) O
located O
at O
the O
. O

 O
Surgical O
of O
was O
performed O
( O
after O
with O
phenoxybenzamine O
and O
with O
) O
through O
a O
, O
confirming O
the O
diagnosis O
of O
pheochromocytoma B
and O
clear O
cell O
renal O
carcinoma O
on O
. O

 O
During O
, O
and O
values O
( O
, O
) O
, O
24 O
- O
hour O
urinary O
values O
returned O
to O
( O
69 O
g/24 O
h O
, O
221 O
g/24 O
h O
, O
202 O
g/24 O
h O
and O
259 O
g/24 O
h O
) O
and O
the O
patient O
had O
no O
new O
episodes O
of O
or O
. O

 O
surgical O
resection O
, O
was O
repeated O
and O
showed O
a O
left O
ventricle O
with O
and O
preserved O
( O
fig.1b O
) O
. O

 O
revealed O
a O
( O
) O
of O
the O
on O
the O
. O

 O
As O
the O
patient O
had O
, O
it O
was O
concluded O
that O
it O
was O
a O
. O

A O
with O
Goldenhar B
syndrome I
with O
post O
- O
natal O
genetic O
diagnosis O
was O
referred O
to O
our O
for O
of O
the O
. O

 O
The O
patient O
underwent O
a O
. O

 O
Brilliance O
CT-64 O
- O
channel O
( O
) O
was O
employed O
. O

 O
The O
protocol O
generated O
and O
a O
current O
of O
150 O
mA. O

 O
of O
the O
images O
was O
with O
a O
. O

 O
Images O
in O
were O
processed O
on O
a O
PC O
using O
commercial O
software O
, O
obtaining O
a O
of O
. O

 O
The O
3 O
- O
dimensional O
reconstruction O
of O
the O
skin O
plans O
showed O
hypoplasia O
of O
the O
that O
on O
the O
right O
side O
consisted O
of O
a O
simple O
dysmorphic O
rough O
. O

 O
The O
had O
regular O
and O
. O

 O
Atresia B
of O
the O
and O
a O
normal O
were O
observed O
. O

 O
The O
upper O
images O
showed O
partial O
ossification O
of O
the O
cranium O
typical O
in O
paediatric O
age O
. O

 O
Description O
of O
the O
profile O
: O
typical O
II O
class O
very O
convex O
profile O
with O
interposition O
of O
the O
inferior O
lip O
and O
a O
reduced O
neck O
- O
chin O
angle.(Fig.1 O
) O
. O

 O
Skeletal O
studies O
show O
that O
the O
mandibular O
condyle O
, O
ramus O
and O
corpus O
were O
shorter O
on O
the O
affected O
side O
. O

 O
Tilting O
of O
oral O
rhyme O
, O
occlusal O
plane O
and O
mandibular O
plane O
were O
evident O
. O

 O
Number O
or O
form O
abnormalities O
were O
not O
found O
during O
mixed O
dentition O
. O

 O
Mandibular O
condyles O
and O
temporo O
- O
mandibular O
joints O
seemed O
to O
be O
asymmetric O
, O
and O
in O
particular O
the O
right O
condyle O
was O
deformed O
, O
shorter O
and O
wider O
than O
the O
other O
side O
( O
mandibular O
condyle O
dimensions O
were O
11 O
 O
7 O
mm O
right O
and O
14 O
 O
7 O
mm O
left O
) O
. O

 O
The O
3 O
- O
dimensional O
reconstruction O
of O
the O
skeleton O
planes O
showed O
the O
different O
morphology O
of O
the O
right O
and O
left O
hemimandibula O
. O

 O
Mandibular O
3 O
- O
dimensional O
reconstruction O
showed O
in O
detail O
the O
shift O
of O
the O
medial O
axis O
to O
the O
hypoplastic O
right O
side O
and O
the O
asymmetry O
of O
the O
right O
mandibular O
condyles O
that O
appears O
dysmorphic O
short O
and O
wide O
in O
axial O
and O
coronal O
scansions O
( O
Figs.2 O
, O
3 O
) O
. O

 O
The O
study O
of O
the O
temporal O
bone O
showed O
on O
the O
right O
side O
an O
external O
auditory O
canal O
atresia O
, O
hypoplasia O
of O
tympanic O
cavity O
that O
was O
not O
pneumatized O
and O
occupied O
by O
dense O
materials O
from O
soft O
parts O
. O

 O
No O
pneumatization O
was O
present O
in O
. O

 O
Left O
external O
auditory O
canal O
dimensions O
and O
morphology O
were O
normal O
. O

 O
The O
was O
normally O
formed O
and O
totally O
occupied O
by O
dense O
materials O
from O
soft O
tissues O
. O

 O
Both O
right O
and O
presented O
minor O
hypoplasia B
of O
in O
the O
. O

 O
In O
agreement O
with O
the O
resolution O
of O
our O
instrument O
, O
normal O
representation O
of O
the O
that O
seemed O
articulated O
with O
a O
dysmorphic O
rough O
of O
a O
deformed O
was O
observed O
; O
it O
was O
impossible O
to O
see O
the O
staples O
. O

 O
The O
and O
were O
visible O
and O
appeared O
to O
be O
articulated O
in O
an O
abnormal O
manner O
( O
reduce O
contact O
surface O
) O
; O
the O
was O
difficult O
to O
observe O
but O
seemed O
to O
have O
regular O
morphology O
. O

 O
and O
of O
, O
and O
were O
unaltered O
( O
Figs.4-7 O
) O
. O

 O
In O
conclusion O
, O
through O
3D O
- O
CT O
valuation O
of O
this O
young O
patient O
we O
observed O
asymmetry O
of O
the O
; O
in O
particular O
, O
the O
was O
, O
short O
and O
wide O
; O
the O
of O
the O
was O
hypoplastic B
, O
only O
a O
dysmorphic O
rough O
was O
present O
; O
the O
had O
a O
hypoplastic O
; O
the O
has O
an O
atresic B
. O

A O
with O
and O
to O
our O
with O
vague O
and O
. O

 O
Her O
pertinent O
history O
includes O
and O
for O
. O

 O
At O
the O
time O
of O
admission O
, O
she O
was O
undergoing O
care O
for O
an O
infected O
diabetic O
of O
her O
. O

 O
Of O
note O
, O
she O
did O
not O
have O
a O
history O
of O
CAPD B
or O
a O
history O
of O
renal B
disease I
: O
1.23 O
mg O
/ O
dL O
, O
16 O
mg O
/ O
dL. O

 O
Her O
were O
via O
subcutaneous O
; O
she O
reported O
a O
( O
due O
to O
poor O
drug O
compliance O
) O
. O

 O
Her O
were O
decreased O
to O
a O
range O
of O
after O
implementation O
of O
a O
stricter O
upon O
admission O
. O

 O
A O
non O
- O
contrast O
showed O
confluent O
, O
bilobar O
geographic O
regions O
of O
in O
a O
throughout O
her O
( O
Fig.1 O
) O
. O

 O
A O
protocol O
was O
performed O
for O
further O
evaluation O
of O
these O
indeterminate O
findings O
to O
assess O
for O
possible O
vascular O
etiology O
as O
areas O
of O
infarction O
could O
also O
be O
possible O
in O
this O
patient O
. O

 O
In O
- O
phase O
images O
demonstrated O
hyperintense O
in O
her O
in O
a O
distribution O
corresponding O
to O
the O
hypoattenuating O
regions O
seen O
on O
CT O
. O

 O
On O
the O
opposed O
- O
phase O
sequence O
, O
there O
was O
loss O
in O
signal O
within O
these O
areas O
indicating O
the O
presence O
of O
intracellular O
fat O
and O
water O
( O
Fig.2 O
) O
. O

 O
In O
addition O
, O
these O
areas O
were O
hypointense O
to O
the O
remaining O
hepatic O
parenchyma O
on O
the O
fat O
suppression O
MR O
sequences O
, O
confirming O
presence O
of O
fat O
and O
thus O
establishing O
a O
diagnosis O
of O
SHS O
. O

 O
Furthermore O
, O
a O
follow O
- O
up O
of O
her O
and O
was O
performed O
, O
which O
showed O
of O
these O
findings O
( O
Fig.3 O
) O
. O

 O
Of O
note O
, O
stricter O
glucose O
control O
had O
decreased O
her O
average O
to O
below O
200 O
mg O
/ O
dL. O

A O
69 O
- O
year O
- O
old O
man O
became O
aware O
of O
the O
onset O
of O
exertional O
in O
. O

 O
He O
had O
a O
history O
of O
. O

 O
His O
. O

 O
His O
. O

 O
He O
had O
. O

 O
Due O
to O
the O
exertional O
, O
he O
was O
to O
the O
for O
and O
( O
) O
. O

 O
indicated O
that O
he O
had O
severe O
PAH B
, O
because O
his O
( O
) O
was O
, O
and O
his O
right O
heart O
was O
( O
the O
: O
) O
. O

 O
showed O
that O
he O
had O
not O
only O
PAH B
, O
but O
also O
a O
thrombus B
in O
the O
. O

 O
However O
, O
the O
region O
in O
the O
lung O
affected O
by O
this O
was O
considered O
too O
small O
to O
induce O
such O
a O
severe O
PAH O
. O

 O
In O
addition O
, O
he O
, O
so O
he O
was O
diagnosed O
as O
IPAH B
combined O
with O
PE B
. O

 O
He O
was O
treated O
with O
( O
with O
a O
target O
of O
the O
[ O
] O
between O
) O
and O
targeted O
PAH O
therapy O
( O
) O
. O

 O
The O
patient O
's O
was O
relieved O
slightly O
after O
the O
use O
of O
these O
for O
and O
the O
retested O
by O
echocardiography O
was O
to O
, O
but O
all O
the O
after O
taking O
these O
for O
. O

 O
In O
, O
he O
to O
the O
in O
for O
further O
treatment O
. O

 O
Right O
heart O
revealed O
, O
( O
) O
, O
, O
, O
and O
7.3 O
Wood O
units O
. O

 O
He O
was O
retested O
for O
that O
showed O
that O
the O
thrombus B
in O
the O
disappeared O
. O

 O
He O
was O
still O
diagnosed O
as O
having O
IPAH B
, O
so O
treated O
with O
( O
) O
and O
( O
) O
targeted O
and O
oral O
( O
, O
but O
the O
daily O
dose O
was O
adjusted O
by O
that O
was O
between O
) O
. O

 O
Disappointingly O
, O
his O
was O
not O
relieved O
and O
the O
tested O
by O
the O
echocardiography O
was O
. O

 O
In O
, O
he O
the O
in O
because O
of O
no O
relief O
of O
. O

 O
showed O
that O
was O
with O
; O
revealed O
a O
mild O
obstructive B
dysfunction I
of O
the O
( O
, O
Prediction O
) O
and O
a O
severe O
reduction O
in O
the O
diffusing O
capacity O
of O
the O
lungs O
for O
carbon O
monoxide O
( O
) O
; O
6 O
- O
minute O
was O
385 O
 O
m. O

 O
Chest O
high O
- O
resolution O
computed O
tomography O
( O
) O
( O
Fig.1A O
and O
B O
) O
showed O
smooth O
thickening O
of O
, O
diffuse O
centrilobular O
, O
and O
the O
of O
. O

 O
The O
right O
heart O
revealed O
that O
was O
and O
was O
. O

 O
was O
. O

 O
and O
were O
both O
; O
pulmonary O
( O
) O
scan O
showed O
a O
. O

 O
showed O
an O
percentage O
( O
) O
of O
with O
the O
( O
the O
normal O
range O
: O
020 O
) O
. O

 O
He O
was O
still O
diagnosed O
as O
having O
IPAH B
, O
but O
he O
was O
suspected O
as O
actually O
having O
PVOD B
. O

 O
He O
was O
continuously O
treated O
with O
the O
targeted O
, O
and O
he O
was O
asked O
to O
continue O
his O
, O
but O
he O
stopped O
anticoagulation O
treatment O
( O
he O
failed O
to O
recall O
the O
exact O
date O
. O
) O
because O
he O
felt O
that O
it O
was O
too O
cumbersome O
to O
frequently O
test O
the O
INR O
for O
blood O
coagulation O
monitoring O
. O

 O
Furthermore O
, O
after O
he O
discontinued O
his O
warfarin O
therapy O
, O
he O
also O
failed O
to O
to O
prevent O
PE O
recurrence O
. O

 O
His O
was O
relatively O
stable O
, O
but O
he O
developed O
many O
, O
but O
not O
fatal O
, O
episodes O
of O
pulmonary B
edema I
during O
the O
therapy O
. O

 O
In O
, O
he O
was O
to O
because O
his O
was O
suddenly O
. O

 O
showed O
a O
thrombus B
in O
the O
( O
Fig.1C O
) O
. O

 O
was O
administered O
for O
, O
but O
this O
medication O
did O
not O
relieve O
his O
, O
therefore O
, O
he O
was O
. O

 O
Instead O
, O
he O
was O
bound O
to O
his O
wheelchair O
for O
. O

 O
The O
severe O
PAH B
( O
suspected O
as O
PVOD B
) O
combined O
with O
a O
life O
- O
threatening O
PE B
mandates O
a O
for O
his O
survival O
. O

 O
, O
he O
was O
undergone O
a O
bilateral O
sequential O
allogenic O
assisted O
by O
( O
) O
after O
he O
signed O
the O
written O
consent O
on O
. O

 O
of O
the O
showed O
pulmonary O
vein O
occlusion O
( O
Fig.1D O
 O
F O
) O
and O
the O
pulmonary O
embolism O
in O
the O
right O
pulmonary O
artery O
. O

 O
Until O
then O
, O
he O
was O
confirmed O
as O
having O
PVOD B
combined O
with O
PE B
, O
instead O
of O
IPAH B
. O

 O
He O
has O
been O
living O
without O
for O
after O
the O
lung O
transplantation O
and O
the O
showed O
the O
normalizations O
of O
and O
the O
once O
. O

 O
This O
study O
was O
approved O
by O
the O
Ethics O
Committee O
of O
The O
People O
's O
Hospital O
of O
Zhongshan O
City O
. O

 O
The O
written O
informed O
consent O
was O
obtained O
from O
the O
patient O
. O

In O
February O
2010 O
, O
a O
with O
a O
history O
of O
stroke B
and O
peripheral B
vascular I
disease I
at O
our O
in O
florid O
pulmonary B
edema I
. O

 O
He O
had O
a O
6 O
- O
month O
history O
of O
, O
paroxysmal O
nocturnal O
, O
and O
leg O
. O

 O
Upon O
, O
he O
had O
diffuse O
and O
a O
. O

 O
A O
2 O
- O
dimensional O
Doppler O
transthoracic O
revealed O
severe O
aortic B
valve I
stenosis I
with O
a O
of O
and O
a O
of O
, O
a O
of O
, O
severe O
mitral B
regurgitation I
, O
and O
a O
severely O
( O
) O
with O
an O
of O
. O

 O
After O
the O
pulmonary B
edema I
had O
resolved O
, O
confirmed O
the O
and O
showed O
nonobstructive O
coronary B
artery I
disease I
. O

 O
Given O
these O
findings O
and O
the O
patient O
's O
comorbidities O
, O
we O
decided O
on O
a O
minimally O
invasive O
. O

 O
The O
patient O
was O
placed O
in O
the O
and O
underwent O
induction O
and O
with O
a O
and O
a O
. O

 O
Intraoperative O
( O
) O
confirmed O
the O
previous O
findings O
, O
also O
showing O
that O
the O
mitral O
valve O
leaflets O
were O
free O
of O
significant B
disease I
and O
that O
the O
mitral B
regurgitation I
originated O
in O
the O
A2 O
 O
P2 O
portion O
of O
the O
( O
Fig.1 O
) O
. O

 O
The O
mitral B
regurgitation I
was O
thought O
to O
be O
, O
caused O
by O
and O
of O
the O
by O
the O
severely O
. O

 O
We O
decided O
to O
perform O
edge O
- O
to O
- O
edge O
of O
the O
from O
a O
. O

 O
A O
femoral O
platform O
was O
used O
to O
establish O
. O

 O
A O
2- O
to O
3 O
- O
cm O
was O
made O
in O
the O
. O

 O
A O
50 O
Prolene O
purse O
- O
string O
( O
) O
was O
placed O
in O
the O
. O

 O
The O
left O
femoral O
artery O
was O
with O
a O
. O

 O
The O
left O
femoral O
vein O
was O
with O
a O
25F O
Bio O
- O
Medicus O
 O
femoral O
venous O
cannula O
( O
) O
, O
which O
was O
placed O
in O
the O
with O
the O
aid O
of O
. O

 O
We O
then O
made O
a O
4- O
to O
5 O
- O
cm O
transverse O
parasternal O
over O
the O
and O
transected O
the O
to O
enable O
adequate O
of O
the O
. O

 O
This O
interspace O
was O
chosen O
in O
the O
event O
that O
the O
left O
atrium O
needed O
to O
be O
entered O
. O

 O
The O
pericardium O
was O
and O
to O
facilitate O
. O

 O
A O
retrograde O
coronary O
sinus O
was O
inserted O
directly O
through O
the O
, O
and O
a O
purse O
- O
string O
was O
placed O
in O
the O
. O

 O
A O
LV O
was O
inserted O
via O
a O
purse O
- O
string O
in O
the O
. O

 O
A O
transverse O
was O
performed O
to O
the O
, O
which O
was O
under O
. O

 O
The O
A2 O
and O
P2 O
segments O
of O
the O
mitral O
valve O
were O
identified O
, O
and O
an O
edge O
- O
to O
- O
edge O
repair O
was O
carried O
out O
with O
a O
50 O
Prolene O
mattress O
suture O
that O
was O
reinforced O
with O
pericardial O
pledgets O
on O
the O
ventricular O
side O
of O
the O
mitral O
valve O
( O
Fig.2 O
) O
. O

 O
Next O
, O
a O
27 O
- O
mm O
Hancock O
 O
II O
bioprosthetic O
aortic O
valve O
( O
Medtronic O
) O
was O
implanted O
by O
use O
of O
standard O
techniques O
. O

 O
The O
aortotomy O
was O
closed O
in O
2 O
- O
layer O
fashion O
, O
and O
the O
patient O
was O
weaned O
from O
cardiopulmonary O
bypass O
. O

 O
The O
transected O
rib O
was O
reattached O
to O
the O
sternum O
with O
a O
1 O
- O
cm O
metal O
plate O
( O
Synthes O
, O
Inc. O
; O
West O
Chester O
, O
Pa O
) O
, O
and O
a O
fiber O
wire O
was O
placed O
in O
figure-8 O
fashion O
. O

 O
A O
single O
chest O
tube O
was O
left O
in O
the O
pleural O
space O
. O

 O
The O
thoracotomy O
was O
closed O
in O
routine O
fashion O
. O

 O
Postoperative O
TEE O
showed O
no O
mitral O
regurgitation O
( O
Fig.3 O
) O
; O
 O
elbowing O
 O
of O
the O
anterior O
leaflet O
during O
mid O
- O
diastole O
due O
to O
tethering O
of O
the O
anterior O
leaflet O
to O
the O
posterior O
leaflet O
( O
Fig.4 O
) O
; O
and O
the O
double O
- O
orifice O
mitral O
valve O
that O
resulted O
from O
the O
edge O
- O
to O
- O
edge O
repair O
( O
Fig.5 O
) O
. O

 O
After O
surgery O
, O
the O
patient O
did O
well O
. O

 O
His O
shortness O
of O
breath O
resolved O
, O
and O
he O
was O
discharged O
from O
the O
hospital O
on O
postoperative O
day O
6 O
. O

 O
Upon O
follow O
- O
up O
evaluation O
in O
March O
2011 O
, O
he O
was O
, O
and O
showed O
grade O
1 O
+ O
mitral B
regurgitation I
. O

This O
is O
the O
case O
of O
a O
with O
a O
( O
Fig.1 O
) O
. O

 O
She O
was O
to O
the O
hospital O
with O
and O
abdominal O
for O
. O

 O
On O
admission O
, O
were O
obtained O
( O
a O
was O
within O
normal O
limits O
, O
: O
136 O
U O
/ O
L O
, O
: O
with O
a O
of O
) O
. O

 O
Cross O
- O
sectional O
, O
abdominal O
( O
) O
, O
showed O
a O
low O
- O
attenuating O
localized O
in O
the O
( O
measuring O
) O
and O
a O
suspicious O
for O
compression O
) O
. O

 O
After O
a O
multidisciplinary O
meeting O
, O
our O
patient O
was O
scheduled O
for O
. O

 O
showed O
a O
solid O
, O
heteroechoic O
with O
predominantly O
hypoechoic O
areas O
, O
well O
- O
defined O
lesion O
with O
regular O
contours O
( O
measuring O
3.1 O
 O
 O
 O
2.6 O
cm O
) O
, O
localized O
between O
the O
head O
and O
neck O
of O
the O
pancreas O
( O
Fig.2 O
) O
. O

 O
There O
was O
no O
identified O
. O

 O
was O
performed O
. O

 O
In O
the O
( O
Fig.3 O
) O
, O
the O
cells O
presented O
have O
a O
, O
with O
marked O
including O
and O
with O
and O
. O

 O
The O
nuclear O
chromatin O
is O
clumping O
and O
irregular O
with O
excessive O
parachromatin O
clearing O
, O
there O
are O
single O
or O
multiple O
macronucleoli O
, O
and O
abundant O
cytoplasm O
with O
deep O
brownish O
- O
black O
granules O
obscuring O
the O
cell O
details O
. O

 O
The O
background O
shows O
and O
. O

 O
Our O
patient O
underwent O
right O
orbital O
and O
followed O
by O
( O
the O
) O
, O
without O
any O
( O
Fig.4 O
) O
. O

 O
The O
showed O
undifferentiated O
, O
with O
, O
infiltrating O
the O
and O
the O
. O

 O
was O
positive O
for O
, O
, O
, O
and O
negative O
for O
, O
all O
consistent O
with O
metastatic O
malignant O
melanoma B
. O

 O
At O
the O
moment O
, O
our O
patient O
is O
receiving O
adjuvant O
at O
an O
. O

A O
at O
40 O
week O
of O
gestation O
was O
to O
a O
for O
elective O
repeated O
cesarean O
delivery O
due O
to O
slanting O
position O
of O
the O
fetus O
. O

 O
Both O
her O
. O

 O
Her O
and O
. O

 O
The O
was O
performed O
following O
the O
administration O
of O
standard O
spinal O
. O

 O
During O
surgery O
the O
patient O
became O
and O
was O
to O
maintain O
her O
blood O
pressure O
in O
the O
normal O
range O
. O

 O
Three O
hours O
after O
delivery O
of O
healthy O
male O
, O
the O
patient O
complained O
of O
, O
increasing O
and O
. O

 O
On O
with O
ventricular O
and O
pulmonary O
were O
detected O
. O

 O
Her O
was O
and O
demanded O
the O
administration O
of O
( O
initially O
continuous O
infusion O
of O
followed O
by O
) O
. O

 O
Owing O
to O
worsening O
of O
and O
gradual O
, O
was O
applied O
and O
the O
patient O
was O
to O
. O

 O
Chest O
indicated O
pulmonary B
congestion I
. O

 O
Emergency O
excluded O
pulmonary B
thromboembolism I
( O
PE B
) O
and O
confirmed O
severe O
pulmonary B
oedema I
( O
Fig.1 O
) O
. O

 O
The O
patient O
received O
, O
, O
at O
initial O
, O
which O
was O
. O

 O
The O
was O
discontinued O
of O
treatment O
. O

 O
The O
disclosed O
with O
of O
with O
in O
and O
of O
in O
II O
, O
III O
, O
aVF O
, O
( O
Fig.2 O
) O
. O

 O
showed O
elevated O
( O
normal O
value O
< O
14 O
pg O
/ O
ml O
) O
, O
( O
normal O
value O
< O
125 O
pg O
/ O
ml O
) O
. O

 O
The O
bedside O
( O
) O
revealed O
severe O
( O
) O
systolic B
dysfunction I
. O

 O
Therefore O
the O
patient O
was O
to O
. O

 O
Repeated O
showed O
LV O
with O
of O
the O
mid O
and O
basal O
segments O
of O
with O
preserved O
of O
the O
. O

 O
Urgent O
presented O
. O

 O
The O
diagnosis O
of O
inverted O
stress- O
induced O
cardiomyopathy B
was O
set O
upon O
the O
overall O
clinical O
data O
. O

 O
the O
patient O
was O
weaned O
from O
and O
. O

 O
Following O
hemodynamic O
improvement O
, O
were O
tapered O
gradually O
. O

 O
Both O
and O
( O
Figs.3 O
and O
4 O
) O
performed O
showed O
complete O
recovery O
of O
. O

 O
The O
patient O
was O
in O
good O
. O

 O
At O
12- O
month O
she O
remained O
with O
no O
. O

A O
patient O
was O
to O
the O
because O
of O
an O
abnormal O
pre O
- O
employment O
chest O
. O

 O
He O
had O
been O
about O
. O

 O
He O
. O

 O
He O
was O
an O
and O
. O

 O
His O
. O

 O
On O
, O
the O
patient O
was O
not O
. O

 O
There O
were O
no O
signs O
of O
or O
pulmonary O
hypertension B
. O

 O
His O
on O
was O
and O
to O
after O
up O
. O

 O
revealed O
a O
restrictive O
pattern O
of O
lung B
disease I
with O
a O
( O
) O
and O
a O
( O
) O
of O
( O
69 O
% O
of O
predicted O
) O
and O
( O
68 O
% O
of O
predicted O
) O
, O
respectively O
. O

 O
The O
was O
. O

 O
His O
( O
) O
, O
serum O
( O
[ O
normal O
, O
1.1 O
- O
7.3 O
] O
) O
and O
( O
) O
levels O
were O
. O

 O
24 O
- O
hour O
urine O
was O
also O
with O
a O
24 O
- O
hour O
of O
2.8 O
L. O

 O
His O
chest O
( O
Fig.1A O
) O
revealed O
dense O
micronodular O
and O
predominantly O
in O
the O
giving O
the O
. O

 O
The O
cardiac O
borders O
were O
obscured O
by O
the O
sand O
- O
like O
. O

 O
A O
high O
- O
resolution O
computed O
tomography O
( O
) O
scan O
of O
the O
( O
Fig.1B O
) O
showed O
widespread O
tiny O
throughout O
the O
with O
a O
preponderance O
of O
in O
the O
. O

 O
There O
were O
associated O
areas O
of O
interlobular O
and O
. O

 O
Subpleural O
were O
also O
seen O
in O
giving O
rise O
to O
the O
' O
' O
( O
Fig.1C O
) O
( O
2 O
) O
. O

 O
No O
pneumothorax B
or O
pleural B
effusion I
was O
present O
. O

 O
Both O
the O
bronchial O
system O
( O
including O
the O
small O
bronchioles O
) O
and O
the O
of O
the O
pulmonary O
vessels O
were O
. O

 O
As O
this O
was O
diffuse B
parenchymal I
lung I
disease I
, O
( O
) O
lung O
was O
planned O
but O
the O
procedure O
was O
converted O
into O
a O
because O
there O
was O
. O

 O
There O
was O
a O
moderate O
pneumothorax B
postmini O
- O
thoracotomy O
from O
which O
the O
patient O
fully O
after O
in O
the O
. O

 O
The O
lung O
specimen O
revealed O
features O
consistent O
with O
PAM B
, O
with O
numerous O
within O
the O
( O
Fig.1D O
) O
. O

 O
The O
intervening O
alveolar O
septae O
were O
and O
showed O
mild O
with O
of O
mainly O
. O

A O
presented O
with O
a O
left O
buttock O
, O
which O
had O
been O
first O
detected O
approximately O
, O
and O
had O
recently O
gradually O
enlarged O
. O

 O
Physical O
examination O
revealed O
a O
relatively O
well O
- O
circumscribed O
skin O
- O
colored O
tumor O
with O
hyperkeratosis O
, O
measuring O
43 O
x O
38 O
mm O
in O
diameter O
, O
in O
her O
left O
buttock O
. O

 O
The O
biopsy O
specimen O
revealed O
Bowen O
s O
disease O
( O
squamous O
cell O
carcinoma O
in O
situ O
) O
, O
and O
subsequently O
, O
total O
resection O
of O
the O
tumor O
was O
performed O
. O

 O
Histopathological O
study O
of O
the O
resected O
specimen O
revealed O
proliferation O
of O
atypical O
squamous O
cells O
in O
the O
entire O
layer O
of O
the O
acanthotic O
epidermis O
accompanied O
by O
hyperparakeratosis O
( O
Figure O
1A O
) O
. O

 O
These O
atypical O
squamous O
cells O
had O
enlarged O
and O
hyperchromatic O
nuclei O
( O
Figure O
1B O
) O
, O
and O
multinucleated O
atypical O
squamous O
cells O
were O
also O
present O
. O

 O
Mitotic O
figures O
were O
scattered O
and O
present O
in O
the O
upper O
portion O
of O
the O
epidermis O
. O

 O
Atypical O
mitotic O
figures O
were O
also O
observed O
( O
Figure O
1B O
) O
. O

 O
No O
invasive O
neoplastic O
growth O
was O
noted O
( O
Figure O
1A O
) O
. O

 O
Approximately O
95 O
% O
of O
the O
lesion O
was O
composed O
of O
the O
above O
- O
mentioned O
Bowen O
s O
disease O
( O
squamous O
cell O
carcinoma O
in O
situ O
) O
, O
and O
superficial O
sebaceous O
carcinoma O
was O
present O
in O
the O
central O
area O
of O
the O
lesion O
. O

 O
This O
latter O
component O
was O
composed O
of O
proliferation O
of O
nests O
of O
atypical O
cells O
with O
vacuolated O
clear O
cytoplasm O
and O
large O
nuclei O
containing O
conspicuous O
nucleoli O
( O
Figure O
1C O
, O
,1D).1D O
) O
. O

 O
Sebaceous O
carcinoma O
had O
invaded O
into O
the O
superficial O
reticular O
dermis O
( O
Figure O
1C O
) O
. O

 O
Moreover O
, O
atypical O
cells O
containing O
vacuolated O
cytoplasm O
were O
present O
within O
the O
lesion O
of O
Bowen O
s O
disease O
adjacent O
to O
the O
sebaceous O
carcinoma O
( O
Figure O
1E O
) O
. O

 O
Immunohistochemical O
studies O
were O
performed O
using O
an O
autostainer O
( O
Ventana O
) O
by O
the O
same O
method O
as O
previously O
reported O
[ O
9 O
- O
12 O
] O
. O

 O
Epithelial O
membrane O
antigen O
( O
EMA O
) O
, O
cytokeratin O
7 O
, O
and O
adipophilin O
were O
expressed O
in O
the O
sebaceous O
carcinoma O
component O
, O
but O
not O
in O
Bowen O
s O
disease O
( O
Figure O
2A O
) O
. O

 O
Androgen O
receptor O
was O
also O
expressed O
in O
some O
of O
the O
tumor O
cells O
of O
the O
sebaceous O
carcinoma O
, O
but O
not O
in O
Bowen O
s O
disease O
. O

 O
Moreover O
, O
atypical O
vacuolated O
cells O
within O
the O
lesion O
of O
Bowen O
s O
disease O
were O
also O
positive O
for O
adipophilin O
( O
Figure O
2B O
) O
. O

 O
Overexpression O
of O
p53 O
protein O
was O
observed O
in O
both O
the O
sebaceous O
carcinoma O
and O
Bowen O
s O
disease O
. O

 O
Accordingly O
, O
an O
ultimate O
diagnosis O
of O
sebaceous B
carcinoma I
associated O
with O
Bowen B
s I
disease I
was O
made O
. O

A O
with O
a O
history O
of O
. O

 O
He O
was O
diagnosed O
with O
a O
middle O
thoracic O
oesophageal O
squamous B
cell I
carcinoma I
by O
both O
a O
and O
a O
. O

 O
A O
chest O
( O
) O
scan O
showed O
an O
( O
a O
diameter O
of O
) O
that O
was O
a O
continuation O
of O
the O
( O
Fig.1a O
, O
b O
) O
. O

 O
A O
scan O
of O
the O
showed O
a O
in O
the O
and O
direct O
of O
the O
into O
the O
. O

 O
After O
with O
the O
and O
the O
, O
we O
decided O
to O
perform O
a O
McKeown O
. O

 O
The O
patient O
was O
with O
a O
and O
underwent O
a O
standard O
posterolateral O
by O
. O

 O
We O
first O
performed O
the O
jugular O
and O
femoral O
vein O
percutaneous O
puncture O
to O
create O
a O
and O
then O
connected O
the O
to O
the O
monitor O
. O

 O
The O
monitor O
displayed O
the O
real O
- O
time O
pressure O
value O
of O
the O
jugular O
vein O
and O
the O
femoral O
vein O
. O

 O
, O
the O
of O
the O
was O
approximately O
( O
Fig.1c O
) O
, O
and O
the O
superior O
edge O
of O
the O
adhered O
tightly O
to O
the O
. O

 O
When O
the O
arch O
of O
the O
azygos O
vein O
was O
with O
a O
to O
dissociate O
it O
from O
the O
, O
the O
monitor O
showed O
that O
the O
femoral O
vein O
to O
; O
the O
pressure O
returned O
to O
a O
when O
we O
opened O
the O
between O
the O
femoral O
vein O
and O
the O
jugular O
vein O
( O
Fig.2 O
) O
. O

 O
The O
surgery O
was O
performed O
smoothly O
, O
without O
injury B
to O
the O
, O
and O
the O
was O
. O

 O
The O
pathology O
of O
the O
resected O
specimen O
showed O
a O
poorly O
differentiated O
squamous B
cell I
carcinoma I
and O
no O
evidence O
of O
in O
15 O
of O
the O
. O

 O
After O
of O
, O
the O
patient O
was O
, O
with O
no O
evidence O
of O
recurrent B
disease I
either O
clinically O
or O
on O
. O

A O
( O
65 O
kg O
) O
underwent O
under O
, O
which O
was O
induced O
using O
a O
combination O
of O
a O
bolus O
of O
( O
0.5 O
g O
/ O
kg O
) O
and O
. O

 O
Muscle O
paralysis O
was O
obtained O
with O
( O
) O
. O

 O
Transoral O
was O
performed O
with O
a O
( O
) O
and O
a O
size O
7 O
mm O
diameter O
reinforced O
was O
easily O
and O
gently O
placed O
in O
the O
, O
on O
the O
first O
attempt O
and O
was O
then O
fixed O
to O
the O
. O

 O
No O
problems B
were O
encountered O
during O
and O
. O

 O
The O
cuff O
of O
the O
was O
inflated O
with O
a O
pressure O
 O
20 O
cm O
H2O. O

 O
No O
was O
made O
intra O
- O
operatively O
. O

 O
was O
not O
used O
for O
inhalation O
anaesthesia O
. O

 O
The O
was O
placed O
in O
the O
to O
avoid O
the O
passage O
of O
blood O
in O
the O
aero O
- O
digestive O
tract O
. O

 O
General O
anaesthesia O
was O
maintained O
with O
and O
in O
. O

 O
Moderate O
was O
maintained O
with O
a O
cuff O
of O
approximately O
. O

 O
The O
operation O
was O
carried O
out O
in O
a O
with O
the O
and O
laterally O
and O
. O

 O
Duration O
of O
the O
operation O
was O
. O

 O
The O
patient O
was O
, O
after O
removal O
of O
the O
without O
problems O
. O

 O
The O
following O
day O
the O
patient O
complained O
of O
, O
and O
. O

 O
Examination O
revealed O
of O
the O
to O
the O
right O
side O
and O
vocal O
cord O
paralysis B
, O
expression O
of O
hypoglossal O
and O
recurrent O
laryngeal O
nerve B
injury I
without O
local O
or O
. O

 O
The O
of O
the O
pharynx O
and O
soft O
palate O
were O
. O

 O
Meticulous O
, O
including O
also O
( O
) O
revealed O
no O
other O
evidence O
of O
central O
or O
cranial O
. O

 O
Conservative O
management O
included O
, O
together O
with O
speech O
and O
swallowing O
. O

 O
Full O
recovery O
of O
lingual O
and O
laryngeal O
was O
obtained O
surgery O
. O

A O
was O
to O
our O
in O
because O
of O
detected O
during O
a O
medical O
checkup O
. O

 O
The O
patient O
had O
been O
diagnosed O
with O
nephrotic B
syndrome I
in O
. O

 O
showed O
elevated O
and O
, O
and O
the O
presence O
of O
. O

 O
Serologic O
markers O
for O
and O
viruses O
were O
. O

 O
of O
a O
liver O
obtained O
at O
revealed O
non O
- O
suppurative O
destructive O
cholangitis B
in O
the O
( O
Figure O
1 O
) O
. O

 O
The O
diagnosis O
of O
PBC B
( O
Scheuer B
stage I
3 I
) O
was O
confirmed O
and O
, O
, O
was O
started O
. O

 O
In O
, O
the O
patient O
underwent O
plus O
as O
well O
as O
for O
worsening O
. O

 O
In O
, O
the O
patient O
was O
for O
the O
treatment O
of O
recurrent O
. O

 O
The O
had O
ranged O
between O
and O
for O
, O
but O
it O
was O
noted O
to O
from O
in O
to O
. O

 O
Before O
the O
deterioration O
of O
, O
the O
patient O
had O
no O
infectious B
diseases I
and O
received O
no O
other O
. O

 O
On O
, O
the O
patient O
had O
neither O
nor O
. O

 O
Table O
1 O
shows O
the O
laboratory O
data O
on O
admission O
. O

 O
The O
was O
markedly O
. O

 O
Bone O
marrow O
revealed O
without O
. O

 O
and O
revealed O
a O
with O
, O
, O
and O
. O

 O
The O
had O
remained O
from O
. O

 O
Based O
on O
these O
findings O
, O
the O
association O
of O
PBC B
( O
decompensated B
liver I
cirrhosis I
) O
with O
ITP B
was O
diagnosed O
. O

 O
determined O
by O
or O
( O
SRL O
, O
Inc. O
, O
Tokyo O
, O
Japan O
) O
detected O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
and O
. O

 O
The O
for O
was O
. O

 O
Figure O
2 O
shows O
the O
clinical O
course O
. O

 O
Oral O
, O
, O
for O
was O
started O
on O
, O
and O
combined O
with O
for O
was O
performed O
. O

 O
As O
the O
, O
with O
, O
, O
was O
added O
on O
. O

 O
However O
, O
the O
was O
and O
. O

 O
On O
, O
mild O
was O
identified O
. O

 O
The O
patient O
was O
given O
a O
trial O
of O
intravenous O
, O
, O
on O
, O
combined O
with O
a O
second O
round O
of O
intravenous O
on O
. O

 O
Because O
a O
moderate O
was O
observed O
, O
prednisolone O
was O
continued O
, O
and O
the O
. O

 O
The O
with O
at O
. O

 O
Considering O
the O
decompensated B
liver I
cirrhosis I
and O
the O
, O
we O
determined O
the O
patient O
required O
careful O
of O
without O
. O

A O
underwent O
for O
the O
treatment O
of O
a O
metachronous O
solitary O
liver O
metastasis O
from O
rectal O
adenocarcinoma B
, O
which O
had O
been O
with O
preoperative O
and O
. O

 O
The O
lesion O
was O
located O
in O
. O

 O
The O
procedure O
went O
well O
and O
the O
patient O
was O
initially O
haemodynamically O
stable O
. O

 O
her O
. O

 O
She O
was O
clinically O
and O
had O
and O
. O

 O
We O
detected O
and O
. O

 O
Emergency O
showed O
a O
of O
and O
markedly O
elevated O
. O

 O
A O
revealed O
an O
accumulation O
of O
intraperitoneal O
fluid O
in O
the O
and O
two O
liver O
haematomas B
. O

 O
The O
showed O
, O
( O
Figure O
(Figure1A1A--C)C O
) O
and O
another O
, O
( O
Figure O
(Figure2).2 O
) O
. O

 O
The O
patient O
had O
no O
serious O
or O
after O
the O
, O
or O
any O
other O
complications O
that O
might O
have O
caused O
increased O
abdominal O
pressure O
and O
tumour O
rupture O
. O

 O
Subsequently O
, O
the O
patient O
received O
a O
and O
. O

 O
She O
was O
after O
the O
second O
and O
. O

 O
The O
patient O
remained O
in O
bed O
for O
. O

 O
No O
was O
required O
. O

A O
, O
, O
presented O
to O
our O
with O
an O
intensely O
pruritic O
generalized O
. O

 O
Two O
days O
after O
, O
the O
patient O
developed O
an O
itchy O
on O
the O
. O

 O
On O
, O
she O
was O
instructed O
to O
follow O
up O
with O
the O
dermatology O
department O
if O
the O
rash O
did O
not O
resolve O
. O

 O
After O
leaving O
the O
hospital O
, O
she O
reported O
that O
the O
eruption O
had O
progressively O
spread O
to O
the O
buttocks O
and O
legs O
and O
the O
itching O
seemed O
to O
be O
worse O
. O

 O
The O
patient O
's O
prenatal O
course O
was O
uneventful O
. O

 O
She O
gained O
13 O
kg O
during O
pregnancy O
, O
with O
a O
prepregnancy O
weight O
of O
. O

 O
A O
healthy O
male O
was O
delivered O
by O
without O
. O

 O
The O
patient O
's O
. O

 O
She O
was O
currently O
not O
taking O
any O
, O
and O
she O
reported O
no O
known O
. O

 O
On O
, O
the O
patient O
was O
afebrile O
and O
her O
was O
. O

 O
revealed O
erythematous O
and O
urticarial O
involving O
the O
abdominal O
striae O
with O
. O

 O
Similar O
were O
noted O
on O
the O
and O
( O
Fig.1a O
) O
. O

 O
The O
, O
, O
and O
were O
uninvolved O
. O

 O
No O
or O
were O
noted O
. O

 O
Based O
on O
the O
characteristic O
clinical O
presentation O
and O
disease O
course O
, O
she O
was O
diagnosed O
with O
PUPPP B
. O

 O
She O
was O
informed O
of O
the O
safety O
profile O
and O
potential O
benefits O
of O
medications O
but O
remained O
reluctant O
to O
use O
medications O
during O
lactation O
, O
despite O
her O
severe O
symptoms O
. O

 O
was O
then O
considered O
for O
her O
treatment O
. O

 O
Venous O
blood O
of O
was O
drawn O
from O
the O
patient O
, O
followed O
by O
intramuscular O
injection O
of O
of O
the O
blood O
on O
each O
side O
of O
her O
buttock O
. O

 O
Seven O
days O
later O
, O
both O
subjective O
and O
objective O
improvements O
of O
symptoms O
were O
noticed O
and O
she O
received O
1 O
more O
session O
of O
AWB O
injection O
( O
Fig.1b O
) O
. O

 O
On O
follow O
- O
up O
, O
all O
subjective O
symptoms O
had O
improved O
, O
leaving O
only O
postinflammatory O
( O
Fig.1c O
) O
. O

 O
No O
complications O
such O
as O
, O
formation O
, O
or O
were O
observed O
at O
. O

A O
presented O
to O
our O
cardiology O
service O
with O
signs O
and O
symptoms O
of O
. O

 O
Her O
was O
, O
however O
and O
soon O
after O
her O
third O
, O
she O
had O
been O
in O
another O
hospital O
for O
acute B
pulmonary I
oedema I
after O
labor O
. O

 O
Cor O
triatriatum O
with O
obstructive O
behavior O
causing O
pulmonary O
hypertension O
had O
bee O
diagnosed O
, O
while O
the O
left O
ventricle O
was O
structurally O
and O
functionally O
intact O
. O

 O
The O
patient O
at O
that O
time O
denied O
and O
had O
been O
on O
medical O
therapy O
. O

 O
At O
present O
admission O
the O
patient O
presented O
with O
NYHA B
functional I
class I
III I
, O
symptoms O
of O
as O
a O
result O
of O
. O

 O
On O
a O
loud O
pulmonary O
component O
of O
the O
2nd O
heart O
sound O
and O
a O
diastolic O
murmur O
was O
heard O
in O
the O
. O

 O
Signs O
of O
right O
- O
sided O
heart B
failure I
were O
absent O
. O

 O
A O
transthoracic O
echocardiography O
revealed O
a O
left O
ventricle O
( O
LV O
) O
, O
globally O
hypokinetic B
, O
with O
severely O
impaired O
systolic O
function O
( O
EF O
estimated O
30 O
% O
) O
. O

 O
( O
) O
was O
dilated O
, O
with O
a O
mobile O
, O
membrane O
- O
like O
into O
it O
. O

 O
( O
) O
documented O
a O
across O
the O
, O
dividing O
it O
into O
two O
compartments O
, O
a O
proximal O
one O
receiving O
the O
pulmonary O
venous O
flow O
and O
a O
distal O
one O
containing O
the O
( O
) O
. O

 O
The O
two O
communicated O
via O
a O
non O
- O
restrictive O
, O
but O
the O
prolapsed O
towards O
the O
inflow O
causing O
severe O
obstruction O
. O

 O
appeared O
normal O
, O
with O
mild O
regurgitation O
. O

 O
Patent B
foramen I
ovale I
( O
PFO B
) O
, O
atrial B
septal I
defect I
( O
ASD B
) O
and O
anomalous O
venous O
connections O
were O
ruled O
out O
and O
the O
diagnosis O
of O
cor B
triatriatum I
was O
. O

 O
( O
) O
of O
the O
heart O
also O
revealed O
the O
into O
the O
and O
the O
low O
left O
[ O
( O
) O
, O
, O
] O
( O
figure O
1 O
) O
. O

 O
Coronary O
angiography O
showed O
normal O
. O

 O
With O
these O
findings O
the O
patient O
was O
for O
surgery O
. O

 O
Anesthetic O
induction O
was O
achieved O
with O
standard O
technique O
including O
of O
, O
, O
fentanyl O
and O
. O

 O
Invasive O
monitoring O
included O
the O
use O
of O
, O
a O
and O
a O
foley O
catheter O
with O
to O
measure O
bladder O
temperature O
as O
an O
indicator O
of O
core O
body O
temperature O
. O

 O
( O
) O
was O
also O
. O

 O
Surgery O
was O
performed O
through O
a O
. O

 O
Connection O
to O
cardiopulmonary O
bypass O
( O
CPB O
) O
was O
achieved O
by O
standard O
ascending O
aorta O
and O
bicaval O
cannulation O
. O

 O
Mildly O
hypothermic O
( O
) O
CPB O
was O
established O
. O

 O
Cold O
blood O
cardioplegia O
was O
administered O
in O
an O
antegrade O
fashion O
through O
the O
aortic O
root O
after O
clamping O
the O
aorta O
. O

 O
The O
interatrial O
groove O
was O
developed O
and O
the O
common O
pulmonary O
venous O
chamber O
of O
the O
left O
atrium O
was O
opened O
through O
a O
vertical O
incision O
anterior O
to O
the O
right O
pulmonary O
veins O
, O
exactly O
as O
for O
mitral O
valve O
surgery O
. O

 O
After O
insertion O
of O
a O
self O
- O
retaining O
retractor O
to O
facilitate O
exposure O
, O
the O
diaphragm O
was O
exposed O
and O
the O
central O
hole O
in O
it O
was O
identified O
. O

 O
A O
preliminary O
incision O
out O
from O
the O
hole O
improved O
exposure O
for O
the O
definitive O
excision O
. O

 O
Orifices O
of O
the O
pulmonary O
veins O
on O
both O
sides O
were O
located O
. O

 O
Position O
of O
the O
atrial O
septum O
was O
also O
identified O
by O
a O
small O
opening O
in O
the O
right O
atrium O
and O
by O
inserting O
a O
curved O
clamp O
to O
displace O
the O
septum O
into O
the O
common O
pulmonary O
venous O
chamber O
of O
the O
left O
atrium O
. O

 O
There O
was O
no O
atrial B
septal I
defect I
or O
patent B
foramen I
ovale I
. O

 O
The O
was O
then O
easily O
completely O
excised O
exposing O
the O
( O
figure O
2 O
) O
. O

 O
The O
left O
atrial O
appendage O
was O
closed O
from O
inside O
the O
left O
atrium O
using O
a O
running O
3 O
- O
0 O
polypropylene O
suture O
to O
prevent O
future O
. O

 O
The O
were O
closed O
, O
the O
heart O
having O
been O
filled O
with O
blood O
before O
the O
last O
few O
sutures O
were O
placed O
. O

 O
The O
patient O
was O
rewarmed O
, O
the O
was O
removed O
and O
additional O
de O
- O
airing O
was O
carried O
out O
in O
the O
usual O
manner O
. O

 O
CPB O
was O
terminated O
with O
minimal O
inotropic O
support O
, O
involving O
milrinone O
and O
levophed O
with O
good O
hemodynamics O
. O

 O
The O
postoperative O
course O
was O
uneventful O
and O
the O
patient O
was O
extubated O
after O
12 O
hours O
and O
discharged O
from O
the O
hospital O
on O
the O
fifth O
postoperative O
day O
. O

 O
At O
3 O
months O
follow O
- O
up O
, O
the O
patient O
was O
( O
NYHA O
class O
I O
) O
, O
in O
sinus O
rhythm O
. O

 O
TTE O
and O
MRI O
revealed O
a O
mildly O
dilated O
LV O
with O
great O
improvement O
in O
systolic O
function O
and O
an O
estimated O
LVEF O
of O
. O

A O
presented O
with O
complaints O
of O
persistent O
, O
severe O
right O
-sided O
upper O
abdominal O
during O
deep O
inspiration O
, O
physical O
exercise O
and O
. O

 O
These O
complaints O
had O
developed O
gradually O
after O
. O

 O
This O
had O
been O
complicated O
by O
HELLP B
syndrome I
with O
a O
subcapsular O
liver O
sized O
, O
which O
had O
. O

 O
At O
current O
presentation O
, O
were O
. O

 O
She O
assured O
having O
never O
experienced O
signs O
suggestive O
of O
sexually B
transmitted I
diseases I
or O
pelvic B
inflammatory I
disease I
( B
PID I
) I
. O

 O
She O
had O
never O
undergone O
intra O
- O
abdominal O
. O

 O
An O
upper O
- O
abdominal O
revealed O
a O
at O
the O
, O
suspect O
of O
( O
Figure O
1 O
) O
. O

 O
She O
was O
to O
the O
, O
who O
performed O
a O
and O
confirmed O
the O
presence O
of O
a O
thick O
( O
Figure O
2 O
) O
. O

 O
was O
performed O
in O
the O
same O
session O
by O
and O
, O
followed O
by O
the O
instillation O
of O
1.5 O
L O
( O
) O
into O
the O
to O
prevent O
the O
formation O
of O
new O
adhesions O
. O

 O
On O
, O
she O
was O
free O
of O
. O

A O
with O
a O
history O
of O
was O
to O
our O
with O
a O
recent O
diagnosis O
of O
Burkitt B
lymphoma I
. O

 O
Her O
level O
was O
and O
the O
diameter O
of O
her O
mediastinal O
was O
. O

 O
Her O
was O
normal O
, O
and O
basal O
( O
) O
showed O
with O
a O
of O
. O

 O
( O
; O
, O
, O
) O
revealed O
normal O
with O
an O
( O
) O
of O
, O
mild O
mitral O
and O
tricuspid O
, O
and O
moderate O
. O

 O
A O
of O
the O
patient O
put O
her O
into O
a O
category O
and O
she O
underwent O
( O
) O
protocol O
. O

 O
Her O
are O
summarized O
in O
Table O
1 O
. O

 O
She O
received O
high O
- O
dose O
for O
, O
for O
, O
for O
, O
for O
, O
and O
2mg O
/ O
day O
for O
2 O
days O
. O

 O
The O
total O
treatment O
dose O
of O
cyclophosphamide O
and O
doxorubicin O
received O
was O
1800mg O
/ O
m2 O
and O
50mg O
/ O
m2 O
, O
respectively O
. O

 O
She O
was O
given O
allopurinol O
300mg O
/ O
day O
perorally O
, O
sodium O
bicarbonate O
( O
8.4 O
% O
, O
10 O
flacon O
/ O
day O
) O
infusion O
for O
24 O
hours O
before O
chemotherapy O
, O
and O
mesna O
600mg O
/ O
m2 O
/ O
day O
for O
2 O
days O
as O
prophylaxis O
against O
tumor O
lysis O
syndrome O
and O
hemorrhagic O
cystitis O
, O
respectively O
. O

 O
She O
also O
received O
granisetron O
2mg O
/ O
day O
and O
lansoprazole O
30mg O
/ O
day O
as O
antiemetogenic O
and O
gastric O
prophylaxis O
, O
respectively O
. O

 O
The O
patient O
developed O
dyspnea O
on O
the O
seventh O
day O
of O
therapy O
. O

 O
A O
physical O
examination O
revealed O
blood O
pressure O
of O
100/60mmHg O
and O
a O
heart O
rate O
of O
110 O
beats O
/ O
minute O
. O

 O
On O
chest O
auscultation O
, O
no O
inspiratory O
sounds O
were O
heard O
at O
lower O
zones O
and O
inspiratory O
crackles O
were O
heard O
at O
middle O
zones O
. O

 O
Neither O
cardiac O
murmurs O
nor O
S3 O
were O
heard O
. O

 O
An O
ECG O
showed O
low O
voltage O
in O
the O
limb O
and O
precordial O
leads O
. O

 O
TTE O
showed O
diffusely O
increased O
myocardial O
echogenicity O
, O
mild O
pericardial O
effusion O
, O
and O
generally O
impaired O
biventricular O
systolic O
functions O
with O
an O
LVEF O
31 O
% O
and O
right O
ventricular O
mid O
- O
apical O
akinesis O
. O

 O
Manifest O
pleural O
effusion O
was O
also O
detected O
. O

 O
Drug O
- O
induced O
cardiotoxicity O
( O
myocarditis O
) O
was O
suspected O
. O

 O
Furosemide O
and O
ramipril O
were O
started O
. O

 O
The O
beta O
- O
blocker O
therapy O
the O
patient O
was O
already O
taking O
for O
hypertension O
was O
continued O
. O

 O
After O
12 O
days O
, O
TTE O
showed O
an O
LVEF O
of O
37 O
% O
and O
normal O
right O
ventricular O
functions O
. O

 O
Her O
dyspnea O
decreased O
and O
she O
was O
discharged O
on O
day O
20 O
. O

 O
After O
1 O
month O
, O
TTE O
showed O
normal O
biventricular O
functions O
with O
an O
LVEF O
of O
60 O
% O
. O

 O
After O
the O
first O
course O
of O
the O
R O
- O
Hyper O
- O
CVAD O
chemotherapy O
protocol O
, O
she O
underwent O
a O
high O
- O
dose O
methotrexate O
and O
cytarabine O
cycle O
. O

 O
She O
had O
severe O
and O
pneumonia B
. O

 O
She O
had O
no O
during O
this O
course O
, O
but O
she O
declined O
another O
course O
of O
. O

 O
She O
is O
still O
in O
despite O
the O
abbreviated O
course O
of O
. O

A O
woman O
, O
, O
, O
with O
good O
, O
with O
a O
normal O
, O
during O
the O
was O
, O
admitted O
for O
elective O
at O
38 O
weeks O
of O
. O

 O
During O
realization O
of O
the O
spinal O
the O
patient O
presented O
peak O
of O
the O
( O
) O
which O
without O
. O

 O
In O
, O
of O
the O
caesarian O
section O
the O
lady O
presented O
a O
severe O
with O
then O
she O
developed O
three O
episodes O
of O
generalized O
tonico O
- O
clonic O
. O

 O
The O
1st O
ceased O
the O
measures O
of O
and O
injection O
of O
. O

 O
The O
post O
- O
critical O
found O
an O
patient O
and O
at O
and O
with O
at O
without O
any O
, O
there O
was O
no O
neck O
, O
was O
preserved O
. O

 O
The O
by O
was O
( O
+ O
+ O
+ O
) O
. O

 O
The O
2nd O
and O
3th O
stoped O
spontaneously O
within O
few O
seconds O
. O

 O
Laboratory O
findings O
of O
HELLP B
syndrome I
include O
raised O
( O
525 O
IU O
/ O
L O
and O
) O
, O
( O
hemoglobinemia O
in O
7 O
mg O
/ O
dl O
) O
and O
low O
platelet O
count O
( O
44 O
000 O
platelet O
/ O
mL O
) O
. O

 O
Other O
investigations O
included O
the O
renal O
function O
tests O
, O
the O
inflammatory O
markers O
, O
the O
thyroid O
hormones O
were O
normal O
. O

 O
The O
viral O
serology O
was O
negative O
. O

 O
The O
patient O
was O
transferred O
to O
intensive O
care O
unit O
; O
she O
was O
treated O
immediately O
by O
magnesium O
sulfate O
associated O
to O
calcium O
channel O
blocker O
( O
nicardipine O
) O
, O
antiepileptic O
( O
phenobarbital O
) O
and O
preventive O
dose O
of O
low O
molecular O
weight O
heparin O
. O

 O
The O
anemia O
and O
thrombopenia O
corrected O
by O
transfusion O
of O
packed O
red O
blood O
cells O
and O
platelet O
respectively O
. O

 O
The O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
realized O
one O
hour O
after O
the O
first O
episode O
of O
convulsion O
showed O
zones O
in O
hyposignal O
T1 O
, O
hypersignal O
T2 O
and O
flair O
sequences O
, O
interesting O
the O
cerebral O
cortex O
, O
parietal O
and O
occipital O
sub O
- O
cortical O
and O
the O
white O
matter O
. O

 O
Intracranial O
venous O
sinuses O
were O
permeable O
. O

 O
The O
diagnosis O
of O
the O
PRES O
syndrome O
secondary O
to O
the O
severe O
preeclampsia O
immediate O
post O
- O
partum O
was O
retained O
( O
Figure O
1 O
) O
. O

 O
The O
electroencephalogram O
( O
EEG O
) O
realized O
in O
the O
second O
day O
did O
not O
showed O
anomaly O
. O

 O
The O
evolution O
was O
marked O
by O
the O
normalization O
of O
blood O
pressure O
, O
the O
normalization O
of O
the O
neurological O
state O
and O
of O
the O
biological O
analysis O
. O

 O
The O
patient O
in O
good O
on O
, O
with O
and O
maintained O
during O
. O

 O
THE O
of O
the O
controle O
made O
showed O
complete O
resolution O
of O
cerebral O
Figure O
2 O
. O

A O
presented O
to O
the O
with O
, O
and O
anterior O
. O

 O
She O
had O
a O
. O

 O
She O
was O
treated O
with O
. O

 O
revealed O
an O
irregular O
of O
, O
of O
, O
pansystolic O
mitral O
of O
, O
of O
of O
, O
lower O
extremities O
. O

 O
The O
conclusion O
was O
of O
anterior O
. O

 O
The O
12 O
 O
lead O
revealed O
atrial O
fibrillation O
, O
inferior O
ischemia O
. O

 O
Her O
( O
) O
was O
of O
. O

 O
The O
two O
 O
dimensional O
transthoracic O
showed O
the O
with O
a O
moderate O
and O
a O
mobile O
round O
in O
the O
, O
, O
, O
of O
in O
size O
, O
attached O
with O
a O
narrow O
stalk O
to O
the O
. O

 O
It O
showed O
a O
tumor O
 O
like O
movement O
with O
a O
cardiac O
cycle O
, O
reaching O
the O
( O
Figure O
1,Figure O
2 O
) O
. O

 O
Also O
, O
showed O
with O
a O
of O
, O
, O
of O
, O
of O
. O

 O
There O
was O
no O
in O
the O
. O

 O
The O
two O
 O
dimensional O
transesophageal O
confirmed O
the O
presence O
of O
the O
intraatrial O
. O

 O
Epistaxis O
was O
considered O
to O
be O
due O
to O
heart B
failure I
and O
the O
increased O
. O

 O
The O
patient O
was O
referred O
to O
the O
, O
but O
she O
refused O
. O

 O
with O
of O
was O
started O
and O
continued O
, O
after O
cessation O
of O
epistaxis O
by O
. O

 O
the O
was O
repeated O
, O
with O
no O
remnant O
in O
the O
left O
atrium O
. O

 O
The O
conclusion O
was O
that O
the O
mass O
must O
have O
been O
a O
that O
has O
melted O
away O
. O

 O
In O
this O
particular O
case O
, O
the O
left O
intraatrial O
thrombus O
may O
have O
been O
due O
to O
the O
presence O
of O
atrial O
fibrillation O
. O

A O
presented O
with O
a O
in O
her O
. O

 O
She O
had O
macrocephaly B
and O
milimetric O
on O
the O
giving O
a O
appearance O
. O

 O
The O
( O
) O
showed O
circumscribed O
, O
oval O
masses B
in O
each O
. O

 O
An O
US O
- O
guided O
core O
was O
performed O
for O
the O
palpable O
masses B
which O
were O
confirmed O
as O
juvenile O
fibroadenomas B
. O

 O
After O
the O
biopsy O
, O
a O
breast O
was O
done O
as O
follow O
- O
up O
for O
. O

 O
During O
the O
surveillance O
period O
, O
core O
were O
performed O
, O
followed O
by O
US O
- O
guided O
vacuum O
- O
assisted O
core O
or O
of O
lesions B
with O
. O

 O
Pathologic O
results O
were O
fibroadenoma B
, O
tubular B
adenoma I
or O
atypical B
ductal I
hyperplasia I
( O
ADH B
) O
involving O
fibroadenoma O
. O

 O
At O
the O
, O
the O
patient O
underwent O
a O
for O
a O
palpable O
mass B
in O
the O
. O

 O
Several O
indeterminate O
were O
revealed O
in O
both O
. O

 O
A O
follow O
- O
up O
revealed O
that O
some O
of O
those O
nodules O
. O

 O
The O
patient O
underwent O
a O
total O
and O
the O
pathologic O
result O
revealed O
an O
invasive O
follicular B
carcinoma I
in O
the O
and O
follicular B
adenoma I
in O
the O
( O
Fig.1A O
) O
. O

 O
At O
the O
age O
of O
21 O
years O
, O
she O
visited O
the O
due O
to O
a O
swelling O
of O
her O
. O

 O
Head O
and O
neck O
revealed O
a O
vascular O
mass B
in O
the O
extended O
into O
the O
. O

 O
An O
external O
carotid O
confirmed O
the O
diagnosis O
of O
an O
AVM O
with O
feeder O
vessel O
arising O
from O
the O
( O
Fig.1B O
) O
. O

 O
A O
partial O
embolization O
decreased O
the O
blood O
flow O
through O
the O
AVM O
, O
alleviating O
the O
patient O
's O
symptom O
. O

 O
She O
was O
referred O
to O
under O
the O
suggestion O
of O
a O
Cowden B
syndrome I
and O
the O
DNA O
sequencing O
test O
of O
her O
revealed O
a O
frameshift O
mutation O
, O
( O
) O
. O

 O
At O
the O
age O
of O
22 O
years O
, O
the O
patient O
presented O
with O
a O
mass B
with O
and O
increased O
vascularity O
in O
the O
. O

 O
An O
US O
- O
guided O
vacuum O
- O
assisted O
core O
revealed O
a O
ductal B
carcinoma I
in I
situ I
( O
DCIS B
) O
of O
and O
a O
involving O
fibroadenoma B
( O
Fig.1C O
) O
. O

 O
The O
contrast O
- O
enhanced O
breast O
for O
the O
preoperative O
evaluation O
demonstrated O
, O
, O
enhancing O
masses B
in O
both O
( O
Fig.1D O
) O
. O

 O
All O
masses B
showed O
high O
or O
intermediate O
on O
( O
Fig.1E O
) O
. O

 O
Several O
masses B
showed O
an O
with O
washout O
kinetic O
pattern O
on O
time O
- O
signal O
intensity O
curve O
evaluation O
, O
which O
tends O
to O
be O
associated O
with O
malignancy B
( O
Fig.1F O
) O
. O

 O
A O
bilateral O
prophylactic O
with O
immediate O
was O
performed O
in O
view O
of O
multiple O
bilateral O
breast O
masses B
with O
suspicious O
on O
breast O
and O
a O
high O
risk O
for O
breast B
cancer I
of O
Cowden B
syndrome I
. O

 O
The O
surgical O
histopathology O
revealed O
ADH B
involving O
tubular B
adenoma I
without O
residual O
carcinoma O
in O
the O
left O
breast O
and O
multiple O
tubular O
adenomas O
, O
fibroadenomas O
and O
intraductal O
papillomas O
in O
both O
breasts O
. O

 O
The O
patient O
had O
no O
family O
history O
of O
breast B
cancer I
or O
Cowden B
syndrome I
. O

A O
with O
lifelong O
secondary O
to O
was O
referred O
for O
symptoms O
of O
and O
( O
) O
. O

 O
She O
averaged O
one O
Bristol O
Type O
12 O
stool O
every O
5 O
days O
requiring O
frequent O
. O

 O
Additionally O
, O
she O
reported O
twice O
weekly O
episodes O
of O
urgent O
, O
which O
required O
the O
use O
of O
daily O
. O

 O
Her O
symptoms O
did O
not O
improve O
with O
the O
addition O
of O
and O
. O

 O
A O
suggested O
of O
the O
and O
with O
EAS O
muscle O
. O

 O
( O
) O
showed O
a O
normal O
resting O
pressure O
with O
no O
augmentation O
of O
squeeze O
pressure O
, O
consistent O
with O
weak O
EAS O
( O
Figure O
1 O
) O
. O

 O
During O
bearing O
down O
, O
fixed O
perineal O
descent O
was O
noted O
with O
the O
inability O
to O
widen O
the O
posterior O
anorectal O
angle O
and O
poor O
evacuation O
of O
contrast O
with O
straining O
, O
consistent O
with O
DD O
. O

 O
With O
pushing O
, O
ARM O
similarly O
demonstrated O
type O
IV O
DD O
, O
which O
is O
classified O
as O
inability O
to O
generate O
adequate O
propulsive O
forces O
along O
with O
absent O
or O
incomplete O
relaxation O
of O
the O
anal O
sphincter O
[ O
8 O
] O
( O
Figure O
2 O
) O
. O

 O
Reflex O
and O
sensory O
testing O
indicated O
an O
intact O
rectoanal O
inhibitory O
reflex O
and O
rectal O
hypersensitivity O
. O

 O
The O
patient O
failed O
management O
with O
home O
and O
conventional O
biofeedback O
therapy O
. O

 O
Following O
a O
successful O
trial O
of O
temporary O
SNS O
with O
improvement O
in O
FI O
symptoms O
by O
75 O
% O
, O
the O
patient O
had O
a O
permanent O
SNS O
placed O
. O

 O
, O
the O
patient O
reports O
sustained O
improvement O
in O
and O
symptoms O
. O

A O
presented O
to O
the O
with O
, O
and O
anterior O
. O

 O
She O
had O
a O
. O

 O
She O
was O
treated O
with O
. O

 O
revealed O
an O
irregular O
of O
, O
of O
, O
pansystolic O
mitral O
of O
, O
of O
of O
, O
lower O
extremities O
. O

 O
The O
conclusion O
was O
of O
anterior O
. O

 O
The O
12 O
 O
lead O
revealed O
atrial O
fibrillation O
, O
inferior O
ischemia O
. O

 O
Her O
( O
) O
was O
of O
. O

 O
The O
two O
 O
dimensional O
transthoracic O
showed O
the O
with O
a O
moderate O
and O
a O
mobile O
round O
in O
the O
, O
, O
, O
of O
in O
size O
, O
attached O
with O
a O
narrow O
stalk O
to O
the O
. O

 O
It O
showed O
a O
tumor O
 O
like O
movement O
with O
a O
cardiac O
cycle O
, O
reaching O
the O
( O
Figure O
1,Figure O
2 O
) O
. O

 O
Also O
, O
showed O
with O
a O
of O
, O
, O
of O
, O
of O
. O

 O
There O
was O
no O
in O
the O
. O

 O
The O
two O
 O
dimensional O
transesophageal O
confirmed O
the O
presence O
of O
the O
intraatrial O
. O

 O
Epistaxis O
was O
considered O
to O
be O
due O
to O
heart B
failure I
and O
the O
increased O
. O

 O
The O
patient O
was O
referred O
to O
the O
, O
but O
she O
refused O
. O

 O
with O
of O
was O
started O
and O
continued O
, O
after O
cessation O
of O
epistaxis O
by O
. O

 O
the O
was O
repeated O
, O
with O
no O
remnant O
in O
the O
left O
atrium O
. O

 O
The O
conclusion O
was O
that O
the O
mass O
must O
have O
been O
a O
that O
has O
melted O
away O
. O

 O
In O
this O
particular O
case O
, O
the O
left O
intraatrial O
thrombus O
may O
have O
been O
due O
to O
the O
presence O
of O
atrial O
fibrillation O
. O

A O
to O
the O
in O
, O
for O
of O
right O
- O
sided O
paralysis B
and O
left O
- O
sided O
after O
being O
down O
in O
her O
home O
between O
her O
nightstand O
and O
her O
bed O
. O

 O
The O
symptoms O
began O
after O
at O
a O
local O
restaurant O
chain O
, O
, O
and O
one O
cigarette O
dipped O
in O
liquid O
phencyclidine O
( O
PCP O
) O
. O

 O
She O
was O
and O
went O
to O
bed O
without O
. O

 O
She O
was O
down O
next O
to O
the O
bed O
. O

 O
The O
patient O
denied O
any O
physical B
trauma I
other O
than O
from O
the O
bed O
. O

 O
She O
had O
. O

 O
The O
patient O
had O
a O
history O
of O
viral B
meningitis I
, O
, O
and O
, O
and O
she O
was O
treated O
for O
a O
presumed O
urinary B
tract I
infection I
to O
admission O
at O
an O
. O

 O
Her O
triage O
were O
as O
follows O
: O
, O
, O
, O
, O
and O
an O
of O
on O
. O

 O
On O
, O
the O
patient O
was O
and O
to O
, O
, O
and O
. O

 O
Her O
cranial O
nerves O
II O
 O
XII O
were O
grossly O
intact O
. O

 O
She O
had O
2/5 O
strength O
in O
her O
right O
lower O
extremity O
, O
3/5 O
in O
her O
left O
lower O
extremity O
, O
and O
4/5 O
bilaterally O
in O
her O
upper O
extremities O
. O

 O
Her O
was O
. O

 O
She O
opened O
her O
eyes O
spontaneously O
, O
her O
verbal O
response O
was O
oriented O
and O
appropriate O
, O
and O
she O
obeyed O
commands O
, O
resulting O
in O
a O
score O
of O
. O

 O
Pupils O
were O
equal O
, O
round O
, O
and O
reactive O
to O
light O
. O

 O
She O
had O
tenderness O
to O
palpation O
over O
the O
cervical O
, O
thoracic O
, O
and O
lumbar O
spine O
without O
obvious O
external O
signs O
of O
trauma O
. O

 O
Her O
anal O
sphincter O
tone O
was O
intact O
. O

 O
Multiple O
laboratory O
abnormalities O
were O
noted O
on O
admission O
, O
including O
hyperlactemia O
, O
elevated O
liver O
function O
tests O
, O
and O
electrolyte O
derangements O
. O

 O
Her O
complete O
blood O
count O
and O
remainder O
of O
her O
complete O
metabolic O
panel O
were O
within O
normal O
limits O
. O

 O
These O
values O
are O
summarized O
along O
with O
reference O
ranges O
in O
Table O
1 O
. O

 O
Her O
was O
positive O
for O
. O

 O
drawn O
on O
admission O
grew O
the O
aerobic O
bacteria O
Salmonella O
enterica O
, O
and O
then O
drawn O
grew O
group O
B O
streptococcus B
( O
and O
) O
. O

 O
Subsequent O
blood O
cultures O
were O
negative O
, O
as O
were O
. O

 O
and O
therapy O
was O
initiated O
empirically O
, O
with O
transition O
to O
upon O
learning O
of O
the O
culture O
results O
. O

 O
In O
addition O
, O
she O
had O
a O
detailed O
including O
( O
ANA O
) O
and O
, O
all O
of O
which O
returned O
. O

 O
Admission O
scan O
of O
her O
cervical O
, O
thoracic O
, O
and O
lumbar O
revealed O
no O
spinal O
fractures B
. O

 O
( O
) O
revealed O
no O
acute O
intracranial O
, O
but O
enhancement O
within O
the O
central O
aspect O
of O
C3 O
 O
T2 O
suggested O
spinal O
cord O
, O
at O
, O
, O
and O
, O
and O
bilateral O
posterior O
neck O
muscle O
. O

 O
A O
was O
not O
initially O
performed O
upon O
patient O
admission O
due O
to O
concerns O
about O
raised O
intracranial O
pressure O
from O
suspected O
trauma O
. O

 O
presentation O
, O
her O
had O
progressively O
to O
in O
. O

 O
She O
lost O
in O
her O
and O
developed O
absent O
. O

 O
The O
patient O
was O
to O
the O
with O
further O
deterioration O
ultimately O
requiring O
endotracheal O
due O
to O
respiratory B
failure I
. O

 O
Upon O
her O
positive O
blood O
culture O
results O
, O
was O
performed O
, O
which O
demonstrated O
a O
pattern O
consistent O
with O
ATM B
, O
the O
results O
of O
which O
are O
summarized O
in O
Table O
2 O
. O

 O
An O
extensive O
was O
also O
completed O
, O
with O
the O
results O
summarized O
in O
Table O
3 O
. O

 O
was O
initiated O
with O
a O
suspected O
diagnosis O
of O
ATM B
. O

 O
Despite O
maximal O
medical O
, O
the O
patient O
remains O
quadriplegic B
, O
is O
experiencing O
neurologic O
, O
received O
a O
due O
to O
prolonged O
respiratory B
failure I
, O
and O
required O
a O
feeding O
placement O
at O
the O
time O
of O
this O
report O
. O

A O
with O
a O
past O
medical O
history O
significant O
for O
stage O
1 O
sarcoidosis B
to O
our O
with O
a O
chief O
complaint O
of O
. O

 O
, O
she O
with O
bilateral O
uveitis B
and O
( O
) O
on O
her O
and O
was O
subsequently O
diagnosed O
with O
sarcoidosis B
. O

 O
She O
was O
successfully O
for O
these O
conditions O
and O
her O
sarcoidosis B
remained O
until O
, O
when O
, O
at O
an O
, O
she O
was O
to O
have O
laryngeal O
. O

 O
She O
was O
with O
for O
and O
eventually O
tapered O
to O
. O

 O
Her O
sarcoidosis B
remained O
on O
this O
maintenance O
dose O
of O
until O
, O
at O
which O
time O
she O
self O
- O
discontinued O
her O
in O
favor O
of O
the O
homeopathic O
treatment O
, O
which O
unsubstantially O
claimed O
to O
have O
anti O
- O
inflammatory O
properties O
[ O
4 O
] O
. O

 O
Subsequently O
, O
she O
developed O
progressing O
to O
. O

 O
During O
this O
time O
her O
voice O
became O
increasingly O
hoarse O
and O
she O
experienced O
frequent O
episodes O
of O
. O

 O
In O
our O
, O
her O
was O
concerning O
for O
as O
she O
presented O
with O
and O
. O

 O
She O
also O
had O
chronic O
- O
appearing O
, O
indurated O
on O
her O
. O

 O
Given O
that O
she O
had O
signs O
of O
upper B
airway I
disease I
for O
impending O
respiratory O
failure O
, O
an O
emergent O
bedside O
was O
performed O
, O
revealing O
an O
obstructed B
with O
the O
epiglottis O
over O
the O
and O
significant O
in O
the O
and O
. O

 O
She O
was O
immediately O
treated O
with O
high O
- O
dose O
intravenous O
and O
emergently O
to O
the O
( O
) O
to O
secure O
her O
airway O
for O
concern O
for O
complete O
upper O
airway O
obstruction B
, O
which O
was O
confirmed O
with O
of O
her O
in O
the O
. O

 O
She O
was O
for O
a O
, O
and O
after O
taking O
from O
the O
lingual O
surface O
of O
her O
, O
a O
# O
4 O
cuffed O
Shiley O
 O
was O
placed O
. O

 O
Her O
immediately O
, O
was O
, O
and O
to O
our O
. O

 O
Her O
was O
exchanged O
to O
a O
# O
4 O
cuffless O
on O
postoperative O
. O

 O
During O
this O
time O
she O
was O
transitioned O
from O
intravenous O
to O
. O

 O
ultimately O
revealed O
non O
- O
necrotizing O
epithelioid O
consistent O
with O
sarcoidosis B
( O
Figure O
1 O
) O
. O

 O
She O
was O
prescribed O
this O
for O
, O
and O
after O
receiving O
education O
for O
self O
- O
tracheostomy O
care O
, O
she O
was O
. O

 O
At O
her O
subsequent O
and O
visits O
, O
she O
denied O
any O
further O
. O

 O
Repeat O
showed O
significant O
in O
the O
in O
the O
and O
, O
but O
the O
epiglottis O
continued O
to O
obscure B
the O
despite O
therapy O
with O
high O
- O
dose O
. O

 O
was O
initiated O
while O
was O
tapered O
to O
; O
however O
, O
this O
regimen O
failed O
and O
her O
dosage O
was O
increased O
to O
to O
reduce O
edema O
. O

 O
Because O
she O
declined O
, O
she O
will O
continue O
with O
medical O
management O
with O
to O
facilitate O
eventual O
de O
- O
cannulation O
. O

A O
at O
our O
complaining O
of O
intracranial O
. O

 O
The O
cranial O
nerve O
and O
were O
. O

 O
A O
DVAF B
was O
considered O
, O
was O
performed O
, O
which O
showed O
a O
Cognard B
II I
DVAF I
in O
the O
location O
of O
( O
) O
. O

 O
The O
was O
fed O
by O
the O
of O
the O
, O
and O
the O
within O
the O
that O
was O
the O
mainly O
. O

 O
was O
insisted O
upon O
by O
the O
patient O
because O
of O
the O
associated O
intolerable O
intracranial O
. O

 O
Treatment O
was O
performed O
by O
under O
using O
a O
. O

 O
were O
used O
. O

 O
The O
into O
the O
. O

 O
Marathon O
flow O
directed O
catheter O
( O
eV3 O
) O
was O
subsequently O
navigated O
over O
a O
Mirage.008 O
microwire O
( O
eV3 O
) O
to O
reach O
as O
near O
as O
possible O
to O
the O
fistula O
. O

 O
The O
with O
of O
. O

 O
The O
dead O
space O
of O
the O
microcatheter O
was O
subsequently O
filled O
with O
dimethyl O
sulfoxide O
( O
DMSO O
) O
. O

 O
Onyx-18 O
was O
then O
injected O
over O
two O
minutes O
to O
fill O
the O
microcatheter O
and O
to O
replace O
the O
DMSO O
in O
the O
dead O
space O
. O

 O
The O
injection O
was O
stopped O
until O
unwanted O
flow O
into O
branches O
of O
the O
right O
ascending O
pharyngeal O
artery O
was O
observed O
. O

 O
The O
follow O
- O
up O
showed O
no O
( O
Figure O
1 O
) O
. O

 O
The O
disappeared O
immediately O
after O
the O
operation O
. O

 O
For O
the O
toxicity O
of O
DMSO O
, O
was O
for O
. O

 O
On O
the O
, O
the O
patient O
complainted O
of O
to O
the O
left O
. O

 O
Cranial O
nerve O
was O
only O
significant O
for O
a O
. O

 O
The O
patient O
was O
from O
our O
without O
. O

 O
At O
, O
the O
patient O
's O
main O
complaint O
were O
difficulty O
swallowing O
( O
) O
and O
slurred O
speech O
( O
) O
. O

 O
In O
addition O
, O
his O
tongue O
deviated O
toward O
the O
right O
during O
tongue O
protrusion O
, O
and O
marked O
right O
- O
sided O
was O
observed O
( O
Figure O
2 O
) O
. O

 O
The O
cranial O
nerve O
showed O
persisted O
. O

 O
We O
telephone O
the O
patient O
at O
and O
requested O
a O
by O
an O
in O
a O
. O

 O
Vocal O
cord O
was O
not O
found O
, O
and O
there O
was O
no O
evidence O
of O
vagus O
nerve O
. O

 O
was O
used O
and O
his O
prognosis O
was O
still O
at O
a O
long O
. O

Our O
non O
- O
smoking O
patient O
with O
repeated O
in O
with O
of O
concomitant O
right O
thoracic O
. O

 O
During O
, O
this O
patient O
suffered O
from O
a O
with O
and O
a O
strong O
. O

 O
The O
strong O
dry O

 O
The O
patient O
did O
not O
report O
any O
. O

 O
The O
initial O
of O
the O
showed O
a O
solid O
paravertebral O
right O
in O
the O
lower O
thorax O
without O
any O
signs O
of O
( O
Figure O
1 O
) O
. O

 O
The O
( O
Figure O
2 O
) O
with O
non O
- O
bleeding O
revealed O
a O
of O
the O
which O
and O
provided O
evidence O
of O
a O
granular B
cell I
or O
Abrikossoff O
tumor B
[ O
1 O
] O
. O

 O
The O
which O
followed O
was O
for O
. O

 O
The O
patient O
was O
and O
surgical O
intervention O
was O
planned O
. O

 O
a O
spontaneous O
developed O
. O

 O
The O
patient O
needed O
to O
be O
and O
the O
hemothorax O
was O
. O

 O
No O
malignant O
cells O
were O
detected O
in O
the O
of O
the O
. O

 O
After O
an O
uneventful O
course O
and O
decreasing O
of O
the O
, O
the O
tumor O
was O
by O
performing O
a O

 O
The O
final O
confirmed O
a O
peribronchial O
and O
infiltrating O
S100 O
positive O
supporting O
the O
Schwann O
cell O
origin O
theory O
with O
very O
low O
of O
and O
a O
of O
( O
Figure O
3 O
) O
. O

A O
the O
in O
because O
of O
a O
complaint O
of O
sudden O
. O

 O
She O
was O
previously O
diagnosed O
with O
and O
prescribed O
a O
combination O
oral O
( O
drospirenone O
/ O
, O
, O
) O
. O

 O
Following O
the O
Kumamoto O
Earthquakes O
and O
subsequent O
aftershocks O
in O
, O
she O
spent O
7 O
nights O
in O
a O
. O

 O
She O
noticed O
sudden O
when O
she O
the O
car O
on O
the O
the O
. O

 O
Although O
she O
for O
personal O
reasons O
during O
the O
daytime O
, O
she O
spent O
nights O
in O
her O
small O
car O
with O
her O
legs O
in O
a O
hanging O
position O
. O

 O
She O
noticed O
swelling O
and O
pain O
in O
her O
left O
lower O
extremity O
, O
and O
her O
serum O
D O
- O
dimer O
levels O
were O
13.2 O
g O
/ O
mL. O

 O
Deep B
vein I
thrombosis I
( O
DVT B
) O
was O
suspected O
by O
her O
home O
doctor O
. O

 O
A O
contrast O
- O
enhanced O
( O
CT)-scan O
revealed O
a O
contrast O
deficit O
in O
the O
bilateral O
pulmonary O
artery O
( O
Fig.2A O
) O
and O
in O
the O
left O
lower O
extremity O
( O
posterior O
tibial O
, O
soleus O
and O
gastrocnemius O
vein O
) O
( O
Fig.2B O
) O
. O

 O
Her O
right O
ventricular O
function O
was O
intact O
( O
estimated O
pulmonary O
artery O
pressure=29/8 O
mmHg O
in O
cardiac O
ultrasound O
) O
. O

 O
Her O
plasma O
brain O
natriuretic O
peptide O
and O
high O
- O
sense O
troponin O
T O
concentration O
levels O
were O
97.2 O
pg O
/ O
mL O
and O
0.0061 O
ng O
/ O
mL O
, O
respectively O
. O

 O
She O
was O
diagnosed O
with O
PTE O
and O
admitted O
to O
our O
department O
. O

 O
On O
admission O
, O
her O
blood O
pressure O
was O
129/80 O
mmHg O
and O
her O
heart O
rate O
was O
72 O
beats O
per O
minute O
. O

 O
Her O
degree O
of O
oxygen O
saturation O
( O
SaO2 O
) O
in O
arterial O
blood O
gas O
was O
97.7 O
% O
. O

 O
Her O
was O
. O

 O
and O
cardiac O
did O
not O
indicate O
heart B
failure I
. O

 O
An O
investigation O
of O
most O
( O
including O
, O
, O
, O
and O
) O
revealed O
that O
all O
such O
factors O
were O
. O

 O
The O
discontinuation O
of O
the O
oral O
and O
the O
administration O
of O
( O
) O
, O
a O
direct O
oral O
( O
, O
) O
was O
initiated O
( O
3 O
) O
. O

 O
, O
a O
contrast O
- O
enhanced O
scan O
revealed O
a O
reduction O
in O
the O
thrombosis B
( O
Fig.3 O
) O
. O

 O
The O
patient O
was O
with O
. O

 O
The O
patient O
gave O
her O
consent O
for O
the O
publication O
of O
this O
study O
. O

An O
was O
to O
our O
because O
of O
and O
massive O
. O

 O
The O
patient O
had O
a O
history O
of O
that O
was O
well O
- O
controlled O
with O
. O

 O
She O
had O
. O

 O
The O
revealed O
diffuse O
bilateral O
. O

 O
She O
suffered O
from O
severe O
( O
pH O
7.362 O
, O
PCO2 O
35.1 O
mmHg O
, O
PO2 O
61.0 O
mmHg O
, O
HCO3- O
20.1 O
mmHg O
, O
BE O
-5.5 O
mmHg O
, O
SpO2 O
90.5 O
% O
, O
under O
10 O
L O
O2 O
/ O
min O
, O
reservoir O
mask O
) O
. O

 O
After O
the O
tracheal O
, O
100 O
mL O
of O
bright O
- O
red O
blood O
was O
. O

 O
A O
chest O
showed O
bilateral O
( O
Fig.1 O
) O
. O

 O
A O
chest O
further O
demonstrated O
multiple O
and O
ground O
glass O
and O
focal O
bronchiectasis B
in O
( O
) O
( O
Fig.2 O
) O
. O

 O
There O
were O
no O
space O
- O
occupying O
. O

 O
admission O
, O
her O
was O
. O

 O
Since O
there O
was O
no O
active O
from O
the O
tracheal O
tube O
, O
she O
was O
then O
. O

 O
After O
that O
, O
only O
a O
small O
amount O
of O
bloody O
was O
coughed O
up O
. O

 O
To O
determine O
the O
origin O
of O
bleeding O
, O
she O
underwent O
contrast O
- O
enhanced O
, O
which O
showed O
bronchiectasis B
in O
and O
regression O
of O
the O
. O

 O
revealed O
an O
abnormal O
vascular O
anastomosis B
between O
the O
and O
beside O
the O
focal O
bronchiectasis B
at O
the O
( O
Fig.3 O
) O
, O
which O
led O
us O
to O
suspect O
it O
as O
the O
possible O
source O
of O
the O
massive O
. O

 O
We O
therefore O
performed O
by O
the O
with O
a O
( O
Fig.4 O
) O
. O

 O
An O
of O
the O
showed O
no O
obvious O
active O
. O

 O
the O
embolization O
, O
she O
was O
successfully O
and O
has O
been O
free O
from O
recurrent O
for O
. O

A O
68 O
- O
year O
- O
old O
female O
smoker O
with O
a O
history O
of O
pulmonary O
embolism O
and O
diabetes O
mellitus O
was O
diagnosed O
with O
Stage O
IIIB O
( O
T4N2M0 O
) O
squamous O
NSCLC B
. O

 O
She O
was O
treated O
by O
definitive O
with O
and O
. O

 O
, O
scan O
demonstrated O
a O
in O
the O
; O
however O
, O
new O
in O
the O
and O
developed O
and O
were O
. O

 O
A O
month O
later O
the O
disease O
progressed O
with O
development O
of O
multiple O
bone O
and O
subcutaneous O
. O

 O
At O
that O
point O
, O
the O
patient O
suffered O
from O
severe O
and O
was O
. O

 O
She O
received O
of O
and O
followed O
by O
, O
and O
treatment O
was O
switched O
to O
. O

 O
, O
a O
subcutaneous O
in O
her O
, O
accompanied O
by O
severe O
and O
significant O
( O
Fig.1 O
) O
. O

 O
Other O
subcutaneous O
as O
well O
. O

 O
After O
the O
second O
cycle O
of O
treatment O
marked O
was O
observed O
, O
including O
and O
and O
reduction O
of O
the O
bone O
. O

 O
The O
patient O
no O
longer O
required O
. O

 O
The O
subcutaneous O
started O
to O
regress O
too O
, O
with O
complete O
resolution O
by O
the O
12th O
week O
as O
well O
as O
improvement O
in O
all O
bone O
( O
Figs.1 O
and O
2 O
) O
. O

 O
The O
patient O
continued O
on O
, O
and O
tolerated O
the O
treatment O
well O
. O

 O
Unfortunately O
, O
she O
developed O
bacterial O
aspiration O
and O
in O
. O

A O
developed O
severe O
viral O
pneumonia B
, O
with O
rapid O
, O
progressive O
deterioration O
in O
her O
. O

 O
She O
developed O
ARDS B
and O
using O
were O
unable O
to O
maintain O
adequate O
. O

 O
As O
a O
result O
, O
bedside O
VV O
- O
was O
planned O
. O

 O
( O
) O
was O
performed O
to O
visualize O
proper O
and O
. O

 O
Using O
the O
Seldinger O
technique O
, O
the O
right O
internal O
jugular O
vein O
was O
accessed O
and O
a O
. O

 O
Placement O
of O
the O
guidewire O
into O
the O
proved O
difficult O
due O
to O
repeated O
into O
the O
. O

 O
After O
multiple O
attempts O
, O
the O
guidewire O
was O
visualized O
to O
course O
properly O
from O
the O
SVC O
to O
the O
IVC O
. O

 O
After O
a O
bolus O
dose O
of O
5000 O
units O
of O
intravenous O
was O
given O
, O
the O
right O
internal O
jugular O
venous O
access O
site O
was O
. O

 O
Just O
as O
the O
final O
dilatation O
was O
completed O
and O
upon O
dilator O
exchange O
with O
simultaneous O
advancement O
of O
the O
23 O
French O
Avalon O
cannula O
, O
TEE O
lost O
visualization O
of O
the O
guidewire O
. O

 O
Multiple O
premature O
ventricular O
beats O
were O
noted O
and O
immediately O
, O
a O
new O
, O
rapidly O
enlarging O
pericardial B
effusion I
was O
detected O
( O
Figure O
(Figure2).2 O
) O
. O

 O
Emergent O
preparations O
were O
made O
for O
bedside O
of O
the O
. O

 O
Quickly O
the O
patient O
lost O
blood O
pressure O
from O
acute O
cardiac B
tamponade I
. O

 O
The O
Avalon O
was O
immediately O
. O

 O
A O
emergent O
subxiphoid O
was O
performed O
, O
resulting O
in O
drainage O
of O
venous O
blood O
and O
restoration O
of O
. O

 O
was O
initiated O
and O
the O
patient O
was O
emergently O
to O
the O
for O
. O

 O
The O
was O
found O
to O
have O
perforated B
the O
. O

 O
The O
was O
primarily O
and O
the O
Avalon O
was O
repositioned O
toward O
the O
IVC O
again O
by O
with O
. O

 O
VV O
- O
was O
initiated O
and O
the O
. O

 O
Due O
to O
excessive O
coagulopathies B
, O
the O
sternum O
was O
but O
was O
on O
postoperative O
. O

 O
From O
that O
point O
, O
she O
remained O
free O
from O
any O
cardiac O
or O
infectious O
and O
her O
. O

 O
She O
was O
successfully O
weaned O
from O
VV O
- O
on O
postoperative O
and O
was O
on O
postoperative O
without O
the O
need O
for O
. O

 O
She O
regained O
full O
at O
home O
and O
recovered O
normal O
by O
following O
from O
the O
. O

In O
, O
a O
was O
to O
with O
symptoms O
of O
intermittent O
, O
, O
, O
skin O
over O
the O
, O
and O
in O
the O
fingers O
and O
palms O
. O

 O
The O
patient O
was O
previously O
, O
had O
, O
and O
took O
. O

 O
He O
also O
had O
and O
. O

 O
He O
had O
been O
in O
his O
usual O
state O
of O
health O
until O
one O
month O
before O
admission O
, O
when O
intermittent O
high O
developed O
( O
, O
) O
. O

 O
In O
addition O
, O
he O
reported O
, O
bilateral O
and O
symmetric O
on O
the O
and O
( O
with O
an O
inflammatory O
pattern O
) O
, O
petechiae O
over O
the O
palms O
and O
fingers O
, O
salmon O
- O
colored O
rash O
on O
the O
trunk O
, O
nausea O
, O
and O
vomiting O
. O

 O
An O
evanescent O
, O
salmon O
- O
colored O
rash O
was O
observed O
on O
his O
chest O
and O
abdomen O
, O
and O
2 O
- O
mm O
petechiae O
covered O
the O
palms O
and O
the O
fingers O
. O

 O
No O
signs O
suggested O
arthritis O
, O
and O
there O
was O
no O
lymphadenopathy O
or O
hepatosplenomegaly O
. O

 O
Blood O
testing O
showed O
elevated O
inflammatory O
markers O
( O
Table O
II O
) O
. O

 O
The O
electrocardiographic O
( O
ECG O
) O
and O
chest O
radiographic O
results O
were O
normal O
. O

 O
Ibuprofen O
( O
1,200 O
mg O
/ O
d O
) O
and O
acetaminophen O
( O
as O
needed O
) O
were O
begun O
and O
provided O
symptomatic O
relief O
. O

 O
An O
extensive O
evaluation O
was O
performed O
, O
including O
blood O
cultures O
, O
viral O
and O
bacterial O
serologic O
studies O
, O
immunologic O
screening O
( O
rheumatoid O
factor O
and O
antinuclear O
antibodies O
) O
, O
and O
computed O
tomographic O
( O
CT O
) O
studies O
of O
the O
chest O
, O
abdomen O
, O
pelvis O
, O
and O
cranium O
. O

 O
No O
significant O
changes O
were O
found O
. O

 O
However O
, O
a O
transthoracic O
echocardiogram O
( O
TTE O
) O
showed O
circumferential O
, O
mild O
pericardial O
effusion O
( O
maximal O
diameter O
, O
8 O
mm O
) O
, O
with O
no O
signs O
of O
tamponade O
or O
other O
relevant O
findings O
. O

 O
A O
few O
days O
later O
, O
dyspnea O
and O
diffuse O
chest O
pain O
developed O
. O

 O
The O
pain O
was O
relieved O
by O
chest O
anteflexion O
and O
aggravated O
by O
deep O
inspiration O
and O
by O
lying O
supine O
. O

 O
The O
patient O
was O
hypotensive O
, O
tachycardic O
, O
and O
hyperpneic O
, O
and O
he O
manifested O
jugular O
venous O
distention O
. O

 O
The O
ECG O
showed O
sinus O
tachycardia O
and O
diffuse O
ST O
- O
segment O
elevation O
( O
Fig.1 O
) O
, O
the O
chest O
radiograph O
revealed O
an O
enlarged O
cardiac O
silhouette O
( O
Fig.2 O
) O
, O
and O
the O
inflammatory O
markers O
were O
again O
elevated O
( O
Table O
II O
) O
. O

 O
A O
repeat O
TTE O
showed O
an O
increase O
in O
the O
pericardial O
effusion O
( O
maximal O
diameter O
, O
12 O
mm O
) O
( O
Fig.3 O
) O
and O
collapse O
of O
the O
right O
heart O
chambers O
. O

 O
Emergency O
pericardiocentesis O
drained O
60 O
mL O
of O
serosanguineous O
fluid O
. O

 O
When O
repeated O
, O
CT O
of O
the O
chest O
and O
abdomen O
revealed O
mild O
right O
and O
severe O
left O
pleural O
effusion O
, O
as O
well O
as O
mild O
ascites O
. O

 O
Thoracocentesis O
was O
then O
performed O
, O
during O
which O
350 O
mL O
of O
serosanguineous O
pleural O
fluid O
was O
drained O
. O

 O
Both O
heart O
and O
lung O
fluids O
were O
exudates O
that O
yielded O
negative O
microbiologic O
examination O
and O
were O
unremarkable O
upon O
histologic O
analysis O
. O

 O
The O
diagnosis O
of O
AOSD O
was O
established O
, O
and O
the O
patient O
was O
medicated O
with O
prednisone O
( O
0.5 O
mg O
/ O
kg O
/ O
d O
) O
, O
with O
major O
clinical O
and O
laboratory O
improvement O
( O
Table O
II O
) O
. O

 O
There O
was O
also O
ST O
- O
segment O
normalization O
, O
and O
the O
follow O
- O
up O
echocardiogram O
showed O
only O
mild O
pericardial O
effusion O
( O
23 O
mm O
) O
, O
without O
hemodynamic O
compromise O
. O

 O
Screening O
for O
autoimmune O
and O
infectious O
disorders O
was O
repeated O
, O
and O
no O
significant O
changes O
were O
found O
. O

 O
The O
patient O
was O
discharged O
from O
the O
hospital O
on O
a O
regimen O
of O
prednisone O
. O

 O
There O
was O
a O
recurrence O
of O
pericardial O
and O
pleural O
effusion O
2 O
months O
after O
discharge O
( O
after O
corticosteroid O
weaning O
and O
withdrawal O
) O
, O
which O
was O
resolved O
by O
resuming O
the O
prednisone O
therapy O
. O

 O
discharge O
, O
the O
patient O
at O
our O
for O
a O
. O

 O
He O
was O
and O
was O
maintained O
on O
therapy O
. O

 O
Follow O
- O
up O
and O
showed O
( O
Figs.4 O
and O
5 O
) O
. O

We O
report O
the O
case O
of O
a O
previously O
healthy O
, O
, O
in O
her O
. O

 O
Our O
patient O
had O
no O
medical O
records O
until O
the O
36th O
pregnancy O
week O
and O
reported O
allergy O
to O
diclofenac O
. O

 O
She O
to O
our O
with O
an O
acute O
onset O
of O
abdominal O
, O
, O
and O
, O
with O
no O
signs O
of O
encephalopathy B
. O

 O
Her O
arterial O
blood O
pressure O
was O
110/60mmHg O
, O
heart O
rate O
was O
98bpm O
, O
axillary O
temperature O
was O
35 O
 O
C O
, O
she O
was O
severely O
dehydrated O
and O
with O
decreased O
peripheral O
perfusion O
. O

 O
The O
laboratory O
examinations O
revealed O
hemoglobin O
12.3g O
/ O
dL O
, O
leukocytes O
13 O
 O
 O
 O
109 O
/ O
mL O
, O
platelets O
97 O
 O
 O
 O
103 O
/ O
mm3 O
, O
international O
nationalized O
ratio O
( O
INR O
) O
6.9 O
, O
fibrinogen O
98mg O
/ O
dL O
, O
total O
bilirubin O
14.2mg O
/ O
dL O
, O
serum O
creatinine O
3.4mg O
/ O
dL O
, O
serum O
aspartate O
aminotransferase O
( O
AST O
) O
306U O
/ O
L O
, O
serum O
alanine O
aminotransferase O
( O
ALP O
) O
302U O
/ O
L O
, O
arterial O
bicarbonate O
11mEq O
/ O
L O
, O
arterial O
pH O
7.21 O
, O
blood O
glucose O
65mg O
/ O
dL O
and O
ionic O
calcium O
1.02mmol O
/ O
L. O

 O
An O
abdominal O
ultrasound O
depicted O
fatty O
infiltration O
of O
the O
liver O
and O
confirmed O
fetal O
viability O
. O

 O
Our O
patient O
received O
an O
initial O
fluid O
load O
with O
crystalloids O
. O

 O
The O
calcium O
, O
glucose O
and O
hypothermia O
were O
reversed O
. O

 O
The O
diagnosis O
of O
AFLP O
was O
confirmed O
following O
the O
Swansea O
s O
criteria O
[ O
9 O
] O
. O

 O
Therefore O
, O
a O
cesarean O
section O
was O
indicated O
. O

 O
A O
thromboelastometry O
( O
ROTEM O
 O
, O
Pentapharm O
Co. O
, O
Munich O
, O
Germany O
) O
was O
performed O
at O
the O
beginning O
of O
the O
surgery O
. O

 O
The O
thromboelastometry O
analysis O
showed O
an O
intense O
kinetic O
and O
structural O
hypocoagulable O
state O
( O
Fig.1 O
and O
Table O
1 O
) O
. O

 O
The O
FIBTEM O
revealed O
an O
impairment O
in O
fibrinogen O
function O
quality O
while O
the O
EXTEM O
depicted O
a O
coagulation O
factor O
deficiency O
( O
Fig.1a O
- O
c O
and O
Table O
1 O
) O
. O

 O
Based O
on O
, O
respectively O
, O
FIBTEM O
maximum O
clot O
firmness O
( O
MCF O
) O
( O
0 O
mm O
; O
Table O
1 O
) O
and O
EXTEM O
clotting O
time O
( O
CT O
) O
( O
228s O
; O
Table O
1 O
) O
, O
4.0 O
g O
of O
fibrinogen O
concentrate O
( O
Haemocomplettan O
 O
P O
, O
CSL O
Behring O
, O
Marburg O
, O
Germany O
) O
and O
1000UI O
of O
prothrombin O
complex O
concentrate O
( O
Beriplex O
 O
P O
/ O
N O
500UI O
, O
CSL O
Behring O
, O
Marburg O
, O
Germany O
) O
were O
administered O
at O
the O
beginning O
of O
the O
cesarean O
section O
. O

 O
The O
fluid O
input O
( O
crystalloids O
) O
and O
output O
during O
the O
caesarian O
section O
were O
, O
respectively O
, O
2000mL O
and O
200mL. O

 O
The O
cesarean O
section O
succeeded O
with O
no O
major O
bleeding O
after O
the O
hemostatic O
therapy O
. O

 O
Additional O
hemocomponent O
transfusion O
, O
such O
as O
fresh O
frozen O
plasma O
( O
FFP O
) O
, O
cryoprecipitate O
, O
platelets O
or O
blood O
concentrates O
, O
was O
not O
necessary O
. O

 O
A O
second O
thromboelastometry O
analysis O
was O
performed O
at O
the O
end O
of O
surgery O
( O
Fig.1d O
- O
e O
and O
Table O
1 O
) O
, O
showing O
a O
mild O
hypocoagulation O
state O
. O

 O
The O
patient O
was O
admitted O
to O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
remained O
stable O
, O
with O
no O
bleeding O
during O
the O
recovery O
phase O
. O

 O
She O
was O
from O
the O
ICU O
3 O
days O
after O
admission O
and O
then O
3 O
days O
later O
she O
was O
from O
the O
. O

A O
patient O
was O
to O
our O
for O
a O
thyroid O
on O
the O
, O
which O
was O
incidentally O
detected O
on O
carotid O
Doppler O
scan O
. O

 O
( O
) O
showed O
a O
follicular O
. O

 O
At O
the O
time O
of O
our O
, O
the O
patient O
was O
in O
good O
. O

 O
The O
medical O
history O
revealed O
, O
, O
and O
. O

 O
On O
, O
a O
small O
( O
) O
was O
palpable O
in O
the O
. O

 O
No O
were O
palpable O
. O

 O
Neck O
showed O
a O
hypoechoic O
with O
in O
the O
together O
with O
bilateral O
small O
thyroid O
( O
) O
and O
the O
absence O
of O
. O

 O
were O
with O
the O
absence O
of O
. O

 O
Serum O
was O
( O
; O
normal O
range O
, O
8.410.4 O
mg O
/ O
dL O
) O
and O
, O
routinely O
measured O
together O
with O
serum O
calcium O
in O
our O
Center O
in O
patients O
undergoing O
thyroid O
surgery O
, O
( O
( O
intact O
PTH O
, O
2nd O
generation O
assay O
; O
normal O
range O
, O
1065 O
pg O
/ O
mL O
) O
) O
. O

 O
The O
re O
- O
review O
of O
the O
original O
slides O
of O
confirmed O
a O
follicular O
. O

 O
In O
particular O
, O
the O
of O
the O
nodule O
showed O
epithelial O
cells O
with O
hyperchromatic O
nuclei O
organized O
in O
small O
cohesive O
clusters O
resembling O
microfollicles O
typically O
observed O
in O
thyroid O
follicular O
lesions O
were O
evident O
( O
Fig.1a O
) O
. O

 O
The O
patients O
underwent O
right O
. O

 O
During O
neck O
, O
there O
were O
no O
macroscopic O
signs O
of O
local O
invasion O
. O

 O
The O
intraoperative O
frozen O
- O
section O
pathological O
examination O
raised O
the O
suspicion O
of O
a O
PC O
. O

 O
Definitive O
showed O
a O
markedly O
irregular O
infiltrative O
growth O
of O
the O
tumor O
with O
invasion O
of O
the O
thyroid O
tissue O
and O
cervical O
soft O
tissues O
( O
Fig.1b O
, O
c O
) O
. O

 O
Immunostaining O
for O
thyroglobulin O
was O
negative O
, O
whereas O
staining O
for O
chromogranin O
A O
and O
PTH O
showed O
a O
strong O
reactivity O
( O
Fig.1d O
 O
f O
) O
. O

 O
Based O
on O
the O
and O
the O
, O
the O
tumor O
was O
diagnosed O
as O
a O
PC B
. O

 O
Postoperative O
serum O
( O
8.7 O
mg O
/ O
dl O
) O
and O
( O
3 O
mg O
/ O
dl O
) O
levels O
were O
in O
the O
normal O
range O
. O

 O
One O
month O
after O
surgery O
, O
serum O
and O
plasma O
were O
9.6 O
mg O
/ O
dL O
and O
47 O
pg O
/ O
mL O
, O
respectively O
. O

 O
Neck O
and O
total O
body O
scan O
were O
negative O
for O
local O
and O
metastatic O
disease O
. O

 O
, O
serum O
and O
plasma O
PTH O
levels O
were O
9.19.2 O
mg O
/ O
dl O
and O
3844 O
pg O
/ O
ml O
( O
184 O
PTH O
3rd O
generation O
assay O
, O
normal O
range O
, O
840 O
pg O
/ O
mL O
) O
, O
respectively O
. O

 O
Neck O
did O
not O
show O
any O
pathological O
. O

 O
In O
order O
to O
exclude O
a O
familiar O
form O
of O
PHPT B
, O
in O
which O
PC B
may O
rarely O
occur O
as O
a O
nonfunctioning O
[ O
11 O
] O
, O
the O
screening O
of O
serum O
and O
in O
the O
was O
. O

A O
to O
our O
with O
severe O
abdominal O
. O

 O
She O
had O
. O

 O
She O
said O
that O
she O
had O
intermittent O
bloody O
. O

 O
revealed O
rebound O
and O
over O
the O
. O

 O
was O
for O
amoeba O
trophozoites O
or O
any O
parasites O
. O

 O
was O
. O

 O
Sedimentation O
was O
27 O
mm O
/ O
s O
, O
CRP O
( O
nephelometry O
) O
was O
65.6 O
mg O
/ O
L O
( O
normal O
range O
05 O
) O
, O
anti O
- O
nuclear O
antibody O
was O
0.4 O
( O
00.8 O
negative O
) O
, O
anti O
- O
ds O
DNA O
< O
10 O
( O
< O
20 O
negative O
) O
, O
white O
blood O
cell O
count O
was O
14.98 O
( O
normal O
range O
410 O
) O
, O
hemoglobin O
level O
was O
10.9 O
, O
neutro O
- O
phil O
count O
was O
13.14 O
, O
platelet O
count O
was O
473 O
( O
100300 O
) O
, O
urea O
level O
was O
17 O
mg O
/ O
dl O
, O
BUN O
level O
was O
7.94 O
mg O
/ O
dl O
, O
creatinine O
level O
was O
0.56 O
mg O
/ O
dl O
, O
AST O
was O
20 O
U O
/ O
L O
, O
and O
ALT O
was O
24 O
U O
/ O
L. O

 O
was O
. O

 O
Abdominal O
scanning O
showed O
free O
fluid O
at O
the O
right O
paracolic O
, O
perihepatic O
, O
left O
paracolic O
gutters O
and O
pelvis O
. O

 O
Upon O
detection O
of O
air O
- O
fluid O
level O
and O
free O
air O
under O
the O
diaphragm O
on O
erect O
abdominal O
, O
emergency O
was O
performed O
. O

 O
In O
the O
operation O
, O
multiple O
areas O
were O
found O
in O
the O
, O
, O
and O
. O

 O
Wide O
of O
the O
with O
descending O
and O
sigmoid O
colon O
was O
undertaken O
( O
Figure O
1 O
) O
. O

 O
was O
. O

 O
The O
patient O
had O
recurrent O
oral O
and O
genital O
aphthous O
ulcers B
. O

 O
results O
were O
. O

 O
revealed O
extensive O
thrombus B
within O
the O
extending O
through O
the O
( O
Figure O
2 O
) O
. O

 O
The O
patient O
received O
, O
, O
and O
. O

 O
Our O
patient O
is O
still O
and O
( O
Figure O
3 O
) O
. O

 O
In O
, O
the O
was O
and O
and O
were O
in O
length O
. O

 O
were O
in O
diameter O
. O

 O
Perforation B
areas O
were O
evident O
in O
the O
. O

 O
Colonic O
wall O
and O
bowel O
mucosa O
was O
and O
. O

 O
were O
in O
their O
course O
. O

 O
There O
were O
3 O
roundish O
, O
punched O
- O
out O
perforations B
in O
the O
and O
in O
the O
, O
which O
were O
somewhat O
separate O
from O
the O
colonic O
wall O
, O
with O
the O
in O
diameter O
( O
Figure O
4 O
) O
. O

 O
There O
were O
multiple O
ulcers O
( O
the O
largest O
was O
1 O
cm O
in O
diameter O
) O
in O
different O
locations O
, O
which O
were O
not O
merging O
together O
, O
and O
were O
somewhat O
separate O
from O
the O
surrounding O
mucosa O
via O
a O
certain O
limit O
, O
covered O
with O
exudate O
and O
surrounded O
by O
a O
hyperemic O
region O
. O

 O
There O
were O
no O
in O
the O
. O

 O
Numerous O
samples O
were O
taken O
from O
ulcerated O
and O
perforated O
regions O
and O
normal O
mucosa O
. O

 O
The O
samples O
were O
submitted O
for O
routine O
. O

 O
, O
and O
were O
prepared O
for O
examination O
. O

 O
In O
, O
there O
were O
neutrophil O
leukocyte O
and O
lymphocyte O
reaction O
around O
and O
within O
the O
walls O
and O
lumens O
of O
arterioles O
, O
and O
venules O
around O
the O
perforated O
and O
ulcerated O
lesions O
( O
Figures O
5 O
and O
and6).6 O
) O
. O

 O
There O
were O
well O
- O
organized O
thrombi O
and O
intimal O
proliferation O
within O
some O
vessels O
( O
Figures O
7 O
and O
and8).8 O
) O
. O

 O
There O
was O
marked O
acute O
peritonitis O
. O

 O
Surface O
epithelium O
and O
colonic O
crypts O
were O
regular O
within O
the O
colonic O
mucosa O
apart O
from O
the O
ulcerated O
or O
perforated O
lesions O
. O

 O
Samples O
were O
free O
of O
parasites B
or O
their O
eggs O
. O

A O
who O
underwent O
was O
found O
to O
have O
a O
2 O
cm O
that O
was O
located O
from O
the O
and O
. O

 O
The O
polyp O
was O
a O
tubulovillous B
adenoma I
with O
focal O
. O

 O
A O
performed O
, O
as O
well O
as O
a O
repeat O
, O
were O
both O
for O
recurrence O
. O

 O
A O
performed O
revealed O
a O
, O
in O
size O
, O
at O
from O
the O
. O

 O
were O
taken O
and O
reported O
to O
be O
fragments O
of O
a O
villous B
adenoma I
with O
. O

 O
Due O
to O
the O
previous O
high O
- O
grade O
dysplasia O
, O
relatively O
rapid O
recurrence O
and O
concern O
that O
a O
cancer O
may O
have O
been O
missed O
by O
sampling O
error O
, O
a O
pelvic O
( O
) O
scan O
and O
an O
( O
) O
were O
performed O
before O
definitive O
excision O
. O

 O
The O
revealed O
an O
invasive O
rectal O
involving O
the O
but O
without O
breach O
of O
the O
adventitia O
, O
consistent O
with O
a O
T2 O
rectal B
carcinoma I
( O
Figure O
1 O
) O
. O

 O
No O
pelvic O
was O
detected O
. O

 O
The O
revealed O
a O
rectal O
involving O
the O
and O
, O
with O
no O
involvement O
of O
the O
muscularis O
propria O
( O
Figure O
2 O
) O
. O

 O
The O
results O
of O
the O
MRI O
and O
EUS O
, O
as O
well O
as O
the O
surgical O
versus O
endoscopic O
resection O
treatment O
options O
, O
were O
discussed O
with O
the O
patient O
, O
who O
opted O
for O
a O
. O

 O
The O
patient O
underwent O
a O
and O
with O
. O

 O
of O
the O
revealed O
a O
villous B
adenoma I
with O
. O

 O
There O
was O
no O
evidence O
of O
muscularis O
propria O
, O
and O
a O
total O
of O
five O
pericolic O
and O
two O
mesorectal O
lymph O
nodes O
were O
excised O
and O
deemed O
benign O
. O

 O
The O
patient O
underwent O
. O

 O
He O
remains O
with O
no O
. O

A O
with O
a O
history O
of O
progressive O
on O
and O
. O

 O
At O
, O
of O
the O
has O
revealed O
random O
and O
. O

 O
was O
normal O
, O
and O
no O
or O
was O
observed O
. O

 O
There O
was O
or O
previous O
known O
pulmonary B
disease I
. O

 O
On O
routine O
, O
and O
were O
found O
to O
be O
. O

 O
and O
showed O
no O
important O
abnormalities O
. O

 O
( O
) O
showed O
a O
, O
with O
a O
reduced O
of O
( O
) O
, O
of O
( O
) O
and O
a O
of O
( O
) O
. O

 O
The O
sputum O
was O
negative O
for O
and O
was O
as O
well O
. O

 O
The O
revealed O
a O
diffuse O
symmetric O
dense O
bilateral O
( O
Figure O
1 O
) O
. O

 O
Based O
on O
this O
finding O
, O
was O
obtained O
, O
revealing O
diffuse O
ground O
glass O
attenuation O
and O
, O
more O
pronounced O
in O
lower O
pulmonary O
regions O
, O
with O
calcifications O
along O
the O
interlobar O
septa O
and O
subpleural O
regions O
. O

 O
Subpleural O
were O
also O
noticed O
( O
Figure O
2 O
) O
. O

 O
The O
patient O
underwent O
a O
with O
and O
transbronchial O
lung O
. O

 O
The O
lavage O
fluid O
was O
negative O
for O
or O
. O

 O
were O
not O
found O
. O

 O
revealed O
round O
, O
concentrically O
laminated O
in O
the O
associated O
with O
slightly O
thickened O
interstitial O
septa O
, O
consistent O
with O
the O
diagnosis O
of O
PAM B
. O

Our O
patient O
( O
ID O
73387 O
) O
is O
a O
, O
born O
by O
an O
emergency O
caesarean O
section O
at O
34 O
weeks O
of O
gestation O
to O
. O

 O
showed O
that O
she O
was O
small O
for O
her O
gestation O
, O
1.19 O
 O
kg O
at O
birth O
with O
a O
of O
, O
considerably O
below O
the O
0.4th O
centile O
. O

 O
Induction O
of O
labour O
had O
been O
attempted O
because O
of O
the O
growth O
retardation O
but O
had O
failed O
, O
leading O
to O
the O
emergency O
. O

 O
The O
were O
4 O
at O
, O
7 O
at O
and O
9 O
at O
. O

 O
She O
was O
to O
the O
for O
. O

 O
At O
a O
, O
she O
developed O
a O
severe O
. O

 O
The O
initial O
was O
and O
increased O
to O
( O
normal O
range O
, O
0.72.1 O
 O
mmol O
/ O
l O
) O
. O

 O
She O
was O
treated O
with O
intravenous O
infusions O
of O
and O
( O
) O
, O
but O
it O
was O
never O
possible O
to O
correct O
the O
. O

 O
She O
also O
developed O
hypoglycaemia O
within O
hours O
of O
birth O
that O
was O
corrected O
with O
an O
intravenous O
infusion O
of O
15 O
% O
glucose O
( O
7.8 O
 O
mg O
/ O
kg O
/ O
min O
) O
. O

 O
The O
ammonia O
concentration O
was O
normal O
. O

 O
Urine O
organic O
acid O
profile O
showed O
massive O
excretion O
of O
lactic O
acid O
and O
increased O
phenolic O
acids O
, O
especially O
hydroxyphenyllactate O
. O

 O
Plasma O
amino O
acids O
showed O
raised O
concentrations O
of O
alanine O
and O
glutamine O
( O
1567 O
and O
1369 O
 O
mol O
/ O
l O
, O
respectively O
) O
, O
consistent O
with O
the O
lactic O
acidosis O
; O
several O
other O
amino O
acids O
were O
also O
mildly O
increased O
. O

 O
There O
was O
gross O
generalised O
aminoaciduria O
. O

 O
Blood O
acylcarnitine O
analysis O
was O
normal O
. O

 O
Echocardiography O
showed O
a O
structurally O
normal O
heart O
and O
good O
ventricular O
function O
. O

 O
Cranial O
ultrasound O
showed O
bilateral O
intraventricular O
cysts O
within O
the O
frontal O
horns O
and O
anterior O
portions O
of O
the O
lateral O
ventricles O
. O

 O
The O
left O
- O
sided O
cysts O
were O
larger O
, O
up O
to O
15 O
 O
mm O
in O
diameter O
, O
whereas O
the O
largest O
cyst O
on O
the O
right O
was O
8 O
 O
mm O
in O
diameter O
. O

 O
The O
choroid O
plexuses O
were O
hyperechoic O
and O
irregular O
, O
suggesting O
previous O
intraventricular O
haemorrhage O
. O

 O
Abdominal O
ultrasound O
showed O
a O
distended O
urinary O
bladder O
but O
was O
otherwise O
unremarkable O
. O

 O
There O
was O
severe O
coagulopathy O
with O
an O
extended O
prothrombin O
time O
of O
47.7 O
 O
s O
( O
normal O
12.316.6 O
 O
s O
) O
, O
a O
very O
low O
plasma O
albumin O
of O
7 O
 O
g O
/ O
l O
( O
normal O
3550 O
 O
g O
/ O
l O
) O
, O
otherwise O
normal O
liver O
function O
tests O
but O
a O
raised O
creatine O
kinase O
of O
2700 O
 O
U O
/ O
l O
( O
normal O
< O
300 O
 O
U O
/ O
l O
) O
. O

 O
She O
was O
transferred O
to O
a O
tertiary O
centre O
because O
of O
her O
worsening O
metabolic O
acidosis O
. O

 O
She O
started O
having O
seizures O
at O
48 O
 O
h O
of O
age O
. O

 O
Despite O
infusions O
of O
bicarbonate O
and O
THAM O
, O
her O
acidosis O
continued O
to O
worsen O
. O

 O
Muscle O
and O
skin O
biopsies O
were O
performed O
and O
the O
family O
agreed O
to O
the O
withdrawal O
of O
intensive O
care O
treatment O
. O

 O
She O
aged O
55 O
 O
h. O

 O
All O
documented O
studies O
were O
approved O
and O
performed O
under O
the O
ethical O
guidelines O
issued O
by O
each O
of O
our O
Institutions O
for O
clinical O
studies O
, O
with O
written O
informed O
consent O
obtained O
from O
the O
family O
. O

A O
complained O
of O
for O
and O
was O
to O
our O
after O
a O
bifrontal O
was O
found O
. O

 O
Other O
than O
dizziness O
, O
the O
patient O
presented O
no O
signs O
or O
symptoms O
that O
are O
commonly O
associated O
with O
neurological O
disease O
, O
such O
as O
headache O
, O
vomiting O
, O
sensory O
disturbances O
, O
altered O
consciousness O
, O
or O
seizures O
. O

 O
Except O
for O
a O
, O
which O
was O
properly O
controlled O
with O
, O
the O
patient O
was O
otherwise O
. O

 O
, O
and O
the O
patient O
was O
found O
to O
be O
normal O
upon O
. O

 O
Plain O
and O
contrast O
- O
enhanced O
( O
) O
of O
the O
showed O
a O
space O
- O
occupying O
in O
the O
, O
, O
and O
the O
. O

 O
The O
5.7 O
 O
 O
 O
5.0 O
 O
 O
 O
5.0 O
 O
cm O
dural O
- O
based O
growing O
revealed O
on O
the O
and O
a O
slight O
on O
the O
and O
was O
homogenously O
enhanced O
with O
a O
( O
Fig.1 O
) O
. O

 O
Diagnosis O
of O
a O
parasagittal O
- O
parafalcine O
meningioma B
was O
made O
, O
and O
a O
craniotomic O
meningioma O
was O
chosen O
as O
treatment O
. O

 O
The O
; O
, O
tests O
; O
; O
chest O
and O
were O
. O

 O
The O
was O
36 O
 O
g O
/ O
L O
, O
the O
( O
) O
was O
12.2 O
 O
mol O
/ O
L O
, O
and O
the O
( O
) O
was O
4.1 O
 O
mol O
/ O
L. O

 O
( O
) O
was O
, O
and O
the O
( O
) O
for O
coagulation O
values O
was O
. O

 O
Because O
of O
the O
patient O
's O
advanced O
age O
and O
history O
of O
hypertension O
, O
we O
performed O
an O
and O
a O
and O
tested O
her O
levels O
and O
. O

 O
The O
results O
revealed O
. O

 O
Written O
consent O
was O
obtained O
from O
the O
patient O
. O

 O
Five O
hundred O
milligrams O
of O
was O
initiated O
. O

 O
The O
patient O
tolerated O
the O
administration O
well O
. O

 O
A O
was O
then O
performed O
with O
a O
radical O
( O
Simpson O
II O
) O
. O

 O
The O
was O
and O
and O
had O
a O
, O
and O
its O
texture O
was O
. O

 O
Thirty O
minutes O
before O
the O
end O
of O
surgery O
, O
800 O
 O
mg O
of O
was O
administered O
by O
. O

 O
After O
the O
operation O
, O
the O
patient O
regained O
within O
30 O
minutes O
and O
scored O
15 O
on O
the O
( O
) O
. O

 O
as O
she O
was O
being O
back O
to O
her O
, O
the O
patient O
underwent O
UGH B
. O

 O
The O
( O
) O
was O
composed O
of O
. O

 O
Excluding O
the O
possible O
etiology O
of O
endotracheal O
intubation O
, O
we O
diagnosed O
the O
patient O
as O
experiencing O
acute O
erosive O
- O
hemorrhagic O
gastritis B
, O
a O
reaction O
to O
the O
craniotomy O
. O

 O
The O
patient O
was O
given O
to O
inhibit O
gastric O
acid O
secretion O
, O
and O
the O
ceased O
. O

 O
The O
patient O
was O
administered O
( O
, O
) O
. O

 O
Because O
of O
her O
stomach O
and O
intestine O
functional O
recovery O
, O
the O
dosage O
was O
changed O
to O
via O
oral O
administration O
. O

 O
A O
brain O
was O
performed O
on O
postoperative O
, O
and O
it O
revealed O
that O
the O
was O
radically O
removed O
and O
the O
was O
( O
Fig.2A O
and O
B O
) O
. O

 O
A O
subsequent O
paraffin O
confirmed O
the O
diagnosis O
of O
meningioma B
. O

 O
At O
on O
postoperative O
, O
the O
patient O
was O
suddenly O
found O
in O
a O
deep O
coma B
. O

 O
Her O
to O
and O
, O
and O
the O
was O
. O

 O
The O
was O
, O
and O
her O
were O
; O
however O
, O
her O
to O
a O
deep O
coma B
( O
 O
= O
 O
8) O
, O
which O
we O
believed O
was O
caused O
by O
intracranial O
. O

 O
A O
( O
) O
scan O
of O
the O
was O
immediately O
performed O
; O
however O
, O
it O
, O
such O
as O
severe O
brain O
, O
intracranial B
hemorrhage I
, O
or O
cerebral B
infarction I
( O
Fig.2C O
) O
. O

 O
Because O
a O
possible O
cerebral B
infarction I
could O
not O
be O
excluded O
, O
, O
, O
and O
a O
were O
used O
. O

 O
The O
patient O
's O
routine O
for O
blood O
cell O
, O
liver O
, O
and O
renal O
were O
in O
. O

 O
The O
was O
, O
the O
was O
13.3 O
 O
mol O
/ O
L O
, O
and O
the O
was O
4.5 O
 O
mol O
/ O
L. O

 O
was O
, O
and O
the O
for O
coagulation O
values O
was O
. O

 O
Because O
of O
her O
, O
we O
checked O
her O
levels O
and O
performed O
a O
and O
. O

 O
Her O
was O
elevated O
( O
181.6 O
 O
mol O
/ O
L O
; O
normal O
range O
is O
1132 O
 O
mol O
/ O
L O
) O
, O
whereas O
the O
was O
. O

 O
Thus O
, O
considering O
her O
history O
and O
elevated O
blood O
ammonia O
, O
she O
was O
diagnosed O
with O
UGH O
- O
induced O
hepatic B
encephalopathy I
, O
and O
the O
oral O
administration O
of O
was O
changed O
to O
administration O
to O
prevent O
seizures O
. O

 O
, O
, O
and O
were O
administered O
, O
with O
was O
performed O
, O
and O
the O
patient O
was O
. O

 O
The O
patient O
's O
level O
( O
) O
, O
and O
she O
remained O
during O
the O
. O

 O
Because O
of O
the O
unremarkable O
progress O
in O
the O
patient O
's O
and O
level O
, O
we O
to O
discuss O
diagnosis O
and O
treatment O
, O
initially O
considering O
hemodialysis O
or O
peritoneal O
dialysis O
. O

 O
After O
the O
multidisciplinary O
discussion O
, O
a O
suspected O
diagnosis O
of O
VHE B
was O
finally O
made O
, O
even O
though O
the O
level O
was O
within O
the O
. O

 O
We O
decided O
to O
stop O
administration O
before O
performing O
any O
dialysis O
and O
administered O
levetiracetam O
instead O
of O
VPA O
. O

 O
The O
patient O
's O
blood O
VPA O
and O
ammonia O
levels O
were O
then O
routinely O
monitored O
. O

 O
The O
patient O
's O
began O
to O
from O
the O
of O
VPA O
discontinuation O
, O
and O
she O
achieved O
complete O
( O
 O
= O
 O
) O
. O

 O
The O
in O
her O
dramatically O
and O
returned O
to O
( O
Fig.3 O
) O
. O

 O
On O
postoperative O
( O
8 O
days O
after O
the O
discontinuation O
of O
VPA O
) O
, O
the O
patient O
was O
with O
no O
. O

 O
The O
interviews O
in O
postoperative O
witnessed O
her O
full O
and O
non O
- O
of O
the O
( O
Fig.2D O
) O
. O

 O
The O
patient O
's O
score O
was O
, O
and O
she O
reported O
enjoying O
a O
satisfying O
. O

Our O
patient O
was O
a O
. O

 O
, O
he O
with O
a O
clinically O
evident O
and O
was O
for O
. O

 O
Initial O
tests O
revealed O
, O
, O
and O
. O

 O
A O
bone O
marrow O
revealed O
the O
presence O
of O
, O
which O
led O
to O
suspicion O
of O
lysosomal B
storage I
disease I
. O

 O
revealed O
elevated O
level O
of O
( O
[ O
normal O
range O
57 O
IU O
/ O
L O
] O
) O
and O
( O
[ O
normal O
range O
5.941.0 O
nmol O
/ O
mg O
protein O
] O
) O
, O
as O
well O
as O
reduced O
( O
[ O
normal O
range O
4.518.0 O
nmol O
/ O
mg O
/ O
protein O
] O
) O
. O

 O
showed O
homozygous O
L444P O
mutations O
in O
the O
GBA O
gene O
( O
OMIM O
reference O
606463 O
) O
, O
confirming O
the O
diagnosis O
of O
chronic O
NGD B
. O

 O
The O
patient O
began O
at O
a O
dosage O
of O
. O

 O
Thereafter O
, O
when O
the O
patient O
reached O
the O
, O
we O
decided O
to O
combine O
with O
with O
. O

 O
This O
clinical O
decision O
was O
approved O
by O
our O
institution O
s O
ethics O
committee O
, O
and O
informed O
consent O
was O
obtained O
from O
the O
patient O
s O
parents O
before O
commencing O
combination O
therapy O
. O

 O
The O
dose O
of O
was O
and O
was O
uptitrated O
during O
the O
first O
4 O
weeks O
with O
the O
following O
scheme O
: O
one O
- O
third O
of O
target O
dose O
during O
weeks O
1 O
and O
2 O
, O
two O
- O
thirds O
of O
target O
dose O
during O
weeks O
3 O
and O
4 O
, O
and O
target O
dose O
( O
) O
. O

 O
From O
2 O
weeks O
before O
starting O
miglustat O
therapy O
, O
the O
patient O
also O
followed O
specific O
, O
, O
especially O
foods O
high O
in O
disaccharides O
, O
such O
as O
sucrose O
and O
maltose O
, O
to O
ensure O
acceptable O
gastrointestinal O
tolerability O
. O

 O
He O
experienced O
mild O
episodes O
of O
after O
commencing O
therapy O
, O
which O
. O

 O
From O
the O
start O
of O
ERT O
/ O
miglustat O
combination O
treatment O
, O
we O
observed O
a O
reduction O
in O
and O
a O
gradual O
normalization O
of O
and O
( O
Table O
1 O
) O
. O

 O
was O
evaluated O
at O
the O
time O
of O
diagnosis O
and O
then O
approximately O
during O
. O

 O
Values O
showed O
an O
after O
the O
start O
of O
ERT O
, O
with O
a O
further O
, O
substantial O
, O
and O
treatment O
( O
Fig.1 O
) O
. O

 O
The O
patient O
has O
been O
, O
which O
specify O
a O
complete O
, O
clinical O
, O
and O
[ O
10 O
] O
. O

 O
After O
of O
and O
, O
the O
patient O
did O
not O
show O
any O
signs O
of O
. O

 O
As O
of O
, O
he O
had O
not O
displayed O
any O
and O
had O
demonstrated O
and O
. O

 O
He O
showed O
good O
, O
normal O
with O
a O
slight O
in O
his O
, O
and O
a O
negative O
. O

 O
His O
was O
. O

 O
In O
particular O
, O
revealed O
no O
evidence O
of O
and O
normal O
. O

 O
The O
patient O
s O
were O
also O
. O

 O
In O
addition O
, O
he O
has O
not O
demonstrated O
any O
, O
and O
he O
has O
regularly O
with O
. O

A O
with O
a O
history O
of O
presented O
with O
a O
generalized O
petechial O
and O
of O
. O

 O
The O
was O
nonpruritic O
, O
painless O
, O
and O
started O
at O
the O
thighs O
, O
but O
rapidly O
disseminated O
to O
the O
rest O
of O
the O
body O
. O

 O
She O
had O
progressive O
on O
, O
with O
a O
significant O
decrease O
in O
. O

 O
She O
denied O
, O
, O
, O
, O
or O
from O
. O

 O
There O
was O
. O

 O
Her O
only O
medication O
was O
, O
which O
she O
had O
been O
taking O
for O
. O

 O
The O
patient O
. O

 O
On O
admission O
, O
she O
was O
, O
with O
mild O
( O
of O
) O
. O

 O
Physical O
examination O
revealed O
scattered O
petechial O
, O
more O
prominent O
in O
, O
and O
. O

 O
revealed O
coarse O
. O

 O
Cardiovascular O
, O
abdominal O
, O
and O
neurological O
were O
. O

 O
There O
was O
no O
palpable O
or O
. O

 O
revealed O
( O
platelets O
7000 O
/ O
L O
) O
, O
( O
hemoglobin O
10.8 O
 O
mg O
/ O
dL O
and O
hematocrit O
34 O
% O
) O
, O
and O
( O
[ O
] O
) O
. O

 O
The O
was O
, O
which O
excluded O
disseminated B
intravascular I
coagulation I
. O

 O
on O
revealed O
a O
( O
) O
of O
, O
a O
( O
) O
of O
( O
) O
, O
and O
an O
increased O
( O
) O
. O

 O
Diffuse O
was O
found O
on O
chest O
( O
Fig.1A O
) O
. O

 O
( O
) O
of O
the O
showed O
diffuse O
ground O
glass O
alveolar O
and O
patchy O
( O
Fig.1B O
, O
C O
) O
. O

 O
She O
was O
started O
on O
broad O
- O
spectrum O
and O
received O
intravenous O
. O

 O
showed O
giant O
platelets O
and O
occasional O
small O
platelet O
clumps O
, O
with O
no O
. O

 O
A O
( O
) O
showed O
normal O
with O
no O
endobronchial O
( O
Fig.2A O
) O
. O

 O
Serial O
aliquots O
of O
( O
) O
turned O
more O
, O
confirming O
the O
bronchoscopic O
diagnosis O
of O
DAH B
( O
Fig.2B O
) O
. O

 O
of O
showed O
a O
substantial O
amount O
of O
hemosiderin O
- O
laden O
, O
further O
supporting O
the O
diagnosis O
. O

 O
All O
BALF O
and O
were O
. O

 O
The O
patient O
remained O
with O
severe O
and O
despite O
and O
. O

 O
High O
doses O
of O
pulse O
and O
( O
IVIGs O
) O
were O
added O
with O
clinico O
- O
radiological O
. O

 O
A O
was O
. O

 O
Additional O
for O
secondary O
thrombocytopenia O
( O
Table O
1 O
) O
, O
supporting O
the O
diagnosis O
of O
ITP B
. O

 O
were O
gradually O
tapered O
. O

 O
Repeat O
chest O
showed O
almost O
complete O
resolution O
of O
bilateral O
( O
Fig.3 O
) O
. O

 O
returned O
to O
by O
after O
admission O
without O
any O
( O
Fig.4 O
) O
. O

A O
with O
a O
presented O
with O
an O
acute O
two O
day O
history O
of O
, O
, O
abdominal O
, O
and O
. O

 O
He O
complained O
of O
joint O
affecting O
the O
, O
, O
, O
, O
and O
. O

 O
There O
was O
also O
a O
on O
the O
, O
and O
, O
which O
began O
as O
erythematous O
and O
evolved O
to O
vesico O
- O
pustular O
followed O
by O
. O

 O
There O
was O
or O
any O
intercurrent O
. O

 O
He O
was O
on O
, O
but O
had O
discontinued O
. O

 O
he O
had O
undergone O
a O
to O
excise O
a O
complex O
ileo O
- O
cutaneous O
with O
, O
and O
a O
defunctioning O
had O
been O
created O
in O
view O
of O
persistent O
abdominal O
. O

 O
The O
fistula O
, O
but O
was O
associated O
with O
a O
terminal O
ileal O
stricture O
and O
ileo O
- O
rectal O
fistula O
. O

 O
His O
had O
been O
resistant O
to O
immunosuppressive O
drugs O
including O
, O
and O
three O
infusions O
of O
. O

 O
There O
had O
been O
. O

 O
On O
to O
the O
, O
he O
was O
, O
with O
a O
resting O
of O
. O

 O
The O
rest O
of O
the O
was O
normal O
. O

 O
The O
was O
minimally O
around O
the O
without O
guarding O
or O
rebound O
tenderness O
. O

 O
revealed O
some O
and O
around O
the O
, O
and O
( O
Fig O
1 O
and O
  O
2 O
) O
. O

 O
The O
buttocks O
were O
spared O
. O

 O
There O
were O
clinical O
signs O
of O
of O
the O
, O
and O
, O
and O
also O
. O

 O
Results O
of O
the O
showed O
a O
of O
13.1 O
gm O
/ O
dl O
, O
15.8 O
 O
109 O
/ O
L O
, O
585 O
 O
109 O
/ O
L O
, O
37.7 O
mg O
/ O
L O
and O
. O

 O
and O
, O
, O
and O
were O
normal O
. O

 O
Rheumatoid O
factor O
, O
antinuclear O
and O
antineutrophil O
cytoplasmic O
antibodies O
, O
cryoglobulins O
and O
Hepatitis O
B O
and O
C O
serology O
were O
. O

 O
Transthoracic O
showed O
, O
and O
were O
. O

 O
A O
skin O
from O
the O
ankle O
revealed O
a O
infiltrate O
with O
prominent O
neutrophils O
and O
associated O
fibrinoid O
necrosis O
of O
vessels O
consistent O
with O
' O
leukocytoclastic O
' O
vasculitis B
. O

 O
He O
was O
commenced O
on O
60 O
mg O
leading O
to O
prompt O
and O
complete O
. O

 O
The O
dose O
of O
was O
rapidly O
tapered O
over O
the O
course O
of O
one O
month O
by O
the O
patient O
, O
faster O
than O
advised O
but O
without O
any O
recurrence O
. O

This O
is O
the O
case O
of O
a O
with O
a O
( O
Fig.1 O
) O
. O

 O
She O
was O
to O
the O
hospital O
with O
and O
abdominal O
for O
. O

 O
On O
admission O
, O
were O
obtained O
( O
a O
was O
within O
normal O
limits O
, O
: O
136 O
U O
/ O
L O
, O
: O
with O
a O
of O
) O
. O

 O
Cross O
- O
sectional O
, O
abdominal O
( O
) O
, O
showed O
a O
low O
- O
attenuating O
localized O
in O
the O
( O
measuring O
) O
and O
a O
suspicious O
for O
compression O
) O
. O

 O
After O
a O
multidisciplinary O
meeting O
, O
our O
patient O
was O
scheduled O
for O
. O

 O
showed O
a O
solid O
, O
heteroechoic O
with O
predominantly O
hypoechoic O
areas O
, O
well O
- O
defined O
lesion O
with O
regular O
contours O
( O
measuring O
3.1 O
 O
 O
 O
2.6 O
cm O
) O
, O
localized O
between O
the O
head O
and O
neck O
of O
the O
pancreas O
( O
Fig.2 O
) O
. O

 O
There O
was O
no O
identified O
. O

 O
was O
performed O
. O

 O
In O
the O
( O
Fig.3 O
) O
, O
the O
cells O
presented O
have O
a O
, O
with O
marked O
including O
and O
with O
and O
. O

 O
The O
nuclear O
chromatin O
is O
clumping O
and O
irregular O
with O
excessive O
parachromatin O
clearing O
, O
there O
are O
single O
or O
multiple O
macronucleoli O
, O
and O
abundant O
cytoplasm O
with O
deep O
brownish O
- O
black O
granules O
obscuring O
the O
cell O
details O
. O

 O
The O
background O
shows O
and O
. O

 O
Our O
patient O
underwent O
right O
orbital O
and O
followed O
by O
( O
the O
) O
, O
without O
any O
( O
Fig.4 O
) O
. O

 O
The O
showed O
undifferentiated O
, O
with O
, O
infiltrating O
the O
and O
the O
. O

 O
was O
positive O
for O
, O
, O
, O
and O
negative O
for O
, O
all O
consistent O
with O
metastatic O
malignant O
melanoma B
. O

 O
At O
the O
moment O
, O
our O
patient O
is O
receiving O
adjuvant O
at O
an O
. O

A O
patient O
was O
with O
acute O
left B
ventricular I
( I
LV I
) I
failure I
and O
was O
treated O
with O
intensive O
. O

 O
He O
had O
severe O
peripheral O
and O
bilateral O
basal O
. O

 O
Initial O
revealed O
normal O
levels O
of O
( O
) O
and O
( O
) O
, O
thereby O
ruling O
out O
acute B
coronary I
syndrome I
. O

 O
The O
level O
of O
was O
confirming O
the O
diagnosis O
of O
heart B
failure I
. O

 O
revealed O
of O
with O
, O
and O
estimated O
( O
) O
was O
with O
. O

 O
was O
performed O
of O
which O
revealed O
critical O
triple B
vessel I
disease I
with O
left O
main O
coronary B
artery I
disease I
( O
Fig.1 O
) O
. O

 O
He O
was O
referred O
for O
. O

 O
The O
patient O
was O
put O
on O
with O
oral O
and O
. O

 O
He O
was O
taken O
up O
for O
elective O
. O

 O
was O
monitored O
regularly O
. O

 O
There O
was O
no O
feature O
of O
end B
organ I
dysfunction I
. O

 O
was O
. O

 O
Repeat O
revealed O
improvement O
of O
to O
and O
decrease O
in O
to O
and O
decrease O
in O
. O

 O
was O
performed O
through O
. O

 O
was O
used O
for O
grafting O
( O
) O
. O

 O
After O
, O
( O
) O
and O
composite O
, O
was O
prepared O
. O

 O
The O
distal O
end O
of O
RITA O
was O
used O
for O
the O
. O

 O
There O
was O
significant O
improvement O
in O
systolic O
after O
this O
distal O
. O

 O
After O
these O
two O
grafts O
, O
heart O
was O
. O

 O
We O
make O
a O
longer O
, O
open O
the O
sternum O
widely O
, O
and O
release O
pericardium O
on O
the O
right O
side O
to O
displace O
the O
heart O
gradually O
. O

 O
This O
was O
supplemented O
with O
headlow O
and O
lateral O
tilt O
position O
. O

 O
Liberal O
doses O
of O
inotropic O
support O
were O
used O
. O

 O
RA O
was O
used O
for O
sequential O
grafting O
of O
obtuse O
marginal O
, O
posterior O
LV O
branch O
, O
and O
posterior O
descending O
artery O
. O

 O
All O
these O
five O
distal O
anastamoses O
were O
performed O
uneventfully O
. O

 O
The O
patient O
was O
electively O
for O
. O

 O
on O
revealed O
improvement O
in O
to O
. O

 O
He O
was O
started O
on O
low O
dose O
after O
were O
weaned O
off O
. O

 O
He O
had O
slow O
and O
uneventful O
. O

 O
on O
revealed O
improvement O
in O
to O
( O
Table O
1 O
) O
. O

 O
He O
had O
persistent O
requiring O
prolonged O
. O

 O
After O
subsided O
and O
drains O
were O
removed O
, O
he O
was O
discharged O
on O
, O
low O
dose O
, O
and O
. O

A O
who O
initially O
with O
, O
and O
painless O
, O
was O
subsequently O
found O
to O
have O
adenocarcinoma B
of O
the O
. O

 O
An O
initial O
workup O
revealed O
localized O
cancer B
with O
no O
evidence O
of O
distant O
metastases B
. O

 O
He O
then O
underwent O
with O
complete O
of O
a O
5 O
cm O
moderately O
differentiated O
pancreatic O
adenocarcinoma B
. O

 O
Although O
our O
patient O
underwent O
complete O
surgical O
resection O
, O
a O
pathological O
examination O
revealed O
a O
neoplastic O
invasion O
of O
the O
resected O
adjacent O
organs O
, O
and O
one O
out O
of O
the O
seven O
resected O
lymph O
nodes O
contained O
cancer O
( O
T3N1M0 O
) O
. O

 O
At O
that O
point O
, O
the O
oncology O
department O
recommended O
to O
proceed O
with O
adjuvant O
chemotherapy O
with O
gemcitabine O
( O
1000mg O
/ O
m2 O
IV O
on O
days O
1 O
, O
8 O
, O
15 O
on O
a O
28 O
- O
day O
cycle O
for O
six O
cycles O
) O
to O
try O
to O
reduce O
the O
likelihood O
of O
recurrence O
. O

 O
However O
, O
after O
completing O
two O
cycles O
( O
a O
total O
of O
six O
doses O
) O
of O
chemotherapy O
, O
he O
presented O
to O
the O
emergency O
department O
with O
worsening O
exertional O
dyspnea O
, O
three O
- O
pillow O
orthopnea O
, O
paroxysmal O
nocturnal O
dyspnea O
and O
fatigue O
. O

 O
His O
physical O
examination O
revealed O
an O
elevated O
jugular O
venous O
pressure O
( O
JVP O
) O
( O
10 O
cm O
above O
the O
sternal O
angle O
) O
, O
bibasilar O
rales O
and O
+2 O
pitting O
edema O
of O
both O
lower O
extremities O
. O

 O
Cardiac O
auscultation O
revealed O
a O
gallop O
rhythm O
with O
an O
S3 O
and O
a O
grade O
3 O
holosystolic O
murmur O
over O
precordium O
. O

 O
A O
chest O
X O
- O
ray O
showed O
cardiomegaly O
with O
mild O
to O
moderate O
- O
sized O
right O
- O
sided O
pleural O
effusion O
. O

 O
It O
was O
thought O
that O
his O
presentation O
was O
consistent O
with O
fluid O
overload O
secondary O
to O
congestive O
heart O
failure O
( O
CHF O
) O
and O
he O
was O
started O
on O
intravenous O
( O
IV O
) O
furosemide O
with O
partial O
improvement O
in O
his O
symptoms O
. O

 O
The O
next O
day O
, O
a O
two O
- O
dimensional O
echocardiography O
( O
2D O
Echo O
) O
was O
performed O
, O
which O
showed O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
of O
15 O
to O
20 O
percent O
with O
global O
hypokinesia O
along O
with O
moderate O
mitral O
regurgitation O
. O

 O
Given O
the O
findings O
of O
2D O
Echo O
and O
the O
absence O
of O
significant O
risk O
factors O
for O
coronary O
artery O
disease O
( O
CAD O
) O
and O
ischemic O
cardiomyopathy O
( O
CMP O
) O
, O
it O
was O
concluded O
that O
our O
patient O
s O
CMP O
was O
related O
to O
the O
recent O
use O
of O
gemcitabine O
. O

 O
Our O
patient O
was O
then O
started O
on O
carvedilol O
and O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
addition O
to O
diuretics O
and O
he O
was O
discharged O
from O
the O
hospital O
two O
days O
later O
in O
a O
euvolemic O
state O
. O

 O
At O
that O
point O
, O
the O
cardiology O
department O
recommended O
stopping O
further O
chemotherapy O
with O
gemcitabine O
. O

 O
The O
oncology O
department O
advised O
further O
testing O
to O
rule O
out O
ischemia O
as O
a O
cause O
of O
CMP O
as O
, O
in O
their O
opinion O
, O
chemotherapy O
with O
gemcitabine O
was O
the O
only O
option O
to O
reduce O
the O
risk O
of O
recurrence O
in O
this O
patient O
. O

 O
Two O
weeks O
later O
, O
our O
patient O
underwent O
myocardial O
perfusion O
imaging O
( O
MPI O
) O
, O
which O
showed O
a O
fixed O
small- O
to O
moderate O
- O
sized O
inferior O
wall O
defect O
without O
any O
evidence O
of O
active O
ischemia O
. O

 O
The O
ejection O
fraction O
( O
EF O
) O
on O
MPI O
was O
calculated O
to O
be O
around O
17 O
to O
20 O
percent O
with O
severe O
global O
hypokinesia O
. O

 O
Our O
patient O
was O
continued O
on O
standard O
heart O
failure O
therapy O
with O
one O
more O
admission O
to O
the O
hospital O
for O
CHF O
exacerbation O
about O
two O
months O
later O
. O

 O
He O
responded O
well O
to O
IV O
furosemide O
and O
adjustment O
of O
heart O
failure O
therapy O
. O

 O
A O
2D O
Echo O
was O
repeated O
a O
few O
months O
later O
and O
it O
showed O
improvement O
in O
systolic O
function O
with O
an O
LVEF O
of O
40 O
percent O
. O

 O
Due O
to O
his O
poor O
functional O
status O
and O
underlying O
CMP O
, O
further O
gemcitabine O
chemotherapy O
was O
stopped O
. O

 O
Later O
, O
our O
patient O
developed O
a O
recurrence O
of O
his O
pancreatic O
cancer O
; O
he O
refused O
further O
chemotherapy O
and O
decided O
to O
proceed O
with O
. O

 O
Although O
the O
exact O
etiology O
of O
our O
patient O
s O
dilated O
cardiomyopathy B
remains O
unclear O
, O
remains O
the O
most O
likely O
culprit O
. O

 O
The O
temporal O
relationship O
of O
his O
symptoms O
to O
the O
initiation O
of O
; O
the O
lack O
of O
and O
prior O
history O
of O
CAD B
, O
finding O
of O
global O
on O
, O
absence O
of O
on O
; O
and O
improvement O
in O
his O
after O
discontinuation O
of O
were O
all O
consistent O
with O
- O
induced O
cardiomyopathy B
. O

This O
is O
a O
patient O
who O
went O
to O
our O
hospital O
with O
chief O
complaint O
of O
massive O
gum O
for O
. O

 O
The O
patient O
had O
a O
history O
of O
chronic O
hepatitis O
C. O

 O
( O
) O
plus O
( O
) O
were O
prescribed O
to O
the O
patient O
. O

 O
He O
before O
treatment O
. O

 O
The O
baseline O
revealed O
high O
( O
) O
with O
1b O
. O

 O
Rapid O
virological O
response O
was O
not O
achieved O
at O
the O
fourth O
week O
( O
: O
) O
. O

 O
Partial O
early O
virological O
response O
( O
HCV O
RNA O
: O
103 O
 O
IU O
/ O
mL O
at O
week O
12 O
) O
and O
delayed O
virological O
response O
( O
HCV O
RNA O
: O
< O
15 O
 O
IU O
/ O
mL O
at O
Week O
24 O
) O
were O
noted O
. O

 O
However O
, O
fatigue O
, O
anemia O
, O
and O
depression O
syndrome O
were O
progressed O
at O
30th O
week O
. O

 O
The O
patient O
requested O
to O
stop O
treatment O
at O
Week O
36 O
. O

 O
The O
viral O
load O
at O
the O
end O
- O
of O
- O
treatment O
( O
EOT O
) O
was O
undetectable O
. O

 O
The O
platelet O
count O
at O
EOT O
was O
92 O
 O
 O
 O
103 O
 O
cells O
/ O
L O
and O
elevated O
to O
159 O
 O
 O
 O
103 O
 O
cells O
/ O
L O
1 O
week O
later O
. O

 O
Two O
weeks O
following O
EOT O
, O
the O
patient O
developed O
massive O
gum O
bleeding O
. O

 O
The O
physical O
examination O
showed O
the O
multiple O
petechiae O
on O
the O
extremities O
. O

 O
There O
is O
no O
sign O
of O
intracerebral O
hemorrhage O
, O
gastrointestinal O
bleeding O
, O
or O
other O
internal O
bleeding O
. O

 O
The O
initial O
platelet O
count O
was O
4 O
 O
 O
 O
103cells O
/ O
L. O

 O
Coagulation O
profile O
showed O
normal O
prothrombin O
time O
, O
activated O
partial O
thromboplastin O
time O
, O
fibrinogen O
, O
d O
- O
dimer O
, O
and O
fibrin O
degradation O
product O
. O

 O
Peripheral O
blood O
smear O
showed O
neither O
fragmented O
red O
blood O
cells O
, O
helmet O
cells O
nor O
abnormal O
platelet O
aggregation O
. O

 O
Concomitant O
autoimmune O
connective O
tissue O
diseases O
such O
as O
systemic O
lupus O
erythematosus O
or O
cryoglobulinemia O
were O
excluded O
due O
to O
negative O
anti O
- O
nuclear O
antibody O
and O
cryoglobulin O
except O
for O
positive O
anti O
- O
cardiolipin O
IgG O
( O
116 O
GPL O
, O
normal O
range O
< O
20 O
GPL O
) O
and O
anti O
- O
phospholipid O
IgG O
( O
165 O
 O
U O
, O
normal O
range O
< O
15 O
 O
U O
) O
. O

 O
Anti O
- O
phospholipid O
syndrome O
was O
excluded O
due O
to O
no O
previous O
thromboembolic O
events O
, O
according O
to O
2006 O
Sapporo O
criteria.12 O
Bone O
marrow O
biopsy O
was O
also O
performed O
, O
which O
revealed O
hypocellular O
marrow O
with O
even O
cellular O
distribution O
and O
without O
evidence O
of O
lymphoid O
neoplasia O
. O

 O
The O
potential O
drugs O
that O
may O
cause O
platelet O
lysis O
were O
ruled O
out O
. O

 O
Blood O
transfusion O
of O
platelet O
was O
performed O
, O
but O
poor O
response O
with O
rapid O
decline O
of O
platelet O
count O
in O
the O
next O
day O
of O
transfusion O
. O

 O
A O
diagnosis O
of O
immune O
thrombocytopenic O
purpura O
was O
made O
. O

 O
We O
started O
intravenous O
methylprednisolone O
therapy O
( O
40 O
 O
mg O
, O
3 O
times O
daily O
) O
on O
November O
27 O
combined O
with O
platelet O
transfusion O
treatments O
. O

 O
It O
still O
showed O
no O
significant O
improvement O
. O

 O
Azathioprine O
( O
100 O
 O
mg O
, O
oral O
, O
once O
daily O
) O
was O
added O
since O
December O
3 O
. O

 O
Hydroxychloroquine O
( O
400 O
 O
mg O
, O
oral O
, O
once O
daily O
) O
was O
also O
prescribed O
due O
to O
positive O
anti O
- O
phospholipid O
antibodies O
. O

 O
Platelet O
count O
gradually O
increased O
to O
93 O
 O
 O
 O
103 O
 O
cells O
/ O
L O
17 O
days O
after O
admission O
, O
so O
methylprednisolone O
was O
changed O
to O
oral O
form O
and O
slowly O
tapered O
off O
. O

 O
On O
December O
15 O
, O
the O
patient O
was O
due O
to O
with O
to O
( O
Figure O
1 O
) O
. O

 O
Followed O
after O
5 O
months O
revealed O
sustained O
, O
, O
and O
decreased O
( O
) O
and O
( O
) O
levels O
. O

A O
to O
her O
general O
practitioner O
because O
of O
left O
- O
sided O
neck O
and O
shoulder O
. O

 O
The O
was O
and O
non O
- O
specific O
and O
the O
patient O
's O
history O
was O
unremarkable O
. O

 O
She O
denied O
a O
history O
of O
smoking O
, O
excessive O
alcohol O
use O
and O
radiation O
exposure O
. O

 O
Physical O
examination O
demonstrated O
mild O
left O
sided O
cervical O
lymphadenopathy O
. O

 O
Routine O
blood O
tests O
revealed O
borderline O
elevated O
calcium O
of O
10.5 O
 O
mg O
/ O
dL O
and O
subsequent O
work O
up O
exhibited O
a O
markedly O
elevated O
parathyroid O
hormone O
level O
of O
286 O
 O
pg O
/ O
mL O
, O
so O
the O
patient O
was O
referred O
to O
otolaryngology O
for O
further O
evaluation O
. O

 O
Thyroid O
ultrasound O
showed O
a O
hypoechoic O
nodule O
in O
the O
left O
lower O
lobe O
of O
the O
thyroid O
. O

 O
CT O
scan O
of O
the O
neck O
revealed O
a O
2 O
 O
cm O
hypodense O
nodule O
on O
the O
posterior O
inferior O
aspect O
of O
the O
left O
lower O
thyroid O
and O
sestamibi O
scan O
showed O
increased O
uptake O
along O
the O
lower O
pole O
of O
the O
left O
thyroid O
lobe O
. O

 O
Elevated O
PTH O
along O
with O
an O
aberrant O
parathyroid O
gland O
on O
imaging O
suggests O
primary O
hyperparathyroidism O
. O

 O
Historically O
, O
hyperparathyroidism O
is O
associated O
with O
bone O
disease O
, O
renal O
stones O
and O
neuromuscular O
dysfunction O
, O
however O
, O
with O
the O
current O
screening O
modalities O
, O
most O
patients O
are O
caught O
early O
and O
often O
asymptomatic.3 O
Primary O
hyperparathyroidism O
is O
most O
commonly O
caused O
by O
a O
parathyroid O
adenoma O
. O

 O
Infrequent O
causes O
include O
parathyroid O
hyperplasia O
, O
which O
would O
affect O
all O
four O
glands O
and O
rarely O
caused O
by O
parathyroid O
carcinoma O
. O

 O
Markedly O
elevated O
serum O
PTH O
and O
calcium O
levels O
leading O
to O
severe O
renal O
and O
bone O
manifestations O
are O
helpful O
in O
the O
diagnosis O
of O
cancer O
, O
however O
, O
it O
is O
usually O
discovered O
operatively O
based O
on O
local O
invasion O
and O
metastases.3 O

 O
The O
primary O
indication O
for O
parathyroidectomy O
, O
historically O
, O
is O
for O
symptomatic O
patients O
. O

 O
Currently O
, O
since O
most O
patients O
are O
caught O
earlier O
, O
there O
are O
newer O
indications O
for O
surgery O
. O

 O
These O
include O
an O
asymptomatic O
patient O
with O
any O
of O
the O
following O
: O
glomerular O
filtration O
rate O
< O
60 O
 O
mL O
/ O
min O
, O
bone O
density O
T O
- O
score O
< O
2.5 O
at O
any O
site O
and/or O
previous O
fractures O
, O
age O
< O
50 O
, O
and O
serum O
calcium O
1.0 O
 O
ng O
/ O
dL O
above O
the O
upper O
limit O
of O
normal.3 O
This O
patient O
presented O
with O
pain O
, O
markedly O
elevated O
PTH O
, O
and O
was O
younger O
than O
50 O
 O
years O
old O
, O
so O
it O
was O
decided O
that O
surgery O
was O
the O
best O
choice O
in O
management O
. O

 O
The O
patient O
was O
brought O
to O
the O
operating O
room O
and O
underwent O
a O
parathyroidectomy O
. O

 O
The O
surgeon O
found O
the O
parathyroid O
gland O
to O
be O
firm O
and O
densely O
adherent O
to O
the O
thyroid O
capsule O
and O
overlying O
strap O
muscle O
, O
making O
it O
difficult O
to O
dissect O
. O

 O
There O
was O
no O
visible O
invasion O
into O
the O
capsule O
, O
surrounding O
muscle O
or O
regional O
lymph O
nodes O
. O

 O
The O
resected O
specimen O
was O
noted O
to O
be O
brownish O
grey O
in O
colour O
with O
scattered O
necrotic O
foci O
, O
and O
irregular O
texture O
. O

 O
On O
postoperative O
pathology O
, O
the O
specimen O
was O
confirmed O
positive O
for O
parathyroid O
carcinoma O
with O
capsular O
invasion O
, O
focal O
tumour O
necrosis O
, O
reactive O
fibrosis O
and O
local O
skeletal O
muscle O
invasion O
( O
figures O
1 O
and O
2 O
) O
. O

 O
Margins O
were O
resected O
. O

 O
Immunohistochemical O
stains O
showed O
increased O
Ki-67 O
reactivity O
as O
well O
as O
strong O
Bcl-1 O
( O
cyclin O
D1 O
) O
reactivity O
, O
which O
support O
the O
diagnosis O
of O
parathyroid O
carcinoma O
( O
figure O
3 O
) O
. O

 O
Additionally O
, O
P57 O
staining O
was O
negative O
. O

 O
Although O
most O
reports O
of O
parathyroid O
carcinomas O
are O
associated O
with O
marked O
hypercalcaemia O
, O
non O
- O
functioning O
cancers O
in O
patients O
tend O
to O
behave O
more O
aggressively.1 O
Owing O
to O
the O
severity O
and O
uncertainty O
of O
the O
lesion O
, O
the O
patient O
was O
followed O
up O
postoperatively O
for O
repeat O
imaging O
to O
determine O
if O
residual O
tumour O
remained O
. O

 O
Repeat O
sestamibi O
and O
positron O
emission O
tomography O
( O
PET O
) O
scan O
revealed O
residual O
activity O
along O
the O
surgical O
area O
so O
the O
patient O
subsequently O
underwent O
a O
second O
operation O
for O
a O
radical O
left O
neck O
dissection O
and O
left O
hemithyroidectomy O
. O

 O
The O
patient O
recovered O
very O
well O
postoperatively O
and O
it O
has O
now O
been O
3 O
 O
years O
since O
the O
second O
surgery O
. O

 O
The O
patient O
continues O
to O
do O
very O
well O
and O
is O
followed O
up O
every O
3 O
 O
months O
to O
monitor O
serum O
PTH O
and O
calcium O
levels O
. O

 O
She O
no O
longer O
reports O
of O
neck O
and O
shoulder O
. O

 O
Sometimes O
the O
patient O
's O
show O
marginally O
elevated O
levels O
, O
however O
, O
she O
remains O
and O
follow O
- O
up O
and O
scans O
continue O
to O
be O
. O

 O
The O
patient O
will O
continue O
to O
be O
monitored O
indefinitely O
. O

We O
present O
the O
case O
of O
a O
, O
admitted O
to O
our O
clinic O
with O
severe O
abdominal O
, O
, O
, O
and O
. O

 O
The O
anamnesis O
revealed O
that O
the O
girl O
comes O
from O
a O
, O
and O
that O
she O
also O
, O
her O
. O

 O
The O
patient O
's O
personal O
history O
underlined O
that O
approximately O
she O
presented O
with O
severe O
abdominal O
, O
being O
diagnosed O
with O
acute O
appendicitis B
and O
she O
underwent O
, O
but O
the O
, O
thus O
due O
to O
, O
the O
suspicion O
of O
saturnine B
colic I
rose O
, O
and O
she O
was O
diagnosed O
with O
lead B
poisoning I
( O
: O
) O
, O
but O
she O
received O
only O
. O

 O
Approximately O
admission O
to O
our O
clinic O
, O
she O
was O
to O
the O
with O
another O
episode O
of O
saturnine B
colic I
( O
: O
) O
, O
and O
with O
EDTA O
( O
the O
admission O
in O
our O
clinic O
) O
was O
initiated O
, O
with O
a O
dose O
of O
, O
associated O
with O
. O

 O
The O
performed O
at O
the O
time O
of O
admission O
revealed O
the O
following O
pathological O
elements O
: O
, O
, O
of O
the O
, O
blue O
of O
the O
, O
at O
, O
and O
: O
. O

 O
The O
performed O
upon O
admission O
revealed O
hypochromic O
( O
( O
): O
, O
( O
): O
, O
( O
): O
) O
, O
increased O
level O
of O
( O
( O
): O
, O
( O
): O
, O
( O
): O
) O
, O
( O
( O
): O
) O
, O
( O
: O
) O
, O
and O
( O
: O
) O
. O

 O
The O
systolic O
was O
, O
and O
the O
diastolic O
was O
. O

 O
The O
blood O
level O
was O
, O
the O
urinary O
one O
was O
( O
normal O
< O
50 O
 O
g O
/ O
L O
) O
and O
the O
value O
of O
was O
( O
normal O
< O
4.5 O
 O
mg O
/ O
L O
) O
. O

 O
We O
also O
performed O
abdominal O
which O
revealed O
a O
of O
the O
in O
. O

 O
We O
requested O
from O
an O
, O
who O
recommended O
the O
continuation O
of O
with O
, O
increasing O
the O
dose O
at O
. O

 O
We O
also O
required O
a O
neurological O
, O
and O
the O
specialist O
established O
the O
diagnosis O
of O
behavioral B
disorders I
with O
depressive B
elements O
, O
and O
recommended O
. O

 O
Based O
on O
all O
these O
clinical O
and O
laboratory O
findings O
, O
we O
established O
the O
diagnosis O
of O
lead B
poisoning I
. O

 O
We O
initiated O
an O
intense O
i.v O
. O
in O
order O
to O
favor O
lead O
elimination O
, O
approximately O
initially O
, O
and O
we O
decreased O
progressively O
the O
quantity O
once O
she O
ceased O
to O
, O
and O
she O
was O
. O

 O
We O
associated O
, O
initially O
, O
but O
the O
values O
of O
the O
persisted O
, O
therefore O
we O
were O
forced O
to O
introduce O
also O
an O
, O
with O
the O
remission O
of O
. O

 O
Regarding O
the O
liver O
function O
, O
we O
administered O
, O
associated O
with O
. O

 O
We O
also O
administered O
in O
order O
to O
improve O
the O
neurological O
impairment O
. O

 O
The O
was O
, O
in O
the O
first O
the O
admission O
, O
the O
patient O
continued O
to O
present O
severe O
abdominal O
, O
, O
and O
she O
also O
complained O
of O
in O
the O
. O

 O
All O
the O
presented O
of O
the O
values O
after O
of O
. O

 O
On O
the O
of O
admission O
, O
we O
ceased O
the O
with O
. O

 O
We O
also O
repeated O
the O
blood O
and O
urinary O
lead O
levels O
. O

 O
The O
blood O
level O
was O
45.57 O
 O
g O
/ O
dL O
, O
and O
the O
urinary O
one O
was O
836.4 O
 O
g O
/ O
L O
before O
the O
patient O
. O

 O
The O
abdominal O
reevaluation O
revealed O
no O
. O

 O
of O
admission O
, O
the O
patient O
was O
without O
any O
, O
and O
we O
recommended O
no O
further O
exposure O
to O
lead O
, O
avoiding O
the O
contact O
and O
the O
working O
in O
the O
pottery O
process O
. O

 O
The O
long O
- O
term O
outcome O
of O
this O
case O
depends O
on O
further O
exposure O
to O
this O
heavy O
metal O
. O

 O
. O

A O
underwent O
a O
primary O
double O
lung O
transplantation O
for O
cystic O
fibrosis O
in O
. O

 O
Her O
and O
the O
patient O
had O
no O
known O
history O
of O
pulmonary O
tuberculosis O
or O
tuberculosis O
contact O
. O

 O
On O
, O
she O
underwent O
for O
chronic O
lung B
allograft I
dysfunction I
. O

 O
During O
the O
retransplantation O
, O
4 O
remained O
for O
and O
and O
real O
- O
time O
( O
) O
testing O
. O

 O
On O
postoperative O
, O
deterioration O
of O
her O
prompted O
a O
chest O
- O
( O
) O
scan O
revealing O
sub O
- O
centimeter O
bilateral O
primarily O
located O
in O
the O
and O
a O
bilateral O
pleural B
effusion I
( O
Fig.1 O
) O
. O

 O
The O
same O
day O
, O
a O
( O
) O
yielded O
a O
positive O
real O
- O
time O
for O
, O
confirmed O
by O
on O
postoperative O
. O

 O
( O
) O
or O
interferon O
- O
 O
release O
assay O
( O
) O
test O
were O
not O
performed O
. O

 O
All O
the O
BALs O
performed O
on O
postoperative O
period O
yielded O
except O
for O
the O
one O
performed O
on O
that O
cultured O
; O
the O
adjunctive O
was O
, O
3 O
 O
g O
/ O
d. O

 O
of O
a O
lung O
performed O
retransplantation O
revealed O
a O
and O
. O

 O
Acid O
- O
fast O
bacilli O
were O
identified O
as O
rifampicin O
- O
susceptible O
M. O
tuberculosis O
by O
real O
- O
time O
. O

 O
On O
postoperative O
, O
the O
patient O
's O
with O
severe O
, O
shock B
unresponsive O
to O
high O
dose O
, O
and O
multiorgan B
failure I
. O

 O
The O
patient O
died O
on O
postoperative O
, O
despite O
treatment O
combining O
, O
, O
, O
and O
. O

 O
Retrospective O
real O
- O
time O
testing O
of O
the O
and O
BALs O
performed O
on O
postoperative O
days O
1 O
, O
7 O
, O
and O
21 O
remained O
. O

 O
The O
died O
of O
posttraumatic O
intracerebral O
hemorrhage O
. O

 O
was O
with O
other O
than O
. O

 O
TST O
results O
were O
not O
available O
. O

 O
During O
hospitalization O
, O
a O
lung O
CT O
- O
scan O
showed O
no O
signs O
of O
active O
or O
previous O
tuberculosis O
and O
no O
TST O
or O
IGRA O
test O
results O
were O
available O
. O

 O
Routine O
cultures O
of O
per O
- O
transplantation O
right O
lung O
biopsy O
yielded O
Candida O
albicans O
. O

 O
Retrospective O
M. O
tuberculosis O
real O
- O
time O
PCR O
yielded O
negative O
results O
on O
the O
left O
and O
right O
donor O
- O
lung O
biopsies O
. O

 O
Both O
kidneys O
from O
the O
same O
were O
. O

 O
Six O
months O
after O
transplantation O
, O
neither O
of O
the O
. O

A O
was O
to O
our O
due O
to O
congestive O
heart B
failure I
and O
ventricular O
arrhythmias B
in O
. O

 O
He O
had O
been O
suffering O
from O
heart B
failure I
and O
ventricular O
despite O
receiving O
the O
( O
ie O
, O
, O
, O
, O
, O
, O
and O
) O
. O

 O
His O
height O
was O
and O
body O
weight O
was O
. O

 O
was O
. O

 O
The O
was O
and O
was O
. O

 O
The O
chest O
showed O
with O
a O
of O
( O
figure O
1A O
) O
. O

 O
, O
as O
shown O
in O
video O
1 O
, O
revealed O
a O
diffused O
with O
markedly O
dilated O
( O
: O
) O
and O
reduced O
( O
) O
. O

 O
The O
coronary O
was O
. O

 O
A O
myocardial O
revealed O
that O
over O
50 O
% O
of O
cardiomyocytes O
were O
replaced O
by O
fibrosis O
( O
figure O
2 O
) O
. O

 O
An O
implantable O
cardioverter O
- O
defibrillator O
was O
implanted O
. O

 O
Due O
to O
the O
typical O
facial O
appearance O
and O
, O
he O
was O
referred O
to O
the O
. O

 O
The O
was O
8.2 O
ng O
/ O
ml O
and O
was O
. O

 O
demonstrated O
a O
macroadenoma B
in O
the O
. O

 O
Thus O
, O
he O
was O
diagnosed O
as O
acromegaly B
. O

 O
He O
was O
treated O
with O
long O
- O
acting O
- O
release O
( O
LAR O
) O
for O
. O

 O
Thereafter O
, O
he O
underwent O
in O
( O
figure O
3 O
) O
. O

 O
The O
plasma O
levels O
of O
GH O
and O
IGF-1 O
were O
decreased O
with O
octreotide O
LAR O
, O
but O
basal O
plasma O
levels O
of O
GH O
were O
always O
more O
than O
4 O
ng O
/ O
ml O
and O
plasma O
IGF-1 O
levels O
were O
above O
the O
appropriate O
age O
range O
( O
figure O
3 O
) O
. O

 O
After O
surgery O
, O
both O
plasma O
levels O
of O
GH O
and O
IGF-1 O
further O
decreased O
. O

 O
Basal O
plasma O
levels O
of O
GH O
were O
mostly O
less O
than O
0.5 O
ng O
/ O
ml O
and O
IGF-1 O
levels O
were O
within O
normal O
ranges O
( O
figure O
3 O
) O
. O

 O
With O
the O
treatment O
of O
LAR O
, O
the O
cardiac O
function O
improved O
partially O
( O
cardiothoracic O
ratio=0.58 O
; O
EF=0.20 O
in O
September O
2008 O
) O
. O

 O
After O
surgery O
, O
the O
cardiac O
function O
improved O
drastically O
( O
cardiothoracic O
ratio=0.47 O
; O
EF=0.55 O
in O
April O
2009 O
; O
figures O
1B O
and O
and2B).2B O
) O
. O

 O
Frequency O
of O
ventricular O
arrhythmias O
decreased O
and O
was O
tapered O
off O
. O

A O
to O
the O
with O
a O
history O
of O
abdominal O
. O

 O
revealed O
a O
huge O
in O
the O
. O

 O
The O
showed O
elevated O
levels O
of O
( O
, O
[ O
normal O
, O
< O
5 O
ng O
/ O
mL O
] O
) O
and O
( O
) O
( O
[ O
normal O
, O
< O
45 O
U O
/ O
mL O
] O
) O
but O
a O
normal O
level O
of O
( O
[ O
normal O
, O
< O
37 O
U O
/ O
mL O
] O
) O
. O

 O
( O
) O
demonstrated O
a O
large O
, O
round O
with O
a O
maximum O
diameter O
of O
in O
the O
without O
the O
presence O
of O
or O
( O
Fig.1a O
, O
b O
) O
. O

 O
identified O
an O
elevated O
with O
severe O
in O
the O
, O
and O
of O
from O
the O
showed O
moderately O
differentiated O
adenocarcinoma B
. O

 O
Although O
we O
scheduled O
an O
early O
, O
the O
patient O
developed O
acute O
and O
general O
the O
first O
CT O
scan O
. O

 O
The O
second O
scan O
examination O
demonstrated O
massive O
bilateral O
with O
and O
( O
Fig.2a O
, O
b O
) O
. O

 O
and O
were O
emergently O
performed O
. O

 O
, O
the O
in O
the O
had O
the O
, O
and O
the O
huge O
pelvic O
was O
found O
to O
contain O
a O
right O
ovarian B
tumor I
. O

 O
Several O
small O
of O
were O
distributed O
over O
the O
. O

 O
Perioperatively O
, O
of O
serous O
was O
. O

 O
of O
the O
drained O
from O
the O
and O
revealed O
no O
. O

 O
Bilateral O
, O
total O
, O
, O
and O
with O
regional O
were O
performed O
( O
Fig.3a O
) O
. O

 O
of O
the O
resected O
specimens O
showed O
moderately O
differentiated O
adenocarcinoma B
in O
the O
of O
both O
the O
and O
the O
( O
Fig.3b O
) O
. O

 O
The O
dissected O
paracolic O
nodes O
showed O
. O

 O
, O
from O
the O
and O
the O
both O
showed O
positive O
expression O
of O
( O
) O
but O
no O
expression O
of O
( O
) O
, O
confirming O
that O
the O
ovarian O
tumors O
were O
metastases O
from O
primary B
colon I
cancer I
( O
Fig.4a O
, O
b O
) O
. O

 O
The O
was O
, O
and O
both O
and O
rapidly O
resolved O
. O

 O
Postoperatively O
, O
a O
regimen O
of O
( O
) O
, O
, O
and O
( O
) O
was O
administered O
. O

 O
At O
the O
first O
operation O
, O
the O
patient O
required O
curative O
hepatic O
resection O
for O
liver O
metastases O
. O

 O
At O
the O
first O
operation O
, O
the O
patient O
remains O
with O
no O
evidence O
of O
a O
disease B
. O

A O
was O
diagnosed O
with O
pulmonary B
tuberculosis I
( O
PTB B
) O
in O
a O
routine O
medical O
and O
received O
that O
included O
( O
INH O
, O
300 O
 O
mg O
/ O
d O
) O
, O
( O
450 O
 O
mg O
/ O
d O
) O
, O
( O
EMB O
, O
750 O
 O
mg O
/ O
d O
) O
, O
and O
( O
, O
) O
. O

 O
After O
of O
continuous O
, O
he O
was O
to O
the O
with O
nasal O
and O
the O
( O
) O
count O
was O
( O
normal O
range O
, O
100300 O
 O
 O
 O
109 O
/ O
L O
) O
. O

 O
was O
cured O
after O
. O

 O
, O
he O
developed O
, O
, O
and O
, O
and O
required O
of O
and O
platelets O
in O
. O

 O
( O
) O
, O
he O
was O
to O
the O
due O
to O
the O
ineffective O
. O

 O
On O
, O
he O
presented O
with O
, O
mild O
on O
the O
, O
, O
( O
) O
and O
at O
the O
. O

 O
on O
indicated O
DIC B
: O
( O
17.8 O
 O
seconds O
; O
normal O
range O
, O
9.612.8 O
 O
seconds O
) O
, O
( O
1.53 O
; O
normal O
range O
, O
0.881.15 O
) O
, O
( O
1.13 O
 O
g O
/ O
L O
; O
normal O
range O
, O
2.04.0 O
 O
g O
/ O
L O
) O
, O
( O
23.45 O
 O
mg O
/ O
L O
; O
normal O
range O
, O
< O
0.55 O
 O
mg O
/ O
L O
) O
, O
( O
60.4 O
 O
mg O
/ O
L O
; O
normal O
range,<5 O
 O
mg O
/ O
L O
) O
, O
and O
( O
; O
normal O
range O
, O
100300 O
 O
 O
 O
109 O
/ O
L O
) O
. O

 O
Other O
abnormal O
data O
were O
as O
follows O
: O
( O
WBC O
, O
48.38 O
 O
 O
 O
109 O
/ O
L O
; O
normal O
range O
, O
3.59.5 O
) O
, O
( O
65 O
 O
g O
/ O
L O
; O
normal O
range O
, O
130175 O
 O
g O
/ O
L O
) O
, O
( O
30.8 O
umol O
/ O
L O
; O
normal O
range O
, O
5.028.0 O
 O
umol O
/ O
L O
) O
, O
( O
16.6 O
umol O
/ O
L O
; O
normal O
range O
, O
< O
8.8 O
umol O
/ O
L O
) O
, O
( O
75 O
U O
/ O
L O
; O
normal O
range O
, O
< O
40 O
U O
/ O
L O
) O
, O
( O
293 O
U O
/ O
L O
; O
normal O
range O
, O
< O
50 O
U O
/ O
L O
) O
, O
( O
380 O
U O
/ O
L O
; O
normal O
range O
, O
110220 O
 O
U O
/ O
L O
) O
, O
( O
13.01 O
mmol O
/ O
L O
; O
normal O
range O
, O
3.27.79 O
mmol O
/ O
L O
) O
, O
( O
16.70 O
 O
mg O
/ O
L O
; O
normal O
range O
, O
< O
5 O
 O
mg O
/ O
L O
) O
, O
( O
0.41 O
 O
g O
/ O
L O
; O
normal O
range O
, O
0.7851.520 O
 O
g O
/ O
L O
) O
, O
and O
( O
; O
normal O
range O
, O
0.1450.360 O
 O
g O
/ O
L O
) O
. O

 O
Routine O
showed O
, O
250 O
Cell O
/ O
uL O
, O
2 O
 O
g O
/ O
L O
, O
and O
70 O
umol O
/ O
L. O

 O
Routine O
showed O
4+/HP O
, O
1+/HP O
, O
( O
) O
. O

 O
result O
was O
. O

 O
Real O
- O
time O
polymerase O
chain O
reaction O
on O
was O
. O

 O
of O
a O
was O
. O

 O
Chest O
( O
) O
on O
( O
) O
( O
Fig.1 O
) O
showed O
on O
the O
, O
left O
pleural B
effusion I
, O
and O
pericardial B
effusion I
, O
accompanied O
by O
of O
. O

 O
Abdominal O
showed O
a O
small O
amount O
of O
adjacent O
to O
the O
and O
. O

 O
were O
negative O
for O
acute O
or O
chronic O
viral B
hepatitis I
, O
HIV B
, O
, O
and O
autoimmune B
hepatitis I
. O

 O
Peripheral O
blood O
were O
. O

 O
Bone O
marrow O
were O
also O
. O

 O
The O
were O
discontinued O
immediately O
after O
. O

 O
Besides O
, O
he O
was O
initiated O
with O
infusion O
of O
fresh O
- O
frozen O
plasma O
, O
platelet O
, O
packed O
red O
blood O
cells O
, O
intravenous O
immune O
globulin O
, O
recombinant O
human O
thrombopoietin O
, O
omeprazole O
, O
and O
polyene O
phosphatidylcholine O
as O
well O
as O
. O

 O
( O
) O
, O
the O
patient O
started O
a O
therapy O
consisting O
of O
, O
, O
and O
, O
while O
he O
had O
no O
further O
active O
. O

 O
( O
) O
, O
the O
counts O
had O
gradually O
. O

 O
( O
, O
) O
was O
administered O
on O
( O
) O
, O
while O
his O
and O
counts O
returned O
to O
. O

 O
The O
main O
are O
summarized O
in O
Table O
1 O
. O

 O
( O
) O
, O
reviewed O
chest O
( O
Fig.1 O
) O
indicated O
the O
, O
, O
and O
pericardial B
effusion I
were O
absorbed O
well O
. O

 O
Almost O
, O
the O
patient O
and O
with O
( O
) O
, O
( O
) O
, O
( O
500 O
 O
mg O
/ O
d O
) O
, O
and O
( O
, O
) O
. O

 O
There O
was O
no O
recurrence O
of O
DIC B
or O
during O
of O
. O

 O
Unfortunately O
, O
the O
patient O
refused O
a O
follow O
- O
up O
chest O
after O
his O
. O

 O
Table O
2 O
shows O
the O
timeline O
of O
this O
case O
. O

We O
present O
the O
case O
of O
a O
who O
was O
, O
with O
known O
, O
, O
and O
. O

 O
She O
was O
to O
our O
complaining O
of O
progressive O
and O
. O

 O
On O
examination O
, O
her O
was O
and O
her O
was O
. O

 O
revealed O
a O
systolic O
at O
the O
with O
and O
. O

 O
revealed O
, O
except O
for O
sinus O
. O

 O
showed O
an O
elevated O
N O
- O
terminal O
and O
chest O
showed O
signs O
of O
. O

 O
The O
patient O
was O
to O
the O
with O
the O
diagnosis O
of O
acute O
decompensated O
heart B
failure I
. O

 O
Transthoracic O
showed O
a O
left O
ventricle O
with O
severely O
depressed O
due O
to O
generalized O
and O
a O
mild O
( O
fig.1a O
) O
. O

 O
During O
admission O
, O
the O
patient O
had O
several O
episodes O
of O
paroxysmal O
despite O
treatment O
with O
and O
. O

 O
Due O
to O
the O
clinical O
suspicion O
of O
adrenal B
gland I
disease I
, O
24 O
- O
hour O
urinary O
and O
metanephrine O
tests O
were O
requested O
. O

 O
Cardiac O
was O
performed O
in O
order O
to O
complete O
the O
, O
and O
confirmed O
the O
echocardiographic O
findings O
as O
well O
as O
revealed O
an O
incidental O
finding O
of O
a O
great O
left O
renal O
. O

 O
The O
24 O
- O
hour O
urine O
showed O
markedly O
elevated O
levels O
of O
, O
, O
and O
with O
normal O
values O
: O
24 O
- O
hour O
norepinephrine O
( O
normal O
range O
: O
23 O
- O
105 O
) O
, O
24 O
- O
hour O
13 O
g O
( O
normal O
range O
: O
4 O
- O
20 O
) O
, O
24 O
- O
hour O
658 O
g O
( O
normal O
range O
: O
217 O
- O
575 O
) O
, O
24 O
- O
hour O
2,988 O
g O
( O
normal O
range O
: O
105 O
- O
354 O
) O
, O
24 O
- O
hour O
( O
normal O
range O
: O
0 O
- O
1,000 O
) O
. O

 O
Therefore O
, O
an O
abdominal O
was O
performed O
, O
which O
showed O
the O
presence O
of O
two O
cystic O
( O
fig.2 O
) O
located O
at O
the O
. O

 O
Surgical O
of O
was O
performed O
( O
after O
with O
phenoxybenzamine O
and O
with O
) O
through O
a O
, O
confirming O
the O
diagnosis O
of O
pheochromocytoma B
and O
clear O
cell O
renal O
carcinoma O
on O
. O

 O
During O
, O
and O
values O
( O
, O
) O
, O
24 O
- O
hour O
urinary O
values O
returned O
to O
( O
69 O
g/24 O
h O
, O
221 O
g/24 O
h O
, O
202 O
g/24 O
h O
and O
259 O
g/24 O
h O
) O
and O
the O
patient O
had O
no O
new O
episodes O
of O
or O
. O

 O
surgical O
resection O
, O
was O
repeated O
and O
showed O
a O
left O
ventricle O
with O
and O
preserved O
( O
fig.1b O
) O
. O

 O
revealed O
a O
( O
) O
of O
the O
on O
the O
. O

 O
As O
the O
patient O
had O
, O
it O
was O
concluded O
that O
it O
was O
a O
. O

CASE O
: O
A O
with O
a O
history O
of O
. O

 O
The O
occurred O
during O
, O
, O
lasted O
up O
to O
30 O
minutes O
at O
a O
time O
and O
were O
associated O
with O
. O

 O
Except O
for O
a O
grade O
2/6 O
holosystolic O
tricuspid O
( O
best O
heard O
at O
the O
with O
) O
, O
yielded O
unremarkable O
findings O
. O

 O
An O
( O
) O
revealed O
normal O
and O
a O
( O
Fig.1 O
: O
Top O
) O
, O
produced O
by O
a O
right O
- O
sided O
accessory B
pathway I
. O

 O
Transthoracic O
demonstrated O
the O
presence O
of O
Ebstein B
's I
anomaly I
of O
the O
, O
with O
of O
the O
and O
formation O
of O
an O
 O
atrialized B
 O
( O
a O
functional O
unit O
between O
the O
and O
the O
inlet O
[ O
inflow O
] O
portion O
of O
the O
) O
( O
Fig.2 O
) O
. O

 O
The O
anterior O
tricuspid O
valve O
leaflet O
was O
( O
Fig.2C O
, O
arrow O
) O
, O
whereas O
the O
septal O
leaflet O
was O
( O
Fig.2C O
, O
arrowhead O
) O
. O

 O
Contrast O
revealed O
a O
patent B
foramen I
ovale I
with O
and O
in O
the O
( O
Fig.2D O
) O
. O

 O
The O
patient O
underwent O
an O
with O
of O
the O
, O
followed O
by O
radiofrequency O
( O
interruption O
of O
the O
pathway O
using O
the O
heat O
generated O
by O
electromagnetic O
waves O
at O
the O
tip O
of O
an O
) O
. O

 O
His O
post O
- O
ablation O
showed O
a O
prolonged O
and O
an O
odd O
 O
second O
 O
in O
( O
Fig.1Bottom O
) O
, O
a O
consequence O
of O
abnormal B
impulse I
conduction I
in O
the O
 O
atrialized B
 O
. O

 O
The O
patient O
reported O
no O
recurrence O
of O
at O
the O
ablation O
. O

A O
patient O
was O
admitted O
for O
, O
, O
and O
acute O
renal B
failure I
. O

 O
He O
had O
, O
did O
not O
take O
any O
, O
and O
. O

 O
He O
had O
. O

 O
his O
admission O
, O
he O
developed O
, O
fluctuant O
, O
, O
and O
in O
the O
. O

 O
On O
, O
was O
, O
. O

 O
showed O
severe O
involving O
both O
, O
as O
well O
as O
and O
. O

 O
Cervical O
and O
axillar O
infracentimetric O
lymphadenopathies B
were O
present O
, O
together O
with O
hepatosplenomegaly B
, O
confirmed O
by O
( O
) O
scan O
. O

 O
Bilateral O
arthritis B
of O
the O
resolved O
spontaneously O
. O

 O
revealed O
( O
Table O
(Table1):1 O
): O
, O
normal O
and O
levels O
with O
no O
biologic O
sign O
of O
, O
elevated O
, O
low O
, O
elevated O
serum O
, O
mild O
and O
no O
. O

 O
Despite O
intravenous O
using O
and O
, O
worsened O
and O
the O
patient O
required O
. O

 O
While O
diagnostic O
investigations O
were O
performed O
, O
hemiplegia B
occurred O
: O
brain O
showed O
multifocal O
ischemic O
. O

 O
Echographic O
and O
rythmologic O
ruled O
out O
any O
cardiologic O
cause O
for O
the O
stroke B
. O

 O
A O
renal O
was O
performed O
( O
Fig.1A O
and O
B O
) O
. O

 O
( O
) O
staining O
showed O
endotheliosis B
in O
all O
( O
Fig.1A O
, O
arrows O
) O
, O
associated O
with O
mesangiolysis B
and O
on O
( O
Fig.1B O
, O
arrows O
) O
, O
and O
no O
arteriolar O
. O

 O
A O
moderate O
CD20 O
+ O
B O
lymphocyte O
infiltrate O
was O
present O
in O
the O
interstitium O
, O
with O
a O
peritubularcapillaritis O
. O

 O
Immunofluorescence O
study O
did O
not O
show O
any O
deposit O
. O

 O
Lymph O
node O
biopsy O
( O
Fig.2A O
and O
B O
) O
showed O
abnormal O
follicles O
with O
hyalinization O
of O
germinal O
center O
, O
and O
an O
onion O
- O
skin O
aspect O
of O
the O
mantle O
zone O
. O

 O
Clinical O
presentation O
and O
lymph O
node O
histology O
were O
consistent O
with O
hyaline O
- O
vascular O
multicentric O
Castleman O
disease O
( O
MCD O
) O
. O

 O
HIV O
and O
HHV-8 O
serology O
, O
as O
well O
as O
HHV-8 O
lymph O
node O
tissue O
staining O
, O
were O
negative O
. O

 O
Serum O
vascular O
endothelium O
growth O
factor O
( O
VEGF O
) O
was O
highly O
elevated O
. O

 O
There O
was O
no O
biologic O
manifestation O
of O
thrombotic O
microangiopathy O
( O
TMA O
) O
, O
but O
the O
renal O
biopsy O
and O
brain O
MRI O
were O
consistent O
with O
glomerular O
and O
neurologic O
TMA O
lesions O
. O

 O
No O
other O
apparent O
cause O
of O
thrombotic O
microvascular O
involvement O
was O
noted O
. O

 O
Notably O
, O
there O
was O
no O
evidence O
for O
infection O
with O
shiga O
toxin O
- O
producing O
germs O
, O
ADAMTS-13 O
activity O
was O
decreased O
up O
to O
14 O
% O
but O
remained O
above O
5 O
% O
, O
and O
the O
alternative O
complement O
pathway O
was O
normal O
. O

 O
Plasma O
exchange O
was O
initiated O
due O
to O
the O
kidney O
histological O
lesions O
and O
the O
multifocal O
ischemic O
brain O
lesions O
. O

 O
It O
was O
discontinued O
after O
1 O
month O
after O
the O
onset O
of O
the O
disease O
, O
since O
the O
patient O
's O
condition O
remained O
stable O
. O

 O
Furthermore O
, O
chemotherapy O
including O
6 O
courses O
of O
rituximab O
( O
375 O
 O
mg O
/ O
m2 O
) O
, O
cyclophosphamide O
( O
750 O
 O
mg O
/ O
m2 O
) O
, O
and O
dexamethasone O
( O
40 O
 O
mg O
/ O
day O
from O
day O
1 O
to O
day O
4 O
) O
was O
started O
together O
with O
plasma O
exchanges O
( O
chemotherapy O
was O
performed O
immediately O
after O
plasma O
exchanges O
) O
. O

 O
Courses O
were O
performed O
every O
3 O
weeks O
. O

 O
Clinical O
manifestations O
of O
vascular O
leak O
syndrome O
regressed O
, O
renal O
function O
normalized O
, O
and O
serum O
VEGF O
level O
decreased O
to O
825 O
 O
pg O
/ O
mL O
after O
1 O
course O
of O
chemotherapy O
. O

 O
The O
patient O
was O
admission O
. O

 O
No O
neurological B
event I
occurred O
after O
initiating O
the O
treatment O
. O

 O
Thoraco O
- O
abdominal O
scan O
was O
performed O
after O
6 O
courses O
of O
chemotherapy O
, O
showing O
a O
normal O
liver O
and O
spleen O
and O
no O
lymph O
node O
. O

 O
One O
year O
after O
the O
diagnosis O
, O
remission O
of O
MCD B
is O
persistent O
and O
plasma O
is O
, O
with O
no O
. O

We O
present O
the O
case O
of O
a O
patient O
with O
with O
chest O
that O
was O
treated O
with O
by O
her O
. O

 O
The O
next O
day O
she O
to O
the O
, O
where O
an O
revealed O
posterolateral O
ST O
elevation O
myocardial B
infarction I
. O

 O
The O
patient O
was O
immediately O
to O
the O
. O

 O
A O
successful O
was O
performed O
on O
an O
acutely O
that O
was O
supplying O
a O
large O
portion O
of O
the O
( O
Figure O
1 O
) O
. O

 O
The O
patient O
, O
but O
she O
suddenly O
went O
into O
cardiogenic B
shock I
. O

 O
An O
was O
placed O
, O
and O
an O
demonstrated O
that O
she O
had O
severe O
mitral B
regurgitation I
from O
a O
ruptured B
( O
Figure O
2 O
) O
. O

 O
The O
patient O
, O
on O
maximal O
, O
with O
progressive O
, O
, O
and O
florid O
pulmonary O
. O

 O
In O
spite O
of O
the O
very O
high O
risk O
, O
we O
decided O
to O
intervene O
surgically O
. O

 O
Once O
in O
the O
operating O
room O
, O
transesophageal O
confirmed O
severe O
mitral B
regurgitation I
with O
a O
ruptured B
and O
a O
. O

 O
Shortly O
after O
the O
patient O
was O
put O
on O
, O
the O
resolved O
and O
she O
began O
to O
. O

 O
Excellent O
of O
the O
was O
obtained O
using O
a O
through O
the O
. O

 O
The O
valve O
was O
carefully O
and O
the O
ruptured B
was O
seen O
( O
Figure O
3 O
) O
. O

 O
There O
was O
a O
large O
chunk O
of O
muscle O
to O
the O
. O

 O
The O
anterior O
leaflet O
of O
the O
mitral O
valve O
was O
while O
keeping O
the O
posterior O
leaflet O
. O

 O
A O
27 O
- O
mm O
St O
Jude O
Epic O
was O
inserted O
( O
Figure O
4 O
) O
. O

 O
She O
was O
placed O
on O
that O
was O
successfully O
. O

 O
Following O
this O
, O
she O
made O
a O
remarkable O
early O
. O

 O
, O
just O
prior O
to O
, O
she O
after O
developing O
pneumonia B
that O
progressed O
to O
sepsis B
with O
multiorgan B
failure I
. O

A O
with O
a O
history O
of O
presented O
with O
a O
generalized O
petechial O
and O
of O
. O

 O
The O
was O
nonpruritic O
, O
painless O
, O
and O
started O
at O
the O
thighs O
, O
but O
rapidly O
disseminated O
to O
the O
rest O
of O
the O
body O
. O

 O
She O
had O
progressive O
on O
, O
with O
a O
significant O
decrease O
in O
. O

 O
She O
denied O
, O
, O
, O
, O
or O
from O
. O

 O
There O
was O
. O

 O
Her O
only O
medication O
was O
, O
which O
she O
had O
been O
taking O
for O
. O

 O
The O
patient O
. O

 O
On O
admission O
, O
she O
was O
, O
with O
mild O
( O
of O
) O
. O

 O
Physical O
examination O
revealed O
scattered O
petechial O
, O
more O
prominent O
in O
, O
and O
. O

 O
revealed O
coarse O
. O

 O
Cardiovascular O
, O
abdominal O
, O
and O
neurological O
were O
. O

 O
There O
was O
no O
palpable O
or O
. O

 O
revealed O
( O
platelets O
7000 O
/ O
L O
) O
, O
( O
hemoglobin O
10.8 O
 O
mg O
/ O
dL O
and O
hematocrit O
34 O
% O
) O
, O
and O
( O
[ O
] O
) O
. O

 O
The O
was O
, O
which O
excluded O
disseminated B
intravascular I
coagulation I
. O

 O
on O
revealed O
a O
( O
) O
of O
, O
a O
( O
) O
of O
( O
) O
, O
and O
an O
increased O
( O
) O
. O

 O
Diffuse O
was O
found O
on O
chest O
( O
Fig.1A O
) O
. O

 O
( O
) O
of O
the O
showed O
diffuse O
ground O
glass O
alveolar O
and O
patchy O
( O
Fig.1B O
, O
C O
) O
. O

 O
She O
was O
started O
on O
broad O
- O
spectrum O
and O
received O
intravenous O
. O

 O
showed O
giant O
platelets O
and O
occasional O
small O
platelet O
clumps O
, O
with O
no O
. O

 O
A O
( O
) O
showed O
normal O
with O
no O
endobronchial O
( O
Fig.2A O
) O
. O

 O
Serial O
aliquots O
of O
( O
) O
turned O
more O
, O
confirming O
the O
bronchoscopic O
diagnosis O
of O
DAH B
( O
Fig.2B O
) O
. O

 O
of O
showed O
a O
substantial O
amount O
of O
hemosiderin O
- O
laden O
, O
further O
supporting O
the O
diagnosis O
. O

 O
All O
BALF O
and O
were O
. O

 O
The O
patient O
remained O
with O
severe O
and O
despite O
and O
. O

 O
High O
doses O
of O
pulse O
and O
( O
IVIGs O
) O
were O
added O
with O
clinico O
- O
radiological O
. O

 O
A O
was O
. O

 O
Additional O
for O
secondary O
thrombocytopenia O
( O
Table O
1 O
) O
, O
supporting O
the O
diagnosis O
of O
ITP B
. O

 O
were O
gradually O
tapered O
. O

 O
Repeat O
chest O
showed O
almost O
complete O
resolution O
of O
bilateral O
( O
Fig.3 O
) O
. O

 O
returned O
to O
by O
after O
admission O
without O
any O
( O
Fig.4 O
) O
. O

A O
outpatient O
in O
her O
50s O
had O
routinely O
our O
because O
of O
liver B
cirrhosis I
resulting O
from O
hepatitis B
B I
virus I
and O
biliary B
duct I
stones I
. O

 O
At O
, O
she O
suffered O
from O
HCC B
with O
BCLC O
early O
stage O
A. O

 O
Her O
was O
, O
and O
was O
A. O

 O
She O
underwent O
left O
lateral O
for O
HCC B
, O
without O
. O

 O
revealed O
bridging O
fibrosis O
and O
pseudolobule B
formation I
. O

 O
Serum O
levels O
of O
( O
) O
and O
after O
primary O
( O
Figure O
1 O
) O
. O

 O
In O
imaging O
studies O
, O
no O
LN O
was O
detected O
at O
the O
time O
of O
primary O
of O
HCC O
. O

 O
postoperatively O
, O
the O
patient O
s O
to O
. O

 O
A O
lobular O
with O
fine O
enhancement O
was O
detected O
by O
contrast O
- O
enhanced O
. O

 O
The O
measured O
and O
was O
located O
. O

 O
In O
contrast O
- O
enhanced O
, O
the O
showed O
strong O
in O
the O
( O
Figure O
2A O
, O
2B O
) O
and O
a O
relatively O
low O
in O
the O
( O
Figure O
2C O
, O
2D O
) O
. O

 O
These O
enhancement O
findings O
appeared O
consistent O
with O
a O
typical O
HCC B
pattern O
. O

 O
Detailed O
imaging O
studies O
of O
both O
magnetic O
resonance O
imaging O
and O
computed O
tomography O
were O
performed O
in O
this O
case O
because O
a O
very O
rare O
metastatic O
LN O
initially O
seemed O
to O
be O
debatable O
and O
we O
needed O
to O
rule O
out O
exclusion O
diagnoses O
. O

 O
proved O
that O
the O
was O
( O
red O
arrow O
) O
and O
by O
an O
( O
Figure O
3 O
) O
. O

 O
( O
) O
and O
did O
not O
detect O
the O
tumor O
( O
Figure O
4 O
) O
, O
although O
we O
thought O
positron O
emission O
tomography O
- O
computed O
tomography O
was O
helpful O
to O
identify O
other O
metastatic O
tumors O
. O

 O
Further O
imaging O
findings O
revealed O
no O
other O
intrahepatic O
or O
extrahepatic O
. O

 O
Based O
on O
the O
tumor O
location O
, O
the O
clinical O
diagnosis O
was O
solitary O
to O
a O
or O
HCC B
. O

 O
Determining O
the O
ideal O
therapeutic O
strategy O
for O
solitary O
but O
extrahepatic O
rare O
metastasis O
was O
difficult O
. O

 O
Although O
rapid O
growth O
was O
a O
critical O
concern O
in O
this O
case O
, O
the O
was O
and O
not O
accompanied O
by O
other O
. O

 O
Considering O
both O
diagnostic O
and O
therapeutic O
viewpoints O
, O
we O
finally O
chose O
in O
this O
case O
. O

 O
No O
, O
lymphadenopathy B
, O
or O
was O
observed O
during O
surgery O
. O

 O
The O
was O
located O
in O
the O
nearly O
, O
and O
partial O
of O
the O
with O
was O
performed O
. O

 O
The O
patient O
s O
was O
, O
and O
she O
was O
on O
postoperative O
. O

 O
Serum O
levels O
of O
after O
surgery O
( O
Figure O
1 O
) O
. O

 O
, O
the O
was O
a O
and O
mass O
with O
a O
( O
Figure O
5A O
) O
. O

 O
A O
yellowish O
was O
( O
Figure O
5B O
) O
. O

 O
The O
enlarged O
LN O
contained O
metastatic O
HCC B
with O
a O
( O
Figure O
6A O
) O
, O
and O
, O
the O
tumor O
was O
positive O
for O
and O
negative O
for O
, O
which O
was O
consistent O
with O
the O
pattern O
of O
primary O
HCC B
( O
Figure O
6B O
) O
. O

 O
The O
histopathological O
diagnosis O
was O
metastatic O
HCC B
to O
a O
. O

 O
As O
of O
the O
writing O
of O
this O
report O
, O
the O
patient O
has O
remained O
free O
of O
for O
the O
second O
surgery O
, O
and O
has O
also O
been O
carefully O
. O

 O
No O
have O
been O
performed O
. O

A O
was O
to O
the O
by O
his O
general O
practitioner O
in O
for O
investigation O
of O
loose O
bowel O
motions O
and O
an O
episode O
of O
. O

 O
The O
patient O
had O
a O
history O
of O
, O
, O
, O
, O
, O
and O
a O
. O

 O
On O
examination O
, O
he O
was O
morbidly O
obese O
( O
) O
and O
was O
noted O
to O
have O
marked O
hepatomegaly B
. O

 O
This O
was O
not O
associated O
with O
any O
recent O
, O
, O
or O
abdominal O
. O

 O
The O
patient O
. O

 O
A O
was O
, O
and O
the O
patient O
s O
last O
was O
. O

 O
He O
was O
to O
our O
for O
further O
management O
after O
an O
( O
) O
displayed O
an O
ovoid O
of O
mixed O
echogenicity O
arising O
from O
the O
, O
measuring O
. O

 O
A O
( O
) O
scan O
confirmed O
a O
malignant O
appearing O
, O
pedunculated O
attached O
to O
( O
Fig.1 O
) O
. O

 O
A O
subsequent O
( O
) O
confirmed O
that O
on O
T2 O
( O
) O
, O
the O
was O
to O
the O
peripherally O
with O
( O
Fig.2a O
) O
which O
corresponded O
to O
the O
hypointensities O
seen O
on O
( O
Fig.2b O
) O
. O

 O
Enhancement O
of O
the O
was O
noted O
in O
( O
Fig.3a O
) O
, O
during O
( O
Fig.3b O
) O
and O
( O
Fig.3c O
) O
, O
with O
some O
. O

 O
The O
becomes O
on O
at O
10 O
( O
Fig.3d O
) O
and O
20 O
min O
compared O
to O
the O
surrounding O
. O

 O
revealed O
a O
mildly O
elevated O
of O
( O
normal O
550 O
IU O
/ O
L O
) O
. O

 O
, O
, O
and O
were O
all O
. O

 O
The O
patient O
underwent O
a O
subsegmental O
of O
the O
15 O
cm O
segment O
IVb O
in O
. O

 O
There O
was O
severe O
hepatic B
steatosis I
, O
but O
no O
cirrhosis B
. O

 O
The O
patient O
was O
postoperative O
without O
. O

 O
of O
the O
confirmed O
SFTL B
. O

 O
The O
specimen O
displayed O
a O
with O
a O
. O

 O
revealed O
in O
with O
a O
. O

 O
There O
was O
, O
and O
. O

 O
The O
displayed O
a O
high O
of O
up O
to O
( O
HPF O
) O
with O
. O

 O
showed O
staining O
for O
, O
and O
. O

 O
The O
tumour O
was O
negative O
for O
, O
, O
, O
, O
( O
) O
, O
and O
. O

 O
The O
margins O
were O
clear O
. O

 O
The O
non O
- O
neoplastic O
remainder O
of O
the O
liver O
displayed O
pericellular O
fibrosis O
indicative O
of O
steatohepatitis B
. O

 O
The O
patient O
was O
regularly O
with O
scans O
by O
the O
who O
liaised O
with O
the O
. O

 O
There O
were O
two O
episodes O
of O
for O
further O
investigation O
of O
recurrent O
right O
upper O
quadrant O
. O

 O
Multiple O
scans O
performed O
during O
this O
period O
revealed O
with O
no O
. O

 O
However O
, O
in O
, O
the O
patient O
to O
his O
with O
progressively O
worsening O
right O
upper O
quadrant O
and O
increasing O
with O
an O
. O

 O
of O
his O
, O
and O
revealed O
extensive O
( O
Fig.4 O
) O
. O

 O
In O
addition O
, O
there O
was O
a O
clinically O
significant O
right O
- O
sided O
pleural B
effusion I
and O
a O
pleural O
at O
the O
measuring O
( O
Fig.5 O
) O
. O

 O
was O
performed O
, O
draining O
of O
. O

 O
was O
negative O
for O
. O

 O
The O
case O
was O
extensively O
in O
a O
, O
and O
it O
was O
decided O
given O
the O
patient O
s O
two O
sites O
of O
disease O
and O
significant O
perioperative O
risk O
that O
he O
was O
not O
a O
candidate O
for O
radical O
. O

 O
There O
were O
also O
no O
suitable O
chemo- O
or O
available O
. O

 O
The O
patient O
was O
subsequently O
to O
the O
for O
management O
of O
his O
symptoms O
and O
back O
to O
the O
. O

 O
He O
was O
still O
discharge O
. O

A O
was O
to O
the O
of O
the O
due O
to O
epigastric O
. O

 O
revealed O
no O
palpable O
, O
, O
or O
. O

 O
On O
, O
several O
submucosal O
were O
identified O
in O
the O
and O
the O
( O
Fig.1 O
) O
. O

 O
( O
) O
( O
, O
) O
demonstrated O
that O
the O
were O
homogeneously O
originating O
from O
the O
( O
Fig.2 O
) O
and O
the O
initial O
diagnosis O
was O
digestive O
neuroendocrine B
tumors I
. O

 O
revealed O
in O
multiple O
regions O
( O
, O
, O
, O
and O
) O
and O
intracavitary O
in O
the O
. O

 O
To O
reach O
a O
definitive O
diagnosis O
, O
the O
patient O
underwent O
repeat O
and O
was O
performed O
. O

 O
On O
, O
a O
2 O
 O
1 O
- O
cm O
columnar O
uplift O
in O
the O
and O
multiple O
submucosal O
in O
the O
were O
identified O
( O
Fig.3 O
) O
. O

 O
EUS O
revealed O
that O
the O
in O
the O
were O
sized O
and O
the O
in O
the O
were O
sized O
almost O
, O
they O
were O
all O
and O
. O

 O
of O
the O
biopsied O
specimens O
from O
the O
of O
the O
showed O
diffuse O
and O
by O
( O
Fig.4 O
) O
. O

 O
On O
, O
the O
cells O
were O
positive O
for O
, O
, O
, O
, O
and O
, O
but O
negative O
for O
and O
, O
which O
was O
compatible O
with O
the O
diagnosis O
of O
MCL B
. O

 O
revealed O
a O
. O

 O
Based O
on O
these O
findings O
, O
the O
diagnosis O
of O
Ann O
Arbor O
stage O
IV O
MCL B
was O
confirmed O
. O

 O
The O
patient O
was O
referred O
for O
combination O
with O
, O
, O
, O
, O
and O
( O
) O
. O

 O
The O
patient O
has O
been O
in O
clinically O
. O

An O
with O
. O

 O
Speech O
was O
normal O
and O
there O
was O
not O
any O
of O
. O

 O
Also O
, O
there O
was O
. O

 O
The O
family O
history O
was O
significant O
as O
. O

 O
and O
there O
was O
. O

 O
The O
was O
normal O
and O
her O
was O
30/30 O
. O

 O
and O
were O
normal O
. O

 O
The O
including O
, O
were O
normal O
, O
and O
no O
saccadic B
intrusions I
or O
nystagmus B
were O
noticed O
. O

 O
The O
and O
were O
normal O
in O
; O
however O
, O
there O
was O
generalised O
exaggeration O
of O
myotatic O
reflexes O
along O
with O
. O

 O
and O
were O
intact O
but O
was O
positive O
. O

 O
Patient O
while O
. O

 O
Fasting O
and O
postprandial O
blood O
glucose O
levels O
were O
normal O
. O

 O
, O
, O
and O
were O
normal O
. O

 O
and O
levels O
were O
within O
normal O
limits O
. O

 O
showed O
absent O
sensory O
nerve O
action O
potential O
with O
normal O
distal O
latency O
, O
conduction O
velocity O
and O
amplitude O
of O
compound O
muscle O
action O
potential O
( O
CMAP O
) O
in O
all O
nerves O
trunks O
. O

 O
showed O
marked O
of O
the O
as O
compared O
to O
which O
was O
normal O
( O
figure O
1 O
) O
. O

 O
The O
using O
disclosed O
in O
. O

 O
A O
variety O
of O
causes O
of O
autosomal O
recessive O
ataxias O
need O
to O
be O
considered O
in O
the O
differential O
diagnosis O
of O
FRDA O
. O

 O
These O
were O
systemically O
excluded O
here O
. O

 O
Ataxia B
with I
vitamin I
E I
deficiency I
( O
AVED O
) O
has O
a O
phenotype O
quite O
similar O
to O
FRDA O
, O
though O
and O
are O
more O
common O
in O
AVED.4 O
A O
favoured O
. O

 O
Ataxia B
with I
oculomotor I
apraxia I
( O
AOA B
) O
types O
1 O
and O
2 O
were O
not O
considered O
owing O
to O
lack O
of O
, O
( O
severe O
) O
, O
of O
and O
involuntary O
movements.5 O
Ataxia B
telengiectesia I
has O
presentation O
very O
similar O
to O
AOA O
types O
1 O
and O
2 O
. O

 O
, O
sino O
- O
pulmonary O
, O
and O
along O
with O
predisposition O
to O
development O
of O
a O
variety O
of O
are O
features O
of O
ataxia O
telengiectasia O
not O
seen O
in O
AOAs O
and O
FRDA O
. O

 O
The O
other O
important O
causes O
of O
autosomal O
recessive O
spastic O
ataxia O
apart O
from O
FRDA O
would O
be O
autosomal B
recessive I
spastic I
ataxia I
of I
Charlevoix I
- I
Saguenay I
and O
Marinesco B
- I
Sjgren I
syndrome I
. O

 O
Charcot B
- I
Marie I
- I
Tooth I
disease I
, O
an O
inherited O
polyneuropathy O
has O
in O
common O
with O
FRDA O
; O
however O
, O
in O
this O
case O
, O
CMT B
was O
improbable O
due O
to O
following O
features O
in O
this O
case O
: O
lack O
of O
, O
retained O
reflexes O
, O
bilaterally O
extensor O
plantar O
and O
pure O
sensory O
neuropathy O
on O
nerve O
conduction O
study O
. O

 O
was O
started O
at O
a O
dose O
of O
for O
its O
antioxidant O
properties O
. O

 O
For O
gait O
ataxia O
, O
 O
 O
was O
initiated O
. O

 O
is O
monitored O
regularly O
. O

 O
At O
, O
there O
was O
no O
significant O
change O
in O
the O
. O

A O
presented O
at O
the O
with O
aggravating O
right O
upper O
abdominal O
for O
. O

 O
The O
patient O
was O
diagnosed O
and O
non O
- O
alcoholics O
. O

 O
. O

 O
Initial O
was O
, O
, O
, O
. O

 O
The O
were O
( O
: O
) O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
, O
16.6/0.7 O
mg O
/ O
dL. O

 O
And O
were O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
< O
20 O
IU O
/ O
mL O
, O
( O
- O
) O
and O
( O
) O
. O

 O
The O
patient O
's O
( O
) O
was O
and O
( O
) O
< O
0.6 O
U O
/ O
mL. O

 O
She O
took O
an O
abdominal O
scan O
, O
which O
showed O
a O
9 O
cm O
sized O
necrotic O
with O
internal O
hemorrhage O
at O
the O
and O
( O
Fig.1A O
) O
, O
so O
an O
emergency O
hepatic O
central O
was O
done O
( O
Fig.2A O
) O
. O

 O
The O
initial O
histological O
diagnosis O
was O
cHCC B
- I
CC I
with O
( O
Fig.2B O
) O
. O

 O
The O
was O
to O
at O
time O
of O
. O

 O
Regarding O
as O
cHCC B
- I
CC I
, O
postoperative O
adjuvant O
with O
( O
) O
was O
administrated O
for O
. O

 O
, O
abdominal O
scanning O
showed O
previously O
unseen O
a O
sized O
left O
subphrenic O
with O
mild O
in O
( O
Fig.3A O
, O
B O
) O
and O
was O
to O
312.06 O
ng O
/ O
mL. O

 O
She O
underwent O
laparoscopic O
with O
. O

 O
On O
, O
mesenchymal O
elements O
consisted O
of O
a O
proliferation O
of O
primitive O
- O
appearing O
mesenchymal O
spindle O
- O
shaped O
cells O
, O
intimately O
admixed O
with O
the O
epithelial O
elements O
in O
a O
highly O
cellular O
pattern O
. O

 O
Cytoplasm O
was O
more O
abundant O
than O
that O
of O
mature O
fibroblasts O
, O
and O
the O
nucleus O
was O
elongated O
and O
plump O
. O

 O
These O
cells O
blended O
progressively O
with O
areas O
of O
less O
intense O
cellular O
mesenchymal O
proliferation O
, O
and O
with O
relatively O
acellular O
, O
fibrous O
septa O
. O

 O
Osteoid O
was O
present O
either O
within O
the O
primitive O
mesenchyme O
, O
near O
the O
fibrous O
septa O
or O
pseudocapsule O
, O
or O
admixed O
within O
the O
epithelial O
elements O
. O

 O
Osteoid O
foci O
contained O
cells O
morphologically O
identical O
to O
osteoblasts O
( O
Fig.4A O
) O
. O

 O
The O
immunohistochemistry O
stains O
showed O
expression O
of O
hepatocyte O
, O
 O
- O
HCG O
, O
AFP O
, O
vimentin O
, O
CK7 O
, O
CK19 O
, O
CD56 O
and O
 O
- O
catenin O
and O
negativity O
for O
CEA.(Fig.4B O
, O
C O
, O
D O
, O
E O
, O
F O
, O
G O
) O
. O

 O
Metastatic O
hepatoblastoma O
was O
confirmed O
by O
histologic O
examination O
with O
immunohistochemistry O
stains O
, O
so O
immunohistochemistrically O
re O
- O
examination O
of O
previous O
surgical O
specimens O
was O
also O
confirmed O
as O
hepatoblastoma O
. O

 O
Follow O
- O
up O
abdominal O
CT O
scan O
performed O
1 O
month O
after O
reoperation O
showed O
a O
newly O
onset O
1.7 O
cm O
sized O
subtle O
enhancing O
soft O
tissue O
mass O
in O
splenic O
bed O
, O
and O
positron O
emission O
tomography O
( O
PET O
) O
showed O
multiple O
FDG O
uptake(max O
SUV O
> O
3.80 O
) O
in O
left O
upper O
and O
lower O
quadrant O
area O
of O
abdomen O
, O
paralumbar O
area O
including O
right O
subphrenic O
area O
( O
Fig.5A O
, O
B O
, O
C O
) O
. O

 O
Follow O
- O
up O
AFP O
was O
162.69 O
ng O
/ O
mL. O

 O
Systemic O
chemotherapy O
started O
with O
cisplatin O
( O
60 O
mg O
/ O
m2 O
) O
, O
5 O
- O
fluorourasil O
( O
5 O
- O
FU O
) O
( O
600 O
mg O
/ O
m2 O
) O
, O
vincristine O
( O
1.5 O
mg O
/ O
m2 O
) O
and O
total O
3 O
cycles O
of O
chemotherapy O
were O
done O
every O
4 O
week O
. O

 O
Entecavir O
0.5 O
mg O
was O
also O
started O
for O
chemoprophylaxis O
of O
CHB O
. O

 O
After O
the O
3rd O
chemotherapy O
cycle O
, O
follow O
- O
up O
abdominal O
CT O
and O
PET O
scan O
showed O
progression O
of O
multiple O
intraperitoneal O
metastasis O
with O
large O
amount O
of O
intraperitoneal O
fluid O
( O
Fig.6A O
, O
B O
) O
and O
follow O
- O
up O
AFP O
was O
further O
increased O
to O
254 O
ng O
/ O
mL. O

 O
So O
chemotherapy O
regimen O
was O
changed O
to O
carboplatin O
( O
350 O
mg O
/ O
m2 O
) O
with O
doxorubicin O
( O
30 O
mg O
/ O
m2 O
) O
every O
3 O
weeks O
. O

 O
The O
patient O
experienced O
neutropenia O
after O
the O
new O
regimen O
, O
but O
recovered O
shortly O
after O
treatment O
with O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
. O

 O
After O
second O
carboplatin O
with O
doxorubicin O
chemotherapy O
, O
follow O
- O
up O
AFP O
was O
increased O
1510.19 O
ng O
/ O
mL O
, O
but O
abdominal O
CT O
scan O
showed O
that O
amount O
of O
ascites O
was O
decreased O
( O
Fig.7 O
) O
. O

 O
Because O
of O
radiologic O
improvements O
, O
third O
and O
fourth O
chemotherapy O
were O
performed O
. O

 O
After O
4th O
chemotherapy O
, O
follow O
- O
up O
abdominal O
CT O
revealed O
progression O
of O
multiple O
intraperitoneal O
metastatic O
masses O
, O
newly O
developed O
hepatic O
metastasis O
and O
large O
amount O
of O
intraperitoneal O
fluid O
( O
Fig.8 O
) O
. O

 O
A O
diagnostic O
paracentesis O
was O
performed O
and O
showed O
white O
blood O
cell O
310 O
/ O
mm3 O
( O
poly O
20 O
% O
, O
lymph O
80 O
% O
) O
, O
protein O
3.6 O
g O
/ O
dL O
and O
albumin O
2.3 O
g O
/ O
dL O
on O
ascitic O
fluid O
analysis O
. O

 O
The O
serum O
albumin O
was O
3.1 O
g O
/ O
dL O
and O
serum O
- O
ascites O
albumin O
gradient O
( O
SAAG O
) O
was O
0.8 O
g O
/ O
dL. O

 O
The O
AFB O
stain O
and O
culture O
were O
all O
negative O
in O
ascitic O
fluid O
. O

 O
The O
AFP O
was O
6881.93 O
ng O
/ O
mL O
on O
serum O
. O

 O
Regarded O
as O
peritoneal O
carcinomatosis O
, O
the O
patient O
underwent O
conservative O
treatments O
including O
the O
use O
of O
repeated O
therapeutic O
paracentesis O
for O
1 O
month O
before O
. O

A O
, O
with O
a O
medical O
history O
of O
hypertension B
with O
new O
- O
onset O
painless O
and O
, O
a O
history O
of O
9.9 O
kg O
and O
chronic O
with O
four O
to O
five O
loose O
. O

 O
included O
, O
and O
. O

 O
was O
except O
for O
and O
muscle B
wasting I
. O

 O
Recent O
had O
been O
. O

 O
Total O
and O
direct O
levels O
were O
( O
) O
and O
( O
) O
, O
respectively O
. O

 O
Other O
results O
included O
an O
of O
, O
level O
( O
normal O
<33 O
U O
/ O
L O
) O
, O
level O
( O
normal O
< O
32 O
U O
/ O
L O
) O
and O
level O
( O
normal O
35 O
to O
104 O
U O
/ O
L O
) O
. O

 O
, O
and O
and O
tests O
were O
. O

 O
Her O
level O
was O
( O
normal O
< O
5 O
ng O
/ O
mL O
) O
, O
was O
( O
normal O
< O
640 O
mg O
/ O
dL O
) O
, O
was O
( O
normal O
<33 O
U O
/ O
mL O
) O
and O
was O
( O
normal O
<3 O
g O
/ O
L O
) O
. O

 O
Doppler O
, O
and O
of O
the O
were O
suspicious O
for O
a O
subtly O
enhancing O
( O
in O
diameter O
) O
in O
the O
region O
of O
the O
and O
, O
both O
the O
. O

 O
Endoscopic O
retrograde O
identified O
in O
the O
, O
which O
was O
concerning O
for O
cholangiocarcinoma B
( O
Figure O
1 O
) O
. O

 O
were O
. O

 O
was O
. O

 O
of O
the O
revealed O
chronic O
active O
duodenitis B
( O
Figures O
2 O
and O
and3);3 O
) O
; O
an O
( O
Figure O
4 O
) O
. O

 O
Treatment O
with O
normalized O
the O
patient O
s O
biochemical O
and O
radiological O
abnormalities B
. O

A O
who O
had O
been O
diagnosed O
with O
, O
who O
had O
severe O
diabetic O
neuropathy O
and O
diabetic O
- O
ESRD O
complained O
of O
respiratory O
distress O
and O
sudden O
chest O
pain O
. O

 O
On O
the O
of O
treatment O
, O
he O
the O
. O

 O
A O
revealed O
that O
his O
body O
temperature O
was O
35.4 O
 O
C O
, O
his O
heart O
rate O
was O
90 O
beats O
/ O
min O
with O
a O
regular O
rhythm O
; O
and O
his O
blood O
pressure O
was O
130/77 O
mmHg O
. O

 O
A O
physical O
examination O
revealed O
coarse O
crackles O
on O
bilateral O
lung O
auscultation O
. O

 O
The O
laboratory O
data O
showed O
a O
WBC O
count O
of O
8,800 O
/ O
L O
with O
a O
shift O
to O
the O
left O
( O
neutrophils O
82 O
% O
) O
, O
Hb O
10.2 O
g O
/ O
dL O
, O
blood O
urea O
nitrogen O
( O
BUN O
) O
82.2 O
mg O
/ O
dL O
, O
creatinine O
( O
Cre O
) O
6.50 O
mg O
/ O
dL O
, O
HbA1c O
5.9 O
% O
, O
creatine O
kinase O
( O
CK O
) O
189 O
IU O
/ O
L O
, O
C O
- O
reactive O
protein O
( O
CRP O
) O
8.51 O
mg O
/ O
dL O
, O
brain O
- O
type O
natriuretic O
peptide O
( O
BNP O
) O
127.4 O
pg O
/ O
mL. O

 O
A O
chest O
radiograph O
revealed O
perihilar O
consolidations O
and O
air O
bronchograms O
( O
Fig.1 O
) O
. O

 O
An O
electrocardiogram O
revealed O
ST O
- O
segment O
elevation O
and O
poor O
R O
- O
wave O
progression O
in O
leads O
V1 O
- O
V3 O
, O
and O
echocardiography O
revealed O
apical O
and O
ventricular O
asynergy O
. O

 O
The O
patient O
was O
therefore O
diagnosed O
with O
acute O
myocardial O
infarction O
and O
congestive O
heart O
failure O
. O

 O
Coronary O
angiography O
was O
performed O
, O
revealing O
severe O
angiostenosis O
in O
the O
septal O
branch O
. O

 O
PCI O
was O
therefore O
performed O
. O

 O
The O
patient O
required O
continuous O
maintenance O
dialysis O
. O

 O
On O
the O
following O
day O
, O
the O
patient O
went O
into O
cardiorespiratory O
arrest O
and O
cardiopulmonary O
resuscitation O
was O
performed O
, O
followed O
by O
mechanical O
ventilation O
. O

 O
On O
day O
8 O
, O
ventilator O
assistance O
was O
discontinued O
. O

 O
However O
, O
the O
patient O
produced O
an O
increasing O
volume O
of O
sputum O
, O
which O
began O
to O
appear O
purulent O
. O

 O
Pseudomonas O
aeruginosa O
was O
identified O
from O
a O
sputum O
culture O
, O
and O
tazobactam O
/ O
piperacillin O
( O
TAZ O
/ O
PIPC O
) O
( O
4.5 O
g O
q12h O
) O
was O
administered O
. O

 O
Despite O
this O
therapy O
, O
the O
patient O
's O
respiratory O
condition O
worsened O
and O
a O
chest O
computed O
tomography O
( O
CT O
) O
scan O
on O
day O
15 O
revealed O
bilateral O
perihilar O
opacities O
, O
pleural O
effusion O
, O
and O
atelectasis.(Fig.2 O
) O
. O

 O
We O
suspected O
the O
development O
of O
complications O
such O
as O
microbial O
substitution O
, O
pneumomycosis O
and O
thus O
performed O
sputum O
culturing O
and O
serum O
fungal O
antigen O
tests O
. O

 O
The O
administration O
of O
TAZ O
/ O
PIPC O
was O
changed O
to O
meropenem O
( O
0.5 O
g O
/ O
day O
) O
. O

 O
On O
day O
16 O
, O
the O
patient O
's O
serum O
tested O
positive O
for O
Cryptococcus O
antigen O
. O

 O
On O
day O
21 O
, O
cryptococcal O
bodies O
were O
identified O
in O
two O
sets O
of O
blood O
cultures O
and O
liposomal O
amphotericin O
B O
( O
L O
- O
AMB O
) O
( O
3 O
mg O
/ O
kg O
/ O
day O
) O
was O
administered O
. O

 O
On O
day O
23 O
, O
cryptococcal O
bodies O
were O
identified O
in O
the O
sputum O
, O
cerebrospinal O
fluid O
, O
and O
bilateral O
pleural O
effusion O
( O
Fig.3 O
) O
. O

 O
The O
patient O
was O
therefore O
diagnosed O
with O
disseminated O
cryptococcosis O
. O

 O
On O
day O
25 O
, O
brain O
CT O
revealed O
the O
absence O
of O
intracranial O
hypertension O
and O
a O
brain O
abscess O
. O

 O
The O
patient O
was O
not O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
. O

 O
The O
administration O
of O
L O
- O
AMB O
( O
3 O
mg O
/ O
kg O
/ O
day O
) O
was O
continued O
. O

 O
On O
day O
31 O
, O
chest O
CT O
revealed O
a O
solitary O
nodule O
in O
the O
left O
lingular O
segment O
for O
the O
first O
time O
, O
which O
was O
suspected O
to O
be O
a O
pulmonary O
cryptococcus O
lesion O
( O
Fig.4a O
) O
. O

 O
After O
several O
days O
, O
all O
of O
the O
sputum O
, O
blood O
, O
bilateral O
pleural O
effusion O
, O
and O
cerebrospinal O
fluid O
cultures O
tested O
negative O
. O

 O
On O
day O
52 O
, O
chest O
CT O
revealed O
another O
lung O
nodule O
in O
the O
right O
pulmonary O
apical O
region O
. O

 O
These O
nodules O
gradually O
decreased O
in O
size O
until O
day O
79 O
( O
Fig.4b O
and O
c O
) O
. O

 O
Although O
L O
- O
AMB O
was O
considered O
effective O
, O
the O
C O
- O
reactive O
protein O
level O
remained O
elevated O
and O
the O
bilateral O
pleural O
effusion O
continuously O
increased O
. O

 O
The O
patient O
lost O
consciousness O
because O
of O
decreased O
vital O
capacity O
with O
increasing O
bilateral O
pleural O
effusion O
and O
was O
diagnosed O
with O
CO2 O
narcosis O
. O

 O
The O
patient O
's O
general O
condition O
deteriorated O
. O

 O
On O
day O
87 O
, O
ventricular O
fibrillation O
occurred O
and O
the O
patient O
. O

 O
was O
not O
performed O
. O

 O
At O
a O
later O
date O
, O
the O
Cryptococcus O
isolate O
was O
identified O
and O
classified O
as O
Cryptococcus O
neoformans O
var O
. O
grubii O
( O
serotype O
A O
) O
by O
a O
. O

A O
to O
our O
with O
a O
history O
of O
; O
productive O
of O
whitish O
. O

 O
At O
presentation O
, O
he O
denied O
, O
, O
, O
chest O
, O
, O
back O
, O
recent O
or O
sick O
. O

 O
He O
reported O
that O
he O
had O
approximately O
a O
1520 O
pound O
during O
the O
. O

 O
He O
, O
socially O
, O
and O
in O
the O
past O
. O

 O
On O
admission O
, O
his O
was O
; O
was O
, O
was O
, O
was O
, O
and O
was O
on O
. O

 O
showed O
oral O
, O
decreased O
and O
on O
the O
. O

 O
No O
cutaneous O
were O
reported O
and O
the O
rest O
of O
was O
. O

 O
His O
( O
) O
showed O
of O
, O
, O
and O
of O
164109 O
/ O
L. O

 O
His O
was O
, O
and O
was O
10 O
mg O
/ O
dL. O

 O
of O
the O
showed O
extensive O
right O
and O
left O
perihilar O
, O
and O
( O
) O
scan O
of O
the O
showed O
a O
right O
sided O
large O
perihilar O
( O
Figure O
1 O
) O
with O
multiple O
thoracic O
and O
lumbar O
vertebrae O
, O
ribs O
, O
and O
sternal O
tiny O
lytic O
consistent O
with O
bony O
metastasis B
( O
Figure O
2 O
) O
. O

 O
Blood O
and O
sputum O
were O
. O

 O
Tuberculosis B
was O
ruled O
out O
by O
three O
consecutive O
negative O
for O
and O
a O
negative O
. O

 O
He O
tested O
for O
( O
) O
and O
his O
came O
back O
at O
7 O
cells O
/ O
uL. O

 O
He O
was O
started O
on O
with O
and O
for O
opportunistic O
infections O
. O

 O
with O
was O
performed O
but O
was O
and O
he O
underwent O
a O
video O
assisted O
with O
of O
the O
. O

 O
showed O
positive O
for O
, O
, O
, O
and O
with O
diffuse O
positivity O
for O
diagnostic O
of O
KS B
. O

 O
He O
started O
treatment O
with O
in O
the O
form O
of O
and O
. O

 O
The O
patient O
was O
actively O
involved O
in O
decisions O
regarding O
management O
options O
. O

 O
He O
favored O
HAART O
isolated O
regimen O
without O
. O

 O
His O
condition O
showed O
continuing O
; O
a O
repeat O
scan O
of O
the O
at O
showed O
profound O
of O
the O
disease O
with O
disappearance O
of O
most O
of O
the O
( O
Figure O
3 O
) O
. O

A O
with O
developed O
, O
and O
on O
over O
the O
to O
her O
to O
our O
. O

 O
At O
the O
time O
of O
presentation O
, O
she O
also O
reported O
of O
dry O
, O
, O
paroxysmal O
nocturnal O
, O
generalised O
and O
intermittent O
of O
her O
and O
. O

 O
Social O
history O
was O
negative O
for O
, O
or O
. O

 O
was O
, O
except O
for O
jugular O
venous O
, O
audible O
S1 O
and O
S2 O
sounds O
, O
bilateral O
crackles O
on O
lung O
auscultation O
and O
bilateral O
pitting O
oedema O
. O

 O
Chest O
X O
- O
ray O
showed O
cardiomegaly O
, O
pulmonary O
oedema O
and O
small O
- O
sized O
bilateral O
pleural O
effusions O
. O

 O
A O
12 O
- O
lead O
ECG O
demonstrated O
normal O
sinus O
rhythm O
, O
low O
- O
voltage O
complexes O
and O
extreme O
right O
- O
axis O
deviation O
( O
figure O
1 O
) O
. O

 O
Transthoracic O
echocardiogram O
( O
TTE O
) O
demonstrated O
asymmetric O
biventricular O
hypertrophy O
with O
preserved O
ejection O
fraction O
of O
60 O
% O
, O
elevated O
right O
- O
ventricular O
systolic O
pressure O
of O
36 O
 O
mm O
 O
Hg O
and O
abnormal O
myocardial O
texture O
, O
described O
as O
 O
granular O
sparkling O
 O
( O
figure O
2 O
) O
. O

 O
Coronary O
CT O
angiogram O
demonstrated O
normal O
coronary O
arteries O
. O

 O
Subsequently O
, O
cardiac O
MRI O
demonstrated O
early O
and O
diffuse O
subendocardial O
delayed O
enhancement O
, O
concerning O
for O
infiltrative O
myocardial O
disease O
and O
for O
diffuse O
biventricular O
hypertrophy O
, O
with O
normal O
ejection O
fraction O
( O
figure O
3 O
) O
. O

 O
The O
patient O
underwent O
right O
heart O
catheterisation O
with O
endomyocardial O
biopsy O
, O
revealing O
diffuse O
amyloidosis O
with O
amorphous O
proteinaceous O
material O
around O
cardiac O
myocytes O
and O
within O
blood O
vessels O
, O
which O
was O
positive O
for O
Congo O
red O
stain O
( O
figure O
4 O
) O
. O

 O
Subsequent O
laboratory O
evaluation O
registered O
elevated O
, O
free O
 O
light O
chains O
( O
86.3 O
 O
mg O
/ O
L O
( O
normal O
: O
5.726.3 O
 O
mg O
/ O
L O
) O
) O
and O
positive O
Bence O
- O
Jones O
protein O
( O
0.37 O
 O
g/24 O
 O
h O
) O
in O
the O
urine O
. O

 O
Bone O
marrow O
biopsy O
revealed O
greater O
than O
10 O
% O
infiltration O
of O
CD19 O
CD56 O
+ O
CD138 O
+ O
plasma O
cells O
with O
reversal O
of O
marrow O
 O
/ O
 O
ratio O
( O
< O
1:2 O
, O
normal O
: O
2:1 O
) O
, O
consistent O
with O
MM O
. O

 O
The O
patient O
was O
eventually O
diagnosed O
with O
systemic O
AL O
amyloidosis O
with O
advanced O
, O
stage O
III O
, O
cardiac O
amyloidosis O
due O
to O
underlying O
MM O
. O

 O
Given O
her O
advanced O
cardiac O
amyloidosis O
, O
the O
patient O
was O
deemed O
a O
poor O
candidate O
for O
autologous O
stem O
- O
cell O
transplantation O
. O

 O
The O
patient O
was O
started O
on O
systemic O
chemotherapy O
with O
melphalan O
and O
dexamethasone O
. O

 O
Despite O
receiving O
standard O
therapy O
for O
heart O
failure O
 O
including O
diuretics O
, O
 O
- O
blockers O
and O
ACE O
inhibitors O
 O
the O
patient O
's O
condition O
continued O
to O
worsen O
and O
she O
to O
sudden B
cardiac I
death I
. O

The O
patient O
was O
a O
of O
. O

 O
His O
height O
was O
and O
his O
. O

 O
Both O
parents O
were O
of O
normal O
height O
and O
neither O
showed O
any O
minor O
anomalies O
of O
the O
EvC O
syndrome O
spectrum O
. O

 O
The O
patient O
had O
two O
healthy O
. O

 O
His O
were O
: O
( O
a O
) O
normal O
mouth O
opening O
with O
missing O
lower O
incisors O
( O
Fig.1 O
) O
; O
( O
b O
) O
small O
chest O
, O
as O
determined O
by O
a O
; O
and O
( O
c O
) O
disproportionately O
short O
extremities O
with O
one O
additional O
postaxial O
digit O
on O
each O
hand O
( O
Fig.2 O
) O
. O

 O
Although O
no O
was O
noted O
, O
the O
patient O
presented O
with O
mild O
mental B
retardation I
. O

 O
in O
his O
early O
infancy O
showed O
a O
previously O
reported O
homozygous O
nonsense O
mutation O
c.1195 O
C1 O
T O
, O
p. O
Arg399X O
of O
EvC2 O
, O
resulting O
in O
loss O
of O
function O
of O
the O
protein.(5 O
) O
His O
were O
of O
the O
. O

 O
In O
, O
the O
patient O
underwent O
successful O
ostium O
primum O
through O
a O
. O

 O
He O
with O
embolic O
cerebral O
in O
, O
and O
cavotricuspid O
isthmus O
for O
common O
atrial B
flutter I
was O
performed O
successfully O
. O

 O
There O
were O
no O
serious O
. O

 O
During O
a O
routine O
in O
, O
a O
high O
- O
pitched O
systolic O
was O
discovered O
. O

 O
showed O
sinus O
rhythm O
with O
hemiblock O
and O
right B
bundle I
branch I
block I
, O
while O
revealed O
a O
and O
. O

 O
These O
abnormalities O
produced O
a O
flow O
that O
was O
directed O
to O
the O
left O
atrial O
appendage O
, O
leading O
to O
severe O
. O

 O
The O
patient O
s O
systolic O
was O
and O
his O
. O

 O
His O
medical O
treatment O
included O
, O
, O
and O
. O

 O
The O
patient O
was O
scheduled O
for O
. O

 O
In O
the O
operating O
theatre O
, O
the O
patient O
s O
right O
femoral O
artery O
was O
. O

 O
A O
right O
was O
performed O
on O
the O
and O
bicaval O
was O
established O
. O

 O
. O

 O
The O
operation O
used O
a O
normothermic O
. O

 O
To O
avoid O
air O
embolisms O
, O
was O
applied O
using O
a O
( O
) O
. O

 O
The O
attempt O
to O
perform O
a O
was O
unsuccessful O
and O
a O
bileaflet O
mechanical O
valve O
( O
no.29 O
) O
was O
. O

 O
No O
occurred O
. O

 O
The O
patient O
s O
was O
and O
he O
was O
on O
. O

 O
After O
two O
years O
of O
, O
revealed O
of O
the O
and O
a O
decrease O
in O
systolic O
( O
) O
. O

A O
with O
known O
diastolic O
congestive B
heart I
failure I
( B
CHF I
) I
presented O
to O
the O
with O
of O
CHF B
and O
a O
decreased O
. O

 O
Brachial O
blood O
pressure O
( O
BP O
) O
was O
measured O
at O
. O

 O
The O
patient O
had O
four O
recent O
with O
exacerbation O
of O
CHF O
. O

 O
Her O
medical O
history O
was O
also O
significant O
for O
autoimmune O
hepatitis B
, O
but O
preserved O
; O
esophageal O
varices O
with O
a O
bleeding O
episode O
; O
and O
long O
- O
term O
complicated O
by O
adrenal O
insufficiency O
, O
type B
2 I
diabetes I
mellitus I
and O
osteoporosis B
. O

 O
Recent O
had O
revealed O
concentric O
left O
ventricular O
hypertrophy B
with O
, O
and O
mild O
to O
moderate O
mitral B
regurgitation I
. O

 O
Cardiac O
catheterization O
in O
a O
recent O
demonstrated O
50 O
% O
stenosis O
in O
the O
, O
with O
mild O
diffuse O
disease O
in O
the O
. O

 O
Right O
ventricular O
endomyocardial O
had O
ruled O
out O
myocarditis O
and O
infiltrative O
cardiomyopathies B
, O
but O
healing O
ischemic B
microinfarcts I
with O
atheroemboli B
were O
observed O
. O

 O
Previous O
were O
also O
; O
was O
between O
and O
, O
and O
was O
between O
and O
. O

 O
Following O
, O
was O
started O
for O
hypotension O
management O
and O
was O
later O
replaced O
with O
. O

 O
The O
patient O
developed O
atrial B
flutter I
but O
successfully O
converted O
to O
sinus O
rhythm O
with O
two O
direct O
current O
. O

 O
Cardiology O
consultation O
resulted O
in O
to O
the O
. O

 O
On O
to O
the O
, O
was O
measured O
at O
in O
the O
but O
was O
not O
detectable O
in O
the O
. O

 O
An O
was O
inserted O
via O
the O
, O
and O
was O
measured O
at O
. O

 O
BP O
values O
were O
consistently O
much O
through O
the O
than O
the O
cuff O
on O
the O
arms O
, O
and O
was O
in O
the O
than O
in O
the O
. O

 O
For O
instance O
, O
, O
was O
measured O
at O
through O
the O
, O
while O
on O
the O
arms O
were O
on O
the O
left O
and O
on O
the O
right O
. O

 O
To O
investigate O
the O
inconsistency O
between O
brachial O
and O
femoral O
BP O
values O
, O
a O
( O
CT O
) O
of O
the O
was O
obtained O
using O
, O
both O
before O
and O
after O
intravenous O
contrast O
injection O
with O
sagittal O
and O
coronal O
planar O
reformatting O
of O
maximum O
- O
intensity O
projection O
images O
. O

 O
Analysis O
of O
the O
initial O
unenhanced O
CT O
images O
showed O
densely O
calcified O
plaque O
or O
thrombus O
at O
the O
origins O
of O
both O
subclavian O
arteries O
and O
the O
right O
common O
carotid O
artery O
. O

 O
The O
CT O
angiogram O
showed O
absence O
of O
flow O
in O
the O
right O
subclavian O
artery O
, O
a O
very O
tight O
stenosis O
at O
the O
origin O
of O
the O
left O
subclavian O
artery O
and O
a O
tight O
stenosis O
at O
the O
origin O
of O
the O
right O
common O
carotid O
artery O
. O

 O
Both O
vertebral O
arteries O
showed O
normal O
calibre O
and O
flow O
( O
Figure O
1 O
) O
. O

 O
Further O
management O
following O
the O
insertion O
of O
the O
femoral O
arterial O
line O
was O
based O
on O
femoral O
BP O
readings O
with O
diuretics O
and O
BP O
- O
lowering O
agents O
. O

 O
The O
patient O
was O
eventually O
discharged O
in O
stable O
condition O
. O

 O
She O
remained O
stable O
, O
without O
further O
exacerbation O
of O
CHF B
or O
related O
. O

A O
to O
the O
of O
in O
September O
2015with O
a O
complaint O
of O
recurrent O
infections B
in O
the O
. O

 O
She O
reported O
abdominal O
similar O
to O
a O
burning O
sensation O
that O
accompanied O
the O
. O

 O
These O
symptoms O
and O
signs O
waxed O
and O
waned O
but O
. O

 O
Our O
attention O
was O
piqued O
by O
the O
fact O
that O
the O
patient O
s O
family O
described O
the O
patient O
as O
an O
individual O
who O
cried O
easily O
. O

 O
The O
patient O
had O
no O
history O
of O
, O
or O
. O

 O
was O
mentioned O
in O
her O
prior O
medical O
history O
. O

 O
Acoordinated O
revealed O
normal O
vital O
signs O
. O

 O
An O
external O
fistula O
was O
located O
in O
the O
umbilical O
region O
with O
redness O
of O
the O
surrounding O
skin O
. O

 O
Morphological O
examination O
indicated O
that O
fistula O
secretions O
mainly O
consisted O
of O
small O
intestinal O
juice O
. O

 O
The O
abdominal O
wall O
was O
soft O
, O
with O
no O
tenderness O
. O

 O
Bowel O
sounds O
were O
regular O
. O

 O
Escherichia O
coli O
and O
Enterococcus O
faecalis O
were O
detected O
in O
the O
fistula O
secretion O
culture O
. O

 O
Other O
findings O
from O
laboratory O
examinations O
were O
normal O
. O

 O
A O
CT O
scan O
of O
the O
abdomen O
revealed O
that O
part O
of O
the O
intestinal O
wall O
was O
adhered O
to O
the O
abdominal O
wall O
in O
the O
navel O
region O
, O
although O
no O
bowel O
obstruction O
was O
detected O
( O
Fig.1 O
) O
. O

 O
A O
presumptive O
diagnosis O
of O
ECF B
was O
reached O
; O
this O
diagnosis O
was O
mainly O
based O
on O
digital O
radiography O
of O
the O
fistulous O
tract O
conducted O
using O
iopamidol-370 O
as O
a O
contrast O
agent O
. O

 O
This O
procedure O
was O
performed O
under O
local O
anaesthesia O
and O
revealed O
that O
the O
distal O
ileum O
approximately O
40 O
cm O
from O
the O
ileocaecal O
junction O
was O
entrapped O
( O
Fig.2 O
) O
. O

 O
The O
patient O
agreed O
to O
surgery O
after O
a O
clear O
preoperative O
conversation O
. O

 O
She O
understood O
the O
operative O
risk O
factors O
and O
signed O
an O
informed O
consent O
. O

 O
After O
bowel O
preparation O
, O
the O
patient O
received O
an O
exploratory O
laparotomy O
. O

 O
The O
abdominal O
cavity O
was O
completely O
exposed O
, O
and O
a O
loop O
of O
the O
terminal O
ileum O
( O
approximately O
40 O
cm O
proximal O
to O
the O
ileocaecal O
junction O
) O
was O
found O
entrapped O
in O
the O
internal O
hernia O
ring O
; O
this O
finding O
was O
consistent O
with O
the O
preoperative O
contrast O
image O
. O

 O
The O
defect O
in O
the O
abdominal O
wall O
was O
less O
than O
1.0 O
cm O
, O
and O
an O
extremely O
small O
portion O
of O
the O
bowel O
wall O
was O
stuck O
and O
could O
not O
be O
retrieved O
back O
into O
the O
cavity O
( O
Fig.3 O
) O
. O

 O
Nonetheless O
, O
this O
defect O
resulted O
in O
perforation O
over O
the O
loop O
( O
Fig.4 O
) O
. O

 O
Side O
- O
to O
- O
side O
ileo O
- O
ileal O
anastomosis O
was O
completed O
by O
utilizing O
a O
75 O
mm O
linear O
stapler O
to O
remove O
the O
affected O
ileum O
segment O
. O

 O
The O
internal O
hernia O
ring O
was O
closed O
with O
plication O
sutures O
instead O
of O
via O
mesh O
repair O
due O
to O
the O
patient O
s O
small O
defect O
and O
infection O
risk O
. O

 O
The O
abdominal O
cavity O
was O
thoroughly O
cleaned O
with O
saline O
solution O
, O
and O
a O
rubber O
drainage O
tube O
was O
placed O
in O
the O
pelvis O
. O

 O
The O
scar O
tissue O
was O
removed O
to O
improve O
wound O
healing O
; O
subsequently O
, O
relaxation O
sutures O
were O
available O
to O
close O
the O
abdomen O
in O
layers O
. O

 O
A O
final O
diagnosis O
of O
Richter B
s I
hernia I
presenting O
as O
spontaneous O
ECF O
was O
reached O
. O

 O
The O
patient O
was O
discharged O
2 O
weeks O
after O
without O
serious O
complications B
. O

 O
No O
hernia B
recurrence O
was O
observed O
during O
of O
. O

This O
was O
the O
first O
child O
to O
. O

 O
. O

 O
He O
was O
well O
until O
starting O
school O
at O
when O
he O
was O
found O
to O
be O
, O
, O
and O
to O
have O
. O

 O
were O
performed O
that O
initially O
revealed O
borderline O
values O
for O
and O
he O
was O
therefore O
treated O
for O
a O
period O
with O
without O
any O
. O

 O
At O
age O
16 O
years O
, O
compared O
with O
a O
standardized O
Swedish O
growth O
chart O
. O

 O
at O
showed O
and O
. O

 O
An O
was O
performed O
and O
showed O
a O
severe O
. O

 O
He O
had O
decreased O
, O
, O
, O
and O
. O

 O
has O
been O
noted O
since O
. O

 O
A O
year O
later O
, O
and O
were O
developed O
. O

 O
The O
at O
. O

 O
He O
is O
now O
blind O
. O

 O
At O
, O
he O
was O
referred O
for O
. O

 O
A O
showed O
mild O
, O
and O
together O
with O
mild O
to O
moderate O
, O
in O
the O
, O
and O
. O

 O
revealed O
a O
mild O
bilateral O
. O

 O
At O
, O
he O
had O
an O
and O
he O
has O
since O
then O
been O
with O
. O

 O
was O
identified O
at O
, O
with O
increased O
to O
( O
reference O
interval O
3090 O
 O
mol O
/ O
l O
) O
, O
with O
at O
( O
reference O
interval<20 O
 O
mg O
/ O
l O
) O
, O
and O
ratio O
at O
( O
reference O
interval O
<3 O
 O
g O
/ O
mol O
) O
. O

 O
A O
demonstrated O
. O

 O
showed O
a O
of O

 O
The O
over O
time O
to O
at O
. O

 O
Since O
14 O
years O
of O
age O
, O
have O
demonstrated O
of O
the O
( O
+3 O
SD O
compared O
with O
normal O
) O
with O
normal O
systolic O
and O
diastolic O
function O
and O
without O
obstruction O
of O
the O
outflow O
. O

 O
were O
performed O
at O
. O

 O
Blood O
levels O
of O
and O
were O
and O
, O
respectively O
, O
leading O
to O
a O
ratio O
of O
33 O
( O
reference O
interval O
< O
20 O
) O
, O
while O
( O
) O
levels O
of O
and O
were O
and O
respectively O
, O
leading O
to O
a O
of O
. O

 O
The O
was O
. O

 O
The O
was O
increased O
to O
( O
reference O
level O
< O
225 O
 O
mg O
/ O
l O
) O
and O
he O
also O
had O
an O
increased O
of O
( O
reference O
level O
< O
5 O
) O
. O

 O
The O
and O
were O
normal O
. O

 O
The O
was O
to O
( O
reference O
interval O
< O
3.5 O
 O
kat O
/ O
l O
) O
. O

We O
report O
the O
case O
of O
a O
previously O
healthy O
, O
, O
in O
her O
. O

 O
Our O
patient O
had O
no O
medical O
records O
until O
the O
36th O
pregnancy O
week O
and O
reported O
allergy O
to O
diclofenac O
. O

 O
She O
to O
our O
with O
an O
acute O
onset O
of O
abdominal O
, O
, O
and O
, O
with O
no O
signs O
of O
encephalopathy B
. O

 O
Her O
arterial O
blood O
pressure O
was O
110/60mmHg O
, O
heart O
rate O
was O
98bpm O
, O
axillary O
temperature O
was O
35 O
 O
C O
, O
she O
was O
severely O
dehydrated O
and O
with O
decreased O
peripheral O
perfusion O
. O

 O
The O
laboratory O
examinations O
revealed O
hemoglobin O
12.3g O
/ O
dL O
, O
leukocytes O
13 O
 O
 O
 O
109 O
/ O
mL O
, O
platelets O
97 O
 O
 O
 O
103 O
/ O
mm3 O
, O
international O
nationalized O
ratio O
( O
INR O
) O
6.9 O
, O
fibrinogen O
98mg O
/ O
dL O
, O
total O
bilirubin O
14.2mg O
/ O
dL O
, O
serum O
creatinine O
3.4mg O
/ O
dL O
, O
serum O
aspartate O
aminotransferase O
( O
AST O
) O
306U O
/ O
L O
, O
serum O
alanine O
aminotransferase O
( O
ALP O
) O
302U O
/ O
L O
, O
arterial O
bicarbonate O
11mEq O
/ O
L O
, O
arterial O
pH O
7.21 O
, O
blood O
glucose O
65mg O
/ O
dL O
and O
ionic O
calcium O
1.02mmol O
/ O
L. O

 O
An O
abdominal O
ultrasound O
depicted O
fatty O
infiltration O
of O
the O
liver O
and O
confirmed O
fetal O
viability O
. O

 O
Our O
patient O
received O
an O
initial O
fluid O
load O
with O
crystalloids O
. O

 O
The O
calcium O
, O
glucose O
and O
hypothermia O
were O
reversed O
. O

 O
The O
diagnosis O
of O
AFLP O
was O
confirmed O
following O
the O
Swansea O
s O
criteria O
[ O
9 O
] O
. O

 O
Therefore O
, O
a O
cesarean O
section O
was O
indicated O
. O

 O
A O
thromboelastometry O
( O
ROTEM O
 O
, O
Pentapharm O
Co. O
, O
Munich O
, O
Germany O
) O
was O
performed O
at O
the O
beginning O
of O
the O
surgery O
. O

 O
The O
thromboelastometry O
analysis O
showed O
an O
intense O
kinetic O
and O
structural O
hypocoagulable O
state O
( O
Fig.1 O
and O
Table O
1 O
) O
. O

 O
The O
FIBTEM O
revealed O
an O
impairment O
in O
fibrinogen O
function O
quality O
while O
the O
EXTEM O
depicted O
a O
coagulation O
factor O
deficiency O
( O
Fig.1a O
- O
c O
and O
Table O
1 O
) O
. O

 O
Based O
on O
, O
respectively O
, O
FIBTEM O
maximum O
clot O
firmness O
( O
MCF O
) O
( O
0 O
mm O
; O
Table O
1 O
) O
and O
EXTEM O
clotting O
time O
( O
CT O
) O
( O
228s O
; O
Table O
1 O
) O
, O
4.0 O
g O
of O
fibrinogen O
concentrate O
( O
Haemocomplettan O
 O
P O
, O
CSL O
Behring O
, O
Marburg O
, O
Germany O
) O
and O
1000UI O
of O
prothrombin O
complex O
concentrate O
( O
Beriplex O
 O
P O
/ O
N O
500UI O
, O
CSL O
Behring O
, O
Marburg O
, O
Germany O
) O
were O
administered O
at O
the O
beginning O
of O
the O
cesarean O
section O
. O

 O
The O
fluid O
input O
( O
crystalloids O
) O
and O
output O
during O
the O
caesarian O
section O
were O
, O
respectively O
, O
2000mL O
and O
200mL. O

 O
The O
cesarean O
section O
succeeded O
with O
no O
major O
bleeding O
after O
the O
hemostatic O
therapy O
. O

 O
Additional O
hemocomponent O
transfusion O
, O
such O
as O
fresh O
frozen O
plasma O
( O
FFP O
) O
, O
cryoprecipitate O
, O
platelets O
or O
blood O
concentrates O
, O
was O
not O
necessary O
. O

 O
A O
second O
thromboelastometry O
analysis O
was O
performed O
at O
the O
end O
of O
surgery O
( O
Fig.1d O
- O
e O
and O
Table O
1 O
) O
, O
showing O
a O
mild O
hypocoagulation O
state O
. O

 O
The O
patient O
was O
admitted O
to O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
remained O
stable O
, O
with O
no O
bleeding O
during O
the O
recovery O
phase O
. O

 O
She O
was O
from O
the O
ICU O
3 O
days O
after O
admission O
and O
then O
3 O
days O
later O
she O
was O
from O
the O
. O

A O
with O
underwent O
living O
- O
donor O
. O

 O
His O
had O
been O
for O
. O

 O
He O
developed O
multifocal O
salmon O
- O
pink O
skin O
, O
and O
swelling O
and O
spontaneous O
in O
the O
and O
. O

 O
The O
symptoms O
had O
gradually O
expanded O
across O
the O
and O
. O

 O
He O
was O
to O
our O
for O
the O
evaluation O
of O
( O
) O
and O
multifocal O
cellulitis B
( O
Fig.1 O
) O
. O

 O
admission O
, O
he O
had O
developed O
chronic O
. O

 O
His O
level O
was O
at O
with O
maintenance O
comprising O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
The O
tacrolimus O
trough O
concentration O
was O
6.3 O
ng O
/ O
mL. O

 O
The O
patient O
had O
been O
. O

 O
On O
admission O
, O
his O
was O
and O
his O
level O
was O
3.9 O
mg O
/ O
dL. O

 O
The O
patient O
was O
initially O
treated O
with O
( O
) O
. O

 O
Two O
days O
after O
the O
initiation O
of O
this O
therapy O
, O
he O
was O
. O

 O
, O
an O
automated O
( O
; O
) O
showed O
positivity O
for O
. O

 O
A O
colony O
obtained O
from O
the O
patient O
s O
blood O
culture O
was O
analyzed O
by O
MALDI O
- O
TOF O
( O
; O
) O
. O

 O
The O
identification O
score O
was O
2.064 O
( O
> O
2.0 O
) O
, O
indicating O
accurate O
identification O
of O
( O
Fig.2 O
) O
. O

 O
Additional O
evaluation O
of O
the O
patient O
s O
blood O
specifically O
for O

 O
by O
means O
of O
gyrase O
subunit O
B O
( O
gyrB)-targeted O
( O
) O
yielded O
results O
. O

 O
We O
performed O
gyrB O
- O
targeted O
using O
a O
. O

 O
We O
used O
to O
prevent O
contamination O
of O
gyrB O
- O
targeted O
PCR O
( O
Fig.3 O
) O
. O

 O
In O
addition O
, O
we O
performed O
of O
this O
strain O
, O
and O
the O
results O
were O
> O
99 O
% O
consistent O
with O
the O
existing O
sequence O
( O
Fig.4 O
) O
. O

 O
Given O
these O
results O
, O
we O
diagnosed O
the O
patient O
with O
H. O

 O
cinaedi O
bacteremia B
with O
cellulitis B
. O

 O
We O
of O
the O
, O
which O
resulted O
in O
identification O
of O
cluster O
B O
. O

 O
A O
obtained O
was O
positive O
for O

 O
, O
but O
a O
obtained O
was O
. O

 O
The O
patient O
s O
cellulitis B
gradually O
resolved O
. O

 O
The O
patient O
continued O
treatment O
for O
a O
total O
of O
( O
in O
a O
for O
and O
oral O
for O
) O
, O
and O
he O
had O
no O
this O
therapy O
. O

 O
His O
was O
negative O
, O
although O
it O
was O
. O

 O
We O
did O
not O
apply O
in O
this O
case O
. O

A O
with O
, O
, O
, O
and O
abdominal O
was O
for O
an O
abdominal O
to O
rule O
out O
intraabdominal B
pathology I
. O

 O
A O
dedicated O
of O
the O
was O
performed O
at O
our O
according O
to O
our O
. O

 O
Following O
ingestion O
of O
material O
( O
, O
) O
and O
injection O
of O
125 O
 O
ml O
of O
, O
( O
) O
, O
helical O
was O
obtained O
with O
a O
65 O
- O
s O
delays O
using O
a O
( O
) O
. O

 O
of O
the O
showed O
a O
large O
( O
182222 O
cm O
) O
heterogeneous O
retroperitoneal O
probably O
arising O
from O
the O
containing O
( O
Fig.1 O
) O
. O

 O
The O
patient O
had O
. O

 O
On O
the O
basis O
of O
the O
clinical O
history O
and O
CT O
findings O
, O
the O
patient O
underwent O
of O
the O
left O
adrenal O
, O
which O
was O
found O
on O
pathologic O
examination O
to O
represent O
a O
low O
- O
grade O
adrenocortical B
carcinoma I
. O

An O
with O
and O
gout B
was O
to O
Taichung O
Veterans O
General O
Hospital O
due O
to O
abdominal O
and O
. O

 O
She O
began O
to O
suffer O
from O
intermittent O
, O
and O
a O
4 O
cm O
gastric O
was O
found O
. O

 O
The O
abdominal O
admission O
, O
and O
she O
to O
a O
where O
abdominal O
scan O
revealed O
a O
gastric O
about O
in O
length O
with O
well O
- O
circumscribed O
calcification(figure O
1 O
) O
. O

 O
was O
suggested O
, O
but O
she O
declined O
. O

 O
About O
admission O
, O
passage O
was O
noted O
, O
and O
was O
found O
. O

 O
revealed O
submucosal O
gastric O
with O
and O
she O
was O
then O
to O
our O
. O

 O
showed O
upper O
abdominal O
with O
mild O
muscle O
. O

 O
The O
plain O
showed O
an O
irregular O
shape O
over O
. O

 O
revealed O
deep O
gastric O
with O
. O

 O
scan O
showed O
an O
irregularly O
shaped O
space O
- O
occupying O
in O
front O
of O
the O
with O
plate O
calcifications O
and O
localized O
( O
figures O
2 O
and O
3 O
) O
. O

 O
Under O
the O
impression O
of O
perforated O
gastric O
tumor O
, O
emergent O
was O
performed O
. O

 O
An O
infiltrative O
between O
the O
and O
was O
noted O
during O
operation O
. O

 O
A O
sharp O
, O
bone O
- O
like O
and O
thick O
penetrating O
into O
the O
and O
was O
observed O
. O

 O
A O
submucosal O
about O
in O
size O
adherent O
to O
the O
was O
also O
noted O
( O
figures O
4 O
and O
5 O
) O
. O

 O
Distal O
subtotal O
and O
partial O
were O
performed O
. O

 O
The O
patient O
was O
operation O
uneventfully O
. O

 O
Microscopically O
, O
spindle O
- O
shaped O
with O
low O
( O
) O
were O
found O
. O

 O
of O
the O
demonstrated O
diffusely O
strong O
positive O
reactivity O
for O
, O
positive O
reactivity O
for O
, O
but O
negative O
reactivity O
for O
and O
. O

 O
The O
diagnosis O
of O
the O
tumor O
was O
established O
as O
GIST B
. O

 O
Due O
to O
the O
small O
size O
and O
the O
paucity O
of O
mitotic O
figures O
of O
the O
tumor O
located O
in O
the O
stomach O
, O
it O
was O
classified O
as O
very O
low O
risk[4 O
] O
. O

 O
Sporadic O
GIST O
was O
impressed O
due O
to O
nor O
other O
GIST O
presented O
in O
this O
patient O
. O

A O
woman O
in O
her O
to O
our O
30 O
 O
min O
after O
her O
expired O
with O
8/10 O
, O
substernal O
chest O
with O
concurrent O
and O
. O

 O
The O
patient O
's O
had O
an O
and O
was O
and O
subsequently O
. O

 O
had O
and O
. O

 O
The O
patient O
's O
medical O
history O
included O
and O
hypothyroidism O
. O

 O
She O
. O

 O
She O
. O

 O
Her O
included O
oral O
20 O
 O
mg O
and O
, O
both O
. O

 O
She O
. O

 O
On O
, O
the O
patient O
was O
, O
with O
a O
of O
, O
of O
, O
of O
and O
an O
of O
on O
. O

 O
On O
, O
she O
was O
in O
significant O
distress O
due O
to O
. O

 O
Her O
was O
and O
, O
with O
minimal O
crackles O
in O
, O
regular O
, O
2/6 O
systolic O
, O
no O
, O
elevated O
jugular O
vein O
of O
, O
strong O
peripheral O
pulses O
and O
no O
peripheral O
. O

 O
The O
was O
, O
, O
, O
, O
and O
the O
patient O
was O
and O
without O
focal O
. O

 O
The O
, O
and O
were O
. O

 O
The O
were O
with O
a O
of O
( O
normal O
range O
0.0150.045 O
 O
ng O
/ O
mL O
) O
, O
of O
( O
normal O
range O
26192 O
 O
U O
/ O
L O
) O
. O

 O
on O
revealed O
normal O
sinus O
rhythm O
with O
23 O
 O
mm O
ST O
segment O
elevations O
in O
leads O
V2 O
 O
V3 O
and O
Q O
waves O
in O
leads O
V1 O
 O
V3 O
, O
suggestive O
of O
anterior O
wall O
infarct O
( O
figure O
2 O
) O
. O

 O
An O
echocardiogram O
revealed O
left O
ventricular O
ejection O
fraction O
of O
3035 O
% O
with O
mild O
concentric O
left O
ventricular O
hypertrophy O
, O
akinesis O
of O
the O
apex O
and O
2/3 O
of O
the O
inferoseptum O
and O
apical O
inferior O
- O
anterior O
wall O
segments O
, O
suggesting O
ischaemic O
damage O
at O
the O
left O
anterior O
descending O
artery O
distribution O
versus O
takotsubo O
cardiomyopathy O
( O
figures O
3 O
and O
4 O
) O
. O

 O
The O
patient O
received O
aspirin O
162 O
 O
mg O
and O
prasugrel O
60 O
 O
mg O
, O
and O
was O
to O
the O
. O

 O
The O
showed O
non O
- O
obstructive O
coronary B
artery I
disease I
with O
luminal O
( O
figures O
5 O
and O
6 O
) O
. O

 O
The O
showed O
an O
of O
with O
of O
and O
of O
( O
figures O
7 O
and O
8) O
. O

 O
The O
patient O
remained O
and O
was O
started O
on O
oral O
, O
including O
and O
. O

 O
Her O
and O
resolved O
and O
she O
was O
of O
hospitalisation O
in O
stable O
. O

 O
A O
repeat O
showed O
resolution O
of O
her O
cardiomyopathy B
and O
an O
of O
, O
with O
normal O
. O

A O
was O
presented O
to O
the O
because O
of O
an O
history O
of O
recurrent O
( O
) O
, O
productive O
, O
and O
. O

 O
Prior O
to O
admission O
, O
he O
was O
diagnosed O
of O
pneumonia B
and O
treated O
with O
, O
, O
, O
and O
at O
. O

 O
However O
, O
no O
was O
observed O
. O

 O
Moreover O
, O
he O
was O
a O
with O
a O
. O

 O
However O
, O
were O
informed O
. O

 O
On O
, O
, O
; O
, O
; O
, O
; O
and O
, O
. O

 O
revealed O
, O
but O
no O
were O
heard O
, O
and O
was O
except O
moderate O
of O
. O

 O
showed O
, O
53.5 O
 O
mm O
 O
Hg O
, O
and O
. O

 O
Laboratory O
data O
( O
Table O
(Table1)1 O
) O
revealed O
of O
with O
, O
and O
elevated O
of O
5.16 O
 O
ng O
/ O
mL. O

 O
Chest O
, O
presence O
of O
, O
, O
, O
and O
, O
is O
noted O
( O
Fig.1A O
) O
. O

 O
Meanwhile O
, O
it O
was O
soon O
alerted O
in O
with O
presence O
of O
filamentous O
, O
gram O
- O
positive O
, O
weakly O
acid O
- O
fast O
, O
and O
beaded O
bacilli O
with O
possible O
diagnosis O
of O
Nocardia B
infection I
( O
Fig.1B O
, O
C O
) O
. O

 O
( O
) O
with O
noninvasive O
was O
promptly O
administered O
. O

 O
showed O
that O
were O
precisely O
determined O
to O
be O
by O
the O
method O
of O
on O
( O
Fig.1D O
) O
. O

 O
were O
thus O
modified O
to O
and O
in O
addition O
to O
in O
accordance O
with O
the O
sensitivity O
test O
. O

 O
However O
, O
the O
patient O
was O
not O
as O
expected O
and O
eventually O
from O
severe O
on O
the O
. O

The O
patient O
was O
a O
who O
with O
complaints O
of O
and O
a O
chronic O
. O

 O
He O
was O
a O
and O
had O
a O
that O
had O
been O
treated O
and O
cured O
. O

 O
A O
scan O
revealed O
multiple O
tiny O
in O
. O

 O
A O
thoracoscopic O
lung O
was O
taken O
from O
the O
. O

 O
The O
revealed O
a O
typical O
. O

 O
The O
had O
vesicular O
and O
grooved O
, O
and O
they O
formed O
small O
aggregations O
( O
Fig.1 O
) O
. O

 O
The O
were O
strongly O
positive O
for O
, O
, O
and O
. O

 O
There O
were O
infiltrations O
of O
and O
around O
the O
. O

 O
With O
performing O
additional O
, O
. O

 O
He O
, O
but O
he O
received O
no O
other O
specific O
treatment O
. O

 O
He O
was O
. O

 O
After O
this O
, O
a O
follow O
- O
up O
was O
performed O
and O
it O
showed O
a O
in O
the O
, O
in O
addition O
to O
the O
multiple O
tiny O
nodules O
in O
( O
Fig.2 O
) O
. O

 O
A O
needle O
specimen O
revealed O
the O
; O
therefore O
, O
a O
was O
performed O
. O

 O
Grossly O
, O
a O
was O
found O
( O
Fig.3 O
) O
, O
and O
there O
were O
a O
few O
around O
the O
. O

 O
, O
the O
were O
and O
they O
showed O
an O
. O

 O
The O
cytologic O
features O
of O
some O
of O
the O
were O
. O

 O
However O
, O
many O
showed O
overtly O
malignant O
such O
as O
and O
prominent O
( O
Fig.4 O
) O
, O
and O
multinucleated O
were O
also O
found O
. O

 O
There O
were O
numerous O
mitotic O
figures O
ranging O
from O
, O
and O
. O

 O
A O
few O
foci O
of O
remained O
. O

 O
, O
the O
tumor O
cells O
were O
for O
( O
Fig.5 O
) O
and O
; O
they O
were O
also O
for O
( O
Dako O
N1577 O
, O
Clone O
KPI O
) O
, O
and O
focally O
for O
( O
Fig.6 O
) O
, O
and O
they O
were O
for O
, O
, O
, O
and O
. O

 O
The O
ultrastructural O
analysis O
in O
the O
of O
the O
. O

 O
Now O
, O
at O
, O
the O
patient O
is O
with O
. O

A O
was O
diagnosed O
with O
pulmonary B
tuberculosis I
( O
PTB B
) O
in O
a O
routine O
medical O
and O
received O
that O
included O
( O
INH O
, O
300 O
 O
mg O
/ O
d O
) O
, O
( O
450 O
 O
mg O
/ O
d O
) O
, O
( O
EMB O
, O
750 O
 O
mg O
/ O
d O
) O
, O
and O
( O
, O
) O
. O

 O
After O
of O
continuous O
, O
he O
was O
to O
the O
with O
nasal O
and O
the O
( O
) O
count O
was O
( O
normal O
range O
, O
100300 O
 O
 O
 O
109 O
/ O
L O
) O
. O

 O
was O
cured O
after O
. O

 O
, O
he O
developed O
, O
, O
and O
, O
and O
required O
of O
and O
platelets O
in O
. O

 O
( O
) O
, O
he O
was O
to O
the O
due O
to O
the O
ineffective O
. O

 O
On O
, O
he O
presented O
with O
, O
mild O
on O
the O
, O
, O
( O
) O
and O
at O
the O
. O

 O
on O
indicated O
DIC B
: O
( O
17.8 O
 O
seconds O
; O
normal O
range O
, O
9.612.8 O
 O
seconds O
) O
, O
( O
1.53 O
; O
normal O
range O
, O
0.881.15 O
) O
, O
( O
1.13 O
 O
g O
/ O
L O
; O
normal O
range O
, O
2.04.0 O
 O
g O
/ O
L O
) O
, O
( O
23.45 O
 O
mg O
/ O
L O
; O
normal O
range O
, O
< O
0.55 O
 O
mg O
/ O
L O
) O
, O
( O
60.4 O
 O
mg O
/ O
L O
; O
normal O
range,<5 O
 O
mg O
/ O
L O
) O
, O
and O
( O
; O
normal O
range O
, O
100300 O
 O
 O
 O
109 O
/ O
L O
) O
. O

 O
Other O
abnormal O
data O
were O
as O
follows O
: O
( O
WBC O
, O
48.38 O
 O
 O
 O
109 O
/ O
L O
; O
normal O
range O
, O
3.59.5 O
) O
, O
( O
65 O
 O
g O
/ O
L O
; O
normal O
range O
, O
130175 O
 O
g O
/ O
L O
) O
, O
( O
30.8 O
umol O
/ O
L O
; O
normal O
range O
, O
5.028.0 O
 O
umol O
/ O
L O
) O
, O
( O
16.6 O
umol O
/ O
L O
; O
normal O
range O
, O
< O
8.8 O
umol O
/ O
L O
) O
, O
( O
75 O
U O
/ O
L O
; O
normal O
range O
, O
< O
40 O
U O
/ O
L O
) O
, O
( O
293 O
U O
/ O
L O
; O
normal O
range O
, O
< O
50 O
U O
/ O
L O
) O
, O
( O
380 O
U O
/ O
L O
; O
normal O
range O
, O
110220 O
 O
U O
/ O
L O
) O
, O
( O
13.01 O
mmol O
/ O
L O
; O
normal O
range O
, O
3.27.79 O
mmol O
/ O
L O
) O
, O
( O
16.70 O
 O
mg O
/ O
L O
; O
normal O
range O
, O
< O
5 O
 O
mg O
/ O
L O
) O
, O
( O
0.41 O
 O
g O
/ O
L O
; O
normal O
range O
, O
0.7851.520 O
 O
g O
/ O
L O
) O
, O
and O
( O
; O
normal O
range O
, O
0.1450.360 O
 O
g O
/ O
L O
) O
. O

 O
Routine O
showed O
, O
250 O
Cell O
/ O
uL O
, O
2 O
 O
g O
/ O
L O
, O
and O
70 O
umol O
/ O
L. O

 O
Routine O
showed O
4+/HP O
, O
1+/HP O
, O
( O
) O
. O

 O
result O
was O
. O

 O
Real O
- O
time O
polymerase O
chain O
reaction O
on O
was O
. O

 O
of O
a O
was O
. O

 O
Chest O
( O
) O
on O
( O
) O
( O
Fig.1 O
) O
showed O
on O
the O
, O
left O
pleural B
effusion I
, O
and O
pericardial B
effusion I
, O
accompanied O
by O
of O
. O

 O
Abdominal O
showed O
a O
small O
amount O
of O
adjacent O
to O
the O
and O
. O

 O
were O
negative O
for O
acute O
or O
chronic O
viral B
hepatitis I
, O
HIV B
, O
, O
and O
autoimmune B
hepatitis I
. O

 O
Peripheral O
blood O
were O
. O

 O
Bone O
marrow O
were O
also O
. O

 O
The O
were O
discontinued O
immediately O
after O
. O

 O
Besides O
, O
he O
was O
initiated O
with O
infusion O
of O
fresh O
- O
frozen O
plasma O
, O
platelet O
, O
packed O
red O
blood O
cells O
, O
intravenous O
immune O
globulin O
, O
recombinant O
human O
thrombopoietin O
, O
omeprazole O
, O
and O
polyene O
phosphatidylcholine O
as O
well O
as O
. O

 O
( O
) O
, O
the O
patient O
started O
a O
therapy O
consisting O
of O
, O
, O
and O
, O
while O
he O
had O
no O
further O
active O
. O

 O
( O
) O
, O
the O
counts O
had O
gradually O
. O

 O
( O
, O
) O
was O
administered O
on O
( O
) O
, O
while O
his O
and O
counts O
returned O
to O
. O

 O
The O
main O
are O
summarized O
in O
Table O
1 O
. O

 O
( O
) O
, O
reviewed O
chest O
( O
Fig.1 O
) O
indicated O
the O
, O
, O
and O
pericardial B
effusion I
were O
absorbed O
well O
. O

 O
Almost O
, O
the O
patient O
and O
with O
( O
) O
, O
( O
) O
, O
( O
500 O
 O
mg O
/ O
d O
) O
, O
and O
( O
, O
) O
. O

 O
There O
was O
no O
recurrence O
of O
DIC B
or O
during O
of O
. O

 O
Unfortunately O
, O
the O
patient O
refused O
a O
follow O
- O
up O
chest O
after O
his O
. O

 O
Table O
2 O
shows O
the O
timeline O
of O
this O
case O
. O

A O
patient O
was O
to O
our O
hospital O
on O
because O
of O
frequent O
episodes O
of O
for O
. O

 O
In O
the O
, O
the O
patient O
had O
frequent O
but O
less O
severe O
episodes O
of O
, O
which O
typically O
ensued O
following O
an O
upper O
respiratory O
tract O
infection B
. O

 O
and O
failed O
to O
identify O
an O
apparent O
. O

 O
CT O
chest O
scan O
revealed O
no O
. O

 O
The O
most O
recent O
episode O
occurred O
after O
an O
upper O
respiratory O
tract O
infection O
. O

 O
The O
patient O
coughed O
up O
as O
much O
as O
about O
500 O
 O
mL O
of O
fresh O
blood O
in O
an O
episode O
of O
, O
which O
was O
alleviated O
by O
. O

 O
The O
patient O
. O

 O
Diagnostic O
workup O
revealed O
no O
evidence O
of O
coagulopathy B
. O

 O
Upon O
, O
revealed O
signs O
of O
and O
reduced O
. O

 O
showed O
a O
1 O
- O
cm O
at O
the O
to O
the O
. O

 O
were O
observed O
running O
in O
the O
( O
Fig.1 O
) O
. O

 O
was O
performed O
, O
demonstrating O
an O
artery O
extending O
into O
the O
submucosa O
from O
the O
descending O
aorta O
( O
Fig.2 O
) O
. O

 O
A O
diagnosis O
of O
of O
the O
was O
entertained O
. O

 O
Since O
the O
blood O
vessel O
was O
considered O
to O
be O
the O
culprit O
of O
hemoptysis O
, O
selective O
was O
performed O
. O

 O
No O
fresh O
episode O
of O
acute O
was O
observed O
and O
the O
patient O
was O
still O
being O
followed O
up O
at O
. O

 O
This O
study O
was O
approved O
by O
Ethics O
Committee O
of O
Shanghai O
Jiao O
Tong O
University O
Affiliated O
Sixth O
People O
's O
Hospital O
, O
and O
also O
got O
an O
informed O
written O
consent O
from O
the O
patient O
. O

A O
who O
had O
been O
diagnosed O
with O
, O
who O
had O
severe O
diabetic O
neuropathy O
and O
diabetic O
- O
ESRD O
complained O
of O
respiratory O
distress O
and O
sudden O
chest O
pain O
. O

 O
On O
the O
of O
treatment O
, O
he O
the O
. O

 O
A O
revealed O
that O
his O
body O
temperature O
was O
35.4 O
 O
C O
, O
his O
heart O
rate O
was O
90 O
beats O
/ O
min O
with O
a O
regular O
rhythm O
; O
and O
his O
blood O
pressure O
was O
130/77 O
mmHg O
. O

 O
A O
physical O
examination O
revealed O
coarse O
crackles O
on O
bilateral O
lung O
auscultation O
. O

 O
The O
laboratory O
data O
showed O
a O
WBC O
count O
of O
8,800 O
/ O
L O
with O
a O
shift O
to O
the O
left O
( O
neutrophils O
82 O
% O
) O
, O
Hb O
10.2 O
g O
/ O
dL O
, O
blood O
urea O
nitrogen O
( O
BUN O
) O
82.2 O
mg O
/ O
dL O
, O
creatinine O
( O
Cre O
) O
6.50 O
mg O
/ O
dL O
, O
HbA1c O
5.9 O
% O
, O
creatine O
kinase O
( O
CK O
) O
189 O
IU O
/ O
L O
, O
C O
- O
reactive O
protein O
( O
CRP O
) O
8.51 O
mg O
/ O
dL O
, O
brain O
- O
type O
natriuretic O
peptide O
( O
BNP O
) O
127.4 O
pg O
/ O
mL. O

 O
A O
chest O
radiograph O
revealed O
perihilar O
consolidations O
and O
air O
bronchograms O
( O
Fig.1 O
) O
. O

 O
An O
electrocardiogram O
revealed O
ST O
- O
segment O
elevation O
and O
poor O
R O
- O
wave O
progression O
in O
leads O
V1 O
- O
V3 O
, O
and O
echocardiography O
revealed O
apical O
and O
ventricular O
asynergy O
. O

 O
The O
patient O
was O
therefore O
diagnosed O
with O
acute O
myocardial O
infarction O
and O
congestive O
heart O
failure O
. O

 O
Coronary O
angiography O
was O
performed O
, O
revealing O
severe O
angiostenosis O
in O
the O
septal O
branch O
. O

 O
PCI O
was O
therefore O
performed O
. O

 O
The O
patient O
required O
continuous O
maintenance O
dialysis O
. O

 O
On O
the O
following O
day O
, O
the O
patient O
went O
into O
cardiorespiratory O
arrest O
and O
cardiopulmonary O
resuscitation O
was O
performed O
, O
followed O
by O
mechanical O
ventilation O
. O

 O
On O
day O
8 O
, O
ventilator O
assistance O
was O
discontinued O
. O

 O
However O
, O
the O
patient O
produced O
an O
increasing O
volume O
of O
sputum O
, O
which O
began O
to O
appear O
purulent O
. O

 O
Pseudomonas O
aeruginosa O
was O
identified O
from O
a O
sputum O
culture O
, O
and O
tazobactam O
/ O
piperacillin O
( O
TAZ O
/ O
PIPC O
) O
( O
4.5 O
g O
q12h O
) O
was O
administered O
. O

 O
Despite O
this O
therapy O
, O
the O
patient O
's O
respiratory O
condition O
worsened O
and O
a O
chest O
computed O
tomography O
( O
CT O
) O
scan O
on O
day O
15 O
revealed O
bilateral O
perihilar O
opacities O
, O
pleural O
effusion O
, O
and O
atelectasis.(Fig.2 O
) O
. O

 O
We O
suspected O
the O
development O
of O
complications O
such O
as O
microbial O
substitution O
, O
pneumomycosis O
and O
thus O
performed O
sputum O
culturing O
and O
serum O
fungal O
antigen O
tests O
. O

 O
The O
administration O
of O
TAZ O
/ O
PIPC O
was O
changed O
to O
meropenem O
( O
0.5 O
g O
/ O
day O
) O
. O

 O
On O
day O
16 O
, O
the O
patient O
's O
serum O
tested O
positive O
for O
Cryptococcus O
antigen O
. O

 O
On O
day O
21 O
, O
cryptococcal O
bodies O
were O
identified O
in O
two O
sets O
of O
blood O
cultures O
and O
liposomal O
amphotericin O
B O
( O
L O
- O
AMB O
) O
( O
3 O
mg O
/ O
kg O
/ O
day O
) O
was O
administered O
. O

 O
On O
day O
23 O
, O
cryptococcal O
bodies O
were O
identified O
in O
the O
sputum O
, O
cerebrospinal O
fluid O
, O
and O
bilateral O
pleural O
effusion O
( O
Fig.3 O
) O
. O

 O
The O
patient O
was O
therefore O
diagnosed O
with O
disseminated O
cryptococcosis O
. O

 O
On O
day O
25 O
, O
brain O
CT O
revealed O
the O
absence O
of O
intracranial O
hypertension O
and O
a O
brain O
abscess O
. O

 O
The O
patient O
was O
not O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
. O

 O
The O
administration O
of O
L O
- O
AMB O
( O
3 O
mg O
/ O
kg O
/ O
day O
) O
was O
continued O
. O

 O
On O
day O
31 O
, O
chest O
CT O
revealed O
a O
solitary O
nodule O
in O
the O
left O
lingular O
segment O
for O
the O
first O
time O
, O
which O
was O
suspected O
to O
be O
a O
pulmonary O
cryptococcus O
lesion O
( O
Fig.4a O
) O
. O

 O
After O
several O
days O
, O
all O
of O
the O
sputum O
, O
blood O
, O
bilateral O
pleural O
effusion O
, O
and O
cerebrospinal O
fluid O
cultures O
tested O
negative O
. O

 O
On O
day O
52 O
, O
chest O
CT O
revealed O
another O
lung O
nodule O
in O
the O
right O
pulmonary O
apical O
region O
. O

 O
These O
nodules O
gradually O
decreased O
in O
size O
until O
day O
79 O
( O
Fig.4b O
and O
c O
) O
. O

 O
Although O
L O
- O
AMB O
was O
considered O
effective O
, O
the O
C O
- O
reactive O
protein O
level O
remained O
elevated O
and O
the O
bilateral O
pleural O
effusion O
continuously O
increased O
. O

 O
The O
patient O
lost O
consciousness O
because O
of O
decreased O
vital O
capacity O
with O
increasing O
bilateral O
pleural O
effusion O
and O
was O
diagnosed O
with O
CO2 O
narcosis O
. O

 O
The O
patient O
's O
general O
condition O
deteriorated O
. O

 O
On O
day O
87 O
, O
ventricular O
fibrillation O
occurred O
and O
the O
patient O
. O

 O
was O
not O
performed O
. O

 O
At O
a O
later O
date O
, O
the O
Cryptococcus O
isolate O
was O
identified O
and O
classified O
as O
Cryptococcus O
neoformans O
var O
. O
grubii O
( O
serotype O
A O
) O
by O
a O
. O

Our O
patient O
was O
a O
. O

 O
, O
he O
with O
a O
clinically O
evident O
and O
was O
for O
. O

 O
Initial O
tests O
revealed O
, O
, O
and O
. O

 O
A O
bone O
marrow O
revealed O
the O
presence O
of O
, O
which O
led O
to O
suspicion O
of O
lysosomal B
storage I
disease I
. O

 O
revealed O
elevated O
level O
of O
( O
[ O
normal O
range O
57 O
IU O
/ O
L O
] O
) O
and O
( O
[ O
normal O
range O
5.941.0 O
nmol O
/ O
mg O
protein O
] O
) O
, O
as O
well O
as O
reduced O
( O
[ O
normal O
range O
4.518.0 O
nmol O
/ O
mg O
/ O
protein O
] O
) O
. O

 O
showed O
homozygous O
L444P O
mutations O
in O
the O
GBA O
gene O
( O
OMIM O
reference O
606463 O
) O
, O
confirming O
the O
diagnosis O
of O
chronic O
NGD B
. O

 O
The O
patient O
began O
at O
a O
dosage O
of O
. O

 O
Thereafter O
, O
when O
the O
patient O
reached O
the O
, O
we O
decided O
to O
combine O
with O
with O
. O

 O
This O
clinical O
decision O
was O
approved O
by O
our O
institution O
s O
ethics O
committee O
, O
and O
informed O
consent O
was O
obtained O
from O
the O
patient O
s O
parents O
before O
commencing O
combination O
therapy O
. O

 O
The O
dose O
of O
was O
and O
was O
uptitrated O
during O
the O
first O
4 O
weeks O
with O
the O
following O
scheme O
: O
one O
- O
third O
of O
target O
dose O
during O
weeks O
1 O
and O
2 O
, O
two O
- O
thirds O
of O
target O
dose O
during O
weeks O
3 O
and O
4 O
, O
and O
target O
dose O
( O
) O
. O

 O
From O
2 O
weeks O
before O
starting O
miglustat O
therapy O
, O
the O
patient O
also O
followed O
specific O
, O
, O
especially O
foods O
high O
in O
disaccharides O
, O
such O
as O
sucrose O
and O
maltose O
, O
to O
ensure O
acceptable O
gastrointestinal O
tolerability O
. O

 O
He O
experienced O
mild O
episodes O
of O
after O
commencing O
therapy O
, O
which O
. O

 O
From O
the O
start O
of O
ERT O
/ O
miglustat O
combination O
treatment O
, O
we O
observed O
a O
reduction O
in O
and O
a O
gradual O
normalization O
of O
and O
( O
Table O
1 O
) O
. O

 O
was O
evaluated O
at O
the O
time O
of O
diagnosis O
and O
then O
approximately O
during O
. O

 O
Values O
showed O
an O
after O
the O
start O
of O
ERT O
, O
with O
a O
further O
, O
substantial O
, O
and O
treatment O
( O
Fig.1 O
) O
. O

 O
The O
patient O
has O
been O
, O
which O
specify O
a O
complete O
, O
clinical O
, O
and O
[ O
10 O
] O
. O

 O
After O
of O
and O
, O
the O
patient O
did O
not O
show O
any O
signs O
of O
. O

 O
As O
of O
, O
he O
had O
not O
displayed O
any O
and O
had O
demonstrated O
and O
. O

 O
He O
showed O
good O
, O
normal O
with O
a O
slight O
in O
his O
, O
and O
a O
negative O
. O

 O
His O
was O
. O

 O
In O
particular O
, O
revealed O
no O
evidence O
of O
and O
normal O
. O

 O
The O
patient O
s O
were O
also O
. O

 O
In O
addition O
, O
he O
has O
not O
demonstrated O
any O
, O
and O
he O
has O
regularly O
with O
. O

A O
reported O
persistent O
back O
for O
. O

 O
The O
would O
be O
severe O
after O
or O
and O
would O
be O
slightly O
relieve O
after O
taking O
. O

 O
The O
patient O
described O
no O
or O
in O
her O
. O

 O
She O
also O
described O
no O
bowel O
or O
bladder O
. O

 O
The O
patient O
reported O
past O
medical O
history O
of O
. O

 O
demonstrated O
kyphosis B
of O
the O
and O
lumbar O
vertebra O
bend O
forward O
and O
backward O
straight O
activities O
were O
limited O
. O

 O
There O
is O
obvious O
rap O
in O
about O
T12 O
level O
. O

 O
The O
patient O
's O
general O
medical O
examination O
was O
unremarkable O
in O
upper O
and O
lower O
extremity O
motor O
, O
stretch O
reflex O
, O
and O
sensory O
examinations O
. O

 O
, O
( O
) O
, O
and O
( O
) O
exams O
were O
performed O
after O
the O
patient O
in O
( O
Fig.1 O
) O
. O

 O
The O
lateral O
showed O
T12 O
fracture B
with O
40 O
 O
kyphotic O
. O

 O
showed O
an O
. O

 O
Sagittal O
T1 O
- O
weighted O
showed O
a O
decreased O
signal O
intravertebral O
vacuum O
cleft O
and O
posterior O
cortex O
breakage O
with O
in O
. O

 O
Sagittal O
T2 O
- O
weighted O
showed O
an O
increased O
signal O
in O
the O
. O

 O
The O
patient O
was O
diagnosed O
with O
Kmmell B
disease I
( O
Stage O
III).[9 O
] O

 O
The O
was O
performed O
under O
and O
. O

 O
A O
standard O
of O
the O
was O
given O
, O
were O
inserted O
in O
target O
, O
, O
, O
and O
under O
C O
- O
arm O
guidance.[10 O
] O
The O
screws O
were O
. O

 O
was O
performed O
to O
decompress O
and O
fully O
visualize O
the O
spinal O
cord.[10 O
] O
Careful O
was O
carried O
out O
on O
the O
to O
exposure O
the O
until O
the O
anterior O
aspect O
was O
reached O
. O

 O
The O
right O
side O
pedicle O
and O
articular O
process O
of O
the O
T12 O
vertebral O
body O
were O
. O

 O
T11 O
/ O
T12 O
and O
T12 O
/ O
L1 O
intervertebral O
disks O
were O
also O
. O

 O
Then O
, O
the O
temporary O
stabilizing O
was O
replaced O
by O
. O

 O
Autologous O
and O
were O
placed O
in O
the O
. O

 O
Another O
was O
connected O
on O
the O
. O

 O
Adequate O
was O
ensured O
and O
wound O
was O
thoroughly O
. O

 O
Drainage O
tube O
was O
inserted O
and O
the O
surgical O
wound O
was O
closed O
layer O
- O
by O
- O
layer.[10 O
] O
Time O
from O
skin O
incision O
to O
completion O
of O
wound O
closure O
lasted O
, O
and O
estimated O
blood B
loss I
totaled O
600 O
 O
mL. O

 O
Postoperatively O
, O
the O
patient O
was O
given O
preventive O
treatment O
for O
, O
for O
, O
and O
therapy O
for O
. O

 O
The O
was O
removed O
at O
postoperative O
when O
was O
. O

 O
Patient O
was O
of O
bed O
with O
a O
custom O
- O
made O
plastic O
at O
operation O
. O

 O
The O
plastic O
was O
kept O
for O
. O

 O
The O
patient O
was O
of O
at O
operation O
when O
had O
been O
removed O
. O

 O
were O
conducted O
using O
the O
( O
) O
. O

 O
VAS O
for O
preoperative O
, O
1 O
week O
after O
operation O
, O
and O
1 O
year O
after O
operation O
were O
, O
, O
and O
, O
respectively O
, O
which O
demonstrated O
significant O
improvement O
. O

 O
The O
patient O
resumed O
and O
at O
operation O
. O

 O
Kyphotic O
for O
preoperative O
, O
operation O
, O
and O
operation O
were O
, O
, O
and O
, O
respectively O
, O
which O
demonstrated O
significant O
( O
Fig.2 O
) O
. O

A O
infant O
with O
a O
and O
was O
admitted O
to O
our O
centre O
for O
the O
. O

 O
We O
received O
an O
patient O
, O
mechanically O
in O
a O
, O
with O
a O
( O
FiO2 O
) O
( O
, O
, O
) O
. O

 O
A O
chest O
of O
the O
was O
performed O
on O
( O
figure O
1A O
) O
, O
and O
the O
first O
surgery O
( O
figure O
1B O
) O
, O
showing O
improvement O
of O
the O
bilateral O
posterior O
atelectasis B
in O
the O
. O

 O
Owing O
to O
the O
difficulty O
of O
progressing O
in O
the O
weaning O
process O
from O
mechanical O
ventilation O
after O
the O
VEPTRs O
were O
implanted O
to O
expand O
the O
thorax O
, O
a O
bronchoscopy O
was O
performed O
, O
showing O
bronchomalacia O
predominantly O
in O
both O
upper O
lobar O
bronchi O
. O

 O
As O
prolonged O
mechanical O
ventilation O
was O
expected O
, O
a O
tracheostomy O
was O
previously O
performed O
. O

 O
After O
an O
initial O
CT O
scan O
( O
figure O
2A O
) O
, O
a O
follow O
- O
up O
CT O
scan O
( O
figure O
2B O
) O
a O
month O
after O
the O
surgery O
showed O
a O
resolution O
of O
the O
posterior O
- O
basal O
atelectasis O
, O
coinciding O
with O
a O
decrease O
of O
FiO2 O
to O
0.21 O
. O

 O
Postoperatively O
, O
the O
patient O
was O
on O
the O
Servo O
- O
i O
ventilator O
in O
a O
volume O
- O
controlled O
mode O
and O
needed O
variable O
PIPs O
between O
25 O
and O
45 O
 O
cm O
 O
H2O O
and O
PEEP O
values O
of O
711 O
 O
cm O
 O
H2O. O

 O
During O
the O
attempts O
to O
wean O
the O
patient O
off O
the O
ventilator O
in O
the O
following O
months O
, O
he O
was O
unable O
to O
activate O
the O
inspiratory O
flow O
trigger O
and O
required O
significant O
sedoanalgesia O
to O
adapt O
to O
the O
ventilator O
due O
to O
repeated O
episodes O
of O
desaturation O
, O
on O
some O
occasions O
with O
bradycardia O
, O
associated O
to O
bronchial O
collapse O
. O

 O
He O
continued O
to O
have O
asynchrony O
which O
required O
boluses O
of O
sedation O
in O
addition O
to O
existing O
medications O
. O

 O
He O
initially O
received O
fentanyl O
and O
midazolam O
through O
a O
continuous O
infusion O
pump O
with O
progressive O
increase O
in O
the O
doses O
as O
well O
as O
continuous O
cisatracurium O
as O
a O
muscular O
relaxant O
to O
adapt O
to O
mechanical O
ventilation O
( O
figure O
3 O
) O
. O

 O
As O
clinical O
stabilisation O
was O
achieved O
, O
the O
muscular O
relaxant O
was O
withdrawn O
and O
a O
progressive O
decrease O
of O
sedation O
was O
initiated O
along O
with O
a O
change O
in O
the O
drug O
regimen O
. O

 O
During O
this O
period O
, O
the O
patient O
developed O
an O
ocular O
flutter O
which O
was O
attributed O
to O
a O
pharmacological O
cause O
after O
neurological O
alterations O
were O
ruled O
out O
with O
normal O
EEG O
, O
ophthalmoscopy O
, O
metabolic O
workup O
and O
cranial O
MRI O
. O

 O
At O
5 O
 O
months O
of O
age O
, O
the O
NAVA O
mode O
started O
to O
improve O
the O
patient O
's O
adaptation O
to O
the O
ventilator O
through O
the O
use O
of O
a O
neural O
trigger O
. O

 O
The O
NAVA O
catheter O
additionally O
costs O
around O
 O
200 O
per O
catheter O
; O
according O
to O
the O
manufacturer O
it O
should O
be O
changed O
every O
5 O
 O
days O
. O

 O
It O
was O
required O
for O
7 O
 O
months O
; O
nevertheless O
the O
catheters O
were O
changed O
every O
15 O
 O
days O
without O
observing O
a O
deterioration O
of O
the O
Edi O
signal O
. O

 O
According O
to O
the O
literature O
, O
Jarcho O
- O
Levin O
syndrome O
does O
not O
appear O
with O
mental O
retardation O
and O
life O
expectancy O
is O
pretty O
long O
, O
so O
ethically O
, O
we O
considered O
that O
this O
patient O
should O
have O
an O
opportunity O
to O
overcome O
his O
thoracic O
insufficiency O
if O
it O
were O
technically O
possible O
. O

 O
Tachypnoea O
was O
initially O
observed O
with O
a O
RR O
of O
55 O
without O
other O
signs O
of O
increase O
in O
his O
work O
of O
breathing O
and O
his O
RR O
eventually O
returned O
to O
normal O
for O
his O
age O
( O
40 O
) O
over O
the O
next O
few O
days O
. O

 O
The O
synchrony O
achieved O
with O
the O
ventilator O
allowed O
a O
progressive O
decrease O
of O
the O
sedoanalgesia O
he O
received O
until O
it O
was O
completely O
withdrawn O
in O
10 O
 O
days O
; O
and O
the O
need O
for O
extra O
boluses O
of O
sedation O
was O
reduced O
to O
zero O
. O

 O
Concurrently O
to O
the O
reduction O
of O
sedation O
, O
his O
ocular O
flutter O
disappeared O
and O
he O
showed O
significant O
progress O
in O
his O
psychomotor O
development O
. O

 O
The O
settings O
used O
were O
: O
NAVA O
level O
of O
1 O
 O
cm O
 O
H2O/V O
, O
PEEP O
11 O
 O
cm O
 O
H2O O
, O
Edi O
trigger O
0.5 O
 O
V. O

 O
The O
patient O
had O
tidal O
volumes O
( O
Vt O
) O
of O
67 O
 O
mL O
/ O
kg O
( O
figure O
3 O
) O
. O

 O
After O
10 O
 O
days O
on O
the O
NAVA O
mode O
, O
he O
did O
not O
require O
any O
type O
of O
sedation O
and O
the O
sporadic O
episodes O
of O
bronchial O
collapse O
were O
resolved O
with O
a O
quick O
increase O
of O
PEEP O
to O
20 O
 O
cm O
 O
H2O O
or O
manual O
ventilation O
with O
the O
self O
- O
inflating O
bag O
. O

 O
Once O
he O
was O
stabilised O
on O
the O
NAVA O
mode O
, O
his O
PIPs O
oscillated O
between O
15 O
and O
45 O
 O
cm O
 O
H2O O
with O
a O
NAVA O
level O
of O
0.4 O
and O
Edi O
peaks O
between O
15 O
and O
100 O
 O
V. O

 O
A O
posterior O
pulmonary O
CT O
scan O
performed O
2 O
 O
months O
after O
the O
first O
surgery O
, O
1 O
 O
month O
after O
starting O
NAVA O
and O
prior O
to O
the O
first O
thoracic O
expansion O
, O
showed O
a O
significant O
reduction O
in O
the O
posterobasal O
atelectases O
previously O
observed O
( O
figure O
2B O
) O
. O

 O
When O
he O
turned O
1 O
 O
year O
old O
, O
after O
several O
attempts O
with O
different O
devices O
Trilogy O
100 O
( O
Philips O
) O
, O
Astral O
150 O
( O
ResMed O
) O
, O
the O
patient O
finally O
tolerated O
mechanical O
ventilation O
with O
a O
home O
ventilator O
( O
Monnal O
T-50 O
, O
Air O
Liquide O
) O
in O
a O
volume O
assisted O
/ O
controlled O
mode O
with O
the O
following O
settings O
: O
Vt O
80 O
 O
mL O
( O
9 O
 O
mL O
/ O
kg O
) O
, O
PEEP O
10 O
 O
cm O
 O
H2O O
, O
flow O
trigger O
0.5 O
 O
L O
/ O
min O
. O

 O
His O
PIPs O
were O
around O
30 O
 O
cm O
 O
H2O. O

 O
He O
did O
not O
tolerate O
a O
decrease O
of O
PEEP O
below O
9 O
 O
cm O
 O
H2O O
or O
short O
disconnections O
from O
the O
ventilator O
. O

 O
Currently O
, O
the O
patient O
is O
19 O
 O
months O
old O
, O
is O
and O
his O
seems O
to O
be O
. O

A O
with O
presented O
with O
a O
sudden O
onset O
of O
requiring O
and O
. O

 O
She O
denied O
preceding O
symptoms O
of O
chest O
, O
, O
or O
infection B
. O

 O
The O
patient O
was O
and O
, O
with O
a O
sinus O
of O
. O

 O
The O
was O
remarkable O
for O
an O
elevated O
at O
the O
, O
a O
left O
- O
sided O
and O
bibasilar O
in O
fields O
. O

 O
The O
, O
and O
were O
within O
normal O
limits O
. O

 O
An O
initial O
revealed O
in O
, O
suggestive O
of O
anterolateral B
ischemia I
( O
Figure O
1 O
) O
. O

 O
A O
chest O
demonstrated O
pulmonary O
consistent O
with O
a O
diagnosis O
of O
pulmonary B
edema I
( O
Figure O
2 O
) O
. O

 O
An O
revealed O
normal O
, O
normal O
and O
mild O
diastolic B
dysfunction I
with O
an O
of O
less O
than O
1 O
, O
prolonged O
( O
) O
and O
a O
reduced O
early O
diastolic O
annular O
velocity O
of O
the O
. O

 O
Following O
aggressive O
and O
requiring O
minimal O
, O
the O
patient O
was O
her O
initial O
presentation O
. O

 O
of O
extubation O
, O
the O
patient O
developed O
recurrent O
pulmonary B
edema I
clinically O
and O
, O
requiring O
. O

 O
was O
performed O
and O
revealed O
. O

 O
of O
the O
coronary O
care O
unit O
, O
the O
patient O
failed O
a O
repeat O
attempt O
at O
. O

 O
A O
scan O
revealed O
a O
4 O
cm O
 O
9 O
cm O
multinodular O
goiter B
extending O
into O
the O
and O
suspected O
associated O
tracheal O
( O
Figure O
3 O
) O
. O

 O
With O
a O
diagnosis O
of O
NPPE B
secondary O
to O
an O
enlarged O
goiter B
, O
the O
patient O
underwent O
for O
a O
. O

 O
Intraoperative O
revealed O
tracheal O
stenosis O
of O
. O

 O
The O
was O
uncomplicated O
, O
and O
, O
the O
patient O
to O
her O
without O
subjective O
. O

A O
with O
a O
history O
of O
metastatic O
mucinous O
appendiceal O
adenocarcinoma O
presents O
for O
evaluation O
of O
a O
desquamating O
rash O
on O
his O
face O
that O
has O
spread O
to O
his O
scalp O
, O
inguinal O
region O
, O
and O
perineum O
over O
the O
past O
4 O
months O
( O
Figure O
1 O
) O
. O

 O
The O
rash O
has O
been O
accompanied O
by O
diffuse O
alopecia O
of O
the O
face O
, O
scalp O
, O
axilla O
, O
and O
groin O
. O

 O
There O
was O
no O
improvement O
in O
the O
rash O
despite O
multiple O
rounds O
of O
oral O
fluconazole O
, O
topical O
antibiotic O
ointment O
, O
and O
intravenous O
antibiotics O
. O

 O
Prior O
to O
the O
development O
of O
his O
rash O
, O
he O
completed O
neoadjuvant O
chemotherapy O
followed O
by O
surgical O
resection O
. O

 O
He O
underwent O
colostomy O
after O
he O
failed O
surgical O
correction O
for O
an O
enterocutaneous O
fistula O
, O
and O
he O
has O
required O
total O
parenteral O
nutrition O
( O
TPN O
) O
for O
the O
past O
year O
. O

 O
He O
did O
not O
notice O
any O
significant O
changes O
in O
ostomy O
output O
during O
this O
time O
. O

 O
Dermatological O
examination O
reveals O
widespread O
erythematous O
plaques O
on O
the O
face O
, O
scalp O
, O
and O
medial O
aspect O
of O
thighs O
bilaterally O
and O
scattered O
papules O
with O
scaling O
on O
face O
, O
scalp O
, O
chest O
, O
and O
back O
. O

 O
Diffuse O
, O
non O
- O
scarring O
alopecia O
is O
present O
on O
the O
face O
, O
scalp O
, O
axillae O
, O
and O
groin O
. O

 O
The O
patient O
had O
acquired O
AE O
, O
a O
rare O
dermatologic O
condition O
caused O
by O
zinc O
deficiency O
. O

 O
This O
patient O
developed O
acquired O
zinc O
deficiency O
in O
the O
setting O
of O
inadequate O
zinc O
supplementation O
in O
TPN O
. O

 O
The O
patient O
had O
not O
received O
trace O
elements O
for O
approximately O
one O
year O
due O
to O
a O
national O
shortage O
. O

 O
The O
key O
to O
the O
correct O
diagnosis O
of O
acquired O
AE O
is O
the O
combination O
of O
desquamating O
rash O
coupled O
with O
alopecia O
in O
the O
setting O
of O
chronic O
supplemental O
alimentation O
. O

 O
Although O
it O
is O
reasonable O
to O
consider O
a O
skin O
biopsy O
, O
a O
skin O
biopsy O
would O
not O
definitively O
establish O
the O
diagnosis O
. O

 O
A O
paraneoplastic O
panel O
could O
be O
considered O
, O
but O
it O
would O
delay O
diagnosis O
, O
and O
the O
presentation O
is O
most O
consistent O
with O
nutritional O
deficiency O
. O

 O
It O
is O
not O
appropriate O
to O
start O
a O
topical O
steroid O
cream O
until O
a O
diagnosis O
is O
determined O
. O

 O
The O
patient O
had O
a O
level O
of O
( O
normal O
range O
56 O
- O
134 O
ug O
/ O
dL O
) O
. O

 O
He O
received O
in O
his O
TPN O
, O
and O
within O
one O
month O
, O
the O
patient O
had O
complete O
resolution O
of O
rash O
and O
fatigue O
, O
and O
gradual O
return O
of O
hair O
growth O
( O
Figure O
2 O
) O
. O

 O
Repeat O
zinc O
level O
following O
supplementation O
was O
90 O
ug O
/ O
dL. O

 O
Although O
the O
patient O
recovered O
from O
his O
zinc O
deficiency O
, O
he O
later O
. O

The O
patient O
is O
a O
who O
had O
noted O
a O
rapidly O
enlarging O
on O
the O
in O
. O

 O
She O
underwent O
a O
total O
and O
central O
neck O
, O
which O
revealed O
a O
anaplastic O
thyroid B
cancer I
arising O
in O
a O
background O
of O
an O
oncocytic O
variant O
of O
poorly O
differentiated O
thyroid B
cancer I
( O
Fig.1A O
, O
and O
Fig O
. O
S1 O
in O
Supplementary O
Appendix O
1 O
, O
available O
with O
the O
full O
text O
of O
this O
article O
at O
NEJM.org O
) O
. O

 O
Resection O
margins O
were O
positive O
, O
and O
3 O
of O
12 O
lymph O
nodes O
were O
. O

 O
At O
surgery O
, O
the O
serum O
level O
was O
, O
with O
undetectable O
. O

 O
The O
patient O
received O
concurrent O
and O
weekly O
and O
. O

 O
The O
serum O
level O
at O
the O
completion O
of O
chemotherapy O
and O
radiation O
therapy O
was O
. O

 O
Restaging O
obtained O
revealed O
a O
new O
, O
right O
- O
sided O
hilar O
( O
Fig.1C O
) O
, O
and O
the O
patient O
enrolled O
in O
a O
phase O
2 O
clinical O
trial O
of O
, O
which O
was O
administered O
at O
a O
dose O
of O
. O

 O
, O
follow O
- O
up O
showed O
that O
the O
had O
greatly O
( O
from O
to O
) O
( O
Fig.1D O
) O
. O

 O
After O
of O
a O
sustained O
to O
, O
revealed O
progressive B
disease I
( O
Fig.1E O
) O
. O

 O
The O
patient O
underwent O
a O
with O
of O
an O
, O
which O
contained O
metastatic O
anaplastic O
thyroid B
cancer I
( O
Fig.1B O
, O
and O
Fig O
. O
S1 O
in O
Supplementary O
Appendix O
1 O
) O
. O

 O
Whole O
- O
exome O
was O
performed O
on O
samples O
of O
the O
as O
well O
as O
on O
a O
. O

A O
was O
to O
our O
for O
the O
evaluation O
of O
for O
9 O
months O
. O

 O
He O
had O
associated O
symptoms O
of O
and O
but O
denied O
, O
, O
, O
and O
. O

 O
He O
was O
an O
and O
consumed O
alcohol O
for O
30 O
years O
. O

 O
revealed O
no O
peripheral O
, O
, O
, O
or O
in O
the O
. O

 O
were O
: O
negative O
, O
negative O
, O
and O
. O

 O
Test O
for O
was O
. O

 O
Chest O
( O
) O
was O
notable O
for O
a O
huge O
well O
- O
circumscribed O
and O
homogeneous O
cylindrical O
mesenchymal O
measuring O
in O
with O
( O
Fig.1A O
) O
. O

 O
revealed O
no O
in O
the O
, O
, O
, O
or O
. O

 O
showed O
a O
submucosal O
in O
the O
starting O
at O
extending O
( O
Fig.1B O
) O
. O

 O
( O
) O
revealed O
hypoechoic O
with O
a O
clear O
boundary O
located O
in O
the O
. O

 O
The O
appeared O
as O
a O
and O
was O
preoperatively O
diagnosed O
as O
esophageal B
leiomyoma I
based O
on O
chest O
CT O
, O
endoscopic O
examination O
, O
and O
EUS O
findings O
. O

 O
Endoscopic O
mucosal O
or O
endoscopic O
submucosal O
was O
not O
possible O
because O
of O
large O
size O
. O

 O
Hence O
, O
surgical O
was O
planned O
and O
informed O
written O
consent O
was O
taken O
. O

 O
The O
patient O
underwent O
thoracoscopic O
- O
assisted O
of O
the O
with O
gastroesophageal O
, O
thoracic O
duct O
, O
and O
. O

 O
was O
. O

 O
Grossly O
, O
a O
spindle O
shaped O
measuring O
, O
was O
observed O
in O
the O
resected O
, O
which O
grew O
into O
the O
and O
blocked O
most O
of O
. O

 O
This O
located O
in O
the O
was O
, O
without O
, O
ulcer B
, O
and O
hemorrhage B
. O

 O
Its O
cut O
surface O
was O
to O
in O
color O
. O

 O
using O
and O
revealed O
that O
was O
, O
arising O
and O
expanding O
in O
to O
the O
. O

 O
The O
was O
. O

 O
( O
Fig.2A O
 O
C O
) O
. O

 O
The O
. O

 O
These O
possessed O
, O
, O
, O
and O
( O
Fig.2D O
) O
. O

 O
was O
. O

 O
No O
lymphoepithelial O
was O
recognized O
in O
the O
. O

 O
On O
, O
epithelium O
was O
diffusely O
positive O
for O
( O
Fig.3A O
) O
, O
and O
the O
tumor O
cells O
were O
diffusely O
positive O
for O
, O
( O
Fig.3B O
) O
, O
and O
( O
Fig.3D O
) O
. O

 O
Small O
deposits O
of O
tumor O
cells O
, O
which O
were O
distributed O
mainly O
in O
the O
collagen O
fibers O
, O
were O
positive O
for O
, O
, O
and O
. O

 O
Several O
tumor O
cells O
were O
also O
positive O
for O
. O

 O
Small O
lymphocytes O
were O
positive O
for O
and O
. O

 O
Follicular O
dendritic O
cells O
were O
for O
and O
( O
Fig.3C O
) O
. O

 O
All O
cells O
were O
negative O
for O
, O
, O
, O
and O
. O

 O
These O
follicular O
dendritic O
cells O
were O
arranged O
in O
nodules O
in O
which O
the O
tumor O
cells O
were O
relatively O
evenly O
distributed O
. O

 O
This O
pattern O
was O
suggestive O
of O
follicular O
colonizations O
seen O
in O
MALT O
lymphoma O
. O

 O
In O
this O
case O
, O
gene O
rearragements O
and O
clonality O
analysis O
of O
immunoglobulin O
heavy O
chain O
gene O
, O
kappa O
light O
chain O
gene O
, O
and O
lambda O
light O
chain O
gene O
was O
performed O
using O
the O
IdentiCloneTM O
IGH O
/ O
IGK O
/ O
IGL O
Gene O
Clonality O
Assay O
( O
InVivoScribe O
Technologies O
, O
CA O
) O
. O

 O
On O
monoclonal O
gene O
rearrangement O
, O
1 O
band O
appeared O
within O
150 O
to O
175 O
base O
pairs O
( O
bp O
) O
in O
heavy O
chain O
gene O
, O
2 O
discrete O
bands O
within O
225 O
to O
250 O
 O
bp O
in O
kappa O
light O
chain O
gene O
, O
and O
1 O
band O
within O
125 O
to O
150 O
 O
bp O
in O
lambda O
light O
chain O
gene O
( O
Fig.4 O
) O
. O

 O
In O
addition O
, O
no O
Epstein O
 O
Barr O
virus O
was O
observed O
in O
this O
lymphoma O
on O
in O
situ O
hybridization O
using O
the O
EB O
virus O
- O
encoded O
small O
RNA O
( O
Fig.3E O
, O
F O
) O
. O

 O
Based O
on O
the O
clinical O
data O
, O
pathological O
, O
immunohistochemical O
, O
and O
gene O
rearragements O
analysis O
, O
final O
diagnosis O
of O
primary O
esophageal O
MALT O
lymphoma O
was O
made O
. O

 O
After O
the O
surgical O
resection O
, O
no O
additional O
therapy O
in O
the O
form O
of O
chemotherapy O
or O
radiotherapy O
was O
administered O
. O

 O
Over O
the O
8 O
months O
of O
, O
no O
evidence O
of O
or O
was O
found O
on O
and O
the O
patient O
has O
been O
. O

 O
Ethical O
approval O
for O
this O
study O
was O
obtained O
from O
Medical O
Ethics O
Committee O
of O
the O
Third O
Affiliated O
Hospital O
, O
the O
Third O
Military O
Medical O
University O
. O

 O
Written O
informed O
consent O
was O
obtained O
from O
the O
patient O
for O
the O
publication O
of O
this O
case O
report O
and O
the O
accompanying O
images O
. O

A O
was O
with O
progressive O
for O
and O
5 O
kg O
. O

 O
Her O
past O
medical O
history O
was O
significant O
for O
treated O
with O
, O
, O
for O
. O

 O
Upper O
gastrointestinal O
described O
a O
4 O
cm O
whitish O
firm O
mass O
in O
the O
middle O
esophagus O
( O
Fig.1 O
) O
and O
a O
semi O
- O
circumferential O
deep O
ulcer O
with O
irregular O
borders O
on O
the O
opposite O
mucosa O
( O
Fig.2 O
) O
. O

 O
During O
endoscopy O
a O
pedicle O
was O
not O
identify O
by O
handling O
a O
polipectomy O
snare O
around O
the O
esophageal O
mass O
. O

 O
Upper O
gastrointestinal O
series O
with O
gastrografin O
( O
Fig.3 O
) O
revealed O
an O
ovoid O
lacunar O
image O
at O
the O
distal O
part O
of O
the O
esophagus O
esophageal O
, O
inhomogeneous O
, O
with O
calcifications O
and O
smooth O
contours O
. O

 O
During O
peristalsis O
the O
image O
was O
mobile O
and O
no O
pedicle O
was O
identified O
. O

 O
The O
esophageal O
lumen O
was O
enlarged O
with O
a O
diverticula O
development O
at O
the O
posterior O
wall O
. O

 O
Also O
computer O
tomography O
of O
the O
thorax O
excluded O
a O
pedunculated O
tumor O
, O
describing O
an O
intra O
- O
luminal O
calcified O
esophageal O
mass O
( O
Fig.4 O
) O
. O

 O
The O
biopsies O
obtained O
from O
the O
esophageal O
ulcerated O
mucosa O
revealed O
inflammatory O
cells O
, O
without O
malignancy O
. O

 O
Based O
on O
these O
endoscopic O
and O
imagistic O
results O
a O
bezoar O
was O
supposed O
to O
have O
been O
developed O
in O
an O
esophageal O
diverticula O
, O
subsequently O
with O
ulcerated O
mucosa O
. O

 O
The O
esophageal O
mass O
was O
removed O
with O
an O
endoscopic O
snare O
in O
one O
piece O
, O
as O
the O
fragmentation O
was O
not O
physically O
possible O
. O

 O
The O
macroscopic O
appearance O
revealed O
a O
4 O
cm O
, O
globular O
mass O
, O
heterogeneous O
, O
dense O
, O
whitish O
, O
in O
places O
with O
harsh O
yellow O
foci O
, O
most O
likely O
dystrophic O
calcification O
. O

 O
The O
macroscopic O
examination O
on O
cross O
section O
revealed O
a O
light O
gray O
aspect O
( O
fibrous O
appearance O
) O
that O
includes O
multiple O
harsh O
yellow O
- O
orange O
structures O
, O
difficult O
to O
section O
( O
Fig.5 O
) O
. O

 O
This O
mass O
was O
immersed O
into O
trichloracetic O
acid O
for O
decalcification O
. O

 O
Microscopic O
examination O
revealed O
hyaline O
fibrous O
tissue O
( O
Fig.6a O
) O
, O
stained O
in O
green O
in O
Tricrom O
Mason O
( O
Fig.6b O
) O
, O
with O
numerous O
crystalline O
basophils O
deposits O
of O
minerals O
, O
rare O
fibrocytes O
and O
very O
few O
vessels O
. O

 O
The O
presence O
of O
capillary O
structures O
, O
rare O
fibroblasts O
and O
collagen O
fibers O
brought O
in O
discussion O
a O
mesenchymal O
originating O
mass O
, O
most O
likely O
a O
fibrovascular O
polyp O
. O

 O
A O
definitive O
histological O
diagnosis O
was O
not O
possible O
, O
as O
the O
pedicle O
was O
not O
identified O
, O
but O
the O
presence O
of O
the O
connective O
tissue O
suggested O
the O
previous O
presence O
of O
a O
pedicle O
into O
the O
lesion O
. O

 O
The O
long O
term O
calcium O
tablets O
intake O
might O
explain O
the O
calcification O
process O
developed O
into O
the O
vascular O
- O
connective O
tissue O
, O
revealed O
on O
histology O
by O
the O
numerous O
crystalline O
basophils O
deposits O
of O
minerals O
. O

 O
One O
month O
later O
the O
patient O
was O
. O

 O
The O
did O
not O
revealed O
an O
, O
the O
of O
the O
esophageal O
mucosa O
was O
( O
without O
) O
and O
no O
was O
identified O
. O

 O
No O
were O
found O
on O
esophageal O
. O

 O
Based O
on O
the O
clinical O
course O
, O
the O
and O
a O
diagnosis O
of O
an O
mesenchymal O
originating O
( O
most O
probably O
a O
fibrovascular B
polyp I
) O
and O
was O
formulated O
. O

A O
68 O
- O
year O
- O
old O
female O
smoker O
with O
a O
history O
of O
pulmonary O
embolism O
and O
diabetes O
mellitus O
was O
diagnosed O
with O
Stage O
IIIB O
( O
T4N2M0 O
) O
squamous O
NSCLC B
. O

 O
She O
was O
treated O
by O
definitive O
with O
and O
. O

 O
, O
scan O
demonstrated O
a O
in O
the O
; O
however O
, O
new O
in O
the O
and O
developed O
and O
were O
. O

 O
A O
month O
later O
the O
disease O
progressed O
with O
development O
of O
multiple O
bone O
and O
subcutaneous O
. O

 O
At O
that O
point O
, O
the O
patient O
suffered O
from O
severe O
and O
was O
. O

 O
She O
received O
of O
and O
followed O
by O
, O
and O
treatment O
was O
switched O
to O
. O

 O
, O
a O
subcutaneous O
in O
her O
, O
accompanied O
by O
severe O
and O
significant O
( O
Fig.1 O
) O
. O

 O
Other O
subcutaneous O
as O
well O
. O

 O
After O
the O
second O
cycle O
of O
treatment O
marked O
was O
observed O
, O
including O
and O
and O
reduction O
of O
the O
bone O
. O

 O
The O
patient O
no O
longer O
required O
. O

 O
The O
subcutaneous O
started O
to O
regress O
too O
, O
with O
complete O
resolution O
by O
the O
12th O
week O
as O
well O
as O
improvement O
in O
all O
bone O
( O
Figs.1 O
and O
2 O
) O
. O

 O
The O
patient O
continued O
on O
, O
and O
tolerated O
the O
treatment O
well O
. O

 O
Unfortunately O
, O
she O
developed O
bacterial O
aspiration O
and O
in O
. O

Our O
patient O
( O
ID O
73387 O
) O
is O
a O
, O
born O
by O
an O
emergency O
caesarean O
section O
at O
34 O
weeks O
of O
gestation O
to O
. O

 O
showed O
that O
she O
was O
small O
for O
her O
gestation O
, O
1.19 O
 O
kg O
at O
birth O
with O
a O
of O
, O
considerably O
below O
the O
0.4th O
centile O
. O

 O
Induction O
of O
labour O
had O
been O
attempted O
because O
of O
the O
growth O
retardation O
but O
had O
failed O
, O
leading O
to O
the O
emergency O
. O

 O
The O
were O
4 O
at O
, O
7 O
at O
and O
9 O
at O
. O

 O
She O
was O
to O
the O
for O
. O

 O
At O
a O
, O
she O
developed O
a O
severe O
. O

 O
The O
initial O
was O
and O
increased O
to O
( O
normal O
range O
, O
0.72.1 O
 O
mmol O
/ O
l O
) O
. O

 O
She O
was O
treated O
with O
intravenous O
infusions O
of O
and O
( O
) O
, O
but O
it O
was O
never O
possible O
to O
correct O
the O
. O

 O
She O
also O
developed O
hypoglycaemia O
within O
hours O
of O
birth O
that O
was O
corrected O
with O
an O
intravenous O
infusion O
of O
15 O
% O
glucose O
( O
7.8 O
 O
mg O
/ O
kg O
/ O
min O
) O
. O

 O
The O
ammonia O
concentration O
was O
normal O
. O

 O
Urine O
organic O
acid O
profile O
showed O
massive O
excretion O
of O
lactic O
acid O
and O
increased O
phenolic O
acids O
, O
especially O
hydroxyphenyllactate O
. O

 O
Plasma O
amino O
acids O
showed O
raised O
concentrations O
of O
alanine O
and O
glutamine O
( O
1567 O
and O
1369 O
 O
mol O
/ O
l O
, O
respectively O
) O
, O
consistent O
with O
the O
lactic O
acidosis O
; O
several O
other O
amino O
acids O
were O
also O
mildly O
increased O
. O

 O
There O
was O
gross O
generalised O
aminoaciduria O
. O

 O
Blood O
acylcarnitine O
analysis O
was O
normal O
. O

 O
Echocardiography O
showed O
a O
structurally O
normal O
heart O
and O
good O
ventricular O
function O
. O

 O
Cranial O
ultrasound O
showed O
bilateral O
intraventricular O
cysts O
within O
the O
frontal O
horns O
and O
anterior O
portions O
of O
the O
lateral O
ventricles O
. O

 O
The O
left O
- O
sided O
cysts O
were O
larger O
, O
up O
to O
15 O
 O
mm O
in O
diameter O
, O
whereas O
the O
largest O
cyst O
on O
the O
right O
was O
8 O
 O
mm O
in O
diameter O
. O

 O
The O
choroid O
plexuses O
were O
hyperechoic O
and O
irregular O
, O
suggesting O
previous O
intraventricular O
haemorrhage O
. O

 O
Abdominal O
ultrasound O
showed O
a O
distended O
urinary O
bladder O
but O
was O
otherwise O
unremarkable O
. O

 O
There O
was O
severe O
coagulopathy O
with O
an O
extended O
prothrombin O
time O
of O
47.7 O
 O
s O
( O
normal O
12.316.6 O
 O
s O
) O
, O
a O
very O
low O
plasma O
albumin O
of O
7 O
 O
g O
/ O
l O
( O
normal O
3550 O
 O
g O
/ O
l O
) O
, O
otherwise O
normal O
liver O
function O
tests O
but O
a O
raised O
creatine O
kinase O
of O
2700 O
 O
U O
/ O
l O
( O
normal O
< O
300 O
 O
U O
/ O
l O
) O
. O

 O
She O
was O
transferred O
to O
a O
tertiary O
centre O
because O
of O
her O
worsening O
metabolic O
acidosis O
. O

 O
She O
started O
having O
seizures O
at O
48 O
 O
h O
of O
age O
. O

 O
Despite O
infusions O
of O
bicarbonate O
and O
THAM O
, O
her O
acidosis O
continued O
to O
worsen O
. O

 O
Muscle O
and O
skin O
biopsies O
were O
performed O
and O
the O
family O
agreed O
to O
the O
withdrawal O
of O
intensive O
care O
treatment O
. O

 O
She O
aged O
55 O
 O
h. O

 O
All O
documented O
studies O
were O
approved O
and O
performed O
under O
the O
ethical O
guidelines O
issued O
by O
each O
of O
our O
Institutions O
for O
clinical O
studies O
, O
with O
written O
informed O
consent O
obtained O
from O
the O
family O
. O

The O
institutional O
review O
board O
( O
Chengdu O
Military O
General O
Hospital O
) O
approved O
this O
work O
and O
waived O
the O
need O
for O
informed O
consent O
. O

 O
In O
, O
a O
with O
a O
history O
of O
and O
hypertension O
presented O
to O
the O
Emergency O
Department O
with O
continuous O
, O
, O
profuse O
and O
with O
no O
obvious O
predisposing O
causes B
. O

 O
The O
patient O
experienced O
a O
sudden O
drop O
in O
and O
acute O
. O

 O
After O
an O
immediate O
, O
his O
was O
gradually O
restored O
, O
and O
relieved O
. O

 O
Then O
, O
this O
patient O
was O
to O
the O
for O
further O
and O
. O

 O
The O
patient O
's O
was O
upon O
admission O
, O
with O
a O
of O
, O
of O
and O
of O
. O

 O
The O
heart O
border O
, O
with O
the O
located O
in O
the O
, O
. O

 O
The O
patient O
had O
a O
history O
of O
hypertension O
over O
without O
regular O
. O

 O
The O
highest O
was O
. O

 O
There O
was O
. O

 O
He O
. O

 O
He O
also O
reported O
. O

 O
Twelve O
- O
lead O
surface O
( O
) O
of O
VT B
indicated O
that O
the O
origin O
of O
VT O
was O
at O
the O
boundary O
between O
( O
) O
and O
. O

 O
When O
VT B
increased O
to O
, O
no O
were O
found O
in O
the O
( O
Figure1A O
and O
B O
) O
. O

 O
In O
contrast O
, O
when O
VT B
to O
, O
appeared O
in O
( O
Figure1C O
) O
. O

 O
Notably O
, O
the O
epsilon O
waves O
preceded O
QRS O
waves O
in O
leads O
V1 O
 O
V2 O
, O
while O
endocardiac O
tracing O
confirmed O
that O
the O
corresponding O
local O
potential O
originating O
from O
RVOT O
appeared O
prior O
to O
the O
ventricular O
rhythm O
( O
Figure O
(Figure1D).1D O
) O
. O

 O
Sinus O
ECG O
in O
the O
year O
of O
2013 O
suggested O
a O
slight O
left O
deviation O
of O
electric O
axis O
, O
with O
a O
heart O
rate O
of O
87 O
beats O
/ O
min O
and O
flat O
T O
waves O
in O
lead O
II O
. O

 O
T O
wave O
inversions O
were O
found O
in O
leads O
III O
, O
avF O
and O
V1 O
 O
V3 O
, O
meanwhile O
epsilon O
waves O
were O
found O
following O
QRS O
complex O
in O
leads O
V1 O
 O
V3 O
( O
Figure O
(Figure2B).2B O
) O
. O

 O
When O
the O
lead O
avR O
was O
amplified O
, O
epsilon O
waves O
were O
also O
found O
behind O
QRS O
waves O
( O
Figure O
2C O
) O
. O

 O
Atrial O
premature O
beats O
appeared O
occasionally O
. O

 O
Moreover O
, O
ventricular O
premature O
beats O
were O
also O
found O
to O
originate O
from O
the O
right O
ventricular O
apex O
, O
with O
epsilon O
waves O
appearing O
behind O
QRS O
waves O
( O
Figure O
(Figure2B).2B O
) O
. O

 O
In O
contrast O
, O
sinus O
ECG O
obtained O
in O
the O
year O
of O
1999 O
revealed O
similar O
left O
deviation O
of O
electric O
axis O
, O
flat O
T O
waves O
and O
T O
wave O
inversions O
, O
but O
absence O
of O
epsilon O
waves O
( O
Figure O
(Figure2A).2A O
) O
. O

 O
Data O
from O
biochemical O
assays O
were O
as O
follows O
: O
cardiac O
troponin O
I O
level O
was O
0.714 O
 O
g O
/ O
L O
( O
normal O
range O
, O
00.06 O
 O
g O
/ O
L O
) O
, O
serum O
B O
- O
type O
natriuretic O
peptide O
level O
was O
466.530 O
 O
pg O
/ O
mL O
( O
normal O
range O
, O
0100 O
 O
pg O
/ O
mL O
) O
, O
serum O
d O
- O
dimer O
level O
was O
8.14 O
 O
mg O
/ O
L O
( O
normal O
range O
, O
00.55 O
 O
mg O
/ O
L O
) O
, O
blood O
urea O
level O
was O
11.69 O
 O
mmol O
/ O
L O
( O
normal O
range O
, O
2.907.20 O
 O
mmol O
/ O
L O
) O
, O
serum O
creatinine O
level O
was O
144.00 O
 O
mol O
/ O
L O
( O
normal O
range O
, O
44133 O
 O
mol O
/ O
L O
) O
, O
serum O
uric O
acid O
level O
was O
611.40 O
 O
mol O
/ O
L O
( O
normal O
range O
, O
100432 O
 O
mol O
/ O
L O
) O
, O
and O
endogenous O
creatinine O
clearing O
value O
was O
57.90 O
 O
mL O
/ O
min O
( O
normal O
range O
, O
> O
80 O
 O
mL O
/ O
min O
) O
. O

 O
Echo O
data O
revealed O
remarkably O
enlarged O
right O
atrium O
and O
right O
ventricle O
, O
and O
widened O
ROVT O
. O

 O
Uncoordinated O
motions O
of O
the O
left O
and O
right O
ventricular O
walls O
were O
also O
detected O
. O

 O
Moreover O
, O
we O
also O
found O
aortic O
valve O
degradation O
with O
slight O
regurgitation O
, O
slight O
mitral O
regurgitation O
, O
and O
moderate O
to O
severe O
tricuspid O
regurgitation O
. O

 O
The O
left O
ventricular O
diastolic O
function O
was O
reduced O
to O
55 O
% O
( O
Figure O
3A O
and O
B O
) O
. O

 O
The O
coronary O
angiogram O
revealed O
no O
vascular O
stenosis O
( O
Figure O
3C O
 O
E O
) O
. O

 O
Based O
on O
the O
above O
- O
mentioned O
examinations O
, O
this O
patient O
met O
at O
least O
2 O
major O
criteria O
, O
the O
bilateral O
ventricular O
dilation O
and O
the O
existence O
of O
epsilon O
waves O
, O
providing O
diagnostic O
support O
for O
ARVC O
. O

 O
A O
diet O
with O
low O
salt O
and O
low O
fat O
was O
suggested O
. O

 O
The O
patient O
was O
also O
treated O
with O
metoprolol O
succinate O
sustained O
- O
release O
tablets O
( O
23.75 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
amiodarone O
( O
200 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
furosemide O
( O
20 O
 O
mg O
daily O
, O
i.v O
. O
) O
, O
and O
compound O
 O
- O
ketoacid O
tablets O
( O
2.52 O
 O
g O
daily O
, O
p.o O
. O
) O
. O

 O
Moreover O
, O
VTs O
with O
different O
morphologies O
and O
cycle O
lengths O
were O
found O
during O
radiofrequency O
ablation O
( O
Figure O
4 O
) O
. O

 O
The O
substrate O
voltage O
mapping O
revealed O
that O
the O
anterior O
wall O
of O
RVOT O
was O
wrapped O
by O
circular O
scar O
( O
Figure O
5A O
) O
. O

 O
Considering O
the O
association O
of O
VT O
with O
scar O
areas O
, O
substrate O
ablation O
was O
chosen O
for O
this O
patient O
. O

 O
The O
residual O
potentials O
in O
the O
scar O
areas O
were O
searched O
, O
and O
then O
linear O
and O
focal O
ablations O
were O
performed O
( O
Figure O
5B O
) O
. O

 O
Neither O
programmed O
stimulation O
nor O
induced O
stimulation O
could O
induce O
VT O
after O
the O
procedure O
was O
completed O
, O
indicating O
the O
success O
of O
operation O
. O

 O
The O
ECG O
after O
radiofrequency O
ablation O
showed O
sinus O
rhythm O
, O
with O
a O
heart O
rate O
of O
61 O
beats O
/ O
min O
, O
T O
wave O
inversions O
in O
leads O
III O
and O
avF O
, O
and O
epsilon O
waves O
and O
T O
wave O
inversions O
in O
leads O
V1 O
 O
V3 O
( O
Figure O
2D O
) O
. O

 O
This O
patient O
was O
discharged O
from O
hospital O
on O
day O
9 O
with O
a O
regimen O
of O
metoprolol O
succinate O
sustained O
- O
release O
tablets O
( O
23.75 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
amiodarone O
hydrochloride O
tablets O
( O
200 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
spironolactone O
tablets O
( O
40 O
 O
mg O
daily O
, O
p.o O
. O
) O
, O
and O
fosinopril O
sodium O
tablets O
( O
10 O
 O
mg O
daily O
, O
p.o O
. O
) O
. O

 O
The O
patient O
was O
followed O
up O
3 O
months O
after O
discharge O
. O

 O
He O
had O
no O
recurrent O
, O
chest O
, O
profuse O
or O
. O

 O
. O

A O
complained O
of O
for O
and O
was O
to O
our O
after O
a O
bifrontal O
was O
found O
. O

 O
Other O
than O
dizziness O
, O
the O
patient O
presented O
no O
signs O
or O
symptoms O
that O
are O
commonly O
associated O
with O
neurological O
disease O
, O
such O
as O
headache O
, O
vomiting O
, O
sensory O
disturbances O
, O
altered O
consciousness O
, O
or O
seizures O
. O

 O
Except O
for O
a O
, O
which O
was O
properly O
controlled O
with O
, O
the O
patient O
was O
otherwise O
. O

 O
, O
and O
the O
patient O
was O
found O
to O
be O
normal O
upon O
. O

 O
Plain O
and O
contrast O
- O
enhanced O
( O
) O
of O
the O
showed O
a O
space O
- O
occupying O
in O
the O
, O
, O
and O
the O
. O

 O
The O
5.7 O
 O
 O
 O
5.0 O
 O
 O
 O
5.0 O
 O
cm O
dural O
- O
based O
growing O
revealed O
on O
the O
and O
a O
slight O
on O
the O
and O
was O
homogenously O
enhanced O
with O
a O
( O
Fig.1 O
) O
. O

 O
Diagnosis O
of O
a O
parasagittal O
- O
parafalcine O
meningioma B
was O
made O
, O
and O
a O
craniotomic O
meningioma O
was O
chosen O
as O
treatment O
. O

 O
The O
; O
, O
tests O
; O
; O
chest O
and O
were O
. O

 O
The O
was O
36 O
 O
g O
/ O
L O
, O
the O
( O
) O
was O
12.2 O
 O
mol O
/ O
L O
, O
and O
the O
( O
) O
was O
4.1 O
 O
mol O
/ O
L. O

 O
( O
) O
was O
, O
and O
the O
( O
) O
for O
coagulation O
values O
was O
. O

 O
Because O
of O
the O
patient O
's O
advanced O
age O
and O
history O
of O
hypertension O
, O
we O
performed O
an O
and O
a O
and O
tested O
her O
levels O
and O
. O

 O
The O
results O
revealed O
. O

 O
Written O
consent O
was O
obtained O
from O
the O
patient O
. O

 O
Five O
hundred O
milligrams O
of O
was O
initiated O
. O

 O
The O
patient O
tolerated O
the O
administration O
well O
. O

 O
A O
was O
then O
performed O
with O
a O
radical O
( O
Simpson O
II O
) O
. O

 O
The O
was O
and O
and O
had O
a O
, O
and O
its O
texture O
was O
. O

 O
Thirty O
minutes O
before O
the O
end O
of O
surgery O
, O
800 O
 O
mg O
of O
was O
administered O
by O
. O

 O
After O
the O
operation O
, O
the O
patient O
regained O
within O
30 O
minutes O
and O
scored O
15 O
on O
the O
( O
) O
. O

 O
as O
she O
was O
being O
back O
to O
her O
, O
the O
patient O
underwent O
UGH B
. O

 O
The O
( O
) O
was O
composed O
of O
. O

 O
Excluding O
the O
possible O
etiology O
of O
endotracheal O
intubation O
, O
we O
diagnosed O
the O
patient O
as O
experiencing O
acute O
erosive O
- O
hemorrhagic O
gastritis B
, O
a O
reaction O
to O
the O
craniotomy O
. O

 O
The O
patient O
was O
given O
to O
inhibit O
gastric O
acid O
secretion O
, O
and O
the O
ceased O
. O

 O
The O
patient O
was O
administered O
( O
, O
) O
. O

 O
Because O
of O
her O
stomach O
and O
intestine O
functional O
recovery O
, O
the O
dosage O
was O
changed O
to O
via O
oral O
administration O
. O

 O
A O
brain O
was O
performed O
on O
postoperative O
, O
and O
it O
revealed O
that O
the O
was O
radically O
removed O
and O
the O
was O
( O
Fig.2A O
and O
B O
) O
. O

 O
A O
subsequent O
paraffin O
confirmed O
the O
diagnosis O
of O
meningioma B
. O

 O
At O
on O
postoperative O
, O
the O
patient O
was O
suddenly O
found O
in O
a O
deep O
coma B
. O

 O
Her O
to O
and O
, O
and O
the O
was O
. O

 O
The O
was O
, O
and O
her O
were O
; O
however O
, O
her O
to O
a O
deep O
coma B
( O
 O
= O
 O
8) O
, O
which O
we O
believed O
was O
caused O
by O
intracranial O
. O

 O
A O
( O
) O
scan O
of O
the O
was O
immediately O
performed O
; O
however O
, O
it O
, O
such O
as O
severe O
brain O
, O
intracranial B
hemorrhage I
, O
or O
cerebral B
infarction I
( O
Fig.2C O
) O
. O

 O
Because O
a O
possible O
cerebral B
infarction I
could O
not O
be O
excluded O
, O
, O
, O
and O
a O
were O
used O
. O

 O
The O
patient O
's O
routine O
for O
blood O
cell O
, O
liver O
, O
and O
renal O
were O
in O
. O

 O
The O
was O
, O
the O
was O
13.3 O
 O
mol O
/ O
L O
, O
and O
the O
was O
4.5 O
 O
mol O
/ O
L. O

 O
was O
, O
and O
the O
for O
coagulation O
values O
was O
. O

 O
Because O
of O
her O
, O
we O
checked O
her O
levels O
and O
performed O
a O
and O
. O

 O
Her O
was O
elevated O
( O
181.6 O
 O
mol O
/ O
L O
; O
normal O
range O
is O
1132 O
 O
mol O
/ O
L O
) O
, O
whereas O
the O
was O
. O

 O
Thus O
, O
considering O
her O
history O
and O
elevated O
blood O
ammonia O
, O
she O
was O
diagnosed O
with O
UGH O
- O
induced O
hepatic B
encephalopathy I
, O
and O
the O
oral O
administration O
of O
was O
changed O
to O
administration O
to O
prevent O
seizures O
. O

 O
, O
, O
and O
were O
administered O
, O
with O
was O
performed O
, O
and O
the O
patient O
was O
. O

 O
The O
patient O
's O
level O
( O
) O
, O
and O
she O
remained O
during O
the O
. O

 O
Because O
of O
the O
unremarkable O
progress O
in O
the O
patient O
's O
and O
level O
, O
we O
to O
discuss O
diagnosis O
and O
treatment O
, O
initially O
considering O
hemodialysis O
or O
peritoneal O
dialysis O
. O

 O
After O
the O
multidisciplinary O
discussion O
, O
a O
suspected O
diagnosis O
of O
VHE B
was O
finally O
made O
, O
even O
though O
the O
level O
was O
within O
the O
. O

 O
We O
decided O
to O
stop O
administration O
before O
performing O
any O
dialysis O
and O
administered O
levetiracetam O
instead O
of O
VPA O
. O

 O
The O
patient O
's O
blood O
VPA O
and O
ammonia O
levels O
were O
then O
routinely O
monitored O
. O

 O
The O
patient O
's O
began O
to O
from O
the O
of O
VPA O
discontinuation O
, O
and O
she O
achieved O
complete O
( O
 O
= O
 O
) O
. O

 O
The O
in O
her O
dramatically O
and O
returned O
to O
( O
Fig.3 O
) O
. O

 O
On O
postoperative O
( O
8 O
days O
after O
the O
discontinuation O
of O
VPA O
) O
, O
the O
patient O
was O
with O
no O
. O

 O
The O
interviews O
in O
postoperative O
witnessed O
her O
full O
and O
non O
- O
of O
the O
( O
Fig.2D O
) O
. O

 O
The O
patient O
's O
score O
was O
, O
and O
she O
reported O
enjoying O
a O
satisfying O
. O

A O
presented O
with O
vaginal O
and O
abnormal O
. O

 O
Upon O
diagnosis O
of O
invasive O
non O
- O
keratinizing O
SCC B
of O
the O
, O
she O
underwent O
a O
radical O
with O
which O
demonstrated O
positive O
spread O
to O
the O
and O
the O
. O

 O
Pathological O
examination O
revealed O
that O
the O
tumour O
also O
extensively O
involved O
the O
. O

 O
, O
the O
woman O
underwent O
external O
beam O
and O
intracavitary O
. O

 O
, O
the O
patient O
presented O
with O
a O
history O
of O
a O
productive O
, O
, O
and O
a O
history O
of O
progressive O
exertional O
. O

 O
of O
the O
demonstrated O
a O
reticular O
nodular O
pattern O
, O
and O
revealed O
multiple O
bilateral O
patchy O
areas O
of O
ground O
glass O
opacity O
scarring O
with O
focal O
areas O
of O
subsegmental O
atelectasis O
within O
both O
lungs O
. O

 O
A O
differential O
diagnosis O
included O
interstitial O
pneumonia O
versus O
non O
- O
cardiogenic O
edema O
. O

 O
The O
woman O
underwent O
a O
, O
left O
, O
and O
an O
open O
wedge O
left O
lung O
. O

 O
of O
the O
left O
lung O
biopsy O
confirmed O
the O
presence O
of O
neoplastic O
sheets O
of O
cells O
classically O
distributed O
along O
the O
septal O
vessels O
, O
perivascular O
, O
peribronchial O
, O
and O
subpleural O
lymphatics O
. O

 O
Subpleural O
nodules O
were O
also O
identified O
with O
the O
presence O
of O
neoplastic O
cells O
distending O
the O
subpleural O
lymphatics O
confirming O
LC O
( O
Figures O
1A O
, O
1B O
, O
1C O
) O
. O

 O
On O
immunohistochemical O
analysis O
, O
the O
lesional O
cells O
were O
strongly O
positive O
to O
p16 O
( O
Figure O
1D O
) O
, O
high O
and O
low O
molecular O
weight O
keratins O
( O
Figure O
1E O
) O
, O
cytokeratin-7 O
( O
CK7 O
) O
( O
Figure O
1F O
) O
, O
CK19 O
, O
and O
pan O
keratin O
, O
and O
negative O
to O
CK20 O
, O
p63 O
, O
and O
EGFR O
. O

 O
Based O
on O
these O
findings O
, O
she O
was O
diagnosed O
to O
have O
lymphangitic B
carcinomatosis I
in O
the O
metastatic O
from O
SCC O
of O
the O
cervix O
. O

 O
She O
was O
started O
on O
chemotherapy O
( O
Carbo O
/ O
) O
with O
while O
in O
the O
hospital O
, O
and O
was O
ten O
days O
later O
. O

 O
Post O
- O
treatment O
improvement O
of O
clinical O
symptoms O
was O
paralleled O
by O
that O
showed O
marked O
interval O
improvement O
of O
the O
nodular O
opacifications O
and O
the O
interstitial O
thickening O
that O
had O
previously O
been O
noted O
. O

 O
Despite O
this O
improvement O
, O
she O
subsequently O
. O

A O
was O
to O
the O
with O
a O
chief O
complaint O
of O
progressive O
for O
. O

 O
He O
also O
complained O
of O
a O
drastic O
of O
in O
the O
. O

 O
He O
, O
but O
had O
a O
chronic O
atrophic O
for O
. O

 O
Also O
, O
there O
was O
. O

 O
showed O
. O

 O
Admission O
showed O
a O
slight O
decrease O
in O
( O
) O
. O

 O
Upper O
gastrointestinal O
( O
GI O
) O
using O
showed O
a O
large O
the O
( O
Figure O
1 O
) O
. O

 O
( O
) O
scan O
revealed O
a O
soft O
in O
the O
with O
lymph O
node O
in O
the O
( O
Figure O
2 O
) O
. O

 O
showed O
a O
black O
in O
the O
and O
a O
bulky O
black O
the O
, O
as O
well O
as O
two O
black O
crater O
- O
like O
in O
the O
( O
Figure O
3 O
) O
. O

 O
specimens O
taken O
from O
the O
were O
identified O
as O
poorly O
differentiated O
adenocarcinoma B
. O

 O
Preoperative O
of O
this O
case O
was O
scored O
based O
on O
the O
( O
NRS O
2002)[6 O
] O
. O

 O
Because O
of O
the O
caused O
by O
the O
, O
a O
of O
distal O
and O
proximal O
was O
performed O
. O

 O
Esophagogastric O
and O
was O
then O
completed O
with O
. O

 O
Intraoperatively O
, O
the O
tumor O
was O
found O
located O
at O
the O
esophago O
- O
gastric O
junction O
and O
the O
tumor O
infiltrated O
the O
whole O
layer O
with O
lymph O
node O
metastasis O
at O
station O
four O
. O

 O
No O
or O
was O
observed O
in O
the O
. O

 O
The O
measured O
in O
size O
with O
( O
Figure O
4 O
) O
. O

 O
There O
were O
several O
pigmented O
satellite O
beside O
the O
, O
the O
being O
in O
diameter O
. O

 O
Moreover O
, O
two O
ulceration O
were O
found O
at O
the O
. O

 O
, O
the O
excised O
was O
composed O
of O
non O
- O
organized O
and O
pleomorphic O
cells O
exhibiting O
atypical O
nuclei O
, O
and O
abundant O
melanin O
granules O
( O
Figure O
5 O
) O
. O

 O
identified O
this O
case O
at O
a O
of O
( O
) O
. O

 O
showed O
that O
the O
was O
positive O
for O
, O
, O
and O
, O
but O
negative O
for O
and O
( O
Figure O
6 O
) O
. O

 O
Based O
on O
these O
results O
, O
a O
diagnosis O
of O
primary O
advanced O
esophago O
- O
gastric O
melanoma B
was O
established O
. O

 O
The O
was O
and O
without O
. O

 O
The O
patient O
gradually O
and O
was O
surgery O
. O

 O
As O
the O
patient O
denied O
a O
postoperative O
, O
abdominal O
and O
hepatic O
were O
found O
by O
a O
postoperative O
. O

 O
No O
was O
administered O
afterwards O
. O

 O
The O
patient O
of O
diffuse O
metastatic B
disease I
. O

A O
to O
the O
with O
low O
- O
grade O
for O
, O
for O
and O
for O
. O

 O
She O
also O
reported O
and O
for O
. O

 O
There O
was O
. O

 O
was O
but O
she O
reported O
gradually O
progressive O
. O

 O
Family O
history O
included O
. O

 O
On O
, O
the O
patient O
was O
conscious O
and O
alert O
. O

 O
She O
was O
dyspnoeic O
and O
. O

 O
Severe O
was O
present O
with O
mild O
pedal O
. O

 O
was O
and O
of O
. O

 O
No O
evidence O
of O
, O
clubbing O
or O
lymphadenopathy B
was O
found O
. O

 O
revealed O
bibasilar O
end O
- O
inspiratory O
in O
and O
. O

 O
There O
was O
no O
hepatosplenomegaly O
or O
. O

 O
was O
. O

 O
She O
was O
found O
to O
have O
bilateral O
, O
which O
was O
gradually O
progressive O
for O
5 O
 O
years O
. O

 O
The O
were O
bilaterally O
. O

 O
The O
patient O
was O
to O
the O
for O
a O
comprehensive O
. O

 O
Her O
was O
documented O
as O
in O
with O
no O
obvious O
. O

 O
showed O
( O
figure O
1 O
) O
with O
( O
figure O
2 O
) O
. O

 O
Distant O
direct O
revealed O
( O
a O
suggestive O
confirmation O
of O
the O
presence O
of O
) O
; O
and O
peripheral O
retina O
revealed O
multiple O
yellowish O
white O
lesion O
- O
like O
flecks O
in O
the O
mid O
- O
periphery O
, O
and O
few O
blot O
haemorrhages O
indicative O
of O
( O
figures O
3 O
and O
4 O
) O
. O

A O
was O
admitted O
with O
a O
history O
of O
increasing O
, O
, O
, O
generalised O
and O
deteriorating O
. O

 O
Her O
medical O
history O
included O
a O
, O
and O
. O

 O
Her O
medications O
included O
, O
, O
and O
. O

 O
On O
admission O
, O
the O
patient O
was O
, O
( O
) O
. O

 O
Her O
( O
) O
was O
, O
her O
abbreviated O
was O
and O
she O
was O
noted O
to O
be O
in O
her O
responses O
. O

 O
showed O
reduced O
power O
in O
her O
lower O
limbs O
( O
34/5 O
) O
in O
a O
pyramidal O
distribution O
, O
and O
brisk O
reflexes O
with O
intact O
sensation O
in O
all O
modalities O
. O

 O
Cardiovascular O
, O
respiratory O
and O
gastrointestinal O
were O
unremarkable O
and O
there O
were O
no O
demonstrable O
features O
of O
hepatic B
disease I
. O

 O
Routine O
was O
. O

 O
The O
patient O
's O
alanine O
transaminase O
was O
7 O
 O
u O
/ O
L O
( O
115 O
) O
, O
alkaline O
phosphatase O
61 O
 O
u O
/ O
L O
( O
30130 O
) O
, O
 O
- O
glutamyl O
transferase O
17 O
 O
u O
/ O
L O
( O
< O
45 O
) O
and O
bilirubin O
was O
6 O
 O
mol O
/ O
L O
( O
< O
21 O
) O
. O

 O
She O
had O
normal O
serum O
and O
levels O
, O
and O
normal O
thyroid O
function O
tests O
. O

 O
Serum O
levels O
were O
. O

 O
Her O
serum O
was O
( O
11.235.4 O
) O
and O
concentrations O
were O
( O
50100 O
) O
. O

 O
Brain O
imaging O
including O
CT O
and O
MRI O
did O
not O
show O
any O
haemorrhage O
or O
intracranial O
mass O
. O

 O
Lumbar O
puncture O
demonstrated O
clear O
cerebrospinal O
fluid O
( O
white O
cell O
count O
< O
1106 O
/ O
L O
, O
protein O
0.25 O
 O
g O
/ O
L O
( O
0.20.4 O
) O
) O
. O

 O
EEG O
demonstrated O
mild O
variable O
slowing O
and O
irregularity O
of O
background O
activity O
( O
likely O
due O
to O
medication O
) O
. O

 O
The O
differential O
diagnosis O
included O
encephalitis B
, O
Guillain B
- I
Barr I
syndrome I
and O
acute B
disseminated I
encephalomyelitis I
( O
ADEM B
) O
, O
which O
were O
excluded O
through O
our O
investigations O
. O

 O
In O
view O
of O
the O
raised O
valproate O
and O
ammonia O
levels O
, O
a O
diagnosis O
of O
valproate B
hyperammonaemic I
encephalopathy I
( O
VHE B
) O
was O
made O
at O
this O
point O

 O
The O
dose O
of O
was O
rather O
than O
being O
completely O
withdrawn O
. O

 O
This O
was O
due O
to O
the O
complex O
and O
challenging O
nature O
of O
managing O
the O
patient O
's O
schizo B
- I
affective I
disorder I
. O

 O
Within O
3 O
 O
days O
, O
there O
was O
evident O
clinical O
in O
her O
. O

 O
The O
patient O
was O
able O
to O
and O
with O
the O
team O
, O
and O
her O
to O
10/10.The O
serum O
ammonia O
normalised O
and O
valproate O
levels O
decreased O
to O
the O
therapeutic O
range O
. O

 O
she O
was O
. O

 O
Results O
of O
of O
her O
were O
awaited O
. O

 O
postdischarge O
, O
the O
patient O
was O
clinically O
stable O
in O
terms O
of O
, O
having O
had O
no O
further O
episodes O
of O
or O
. O

 O
However O
, O
she O
continued O
to O
have O
and O
( O
due O
to O
residual O
leg O
) O
. O

 O
Results O
of O
her O
serum O
revealed O
that O
our O
patient O
had O
carnitine B
deficiency I
evident O
by O
low O
, O
low O
free O
serum O
( O
, O
normal O
range O
: O
2352 O
) O
and O
low O
total O
serum O
( O
, O
normal O
range O
: O
2763 O
) O
. O

 O
She O
was O
started O
on O
oral O
. O

 O
, O
her O
resolved O
completely O
with O
normalisation O
of O
serum O
levels O
( O
free O
25.2 O
 O
mol O
/ O
L O
and O
total O
of O
) O
. O

 O
The O
was O
initially O
stopped O
completely O
, O
but O
due O
to O
a O
serious O
relapse O
of O
the O
patient O
's O
schizo B
- I
affective I
disorder I
, O
it O
was O
restarted O
and O
she O
is O
now O
well O
on O
and O
long O
- O
term O
. O

A O
was O
to O
our O
because O
of O
and O
( O
) O
, O
, O
and O
developmental B
delay I
on O
. O

 O
He O
was O
at O
, O
with O
a O
body O
weight O
of O
3.2 O
kg O
. O

 O
birth O
, O
he O
was O
owing O
to O
persistent O
. O

 O
A O
chest O
showed O
, O
and O
an O
revealed O
decreased O
( O
: O
24 O
% O
) O
. O

 O
Under O
the O
impression O
of O
myocarditis O
, O
he O
had O
been O
managed O
for O
1 O
yr O
before O
in O
our O
. O

 O
Moreover O
, O
the O
patient O
showed O
and O
from O
birth O
. O

 O
Before O
referral O
, O
he O
had O
been O
to O
because O
of O
infection B
episodes O
. O

 O
He O
was O
taking O
, O
, O
, O
and O
before O
referral O
. O

 O
When O
he O
was O
to O
our O
at O
, O
his O
was O
( O
less O
than O
3rd O
percentile O
) O
and O
his O
height O
was O
71 O
cm O
( O
less O
than O
3rd O
percentile O
) O
. O

 O
His O
overall O
motor O
development O
was O
delayed O
, O
and O
he O
could O
not O
sit O
alone O
. O

 O
He O
could O
say O
" O
mama O
" O
and O
" O
papa O
. O
" O
The O
recorded O
blood O
pressure O
and O
heart O
rate O
were O
94/30 O
mmHg O
and O
132 O
beats O
per O
minute O
, O
respectively O
. O

 O
On O
physical O
examination O
, O
no O
definite O
heart O
murmur O
was O
audible O
and O
the O
liver O
was O
not O
palpable O
. O

 O
He O
also O
showed O
persistent O
neutropenia O
, O
which O
started O
during O
his O
stay O
in O
the O
previous O
hospital O
. O

 O
His O
WBC O
and O
neutrophil O
counts O
were O
8,800/L O
and O
only O
2 O
% O
( O
176/L O
) O
, O
respectively O
. O

 O
The O
B O
- O
natriuretic O
peptide O
level O
was O
1,045 O
pg O
/ O
mL. O

 O
A O
chest O
radiograph O
showed O
mild O
cardiomegaly O
( O
cardiothoracic O
ratio O
: O
62.8 O
% O
; O
Fig.1A O
) O
, O
and O
an O
electrocardiogram O
showed O
a O
low O
QRS O
voltage O
at O
the O
limb O
leads O
. O

 O
An O
echocardiogram O
revealed O
a O
dilated O
and O
hypertrophied O
globular O
LV O
with O
a O
hypertrophied O
papillary O
muscle O
and O
hyper O
- O
trabeculation O
, O
which O
did O
not O
meet O
the O
criteria O
of O
LV O
non O
- O
compaction O
. O

 O
The O
other O
echocardiographic O
parameters O
were O
as O
follows O
: O
LV O
internal O
diameter O
at O
diastole O
, O
37.7 O
mm O
( O
Z O
= O
10.2 O
) O
; O
ejection O
fraction O
, O
36.6 O
% O
; O
and O
LV O
mass O
index O
, O
75.6 O
g O
( O
Z O
= O
6.3 O
; O
Fig.1B O
) O
. O

 O
To O
rule O
out O
the O
systemic O
cause O
of O
the O
dilated O
and O
hypertrophied O
LV O
, O
we O
performed O
a O
thoraco O
- O
abdominal O
computed O
tomographic O
( O
CT O
) O
angiography O
with O
contrast O
dye O
. O

 O
The O
CT O
findings O
showed O
no O
abnormality O
in O
the O
kidney O
and O
other O
organs O
and O
vessels O
. O

 O
However O
, O
after O
undergoing O
CT O
angiography O
, O
the O
patient O
showed O
abrupt O
high O
- O
grade O
spiking O
fever O
( O
Fig.2 O
) O
and O
developed O
secretory O
diarrhea O
( O
800 O
cc O
per O
day O
) O
associated O
with O
metabolic O
acidosis O
. O

 O
At O
this O
time O
, O
his O
WBC O
and O
neutrophil O
counts O
decreased O
to O
3,290/L O
and O
1 O
% O
( O
33/L O
) O
, O
respectively O
. O

 O
The O
B O
- O
natriuretic O
peptide O
level O
was O
greater O
than O
4,901 O
pg O
/ O
mL. O

 O
He O
did O
not O
show O
associated O
respiratory O
symptoms O
. O

 O
The O
results O
of O
the O
respiratory O
and O
gastrointestinal O
viral O
studies O
were O
negative O
, O
and O
the O
blood O
and O
stool O
cultures O
were O
negative O
for O
pathogens O
. O

 O
The O
C O
- O
reactive O
protein O
level O
was O
7.08 O
mg O
/ O
dL. O

 O
Despite O
supportive O
care O
including O
intravenous O
fluid O
resuscitation O
and O
empirical O
antibiotics O
, O
the O
patient O
's O
condition O
worsened O
, O
with O
aggravated O
metabolic O
acidosis O
and O
respiratory O
difficulty O
, O
requiring O
transfer O
to O
the O
intensive O
care O
unit O
( O
ICU O
) O
. O

 O
Just O
before O
the O
ICU O
transfer O
, O
the O
serum O
pH O
was O
6.881 O
; O
bicarbonate O
level O
, O
7.8 O
mmol O
/ O
L O
; O
and O
total O
CO2 O
was O
41.4 O
mm O
Hg O
. O

 O
Although O
the O
patient O
had O
been O
treated O
with O
intensive O
ventilator O
care O
, O
several O
inotropic O
agents O
, O
and O
other O
supportive O
care O
measures O
, O
he O
eventually O
from O
the O
aggravated O
metabolic O
acidosis O
and O
acutely O
decompensated O
heart B
failure I
the O
ICU O
. O

 O
During O
the O
in O
, O
we O
performed O
from O
the O
evidence O
of O
displayed O
cardiomyopathy B
, O
, O
and O
developmental B
delay I
. O

 O
The O
revealed O
that O
his O
TAZ O
gene O
harbored O
a O
novel O
hemizygous O
frameshift O
, O
( O
) O
, O
which O
he O
inherited O
from O
his O
( O
Fig.3 O
) O
. O

n O
, O
a O
was O
to O
our O
. O

 O
She O
complained O
of O
progressive O
, O
which O
began O
about O
and O
was O
treated O
as O
cataract B
in O
, O
but O
no O
was O
seen O
. O

 O
On O
the O
contrary O
, O
the O
symptoms O
aggravated O
, O
together O
with O
, O
left O
eye O
, O
and O
increased O
, O
and O
the O
( O
) O
scan O
of O
the O
in O
showed O
a O
sellar O
region O
. O

 O
Besides O
, O
, O
the O
patient O
underwent O
of O
melanoma B
in O
the O
( O
, O
, O
) O
, O
followed O
by O
of O
the O
recurred O
melanoma B
( O
, O
) O
, O
without O
. O

 O
She O
had O
. O

 O
On O
, O
the O
patient O
had O
bilateral O
temporal O
, O
the O
was O
, O
and O
the O
was O
no O
more O
than O
0.5 O
 O
m. O

 O
were O
palpable O
in O
the O
. O

 O
On O
, O
the O
patient O
had O
of O
and O
of O
, O
with O
the O
same O
. O

 O
The O
found O
the O
right O
eye O
of O
and O
the O
left O
eye O
of O
. O

 O
The O
patient O
had O
maculopathy B
of O
and O
optic B
atrophy I
of O
the O
. O

 O
and O
of O
were O
. O

 O
scans O
of O
the O
, O
, O
and O
were O
. O

 O
scan O
and O
examination O
of O
the O
showed O
hepatic O
portal O
and O
retroperitoneal O
lymphadenectasis O
and O
enlarged O
left O
lobe O
of O
the O
liver O
with O
substantial O
placeholder O
lesions O
. O

 O
Ultrasound O
examination O
of O
bilateral O
inguinal O
lymph O
nodes O
discovered O
multiple O
low O
echo O
light O
groups O
, O
the O
largest O
of O
which O
was O
31 O
 O
mm O
in O
diameter O
, O
with O
hilus O
of O
the O
echo O
and O
asymmetrical O
thickening O
of O
the O
skin O
. O

 O
CT O
scan O
of O
sellar O
region O
revealed O
a O
crumby O
mass O
, O
protruding O
out O
of O
the O
sphenoid O
sinus O
, O
with O
obscure O
boundary O
and O
bone O
destruction O
. O

 O
And O
the O
average O
CT O
value O
of O
the O
mass O
was O
46 O
 O
HU O
. O

 O
Sellar O
region O
magnetic O
resonance O
imaging O
( O
MRI O
) O
revealed O
a O
round O
mass O
of O
30 O
 O
mm O
in O
diameter O
in O
the O
enlarged O
sellae O
( O
Fig.1A O
, O
B O
) O
. O

 O
The O
mass O
showed O
isointense O
in O
T1 O
- O
weighted O
images O
( O
T1 O
- O
WI O
) O
and O
T2 O
- O
weighted O
images O
( O
T2 O
- O
WI O
) O
, O
with O
homogeneous O
enhancement O
after O
Gadolinium O
- O
DTPA O
injection O
, O
and O
dural O
tail O
sign O
was O
seen O
. O

 O
Small O
foci O
inside O
the O
tumor O
showed O
hyperintense O
signals O
in O
T1 O
- O
WI O
and O
hypointense O
signals O
in O
T2 O
- O
WI O
, O
without O
enhancement O
. O

 O
And O
it O
was O
seen O
that O
the O
mass O
penetrated O
meninges O
, O
surrounded O
the O
left O
internal O
carotid O
artery O
, O
and O
was O
blurred O
with O
the O
left O
optic O
nerve O
. O

 O
Pituitary O
stalk O
became O
shorter O
with O
a O
right O
displacement O
. O

 O
Laboratory O
findings O
revealed O
increased O
levels O
of O
prolactin O
( O
119.08 O
 O
g O
/ O
L O
, O
normal O
range O
5.9930.04 O
 O
g O
/ O
L O
) O
and O
cortisol O
( O
677.10 O
 O
nmol O
/ O
L O
, O
normal O
range O
118.60618.00 O
 O
nmol O
/ O
L O
) O
and O
decreased O
levels O
of O
free O
thyroxine O
( O
FT4 O
) O
( O
6.04 O
 O
pmol O
/ O
L O
, O
normal O
range O
12.0022.00 O
 O
pmol O
/ O
L O
) O
and O
free O
triiodothyronine O
( O
FT3 O
) O
( O
2.09 O
 O
pmol O
/ O
L O
, O
normal O
range O
3.506.50 O
 O
pmol O
/ O
L O
) O
. O

 O
The O
patient O
was O
diagnosed O
with O
a O
giant O
prolactinoma O
. O

 O
The O
patient O
underwent O
transnasal O
transsphenoidal O
surgery O
to O
remove O
the O
tumor O
and O
relieve O
the O
compression O
of O
the O
optic O
nerve O
. O

 O
Intraoperatively O
, O
it O
was O
seen O
that O
the O
tumor O
invaded O
and O
filled O
the O
left O
interval O
of O
the O
sphenoid O
sinus O
, O
and O
part O
of O
bone O
in O
sellar O
floor O
and O
left O
side O
parasellar O
was O
destroyed O
and O
absorbed O
. O

 O
A O
little O
normal O
pituitary O
tissue O
was O
seen O
in O
the O
top O
right O
of O
tumor O
in O
the O
sellar O
turcica O
. O

 O
The O
tumor O
was O
reddish O
black O
with O
extremely O
rich O
blood O
supply O
and O
had O
close O
adhesion O
to O
the O
surrounding O
structure O
. O

 O
The O
texture O
in O
the O
center O
of O
the O
tumor O
was O
soft O
and O
much O
tougher O
over O
the O
rim O
. O

 O
Intraoperative O
frozen O
- O
section O
examination O
found O
melanin O
granules O
, O
and O
it O
was O
considered O
to O
be O
malignant O
melanoma O
or O
meningioma O
. O

 O
The O
tumor O
cells O
were O
composed O
of O
eosinophilic O
staining O
epithelial O
cells O
. O

 O
Most O
of O
cell O
nuclei O
were O
round O
, O
a O
few O
were O
reniform O
and O
hippocrepiform O
with O
evident O
nucleoli O
, O
and O
nuclear O
fission O
was O
seen O
. O

 O
The O
tumor O
showed O
no O
evidence O
of O
necrosis O
( O
Fig.2 O
) O
. O

 O
The O
tumor O
was O
immunopositive O
focally O
for O
melanoma O
- O
specific O
markers O
such O
as O
S-100 O
, O
HMB45 O
, O
and O
Vimentin O
, O
and O
immunopositive O
for O
neuroendocrine O
tumor O
markers O
such O
as O
CgA O
and O
Syn O
( O
Fig.3 O
) O
. O

 O
The O
Ki67 O
index O
was O
3 O
% O
to O
5 O
% O
; O
it O
was O
higher O
in O
metastatic O
melanoma O
than O
in O
the O
adenomatous O
component O
. O

 O
Taken O
the O
melanoma O
history O
and O
suspected O
lymph O
node O
and O
hepatic O
metastasis O
into O
consideration O
, O
the O
patient O
was O
diagnosised O
with O
MMPA O
. O

 O
After O
surgery O
, O
significant O
relief O
was O
seen O
in O
visual O
field O
and O
headache O
, O
and O
the O
level O
of O
prolactin O
, O
cortisol O
, O
and O
FT4 O
returned O
to O
normal O
with O
hormone O
replacement O
therapy O
. O

 O
Because O
the O
focal O
liver O
lesions O
and O
lymphadenectasis O
did O
not O
cause O
much O
discomfort O
, O
the O
patient O
refused O
any O
further O
surgical O
intervention O
or O
other O
treatment O
. O

 O
She O
was O
discharged O
from O
the O
hospital O
immediately O
and O
was O
disease O
free O
until O
2 O
months O
after O
the O
third O
surgery O
. O

 O
The O
patient O
successively O
found O
new O
melanoma O
metastatic O
sites O
in O
the O
skin O
of O
lower O
left O
leg O
, O
knees O
, O
the O
upper O
left O
leg O
, O
the O
left O
groin O
and O
the O
right O
groin O
, O
and O
the O
right O
leg O
. O

 O
At O
the O
follow O
- O
up O
in O
late O
January O
2016 O
, O
the O
patient O
could O
not O
walk O
and O
live O
by O
herself O
and O
was O
depressed O
. O

 O
At O
the O
latest O
follow O
- O
up O
, O
in O
, O
the O
patient O
was O
with O
worse O
, O
she O
had O
of O
, O
which O
, O
of O
and O
, O
, O
but O
she O
lived O
well O
with O
the O
disease O
by O
careful O
of O
her O
. O

A O
patient O
had O
noticed O
left O
- O
sided O
visual B
loss I
and O
amenorrhea B
to O
being O
seen O
, O
with O
right O
hemiparesis B
developing O
. O

 O
Aggravated O
( O
at O
and O
bilateral O
temporal O
hemianopia B
) O
finally O
prompted O
. O

 O
At O
that O
time O
, O
a O
massive O
( O
) O
of O
, O
, O
was O
seen O
on O
( O
) O
of O
the O
( O
Fig.1a O
) O
. O

 O
Further O
testing O
revealed O
an O
exceedingly O
high O
- O
serum O
level O
of O
( O
) O
( O
) O
, O
whereas O
levels O
of O
all O
were O
( O
) O
, O
; O
( O
) O
, O
; O
( O
) O
, O
4.57 O
mIU O
/ O
ml O
; O
( O
) O
, O
; O
( O
) O
, O
) O
. O

 O
( O
) O
imaging O
with O
( O
) O
showed O
homogeneous O
enhancement O
, O
but O
adjacent O
tissue O
was O
not O
in O
. O

 O
The O
did O
not O
, O
despite O
a O
course O
of O
the O
, O
( O
) O
, O
and O
serum O
level O
( O
) O
remained O
. O

 O
Relative O
to O
status O
at O
admission O
, O
the O
right O
lateral O
ventricle O
also O
had O
, O
due O
to O
at O
( O
Fig.1b O
) O
. O

 O
In O
light O
of O
this O
intransigence O
, O
surgical O
of O
tumor O
was O
elected O
first O
, O
through O
and O
then O
via O
. O

 O
The O
hardened O
elastic O
quality O
of O
the O
and O
its O
strong O
to O
prevented O
, O
but O
related O
was O
significantly O
reduced O
and O
serum O
level O
( O
to O
) O
in O
steps O
at O
each O
procedural O
stage O
. O

 O
But O
the O
normalization O
of O
level O
had O
not O
been O
achieved O
with O
the O
administration O
of O
increased O
up O
to O
. O

 O
The O
residual O
tumor O
showed O
no O
evidence O
of O
or O
distant O
surgery O
. O

 O
, O
( O
H&E)-stained O
sections O
of O
specimens O
from O
the O
first O
and O
second O
surgical O
procedures O
similarly O
were O
composed O
of O
polygonal O
and O
spindle O
cells O
with O
round O
, O
oval O
, O
or O
elongated O
nuclei O
and O
eosinophilic O
( O
Fig.2a O
 O
c O
) O
. O

 O
The O
formed O
or O
, O
accompanied O
by O
( O
Fig.2d O
) O
. O

 O
Some O
was O
prominent O
; O
on O
the O
other O
hand O
, O
neither O
a O
nor O
was O
evident O
( O
Fig.2b O
, O
c O
) O
. O

 O
Conspicuous O
of O
was O
noted O
focally O
as O
well O
( O
Fig.3a O
) O
. O

 O
The O
chromophobic O
nature O
of O
tumor O
cells O
was O
confirmed O
by O
( O
) O
stain O
( O
Fig.3b O
) O
. O

 O
showed O
strong O
diffuse O
positivity O
for O
( O
Fig.3c O
) O
, O
, O
and O
. O

 O
No O
( O
, O
, O
, O
, O
) O
were O
expressed O
by O
tumor O
cells O
, O
and O
the O
, O
including O
S-100 O
protein O
( O
Fig.3d O
) O
, O
glial O
fibrillary O
acidic O
protein O
( O
GFAP O
) O
, O
epithelial O
membrane O
antigen O
( O
EMA O
) O
, O
cytokeratin O
AE1 O
/ O
AE3 O
( O
CK O
AE1 O
/ O
AE3 O
) O
, O
vimentin O
, O
p53 O
, O
and O
bcl-2 O
, O
were O
also O
by O
immunostaining O
. O

 O
was O
approximately O
. O

 O
A O
final O
diagnosis O
of O
PRL O
- O
producing O
pituitary B
adenoma I
was O
reached O
after O
considering O
the O
immunohistochemical O
profile O
, O
suprasellar O
location O
, O
and O
prolactin O
production O
of O
the O
tumor O
, O
as O
well O
as O
the O
absence O
of O
metastatic O
foci O
and O
invasion O
into O
surrounding O
tissue O
. O

Our O
patient O
was O
a O
with O
bicuspid O
and O
ascending O
. O

 O
He O
had O
undergone O
a O
free O
- O
hand O
aortic O
with O
of O
the O
using O
a O
in O
( O
at O
the O
age O
of O
41 O
) O
. O

 O
evaluations O
were O
performed O
and O
showed O
mild O
. O

 O
After O
8 O
years O
of O
, O
the O
patient O
to O
with O
and O
the O
showed O
severe O
due O
to O
a O
of O
, O
worsening O
of O
with O
( O
) O
( O
4045 O
% O
) O
and O
( O
, O
respectively O
) O
. O

 O
The O
patient O
presented O
and O
, O
which O
needed O
infusion O
of O
and O
. O

 O
scan O
showed O
on O
the O
, O
and O
no O
signs O
of O
( O
Fig.1 O
) O
. O

 O
Since O
the O
were O
, O
the O
final O
diagnosis O
was O
an O
early O
structural B
deterioration I
of O
the O
, O
due O
to O
a O
severe O
process O
. O

 O
The O
operation O
was O
performed O
through O
median O
and O
with O
standard O
aorta O
- O
right O
atrium O
for O
the O
extracorporeal O
circulation O
. O

 O
The O
leaflets O
and O
the O
annulus O
of O
the O
homograft O
presented O
severe O
calcifications O
and O
no O
signs O
of O
endocarditis B
were O
found O
. O

 O
An O
Edwards O
Intuity O
bioprosthesis O
( O
21 O
mm O
) O
was O
then O
( O
Fig.2 O
) O
. O

 O
The O
time O
was O
41 O
min O
, O
and O
the O
time O
was O
. O

 O
The O
patient O
required O
and O
at O
for O
bypass O
weaning O
. O

 O
No O
occurred O
during O
the O
postoperative O
period O
. O

 O
before O
the O
showed O
the O
absence O
of O
, O
a O
of O
and O
an O
of O
. O

 O
Follow O
- O
up O
from O
the O
operation O
showed O
neither O
nor O
of O
the O
Edwards O
Intuity O
, O
a O
of O
and O
initial O
recovery O
of O
the O
( O
valued O
) O
. O

 O
Patient O
was O
again O
. O

A O
presented O
with O
vaginal O
and O
abnormal O
. O

 O
Upon O
diagnosis O
of O
invasive O
non O
- O
keratinizing O
SCC B
of O
the O
, O
she O
underwent O
a O
radical O
with O
which O
demonstrated O
positive O
spread O
to O
the O
and O
the O
. O

 O
Pathological O
examination O
revealed O
that O
the O
tumour O
also O
extensively O
involved O
the O
. O

 O
, O
the O
woman O
underwent O
external O
beam O
and O
intracavitary O
. O

 O
, O
the O
patient O
presented O
with O
a O
history O
of O
a O
productive O
, O
, O
and O
a O
history O
of O
progressive O
exertional O
. O

 O
of O
the O
demonstrated O
a O
reticular O
nodular O
pattern O
, O
and O
revealed O
multiple O
bilateral O
patchy O
areas O
of O
ground O
glass O
opacity O
scarring O
with O
focal O
areas O
of O
subsegmental O
atelectasis O
within O
both O
lungs O
. O

 O
A O
differential O
diagnosis O
included O
interstitial O
pneumonia O
versus O
non O
- O
cardiogenic O
edema O
. O

 O
The O
woman O
underwent O
a O
, O
left O
, O
and O
an O
open O
wedge O
left O
lung O
. O

 O
of O
the O
left O
lung O
biopsy O
confirmed O
the O
presence O
of O
neoplastic O
sheets O
of O
cells O
classically O
distributed O
along O
the O
septal O
vessels O
, O
perivascular O
, O
peribronchial O
, O
and O
subpleural O
lymphatics O
. O

 O
Subpleural O
nodules O
were O
also O
identified O
with O
the O
presence O
of O
neoplastic O
cells O
distending O
the O
subpleural O
lymphatics O
confirming O
LC O
( O
Figures O
1A O
, O
1B O
, O
1C O
) O
. O

 O
On O
immunohistochemical O
analysis O
, O
the O
lesional O
cells O
were O
strongly O
positive O
to O
p16 O
( O
Figure O
1D O
) O
, O
high O
and O
low O
molecular O
weight O
keratins O
( O
Figure O
1E O
) O
, O
cytokeratin-7 O
( O
CK7 O
) O
( O
Figure O
1F O
) O
, O
CK19 O
, O
and O
pan O
keratin O
, O
and O
negative O
to O
CK20 O
, O
p63 O
, O
and O
EGFR O
. O

 O
Based O
on O
these O
findings O
, O
she O
was O
diagnosed O
to O
have O
lymphangitic B
carcinomatosis I
in O
the O
metastatic O
from O
SCC O
of O
the O
cervix O
. O

 O
She O
was O
started O
on O
chemotherapy O
( O
Carbo O
/ O
) O
with O
while O
in O
the O
hospital O
, O
and O
was O
ten O
days O
later O
. O

 O
Post O
- O
treatment O
improvement O
of O
clinical O
symptoms O
was O
paralleled O
by O
that O
showed O
marked O
interval O
improvement O
of O
the O
nodular O
opacifications O
and O
the O
interstitial O
thickening O
that O
had O
previously O
been O
noted O
. O

 O
Despite O
this O
improvement O
, O
she O
subsequently O
. O

An O
with O
a O
history O
of O
headaches O
and O
vomiting O
that O
had O
been O
present O
for O
. O

 O
Physical O
examination O
showed O
papilledema B
without O
the O
presence O
of O
any O
other O
neurological B
deficits I
. O

 O
( O
) O
revealed O
a O
large O
prepontine O
with O
dorsal O
of O
the O
and O
a O
secondary O
obstructive O
hydrocephalus B
due O
to O
of O
the O
. O

 O
The O
had O
an O
inhomogeneous O
on O
the O
( O
) O
and O
an O
inhomogeneous O
on O
the O
( O
) O
. O

 O
After O
administration O
of O
IV O
, O
there O
was O
some O
inhomogeneous O
( O
Fig.1 O
) O
. O

 O
( O
) O
imaging O
showed O
no O
. O

 O
During O
the O
first O
operation O
, O
a O
ventriculoperitoneal O
was O
inserted O
into O
the O
to O
treat O
the O
. O

 O
A O
careful O
study O
of O
the O
MRI O
suggested O
that O
this O
infra- O
and O
supratentorially O
located O
tumour O
might O
be O
resected O
through O
a O
single O
approach O
. O

 O
A O
left O
frontotemporal O
was O
performed O
to O
gain O
access O
to O
the O
tumour O
. O

 O
The O
tumour O
had O
well O
- O
defined O
margins O
and O
was O
entirely O
located O
in O
the O
intradural O
plane O
. O

 O
There O
were O
no O
attachments O
to O
the O
cranial O
nerves O
or O
brainstem O
. O

 O
A O
macroscopic O
complete O
resection O
was O
performed O
. O

 O
Postoperatively O
, O
the O
patient O
had O
developed O
a O
left O
oculomotor O
nerve O
palsy O
, O
which O
completely O
recovered O
within O
the O
next O
4 O
weeks O
. O

 O
The O
postoperative O
MRI O
showed O
a O
complete O
removal O
of O
the O
tumour O
( O
Fig.2 O
) O
. O

 O
After O
careful O
consideration O
by O
a O
multidisciplinary O
team O
, O
we O
decided O
that O
there O
was O
no O
indication O
for O
postoperative O
radiation O
therapy O
. O

 O
At O
follow O
- O
up O
one O
and O
a O
half O
years O
later O
, O
the O
patient O
was O
found O
to O
have O
remained O
asymptomatic O
. O

 O
There O
were O
no O
signs O
of O
tumour O
recurrence O
on O
the O
MRI O
scan O
. O

 O
At O
a O
follow O
- O
up O
of O
more O
than O
6 O
years O
after O
treatment O
, O
there O
were O
still O
no O
signs O
of O
tumour O
recurrence O
on O
the O
MRI O
scan O
. O

 O
Histological O
examination O
showed O
a O
slightly O
lobulated O
tumour O
consisting O
of O
a O
chondromyxoid O
matrix O
. O

 O
The O
tumour O
cells O
showed O
a O
vacuolated O
and O
pale O
cytoplasm O
. O

 O
Moderate O
nuclear O
polymorphism O
was O
observed O
but O
no O
obvious O
mitotic O
activity O
( O
Fig.3 O
) O
. O

 O
Some O
calcifications O
were O
seen O
. O

 O
The O
tumour O
cells O
stained O
positive O
for O
pan O
- O
keratin O
, O
S-100 O
and O
epithelial O
membrane O
antigen O
( O
EMA O
) O
. O

 O
These O
findings O
suggest O
a O
histopathological O
diagnosis O
of O
chordoma B
. O

A O
who O
to O
the O
with O
, O
and O
for O
. O

 O
He O
complained O
of O
mild O
but O
had O
normal O
. O

 O
He O
did O
not O
have O
chest O
or O
. O

 O
Further O
inquiry O
revealed O
that O
he O
was O
. O

 O
On O
, O
patient O
was O
, O
. O

 O
His O
was O
and O
. O

 O
Rest O
of O
the O
was O
. O

 O
Initial O
performed O
on O
the O
day O
of O
admission O
revealed O
neutrophil O
, O
mild O
and O
microscopic O
( O
Table O
1 O
) O
. O

 O
and O
were O
. O

 O
revealed O
, O
. O

 O
( O
) O
was O
. O

 O
A O
clinical O
diagnosis O
of O
leptospirosis B
was O
made O
and O
he O
was O
started O
on O
intravenous O
in O
addition O
to O
adequate O
. O

 O
On O
the O
of O
illness O
, O
he O
developed O
with O
and O
. O

 O
revealed O
sinus O
with O
[ O
Figure O
1 O
] O
. O

 O
His O
( O
) O
showed O
gross O
cardiomegaly B
and O
bilateral O
pulmonary O
[ O
Figure O
2 O
] O
. O

 O
CVP O
( O
) O
was O
and O
2D O
revealed O
of O
, O
severe O
global O
hypokinesia B
and O
of O
20 O
% O
. O

 O
Troponin O
I O
was O
12.77 O
ng O
/ O
ml O
( O
normal O
range O
 O
< O
 O
0.40 O
) O
. O

 O
He O
was O
diagnosed O
to O
have O
early O
and O
severe O
myocarditis B
. O

 O
Patient O
was O
to O
( O
) O
as O
he O
needed O
. O

 O
Intravenous O
including O
, O
and O
were O
continued O
. O

 O
Patient O
was O
electively O
on O
the O
of O
illness O
due O
to O
severe O
respiratory B
distress I
. O

 O
On O
the O
same O
day O
, O
he O
developed O
rapid O
atrial B
fibrillation I
[ O
Figure O
3 O
] O
unresponsive O
to O
and O
intravenous O
. O

 O
to O
and O
he O
was O
given O
to O
prevent O
bleeding O
[ O
Table O
1 O
] O
. O

 O
We O
started O
intravenous O
based O
on O
previous O
studies O
showing O
a O
mortality O
benefit O
in O
severe O
leptospirosis O
complicated O
with O
myocarditis O
[ O
11 O
] O
. O

 O
His O
serum O
to O
by O
the O
of O
illness O
and O
( O
) O
and O
( O
) O
were O
markedly O
up O
to O
and O
respectively O
. O

 O
Dengue O
and O
Mycoplasma O
infections B
were O
excluded O
. O

 O
were O
. O

 O
Leptospira O
IgM O
performed O
on O
the O
of O
illness O
was O
positive O
( O
) O
. O

 O
Patient O
developed O
refractory B
shock I
and O
of O
persistent O
ventricular O
despite O
optimal O
in O
the O
. O

A O
was O
referred O
by O
to O
with O
suspected O
LTG B
due O
to O
repeatedly O
irregular O
, O
advanced O
optic O
disc O
cupping O
, O
normal O
( O
) O
and O
a O
family O
history O
of O
glaucoma B
. O

 O
The O
patient O
subjectively O
felt O
that O
vision O
in O
his O
 O
good O
 O
( O
) O
, O
which O
normally O
had O
a O
visual O
acuity O
of O
, O
started O
to O
deteriorate O
; O
at O
the O
point O
of O
referral O
it O
was O
best O
corrected O
to O
. O

 O
His O
( O
) O
was O
known O
to O
be O
amblyopic B
with O
a O
visual O
acuity O
of O
. O

 O
His O
medical O
history O
included O
considerable O
risk O
factors O
for O
systemic O
vasculopathy O
, O
such O
as O
hypertension B
, O
hypercholesterolaemia B
, O
of O
and O
type B
2 I
diabetes I
with O
no O
diabetic B
retinopathy I
. O

 O
Despite O
detailed O
questioning O
, O
he O
denied O
any O
apart O
from O
experiencing O
increased O
. O

 O
Clinical O
examination O
at O
revealed O
advanced O
bilateral O
with O
a O
right O
( O
) O
and O
left O
( O
; O
figure O
1 O
) O
. O

 O
Furthermore O
, O
the O
findings O
from O
the O
referring O
of O
equal O
and O
reactive O
pupils O
, O
normal O
eye O
movements O
and O
in O
were O
confirmed O
. O

 O
showed O
constricted O
in O
both O
, O
albeit O
with O
considerably O
raised O
false O
- O
negative O
error O
rates O
( O
figure O
2A O
) O
. O

 O
Since O
this O
can O
be O
a O
result O
of O
poor O
concentration O
and O
attention O
span O
with O
testing O
compounded O
, O
especially O
with O
an O
amblyopic O
, O
the O
was O
repeated O
( O
figure O
2B O
) O
. O

 O
At O
this O
visit O
, O
the O
patient O
experienced O
further O
deterioration O
of O
his O
 O
good O
 O
. O

 O
measured O
( O
loss O
of O
one O
Snellen O
line O
) O
in O
his O
amblyopic O
, O
and O
( O
loss O
of O
two O
Snellen O
lines O
) O
in O
his O
, O
which O
now O
also O
showed O
depressed O
. O

 O
An O
urgent O
of O
the O
patient O
's O
and O
was O
requested O
to O
rule O
out O
a O
compressive O
lesion B
and O
was O
carried O
out O
to O
screen O
for O
other O
causes O
of O
optic B
neuropathy I
including O
, O
and O
. O

 O
revealed O
a O
large O
mass B
centred O
at O
the O
measuring O
approximately O
( O
figure O
3A O
 O
C O
) O
extending O
into O
the O
and O
. O

 O
The O
and O
both O
were O
and O
. O

 O
The O
mass B
showed O
heterogeneous O
and O
T2 O
with O
multiple O
most O
likely O
due O
to O
previous O
haemorrhage B
and O
low O
- O
signal O
components O
suggesting O
calcifications B
. O

 O
The O
appearance O
was O
probably O
due O
to O
a O
craniopharyngioma B
or O
haemorrhagic O
pituitary B
adenoma I
. O

 O
The O
patient O
was O
referred O
urgently O
to O
the O
and O
was O
found O
to O
have O
markedly O
raised O
of O
, O
confirming O
the O
diagnosis O
of O
a O
giant O
prolactinoma B
. O

 O
In O
cooperation O
with O
the O
local O
endocrinology O
service O
, O
he O
was O
started O
on O
and O
. O

 O
this O
led O
to O
a O
dramatic O
improvement O
of O
the O
patient O
's O
to O
RE O
and O
to O
. O

 O
His O
showed O
a O
similar O
dramatic O
response O
with O
levels O
coming O
down O
to O
336 O
 O
mIU O
/ O
L. O

 O
his O
in O
his O
and O
were O
and O
, O
respectively O
, O
and O
showed O
striking O
recovery O
with O
( O
figure O
2C O
) O
. O

A O
to O
our O
with O
complaints O
of O
since O
to O
admission O
. O

 O
on O
admission O
revealed O
an O
elevation O
of O
, O
, O
, O
and O
. O

 O
Serum O
total O
bilirubin O
and O
tumor O
markers O
, O
carcinoembryonic O
antigen O
( O
CEA O
) O
, O
carbohydrate O
antigen O
19 O
- O
9 O
( O
CA19 O
- O
9 O
) O
, O
SPan-1 O
, O
and O
neuron O
- O
specific O
enolase O
( O
NSE O
) O
, O
were O
all O
within O
normal O
ranges O
. O

 O
Abdominal O
computed O
tomography O
( O
CT O
) O
and O
magnetic O
resonance O
cholangiopancreatography O
( O
MRCP O
) O
showed O
a O
mass O
in O
an O
enlarged O
gallbladder O
and O
bulky O
hepatic O
lymph O
nodes O
surrounding O
the O
hepatic O
hilum O
( O
Fig.1a O
, O
b O
) O
. O

 O
There O
were O
also O
no O
apparent O
lesions O
in O
upper O
and O
lower O
gastrointestinal O
endoscopy O
. O

 O
Endoscopic O
ultrasound O
- O
guided O
fine O
- O
needle O
aspiration O
( O
EUS O
- O
FNA O
) O
was O
performed O
to O
obtain O
tissue O
from O
the O
hilar O
lymph O
node O
. O

 O
Immunohistochemical O
staining O
of O
the O
specimen O
identified O
diffuse O
positivity O
for O
keratin O
, O
CD56 O
, O
and O
synaptophysin O
in O
the O
tumor O
cells O
, O
which O
is O
consistent O
with O
NEC O
. O

 O
An O
endoscopic O
naso O
- O
gallbladder O
drainage O
( O
ENGBD O
) O
catheter O
was O
placed O
, O
and O
the O
bile O
cytology O
revealed O
class O
V O
malignant O
cells O
. O

 O
Therefore O
, O
positron O
emission O
tomography O
/ O
computed O
tomography O
( O
PET O
/ O
CT O
) O
examination O
was O
performed O
to O
evaluate O
other O
primary O
or O
metastatic O
lesions O
. O

 O
It O
revealed O
that O
no O
other O
accumulated O
lesions O
were O
identified O
, O
and O
the O
accumulation O
of O
18F O
fluorodeoxyglucose O
( O
FDG O
) O
was O
in O
the O
gallbladder O
( O
SUVmax O
7.8 O
) O
and O
lymph O
nodes O
( O
SUVmax O
13.4 O
) O
( O
Fig.1c O
, O
d O
) O
. O

 O
On O
the O
basis O
of O
these O
findings O
, O
the O
most O
likely O
diagnosis O
was O
a O
gallbladder O
NEC O
that O
was O
confined O
to O
the O
regional O
hepatic O
hilar O
lymph O
nodes O
metastasis O
. O

 O
Finally O
, O
we O
decided O
to O
perform O
surgical O
resection O
prior O
to O
chemotherapy O
because O
of O
concerns O
about O
complications O
developing O
from O
mechanical O
obstruction O
of O
the O
hepatic O
hilum O
by O
the O
enlarged O
lymph O
node O
. O

 O
She O
underwent O
cholecystectomy O
, O
hepatic O
hilar O
lymphadenectomy O
, O
extrahepatic O
biliary O
duct O
resection O
, O
and O
hepaticojejunostomy O
. O

 O
The O
bulky O
lymph O
nodes O
were O
totally O
resected O
as O
 O
en O
bloc O
 O
. O

 O
There O
were O
no O
apparent O
residual O
lesions O
surgically O
. O

 O
The O
postoperative O
course O
was O
uneventful O
and O
she O
was O
discharged O
on O
the O
tenth O
day O
after O
surgery O
. O

 O
Macroscopically O
, O
the O
tumor O
was O
58 O
 O
 O
 O
42 O
mm O
in O
size O
and O
was O
located O
in O
the O
fundus O
, O
which O
contained O
a O
yellowish O
gallstone O
( O
Fig.2a O
) O
. O

 O
A O
portion O
of O
the O
hepatic O
hilar O
lymph O
nodes O
( O
71 O
 O
 O
 O
37 O
mm O
) O
was O
also O
excised O
separately O
( O
Fig.2b O
) O
. O

 O
Microscopic O
examination O
of O
the O
gallbladder O
revealed O
a O
moderate O
to O
well O
differentiated O
tubular O
adenocarcinoma O
infiltrating O
from O
the O
mucosa O
to O
the O
muscular O
layer O
, O
but O
not O
the O
serosal O
surface O
, O
without O
any O
NEC O
components O
( O
Fig.2c O
, O
d O
) O
. O

 O
The O
tumor O
cells O
in O
the O
gallbladder O
are O
slightly O
positive O
for O
synaptophysin O
and O
CD56 O
, O
but O
negative O
for O
chromogranin O
A O
( O
Fig.2e O
 O
g O
) O
. O

 O
The O
resection O
margin O
from O
the O
liver O
bed O
was O
negative O
for O
tumor O
cells O
. O

 O
The O
epithelium O
around O
the O
carcinoma O
showed O
intestinal O
metaplasia O
with O
the O
goblet O
cells O
( O
Fig.4a O
) O
, O
which O
area O
was O
stained O
by O
alcian O
blue O
( O
Fig.4b O
) O
. O

 O
On O
the O
other O
hand O
, O
the O
hepatic O
hilar O
lymph O
nodes O
were O
composed O
of O
small O
round O
tumor O
cells O
with O
hyperchromatic O
nuclei O
and O
scant O
cytoplasm O
( O
Fig.3a O
) O
. O

 O
Some O
of O
the O
tumor O
cells O
were O
large O
and O
had O
vesicular O
nuclei O
. O

 O
The O
tumor O
cells O
were O
arranged O
in O
sheets O
, O
cords O
, O
or O
in O
a O
trabecular O
or O
rosette O
fashion O
and O
were O
interspersed O
with O
focal O
necrosis O
. O

 O
They O
were O
immunohistochemically O
positive O
for O
CD56 O
, O
synaptophysin O
, O
and O
chromogranin O
A O
( O
Fig.3b3d O
) O
. O

 O
The O
mitotic O
count O
was O
24 O
per O
10 O
high O
- O
power O
microscopic O
fields O
, O
and O
the O
Ki-67 O
proliferation O
index O
was O
7080 O
% O
, O
consistent O
with O
NEC O
. O

 O
The O
surgical O
dissection O
margin O
of O
the O
hepatic O
lymph O
nodes O
was O
microscopically O
cauterized O
within O
the O
tumor O
cells O
. O

 O
There O
was O
no O
invasion O
to O
the O
extrahepatic O
biliary O
duct O
. O

 O
As O
the O
result O
of O
thorough O
pathological O
re O
- O
evaluation O
by O
total O
segmentation O
, O
a O
negligible O
area O
of O
adenocarcinoma O
was O
detected O
in O
the O
lymph O
nodes O
( O
Fig.3e O
, O
f O
) O
. O

 O
The O
adenocarcinoma O
component O
and O
the O
intestinal O
metaplastic O
epithelium O
in O
the O
gallbladder O
were O
both O
positive O
for O
CDX2 O
( O
Fig.4a O
) O
, O
but O
the O
neuroendocrine O
component O
in O
hilar O
lymph O
nodes O
was O
negative O
for O
CDX2 O
( O
Fig.4b O
) O
. O

 O
Postoperatively O
, O
the O
patient O
received O
three O
cycles O
of O
carboplatin O
( O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
repeated O
every O
21 O
days O
) O
and O
etoposide O
( O
80 O
mg O
/ O
m2 O
on O
days O
1 O
through O
3 O
repeated O
every O
21 O
days O
) O
. O

 O
During O
the O
first O
course O
, O
grade O
4 O
neutropenia O
occurred O
and O
it O
was O
managed O
with O
prophylactic O
fluoroquinolones O
. O

 O
After O
4 O
months O
, O
multiple O
recurrences O
in O
the O
para O
- O
aortic O
lymph O
nodes O
were O
detected O
, O
which O
was O
pathologically O
demonstrated O
via O
EUS O
- O
FNA O
to O
be O
NEC O
. O

 O
The O
patient O
underwent O
second O
- O
line O
chemotherapy O
with O
amrubicin O
( O
24 O
mg O
/ O
m2 O
on O
days O
1 O
through O
3 O
repeated O
every O
21 O
days O
) O
. O

 O
Grade O
4 O
neutropenia O
and O
anemia O
developed O
during O
the O
courses O
, O
and O
she O
needed O
to O
receive O
pegylated O
granulocyte O
colony O
- O
stimulating O
factor O
and O
red O
blood O
cell O
transfusion O
. O

 O
However O
, O
she O
of O
progressive B
disease I
surgery O
. O

A O
was O
to O
our O
because O
of O
and O
( O
) O
, O
, O
and O
developmental B
delay I
on O
. O

 O
He O
was O
at O
, O
with O
a O
body O
weight O
of O
3.2 O
kg O
. O

 O
birth O
, O
he O
was O
owing O
to O
persistent O
. O

 O
A O
chest O
showed O
, O
and O
an O
revealed O
decreased O
( O
: O
24 O
% O
) O
. O

 O
Under O
the O
impression O
of O
myocarditis O
, O
he O
had O
been O
managed O
for O
1 O
yr O
before O
in O
our O
. O

 O
Moreover O
, O
the O
patient O
showed O
and O
from O
birth O
. O

 O
Before O
referral O
, O
he O
had O
been O
to O
because O
of O
infection B
episodes O
. O

 O
He O
was O
taking O
, O
, O
, O
and O
before O
referral O
. O

 O
When O
he O
was O
to O
our O
at O
, O
his O
was O
( O
less O
than O
3rd O
percentile O
) O
and O
his O
height O
was O
71 O
cm O
( O
less O
than O
3rd O
percentile O
) O
. O

 O
His O
overall O
motor O
development O
was O
delayed O
, O
and O
he O
could O
not O
sit O
alone O
. O

 O
He O
could O
say O
" O
mama O
" O
and O
" O
papa O
. O
" O
The O
recorded O
blood O
pressure O
and O
heart O
rate O
were O
94/30 O
mmHg O
and O
132 O
beats O
per O
minute O
, O
respectively O
. O

 O
On O
physical O
examination O
, O
no O
definite O
heart O
murmur O
was O
audible O
and O
the O
liver O
was O
not O
palpable O
. O

 O
He O
also O
showed O
persistent O
neutropenia O
, O
which O
started O
during O
his O
stay O
in O
the O
previous O
hospital O
. O

 O
His O
WBC O
and O
neutrophil O
counts O
were O
8,800/L O
and O
only O
2 O
% O
( O
176/L O
) O
, O
respectively O
. O

 O
The O
B O
- O
natriuretic O
peptide O
level O
was O
1,045 O
pg O
/ O
mL. O

 O
A O
chest O
radiograph O
showed O
mild O
cardiomegaly O
( O
cardiothoracic O
ratio O
: O
62.8 O
% O
; O
Fig.1A O
) O
, O
and O
an O
electrocardiogram O
showed O
a O
low O
QRS O
voltage O
at O
the O
limb O
leads O
. O

 O
An O
echocardiogram O
revealed O
a O
dilated O
and O
hypertrophied O
globular O
LV O
with O
a O
hypertrophied O
papillary O
muscle O
and O
hyper O
- O
trabeculation O
, O
which O
did O
not O
meet O
the O
criteria O
of O
LV O
non O
- O
compaction O
. O

 O
The O
other O
echocardiographic O
parameters O
were O
as O
follows O
: O
LV O
internal O
diameter O
at O
diastole O
, O
37.7 O
mm O
( O
Z O
= O
10.2 O
) O
; O
ejection O
fraction O
, O
36.6 O
% O
; O
and O
LV O
mass O
index O
, O
75.6 O
g O
( O
Z O
= O
6.3 O
; O
Fig.1B O
) O
. O

 O
To O
rule O
out O
the O
systemic O
cause O
of O
the O
dilated O
and O
hypertrophied O
LV O
, O
we O
performed O
a O
thoraco O
- O
abdominal O
computed O
tomographic O
( O
CT O
) O
angiography O
with O
contrast O
dye O
. O

 O
The O
CT O
findings O
showed O
no O
abnormality O
in O
the O
kidney O
and O
other O
organs O
and O
vessels O
. O

 O
However O
, O
after O
undergoing O
CT O
angiography O
, O
the O
patient O
showed O
abrupt O
high O
- O
grade O
spiking O
fever O
( O
Fig.2 O
) O
and O
developed O
secretory O
diarrhea O
( O
800 O
cc O
per O
day O
) O
associated O
with O
metabolic O
acidosis O
. O

 O
At O
this O
time O
, O
his O
WBC O
and O
neutrophil O
counts O
decreased O
to O
3,290/L O
and O
1 O
% O
( O
33/L O
) O
, O
respectively O
. O

 O
The O
B O
- O
natriuretic O
peptide O
level O
was O
greater O
than O
4,901 O
pg O
/ O
mL. O

 O
He O
did O
not O
show O
associated O
respiratory O
symptoms O
. O

 O
The O
results O
of O
the O
respiratory O
and O
gastrointestinal O
viral O
studies O
were O
negative O
, O
and O
the O
blood O
and O
stool O
cultures O
were O
negative O
for O
pathogens O
. O

 O
The O
C O
- O
reactive O
protein O
level O
was O
7.08 O
mg O
/ O
dL. O

 O
Despite O
supportive O
care O
including O
intravenous O
fluid O
resuscitation O
and O
empirical O
antibiotics O
, O
the O
patient O
's O
condition O
worsened O
, O
with O
aggravated O
metabolic O
acidosis O
and O
respiratory O
difficulty O
, O
requiring O
transfer O
to O
the O
intensive O
care O
unit O
( O
ICU O
) O
. O

 O
Just O
before O
the O
ICU O
transfer O
, O
the O
serum O
pH O
was O
6.881 O
; O
bicarbonate O
level O
, O
7.8 O
mmol O
/ O
L O
; O
and O
total O
CO2 O
was O
41.4 O
mm O
Hg O
. O

 O
Although O
the O
patient O
had O
been O
treated O
with O
intensive O
ventilator O
care O
, O
several O
inotropic O
agents O
, O
and O
other O
supportive O
care O
measures O
, O
he O
eventually O
from O
the O
aggravated O
metabolic O
acidosis O
and O
acutely O
decompensated O
heart B
failure I
the O
ICU O
. O

 O
During O
the O
in O
, O
we O
performed O
from O
the O
evidence O
of O
displayed O
cardiomyopathy B
, O
, O
and O
developmental B
delay I
. O

 O
The O
revealed O
that O
his O
TAZ O
gene O
harbored O
a O
novel O
hemizygous O
frameshift O
, O
( O
) O
, O
which O
he O
inherited O
from O
his O
( O
Fig.3 O
) O
. O

A O
presented O
with O
complaints O
of O
persistent O
, O
severe O
right O
-sided O
upper O
abdominal O
during O
deep O
inspiration O
, O
physical O
exercise O
and O
. O

 O
These O
complaints O
had O
developed O
gradually O
after O
. O

 O
This O
had O
been O
complicated O
by O
HELLP B
syndrome I
with O
a O
subcapsular O
liver O
sized O
, O
which O
had O
. O

 O
At O
current O
presentation O
, O
were O
. O

 O
She O
assured O
having O
never O
experienced O
signs O
suggestive O
of O
sexually B
transmitted I
diseases I
or O
pelvic B
inflammatory I
disease I
( B
PID I
) I
. O

 O
She O
had O
never O
undergone O
intra O
- O
abdominal O
. O

 O
An O
upper O
- O
abdominal O
revealed O
a O
at O
the O
, O
suspect O
of O
( O
Figure O
1 O
) O
. O

 O
She O
was O
to O
the O
, O
who O
performed O
a O
and O
confirmed O
the O
presence O
of O
a O
thick O
( O
Figure O
2 O
) O
. O

 O
was O
performed O
in O
the O
same O
session O
by O
and O
, O
followed O
by O
the O
instillation O
of O
1.5 O
L O
( O
) O
into O
the O
to O
prevent O
the O
formation O
of O
new O
adhesions O
. O

 O
On O
, O
she O
was O
free O
of O
. O

The O
patient O
was O
a O
with O
the O
following O
features O
of O
: O
absent O
C1 O
vertebra O
, O
supernumerary O
lumbar O
vertebrae O
, O
hypoplastic O
sacrum O
/ O
coccyx O
, O
fatty O
filum O
terminale O
with O
tethered O
spinal O
cord O
, O
and O
three O
fused O
ribs O
; O
an O
anorectal O
malformation O
including O
a O
cloaca O
consisting O
of O
a O
common O
urogenital O
sinus O
and O
a O
duplex O
vagina O
with O
midline O
septum O
; O
type O
C O
TE O
fistula O
; O
right O
renal O
agenesis O
with O
moderate O
left O
hydronephrosis O
and O
vesicoureteral O
reflux O
. O

 O
She O
had O
no O
cardiac O
or O
limb O
malformations O
, O
and O
no O
other O
major O
organ O
anomalies O
. O

 O
Both O
she O
and O
were O
additionally O
clinically O
diagnosed O
with O
hypermobile O
type O
Ehlers B
 I
Danlos I
syndrome I
, O
but O
family O
history O
was O
otherwise O
noncontributory O
. O

 O
The O
diagnosis O
of O
hypermobile O
type O
Ehlers B
 I
Danlos I
was O
based O
on O
the O
patient O
s O
hypermobility O
( O
9/9 O
on O
the O
Beighton O
hypermobility O
scale O
) O
, O
very O
soft O
, O
fragile O
skin O
with O
unusual O
scarring O
, O
and O
poor O
skin O
healing O
. O

 O
Skin O
biopsy O
was O
not O
performed O
, O
but O
testing O
on O
peripheral O
blood O
did O
not O
reveal O
mutations O
associated O
with O
other O
forms O
of O
Ehlers O
 O
Danlos O
syndrome O
. O

 O
Microarray O
analysis O
initially O
showed O
a O
maternally O
- O
inherited O
deletion O
at O
4q35.1 O
detected O
with O
one O
clone O
and O
confirmed O
by O
FISH O
( O
RP11 O
- O
173M11 O
) O
. O

 O
Subsequent O
performance O
of O
an O
180 O
K O
custom O
oligonucleotide O
microarray O
( O
Baylor O
College O
of O
Medicine O
Medical O
Genetics O
Laboratories O
) O
refined O
the O
deleted O
region O
deletion O
to O
a O
maximum O
size O
of O
1.37 O
Mb O
, O
with O
karyotype O
revised O
to O
46,XX O
, O
arr O
cgh O
4q35.1q35.2 O
( O
187,321 O
- O
768 O
- O
188,694 O
- O
589 O
) O
3 O
1 O
. O

 O
Genes O
in O
the O
deleted O
region O
, O
which O
contains O
a O
number O
of O
much O
smaller O
copy O
number O
variations O
( O
CNVs O
) O
identified O
in O
normal O
controls O
, O
include O
CYP4V2 O
, O
KLKB2 O
, O
F11 O
, O
MTRNR1A O
, O
and O
FAT1 O
, O
none O
of O
which O
can O
be O
clearly O
related O
to O
her O
phenotype O
, O
especially O
as O
her O
mother O
, O
from O
whom O
the O
deletion O
was O
inherited O
, O
is O
unaffected O
. O

 O
Evidence O
for O
mitochondrial O
dysfunction O
began O
at O
13 O
months O
of O
age O
with O
progressive O
muscle O
weakness O
, O
autonomic O
dysregulation O
, O
hypoglycemic O
episodes O
, O
exocrine O
pancreatic O
dysfunction O
, O
and O
decline O
of O
gastrointestinal O
function O
, O
eventually O
leading O
to O
total O
parenteral O
nutrition O
dependency O
due O
to O
visceral O
hyperalgesia O
, O
dysmotility O
, O
and O
malabsorption O
. O

 O
Muscle O
biopsy O
showed O
a O
mild O
increase O
in O
fiber O
size O
variability O
but O
no O
other O
findings O
consistent O
with O
mitochondrial O
disease O
, O
including O
via O
electron O
microscopy O
. O

 O
However O
, O
analysis O
of O
electron O
transport O
chain O
( O
ETC O
) O
activity O
showed O
normal O
activity O
of O
complexes O
I O
, O
II O
, O
and O
III O
, O
but O
complex O
IV O
, O
or O
cytochrome O
c O
oxidase O
, O
activity O
was O
45.4 O
lmol O
/ O
min O
/ O
g O
weight O
, O
well O
below O
the O
control O
range O
( O
148.9 O
+ O
/ O
67.2 O
lmol O
/ O
min O
/ O
g O
weight O
) O
. O

 O
Repeat O
ETC O
analysis O
in O
isolated O
mitochondria O
confirmed O
a O
profound O
and O
reproducible O
complex O
IV O
deficiency O
. O

 O
Citrate O
synthase O
activity O
and O
content O
in O
both O
ETC O
analyses O
were O
normal O
, O
confirming O
good O
sample O
quality O
and O
normal O
mitochondrial O
content O
. O

 O
Whole O
mitochondrial O
genome O
sequencing O
, O
and O
sequencing O
of O
and O
( O
and O
) O
and O
did O
not O
reveal O
abnormalities O
. O

A O
complained O
of O
in O
the O
for O
without O
scalp O
or O
. O

 O
( O
) O
was O
right O
eye O
and O
. O

 O
were O
. O

 O
revealed O
left O
optic O
nerve O
and O
a O
small O
disc O
margin O
. O

 O
was O
, O
was O
( O
normal O
020 O
mm O
/ O
hr O
) O
and O
was O
( O
normal O
01.0 O
mg O
/ O
dL O
) O
. O

 O
, O
she O
noted O
new O
left O
eye O
and O
her O
declined O
to O
. O

 O
There O
was O
no O
. O

 O
The O
was O
and O
; O
the O
was O
, O
and O
there O
was O
a O
relative O
left O
afferent O
pupillary O
. O

 O
The O
left O
optic O
nerve O
was O
with O
a O
few O
peripapillary O
nerve O
fiber O
layer O
along O
with O
a O
cherry O
red O
and O
mild O
macular O
consistent O
with O
central B
retinal I
artery I
occlusion I
; O
there O
were O
no O
posterior O
pole O
or O
peripheral O
retinal O
. O

 O
were O
seen O
in O
the O
, O
but O
in O
the O
. O

 O
Repeat O
, O
and O
were O
. O

 O
Treponemal O
and O
Bartonella O
, O
the O
, O
, O
and O
carotid O
Doppler O
were O
. O

 O
Brain O
contrast O
demonstrated O
no O
enhancement O
. O

 O
, O
left O
eye O
and O
, O
and O
the O
patient O
complained O
of O
jaw O
and O
scalp O
. O

 O
declined O
to O
in O
the O
with O
1 O
+ O
in O
and O
2 O
+ O
. O

 O
revealed O
extensive O
retinal O
and O
diffuse O
with O
multiple O
areas O
of O
focal O
( O
Fig.1 O
) O
, O
consistent O
with O
acute B
retinal I
necrosis I
. O

 O
Vitreous O
fluid O
was O
examined O
by O
for O
amplifiable O
, O
, O
and O
sequences O
and O
returned O
positive O
for O
. O

 O
She O
was O
treated O
with O
a O
one O
- O
time O
intravitreal O
injection O
of O
in O
the O
, O
oral O
for O
14 O
days O
and O
oral O
for O
followed O
by O
for O
. O

 O
starting O
treatment O
, O
because O
she O
had O
recently O
developed O
jaw O
claudication O
and O
intermittent O
scalp O
pain O
, O
a O
temporal O
artery O
was O
performed O
. O

 O
was O
( O
Fig.2 O
) O
while O
demonstrated O
in O
the O
; O
evaluation O
of O
adjacent O
sections O
for O
and O
( O
CD45 O
, O
not O
shown O
) O
was O
( O
Fig.3 O
) O
. O

 O
Antiviral O
therapy O
was O
altered O
to O
intravenous O
, O
for O
, O
and O
were O
discontinued O
. O

A O
was O
to O
our O
with O
 O
history O
of O
massive O
rectal O
( O
rectorrhagia O
) O
. O

 O
He O
had O
past O
history O
of O
passage O
of O
fresh O
blood O
mixed O
stool O
since O
. O

 O
He O
first O
complained O
of O
. O

 O
He O
went O
numerous O
times O
for O
this O
; O
multiple O
were O
done O
but O
disease O
was O
not O
cured O
completely O
. O

 O
During O
one O
of O
his O
hospital O
visit O
in O
the O
past O
( O
patient O
forgot O
the O
date O
) O
, O
he O
was O
diagnosed O
and O
treated O
as O
hemorrhoids O
. O

 O
The O
symptom O
was O
relieved O
for O
a O
while O
and O
then O
recurred O
again O
. O

 O
Thirty O
years O
ago O
, O
he O
was O
diagnosed O
as O
rectal O
hemangioma O
and O
managed O
with O
cryotherapy O
in O
our O
hospital O
. O

 O
That O
could O
also O
just O
relieve O
the O
symptom O
for O
few O
years O
and O
it O
recurred O
again O
. O

 O
Then O
, O
he O
consulted O
many O
other O
hospitals O
, O
but O
could O
only O
get O
short O
- O
term O
symptomatic O
relief O
without O
proper O
treatment O
of O
the O
cause O
. O

 O
Since O
5 O
months O
, O
the O
severity O
of O
rectal O
bleeding O
increased O
. O

 O
He O
then O
went O
to O
local O
hospital O
where O
intervention O
was O
done O
to O
control O
bleeding O
and O
symptomatic O
treatment O
was O
done O
with O
intravenous O
fluid O
and O
blood O
transfusion O
. O

 O
He O
finally O
referred O
to O
our O
hospital O
for O
further O
evaluation O
. O

 O
Intermediate O
rectal O
bleeding O
of O
fresh O
blood O
was O
presented O
on O
admission O
. O

 O
Patient O
complained O
of O
dizziness O
on O
standing O
, O
shortness O
of O
breath O
, O
and O
palpitation O
on O
walking O
a O
short O
distance O
. O

 O
There O
was O
. O

 O
On O
, O
patient O
appeared O
, O
but O
his O
and O
were O
during O
rest O
. O

 O
He O
lost O
5 O
 O
kg O
of O
his O
body O
weight O
. O

 O
On O
, O
was O
seen O
and O
soft O
was O
felt O
on O
. O

 O
On O
, O
and O
rectum O
were O
seen O
filled O
with O
, O
but O
, O
, O
or O
was O
not O
detected O
. O

 O
On O
, O
was O
( O
Normal O
: O
4.325.72 O
 O
 O
 O
1012 O
/ O
L O
) O
and O
was O
( O
Normal O
: O
135175 O
 O
g O
/ O
L O
) O
. O

 O
were O
. O

 O
None O
enhanced O
showed O
isodense O
( O
35 O
 O
HU O
) O
homogenous O
bowel O
wall O
that O
on O
contrast O
- O
enhanced O
venous O
phase O
. O

 O
Multiple O
were O
seen O
in O
the O
and O
around O
the O
. O

 O
was O
seen O
extending O
from O
to O
( O
Fig.1 O
) O
. O

 O
Multiple O
hypodense O
were O
also O
seen O
in O
( O
Fig.2 O
) O
. O

 O
After O
initial O
management O
of O
, O
the O
patient O
underwent O
abdominal O
followed O
by O
. O

 O
During O
surgery O
, O
25 O
 O
cm O
long O
was O
found O
extending O
from O
to O
. O

 O
Whole O
of O
the O
rectum O
and O
part O
of O
the O
sigmoid O
colon O
were O
excised O
and O
sigmoid O
- O
anus O
was O
done O
. O

 O
Postsurgical O
of O
showed O
submucosal O
multiple O
thin O
- O
walled O
vessel O
of O
varying O
size O
with O
interposed O
stroma O
. O

 O
Some O
vessels O
lumen O
consisted O
of O
blood O
cells O
( O
consistent O
with O
blood O
vessel O
) O
, O
whereas O
other O
consisted O
of O
clear O
fluid O
( O
consistent O
with O
lymph O
vessel O
) O
. O

 O
of O
specimen O
showed O
endothelial O
cells O
positive O
for O
and O
. O

 O
Some O
cells O
were O
positive O
for O
, O
while O
others O
were O
negative O
for O
( O
Fig.3 O
) O
. O

 O
On O
the O
basis O
of O
histopathological O
report O
and O
immunohistochemistry O
, O
hemolymphangioma B
was O
diagnosed O
. O

 O
The O
surgery O
, O
which O
followed O
by O
complication O
( O
intestinal O
infection B
) O
, O
was O
well O
managed O
and O
the O
patient O
was O
from O
on O
the O
of O
surgery O
. O

 O
Then O
after O
, O
no O
further O
or O
was O
noticed O
during O
. O

 O
This O
study O
was O
approved O
by O
the O
First O
Affiliated O
Hospital O
of O
Sun O
Yat O
- O
Sen O
University O
Institutional O
Review O
Board O
. O

 O
Written O
consent O
for O
this O
case O
report O
was O
obtained O
from O
the O
patient O
. O

A O
with O
a O
of O
enlarging O
involving O
the O
history O
of O
trauma O
. O

 O
Physical O
examination O
showed O
a O
mass O
of O
an O
3x4 O
cm O
in O
diameter O
, O
localized O
in O
the O
right O
inter O
- O
scapular O
region O
. O

 O
The O
mass O
was O
ulcerative O
helophytic O
, O
grayish O
in O
colour O
, O
hard O
in O
consistency O
and O
easily O
bleeding O
on O
manipulation O
. O

 O
The O
remainder O
of O
the O
examination O
was O
unremarkable O
; O
no O
lymphadenopathy O
and O
no O
abdominal O
masses O
were O
felt O
. O

 O
After O
resection O
, O
the O
histological O
examinations O
of O
the O
specimens O
have O
concluded O
for O
basal O
cell O
carcinoma O
. O

 O
A O
local O
recurrence O
was O
observed O
18 O
months O
later O
; O
the O
patient O
was O
admitted O
to O
our O
institution O
for O
Lumpectomy O
( O
Figure O
1 O
) O
. O

 O
Histopathological O
examination O
revealed O
a O
syringomatous O
pattern O
infiltrating O
the O
dermis O
( O
Figure O
2 O
, O
Figure O
3 O
) O
, O
subcutis O
and O
skeletal O
muscle O
. O

 O
The O
neoplastic O
epithelial O
cells O
were O
arranged O
in O
interconnecting O
cords O
with O
microcystic O
areas O
. O

 O
Nests O
, O
cords O
, O
and O
tubules O
of O
the O
tumour O
extended O
into O
the O
dermis O
and O
into O
the O
adjacent O
muscle O
. O

 O
Many O
lobules O
showed O
squamous O
differentiation O
. O

 O
Sclerosis O
of O
stroma O
around O
the O
cords O
was O
present O
. O

 O
Tumour O
cells O
were O
not O
connected O
to O
the O
epidermis O
. O

 O
The O
immunohistochemical O
analysis O
showed O
positivity O
for O
anti O
- O
CK7 O
( O
Figure O
4 O
) O
, O
AE1 O
/ O
AE3 O
and O
negativity O
for O
anti O
CEA O
and O
anti O
CK20 O
. O

 O
Based O
upon O
her O
histological O
and O
immunohistochemical O
presentation O
, O
the O
diagnosis O
of O
syringomatous B
eccrine I
carcinoma I
was O
established O
. O

 O
of O
the O
involved O
area O
was O
performed O
( O
) O

A O
in O
her O
was O
found O
to O
have O
screen O
detected O
invasive O
lobular O
breast O
carcinoma O
of O
the O
right O
breast O
and O
invasive O
ductal O
carcinoma O
, O
no O
special O
type O
, O
of O
the O
left O
breast O
. O

 O
Staging O
CT O
imaging O
prior O
to O
mastectomy O
showed O
a O
12 O
 O
cm O
pelvic O
mass O
which O
on O
initial O
impression O
was O
thought O
to O
be O
a O
fibroid O
uterus O
. O

 O
Associated O
postmenopausal O
bleeding O
led O
to O
pelvic O
ultrasound O
, O
hysteroscopy O
and O
biopsy O
. O

 O
The O
biopsy O
showed O
undifferentiated O
sarcoma O
, O
unclassifiable O
with O
immunohistochemistry O
. O

 O
Following O
discussion O
at O
a O
multidisciplinary O
team O
meeting O
it O
was O
felt O
that O
the O
uterine O
tumour O
was O
a O
separate O
primary O
malignancy O
rather O
than O
metastasis O
from O
the O
breast O
. O

 O
Hysterectomy O
and O
bilateral O
salpingo O
- O
oophorectomy O
was O
performed O
for O
both O
treatment O
purposes O
and O
to O
fully O
categorise O
the O
malignancy O
to O
guide O
further O
adjuvant O
therapy O
. O

 O
Histological O
examination O
of O
the O
resection O
specimen O
showed O
a O
partially O
necrotic O
tumour O
with O
a O
discrete O
outline O
located O
within O
and O
extending O
throughout O
the O
myometrium O
. O

 O
The O
tumour O
was O
composed O
of O
malignant O
spindle O
cells O
( O
figure O
1A O
) O
, O
with O
an O
intermittent O
component O
of O
pleomorphic O
cells O
with O
abundant O
eosinophilic O
cytoplasm O
. O

 O
Plentiful O
osteoclast O
- O
like O
giant O
cells O
were O
present O
( O
figure O
1B O
) O
. O

 O
Mitoses O
were O
numerous O
and O
structurally O
abnormal O
forms O
were O
common O
. O

 O
Neoplastic O
cells O
were O
surrounded O
by O
hyaline O
osteoid O
matrix O
and O
foci O
of O
coarse O
neoplastic O
woven O
bone O
( O
figure O
1C O
) O
. O

 O
Generous O
sampling O
of O
the O
tumour O
showed O
no O
admixed O
neoplastic O
epithelial O
elements O
, O
thus O
ruling O
out O
the O
more O
common O
carcinosarcoma O
( O
malignant O
mixed O
Mllerian O
tumour O
) O
. O

 O
Tumour O
cells O
showed O
immunohistochemical O
expression O
for O
vimentin O
, O
smooth O
muscle O
actin O
( O
SMA O
) O
, O
desmin O
( O
focally O
) O
and O
CD99 O
. O

 O
Epithelial O
markers O
were O
not O
expressed O
. O

 O
The O
morphological O
and O
immunohistochemical O
appearances O
were O
in O
keeping O
with O
primary O
uterine O
osteoblastic O
variant O
of O
osteosarcoma O
. O

 O
Unfortunately O
, O
despite O
treatment O
, O
further O
CT O
imaging O
showed O
the O
development O
of O
multiple O
peritoneal O
and O
pulmonary O
deposits O
, O
confirmed O
on O
biopsy O
to O
be O
metastatic O
osteosarcoma O
. O

 O
The O
patient O
received O
palliative O
chemotherapy O
and O
. O

A O
with O
a O
complaint O
of O
right O
upper O
quadrant O
. O

 O
, O
the O
patient O
was O
incidentally O
diagnosed O
with O
idiopathic O
BCS B
during O
health O
; O
Doppler O
( O
) O
examination O
showed O
of O
the O
, O
and O
investigations O
for O
underlying O
thrombophilia B
were O
unremarkable O
. O

 O
She O
was O
treated O
with O
to O
maintain O
an O
, O
but O
discontinued O
after O
at O
least O
1 O
year O
due O
to O
non O
- O
compliance O
; O
the O
patient O
did O
not O
with O
any O
doctors O
for O
. O

 O
She O
has O
remained O
for O
the O
until O
recently O
she O
started O
experiencing O
steadily O
worsening O
, O
intermittent O
in O
the O
of O
her O
abdomen O
, O
with O
no O
associated O
or O
alleviating O
factors O
. O

 O
was O
only O
notable O
for O
mild O
right O
upper O
quadrant O
. O

 O
Laboratory O
tests O
revealed O
mildly O
elevated O
bilirubin O
( O
2.2 O
mg O
/ O
dL O
) O
and O
albumin O
deficit O
( O
2.38 O
g O
/ O
dL O
) O
. O

 O
Her O
Child O
- O
Pugh O
( O
CP O
) O
score O
was O
8 O
, O
Model O
for O
End O
- O
Stage O
Liver O
Disease O
( O
MELD O
) O
score O
was O
11 O
, O
Rotterdam O
score O
was O
0.15 O
, O
and O
BCS O
- O
TIPS O
prognostic O
index O
( O
BCS O
- O
TIPS O
PI O
) O
score O
was O
6.3 O
. O

 O
A O
contrast O
- O
enhanced O
computed O
tomography O
( O
CT O
) O
scan O
showed O
non O
- O
visualized O
middle O
and O
left O
hepatic O
veins O
, O
hepatomegaly O
with O
hypertrophy O
of O
the O
caudate O
lobe O
, O
splenomegaly O
, O
hepatic O
venous O
collaterals O
, O
and O
a O
saccular O
aneurysm O
located O
at O
the O
extrahepatic O
portal O
vein O
main O
branch O
measuring O
3.2 O
cm O
in O
height O
and O
2.5 O
cm O
 O
2.4 O
cm O
in O
diameter O
( O
Figure O
1A O
) O
. O

 O
The O
aneurysm O
was O
thought O
to O
be O
associated O
with O
BCS O
as O
there O
was O
no O
preceding O
history O
of O
trauma O
and O
it O
had O
not O
been O
present O
on O
Doppler O
US O
examination O
performed O
3 O
years O
previously O
. O

 O
Although O
the O
patient O
had O
no O
ascites O
or O
variceal O
bleeding O
, O
the O
decision O
was O
made O
to O
create O
a O
TIPS O
to O
relieve O
hepatic O
venous O
outflow O
obstruction O
because O
of O
increasing O
pain O
and O
concern O
for O
complications O
due O
to O
aneurysm O
size O
; O
direct O
approach O
to O
the O
aneurysm O
was O
not O
considered O
due O
to O
risk O
of O
associated O
complications O
in O
the O
setting O
of O
portal O
hypertension O
, O
and O
stent O
- O
grafting O
was O
not O
considered O
due O
to O
concerns O
about O
patency O
in O
the O
settings O
of O
hepatic O
venous O
outflow O
obstruction O
and O
underlying O
thrombophilia O
. O

 O
After O
informed O
consent O
was O
obtained O
, O
the O
patient O
was O
brought O
to O
the O
interventional O
radiology O
suite O
. O

 O
The O
procedure O
was O
performed O
with O
the O
patient O
under O
conscious O
sedation O
. O

 O
Portal O
vein O
access O
was O
obtained O
via O
the O
right O
hepatic O
vein O
under O
fluoroscopy O
, O
and O
portography O
showed O
a O
saccular O
aneurysm O
located O
at O
the O
main O
portal O
vein O
, O
extensive O
intrahepatic O
portal O
vein O
thrombosis O
, O
and O
small O
splenorenal O
varices O
( O
Figure O
2A O
) O
. O

 O
A O
10 O
- O
mm O
diameter O
expanded O
polytetrafluoroethylene O
( O
ePTFE O
) O
covered O
stent O
- O
graft O
( O
Fluency O
Plus O
; O
Bard O
Peripheral O
Vascular O
, O
Tempe O
, O
Arizona O
, O
United O
States O
) O
was O
deployed O
across O
the O
liver O
parenchymal O
tract O
; O
deploying O
the O
stent O
- O
graft O
into O
the O
main O
portal O
vein O
trunk O
to O
cover O
the O
aneurysm O
neck O
was O
not O
considered O
because O
it O
would O
obstruct O
blood O
flow O
to O
the O
portal O
vein O
branches O
. O

 O
Completion O
portography O
showed O
a O
widely O
patent O
shunt O
and O
markedly O
decreased O
aneurysm O
filling O
( O
Figure O
2B O
) O
. O

 O
The O
portosystemic O
pressure O
gradient O
( O
PPG O
) O
was O
decreased O
from O
19 O
mmHg O
to O
8 O
mmHg O
. O

 O
The O
patient O
recovered O
uneventfully O
and O
had O
complete O
resolution O
of O
her O
abdominal O
pain O
in O
2 O
d. O

 O
She O
was O
discharged O
on O
long O
- O
term O
warfarin O
and O
remained O
after O
of O
. O

 O
Most O
recent O
revealed O
normal O
, O
and O
Doppler O
examination O
performed O
at O
confirmed O
a O
. O

 O
Her O
score O
was O
5 O
, O
score O
was O
8 O
, O
score O
was O
0.12 O
, O
and O
score O
was O
. O

 O
scans O
showed O
that O
the O
had O
decreased O
in O
size O
to O
and O
at O
( O
Figure O
1B O
) O
, O
and O
had O
further O
decreased O
to O
and O
at O
( O
Figure O
1C O
) O
. O

A O
to O
the O
( O
) O
with O
acute O
onset O
of O
, O
, O
, O
and O
with O
associated O
generalized O
, O
, O
and O
. O

 O
He O
had O
been O
diagnosed O
with O
CML B
, O
with O
no O
hematological O
response O
to O
multiple O
; O
he O
was O
at O
that O
time O
on O
treatment O
with O
and O
allogenic O
. O

 O
on O
to O
the O
included O
of O
, O
of O
and O
of O
( O
) O
. O

 O
There O
were O
no O
remarkable O
findings O
on O
except O
for O
altered O
mental O
status O
and O
. O

 O
were O
: O
, O
( O
, O
, O
and O
) O
, O
and O
910109 O
/ O
L. O

 O
were O
: O
, O
, O
, O
, O
, O
, O
, O
, O
, O
and O
71 O
IU O
/ O
L. O

 O
was O
. O

 O
were O
: O
8.5 O
pg O
/ O
L O
( O
1565 O
pg O
/ O
L O
) O
, O
( O
< O
2 O
pg O
/ O
L O
) O
, O
( O
2050 O
ng O
/ O
mL O
) O
and O
( O
1864 O
) O
ng O
/ O
mL. O

 O
Chest O
showed O
diffuse O
lytic O
and O
throughout O
the O
visualized O
, O
concerning O
for O
diffuse O
. O

 O
The O
clinical O
history O
and O
biochemical O
findings O
led O
to O
a O
diagnosis O
of O
CML O
- O
associated O
hypercalcemia O
in O
the O
context O
of O
a O
. O

 O
Treatment O
with O
aggressive O
with O
0.9 O
% O
and O
was O
administered O
. O

 O
Additionally O
, O
, O
, O
was O
given O
. O

 O
of O
treatment O
, O
normalization O
of O
and O
were O
achieved O
. O

 O
After O
from O
the O
, O
the O
patient O
continued O
with O
with O
and O
. O

 O
Acceptable O
were O
with O
. O

 O
Despite O
these O
therapies O
, O
his O
cancer B
progressed O
and O
he O
approximately O
the O
initial O
admission O
for O
hypercalcemia O
. O

An O
presented O
to O
a O
local O
clinic O
with O
on O
exertion O
and O
left O
back O
persisting O
for O
a O
month O
. O

 O
She O
was O
to O
our O
because O
of O
left O
on O
a O
chest O
. O

 O
She O
suffered O
and O
dyslipidemia O
but O
had O
, O
nor O
a O
smoking O
history O
or O
dust O
exposure O
. O

 O
On O
, O
her O
and O
were O
( O
: O
) O
. O

 O
A O
revealed O
a O
on O
the O
left O
side O
of O
her O
back O
with O
and O
in O
the O
. O

 O
The O
rest O
of O
the O
were O
. O

 O
revealed O
elevated O
levels O
of O
, O
( O
) O
, O
and O
( O
) O
( O
Table O
1 O
) O
. O

 O
A O
chest O
( O
Fig.1 O
) O
showed O
left O
with O
. O

 O
, O
an O
was O
inserted O
, O
and O
after O
drainage O
, O
chest O
( O
) O
( O
Fig.2 O
) O
revealed O
an O
irregular O
pleural O
invading O
her O
with O
rib O
and O
. O

 O
The O
was O
, O
but O
the O
lateral O
side O
of O
the O
mass O
was O
thick O
and O
invading O
the O
chest O
wall O
, O
so O
we O
diagnosed O
this O
mass O
as O
a O
chest O
wall O
tumor O
. O

 O
The O
pleural O
fluid O
was O
serous O
and O
not O
. O

 O
A O
showed O
it O
to O
be O
, O
and O
. O

 O
The O
was O
, O
and O
did O
not O
show O
any O
evidence O
of O
( O
Table O
1 O
) O
. O

 O
CT O
- O
guided O
needle O
was O
performed O
. O

 O
The O
results O
supported O
a O
diagnosis O
of O
diffuse B
large I
B I
- I
cell I
lymphoma I
( O
DLBCL B
) O
that O
was O
positive O
for O
and O
but O
negative O
for O
and O
( O
Fig.3 O
) O
. O

 O
( O
) O
revealed O
in O
the O
left O
chest O
wall O
mass O
without O
any O
other O
uptake O
( O
Fig.4A O
and O
B O
) O
, O
so O
we O
diagnosed O
her O
with O
primary O
malignant O
lymphoma O
originating O
from O
the O
chest O
wall O
. O

 O
We O
reconfirmed O
her O
medical O
history O
, O
and O
she O
. O

 O
Her O
( O
) O
was O
because O
of O
her O
back O
pain O
and O
. O

 O
Owing O
to O
her O
bad O
PS O
and O
age O
, O
it O
was O
difficult O
to O
perform O
an O
operation O
or O
administer O
combination O
chemotherapy O
with O
Rituximab O
, O
so O
low O
- O
dose O
oral O
( O
) O
was O
administered O
. O

 O
Her O
disappeared O
, O
her O
back O
disappeared O
, O
and O
her O
improved O
to O
. O

 O
performed O
showed O
( O
Fig.4C O
and O
D O
) O
. O

 O
She O
continued O
oral O
and O
maintained O
a O
good O
for O
. O

The O
patient O
was O
a O
who O
with O
complaints O
of O
and O
a O
chronic O
. O

 O
He O
was O
a O
and O
had O
a O
that O
had O
been O
treated O
and O
cured O
. O

 O
A O
scan O
revealed O
multiple O
tiny O
in O
. O

 O
A O
thoracoscopic O
lung O
was O
taken O
from O
the O
. O

 O
The O
revealed O
a O
typical O
. O

 O
The O
had O
vesicular O
and O
grooved O
, O
and O
they O
formed O
small O
aggregations O
( O
Fig.1 O
) O
. O

 O
The O
were O
strongly O
positive O
for O
, O
, O
and O
. O

 O
There O
were O
infiltrations O
of O
and O
around O
the O
. O

 O
With O
performing O
additional O
, O
. O

 O
He O
, O
but O
he O
received O
no O
other O
specific O
treatment O
. O

 O
He O
was O
. O

 O
After O
this O
, O
a O
follow O
- O
up O
was O
performed O
and O
it O
showed O
a O
in O
the O
, O
in O
addition O
to O
the O
multiple O
tiny O
nodules O
in O
( O
Fig.2 O
) O
. O

 O
A O
needle O
specimen O
revealed O
the O
; O
therefore O
, O
a O
was O
performed O
. O

 O
Grossly O
, O
a O
was O
found O
( O
Fig.3 O
) O
, O
and O
there O
were O
a O
few O
around O
the O
. O

 O
, O
the O
were O
and O
they O
showed O
an O
. O

 O
The O
cytologic O
features O
of O
some O
of O
the O
were O
. O

 O
However O
, O
many O
showed O
overtly O
malignant O
such O
as O
and O
prominent O
( O
Fig.4 O
) O
, O
and O
multinucleated O
were O
also O
found O
. O

 O
There O
were O
numerous O
mitotic O
figures O
ranging O
from O
, O
and O
. O

 O
A O
few O
foci O
of O
remained O
. O

 O
, O
the O
tumor O
cells O
were O
for O
( O
Fig.5 O
) O
and O
; O
they O
were O
also O
for O
( O
Dako O
N1577 O
, O
Clone O
KPI O
) O
, O
and O
focally O
for O
( O
Fig.6 O
) O
, O
and O
they O
were O
for O
, O
, O
, O
and O
. O

 O
The O
ultrastructural O
analysis O
in O
the O
of O
the O
. O

 O
Now O
, O
at O
, O
the O
patient O
is O
with O
. O

A O
patient O
was O
with O
acute O
left B
ventricular I
( I
LV I
) I
failure I
and O
was O
treated O
with O
intensive O
. O

 O
He O
had O
severe O
peripheral O
and O
bilateral O
basal O
. O

 O
Initial O
revealed O
normal O
levels O
of O
( O
) O
and O
( O
) O
, O
thereby O
ruling O
out O
acute B
coronary I
syndrome I
. O

 O
The O
level O
of O
was O
confirming O
the O
diagnosis O
of O
heart B
failure I
. O

 O
revealed O
of O
with O
, O
and O
estimated O
( O
) O
was O
with O
. O

 O
was O
performed O
of O
which O
revealed O
critical O
triple B
vessel I
disease I
with O
left O
main O
coronary B
artery I
disease I
( O
Fig.1 O
) O
. O

 O
He O
was O
referred O
for O
. O

 O
The O
patient O
was O
put O
on O
with O
oral O
and O
. O

 O
He O
was O
taken O
up O
for O
elective O
. O

 O
was O
monitored O
regularly O
. O

 O
There O
was O
no O
feature O
of O
end B
organ I
dysfunction I
. O

 O
was O
. O

 O
Repeat O
revealed O
improvement O
of O
to O
and O
decrease O
in O
to O
and O
decrease O
in O
. O

 O
was O
performed O
through O
. O

 O
was O
used O
for O
grafting O
( O
) O
. O

 O
After O
, O
( O
) O
and O
composite O
, O
was O
prepared O
. O

 O
The O
distal O
end O
of O
RITA O
was O
used O
for O
the O
. O

 O
There O
was O
significant O
improvement O
in O
systolic O
after O
this O
distal O
. O

 O
After O
these O
two O
grafts O
, O
heart O
was O
. O

 O
We O
make O
a O
longer O
, O
open O
the O
sternum O
widely O
, O
and O
release O
pericardium O
on O
the O
right O
side O
to O
displace O
the O
heart O
gradually O
. O

 O
This O
was O
supplemented O
with O
headlow O
and O
lateral O
tilt O
position O
. O

 O
Liberal O
doses O
of O
inotropic O
support O
were O
used O
. O

 O
RA O
was O
used O
for O
sequential O
grafting O
of O
obtuse O
marginal O
, O
posterior O
LV O
branch O
, O
and O
posterior O
descending O
artery O
. O

 O
All O
these O
five O
distal O
anastamoses O
were O
performed O
uneventfully O
. O

 O
The O
patient O
was O
electively O
for O
. O

 O
on O
revealed O
improvement O
in O
to O
. O

 O
He O
was O
started O
on O
low O
dose O
after O
were O
weaned O
off O
. O

 O
He O
had O
slow O
and O
uneventful O
. O

 O
on O
revealed O
improvement O
in O
to O
( O
Table O
1 O
) O
. O

 O
He O
had O
persistent O
requiring O
prolonged O
. O

 O
After O
subsided O
and O
drains O
were O
removed O
, O
he O
was O
discharged O
on O
, O
low O
dose O
, O
and O
. O

A O
patient O
was O
admitted O
for O
, O
, O
and O
acute O
renal B
failure I
. O

 O
He O
had O
, O
did O
not O
take O
any O
, O
and O
. O

 O
He O
had O
. O

 O
his O
admission O
, O
he O
developed O
, O
fluctuant O
, O
, O
and O
in O
the O
. O

 O
On O
, O
was O
, O
. O

 O
showed O
severe O
involving O
both O
, O
as O
well O
as O
and O
. O

 O
Cervical O
and O
axillar O
infracentimetric O
lymphadenopathies B
were O
present O
, O
together O
with O
hepatosplenomegaly B
, O
confirmed O
by O
( O
) O
scan O
. O

 O
Bilateral O
arthritis B
of O
the O
resolved O
spontaneously O
. O

 O
revealed O
( O
Table O
(Table1):1 O
): O
, O
normal O
and O
levels O
with O
no O
biologic O
sign O
of O
, O
elevated O
, O
low O
, O
elevated O
serum O
, O
mild O
and O
no O
. O

 O
Despite O
intravenous O
using O
and O
, O
worsened O
and O
the O
patient O
required O
. O

 O
While O
diagnostic O
investigations O
were O
performed O
, O
hemiplegia B
occurred O
: O
brain O
showed O
multifocal O
ischemic O
. O

 O
Echographic O
and O
rythmologic O
ruled O
out O
any O
cardiologic O
cause O
for O
the O
stroke B
. O

 O
A O
renal O
was O
performed O
( O
Fig.1A O
and O
B O
) O
. O

 O
( O
) O
staining O
showed O
endotheliosis B
in O
all O
( O
Fig.1A O
, O
arrows O
) O
, O
associated O
with O
mesangiolysis B
and O
on O
( O
Fig.1B O
, O
arrows O
) O
, O
and O
no O
arteriolar O
. O

 O
A O
moderate O
CD20 O
+ O
B O
lymphocyte O
infiltrate O
was O
present O
in O
the O
interstitium O
, O
with O
a O
peritubularcapillaritis O
. O

 O
Immunofluorescence O
study O
did O
not O
show O
any O
deposit O
. O

 O
Lymph O
node O
biopsy O
( O
Fig.2A O
and O
B O
) O
showed O
abnormal O
follicles O
with O
hyalinization O
of O
germinal O
center O
, O
and O
an O
onion O
- O
skin O
aspect O
of O
the O
mantle O
zone O
. O

 O
Clinical O
presentation O
and O
lymph O
node O
histology O
were O
consistent O
with O
hyaline O
- O
vascular O
multicentric O
Castleman O
disease O
( O
MCD O
) O
. O

 O
HIV O
and O
HHV-8 O
serology O
, O
as O
well O
as O
HHV-8 O
lymph O
node O
tissue O
staining O
, O
were O
negative O
. O

 O
Serum O
vascular O
endothelium O
growth O
factor O
( O
VEGF O
) O
was O
highly O
elevated O
. O

 O
There O
was O
no O
biologic O
manifestation O
of O
thrombotic O
microangiopathy O
( O
TMA O
) O
, O
but O
the O
renal O
biopsy O
and O
brain O
MRI O
were O
consistent O
with O
glomerular O
and O
neurologic O
TMA O
lesions O
. O

 O
No O
other O
apparent O
cause O
of O
thrombotic O
microvascular O
involvement O
was O
noted O
. O

 O
Notably O
, O
there O
was O
no O
evidence O
for O
infection O
with O
shiga O
toxin O
- O
producing O
germs O
, O
ADAMTS-13 O
activity O
was O
decreased O
up O
to O
14 O
% O
but O
remained O
above O
5 O
% O
, O
and O
the O
alternative O
complement O
pathway O
was O
normal O
. O

 O
Plasma O
exchange O
was O
initiated O
due O
to O
the O
kidney O
histological O
lesions O
and O
the O
multifocal O
ischemic O
brain O
lesions O
. O

 O
It O
was O
discontinued O
after O
1 O
month O
after O
the O
onset O
of O
the O
disease O
, O
since O
the O
patient O
's O
condition O
remained O
stable O
. O

 O
Furthermore O
, O
chemotherapy O
including O
6 O
courses O
of O
rituximab O
( O
375 O
 O
mg O
/ O
m2 O
) O
, O
cyclophosphamide O
( O
750 O
 O
mg O
/ O
m2 O
) O
, O
and O
dexamethasone O
( O
40 O
 O
mg O
/ O
day O
from O
day O
1 O
to O
day O
4 O
) O
was O
started O
together O
with O
plasma O
exchanges O
( O
chemotherapy O
was O
performed O
immediately O
after O
plasma O
exchanges O
) O
. O

 O
Courses O
were O
performed O
every O
3 O
weeks O
. O

 O
Clinical O
manifestations O
of O
vascular O
leak O
syndrome O
regressed O
, O
renal O
function O
normalized O
, O
and O
serum O
VEGF O
level O
decreased O
to O
825 O
 O
pg O
/ O
mL O
after O
1 O
course O
of O
chemotherapy O
. O

 O
The O
patient O
was O
admission O
. O

 O
No O
neurological B
event I
occurred O
after O
initiating O
the O
treatment O
. O

 O
Thoraco O
- O
abdominal O
scan O
was O
performed O
after O
6 O
courses O
of O
chemotherapy O
, O
showing O
a O
normal O
liver O
and O
spleen O
and O
no O
lymph O
node O
. O

 O
One O
year O
after O
the O
diagnosis O
, O
remission O
of O
MCD B
is O
persistent O
and O
plasma O
is O
, O
with O
no O
. O

A O
was O
with O
a O
history O
of O
continuous O
, O
moderate O
right O
upper O
quadrant O
associated O
with O
, O
as O
well O
as O
( O
over O
) O
and O
a O
liver O
identified O
by O
. O

 O
The O
pain O
sensation O
seemed O
different O
from O
previous O
the O
patient O
had O
experienced O
before O
she O
underwent O
laparoscopic O
. O

 O
On O
, O
she O
was O
( O
) O
, O
with O
noted O
over O
the O
, O
and O
. O

 O
Imaging O
modalities O
included O
( O
) O
, O
( O
) O
and O
( O
) O
( O
Fig.1 O
) O
. O

 O
The O
patient O
underwent O
exploratory O
. O

 O
Intraoperative O
revealed O
a O
cystic O
measuring O
within O
the O
, O
. O

 O
Intraoperative O
demonstrated O
an O
extensive O
obliterating O
the O
, O
with O
partial O
of O
the O
. O

 O
An O
extended O
left O
was O
done O
. O

 O
On O
, O
all O
were O
. O

 O
was O
performed O
with O
a O
Roux O
- O
en O
- O
Y O
to O
in O
the O
. O

 O
Intraoperatively O
, O
was O
applied O
to O
the O
. O

 O
After O
this O
, O
the O
patient O
underwent O
of O
image O
- O
guided O
external O
beam O
centred O
on O
the O
labelled O
at O
surgery O
. O

 O
The O
final O
pathology O
described O
this O
tumour O
as O
an O
infiltrating O
, O
moderately O
differentiated O
squamous B
cell I
carcinoma I
associated O
with O
severe O
dysplasia B
of O
the O
( O
Fig.2 O
) O
. O

 O
The O
patient O
without O
and O
was O
the O
initial O
surgical O
procedure O
, O
with O
an O
unremarkable O
. O

A O
to O
the O
of O
in O
September O
2015with O
a O
complaint O
of O
recurrent O
infections B
in O
the O
. O

 O
She O
reported O
abdominal O
similar O
to O
a O
burning O
sensation O
that O
accompanied O
the O
. O

 O
These O
symptoms O
and O
signs O
waxed O
and O
waned O
but O
. O

 O
Our O
attention O
was O
piqued O
by O
the O
fact O
that O
the O
patient O
s O
family O
described O
the O
patient O
as O
an O
individual O
who O
cried O
easily O
. O

 O
The O
patient O
had O
no O
history O
of O
, O
or O
. O

 O
was O
mentioned O
in O
her O
prior O
medical O
history O
. O

 O
Acoordinated O
revealed O
normal O
vital O
signs O
. O

 O
An O
external O
fistula O
was O
located O
in O
the O
umbilical O
region O
with O
redness O
of O
the O
surrounding O
skin O
. O

 O
Morphological O
examination O
indicated O
that O
fistula O
secretions O
mainly O
consisted O
of O
small O
intestinal O
juice O
. O

 O
The O
abdominal O
wall O
was O
soft O
, O
with O
no O
tenderness O
. O

 O
Bowel O
sounds O
were O
regular O
. O

 O
Escherichia O
coli O
and O
Enterococcus O
faecalis O
were O
detected O
in O
the O
fistula O
secretion O
culture O
. O

 O
Other O
findings O
from O
laboratory O
examinations O
were O
normal O
. O

 O
A O
CT O
scan O
of O
the O
abdomen O
revealed O
that O
part O
of O
the O
intestinal O
wall O
was O
adhered O
to O
the O
abdominal O
wall O
in O
the O
navel O
region O
, O
although O
no O
bowel O
obstruction O
was O
detected O
( O
Fig.1 O
) O
. O

 O
A O
presumptive O
diagnosis O
of O
ECF B
was O
reached O
; O
this O
diagnosis O
was O
mainly O
based O
on O
digital O
radiography O
of O
the O
fistulous O
tract O
conducted O
using O
iopamidol-370 O
as O
a O
contrast O
agent O
. O

 O
This O
procedure O
was O
performed O
under O
local O
anaesthesia O
and O
revealed O
that O
the O
distal O
ileum O
approximately O
40 O
cm O
from O
the O
ileocaecal O
junction O
was O
entrapped O
( O
Fig.2 O
) O
. O

 O
The O
patient O
agreed O
to O
surgery O
after O
a O
clear O
preoperative O
conversation O
. O

 O
She O
understood O
the O
operative O
risk O
factors O
and O
signed O
an O
informed O
consent O
. O

 O
After O
bowel O
preparation O
, O
the O
patient O
received O
an O
exploratory O
laparotomy O
. O

 O
The O
abdominal O
cavity O
was O
completely O
exposed O
, O
and O
a O
loop O
of O
the O
terminal O
ileum O
( O
approximately O
40 O
cm O
proximal O
to O
the O
ileocaecal O
junction O
) O
was O
found O
entrapped O
in O
the O
internal O
hernia O
ring O
; O
this O
finding O
was O
consistent O
with O
the O
preoperative O
contrast O
image O
. O

 O
The O
defect O
in O
the O
abdominal O
wall O
was O
less O
than O
1.0 O
cm O
, O
and O
an O
extremely O
small O
portion O
of O
the O
bowel O
wall O
was O
stuck O
and O
could O
not O
be O
retrieved O
back O
into O
the O
cavity O
( O
Fig.3 O
) O
. O

 O
Nonetheless O
, O
this O
defect O
resulted O
in O
perforation O
over O
the O
loop O
( O
Fig.4 O
) O
. O

 O
Side O
- O
to O
- O
side O
ileo O
- O
ileal O
anastomosis O
was O
completed O
by O
utilizing O
a O
75 O
mm O
linear O
stapler O
to O
remove O
the O
affected O
ileum O
segment O
. O

 O
The O
internal O
hernia O
ring O
was O
closed O
with O
plication O
sutures O
instead O
of O
via O
mesh O
repair O
due O
to O
the O
patient O
s O
small O
defect O
and O
infection O
risk O
. O

 O
The O
abdominal O
cavity O
was O
thoroughly O
cleaned O
with O
saline O
solution O
, O
and O
a O
rubber O
drainage O
tube O
was O
placed O
in O
the O
pelvis O
. O

 O
The O
scar O
tissue O
was O
removed O
to O
improve O
wound O
healing O
; O
subsequently O
, O
relaxation O
sutures O
were O
available O
to O
close O
the O
abdomen O
in O
layers O
. O

 O
A O
final O
diagnosis O
of O
Richter B
s I
hernia I
presenting O
as O
spontaneous O
ECF O
was O
reached O
. O

 O
The O
patient O
was O
discharged O
2 O
weeks O
after O
without O
serious O
complications B
. O

 O
No O
hernia B
recurrence O
was O
observed O
during O
of O
. O

A O
with O
Crohn B
's I
disease I
( O
CD B
) O
of O
the O
diagnosed O
at O
the O
, O
with O
multiple O
nonmelanoma B
skin I
cancers I
( O
NMSCs B
) O
; O
these O
had O
developed O
coinciding O
with O
the O
initiation O
of O
a O
prolonged O
course O
of O
the O
( O
, O
6 O
- O
MP O
) O
. O

 O
He O
was O
diagnosed O
with O
a O
total O
of O
84 O
NMSC B
: O
72 O
NMSC O
at O
, O
12 O
from O
. O

 O
He O
was O
also O
awaiting O
and O
for O
additional O
lesions O
. O

 O
His O
CD B
was O
initially O
treated O
with O
and O
intermittent O
at O
diagnosis O
, O
but O
for O
the O
he O
had O
been O
taking O
. O

 O
In O
the O
after O
beginning O
he O
developed O
NMSC B
; O
14 O
were O
squamous B
cell I
carcinoma I
( O
SCC B
) O
and O
were O
basal B
cell I
carcinoma I
( O
BCC B
) O
. O

 O
The O
patient O
was O
then O
for O
the O
. O

 O
This O
, O
however O
, O
he O
to O
the O
with O
over O
new O
suggestive O
of O
malignancy B
on O
his O
and O
. O

 O
Subsequent O
to O
this O
exam O
, O
he O
had O
biopsy O
- O
proven O
of O
NMCS B
; O
were O
SCC B
and O
were O
BCC B
. O

 O
In O
addition O
, O
of O
the O
SCCs B
were O
and O
were O
and O
some O
of O
his O
larger O
skin O
cancers O
have O
necessitated O
and O
. O

 O
The O
largest O
of O
his O
was O
and O
measured O
( O
Figure O
1 O
) O
. O

 O
He O
was O
awaiting O
for O
many O
other O
suspicious O
lesions O
. O

 O
The O
patient O
had O
Fitzpatrick O
II O
and O
admitted O
to O
excessive O
for O
in O
. O

 O
Early O
on O
he O
did O
not O
use O
, O
and O
would O
a O
catamaran O
. O

 O
He O
also O
revealed O
that O
his O
had O
and O
denied O
ever O
having O
been O
a O
. O

 O
Within O
the O
he O
discontinued O
and O
began O
using O
( O
) O
and O
later O
( O
) O
hoping O
to O
attenuate O
the O
progression O
of O
NMSC O
, O
and O
continued O
to O
have O
monthly O
. O

 O
Overall O
, O
he O
was O
for O
his O
CD B
, O
but O
never O
required O
any O
intestinal O
. O

 O
Unfortunately O
, O
in O
his O
most O
recent O
he O
was O
diagnosed O
with O
metastatic O
adenocarcinoma B
of O
the O
, O
and O
. O

A O
reported O
persistent O
back O
for O
. O

 O
The O
would O
be O
severe O
after O
or O
and O
would O
be O
slightly O
relieve O
after O
taking O
. O

 O
The O
patient O
described O
no O
or O
in O
her O
. O

 O
She O
also O
described O
no O
bowel O
or O
bladder O
. O

 O
The O
patient O
reported O
past O
medical O
history O
of O
. O

 O
demonstrated O
kyphosis B
of O
the O
and O
lumbar O
vertebra O
bend O
forward O
and O
backward O
straight O
activities O
were O
limited O
. O

 O
There O
is O
obvious O
rap O
in O
about O
T12 O
level O
. O

 O
The O
patient O
's O
general O
medical O
examination O
was O
unremarkable O
in O
upper O
and O
lower O
extremity O
motor O
, O
stretch O
reflex O
, O
and O
sensory O
examinations O
. O

 O
, O
( O
) O
, O
and O
( O
) O
exams O
were O
performed O
after O
the O
patient O
in O
( O
Fig.1 O
) O
. O

 O
The O
lateral O
showed O
T12 O
fracture B
with O
40 O
 O
kyphotic O
. O

 O
showed O
an O
. O

 O
Sagittal O
T1 O
- O
weighted O
showed O
a O
decreased O
signal O
intravertebral O
vacuum O
cleft O
and O
posterior O
cortex O
breakage O
with O
in O
. O

 O
Sagittal O
T2 O
- O
weighted O
showed O
an O
increased O
signal O
in O
the O
. O

 O
The O
patient O
was O
diagnosed O
with O
Kmmell B
disease I
( O
Stage O
III).[9 O
] O

 O
The O
was O
performed O
under O
and O
. O

 O
A O
standard O
of O
the O
was O
given O
, O
were O
inserted O
in O
target O
, O
, O
, O
and O
under O
C O
- O
arm O
guidance.[10 O
] O
The O
screws O
were O
. O

 O
was O
performed O
to O
decompress O
and O
fully O
visualize O
the O
spinal O
cord.[10 O
] O
Careful O
was O
carried O
out O
on O
the O
to O
exposure O
the O
until O
the O
anterior O
aspect O
was O
reached O
. O

 O
The O
right O
side O
pedicle O
and O
articular O
process O
of O
the O
T12 O
vertebral O
body O
were O
. O

 O
T11 O
/ O
T12 O
and O
T12 O
/ O
L1 O
intervertebral O
disks O
were O
also O
. O

 O
Then O
, O
the O
temporary O
stabilizing O
was O
replaced O
by O
. O

 O
Autologous O
and O
were O
placed O
in O
the O
. O

 O
Another O
was O
connected O
on O
the O
. O

 O
Adequate O
was O
ensured O
and O
wound O
was O
thoroughly O
. O

 O
Drainage O
tube O
was O
inserted O
and O
the O
surgical O
wound O
was O
closed O
layer O
- O
by O
- O
layer.[10 O
] O
Time O
from O
skin O
incision O
to O
completion O
of O
wound O
closure O
lasted O
, O
and O
estimated O
blood B
loss I
totaled O
600 O
 O
mL. O

 O
Postoperatively O
, O
the O
patient O
was O
given O
preventive O
treatment O
for O
, O
for O
, O
and O
therapy O
for O
. O

 O
The O
was O
removed O
at O
postoperative O
when O
was O
. O

 O
Patient O
was O
of O
bed O
with O
a O
custom O
- O
made O
plastic O
at O
operation O
. O

 O
The O
plastic O
was O
kept O
for O
. O

 O
The O
patient O
was O
of O
at O
operation O
when O
had O
been O
removed O
. O

 O
were O
conducted O
using O
the O
( O
) O
. O

 O
VAS O
for O
preoperative O
, O
1 O
week O
after O
operation O
, O
and O
1 O
year O
after O
operation O
were O
, O
, O
and O
, O
respectively O
, O
which O
demonstrated O
significant O
improvement O
. O

 O
The O
patient O
resumed O
and O
at O
operation O
. O

 O
Kyphotic O
for O
preoperative O
, O
operation O
, O
and O
operation O
were O
, O
, O
and O
, O
respectively O
, O
which O
demonstrated O
significant O
( O
Fig.2 O
) O
. O

A O
woman O
in O
her O
to O
our O
30 O
 O
min O
after O
her O
expired O
with O
8/10 O
, O
substernal O
chest O
with O
concurrent O
and O
. O

 O
The O
patient O
's O
had O
an O
and O
was O
and O
subsequently O
. O

 O
had O
and O
. O

 O
The O
patient O
's O
medical O
history O
included O
and O
hypothyroidism O
. O

 O
She O
. O

 O
She O
. O

 O
Her O
included O
oral O
20 O
 O
mg O
and O
, O
both O
. O

 O
She O
. O

 O
On O
, O
the O
patient O
was O
, O
with O
a O
of O
, O
of O
, O
of O
and O
an O
of O
on O
. O

 O
On O
, O
she O
was O
in O
significant O
distress O
due O
to O
. O

 O
Her O
was O
and O
, O
with O
minimal O
crackles O
in O
, O
regular O
, O
2/6 O
systolic O
, O
no O
, O
elevated O
jugular O
vein O
of O
, O
strong O
peripheral O
pulses O
and O
no O
peripheral O
. O

 O
The O
was O
, O
, O
, O
, O
and O
the O
patient O
was O
and O
without O
focal O
. O

 O
The O
, O
and O
were O
. O

 O
The O
were O
with O
a O
of O
( O
normal O
range O
0.0150.045 O
 O
ng O
/ O
mL O
) O
, O
of O
( O
normal O
range O
26192 O
 O
U O
/ O
L O
) O
. O

 O
on O
revealed O
normal O
sinus O
rhythm O
with O
23 O
 O
mm O
ST O
segment O
elevations O
in O
leads O
V2 O
 O
V3 O
and O
Q O
waves O
in O
leads O
V1 O
 O
V3 O
, O
suggestive O
of O
anterior O
wall O
infarct O
( O
figure O
2 O
) O
. O

 O
An O
echocardiogram O
revealed O
left O
ventricular O
ejection O
fraction O
of O
3035 O
% O
with O
mild O
concentric O
left O
ventricular O
hypertrophy O
, O
akinesis O
of O
the O
apex O
and O
2/3 O
of O
the O
inferoseptum O
and O
apical O
inferior O
- O
anterior O
wall O
segments O
, O
suggesting O
ischaemic O
damage O
at O
the O
left O
anterior O
descending O
artery O
distribution O
versus O
takotsubo O
cardiomyopathy O
( O
figures O
3 O
and O
4 O
) O
. O

 O
The O
patient O
received O
aspirin O
162 O
 O
mg O
and O
prasugrel O
60 O
 O
mg O
, O
and O
was O
to O
the O
. O

 O
The O
showed O
non O
- O
obstructive O
coronary B
artery I
disease I
with O
luminal O
( O
figures O
5 O
and O
6 O
) O
. O

 O
The O
showed O
an O
of O
with O
of O
and O
of O
( O
figures O
7 O
and O
8) O
. O

 O
The O
patient O
remained O
and O
was O
started O
on O
oral O
, O
including O
and O
. O

 O
Her O
and O
resolved O
and O
she O
was O
of O
hospitalisation O
in O
stable O
. O

 O
A O
repeat O
showed O
resolution O
of O
her O
cardiomyopathy B
and O
an O
of O
, O
with O
normal O
. O

A O
was O
to O
our O
for O
evaluation O
of O
stuttering O
chest O
for O
, O
and O
he O
was O
a O
. O

 O
There O
was O
no O
positive O
finding O
from O
the O
relevant O
. O

 O
He O
has O
, O
and O
relevant O
genetic O
information O
. O

 O
His O
showed O
over O
( O
Figure O
1 O
) O
. O

 O
showed O
90 O
% O
in O
the O
( O
) O
, O
which O
was O
( O
Figure O
2 O
) O
. O

 O
T O
- O
wave O
still O
inversion O
over O
leads O
V1 O
to O
V4 O
after O
the O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
( O
Figure O
3 O
) O
. O

 O
The O
patient O
after O
the O
PCI O
in O
and O
in O
the O
because O
of O
a O
. O

 O
His O
demonstrated O
ventricular B
tachycardia I
( O
Figure O
4 O
) O
, O
and O
severe O
, O
remarkable O
. O

 O
Although O
several O
were O
used O
, O
ventricular B
tachycardia I
still O
occurred O
on O
him O
for O
, O
each O
was O
preceded O
by O
a O
period O
of O
blood O
pressure O
fluctuation O
and O
burst O
out O
concomitantly O
at O
the O
peak O
of O
a O
hypertension B
crisis I
. O

 O
The O
patient O
felt O
abdominal O
and O
his O
abdominal O
showed O
suspicious O
right O
adrenal O
gland O
. O

 O
Enhanced O
of O
conformed O
that O
there O
was O
a O
in O
accompanied O
by O
an O
upset O
level O
of O
( O
Figure O
5 O
) O
. O

 O
The O
tumor O
was O
removed O
by O
, O
and O
showed O
pheochromocytoma B
( O
Figure O
6 O
) O
. O

 O
After O
the O
, O
the O
turned O
gradually O
. O

 O
There O
was O
no O
in O
( O
Figure O
7 O
) O
. O

A O
presented O
in O
the O
, O
with O
, O
, O
lower O
extremities O
swelling O
, O
. O

 O
She O
had O
a O
history O
of O
diagnosed O
by O
her O
and O
history O
of O
cardiac B
failure I
NYHA O
( O
New O
York O
Heart O
Association O
) O
class O
. O

 O
revealed O
an O
irregular O
pulse O
, O
of O
, O
on O
chest O
, O
. O

 O
revealed O
a O
IVth O
degree O
at O
the O
. O

 O
The O
jugular O
veins O
were O
. O

 O
The O
patient O
complained O
of O
in O
the O
, O
. O

 O
The O
liver O
margin O
was O
tender O
, O
round O
, O
of O
6 O
cm O
below O
the O
costal O
rib O
, O
with O
a O
smooth O
liver O
surface O
. O

 O
The O
spleen O
could O
not O
be O
felt O
. O

 O
: O
of O
, O
, O
infero O
- O
lateral O
. O

 O
Transabdominal O
showed O
a O
homogenous O
, O
. O

 O
The O
suprahepatic O
veins O
were O
, O
as O
well O
as O
the O
( O
, O
without O
respiratory O
variations O
) O
. O

 O
revealed O
a O
of O
( O
Figure O
1 O
) O
, O
of O
, O
of O
, O
of O
. O

 O
Atrial O
septal O
defect O
ostium O
secundum O
type O
, O
of O
6 O
cm O
( O
Figure O
2 O
) O
, O
with O
left O
 O
to O
 O
right O
shunt O
. O

 O
Severe O
tricuspid O
insufficiency O
with O
maximum O
gradient O
of O
55,4 O
mm O
Hg O
. O

 O
4th O
degree O
mitral B
insufficiency I
. O

 O
Severe O
pulmonary O
of O
. O

 O
The O
of O
. O

 O
. O

 O
Interventricular O
sept O
with O
paradoxical O
motion O
. O

 O
of O
the O
( O
Figure O
3 O
) O
. O

 O
The O
diagnosis O
was O
IVth O
degree O
chronic B
heart I
failure I
NYHA O
. O

 O

 O

 O

 O

 O

 O
. O

On O
, O
a O
complaining O
of O
abdominal O
, O
, O
and O
was O
referred O
to O
the O
. O

 O
showed O
irregular O
hemorrhagic O
ulcerative B
lesions I
extending O
from O
the O
to O
the O
and O
pyloric B
stenosis I
of O
the O
. O

 O
Gastric O
revealed O
adenocarcinoma B
. O

 O
On O
, O
palliative O
plus O
near O
were O
performed O
. O

 O
Diffuse O
enlarged O
para O
- O
aortic O
and O
anterior O
superior O
, O
as O
well O
as O
lymph O
nodes O
around O
the O
common O
hepatic O
artery O
, O
could O
not O
be O
. O

 O
Postoperative O
demonstrated O
moderately O
differentiated O
gastric B
adenocarcinoma I
( O
Fig.1A O
) O
. O

 O
showed O
the O
following O
: O
( O
) O
( O
) O
, O
( O
) O
( O
) O
, O
( O
) O
, O
( O
) O
( O
Fig.1B O
 O
E O
) O
, O
( O
) O
( O
) O
, O
( O
) O
( O
) O
, O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
The O
diagnosis O
was O
stage O
IV O
gastric B
adenocarcinoma I
with O
metastases B
( O
) O
. O

 O
The O
patient O
was O
administered O
1 O
with O
and O
; O
however O
, O
the O
treatment O
was O
terminated O
, O
as O
the O
patient O
could O
not O
tolerate O
the O
associated O
. O

 O
On O
, O
was O
administered O
. O

 O
Before O
radiotherapy O
, O
( O
) O
showed O
metastasis B
( O
left O
supraclavicular O
and O
mediastinal O
, O
and O
throughout O
the O
) O
. O

 O
The O
patient O
's O
( O
) O
performance O
status O
was O
, O
and O
his O
( O
) O
was O
; O
therefore O
, O
he O
was O
considered O
to O
be O
at O
risk O
of O
. O

 O
combined O
with O
and O
following O
was O
prescribed O
. O

 O
Informed O
consent O
was O
obtained O
from O
the O
patient O
prior O
to O
treatment O
. O

 O
In O
an O
attempt O
to O
improve O
tolerance O
to O
treatment O
, O
palliative O
( O
) O
was O
used O
. O

 O
The O
patient O
received O
a O
dose O
of O
to O
the O
and O
doses O
of O
to O
the O
other O
abdominal O
metastatic B
lesions I
( O
n O
 O
= O
 O
5 O
) O
. O

 O
The O
left O
supraclavicular O
was O
treated O
with O
alone O
( O
Figs.2 O
and O
3A O
 O
C O
) O
. O

 O
A O
scan O
performed O
showed O
an O
in O
the O
( O
) O
of O
( O
) O
. O

 O
was O
in O
the O
left O
supraclavicular O
compared O
to O
the O
treated O
with O
concurrent O
and O
. O

 O
According O
to O
( O
) O
, O
the O
clinical O
effect O
was O
( O
Fig.2 O
) O
. O

 O
The O
patient O
received O
further O
( O
) O
to O
the O
left O
supraclavicular O
due O
to O
residual B
metastasis I
. O

 O
and O
were O
evaluated O
. O

 O
, O
chest O
, O
and O
abdominal O
indicated O
stable O
disease B
; O
and O
had O
, O
performance O
status O
was O
0 O
, O
and O
was O
. O

 O
, O
, O
, O
, O
and O
were O
not O
observed O
during O
therapy O
. O

 O
In O
, O
a O
showed O
and O
; O
however O
, O
and O
abdominal O
revealed O
no O
. O

 O
In O
, O
the O
patient O
had O
and O
experienced O
intermittent O
. O

 O
Apatinib O
was O
terminated O
due O
to O
gastrointestinal O
bleeding O
. O

 O
revealed O
due O
to O
gastric B
cancer I
and O
intragastric O
hemorrhage O
( O
Fig.3D O
 O
F O
) O
. O

 O
The O
patient O
and O
his O
family O
refused O
. O

 O
Symptomatic O
treatment O
with O
a O
and O
best O
were O
prescribed O
. O

 O
of O
therapy O
, O
hemorrhaging B
was O
resolved O
. O

 O
the O
patient O
again O
experienced O
. O

 O
On O
, O
demonstrated O
extensive O
metastasis B
. O

 O
The O
patient O
and O
his O
family O
requested O
best O
. O

 O
On O
, O
the O
patient O
due O
to O
pulmonary O
infection B
. O

A O
with O
a O
5 O
- O
month O
history O
of O
recurring O
sinusitis O
presented O
with O
, O
, O
, O
and O
. O

 O
Thoracic O
revealed O
reduced O
, O
and O
chest O
showed O
bilateral O
diffuse O
alveolar O
. O

 O
showed O
elevation O
of O
( O
) O
and O
( O
) O
with O
nonnephrotic O
and O
microscopic O
glomerular O
. O

 O
An O
for O
community O
acquired O
and O
atypical O
pneumoniae O
with O
levofloxacin O
500 O
 O
mg O
daily O
iv O
was O
established O
, O
but O
on O
the O
3rd O
day O
from O
admission O
the O
patient O
developed O
respiratory O
failure O
unresponsive O
to O
noninvasive O
ventilation O
and O
had O
to O
be O
intubated O
. O

 O
White O
lung O
with O
consolidations O
and O
ground O
glass O
areas O
at O
computed O
tomography O
scan O
( O
Fig.1 O
) O
, O
diffuse O
airways O
bleeding O
at O
fiberoptic O
bronchoscopy O
, O
mild O
normocytic O
anemia O
( O
9 O
 O
g O
/ O
dL O
) O
, O
and O
ANCA O
- O
PR3 O
positivity O
( O
18.9 O
 O
U O
/ O
mL O
) O
were O
consistent O
with O
the O
diagnosis O
of O
GPA O
. O

 O
Despite O
maximal O
ventilatory O
support O
, O
gas O
exchange O
did O
not O
improve O
( O
pH O
7.33 O
, O
PaO2 O
71 O
 O
mm O
 O
Hg O
, O
PaCO2 O
51 O
 O
mm O
 O
Hg O
, O
HCO3 O
 O
25 O
 O
mmol O
/ O
L O
, O
SaO2 O
94 O
% O
) O
requiring O
extracorporeal O
membrane O
oxygenation O
( O
ECMO O
) O
. O

 O
Treatment O
with O
high O
- O
dose O
methylprednisolone O
( O
1 O
 O
g O
daily O
for O
3 O
days O
and O
1 O
 O
mg O
/ O
kg O
daily O
thereafter O
) O
, O
cyclophosphamide O
( O
1.2 O
 O
g O
/ O
pulse O
every O
2 O
weeks O
for O
the O
1st O
3 O
pulses O
, O
followed O
by O
infusions O
every O
3 O
weeks O
for O
the O
next O
2 O
pulses O
) O
, O
and O
plasma O
exchange O
( O
PE O
) O
, O
according O
to O
European O
vasculitis O
study O
group O
recommendations,[4 O
] O
was O
immediately O
started O
with O
respiratory O
improvement O
that O
allowed O
ECMO O
and O
orotracheal O
tube O
withdrawal O
and O
subsequent O
discharge O
from O
intensive O
care O
unit O
. O

 O
After O
9 O
days O
from O
the O
beginning O
of O
treatment O
ANCA O
- O
PR3 O
levels O
normalized O
( O
3 O
 O
U O
/ O
mL O
) O
. O

 O
Two O
months O
later O
, O
after O
the O
5th O
bolus O
of O
cyclophosphamide O
and O
with O
prednisone O
0.3 O
 O
mg O
/ O
kg O
/ O
day O
, O
the O
patient O
complained O
arthromyalgia O
and O
testicular O
pain O
with O
edema O
, O
cough O
, O
and O
shortness O
of O
breath O
: O
laboratory O
data O
showed O
worsening O
of O
renal O
function O
, O
mild O
anemia O
, O
and O
hypoxemia O
( O
PaO2 O
61 O
 O
mm O
 O
Hg O
) O
. O

 O
Epididymitis O
was O
confirmed O
by O
ultrasound O
. O

 O
Because O
of O
rapidly O
progressive O
renal O
failure O
( O
estimated O
glomerular O
filtration O
rate O
35 O
 O
mL O
/ O
min O
) O
renal O
biopsy O
was O
performed O
and O
showed O
prominent O
intracapillary O
and O
extracapillary O
proliferation O
, O
with O
the O
formation O
of O
some O
fibrocellular O
crescents O
and O
focal O
capillary O
necrosis O
( O
Fig.2 O
) O
. O

 O
Lung O
computed O
tomography O
- O
scan O
and O
fiberoptic O
bronchoscopy O
also O
confirmed O
alveolar O
hemorrhage O
relapse O
. O

 O
Treatment O
with O
high O
- O
dose O
methylprednisolone O
( O
1 O
 O
g O
daily O
for O
3 O
consecutive O
days O
) O
and O
rituximab O
( O
375 O
 O
mg O
/ O
m2 O
weekly O
for O
4 O
weeks O
) O
was O
started O
with O
rapid O
resolution O
of O
urologic O
and O
pulmonary O
involvement O
but O
delayed O
and O
partial O
improvement O
of O
renal O
function O
. O

 O
At O
a O
1 O
- O
year O
, O
the O
patient O
is O
and O
under O
treatment O
with O
( O
) O
and O
( O
) O
. O

 O
has O
( O
estimated O
) O
same O
as O
( O
7.42 O
, O
86 O
 O
mm O
 O
Hg O
, O
36 O
 O
mm O
 O
Hg O
, O
 O
23 O
 O
mmol O
/ O
L O
, O
) O
. O

 O
The O
patient O
signed O
institutional O
informed O
consent O
form O
at O
the O
time O
of O
admission O
to O
hospitalization O
. O

 O
An O
approval O
by O
ethics O
committee O
was O
not O
necessary O
because O
of O
the O
routine O
health O
care O
. O

A O
with O
a O
1 O
month O
history O
of O
intermittent O
episodes O
of O
small O
volume O
epistaxis O
. O

 O
There O
was O
. O

 O
revealed O
a O
left O
palatal O
fleshy O
centered O
at O
. O

 O
A O
demonstrated O
a O
large O
on O
the O
, O
involving O
the O
and O
abutting O
the O
. O

 O
( O
) O
of O
the O
showed O
a O
lobulated O
, O
expansile O
lytic O
of O
[ O
Fig O
1 O
] O
with O
a O
and O
. O

 O
The O
was O
associated O
with O
a O
that O
demonstrated O
mild O
heterogeneous O
. O

 O
The O
was O
centered O
at O
the O
, O
involving O
the O
, O
and O
. O

 O
The O
also O
involved O
the O
and O
was O
abutting O
the O
, O
with O
no O
gross O
orbital O
. O

 O
The O
patient O
subsequently O
underwent O
. O

 O
The O
mass O
centered O
in O
left O
maxilla O
was O
hypermetabolic O
, O
with O
index O
SUVmax O
9.7 O
[ O
Fig O
2 O
] O
. O

 O
There O
was O
no O
FDG O
- O
avid O
metastatic B
disease I
. O

 O
A O
trans O
- O
oral O
of O
the O
left O
palatal O
was O
performed O
and O
was O
suggestive O
of O
a O
preliminary O
diagnosis O
of O
mesenchymal B
chondrosarcoma I
, O
as O
evidenced O
by O
a O
featuring O
with O
and O
. O

 O
The O
patient O
underwent O
left O
subtotal O
via O
lateral O
and O
. O

 O
The O
final O
was O
conclusive O
of O
a O
5 O
cm O
high O
- O
grade O
( O
Grade O
3 O
) O
mesenchymal B
chondrosarcoma I
. O

 O
One O
of O
the O
resection O
margins O
was O
positive O
for O
and O
the O
patient O
was O
planned O
for O
adjuvant O
. O

A O
patient O
had O
noticed O
left O
- O
sided O
visual B
loss I
and O
amenorrhea B
to O
being O
seen O
, O
with O
right O
hemiparesis B
developing O
. O

 O
Aggravated O
( O
at O
and O
bilateral O
temporal O
hemianopia B
) O
finally O
prompted O
. O

 O
At O
that O
time O
, O
a O
massive O
( O
) O
of O
, O
, O
was O
seen O
on O
( O
) O
of O
the O
( O
Fig.1a O
) O
. O

 O
Further O
testing O
revealed O
an O
exceedingly O
high O
- O
serum O
level O
of O
( O
) O
( O
) O
, O
whereas O
levels O
of O
all O
were O
( O
) O
, O
; O
( O
) O
, O
; O
( O
) O
, O
4.57 O
mIU O
/ O
ml O
; O
( O
) O
, O
; O
( O
) O
, O
) O
. O

 O
( O
) O
imaging O
with O
( O
) O
showed O
homogeneous O
enhancement O
, O
but O
adjacent O
tissue O
was O
not O
in O
. O

 O
The O
did O
not O
, O
despite O
a O
course O
of O
the O
, O
( O
) O
, O
and O
serum O
level O
( O
) O
remained O
. O

 O
Relative O
to O
status O
at O
admission O
, O
the O
right O
lateral O
ventricle O
also O
had O
, O
due O
to O
at O
( O
Fig.1b O
) O
. O

 O
In O
light O
of O
this O
intransigence O
, O
surgical O
of O
tumor O
was O
elected O
first O
, O
through O
and O
then O
via O
. O

 O
The O
hardened O
elastic O
quality O
of O
the O
and O
its O
strong O
to O
prevented O
, O
but O
related O
was O
significantly O
reduced O
and O
serum O
level O
( O
to O
) O
in O
steps O
at O
each O
procedural O
stage O
. O

 O
But O
the O
normalization O
of O
level O
had O
not O
been O
achieved O
with O
the O
administration O
of O
increased O
up O
to O
. O

 O
The O
residual O
tumor O
showed O
no O
evidence O
of O
or O
distant O
surgery O
. O

 O
, O
( O
H&E)-stained O
sections O
of O
specimens O
from O
the O
first O
and O
second O
surgical O
procedures O
similarly O
were O
composed O
of O
polygonal O
and O
spindle O
cells O
with O
round O
, O
oval O
, O
or O
elongated O
nuclei O
and O
eosinophilic O
( O
Fig.2a O
 O
c O
) O
. O

 O
The O
formed O
or O
, O
accompanied O
by O
( O
Fig.2d O
) O
. O

 O
Some O
was O
prominent O
; O
on O
the O
other O
hand O
, O
neither O
a O
nor O
was O
evident O
( O
Fig.2b O
, O
c O
) O
. O

 O
Conspicuous O
of O
was O
noted O
focally O
as O
well O
( O
Fig.3a O
) O
. O

 O
The O
chromophobic O
nature O
of O
tumor O
cells O
was O
confirmed O
by O
( O
) O
stain O
( O
Fig.3b O
) O
. O

 O
showed O
strong O
diffuse O
positivity O
for O
( O
Fig.3c O
) O
, O
, O
and O
. O

 O
No O
( O
, O
, O
, O
, O
) O
were O
expressed O
by O
tumor O
cells O
, O
and O
the O
, O
including O
S-100 O
protein O
( O
Fig.3d O
) O
, O
glial O
fibrillary O
acidic O
protein O
( O
GFAP O
) O
, O
epithelial O
membrane O
antigen O
( O
EMA O
) O
, O
cytokeratin O
AE1 O
/ O
AE3 O
( O
CK O
AE1 O
/ O
AE3 O
) O
, O
vimentin O
, O
p53 O
, O
and O
bcl-2 O
, O
were O
also O
by O
immunostaining O
. O

 O
was O
approximately O
. O

 O
A O
final O
diagnosis O
of O
PRL O
- O
producing O
pituitary B
adenoma I
was O
reached O
after O
considering O
the O
immunohistochemical O
profile O
, O
suprasellar O
location O
, O
and O
prolactin O
production O
of O
the O
tumor O
, O
as O
well O
as O
the O
absence O
of O
metastatic O
foci O
and O
invasion O
into O
surrounding O
tissue O
. O

A O
to O
her O
general O
practitioner O
because O
of O
left O
- O
sided O
neck O
and O
shoulder O
. O

 O
The O
was O
and O
non O
- O
specific O
and O
the O
patient O
's O
history O
was O
unremarkable O
. O

 O
She O
denied O
a O
history O
of O
smoking O
, O
excessive O
alcohol O
use O
and O
radiation O
exposure O
. O

 O
Physical O
examination O
demonstrated O
mild O
left O
sided O
cervical O
lymphadenopathy O
. O

 O
Routine O
blood O
tests O
revealed O
borderline O
elevated O
calcium O
of O
10.5 O
 O
mg O
/ O
dL O
and O
subsequent O
work O
up O
exhibited O
a O
markedly O
elevated O
parathyroid O
hormone O
level O
of O
286 O
 O
pg O
/ O
mL O
, O
so O
the O
patient O
was O
referred O
to O
otolaryngology O
for O
further O
evaluation O
. O

 O
Thyroid O
ultrasound O
showed O
a O
hypoechoic O
nodule O
in O
the O
left O
lower O
lobe O
of O
the O
thyroid O
. O

 O
CT O
scan O
of O
the O
neck O
revealed O
a O
2 O
 O
cm O
hypodense O
nodule O
on O
the O
posterior O
inferior O
aspect O
of O
the O
left O
lower O
thyroid O
and O
sestamibi O
scan O
showed O
increased O
uptake O
along O
the O
lower O
pole O
of O
the O
left O
thyroid O
lobe O
. O

 O
Elevated O
PTH O
along O
with O
an O
aberrant O
parathyroid O
gland O
on O
imaging O
suggests O
primary O
hyperparathyroidism O
. O

 O
Historically O
, O
hyperparathyroidism O
is O
associated O
with O
bone O
disease O
, O
renal O
stones O
and O
neuromuscular O
dysfunction O
, O
however O
, O
with O
the O
current O
screening O
modalities O
, O
most O
patients O
are O
caught O
early O
and O
often O
asymptomatic.3 O
Primary O
hyperparathyroidism O
is O
most O
commonly O
caused O
by O
a O
parathyroid O
adenoma O
. O

 O
Infrequent O
causes O
include O
parathyroid O
hyperplasia O
, O
which O
would O
affect O
all O
four O
glands O
and O
rarely O
caused O
by O
parathyroid O
carcinoma O
. O

 O
Markedly O
elevated O
serum O
PTH O
and O
calcium O
levels O
leading O
to O
severe O
renal O
and O
bone O
manifestations O
are O
helpful O
in O
the O
diagnosis O
of O
cancer O
, O
however O
, O
it O
is O
usually O
discovered O
operatively O
based O
on O
local O
invasion O
and O
metastases.3 O

 O
The O
primary O
indication O
for O
parathyroidectomy O
, O
historically O
, O
is O
for O
symptomatic O
patients O
. O

 O
Currently O
, O
since O
most O
patients O
are O
caught O
earlier O
, O
there O
are O
newer O
indications O
for O
surgery O
. O

 O
These O
include O
an O
asymptomatic O
patient O
with O
any O
of O
the O
following O
: O
glomerular O
filtration O
rate O
< O
60 O
 O
mL O
/ O
min O
, O
bone O
density O
T O
- O
score O
< O
2.5 O
at O
any O
site O
and/or O
previous O
fractures O
, O
age O
< O
50 O
, O
and O
serum O
calcium O
1.0 O
 O
ng O
/ O
dL O
above O
the O
upper O
limit O
of O
normal.3 O
This O
patient O
presented O
with O
pain O
, O
markedly O
elevated O
PTH O
, O
and O
was O
younger O
than O
50 O
 O
years O
old O
, O
so O
it O
was O
decided O
that O
surgery O
was O
the O
best O
choice O
in O
management O
. O

 O
The O
patient O
was O
brought O
to O
the O
operating O
room O
and O
underwent O
a O
parathyroidectomy O
. O

 O
The O
surgeon O
found O
the O
parathyroid O
gland O
to O
be O
firm O
and O
densely O
adherent O
to O
the O
thyroid O
capsule O
and O
overlying O
strap O
muscle O
, O
making O
it O
difficult O
to O
dissect O
. O

 O
There O
was O
no O
visible O
invasion O
into O
the O
capsule O
, O
surrounding O
muscle O
or O
regional O
lymph O
nodes O
. O

 O
The O
resected O
specimen O
was O
noted O
to O
be O
brownish O
grey O
in O
colour O
with O
scattered O
necrotic O
foci O
, O
and O
irregular O
texture O
. O

 O
On O
postoperative O
pathology O
, O
the O
specimen O
was O
confirmed O
positive O
for O
parathyroid O
carcinoma O
with O
capsular O
invasion O
, O
focal O
tumour O
necrosis O
, O
reactive O
fibrosis O
and O
local O
skeletal O
muscle O
invasion O
( O
figures O
1 O
and O
2 O
) O
. O

 O
Margins O
were O
resected O
. O

 O
Immunohistochemical O
stains O
showed O
increased O
Ki-67 O
reactivity O
as O
well O
as O
strong O
Bcl-1 O
( O
cyclin O
D1 O
) O
reactivity O
, O
which O
support O
the O
diagnosis O
of O
parathyroid O
carcinoma O
( O
figure O
3 O
) O
. O

 O
Additionally O
, O
P57 O
staining O
was O
negative O
. O

 O
Although O
most O
reports O
of O
parathyroid O
carcinomas O
are O
associated O
with O
marked O
hypercalcaemia O
, O
non O
- O
functioning O
cancers O
in O
patients O
tend O
to O
behave O
more O
aggressively.1 O
Owing O
to O
the O
severity O
and O
uncertainty O
of O
the O
lesion O
, O
the O
patient O
was O
followed O
up O
postoperatively O
for O
repeat O
imaging O
to O
determine O
if O
residual O
tumour O
remained O
. O

 O
Repeat O
sestamibi O
and O
positron O
emission O
tomography O
( O
PET O
) O
scan O
revealed O
residual O
activity O
along O
the O
surgical O
area O
so O
the O
patient O
subsequently O
underwent O
a O
second O
operation O
for O
a O
radical O
left O
neck O
dissection O
and O
left O
hemithyroidectomy O
. O

 O
The O
patient O
recovered O
very O
well O
postoperatively O
and O
it O
has O
now O
been O
3 O
 O
years O
since O
the O
second O
surgery O
. O

 O
The O
patient O
continues O
to O
do O
very O
well O
and O
is O
followed O
up O
every O
3 O
 O
months O
to O
monitor O
serum O
PTH O
and O
calcium O
levels O
. O

 O
She O
no O
longer O
reports O
of O
neck O
and O
shoulder O
. O

 O
Sometimes O
the O
patient O
's O
show O
marginally O
elevated O
levels O
, O
however O
, O
she O
remains O
and O
follow O
- O
up O
and O
scans O
continue O
to O
be O
. O

 O
The O
patient O
will O
continue O
to O
be O
monitored O
indefinitely O
. O

A O
had O
a O
diagnosis O
of O
MCTD B
with O
the O
presence O
of O
Raynaud B
's I
phenomenon I
, O
, O
elevated O
plasma O
, O
and O
antibodies O
against O
in O
and O
received O
10 O
mg O
of O
. O

 O
estimated O
by O
was O
( O
) O
in O
. O

 O
She O
felt O
progressive O
on O
in O
. O

 O
Pulmonary O
arterial O
hypertension O
was O
diagnosed O
with O
74 O
mmHg O
of O
( O
) O
evaluated O
by O
( O
) O
in O
. O

 O
Cyclophosphamide O
- O
based O
was O
proposed O
but O
refused O
because O
of O
possible O
early O
. O

 O
Treatment O
with O
of O
and O
of O
was O
initiated O
. O

 O
However O
, O
in O
, O
her O
deteriorated O
( O
) O
, O
and O
she O
was O
to O
our O
. O

 O
A O
showed O
low O
( O
) O
, O
( O
) O
, O
low O
( O
( O
) O
) O
, O
jugular O
venous O
, O
and O
severe O
systemic O
. O

 O
Coarse O
and O
were O
detected O
. O

 O
She O
was O
unable O
to O
undergo O
the O
due O
to O
severe O
. O

 O
showed O
elevated O
plasma O
( O
) O
level O
( O
) O
, O
( O
, O
) O
, O
and O
the O
( O
) O
as O
well O
as O
( O
, O
) O
. O

 O
A O
chest O
showed O
and O
( O
Figure O
) O
. O

 O
showed O
in O
the O
. O

 O
demonstrated O
elevated O
( O
) O
with O
normal O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
A O
showed O
no O
signs O
of O
pulmonary B
thromboembolism I
. O

 O
No O
signs O
of O
chronic B
obstructive I
pulmonary I
disease I
or O
interstitial B
lung I
diseases I
were O
found O
with O
. O

 O
Her O
was O
therefore O
considered O
to O
be O
due O
to O
MCTD O
- O
associated O
PAH B
which O
was O
refractory O
to O
and O
therapy O
. O

 O
In O
addition O
to O
with O
and O
( O
of O
) O
, O
initiation O
of O
of O
as O
well O
as O
gradual O
increment O
in O
the O
dose O
of O
was O
chosen O
as O
an O
additional O
treatment O
. O

 O
However O
, O
her O
remained O
unchanged O
, O
and O
her O
plasma O
level O
. O

 O
( O
) O
was O
initiated O
, O
and O
the O
dose O
of O
was O
increased O
to O
. O

 O
Her O
then O
ameliorated O
, O
and O
she O
became O
able O
to O
undergo O
the O
( O
, O
) O
. O

 O
Her O
plasma O
level O
also O
after O
the O
initiation O
of O
( O
Figure O
) O
. O

 O
the O
, O
a O
follow O
- O
up O
revealed O
improved O
( O
65 O
to O
) O
, O
( O
1,547 O
to O
) O
, O
and O
( O
1.69 O
to O
) O
( O
Table O
) O
. O

 O
Since O
she O
remained O
but O
did O
not O
obtain O
further O
improvements O
the O
( O
Table O
) O
, O
we O
consider O
parenteral O
or O
as O
a O
subsequent O
treatment O
. O

A O
had O
been O
diagnosed O
with O
LCNEC B
of O
the O
with O
bone O
at O
a O
. O

 O
The O
serum O
levels O
of O
and O
were O
, O
but O
brain O
revealed O
that O
his O
was O
. O

 O
However O
, O
of O
the O
revealed O
partial O
. O

 O
The O
was O
therefore O
determined O
to O
be O
. O

 O
The O
patient O
underwent O
with O
and O
, O
but O
the O
continuation O
of O
chemotherapy O
was O
. O

 O
Treatment O
for O
and O
diabetes B
caused O
by O
the O
ectopic B
ACTH I
syndrome I
was O
initiated O
, O
as O
was O
treatment O
with O
for O
bone O
. O

 O
The O
patient O
was O
to O
the O
due O
to O
a O
and O
the O
worsening O
of O
his O
. O

 O
A O
revealed O
, O
a O
subcutaneous O
that O
was O
in O
the O
, O
and O
and O
of O
the O
without O
, O
, O
, O
or O
. O

 O
The O
by O
in O
and O
was O
and O
his O
was O
. O

 O
Among O
the O
, O
the O
and O
counts O
, O
and O
, O
, O
and O
levels O
were O
found O
to O
be O
, O
and O
the O
patient O
's O
level O
was O
to O
2.8 O
mEq O
/ O
L. O

 O
The O
patient O
's O
( O
) O
, O
( O
) O
, O
( O
) O
, O
and O
( O
) O
levels O
were O
also O
. O

 O
The O
patient O
's O
was O
negative O
for O
, O
, O
and O
; O
a O
also O
yielded O
a O
result O
. O

 O
These O
data O
suggested O
that O
the O
increased O
production O
of O
ACTH O
by O
the O
tumor O
, O
along O
with O
the O
progression O
of O
the O
disease O
, O
had O
promoted O
the O
elevation O
of O
the O
patient O
's O
serum O
levels O
of O
ACTH O
and O
cortisol O
. O

 O
( O
) O
revealed O
the O
progression O
of O
the O
disease O
in O
the O
both O
thymic O
and O
metastatic O
bone O
, O
along O
with O
the O
multiple O
ground O
- O
glass O
in O
( O
Fig.1 O
, O
2 O
) O
. O

 O
The O
patient O
underwent O
( O
) O
in O
the O
with O
, O
and O
. O

 O
The O
in O
the O
was O
, O
and O
the O
in O
the O
was O
, O
, O
and O
, O
with O
a O
. O

 O
, O
, O
and O
were O
all O
. O

 O
A O
revealed O
that O
the O
patient O
's O
was O
positive O
for O
. O

 O
PCP B
was O
diagnosed O
based O
on O
the O
above O
results O
. O

 O
The O
patient O
was O
treated O
with O
( O
) O
for O
. O

 O
with O
was O
also O
initiated O
at O
the O
same O
time O
with O
a O
to O
slowly O
correct O
the O
hypercortisolemia B
. O

 O
Intensive O
therapy O
, O
supplementation O
were O
initiated O
, O
while O
was O
administered O
to O
treat O
cellulitis B
of O
the O
. O

 O
The O
patient O
's O
PCP B
fully O
improved O
without O
the O
exacerbation O
of O
his O
. O

 O
Thereafter O
, O
we O
continued O
to O
administer O
at O
a O
. O

 O
The O
dosage O
was O
gradually O
increased O
from O
, O
and O
the O
value O
was O
observed O
to O
( O
Fig.3 O
) O
. O

 O
In O
order O
to O
prevent O
hypocortisolemia O
, O
the O
patient O
was O
temporarily O
treated O
with O
. O

 O
After O
an O
improvement O
of O
his O
left O
lower O
leg O
cellulitis B
, O
PCP B
, O
and O
hyperglycemia B
, O
the O
patient O
underwent O
and O
for O
spinal B
cord I
compression I
, O
which O
had O
been O
caused O
by O
a O
metastatic O
spinal O
. O

 O
therapy O
was O
initiated O
, O
and O
he O
was O
on O
the O
of O
hospitalization O
. O

A O
, O
, O
presented O
to O
our O
with O
an O
intensely O
pruritic O
generalized O
. O

 O
Two O
days O
after O
, O
the O
patient O
developed O
an O
itchy O
on O
the O
. O

 O
On O
, O
she O
was O
instructed O
to O
follow O
up O
with O
the O
dermatology O
department O
if O
the O
rash O
did O
not O
resolve O
. O

 O
After O
leaving O
the O
hospital O
, O
she O
reported O
that O
the O
eruption O
had O
progressively O
spread O
to O
the O
buttocks O
and O
legs O
and O
the O
itching O
seemed O
to O
be O
worse O
. O

 O
The O
patient O
's O
prenatal O
course O
was O
uneventful O
. O

 O
She O
gained O
13 O
kg O
during O
pregnancy O
, O
with O
a O
prepregnancy O
weight O
of O
. O

 O
A O
healthy O
male O
was O
delivered O
by O
without O
. O

 O
The O
patient O
's O
. O

 O
She O
was O
currently O
not O
taking O
any O
, O
and O
she O
reported O
no O
known O
. O

 O
On O
, O
the O
patient O
was O
afebrile O
and O
her O
was O
. O

 O
revealed O
erythematous O
and O
urticarial O
involving O
the O
abdominal O
striae O
with O
. O

 O
Similar O
were O
noted O
on O
the O
and O
( O
Fig.1a O
) O
. O

 O
The O
, O
, O
and O
were O
uninvolved O
. O

 O
No O
or O
were O
noted O
. O

 O
Based O
on O
the O
characteristic O
clinical O
presentation O
and O
disease O
course O
, O
she O
was O
diagnosed O
with O
PUPPP B
. O

 O
She O
was O
informed O
of O
the O
safety O
profile O
and O
potential O
benefits O
of O
medications O
but O
remained O
reluctant O
to O
use O
medications O
during O
lactation O
, O
despite O
her O
severe O
symptoms O
. O

 O
was O
then O
considered O
for O
her O
treatment O
. O

 O
Venous O
blood O
of O
was O
drawn O
from O
the O
patient O
, O
followed O
by O
intramuscular O
injection O
of O
of O
the O
blood O
on O
each O
side O
of O
her O
buttock O
. O

 O
Seven O
days O
later O
, O
both O
subjective O
and O
objective O
improvements O
of O
symptoms O
were O
noticed O
and O
she O
received O
1 O
more O
session O
of O
AWB O
injection O
( O
Fig.1b O
) O
. O

 O
On O
follow O
- O
up O
, O
all O
subjective O
symptoms O
had O
improved O
, O
leaving O
only O
postinflammatory O
( O
Fig.1c O
) O
. O

 O
No O
complications O
such O
as O
, O
formation O
, O
or O
were O
observed O
at O
. O

A O
child O
to O
our O
for O
abdominal O
. O

 O
The O
child O
occasionally O
felt O
that O
was O
. O

 O
The O
child O
showed O
no O
obvious O
and O
. O

 O
He O
was O
. O

 O
His O
medical O
history O
included O
, O
but O
he O
had O
only O
received O
an O
. O

 O
. O

 O
of O
this O
child O
showed O
that O
the O
abdomen O
was O
obviously O
. O

 O
The O
could O
be O
touched O
. O

 O
There O
were O
no O
other O
positive O
signs O
. O

 O
The O
results O
of O
were O
, O
including O
( O
) O
level O
. O

 O
The O
was O
. O

 O
Abdominal O
showed O
an O
uneven O
in O
the O
and O
a O
diagnosis O
of O
HB B
was O
considered O
. O

 O
Enhancement O
( O
) O
scanning O
showed O
a O
large O
in O
the O
and O
with O
an O
. O

 O
The O
size O
of O
the O
was O
( O
Fig.1 O
) O
. O

 O
There O
was O
an O
uneven O
nodular O
shadow O
and O
the O
edge O
was O
obvious O
when O
the O
was O
enhanced O
. O

 O
and O
an O
were O
not O
observed O
. O

 O
The O
was O
pressed O
and O
the O
. O

 O
Abnormal O
was O
not O
observed O
in O
the O
. O

 O
According O
to O
the O
medical O
history O
, O
the O
diagnosis O
of O
HB B
was O
considered O
. O

 O
We O
did O
not O
recommend O
a O
to O
the O
patient O
because O
it O
might O
cause O
bleeding O
and O
tumor O
diffusion O
. O

 O
An O
was O
necessary O
. O

 O
The O
patient O
underwent O
. O

 O
showed O
an O
in O
the O
( O
Fig.2 O
) O
. O

 O
After O
the O
operation O
, O
the O
sample O
was O
split O
. O

 O
The O
edge O
of O
the O
tumor O
was O
clear O
but O
no O
envelope O
. O

 O
Tremelloid O
mesenchyme O
was O
seen O
on O
the O
section O
( O
Fig.2C O
) O
. O

 O
The O
pathological O
examination O
showed O
that O
the O
sample O
was O
grey O
red O
and O
14 O
 O
 O
 O
13 O
 O
 O
 O
7 O
 O
cm O
in O
size O
. O

 O
The O
color O
of O
the O
section O
was O
grey O
red O
and O
grey O
white O
. O

 O
MHL B
was O
diagnosed O
( O
Fig.3 O
) O
. O

 O
( O
Fig.4 O
) O
were O
the O
following O
: O
( O
+ O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
+ O
) O
, O
( O
- O
) O
, O
( O
) O
. O

 O
After O
9 O
days O
of O
, O
the O
patient O
without O
. O

 O
A O
follow O
- O
up O
examination O
, O
which O
included O
, O
, O
, O
and O
at O
, O
did O
not O
show O
any O
. O

 O
No O
was O
presented O
. O

A O
with O
a O
retroperitoneal O
in O
( O
) O
imaging O
with O
a O
history O
of O
right O
liver O
in O
, O
pulmonary O
wedge O
in O
, O
and O
in O
, O
in O
which O
the O
postoperative O
suggested O
the O
mixed O
liver B
cancer I
, O
and O
poorly O
differentiated O
lung B
cancer I
from O
liver O
. O

 O
At O
, O
the O
was O
very O
close O
to O
the O
, O
, O
, O
and O
. O

 O
The O
patient O
with O
unresectable O
had O
and O
when O
he O
was O
treated O
with O
, O
and O
for O
. O

 O
He O
kept O
a O
constant O
of O
, O
the O
of O
, O
and O
the O
of O
. O

 O
The O
patient O
had O
no O
obvious O
sense O
of O
abdominal O
, O
, O
, O
and O
. O

 O
On O
a O
test O
of O
levels O
, O
the O
results O
were O
, O
which O
showed O
3.7 O
 O
ng O
/ O
mL O
, O
17.3 O
 O
ng O
/ O
mL O
, O
and O
levels O
6.1 O
 O
U O
/ O
mL. O

 O
In O
this O
study O
, O
the O
procedure O
was O
approved O
by O
the O
ethics O
committee O
of O
the O
First O
Affiliated O
Hospital O
of O
Zhejiang O
University O
. O

 O
The O
efficacy O
of O
local O
was O
estimated O
with O
, O
which O
appraised O
the O
variations O
both O
in O
tumor O
size O
and O
lesion O
density O
on O
( O
) O
imaging O
: O
complete O
response O
, O
disappearance O
of O
all O
lesions O
and O
no O
new O
lesions O
; O
partial O
response O
( O
PR O
) O
, O
a O
decrease O
in O
size O
of O
10 O
% O
or O
a O
decrease O
in O
tumor O
density O
over O
15 O
% O
on O
CT O
and O
no O
new O
lesions O
; O
stable O
disease O
, O
not O
fit O
for O
complete O
response O
, O
PR O
, O
or O
progressive O
disease O
; O
and O
progressive O
disease O
, O
an O
increase O
in O
tumor O
size O
over O
10 O
% O
and O
not O
fit O
for O
PR O
by O
tumor O
density O
on O
CT O
or O
new O
lesions.[19 O
] O

 O
Preoperative O
imaging O
scan O
showed O
a O
of O
in O
size O
close O
to O
the O
, O
, O
and O
( O
Fig.1A O
) O
. O

 O
During O
substance O
phase O
, O
MR O
images O
indicated O
mildly O
high O
around O
the O
and O
intermediate O
low O
in O
the O
and O
in O
the O
( O
Fig.1B O
) O
. O

 O
Before O
the O
initial O
, O
there O
was O
a O
retroperitoneal O
mild O
on O
axial O
image O
( O
Fig.1C O
) O
. O

 O
In O
this O
study O
, O
the O
inpatient O
underwent O
percutaneous O
transhepatic O
and O
to O
avoid O
the O
nearby O
blood O
vessels O
, O
the O
procedure O
of O
which O
was O
performed O
under O
and O
mild O
. O

 O
We O
used O
to O
guide O
the O
inserting O
of O
2 O
Nd O
: O
YAG O
laser O
fibers O
( O
Echolaser O
X4 O
, O
ESAOTE O
, O
Italy O
) O
in O
0.3 O
 O
mm O
diameter O
through O
a O
21 O
- O
gauge O
Chiba O
needle O
into O
the O
lesions O
( O
Fig.1D O
) O
. O

 O
Although O
part O
of O
the O
heat O
ran O
off O
by O
blood O
flow,[20 O
] O
ablation O
could O
keep O
valid O
area O
from O
12 O
to O
15 O
 O
mm O
with O
the O
power O
of O
5 O
 O
W O
in O
5 O
to O
6 O
minutes O
. O

 O
Subsequently O
, O
immediate O
ultrasonography O
showed O
that O
the O
whole O
lesion O
was O
covered O
with O
hyperechoic O
zone O
( O
Fig.(Fig.1E O
and O
F O
) O
. O

 O
However O
, O
the O
next O
day O
contrast O
- O
enhanced O
ultrasound O
( O
CEUS O
) O
revealed O
an O
abnormal O
residual O
of O
proximal O
part O
of O
the O
pancreatic O
head O
( O
Fig.2A O
) O
. O

 O
At O
5 O
- O
day O
follow O
- O
up O
contrast O
- O
enhanced O
CT O
images O
, O
the O
lower O
mass O
had O
low O
signal O
intensity O
and O
upper O
tumor O
revealed O
intermediate O
high O
signal O
intensity O
of O
residual O
in O
substance O
phase O
( O
Fig.2B O
and O
C O
) O
. O

 O
Surprizingly O
, O
1 O
- O
week O
follow O
- O
up O
CEUS O
image O
showed O
an O
enlarged O
retroperitoneal O
lymph O
node O
located O
near O
the O
pancreatic O
head O
, O
which O
could O
be O
fusion O
of O
these O
residuary O
small O
nodules O
( O
Fig.2D O
) O
. O

 O
Then O
the O
patient O
undergoing O
the O
2nd O
ablation O
with O
2 O
laser O
fibers O
showed O
the O
lesions O
well O
- O
defined O
hyperechoic O
zone O
( O
Fig.2E O
and O
F O
) O
. O

 O
On O
the O
2nd O
day O
, O
postoperative O
CEUS O
images O
showed O
they O
were O
still O
remanent O
( O
Fig.2 O
G O
and O
I O
) O
. O

 O
At O
the O
corresponding O
MR O
imaging O
, O
it O
also O
showed O
this O
in O
left O
of O
tumor O
( O
Fig.2H O
) O
. O

 O
Thus O
, O
the O
3rd O
laser O
ablation O
was O
performed O
( O
Fig.2J)2J O
) O
and O
3 O
days O
later O
CEUS O
found O
that O
there O
was O
still O
a O
minor O
lesion O
located O
in O
the O
separation O
gap O
of O
last O
2 O
needles O
( O
Fig.3A O
) O
. O

 O
Subsequently O
the O
patient O
had O
the O
4th O
ablation O
along O
this O
separation O
gap O
until O
hyperechoic O
overlay O
( O
Fig.3B O
 O
D O
) O
, O
then O
3 O
days O
later O
, O
based O
on O
these O
4 O
treatments O
, O
enhanced O
CT O
image O
of O
the O
retroperitoneal O
mass O
suggested O
complete O
necrosis O
( O
Fig.3E O
 O
G).3E O
 O
G O
) O
. O

 O
After O
the O
following O
1 O
month O
, O
substance O
phase O
MR O
revealed O
low O
- O
intensity O
signal O
of O
tumor O
necrosis O
with O
resolution O
of O
his O
problems O
( O
Fig.3H O
) O
. O

 O
Until O
5 O
months O
after O
4 O
ablations O
, O
CT O
showed O
the O
tumor O
PR O
with O
little O
enhanced O
recurrence O
( O
yellow O
arrows O
) O
, O
which O
located O
in O
the O
left O
lower O
edge O
of O
original O
lesions O
( O
Fig.4A O
and O
B O
) O
. O

 O
On O
laboratory O
test O
of O
tumor O
markers O
, O
the O
levels O
of O
carcinoembryonic O
antigen O
, O
alpha O
fetoprotein O
, O
and O
carbohydrate O
antigen O
199 O
indicated O
3.6 O
 O
ng O
/ O
mL O
, O
26.7 O
 O
ng O
/ O
mL O
, O
and O
8.1 O
 O
U O
/ O
mL O
, O
respectively O
. O

 O
No O
obvious O
were O
discovered O
in O
this O
case O
during O
these O
procedures O
. O

A O
to O
our O
with O
and O
features O
of O
uremic O
encephalopathy B
. O

 O
Ten O
days O
prior O
to O
this O
presentation O
, O
he O
had O
experienced O
severe O
upper O
abdominal O
pain O
and O
vomiting O
, O
and O
he O
had O
been O
treated O
in O
a O
primary O
care O
facility O
for O
having O
a O
case O
of O
acute O
pancreatitis O
. O

 O
His O
initial O
symptoms O
improved O
; O
however O
, O
he O
gradually O
became O
anuric O
and O
disoriented O
. O

 O
Then O
he O
was O
transferred O
to O
our O
hospital O
for O
further O
management O
. O

 O
At O
presentation O
to O
our O
hospital O
, O
he O
was O
severely O
agitated O
, O
restless O
, O
and O
disoriented O
. O

 O
He O
was O
tachypneic O
with O
. O

 O
Mild O
pedal O
was O
present O
; O
however O
, O
his O
was O
. O

 O
His O
was O
, O
his O
was O
, O
and O
his O
was O
. O

 O
Signs O
of O
meningeal O
were O
absent O
, O
and O
his O
was O
. O

 O
His O
fundus O
could O
not O
be O
evaluated O
, O
and O
of O
his O
was O
. O

 O
His O
showed O
features O
of O
renal B
dysfunction I
( O
, O
) O
, O
( O
[ O
reference O
up O
to O
100 O
U O
/ O
L O
] O
, O
[ O
reference O
1360 O
U O
/ O
L O
) O
, O
normal O
tests O
( O
, O
, O
, O
, O
) O
, O
normal O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
His O
, O
including O
, O
, O
, O
, O
and O
, O
were O
. O

 O
An O
of O
his O
whole O
was O
, O
but O
non O
- O
contrast O
- O
enhanced O
( O
) O
findings O
were O
suggestive O
of O
acute O
pancreatitis B
( O
Fig.1 O
) O
. O

 O
His O
were O
, O
however O
. O

 O
The O
patient O
was O
managed O
as O
having O
a O
case O
of O
AKI B
and O
acute O
pancreatitis B
. O

 O
Urgent O
was O
initiated O
. O

 O
After O
he O
had O
received O
two O
sessions O
of O
, O
his O
, O
but O
he O
complained O
of O
profound O
visual B
loss I
. O

 O
An O
assessment O
revealed O
only O
. O

 O
A O
showed O
and O
extensive O
cotton O
wool O
exudates O
as O
well O
as O
( O
Fig.2 O
) O
compatible O
with O
Purtscher B
s I
retinopathy I
. O

 O
High O
- O
dose O
parenteral O
( O
1 O
g O
intravenously O
for O
) O
was O
administered O
. O

 O
For O
, O
a O
renal O
was O
done O
; O
the O
were O
compatible O
with O
renal B
cortical I
necrosis I
( O
Fig.3 O
) O
. O

 O
The O
patient O
. O

 O
He O
. O

 O
, O
nor O
did O
he O
have O
a O
history O
of O
throughout O
the O
course O
of O
his O
current O
illness O
. O

 O
The O
patient O
was O
finally O
diagnosed O
with O
acute O
pancreatitis B
complicated O
with O
renal B
cortical I
necrosis I
leading O
to O
AKI B
and O
Purtscher B
s I
retinopathy I
leading O
to O
complete O
bilateral O
blindness B
. O

 O
He O
his O
initial O
presentation O
as O
a O
result O
of O
a O
recurrent O
attack O
of O
acute O
pancreatitis B
. O

 O
Before O
that O
, O
he O
had O
been O
undergoing O
maintenance O
; O
however O
, O
his O
, O
though O
his O
vision O
was O
improved O
to O
at O
. O

A O
patient O
had O
a O
history O
of O
under O
regular O
bronchodilator O
treatment O
. O

 O
In O
, O
he O
suffered O
from O
severe O
productive O
with O
and O
unintentional O
body O
. O

 O
After O
and O
chest O
in O
, O
he O
was O
diagnosed O
of O
squamous B
cell I
carcinoma I
in O
( O
, O
) O
. O

 O
Then O
he O
received O
neoadjuvant O
chemoradiotherapy O
( O
etoposide O
70 O
 O
mg O
[ O
45 O
 O
mg O
/ O
m2 O
] O
 O
+ O
 O
cisplatin O
79 O
 O
mg O
[ O
50 O
 O
mg O
/ O
m2 O
] O
; O
4500 O
 O
cGY O
in O
25 O
fractions O
) O
. O

 O
In O
, O
was O
arranged O
. O

 O
Because O
the O
was O
located O
at O
and O
invaded O
and O
, O
video O
- O
assisted O
thoracoscopic O
with O
right O
side O
intrapericardial O
was O
performed O
. O

 O
Postoperatively O
, O
revealed O
squamous B
cell I
carcinoma I
, O
, O
. O

 O
The O
was O
but O
he O
suffered O
from O
severe O
and O
right O
chest O
. O

 O
revealed O
( O
 O
= O
 O
) O
and O
elevated O
to O
23.94 O
 O
mg O
/ O
dL. O

 O
Chest O
showed O
and O
showed O
and O
with O
in O
the O
( O
Fig.1A O
) O
. O

 O
According O
to O
the O
patient O
's O
history O
, O
results O
of O
laboratory O
exams O
, O
and O
imaging O
findings O
, O
postpneumonectomy O
empyema O
was O
diagnosed O
and O
bronchopleural B
fistula I
was O
highly O
suspected O
. O

 O
After O
admission O
, O
chest O
was O
inserted O
and O
bronchoscopic O
was O
performed O
. O

 O
However O
, O
persistent O
was O
presented O
and O
we O
decided O
to O
the O
bronchial O
stump O
with O
. O

 O
Because O
the O
patient O
just O
received O
neoadjuvant O
a O
few O
months O
ago O
, O
the O
flaps O
harvested O
from O
chest O
area O
were O
not O
appropriate O
because O
the O
pedicle O
arteries O
might O
have O
been O
injured O
by O
irradiation O
. O

 O
After O
discussing O
with O
the O
plastic O
surgeon O
, O
we O
decided O
to O
the O
bronchial O
stump O
by O
a O
. O

 O
Intraoperatively O
, O
the O
patient O
was O
. O

 O
Right O
side O
exploratory O
was O
performed O
and O
the O
was O
located O
. O

 O
The O
and O
was O
identified O
and O
the O
location O
of O
the O
was O
( O
Fig.2A O
) O
. O

 O
Then O
the O
TRAM O
flap O
was O
harvested O
from O
right O
rectus O
abdominis O
( O
Fig.2B O
) O
and O
was O
deepithelialized O
( O
Fig.2C O
) O
. O

 O
Through O
a O
subcutaneous O
tunnel O
, O
the O
TRAM O
flap O
was O
moved O
toward O
the O
right O
thoracic O
space O
with O
no O
tension O
or O
kinking O
on O
the O
pedicle O
( O
Fig.2D O
) O
. O

 O
Then O
the O
TRAM O
flap O
was O
fixed O
to O
posterior O
chest O
wall O
to O
cover O
the O
bronchial O
stump O
( O
Fig.2E O
) O
and O
the O
tissue O
glue O
was O
also O
applied O
to O
the O
bronchial O
stump O
under O
bronchoscope O
. O

 O
The O
donor O
site O
of O
flap O
was O
closed O
with O
mesh O
repair O
. O

 O
The O
was O
and O
the O
was O
gradually O
. O

 O
Then O
the O
patient O
was O
under O
and O
was O
free O
from O
( O
Fig.1B O
) O
. O

 O
The O
patient O
provided O
written O
informed O
consent O
for O
publication O
of O
this O
report O
and O
all O
accompanying O
images O
. O

, O
a O
patient O
complaining O
of O
local O
bone O
in O
the O
. O

 O
On O
, O
the O
patient O
underwent O
a O
left O
distal O
femoral O
tumor O
en O
bloc O
resection O
and O
reconstruction O
with O
a O
modular O
femoral O
prosthetic O
system O
. O

 O
Pathology O
diagnosis O
confirmed O
osteoblastic O
osteosarcoma B
( O
Fig.2 O
) O
. O

 O
One O
cycle O
of O
neoadjuvant O
and O
of O
with O
( O
high O
- O
dose O
, O
, O
and O
) O
were O
administered O
. O

 O
In O
, O
a O
was O
found O
on O
the O
. O

 O
Tumor O
was O
confirmed O
by O
on O
. O

 O
However O
, O
only O
an O
upper O
femur O
was O
carried O
out O
, O
as O
the O
patient O
refused O
hip O
. O

 O
After O
, O
the O
patient O
in O
the O
help O
of O
, O
but O
refused O
to O
receive O
further O
due O
to O
concerns O
regarding O
the O
chemotherapy O
toxicities O
such O
as O
nausea O
, O
vomiting O
, O
leucopenia O
, O
deadlimb O
, O
and O
headache O
. O

 O
About O
the O
amputation O
, O
the O
patient O
got O
occasional O
and O
chest O
. O

 O
Then O
a O
thin O
chest O
( O
) O
was O
performed O
on O
. O

 O
The O
CT O
results O
revealed O
multiple O
pulmonary O
( O
Table O
1 O
) O
, O
considering O
the O
possibility O
of O
. O

 O
The O
patient O
still O
rejected O
further O
. O

 O
was O
suggestive O
of O
CD31 O
+ O
and O
CD34 O
+ O
cells O
( O
Fig.3 O
) O
. O

 O
Furthermore O
, O
most O
showed O
strong O
positive O
( O
Fig.3 O
) O
. O

 O
was O
administered O
at O
a O
dose O
of O
. O

 O
Half O
a O
month O
later O
, O
the O
symptoms O
disappeared O
, O
but O
a O
progressive O
wound O
necrosis O
appeared O
. O

 O
A O
debridement O
surgery O
was O
finally O
conducted O
and O
an O
enlarged O
lymph O
node O
near O
iliac O
vessels O
was O
resected O
on O
February O
24 O
, O
2016 O
( O
Fig.(Fig.4).4 O
) O
. O

 O
The O
result O
of O
pathological O
examination O
revealed O
an O
inflammatory O
hyperplasia O
lymph O
node O
. O

 O
Apatinib O
administration O
was O
stopped O
during O
the O
3 O
weeks O
of O
wound O
healing O
period O
. O

 O
The O
thin O
chest O
CT O
was O
performed O
7 O
and O
11 O
months O
following O
apatinib O
administration O
. O

 O
At O
the O
7 O
- O
month O
follow O
- O
up O
time O
point O
, O
2 O
out O
of O
5 O
measurable O
and O
9 O
out O
of O
17 O
non O
- O
measurable O
lesions O
disappeared O
, O
but O
1 O
new O
measurable O
nodule O
and O
6 O
new O
non O
- O
measurable O
lesions O
were O
observed O
( O
Table O
1 O
, O
Fig.5 O
) O
, O
which O
considered O
PD O
according O
to O
the O
Response O
Evaluation O
Criteria O
in O
Solid O
Tumors O
( O
RECIST O
) O
1.1 O
standard O
. O

 O
However O
, O
at O
the O
11 O
- O
month O
follow O
- O
up O
time O
point O
, O
a O
total O
of O
9 O
lesions O
disappeared O
, O
including O
1 O
measurable O
nodule O
and O
2 O
non O
- O
measurable O
lesions O
presented O
before O
apatinib O
treatment O
as O
well O
as O
6 O
non O
- O
measureable O
lesions O
presented O
7 O
months O
after O
apatinib O
treatment O
. O

 O
No O
new O
lesion O
was O
raised O
. O

 O
After O
target O
lesion O
measurement O
according O
to O
the O
RECIST O
1.1 O
standard O
, O
it O
was O
narrowly O
considered O
PR O
. O

 O
The O
toxicities O
the O
patient O
experienced O
included O
mild O
hand O
- O
foot O
syndrome O
and O
slight O
high O
blood O
pressure O
. O

 O
Both O
were O
well O
controlled O
after O
appropriate O
treatment O
. O

 O
No O
severe O
toxicities O
and O
other O
treatment O
- O
related O
adverse O
events O
were O
observed O
. O

 O
The O
patient O
continued O
to O
use O
apatinib O
as O
maintenance O
therapy O
without O
major O
toxic O
effects O
, O
and O
went O
back O
to O
normal O
life O
, O
even O
an O
. O

The O
patient O
was O
a O
who O
had O
previously O
been O
due O
to O
. O

 O
At O
that O
time O
, O
a O
chest O
and O
( O
) O
revealed O
diffuse O
( O
) O
in O
the O
fields O
( O
Fig.1,2 O
) O
, O
and O
a O
revealed O
the O
of O
large O
amounts O
of O
in O
the O
and O
( O
Fig.3 O
) O
. O

 O
The O
patient O
's O
( O
) O
was O
and O
contained O
numerous O
. O

 O
A O
of O
the O
revealed O
. O

 O
An O
and O
transthoracic O
revealed O
. O

 O
A O
questionnaire O
that O
was O
completed O
at O
that O
time O
did O
not O
reveal O
the O
patient O
's O
hemorrhagic O
episode O
or O
a O
family O
history O
of O
bleeding O
disease O
, O
with O
the O
exception O
of O
his O
younger O
brother O
who O
had O
been O
diagnosed O
with O
hepatitis O
C. O

 O
Furthermore O
, O
he O
had O
not O
received O
any O
that O
had O
the O
. O

 O
Following O
the O
above O
- O
mentioned O
examinations O
, O
DAH B
due O
to O
some O
sort O
of O
vasculitis B
was O
suspected O
. O

 O
Thus O
, O
treatment O
with O
high O
- O
dose O
intravenous O
( O
) O
for O
followed O
by O
( O
) O
was O
initiated O
. O

 O
This O
relieved O
his O
. O

 O
Chest O
showed O
the O
resolution O
of O
the O
. O

 O
The O
patient O
's O
dose O
was O
and O
eventually O
at O
after O
his O
from O
our O
. O

 O
The O
patient O
was O
to O
our O
with O
a O
recurrence O
of O
. O

 O
The O
above O
- O
described O
therapy O
was O
initiated O
and O
led O
to O
the O
improvement O
of O
his O
condition O
. O

 O
The O
dose O
was O
from O
to O
a O
maintenance O
dose O
of O
. O

 O
, O
he O
was O
to O
our O
with O
a O
further O
recurrence O
of O
. O

 O
At O
this O
point O
, O
he O
had O
- O
induced O
diabetes B
mellitus I
, O
which O
was O
treated O
with O
( O
) O
. O

 O
At O
, O
his O
was O
and O
; O
his O
were O
as O
follows O
: O
, O
; O
, O
, O
, O
in O
; O
and O
, O
. O

 O
Chest O
revealed O
fine O
in O
the O
field O
. O

 O
No O
skin O
, O
subcutaneous O
or O
joint O
were O
present O
. O

 O
A O
chest O
and O
showed O
the O
presence O
of O
diffuse O
in O
the O
fields O
. O

 O
Mild O
was O
observed O
( O
, O
) O
, O
although O
levels O
had O
been O
prior O
to O
the O
hemoptysis O
episode O
. O

 O
The O
( O
) O
was O
prolonged O
to O
( O
normal O
range O
, O
25.1 O
- O
40.7 O
seconds O
) O
. O

 O
showed O
that O
the O
patient O
's O
and O
levels O
were O
and O
, O
respectively O
, O
due O
to O
the O
steroid O
- O
induced O
diabetes B
mellitus I
. O

 O
were O
( O
Table O
) O
. O

 O
We O
diagnosed O
the O
condition O
as O
a O
recurrence O
of O
DAH B
and O
again O
administered O
high O
- O
dose O
intravenous O
for O
, O
followed O
by O
( O
) O
. O

 O
His O
, O
as O
had O
been O
observed O
during O
the O
previous O
episodes O
. O

 O
A O
further O
detailed O
inquiry O
regarding O
the O
patient O
's O
medical O
history O
revealed O
that O
, O
, O
he O
had O
been O
and O
; O
however O
, O
a O
specific O
congenital O
bleeding O
disorder O
had O
not O
been O
diagnosed O
. O

 O
It O
was O
also O
revealed O
that O
his O
. O

 O
Considering O
the O
possibility O
of O
hemophilia B
, O
his O
were O
examined O
, O
revealing O
that O
his O
was O
. O

 O
The O
patient O
was O
subsequently O
diagnosed O
with O
moderate O
hemophilia O
B. O

 O
By O
the O
time O
of O
this O
diagnosis O
, O
the O
patient O
's O
DAH B
had O
already O
resolved O
with O
the O
. O

 O
We O
decided O
to O
continue O
treating O
the O
patient O
using O
alone O
, O
without O
. O

 O
No O
recurrence O
of O
DAH B
or O
have O
been O
observed O
since O
the O
tapering O
and O
discontinuation O
of O
. O

A O
developed O
severe O
viral O
pneumonia B
, O
with O
rapid O
, O
progressive O
deterioration O
in O
her O
. O

 O
She O
developed O
ARDS B
and O
using O
were O
unable O
to O
maintain O
adequate O
. O

 O
As O
a O
result O
, O
bedside O
VV O
- O
was O
planned O
. O

 O
( O
) O
was O
performed O
to O
visualize O
proper O
and O
. O

 O
Using O
the O
Seldinger O
technique O
, O
the O
right O
internal O
jugular O
vein O
was O
accessed O
and O
a O
. O

 O
Placement O
of O
the O
guidewire O
into O
the O
proved O
difficult O
due O
to O
repeated O
into O
the O
. O

 O
After O
multiple O
attempts O
, O
the O
guidewire O
was O
visualized O
to O
course O
properly O
from O
the O
SVC O
to O
the O
IVC O
. O

 O
After O
a O
bolus O
dose O
of O
5000 O
units O
of O
intravenous O
was O
given O
, O
the O
right O
internal O
jugular O
venous O
access O
site O
was O
. O

 O
Just O
as O
the O
final O
dilatation O
was O
completed O
and O
upon O
dilator O
exchange O
with O
simultaneous O
advancement O
of O
the O
23 O
French O
Avalon O
cannula O
, O
TEE O
lost O
visualization O
of O
the O
guidewire O
. O

 O
Multiple O
premature O
ventricular O
beats O
were O
noted O
and O
immediately O
, O
a O
new O
, O
rapidly O
enlarging O
pericardial B
effusion I
was O
detected O
( O
Figure O
(Figure2).2 O
) O
. O

 O
Emergent O
preparations O
were O
made O
for O
bedside O
of O
the O
. O

 O
Quickly O
the O
patient O
lost O
blood O
pressure O
from O
acute O
cardiac B
tamponade I
. O

 O
The O
Avalon O
was O
immediately O
. O

 O
A O
emergent O
subxiphoid O
was O
performed O
, O
resulting O
in O
drainage O
of O
venous O
blood O
and O
restoration O
of O
. O

 O
was O
initiated O
and O
the O
patient O
was O
emergently O
to O
the O
for O
. O

 O
The O
was O
found O
to O
have O
perforated B
the O
. O

 O
The O
was O
primarily O
and O
the O
Avalon O
was O
repositioned O
toward O
the O
IVC O
again O
by O
with O
. O

 O
VV O
- O
was O
initiated O
and O
the O
. O

 O
Due O
to O
excessive O
coagulopathies B
, O
the O
sternum O
was O
but O
was O
on O
postoperative O
. O

 O
From O
that O
point O
, O
she O
remained O
free O
from O
any O
cardiac O
or O
infectious O
and O
her O
. O

 O
She O
was O
successfully O
weaned O
from O
VV O
- O
on O
postoperative O
and O
was O
on O
postoperative O
without O
the O
need O
for O
. O

 O
She O
regained O
full O
at O
home O
and O
recovered O
normal O
by O
following O
from O
the O
. O

A O
to O
the O
( O
) O
with O
acute O
onset O
of O
, O
, O
, O
and O
with O
associated O
generalized O
, O
, O
and O
. O

 O
He O
had O
been O
diagnosed O
with O
CML B
, O
with O
no O
hematological O
response O
to O
multiple O
; O
he O
was O
at O
that O
time O
on O
treatment O
with O
and O
allogenic O
. O

 O
on O
to O
the O
included O
of O
, O
of O
and O
of O
( O
) O
. O

 O
There O
were O
no O
remarkable O
findings O
on O
except O
for O
altered O
mental O
status O
and O
. O

 O
were O
: O
, O
( O
, O
, O
and O
) O
, O
and O
910109 O
/ O
L. O

 O
were O
: O
, O
, O
, O
, O
, O
, O
, O
, O
, O
and O
71 O
IU O
/ O
L. O

 O
was O
. O

 O
were O
: O
8.5 O
pg O
/ O
L O
( O
1565 O
pg O
/ O
L O
) O
, O
( O
< O
2 O
pg O
/ O
L O
) O
, O
( O
2050 O
ng O
/ O
mL O
) O
and O
( O
1864 O
) O
ng O
/ O
mL. O

 O
Chest O
showed O
diffuse O
lytic O
and O
throughout O
the O
visualized O
, O
concerning O
for O
diffuse O
. O

 O
The O
clinical O
history O
and O
biochemical O
findings O
led O
to O
a O
diagnosis O
of O
CML O
- O
associated O
hypercalcemia O
in O
the O
context O
of O
a O
. O

 O
Treatment O
with O
aggressive O
with O
0.9 O
% O
and O
was O
administered O
. O

 O
Additionally O
, O
, O
, O
was O
given O
. O

 O
of O
treatment O
, O
normalization O
of O
and O
were O
achieved O
. O

 O
After O
from O
the O
, O
the O
patient O
continued O
with O
with O
and O
. O

 O
Acceptable O
were O
with O
. O

 O
Despite O
these O
therapies O
, O
his O
cancer B
progressed O
and O
he O
approximately O
the O
initial O
admission O
for O
hypercalcemia O
. O

A O
with O
a O
history O
of O
progressive O
on O
and O
. O

 O
At O
, O
of O
the O
has O
revealed O
random O
and O
. O

 O
was O
normal O
, O
and O
no O
or O
was O
observed O
. O

 O
There O
was O
or O
previous O
known O
pulmonary B
disease I
. O

 O
On O
routine O
, O
and O
were O
found O
to O
be O
. O

 O
and O
showed O
no O
important O
abnormalities O
. O

 O
( O
) O
showed O
a O
, O
with O
a O
reduced O
of O
( O
) O
, O
of O
( O
) O
and O
a O
of O
( O
) O
. O

 O
The O
sputum O
was O
negative O
for O
and O
was O
as O
well O
. O

 O
The O
revealed O
a O
diffuse O
symmetric O
dense O
bilateral O
( O
Figure O
1 O
) O
. O

 O
Based O
on O
this O
finding O
, O
was O
obtained O
, O
revealing O
diffuse O
ground O
glass O
attenuation O
and O
, O
more O
pronounced O
in O
lower O
pulmonary O
regions O
, O
with O
calcifications O
along O
the O
interlobar O
septa O
and O
subpleural O
regions O
. O

 O
Subpleural O
were O
also O
noticed O
( O
Figure O
2 O
) O
. O

 O
The O
patient O
underwent O
a O
with O
and O
transbronchial O
lung O
. O

 O
The O
lavage O
fluid O
was O
negative O
for O
or O
. O

 O
were O
not O
found O
. O

 O
revealed O
round O
, O
concentrically O
laminated O
in O
the O
associated O
with O
slightly O
thickened O
interstitial O
septa O
, O
consistent O
with O
the O
diagnosis O
of O
PAM B
. O

A O
presented O
to O
the O
with O
and O
a O
blocked O
left O
- O
sided O
nasal O
canal O
with O
for O
. O

 O
Medical O
history O
revealed O
secondary O
for O
the O
past O
with O
with O
no O
. O

 O
and O
were O
. O

 O
revealed O
a O
left O
- O
sided O
choanal O
. O

 O
As O
the O
was O
, O
was O
advised O
prior O
to O
performing O
a O
biopsy O
. O

 O
of O
the O
showed O
a O
sellar O
and O
infra O
- O
sellar O
( O
figure O
1 O
) O
. O

 O
The O
patient O
was O
then O
referred O
to O
the O
for O
further O
. O

 O
Her O
was O
very O
high7443 O
 O
g O
/ O
L O
( O
N<20 O
) O
. O

 O
were O
. O

 O
A O
final O
diagnosis O
of O
giant B
prolactinoma I
was O
made O
and O
the O
patient O
was O
prescribed O
with O
the O
associated O
risks O
explained O
in O
advance O
. O

In O
February O
2010 O
, O
a O
with O
a O
history O
of O
stroke B
and O
peripheral B
vascular I
disease I
at O
our O
in O
florid O
pulmonary B
edema I
. O

 O
He O
had O
a O
6 O
- O
month O
history O
of O
, O
paroxysmal O
nocturnal O
, O
and O
leg O
. O

 O
Upon O
, O
he O
had O
diffuse O
and O
a O
. O

 O
A O
2 O
- O
dimensional O
Doppler O
transthoracic O
revealed O
severe O
aortic B
valve I
stenosis I
with O
a O
of O
and O
a O
of O
, O
a O
of O
, O
severe O
mitral B
regurgitation I
, O
and O
a O
severely O
( O
) O
with O
an O
of O
. O

 O
After O
the O
pulmonary B
edema I
had O
resolved O
, O
confirmed O
the O
and O
showed O
nonobstructive O
coronary B
artery I
disease I
. O

 O
Given O
these O
findings O
and O
the O
patient O
's O
comorbidities O
, O
we O
decided O
on O
a O
minimally O
invasive O
. O

 O
The O
patient O
was O
placed O
in O
the O
and O
underwent O
induction O
and O
with O
a O
and O
a O
. O

 O
Intraoperative O
( O
) O
confirmed O
the O
previous O
findings O
, O
also O
showing O
that O
the O
mitral O
valve O
leaflets O
were O
free O
of O
significant B
disease I
and O
that O
the O
mitral B
regurgitation I
originated O
in O
the O
A2 O
 O
P2 O
portion O
of O
the O
( O
Fig.1 O
) O
. O

 O
The O
mitral B
regurgitation I
was O
thought O
to O
be O
, O
caused O
by O
and O
of O
the O
by O
the O
severely O
. O

 O
We O
decided O
to O
perform O
edge O
- O
to O
- O
edge O
of O
the O
from O
a O
. O

 O
A O
femoral O
platform O
was O
used O
to O
establish O
. O

 O
A O
2- O
to O
3 O
- O
cm O
was O
made O
in O
the O
. O

 O
A O
50 O
Prolene O
purse O
- O
string O
( O
) O
was O
placed O
in O
the O
. O

 O
The O
left O
femoral O
artery O
was O
with O
a O
. O

 O
The O
left O
femoral O
vein O
was O
with O
a O
25F O
Bio O
- O
Medicus O
 O
femoral O
venous O
cannula O
( O
) O
, O
which O
was O
placed O
in O
the O
with O
the O
aid O
of O
. O

 O
We O
then O
made O
a O
4- O
to O
5 O
- O
cm O
transverse O
parasternal O
over O
the O
and O
transected O
the O
to O
enable O
adequate O
of O
the O
. O

 O
This O
interspace O
was O
chosen O
in O
the O
event O
that O
the O
left O
atrium O
needed O
to O
be O
entered O
. O

 O
The O
pericardium O
was O
and O
to O
facilitate O
. O

 O
A O
retrograde O
coronary O
sinus O
was O
inserted O
directly O
through O
the O
, O
and O
a O
purse O
- O
string O
was O
placed O
in O
the O
. O

 O
A O
LV O
was O
inserted O
via O
a O
purse O
- O
string O
in O
the O
. O

 O
A O
transverse O
was O
performed O
to O
the O
, O
which O
was O
under O
. O

 O
The O
A2 O
and O
P2 O
segments O
of O
the O
mitral O
valve O
were O
identified O
, O
and O
an O
edge O
- O
to O
- O
edge O
repair O
was O
carried O
out O
with O
a O
50 O
Prolene O
mattress O
suture O
that O
was O
reinforced O
with O
pericardial O
pledgets O
on O
the O
ventricular O
side O
of O
the O
mitral O
valve O
( O
Fig.2 O
) O
. O

 O
Next O
, O
a O
27 O
- O
mm O
Hancock O
 O
II O
bioprosthetic O
aortic O
valve O
( O
Medtronic O
) O
was O
implanted O
by O
use O
of O
standard O
techniques O
. O

 O
The O
aortotomy O
was O
closed O
in O
2 O
- O
layer O
fashion O
, O
and O
the O
patient O
was O
weaned O
from O
cardiopulmonary O
bypass O
. O

 O
The O
transected O
rib O
was O
reattached O
to O
the O
sternum O
with O
a O
1 O
- O
cm O
metal O
plate O
( O
Synthes O
, O
Inc. O
; O
West O
Chester O
, O
Pa O
) O
, O
and O
a O
fiber O
wire O
was O
placed O
in O
figure-8 O
fashion O
. O

 O
A O
single O
chest O
tube O
was O
left O
in O
the O
pleural O
space O
. O

 O
The O
thoracotomy O
was O
closed O
in O
routine O
fashion O
. O

 O
Postoperative O
TEE O
showed O
no O
mitral O
regurgitation O
( O
Fig.3 O
) O
; O
 O
elbowing O
 O
of O
the O
anterior O
leaflet O
during O
mid O
- O
diastole O
due O
to O
tethering O
of O
the O
anterior O
leaflet O
to O
the O
posterior O
leaflet O
( O
Fig.4 O
) O
; O
and O
the O
double O
- O
orifice O
mitral O
valve O
that O
resulted O
from O
the O
edge O
- O
to O
- O
edge O
repair O
( O
Fig.5 O
) O
. O

 O
After O
surgery O
, O
the O
patient O
did O
well O
. O

 O
His O
shortness O
of O
breath O
resolved O
, O
and O
he O
was O
discharged O
from O
the O
hospital O
on O
postoperative O
day O
6 O
. O

 O
Upon O
follow O
- O
up O
evaluation O
in O
March O
2011 O
, O
he O
was O
, O
and O
showed O
grade O
1 O
+ O
mitral B
regurgitation I
. O

Here O
, O
we O
describe O
another O
case O
in O
a O
from O
who O
had O
consumed O
raw O
pork O
while O
in O
the O
. O

 O
In O
, O
this O
man O
became O
with O
, O
, O
, O
, O
and O
. O

 O
He O
had O
just O
returned O
from O
a O
vacation O
in O
the O
. O

 O
, O
his O
physician O
prescribed O
. O

 O
Symptoms O
continued O
and O
he O
was O
to O
a O
with O
a O
fever O
of O
, O
, O
, O
and O
general O
. O

 O
The O
patient O
described O
no O
recent O
contact O
with O
sick O
persons O
; O
. O

 O
On O
, O
he O
was O
but O
, O
with O
no O
focal O
findings O
on O
and O
only O
slight O
. O

 O
He O
had O
a O
of O
, O
including O
16,400 O
/ O
mm3 O
. O

 O
( O
) O
showed O
of O
with O
and O
, O
and O
and O
levels O
and O
, O
respectively O
. O

 O
of O
showed O
( O
Figure O
) O
. O

 O
Empiric O
therapy O
( O
, O
, O
and O
) O
for O
bacterial B
meningitis I
was O
begun O
. O

 O
of O
the O
showed O
only O
; O
findings O
of O
chest O
and O
were O
. O

 O
On O
, O
grew O
in O
and O
. O

 O
The O
was O
- O
, O
- O
, O
and O
- O
, O
consistent O
with O
. O

 O
A O
did O
not O
detect O
. O

 O
showed O
that O
the O
isolate O
was O
but O
. O

 O
was O
changed O
to O
, O
. O

 O
On O
, O
the O
patient O
complained O
of O
in O
his O
. O

 O
Results O
of O
were O
. O

 O
By O
, O
the O
organism O
was O
identified O
by O
the O
( O
bioMerieux O
, O
Marcy O
lEtoile O
, O
France O
) O
, O
as O
. O

 O
The O
patient O
subsequently O
stated O
that O
he O
was O
a O
with O
a O
which O
he O
had O
eaten O
in O
the O
Philippines O
. O

 O
On O
, O
a O
showed O
severe O
( O
) O
. O

 O
The O
patient O
completed O
a O
of O
and O
was O
on O
continued O
with O
close O
followup O
. O

 O
, O
the O
patient O
reported O
without O
other O
. O

A O
patient O
progressively O
worsening O
in O
the O
, O
, O
and O
bilateral O
lower O
extremities O
as O
well O
as O
. O

 O
She O
. O

 O
was O
. O

 O
Bone O
showed O
increased O
in O
the O
, O
, O
, O
, O
, O
and O
( O
Fig.1 O
) O
. O

 O
Plain O
revealed O
osteoporosis B
change O
of O
as O
well O
as O
change O
of O
, O
consistent O
with O
findings O
of O
and O
( O
) O
( O
Fig.1 O
) O
. O

 O
Decreased O
was O
presented O
in O
the O
( O
T O
- O
score O
: O
3.4 O
) O
, O
( O
T O
- O
score O
: O
3.1 O
) O
, O
and O
( O
) O
. O

 O
Main O
laboratory O
data O
are O
shown O
in O
Table O
1 O
. O

 O
She O
demonstrated O
, O
, O
, O
elevated O
level O
of O
, O
and O
, O
and O
decreased O
. O

 O
The O
revealed O
a O
high O
value O
, O
increased O
level O
of O
, O
and O
decreased O
level O
of O
, O
, O
and O
. O

 O
Persistent O
and O
were O
repeatedly O
found O
, O
despite O
normal O
and O
level O
. O

 O
Other O
results O
including O
test O
, O
, O
, O
and O
were O
. O

 O
In O
addition O
, O
all O
of O
were O
. O

 O
Due O
to O
limited O
technique O
, O
we O
can O
not O
determine O
the O
level O
of O
. O

 O
With O
the O
clinical O
diagnosis O
of O
HO B
, O
fluorodeoxyglucose O
positron O
emission O
tomography O
/ O
( O
/ O
) O
and O
technetium-99 O
m O
octreotide O
( O
99mTc O
- O
OCT O
) O
were O
performed O
to O
confirm O
whether O
the O
occult O
causative O
exist O
. O

 O
However O
, O
the O
results O
of O
were O
except O
that O
mild O
in O
the O
was O
found O
on O
/ O
, O
which O
identified O
no O
evidence O
of O
a O
neoplastic O
potentially O
responsible O
for O
HO O
( O
Fig.2 O
) O
. O

 O
The O
showed O
elevated O
level O
of O
, O
, O
and O
, O
as O
well O
as O
positive O
, O
, O
and O
. O

 O
Subsequently O
, O
was O
and O
lip O
supported O
the O
diagnosis O
of O
SS B
( O
Fig.3 O
) O
. O

 O
Eventually O
, O
this O
patient O
was O
diagnosed O
with O
HO B
secondary O
to O
SS B
, O
and O
she O
was O
then O
treated O
with O
( O
and O
for O
) O
, O
( O
for O
, O
for O
) O
, O
( O
for O
) O
, O
( O
for O
) O
, O
and O
together O
with O
( O
for O
) O
. O

 O
So O
far O
, O
she O
uneventfully O
with O
relieved O
and O
increased O
level O
. O

 O
This O
case O
report O
was O
approved O
by O
the O
ethics O
committee O
of O
West O
China O
Hospital O
of O
Sichuan O
University O
, O
Chengdu O
, O
China O
, O
and O
the O
written O
informed O
consent O
was O
obtained O
. O

A O
had O
been O
suffering O
from O
and O
severe O
for O
. O

 O
His O
were O
( O
normal O
range O
: O
1216 O
g O
/ O
dl O
) O
. O

 O
He O
had O
and O
. O

 O
and O
did O
not O
reveal O
any O
significant O
. O

 O
Abdominal O
revealed O
a O
2 O
- O
cm O
hypervascular O
in O
the O
( O
Fig.1 O
) O
. O

 O
Oral O
detected O
a O
2 O
- O
cm O
- O
diameter O
reddish O
, O
submucosal O
tumor O
- O
like O
with O
surface O
ulceration O
in O
the O
, O
approximately O
( O
Fig.2 O
) O
. O

 O
We O
did O
not O
perform O
because O
it O
can O
be O
difficult O
to O
stop O
bleeding O
in O
the O
case O
of O
hypervascular O
lesions O
. O

 O
Under O
the O
diagnosis O
of O
a O
small O
bowel O
tumor O
, O
gastrointestinal O
stromal O
tumor O
( O
GIST O
) O
, O
malignant O
lymphoma O
, O
or O
cancer O
, O
we O
performed O
laparoscopic O
- O
assisted O
segmental O
of O
the O
with O
the O
. O

 O
Examination O
of O
the O
resected O
tumor O
showed O
that O
it O
measured O
in O
diameter O
( O
Fig.3 O
) O
. O

 O
revealed O
the O
proliferation O
of O
blood O
capillaries O
and O
granulation O
tissue O
, O
which O
was O
consistent O
with O
PG B
( O
Fig.4 O
) O
. O

 O
The O
patient O
was O
on O
without O
and O
his O
gradually O
without O
the O
need O
for O
after O
surgery O
. O

A O
with O
a O
was O
to O
in O
for O
a O
left O
upper O
lobe O
lung O
with O
multiple O
bilateral O
intrapulmonary O
, O
left O
pleural B
effusion I
, O
and O
2R/4R/10L/11L O
lymphadenopathy B
. O

 O
Pleural O
fluid O
revealed O
adenocarcinoma B
and O
( O
) O
. O

 O
showed O
no O
detectable O
. O

 O
He O
commenced O
with O
and O
. O

 O
However O
, O
after O
a O
single O
cycle O
, O
his O
worsened O
and O
imaging O
confirmed O
progressive O
disease B
. O

 O
A O
from O
the O
and O
a O
computed O
tomography O
 O
guided O
of O
the O
left O
upper O
lobe O
was O
performed O
to O
permit O
additional O
molecular O
testing O
. O

 O
In O
the O
interim O
, O
the O
patient O
commenced O
and O
. O

 O
Unfortunately O
, O
after O
two O
cycles O
his O
worsened O
, O
with O
evidence O
of O
further O
progression O
on O
his O
( O
Fig.1A O
) O
. O

 O
Molecular O
testing O
on O
his O
repeat O
specimen O
revealed O
no O
mutations O
by O
SNaPshot O
multiplex O
( O
Life O
Technologies O
, O
Carlsbad O
, O
CA O
) O
. O

 O
However O
, O
although O
technically O
negative O
, O
the O
ALK O
break O
- O
apart O
showed O
an O
. O

 O
Specifically O
, O
68 O
% O
of O
cells O
demonstrated O
single O
copies O
of O
the O
5 O
ALK O
signal O
and O
numerous O
cells O
with O
doublets O
of O
the O
5 O
ALK O
signal O
combined O
with O
one O
3 O
ALK O
signal O
( O
Fig.2A O
) O
. O

 O
Subsequently O
, O
confirmatory O
demonstrated O
ALK O
protein O
expression O
by O
IHC O
using O
the O
D5F3 O
antibody O
( O
Cell O
Signaling O
Technology O
Inc. O
, O
Danvers O
, O
MA O
; O
H O
score O
= O
150 O
; O
Fig.2B O
) O
and O
the O
presence O
of O
an O
echinoderm O
microtubule O
- O
associated O
protein O
- O
like O
4 O
( O
EML4)-ALK O
transcript O
( O
E13 O
; O
A20 O
) O
by O
RT O
- O
PCR O
( O
Fig.2C O
) O
. O

 O
The O
patient O
then O
received O
( O
) O
as O
third O
- O
line O
therapy O
in O
with O
an O
impressive O
and O
CT O
response O
after O
1 O
month O
of O
therapy O
( O
Fig.1B O
) O
. O

 O
He O
remains O
on O
treatment O
with O
with O
no O
evidence O
of O
as O
of O
. O

In O
, O
a O
emergently O
with O
acute O
. O

 O
She O
had O
a O
history O
of O
progressive O
and O
a O
gradual O
decrease O
in O
secondary O
to O
mild O
. O

 O
She O
reported O
no O
. O

 O
At O
, O
she O
had O
been O
with O
a O
stage O
IIA O
, O
T1bN1 O
, O
left O
- O
sided O
breast B
cancer I
. O

 O
Initial O
treatment O
had O
included O
a O
and O
axillary O
. O

 O
She O
subsequently O
underwent O
4 O
cycles O
of O
( O
) O
, O
followed O
by O
of O
, O
, O
and O
. O

 O
before O
and O
after O
showed O
normal O
. O

 O
After O
, O
she O
underwent O
left O
whole O
- O
breast O
with O
an O
. O

 O
Because O
the O
had O
been O
, O
her O
subsequent O
medical O
regimen O
consisted O
only O
of O
. O

 O
She O
took O
for O
, O
and O
, O
ever O
since O
, O
the O
aromatase O
inhibitor O
. O

 O
In O
the O
chemotherapy O
, O
she O
had O
been O
and O
in O
relatively O
good O
. O

 O
In O
addition O
to O
her O
other O
symptoms O
, O
she O
now O
presented O
with O
, O
, O
and O
. O

 O
She O
had O
marked O
jugular O
venous O
, O
an O
, O
, O
and O
trace O
peripheral O
. O

 O
Initial O
were O
except O
for O
an O
elevated O
level O
of O
( O
) O
. O

 O
Results O
of O
investigation O
into O
the O
new O
- O
onset O
cardiomyopathy B
included O
normal O
levels O
, O
an O
( O
) O
that O
revealed O
no O
, O
and O
a O
coronary O
of O
appearance O
. O

 O
The O
showed O
sinus O
with O
frequent O
premature O
ventricular O
complexes O
, O
, O
left O
atrial O
, O
and O
low O
- O
voltage O
with O
nonspecific O
( O
Fig.1 O
) O
. O

 O
A O
2 O
- O
dimensional O
revealed O
a O
( O
) O
of O
, O
severe O
diffuse O
left O
ventricular O
( O
LV O
) O
, O
and O
a O
mildly O
. O

 O
To O
better O
define O
the O
cause O
of O
the O
LV O
systolic O
dysfunction O
, O
( O
) O
was O
performed O
. O

 O
It O
confirmed O
the O
of O
. O

 O
The O
showed O
slow O
flow O
secondary O
to O
LV O
dysfunction B
, O
and O
no O
myocardial O
( O
Fig.2A O
) O
. O

 O
Late O
disclosed O
diffuse O
myocardial O
and O
no O
scarring O
( O
Fig.2B O
) O
. O

 O
The O
patient O
was O
. O

 O
Her O
progressively O
during O
, O
which O
consisted O
of O
a O
, O
an O
, O
, O
and O
a O
. O

 O
The O
was O
slowly O
, O
and O
her O
from O
to O
during O
an O
. O

 O
All O
except O
for O
low O
- O
dose O
metoprolol O
were O
, O
and O
she O
remained O
. O

A O
was O
to O
because O
of O
and O
. O

 O
Her O
medical O
history O
included O
with O
regular O
hemodialysis O
3 O
times O
per O
week O
for O
, O
hyperuricemia B
and O
gout B
. O

 O
She O
also O
had O
comorbidity O
such O
as O
dyslipidemia B
, O
, O
secondary O
hyperparathyroidism B
, O
and O
diabetes B
. O

 O
The O
revealed O
a O
white O
blood O
cell O
count O
( O
WBC O
) O
of O
700 O
/ O
L O
, O
with O
2 O
% O
neutrophils O
, O
94 O
% O
lymphocytes O
and O
2 O
% O
monocytes O
, O
hemoglobin O
11.1 O
 O
g O
/ O
dL O
, O
and O
platelet O
count O
, O
131,000 O
/ O
L. O

 O
Under O
the O
impression O
of O
febrile O
neutropenia O
and O
acute O
pharyngitis O
, O
she O
was O
admitted O
to O
our O
hematologic O
ward O
for O
further O
survey O
and O
management O
. O

 O
Broad O
- O
spectrum O
with O
2 O
 O
g O
and O
0.25 O
 O
gm O

 O
q8h O
had O
been O
administered O
and O
her O
infection O
sign O
resolved O
gradually O
. O

 O
Upon O
admission O
, O
we O
reviewed O
her O
oral O
medication O
: O
glipizide O
5 O
 O
mg O
tid O
, O
saxagliptin O
2.5 O
 O
mg O
qd O
, O
fenofibrate O
600 O
 O
mg O
qd O
, O
aluminum O
hydroxide O
324 O
 O
mg O
tid O
, O
folic O
acid O
5 O
 O
mg O
qd O
, O
calcium O
carbonate O
1000 O
 O
mg O
tid O
, O
and O
febuxostat O
40 O
 O
mg O
qd O
. O

 O
Besides O
, O
she O
also O
received O
epoetin O
- O
beta O
2000 O
iu O
i.v.tiw O
. O

 O
Except O
for O
febuxostat O
, O
all O
the O
other O
drugs O
had O
been O
used O
for O
more O
than O
1 O
year O
. O

 O
Febuxostat O
was O
administered O
2 O
months O
before O
admission O
for O
inadequate O
serum O
uric O
acid O
control O
by O
allopurinol O
50 O
 O
mg O
qd O
. O

 O
Two O
weeks O
before O
febuxostat O
exposure O
, O
routine O
laboratory O
test O
revealed O
WBC O
6000 O
/ O
L O
and O
serum O
uric O
acid O
level O
9.8 O
 O
mg O
/ O
dL. O

 O
Febuxostat O
was O
discontinued O
thereafter O
due O
to O
the O
causal O
relationship O
of O
agranulocytosis O
can O
not O
be O
excluded O
. O

 O
Besides O
, O
we O
also O
surveyed O
viral O
infection O
and O
autoimmune O
disorder O
. O

 O
There O
were O
no O
clinical O
or O
laboratory O
evidence O
of O
Epstein O
 O
Barr O
virus O
, O
cytomegalovirus O
, O
or O
human O
immunodeficiency O
virus O
infections O
; O
antinuclear O
antibody O
( O
ANA O
) O
and O
antiextractable O
nuclear O
antigen O
( O
anti O
- O
ENA O
) O
were O
both O
negative O
. O

 O
Bone O
marrow O
examination O
during O
hospitalization O
showed O
hypocellular O
marrow O
with O
a O
marked O
decrease O
in O
myeloid O
component O
but O
no O
evidence O
of O
hematologic O
neoplasms O
. O

 O
of O
was O
. O

 O
The O
patient O
. O

 O
After O
stopping O
for O
, O
her O
neutropenia O
improved O
significantly O
( O
WBC O
2100 O
/ O
L O
, O
and O
neutrophil O
66 O
% O
) O
, O
without O
any O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
support O
. O

 O
After O
, O
her O
and O
was O
completely O
during O
( O
Fig.1 O
) O
. O

 O
This O
study O
was O
approved O
by O
our O
institutional O
review O
board O
. O

An O
with O
S549R/1717 O
- O
1 O
G O
 O
> O
 O
A O
genotype O
was O
started O
on O
( O
) O
on O
compassionate O
use O
. O

 O
At O
the O
he O
was O
diagnosed O
with O
CF B
due O
to O
failure B
to I
thrive I
. O

 O
His O
previous O
history O
was O
remarkable O
for O
requiring O
endoscopic O
surgery O
and O
necessitating O
enzyme O
replacement O
therapy O
. O

 O
He O
. O

 O
He O
suffered O
from O
rather O
mild O
, O
primarily O
intermittent O
productive O
, O
and O
had O
close O
to O
normal O
parameters O
in O
previous O
years O
as O
measured O
by O
and O
( O
) O
. O

 O
grew O
and O
on O
. O

 O
After O
of O
treatment O
, O
the O
patient O
reported O
clinical O
improvements O
in O
frequency O
, O
sputum O
production O
, O
physical O
performance O
, O
and O
less O
. O

 O
He O
gained O
1.4 O
kg O
in O
without O
changing O
the O
dose O
of O
his O
therapy O
. O

 O
His O
( O
Macroduct O
 O
) O
decreased O
from O
before O
ivacaftor O
to O
and O
( O
normal O
 O
< O
 O
30 O
mmol O
/ O
l O
[ O
11 O
] O
) O
of O
treatment O
. O

 O
His O
increased O
from O
( O
) O
to O
( O
) O
of O
therapy O
. O

 O
The O
( O
normal O
 O
< O
 O
8) O
decreased O
from O
to O
and O
of O
treatment O
( O
Table O
1 O
and O
Fig.1 O
) O
. O

A O
with O
a O
history O
of O
was O
to O
our O
on O
suspicion O
of O
DKA B
. O

 O
She O
had O
noticed O
, O
, O
and O
approximately O
. O

 O
She O
had O
also O
been O
suffering O
from O
a O
complaint O
of O
, O
approximately O
7 O
kg O
, O
, O
, O
and O
. O

 O
Her O
medical O
history O
included O
. O

 O
However O
, O
she O
had O
poor O
compliance O
with O
. O

 O
She O
. O

 O
, O
she O
was O
also O
diagnosed O
with O
influenza B
A I
at O
a O
, O
and O
was O
prescribed O
. O

 O
At O
the O
, O
she O
with O
and O
a O
of O
, O
of O
, O
of O
, O
of O
, O
of O
in O
, O
and O
a O
( O
) O
score O
of O
. O

 O
Her O
revealed O
a O
diffuse O
with O
. O

 O
Her O
lungs O
were O
clear O
when O
. O

 O
Her O
was O
soft O
and O
non O
- O
tender O
. O

 O
Her O
was O
and O
. O

 O
She O
had O
no O
lower O
extremity O
. O

 O
The O
showed O
marked O
with O
atrial B
fibrillation I
, O
and O
a O
chest O
was O
. O

 O
The O
are O
shown O
in O
Table O
1 O
. O

 O
Her O
initial O
laboratory O
data O
demonstrated O
marked O
, O
an O
increased O
level O
of O
, O
an O
increased O
level O
of O
, O
an O
increased O
level O
of O
, O
and O
a O
level O
of O
, O
with O
a O
( O
TSH O
) O
level O
of O
0.005 O
IU O
/ O
mL. O

 O
She O
scored O
55 O
on O
the O
diagnostic O
criteria O
of O
Burch O
& O
Wartofsky O
for O
thyroid O
storm O
, O
and O
the O
diagnostic O
criteria O
of O
the O
Japan O
Thyroid O
Association O
for O
thyroid O
storm O
were O
also O
satisfied O
, O
since O
she O
had O
thyrotoxicosis B
, O
, O
, O
and O
( O
4 O
) O
. O

 O
Accordingly O
, O
she O
was O
diagnosed O
with O
DKA B
and O
thyroid B
storm I
and O
to O
the O
for O
further O
and O
. O

 O
The O
clinical O
course O
is O
shown O
in O
Figure O
. O

 O
She O
was O
treated O
with O
an O
intravenous O
and O
aggressive O
intravenous O
. O

 O
The O
thyroid B
storm I
with O
GD B
was O
treated O
with O
intravenous O
, O
oral O
, O
and O
oral O
. O

 O
Since O
she O
had O
a O
history O
of O
, O
, O
a O
short O
- O
acting O
beta O
- O
adrenoceptor O
blocker O
, O
was O
used O
at O
to O
control O
her O
heart O
rate O
. O

 O
By O
, O
her O
had O
resolved O
, O
and O
was O
discontinued O
. O

 O
On O
, O
the O
had O
decreased O
to O
[ O
] O
. O

 O
was O
discontinued O
because O
methimazole O
- O
induced O
was O
suspected O
. O

 O
The O
patient O
was O
to O
an O
, O
and O
was O
performed O
on O
. O

 O
She O
was O
from O
the O
hospital O
on O
and O
maintained O
on O
multiple O
daily O
and O
. O

 O
Further O
revealed O
elevated O
levels O
of O
, O
, O
and O
, O
consistent O
with O
T1D. O

 O
The O
was O
performed O
with O
blood O
samples O
for O
glucose O
and O
C O
- O
peptide O
taken O
at O
baseline O
and O
6 O
minutes O
. O

 O
Her O
levels O
were O
and O
at O
and O
, O
respectively O
. O

 O
The O
corresponding O
levels O
were O
and O
at O
and O
, O
respectively O
. O

An O
was O
in O
our O
due O
to O
abdominal O
and O
. O

 O
He O
had O
a O
previous O
history O
of O
in O
treatment O
with O
a O
and O
a O
previous O
episode O
of O
abdominal O
which O
was O
diagnosed O
as O
spontaneous O
mesenchimal B
haematoma I
and O
. O

 O
He O
denied O
any O
kind O
of O
, O
and O
had O
no O
or O
. O

 O
At O
the O
patient O
was O
and O
suffered O
from O
intense O
at O
the O
with O
no O
defense O
. O

 O
Blood O
tests O
showed O
a O
of O
. O

 O
was O
as O
expected O
. O

 O
showed O
massive O
( O
Figure O
1 O
) O
and O
the O
already O
known O
mesenteric B
hematoma I
( O
Figure O
2 O
) O
. O

 O
Assuming O
the O
diagnosis O
of O
expansive O
mesenteric B
hematoma I
plus O
ongoing O
a O
was O
performed O
. O

 O
During O
first O
exploration O
, O
of O
were O
found O
. O

 O
At O
the O
a O
torsionated O
and O
perforated O
meckel B
diverticulum I
with O
intradiverticular O
was O
found O
( O
Figure O
3 O
) O
and O
a O
diverticular O
was O
performed O
. O

 O
The O
was O
and O
the O
patient O
was O
at O
the O
. O

An O
was O
to O
our O
because O
of O
and O
massive O
. O

 O
The O
patient O
had O
a O
history O
of O
that O
was O
well O
- O
controlled O
with O
. O

 O
She O
had O
. O

 O
The O
revealed O
diffuse O
bilateral O
. O

 O
She O
suffered O
from O
severe O
( O
pH O
7.362 O
, O
PCO2 O
35.1 O
mmHg O
, O
PO2 O
61.0 O
mmHg O
, O
HCO3- O
20.1 O
mmHg O
, O
BE O
-5.5 O
mmHg O
, O
SpO2 O
90.5 O
% O
, O
under O
10 O
L O
O2 O
/ O
min O
, O
reservoir O
mask O
) O
. O

 O
After O
the O
tracheal O
, O
100 O
mL O
of O
bright O
- O
red O
blood O
was O
. O

 O
A O
chest O
showed O
bilateral O
( O
Fig.1 O
) O
. O

 O
A O
chest O
further O
demonstrated O
multiple O
and O
ground O
glass O
and O
focal O
bronchiectasis B
in O
( O
) O
( O
Fig.2 O
) O
. O

 O
There O
were O
no O
space O
- O
occupying O
. O

 O
admission O
, O
her O
was O
. O

 O
Since O
there O
was O
no O
active O
from O
the O
tracheal O
tube O
, O
she O
was O
then O
. O

 O
After O
that O
, O
only O
a O
small O
amount O
of O
bloody O
was O
coughed O
up O
. O

 O
To O
determine O
the O
origin O
of O
bleeding O
, O
she O
underwent O
contrast O
- O
enhanced O
, O
which O
showed O
bronchiectasis B
in O
and O
regression O
of O
the O
. O

 O
revealed O
an O
abnormal O
vascular O
anastomosis B
between O
the O
and O
beside O
the O
focal O
bronchiectasis B
at O
the O
( O
Fig.3 O
) O
, O
which O
led O
us O
to O
suspect O
it O
as O
the O
possible O
source O
of O
the O
massive O
. O

 O
We O
therefore O
performed O
by O
the O
with O
a O
( O
Fig.4 O
) O
. O

 O
An O
of O
the O
showed O
no O
obvious O
active O
. O

 O
the O
embolization O
, O
she O
was O
successfully O
and O
has O
been O
free O
from O
recurrent O
for O
. O

An O
patient O
with O
a O
history O
of O
was O
to O
our O
in O
because O
of O
progressive O
and O
recurring O
. O

 O
revealed O
a O
grade O
III O
severe O
symptomatic O
aortic B
stenosis I
. O

 O
Due O
to O
relevant O
comorbidities O
( O
of O
) O
and O
severe O
femoral O
arteriopathy O
, O
he O
was O
scheduled O
for O
trans O
- O
subclavian O
. O

 O
After O
successful O
implantation O
of O
a O
( O
) O
[ O
Medtronic O
World O
Headquarters O
Medtronic O
Parkway O
Minneapolis O
, O
Minnesota O
, O
USA O
] O
( O
) O
and O
initial O
, O
he O
was O
back O
to O
the O
because O
of O
due O
to O
bilateral O
pleural B
effusions I
. O

 O
( O
) O
showed O
a O
severe O
( O
MR O
) O
, O
which O
was O
subsequently O
treated O
by O
interventional O
using O
the O
( O
) O
and O
procedurally O
dependent O
( O
St. O

 O
Jude O
Medical O
GmbH O
, O
Helfmann O
- O
Park O
7 O
, O
Eschborn O
, O
Germany O
) O
. O

 O
secondary O
, O
the O
patient O
developed O
progressive O
heart B
failure I
in O
combination O
with O
acute O
renal B
failure I
. O

 O
Immediate O
revealed O
a O
moderate O
- O
to O
- O
severe O
aortic O
regurgitation O
and O
recurrent O
severe O
. O

 O
resulted O
from O
a O
slight O
but O
significant O
towards O
the O
, O
which O
had O
caused O
and O
partial O
posterior O
( O
Fig.1 O
) O
. O

 O
As O
a O
consequence O
of O
these O
findings O
, O
the O
patient O
was O
to O
our O
. O

 O
Preoperative O
coronary O
revealed O
a O
progression O
of O
the O
coronary B
artery I
disease I
. O

 O
Consequently O
the O
patient O
was O
scheduled O
for O
conventional O
aortic O
and O
mitral O
, O
as O
well O
as O
coronary O
artery O
bypass O
surgery O
. O

 O
The O
operation O
was O
performed O
via O
. O

 O
On O
initialization O
of O
cardiopulmonary O
bypass O
, O
the O
ascending O
aorta O
was O
opened O
for O
exploration O
of O
the O
aortic O
valve O
( O
Fig.2A O
) O
. O

 O
After O
careful O
removal O
of O
the O
CoreValve O
prosthesis O
, O
an O
Edwards O
Perimount O
aortic O
valve O
prosthesis O
( O
diameter O
25 O
mm O
) O
was O
implanted O
. O

 O
After O
vein O
- O
grafting O
of O
the O
circumflex O
coronary O
artery O
, O
the O
mitral O
valve O
was O
explored O
via O
the O
left O
atrium O
and O
excised O
with O
the O
attached O
clip O
. O

 O
Thereafter O
, O
an O
Edwards O
Perimount O
mitral O
valve O
prosthesis O
( O
diameter O
31 O
mm O
) O
was O
implanted O
. O

 O
More O
recently O
, O
the O
atrial O
septal O
occluder O
was O
removed O
prior O
to O
direct O
closure O
of O
the O
resulting O
septal O
defect O
with O
a O
single O
- O
suture O
line O
( O
Fig.2B O
) O
. O

 O
Intraoperative O
echocardiography O
revealed O
adequate O
function O
of O
both O
prostheses O
and O
the O
operation O
was O
completed O
in O
the O
usual O
manner O
. O

 O
During O
the O
postoperative O
phase O
, O
the O
patient O
recovered O
well O
from O
surgery O
although O
hospitalization O
was O
prolonged O
by O
transient O
renal O
failure O
and O
recurring O
pleural O
effusions O
. O

 O
After O
a O
month O
of O
postoperative O
care O
, O
the O
patient O
was O
discharged O
from O
hospital O
to O
rehabilitation O
in O
a O
good O
condition O
, O
without O
signs O
for O
heart O
failure O
. O

 O
At O
surgery O
, O
the O
patient O
was O
still O
in O
a O
cardiopulmonary O
stable O
, O
undergoing O
additional O
. O

The O
patient O
is O
an O
to O
due O
to O
adrenal O
crisis O
triggered O
by O
pneumonia B
. O

 O
She O
has O
developed O
recurrent O
respiratory O
infections B
since O
, O
and O
failed O
to O
respond O
to O
multiple O
hepatitis O
B O
virus O
( O
HBV O
) O
. O

 O
Reduced O
serum O
and O
levels O
were O
discovered O
at O
when O
was O
initiated O
. O

 O
In O
addition O
, O
started O
from O
, O
and O
was O
noticed O
after O
. O

 O
Her O
history O
includes O
nephrotic B
syndrome I
, O
which O
was O
confirmed O
to O
be O
minimal B
change I
nephropathy I
by O
renal O
. O

 O
at O
admission O
revealed O
alopecia B
totalis I
, O
oral O
candidiasis B
, O
hypohidrosis B
, O
and O
. O

 O
Facial O
or O
dental O
abnormalities O
was O
not O
noted O
. O

 O
She O
is O
the O
in O
her O
family O
. O

 O
. O

 O
Initial O
revealed O
remarkable O
and O
reduced O
of O
, O
, O
and O
( O
Table O
(Table1).1 O
) O
. O

 O
, O
as O
well O
as O
of O
various O
were O
in O
, O
except O
increased O
. O

 O
( O
) O
and O
( O
) O
were O
. O

 O
When O
regular O
was O
suspended O
, O
her O
8:00 O
am O
serum O
was O
measured O
at O
, O
with O
< O
5.00 O
 O
pg O
/ O
mL. O

 O
Serum O
levels O
of O
other O
, O
as O
well O
as O
serum O
and O
urine O
were O
. O

 O
Both O
and O
were O
. O

 O
She O
had O
positive O
, O
with O
at O
5.9 O
 O
mmol O
/ O
L. O

 O
with O
suggested O
a O
normal O
. O

 O
She O
was O
diagnosed O
with O
CVID B
, O
isolated B
ACTH I
deficiency I
, O
and O
ectodermal B
dysplasia I
. O

 O
Symptoms O
of O
, O
, O
and O
cleared O
with O
and O
stress O
- O
dose O
treatment O
. O

 O
( O
) O
therapy O
was O
suggested O
but O
denied O
by O
the O
parents O
. O

 O
At O
her O
discharge O
, O
she O
reported O
no O
infection B
events O
as O
she O
at O
and O
avoided O
. O

 O
Her O
was O
withdrawn O
discharge O
, O
and O
she O
has O
only O
received O
ever O
since O
. O

 O
done O
at O
the O
follow O
- O
up O
documented O
increased O
levels O
of O
and O
, O
while O
remained O
. O

 O
To O
assess O
her O
NK O
- O
cell O
activity O
, O
a O
was O
done O
following O
previously O
described O
method.[10,11 O
] O
Effector O
to O
target O
cell O
ratio O
was O
set O
at O
10:1 O
. O

 O
Less O
apoptosis O
of O
target O
cell O
line O
( O
12.43 O
% O
, O
reference O
range O
15.1126.91 O
% O
) O
was O
observed O
when O
cocultured O
with O
patient O
's O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
, O
indicating O
a O
deficient O
NK O
- O
cell O
cytotoxicity O
. O

This O
, O
with O
a O
and O
, O
had O
recently O
noticed O
left O
arm O
exercise O
. O

 O
The O
and O
of O
the O
showed O
critical O
of O
the O
with O
near O
the O
( O
Fig.1 O
) O
. O

 O
Percutaneous O
was O
done O
via O
, O
and O
severe O
left O
SCA O
was O
confirmed O
( O
Fig.2A O
) O
( O
Supplementary O
Video O
1 O
, O
only O
online O
) O
. O

 O
Direct O
in O
the O
was O
carried O
out O
with O
a O
( O
Boston O
Scientific O
Corporation O
, O
Natick O
, O
MA O
, O
USA O
) O
( O
Fig.2B O
) O
up O
to O
. O

 O
However O
, O
and O
developed O
after O
. O

 O
The O
was O
down O
to O
, O
and O
the O
was O
up O
to O
. O

 O
The O
was O
down O
to O
. O

 O
Emergent O
, O
, O
with O
were O
given O
. O

 O
The O
immediate O
showed O
in O
the O
( O
Fig.2C O
) O
( O
Supplementary O
Video O
2 O
, O
only O
online O
) O
. O

 O
Emergency O
was O
done O
with O
an O
. O

 O
The O
cardiovascular O
surgeon O
was O
also O
. O

 O
However O
, O
due O
to O
the O
high O
surgical O
risk O
of O
bypass O
, O
was O
suggested O
. O

 O
We O
decided O
to O
do O
a O
retrograde O
approach O
through O
the O
left O
brachial O
artery O
by O
surgical O
cut O
- O
down O
. O

 O
Since O
there O
was O
no O
suitable O
graft O
stent O
in O
our O
cath O
lab O
, O
we O
modified O
and O
cut O
the O
iliac O
extension O
of O
self O
- O
expanding O
Endurant O
II O
graft O
stent O
1082 O
mm O
( O
Medtronic O
, O
Inc. O
, O
Minneapolis O
, O
MN O
, O
USA O
) O
, O
which O
was O
originally O
designed O
to O
treat O
abdominal O
aortic O
aneurysms O
( O
AAA O
) O
, O
to O
a O
suitable O
length O
( O
around O
30 O
mm O
) O
( O
Fig.3 O
) O
. O

 O
After O
retrograde O
wiring O
, O
an O
operator O
- O
modified O
Endurant O
II O
graft O
stent O
was O
deployed O
in O
the O
stent O
segment O
( O
Fig.2D O
) O
and O
the O
perforation O
was O
sealed O
successfully O
. O

 O
After O
stenting O
of O
the O
graft O
stent O
, O
however O
, O
slow O
flow O
of O
left O
common O
carotid O
artery O
( O
LCCA O
) O
was O
noted O
, O
and O
angiography O
confirmed O
the O
near O
total O
occlusion O
of O
the O
LCCA O
, O
occluded O
by O
the O
SCA O
graft O
stent O
( O
Fig.2E O
) O
( O
Supplementary O
Video O
3 O
, O
only O
online O
) O
. O

 O
A O
firm O
wire O
( O
Conquest O
pro O
, O
Asahi O
Inc O
, O
Seto O
, O
Japan O
) O
was O
successfully O
advanced O
outside O
the O
graft O
stent O
and O
into O
the O
LCCA O
. O

 O
Despite O
sequent O
balloon O
dilations O
at O
the O
bifurcation O
site O
, O
the O
flow O
to O
the O
LCCA O
was O
still O
poor O
. O

 O
Intravascular O
ultrasound O
also O
confirmed O
the O
severe O
compromise O
of O
the O
LCCA O
ostium O
which O
was O
caused O
by O
the O
graft O
stent O
( O
Fig.2F O
) O
. O

 O
Therefore O
, O
we O
put O
a O
balloon O
- O
expansible O
carotid O
stent O
, O
Express O
737 O
mm O
( O
Boston O
Scientific O
Corporation O
) O
, O
from O
the O
LCCA O
to O
the O
left O
brachiocephalic O
artery O
( O
Fig.4A O
) O
. O

 O
TIMI O
III O
flow O
of O
the O
LCCA O
was O
restored O
after O
stenting O
( O
Fig.4B O
- O
E O
) O
( O
Supplementary O
Video O
4 O
, O
only O
online O
) O
. O

 O
Intravascular O
ultrasound O
also O
confirmed O
proper O
expansion O
of O
the O
LCCA O
stent O
( O
Fig.4F O
) O
. O

 O
The O
follow O
- O
up O
chest O
radiography O
revealed O
left O
- O
side O
hemothorax O
. O

 O
After O
thoracocentesis O
with O
drainage O
and O
proper O
care O
, O
the O
patient O
was O
discharged O
. O

 O
Till O
now O
, O
the O
patient O
has O
been O
free O
from O
for O
. O

A O
with O
a O
history O
of O
was O
to O
our O
on O
suspicion O
of O
DKA B
. O

 O
She O
had O
noticed O
, O
, O
and O
approximately O
. O

 O
She O
had O
also O
been O
suffering O
from O
a O
complaint O
of O
, O
approximately O
7 O
kg O
, O
, O
, O
and O
. O

 O
Her O
medical O
history O
included O
. O

 O
However O
, O
she O
had O
poor O
compliance O
with O
. O

 O
She O
. O

 O
, O
she O
was O
also O
diagnosed O
with O
influenza B
A I
at O
a O
, O
and O
was O
prescribed O
. O

 O
At O
the O
, O
she O
with O
and O
a O
of O
, O
of O
, O
of O
, O
of O
, O
of O
in O
, O
and O
a O
( O
) O
score O
of O
. O

 O
Her O
revealed O
a O
diffuse O
with O
. O

 O
Her O
lungs O
were O
clear O
when O
. O

 O
Her O
was O
soft O
and O
non O
- O
tender O
. O

 O
Her O
was O
and O
. O

 O
She O
had O
no O
lower O
extremity O
. O

 O
The O
showed O
marked O
with O
atrial B
fibrillation I
, O
and O
a O
chest O
was O
. O

 O
The O
are O
shown O
in O
Table O
1 O
. O

 O
Her O
initial O
laboratory O
data O
demonstrated O
marked O
, O
an O
increased O
level O
of O
, O
an O
increased O
level O
of O
, O
an O
increased O
level O
of O
, O
and O
a O
level O
of O
, O
with O
a O
( O
TSH O
) O
level O
of O
0.005 O
IU O
/ O
mL. O

 O
She O
scored O
55 O
on O
the O
diagnostic O
criteria O
of O
Burch O
& O
Wartofsky O
for O
thyroid O
storm O
, O
and O
the O
diagnostic O
criteria O
of O
the O
Japan O
Thyroid O
Association O
for O
thyroid O
storm O
were O
also O
satisfied O
, O
since O
she O
had O
thyrotoxicosis B
, O
, O
, O
and O
( O
4 O
) O
. O

 O
Accordingly O
, O
she O
was O
diagnosed O
with O
DKA B
and O
thyroid B
storm I
and O
to O
the O
for O
further O
and O
. O

 O
The O
clinical O
course O
is O
shown O
in O
Figure O
. O

 O
She O
was O
treated O
with O
an O
intravenous O
and O
aggressive O
intravenous O
. O

 O
The O
thyroid B
storm I
with O
GD B
was O
treated O
with O
intravenous O
, O
oral O
, O
and O
oral O
. O

 O
Since O
she O
had O
a O
history O
of O
, O
, O
a O
short O
- O
acting O
beta O
- O
adrenoceptor O
blocker O
, O
was O
used O
at O
to O
control O
her O
heart O
rate O
. O

 O
By O
, O
her O
had O
resolved O
, O
and O
was O
discontinued O
. O

 O
On O
, O
the O
had O
decreased O
to O
[ O
] O
. O

 O
was O
discontinued O
because O
methimazole O
- O
induced O
was O
suspected O
. O

 O
The O
patient O
was O
to O
an O
, O
and O
was O
performed O
on O
. O

 O
She O
was O
from O
the O
hospital O
on O
and O
maintained O
on O
multiple O
daily O
and O
. O

 O
Further O
revealed O
elevated O
levels O
of O
, O
, O
and O
, O
consistent O
with O
T1D. O

 O
The O
was O
performed O
with O
blood O
samples O
for O
glucose O
and O
C O
- O
peptide O
taken O
at O
baseline O
and O
6 O
minutes O
. O

 O
Her O
levels O
were O
and O
at O
and O
, O
respectively O
. O

 O
The O
corresponding O
levels O
were O
and O
at O
and O
, O
respectively O
. O

A O
patient O
was O
to O
our O
hospital O
on O
because O
of O
frequent O
episodes O
of O
for O
. O

 O
In O
the O
, O
the O
patient O
had O
frequent O
but O
less O
severe O
episodes O
of O
, O
which O
typically O
ensued O
following O
an O
upper O
respiratory O
tract O
infection B
. O

 O
and O
failed O
to O
identify O
an O
apparent O
. O

 O
CT O
chest O
scan O
revealed O
no O
. O

 O
The O
most O
recent O
episode O
occurred O
after O
an O
upper O
respiratory O
tract O
infection O
. O

 O
The O
patient O
coughed O
up O
as O
much O
as O
about O
500 O
 O
mL O
of O
fresh O
blood O
in O
an O
episode O
of O
, O
which O
was O
alleviated O
by O
. O

 O
The O
patient O
. O

 O
Diagnostic O
workup O
revealed O
no O
evidence O
of O
coagulopathy B
. O

 O
Upon O
, O
revealed O
signs O
of O
and O
reduced O
. O

 O
showed O
a O
1 O
- O
cm O
at O
the O
to O
the O
. O

 O
were O
observed O
running O
in O
the O
( O
Fig.1 O
) O
. O

 O
was O
performed O
, O
demonstrating O
an O
artery O
extending O
into O
the O
submucosa O
from O
the O
descending O
aorta O
( O
Fig.2 O
) O
. O

 O
A O
diagnosis O
of O
of O
the O
was O
entertained O
. O

 O
Since O
the O
blood O
vessel O
was O
considered O
to O
be O
the O
culprit O
of O
hemoptysis O
, O
selective O
was O
performed O
. O

 O
No O
fresh O
episode O
of O
acute O
was O
observed O
and O
the O
patient O
was O
still O
being O
followed O
up O
at O
. O

 O
This O
study O
was O
approved O
by O
Ethics O
Committee O
of O
Shanghai O
Jiao O
Tong O
University O
Affiliated O
Sixth O
People O
's O
Hospital O
, O
and O
also O
got O
an O
informed O
written O
consent O
from O
the O
patient O
. O

A O
was O
to O
our O
because O
of O
a O
suspicion O
of O
mediastinal O
incidentally O
found O
through O
a O
plain O
( O
) O
( O
Figure O
(Figure1A).1A O
) O
. O

 O
Chest O
revealed O
a O
3 O
 O
cm O
diameter O
which O
seemed O
to O
connect O
to O
the O
right O
lobe O
of O
thyroid O
and O
projected O
into O
the O
( O
Figure O
1B O
) O
. O

 O
By O
, O
was O
detected O
( O
Figure O
1C O
) O
. O

 O
A O
fine O
needle O
aspiration O
, O
which O
is O
viewed O
as O
the O
 O
gold O
standard O
 O
for O
diagnosis O
in O
most O
cases O
, O
was O
tried O
but O
. O

 O
Thereby O
, O
was O
performed O
and O
a O
was O
revealed O
with O
( O
) O
of O
( O
Figure O
1D O
) O
. O

 O
Thus O
, O
as O
a O
possibility O
of O
malignancy B
could O
not O
be O
excluded O
, O
the O
right O
lobe O
excision O
procedure O
for O
thyroid O
gland O
was O
enforced O
. O

 O
The O
obtained O
tumor O
was O
continuous O
to O
the O
right O
lobe O
as O
expected O
. O

 O
The O
surface O
was O
flat O
and O
smooth O
and O
the O
exfoliation O
from O
the O
circumference O
organization O
was O
easy O
( O
Figure O
2A O
) O
. O

 O
Microscopically O
, O
the O
encapsulated O
tumor O
consisted O
of O
atypical O
large O
- O
sized O
follicles O
without O
malignant O
characteristics O
, O
the O
background O
thyroid O
tissue O
showing O
no O
remarkable O
change O
( O
Figure O
2B O
) O
. O

 O
Thus O
, O
was O
follicular B
thyroid I
adenoma I
. O

 O
Ethical O
approval O
was O
not O
thought O
to O
be O
necessary O
because O
all O
the O
clinical O
course O
of O
the O
case O
was O
completely O
within O
usual O
medical O
cares O
. O

 O
Informed O
consent O
was O
given O
from O
the O
case O
on O
each O
occasion O
of O
diagnostic O
examinations O
and O
therapeutic O
procedures O
. O

A O
with O
in O
the O
and O
. O

 O
and O
a O
revealed O
a O
in O
the O
, O
with O
a O
well O
defined O
located O
at O
the O
. O

 O
The O
patient O
underwent O
, O
and O
her O
postoperative O
clinical O
course O
was O
uneventful O
. O

 O
of O
the O
showed O
an O
, O
which O
was O
filled O
with O
mucinous O
material O
. O

 O
A O
distinct O
which O
involved O
the O
, O
and O
measured O
maximally O
, O
was O
identified O
in O
the O
. O

 O
There O
was O
no O
evidence O
of O
, O
of O
into O
the O
, O
or O
pseudomyxoma B
peritonei I
during O
surgery O
. O

 O
showed O
combined O
GCC B
and O
MCA B
of O
the O
( O
Figure O
1A O
) O
. O

 O
The O
was O
and O
lined O
by O
mucin O
- O
containing O
( O
Figure O
1B O
) O
. O

 O
There O
was O
no O
significant O
, O
and O
no O
were O
identified O
. O

 O
of O
the O
, O
and O
mild O
were O
present O
. O

 O
In O
addition O
, O
the O
appendiceal O
wall O
was O
infiltrated O
by O
of O
which O
were O
arranged O
in O
and O
. O

 O
These O
comprised O
2 O
distinct O
types O
of O
cells O
: O
( O
1 O
) O
small O
to O
intermediate O
sized O
monotonous O
with O
a O
small O
amount O
of O
finely O
granular O
eosinophilic O
cytoplasm O
, O
and O
mild O
( O
Figure O
(Figure1C);1C O
) O
; O
( O
2 O
) O
mucin O
- O
filled O
intermediate O
sized O
cells O
( O
) O
, O
with O
peripherally O
located O
small O
, O
crescent O
- O
like O
, O
and O
indistinct O
( O
Figure O
(Figure1D).1D O
) O
. O

 O
Scattered O
infiltrating O
single O
goblet O
neoplastic O
cells O
were O
. O

 O
As O
previously O
described[1 O
] O
the O
tumor O
nests O
appeared O
to O
arise O
from O
the O
basiglandular O
region O
of O
the O
intestinal O
crypts O
in O
close O
proximity O
to O
the O
MCA O
( O
Figure O
(Figure1E).1E O
) O
. O

 O
There O
was O
no O
lymphovascular O
, O
although O
perineural O
and O
intraneural O
was O
present O
. O

 O
The O
infiltrated O
the O
full O
thickness O
of O
the O
and O
extended O
to O
the O
. O

 O
Ten O
lymph O
nodes O
were O
histologically O
identified O
, O
of O
which O
all O
were O
negative O
for O
malignancy B
. O

 O
( O
Table O
1 O
) O
, O
the O
of O
the O
GCC B
were O
positive O
for O
, O
, O
and O
, O
which O
are O
. O

 O
Diffuse O
staining O
for O
( O
CK O
) O
20 O
( O
Figure O
2 O
) O
, O
and O
was O
also O
present O
. O

 O
The O
revealed O
nuclear O
staining O
in O
approximately O
15 O
% O
of O
the O
tumor O
cells O
. O

 O
There O
was O
no O
staining O
for O

The O
patient O
, O
a O
, O
was O
first O
diagnosed O
with O
medulloblastoma B
at O
. O

 O
included O
of O
the O
followed O
by O
systemic O
( O
, O
, O
, O
, O
, O
) O
, O
and O
craniospinal O
( O
) O
with O
boost O
to O
the O
posterior O
fossa O
( O
) O
. O

 O
was O
subsequently O
administered O
for O
eleven O
, O
14 O
- O
day O
cycles O
( O
) O
, O
over O
a O
for O
a O
cumulative O
dose O
of O
( O
) O
. O

 O
She O
completed O
at O
. O

 O
At O
, O
she O
was O
diagnosed O
with O
radiation O
- O
induced O
central O
hypothyroidism B
and O
growth B
hormone I
deficiency I
( O
GHD B
) O
. O

 O
She O
was O
treated O
with O
with O
subsequent O
biochemical O
. O

 O
Given O
status O
and O
an O
abnormal O
of O
, O
( O
) O
therapy O
was O
initiated O
at O
( O
) O
with O
subsequent O
increased O
of O
; O
however O
, O
initiation O
of O
, O
increased O
was O
noted O
at O
and O
, O
concomitant O
with O
declining O
( O
) O
. O

 O
and O
were O
significant O
for O
discrepancy O
: O
the O
right O
lower O
extremity O
1.75 O
cm O
shorter O
than O
the O
left O
( O
right O
femur O
24.9 O
cm O
, O
right O
tibia O
19.6 O
cm O
, O
right O
lower O
extremity O
44.5 O
cm O
, O
left O
femur O
25.25 O
cm O
, O
left O
tibia O
21 O
cm O
, O
and O
left O
lower O
extremity O
46.25 O
cm O
) O
. O

 O
Prior O
to O
initiation O
of O
GH O
, O
height O
( O
102 O
cm O
) O
( O
Figure O
1 O
) O
and O
armspan O
( O
102 O
cm O
) O
were O
similar O
, O
with O
upper O
segment O
/ O
lower O
segment O
ratio O
of O
one O
; O
seven O
months O
after O
GH O
, O
height O
increased O
minimally O
( O
105.6 O
cm O
) O
compared O
to O
the O
more O
significant O
increase O
in O
armspan O
( O
109.2 O
cm O
) O
, O
with O
upper O
segment O
/ O
lower O
segment O
ratio O
remaining O
at O
one O
. O

 O
revealed O
poorly O
visualized O
growth O
plates O
in O
both O
distal O
and O
proximal O
femurs O
and O
tibias O
( O
Figure O
2A O
- O
B O
) O
, O
raising O
concern O
for O
premature B
closure I
of I
the I
physes I
. O

 O
This O
lower O
limb O
growth O
plate O
closure O
would O
normally O
be O
observed O
at O
the O
time O
of O
late O
- O
stage O
puberty O
. O

 O
By O
contrast O
, O
all O
using O
left O
hand O
and O
wrist O
over O
the O
displayed O
open O
( O
Figure O
2C O
- O
D O
) O
. O

We O
report O
the O
case O
of O
a O
with O
, O
presented O
with O
an O
upper O
gastrointestinal O
and O
in O
. O

 O
Physical O
examination O
found O
a O
and O
signs O
of O
portosystemic B
collateral I
formation I
including O
abdominal O
wall O
and O
rectal O
. O

 O
No O
were O
noted O
besides O
those O
due O
to O
hypersplenism B
( O
and O
) O
. O

 O
The O
patient O
underwent O
upper O
gastrointestinal O
that O
showed O
stage O
III O
oesophageal O
with O
portal B
hypertensive I
gastropathy I
and O
. O

 O
revealed O
a O
of O
the O
measuring O
in O
diameter O
with O
; O
no O
were O
detected O
( O
Figure O
1 O
) O
. O

 O
The O
portal O
showed O
a O
. O

 O
were O
found O
, O
including O
, O
of O
the O
and O
a O
splenorenal O
. O

 O
A O
complementary O
angio O
- O
allowed O
a O
better O
assessment O
of O
the O
portal O
system O
that O
contained O
some O
in O
the O
and O
the O
( O
Figure O
2 O
, O
Figure O
3 O
, O
Figure O
4 O
) O
. O

 O
were O
noted O
such O
as O
oesophageal O
and O
gastric O
, O
parietal O
collateral O
circulation O
associated O
to O
findings O
. O

 O
Liver B
cirrhosis I
was O
confirmed O
by O
and O
. O

A O
presented O
with O
a O
right O
breast O
, O
lower O
back O
, O
, O
marked O
and O
. O

 O
Core O
from O
the O
showed O
ductal B
carcinoma I
in O
situ O
( O
sample O
labelled O
P1.1 O
; O
Supplementary O
Fig.1 O
and O
Supplementary O
Table O
1 O
) O
. O

 O
An O
additional O
from O
an O
( O
P1.2 O
) O
revealed O
metastatic O
ductal B
adenocarcinoma I
( O
ER+ O
( O
8/8 O
) O
and O
HER2 O
+ O
( O
3 O
+ O
) O
) O
. O

 O
scan O
revealed O
widespread O
metastatic B
disease I
in O
, O
and O
( O
Supplementary O
Fig.2 O
and O
Supplementary O
Table O
2 O
) O
. O

 O
The O
patient O
was O
started O
on O
treatment O
with O
and O
, O
with O
a O
significant O
partial O
( O
Supplementary O
Fig.3 O
) O
. O

 O
After O
induction O
, O
she O
was O
maintained O
on O
and O
. O

 O
After O
on O
treatment O
, O
she O
presented O
with O
and O
head O
revealed O
a O
large O
in O
the O
( O
Supplementary O
Fig.4 O
) O
, O
which O
was O
( O
M2.1 O
) O
. O

 O
Therapy O
with O
and O
was O
continued O
and O
collection O
of O
was O
initiated O
( O
samples O
T1 O
 O
T9 O
) O
. O

 O
surgery O
, O
she O
had O
enlarging O
liver O
and O
a O
new O
in O
the O
( O
Supplementary O
Fig.5 O
) O
. O

 O
Treatment O
was O
switched O
to O
a O
combination O
of O
and O
, O
resulting O
in O
for O
( O
Supplementary O
Fig.6 O
) O
. O

 O
then O
occurred O
, O
with O
in O
the O
( O
new O
pulmonary O
nodules O
, O
bilateral O
pleural B
effusions I
and O
posterior O
chest O
wall O
, O
Supplementary O
Fig.7 O
; O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
23 O
) O
. O

 O
Treatment O
was O
stopped O
and O
the O
patient O
4 O
months O
later O
. O

 O
Tumour O
samples O
were O
obtained O
at O
diagnosis O
from O
the O
primary O
breast O
site O
( O
P1.1 O
) O
and O
an O
axillary O
lymph O
node O
( O
P1.2 O
) O
; O
after O
19 O
months O
from O
the O
brain O
metastasis O
area O
( O
M2.1 O
) O
; O
and O
at O
autopsy O
after O
3 O
years O
on O
treatment O
( O
from O
the O
primary O
breast O
site O
, O
and O
from O
metastatic O
deposits O
in O
the O
chest O
, O
liver O
, O
ovary O
and O
vertebrae O
, O
labelled O
P3.1 O
and O
M3.1 O
 O
M3.4 O
, O
respectively O
) O
. O

 O
Serial O
plasma O
samples O
were O
obtained O
over O
the O
last O
500 O
days O
of O
clinical O
follow O
- O
up O
( O
T1 O
 O
T9 O
) O
. O

 O
Tumour O
and O
plasma O
samples O
collected O
and O
the O
clinical O
course O
are O
summarized O
in O
Fig.1a O
, O
b. O

On O
, O
a O
complaining O
of O
abdominal O
, O
, O
and O
was O
referred O
to O
the O
. O

 O
showed O
irregular O
hemorrhagic O
ulcerative B
lesions I
extending O
from O
the O
to O
the O
and O
pyloric B
stenosis I
of O
the O
. O

 O
Gastric O
revealed O
adenocarcinoma B
. O

 O
On O
, O
palliative O
plus O
near O
were O
performed O
. O

 O
Diffuse O
enlarged O
para O
- O
aortic O
and O
anterior O
superior O
, O
as O
well O
as O
lymph O
nodes O
around O
the O
common O
hepatic O
artery O
, O
could O
not O
be O
. O

 O
Postoperative O
demonstrated O
moderately O
differentiated O
gastric B
adenocarcinoma I
( O
Fig.1A O
) O
. O

 O
showed O
the O
following O
: O
( O
) O
( O
) O
, O
( O
) O
( O
) O
, O
( O
) O
, O
( O
) O
( O
Fig.1B O
 O
E O
) O
, O
( O
) O
( O
) O
, O
( O
) O
( O
) O
, O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
The O
diagnosis O
was O
stage O
IV O
gastric B
adenocarcinoma I
with O
metastases B
( O
) O
. O

 O
The O
patient O
was O
administered O
1 O
with O
and O
; O
however O
, O
the O
treatment O
was O
terminated O
, O
as O
the O
patient O
could O
not O
tolerate O
the O
associated O
. O

 O
On O
, O
was O
administered O
. O

 O
Before O
radiotherapy O
, O
( O
) O
showed O
metastasis B
( O
left O
supraclavicular O
and O
mediastinal O
, O
and O
throughout O
the O
) O
. O

 O
The O
patient O
's O
( O
) O
performance O
status O
was O
, O
and O
his O
( O
) O
was O
; O
therefore O
, O
he O
was O
considered O
to O
be O
at O
risk O
of O
. O

 O
combined O
with O
and O
following O
was O
prescribed O
. O

 O
Informed O
consent O
was O
obtained O
from O
the O
patient O
prior O
to O
treatment O
. O

 O
In O
an O
attempt O
to O
improve O
tolerance O
to O
treatment O
, O
palliative O
( O
) O
was O
used O
. O

 O
The O
patient O
received O
a O
dose O
of O
to O
the O
and O
doses O
of O
to O
the O
other O
abdominal O
metastatic B
lesions I
( O
n O
 O
= O
 O
5 O
) O
. O

 O
The O
left O
supraclavicular O
was O
treated O
with O
alone O
( O
Figs.2 O
and O
3A O
 O
C O
) O
. O

 O
A O
scan O
performed O
showed O
an O
in O
the O
( O
) O
of O
( O
) O
. O

 O
was O
in O
the O
left O
supraclavicular O
compared O
to O
the O
treated O
with O
concurrent O
and O
. O

 O
According O
to O
( O
) O
, O
the O
clinical O
effect O
was O
( O
Fig.2 O
) O
. O

 O
The O
patient O
received O
further O
( O
) O
to O
the O
left O
supraclavicular O
due O
to O
residual B
metastasis I
. O

 O
and O
were O
evaluated O
. O

 O
, O
chest O
, O
and O
abdominal O
indicated O
stable O
disease B
; O
and O
had O
, O
performance O
status O
was O
0 O
, O
and O
was O
. O

 O
, O
, O
, O
, O
and O
were O
not O
observed O
during O
therapy O
. O

 O
In O
, O
a O
showed O
and O
; O
however O
, O
and O
abdominal O
revealed O
no O
. O

 O
In O
, O
the O
patient O
had O
and O
experienced O
intermittent O
. O

 O
Apatinib O
was O
terminated O
due O
to O
gastrointestinal O
bleeding O
. O

 O
revealed O
due O
to O
gastric B
cancer I
and O
intragastric O
hemorrhage O
( O
Fig.3D O
 O
F O
) O
. O

 O
The O
patient O
and O
his O
family O
refused O
. O

 O
Symptomatic O
treatment O
with O
a O
and O
best O
were O
prescribed O
. O

 O
of O
therapy O
, O
hemorrhaging B
was O
resolved O
. O

 O
the O
patient O
again O
experienced O
. O

 O
On O
, O
demonstrated O
extensive O
metastasis B
. O

 O
The O
patient O
and O
his O
family O
requested O
best O
. O

 O
On O
, O
the O
patient O
due O
to O
pulmonary O
infection B
. O

A O
with O
dysphagia O
with O
a O
of O
characterized O
by O
brown O
with O
and O
involving O
the O
and O
a O
prior O
percutaneous O
endoscopic O
gastrostomy O
( O
PEG O
) O
tube O
site O
( O
Fig.1a O
, O
c O
) O
. O

 O
No O
oral O
or O
conjunctival O
was O
present O
. O

 O
She O
had O
been O
receiving O
for O
following O
removal O
of O
the O
due O
to O
infection B
. O

 O
Although O
the O
differential O
diagnosis O
included O
drug B
hypersensitivity I
, O
autoimmune B
disorders I
and O
nutritional B
deficiency I
, O
the O
appearance O
was O
most O
consistent O
with O
acrodermatitis B
enteropathica I
- O
like O
eruption O
secondary O
to O
zinc B
deficiency I
. O

 O
Her O
serum O
level O
was O
( O
normal O
, O
55150 O
mcg O
/ O
dL O
) O
, O
and O
the O
resolved O
of O
parenteral O
( O
Fig.1b O
, O
d O
) O
. O

 O
Zinc O
is O
essential O
for O
protein O
synthesis O
and O
wound O
healing O
. O

 O
Acrodermatitis O
enteropathica O
presents O
in O
infancy O
as O
a O
periorificial O
desquamative O
dermatitis O
, O
resulting O
from O
an O
autosomal O
recessive O
mutation O
that O
impairs O
zinc O
absorption O
. O
A O
similar O
syndrome O
may O
occur O
due O
to O
nutritional O
zinc O
deficiency O
, O
and O
has O
been O
reported O
in O
the O
setting O
of O
parenteral O
nutrition O
that O
fails O
to O
include O
zinc O
supplementation O
; O
a O
prompt O
response O
to O
supplementation O
helps O
to O
confirm O
the O
diagnosis O
. O

 O
A O
recent O
in O
the O
likely O
contributed O
to O
this O
patient O
s O
presentation O
. O

The O
proband O
( O
II-2 O
in O
Fig.2 O
) O
is O
a O
, O
who O
first O
presented O
to O
our O
and O
was O
referred O
to O
us O
because O
of O
her O
. O

 O
She O
has O
, O
first O
experienced O
syncope O
at O
the O
age O
of O
3 O
, O
and O
was O
diagnosed O
with O
. O

 O
She O
was O
treated O
with O
; O
however O
, O
she O
subsequently O
experienced O
several O
instances O
of O
. O

 O
At O
the O
, O
she O
had O
a O
event O
, O
and O
was O
suspected O
of O
having O
JLNS B
because O
of O
her O
congenital O
deafness O
and O
. O

 O
Her O
was O
diagnosed O
as O
an O
arrhythmic O
episode O
when O
she O
was O
aware O
of O
tachycardia O
and O
as O
epilepsy O
when O
she O
was O
not O
. O

 O
She O
also O
had O
a O
subarachnoid O
hemorrhage O
at O
the O
. O

 O
When O
she O
first O
at O
our O
, O
she O
was O
not O
taking O
, O
because O
of O
a O
history O
of O
, O
but O
was O
taking O
in O
addition O
to O
. O

 O
Her O
was O
found O
to O
be O
( O
) O
at O
and O
administration O
of O
was O
initiated O
. O

 O
She O
her O
baby O
( O
III-1 O
in O
Fig.2 O
) O
through O
at O
our O
at O
the O
. O

 O
, O
she O
her O
( O
III-2 O
in O
Fig.2 O
) O
through O
at O
our O
. O

 O
Despite O
administration O
of O
, O
her O
remained O
( O
at O
the O
age O
of O
37 O
, O
at O
) O
( O
Figs.2 O
and O
3a O
) O
, O
which O
is O
not O
unexpected O
because O
treatment O
with O
beta O
- O
blockers O
in O
LQTS1 O
is O
not O
expected O
to O
overtly O
reduce O
QTc O
[ O
18 O
] O
. O

 O
However O
, O
she O
continued O
to O
experience O
occasional O
and O
finally O
underwent O
an O
( O
) O
operation O
at O
. O

 O
Subsequently O
, O
she O
is O
in O
a O
. O

 O
Because O
the O
proband O
was O
suspected O
of O
JLNS B
and O
had O
a O
, O
beta O
blockers O
were O
initiated O
and O
both O
children O
remain O
in O
( O
Figs.2 O
and O
3b O
, O
c O
) O
. O

 O
QTc O
of O
the O
( O
III-1 O
in O
Fig.2 O
) O
was O
measured O
as O
, O
while O
the O
QTc O
of O
his O
( O
III-2 O
) O
was O
. O

 O
. O

 O
There O
is O
no O
history O
of O
sudden O
unexplained O
syncope O
or O
death O
of O
children O
or O
adults O
in O
the O
, O
despite O
the O
prolonged O
QTc O
of O
the O
children O
. O

 O
Clinical O
evaluation O
and O
consultation O
of O
the O
proband O
and O
her O
family O
members O
were O
performed O
at O
. O

 O
Clinical O
phenotypes O
were O
deduced O
from O
the O
clinical O
history O
, O
physical O
examinations O
, O
and O
. O

 O
were O
collected O
from O
the O
proband O
and O
her O
family O
members O
following O
, O
and O
written O
informed O
consent O
was O
obtained O
prior O
to O
sample O
collection O
. O

 O
was O
isolated O
from O
according O
to O
established O
protocols O
at O
our O
laboratory O
[ O
19 O
] O
. O

 O
Entire O
coding O
exons O
, O
including O
the O
intronic O
boundaries O
of O
the O
genes O
, O
of O
KCNQ1 O
( O
NCBI O
ref O
: O
NM_000218 O
) O
and O
other O
LQT O
causative O
genes O
( O
KCNH2 O
, O
SCN5A O
, O
KCNE1 O
, O
KCNE2 O
, O
KCNJ2 O
, O
SCN4B O
, O
KCNJ5 O
) O
were O
amplified O
by O
( O
) O
, O
according O
to O
established O
protocols O
in O
our O
laboratory O
. O

 O
Briefly O
, O
was O
subjected O
to O
with O
( O
) O
and O
. O

 O
The O
amplicons O
were O
subjected O
to O
conventional O
with O
( O
) O
. O

 O
The O
sequence O
data O
were O
( O
) O
and O
( O
) O
. O

 O
was O
performed O
to O
screen O
all O
coding O
exons O
and O
the O
exon O
 O
intron O
boundaries O
of O
the O
( O
NCBI O
ref O
: O
NM_000218.2 O
, O
NP_000209.2 O
) O
with O
concurrent O
screening O
of O
other O
( O
) O
. O

 O
We O
detected O
a O
novel O
, O
NM_000218.2 O
: O
c.115 O
G O
 O
> O
 O
T O
( O
p. O
Glu39X O
, O
in O
exon O
1a O
) O
, O
in O
the O
KCNQ1 O
gene O
of O
the O
proband O
, O
as O
well O
as O
a O
( O
, O
p. O
Pro448Arg O
) O
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O

 O
of O
her O
( O
I-2 O
) O
and O
( O
III-1 O
and O
III-2 O
) O
revealed O
that O
they O
were O
( O
Fig.2 O
) O
. O

 O
Her O
( O
II-3 O
) O
was O
also O
screened O
and O
found O
to O
be O
( O
NM_000218.2 O
: O
c.1343C O
 O
> O
 O
G O
, O
p. O
Pro448Arg O
) O
. O

 O
, O
and O
we O
have O
concluded O
the O
homozygous O
nonsense O
variant O
in O
the O
proband O
is O
the O
cause O
of O
her O
JLNS1 B
. O

 O
The O
proband O
was O
negative O
for O
, O
including O
the O
KCNE1 O
gene O
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O

The O
patient O
presented O
to O
the O
closest O
emergency O
department O
at O
8 O
PM O
for O
nausea O
, O
numbness O
of O
the O
left O
limbs O
, O
incoordination O
of O
walking O
and O
dysarthria O
, O
with O
the O
symptomatology O
installed O
in O
a O
progressive O
mode O
4 O
hours O
before O
presentation O
. O

 O
The O
nausea O
was O
the O
initial O
symptom O
, O
starting O
at O
4 O
PM O
( O
without O
headache O
, O
nuchal O
pain O
, O
or O
vomit O
) O
and O
then O
, O
after O
5.30 O
PM O
, O
the O
numbness O
of O
the O
left O
limbs O
and O
the O
incoordination O
of O
walking O
and O
by O
7 O
PM O
dysarthria O
was O
added O
to O
the O
entire O
clinical O
constellation O
. O

 O
. O

 O
He O
was O
a O
. O

 O
. O

 O
. O

 O
. O

 O
He O
was O
first O
by O
a O
in O
the O
and O
had O
a O
brain O
scan O
that O
highlighted O
infracentimetric O
in O
the O
, O
on O
the O
and O
at O
the O
in O
the O
, O
and O
also O
a O
chest O
that O
revealed O
a O
of O
the O
, O
without O
any O
. O

 O
Following O
this O
evaluation O
, O
he O
was O
to O
the O
for O
and O
. O

 O
During O
the O
ambulance O
, O
he O
had O
repeated O
episodes O
of O
. O

 O
The O
initial O
( O
at O
) O
showed O
normal O
: O
, O
and O
normal O
. O

 O
The O
was O
. O

 O
No O
were O
registered O
. O

 O
The O
was O
notable O
for O
. O

 O
The O
patient O
had O
equal O
, O
reactive O
, O
divergent O
to O
the O
, O
horizontal O
, O
normal O
, O
mild O
paresis B
of O
the O
, O
ataxia B
of O
, O
with O
an O
, O
of O
the O
, O
bilateral O
response O
present O
at O
all O
deep O
tendons O
, O
on O
the O
, O
stereotypical O
. O

 O
The O
patient O
was O
and O
to O
. O

 O
The O
highlighted O
a O
normal O
, O
normal O
level O
( O
normal O
range O
3,9 O
- O
5,8mmol/ O
L O
) O
, O
( O
range O
0,5 O
- O
0,9mmol/ O
L O
) O
, O
( O
normal O
range O
< O
5,2 O
mmol/ O
L O
) O
. O

 O
The O
tests O
for O
were O
. O

 O
He O
also O
presented O
a O
normal O
on O
the O
. O

 O
The O
brain O
performed O
at O
the O
first O
emergency O
unit O
, O
as O
mentioned O
above O
, O
revealed O
a O
infracentimetric O
at O
the O
and O
at O
the O
in O
the O
. O

 O
Doppler O
for O
highlighted O
the O
marked O
frena O
in O
the O
of O
the O
, O
an O
accentuated O
aspect O
in O
the O
high O
V2 O
segments O
with O
the O
complete O
disappearance O
of O
the O
in O
the O
, O
without O
carotid O
atheromatous O
or O
. O

 O
Overall O
, O
there O
was O
a O
possibility O
of O
a O
dissection B
of O
the O
in O
the O
with O
indication O
of O
cerebral O
and O
angio O
. O

 O
Cerebral O
and O
angio O
showed O
: O
areas O
with O
T2 O
, O
, O
with O
an O
important O
and O
low O
, O
situated O
in O
the O
, O
, O
, O
, O
as O
well O
as O
, O
with O
an O
that O
was O
recently O
constituted O
. O

 O
was O
present O
on O
the O
and O
the O
. O

 O
On O
the O
sequence O
, O
the O
presence O
of O
the O
rapid O
of O
the O
could O
be O
viewed O
, O
, O
where O
there O
was O
a O
progressive O
with O
an O
aspect O
of O
. O

 O
Distal O
of O
this O
level O
, O
there O
was O
an O
absence O
of O
the O
signal O
and O
also O
a O
lack O
of O
. O

 O
The O
aspect O
suggested O
a O
subacute O
dissection B
of O
the O
. O

 O
The O
cerebral O
ventricular O
system O
had O
normal O
, O
, O
and O
. O

 O
The O
pericerebral O
fluid O
spaces O
and O
the O
basal O
cisterns O
were O
normal O
. O

 O
Conclusions O
: O
there O
were O
some O
ischemic O
lesions O
recently O
constituted O
in O
the O
vertebrobasilar O
territory O
and O
also O
a O
subacute O
dissection O
of O
the O
right O
vertebral O
artery O
. O

 O
administration O
was O
started O
immediately O
in O
the O
process O
of O
hospitalization O
because O
of O
the O
dissection O
. O

 O
The O
was O
kept O
in O
the O
. O

 O
Also O
, O
the O
for O
was O
performed O
. O

 O
from O
the O
debut O
, O
the O
patient O
was O
transitioned O
to O
for O
long O
- O
term O
anticoagulation O
. O

 O
The O
treatment O
with O
acenocumarol O
was O
instituted O
with O
the O
heparin O
overlap O
until O
getting O
the O
in O
the O
. O

 O
The O
was O
, O
the O
patient O
regaining O
the O
and O
the O
capacity O
for O
. O

 O
The O
ataxia B
was O
and O
, O
but O
registered O
a O
lot O
of O
improvement O
. O

 O
The O
patient O
was O
with O
the O
. O

 O
The O
was O
not O
possible O
because O
the O
patient O
did O
not O
return O
to O
the O
hospital O
. O

Bile B
duct I
hamartoma B
occurring O
in O
association O
with O
long-term O
treatment O
with O
danazol. O

The O
relationship O
between O
hippocampal O
acetylcholine O
release O
and O
cholinergic O
convulsant O
sensitivity O
in O
withdrawal O
seizure-prone B
and O
withdrawal O
seizure-resistant O
selected O
mouse O
lines. O

The O
present O
report O
describes O
a O
case O
of O
cardiac B
arrest I
and O
subsequent O
death B
as O
a O
result O
of O
hyperkalaemia B
following O
the O
use O
of O
suxamethonium O
in O
a O
23-year-old O
Malawian O
woman. O
Five O
days O
after O
the O
onset O
of O
the O
symptoms O
of O
meningitis, B
the O
patient O
aspirated O
stomach O
contents O
and O
needed O
endotracheal O
intubation. O
Forty O
seconds O
after O
injection O
of O
suxamethonium, O
bradycardia B
and O
cardiac O
arrest O
occurred. O
Attempts O
to O
resuscitate O
the O
patient O
were O
not O
successful. O
The O
serum O
level O
of O
potassium O
was O
observed O
to O
be O
8.4 O
mequiv O
L-1. O
Apart O
from O
the O
reduction O
in O
the O
patient's O
level O
of O
consciousness, O
there O
were O
no O
signs O
of O
motor O
neurone O
damage O
or O
of O
any O
of O
the O
other O
known O
predisposing O
conditions O
for O
hyperkalaemia O
following O
the O
administration O
of O
suxamethonium. O
It O
is O
postulated O
that O
her O
death O
was O
caused O
by O
hypersensitivity B
to O
suxamethonium, O
associated O
with O
her O
5-day O
immobilization. O

Immediate O
allergic B
reactions I
to O
amoxicillin. O

The O
appearance O
of O
nephrotic B
syndromes I
such O
as O
proteinuria, B
hypoalbuminemia, B
hypercholesterolemia B
and O
increase O
in O
blood O
nitrogen O
urea, O
induced O
in O
rats O
by O
injection O
of O
puromycin O
aminonucleoside O
was O
markedly O
inhibited O
by O
oral O
administration O
of O
Dup O
753 O
(losartan), O
a O
novel O
angiotensin O
II O
receptor O
antagonist, O
at O
a O
dose O
of O
1 O
or O
2 O
mg/kg O
per O
day. O
The O
results O
suggest O
a O
possible O
involvement O
of O
the O
renin-angiotensin O
system O
in O
the O
development O
of O
puromycin O
aminonucleoside-induced O
nephrosis. B

Ketoconazole-induced O
neurologic B
sequelae. I

Ventricular B
tachyarrhythmias I
during O
cesarean O
section O
after O
ritodrine O
therapy: O
interaction O
with O
anesthetics. O

Norepinephrine O
signaling O
through O
beta-adrenergic O
receptors O
is O
critical O
for O
expression O
of O
cocaine-induced O
anxiety. B

Higher O
optical O
density O
of O
an O
antigen O
assay O
predicts O
thrombosis B
in O
patients O
with O
heparin-induced O
thrombocytopenia. B

Carbonic O
anhydrase O
inhibitors O
can O
cause O
nephrolithiasis. B
We O
studied O
20 O
patients O
receiving O
long-term O
carbonic O
anhydrase O
inhibitor O
treatment O
for O
periodic O
paralysis B
and O
myotonia. B
Three O
patients O
on O
acetazolamide O
(15%) O
developed O
renal B
calculi. I
Extracorporeal O
lithotripsy O
successfully O
removed O
a O
renal B
calculus B
in O
one O
patient O
and O
surgery O
removed O
a O
staghorn O
calculus O
in O
another, O
permitting O
continued O
treatment. O
Renal O
function O
remained O
normal O
in O
all O
patients. O
Nephrolithiasis B
is O
a O
complication O
of O
acetazolamide O
but O
does O
not O
preclude O
its O
use. O

This O
case O
study O
reveals O
an O
unusual O
finding O
of O
rapidly O
proliferative O
crescentic O
glomerulonephritis B
in O
a O
patient O
treated O
with O
rifampin O
who O
had O
no O
other O
identifiable O
causes O
for O
developing O
this O
disease. O
This O
patient O
underwent O
a O
10-month O
regimen O
of O
rifampin O
and O
isoniazid O
for O
pulmonary B
tuberculosis I
and O
was O
discovered O
to O
have O
developed O
signs O
of O
severe O
renal B
failure I
five O
weeks O
after O
completion O
of O
therapy. O
Renal O
biopsy O
revealed O
severe O
glomerulonephritis O
with O
crescents, O
electron O
dense O
fibrillar O
deposits O
and O
moderate O
lymphocytic O
interstitial O
infiltrate. O
Other O
possible O
causes O
of O
rapidly O
progressive O
glomerulonephritis O
were O
investigated O
and O
ruled O
out. O
This O
report O
documents O
the O
unusual O
occurrence O
of O
rapidly O
progressive O
glomerulonephritis O
with O
crescents O
and O
fibrillar O
glomerulonephritis O
in O
a O
patient O
treated O
with O
rifampin. O

Hyperprolactinemia B
can O
reduce O
fertility O
and O
libido. O
Although O
central O
prolactin O
actions O
are O
thought O
to O
contribute O
to O
this, O
the O
mechanisms O
are O
poorly O
understood. O
We O
first O
tested O
whether O
chronic O
hyperprolactinemia B
inhibited O
two O
neuroendocrine O
parameters O
necessary O
for O
female O
fertility: O
pulsatile O
LH O
secretion O
and O
the O
estrogen-induced O
LH O
surge. O
Chronic O
hyperprolactinemia O
induced O
by O
the O
dopamine O
antagonist O
sulpiride O
caused O
a O
40% O
reduction O
LH O
pulse O
frequency O
in O
ovariectomized O
rats, O
but O
only O
in O
the O
presence O
of O
chronic O
low O
levels O
of O
estradiol. O
Sulpiride O
did O
not O
affect O
the O
magnitude O
of O
a O
steroid-induced O
LH O
surge O
or O
the O
percentage O
of O
GnRH O
neurons O
activated O
during O
the O
surge. O
Estradiol O
is O
known O
to O
influence O
expression O
of O
the O
long O
form O
of O
prolactin O
receptors O
(PRL-R) O
and O
components O
of O
prolactin's O
signaling O
pathway. O
To O
test O
the O
hypothesis O
that O
estrogen O
increases O
PRL-R O
expression O
and O
sensitivity O
to O
prolactin, O
we O
next O
demonstrated O
that O
estradiol O
greatly O
augments O
prolactin-induced O
STAT5 O
activation. O
Lastly, O
we O
measured O
PRL-R O
and O
suppressor O
of O
cytokine O
signaling O
(SOCS-1 O
and O
-3 O
and O
CIS, O
which O
reflect O
the O
level O
of O
prolactin O
signaling) O
mRNAs O
in O
response O
to O
sulpiride O
and O
estradiol. O
Sulpiride O
induced O
only O
SOCS-1 O
in O
the O
medial O
preoptic O
area, O
where O
GnRH O
neurons O
are O
regulated, O
but O
in O
the O
arcuate O
nucleus O
and O
choroid O
plexus, O
PRL-R, O
SOCS-3, O
and O
CIS O
mRNA O
levels O
were O
also O
induced. O
Estradiol O
enhanced O
these O
effects O
on O
SOCS-3 O
and O
CIS. O
Interestingly, O
estradiol O
also O
induced O
PRL-R, O
SOCS-3, O
and O
CIS O
mRNA O
levels O
independently. O
These O
data O
show O
that O
GnRH O
pulse O
frequency O
is O
inhibited O
by O
chronic O
hyperprolactinemia O
in O
a O
steroid-dependent O
manner. O
They O
also O
provide O
evidence O
for O
estradiol-dependent O
and O
brain O
region-specific O
regulation O
of O
PRL-R O
expression O
and O
signaling O
responses O
by O
prolactin. O

Estrogens O
protect O
ovariectomized O
rats O
from O
hippocampal B
injury I
induced O
by O
kainic O
acid-induced O
status B
epilepticus I
(SE). O
We B
compared O
the O
effects O
of O
17beta-estradiol O
in O
adult O
male O
and O
ovariectomized O
female O
rats O
subjected O
to O
lithium-pilocarpine-induced O
SE. O
Rats O
received O
subcutaneous O
injections O
of O
17beta-estradiol O
(2 O
microg/rat) O
or O
oil O
once O
daily O
for O
four O
consecutive O
days. O
SE O
was O
induced O
20 O
h O
following O
the O
second O
injection O
and O
terminated O
3 O
h O
later. O
The O
extent O
of O
silver-stained O
CA3 O
and O
CA1 O
hippocampal O
neurons O
was O
evaluated O
2 O
days O
after O
SE. O
17beta-Estradiol O
did O
not O
alter O
the O
onset O
of O
first O
clonus O
in O
ovariectomized O
rats O
but O
accelerated O
it O
in O
males. O
17beta-Estradiol O
reduced O
the O
argyrophilic O
neurons O
in O
the O
CA1 O
and O
CA3-C O
sectors O
of O
ovariectomized O
rats. O
In O
males, O
estradiol O
increased O
the O
total O
damage O
score. O
These O
findings O
suggest O
that O
the O
effects O
of O
estradiol O
on O
seizure B
threshold O
and O
damage O
may O
be O
altered O
by O
sex-related O
differences O
in O
the O
hormonal O
environment. O

Pseudoacromegaly B
induced O
by O
the O
long-term O
use O
of O
minoxidil. O

Carbamazepine O
was O
switched O
to O
its O
10-keto O
analogue O
oxcarbazepine O
among O
six O
difficult-to-treat O
schizophrenic B
or O
organic B
psychotic I
patients O
using O
concomitantly O
haloperidol, O
chlorpromazine O
or O
clozapine. O
This O
change O
resulted O
within O
2-4 O
weeks O
in O
the O
50-200% O
increase O
in O
the O
plasma O
levels O
of O
these O
neuroleptics O
and O
the O
appearance O
of O
extrapyramidal B
symptoms. I
None O
of O
the O
patients O
showed O
any O
clinical O
deteriotation O
during O
the O
following O
3-6 O
months. O
The O
results O
of O
this O
case O
report O
support O
the O
idea O
that O
in O
contrast O
with O
carbamazepine O
oxcarbazepine O
does O
not O
induce O
the O
hepatic O
microsomal O
enzyme O
systems O
regulating O
the O
inactivation O
of O
antipsychotic O
drugs. O

Previous O
reports O
have O
suggested O
that O
pain B
associated O
with O
the O
injection O
of O
lidocaine O
is O
related O
to O
the O
acidic O
pH O
of O
the O
solution. O
To O
determine O
if O
the O
addition O
of O
a O
buffering O
solution O
to O
adjust O
the O
pH O
of O
lidocaine O
into O
the O
physiologic O
range O
would O
reduce O
pain O
during O
injection, O
we O
performed O
a O
blinded O
randomized O
study O
in O
patients O
undergoing O
cardiac O
catheterization. O
Twenty O
patients O
were O
asked O
to O
quantify O
the O
severity O
of O
pain O
after O
receiving O
standard O
lidocaine O
in O
one O
femoral O
area O
and O
buffered O
lidocaine O
in O
the O
opposite O
femoral O
area. O
The O
mean O
pain O
score O
for O
buffered O
lidocaine O
was O
significantly O
lower O
than O
the O
mean O
score O
for O
standard O
lidocaine O
(2.7 O
+/- O
1.9 O
vs. O
3.8 O
+/- O
2.2, O
P O
= O
0.03). O
The O
pH O
adjustment O
of O
standard O
lidocaine O
can O
be O
accomplished O
easily O
in O
the O
catheterization O
laboratory O
before O
injection O
and O
results O
in O
a O
reduction O
of O
the O
pain O
occurring O
during O
the O
infiltration O
of O
tissues. O

Reversibility O
of O
captopril-induced O
renal B
insufficiency I
after O
prolonged O
use O
in O
an O
unusual O
case O
of O
renovascular B
hypertension. I

Immunological O
activation O
has O
been O
proposed O
to O
play O
a O
role O
in O
methamphetamine-induced O
dopaminergic B
terminal I
damage. I
In O
this O
study, O
we O
examined O
the O
roles O
of O
lipopolysaccharide, O
a O
pro-inflammatory O
and O
inflammatory O
factor, O
treatment O
in O
modulating O
the O
methamphetamine-induced O
nigrostriatal O
dopamine O
neurotoxicity. B
Lipopolysaccharide O
pretreatment O
did O
not O
affect O
the O
basal O
body O
temperature O
or O
methamphetamine-elicited O
hyperthermia B
three O
days O
later. O
Such O
systemic O
lipopolysaccharide O
treatment O
mitigated O
methamphetamine-induced O
striatal O
dopamine O
and O
3,4-dihydroxyphenylacetic O
acid O
depletions O
in O
a O
dose-dependent O
manner. O
As O
the O
most O
potent O
dose O
(1 O
mg/kg) O
of O
lipopolysaccharide O
was O
administered O
two O
weeks, O
one O
day O
before O
or O
after O
the O
methamphetamine O
dosing O
regimen, O
methamphetamine-induced O
striatal O
dopamine O
and O
3,4-dihydroxyphenylacetic O
acid O
depletions O
remained O
unaltered. O
Moreover, O
systemic O
lipopolysaccharide O
pretreatment O
(1 O
mg/kg) O
attenuated O
local O
methamphetamine O
infusion-produced O
dopamine O
and O
3,4-dihydroxyphenylacetic O
acid O
depletions O
in O
the O
striatum, O
indicating O
that O
the O
protective O
effect O
of O
lipopolysaccharide O
is O
less O
likely O
due O
to O
interrupted O
peripheral O
distribution O
or O
metabolism O
of O
methamphetamine. O
We O
concluded O
a O
critical O
time O
window O
for O
systemic O
lipopolysaccharide O
pretreatment O
in O
exerting O
effective O
protection O
against O
methamphetamine-induced O
nigrostriatal O
dopamine O
neurotoxicity. O

Toxic B
hepatitis I
induced O
by O
antithyroid O
drugs: O
four O
cases O
including O
one O
with O
cross-reactivity O
between O
carbimazole O
and O
benzylthiouracil. O

Similar O
to O
rats, O
systemic O
pilocarpine O
injection O
causes O
status B
epilepticus I
(SE) O
and B
the O
eventual O
development O
of O
spontaneous O
seizures B
and O
mossy O
fiber O
sprouting O
in O
C57BL/6 O
and O
CD1 O
mice, O
but O
the O
physiological O
correlates O
of O
these O
events O
have O
not O
been O
identified O
in O
mice. O
Population O
responses O
in O
granule O
cells O
of O
the O
dentate O
gyrus O
were O
examined O
in O
transverse O
slices O
of O
the O
ventral O
hippocampus O
from O
pilocarpine-treated O
and O
untreated O
mice. O
In O
Mg(2+)-free O
bathing O
medium O
containing O
bicuculline, O
conditions O
designed O
to O
increase O
excitability O
in O
the O
slices, O
electrical O
stimulation O
of O
the O
hilus O
resulted O
in O
a O
single O
population O
spike O
in O
granule O
cells O
from O
control O
mice O
and O
pilocarpine-treated O
mice O
that O
did O
not O
experience O
SE. O
In O
SE O
survivors, O
similar O
stimulation O
resulted O
in O
a O
population O
spike O
followed, O
at O
a O
variable O
latency, O
by O
negative O
DC O
shifts O
and O
repetitive O
afterdischarges O
of O
3-60 O
s O
duration, O
which O
were O
blocked O
by O
ionotropic O
glutamate O
receptor O
antagonists. O
Focal O
glutamate O
photostimulation O
of O
the O
granule O
cell O
layer O
at O
sites O
distant O
from O
the O
recording O
pipette O
resulted O
in O
population O
responses O
of O
1-30 O
s O
duration O
in O
slices O
from O
SE O
survivors O
but O
not O
other O
groups. O
These O
data O
support O
the O
hypothesis O
that O
SE-induced O
mossy O
fiber O
sprouting O
and O
synaptic O
reorganization O
are O
relevant O
characteristics O
of O
seizure O
development O
in O
these O
murine O
strains, O
resembling O
rat O
models O
of O
human O
temporal B
lobe I
epilepsy. I

OBJECTIVE: O
To O
report O
a O
case O
of O
venlafaxine O
overdose. B
CASE O
SUMMARY: O
A O
40-year-old O
woman O
with O
major B
depression I
took O
an O
overdose O
of O
venlafaxine O
in O
an O
apparent O
suicide O
attempt. O
After O
the O
ingestion O
of O
26 O
venlafaxine O
50-mg O
tablets, O
the O
patient O
experienced O
a O
witnessed O
generalized O
seizure. B
She O
was O
admitted O
to O
the O
medical O
intensive O
care O
unit, O
venlafaxine O
was O
discontinued, O
and O
no O
further O
sequelae O
were O
seen. O
DISCUSSION: O
To O
our O
knowledge, O
this O
is O
the O
first O
reported O
case O
of O
venlafaxine O
overdose O
that O
resulted O
in O
a O
generalized O
seizure. O
Based O
on O
nonoverdose O
pharmacokinetics O
and O
pharmacodynamics O
of O
venlafaxine O
and O
the O
potential O
risks O
of O
available O
interventions, O
no O
emergent O
therapy O
was O
instituted. O
CONCLUSIONS: O
The O
venlafaxine O
overdose O
in O
our O
patient O
resulted O
in O
a O
single O
episode O
of O
generalized O
seizure O
but O
elicited O
no O
further O
sequelae. O

Antibacterial O
medication O
use O
during O
pregnancy O
and O
risk O
of O
birth B
defects: I
National O
Birth B
Defects I
Prevention O
Study. O

We O
observed O
sinoatrial B
block I
due O
to O
chronic O
amiodarone O
administration O
in O
a O
5-year-old O
boy O
with O
primary B
cardiomyopathy, I
Wolff-Parkinson-White B
syndrome I
and O
supraventricular B
tachycardia. I
Reduction O
in O
the O
dosage O
of O
amiodarone O
resulted O
in O
the O
disappearance O
of O
the O
sinoatrial O
block O
and O
the O
persistence O
of O
asymptomatic O
sinus B
bradycardia. I

A O
34-year-old O
lady O
developed O
a O
constellation O
of O
dermatitis, B
fever, B
lymphadenopathy B
and O
hepatitis, B
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine O
for O
sero-negative O
rheumatoid B
arthritis. I
Cervical O
and O
inguinal O
lymph O
node O
biopsies O
showed O
the O
features O
of O
severe O
necrotising O
lymphadenitis, B
associated O
with O
erythrophagocytosis O
and O
prominent O
eosinophilic O
infiltrates, O
without O
viral O
inclusion O
bodies, O
suggestive O
of O
an O
adverse B
drug I
reaction.A I
week O
later, O
fulminant O
drug-induced B
hepatitis, I
associated O
with O
the O
presence O
of O
anti-nuclear O
autoantibodies O
(but O
not O
with O
other O
markers O
of O
autoimmunity), B
and O
accompanied O
by O
multi-organ B
failure I
and O
sepsis, B
supervened. O
She O
subsequently O
died O
some O
5 O
weeks O
after O
the O
commencement O
of O
her O
drug O
therapy.Post-mortem O
examination O
showed O
evidence O
of O
massive B
hepatocellular I
necrosis, I
acute O
hypersensitivity O
myocarditis, B
focal O
acute O
tubulo-interstitial O
nephritis B
and O
extensive O
bone B
marrow I
necrosis, I
with O
no O
evidence O
of O
malignancy. B
It O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
"3-week O
sulphasalazine O
syndrome", O
a O
rare, O
but O
often O
fatal, O
immunoallergic O
reaction O
to O
sulphasalazine. O

Neuroinflammation B
and O
behavioral B
abnormalities I
after O
neonatal O
terbutaline O
treatment O
in O
rats: O
implications O
for O
autism. B

Regional O
localization O
of O
the O
antagonism O
of O
amphetamine-induced O
hyperactivity B
by O
intracerebral O
calcitonin O
injections. O

A O
3-year-old O
girl O
had O
behavioral B
deterioration, I
with O
hyperkinesis, B
irritability, B
and O
sleeping B
difficulties I
after O
the O
therapeutic O
administration O
of O
isoniazid. O
The O
administration O
of O
pharmacologic O
doses O
of O
pyridoxine O
hydrochloride O
led O
to O
a O
disappearance O
of O
symptoms. O
After O
discontinuing O
isoniazid O
therapy O
a O
similar O
pattern O
of O
behavior O
was O
noted O
that O
was O
controlled O
by O
pyridoxine. O
A O
placebo O
had O
no O
effect, O
but O
niacinamide O
was O
as O
effective O
as O
pyridoxine. O
Periodic O
withdrawal O
of O
pyridoxine O
was O
associated O
with O
return O
of O
the O
hyperkinesis. O
The O
level O
of O
pyridoxal O
in O
the O
blood O
was O
normal O
during O
the O
periods O
of O
relapse. O
Metabolic O
studies O
suggested O
a O
block O
in O
the O
kynurenine O
pathway O
of O
tryptophan O
metabolism. O
The O
patient O
has O
been O
followed O
for O
six O
years O
and O
has O
required O
pharmacologic O
doses O
of O
pyridoxine O
to O
control O
her O
behavior. O

PURPOSE: O
The O
influence O
of O
an O
irreversible O
inhibitor O
of O
constitutive O
NO O
synthase O
(L-NOArg; O
1.0 O
mg/kg O
ip), O
a O
relatively O
selective O
inhibitor O
of O
inducible O
NO O
synthase O
(L-NIL; O
1.0 O
mg/kg O
ip) O
and O
a O
relatively O
specific O
inhibitor O
of O
neuronal O
NO O
synthase O
(7-NI; O
0.1 O
mg/kg O
ip), O
on O
antihyperalgesic O
action O
of O
selective O
antagonists O
of O
B2 O
and O
B1 O
receptors: O
D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] O
bradykinin O
(HOE O
140; O
70 O
nmol/kg O
ip) O
or O
des O
Arg10 O
HOE O
140 O
(70 O
nmol/kg O
ip) O
respectively, O
in O
model O
of O
diabetic B
(streptozotocin-induced) I
and I
toxic B
(vincristine-induced) I
neuropathy I
was O
investigated. O
METHODS: O
The O
changes O
in O
pain B
thresholds O
were O
determined O
using O
mechanical O
stimuli--the O
modification O
of O
the O
classic O
paw O
withdrawal O
test O
described O
by O
Randall-Selitto. O
RESULTS: O
The O
results O
of O
this O
paper O
confirm O
that O
inhibition O
of O
bradykinin O
receptors O
and O
inducible O
NO O
synthase O
but O
not O
neuronal O
NO O
synthase O
activity O
reduces O
diabetic B
hyperalgesia. B
Pretreatment O
with O
L-NOArg O
and O
L-NIL O
but O
not O
7-NI, O
significantly O
increases O
antihyperalgesic O
activity O
both O
HOE O
140 O
and O
des O
Arg10 O
HOE O
140. O
It O
was O
also O
shown O
that O
both O
products O
of O
inducible O
NO O
synthase O
and O
neuronal O
NO O
synthase O
activation O
as O
well O
as O
bradykinin O
are O
involved O
in O
hyperalgesia O
produced O
by O
vincristine. O
Moreover, O
L-NOArg O
and O
7-NI O
but O
not O
L-NIL O
intensify O
antihyperalgesic O
activity O
of O
HOE O
140 O
or O
des-Arg10HOE O
140 O
in O
toxic B
neuropathy. I
CONCLUSIONS: O
Results O
of O
these O
studies O
suggest O
that O
B1 O
and O
B2 O
receptors O
are O
engaged O
in O
transmission O
of O
nociceptive O
stimuli O
in O
both O
diabetic B
and I
toxic I
neuropathy. I
In O
streptozotocin-induced O
hyperalgesia, O
inducible O
NO O
synthase O
participates O
in O
pronociceptive O
activity O
of O
bradykinin, O
whereas O
in O
vincristine-induced O
hyperalgesia O
bradykinin O
seemed O
to O
activate O
neuronal O
NO O
synthase O
pathway. O
Therefore, O
concomitant O
administration O
of O
small O
doses O
of O
bradykinin O
receptor O
antagonists O
and O
NO O
synthase O
inhibitors O
can O
be O
effective O
in O
alleviation O
of O
neuropathic B
pain, I
even O
in O
hospital O
care. O

Role O
of O
xanthine O
oxidase O
in O
dexamethasone-induced O
hypertension B
in O
rats. O

A O
63-year-old O
male O
experienced O
sudden O
diplopia B
after O
9 O
weeks O
of O
administration O
of O
pegylated O
interferon O
(IFN) O
alpha-2b O
and O
ribavirin O
for O
chronic B
hepatitis I
C I
(CHC). O
Ophthalmologic B
examinations O
showed O
ptosis B
on I
the I
right I
upper I
lid I
and O
restricted B
right I
eye I
movement I
without O
any O
other O
neurological O
signs. O
A O
brain O
imaging O
study O
and O
repetitive O
nerve O
stimulation O
test O
indicated O
no O
abnormality. O
The O
acetylcholine O
receptor O
antibody O
titer O
and O
response O
to O
acetylcholinesterase O
inhibitors O
were O
negative, O
and O
the O
results O
of O
thyroid O
function O
tests O
were O
normal. O
The O
patient's O
ophthalmological O
symptoms O
improved O
rapidly O
3 O
weeks O
after O
discontinuation O
of O
pegylated O
IFN O
alpha-2b O
and O
ribavirin. O
The O
ocular B
myasthenia I
associated O
with O
combination O
therapy O
of O
pegylated O
IFN O
alpha-2b O
and O
ribavirin O
for O
CHC O
is O
very O
rarely O
reported; O
therefore, O
we O
present O
this O
case O
with O
a O
review O
of O
the O
various O
eye O
complications O
of O
IFN O
therapy. O

Sirolimus O
is O
a O
novel O
immunosuppressant O
with O
potent O
antiproliferative O
actions O
through O
its O
ability O
to O
inhibit O
the O
raptor-containing O
mammalian O
target O
of O
rapamycin O
protein O
kinase. O
Sirolimus O
represents O
a O
major O
therapeutic O
advance O
in O
the O
prevention O
of O
acute O
renal O
allograft O
rejection O
and O
chronic O
allograft O
nephropathy. B
Its O
role O
in O
the O
therapy O
of O
glomerulonephritis, B
autoimmunity, B
cystic B
renal I
diseases I
and O
renal B
cancer I
is O
under O
investigation. O
Because O
sirolimus O
does O
not O
share O
the O
vasomotor O
renal O
adverse O
effects O
exhibited O
by O
calcineurin O
inhibitors, O
it O
has O
been O
designated O
a O
'non-nephrotoxic O
drug'. B
However, O
clinical O
reports O
suggest O
that, O
under O
some O
circumstances, O
sirolimus O
is O
associated O
with O
proteinuria B
and O
acute B
renal I
dysfunction. I
A O
common O
risk O
factor O
appears O
to O
be O
presence O
of O
pre-existing O
chronic B
renal I
damage. I
The O
mechanisms O
of O
sirolimus-associated O
proteinuria O
are O
multifactorial O
and O
may O
be O
due O
to O
an O
increase O
in O
glomerular O
capillary O
pressure O
following O
calcineurin O
inhibitor O
withdrawal. O
It O
has O
also O
been O
suggested O
that O
sirolimus O
directly O
causes O
increased O
glomerular O
permeability/injury, O
but O
evidence O
for O
this O
mechanism O
is O
currently O
inconclusive. O
The O
acute O
renal O
dysfunction O
associated O
with O
sirolimus O
(such O
as O
in O
delayed O
graft O
function) O
may O
be O
due O
to O
suppression O
of O
compensatory O
renal O
cell O
proliferation O
and O
survival/repair O
processes. O
Although O
these O
adverse O
effects O
occur O
in O
some O
patients, O
their O
occurrence O
could O
be O
minimised O
by O
knowledge O
of O
the O
molecular O
effects O
of O
sirolimus O
on O
the O
kidney, O
the O
use O
of O
sirolimus O
in O
appropriate O
patient O
populations, O
close O
monitoring O
of O
proteinuria O
and O
renal O
function, O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
or O
angiotensin O
II O
receptor O
blockers O
if O
proteinuria O
occurs O
and O
withdrawal O
if O
needed. O
Further O
long-term O
analysis O
of O
renal O
allograft O
studies O
using O
sirolimus O
as O
de O
novo O
immunosuppression O
along O
with O
clinical O
and O
laboratory O
studies O
will O
refine O
these O
issues O
in O
the O
future. O

Pseudo-allergic O
reactions B
to I
corticosteroids: O
diagnosis O
and O
alternatives. O

AIM: O
This O
study O
was O
carried O
out O
to O
determine O
the O
effect O
of O
injection O
duration O
on O
bruising B
and O
pain B
following O
the O
administration O
of O
the O
subcutaneous O
injection O
of O
heparin. O
BACKGROUND: O
Although O
different O
methods O
to O
prevent O
bruising O
and O
pain O
following O
the O
subcutaneous O
injection O
of O
heparin O
have O
been O
widely O
studied O
and O
described, O
the O
effect O
of O
injection O
duration O
on O
the O
occurrence O
of O
bruising O
and O
pain O
is O
little O
documented. O
DESIGN: O
This O
study O
was O
designed O
as O
within-subject, O
quasi-experimental O
research. O
METHOD: O
The O
sample O
for O
the O
study O
consisted O
of O
50 O
patients O
to O
whom O
subcutaneous O
heparin O
was O
administered. O
Heparin O
was O
injected O
over O
10 O
seconds O
on O
the O
right O
abdominal O
site O
and O
30 O
seconds O
on O
the O
left O
abdominal O
site. O
Injections O
areas O
were O
assessed O
for O
the O
presence O
of O
bruising O
at O
48 O
and O
72 O
hours O
after O
each O
injection. O
Dimensions O
of O
the O
bruising O
on O
the O
heparin O
applied O
areas O
were O
measured O
using O
transparent O
millimetric O
measuring O
paper. O
The O
visual O
analog O
scale O
(VAS) O
was O
used O
to O
measure O
pain O
intensity O
and O
a O
stop-watch O
was O
used O
to O
time O
the O
pain O
period. O
Data O
were O
analysed O
using O
chi-square O
test, O
Mann-Whitney O
U, O
Wilcoxon O
signed O
ranks O
tests O
and O
correlation. O
RESULTS: O
The O
percentage O
of O
bruising O
occurrence O
was O
64% O
with O
the O
injection O
of O
10 O
seconds O
duration O
and O
42% O
in O
the O
30-second O
injection. O
It O
was O
determined O
that O
the O
size O
of O
the O
bruising O
was O
smaller O
in O
the O
30-second O
injection. O
Pain B
intensity O
and O
pain O
period O
were O
statistically O
significantly O
lower O
for O
the O
30-second O
injection O
than O
for O
the O
10-second O
injection. O
CONCLUSIONS: O
It O
was O
determined O
that O
injection O
duration O
had O
an O
effect O
on O
bruising O
and O
pain O
following O
the O
subcutaneous O
administration O
of O
heparin. O
This O
study O
should O
be O
repeated O
on O
a O
larger O
sample. O
RELEVANCE O
TO O
CLINICAL O
PRACTICE: O
When O
administering O
subcutaneous O
heparin O
injections, O
it O
is O
important O
to O
extend O
the O
duration O
of O
the O
injection. O

Tetrandrine O
(TET) O
and O
fangchinoline O
(FAN) O
are O
two O
naturally O
occurring O
analogues O
with O
a O
bisbenzylisoquinoline O
structure. O
The O
present O
study O
was O
undertaken O
to O
investigate O
the O
effects O
of O
TET O
and O
FAN O
on O
the O
experimental O
thrombosis B
induced O
by O
collagen O
plus O
epinephrine O
(EP) O
in O
mice, O
and O
platelet B
aggregation I
and O
blood B
coagulation I
in O
vitro. O
In O
the O
in O
vivo O
study, O
the O
administration O
(50 O
mg/kg, O
i.p.) O
of O
TET O
and O
FAN O
in O
mice O
showed O
the O
inhibition O
of O
thrombosis O
by O
55% O
and O
35%, O
respectively, O
while O
acetylsalicylic O
acid O
(ASA, O
50 O
mg/kg, O
i.p.), O
a O
positive O
control, O
showed O
only O
30% O
inhibition. O
In O
the O
vitro O
human O
platelet B
aggregations I
induced O
by O
the O
agonists O
used O
in O
tests, O
TET O
and O
FAN O
showed O
the O
inhibitions O
dose O
dependently. O
In O
addition, O
neither O
TET O
nor O
FAN O
showed O
any O
anticoagulation O
activities O
in O
the O
measurement O
of O
the O
activated O
partial O
thromboplastin O
time O
(APTT), O
prothrombin O
time O
(PT) O
and O
thrombin O
time O
(TT) O
using O
human-citrated O
plasma. O
These O
results O
suggest O
that O
antithrombosis O
of O
TET O
and O
FAN O
in O
mice O
may O
be O
mainly O
related O
to O
the O
antiplatelet O
aggregation O
activities. O

Development O
of O
proteinuria B
after O
switch O
to O
sirolimus-based O
immunosuppression O
in O
long-term O
cardiac O
transplant O
patients. O

Formation O
of O
coronary B
aneurysm B
is O
a O
rare O
complication O
of O
stenting O
with O
bare O
metal O
stents, O
but O
based O
on O
experimental O
studies O
drug-eluting O
stents O
may O
induce O
toxic O
effects O
on O
the O
vessel O
wall O
with O
incomplete O
stent O
apposition, O
aneurysm O
formation O
and O
with O
the O
potential O
of O
stent O
thrombosis B
or O
vessel B
rupture. I
We O
present O
a O
43-year-old O
man O
who O
developed O
a O
coronary O
aneurysm O
in O
the O
right O
coronary O
artery O
6 O
months O
after O
receiving O
a O
paclitaxel-eluting O
stent. O
The O
patient O
was O
asymptomatic O
and O
the O
aneurysm O
was O
detected O
in O
a O
routine O
control. O
Angiography O
and O
intracoronary O
ultrasound O
demonstrated O
lack O
of O
contact O
between O
stent O
and O
vessel O
wall O
in O
a O
15-mm O
long O
segment O
with O
maximal O
aneurysm O
diameter O
of O
6.0 O
mm. O
The O
patient O
was O
successfully O
treated O
with O
a O
graft O
stent. O

Sex O
differences O
in O
NMDA O
antagonist O
enhancement O
of O
morphine O
antihyperalgesia O
in O
a O
capsaicin O
model O
of O
persistent O
pain: B
comparisons O
to O
two O
models O
of O
acute B
pain. I

Tremor B
side O
effects O
of O
salbutamol, O
quantified O
by O
a O
laser O
pointer O
technique. O

Reactive O
oxygen O
species O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
acute O
puromycin O
aminonucleoside O
(PAN)-induced O
nephropathy, B
with O
antioxidants O
significantly O
reducing O
the O
proteinuria. B
The O
temporal O
relationship O
between O
lipid O
peroxidation O
in O
the O
kidney O
and O
proteinuria O
was O
examined O
in O
this O
study. O
Rats O
were O
treated O
with O
a O
single O
IV O
injection O
of O
puromycin O
aminonucleoside, O
(PAN, O
7.5 O
mg/kg) O
and O
24 O
hour O
urine O
samples O
were O
obtained O
prior O
to O
sacrifice O
on O
days O
3,5,7,10,17,27,41 O
(N O
= O
5-10 O
per O
group). O
The O
kidneys O
were O
removed, O
flushed O
with O
ice O
cold O
TRIS O
buffer. O
Kidney O
cortices O
from O
each O
animal O
were O
used O
to O
prepare O
homogenates. O
Tissue O
lipid O
peroxidation O
was O
measured O
in O
whole O
homogenates O
as O
well O
as O
in O
lipid O
extracts O
from O
homogenates O
as O
thiobarbituric O
acid O
reactive O
substances. O
Proteinuria B
was O
evident O
at O
day O
5, O
peaked O
at O
day O
7 O
and O
persisted O
to O
day O
27. O
Lipid O
peroxidation O
in O
homogenates O
was O
maximal O
at O
day O
3 O
and O
declined O
rapidly O
to O
control O
levels O
by O
day O
17. O
This O
study O
supports O
the O
role O
of O
lipid O
peroxidation O
in O
mediating O
the O
proteinuric B
injury I
in O
PAN O
nephropathy. O

Angioedema B
due O
to O
ACE O
inhibitors: O
common O
and O
inadequately O
diagnosed. O

OBJECTIVE: O
This O
study O
was O
conducted O
to O
assess O
the O
occurrence O
of O
hepatic B
adverse I
effects I
encountered O
with O
antithyroid O
drugs. O
METHODS: O
Retrospective O
review O
of O
medical O
records O
of O
236 O
patients O
with O
hyperthyroidism B
admitted O
in O
our O
department O
(in- O
or O
out-patients) O
from O
1986 O
to O
1992. O
RESULTS: O
Four O
patients O
(1.7%) O
were O
identified O
with O
toxic B
hepatitis B
which O
could O
reasonably O
be O
attributed O
to O
the O
use O
of O
antithyroid O
agent. O
Two O
patients O
had O
a O
cholestatic B
hepatitis I
induced O
by O
carbimazole O
(N O
omercazole). O
Two O
others O
had O
a O
mixed O
(cholestatic O
and O
cytolytic) O
hepatitis O
following O
carbimazole. O
One O
of O
the O
latter O
two O
patients O
further O
experienced O
a O
cytolytic O
hepatitis O
which O
appeared O
after O
Benzylthiouracil O
(Basd O
ne) O
had O
replaced O
carbimazole. O
Biological O
features O
of O
hepatitis O
disappeared O
in O
all O
cases O
after O
cessation O
of O
the O
incriminated O
drug, O
while O
biliary, O
viral O
and O
immunological O
searches O
were O
negative. O
Only O
2 O
patients O
of O
our O
retrospective O
study O
experienced O
a O
mild O
or O
severe O
neutropenia. B
CONCLUSION: O
Toxic B
hepatitis I
is O
a O
potential O
adverse O
effect O
of O
antithyroid O
drugs O
which O
warrants, O
as O
for O
haematological O
disturbances, O
a O
pre-therapeutic O
determination O
and O
a O
careful O
follow-up O
of O
relevant O
biological O
markers. O
Moreover, O
hepatotoxicity B
may O
not O
be O
restricted O
to O
one O
class O
of O
antithyroid O
agents. O

The O
marked O
vasodilator O
and O
negative O
inotropic O
effects O
of O
propofol O
are O
disadvantages O
in O
frail O
elderly O
patients. O
We O
investigated O
the O
safety O
and O
efficacy O
of O
adding O
different O
doses O
of O
ephedrine O
to O
propofol O
in O
order O
to O
obtund O
the O
hypotensive B
response. O
The O
haemodynamic O
effects O
of O
adding O
15, O
20 O
or O
25 O
mg O
of O
ephedrine O
to O
200 O
mg O
of O
propofol O
were O
compared O
to O
control O
in O
40 O
ASA O
3/4 O
patients O
over O
60 O
years O
presenting O
for O
genito-urinary O
surgery. O
The O
addition O
of O
ephedrine O
to O
propofol O
appears O
to O
be O
an O
effective O
method O
of O
obtunding O
the O
hypotensive O
response O
to O
propofol O
at O
all O
doses O
used O
in O
this O
study. O
However, O
marked O
tachycardia B
associated O
with O
the O
use O
of O
ephedrine O
in O
combination O
with O
propofol O
occurred O
in O
the O
majority O
of O
patients, O
occasionally O
reaching O
high O
levels O
in O
individual O
patients. O
Due O
to O
the O
risk O
of O
this O
tachycardia O
inducing O
myocardial B
ischemia, I
we O
would O
not O
recommend O
the O
use O
in O
elderly O
patients O
of O
any O
of O
the O
ephedrine/propofol/mixtures O
studied. O

Tamoxifen O
(TAM), O
the O
antiestrogenic O
drug O
most O
widely O
prescribed O
in O
the O
chemotherapy O
of O
breast B
cancer, I
induces O
changes O
in O
normal O
discoid O
shape O
of O
erythrocytes O
and O
hemolytic B
anemia. I
This O
work O
evaluates O
the O
effects O
of O
TAM O
on O
isolated O
human O
erythrocytes, O
attempting O
to O
identify O
the O
underlying O
mechanisms O
on O
TAM-induced O
hemolytic O
anemia O
and O
the O
involvement O
of O
biomembranes O
in O
its O
cytostatic O
action O
mechanisms. O
TAM O
induces O
hemolysis B
of O
erythrocytes O
as O
a O
function O
of O
concentration. O
The O
extension O
of O
hemolysis O
is O
variable O
with O
erythrocyte O
samples, O
but O
12.5 O
microM O
TAM O
induces O
total O
hemolysis O
of O
all O
tested O
suspensions. O
Despite O
inducing O
extensive O
erythrocyte O
lysis, O
TAM O
does O
not O
shift O
the O
osmotic O
fragility O
curves O
of O
erythrocytes. O
The O
hemolytic O
effect O
of O
TAM O
is O
prevented O
by O
low O
concentrations O
of O
alpha-tocopherol O
(alpha-T) O
and O
alpha-tocopherol O
acetate O
(alpha-TAc) O
(inactivated O
functional O
hydroxyl) O
indicating O
that O
TAM-induced O
hemolysis O
is O
not O
related O
to O
oxidative O
membrane O
damage. O
This O
was O
further O
evidenced O
by O
absence O
of O
oxygen O
consumption O
and O
hemoglobin O
oxidation O
both O
determined O
in O
parallel O
with O
TAM-induced O
hemolysis. O
Furthermore, O
it O
was O
observed O
that O
TAM O
inhibits O
the O
peroxidation O
of O
human O
erythrocytes O
induced O
by O
AAPH, O
thus O
ruling O
out O
TAM-induced O
cell O
oxidative O
stress. O
Hemolysis B
caused O
by O
TAM O
was O
not O
preceded O
by O
the O
leakage O
of O
K(+) O
from O
the O
cells, O
also O
excluding O
a O
colloid-osmotic O
type O
mechanism O
of O
hemolysis, O
according O
to O
the O
effects O
on O
osmotic O
fragility O
curves. O
However, O
TAM O
induces O
release O
of O
peripheral O
proteins O
of O
membrane-cytoskeleton O
and O
cytosol O
proteins O
essentially O
bound O
to O
band O
3. O
Either O
alpha-T O
or O
alpha-TAc O
increases O
membrane O
packing O
and O
prevents O
TAM O
partition O
into O
model O
membranes. O
These O
effects O
suggest O
that O
the O
protection O
from O
hemolysis O
by O
tocopherols O
is O
related O
to O
a O
decreased O
TAM O
incorporation O
in O
condensed O
membranes O
and O
the O
structural O
damage O
of O
the O
erythrocyte O
membrane O
is O
consequently O
avoided. O
Therefore, O
TAM-induced O
hemolysis O
results O
from O
a O
structural O
perturbation O
of O
red O
cell O
membrane, O
leading O
to O
changes O
in O
the O
framework O
of O
the O
erythrocyte O
membrane O
and O
its O
cytoskeleton O
caused O
by O
its O
high O
partition O
in O
the O
membrane. O
These O
defects O
explain O
the O
abnormal O
erythrocyte O
shape O
and O
decreased O
mechanical O
stability O
promoted O
by O
TAM, O
resulting O
in O
hemolytic O
anemia. O
Additionally, O
since O
membrane O
leakage O
is O
a O
final O
stage O
of O
cytotoxicity, O
the O
disruption O
of O
the O
structural O
characteristics O
of O
biomembranes O
by O
TAM O
may O
contribute O
to O
the O
multiple O
mechanisms O
of O
its O
anticancer O
action. O

Paclitaxel, O
cisplatin, O
and O
gemcitabine O
combination O
chemotherapy O
within O
a O
multidisciplinary O
therapeutic O
approach O
in O
metastatic O
nonsmall B
cell I
lung I
carcinoma. I

BACKGROUND: O
There O
recently O
has O
been O
a O
resurgence O
in O
the O
utilization O
of O
ketamine, O
a O
unique O
anesthetic, O
for O
emergency-department O
procedures O
requiring O
sedation. O
The O
purpose O
of O
the O
present O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
ketamine O
for O
sedation O
in O
the O
treatment O
of O
children's O
fractures B
in O
the O
emergency O
department. O
METHODS: O
One O
hundred O
and O
fourteen O
children O
(average O
age, O
5.3 O
years; O
range, O
twelve O
months O
to O
ten O
years O
and O
ten O
months) O
who O
underwent O
closed O
reduction O
of O
an O
isolated O
fracture O
or O
dislocation B
in O
the O
emergency O
department O
at O
a O
level-I O
trauma B
center O
were O
prospectively O
evaluated. O
Ketamine O
hydrochloride O
was O
administered O
intravenously O
(at O
a O
dose O
of O
two O
milligrams O
per O
kilogram O
of O
body O
weight) O
in O
ninety-nine O
of O
the O
patients O
and O
intramuscularly O
(at O
a O
dose O
of O
four O
milligrams O
per O
kilogram O
of O
body O
weight) O
in O
the O
other O
fifteen. O
A O
board-certified O
emergency O
physician O
skilled O
in O
airway O
management O
supervised O
administration O
of O
the O
anesthetic, O
and O
the O
patients O
were O
monitored O
by O
a O
registered O
nurse. O
Any O
pain B
during O
the O
reduction O
was O
rated O
by O
the O
orthopaedic O
surgeon O
treating O
the O
patient O
according O
to O
the O
Children's O
Hospital O
of O
Eastern O
Ontario O
Pain B
Scale O
(CHEOPS). O
RESULTS: O
The O
average O
time O
from O
intravenous O
administration O
of O
ketamine O
to O
manipulation O
of O
the O
fracture O
or O
dislocation O
was O
one O
minute O
and O
thirty-six O
seconds O
(range, O
twenty O
seconds O
to O
five O
minutes), O
and O
the O
average O
time O
from O
intramuscular O
administration O
to O
manipulation O
was O
four O
minutes O
and O
forty-two O
seconds O
(range, O
sixty O
seconds O
to O
fifteen O
minutes). O
The O
average O
score O
according O
to O
the O
Children's O
Hospital O
of O
Eastern O
Ontario O
Pain O
Scale O
was O
6.4 O
points O
(range, O
5 O
to O
10 O
points), O
reflecting O
minimal O
or O
no O
pain O
during O
fracture O
reduction. O
Adequate O
fracture O
reduction O
was O
obtained O
in O
111 O
of O
the O
children. O
Ninety-nine O
percent O
(sixty-eight) O
of O
the O
sixty-nine O
parents O
present O
during O
the O
reduction O
were O
pleased O
with O
the O
sedation O
and O
would O
allow O
it O
to O
be O
used O
again O
in O
a O
similar O
situation. O
Patency O
of O
the O
airway O
and O
independent O
respiration O
were O
maintained O
in O
all O
of O
the O
patients. O
Blood O
pressure O
and O
heart O
rate O
remained O
stable. O
Minor O
side O
effects O
included O
nausea B
(thirteen O
patients), O
emesis B
(eight O
of O
the O
thirteen O
patients O
with O
nausea), O
clumsiness B
(evident O
as O
ataxic B
movements I
in O
ten O
patients), O
and O
dysphoric B
reaction I
(one O
patient). O
No O
long-term O
sequelae O
were O
noted, O
and O
no O
patients O
had O
hallucinations B
or O
nightmares. O
CONCLUSIONS: O
Ketamine O
reliably, O
safely, O
and O
quickly O
provided O
adequate O
sedation O
to O
effectively O
facilitate O
the O
reduction O
of O
children's O
fractures O
in O
the O
emergency O
department O
at O
our O
institution. O
Ketamine O
should O
only O
be O
used O
in O
an O
environment O
such O
as O
the O
emergency O
department, O
where O
proper O
one-on-one O
monitoring O
is O
used O
and O
board-certified O
physicians O
skilled O
in O
airway O
management O
are O
directly O
involved O
in O
the O
care O
of O
the O
patient. O

Massive O
urinary O
protein O
excretion O
has O
been O
observed O
after O
conversion O
from O
calcineurin O
inhibitors O
to O
mammalian O
target O
of O
rapamycin O
(mToR) O
inhibitors, O
especially O
sirolimus, O
in O
renal O
transplant O
recipients O
with O
chronic B
allograft I
nephropathy. I
Because O
proteinuria B
is O
a O
major O
predictive O
factor O
of O
poor O
transplantation O
outcome, O
many O
studies O
focused O
on O
this O
adverse O
event O
during O
the O
past O
years. O
Whether O
proteinuria O
was O
due O
to O
sirolimus O
or O
only O
a O
consequence O
of O
calcineurin O
inhibitors O
withdrawal O
remained O
unsolved O
until O
high O
range O
proteinuria O
has O
been O
observed O
during O
sirolimus O
therapy O
in O
islet O
transplantation O
and O
in O
patients O
who O
received O
sirolimus O
de O
novo. O
Podocyte O
injury O
and O
focal O
segmental O
glomerulosclerosis B
have O
been O
related O
to O
mToR O
inhibition O
in O
some O
patients, O
but O
the O
pathways O
underlying O
these O
lesions O
remain O
hypothetic. O
We O
discuss O
herein O
the O
possible O
mechanisms O
and O
the O
significance O
of O
mToR O
blockade-induced O
proteinuria. O

Provocation O
of O
postural O
hypotension B
by O
nitroglycerin O
in O
diabetic B
autonomic I
neuropathy? I

BACKGROUND: O
Vasopressor O
agents O
are O
used O
to O
correct O
anesthesia-induced O
hypotension. B
We O
describe O
the O
effect O
of O
phenylephrine O
and O
ephedrine O
on O
frontal O
lobe O
oxygenation O
(S(c)O(2)) O
following O
anesthesia-induced O
hypotension. O
METHODS: O
Following O
induction O
of O
anesthesia O
by O
fentanyl O
(0.15 O
mg O
kg(-1)) O
and O
propofol O
(2.0 O
mg O
kg(-1)), O
13 O
patients O
received O
phenylephrine O
(0.1 O
mg O
iv) O
and O
12 O
patients O
received O
ephedrine O
(10 O
mg O
iv) O
to O
restore O
mean O
arterial O
pressure O
(MAP). O
Heart O
rate O
(HR), O
MAP, O
stroke B
volume O
(SV), O
cardiac O
output O
(CO), O
and O
frontal O
lobe O
oxygenation O
(S(c)O(2)) O
were O
registered. O
RESULTS: O
Induction O
of O
anesthesia O
was O
followed O
by O
a B
decrease I
in I
MAP, I
HR, I
SV, I
and I
CO I
concomitant O
with O
an O
elevation O
in O
S(c)O(2). O
After O
administration O
of O
phenylephrine, O
MAP O
increased O
(51 O
+/- O
12 O
to O
81 O
+/- O
13 O
mmHg; O
P O
< O
0.001; O
mean O
+/- O
SD). O
However, O
a O
14% O
(from O
70 O
+/- O
8% O
to O
60 O
+/- O
7%) O
reduction O
in O
S(c)O(2) O
(P O
< O
0.05) O
followed O
with O
no O
change O
in O
CO O
(3.7 O
+/- O
1.1 O
to O
3.4 O
+/- O
0.9 O
l O
min(-1)). O
The O
administration O
of O
ephedrine O
led O
to O
a O
similar O
increase O
in O
MAP O
(53 O
+/- O
9 O
to O
79 O
+/- O
8 O
mmHg; O
P O
< O
0.001), O
restored O
CO O
(3.2 O
+/- O
1.2 O
to O
5.0 O
+/- O
1.3 O
l O
min(-1)), O
and O
preserved O
S(c)O(2). O
CONCLUSIONS: O
The O
utilization O
of O
phenylephrine O
to O
correct O
hypotension O
induced O
by O
anesthesia O
has O
a O
negative O
impact O
on O
S(c)O(2) O
while O
ephedrine O
maintains O
frontal O
lobe O
oxygenation O
potentially O
related O
to O
an O
increase O
in O
CO. O

Ketoconazole O
is O
not O
known O
to O
be O
proarrhythmic O
without O
concomitant O
use O
of O
QT O
interval-prolonging O
drugs. O
We O
report O
a O
woman O
with O
coronary B
artery I
disease I
who O
developed O
a O
markedly O
prolonged B
QT I
interval I
and O
torsades B
de I
pointes I
(TdP) O
after B
taking O
ketoconazole O
for O
treatment O
of O
fungal B
infection. I
Her O
QT O
interval O
returned O
to O
normal O
upon O
withdrawal O
of O
ketoconazole. O
Genetic O
study O
did O
not O
find O
any O
mutation O
in O
her O
genes O
that O
encode O
cardiac O
IKr O
channel O
proteins. O
We O
postulate O
that O
by O
virtue O
of O
its O
direct O
blocking O
action O
on O
IKr, O
ketoconazole O
alone O
may O
prolong O
QT O
interval O
and O
induce O
TdP. O
This O
calls O
for O
attention O
when O
ketoconazole O
is O
administered O
to O
patients O
with O
risk O
factors O
for O
acquired O
long B
QT I
syndrome. I

A O
randomized, O
placebo-controlled O
dose-comparison O
trial O
of O
haloperidol O
for O
psychosis B
and O
disruptive B
behaviors I
in O
Alzheimer's B
disease. I

Long-term O
follow-up O
of O
ifosfamide O
renal B
toxicity I
in O
children O
treated O
for O
malignant B
mesenchymal I
tumors: I
an O
International O
Society O
of O
Pediatric O
Oncology O
report. O

Transient B
neurologic I
symptoms I
after O
spinal O
anesthesia: O
a O
lower O
incidence O
with O
prilocaine O
and O
bupivacaine O
than O
with O
lidocaine. O

This O
work O
evaluates O
the O
antinociceptive O
and O
constipating B
effects O
of O
the O
combination O
of O
3.2 O
mg/kg O
s.c. O
morphine O
with O
177.8 O
mg/kg O
s.c. O
metamizol O
in O
acutely O
and O
chronically O
treated O
(once O
a O
day O
for O
12 O
days) O
rats. O
On O
the O
13th O
day, O
antinociceptive O
effects O
were O
assessed O
using O
a O
model O
of O
inflammatory O
nociception, O
pain-induced B
functional O
impairment O
model, O
and O
the O
charcoal O
meal O
test O
was O
used O
to O
evaluate O
the O
intestinal O
transit. O
Simultaneous O
administration O
of O
morphine O
with O
metamizol O
resulted O
in O
a O
markedly O
antinociceptive O
potentiation O
and O
an O
increasing O
of O
the O
duration O
of O
action O
after O
a O
single O
(298+/-7 O
vs. O
139+/-36 O
units O
area O
(ua); O
P<0.001) O
and O
repeated O
administration O
(280+/-17 O
vs. O
131+/-22 O
ua; O
P<0.001). O
Antinociceptive O
effect O
of O
morphine O
was O
reduced O
in O
chronically O
treated O
rats O
(39+/-10 O
vs. O
18+/-5 O
au) O
while O
the O
combination-induced O
antinociception O
was O
remained O
similar O
as O
an O
acute O
treatment O
(298+/-7 O
vs. O
280+/-17 O
au). O
Acute O
antinociceptive O
effects O
of O
the O
combination O
were O
partially O
prevented O
by O
3.2 O
mg/kg O
naloxone O
s.c. O
(P<0.05), O
suggesting O
the O
partial O
involvement O
of O
the O
opioidergic O
system O
in O
the O
synergism O
observed. O
In O
independent O
groups, O
morphine O
inhibited O
the O
intestinal O
transit O
in O
48+/-4% O
and O
38+/-4% O
after O
acute O
and O
chronic O
treatment, O
respectively, O
suggesting O
that O
tolerance O
did O
not O
develop O
to O
the O
constipating O
effects. O
The O
combination O
inhibited O
intestinal O
transit O
similar O
to O
that O
produced O
by O
morphine O
regardless O
of O
the O
time O
of O
treatment, O
suggesting O
that O
metamizol O
did O
not O
potentiate O
morphine-induced O
constipation. B
These O
findings O
show O
a O
significant O
interaction O
between O
morphine O
and O
metamizol O
in O
chronically O
treated O
rats, O
suggesting O
that O
this O
combination O
could O
be O
useful O
for O
the O
treatment O
of O
chronic B
pain. I

The O
present O
study O
was O
aimed O
to O
investigate O
the O
combined O
effects O
of O
green O
tea O
and O
vitamin O
E O
on O
heart O
weight, O
body O
weight, O
serum O
marker O
enzymes, O
lipid O
peroxidation, O
endogenous O
antioxidants O
and O
membrane O
bound O
ATPases O
in O
isoproterenol O
(ISO)-induced O
myocardial B
infarction I
in O
rats. O
Adult O
male O
albino O
rats, O
treated O
with O
ISO O
(200 O
mg/kg, O
s.c.) O
for O
2 O
days O
at O
an O
interval O
of O
24 O
h O
caused O
a O
significant O
(P<0.05) O
elevation O
of O
heart O
weight, O
serum O
marker O
enzymes, O
lipid O
peroxidation O
and O
Ca+2 O
ATPase O
level O
whereas O
there O
was O
a O
significant O
(P<0.05) O
decrease O
in O
body O
weight, O
endogenous O
antioxidants, O
Na+/ O
K+ O
ATPase O
and O
Mg+2 O
ATPase O
levels. O
Administration O
of O
green O
tea O
(100 O
mg/kg/day, O
p.o.) O
and O
vitamin O
E O
(100 O
mg/kg/day, O
p.o.) O
together O
for O
30 O
consecutive O
days O
and O
challenged O
with O
ISO O
on O
the O
day O
29th O
and O
30th, O
showed O
a O
significant O
(P<0.05) O
decrease O
in O
heart O
weight, O
serum O
marker O
enzymes, O
lipid O
peroxidation, O
Ca+2 O
ATPase O
and O
a O
significant O
increase O
in O
the O
body O
weight, O
endogenous O
antioxidants, O
Na+/K+ O
ATPase O
and O
Mg+2 O
ATPase O
when O
compared O
with O
ISO O
treated O
group O
and O
green O
tea O
or O
vitamin O
E O
alone O
treated O
groups. O
These O
findings O
indicate O
the O
synergistic O
protective O
effect O
of O
green O
tea O
and O
vitamin O
E O
during O
ISO O
induced O
myocardial O
infarction O
in O
rats. O

Pneumonitis O
with O
pleural B
and I
pericardial B
effusion I
and O
neuropathy B
during O
amiodarone O
therapy. O

Twelve O
patients O
with O
liver B
disease I
related O
to O
methyldopa O
were O
seen O
between O
1967 O
and O
1977. O
Illness O
occurred O
within O
1--9 O
weeks O
of O
commencement O
of O
therapy O
in O
9 O
patients, O
the O
remaining O
3 O
patients O
having O
received O
the O
drug O
for O
13 O
months, O
15 O
months O
and O
7 O
years O
before O
experiencing O
symptoms. O
Jaundice B
with O
tender O
hepatomegaly, B
usually O
preceded O
by O
symptoms O
of O
malaise, O
anorexia, B
nausea B
and O
vomiting, B
and O
associated O
with O
upper O
abdominal B
pain, I
was O
an O
invariable O
finding O
in O
all O
patients. O
Biochemical O
liver O
function O
tests O
indicated O
hepatocellular O
necrosis B
and O
correlated O
with O
histopathological O
evidence O
of O
hepatic B
injury, I
the O
spectrum O
of O
which O
ranged O
from O
fatty B
change I
and O
focal O
hepatocellular O
necrosis O
to O
massive B
hepatic I
necrosis. I
Most O
patients O
showed O
moderate O
to O
severe O
acute B
hepatitis B
or O
chronic B
active I
hepatitis I
with O
associated O
cholestasis. B
The O
drug O
was O
withdrawn O
on O
presentation O
to O
hospital O
in O
11 O
patients, O
with O
rapid O
clinical O
improvement O
in O
9. O
One O
patient O
died, O
having O
presented O
in O
hepatic B
failure, I
and O
another, O
who O
had O
been O
taking O
methyldopa O
for O
7 O
years, O
showed O
slower O
clinical O
and O
biochemical O
resolution O
over O
a O
period O
of O
several O
months. O
The O
remaining O
patient O
in O
the O
series O
developed O
fulminant B
hepatitis I
when O
the O
drug O
was O
accidentally O
recommenced O
1 O
year O
after O
a O
prior O
episode O
of O
methyldopa-induced O
hepatitis. O
In O
this O
latter O
patient, O
and O
in O
2 O
others, O
the O
causal O
relationship O
between O
methyldopa O
and O
hepatic B
dysfunction I
was O
proved O
with O
the O
recurrence O
of O
hepatitis O
within O
2 O
weeks O
of O
re-exposure O
to O
the O
drug. O

Rabbit B
syndrome, I
antidepressant O
use, O
and O
cerebral O
perfusion O
SPECT O
scan O
findings. O

Acute O
cocaine-induced O
seizures: B
differential O
sensitivity O
of O
six O
inbred O
mouse O
strains. O

Reduction O
in O
caffeine O
toxicity B
by O
acetaminophen. O

GLEPP1 O
receptor O
tyrosine O
phosphatase O
(Ptpro) O
in O
rat O
PAN O
nephrosis. B
A O
marker O
of O
acute O
podocyte O
injury. O

Rabbit B
syndrome I
(RS) O
is B
a O
rare O
extrapyramidal O
side O
effect O
caused O
by O
prolonged O
neuroleptic O
medication. O
Here O
we O
present O
a O
case O
of O
withdrawal-emergent B
RS, B
which I
is O
the O
first O
of O
its O
kind O
to O
be O
reported. O
The O
patient O
developed O
RS O
during O
dose O
reduction O
of O
risperidone. O
The O
symptom O
was O
treated O
successfully O
with O
trihexyphenidyl O
anticholinergic O
therapy. O
The O
underlying O
mechanism O
of O
withdrawal-emergent O
RS O
in O
the O
present O
case O
may O
have O
been O
related O
to O
the O
pharmacological O
profile O
of O
risperidone, O
a O
serotonin-dopamine O
antagonist, O
suggesting O
the O
pathophysiologic O
influence O
of O
the O
serotonin O
system O
in O
the O
development O
of O
RS. O

Lone O
atrial B
fibrillation I
associated O
with O
creatine O
monohydrate O
supplementation. O

Multiple O
cytotoxic O
drug O
administration O
is O
the O
generally O
accepted O
treatment O
of O
patients O
with O
a O
high-risk O
stage O
of O
choriocarcinoma. B
Based O
on O
this O
principle O
a O
27-year O
old O
woman, O
classified O
as O
being O
in O
the O
high-risk O
group O
(Goldstein O
and O
Berkowitz O
score: O
11), O
was O
treated O
with O
multiple O
cytotoxic O
drugs. O
The O
multiple O
drug O
schema O
consisted O
of: O
Etoposide O
16.213, O
Methotrexate, O
Cyclophosphamide, O
Actomycin-D, O
and O
Cisplatin. O
On O
the O
first O
day O
of O
the O
schedule, O
moderate O
high O
doses O
of O
Methotrexate, O
Etoposide O
and O
Cyclophosphamide O
were O
administered. O
Within O
8 O
hours O
after O
initiation O
of O
therapy O
the O
patient O
died O
with O
a O
clinical O
picture O
resembling O
massive O
pulmonary B
obstruction I
due O
to O
choriocarcinomic O
tissue O
plugs, O
probably O
originating O
from O
the O
uterus. O
Formation O
of O
these O
plugs O
was O
probably O
due O
to O
extensive O
tumor B
necrosis B
at O
the O
level O
of O
the O
walls O
of O
the O
major O
uterine O
veins, O
which O
resulted O
in O
an O
open O
exchange O
of O
tumor O
plugs O
to O
the O
vascular O
spaces; O
decrease O
in O
tumor O
tissue O
coherence O
secondary O
to O
chemotherapy O
may O
have O
further O
contributed O
to O
the O
formation O
of O
tumor O
emboli. O
In O
view O
of O
the O
close O
time O
association O
between O
the O
start O
of O
chemotherapy O
and O
the O
acute O
onset O
of O
massive O
embolism B
other O
explanations, O
such O
as O
spontaneous O
necrosis, O
must O
be O
considered O
less O
likely. O
Patients O
with O
large O
pelvic B
tumor I
loads O
are, O
according O
to O
existing O
classifications, O
at O
high O
risk O
to O
die O
and O
to O
develop O
drug O
resistance. O
Notwithstanding O
these O
facts O
our O
findings O
suggest O
that O
these O
patients O
might O
benefit O
from O
relatively O
mild O
initial O
treatment, O
especially O
true O
for O
patients O
not O
previously O
exposed O
to O
this O
drug. O
Close O
observation O
of O
the O
response O
status O
both O
clinically O
and O
with O
beta-hCG O
values O
may O
indicate O
whether O
and O
when O
more O
agressive O
combination O
chemotherapy O
should O
be O
started.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

In O
six O
conscious, O
trained O
dogs, O
maintained O
on O
a O
normal O
sodium O
intake O
of O
2 O
to O
4 O
mEq/kg/day, O
sympathetic O
activity O
was O
assessed O
as O
the O
release O
rate O
of O
norepinephrine O
and O
epinephrine O
during O
15-minute O
i.v. O
infusions O
of O
human O
alpha-atrial O
natriuretic O
factor. O
Mean O
arterial O
pressure O
(as O
a O
percentage O
of O
control O
+/- O
SEM) O
during O
randomized O
infusions O
of O
0.03, O
0.1, O
0.3, O
or O
1.0 O
microgram/kg/min O
was O
99 O
+/- O
1, O
95 O
+/- O
1 O
(p O
less O
than O
0.05), O
93 O
+/- O
1 O
(p O
less O
than O
0.01), O
or O
79 O
+/- O
6% O
(p O
less O
than O
0.001), O
respectively, O
but O
no O
tachycardia B
and O
no O
augmentation O
of O
the O
norepinephrine O
release O
rate O
(up O
to O
0.3 O
microgram/kg/min) O
were O
observed, O
which O
is O
in O
contrast O
to O
comparable O
hypotension B
induced O
by O
hydralazine O
or O
nitroglycerin. O
The O
release O
rate O
of O
epinephrine O
(control, O
6.7 O
+/- O
0.6 O
ng/kg/min) O
declined O
immediately O
during O
infusions O
of O
atrial O
natriuretic O
factor O
to O
a O
minimum O
of O
49 O
+/- O
5% O
of O
control O
(p O
less O
than O
0.001) O
during O
0.1 O
microgram/kg/min O
and O
to O
63 O
+/- O
5% O
(0.1 O
greater O
than O
p O
greater O
than O
0.05) O
or O
95 O
+/- O
13% O
(not O
significant) O
during O
0.3 O
or O
1.0 O
microgram/kg/min. O
Steady O
state O
arterial O
plasma O
concentrations O
of O
atrial O
natriuretic O
factor O
were O
39 O
+/- O
10 O
pg/ml O
(n O
= O
6) O
during O
infusions O
of O
saline O
and O
284 O
+/- O
24 O
pg/ml O
(n O
= O
6) O
and O
1520 O
+/- O
300 O
pg/ml O
(n O
= O
9) O
during O
0.03 O
and O
0.1 O
microgram/kg/min O
infusions O
of O
the O
factor.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

A O
pyridoxine-dependent O
behavioral B
disorder I
unmasked O
by O
isoniazid. O

Under O
controlled O
conditions, O
infant O
rats O
emit O
ultrasonic O
vocalizations O
during O
extreme O
cold O
exposure O
and O
after O
administration O
of O
the O
alpha(2) O
adrenoceptor O
agonist, O
clonidine. O
Previous O
investigations O
have O
determined O
that, O
in O
response O
to O
clonidine, O
ultrasound O
production O
increases O
through O
the O
2nd-week O
postpartum O
and O
decreases O
thereafter. O
Given O
that O
sympathetic O
neural O
dominance O
exhibits O
a O
similar O
developmental O
pattern, O
and O
given O
that O
clonidine O
induces O
sympathetic O
withdrawal O
and O
bradycardia, B
we O
hypothesized O
that O
clonidine's O
developmental O
effects O
on O
cardiac O
rate O
and O
ultrasound O
production O
would O
mirror O
each O
other. O
Therefore, O
in O
the O
present O
experiment, O
the O
effects O
of O
clonidine O
administration O
(0.5 O
mg/kg) O
on O
cardiac O
rate O
and O
ultrasound O
production O
were O
examined O
in O
2-, O
8-, O
15-, O
and O
20-day-old O
rats. O
Age-related O
changes O
in O
ultrasound O
production O
corresponded O
with O
changes O
in O
cardiovascular O
variables, O
including O
baseline O
cardiac O
rate O
and O
clonidine-induced O
bradycardia. O
This O
experiment O
is O
discussed O
with O
regard O
to O
the O
hypothesis O
that O
ultrasound O
production O
is O
the O
acoustic O
by-product O
of O
a O
physiological O
maneuver O
that O
compensates O
for O
clonidine's O
detrimental O
effects O
on O
cardiovascular O
function. O

Liver B
disease I
caused O
by O
propylthiouracil. O

Many O
new O
serotonergic O
antidepressants O
have O
been O
introduced O
over O
the O
past O
decade. O
Although O
urinary B
incontinence B
is O
listed O
as O
one O
side O
effect O
of O
these O
drugs O
in O
their O
package O
inserts O
there O
is O
only O
one O
report O
in O
the O
literature. O
This O
concerns O
2 O
male O
patients O
who O
experienced O
incontinence O
while O
taking O
venlafaxine. O
In O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence O
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine O
and O
sertraline, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine. O
In O
2 O
of O
the O
3 O
cases O
the O
patients O
were O
also O
taking O
lithium O
carbonate O
and O
beta-blockers, O
both O
of O
which O
could O
have O
contributed O
to O
the O
incontinence. O
Animal O
studies O
suggest O
that O
incontinence O
secondary O
to O
serotonergic O
antidepressants O
could O
be O
mediated O
by O
the O
5HT4 O
receptors O
found O
on O
the O
bladder. O
Further O
research O
is O
needed O
to O
delineate O
the O
frequency O
of O
this O
troubling O
side O
effect O
and O
how O
best O
to O
treat O
it. O

Oral O
contraceptives O
and O
the O
risk O
of O
myocardial B
infarction. I

Time O
course O
of O
lipid O
peroxidation O
in O
puromycin O
aminonucleoside-induced O
nephropathy. B

Noradrenergic O
involvement O
in O
catalepsy B
induced O
by O
delta O
9-tetrahydrocannabinol. O

Acute O
confusion B
induced O
by O
a O
high-dose O
infusion O
of O
5-fluorouracil O
and O
folinic O
acid. O

A O
72-year-old O
woman O
was O
admitted O
to O
the O
hospital O
with O
"flash" O
pulmonary B
edema, I
preceded O
by O
chest B
pain, I
requiring O
intubation. O
Her O
medical O
history O
included O
coronary B
artery I
disease I
with O
previous O
myocardial B
infarctions, I
hypertension, B
and O
diabetes B
mellitus. I
A O
history O
of O
angioedema B
secondary O
to O
lisinopril O
therapy O
was O
elicited. O
Current O
medications O
did O
not O
include O
angiotensin-converting O
enzyme O
inhibitors O
or O
beta-blockers. O
She O
had O
no O
previous O
beta-blocking O
drug O
exposure. O
During O
the O
first O
day O
of O
hospitalization O
(while O
intubated), O
intravenous O
metoprolol O
was O
given, O
resulting O
in O
severe O
angioedema. O
The O
angioedema O
resolved O
after O
therapy O
with O
intravenous O
steroids O
and O
diphenhydramine O
hydrochloride. O

OBJECTIVE: O
Maternal O
tobacco O
smoking O
has O
negative O
effects O
on O
fetal O
growth. O
The O
influence O
of O
smoking O
during O
pregnancy O
on O
the O
developing O
cochlea O
has O
not O
been O
estimated, O
although O
smoking O
has O
been O
positively O
associated O
with O
hearing B
loss I
in O
adults. O
The O
objective O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
maternal O
smoking O
on O
transient O
evoked O
otoacoustic O
emissions O
(TEOAEs) O
of O
healthy O
neonates. O
METHODS: O
This O
study O
was O
undertaken O
as O
part O
of O
neonatal O
screening O
for O
hearing B
impairment I
and O
involved O
both O
ears O
of O
200 O
newborns. O
Newborns O
whose O
mothers O
reported O
smoking O
during O
pregnancy O
(n=200 O
ears) O
were O
compared O
to O
a O
control O
group O
of O
newborns O
(n=200 O
ears), O
whose O
mothers O
were O
non-smokers. O
Exposure O
to O
tobacco O
was O
characterized O
as O
low O
(<5 O
cigarettes O
per O
day, O
n=88 O
ears), O
moderate O
(5< O
or O
=cigarettes O
per O
day<10, O
n=76) O
or O
high O
(> O
or O
=10 O
cigarettes O
per O
day, O
n=36). O
RESULTS: O
In O
exposed O
neonates, O
TEOAEs O
mean O
response O
(across O
frequency) O
and O
mean O
amplitude O
at O
4000Hz O
was O
significantly O
lower O
than O
in O
non-exposed O
neonates. O
Comparisons O
between O
exposed O
newborns' O
subgroups O
revealed O
no O
significant O
differences. O
However, O
by O
comparing O
each O
subgroup O
to O
control O
group, O
we O
found O
statistically O
significant O
decreases B
of I
TEOAEs I
amplitudes I
at O
4000Hz O
for O
all O
three O
groups. O
Mean O
TEOAEs O
responses O
of O
highly O
exposed O
newborns O
were O
also O
significantly O
lower O
in O
comparison O
to O
our O
control O
group. O
CONCLUSION: O
In O
utero, O
exposure O
to O
tobacco O
smoking O
seems O
to O
have O
a O
small O
impact O
on O
outer O
hair O
cells. O
These O
effects O
seem O
to O
be O
equally O
true O
for O
all O
exposed O
newborns, O
regardless O
of O
the O
degree O
of O
exposure. O
Further O
studies O
are O
needed O
in O
order O
to O
establish O
a O
potential O
negative O
effect O
of O
maternal O
smoking O
on O
the O
neonate's O
hearing O
acuity. O

Previous O
studies O
have O
suggested O
that O
repeated O
exposure O
of O
rats O
to O
the O
drug O
or O
to O
the O
experimental O
environment O
is O
necessary O
to O
observe O
nicotine-induced O
locomotor O
stimulation. O
In O
the O
present O
study O
the O
role O
of O
habituation O
to O
the O
experimental O
environment O
on O
the O
stimulant O
effect O
of O
nicotine O
in O
rats O
was O
examined. O
In O
addition, O
the O
role O
of O
dopamine O
receptors O
in O
mediating O
nicotine-induced O
locomotor O
stimulation O
was O
investigated O
by O
examining O
the O
effects O
of O
selective O
D1 O
and O
D2 O
dopamine O
receptor O
antagonists O
on O
activity O
induced O
by O
nicotine. O
Locomotor O
activity O
was O
assessed O
in O
male O
Sprague-Dawley O
rats O
tested O
in O
photocell O
cages. O
Nicotine O
(1.0 O
mg/kg) O
caused O
a O
significant O
increase B
in I
locomotor I
activity I
in O
rats O
that O
were O
habituated O
to O
the O
test O
environment, O
but O
had O
only O
a O
weak O
and O
delayed O
stimulant O
action O
in O
rats O
that O
were O
unfamiliar O
with O
the O
test O
environment. O
The O
stimulant O
action O
of O
nicotine O
was O
blocked O
by O
the O
central O
nicotinic O
antagonist O
mecamylamine O
but O
not O
by O
the O
peripheral O
nicotinic O
blocker O
hexamethonium, O
indicating O
that O
the O
response O
is O
probably O
mediated O
by O
central O
nicotinic O
receptors. O
Nicotine-induced O
hyperactivity B
was O
blocked O
by O
the O
selective O
D1 O
antagonist O
SCH O
23390, O
the O
selective O
D2 O
antagonist O
raclopride O
and O
the O
D1/D2 O
antagonist O
fluphenazine. O
Pretreatment O
with O
the O
D2 O
agonist O
PHNO O
enhanced O
nicotine-induced O
hyperactivity, O
whereas O
the O
D1 O
agonist O
SKF O
38393 O
had O
no O
effect. O
The O
results O
indicate O
that O
acute O
nicotine O
injection O
induces O
a O
pronounced O
hyperactivity O
in O
rats O
habituated O
to O
the O
test O
environment. O
The O
effect O
appears O
to O
be O
mediated O
by O
central O
nicotine O
receptors, O
possibly O
located O
on O
dopaminergic O
neurons, O
and O
also O
requires O
the O
activation O
of O
both O
D1 O
and O
D2 O
dopamine O
receptors. O

RATIONALE: O
gamma-Vinyl O
GABA O
(GVG) O
irreversibly O
inhibits O
GABA-transaminase. O
This O
non-receptor O
mediated O
inhibition O
requires O
de O
novo O
synthesis O
for O
restoration O
of O
functional O
GABA O
catabolism. O
OBJECTIVES: O
Given O
its O
preclinical O
success O
for O
treating O
substance B
abuse I
and O
the O
increased O
risk O
of O
visual B
field I
defects I
(VFD) O
associated B
with O
cumulative O
lifetime O
exposure, O
we O
explored O
the O
effects O
of O
sub-chronic O
low O
dose O
GVG O
on O
cocaine-induced O
increases O
in O
nucleus O
accumbens O
(NAcc) O
dopamine O
(DA). O
METHODS: O
Using O
in O
vivo O
microdialysis, O
we O
compared O
acute O
exposure O
(450 O
mg/kg) O
to O
an O
identical O
sub-chronic O
exposure O
(150 O
mg/kg O
per O
day O
for O
3 O
days), O
followed O
by O
1- O
or O
3-day O
washout. O
Finally, O
we O
examined O
the O
low O
dose O
of O
150 O
mg/kg O
(50 O
mg/kg O
per O
day) O
using O
a O
similar O
washout O
period. O
RESULTS: O
Sub-chronic O
GVG O
exposure O
inhibited O
the O
effect O
of O
cocaine O
for O
3 O
days, O
which O
exceeded O
in O
magnitude O
and O
duration O
the O
identical O
acute O
dose. O
CONCLUSIONS: O
Sub-chronic O
low O
dose O
GVG O
potentiates O
and O
extends O
the O
inhibition O
of O
cocaine-induced O
increases O
in O
dopamine, O
effectively O
reducing O
cumulative O
exposures O
and O
the O
risk O
for O
VFDS. O

Levodopa-induced O
dyskinesias B
(LIDs) O
present B
a O
major O
problem O
for O
the O
long-term O
management O
of O
Parkinson's B
disease I
(PD) O
patients. B
Due O
to O
the O
interdependence O
of O
risk O
factors O
in O
clinical O
populations, O
it O
is O
difficult O
to O
independently O
examine O
factors O
that O
may O
influence O
the O
development O
of O
LIDs. O
Using O
macaque O
monkeys O
with O
different O
types O
of O
MPTP-induced O
parkinsonism, B
the O
current O
study O
evaluated O
the O
degree O
to O
which O
rate O
of O
symptom O
progression, O
symptom O
severity, O
and O
response O
to O
and O
duration O
of O
levodopa O
therapy O
may O
be O
involved O
in O
the O
development O
of O
LIDs. O
Monkeys O
with O
acute O
(short-term) O
MPTP O
exposure, O
rapid O
symptom O
onset O
and O
short O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
developed O
dyskinesia O
between O
11 O
and O
24 O
days O
of O
daily O
levodopa O
administration. O
In O
contrast, O
monkeys O
with O
long-term O
MPTP O
exposure, O
slow O
symptom O
progression O
and/or O
long O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
were O
more O
resistant O
to O
developing O
LIDs O
(e.g., O
dyskinesia O
developed O
no O
sooner O
than O
146 O
days O
of O
chronic O
levodopa O
administration). O
All O
animals O
were O
similarly O
symptomatic O
at O
the O
start O
of O
levodopa O
treatment O
and O
had O
similar O
therapeutic O
responses O
to O
the O
drug. O
These O
data O
suggest O
distinct O
differences O
in O
the O
propensity O
to O
develop O
LIDs O
in O
monkeys O
with O
different O
rates O
of O
symptom O
progression O
or O
symptom O
durations O
prior O
to O
levodopa O
and O
demonstrate O
the O
value O
of O
these O
models O
for O
further O
studying O
the O
pathophysiology O
of O
LIDs. O

We O
present O
the O
case O
of O
a O
28-year-old O
man O
on O
chronic O
warfarin O
therapy O
who O
sustained O
a O
minor O
muscle B
tear I
and O
developed O
increasing O
pain B
and O
a O
flexure O
contracture B
of O
the O
right O
hip. O
Surgical O
exploration O
revealed O
an O
iliopsoas O
hematoma B
and O
femoral O
nerve B
entrapment, I
resulting O
in O
a O
femoral B
nerve I
palsy I
and O
partial B
loss I
of I
quadriceps I
functions. I
Anticoagulant-induced O
femoral O
nerve O
palsy O
represents O
the O
most O
common O
form O
of O
warfarin-induced O
peripheral B
neuropathy; I
it O
is O
characterized O
by O
severe O
pain O
in O
the O
inguinal O
region, O
varying O
degrees O
of O
motor B
and I
sensory I
impairment, I
and O
flexure O
contracture O
of O
the O
involved O
extremity. O

Trimipramine O
(TRI), O
which O
shows O
a O
clinical O
antidepressant O
activity, O
is O
chemically O
related O
to O
imipramine O
but O
does O
not O
inhibit O
the O
reuptake O
of O
noradrenaline O
and O
5-hydroxytryptamine, O
nor O
does O
it O
induce O
beta-adrenergic O
down-regulation. O
The O
mechanism O
of O
its O
antidepressant O
activity O
is O
still O
unknown. O
The O
aim O
of O
the O
present O
study O
was O
to O
find O
out O
whether O
TRI O
given O
repeatedly O
was O
able O
to O
induce O
adaptive O
changes O
in O
the O
dopaminergic O
and O
alpha1-adrenergic O
systems, O
demonstrated O
by O
us O
previously O
for O
various O
antidepressants. O
TRI O
was O
given O
to O
male O
Wistar O
rats O
and O
male O
Albino O
Swiss O
mice O
perorally O
twice O
daily O
for O
14 O
days. O
In O
the O
acute O
experiment O
TRI O
(given O
i.p.) O
does O
not O
antagonize O
the O
reserpine O
hypothermia B
in O
mice O
and O
does O
not O
potentiate O
the O
5-hydroxytryptophan O
head O
twitches O
in O
rats. O
TRI O
given O
repeatedly O
to O
rats O
increases O
the O
locomotor O
hyperactivity B
induced O
by O
d-amphetamine, O
quinpirole O
and O
(+)-7-hydroxy-dipropyloaminotetralin O
(dopamine O
D2 O
and O
D3 O
effects). O
The O
stereotypies O
induced O
by O
d-amphetamine O
or O
apomorphine O
are O
not O
potentiated O
by O
TRI. O
It O
increases O
the O
behaviour O
stimulation O
evoked O
by O
phenylephrine O
(given O
intraventricularly) O
in O
rats, O
evaluated O
in O
the O
open O
field O
test O
as O
well O
as O
the O
aggressiveness B
evoked O
by O
clonidine O
in O
mice, O
both O
these O
effects O
being O
mediated O
by O
an O
alpha1-adrenergic O
receptor. O
It O
may O
be O
concluded O
that, O
like O
other O
tricyclic O
antidepressants O
studied O
previously, O
TRI O
given O
repeatedly O
increases O
the O
responsiveness O
of O
brain O
dopamine O
D2 O
and O
D3 O
(locomotor O
activity O
but O
not O
stereotypy) O
as O
well O
as O
alpha1-adrenergic O
receptors O
to O
their O
agonists. O
A O
question O
arises O
whether O
the O
reuptake O
inhibition O
is O
of O
any O
importance O
to O
the O
adaptive O
changes O
induced O
by O
repeated O
antidepressants, O
suggested O
to O
be O
responsible O
for O
the O
antidepressant O
activity. O

We O
present O
a O
case O
of O
paramedic O
misjudgment O
in O
the O
execution O
of O
a O
protocol O
for O
the O
treatment O
of O
allergic B
reaction I
in O
a O
case O
of O
pulmonary B
edema I
with O
wheezing. B
The O
sudden O
onset O
of O
respiratory B
distress, I
rash, B
and O
a O
history O
of O
a O
new O
medicine O
led O
the O
two O
paramedics O
on O
the O
scene O
to O
administer O
subcutaneous O
epinephrine. O
Subsequently, O
acute O
cardiac B
arrest I
and O
fatal O
subarachnoid B
hemorrhage I
occurred. O
Epinephrine O
has O
a O
proven O
role O
in O
cardiac O
arrest O
in O
prehospital O
care; O
however, O
use O
by O
paramedics O
in O
patients O
with O
suspected O
allergic O
reaction O
and O
severe O
hypertension B
should O
be O
viewed O
with O
caution. O

Galanthamine O
hydrobromide, O
an O
anticholinesterase O
drug O
capable O
of O
penetrating O
the O
blood-brain O
barrier, O
was O
used O
in O
a O
patient O
demonstrating O
central O
effects O
of O
scopolamine O
(hyoscine) O
overdosage. B
It O
is O
longer O
acting O
than O
physostigmine O
and O
is O
used O
in O
anaesthesia O
to O
reverse O
the O
non-depolarizing O
neuromuscular O
block. O
However, O
studies O
into O
the O
dose O
necessary O
to O
combating O
scopolamine O
intoxication O
are O
indicated. O

Changes O
in O
heart O
size O
during O
long-term O
timolol O
treatment O
after O
myocardial B
infarction. I

BACKGROUND: O
Cyproterone O
acetate O
combined O
with O
ethinyl O
estradiol O
(CPA/EE) O
is O
licensed O
in O
the O
UK O
for O
the O
treatment O
of O
women O
with O
acne B
and O
hirsutism B
and O
is O
also O
a O
treatment O
option O
for O
polycystic B
ovary I
syndrome I
(PCOS). O
Previous B
studies O
have O
demonstrated O
an O
increased O
risk O
of O
venous B
thromboembolism I
(VTE) O
associated B
with O
CPA/EE O
compared O
with O
conventional O
combined O
oral O
contraceptives O
(COCs). O
We O
believe O
the O
results O
of O
those O
studies O
may O
have O
been O
affected O
by O
residual O
confounding. O
METHODS: O
Using O
the O
General O
Practice O
Research O
Database O
we O
conducted O
a O
cohort O
analysis O
and O
case-control O
study O
nested O
within O
a O
population O
of O
women O
aged O
between O
15 O
and O
39 O
years O
with O
acne, O
hirsutism O
or O
PCOS O
to O
estimate O
the O
risk O
of O
VTE O
associated O
with O
CPA/EE. O
RESULTS: O
The O
age-adjusted O
incidence O
rate O
ratio O
for O
CPA/EE O
versus O
conventional O
COCs O
was O
2.20 O
[95% O
confidence O
interval O
(CI) O
1.35-3.58]. O
Using O
as O
the O
reference O
group O
women O
who O
were O
not O
using O
oral O
contraception, O
had O
no O
recent O
pregnancy O
or O
menopausal O
symptoms, O
the O
case-control O
analysis O
gave O
an O
adjusted O
odds O
ratio O
(OR(adj)) O
of O
7.44 O
(95% O
CI O
3.67-15.08) O
for O
CPA/EE O
use O
compared O
with O
an O
OR(adj) O
of O
2.58 O
(95% O
CI O
1.60-4.18) O
for O
use O
of O
conventional O
COCs. O
CONCLUSIONS: O
We O
have O
demonstrated O
an O
increased O
risk O
of O
VTE O
associated O
with O
the O
use O
of O
CPA/EE O
in O
women O
with O
acne, O
hirsutism O
or O
PCOS O
although O
residual O
confounding O
by O
indication O
cannot O
be O
excluded. O

A O
61-year-old O
Japanese O
man O
with O
nephrotic B
syndrome I
due O
to O
focal B
segmental I
glomerulosclerosis I
was O
initially O
responding O
well O
to O
steroid O
therapy. O
The O
amount O
of O
daily O
urinary O
protein O
decreased O
from O
15.6 O
to O
2.8 O
g. O
Within O
14 O
days O
of O
the O
oral O
bisphosphonate O
(alendronate O
sodium) O
administration, O
the O
amount O
of O
daily O
urinary O
protein O
increased O
rapidly O
up O
to O
12.8 O
g O
with O
acute B
renal I
failure. I
After O
discontinuing O
the O
oral O
alendronate, O
the O
patient O
underwent O
six O
cycles O
of O
hemodialysis O
and O
four O
cycles O
of O
LDL O
apheresis. O
Urinary O
volume O
and O
serum O
creatinine O
levels O
recovered O
to O
the O
normal O
range, O
with O
urinary O
protein O
disappearing O
completely O
within O
40 O
days. O
This O
report O
demonstrates O
that O
not O
only O
intravenous, O
but O
also O
oral O
bisphosphonates O
can O
aggravate O
proteinuria B
and O
acute O
renal O
failure. O

Reduction O
in O
injection O
pain B
using O
buffered O
lidocaine O
as O
a O
local O
anesthetic O
before O
cardiac O
catheterization. O

Perceived O
pain B
intensity O
is O
modulated O
by O
attention. O
However, O
it O
is O
not O
known O
that O
how O
pain O
intensity O
ratings O
are O
affected O
by O
attention O
in O
capsaicin-induced O
secondary O
hyperalgesia. B
Here O
we O
show O
that O
perceived O
pain O
intensity O
in O
secondary O
hyperalgesia O
is O
decreased O
when O
attention O
is O
distracted O
away O
from O
the O
painful O
pinprick O
stimulus O
with O
a O
visual O
task. O
Furthermore, O
it O
was O
found O
that O
the O
magnitude O
of O
attentional O
modulation O
in O
secondary O
hyperalgesia O
is O
very O
similar O
to O
that O
of O
capsaicin-untreated, O
control O
condition. O
Our O
findings, O
showing O
no O
interaction O
between O
capsaicin O
treatment O
and O
attentional O
modulation O
suggest O
that O
capsaicin-induced O
secondary O
hyperalgesia O
and O
attention O
might O
affect O
mechanical O
pain O
through O
independent O
mechanisms. O

Gemcitabine O
plus O
vinorelbine O
in O
nonsmall B
cell I
lung I
carcinoma I
patients O
age O
70 O
years O
or O
older O
or O
patients O
who O
cannot O
receive O
cisplatin. O
Oncopaz O
Cooperative O
Group. O

Study O
of O
the O
role O
of O
vitamin O
B12 O
and O
folinic O
acid O
supplementation O
in O
preventing O
hematologic O
toxicity B
of O
zidovudine. O

BACKGROUND: O
Recent O
evidence O
suggests O
that O
transient B
neurologic I
symptoms I
(TNSs) O
frequently B
follow O
lidocaine O
spinal O
anesthesia O
but O
are O
infrequent O
with O
bupivacaine. O
However, O
identification O
of O
a O
short-acting O
local O
anesthetic O
to O
substitute O
for O
lidocaine O
for O
brief O
surgical O
procedures O
remains O
an O
important O
goal. O
Prilocaine O
is O
an O
amide O
local O
anesthetic O
with O
a O
duration O
of O
action O
similar O
to O
that O
of O
lidocaine. O
Accordingly, O
the O
present, O
prospective O
double-blind O
study O
compares O
prilocaine O
with O
lidocaine O
and O
bupivacaine O
with O
respect O
to O
duration O
of O
action O
and O
relative O
risk O
of O
TNSs. O
METHODS: O
Ninety O
patients O
classified O
as O
American O
Society O
of O
Anesthesiologists O
physical O
status O
I O
or O
II O
who O
were O
scheduled O
for O
short O
gynecologic O
procedures O
under O
spinal O
anesthesia O
were O
randomly O
allocated O
to O
receive O
2.5 O
ml O
2% O
lidocaine O
in O
7.5% O
glucose, O
2% O
prilocaine O
in O
7.5% O
glucose, O
or O
0.5% O
bupivacaine O
in O
7.5% O
glucose. O
All O
solutions O
were O
provided O
in O
blinded O
vials O
by O
the O
hospital O
pharmacy. O
Details O
of O
spinal O
puncture, O
extension O
and O
regression O
of O
spinal O
block, O
and O
the O
times O
to O
reach O
discharge O
criteria O
were O
noted. O
In O
the O
evening O
of O
postoperative O
day O
1, O
patients O
were O
evaluated O
for O
TNSs O
by O
a O
physician O
unaware O
of O
the O
drug O
administered O
and O
the O
details O
of O
the O
anesthetic O
procedure. O
RESULTS: O
Nine O
of O
30 O
patients O
receiving O
lidocaine O
experienced O
TNSs, O
1 O
of O
30 O
patients O
receiving O
prilocaine O
(P O
= O
0.03) O
had O
them, O
and O
none O
of O
30 O
patients O
receiving O
bupivacaine O
had O
TNSs. O
Times O
to O
ambulate O
and O
to O
void O
were O
similar O
after O
lidocaine O
and O
prilocaine O
(150 O
vs. O
165 O
min O
and O
238 O
vs. O
253 O
min, O
respectively) O
but O
prolonged O
after O
bupivacaine O
(200 O
and O
299 O
min, O
respectively; O
P O
< O
0.05). O
CONCLUSIONS: O
Prilocaine O
may O
be O
preferable O
to O
lidocaine O
for O
short O
surgical O
procedures O
because O
it O
has O
a O
similar O
duration O
of O
action O
but O
a O
lower O
incidence O
of O
TNSs. O

Cocaine O
related O
chest B
pain: I
are O
we O
seeing O
the O
tip O
of O
an O
iceberg? O

This O
study O
investigated O
propofol O
injection O
pain B
in O
patients O
undergoing O
ambulatory O
anaesthesia. O
In O
a O
randomized, O
double-blind O
trial, O
90 O
women O
were O
allocated O
to O
receive O
one O
of O
three O
treatments O
prior O
to O
induction O
of O
anaesthesia O
with O
propofol. O
Patients O
in O
Group O
C O
received O
2 O
ml O
normal O
saline, O
Group O
L, O
2 O
ml, O
lidocaine O
2% O
(40 O
mg) O
and O
Group O
T, O
2 O
ml O
thiopentone O
2.5% O
(50 O
mg). O
Venous O
discomfort O
was O
assessed O
with O
a O
visual O
analogue O
scale O
(VAS) O
5-15 O
sec O
after O
commencing O
propofol O
administration O
using O
an O
infusion O
pump O
(rate O
1000 O
micrograms.kg-1.min-1). O
Loss B
of I
consciousness I
occurred O
in O
60-90 O
sec. O
Visual O
analogue O
scores O
(mean O
+/- O
SD) O
during O
induction O
were O
lower O
in O
Groups O
L O
(3.3 O
+/- O
2.5) O
and O
T O
(4.1 O
+/- O
2.7) O
than O
in O
Group O
C O
(5.6 O
+/- O
2.3); O
P O
= O
0.0031. O
The O
incidence O
of O
venous O
discomfort O
was O
lower O
in O
Group O
L O
(76.6%; O
P O
< O
0.05) O
than O
in O
Group O
C O
(100%) O
but O
not O
different O
from O
Group O
T O
(90%). O
The O
VAS O
scores O
for O
recall O
of O
pain O
in O
the O
recovery O
room O
were O
correlated O
with O
the O
VAS O
scores O
during O
induction O
(r O
= O
0.7045; O
P O
< O
0.0001). O
Recovery O
room O
discharge O
times O
were O
similar: O
C O
(75.9 O
+/- O
19.4 O
min); O
L O
73.6 O
+/- O
21.6 O
min); O
T O
(77.1 O
+/- O
18.9 O
min). O
Assessing O
their O
overall O
satisfaction, O
89.7% O
would O
choose O
propofol O
anaesthesia O
again. O
We O
conclude O
that O
lidocaine O
reduces O
the O
incidence O
and O
severity O
of O
propofol O
injection O
pain O
in O
ambulatory O
patients O
whereas O
thiopentone O
only O
reduces O
its O
severity. O

Nitro-L-arginine O
methyl O
ester: O
a O
potential O
protector O
against O
gentamicin O
ototoxicity. B

Individuals O
with O
HIV O
can O
now O
live O
long O
lives O
with O
drug O
therapy O
that O
often O
includes O
protease O
inhibitors O
such O
as O
ritonavir. O
Many O
patients, O
however, O
develop O
negative O
long-term O
side O
effects O
such O
as O
premature B
atherosclerosis. I
We O
have O
previously O
demonstrated O
that O
ritonavir O
treatment O
increases O
atherosclerotic B
lesion I
formation O
in O
male O
mice O
to O
a O
greater O
extent O
than O
in O
female O
mice. O
Furthermore, O
peripheral O
blood O
monocytes O
isolated O
from O
ritonavir-treated O
females O
had O
less O
cholesteryl O
ester O
accumulation. O
In O
the O
present O
study, O
we O
have O
investigated O
the O
molecular O
mechanisms O
by O
which O
female O
hormones O
influence O
cholesterol O
metabolism O
in O
macrophages O
in O
response O
to O
the O
HIV O
protease O
inhibitor O
ritonavir. O
We O
have O
utilized O
the O
human O
monocyte O
cell O
line, O
THP-1 O
as O
a O
model O
to O
address O
this O
question. O
Briefly, O
cells O
were O
differentiated O
for O
72 O
h O
with O
100 O
nM O
PMA O
to O
obtain O
a O
macrophage-like O
phenotype O
in O
the O
presence O
or O
absence O
of O
1 O
nM O
17beta-estradiol O
(E2), O
100 O
nM O
progesterone O
or O
vehicle O
(0.01% O
ethanol). O
Cells O
were O
then O
treated O
with O
30 O
ng/ml O
ritonavir O
or O
vehicle O
in O
the O
presence O
of O
aggregated O
LDL O
for O
24 O
h. O
Cell O
extracts O
were O
harvested, O
and O
lipid O
or O
total O
RNA O
was O
isolated. O
E2 O
decreased O
the O
accumulation O
of O
cholesteryl O
esters O
in O
macrophages O
following O
ritonavir O
treatment. O
Ritonavir O
increased O
the O
expression O
of O
the O
scavenger O
receptor, O
CD36 O
mRNA, O
responsible O
for O
the O
uptake O
of O
LDL. O
Additionally, O
ritonavir O
treatment O
selectively O
increased O
the O
relative O
levels O
of O
PPARgamma O
mRNA, O
a O
transcription O
factor O
responsible O
for O
the O
regulation O
of O
CD36 O
mRNA O
expression. O
Treatment O
with O
E2, O
however, O
failed O
to O
prevent O
these O
increases O
at O
the O
mRNA O
level. O
E2 O
did, O
however, O
significantly O
suppress O
CD36 O
protein O
levels O
as O
measured O
by O
fluorescent O
immunocytochemistry. O
This O
data O
suggests O
that O
E2 O
modifies O
the O
expression O
of O
CD36 O
at O
the O
level O
of O
protein O
expression O
in O
monocyte-derived O
macrophages O
resulting O
in O
reduced O
cholesteryl O
ester O
accumulation O
following O
ritonavir O
treatment. O

Effects O
of O
an O
inhibitor O
of O
angiotensin O
converting O
enzyme O
(Captopril) O
on O
pulmonary B
and I
renal B
insufficiency I
due O
to O
intravascular B
coagulation I
in O
the O
rat. O

Epidural O
blood O
flow O
during O
prostaglandin O
E1 O
or O
trimethaphan O
induced O
hypotension. B

Electrocardiographic O
evidence O
of O
myocardial B
injury I
in O
psychiatrically O
hospitalized O
cocaine O
abusers. O

Angina B
and O
ischemic O
electrocardiographic O
changes O
occurred O
after O
administration O
of O
oral O
dipyridamole O
in O
four O
patients O
awaiting O
urgent O
myocardial O
revascularization O
procedures. O
To O
our O
knowledge, O
this O
has O
not O
previously O
been O
reported O
as O
a O
side O
effect O
of O
preoperative O
dipyridamole O
therapy, O
although O
dipyridamole-induced O
myocardial B
ischemia B
has O
been O
demonstrated O
to O
occur O
in O
animals O
and O
humans O
with O
coronary B
artery I
disease. I
Epicardial O
coronary O
collateral O
vessels O
were O
demonstrated O
in O
all O
four O
patients; O
a O
coronary O
"steal" O
phenomenon O
may O
be O
the O
mechanism O
of O
the O
dipyridamole-induced O
ischemia O
observed. O

Fatal O
myeloencephalopathy B
due O
to O
accidental O
intrathecal O
vincristin O
administration: O
a O
report O
of O
two O
cases. O

The O
cause O
of O
hearing B
loss I
after O
spinal O
anaesthesia O
is O
unknown. O
Up O
until O
now, O
the O
only O
factor O
studied O
has O
been O
the O
effect O
of O
the O
diameter O
of O
the O
spinal O
needle O
on O
post-operative O
sensorineural B
hearing I
loss. I
The O
aim O
of O
this O
study O
was O
to O
describe O
this O
hearing O
loss O
and O
to O
investigate O
other O
factors O
influencing O
the O
degree O
of O
hearing O
loss. O
Two O
groups O
of O
22 O
similar O
patients O
were O
studied: O
one O
group O
received O
6 O
mL O
prilocaine O
2%; O
and O
the O
other O
received O
3 O
mL O
bupivacaine O
0.5%. O
Patients O
given O
prilocaine O
were O
more O
likely O
to O
develop O
hearing O
loss O
(10 O
out O
of O
22) O
than O
those O
given O
bupivacaine O
(4 O
out O
of O
22) O
(P O
< O
0.05). O
The O
average O
hearing O
loss O
for O
speech O
frequencies O
was O
about O
10 O
dB O
after O
prilocaine O
and O
15 O
dB O
after O
bupivacaine. O
None O
of O
the O
patients O
complained O
of O
subjective O
hearing O
loss. O
Long-term O
follow-up O
of O
the O
patients O
was O
not O
possible. O

Development O
of O
apomorphine-induced O
aggressive B
behavior: I
comparison O
of O
adult O
male O
and O
female O
Wistar O
rats. O

L-DOPA-induced O
dyskinesia B
(LID) O
is B
among O
the O
motor O
complications O
that O
arise O
in O
Parkinson's B
disease I
(PD) O
patients B
after O
a O
prolonged O
treatment O
with O
L-DOPA. O
To O
this O
day, O
transcriptome O
analysis O
has O
been O
performed O
in O
a O
rat O
model O
of O
LID O
[Neurobiol. O
Dis., O
17 O
(2004), O
219] O
but O
information O
regarding O
the O
proteome O
is O
still O
lacking. O
In O
the O
present O
study, O
we O
investigated O
the O
changes O
occurring O
at O
the O
protein O
level O
in O
striatal O
samples O
obtained O
from O
the O
unilaterally O
6-hydroxydopamine-lesion O
rat O
model O
of O
PD O
treated O
with O
saline, O
L-DOPA O
or O
bromocriptine O
using O
two-dimensional O
difference O
gel O
electrophoresis O
and O
mass O
spectrometry O
(MS). O
Rats O
treated O
with O
L-DOPA O
were O
allocated O
to O
two O
groups O
based O
on O
the O
presence O
or O
absence O
of O
LID. O
Among O
the O
2000 O
spots O
compared O
for O
statistical O
difference, O
67 O
spots O
were O
significantly O
changed O
in O
abundance O
and O
identified O
using O
matrix-assisted O
laser O
desorption/ionization O
time-of-flight O
MS, O
atmospheric O
pressure O
matrix-assisted O
laser O
desorption/ionization O
and O
HPLC O
coupled O
tandem O
MS O
(LC/MS/MS). O
Out O
of O
these O
67 O
proteins, O
LID O
significantly O
changed O
the O
expression O
level O
of O
five O
proteins: O
alphabeta-crystalin, O
gamma-enolase, O
guanidoacetate O
methyltransferase, O
vinculin, O
and O
proteasome O
alpha-2 O
subunit. O
Complementary O
techniques O
such O
as O
western O
immunoblotting O
and O
immunohistochemistry O
were O
performed O
to O
investigate O
the O
validity O
of O
the O
data O
obtained O
using O
the O
proteomic O
approach. O
In O
conclusion, O
this O
study O
provides O
new O
insights O
into O
the O
protein O
changes O
occurring O
in O
LID. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
changes O
in O
the O
plasma O
calcitonin O
gene-related O
peptide O
(CGRP) O
concentration O
and O
platelet O
serotonin O
(5-hydroxytriptamine, O
5-HT) O
content O
during O
the O
immediate O
headache B
and O
the O
delayed O
genuine O
migraine B
attack O
provoked O
by O
nitroglycerin. O
Fifteen O
female O
migraineurs B
(without I
aura) I
and O
eight O
controls O
participated O
in O
the O
study. O
Sublingual O
nitroglycerin O
(0.5 O
mg) O
was O
administered. O
Blood O
was O
collected O
from O
the O
antecubital O
vein O
four O
times: O
60 O
min O
before O
and O
after O
the O
nitroglycerin O
application, O
and O
60 O
and O
120 O
min O
after O
the O
beginning O
of O
the O
migraine O
attack O
(mean O
344 O
and O
404 O
min; O
12 O
subjects). O
In O
those O
subjects O
who O
had O
no O
migraine O
attack O
(11 O
subjects) O
a O
similar O
time O
schedule O
was O
used. O
Plasma O
CGRP O
concentration O
increased O
significantly O
(P<0.01) O
during O
the O
migraine O
attack O
and O
returned O
to O
baseline O
after O
the O
cessation O
of O
the O
migraine. O
In O
addition, O
both O
change O
and O
peak, O
showed O
significant O
positive O
correlations O
with O
migraine O
headache O
intensity O
(P<0.001). O
However, O
plasma O
CGRP O
concentrations O
failed O
to O
change O
during O
immediate O
headache O
and O
in O
the O
subjects O
with O
no O
migraine O
attack. O
Basal O
CGRP O
concentration O
was O
significantly O
higher O
and O
platelet O
5-HT O
content O
tended O
to O
be O
lower O
in O
subjects O
who O
experienced O
a O
migraine O
attack. O
Platelet O
serotonin O
content O
decreased O
significantly O
(P<0.01) O
after O
nitroglycerin O
in O
subjects O
with O
no O
migraine O
attack O
but O
no O
consistent O
change O
was O
observed O
in O
patients O
with O
migraine O
attack. O
In O
conclusion, O
the O
fact O
that O
plasma O
CGRP O
concentration O
correlates O
with O
the O
timing O
and O
severity O
of O
a O
migraine O
headache O
suggests O
a O
direct O
relationship O
between O
CGRP O
and O
migraine. O
In O
contrast, O
serotonin O
release O
from O
platelets O
does O
not O
provoke O
migraine, O
it O
may O
even O
counteract O
the O
headache O
and O
the O
concomitant O
CGRP O
release O
in O
this O
model. O

Autism B
is O
a O
neurodevelopmental B
disorder I
presenting O
before O
3 O
years O
of O
age O
with O
deficits B
in I
communication I
and I
social I
skills I
and O
repetitive B
behaviors. I
In O
addition O
to O
genetic O
influences, O
recent O
studies O
suggest O
that O
prenatal O
drug O
or O
chemical O
exposures O
are O
risk O
factors O
for O
autism. B
Terbutaline, O
a O
beta2-adrenoceptor O
agonist O
used O
to O
arrest O
preterm B
labor, I
has O
been O
associated O
with O
increased O
concordance O
for O
autism O
in O
dizygotic O
twins. O
We O
studied O
the O
effects O
of O
terbutaline O
on O
microglial O
activation O
in O
different O
brain O
regions O
and O
behavioral O
outcomes O
in O
developing O
rats. O
Newborn O
rats O
were O
given O
terbutaline O
(10 O
mg/kg) O
daily O
on O
postnatal O
days O
(PN) O
2 O
to O
5 O
or O
PN O
11 O
to O
14 O
and O
examined O
24 O
h O
after O
the O
last O
dose O
and O
at O
PN O
30. O
Immunohistochemical O
studies O
showed O
that O
administration O
of O
terbutaline O
on O
PN O
2 O
to O
5 O
produced O
a O
robust O
increase O
in O
microglial O
activation O
on O
PN O
30 O
in O
the O
cerebral O
cortex, O
as O
well O
as O
in O
cerebellar O
and O
cerebrocortical O
white O
matter. O
None O
of O
these O
effects O
occurred O
in O
animals O
given O
terbutaline O
on O
PN O
11 O
to O
14. O
In O
behavioral O
tests, O
animals O
treated O
with O
terbutaline O
on O
PN O
2 O
to O
5 O
showed O
consistent O
patterns O
of O
hyper-reactivity O
to O
novelty O
and O
aversive O
stimuli O
when O
assessed O
in O
a O
novel O
open O
field, O
as O
well O
as O
in O
the O
acoustic O
startle O
response O
test. O
Our O
findings O
indicate O
that O
beta2-adrenoceptor O
overstimulation O
during O
an O
early O
critical O
period O
results O
in O
microglial O
activation O
associated O
with O
innate O
neuroinflammatory O
pathways O
and O
behavioral B
abnormalities, I
similar O
to O
those O
described O
in O
autism. O
This O
study O
provides O
a O
useful O
animal O
model O
for O
understanding O
the O
neuropathological O
processes O
underlying O
autism B
spectrum I
disorders. I

Changes O
in O
depressive B
status O
associated O
with O
topical O
beta-blockers. O

Chronic O
carbamazepine O
treatment O
in O
the O
rat: O
efficacy, O
toxicity, B
and O
effect O
on O
plasma O
and O
tissue O
folate O
concentrations. O

The O
effect O
of O
long-term O
timolol O
treatment O
on O
heart O
size O
after O
myocardial B
infarction B
was O
evaluated O
by O
X-ray O
in O
a O
double-blind O
study O
including O
241 O
patients O
(placebo O
126, O
timolol O
115). O
The O
follow-up O
period O
was O
12 O
months. O
The O
timolol-treated O
patients O
showed O
a O
small O
but O
significant O
increase O
in O
heart O
size O
from O
baseline O
in O
contrast O
to O
a O
decrease O
in O
the O
placebo O
group. O
These O
differences O
may O
be O
caused O
by O
timolol-induced O
bradycardia B
and O
a O
compensatory O
increase O
in O
end-diastolic O
volume. O
The O
timolol-related O
increase O
in O
heart O
size O
was O
observed O
only O
in O
patients O
with O
normal O
and O
borderline O
heart O
size. O
In O
patients O
with O
cardiomegaly, B
the O
increase O
in O
heart O
size O
was O
similar O
in O
both O
groups. O
After O
re-infarction, O
heart O
size O
increased O
in O
the O
placebo O
group O
and O
remained O
unchanged O
in O
the O
timolol O
group. O

Ifosfamide O
encephalopathy B
presenting O
with O
asterixis. B

Long-term O
intragastric O
application O
of O
the O
antiepileptic O
drug O
sodium O
valproate O
(Vupral O
"Polfa") O
at O
the O
effective O
dose O
of O
200 O
mg/kg O
b. O
w. O
once O
daily O
to O
rats O
for O
1, O
3, O
6, O
9 O
and O
12 O
months O
revealed O
neurological B
disorders I
indicating O
cerebellum B
damage I
("valproate O
encephalopathy"). B
The O
first O
ultrastructural O
changes O
in O
structural O
elements O
of O
the O
blood-brain-barrier O
(BBB) O
in O
the O
cerebellar O
cortex O
were O
detectable O
after O
3 O
months O
of O
the O
experiment. O
They O
became O
more O
severe O
in O
the O
later O
months O
of O
the O
experiment, O
and O
were O
most O
severe O
after O
12 O
months, O
located O
mainly O
in O
the O
molecular O
layer O
of O
the O
cerebellar O
cortex. O
Lesions O
of O
the O
capillary O
included O
necrosis B
of O
endothelial O
cells. O
Organelles O
of O
these O
cells, O
in O
particular O
the O
mitochondria O
(increased O
number O
and O
size, O
distinct O
degeneration O
of O
their O
matrix O
and O
cristae) O
and O
Golgi O
apparatus O
were O
altered. O
Reduced O
size O
of O
capillary O
lumen O
and O
occlusion O
were O
caused O
by O
swollen O
endothelial O
cells O
which O
had O
luminal O
protrusions O
and O
swollen O
microvilli. O
Pressure O
on O
the O
vessel O
wall O
was O
produced O
by O
enlarged O
perivascular O
astrocytic O
processes. O
Fragments O
of O
necrotic B
endothelial O
cells O
were O
in O
the O
vascular O
lumens O
and O
in O
these O
there O
was O
loosening O
and O
breaking O
of O
tight O
cellular O
junctions. O
Damage O
to O
the O
vascular O
basement O
lamina O
was O
also O
observed. O
Damage O
to O
the O
capillary O
was O
accompanied O
by O
marked O
damage O
to O
neuroglial O
cells, O
mainly O
to O
perivascular O
processes O
of O
astrocytes. O
The O
proliferation O
of O
astrocytes O
(Bergmann's O
in O
particular) O
and O
occasionally O
of O
oligodendrocytes O
was O
found. O
Alterations O
in O
the O
structural O
elements O
of O
the O
BBB O
coexisted O
with O
marked O
lesions O
of O
neurons O
of O
the O
cerebellum O
(Purkinje O
cells O
are O
earliest). O
In O
electron O
micrographs O
both O
luminal O
and O
antiluminal O
sides O
of O
the O
BBB O
of O
the O
cerebellar O
cortex O
had O
similar O
lesions. O
The O
possible O
influence O
of O
the O
hepatic B
damage, I
mainly O
hyperammonemia, B
upon O
the O
development O
of O
valproate O
encephalopathy O
is O
discussed. O

Zonisamide O
is O
a O
broad-spectrum O
antiepileptic O
drug O
used O
to O
treat O
various O
types O
of O
seizures. B
Although O
visual B
hallucinations I
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual O
hallucinations O
and O
altered O
mental O
status O
after O
zonisamide O
treatment O
was O
begun O
or O
its O
dosage O
increased. O
All O
three O
had O
been O
diagnosed O
earlier O
with O
epilepsy, B
and O
their O
electroencephalogram O
(EEG) O
findings O
were O
abnormal. O
During O
monitoring, O
visual O
hallucinations O
did O
not O
correlate O
with O
EEG O
readings, O
nor O
did O
video O
recording O
capture O
any O
of O
the O
described O
events. O
None O
of O
the O
patients O
had O
experienced O
visual O
hallucinations O
before O
this O
event. O
The O
only O
recent O
change O
in O
their O
treatment O
was O
the O
introduction O
or O
increased O
dosage O
of O
zonisamide. O
With O
either O
discontinuation O
or O
decreased O
dosage O
of O
the O
drug O
the O
symptoms O
disappeared O
and O
did O
not O
recur. O
Further O
observations O
and O
reports O
will O
help O
clarify O
this O
adverse O
effect. O
Until O
then, O
clinicians O
need O
to O
be O
aware O
of O
this O
possible O
complication O
associated O
with O
zonisamide. O

Amnesia B
produced O
by O
scopolamine O
and O
cycloheximide O
were O
reversed O
by O
morphine O
given O
30 O
min O
before O
the O
test O
trial O
(pre-test), O
and O
pre-test O
morphine O
also O
facilitated O
the O
memory O
retrieval O
in O
the O
animals O
administered O
naloxone O
during O
the O
training O
trial. O
Similarly, O
pre-test O
scopolamine O
partially O
reversed O
the O
scopolamine-induced O
amnesia, B
but O
not O
significantly; O
and O
pre-test O
cycloheximide O
failed O
to O
reverse O
the O
cycloheximide-induced O
amnesia. O
These O
results O
suggest O
that O
the O
facilitation O
of O
memory O
retrieval O
by O
pre-test O
morphine O
might O
be O
the O
direct O
action O
of O
morphine O
rather O
than O
a O
state O
dependent O
effect. O

An O
allergic B
reaction I
consisting O
of O
angioneurotic B
edema I
secondary O
to O
continuous O
infusion O
5-fluorouracil O
occurred O
in O
a O
patient O
with O
recurrent O
carcinoma B
of I
the I
oral I
cavity, I
cirrhosis, B
and O
cisplatin-induced O
impaired B
renal I
function. I
This O
reaction O
occurred O
during O
the O
sixth O
and O
seventh O
courses O
of O
infusional O
chemotherapy. O
Oral O
diphenhydramine O
and O
prednisone O
were O
ineffective O
in O
preventing O
the O
recurrence O
of O
the O
allergic O
reaction. O
Discontinuance O
of O
effective O
chemotherapy O
in O
this O
patient O
during O
partial O
remission O
resulted O
in O
fatal O
disease O
progression. O

Acute O
vanishing B
bile I
duct I
syndrome I
is O
a O
rare O
but O
established O
cause O
of O
progressive O
cholestasis B
in O
adults, O
is O
most O
often O
drug O
or O
toxin O
related, O
and O
is O
of O
unknown O
pathogenesis. O
It O
has O
not O
been O
reported O
previously O
in O
children. O
Stevens-Johnson B
syndrome I
is O
a O
well-recognized O
immune O
complex-mediated O
hypersensitivity B
reaction O
that O
affects O
all O
age O
groups, O
is O
drug O
or O
infection B
induced, O
and O
has O
classic O
systemic, O
mucosal, O
and O
dermatologic O
manifestations. O
A O
previously O
healthy O
child O
who O
developed O
acute, O
severe, O
rapidly O
progressive O
vanishing O
bile O
duct O
syndrome O
shortly O
after O
Stevens-Johnson O
syndrome O
is O
described; O
this O
was O
temporally O
associated O
with O
ibuprofen O
use. O
Despite O
therapy O
with O
ursodeoxycholic O
acid, O
prednisone, O
and O
then O
tacrolimus, O
her O
cholestatic B
disease I
was O
unrelenting, O
with O
cirrhosis B
shown O
by O
biopsy O
6 O
months O
after O
presentation. O
This O
case O
documents O
acute O
drug-related O
vanishing O
bile O
duct O
syndrome O
in O
the O
pediatric O
age O
group O
and O
suggests O
shared O
immune O
mechanisms O
in O
the O
pathogenesis O
of O
both O
Stevens-Johnson O
syndrome O
and O
vanishing O
bile O
duct O
syndrome. O

Angioedema B
following O
the O
intravenous O
administration O
of O
metoprolol. O

This O
was O
an O
exploratory O
study O
to O
investigate O
lamivudine-resistant O
hepatitis B
B I
virus O
(HBV) O
strains B
in O
selected O
lamivudine-na O
ve O
HBV O
carriers O
with O
and O
without O
human B
immunodeficiency I
virus I
(HIV) I
co-infection B
in O
South O
African O
patients. O
Thirty-five O
lamivudine-na O
ve O
HBV B
infected I
patients O
with O
or O
without O
HIV B
co-infection I
were O
studied: O
15 O
chronic O
HBV B
mono-infected I
patients O
and O
20 O
HBV-HIV B
co-infected I
patients. O
The O
latter O
group O
was O
further O
sub-divided O
into O
13 O
occult O
HBV O
(HBsAg-negative) O
and O
7 O
overt O
HBV O
(HBsAg- O
positive) O
patients. O
HBsAg, O
anti-HBs, O
anti-HBc, O
and O
anti-HIV O
1/2 O
were O
determined O
as O
part O
of O
routine O
diagnosis O
using O
Axsym O
assays O
(Abbott O
Laboratories, O
North O
Chicago, O
IL). O
Serum O
samples O
were O
PCR O
amplified O
with O
HBV O
reverse O
transcriptase O
(RT) O
primers, O
followed O
by O
direct O
sequencing O
across O
the O
tyrosine-methionine-aspartate-aspartate O
(YMDD) O
motif O
of O
the O
major O
catalytic O
region O
in O
the O
C O
domain O
of O
the O
HBV O
RT O
enzyme. O
HBV O
viral O
load O
was O
performed O
with O
Amplicor O
HBV O
Monitor O
test O
v2.0 O
(Roche O
Diagnostics, O
Penzberg, O
Germany). O
HBV O
lamivudine-resistant O
strains O
were O
detected O
in O
3 O
of O
15 O
mono-infected O
chronic O
hepatitis O
B O
patients O
and O
10 O
of O
20 O
HBV-HIV O
co-infected O
patients. O
To O
the O
best O
of O
our O
knowledge, O
this O
constitutes O
the O
first O
report O
of O
HBV O
lamivudine-resistant O
strains O
in O
therapy-na O
ve O
HBV-HIV O
co-infected O
patients. O
The O
HBV O
viral O
loads O
for O
mono-infected O
and O
co-infected O
patients O
ranged O
from O
3.32 O
x O
10(2) O
to O
3.82 O
x O
10(7) O
and O
<200 O
to O
4.40 O
x O
10(3) O
copies/ml, O
respectively. O
It O
remains O
to O
be O
seen O
whether O
such O
pre-existing O
antiviral O
mutations O
could O
result O
in O
widespread O
emergence O
of O
HBV O
resistant O
strains O
when O
lamivudine-containing O
highly O
active O
antiretroviral O
(ARV) O
treatment O
(HAART) O
regimens O
become O
widely O
applied O
in O
South O
Africa, O
as O
this O
is O
likely O
to O
have O
potential O
implications O
in O
the O
management O
of O
HBV-HIV O
co-infected O
patients. O

Lovastatin O
and O
simvastatin O
are O
the O
2 O
best-known O
members O
of O
the O
class O
of O
hypolipidaemic O
agents O
known O
as O
HMG O
CoA O
reductase O
inhibitors. O
Clinical O
experience O
with O
lovastatin O
includes O
over O
5000 O
patients, O
700 O
of O
whom O
have O
been O
treated O
for O
2 O
years O
or O
more, O
and O
experience O
with O
simvastatin O
includes O
over O
3500 O
patients, O
of O
whom O
350 O
have O
been O
treated O
for O
18 O
months O
or O
more. O
Lovastatin O
has O
been O
marketed O
in O
the O
United O
States O
for O
over O
6 O
months. O
Both O
agents O
show O
substantial O
clinical O
efficacy, O
with O
reductions O
in O
total O
cholesterol O
of O
over O
30% O
and O
in O
LDL-cholesterol O
of O
40% O
in O
clinical O
studies. O
Modest O
increases O
in O
HDL-cholesterol O
levels O
of O
about O
10% O
are O
also O
reported. O
Clinical O
tolerability O
of O
both O
agents O
has O
been O
good, O
with O
fewer O
than O
3% O
of O
patients O
withdrawn O
from O
treatment O
because O
of O
clinical O
adverse O
experiences. O
Ophthalmological O
examinations O
in O
over O
1100 O
patients O
treated O
with O
one O
or O
the O
other O
agent O
have O
revealed O
no O
evidence O
of O
significant O
short O
term O
(up O
to O
2 O
years) O
cataractogenic O
potential. O
One O
to O
2% O
of O
patients O
have O
elevations O
of O
serum O
transaminases O
to O
greater O
than O
3 O
times O
the O
upper O
limit O
of O
normal. O
These O
episodes O
are O
asymptomatic O
and O
reversible O
when O
therapy O
is O
discontinued. O
Minor O
elevations O
of O
creatine O
kinase O
levels O
are O
reported O
in O
about O
5% O
of O
patients. O
Myopathy, B
associated O
in O
some O
cases O
with O
myoglobinuria, B
and O
in O
2 O
cases O
with O
transient O
renal B
failure, I
has O
been O
rarely O
reported O
with O
lovastatin, O
especially O
in O
patients O
concomitantly O
treated O
with O
cyclosporin, O
gemfibrozil O
or O
niacin. O
Lovastatin O
and O
simvastatin O
are O
both O
effective O
and O
well-tolerated O
agents O
for O
lowering O
elevated O
levels O
of O
serum O
cholesterol. O
As O
wider O
use O
confirms O
their O
safety O
profile, O
they O
will O
gain O
increasing O
importance O
in O
the O
therapeutic O
approach O
to O
hypercholesterolaemia B
and O
its O
consequences. O

Cellular O
mechanisms O
which O
account O
for O
disruption O
the O
blood-brain O
barrier O
during O
acute O
hypertension B
are O
not O
clear. O
The O
goal O
of O
this O
study O
was O
to O
determine O
the O
role O
of O
synthesis/release O
of O
bradykinin O
to O
activate O
B2 O
receptors O
in O
disruption O
of O
the O
blood-brain O
barrier O
during O
acute O
hypertension. O
Permeability O
of O
the O
blood-brain O
barrier O
was O
quantitated O
by O
clearance O
of O
fluorescent-labeled O
dextran O
before O
and O
during O
phenylephrine-induced O
acute O
hypertension O
in O
rats O
treated O
with O
vehicle O
and O
Hoe-140 O
(0.1 O
microM). O
Phenylephrine O
infusion O
increased O
arterial O
pressure, O
arteriolar O
diameter O
and O
clearance O
of O
fluorescent O
dextran O
by O
a O
similar O
magnitude O
in O
both O
groups. O
These O
findings O
suggest O
that O
disruption O
of O
the O
blood-brain O
barrier O
during O
acute O
hypertension O
is O
not O
related O
to O
the O
synthesis/release O
of O
bradykinin O
to O
activate O
B2 O
receptors. O

It O
is O
well O
known O
that O
ceftriaxone O
leads O
to O
pseudolithiasis B
in O
some O
patients. O
Clinical O
and O
experimental O
studies O
also O
suggest O
that O
situations O
causing O
gallbladder B
dysfunction, I
such O
as O
fasting, O
may O
have O
a O
role O
for O
the O
development O
of O
pseudolithiasis. O
In O
this O
study, O
we O
prospectively O
evaluated O
the O
incidence O
and O
clinical O
importance O
of O
pseudolithiasis O
in O
paediatric O
surgical O
patients O
receiving O
ceftriaxone O
treatment, O
who O
often O
had O
to O
fast O
in O
the O
post-operative O
period. O
Fifty O
children O
who O
were O
given O
ceftriaxone O
were O
evaluated O
by O
serial O
abdominal O
sonograms. O
Of O
those, O
13 O
(26%) O
developed O
biliary O
pathology. O
Comparison O
of O
the O
patients O
with O
or O
without O
pseudolithiasis O
revealed O
no O
significant O
difference O
with O
respect O
to O
age, O
sex, O
duration O
of O
the O
treatment O
and O
starvation O
variables. O
After O
cessation O
of O
the O
treatment, O
pseudolithiasis O
resolved O
spontaneously O
within O
a O
short O
period. O
The O
incidence O
of O
pseudolithiasis O
is O
not O
affected O
by O
fasting. O

OBJECTIVES: O
Thrombotic B
microangiopathy I
is O
a O
well-known O
problem O
in O
patients O
following O
renal O
transplantation. O
In O
postrenal O
transplantation, O
thrombotic B
microangiopathy I
is O
often O
a O
reflection O
of O
hemolytic B
uremic I
syndrome. I
We O
aimed O
to O
determine O
the O
causes O
of O
thrombotic O
microangiopathy O
in O
a O
population O
of O
renal O
transplantation O
recipients O
and O
discuss O
the O
literature. O
MATERIALS O
AND O
METHODS: O
We O
investigated O
the O
causes O
of O
thrombotic O
microangiopathy O
during O
a O
1-year O
period, O
from O
June O
2003 O
to O
June O
2004, O
at O
the O
King O
Fahad O
National O
Guard O
Hospital O
in O
Riyadh, O
Saudi O
Arabia, O
by O
reviewing O
the O
slides O
of O
all O
transplant O
biopsies O
(n=25) O
performed O
during O
this O
interval. O
Pre- O
and O
posttransplant O
crossmatching O
was O
done O
when O
possible. O
RESULTS: O
Five O
cases O
of O
thrombotic O
microangiopathy O
were O
found. O
Three O
of O
these O
cases O
were O
from O
the O
25 O
transplantations O
performed O
at O
King O
Fahad O
National O
Guard O
Hospital, O
while O
the O
other O
2 O
transplantations O
had O
been O
performed O
abroad O
and O
were O
referred O
to O
us O
for O
follow-up. O
Three O
cases O
were O
related O
to O
cyclosporine, O
and O
1 O
case O
was O
secondary O
to O
both O
cyclosporine O
and O
tacrolimus. O
The O
fifth O
case O
had O
features O
of O
thrombotic O
microangiopathy O
related O
to O
an O
antiphospholipid B
syndrome I
in O
a O
patient O
with O
systemic B
lupus I
erythematosus. I
CONCLUSIONS: O
In O
the O
literature, O
the O
most-frequent O
cause O
of O
hemolytic O
uremic O
syndrome O
in O
patients O
following O
renal O
transplantation O
is O
recurrence O
of O
the O
hemolytic O
uremic O
syndrome. O
Other O
causes O
include O
drug-related O
(cyclosporine, O
tacrolimus) O
toxicity, B
procoagulant O
status, O
and O
antibody-mediated O
rejection. O
We O
found O
that O
the O
most-frequent O
cause O
of O
thrombotic O
microangiopathy O
was O
drug O
related, O
secondary O
mainly O
to O
cyclosporine. O
In O
the O
current O
study, O
the O
frequency O
of O
thrombotic O
microangiopathy O
was O
similar O
to O
the O
percentage O
reported O
in O
the O
literature O
(20%). O

A O
case O
is O
presented O
of O
a O
reversible O
intra-Hisian B
block I
occurring O
under O
amiodarone O
treatment O
for O
atrial B
tachycardia I
in O
a O
patient O
without O
clear O
intraventricular B
conduction I
abnormalities. I
His O
bundle O
recordings O
showed O
an O
atrial O
tachycardia O
with O
intermittent O
exit O
block O
and O
greatly O
prolonged O
BH O
and O
HV O
intervals O
(40 O
and O
100 O
msec, O
respectively). O
Thirty O
days O
after O
amiodarone O
discontinuation, O
His O
bundle O
electrograms O
showed O
atrial B
flutter I
without O
intra-Hisian O
or O
infra-Hisian O
delay. O
Amiodarone O
should O
be O
used O
with O
caution O
during O
long-term O
oral O
therapy O
in O
patients O
with O
or O
without O
clear O
intraventricular O
conduction O
defects. O

Haematological O
adverse O
reactions O
associated O
with O
fatal O
outcome O
are O
rare O
during O
treatment O
with O
ciprofloxacin. O
A O
30-year O
old O
Caucasian O
man O
reported O
with O
abdominal B
pain I
and O
jaundice B
after O
3-day O
administration O
of O
oral O
ciprofloxacin O
for O
a O
suspect O
of O
urinary B
tract I
infection. I
Clinical O
evaluations O
suggested O
an O
initial O
diagnosis O
of O
severe O
thrombocytopenia B
and O
haemolysis. B
The O
patient O
progressively O
developed O
petechiae B
and O
purpura B
on O
thorax O
and O
lower O
limbs. O
Despite O
pharmacological O
and O
supportive O
interventions, O
laboratory O
parameters O
worsened O
and O
the O
patient O
died O
17 O
hours O
after O
admission. O
An O
accurate O
autopsy O
revealed O
most O
organs O
with O
diffuse O
petechial O
haemorrhages. B
No O
signs O
of O
bone B
marrow I
depression I
were O
found. O
No O
thrombi B
or O
signs O
of O
microangiopathies B
were O
observed O
in O
arterial O
vessels. O
Blood O
and O
urine O
cultures O
did O
not O
show O
any O
bacterial O
growth. O
This O
case O
report O
shows O
that O
ciprofloxacin O
may O
precipitate O
life-threatening O
thrombocytopenia O
and O
haemolytic B
anaemia, I
even O
in O
the O
early O
phases O
of O
treatment O
and O
without O
apparent O
previous O
exposures. O

Previous O
research O
in O
this O
laboratory O
has O
shown O
that O
a O
diet O
of O
intermittent O
excessive O
sugar O
consumption O
produces O
a O
state O
with O
neurochemical O
and O
behavioral O
similarities O
to O
drug B
dependency. I
The O
present O
study O
examined O
whether O
female O
rats O
on O
various O
regimens O
of O
sugar O
access O
would O
show O
behavioral B
cross-sensitization I
to O
a O
low O
dose O
of O
amphetamine. O
After O
a O
30-min O
baseline O
measure O
of O
locomotor O
activity O
(day O
0), O
animals O
were O
maintained O
on O
a O
cyclic O
diet O
of O
12-h O
deprivation O
followed O
by O
12-h O
access O
to O
10% O
sucrose O
solution O
and O
chow O
pellets O
(12 O
h O
access O
starting O
4 O
h O
after O
onset O
of O
the O
dark O
period) O
for O
21 O
days. O
Locomotor O
activity O
was O
measured O
again O
for O
30 O
min O
at O
the O
beginning O
of O
days O
1 O
and O
21 O
of O
sugar O
access. O
Beginning O
on O
day O
22, O
all O
rats O
were O
maintained O
on O
ad O
libitum O
chow. O
Nine O
days O
later O
locomotor O
activity O
was O
measured O
in O
response O
to O
a O
single O
low O
dose O
of O
amphetamine O
(0.5 O
mg/kg). O
The O
animals O
that O
had O
experienced O
cyclic O
sucrose O
and O
chow O
were O
hyperactive B
in O
response O
to O
amphetamine O
compared O
with O
four O
control O
groups O
(ad O
libitum O
10% O
sucrose O
and O
chow O
followed O
by O
amphetamine O
injection, O
cyclic O
chow O
followed O
by O
amphetamine O
injection, O
ad O
libitum O
chow O
with O
amphetamine, O
or O
cyclic O
10% O
sucrose O
and O
chow O
with O
a O
saline O
injection). O
These O
results O
suggest O
that O
a O
diet O
comprised O
of O
alternating O
deprivation O
and O
access O
to O
a O
sugar O
solution O
and O
chow O
produces O
bingeing O
on O
sugar O
that O
leads O
to O
a O
long O
lasting O
state O
of O
increased O
sensitivity O
to O
amphetamine, O
possibly O
due O
to O
a O
lasting O
alteration O
in O
the O
dopamine O
system. O

Statins O
can O
cause O
a O
necrotizing O
myopathy B
and O
hyperCKaemia B
which O
is O
reversible O
on O
cessation O
of O
the O
drug. O
What O
is O
less O
well O
known O
is O
a O
phenomenon O
whereby O
statins O
may O
induce O
a O
myopathy, O
which O
persists O
or O
may O
progress O
after O
stopping O
the O
drug. O
We O
investigated O
the O
muscle O
pathology O
in O
8 O
such O
cases. O
All O
had O
myofibre O
necrosis B
but O
only O
3 O
had O
an O
inflammatory O
infiltrate. O
In O
all O
cases O
there O
was O
diffuse O
or O
multifocal O
up-regulation O
of O
MHC-I O
expression O
even O
in O
non-necrotic O
fibres. B
Progressive O
improvement O
occurred O
in O
7 O
cases O
after O
commencement O
of O
prednisolone O
and O
methotrexate, O
and O
in O
one O
case O
spontaneously. O
These O
observations O
suggest O
that O
statins O
may O
initiate O
an O
immune-mediated O
myopathy O
that O
persists O
after O
withdrawal O
of O
the O
drug O
and O
responds O
to O
immunosuppressive O
therapy. O
The O
mechanism O
of O
this O
myopathy O
is O
uncertain O
but O
may O
involve O
the O
induction O
by O
statins O
of O
an O
endoplasmic O
reticulum O
stress O
response O
with O
associated O
up-regulation O
of O
MHC-I O
expression O
and O
antigen O
presentation O
by O
muscle O
fibres. O

Hyperbaric O
oxygen O
therapy O
for O
control O
of O
intractable O
cyclophosphamide-induced O
hemorrhagic B
cystitis. B

Atypical B
sensations I
following O
the O
use O
of O
subcutaneous O
sumatriptan O
are O
common, O
but O
of O
uncertain O
origin. O
They O
are O
almost O
always O
benign, O
but O
can O
be O
mistaken O
for O
a O
serious O
adverse O
event O
by O
the O
patient. O
Two O
patients O
are O
presented O
with O
tingling B
or I
burning I
sensations I
limited O
to O
areas O
of O
heat O
exposure O
or O
sunburn. B
In O
these O
individuals, O
side O
effects O
are O
most O
likely O
generated O
superficially O
in O
the O
skin. O

The O
effect O
of O
a O
widely O
used O
organic O
solvent, O
polyethylene O
glycol O
400 O
(PEG O
400), O
on O
the O
toxic O
action O
of O
an O
acute O
or O
chronic O
treatment O
with O
adriamycin O
(ADR) O
was O
evaluated O
in O
mice. O
PEG O
400 O
impressively O
decreased O
both O
acute O
high-dose O
and O
chronic O
low-dose-ADR-associated O
lethality. O
Light O
microscopic O
analysis O
showed O
a O
significant O
protection O
against O
ADR-induced O
cardiac B
morphological I
alterations. I
Such O
treatment O
did O
not O
diminish O
the O
ADR O
antitumor O
activity O
in O
L1210 B
leukemia I
and O
in O
Ehrlich B
ascites I
tumor. I

Twenty-three O
hours O
after O
heart O
transplantation, O
life-threatening O
acute O
right B
heart I
failure I
was O
diagnosed O
in O
a O
patient O
requiring O
continuous O
venovenous O
hemodiafiltration O
(CVVHDF). O
Increasing O
doses O
of O
catecholamines, O
sedatives, O
and O
muscle O
relaxants O
administered O
through O
a O
central O
venous O
catheter O
were O
ineffective. O
However, O
a O
bolus O
of O
epinephrine O
injected O
through O
an O
alternative O
catheter O
provoked O
a O
hypertensive B
crisis. O
Thus, O
interference O
with O
the O
central O
venous O
infusion O
by O
the O
dialysis O
catheter O
was O
suspected. O
The O
catheters O
were O
changed, O
and O
hemodynamics O
stabilized O
at O
lower O
catecholamine O
doses. O
When O
the O
effects O
of O
IV O
drugs O
are O
inadequate O
in O
patients O
receiving O
CVVHDF, O
interference O
with O
adjacent O
catheters O
resulting O
in O
elimination O
of O
the O
drug O
by O
CVVHDF O
should O
be O
suspected. O

Doxorubicin O
is O
an O
effective O
anticancer O
chemotherapeutic B
agent O
known O
to O
cause O
acute O
and O
chronic O
cardiomyopathy. B
To O
develop O
a O
more O
sensitive O
echocardiographic O
screening O
test O
for O
cardiac B
damage I
due O
to O
doxorubicin, O
a O
cohort O
study O
was O
performed O
using O
dobutamine O
infusion O
to O
differentiate O
asymptomatic O
long-term O
survivors O
of O
childhood O
cancer O
treated O
with O
doxorubicin O
from O
healthy O
control O
subjects. O
Echocardiographic O
data O
from O
the O
experimental O
group O
of O
21 O
patients O
(mean O
age O
16 O
+/- O
5 O
years) O
treated O
from O
1.6 O
to O
14.3 O
years O
(median O
5.3) O
before O
this O
study O
with O
27 O
to O
532 O
mg/m2 O
of O
doxorubicin O
(mean O
196) O
were O
compared O
with O
echocardiographic O
data O
from O
12 O
normal O
age-matched O
control O
subjects. O
Graded O
dobutamine O
infusions O
of O
0.5, O
2.5, O
5 O
and O
10 O
micrograms/kg O
per O
min O
were O
administered. O
Echocardiographic O
Doppler O
studies O
were O
performed O
before O
infusion O
and O
after O
15 O
min O
of O
infusion O
at O
each O
rate. O
Dobutamine O
infusion O
at O
10 O
micrograms/kg O
per O
min O
was O
discontinued O
after O
six O
studies O
secondary O
to O
a O
50% O
incidence O
rate O
of O
adverse O
symptoms. O
The O
most O
important O
findings O
were O
that O
compared O
with O
values O
in O
control O
subjects, O
end-systolic O
left O
ventricular O
posterior O
wall O
dimension O
and O
percent O
of O
left O
ventricular O
posterior O
wall O
thickening O
in O
doxorubicin-treated O
patients O
were O
decreased O
at O
baseline O
study O
and O
these O
findings O
were O
more O
clearly O
delineated O
with O
dobutamine O
stimulation. O
End-systolic O
left O
ventricular O
posterior O
wall O
dimension O
at O
baseline O
for O
the O
doxorubicin-treated O
group O
was O
11 O
+/- O
1.9 O
mm O
versus O
13.1 O
+/- O
1.5 O
mm O
for O
control O
subjects O
(p O
less O
than O
0.01). O
End-systolic O
left O
ventricular O
posterior O
wall O
dimension O
at O
the O
5-micrograms/kg O
per O
min O
dobutamine O
infusion O
for O
the O
doxorubicin-treated O
group O
was O
14.1 O
+/- O
2.4 O
mm O
versus O
19.3 O
+/- O
2.6 O
mm O
for O
control O
subjects O
(p O
less O
than O
0.01).(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

In O
this O
study, O
we O
investigated O
the O
therapeutic O
potential O
of O
bone O
marrow O
mononuclear O
cells O
(BMCs) O
in O
a O
model O
of O
epilepsy B
induced O
by O
pilocarpine O
in O
rats. O
BMCs O
obtained O
from O
green O
fluorescent O
protein O
(GFP) O
transgenic O
mice O
or O
rats O
were O
transplanted O
intravenously O
after O
induction O
of O
status B
epilepticus B
(SE). O
Spontaneous B
recurrent I
seizures B
(SRS) O
were B
monitored O
using O
Racine's O
seizure O
severity O
scale. O
All O
of O
the O
rats O
in O
the O
saline-treated O
epileptic O
control O
group O
developed O
SRS, O
whereas O
none O
of O
the O
BMC-treated O
epileptic O
animals O
had O
seizures O
in O
the O
short O
term O
(15 O
days O
after O
transplantation), O
regardless O
of O
the O
BMC O
source. O
Over O
the O
long-term O
chronic O
phase O
(120 O
days O
after O
transplantation), O
only O
25% O
of O
BMC-treated O
epileptic O
animals O
had O
seizures, O
but O
with O
a O
lower O
frequency O
and O
duration O
compared O
to O
the O
epileptic O
control O
group. O
The O
density O
of O
hippocampal O
neurons O
in O
the O
brains O
of O
animals O
treated O
with O
BMCs O
was O
markedly O
preserved. O
At O
hippocampal O
Schaeffer O
collateral-CA1 O
synapses, O
long-term O
potentiation O
was O
preserved O
in O
BMC-transplanted O
rats O
compared O
to O
epileptic O
controls. O
The O
donor-derived O
GFP(+) O
cells O
were O
rarely O
found O
in O
the O
brains O
of O
transplanted O
epileptic O
rats. O
In O
conclusion, O
treatment O
with O
BMCs O
can O
prevent O
the O
development O
of O
chronic O
seizures, O
reduce O
neuronal B
loss, I
and O
influence O
the O
reorganization O
of O
the O
hippocampal O
neuronal O
network. O

A O
patient O
who O
allegedly O
consumed O
100 O
tablets O
of O
an O
over-the-counter O
analgesic O
containing O
sodium O
acetylsalicylate, O
caffeine, O
and O
acetaminophen O
displayed O
no O
significant O
CNS O
stimulation O
despite O
the O
presence O
of O
175 O
micrograms O
of O
caffeine O
per O
mL O
of O
serum. O
Because O
salicylates O
have O
been O
reported O
to O
augment O
the O
stimulatory O
effects O
of O
caffeine O
on O
the O
CNS, O
attention O
was O
focused O
on O
the O
possibility O
that O
the O
presence O
of O
acetaminophen O
(52 O
micrograms/mL) O
reduced O
the O
CNS O
toxicity B
of O
caffeine. O
Studies O
in O
DBA/2J O
mice O
showed O
that: O
1) O
pretreatment O
with O
acetaminophen O
(100 O
mg/kg) O
increased O
the O
interval O
between O
the O
administration O
of O
caffeine O
(300 O
to O
450 O
mg/kg O
IP) O
and O
the O
onset O
of O
fatal O
convulsions B
by O
a O
factor O
of O
about O
two; O
and O
2) O
pretreatment O
with O
acetaminophen O
(75 O
mg/kg) O
reduced O
the O
incidence O
of O
audiogenic O
seizures B
produced O
in O
the O
presence O
of O
caffeine O
(12.5 O
to O
75 O
mg/kg O
IP). O
The O
frequency O
of O
sound-induced O
seizures O
after O
12.5 O
or O
25 O
mg/kg O
caffeine O
was O
reduced O
from O
50 O
to O
5% O
by O
acetaminophen. O
In O
the O
absence O
of O
caffeine, O
acetaminophen O
(up O
to O
300 O
mg/kg) O
did O
not O
modify O
the O
seizures O
induced O
by O
maximal O
electroshock O
and O
did O
not O
alter O
the O
convulsant O
dose O
of O
pentylenetetrezol O
in O
mice O
(tests O
performed O
by O
the O
Anticonvulsant O
Screening O
Project O
of O
NINCDS). O
Acetaminophen O
(up O
to O
150 O
micrograms/mL) O
did O
not O
retard O
the O
incorporation O
of O
radioactive O
adenosine O
into O
ATP O
in O
slices O
of O
rat O
cerebral O
cortex. O
Thus O
the O
mechanism O
by O
which O
acetaminophen O
antagonizes O
the O
actions O
of O
caffeine O
in O
the O
CNS O
remains O
unknown. O

The O
anatomical O
and O
aetiological O
diagnoses O
of O
peripheral B
nerve I
disease I
excluding O
its O
primary O
benign O
and O
malignant O
disorders, O
as O
seen O
in O
358 O
Nigerians O
are O
presented. O
There O
is O
a O
male O
preponderance O
and O
the O
peak O
incidence O
is O
in O
the O
fourth O
decade. O
Sensori-motor B
neuropathy B
was I
the O
commonest O
presentation O
(50%). O
Guillain-Barr B
syndrome I
was O
the O
commonest O
identifiable O
cause O
(15.6%), O
accounting O
for O
half O
of O
the O
cases O
with O
motor O
neuropathy. O
Peripheral B
neuropathy I
due O
to O
nutritional B
deficiency I
of O
thiamine O
and O
riboflavin O
was O
common O
(10.1%) O
and O
presented O
mainly O
as O
sensory O
and O
sensori-motor B
neuropathy. I
Diabetes B
mellitus I
was O
the O
major O
cause O
of O
autonomic B
neuropathy. I
Isoniazid O
was O
the O
most O
frequent O
agent O
in O
drug-induced O
neuropathy. O
Migraine B
(20%) O
was O
not O
an O
uncommon O
cause O
of O
cranial B
neuropathy I
although O
malignancies B
arising O
from O
the O
reticuloendothelial O
system O
or O
related O
structures O
of O
the O
head O
and O
neck O
were O
more O
frequent O
(26%). O
In O
26.5% O
of O
all O
the O
cases, O
the O
aetiology O
of O
the O
neuropathy O
was O
undetermined. O
Heredofamilial O
and O
connective B
tissue I
disorders I
were O
rare. O
Some O
of O
the O
factors O
related O
to O
the O
clinical O
presentation O
and O
pathogenesis O
of O
the O
neuropathies B
are O
briefly O
discussed. O

A O
case O
is O
reported O
of O
the O
hemolytic B
uremic I
syndrome I
(HUS) O
in B
a O
woman O
taking O
oral O
contraceptives. O
She O
was O
treated O
with O
heparin, O
dipyridamole O
and O
hemodialysis; O
and O
after O
more O
than O
three O
months, O
her O
urinary O
output O
rose O
above O
500 O
ml; O
and O
six O
months O
after O
the O
onset O
of O
anuria, B
dialysis O
treatment O
was O
stopped. O
This O
case O
emphasizes O
the O
possibility O
that O
HUS O
in O
adults O
is O
not O
invariably O
irreversible O
and O
that, O
despite O
prolonged O
oliguria, B
recovery O
of O
renal O
function O
can O
be O
obtained. O
Therefore, O
in O
adult O
patients O
affected O
by O
HUS, O
dialysis O
should O
not O
be O
discontinued O
prematurely; O
moreover, O
bilateral O
nephrectomy, O
for O
treatment O
of O
severe O
hypertension B
and O
microangiopathic B
hemolytic I
anemia, I
should O
be O
performed O
with O
caution. O

Curcumin O
ameliorates O
cognitive B
dysfunction I
and O
oxidative O
damage O
in O
phenobarbitone O
and O
carbamazepine O
administered O
rats. O

BACKGROUND: O
The O
widespread O
use O
of O
benzodiazepines O
has O
led O
to O
increasing O
recognition O
of O
their O
unwanted O
effects. O
The O
efficacy O
of O
alprazolam O
and O
placebo O
in O
panic B
disorder I
with O
agoraphobia, B
and O
the O
side-effect O
and O
adverse O
effect O
profiles O
of O
both O
drug O
groups O
were O
measured. O
METHOD: O
In O
London O
and O
Toronto O
154 O
patients O
who O
met O
DSM-III O
criteria O
for O
panic O
disorder O
with O
agoraphobia O
were O
randomised O
to O
alprazolam O
or O
placebo. O
Subjects O
in O
each O
drug O
group O
also O
received O
either O
exposure O
or O
relaxation. O
Treatment O
was O
from O
weeks O
0 O
to O
8 O
and O
was O
then O
tapered O
from O
weeks O
8 O
to O
16. O
RESULTS: O
Mean O
alprazolam O
dose O
was O
5 O
mg O
daily. O
Compared O
with O
placebo O
subjects, O
alprazolam O
patients O
developed O
more O
adverse O
reactions O
(21% O
v. O
0%) O
of O
depression, B
enuresis, B
disinhibition O
and O
aggression; B
and O
more O
side-effects, O
particularly O
sedation, O
irritability, B
impaired B
memory, I
weight B
loss I
and O
ataxia. B
Side-effects O
tended O
to O
diminish O
during O
treatment O
but O
remained O
significant O
at O
week O
8. O
Despite O
this, O
the O
drop-out O
rate O
was O
low. O
CONCLUSIONS: O
Alprazolam O
caused O
side-effects O
and O
adverse O
effects O
during O
treatment O
but O
many O
patients O
were O
willing O
to O
accept O
these. O

A O
patient O
who O
received O
antithymocyte O
globulin O
therapy O
for O
aplastic B
anemia I
due O
to O
D-penicillamine O
therapy O
is O
described. O
Bone O
marrow O
recovery O
and O
peripheral O
blood O
recovery O
were O
complete O
1 O
month O
and O
3 O
months, O
respectively, O
after O
treatment, O
and O
blood O
transfusion O
or O
other O
therapies O
were O
not O
necessary O
in O
a O
follow-up O
period O
of O
more O
than O
2 O
years. O
Use O
of O
antithymocyte O
globulin O
may O
be O
the O
optimal O
treatment O
of O
D-penicillamine-induced O
aplastic O
anemia. O

BACKGROUND/AIMS: O
It O
is O
still O
unclear O
what O
happens O
in O
the O
glomerulus O
when O
proteinuria B
starts. O
Using O
puromycin O
aminonucleoside O
nephrosis B
(PAN) O
rats, O
we O
studied O
early O
ultrastructural O
and O
permeability O
changes O
in O
relation O
to O
the O
expression O
of O
the O
podocyte-associated O
molecules O
nephrin, O
a-actinin, O
dendrin, O
and O
plekhh2, O
the O
last O
two O
of O
which O
were O
only O
recently O
discovered O
in O
podocytes. O
METHODS: O
Using O
immune O
stainings, O
semiquantitative O
measurement O
was O
performed O
under O
the O
electron O
microscope. O
Permeability O
was O
assessed O
using O
isolated O
kidney O
perfusion O
with O
tracers. O
Possible O
effects O
of O
ACE O
inhibition O
were O
tested. O
RESULTS: O
By O
day O
2, O
some O
patchy O
foot O
process O
effacement, O
but O
no O
proteinuria, O
appeared. O
The O
amount O
of O
nephrin O
was O
reduced O
in O
both O
diseased O
and O
normal O
areas. O
The O
other O
proteins O
showed O
few O
changes, O
which O
were O
limited O
to O
diseased O
areas. O
By O
day O
4, O
foot O
process O
effacement O
was O
complete O
and O
proteinuria O
appeared O
in O
parallel O
with O
signs O
of O
size O
barrier O
damage. O
Nephrin O
decreased O
further, O
while O
dendrin O
and O
plekhh2 O
also O
decreased O
but O
a-actinin O
remained O
unchanged. O
ACE O
inhibition O
had O
no O
significant O
protective O
effect. O
CONCLUSIONS: O
PAN O
glomeruli O
already O
showed O
significant O
pathology O
by O
day O
4, O
despite O
relatively O
mild O
proteinuria. O
This O
was O
preceded O
by O
altered O
nephrin O
expression, O
supporting O
its O
pivotal O
role O
in O
podocyte O
morphology. O
The O
novel O
proteins O
dendrin O
and O
plekhh2 O
were O
both O
reduced, O
suggesting O
roles O
in O
PAN, O
whereas O
a-actinin O
was O
unchanged. O

OBJECTIVE: O
A O
case O
of O
acute O
myocarditis B
associated O
with O
the O
commencement O
of O
clozapine O
is O
described, O
highlighting O
the O
onset, O
course O
and O
possible O
contributing O
factors. O
There O
is O
an O
urgent O
need O
to O
raise O
awareness O
about O
this O
potentially O
fatal O
complication O
of O
clozapine O
use. O
RESULTS: O
A O
20-year-old O
male O
with O
schizophrenia B
developed O
a O
sudden O
onset O
of O
myocarditis O
after O
commencement O
of O
clozapine. O
The O
patient O
recovered O
with O
intensive O
medical O
support. O
The O
symptoms O
occurred O
around O
2 O
weeks O
after O
starting O
clozapine O
in O
an O
inpatient O
setting. O
Possible O
contributing O
factors O
may O
have O
been O
concomitant O
antidepressant O
use O
and O
unaccustomed O
physical O
activity. O
CONCLUSIONS: O
Myocarditis B
is O
an O
increasingly O
recognized O
complication O
associated O
with O
the O
use O
of O
clozapine. O
It O
can O
be O
fatal O
if O
not O
recognized O
and O
treated O
early. O
Considering O
that O
clozapine O
remains O
the O
gold O
standard O
in O
treatment O
of O
resistant O
psychosis, B
there O
is O
an O
urgent O
need O
to O
raise O
awareness O
among O
medical O
and O
paramedical O
staff O
involved O
in O
the O
care O
of O
these O
patients. O
There O
are O
also O
implications O
for O
recommendations O
and O
regulations O
regarding O
the O
use O
of O
clozapine. O

Rats O
with O
lithium-induced O
nephropathy B
were O
subjected O
to O
high O
protein O
(HP) O
feeding, O
uninephrectomy O
(NX) O
or O
a O
combination O
of O
these, O
in O
an O
attempt O
to O
induce O
glomerular O
hyperfiltration O
and O
further O
progression O
of O
renal B
failure. I
Newborn O
female O
Wistar O
rats O
were O
fed O
a O
lithium-containing O
diet O
(50 O
mmol/kg) O
for O
8 O
weeks O
and O
then O
randomized O
to O
normal O
diet, O
HP O
diet O
(40 O
vs. O
19%), O
NX O
or O
HP+NX O
for O
another O
8 O
weeks. O
Corresponding O
non-lithium O
pretreated O
groups O
were O
generated. O
When O
comparing O
all O
lithium O
treated O
versus O
non-lithium-treated O
groups, O
lithium O
caused O
a O
reduction O
in O
glomerular O
filtration O
rate O
(GFR) O
without O
significant O
changes O
in O
effective O
renal O
plasma O
flow O
(as O
determined O
by O
a O
marker O
secreted O
into O
the O
proximal O
tubules) O
or O
lithium O
clearance. O
Consequently, O
lithium O
pretreatment O
caused O
a O
fall O
in O
filtration O
fraction O
and O
an O
increase O
in O
fractional O
Li O
excretion. O
Lithium O
also O
caused O
proteinuria B
and O
systolic O
hypertension B
in O
absence O
of O
glomerulosclerosis. B
HP O
failed O
to O
accentuante O
progression O
of O
renal O
failure O
and O
in O
fact O
tended O
to O
increase O
GFR O
and O
decrease O
plasma O
creatinine O
levels O
in O
lithium O
pretreated O
rats. O
NX O
caused O
an O
additive O
deterioration O
in O
GFR O
which, O
however, O
was O
ameliorated O
by O
HP. O
NX+HP O
caused O
a O
further O
rise O
in O
blood O
pressure O
in O
Li-pretreated O
rats. O
The O
results O
indicate O
that O
Li-induced O
nephropathy, O
even O
when O
the O
GFR O
is O
only O
modestly O
reduced, O
is O
associated O
with O
proteinuria O
and O
arterial O
systolic O
hypertension. O
In O
this O
model O
of O
chronic B
renal I
failure I
the O
decline O
in O
GFR O
is O
not O
accompanied O
by O
a O
corresponding O
fall O
in O
effective O
renal O
plasma O
flow, O
which O
may O
be O
the O
functional O
expression O
of O
the O
formation O
of O
nonfiltrating O
atubular O
glomeruli. O
The O
fractional O
reabsorption O
of O
tubular O
fluid O
by O
the O
proximal O
tubules O
is O
reduced, O
leaving O
the O
distal O
delivery O
unchanged.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

Mechanisms O
of O
FK O
506-induced O
hypertension B
in O
the O
rat. O

Central B
nervous I
system I
complications I
during O
treatment O
of O
acute B
lymphoblastic I
leukemia I
in O
a O
single O
pediatric O
institution. O

Azathioprine O
treatment O
benefited O
19 O
(66%) O
out O
of O
29 O
patients O
suffering O
from O
severe O
psoriasis. B
Haematological O
complications O
were O
not O
troublesome O
and O
results O
of O
biochemical O
liver O
function O
tests O
remained O
normal. O
Minimal O
cholestasis B
was O
seen O
in O
two O
cases O
and O
portal O
fibrosis B
of O
a O
reversible O
degree O
in O
eight. O
Liver O
biopsies O
should O
be O
undertaken O
at O
regular O
intervals O
if O
azathioprine O
therapy O
is O
continued O
so O
that O
structural O
liver B
damage I
may O
be O
detected O
at O
an O
early O
and O
reversible O
stage. O

Propylthiouracil-induced O
perinuclear-staining O
antineutrophil O
cytoplasmic O
autoantibody-positive O
vasculitis B
in O
conjunction O
with O
pericarditis. B

Antidepressant-induced O
mania B
in O
bipolar B
patients: O
identification O
of O
risk O
factors. O

Three O
infants, O
born O
of O
two O
mothers O
with O
inflammatory B
bowel I
disease I
who O
received O
treatment O
with O
sulphasalazine O
throughout O
pregnancy, O
were O
found O
to O
have O
major O
congenital B
anomalies. I
In O
the O
singleton O
pregnancy, O
the O
mother O
had O
ulcerative B
colitis, I
and O
the O
infant, O
a O
male, O
had O
coarctation B
of I
the I
aorta I
and O
a O
ventricular B
septal I
defect. I
In O
the O
twin O
pregnancy, O
the O
mother O
had O
Crohn's B
disease. I
The O
first O
twin, O
a O
female, O
had O
a O
left O
Potter-type B
IIa I
polycystic I
kidney I
and O
a O
rudimentary B
left I
uterine I
cornu. I
The O
second O
twin, O
a O
male, O
had O
some O
features O
of O
Potter's B
facies, I
hypoplastic B
lungs, I
absent B
kidneys I
and I
ureters, I
and O
talipes B
equinovarus. I
Despite O
reports O
to O
the O
contrary, O
it O
is O
suggested O
that O
sulphasalazine O
may O
be O
teratogenic. O

It O
has O
been O
shown O
that O
bromocriptine-induced O
tachycardia, B
which O
persisted O
after O
adrenalectomy, O
is O
(i) O
mediated O
by O
central O
dopamine O
D2 O
receptor O
activation O
and O
(ii) O
reduced O
by O
5-day O
isoproterenol O
pretreatment, O
supporting O
therefore O
the O
hypothesis O
that O
this O
effect O
is O
dependent O
on O
sympathetic O
outflow O
to O
the O
heart. O
This O
study O
was O
conducted O
to O
examine O
whether O
prolonged O
pretreatment O
with O
isoproterenol O
could O
abolish O
bromocriptine-induced O
tachycardia O
in O
conscious O
rats. O
Isoproterenol O
pretreatment O
for O
15 O
days O
caused O
cardiac B
hypertrophy I
without O
affecting O
baseline O
blood O
pressure O
and O
heart O
rate. O
In O
control O
rats, O
intravenous O
bromocriptine O
(150 O
microg/kg) O
induced O
significant O
hypotension B
and O
tachycardia. O
Bromocriptine-induced O
hypotension O
was O
unaffected O
by O
isoproterenol O
pretreatment, O
while O
tachycardia O
was O
reversed O
to O
significant O
bradycardia, B
an O
effect O
that O
was O
partly O
reduced O
by O
i.v. O
domperidone O
(0.5 O
mg/kg). O
Neither O
cardiac O
vagal O
nor O
sympathetic O
tone O
was O
altered O
by O
isoproterenol O
pretreatment. O
In O
isolated O
perfused O
heart O
preparations O
from O
isoproterenol-pretreated O
rats, O
the O
isoproterenol-induced O
maximal O
increase O
in O
left O
ventricular O
systolic O
pressure O
was O
significantly O
reduced, O
compared O
with O
saline-pretreated O
rats O
(the O
EC50 O
of O
the O
isoproterenol-induced O
increase O
in O
left O
ventricular O
systolic O
pressure O
was O
enhanced O
approximately O
22-fold). O
These O
results O
show O
that O
15-day O
isoproterenol O
pretreatment O
not O
only O
abolished O
but O
reversed O
bromocriptine-induced O
tachycardia O
to O
bradycardia, O
an O
effect O
that O
is O
mainly O
related O
to O
further O
cardiac O
beta-adrenoceptor O
desensitization O
rather O
than O
to O
impairment O
of O
autonomic O
regulation O
of O
the O
heart. O
They O
suggest O
that, O
in O
normal O
conscious O
rats, O
the O
central O
tachycardia O
of O
bromocriptine O
appears O
to O
predominate O
and O
to O
mask O
the O
bradycardia O
of O
this O
agonist O
at O
peripheral O
dopamine O
D2 O
receptors. O

Cerebral B
infarction I
with O
a O
single O
oral O
dose O
of O
phenylpropanolamine. O

Intracavernous O
epinephrine: O
a O
minimally O
invasive O
treatment O
for O
priapism B
in O
the O
emergency O
department. O

Assessment O
of O
a O
new O
non-invasive O
index O
of O
cardiac O
performance O
for O
detection O
of O
dobutamine-induced O
myocardial B
ischemia. I

We O
have O
described O
a O
unique O
patient O
who O
had O
reversible O
and O
dose-related O
myasthenia B
gravis I
after O
penicillamine O
and O
chloroquine O
therapy O
for O
rheumatoid B
arthritis. I
Although O
acetylcholine O
receptor O
antibodies O
were O
not O
detectable, O
the O
time O
course O
was O
consistent O
with O
an O
autoimmune O
process. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
neurologic O
consequences O
of O
deliberate O
subarachnoid O
injection O
of O
large O
volumes O
of O
2-chloroprocaine-CE O
in O
experimental O
animals. O
The O
possible O
role O
of O
low O
pH O
as O
well O
as O
total O
volume O
as O
potential O
factors O
in O
causing O
neurotoxicity B
was O
evaluated. O
The O
65 O
dogs O
in O
the O
study O
received O
injections O
in O
the O
subarachnoid O
space O
as O
follows: O
6 O
to O
8 O
ml O
of O
bupivacaine O
(N O
= O
15), O
2-chloroprocaine-CE O
(N O
= O
20), O
low O
pH O
normal O
saline O
(pH O
3.0) O
(N O
= O
20), O
or O
normal O
saline O
(N O
= O
10). O
Of O
the O
20 O
animals O
that O
received O
subarachnoid O
injection O
of O
2-chloroprocaine-CE O
seven O
(35%) O
developed O
hind-limb O
paralysis. B
None O
of O
the O
animals O
that O
received O
bupivacaine, O
normal O
saline, O
or O
normal O
saline O
titrated O
to O
a O
pH O
3.0 O
developed O
hind-limb O
paralysis. O
Of O
the O
15 O
spinal O
cords O
of O
the O
animals O
that O
received O
2-chloroprocaine-CE, O
13 O
showed O
subpial B
necrosis; I
the O
nerve O
roots O
and O
subarachnoid O
vessels O
were O
normal. O
The O
spinal O
cords O
of O
the O
animals O
that O
received O
bupivacaine, O
low O
pH O
normal O
saline O
(pH O
3.0), O
or O
normal O
saline O
did O
not O
show O
abnormal O
findings. O

The O
effect O
of O
humoral O
modulators O
on O
the O
morphine-induced O
increase B
in I
locomotor I
activity I
of O
mice O
was O
studied. O
The O
subcutaneous O
administration O
of O
10 O
mg/kg O
of O
morphine-HC1 O
produced O
a O
marked O
increase O
in O
locomotor O
activity O
in O
mice. O
The O
morphine-induced O
hyperactivity B
was O
potentiated O
by O
scopolamine O
and O
attenuated O
by O
physostigmine. O
In O
contrast, O
both O
methscopolamine O
and O
neostigmine, O
which O
do O
not O
penetrate O
the O
blood-brain O
barrier, O
had O
no O
effect O
on O
the O
hyperactivity O
produced O
by O
morphine. O
Pretreatment O
of O
mice O
with O
alpha-methyltyrosine O
(20 O
mg/kg O
i.p., O
one O
hour), O
an O
inhibitor O
of O
tyrosine O
hydroxylase, O
significantly O
decreased O
the O
activity-increasing O
effects O
of O
morphine. O
On O
the O
other O
hand, O
pretreatment O
with O
p-chlorophenylalamine O
(3 O
X O
320 O
mg/kg O
i.p., O
24 O
hr), O
a O
serotonin O
depletor, O
caused O
no O
significant O
change O
in O
the O
hyperactivity. O
The O
study O
suggests O
that O
the O
activity-increasing O
effects O
of O
morphine O
are O
mediated O
by O
the O
release O
of O
catecholamines O
from O
adrenergic O
neurons O
in O
the O
brain. O
And O
the O
results O
are O
consistent O
with O
the O
hypothesis O
that O
morphine O
acts O
by O
retarding O
the O
release O
of O
acetylcholine O
at O
some O
central O
cholinergic O
synapses. O
It O
is O
also O
suggested O
from O
collected O
evidence O
that O
the O
activity-increasing O
effects O
of O
morphine O
in O
mice O
are O
mediated O
by O
mechanisms O
different O
from O
those O
which O
mediate O
the O
activity-increasing O
effects O
of O
morphine O
in O
rats. O

BACKGROUND: O
Hydrochlorofluorocarbons O
(HCFCs) O
are O
used O
increasingly O
in O
industry O
as O
substitutes O
for O
ozone-depleting O
chlorofluorocarbons O
(CFCs). O
Limited O
studies O
in O
animals O
indicate O
potential O
hepatotoxicity B
of O
some O
of O
these O
compounds. O
We O
investigated O
an O
epidemic O
of O
liver B
disease I
in O
nine O
industrial O
workers O
who O
had O
had O
repeated O
accidental O
exposure O
to O
a O
mixture O
of O
1,1-dichloro-2,2,2-trifluoroethane O
(HCFC O
123) O
and O
1-chloro-1,2,2,2-tetrafluoroethane O
(HCFC O
124). O
All O
nine O
exposed O
workers O
were O
affected O
to O
various O
degrees. O
Both O
compounds O
are O
metabolised O
in O
the O
same O
way O
as O
1-bromo-1-chloro-2,2,2-trifluoroethane O
(halothane) O
to O
form O
reactive O
trifluoroacetyl O
halide O
intermediates, O
which O
have O
been O
implicated O
in O
the O
hepatotoxicity O
of O
halothane. O
We O
aimed O
to O
test O
whether O
HCFCs O
123 O
and O
124 O
can O
result O
in O
serious O
liver O
disease. O
METHODS: O
For O
one O
severely O
affected O
worker O
liver O
biopsy O
and O
immunohistochemical O
stainings O
for O
the O
presence O
of O
trifluoroacetyl O
protein O
adducts O
were O
done. O
The O
serum O
of O
six O
affected O
workers O
and O
five O
controls O
was O
tested O
for O
autoantibodies O
that O
react O
with O
human O
liver O
cytochrome-P450 O
2E1 O
(P450 O
2E1) O
and O
P58 O
protein O
disulphide O
isomerase O
isoform O
(P58). O
FINDINGS: O
The O
liver O
biopsy O
sample O
showed O
hepatocellular O
necrosis B
which O
was O
prominent O
in O
perivenular O
zone O
three O
and O
extended O
focally O
from O
portal O
tracts O
to O
portal O
tracts O
and O
centrilobular O
areas O
(bridging O
necrosis). O
Trifluoroacetyl-adducted O
proteins O
were O
detected O
in O
surviving O
hepatocytes. O
Autoantibodies O
against O
P450 O
2E1 O
or O
P58, O
previously O
associated O
with O
halothane B
hepatitis, I
were O
detected O
in O
the O
serum O
of O
five O
affected O
workers. O
INTERPRETATION: O
Repeated O
exposure O
of O
human O
beings O
to O
HCFCs O
123 O
and O
124 O
can O
result O
in O
serious O
liver B
injury I
in O
a O
large O
proportion O
of O
the O
exposed O
population. O
Although O
the O
exact O
mechanism O
of O
hepatotoxicity O
of O
these O
agents O
is O
not O
known, O
the O
results O
suggest O
that O
trifluoroacetyl-altered O
liver O
proteins O
are O
involved. O
In O
view O
of O
the O
potentially O
widespread O
use O
of O
these O
compounds, O
there O
is O
an O
urgent O
need O
to O
develop O
safer O
alternatives. O

Intravenous O
administration O
of O
a O
single O
50-mg O
bolus O
of O
lidocaine O
in O
a O
67-year-old O
man O
resulted O
in O
profound O
depression B
of O
the O
activity O
of O
the O
sinoatrial O
and O
atrioventricular O
nodal O
pacemakers. O
The O
patient O
had O
no O
apparent O
associated O
conditions O
which O
might O
have O
predisposed O
him O
to O
the O
development O
of O
bradyarrhythmias; B
and, O
thus, O
this O
probably O
represented O
a O
true O
idiosyncrasy O
to O
lidocaine. O

Repetitive O
transcranial O
magnetic O
stimulation O
for O
levodopa-induced O
dyskinesias B
in O
Parkinson's B
disease. I

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
influence O
of O
calcium O
channel O
blockers O
on O
bupivacaine-induced O
acute O
toxicity. B
For O
each O
of O
the O
three O
tested O
calcium O
channel O
blockers O
(diltiazem, O
verapamil O
and O
bepridil) O
6 O
groups O
of O
mice O
were O
treated O
by O
two O
different O
doses, O
i.e. O
2 O
and O
10 O
mg/kg/i.p., O
or O
an O
equal O
volume O
of O
saline O
for O
the O
control O
group O
(n O
= O
20); O
15 O
minutes O
later, O
all O
the O
animals O
were O
injected O
with O
a O
single O
50 O
mg/kg/i.p. O
dose O
of O
bupivacaine. O
The O
convulsant O
activity, O
the O
time O
of O
latency O
to O
convulse O
and O
the O
mortality O
rate O
were O
assessed O
in O
each O
group. O
The O
local O
anesthetic-induced O
mortality O
was O
significantly O
increased O
by O
the O
three O
different O
calcium O
channel O
blockers. O
The O
convulsant O
activity O
of O
bupivacaine O
was O
not O
significantly O
modified O
but O
calcium O
channel O
blockers O
decreased O
the O
time O
of O
latency O
to O
obtain O
bupivacaine-induced O
convulsions; B
this O
effect O
was O
less O
pronounced O
with O
bepridil. O

Verapamil-induced O
carbamazepine O
neurotoxicity. B
A O
report O
of O
two O
cases. O

Differential O
modulation O
by O
estrogen O
of O
alpha2-adrenergic O
and O
I1-imidazoline O
receptor-mediated O
hypotension B
in O
female O
rats. O

Effects O
of O
pallidal O
neurotensin O
on O
haloperidol-induced O
parkinsonian B
catalepsy: I
behavioral O
and O
electrophysiological O
studies. O

The O
pathophysiology O
of O
painful B
temporomandibular B
disorders I
is O
not O
fully O
understood, O
but O
evidence O
suggests O
that O
muscle B
pain I
modulates O
motor O
function O
in O
characteristic O
ways. O
This O
study O
tested O
the O
hypothesis O
that O
activation O
of O
nociceptive B
muscle I
afferent O
fibers O
would O
be O
linked O
to O
an O
increased O
excitability O
of O
the O
human O
jaw-stretch O
reflex O
and O
whether O
this O
process O
would O
be O
sensitive O
to O
length O
and O
velocity O
of O
the O
stretch. O
Capsaicin O
(10 O
micro O
g) O
was O
injected O
into O
the O
masseter O
muscle O
to O
induce O
pain O
in O
11 O
healthy O
volunteers. O
Short-latency O
reflex O
responses O
were O
evoked O
in O
the O
masseter O
and O
temporalis O
muscles O
by O
a O
stretch O
device O
with O
different O
velocities O
and O
displacements O
before, O
during, O
and O
after O
the O
pain. O
The O
normalized O
reflex O
amplitude O
increased O
with O
an O
increase O
in O
velocity O
at O
a O
given O
displacement, O
but O
remained O
constant O
with O
different O
displacements O
at O
a O
given O
velocity. O
The O
normalized O
reflex O
amplitude O
was O
significantly O
higher O
during O
pain, O
but O
only O
at O
faster O
stretches O
in O
the O
painful B
muscle. I
Increased O
sensitivity O
of O
the O
fusimotor O
system O
during O
acute O
muscle O
pain O
could O
be O
one O
likely O
mechanism O
to O
explain O
the O
findings. O

BACKGROUND/AIMS: O
Recently O
ribavirin O
has O
been O
found O
to O
inhibit O
angiogenesis O
and O
a O
number O
of O
angiogenesis O
inhibitors O
such O
as O
sunitinib O
and O
sorafenib O
have O
been O
found O
to O
cause O
acute O
hemolysis. B
We O
aimed O
to O
investigate O
whether O
there O
is O
a O
relation O
between O
hemoglobin, O
haptoglobin O
and O
angiogenesis O
soluble O
markers O
which O
are O
modifiable O
and O
can O
help O
in O
developing O
strategies O
against O
anemia. B
METHODS: O
Fourteen O
patients O
chronically B
infected I
with I
hepatitis B
C I
virus I
were O
treated O
by O
pegylated O
interferon O
alpha O
2a O
and O
ribavirin. O
Serum O
hemoglobin, O
haptoglobin O
and O
angiogenesis O
markers O
of O
vascular O
endothelial O
growth O
factor O
and O
angiopoetin-2 O
were O
investigated O
before O
and O
after O
therapy. O
RESULTS: O
We O
observed O
a O
significant O
decrease O
in O
haptoglobin O
levels O
at O
the O
end O
of O
the O
treatment O
period. O
Hemoglobin O
levels O
also O
decreased O
but O
insignificantly O
by O
treatment. O
In O
contrast O
with O
the O
literature, O
serum O
levels O
of O
angiogenesis O
factors O
did O
not O
change O
significantly O
by O
pegylated O
interferon O
and O
ribavirin O
therapy. O
We O
found O
no O
correlation O
of O
angiogenesis O
soluble O
markers O
with O
either O
hemoglobin O
or O
haptoglobin. O
CONCLUSION: O
This O
is O
the O
first O
study O
in O
the O
literature O
investigating O
a O
link O
between O
angiogenesis O
soluble O
markers O
and O
ribavirin O
induced O
anemia O
in O
patients O
with O
hepatitis O
C O
and O
we O
could O
not O
find O
any O
relation. O
Future O
research O
with O
larger O
number O
of O
patients O
is O
needed O
to O
find O
out O
modifiable O
factors O
that O
will O
improve O
the O
safety O
of O
ribavirin O
therapy. O

Remission O
induction O
of O
meningeal B
leukemia I
with O
high-dose O
intravenous O
methotrexate. O

Tolerance O
and O
antiviral O
effect O
of O
ribavirin O
was O
studied O
in O
6 O
patients O
with O
Argentine B
hemorrhagic I
fever I
(AHF) O
of B
more O
than O
8 O
days O
of O
evolution. O
Administration O
of O
ribavirin O
resulted O
in O
a O
neutralization O
of O
viremia B
and O
a O
drop O
of O
endogenous O
interferon O
titers. O
The O
average O
time O
of O
death B
was O
delayed. O
A O
reversible O
anemia B
was O
the O
only O
adverse O
effect O
observed. O
From O
these O
results, O
we O
conclude O
that O
ribavirin O
has O
an O
antiviral O
effect O
in O
advanced O
cases O
of O
AHF, O
and O
that O
anemia, O
the O
only O
secondary O
reaction O
observed, O
can O
be O
easily O
managed. O
The O
possible O
beneficial O
effect O
of O
ribavirin O
during O
the O
initial O
days O
of O
AHF O
is O
discussed. O

Liver B
enlargement I
and O
muscle B
wastage I
occurred O
in O
Wistar O
rats O
following O
the O
subcutaneous O
administration O
of O
prednisolone. O
In O
the O
liver O
both O
the O
content O
of O
RNA O
and O
the O
biosynthesis O
of O
ribosomal O
RNA O
increased O
while O
both O
the O
RNA O
content O
and O
ribosomal O
RNA O
biosynthesis O
were O
reduced O
in O
the O
gastrocnemius O
muscle. O
It O
is O
suggested O
that O
the O
drug O
acted O
in O
a O
selective O
and O
tissue-specific O
manner O
to O
enhance O
ribosomal O
RNA O
synthesis O
in O
the O
liver O
and O
depress O
such O
synthesis O
in O
the O
muscle. O
This O
view O
supports O
the O
contention O
that O
the O
liver O
and O
muscle O
are O
independent O
sites O
of O
prednisolone O
action. O

Cocaine O
causes O
memory B
and I
learning B
impairments I
in O
rats: O
involvement O
of O
nuclear O
factor O
kappa O
B O
and O
oxidative O
stress, O
and O
prevention O
by O
topiramate. O

PURPOSE: O
To O
evaluate O
the O
frequency, O
severity O
and O
preventability O
of O
warfarin-induced O
cerebral B
haemorrhages I
due O
to O
warfarin O
and O
warfarin-drug O
interactions O
in O
patients O
living O
in O
the O
county O
of O
Osterg O
tland, O
Sweden. O
METHODS: O
All O
patients O
with O
a O
diagnosed O
cerebral O
haemorrhage O
at O
three O
hospitals O
during O
the O
period O
2000-2002 O
were O
identified. O
Medical O
records O
were O
studied O
retrospectively O
to O
evaluate O
whether O
warfarin O
and O
warfarin-drug O
interactions O
could O
have O
caused O
the O
cerebral O
haemorrhage. O
The O
proportion O
of O
possibly O
avoidable O
cases O
due O
to O
drug O
interactions O
was O
estimated. O
RESULTS: O
Among O
593 O
patients O
with O
cerebral O
haemorrhage, O
59 O
(10%) O
were O
assessed O
as O
related O
to O
warfarin O
treatment. O
This O
imply O
an O
incidence O
of O
1.7/100,000 O
treatment O
years. O
Of O
the O
59 O
cases, O
26 O
(44%) O
had O
a O
fatal O
outcome, O
compared O
to O
136 O
(25%) O
among O
the O
non-warfarin O
patients O
(p O
< O
0.01). O
A O
warfarin-drug O
interaction O
could O
have O
contributed O
to O
the O
haemorrhage O
in O
24 O
(41%) O
of O
the O
warfarin O
patients O
and O
in O
7 O
of O
these O
(12%) O
the O
bleeding B
complication O
was O
considered O
being O
possible O
to O
avoid. O
CONCLUSIONS: O
Warfarin-induced O
cerebral O
haemorrhages O
are O
a O
major O
clinical O
problem O
with O
a O
high O
fatality O
rate. O
Almost O
half O
of O
the O
cases O
was O
related O
to O
a O
warfarin-drug O
interaction. O
A O
significant O
proportion O
of O
warfarin-related O
cerebral O
haemorrhages O
might O
have O
been O
prevented O
if O
greater O
caution O
had O
been O
taken O
when O
prescribing O
drugs O
known O
to O
interact O
with O
warfarin. O

Ranitidine-induced O
acute O
interstitial B
nephritis I
in O
a O
cadaveric O
renal O
allograft. O

Clinical O
nephrotoxicity B
of O
tobramycin O
and O
gentamicin. O
A O
prospective O
study. O

Effect O
of O
polyethylene O
glycol O
400 O
on O
adriamycin O
toxicity B
in O
mice. O

Because O
of O
the O
rapid O
systemic O
clearance O
of O
BCNU O
(1,3-bis-(2-chloroethyl)-1-nitrosourea), O
intra-arterial O
administration O
should O
provide O
a O
substantial O
advantage O
over O
intravenous O
administration O
for O
the O
treatment O
of O
malignant B
gliomas. I
Thirty-six O
patients O
were O
treated O
with O
BCNU O
every O
6 O
to O
8 O
weeks, O
either O
by O
transfemoral O
catheterization O
of O
the O
internal O
carotid O
or O
vertebral O
artery O
or O
through O
a O
fully O
implantable O
intracarotid O
drug O
delivery O
system, O
beginning O
with O
a O
dose O
of O
200 O
mg/sq O
m O
body O
surface O
area. O
Twelve O
patients O
with O
Grade O
III O
or O
IV O
astrocytomas B
were O
treated O
after O
partial O
resection O
of O
the O
tumor B
without O
prior O
radiation O
therapy. O
After O
two O
to O
seven O
cycles O
of O
chemotherapy, O
nine O
patients O
showed O
a O
decrease O
in O
tumor O
size O
and O
surrounding O
edema B
on O
contrast-enhanced O
computerized O
tomography O
scans. O
In O
the O
nine O
responders, O
median O
duration O
of O
chemotherapy O
response O
from O
the O
time O
of O
operation O
was O
25 O
weeks O
(range O
12 O
to O
more O
than O
91 O
weeks). O
The O
median O
duration O
of O
survival O
in O
the O
12 O
patients O
was O
54 O
weeks O
(range O
21 O
to O
more O
than O
156 O
weeks), O
with O
an O
18-month O
survival O
rate O
of O
42%. O
Twenty-four O
patients O
with O
recurrent O
Grade O
I O
to O
IV O
astrocytomas, O
whose O
resection O
and O
irradiation O
therapy O
had O
failed, O
received O
two O
to O
eight O
courses O
of O
intra-arterial O
BCNU O
therapy. O
Seventeen O
of O
these O
had O
a O
response O
or O
were O
stable O
for O
a O
median O
of O
20 O
weeks O
(range O
6 O
to O
more O
than O
66 O
weeks). O
The O
catheterization O
procedure O
is O
safe, O
with O
no O
immediate O
complication O
in O
111 O
infusions O
of O
BCNU. O
A O
delayed O
complication O
in O
nine O
patients O
has O
been O
unilateral O
loss B
of I
vision I
secondary O
to O
a O
retinal B
vasculitis. I
The O
frequency O
of O
visual B
loss I
decreased O
after O
the O
concentration O
of O
the O
ethanol O
diluent O
was O
lowered. O

OBJECTIVE: O
The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
the O
effect O
of O
morning-dosed O
modafinil O
on O
sleep O
and O
daytime B
sleepiness I
in O
chronic O
cocaine O
users. O
METHOD: O
Twenty O
cocaine-dependent O
participants O
were O
randomly O
assigned O
to O
receive O
modafinil, O
400 O
mg O
(N=10), O
or O
placebo O
(N=10) O
every O
morning O
at O
7:30 O
a.m. O
for O
16 O
days O
in O
an O
inpatient, O
double-blind O
randomized O
trial. O
Participants O
underwent O
polysomnographic O
sleep O
recordings O
on O
days O
1 O
to O
3, O
7 O
to O
9, O
and O
14 O
to O
16 O
(first, O
second, O
and O
third O
weeks O
of O
abstinence). O
The O
Multiple O
Sleep O
Latency O
Test O
was O
performed O
at O
11:30 O
a.m., O
2:00 O
p.m., O
and O
4:30 O
p.m. O
on O
days O
2, O
8, O
and O
15. O
For O
comparison O
of O
sleep O
architecture O
variables, O
12 O
healthy O
comparison O
participants O
underwent O
a O
single O
night O
of O
experimental O
polysomnography O
that O
followed O
1 O
night O
of O
accommodation O
polysomnography. O
RESULTS: O
Progressive O
abstinence O
from O
cocaine O
was O
associated O
with O
worsening O
of O
all O
measured O
polysomnographic O
sleep O
outcomes. O
Compared O
with O
placebo, O
modafinil O
decreased O
nighttime O
sleep O
latency O
and O
increased O
slow-wave O
sleep O
time O
in O
cocaine-dependent O
participants. O
The O
effect O
of O
modafinil O
interacted O
with O
the O
abstinence O
week O
and O
was O
associated O
with O
longer O
total O
sleep O
time O
and O
shorter O
REM O
sleep O
latency O
in O
the O
third O
week O
of O
abstinence. O
Comparison O
of O
slow-wave O
sleep O
time, O
total O
sleep O
time, O
and O
sleep O
latency O
in O
cocaine-dependent O
and O
healthy O
participants O
revealed O
a O
normalizing O
effect O
of O
modafinil O
in O
cocaine-dependent O
participants. O
Modafinil O
was O
associated O
with O
increased O
daytime O
sleep O
latency, O
as O
measured O
by O
the O
Multiple O
Sleep O
Latency O
Test, O
and O
a O
nearly O
significant O
decrease O
in O
subjective O
daytime O
sleepiness. O
CONCLUSIONS: O
Morning-dosed O
modafinil O
promotes O
nocturnal O
sleep, O
normalizes O
sleep O
architecture, O
and O
decreases O
daytime O
sleepiness O
in O
abstinent O
cocaine O
users. O
These O
effects O
may O
be O
relevant O
in O
the O
treatment O
of O
cocaine O
dependence. O

Immunosuppressive O
drugs O
have O
been O
used O
during O
the O
last O
30 O
years O
in O
treatment O
of O
patients O
with O
severe O
rheumatoid B
arthritis. I
The O
drugs O
commonly O
used O
are O
cyclophosphamide O
and O
chlorambucil O
(alkylating O
agents), O
azathioprine O
(purine O
analogue), O
and O
methotrexate O
(folic O
acid O
analogue). O
There O
is O
evidence O
that O
all O
four O
immunosuppressive O
drugs O
can O
reduce O
synovitis, B
but O
disease O
activity O
almost O
always O
recurs O
after O
therapy O
is O
stopped. O
Since O
adverse O
reactions O
are O
frequent, O
less O
than O
50 O
percent O
of O
patients O
are O
able O
to O
continue O
a O
particular O
drug O
for O
more O
than O
one O
year. O
Since O
it O
takes O
three O
to O
12 O
months O
to O
achieve O
maximal O
effects, O
those O
patients O
who O
are O
unable O
to O
continue O
the O
drug O
receive O
little O
benefit O
from O
it. O
Patients O
treated O
with O
alkylating O
agents O
have O
an O
increased O
risk O
of O
development O
of O
acute B
nonlymphocytic I
leukemia, I
and O
both O
alkylating O
agents O
and O
azathioprine O
are O
associated O
with O
the O
development O
of O
non-Hodgkin's B
lymphoma. I
Cyclophosphamide O
therapy O
increases O
the O
risk O
of O
carcinoma B
of I
the I
bladder. I
There O
have O
been O
several O
long-term O
studies O
of O
patients O
with O
rheumatoid O
arthritis O
treated O
with O
azathioprine O
and O
cyclophosphamide O
and O
the O
incidence O
of O
most O
of O
the O
common O
cancers B
is O
not O
increased. O
Data O
on O
the O
possible O
increased O
risk O
of O
malignancy B
in O
rheumatoid O
arthritis O
are O
still O
being O
collected, O
and O
until O
further O
information O
is O
available, O
the O
use O
of O
immunosuppressive O
drugs, O
particularly O
alkylating O
agents, O
in O
the O
treatment O
of O
rheumatoid O
arthritis O
should O
be O
reserved O
for O
patients O
with O
severe O
progressive O
disease O
or O
life-threatening O
complications. O

Improved O
outcomes O
among O
patients O
with O
head B
and I
neck I
carcinomas I
require O
investigations O
of O
new O
drugs O
for O
induction O
therapy. O
Preliminary O
results O
of O
an O
Eastern O
Cooperative O
Oncology O
Group O
study O
of O
single-agent O
paclitaxel O
(Taxol; O
Bristol-Myers O
Squibb O
Company, O
Princeton, O
NJ) O
reported O
a O
37% O
response O
rate O
in O
patients O
with O
head B
and I
neck I
cancer, I
and O
the O
paclitaxel/cisplatin O
combination O
has O
been O
used O
successfully O
and O
has O
significantly O
improved O
median O
response O
duration O
in O
ovarian B
cancer I
patients. O
We O
initiated O
a O
phase O
I/II O
trial O
to O
determine O
the O
response O
and O
toxicity B
of O
escalating O
paclitaxel O
doses O
combined O
with O
fixed-dose O
cisplatin O
with O
granulocyte O
colony-stimulating O
factor O
support O
in O
patients O
with O
untreated O
locally O
advanced O
inoperable O
head O
and O
neck O
carcinoma. O
To O
date, O
23 O
men O
with O
a O
median O
age O
of O
50 O
years O
and O
good O
performance O
status O
have O
entered O
the O
trial. O
Primary O
tumor B
sites O
were O
oropharynx, O
10 O
patients; O
hypopharynx, O
four; O
larynx, O
two; O
oral O
cavity, O
three; O
unknown O
primary, O
two; O
and O
nasal O
cavity O
and O
parotid O
gland, O
one O
each. O
Of O
20 O
patients O
evaluable O
for O
toxicity, O
four O
had O
stage O
III O
and O
16 O
had O
stage O
IV O
disease. O
Treatment, O
given O
every O
21 O
days O
for O
a O
maximum O
of O
three O
cycles, O
consisted O
of O
paclitaxel O
by O
3-hour O
infusion O
followed O
the O
next O
day O
by O
a O
fixed O
dose O
of O
cisplatin O
(75 O
mg/m2). O
The O
dose O
levels O
incorporate O
escalating O
paclitaxel O
doses, O
and O
intrapatient O
escalations O
within O
a O
given O
dose O
level O
are O
permitted O
if O
toxicity O
permits. O
At O
the O
time O
of O
this O
writing, O
dose O
level O
4 O
(260, O
270, O
and O
280 O
mg/m2) O
is O
being O
evaluated; O
three O
patients O
from O
this O
level O
are O
evaluable. O
With O
paclitaxel O
doses O
of O
200 O
mg/m2 O
and O
higher, O
granulocyte O
colony-stimulating O
factor O
5 O
micrograms/kg/d O
is O
given O
(days O
4 O
through O
12). O
Of O
18 O
patients O
evaluable O
for O
response, O
seven O
(39%) O
achieved O
a O
complete O
response O
and O
six O
(33%) O
achieved O
a O
partial O
response. O
Three O
patients O
had O
no O
change O
and O
disease O
progressed O
in O
two. O
The O
overall O
response O
rate O
is O
72%. O
Eleven O
responding O
patients O
had O
subsequent O
surgery/radiotherapy O
or O
radical O
radiotherapy. O
Two O
pathologic O
complete O
responses O
were O
observed O
in O
patients O
who O
had O
achieved O
clinical O
complete O
responses. O
Alopecia, B
paresthesias, B
and O
arthralgias/myalgias B
have B
occurred O
frequently, O
but O
with O
one O
exception O
(a O
grade O
3 O
myalgia) O
they O
have O
been O
grade O
1 O
or O
2. O
No O
dose-limiting O
hematologic O
toxicity O
has O
been O
seen. O
Paclitaxel/cisplatin O
is O
an O
effective O
first-line O
regimen O
for O
locoregionally O
advanced O
head O
and O
neck O
cancer O
and O
continued O
study O
is O
warranted. O
Results O
thus O
far O
suggest O
no O
dose-response O
effect O
for O
paclitaxel O
doses O
above O
200 O
mg/m2. O

A O
prospective, O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
role O
of O
vitamin O
B12 O
and O
folinic O
acid O
supplementation O
in O
preventing O
zidovudine O
(ZDV)-induced O
bone B
marrow I
suppression. I
Seventy-five O
human B
immunodeficiency I
virus I
(HIV)-infected I
patients O
with O
CD4+ O
cell O
counts O
< O
500/mm3 O
were O
randomized O
to O
receive O
either O
ZDV O
(500 O
mg O
daily) O
alone O
(group O
I, O
n O
= O
38) O
or O
in O
combination O
with O
folinic O
acid O
(15 O
mg O
daily) O
and O
intramascular O
vitamin O
B12 O
(1000 O
micrograms O
monthly) O
(group O
II, O
n O
= O
37). O
Finally, O
15 O
patients O
were O
excluded O
from O
the O
study O
(noncompliance O
14, O
death B
1); O
thus, O
60 O
patients O
(31 O
in O
group O
I O
and O
29 O
in O
group O
II) O
were O
eligible O
for O
analysis. O
No O
significant O
differences O
between O
groups O
were O
found O
at O
enrollment. O
During O
the O
study, O
vitamin O
B12 O
and O
folate O
levels O
were O
significantly O
higher O
in O
group O
II O
patients; O
however, O
no O
differences O
in O
hemoglobin, O
hematocrit, O
mean O
corpuscular O
volume, O
and O
white-cell, O
neutrophil O
and O
platelet O
counts O
were O
observed O
between O
groups O
at O
3, O
6, O
9 O
and O
12 O
months. O
Severe O
hematologic O
toxicity B
(neutrophil O
count O
< O
1000/mm3 O
and/or O
hemoglobin O
< O
8 O
g/dl) O
occurred O
in O
4 O
patients O
assigned O
to O
group O
I O
and O
7 O
assigned O
to O
group O
II. O
There O
was O
no O
correlation O
between O
vitamin O
B12 O
or O
folate O
levels O
and O
development O
of O
myelosuppression. B
Vitamin O
B12 O
and O
folinic O
acid O
supplementation O
of O
ZDV O
therapy O
does O
not O
seem O
useful O
in O
preventing O
or O
reducing O
ZDV-induced O
myelotoxicity B
in O
the O
overall O
treated O
population, O
although O
a O
beneficial O
effect O
in O
certain O
subgroups O
of O
patients O
cannot O
be O
excluded. O

Clomipramine-induced O
sleep B
disturbance I
does O
not O
impair O
its O
prolactin-releasing O
action. O

INTRODUCTION: O
Confusion B
is O
an O
adverse O
drug O
reaction O
frequently O
observed O
with O
valproic O
acid. O
Some O
case O
reports O
are O
published O
in O
the O
literature O
but O
no O
systematic O
study O
from O
a O
sample O
of O
patients O
has O
been O
published. O
We O
performed O
this O
study O
in O
order O
to O
describe O
the O
main O
characteristics O
of O
this O
adverse O
drug O
reaction. O
METHODS: O
Using O
the O
French O
Pharmacovigilance O
database, O
we O
selected O
the O
cases O
of O
confusion B
reported O
since O
1985 O
with O
valproic O
acid. O
RESULTS: O
272 O
cases O
of O
confusion O
were O
reported O
with O
valproic O
acid: O
153 O
women O
and O
119 O
men. O
Confusion O
mostly O
occurred O
during O
the O
two O
first O
weeks O
following O
valproic O
acid O
exposure O
(39.7%). O
It O
was O
"serious" O
for O
almost O
2/3 O
of O
the O
patients O
(62.5%) O
and O
its O
outcome O
favourable O
in O
most O
of O
the O
cases O
(82%). O
The O
occurrence O
of O
this O
ADR O
was O
more O
frequent O
in O
patients O
aged O
between O
61 O
and O
80 O
years. O
CONCLUSION: O
This O
work O
shows O
that O
confusion O
with O
valproic O
acid O
is O
a O
serious, O
rather O
frequent O
but O
reversible O
adverse O
drug O
reaction. O
It O
occurs O
especially O
in O
older O
patients O
and O
during O
the O
first O
two O
weeks O
of O
treatment. O

Simvastatin-ezetimibe-induced O
hepatic B
failure I
necessitating O
liver O
transplantation. O

Components O
of O
lemon O
essential O
oil O
attenuate O
dementia B
induced O
by O
scopolamine. O

15 O
cases O
of O
cimetidine-associated O
mental O
confusion B
have O
been O
reported. O
In O
order O
that O
this O
syndrome O
might O
be O
investigated O
changes O
in O
mental O
status O
(M.S.) O
were O
correlated O
with O
serum O
concentrations O
and O
renal B
and O
hepatic O
function O
in O
36 O
patients, O
30 O
patients O
had O
no O
M.S. O
change O
on O
cimetidine O
and O
6 O
had O
moderate O
to O
severe O
changes. O
These O
6 O
patients O
had O
both O
renal B
and I
liver B
dysfunction I
(P O
less O
than O
0.05), O
as O
well O
as O
cimetidine O
trough-concentrations O
of O
more O
than O
1.25 O
microgram/ml O
(P O
less O
than O
0.05). O
The O
severity O
of O
M.S. O
changes O
increased O
as O
trough-concentrations O
rose, O
5 O
patients O
had O
lumbar O
puncture. O
The O
cerebrospinal O
fluid: O
serum O
ratio O
of O
cimetidine O
concentrations O
was O
0.24:1 O
and O
indicates O
that O
cimetidine O
passes O
the O
blood-brain O
barrier; O
it O
also O
raises O
the O
possibility O
that O
M.S. O
changes O
are O
due O
to O
blockade O
of O
histamine O
H2-receptors O
in O
the O
central O
nervous O
system. O
Patients O
likely O
to O
have O
both O
raised O
trough-concentrations O
and O
mental O
confusion O
are O
those O
with O
both O
severe O
renal B
and I
hepatic B
dysfunction. I
They O
should O
be O
closely O
observed O
and O
should O
be O
given O
reduced O
doses O
of O
cimetidine. O

In O
a O
patient O
with O
WPW B
syndrome I
and O
idiopathic B
dilated I
cardiomyopathy, I
intractable O
atrioventricular B
reentrant I
tachycardia I
(AVRT) O
was B
iatrogenically O
induced. O
QRS O
without O
preexcitation, O
caused O
by O
junctional O
escape O
beats O
after O
verapamil O
or O
unidirectional O
antegrade O
block O
of O
accessory O
pathway O
after O
catheter O
ablation, O
established O
frequent O
AVRT O
attack. O

Organic B
mental I
disorder I
was O
observed O
in O
a O
29-year-old O
female O
in O
the O
prognostic O
period O
after O
the O
onset O
of O
carmofur-induced O
leukoencephalopathy. B
Symptoms O
such O
as O
euphoria, O
emotional O
lability O
and O
puerile O
attitude O
noted O
in O
the O
patient O
were O
diagnosed O
as O
organic B
personality I
syndrome I
according O
to O
the O
criteria O
defined O
in O
the O
DSM-III-R. O
It O
is O
referred O
to O
as O
a O
frontal B
lobe I
syndrome. I
Brain O
CT O
revealed O
a O
periventricular O
low O
density O
area O
in O
the O
frontal O
white O
matter O
and O
moderate O
dilatation O
of O
the O
lateral O
ventricles O
especially O
at O
the O
bilateral O
anterior O
horns. O
Consequently, O
carmofur-induced O
leukoencephalopathy O
may O
uncommonly O
result O
in O
organic O
personality O
syndrome O
in O
the O
residual O
state. O
It O
may O
be O
attributed O
to O
the O
structural B
damage I
to I
the I
frontal I
lobe. I

In O
cyclophosphamide-induced O
cystitis B
in O
the O
rat, O
detrusor O
function O
is O
impaired O
and O
the O
expression O
and O
effects O
of O
muscarinic O
receptors O
altered. O
Whether O
or O
not O
the O
neuronal O
transmission O
may O
be O
affected O
by O
cystitis O
was O
presently O
investigated. O
Responses O
of O
urinary O
strip O
preparations O
from O
control O
and O
cyclophosphamide-pretreated O
rats O
to O
electrical O
field O
stimulation O
and O
to O
agonists O
were O
assessed O
in O
the O
absence O
and O
presence O
of O
muscarinic, O
adrenergic O
and O
purinergic O
receptor O
antagonists. O
Generally, O
atropine O
reduced O
contractions, O
but O
in O
contrast O
to O
controls, O
it O
also O
reduced O
responses O
to O
low O
electrical O
field O
stimulation O
intensity O
(1-5 O
Hz) O
in O
inflamed O
preparations. O
In O
both O
types, O
purinoceptor O
desensitization O
with O
alpha,beta-methylene O
adenosine-5'-triphosphate O
(alpha,beta-meATP) O
caused O
further O
reductions O
at O
low O
frequencies O
(<10 O
Hz). O
The O
muscarinic O
receptor O
antagonists O
atropine, O
4-diphenylacetoxy-N-methylpiperidine O
(4-DAMP) O
('M(1)/M(3)/M(5)-selective'), O
methoctramine O
('M(2)-selective') O
and O
pirenzepine O
('M(1)-selective') O
antagonized O
the O
tonic O
component O
of O
the O
electrical O
field O
stimulation-evoked O
contractile O
response O
more O
potently O
than O
the O
phasic O
component. O
4-DAMP O
inhibited O
the O
tonic O
contractions O
in O
controls O
more O
potently O
than O
methoctramine O
and O
pirenzepine. O
In O
inflamed O
preparations, O
the O
muscarinic O
receptor O
antagonism O
on O
the O
phasic O
component O
of O
the O
electrical O
field O
stimulation-evoked O
contraction O
was O
decreased O
and O
the O
pirenzepine O
and O
4-DAMP O
antagonism O
on O
the O
tonic O
component O
was O
much O
less O
efficient O
than O
in O
controls. O
In O
contrast O
to O
controls, O
methoctramine O
increased O
-- O
instead O
of O
decreased O
-- O
the O
tonic O
responses O
at O
high O
frequencies. O
While O
contractions O
to O
carbachol O
and O
ATP O
were O
the O
same O
in O
inflamed O
and O
in O
control O
strips O
when O
related O
to O
a O
reference O
potassium O
response, O
isoprenaline-induced O
relaxations O
were O
smaller O
in O
inflamed O
strips. O
Thus, O
in O
cystitis O
substantial O
changes O
of O
the O
efferent O
functional O
responses O
occur. O
While O
postjunctional O
beta-adrenoceptor-mediated O
relaxations O
are O
reduced, O
effects O
by O
prejunctional O
inhibitory O
muscarinic O
receptors O
may O
be O
increased. O

The O
authors O
report O
2 O
cases O
of O
premature O
neonates O
who O
had O
enterocutaneous O
fistula B
complicating O
necrotizing B
enterocolitis. I
Pulmonary B
hypertension I
developed O
after O
administration O
of O
a O
somatostatin O
analogue, O
octreotide, O
to O
enhance O
resolution O
of O
the O
fistula. O
The O
authors O
discuss O
the O
mechanism O
of O
the O
occurrence O
of O
this O
complication O
and O
recommend O
caution O
of O
its O
use O
in O
high-risk O
premature O
neonates. O

Acute O
effects O
of O
N-(2-propylpentanoyl)urea O
on O
hippocampal O
amino O
acid O
neurotransmitters O
in O
pilocarpine-induced O
seizure B
in O
rats. O

Phenylpropanolamine O
(PPA), O
a O
synthetic O
sympathomimetic O
that O
is O
structurally O
similar O
to O
amphetamine, O
is O
available O
over O
the O
counter O
in O
anorectics, O
nasal O
congestants, O
and O
cold O
preparations. O
Its O
prolonged O
use O
or O
overuse O
has O
been O
associated O
with O
seizures, B
intracerebral B
hemorrhage, I
neuropsychiatric B
symptoms, I
and O
nonhemorrhagic O
cerebral B
infarction. I
We O
report O
the O
case O
of O
a O
young O
woman O
who O
suffered O
a O
cerebral O
infarction O
after O
taking O
a O
single O
oral O
dose O
of O
PPA. O

Endocrine O
screening O
in O
1,022 O
men O
with O
erectile B
dysfunction: I
clinical O
significance O
and O
cost-effective O
strategy. O

The O
selective O
5-HT6 O
receptor O
antagonist O
Ro4368554 O
restores O
memory O
performance O
in O
cholinergic O
and O
serotonergic O
models O
of O
memory B
deficiency I
in O
the O
rat. O

Massive O
proteinuria B
and O
acute B
renal I
failure I
after O
oral O
bisphosphonate O
(alendronate) O
administration O
in O
a O
patient O
with O
focal B
segmental I
glomerulosclerosis. I

Cocaine-induced O
mood B
disorder: I
prevalence O
rates O
and O
psychiatric B
symptoms O
in O
an O
outpatient O
cocaine-dependent O
sample. O

A O
14-year-old O
girl O
is O
reported O
with O
recurrent, O
azithromycin-induced, O
acute O
interstitial B
nephritis. I
The O
second O
episode O
was O
more O
severe O
than O
the O
first; O
and O
although O
both O
were O
treated O
with O
intensive O
corticosteroid O
therapy, O
renal O
function O
remained O
impaired. O
Although O
most O
cases O
of O
antibiotic O
induced O
acute O
interstitial O
nephritis O
are O
benign O
and O
self-limited, O
some O
patients O
are O
at O
risk O
for O
permanent O
renal B
injury. I

A O
combination O
of O
5 O
d O
of O
nelarabine O
(AraG) O
with O
5 O
d O
of O
etoposide O
(VP) O
and O
cyclophosphamide O
(CPM) O
and O
prophylactic O
intrathecal O
chemotherapy O
was O
used O
as O
salvage O
therapy O
in O
seven O
children O
with O
refractory O
or O
relapsed O
T-cell B
leukaemia I
or I
lymphoma. I
The O
most O
common O
side O
effects O
attributable O
to O
the O
AraG O
included O
Grade O
2 O
and O
3 O
sensory O
and O
motor O
neuropathy B
and O
musculoskeletal B
pain. I
Haematological B
toxicity I
was O
greater O
for O
the O
combination O
than O
AraG O
alone, O
although O
median O
time O
to O
neutrophil O
and O
platelet O
recovery O
was O
consistent O
with O
other O
salvage O
therapies. O
All O
patients O
had O
some O
response O
to O
the O
combined O
therapy O
and O
five O
of O
the O
seven O
went O
into O
complete O
remission O
after O
one O
or O
two O
courses O
of O
AraG/VP/CPM. O
Our O
experience O
supports O
the O
safety O
of O
giving O
AraG O
as O
salvage O
therapy O
in O
synchrony O
with O
etoposide O
and O
cyclophosphamide, O
although O
neurological B
toxicity I
must O
be O
closely O
monitored. O

BACKGROUND: O
Cocaine O
is O
a O
widely O
abused O
psychostimulant O
that O
has O
both O
rewarding O
and O
aversive O
properties. O
While O
the O
mechanisms O
underlying O
cocaine's O
rewarding O
effects O
have O
been O
studied O
extensively, O
less O
attention O
has O
been O
paid O
to O
the O
unpleasant O
behavioral O
states O
induced O
by O
cocaine, O
such O
as O
anxiety. B
METHODS: O
In O
this O
study, O
we O
evaluated O
the O
performance O
of O
dopamine O
beta-hydroxylase O
knockout O
(Dbh O
-/-) O
mice, O
which O
lack O
norepinephrine O
(NE), O
in O
the O
elevated O
plus O
maze O
(EPM) O
to O
examine O
the O
contribution O
of O
noradrenergic O
signaling O
to O
cocaine-induced O
anxiety. O
RESULTS: O
We O
found O
that O
cocaine O
dose-dependently O
increased O
anxiety-like O
behavior O
in O
control O
(Dbh O
+/-) O
mice, O
as O
measured O
by O
a O
decrease O
in O
open O
arm O
exploration. O
The O
Dbh O
-/- O
mice O
had O
normal O
baseline O
performance O
in O
the O
EPM O
but O
were O
completely O
resistant O
to O
the O
anxiogenic O
effects O
of O
cocaine. O
Cocaine-induced O
anxiety O
was O
also O
attenuated O
in O
Dbh O
+/- O
mice O
following O
administration O
of O
disulfiram, O
a O
dopamine O
beta-hydroxylase O
(DBH) O
inhibitor. O
In O
experiments O
using O
specific O
adrenergic O
antagonists, O
we O
found O
that O
pretreatment O
with O
the O
beta-adrenergic O
receptor O
antagonist O
propranolol O
blocked O
cocaine-induced O
anxiety-like O
behavior O
in O
Dbh O
+/- O
and O
wild-type O
C57BL6/J O
mice, O
while O
the O
alpha(1) O
antagonist O
prazosin O
and O
the O
alpha(2) O
antagonist O
yohimbine O
had O
no O
effect. O
CONCLUSIONS: O
These O
results O
indicate O
that O
noradrenergic O
signaling O
via O
beta-adrenergic O
receptors O
is O
required O
for O
cocaine-induced O
anxiety O
in O
mice. O

Irreversible O
damage O
to O
the O
medullary O
interstitium O
in O
experimental O
analgesic O
nephropathy B
in O
F344 O
rats. O

Pain B
not O
responsive O
to O
morphine O
is O
often O
problematic. O
Animal O
and O
clinical O
studies O
have O
suggested O
that O
N-methyl-D-aspartate O
(NMDA) O
antagonists, O
such O
as O
ketamine, O
may O
be O
effective O
in O
improving O
opioid O
analgesia O
in O
difficult O
pain B
syndromes, O
such O
as O
neuropathic B
pain. I
A O
slow O
bolus O
of O
subhypnotic O
doses O
of O
ketamine O
(0.25 O
mg/kg O
or O
0.50 O
mg/kg) O
was O
given O
to O
10 O
cancer B
patients O
whose O
pain O
was O
unrelieved O
by O
morphine O
in O
a O
randomized, O
double-blind, O
crossover, O
double-dose O
study. O
Pain O
intensity O
on O
a O
0 O
to O
10 O
numerical O
scale; O
nausea B
and O
vomiting, B
drowsiness, O
confusion, B
and O
dry B
mouth, I
using O
a O
scale O
from O
0 O
to O
3 O
(not O
at O
all, O
slight, O
a O
lot, O
awful); O
Mini-Mental O
State O
Examination O
(MMSE) O
(0-30); O
and O
arterial O
pressure O
were O
recorded O
before O
administration O
of O
drugs O
(T0) O
and O
after O
30 O
minutes O
(T30), O
60 O
minutes O
(T60), O
120 O
minutes O
(T120), O
and O
180 O
minutes O
(T180). O
Ketamine, O
but O
not O
saline O
solution, O
significantly O
reduced O
the O
pain O
intensity O
in O
almost O
all O
the O
patients O
at O
both O
doses. O
This O
effect O
was O
more O
relevant O
in O
patients O
treated O
with O
higher O
doses. O
Hallucinations B
occurred O
in O
4 O
patients, O
and O
an O
unpleasant O
sensation O
("empty O
head") O
was O
also O
reported O
by O
2 O
patients. O
These O
episodes O
reversed O
after O
the O
administration O
of O
diazepam O
1 O
mg O
intravenously. O
Significant O
increases O
in O
drowsiness O
were O
reported O
in O
patients O
treated O
with O
ketamine O
in O
both O
groups O
and O
were O
more O
marked O
with O
ketamine O
0.50 O
mg/kg. O
A O
significant O
difference O
in O
MMSE O
was O
observed O
at O
T30 O
in O
patients O
who O
received O
0.50 O
mg/kg O
of O
ketamine. O
Ketamine O
can O
improve O
morphine O
analgesia O
in O
difficult O
pain O
syndromes, O
such O
as O
neuropathic O
pain. O
However, O
the O
occurrence O
of O
central O
adverse O
effects O
should O
be O
taken O
into O
account, O
especially O
when O
using O
higher O
doses. O
This O
observation O
should O
be O
tested O
in O
studies O
of O
prolonged O
ketamine O
administration. O

Depression B
and O
sexual B
dysfunction I
have O
been O
related O
to O
side O
effects O
of O
topical O
beta-blockers. O
We O
performed O
a O
preliminary O
study O
in O
order O
to O
determine O
any O
difference O
between O
a O
non O
selective O
beta-blocker O
(timolol) O
and O
a O
selective O
beta-blocker O
(betaxolol) O
regarding O
CNS O
side O
effects. O
Eight O
glaucomatous B
patients O
chronically O
treated O
with O
timolol O
0.5%/12h, O
suffering O
from O
depression B
diagnosed O
through O
DMS-III-R O
criteria, O
were O
included O
in O
the O
study. O
During O
the O
six-month O
follow O
up, O
depression O
was O
quantified O
through O
the O
Beck O
and O
Zung-Conde O
scales O
every O
two O
months. O
In O
a O
double O
blind O
cross-over O
study O
with O
control O
group, O
the O
patients O
under O
timolol O
treatment O
presented O
higher O
depression O
values O
measured O
through O
the O
Beck O
and O
the O
Zung-Conde O
scales O
(p O
< O
0.001 O
vs O
control). O
These O
results O
suggest O
that O
betaxolol O
could O
be O
less O
of O
a O
depression-inducer O
than O
timolol O
in O
predisposed O
patients. O

Efficacy O
and O
safety O
of O
asenapine O
in O
a O
placebo- O
and O
haloperidol-controlled O
trial O
in O
patients O
with O
acute O
exacerbation O
of O
schizophrenia. B

An O
experiment O
was O
performed O
to O
test O
whether O
inclusion O
of O
phenobarbital O
in O
a O
choline-devoid O
diet O
would O
increase O
the O
hepatocarcinogenicity O
of O
the O
diet. O
Groups O
of O
5-week O
old O
male O
Fischer-344 O
rats O
were O
fed O
for O
7-25 O
months O
semipurified O
choline-devoid O
or O
choline-supplemented O
diets, O
containing O
or O
not O
0.06% O
phenobarbital. O
No O
hepatic O
preneoplastic O
nodules O
or O
hepatocellular B
carcinomas I
developed O
in O
rats O
fed O
the O
plain O
choline-supplemented O
diet, O
while O
one O
preneoplastic O
nodule O
and O
one O
hepatocellular O
carcinoma O
developed O
in O
two O
rats O
fed O
the O
same O
diet O
containing O
phenobarbital. O
The O
incidence O
of O
preneoplastic O
nodules O
and O
of O
hepatocellular O
carcinomas O
was O
10% O
and O
37%, O
respectively, O
in O
rats O
fed O
the O
plain O
choline-devoid O
diet, O
and O
17% O
and O
30%, O
in O
rats O
fed O
the O
phenobarbital-containing O
choline-devoid O
diet. O
The O
results O
evinced O
no O
enhancement O
of O
the O
hepatocarcinogenicity O
of O
the O
choline-devoid O
diet O
by O
phenobarbital. O
Sporadic O
neoplastic O
lesions O
were O
observed O
in O
organs O
other O
than O
the O
liver O
of O
some O
of O
the O
animals, O
irrespective O
of O
the O
diet O
fed. O

Acetaminophen-induced O
hypotension. B

We O
report O
a O
case O
of O
intractable O
hemorrhagic B
cystitis B
due O
to O
cyclophosphamide O
therapy O
for O
Wegener's B
granulomatosis. I
Conservative O
treatment, O
including O
bladder O
irrigation O
with O
physiological O
saline O
and O
instillation O
of O
prostaglandin O
F2 O
alpha, O
failed O
to O
totally O
control O
hemorrhage. B
We O
then O
used O
hyperbaric O
oxygen O
at O
an O
absolute O
pressure O
of O
2 O
atm, O
5 O
days O
a O
week O
for O
8 O
consecutive O
weeks. O
The O
bleeding B
ceased O
completely O
by O
the O
end O
of O
treatment O
and O
the O
patient O
remained O
free O
of O
hematuria B
thereafter. O
No O
side O
effect O
was O
noted O
during O
the O
course O
of O
therapy. O
In O
future, O
this O
form O
of O
therapy O
can O
offer O
a O
safe O
alternative O
in O
the O
treatment O
of O
cyclophosphamide-induced O
hemorrhagic O
cystitis. O

Fluoxetine-induced O
akathisia: B
clinical O
and O
theoretical O
implications. O

-Tacrolimus O
(FK O
506) O
is O
a O
powerful, O
widely O
used O
immunosuppressant. O
The O
clinical O
utility O
of O
FK O
506 O
is O
complicated O
by O
substantial O
hypertension B
and O
nephrotoxicity. B
To O
clarify O
the O
mechanisms O
of O
FK O
506-induced O
hypertension, O
we O
studied O
the O
chronic O
effects O
of O
FK O
506 O
on O
the O
synthesis O
of O
endothelin-1 O
(ET-1), O
the O
expression O
of O
mRNA O
of O
ET-1 O
and O
endothelin-converting O
enzyme-1 O
(ECE-1), O
the O
endothelial O
nitric O
oxide O
synthase O
(eNOS) O
activity, O
and O
the O
expression O
of O
mRNA O
of O
eNOS O
and O
C-type O
natriuretic O
peptide O
(CNP) O
in O
rat O
blood O
vessels. O
In O
addition, O
the O
effect O
of O
the O
specific O
endothelin O
type O
A O
receptor O
antagonist O
FR O
139317 O
on O
FK O
506-induced O
hypertension O
in O
rats O
was O
studied. O
FK O
506, O
5 O
mg. O
kg-1. O
d-1 O
given O
for O
4 O
weeks, O
elevated O
blood O
pressure O
from O
102+/-13 O
to O
152+/-15 O
mm O
Hg O
and O
increased O
the O
synthesis O
of O
ET-1 O
and O
the O
levels O
of O
ET-1 O
mRNA O
in O
the O
mesenteric O
artery O
(240% O
and O
230%, O
respectively). O
Little O
change O
was O
observed O
in O
the O
expression O
of O
ECE-1 O
mRNA O
and O
CNP O
mRNA. O
FK O
506 O
decreased O
eNOS O
activity O
and O
the O
levels O
of O
eNOS O
mRNA O
in O
the O
aorta O
(48% O
and O
55%, O
respectively). O
The O
administration O
of O
FR O
139317 O
(10 O
mg. O
kg-1. O
d-1) O
prevented O
FK O
506-induced O
hypertension O
in O
rats. O
These O
results O
indicate O
that O
FK O
506 O
may O
increase O
blood O
pressure O
not O
only O
by O
increasing O
ET-1 O
production O
but O
also O
by O
decreasing O
NO O
synthesis O
in O
the O
vasculature. O

The O
antiepileptic O
drugs, O
phenobarbitone O
and O
carbamazepine O
are O
well O
known O
to O
cause O
cognitive B
impairment I
on O
chronic O
use. O
The O
increase O
in O
free O
radical O
generation O
has O
been O
implicated O
as O
one O
of O
the O
important O
mechanisms O
of O
cognitive O
impairment O
by O
antiepileptic O
drugs. O
Curcumin O
has O
shown O
antioxidant, O
anti-inflammatory O
and O
neuro-protective O
properties. O
Therefore, O
the O
present O
study O
was O
carried O
out O
to O
investigate O
the O
effect O
of O
chronic O
curcumin O
administration O
on O
phenobarbitone- O
and O
carbamazepine-induced O
cognitive O
impairment O
and O
oxidative O
stress O
in O
rats. O
Pharmacokinetic O
interactions O
of O
curcumin O
with O
phenobarbitone O
and O
carbamazepine O
were O
also O
studied. O
Vehicle/drugs O
were O
administered O
daily O
for O
21days O
to O
male O
Wistar O
rats. O
Passive O
avoidance O
paradigm O
and O
elevated O
plus O
maze O
test O
were O
used O
to O
assess O
cognitive O
function. O
At O
the O
end O
of O
study O
period, O
serum O
phenobarbitone O
and O
carbamazepine, O
whole O
brain O
malondialdehyde O
and O
reduced O
glutathione O
levels O
were O
estimated. O
The O
administration O
of O
phenobarbitone O
and O
carbamazepine O
for O
21days O
caused O
a O
significant O
impairment B
of I
learning I
and I
memory I
as O
well O
as O
an O
increased O
oxidative O
stress. O
Concomitant O
curcumin O
administration O
prevented O
the O
cognitive O
impairment O
and O
decreased O
the O
increased O
oxidative O
stress O
induced O
by O
these O
antiepileptic O
drugs. O
Curcumin O
co-administration O
did O
not O
cause O
any O
significant O
alteration O
in O
the O
serum O
concentrations O
of O
both O
phenobarbitone O
as O
well O
as O
carbamazepine. O
These O
results O
show O
that O
curcumin O
has O
beneficial O
effect O
in O
mitigating O
the O
deterioration B
of I
cognitive I
functions I
and O
oxidative O
damage O
in O
rats O
treated O
with O
phenobarbitone O
and O
carbamazepine O
without O
significantly O
altering O
their O
serum O
concentrations. O
The O
findings O
suggest O
that O
curcumin O
can O
be O
considered O
as O
a O
potential O
safe O
and O
effective O
adjuvant O
to O
phenobarbitone O
and O
carbamazepine O
therapy O
in O
preventing O
cognitive O
impairment O
associated O
with O
these O
drugs. O

Triamterene O
nephrolithiasis B
complicating O
dyazide O
therapy. O

High-dose O
testosterone O
is O
associated O
with O
atherosclerosis B
in O
postmenopausal O
women. O

Sirolimus O
(SRL) O
is O
a O
new, O
potent O
immunosuppressive O
agent. O
More O
recently, O
proteinuria B
has O
been O
reported O
as O
a O
consequence O
of O
sirolimus O
therapy, O
although O
the O
mechanism O
has O
remained O
unclear. O
We O
retrospectively O
examined O
the O
records O
of O
25 O
renal O
transplant O
patients, O
who O
developed O
or O
displayed O
increased O
proteinuria O
after O
SRL O
conversion. O
The O
patient O
cohort O
(14 O
men, O
11 O
women) O
was O
treated O
with O
SRL O
as O
conversion O
therapy, O
due O
to O
chronic B
allograft I
nephropathy B
(CAN) O
(n B
= O
15) O
neoplasia B
(n O
= O
8); O
Kaposi's B
sarcoma, I
Four O
skin B
cancers, I
One O
intestinal B
tumors, I
One O
renal B
cell I
carsinom) I
or O
BK O
virus O
nephropathy O
(n O
= O
2). O
SRL O
was O
started O
at O
a O
mean O
of O
78 O
+/- O
42 O
(15 O
to O
163) O
months O
after O
transplantation. O
Mean O
follow-up O
on O
SRL O
therapy O
was O
20 O
+/- O
12 O
(6 O
to O
43) O
months. O
Proteinuria B
increased O
from O
0.445 O
(0 O
to O
1.5) O
g/d O
before O
conversion O
to O
3.2 O
g/dL O
(0.2 O
to O
12) O
after O
conversion O
(P O
= O
0.001). O
Before O
conversion O
8 O
(32%) O
patients O
had O
no O
proteinuria, O
whereas O
afterwards O
all O
patients O
had O
proteinuria. O
In O
28% O
of O
patients O
proteinuria O
remained O
unchanged, O
whereas O
it O
increased O
in O
68% O
of O
patients. O
In O
40% O
it O
increased O
by O
more O
than O
100%. O
Twenty-eight O
percent O
of O
patients O
showed O
increased O
proteinuria O
to O
the O
nephrotic B
range. O
Biopsies O
performed O
in O
five O
patients O
revealed O
new O
pathological O
changes: O
One O
membranoproliferative B
glomerulopathy I
and O
interstitial B
nephritis. I
These O
patients O
showed O
persistently O
good O
graft O
function. O
Serum O
creatinine O
values O
did O
not O
change O
significantly: O
1.98 O
+/- O
0.8 O
mg/dL O
before O
SRL O
therapy O
and O
2.53 O
+/- O
1.9 O
mg/dL O
at O
last O
follow-up O
(P O
= O
.14). O
Five O
grafts O
were O
lost O
and O
the O
patients O
returned O
to O
dialysis. O
Five O
patients O
displayed O
CAN O
and O
Kaposi's O
sarcoma. O
Mean O
urinary O
protein O
of O
patients O
who O
returned O
to O
dialysis O
was O
1.26 O
(0.5 O
to O
3.5) O
g/d O
before O
and O
4.7 O
(3 O
to O
12) O
g/d O
after O
conversion O
(P O
= O
.01). O
Mean O
serum O
creatinine O
level O
before O
conversion O
was O
2.21 O
mg/dL O
and O
thereafter, O
4.93 O
mg/dL O
(P O
= O
.02). O
Heavy O
proteinuria O
was O
common O
after O
the O
use O
of O
SRL O
as O
rescue O
therapy O
for O
renal O
transplantation. O
Therefore, O
conversion O
should O
be O
considered O
for O
patients O
who O
have O
not O
developed O
advanced O
CAN O
and O
proteinuria. O
The O
possibility O
of O
de O
novo O
glomerular O
pathology O
under O
SRL O
treatment O
requires O
further O
investigation O
by O
renal O
biopsy. O

Acute O
reserpine O
and O
subchronic O
haloperidol O
treatments O
change O
synaptosomal O
brain O
glutamate O
uptake O
and O
elicit O
orofacial B
dyskinesia I
in O
rats. O

Dissociated O
learning O
of O
rats O
in O
the O
normal O
state O
and O
the O
state O
of O
amnesia B
produced O
by O
pentobarbital O
(15 O
mg/kg, O
ip) O
was O
carried O
out. O
Rats O
were O
trained O
to O
approach O
a O
shelf O
where O
they O
received O
food O
reinforcement. O
In O
Group O
1 O
the O
rats O
were O
trained O
under O
the O
influence O
of O
pentobarbital O
to O
run O
to O
the O
same O
shelf O
as O
in O
the O
normal O
state. O
In O
Group O
2 O
the O
rats O
were O
trained O
to O
approach O
different O
shelves O
in O
different O
drug O
states. O
It O
was O
shown O
that O
memory B
dissociation I
occurred O
in O
both O
groups. O
Differences O
in O
the O
parameters O
of O
training O
under O
the O
influence O
of O
pentobarbital O
between O
Groups O
1 O
and O
2 O
were O
revealed. O
These O
findings O
show O
that O
the O
brain-dissociated O
state O
induced O
by O
pentobarbital O
is O
formed O
with O
the O
participation O
of O
the O
mechanisms O
of O
information O
perception. O

Acute O
vocal B
fold I
palsy I
after O
acute O
disulfiram O
intoxication. O

Mediation O
of O
enhanced O
reflex O
vagal O
bradycardia B
by O
L-dopa O
via O
central O
dopamine O
formation O
in O
dogs. O

In O
a O
randomized O
study, O
labetalol-induced O
hypotension B
and O
nitroprusside-induced O
hypotension O
were O
compared O
in O
20 O
patients O
(10 O
in O
each O
group) O
scheduled O
for O
major O
orthopedic O
procedures. O
Each O
patient O
was O
subjected O
to O
an O
identical O
anesthetic O
protocol O
and O
similar O
drug-induced O
reductions B
in I
mean I
arterial I
blood I
pressure I
(BP) O
(50 O
to O
55 O
mmHg). O
Nitroprusside O
infusion O
was O
associated O
with O
a O
significant O
(p O
less O
than O
0.05) O
increase B
in I
heart I
rate I
and I
cardiac I
output; I
rebound O
hypertension B
was O
observed O
in O
three O
patients O
after O
discontinuation O
of O
nitroprusside. O
Labetalol O
administration O
was O
not O
associated O
with O
any O
of O
these O
findings. O
Arterial O
PO2 O
decreased O
in O
both O
groups. O
It O
was O
concluded O
that O
labetalol O
offers O
advantages O
over O
nitroprusside. O

Prophylactic O
use O
of O
lamivudine O
with O
chronic O
immunosuppressive O
therapy O
for O
rheumatologic B
disorders. I

Cerebral O
blood O
flow O
and O
metabolism O
during O
isoflurane-induced O
hypotension B
in O
patients O
subjected O
to O
surgery O
for O
cerebral B
aneurysms. I

BACKGROUND: O
Current O
animal O
models O
of O
obsessive-compulsive B
disorder I
(OCD) O
typically B
involve O
acute, O
drug-induced O
symptom O
provocation O
or O
a O
genetic O
association O
with O
stereotypies O
or O
anxiety. B
None O
of O
these O
current O
models O
demonstrate O
multiple O
OCD-like O
behaviors. O
METHODS: O
Neonatal O
rats O
were O
treated O
with O
the O
tricyclic O
antidepressant O
clomipramine O
or O
vehicle O
between O
days O
9 O
and O
16 O
twice O
daily O
and O
behaviorally O
tested O
in O
adulthood. O
RESULTS: O
Clomipramine O
exposure O
in O
immature O
rats O
produced O
significant O
behavioral O
and O
biochemical O
changes O
that O
include O
enhanced O
anxiety O
(elevated O
plus O
maze O
and O
marble O
burying), O
behavioral B
inflexibility I
(perseveration O
in O
the O
spontaneous O
alternation O
task O
and O
impaired O
reversal O
learning), O
working O
memory B
impairment I
(e.g., O
win-shift O
paradigm), O
hoarding, B
and O
corticostriatal B
dysfunction. I
Dopamine O
D2 O
receptors O
were O
elevated O
in O
the O
striatum, O
whereas O
serotonin O
2C, O
but O
not O
serotonin O
1A, O
receptors O
were O
elevated O
in O
the O
orbital O
frontal O
cortex. O
CONCLUSIONS: O
This O
is O
the O
first O
demonstration O
of O
multiple O
symptoms O
consistent O
with O
an O
OCD-like O
profile O
in O
animals. O
Moreover, O
these O
behaviors O
are O
accompanied O
by O
biochemical O
changes O
in O
brain O
regions O
previously O
identified O
as O
relevant O
to O
OCD. O
This O
novel O
model O
of O
OCD O
demonstrates O
that O
drug O
exposure O
during O
a O
sensitive O
period O
can O
program O
disease-like O
systems O
permanently, O
which O
could O
have O
implications O
for O
current O
and O
future O
therapeutic O
strategies O
for O
this O
and O
other O
psychiatric B
disorders. I

The O
recreational O
use O
of O
cocaine O
is O
on O
the O
increase. O
The O
emergency O
nurse O
ought O
to O
be O
familiar O
with O
some O
of O
the O
cardiovascular O
consequences O
of O
cocaine O
use. O
In O
particular, O
the O
tendency O
of O
cocaine O
to O
produce O
chest B
pain I
ought O
to O
be O
in O
the O
mind O
of O
the O
emergency O
nurse O
when O
faced O
with O
a O
young O
victim O
of O
chest O
pain O
who O
is O
otherwise O
at O
low O
risk. O
The O
mechanism O
of O
chest O
pain O
related O
to O
cocaine O
use O
is O
discussed O
and O
treatment O
dilemmas O
are O
discussed. O
Finally, O
moral O
issues O
relating O
to O
the O
testing O
of O
potential O
cocaine O
users O
will O
be O
addressed. O

The O
rabbit B
syndrome I
is O
an O
extrapyramidal O
side O
effect O
associated O
with O
chronic O
neuroleptic O
therapy. O
Its O
occurrence O
in O
a O
patient O
being O
treated O
with O
imipramine O
is O
described, O
representing O
the O
first O
reported O
case O
of O
this O
syndrome O
in O
conjunction O
with O
antidepressants. O
Repeated O
cerebral O
perfusion O
SPECT O
scans O
revealed O
decreased B
basal I
ganglia I
perfusion I
while O
the O
movement B
disorder I
was O
present, O
and O
a O
return O
to O
normal O
perfusion O
when O
the O
rabbit O
syndrome O
resolved. O

Cardiovascular B
alterations I
in O
rat O
fetuses O
exposed O
to O
calcium O
channel O
blockers. O

OBJECTIVE: O
To O
report O
a O
case O
of O
central O
retinal B
vein I
occlusion I
associated O
with O
clomiphene O
citrate O
(CC). O
DESIGN: O
Case O
study. O
SETTING: O
Ophthalmology O
clinic O
of O
an O
academic O
hospital. O
PATIENT(S): O
A O
36-year-old O
woman O
referred O
from O
the O
infertility B
clinic O
for O
blurred B
vision. I
INTERVENTION(S): O
Ophthalmic O
examination O
after O
CC O
therapy. O
MAIN O
OUTCOME O
MEASURE(S): O
Central O
retinal O
vein O
occlusion O
after O
ovulation O
induction O
with O
CC. O
RESULT(S): O
A O
36-year-old O
Chinese O
woman O
developed O
central O
retinal O
vein O
occlusion O
after O
eight O
courses O
of O
CC. O
A O
search O
of O
the O
literature O
on O
the O
thromboembolic B
complications O
of O
CC O
does O
not O
include O
this O
severe O
ophthalmic O
complication, O
although O
mild O
visual B
disturbance I
after O
CC O
intake O
is O
not O
uncommon. O
CONCLUSION(S): O
This O
is O
the O
first O
reported O
case O
of O
central O
retinal O
vein O
occlusion O
after O
treatment O
with O
CC. O
Extra O
caution O
is O
warranted O
in O
treating O
infertility O
patients O
with O
CC, O
and O
patients O
should O
be O
well O
informed O
of O
this O
side O
effect O
before O
commencement O
of O
therapy. O

Renal B
papillary I
necrosis I
(RPN) O
and B
a O
decreased O
urinary O
concentrating O
ability O
developed O
during O
continuous O
long-term O
treatment O
with O
aspirin O
and O
paracetamol O
in O
female O
Fischer O
344 O
rats. O
Renal O
structure O
and O
concentrating O
ability O
were O
examined O
after O
a O
recovery O
period O
of O
up O
to O
18 O
weeks, O
when O
no O
analgesics O
were O
given, O
to O
investigate O
whether O
the O
analgesic-induced O
changes O
were O
reversible. O
There O
was O
no O
evidence O
of O
repair O
to O
the O
damaged O
medullary O
interstitial O
matrix, O
or O
proliferation O
of O
remaining O
undamaged O
type O
1 O
medullary O
interstitial O
cells O
after O
the O
recovery O
period O
following O
analgesic O
treatment. O
The O
recovery O
of O
urinary O
concentrating O
ability O
was O
related O
to O
the O
length O
of O
analgesic O
treatment O
and O
the O
extent O
of O
the O
resulting O
inner O
medullary O
structural O
damage. O
During O
the O
early O
stages O
of O
analgesic O
treatment, O
the O
changes O
in O
urinary O
concentrating O
ability O
were O
reversible, O
but O
after O
prolonged O
analgesic O
treatment, O
maximum O
urinary O
concentrating O
ability O
failed O
to O
recover. O
This O
study O
shows O
that O
prolonged O
analgesic O
treatment O
in O
Fischer O
344 O
rats O
causes O
progressive O
and O
irreversible O
damage O
to O
the O
interstitial O
matrix O
and O
type O
1 O
interstitial O
cells O
leading O
to O
RPN. O
The O
associated O
urinary O
concentrating O
defect O
is O
reversible O
only O
during O
the O
early O
stages O
of O
structural O
damage O
to O
the O
inner O
medulla. O

Effects O
of O
uninephrectomy O
and O
high O
protein O
feeding O
on O
lithium-induced O
chronic B
renal I
failure I
in O
rats. O

PURPOSE: O
To O
evaluate O
the O
response O
rate O
and O
toxic O
effects O
of O
vinorelbine O
(VNB) O
administered O
as O
a O
single O
agent O
in O
metastatic O
squamous B
cell I
esophageal I
carcinoma. I
PATIENTS O
AND O
METHODS: O
Forty-six O
eligible O
patients O
with O
measurable O
lesions O
were O
included O
and O
were O
stratified O
according O
to O
previous O
chemotherapy. O
Thirty O
patients O
without O
prior O
chemotherapy O
and O
16 O
pretreated O
with O
cisplatin-based O
chemotherapy O
were O
assessable O
for O
toxicity B
and O
response. O
VNB O
was O
administered O
weekly O
as O
a O
25-mg/m2 O
short O
intravenous O
(i.v.) O
infusion. O
RESULTS: O
Six O
of O
30 O
patients O
(20%) O
without O
prior O
chemotherapy O
achieved O
a O
partial O
response O
(PR) O
(95% O
confidence O
interval O
[CI], O
8% O
to O
39%). O
The O
median O
duration O
of O
response O
was O
21 O
weeks O
(range, O
17 O
to O
28). O
One O
of O
16 O
patients O
(6%) O
with O
prior O
chemotherapy O
had O
a O
complete O
response O
(CR) O
of O
31 O
weeks' O
duration O
(95% O
CI, O
0% O
to O
30%). O
The O
overall O
response O
rate O
(World O
Health O
Organization O
[WHO] O
criteria) O
was O
15% O
(CR, O
2%; O
PR O
13%; O
95% O
CI, O
6% O
to O
29%). O
The O
median O
dose-intensity O
(DI) O
was O
20 O
mg/m2/wk. O
VNB O
was O
well O
tolerated O
and O
zero O
instances O
of O
WHO O
grade O
4 O
nonhematologic O
toxicity O
occurred. O
At O
least O
one O
episode O
of O
grade O
3 O
or O
4 O
granulocytopenia B
was O
seen O
in O
59% O
of O
patients. O
A O
grade O
2 O
or O
3 O
infection B
occurred O
in O
16% O
of O
patients, O
but O
no O
toxic O
deaths B
occurred. O
Other O
side O
effects O
were O
rare, O
and O
peripheral B
neurotoxicity I
has O
been O
minor O
(26% O
grade O
1). O
CONCLUSION: O
These O
data O
indicate O
that O
VNB O
is O
an O
active O
agent O
in O
metastatic O
esophageal B
squamous I
cell I
carcinoma. I
Given O
its O
excellent O
tolerance O
profile O
and O
low O
toxicity, O
further O
evaluation O
of O
VNB O
in O
combination O
therapy O
is O
warranted. O

Seven O
patients O
suffering O
from O
Parkinson's B
disease I
(PD) O
with B
severely O
disabling O
dyskinesia B
received O
low-dose O
propranolol O
as O
an O
adjunct O
to O
the O
currently O
used O
medical O
treatment. O
There O
was O
a O
significant O
40% O
improvement O
in O
the O
dyskinesia O
score O
without O
increase O
of O
parkinsonian B
motor B
disability. I
Ballistic O
and O
choreic O
dyskinesia O
were O
markedly O
ameliorated, O
whereas O
dystonia B
was O
not. O
This O
study O
suggests O
that O
administration O
of O
low O
doses O
of O
beta-blockers O
may O
improve O
levodopa-induced O
ballistic O
and O
choreic O
dyskinesia O
in O
PD. O

Age-dependent O
sensitivity O
of O
the O
rat O
to O
neurotoxic B
effects O
of O
streptomycin. O

Haemolytic-uraemic B
syndrome I
after O
treatment O
with O
metronidazole. O

An O
elderly O
patient O
treated O
with O
low O
dose O
Desipramine O
developed O
a O
delirium B
while O
her O
plasma O
level O
was O
in O
the O
"subtherapeutic" O
range. O
Delirium, B
which O
may O
be O
induced O
by O
tricyclic O
drug O
therapy O
in O
the O
elderly, O
can O
be O
caused O
by O
tricyclics O
with O
low O
anticholinergic O
potency. O
Therapeutic O
ranges O
for O
antidepressants O
that O
have O
been O
derived O
from O
general O
adult O
population O
studies O
may O
not O
be O
appropriate O
for O
the O
elderly. O
Further O
studies O
of O
specifically O
elderly O
patients O
are O
now O
required O
to O
establish O
safer O
and O
more O
appropriate O
guidelines O
for O
drug O
therapy. O

Comparison O
of O
i.v. O
glycopyrrolate O
and O
atropine O
in O
the O
prevention O
of O
bradycardia B
and O
arrhythmias B
following O
repeated O
doses O
of O
suxamethonium O
in O
children. O

Adriamycin-induced O
autophagic O
cardiomyocyte O
death B
plays O
a O
pathogenic O
role O
in O
a O
rat O
model O
of O
heart B
failure. I

Suxamethonium-induced O
cardiac B
arrest I
and O
death B
following O
5 O
days O
of O
immobilization. O

Persistent O
paralysis B
after O
prolonged O
use O
of O
atracurium O
in O
the O
absence O
of O
corticosteroids. O

Five O
patients O
with O
carcinoma B
developed O
thrombotic B
microangiopathy I
(characterized O
by O
renal B
insufficiency, I
microangiopathic B
hemolytic I
anemia, B
and O
usually O
thrombocytopenia) B
after O
treatment O
with O
cisplatin, O
bleomycin, O
and O
a O
vinca O
alkaloid. O
One O
patient O
had O
thrombotic B
thrombocytopenic I
purpura, I
three O
the O
hemolytic-uremic B
syndrome, I
and O
one O
an O
apparent O
forme O
fruste O
of O
one O
of O
these O
disorders. O
Histologic O
examination O
of O
the O
renal O
tissue O
showed O
evidence O
of O
intravascular B
coagulation, I
primarily O
affecting O
the O
small O
arteries, O
arterioles, O
and O
glomeruli. O
Because O
each O
patient O
was O
tumor-free B
or O
had O
only O
a O
small O
tumor O
at O
the O
onset O
of O
this O
syndrome, O
the O
thrombotic O
microangiopathy O
may O
have O
been O
induced O
by O
chemotherapy. O
Diagnosis O
of O
this O
potentially O
fatal O
complication O
may O
be O
delayed O
or O
missed O
if O
renal O
tissue O
or O
the O
peripheral O
blood O
smear O
is O
not O
examined, O
because O
renal B
failure I
may O
be O
ascribed O
to O
cisplatin O
nephrotoxicity B
and O
the O
anemia O
and O
thrombocytopenia O
to O
drug-induced O
bone B
marrow I
suppression. I

High O
incidence O
of O
primary B
pulmonary I
hypertension I
associated O
with O
appetite O
suppressants O
in O
Belgium. O

In O
vitro O
characterization O
of O
parasympathetic O
and O
sympathetic O
responses O
in O
cyclophosphamide-induced O
cystitis B
in O
the O
rat. O

Is O
the O
treatment O
of O
scabies B
hazardous? O

The O
influence O
of O
sevoflurane O
on O
lidocaine-induced O
convulsions B
was O
studied O
in O
cats. O
The O
convulsive B
threshold O
(mean O
+/- O
SD) O
was O
41.4 O
+/- O
6.5 O
mg. O
l(-1) O
with O
lidocaine O
infusion O
(6 O
mg.kg(-1).min(-1)), O
increasing O
significantly O
to O
66.6 O
+/- O
10.9 O
mg. O
l(-1) O
when O
the O
end-tidal O
concentration O
of O
sevoflurane O
was O
0.8%. O
However, O
the O
threshold O
(61.6 O
+/- O
8.7 O
mg. O
l(-1)) O
during O
1.6% O
sevoflurane O
was O
not O
significant O
from O
that O
during O
0.8% O
sevoflurane, O
indicating O
a O
celling O
effect. O
There O
was O
no O
significant O
difference O
in O
the O
convulsive O
threshold O
between O
sevoflurane O
and O
enflurane. O
The O
rise O
in O
blood O
pressure O
became O
less O
marked O
when O
higher O
concentrations O
of O
sevoflurane O
or O
enflurane O
were O
administered O
and O
the O
blood O
pressure O
at O
convulsions O
decreased O
significantly O
in O
1.6% O
sevoflurane, O
and O
in O
0.8% O
and O
1.6% O
enflurane. O
However, O
there O
was O
no O
significant O
difference O
in O
the O
lidocaine O
concentrations O
measured O
when O
the O
systolic O
blood O
pressure O
became O
70 O
mmHg. O
Apamin, O
a O
selective O
blocker O
of O
calcium-dependent O
potassium O
channels, O
was O
administered O
intracerebroventricularly O
in O
rats O
anesthetized O
with O
0.8% O
sevoflurane O
to O
investigate O
the O
mechanism O
of O
the O
anticonvulsive O
effects. O
Apamin O
(10 O
ng) O
had O
a O
tendency O
to O
decrease O
the O
convulsive O
threshold O
(21.6 O
+/- O
2.2 O
to O
19.9 O
+/- O
2.5 O
mg. O
l(-1)) O
but O
this O
was O
not O
statistically O
significant. O
It O
is O
suggested O
that O
sevoflurane O
reduces O
the O
convulsive O
effect O
of O
lidocaine O
toxicity B
but O
carries O
some O
risk O
due O
to O
circulatory O
depression. B

Stroke B
associated O
with O
cocaine O
use. O

Triazolam-induced O
brief O
episodes O
of O
secondary O
mania B
in O
a O
depressed B
patient. O

Granulomatous B
hepatitis B
due O
to O
combination O
of O
amoxicillin O
and O
clavulanic O
acid. O

Highly O
active O
antiretroviral O
therapy O
(HAART) O
is O
implicated O
in O
cardiomyopathy B
(CM) O
and B
in O
elevated O
plasma O
lactate O
(LA) O
in O
AIDS B
through O
mechanisms O
of O
mitochondrial B
dysfunction. I
To O
determine O
mitochondrial O
events O
from O
HAART O
in O
vivo, O
8-week-old O
hemizygous O
transgenic O
AIDS O
mice O
(NL4-3Delta O
gag/pol; O
TG) O
and O
wild-type O
FVB/n O
littermates O
were O
treated O
with O
the O
HAART O
combination O
of O
zidovudine, O
lamivudine, O
and O
indinavir O
or O
vehicle O
control O
for O
10 O
days O
or O
35 O
days. O
At O
termination O
of O
the O
experiments, O
mice O
underwent O
echocardiography, O
quantitation O
of O
abundance O
of O
molecular O
markers O
of O
CM O
(ventricular O
mRNA O
encoding O
atrial O
natriuretic O
factor O
[ANF] O
and O
sarcoplasmic O
calcium O
ATPase O
[SERCA2]), O
and O
determination O
of O
plasma O
LA. O
Myocardial O
histologic O
features O
were O
analyzed O
semiquantitatively O
and O
results O
were O
confirmed O
by O
transmission O
electron O
microscopy. O
After O
35 O
days O
in O
the O
TG O
+ O
HAART O
cohort, O
left O
ventricular O
mass O
increased O
160% O
by O
echocardiography. O
Molecularly, O
ANF O
mRNA O
increased O
250% O
and O
SERCA2 O
mRNA O
decreased O
57%. O
Biochemically, O
LA O
was O
elevated O
(8.5 O
+/- O
2.0 O
mM). O
Pathologically, O
granular O
cytoplasmic O
changes O
were O
found O
in O
cardiac O
myocytes, O
indicating O
enlarged, O
damaged O
mitochondria. O
Findings O
were O
confirmed O
ultrastructurally. O
No O
changes O
were O
found O
in O
other O
cohorts. O
After O
10 O
days, O
only O
ANF O
was O
elevated, O
and O
only O
in O
the O
TG O
+ O
HAART O
cohort. O
Results O
show O
that O
cumulative O
HAART O
caused O
mitochondrial O
CM O
with O
elevated O
LA O
in O
AIDS O
transgenic O
mice. O

PURPOSE: O
The O
multidrug O
resistance O
protein O
2 O
(MRP2) O
is O
a O
drug O
efflux O
transporter O
that O
is O
expressed O
predominantly O
at O
the O
apical O
domain O
of O
hepatocytes O
but O
seems O
also O
to O
be O
expressed O
at O
the O
apical O
membrane O
of O
brain O
capillary O
endothelial O
cells O
that O
form O
the O
blood-brain O
barrier O
(BBB). O
MRP2 O
is O
absent O
in O
the O
transport-deficient O
(TR(-)) O
Wistar O
rat O
mutant, O
so O
that O
this O
rat O
strain O
was O
very O
helpful O
in O
defining O
substrates O
of O
MRP2 O
by O
comparing O
tissue O
concentrations O
or O
functional O
activities O
of O
compounds O
in O
MRP2-deficient O
rats O
with O
those O
in O
transport-competent O
Wistar O
rats. O
By O
using O
this O
strategy O
to O
study O
the O
involvement O
of O
MRP2 O
in O
brain O
access O
of O
antiepileptic O
drugs O
(AEDs), O
we O
recently O
reported O
that O
phenytoin O
is O
a O
substrate O
for O
MRP2 O
in O
the O
BBB. O
However, O
one O
drawback O
of O
such O
studies O
in O
genetically O
deficient O
rats O
is O
the O
fact O
that O
compensatory O
changes O
with O
upregulation O
of O
other O
transporters O
can O
occur. O
This O
prompted O
us O
to O
study O
the O
brain O
expression O
of O
P-glycoprotein O
(Pgp), O
a O
major O
drug O
efflux O
transporter O
in O
many O
tissues, O
including O
the O
BBB, O
in O
TR(-) O
rats O
compared O
with O
nonmutant O
(wild-type) O
Wistar O
rats. O
METHODS: O
The O
expression O
of O
MRP2 O
and O
Pgp O
in O
brain O
and O
liver O
sections O
of O
TR(-) O
rats O
and O
normal O
Wistar O
rats O
was O
determined O
with O
immunohistochemistry, O
by O
using O
a O
novel, O
highly O
selective O
monoclonal O
MRP2 O
antibody O
and O
the O
monoclonal O
Pgp O
antibody O
C219, O
respectively. O
RESULTS: O
Immunofluorescence O
staining O
with O
the O
MRP2 O
antibody O
was O
found O
to O
label O
a O
high O
number O
of O
microvessels O
throughout O
the O
brain O
in O
normal O
Wistar O
rats, O
whereas O
such O
labeling O
was O
absent O
in O
TR(-) O
rats. O
TR(-) O
rats O
exhibited O
a O
significant O
up-regulation O
of O
Pgp O
in O
brain O
capillary O
endothelial O
cells O
compared O
with O
wild-type O
controls. O
No O
such O
obvious O
upregulation O
of O
Pgp O
was O
observed O
in O
liver O
sections. O
A O
comparable O
overexpression O
of O
Pgp O
in O
the O
BBB O
was O
obtained O
after O
pilocarpine-induced O
seizures B
in O
wild-type O
Wistar O
rats. O
Experiments O
with O
systemic O
administration O
of O
the O
Pgp O
substrate O
phenobarbital O
and O
the O
selective O
Pgp O
inhibitor O
tariquidar O
in O
TR(-) O
rats O
substantiated O
that O
Pgp O
is O
functional O
and O
compensates O
for O
the O
lack O
of O
MRP2 O
in O
the O
BBB. O
CONCLUSIONS: O
The O
data O
on O
TR(-) O
rats O
indicate O
that O
Pgp O
plays O
an O
important O
role O
in O
the O
compensation O
of O
MRP2 O
deficiency O
in O
the O
BBB. O
Because O
such O
a O
compensatory O
mechanism O
most O
likely O
occurs O
to O
reduce O
injury B
to I
the I
brain I
from O
cytotoxic O
compounds, O
the O
present O
data O
substantiate O
the O
concept O
that O
MRP2 O
performs O
a O
protective O
role O
in O
the O
BBB. O
Furthermore, O
our O
data O
suggest O
that O
TR(-) O
rats O
are O
an O
interesting O
tool O
to O
study O
consequences O
of O
overexpression O
of O
Pgp O
in O
the O
BBB O
on O
access O
of O
drugs O
in O
the O
brain, O
without O
the O
need O
of O
inducing O
seizures O
or O
other O
Pgp-enhancing O
events O
for O
this O
purpose. O

Vitamin O
D3 O
toxicity B
in O
dairy O
cows. O

Reversible O
inferior B
colliculus I
lesion I
in O
metronidazole-induced O
encephalopathy: B
magnetic O
resonance O
findings O
on O
diffusion-weighted O
and O
fluid O
attenuated O
inversion O
recovery O
imaging. O

Treatment O
of O
psoriasis B
with O
azathioprine. O

We O
report O
a O
patient O
in O
whom O
hypersensitivity B
to O
carbamazepine O
presented O
with O
generalized O
erythroderma, B
a O
severe O
leukemoid B
reaction, I
eosinophilia, B
hyponatremia, B
and O
renal B
failure. I
This O
is O
the O
first O
report O
of O
such O
an O
unusual O
reaction O
to O
carbamazepine. O

Two O
of O
14 O
patients O
with O
Cushing's B
syndrome I
treated O
on O
a O
long-term O
basis O
with O
ketoconazole O
developed O
sustained O
hypertension. B
In O
both O
cases O
normal O
plasma O
and O
urinary O
free O
cortisol O
levels O
had O
been O
achieved O
following O
ketoconazole O
therapy, O
yet O
continuous O
blood O
pressure O
monitoring O
demonstrated O
hypertension O
31 O
(patient O
1) O
and O
52 O
weeks O
(patient O
2) O
after O
treatment. O
In O
patient O
1, O
plasma O
levels O
of O
deoxycorticosterone O
and O
11-deoxycortisol O
were O
elevated. O
In O
patient O
2, O
in O
addition O
to O
an O
increase O
in O
both O
deoxycorticosterone O
and O
11-deoxycortisol O
levels, O
plasma O
aldosterone O
values O
were O
raised, O
with O
a O
concomitant O
suppression O
of O
renin O
levels. O
Our O
findings O
show O
that O
long-term O
treatment O
with O
high O
doses O
of O
ketoconazole O
may O
induce O
enzyme O
blockade O
leading O
to O
mineralocorticoid-related O
hypertension. O

Effects O
of O
training O
on O
the O
extent O
of O
experimental O
myocardial B
infarction I
in O
aging O
rats. O

Recurrent O
acute O
interstitial B
nephritis I
induced O
by O
azithromycin. O

Cerebral B
vasculitis I
following O
oral O
methylphenidate O
intake O
in O
an O
adult: O
a O
case O
report. O

Indomethacin-induced O
renal B
insufficiency: I
recurrence O
on O
rechallenge. O

In O
vivo O
protection O
of O
dna O
damage O
associated O
apoptotic O
and O
necrotic B
cell O
deaths O
during O
acetaminophen-induced O
nephrotoxicity, B
amiodarone-induced O
lung B
toxicity I
and O
doxorubicin-induced O
cardiotoxicity B
by O
a O
novel O
IH636 O
grape O
seed O
proanthocyanidin O
extract. O

Bupropion O
is O
a O
monocyclic O
antidepressant O
structurally O
related O
to O
amphetamine. O
Zyban, O
a O
sustained-release O
formulation O
of O
bupropion O
hydrochloride, O
was O
recently O
released O
in O
Ireland, O
as O
a O
smoking O
cessation O
aid. O
In O
the O
initial O
6 O
months O
since O
it's O
introduction, O
12 O
overdose B
cases O
have O
been O
reported O
to O
The O
National O
Poisons O
Information O
Centre. O
8 O
patients O
developed O
symptoms O
of O
toxicity. B
Common O
features O
included O
tachycardia, B
drowsiness, O
hallucinations B
and O
convulsions. B
Two O
patients O
developed O
severe O
cardiac B
arrhythmias, I
including O
one O
patient O
who O
was O
resuscitated O
following O
a O
cardiac B
arrest. I
All O
patients O
recovered O
without O
sequelae. O
We O
report O
a O
case O
of O
a O
31 O
year O
old O
female O
who O
required O
admission O
to O
the O
Intensive O
Care O
Unit O
for O
ventilation O
and O
full O
supportive O
therapy, O
following O
ingestion O
of O
13.5g O
bupropion. O
Recurrent O
seizures B
were O
treated O
with O
diazepam O
and O
broad O
complex O
tachycardia O
was O
successfully O
treated O
with O
adenosine. O
Zyban O
caused O
significant O
neurological B
and I
cardiovascular B
toxicity I
in O
overdose. O
The O
potential O
toxic O
effects O
should O
be O
considered O
when O
prescribing O
it O
as O
a O
smoking O
cessation O
aid. O

BACKGROUND: O
Electrocardiography O
has O
a O
very O
low O
sensitivity O
in O
detecting O
dobutamine-induced O
myocardial B
ischemia. I
OBJECTIVES: O
To O
assess O
the O
added O
diagnostic O
value O
of O
a O
new O
cardiac O
performance O
index O
(dP/dtejc) O
measurement, O
based O
on O
brachial O
artery O
flow O
changes, O
as O
compared O
to O
standard O
12-lead O
ECG, O
for O
detecting O
dobutamine-induced O
myocardial O
ischemia, O
using O
Tc99m-Sestamibi O
single-photon O
emission O
computed O
tomography O
as O
the O
gold O
standard O
of O
comparison O
to O
assess O
the O
presence O
or O
absence O
of O
ischemia. O
METHODS: O
The O
study O
group O
comprised O
40 O
patients O
undergoing O
Sestamibi-SPECT/dobutamine O
stress O
test. O
Simultaneous O
measurements O
of O
ECG O
and O
brachial O
artery O
dP/dtejc O
were O
performed O
at O
each O
dobutamine O
level. O
In O
19 O
of O
the O
40 O
patients O
perfusion O
defects O
compatible O
with O
ischemia O
were O
detected O
on O
SPECT. O
The O
increase O
in O
dP/dtejc O
during O
infusion O
of O
dobutamine O
in O
this O
group O
was O
severely O
impaired O
as O
compared O
to O
the O
non-ischemic O
group. O
dP/dtejc O
outcome O
was O
combined O
with O
the O
ECG O
results, O
giving O
an O
ECG-enhanced O
value, O
and O
compared O
to O
ECG O
alone. O
RESULTS: O
The O
sensitivity O
improved O
dramatically O
from O
16% O
to O
79%, O
positive O
predictive O
value O
increased O
from O
60% O
to O
68% O
and O
negative O
predictive O
value O
from O
54% O
to O
78%, O
and O
specificity O
decreased O
from O
90% O
to O
67%. O
CONCLUSIONS: O
If O
ECG O
alone O
is O
used O
for O
specificity, O
the O
combination O
with O
dP/dtejc O
improved O
the O
sensitivity O
of O
the O
test O
and O
could O
be O
a O
cost-savings O
alternative O
to O
cardiac O
imaging O
or O
perfusion O
studies O
to O
detect O
myocardial O
ischemia, O
especially O
in O
patients O
unable O
to O
exercise. O

The O
risk O
of O
venous B
thromboembolism I
in O
women O
prescribed O
cyproterone O
acetate O
in O
combination O
with O
ethinyl O
estradiol: O
a O
nested O
cohort O
analysis O
and O
case-control O
study. O

The O
anti-dementia O
effects B
of O
s-limonene O
and O
s-perillyl O
alcohol O
were O
observed O
using O
the O
passive O
avoidance O
test O
(PA) O
and O
the O
open O
field O
habituation O
test O
(OFH). O
These O
lemon O
essential O
oils O
showed O
strong O
ability O
to O
improve O
memory B
impaired I
by O
scopolamine; O
however, O
s-perillyl O
alcohol O
relieved O
the O
deficit B
of I
associative I
memory I
in O
PA O
only, O
and O
did O
not O
improve O
non-associative O
memory O
significantly O
in O
OFH. O
Analysis O
of O
neurotransmitter O
concentration O
in O
some O
brain O
regions O
on O
the O
test O
day O
showed O
that O
dopamine O
concentration O
of O
the O
vehicle/scopolamine O
group O
was O
significantly O
lower O
than O
that O
of O
the O
vehicle/vehicle O
group, O
but O
this O
phenomenon O
was O
reversed O
when O
s-limonene O
or O
s-perillyl O
alcohol O
were O
administered O
before O
the O
injection O
of O
scopolamine. O
Simultaneously, O
we O
found O
that O
these O
two O
lemon O
essential O
oil O
components O
could O
inhibit O
acetylcholinesterase O
activity O
in O
vitro O
using O
the O
Ellman O
method. O

Valproic O
acid O
(VPA) O
is O
a O
broad-spectrum O
antiepileptic O
drug O
and O
is O
usually O
well-tolerated. O
Rare O
serious O
complications O
may O
occur O
in O
some O
patients, O
including O
haemorrhagic O
pancreatitis, B
bone B
marrow I
suppression, I
VPA-induced O
hepatotoxicity B
and O
VPA-induced O
encephalopathy. B
The O
typical O
signs O
of O
VPA-induced O
encephalopathy O
are O
impaired B
consciousness, I
sometimes O
marked O
EEG O
background O
slowing, O
increased O
seizure B
frequency, O
with O
or O
without O
hyperammonemia. B
There O
is O
still O
no O
proof O
of O
causative O
effect O
of O
VPA O
in O
patients O
with O
encephalopathy, O
but O
only O
of O
an O
association O
with O
an O
assumed O
causal O
relation. O
We O
report O
19 O
patients O
with O
VPA-associated O
encephalopathy O
in O
Germany O
from O
the O
years O
1994 O
to O
2003, O
none O
of O
whom O
had O
been O
published O
previously. O

Cardiac B
toxicity I
observed O
in O
association O
with O
high-dose O
cyclophosphamide-based O
chemotherapy O
for O
metastatic O
breast B
cancer. I

Inappropriate O
use O
of O
carbamazepine O
and O
vigabatrin O
in O
typical O
absence B
seizures. I

Based O
on O
clinical O
data, O
indicating O
that O
chloroacetaldehyde O
(CAA) O
is O
an O
important O
metabolite O
of O
oxazaphosphorine O
cytostatics, O
an O
experimental O
study O
was O
carried O
out O
in O
order O
to O
elucidate O
the O
role O
of O
CAA O
in O
the O
development O
of O
hemorrhagic B
cystitis. B
The O
data O
demonstrate O
that O
CAA O
after O
i.v. O
administration O
does O
not O
contribute O
to O
bladder B
damage. I
When O
instilled O
directly O
into O
the O
bladder, O
CAA O
exerts O
urotoxic O
effects, O
it O
is, O
however, O
susceptible O
to O
detoxification O
with O
mesna. O

BACKGROUND: O
Fibrin O
sealants O
(FS) O
derived O
from O
human O
plasma O
are O
frequently O
used O
in O
neurosurgery. O
In O
order O
to O
increase O
clot O
stability, O
FS O
typically O
contain O
aprotinin, O
a O
natural O
fibrinolysis O
inhibitor. O
Recently, O
synthetic O
fibrinolysis O
inhibitors O
such O
as O
tranexamic O
acid O
(tAMCA) O
have O
been O
considered O
as O
substitutes O
for O
aprotinin. O
However, O
tAMCA O
has O
been O
shown O
to O
cause O
epileptic B
seizures. B
We O
wanted O
to O
study O
whether O
tAMCA O
retains O
its O
convulsive B
action O
if O
incorporated O
into O
a O
FS. O
METHOD: O
FS O
containing O
aprotinin O
or O
different O
concentrations O
of O
tAMCA O
(0.5-47.5 O
mg/ml) O
were O
applied O
to O
the O
pial O
surface O
of O
the O
cortex O
of O
anaesthetized O
rats. O
The O
response O
of O
the O
animals O
was O
evaluated O
using O
electroencephalography O
and O
by O
monitoring O
the O
clinical O
behaviour O
during O
and O
after O
recovery O
from O
anaesthesia. O
FINDINGS: O
FS O
containing O
tAMCA O
caused O
paroxysmal O
brain O
activity O
which O
was O
associated O
with O
distinct O
convulsive O
behaviours. O
The O
degree O
of O
these O
seizures O
increased O
with O
increasing O
concentration O
of O
tAMCA. O
Thus, O
FS O
containing O
47.5 O
mg/ml O
tAMCA O
evoked O
generalized B
seizures I
in O
all O
tested O
rats O
(n=6) O
while O
the O
lowest O
concentration O
of O
tAMCA O
(0.5 O
mg/ml) O
only O
evoked O
brief O
episodes O
of O
jerk-correlated O
convulsive O
potentials O
in O
1 O
of O
6 O
rats. O
In O
contrast, O
FS O
containing O
aprotinin O
did O
not O
evoke O
any O
paroxysmal O
activity. O
INTERPRETATION: O
Tranexamic O
acid O
retains O
its O
convulsive O
action O
within O
FS. O
Thus, O
use O
of O
FS O
containing O
tAMCA O
for O
surgery O
within O
or O
close O
to O
the O
CNS O
may O
pose O
a O
substantial O
risk O
to O
the O
patient. O

Investigation O
of O
mitochondrial O
involvement O
in O
the O
experimental O
model O
of O
epilepsy B
induced O
by O
pilocarpine. O

This O
report O
presents O
the O
clinical, O
laboratory, O
and O
light O
and O
electron O
microscopic O
observations O
on O
a O
patient O
with O
chronic B
active I
(aggressive) I
hepatitis I
caused O
by O
the O
administration O
of O
propylthiouracil. O
This O
is O
an O
addition O
to O
the O
list O
of O
drugs O
that O
must O
be O
considered O
in O
the O
evaluation O
of O
chronic O
liver B
disease. I

Coniine, O
an O
alkaloid O
from O
Conium O
maculatum O
(poison O
hemlock), O
has O
been O
shown O
to O
be O
teratogenic O
in O
livestock. O
The O
major O
teratogenic O
outcome O
is O
arthrogryposis, B
presumably O
due O
to O
nicotinic O
receptor O
blockade. O
However, O
coniine O
has O
failed O
to O
produce O
arthrogryposis O
in O
rats O
or O
mice O
and O
is O
only O
weakly O
teratogenic O
in O
rabbits. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
and O
compare O
the O
effects O
of O
coniine O
and O
nicotine O
in O
the O
developing O
chick. O
Concentrations O
of O
coniine O
and O
nicotine O
sulfate O
were O
0.015%, O
0.03%, O
0.075%, O
0.15%, O
0.75%, O
1.5%, O
3%, O
and O
6% O
and O
1%, O
5%, O
and O
10%, O
respectively. O
Both O
compounds O
caused O
deformations B
and O
lethality O
in O
a O
dose-dependent O
manner. O
All O
concentrations O
of O
nicotine O
sulfate O
caused O
some O
lethality O
but O
a O
no O
effect O
level O
for O
coniine O
lethality O
was O
0.75%. O
The O
deformations O
caused O
by O
both O
coniine O
and O
nicotine O
sulfate O
were O
excessive B
flexion I
or I
extension I
of I
one I
or I
more I
toes. I
No O
histopathological O
alterations O
or O
differences O
in O
bone O
formation O
were O
seen O
in O
the O
limbs O
or O
toes O
of O
any O
chicks O
from O
any O
group; O
however, O
extensive O
cranial B
hemorrhage I
occurred O
in O
all O
nicotine O
sulfate-treated O
chicks. O
There O
was O
a O
statistically O
significant O
(P O
< O
or O
= O
0.01) O
decrease O
in O
movement O
in O
coniine O
and O
nicotine O
sulfate O
treated O
chicks O
as O
determined O
by O
ultrasound. O
Control O
chicks O
were O
in O
motion O
an O
average O
of O
33.67% O
of O
the O
time, O
while O
coniine-treated O
chicks O
were O
only O
moving O
8.95% O
of O
a O
5-min O
interval, O
and O
no O
movement O
was O
observed O
for O
nicotine O
sulfate O
treated O
chicks. O
In O
summary, O
the O
chick O
embryo O
provides O
a O
reliable O
and O
simple O
experimental O
animal O
model O
of O
coniine-induced O
arthrogryposis. O
Data O
from O
this O
model O
support O
a O
mechanism O
involving O
nicotinic O
receptor O
blockade O
with O
subsequent O
decreased O
fetal O
movement. O

In O
a O
6-week O
double-blind O
parallel O
treatment O
study, O
dothiepin O
and O
amitriptyline O
were O
compared O
to O
placebo O
in O
the O
treatment O
of O
33 O
depressed B
outpatients. O
Dothiepin O
and O
amitriptyline O
were O
equally O
effective O
in O
alleviating O
the O
symptoms O
of O
depressive B
illness, I
and O
both O
were O
significantly O
superior O
to O
placebo. O
The O
overall O
incidence O
of O
side O
effects O
and O
the O
frequency O
and O
severity O
of O
blurred B
vision, I
dry B
mouth, I
and O
drowsiness O
were O
significantly O
less O
with O
dothiepin O
than O
with O
amitriptyline. O
Dothiepin O
also O
produced O
fewer O
CNS O
and O
cardiovascular O
effects. O
There O
were O
no O
clinically O
important O
changes O
in O
laboratory O
parameters. O
Dothiepin O
thus O
was O
found O
to O
be O
an O
effective O
antidepressant O
drug O
associated O
with O
fewer O
side O
effects O
than O
amitriptyline O
in O
the O
treatment O
of O
depressed O
outpatients. O

Although O
the O
United O
States O
Food O
and O
Drug O
Administration O
banned O
its O
use O
for O
nocturnal B
leg I
cramps I
due O
to O
lack O
of O
safety O
and O
efficacy, O
quinine O
is O
widely O
available O
in O
beverages O
including O
tonic O
water O
and O
bitter O
lemon. O
Numerous O
anecdotal O
reports O
suggest O
that O
products O
containing O
quinine O
may O
produce O
neurological B
complications, I
including O
confusion, B
altered O
mental O
status, O
seizures, B
and O
coma, B
particularly O
in O
older O
women. O
Psychologists O
need O
to O
inquire O
about O
consumption O
of O
quinine-containing O
beverages O
as O
part O
of O
an O
evaluation O
process. O

Ketoconazole O
induced O
torsades B
de I
pointes I
without O
concomitant O
use O
of O
QT O
interval-prolonging O
drug. O

Effects O
of O
aminophylline O
on O
the O
threshold O
for O
initiating O
ventricular B
fibrillation I
during O
respiratory B
failure. I

Pneumocystis B
pneumonia I
(PCP), O
a B
common O
opportunistic B
infection I
in O
HIV-infected B
individuals, O
is O
generally O
treated O
with O
high O
doses O
of O
co-trimoxazole. O
However, O
treatment O
is O
often O
limited O
by O
adverse O
effects. O
Here, O
we O
report O
two O
cases O
of O
severely O
immunocompromised O
HIV-infected O
patients O
who O
developed O
severe O
intrahepatic B
cholestasis, I
and O
in O
one O
patient O
lesions O
mimicking O
liver B
abscess I
formation O
on O
radiologic O
exams, O
during O
co-trimoxazole O
treatment O
for O
PCP. O
Whereas O
patient O
1 O
showed O
lesions O
of O
up O
to O
1 O
cm O
readily O
detectable O
on O
magnetic O
resonance O
imaging O
under O
prolonged O
co-trimoxazole O
treatment, O
therapy O
of O
patient O
2 O
was O
switched O
early. O

Sulpiride-induced O
tardive B
dystonia. I

Five O
patients O
receiving O
fluoxetine O
for O
the O
treatment O
of O
obsessive B
compulsive I
disorder I
or O
major B
depression I
developed O
akathisia. B
The O
typical O
fluoxetine-induced O
symptoms O
of O
restlessness, O
constant O
pacing, O
purposeless O
movements O
of O
the O
feet O
and O
legs, O
and O
marked O
anxiety B
were O
indistinguishable O
from O
those O
of O
neuroleptic-induced O
akathisia. O
Three O
patients O
who O
had O
experienced O
neuroleptic-induced O
akathisia O
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine-induced O
akathisia O
were O
identical, O
although O
somewhat O
milder. O
Akathisia B
appeared O
to O
be O
a O
common O
side O
effect O
of O
fluoxetine O
and O
generally O
responded O
well O
to O
treatment O
with O
the O
beta-adrenergic O
antagonist O
propranolol, O
dose O
reduction, O
or O
both. O
The O
authors O
suggest O
that O
fluoxetine-induced O
akathisia O
may O
be O
caused O
by O
serotonergically O
mediated O
inhibition O
of O
dopaminergic O
neurotransmission O
and O
that O
the O
pathophysiology O
of O
fluoxetine-induced O
akathisia O
and O
tricyclic O
antidepressant-induced O
"jitteriness" O
may O
be O
identical. O

The O
antiarrhythmic O
effects O
of O
the O
sustained O
release O
form O
of O
mexiletine O
(Mexitil-Perlongets) O
were O
evaluated O
in O
a O
double-blind O
placebo O
trial O
in O
630 O
patients O
with O
recent O
documented O
myocardial B
infarction. I
The O
primary O
response O
variable O
was O
based O
on O
central O
reading O
of O
24 O
hour O
ambulatory O
electrocardiographic O
recordings O
and O
was O
defined O
as O
the O
occurrence O
of O
30 O
or O
more O
single O
premature O
ventricular O
complexes O
in O
any O
two O
consecutive O
30 O
minute O
blocks O
or O
one O
or O
more O
runs O
of O
two O
or O
more O
premature O
ventricular O
complexes O
in O
the O
entire O
24 O
hour O
electrocardiographic O
recording. O
Large O
differences, O
regarded O
as O
statistically O
significant, O
between O
the O
mexiletine O
and O
placebo O
groups O
were O
noted O
in O
that O
end O
point O
at O
months O
1 O
and O
4, O
but O
only O
trends O
were O
observed O
at O
month O
12. O
These O
differences O
were O
observed O
even O
though O
the O
serum O
mexiletine O
levels O
obtained O
in O
this O
study O
were O
generally O
lower O
than O
those O
observed O
in O
studies O
that O
have O
used O
the O
regular O
form O
of O
the O
drug. O
There O
were O
more O
deaths B
in O
the O
mexiletine O
group O
(7.6%) O
than O
in O
the O
placebo O
group O
(4.8%); O
the O
difference O
was O
not O
statistically O
significant. O
The O
incidence O
of O
coronary O
events O
was O
similar O
in O
both O
groups. O
Previously O
recognized O
side O
effects, O
particularly O
tremor B
and O
gastrointestinal B
problems, I
were O
more O
frequent O
in O
the O
mexiletine O
group O
than O
in O
the O
placebo O
group. O

Omeprazole O
is O
the O
first O
drug O
designed O
to O
block O
the O
final O
step O
in O
the O
acid O
secretory O
process O
within O
the O
parietal O
cell. O
It O
has O
been O
shown O
to O
be O
extremely O
effective O
in O
the O
treatment O
of O
peptic B
ulcer I
disease, I
reflux B
esophagitis, I
and O
the O
Zollinger-Ellison B
syndrome. I
Although O
clinical O
experience O
with O
omeprazole O
is O
still O
limited, O
many O
controlled O
studies O
have O
established O
the O
short-term O
safety O
of O
this O
drug. O
We O
report O
the O
first O
case O
of O
a O
serious O
short-term O
adverse O
reaction O
with O
the O
use O
of O
omeprazole: O
hemolytic B
anemia. I
The O
patient O
developed O
weakness, O
lethargy, B
and O
shortness B
of I
breath I
2 O
days O
after O
starting O
therapy O
with O
omeprazole. O
Two O
weeks O
after O
the O
initiation O
of O
therapy, O
her O
hematocrit O
had O
decreased O
from O
44.1% O
to O
20.4%, O
and O
she O
had O
a O
positive O
direct O
Coombs O
antiglobulin O
test O
and O
an O
elevated O
indirect O
bilirubin. O
After O
she O
discontinued O
the O
omeprazole, O
her O
hemoglobin O
and O
hematocrit O
gradually O
returned O
to O
normal. O
The O
mechanism O
by O
which O
omeprazole O
caused O
the O
patient's O
hemolytic O
anemia O
is O
uncertain, O
but O
physicians O
should O
be O
alerted O
to O
this O
possible O
adverse O
effect. O

Six O
epidemiologic O
studies O
in O
the O
United O
States O
and O
Europe O
indicate O
that O
habitual O
use O
of O
phenacetin O
is O
associated O
with O
the O
development O
of O
chronic B
renal I
failure I
and O
end-stage B
renal I
disease I
(ESRD), O
with B
a O
relative O
risk O
in O
the O
range O
of O
4 O
to O
19. O
As O
a O
result O
of O
these O
and O
other O
studies, O
phenacetin O
has O
now O
been O
withdrawn O
from O
the O
market O
in O
most O
countries. O
However, O
three O
case O
control O
studies, O
one O
each O
in O
North O
Carolina, O
northern O
Maryland, O
and O
West O
Berlin, O
Germany, O
showed O
that O
habitual O
use O
of O
acetaminophen O
is O
also O
associated O
with O
chronic O
renal O
failure O
and O
ESRD, O
with O
a O
relative O
risk O
in O
the O
range O
of O
2 O
to O
4. O
These O
studies O
suggest O
that O
both O
phenacetin O
and O
acetaminophen O
may O
contribute O
to O
the O
burden O
of O
ESRD, O
with O
the O
risk O
of O
the O
latter O
being O
somewhat O
less O
than O
that O
of O
the O
former. O
This O
apparent O
difference O
in O
risk O
may O
not O
be O
due O
to O
differences O
in O
nephrotoxic B
potential O
of O
the O
drugs O
themselves. O
A O
lower O
relative O
risk O
would O
be O
expected O
for O
acetaminophen O
if O
the O
risk O
of O
both O
drugs O
in O
combination O
with O
other O
analgesics O
was O
higher O
than O
the O
risk O
of O
either O
agent O
alone. O
Thus, O
acetaminophen O
has O
been O
used O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
other O
analgesics, O
whereas O
phenacetin O
was O
available O
only O
in O
combinations. O
The O
possibility O
that O
habitual O
use O
of O
acetaminophen O
alone O
increases O
the O
risk O
of O
ESRD O
has O
not O
been O
clearly O
demonstrated, O
but O
cannot O
be O
dismissed. O

Cardiac B
toxicity I
is O
a O
major O
complication O
which O
limits O
the O
use O
of O
adriamycin O
as O
a O
chemotherapeutic O
agent. O
Cardiomyopathy B
is O
frequent O
when O
the O
total O
dose O
exceeds O
600 O
mg/m2 O
and O
occurs O
within O
one O
to O
six O
months O
after O
cessation O
of O
therapy. O
A O
patient O
is O
reported O
who O
developed O
progressive O
cardiomyopathy B
two O
and O
one-half O
years O
after O
receiving O
580 O
mg/m2 O
which O
apparently O
represents O
late, O
late O
cardiotoxicity. B

The O
hematologic O
effects O
of O
cefonicid O
and O
cefazedone O
in O
the O
dog: O
a O
potential O
model O
of O
cephalosporin O
hematotoxicity B
in O
man. O

Choreatiform B
hyperkinesias B
are O
known O
to O
be O
occasional O
movement B
abnormalities I
during O
intoxications O
with O
cocaine O
but O
not O
opiates. O
This O
is O
a O
case O
report O
of O
euphoria O
and O
choreoathetoid B
movements I
both O
transiently O
induced O
by O
rapid O
adjustment O
to O
the O
selective O
mu-opioid O
receptor O
agonist O
methadone O
in O
an O
inpatient O
previously O
abusing O
heroine O
and O
cocaine. O
In O
addition, O
minor O
EEG O
abnormalities O
occurred. O
Possible O
underlying O
neurobiological O
phenomena O
are O
discussed. O

Cyclosporine O
and O
tacrolimus-associated O
thrombotic B
microangiopathy. I

Ranitidine O
frequently O
is O
used O
for O
preventing O
peptic O
ulceration O
after O
renal O
transplantation. O
This O
drug O
occasionally O
has O
been O
associated O
with O
acute O
interstitial B
nephritis I
in O
native O
kidneys. O
There O
are O
no O
similar O
reports O
with O
renal O
transplantation. O
We O
report O
a O
case O
of O
ranitidine-induced O
acute O
interstitial O
nephritis O
in O
a O
recipient O
of O
a O
cadaveric O
renal O
allograft O
presenting O
with O
acute O
allograft O
dysfunction O
within O
48 O
hours O
of O
exposure O
to O
the O
drug. O
The O
biopsy O
specimen O
showed O
pathognomonic O
features, O
including O
eosinophilic O
infiltration O
of O
the O
interstitial O
compartment. O
Allograft O
function O
improved O
rapidly O
and O
returned O
to O
baseline O
after O
stopping O
the O
drug. O

We O
report O
a O
case O
of O
bile B
duct I
hamartoma B
which O
developed O
in O
a O
patient O
who O
had O
been O
on O
long-term O
danazol O
treatment. O
Such O
patients O
should O
be O
under O
close O
follow-up, O
preferably O
with O
periodic O
ultrasound O
examination O
of O
the O
liver. O
If O
the O
patient O
develops O
a O
liver B
mass, I
because O
of O
non-specific O
clinical O
features O
and O
imaging O
appearances, O
biopsy O
may O
be O
the O
only O
way O
to O
achieve O
a O
definitive O
diagnosis. O

Thermal O
enhancement O
of O
Adriamycin-mediated O
antitumor O
activity B
and O
normal O
tissue O
toxicities B
by O
whole O
body O
hyperthermia B
were O
compared O
using O
a O
F344 O
rat O
model. O
Antitumor O
activity O
was O
studied O
using O
a O
tumor O
growth O
delay O
assay. O
Acute O
normal O
tissue O
toxicities O
(i.e., O
leukopenia B
and O
thrombocytopenia) B
and O
late O
normal O
tissue O
toxicities O
(i.e., O
myocardial B
and I
kidney B
injury) I
were O
evaluated O
by O
functional/physiological O
assays O
and O
by O
morphological O
techniques. O
Whole O
body O
hyperthermia O
(120 O
min O
at O
41.5 O
degrees O
C) O
enhanced O
both O
Adriamycin-mediated O
antitumor O
activity O
and O
toxic O
side O
effects. O
The O
thermal O
enhancement O
ratio O
calculated O
for O
antitumor O
activity O
was O
1.6. O
Thermal O
enhancement O
ratios O
estimated O
for O
"acute" O
hematological O
changes O
were O
1.3, O
whereas O
those O
estimated O
for O
"late" O
damage O
(based O
on O
morphological O
cardiac B
and I
renal B
lesions) I
varied O
between O
2.4 O
and O
4.3. O
Thus, O
while O
whole O
body O
hyperthermia O
enhances O
Adriamycin-mediated O
antitumor O
effect, O
normal O
tissue O
toxicity B
is O
also O
increased, O
and O
the O
potential O
therapeutic O
gain O
of O
the O
combined O
modality O
treatment O
is O
eroded. O

Prolonged O
cholestasis B
after O
troleandomycin-induced O
acute O
hepatitis. B

Warfarin O
is O
the O
most O
widely O
used O
oral O
anticoagulant O
and O
is O
indicated O
for O
many O
clinical O
conditions. O
Levofloxacin, O
a O
fluoroquinolone, O
is O
one O
of O
the O
most O
commonly O
prescribed O
antibiotics O
in O
clinical O
practice O
and O
is O
effective O
against O
Gram-positive, O
Gram-negative, O
and O
atypical O
bacteria. O
While O
small O
prospective O
studies O
have O
not O
revealed O
any O
significant O
drug-drug O
interaction O
between O
warfarin O
and O
levofloxacin, O
several O
case O
reports O
have O
indicated O
that O
levofloxacin O
may O
significantly O
potentiate O
the O
anticoagulation O
effect O
of O
warfarin. O
We O
report O
3 O
cases O
of O
serious O
bleeding B
complications O
that O
appear O
to O
be O
the O
result O
of O
the O
interaction O
between O
warfarin O
and O
levofloxacin. O
Physicians O
should O
be O
aware O
of O
this O
potential O
interaction O
and O
use O
caution O
when O
prescribing O
levofloxacin O
to O
patients O
taking O
warfarin. O

Amount O
of O
bleeding B
and O
hematoma B
size O
in O
the O
collagenase-induced O
intracerebral B
hemorrhage I
rat O
model. O

The O
effects O
of O
continuous O
positive O
airway O
pressure O
(CPAP) O
on O
cardiovascular O
dynamics O
and O
pulmonary O
shunt O
(QS/QT) O
were O
investigated O
in O
12 O
dogs O
before O
and O
during O
sodium O
nitroprusside O
infusion O
that O
decreased O
mean O
arterial O
blood O
pressure O
40-50 O
per O
cent. O
Before O
nitroprusside O
infusion, O
5 O
cm O
H2O O
CPAP O
significantly, O
P O
less O
than O
.05, O
decreased O
arterial O
blood O
pressure, O
but O
did O
not O
significantly O
alter O
heart O
rate, O
cardiac O
output, O
systemic O
vascular O
resistance, O
or O
QS/QT. O
Ten O
cm O
H2O O
CPAP O
before O
nitroprusside O
infusion O
produced O
a O
further O
decrease B
in I
arterial I
blood I
pressure I
and O
significantly O
increased O
heart O
rate O
and O
decreased B
cardiac I
output I
and O
QS/QT. O
Nitroprusside O
caused O
significant O
decreases B
in I
arterial I
blood I
pressure I
and O
systemic O
vascular O
resistance O
and O
increases O
in O
heart O
rate, O
but O
did O
not O
change O
cardiac O
output O
or O
QS/QT. O
Five O
cm O
H2O O
CPAP O
during O
nitroprusside O
did O
not O
further O
alter O
any O
of O
the O
above-mentioned O
variables. O
However, O
10 O
cm O
H2O O
CPAP O
decreased O
arterial O
blood O
pressure, O
cardiac O
output, O
and O
QS/QT. O
These O
data O
indicate O
that O
nitroprusside O
infusion O
rates O
that O
decrease O
mean O
arterial O
blood O
pressure O
by O
40-50 O
per O
cent O
do O
not O
change O
cardiac O
output O
or O
QS/QT. O
During O
nitroprusside O
infusion O
low O
levels O
of O
CPAP O
do O
not O
markedly O
alter O
cardiovascular O
dynamics, O
but O
high O
levels O
of O
CPAP O
(10 O
cm O
H2O), O
while O
decreasing O
QS/QT, O
produce O
marked O
decreases B
in I
arterial I
blood I
pressure I
and I
cardiac I
output. I

Hypotension B
following O
the O
initiation O
of O
tizanidine O
in O
a O
patient O
treated O
with O
an O
angiotensin O
converting O
enzyme O
inhibitor O
for O
chronic O
hypertension. B

Acute B
liver I
failure I
in O
two O
patients O
with O
regular O
alcohol O
consumption O
ingesting O
paracetamol O
at O
therapeutic O
dosage. O

A O
deficient O
L-arginine-nitric O
oxide O
system O
is O
implicated O
in O
cortisol-induced O
hypertension. B
We O
investigate O
whether O
abnormalities O
in O
L-arginine O
uptake O
contribute O
to O
this O
deficiency. O
Eight O
healthy O
men O
were O
recruited. O
Hydrocortisone O
acetate O
(50 O
mg) O
was O
given O
orally O
every O
6 O
hours O
for O
24 O
hours O
after O
a O
5-day O
fixed-salt O
diet O
(150 O
mmol/d). O
Crossover O
studies O
were O
performed O
2 O
weeks O
apart. O
Thirty O
milliliters O
of O
blood O
was O
obtained O
for O
isolation O
of O
peripheral O
blood O
mononuclear O
cells O
after O
each O
treatment O
period. O
L-arginine O
uptake O
was O
assessed O
in O
mononuclear O
cells O
incubated O
with O
L-arginine O
(1 O
to O
300 O
micromol/L), O
incorporating O
100 O
nmol/L O
[3H]-l-arginine O
for O
a O
period O
of O
5 O
minutes O
at O
37 O
degrees O
C. O
Forearm O
[3H]-L-arginine O
extraction O
was O
calculated O
after O
infusion O
of O
[3H]-L-arginine O
into O
the O
brachial O
artery O
at O
a O
rate O
of O
100 O
nCi/min O
for O
80 O
minutes. O
Deep O
forearm O
venous O
samples O
were O
collected O
for O
determination O
of O
L-arginine O
extraction. O
Plasma O
cortisol O
concentrations O
were O
significantly O
raised O
during O
the O
active O
phase O
(323+/-43 O
to O
1082+/-245 O
mmol/L, O
P<0.05). O
Systolic O
blood O
pressure O
was O
elevated O
by O
an O
average O
of O
7 O
mm O
Hg. O
Neither O
L-arginine O
transport O
into O
mononuclear O
cells O
(placebo O
vs O
active, O
26.3+/-3.6 O
vs O
29.0+/-2.1 O
pmol/10 O
000 O
cells O
per O
5 O
minutes, O
respectively, O
at O
an O
l-arginine O
concentration O
of O
300 O
micromol/L) O
nor O
L-arginine O
extraction O
in O
the O
forearm O
(at O
80 O
minutes, O
placebo O
vs O
active, O
1 O
868 O
904+/-434 O
962 O
vs O
2 O
013 O
910+/-770 O
619 O
disintegrations O
per O
minute) O
was O
affected O
by O
cortisol O
treatment; O
ie, O
that O
L-arginine O
uptake O
is O
not O
affected O
by O
short-term O
cortisol O
treatment. O
We O
conclude O
that O
cortisol-induced O
increases B
in I
blood I
pressure I
are O
not O
associated O
with O
abnormalities O
in O
the O
l-arginine O
transport O
system. O

Streptomycin O
sulfate O
(300 O
mg/kg O
s.c.) O
was O
injected O
for O
various O
periods O
into O
preweanling O
rats O
and O
for O
3 O
weeks O
into O
weanling O
rats. O
Beginning O
at O
8 O
days O
of O
age, O
body O
movement O
and O
hearing O
were O
examined O
for O
6 O
and O
up O
to O
17 O
weeks, O
respectively. O
Abnormal B
movements I
and O
deafness B
occurred O
only O
in O
rats O
treated O
during O
the O
preweaning O
period; O
within O
this O
period O
the O
greatest O
sensitivities O
for O
these O
abnormalities O
occurred O
from O
2 O
to O
11-17 O
and O
5 O
to O
11 O
days O
of O
age, O
respectively, O
indicating O
that O
the O
cochlea O
is O
more O
sensitive O
to O
streptomycin O
than O
the O
site O
(vestibular O
or O
central) O
responsible O
for O
the O
dyskinesias. B

Ticlopidine-induced O
cholestatic B
hepatitis. B

Explicit O
episodic O
memory O
for O
sensory-discriminative O
components O
of O
capsaicin-induced O
pain: B
immediate O
and O
delayed O
ratings. O

Ketamine O
sedation O
for O
the O
reduction O
of O
children's O
fractures B
in O
the O
emergency O
department. O

We O
describe O
a O
25-year-old O
woman O
with O
pre-existing O
mitral B
valve I
prolapse I
who O
developed O
intractable O
ventricular B
fibrillation I
after O
consuming O
a O
"natural O
energy" O
guarana O
health O
drink O
containing O
a O
high O
concentration O
of O
caffeine. O
This O
case O
highlights O
the O
need O
for O
adequate O
labelling O
and O
regulation O
of O
such O
products. O

OBJECTIVE: O
To O
report O
2 O
cases O
of O
ticlopidine-induced O
cholestatic B
hepatitis, B
investigate O
its O
mechanism, O
and O
compare O
the O
observed O
main O
characteristics O
with O
those O
of O
the O
published O
cases. O
CASE O
SUMMARIES: O
Two O
patients O
developed O
prolonged O
cholestatic O
hepatitis O
after O
receiving O
ticlopidine O
following O
percutaneous O
coronary O
angioplasty, O
with O
complete O
remission O
during O
the O
follow-up O
period. O
T-cell O
stimulation O
by O
therapeutic O
concentration O
of O
ticlopidine O
was O
demonstrated O
in O
vitro O
in O
the O
patients, O
but O
not O
in O
healthy O
controls. O
DISCUSSION: O
Cholestatic B
hepatitis I
is O
a O
rare O
complication O
of O
the O
antiplatelet O
agent O
ticlopidine; O
several O
cases O
have O
been O
reported O
but O
few O
in O
the O
English O
literature. O
Our O
patients O
developed O
jaundice B
following O
treatment O
with O
ticlopidine O
and O
showed O
the O
clinical O
and O
laboratory O
characteristics O
of O
cholestatic O
hepatitis, O
which O
resolved O
after O
discontinuation O
of O
the O
drug. O
Hepatitis B
may O
develop O
weeks O
after O
discontinuation O
of O
the O
drug O
and O
may O
run O
a O
prolonged O
course, O
but O
complete O
remission O
was O
observed O
in O
all O
reported O
cases. O
An O
objective O
causality O
assessment O
revealed O
that O
the O
adverse O
drug O
event O
was O
probably O
related O
to O
the O
use O
of O
ticlopidine. O
The O
mechanisms O
of O
this O
ticlopidine-induced O
cholestasis B
are O
unclear. O
Immune O
mechanisms O
may O
be O
involved O
in O
the O
drug's O
hepatotoxicity, B
as O
suggested O
by O
the O
T-cell O
stimulation O
study O
reported O
here. O
CONCLUSIONS: O
Cholestatic O
hepatitis O
is O
a O
rare O
adverse O
effect O
of O
ticlopidine O
that O
may O
be O
immune O
mediated. O
Patients O
receiving O
the O
drug O
should O
be O
monitored O
with O
liver O
function O
tests O
along O
with O
complete O
blood O
cell O
counts. O
This O
complication O
will O
be O
observed O
even O
less O
often O
in O
the O
future O
as O
ticlopidine O
is O
being O
replaced O
by O
the O
newer O
antiplatelet O
agent O
clopidogrel. O

Hemolysis B
of O
human O
erythrocytes O
induced O
by O
tamoxifen O
is O
related O
to O
disruption O
of O
membrane O
structure. O

Acute O
hepatitis, B
autoimmune B
hemolytic I
anemia, I
and O
erythroblastocytopenia B
induced O
by O
ceftriaxone. O

BACKGROUND: O
TEE O
is O
a O
semi-invasive O
tool O
broadly O
used O
and O
its O
utilization O
associated O
to O
sedatives O
drugs O
might O
to O
affect O
the O
procedure O
safety. O
OBJECTIVE: O
to O
analyze O
aspects O
of O
TEE O
safety O
associated O
to O
the O
use O
of O
Midazolan O
(MZ) O
and O
Flumazenil O
(FL) O
and O
the O
influence O
of O
the O
clinical O
variables O
on O
the O
event O
rate. O
METHOD: O
prospective O
study O
with O
137 O
patients O
that O
underwent O
TEE O
with O
MZ O
associated O
to O
moderate O
sedation. O
We O
analyzed O
the O
following O
events: O
complications O
related O
with O
the O
topical O
anesthesia, O
with O
MZ O
use O
and O
with O
the O
procedure. O
Uni- O
and O
multivariate O
analyses O
were O
used O
to O
test O
the O
influence O
of O
the O
clinical O
variables: O
age, O
sex, O
stroke, B
myocardiopathy B
(MP), O
duration B
of O
the O
test, O
mitral B
regurgitation I
(MR) O
and B
the O
MZ O
dose. O
RESULTS: O
All O
patients O
(65+/-16 O
yrs; O
58% O
males) O
finished O
the O
examination. O
The O
mean O
doses O
of O
MZ O
and O
FL O
were O
4.3+/-1.9 O
mg O
and O
0.28+/-0.2 O
mg, O
respectively. O
The O
duration O
of O
the O
examination O
and O
the O
mean O
ejection O
fraction O
(EF) O
were O
16.4+/-6.1 O
minutes O
and O
60+/-9%, O
respectively. O
Mild O
hypoxia B
(SO2<90%) O
was O
the O
most O
common O
event O
(11 O
patients); O
3 O
patients O
(2%) O
presented O
transient O
hypoxia O
due O
to O
upper O
airway B
obstruction I
by O
probe O
introduction O
and O
8 O
(5.8%) O
due O
to O
hypoxia O
caused O
by O
MZ O
use. O
Transient O
hypotension B
(SAP<90mmHg) O
occurred O
in O
1 O
patient O
(0.7%). O
The O
multivariate O
analysis O
showed O
that O
severe O
MR, O
MP O
(EF<45%) O
and O
high O
doses O
of O
MZ O
(>5mg) O
were O
associated O
with O
events O
(p<0.001). O
The O
EF O
was O
40%, O
in O
the O
group O
with O
MP O
and O
44% O
in O
the O
group O
with O
severe O
MR O
and O
it O
can O
be O
a O
factor O
associated O
with O
clinical O
events O
in O
the O
last O
group. O
CONCLUSION: O
TEE O
with O
sedation O
presents O
a O
low O
rate O
of O
events. O
There O
were O
no O
severe O
events O
and O
there O
was O
no O
need O
to O
interrupt O
the O
examinations. O

Depression B
is O
a O
major O
clinical O
feature O
of O
Parkinson's B
disease. I
We O
report O
the O
increased O
amount O
of O
motor B
disability I
in O
four O
patients O
with O
idiopathic B
Parkinson's I
disease I
after O
exposure O
to O
the O
antidepressant O
fluoxetine. O
The O
possibility O
of O
a O
clinically O
relevant O
dopamine-antagonistic O
capacity O
of O
fluoxetine O
in O
Parkinson's O
disease O
patients O
must O
be O
considered. O

There O
is O
evidence O
that O
growth O
hormone O
may O
be O
related O
to O
the O
progression O
of O
weakness B
in O
Duchenne B
dystrophy. I
We O
conducted O
a O
12-month O
controlled O
trial O
of O
mazindol, O
a O
putative O
growth O
hormone O
secretion O
inhibitor, O
in O
83 O
boys O
with O
Duchenne O
dystrophy. O
Muscle O
strength, O
contractures, O
functional O
ability O
and O
pulmonary O
function O
were O
tested O
at O
baseline, O
and O
6 O
and O
12 O
months O
after O
treatment O
with O
mazindol O
(3 O
mg/d) O
or O
placebo. O
The O
study O
was O
designed O
to O
have O
a O
power O
of O
greater O
than O
0.90 O
to O
detect O
a O
slowing O
to O
25% O
of O
the O
expected O
rate O
of O
progression O
of O
weakness O
at O
P O
less O
than O
0.05. O
Mazindol O
did O
not O
benefit O
strength O
at O
any O
point O
in O
the O
study. O
Side O
effects O
attributable O
to O
mazindol O
included O
decreased B
appetite I
(36%), O
dry B
mouth I
(10%), O
behavioral O
change O
(22%), O
and O
gastrointestinal B
symptoms I
(18%); O
mazindol O
dosage O
was O
reduced O
in O
43% O
of O
patients. O
The O
effect O
of O
mazindol O
on O
GH O
secretion O
was O
estimated O
indirectly O
by O
comparing O
the O
postabsorptive O
IGF-I O
levels O
obtained O
following O
3, O
6, O
9, O
and O
12 O
months O
in O
the O
mazindol O
treated O
to O
those O
in O
the O
placebo O
groups. O
Although O
mazindol-treated O
patients O
gained O
less O
weight O
and O
height O
than O
placebo-treated O
patients, O
no O
significant O
effect O
on O
IGF-I O
levels O
was O
observed. O
Mazindol O
doses O
not O
slow O
the O
progression O
of O
weakness O
in O
Duchenne O
dystrophy. O

Acute B
psychosis I
due O
to O
treatment O
with O
phenytoin O
in O
a O
nonepileptic O
patient. O

PURPOSE: O
We O
evaluated O
the O
safety O
of O
indocyanine O
green O
for O
use O
in O
fundus O
angiography. O
METHODS: O
We O
sent O
a O
questionnaire O
concerning O
complications O
of O
indocyanine O
green O
to O
32 O
institutions O
in O
Japan, O
which O
were O
selected O
on O
the O
basis O
of O
the O
client O
list O
from O
the O
Topcon O
Company, O
which O
manufactures O
the O
indocyanine O
green O
fundus O
camera. O
RESULTS: O
Ophthalmologists O
at O
15 O
institutions O
responded, O
reporting O
a O
total O
of O
3,774 O
indocyanine O
green O
angiograms O
performed O
on O
2,820 O
patients O
between O
June O
1984 O
and O
September O
1992. O
Before O
angiography, O
intradermal O
or O
intravenous O
indocyanine O
green O
testing, O
or O
both O
was O
performed O
at O
13 O
of O
15 O
institutions. O
For O
three O
patients, O
the O
decision O
was O
made O
not O
to O
proceed O
with O
angiography O
after O
positive O
preangiographic O
testing. O
The O
dosage O
of O
indocyanine O
green O
used O
for O
angiography O
varied O
from O
25 O
to O
75 O
mg, O
depending O
upon O
the O
institution. O
There O
were O
13 O
cases O
of O
adverse O
reactions O
(0.34%), O
ten O
of O
which O
were O
mild O
reactions O
such O
as O
nausea, B
exanthema, B
urtication, B
itchiness, B
and O
urgency O
to O
defecate, O
and O
did O
not O
require O
treatment. O
Also O
recorded O
were O
one O
case O
of O
pain B
of O
the O
vein, O
which O
required O
treatment, O
and O
two O
cases O
of O
hypotension. B
The O
two O
hypotensive B
patients O
required O
treatment O
for O
shock. B
CONCLUSIONS: O
A O
comparison O
of O
frequency O
of O
adverse O
reactions O
to O
indocyanine O
green O
with O
the O
previously O
reported O
frequency O
of O
such O
reactions O
to O
fluorescein O
sodium O
indicated O
that O
indocyanine O
green O
is O
a O
safe O
as O
fluorescein O
for O
use O
in O
angiography. O

Can O
angiogenesis O
be O
a O
target O
of O
treatment O
for O
ribavirin O
associated O
hemolytic B
anemia? I

Dobutamine O
stress O
echocardiography: O
a O
sensitive O
indicator O
of O
diminished O
myocardial O
function O
in O
asymptomatic O
doxorubicin-treated O
long-term O
survivors O
of O
childhood O
cancer. B

Neuroplasticity O
of O
the O
adult O
primate O
auditory O
cortex O
following O
cochlear O
hearing B
loss. I

The O
effectiveness O
of O
administration O
of O
glycopyrrolate O
5 O
and O
10 O
micrograms O
kg-1 O
and O
atropine O
10 O
and O
20 O
micrograms O
kg-1 O
i.v. O
immediately O
before O
the O
induction O
of O
anaesthesia, O
to O
prevent O
arrhythmia B
and O
bradycardia B
following O
repeated O
doses O
of O
suxamethonium O
in O
children, O
was O
studied. O
A O
control O
group O
was O
included O
for O
comparison O
with O
the O
lower O
dose O
range O
of O
glycopyrrolate O
and O
atropine. O
A O
frequency O
of O
bradycardia O
of O
50% O
was O
noted O
in O
the O
control O
group, O
but O
this O
was O
not O
significantly O
different O
from O
the O
frequency O
with O
the O
active O
drugs. O
Bradycardia B
(defined O
as O
a O
decrease O
in O
heart O
rate O
to O
less O
than O
50 O
beat O
min-1) O
was O
prevented O
when O
the O
larger O
dose O
of O
either O
active O
drug O
was O
used. O
It O
is O
recommended O
that O
either O
glycopyrrolate O
10 O
micrograms O
kg-1 O
or O
atropine O
20 O
micrograms O
kg-1 O
i.v. O
should O
immediately O
precede O
induction O
of O
anaesthesia, O
in O
children, O
if O
the O
repeated O
administration O
of O
suxamethonium O
is O
anticipated. O

Adverse O
effects O
of O
antipsychotics O
often O
lead O
to O
noncompliance. O
Thus, O
clinicians O
should O
address O
patients' O
concerns O
about O
adverse O
effects O
and O
attempt O
to O
choose O
medications O
that O
will O
improve O
their O
patients' O
quality O
of O
life O
as O
well O
as O
overall O
health. O
The O
side O
effect O
profiles O
of O
the O
atypical O
antipsychotics O
are O
more O
advantageous O
than O
those O
of O
the O
conventional O
neuroleptics. O
Conventional O
agents O
are O
associated O
with O
unwanted O
central O
nervous O
system O
effects, O
including O
extrapyramidal B
symptoms I
(EPS), O
tardive B
dyskinesia, I
sedation, O
and O
possible O
impairment O
of O
some O
cognitive O
measures, O
as O
well O
as O
cardiac O
effects, O
orthostatic B
hypotension, I
hepatic O
changes, O
anticholinergic O
side O
effects, O
sexual B
dysfunction, I
and O
weight B
gain. I
The O
newer O
atypical O
agents O
have O
a O
lower O
risk O
of O
EPS, O
but O
are O
associated O
in O
varying O
degrees O
with O
sedation, O
cardiovascular O
effects, O
anticholinergic O
effects, O
weight O
gain, O
sexual O
dysfunction, O
hepatic O
effects, O
lowered O
seizure B
threshold O
(primarily O
clozapine), O
and O
agranulocytosis B
(clozapine O
only). O
Since O
the O
incidence O
and O
severity O
of O
specific O
adverse O
effects O
differ O
among O
the O
various O
atypicals, O
the O
clinician O
should O
carefully O
consider O
which O
side O
effects O
are O
most O
likely O
to O
lead O
to O
the O
individual's O
dissatisfaction O
and O
noncompliance O
before O
choosing O
an O
antipsychotic O
for O
a O
particular O
patient. O

The O
electrocardiograms O
(ECG) O
of O
99 O
cocaine-abusing O
patients O
were O
compared O
with O
the O
ECGs O
of O
50 O
schizophrenic B
controls. O
Eleven O
of O
the O
cocaine O
abusers O
and O
none O
of O
the O
controls O
had O
ECG O
evidence O
of O
significant O
myocardial B
injury I
defined O
as O
myocardial B
infarction, I
ischemia, B
and O
bundle B
branch I
block. I

Valproate-induced O
encephalopathy. B

On O
the O
mechanisms O
of O
the O
development O
of O
tolerance O
to O
the O
muscular B
rigidity I
produced O
by O
morphine O
in O
rats. O

Large O
doses O
of O
triazolam O
repeatedly O
induced O
brief O
episodes O
of O
mania B
in O
a O
depressed B
elderly O
woman. O
Features O
of O
organic B
mental I
disorder I
(delirium) O
were B
not O
present. O
Manic B
excitement O
was O
coincident O
with O
the O
duration O
of O
action O
of O
triazolam. O
The O
possible O
contribution O
of O
the O
triazolo O
group O
to O
changes O
in O
affective O
status O
is O
discussed. O

The O
renal O
function O
of O
74 O
children O
with O
malignant B
mesenchymal B
tumors I
in O
complete O
remission O
and O
who O
have O
received O
the O
same O
ifosfamide O
chemotherapy O
protocol O
(International O
Society O
of O
Pediatric O
Oncology O
Malignant B
Mesenchymal I
Tumor I
Study O
84 O
[SIOP O
MMT O
84]) O
were O
studied O
1 O
year O
after O
the O
completion O
of O
treatment. O
Total O
cumulative O
doses O
were O
36 O
or O
60 O
g/m2 O
of O
ifosfamide O
(six O
or O
10 O
cycles O
of O
ifosfamide, O
vincristine, O
and O
dactinomycin O
[IVA]). O
None O
of O
them O
had O
received O
cisplatin O
chemotherapy. O
Ages O
ranged O
from O
4 O
months O
to O
17 O
years; O
58 O
patients O
were O
males O
and O
42 O
females. O
The O
most O
common O
primary O
tumor O
site O
was O
the O
head O
and O
neck. O
Renal O
function O
was O
investigated O
by O
measuring O
plasma O
and O
urinary O
electrolytes, O
glucosuria, B
proteinuria, B
aminoaciduria, B
urinary O
pH, O
osmolarity, O
creatinine O
clearance, O
phosphate O
tubular O
reabsorption, O
beta O
2 O
microglobulinuria, O
and O
lysozymuria. O
Fifty-eight O
patients O
(78%) O
had O
normal O
renal O
tests, O
whereas O
16 O
patients O
(22%) O
had O
renal B
abnormalities. I
Two O
subsets O
of O
patients O
were O
identified O
from O
this O
latter O
group: O
the O
first O
included O
four O
patients O
(5% O
of O
the O
total O
population) O
who O
developed O
major O
toxicity B
resulting O
in O
Fanconi's B
syndrome I
(TDFS); O
and B
the O
second O
group O
included O
five O
patients O
with O
elevated O
beta O
2 O
microglobulinuria O
and O
low O
phosphate O
reabsorption. O
The O
remaining O
seven O
patients O
had O
isolated O
beta O
2 O
microglobulinuria. O
Severe O
toxicity O
was O
correlated O
with O
the O
higher O
cumulative O
dose O
of O
60 O
g/m2 O
of O
ifosfamide, O
a O
younger O
age O
(less O
than O
2 O
1/2 O
years O
old), O
and O
a O
predominance O
of O
vesicoprostatic O
tumor O
involvement. O
This O
low O
percentage O
(5%) O
of O
TDFS O
must O
be O
evaluated O
with O
respect O
to O
the O
efficacy O
of O
ifosfamide O
in O
the O
treatment O
of O
mesenchymal O
tumors O
in O
children. O

Clinical O
and O
experimental O
data O
published O
to O
date O
suggest O
several O
possible O
mechanisms O
by O
which O
cocaine O
may O
result O
in O
acute B
myocardial I
infarction. B
In O
individuals O
with O
preexisting, O
high-grade O
coronary O
arterial O
narrowing, O
acute O
myocardial O
infarction O
may O
result O
from O
an O
increase O
in O
myocardial O
oxygen O
demand O
associated O
with O
cocaine-induced O
increase O
in O
rate-pressure O
product. O
In O
other O
individuals O
with O
no O
underlying O
atherosclerotic B
obstruction, I
coronary B
occlusion I
may O
be O
due O
to O
spasm, B
thrombus, B
or O
both. O
With O
regard O
to O
spasm, O
the O
clinical O
findings O
are O
largely O
circumstantial, O
and O
the O
locus O
of O
cocaine-induced O
vasoconstriction O
remains O
speculative. O
Although O
certain O
clinical O
and O
experimental O
findings O
support O
the O
hypothesis O
that O
spasm O
involves O
the O
epicardial, O
medium-size O
vessels, O
other O
data O
suggest O
intramural O
vasoconstriction. O
Diffuse O
intramural O
vasoconstriction O
is O
not O
consistent O
with O
reports O
of O
segmental, O
discrete O
infarction. O
Whereas O
certain O
in O
vivo O
data O
suggest O
that O
these O
effects O
are O
alpha-mediated, O
other O
in O
vitro O
data O
suggest O
the O
opposite. O
The O
finding O
of O
cocaine-induced O
vasoconstriction O
in O
segments O
of O
(noninnervated) O
human O
umbilical O
artery O
suggests O
that O
the O
presence O
or O
absence O
of O
intact O
innervation O
is O
not O
sufficient O
to O
explain O
the O
discrepant O
data O
involving O
the O
possibility O
of O
alpha-mediated O
effects. O
Finally, O
the O
contribution O
of O
a O
primary, O
thrombotic B
effect O
of O
cocaine O
has O
not O
been O
excluded. O

Mitochondrial B
abnormalities I
have O
been O
associated O
with O
several O
aspects O
of O
epileptogenesis, O
such O
as O
energy O
generation, O
control O
of O
cell O
death, B
neurotransmitter O
synthesis, O
and O
free O
radical O
(FR) O
production. O
Increased O
production O
of O
FRs O
may O
cause O
mtDNA O
damage O
leading O
to O
decreased O
activities O
of O
oxidative O
phosphorylation O
complexes O
containing O
mtDNA-encoded O
subunits. O
In O
this O
study, O
we O
investigated O
whether O
increased O
generation O
of O
FR O
during O
status B
epilepticus I
would O
be O
sufficient O
to O
provoke O
abnormalities O
in O
mtDNA O
and O
in O
the O
expression O
and O
activity O
of O
cytochrome O
c O
oxidase O
(CCO), O
complex O
IV O
of O
the O
respiratory O
chain, O
in O
the O
chronic O
phase O
of O
the O
pilocarpine O
model O
of O
temporal B
lobe I
epilepsy. I
DNA O
analysis O
revealed O
low O
amounts O
of O
a O
4.8 O
kb O
mtDNA O
deletion O
but O
with O
no O
differences O
in O
frequency O
or O
quantity O
in O
the O
control O
and O
experimental O
groups. O
We O
did O
not O
find O
abnormalities O
in O
the O
expression O
and O
distribution O
of O
an O
mtDNA-encoded O
subunit O
of O
CCO O
(CCO-I) O
or O
a O
relative O
decrease O
in O
CCO-I O
when O
compared O
with O
nuclear-encoded O
subunits O
(CCO-IV O
and O
SDH-fp). O
No O
abnormality O
in O
CCO O
activity O
was O
observed O
through O
histochemistry. O
Although O
evidences O
of O
mitochondrial B
abnormalities I
were O
found O
in O
previously O
published O
studies, O
our O
results O
do O
not O
suggest O
that O
the O
FRs, O
generated O
during O
the O
acute O
phase, O
determined O
important O
abnormalities O
in O
mtDNA, O
in O
expression O
of O
CCO-I, O
and O
in O
CCO O
activity. O

OBJECTIVE: O
To O
study O
tremor B
side O
effects O
of O
salbutamol O
an O
easily O
applicable, O
quick O
and O
low-priced O
method O
is O
needed. O
A O
new O
method O
using O
a O
commercially O
available, O
pen-shaped O
laser O
pointer O
was O
developed. O
Aim O
of O
the O
study O
was O
to O
determine O
sensitivity, O
reproducibility, O
reference O
values O
and O
the O
agreement O
with O
a O
questionnaire. O
METHODS: O
Tremor B
was O
measured O
using O
a O
laser O
pointer O
technique. O
To O
determine O
sensitivity O
we O
assessed O
tremor O
in O
44 O
patients O
with O
obstructive B
lung I
disease I
after O
administration O
of O
cumulative O
doses O
of O
salbutamol. O
Subjects O
were O
asked O
to O
aim O
at O
the O
centre O
of O
a O
target, O
subdivided O
in O
concentric O
circles, O
from O
5 O
m O
distance. O
The O
circle O
in O
which O
the O
participant O
succeeded O
to O
aim O
was O
recorded O
in O
millimetres O
radius. O
In O
another O
series O
of O
measurements, O
reproducibility O
and O
reference O
values O
of O
the O
tremor O
was O
assessed O
in O
65 O
healthy O
subjects O
in O
three O
sessions, O
at O
9 O
a.m., O
4 O
p.m. O
and O
9 O
a.m., O
respectively, O
1 O
week O
later. O
Postural O
tremor O
was O
measured O
with O
the O
arm O
horizontally O
outstretched O
rest O
tremor O
with O
the O
arm O
supported O
by O
an O
armrest O
and O
finally O
tremor O
was O
measured O
after O
holding O
a O
2-kg O
weight O
until O
exhaustion. O
Inter-observer O
variability O
was O
measured O
in O
a O
series O
of O
10 O
healthy O
subjects. O
Tremor O
was O
measured O
simultaneously O
by O
two O
independent O
observers. O
RESULTS: O
Salbutamol O
significantly O
increased O
tremor O
severity O
in O
patients O
in O
a O
dose-dependent O
way. O
Within O
healthy O
adults O
no O
age-dependency O
could O
be O
found O
(b O
= O
0.262 O
mm/year; O
P O
= O
0.72). O
There O
was O
no O
agreement O
between O
the O
questionnaire O
and O
tremor O
severity O
(r O
= O
0.093; O
P O
= O
0.53). O
Postural O
tremor O
showed O
no O
significant O
difference O
between O
the O
first O
and O
third O
session O
(P O
= O
0.07). O
Support O
of O
the O
arm O
decreased O
tremor O
severity, O
exhaustion O
increased O
tremor O
severity O
significantly. O
A O
good O
agreement O
was O
found O
between O
two O
independent O
observers O
(interclass O
correlation O
coefficient O
0.72). O
DISCUSSION: O
Quantifying O
tremor O
by O
using O
an O
inexpensive O
laser O
pointer O
is, O
with O
the O
exception O
of O
children O
(<12 O
years) O
a O
sensitive O
and O
reproducible O
method. O

While O
there O
is O
no O
single O
correct O
starting O
dose O
for O
levodopa O
therapy, O
many O
individuals O
can O
be O
started O
on O
either O
the O
25/100 O
or O
controlled-release O
formula, O
following O
the O
general O
rule O
not O
to O
attempt O
to O
titrate O
carbidopa-levodopa O
to O
the O
point O
of O
"normality," O
which O
can O
lead O
to O
toxicity. B
The O
physician O
should O
also O
determine O
the O
proper O
use O
of O
any O
adjunctive O
medications; O
such O
combined O
therapy O
has O
become O
the O
standard O
approach O
to O
treatment. O
Following O
the O
initial O
period O
of O
therapy, O
emerging O
difficulties O
require O
a O
reassessment O
of O
therapeutic O
approaches, O
such O
as O
dosage O
adjustment O
or O
introduction O
of O
a O
dopamine O
agonist. O
Other O
possible O
adverse O
effects--such O
as O
gastrointestinal B
disorders, I
orthostatic B
hypotension, I
levodopa-induced O
psychosis, B
sleep B
disturbances I
or O
parasomnias, B
or O
drug O
interactions--also O
require O
carefully O
monitored O
individual O
treatment. O
Nonpharmacologic O
concerns O
can O
help O
the O
Parkinson's B
disease I
patient O
achieve O
and O
maintain O
optimal O
functioning, O
including O
daily O
exercise, O
physical O
therapy, O
and O
involvement O
with O
support O
groups. O

The O
present O
studies O
demonstrate O
that O
growth O
and O
vitamin O
D O
treatment O
enhance O
the O
extent O
of O
artery B
calcification B
in O
rats O
given O
sufficient O
doses O
of O
Warfarin O
to O
inhibit O
gamma-carboxylation O
of O
matrix O
Gla O
protein, O
a O
calcification O
inhibitor O
known O
to O
be O
expressed O
by O
smooth O
muscle O
cells O
and O
macrophages O
in O
the O
artery O
wall. O
The O
first O
series O
of O
experiments O
examined O
the O
influence O
of O
age O
and O
growth O
status O
on O
artery O
calcification O
in O
Warfarin-treated O
rats. O
Treatment O
for O
2 O
weeks O
with O
Warfarin O
caused O
massive O
focal O
calcification B
of I
the I
artery I
media O
in O
20-day-old O
rats O
and O
less O
extensive O
focal O
calcification O
in O
42-day-old O
rats. O
In O
contrast, O
no O
artery O
calcification O
could O
be O
detected O
in O
10-month-old O
adult O
rats O
even O
after O
4 O
weeks O
of O
Warfarin O
treatment. O
To O
directly O
examine O
the O
importance O
of O
growth O
to O
Warfarin-induced O
artery O
calcification O
in O
animals O
of O
the O
same O
age, O
20-day-old O
rats O
were O
fed O
for O
2 O
weeks O
either O
an O
ad O
libitum O
diet O
or O
a O
6-g/d O
restricted O
diet O
that O
maintains O
weight O
but O
prevents O
growth. O
Concurrent O
treatment O
of O
both O
dietary O
groups O
with O
Warfarin O
produced O
massive O
focal O
calcification O
of O
the O
artery O
media O
in O
the O
ad O
libitum-fed O
rats O
but O
no O
detectable O
artery O
calcification O
in O
the O
restricted-diet, O
growth-inhibited O
group. O
Although O
the O
explanation O
for O
the O
association O
between O
artery O
calcification O
and O
growth O
status O
cannot O
be O
determined O
from O
the O
present O
study, O
there O
was O
a O
relationship O
between O
higher O
serum O
phosphate O
and O
susceptibility O
to O
artery O
calcification, O
with O
30% O
higher O
levels O
of O
serum O
phosphate O
in O
young, O
ad O
libitum-fed O
rats O
compared O
with O
either O
of O
the O
groups O
that O
was O
resistant O
to O
Warfarin-induced O
artery O
calcification, O
ie, O
the O
10-month-old O
rats O
and O
the O
restricted-diet, O
growth-inhibited O
young O
rats. O
This O
observation O
suggests O
that O
increased O
susceptibility O
to O
Warfarin-induced O
artery O
calcification O
could O
be O
related O
to O
higher O
serum O
phosphate O
levels. O
The O
second O
set O
of O
experiments O
examined O
the O
possible O
synergy O
between O
vitamin O
D O
and O
Warfarin O
in O
artery O
calcification. O
High O
doses O
of O
vitamin O
D O
are O
known O
to O
cause O
calcification O
of O
the O
artery O
media O
in O
as O
little O
as O
3 O
to O
4 O
days. O
High O
doses O
of O
the O
vitamin O
K O
antagonist O
Warfarin O
are O
also O
known O
to O
cause O
calcification O
of O
the O
artery O
media, O
but O
at O
treatment O
times O
of O
2 O
weeks O
or O
longer O
yet O
not O
at O
1 O
week. O
In O
the O
current O
study, O
we O
investigated O
the O
synergy O
between O
these O
2 O
treatments O
and O
found O
that O
concurrent O
Warfarin O
administration O
dramatically O
increased O
the O
extent O
of O
calcification O
in O
the O
media O
of O
vitamin O
D-treated O
rats O
at O
3 O
and O
4 O
days. O
There O
was O
a O
close O
parallel O
between O
the O
effect O
of O
vitamin O
D O
dose O
on O
artery O
calcification O
and O
the O
effect O
of O
vitamin O
D O
dose O
on O
the O
elevation O
of O
serum O
calcium, O
which O
suggests O
that O
vitamin O
D O
may O
induce O
artery O
calcification O
through O
its O
effect O
on O
serum O
calcium. O
Because O
Warfarin O
treatment O
had O
no O
effect O
on O
the O
elevation O
in O
serum O
calcium O
produced O
by O
vitamin O
D, O
the O
synergy O
between O
Warfarin O
and O
vitamin O
D O
is O
probably O
best O
explained O
by O
the O
hypothesis O
that O
Warfarin O
inhibits O
the O
activity O
of O
matrix O
Gla O
protein O
as O
a O
calcification O
inhibitor. O
High O
levels O
of O
matrix O
Gla O
protein O
are O
found O
at O
sites O
of O
artery O
calcification O
in O
rats O
treated O
with O
vitamin O
D O
plus O
Warfarin, O
and O
chemical O
analysis O
showed O
that O
the O
protein O
that O
accumulated O
was O
indeed O
not O
gamma-carboxylated. O
These O
observations O
indicate O
that O
although O
the O
gamma-carboxyglutamate O
residues O
of O
matrix O
Gla O
protein O
are O
apparently O
required O
for O
its O
function O
as O
a O
calcification O
inhibitor, O
they O
are O
not O
required O
for O
its O
accumulation O
at O
calcification O
sites. O

A O
case O
of O
genuine O
stress B
incontinence B
due O
to O
prazosin, O
a O
common O
antihypertensive O
drug, O
is O
presented. O
Prazosin O
exerts O
its O
antihypertensive O
effects O
through O
vasodilatation O
caused O
by O
selective O
blockade O
of O
postsynaptic O
alpha-1 O
adrenergic O
receptors. O
As O
an O
alpha-blocker, O
it O
also O
exerts O
a O
significant O
relaxant O
effect O
on O
the O
bladder O
neck O
and O
urethra. O
The O
patient's O
clinical O
course O
is O
described O
and O
correlated O
with O
initial O
urodynamic O
studies O
while O
on O
prazosin O
and O
subsequent O
studies O
while O
taking O
verapamil. O
Her O
incontinence O
resolved O
with O
the O
change O
of O
medication. O
The O
restoration O
of O
continence O
was O
accompanied O
by O
a O
substantial O
rise O
in O
maximum O
urethral O
pressure, O
maximum O
urethral O
closure O
pressure, O
and O
functional O
urethral O
length. O
Patients O
who O
present O
with O
stress O
incontinence O
while O
taking O
prazosin O
should O
change O
their O
antihypertensive O
medication O
before O
considering O
surgery, O
because O
their O
incontinence O
may O
resolve O
spontaneously O
with O
a O
change O
in O
drug O
therapy. O

International O
mexiletine O
and O
placebo O
antiarrhythmic O
coronary O
trial: O
I. O
Report O
on O
arrhythmia B
and O
other O
findings. O
Impact O
Research O
Group. O

Urinary B
bladder I
cancer I
in O
Wegener's B
granulomatosis: I
risks O
and O
relation O
to O
cyclophosphamide. O

The O
effects O
of O
sevoflurane O
on O
lidocaine-induced O
convulsions. B

Prazosin-induced O
stress B
incontinence. I

Antagonism O
between O
interleukin O
3 O
and O
erythropoietin O
in O
mice O
with O
azidothymidine-induced O
anemia B
and O
in O
bone O
marrow O
endothelial O
cells. O

Proteomic O
analysis O
of O
striatal O
proteins O
in O
the O
rat O
model O
of O
L-DOPA-induced O
dyskinesia. B

Levodopa-induced O
dyskinesias B
in O
patients O
with O
Parkinson's B
disease: I
filling O
the O
bench-to-bedside O
gap. O

Atrial B
fibrillation I
in O
young O
patients O
without O
structural O
heart B
disease I
is O
rare. O
Therefore, O
when O
the O
arrhythmia B
is O
present O
in O
this O
population, O
reversible O
causes O
must O
be O
identified O
and O
resolved. O
Thyroid B
disorders, I
illicit O
drug O
or O
stimulant O
use, O
and O
acute B
alcohol I
intoxication I
are O
among O
these O
causes. O
We O
report O
the O
case O
of O
a O
30-year-old O
Caucasian O
man O
who O
came O
to O
the O
emergency O
department O
in O
atrial B
fibrillation I
with O
rapid O
ventricular O
response. O
His O
medical O
history O
was O
unremarkable, O
except O
for O
minor O
fractures B
of O
the O
fingers O
and O
foot. O
Thyroid-stimulating O
hormone, O
magnesium, O
and O
potassium O
levels O
were O
within O
normal O
limits, O
urine O
drug O
screen O
was O
negative, O
and O
alcohol O
use O
was O
denied. O
However, O
when O
the O
patient O
was O
questioned O
about O
use O
of O
herbal O
products O
and O
supplements, O
the O
use O
of O
creatine O
monohydrate O
was O
revealed. O
The O
patient O
was O
admitted O
to O
the O
hospital, O
anticoagulated O
with O
unfractionated O
heparin, O
and O
given O
intravenous O
diltiazem O
for O
rate O
control O
and O
intravenous O
amiodarone O
for O
rate O
and O
rhythm O
control. O
When O
discharged O
less O
than O
24 O
hours O
later, O
he O
was O
receiving O
metoprolol O
and O
aspirin, O
with O
follow-up O
plans O
for O
echocardiography O
and O
nuclear O
imaging O
to O
assess O
perfusion. O
Exogenous O
creatine O
is O
used O
by O
athletes O
to O
theoretically O
improve O
exercise O
performance. O
Vegetarians O
may O
also O
take O
creatine O
to O
replace O
what O
they O
are O
not O
consuming O
from O
meat, O
fish, O
and O
other O
animal O
products. O
Previous O
anecdotal O
reports O
have O
linked O
creatine O
to O
the O
development O
of O
arrhythmia. O
Clinicians O
must O
be O
diligent O
when O
interviewing O
patients O
about O
their O
drug O
therapy O
histories O
and O
include O
questions O
about O
their O
use O
of O
herbal O
products O
and O
dietary O
supplements. O
In O
addition, O
it O
is O
important O
to O
report O
adverse O
effects O
associated O
with O
frequently O
consumed O
supplements O
and O
herbal O
products O
to O
the O
Food O
and O
Drug O
Administration O
and O
in O
the O
literature. O

Sodium O
bicarbonate O
alleviates O
penile B
pain I
induced O
by O
intracavernous O
injections O
for O
erectile B
dysfunction. I

STUDY O
OBJECTIVE: O
We O
sought O
to O
compare O
the O
rate O
of O
akathisia B
after O
administration O
of O
intravenous O
prochlorperazine O
as O
a O
2-minute O
bolus O
or O
15-minute O
infusion. O
METHODS: O
We O
conducted O
a O
prospective, O
randomized, O
double-blind O
study O
in O
the O
emergency O
department O
of O
a O
central-city O
teaching O
hospital. O
Patients O
aged O
18 O
years O
or O
older O
treated O
with O
prochlorperazine O
for O
headache, B
nausea, B
or O
vomiting B
were O
eligible O
for O
inclusion. O
Study O
participants O
were O
randomized O
to O
receive O
10 O
mg O
of O
prochlorperazine O
administered O
intravenously O
by O
means O
of O
2-minute O
push O
(bolus O
group) O
or O
10 O
mg O
diluted O
in O
50 O
mL O
of O
normal O
saline O
solution O
administered O
by O
means O
of O
intravenous O
infusion O
during O
a O
15-minute O
period O
(infusion O
group). O
The O
main O
outcome O
was O
the O
number O
of O
study O
participants O
experiencing O
akathisia O
within O
60 O
minutes O
of O
administration. O
Akathisia O
was O
defined O
as O
either O
a O
spontaneous O
report O
of O
restlessness O
or O
agitation B
or O
a O
change O
of O
2 O
or O
more O
in O
the O
patient-reported O
akathisia O
rating O
scale O
and O
a O
change O
of O
at O
least O
1 O
in O
the O
investigator-observed O
akathisia O
rating O
scale. O
The O
intensity O
of O
headache O
and O
nausea O
was O
measured O
with O
a O
100-mm O
visual O
analog O
scale. O
RESULTS: O
One O
hundred O
patients O
were O
enrolled. O
One O
study O
participant O
was O
excluded O
after O
protocol O
violation. O
Seventy-three O
percent O
(73/99) O
of O
the O
study O
participants O
were O
treated O
for O
headache O
and O
70% O
(70/99) O
for O
nausea. O
In O
the O
bolus O
group, O
26.0% O
(13/50) O
had O
akathisia O
compared O
with O
32.7% O
(16/49) O
in O
the O
infusion O
group O
(Delta=-6.7%; O
95% O
confidence O
interval O
[CI] O
-24.6% O
to O
11.2%). O
The O
difference O
between O
the O
bolus O
and O
infusion O
groups O
in O
the O
percentage O
of O
participants O
who O
saw O
a O
50% O
reduction O
in O
their O
headache O
intensity O
within O
30 O
minutes O
was O
11.8% O
(95% O
CI O
-9.6% O
to O
33.3%). O
The O
difference O
in O
the O
percentage O
of O
patients O
with O
a O
50% O
reduction O
in O
their O
nausea O
was O
12.6% O
(95% O
CI O
-4.6% O
to O
29.8%). O
CONCLUSION: O
A O
50% O
reduction O
in O
the O
incidence O
of O
akathisia O
when O
prochlorperazine O
was O
administered O
by O
means O
of O
15-minute O
intravenous O
infusion O
versus O
a O
2-minute O
intravenous O
push O
was O
not O
detected. O
The O
efficacy O
of O
prochlorperazine O
in O
the O
treatment O
of O
headache O
and O
nausea O
likewise O
did O
not O
appear O
to O
be O
affected O
by O
the O
rate O
of O
administration, O
although O
no O
formal O
statistical O
comparisons O
were O
made. O

PURPOSE: O
To O
assess O
the O
incidence O
of O
postoperative O
emetic O
side O
effects O
after O
the O
administration O
of O
methylprednisolone O
and O
gentamicin O
into O
the O
posterior O
sub-Tenon's O
space O
at O
the O
end O
of O
routine O
cataract B
surgery. O
SETTING: O
St. O
Luke's O
Hospital, O
Gwardamangia, O
Malta. O
METHODS: O
A O
double-blind O
double-armed O
prospective O
study O
comprised O
40 O
patients O
who O
had O
uneventful O
sutureless O
phacoemulsification O
under O
sub-Tenon's O
local O
infiltration O
of O
3 O
mL O
of O
plain O
lignocaine. O
At O
the O
end O
of O
the O
procedure, O
Group O
A O
(n O
= O
20) O
had O
20 O
mg/0.5 O
mL O
of O
methylprednisolone O
and O
10 O
mg/0.5 O
mL O
of O
gentamicin O
injected O
into O
the O
posterior O
sub-Tenon's O
space O
and O
Group O
B O
(n O
= O
20) O
had O
the O
same O
combination O
injected O
into O
the O
anterior O
sub-Tenon's O
space. O
Postoperatively, O
all O
patients O
were O
assessed O
for O
symptoms O
of O
nausea, B
vomiting, I
and O
headache. B
A O
chi-square O
test O
was O
used O
to O
assess O
the O
statistical O
significance O
of O
results. O
RESULTS: O
Sixty O
percent O
in O
Group O
A O
developed O
postoperative B
emetic I
symptoms, I
headache, O
or O
both; O
1 O
patient O
in O
Group O
B O
developed O
symptoms. O
CONCLUSIONS: O
The O
administration O
of O
methylprednisolone O
and O
gentamicin O
in O
the O
posterior O
sub-Tenon's O
space O
was O
related O
to O
a O
high O
incidence O
of O
side O
effects O
including O
nausea, O
vomiting, O
and O
headache. O
All O
adverse O
effects O
were O
self-limiting. O

Randomized, O
double-blind O
trial O
of O
mazindol O
in O
Duchenne B
dystrophy. I

Alpha O
and O
beta O
coma B
in O
drug O
intoxication O
uncomplicated O
by O
cerebral B
hypoxia. I

During O
an O
18-month O
period O
of O
study O
41 O
hemodialyzed O
patients O
receiving O
desferrioxamine O
(10-40 O
mg/kg O
BW/3 O
times O
weekly) O
for O
the O
first O
time O
were O
monitored O
for O
detection O
of O
audiovisual B
toxicity. I
6 O
patients O
presented O
clinical O
symptoms O
of O
visual B
or I
auditory B
toxicity. I
Moreover, O
detailed O
ophthalmologic O
and O
audiologic O
studies O
disclosed O
abnormalities O
in O
7 O
more O
asymptomatic O
patients. O
Visual B
toxicity I
was O
of O
retinal O
origin O
and O
was O
characterized O
by O
a O
tritan-type O
dyschromatopsy, B
sometimes O
associated O
with O
a B
loss I
of I
visual I
acuity I
and O
pigmentary B
retinal I
deposits. I
Auditory B
toxicity I
was O
characterized O
by O
a O
mid- O
to O
high-frequency O
neurosensorial B
hearing B
loss I
and O
the O
lesion O
was O
of O
the O
cochlear O
type. O
Desferrioxamine O
withdrawal O
resulted O
in O
a O
complete O
recovery O
of O
visual O
function O
in O
1 O
patient O
and O
partial O
recovery O
in O
3, O
and O
a O
complete O
reversal O
of O
hearing O
loss O
in O
3 O
patients O
and O
partial O
recovery O
in O
3. O
This O
toxicity O
appeared O
in O
patients O
receiving O
the O
higher O
doses O
of O
desferrioxamine O
or O
coincided O
with O
the O
normalization O
of O
ferritin O
or O
aluminium O
serum O
levels. O
The O
data O
indicate O
that O
audiovisual O
toxicity O
is O
not O
an O
infrequent O
complication O
in O
hemodialyzed O
patients O
receiving O
desferrioxamine. O
Periodical O
audiovisual O
monitoring O
should O
be O
performed O
on O
hemodialyzed O
patients O
receiving O
the O
drug O
in O
order O
to O
detect O
adverse O
effects O
as O
early O
as O
possible. O

Suxamethonium O
infusion O
rate O
and O
observed O
fasciculations. B
A O
dose-response O
study. O

Metamizol O
potentiates O
morphine O
antinociception O
but O
not O
constipation B
after O
chronic O
treatment. O

Intravenous O
administration O
of O
prochlorperazine O
by O
15-minute O
infusion O
versus O
2-minute O
bolus O
does O
not O
affect O
the O
incidence O
of O
akathisia: B
a O
prospective, O
randomized, O
controlled O
trial. O

BACKGROUND: O
Cisplatin O
has O
minimal O
antitumor O
activity B
when O
used O
as O
second- O
or O
third-line O
treatment O
of O
metastatic O
breast B
carcinoma. I
Older O
reports O
suggest O
an O
objective O
response O
rate O
of O
8% O
when O
60-120 O
mg/m2 O
of O
cisplatin O
is O
administered O
every O
3-4 O
weeks. O
Although O
a O
dose-response O
effect O
has O
been O
observed O
with O
cisplatin, O
the O
dose-limiting O
toxicities B
associated O
with O
cisplatin O
(e.g., O
nephrotoxicity, B
ototoxicity, B
and O
neurotoxicity) B
have O
limited O
its O
use O
as O
a O
treatment O
for O
breast O
carcinoma. O
WR-2721 O
or O
amifostine O
initially O
was O
developed O
to O
protect O
military O
personnel O
in O
the O
event O
of O
nuclear O
war. O
Amifostine O
subsequently O
was O
shown O
to O
protect O
normal O
tissues O
from O
the O
toxic O
effects O
of O
alkylating O
agents O
and O
cisplatin O
without O
decreasing O
the O
antitumor O
effect O
of O
the O
chemotherapy. O
Early O
trials O
of O
cisplatin O
and O
amifostine O
also O
suggested O
that O
the O
incidence O
and O
severity O
of O
cisplatin-induced O
nephrotoxicity, O
ototoxicity, O
and O
neuropathy B
were O
reduced. O
METHODS: O
A O
Phase O
II O
study O
of O
the O
combination O
of O
cisplatin O
plus O
amifostine O
was O
conducted O
in O
patients O
with O
progressive O
metastatic O
breast O
carcinoma O
who O
had O
received O
one, O
but O
not O
more O
than O
one, O
chemotherapy O
regimen O
for O
metastatic O
disease. O
Patients O
received O
amifostine, O
910 O
mg/m2 O
intravenously O
over O
15 O
minutes. O
After O
completion O
of O
the O
amifostine O
infusion, O
cisplatin O
120 O
mg/m2 O
was O
administered O
over O
30 O
minutes. O
Intravenous O
hydration O
and O
mannitol O
was O
administered O
before O
and O
after O
cisplatin. O
Treatment O
was O
administered O
every O
3 O
weeks O
until O
disease O
progression. O
RESULTS: O
Forty-four O
patients O
were O
enrolled O
in O
the O
study O
of O
which O
7 O
(16%) O
were O
ineligible. O
A O
median O
of O
2 O
cycles O
of O
therapy O
was O
administered O
to O
the O
37 O
eligible O
patients. O
Six O
partial O
responses O
were O
observed O
for O
an O
overall O
response O
rate O
of O
16%. O
Most O
patients O
(57%) O
stopped O
treatment O
because O
of O
disease O
progression. O
Neurologic B
toxicity I
was O
reported O
in O
52% O
of O
patients. O
Seven O
different O
life-threatening O
toxicities O
were O
observed O
in O
patients O
while O
receiving O
treatment. O
CONCLUSIONS: O
The O
combination O
of O
cisplatin O
and O
amifostine O
in O
this O
study O
resulted O
in O
an O
overall O
response O
rate O
of O
16%. O
Neither O
a O
tumor-protective O
effect O
nor O
reduced O
toxicity O
to O
normal O
tissues O
was O
observed O
with O
the O
addition O
of O
amifostine O
to O
cisplatin O
in O
this O
trial. O

Angiosarcoma B
of I
the I
liver I
associated O
with O
diethylstilbestrol. O

A O
77-y-old O
patient O
developed O
weakness B
of I
extremities, I
legs B
paralysis, I
dysarthria B
and O
tremor B
1 O
h O
after O
ingestion O
of O
200 O
mg O
ketoconazole O
for O
the O
first O
time O
in O
his O
life. O
All O
complaints O
faded O
away O
within O
24 O
h. O
Few O
days O
later, O
the O
patient O
used O
another O
200 O
mg O
ketoconazole O
tablet, O
and O
within O
an O
hour O
experienced O
a O
similar O
clinical O
picture, O
which O
resolved O
again O
spontaneously O
within O
hours. O
Laboratory O
evaluations, O
including O
head O
CT O
scan, O
were O
normal. O
This O
case O
illustrates O
the O
need O
for O
close O
vigilance O
in O
adverse B
drug I
reactions, I
particularly O
in O
the O
elderly. O

Iatrogenically O
induced O
intractable O
atrioventricular B
reentrant I
tachycardia I
after O
verapamil O
and O
catheter O
ablation O
in O
a O
patient O
with O
Wolff-Parkinson-White B
syndrome I
and O
idiopathic B
dilated I
cardiomyopathy. I

Habitual O
use O
of O
acetaminophen O
as O
a O
risk O
factor O
for O
chronic B
renal I
failure: I
a O
comparison O
with O
phenacetin. O

Myocardial B
infarction I
following O
sublingual O
administration O
of O
isosorbide O
dinitrate. O

This O
study O
measured O
the O
objective O
and O
subjective O
neurocognitive O
effects O
of O
a O
single O
10-mg O
dose O
of O
immediate-release O
oxycodone O
in O
healthy, O
older O
(> O
65 O
years), O
and O
middle-aged O
(35 O
to O
55 O
years) O
adults O
who O
were O
not O
suffering O
from O
chronic O
or O
significant O
daily O
pain. B
Seventy-one O
participants O
completed O
2 O
separate O
study O
days O
and O
were O
blind O
to O
medication O
condition O
(placebo, O
10-mg O
oxycodone). O
Plasma O
oxycodone O
concentration O
peaked O
between O
60 O
and O
90 O
minutes O
postdose O
(P O
< O
.01) O
and O
pupil O
size, O
an O
indication O
of O
physiological O
effects O
of O
the O
medication, O
peaked O
at O
approximately O
90 O
to O
120 O
minutes O
postdose O
(P O
< O
.01). O
Significant O
declines B
in I
simple I
and I
sustained I
attention, I
working I
memory, I
and I
verbal I
memory I
were O
observed O
at O
1 O
hour O
postdose O
compared O
to O
baseline O
for O
both O
age O
groups O
with O
a O
trend O
toward O
return O
to O
baseline O
by O
5 O
hours O
postdose. O
For O
almost O
all O
cognitive O
measures, O
there O
were O
no O
medication O
by O
age-interaction O
effects, O
which O
indicates O
that O
the O
2 O
age O
groups O
exhibited O
similar O
responses O
to O
the O
medication O
challenge. O
This O
study O
suggests O
that O
for O
healthy O
older O
adults O
who O
are O
not O
suffering O
from O
chronic B
pain, I
neurocognitive O
and O
pharmacodynamic O
changes O
in O
response O
to O
a O
10-mg O
dose O
of O
immediate-release O
oxycodone O
are O
similar O
to O
those O
observed O
for O
middle-aged O
adults. O
PERSPECTIVE: O
Study O
findings O
indicate O
that O
the O
metabolism, O
neurocognitive O
effects, O
and O
physical O
side O
effects O
of O
oral O
oxycodone O
are O
similar O
for O
healthy O
middle-aged O
and O
older O
adults. O
Therefore, O
clinicians O
should O
not O
avoid O
prescribing O
oral O
opioids O
to O
older O
adults O
based O
on O
the O
belief O
that O
older O
adults O
are O
at O
higher O
risk O
for O
side O
effects O
than O
younger O
adults. O

Neuroprotective O
action O
of O
MPEP, O
a O
selective O
mGluR5 O
antagonist, O
in O
methamphetamine-induced O
dopaminergic O
neurotoxicity B
is O
associated O
with O
a O
decrease O
in O
dopamine O
outflow O
and O
inhibition O
of O
hyperthermia B
in O
rats. O

Effects O
of O
acetylsalicylic O
acid, O
dipyridamole, O
and O
hydrocortisone O
on O
epinephrine-induced O
myocardial B
injury I
in O
dogs. O

We O
report O
an O
undiagnosed O
case O
of O
myotonia B
congenita I
in O
a O
24-year-old O
previously O
healthy O
primigravida, O
who O
developed O
life O
threatening O
masseter B
spasm I
following O
a O
standard O
dose O
of O
intravenous O
suxamethonium O
for O
induction O
of O
anaesthesia. O
Neither O
the O
patient O
nor O
the O
anaesthetist O
was O
aware O
of O
the O
diagnosis O
before O
this O
potentially O
lethal O
complication O
occurred. O

Fusidic O
acid O
is O
an O
antibiotic O
with O
T-cell O
specific O
immunosuppressive O
effects O
similar O
to O
those O
of O
cyclosporin. O
Because O
of O
the O
need O
for O
the O
development O
of O
new O
treatments O
for O
Crohn's B
disease, I
a O
pilot O
study O
was O
undertaken O
to O
estimate O
the O
pharmacodynamics O
and O
tolerability O
of O
fusidic O
acid O
treatment O
in O
chronic O
active, O
therapy-resistant O
patients. O
Eight O
Crohn's O
disease O
patients O
were O
included. O
Fusidic O
acid O
was O
administered O
orally O
in O
a O
dose O
of O
500 O
mg O
t.d.s. O
and O
the O
treatment O
was O
planned O
to O
last O
8 O
weeks. O
The O
disease O
activity O
was O
primarily O
measured O
by O
a O
modified O
individual O
grading O
score. O
Five O
of O
8 O
patients O
(63%) O
improved O
during O
fusidic O
acid O
treatment: O
3 O
at O
two O
weeks O
and O
2 O
after O
four O
weeks. O
There O
were O
no O
serious O
clinical O
side O
effects, O
but O
dose O
reduction O
was O
required O
in O
two O
patients O
because O
of O
nausea. B
Biochemically, O
an O
increase O
in O
alkaline O
phosphatases O
was O
noted O
in O
5 O
of O
8 O
cases O
(63%), O
and O
the O
greatest O
increases O
were O
seen O
in O
those O
who O
had O
elevated O
levels O
prior O
to O
treatment. O
All O
reversed O
to O
pre-treatment O
levels O
after O
cessation O
of O
treatment. O
The O
results O
of O
this O
pilot O
study O
suggest O
that O
fusidic O
acid O
may O
be O
of O
benefit O
in O
selected O
chronic O
active O
Crohn's O
disease O
patients O
in O
whom O
conventional O
treatment O
is O
ineffective. O
Because O
there O
seems O
to O
exist O
a O
scientific O
rationale O
for O
the O
use O
of O
fusidic O
acid O
at O
the O
cytokine O
level O
in O
inflammatory B
bowel I
disease, I
we O
suggest O
that O
the O
role O
of O
this O
treatment O
should O
be O
further O
investigated. O

Centrally O
acting O
alpha-2 O
adrenergic O
agonists O
are O
one O
of O
several O
pharmacologic O
agents O
used O
in O
the O
treatment O
of O
spasticity B
related O
to O
disorders B
of I
the I
central I
nervous I
system. I
In O
addition O
to O
their O
effects O
on O
spasticity, O
certain O
adverse O
cardiorespiratory O
effects O
have O
been O
reported. O
Adults O
chronically O
treated O
with O
angiotensin O
converting O
enzyme O
inhibitors O
may O
have O
a O
limited O
ability O
to O
respond O
to O
hypotension B
when O
the O
sympathetic O
response O
is O
simultaneously O
blocked. O
The O
authors O
present O
a O
10-year-old O
boy O
chronically O
treated O
with O
lisinopril, O
an O
angiotensin O
converting O
enzyme O
inhibitor, O
to O
control O
hypertension B
who O
developed O
hypotension O
following O
the O
addition O
of O
tizanidine, O
an O
alpha-2 O
agonist, O
for O
the O
treatment O
of O
spasticity. O
The O
possible O
interaction O
of O
tizanidine O
and O
other O
antihypertensive O
agents O
should O
be O
kept O
in O
mind O
when O
prescribing O
therapy O
to O
treat O
either O
hypertension O
or O
spasticity O
in O
such O
patients. O

We O
report O
the O
case O
of O
a O
patient O
who O
developed O
acute O
hepatitis B
with O
extensive B
hepatocellular I
necrosis, I
7 O
months O
after O
the O
onset O
of O
administration O
of O
clotiazepam, O
a O
thienodiazepine O
derivative. O
Clotiazepam O
withdrawal O
was O
followed O
by O
prompt O
recovery. O
The O
administration O
of O
several O
benzodiazepines, O
chemically O
related O
to O
clotiazepam, O
did O
not O
interfere O
with O
recovery O
and O
did O
not O
induce O
any O
relapse O
of O
hepatitis. O
This O
observation O
shows O
that O
clotiazepam O
can O
induce O
acute O
hepatitis O
and O
suggests O
that O
there O
is O
no O
cross O
hepatotoxicity B
between O
clotiazepam O
and O
several O
benzodiazepines. O

Thirty-four O
patients O
with O
juvenile B
rheumatoid I
arthritis, B
who O
were O
treated O
with O
flurbiprofen O
at O
a O
maximum O
dose O
of O
4 O
mg/kg/day, O
had O
statistically O
significant O
decreases O
from O
baseline O
in O
6 O
arthritis O
indices O
after O
12 O
weeks O
of O
treatment. O
Improvements O
were O
seen O
in O
the O
number O
of O
tender B
joints, I
the O
severity O
of O
swelling B
and O
tenderness, B
the O
time O
of O
walk O
50 O
feet, O
the O
duration O
of O
morning B
stiffness I
and O
the O
circumference O
of O
the O
left O
knee. O
The O
most O
frequently O
observed O
side O
effect O
was O
fecal B
occult I
blood I
(25% O
of O
patients); O
however, O
there O
was O
no O
other O
evidence O
of O
gastrointestinal B
(GI) I
bleeding I
in O
these O
patients. O
One O
patient O
was O
prematurely O
discontinued O
from O
the O
study O
for O
severe O
headache B
and O
abdominal B
pain. I
Most O
side O
effects O
were O
mild O
and O
related O
to O
the O
GI O
tract. O

Neuromuscular O
blocking O
agents O
(NMBAs) O
are O
often O
used O
for O
patients O
requiring O
prolonged O
mechanical O
ventilation. O
Reports O
of O
persistent O
paralysis B
after O
the O
discontinuance O
of O
these O
drugs O
have O
most O
often O
involved O
aminosteroid-based O
NMBAs O
such O
as O
vecuronium O
bromide, O
especially O
when O
used O
in O
conjunction O
with O
corticosteroids. O
Atracurium O
besylate, O
a O
short-acting O
benzylisoquinolinium O
NMBA O
that O
is O
eliminated O
independently O
of O
renal O
or O
hepatic O
function, O
has O
also O
been O
associated O
with O
persistent O
paralysis, O
but O
only O
when O
used O
with O
corticosteroids. O
We O
report O
a O
case O
of O
atracurium-related O
paralysis O
persisting O
for O
approximately O
50 O
hours O
in O
a O
patient O
who O
was O
not O
treated O
with O
corticosteroids. O

Individual O
differences O
in O
renal O
ACE O
activity O
in O
healthy O
rats O
predict O
susceptibility O
to O
adriamycin-induced O
renal B
damage. I

Testosterone-dependent O
hypertension B
and O
upregulation O
of O
intrarenal O
angiotensinogen O
in O
Dahl O
salt-sensitive O
rats. O

Rg1, O
as O
a O
ginsenoside O
extracted O
from O
Panax O
ginseng, O
could O
ameliorate O
spatial O
learning B
impairment. I
Previous O
studies O
have O
demonstrated O
that O
Rg1 O
might O
be O
a O
useful O
agent O
for O
the O
prevention O
and O
treatment O
of O
the O
adverse O
effects O
of O
morphine. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
Rg1 O
on O
learning O
impairment O
by O
chronic O
morphine O
administration O
and O
the O
mechanism O
responsible O
for O
this O
effect. O
Male O
rats O
were O
subcutaneously O
injected O
with O
morphine O
(10 O
mg/kg) O
twice O
a O
day O
at O
12 O
hour O
intervals O
for O
10 O
days, O
and O
Rg1 O
(30 O
mg/kg) O
was O
intraperitoneally O
injected O
2 O
hours O
after O
the O
second O
injection O
of O
morphine O
once O
a O
day O
for O
10 O
days. O
Spatial O
learning O
capacity O
was O
assessed O
in O
the O
Morris O
water O
maze. O
The O
results O
showed O
that O
rats O
treated O
with O
Morphine/Rg1 O
decreased O
escape O
latency O
and O
increased O
the O
time O
spent O
in O
platform O
quadrant O
and O
entering O
frequency. O
By O
implantation O
of O
electrodes O
and O
electrophysiological O
recording O
in O
vivo, O
the O
results O
showed O
that O
Rg1 O
restored O
the O
long-term O
potentiation O
(LTP) O
impaired O
by O
morphine O
in O
both O
freely O
moving O
and O
anaesthetised O
rats. O
The O
electrophysiological O
recording O
in O
vitro O
showed O
that O
Rg1 O
restored O
the O
LTP O
in O
slices O
from O
the O
rats O
treated O
with O
morphine, O
but O
not O
changed O
LTP O
in O
the O
slices O
from O
normal O
saline- O
or O
morphine/Rg1-treated O
rats; O
this O
restoration O
could O
be O
inhibited O
by O
N-methyl-D-aspartate O
(NMDA) O
receptor O
antagonist O
MK801. O
We O
conclude O
that O
Rg1 O
may O
significantly O
improve O
the O
spatial O
learning O
capacity O
impaired O
by O
chonic O
morphine O
administration O
and O
restore O
the O
morphine-inhibited O
LTP. O
This O
effect O
is O
NMDA O
receptor O
dependent. O

BACKGROUND O
AND O
PURPOSE: O
The O
Intravenous O
Nimodipine O
West O
European O
Stroke B
Trial O
(INWEST) O
found O
a O
correlation O
between O
nimodipine-induced O
reduction B
in I
blood I
pressure I
(BP) O
and O
an O
unfavorable O
outcome O
in O
acute B
stroke. I
We O
sought O
to O
confirm O
this O
correlation O
with O
and O
without O
adjustment O
for O
prognostic O
variables O
and O
to O
investigate O
outcome O
in O
subgroups O
with O
increasing O
levels O
of O
BP B
reduction. I
METHODS: O
Patients O
with O
a O
clinical O
diagnosis O
of O
ischemic B
stroke I
(within O
24 O
hours) O
were O
consecutively O
allocated O
to O
receive O
placebo O
(n=100), O
1 O
mg/h O
(low-dose) O
nimodipine O
(n=101), O
or O
2 O
mg/h O
(high-dose) O
nimodipine O
(n=94). O
The O
correlation O
between O
average O
BP O
change O
during O
the O
first O
2 O
days O
and O
the O
outcome O
at O
day O
21 O
was O
analyzed. O
RESULTS: O
Two O
hundred O
sixty-five O
patients O
were O
included O
in O
this O
analysis O
(n=92, O
93, O
and O
80 O
for O
placebo, O
low O
dose, O
and O
high O
dose, O
respectively). O
Nimodipine O
treatment O
resulted O
in O
a O
statistically O
significant O
reduction B
in I
systolic I
BP I
(SBP) O
and O
diastolic O
BP O
(DBP) O
from O
baseline O
compared O
with O
placebo O
during O
the O
first O
few O
days. O
In O
multivariate O
analysis, O
a O
significant O
correlation O
between O
DBP B
reduction I
and O
worsening O
of O
the O
neurological O
score O
was O
found O
for O
the O
high-dose O
group O
(beta=0.49, O
P=0. O
048). O
Patients O
with O
a O
DBP O
reduction O
of O
> O
or O
=20% O
in O
the O
high-dose O
group O
had O
a O
significantly O
increased O
adjusted O
OR O
for O
the O
compound O
outcome O
variable O
death B
or O
dependency O
(Barthel O
Index O
<60) O
(n/N=25/26, O
OR O
10. O
16, O
95% O
CI O
1.02 O
to O
101.74) O
and O
death O
alone O
(n/N=9/26, O
OR O
4.336, O
95% O
CI O
1.131 O
16.619) O
compared O
with O
all O
placebo O
patients O
(n/N=62/92 O
and O
14/92, O
respectively). O
There O
was O
no O
correlation O
between O
SBP O
change O
and O
outcome. O
CONCLUSIONS: O
DBP, O
but O
not O
SBP, O
reduction O
was O
associated O
with O
neurological O
worsening O
after O
the O
intravenous O
administration O
of O
high-dose O
nimodipine O
after O
acute O
stroke. O
For O
low-dose O
nimodipine, O
the O
results O
were O
not O
conclusive. O
These O
results O
do O
not O
confirm O
or O
exclude O
a O
neuroprotective O
property O
of O
nimodipine. O

Causes O
of O
death, B
with O
special O
reference O
to O
cerebral B
haemorrhage, I
among O
240 O
patients O
with O
pathologically O
verified O
Parkinson's B
disease I
were O
investigated O
using O
the O
Annuals O
of O
the O
Pathological O
Autopsy O
Cases O
in O
Japan O
from O
1981 O
to O
1985. O
The O
leading O
causes O
of O
death O
were O
pneumonia B
and O
bronchitis B
(44.1%), O
malignant O
neoplasms B
(11.6%), O
heart B
diseases I
(4.1%), O
cerebral B
infarction I
(3.7%) O
and O
septicaemia B
(3.3%). O
Cerebral B
haemorrhage I
was O
the O
11th O
most O
frequent O
cause O
of O
death, O
accounting O
for O
only O
0.8% O
of O
deaths B
among O
the O
patients, O
whereas O
it O
was O
the O
5th O
most O
common O
cause O
of O
death O
among O
the O
Japanese O
general O
population O
in O
1985. O
The O
low O
incidence O
of O
cerebral O
haemorrhage O
as O
a O
cause O
of O
death O
in O
patients O
with O
Parkinson's O
disease O
may O
reflect O
the O
hypotensive B
effect O
of O
levodopa O
and O
a O
hypotensive O
mechanism O
due O
to O
reduced O
noradrenaline O
levels O
in O
the O
parkinsonian B
brain. O

CNS O
toxic O
effects O
of O
the O
antineoplastic O
agent O
ifosfamide O
(IFX) O
are O
frequent O
and O
include O
a O
variety O
of O
neurological O
symptoms O
that O
can O
limit O
drug O
use. O
We O
report O
a O
case O
of O
a O
51-year-old O
man O
who O
developed O
severe, O
disabling O
negative O
myoclonus B
of O
the O
upper O
and O
lower O
extremities O
after O
the O
infusion O
of O
ifosfamide O
for O
plasmacytoma. B
He O
was O
awake, O
revealed O
no O
changes O
of O
mental O
status O
and O
at O
rest O
there O
were O
no O
further O
motor O
symptoms. O
Cranial O
magnetic O
resonance O
imaging O
and O
extensive O
laboratory O
studies O
failed O
to O
reveal O
structural B
lesions I
of I
the I
brain I
and O
metabolic B
abnormalities. I
An O
electroencephalogram O
showed O
continuous, O
generalized O
irregular O
slowing O
with O
admixed O
periodic O
triphasic O
waves O
indicating O
symptomatic O
encephalopathy. B
The O
administration O
of O
ifosfamide O
was O
discontinued O
and O
within O
12 O
h O
the O
asterixis B
resolved O
completely. O
In O
the O
patient O
described, O
the O
presence O
of O
asterixis O
during O
infusion O
of O
ifosfamide, O
normal O
laboratory O
findings O
and O
imaging O
studies O
and O
the O
resolution O
of O
symptoms O
following O
the O
discontinuation O
of O
the O
drug O
suggest O
that O
negative O
myoclonus O
is O
associated O
with O
the O
use O
of O
IFX. O

L-arginine O
transport O
in O
humans O
with O
cortisol-induced O
hypertension. B

In O
a O
placebo-controlled, O
single-blinded, O
crossover O
study, O
we O
assessed O
the O
effect O
of O
"real" O
repetitive O
transcranial O
magnetic O
stimulation O
(rTMS) O
versus O
"sham" O
rTMS O
(placebo) O
on O
peak O
dose O
dyskinesias B
in O
patients O
with O
Parkinson's B
disease I
(PD). O
Ten B
patients O
with O
PD O
and O
prominent O
dyskinesias O
had O
rTMS O
(1,800 O
pulses; O
1 O
Hz O
rate) O
delivered O
over O
the O
motor O
cortex O
for O
4 O
consecutive O
days O
twice, O
once O
real O
stimuli O
and O
once O
sham O
stimulation O
were O
used; O
evaluations O
were O
done O
at O
the O
baseline O
and O
1 O
day O
after O
the O
end O
of O
each O
of O
the O
treatment O
series. O
Direct O
comparison O
between O
sham O
and O
real O
rTMS O
effects O
showed O
no O
significant O
difference O
in O
clinician-assessed O
dyskinesia O
severity. O
However, O
comparison O
with O
the O
baseline O
showed O
small O
but O
significant O
reduction O
in O
dyskinesia O
severity O
following O
real O
rTMS O
but O
not O
placebo. O
The O
major O
effect O
was O
on O
dystonia B
subscore. O
Similarly, O
in O
patient O
diaries, O
although O
both O
treatments O
caused O
reduction O
in O
subjective O
dyskinesia O
scores O
during O
the O
days O
of O
intervention, O
the O
effect O
was O
sustained O
for O
3 O
days O
after O
the O
intervention O
for O
the O
real O
rTMS O
only. O
Following O
rTMS, O
no O
side O
effects O
and O
no O
adverse O
effects O
on O
motor O
function O
and O
PD O
symptoms O
were O
noted. O
The O
results O
suggest O
the O
existence O
of O
residual O
beneficial O
clinical O
aftereffects O
of O
consecutive O
daily O
applications O
of O
low-frequency O
rTMS O
on O
dyskinesias O
in O
PD. O
The O
effects O
may O
be O
further O
exploited O
for O
potential O
therapeutic O
uses. O

Abnormal B
involuntary I
movements I
appeared O
in O
the O
mouth, O
tongue, O
neck O
and O
abdomen O
of O
a O
64-year-old O
male O
patient O
after O
he O
took O
metoclopramide O
for O
gastrointestinal B
disorder I
in O
a O
regimen O
of O
30 O
mg O
per O
day O
for O
a O
total O
of O
about O
260 O
days. O
The O
symptoms O
exacerbated O
to O
a O
maximum O
in O
a O
month. O
When O
the O
metoclopramide O
administration O
was O
discontinued, O
the O
abnormal B
movements I
gradually O
improved O
to O
a O
considerable O
extent. O
Attention O
to O
the O
possible O
induction O
of O
specific O
tardive B
dyskinesia I
is O
called O
for O
in O
the O
use O
of O
this O
drug. O

BACKGROUND: O
We O
clinically O
and O
pathologically O
analyzed O
renal O
allografts O
from O
1 O
9 O
renal O
transplant O
patients O
treated O
with O
tacrolimus O
(FK506) O
for O
more O
than O
1 O
year. O
METHODS: O
Twenty-six O
renal O
allograft O
biopsy O
specimens O
from O
1 O
9 O
renal O
transplant O
patients O
who O
underwent O
transplantations O
between O
1991 O
and O
1993 O
were O
evaluated. O
Thirteen O
biopsies O
were O
performed O
from O
stable O
functioning O
renal O
allografts O
with O
informed O
consent O
(nonepisode O
biopsy) O
and O
the O
other O
13 O
were O
from O
dysfunctional O
renal O
allografts O
with O
a O
clinical O
indication O
for O
biopsy O
(episode O
biopsy). O
RESULTS: O
The O
main O
pathologic O
diagnoses O
(some O
overlap) O
were O
acute O
rejection O
(AR; O
n O
= O
4), O
chronic O
rejection O
(CR; O
n=5), O
AR+CR O
(n O
=4), O
recurrent O
IgA B
nephropathy B
(n O
=5), O
normal O
findings O
(n O
=2), O
minimal-type O
chronic O
FK506 O
nephropathy O
(n O
= O
9), O
and O
mild-type O
FK506 O
nephropathy O
(n O
= O
11). O
Of O
the O
nonepisode O
biopsies, O
7 O
and O
4 O
biopsies O
showed O
minimal-type O
and O
mild-type O
chronic O
FK506 O
nephropathy, O
respectively. O
Chronic O
FK506 O
nephropathy O
consisted O
of O
rough O
and O
foamy O
tubular O
vacuolization O
(5 O
biopsies), O
arteriolopathy O
(angiodegeneration O
of O
the O
arteriolar O
wall; O
20 O
biopsies), O
focal B
segmental I
glomerulosclerosis I
(4 O
biopsies) O
and O
the O
striped O
form O
of O
interstitial B
fibrosis I
(11 O
biopsies). O
The O
serum O
creatinine O
levels O
of O
patients O
in O
the O
mild-type O
chronic O
FK506 O
nephropathy O
group, O
which O
included O
7 O
episode O
biopsies, O
were O
statistically O
higher O
than O
those O
in O
the O
minimum-type O
chronic O
FK506-nephropathy O
group O
(P< O
0.001). O
CONCLUSIONS: O
This O
study O
demonstrates O
that O
chronic O
FK506 O
nephropathy O
consists O
primarily O
of O
arteriolopathy O
manifesting O
as O
insudative O
hyalinosis O
of O
the O
arteriolar O
wall, O
and O
suggests O
that O
mild-type O
chronic O
FK506 O
nephropathy O
is O
a O
condition O
which O
may O
lead O
to O
deterioration O
of O
renal O
allograft O
function. O

An O
80-yr-old O
man O
developed O
acute O
hepatitis B
shortly O
after O
ingesting O
oral O
ceftriaxone. O
Although O
the O
transaminases O
gradually O
returned O
to O
baseline O
after O
withholding O
the O
beta O
lactam O
antibiotic, O
there O
was O
a O
gradual O
increase O
in O
serum O
bilirubin O
and O
a O
decrease O
in O
hemoglobin O
concentration O
caused O
by O
an O
autoimmune B
hemolytic I
anemia I
and O
erythroblastocytopenia. B
These O
responded O
to O
systemic O
steroids O
and O
immunoglobulins. O
Despite O
the O
widespread O
use O
of O
these O
agents O
this O
triad O
of O
side O
effects O
has O
not O
previously O
been O
reported O
in O
connection O
with O
beta O
lactam O
antibiotics. O

Attenuation O
of O
methamphetamine-induced O
nigrostriatal O
dopaminergic O
neurotoxicity B
in O
mice O
by O
lipopolysaccharide O
pretreatment. O

Severe O
cardiovascular B
complications I
occurred O
in O
eight O
of O
160 O
patients O
treated O
with O
terbutaline O
for O
preterm B
labor. I
Associated O
corticosteroid O
therapy O
and O
twin O
gestations O
appear O
to O
be O
predisposing O
factors. O
Potential O
mechanisms O
of O
the O
pathophysiology O
are O
briefly O
discussed. O

Hepatocyte O
tight O
junctions O
(TJs), O
the O
only O
intercellular O
barrier O
between O
the O
sinusoidal O
and O
the O
canalicular O
spaces, O
play O
a O
key O
role O
in O
bile O
formation. O
Although O
hepatocyte O
TJs O
are O
impaired O
in O
cholestasis, B
attempts O
to O
localize O
the O
precise O
site O
of O
hepatocyte O
TJ O
damage O
by O
freeze-fracture O
electron O
microscopy O
have O
produced O
limited O
information. O
Recently, O
several O
TJ-associated O
proteins O
like O
ZO-1 O
and O
7H6 O
have O
been O
identified O
and O
characterized. O
Immunolocalization O
of O
7H6 O
appears O
to O
closely O
correlate O
with O
paracellular O
permeability. O
We O
used O
rat O
models O
of O
intrahepatic B
cholestasis I
by O
ethinyl O
estradiol O
(EE) O
treatment O
and O
extrahepatic B
cholestasis I
by O
bile O
duct O
ligation O
(BDL) O
to O
precisely O
determine O
the O
site O
of O
TJ O
damage. O
Alterations O
in O
hepatocyte O
TJs O
were O
assessed O
by O
double-immunolabeling O
for O
7H6 O
and O
ZO-1 O
using O
a O
confocal O
laser O
scanning O
microscope. O
In O
control O
rats, O
immunostaining O
for O
7H6 O
and O
ZO-1 O
colocalized O
to O
outline O
bile O
canaliculi O
in O
a O
continuous O
fashion. O
In O
contrast, O
7H6 O
and O
ZO-1 O
immunostaining O
was O
more O
discontinuous, O
outlining O
the O
bile O
canaliculi O
after O
BDL. O
Immunostaining O
for O
7H6, O
not O
ZO-1, O
decreased O
and O
predominantly O
appeared O
as O
discrete O
signals O
in O
the O
submembranous O
cytoplasm O
of O
periportal O
hepatocytes O
after O
BDL. O
After O
EE O
treatment, O
changes O
in O
immunostaining O
for O
7H6 O
and O
ZO-1 O
were O
similar O
to O
those O
seen O
in O
periportal O
hepatocytes O
after O
BDL, O
but O
distributed O
more O
diffusely O
throughout O
the O
lobule. O
This O
study O
is O
the O
first O
to O
demonstrate O
that O
impairment O
of O
hepatocyte O
TJs O
occurs O
heterogenously O
in O
the O
liver O
lobule O
after O
BDL O
and O
suggests O
that O
BDL O
and O
EE O
treatments O
produce O
different O
lobular O
distributions O
of O
increased O
paracellular O
permeability. O

BACKGROUND: O
Markers O
of O
fibrinolysis, O
thrombin-activatable O
fibrinolysis O
inhibitor O
(TAFI), O
tissue-type O
plasminogen O
activator O
(tPA), O
and O
plasminogen O
activator O
inhibitor-1 O
(PAI-1) O
levels O
were O
studied O
for O
the O
evaluation O
of O
short-term O
effects O
of O
raloxifene O
administration O
in O
postmenopausal O
women. O
METHODS: O
Thirty-nine O
postmenopausal O
women O
with O
osteopenia B
or O
osteoporosis B
were O
included O
in O
this O
prospective, O
controlled O
clinical O
study. O
Twenty-five O
women O
were O
given O
raloxifene O
hydrochloride O
(60 O
mg/day) O
plus O
calcium O
(500 O
mg/day). O
Age-matched O
controls O
(n O
= O
14) O
were O
given O
only O
calcium. O
Plasma O
TAFI, O
tPA, O
and O
PAI-1 O
antigen O
levels O
were O
measured O
at O
baseline O
and O
after O
3 O
months O
of O
treatment O
by O
commercially O
available O
ELISA O
kits. O
Variations O
of O
individuals O
were O
assessed O
by O
Wilcoxon's O
test. O
Relationship O
between O
those O
markers O
and O
demographic O
characteristics O
were O
investigated. O
RESULTS: O
Three O
months O
of O
raloxifene O
treatment O
was O
associated O
with O
a O
significant O
decrease O
in O
the O
plasma O
TAFI O
antigen O
concentrations O
(16% O
change, O
P O
< O
0.01), O
and O
a O
significant O
increase O
in O
tPA O
antigen O
concentrations O
(25% O
change, O
P O
< O
0.05). O
A O
significant O
correlation O
was O
found O
between O
baseline O
TAFI O
antigen O
concentrations O
and O
the O
duration O
of O
amenorrhea B
(P O
< O
0.05; O
r O
= O
0.33). O
CONCLUSION: O
We O
suggest O
that O
the O
increased O
risk O
of O
venous B
thromboembolism I
due O
to O
raloxifene O
treatment O
may O
be O
related O
to O
increased O
tPA O
levels, O
but O
not O
TAFI O
levels. O

Diclofenac O
sodium O
(Voltarol, O
Geigy O
Pharmaceuticals) O
is O
a O
non-steroidal O
anti-inflammatory O
derivative O
of O
phenylacetic O
acid. O
Although O
generally O
well-tolerated, O
asymptomatic O
abnormalities B
of I
liver I
function I
have O
been O
recorded O
and, O
less O
commonly, O
severe O
hepatitis B
induced O
by O
diclofenac. O
The O
patient O
described O
developed O
chronic B
active I
hepatitis I
after O
six O
months O
therapy O
with O
diclofenac O
sodium O
which O
progressed O
despite O
the O
withdrawal O
of O
the O
drug, O
a O
finding O
not O
previously O
reported. O

INTRODUCTION: O
Antibiotic-associated O
hepatotoxicity B
is O
rare. O
With O
widespread O
use O
of O
antimicrobial O
agents, O
however, O
hepatic B
injury I
occurs O
frequently, O
and O
among O
adverse B
drug I
reactions, I
idiosyncratic O
reactions O
are O
the O
most O
serious. O
CASE O
SUMMARY: O
A O
25-year-old O
male O
patient, O
with O
a O
height O
of O
175 O
cm O
and O
weight O
of O
72 O
kg O
presented O
to O
Marmara O
University O
Hospital O
Emergency O
Department, O
Istanbul, O
Turkey, O
with O
5 O
days' O
history O
of O
jaundice, B
malaise, O
nausea, B
and O
vomiting. B
He O
had O
been O
prescribed O
telithromycin O
400 O
mg/d O
PO O
to O
treat O
an O
upper B
respiratory I
tract I
infection I
7 O
days O
prior. O
Admission O
laboratory O
tests O
were O
as O
follows: O
alanine O
aminotransferase, O
67 O
U/L O
(reference O
range, O
10-37 O
U/L); O
aspartate O
aminotransferase, O
98 O
U/L O
(10-40 O
U/L); O
alkaline O
phosphatase, O
513 O
U/L O
(0-270 O
U/L); O
gamma-glutamyltransferase, O
32 O
U/L O
(7-49 O
U/L); O
amylase, O
46 O
U/L O
(0-220 O
U/L); O
total O
bilirubin, O
20.1 O
mg/dL O
(0.2-1.0 O
mg/dL); O
direct O
bilirubin, O
14.8 O
mg/dL O
(0-0.3 O
mg/dL); O
and O
albumin, O
4.7 O
mg/dL O
(3.5-5.4 O
mg/dL). O
No O
toxin, O
alcohol, O
or O
other O
drugs O
were O
reported. O
The O
patient O
had O
suffered O
a O
previous O
episode O
of O
"acute O
hepatitis B
of O
unknown O
origin," O
that O
occurred O
after O
telithromycin O
usage. O
Both O
incidents O
occurred O
within O
a O
year. O
DISCUSSION: O
Telithromycin O
is O
the O
first O
of O
the O
ketolide O
antibacterials O
to O
receive O
US O
Food O
and O
Drug O
Administration O
approval O
for O
clinical O
use. O
It O
has O
been O
associated O
with O
infrequent O
and O
usually O
reversible O
severe O
hepatic B
dysfunction. I
Based O
on O
a O
score O
of O
8 O
on O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale, O
telithromycin O
was O
the O
probable O
cause O
of O
acute O
hepatitis O
in O
this O
patient, O
and O
pathological O
findings O
suggested O
drug-induced O
toxic B
hepatitis. I
Recurrence O
of O
hepatitis O
attack O
might O
have O
been O
avoided O
if O
the O
initial O
incident O
had O
been O
communicated O
to O
the O
attending O
physician O
who O
prescribed O
telithromycin O
the O
second O
time. O
CONCLUSION: O
Here O
we O
report O
a O
case O
of O
acute O
hepatitis O
probably O
associated O
with O
the O
administration O
of O
telithromycin. O

The O
aggravated O
risk O
on O
intracerebral B
hemorrhage I
(ICH) O
with B
drugs O
used O
for O
stroke B
patients O
should O
be O
estimated O
carefully. O
We O
therefore O
established O
sensitive O
quantification O
methods O
and O
provided O
a O
rat O
ICH O
model O
for O
detection O
of O
ICH O
deterioration. O
In O
ICH O
intrastriatally O
induced O
by O
0.014-unit, O
0.070-unit, O
and O
0.350-unit O
collagenase, O
the O
amount O
of O
bleeding B
was O
measured O
using O
a O
hemoglobin O
assay O
developed O
in O
the O
present O
study O
and O
was O
compared O
with O
the O
morphologically O
determined O
hematoma B
volume. O
The O
blood O
amounts O
and O
hematoma O
volumes O
were O
significantly O
correlated, O
and O
the O
hematoma O
induced O
by O
0.014-unit O
collagenase O
was O
adequate O
to O
detect O
ICH O
deterioration. O
In O
ICH O
induction O
using O
0.014-unit O
collagenase, O
heparin O
enhanced O
the O
hematoma O
volume O
3.4-fold O
over O
that O
seen O
in O
control O
ICH O
animals O
and O
the O
bleeding O
7.6-fold. O
Data O
suggest O
that O
this O
sensitive O
hemoglobin O
assay O
is O
useful O
for O
ICH O
detection, O
and O
that O
a O
model O
with O
a O
small O
ICH O
induced O
with O
a O
low-dose O
collagenase O
should O
be O
used O
for O
evaluation O
of O
drugs O
that O
may O
affect O
ICH. O

Abstract O
Serum O
aminotransferase O
elevations O
are O
a O
commonly O
known O
adverse O
effect O
of O
3-hydroxy-3-methylglutaryl O
coenzyme O
A O
reductase O
inhibitor O
(statin) O
therapy. O
However, O
hepatotoxic B
events O
have O
not O
been O
widely O
published O
with O
ezetimibe O
or O
the O
combination O
agent O
simvastatin-ezetimibe. O
We O
describe O
a O
70-year-old O
Hispanic O
woman O
who O
developed O
fulminant B
hepatic I
failure I
necessitating O
liver O
transplantation O
10 O
weeks O
after O
conversion O
from O
simvastatin O
40 O
mg/day O
to O
simvastatin O
10 O
mg-ezetimibe O
40 O
mg/day. O
The O
patient's O
lipid O
panel O
had O
been O
maintained O
with O
simvastatin O
for O
18 O
months O
before O
the O
conversion O
without O
evidence O
of O
hepatotoxicity. B
A O
routine O
laboratory O
work-up O
10 O
weeks O
after O
conversion O
revealed O
elevated O
serum O
aminotransferase O
levels. O
Simvastatinezetimibe O
and O
escitalopram O
(which O
she O
was O
taking O
for O
depression) B
were O
discontinued, O
and O
other O
potential O
causes O
of O
hepatotoxicity O
were O
excluded. O
A O
repeat O
work-up O
revealed O
further O
elevations O
in O
aminotransferase O
levels, O
and O
liver O
biopsy O
revealed O
evidence O
of O
moderate-to-severe O
drug B
toxicity. I
She O
underwent O
liver O
transplantation O
with O
an O
uneventful O
postoperative O
course. O
Her O
aminotransferase O
levels O
returned O
to O
normal O
by O
postoperative O
day O
23, O
and O
her O
2-year O
follow-up O
showed O
no O
adverse O
events. O
Ezetimibe O
undergoes O
extensive O
glucuronidation O
by O
uridine O
diphosphate O
glucoronosyltransferases O
(UGT) O
in O
the O
intestine O
and O
liver O
and O
may O
have O
inhibited O
the O
glucuronidation O
of O
simvastatin O
hydroxy O
acid, O
resulting O
in O
increased O
simvastatin O
exposure O
and O
subsequent O
hepatotoxicity. O
To O
our O
knowledge, O
this O
is O
the O
first O
case O
report O
of O
simvastatin-ezetimibe-induced O
liver B
failure I
that O
resulted O
in O
liver O
transplantation. O
We O
postulate O
that O
the O
mechanism O
of O
the O
simvastatinezetimibe-induced O
hepatotoxicity O
is O
the O
increased O
simvastatin O
exposure O
by O
ezetimibe O
inhibition O
of O
UGT O
enzymes. O
Clinicians O
should O
be O
aware O
of O
potential O
hepatotoxicity O
with O
simvastatin-ezetimibe O
especially O
in O
elderly O
patients O
and O
should O
carefully O
monitor O
serum O
aminotransferase O
levels O
when O
starting O
therapy O
and O
titrating O
the O
dosage. O

Antituberculosis O
therapy-induced O
acute B
liver I
failure: I
magnitude, O
profile, O
prognosis, O
and O
predictors O
of O
outcome. O

Crescentic O
fibrillary O
glomerulonephritis B
associated O
with O
intermittent O
rifampin O
therapy O
for O
pulmonary B
tuberculosis. I

Valproate-induced O
encephalopathy B
is O
a O
rare O
syndrome O
that O
may O
manifest O
in O
otherwise O
normal O
epileptic B
individuals. O
It O
may O
even O
present O
in O
patients O
who O
have O
tolerated O
this O
medicine O
well O
in O
the O
past. O
It O
is O
usually O
but O
not O
necessarily O
associated O
with O
hyperammonemia. B
The O
EEG O
shows O
characteristic O
triphasic O
waves O
in O
most O
patients O
with O
this O
complication. O
A O
case O
of O
valproate-induced O
encephalopathy O
is O
presented. O
The O
problems O
in O
diagnosing O
this O
condition O
are O
subsequently O
discussed. O

Severe O
ocular B
and I
orbital B
toxicity I
after O
intracarotid O
injection O
of O
carboplatin O
for O
recurrent O
glioblastomas. B

OBJECTIVE: O
To O
report O
a O
case O
of O
a O
severe O
interaction O
between O
simvastatin, O
amiodarone, O
and O
atazanavir O
resulting O
in O
rhabdomyolysis B
and O
acute B
renal I
failure. I
BACKGROUND: O
A O
72-year-old O
white O
man O
with O
underlying O
human B
immunodeficiency I
virus, I
atrial B
fibrillation, I
coronary B
artery I
disease, I
and O
hyperlipidemia B
presented O
with O
generalized O
pain, B
fatigue, B
and O
dark O
orange O
urine O
for O
3 O
days. O
The O
patient O
was O
taking O
80 O
mg O
simvastatin O
at O
bedtime O
(initiated O
27 O
days O
earlier); O
amiodarone O
at O
a O
dose O
of O
400 O
mg O
daily O
for O
7 O
days, O
then O
200 O
mg O
daily O
(initiated O
19 O
days O
earlier); O
and O
400 O
mg O
atazanavir O
daily O
(initiated O
at O
least O
2 O
years O
previously). O
Laboratory O
evaluation O
revealed O
66,680 O
U/L O
creatine O
kinase, O
93 O
mg/dL O
blood O
urea O
nitrogen, O
4.6 O
mg/dL O
creatinine, O
1579 O
U/L O
aspartate O
aminotransferase, O
and O
738 O
U/L O
alanine O
aminotransferase. O
Simvastatin, O
amiodarone, O
and O
the O
patient's O
human O
immunodeficiency O
virus O
medications O
were O
all O
temporarily O
discontinued O
and O
the O
patient O
was O
given O
forced O
alkaline O
diuresis O
and O
started O
on O
dialysis. O
Nine O
days O
later O
the O
patient's O
creatine O
kinase O
had O
dropped O
to O
1695 O
U/L O
and O
creatinine O
was O
3.3 O
mg/dL. O
The O
patient O
was O
discharged O
and O
continued O
outpatient O
dialysis O
for O
1 O
month O
until O
his O
renal O
function O
recovered. O
DISCUSSION: O
The O
risk O
of O
rhabdomyolysis O
is O
increased O
in O
the O
presence O
of O
concomitant O
drugs O
that O
inhibit O
simvastatin O
metabolism. O
Simvastatin O
is O
metabolized O
by O
CYP3A4. O
Amiodarone O
and O
atazanavir O
are O
recognized O
CYP3A4 O
inhibitors. O
CONCLUSIONS: O
Pharmacokinetic O
differences O
in O
statins O
are O
an O
important O
consideration O
for O
assessing O
the O
risk O
of O
potential O
drug O
interactions. O
In O
patients O
requiring O
the O
concurrent O
use O
of O
statins O
and O
CYP3A4 O
inhibitors, O
pravastatin, O
fluvastatin, O
and O
rosuvastatin O
carry O
the O
lowest O
risk O
of O
drug O
interactions; O
atorvastatin O
carries O
moderate O
risk, O
whereas O
simvastatin O
and O
lovastatin O
have O
the O
highest O
risk O
and O
should O
be O
avoided O
in O
patients O
taking O
concomitant O
CYP3A4 O
inhibitors. O

Cardioprotective O
effect O
of O
tincture O
of O
Crataegus O
on O
isoproterenol-induced O
myocardial B
infarction I
in O
rats. O

Pituitary B
tumors B
were O
induced O
in O
F344 O
female O
rats O
by O
chronic O
treatment O
with O
diethylstilbestrol O
(DES, O
8-10 O
mg) O
implanted O
subcutaneously O
in O
silastic O
capsules. O
Over O
a O
range O
of O
1-150 O
days O
of O
DES O
treatment, O
pairs O
of O
control O
and O
DES-treated O
rats O
were O
sacrificed, O
and O
their O
pituitaries O
dissociated O
enzymatically O
into O
single-cell O
preparations. O
The O
cell O
populations O
were O
examined O
regarding O
total O
cell O
recovery O
correlated O
with O
gland O
weight, O
intracellular O
prolactin O
(PRL) O
content O
and O
subsequent O
release O
in O
primary O
culture, O
immunocytochemical O
PRL O
staining, O
density O
and/or O
size O
alterations O
via O
separation O
on O
Ficoll-Hypaque O
and O
by O
unit O
gravity O
sedimentation, O
and O
cell O
cycle O
analysis, O
after O
acriflavine O
DNA O
staining, O
by O
laser O
flow O
cytometry. O
Total O
cell O
yields O
from O
DES-treated O
pituitaries O
increased O
from O
1.3 O
times O
control O
yields O
at O
8 O
days O
of O
treatment O
to O
58.9 O
times O
control O
values O
by O
day O
150. O
Intracellular O
PRL O
content O
ranged O
from O
1.9 O
to O
9.4 O
times O
control O
levels, O
and O
PRL O
release O
in O
vitro O
was O
significantly O
and O
consistently O
higher O
than O
controls, O
after O
at O
least O
8 O
days O
of O
DES O
exposure. O
Beyond O
8 O
days O
of O
DES O
exposure, O
the O
immunochemically O
PRL-positive O
proportion O
of O
cells O
increased O
to O
over O
50% O
of O
the O
total O
population. O
Increased O
density O
and/or O
size O
and O
PRL O
content O
were O
indicated O
for O
the O
majority O
of O
the O
PRL O
cell O
population O
in O
both O
types O
of O
separation O
protocols. O
All O
these O
effects O
of O
DES O
were O
more O
pronounced O
among O
previously O
ovariectomized O
animals. O
The O
data O
extend O
the O
findings O
of O
other O
investigators, O
further O
establishing O
the O
DES-induced O
tumor O
as O
a O
model O
for O
study O
of O
PRL O
cellular O
control O
mechanisms. O

Binding O
of O
nicotine O
to O
nicotinic O
acetylcholine O
receptors O
(nAChRs) O
elicits O
a O
series O
of O
dose-dependent O
behaviors O
that O
go O
from O
altered O
exploration, O
sedation, O
and O
tremors, B
to O
seizures B
and O
death. B
nAChRs O
are O
pentameric O
ion O
channels O
usually O
composed O
of O
alpha O
and O
beta O
subunits. O
A O
gene O
cluster O
comprises O
the O
alpha3, O
alpha5 O
and O
beta4 O
subunits, O
which O
coassemble O
to O
form O
functional O
receptors. O
We O
examined O
the O
role O
of O
the O
beta4 O
subunits O
in O
nicotine-induced O
seizures O
and O
hypolocomotion B
in O
beta4 O
homozygous O
null O
(beta4 O
-/-) O
and O
alpha3 O
heterozygous O
(+/-) O
mice. O
beta4 O
-/- O
mice O
were O
less O
sensitive O
to O
the O
effects O
of O
nicotine O
both O
at O
low O
doses, O
measured O
as O
decreased O
exploration O
in O
an O
open O
field, O
and O
at O
high O
doses, O
measured O
as O
sensitivity O
to O
nicotine-induced O
seizures. O
Using O
in O
situ O
hybridization O
probes O
for O
the O
alpha3 O
and O
alpha5 O
subunits, O
we O
showed O
that O
alpha5 O
mRNA O
levels O
are O
unchanged, O
whereas O
alpha3 O
mRNA O
levels O
are O
selectively O
decreased O
in O
the O
mitral O
cell O
layer O
of O
the O
olfactory O
bulb, O
and O
the O
inferior O
and O
the O
superior O
colliculus O
of O
beta4 O
-/- O
brains. O
alpha3 O
+/- O
mice O
were O
partially O
resistant O
to O
nicotine-induced O
seizures O
when O
compared O
to O
wild-type O
littermates. O
mRNA O
levels O
for O
the O
alpha5 O
and O
the O
beta4 O
subunits O
were O
unchanged O
in O
alpha3 O
+/- O
brains. O
Together, O
these O
results O
suggest O
that O
the O
beta4 O
and O
the O
alpha3 O
subunits O
are O
mediators O
of O
nicotine-induced O
seizures O
and O
hypolocomotion. O

Twenty O
children O
with O
acute B
lymphoblastic I
leukemia I
who O
developed O
meningeal B
disease I
were O
treated O
with O
a O
high-dose O
intravenous O
methotrexate O
regimen O
that O
was O
designed O
to O
achieve O
and O
maintain O
CSF O
methotrexate O
concentrations O
of O
10(-5) O
mol/L O
without O
the O
need O
for O
concomitant O
intrathecal O
dosing. O
The O
methotrexate O
was O
administered O
as O
a O
loading O
dose O
of O
6,000 O
mg/m2 O
for O
a O
period O
of O
one O
hour O
followed O
by O
an O
infusion O
of O
1,200 O
mg/m2/h O
for O
23 O
hours. O
Leucovorin O
rescue O
was O
initiated O
12 O
hours O
after O
the O
end O
of O
the O
infusion O
with O
a O
loading O
dose O
of O
200 O
mg/m2 O
followed O
by O
12 O
mg/m2 O
every O
three O
hours O
for O
six O
doses O
and O
then O
every O
six O
hours O
until O
the O
plasma O
methotrexate O
level O
decreased O
to O
less O
than O
1 O
X O
10(-7) O
mol/L. O
The O
mean O
steady-state O
plasma O
and O
CSF O
methotrexate O
concentrations O
achieved O
were O
1.1 O
X O
10(-3) O
mol/L O
and O
3.6 O
X O
10(-5) O
mol/L, O
respectively. O
All O
20 O
patients O
responded O
to O
this O
regimen, O
16/20 O
(80%) O
achieved O
a O
complete O
remission, O
and O
20% O
obtained O
a O
partial O
remission. O
The O
most O
common O
toxicities B
encountered O
were O
transient O
serum O
transaminase O
and O
bilirubin O
elevations, O
neutropenia, B
and O
mucositis. B
One O
patient O
had O
focal O
seizures B
and O
transient B
hemiparesis I
but O
recovered O
completely. O
High-dose O
intravenous O
methotrexate O
is O
an O
effective O
treatment O
for O
the O
induction O
of O
remission O
after O
meningeal O
relapse O
in O
acute O
lymphoblastic O
leukemia. O

Drug-induced O
hepatotoxicity, B
although O
common, O
has O
been O
reported O
only O
infrequently O
with O
sulfonylureas. O
For O
glyburide, O
a O
second-generation O
sulfonylurea, O
only O
two O
brief O
reports O
of O
hepatotoxicity O
exist. O
Two O
patients O
with O
type B
II I
diabetes I
mellitus I
developed O
an O
acute B
hepatitis-like I
syndrome I
soon O
after O
initiation O
of O
glyburide O
therapy. O
There O
was O
no O
serologic O
evidence O
of O
viral B
infection, I
and O
a O
liver O
biopsy O
sample O
showed O
a O
histologic O
pattern O
consistent O
with O
drug-induced B
hepatitis. I
Both O
patients O
recovered O
quickly O
after O
stopping O
glyburide O
therapy O
and O
have O
remained O
well O
for O
a O
follow-up O
period O
of O
1 O
year. O
Glyburide O
can O
produce O
an O
acute B
hepatitis-like I
illness I
in O
some O
persons. O

We O
describe O
a O
patient O
who O
developed O
dilated B
cardiomyopathy I
and O
clinical O
congestive O
heart B
failure I
after O
2 O
months O
of O
therapy O
with O
amphotericin O
B O
(AmB) O
for O
disseminated O
coccidioidomycosis. B
His O
echocardiographic O
abnormalities O
and O
heart O
failure O
resolved O
after O
posaconazole O
was O
substituted O
for O
AmB. O
It O
is O
important O
to O
recognize O
the O
rare O
and O
potentially O
reversible O
toxicity B
of O
AmB. O

The O
study O
investigates O
if O
alpha-lipoic O
acid O
is O
neuroprotective O
against O
chemotherapy O
induced O
neurotoxicity, B
if O
mitochondrial B
damage I
plays O
a O
critical O
role O
in O
toxic B
neurodegenerative I
cascade, I
and O
if O
neuroprotective O
effects O
of O
alpha-lipoic O
acid O
depend O
on O
mitochondria O
protection. O
We O
used O
an O
in O
vitro O
model O
of O
chemotherapy O
induced O
peripheral B
neuropathy I
that O
closely O
mimic O
the O
in O
vivo O
condition O
by O
exposing O
primary O
cultures O
of O
dorsal O
root O
ganglion O
(DRG) O
sensory O
neurons O
to O
paclitaxel O
and O
cisplatin, O
two O
widely O
used O
and O
highly O
effective O
chemotherapeutic O
drugs. O
This O
approach O
allowed O
investigating O
the O
efficacy O
of O
alpha-lipoic O
acid O
in O
preventing O
axonal B
damage I
and O
apoptosis O
and O
the O
function O
and O
ultrastructural O
morphology O
of O
mitochondria O
after O
exposure O
to O
toxic O
agents O
and O
alpha-lipoic O
acid. O
Our O
results O
demonstrate O
that O
both O
cisplatin O
and O
paclitaxel O
cause O
early O
mitochondrial B
impairment I
with O
loss O
of O
membrane O
potential O
and O
induction O
of O
autophagic O
vacuoles O
in O
neurons. O
Alpha-lipoic O
acid O
exerts O
neuroprotective O
effects O
against O
chemotherapy O
induced O
neurotoxicity O
in O
sensory O
neurons: O
it O
rescues O
the O
mitochondrial B
toxicity I
and O
induces O
the O
expression O
of O
frataxin, O
an O
essential O
mitochondrial O
protein O
with O
anti-oxidant O
and O
chaperone O
properties. O
In O
conclusion O
mitochondrial O
toxicity O
is O
an O
early O
common O
event O
both O
in O
paclitaxel O
and O
cisplatin O
induced O
neurotoxicity. O
Alpha-lipoic O
acid O
protects O
sensory O
neurons O
through O
its O
anti-oxidant O
and O
mitochondrial O
regulatory O
functions, O
possibly O
inducing O
the O
expression O
of O
frataxin. O
These O
findings O
suggest O
that O
alpha-lipoic O
acid O
might O
reduce O
the O
risk O
of O
developing O
peripheral B
nerve I
toxicity I
in O
patients O
undergoing O
chemotherapy O
and O
encourage O
further O
confirmatory O
clinical O
trials. O

Role O
of O
activation O
of O
bradykinin O
B2 O
receptors O
in O
disruption O
of O
the O
blood-brain O
barrier O
during O
acute O
hypertension. B

An O
increase B
in I
blood I
pressure, I
accompanied O
by O
atrial B
fibrillation, I
agitation, B
incomprehensible B
shouts I
and O
loss B
of I
consciousness, I
was O
observed O
in O
an O
elderly, O
ASA O
classification O
group O
II, O
cardiovascularly O
medicated O
male, O
12 O
min O
after O
performance O
of O
axillary O
block O
with O
mepivacaine O
850 O
mg O
containing O
adrenaline O
0.225 O
mg, O
for O
correction O
of O
Dupuytren's B
contracture. I
After O
intravenous O
administration O
of O
labetalol, O
metoprolol O
and O
midazolam O
the O
patient's O
condition O
improved, O
and O
15 O
min O
later O
he O
woke O
up. O
The O
block O
was O
successful O
and O
surgery O
was O
conducted O
as O
scheduled O
despite O
persisting O
atrial O
fibrillation. O
Postoperatively, O
the O
patient O
refused O
DC O
cardioversion O
and O
was O
treated O
medically. O
Both O
the O
temporal O
relationship O
of O
events O
and O
the O
response O
to O
treatment O
suggest O
that O
a O
rapid O
systemic O
absorption O
of O
mepivacaine O
with O
adrenaline O
and/or O
interaction O
of O
these O
drugs O
with O
the O
patient's O
cardiovascular O
medications O
were O
responsible O
for O
the O
perioperative O
complications. O

Increase O
of O
Parkinson B
disability I
after O
fluoxetine O
medication. O

Neonatal O
pyridoxine O
responsive O
convulsions B
due O
to O
isoniazid O
therapy. O

NO-induced O
migraine B
attack: O
strong O
increase O
in O
plasma O
calcitonin O
gene-related O
peptide O
(CGRP) O
concentration O
and O
negative O
correlation O
with O
platelet O
serotonin O
release. O

Abnormal O
processing O
of O
somatosensory O
inputs O
in O
the O
central O
nervous O
system O
(central O
sensitization) O
is O
the O
mechanism O
accounting O
for O
the O
enhanced O
pain B
sensitivity O
in O
the O
skin O
surrounding O
tissue B
injury I
(secondary O
hyperalgesia). B
Secondary I
hyperalgesia I
shares O
clinical O
characteristics O
with O
neurogenic B
hyperalgesia I
in O
patients O
with O
neuropathic B
pain. I
Abnormal O
brain O
responses O
to O
somatosensory O
stimuli O
have O
been O
found O
in O
patients O
with O
hyperalgesia O
as O
well O
as O
in O
normal O
subjects O
during O
experimental O
central O
sensitization. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
gabapentin, O
a O
drug O
effective O
in O
neuropathic O
pain O
patients, O
on O
brain O
processing O
of O
nociceptive O
information O
in O
normal O
and O
central O
sensitization O
states. O
Using O
functional O
magnetic O
resonance O
imaging O
(fMRI) O
in O
normal O
volunteers, O
we O
studied O
the O
gabapentin-induced O
modulation O
of O
brain O
activity O
in O
response O
to O
nociceptive O
mechanical O
stimulation O
of O
normal O
skin O
and O
capsaicin-induced O
secondary O
hyperalgesia. O
The O
dose O
of O
gabapentin O
was O
1,800 O
mg O
per O
os, O
in O
a O
single O
administration. O
We O
found O
that O
(i) O
gabapentin O
reduced O
the O
activations O
in O
the O
bilateral O
operculoinsular O
cortex, O
independently O
of O
the O
presence O
of O
central O
sensitization; O
(ii) O
gabapentin O
reduced O
the O
activation O
in O
the O
brainstem, O
only O
during O
central O
sensitization; O
(iii) O
gabapentin O
suppressed O
stimulus-induced O
deactivations, O
only O
during O
central O
sensitization; O
this O
effect O
was O
more O
robust O
than O
the O
effect O
on O
brain O
activation. O
The O
observed O
drug-induced O
effects O
were O
not O
due O
to O
changes O
in O
the O
baseline O
fMRI O
signal. O
These O
findings O
indicate O
that O
gabapentin O
has O
a O
measurable O
antinociceptive O
effect O
and O
a O
stronger O
antihyperalgesic O
effect O
most O
evident O
in O
the O
brain O
areas O
undergoing O
deactivation, O
thus O
supporting O
the O
concept O
that O
gabapentin O
is O
more O
effective O
in O
modulating O
nociceptive O
transmission O
when O
central O
sensitization O
is O
present. O

The O
effect O
of O
nifedipine O
on O
renal O
function O
in O
liver O
transplant O
recipients O
who O
were O
receiving O
tacrolimus O
was O
evaluated O
between O
January O
1992 O
and O
January O
1996. O
Two O
groups O
of O
patients O
receiving O
tacrolimus O
were O
compared O
over O
a O
period O
of O
1 O
year, O
one O
group O
comprising O
hypertensive B
patients O
who O
were O
receiving O
nifedipine, O
and O
the O
other O
comprising O
nonhypertensive O
patients O
not O
receiving O
nifedipine. O
The O
time O
from O
transplant O
to O
baseline O
was O
similar O
in O
all O
patients. O
Nifedipine O
significantly O
improved O
kidney O
function O
as O
indicated O
by O
a O
significant O
lowering O
of O
serum O
creatinine O
levels O
at O
6 O
and O
12 O
months. O
The O
observed O
positive O
impact O
of O
nifedipine O
on O
reducing O
the O
nephrotoxicity B
associated O
with O
tacrolimus O
in O
liver O
transplant O
recipients O
should O
be O
an O
important O
factor O
in O
selecting O
an O
agent O
to O
treat O
hypertension B
in O
this O
population. O

Cauda B
equina I
syndrome I
after O
epidural O
steroid O
injection: O
a O
case O
report. O

The O
effects O
of O
PG-9 O
(3alpha-tropyl O
2-(p-bromophenyl)propionate), O
the O
acetylcholine O
releaser, O
on O
memory O
processes O
and O
nerve O
growth O
factor O
(NGF) O
synthesis O
were O
evaluated. O
In O
the O
mouse O
passive-avoidance O
test, O
PG-9 O
(10-30 O
mg/kg, O
i.p.), O
administered O
20 O
min O
before O
the O
training O
session, O
prevented O
amnesia B
induced O
by O
both O
the O
non O
selective O
antimuscarinic O
drug O
scopolamine O
and O
the O
M1-selective O
antagonist O
S-(-)-ET-126. O
In O
the O
same O
experimental O
conditions, O
PG-9 O
(5-20 O
microg O
per O
mouse, O
i.c.v.) O
was O
also O
able O
to O
prevent O
antimuscarine-induced O
amnesia, O
demonstrating O
a O
central O
localization O
of O
the O
activity. O
At O
the O
highest O
effective O
doses, O
PG-9 O
did O
not O
produce O
any O
collateral O
symptoms O
as O
revealed O
by O
the O
Irwin O
test, O
and O
it O
did O
not O
modify O
spontaneous O
motility O
and O
inspection O
activity, O
as O
revealed O
by O
the O
hole-board O
test. O
PG-9 O
was O
also O
able O
to O
increase O
the O
amount O
of O
NGF O
secreted O
in O
vitro O
by O
astrocytes O
in O
a O
dose-dependent O
manner. O
The O
maximal O
NGF O
contents O
obtained O
by O
PG-9 O
were O
17.6-fold O
of O
the O
control O
value. O
During O
culture, O
no O
morphological O
changes O
were O
found O
at O
effective O
concentrations O
of O
PG-9. O
The O
current O
work O
indicates O
the O
ability O
of O
PG-9 O
to O
induce O
beneficial O
effects O
on O
cognitive O
processes O
and O
stimulate O
activity O
of O
NGF O
synthesis O
in O
astroglial O
cells. O
Therefore, O
PG-9 O
could O
represent O
a O
potential O
useful O
drug O
able O
to O
improve O
the O
function O
of O
impaired O
cognitive O
processes. O

In O
unanesthetized, O
spontaneously O
hypertensive B
rats O
the O
decrease O
in O
blood O
pressure O
and O
heart O
rate O
produced O
by O
intravenous O
clonidine, O
5 O
to O
20 O
micrograms/kg, O
was O
inhibited O
or O
reversed O
by O
nalozone, O
0.2 O
to O
2 O
mg/kg. O
The O
hypotensive B
effect O
of O
100 O
mg/kg O
alpha-methyldopa O
was O
also O
partially O
reversed O
by O
naloxone. O
Naloxone O
alone O
did O
not O
affect O
either O
blood O
pressure O
or O
heart O
rate. O
In O
brain O
membranes O
from O
spontaneously O
hypertensive O
rats O
clonidine, O
10(-8) O
to O
10(-5) O
M, O
did O
not O
influence O
stereoselective O
binding O
of O
[3H]-naloxone O
(8 O
nM), O
and O
naloxone, O
10(-8) O
to O
10(-4) O
M, O
did O
not O
influence O
clonidine-suppressible O
binding O
of O
[3H]-dihydroergocryptine O
(1 O
nM). O
These O
findings O
indicate O
that O
in O
spontaneously O
hypertensive O
rats O
the O
effects O
of O
central O
alpha-adrenoceptor O
stimulation O
involve O
activation O
of O
opiate O
receptors. O
As O
naloxone O
and O
clonidine O
do O
not O
appear O
to O
interact O
with O
the O
same O
receptor O
site, O
the O
observed O
functional O
antagonism O
suggests O
the O
release O
of O
an O
endogenous O
opiate O
by O
clonidine O
or O
alpha-methyldopa O
and O
the O
possible O
role O
of O
the O
opiate O
in O
the O
central O
control O
of O
sympathetic O
tone. O

The O
effect O
of O
treatment O
with O
gum O
Arabic O
on O
gentamicin O
nephrotoxicity B
in O
rats: O
a O
preliminary O
study. O

Acute O
hepatitis B
attack O
after O
exposure O
to O
telithromycin. O

Use O
of O
chromosome O
substitution O
strains O
to O
identify O
seizure B
susceptibility O
loci O
in O
mice. O

Epidemic O
of O
liver B
disease I
caused O
by O
hydrochlorofluorocarbons O
used O
as O
ozone-sparing O
substitutes O
of O
chlorofluorocarbons. O

Toxicity B
in O
rhesus O
monkeys O
following O
administration O
of O
the O
8-aminoquinoline O
8-[(4-amino-l-methylbutyl)amino]- O
5-(l-hexyloxy)-6-methoxy-4-methylquinoline O
(WR242511). O

MDMA O
polydrug O
users O
show O
process-specific O
central O
executive O
impairments O
coupled O
with O
impaired B
social I
and I
emotional I
judgement I
processes. I

Tincture O
of O
Crataegus O
(TCR), O
an O
alcoholic O
extract O
of O
the O
berries O
of O
hawthorn O
(Crataegus O
oxycantha), O
is O
used O
in O
herbal O
and O
homeopathic O
medicine. O
The O
present O
study O
was O
done O
to O
investigate O
the O
protective O
effect O
of O
TCR O
on O
experimentally O
induced O
myocardial B
infarction I
in O
rats. O
Pretreatment O
of O
TCR, O
at O
a O
dose O
of O
0.5 O
mL/100 O
g O
bodyweight O
per O
day, O
orally O
for O
30 O
days, O
prevented O
the O
increase O
in O
lipid O
peroxidation O
and O
activity O
of O
marker O
enzymes O
observed O
in O
isoproterenol-induced O
rats O
(85 O
mg O
kg(-1) O
s. O
c. O
for O
2 O
days O
at O
an O
interval O
of O
24 O
h). O
TCR O
prevented O
the O
isoproterenol-induced O
decrease O
in O
antioxidant O
enzymes O
in O
the O
heart O
and O
increased O
the O
rate O
of O
ADP-stimulated O
oxygen O
uptake O
and O
respiratory O
coupling O
ratio. O
TCR O
protected O
against O
pathological O
changes O
induced O
by O
isoproterenol O
in O
rat O
heart. O
The O
results O
show O
that O
pretreatment O
with O
TCR O
may O
be O
useful O
in O
preventing O
the O
damage O
induced O
by O
isoproterenol O
in O
rat O
heart. O

Nephrotoxicity B
of O
combined O
cephalothin-gentamicin O
regimen. O

In O
experimental O
nephrotic B
syndrome, I
urinary O
sodium O
excretion O
is O
decreased O
during O
the O
early O
phase O
of O
the O
disease. O
The O
molecular O
mechanism(s) O
leading O
to O
salt O
retention O
has O
not O
been O
completely O
elucidated. O
The O
rate-limiting O
constituent O
of O
collecting O
duct O
sodium O
transport O
is O
the O
epithelial O
sodium O
channel O
(ENaC). O
We O
examined O
the O
abundance O
of O
ENaC O
subunit O
mRNAs O
and O
proteins O
in O
puromycin O
aminonucleoside O
(PAN)-induced O
nephrotic O
syndrome. O
The O
time O
courses O
of O
urinary O
sodium O
excretion, O
plasma O
aldosterone O
concentration O
and O
proteinuria B
were O
studied O
in O
male O
Sprague-Dawley O
rats O
treated O
with O
a O
single O
dose O
of O
either O
PAN O
or O
vehicle. O
The O
relative O
amounts O
of O
alphaENaC, O
betaENaC O
and O
gammaENaC O
mRNAs O
were O
determined O
in O
kidneys O
from O
these O
rats O
by O
real-time O
quantitative O
TaqMan O
PCR, O
and O
the O
amounts O
of O
proteins O
by O
Western O
blot. O
The O
kinetics O
of O
urinary O
sodium O
excretion O
and O
the O
appearance O
of O
proteinuria O
were O
comparable O
with O
those O
reported O
previously. O
Sodium O
retention O
occurred O
on O
days O
2, O
3 O
and O
6 O
after O
PAN O
injection. O
A O
significant O
up-regulation O
of O
alphaENaC O
and O
betaENaC O
mRNA O
abundance O
on O
days O
1 O
and O
2 O
preceded O
sodium O
retention O
on O
days O
2 O
and O
3. O
Conversely, O
down-regulation O
of O
alphaENaC, O
betaENaC O
and O
gammaENaC O
mRNA O
expression O
on O
day O
3 O
occurred O
in O
the O
presence O
of O
high O
aldosterone O
concentrations, O
and O
was O
followed O
by O
a O
return O
of O
sodium O
excretion O
to O
control O
values. O
The O
amounts O
of O
alphaENaC, O
betaENaC O
and O
gammaENaC O
proteins O
were O
not O
increased O
during O
PAN-induced O
sodium O
retention. O
In O
conclusion, O
ENaC O
mRNA O
expression, O
especially O
alphaENaC, O
is O
increased O
in O
the O
very O
early O
phase O
of O
the O
experimental O
model O
of O
PAN-induced O
nephrotic O
syndrome O
in O
rats, O
but O
appears O
to O
escape O
from O
the O
regulation O
by O
aldosterone O
after O
day O
3. O

TAC O
has O
been O
shown O
to O
be O
a O
potent O
immunosuppressive O
agent O
for O
solid O
organ O
transplantation O
in O
pediatrics. O
Neurotoxicity B
is O
a O
potentially O
serious O
toxic O
effect. O
It O
is O
characterized O
by O
encephalopathy, B
headaches, B
seizures, B
or O
neurological B
deficits. I
Here, O
we O
describe O
an O
eight-and-a-half-yr-old O
male O
renal O
transplant O
recipient O
with O
right O
BN. O
MRI O
demonstrated O
hyperintense O
T2 O
signals O
in O
the O
cervical O
cord O
and O
right O
brachial O
plexus O
roots O
indicative O
of O
both O
myelitis B
and O
right O
brachial B
plexitis. I
Symptoms O
persisted O
for O
three O
months O
despite O
TAC O
dose O
reduction, O
administration O
of O
IVIG O
and O
four O
doses O
of O
methylprednisolone O
pulse O
therapy. O
Improvement O
and O
eventually O
full O
recovery O
only O
occurred O
after O
TAC O
was O
completely O
discontinued O
and O
successfully O
replaced O
by O
everolimus. O

Lithium-associated O
cognitive B
and I
functional I
deficits I
reduced O
by O
a O
switch O
to O
divalproex O
sodium: O
a O
case O
series. O

OBJECTIVE: O
The O
objective O
of O
this O
study O
was O
to O
identify O
the O
incidence O
and O
to O
monitor O
the O
progression O
of O
hearing B
loss I
in O
children O
and O
young O
adults O
with O
beta-thalassemia B
major. O
METHODS: O
One O
hundred O
and O
four O
(104) O
patients O
aged O
6-35 O
years O
(mean O
17,2 O
years) O
participated O
in O
the O
study. O
All O
patients O
were O
on O
a O
regular O
transfusion-chelation O
program O
maintaining O
a O
mean O
hemoglobin O
level O
of O
9.5 O
gr/dl. O
Subjects O
were O
receiving O
desferrioxamine O
(DFO) O
chelation O
treatment O
with O
a O
mean O
daily O
dose O
of O
50-60 O
mg/kg, O
5-6 O
days O
a O
week O
during O
the O
first O
six O
years O
of O
the O
study, O
which O
was O
then O
reduced O
to O
40-50 O
mg/kg O
for O
the O
following O
eight O
years. O
Patients O
were O
followed O
for O
8-14 O
years. O
RESULTS: O
Overall, O
21 O
out O
of O
104 O
patients O
(20.2%) O
presented O
with O
high O
frequency O
sensorineural B
hearing I
loss I
(SNHL), O
either B
unilateral O
or O
bilateral. O
No O
ototoxic B
factor, O
other O
than O
DFO, O
was O
present O
in O
any O
of O
the O
patients. O
Patients O
with O
SNHL O
presented O
with O
relatively O
lower O
serum O
ferritin O
levels O
than O
those O
with O
normal O
hearing, O
however, O
no O
statistically O
significant O
difference O
was O
observed. O
Subjects O
with O
SNHL O
were O
submitted O
to O
DFO O
reduction O
or O
temporary O
withdrawal. O
Following O
intervention, O
7 O
out O
of O
21 O
affected O
patients O
recovered, O
10 O
remained O
stable O
and O
4 O
demonstrated O
aggravation. O
CONCLUSION: O
The O
findings O
are O
indicative O
of O
DFO's O
contributing O
role O
in O
the O
development O
of O
hearing B
impairment. I
Regular O
audiologic O
evaluation O
is O
imperative O
in O
all O
thalassemic B
patients O
so O
that O
early O
changes O
may O
be O
recognized O
and O
treatment O
may O
be O
judiciously O
adjusted O
in O
order O
to O
prevent O
or O
reverse O
hearing O
impairment. O

A O
Phase O
I O
study O
of O
intravenous O
(IV) O
bolus O
4'-0-tetrahydropyranyladriamycin O
(Pirarubicin) O
was O
done O
in O
55 O
patients O
in O
good O
performance O
status O
with O
refractory O
tumors. B
Twenty-six O
had O
minimal O
prior O
therapy O
(good O
risk), O
23 O
had O
extensive O
prior O
therapy O
(poor O
risk), O
and O
six O
had O
renal B
and/or I
hepatic B
dysfunction. I
A O
total O
of O
167 O
courses O
at O
doses O
of O
15 O
to O
70 O
mg/m2 O
were O
evaluable. O
Maximum O
tolerated O
dose O
in O
good-risk O
patients O
was O
70 O
mg/m2, O
and O
in O
poor-risk O
patients, O
60 O
mg/m2. O
The O
dose-limiting O
toxic O
effect O
was O
transient O
noncumulative O
granulocytopenia. B
Granulocyte O
nadir O
was O
on O
day O
14 O
(range, O
4-22). O
Less O
frequent O
toxic O
effects O
included O
thrombocytopenia, B
anemia, B
nausea, B
mild O
alopecia, B
phlebitis, B
and O
mucositis. B
Myelosuppression B
was O
more O
in O
patients O
with O
hepatic O
dysfunction. O
Pharmacokinetic O
analyses O
in O
21 O
patients O
revealed O
Pirarubicin O
plasma O
T O
1/2 O
alpha O
(+/- O
SE) O
of O
2.5 O
+/- O
0.85 O
minutes, O
T O
beta O
1/2 O
of O
25.6 O
+/- O
6.5 O
minutes, O
and O
T O
1/2 O
gamma O
of O
23.6 O
+/- O
7.6 O
hours. O
The O
area O
under O
the O
curve O
was O
537 O
+/- O
149 O
ng/ml O
x O
hours, O
volume O
of O
distribution O
(Vd) O
3504 O
+/- O
644 O
l/m2, O
and O
total O
clearance O
(ClT) O
was O
204 O
+ O
39.3 O
l/hour/m2. O
Adriamycinol, O
doxorubicin, O
adriamycinone, O
and O
tetrahydropyranyladriamycinol O
were O
the O
metabolites O
detected O
in O
plasma O
and O
the O
amount O
of O
doxorubicin O
was O
less O
than O
or O
equal O
to O
10% O
of O
the O
total O
metabolites. O
Urinary O
excretion O
of O
Pirarubicin O
in O
the O
first O
24 O
hours O
was O
less O
than O
or O
equal O
to O
10%. O
Activity O
was O
noted O
in O
mesothelioma, B
leiomyosarcoma, B
and O
basal B
cell I
carcinoma. I
The O
recommended O
starting O
dose O
for O
Phase O
II O
trials O
is O
60 O
mg/m2 O
IV O
bolus O
every O
3 O
weeks. O

Large O
parenteral O
doses O
of O
vitamin O
D3 O
(15 O
to O
17.5 O
x O
10(6) O
IU O
vitamin O
D3) O
were O
associated O
with O
prolonged O
hypercalcemia, B
hyperphosphatemia, B
and O
large O
increases O
of O
vitamin O
D3 O
and O
its O
metabolites O
in O
the O
blood O
plasma O
of O
nonlactating O
nonpregnant O
and O
pregnant O
Jersey O
cows. O
Calcium O
concentrations O
1 O
day O
postpartum O
were O
higher O
in O
cows O
treated O
with O
vitamin O
D3 O
about O
32 O
days O
prepartum O
(8.8 O
mg/100 O
ml) O
than O
in O
control O
cows O
(5.5 O
mg/100 O
ml). O
None O
of O
the O
cows O
treated O
with O
vitamin O
D3 O
showed O
signs O
of O
milk B
fever I
during O
the O
peripartal O
period; O
however, O
22% O
of O
the O
control O
cows O
developed O
clinical O
signs O
of O
milk O
fever O
during O
this O
period. O
Signs O
of O
vitamin O
D3 O
toxicity B
were O
not O
observed O
in O
nonlactating O
nonpregnant O
cows; O
however, O
pregnant O
cows O
commonly O
developed O
severe O
signs O
of O
vitamin O
D3 O
toxicity O
and O
10 O
of O
17 O
cows O
died. O
There O
was O
widespread O
metastatic O
calcification O
in O
the O
cows O
that O
died. O
Because O
of O
the O
extreme O
toxicity O
of O
vitamin O
D3 O
in O
pregnant O
Jersey O
cows O
and O
the O
low O
margin O
of O
safety O
between O
doses O
of O
vitamin O
D3 O
that O
prevent O
milk O
fever O
and O
doses O
that O
induce O
milk O
fever, O
we O
concluded O
that O
vitamin O
D3 O
cannot O
be O
used O
practically O
to O
prevent O
milk O
fever O
when O
injected O
several O
weeks O
prepartum. O

Capsaicin-induced O
muscle B
pain I
alters O
the O
excitability O
of O
the O
human O
jaw-stretch O
reflex. O

Such O
organophosphorus O
(OP) O
compounds O
as O
diisopropylfluorophosphate O
(DFP), O
sarin O
and O
soman O
are O
potent O
inhibitors O
of O
acetylcholinesterases O
(AChEs) O
and O
butyrylcholinesterases O
(BChEs). O
The O
acute O
toxicity B
of O
OPs O
is O
the O
result O
of O
their O
irreversible O
binding O
with O
AChEs O
in O
the O
central O
nervous O
system O
(CNS), O
which O
elevates O
acetylcholine O
(ACh) O
levels. O
The O
protective O
action O
of O
subcutaneously O
(SC) O
administered O
antidotes O
or O
their O
combinations O
in O
DFP O
(2.0 O
mg/kg O
BW) O
intoxication O
was O
studied O
in O
9-10-weeks-old O
Han-Wistar O
male O
rats. O
The O
rats O
received O
AChE O
reactivator O
pralidoxime-2-chloride O
(2PAM) O
(30.0 O
mg/kg O
BW), O
anticonvulsant O
diazepam O
(2.0 O
mg/kg O
BW), O
A(1)-adenosine O
receptor O
agonist O
N(6)-cyclopentyl O
adenosine O
(CPA) O
(2.0 O
mg/kg O
BW), O
NMDA-receptor O
antagonist O
dizocilpine O
maleate O
(+-MK801 O
hydrogen O
maleate) O
(2.0 O
mg/kg O
BW) O
or O
their O
combinations O
with O
cholinolytic O
drug O
atropine O
sulfate O
(50.0 O
mg/kg O
BW) O
immediately O
or O
30 O
min O
after O
the O
single O
SC O
injection O
of O
DFP. O
The O
control O
rats O
received O
atropine O
sulfate, O
but O
also O
saline O
and O
olive O
oil O
instead O
of O
other O
antidotes O
and O
DFP, O
respectively. O
All O
rats O
were O
terminated O
either O
24 O
h O
or O
3 O
weeks O
after O
the O
DFP O
injection. O
The O
rats O
treated O
with O
DFP-atropine O
showed O
severe O
typical O
OP-induced O
toxicity O
signs. O
When O
CPA, O
diazepam O
or O
2PAM O
was O
given O
immediately O
after O
DFP-atropine, O
these O
treatments O
prevented, O
delayed O
or O
shortened O
the O
occurrence O
of O
serious O
signs O
of O
poisoning. B
Atropine-MK801 O
did O
not O
offer O
any O
additional O
protection O
against O
DFP O
toxicity. O
In O
conclusion, O
CPA, O
diazepam O
and O
2PAM O
in O
combination O
with O
atropine O
prevented O
the O
occurrence O
of O
serious O
signs O
of O
poisoning O
and O
thus O
reduced O
the O
toxicity O
of O
DFP O
in O
rat. O

Phenylephrine O
but O
not O
ephedrine O
reduces B
frontal I
lobe I
oxygenation I
following O
anesthesia-induced O
hypotension. B

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
role O
of O
metabotropic O
glutamate O
receptor O
5 O
(mGluR5) O
in O
the O
toxic O
action O
of O
methamphetamine O
on O
dopaminergic O
neurones O
in O
rats. O
Methamphetamine O
(10 O
mg/kg O
sc), O
administered O
five O
times, O
reduced O
the O
levels O
of O
dopamine O
and O
its O
metabolites O
in O
striatal O
tissue O
when O
measured O
72 O
h O
after O
the O
last O
injection. O
A O
selective O
antagonist O
of O
mGluR5, O
2-methyl-6-(phenylethynyl)pyridine O
(MPEP; O
5 O
mg/kg O
ip), O
when O
administered O
five O
times O
immediately O
before O
each O
methamphetamine O
injection O
reversed O
the O
above-mentioned O
methamphetamine O
effects. O
A O
single O
MPEP O
(5 O
mg/kg O
ip) O
injection O
reduced O
the O
basal O
extracellular O
dopamine O
level O
in O
the O
striatum, O
as O
well O
as O
dopamine O
release O
stimulated O
either O
by O
methamphetamine O
(10 O
mg/kg O
sc) O
or O
by O
intrastriatally O
administered O
veratridine O
(100 O
microM). O
Moreover, O
it O
transiently O
diminished O
the O
methamphetamine O
(10 O
mg/kg O
sc)-induced O
hyperthermia B
and O
reduced O
basal O
body O
temperature. O
MPEP O
administered O
into O
the O
striatum O
at O
high O
concentrations O
(500 O
microM) O
increased O
extracellular O
dopamine O
levels, O
while O
lower O
concentrations O
(50-100 O
microM) O
were O
devoid O
of O
any O
effect. O
The O
results O
of O
this O
study O
suggest O
that O
the O
blockade O
of O
mGluR5 O
by O
MPEP O
may O
protect O
dopaminergic O
neurones O
against O
methamphetamine-induced O
toxicity. B
Neuroprotection O
rendered O
by O
MPEP O
may O
be O
associated O
with O
the O
reduction O
of O
the O
methamphetamine-induced O
dopamine O
efflux O
in O
the O
striatum O
due O
to O
the O
blockade O
of O
extrastriatal O
mGluR5, O
and O
with O
a O
decrease O
in O
hyperthermia. O

Studies O
concerning O
with O
pathogenesis O
of O
gastric B
hemorrhage I
and O
mucosal O
ulceration B
produced O
in O
atherosclerotic B
rats O
are O
lacking. O
The O
aim O
of O
this O
study O
is O
to O
examine O
the O
role O
of O
gastric O
acid O
back-diffusion, O
mast O
cell O
histamine O
release, O
lipid O
peroxide O
(LPO) O
generation O
and O
mucosal O
microvascular O
permeability O
in O
modulating O
gastric O
hemorrhage O
and O
ulcer O
in O
rats O
with O
atherosclerosis B
induced O
by O
coadministration O
of O
vitamin O
D2 O
and O
cholesterol. O
Additionally, O
the O
protective O
effect O
of O
verapamil O
on O
this O
ulcer O
model O
was O
evaluated. O
Male O
Wistar O
rats O
were O
challenged O
intragastrically O
once O
daily O
for O
9 O
days O
with O
1.0 O
ml/kg O
of O
corn O
oil O
containing O
vitamin O
D2 O
and O
cholesterol O
to O
induce O
atherosclerosis. O
Control O
rats O
received O
corn O
oil O
only. O
After O
gastric O
surgery, O
rat O
stomachs O
were O
irrigated O
for O
3 O
h O
with O
either O
simulated O
gastric O
juice O
or O
normal O
saline. O
Gastric O
acid O
back-diffusion, O
mucosal O
LPO O
generation, O
histamine O
concentration, O
microvascular O
permeability, O
luminal O
hemoglobin O
content O
and O
ulcer O
areas O
were O
determined. O
Elevated O
atherosclerotic O
parameters, O
such O
as O
serum O
calcium, O
total O
cholesterol O
and O
low-density O
lipoprotein O
concentration O
were O
obtained O
in O
atherosclerotic O
rats. O
Severe O
gastric O
ulcers B
accompanied O
with O
increased O
ulcerogenic O
factors, O
including O
gastric O
acid O
back-diffusion, O
histamine O
release, O
LPO O
generation O
and O
luminal O
hemoglobin O
content O
were O
also O
observed O
in O
these O
rats. O
Moreover, O
a O
positive O
correlation O
of O
histamine O
to O
gastric O
hemorrhage O
and O
to O
ulcer O
was O
found O
in O
those O
atherosclerotic O
rats. O
This O
hemorrhagic B
ulcer O
and O
various O
ulcerogenic O
parameters O
were O
dose-dependently O
ameliorated O
by O
daily O
intragastric O
verapamil. O
Atherosclerosis B
could O
produce O
gastric B
hemorrhagic I
ulcer O
via O
aggravation O
of O
gastric O
acid O
back-diffusion, O
LPO O
generation, O
histamine O
release O
and O
microvascular O
permeability O
that O
could O
be O
ameliorated O
by O
verapamil O
in O
rats. O

BACKGROUND: O
Cardiac O
troponins O
I O
(cTnI) O
and O
T O
(cTnT) O
have O
been O
shown O
to O
be O
highly O
sensitive O
and O
specific O
markers O
of O
myocardial B
cell I
injury. I
We O
investigated O
the O
diagnostic O
value O
of O
cTnI O
and O
cTnT O
for O
the O
diagnosis O
of O
myocardial B
damage I
in O
a O
rat O
model O
of O
doxorubicin O
(DOX)-induced O
cardiomyopathy, B
and O
we O
examined O
the O
relationship O
between O
serial O
cTnI O
and O
cTnT O
with O
the O
development O
of O
cardiac B
disorders I
monitored O
by O
echocardiography O
and O
histological O
examinations O
in O
this O
model. O
METHODS: O
Thirty-five O
Wistar O
rats O
were O
given O
1.5 O
mg/kg O
DOX, O
i.v., O
weekly O
for O
up O
to O
8 O
weeks O
for O
a O
total O
cumulative O
dose O
of O
12 O
mg/kg O
BW. O
Ten O
rats O
received O
saline O
as O
a O
control O
group. O
cTnI O
was O
measured O
with O
Access(R) O
(ng/ml) O
and O
a O
research O
immunoassay O
(pg/ml), O
and O
compared O
with O
cTnT, O
CK-MB O
mass O
and O
CK. O
By O
using O
transthoracic O
echocardiography, O
anterior O
and O
posterior O
wall O
thickness, O
LV O
diameters O
and O
LV O
fractional O
shortening O
(FS) O
were O
measured O
in O
all O
rats O
before O
DOX O
or O
saline, O
and O
at O
weeks O
6 O
and O
9 O
after O
treatment O
in O
all O
surviving O
rats. O
Histology O
was O
performed O
in O
DOX-rats O
at O
6 O
and O
9 O
weeks O
after O
the O
last O
DOX O
dose O
and O
in O
all O
controls. O
RESULTS: O
Eighteen O
of O
the O
DOX O
rats O
died O
prematurely O
of O
general O
toxicity B
during O
the O
9-week O
period. O
End-diastolic O
(ED) O
and O
end-systolic O
(ES) O
LV O
diameters/BW O
significantly O
increased, O
whereas O
LV O
FS O
was O
decreased O
after O
9 O
weeks O
in O
the O
DOX O
group O
(p<0.001). O
These O
parameters O
remained O
unchanged O
in O
controls. O
Histological O
evaluation O
of O
hearts O
from O
all O
rats O
given O
DOX O
revealed O
significant O
slight O
degrees O
of O
perivascular O
and O
interstitial O
fibrosis. B
In O
7 O
of O
the O
18 O
rats, O
degeneration O
and O
myocyte O
vacuolisation O
were O
found. O
Only O
five O
of O
the O
controls O
exhibited O
evidence O
of O
very O
slight O
perivascular O
fibrosis. O
A O
significant O
rise O
in O
cTnT O
was O
found O
in O
DOX O
rats O
after O
cumulative O
doses O
of O
7.5 O
and O
12 O
mg/kg O
in O
comparison O
with O
baseline O
(p<0.05). O
cTnT O
found O
in O
rats O
after O
12 O
mg/kg O
were O
significantly O
greater O
than O
that O
found O
after O
7.5 O
mg/kg O
DOX. O
Maximal O
cTnI O
(pg/ml) O
and O
cTnT O
levels O
were O
significantly O
increased O
in O
DOX O
rats O
compared O
with O
controls O
(p=0.006, O
0.007). O
cTnI O
(ng/ml), O
CK-MB O
mass O
and O
CK O
remained O
unchanged O
in O
DOX O
rats O
compared O
with O
controls. O
All O
markers O
remained O
stable O
in O
controls. O
Analysis O
of O
data O
revealed O
a O
significant O
correlation O
between O
maximal O
cTnT O
and O
ED O
and O
ES O
LV O
diameters/BW O
(r=0.81 O
and O
0.65; O
p<0.0001). O
A O
significant O
relationship O
was O
observed O
between O
maximal O
cTnT O
and O
the O
extent O
of O
myocardial O
morphological O
changes, O
and O
between O
LV O
diameters/BW O
and O
histological O
findings. O
CONCLUSIONS: O
Among O
markers O
of O
ischemic B
injury I
after O
DOX O
in O
rats, O
cTnT O
showed O
the O
greatest O
ability O
to O
detect O
myocardial O
damage O
assessed O
by O
echocardiographic O
detection O
and O
histological O
changes. O
Although O
there O
was O
a O
discrepancy O
between O
the O
amount O
of O
cTnI O
and O
cTnT O
after O
DOX, O
probably O
due O
to O
heterogeneity O
in O
cross-reactivities O
of O
mAbs O
to O
various O
cTnI O
and O
cTnT O
forms, O
it O
is O
likely O
that O
cTnT O
in O
rats O
after O
DOX O
indicates O
cell O
damage O
determined O
by O
the O
magnitude O
of O
injury O
induced O
and O
that O
cTnT O
should O
be O
a O
useful O
marker O
for O
the O
prediction O
of O
experimentally O
induced O
cardiotoxicity B
and O
possibly O
for O
cardioprotective O
experiments. O

To O
test O
the O
validity O
of O
the O
hypothesis O
that O
hypomethylation O
of O
DNA O
plays O
an O
important O
role O
in O
the O
initiation B
of I
carcinogenic I
process, I
5-azacytidine O
(5-AzC) O
(10 O
mg/kg), O
an O
inhibitor O
of O
DNA O
methylation, O
was O
given O
to O
rats O
during O
the O
phase O
of O
repair O
synthesis O
induced O
by O
the O
three O
carcinogens, O
benzo[a]-pyrene O
(200 O
mg/kg), O
N-methyl-N-nitrosourea O
(60 O
mg/kg) O
and O
1,2-dimethylhydrazine O
(1,2-DMH) O
(100 O
mg/kg). O
The O
initiated O
hepatocytes O
in O
the O
liver O
were O
assayed O
as O
the O
gamma-glutamyltransferase O
(gamma-GT) O
positive O
foci O
formed O
following O
a O
2-week O
selection O
regimen O
consisting O
of O
dietary O
0.02% O
2-acetylaminofluorene O
coupled O
with O
a O
necrogenic O
dose O
of O
CCl4. O
The O
results O
obtained O
indicate O
that O
with O
all O
three O
carcinogens, O
administration O
of O
5-AzC O
during O
repair O
synthesis O
increased O
the O
incidence O
of O
initiated O
hepatocytes, O
for O
example O
10-20 O
foci/cm2 O
in O
5-AzC O
and O
carcinogen-treated O
rats O
compared O
with O
3-5 O
foci/cm2 O
in O
rats O
treated O
with O
carcinogen O
only. O
Administration O
of O
[3H]-5-azadeoxycytidine O
during O
the O
repair O
synthesis O
induced O
by O
1,2-DMH O
further O
showed O
that O
0.019 O
mol O
% O
of O
cytosine O
residues O
in O
DNA O
were O
substituted O
by O
the O
analogue, O
indicating O
that O
incorporation O
of O
5-AzC O
occurs O
during O
repair O
synthesis. O
In O
the O
absence O
of O
the O
carcinogen, O
5-AzC O
given O
after O
a O
two O
thirds O
partial O
hepatectomy, O
when O
its O
incorporation O
should O
be O
maximum, O
failed O
to O
induce O
any O
gamma-GT O
positive O
foci. O
The O
results O
suggest O
that O
hypomethylation O
of O
DNA O
per O
se O
may O
not O
be O
sufficient O
for O
initiation. O
Perhaps O
two O
events O
might O
be O
necessary O
for O
initiation, O
the O
first O
caused O
by O
the O
carcinogen O
and O
a O
second O
involving O
hypomethylation O
of O
DNA. O

Rizatriptan O
is O
a O
selective O
5-HT(1B/1D) O
receptor O
agonist O
with O
rapid O
oral O
absorption O
and O
early O
onset O
of O
action O
in O
the O
acute O
treatment O
of O
migraine. B
This O
randomized O
double- O
blind O
crossover O
outpatient O
study O
assessed O
the O
preference O
for O
1 O
rizatriptan O
10 O
mg O
tablet O
to O
2 O
ergotamine O
1 O
mg/caffeine O
100 O
mg O
tablets O
in O
439 O
patients O
treating O
a O
single O
migraine O
attack O
with O
each O
therapy. O
Of O
patients O
expressing O
a O
preference O
(89.1%), O
more O
than O
twice O
as O
many O
preferred O
rizatriptan O
to O
ergotamine/caffeine O
(69.9 O
vs. O
30.1%, O
p O
< O
or O
= O
0.001). O
Faster O
relief O
of O
headache B
was O
the O
most O
important O
reason O
for O
preference, O
cited O
by O
67.3% O
of O
patients O
preferring O
rizatriptan O
and O
54.2% O
of O
patients O
who O
preferred O
ergotamine/caffeine. O
The O
co-primary O
endpoint O
of O
being O
pain B
free O
at O
2 O
h O
was O
also O
in O
favor O
of O
rizatriptan. O
Forty-nine O
percent O
of O
patients O
were O
pain O
free O
2 O
h O
after O
rizatriptan, O
compared O
with O
24.3% O
treated O
with O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001), O
rizatriptan O
being O
superior O
within O
1 O
h O
of O
treatment. O
Headache B
relief O
at O
2 O
h O
was O
75.9% O
for O
rizatriptan O
and O
47.3% O
for O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001), O
with O
rizatriptan O
being O
superior O
to O
ergotamine/caffeine O
within O
30 O
min O
of O
dosing. O
Almost O
36% O
of O
patients O
taking O
rizatriptan O
were O
pain O
free O
at O
2 O
h O
and O
had O
no O
recurrence O
or O
need O
for O
additional O
medication O
within O
24 O
h, O
compared O
to O
20% O
of O
patients O
on O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001). O
Rizatriptan O
was O
also O
superior O
to O
ergotamine/caffeine O
in O
the O
proportions O
of O
patients O
with O
no O
nausea, B
vomiting, B
phonophobia B
or O
photophobia B
and O
for O
patients O
with O
normal O
function O
2 O
h O
after O
drug O
intake O
(p O
< O
or O
= O
0.001). O
More O
patients O
were O
(completely, O
very O
or O
somewhat) O
satisfied O
2 O
h O
after O
treatment O
with O
rizatriptan O
(69.8%) O
than O
at O
2 O
h O
after O
treatment O
with O
ergotamine/caffeine O
(38.6%, O
p O
< O
or O
= O
0.001). O
Recurrence O
rates O
were O
31.4% O
with O
rizatriptan O
and O
15.3% O
with O
ergotamine/caffeine. O
Both O
active O
treatments O
were O
well O
tolerated. O
The O
most O
common O
adverse O
events O
(incidence O
> O
or O
= O
5% O
in O
one O
group) O
after O
rizatriptan O
and O
ergotamine/caffeine, O
respectively, O
were O
dizziness B
(6.7 O
and O
5.3%), O
nausea O
(4.2 O
and O
8.5%) O
and O
somnolence B
(5.5 O
and O
2.3%). O

A O
diet O
promoting O
sugar B
dependency I
causes O
behavioral B
cross-sensitization I
to O
a O
low O
dose O
of O
amphetamine. O

Intra-arterial O
BCNU O
chemotherapy O
for O
treatment O
of O
malignant B
gliomas I
of O
the O
central O
nervous O
system. O

Combined O
androgen O
blockade-induced O
anemia B
in O
prostate B
cancer I
patients O
without O
bone O
involvement. O

Design O
and O
analysis O
of O
the O
HYPREN-trial: O
safety O
of O
enalapril O
and O
prazosin O
in O
the O
initial O
treatment O
phase O
of O
patients O
with O
congestive B
heart I
failure. I

Clonidine O
for O
attention-deficit/hyperactivity B
disorder: I
II. O
ECG O
changes O
and O
adverse O
events O
analysis. O

We O
report O
the O
case O
of O
a O
70-year-old O
hypertensive B
man O
with O
a O
solitary O
kidney O
and O
chronic B
renal I
insufficiency I
who O
developed O
two O
episodes O
of O
transient O
anuria B
after O
losartan O
administration. O
He O
was O
hospitalized O
for O
a O
myocardial B
infarction I
with O
pulmonary B
edema, I
treated O
with O
high-dose O
diuretics. O
Due O
to O
severe O
systolic B
dysfunction I
losartan O
was O
prescribed. O
Surprisingly, O
the O
first O
dose O
of O
50 O
mg O
of O
losartan O
resulted O
in O
a O
sudden O
anuria, O
which O
lasted O
eight O
hours O
despite O
high-dose O
furosemide O
and O
amine O
infusion. O
One O
week O
later, O
by O
mistake, O
losartan O
was O
prescribed O
again O
and O
after O
the O
second O
dose O
of O
50 O
mg, O
the O
patient O
developed O
a O
second O
episode O
of O
transient O
anuria O
lasting O
10 O
hours. O
During O
these O
two O
episodes, O
his O
blood O
pressure O
diminished O
but O
no O
severe O
hypotension B
was O
noted. O
Ultimately, O
an O
arteriography O
showed O
a O
70-80% O
renal B
artery I
stenosis. I
In O
this O
patient, O
renal O
artery O
stenosis O
combined O
with O
heart B
failure I
and O
diuretic O
therapy O
certainly O
resulted O
in O
a O
strong O
activation O
of O
the O
renin-angiotensin O
system O
(RAS). O
Under O
such O
conditions, O
angiotensin O
II O
receptor O
blockade O
by O
losartan O
probably O
induced O
a O
critical O
fall O
in O
glomerular O
filtration O
pressure. O
This O
case O
report O
highlights O
the O
fact O
that O
the O
angiotensin O
II O
receptor O
antagonist O
losartan O
can O
cause O
serious O
unexpected O
complications O
in O
patients O
with O
renovascular B
disease I
and O
should O
be O
used O
with O
extreme O
caution O
in O
this O
setting. O

Thalidomide O
is O
an O
immunomodulatory O
agent O
with O
demonstrated O
activity O
in O
multiple B
myeloma, I
mantle B
cell I
lymphoma I
and O
lymphoplasmacytic B
lymphoma. I
Its O
activity O
is O
believed O
to O
be O
due O
modulation O
of O
the O
tumour B
milieu, O
including O
downregulation O
of O
angiogenesis O
and O
inflammatory O
cytokines. O
Between O
July O
2001 O
and O
April O
2004, O
24 O
patients O
with O
relapsed/refractory O
indolent O
lymphomas B
received O
thalidomide O
200 O
mg O
daily O
with O
escalation O
by O
100 O
mg O
daily O
every O
1-2 O
weeks O
as O
tolerated, O
up O
to O
a O
maximum O
of O
800 O
mg O
daily. O
Patients O
had O
received O
a O
median O
of O
2 O
(range, O
1-4) O
prior O
regimens. O
Of O
24 O
evaluable O
patients, O
two O
achieved O
a O
complete O
remission O
and O
one O
achieved O
a O
partial O
remission O
for O
an O
overall O
response O
rate O
of O
12.5% O
(95% O
confidence O
interval: O
2.6-32.4%). O
Eleven O
patients O
progressed O
during O
therapy. O
Grade O
3-4 O
adverse O
effects O
included O
myelosuppression, B
fatigue, B
somnolence/depressed B
mood, B
neuropathy B
and O
dyspnea. B
Of O
concern O
was O
the O
occurrence O
of O
four O
thromboembolic B
events. O
Our O
results O
failed O
to O
demonstrate O
an O
important O
response O
rate O
to O
single O
agent O
thalidomide O
in O
indolent O
lymphomas O
and O
contrast O
with O
the O
higher O
activity O
level O
reported O
with O
the O
second O
generation O
immunomodulatory O
agent, O
lenalidomide. O

Visual B
and I
auditory B
neurotoxicity I
was B
previously O
documented O
in O
42 O
of O
89 O
patients O
with O
transfusion-dependent O
anemia B
who O
were O
receiving O
iron O
chelation O
therapy O
with O
daily O
subcutaneous O
deferoxamine. O
Twenty-two O
patients O
in O
the O
affected O
group O
had O
abnormal B
audiograms I
with I
deficits I
mostly I
in I
the I
high I
frequency I
range I
of I
4,000 I
to I
8,000 I
Hz I
and O
in O
the O
hearing O
threshold O
levels O
of O
30 O
to O
100 O
decibels. O
When O
deferoxamine O
therapy O
was O
discontinued O
and O
serial O
studies O
were O
performed, O
audiograms O
in O
seven O
cases O
reverted O
to O
normal O
or O
near O
normal O
within O
two O
to O
three O
weeks, O
and O
nine O
of O
13 O
patients O
with O
symptoms O
became O
asymptomatic. O
Audiograms O
from O
15 O
patients O
remained O
abnormal O
and O
four O
patients O
required O
hearing O
aids O
because O
of O
permanent B
disability. I
Since O
18 O
of O
the O
22 O
patients O
were O
initially O
receiving O
deferoxamine O
doses O
in O
excess O
of O
the O
commonly O
recommended O
50 O
mg/kg O
per O
dose, O
therapy O
was O
restarted O
with O
lower O
doses, O
usually O
50 O
mg/kg O
per O
dose O
or O
less O
depending O
on O
the O
degree O
of O
auditory B
abnormality, I
and O
with O
the O
exception O
of O
two O
cases O
no O
further O
toxicity O
was O
demonstrated. O
Auditory O
deterioration O
and O
improvement, O
demonstrated O
serially O
in O
individual O
patients O
receiving O
and O
not O
receiving O
deferoxamine, O
respectively, O
provided O
convincing O
evidence O
for O
a O
cause-and-effect O
relation O
between O
deferoxamine O
administration O
and O
ototoxicity. B
Based O
on O
these O
data, O
a O
plan O
of O
management O
was O
developed O
that O
allows O
effective O
yet O
safe O
administration O
of O
deferoxamine. O
A O
dose O
of O
50 O
mg/kg O
is O
recommended O
in O
those O
without O
audiogram O
abnormalities. O
With O
mild O
toxicity, O
a O
reduction O
to O
30 O
or O
40 O
mg/kg O
per O
dose O
should O
result O
in O
a O
reversal O
of O
the O
abnormal O
results O
to O
normal O
within O
four O
weeks. O
Moderate O
abnormalities O
require O
a O
reduction O
of O
deferoxamine O
to O
25 O
mg/kg O
per O
dose O
with O
careful O
monitoring. O
In O
those O
with O
symptoms O
of O
hearing B
loss, I
the O
drug O
should O
be O
stopped O
for O
four O
weeks, O
and O
when O
the O
audiogram O
is O
stable O
or O
improved, O
therapy O
should O
be O
restarted O
at O
10 O
to O
25 O
mg/kg O
per O
dose. O
Serial O
audiograms O
should O
be O
performed O
every O
six O
months O
in O
those O
without O
problems O
and O
more O
frequently O
in O
young O
patients O
with O
normal O
serum O
ferritin O
values O
and O
in O
those O
with O
auditory B
dysfunction. I

Fibrous B
myopathy B
is O
a O
common, O
well-known O
side O
effect O
of O
repeated O
pentazocine O
injection. O
However, O
compression B
neuropathy I
due O
to O
fibrotic O
muscle O
affected O
by O
pentazocine-induced O
myopathy O
has O
not O
previously O
been O
reported. O
In O
a O
37-year-old O
woman O
with O
documented O
pentazocine-induced O
fibrous B
myopathy I
of O
triceps O
and O
deltoid O
muscles O
bilaterally O
and O
a O
three-week O
history O
of O
right O
wrist O
drop, O
electrodiagnostic O
examination O
showed O
a O
severe O
but O
partial O
lesion O
of O
the O
right O
radial O
nerve O
distal O
to O
the O
branches O
to O
the O
triceps, O
in O
addition O
to O
the O
fibrous O
myopathy. O
Surgery O
revealed O
the O
right O
radial O
nerve O
to O
be O
severely O
compressed O
by O
the O
densely O
fibrotic O
lateral O
head O
of O
the O
triceps. O
Decompression O
and O
neurolysis O
were O
performed O
with O
good O
subsequent O
recovery O
of O
function. O

Intracranial O
pressure O
(ICP) O
was O
measured O
during O
alfentanil-induced O
rigidity B
in O
rats. O
Ten O
rats O
had O
arterial, O
central O
venous O
(CVP), O
and O
subdural O
cannulae O
inserted O
under O
halothane O
anesthesia. O
The O
animals O
were O
mechanically O
ventilated O
to O
achieve O
normocarbia O
(PCO2 O
= O
42 O
+/- O
1 O
mmHg, O
mean O
+/- O
SE). O
Following O
instrumentation, O
halothane O
was O
discontinued O
and O
alfentanil O
(125 O
mu/kg) O
administered O
iv O
during O
emergence O
from O
halothane O
anesthesia. O
In O
the O
five O
rats O
that O
developed O
somatic B
rigidity, I
ICP O
and O
CVP O
increased O
significantly O
above O
baseline O
(delta O
ICP O
7.5 O
+/- O
1.0 O
mmHg, O
delta O
CVP O
5.9 O
+/- O
1.3 O
mmHg). O
These O
variables O
returned O
to O
baseline O
when O
rigidity O
was O
abolished O
with O
metocurine. O
In O
five O
rats O
that O
did O
not O
become O
rigid, O
ICP O
and O
CVP O
did O
not O
change O
following O
alfentanil. O
These O
observations O
suggest O
that O
rigidity O
should O
be O
prevented O
when O
alfentanil, O
and, O
presumably, O
other O
opiates, O
are O
used O
in O
the O
anesthetic O
management O
of O
patients O
with O
ICP O
problems. O

Sodium O
chloride O
solution O
(0.9%) O
or O
noradrenaline O
in O
doses O
of O
4, O
12 O
and O
36 O
micrograms O
h-1 O
kg-1 O
was O
infused O
for O
five O
consecutive O
days, O
either O
intrarenally O
(by O
a O
new O
technique) O
or O
intravenously O
into O
rats O
with O
one O
kidney O
removed. O
Intrarenal O
infusion O
of O
noradrenaline O
caused O
hypertension B
at O
doses O
which O
did O
not O
do O
so O
when O
infused O
intravenously. O
Intrarenal O
compared O
with O
intravenous O
infusion O
of O
noradrenaline O
caused O
higher O
plasma O
noradrenaline O
concentrations O
and O
a O
shift O
of O
the O
plasma O
noradrenaline O
concentration-blood O
pressure O
effect O
curve O
towards O
lower O
plasma O
noradrenaline O
levels. O
These O
results O
suggest O
that O
hypertension O
after O
chronic O
intrarenal O
noradrenaline O
infusion O
is O
produced O
by O
relatively O
higher O
levels O
of O
circulating O
noradrenaline O
and O
by O
triggering O
of O
an O
additional O
intrarenal O
pressor O
mechanism. O

Serum- O
and O
glucocorticoid-inducible O
kinase O
1 O
in O
doxorubicin-induced O
nephrotic B
syndrome. I

Phase O
II O
trial O
of O
vinorelbine O
in O
metastatic O
squamous B
cell I
esophageal I
carcinoma. I
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer B
Gastrointestinal O
Treat O
Cancer O
Cooperative O
Group. O

BACKGROUND: O
The O
septo-hippocampal O
cholinergic O
pathway O
has O
been O
implicated O
in O
epileptogenesis, O
and O
genetic O
factors O
influence O
the O
response O
to O
cholinergic O
agents, O
but O
limited O
data O
are O
available O
on O
cholinergic O
involvement O
in O
alcohol O
withdrawal O
severity. O
Thus, O
the O
relationship O
between O
cholinergic O
activity O
and O
responsiveness O
and O
alcohol O
withdrawal O
was O
investigated O
in O
a O
genetic O
animal O
model O
of O
ethanol O
withdrawal O
severity. O
METHODS: O
Cholinergic O
convulsant O
sensitivity O
was O
examined O
in O
alcohol-na O
ve O
Withdrawal O
Seizure-Prone B
(WSP) O
and-Resistant O
(WSR) O
mice. O
Animals O
were O
administered O
nicotine, O
carbachol, O
or O
neostigmine O
via O
timed O
tail O
vein O
infusion, O
and O
the O
latencies O
to O
onset O
of O
tremor B
and O
clonus O
were O
recorded O
and O
converted O
to O
threshold O
dose. O
We O
also O
used O
microdialysis O
to O
measure O
basal O
and O
potassium-stimulated O
acetylcholine O
(ACh) O
release O
in O
the O
CA1 O
region O
of O
the O
hippocampus. O
Potassium O
was O
applied O
by O
reverse O
dialysis O
twice, O
separated O
by O
75 O
min. O
Hippocampal O
ACh O
also O
was O
measured O
during O
testing O
for O
handling-induced O
convulsions. B
RESULTS: O
Sensitivity O
to O
several O
convulsion O
endpoints O
induced O
by O
nicotine, O
carbachol, O
and O
neostigmine O
were O
significantly O
greater O
in O
WSR O
versus O
WSP O
mice. O
In O
microdialysis O
experiments, O
the O
lines O
did O
not O
differ O
in O
basal O
release O
of O
ACh, O
and O
50 O
mM O
KCl O
increased O
ACh O
output O
in O
both O
lines O
of O
mice. O
However, O
the O
increase O
in O
release O
of O
ACh O
produced O
by O
the O
first O
application O
of O
KCl O
was O
2-fold O
higher O
in O
WSP O
versus O
WSR O
mice. O
When O
hippocampal O
ACh O
was O
measured O
during O
testing O
for O
handling-induced O
convulsions, O
extracellular O
ACh O
was O
significantly O
elevated O
(192%) O
in O
WSP O
mice, O
but O
was O
nonsignificantly O
elevated O
(59%) O
in O
WSR O
mice. O
CONCLUSIONS: O
These O
results O
suggest O
that O
differences O
in O
cholinergic O
activity O
and O
postsynaptic O
sensitivity O
to O
cholinergic O
convulsants B
may O
be O
associated O
with O
ethanol O
withdrawal O
severity O
and O
implicate O
cholinergic O
mechanisms O
in O
alcohol O
withdrawal. O
Specifically, O
WSP O
mice O
may O
have O
lower O
sensitivity O
to O
cholinergic O
convulsants O
compared O
with O
WSR O
because O
of O
postsynaptic O
receptor O
desensitization O
brought O
on O
by O
higher O
activity O
of O
cholinergic O
neurons. O

Allergic B
reaction I
to O
5-fluorouracil O
infusion. O

These O
studies O
were O
conducted O
to O
examine O
the O
differential O
response O
to O
a O
drug O
challenge O
under O
varied O
experimental O
test O
conditions O
routinely O
employed O
to O
study O
drug-induced O
behavioral O
and O
neurophysiological O
responses O
in O
rodents. O
Apomorphine, O
a O
nonselective O
dopamine O
agonist, O
was O
selected O
due O
to O
its O
biphasic O
behavioral O
effects, O
its O
ability O
to O
induce O
hypothermia, B
and O
to O
produce O
distinct O
changes O
to O
dopamine O
turnover O
in O
the O
rodent O
brain. O
From O
such O
experiments O
there O
is O
evidence O
that O
characterization O
and O
detection O
of O
apomorphine-induced O
activity O
in O
rodents O
critically O
depends O
upon O
the O
test O
conditions O
employed. O
In O
rats, O
detection O
of O
apomorphine-induced O
hyperactivity B
was O
facilitated O
by O
a O
period O
of O
acclimatization O
to O
the O
test O
conditions. O
Moreover, O
test O
conditions O
can O
impact O
upon O
other O
physiological O
responses O
to O
apomorphine O
such O
as O
drug-induced O
hypothermia. O
In O
mice, O
apomorphine O
produced O
qualitatively O
different O
responses O
under O
novel O
conditions O
when O
compared O
to O
those O
behaviors O
elicited O
in O
the O
home O
test O
cage. O
Drug-induced O
gross O
activity O
counts O
were O
increased O
in O
the O
novel O
exploratory O
box O
only, O
while O
measures O
of O
stereotypic O
behavior O
were O
similar O
in O
both. O
By O
contrast, O
apomorphine-induced O
locomotion O
was O
more O
prominent O
in O
the O
novel O
exploratory O
box. O
Dopamine O
turnover O
ratios O
(DOPAC:DA O
and O
HVA:DA) O
were O
found O
to O
be O
lower O
in O
those O
animals O
exposed O
to O
the O
exploratory O
box O
when O
compared O
to O
their O
home O
cage O
counterparts. O
However, O
apomorphine-induced O
reductions O
in O
striatal O
dopamine O
turnover O
were O
detected O
in O
both O
novel O
and O
home O
cage O
environments. O
The O
implications O
of O
these O
findings O
are O
discussed O
with O
particular O
emphasis O
upon O
conducting O
psychopharmacological O
challenge O
tests O
in O
rodents. O

Immunohistochemical, O
electron O
microscopic O
and O
morphometric O
studies O
of O
estrogen-induced O
rat O
prolactinomas B
after O
bromocriptine O
treatment. O

Epidemiological O
evidence O
indicates O
that O
prenatal O
nutritional O
deprivation O
may O
increase O
the O
risk O
of O
schizophrenia. B
The O
goal O
of O
these O
studies O
was O
to O
use O
an O
animal O
model O
to O
examine O
the O
effects O
of O
prenatal O
protein O
deprivation O
on O
behaviors O
and O
receptor O
binding O
with O
relevance O
to O
schizophrenia. O
We O
report O
that O
prenatally O
protein O
deprived O
(PD) O
female O
rats O
showed O
an O
increased O
stereotypic O
response O
to O
apomorphine O
and O
an O
increased O
locomotor O
response O
to O
amphetamine O
in O
adulthood. O
These O
differences O
were O
not O
observed O
during O
puberty. O
No O
changes O
in O
haloperidol-induced O
catalepsy B
or O
MK-801-induced O
locomotion O
were O
seen O
following O
PD. O
In O
addition, O
PD O
female O
rats O
showed O
increased O
(3)H-MK-801 O
binding O
in O
the O
striatum O
and O
hippocampus, O
but O
not O
in O
the O
cortex. O
PD O
female O
rats O
also O
showed O
increased O
(3)H-haloperidol O
binding O
and O
decreased O
dopamine O
transporter O
binding O
in O
striatum. O
No O
statistically O
significant O
changes O
in O
behavior O
or O
receptor O
binding O
were O
found O
in O
PD O
males O
with O
the O
exception O
of O
increased O
(3)H-MK-801 O
binding O
in O
cortex. O
This O
animal O
model O
may O
be O
useful O
to O
explore O
the O
mechanisms O
by O
which O
prenatal O
nutritional B
deficiency I
enhances O
risk O
for O
schizophrenia O
in O
humans O
and O
may O
also O
have O
implications O
for O
developmental O
processes O
leading O
to O
differential O
sensitivity O
to O
drugs O
of O
abuse. O

Dexamethasone O
is O
frequently O
administered O
to O
the O
developing O
fetus O
to O
accelerate O
pulmonary O
development. O
The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
prenatal O
dexamethasone O
programmed O
a O
progressive O
increase B
in I
blood I
pressure I
and O
renal B
injury I
in O
rats. O
Pregnant O
rats O
were O
given O
either O
vehicle O
or O
2 O
daily O
intraperitoneal O
injections O
of O
dexamethasone O
(0.2 O
mg/kg O
body O
weight) O
on O
gestational O
days O
11 O
and O
12, O
13 O
and O
14, O
15 O
and O
16, O
17 O
and O
18, O
or O
19 O
and O
20. O
Offspring O
of O
rats O
administered O
dexamethasone O
on O
days O
15 O
and O
16 O
gestation O
had O
a O
20% O
reduction B
in I
glomerular I
number I
compared O
with O
control O
at O
6 O
to O
9 O
months O
of O
age O
(22 O
527+/-509 O
versus O
28 O
050+/-561, O
P<0.05), O
which O
was O
comparable O
to O
the O
percent O
reduction O
in O
glomeruli O
measured O
at O
3 O
weeks O
of O
age. O
Six- O
to O
9-month O
old O
rats O
receiving O
prenatal O
dexamethasone O
on O
days O
17 O
and O
18 O
of O
gestation O
had O
a O
17% O
reduction O
in O
glomeruli O
(23 O
380+/-587) O
compared O
with O
control O
rats O
(P<0.05). O
Male O
rats O
that O
received O
prenatal O
dexamethasone O
on O
days O
15 O
and O
16, O
17 O
and O
18, O
and O
13 O
and O
14 O
of O
gestation O
had O
elevated B
blood I
pressures I
at O
6 O
months O
of O
age; O
the O
latter O
group O
did O
not O
have O
a O
reduction O
in O
glomerular O
number. O
Adult O
rats O
given O
dexamethasone O
on O
days O
15 O
and O
16 O
of O
gestation O
had O
more O
glomeruli O
with O
glomerulosclerosis B
than O
control O
rats. O
This O
study O
shows O
that O
prenatal O
dexamethasone O
in O
rats O
results O
in O
a O
reduction O
in O
glomerular O
number, O
glomerulosclerosis, O
and O
hypertension B
when O
administered O
at O
specific O
points O
during O
gestation. O
Hypertension B
was O
observed O
in O
animals O
that O
had O
a O
reduction O
in O
glomeruli O
as O
well O
as O
in O
a O
group O
that O
did O
not O
have O
a O
reduction O
in O
glomerular O
number, O
suggesting O
that O
a O
reduction O
in O
glomerular O
number O
is O
not O
the O
sole O
cause O
for O
the O
development O
of O
hypertension. O

Recurrent O
excitation O
in O
the O
dentate O
gyrus O
of O
a O
murine O
model O
of O
temporal B
lobe I
epilepsy. I

Prevention O
of O
seizures B
and O
reorganization O
of O
hippocampal O
functions O
by O
transplantation O
of O
bone O
marrow O
cells O
in O
the O
acute O
phase O
of O
experimental O
epilepsy. B

BACKGROUND: O
We O
report O
on O
the O
manifestation O
of O
a O
levetiracetam O
(LEV)-induced O
encephalopathy. B
FINDINGS: O
A O
28-year-old O
man O
suffering O
from O
idiopathic B
epilepsy I
with O
generalized O
seizures B
was O
treated O
with O
LEV O
(3000 O
mg) O
added O
to O
valproate O
(VPA) O
(2000 O
mg). O
Frequency O
of O
generalized O
tonic-clonic B
seizures I
increased O
from O
one O
per O
6 O
months O
to O
two O
per O
month. O
Neuropsychological O
testing O
showed O
impaired B
word I
fluency, I
psychomotor I
speed I
and I
working I
memory. I
The O
interictal O
electroencephalogram O
(EEG) O
showed O
a O
generalized O
slowing O
to O
5 O
per O
second O
theta O
rhythms O
with O
bilateral O
generalized O
high-amplitude O
discharges. O
OUTCOME: O
Following O
discontinuation O
of O
LEV, O
EEG O
and O
neuropsychological O
findings O
improved O
and O
seizure O
frequency O
decreased. O

Tolerance O
and O
antiviral O
effect O
of O
ribavirin O
in O
patients O
with O
Argentine B
hemorrhagic I
fever. I

The O
effect O
of O
a O
6-week O
treatment O
with O
the O
calcium O
channel O
blocker O
nitrendipine O
or O
the O
angiotensin O
converting O
enzyme O
inhibitor O
enalapril O
on O
blood O
pressure, O
albuminuria, B
renal O
hemodynamics, O
and O
morphology O
of O
the O
nonclipped O
kidney O
was O
studied O
in O
rats O
with O
two-kidney, O
one O
clip O
renovascular B
hypertension. I
Six O
weeks O
after O
clipping O
of O
one O
renal O
artery, O
hypertensive B
rats O
(178 O
+/- O
4 O
mm O
Hg) O
were O
randomly O
assigned O
to O
three O
groups: O
untreated O
hypertensive O
controls O
(n O
= O
8), O
enalapril-treated O
(n O
= O
8), O
or O
nitrendipine-treated O
(n O
= O
10). O
Sham-operated O
rats O
served O
as O
normotensive O
controls O
(128 O
+/- O
3 O
mm O
Hg, O
n O
= O
8). O
After O
6 O
weeks O
of O
treatment, O
renal O
hemodynamics O
(glomerular O
filtration O
rate O
and O
renal O
plasma O
flow) O
were O
measured O
in O
the O
anesthetized O
rats. O
Renal O
tissue O
was O
obtained O
for O
determination O
of O
glomerular O
size O
and O
sclerosis. O
Enalapril O
but O
not O
nitrendipine O
reduced O
blood O
pressure O
significantly. O
After O
6 O
weeks O
of O
therapy, O
glomerular O
filtration O
rate O
was O
not O
different O
among O
the O
studied O
groups. O
Renal O
plasma O
flow O
increased, O
but O
albumin O
excretion O
and O
glomerulosclerosis B
did O
not O
change O
after O
enalapril O
treatment. O
In O
contrast, O
in O
the O
nitrendipine-treated O
group O
albuminuria O
increased O
from O
12.8 O
+/- O
2 O
progressively O
to O
163 O
+/- O
55 O
compared O
with O
19.2 O
+/- O
9 O
mg/24 O
hr O
in O
the O
hypertensive O
controls. O
Furthermore, O
glomerulosclerosis O
index O
was O
significantly O
increased O
in O
the O
nitrendipine-treated O
group O
compared O
with O
the O
hypertensive O
controls O
(0.38 O
+/- O
0.1 O
versus O
0.13 O
+/- O
0.04). O
In O
addition, O
glomerular O
size O
was O
higher O
in O
the O
nitrendipine-treated O
group O
(14.9 O
+/- O
0.17 O
10(-3) O
mm2) O
but O
lower O
in O
the O
enalapril-treated O
group O
(11.5 O
+/- O
0.15 O
10(-3) O
mm2) O
compared O
with O
the O
hypertensive O
controls O
(12.1 O
+/- O
0.17 O
10(-3) O
mm2).(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

Learning B
and I
memory B
deficits I
in O
ecstasy O
users O
and O
their O
neural O
correlates O
during O
a O
face-learning O
task. O

Pharmacological O
modulation O
of O
pain-related B
brain O
activity O
during O
normal O
and O
central O
sensitization O
states O
in O
humans. O

Effect O
of O
fucoidan O
treatment O
on O
collagenase-induced O
intracerebral B
hemorrhage I
in O
rats. O

A O
patient O
with O
sinuatrial B
disease I
and O
implanted O
pacemaker O
was O
treated O
with O
amiodarone O
(maximum O
dose O
1000 O
mg, O
maintenance O
dose O
800 O
mg O
daily) O
for O
10 O
months, O
for O
control O
of O
supraventricular B
tachyarrhythmias. I
He O
developed O
pneumonitis, B
pleural B
and I
pericardial B
effusions, I
and O
a O
predominantly O
proximal B
motor I
neuropathy. I
Immediate O
but O
gradual O
improvement O
followed O
withdrawal O
of O
amiodarone O
and O
treatment O
with O
prednisolone. O
Review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of O
amiodarone O
pneumonitis, O
immediate O
withdrawal O
of O
amiodarone, O
and O
prompt O
but O
continued O
steroid O
therapy O
to O
ensure O
full O
recovery. O

Serial O
studies O
of O
auditory B
neurotoxicity I
in O
patients O
receiving O
deferoxamine O
therapy. O

Carbamazepine O
and O
vigabatrin O
are O
contraindicated O
in O
typical O
absence B
seizures. I
Of O
18 O
consecutive O
referrals O
of O
children O
with O
resistant O
typical O
absences O
only, O
eight O
were O
erroneously O
treated O
with O
carbamazepine O
either O
as O
monotherapy O
or O
as O
an O
add-on. O
Vigabatrin O
was O
also O
used O
in O
the O
treatment O
of O
two O
children. O
Frequency O
of O
absences O
increased O
in O
four O
children O
treated O
with O
carbamazepine O
and O
two O
of O
these O
developed O
myoclonic B
jerks, I
which O
resolved O
on O
withdrawal O
of O
carbamazepine. O
Absences O
were O
aggravated O
in O
both O
cases O
where O
vigabatrin O
was O
added O
on O
to O
concurrent O
treatment. O
Optimal O
control O
of O
the O
absences O
was O
achieved O
with O
sodium O
valproate, O
lamotrigine, O
or O
ethosuximide O
alone O
or O
in O
combination. O

The O
pathomechanism O
of O
nicotine-induced O
nystagmus B
(NIN) O
is B
unknown. O
The O
aim O
of O
this O
study O
was O
to O
delineate O
brain O
structures O
that O
are O
involved O
in O
NIN O
generation. O
Eight O
healthy O
volunteers O
inhaled O
nicotine O
in O
darkness O
during O
a O
functional O
magnetic O
resonance O
imaging O
(fMRI) O
experiment; O
eye O
movements O
were O
registered O
using O
video-oculography. O
NIN O
correlated O
with O
blood O
oxygen O
level-dependent O
(BOLD) O
activity O
levels O
in O
a O
midpontine O
site O
in O
the O
posterior O
basis O
pontis. O
NIN-induced O
midpontine O
activation O
may O
correspond O
to O
activation O
of O
the O
dorsomedial O
pontine O
nuclei O
and O
the O
nucleus O
reticularis O
tegmenti O
pontis, O
structures O
known O
to O
participate O
in O
the O
generation O
of O
multidirectional O
saccades O
and O
smooth O
pursuit O
eye O
movements. O

Methamphetamine-induced O
neurotoxicity B
and O
microglial O
activation O
are O
not O
mediated O
by O
fractalkine O
receptor O
signaling. O

A O
transient O
neurological B
deficit I
following O
intrathecal O
injection O
of O
1% O
hyperbaric O
bupivacaine O
for O
unilateral O
spinal O
anaesthesia. O

Octreotide, O
an O
effective O
treatment O
for O
acromegaly, B
induces O
gall B
bladder I
stones I
in O
13-60% O
of O
patients. O
Because O
knowledge O
of O
stone O
composition O
is O
essential O
for O
studies O
of O
their O
pathogenesis, O
treatment, O
and O
prevention, O
this O
was O
investigated O
by O
direct O
and O
indirect O
methods O
in O
14 O
octreotide O
treated O
acromegalic B
patients O
with O
gall B
stones. I
Chemical O
analysis O
of O
gall O
stones O
retrieved O
at O
cholecystectomy O
from O
two O
patients, O
showed O
that O
they O
contained O
71% O
and O
87% O
cholesterol O
by O
weight. O
In O
the O
remaining O
12 O
patients, O
localised O
computed O
tomography O
of O
the O
gall O
bladder O
showed O
that O
eight O
had O
stones O
with O
maximum O
attenuation O
scores O
of O
< O
100 O
Hounsfield O
units O
(values O
of O
< O
100 O
HU O
predict O
cholesterol O
rich, O
dissolvable O
stones). O
Gall O
bladder O
bile O
was O
obtained O
by O
ultrasound O
guided, O
fine O
needle O
puncture O
from O
six O
patients. O
All O
six O
patients O
had O
supersaturated O
bile O
(mean O
(SEM) O
cholesterol O
saturation O
index O
of O
1.19 O
(0.08) O
(range O
1.01-1.53)) O
and O
all O
had O
abnormally O
rapid O
cholesterol O
microcrystal O
nucleation O
times O
(< O
4 O
days O
(range O
1-4)), O
whilst O
in O
four, O
the O
bile O
contained O
cholesterol O
microcrystals O
immediately O
after O
sampling. O
Of O
the O
12 O
patients O
considered O
for O
oral O
ursodeoxycholic O
acid O
(UDCA) O
treatment, O
two O
had O
a O
blocked O
cystic O
duct O
and O
were O
not O
started O
on O
UDCA O
while O
one O
was O
lost O
to O
follow O
up. O
After O
one O
year O
of O
treatment, O
five O
of O
the O
remaining O
nine O
patients O
showed O
either O
partial O
(n O
= O
3) O
or O
complete O
(n O
= O
2) O
gall O
stone O
dissolution, O
suggesting O
that O
their O
stones O
were O
cholesterol O
rich. O
This O
corresponds, O
by O
actuarial O
(life O
table) O
analysis, O
to O
a O
combined O
gall O
stone O
dissolution O
rate O
of O
58.3 O
(15.9%). O
In O
conclusion, O
octreotide O
induced O
gall O
stones O
are O
generally O
small, O
multiple, O
and O
cholesterol O
rich O
although, O
in O
common O
with O
spontaneous O
gall B
stone I
disease, I
at O
presentation O
some O
patients O
will O
have O
a O
blocked O
cystic O
duct O
and O
some O
gall O
stones O
containing O
calcium. O

A O
novel, O
multiple O
symptom O
model O
of O
obsessive-compulsive-like B
behaviors I
in O
animals. O

Source O
of O
pain B
and O
primitive O
dysfunction O
in O
migraine: B
an O
identical O
site? O

Composition O
of O
gall B
bladder I
stones I
associated O
with O
octreotide: O
response O
to O
oral O
ursodeoxycholic O
acid. O

Two O
patients O
with O
similar O
clinical O
features O
are O
presented: O
both O
patients O
had O
chronic B
renal I
failure, I
on O
hemodialysis O
for O
many O
years O
but O
recently O
begun O
on O
a O
high-flux O
dialyzer; O
both O
had O
been O
receiving O
a O
carbidopa/levodopa O
preparation; O
and O
both O
had O
the O
onset O
of O
hallucinosis B
and O
recurrent O
seizures, B
which O
were O
refractory O
to O
anticonvulsants. O
The O
first O
patient O
died O
without O
a O
diagnosis; O
the O
second O
patient O
had O
a O
dramatic O
recovery O
following O
the O
administration O
of O
vitamin O
B6. O
Neither O
patient O
was O
considered O
to O
have O
a O
renal O
state O
sufficiently O
severe O
enough O
to O
explain O
their O
presentation. O

BACKGROUND: O
The O
calcineurin O
inhibitors O
cyclosporine O
and O
tacrolimus O
are O
both O
known O
to O
be O
nephrotoxic. B
Their O
use O
in O
orthotopic O
liver O
transplantation O
(OLTX) O
has O
dramatically O
improved O
success O
rates. O
Recently, O
however, O
we O
have O
had O
an O
increase O
of O
patients O
who O
are O
presenting O
after O
OLTX O
with O
end-stage B
renal I
disease I
(ESRD). O
This B
retrospective O
study O
examines O
the O
incidence O
and O
treatment O
of O
ESRD O
and O
chronic B
renal I
failure I
(CRF) O
in B
OLTX O
patients. O
METHODS: O
Patients O
receiving O
an O
OLTX O
only O
from O
June O
1985 O
through O
December O
of O
1994 O
who O
survived O
6 O
months O
postoperatively O
were O
studied O
(n=834). O
Our O
prospectively O
collected O
database O
was O
the O
source O
of O
information. O
Patients O
were O
divided O
into O
three O
groups: O
Controls, O
no O
CRF O
or O
ESRD, O
n=748; O
CRF, O
sustained O
serum O
creatinine O
>2.5 O
mg/dl, O
n=41; O
and O
ESRD, O
n=45. O
Groups O
were O
compared O
for O
preoperative O
laboratory O
variables, O
diagnosis, O
postoperative O
variables, O
survival, O
type O
of O
ESRD O
therapy, O
and O
survival O
from O
onset O
of O
ESRD. O
RESULTS: O
At O
13 O
years O
after O
OLTX, O
the O
incidence O
of O
severe O
renal B
dysfunction I
was O
18.1% O
(CRF O
8.6% O
and O
ESRD O
9.5%). O
Compared O
with O
control O
patients, O
CRF O
and O
ESRD O
patients O
had O
higher O
preoperative O
serum O
creatinine O
levels, O
a O
greater O
percentage O
of O
patients O
with O
hepatorenal B
syndrome, I
higher O
percentage O
requirement O
for O
dialysis O
in O
the O
first O
3 O
months O
postoperatively, O
and O
a O
higher O
1-year O
serum O
creatinine. O
Multivariate O
stepwise O
logistic O
regression O
analysis O
using O
preoperative O
and O
postoperative O
variables O
identified O
that O
an O
increase O
of O
serum O
creatinine O
compared O
with O
average O
at O
1 O
year, O
3 O
months, O
and O
4 O
weeks O
postoperatively O
were O
independent O
risk O
factors O
for O
the O
development O
of O
CRF O
or O
ESRD O
with O
odds O
ratios O
of O
2.6, O
2.2, O
and O
1.6, O
respectively. O
Overall O
survival O
from O
the O
time O
of O
OLTX O
was O
not O
significantly O
different O
among O
groups, O
but O
by O
year O
13, O
the O
survival O
of O
the O
patients O
who O
had O
ESRD O
was O
only O
28.2% O
compared O
with O
54.6% O
in O
the O
control O
group. O
Patients O
developing O
ESRD O
had O
a O
6-year O
survival O
after O
onset O
of O
ESRD O
of O
27% O
for O
the O
patients O
receiving O
hemodialysis O
versus O
71.4% O
for O
the O
patients O
developing O
ESRD O
who O
subsequently O
received O
kidney O
transplants. O
CONCLUSIONS: O
Patients O
who O
are O
more O
than O
10 O
years O
post-OLTX O
have O
CRF O
and O
ESRD O
at O
a O
high O
rate. O
The O
development O
of O
ESRD O
decreases O
survival, O
particularly O
in O
those O
patients O
treated O
with O
dialysis O
only. O
Patients O
who O
develop O
ESRD O
have O
a O
higher O
preoperative O
and O
1-year O
serum O
creatinine O
and O
are O
more O
likely O
to O
have O
hepatorenal O
syndrome. O
However, O
an O
increase O
of O
serum O
creatinine O
at O
various O
times O
postoperatively O
is O
more O
predictive O
of O
the O
development O
of O
CRF O
or O
ESRD. O
New O
strategies O
for O
long-term O
immunosuppression O
may O
be O
needed O
to O
decrease O
this O
complication. O

Choreoathetoid B
movements I
associated O
with O
rapid O
adjustment O
to O
methadone. O

Acetazolamide-induced O
nephrolithiasis: B
implications O
for O
treatment O
of O
neuromuscular B
disorders. I

5-azacytidine O
potentiates O
initiation B
induced I
by I
carcinogens I
in O
rat O
liver. O

Dapsone-associated O
Heinz O
body O
hemolytic B
anemia I
in O
a O
Cambodian O
woman O
with O
hemoglobin O
E O
trait. O

Effect O
of O
adriamycin O
combined O
with O
whole O
body O
hyperthermia B
on O
tumor B
and O
normal O
tissues. O

The O
development O
of O
apomorphine-induced O
(1.0 O
mg/kg O
s.c. O
once O
daily) O
aggressive B
behavior I
of O
adult O
male O
and O
female O
Wistar O
rats O
obtained O
from O
the O
same O
breeder O
was O
studied O
in O
two O
consecutive O
sets. O
In O
male O
animals, O
repeated O
apomorphine O
treatment O
induced O
a O
gradual O
development O
of O
aggressive O
behavior O
as O
evidenced O
by O
the O
increased O
intensity O
of O
aggressiveness B
and O
shortened O
latency O
before O
the O
first O
attack O
toward O
the O
opponent. O
In O
female O
rats, O
only O
a O
weak O
tendency O
toward O
aggressiveness O
was O
found. O
In O
conclusion, O
the O
present O
study O
demonstrates O
gender O
differences O
in O
the O
development O
of O
the O
apomorphine-induced O
aggressive O
behavior O
and O
indicates O
that O
the O
female O
rats O
do O
not O
fill O
the O
validation O
criteria O
for O
use O
in O
this O
method. O

Hyperkalemia B
associated O
with O
sulindac O
therapy. O

In O
the O
present O
work O
we O
assessed O
the O
effect O
of O
treatment O
of O
rats O
with O
gum O
Arabic O
on O
acute B
renal I
failure I
induced O
by O
gentamicin O
(GM) O
nephrotoxicity. B
Rats O
were O
treated O
with O
the O
vehicle O
(2 O
mL/kg O
of O
distilled O
water O
and O
5% O
w/v O
cellulose, O
10 O
days), O
gum O
Arabic O
(2 O
mL/kg O
of O
a O
10% O
w/v O
aqueous O
suspension O
of O
gum O
Arabic O
powder, O
orally O
for O
10 O
days), O
or O
gum O
Arabic O
concomitantly O
with O
GM O
(80mg/kg/day O
intramuscularly, O
during O
the O
last O
six O
days O
of O
the O
treatment O
period). O
Nephrotoxicity B
was O
assessed O
by O
measuring O
the O
concentrations O
of O
creatinine O
and O
urea O
in O
the O
plasma O
and O
reduced O
glutathione O
(GSH) O
in O
the O
kidney O
cortex, O
and O
by O
light O
microscopic O
examination O
of O
kidney O
sections. O
The O
results O
indicated O
that O
concomitant O
treatment O
with O
gum O
Arabic O
and O
GM O
significantly O
increased O
creatinine O
and O
urea O
by O
about O
183 O
and O
239%, O
respectively O
(compared O
to O
432 O
and O
346%, O
respectively, O
in O
rats O
treated O
with O
cellulose O
and O
GM), O
and O
decreased O
that O
of O
cortical O
GSH O
by O
21% O
(compared O
to O
27% O
in O
the O
cellulose O
plus O
GM O
group) O
The O
GM-induced O
proximal O
tubular B
necrosis I
appeared O
to O
be O
slightly O
less O
severe O
in O
rats O
given O
GM O
together O
with O
gum O
Arabic O
than O
in O
those O
given O
GM O
and O
cellulose. O
It O
could O
be O
inferred O
that O
gum O
Arabic O
treatment O
has O
induced O
a O
modest O
amelioration O
of O
some O
of O
the O
histological O
and O
biochemical O
indices O
of O
GM O
nephrotoxicity. O
Further O
work O
is O
warranted O
on O
the O
effect O
of O
the O
treatments O
on O
renal O
functional O
aspects O
in O
models O
of O
chronic B
renal I
failure, I
and O
on O
the O
mechanism(s) O
involved. O

Cardiovascular B
complications I
associated O
with O
terbutaline O
treatment O
for O
preterm B
labor. I

Toxic O
peripheral B
neuropathy I
is O
still O
a O
significant O
limiting O
factor O
for O
chemotherapy O
with O
paclitaxel O
(PAC), O
although O
glutamate O
and O
its O
closely O
related O
amino O
acid O
glutamine O
were O
claimed O
to O
ameliorate O
PAC O
neurotoxicity. B
This O
pilot O
trial O
aimed O
to O
evaluate O
the O
role O
of O
glutamate O
supplementation O
for O
preventing O
PAC-induced O
peripheral O
neuropathy O
in O
a O
randomized, O
placebo-controlled, O
double-blinded O
clinical O
and O
electro-diagnostic O
study. O
Forty-three O
ovarian B
cancer I
patients O
were O
available O
for O
analysis O
following O
six O
cycles O
of O
the O
same O
PAC-containing O
regimen: O
23 O
had O
been O
supplemented O
by O
glutamate O
all O
along O
the O
treatment O
period, O
at O
a O
daily O
dose O
of O
three O
times O
500 O
mg O
(group O
G), O
and O
20 O
had O
received O
a O
placebo O
(group O
P). O
Patients O
were O
evaluated O
by O
neurological O
examinations, O
questionnaires O
and O
sensory-motor O
nerve O
conduction O
studies. O
There O
was O
no O
significant O
difference O
in O
the O
frequency O
of O
signs O
or O
symptoms O
between O
the O
two O
groups O
although O
neurotoxicity O
symptoms O
presented O
mostly O
with O
lower O
scores O
of O
severity O
in O
group O
G. O
However, O
this O
difference O
reached O
statistical O
significance O
only O
with O
regard O
to O
reported O
pain B
sensation O
(P O
= O
0.011). O
Also O
the O
frequency O
of O
abnormal O
electro-diagnostic O
findings O
showed O
similarity O
between O
the O
two O
groups O
(G: O
7/23 O
= O
30.4%; O
P: O
6/20 O
= O
30%). O
This O
pilot O
study O
leads O
to O
the O
conclusion O
that O
glutamate O
supplementation O
at O
the O
chosen O
regimen O
fails O
to O
protect O
against O
peripheral B
neurotoxicity I
of O
PAC. O

Antituberculosis O
therapy B
(ATT)-associated O
acute B
liver I
failure I
(ATT-ALF) O
is B
the O
commonest O
drug-induced O
ALF O
in O
South O
Asia. O
Prospective O
studies O
on O
ATT-ALF O
are O
lacking. O
The O
current O
study O
prospectively O
evaluated O
the O
magnitude, O
clinical O
course, O
outcome, O
and O
prognostic O
factors O
in O
ATT-ALF. O
From O
January O
1986 O
to O
January O
2009, O
1223 O
consecutive O
ALF O
patients O
were O
evaluated: O
ATT O
alone O
was O
the O
cause O
in O
70 O
(5.7%) O
patients. O
Another O
15 O
(1.2%) O
had O
ATT O
and O
simultaneous O
hepatitis B
virus I
infection. B
In O
44 O
(62.8%) O
patients, O
ATT O
was O
prescribed O
empirically O
without O
definitive O
evidence O
of O
tuberculosis. O
ATT-ALF O
patients O
were O
younger O
(32.87 O
[+/-15.8] O
years), O
and O
49 O
(70%) O
of O
them O
were O
women. O
Most O
had O
hyperacute O
presentation; O
the O
median O
icterus B
encephalopathy B
interval O
was O
4.5 O
(0-30) O
days. O
The O
median O
duration O
of O
ATT O
before O
ALF O
was O
30 O
(7-350) O
days. O
At O
presentation, O
advanced O
encephalopathy O
and O
cerebral B
edema I
were O
present O
in O
51 O
(76%) O
and O
29 O
(41.4%) O
patients, O
respectively. O
Gastrointestinal B
bleed, I
seizures, B
infection, O
and O
acute B
renal I
failure I
were O
documented O
in O
seven O
(10%), O
five O
(7.1%), O
26 O
(37.1%), O
and O
seven O
(10%) O
patients, O
respectively. O
Compared O
with O
hepatitis B
E I
virus O
(HEV) O
and O
non-A O
non-E-induced O
ALF, O
ATT-ALF O
patients O
had O
nearly O
similar O
presentations O
except O
for O
older O
age O
and O
less O
elevation O
of O
liver O
enzymes. O
The O
mortality O
rate O
among O
patients O
with O
ATT-ALF O
was O
high O
(67.1%, O
n O
= O
47), O
and O
only O
23 O
(32.9%) O
patients O
recovered O
with O
medical O
treatment. O
In O
multivariate O
analysis, O
three O
factors O
independently O
predicted O
mortality: O
serum O
bilirubin O
(>or=10.8 O
mg/dL), O
prothrombin O
time O
(PT) O
prolongation O
(>or=26 O
seconds), O
and O
grade O
III/IV O
encephalopathy O
at O
presentation. O
CONCLUSION: O
ATT-ALF O
constituted O
5.7% O
of O
ALF O
at O
our O
center O
and O
had O
a O
high O
mortality O
rate. O
Because O
the O
mortality O
rate O
is O
so O
high, O
determining O
which O
factors O
are O
predictors O
is O
less O
important. O
A O
high O
proportion O
of O
patients O
had O
consumed O
ATT O
empirically, O
which O
could O
have O
been O
prevented. O

Pharmacological O
evidence O
for O
the O
potential O
of O
Daucus O
carota O
in O
the O
management O
of O
cognitive B
dysfunctions. I

UM-272 O
(N,N-dimethylpropranolol), O
a O
quaternary O
antiarrhythmic O
agent, O
was O
administered O
sublingually O
to O
dogs O
with O
ouabain-induced O
ventricular B
tachycardias. I
Both O
anti-arrhythmic O
efficacy O
and O
bioavailability O
were O
compared O
to O
oral O
drug. O
Sublingual O
UM-272 O
converted O
ventricular O
tachycardia O
to O
sinus O
rhythm O
in O
all O
5 O
dogs. O
The O
area O
under O
the O
plasma O
concentration O
time O
curve O
at O
90 O
min O
was O
4-12 O
times O
greater O
than O
for O
oral O
drug, O
suggesting O
the O
existence O
of O
an O
absorption-limiting O
process O
in O
the O
intestine, O
and O
providing O
an O
alternate O
form O
of O
administration O
for O
quaternary O
drugs. O

We O
studied O
a O
patient O
with O
no O
prior O
history O
of O
neuromuscular B
disease I
who O
became O
virtually O
quadriplegic B
after O
parenteral O
magnesium O
administration O
for O
preeclampsia. B
The O
serum O
magnesium O
concentration O
was O
3.0 O
mEq/L, O
which O
is O
usually O
well O
tolerated. O
The O
magnesium O
was O
stopped O
and O
she O
recovered O
over O
a O
few O
days. O
While O
she O
was O
weak, O
2-Hz O
repetitive O
stimulation O
revealed O
a O
decrement O
without O
significant O
facilitation O
at O
rapid O
rates O
or O
after O
exercise, O
suggesting O
postsynaptic B
neuromuscular I
blockade. I
After O
her O
strength O
returned, O
repetitive O
stimulation O
was O
normal, O
but O
single O
fiber O
EMG O
revealed O
increased O
jitter O
and O
blocking. O
Her O
acetylcholine O
receptor O
antibody O
level O
was O
markedly O
elevated. O
Although O
paralysis B
after O
magnesium O
administration O
has O
been O
described O
in O
patients O
with O
known O
myasthenia B
gravis, I
it O
has O
not O
previously O
been O
reported O
to O
be O
the O
initial O
or O
only O
manifestation O
of O
the O
disease. O
Patients O
who O
are O
unusually O
sensitive O
to O
the O
neuromuscular O
effects O
of O
magnesium O
should O
be O
suspected O
of O
having O
an O
underlying O
disorder B
of I
neuromuscular I
transmission. I

In O
recent O
years O
working O
memory B
deficits I
have O
been O
reported O
in O
users O
of O
MDMA O
(3,4-methylenedioxymethamphetamine, O
ecstasy). O
The O
current O
study O
aimed O
to O
assess O
the O
impact O
of O
MDMA O
use O
on O
three O
separate O
central O
executive O
processes O
(set O
shifting, O
inhibition O
and O
memory O
updating) O
and O
also O
on O
"prefrontal" O
mediated O
social O
and O
emotional O
judgement O
processes. O
Fifteen O
polydrug O
ecstasy O
users O
and O
15 O
polydrug O
non-ecstasy O
user O
controls O
completed O
a O
general O
drug O
use O
questionnaire, O
the O
Brixton O
Spatial O
Anticipation O
task O
(set O
shifting), O
Backward O
Digit O
Span O
procedure O
(memory O
updating), O
Inhibition O
of O
Return O
(inhibition), O
an O
emotional O
intelligence O
scale, O
the O
Tromso O
Social O
Intelligence O
Scale O
and O
the O
Dysexecutive O
Questionnaire O
(DEX). O
Compared O
with O
MDMA-free O
polydrug O
controls, O
MDMA O
polydrug O
users O
showed O
impairments O
in O
set O
shifting O
and O
memory O
updating, O
and O
also O
in O
social O
and O
emotional O
judgement O
processes. O
The O
latter O
two O
deficits O
remained O
significant O
after O
controlling O
for O
other O
drug O
use. O
These O
data O
lend O
further O
support O
to O
the O
proposal O
that O
cognitive O
processes O
mediated O
by O
the O
prefrontal O
cortex O
may O
be O
impaired O
by O
recreational O
ecstasy O
use. O

Late O
recovery O
of O
renal O
function O
in O
a O
woman O
with O
the O
hemolytic B
uremic I
syndrome. I

We O
report O
on O
two O
fatal O
cases O
of O
accidental O
intrathecal O
vincristine O
instillation O
in O
a O
5-year O
old O
girl O
with O
recurrent O
acute B
lymphoblastic I
leucemia I
and O
a O
57-year O
old O
man O
with O
lymphoblastic B
lymphoma. I
The O
girl O
died O
seven O
days, O
the O
man O
four O
weeks O
after O
intrathecal O
injection O
of O
vincristine. O
Clinically, O
the O
onset O
was O
characterized O
by O
the O
signs O
of O
opistothonus, B
sensory B
and I
motor B
dysfunction I
and O
ascending O
paralysis. B
Histological O
and O
immunohistochemical O
investigations O
(HE-LFB, O
CD-68, O
Neurofilament) O
revealed O
degeneration B
of I
myelin I
and I
axons I
as O
well O
as O
pseudocystic B
transformation I
in O
areas O
exposed O
to O
vincristine, O
accompanied O
by O
secondary O
changes O
with O
numerous O
prominent O
macrophages. O
The O
clinical O
course O
and O
histopathological O
results O
of O
the O
two O
cases O
are O
presented. O
A O
review O
of O
all O
reported O
cases O
in O
the O
literature O
is O
given. O
A O
better O
controlled O
regimen O
for O
administering O
vincristine O
and O
intrathecal O
chemotherapy O
is O
recommended. O

Immune O
escape O
variants O
of O
the O
hepatitis B
B I
virus O
(HBV) O
represent O
an O
emerging O
clinical O
challenge, O
because O
they O
can O
be O
associated O
with O
vaccine O
escape, O
HBV O
reactivation, O
and O
failure O
of O
diagnostic O
tests. O
Recent O
data O
suggest O
a O
preferential O
selection O
of O
immune O
escape O
mutants O
in O
distinct O
peripheral O
blood O
leukocyte O
compartments O
of O
infected O
individuals. O
We O
therefore O
systematically O
analyzed O
the O
functional O
impact O
of O
the O
most O
prevalent O
immune O
escape O
variants, O
the O
sG145R O
and O
sP120T O
mutants, O
on O
the O
viral O
replication O
efficacy O
and O
antiviral O
drug O
susceptibility O
of O
common O
treatment-associated O
mutants O
with O
resistance O
to O
lamivudine O
(LAM) O
and/or O
HBeAg O
negativity. O
Replication-competent O
HBV O
strains O
with O
sG145R O
or O
sP120T O
and O
LAM O
resistance O
(rtM204I O
or O
rtL180M/rtM204V) O
were O
generated O
on O
an O
HBeAg-positive O
and O
an O
HBeAg-negative O
background O
with O
precore O
(PC) O
and O
basal O
core O
promoter O
(BCP) O
mutants. O
The O
sG145R O
mutation O
strongly O
reduced O
HBsAg O
levels O
and O
was O
able O
to O
fully O
restore O
the O
impaired O
replication O
of O
LAM-resistant O
HBV O
mutants O
to O
the O
levels O
of O
wild-type O
HBV, O
and O
PC O
or O
BCP O
mutations O
further O
enhanced O
viral O
replication. O
Although O
the O
sP120T O
substitution O
also O
impaired O
HBsAg O
secretion, O
it O
did O
not O
enhance O
the O
replication O
of O
LAM-resistant O
clones. O
However, O
the O
concomitant O
occurrence O
of O
HBeAg O
negativity O
(PC/BCP), O
sP120T, O
and O
LAM O
resistance O
resulted O
in O
the O
restoration O
of O
replication O
to O
levels O
of O
wild-type O
HBV. O
In O
all O
clones O
with O
combined O
immune O
escape O
and O
LAM O
resistance O
mutations, O
the O
nucleotide O
analogues O
adefovir O
and O
tenofovir O
remained O
effective O
in O
suppressing O
viral O
replication O
in O
vitro. O
These O
findings O
reveal O
the O
differential O
impact O
of O
immune O
escape O
variants O
on O
the O
replication O
and O
drug O
susceptibility O
of O
complex O
HBV O
mutants, O
supporting O
the O
need O
of O
close O
surveillance O
and O
treatment O
adjustment O
in O
response O
to O
the O
selection O
of O
distinct O
mutational O
patterns. O

Flestolol O
(ACC-9089) O
is O
a O
nonselective, O
competitive, O
ultra-short-acting O
beta-adrenergic O
blocking O
agent, O
without O
any O
intrinsic O
sympathomimetic O
activity. O
Flestolol O
is O
metabolized O
by O
plasma O
esterases O
and O
has O
an O
elimination O
half-life O
of O
approximately O
6.5 O
minutes. O
This O
agent O
was O
well O
tolerated O
in O
healthy O
volunteers O
at O
doses O
up O
to O
100 O
micrograms/kg/min. O
In O
long-term O
infusion O
studies, O
flestolol O
was O
well O
tolerated O
at O
the O
effective O
beta-blocking O
dose O
(5 O
micrograms/kg/min) O
for O
up O
to O
seven O
days. O
Flestolol O
blood O
concentrations O
increased O
linearly O
with O
increasing O
dose O
and O
good O
correlation O
exists O
between O
blood O
concentrations O
of O
flestolol O
and O
beta-adrenergic O
blockade. O
Flestolol O
produced O
a O
dose-dependent O
attenuation O
of O
isoproterenol-induced O
tachycardia. B
Electrophysiologic O
and O
hemodynamic O
effects O
of O
flestolol O
are O
similar O
to O
those O
of O
other O
beta O
blockers. O
In O
contrast O
with O
other O
beta O
blockers, O
flestolol-induced O
effects O
reverse O
rapidly O
(within O
30 O
minutes) O
following O
discontinuation O
because O
of O
its O
short O
half-life. O
Flestolol O
effectively O
reduced O
heart O
rate O
in O
patients O
with O
supraventricular B
tachyarrhythmia. I
In O
patients O
with O
unstable B
angina, I
flestolol O
infusion O
was O
found O
to O
be O
safe O
and O
effective O
in O
controlling O
chest B
pain. I
It O
is O
concluded O
that O
flestolol O
is O
a O
potent, O
well-tolerated, O
ultra-short-acting O
beta-adrenergic O
blocking O
agent. O
Use O
of O
flestolol O
in O
the O
critical O
care O
setting O
is O
currently O
undergoing O
investigation. O

The O
systolic O
pressure O
variation O
(SPV), O
which O
is O
the O
difference O
between O
the O
maximal O
and O
minimal O
values O
of O
the O
systolic O
blood O
pressure O
(SBP) O
after O
one O
positive-pressure O
breath, O
was O
studied O
in O
ventilated O
dogs O
subjected O
to O
hypotension. B
Mean O
arterial O
pressure O
was O
decreased O
to O
50 O
mm O
Hg O
for O
30 O
minutes O
either O
by O
hemorrhage B
(HEM, O
n B
= O
7) O
or O
by O
continuous O
infusion O
of O
sodium O
nitroprusside O
(SNP, O
n O
= O
7). O
During O
HEM-induced O
hypotension O
the O
cardiac O
output O
was O
significantly O
lower O
and O
systemic O
vascular O
resistance O
higher O
compared O
with O
that O
in O
the O
SNP O
group. O
The O
systemic, O
central O
venous, O
pulmonary O
capillary O
wedge O
pressures, O
and O
heart O
rates, O
were O
similar O
in O
the O
two O
groups. O
Analysis O
of O
the O
respiratory O
changes O
in O
the O
arterial O
pressure O
waveform O
enabled O
differentiation O
between O
the O
two O
groups. O
The O
SPV O
during O
hypotension O
was O
15.7 O
+/- O
6.7 O
mm O
Hg O
in O
the O
HEM O
group, O
compared O
with O
9.1 O
+/- O
2.0 O
mm O
Hg O
in O
the O
SNP O
group O
(P O
less O
than O
0.02). O
The O
delta O
down, O
which O
is O
the O
measure O
of O
decrease O
of O
SBP O
after O
a O
mechanical O
breath, O
was O
20.3 O
+/- O
8.4 O
and O
10.1 O
+/- O
3.8 O
mm O
Hg O
in O
the O
HEM O
and O
SNP O
groups, O
respectively, O
during O
hypotension O
(P O
less O
than O
0.02). O
It O
is O
concluded O
that O
increases O
in O
the O
SPV O
and O
the O
delta O
down O
are O
characteristic O
of O
a O
hypotensive B
state O
due O
to O
a O
predominant O
decrease O
in O
preload. O
They O
are O
thus O
more O
important O
during O
absolute O
hypovolemia B
than O
during O
deliberate O
hypotension. O

Epithelial O
sodium O
channel O
(ENaC) O
subunit O
mRNA O
and O
protein O
expression O
in O
rats O
with O
puromycin O
aminonucleoside-induced O
nephrotic B
syndrome. I

Atrial B
fibrillation I
is O
associated O
with O
substantial O
morbidity O
and O
mortality. O
Pooled O
data O
from O
trials O
comparing O
antithrombotic O
treatment O
with O
placebo O
have O
shown O
that O
warfarin O
reduces O
the O
risk O
of O
stroke B
by O
62%, O
and O
that O
aspirin O
alone O
reduces O
the O
risk O
by O
22%. O
Overall, O
in O
high-risk O
patients, O
warfarin O
is O
superior O
to O
aspirin O
in O
preventing O
strokes, B
with O
a O
relative O
risk O
reduction O
of O
36%. O
Ximelagatran, O
an O
oral O
direct O
thrombin O
inhibitor, O
was O
found O
to O
be O
as O
efficient O
as O
vitamin O
K O
antagonist O
drugs O
in O
the O
prevention O
of O
embolic B
events, I
but O
has O
been O
recently O
withdrawn O
because O
of O
abnormal B
liver I
function I
tests. O
The O
ACTIVE-W O
(Atrial O
Fibrillation B
Clopidogrel I
Trial O
with O
Irbesartan O
for O
Prevention O
of O
Vascular O
Events) O
study O
has O
demonstrated O
that O
warfarin O
is O
superior O
to O
platelet O
therapy O
(clopidogrel O
plus O
aspirin) O
in O
the O
prevention O
af O
embolic O
events. O
Idraparinux, O
a O
Factor O
Xa O
inhibitor, O
is O
being O
evaluated O
in O
patients O
with O
atrial B
fibrillation. I
Angiotensin-converting O
enzyme O
inhibitors O
and O
angiotensin O
II O
receptor-blocking O
drugs O
hold O
promise O
in O
atrial O
fibrillation O
through O
cardiac B
remodelling. I
Preliminary O
studies O
suggest O
that O
statins O
could O
interfere O
with O
the O
risk O
of O
recurrence O
after O
electrical O
cardioversion. O
Finally, O
percutaneous O
methods O
for O
the O
exclusion O
of O
left O
atrial O
appendage O
are O
under O
investigation O
in O
high-risk O
patients. O

A O
78-year-old O
with O
healed O
septal O
necrosis B
suffered O
a O
recurrent O
myocardial B
infarction I
of O
the O
anterior O
wall O
following O
the O
administration O
of O
isosorbide O
dinitrate O
5 O
mg O
sublingually. O
After O
detailing O
the O
course O
of O
events, O
we O
discuss O
the O
role O
of O
paradoxical O
coronary O
spasm B
and O
hypotension-mediated B
myocardial B
ischemia I
occurring O
downstream O
to O
significant O
coronary B
arterial I
stenosis I
in O
the O
pathophysiology O
of O
acute B
coronary I
insufficiency. I

Acute O
myocarditis B
associated O
with O
clozapine. O

Omitting O
fentanyl O
reduces O
nausea B
and O
vomiting, B
without O
increasing O
pain, B
after O
sevoflurane O
for O
day O
surgery. O

Neurotoxicity B
of O
halogenated O
hydroxyquinolines: O
clinical O
analysis O
of O
cases O
reported O
outside O
Japan. O

Incidence O
of O
neoplasms B
in O
patients O
with O
rheumatoid B
arthritis I
exposed O
to O
different O
treatment O
regimens. O

Risk O
factors O
of O
sensorineural B
hearing I
loss I
in O
preterm O
infants. O

D-penicillamine-induced O
angiopathy B
in O
rats. O
The O
effect O
of O
high O
dose O
D-penicillamine O
treatment O
on O
aortic O
permeability O
to O
albumin O
and O
on O
the O
ultrastructure O
of O
the O
vessel. O

Effects O
of O
calcium O
channel O
blockers O
on O
bupivacaine-induced O
toxicity. B

A O
study O
on O
the O
effect O
of O
the O
duration O
of O
subcutaneous O
heparin O
injection O
on O
bruising B
and O
pain. B

Compression B
neuropathy B
of I
the I
radial I
nerve I
due O
to O
pentazocine-induced O
fibrous B
myopathy. I

Development O
of O
levodopa-induced O
dyskinesias B
in O
parkinsonian B
monkeys O
may O
depend O
upon O
rate O
of O
symptom O
onset O
and/or O
duration O
of O
symptoms. O

IMPORTANCE O
OF O
THE O
FIELD: O
Fluoropyrimidines, O
in O
particular O
5-fluorouracil O
(5-FU), O
have O
been O
the O
mainstay O
of O
treatment O
for O
several O
solid O
tumors, B
including O
colorectal, B
breast B
and I
head B
and I
neck I
cancers, I
for O
> O
40 O
years. O
AREAS O
COVERED O
IN O
THIS O
REVIEW: O
This O
article O
reviews O
the O
pharmacology O
and O
efficacy O
of O
capecitabine O
with O
a O
special O
emphasis O
on O
its O
safety. O
WHAT O
THE O
READER O
WILL O
GAIN: O
The O
reader O
will O
gain O
better O
insight O
into O
the O
safety O
of O
capecitabine O
in O
special O
populations O
such O
as O
patients O
with O
advanced O
age, O
renal B
and I
kidney I
disease. I
We O
also O
explore O
different O
dosing O
and O
schedules O
of O
capecitabine O
administration. O
TAKE O
HOME O
MESSAGE: O
Capecitabine O
is O
an O
oral O
prodrug O
of O
5-FU O
and O
was O
developed O
to O
fulfill O
the O
need O
for O
a O
more O
convenient O
therapy O
and O
provide O
an O
improved O
safety/efficacy O
profile. O
It O
has O
shown O
promising O
results O
alone O
or O
in O
combination O
with O
other O
chemotherapeutic O
agents O
in O
colorectal, B
breast, I
pancreaticobiliary, B
gastric, B
renal B
cell I
and I
head I
and I
neck I
cancers. I
The O
most O
commonly O
reported O
toxic O
effects O
of O
capecitabine O
are O
diarrhea, B
nausea, B
vomiting, B
stomatitis B
and O
hand-foot B
syndrome. I
Capecitabine O
has O
a O
well-established O
safety O
profile O
and O
can O
be O
given O
safely O
to O
patients O
with O
advanced O
age, O
hepatic B
and I
renal B
dysfunctions. I

The O
present O
study O
aimed O
to O
investigate O
the O
anticonvulsant O
activity O
as O
well O
as O
the O
effects O
on O
the O
level O
of O
hippocampal O
amino O
acid O
neurotransmitters O
(glutamate, O
aspartate, O
glycine O
and O
GABA) O
of O
N-(2-propylpentanoyl)urea O
(VPU) O
in O
comparison O
to O
its O
parent O
compound, O
valproic O
acid O
(VPA). O
VPU O
was O
more O
potent O
than O
VPA, O
exhibiting O
the O
median O
effective O
dose O
(ED(50)) O
of O
49 O
mg/kg O
in O
protecting O
rats O
against O
pilocarpine-induced O
seizure B
whereas O
the O
corresponding O
value O
for O
VPA O
was O
322 O
mg/kg. O
In O
vivo O
microdialysis O
demonstrated O
that O
an O
intraperitoneal O
administration O
of O
pilocarpine O
induced O
a O
pronounced O
increment O
of O
hippocampal O
glutamate O
and O
aspartate O
whereas O
no O
significant O
change O
was O
observed O
on O
the O
level O
of O
glycine O
and O
GABA. O
Pretreatment O
with O
either O
VPU O
(50 O
and O
100 O
mg/kg) O
or O
VPA O
(300 O
and O
600 O
mg/kg) O
completely O
abolished O
pilocarpine-evoked O
increases O
in O
extracellular O
glutamate O
and O
aspartate. O
In O
addition, O
a O
statistically O
significant O
reduction O
was O
also O
observed O
on O
the O
level O
of O
GABA O
and O
glycine O
but O
less O
than O
a O
drastic O
reduction O
of O
glutamate O
and O
aspartate O
level. O
Based O
on O
the O
finding O
that O
VPU O
and O
VPA O
could O
protect O
the O
animals O
against O
pilocarpine-induced O
seizure O
it O
is O
suggested O
that O
the O
reduction O
of O
inhibitory O
amino O
acid O
neurotransmitters O
was O
comparatively O
minor O
and O
offset O
by O
a O
pronounced O
reduction O
of O
glutamate O
and O
aspartate. O
Therefore, O
like O
VPA, O
the O
finding O
that O
VPU O
could O
drastically O
reduce O
pilocarpine-induced O
increases O
in O
glutamate O
and O
aspartate O
should O
account, O
at O
least O
partly, O
for O
its O
anticonvulsant O
activity O
observed O
in O
pilocarpine-induced O
seizure O
in O
experimental O
animals. O
Some O
other O
mechanism O
than O
those O
being O
reported O
herein O
should O
be O
further O
investigated. O

The O
bronchodilator O
effects O
of O
a O
single O
dose O
of O
ipratropium O
bromide O
aerosol O
(36 O
micrograms) O
and O
short-acting O
theophylline O
tablets O
(dose O
titrated O
to O
produce O
serum O
levels O
of O
10-20 O
micrograms/mL) O
were O
compared O
in O
a O
double-blind, O
placebo-controlled O
crossover O
study O
in O
21 O
patients O
with O
stable, O
chronic B
obstructive I
pulmonary I
disease. I
Mean O
peak O
forced O
expiratory O
volume O
in O
1 O
second O
(FEV1) O
increases O
over O
baseline O
and O
the O
proportion O
of O
patients O
attaining O
at O
least O
a O
15% O
increase O
in O
the O
FEV1 O
(responders) O
were O
31% O
and O
90%, O
respectively, O
for O
ipratropium O
and O
17% O
and O
50%, O
respectively, O
for O
theophylline. O
The O
average O
FEV1 O
increases O
during O
the O
6-hour O
observation O
period O
were O
18% O
for O
ipratropium O
and O
8% O
for O
theophylline. O
The O
mean O
duration O
of O
action O
was O
3.8 O
hours O
with O
ipratropium O
and O
2.4 O
hours O
with O
theophylline. O
While O
side O
effects O
were O
rare, O
those O
experienced O
after O
theophylline O
use O
did O
involve O
the O
cardiovascular B
and I
gastrointestinal B
systems. I
These O
results O
show O
that O
ipratropium O
is O
a O
more O
potent O
bronchodilator O
than O
oral O
theophylline O
in O
patients O
with O
chronic B
airflow I
obstruction. I

Myasthenia B
gravis I
presenting O
as O
weakness O
after O
magnesium O
administration. O

BACKGROUND: O
patients O
undergoing O
electroconvulsive O
therapy O
(ECT) O
often O
receive O
succinylcholine O
as O
part O
of O
the O
anesthetic O
procedure. O
The O
duration O
of O
action O
may O
be O
prolonged O
in O
patients O
with O
genetic O
variants O
of O
the O
butyrylcholinesterase O
enzyme O
(BChE), O
the O
most O
common O
being O
the O
K- O
and O
the O
A-variants. O
The O
aim O
of O
the O
study O
was O
to O
assess O
the O
clinical O
significance O
of O
genetic O
variants O
in O
butyrylcholinesterase O
gene O
(BCHE) O
in O
patients O
with O
a O
suspected O
prolonged O
duration O
of O
action O
of O
succinylcholine O
after O
ECT. O
METHODS: O
a O
total O
of O
13 O
patients O
were O
referred O
to O
the O
Danish O
Cholinesterase O
Research O
Unit O
after O
ECT O
during O
38 O
months. O
We O
determined O
the O
BChE O
activity O
and O
the O
BCHE O
genotype O
using O
molecular O
genetic O
methods, O
the O
duration O
of O
apnea, B
time O
to O
sufficient O
spontaneous O
ventilation O
and O
whether O
neuromuscular O
monitoring O
was O
used. O
The O
duration O
of O
apnea O
was O
compared O
with O
published O
data O
on O
normal O
subjects. O
RESULTS: O
in O
11 O
patients, O
mutations O
were O
found O
in O
the O
BCHE O
gene, O
the O
K-variant O
being O
the O
most O
frequent. O
The O
duration O
of O
apnea O
was O
5-15 O
min O
compared O
with O
3-5.3 O
min O
from O
the O
literature. O
Severe O
distress O
was O
noted O
in O
the O
recovery O
phase O
in O
two O
patients. O
Neuromuscular O
monitoring O
was O
used O
in O
two O
patients. O
CONCLUSION: O
eleven O
of O
13 O
patients O
with O
a O
prolonged O
duration O
of O
action O
of O
succinylcholine O
had O
mutations O
in O
BCHE, O
indicating O
that O
this O
is O
the O
possible O
reason O
for O
a O
prolonged O
period O
of O
apnea. O
We O
recommend O
objective O
neuromuscular O
monitoring O
during O
the O
first O
ECT. O

A O
patient O
with O
cryptogenic O
cirrhosis B
and O
disseminated O
sporotrichosis B
developed O
acute B
renal I
failure I
immediately O
following O
the O
administration O
of O
amphotericin O
B O
on O
four O
separate O
occasions. O
The O
abruptness O
of O
the O
renal O
failure O
and O
its O
reversibility O
within O
days O
suggests O
that O
there O
was O
a O
functional O
component O
to O
the O
renal B
dysfunction. I
We O
propose O
that O
amphotericin, O
in O
the O
setting O
of O
reduced O
effective O
arterial O
volume, O
may O
activate O
tubuloglomerular O
feedback, O
thereby O
contributing O
to O
acute O
renal O
failure. O

Peripheral B
neuropathy B
has O
been O
noted O
as O
a O
complication O
of O
therapy O
with O
perhexiline O
maleate, O
a O
drug O
widely O
used O
in O
France O
(and O
in O
clinical O
trials O
in O
the O
United O
States) O
for O
the O
prophylactic O
treatment O
of O
angina B
pectoris. I
In O
24 O
patients O
with O
this O
complication, O
the O
marked O
slowing O
of O
motor O
nerve O
conduction O
velocity O
and O
the O
electromyographic O
changes O
imply O
mainly O
a O
demyelinating B
disorder. I
Improvement O
was O
noted O
with O
cessation O
of O
therapy. O
In O
a O
few O
cases O
the O
presence O
of O
active O
denervation O
signified O
a O
poor O
prognosis, O
with O
only O
slight O
improvement. O
The O
underlying O
mechanism O
causing O
the O
neuropathy O
is O
not O
yet O
fully O
known, O
although O
some O
evidence O
indicates O
that O
it O
may O
be O
a O
lipid O
storage O
process. O

Suxamethonium O
causes O
prolonged O
apnea B
in O
patients O
in O
whom O
pseudocholinesterase O
enzyme O
gets O
deactivated O
by O
organophosphorus O
(OP) O
poisons. O
Here, O
we O
present O
a O
similar O
incident O
in O
a O
severely O
depressed B
patient O
who O
received O
electroconvulsive O
therapy O
(ECT). O
Prolonged O
apnea O
in O
our O
case O
ensued O
because O
the O
information O
about O
suicidal O
attempt O
by O
OP O
compound O
was O
concealed O
from O
the O
treating O
team. O

The O
objective O
of O
this O
study O
was O
to O
report O
our O
experience O
concerning O
the O
effectiveness O
of O
the O
prophylactic O
administration O
of O
lamivudine O
in O
hepatitis B
B I
virus O
surface O
antigen O
(HBs O
Ag) O
positive O
patients O
with O
rheumatologic B
disease. I
From O
June O
2004 O
to O
October O
2006, O
11 O
HBs O
Ag O
positive O
patients O
with O
rheumatologic B
diseases, I
who O
were O
on O
both O
immunosuppressive O
and O
prophylactic O
lamivudine O
therapies, O
were O
retrospectively O
assessed. O
Liver O
function O
tests, O
hepatitis O
B O
virus O
(HBV) O
serologic O
markers, O
and O
HBV O
DNA O
levels O
of O
the O
patients O
during O
follow-up O
were O
obtained O
from O
hospital O
file O
records. O
Eleven O
patients O
(six O
male) O
with O
median O
age O
47 O
years O
(range O
27-73), O
median O
disease O
duration O
50 O
months O
(range O
9-178) O
and O
median O
follow-up O
period O
of O
patients O
13.8 O
months O
(range O
5-27) O
were O
enrolled O
in O
this O
study. O
Lamivudine O
therapy O
was O
started O
3-7 O
days O
prior O
to O
immunosuppressive O
therapy O
in O
all O
patients. O
Baseline, O
liver O
function O
tests O
were O
elevated O
in O
two O
patients O
(fourth O
patient: O
ALT:122 O
IU/l, O
AST:111 O
IU/l, O
tenth O
patient:ALT:294 O
IU/l, O
AST:274 O
IU/l, O
with O
minimal O
changes O
in O
the O
liver O
biopsy O
in O
both). O
Shortly O
after O
treatment O
their O
tests O
normalized O
and O
during O
follow-up O
period O
none O
of O
the O
patients O
had O
abnormal B
liver I
function I
tests. O
In O
four O
patients O
HBV O
DNA O
levels O
were O
higher O
than O
normal O
at O
baseline. O
Two O
of O
these O
normalized O
and O
the O
others O
increased O
later. O
In O
three O
additional O
patients, O
HBV O
DNA O
levels O
were O
increased O
during O
follow-up. O
None O
of O
the O
patients O
had O
significant O
clinical O
sings O
of O
HBV O
activation. O
Lamivudine O
was O
well O
tolerated O
and O
was O
continued O
in O
all O
patients. O
Prophylactic O
administration O
of O
lamivudine O
in O
patients O
who O
required O
immunosuppressive O
therapy O
seems O
to O
be O
safe, O
well O
tolerated O
and O
effective O
in O
preventing O
HBV O
reactivation. O

Among O
547 O
preterm O
infants O
of O
< O
or O
= O
34 O
weeks O
gestation O
born O
between O
1987 O
and O
1991, O
8 O
children O
(1.46%) O
developed O
severe O
progressive O
and O
bilateral O
sensorineural B
hearing B
loss. I
Perinatal O
risk O
factors O
of O
infants O
with O
hearing O
loss O
were O
compared O
with O
those O
of O
two O
control O
groups O
matched O
for O
gestation O
and O
birth O
weight O
and O
for O
perinatal O
complications. O
Our O
observations O
demonstrated O
an O
association O
of O
hearing O
loss O
with O
a O
higher O
incidence O
of O
perinatal O
complications. O
Ototoxicity B
appeared O
closely O
related O
to O
a O
prolonged O
administration O
and O
higher O
total O
dose O
of O
ototoxic B
drugs, O
particularly O
aminoglycosides O
and O
furosemide. O
Finally, O
we O
strongly O
recommend O
to O
prospectively O
and O
regularly O
perform O
audiologic O
assessment O
in O
sick O
preterm O
children O
as O
hearing O
loss O
is O
of O
delayed O
onset O
and O
in O
most O
cases O
bilateral O
and O
severe. O

Doxorubicin-induced O
nephropathy B
leads O
to O
epithelial O
sodium O
channel O
(ENaC)-dependent O
volume B
retention I
and O
renal O
fibrosis. B
The O
aldosterone-sensitive O
serum- O
and O
glucocorticoid-inducible O
kinase O
SGK1 O
has O
been O
shown O
to O
participate O
in O
the O
stimulation O
of O
ENaC O
and O
to O
mediate O
renal O
fibrosis O
following O
mineralocorticoid O
and O
salt O
excess. O
The O
present O
study O
was O
performed O
to O
elucidate O
the O
role O
of O
SGK1 O
in O
the O
volume O
retention O
and O
fibrosis O
during O
nephrotic B
syndrome. I
To O
this O
end, O
doxorubicin O
(15 O
mug/g O
body O
wt) O
was O
injected O
intravenously O
into O
gene-targeted O
mice O
lacking O
SGK1 O
(sgk1(-/-)) O
and O
their O
wild-type O
littermates O
(sgk1(+/+)). O
Doxorubicin O
treatment O
resulted O
in O
heavy O
proteinuria B
(>100 O
mg O
protein/mg O
crea) O
in O
15/44 O
of O
sgk1(+/+) O
and O
15/44 O
of O
sgk1(-/-) O
mice O
leading O
to O
severe O
nephrotic O
syndrome O
with O
ascites, B
lipidemia, B
and O
hypoalbuminemia B
in O
both O
genotypes. O
Plasma O
aldosterone O
levels O
increased O
in O
nephrotic O
mice O
of O
both O
genotypes O
and O
was O
followed O
by O
increased O
SGK1 O
protein O
expression O
in O
sgk1(+/+) O
mice. O
Urinary O
sodium O
excretion O
reached O
signficantly O
lower O
values O
in O
sgk1(+/+) O
mice O
(15 O
+/- O
5 O
mumol/mg O
crea) O
than O
in O
sgk1(-/-) O
mice O
(35 O
+/- O
5 O
mumol/mg O
crea) O
and O
was O
associated O
with O
a O
significantly O
higher O
body O
weight B
gain I
in O
sgk1(+/+) O
compared O
with O
sgk1(-/-) O
mice O
(+6.6 O
+/- O
0.7 O
vs. O
+4.1 O
+/- O
0.8 O
g). O
During O
the O
course O
of O
nephrotic O
syndrome, O
serum O
urea O
concentrations O
increased O
significantly O
faster O
in O
sgk1(-/-) O
mice O
than O
in O
sgk1(+/+) O
mice O
leading O
to O
uremia B
and O
a O
reduced O
median O
survival O
in O
sgk1(-/-) O
mice O
(29 O
vs. O
40 O
days O
in O
sgk1(+/+) O
mice). O
In O
conclusion, O
gene-targeted O
mice O
lacking O
SGK1 O
showed O
blunted O
volume O
retention, O
yet O
were O
not O
protected O
against O
renal O
fibrosis O
during O
experimental O
nephrotic O
syndrome. O

The O
illicit O
use O
of O
cocaine O
continues O
in O
epidemic O
proportions O
and O
treatment O
for O
cocaine B
overdose I
remains O
elusive. O
Current O
protein-based O
technology O
offers O
a O
new O
therapeutic O
venue O
by O
which O
antibodies O
bind O
the O
drug O
in O
the O
blood O
stream, O
inactivating O
its O
toxic O
effects. O
The O
therapeutic O
potential O
of O
the O
anticocaine O
antibody O
GNC92H2 O
was O
examined O
using O
a O
model O
of O
cocaine O
overdose. O
Swiss O
albino O
mice O
prepared O
with O
intrajugular O
catheters O
were O
tested O
in O
photocell O
cages O
after O
administration O
of O
93 O
mg/kg O
(LD50) O
of O
cocaine O
and O
GNC92H2 O
infusions O
ranging O
from O
30 O
to O
190 O
mg/kg. O
GNC92H2 O
was O
delivered O
30 O
min O
before, O
concomitantly O
or O
3 O
min O
after O
cocaine O
treatment. O
Significant O
blockade O
of O
cocaine O
toxicity B
was O
observed O
with O
the O
higher O
dose O
of O
GNC92H2 O
(190 O
mg/kg), O
where O
premorbid O
behaviors O
were O
reduced O
up O
to O
40%, O
seizures B
up O
to O
77% O
and O
death B
by O
72%. O
Importantly, O
GNC92H2 O
prevented O
death O
even O
post-cocaine O
injection. O
The O
results O
support O
the O
important O
potential O
of O
GNC92H2 O
as O
a O
therapeutic O
tool O
against O
cocaine O
overdose. O

Rhabdomyolysis B
is O
a O
potentially O
lethal O
syndrome O
that O
psychiatric B
patients O
seem O
predisposed O
to O
develop. O
The O
clinical O
signs O
and O
symptoms, O
typical O
laboratory O
features, O
and O
complications O
of O
rhabdomyolysis B
are O
presented. O
The O
case O
of O
a O
schizophrenic B
patient O
is O
reported O
to O
illustrate O
massive O
rhabdomyolysis O
and O
subsequent O
acute B
renal I
failure I
following O
molindone O
administration. O
Physicians O
who O
prescribe O
molindone O
should O
be O
aware O
of O
this O
reaction. O

Heparan O
sulphate-associated O
anionic O
sites O
in O
the O
glomerular O
basement O
membrane O
were O
studied O
in O
rats O
8 O
months O
after O
induction O
of O
diabetes B
by O
streptozotocin O
and O
in O
age- O
adn O
sex-matched O
control O
rats, O
employing O
the O
cationic O
dye O
cuprolinic O
blue. O
Morphometric O
analysis O
at O
the O
ultrastructural O
level O
was O
performed O
using O
a O
computerized O
image O
processor. O
The O
heparan O
sulphate O
specificity O
of O
the O
cuprolinic O
blue O
staining O
was O
demonstrated O
by O
glycosaminoglycan-degrading O
enzymes, O
showing O
that O
pretreatment O
of O
the O
sections O
with O
heparitinase O
abolished O
all O
staining, O
whereas O
chondroitinase O
ABC O
had O
no O
effect. O
The O
majority O
of O
anionic O
sites O
(74% O
in O
diabetic B
and O
81% O
in O
control O
rats) O
were O
found O
within O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane. O
A O
minority O
of O
anionic O
sites O
were O
scattered O
throughout O
the O
lamina O
densa O
and O
lamina O
rara O
interna, O
and O
were O
significantly O
smaller O
than O
those O
in O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
(p<0.001 O
and O
p<0.01 O
for O
diabetic O
and O
control O
rats, O
respectively). O
Diabetic B
rats O
progressively O
developed O
albuminuria B
reaching O
40.3 O
(32.2-62.0) O
mg/24 O
h O
after O
8 O
months O
in O
contrast O
to O
the O
control O
animals O
(0.8 O
(0.2-0.9) O
mg/24 O
h, O
p<0.002). O
At O
the O
same O
time, O
the O
number O
of O
heparan O
sulphate O
anionic O
sites O
and O
the O
total O
anionic O
site O
surface O
(number O
of O
anionic O
sites O
x O
mean O
anionic O
site O
surface) O
in O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
was O
reduced O
by O
19% O
(p<0.021) O
and O
by O
26% O
(p<0.02), O
respectively. O
Number O
and O
total O
anionic O
site O
surface O
in O
the O
remaining O
part O
of O
the O
glomerular O
basement O
membrane O
(lamina O
densa O
and O
lamina O
rara O
interna) O
were O
not O
significantly O
changed. O
We O
conclude O
that O
in O
streptozotocin-diabetic O
rats O
with O
an O
increased O
urinary O
albumin O
excretion, O
a O
reduced O
heparan O
sulphate O
charge O
barrier/density O
is O
found O
at O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane. O

Induction O
of O
intravascular B
coagulation I
and O
inhibition O
of O
fibrinolysis O
by O
injection O
of O
thrombin O
and O
tranexamic O
acid O
(AMCA) O
in O
the O
rat O
gives O
rise O
to O
pulmonary B
and I
renal B
insufficiency I
resembling O
that O
occurring O
after O
trauma B
or O
sepsis B
in O
man. O
Injection O
of O
Captopril O
(1 O
mg/kg), O
an O
inhibitor O
of O
angiotensin O
converting O
enzyme O
(ACE), O
reduced O
both O
pulmonary O
and O
renal O
insufficiency O
in O
this O
rat O
model. O
The O
lung O
weights O
were O
lower O
and O
PaO2 O
was O
improved O
in O
rats O
given O
this O
enzyme-blocking O
agent. O
The O
contents O
of O
albumin O
in O
the O
lungs O
were O
not O
changed, O
indicating O
that O
Captopril O
did O
not O
influence O
the O
extravasation O
of O
protein. O
Renal B
damage I
as O
reflected O
by O
an O
increase O
in O
serum O
urea O
and O
in O
kidney O
weight O
was O
prevented O
by O
Captopril. O
The O
amount O
of O
fibrin O
in O
the O
kidneys O
was O
also O
considerably O
lower O
than O
in O
animals O
which O
received O
thrombin O
and O
AMCA O
alone. O
It O
is O
suggested O
that O
the O
effects O
of O
Captopril O
on O
the O
lungs O
may O
be O
attributable O
to O
a O
vasodilatory O
effect O
due O
to O
a O
reduction O
in O
the O
circulating O
level O
of O
Angiotension O
II O
and O
an O
increase O
in O
prostacyclin O
(secondary O
to O
an O
increase O
in O
bradykinin). O
Captopril O
may, O
by O
the O
same O
mechanism, O
reduce O
the O
increase O
in O
glomerular O
filtration O
that O
is O
known O
to O
occur O
after O
an O
injection O
of O
thrombin, O
thereby O
diminishing O
the O
aggregation O
of O
fibrin O
monomers O
in O
the O
glomeruli, O
with O
the O
result O
that O
less O
fibrin O
will O
be O
deposited O
and O
thus O
less O
kidney B
damage I
will O
be O
produced. O

BACKGROUND: O
Cyclooxygenase O
(COX) O
inhibitors O
are O
one O
of O
the O
most O
often O
ingested O
drugs O
during O
pregnancy. O
Unlike O
general O
toxicity B
data, O
their O
prenatal O
toxic O
effects O
were O
not O
extensively O
studied O
before. O
The O
aim O
of O
the O
experiment O
was O
to O
evaluate O
the O
developmental O
toxicity O
of O
the O
non-selective O
(piroxicam) O
and O
selective O
(DFU; O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) O
phenyl-2(5H)-furanon) O
COX-2 O
inhibitors. O
METHODS: O
Drugs O
were O
separately, O
orally O
once O
daily O
dosed O
to O
pregnant O
rats O
from O
day O
8 O
to O
21 O
(GD1=plug O
day). O
Doses O
were O
set O
at O
0.3, O
3.0 O
and O
30.0mg/kg O
for O
piroxicam O
and O
0.2, O
2.0 O
and O
20.0mg/kg O
for O
DFU. O
Fetuses O
were O
delivered O
on O
GD O
21 O
and O
routinely O
examined. O
Comprehensive O
clinical O
and O
developmental O
measurements O
were O
done. O
The O
pooled O
statistical O
analysis O
for O
ventricular B
septal I
(VSD) I
and I
midline B
(MD) I
defects I
was O
performed O
for O
rat O
fetuses O
exposed O
to O
piroxicam, O
selective O
and O
non-selective O
COX-2 O
inhibitor O
based O
on O
present O
and O
historic O
data. O
RESULTS: O
Maternal O
toxicity, O
intrauterine B
growth I
retardation, I
and O
increase B
of I
external I
and I
skeletal I
variations I
were O
found O
in O
rats O
treated O
with O
the O
highest O
dose O
of O
piroxicam. O
Decrease O
of O
fetal O
length O
was O
the O
only O
signs O
of O
the O
DFU O
developmental O
toxicity O
observed O
in O
pups O
exposed O
to O
the O
highest O
compound O
dose. O
Lack O
of O
teratogenicity O
was O
found O
in O
piroxicam O
and O
DFU-exposed O
groups. O
Prenatal O
exposure O
to O
non-selective O
COX O
inhibitors O
increases O
the O
risk O
of O
VSD O
and O
MD O
when O
compared O
to O
historic O
control O
but O
not O
with O
selective O
COX-2 O
inhibitors. O
CONCLUSION: O
Both O
selective O
and O
non-selective O
COX-2 O
inhibitors O
were O
toxic O
for O
rats O
fetuses O
when O
administered O
in O
the O
highest O
dose. O
Unlike O
DFU, O
piroxicam O
was O
also O
highly O
toxic O
to O
the O
dams. O
Prenatal O
exposure O
to O
selective O
COX-2 O
inhibitors O
does O
not O
increase O
the O
risk O
of O
ventricular B
septal I
and I
midline B
defects I
in O
rat O
when O
compared O
to O
non-selective O
drugs O
and O
historic O
control. O

Delirium B
during O
clozapine O
treatment: O
incidence O
and O
associated O
risk O
factors. O

OBJECTIVE: O
To O
describe O
a O
case O
of O
propylthiouracil-induced O
vasculitis B
manifesting O
with O
pericarditis. B
METHODS: O
We O
present O
the O
first O
case O
report O
of O
a O
woman O
with O
hyperthyroidism B
treated O
with O
propylthiouracil O
in O
whom O
a O
syndrome O
of O
pericarditis, O
fever, B
and O
glomerulonephritis B
developed. O
Serologic O
testing O
and O
immunologic O
studies O
were O
done, O
and O
a O
pericardial O
biopsy O
was O
performed. O
RESULTS: O
A O
25-year-old O
woman O
with O
Graves' B
disease I
had O
a O
febrile B
illness I
and O
evidence O
of O
pericarditis, O
which O
was O
confirmed O
by O
biopsy. O
Serologic O
evaluation O
revealed O
the O
presence O
of O
perinuclear-staining O
antineutrophil O
cytoplasmic O
autoantibodies O
(pANCA) O
against O
myeloperoxidase O
(MPO). O
Propylthiouracil O
therapy O
was O
withdrawn, O
and O
she O
was O
treated O
with O
a O
1-month O
course O
of O
prednisone, O
which O
alleviated O
her O
symptoms. O
A O
literature O
review O
revealed O
no O
prior O
reports O
of O
pericarditis O
in O
anti-MPO O
pANCA-positive O
vasculitis O
associated O
with O
propylthio- O
uracil O
therapy. O
CONCLUSION: O
Pericarditis B
may O
be O
the O
initial O
manifestation O
of O
drug-induced O
vasculitis O
attributable O
to O
propylthio- O
uracil O
therapy. O

Cross-sectional O
echocardiography O
was O
used O
to O
evaluate O
two O
neonates O
whose O
mothers O
ingested O
lithium O
during O
pregnancy. O
In O
one O
infant, O
Ebstein's B
anomaly I
of O
the O
tricuspid O
valve O
was O
identified. O
In O
the O
other O
infant O
cross-sectional O
echocardiography O
provided O
reassurance O
that O
the O
infant O
did O
not O
have O
Ebstein's O
anomaly. O
Cross-sectional O
echocardiographic O
screening O
of O
newborns O
exposed O
to O
lithium O
during O
gestation O
can O
provide O
highly O
accurate, O
noninvasive O
assessment O
of O
the O
presence O
or O
absence O
of O
lithium-induced O
cardiac B
malformations. I

BACKGROUND: O
Lithium O
remains O
a O
first-line O
treatment O
for O
the O
acute O
and O
maintenance O
treatment O
of O
bipolar B
disorder. I
Although O
much O
has O
been O
written O
about O
the O
management O
of O
the O
more O
common O
adverse O
effects O
of O
lithium, O
such O
as O
polyuria B
and O
tremor, B
more O
subtle O
lithium O
side O
effects O
such O
as O
cognitive B
deficits, I
loss B
of I
creativity, I
and O
functional B
impairments I
remain O
understudied. O
This O
report O
summarizes O
our O
experience O
in O
switching O
bipolar O
patients O
from O
lithium O
to O
divalproex O
sodium O
to O
alleviate O
such O
cognitive B
and I
functional I
impairments. I
METHOD: O
Open, O
case O
series O
design. O
RESULTS: O
We O
report O
seven O
cases O
where O
substitution O
of O
lithium, O
either O
fully O
or O
partially, O
with O
divalproex O
sodium O
was O
extremely O
helpful O
in O
reducing O
the O
cognitive, B
motivational, I
or I
creative I
deficits I
attributed O
to O
lithium O
in O
our O
bipolar O
patients. O
CONCLUSION: O
In O
this O
preliminary O
report, O
divalproex O
sodium O
was O
a O
superior O
alternative O
to O
lithium O
in O
bipolar O
patients O
experiencing O
cognitive O
deficits, O
loss O
of O
creativity, O
and O
functional O
impairments. O

The O
risk O
of O
developing O
renal B
papillary I
necrosis I
or O
cancer B
of I
the I
renal I
pelvis, I
ureter I
or I
bladder I
associated O
with O
consumption O
of O
either O
phenacetin O
or O
paracetamol O
was O
calculated O
from O
data O
acquired O
by O
questionnaire O
from O
381 O
cases O
and O
808 O
controls. O
The O
risk O
of O
renal O
papillary O
necrosis O
was O
increased O
nearly O
20-fold O
by O
consumption O
of O
phenacetin, O
which O
also O
increased O
the O
risk O
for O
cancer B
of I
the I
renal I
pelvis I
and I
bladder I
but O
not O
for O
ureteric B
cancer. I
By O
contrast, O
we O
were O
unable O
to O
substantiate O
an O
increased O
risk O
from O
paracetamol O
consumption O
for O
renal O
papillary O
necrosis O
or O
any O
of O
these O
cancers B
although O
there O
was O
a O
suggestion O
of O
an O
association O
with O
cancer B
of I
the I
ureter. I

Adverse O
effect O
of O
the O
calcium O
channel O
blocker O
nitrendipine O
on O
nephrosclerosis B
in O
rats O
with O
renovascular B
hypertension. I

Two O
cases O
of O
clear B
cell I
adenocarcinoma B
of B
the I
vagina I
detected O
at O
follow-up O
in O
young O
women O
exposed O
in O
utero O
to O
diethylstilbestrol O
are O
reported. O
One O
patient, O
aged O
23, O
had O
been O
followed O
for O
2 O
years O
before O
carcinoma O
was O
diagnosed; O
the O
second O
patient, O
aged O
22, O
had O
been O
seen O
on O
a O
regular O
basis O
for O
5 O
years, O
8 O
months. O
In O
both O
instances, O
suspicion O
of O
the O
presence O
of O
carcinoma O
was O
aroused O
by O
the O
palpation O
of O
a O
small O
nodule O
in O
the O
vaginal O
fornix. O
Hysterosalpingography O
was O
performed O
on O
both O
patients O
and, O
in O
1 O
instance, O
an O
abnormal O
x-ray O
film O
was O
reflected O
by O
the O
gross O
appearance O
of O
the O
uterine O
cavity O
found O
in O
the O
surgical O
specimen. O

A O
series O
of O
N-pyrimidinyl-2-phenoxyacetamide O
adenosine O
A(2A) O
antagonists O
is O
described. O
SAR O
studies O
led O
to O
compound O
14 O
with O
excellent O
potency O
(K(i) O
= O
0.4 O
nM), O
selectivity O
(A(1)/A(2A) O
> O
100), O
and O
efficacy O
(MED O
10 O
mg/kg O
p.o.) O
in O
the O
rat O
haloperidol-induced O
catalepsy B
model O
for O
Parkinson's B
disease. I

Treatment O
of O
tinnitus B
by O
intratympanic O
instillation O
of O
lignocaine O
(lidocaine) O
2 O
per O
cent O
through O
ventilation O
tubes. O

A O
17-day-old O
infant O
on O
isoniazid O
therapy O
13 O
mg/kg O
daily O
from O
birth O
because O
of O
maternal O
tuberculosis B
was O
admitted O
after O
4 O
days O
of O
clonic B
fits. B
No O
underlying O
infective O
or O
biochemical O
cause O
could O
be O
found. O
The O
fits O
ceased O
within O
4 O
hours O
of O
administering O
intramuscular O
pyridoxine, O
suggesting O
an O
aetiology O
of O
pyridoxine O
deficiency O
secondary O
to O
isoniazid O
medication. O

Patterns O
of O
hepatic B
injury I
induced O
by O
methyldopa. O

Cerebral O
blood O
flow O
and O
cerebral O
metabolic O
rate O
for O
oxygen O
were O
measured O
during O
isoflurane-induced O
hypotension B
in O
10 O
patients O
subjected O
to O
craniotomy O
for O
clipping O
of O
a O
cerebral B
aneurysm. B
Flow O
and O
metabolism O
were O
measured O
5-13 O
days O
after O
the O
subarachnoid B
haemorrhage I
by O
a O
modification O
of O
the O
classical O
Kety-Schmidt O
technique O
using O
xenon-133 O
i.v. O
Anaesthesia O
was O
maintained O
with O
an O
inspired O
isoflurane O
concentration O
of O
0.75% O
(plus O
67% O
nitrous O
oxide O
in O
oxygen), O
during O
which O
CBF O
and O
CMRO2 O
were O
34.3 O
+/- O
2.1 O
ml/100 O
g O
min-1 O
and O
2.32 O
+/- O
0.16 O
ml/100 O
g O
min-1 O
at O
PaCO2 O
4.1 O
+/- O
0.1 O
kPa O
(mean O
+/- O
SEM). O
Controlled O
hypotension O
to O
an O
average O
MAP O
of O
50-55 O
mm O
Hg O
was O
induced O
by O
increasing O
the O
dose O
of O
isoflurane, O
and O
maintained O
at O
an O
inspired O
concentration O
of O
2.2 O
+/- O
0.2%. O
This O
resulted O
in O
a O
significant O
decrease O
in O
CMRO2 O
(to O
1.73 O
+/- O
0.16 O
ml/100 O
g O
min-1), O
while O
CBF O
was O
unchanged. O
After O
the O
clipping O
of O
the O
aneurysm O
the O
isoflurane O
concentration O
was O
reduced O
to O
0.75%. O
There O
was O
a O
significant O
increase O
in O
CBF, O
although O
CMRO2 O
was O
unchanged, O
compared O
with O
pre-hypotensive O
values. B
These O
changes O
might O
offer O
protection O
to O
brain O
tissue O
during O
periods O
of O
induced O
hypotension. O

Elevation O
of O
ADAM10, O
ADAM17, O
MMP-2 O
and O
MMP-9 O
expression O
with O
media O
degeneration O
features O
CaCl2-induced O
thoracic B
aortic I
aneurysm I
in O
a O
rat O
model. O

MR O
imaging O
with O
quantitative O
diffusion O
mapping O
of O
tacrolimus-induced O
neurotoxicity B
in O
organ O
transplant O
patients. O

AIM: O
The O
aim O
of O
the O
documentation O
of O
this O
clinical O
case O
is O
to O
make O
clinicians O
aware O
of O
"meth O
mouth" B
and I
the O
medical O
risks O
associated O
with O
this O
serious O
condition. O
BACKGROUND: O
Methamphetamine O
is O
a O
very O
addictive, O
powerful O
stimulant O
that O
increases O
wakefulness O
and O
physical O
activity O
and O
can O
produce O
other O
effects O
such O
as O
cardiac B
dysrhythmias, I
hypertension, B
hallucinations, B
and O
violent B
behavior. I
Dental O
patients O
abusing O
methamphetamine O
can O
present O
with O
poor O
oral O
hygiene, O
xerostomia, B
rampant O
caries B
("meth O
mouth"), O
and O
excessive O
tooth B
wear. I
Oral O
rehabilitation O
of O
patients O
using O
methamphetamine O
can O
be O
challenging. O
CASE O
DESCRIPTION: O
A O
30-year-old O
Caucasian O
woman O
presented O
with O
dental O
pain, B
bad B
breath, I
and O
self-reported O
poor O
esthetics. O
A O
comprehensive O
examination O
including O
her O
medical O
history, O
panoramic O
radiograph, O
and O
intraoral O
examination O
revealed O
19 O
carious B
lesions, I
which O
is O
not O
very O
common O
for O
a O
healthy O
adult. O
She O
reported O
her O
use O
of O
methamphetamine O
for O
five O
years O
and O
had O
not O
experienced O
any O
major O
carious B
episodes I
before O
she O
started O
using O
the O
drug. O
SUMMARY: O
The O
patient's O
medical O
and O
dental O
histories O
along O
with O
radiographic O
and O
clinical O
findings O
lead O
to O
a O
diagnosis O
of O
"meth O
mouth." O
Although O
three O
different O
dental O
treatment O
modalities O
(either O
conventional O
or O
implant-supported) O
have O
been O
offered O
to O
the O
patient O
since O
August O
2007, O
the O
patient O
has O
yet O
to O
initiate O
any O
treatment. O
CLINICAL O
SIGNIFICANCE: O
This O
clinical O
case O
showing O
oral O
manifestations O
of O
meth O
mouth O
was O
presented O
to O
help O
dental O
practitioners O
recognize O
and O
manage O
patients O
who O
may O
be O
abusing O
methamphetamines. O
Dental O
practitioners O
also O
may O
be O
skeptical O
about O
the O
reliability O
of O
appointment O
keeping O
by O
these O
patients, O
as O
they O
frequently O
miss O
their O
appointments O
without O
reasonable O
justification. O

Perhexiline O
maleate O
and O
peripheral B
neuropathy. I

Hyperkalemia B
has O
recently O
been O
recognized O
as O
a O
complication O
of O
nonsteroidal O
antiinflammatory O
agents O
(NSAID) O
such O
as O
indomethacin. O
Several O
recent O
studies O
have O
stressed O
the O
renal O
sparing O
features O
of O
sulindac, O
owing O
to O
its O
lack O
of O
interference O
with O
renal O
prostacyclin O
synthesis. O
We O
describe O
4 O
patients O
in O
whom O
hyperkalemia B
ranging O
from O
6.1 O
to O
6.9 O
mEq/l O
developed O
within O
3 O
to O
8 O
days O
of O
sulindac O
administration. O
In O
all O
of O
them O
normal O
serum O
potassium O
levels O
reached O
within O
2 O
to O
4 O
days O
of O
stopping O
sulindac. O
As O
no O
other O
medications O
known O
to O
effect O
serum O
potassium O
had O
been O
given O
concomitantly, O
this O
course O
of O
events O
is O
suggestive O
of O
a O
cause-and-effect O
relationship O
between O
sulindac O
and O
hyperkalemia. O
These O
observations O
indicate O
that O
initial O
hopes O
that O
sulindac O
may O
not O
be O
associated O
with O
the O
adverse O
renal O
effects O
of O
other O
NSAID O
are O
probably O
not O
justified. O

Partial O
lesions O
were O
made O
with O
kainic O
acid O
in O
the O
interpeduncular O
nucleus O
of O
the O
ventral O
midbrain O
of O
the O
rat. O
Compared O
with O
sham-operated O
controls, O
lesions O
significantly O
(p O
< O
0.25) O
blunted O
the O
early O
(<60 O
min) O
free-field O
locomotor B
hypoactivity I
caused O
by O
nicotine O
(0.5 O
mg O
kg(-1), O
i.m.), O
enhanced O
the O
later O
(60-120 O
min) O
nicotine-induced O
hyperactivity, B
and O
raised O
spontaneous O
nocturnal O
activity. O
Lesions O
reduced O
the O
extent O
of O
immunohistological O
staining O
for O
choline O
acetyltransferase O
in O
the O
interpeduncular O
nucleus O
(p O
<0.025), O
but O
not O
for O
tyrosine O
hydroxylase O
in O
the O
surrounding O
catecholaminergic O
A10 O
region. O
We O
conclude O
that O
the O
interpeduncular O
nucleus O
mediates O
nicotinic O
depression B
of O
locomotor O
activity O
and O
dampens O
nicotinic O
arousal O
mechanisms O
located O
elsewhere O
in O
the O
brain. O

Idiopathic B
subjective I
tinnitus B
(IST) O
is B
one O
of O
the O
most O
obscure O
otological O
pathologies. O
This O
paper O
presents O
the O
results O
of O
treating O
IST O
by O
intratympanic O
instillation O
of O
lignocaine O
(lidocaine) O
2 O
per O
cent O
through O
a O
grommet, O
for O
five O
weekly O
courses. O
Fifty-two O
patients O
suffering O
from O
intractable O
tinnitus O
entered O
this O
therapeutic O
trial, O
but O
only O
nine O
finished O
all O
five O
courses. O
In O
one O
patient, O
the O
tinnitus O
was O
almost O
completely O
abolished, O
but O
in O
all O
the O
nine O
patients O
the O
decompensated O
tinnitus O
changed O
to O
a O
compensated O
one. O
We O
suggest O
this O
mode O
of O
treatment O
for O
patients O
that O
were O
previously O
treated O
by O
drugs, O
acupuncture O
and O
biofeedback, O
with O
disappointing O
results. O
Patients O
should O
be O
warned O
about O
the O
side O
effects O
of O
vertigo B
and O
vomiting, B
which O
subsides O
gradually O
with O
every O
new O
instillation, O
and O
that O
the O
tinnitus O
may O
not O
disappear O
but O
will O
be O
alleviated, O
enabling O
them O
to O
cope O
more O
easily O
with O
the O
disease O
and O
lead O
a O
more O
normal O
life. O

Pulmonary O
shunt O
and O
cardiovascular O
responses O
to O
CPAP O
during O
nitroprusside-induced O
hypotension. B

OBJECTIVE: O
This O
is O
to O
present O
reversible O
inferior B
colliculus I
lesions I
in O
metronidazole-induced O
encephalopathy, B
to O
focus O
on O
the O
diffusion-weighted O
imaging O
(DWI) O
and O
fluid O
attenuated O
inversion O
recovery O
(FLAIR) O
imaging. O
MATERIALS O
AND O
METHODS: O
From O
November O
2005 O
to O
September O
2007, O
8 O
patients O
(5 O
men O
and O
3 O
women) O
were O
diagnosed O
as O
having O
metronidazole-induced O
encephalopathy O
(age O
range; O
43-78 O
years). O
They O
had O
been O
taking O
metronidazole O
(total O
dosage, O
45-120 O
g; O
duration, O
30 O
days O
to O
2 O
months) O
to O
treat O
the O
infection B
in O
various O
organs. O
Initial O
brain O
magnetic O
resonance O
imaging O
(MRI) O
were O
obtained O
after O
the O
hospitalization, O
including O
DWI O
(8/8), O
apparent O
diffusion O
coefficient O
(ADC) O
map O
(4/8), O
FLAIR O
(7/8), O
and O
T2-weighted O
image O
(8/8). O
Follow-up O
MRIs O
were O
performed O
on O
5 O
patients O
from O
third O
to O
14th O
days O
after O
discontinuation O
of O
metronidazole O
administration. O
Findings O
of O
initial O
and O
follow-up O
MRIs O
were O
retrospectively O
evaluated O
by O
2 O
neuroradiologists O
by O
consensus, O
to O
analyze O
the O
presence O
of O
abnormal O
signal O
intensities, O
their O
locations, O
and O
signal O
changes O
on O
follow-up O
images. O
RESULTS: O
Initial O
MRIs O
showed O
abnormal O
high O
signal O
intensities O
on O
DWI O
and O
FLAIR O
(or O
T2-weighted O
image) O
at O
the O
dentate O
nucleus O
(8/8), O
inferior O
colliculus O
(6/8), O
corpus O
callosum O
(2/8), O
pons O
(2/8), O
medulla O
(1/8), O
and O
bilateral O
cerebral O
white O
matter O
(1/8). O
High-signal O
intensity O
lesions O
on O
DWI O
tended O
to O
show O
low O
signal O
intensity O
on O
ADC O
map O
(3/4), O
but O
in O
one O
patient, O
high O
signal O
intensity O
was O
shown O
at O
bilateral O
dentate O
nuclei O
on O
not O
only O
DWI O
but O
also O
ADC O
map. O
All O
the O
lesions O
in O
dentate, O
inferior O
colliculus, O
pons, O
and O
medullas O
had O
been O
resolved O
completely O
on O
follow-up O
MRIs O
in O
5 O
patients, O
but O
in O
1 O
patient O
of O
them, O
corpus O
callosal B
lesion I
persisted. O
CONCLUSIONS: O
Reversible O
inferior O
colliculus O
lesions O
could O
be O
considered O
as O
the O
characteristic O
for O
metronidazole-induced O
encephalopathy, O
next O
to O
the O
dentate O
nucleus O
involvement. O

BACKGROUND: O
Direct O
thrombin O
inhibitors O
(DTIs) O
provide O
an O
alternative O
method O
of O
anticoagulation O
for O
patients O
with O
a O
history O
of O
heparin-induced O
thrombocytopenia B
(HIT) O
or B
HIT O
with O
thrombosis B
(HITT) O
undergoing B
cardiopulmonary O
bypass O
(CPB). O
In O
the O
following O
report, O
a O
65-year-old O
critically B
ill I
patient O
with O
a O
suspected O
history O
of O
HITT O
was O
administered O
argatroban O
for O
anticoagulation O
on O
bypass O
during O
heart O
transplantation. O
The O
patient O
required O
massive O
transfusion O
support O
(55 O
units O
of O
red O
blood O
cells, O
42 O
units O
of O
fresh-frozen O
plasma, O
40 O
units O
of O
cryoprecipitate, O
40 O
units O
of O
platelets, O
and O
three O
doses O
of O
recombinant O
Factor O
VIIa) O
for O
severe O
intraoperative B
and I
postoperative B
bleeding. I
STUDY O
DESIGN O
AND O
METHODS: O
Plasma O
samples O
from O
before O
and O
after O
CPB O
were O
analyzed O
postoperatively O
for O
argatroban O
concentration O
using O
a O
modified O
ecarin O
clotting O
time O
(ECT) O
assay. O
RESULTS: O
Unexpectedly O
high O
concentrations O
of O
argatroban O
were O
measured O
in O
these O
samples O
(range, O
0-32 O
microg/mL), O
and O
a O
prolonged O
plasma O
argatroban O
half O
life O
(t(1/2)) O
of O
514 O
minutes O
was O
observed O
(published O
elimination O
t(1/2) O
is O
39-51 O
minutes O
[< O
or O
= O
181 O
minutes O
with O
hepatic B
impairment]). I
CONCLUSIONS: O
Correlation O
of O
plasma O
argatroban O
concentration O
versus O
the O
patient's O
coagulation O
variables O
and O
clinical O
course O
suggest O
that O
prolonged O
elevated O
levels O
of O
plasma O
argatroban O
may O
have O
contributed O
to O
the O
patient's O
extended O
coagulopathy. B
Because O
DTIs O
do O
not O
have O
reversal O
agents, O
surgical O
teams O
and O
transfusion O
services O
should O
remain O
aware O
of O
the O
possibility O
of O
massive O
transfusion O
events O
during O
anticoagulation O
with O
these O
agents. O
This O
is O
the O
first O
report O
to O
measure O
plasma O
argatroban O
concentration O
in O
the O
context O
of O
CPB O
and O
extended O
coagulopathy. O

Ginsenoside O
Rg1 O
restores O
the O
impairment B
of I
learning I
induced O
by O
chronic O
morphine O
administration O
in O
rats. O

To O
clarify O
the O
effects O
of O
bromocriptine O
on O
prolactinoma B
cells O
in O
vivo, O
immunohistochemical, O
ultrastructural O
and O
morphometrical O
analyses O
were O
applied O
to O
estrogen-induced O
rat O
prolactinoma O
cells O
1 O
h O
and O
6 O
h O
after O
injection O
of O
bromocriptine O
(3 O
mg/kg O
of O
body O
weight). O
One O
h O
after O
treatment, O
serum O
prolactin O
levels O
decreased O
markedly. O
Electron O
microscopy O
disclosed O
many O
secretory O
granules, O
slightly O
distorted O
rough O
endoplasmic O
reticulum, O
and O
partially O
dilated O
Golgi O
cisternae O
in O
the O
prolactinoma O
cells. O
Morphometric O
analysis O
revealed O
that O
the O
volume O
density O
of O
secretory O
granules O
increased, O
while O
the O
volume O
density O
of O
cytoplasmic O
microtubules O
decreased. O
These O
findings O
suggest O
that O
lowered O
serum O
prolactin O
levels O
in O
the O
early O
phase O
of O
bromocriptine O
treatment O
may O
result O
from O
an O
impaired O
secretion O
of O
prolactin O
due O
to O
decreasing O
numbers O
of O
cytoplasmic O
microtubules. O
At O
6 O
h O
after O
injection, O
serum O
prolactin O
levels O
were O
still O
considerably O
lower O
than O
in O
controls. O
The O
prolactinoma O
cells O
at O
this O
time O
were O
well O
granulated, O
with O
vesiculated O
rough O
endoplasmic O
reticulum O
and O
markedly O
dilated O
Golgi O
cisternae. O
Electron O
microscopical O
immunohistochemistry O
revealed O
positive O
reaction O
products O
noted O
on O
the O
secretory O
granules, O
Golgi O
cisternae, O
and O
endoplasmic O
reticulum O
of O
the O
untreated O
rat O
prolactinoma O
cells. O
However, O
only O
secretory O
granules O
showed O
the O
positive O
reaction O
products O
for O
prolactin O
6 O
h O
after O
bromocriptine O
treatment O
of O
the O
adenoma B
cells. O
An O
increase O
in O
the O
volume O
density O
of O
secretory O
granules O
and O
a O
decrease O
in O
the O
volume O
densities O
of O
rough O
endoplasmic O
reticulum O
and O
microtubules O
was O
determined O
by O
morphometric O
analysis, O
suggesting O
that O
bromocriptine O
inhibits O
protein O
synthesis O
as O
well O
as O
bringing O
about O
a O
disturbance O
of O
the O
prolactin O
secretion. O

Renal B
Fanconi I
syndrome I
and O
myopathy B
after O
liver O
transplantation: O
drug-related O
mitochondrial B
cytopathy? I

Effects O
of O
5-HT1B O
receptor O
ligands O
microinjected O
into O
the O
accumbal O
shell O
or O
core O
on O
the O
cocaine-induced O
locomotor B
hyperactivity I
in O
rats. O

Effect O
of O
some O
anticancer O
drugs O
and O
combined O
chemotherapy O
on O
renal B
toxicity. I

Pharmacokinetic O
and O
clinical O
studies O
in O
patients O
with O
cimetidine-associated O
mental O
confusion. B

Caffeine-induced O
cardiac B
arrhythmia: I
an O
unrecognised O
danger O
of O
healthfood O
products. O

The O
development O
of O
thrombotic B
microangiopathy I
(TMA) O
associated B
with O
the O
use O
of O
cyclosporine O
has O
been O
well O
documented. O
Treatments O
have O
included O
discontinuation O
or O
reduction O
of O
cyclosporine O
dose O
with O
or O
without O
concurrent O
plasma O
exchange, O
plasma O
infusion, O
anticoagulation, O
and O
intravenous O
immunoglobulin O
G O
infusion. O
However, O
for O
recipients O
of O
organ O
transplantation, O
removing O
the O
inciting O
agent O
is O
not O
without O
the O
attendant O
risk O
of O
precipitating O
acute O
rejection O
and O
graft O
loss. O
The O
last O
decade O
has O
seen O
the O
emergence O
of O
tacrolimus O
as O
a O
potent O
immunosuppressive O
agent O
with O
mechanisms O
of O
action O
virtually O
identical O
to O
those O
of O
cyclosporine. O
As O
a O
result, O
switching O
to O
tacrolimus O
has O
been O
reported O
to O
be O
a O
viable O
therapeutic O
option O
in O
the O
setting O
of O
cyclosporine-induced O
TMA. O
With O
the O
more O
widespread O
application O
of O
tacrolimus O
in O
organ O
transplantation, O
tacrolimus-associated O
TMA O
has O
also O
been O
recognized. O
However, O
literature O
regarding O
the O
incidence O
of O
the O
recurrence O
of O
TMA O
in O
patients O
exposed O
sequentially O
to O
cyclosporine O
and O
tacrolimus O
is O
limited. O
We O
report O
a O
case O
of O
a O
living O
donor O
renal O
transplant O
recipient O
who O
developed O
cyclosporine-induced O
TMA O
that O
responded O
to O
the O
withdrawal O
of O
cyclosporine O
in O
conjunction O
with O
plasmapheresis O
and O
fresh O
frozen O
plasma O
replacement O
therapy. O
Introduction O
of O
tacrolimus O
as O
an O
alternative O
immunosuppressive O
agent O
resulted O
in O
the O
recurrence O
of O
TMA O
and O
the O
subsequent O
loss O
of O
the O
renal O
allograft. O
Patients O
who O
are O
switched O
from O
cyclosporine O
to O
tacrolimus O
or O
vice O
versa O
should O
be O
closely O
monitored O
for O
the O
signs O
and O
symptoms O
of O
recurrent O
TMA. O

We O
have O
examined O
the O
effect O
of O
systemic O
administration O
of O
ketamine O
and O
lidocaine O
on O
brush-evoked O
(dynamic) O
pain B
and O
punctate-evoked O
(static) O
hyperalgesia B
induced O
by O
capsaicin. O
In O
a O
randomized, O
double-blind, O
placebo-controlled, O
crossover O
study, O
we O
studied O
12 O
volunteers O
in O
three O
experiments. O
Capsaicin O
100 O
micrograms O
was O
injected O
intradermally O
on O
the O
volar O
forearm O
followed O
by O
an O
i.v. O
infusion O
of O
ketamine O
(bolus O
0.1 O
mg O
kg-1 O
over O
10 O
min O
followed O
by O
infusion O
of O
7 O
micrograms O
kg-1 O
min-1), O
lidocaine O
5 O
mg O
kg-1 O
or O
saline O
for O
50 O
min. O
Infusion O
started O
15 O
min O
after O
injection O
of O
capsaicin. O
The O
following O
were O
measured: O
spontaneous O
pain, O
pain O
evoked O
by O
punctate O
and O
brush O
stimuli O
(VAS), O
and O
areas O
of O
brush-evoked O
and O
punctate-evoked O
hyperalgesia. O
Ketamine O
reduced O
both O
the O
area O
of O
brush-evoked O
and O
punctate-evoked O
hyperalgesia O
significantly O
and O
it O
tended O
to O
reduce O
brush-evoked O
pain. O
Lidocaine O
reduced O
the O
area O
of O
punctate-evoked O
hyperalgesia O
significantly. O
It O
tended O
to O
reduce O
VAS O
scores O
of O
spontaneous O
pain O
but O
had O
no O
effect O
on O
evoked O
pain. O
The O
differential O
effects O
of O
ketamine O
and O
lidocaine O
on O
static O
and O
dynamic O
hyperalgesia O
suggest O
that O
the O
two O
types O
of O
hyperalgesia O
are O
mediated O
by O
separate O
mechanisms O
and O
have O
a O
distinct O
pharmacology. O

Severe O
rhabdomyolysis B
and O
acute B
renal I
failure I
secondary O
to O
concomitant O
use O
of O
simvastatin, O
amiodarone, O
and O
atazanavir. O

Coronary B
aneurysm I
after O
implantation O
of O
a O
paclitaxel-eluting O
stent. O

Flunitrazepam O
0.5, O
1.0 O
or O
2.0 O
mg O
was O
given O
by O
the O
oral O
or O
i.m. O
routes O
to O
groups O
of O
volunteers O
and O
its O
effects O
compared. O
Plasma O
concentrations O
of O
the O
drug O
were O
estimated O
by O
gas-liquid O
chromatography, O
in O
a O
smaller O
number O
of O
the O
subjects. O
The O
most O
striking O
effect O
was O
sedation O
which O
increased O
with O
the O
dose, O
2 O
mg O
producing O
deep O
sleep O
although O
the O
subjects O
could O
still O
be O
aroused. O
The O
effects O
of O
i.m. O
administration O
were O
apparent O
earlier O
and O
sometimes O
lasted O
longer O
than O
those O
following O
oral O
administration. O
Dizziness B
was O
less O
marked O
than O
sedation, O
but O
increased O
with O
the O
dose. O
There O
was O
pain B
on O
i.m. O
injection O
of O
flunitrazepam O
significantly O
more O
often O
than O
with O
isotonic O
saline. O
Plasma O
concentrations O
varied O
with O
dose O
and O
route O
and O
corresponded O
qualitatively O
with O
the O
subjective O
effects. O
The O
drug O
was O
still O
present O
in O
measurable O
quantities O
after O
24 O
h O
even O
with O
the O
smallest O
dose. O

Prolonged O
elevation O
of O
plasma O
argatroban O
in O
a O
cardiac O
transplant O
patient O
with O
a O
suspected O
history O
of O
heparin-induced O
thrombocytopenia B
with O
thrombosis. B

Drug-associated O
acute-onset O
vanishing B
bile I
duct I
and O
Stevens-Johnson B
syndromes I
in O
a O
child. O

Pyrrolidine O
dithiocarbamate O
(PDTC) O
has O
a O
dual O
mechanism O
of O
action O
as O
an O
antioxidant O
and O
an O
inhibitor O
of O
the O
transcription O
factor O
kappa-beta. O
Both, O
production O
of O
reactive O
oxygen O
species O
as O
well O
as O
activation O
of O
NF-kappaB O
have O
been O
implicated O
in O
severe O
neuronal B
damage I
in O
different O
sub-regions O
of O
the O
hippocampus O
as O
well O
as O
in O
the O
surrounding O
cortices. O
The O
effect O
of O
PDTC O
on O
status B
epilepticus-associated I
cell O
loss O
in O
the O
hippocampus O
and O
piriform O
cortex O
was O
evaluated O
in O
the O
rat O
fractionated O
pilocarpine O
model. O
Treatment O
with O
150 O
mg/kg O
PDTC O
before O
and O
following O
status O
epilepticus O
significantly O
increased O
the O
mortality O
rate O
to O
100%. O
Administration O
of O
50 O
mg/kg O
PDTC O
(low-dose) O
did O
not O
exert O
major O
effects O
on O
the O
development O
of O
a O
status O
epilepticus O
or O
the O
mortality O
rate. O
In O
vehicle-treated O
rats, O
status O
epilepticus O
caused O
pronounced O
neuronal O
damage O
in O
the O
piriform O
cortex O
comprising O
both O
pyramidal O
cells O
and O
interneurons. O
Low-dose O
PDTC O
treatment O
almost O
completely O
protected O
from O
lesions O
in O
the O
piriform O
cortex. O
A O
significant O
decrease O
in O
neuronal O
density O
of O
the O
hippocampal O
hilar O
formation O
was O
identified O
in O
vehicle- O
and O
PDTC-treated O
rats O
following O
status O
epilepticus. O
In O
conclusion, O
the O
NF-kappaB O
inhibitor O
and O
antioxidant O
PDTC O
protected O
the O
piriform O
cortex, O
whereas O
it O
did O
not O
affect O
hilar O
neuronal B
loss. I
These O
data O
might O
indicate O
that O
the O
generation O
of O
reactive O
oxygen O
species O
and O
activation O
of O
NF-kappaB O
plays O
a O
more O
central O
role O
in O
seizure-associated B
neuronal O
damage O
in O
the O
temporal O
cortex O
as O
compared O
to O
the O
hippocampal O
hilus. O
However, O
future O
investigations O
are O
necessary O
to O
exactly O
analyze O
the O
biochemical O
mechanisms O
by O
which O
PDTC O
exerted O
its O
beneficial O
effects O
in O
the O
piriform O
cortex. O

Rebound O
hypertensive B
after O
sodium O
nitroprusside O
prevented O
by O
saralasin O
in O
rats. O

Attentional O
modulation O
of O
perceived O
pain B
intensity O
in O
capsaicin-induced O
secondary O
hyperalgesia. B

BACKGROUND: O
A O
previous O
randomized O
controlled O
trial O
evaluating O
the O
use O
of O
spironolactone O
in O
heart B
failure I
patients O
reported O
a O
low O
risk O
of O
hyperkalemia B
(2%) O
and O
renal B
insufficiency I
(0%). O
Because O
treatments O
for O
heart O
failure O
have O
changed O
since O
the O
benefits O
of O
spironolactone O
were O
reported, O
the O
prevalence O
of O
these O
complications O
may O
differ O
in O
current O
clinical O
practice. O
We O
therefore O
sought O
to O
determine O
the O
prevalence O
and O
clinical O
associations O
of O
hyperkalemia O
and O
renal O
insufficiency O
in O
heart O
failure O
patients O
treated O
with O
spironolactone. O
METHODS: O
We O
performed O
a O
case O
control O
study O
of O
heart O
failure O
patients O
treated O
with O
spironolactone O
in O
our O
clinical O
practice. O
Cases O
were O
patients O
who O
developed O
hyperkalemia O
(K(+) O
>5.0 O
mEq/L) O
or O
renal O
insufficiency O
(Cr O
>or=2.5 O
mg/dL), O
and O
they O
were O
compared O
to O
2 O
randomly O
selected O
controls O
per O
case. O
Clinical O
characteristics, O
medications, O
and O
serum O
chemistries O
at O
baseline O
and O
follow-up O
time O
periods O
were O
compared. O
RESULTS: O
Sixty-seven O
of O
926 O
patients O
(7.2%) O
required O
discontinuation O
of O
spironolactone O
due O
to O
hyperkalemia O
(n O
= O
33) O
or O
renal B
failure I
(n O
= O
34). O
Patients O
who O
developed O
hyperkalemia O
were O
older O
and O
more O
likely O
to O
have O
diabetes, B
had O
higher O
baseline O
serum O
potassium O
levels O
and O
lower O
baseline O
potassium O
supplement O
doses, O
and O
were O
more O
likely O
to O
be O
treated O
with O
beta-blockers O
than O
controls O
(n O
= O
134). O
Patients O
who O
developed O
renal O
insufficiency O
had O
lower O
baseline O
body O
weight O
and O
higher O
baseline O
serum O
creatinine, O
required O
higher O
doses O
of O
loop O
diuretics, O
and O
were O
more O
likely O
to O
be O
treated O
with O
thiazide O
diuretics O
than O
controls. O
CONCLUSIONS: O
Spironolactone-induced O
hyperkalemia O
and O
renal O
insufficiency O
are O
more O
common O
in O
our O
clinical O
experience O
than O
reported O
previously. O
This O
difference O
is O
explained O
by O
patient O
comorbidities O
and O
more O
frequent O
use O
of O
beta-blockers. O

Treatment O
of O
Crohn's B
disease I
with O
fusidic O
acid: O
an O
antibiotic O
with O
immunosuppressive O
properties O
similar O
to O
cyclosporin. O

End-stage B
renal I
disease I
(ESRD) O
after B
orthotopic O
liver O
transplantation O
(OLTX) O
using O
calcineurin-based O
immunotherapy: O
risk O
of O
development O
and O
treatment. O

Does O
paracetamol O
cause O
urothelial B
cancer I
or O
renal B
papillary I
necrosis? I

The O
nitric O
oxide O
(NO) O
inhibitor O
nitro-L-arginine O
methyl O
ester O
(L-NAME) O
may O
act O
as O
an O
otoprotectant O
against O
high-frequency B
hearing B
loss I
caused O
by O
gentamicin, O
but O
further O
studies O
are O
needed O
to O
confirm O
this.Aminoglycoside O
antibiotics O
are O
still O
widely O
used O
by O
virtue O
of O
their O
efficacy O
and O
low O
cost. O
Their O
ototoxicity B
is O
a O
serious O
health O
problem O
and, O
as O
their O
ototoxic O
mechanism O
involves O
the O
production O
of O
NO, O
we O
need O
to O
assess O
the O
use O
of O
NO O
inhibitors O
for O
the O
prevention O
of O
aminoglycoside-induced O
sensorineural B
hearing I
loss. I
In O
this O
experimental O
study O
we O
used O
30 O
Sprague-Dawley O
rats, O
27 O
of O
which O
had O
gentamicin O
instilled O
into O
the O
middle O
ear. O
The O
otoprotectant O
L-NAME O
was O
administered O
topically O
to O
12/27 O
animals. O
Its O
effect O
was O
determined O
in O
terms O
of O
attenuation O
of O
hearing O
loss, O
measured O
by O
shifts O
in O
the O
auditory O
brainstem O
response O
threshold. O
L-NAME O
reduced O
gentamicin-induced O
hearing O
loss O
in O
the O
high-frequency O
range, O
but O
gave O
no O
protection O
in O
the O
middle O
or O
low O
frequencies. O

1. O
Torsades B
de I
pointes I
(TDP) O
is B
a O
potentially O
fatal O
ventricular B
tachycardia I
associated O
with O
increases O
in O
QT O
interval O
and O
monophasic O
action O
potential O
duration O
(MAPD). O
TDP O
is O
a O
side-effect O
that O
has O
led O
to O
withdrawal O
of O
several O
drugs O
from O
the O
market O
(e.g. O
terfenadine O
and O
terodiline). O
2. O
The O
potential O
of O
compounds O
to O
cause O
TDP O
was O
evaluated O
by O
monitoring O
their O
effects O
on O
MAPD O
in O
dog. O
Four O
compounds O
known O
to O
increase O
QT O
interval O
and O
cause O
TDP O
were O
investigated: O
terfenadine, O
terodiline, O
cisapride O
and O
E4031. O
On O
the O
basis O
that O
only O
free O
drug O
in O
the O
systemic O
circulation O
will O
elicit O
a O
pharmacological O
response O
target, O
free O
concentrations O
in O
plasma O
were O
selected O
to O
mimic O
the O
free O
drug O
exposures O
in O
man. O
Infusion O
regimens O
were O
designed O
that O
rapidly O
achieved O
and O
maintained O
target-free O
concentrations O
of O
these O
drugs O
in O
plasma O
and O
data O
on O
the O
relationship O
between O
free O
concentration O
and O
changes O
in O
MAPD O
were O
obtained O
for O
these O
compounds. O
3. O
These O
data O
indicate O
that O
the O
free O
ED50 O
in O
plasma O
for O
terfenadine O
(1.9 O
nM), O
terodiline O
(76 O
nM), O
cisapride O
(11 O
nM) O
and O
E4031 O
(1.9 O
nM) O
closely O
correlate O
with O
the O
free O
concentration O
in O
man O
causing O
QT O
effects. O
For O
compounds O
that O
have O
shown O
TDP O
in O
the O
clinic O
(terfenadine, O
terodiline, O
cisapride) O
there O
is O
little O
differentiation O
between O
the O
dog O
ED50 O
and O
the O
efficacious O
free O
plasma O
concentrations O
in O
man O
(< O
10-fold) O
reflecting O
their O
limited O
safety O
margins. O
These O
data O
underline O
the O
need O
to O
maximize O
the O
therapeutic O
ratio O
with O
respect O
to O
TDP O
in O
potential O
development O
candidates O
and O
the O
importance O
of O
using O
free O
drug O
concentrations O
in O
pharmacokinetic/pharmacodynamic O
studies. O

Encephalopathy B
induced O
by O
levetiracetam O
added O
to O
valproate. O

Warfarin-induced O
iliopsoas O
hemorrhage B
with O
subsequent O
femoral B
nerve I
palsy. I

Withdrawal-emergent B
rabbit B
syndrome I
during I
dose O
reduction O
of O
risperidone. O

Two O
patients O
treated O
with O
parenteral O
paramethasone O
(Triniol) O
and O
dexamethasone O
(Sedionbel) O
are O
described. O
A O
few O
minutes O
after O
administration O
of O
the O
drugs, O
they O
presented O
urticaria B
(patients O
1 O
and O
2) O
and O
conjunctivitis B
(patient O
1). O
The O
purpose O
of O
our O
study O
was O
to O
determine O
the O
cause O
of O
the O
patients' O
reactions, O
the O
immunological O
mechanisms O
involved O
and O
whether O
these O
patients O
would O
be O
able O
to O
tolerate O
any O
kind O
of O
corticoid. O
Clinical O
examinations O
and O
skin, O
oral O
and O
parenteral O
challenges O
with O
different O
corticosteroids O
and O
ELISA O
tests O
were O
performed. O
In O
the O
two O
patients, O
skin O
and O
ELISA O
tests O
with O
paramethasone O
were O
negative, O
as O
was O
the O
prick O
test O
with O
each O
of O
its O
excipients. O
A O
single-blind O
parenteral O
challenge O
with O
Triniol O
was O
positive O
in O
both O
patients O
after O
the O
administration O
of O
1 O
ml O
of O
the O
drug, O
and O
negative O
with O
its O
excipients. O
We O
also O
carried O
out O
oral O
and O
parenteral O
challenges O
with O
other O
corticosteroids O
and O
found O
intolerance O
to O
some O
of O
them. O
These O
results O
suggest O
that O
paramethasone O
caused O
pseudoallergic O
reactions O
in O
our O
patients. O
Corticosteroids O
different O
from O
paramethasone O
also O
produced O
hypersensitivity B
reactions O
in O
these O
patients; O
however, O
a O
few O
of O
them O
were O
tolerated. O
The O
basic O
mechanisms O
of O
those O
reactions O
are O
not O
yet O
fully O
understood. O
To O
our O
knowledge, O
this O
is O
the O
first O
report O
of O
a O
pseudo-allergy O
caused B
by O
paramethasone. O

Bone O
pain B
after O
transplantation O
is O
a O
frequent O
complication O
that O
can O
be O
caused O
by O
several O
diseases. O
Treatment O
strategies O
depend O
on O
the O
correct O
diagnosis O
of O
the O
pain. O
Nine O
patients O
with O
severe O
pain O
in O
their O
feet, O
which O
was O
registered O
after O
transplantation, O
were O
investigated. O
Bone O
scans O
showed O
an O
increased O
tracer O
uptake O
of O
the O
foot O
bones. O
Magnetic O
resonance O
imaging O
demonstrated O
bone B
marrow I
oedema B
in O
the O
painful O
bones. O
Pain B
was O
not O
explained O
by O
other O
diseases O
causing O
foot O
pain, O
like O
reflex B
sympathetic I
dystrophy, I
polyneuropathy, B
Morton's B
neuralgia, I
gout, B
osteoporosis, B
avascular B
necrosis, I
intermittent B
claudication, I
orthopaedic O
foot B
deformities, I
stress B
fractures, I
and O
hyperparathyroidism. B
The O
reduction O
of O
cyclosporine- O
or O
tacrolimus O
trough O
levels O
and O
the O
administration O
of O
calcium O
channel O
blockers O
led O
to O
relief O
of O
pain. O
The O
Calcineurin-inhibitor O
Induced O
Pain O
Syndrome O
(CIPS) O
is B
a O
rare O
but O
severe O
side O
effect O
of O
cyclosporine O
or O
tacrolimus O
and O
is O
accurately O
diagnosed O
by O
its O
typical O
presentation, O
magnetic O
resonance O
imaging O
and O
bone O
scans. O
Incorrect O
diagnosis O
of O
the O
syndrome O
will O
lead O
to O
a O
significant O
reduction O
of O
life O
quality O
in O
patients O
suffering O
from O
CIPS. O

Brain O
natriuretic O
peptide O
is O
a O
predictor O
of O
anthracycline-induced O
cardiotoxicity. B

Prenatal O
dexamethasone O
programs O
hypertension B
and O
renal B
injury I
in O
the O
rat. O

Infarct-avid B
radiopharmaceuticals O
are O
necessary O
for O
rapid O
and O
timely O
diagnosis O
of O
acute O
myocardial B
infarction. B
The O
animal O
model O
used O
to O
produce O
infarction O
implies O
artery O
ligation O
but O
chemical O
induction O
can O
be O
easily O
obtained O
with O
isoproterenol. O
A O
new O
infarct-avid O
radiopharmaceutical O
based O
on O
glucaric O
acid O
was O
prepared O
in O
the O
hospital O
radiopharmacy O
of O
the O
INCMNSZ. O
99mTc-glucarate O
was O
easy O
to O
prepare, O
stable O
for O
96 O
h O
and O
was O
used O
to O
study O
its O
biodistribution O
in O
rats O
with O
isoproterenol-induced O
acute O
myocardial O
infarction. O
Histological O
studies O
demonstrated O
that O
the O
rats O
developed O
an O
infarct O
18 O
h O
after O
isoproterenol O
administration. O
The O
rat O
biodistribution O
studies O
showed O
a O
rapid O
blood O
clearance O
via O
the O
kidneys. O
Thirty O
minutes O
after O
99mTc-glucarate O
administration O
the O
standardised O
heart O
uptake O
value O
S(h)UV O
was O
4.7 O
in O
infarcted O
rat O
heart O
which O
is O
six O
times O
more O
than O
in O
normal O
rats. O
ROIs O
drawn O
over O
the O
gamma O
camera O
images O
showed O
a O
ratio O
of O
4.4. O
The O
high O
image O
quality O
suggests O
that O
high O
contrast O
images O
can O
be O
obtained O
in O
humans O
and O
the O
96 O
h O
stability O
makes O
it O
an O
ideal O
agent O
to O
detect, O
in O
patients, O
early O
cardiac B
infarction. I

BACKGROUND: O
Inhibition O
of O
cardiac O
sympathetic O
tone O
represents O
an O
important O
strategy O
for O
treatment O
of O
cardiovascular B
disease, I
including O
arrhythmia, B
coronary B
heart I
disease, I
and O
chronic O
heart B
failure. I
Activation O
of O
presynaptic O
alpha2-adrenoceptors O
is O
the O
most O
widely O
accepted O
mechanism O
of O
action O
of O
the O
antisympathetic O
drug O
clonidine; O
however, O
other O
target O
proteins O
have O
been O
postulated O
to O
contribute O
to O
the O
in O
vivo O
actions O
of O
clonidine. O
METHODS O
AND O
RESULTS: O
To O
test O
whether O
clonidine O
elicits O
pharmacological O
effects O
independent O
of O
alpha2-adrenoceptors, O
we O
have O
generated O
mice O
with O
a O
targeted O
deletion O
of O
all O
3 O
alpha2-adrenoceptor O
subtypes O
(alpha2ABC-/-). O
Alpha2ABC-/- O
mice O
were O
completely O
unresponsive O
to O
the O
analgesic O
and O
hypnotic O
effects O
of O
clonidine; O
however, O
clonidine O
significantly O
lowered O
heart O
rate O
in O
alpha2ABC-/- O
mice O
by O
up O
to O
150 O
bpm. O
Clonidine-induced O
bradycardia B
in O
conscious O
alpha2ABC-/- O
mice O
was O
32.3% O
(10 O
microg/kg) O
and O
26.6% O
(100 O
microg/kg) O
of O
the O
effect O
in O
wild-type O
mice. O
A O
similar O
bradycardic O
effect O
of O
clonidine O
was O
observed O
in O
isolated O
spontaneously O
beating O
right O
atria O
from O
alpha2ABC-knockout O
and O
wild-type O
mice. O
Clonidine O
inhibited O
the O
native O
pacemaker O
current O
(I(f)) O
in O
isolated O
sinoatrial O
node O
pacemaker O
cells O
and O
the O
I(f)-generating O
hyperpolarization-activated O
cyclic O
nucleotide-gated O
(HCN) O
2 O
and O
HCN4 O
channels O
in O
transfected O
HEK293 O
cells. O
As O
a O
consequence O
of O
blocking O
I(f), O
clonidine O
reduced O
the O
slope O
of O
the O
diastolic O
depolarization O
and O
the O
frequency O
of O
pacemaker O
potentials O
in O
sinoatrial O
node O
cells O
from O
wild-type O
and O
alpha2ABC-knockout O
mice. O
CONCLUSIONS: O
Direct O
inhibition O
of O
cardiac O
HCN O
pacemaker O
channels O
contributes O
to O
the O
bradycardic O
effects O
of O
clonidine O
gene-targeted O
mice O
in O
vivo, O
and O
thus, O
clonidine-like O
drugs O
represent O
novel O
structures O
for O
future O
HCN O
channel O
inhibitors. O

In O
the O
cardiovascular O
system, O
NO O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
functions. O
Inhibition O
of O
NO O
synthesis O
induces O
sustained O
hypertension. B
In O
several O
models O
of O
hypertension, O
elevation O
of O
intracellular O
sodium O
level O
was O
documented O
in O
cardiac O
tissue. O
To O
assess O
the O
molecular O
basis O
of O
disturbances O
in O
transmembraneous O
transport O
of O
Na+, O
we O
studied O
the O
response O
of O
cardiac O
(Na,K)-ATPase O
to O
NO-deficient O
hypertension O
induced O
in O
rats O
by O
NO-synthase O
inhibition O
with O
40 O
mg/kg/day O
N(G)-nitro-L-arginine O
methyl O
ester O
(L-NAME) O
for O
4 O
four O
weeks. O
After O
4-week O
administration O
of O
L-NAME, O
the O
systolic O
blood O
pressure O
(SBP) O
increased O
by O
36%. O
Two O
weeks O
after O
terminating O
the O
treatment, O
the O
SBP O
recovered O
to O
control O
value. O
When O
activating O
the O
(Na,K)-ATPase O
with O
its O
substrate O
ATP, O
no O
changes O
in O
Km O
and O
Vmax O
values O
were O
observed O
in O
NO-deficient O
rats. O
During O
activation O
with O
Na+, O
the O
Vmax O
remained O
unchanged, O
however O
the O
K(Na) O
increased O
by O
50%, O
indicating O
a O
profound O
decrease O
in O
the O
affinity O
of O
the O
Na+-binding O
site O
in O
NO-deficient O
rats. O
After O
recovery O
from O
hypertension, O
the O
activity O
of O
(Na,K)-ATPase O
increased, O
due O
to O
higher O
affinity O
of O
the O
ATP-binding O
site, O
as O
revealed O
from O
the O
lowered O
Km O
value O
for O
ATP. O
The O
K(Na) O
value O
for O
Na+ O
returned O
to O
control O
value. O
Inhibition O
of O
NO-synthase O
induced O
a O
reversible O
hypertension O
accompanied O
by O
depressed B
Na+-extrusion O
from O
cardiac O
cells O
as O
a O
consequence O
of O
deteriorated O
Na+-binding O
properties O
of O
the O
(Na,K)-ATPase. O
After O
recovery O
of O
blood O
pressure O
to O
control O
values, O
the O
extrusion O
of O
Na+ O
from O
cardiac O
cells O
was O
normalized, O
as O
revealed O
by O
restoration O
of O
the O
(Na,K)-ATPase O
activity. O

It O
has O
been O
consistently O
shown O
that O
ecstasy O
users O
display O
impairments B
in I
learning I
and I
memory I
performance. O
In O
addition, O
working O
memory O
processing O
in O
ecstasy O
users O
has O
been O
shown O
to O
be O
associated O
with O
neural O
alterations O
in O
hippocampal O
and/or O
cortical O
regions O
as O
measured O
by O
functional O
magnetic O
resonance O
imaging O
(fMRI). O
Using O
functional O
imaging O
and O
a O
face-learning O
task, O
we O
investigated O
neural O
correlates O
of O
encoding O
and O
recalling O
face-name O
associations O
in O
20 O
recreational O
drug O
users O
whose O
predominant O
drug O
use O
was O
ecstasy O
and O
20 O
controls. O
To O
address O
the O
potential O
confounding O
effects O
of O
the O
cannabis O
use O
of O
the O
ecstasy O
using O
group, O
a O
second O
analysis O
included O
14 O
previously O
tested O
cannabis O
users O
(Nestor, O
L., O
Roberts, O
G., O
Garavan, O
H., O
Hester, O
R., O
2008. O
Deficits B
in I
learning I
and I
memory: I
parahippocampal O
hyperactivity B
and O
frontocortical O
hypoactivity O
in O
cannabis O
users. O
Neuroimage O
40, O
1328-1339). O
Ecstasy O
users O
performed O
significantly O
worse O
in O
learning O
and O
memory O
compared O
to O
controls O
and O
cannabis O
users. O
A O
conjunction O
analysis O
of O
the O
encode O
and O
recall O
phases O
of O
the O
task O
revealed O
ecstasy-specific O
hyperactivity O
in O
bilateral O
frontal O
regions, O
left O
temporal, O
right O
parietal, O
bilateral O
temporal, O
and O
bilateral O
occipital O
brain O
regions. O
Ecstasy-specific O
hypoactivity O
was O
evident O
in O
the O
right O
dorsal O
anterior O
cingulated O
cortex O
(ACC) O
and O
left O
posterior O
cingulated O
cortex. O
In O
both O
ecstasy O
and O
cannabis O
groups O
brain O
activation O
was O
decreased O
in O
the O
right O
medial O
frontal O
gyrus, O
left O
parahippocampal O
gyrus, O
left O
dorsal O
cingulate O
gyrus, O
and O
left O
caudate. O
These O
results O
elucidated O
ecstasy-related O
deficits, O
only O
some O
of O
which O
might O
be O
attributed O
to O
cannabis O
use. O
These O
ecstasy-specific O
effects O
may O
be O
related O
to O
the O
vulnerability O
of O
isocortical O
and O
allocortical O
regions O
to O
the O
neurotoxic B
effects O
of O
ecstasy. O

Paracetamol-associated O
coma, B
metabolic B
acidosis, I
renal B
and I
hepatic B
failure. I

The O
effects O
of O
varying O
the O
extracellular O
concentrations O
of O
Na O
and O
Ca O
([Na]o O
and O
[Ca]o) O
on O
both, O
the O
spontaneous O
beating O
and O
the O
negative O
chronotropic O
action O
of O
verapamil, O
were O
studied O
in O
the O
isolated O
rat O
atria. O
Basal O
frequency O
(BF) O
evaluated O
by O
surface O
electrogram O
was O
223 O
+/- O
4 O
beats/min. O
in O
control O
Krebs-Ringer O
containing O
137 O
mM O
Na O
and O
1.35 O
mM O
Ca O
(N). O
It O
decreased O
by O
16 O
+/- O
3% O
by O
lowering O
[Na]o O
to O
78 O
mM O
(LNa), O
23 O
+/- O
2% O
by O
lowering O
simultaneously O
[Na]o O
to O
78 O
mM O
and O
[Ca]o O
to O
0.675 O
mM O
(LNa+LCa) O
and O
31 O
+/- O
5% O
by O
lowering O
[Na]o O
to O
78 O
mM O
plus O
increasing O
[Ca]o O
to O
3.6 O
mM O
(LNa+HCa). O
At O
normal O
[Na]o, O
decrease O
(0.675 O
mM) O
or O
increase O
(3.6 O
mM) O
of O
[Ca]o O
did O
not O
modify O
BF; O
a O
reduction O
of O
ten O
times O
(0.135 O
mM O
of O
normal O
[Ca]o O
was O
effective O
to O
reduce O
BF O
by O
40 O
+/- O
13%. O
All O
negative O
chronotropic O
effects O
were O
BF-dependent. O
Dose-dependent O
bradycardia B
induced O
by O
verapamil O
was O
potentiated O
by O
LNa, O
LCa, O
and O
HCa. O
Independent O
but O
not O
additive O
effects O
of O
Na O
and O
Ca O
are O
shown O
by O
decreases O
in O
the O
values O
of O
[verapamil]o O
needed O
to O
reduce O
BF O
by O
30% O
(IC30) O
with O
the O
following O
order O
of O
inhibitory O
potency: O
LNa O
> O
LCa O
> O
HCa O
> O
N, O
resulting O
LNa+HCa O
similar O
to O
LNa. O
The O
[verapamil]o O
that O
arrested O
atrial O
beating O
(AC) O
was O
also O
potentiated O
with O
the O
order O
LNa O
= O
LNa+LCa O
= O
LNa+HCa O
= O
LCa O
> O
HCa O
= O
N. O
The O
results O
indicate O
that O
rat O
atrial O
spontaneous O
beating O
is O
more O
dependent O
on O
[Na]o O
than O
on O
[Ca]o O
in O
a O
range O
of O
+/- O
50% O
of O
their O
normal O
concentration. O
Also O
the O
enhancement O
of O
verapamil O
effects O
on O
atrial O
beating O
was O
more O
pronounced O
at O
LNa O
than O
at O
LCa.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

Octreotide-induced O
hypoxemia B
and O
pulmonary B
hypertension I
in O
premature O
neonates. O

Increased O
frequency O
of O
venous B
thromboembolism I
with O
the O
combination O
of O
docetaxel O
and O
thalidomide O
in O
patients O
with O
metastatic O
androgen-independent O
prostate B
cancer. I

We O
describe O
3 O
episodes O
of O
microangiopathic B
hemolytic I
anemia I
(MAHA) O
in B
2 O
solid O
organ O
recipients O
under O
FK506 O
(tacrolimus) O
therapy. O
In O
both O
cases, O
discontinuation O
of O
FK506 O
and O
treatment O
with O
plasma O
exchange, O
fresh O
frozen O
plasma O
replacement, O
corticosteroids, O
aspirin, O
and O
dipyridamole O
led O
to O
resolution O
of O
MAHA. O
In O
one O
patient, O
reintroduction O
of O
FK506 O
led O
to O
rapid O
recurrence O
of O
MAHA. O
FK506-associated O
MAHA O
is O
probably O
rare O
but O
physicians O
must O
be O
aware O
of O
this O
severe O
complication. O
In O
our O
experience O
and O
according O
to O
the O
literature, O
FK506 O
does O
not O
seem O
to O
cross-react O
with O
cyclosporin O
A O
(CyA), O
an O
immuno-suppressive O
drug O
already O
known O
to O
induce O
MAHA. O

Asenapine O
is O
approved O
by O
the O
Food O
and O
Drugs O
Administration O
in O
adults O
for O
acute O
treatment O
of O
schizophrenia B
or O
of O
manic B
or O
mixed O
episodes O
associated O
with O
bipolar B
I I
disorder I
with O
or O
without O
psychotic B
features. O
In O
a O
double-blind O
6-week O
trial, O
458 O
patients O
with O
acute O
schizophrenia O
were O
randomly O
assigned O
to O
fixed-dose O
treatment O
with O
asenapine O
at O
5 O
mg O
twice O
daily O
(BID), O
asenapine O
at O
10 O
mg O
BID, O
placebo, O
or O
haloperidol O
at O
4 O
mg O
BID O
(to O
verify O
assay O
sensitivity). O
With O
last O
observations O
carried O
forward O
(LOCF), O
mean O
Positive O
and O
Negative O
Syndrome O
Scale O
total O
score O
reductions O
from O
baseline O
to O
endpoint O
were O
significantly O
greater O
with O
asenapine O
at O
5 O
mg O
BID O
(-16.2) O
and O
haloperidol O
(-15.4) O
than O
placebo O
(-10.7; O
both O
P O
< O
0.05); O
using O
mixed O
model O
for O
repeated O
measures O
(MMRM), O
changes O
at O
day O
42 O
were O
significantly O
greater O
with O
asenapine O
at O
5 O
and O
10 O
mg O
BID O
(-21.3 O
and O
-19.4, O
respectively) O
and O
haloperidol O
(-20.0) O
than O
placebo O
(-14.6; O
all O
P O
< O
0.05). O
On O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
positive O
subscale, O
all O
treatments O
were O
superior O
to O
placebo O
with O
LOCF O
and O
MMRM; O
asenapine O
at O
5 O
mg O
BID O
was O
superior O
to O
placebo O
on O
the O
negative O
subscale O
with O
MMRM O
and O
on O
the O
general O
psychopathology O
subscale O
with O
LOCF O
and O
MMRM. O
Treatment-related O
adverse O
events O
(AEs) O
occurred O
in O
44% O
and O
52%, O
57%, O
and O
41% O
of O
the O
asenapine O
at O
5 O
and O
10 O
mg O
BID, O
haloperidol, O
and O
placebo O
groups, O
respectively. O
Extrapyramidal B
symptoms I
reported O
as O
AEs O
occurred O
in O
15% O
and O
18%, O
34%, O
and O
10% O
of O
the O
asenapine O
at O
5 O
and O
10 O
mg O
BID, O
haloperidol, O
and O
placebo O
groups, O
respectively. O
Across O
all O
groups, O
no O
more O
than O
5% O
of O
patients O
had O
clinically O
significant O
weight O
change. O
Post O
hoc O
analyses O
indicated O
that O
efficacy O
was O
similar O
with O
asenapine O
and O
haloperidol; O
greater O
contrasts O
were O
seen O
in O
AEs, O
especially O
extrapyramidal B
symptoms. I

Confusion, B
a O
rather O
serious O
adverse O
drug O
reaction O
with O
valproic O
acid: O
a O
review O
of O
the O
French O
Pharmacovigilance O
database. O

BACKGROUND: O
The O
mechanisms O
underlying O
heart B
failure I
induced O
by O
adriamycin O
are O
very O
complicated O
and O
still O
unclear. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
autophagy O
was O
involved O
in O
the O
progression O
of O
heart O
failure O
induced O
by O
adriamycin, O
so O
that O
we O
can O
develop O
a O
novel O
treatment O
strategy O
for O
heart O
failure. O
METHODS: O
3-methyladenine O
(3MA), O
a O
specific O
inhibitor O
on O
autophagy O
was O
used O
in O
a O
heart O
failure O
model O
of O
rats O
induced O
by O
adriamycin. O
Neonatal O
cardiomyocytes O
were O
isolated O
from O
Sprague-Dawley O
rat O
hearts O
and O
randomly O
divided O
into O
controls, O
an O
adriamycin-treated O
group, O
and O
a O
3MA O
plus O
adriamycin-treated O
group. O
We O
then O
examined O
the O
morphology, O
expression O
of O
beclin O
1 O
gene, O
mitochondrial O
permeability O
transition O
(MPT), O
and O
Na+-K+ O
ATPase O
activity O
in O
vivo. O
We O
also O
assessed O
cell O
viability, O
mitochondrial O
membrane O
potential O
changes O
and O
counted O
autophagic O
vacuoles O
in O
cultured O
cardiomyocytes. O
In O
addition, O
we O
analyzed O
the O
expression O
of O
autophagy O
associated O
gene, O
beclin O
1 O
using O
RT-PCR O
and O
Western O
blotting O
in O
an O
animal O
model. O
RESULTS: O
3MA O
significantly O
improved O
cardiac O
function O
and O
reduced O
mitochondrial O
injury. O
Furthermore, O
adriamycin O
induced O
the O
formation O
of O
autophagic O
vacuoles, O
and O
3MA O
strongly O
downregulated O
the O
expression O
of O
beclin O
1 O
in O
adriamycin-induced O
failing O
heart O
and O
inhibited O
the O
formation O
of O
autophagic O
vacuoles. O
CONCLUSION: O
Autophagic O
cardiomyocyte O
death B
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
heart O
failure O
in O
rats O
induced O
by O
adriamycin. O
Mitochondrial O
injury O
may O
be O
involved O
in O
the O
progression O
of O
heart O
failure O
caused O
by O
adriamycin O
via O
the O
autophagy O
pathway. O

OBJECTIVE: O
To O
determine O
the O
safety O
and O
efficacy O
of O
adjunctive O
bupropion O
sustained-release O
(SR) O
on O
male O
sexual B
dysfunction I
(SD) O
induced B
by O
a O
selective O
serotonin O
reuptake O
inhibitor O
(SSRI), O
as O
SD O
is O
a O
common O
side-effect O
of O
SSRIs O
and O
the O
most O
effective O
treatments O
have O
yet O
to O
be O
determined. O
PATIENTS O
AND O
METHODS: O
The O
randomized O
sample O
consisted O
of O
234 O
euthymic O
men O
who O
were O
receiving O
some O
type O
of O
SSRI. O
The O
men O
were O
randomly O
assigned O
to O
bupropion O
SR O
(150 O
mg O
twice O
daily, O
117) O
or O
placebo O
(twice O
daily, O
117) O
for O
12 O
weeks. O
Efficacy O
was O
evaluated O
using O
the O
Clinical O
Global O
Impression-Sexual O
Function O
(CGI-SF; O
the O
primary O
outcome O
measure), O
the O
International O
Index O
of O
Erectile O
Function O
(IIEF), O
Arizona O
Sexual O
Experience O
Scale O
(ASEX), O
and O
Erectile B
Dysfunction I
Inventory O
of O
Treatment O
Satisfaction O
(EDITS) O
(secondary O
outcome O
measures). O
Participants O
were O
followed O
biweekly O
during O
study O
period. O
RESULTS: O
After O
12 O
weeks O
of O
treatment, O
the O
mean O
(sd) O
scores O
for O
CGI-SF O
were O
significantly O
lower, O
i.e. O
better, O
in O
patients O
on O
bupropion O
SR, O
at O
2.4 O
(1.2), O
than O
in O
the O
placebo O
group, O
at O
3.9 O
(1.1) O
(P= O
0.01). O
Men O
who O
received O
bupropion O
had O
a O
significant O
increase O
in O
the O
total O
IIEF O
score O
(54.4% O
vs O
1.2%; O
P= O
0.003), O
and O
in O
the O
five O
different O
domains O
of O
the O
IIEF. O
Total O
ASEX O
scores O
were O
significantly O
lower, O
i.e. O
better, O
among O
men O
who O
received O
bupropion O
than O
placebo, O
at O
15.5 O
(4.3) O
vs O
21.5 O
(4.7) O
(P= O
0.002). O
The O
EDITS O
scores O
were O
67.4 O
(10.2) O
for O
the O
bupropion O
and O
36.3 O
(11.7) O
for O
the O
placebo O
group O
(P= O
0.001). O
The O
ASEX O
score O
and O
CGI-SF O
score O
were O
correlated O
(P= O
0.003). O
In O
linear O
regression O
analyses O
the O
CGI-SF O
score O
was O
not O
affected O
significantly O
by O
the O
duration O
of O
SD, O
type O
of O
SSRI O
used O
and O
age. O
CONCLUSIONS: O
Bupropion O
is O
an O
effective O
treatment O
for O
male O
SD O
induced O
by O
SSRIs. O
These O
results O
provide O
empirical O
support O
for O
conducting O
a O
further O
study O
of O
bupropion. O

The O
use O
and O
toxicity B
of O
didanosine O
(ddI) O
in O
HIV B
antibody-positive I
individuals O
intolerant O
to O
zidovudine O
(AZT) O

Alpha-lipoic O
acid O
prevents O
mitochondrial B
damage I
and O
neurotoxicity B
in O
experimental O
chemotherapy O
neuropathy. B

Intracranial O
pressure O
increases O
during O
alfentanil-induced O
rigidity. B

Mutations O
associated O
with O
lamivudine-resistance O
in O
therapy-na O
ve O
hepatitis B
B I
virus I
(HBV) I
infected B
patients O
with O
and O
without O
HIV B
co-infection: I
implications O
for O
antiretroviral O
therapy O
in O
HBV B
and I
HIV I
co-infected I
South O
African O
patients. O

A O
reproducible O
model O
for O
producing O
diffuse O
myocardial B
injury I
(epinephrine O
infusion) O
has O
been O
developed O
to O
study O
the O
cardioprotective O
effects O
of O
agents O
or O
maneuvers O
which O
might O
alter O
the O
evolution O
of O
acute O
myocardial B
infarction. I
Infusions O
of O
epinephrine O
(4 O
mug O
per O
kilogram O
per O
minute O
for O
6 O
hours) O
increased O
radiocalcium O
uptakes O
into O
intact O
myocardium O
and O
each O
of O
its O
subcellular O
components O
with O
the O
mitochondrial O
fraction O
showing O
the O
most O
consistent O
changes O
when O
compared O
to O
saline-infused O
control O
animals O
(4,957 O
vs. O
827 O
counts O
per O
minute O
per O
gram O
of O
dried O
tissue O
or O
fraction). O
Myocardial O
concentrations O
of O
calcium O
also O
increased O
significantly O
(12.0 O
vs. O
5.0 O
mg.per O
100 O
Gm. O
of O
fat-free O
dry O
weight). O
Infusions O
of O
calcium O
chloride O
sufficient O
to O
raise O
serum O
calcium O
concentrations O
2 O
mEq. O
per O
liter O
failed O
to O
increase O
calcium O
influx O
into O
the O
myocardial O
cell. O
Mitochondrial O
radiocalcium O
uptakes O
were O
significantly O
decreased O
in O
animals O
pretreated O
with O
acetylsalicylic O
acid O
or O
dipyridamole O
or O
when O
hydrocortisone O
was O
added O
to O
the O
epinephrine O
infusion O
(2,682,2,803, O
and O
3,424 O
counts O
per O
minute O
per O
gram O
of O
dried O
fraction, O
respectively). O
Myocardial O
calcium O
concentrations O
also O
were O
decreased O
(11.2, O
8.3, O
and O
8.9 O
mg. O
per O
100 O
Gm. O
of O
fat-free O
dry O
weight, O
respectively) O
in O
the O
three O
treatment O
groups, O
being O
significantly O
decreased O
only O
in O
the O
last O
two. O
Evidence O
of O
microscopic O
damage O
was O
graded O
as O
less O
severe O
in O
the O
three O
treatment O
groups. O
Acetylsalicylic O
acid, O
dipyridamole, O
and O
hydrocortisone O
all O
appear O
to O
have O
cardioprotective O
effects O
when O
tested O
in O
this O
model. O

We O
describe O
eight O
patients O
in O
whom O
cocaine O
use O
was O
related O
to O
stroke B
and O
review O
39 O
cases O
from O
the O
literature. O
Among O
these O
47 O
patients O
the O
mean O
(+/- O
SD) O
age O
was O
32.5 O
+/- O
12.1 O
years; O
76% O
(34/45) O
were O
men. O
Stroke B
followed O
cocaine O
use O
by O
inhalation, O
intranasal, O
intravenous, O
and O
intramuscular O
routes. O
Intracranial B
aneurysms I
or O
arteriovenous B
malformations I
were O
present O
in O
17 O
of O
32 O
patients O
studied O
angiographically O
or O
at O
autopsy; O
cerebral B
vasculitis I
was O
present O
in O
two O
patients. O
Cerebral B
infarction I
occurred O
in O
10 O
patients O
(22%), O
intracerebral B
hemorrhage I
in O
22 O
(49%), O
and O
subarachnoid B
hemorrhage I
in O
13 O
(29%). O
These O
data O
indicate O
that O
(1) O
the O
apparent O
incidence O
of O
stroke O
related O
to O
cocaine O
use O
is O
increasing; O
(2) O
cocaine-associated O
stroke O
occurs O
primarily O
in O
young O
adults; O
(3) O
stroke O
may O
follow O
any O
route O
of O
cocaine O
administration; O
(4) O
stroke O
after O
cocaine O
use O
is O
frequently O
associated O
with O
intracranial B
aneurysms I
and O
arteriovenous O
malformations; O
and O
(5) O
in O
cocaine-associated O
stroke, O
the O
frequency O
of O
intracranial B
hemorrhage I
exceeds O
that O
of O
cerebral B
infarction. I

We O
report O
the O
case O
of O
a O
woman O
complaining O
of O
dysphonia B
while O
she O
was O
treated O
by O
acitretin. O
Her O
symptoms O
totally O
regressed O
after O
drug O
withdrawal O
and O
reappeared O
when O
acitretin O
was O
reintroduced. O
To O
our O
knowledge, O
this O
is O
the O
first O
case O
of O
acitretin-induced O
dysphonia. O
This O
effect O
may O
be O
related O
to O
the O
pharmacological O
effect O
of O
this O
drug O
on O
mucous O
membranes. O

Nitroglycerin O
has O
been O
shown O
to O
reduce O
ST-segment O
elevation O
during O
acute B
myocardial I
infarction, I
an O
effect O
potentiated O
in O
the O
dog O
by O
agents O
that O
reverse O
nitroglycerin-induced O
hypotension. B
Our O
study O
was O
designed O
to O
determine O
the O
effects O
of O
combined O
nitroglycerin O
and O
phenylephrine O
therapy. O
Ten O
patients O
with O
acute O
transmural O
myocardial B
infarctions I
received O
intravenous O
nitroglycerin, O
sufficient O
to O
reduce O
mean O
arterial O
pressure O
from O
107 O
+/- O
6 O
to O
85 O
+/- O
6 O
mm O
Hg O
(P O
less O
than O
0.001), O
for O
60 O
minutes. O
Left O
ventricular O
filling O
pressure O
decreased O
from O
19 O
+/- O
2 O
to O
11 O
+/- O
2 O
mm O
Hg O
(P O
less O
than O
0.001). O
SigmaST, O
the O
sum O
of O
ST-segment O
elevations O
in O
16 O
precordial O
leads, O
decreased O
(P O
less O
than O
0.02) O
with O
intravenous O
nitroglycerin. O
Subsequent O
addition O
of O
phenylephrine O
infusion, O
sufficient O
to O
re-elevate O
mean O
arterial O
pressure O
to O
106 O
+/- O
4 O
mm O
Hg O
(P O
less O
than O
0.001) O
for O
30 O
minutes, O
increased O
left O
ventricular O
filling O
pressure O
to O
17 O
+/- O
2 O
mm O
Hg O
(P O
less O
than O
0.05) O
and O
also O
significantly O
increased O
sigmaST O
(P O
less O
than O
0.05). O
Our O
results O
suggest O
that O
addition O
of O
phenylephrine O
to O
nitroglycerin O
is O
not O
beneficial O
in O
the O
treatment O
of O
patients O
with O
acute O
myocardial O
infarction. O

1. O
Dexamethasone O
(Dex)-induced O
hypertension B
is O
characterized O
by O
endothelial O
dysfunction O
associated O
with O
nitric O
oxide O
(NO) O
deficiency O
and O
increased O
superoxide O
(O2-) O
production. O
Atorvastatin O
(Ato) O
possesses O
pleiotropic O
properties O
that O
have O
been O
reported O
to O
improve O
endothelial O
function O
through O
increased O
availability O
of O
NO O
and O
reduced O
O2- O
production O
in O
various O
forms O
of O
hypertension. O
In O
the O
present O
study, O
we O
investigated O
whether O
50 O
mg/kg O
per O
day, O
p.o., O
Ato O
could O
prevent O
endothelial O
NO O
synthase O
(eNOS) O
downregulation O
and O
the O
increase O
in O
O2- O
in O
Sprague-Dawley O
(SD) O
rats, O
thereby O
reducing O
blood O
pressure. O
2. O
Male O
SD O
rats O
(n O
= O
30) O
were O
treated O
with O
Ato O
(50 O
mg/kg O
per O
day O
in O
drinking O
water) O
or O
tap O
water O
for O
15 O
days. O
Dexamethasone O
(10 O
microg/kg O
per O
day, O
s.c.) O
or O
saline O
was O
started O
after O
4 O
days O
in O
Ato-treated O
and O
non-treated O
rats O
and O
continued O
for O
11-13 O
days. O
Systolic O
blood O
pressure O
(SBP) O
was O
measured O
on O
alternate O
days O
using O
the O
tail-cuff O
method. O
Endothelial O
function O
was O
assessed O
by O
acetylcholine-induced O
vasorelaxation O
and O
phenylephrine-induced O
vasoconstriction O
in O
aortic O
segments. O
Vascular O
eNOS O
mRNA O
was O
assessed O
by O
semi-quantitative O
reverse O
transcription-polymerase O
chain O
reaction. O
3. O
In O
rats O
treated O
with O
Dex O
alone, O
SBP O
was O
increased O
from O
109 O
+/- O
2 O
to O
133 O
+/- O
2 O
mmHg O
on O
Days O
4 O
and O
Day O
14, O
respectively O
(P O
< O
0.001). O
In O
the O
Ato O
+ O
Dex O
group, O
SBP O
was O
increased O
from O
113 O
+/- O
2 O
to O
119 O
+/- O
2 O
mmHg O
on O
Days O
4 O
to O
14, O
respectively O
(P O
< O
0.001), O
but O
was O
significantly O
lower O
than O
SBP O
in O
the O
group O
treated O
with O
Dex O
alone O
(P O
< O
0.05). O
Endothelial-dependent O
relaxation O
and O
eNOS O
mRNA O
expression O
were O
greater O
in O
the O
Dex O
+ O
Ato O
group O
than O
in O
the O
Dex O
only O
group O
(P O
< O
0.05 O
and O
P O
< O
0.0001, O
respectively). O
Aortic O
superoxide O
production O
was O
lower O
in O
the O
Dex O
+ O
Ato O
group O
compared O
with O
the O
group O
treated O
with O
Dex O
alone O
(P O
< O
0.0001). O
4. O
Treatment O
with O
Ato O
improved O
endothelial O
function, O
reduced O
superoxide O
production O
and O
reduced O
SBP O
in O
Dex-treated O
SD O
rats. O

Protective O
effect O
of O
verapamil O
on O
gastric B
hemorrhagic I
ulcers B
in O
severe O
atherosclerotic B
rats. O

Thiopentone O
pretreatment O
for O
propofol O
injection O
pain B
in O
ambulatory O
patients. O

Amiodarone-induced O
sinoatrial B
block. I

99mTc-glucarate O
for O
detection O
of O
isoproterenol-induced O
myocardial B
infarction I
in O
rats. O

OBJECTIVE: O
To O
examine O
the O
effect O
of O
raloxifene O
on O
major O
adverse O
events O
that O
occur O
with O
postmenopausal O
estrogen O
therapy O
or O
tamoxifen. O
METHODS: O
The O
Multiple O
Outcomes O
of O
Raloxifene O
Evaluation, O
a O
multicenter, O
randomized, O
double-blind O
trial, O
enrolled O
7,705 O
postmenopausal O
women O
with O
osteoporosis. B
Women O
were O
randomly O
assigned O
to O
raloxifene O
60 O
mg/d O
or O
120 O
mg/d O
or O
placebo. O
Outcomes O
included O
venous B
thromboembolism, I
cataracts, B
gallbladder B
disease, I
and O
endometrial B
hyperplasia I
or I
cancer. I
RESULTS: O
During O
a O
mean O
follow-up O
of O
3.3 O
years, O
raloxifene O
was O
associated O
with O
an O
increased O
risk O
for O
venous O
thromboembolism O
(relative O
risk O
[RR] O
2.1; O
95% O
confidence O
interval O
[CI] O
1.2-3.8). O
The O
excess O
event O
rate O
was O
1.8 O
per O
1,000 O
woman-years O
(95% O
CI O
-0.5-4.1), O
and O
the O
number O
needed O
to O
treat O
to O
cause O
1 O
event O
was O
170 O
(95% O
CI O
100-582) O
over O
3.3 O
years. O
Risk O
in O
the O
raloxifene O
group O
was O
higher O
than O
in O
the O
placebo O
group O
for O
the O
first O
2 O
years, O
but O
decreased O
to O
about O
the O
same O
rate O
as O
in O
the O
placebo O
group O
thereafter. O
Raloxifene O
did O
not O
increase O
risk O
for O
cataracts O
(RR O
0.9; O
95% O
CI O
0.8-1.1), O
gallbladder O
disease O
(RR O
1.0; O
95% O
CI O
0.7-1.3), O
endometrial O
hyperplasia O
(RR O
1.3; O
95% O
CI O
0.4-5.1), O
or O
endometrial B
cancer I
(RR O
0.9; O
95% O
CI O
0.3-2.7). O
CONCLUSION: O
Raloxifene O
was O
associated O
with O
an O
increased O
risk O
for O
venous O
thromboembolism, O
but O
there O
was O
no O
increased O
risk O
for O
cataracts, O
gallbladder O
disease, O
endometrial O
hyperplasia, O
or O
endometrial O
cancer. O
LEVEL O
OF O
EVIDENCE: O
I O

Sirolimus-associated O
proteinuria B
and O
renal B
dysfunction. I

We O
describe O
a O
case O
of O
transient O
neurological B
deficit I
that O
occurred O
after O
unilateral O
spinal O
anaesthesia O
with O
8 O
mg O
of O
1% O
hyperbaric O
bupivacaine O
slowly O
injected O
through O
a O
25-gauge O
pencil-point O
spinal O
needle. O
The O
surgery O
and O
anaesthesia O
were O
uneventful, O
but O
3 O
days O
after O
surgery, O
the O
patient O
reported O
an O
area O
of O
hypoaesthesia O
over O
L3-L4 O
dermatomes O
of O
the O
leg O
which O
had O
been O
operated O
on O
(loss O
of B
pinprick I
sensation) I
without I
reduction O
in O
muscular O
strength. O
Sensation O
in O
this O
area O
returned O
to O
normal O
over O
the O
following O
2 O
weeks. O
Prospective O
multicentre O
studies O
with O
a O
large O
population O
and O
a O
long O
follow-up O
should O
be O
performed O
in O
order O
to O
evaluate O
the O
incidence O
of O
this O
unusual O
side O
effect. O
However, O
we O
suggest O
that O
a O
low O
solution O
concentration O
should O
be O
preferred O
for O
unilateral O
spinal O
anaesthesia O
with O
a O
hyperbaric O
anaesthetic O
solution O
(if O
pencil-point O
needle O
and O
slow O
injection O
rate O
are O
employed), O
in O
order O
to O
minimize O
the O
risk O
of O
a O
localized O
high O
peak O
anaesthetic O
concentration, O
which O
might O
lead O
to O
a O
transient O
neurological O
deficit. O

Recurrent O
dysphonia B
and O
acitretin. O

Chronic B
active I
hepatitis I
associated O
with O
diclofenac O
sodium O
therapy. O

A O
case O
of O
tardive B
dyskinesia I
caused O
by O
metoclopramide. O

BACKGROUND: O
Incidence O
and O
risk O
factors O
for O
delirium B
during O
clozapine O
treatment O
require O
further O
clarification. O
METHODS: O
We O
used O
computerized O
pharmacy O
records O
to O
identify O
all O
adult O
psychiatric B
inpatients O
treated O
with O
clozapine O
(1995-96), O
reviewed O
their O
medical O
records O
to O
score O
incidence O
and O
severity O
of O
delirium, O
and O
tested O
associations O
with O
potential O
risk O
factors. O
RESULTS: O
Subjects O
(n O
= O
139) O
were O
72 O
women O
and O
67 O
men, O
aged O
40.8 O
+/- O
12.1 O
years, O
hospitalized O
for O
24.9 O
+/- O
23.3 O
days, O
and O
given O
clozapine, O
gradually O
increased O
to O
an O
average O
daily O
dose O
of O
282 O
+/- O
203 O
mg O
(3.45 O
+/- O
2.45 O
mg/kg) O
for O
18.9 O
+/- O
16.4 O
days. O
Delirium B
was O
diagnosed O
in O
14 O
(10.1 O
% O
incidence, O
or O
1.48 O
cases/person-years O
of O
exposure); O
71.4 O
% O
of O
cases O
were O
moderate O
or O
severe. O
Associated O
factors O
were O
co-treatment O
with O
other O
centrally O
antimuscarinic O
agents, O
poor O
clinical O
outcome, O
older O
age, O
and O
longer O
hospitalization O
(by O
17.5 O
days, O
increasing O
cost); O
sex, O
diagnosis O
or O
medical O
co-morbidity, O
and O
daily O
clozapine O
dose, O
which O
fell O
with O
age, O
were O
unrelated. O
CONCLUSIONS: O
Delirium O
was O
found O
in O
10 O
% O
of O
clozapine-treated O
inpatients, O
particularly O
in O
older O
patients O
exposed O
to O
other O
central O
anticholinergics. O
Delirium O
was O
inconsistently O
recognized O
clinically O
in O
milder O
cases O
and O
was O
associated O
with O
increased O
length-of-stay O
and O
higher O
costs, O
and O
inferior O
clinical O
outcome. O

Serotonergic O
antidepressants O
and O
urinary B
incontinence. I

Effects O
of O
long-term O
pretreatment O
with O
isoproterenol O
on O
bromocriptine-induced O
tachycardia B
in O
conscious O
rats. O

Mature O
male O
and O
female O
mice O
from O
six O
inbred O
stains O
were O
tested O
for O
susceptibility O
to O
behavioral O
seizures B
induced O
by O
a O
single O
injection O
of O
cocaine. O
Cocaine O
was O
injected O
ip O
over O
a O
range O
of O
doses O
(50-100 O
mg/kg) O
and O
behavior O
was O
monitored O
for O
20 O
minutes. O
Seizure B
end O
points O
included O
latency O
to O
forelimb O
or O
hindlimb O
clonus, O
latency O
to O
clonic O
running O
seizure O
and O
latency O
to O
jumping O
bouncing O
seizure. O
A O
range O
of O
strain O
specific O
sensitivities O
was O
documented O
with O
A/J O
and O
SJL O
mice O
being O
most O
sensitive O
and O
C57BL/6J O
most O
resistant. O
DBA/2J, O
BALB/cByJ O
and O
NZW/LacJ O
strains O
exhibited O
intermediate O
sensitivity. O
EEG O
recordings O
were O
made O
in O
SJL, O
A/J O
and O
C57BL/6J O
mice O
revealing O
a O
close O
correspondence O
between O
electrical O
activity O
and O
behavior. O
Additionally, O
levels O
of O
cocaine O
determined O
in O
hippocampus O
and O
cortex O
were O
not O
different O
between O
sensitive O
and O
resistant O
strains. O
Additional O
studies O
of O
these O
murine O
strains O
may O
be O
useful O
for O
investigating O
genetic O
influences O
on O
cocaine-induced O
seizures. O

Our O
objective O
was O
to O
investigate O
brain O
MR O
imaging O
findings O
and O
the O
utility O
of O
diffusion-weighted O
(DW) O
imaging O
in O
organ O
transplant O
patients O
who O
developed O
neurologic O
symptoms O
during O
tacrolimus O
therapy. O
Brain O
MR O
studies, O
including O
DW O
imaging, O
were O
prospectively O
performed O
in O
14 O
organ O
transplant O
patients O
receiving O
tacrolimus O
who O
developed O
neurologic B
complications. I
In O
each O
patient O
who O
had O
abnormalities O
on O
the O
initial O
MR O
study, O
a O
follow-up O
MR O
study O
was O
performed O
1 O
month O
later. O
Apparent O
diffusion O
coefficient O
(ADC) O
values O
on O
the O
initial O
MR O
study O
were O
correlated O
with O
reversibility O
of O
the O
lesions. O
Of O
the O
14 O
patients, O
5 O
(35.7%) O
had O
white B
matter I
abnormalities, I
1 O
(7.1%) O
had O
putaminal B
hemorrhage, I
and O
8 O
(57.1%) O
had O
normal O
findings O
on O
initial O
MR O
images. O
Among O
the O
5 O
patients O
with O
white O
matter O
abnormalities, O
4 O
patients O
(80.0%) O
showed O
higher O
than O
normal O
ADC O
values O
on O
initial O
MR O
images, O
and O
all O
showed O
complete O
resolution O
on O
follow-up O
images. O
The O
remaining O
1 O
patient O
(20.0%) O
showed O
lower O
than O
normal O
ADC O
value O
and O
showed O
incomplete O
resolution O
with O
cortical B
laminar I
necrosis. I
Diffusion-weighted O
imaging O
may O
be O
useful O
in O
predicting O
the O
outcomes O
of O
the O
lesions O
of O
tacrolimus-induced O
neurotoxicity. B

We O
report O
a O
case O
of O
severe O
citrate O
toxicity B
during O
volunteer O
donor O
apheresis O
platelet O
collection. O
The O
donor O
was O
a O
40-year-old O
female, O
first-time O
apheresis O
platelet O
donor. O
Past O
medical O
history O
was O
remarkable O
for O
hypertension, B
hyperlipidemia, B
and O
depression. B
Reported O
medications O
included O
bumetanide, O
pravastatin, O
and O
paroxetine. O
Thirty O
minutes O
from O
the O
start O
of O
the O
procedure, O
the O
donor O
noted O
tingling O
around O
the O
mouth, O
hands, O
and O
feet. O
She O
then O
very O
rapidly O
developed O
acute O
onset O
of O
severe O
facial O
and O
extremity O
tetany. B
Empirical O
treatment O
with O
intravenous O
calcium O
gluconate O
was O
initiated, O
and O
muscle B
contractions I
slowly O
subsided O
over O
approximately O
10 O
to O
15 O
minutes. O
The O
events O
are O
consistent O
with O
a O
severe O
reaction O
to O
calcium O
chelation O
by O
sodium O
citrate O
anticoagulant O
resulting O
in O
symptomatic O
systemic O
hypocalcemia. B
Upon O
additional O
retrospective O
analysis, O
it O
was O
noted O
that O
bumetanide O
is O
a O
loop O
diuretic O
that O
may O
cause O
significant O
hypocalcemia. O
We O
conclude O
that O
careful O
screening O
for O
medications O
and O
underlying O
conditions O
predisposing O
to O
hypocalcemia O
is O
recommended O
to O
help O
prevent O
severe O
reactions O
due O
to O
citrate O
toxicity. O
Laboratory O
measurement O
of O
pre-procedure O
serum O
calcium O
levels O
in O
selected O
donors O
may O
identify O
cases O
requiring O
heightened O
vigilance. O
The O
case O
also O
illustrates O
the O
importance O
of O
maintaining O
preparedness O
for O
managing O
rare O
but O
serious O
reactions O
in O
volunteer O
apheresis O
blood O
donors. O

Since O
the O
introduction O
of O
angiotensin O
converting O
enzyme O
(ACE) O
inhibitors O
into O
the O
adjunctive O
treatment O
of O
patients O
with O
congestive B
heart I
failure, I
cases O
of O
severe O
hypotension, B
especially O
on O
the O
first O
day O
of O
treatment, O
have O
occasionally O
been O
reported. O
To O
assess O
the O
safety O
of O
the O
ACE O
inhibitor O
enalapril O
a O
multicenter, O
randomized, O
prazosin-controlled O
trial O
was O
designed O
that O
compared O
the O
incidence O
and O
severity O
of O
symptomatic O
hypotension O
on O
the O
first O
day O
of O
treatment. O
Trial O
medication O
was O
2.5 O
mg O
enalapril O
or O
0.5 O
prazosin. O
Subjects O
were O
1210 O
inpatients O
with O
New O
York O
Heart O
Association O
(NYHA) O
functional O
class O
II O
and O
III. O
Patients O
who O
received O
enalapril O
experienced O
clinically O
and O
statistically O
significantly O
less O
symptomatic O
hypotension O
(5.2%) O
than O
the O
patients O
who O
received O
prazosin O
(12.9%). O
All O
patients O
recovered. O
It O
was O
concluded O
that O
treatment O
with O
enalapril O
was O
well O
tolerated O
and O
it O
is, O
therefore, O
unreasonable O
to O
restrict O
the O
initiation O
of O
treatment O
with O
enalapril O
to O
inpatients. O

A O
healthy O
17-year-old O
male O
received O
standard O
intermittent O
doses O
of O
pethidine O
via O
a O
patient-controlled O
analgesia O
(PCA) O
pump O
for O
management O
of O
postoperative B
pain I
control. O
Twenty-three O
h O
postoperatively O
he O
developed O
a O
brief O
self-limited O
seizure. B
Both O
plasma O
pethidine O
and O
norpethidine O
were O
elevated O
in O
the O
range O
associated O
with O
clinical O
manifestations O
of O
central O
nervous O
system O
excitation. O
No O
other O
risk O
factors O
for O
CNS O
toxicity B
were O
identified. O
This O
method O
allowed O
frequent O
self-dosing O
of O
pethidine O
at O
short O
time O
intervals O
and O
rapid O
accumulation O
of O
pethidine O
and O
norpethidine. O
The O
routine O
use O
of O
pethidine O
via O
PCA O
even O
for O
a O
brief O
postoperative O
analgesia O
should O
be O
reconsidered. O

Sequential O
observations O
of O
exencephaly B
and O
subsequent O
morphological O
changes O
by O
mouse O
exo O
utero O
development O
system: O
analysis O
of O
the O
mechanism O
of O
transformation O
from O
exencephaly O
to O
anencephaly. B

Myasthenia B
gravis I
caused O
by O
penicillamine O
and O
chloroquine O
therapy O
for O
rheumatoid B
arthritis. I

Thrombotic B
microangiopathy I
and O
renal B
failure I
associated O
with O
antineoplastic O
chemotherapy. O

A O
large O
group O
of O
patients O
with O
suspected O
allergic B
reactions I
to O
beta-lactam O
antibiotics O
was O
evaluated. O
A O
detailed O
clinical O
history, O
together O
with O
skin O
tests, O
RAST O
(radioallergosorbent O
test), O
and O
controlled O
challenge O
tests, O
was O
used O
to O
establish O
whether O
patients O
allergic O
to O
beta-lactam O
antibiotics O
had O
selective O
immediate O
allergic O
responses O
to O
amoxicillin O
(AX) O
or O
were O
cross-reacting O
with O
other O
penicillin O
derivatives. O
Skin O
tests O
were O
performed O
with O
benzylpenicilloyl-poly-L-lysine O
(BPO-PLL), O
benzylpenicilloate, O
benzylpenicillin O
(PG), O
ampicillin O
(AMP), O
and O
AX. O
RAST O
for O
BPO-PLL O
and O
AX-PLL O
was O
done. O
When O
both O
skin O
test O
and O
RAST O
for O
BPO O
were O
negative, O
single-blind, O
placebo-controlled O
challenge O
tests O
were O
done O
to O
ensure O
tolerance O
of O
PG O
or O
sensitivity O
to O
AX. O
A O
total O
of O
177 O
patients O
were O
diagnosed O
as O
allergic O
to O
beta-lactam O
antibiotics. O
We O
selected O
the O
54 O
(30.5%) O
cases O
of O
immediate O
AX O
allergy B
with O
good O
tolerance O
of O
PG. O
Anaphylaxis B
was O
seen O
in O
37 O
patients O
(69%), O
the O
other O
17 O
(31%) O
having O
urticaria B
and/or O
angioedema. B
All O
the O
patients O
were O
skin O
test O
negative O
to O
BPO; O
49 O
of O
51 O
(96%) O
were O
also O
negative O
to O
MDM, B
and O
44 O
of O
46 O
(96%) O
to O
PG. O
Skin O
tests O
with O
AX O
were O
positive O
in O
34 O
(63%) O
patients. O
RAST O
was O
positive O
for O
AX O
in O
22 O
patients O
(41%) O
and O
to O
BPO O
in O
just O
5 O
(9%). O
None O
of O
the O
sera O
with O
negative O
RAST O
for O
AX O
were O
positive O
to O
BPO. O
Challenge O
tests O
with O
AX O
were O
performed O
in O
23 O
subjects O
(43%) O
to O
establish O
the O
diagnosis O
of O
immediate O
allergic O
reaction O
to O
AX, O
and O
in O
15 O
cases O
(28%) O
both O
skin O
test O
and O
RAST O
for O
AX O
were O
negative. O
PG O
was O
well O
tolerated O
by O
all O
54 O
patients. O
We O
describe O
the O
largest O
group O
of O
AX-allergic O
patients O
who O
have O
tolerated O
PG O
reported O
so O
far. O
Diagnosis O
of O
these O
patients O
can O
be O
achieved O
only O
if O
specific O
AX-related O
reagents O
are O
employed. O
Further O
studies O
are O
necessary O
to O
determine O
the O
exact O
extent O
of O
this O
problem O
and O
to O
improve O
the O
efficacy O
of O
diagnostic O
methods. O

Sodium O
status O
influences O
chronic O
amphotericin O
B O
nephrotoxicity B
in O
rats. O

Salvage O
therapy O
with O
nelarabine, O
etoposide, O
and O
cyclophosphamide O
in O
relapsed/refractory O
paediatric O
T-cell B
lymphoblastic I
leukaemia I
and I
lymphoma. I

We O
report O
the O
case O
of O
a O
patient O
in O
whom O
troleandomycin-induced O
hepatitis B
was O
followed O
by O
prolonged O
anicteric O
cholestasis. B
Jaundice B
occurred O
after O
administration O
of O
troleandomycin O
for O
7 O
days O
and O
was O
associated O
with O
hypereosinophilia. B
Jaundice O
disappeared O
within O
3 O
months O
but O
was O
followed O
by O
prolonged O
anicteric O
cholestasis O
marked O
by O
pruritus B
and O
high O
levels O
of O
alkaline O
phosphatase O
and O
gammaglutamyltransferase O
activities. O
Finally, O
pruritus O
disappeared O
within O
19 O
months, O
and O
liver O
tests O
returned O
to O
normal O
27 O
months O
after O
the O
onset O
of O
hepatitis. O
This O
observation O
demonstrates O
that O
prolonged O
cholestasis O
can O
follow O
troleandomycin-induced O
acute O
hepatitis. O

In O
this O
study, O
three O
Chinese O
patients O
with O
ticlopidine-induced O
aplastic B
anemia I
were O
reported O
and O
another O
13 O
patients O
in O
the O
English O
literature O
were O
reviewed. O
We O
attempted O
to O
find O
underlying O
similarities, O
evaluate O
the O
risk O
factors, O
and O
identify O
appropriate O
treatment O
for O
this O
complication. O
All O
but O
one O
of O
the O
patients O
were O
over O
60 O
years O
old, O
and O
the O
6 O
who O
died O
were O
all O
older O
than O
65. O
Therefore, O
old O
age O
may O
be O
a O
risk O
factor O
for O
developing O
this O
complication. O
Agranulocytosis B
occurred O
3-20 O
weeks O
after O
initiation O
of O
ticlopidine, O
so O
frequent O
examination O
of O
white O
cell O
count O
during O
treatment O
is O
recommended. O
There O
seemed O
to O
be O
no O
direct O
correlation O
between O
the O
dose O
or O
duration O
used O
and O
the O
severity O
of O
bone B
marrow I
suppression. I
Treatment O
for O
ticlopidine-induced O
aplastic O
anemia O
with O
colony-stimulating O
factors O
seemed O
to O
have O
little O
effect. O
The O
fact O
that O
5 O
of O
the O
6 O
patients O
who O
received O
concurrent O
calcium O
channel O
blockers O
died, O
should O
alert O
clinicians O
to O
be O
more O
cautious O
when O
using O
these O
two O
drugs O
simultaneously. O

Valproic O
acid O
induced O
encephalopathy--19 B
new O
cases O
in O
Germany O
from O
1994 O
to O
2003--a O
side O
effect O
associated O
to O
VPA-therapy O
not O
only O
in O
young O
children. O

Possible O
intramuscular O
midazolam-associated O
cardiorespiratory B
arrest I
and O
death. B

BACKGROUND O
AND O
OBJECTIVE: O
Despite O
advantages O
of O
induction O
and O
maintenance O
of O
anaesthesia O
with O
sevoflurane, O
postoperative B
nausea I
and I
vomiting I
occurs O
frequently. O
Fentanyl O
is O
a O
commonly O
used O
supplement O
that O
may O
contribute O
to O
this, O
although O
it O
may O
also O
improve O
analgesia. O
METHODS: O
This O
double-blind O
study O
examined O
the O
incidence O
and O
severity O
of O
postoperative O
nausea O
and O
vomiting O
and O
pain B
in O
the O
first O
24 O
h O
after O
sevoflurane O
anaesthesia O
in O
216 O
adult O
day O
surgery O
patients. O
Patients O
were O
randomly O
allocated O
to O
either O
receive O
or O
not O
receive O
1 O
1 O
fentanyl, O
while O
a O
third O
group O
received O
dexamethasone O
in O
addition O
to O
fentanyl. O
RESULTS: O
Omission O
of O
fentanyl O
did O
not O
reduce O
the O
overall O
incidence O
of O
postoperative O
nausea O
and O
vomiting, O
but O
did O
reduce O
the O
incidence O
of O
vomiting O
and/or O
moderate O
to O
severe O
nausea O
prior O
to O
discharge O
from O
20% O
and O
17% O
with O
fentanyl O
and O
fentanyl-dexamethasone, O
respectively, O
to O
5% O
(P O
= O
0.013). O
Antiemetic O
requirements O
were O
reduced O
from O
24% O
and O
31% O
to O
7% O
(P O
= O
0.0012). O
Dexamethasone O
had O
no O
significant O
effect O
on O
the O
incidence O
or O
severity O
of O
postoperative O
nausea O
and O
vomiting. O
Combining O
the O
two O
fentanyl O
groups O
revealed O
further O
significant O
benefits O
from O
the O
avoidance O
of O
opioids, O
reducing O
postoperative O
nausea O
and O
vomiting O
and O
nausea O
prior O
to O
discharge O
from O
35% O
and O
33% O
to O
22% O
and O
19% O
(P O
= O
0.049 O
and O
P O
= O
0.035), O
respectively, O
while O
nausea O
in O
the O
first O
24 O
h O
was O
decreased O
from O
42% O
to O
27% O
(P O
= O
0.034). O
Pain B
severity O
and O
analgesic O
requirements O
were O
unaffected O
by O
the O
omission O
of O
fentanyl. O
Fentanyl O
did O
reduce O
minor O
intraoperative O
movement O
but O
had O
no O
sevoflurane-sparing O
effect O
and O
increased O
respiratory B
depression, I
hypotension B
and O
bradycardia. B
CONCLUSION: O
As O
fentanyl O
exacerbated O
postoperative O
nausea O
and O
vomiting O
without O
an O
improvement O
in O
postoperative B
pain I
and O
also O
had O
adverse O
cardiorespiratory O
effects, O
it O
appears O
to O
be O
an O
unnecessary O
and O
possibly O
detrimental O
supplement O
to O
sevoflurane O
in O
day O
surgery. O

This O
article O
reports O
the O
changes O
in O
gallbladder O
function O
examined O
by O
ultrasonography O
in O
20 O
Chinese O
patients O
with O
active O
acromegaly B
treated O
with O
sc O
injection O
of O
the O
somatostatin O
analog O
octreotide O
in O
dosages O
of O
300-1500 O
micrograms/day O
for O
a O
mean O
of O
24.2 O
+/- O
13.9 O
months. O
During O
treatment O
with O
octreotide, O
17 O
patients O
developed O
sludge, O
10 O
had O
gallstones, B
and O
1 O
developed O
acute B
cholecystitis B
requiring O
surgery. O
In O
all O
of O
7 O
patients O
examined O
acutely, O
gallbladder O
contractility O
was O
inhibited O
after O
a O
single O
100-micrograms O
injection. O
In O
8 O
patients O
followed O
for O
24 O
weeks, O
gallbladder O
contractility O
remained O
depressed B
throughout O
therapy. O
After O
withdrawal O
of O
octreotide O
in O
10 O
patients O
without O
gallstones, O
8 O
patients O
assessed O
had O
return O
of O
normal O
gallbladder O
contractility O
within O
1 O
month. O
In O
8 O
of O
the O
remaining O
10 O
patients O
who O
developed O
gallstones O
during O
treatment, O
gallbladder O
contractility O
normalized O
in O
5 O
patients O
(3 O
of O
whom O
has O
disappearance O
of O
their O
stones O
within O
3 O
weeks), O
and O
remained O
depressed O
in O
3 O
(2 O
of O
whom O
had O
stones O
present O
at O
6 O
months). O
Our O
results O
suggest O
that O
the O
suppression O
of O
gallbladder O
contractility O
is O
the O
cause O
of O
the O
successive O
formation O
of O
bile O
sludge, O
gallstones, O
and O
cholecystitis O
during O
octreotide O
therapy O
in O
Chinese O
acromegalic B
patients. O
It O
is O
therefore O
very O
important O
to O
follow O
the O
changes O
of O
gallbladder O
function O
during O
long-term O
octreotide O
therapy O
of O
acromegalic O
patients. O

Effect O
of O
humoral O
modulators O
of O
morphine-induced O
increase B
in I
locomotor I
activity I
of O
mice. O

The O
effect O
of O
the O
converting O
enzyme O
inhibitor O
(CEI) O
enalapril O
was O
assessed O
in O
Munich-Wistar O
rats O
with O
established O
adriamycin O
nephrosis. B
Rats O
were O
given O
a O
single O
dose O
of O
adriamycin O
and O
one O
month O
later O
divided O
into O
four O
groups O
matched O
for O
albuminuria, B
blood O
pressure, O
and O
plasma O
albumin O
concentration. O
Groups O
1 O
and O
3 O
remained O
untreated O
while O
groups O
2 O
and O
4 O
received O
enalapril. O
Groups O
1 O
and O
2 O
underwent O
micropuncture O
studies O
after O
10 O
days. O
These O
short-term O
studies O
showed O
that O
enalapril O
reduced O
arterial O
blood O
pressure O
(101 O
+/- O
2 O
vs. O
124 O
+/- O
3 O
mm O
Hg, O
group O
2 O
vs. O
1, O
P O
less O
than O
0.05) O
and O
glomerular O
capillary O
pressure O
(54 O
+/- O
1 O
vs. O
61 O
+/- O
2 O
mm O
Hg, O
P O
less O
than O
0.05) O
without O
reducing O
albuminuria O
(617 O
+/- O
50 O
vs. O
570 O
+/- O
47 O
mg/day) O
or O
GFR O
(1.03 O
+/- O
0.04 O
vs. O
1.04 O
+/- O
0.11 O
ml/min). O
Groups O
3 O
and O
4 O
were O
studied O
at O
four O
and O
at O
six O
months O
to O
assess O
the O
effect O
of O
enalapril O
on O
progression O
of O
renal B
injury I
in O
adriamycin O
nephrosis. O
Chronic O
enalapril O
treatment O
reduced O
blood O
pressure O
without O
reducing O
albuminuria O
in O
group O
4. O
Untreated O
group O
3 O
rats O
exhibited O
a O
progressive O
reduction O
in O
GFR O
(0.35 O
+/- O
0.08 O
ml/min O
at O
4 O
months, O
0.27 O
+/- O
0.07 O
ml/min O
at O
6 O
months). O
Enalapril O
treatment O
blunted O
but O
did O
not O
prevent O
reduction O
in O
GFR O
in O
group O
4 O
(0.86 O
+/- O
0.15 O
ml/min O
at O
4 O
months, O
0.69 O
+/- O
0.13 O
ml/min O
at O
6 O
months, O
both O
P O
less O
than O
0.05 O
vs. O
group O
3). O
Reduction O
in O
GFR O
was O
associated O
with O
the O
development O
of O
glomerular B
sclerosis I
in O
both O
treated O
and O
untreated O
rats.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O

Acromegaly B
is O
an O
endocrine B
disorder I
caused O
by O
chronic O
excessive O
growth O
hormone O
secretion O
from O
the O
anterior O
pituitary O
gland. O
Significant O
disfiguring O
changes O
occur O
as O
a O
result O
of O
bone, O
cartilage, O
and O
soft O
tissue O
hypertrophy, B
including O
the O
thickening O
of O
the O
skin, O
coarsening O
of O
facial O
features, O
and O
cutis B
verticis I
gyrata. I
Pseudoacromegaly, B
on O
the O
other O
hand, O
is O
the O
presence O
of O
similar O
acromegaloid O
features O
in O
the O
absence O
of O
elevated O
growth O
hormone O
or O
insulin-like O
growth O
factor O
levels. O
We O
present O
a O
patient O
with O
pseudoacromegaly B
that O
resulted O
from O
the O
long-term O
use O
of O
minoxidil O
at O
an O
unusually O
high O
dose. O
This O
is O
the O
first O
case O
report O
of O
pseudoacromegaly O
as O
a O
side O
effect O
of O
minoxidil O
use. O

Sinus B
arrest I
associated O
with O
continuous-infusion O
cimetidine. O

Noxious O
chemical O
stimulation O
of O
rat O
facial O
mucosa O
increases O
intracranial O
blood O
flow O
through O
a O
trigemino-parasympathetic O
reflex--an O
experimental O
model O
for O
vascular B
dysfunctions I
in O
cluster B
headache. I

Angiosarcoma B
of I
the I
liver I
occurred O
in O
a O
76-year-old O
man O
who O
had O
been O
treated O
for O
a O
well-differentiated O
adenocarcinoma B
of I
the I
liver I
with O
diethylstilbestrol O
for O
13 O
years. O
Angiosarcoma O
was O
also O
present O
within O
pulmonary O
and O
renal O
arteries. O
The O
possibility O
that O
the O
intraarterial B
lesions I
might O
represent O
independent O
primary O
tumors B
is O
considered. O

The O
present O
study O
was O
designed O
to O
examine O
the O
effect O
of O
5-HT1B O
receptor O
ligands O
microinjected O
into O
the O
subregions O
of O
the O
nucleus O
accumbens O
(the O
shell O
and O
the O
core) O
on O
the O
locomotor B
hyperactivity I
induced O
by O
cocaine O
in O
rats. O
Male O
Wistar O
rats O
were O
implanted O
bilaterally O
with O
cannulae O
into O
the O
accumbens O
shell O
or O
core, O
and O
then O
were O
locally O
injected O
with O
GR O
55562 O
(an O
antagonist O
of O
5-HT1B O
receptors) O
or O
CP O
93129 O
(an O
agonist O
of O
5-HT1B O
receptors). O
Given O
alone O
to O
any O
accumbal O
subregion, O
GR O
55562 O
(0.1-10 O
microg/side) O
or O
CP O
93129 O
(0.1-10 O
microg/side) O
did O
not O
change O
basal O
locomotor O
activity. O
Systemic O
cocaine O
(10 O
mg/kg) O
significantly O
increased O
the O
locomotor O
activity O
of O
rats. O
GR O
55562 O
(0.1-10 O
microg/side), O
administered O
intra-accumbens O
shell O
prior O
to O
cocaine, O
dose-dependently O
attenuated O
the O
psychostimulant-induced O
locomotor O
hyperactivity. O
Such O
attenuation O
was O
not O
found O
in O
animals O
which O
had O
been O
injected O
with O
GR O
55562 O
into O
the O
accumbens O
core. O
When O
injected O
into O
the O
accumbens O
shell O
(but O
not O
the O
core) O
before O
cocaine, O
CP O
93129 O
(0.1-10 O
microg/side) O
enhanced O
the O
locomotor O
response O
to O
cocaine; O
the O
maximum O
effect O
being O
observed O
after O
10 O
microg/side O
of O
the O
agonist. O
The O
later O
enhancement O
was O
attenuated O
after O
intra-accumbens O
shell O
treatment O
with O
GR O
55562 O
(1 O
microg/side). O
Our O
findings O
indicate O
that O
cocaine O
induced O
hyperlocomotion B
is O
modified O
by O
5-HT1B O
receptor O
ligands O
microinjected O
into O
the O
accumbens O
shell, O
but O
not O
core, O
this O
modification O
consisting O
in O
inhibitory O
and O
facilitatory O
effects O
of O
the O
5-HT1B O
receptor O
antagonist O
(GR O
55562) O
and O
agonist O
(CP O
93129), O
respectively. O
In O
other O
words, O
the O
present O
results O
suggest O
that O
the O
accumbal O
shell O
5-HT1B O
receptors O
play O
a O
permissive O
role O
in O
the O
behavioural O
response O
to O
the O
psychostimulant. O

Pneumonitis, B
bilateral O
pleural B
effusions, I
echocardiographic O
evidence O
of O
cardiac B
tamponade, I
and O
positive O
autoantibodies O
developed O
in O
a O
43-year-old O
man, O
who O
was O
receiving O
long-term O
sulfasalazine O
therapy O
for O
chronic O
ulcerative B
colitis. I
After O
cessation O
of O
the O
sulfasalazine O
and O
completion O
of O
a O
six-week O
course O
of O
corticosteroids, O
these O
problems O
resolved O
over O
a O
period O
of O
four O
to O
six O
months. O
It O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine-induced O
lupus, B
which O
manifested O
with O
serositis B
and O
pulmonary O
parenchymal O
involvement O
in O
the O
absence O
of O
joint O
symptoms. O
Physicians O
who O
use O
sulfasalazine O
to O
treat O
patients O
with O
inflammatory B
bowel I
disease I
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine-induced O
lupus B
syndrome. I

Upregulation O
of O
the O
expression O
of O
vasopressin O
gene O
in O
the O
paraventricular O
and O
supraoptic O
nuclei O
of O
the O
lithium-induced O
diabetes B
insipidus I
rat. O

Upregulation O
of O
brain O
expression O
of O
P-glycoprotein O
in O
MRP2-deficient O
TR(-) O
rats O
resembles O
seizure-induced B
up-regulation O
of O
this O
drug O
efflux O
transporter O
in O
normal O
rats. O

Anti-oxidant O
effects O
of O
atorvastatin O
in O
dexamethasone-induced O
hypertension B
in O
the O
rat. O

Differential O
effects O
of O
gamma-hexachlorocyclohexane O
(lindane) O
on O
pharmacologically-induced O
seizures. B

Development O
of O
clear B
cell I
adenocarcinoma I
in O
DES-exposed O
offspring O
under O
observation. O

Hepatitis B
B I
virus O
(HBV) O
is O
one O
of O
the O
major O
causes O
of O
chronic O
liver B
disease I
worldwide. O
Cancer B
patients O
who O
are O
chronic O
carriers O
of O
HBV O
have O
a O
higher O
hepatic B
complication I
rate O
while O
receiving O
cytotoxic O
chemotherapy O
(CT) O
and O
this O
has O
mainly O
been O
attributed O
to O
HBV O
reactivation. O
In O
this O
study, O
cancer B
patients O
who O
have O
solid O
and O
hematological B
malignancies I
with O
chronic O
HBV B
infection I
received O
the O
antiviral O
agent O
lamivudine O
prior O
and O
during O
CT O
compared O
with O
historical O
control O
group O
who O
did O
not O
receive O
lamivudine. O
The O
objectives O
were O
to O
assess O
the O
efficacy O
of O
lamivudine O
in O
reducing O
the O
incidence O
of O
HBV O
reactivation, O
and O
diminishing O
morbidity O
and O
mortality O
during O
CT. O
Two O
groups O
were O
compared O
in O
this O
study. O
The O
prophylactic O
lamivudin O
group O
consisted O
of O
37 O
patients O
who O
received O
prophylactic O
lamivudine O
treatment. O
The O
historical O
controls O
consisted O
of O
50 O
consecutive O
patients O
who O
underwent O
CT O
without O
prophylactic O
lamivudine. O
They O
were O
followed O
up O
during O
and O
for O
8 O
weeks O
after O
CT. O
The O
outcomes O
were O
compared O
for O
both O
groups. O
Of O
our O
control O
group O
(n= O
50), O
21 O
patients O
(42%) O
were O
established O
hepatitis. B
Twelve O
(24%) O
of O
them O
were O
evaluated O
as O
severe O
hepatitis. O
In O
the O
prophylactic O
lamivudine O
group O
severe O
hepatitis O
were O
observed O
only O
in O
1 O
patient O
(2.7%) O
of O
37 O
patients O
(p O
< O
0.006). O
Comparison O
of O
the O
mean O
ALT O
values O
revealed O
significantly O
higher O
mean O
alanine O
aminotransferase O
(ALT) O
values O
in O
the O
control O
group O
than O
the O
prophylactic O
lamivudine O
group; O
154:64 O
(p O
< O
0.32). O
Our O
study O
suggests O
that O
prophylactic O
lamivudine O
significantly O
decreases O
the O
incidence O
of O
HBV O
reactivation O
and O
overall O
morbidity O
in O
cancer O
patients O
during O
and O
after O
immunosuppressive O
therapy. O
Further O
studies O
are O
needed O
to O
determine O
the O
most O
appropriate O
nucleoside O
or O
nucleotide O
analogue O
for O
antiviral O
prophylaxis O
during O
CT O
and O
the O
optimal O
duration O
of O
administration O
after O
completion O
of O
CT. O

Crossover O
comparison O
of O
efficacy O
and O
preference O
for O
rizatriptan O
10 O
mg O
versus O
ergotamine/caffeine O
in O
migraine. B

The O
expression O
of O
arginine O
vasopressin O
(AVP) O
gene O
in O
the O
paraventricular O
(PVN) O
and O
supraoptic O
nuclei O
(SON) O
was O
investigated O
in O
rats O
with O
lithium O
(Li)-induced O
polyuria, B
using O
in O
situ O
hybridization O
histochemistry O
and O
radioimmunoassay. O
The O
male O
Wistar O
rats O
consuming O
a O
diet O
that O
contained O
LiCl O
(60 O
mmol/kg) O
for O
4 O
weeks O
developed O
marked O
polyuria. O
The O
Li-treated O
rats O
produced O
a O
large O
volume O
of O
hypotonic O
urine O
with O
low O
ionic O
concentrations. O
Plasma O
sodium O
concentrations O
were O
found O
to O
be O
slightly O
increased O
in O
the O
Li-treated O
rats O
compared O
with O
those O
in O
controls. O
Plasma O
concentration O
of O
AVP O
and O
transcripts O
of O
AVP O
gene O
in O
the O
PVN O
and O
SON O
were O
significantly O
increased O
in O
the O
Li-treated O
rats O
compared O
with O
controls. O
These O
results O
suggest O
that O
dehydration B
and/or O
the O
activation O
of O
visceral O
afferent O
inputs O
may O
contribute O
to O
the O
elevation O
of O
plasma O
AVP O
and O
the O
upregulation O
of O
AVP O
gene O
expression O
in O
the O
PVN O
and O
the O
SON O
of O
the O
Li-induced O
diabetes B
insipidus I
rat. O

BACKGROUND: O
Sirolimus O
(SRL) O
may O
supplement O
calcineurin O
inhibitors O
in O
clinical O
organ O
transplantation. O
These O
are O
nephrotoxic, B
but O
SRL O
seems O
to O
act O
differently O
displaying O
only O
minor O
nephrotoxic O
effects, O
although O
this O
question O
is O
still O
open. O
In O
a O
number O
of O
treatment O
protocols O
where O
SRL O
was O
combined O
with O
a O
calcineurin O
inhibitor O
indications O
of O
a O
synergistic O
nephrotoxic O
effect O
were O
described. O
The O
aim O
of O
this O
study O
was O
to O
examine O
further O
the O
renal O
function, O
including O
morphological O
analysis O
of O
the O
kidneys O
of O
male O
Sprague-Dawley O
rats O
treated O
with O
either O
cyclosporine O
A O
(CsA), O
tacrolimus O
(FK506) O
or O
SRL O
as O
monotherapies O
or O
in O
different O
combinations. O
METHODS: O
For O
a O
period O
of O
2 O
weeks, O
CsA O
15 O
mg/kg/day O
(given O
orally), O
FK506 O
3.0 O
mg/kg/day O
(given O
orally) O
or O
SRL O
0.4 O
mg/kg/day O
(given O
intraperitoneally) O
was O
administered O
once O
a O
day O
as O
these O
doses O
have O
earlier O
been O
found O
to O
achieve O
a O
significant O
immunosuppressive O
effect O
in O
Sprague-Dawley O
rats. O
In O
the O
'conscious O
catheterized O
rat' O
model, O
the O
glomerular O
filtration O
rate O
(GFR) O
was O
measured O
as O
the O
clearance O
of O
Cr(EDTA). O
The O
morphological O
analysis O
of O
the O
kidneys O
included O
a O
semi-quantitative O
scoring O
system O
analysing O
the O
degree O
of O
striped O
fibrosis, B
subcapsular O
fibrosis O
and O
the O
number O
of O
basophilic O
tubules, O
plus O
an O
additional O
stereological O
analysis O
of O
the O
total O
grade O
of O
fibrosis O
in O
the O
cortex O
stained O
with O
Sirius O
Red. O
RESULTS: O
CsA, O
FK506 O
and O
SRL O
all O
significantly O
decreased O
the O
GFR. O
A O
further O
deterioration O
was O
seen O
when O
CsA O
was O
combined O
with O
either O
FK506 O
or O
SRL, O
whereas O
the O
GFR O
remained O
unchanged O
in O
the O
group O
treated O
with O
FK506 O
plus O
SRL O
when O
compared O
with O
treatment O
with O
any O
of O
the O
single O
substances. O
The O
morphological O
changes O
presented O
a O
similar O
pattern. O
The O
semi-quantitative O
scoring O
was O
significantly O
worst O
in O
the O
group O
treated O
with O
CsA O
plus O
SRL O
(P<0.001 O
compared O
with O
controls) O
and O
the O
analysis O
of O
the O
total O
grade O
of O
fibrosis O
also O
showed O
the O
highest O
proportion O
in O
the O
same O
group O
and O
was O
significantly O
different O
from O
controls O
(P<0.02). O
The O
FK506 O
plus O
SRL O
combination O
showed O
only O
a O
marginally O
higher O
degree O
of O
fibrosis O
as O
compared O
with O
controls O
(P=0.05). O
CONCLUSION: O
This O
rat O
study O
demonstrated O
a O
synergistic O
nephrotoxic O
effect O
of O
CsA O
plus O
SRL, O
whereas O
FK506 O
plus O
SRL O
was O
better O
tolerated. O

CI-921 O
(NSC O
343499; O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] O
-N,5-dimethyl- O
4-acridinecarboxamide) O
is O
a O
topoisomerase O
II O
poison O
with O
high O
experimental O
antitumour O
activity. B
It O
was O
administered O
by O
15 O
min O
infusion O
to O
16 O
evaluable O
patients O
with O
non-small B
cell I
lung I
cancer I
(NSCLC) O
(7 B
with O
no O
prior O
treatment, O
9 O
patients O
in O
relapse O
following O
surgery/radiotherapy) O
at O
a O
dose O
(648 O
mg/m2 O
divided O
over O
3 O
days, O
repeated O
every O
3 O
weeks) O
determined O
by O
phase O
I O
trial. O
Patients O
had O
a O
median O
performance O
status O
of O
1 O
(WHO), O
and O
median O
age O
of O
61 O
years. O
The O
histology O
comprised O
squamous B
carcinoma I
(11), O
adenocarcinoma B
(1), O
mixed O
histology O
(2), O
bronchio-alveolar B
carcinoma I
(1) O
and O
large O
cell O
undifferentiated B
carcinoma I
(1). O
Neutropenia B
grade O
greater O
than O
or O
equal O
to O
3 O
was O
seen O
in O
15 O
patients, O
infections B
with O
recovery O
in O
3, O
and O
grand O
mal O
seizures B
in O
1 O
patient. O
Grade O
less O
than O
or O
equal O
to O
2 O
nausea B
and O
vomiting B
occurred O
in O
66% O
courses O
and O
phlebitis B
in O
the O
infusion O
arm O
in O
37%. O
1 O
patient O
with O
squamous B
cell I
carcinoma I
achieved O
a O
partial O
response O
lasting O
5 O
months. O
Further O
testing O
in O
this O
and O
other O
tumour O
types O
using O
multiple O
daily O
schedules O
is O
warranted. O

Schizophrenia B
has O
been O
initially O
associated O
with O
dysfunction O
in O
dopamine O
neurotransmission. O
However, O
the O
observation O
that O
antagonists O
of O
the O
glutamate O
N-methyl-D-aspartate O
(NMDA) O
receptor O
produce O
schizophrenic-like B
symptoms O
in O
humans O
has O
led O
to O
the O
idea O
of O
a O
dysfunctioning O
of O
the O
glutamatergic O
system O
via O
its O
NMDA O
receptor. O
As O
a O
result, O
there O
is O
a O
growing O
interest O
in O
the O
development O
of O
pharmacological O
agents O
with O
potential O
antipsychotic O
properties O
that O
enhance O
the O
activity O
of O
the O
glutamatergic O
system O
via O
a O
modulation O
of O
the O
NMDA O
receptor. O
Among O
them O
are O
glycine O
transporter-1 O
(GlyT1) O
inhibitors O
such O
as O
SSR103800, O
which O
indirectly O
enhance O
NMDA O
receptor O
function O
by O
increasing O
the O
glycine O
(a O
co-agonist O
for O
the O
NMDA O
receptor) O
levels O
in O
the O
synapse. O
This O
study O
aimed O
at O
investigating O
the O
potential O
antipsychotic-like O
properties O
of O
SSR103800, O
with O
a O
particular O
focus O
on O
models O
of O
hyperactivity, B
involving O
either O
drug O
challenge O
(ie, O
amphetamine O
and O
MK-801) O
or O
transgenic O
mice O
(ie, O
NMDA O
Nr1(neo-/-) O
and O
DAT(-/-)). O
Results O
showed O
that O
SSR103800 O
(10-30 O
mg/kg O
p.o.) O
blocked O
hyperactivity O
induced O
by O
the O
non-competitive O
NMDA O
receptor O
antagonist, O
MK-801 O
and O
partially O
reversed O
spontaneous O
hyperactivity O
of O
NMDA O
Nr1(neo-/-) O
mice. O
In O
contrast, O
SSR103800 O
failed O
to O
affect O
hyperactivity O
induced O
by O
amphetamine O
or O
naturally O
observed O
in O
dopamine O
transporter O
(DAT(-/-)) O
knockout O
mice O
(10-30 O
mg/kg O
p.o.). O
Importantly, O
both O
classical O
(haloperidol) O
and O
atypical O
(olanzapine, O
clozapine O
and O
aripiprazole) O
antipsychotics O
were O
effective O
in O
all O
these O
models O
of O
hyperactivity. O
However, O
unlike O
these O
latter, O
SSR103800 O
did O
not O
produce O
catalepsy B
(retention O
on O
the O
bar O
test) O
up O
to O
30 O
mg/kg O
p.o. O
Together O
these O
findings O
show O
that O
the O
GlyT1 O
inhibitor, O
SSR103800, O
produces O
antipsychotic-like O
effects, O
which O
differ O
from O
those O
observed O
with O
compounds O
primarily O
targeting O
the O
dopaminergic O
system, O
and O
has O
a O
reduced O
side-effect O
potential O
as O
compared O
with O
these O
latter O
drugs. O

Evaluation O
of O
cardiac O
troponin O
I O
and O
T O
levels O
as O
markers O
of O
myocardial B
damage I
in O
doxorubicin-induced O
cardiomyopathy B
rats, O
and O
their O
relationship O
with O
echocardiographic O
and O
histological O
findings. O

This O
paper O
attempts O
to O
examine O
and O
compare O
prevalence O
rates O
and O
symptom O
patterns O
of O
DSM O
substance-induced O
and O
other O
mood B
disorders. I
243 O
cocaine-dependent O
outpatients O
with O
cocaine-induced O
mood O
disorder O
(CIMD), O
other B
mood O
disorders, O
or O
no O
mood O
disorder O
were O
compared O
on O
measures O
of O
psychiatric B
symptoms. O
The O
prevalence O
rate O
for O
CIMD O
was O
12% O
at O
baseline. O
Introduction O
of O
the O
DSM-IV O
diagnosis O
of O
CIMD O
did O
not O
substantially O
affect O
rates O
of O
the O
other O
depressive B
disorders. I
Patients O
with O
CIMD O
had O
symptom O
severity O
levels O
between O
those O
of O
patients O
with O
and O
without O
a O
mood O
disorder. O
These O
findings O
suggest O
some O
validity O
for O
the O
new O
DSM-IV O
diagnosis O
of O
CIMD, O
but O
also O
suggest O
that O
it O
requires O
further O
specification O
and O
replication. O

INTRODUCTION: O
Intoxications O
with O
carbachol, O
a O
muscarinic O
cholinergic O
receptor O
agonist O
are O
rare. O
We O
report O
an O
interesting O
case O
investigating O
a O
(near) O
fatal O
poisoning. B
METHODS: O
The O
son O
of O
an O
84-year-old O
male O
discovered O
a O
newspaper O
report O
stating O
clinical O
success O
with O
plant O
extracts O
in O
Alzheimer's B
disease. I
The O
mode O
of O
action O
was O
said O
to O
be O
comparable O
to O
that O
of O
the O
synthetic O
compound O
'carbamylcholin'; O
that O
is, O
carbachol. O
He O
bought O
25 O
g O
of O
carbachol O
as O
pure O
substance O
in O
a O
pharmacy, O
and O
the O
father O
was O
administered O
400 O
to O
500 O
mg. O
Carbachol O
concentrations O
in O
serum O
and O
urine O
on O
day O
1 O
and O
2 O
of O
hospital O
admission O
were O
analysed O
by O
HPLC-mass O
spectrometry. O
RESULTS: O
Minutes O
after O
oral O
administration, O
the O
patient O
developed O
nausea, B
sweating O
and O
hypotension, B
and O
finally O
collapsed. O
Bradycardia, B
cholinergic O
symptoms O
and O
asystole B
occurred. O
Initial O
cardiopulmonary O
resuscitation O
and O
immediate O
treatment O
with O
adrenaline O
(epinephrine), O
atropine O
and O
furosemide O
was O
successful. O
On O
hospital O
admission, O
blood O
pressure O
of O
the O
intubated, O
bradyarrhythmic O
patient O
was O
100/65 O
mmHg. O
Further O
signs O
were O
hyperhidrosis, B
hypersalivation, B
bronchorrhoea, B
and O
severe O
miosis; B
the O
electrocardiographic O
finding O
was O
atrio-ventricular B
dissociation. I
High O
doses O
of O
atropine O
(up O
to O
50 O
mg O
per O
24 O
hours), O
adrenaline O
and O
dopamine O
were O
necessary. O
The O
patient O
was O
extubated O
1 O
week O
later. O
However, O
increased O
dyspnoea B
and O
bronchospasm B
necessitated O
reintubation. O
Respiratory B
insufficiency I
was O
further O
worsened O
by O
Proteus B
mirabilis I
infection I
and O
severe O
bronchoconstriction. O
One O
week O
later, O
the O
patient O
was O
again O
extubated O
and O
3 O
days O
later O
was O
transferred O
to O
a O
peripheral O
ward. O
On O
the O
next O
day O
he O
died, O
probably O
as O
a O
result O
of O
heart B
failure. I
Serum O
samples O
from O
the O
first O
and O
second O
days O
contained O
3.6 O
and O
1.9 O
mg/l O
carbachol, O
respectively. O
The O
corresponding O
urine O
concentrations O
amounted O
to O
374 O
and O
554 O
mg/l. O
CONCLUSION: O
This O
case O
started O
with O
a O
media O
report O
in O
a O
popular O
newspaper, O
initiated O
by O
published, O
peer-reviewed O
research O
on O
herbals, O
and O
involved O
human O
failure O
in O
a O
case O
history, O
medical O
examination O
and O
clinical O
treatment. O
For O
the O
first O
time, O
an O
analytical O
method O
for O
the O
determination O
of O
carbachol O
in O
plasma O
and O
urine O
has O
been O
developed. O
The O
analysed O
carbachol O
concentration O
exceeded O
the O
supposed O
serum O
level O
resulting O
from O
a O
therapeutic O
dose O
by O
a O
factor O
of O
130 O
to O
260. O
Especially O
in O
old O
patients, O
intensivists O
should O
consider O
intoxications O
(with O
cholinergics) O
as O
a O
cause O
of O
acute B
cardiovascular I
failure. I

Two O
patients O
developed O
acute B
tubular I
necrosis, I
characterized O
clinically O
by O
acute O
oliguric B
renal B
failure, I
while O
they O
were O
receiving O
a O
combination O
of O
cephalothin O
sodium O
and O
gentamicin O
sulfate O
therapy. O
Patients O
who O
are O
given O
this O
drug O
regimen O
should O
be O
observed O
very O
carefully O
for O
early O
signs O
of O
nephrotoxicity. B
High O
doses O
of O
this O
antibiotic O
combination O
should O
be O
avoided O
especially O
in O
elderly O
patients. O
Patients O
with O
renal B
insufficiency I
should O
not O
be O
given O
this O
regimen. O

The O
correlation O
between O
neuropathic B
damage I
and O
inhibition O
of O
neurotoxic B
esterase O
or O
neuropathy B
target O
enzyme O
(NTE) O
was O
examined O
in O
rats O
acutely O
exposed O
to O
Mipafox O
(N, O
N'-diisopropylphosphorodiamidofluoridate), O
a O
neurotoxic O
organophosphate. O
Brain O
and O
spinal O
cord O
NTE O
activities O
were O
measured O
in O
Long-Evans O
male O
rats O
1 O
hr O
post-exposure O
to O
various O
dosages O
of O
Mipafox O
(ip, O
1-15 O
mg/kg). O
These O
data O
were O
correlated O
with O
histologically O
scored O
cervical O
cord B
damage I
in O
a O
separate O
group O
of O
similarly O
dosed O
rats O
sampled O
14-21 O
days O
post-exposure. O
Those O
dosages O
(greater O
than O
or O
equal O
to O
10 O
mg/kg) O
that O
inhibited O
mean O
NTE O
activity O
in O
the O
spinal O
cord O
greater O
than O
or O
equal O
to O
73% O
and O
brain O
greater O
than O
or O
equal O
to O
67% O
of O
control O
values O
produced O
severe O
(greater O
than O
or O
equal O
to O
3) O
cervical O
cord O
pathology O
in O
85% O
of O
the O
rats. O
In O
contrast, O
dosages O
of O
Mipafox O
(less O
than O
or O
equal O
to O
5 O
mg/kg) O
which O
inhibited O
mean O
NTE O
activity O
in O
spinal O
cord O
less O
than O
or O
equal O
to O
61% O
and O
brain O
less O
than O
or O
equal O
to O
60% O
produced O
this O
degree O
of O
cord O
damage O
in O
only O
9% O
of O
the O
animals. O
These O
data O
indicate O
that O
a O
critical O
percentage O
of O
NTE O
inhibition O
in O
brain O
and O
spinal O
cord O
sampled O
shortly O
after O
Mipafox O
exposure O
can O
predict O
neuropathic O
damage O
in O
rats O
several O
weeks O
later. O

Antithymocyte O
globulin O
in O
the O
treatment O
of O
D-penicillamine-induced O
aplastic B
anemia. I

This O
paper O
describes O
the O
clinical O
features O
of O
six O
children O
who O
developed O
the O
haemolytic-uraemic B
syndrome I
after O
treatment O
with O
metronidazole. O
These O
children O
were O
older O
and O
were O
more O
likely O
to O
have O
undergone O
recent O
bowel O
surgery O
than O
are O
other O
children O
with O
this O
condition. O
While O
the O
involvement O
of O
metronidazole O
in O
the O
aetiology O
of O
the O
haemolytic-uraemic O
syndrome O
is O
not O
established O
firmly, O
the O
action O
of O
this O
drug O
in O
sensitizing O
tissues O
to O
oxidation O
injury O
and O
the O
reported O
evidence O
of O
oxidation O
changes O
in O
the O
haemolytic-uraemic O
syndrome O
suggest O
a O
possible O
link O
between O
metronidazole O
treatment O
and O
some O
cases O
of O
the O
haemolytic-uraemic O
syndrome. O

Different O
lobular O
distributions O
of O
altered O
hepatocyte O
tight O
junctions O
in O
rat O
models O
of O
intrahepatic B
and I
extrahepatic B
cholestasis. I

Evaluation O
of O
the O
anticocaine O
monoclonal O
antibody O
GNC92H2 O
as O
an O
immunotherapy O
for O
cocaine B
overdose. I

The O
yield O
of O
severe O
cirrhosis B
of I
the I
liver I
(defined O
as O
a O
shrunken O
finely O
nodular O
liver O
with O
micronodular O
histology, O
ascites B
greater O
than O
30 O
ml, O
plasma O
albumin O
less O
than O
2.2 O
g/dl, O
splenomegaly B
2-3 O
times O
normal, O
and O
testicular O
atrophy B
approximately O
half O
normal O
weight) O
after O
12 O
doses O
of O
carbon O
tetrachloride O
given O
intragastrically O
in O
the O
phenobarbitone-primed O
rat O
was O
increased O
from O
25% O
to O
56% O
by O
giving O
the O
initial O
"calibrating" O
dose O
of O
carbon O
tetrachloride O
at O
the O
peak O
of O
the O
phenobarbitone-induced O
enlargement B
of I
the I
liver. I
At O
this O
point O
it O
was O
assumed O
that O
the O
cytochrome O
P450/CCl4 O
toxic O
state O
was O
both O
maximal O
and O
stable. O
The O
optimal O
rat O
size O
to O
begin O
phenobarbitone O
was O
determined O
as O
100 O
g, O
and O
this O
size O
as O
a O
group O
had O
a O
mean O
maximum O
relative O
liver O
weight O
increase O
47% O
greater O
than O
normal O
rats O
of O
the O
same O
body O
weight. O
The O
optimal O
time O
for O
the O
initial O
dose O
of O
carbon O
tetrachloride O
was O
after O
14 O
days O
on O
phenobarbitone. O

In O
an O
attempt O
to O
determine O
whether O
penile B
pain I
associated O
with O
intracorporeal O
injections O
could O
be O
due O
to O
the O
acidity O
of O
the O
medication, O
we O
performed O
a O
randomized O
study O
comparing O
the O
incidence O
of O
penile O
pain O
following O
intracorporeal O
injections O
with O
or O
without O
the O
addition O
of O
sodium O
bicarbonate O
to O
the O
intracorporeal O
medications. O
A O
total O
of O
38 O
consecutive O
patients O
who O
presented O
to O
our O
clinic O
with O
impotence B
received O
0.2 O
ml. O
of O
a O
combination O
of O
3 O
drugs: O
6 O
mg. O
papaverine, O
100 O
micrograms. O
phentolamine O
and O
10 O
micrograms. O
prostaglandin O
E1 O
with O
(pH O
7.05) O
or O
without O
(pH O
4.17) O
the O
addition O
of O
sodium O
bicarbonate O
(0.03 O
mEq.). O
Of O
the O
19 O
patients O
without O
sodium O
bicarbonate O
added O
to O
the O
medication O
11 O
(58%) O
complained O
of O
penile O
pain O
due O
to O
the O
medication, O
while O
only O
1 O
of O
the O
19 O
men O
(5%) O
who O
received O
sodium O
bicarbonate O
complained O
of O
penile O
pain. O
From O
these O
data O
we O
conclude O
that O
the O
penile O
pain O
following O
intracorporeal O
injections O
is O
most O
likely O
due O
to O
the O
acidity O
of O
the O
medication, O
which O
can O
be O
overcome O
by O
elevating O
the O
pH O
to O
a O
neutral O
level. O

Reduction O
of O
heparan O
sulphate-associated O
anionic O
sites O
in O
the O
glomerular O
basement O
membrane O
of O
rats O
with O
streptozotocin-induced O
diabetic B
nephropathy. I

Two O
mouse O
lines O
were O
selectively O
bred O
according O
to O
their O
sensitivity O
(BS O
line) O
or O
resistance O
(BR O
line) O
to O
seizures B
induced O
by O
a O
single O
i.p. O
injection O
of O
methyl O
beta-carboline-3-carboxylate O
(beta-CCM), O
an O
inverse O
agonist O
of O
the O
GABA(A) O
receptor O
benzodiazepine O
site. O
Our O
aim O
was O
to O
characterize O
both O
lines' O
sensitivities O
to O
various O
physiological O
effects O
of O
other O
ligands O
of O
the O
GABA(A) O
receptor. O
We O
measured O
diazepam-induced O
anxiolysis O
with O
the O
elevated O
plus-maze O
test, O
diazepam-induced O
sedation O
by O
recording O
the O
vigilance O
states, O
and O
picrotoxin- O
and O
pentylenetetrazol-induced O
seizures O
after O
i.p. O
injections. O
Results O
presented O
here O
show O
that O
the O
differential O
sensitivities O
of O
BS O
and O
BR O
lines O
to O
beta-CCM O
can O
be O
extended O
to O
diazepam, O
picrotoxin, O
and O
pentylenetetrazol, O
suggesting O
a O
genetic O
selection O
of O
a O
general O
sensitivity O
and O
resistance O
to O
several O
ligands O
of O
the O
GABA(A) O
receptor. O

The O
role O
of O
nicotine O
in O
smoking-related O
cardiovascular B
disease. I

Recovery O
of O
tacrolimus-associated O
brachial B
neuritis I
after O
conversion O
to O
everolimus O
in O
a O
pediatric O
renal O
transplant O
recipient--case O
report O
and O
review O
of O
the O
literature. O

In O
order O
to O
elucidate O
the O
role O
of O
the O
catecholaminergic O
system O
in O
the O
cataleptogenic O
effect O
of O
delta O
9-tetrahydrocannabinol O
(THC), O
the O
effect O
of O
pretreatment O
with O
6-hydroxydopamine O
(6-OHDA) O
or O
with O
desipramine O
and O
6-OHDA O
and O
lesions O
of O
the O
locus O
coeruleus O
were O
investigated O
in O
rats. O
The O
cataleptogenic O
effect O
of O
THC O
was O
significantly O
reduced O
in O
rats O
treated O
with O
6-OHDA O
and O
in O
rats O
with O
lesions O
of O
the O
locus O
coeruleus O
but O
not O
in O
rats O
treated O
with O
desipramine O
and O
6-OHDA, O
as O
compared O
with O
control O
rats. O
On O
the O
contrary, O
the O
cataleptogenic O
effect O
of O
haloperidol O
was O
significantly O
reduced O
in O
rats O
treated O
with O
desipramine O
and O
6-OHDA O
but O
not O
in O
rats O
treated O
with O
6-OHDA O
or O
in O
rats O
with O
lesions O
of O
the O
locus O
coeruleus. O
These O
results O
indicate O
that O
noradrenergic O
neurons O
have O
an O
important O
role O
in O
the O
manifestation O
of O
catalepsy B
induced O
by O
THC, O
whereas O
dopaminergic O
neurons O
are O
important O
in O
catalepsy O
induced O
by O
haloperidol. O

Eating B
disorders I
and O
the O
associated O
behavioural O
problems O
and O
drug B
abuse I
are O
uncommon O
in O
pregnancy. O
When O
they O
do O
occur O
they O
are O
often O
unrecognized O
because O
of O
denial O
but O
when O
significant O
may O
pose O
a O
risk O
to O
both O
the O
mother O
and O
her O
fetus. O
This O
case O
illustrates O
a O
number O
of O
problems O
that O
may O
be O
encountered O
in O
women O
with O
eating B
disorders I
in O
pregnancy, O
including O
prolonged O
and O
recurrent O
metabolic O
disturbances O
and O
diuretic O
abuse. O
In O
particular O
it O
illustrates O
the O
derangements O
of O
thyroid O
function O
seen O
in O
pregnant O
women O
with O
eating O
disorders O
and O
reminds O
us O
that O
when O
a O
cause O
for O
thyrotoxicosis B
remains O
obscure, O
thyroxine O
abuse O
should O
be O
considered O
and O
explored. O

Azidothymidine O
(AZT)-induced O
anemia B
in O
mice O
can O
be O
reversed O
by O
the O
administration O
of O
IGF-IL-3 O
(fusion O
protein O
of O
insulin-like O
growth O
factor O
II O
(IGF O
II) O
and O
interleukin O
3). O
Although O
interleukin O
3 O
(IL-3) O
and O
erythropoietin O
(EPO) O
are O
known O
to O
act O
synergistically O
on O
hematopoietic O
cell O
proliferation O
in O
vitro, O
injection O
of O
IGF-IL-3 O
and O
EPO O
in O
AZT-treated O
mice O
resulted O
in O
a O
reduction O
of O
red O
cells O
and O
an O
increase O
of O
plasma O
EPO O
levels O
as O
compared O
to O
animals O
treated O
with O
IGF-IL-3 O
or O
EPO O
alone. O
We O
tested O
the O
hypothesis O
that O
the O
antagonistic O
effect O
of O
IL-3 O
and O
EPO O
on O
erythroid O
cells O
may O
be O
mediated O
by O
endothelial O
cells. O
Bovine O
liver O
erythroid O
cells O
were O
cultured O
on O
monolayers O
of O
human O
bone O
marrow O
endothelial O
cells O
previously O
treated O
with O
EPO O
and O
IGF-IL-3. O
There O
was O
a O
significant O
reduction O
of O
thymidine O
incorporation O
into O
both O
erythroid O
and O
endothelial O
cells O
in O
cultures O
pre-treated O
with O
IGF-IL-3 O
and O
EPO. O
Endothelial O
cell O
culture O
supernatants O
separated O
by O
ultrafiltration O
and O
ultracentrifugation O
from O
cells O
treated O
with O
EPO O
and O
IL-3 O
significantly O
reduced O
thymidine O
incorporation O
into O
erythroid O
cells O
as O
compared O
to O
identical O
fractions O
obtained O
from O
the O
media O
of O
cells O
cultured O
with O
EPO O
alone. O
These O
results O
suggest O
that O
endothelial O
cells O
treated O
simultaneously O
with O
EPO O
and O
IL-3 O
have O
a O
negative O
effect O
on O
erythroid O
cell O
production. O

Reserpine- O
and O
haloperidol-induced O
orofacial B
dyskinesia I
are O
putative O
animal O
models O
of O
tardive B
dyskinesia I
(TD) O
whose B
pathophysiology O
has O
been O
related O
to O
free O
radical O
generation O
and O
oxidative O
stress. O
In O
the O
present O
study, O
the O
authors O
induced O
orofacial O
dyskinesia O
by O
acute O
reserpine O
and O
subchronic O
haloperidol O
administration O
to O
rats. O
Reserpine O
injection O
(one O
dose O
of O
1 O
mg/kg O
s.c.) O
every O
other O
day O
for O
3 O
days O
caused O
a O
significant O
increase O
in O
vacuous O
chewing, O
tongue O
protrusion O
and O
duration O
of O
facial O
twitching, O
compared O
to O
the O
control. O
Haloperidol O
administration O
(one O
dose O
of O
12 O
mg/kg O
once O
a O
week O
s.c.) O
for O
4 O
weeks O
caused O
an O
increase O
in O
vacuous O
chewing, O
tongue O
protrusion O
and O
duration O
of O
facial O
twitching O
observed O
in O
four O
weekly O
evaluations. O
After O
the O
treatments O
and O
behavioral O
observation, O
glutamate O
uptake O
by O
segments O
of O
the O
brain O
was O
analyzed. O
A O
decreased O
glutamate O
uptake O
was O
observed O
in O
the O
subcortical O
parts O
of O
animals O
treated O
with O
reserpine O
and O
haloperidol, O
compared O
to O
the O
control. O
Importantly, O
a O
decrease O
in O
glutamate O
uptake O
correlates O
negatively O
with O
an O
increase O
in O
the O
incidence O
of O
orofacial B
diskinesia. I
These O
results O
indicate O
that O
early O
changes O
in O
glutamate O
transport O
may O
be O
related O
to O
the O
development O
of O
vacuous O
chewing O
movements O
in O
rats. O

Hemolytic B
anemia I
associated O
with O
the O
use O
of O
omeprazole. O

The O
effects O
of O
intracoronary O
administration O
of O
methylergonovine O
were O
studied O
in O
21 O
patients O
with O
variant B
angina I
and O
22 O
patients O
with O
atypical O
chest B
pain I
and O
in O
others O
without O
angina B
pectoris I
(control O
group). O
Methylergonovine O
was O
administered O
continuously O
at O
a O
rate O
of O
10 O
micrograms/min O
up O
to O
50 O
micrograms. O
In O
all O
patients O
with O
variant O
angina, O
coronary B
spasm B
was O
provoked O
at O
a O
mean O
dose O
of O
28 O
+/- O
13 O
micrograms O
(mean O
+/- O
SD). O
In O
the O
control O
group O
neither O
ischemic O
ST O
change O
nor O
localized O
spasm O
occurred. O
The O
basal O
tone O
of O
the O
right O
coronary O
artery O
was O
significantly O
lower O
than O
that O
of O
the O
left O
coronary O
artery. O
The O
percentage O
of O
vasoconstriction O
of O
the O
right O
coronary O
artery O
was O
significantly O
higher O
than O
that O
of O
the O
left O
coronary O
artery. O
These O
results O
suggest O
that O
spasm O
provocation O
tests, O
which O
use O
an O
intracoronary O
injection O
of O
a O
relatively O
low O
dose O
of O
methylergonovine, O
have O
a O
high O
sensitivity O
in O
variant O
angina O
and O
the O
vasoreactivity O
of O
the O
right O
coronary O
artery O
may O
be O
greater O
than O
that O
of O
the O
other O
coronary O
arteries. O

OBJECTIVE: O
In O
vitro O
work O
has O
demonstrated O
that O
cinacalcet O
is O
a O
strong O
inhibitor O
of O
cytochrome O
P450 O
isoenzyme O
(CYP) O
2D6. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
cinacalcet O
on O
CYP2D6 O
activity, O
using O
desipramine O
as O
a O
probe O
substrate, O
in O
healthy O
subjects. O
METHODS: O
Seventeen O
subjects O
who O
were O
genotyped O
as O
CYP2D6 O
extensive O
metabolizers O
were O
enrolled O
in O
this O
randomized, O
open-label, O
crossover O
study O
to O
receive O
a O
single O
oral O
dose O
of O
desipramine O
(50 O
mg) O
on O
two O
separate O
occasions, O
once O
alone O
and O
once O
after O
multiple O
doses O
of O
cinacalcet O
(90 O
mg O
for O
7 O
days). O
Blood O
samples O
were O
obtained O
predose O
and O
up O
to O
72 O
h O
postdose. O
RESULTS: O
Fourteen O
subjects O
completed O
both O
treatment O
arms. O
Relative O
to O
desipramine O
alone, O
mean O
AUC O
and O
C(max) O
of O
desipramine O
increased O
3.6- O
and O
1.8-fold O
when O
coadministered O
with O
cinacalcet. O
The O
t O
(1/2,z) O
of O
desipramine O
was O
longer O
when O
desipramine O
was O
coadministered O
with O
cinacalcet O
(21.0 O
versus O
43.3 O
hs). O
The O
t O
(max) O
was O
similar O
between O
the O
regimens. O
Fewer O
subjects O
reported O
adverse O
events O
following O
treatment O
with O
desipramine O
alone O
than O
when O
receiving O
desipramine O
with O
cinacalcet O
(33 O
versus O
86%), O
the O
most O
frequent O
of O
which O
(nausea O
and B
headache) B
have O
been O
reported O
for O
patients O
treated O
with O
either O
desipramine O
or O
cinacalcet. O
CONCLUSION: O
This O
study O
demonstrates O
that O
cinacalcet O
is O
a O
strong O
inhibitor O
of O
CYP2D6. O
These O
data O
suggest O
that O
during O
concomitant O
treatment O
with O
cinacalcet, O
dose O
adjustment O
may O
be O
necessary O
for O
drugs O
that O
demonstrate O
a O
narrow O
therapeutic O
index O
and O
are O
metabolized O
by O
CYP2D6. O

Analgesic O
effect O
of O
intravenous O
ketamine O
in O
cancer B
patients O
on O
morphine O
therapy: O
a O
randomized, O
controlled, O
double-blind, O
crossover, O
double-dose O
study. O

The O
incidence O
of O
postoperative O
respiratory O
apnoea B
was O
compared O
between O
five O
patients O
receiving O
a O
continuous O
i.v. O
infusion O
of O
morphine O
(mean O
73.6 O
mg) O
and O
five O
patients O
receiving O
a O
continuous O
extradural O
infusion O
of O
0.25% O
bupivacaine O
(mean O
192 O
mg) O
in O
the O
24-h O
period O
following O
upper O
abdominal O
surgery. O
Monitoring O
consisted O
of O
airflow O
detection O
by O
a O
carbon O
dioxide O
analyser, O
chest O
wall O
movement O
detected O
by O
pneumatic O
capsules, O
and O
continuous O
electrocardiograph O
recorded O
with O
a O
Holter O
ambulatory O
monitor. O
Both O
obstructive B
(P I
less I
than I
0.05) I
and I
central B
apnoea I
(P O
less O
than O
0.05) O
occurred O
more O
frequently O
in O
patients O
who O
had O
a O
morphine O
infusion. O
There O
was O
also O
a O
higher O
incidence O
of O
tachyarrhythmias B
(P O
less O
than O
0.05) O
and O
ventricular B
ectopic I
beats I
(P O
less O
than O
0.05) O
in O
the O
morphine O
infusion O
group. O

The O
half-life O
(t1/2) O
of O
cocaine O
is O
relatively O
short, O
but O
some O
of O
the O
consequences O
of O
its O
use, O
such O
as O
seizures B
and O
strokes, B
can O
occur O
hours O
after O
exposure. O
This O
led O
us O
to O
hypothesize O
that O
a O
metabolite O
of O
cocaine O
may O
be O
responsible O
for O
some O
of O
those O
delayed O
sequelae. O
We O
evaluated O
the O
potential O
of O
the O
major O
metabolite O
of O
cocaine, O
benzoylecgonine O
(BE), O
to O
cause O
seizures. O
Two O
separate O
equimolar O
doses O
(0.2 O
and O
0.4 O
mumol) O
of O
either O
cocaine O
or O
BE O
were O
injected O
ventricularly O
in O
unanesthetized O
juvenile O
rats. O
Treated O
rats O
were O
then O
evaluated O
for O
incidence, O
latency, O
and O
seizure O
pattern O
or O
for O
locomotor O
activity O
in O
animals O
without O
seizures. O
BE-Induced O
seizures O
occurred O
more O
frequently O
and O
had O
significantly O
longer O
latencies O
than O
those O
induced O
by O
equimolar O
amounts O
of O
cocaine. O
Whereas O
cocaine-induced O
seizures O
were O
best O
characterized O
as O
brief, O
generalized, O
and O
tonic O
and O
resulted O
in O
death, B
those O
induced O
by O
BE O
were O
prolonged, O
often O
multiple O
and O
mixed O
in O
type, O
and O
rarely O
resulted O
in O
death. O
Electrical O
recordings O
from O
the O
hippocampus O
showed O
a O
rhythmic O
progression O
in O
EEG O
frequency O
and O
voltage O
with O
clinical O
seizure O
expression. O
BE-Injected O
rats O
that O
did O
not O
have O
seizures O
had O
significantly O
more O
locomotor O
activity O
than O
cocaine-injected O
animals O
without O
seizures. O
The O
finding O
that O
cocaine- O
and O
BE-induced O
seizures O
differ O
in O
several O
respects O
suggests O
more O
than O
one O
mechanism O
for O
cocaine-induced O
seizures O
and O
emphasizes O
the O
importance O
of O
a O
cocaine O
metabolite, O
BE. O

A O
54-year-old O
hypothyroid B
male O
taking O
thyroxine O
and O
simvastatin O
presented O
with O
bilateral O
leg O
compartment B
syndrome I
and O
myonecrosis. B
Urgent O
fasciotomies O
were O
performed O
and O
the O
patient O
made O
an O
uneventful O
recovery O
with O
the O
withdrawal O
of O
simvastatin. O
It O
is O
likely O
that O
this O
complication O
will O
be O
seen O
more O
often O
with O
the O
increased O
worldwide O
use O
of O
this O
drug O
and O
its O
approval O
for O
all O
arteriopathic B
patients. O

PURPOSE: O
We O
reviewed O
the O
results O
of O
serum O
testosterone O
and O
prolactin O
determination O
in O
1,022 O
patients O
referred O
because O
of O
erectile B
dysfunction I
and O
compared O
the O
data O
with O
history, O
results O
of O
physical O
examination, O
other O
etiological O
investigations O
and O
effects O
of O
endocrine O
therapy O
to O
refine O
the O
rules O
of O
cost-effective O
endocrine O
screening O
and O
to O
pinpoint O
actual O
responsibility O
for O
hormonal O
abnormalities. O
MATERIALS O
AND O
METHODS: O
Testosterone O
and O
prolactin O
were O
determined O
by O
radioimmunoassay. O
Every O
patient O
was O
screened O
for O
testosterone O
and O
451 O
were O
screened O
for O
prolactin O
on O
the O
basis O
of O
low B
sexual I
desire, I
gynecomastia B
or O
testosterone O
less O
than O
4 O
ng./ml. O
Determination O
was O
repeated O
in O
case O
of O
abnormal O
first O
results. O
Prolactin O
results O
were O
compared O
with O
those O
of O
a O
previous O
personal O
cohort O
of O
1,340 O
patients O
with O
erectile O
dysfunction O
and O
systematic O
prolactin O
determination. O
Main O
clinical O
criteria O
tested O
regarding O
efficiency O
in O
hormone O
determination O
were O
low O
sexual O
desire, O
small O
testes O
and O
gynecomastia. O
Endocrine O
therapy O
consisted O
of O
testosterone O
heptylate O
or O
human O
chorionic O
gonadotropin O
for O
hypogonadism B
and O
bromocriptine O
for O
hyperprolactinemia. B
RESULTS: O
Testosterone O
was O
less O
than O
3 O
ng./ml. O
in O
107 O
patients O
but O
normal O
in O
40% O
at O
repeat O
determination. O
The O
prevalence O
of O
repeatedly O
low O
testosterone O
increased O
with O
age O
(4% O
before O
age O
50 O
years O
and O
9% O
50 O
years O
or O
older). O
Two O
pituitary B
tumors I
were O
discovered O
after O
testosterone O
determination. O
Most O
of O
the O
other O
low O
testosterone O
levels O
seemed O
to O
result O
from O
nonorganic O
hypothalamic B
dysfunction I
because O
of O
normal O
serum O
luteinizing O
hormone O
and O
prolactin O
and O
to O
have O
only O
a O
small O
role O
in O
erectile O
dysfunction O
(definite O
improvement O
in O
only O
16 O
of O
44 O
[36%] O
after O
androgen O
therapy, O
normal O
morning O
or O
nocturnal O
erections O
in O
30% O
and O
definite O
vasculogenic O
contributions O
in O
42%). O
Determining O
testosterone O
only O
in O
cases O
of O
low O
sexual O
desire O
or O
abnormal O
physical O
examination O
would O
have O
missed O
40% O
of O
the O
cases O
with O
low O
testosterone, O
including O
37% O
of O
those O
subsequently O
improved O
by O
androgen O
therapy. O
Prolactin O
exceeded O
20 O
ng./ml. O
in O
5 O
men O
and O
was O
normal O
in O
2 O
at O
repeat O
determination. O
Only O
1 O
prolactinoma B
was O
discovered. O
These O
data O
are O
lower O
than O
those O
we O
found O
during O
the O
last O
2 O
decades O
(overall O
prolactin O
greater O
than O
20 O
ng./ml. O
in O
1.86% O
of O
1,821 O
patients, O
prolactinomas B
in O
7, O
0.38%). O
Bromocriptine O
was O
definitely O
effective O
in O
cases O
with O
prolactin O
greater O
than O
35 O
ng./ml. O
(8 O
of O
12 O
compared O
to O
only O
9 O
of O
22 O
cases O
with O
prolactin O
between O
20 O
and O
35 O
ng./ml.). O
Testosterone O
was O
low O
in O
less O
than O
50% O
of O
cases O
with O
prolactin O
greater O
than O
35 O
ng./ml. O
CONCLUSIONS: O
Low O
prevalences O
and O
effects O
of O
low O
testosterone O
and O
high O
prolactin O
in O
erectile O
dysfunction O
cannot O
justify O
their O
routine O
determination. O
However, O
cost-effective O
screening O
strategies O
recommended O
so O
far O
missed O
40 O
to O
50% O
of O
cases O
improved O
with O
endocrine O
therapy O
and O
the O
pituitary O
tumors. O
We O
now O
advocate O
that O
before O
age O
50 O
years O
testosterone O
be O
determined O
only O
in O
cases O
of O
low O
sexual O
desire O
and O
abnormal O
physical O
examination O
but O
that O
it O
be O
measured O
in O
all O
men O
older O
than O
50 O
years. O
Prolactin O
should O
be O
determined O
only O
in O
cases O
of O
low O
sexual O
desire, O
gynecomastia O
and/or O
testosterone O
less O
than O
4 O
ng./ml. O

Hypersensitivity B
to O
carbamazepine O
presenting O
with O
a O
leukemoid B
reaction, I
eosinophilia, B
erythroderma, B
and O
renal B
failure. I

To O
evaluate O
the O
effect O
of O
prostaglandin O
E1 O
(PGE1) O
or O
trimethaphan O
(TMP) O
induced O
hypotension B
on O
epidural O
blood O
flow O
(EBF) O
during O
spinal O
surgery, O
EBF O
was O
measured O
using O
the O
heat O
clearance O
method O
in O
30 O
patients O
who O
underwent O
postero-lateral O
interbody O
fusion O
under O
isoflurane O
anaesthesia. O
An O
initial O
dose O
of O
0.1 O
microgram.kg-1.min-1 O
of O
PGE1 O
(15 O
patients), O
or O
10 O
micrograms.kg-1.min-1 O
of O
TMP O
(15 O
patients) O
was O
administered O
intravenously O
after O
the O
dural O
opening O
and O
the O
dose O
was O
adjusted O
to O
maintain O
the O
mean O
arterial O
blood O
pressure O
(MAP) O
at O
about O
60 O
mmHg. O
The O
hypotensive B
drug O
was O
discontinued O
at O
the O
completion O
of O
the O
operative O
procedure. O
After O
starting O
PGE1 O
or O
TMP, O
MAP O
and O
rate O
pressure O
product O
(RPP) O
decreased O
significantly O
compared O
with O
preinfusion O
values O
(P O
< O
0.01), O
and O
the O
degree O
of O
hypotension O
due O
to O
PGE1 O
remained O
constant O
until O
60 O
min O
after O
its O
discontinuation. O
Heart O
rate O
(HR) O
did O
not O
change O
in O
either O
group. O
EBFF O
did O
not O
change O
during O
PGE1 O
infusion O
whereas O
in O
the O
TMP O
group, O
EBF O
decreased O
significantly O
at O
30 O
and O
60 O
min O
after O
the O
start O
of O
TMP O
(preinfusion: O
45.9 O
+/- O
13.9 O
ml/100g/min. O
30 O
min: O
32.3 O
+/- O
9.9 O
ml/100 O
g/min O
(P O
< O
0.05). O
60 O
min: O
30 O
+/- O
7.5 O
ml/100 O
g/min O
(P O
< O
0.05)). O
These O
results O
suggest O
that O
PGE1 O
may O
be O
preferable O
to O
TMP O
for O
hypotensive O
anaesthesia O
in O
spinal O
surgery O
because O
TMP O
decreased O
EBF. O

Recurrent O
use O
of O
newer O
oral O
contraceptives O
and O
the O
risk O
of O
venous B
thromboembolism. I

Advances O
in O
the O
field O
of O
transplantation O
provide O
a O
better O
quality O
of O
life O
and O
allow O
more O
favorable O
conditions O
for O
growth O
and O
development O
in O
children. O
However, O
combinations O
of O
different O
therapeutic O
regimens O
require O
consideration O
of O
potential O
adverse O
reactions. O
We O
describe O
a O
15-yr-old O
girl O
who O
had O
orthotopic O
liver O
transplantation O
because O
of O
Wilson's B
disease. I
Tacrolimus, O
MMF, O
and O
steroids O
were O
given O
as O
immunosuppressant. O
Lamivudine O
was O
added O
because O
of O
de O
nova O
hepatitis B
B I
infection I
during O
her O
follow-up. O
Three O
yr O
after O
transplantation O
she O
developed O
renal B
Fanconi B
syndrome I
with O
severe O
metabolic B
acidosis, B
hypophosphatemia, B
glycosuria, B
and O
aminoaciduria. B
Although O
tacrolimus O
was O
suspected O
to O
be O
the O
cause O
of O
late O
post-transplant O
renal O
acidosis O
and O
was O
replaced O
by O
sirolimus, O
acidosis, O
and O
electrolyte O
imbalance O
got O
worse. O
Proximal O
muscle B
weakness I
has O
developed O
during O
her O
follow-up. O
Fanconi O
syndrome, O
as O
well O
as O
myopathy, B
is O
well O
recognized O
in O
patients O
with O
mitochondrial B
disorders I
and O
caused O
by O
depletion O
of O
mtDNA. O
We O
suggest O
that O
our O
patient's O
tubular B
dysfunction I
and O
myopathy O
may O
have O
resulted O
from O
mitochondrial B
dysfunction I
which O
is O
triggered O
by O
tacrolimus O
and O
augmented O
by O
lamivudine. O

OBJECTIVE: O
The O
globus O
pallidus O
plays O
a O
critical O
role O
in O
movement O
regulation. O
Previous O
studies O
have O
indicated O
that O
the O
globus O
pallidus O
receives O
neurotensinergic O
innervation O
from O
the O
striatum, O
and O
systemic O
administration O
of O
a O
neurotensin O
analog O
could O
produce O
antiparkinsonian O
effects. O
The O
present O
study O
aimed O
to O
investigate O
the O
effects O
of O
pallidal O
neurotensin O
on O
haloperidol-induced O
parkinsonian B
symptoms. I
METHODS: O
Behavioral O
experiments O
and O
electrophysiological O
recordings O
were O
performed O
in O
the O
present O
study. O
RESULTS: O
Bilateral O
infusions O
of O
neurotensin O
into O
the O
globus O
pallidus O
reversed O
haloperidol-induced O
parkinsonian B
catalepsy I
in O
rats. O
Electrophysiological O
recordings O
showed O
that O
microinjection O
of O
neurotensin O
induced O
excitation O
of O
pallidal O
neurons O
in O
the O
presence O
of O
systemic O
haloperidol O
administration. O
The O
neurotensin O
type-1 O
receptor O
antagonist O
SR48692 O
blocked O
both O
the O
behavioral O
and O
the O
electrophysiological O
effects O
induced O
by O
neurotensin. O
CONCLUSION: O
Activation O
of O
pallidal O
neurotensin O
receptors O
may O
be O
involved O
in O
neurotensin-induced O
antiparkinsonian O
effects. O

We O
report O
a O
case O
of O
severe O
hypertension B
with O
an O
occluded O
renal O
artery O
to O
a O
solitary O
kidney, O
who O
developed O
sudden B
deterioration I
of I
renal I
function I
following O
treatment O
with O
captopril. O
His O
renal O
function O
remained O
impaired O
but O
stable O
during O
2 O
years' O
treatment O
with O
captopril O
but O
returned O
to O
pre-treatment O
levels O
soon O
after O
cessation O
of O
the O
drug. O
This O
indicates O
reversibility O
in O
captopril-induced O
renal B
failure I
even O
after O
its O
prolonged O
use O
and O
suggests O
that O
no O
organic O
damage O
occurs O
to O
glomerular O
arterioles O
following O
chronic O
ACE O
inhibition. O

The O
relationship O
of O
arthritis B
and O
sexual B
dysfunction I
was O
investigated O
among O
169 O
patients O
with O
rheumatoid B
arthritis, I
osteoarthritis B
and O
spondyloarthropathy, B
130 O
of O
whom O
were O
pair-matched O
to O
controls. O
Assessments O
of O
marital O
happiness O
and O
depressed B
mood I
were O
also O
made O
using O
the O
CES-D O
and O
the O
Azrin O
Marital O
Happiness O
Scale O
(AMHS). O
Sexual B
dysfunctions I
were O
found O
to O
be O
common O
among O
patients O
and O
controls, O
the O
majority O
in O
both O
groups O
reporting O
one O
or O
more O
dysfunctions. O
Impotence B
was O
more O
common O
among O
male O
patients O
than O
controls O
and O
was O
found O
to O
be O
associated O
with O
co-morbidity O
and O
the O
taking O
of O
methotrexate. O
Depressed B
mood I
was O
more O
common O
among O
patients O
and O
was O
associated O
with O
certain O
sexual O
difficulties, O
but O
not O
with O
impotence. B
Marital O
unhappiness, O
as O
indicated O
by O
AMHS O
scores, O
was O
not O
associated O
with O
arthritis O
but O
was O
associated O
with O
sexual O
dysfunction, O
sexual O
dissatisfaction O
and O
being O
female. O

Treatment O
for O
scabies B
is O
usually O
initiated O
by O
general O
practitioners; O
most O
consider O
lindane O
(gamma O
benzene O
hexachloride) O
the O
treatment O
of O
choice. O
Lindane O
is O
also O
widely O
used O
as O
an O
agricultural O
and O
industrial O
pesticide, O
and O
as O
a O
result O
the O
toxic O
profile O
of O
this O
insecticide O
is O
well O
understood. O
Evidence O
is O
accumulating O
that O
lindane O
can O
be O
toxic B
to I
the I
central I
nervous I
system I
and O
may O
be O
associated O
with O
aplastic B
anaemia. I
Preparations O
containing O
lindane O
continue O
to O
be O
sold O
over O
the O
counter O
and O
may O
represent O
a O
hazard O
to O
poorly O
informed O
patients. O
This O
literature O
review O
suggests O
that O
general O
practitioners O
should O
prescribe O
scabicides O
with O
increased O
caution O
for O
certain O
at-risk O
groups, O
and O
give O
adequate O
warnings O
regarding O
potential O
toxicity. B

Acute O
bronchodilating O
effects O
of O
ipratropium O
bromide O
and O
theophylline O
in O
chronic B
obstructive I
pulmonary I
disease. I

An O
analysis O
is O
presented O
of O
220 O
cases O
of O
possible O
neurotoxic B
reactions O
to O
halogenated O
hydroxyquinolines O
reported O
from O
outside O
Japan. O
In O
80 O
cases O
insufficient O
information O
was O
available O
for O
adequate O
comment O
and O
in O
29 O
a O
relationship O
to O
the O
administration O
of O
clioquinol O
could O
be O
excluded. O
Of O
the O
remainder, O
a O
relationship O
to O
clioquinol O
was O
considered O
probable O
in O
42 O
and O
possible O
in O
69 O
cases. O
In O
six O
of O
the O
probable O
cases O
the O
neurological B
disturbance I
consisted O
of O
an O
acute O
reversible O
encephalopathy B
usually O
related O
to O
the O
ingestion O
of O
a O
high O
dose O
of O
clioquinol O
over O
a O
short O
period. O
The O
most O
common O
manifestation, O
observed O
in O
15 O
further O
cases, O
was O
isolated O
optic B
atrophy. I
This O
was O
most O
frequently O
found O
in O
children, O
many O
of O
whom O
had O
received O
clioquinol O
as O
treatment O
for O
acrodermatitis B
enteropathica. I
In O
the O
remaining O
cases, O
a O
combination O
of O
myelopathy, B
visual B
disturbance, I
and O
peripheral B
neuropathy I
was O
the O
most O
common O
manifestation. O
Isolated O
myelopathy O
or O
peripheral O
neuropathy, O
or O
these O
manifestations O
occurring O
together, O
were O
infrequent. O
The O
onset O
of O
all O
manifestations O
(except O
toxic O
encephalopathy) O
was O
usually O
subacute, O
with O
subsequent O
partial O
recovery. O
Older O
subjects O
tended O
to O
display O
more O
side O
effects. O
The O
full O
syndrome O
of O
subacute O
myelo-optic B
neuropathy B
was I
more O
frequent O
in O
women, O
but O
they O
tended O
to O
have O
taken O
greater O
quantities O
of O
the O
drug. O

Long-term O
glutamate O
supplementation O
failed O
to O
protect O
against O
peripheral B
neurotoxicity I
of O
paclitaxel. O

Bradykinin O
receptors O
antagonists O
and O
nitric O
oxide O
synthase O
inhibitors O
in O
vincristine O
and O
streptozotocin O
induced O
hyperalgesia B
in O
chemotherapy O
and O
diabetic B
neuropathy I
rat O
model. O

Pyrrolidine O
dithiocarbamate O
protects O
the O
piriform O
cortex O
in O
the O
pilocarpine O
status B
epilepticus I
model. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
cardioprotective O
potential O
of O
salvianolic O
acid O
A O
on O
isoproterenol-induced O
myocardial B
infarction I
in O
rats. O
Hemodynamic O
parameters O
and O
lead O
II O
electrocardiograph O
were O
monitored O
and O
recorded O
continuously. O
Cardiac O
marker O
enzymes O
and O
antioxidative O
parameters O
in O
serum O
and O
heart O
tissues O
were O
measured. O
Assay O
for O
mitochondrial O
respiratory O
function O
and O
histopathological O
examination O
of O
heart O
tissues O
were O
performed. O
Isoproterenol-treated O
rats O
showed O
significant O
increases O
in O
the O
levels O
of O
lactate O
dehydrogenase, O
aspartate O
transaminase, O
creatine O
kinase O
and O
malondialdehyde O
and O
significant O
decreases O
in O
the O
activities O
of O
superoxide O
dismutase, O
catalase O
and O
glutathione O
peroxidase O
in O
serum O
and O
heart. O
These O
rats O
also O
showed O
declines O
in O
left O
ventricular O
systolic O
pressure, O
maximum O
and O
minimum O
rate O
of O
developed O
left O
ventricular O
pressure, O
and O
elevation O
of O
left O
ventricular O
end-diastolic O
pressure O
and O
ST-segment. O
In O
addition, O
mitochondrial O
respiratory B
dysfunction I
characterized O
by O
decreased O
respiratory O
control O
ratio O
and O
ADP/O O
was O
observed O
in O
isoproterenol-treated O
rats. O
Administration O
of O
salvianolic O
acid O
A O
for O
a O
period O
of O
8 O
days O
significantly O
attenuated O
isoproterenol-induced O
cardiac B
dysfunction I
and O
myocardial B
injury I
and O
improved O
mitochondrial O
respiratory O
function. O
The O
protective O
role O
of O
salvianolic O
acid O
A O
against O
isoproterenol-induced O
myocardial B
damage I
was O
further O
confirmed O
by O
histopathological O
examination. O
The O
results O
of O
our O
study O
suggest O
that O
salvianolic O
acid O
A O
possessing O
antioxidant O
activity O
has O
a O
significant O
protective O
effect O
against O
isoproterenol-induced O
myocardial O
infarction. O

Effects O
of O
tetrandrine O
and O
fangchinoline O
on O
experimental O
thrombosis B
in O
mice O
and O
human O
platelet B
aggregation. I

Anti-epileptic O
drugs-induced B
de O
novo O
absence B
seizures. I

The O
estimated O
incidence O
of O
angioedema B
during O
angiotensin-converting O
enzyme O
(ACE) O
inhibitor O
treatment O
is O
between O
1 O
and O
7 O
per O
thousand O
patients. O
This O
potentially O
serious O
adverse O
effect O
is O
often O
preceded O
by O
minor O
manifestations O
that O
may O
serve O
as O
a O
warning. O

Effect O
of O
intravenous O
nimodipine O
on O
blood O
pressure O
and O
outcome O
after O
acute B
stroke. I

Verapamil O
is O
an O
effective O
and O
relatively-safe O
antihypertensive O
drug. O
Serious O
adverse O
effects O
are O
uncommon O
and O
mainly O
have O
been O
related O
to O
the O
depression B
of O
cardiac O
contractility O
and O
conduction, O
especially O
when O
the O
drug O
is O
combined O
with O
beta-blocking O
agents. O
We O
report O
a O
case O
in O
which O
myocardial B
infarction I
coincided O
with O
the O
introduction O
of O
captopril O
and O
the O
withdrawal O
of O
verapamil O
in O
a O
previously O
asymptomatic O
woman O
with O
severe O
hypertension. B
Possible O
mechanisms O
that O
involve O
a O
verapamil-related O
increase O
in O
platelet O
and/or O
vascular O
alpha O
2-adrenoreceptor O
affinity O
for O
catecholamines O
are O
discussed. O

Sulfasalazine-induced O
lupus B
erythematosus. I

A O
novel O
compound, O
maltolyl O
p-coumarate, O
attenuates O
cognitive B
deficits I
and O
shows O
neuroprotective O
effects O
in O
vitro O
and O
in O
vivo O
dementia B
models. O

Severe O
thrombocytopenia B
and O
haemolytic B
anaemia I
associated O
with O
ciprofloxacin: O
a O
case O
report O
with O
fatal O
outcome. O

Causes O
of O
acute O
thrombotic B
microangiopathy I
in O
patients O
receiving O
kidney O
transplantation. O

A O
case O
of O
a O
busulfan-induced O
hemorrhage B
cystitis B
is O
reported. O
Spontaneous O
resolution O
occurred O
following O
cessation O
of O
the O
drug. O
The O
similarity O
between O
the O
histologic O
appearances O
of O
busulfan O
cystitis O
and O
both O
radiation O
and O
cyclophosphamide-induced O
cystitis O
is O
discussed O
and O
the O
world O
literature O
reviewed. O
In O
view O
of O
the O
known O
tendency O
of O
busulfan O
to O
induce O
cellular O
atypia O
and O
carcinoma B
in O
other O
sites, O
periodic O
urinary O
cytology O
is O
suggested O
in O
patients O
on O
long-term O
therapy. O

BACKGROUND: O
Although O
intravitreal O
aminoglycosides O
have O
substantially O
improved O
visual O
prognosis O
in O
endophthalmitis, B
macular O
infarction B
may O
impair O
full O
visual O
recovery. O
METHODS: O
We O
present O
a O
case O
of O
presumed O
amikacin O
retinal B
toxicity I
following O
treatment O
with O
amikacin O
and O
vancomycin O
for O
alpha-haemolytic O
streptococcal B
endophthalmitis. I
RESULTS: O
Endophthalmitis B
resolved O
with O
improvement O
in O
visual O
acuity O
to O
6/24 O
at O
three O
months. O
Fundus O
fluorescein O
angiography O
confirmed O
macular O
capillary O
closure O
and O
telangiectasis. B
CONCLUSIONS: O
Currently O
accepted O
intravitreal O
antibiotic O
regimens O
may O
cause O
retinal O
toxicity O
and O
macular O
ischaemia. B
Treatment O
strategies O
aimed O
at O
avoiding O
retinal O
toxicity O
are O
discussed. O

The O
effect O
of O
different O
anaesthetic O
agents O
in O
hearing B
loss I
following O
spinal O
anaesthesia. O

One O
hundred O
and O
fifty-one O
patients O
intolerant O
to O
zidovudine O
(AZT) O
received O
didanosine O
(ddI) O
to O
a O
maximum O
dose O
of O
12.5 O
mg/kg/day. O
Patient O
response O
was O
assessed O
using O
changes O
in O
CD4+ O
lymphocyte O
subset O
count, O
HIV O
p24 O
antigen, O
weight, O
and O
quality O
of O
life. O
Seventy O
patients O
developed O
major O
opportunistic B
infections I
whilst O
on O
therapy; O
this O
was O
the O
first O
AIDS B
diagnosis O
in O
17. O
Only O
minor O
changes O
in O
CD4+ O
lymphocyte O
subset O
count O
were O
observed O
in O
AIDS O
patients, O
although O
a O
more O
significant O
rise O
occurred O
in O
those O
with O
earlier O
stages O
of O
disease. O
Of O
those O
positive O
for O
p24 O
antigen O
at O
the O
commencement O
of O
the O
study O
67% O
showed O
a O
positive O
response, O
and O
this O
was O
most O
likely O
in O
those O
with O
CD4+ O
lymphocyte O
subset O
counts O
above O
100 O
mm3. O
A O
positive O
weight O
response O
was O
seen O
in O
16% O
of O
patients. O
Most O
patients O
showed O
improvement O
in O
individual O
parameters O
and O
global O
score O
of O
quality O
of O
life. O
Adverse O
reactions O
possibly O
attributable O
to O
didanosine O
were O
common. O
The O
most O
common O
side-effect O
was O
diarrhoea, B
which O
resulted O
in O
cessation O
of O
therapy O
in O
19 O
individuals. O
Peripheral B
neuropathy I
occurred O
in O
12 O
patients O
and O
pancreatitis B
in O
six. O
Thirteen O
patients O
developed O
a O
raised O
serum O
amylase O
without O
abdominal B
pain. I
Seven O
patients O
developed O
glucose B
tolerance I
curves I
characteristic O
of O
diabetes B
but O
these O
were O
mild, O
did O
not O
require O
treatment O
and O
returned O
to O
normal O
on O
ceasing O
didanosine. O

OBJECTIVE: O
To O
report O
a O
case O
of O
erythema B
multiforme I
and O
hypersensitivity B
myocarditis B
caused O
by O
ampicillin. O
CASE O
SUMMARY: O
A O
13-year-old O
boy O
was O
treated O
with O
ampicillin O
and O
gentamicin O
because O
of O
suspected O
septicemia. B
Medications O
were O
discontinued O
when O
erythema O
multiforme O
and O
congestive B
heart I
failure I
caused O
by O
myocarditis O
occurred. O
The O
patient O
was O
treated O
with O
methylprednisolone O
and O
gradually O
improved. O
Macrophage-migration O
inhibition O
(MIF) O
test O
with O
ampicillin O
was O
positive. O
DISCUSSION: O
After O
most O
infections B
causing O
erythema O
multiforme O
and O
myocarditis O
were O
ruled O
out, O
a O
drug-induced B
allergic I
reaction I
was O
suspected. O
Positive O
MIF O
test O
for O
ampicillin O
showed O
sensitization O
of O
the O
patient's O
lymphocytes O
to O
ampicillin. O
CONCLUSIONS: O
Hypersensitivity B
myocarditis I
is O
a O
rare O
and O
dangerous O
manifestation O
of O
allergy B
to O
penicillins. O

Suxamethonium O
chloride O
(Sch) O
was O
administered O
i.v. O
to O
36 O
adult O
males O
at O
six O
rates: O
0.25 O
mg O
s-1 O
to O
20 O
mg O
s-1. O
The O
infusion O
was O
discontinued O
either O
when O
there O
was O
no O
muscular O
response O
to O
tetanic B
stimulation O
of O
the O
ulnar O
nerve O
or O
when O
Sch O
120 O
mg O
was O
exceeded. O
Six O
additional O
patients O
received O
a O
30-mg O
i.v. O
bolus O
dose. O
Fasciculations B
in O
six O
areas O
of O
the O
body O
were O
scored O
from O
0 O
to O
3 O
and O
summated O
as O
a O
total O
fasciculation B
score. O
The O
times O
to O
first O
fasciculation, O
twitch B
suppression O
and O
tetanus B
suppression O
were O
inversely O
related O
to O
the O
infusion O
rates. O
Fasciculations O
in O
the O
six O
areas O
and O
the O
total O
fasciculation O
score O
were O
related O
directly O
to O
the O
rate O
of O
infusion. O
Total O
fasciculation O
scores O
in O
the O
30-mg O
bolus O
group O
and O
the O
5-mg O
s-1 O
and O
20-mg O
s-1 O
infusion O
groups O
were O
not O
significantly O
different. O

The O
nephrotoxic B
potential O
of O
amphotericin O
B O
(5 O
mg/kg O
per O
day O
intraperitoneally O
for O
3 O
weeks) O
has O
been O
investigated O
in O
salt-depleted, O
normal-salt, O
and O
salt-loaded O
rats. O
In O
salt-depleted O
rats, O
amphotericin O
B O
decreased O
creatinine O
clearance O
linearly O
with O
time, O
with O
an O
85% O
reduction O
by O
week O
3. O
In O
contrast, O
in O
normal-salt O
rats O
creatinine O
clearance O
was O
decreased O
but O
to O
a O
lesser O
extent O
at O
week O
2 O
and O
3, O
and O
in O
salt-loaded O
rats O
creatinine O
clearance O
did O
not O
change O
for O
2 O
weeks O
and O
was O
decreased O
by O
43% O
at O
week O
3. O
All O
rats O
in O
the O
sodium-depleted O
group O
had O
histopathological O
evidence O
of O
patchy O
tubular O
cytoplasmic O
degeneration O
in O
tubules O
that O
was O
not O
observed O
in O
any O
normal-salt O
or O
salt-loaded O
rat. O
Concentrations O
of O
amphotericin O
B O
in O
plasma O
were O
not O
significantly O
different O
among O
the O
three O
groups O
at O
any O
time O
during O
the O
study. O
However, O
at O
the O
end O
of O
3 O
weeks, O
amphotericin O
B O
levels O
in O
the O
kidneys O
and O
liver O
were O
significantly O
higher O
in O
salt-depleted O
and O
normal-salt O
rats O
than O
those O
in O
salt-loaded O
rats, O
with O
plasma/kidney O
ratios O
of O
21, O
14, O
and O
8 O
in O
salt-depleted, O
normal-salt, O
and O
salt-loaded O
rats, O
respectively. O
In O
conclusion, O
reductions O
in O
creatinine O
clearance O
and O
renal O
amphotericin O
B O
accumulation O
after O
chronic O
amphotericin O
B O
administration O
were O
enhanced O
by O
salt O
depletion O
and O
attenuated O
by O
sodium O
loading O
in O
rats. O

Variant O
ventricular B
tachycardia I
in O
desipramine O
toxicity. B

OBJECTIVE: O
The O
goal O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
side O
effects O
of O
two O
doses O
of O
haloperidol O
and O
placebo O
in O
the O
treatment O
of O
psychosis B
and O
disruptive B
behaviors I
in O
patients O
with O
Alzheimer's B
disease. I
METHOD: O
In O
a O
6-week O
random-assignment, O
double-blind, O
placebo-controlled O
trial O
(phase O
A), O
haloperidol, O
2-3 O
mg/day O
(standard O
dose), O
and O
haloperidol, O
0.50-0.75 O
mg/day O
(low O
dose), O
were O
compared O
in O
71 O
outpatients O
with O
Alzheimer's O
disease. O
For O
the O
subsequent O
6-week O
double-blind O
crossover O
phase O
(phase O
B), O
patients O
taking O
standard- O
or O
low-dose O
haloperidol O
were O
switched O
to O
placebo, O
and O
patients O
taking O
placebo O
were O
randomly O
assigned O
to O
standard- O
or O
low-dose O
haloperidol. O
RESULTS: O
For O
the O
60 O
patients O
who O
completed O
phase O
A, O
standard-dose O
haloperidol O
was O
efficacious O
and O
superior O
to O
both O
low-dose O
haloperidol O
and O
placebo O
for O
scores O
on O
the O
Brief O
Psychiatric O
Rating O
Scale O
psychosis O
factor O
and O
on O
psychomotor B
agitation. I
Response O
rates O
according O
to O
three O
sets O
of O
criteria O
were O
greater O
with O
the O
standard O
dose O
(55%-60%) O
than O
the O
low O
dose O
(25%-35%) O
and O
placebo O
(25%-30%). O
The O
advantage O
of O
standard O
dose O
over O
low O
dose O
was O
replicated O
in O
phase O
B. O
In O
phase O
A, O
extrapyramidal B
signs I
tended O
to O
be O
greater O
with O
the O
standard O
dose O
than O
in O
the O
other O
two O
conditions, O
primarily O
because O
of O
a O
subgroup O
(20%) O
who O
developed O
moderate O
to O
severe O
signs. O
Low-dose O
haloperidol O
did O
not O
differ O
from O
placebo O
on O
any O
measure O
of O
efficacy O
or O
side O
effects. O
CONCLUSIONS: O
The O
results O
indicated O
a O
favorable O
therapeutic O
profile O
for O
haloperidol O
in O
doses O
of O
2-3 O
mg/day, O
although O
a O
subgroup O
developed O
moderate O
to O
severe O
extrapyramidal O
signs. O
A O
starting O
dose O
of O
1 O
mg/day O
with O
gradual, O
upward O
dose O
titration O
is O
recommended. O
The O
narrow O
therapeutic O
window O
observed O
with O
haloperidol O
may O
also O
apply O
to O
other O
neuroleptics O
used O
in O
Alzheimer's O
disease O
patients O
with O
psychosis O
and O
disruptive O
behaviors. O

Spironolactone-induced O
renal B
insufficiency I
and O
hyperkalemia B
in O
patients O
with O
heart B
failure. I

Tonotopic O
organization O
is O
an O
essential O
feature O
of O
the O
primary O
auditory O
area O
(A1) O
of O
primate O
cortex. O
In O
A1 O
of O
macaque O
monkeys, O
low O
frequencies O
are O
represented O
rostrolaterally O
and O
high O
frequencies O
are O
represented O
caudomedially. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
changes O
occur O
in O
this O
tonotopic O
organization O
following O
cochlear O
hearing B
loss. I
Under O
anesthesia, O
the O
superior O
temporal O
gyrus O
of O
adult O
macaque O
monkeys O
was O
exposed, O
and O
the O
tonotopic O
organization O
of O
A1 O
was O
mapped O
using O
conventional O
microelectrode O
recording O
techniques. O
Following O
recovery, O
the O
monkeys O
were O
selectively O
deafened O
for O
high O
frequencies O
using O
kanamycin O
and O
furosemide. O
The O
actual O
frequencies O
deafened O
were O
determined O
by O
the O
loss O
of O
tone-burst O
elicited O
auditory O
brainstem O
responses. O
Three O
months O
after O
deafening, O
A1 O
was O
remapped. O
Postmortem O
cytoarchitectural O
features O
identifying O
A1 O
were O
correlated O
with O
the O
electrophysiologic O
data. O
The O
results O
indicate O
that O
the O
deprived O
area O
of O
A1 O
undergoes O
extensive O
reorganization O
and O
becomes O
responsive O
to O
intact O
cochlear O
frequencies. O
The O
region O
of O
cortex O
that O
represents O
the O
low O
frequencies O
was O
not O
obviously O
affected O
by O
the O
cochlear O
hearing O
loss. O

Ketoconazole O
was O
introduced O
in O
the O
United O
Kingdom O
in O
1981. O
By O
November O
1984 O
the O
Committee O
on O
Safety O
of O
Medicines O
had O
received O
82 O
reports O
of O
possible O
hepatotoxicity B
associated O
with O
the O
drug, O
including O
five O
deaths. B
An O
analysis O
of O
the O
75 O
cases O
that O
had O
been O
adequately O
followed O
up O
suggested O
that O
16, O
including O
three O
deaths, O
were O
probably O
related O
to O
treatment O
with O
the O
drug. O
Of O
the O
remainder, O
48 O
were O
possibly O
related O
to O
treatment, O
five O
were O
unlikely O
to O
be O
so, O
and O
six O
were O
unclassifiable. O
The O
mean O
age O
of O
patients O
in O
the O
16 O
probable O
cases O
was O
57.9, O
with O
hepatotoxicity O
being O
more O
common O
in O
women. O
The O
average O
duration O
of O
treatment O
before O
the O
onset O
of O
jaundice B
was O
61 O
days. O
None O
of O
these O
well O
validated O
cases O
occurred O
within O
the O
first O
10 O
days O
after O
treatment. O
The O
results O
of O
serum O
liver O
function O
tests O
suggested O
hepatocellular B
injury I
in O
10 O
(63%); O
the O
rest O
showed O
a O
mixed O
pattern. O
In O
contrast, O
the O
results O
of O
histological O
examination O
of O
the O
liver O
often O
showed O
evidence O
of O
cholestasis. B
The O
characteristics O
of O
the O
48 O
patients O
in O
the O
possible O
cases O
were O
similar. O
Allergic O
manifestations O
such O
as O
rash B
and O
eosinophilia B
were O
rare. O
Hepatitis B
was O
usually O
reversible O
when O
treatment O
was O
stopped, O
with O
the O
results O
of O
liver O
function O
tests O
returning O
to O
normal O
after O
an O
average O
of O
3.1 O
months. O
In O
two O
of O
the O
three O
deaths O
probably O
associated O
with O
ketoconazole O
treatment O
the O
drug O
had O
been O
continued O
after O
the O
onset O
of O
jaundice O
and O
other O
symptoms O
of O
hepatitis. B
Clinical O
and O
biochemical O
monitoring O
at O
regular O
intervals O
for O
evidence O
of O
hepatitis O
is O
advised O
during O
long O
term O
treatment O
with O
ketoconazole O
to O
prevent O
possible O
serious O
hepatic B
injury. I

Cephalosporin O
antibiotics O
cause O
a O
variety O
of O
hematologic B
disturbances I
in O
man, O
the O
pathogeneses O
and O
hematopathology O
of O
which O
remain O
poorly O
characterized. O
There O
is O
a O
need O
for O
a O
well-defined O
animal O
model O
in O
which O
these O
blood B
dyscrasias I
can O
be O
studied. O
In O
four O
subacute O
toxicity B
studies, O
the O
intravenous O
administration O
of O
cefonicid O
or O
cefazedone O
to O
beagle O
dogs O
caused O
a O
dose-dependent O
incidence O
of O
anemia, B
neutropenia, B
and O
thrombocytopenia B
after B
1-3 O
months O
of O
treatment. O
A O
nonregenerative O
anemia O
was O
the O
most O
compromising O
of O
the O
cytopenias B
and O
occurred O
in O
approximately O
50% O
of O
dogs O
receiving O
400-500 O
mg/kg O
cefonicid O
or O
540-840 O
mg/kg O
cefazedone. O
All O
three O
cytopenias O
were O
completely O
reversible O
following O
cessation O
of O
treatment; O
the O
time O
required O
for O
recovery O
of O
the O
erythron O
(approximately O
1 O
month) O
was O
considerably O
longer O
than O
that O
of O
the O
granulocytes O
and O
platelets O
(hours O
to O
a O
few O
days). O
Upon O
rechallenge O
with O
either O
cephalosporin, O
the O
hematologic B
syndrome I
was O
reproduced O
in O
most O
dogs O
tested; O
cefonicid O
(but O
not O
cefazedone)-treated O
dogs O
showed O
a O
substantially O
reduced O
induction O
period O
(15 O
+/- O
5 O
days) O
compared O
to O
that O
of O
the O
first O
exposure O
to O
the O
drug O
(61 O
+/- O
24 O
days). O
This O
observation, O
along O
with O
the O
rapid O
rate O
of O
decline O
in O
red O
cell O
mass O
parameters O
of O
affected O
dogs, O
suggests O
that O
a O
hemolytic B
component O
complicated O
the O
red O
cell O
production O
problem O
and O
that O
multiple O
toxicologic O
mechanisms O
contributed O
to O
the O
cytopenia. O
We O
conclude O
that O
the O
administration O
of O
high O
doses O
of O
cefonicid O
or O
cefazedone O
to O
dogs O
can O
induce O
hematotoxicity B
similar O
to O
the O
cephalosporin-induced O
blood O
dyscrasias O
described O
in O
man O
and O
thus O
provides O
a O
useful O
model O
for O
studying O
the O
mechanisms O
of O
these O
disorders. O

BACKGROUND: O
Although O
the O
prevalence O
of O
nonsmall B
cell I
lung I
carcinoma I
(NSCLC) O
is B
high O
among O
elderly O
patients, O
few O
data O
are O
available O
regarding O
the O
efficacy O
and O
toxicity B
of O
chemotherapy O
in O
this O
group O
of O
patients. O
Recent O
reports O
indicate O
that O
single O
agent O
therapy O
with O
vinorelbine O
(VNB) O
or O
gemcitabine O
(GEM) O
may O
obtain O
a O
response O
rate O
of O
20-30% O
in O
elderly O
patients, O
with O
acceptable O
toxicity O
and O
improvement O
in O
symptoms O
and O
quality O
of O
life. O
In O
the O
current O
study O
the O
efficacy O
and O
toxicity O
of O
the O
combination O
of O
GEM O
and O
VNB O
in O
elderly O
patients O
with O
advanced O
NSCLC O
or O
those O
with O
some O
contraindication O
to O
receiving O
cisplatin O
were O
assessed. O
METHODS: O
Forty-nine O
patients O
with O
advanced O
NSCLC O
were O
included, O
38 O
of O
whom O
were O
age O
>/= O
70 O
years O
and O
11 O
were O
age O
< O
70 O
years O
but O
who O
had O
some O
contraindication O
to O
receiving O
cisplatin. O
All O
patients O
were O
evaluable O
for O
response O
and O
toxicity. O
Treatment O
was O
comprised O
of O
VNB, O
25 O
mg/m(2), O
plus O
GEM, O
1000 O
mg/m(2), O
both O
on O
Days O
1, O
8, O
and O
15 O
every O
28 O
days. O
Patients O
received O
a O
minimum O
of O
three O
courses O
unless O
progressive O
disease O
was O
detected. O
RESULTS: O
One O
hundred O
sixty-five O
courses O
were O
administered, O
with O
a O
median O
of O
3. O
6 O
courses O
per O
patient. O
The O
overall O
response O
rate O
was O
26% O
(95% O
confidence O
interval, O
15-41%). O
Two O
patients O
attained O
a O
complete O
response O
(4%) O
and O
11 O
patients O
(22%) O
achieved O
a O
partial O
response. O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
improved O
in O
35% O
of O
those O
patients O
with O
an O
initial O
value O
> O
0, O
whereas O
relief O
of O
at O
least O
1 O
symptom O
without O
worsening O
of O
other O
symptoms O
was O
noted O
in O
27 O
patients O
(55%). O
The O
median O
time O
to O
progression O
was O
16 O
weeks O
and O
the O
1-year O
survival O
rate O
was O
33%. O
Toxicity B
was O
mild. O
Six O
patients O
(12%) O
had O
World O
Health O
Organization O
Grade O
3-4 O
neutropenia, B
2 O
patients O
(4%) O
had O
Grade O
3-4 O
thrombocytopenia, B
and O
2 O
patients O
(4%) O
had O
Grade O
3 O
neurotoxicity. B
Three O
patients O
with O
severe O
neutropenia O
(6%) O
died O
of O
sepsis. B
The O
median O
age O
of O
those O
patients O
developing O
Grade O
3-4 O
neutropenia O
was O
significantly O
higher O
than O
that O
of O
the O
remaining O
patients O
(75 O
years O
vs. O
72 O
years; O
P O
= O
0.047). O
CONCLUSIONS: O
The O
combination O
of O
GEM O
and O
VNB O
is O
moderately O
active O
and O
well O
tolerated O
except O
in O
patients O
age O
>/= O
75 O
years. O
This O
age O
group O
had O
an O
increased O
risk O
of O
myelosuppression. B
Therefore O
the O
prophylactic O
use O
of O
granulocyte-colony O
stimulating O
factor O
should O
be O
considered O
with O
this O
treatment. O
New O
chemotherapy O
combinations O
with O
higher O
activity O
and O
lower O
toxicity O
are O
needed O
for O
elderly O
patients O
with O
advanced O
NSCLC. O

Combined O
effects O
of O
prolonged O
prostaglandin O
E1 O
(PGE1)-induced O
hypotension B
and O
haemodilution B
on O
hepatic O
function O
were O
studied O
in O
30 O
patients O
undergoing O
hip O
surgery. O
The O
patients O
were O
randomly O
allocated O
to O
one O
of O
three O
groups; O
those O
in O
group O
A O
(n O
= O
10) O
were O
subjected O
to O
controlled O
hypotension O
alone, O
those O
in O
group O
B O
(n O
= O
10) O
to O
haemodilution O
alone O
and O
those O
in O
group O
C O
(n O
= O
10) O
to O
both O
controlled O
hypotension O
and O
haemodilution. O
Haemodilution B
in O
groups O
B O
and O
C O
was O
produced O
by O
withdrawing O
approximately O
1000 O
mL O
of O
blood O
and O
replacing O
it O
with O
the O
same O
amount O
of O
dextran O
solution, O
and O
final O
haematocrit O
values O
were O
21 O
or O
22%. O
Controlled O
hypotension O
in O
groups O
A O
and O
C O
was O
induced O
with O
PGE1 O
to O
maintain O
mean O
arterial O
blood O
pressure O
at O
55 O
mmHg O
for O
180 O
min. O
Measurements O
included O
arterial O
ketone O
body O
ratio O
(AKBR, O
aceto-acetate/3-hydroxybutyrate) O
and O
clinical O
hepatic O
function O
parameters. O
AKBR O
and O
biological O
hepatic O
function O
tests O
showed O
no O
change O
throughout O
the O
time O
course O
in O
groups O
A O
and O
B. O
In O
group O
C, O
AKBR O
showed O
a O
significant O
decrease O
at O
120 O
min O
(-40%) O
and O
at O
180 O
min O
(-49%) O
after O
the O
start O
of O
hypotension O
and O
at O
60 O
min O
(-32%) O
after O
recovery O
of O
normotension, O
and O
SGOT, O
SGPT, O
LDH O
and O
total O
bilirubin O
showed O
significant O
increases O
after O
operation. O
The O
results O
suggest O
that O
a O
prolonged O
combination O
of O
more O
than O
120 O
min O
of O
PGE1-induced O
hypotension O
and O
moderate O
haemodilution O
would O
cause O
impairment B
of I
hepatic I
function. I

Verapamil O
withdrawal O
as O
a O
possible O
cause O
of O
myocardial B
infarction I
in O
a O
hypertensive B
woman O
with O
a O
normal O
coronary O
angiogram. O

Primary B
pulmonary I
hypertension I
is O
a O
rare, O
progressive O
and O
incurable O
disease, O
which O
has O
been O
associated O
with O
the O
intake O
of O
appetite O
suppressant O
drugs. O
The O
importance O
of O
this O
association O
was O
evaluated O
in O
Belgium O
while O
this O
country O
still O
had O
no O
restriction O
on O
the O
prescription O
of O
appetite O
suppressants. O
Thirty-five O
patients O
with O
primary B
pulmonary I
hypertension I
and O
85 O
matched O
controls O
were O
recruited O
over O
32 O
months O
(1992-1994) O
in O
Belgium. O
Exposure O
to O
appetite-suppressants O
was O
assessed O
on O
the O
basis O
of O
hospital O
records O
and O
standardized O
interview. O
Twenty-three O
of O
the O
patients O
had O
previously O
taken O
appetite O
suppressants, O
mainly O
fenfluramines, O
as O
compared O
with O
only O
5 O
of O
the O
controls O
(66 O
versus O
6%, O
p<0.0001). O
Five O
patients O
died O
before O
the O
interview, O
all O
of O
them O
had O
taken O
appetite O
suppressants. O
In O
8 O
patients O
the O
diagnosis O
of O
primary O
pulmonary O
hypertension O
was O
uncertain, O
5 O
of O
them O
had O
taken O
appetite O
suppressants. O
The O
patients O
who O
had O
been O
exposed O
to O
appetite O
suppressants O
tended O
to O
be O
on O
average O
more O
severely O
ill, O
and O
to O
have O
a O
shorter O
median O
delay O
between O
onset O
of O
symptoms O
and O
diagnosis. O
A O
policy O
of O
unrestricted O
prescription O
of O
appetite O
suppressants O
may O
lead O
to O
a O
high O
incidence O
of O
associated O
primary O
pulmonary O
hypertension. O
Intake O
of O
appetite O
suppressants O
may O
accelerate O
the O
progression O
of O
the O
disease. O

Oral O
manifestations O
of O
"meth O
mouth": B
a I
case O
report. O

Recurrent O
reversible O
acute B
renal I
failure I
from O
amphotericin. O

Death B
from O
chemotherapy O
in O
gestational B
trophoblastic I
disease. I

Reversal O
by O
phenylephrine O
of O
the O
beneficial O
effects O
of O
intravenous O
nitroglycerin O
in O
patients O
with O
acute B
myocardial I
infarction. I

Veno-occlusive B
liver I
disease I
after O
dacarbazine O
therapy O
(DTIC) O
for O
melanoma. B

OBJECTIVE: O
To O
describe O
associations O
between O
the O
use O
of O
benzodiazepines O
or O
related O
drugs O
(BZDs/RDs) O
and O
health, O
functional O
abilities O
and O
cognitive O
function O
in O
the O
elderly. O
METHODS: O
A O
non-randomised O
clinical O
study O
of O
patients O
aged O
> O
or O
=65 O
years O
admitted O
to O
acute O
hospital O
wards O
during O
1 O
month. O
164 O
patients O
(mean O
age O
+/- O
standard O
deviation O
[SD] O
81.6 O
+/- O
6.8 O
years) O
were O
admitted. O
Of O
these, O
nearly O
half O
(n O
= O
78) O
had O
used O
BZDs/RDs O
before O
admission, O
and O
the O
remainder O
(n O
= O
86) O
were O
non-users. O
Cognitive O
ability O
was O
assessed O
by O
the O
Mini-Mental O
State O
Examination O
(MMSE). O
Patients O
scoring O
> O
or O
=20 O
MMSE O
sum O
points O
were O
interviewed O
(n O
= O
79) O
and O
questioned O
regarding O
symptoms O
and O
functional O
abilities O
during O
the O
week O
prior O
to O
admission. O
Data O
on O
use O
of O
BZDs/RDs O
before O
admission, O
current O
medications O
and O
discharge O
diagnoses O
were O
collected O
from O
medical O
records. O
Health, O
physical O
abilities O
and O
cognitive O
function O
were O
compared O
between O
BZD/RD O
users O
and O
non-users, O
and O
adjustments O
were O
made O
for O
confounding O
variables. O
The O
residual O
serum O
concentrations O
of O
oxazepam, O
temazepam O
and O
zopiclone O
were O
analysed. O
RESULTS: O
The O
mean O
+/- O
SD O
duration O
of O
BZD/RD O
use O
was O
7 O
+/- O
7 O
years O
(range O
1-31). O
Two O
or O
three O
BZDs/RDs O
were O
concomitantly O
taken O
by O
26% O
of O
users O
(n O
= O
20). O
Long-term O
use O
of O
these O
drugs O
was O
associated O
with O
female O
sex O
and O
use O
of O
a O
higher O
number O
of O
drugs O
with O
effects O
on O
the O
CNS, O
which O
tended O
to O
be O
related O
to O
diagnosed O
dementia. B
After O
adjustment O
for O
these O
variables O
as O
confounders, O
use O
of O
BZDs/RDs O
was O
not O
associated O
with O
cognitive O
function O
as O
measured O
by O
the O
MMSE. O
However, O
use O
of O
BZDs/RDs O
was O
associated O
with O
dizziness, B
inability B
to I
sleep I
after O
awaking O
at O
night O
and O
tiredness B
in O
the O
mornings O
during O
the O
week O
prior O
to O
admission O
and O
with O
stronger O
depressive B
symptoms I
measured O
at O
the O
beginning O
of O
the O
hospital O
stay. O
Use O
of O
BZDs/RDs O
tended O
to O
be O
associated O
with O
a O
reduced O
ability O
to O
walk O
and O
shorter O
night-time O
sleep O
during O
the O
week O
prior O
to O
admission. O
A O
higher O
residual O
serum O
concentration O
of O
temazepam O
correlated O
with O
a O
lower O
MMSE O
sum O
score O
after O
adjustment O
for O
confounding O
variables. O
CONCLUSIONS: O
Long-term O
use O
and O
concomitant O
use O
of O
more O
than O
one O
BZD/RD O
were O
common O
in O
elderly O
patients O
hospitalised O
because O
of O
acute O
illnesses. O
Long-term O
use O
was O
associated O
with O
daytime O
and O
night-time O
symptoms O
indicative O
of O
poorer O
health O
and O
potentially O
caused O
by O
the O
adverse O
effects O
of O
these O
drugs. O

A O
randomized O
comparison O
of O
labetalol O
and O
nitroprusside O
for O
induced O
hypotension. B

Severe O
reversible O
left B
ventricular I
systolic I
and I
diastolic I
dysfunction I
due O
to O
accidental O
iatrogenic O
epinephrine O
overdose. B

Treatment O
of O
previously O
treated O
metastatic O
breast B
cancer I
by O
mitoxantrone O
and O
48-hour O
continuous O
infusion O
of O
high-dose O
5-FU O
and O
leucovorin O
(MFL): O
low O
palliative O
benefit O
and O
high O
treatment-related O
toxicity. B

Permeability, O
ultrastructural O
changes, O
and O
distribution O
of O
novel O
proteins O
in O
the O
glomerular O
barrier O
in O
early O
puromycin O
aminonucleoside O
nephrosis. B

The O
present O
study O
was O
carried O
out O
to O
test O
the O
effects O
of O
L-alpha-glycerylphosphorylcholine O
(L-alpha-GFC) O
on O
memory B
impairment I
induced O
by O
scopolamine O
in O
man. O
Thirty-two O
healthy O
young O
volunteers O
were O
randomly O
allocated O
to O
four O
different O
groups. O
They O
were O
given O
a O
ten O
day O
pretreatment O
with O
either O
L-alpha-GFC O
or O
placebo, O
p.o., O
and O
on O
the O
eleventh O
day O
either O
scopolamine O
or O
placebo, O
i.m. O
Before O
and O
0.5, O
1, O
2, O
3, O
and O
6 O
h O
after O
injection O
the O
subjects O
were O
given O
attention O
and O
mnemonic O
tests. O
The O
findings O
of O
this O
study O
indicate O
that O
the O
drug O
is O
able O
to O
antagonize O
impairment B
of I
attention I
and I
memory I
induced O
by O
scopolamine. O

The O
effect O
of O
amiloride O
on O
lithium-induced O
polydipsia B
and O
polyuria B
and O
on O
the O
lithium O
concentration O
in O
the O
plasma, O
brain, O
kidney, O
thyroid O
and O
red O
blood O
cells O
was O
investigated O
in O
rats, O
chronically O
treated O
with O
LiCl. O
Amiloride O
reduced O
the O
drinking O
and O
urine O
volume O
of O
rats O
in O
an O
acute O
(6 O
or O
12 O
h) O
and O
a O
subacute O
(3 O
days) O
experiment. O
6 O
h O
after O
the O
administration O
of O
amiloride, O
a O
reduction O
was O
observed O
in O
the O
lithium O
content O
of O
the O
renal O
medulla O
but O
not O
in O
the O
other O
organs O
studied. O
At O
12 O
h, O
all O
the O
tissues O
showed O
a O
slight O
increase O
in O
lithium O
levels. O
After O
3 O
days O
of O
combined O
treatment, O
a O
marked O
elevation O
in O
plasma O
and O
tissue O
lithium O
levels O
accompanied O
a O
reduction O
in O
water O
intake. O
In O
all O
the O
experiments, O
the O
attenuation O
of O
the O
lithium-induced O
diabetes-insipidus-like B
syndrome I
by O
amiloride O
was O
accompanied O
by O
a O
reduction O
of O
the O
ratio O
between O
the O
lithium O
concentration O
in O
the O
renal O
medulla O
and O
its O
levels O
in O
the O
blood O
and O
an O
elevation O
in O
the O
plasma O
potassium O
level. O
It O
is O
concluded O
that O
acute O
amiloride O
administration O
to O
lithium-treated O
patients O
suffering O
from O
polydipsia O
and O
polyuria O
might O
relieve O
these O
patients O
but O
prolonged O
amiloride O
supplementation O
would O
result O
in O
elevated O
lithium O
levels O
and O
might O
be O
hazardous. O

The O
present O
study O
was O
aimed O
at O
investigating O
the O
effects O
of O
Daucus O
carota O
seeds O
on O
cognitive O
functions, O
total O
serum O
cholesterol O
levels O
and O
brain O
cholinesterase O
activity O
in O
mice. O
The O
ethanolic O
extract O
of O
Daucus O
carota O
seeds O
(DCE) O
was O
administered O
orally O
in O
three O
doses O
(100, O
200, O
400 O
mg/kg) O
for O
seven O
successive O
days O
to O
different O
groups O
of O
young O
and O
aged O
mice. O
Elevated O
plus O
maze O
and O
passive O
avoidance O
apparatus O
served O
as O
the O
exteroceptive O
behavioral O
models O
for O
testing O
memory. O
Diazepam-, O
scopolamine- O
and O
ageing-induced O
amnesia B
served O
as O
the O
interoceptive O
behavioral O
models. O
DCE O
(200, O
400 O
mg/kg, O
p.o.) O
showed O
significant O
improvement O
in O
memory O
scores O
of O
young O
and O
aged O
mice. O
The O
extent O
of O
memory O
improvement O
evoked O
by O
DCE O
was O
23% O
at O
the O
dose O
of O
200 O
mg/kg O
and O
35% O
at O
the O
dose O
of O
400 O
mg/kg O
in O
young O
mice O
using O
elevated O
plus O
maze. O
Similarly, O
significant O
improvements O
in O
memory O
scores O
were O
observed O
using O
passive O
avoidance O
apparatus O
and O
aged O
mice. O
Furthermore, O
DCE O
reversed O
the O
amnesia O
induced O
by O
scopolamine O
(0.4 O
mg/kg, O
i.p.) O
and O
diazepam O
(1 O
mg/kg, O
i.p.). O
Daucus O
carota O
extract O
(200, O
400 O
mg/kg, O
p.o.) O
reduced O
significantly O
the O
brain O
acetylcholinesterase O
activity O
and O
cholesterol O
levels O
in O
young O
and O
aged O
mice. O
The O
extent O
of O
inhibition O
of O
brain O
cholinesterase O
activity O
evoked O
by O
DCE O
at O
the O
dose O
of O
400 O
mg/kg O
was O
22% O
in O
young O
and O
19% O
in O
aged O
mice. O
There O
was O
a O
remarkable O
reduction O
in O
total O
cholesterol O
level O
as O
well, O
to O
the O
extent O
of O
23% O
in O
young O
and O
21% O
in O
aged O
animals O
with O
this O
dose O
of O
DCE. O
Therefore, O
DCE O
may O
prove O
to O
be O
a O
useful O
remedy O
for O
the O
management O
of O
cognitive B
dysfunctions I
on O
account O
of O
its O
multifarious O
beneficial O
effects O
such O
as, O
memory O
improving O
property, O
cholesterol O
lowering O
property O
and O
anticholinesterase O
activity. O

Differential O
effects O
of O
systemically O
administered O
ketamine O
and O
lidocaine O
on O
dynamic O
and O
static O
hyperalgesia B
induced O
by O
intradermal O
capsaicin O
in O
humans. O

BACKGROUND: O
Glioblastoma B
is O
a O
malignant B
tumor I
that O
occurs O
in O
the O
cerebrum O
during O
adulthood. O
With O
current O
treatment O
regimens O
including O
combined O
surgery, O
radiation O
and O
chemotherapy, O
the O
average O
life O
expectancy O
of O
the O
patients O
is O
limited O
to O
approximately O
1 O
year. O
Therefore, O
patients O
with O
glioblastoma B
sometimes O
have O
intracarotid O
injection O
of O
carcinostatics O
added O
to O
the O
treatment O
regimen. O
Generally, O
carboplatin O
is O
said O
to O
have O
milder O
side O
effects O
than O
cisplatin, O
whose O
ocular B
and I
orbital B
toxicity B
are O
well O
known. O
However, O
we O
experienced O
a O
case O
of O
severe O
ocular O
and O
orbital O
toxicity O
after O
intracarotid O
injection O
of O
carboplatin, O
which O
is O
infrequently O
reported. O
CASE: O
A O
58-year-old O
man O
received O
an O
intracarotid O
injection O
of O
carboplatin O
for O
recurrent O
glioblastomas B
in O
his O
left O
temporal O
lobe. O
He O
complained O
of O
pain B
and I
visual B
disturbance I
in I
the I
ipsilateral I
eye I
30 O
h O
after O
the O
injection. O
Various O
ocular O
symptoms O
and O
findings O
caused O
by O
carboplatin O
toxicity O
were O
seen. O
RESULTS: O
He O
was O
treated O
with O
intravenous O
administration O
of O
corticosteroids O
and O
glycerin O
for O
6 O
days O
after O
the O
injection. O
Although O
the O
intraocular O
pressure O
elevation O
caused O
by O
secondary O
acute O
angle-closure O
glaucoma B
decreased O
and O
ocular B
pain I
diminished, O
inexorable O
papilledema B
and O
exudative O
retinal B
detachment I
continued O
for O
3 O
weeks. O
Finally, O
6 O
weeks O
later, O
diffuse O
chorioretinal B
atrophy I
with O
optic B
atrophy I
occurred O
and O
the O
vision O
in O
his O
left O
eye O
was O
lost. O
CONCLUSION: O
When O
performing O
intracarotid O
injection O
of O
carboplatin, O
we O
must O
be O
aware O
of O
its O
potentially O
blinding O
ocular B
toxicity. I
It O
is O
recommended O
that O
further O
studies O
and O
investigations O
are O
undertaken O
in O
the O
effort O
to O
minimize O
such O
severe O
side O
effects. O

Macula O
toxicity B
after O
intravitreal O
amikacin. O

We O
prospectively O
evaluated O
the O
adverse O
reactions O
of O
apraclonidine O
in O
20 O
normal O
volunteers O
by O
instilling O
a O
single O
drop O
of O
1% O
apraclonidine O
in O
their O
right O
eyes. O
Examinations, O
including O
blood O
pressure, O
pulse O
rate, O
conjunctiva O
and O
cornea, O
intraocular O
pressure O
(IOP), O
pupil O
diameter, O
basal O
tear O
secretion O
and O
margin O
reflex O
distance O
of O
both O
upper O
and O
lower O
eyelids, O
were O
performed O
prior O
to O
entry O
and O
at O
1, O
3, O
5 O
and O
7 O
hours O
after O
instillation. O
The O
ocular B
hypotensive I
effects O
were O
statistically O
significant O
for O
apraclonidine-treated O
eyes O
throughout O
the O
study O
and O
also O
statistically O
significant O
for O
contralateral O
eyes O
from O
three O
hours O
after O
topical O
administration O
of O
1% O
apraclonidine. O
Decreases B
in I
systolic I
blood I
pressure I
were O
statistically, O
but O
not O
clinically, O
significant. O
No O
significant O
changes O
in O
diastolic O
blood O
pressure, O
pulse O
rate O
and O
basal O
tear O
secretion O
were O
noted. O
Conjunctival B
blanching I
and O
mydriasis B
were O
commonly O
found. O
Upper O
lid O
retraction O
was O
frequently O
noted. O
While O
the O
elevations O
of O
the O
upper O
lid O
margin O
in O
most O
subjects O
were O
not O
more O
than O
2 O
mm O
and O
did O
not O
cause O
noticeable O
change O
in O
appearance, O
one O
subject O
suffered O
from O
mechanical O
entropion B
and O
marked O
corneal B
abrasion I
3 O
hours O
after O
instillation O
of O
the O
medication. O
This O
may O
well O
be O
a O
particularly O
notable O
finding O
in O
Asian O
people. O

1. O
Glucocorticoid-induced O
hypertension B
(GC-HT) O
in B
the O
rat O
is O
associated O
with O
nitric O
oxide-redox O
imbalance. O
2. O
We O
studied O
the O
role O
of O
xanthine O
oxidase O
(XO), O
which O
is O
implicated O
in O
the O
production O
of O
reactive O
oxygen O
species, O
in O
dexamethasone-induced O
hypertension O
(dex-HT). O
3. O
Thirty O
male O
Sprague-Dawley O
rats O
were O
divided O
randomly O
into O
four O
treatment O
groups: O
saline, O
dexamethasone O
(dex), O
allopurinol O
plus O
saline, O
and O
allopurinol O
plus O
dex. O
4. O
Systolic O
blood O
pressures O
(SBP) O
and O
bodyweights O
were O
recorded O
each O
alternate O
day. O
Thymus O
weight O
was O
used O
as O
a O
marker O
of O
glucocorticoid O
activity, O
and O
serum O
urate O
to O
assess O
XO O
inhibition. O
5. O
Dex O
increased B
SBP I
(110 O
+/- O
2-126 O
+/- O
3 O
mmHg; O
P O
< O
0.001) O
and O
decreased B
thymus I
(P I
< I
0.001) I
and I
bodyweights I
(P" O
< O
0.01). O
Allopurinol O
decreased O
serum O
urate O
from O
76 O
+/- O
5 O
to O
30 O
+/- O
3 O
micromol/L O
(P O
< O
0.001) O
in O
saline O
and O
from O
84 O
+/- O
13 O
to O
28 O
+/- O
2 O
micromol/L O
in O
dex-treated O
(P O
< O
0.01) O
groups. O
6. O
Allopurinol O
did O
not O
prevent O
dex-HT. O
This, O
together O
with O
our O
previous O
findings O
that O
allopurinol O
failed O
to O
prevent O
adrenocorticotrophic O
hormone O
induced O
hypertension, O
suggests O
that O
XO O
activity O
is O
not O
a O
major O
determinant O
of O
GC-HT O
in O
the O
rat. O

OBJECTIVES: O
To O
correlate O
optical O
density O
and O
percent O
inhibition O
of O
a O
two-step O
heparin-induced O
thrombocytopenia B
(HIT) O
antigen B
assay O
with O
thrombosis; B
the O
assay O
utilizes O
reaction O
inhibition O
characteristics O
of O
a O
high O
heparin O
concentration. O
PATIENTS O
AND O
METHODS: O
Patients O
with O
more O
than O
50% O
decrease O
in O
platelet O
count O
or O
thrombocytopenia O
(<150 O
x O
10(9)/L) O
after O
exposure O
to O
heparin, O
who O
had O
a O
positive O
two-step O
antigen O
assay O
[optical O
density O
(OD) O
>0.4 O
and O
>50 O
inhibition O
with O
high O
concentration O
of O
heparin] O
were O
included O
in O
the O
study. O
RESULTS: O
Forty O
of O
94 O
HIT O
patients O
had O
thrombosis O
at O
diagnosis; O
54/94 O
had O
isolated-HIT O
without O
thrombosis. O
Eight O
of O
the O
isolated-HIT O
patients O
developed O
thrombosis O
within O
the O
next O
30 O
d; O
thus, O
a O
total O
of O
48 O
patients O
had O
thrombosis O
at O
day O
30. O
At O
diagnosis O
there O
was O
no O
significant O
difference O
in O
OD O
between O
HIT O
patients O
with O
thrombosis O
and O
those O
with O
isolated-HIT. O
However, O
OD O
was O
significantly O
higher O
in O
all O
patients O
with O
thrombosis O
(n O
= O
48, O
1.34 O
+/- O
0.89), O
including O
isolated-HIT O
patients O
who O
later O
developed O
thrombosis O
within O
30 O
d O
(n O
= O
8, O
1.84 O
+/- O
0.64) O
as O
compared O
to O
isolated-HIT O
patients O
who O
did O
not O
develop O
thrombosis O
(0.96 O
+/- O
0.75; O
P O
= O
0.011 O
and O
P O
= O
0.008). O
The O
Receiver O
Operative O
Characteristic O
Curve O
showed O
that O
OD O
>1.27 O
in O
the O
isolated-HIT O
group O
had O
a O
significantly O
higher O
chance O
of O
developing O
thrombosis O
by O
day O
30. O
None O
of O
these O
groups O
showed O
significant O
difference O
in O
percent O
inhibition. O
Multivariate O
analysis O
showed O
a O
2.8-fold O
increased O
risk O
of O
thrombosis O
in O
females. O
Similarly, O
thrombotic B
risk O
increased O
with O
age O
and O
OD O
values. O
CONCLUSION: O
Higher O
OD O
is O
associated O
with O
significant O
risk O
of O
subsequent O
thrombosis O
in O
patients O
with O
isolated-HIT; O
percent O
inhibition, O
however, O
was O
not O
predictive. O

Behavioral O
effects O
of O
diazepam O
and O
propranolol O
in O
patients O
with O
panic B
disorder I
and O
agoraphobia. B

Methamphetamine O
(METH) O
damages O
dopamine O
(DA) O
nerve O
endings O
by O
a O
process O
that O
has O
been O
linked O
to O
microglial O
activation O
but O
the O
signaling O
pathways O
that O
mediate O
this O
response O
have O
not O
yet O
been O
delineated. O
Cardona O
et O
al. O
[Nat. O
Neurosci. O
9 O
(2006), O
917] O
recently O
identified O
the O
microglial-specific O
fractalkine O
receptor O
(CX3CR1) O
as O
an O
important O
mediator O
of O
MPTP-induced O
neurodegeneration B
of O
DA O
neurons. O
Because O
the O
CNS B
damage I
caused O
by O
METH O
and O
MPTP O
is O
highly O
selective O
for O
the O
DA O
neuronal O
system O
in O
mouse O
models O
of O
neurotoxicity, B
we O
hypothesized O
that O
the O
CX3CR1 O
plays O
a O
role O
in O
METH-induced O
neurotoxicity O
and O
microglial O
activation. O
Mice O
in O
which O
the O
CX3CR1 O
gene O
has O
been O
deleted O
and O
replaced O
with O
a O
cDNA O
encoding O
enhanced O
green O
fluorescent O
protein O
(eGFP) O
were O
treated O
with O
METH O
and O
examined O
for O
striatal O
neurotoxicity. O
METH O
depleted O
DA, O
caused O
microglial O
activation, O
and O
increased O
body O
temperature O
in O
CX3CR1 O
knockout O
mice O
to O
the O
same O
extent O
and O
over O
the O
same O
time O
course O
seen O
in O
wild-type O
controls. O
The O
effects O
of O
METH O
in O
CX3CR1 O
knockout O
mice O
were O
not O
gender-dependent O
and O
did O
not O
extend O
beyond O
the O
striatum. O
Striatal O
microglia O
expressing O
eGFP O
constitutively O
show O
morphological O
changes O
after O
METH O
that O
are O
characteristic O
of O
activation. O
This O
response O
was O
restricted O
to O
the O
striatum O
and O
contrasted O
sharply O
with O
unresponsive O
eGFP-microglia O
in O
surrounding O
brain O
areas O
that O
are O
not O
damaged O
by O
METH. O
We O
conclude O
from O
these O
studies O
that O
CX3CR1 O
signaling O
does O
not O
modulate O
METH O
neurotoxicity O
or O
microglial O
activation. O
Furthermore, O
it O
appears O
that O
striatal-resident O
microglia O
respond O
to O
METH O
with O
an O
activation O
cascade O
and O
then O
return O
to O
a O
surveying O
state O
without O
undergoing O
apoptosis O
or O
migration. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relationship O
between O
phenytoin O
medication O
and O
cerebellar B
atrophy I
in O
patients O
who O
had O
experienced O
clinical O
intoxication. O
Five O
females O
and O
6 O
males, O
21-59 O
years O
of O
age, O
were O
examined O
with O
a O
1.5-T O
whole-body O
system O
using O
a O
circular O
polarized O
head O
coil. O
Conventional O
spin O
echo O
images O
were O
acquired O
in O
the O
sagittal O
and O
transverse O
orientation. O
In O
addition, O
we O
performed O
a O
high-resolution O
3D O
gradient O
echo, O
T1-weighted O
sequences O
at O
a O
1-mm O
slice O
thickness. O
The O
images O
were O
subsequently O
processed O
to O
obtain O
volumetric O
data O
for O
the O
cerebellum. O
Cerebellar O
volume O
for O
the O
patient O
group O
ranged O
between O
67.66 O
and O
131.08 O
ml O
(mean O
108.9 O
ml). O
In O
addition O
3D O
gradient O
echo O
data O
sets O
from O
10 O
healthy O
male O
and O
10 O
healthy O
female O
age-matched O
volunteers O
were O
used O
to O
compare O
cerebellar O
volumes. O
Using O
linear O
regression O
we O
found O
that O
no O
correlation O
exists O
between O
seizure B
duration, O
elevation O
of O
phenytoin O
serum O
levels O
and O
cerebellar O
volume. O
However, O
multiple O
regression O
for O
the O
daily O
dosage, O
duration O
of O
phenytoin O
treatment O
and O
cerebellar O
volume O
revealed O
a O
correlation O
of O
these O
parameters. O
We O
conclude O
that O
phenytoin O
overdosage B
does O
not O
necessarily O
result O
in O
cerebellar O
atrophy O
and O
it O
is O
unlikely O
that O
phenytoin O
medication O
was O
the O
only O
cause O
of O
cerebellar O
atrophy O
in O
the O
remaining O
patients. O
Quantitative O
morphometric O
studies O
of O
the O
cerebellum O
provide O
valuable O
insights O
into O
the O
pathogenesis O
of O
cerebellar B
disorders. I

Severe O
citrate O
toxicity B
complicating O
volunteer O
apheresis O
platelet O
donation. O

Suxamethonium O
induced O
prolonged O
apnea B
in O
a O
patient O
receiving O
electroconvulsive O
therapy. O

OBJECTIVES: O
The O
United O
Kingdom O
Parkinson's B
Disease I
Research O
Group O
(UKPDRG) O
trial B
found O
an O
increased O
mortality O
in O
patients O
with O
Parkinson's B
disease I
(PD) O
randomized O
to O
receive O
10 O
mg O
selegiline O
per O
day O
and O
L-dopa O
compared O
with O
those O
taking O
L-dopa O
alone. O
Recently, O
we O
found O
that O
therapy O
with O
selegiline O
and O
L-dopa O
was O
associated O
with O
selective O
systolic B
orthostatic B
hypotension I
which O
was O
abolished O
by O
withdrawal O
of O
selegiline. O
This O
unwanted O
effect O
on O
postural O
blood O
pressure O
was O
not O
the O
result O
of O
underlying O
autonomic O
failure. O
The O
aims O
of O
this O
study O
were O
to O
confirm O
our O
previous O
findings O
in O
a O
separate O
cohort O
of O
patients O
and O
to O
determine O
the O
time O
course O
of O
the O
cardiovascular O
consequences O
of O
stopping O
selegiline O
in O
the O
expectation O
that O
this O
might O
shed O
light O
on O
the O
mechanisms O
by O
which O
the O
drug O
causes O
orthostatic O
hypotension. O
METHODS: O
The O
cardiovascular O
responses O
to O
standing O
and O
head-up O
tilt O
were O
studied O
repeatedly O
in O
PD O
patients O
receiving O
selegiline O
and O
as O
the O
drug O
was O
withdrawn. O
RESULTS: O
Head-up O
tilt O
caused O
systolic O
orthostatic O
hypotension O
which O
was O
marked O
in O
six O
of O
20 O
PD O
patients O
on O
selegiline, O
one O
of O
whom O
lost O
consciousness O
with O
unrecordable O
blood O
pressures. O
A O
lesser O
degree O
of O
orthostatic O
hypotension O
occurred O
with O
standing. O
Orthostatic B
hypotension I
was O
ameliorated O
4 O
days O
after O
withdrawal O
of O
selegiline O
and O
totally O
abolished O
7 O
days O
after O
discontinuation O
of O
the O
drug. O
Stopping O
selegiline O
also O
significantly O
reduced B
the I
supine I
systolic I
and I
diastolic I
blood I
pressures I
consistent O
with O
a O
previously O
undescribed O
supine O
pressor O
action. O
CONCLUSION: O
This O
study O
confirms O
our O
previous O
finding O
that O
selegiline O
in O
combination O
with O
L-dopa O
is O
associated O
with O
selective O
orthostatic O
hypotension. O
The O
possibilities O
that O
these O
cardiovascular O
findings O
might O
be O
the O
result O
of O
non-selective O
inhibition O
of O
monoamine O
oxidase O
or O
of O
amphetamine O
and O
metamphetamine O
are O
discussed. O

The O
co-administration O
of O
aspirin O
with O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide O
(FANFT) O
to O
rats O
resulted O
in O
a O
reduced O
incidence O
of O
FANFT-induced O
bladder B
carcinomas I
but O
a O
concomitant O
induction O
of O
forestomach B
tumors. I
An O
autoradiographic O
study O
was O
performed O
on O
male O
F-344 O
rats O
fed O
diet O
containing O
FANFT O
at O
a O
level O
of O
0.2% O
and/or O
aspirin O
at O
a O
level O
of O
0.5% O
to O
evaluate O
the O
effect O
of O
aspirin O
on O
the O
increased O
cell O
proliferation O
induced O
by O
FANFT O
in O
the O
forestomach O
and O
bladder. O
FANFT-induced O
cell O
proliferation O
in O
the O
bladder O
was O
significantly O
suppressed O
by O
aspirin O
co-administration O
after O
4 O
weeks O
but O
not O
after O
12 O
weeks. O
In O
the O
forestomach, O
and O
also O
in O
the O
liver, O
aspirin O
did O
not O
affect O
the O
FANFT-induced O
increase O
in O
labeling O
index. O
The O
present O
results O
are O
consistent O
with O
the O
carcinogenicity O
experiment O
suggesting O
that O
different O
mechanisms O
are O
involved O
in O
FANFT O
carcinogenesis B
in O
the O
bladder O
and O
forestomach, O
and O
that O
aspirin's O
effect O
on O
FANFT O
in O
the O
forestomach O
is O
not O
due O
to O
an O
irritant O
effect O
associated O
with O
increased O
cell O
proliferation. O
Also, O
there O
appears O
to O
be O
an O
adaptation O
by O
the O
rats O
to O
the O
chronic O
ingestion O
of O
aspirin. O

Ocular B
and I
auditory B
toxicity I
in O
hemodialyzed O
patients O
receiving O
desferrioxamine. O

Central B
nervous I
system I
(CNS) I
complications I
during O
treatment O
of O
childhood O
acute B
lymphoblastic I
leukemia I
(ALL) O
remain B
a O
challenging O
clinical O
problem. O
Outcome O
improvement O
with O
more O
intensive O
chemotherapy O
has O
significantly O
increased O
the O
incidence O
and O
severity O
of O
adverse O
events. O
This O
study O
analyzed O
the O
incidence O
of O
neurological B
complications I
during O
ALL O
treatment O
in O
a O
single O
pediatric O
institution, O
focusing O
on O
clinical, O
radiological, O
and O
electrophysiological O
findings. O
Exclusion O
criteria O
included O
CNS O
leukemic B
infiltration I
at O
diagnosis, O
therapy-related O
peripheral B
neuropathy, I
late-onset O
encephalopathy, B
or O
long-term O
neurocognitive B
defects. I
During O
a O
9-year O
period, O
we O
retrospectively O
collected O
27 O
neurological O
events O
(11%) O
in O
as O
many O
patients, O
from O
253 O
children O
enrolled O
in O
the O
ALL O
front-line O
protocol. O
CNS O
complications O
included O
posterior O
reversible O
leukoencephalopathy B
syndrome O
(n O
= O
10), O
stroke B
(n O
= O
5), O
temporal B
lobe I
epilepsy I
(n O
= O
2), O
high-dose O
methotrexate O
toxicity B
(n O
= O
2), O
syndrome O
of O
inappropriate B
antidiuretic I
hormone I
secretion I
(n O
= O
1), O
and O
other O
unclassified O
events O
(n O
= O
7). O
In O
conclusion, O
CNS O
complications O
are O
frequent O
events O
during O
ALL O
therapy, O
and O
require O
rapid O
detection O
and O
prompt O
treatment O
to O
limit O
permanent O
damage. O

A O
47-year-old O
patient O
suffering O
from O
coronary B
artery I
disease I
was O
admitted O
to O
the O
CCU O
in O
shock B
with O
III. O
AV B
block, I
severe O
hypotension, B
and O
impairment B
of I
ventricular I
function. I
One O
week O
prior O
to O
admission O
a O
therapy O
with O
standard O
doses O
of O
metoprolol O
(100 O
mg O
t.i.d. O
and O
then O
100 O
mg O
b.i.d.) O
had O
been O
initiated. O
Two O
days O
before O
admission O
diltiazem O
(60 O
mg O
b.i.d.) O
was O
prescribed O
in O
addition. O
Analyses O
of O
a O
blood O
sample O
revealed O
unusually O
high O
plasma O
concentrations O
of O
metoprolol O
(greater O
than O
3000 O
ng/ml) O
and O
diltiazem O
(526 O
ng/ml). O
The O
patient O
recovered O
within O
1 O
week O
following O
discontinuation O
of O
antianginal O
therapy. O
Three O
months O
later O
the O
patient O
was O
exposed O
to O
a O
single O
dose O
of O
metoprolol, O
diltiazem, O
propafenone O
(since O
he O
had O
received O
this O
drug O
in O
the O
past), O
and O
sparteine O
(as O
a O
probe O
for O
the O
debrisoquine/sparteine O
type O
polymorphism O
of O
oxidative O
drug O
metabolism). O
It O
was O
found O
that O
he O
was O
a O
poor O
metabolizer O
of O
all O
four O
drugs, O
indicating O
that O
their O
metabolism O
is O
under O
the O
same O
genetic O
control. O
Therefore, O
patients O
belonging O
to O
the O
poor-metabolizer O
phenotype O
of O
sparteine/debrisoquine O
polymorphism O
in O
drug O
metabolism, O
which O
constitutes O
6.4% O
of O
the O
German O
population, O
may O
experience O
adverse B
drug I
reactions I
when O
treated O
with O
standard O
doses O
of O
one O
of O
these O
drugs O
alone. O
Moreover, O
the O
coadministration O
of O
these O
frequently O
used O
drugs O
is O
expected O
to O
be O
especially O
harmful O
in O
this O
subgroup O
of O
patients. O

We O
report O
twin O
neonates O
who O
were O
born O
prematurely O
at O
32 O
weeks O
of O
gestation O
to O
a O
mother O
with O
human B
immunodeficiency I
virus I
infection. I
One O
of O
the O
twins O
developed O
complete O
heart B
block I
and O
dilated B
cardiomyopathy I
related O
to O
lopinavir/ritonavir O
therapy, O
a O
boosted O
protease-inhibitor O
agent, O
while O
the O
other O
twin O
developed O
mild O
bradycardia. B
We O
recommend O
caution O
in O
the O
use O
of O
lopinavir/ritonavir O
in O
the O
immediate O
neonatal O
period. O

Safety O
and O
side-effects O
of O
alprazolam. O
Controlled O
study O
in O
agoraphobia B
with O
panic B
disorder. I

Glyburide-induced O
hepatitis. B

This O
case O
illustrates O
that O
patients O
receiving O
ritodrine O
for O
preterm B
labor I
may O
risk O
interactions O
between O
the O
residual O
betamimetic O
effects O
of O
ritodrine O
and O
the O
effects O
of O
anesthetics O
during O
cesarean O
section. O
Such O
interactions O
may O
result O
in O
serious O
cardiovascular B
complications I
even O
after O
cessation O
of O
an O
infusion O
of O
ritodrine. O
Preoperative O
assessment O
should O
focus O
on O
cardiovascular O
status O
and O
serum O
potassium O
level. O
Delaying O
induction O
of O
anesthesia O
should O
be O
considered O
whenever O
possible. O
Careful O
fluid O
administration O
and O
cautious O
use O
of O
titrated O
doses O
of O
ephedrine O
are O
advised. O
After O
delivery O
of O
the O
infant, O
there O
should O
be O
no O
contraindication O
to O
the O
use O
of O
an O
alpha-adrenergic O
vasopressor O
such O
as O
phenylephrine O
to O
treat O
hypotensive B
patients O
with O
tachycardia. B

Erythema B
multiforme I
and O
hypersensitivity B
myocarditis I
caused O
by O
ampicillin. O

mToR O
inhibitors-induced O
proteinuria: B
mechanisms, O
significance, O
and O
management. O

We O
have O
reported O
a O
case O
of O
acute O
oliguric O
renal B
failure I
with O
hyperkalemia B
in O
a O
patient O
with O
cirrhosis, B
ascites, B
and O
cor B
pulmonale I
after O
indomethacin O
therapy. O
Prompt O
restoration O
of O
renal O
function O
followed O
drug O
withdrawal, O
while O
re-exposure O
to O
a O
single O
dose O
of O
indomethacin O
caused O
recurrence O
of O
acute O
reversible O
oliguria. B
Our O
case O
supports O
the O
hypothesis O
that O
endogenous O
renal O
prostaglandins O
play O
a O
role O
in O
the O
maintenance O
of O
renal O
blood O
flow O
when O
circulating O
plasma O
volume O
is O
diminished. O
Since O
nonsteroidal O
anti-inflammatory O
agents O
interfere O
with O
this O
compensatory O
mechanism O
and O
may O
cause O
acute B
renal I
failure, I
they O
should O
be O
used O
with O
caution O
in O
such O
patients. O

Pentoxifylline O
(Trental) O
does O
not O
inhibit O
dipyridamole-induced O
coronary O
hyperemia: B
implications O
for O
dipyridamole-thallium-201 O
myocardial O
imaging. O

Seizure B
resulting O
from O
a O
venlafaxine O
overdose. B

Neuroactive O
steroids O
demonstrate O
pharmacological O
actions O
that O
have O
relevance O
for O
a O
host O
of O
neurological B
and I
psychiatric B
disorders. I
They O
offer O
protection O
against O
seizures B
in O
a O
range O
of O
models O
and O
seem O
to O
inhibit O
certain O
stages O
of O
drug B
dependence I
in O
preclinical O
assessments. O
The O
present O
study O
was O
designed O
to O
evaluate O
two O
endogenous O
and O
one O
synthetic O
neuroactive O
steroid O
that O
positively O
modulate O
the O
gamma-aminobutyric O
acid O
(GABA(A)) O
receptor O
against O
the O
increase O
in O
sensitivity O
to O
the O
convulsant O
effects O
of O
cocaine O
engendered O
by O
repeated O
cocaine O
administration O
(seizure O
kindling). O
Allopregnanolone O
(3alpha-hydroxy-5alpha-pregnan-20-one), O
pregnanolone O
(3alpha-hydroxy-5beta-pregnan-20-one) O
and O
ganaxolone O
(a O
synthetic O
derivative O
of O
allopregnanolone O
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) O
were O
tested O
for O
their O
ability O
to O
suppress O
the O
expression O
(anticonvulsant O
effect) O
and O
development O
(antiepileptogenic O
effect) O
of O
cocaine-kindled O
seizures O
in O
male, O
Swiss-Webster O
mice. O
Kindled O
seizures O
were O
induced O
by O
daily O
administration O
of O
60 O
mg/kg O
cocaine O
for O
5 O
days. O
All O
of O
these O
positive O
GABA(A) O
modulators O
suppressed O
the O
expression O
of O
kindled O
seizures, O
whereas O
only O
allopregnanolone O
and O
ganaxolone O
inhibited O
the O
development O
of O
kindling. O
Allopregnanolone O
and O
pregnanolone, O
but O
not O
ganaxolone, O
also O
reduced O
cumulative O
lethality O
associated O
with O
kindling. O
These O
findings O
demonstrate O
that O
some O
neuroactive O
steroids O
attenuate O
convulsant O
and O
sensitizing O
properties O
of O
cocaine O
and O
add O
to O
a O
growing O
literature O
on O
their O
potential O
use O
in O
the O
modulation O
of O
effects O
of O
drugs O
of O
abuse. O

A O
case O
of O
metabolic B
acidosis, I
acute B
renal I
failure I
and I
hepatic I
failure I
following O
paracetamol O
ingestion O
is O
presented. O
The O
diagnostic O
difficulty O
at O
presentation O
is O
highlighted. O
Continuous O
arteriovenous O
haemofiltration O
proved O
a O
valuable O
means O
of O
maintaining O
fluid O
and O
electrolyte O
balance. O
The O
patient O
recovered. O

Progressive O
myopathy B
with O
up-regulation O
of O
MHC-I O
associated O
with O
statin O
therapy. O

In O
this O
report O
we O
describe O
the O
case O
of O
a O
37-year-old O
white O
woman O
with O
Ebstein's B
anomaly, I
who O
developed O
a O
rare O
syndrome O
called O
platypnea-orthodeoxia, B
characterized O
by O
massive O
right-to-left O
interatrial O
shunting O
with O
transient O
profound O
hypoxia B
and O
cyanosis. B
This O
shunt O
of O
blood O
via O
a O
patent B
foramen I
ovale I
occurred O
in O
the O
presence O
of O
a O
normal O
pulmonary O
artery O
pressure, O
and O
was O
probably O
precipitated O
by O
a O
propafenone O
overdose. B
This O
drug O
caused O
biventricular B
dysfunction, I
due O
to O
its O
negative O
inotropic O
effect, O
and O
hypotension, B
due O
to O
its O
peripheral O
vasodilatory O
effect. O
These O
effects O
gave O
rise O
to O
an O
increase O
in O
the O
right O
atrial O
pressure O
and O
a O
decrease O
in O
the O
left O
one O
with O
a O
consequent O
stretching O
of O
the O
foramen O
ovale O
and O
the O
creation O
of O
massive O
right-to-left O
shunting. O
In O
our O
case O
this O
interatrial O
shunt O
was O
very O
accurately O
detected O
at O
bubble O
contrast O
echocardiography. O

BACKGROUND: O
An O
association O
has O
been O
found O
between O
transplant B
glomerulopathy I
(TG) O
and B
reduplication O
of O
peritubular O
capillary O
basement O
membranes O
(PTCR). O
Although O
such O
an O
association O
is O
of O
practical O
and O
theoretical O
importance, O
only O
one O
prospective O
study O
has O
tried O
to O
confirm O
it. O
METHODS: O
We O
examined O
278 O
consecutive O
renal O
specimens O
(from O
135 O
transplants O
and O
143 O
native O
kidneys) O
for O
ultrastructural O
evidence O
of O
PTCR. O
In O
addition O
to O
renal O
allografts O
with O
TG, O
we O
also O
examined O
grafts O
with O
acute O
rejection, O
recurrent O
glomerulonephritis, B
chronic B
allograft I
nephropathy I
and O
stable O
grafts O
("protocol O
biopsies"). O
Native O
kidney O
specimens O
included O
a O
wide O
range O
of O
glomerulopathies B
as O
well O
as O
cases O
of O
thrombotic B
microangiopathy, I
malignant B
hypertension, I
acute O
interstitial B
nephritis, I
and O
acute B
tubular I
necrosis. I
RESULTS: O
We O
found O
PTCR O
in O
14 O
of O
15 O
cases O
of O
TG, O
in O
7 O
transplant O
biopsy O
specimens O
without O
TG, O
and O
in O
13 O
of O
143 O
native O
kidney O
biopsy O
specimens. O
These O
13 O
included O
cases O
of O
malignant O
hypertension, O
thrombotic O
microangiopathy, O
lupus B
nephritis, I
Henoch-Schonlein B
nephritis, I
crescentic O
glomerulonephritis, O
and O
cocaine-related O
acute B
renal B
failure. I
Mild O
PTCR O
in O
allografts O
without O
TG O
did O
not O
predict O
renal O
failure O
or O
significant O
proteinuria B
after O
follow-up O
periods O
of O
between O
3 O
months O
and O
1 O
year. O
CONCLUSIONS: O
We O
conclude O
that O
in O
transplants, O
there O
is O
a O
strong O
association O
between O
well-developed O
PTCR O
and O
TG, O
while O
the O
significance O
of O
mild O
PTCR O
and O
its O
predictive O
value O
in O
the O
absence O
of O
TG O
is O
unclear. O
PTCR O
also O
occurs O
in O
certain O
native O
kidney B
diseases, I
though O
the O
association O
is O
not O
as O
strong O
as O
that O
for O
TG. O
We O
suggest O
that O
repeated O
endothelial B
injury, I
including O
immunologic B
injury, I
may O
be O
the O
cause O
of O
this O
lesion O
both O
in O
allografts O
and O
native O
kidneys. O

Combined O
effects O
of O
prolonged O
prostaglandin O
E1-induced O
hypotension B
and O
haemodilution B
on O
human O
hepatic O
function. O

To O
develop O
a O
novel O
and O
effective O
drug O
that O
could O
enhance O
cognitive O
function O
and O
neuroprotection, O
we O
newly O
synthesized O
maltolyl O
p-coumarate O
by O
the O
esterification O
of O
maltol O
and O
p-coumaric O
acid. O
In O
the O
present O
study, O
we O
investigated O
whether O
maltolyl O
p-coumarate O
could O
improve O
cognitive B
decline I
in O
scopolamine-injected O
rats O
and O
in O
amyloid O
beta O
peptide(1-42)-infused O
rats. O
Maltolyl O
p-coumarate O
was O
found O
to O
attenuate O
cognitive B
deficits I
in O
both O
rat O
models O
using O
passive O
avoidance O
test O
and O
to O
reduce O
apoptotic O
cell O
death O
observed O
in O
the O
hippocampus O
of O
the O
amyloid O
beta O
peptide(1-42)-infused O
rats. O
We O
also O
examined O
the O
neuroprotective O
effects O
of O
maltolyl O
p-coumarate O
in O
vitro O
using O
SH-SY5Y O
cells. O
Cells O
were O
pretreated O
with O
maltolyl O
p-coumarate, O
before O
exposed O
to O
amyloid O
beta O
peptide(1-42), O
glutamate O
or O
H2O2. O
We O
found O
that O
maltolyl O
p-coumarate O
significantly O
decreased O
apoptotic O
cell O
death O
and O
reduced O
reactive O
oxygen O
species, O
cytochrome O
c O
release, O
and O
caspase O
3 O
activation. O
Taking O
these O
in O
vitro O
and O
in O
vivo O
results O
together, O
our O
study O
suggests O
that O
maltolyl O
p-coumarate O
is O
a O
potentially O
effective O
candidate O
against O
Alzheimer's B
disease I
that O
is O
characterized O
by O
wide O
spread O
neuronal B
death I
and O
progressive O
decline B
of I
cognitive I
function. I

Cerebral B
haemorrhage I
induced O
by O
warfarin O
- O
the O
influence O
of O
drug-drug O
interactions. O

Ticlopidine-induced O
aplastic B
anemia: I
report O
of O
three O
Chinese O
patients O
and O
review O
of O
the O
literature. O

Anencephaly B
has O
been O
suggested O
to O
develop O
from O
exencephaly; B
however, O
there O
is O
little O
direct O
experimental O
evidence O
to O
support O
this, O
and O
the O
mechanism O
of O
transformation O
remains O
unclear. O
We O
examined O
this O
theory O
using O
the O
exo O
utero O
development O
system O
that O
allows O
direct O
and O
sequential O
observations O
of O
mid- O
to O
late-gestation O
mouse O
embryos. O
We O
observed O
the O
exencephaly O
induced O
by O
5-azacytidine O
at O
embryonic O
day O
13.5 O
(E13.5), O
let O
the O
embryos O
develop O
exo O
utero O
until O
E18.5, O
and O
re-observed O
the O
same O
embryos O
at O
E18.5. O
We O
confirmed O
several O
cases O
of O
transformation O
from O
exencephaly O
to O
anencephaly. B
However, O
in O
many O
cases, O
the O
exencephalic B
brain O
tissue O
was O
preserved O
with O
more O
or O
less O
reduction O
during O
this O
period. O
To O
analyze O
the O
transformation O
patterns, O
we O
classified O
the O
exencephaly O
by O
size O
and O
shape O
of O
the O
exencephalic O
tissue O
into O
several O
types O
at O
E13.5 O
and O
E18.5. O
It O
was O
found O
that O
the O
transformation O
of O
exencephalic O
tissue O
was O
not O
simply O
size-dependent, O
and O
all O
cases O
of O
anencephaly O
at O
E18.5 O
resulted O
from O
embryos O
with O
a O
large O
amount O
of O
exencephalic O
tissue O
at O
E13.5. O
Microscopic O
observation O
showed O
the O
configuration O
of O
exencephaly O
at O
E13.5, O
frequent O
hemorrhaging B
and O
detachment O
of O
the O
neural O
plate O
from O
surface O
ectoderm O
in O
the O
exencephalic O
head O
at O
E15.5, O
and O
multiple O
modes O
of O
reduction O
in O
the O
exencephalic O
tissue O
at O
E18.5. O
From O
observations O
of O
the O
vasculature, O
altered O
distribution O
patterns O
of O
vessels O
were O
identified O
in O
the O
exencephalic O
head. O
These O
findings O
suggest O
that O
overgrowth O
of O
the O
exencephalic O
neural O
tissue O
causes O
the O
altered O
distribution O
patterns O
of O
vessels, O
subsequent O
peripheral O
circulatory B
failure I
and/or O
hemorrhaging O
in O
various O
parts O
of O
the O
exencephalic O
head, O
leading O
to O
the O
multiple O
modes O
of O
tissue O
reduction O
during O
transformation O
from O
exencephaly O
to O
anencephaly. O

BACKGROUND: O
To O
determine O
the O
onset O
and O
extent O
of O
combined O
androgen O
blockade O
(CAB)-induced O
anemia B
in O
prostate B
cancer I
patients O
without O
bone O
involvement. O
PATIENTS O
AND O
METHODS: O
Forty-two O
patients O
with O
biopsy-proven O
prostatic B
adenocarcinoma I
[26 O
with O
stage O
C O
(T3N0M0) O
and O
16 O
with O
stage O
D1 O
(T3N1M0)] O
were O
included O
in O
this O
study. O
All O
patients O
received O
CAB O
[leuprolide O
acetate O
(LHRH-A) O
3.75 O
mg, O
intramuscularly, O
every O
28 O
days O
plus O
250 O
mg O
flutamide, O
tid, O
per O
Os] O
and O
were O
evaluated O
for O
anemia O
by O
physical O
examination O
and O
laboratory O
tests O
at O
baseline O
and O
4 O
subsequent O
intervals O
(1, O
2, O
3 O
and O
6 O
months O
post-CAB). O
Hb, O
PSA O
and O
Testosterone O
measurements O
were O
recorded. O
Patients O
with O
stage O
D2-3 O
disease, O
abnormal O
hemoglobin O
level O
or O
renal O
and O
liver O
function O
tests O
that O
were O
higher O
than O
the O
upper O
limits O
were O
excluded O
from O
the O
study. O
The O
duration O
of O
the O
study O
was O
six O
months. O
RESULTS: O
The O
mean O
hemoglobin O
(Hb) O
levels O
were O
significantly O
declined O
in O
all O
patients O
from O
baseline O
of O
14.2 O
g/dl O
to O
14.0 O
g/dl, O
13.5 O
g/dl, O
13.2 O
g/dl O
and O
12.7 O
g/dl O
at O
1, O
2, O
3 O
and O
6 O
months O
post-CAB, O
respectively. O
Severe O
and O
clinically O
evident O
anemia O
of O
Hb O
< O
11 O
g/dl O
with O
clinical O
symptoms O
was O
detected O
in O
6 O
patients O
(14.3%). O
This O
CAB-induced O
anemia O
was O
normochromic O
and O
normocytic. O
At O
six O
months O
post-CAB, O
patients O
with O
severe O
anemia O
had O
a O
Hb O
mean O
value O
of O
10.2 O
+/- O
0.1 O
g/dl O
(X O
+/- O
SE), O
whereas O
the O
other O
patients O
had O
mild O
anemia O
with O
Hb O
mean O
value O
of O
13.2 O
+/- O
0.17 O
(X O
+/- O
SE). O
The O
development O
of O
severe O
anemia O
at O
6 O
months O
post-CAB O
was O
predictable O
by O
the O
reduction O
of O
Hb O
baseline O
value O
of O
more O
than O
2.5 O
g/dl O
after O
3 O
months O
of O
CAB O
(p O
= O
0.01). O
The O
development O
of O
severe O
CAB-induced O
anemia O
in O
prostate O
cancer O
patients O
did O
not O
correlate O
with O
T O
baseline O
values O
(T O
< O
3 O
ng/ml O
versus O
T O
> O
or O
= O
3 O
ng/ml), O
with O
age O
(< O
76 O
yrs O
versus O
> O
or O
= O
76 O
yrs), O
and O
clinical O
stage O
(stage O
C O
versus O
stage O
D1). O
Severe O
and O
clinically O
evident O
anemia O
was O
easily O
corrected O
by O
subcutaneous O
injections O
(3 O
times/week O
for O
1 O
month) O
of O
recombinant O
erythropoietin O
(rHuEPO-beta). O
CONCLUSION: O
Our O
data O
suggest O
that O
rHuEPO-beta O
correctable O
CAB-induced O
anemia O
occurs O
in O
14.3% O
of O
prostate O
cancer O
patients O
after O
6 O
months O
of O
therapy. O

A O
case O
of O
veno-occlusive B
disease I
of I
the I
liver I
with O
fatal O
outcome O
after O
dacarbazine O
(DTIC) O
therapy O
for O
melanoma B
is O
reported. O
There O
was O
a O
fulminant O
clinical O
course O
from O
start O
of O
symptoms O
until O
death. B
At O
autopsy O
the O
liver O
was O
enlarged O
and O
firm O
with O
signs O
of O
venous B
congestion. I
Small- O
and O
medium-sized O
hepatic O
veins O
were O
blocked O
by O
thrombosis. B
Eosinophilic O
infiltrations O
were O
found O
around O
the O
vessels. O
Published O
cases O
from O
the O
literature O
are O
reviewed O
and O
pertinent O
features O
discussed. O

Eighty-nine O
new O
referral O
hypertensive B
out-patients O
and O
46 O
new O
referral O
non-hypertensive O
chronically O
physically O
ill O
out-patients O
completed O
a O
mood O
rating O
scale O
at O
regular O
intervals O
for O
one O
year. O
The O
results O
showed O
a O
high O
prevalence O
of O
depression B
in O
both O
groups O
of O
patients, O
with O
no O
preponderance O
in O
the O
hypertensive O
group. O
Hypertensive B
patients O
with O
psychiatric B
histories O
had O
a O
higher O
prevalence O
of O
depression O
than O
the O
comparison O
patients. O
This O
was O
accounted O
for O
by O
a O
significant O
number O
of O
depressions B
occurring O
in O
methyl O
dopa O
treated O
patients O
with O
psychiatric O
histories. O

Simvastatin-induced O
bilateral O
leg O
compartment B
syndrome I
and O
myonecrosis B
associated O
with O
hypothyroidism. B

Levodopa O
is O
the O
most O
effective O
drug O
for O
the O
treatment O
of O
Parkinson's B
disease. I
However, O
the O
long-term O
use O
of O
this O
dopamine O
precursor O
is O
complicated O
by O
highly O
disabling O
fluctuations O
and O
dyskinesias. B
Although O
preclinical O
and O
clinical O
findings O
suggest O
pulsatile O
stimulation O
of O
striatal O
postsynaptic O
receptors O
as O
a O
key O
mechanism O
underlying O
levodopa-induced O
dyskinesias, O
their O
pathogenesis O
is O
still O
unclear. O
In O
recent O
years, O
evidence O
from O
animal O
models O
of O
Parkinson's O
disease O
has O
provided O
important O
information O
to O
understand O
the O
effect O
of O
specific O
receptor O
and O
post-receptor O
molecular O
mechanisms O
underlying O
the O
development O
of O
dyskinetic B
movements. I
Recent O
preclinical O
and O
clinical O
data O
from O
promising O
lines O
of O
research O
focus O
on O
the O
differential O
role O
of O
presynaptic O
versus O
postsynaptic O
mechanisms, O
dopamine O
receptor O
subtypes, O
ionotropic O
and O
metabotropic O
glutamate O
receptors, O
and O
non-dopaminergic O
neurotransmitter O
systems O
in O
the O
pathophysiology O
of O
levodopa-induced O
dyskinesias. O

Pethidine-associated O
seizure B
in O
a O
healthy O
adolescent O
receiving O
pethidine O
for O
postoperative B
pain I
control. O

A O
Phase O
II O
trial O
of O
cisplatin O
plus O
WR-2721 O
(amifostine) O
for O
metastatic O
breast B
carcinoma: I
an O
Eastern O
Cooperative O
Oncology O
Group O
Study O
(E8188). O

BACKGROUND: O
Papaverine O
hydrochloride O
is O
a O
direct-acting O
vasodilator O
used O
to O
manage O
vasospasm B
during O
various O
neurosurgical O
operations. O
Transient O
cranial B
nerve I
dysfunction I
has O
been O
described O
in O
a O
few O
cases O
with O
topical O
papaverine. O
This O
study O
supports O
previous O
reports O
and O
provides O
neurophysiological O
evidence O
of O
an O
adverse O
effect O
on O
the O
auditory O
nerve. O
METHODS: O
We O
conducted O
a O
retrospective O
review O
of O
70 O
consecutive O
microvascular O
decompression O
operations O
and O
studied O
those O
patients O
who O
received O
topical O
papaverine O
for O
vasospasm. O
Topical O
papaverine O
was O
used O
as O
a O
direct O
therapeutic O
action O
to O
manage O
vasospasm O
in O
a O
total O
of O
11 O
patients. O
The O
timing O
of O
papaverine O
application O
and O
ongoing O
operative O
events O
was O
reviewed O
relative O
to O
changes O
in O
neurophysiological O
recordings. O
Brainstem O
auditory O
evoked O
potentials O
(BAEPs) O
were O
routinely O
used O
to O
monitor O
cochlear O
nerve O
function O
during O
these O
operations. O
FINDINGS: O
A O
temporal O
relationship O
was O
found O
between O
topical O
papaverine O
and O
BAEP O
changes O
leading O
to O
complete O
waveform O
loss. O
The O
average O
temporal O
delay O
between O
papaverine O
and O
the O
onset O
of O
an O
adverse O
BAEP O
change O
was O
5 O
min. O
In O
10 O
of O
11 O
patients, O
BAEP O
waves O
II/III-V O
completely O
disappeared O
within O
2 O
to O
25 O
min O
after O
papaverine. O
Eight O
of O
these O
10 O
patients O
had O
complete O
loss O
of O
BAEP O
waveforms O
within O
10 O
min. O
One O
patient O
showed O
no O
recovery O
of O
later O
waves O
and O
a O
delayed O
profound O
sensorineural B
hearing I
loss. I
The O
average O
recovery O
time O
of O
BAEP O
waveforms O
to O
pre-papaverine O
baseline O
values O
was O
39 O
min. O
CONCLUSIONS: O
Topical O
papaverine O
for O
the O
treatment O
of O
vasospasm O
was O
associated O
with O
the O
onset O
of O
a O
transient O
disturbance O
in O
neurophysiological O
function O
of O
the O
ascending O
auditory O
brainstem O
pathway. O
The O
complete O
disappearance O
of O
BAEP O
waveforms O
with O
a O
consistent O
temporal O
delay O
suggests O
a O
possible O
adverse B
effect I
on I
the I
proximal I
eighth I
nerve. I
Recommendations O
to O
avoid O
potential O
cranial B
nerve I
deficits I
from O
papaverine O
are O
provided. O

We O
report O
a O
case O
of O
variant O
ventricular B
tachycardia I
induced O
by O
desipramine O
toxicity. B
Unusual O
features O
of O
the O
arrhythmia B
are O
repetitive O
group O
beating, O
progressive O
shortening O
of O
the O
R-R O
interval, O
progressive O
widening O
of O
the O
QRS O
complex O
with O
eventual O
failure O
of O
intraventricular O
conduction, O
and O
changes O
in O
direction O
of O
the O
QRS O
axis. O
Recognition O
of O
variant O
ventricular O
tachycardia O
is O
important O
because O
therapy O
differs O
from O
that O
of O
classic O
ventricular O
tachycardia. O

Effect O
of O
L-alpha-glyceryl-phosphorylcholine O
on O
amnesia B
caused O
by O
scopolamine. O

Bladder O
retention B
of I
urine I
as O
a O
result O
of O
continuous O
intravenous O
infusion O
of O
fentanyl: O
2 O
case O
reports. O

Procainamide-induced O
polymorphous O
ventricular B
tachycardia. I

Morphological O
features O
of O
encephalopathy B
after O
chronic O
administration O
of O
the O
antiepileptic O
drug O
valproate O
to O
rats. O
A O
transmission O
electron O
microscopic O
study O
of O
capillaries O
in O
the O
cerebellar O
cortex. O

Lidocaine-induced O
cardiac B
asystole. I

The O
antinociceptive O
effect O
of O
3 O
alpha-tropyl O
2-(p-bromophenyl)propionate O
[(+/-)-PG-9] O
(10-40 O
mg O
kg-1 O
s.c.; O
30-60 O
mg O
kg-1 O
p.o.; O
10-30 O
mg O
kg-1 O
i.v.; O
10-30 O
micrograms/mouse O
i.c.v.) O
was O
examined O
in O
mice, O
rats O
and O
guinea O
pigs O
by O
use O
of O
the O
hot-plate, O
abdominal-constriction, O
tail-flick O
and O
paw-pressure O
tests. O
(+/-)-PG-9 O
antinociception O
peaked O
15 O
min O
after O
injection O
and O
then O
slowly O
diminished. O
The O
antinociception O
produced O
by O
(+/-)-PG-9 O
was O
prevented O
by O
the O
unselective O
muscarinic O
antagonist O
atropine, O
the O
M1-selective O
antagonists O
pirenzepine O
and O
dicyclomine O
and O
the O
acetylcholine O
depletor O
hemicholinium-3, O
but O
not O
by O
the O
opioid O
antagonist O
naloxone, O
the O
gamma-aminobutyric O
acidB O
antagonist O
3-aminopropyl-diethoxy-methyl-phosphinic O
acid, O
the O
H3 O
agonist O
R-(alpha)-methylhistamine, O
the O
D2 O
antagonist O
quinpirole, O
the O
5-hydroxytryptamine4 O
antagonist O
2-methoxy-4-amino-5-chlorobenzoic O
acid O
2-(diethylamino)ethyl O
ester O
hydrochloride, O
the O
5-hydroxytryptamin1A O
antagonist O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine O
hydrobromide O
and O
the O
polyamines O
depletor O
reserpine. O
Based O
on O
these O
data, O
it O
can O
be O
postulated O
that O
(+/-)-PG-9 O
exerted O
an O
antinociceptive O
effect O
mediated O
by O
a O
central O
potentiation O
of O
cholinergic O
transmission. O
(+/-)-PG-9 O
(10-40 O
mg O
kg-1 O
i.p.) O
was O
able O
to O
prevent O
amnesia B
induced O
by O
scopolamine O
(1 O
mg O
kg-1 O
i.p.) O
and O
dicyclomine O
(2 O
mg O
kg-1 O
i.p.) O
in O
the O
mouse O
passive-avoidance O
test. O
Affinity O
profiles O
of O
(+/-)-PG-9 O
for O
muscarinic O
receptor O
subtypes, O
determined O
by O
functional O
studies O
(rabbit O
vas O
deferens O
for O
M1, O
guinea O
pig O
atrium O
for O
M2, O
guinea O
pig O
ileum O
for O
M3 O
and O
immature O
guinea O
pig O
uterus O
for O
putative O
M4), O
have O
shown O
an O
M4/M1 O
selectivity O
ratio O
of O
10.2 O
that O
might O
be O
responsible O
for O
the O
antinociception O
and O
the O
anti-amnesic O
effect B
induced O
by O
(+/-)-PG-9 O
through O
an O
increase O
in O
acetylcholine O
extracellular O
levels. O
In O
the O
antinociceptive O
and O
antiamnesic O
dose O
range, O
(+/-)-PG-9 O
did O
not O
impair O
mouse O
performance O
evaluated O
by O
the O
rota-rod O
test O
and O
Animex O
apparatus. O

Intracranial B
aneurysms I
and O
cocaine B
abuse: I
analysis O
of O
prognostic O
indicators. O

The O
present O
study O
was O
undertaken O
to O
examine O
the O
role O
of O
sleep B
disturbance, I
induced O
by O
clomipramine O
administration, O
on O
the O
secretory O
rate O
of O
prolactin O
(PRL) O
in O
addition O
to O
the O
direct O
drug O
effect. O
Two O
groups O
of O
supine O
subjects O
were O
studied O
under O
placebo-controlled O
conditions, O
one O
during O
the O
night, O
when O
sleeping O
(n O
= O
7) O
and O
the O
other O
at O
daytime, O
when O
awake O
(n O
= O
6). O
Each O
subject O
received O
a O
single O
50 O
mg O
dose O
of O
clomipramine O
given O
orally O
2 O
hours O
before O
blood O
collection. O
Plasma O
PRL O
concentrations O
were O
analysed O
at O
10 O
min O
intervals O
and O
underlying O
secretory O
rates O
calculated O
by O
a O
deconvolution O
procedure. O
For O
both O
experiments O
the O
drug O
intake O
led O
to O
significant O
increases O
in O
PRL O
secretion, O
acting O
preferentially O
on O
tonic O
secretion O
as O
pulse O
amplitude O
and O
frequency O
did O
not O
differ O
significantly O
from O
corresponding O
control O
values. O
During O
the O
night O
clomipramine O
ingestion O
altered O
the O
complete O
sleep O
architecture O
in O
that O
it O
suppressed O
REM O
sleep O
and O
the O
sleep O
cycles O
and O
induced O
increased O
wakefulness. O
As O
the O
relative O
increase O
in O
PRL O
secretion O
expressed O
as O
a O
percentage O
of O
the O
mean O
did O
not O
significantly O
differ O
between O
the O
night O
and O
day O
time O
studies O
(46 O
+/- O
19% O
vs O
34 O
+/- O
10%), O
it O
can O
be O
concluded O
that O
the O
observed O
sleep O
disturbance O
did O
not O
interfere O
with O
the O
drug O
action O
per O
se. O
The O
presence O
of O
REM O
sleep O
was O
shown O
not O
to O
be O
a O
determining O
factor O
either O
for O
secretory O
pulse O
amplitude O
and O
frequency, O
as, O
for O
both, O
mean O
nocturnal O
values O
were O
similar O
with O
and O
without O
prior O
clomipramine O
ingestion. O

Busulfan-induced O
hemorrhagic B
cystitis. B

Sexual B
dysfunction I
among O
patients O
with O
arthritis. B

Protection O
against O
amphetamine-induced O
neurotoxicity B
toward O
striatal O
dopamine O
neurons O
in O
rodents O
by O
LY274614, O
an O
excitatory O
amino O
acid O
antagonist. O

Effect O
of O
converting O
enzyme O
inhibition O
on O
the O
course O
of O
adriamycin-induced O
nephropathy. B

Current O
estimates O
suggest O
that O
between O
0.4% O
and O
8.3% O
of O
children O
and O
adolescents O
are O
affected O
by O
major B
depression. I
We O
report O
a O
favorable O
response O
to O
treatment O
with O
citalopram O
by O
a O
15-year-old O
boy O
with O
major O
depression O
who O
exhibited O
palpebral B
twitching I
during O
his O
first O
2 O
weeks O
of O
treatment. O
This O
may O
have O
been O
a O
side O
effect O
of O
citalopram O
as O
it O
remitted O
with O
redistribution O
of O
doses. O

Methylphenidate O
is O
structurally O
and O
functionally O
similar O
to O
amphetamine. O
Cerebral B
vasculitis B
associated O
with O
amphetamine B
abuse I
is O
well O
documented, O
and O
in O
rare O
cases O
ischaemic B
stroke I
has O
been O
reported O
after O
methylphenidate O
intake O
in O
children. O
We O
report O
the O
case O
of O
a O
63-year-old O
female O
who O
was O
treated O
with O
methylphenidate O
due O
to O
hyperactivity B
and O
suffered O
from O
multiple O
ischaemic B
strokes. I
We O
consider O
drug-induced O
cerebral B
vasculitis I
as O
the O
most O
likely O
cause O
of O
recurrent O
ischaemic O
strokes O
in O
the O
absence O
of O
any O
pathological O
findings O
during O
the O
diagnostic O
work-up. O
We O
conclude O
that O
methylphenidate O
mediated O
vasculitis O
should O
be O
considered O
in O
patients O
with O
neurological O
symptoms O
and O
a O
history O
of O
methylphenidate O
therapy. O
This O
potential O
side-effect, O
though O
very O
rare, O
represents O
one O
more O
reason O
to O
be O
very O
restrictive O
in O
the O
use O
of O
methylphenidate. O

The O
effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol-induced O
myocardial B
infarction I
were O
studied O
in O
female O
albino O
rats O
of O
20,40,60 O
and O
80 O
weeks O
of O
age. O
The O
rats O
were O
trained O
to O
swim O
for O
a O
specific O
duration O
and O
for O
a O
particular O
period. O
The O
occurrence O
of O
infarcts B
were O
confirmed O
by O
histological O
methods. O
Elevations O
in O
the O
serum O
GOT O
and O
GPT O
were O
maximum O
in O
the O
sedentary-isoproterenols O
and O
minimum O
in O
the O
exercise-controls. O
These O
changes O
in O
the O
serum O
transaminases O
were O
associated O
with O
corresponding O
depletions O
in O
the O
cardiac O
GOT O
and O
GPT. O
However, O
age O
was O
seen O
to O
interfere O
with O
the O
responses O
exhibited O
by O
the O
young O
and O
old O
rats. O
Studies O
dealing O
with O
myocardial O
infarction O
are O
more O
informative O
when O
dealt O
with O
age. O

Through O
30 O
years O
of O
widespread O
use, O
acetaminophen O
has O
been O
shown O
to O
be O
a O
remarkably O
safe O
medication O
in O
therapeutic O
dosages. O
The O
potential O
for O
acetaminophen O
to O
produce O
cardiovascular B
toxicities I
is O
very O
low. O
However, O
acetaminophen O
has O
been O
demonstrated O
to O
produce O
symptoms O
of O
anaphylaxis, B
including O
hypotension, B
in O
sensitive O
individuals. O
This O
article O
describes O
two O
critically B
ill I
patients O
in O
whom O
transient O
episodes O
of O
hypotension O
reproducibly O
developed O
after O
administration O
of O
acetaminophen. O
Other O
symptoms O
of O
allergic B
reactions I
were O
not O
clinically O
detectable. O
The O
hypotensive B
episodes O
were O
severe O
enough O
to O
require O
vasopressor O
administration. O
The O
reports O
illustrate O
the O
need O
for O
clinicians O
to O
consider O
acetaminophen O
in O
patients O
with O
hypotension O
of O
unknown O
origin. O

Cause O
of O
death B
among O
patients O
with O
Parkinson's B
disease: I
a O
rare O
mortality O
due O
to O
cerebral B
haemorrhage. I

The O
authors O
present O
three O
patients O
with O
de O
novo O
absence B
epilepsy B
after O
administration O
of O
carbamazepine O
and O
vigabatrin. O
Despite O
the O
underlying O
diseases, O
the O
prognosis O
for O
drug-induced O
de O
novo O
absence B
seizure B
is O
good O
because O
it O
subsides O
rapidly O
after O
discontinuing O
the O
use O
of O
the O
offending O
drugs. O
The O
gamma-aminobutyric O
acid-transmitted O
thalamocortical O
circuitry O
accounts O
for O
a O
major O
part O
of O
the O
underlying O
neurophysiology O
of O
the O
absence O
epilepsy. O
Because O
drug-induced O
de O
novo O
absence O
seizure O
is O
rare, O
pro-absence O
drugs O
can O
only O
be O
considered O
a O
promoting O
factor. O
The O
underlying O
epileptogenecity O
of O
the O
patients O
or O
the O
synergistic O
effects O
of O
the O
accompanying O
drugs O
is O
required O
to O
trigger O
the O
de O
novo O
absence O
seizure. O
The O
possibility O
of O
drug-induced O
aggravation O
should O
be O
considered O
whenever O
an O
unexpected O
increase O
in O
seizure O
frequency O
and/or O
new O
seizure O
types O
appear O
following O
a O
change O
in O
drug O
treatment. O
By O
understanding O
the O
underlying O
mechanism O
of O
absence O
epilepsy, O
we O
can O
avoid O
the O
inappropriate O
use O
of O
anticonvulsants O
in O
children O
with O
epilepsy O
and O
prevent O
drug-induced O
absence B
seizures. I

Nitroprusside-induced O
hypotension B
evokes O
ACTH O
secretion O
which O
is O
primarily O
mediated O
by O
enhanced O
secretion O
of O
immunoreactive O
corticotropin-releasing O
factor O
(irCRF) O
into O
the O
hypophysial-portal O
circulation. O
Portal O
plasma O
concentrations O
of O
neither O
arginine O
vasopressin O
nor O
oxytocin O
are O
significantly O
altered O
in O
this O
paradigm. O
Application O
of O
a O
delayed O
feedback O
signal, O
in O
the O
form O
of O
a O
2-h O
systemic O
corticosterone O
infusion O
in O
urethane-anesthetized O
rats O
with O
pharmacological O
blockade O
of O
glucocorticoid O
synthesis, O
is O
without O
effect O
on O
the O
resting O
secretion O
of O
arginine O
vasopressin O
and O
oxytocin O
at O
any O
corticosterone O
feedback O
dose O
tested. O
Resting O
irCRF O
levels O
are O
suppressed O
only O
at O
the O
highest O
corticosterone O
infusion O
rate, O
which O
resulted O
in O
systemic O
corticosterone O
levels O
of O
40 O
micrograms/dl. O
Suppression O
of O
irCRF O
secretion O
in O
response O
to O
nitroprusside-induced O
hypotension O
is O
observed O
and O
occurs O
at O
a O
plasma O
corticosterone O
level O
between O
8-12 O
micrograms/dl. O
These O
studies O
provide O
further O
evidence O
for O
a O
strong O
central O
component O
of O
the O
delayed O
feedback O
process O
which O
is O
mediated O
by O
modulation O
of O
irCRF O
release. O

LY274614, O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr O
oisoquinoline-3- O
carboxylic O
acid, O
has O
been O
described O
as O
a O
potent O
antagonist O
of O
the O
N-methyl-D-aspartate O
(NMDA) O
subtype O
of O
glutamate O
receptor. O
Here O
its O
ability O
to O
antagonize O
the O
prolonged O
depletion O
of O
dopamine O
in O
the O
striatum O
by O
amphetamine O
in O
iprindole-treated O
rats O
is O
reported. O
A O
single O
18.4 O
mg/kg O
(i.p.) O
dose O
of O
(+/-)-amphetamine O
hemisulfate, O
given O
to O
rats O
pretreated O
with O
iprindole, O
resulted O
in O
persistent O
depletion O
of O
dopamine O
in O
the O
striatum O
1 O
week O
later. O
This O
prolonged O
depletion O
of O
dopamine O
in O
the O
striatum O
was O
antagonized O
by O
dizocilpine O
(MK-801, O
a O
non-competitive O
antagonist O
of O
NMDA O
receptors) O
or O
by O
LY274614 O
(a O
competitive O
antagonist O
of O
NMDA O
receptors). O
The O
protective O
effect O
of O
LY274614 O
was O
dose-dependent, O
being O
maximum O
at O
10-40 O
mgkg O
(i.p.). O
A O
10 O
mg/kg O
dose O
of O
LY274614 O
was O
effective O
in O
antagonizing O
the O
depletion O
of O
dopamine O
in O
the O
striatum, O
when O
given O
as O
long O
as O
8 O
hr O
prior O
to O
amphetamine O
but O
not O
when O
given O
24 O
hr O
prior O
to O
amphetamine. O
Depletion O
of O
dopamine O
in O
the O
striatum O
was O
also O
antagonized O
when O
LY274614 O
was O
given O
after O
the O
injection O
of O
amphetamine; O
LY274614 O
protected O
when O
given O
up O
to O
4 O
hr O
after O
but O
not O
when O
given O
8 O
or O
24 O
hr O
after O
amphetamine. O
The O
prolonged O
depletion O
of O
dopamine O
in O
the O
striatum O
in O
mice, O
given O
multiple O
injections O
of O
methamphetamine, O
was O
also O
antagonized O
dose-dependently O
and O
completely O
by O
LY274614. O
The O
data O
strengthen O
the O
evidence O
that O
the O
neurotoxic B
effect O
of O
amphetamine O
and O
related O
compounds O
toward O
nigrostriatal O
dopamine O
neurons O
involves O
NMDA O
receptors O
and O
that O
LY274614 O
is O
an O
NMDA O
receptor O
antagonist O
with O
long-lasting O
in O
vivo O
effects O
in O
rats. O

A O
case O
of O
recurarization O
in O
the O
recovery O
room O
is O
reported. O
Accumulation O
of O
atracurium O
in O
the O
intravenous O
line O
led O
to O
recurarization O
after O
flushing O
the O
line O
in O
the O
recovery O
room. O
A O
respiratory B
arrest I
with O
severe O
desaturation B
and O
bradycardia B
occurred. O
Circumstances O
leading O
to O
this O
event O
and O
the O
mechanisms O
enabling O
a O
neuromuscular B
blockade I
to O
occur, O
following O
the O
administration O
of O
a O
small O
dose O
of O
relaxant, O
are O
discussed. O

Sulpiride O
is O
a O
selective O
D2-receptor O
antagonist O
with O
antipsychotic O
and O
antidepressant O
properties. O
Although O
initially O
thought O
to O
be O
free O
of O
extrapyramidal O
side O
effects, O
sulpiride-induced O
tardive B
dyskinesia I
and O
parkinsonism B
have O
been O
reported O
occasionally. O
We O
studied O
a O
37-year-old O
man O
who O
developed O
persistent O
segmental O
dystonia B
within O
2 O
months O
after O
starting O
sulpiride O
therapy. O
We O
could O
not O
find O
any O
previous O
reports O
of O
sulpiride-induced O
tardive B
dystonia. I

Development O
of O
ocular B
myasthenia I
during O
pegylated O
interferon O
and O
ribavirin O
treatment O
for O
chronic B
hepatitis I
C. I

A O
case O
of O
massive O
rhabdomyolysis B
following O
molindone O
administration. O

Improvement O
of O
levodopa-induced O
dyskinesia B
by O
propranolol O
in O
Parkinson's B
disease. I

Organophosphate-induced O
convulsions B
and O
prevention O
of O
neuropathological B
damages. I

Cocaine-induced O
myocardial B
infarction: I
clinical O
observations O
and O
pathogenetic O
considerations. O

Bupropion O
(Zyban) O
toxicity. B

Visual B
hallucinations I
associated O
with O
zonisamide. O

Magnetic O
resonance O
volumetry O
of O
the O
cerebellum O
in O
epileptic B
patients O
after O
phenytoin O
overdosages. B

Microangiopathic B
hemolytic I
anemia I
complicating O
FK506 O
(tacrolimus) O
therapy. O

BACKGROUND: O
Sirolimus O
is O
the O
latest O
immunosuppressive O
agent O
used O
to O
prevent O
rejection, O
and O
may O
have O
less O
nephrotoxicity B
than O
calcineurin O
inhibitor O
(CNI)-based O
regimens. O
To O
date O
there O
has O
been O
little O
documentation O
of O
clinically O
significant O
proteinuria B
linked O
with O
the O
use O
of O
sirolimus. O
We O
have O
encountered O
several O
patients O
who O
developed O
substantial O
proteinuria O
associated O
with O
sirolimus O
use. O
In O
each O
patient, O
the O
close O
temporal O
association O
between O
the O
commencement O
of O
sirolimus O
therapy O
and O
proteinuria O
implicated O
sirolimus O
as O
the O
most O
likely O
etiology O
of O
the O
proteinuria. O
METHODS: O
We O
analyzed O
the O
clinical O
and O
laboratory O
information O
available O
for O
all O
119 O
patients O
transplanted O
at O
the O
Washington O
Hospital O
Center O
between O
1999-2003 O
for O
whom O
sirolimus O
was O
a O
component O
of O
their O
immunosuppressant O
regimen. O
In O
these O
patients, O
the O
magnitude O
of O
proteinuria O
was O
assessed O
on O
morning O
urine O
samples O
by O
turbidometric O
measurement O
or O
random O
urine O
protein:creatinine O
ratios, O
an O
estimate O
of O
grams O
of O
proteinuria/day. O
Laboratory O
results O
were O
compared O
between O
prior, O
during O
and O
following O
sirolimus O
use. O
RESULTS: O
Twenty-eight O
patients O
(24%) O
developed O
increased O
proteinuria O
from O
baseline O
during O
their O
post-transplantation O
course. O
In O
21 O
patients O
an O
alternative O
cause O
of O
proteinuria O
was O
either O
obvious O
or O
insufficient O
data O
was O
available O
to O
be O
conclusive. O
In O
7 O
of O
the O
28 O
patients O
there O
was O
a O
striking O
temporal O
association O
between O
the O
initiation O
of O
sirolimus O
and O
the O
development O
of O
nephrotic-range B
proteinuria. O
Proteinuria B
correlated O
most O
strongly O
with O
sirolimus O
therapy O
when O
compared O
to O
other O
demographic O
and O
clinical O
variables. O
In O
most O
patients, O
discontinuation O
of O
sirolimus O
resulted O
in O
a O
decrease, O
but O
not O
resolution, O
of O
proteinuria. O
CONCLUSIONS: O
Sirolimus O
induces O
or O
aggravates O
pre-existing O
proteinuria O
in O
an O
unpredictable O
subset O
of O
renal O
allograft O
recipients. O
Proteinuria O
may O
improve, O
but O
does O
not O
resolve, O
when O
sirolimus O
is O
withdrawn. O

Lamivudine O
for O
the O
prevention O
of O
hepatitis B
B I
virus O
reactivation O
in O
hepatitis-B O
surface O
antigen O
(HBSAG) O
seropositive O
cancer B
patients O
undergoing O
cytotoxic O
chemotherapy. O

Thyroxine O
abuse: O
an O
unusual O
case O
of O
thyrotoxicosis B
in O
pregnancy. O

Cardiac B
arrhythmias I
have O
frequently O
been O
reported O
in O
association O
with O
respiratory B
failure. I
The O
possible O
additive O
role O
of O
pharmacologic O
agents O
in O
precipitating O
cardiac B
disturbances I
in O
patients O
with O
respiratory O
failure O
has O
only O
recently O
been O
emphasized. O
The O
effects O
of O
aminophylline O
on O
the O
ventricular B
fibrillation I
threshold O
during O
normal O
acid-base O
conditions O
and O
during O
respiratory O
failure O
were O
studied O
in O
anesthetized O
open O
chest O
dogs. O
The O
ventricular O
fibrillation O
threshold O
was O
measured O
by O
passing O
a O
gated O
train O
of O
12 O
constant O
current O
pulses O
through O
the O
ventricular O
myocardium O
during O
the O
vulnerable O
period O
of O
the O
cardiac O
cycle. O
During O
the O
infusion O
of O
aminophylline, O
the O
ventricular O
fibrillation O
threshold O
was O
reduced O
by O
30 O
to O
40 O
percent O
of O
the O
control O
when O
pH O
and O
partial O
pressures O
of O
oxygen O
(PO2) O
and O
carbon O
dioxide O
(CO2) O
were O
kept O
within O
normal O
limits. O
When O
respiratory O
failure O
was O
produced O
by O
hypoventilation B
(pH O
7.05 O
to O
7.25; O
PC02 O
70 O
to O
100 O
mm O
Hg: O
P02 O
20 O
to O
40 O
mm O
Hg), O
infusion O
of O
aminophylline O
resulted O
in O
an O
even O
greater O
decrease O
in O
ventricular O
fibrillation O
threshold O
to O
60 O
percent O
of O
the O
control O
level. O
These O
experiments O
suggest O
that O
although O
many O
factors O
may O
contribute O
to O
the O
increased O
incidence O
of O
ventricular B
arrhythmias I
in O
respiratory O
failure, O
pharmacologic O
agents, O
particularly O
aminophylline, O
may O
play O
a O
significant O
role. O

The O
epidemiological O
studies O
that O
assessed O
the O
risk O
of O
venous B
thromboembolism I
(VTE) O
associated B
with O
newer O
oral O
contraceptives O
(OC) O
did O
not O
distinguish O
between O
patterns O
of O
OC O
use, O
namely O
first-time O
users, O
repeaters O
and O
switchers. O
Data O
from O
a O
Transnational O
case-control O
study O
were O
used O
to O
assess O
the O
risk O
of O
VTE O
for O
the O
latter O
patterns O
of O
use, O
while O
accounting O
for O
duration O
of O
use. O
Over O
the O
period O
1993-1996, O
551 O
cases O
of O
VTE O
were O
identified O
in O
Germany O
and O
the O
UK O
along O
with O
2066 O
controls. O
Totals O
of O
128 O
cases O
and O
650 O
controls O
were O
analysed O
for O
repeat O
use O
and O
135 O
cases O
and O
622 O
controls O
for O
switching O
patterns. O
The O
adjusted O
rate O
ratio O
of O
VTE O
for O
repeat O
users O
of O
third O
generation O
OC O
was O
0.6 O
(95% O
CI:0.3-1.2) O
relative O
to O
repeat O
users O
of O
second O
generation O
pills, O
whereas O
it O
was O
1.3 O
(95% O
CI:0.7-2.4) O
for O
switchers O
from O
second O
to O
third O
generation O
pills O
relative O
to O
switchers O
from O
third O
to O
second O
generation O
pills. O
We O
conclude O
that O
second O
and O
third O
generation O
agents O
are O
associated O
with O
equivalent O
risks O
of O
VTE O
when O
the O
same O
agent O
is O
used O
repeatedly O
after O
interruption O
periods O
or O
when O
users O
are O
switched O
between O
the O
two O
generations O
of O
pills. O
These O
analyses O
suggest O
that O
the O
higher O
risk O
observed O
for O
the O
newer O
OC O
in O
other O
studies O
may O
be O
the O
result O
of O
inadequate O
comparisons O
of O
pill O
users O
with O
different O
patterns O
of O
pill O
use. O

Seven O
cases O
of O
procainamide-induced O
polymorphous O
ventricular B
tachycardia I
are O
presented. O
In O
four O
patients, O
polymorphous O
ventricular O
tachycardia O
appeared O
after O
intravenous O
administration O
of O
200 O
to O
400 O
mg O
of O
procainamide O
for O
the O
treatment O
of O
sustained O
ventricular O
tachycardia. O
In O
the O
remaining O
three O
patients, O
procainamide O
was O
administered O
orally O
for O
treatment O
of O
chronic O
premature B
ventricular I
contractions I
or O
atrial B
flutter. I
These O
patients O
had O
Q-T B
prolongation I
and O
recurrent O
syncope B
due O
to O
polymorphous O
ventricular O
tachycardia. O
In O
four O
patients, O
the O
arrhythmia B
was O
rapidly O
diagnosed O
and O
treated O
with O
disappearance O
of O
further O
episodes O
of O
the O
arrhythmia. O
In O
two O
patients, O
the O
arrhythmia O
degenerated O
into O
irreversible O
ventricular B
fibrillation I
and O
both O
patients O
died. O
In O
the O
seventh O
patient, O
a O
permanent O
ventricular O
pacemaker O
was O
inserted O
and, O
despite O
continuation O
of O
procainamide O
therapy, O
polymorphous O
ventricular O
tachycardia O
did O
not O
reoccur. O
These O
seven O
cases O
demonstrate O
that O
procainamide O
can O
produce O
an O
acquired O
prolonged B
Q-T I
syndrome I
with O
polymorphous O
ventricular O
tachycardia. O

OBJECTIVE: O
The O
outcome O
of O
subarachnoid B
hemorrhage I
associated O
with O
cocaine B
abuse I
is O
reportedly O
poor. O
However, O
no O
study O
in O
the O
literature O
has O
reported O
the O
use O
of O
a O
statistical O
model O
to O
analyze O
the O
variables O
that O
influence O
outcome. O
METHODS: O
A O
review O
of O
admissions O
during O
a O
6-year O
period O
revealed O
14 O
patients O
with O
cocaine-related O
aneurysms. B
This O
group O
was O
compared O
with O
a O
control O
group O
of O
135 O
patients O
with O
ruptured B
aneurysms I
and O
no O
history O
of O
cocaine O
abuse. O
Age O
at O
presentation, O
time O
of O
ictus O
after O
intoxication, O
Hunt O
and O
Hess O
grade O
of O
subarachnoid O
hemorrhage, O
size O
of O
the O
aneurysm, O
location O
of O
the O
aneurysm, O
and O
the O
Glasgow O
Outcome O
Scale O
score O
were O
assessed O
and O
compared. O
RESULTS: O
The O
patients O
in O
the O
study O
group O
were O
significantly O
younger O
than O
the O
patients O
in O
the O
control O
group O
(P O
< O
0.002). O
In O
patients O
in O
the O
study O
group, O
all O
aneurysms O
were O
located O
in O
the O
anterior O
circulation. O
The O
majority O
of O
these O
aneurysms O
were O
smaller O
than O
those O
of O
the O
control O
group O
(8 O
+/- O
6.08 O
mm O
versus O
11 O
+/- O
5.4 O
mm; O
P O
= O
0.05). O
The O
differences O
in O
mortality O
and O
morbidity O
between O
the O
two O
groups O
were O
not O
significant. O
Hunt O
and O
Hess O
grade O
(P O
< O
0.005) O
and O
age O
(P O
< O
0.007) O
were O
significant O
predictors O
of O
outcome O
for O
the O
patients O
with O
cocaine-related O
aneurysms. O
CONCLUSION: O
Cocaine O
use O
predisposed O
aneurysmal B
rupture I
at O
a O
significantly O
earlier O
age O
and O
in O
much O
smaller O
aneurysms. O
Contrary O
to O
the O
published O
literature, O
this O
group O
did O
reasonably O
well O
with O
aggressive O
management. O

NRA0160, O
5 O
- O
[2- O
( O
4- O
( O
3 O
- O
fluorobenzylidene) O
piperidin-1-yl) O
ethyl] O
- O
4 O
-(4-fluorophenyl) O
thiazole-2-carboxamide, O
has O
a O
high O
affinity O
for O
human O
cloned O
dopamine O
D4.2, O
D4.4 O
and O
D4.7 O
receptors, O
with O
Ki O
values O
of O
0.5, O
0.9 O
and O
2.7 O
nM, O
respectively. O
NRA0160 O
is O
over O
20,000fold O
more O
potent O
at O
the O
dopamine O
D4.2 O
receptor O
compared O
with O
the O
human O
cloned O
dopamine O
D2L O
receptor. O
NRA0160 O
has O
negligible O
affinity O
for O
the O
human O
cloned O
dopamine O
D3 O
receptor O
(Ki=39 O
nM), O
rat O
serotonin O
(5-HT)2A O
receptors O
(Ki=180 O
nM) O
and O
rat O
alpha1 O
adrenoceptor O
(Ki=237 O
nM). O
NRA0160 O
and O
clozapine O
antagonized O
locomotor O
hyperactivity B
induced O
by O
methamphetamine O
(MAP) O
in O
mice. O
NRA0160 O
and O
clozapine O
antagonized O
MAP-induced O
stereotyped O
behavior O
in O
mice, O
although O
their O
effects O
did O
not O
exceed O
50% O
inhibition, O
even O
at O
the O
highest O
dose O
given. O
NRA0160 O
and O
clozapine O
significantly O
induced O
catalepsy B
in O
rats, O
although O
their O
effects O
did O
not O
exceed O
50% O
induction O
even O
at O
the O
highest O
dose O
given. O
NRA0160 O
and O
clozapine O
significantly O
reversed O
the O
disruption O
of O
prepulse O
inhibition O
(PPI) O
in O
rats O
produced O
by O
apomorphine. O
NRA0160 O
and O
clozapine O
significantly O
shortened O
the O
phencyclidine O
(PCP)-induced O
prolonged O
swimming O
latency O
in O
rats O
in O
a O
water O
maze O
task. O
These O
findings O
suggest O
that O
NRA0160 O
may O
have O
unique O
antipsychotic O
activities O
without O
the O
liability O
of O
motor O
side O
effects O
typical O
of O
classical O
antipsychotics. O

Systolic O
pressure O
variation O
is O
greater O
during O
hemorrhage B
than O
during O
sodium O
nitroprusside-induced O
hypotension B
in O
ventilated O
dogs. O

PURPOSE: O
This O
study O
was O
designed O
to O
establish O
a O
rat O
model O
of O
thoracic B
aortic I
aneurysm I
(TAA) O
by B
calcium O
chloride O
(CaCl(2))-induced O
arterial B
injury I
and O
to O
explore O
the O
potential O
role O
of O
a O
disintegrin O
and O
metalloproteinase O
(ADAM), O
matrix O
metalloproteinases O
(MMPs) O
and O
their O
endogenous O
inhibitors O
(TIMPs) O
in O
TAA O
formation. O
METHODS: O
Thoracic O
aorta O
of O
male O
Sprague-Dawley O
rats O
was O
exposed O
to O
0.5M O
CaCl(2) O
or O
normal O
saline O
(NaCl). O
After O
12weeks, O
animals O
were O
euthanized, O
and O
CaCl(2)-treated, O
CaCl(2)-untreated O
(n=12) O
and O
NaCl-treated O
aortic O
segments O
(n=12) O
were O
collected O
for O
histological O
and O
molecular O
assessments. O
MMP-TIMP O
and O
ADAM O
mRNAs O
were O
semi-quantitatively O
analyzed O
and O
protein O
expressions O
were O
determined O
by O
immunohistochemistry. O
RESULTS: O
Despite O
similar O
external O
diameters O
among O
CaCl(2)-treated, O
non-CaCl(2)-treated O
and O
NaCl-treated O
segments, O
aneurymal O
alteration O
(n=6, O
50%), O
media O
degeneration O
with O
regional O
disruption, O
fragmentation O
of O
elastic O
fiber, O
and O
increased O
collagen O
deposition O
(n=12, O
100%) O
were O
demonstrated O
in O
CaCl(2)-treated O
segments. O
MMP-2, O
MMP-9, O
ADAM-10 O
and O
ADAM-17 O
mRNA O
levels O
were O
increased O
in O
CaCl(2)-treated O
segments O
(all O
p<0.01), O
with O
trends O
of O
elevation O
in O
CaCl(2)-untreated O
segments, O
as O
compared O
with O
NaCl-treated O
segments. O
Immunohistochemistry O
displayed O
significantly O
increased O
expressions O
of O
MMP-2, O
MMP-9, O
ADAM-10 O
and O
ADAM-17 O
(all O
p<0.01) O
in O
intima O
and O
media O
for O
CaCl(2)-treated O
segments. O
TIMP O
mRNA O
and O
tissue O
levels O
did O
not O
differ O
obviously O
among O
the O
three O
aortic O
segments. O
CONCLUSION: O
This O
study O
establishes O
a O
TAA O
model O
by O
periarterial O
CaCl(2) O
exposure O
in O
rats, O
and O
demonstrates O
a O
significant O
elevation O
of O
expression O
of O
MMP-2, O
MMP-9, O
ADAM10 O
and O
ADAM17 O
in O
the O
pathogenesis O
of O
vascular O
remodeling. O

Experimental O
and O
clinical O
evidence O
points O
to O
a O
role O
of O
central O
histaminergic O
system O
in O
the O
pathogenesis O
of O
schizophrenia. B
The O
present O
study O
was O
designed O
to O
study O
the O
effect O
of O
histamine O
H(3)-receptor O
ligands O
on O
neuroleptic-induced O
catalepsy, B
apomorphine-induced O
climbing O
behavior O
and O
amphetamine-induced O
locomotor O
activities O
in O
mice. O
Catalepsy B
was O
induced O
by O
haloperidol O
(2 O
mg/kg O
p.o.), O
while O
apomorphine O
(1.5 O
mg/kg O
s.c.) O
and O
amphetamine O
(2 O
mg/kg O
s.c.) O
were O
used O
for O
studying O
climbing O
behavior O
and O
locomotor O
activities, O
respectively. O
(R)-alpha-methylhistamine O
(RAMH) O
(5 O
microg O
i.c.v.) O
and O
thioperamide O
(THP) O
(15 O
mg/kg O
i.p.), O
per O
se O
did O
not O
cause O
catalepsy. O
Administration O
of O
THP O
(3.75, O
7.5 O
and O
15 O
mg/kg O
i.p.) O
1 O
h O
prior O
to O
haloperidol O
resulted O
in O
a O
dose-dependent O
increase O
in O
the O
catalepsy O
times O
(P O
< O
0.05). O
However, O
pretreatment O
with O
RAMH O
significantly O
reversed O
such O
an O
effect O
of O
THP O
(15 O
mg/kg O
i.p.). O
RAMH O
per O
se O
showed O
significant O
reduction O
in O
locomotor O
time, O
distance O
traveled O
and O
average O
speed O
but O
THP O
(15 O
mg/kg O
i.p.) O
per O
se O
had O
no O
effect O
on O
these O
parameters. O
On O
amphetamine-induced O
hyperactivity, B
THP O
(3.75 O
and O
7.5 O
mg/kg O
i.p.) O
reduced O
locomotor O
time, O
distance O
traveled O
and O
average O
speed O
(P O
< O
0.05). O
Pretreatment O
with O
RAMH O
(5 O
microg O
i.c.v.) O
could O
partially O
reverse O
such O
effects O
of O
THP O
(3.75 O
mg/kg O
i.p.). O
Climbing O
behavior O
induced O
by O
apomorphine O
was O
reduced O
in O
animals O
treated O
with O
THP. O
Such O
an O
effect O
was, O
however, O
reversed O
in O
presence O
of O
RAMH. O
THP O
exhibited O
an O
antipsychotic-like O
profile O
by O
potentiating O
haloperidol-induced O
catalepsy, O
reducing O
amphetamine-induced O
hyperactivity O
and O
reducing O
apomorphine-induced O
climbing O
in O
mice. O
Such O
effects O
of O
THP O
were O
reversed O
by O
RAMH O
indicating O
the O
involvement O
of O
histamine O
H(3)-receptors. O
Findings O
suggest O
a O
potential O
for O
H(3)-receptor O
antagonists O
in O
improving O
the O
refractory O
cases O
of O
schizophrenia. O

Valvular B
heart I
abnormalities I
have O
been O
reported O
in O
patients O
with O
Parkinson's B
disease I
(PD) O
treated B
with O
pergolide. O
However, O
the O
incidence O
and O
severity O
of O
these O
abnormalities O
vary O
from O
study O
to O
study O
and O
their O
course O
after O
drug O
withdrawal O
has O
not O
been O
systematically O
assessed. O
OBJECTIVES: O
To O
estimate O
the O
frequency O
and O
severity O
of O
valvular B
heart I
abnormality I
and O
its O
possible O
reversibility O
after O
drug O
withdrawal O
in O
a O
case-control O
study. O
METHODS: O
All O
PD O
patients O
in O
the O
Amiens O
area O
treated O
with O
pergolide O
were O
invited O
to O
attend O
a O
cardiologic O
assessment O
including O
transthoracic O
echocardiography. O
Thirty O
PD O
patients O
participated O
in O
the O
study. O
A O
second O
echocardiography O
was O
performed O
(median O
interval: O
13 O
months) O
after O
pergolide O
withdrawal O
(n=10 O
patients). O
Controls O
were O
age- O
and O
sex-matched O
non-PD O
patients O
referred O
to O
the O
cardiology O
department. O
RESULTS: O
Compared O
to O
controls, O
aortic B
regurgitation I
(OR: O
3.1; O
95% O
IC: O
1.1-8.8) O
and O
mitral B
regurgitation I
(OR: O
10.7; O
95% O
IC: O
2.1-53) O
were O
more O
frequent O
in O
PD O
patients O
(tricuspid: O
NS). O
The O
number O
of O
affected O
valves O
(n=2.4+/-0.7) O
and O
the O
sum O
of O
regurgitation O
grades O
(n=2.8+/-1.09) O
were O
higher O
(p=0.008 O
and O
p=0.006, O
respectively) O
in O
the O
pergolide O
group. O
Severity O
of O
regurgitation O
was O
not O
correlated O
with O
pergolide O
cumulative O
dose. O
A O
restrictive O
pattern O
of O
valvular B
regurgitation, I
suggestive O
of O
the O
role O
of O
pergolide, O
was O
observed O
in O
12/30 O
(40%) O
patients O
including O
two O
with O
heart B
failure. I
Pergolide O
was O
discontinued O
in O
10 O
patients O
with O
valvular B
heart I
disease, I
resulting O
in O
a O
lower O
regurgitation O
grade O
(p=0.01) O
at O
the O
second O
transthoracic O
echocardiography O
and O
the O
two O
patients O
with O
heart O
failure O
returned O
to O
nearly O
normal O
clinical O
examination. O
This O
study O
supports O
the O
high O
frequency O
of O
restrictive O
valve B
regurgitation I
in O
PD O
patients O
treated O
with O
pergolide O
and O
reveals O
that O
a O
significant O
improvement O
is O
usual O
when O
the O
treatment O
is O
converted O
to O
non-ergot O
dopamine O
agonists. O

A O
synergistic O
effect O
of O
etoposide O
and O
cyclosporin O
A O
was O
observed O
in O
a O
patient O
with O
acute B
T-lymphocytic I
leukemia I
in O
relapse. O
The O
concomitant O
administration O
of O
etoposide O
and O
cyclosporin O
A O
resulted O
in O
eradication O
of O
hitherto O
refractory O
leukemic B
infiltration I
of O
bone O
marrow. O
Severe O
side O
effects O
in O
terms O
of O
mental O
confusion B
and O
progressive O
hyperbilirubinemia, B
however, O
point O
to O
an O
enhancement O
not O
only O
of O
antineoplastic O
effects O
but O
also O
of O
toxicity B
in O
normal O
tissues. O
This O
report O
demonstrates O
for O
the O
first O
time O
that O
the O
pharmacodynamic O
properties O
of O
cyclosporin O
A O
may O
not O
be O
confined O
strictly O
to O
suppression O
of O
normal O
T-cell O
functions. O

Butyrylcholinesterase O
gene O
mutations O
in O
patients O
with O
prolonged O
apnea B
after O
succinylcholine O
for O
electroconvulsive O
therapy. O

Diseases B
of I
peripheral I
nerves I
as O
seen O
in O
the O
Nigerian O
African. O

Valvular B
heart I
disease I
in O
patients O
with O
Parkinson's B
disease I
treated O
with O
pergolide. O
Course O
following O
treatment O
modifications. O

We O
report O
the O
case O
of O
a O
patient O
with O
amoxicillin-clavulanic O
acid-induced O
hepatitis B
with O
histologic O
multiple O
granulomas. B
This O
type O
of O
lesion O
broadens O
the O
spectrum O
of O
liver B
injury I
due O
to O
this O
drug O
combination, O
mainly O
represented O
by O
a O
benign O
cholestatic B
syndrome. I
The O
association O
of O
granulomas O
and O
eosinophilia B
favor O
an O
immunoallergic O
mechanism. O
As O
penicillin O
derivatives O
and O
amoxicillin O
alone O
are O
known O
to O
induce O
such O
types O
of O
lesions, O
the O
amoxicillin O
component, O
with O
or O
without O
a O
potentiating O
effect O
of O
clavulanic O
acid, O
might O
have O
a O
major O
role. O

Different O
mechanisms O
have O
been O
suggested O
for O
cocaine O
toxicity B
including O
an O
increase O
in O
oxidative O
stress O
but O
the O
association O
between O
oxidative O
status O
in O
the O
brain O
and O
cocaine O
induced-behaviour O
is O
poorly O
understood. O
Nuclear O
factor O
kappa O
B O
(NFkappaB) O
is O
a O
sensor O
of O
oxidative O
stress O
and O
participates O
in O
memory O
formation O
that O
could O
be O
involved O
in O
drug O
toxicity O
and O
addiction O
mechanisms. O
Therefore O
NFkappaB O
activity, O
oxidative O
stress, O
neuronal O
nitric O
oxide O
synthase O
(nNOS) O
activity, O
spatial O
learning O
and O
memory O
as O
well O
as O
the O
effect O
of O
topiramate, O
a O
previously O
proposed O
therapy O
for O
cocaine B
addiction, I
were O
evaluated O
in O
an O
experimental O
model O
of O
cocaine O
administration O
in O
rats. O
NFkappaB O
activity O
was O
decreased O
in O
the O
frontal O
cortex O
of O
cocaine O
treated O
rats, O
as O
well O
as O
GSH O
concentration O
and O
glutathione O
peroxidase O
activity O
in O
the O
hippocampus, O
whereas O
nNOS O
activity O
in O
the O
hippocampus O
was O
increased. O
Memory O
retrieval O
of O
experiences O
acquired O
prior O
to O
cocaine O
administration O
was O
impaired O
and O
negatively O
correlated O
with O
NFkappaB O
activity O
in O
the O
frontal O
cortex. O
In O
contrast, O
learning O
of O
new O
tasks O
was O
enhanced O
and O
correlated O
with O
the O
increase O
of O
nNOS O
activity O
and O
the O
decrease O
of O
glutathione O
peroxidase. O
These O
results O
provide O
evidence O
for O
a O
possible O
mechanistic O
role O
of O
oxidative O
and O
nitrosative O
stress O
and O
NFkappaB O
in O
the O
alterations O
induced O
by O
cocaine. O
Topiramate O
prevented O
all O
the O
alterations O
observed, O
showing O
novel O
neuroprotective O
properties. O

Nicotine O
activates O
the O
sympathetic O
nervous O
system O
and O
in O
this O
way O
could O
contribute O
to O
cardiovascular B
disease. I
Animal O
studies O
and O
mechanistic O
studies O
indicate O
that O
nicotine O
could O
play O
a O
role O
in O
accelerating O
atherosclerosis, B
but O
evidence O
among O
humans O
is O
too O
inadequate O
to O
be O
definitive O
about O
such O
an O
effect. O
Almost O
certainly, O
nicotine O
via O
its O
hemodynamic O
effects O
contributes O
to O
acute O
cardiovascular O
events, O
although O
current O
evidence O
suggests O
that O
the O
effects O
of O
nicotine O
are O
much O
less O
important O
than O
are O
the O
prothrombotic O
effects O
of O
cigarette O
smoking O
or O
the O
effects O
of O
carbon O
monoxide. O
Nicotine O
does O
not O
appear O
to O
enhance O
thrombosis B
among O
humans. O
Clinical O
studies O
of O
pipe O
smokers O
and O
people O
using O
transdermal O
nicotine O
support O
the O
idea O
that O
toxins O
other O
than O
nicotine O
are O
the O
most O
important O
causes O
of O
acute O
cardiovascular O
events. O
Finally, O
the O
dose O
response O
for O
cardiovascular O
events O
of O
nicotine O
appears O
to O
be O
flat, O
suggesting O
that O
if O
nicotine O
is O
involved, O
adverse O
effects O
might O
be O
seen O
with O
relatively O
low-level O
cigarette O
exposures. O

Cocaine's O
ability O
to O
interact O
with O
sigma O
receptors O
suggests O
that O
these O
proteins O
mediate O
some O
of O
its O
behavioral O
effects. O
Therefore, O
three O
novel O
sigma O
receptor O
ligands O
with O
antagonist O
activity O
were O
evaluated O
in O
Swiss O
Webster O
mice: O
BD1018 O
(3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), O
BD1063 O
(1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), O
and O
LR132 O
(1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine). O
Competition O
binding O
assays O
demonstrated O
that O
all O
three O
compounds O
have O
high O
affinities O
for O
sigma1 O
receptors. O
The O
three O
compounds O
vary O
in O
their O
affinities O
for O
sigma2 O
receptors O
and O
exhibit O
negligible O
affinities O
for O
dopamine, O
opioid, O
GABA(A) O
and O
NMDA O
receptors. O
In O
behavioral O
studies, O
pre-treatment O
of O
mice O
with O
BD1018, O
BD1063, O
or O
LR132 O
significantly O
attenuated O
cocaine-induced O
convulsions B
and O
lethality. O
Moreover, O
post-treatment O
with O
LR132 O
prevented O
cocaine-induced O
lethality O
in O
a O
significant O
proportion O
of O
animals. O
In O
contrast O
to O
the O
protection O
provided O
by O
the O
putative O
antagonists, O
the O
well-characterized O
sigma O
receptor O
agonist O
di-o-tolylguanidine O
(DTG) O
and O
the O
novel O
sigma O
receptor O
agonist O
BD1031 O
(3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) O
each O
worsened O
the O
behavioral O
toxicity B
of O
cocaine. O
At O
doses O
where O
alone, O
they O
produced O
no O
significant O
effects O
on O
locomotion, O
BD1018, O
BD1063 O
and O
LR132 O
significantly O
attenuated O
the O
locomotor O
stimulatory O
effects O
of O
cocaine. O
To O
further O
validate O
the O
hypothesis O
that O
the O
anti-cocaine O
effects O
of O
the O
novel O
ligands O
involved O
antagonism O
of O
sigma O
receptors, O
an O
antisense O
oligodeoxynucleotide O
against O
sigma1 O
receptors O
was O
also O
shown O
to O
significantly O
attenuate O
the O
convulsive B
and O
locomotor O
stimulatory O
effects O
of O
cocaine. O
Together, O
the O
data O
suggests O
that O
functional O
antagonism O
of O
sigma O
receptors O
is O
capable O
of O
attenuating O
a O
number O
of O
cocaine-induced O
behaviors. O

Clotiazepam-induced O
acute O
hepatitis. B

Effect O
of O
green O
tea O
and O
vitamin O
E O
combination O
in O
isoproterenol O
induced O
myocardial B
infarction I
in O
rats. O

BACKGROUND: O
No O
direct O
comparisons O
exist O
of O
the O
renal O
tolerability O
of O
the O
low-osmolality O
contrast O
medium O
iopamidol O
with O
that O
of O
the O
iso-osmolality O
contrast O
medium O
iodixanol O
in O
high-risk O
patients. O
METHODS O
AND O
RESULTS: O
The O
present O
study O
is O
a O
multicenter, O
randomized, O
double-blind O
comparison O
of O
iopamidol O
and O
iodixanol O
in O
patients O
with O
chronic B
kidney I
disease I
(estimated O
glomerular O
filtration O
rate, O
20 O
to O
59 O
mL/min) O
who O
underwent O
cardiac O
angiography O
or O
percutaneous O
coronary O
interventions. O
Serum O
creatinine O
(SCr) O
levels O
and O
estimated O
glomerular O
filtration O
rate O
were O
assessed O
at O
baseline O
and O
2 O
to O
5 O
days O
after O
receiving O
medications. O
The O
primary O
outcome O
was O
a O
postdose O
SCr O
increase O
> O
or O
= O
0.5 O
mg/dL O
(44.2 O
micromol/L) O
over O
baseline. O
Secondary O
outcomes O
were O
a O
postdose O
SCr O
increase O
> O
or O
= O
25%, O
a O
postdose O
estimated O
glomerular O
filtration O
rate O
decrease O
of O
> O
or O
= O
25%, O
and O
the O
mean O
peak O
change O
in O
SCr. O
In O
414 O
patients, O
contrast O
volume, O
presence O
of O
diabetes B
mellitus, I
use O
of O
N-acetylcysteine, O
mean O
baseline O
SCr, O
and O
estimated O
glomerular O
filtration O
rate O
were O
comparable O
in O
the O
2 O
groups. O
SCr O
increases O
> O
or O
= O
0.5 O
mg/dL O
occurred O
in O
4.4% O
(9 O
of O
204 O
patients) O
after O
iopamidol O
and O
6.7% O
(14 O
of O
210 O
patients) O
after O
iodixanol O
(P=0.39), O
whereas O
rates O
of O
SCr O
increases O
> O
or O
= O
25% O
were O
9.8% O
and O
12.4%, O
respectively O
(P=0.44). O
In O
patients O
with O
diabetes, O
SCr O
increases O
> O
or O
= O
0.5 O
mg/dL O
were O
5.1% O
(4 O
of O
78 O
patients) O
with O
iopamidol O
and O
13.0% O
(12 O
of O
92 O
patients) O
with O
iodixanol O
(P=0.11), O
whereas O
SCr O
increases O
> O
or O
= O
25% O
were O
10.3% O
and O
15.2%, O
respectively O
(P=0.37). O
Mean O
post-SCr O
increases O
were O
significantly O
less O
with O
iopamidol O
(all O
patients: O
0.07 O
versus O
0.12 O
mg/dL, O
6.2 O
versus O
10.6 O
micromol/L, O
P=0.03; O
patients O
with O
diabetes: O
0.07 O
versus O
0.16 O
mg/dL, O
6.2 O
versus O
14.1 O
micromol/L, O
P=0.01). O
CONCLUSIONS: O
The O
rate O
of O
contrast-induced O
nephropathy, B
defined O
by O
multiple O
end O
points, O
is O
not O
statistically O
different O
after O
the O
intraarterial O
administration O
of O
iopamidol O
or O
iodixanol O
to O
high-risk O
patients, O
with O
or O
without O
diabetes O
mellitus. O
Any O
true O
difference O
between O
the O
agents O
is O
small O
and O
not O
likely O
to O
be O
clinically O
significant. O

Antihypertensive O
drugs O
and O
depression: B
a O
reappraisal. O

We O
have O
recently O
shown O
that O
estrogen O
negatively O
modulates O
the O
hypotensive B
effect O
of O
clonidine O
(mixed O
alpha2-/I1-receptor O
agonist) O
in O
female O
rats O
and O
implicates O
the O
cardiovascular O
autonomic O
control O
in O
this O
interaction. O
The O
present O
study O
investigated O
whether O
this O
effect O
of O
estrogen O
involves O
interaction O
with O
alpha2- O
and/or O
I1-receptors. O
Changes O
evoked O
by O
a O
single O
intraperitoneal O
injection O
of O
rilmenidine O
(600 O
microg/kg) O
or O
alpha-methyldopa O
(100 O
mg/kg), O
selective O
I1- O
and O
alpha2-receptor O
agonists, O
respectively, O
in O
blood O
pressure, O
hemodynamic O
variability, O
and O
locomotor O
activity O
were O
assessed O
in O
radiotelemetered O
sham-operated O
and O
ovariectomized O
(Ovx) O
Sprague-Dawley O
female O
rats O
with O
or O
without O
12-wk O
estrogen O
replacement. O
Three O
time O
domain O
indexes O
of O
hemodynamic O
variability O
were O
employed: O
the O
standard O
deviation O
of O
mean O
arterial O
pressure O
as O
a O
measure O
of O
blood O
pressure O
variability O
and O
the O
standard O
deviation O
of O
beat-to-beat O
intervals O
(SDRR) O
and O
the O
root O
mean O
square O
of O
successive O
differences O
in O
R-wave-to-R-wave O
intervals O
as O
measures O
of O
heart O
rate O
variability. O
In O
sham-operated O
rats, O
rilmenidine O
or O
alpha-methyldopa O
elicited O
similar O
hypotension B
that O
lasted O
at O
least O
5 O
h O
and O
was O
associated O
with O
reductions O
in O
standard O
deviation O
of O
mean O
arterial O
pressure. O
SDRR O
was O
reduced O
only O
by O
alpha-methyldopa. O
Ovx O
significantly O
enhanced O
the O
hypotensive O
response O
to O
alpha-methyldopa, O
in O
contrast O
to O
no O
effect O
on O
rilmenidine O
hypotension. O
The O
enhanced O
alpha-methyldopa O
hypotension O
in O
Ovx O
rats O
was O
paralleled O
with O
further O
reduction O
in O
SDRR O
and O
a B
reduced I
locomotor I
activity. I
Estrogen O
replacement O
(17beta-estradiol O
subcutaneous O
pellet, O
14.2 O
microg/day, O
12 O
wk) O
of O
Ovx O
rats O
restored O
the O
hemodynamic O
and O
locomotor O
effects O
of O
alpha-methyldopa O
to O
sham-operated O
levels. O
These O
findings O
suggest O
that O
estrogen O
downregulates O
alpha2- O
but O
not O
I1-receptor-mediated O
hypotension O
and O
highlight O
a O
role O
for O
the O
cardiac O
autonomic O
control O
in O
alpha-methyldopa-estrogen O
interaction. O

Drug-induced O
arterial O
spasm B
relieved O
by O
lidocaine. O
Case O
report. O

Prospective O
study O
of O
the O
long-term O
effects O
of O
somatostatin O
analog O
(octreotide) O
on O
gallbladder O
function O
and O
gallstone B
formation O
in O
Chinese O
acromegalic B
patients. O

Catecholamine-induced O
cardiomyopathy B
due O
to O
chronic O
excess O
of O
endogenous O
catecholamines O
has O
been O
recognized O
for O
decades O
as O
a O
clinical O
phenomenon. O
In O
contrast, O
reports O
of O
myocardial B
dysfunction I
due O
to O
acute O
iatrogenic O
overdose B
are O
rare. O
A O
35-year-old O
woman O
whose O
cervix O
uteri O
was O
inadvertently O
injected O
with O
8 O
mg O
of O
epinephrine O
developed O
myocardial B
stunning I
that O
was O
characterized O
by O
severe O
hemodynamic O
compromise, O
profound, O
albeit O
transient, O
left B
ventricular I
systolic I
and I
diastolic I
dysfunction, I
and O
only O
modestly O
elevated O
biochemical O
markers O
of O
myocardial B
necrosis. I
Our O
case O
illustrates O
the O
serious O
consequences O
of O
medical O
errors O
that O
can O
be O
avoided O
through O
improved O
medication O
labeling O
and O
staff O
supervision. O

Changes O
of O
sodium O
and O
ATP O
affinities O
of O
the O
cardiac O
(Na,K)-ATPase O
during O
and O
after O
nitric O
oxide O
deficient O
hypertension. B

Twin O
preterm O
neonates O
with O
cardiac B
toxicity I
related O
to O
lopinavir/ritonavir O
therapy. O

Dipyridamole-induced O
myocardial B
ischemia. I

Serial O
epilepsy B
caused O
by O
levodopa/carbidopa O
administration O
in O
two O
patients O
on O
hemodialysis. O

OBJECTIVE: O
To O
examine O
the O
safety O
and O
tolerability O
of O
clonidine O
used O
alone O
or O
with O
methylphenidate O
in O
children O
with O
attention-deficit/hyperactivity B
disorder I
(ADHD). O
METHOD: B
In O
a O
16-week O
multicenter, O
double-blind O
trial, O
122 O
children O
with O
ADHD O
were O
randomly O
assigned O
to O
clonidine O
(n O
= O
31), O
methylphenidate O
(n O
= O
29), O
clonidine O
and O
methylphenidate O
(n O
= O
32), O
or O
placebo O
(n O
= O
30). O
Doses O
were O
flexibly O
titrated O
up O
to O
0.6 O
mg/day O
for O
clonidine O
and O
60 O
mg/day O
for O
methylphenidate O
(both O
with O
divided O
dosing). O
Groups O
were O
compared O
regarding O
adverse O
events O
and O
changes O
from O
baseline O
to O
week O
16 O
in O
electrocardiograms O
and O
vital O
signs. O
RESULTS: O
There O
were O
more O
incidents O
of O
bradycardia B
in O
subjects O
treated O
with O
clonidine O
compared O
with O
those O
not O
treated O
with O
clonidine O
(17.5% O
versus O
3.4%; O
p O
=.02), O
but O
no O
other O
significant O
group O
differences O
regarding O
electrocardiogram O
and O
other O
cardiovascular O
outcomes. O
There O
were O
no O
suggestions O
of O
interactions O
between O
clonidine O
and O
methylphenidate O
regarding O
cardiovascular O
outcomes. O
Moderate O
or O
severe O
adverse O
events O
were O
more O
common O
in O
subjects O
on O
clonidine O
(79.4% O
versus O
49.2%; O
p O
=.0006) O
but O
not O
associated O
with O
higher O
rates O
of O
early O
study O
withdrawal. O
Drowsiness B
was O
common O
on O
clonidine, O
but O
generally O
resolved O
by O
6 O
to O
8 O
weeks. O
CONCLUSIONS: O
Clonidine, O
used O
alone O
or O
with O
methylphenidate, O
appears O
safe O
and O
well O
tolerated O
in O
childhood O
ADHD. O
Physicians O
prescribing O
clonidine O
should O
monitor O
for O
bradycardia O
and O
advise O
patients O
about O
the O
high O
likelihood O
of O
initial O
drowsiness. B

Anthracyclines O
are O
effective O
antineoplastic O
drugs, O
but O
they O
frequently O
cause O
dose-related O
cardiotoxicity. B
The O
cardiotoxicity O
of O
conventional O
anthracycline O
therapy O
highlights O
a O
need O
to O
search O
for O
methods O
that O
are O
highly O
sensitive O
and O
capable O
of O
predicting O
cardiac B
dysfunction. I
We O
measured O
the O
plasma O
level O
of O
brain O
natriuretic O
peptide O
(BNP) O
to O
determine O
whether O
BNP O
might O
serve O
as O
a O
simple O
diagnostic O
indicator O
of O
anthracycline-induced O
cardiotoxicity O
in O
patients O
with O
acute B
leukemia I
treated O
with O
a O
daunorubicin O
(DNR)-containing O
regimen. O
Thirteen O
patients O
with O
acute O
leukemia O
were O
treated O
with O
a O
DNR-containing O
regimen. O
Cardiac O
functions O
were O
evaluated O
with O
radionuclide O
angiography O
before O
chemotherapies. O
The O
plasma O
levels O
of O
atrial O
natriuretic O
peptide O
(ANP) O
and O
BNP O
were O
measured O
at O
the O
time O
of O
radionuclide O
angiography. O
Three O
patients O
developed O
congestive B
heart B
failure I
after O
the O
completion O
of O
chemotherapy. O
Five O
patients O
were O
diagnosed O
as O
having O
subclinical O
heart O
failure O
after O
the O
completion O
of O
chemotherapy. O
The O
plasma O
levels O
of O
BNP O
in O
all O
the O
patients O
with O
clinical O
and O
subclinical O
heart O
failure O
increased O
above O
the O
normal O
limit O
(40 O
pg/ml) O
before O
the O
detection O
of O
clinical O
or O
subclinical O
heart O
failure O
by O
radionuclide O
angiography. O
On O
the O
other O
hand, O
BNP O
did O
not O
increase O
in O
the O
patients O
without O
heart O
failure O
given O
DNR, O
even O
at O
more O
than O
700 O
mg/m(2). O
The O
plasma O
level O
of O
ANP O
did O
not O
always O
increase O
in O
all O
the O
patients O
with O
clinical O
and O
subclinical O
heart O
failure. O
These O
preliminary O
results O
suggest O
that O
BNP O
may O
be O
useful O
as O
an O
early O
and O
sensitive O
indicator O
of O
anthracycline-induced O
cardiotoxicity. O

Proteinuria B
after O
conversion O
to O
sirolimus O
in O
renal O
transplant O
recipients. O

OBJECTIVE: O
To O
estimate O
the O
association O
between O
antibacterial O
medications O
and O
selected O
birth B
defects. I
DESIGN, O
SETTING, O
AND O
PARTICIPANTS: O
Population-based, O
multisite, O
case-control O
study O
of O
women O
who O
had O
pregnancies O
affected O
by O
1 O
of O
more O
than O
30 O
eligible O
major O
birth O
defects O
identified O
via O
birth O
defect O
surveillance O
programs O
in O
10 O
states O
(n O
= O
13 O
155) O
and O
control O
women O
randomly O
selected O
from O
the O
same O
geographical O
regions O
(n O
= O
4941). O
MAIN O
EXPOSURE: O
Reported O
maternal O
use O
of O
antibacterials O
(1 O
month O
before O
pregnancy O
through O
the O
end O
of O
the O
first O
trimester). O
MAIN O
OUTCOME O
MEASURE: O
Odds O
ratios O
(ORs) O
measuring O
the O
association O
between O
antibacterial O
use O
and O
selected O
birth O
defects O
adjusted O
for O
potential O
confounders. O
RESULTS: O
The O
reported O
use O
of O
antibacterials O
increased O
during O
pregnancy, O
peaking O
during O
the O
third O
month. O
Sulfonamides O
were O
associated O
with O
anencephaly B
(adjusted O
OR O
[AOR] O
= O
3.4; O
95% O
confidence O
interval O
[CI], O
1.3-8.8), O
hypoplastic B
left I
heart I
syndrome I
(AOR O
= O
3.2; O
95% O
CI, O
1.3-7.6), O
coarctation B
of I
the I
aorta I
(AOR O
= O
2.7; O
95% O
CI, O
1.3-5.6), O
choanal B
atresia I
(AOR O
= O
8.0; O
95% O
CI, O
2.7-23.5), O
transverse B
limb I
deficiency I
(AOR O
= O
2.5; O
95% O
CI, O
1.0-5.9), O
and O
diaphragmatic B
hernia I
(AOR O
= O
2.4; O
95% O
CI, O
1.1-5.4). O
Nitrofurantoins O
were O
associated O
with O
anophthalmia B
or O
microphthalmos B
(AOR O
= O
3.7; O
95% O
CI, O
1.1-12.2), O
hypoplastic O
left O
heart O
syndrome O
(AOR O
= O
4.2; O
95% O
CI, O
1.9-9.1), O
atrial B
septal I
defects I
(AOR O
= O
1.9; O
95% O
CI, O
1.1-3.4), O
and O
cleft B
lip I
with O
cleft B
palate I
(AOR O
= O
2.1; O
95% O
CI, O
1.2-3.9). O
Other O
antibacterial O
agents O
that O
showed O
associations O
included O
erythromycins O
(2 O
defects), O
penicillins O
(1 O
defect), O
cephalosporins O
(1 O
defect), O
and O
quinolones O
(1 O
defect). O
CONCLUSIONS: O
Reassuringly, O
penicillins, O
erythromycins, O
and O
cephalosporins, O
although O
used O
commonly O
by O
pregnant O
women, O
were O
not O
associated O
with O
many O
birth O
defects. O
Sulfonamides O
and O
nitrofurantoins O
were O
associated O
with O
several O
birth O
defects, O
indicating O
a O
need O
for O
additional O
scrutiny. O

Two O
mouse O
lines O
selected O
for O
differential O
sensitivities O
to O
beta-carboline-induced O
seizures B
are O
also O
differentially O
sensitive O
to O
various O
pharmacological O
effects O
of O
other O
GABA(A) O
receptor O
ligands. O

Warfarin-induced O
artery B
calcification I
is O
accelerated O
by O
growth O
and O
vitamin O
D. O

In O
35 O
patients O
(ages O
20 O
to O
86 O
yr) O
receiving O
cimetidine O
therapeutically O
two O
serum O
samples O
and O
all O
urine O
formed O
in O
the O
interim O
were O
collected O
for O
analysis O
of O
cimetidine O
by O
high-pressure O
liquid O
chromatography O
and O
for O
creatinine. O
Cimetidine O
clearance O
decreased O
with O
age. O
The O
extrapolated O
6-hr O
serum O
concentration O
of O
cimetidine O
per O
unit O
dose, O
after O
intravenous O
cimetidine, O
increased O
with O
age O
of O
the O
patients. O
The O
ratio O
of O
cimetidine O
clearance O
to O
creatinine O
clearance O
(Rc) O
averaged O
4.8 O
+/- O
2.0, O
indicating O
net O
tubular O
secretion O
for O
cimetidine. O
Rc O
seemed O
to O
be O
independent O
of O
age O
and O
decreased O
with O
increasing O
serum O
concentration O
of O
cimetidine, O
suggesting O
that O
secretion O
of O
cimetidine O
is O
a O
saturable O
process. O
There O
was O
only O
one O
case O
of O
dementia B
possibly O
due O
to O
cimetidine O
(with O
a O
drug O
level O
of O
1.9 O
microgram/ml O
6 O
hr O
after O
a O
dose) O
in O
a O
group O
of O
13 O
patients O
without O
liver B
or I
kidney B
disease I
who O
had O
cimetidine O
levels O
above O
1.25 O
microgram/ml. O
Thus, O
high O
cimetidine O
levels O
alone O
do O
not O
always O
induce O
dementia. O

Immunohistochemistry O
with O
monoclonal O
antibodies O
against O
neurofilament O
(NF) O
proteins O
of O
middle O
and O
high O
molecular O
weight O
class, O
NF-M O
and O
NF-H, O
was O
used O
to O
study O
axonal B
injury I
in O
the O
borderzone O
of O
focal O
lesions O
in O
rats. O
Focal O
injury B
in I
the I
cortex I
was O
produced O
by O
infusion O
of O
lactate O
at O
acid O
pH O
or O
by O
stab O
caused O
by O
needle O
insertion. O
Infarcts B
in I
substantia I
nigra I
pars I
reticulata I
were O
evoked O
by O
prolonged O
pilocarpine-induced O
status B
epilepticus. I
Immunohistochemical O
staining O
for O
NFs O
showed O
characteristic O
terminal O
clubs O
of O
axons O
in O
the O
borderzone O
of O
lesions. O
Differences O
in O
the O
labelling O
pattern O
occurred O
with O
different O
antibodies O
which O
apparently O
depended O
on O
molecular O
weight O
class O
of O
NFs O
and O
phosphorylation O
state. O
These O
immunohistochemical O
changes O
of O
NFs O
can O
serve O
as O
a O
marker O
for O
axonal B
damage I
in O
various O
experimental O
traumatic B
or O
ischemic O
lesions. O

Cardiac O
Angiography O
in O
Renally O
Impaired O
Patients O
(CARE) O
study: O
a O
randomized O
double-blind O
trial O
of O
contrast-induced O
nephropathy B
in O
patients O
with O
chronic B
kidney I
disease. I

Evidence O
for O
an O
involvement O
of O
D1 O
and O
D2 O
dopamine O
receptors O
in O
mediating O
nicotine-induced O
hyperactivity B
in O
rats. O

A O
61-year-old O
man O
was O
treated O
with O
combination O
chemotherapy O
incorporating O
cisplatinum, O
etoposide, O
high-dose O
5-fluorouracil O
(2,250 O
mg/m2/24 O
hours) O
and O
folinic O
acid O
for O
an O
inoperable O
gastric B
adenocarcinoma. I
He O
developed O
acute O
neurologic O
symptoms O
of O
mental O
confusion, B
disorientation B
and O
irritability, B
and O
then O
lapsed O
into O
a O
deep O
coma, B
lasting O
for O
approximately O
40 O
hours O
during O
the O
first O
dose O
(day O
2) O
of O
5-fluorouracil O
and O
folinic O
acid O
infusion. O
This O
complication O
reappeared O
on O
day O
25 O
during O
the O
second O
dose O
of O
5-fluorouracil O
and O
folinic O
acid, O
which O
were O
then O
the O
only O
drugs O
given. O
Because O
folinic O
acid O
was O
unlikely O
to O
be O
associated O
with O
this O
condition, O
neurotoxicity B
due O
to O
high-dose O
5-fluorouracil O
was O
highly O
suspected. O
The O
pathogenesis O
of O
5-fluorouracil O
neurotoxicity O
may O
be O
due O
to O
a O
Krebs O
cycle O
blockade O
by O
fluoroacetate O
and O
fluorocitrate, O
thiamine O
deficiency, O
or O
dihydrouracil O
dehydrogenase O
deficiency. O
High-dose O
5-fluorouracil/folinic O
acid O
infusion O
therapy O
has O
recently O
become O
a O
popular O
regimen O
for O
various O
cancers. B
It O
is O
necessary O
that O
both O
oncologists O
and O
neurologists O
be O
fully O
aware O
of O
this O
unusual O
complication. O

In O
acute B
pain I
models, O
N-methyl-D-aspartate O
(NMDA) O
antagonists O
enhance O
the O
antinociceptive O
effects O
of O
morphine O
to O
a O
greater O
extent O
in O
males O
than O
females. O
The O
purpose O
of O
this O
investigation O
was O
to O
extend O
these O
findings O
to O
a O
persistent O
pain O
model O
which O
could O
be O
distinguished O
from O
acute O
pain O
models O
on O
the O
basis O
of O
the O
nociceptive O
fibers O
activated, O
neurochemical O
substrates, O
and O
duration O
of O
the O
nociceptive O
stimulus. O
To O
this O
end, O
persistent O
hyperalgesia B
was O
induced O
by O
administration O
of O
capsaicin O
in O
the O
tail O
of O
gonadally O
intact O
F344 O
rats, O
following O
which O
the O
tail O
was O
immersed O
in O
a O
mildly O
noxious O
thermal O
stimulus, O
and O
tail-withdrawal O
latencies O
measured. O
For O
comparison, O
tests O
were O
conducted O
in O
two O
acute O
pain O
models, O
the O
hotplate O
and O
warm O
water O
tail-withdrawal O
procedures. O
In O
males, O
the O
non-competitive O
NMDA O
antagonist O
dextromethorphan O
enhanced O
the O
antihyperalgesic O
effect O
of O
low O
to O
moderate O
doses O
of O
morphine O
in O
a O
dose-and O
time-dependent O
manner. O
Across O
the O
doses O
and O
pretreatment O
times O
examined, O
enhancement O
was O
not O
observed O
in O
females. O
Enhancement O
of O
morphine O
antinociception O
by O
dextromethorphan O
was O
seen O
in O
both O
males O
and O
females O
in O
the O
acute O
pain O
models, O
with O
the O
magnitude O
of O
this O
effect O
being O
greater O
in O
males. O
These O
findings O
demonstrate O
a O
sexually-dimorphic O
interaction O
between O
NMDA O
antagonists O
and O
morphine O
in O
a O
persistent O
pain O
model O
that O
can O
be O
distinguished O
from O
those O
observed O
in O
acute O
pain O
models. O

Urotensin-II O
(U-II) O
receptors O
are O
widely O
distributed O
in O
the O
central O
nervous O
system. O
Intracerebroventricular O
(i.c.v.) O
injection O
of O
U-II O
causes O
hypertension B
and O
bradycardia B
and O
stimulates O
prolactin O
and O
thyrotropin O
secretion. O
However, O
the O
behavioral O
effects O
of O
centrally O
administered O
U-II O
have O
received O
little O
attention. O
In O
the O
present O
study, O
we O
tested O
the O
effects O
of O
i.c.v. O
injections O
of O
U-II O
on O
behavioral, O
metabolic, O
and O
endocrine O
responses O
in O
mice. O
Administration O
of O
graded O
doses O
of O
U-II O
(1-10,000 O
ng/mouse) O
provoked: O
(1) O
a O
dose-dependent O
reduction O
in O
the O
number O
of O
head O
dips O
in O
the O
hole-board O
test; O
(2) O
a O
dose-dependent O
reduction O
in O
the O
number O
of O
entries O
in O
the O
white O
chamber O
in O
the O
black-and-white O
compartment O
test, O
and O
in O
the O
number O
of O
entries O
in O
the O
central O
platform O
and O
open O
arms O
in O
the O
plus-maze O
test; O
and O
(3) O
a O
dose-dependent O
increase O
in O
the O
duration O
of O
immobility O
in O
the O
forced-swimming O
test O
and O
tail O
suspension O
test. O
Intracerebroventricular O
injection O
of O
U-II O
also O
caused O
an O
increase O
in: O
food O
intake O
at O
doses O
of O
100 O
and O
1,000 O
ng/mouse, O
water O
intake O
at O
doses O
of O
100-10,000 O
ng/mouse, O
and O
horizontal O
locomotion O
activity O
at O
a O
dose O
of O
10,000 O
ng/mouse. O
Whatever O
was O
the O
dose, O
the O
central O
administration O
of O
U-II O
had O
no O
effect O
on O
body O
temperature, O
nociception, O
apomorphine-induced O
penile B
erection I
and O
climbing O
behavior, O
and O
stress-induced O
plasma O
corticosterone O
level. O
Taken O
together, O
the O
present O
study O
demonstrates O
that O
the O
central O
injection O
of O
U-II O
at O
doses O
of O
1-10,000 O
ng/mouse O
induces O
anxiogenic- O
and O
depressant-like O
effects O
in O
mouse. O
These O
data O
suggest O
that O
U-II O
may O
be O
involved O
in O
some O
aspects O
of O
psychiatric B
disorders. I

BACKGROUND: O
In O
man, O
differences O
in O
angiotensin-converting O
enzyme O
(ACE) O
levels, O
related O
to O
ACE O
(I/D) O
genotype, O
are O
associated O
with O
renal O
prognosis. O
This O
raises O
the O
hypothesis O
that O
individual O
differences O
in O
renal O
ACE O
activity O
are O
involved O
in O
renal O
susceptibility O
to O
inflicted O
damage. O
Therefore, O
we O
studied O
the O
predictive O
effect O
of O
renal O
ACE O
activity O
for O
the O
severity O
of O
renal B
damage I
induced O
by O
a O
single O
injection O
of O
adriamycin O
in O
rats. O
METHODS: O
Renal O
ACE O
activity O
(Hip-His-Leu O
cleavage O
by O
cortical O
homogenates) O
was O
determined O
by O
renal O
biopsy O
in O
27 O
adult O
male O
Wistar O
rats. O
After O
1 O
week O
of O
recovery, O
proteinuria B
was O
induced O
by O
adriamycin O
[1.5 O
mg/kg O
intravenously O
(i.v.) O
n O
= O
18; O
controls, O
saline O
i.v. O
n O
= O
9]. O
Proteinuria B
was O
measured O
every O
2 O
weeks. O
After O
12 O
weeks, O
rats O
were O
sacrificed O
and O
their O
kidneys O
harvested. O
RESULTS: O
As O
anticipated, O
adriamycin O
elicited O
nephrotic B
range O
proteinuria, O
renal B
interstitial I
damage I
and O
mild O
focal B
glomerulosclerosis. I
Baseline O
renal O
ACE O
positively O
correlated O
with O
the O
relative O
rise O
in O
proteinuria O
after O
adriamycin O
(r O
= O
0.62, O
P<0.01), O
renal O
interstitial O
alpha-smooth O
muscle O
actin O
(r O
= O
0.49, O
P<0.05), O
interstitial O
macrophage O
influx O
(r O
= O
0.56, O
P<0.05), O
interstitial O
collagen O
III O
(r O
= O
0.53, O
P<0.05), O
glomerular O
alpha-smooth O
muscle O
actin O
(r O
= O
0.74, O
P<0.01) O
and O
glomerular O
desmin O
(r O
= O
0.48, O
P<0.05). O
Baseline O
renal O
ACE O
did O
not O
correlate O
with O
focal O
glomerulosclerosis O
(r O
= O
0.22, O
NS). O
In O
controls, O
no O
predictive O
values O
for O
renal O
parameters O
were O
observed. O
CONCLUSION: O
Individual O
differences O
in O
renal O
ACE O
activity O
predict O
the O
severity O
of O
adriamycin-induced O
renal O
damage O
in O
this O
outbred O
rat O
strain. O
This O
supports O
the O
assumption O
that O
differences O
in O
renal O
ACE O
activity O
predispose O
to O
a O
less O
favourable O
course O
of O
renal O
damage. O

Twenty O
common O
migraine B
patients O
received O
a O
one O
sided O
frontotemporal O
application O
of O
nitroglycerin O
(10 O
patients) O
or O
placebo O
ointment O
(10 O
patients) O
in O
a O
double O
blind O
study. O
Early O
onset O
migraine O
attacks O
were O
induced O
by O
nitroglycerin O
in O
seven O
out O
of O
10 O
patients O
versus O
no O
patient O
in O
the O
placebo O
group. O
Subsequently O
20 O
migraine O
patients, O
who O
developed O
an O
early O
onset O
attack O
with O
frontotemporal O
nitroglycerin, O
received O
the O
drug O
in O
a O
second O
induction O
test O
at O
other O
body O
areas. O
No O
early O
onset O
migraine O
was O
observed. O
Thus O
the O
migraine-inducing O
effect O
of O
nitroglycerin O
seems O
to O
depend O
on O
direct O
stimulation O
of O
the O
habitual O
site O
of O
pain, B
suggesting O
that O
the O
frontotemporal O
region O
is O
of O
crucial O
importance O
in O
the O
development O
of O
a O
migraine O
crisis. O
This O
is O
not O
consistent O
with O
a O
CNS O
origin O
of O
migraine O
attack. O

Transient O
platypnea-orthodeoxia-like B
syndrome I
induced O
by O
propafenone O
overdose B
in O
a O
young O
woman O
with O
Ebstein's B
anomaly. I

Metabolic O
involvement O
in O
adriamycin O
cardiotoxicity. B

Sedation O
has O
been O
commonly O
used O
in O
the O
neonate O
to O
decrease O
the O
stress O
and O
pain B
from O
the O
noxious O
stimuli O
and O
invasive O
procedures O
in O
the O
neonatal O
intensive O
care O
unit, O
as O
well O
as O
to O
facilitate O
synchrony O
between O
ventilator O
and O
spontaneous O
breaths. O
Fentanyl, O
an O
opioid O
analgesic, O
is O
frequently O
used O
in O
the O
neonatal O
intensive O
care O
unit O
setting O
for O
these O
very O
purposes. O
Various O
reported O
side O
effects O
of O
fentanyl O
administration O
include O
chest B
wall I
rigidity, I
hypotension, B
respiratory B
depression, I
and O
bradycardia. B
Here, O
2 O
cases O
of O
urinary B
bladder I
retention I
leading O
to O
renal O
pelvocalyceal O
dilatation O
mimicking O
hydronephrosis B
as O
a O
result O
of O
continuous O
infusion O
of O
fentanyl O
are O
reported. O

Reversible O
dilated B
cardiomyopathy I
related O
to O
amphotericin O
B O
therapy. O

Further O
studies O
on O
the O
effects O
of O
certain O
irrigating O
fluids O
on O
the O
rat O
bladder O
for O
18 O
hours O
are O
reported. O
The O
results O
have O
shown O
that O
the O
degradation O
product O
p-choloroaniline O
is O
not O
a O
significant O
factor O
in O
chlorhexidine-digluconate O
associated O
erosive O
cystitis. B
A O
high O
percentage O
of O
kanamycin-colistin O
and O
povidone-iodine O
irrigations O
were O
associated O
with O
erosive O
cystitis O
and O
suggested O
a O
possible O
complication O
with O
human O
usage. O
Picloxydine O
irrigations O
appeared O
to O
have O
a O
lower O
incidence O
of O
erosive O
cystitis O
but O
further O
studies O
would O
have O
to O
be O
performed O
before O
it O
could O
be O
recommended O
for O
use O
in O
urological O
procedures. O

Estradiol O
reduces O
seizure-induced B
hippocampal B
injury I
in O
ovariectomized O
female O
but O
not O
in O
male O
rats. O

BACKGROUND: O
Concerns O
about O
possible O
risks O
of O
switching O
to O
mania B
associated O
with O
antidepressants O
continue O
to O
interfere O
with O
the O
establishment O
of O
an O
optimal O
treatment O
paradigm O
for O
bipolar B
depression. I
METHOD: O
The O
response O
of O
44 O
patients O
meeting O
DSM-IV O
criteria O
for O
bipolar B
disorder I
to O
naturalistic O
treatment O
was O
assessed O
for O
at O
least O
6 O
weeks O
using O
the O
Montgomery-Asberg O
Depression O
Rating O
Scale O
and O
the O
Bech-Rafaelson O
Mania O
Rating O
Scale. O
Patients O
who O
experienced O
a O
manic B
or O
hypomanic B
switch O
were O
compared O
with O
those O
who O
did O
not O
on O
several O
variables O
including O
age, O
sex, O
diagnosis O
(DSM-IV O
bipolar B
I I
vs. I
bipolar B
II), I
number O
of O
previous O
manic O
episodes, O
type O
of O
antidepressant O
therapy O
used O
(electroconvulsive O
therapy O
vs. O
antidepressant O
drugs O
and, O
more O
particularly, O
selective O
serotonin O
reuptake O
inhibitors O
[SSRIs]), O
use O
and O
type O
of O
mood O
stabilizers O
(lithium O
vs. O
anticonvulsants), O
and O
temperament O
of O
the O
patient, O
assessed O
during O
a O
normothymic O
period O
using O
the O
hyperthymia O
component O
of O
the O
Semi-structured O
Affective O
Temperament O
Interview. O
RESULTS: O
Switches O
to O
hypomania B
or O
mania O
occurred O
in O
27% O
of O
all O
patients O
(N O
= O
12) O
(and O
in O
24% O
of O
the O
subgroup O
of O
patients O
treated O
with O
SSRIs O
[8/33]); O
16% O
(N O
= O
7) O
experienced O
manic O
episodes, O
and O
11% O
(N O
= O
5) O
experienced O
hypomanic O
episodes. O
Sex, O
age, O
diagnosis O
(bipolar O
I O
vs. O
bipolar O
II), O
and O
additional O
treatment O
did O
not O
affect O
the O
risk O
of O
switching. O
The O
incidence O
of O
mood O
switches O
seemed O
not O
to O
differ O
between O
patients O
receiving O
an O
anticonvulsant O
and O
those O
receiving O
no O
mood O
stabilizer. O
In O
contrast, O
mood O
switches O
were O
less O
frequent O
in O
patients O
receiving O
lithium O
(15%, O
4/26) O
than O
in O
patients O
not O
treated O
with O
lithium O
(44%, O
8/18; O
p O
= O
.04). O
The O
number O
of O
previous O
manic O
episodes O
did O
not O
affect O
the O
probability O
of O
switching, O
whereas O
a O
high O
score O
on O
the O
hyperthymia O
component O
of O
the O
Semistructured O
Affective O
Temperament O
Interview O
was O
associated O
with O
a O
greater O
risk O
of O
switching O
(p O
= O
.008). O
CONCLUSION: O
The O
frequency O
of O
mood O
switching O
associated O
with O
acute O
antidepressant O
therapy O
may O
be O
reduced O
by O
lithium O
treatment. O
Particular O
attention O
should O
be O
paid O
to O
patients O
with O
a O
hyperthymic O
temperament, O
who O
have O
a O
greater O
risk O
of O
mood O
switches. O

